Comparison O
with O
alkaline I-GENE
phosphatases I-GENE
and O
5 I-GENE
- I-GENE
_RARE_ I-GENE

_RARE_ I-GENE
aspects O
of O
neonatal O
hyperbilirubinemia O
. O

When O
CSF I-GENE
[ O
HCO3 O
_RARE_ I-GENE
is O
shown O
as O
a O
function O
of O
CSF I-GENE
PCO2 O
the O
data O
of O
K I-GENE
- I-GENE
depleted O
rats O
are O
no O
longer O
_RARE_ I-GENE
when O
compared O
to O
controls O
but O
still O
have O
a O
significantly O
greater O
slope O
( O
1 I-GENE
. O
21 O
+/- O
0 O
. O
23 O
vs O
. O

_RARE_ I-GENE
thus O
appears O
to O
be O
an O
effective O
_RARE_ I-GENE
drug O
with O
the O
_RARE_ I-GENE
dose O
for O
use O
in O
general O
practice O
being O
15 O
mg O
at O
night O
. O

_RARE_ I-GENE
blocking O
agents O
. O

When O
_RARE_ I-GENE
CO2 O
removal O
_RARE_ I-GENE
CO2 O
production O
( O
_RARE_ I-GENE
), O
alveolar O
ventilation O
almost O
_RARE_ I-GENE
. O

Intravenous O
administration O
( O
25 O
mg O
/ I-GENE
kg O
) O
of O
_RARE_ I-GENE
anhydrase I-GENE
inhibitors O
( O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
) O
induced O
an O
early I-GENE
important O
rise O
of O
cortical O
p O
O2 O
, O
which O
is O
not O
dependent I-GENE
on O
increase O
of O
p O
O2 O
and O
p O
CO2 O
and O
decrease O
of O
pH O
in O
arterial O
blood O
. O

_RARE_ I-GENE
study O
of O
_RARE_ I-GENE
in O
the O
rat I-GENE
and O
rabbit I-GENE
. O

_RARE_ I-GENE
polyps O
should O
be O
removed O
_RARE_ I-GENE
_RARE_ I-GENE
possible O
. O

The O
variable O
HMG I-GENE
dosage O
regimen O
was O
found O
to O
offer O
no O
advantages O
when O
compared O
with O
our O
standard O
daily O
dosage O
regimen O
. O

When O
the O
CO2 O
content O
reached O
9 O
_RARE_ I-GENE
% O
the O
animals O
became O
_RARE_ I-GENE
and O
lost O
body O
weight O
. O

Serum I-GENE
gamma I-GENE
_RARE_ I-GENE
in O
the O
diagnosis O
of O
liver O
disease O
in O
cattle O
. O

By O
contrast O
, O
secretory I-GENE
_RARE_ I-GENE
antibodies I-GENE
were O
not O
demonstrated O
at O
the O
onset O
of O
illness O
in O
any O
of O
the O
patients O
, O
but O
their O
formation O
started O
early I-GENE
and O
the O
antibodies I-GENE
reached O
maximal O
levels O
about O
10 O
days O
after O
onset O
of O
illness O
. O

With O
the O
exception O
of O
virus I-GENE
assay O
and O
_RARE_ I-GENE
, O
these O
methods O
are O
simple O
and O
_RARE_ I-GENE
enough O
to O
be O
done O
in O
typical O
_RARE_ I-GENE
_RARE_ I-GENE
laboratories O
. O

_RARE_ I-GENE
of O
lipase I-GENE
activity O
. O

_RARE_ I-GENE
' O
s O
disease O
: O
association O
with O
HLA I-GENE
- I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
and O
alkaline I-GENE
phosphatase I-GENE
concentrations O
were O
essentially O
normal O
in O
all O
subjects O
. O

_RARE_ I-GENE
glutamyl I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
activity O
in O
the O
seminal I-GENE
fluid O

Patients O
with O
Parkinson O
' O
s O
disease O
showed O
a O
relatively O
high O
incidence O
to O
_RARE_ I-GENE
during O
drug O
treatment O
( O
51 O
. O
47 O
%). O

Selective O
stimulation O
of O
central O
alpha I-GENE
- I-GENE
_RARE_ I-GENE
following O
treatment O
with O
alpha I-GENE
- I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
136 O
. O

Anti I-GENE
- I-GENE
anxiety O
action O
of O
diazepam I-GENE
after O
intra O
- I-GENE
_RARE_ I-GENE
application O
in O
the O
rat I-GENE
. O

_RARE_ I-GENE
. O

Removal O
of O
thick O
, O
_RARE_ I-GENE
altered O
_RARE_ I-GENE
is O
recommended O
even O
in O
the O
absence O
of O
squamous O
epithelium O
. O

An O
IgG I-GENE
monoclonal I-GENE
_RARE_ I-GENE
was O
present O
in O
the O
serum I-GENE
of O
4 I-GENE
patients O
and O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
was O
found O
in O
1 I-GENE
patient O
. O

Studies O
on O
immunoglobulin I-GENE
E I-GENE
: O
the O
impact O
of O
a O
_RARE_ I-GENE
with O
_RARE_ I-GENE
_RARE_ I-GENE
H I-GENE
. O

_RARE_ I-GENE
reaction O
_RARE_ I-GENE
were O
negative O
, O
_RARE_ I-GENE
esterase I-GENE
were O
strongly O
positive O
. O

Ten O
out O
- I-GENE
patients O
with O
_RARE_ I-GENE
_RARE_ I-GENE
et O
_RARE_ I-GENE
were O
examined O
with O
direct O
immunofluorescence O
( O
IF O
) O
technique O
for O
deposition O
of O
fibrinogen I-GENE
, O
fibrin I-GENE
or O
its O
degradation O
products I-GENE
( O
FR I-GENE
- I-GENE
antigen I-GENE
) O
in O
affected O
and O
unaffected O
skin O
, O
together O
with O
heparin O
- I-GENE
_RARE_ I-GENE
fraction O
( O
_RARE_ I-GENE
), O
_RARE_ I-GENE
and O
total O
plasma I-GENE
fibrinogen I-GENE
in O
the O
blood O
. O

Of O
600 O
_RARE_ I-GENE
carried O
out O
from O
_RARE_ I-GENE
to O
_RARE_ I-GENE
, O
_RARE_ I-GENE
were O
performed O
to O
assess O
the O
_RARE_ I-GENE
of O
a O
pulmonary O
carcinoma O
. O

A I-GENE
mixture O
of O
human I-GENE
albumin I-GENE
5 I-GENE
% O
and O
hydroxy I-GENE
- I-GENE
ethyl O
- I-GENE
_RARE_ I-GENE
was O
used O
as O
a O
solution O
for O
dilution O
. O

In O
the O
matched O
control O
group O
the O
acquisition O
- I-GENE
rate O
of O
both O
symptomatic O
and O
asymptomatic O
_RARE_ I-GENE
was O
over O
12 O
%, O
a O
_RARE_ I-GENE
similar O
to O
the O
percentage O
of O
women O
present O
in O
the O
practice O
population O
during O
one O
year O
with O
transient O
, O
symptomatic O
, O
and O
persistent O
A I-GENE
. O
B I-GENE
. O

_RARE_ I-GENE
complications O
of O
_RARE_ I-GENE
for O
intravenous O
nutrition O
. O

_RARE_ I-GENE
diagnosis O
of O
_RARE_ I-GENE
. O

_RARE_ I-GENE
which O
are O
indicative O
of O
_RARE_ I-GENE
_RARE_ I-GENE
are O
absent O
. O

_RARE_ I-GENE
positive O
amniotic I-GENE
fluid O
alpha I-GENE
fetoprotein I-GENE
levels O
resulting O
from O
contamination O
with O
fetal O
blood O
: O
results O
of O
an O
experiment O
. O

Serum I-GENE
- I-GENE
ferritin I-GENE
in O
diagnosis O
of O
_RARE_ I-GENE
. O

In O
2 I-GENE
subjects O
the O
_RARE_ I-GENE
reactivity O
of O
the O
lymphocytes O
was O
improved O
after O
treatment O
. O

Patients O
at O
risk O
of O
hypothyroidism O
. O

_RARE_ I-GENE
and O
cyclic I-GENE
AMP I-GENE
levels O
in O
peritoneal O
fluids O
in O
the O
child O

_RARE_ I-GENE
. O

Thirty O
- I-GENE
five O
strains O
of O
_RARE_ I-GENE
' O
disease O
bacteria O
were O
shown O
to O
belong O
in O
four O
distinct O
serologic O
groups O
on O
the O
basis O
of O
findings O
obtained O
with O
direct O
fluorescent O
antibody I-GENE
testing O
. O

On O
the O
other O
hand O
factor I-GENE
IX I-GENE
activity O
is O
decreased O
in O
_RARE_ I-GENE
treatment O
with O
factor I-GENE
IX I-GENE
antigen I-GENE
remaining O
normal O
. O

The O
concentration O
of O
alpha I-GENE
2 I-GENE
- I-GENE
_RARE_ I-GENE
, O
alpha I-GENE
1 I-GENE
- I-GENE
antitrypsin I-GENE
, O
plasminogen I-GENE
, O
C3 I-GENE
- I-GENE
complement I-GENE
, O
fibrinogen I-GENE
degradation O
products I-GENE
( O
_RARE_ I-GENE
) O
and O
_RARE_ I-GENE
activity O
, O
were O
studied O
in O
the O
aqueous O
_RARE_ I-GENE
and O
serum I-GENE
from O
nine O
patients O
with O
_RARE_ I-GENE
' O
endothelial I-GENE
dystrophy I-GENE
, O
17 O
patients O
with O
_RARE_ I-GENE
senile O
_RARE_ I-GENE
and O
in O
the O
secondary O
aqueous O
from O
six O
_RARE_ I-GENE
patients O
. O

Only O
17 O
% O
of O
all O
patients O
_RARE_ I-GENE
it O
at O
all O
times O
. O

_RARE_ I-GENE
alone O
was O
effective O
in O
volume O
responsive I-GENE
patients O
at O
a O
dose O
of O
5 I-GENE
+/- O
1 I-GENE
. O
0 O
mg O
daily O
. O

T4 I-GENE
and O
_RARE_ I-GENE
followed O
parallel O
courses O
in O
both O
groups O
; O
during O
the O
first O
45 O
days O
, O
however O
, O
the O
values O
were O
significantly O
lower O
in O
premature O
infants O
under O
34 O
weeks O
' O
_RARE_ I-GENE
than O
in O
term O
infants O
( O
P I-GENE
less O
than O
0 O
. O
001 O
). O

A I-GENE
three O
- I-GENE
_RARE_ I-GENE
analysis O
of O
treatment O
_RARE_ I-GENE
for O
45 O
patients O
was O
undertaken O
. O

_RARE_ I-GENE
_RARE_ I-GENE
: O
unaltered O
susceptibility I-GENE
of O
platelet I-GENE
_RARE_ I-GENE
- I-GENE
oxygenase I-GENE
to O
inhibition O
by O
aspirin I-GENE
in O
vitro O
. O

These O
results O
indicate O
that O
_RARE_ I-GENE
monkeys O
are O
either O
less O
sensitive O
or O
respond O
differently O
than O
rhesus I-GENE
monkeys O
to O
some O
of O
the O
pharmacological O
effects O
of O
_RARE_ I-GENE
. O

59 O
cases O
of O
surgically O
_RARE_ I-GENE
cancers O
( O
T1 O
, O
T2 I-GENE
, O
T3 O
, O
_RARE_ I-GENE
, O
N1 O
) O
had O
a O
minimum O
_RARE_ I-GENE
of O
two O
years O
( O
average O
4 I-GENE
years O
+/- O
3 I-GENE
months O
). O

The O
effect O
of O
_RARE_ I-GENE
and O
_RARE_ I-GENE
can O
be O
explained O
by O
interference O
with O
thyroid I-GENE
hormone I-GENE
binding I-GENE
to O
_RARE_ I-GENE
combined O
with O
enzyme I-GENE
- I-GENE
induced O
increased O
metabolic O
clearance O
rate O
of O
thyroid I-GENE
hormones O
without O
_RARE_ I-GENE
maintenance O
of O
_RARE_ I-GENE
levels O
of O
_RARE_ I-GENE
and O
_RARE_ I-GENE
. O

The O
present O
research O
evaluated O
the O
possibility O
that O
_RARE_ I-GENE
glycol O
400 O
( O
_RARE_ I-GENE
400 O
) O
might O
be O
_RARE_ I-GENE
, O
toxic O
, O
or O
both O
. O

According O
to O
their O
functional O
properties O
the O
latter O
neurons O
were O
_RARE_ I-GENE
into O
: O
( O
a O
) O
neurons O
responding O
to O
stimuli O
near O
the O
eyes O
; O
( O
b I-GENE
) O
neurons O
triggered O
by O
complex I-GENE
visual O
stimuli O
; O
( O
c I-GENE
) O
neurons O
inhibited O
by O
visual O
stimuli O
. O

_RARE_ I-GENE
( O
1 I-GENE
, O
3 I-GENE
, O
10 O
, O
and O
17 O
. O
5 I-GENE
mg O
/ I-GENE
kg O
) O
was O
also O
tested O
in O
combination O
with O
rate O
- I-GENE
decreasing O
doses O
of O
_RARE_ I-GENE
( O
17 O
. O
5 I-GENE
mg O
/ I-GENE
kg O
), O
_RARE_ I-GENE
( O
10 O
mg O
/ I-GENE
kg O
), O
_RARE_ I-GENE
( O
10 O
mg O
/ I-GENE
kg O
), O
and O
fentanyl O
( O
0 O
. O
3 I-GENE
mg O
/ I-GENE
kg O
). O

_RARE_ I-GENE
_RARE_ I-GENE
( O
0 O
. O
55 O
_RARE_ I-GENE
- I-GENE
2 I-GENE
) O
provided O
the O
best O
overall O
improvement O
. O

An O
anatomical O
and O
_RARE_ I-GENE
study O
has O
been O
undertaken O
and O
as O
a O
result O
_RARE_ I-GENE
is O
given O
to O
recent O
_RARE_ I-GENE
that O
suggest O
there O
are O
similarities O
with O
Type O
IV I-GENE
glycogen I-GENE
storage O
disease O
( O
_RARE_ I-GENE
' O
s O
disease O
) O
which O
, O
although O
clinically O
distinct O
, O
has O
the O
same O
enzyme I-GENE
defect O
. O

All O
groups O
were O
tested O
in O
a O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
at O
100 O
approximately O
10 O
days O
of O
age O
. O

_RARE_ I-GENE
and O
clindamycin O
resistance O
in O
_RARE_ I-GENE
_RARE_ I-GENE
from O
skin O
lesions O
. O

_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
of O
monkey I-GENE
' O
s O
wrist O
produce O
three O
major I-GENE
peaks O
of O
activity O
( O
terms O
M1 I-GENE
, O
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
peaks O
) O
in O
the O
averaged O
gross O
EMG O
activity O
_RARE_ I-GENE
the O
_RARE_ I-GENE
muscles O
. O

_RARE_ I-GENE
disease O
of O
African O
newborn O
. O

In O
this O
animal O
, O
infected O
with O
what O
was O
judged O
previously O
to O
be O
the O
less O
virulent O
of O
the O
two O
T I-GENE
. O
_RARE_ I-GENE
_RARE_ I-GENE
used O
_RARE_ I-GENE
strain O
7 O
_RARE_ I-GENE
there O
was O
severe O
_RARE_ I-GENE
, O
with O
_RARE_ I-GENE
degeneration O
, O
and O
lesions O
of O
the O
_RARE_ I-GENE
. O

The O
majority O
of O
_RARE_ I-GENE
units O
were O
_RARE_ I-GENE
_RARE_ I-GENE
; O
in O
the O
most O
frequently O
observed O
case O
, O
their O
activity O
failed O
to O
change O
_RARE_ I-GENE
when O
behavior O
_RARE_ I-GENE
. O

_RARE_ I-GENE
within O
_RARE_ I-GENE
' O
s O
syndrome O
( O
_RARE_ I-GENE
- I-GENE
21 O
): O
_RARE_ I-GENE
observed O
sex I-GENE
differences O
in O
_RARE_ I-GENE
. O

VII I-GENE
. O

Several O
_RARE_ I-GENE
indices O
of O
isolated O
populations O
in O
_RARE_ I-GENE

2 I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
of O
higher O
nervous O
function O
in O
the O
_RARE_ I-GENE
. O

The O
maintenance O
of O
increased O
myocardial O
capillary O
density I-GENE
required O
a O
similar O
amount O
of O
exercise O
, O
and O
at O
least O
1 I-GENE
h O
of O
exercise O
once O
a O
week O
was O
necessary O
to O
maintain O
the O
enlargement O
of O
_RARE_ I-GENE
. O
20 O

These O
observations O
have O
led O
us O
to O
conclude O
that O
an O
elevated O
VIII I-GENE
- I-GENE
ratio O
is O
a O
very O
sensitive O
indicator O
of O
intravascular O
coagulation I-GENE
. O

Eight O
hours O
after O
the O
administration O
of O
_RARE_ I-GENE
, O
the O
serum I-GENE
_RARE_ I-GENE
level O
_RARE_ I-GENE
to O
rise O
again O
in O
female O
rats O
, O
but O
not O
in O
male O
rats O
. O

_RARE_ I-GENE
of O
_RARE_ I-GENE
, O
progesterone I-GENE
, O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
16 O
alpha I-GENE
- I-GENE
hydroxy I-GENE
- I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
and O
cortisol O
were O
performed O
on O
a O
total O
of O
0 O
; O
1 I-GENE
ml O
; O
of O
fetal O
plasma I-GENE
, O
collected O
during O
the O
course O
of O
normal O
vaginal O
delivery O
. O

In O
only O
two O
patients O
were O
we O
able O
to O
demonstrate O
changes O
suggestive O
of O
pulmonary O
metastases O
any O
earlier O
with O
a O
99mTc O
- I-GENE
_RARE_ I-GENE
scan O
than O
with O
chest O
radiographs O
and O
one O
of O
these O
resolved O
spontaneously O
. O

The O
majority O
of O
tumors O
occurred O
in O
the O
nasal O
_RARE_ I-GENE
, O
although O
significant O
_RARE_ I-GENE
were O
also O
found O
in O
the O
larynx O
, O
_RARE_ I-GENE
and O
stem O
_RARE_ I-GENE
. O

_RARE_ I-GENE
of O
the O
times O
of O
_RARE_ I-GENE
development O

_RARE_ I-GENE
human I-GENE
fibrinogen I-GENE
was O
_RARE_ I-GENE
to O
coagulation I-GENE
by O
adding O
thrombin I-GENE
. O

No O
post O
- I-GENE
operative O
_RARE_ I-GENE
from O
the O
_RARE_ I-GENE
were O
observed O
. O

The O
Southern O
technique O
allowed O
a O
further O
localization O
of O
the O
region O
of O
most O
extensive O
transcription I-GENE
to O
a O
1 I-GENE
. O
8 O
kb O
HindIII I-GENE
- I-GENE
EcoRI I-GENE
fragment I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
chosen O
limits O
of O
_RARE_ I-GENE
_RARE_ I-GENE
of O
+/- O
10 O
%, O
it O
could O
be O
shown O
that O
the O
system O
did O
not O
work O
_RARE_ I-GENE
when O
the O
mean O
carbon O
dioxide O
concentration O
was O
below O
1 I-GENE
. O
5 I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
within O
the O
fresh O
gas O
flow O
rates O
( O
2 I-GENE
. O
2 I-GENE
-- O
7 O
. O
7 O
1 I-GENE
min O
- I-GENE
1 I-GENE
) O
and O
the O
range O
of O
minute O
ventilation O
( O
4 I-GENE
-- O
10 O
1 I-GENE
min O
- I-GENE
1 I-GENE
) O
employed O
. O

SV O
increased O
less O
in O
_RARE_ I-GENE
, O
mainly O
reflecting O
the O
reduced O
diastolic O
compliance O
of O
the O
_RARE_ I-GENE
_RARE_ I-GENE
left O
ventricle O
and O
the O
_RARE_ I-GENE
_RARE_ I-GENE
shift O
of O
its O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
curve O
. O

The O
_RARE_ I-GENE
of O
a O
great O
_RARE_ I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
_RARE_ I-GENE
), O
which O
had O
been O
found O
_RARE_ I-GENE
in O
southern O
_RARE_ I-GENE
, O
was O
presented O
for O
_RARE_ I-GENE
. O

The O
inner O
ears O
were O
exposed O
by O
_RARE_ I-GENE
, O
and O
the O
vestibular O
sensory O
regions O
were O
either O
_RARE_ I-GENE
and O
studied O
with O
light I-GENE
or O
electron O
microscopy O
, O
or O
prepared O
and O
studied O
with O
the O
surface O
_RARE_ I-GENE
technique O
. O

_RARE_ I-GENE
is O
extracted O
from O
_RARE_ I-GENE
_RARE_ I-GENE
samples O
with O
ethyl O
acetate O
and O
the O
extract O
is O
_RARE_ I-GENE
up O
on O
a O
_RARE_ I-GENE
gel O
column O
, O
using O
_RARE_ I-GENE
- I-GENE
ethyl O
acetate O
( O
75 O
+ I-GENE
25 O
) O
as O
the O
_RARE_ I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
in O
amniotic I-GENE
fluid O
at O
term O
. O

The O
matrix I-GENE
surrounding O
the O
clusters O
either O
showed O
a O
normal O
morphology O
or O
a O
_RARE_ I-GENE
appearance O
, O
within O
which O
_RARE_ I-GENE
cross O
_RARE_ I-GENE
but O
no O
distinctly O
_RARE_ I-GENE
_RARE_ I-GENE
could O
be O
identified O
. O

_RARE_ I-GENE
did O
not O
affect O
the O
percentage O
of O
_RARE_ I-GENE
- I-GENE
treated O
animals O
with O
abnormal O
urinary O
excretion O
patterns O
, O
but O
did O
increase O
the O
magnitude O
of O
the O
disturbances O
in O
elimination O
of O
_RARE_ I-GENE
and O
_RARE_ I-GENE
acids O
. O

_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
absorption O
and O
the O
role O
of O
cellular O
enzymes O
. O

The O
incidence O
of O
_RARE_ I-GENE
reactions O
was O
78 O
per O
cent O
for O
Stage O
I I-GENE
and O
II I-GENE
cancers O
( O
37 O
_RARE_ I-GENE
), O
73 O
per O
cent O
for O
_RARE_ I-GENE
Stage O
III I-GENE
cancer O
( O
22 O
patients O
), O
and O
66 O
per O
cent O
in O
patients O
with O
_RARE_ I-GENE
or O
_RARE_ I-GENE
Stage O
III I-GENE
cancer O
. O

Studies O
of O
lipoproteins I-GENE
should O
, O
however O
, O
be O
made O
in O
children O
from O
families O
known O
to O
have O
_RARE_ I-GENE
or O
early I-GENE
coronary O
heart O
disease O
. O

_RARE_ I-GENE
other O
normal O
subjects O
with O
2 I-GENE
g O
of O
_RARE_ I-GENE
are O
best O
responses O
. O

EEG O
_RARE_ I-GENE
waves O
and O
psychological O
phenomena O
: O
a O
review O
and O
analysis O
. O

REM O
_RARE_ I-GENE
content O
was O
_RARE_ I-GENE
for O
categories O
suggesting O
the O
predominant O
influence O
of O
the O
left O
hemisphere O
, O
e O
. O
g O
., O
good O
_RARE_ I-GENE
functioning O
, O
_RARE_ I-GENE
, O
or O
the O
right O
hemisphere O
, O
e O
. O
g O
., O
_RARE_ I-GENE
, O
spatial O
_RARE_ I-GENE
, O
_RARE_ I-GENE
. O

_RARE_ I-GENE
of O
the O
ventral O
diaphragm O
of O
the O
_RARE_ I-GENE
( O
_RARE_ I-GENE
_RARE_ I-GENE
). O

_RARE_ I-GENE
ACTH I-GENE
syndrome O
and O
_RARE_ I-GENE
thyroid I-GENE
carcinoma O
. O

A I-GENE
striking O
finding O
in O
all O
of O
the O
studies O
was O
a O
positive O
correlation O
between O
PI I-GENE
ACTH I-GENE
and O
MSH I-GENE
contents O
. O

Chronic O
_RARE_ I-GENE
is O
the O
most O
common O
type I-GENE
of O
" O
resistant O
" O
_RARE_ I-GENE
. O

There O
was O
no O
correlation O
between O
serum I-GENE
LH I-GENE
and O
_RARE_ I-GENE
or O
bone O
age O
in O
this O
age O
group O
, O
which O
suggests O
that O
the O
correlation O
found O
is O
not O
due O
to O
age O
- I-GENE
related I-GENE
parallel O
phenomena O
. O

Molecular O
_RARE_ I-GENE
of O
_RARE_ I-GENE
drugs O
. O

_RARE_ I-GENE
were O
made O
to O
determine O
the O
amount O
of O
time O
required O
for O
kidney O
lesions O
to O
develop O
and O
, O
if O
possible O
, O
to O
_RARE_ I-GENE
the O
potential O
site I-GENE
of O
action O
of O
_RARE_ I-GENE
. O

Effect O
of O
_RARE_ I-GENE
on O
the O
intensity O
of O
_RARE_ I-GENE
acid I-GENE
dehydrogenase I-GENE
reactions O
in O
the O
brain O
of O
rats O
_RARE_ I-GENE
with O
_RARE_ I-GENE
chloride O

_RARE_ I-GENE
and O
correlations O
of O
serum I-GENE
uric O
- I-GENE
acid I-GENE
in O
two O
_RARE_ I-GENE
adult O
populations O
: O
13 O
, O
_RARE_ I-GENE
men O
and O
6 I-GENE
, O
_RARE_ I-GENE
women O

The O
incidence O
of O
hepatitis I-GENE
B I-GENE
antigen I-GENE
following O
transfusion O
was O
about O
2 I-GENE
. O
8 O
per O
cent O
. O

_RARE_ I-GENE
- I-GENE
99m O
_RARE_ I-GENE
_RARE_ I-GENE
myocardial O
_RARE_ I-GENE
were O
obtained O
in O
_RARE_ I-GENE
clinically O
stable O
patients O
32 O
. O
7 O
+/- O
47 O
. O
3 I-GENE
weeks O
( O
range O
6 I-GENE
to O
260 O
) O
after O
acute O
myocardial O
infarction O
. O

A I-GENE
similar O
phenomenon O
has O
been O
reported O
in O
a O
few O
humans O
. O

The O
decline O
in O
the O
activity O
of O
cytochrome I-GENE
oxidase I-GENE
, O
peroxidase I-GENE
and O
in O
the O
lipid O
content O
of O
peripheral O
neutrophils O
was O
followed O
by O
a O
decrease O
in O
the O
phagocytic O
activity O
. O

Treatment O
of O
2 I-GENE
patients O
with O
_RARE_ I-GENE
type I-GENE
I I-GENE
with O
vitamin O
- I-GENE
D I-GENE
- I-GENE
3 I-GENE
and O
1 I-GENE
alpha I-GENE
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
resulted O
in O
a O
_RARE_ I-GENE
response O
with O
regard O
to O
the O
_RARE_ I-GENE
of O
serum I-GENE
- I-GENE
calcium O
. O

_RARE_ I-GENE
with O
" O
sensitivity O
" O
to O
toluene O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
studied O
in O
depth O
in O
an O
attempt O
to O
determine O
mechanisms O
of O
bronchial O
_RARE_ I-GENE
. O

Total O
VO2 O
was O
decreased O
in O
both O
groups O
during O
severe O
hypoxia O
but O
limb O
VO2 O
was O
maintained O
in O
the O
beta I-GENE
- I-GENE
block O
group O
. O
beta I-GENE
- I-GENE
_RARE_ I-GENE
prevented O
the O
fall O
in O
total O
and O
limb O
peripheral O
resistance O
seen O
in O
severe O
hypoxia O
but O
did O
not O
alter O
the O
consistently O
more O
efficient O
utilization O
of O
total O
O2 O
delivery O
shown O
by O
the O
limb O
in O
comparison O
to O
the O
whole O
body O
by O
higher O
O2 O
extraction O
ratios O
and O
lower O
venous O
O2 O
pressure O
. O
beta I-GENE
- I-GENE
_RARE_ I-GENE
receptors I-GENE
_RARE_ I-GENE
played O
an O
active O
part O
in O
the O
_RARE_ I-GENE
seen O
during O
severe O
hypoxia O
. O

_RARE_ I-GENE
- I-GENE
induced O
alterations O
in O
the O
metabolism O
of O
[ O
3H O
] O
vitamin O
D3 I-GENE
by O
the O
perfused O
_RARE_ I-GENE
rat I-GENE
liver O
in O
vitro O
. O

_RARE_ I-GENE
of O
25 O
- I-GENE
_RARE_ I-GENE
D3 I-GENE
- I-GENE
24 O
- I-GENE
hydroxylase I-GENE
by O
_RARE_ I-GENE
: O
a O
cytochrome I-GENE
P I-GENE
- I-GENE
450 I-GENE
_RARE_ I-GENE
system O
. O

In O
both O
these O
_RARE_ I-GENE
, O
however O
, O
the O
DBP I-GENE
mRNA I-GENE
resembles O
the O
late O
_RARE_ I-GENE
of O
SV40 I-GENE
and O
_RARE_ I-GENE
viruses O
. O

Effect O
of O
corticosteroid I-GENE
- I-GENE
containing O
_RARE_ I-GENE
combination O
drugs O
on O
endogenous I-GENE
ACTH I-GENE
and O
cortisol O
production O
. O

Serum I-GENE
ACTH I-GENE
did O
not O
respond O
to O
insulin I-GENE
and O
_RARE_ I-GENE
. O

_RARE_ I-GENE
of O
the O
RNA I-GENE
and O
gene I-GENE
products I-GENE
of O
_RARE_ I-GENE
and O
_RARE_ I-GENE
, O
two O
defective O
avian I-GENE
tumor I-GENE
viruses O
causing O
acute O
leukemia I-GENE
and O
carcinoma O
: O
evidence O
for O
a O
new O
class I-GENE
of O
transforming I-GENE
genes I-GENE
. O

_RARE_ I-GENE
( O
_RARE_ I-GENE
group O
) O
and O
_RARE_ I-GENE
( O
_RARE_ I-GENE
group O
), O
two O
new O
_RARE_ I-GENE
isolated O
in O
_RARE_ I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
. O

_RARE_ I-GENE
glutamyl I-GENE
_RARE_ I-GENE
activity O
was O
increased O
up O
to O
15 O
times O
above O
the O
upper O
normal O
limit O
in O
children O
, O
who O
received O
_RARE_ I-GENE
for O
two O
weeks O
or O
longer O
. O

_RARE_ I-GENE
. O

A I-GENE
gas O
- I-GENE
liquid O
chromatographic O
method O
for O
the O
determination O
of O
p O
- I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
acid I-GENE
in O
blood O
plasma I-GENE
is O
described O
. O

Dopamine I-GENE
receptor I-GENE
blockade O
and O
the O
_RARE_ I-GENE
, O
a O
_RARE_ I-GENE
study O
. O

V I-GENE
. O

A I-GENE
rapid O
_RARE_ I-GENE
procedure O
for O
the O
determination O
of O
the O
_RARE_ I-GENE
5 I-GENE
- I-GENE
_RARE_ I-GENE
in O
serum I-GENE
is O
described O
. O

The O
' O
field O
of O
stress O
' O
of O
the O
_RARE_ I-GENE
nurse O

_RARE_ I-GENE
do O
_RARE_ I-GENE
of O
different O
types O
of O
programs O
perform O
on O
state O
_RARE_ I-GENE
? O

Similarly O
, O
maternal I-GENE
serum I-GENE
_RARE_ I-GENE
A I-GENE
was O
significantly O
reduced O
in O
rats O
nursing O
large O
_RARE_ I-GENE
. O

The O
sequences I-GENE
following O
the O
X I-GENE
. O
_RARE_ I-GENE
oocyte O
and O
somatic O
5S I-GENE
genes I-GENE
are O
identical O
in O
12 O
of O
the O
first O
14 O
residues O
and O
contain O
two O
or O
more O
T I-GENE
clusters O
, O
as O
does O
the O
corresponding O
region O
of O
X I-GENE
. O
laevis I-GENE
oocyte O
5S I-GENE
DNA I-GENE
. O

This O
mechanism O
is O
not O
due O
to O
the O
observed O
_RARE_ I-GENE
boundary O
_RARE_ I-GENE
. O

This O
report O
has O
reviewed O
some O
of O
the O
_RARE_ I-GENE
for O
treatment O
_RARE_ I-GENE
and O
has O
presented O
a O
_RARE_ I-GENE
for O
their O
management O
. O

Diagnosis O
and O
treatment O
planning O
in O
Class I-GENE
II I-GENE
, O
division O
2 I-GENE

Because O
of O
serious O
infections O
( O
fever O
larger O
than O
or O
equal O
to O
101 I-GENE
degrees O
F I-GENE
. O
_RARE_ I-GENE
less O
than O
1 I-GENE
, O
000 O
/ I-GENE
mm O
, O
3 I-GENE
and O
_RARE_ I-GENE
) O
and O
1 I-GENE
drug O
death O
in O
the O
first O
4 I-GENE
patients O
, O
oral O
calcium O
_RARE_ I-GENE
, O
20 O
to O
30 O
mg O
/ I-GENE
m2 O
orally O
, O
was O
given O
2 I-GENE
days O
after O
methotrexate O
in O
subsequent O
treatment O
cycles O
. O

It O
seems O
that O
the O
way O
in O
which O
drugs O
modify O
a O
patient O
' O
s O
serum I-GENE
chemistry O
may O
be O
used O
to O
assess O
the O
efficacy O
with O
which O
they O
control O
the O
inflammatory O
process O
. O

Here O
the O
conventional O
tests O
clearly O
_RARE_ I-GENE
to O
the O
presence O
of O
_RARE_ I-GENE
disease O
. O

The O
end O
- I-GENE
stage O
or O
_RARE_ I-GENE
phase O
of O
proliferative O
diabetic O
_RARE_ I-GENE
may O
result O
in O
stabilization O
of O
vision O
for O
long O
periods O
of O
time O
. O

On O
the O
basis O
of O
serum I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
, O
newborn O
infants O
may O
be O
separated O
into O
two O
groups O
, O
characterized O
respectively O
by O
concentrations O
above O
or O
below O
150 O
mg O
%. O

In O
patients O
who O
were O
not O
_RARE_ I-GENE
, O
there O
was O
overall O
significant O
depression O
of O
function O
( O
67 O
+/- O
5 I-GENE
% O
of O
control O
; O
range O
, O
91 O
-- O
45 O
%, O
p O
less O
than O
0 O
. O
01 O
). O

Changes O
in O
body O
weight O
and O
_RARE_ I-GENE
behavior O
were O
also O
recorded O
. O

The O
uterine O
response O
to O
prostaglandin I-GENE
E2 I-GENE
( O
PGE2 O
) O
and O
prostaglandin I-GENE
_RARE_ I-GENE
( O
administered O
by O
intravenous O
and O
intrauterine O
routes O
) O
was O
evaluated O
during O
different O
phases O
of O
the O
menstrual O
cycle O
in O
five O
functionally O
_RARE_ I-GENE
women O
. O

A I-GENE
total O
of O
26 O
BCG O
strains O
, O
out O
of O
them O
10 O
_RARE_ I-GENE
strains O
( O
2 I-GENE
_RARE_ I-GENE
cultures O
of O
BCG O
of O
different O
_RARE_ I-GENE
, O
6 I-GENE
strains O
isolated O
from O
_RARE_ I-GENE
of O
children O
after O
BCG O
- I-GENE
vaccination O
and O
2 I-GENE
strains O
from O
fatal O
cases O
after O
BCG O
- I-GENE
vaccination O
) O
and O
16 O
strains O
obtained O
from O
foreign O
laboratories O
, O
were O
used O
. O

High O
levels O
of O
serum I-GENE
calcitonin I-GENE
were O
found O
in O
patients O
with O
chronic O
renal O
failure O
. O

Detection O
of O
anti I-GENE
- I-GENE
lymphocyte I-GENE
antibodies I-GENE
using O
the O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
. O

The O
response O
of O
serum I-GENE
GH I-GENE
to O
arginine I-GENE
infusion O
was O
normal O
, O
while O
that O
to O
insulin I-GENE
- I-GENE
induced O
_RARE_ I-GENE
was O
poor O
. O

The O
mortality O
rate O
and O
histopathological O
features O
of O
_RARE_ I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
infections O
in O
_RARE_ I-GENE
_RARE_ I-GENE
( O
nude O
) O
mice O
of O
_RARE_ I-GENE
and O
C3H O
/ I-GENE
_RARE_ I-GENE
origins O
were O
quite O
different O
from O
what O
we O
found O
for O
_RARE_ I-GENE
white O
mice O
and O
other O
_RARE_ I-GENE
mouse I-GENE
strains O
( O
namely O
, O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
, O
New O
_RARE_ I-GENE
_RARE_ I-GENE
, O
BALB O
/ I-GENE
c I-GENE
, O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
, O
and O
C3H O
/ I-GENE
_RARE_ I-GENE
). O

_RARE_ I-GENE
, O
2 I-GENE
August O
_RARE_ I-GENE
. O

Use O
of O
_RARE_ I-GENE
_RARE_ I-GENE
in O
the O
chemistry O
of O
proteins I-GENE

( O
_RARE_ I-GENE
) O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE

_RARE_ I-GENE
vaccines O
and O
whole O
- I-GENE
virus I-GENE
vaccines O
containing O
type I-GENE
B I-GENE
antigen I-GENE
only O
did O
not O
cause O
significant O
reactivity O
. O

_RARE_ I-GENE
- I-GENE
61 O
. O

_RARE_ I-GENE
diagnosis O
of O
_RARE_ I-GENE
disorders O
_RARE_ I-GENE
_RARE_ I-GENE
'. O

_RARE_ I-GENE
oxygen O
supply O
and O
selected O
blood O
parameters O
were O
recorded O
in O
fasted O
male O
rates O
given O
20 O
-- O
30 O
mg O
/ I-GENE
kg O
Escherichia I-GENE
coli I-GENE
endotoxin I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
dysfunction O
in O
patients O
with O
_RARE_ I-GENE
_RARE_ I-GENE
. O

The O
maximum O
period O
of O
treatment O
was O
73 O
( O
oral O
), O
73 O
( O
_RARE_ I-GENE
) O
or O
75 O
( O
dermal O
) O
weeks O
. O

A I-GENE
study O
of O
the O
comparative O
efficacy O
of O
_RARE_ I-GENE
_RARE_ I-GENE
0 O
. O
3 I-GENE
% O
_RARE_ I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
0 O
. O
05 O
% O
_RARE_ I-GENE
. O

Most O
of O
the O
phenomena O
of O
_RARE_ I-GENE
_RARE_ I-GENE
are O
_RARE_ I-GENE
in O
simple O
vitamin O
D I-GENE
deficiency O
; O
as O
in O
that O
condition O
, O
deficiency O
of O
1 I-GENE
, O
25 O
- I-GENE
_RARE_ I-GENE
may O
be O
of O
primary O
significance O
in O
causing O
secondary O
_RARE_ I-GENE
in O
renal O
failure O
. O

Basal O
FSH I-GENE
and O
LH I-GENE
levels O
were O
significantly O
lower O
in O
addicts O
; O
after O
GnRH I-GENE
stimulation O
the O
addicts O
' O
FSH I-GENE
and O
LH I-GENE
values O
increased O
but O
not O
significantly O
compared O
to O
controls O
. O

_RARE_ I-GENE
: O
comparison O
of O
a O
5 I-GENE
- I-GENE
week O
schedule O
with O
a O
3 I-GENE
- I-GENE
week O
schedule O
in O
the O
treatment O
of O
breast O
cancer O
. O

_RARE_ I-GENE
- I-GENE
up O
controls O
of O
_RARE_ I-GENE
hormone I-GENE
( O
LH I-GENE
), O
follicle I-GENE
stimulating I-GENE
hormone I-GENE
( O
FSH I-GENE
), O
prolactin I-GENE
( O
_RARE_ I-GENE
), O
oestradiol O
( O
E2 I-GENE
), O
progesterone I-GENE
( O
P I-GENE
) O
and O
testosterone O
( O
T I-GENE
) O
in O
the O
_RARE_ I-GENE
and O
healing O
phase O
of O
burn O
disease O
. O

_RARE_ I-GENE
studies O
performed O
in O
34 O
hypertensive O
patients O
and O
in O
a O
control O
group O
of O
11 O
recipients O
showed O
that O
elevation O
of O
plasma I-GENE
renin I-GENE
activity O
and O
of O
plasma I-GENE
aldosterone O
level O
is O
frequent O
but O
difficult O
to O
_RARE_ I-GENE
, O
particularly O
when O
a O
renal O
artery O
stenosis O
is O
observed O
. O

A I-GENE
randomized O
clinical O
trial O
in O
_RARE_ I-GENE
- I-GENE
two O
adult O
patients O
suffering O
from O
_RARE_ I-GENE
fever O
, O
proved O
by O
blood O
and O
marrow O
culture O
, O
showed O
that O
_RARE_ I-GENE
in O
a O
dosage O
schedule O
of O
1 I-GENE
g O
8 O
- I-GENE
_RARE_ I-GENE
orally O
for O
_RARE_ I-GENE
days O
was O
better O
than O
chloramphenicol I-GENE
with O
regard O
to O
clinical O
and O
temperature O
response O
and O
in O
respect O
of O
carriers O
and O
relapse O
rates O
. O

_RARE_ I-GENE
- I-GENE
8 O
. O

_RARE_ I-GENE
marrow O
transplantation O
- I-GENE
_RARE_ I-GENE
. O

In O
this O
article O
, O
the O
clinical O
actions O
of O
the O
principal O
dopamine I-GENE
receptor I-GENE
stimulating I-GENE
agents O
( O
_RARE_ I-GENE
and O
its O
derivatives O
; O
_RARE_ I-GENE
, O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
derivatives O
) O
are O
discussed O
on O
the O
basis O
of O
their O
biochemical O
and O
pharmacological O
properties O
. O

The O
unilateral O
vestibular O
_RARE_ I-GENE
. O

Thus O
, O
the O
inhibition O
of O
_RARE_ I-GENE
in O
human I-GENE
gastric O
juice O
does O
not O
appear O
to O
have O
a O
major I-GENE
influence O
on O
the O
healing O
of O
duodenal O
ulcer O
. O

The O
_RARE_ I-GENE
standard O
method O
for O
the O
detection O
of O
penicillin I-GENE
in O
milk O
is O
not O
suitable O
for O
the O
detection O
of O
_RARE_ I-GENE
residues O
in O
milk O
. O

_RARE_ I-GENE
antigens I-GENE
of O
Staphylococcus I-GENE
aureus I-GENE

The O
course O
of O
endotoxin I-GENE
fever O
remained O
_RARE_ I-GENE
by O
_RARE_ I-GENE
. O

2 I-GENE
new O
_RARE_ I-GENE
cases O

Seventy O
- I-GENE
one O
percent O
of O
patients O
treated O
with O
_RARE_ I-GENE
alone O
responded O
_RARE_ I-GENE
. O

_RARE_ I-GENE
pathologic O
_RARE_ I-GENE
identifies O
patients O
who O
are O
potentially O
_RARE_ I-GENE
with O
radiotherapy O
. O

_RARE_ I-GENE
_RARE_ I-GENE
of O
old O
age O

_RARE_ I-GENE
is O
_RARE_ I-GENE
effective O
against O
_RARE_ I-GENE
, O
less O
effective O
against O
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
effective O
against O
gram O
- I-GENE
negative O
intestinal O
organisms O
. O

It O
was O
concluded O
, O
that O
on O
a O
given O
section O
, O
75 O
, O
7 O
per O
cent O
of O
the O
_RARE_ I-GENE
were O
in O
contact O
with O
vascular I-GENE
_RARE_ I-GENE
. O

2 I-GENE
. O

Changes O
in O
tissue I-GENE
PCO2 O
were O
less O
dramatic O
and O
did O
not O
vary O
significantly O
from O
those O
recorded O
in O
venous O
blood O
. O

_RARE_ I-GENE
evaluation O
of O
renal O
_RARE_ I-GENE
. O

_RARE_ I-GENE
of O
emphysema O
was O
poor O
when O
radiographs O
of O
_RARE_ I-GENE
quality O
were O
included O
( O
anteroposterior O
films O
or O
films O
from O
patients O
with O
acute O
or O
chronic O
lung O
disease O
). O

Isolation O
of O
T I-GENE
. O
_RARE_ I-GENE
strains O
in O
_RARE_ I-GENE
and O
their O
adaptation O
to O
laboratory O
animals O

_RARE_ I-GENE
profile O
of O
_RARE_ I-GENE
in O
rhesus I-GENE
monkeys O
. O

_RARE_ I-GENE
mechanisms O
in O
chronic O
_RARE_ I-GENE
in O
humans O
. O

_RARE_ I-GENE
adaptation O
( O
first O
of O
two O
parts O
). O

In O
patients O
who O
had O
received O
no O
previous O
drug O
treatment O
, O
log O
baseline O
plasma I-GENE
renin I-GENE
activity O
and O
change O
in O
mean O
blood O
pressure O
after O
_RARE_ I-GENE
_RARE_ I-GENE
correlated O
significantly O
( O
r O
= O
0 O
. O
_RARE_ I-GENE
, O
P I-GENE
less O
than O
0 O
. O
05 O
). O

These O
techniques O
have O
been O
used O
by O
many O
people O
for O
many O
years O
and O
no O
_RARE_ I-GENE
is O
being O
made O
for O
any O
_RARE_ I-GENE
in O
this O
regard O
. O

40 I-GENE
patients O
with O
chronic O
_RARE_ I-GENE
were O
treated O
per O
_RARE_ I-GENE
with O
the O
bactericidal O
beta I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
antibiotic O
_RARE_ I-GENE
during O
3 I-GENE
to O
60 O
weeks O
. O

A I-GENE
total O
of O
57 O
patients O
with O
Hodgkin O
' O
s O
disease O
limited O
to O
above O
the O
diaphragm O
( O
_RARE_ I-GENE
I I-GENE
and O
II I-GENE
, O
A I-GENE
and O
B I-GENE
) O
were O
treated O
with O
radiation O
therapy O
alone O
at O
the O
University O
of O
_RARE_ I-GENE
between O
_RARE_ I-GENE
and O
_RARE_ I-GENE
. O

_RARE_ I-GENE
one O
of O
the O
first O
general O
_RARE_ I-GENE
medical O
unit I-GENE
in O
the O
greater O
_RARE_ I-GENE
area O
. O

This O
multiple O
- I-GENE
electrode O
_RARE_ I-GENE
for O
round O
_RARE_ I-GENE
cochlear O
implantation O
is O
a O
_RARE_ I-GENE
, O
reliable O
system O
for O
inserting O
20 O
mm O
along O
the O
_RARE_ I-GENE
_RARE_ I-GENE
with O
a O
minimum O
of O
trauma O
and O
can O
provide O
for O
bipolar O
stimulation O
. O

As O
_RARE_ I-GENE
by O
the O
_RARE_ I-GENE
Health O
Organization O
_RARE_ I-GENE
_RARE_ I-GENE
Committee O
on O
Biological O
_RARE_ I-GENE
, O
the O
preparation O
of O
human I-GENE
prolactin I-GENE
in O
_RARE_ I-GENE
coded O
75 O
/ I-GENE
_RARE_ I-GENE
has O
been O
established O
as O
the O
International O
_RARE_ I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
of O
human I-GENE
prolactin I-GENE
for O
immunoassay O
. O

i O
. O

_RARE_ I-GENE
- I-GENE
enteric O
_RARE_ I-GENE

Plasma I-GENE
ion O
changes O
in O
venous O
blood O
incubated O
with O
beta I-GENE
receptor I-GENE
blockers O
and O
subjected O
to O
_RARE_ I-GENE
in O
vitro O
. O

Such O
marked O
differences O
are O
found O
_RARE_ I-GENE
in O
the O
literature O
: O
_RARE_ I-GENE
antibodies I-GENE
against O
bovine I-GENE
_RARE_ I-GENE
are O
regarded O
as O
responsible O
for O
the O
interference O
in O
the O
_RARE_ I-GENE
system O
of O
_RARE_ I-GENE
. O

" O
_RARE_ I-GENE
the O
hundred O
_RARE_ I-GENE
_RARE_ I-GENE
". O

Various O
treatment O
modalities O
are O
reviewed O
in O
the O
context O
of O
the O
_RARE_ I-GENE
as O
well O
as O
the O
physiology O
of O
severe O
_RARE_ I-GENE
pain O
. O

_RARE_ I-GENE
_RARE_ I-GENE
( O
4 I-GENE
-( O
3 I-GENE
'- O
_RARE_ I-GENE
- I-GENE
2 I-GENE
'- O
_RARE_ I-GENE
)- I-GENE
_RARE_ I-GENE
) O
poisoning O
in O
childhood O

_RARE_ I-GENE
evaluation O
of O
blood O
flow O
velocity O
in O
_RARE_ I-GENE
_RARE_ I-GENE

Serum I-GENE
ferritin I-GENE
concentration O
and O
bone O
marrow O
iron O
_RARE_ I-GENE
. O

The O
systolic O
pressure O
gradient O
( O
_RARE_ I-GENE
) O
between O
the O
left O
ventricle O
( O
LV O
) O
and O
left O
atrium O
( O
LA O
) O
was O
obtained O
from O
high O
- I-GENE
fidelity I-GENE
pressure O
_RARE_ I-GENE
. O

A I-GENE
prospective O
_RARE_ I-GENE
comparing O
hysterectomy O
, O
hysterectomy O
plus O
vaginal O
_RARE_ I-GENE
, O
and O
uterine O
_RARE_ I-GENE
plus O
hysterectomy O
in O
stage O
I I-GENE
endometrial O
carcinoma O
. O

On O
the O
basis O
of O
a O
patient O
' O
s O
report O
of O
one O
_RARE_ I-GENE
_RARE_ I-GENE
, O
we O
_RARE_ I-GENE
to O
investigate O
the O
accuracy O
of O
this O
_RARE_ I-GENE
. O

_RARE_ I-GENE
in O
_RARE_ I-GENE
' O
s O
syndrome O

Data O
were O
processed O
with O
a O
_RARE_ I-GENE
- I-GENE
automatic O
computer O
program O
which O
_RARE_ I-GENE
an O
averaged O
- I-GENE
volume O
curve O
from O
an O
assigned O
LV O
region O
- I-GENE
of O
- I-GENE
interest O
. O

The O
preferential O
serum I-GENE
IgA I-GENE
response O
observed O
in O
the O
patient O
population O
suggests O
that O
bronchial O
associated I-GENE
lymphoid I-GENE
tissue I-GENE
in O
the O
diseased O
lung O
is O
an O
important O
source O
of O
circulating O
IgA I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
seem O
to O
be O
reached O
for O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
, O
whereas O
_RARE_ I-GENE
_RARE_ I-GENE
, O
such O
as O
_RARE_ I-GENE
6 I-GENE
V I-GENE
, O
present O
very O
high O
_RARE_ I-GENE
limit O
under O
_RARE_ I-GENE
. O

The O
effects O
of O
_RARE_ I-GENE
injection O
( O
i O
. O
c I-GENE
. O
i O
.) O
of O
_RARE_ I-GENE
( O
1 I-GENE
microgram O
kg O
- I-GENE
1 I-GENE
) O
on O
blood O
pressure O
and O
heart O
rate O
were O
studied O
in O
conscious O
rabbits O
with O
an O
implanted O
catheter O
in O
the O
_RARE_ I-GENE
_RARE_ I-GENE
. O

Platelet I-GENE
number O
and O
life O
span O
were O
determined O
in O
the O
last O
_RARE_ I-GENE
of O
pregnancy O
in O
22 O
women O
who O
were O
delivered O
of O
small I-GENE
- I-GENE
for O
- I-GENE
gestational O
age O
( O
_RARE_ I-GENE
) O
infants O
and O
in O
21 O
women O
with O
infants O
having O
normal O
birth O
weights O
. O

_RARE_ I-GENE
measurements O
of O
total O
serum I-GENE
IgE I-GENE
appears O
to O
be O
a O
useful O
index O
of O
disease O
activity O
in O
_RARE_ I-GENE
. O

In O
the O
8 O
patients O
the O
difference O
_RARE_ I-GENE
_RARE_ I-GENE
mean O
diastolic O
values O
of O
delta I-GENE
PU I-GENE
and O
delta I-GENE
_RARE_ I-GENE
was O
- I-GENE
0 O
. O
54 I-GENE
+/- O
1 I-GENE
. O
0 O
( O
SD O
) O
mmHg O
. O

A I-GENE
rise O
of O
hemoglobin I-GENE
concentration O
accompanied O
by O
an O
increase O
of O
the O
total O
iron O
in O
the O
blood O
serum I-GENE
of O
white O
mice O
was O
found O
under O
oxygen O
pressure O
of O
4 I-GENE
_RARE_ I-GENE
for O
an O
hour O
( O
_RARE_ I-GENE
state O
) O
and O
6 I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
state O
). O

_RARE_ I-GENE
-- O
_RARE_ I-GENE
analog O
_RARE_ I-GENE
and O
stationary O
state O
membrane I-GENE
_RARE_ I-GENE
potentials O
. O

Effects O
of O
methylene O
chloride O
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
and O
toluene O
on O
the O
development O
of O
chick I-GENE
embryos O
. O

Effect O
of O
_RARE_ I-GENE
administration O
of O
_RARE_ I-GENE
O O
on O
the O
_RARE_ I-GENE
of O
rabbits O
. O

In O
this O
_RARE_ I-GENE
the O
_RARE_ I-GENE
threshold O
for O
the O
8 O
substances O
is O
as O
follows O
: O
_RARE_ I-GENE
20 O
mg O
. O
kg O
- I-GENE
1 I-GENE
I I-GENE
. O
V I-GENE
., O
_RARE_ I-GENE
30 O
, O
morphine O
180 O
, O
_RARE_ I-GENE
4 I-GENE
, O
R I-GENE
39 O
_RARE_ I-GENE
5 I-GENE
, O
fentanyl O
4 I-GENE
, O
_RARE_ I-GENE
4 I-GENE
and O
R I-GENE
34 O
_RARE_ I-GENE
10 O
mg O
. O
kg O
- I-GENE
1 I-GENE
I I-GENE
. O
V I-GENE
. O

The O
_RARE_ I-GENE
of O
amniotic I-GENE
fluid O
with O
poor O
fetal O
growth I-GENE
. O

_RARE_ I-GENE
, O
the O
lesion O
was O
usually O
a O
well O
- I-GENE
defined O
and O
benign O
_RARE_ I-GENE
one O
, O
either O
_RARE_ I-GENE
lytic O
( O
3 I-GENE
cases O
) O
or O
with O
central O
_RARE_ I-GENE
( O
2 I-GENE
cases O
). O

Effects O
of O
chronic O
_RARE_ I-GENE
_RARE_ I-GENE
on O
the O
response O
patterns O
of O
neurons O
in O
the O
_RARE_ I-GENE
nuclei O
_RARE_ I-GENE
and O
_RARE_ I-GENE
. O

_RARE_ I-GENE
of O
a O
three O
- I-GENE
versus O
a O
five O
- I-GENE
week O
alcohol O
treatment O
program O
. O

Resistance O
to O
the O
simulated O
_RARE_ I-GENE
environment O
was O
tested O
by O
measured O
retention O
of O
mechanical O
properties O
after O
immersion O
times O
in O
_RARE_ I-GENE
- I-GENE
extracellular I-GENE
fluid O
( O
_RARE_ I-GENE
) O
at O
37 O
degrees O
C I-GENE
for O
as O
long O
as O
three O
years O
. O

_RARE_ I-GENE
_RARE_ I-GENE
tuberculous O
_RARE_ I-GENE
. O

It O
is O
concluded O
that O
opiate I-GENE
receptors I-GENE
_RARE_ I-GENE
the O
fourth O
cerebral O
ventricle O
mediate O
the O
cardiovascular O
and O
_RARE_ I-GENE
action O
of O
fentanyl O
. O

In O
case O
of O
a O
_RARE_ I-GENE
_RARE_ I-GENE
internal O
carotid O
the O
common O
carotid O
artery O
was O
_RARE_ I-GENE
with O
an O
end O
- I-GENE
to O
- I-GENE
end O
anastomosis O
. O

This O
expression O
_RARE_ I-GENE
: O
( O
1 I-GENE
) O
a O
_RARE_ I-GENE
flow O
regimen O
during O
_RARE_ I-GENE
, O
and O
( O
2 I-GENE
) O
a O
constant O
CT I-GENE
value O
over O
the O
range O
of O
VT O
. O

These O
data O
confirm O
the O
existence O
of O
_RARE_ I-GENE
abdominal O
_RARE_ I-GENE
as O
a O
distinct O
_RARE_ I-GENE
and O
_RARE_ I-GENE
to O
the O
importance O
of O
_RARE_ I-GENE
this O
syndrome O
in O
order O
to O
avoid O
the O
occurrence O
of O
acute O
pancreatitis O
and O
the O
performance O
of O
_RARE_ I-GENE
and O
potentially O
_RARE_ I-GENE
surgery O
. O

In O
addition O
a O
significant O
Treatment O
X I-GENE
_RARE_ I-GENE
interaction O
was O
due O
to O
the O
larger O
_RARE_ I-GENE
numbers O
displayed O
by O
the O
_RARE_ I-GENE
- I-GENE
injected O
MR O
rats O
relative O
to O
the O
saline O
- I-GENE
injected O
MR O
rats O
. O

Their O
conduction O
velocity O
ranged O
from O
0 O
. O
23 O
to O
0 O
. O
98 O
m I-GENE
/ I-GENE
sec O
( O
group O
C I-GENE
). O

The O
_RARE_ I-GENE
frequently O
were O
related I-GENE
to O
patient O
_RARE_ I-GENE
or O
poor O
mechanical O
fit O
and O
occurred O
in O
the O
first O
few O
days O
or O
first O
few O
months O
after O
insertion O
. O

The O
major I-GENE
urinary O
metabolites O
were O
3 I-GENE
-( O
3 I-GENE
- I-GENE
_RARE_ I-GENE
)- I-GENE
5 I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
2 I-GENE
- I-GENE
_RARE_ I-GENE
and O
a O
_RARE_ I-GENE
of O
_RARE_ I-GENE
. O

These O
characteristics O
indicated O
the O
pronounced O
activity O
of O
_RARE_ I-GENE
fiber O
synthesis O
and O
the O
matrix I-GENE
of O
the O
_RARE_ I-GENE
tissue I-GENE
. O

The O
ventilation O
did O
not O
increase O
when O
_RARE_ I-GENE
was O
increased O
. O

_RARE_ I-GENE
metabolism O
and O
the O
semen O
profile O
: O
glucose O
, O
insulin I-GENE
, O
and O
sperm O
studies O
. O

It O
has O
_RARE_ I-GENE
out O
that O
_RARE_ I-GENE
is O
between O
CC O
and O
_RARE_ I-GENE
and O
that O
attacks O
of O
biliary O
fever O
and O
high O
levels O
of O
alkaline I-GENE
phosphatase I-GENE
and O
_RARE_ I-GENE
in O
the O
serum I-GENE
are O
the O
helpful O
findings O
for O
preoperative O
diagnosis O
. O

The O
sub O
- I-GENE
acute O
inhalation O
toxicity O
of O
_RARE_ I-GENE
was O
studied O
in O
Syrian I-GENE
_RARE_ I-GENE
hamsters O
. O

Changes O
of O
_RARE_ I-GENE
serum I-GENE
protein I-GENE
components O
following O
surgical O
stress O
. O

These O
differences O
are O
smaller O
than O
those O
described O
in O
standard O
_RARE_ I-GENE
. O

A I-GENE
study O
of O
the O
E I-GENE
. O
O O
. O
R I-GENE
. O
T I-GENE
. O
C I-GENE
. O

The O
present O
study O
examined O
the O
dependence O
of O
difference O
tone O
level O
[ O
L I-GENE
( O
_RARE_ I-GENE
- I-GENE
f1 I-GENE
)] O
on O
the O
following O
parameters O
of O
the O
two O
- I-GENE
tone O
input O
: O
f1 I-GENE
, O
_RARE_ I-GENE
/ I-GENE
f1 I-GENE
( O
_RARE_ I-GENE
greater O
than O
f1 I-GENE
), O
L1 I-GENE
, O
L2 O
, O
and O
L1 I-GENE
= O
L2 O
. O

An O
intravenous O
preparation O
of O
_RARE_ I-GENE
( O
_RARE_ I-GENE
, O
_RARE_ I-GENE
' O
_RARE_ I-GENE
_RARE_ I-GENE
a O
long O
- I-GENE
lasting O
_RARE_ I-GENE
, O
was O
administered O
mainly O
by O
_RARE_ I-GENE
infusion O
for O
a O
series O
of O
study O
in O
the O
_RARE_ I-GENE
field O
, O
and O
the O
results O
were O
as O
follows O
: O
1 I-GENE
) O
_RARE_ I-GENE
( O
100 O
mg O
) O
was O
_RARE_ I-GENE
in O
a O
100 O
ml O
of O
glucose O
solution O
and O
2 I-GENE
-- O
3 I-GENE
mg O
/ I-GENE
kg O
was O
administered O
intravenously O
. O

5 I-GENE
) O
_RARE_ I-GENE
and O
ten O
days O
after O
_RARE_ I-GENE
infusion O
, O
laboratory O
tests O
for O
liver O
and O
renal O
functions O
and O
blood O
were O
performed O
. O

Structural O
characteristics O
of O
the O
erythrocyte I-GENE
membrane I-GENE
, O
peroxidation O
processes O
and O
antioxidant O
function O
in O
children O
with O
diffuse O
glomerulonephritis O

The O
enteric O
route O
is O
the O
principal O
mode O
of O
transmission O
for O
hepatitis I-GENE
A I-GENE
, O
but O
maximal O
levels O
of O
hepatitis I-GENE
A I-GENE
virus I-GENE
excretion O
occur O
before O
the O
onset O
of O
jaundice O
. O

All O
13 O
patients O
showed O
_RARE_ I-GENE
evidence O
of O
_RARE_ I-GENE
, O
moderate O
in O
4 I-GENE
and O
severe O
in O
9 O
. O

_RARE_ I-GENE
excretion O
of O
_RARE_ I-GENE
, O
oestradiol O
- I-GENE
17 O
beta I-GENE
and O
_RARE_ I-GENE
in O
_RARE_ I-GENE
complicated O
by O
steroid I-GENE
_RARE_ I-GENE
deficiency O
. O

Both O
reduced O
spontaneous O
locomotor O
activity O
in O
mice O
, O
protected O
them O
from O
death O
from O
amphetamine O
induced O
toxicity O
, O
prolonged O
_RARE_ I-GENE
_RARE_ I-GENE
time O
and O
caused O
a O
depletion O
of O
catecholamines O
from O
various O
organs O
of O
the O
rat I-GENE
. O

On O
the O
role O
of O
transferrin I-GENE
in O
the O
uptake O
of O
_RARE_ I-GENE
by O
tumor I-GENE
cells O
. O

_RARE_ I-GENE
of O
human I-GENE
blood O
platelets O
with O
UV O
- I-GENE
A I-GENE
in O
vitro O
_RARE_ I-GENE
their O
ability O
to O
_RARE_ I-GENE
after O
challenge O
with O
collagen I-GENE
. O

With O
certain O
_RARE_ I-GENE
the O
method O
was O
considered O
suitable O
in O
the O
routine O
intravenous O
_RARE_ I-GENE
. O

Following O
the O
satisfactory O
results O
and O
taking O
into O
account O
that O
the O
complications O
had O
reduced O
to O
a O
very O
low O
rate O
( O
in O
2 I-GENE
cases O
lead O
tip O
displacement I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
occurred O
respectively O
), O
the O
_RARE_ I-GENE
consider O
the O
adopted O
method O
an O
useful O
approach O
for O
_RARE_ I-GENE
implantation O
particularly O
when O
the O
use O
of O
the O
_RARE_ I-GENE
_RARE_ I-GENE
is O
_RARE_ I-GENE
_RARE_ I-GENE
. O

When O
two O
determinations O
were O
performed O
on O
12 O
samples O
of O
plasma I-GENE
taken O
from O
normal O
adults O
in O
_RARE_ I-GENE
, O
the O
values O
were O
22 O
. O
6 I-GENE
+/- O
4 I-GENE
. O
8 O
and O
21 O
. O
0 O
+/- O
3 I-GENE
. O
6 I-GENE
( O
mean O
+/- O
SD O
) O
ng O
/ I-GENE
ml O
, O
respectively O
. O

The O
six O
_RARE_ I-GENE
causes O
of O
death O
varied O
in O
the O
three O
_RARE_ I-GENE
groups O
. O

Although O
_RARE_ I-GENE
' O
s O
operation O
has O
been O
used O
all O
over O
the O
world O
, O
no O
systematic O
account O
of O
it O
has O
been O
found O
in O
the O
literature O
( O
including O
_RARE_ I-GENE
_RARE_ I-GENE
with O
technique O
), O
which O
presents O
it O
in O
terms O
related I-GENE
to O
the O
basic I-GENE
" O
classical O
" O
_RARE_ I-GENE
on O
which O
the O
operation O
was O
_RARE_ I-GENE
. O

( O
5 I-GENE
) O
No O
changes O
were O
observed O
in O
the O
gastric O
venous O
blood O
flow O
by O
continuous O
intravenous O
injection O
of O
cimetidine O
, O
but O
by O
rapid O
injection O
both O
the O
flow O
was O
augmented O
and O
the O
systemic O
blood O
pressure O
decreased O
transiently O
. O

Study O
on O
re O
- I-GENE
establishment O
of O
ovulation O
after O
termination O
of O
sex I-GENE
- I-GENE
_RARE_ I-GENE
treatment O
-- O
compared O
with O
re O
- I-GENE
appearance O
of O
ovulation O
after O
abortion O
and O
premature O
delivery O
. O

_RARE_ I-GENE
of O
_RARE_ I-GENE
in O
man O
: O
a O
review O
. O

Of O
the O
compounds O
tested O
, O
alpha I-GENE
-( O
3 I-GENE
- I-GENE
methyl O
- I-GENE
2 I-GENE
- I-GENE
_RARE_ I-GENE
)- I-GENE
N I-GENE
- I-GENE
_RARE_ I-GENE
1 I-GENE
, O
4 I-GENE
- I-GENE
dioxide O
( O
2 I-GENE
) O
was O
the O
most O
active O
agent O
in O
vivo O
against O
the O
gram O
- I-GENE
negative O
and O
the O
gram O
- I-GENE
positive O
organisms O
. O

Changes O
in O
ionic O
content O
of O
the O
_RARE_ I-GENE
suggest O
that O
cholinergic O
mechanisms O
affect O
pressure O
in O
the O
_RARE_ I-GENE
duct O
of O
the O
gland O
. O

_RARE_ I-GENE
fed O
_RARE_ I-GENE
- I-GENE
milk O
had O
significantly O
lower O
blood O
cholesterol I-GENE
than O
calves O
fed O
T I-GENE
- I-GENE
or O
_RARE_ I-GENE
- I-GENE
milk O
. O

_RARE_ I-GENE
mortality O
of O
mice O
following O
inhalation O
of O
acute O
doses O
of O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
. O

_RARE_ I-GENE
pigs O
_RARE_ I-GENE
300 O
approximately O
350 O
g O
were O
used O
. O

Under O
halothane O
anesthesia O
, O
the O
flow O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
and O
its O
time O
derivative O
( O
_RARE_ I-GENE
_RARE_ I-GENE
or O
_RARE_ I-GENE
/ I-GENE
dt O
) O
were O
_RARE_ I-GENE
during O
apnea O
by O
a O
small I-GENE
high O
- I-GENE
gain O
_RARE_ I-GENE
. O

_RARE_ I-GENE
kindling O
: O
implications O
for O
development O
of O
sensory O
_RARE_ I-GENE
. O

It O
is O
concluded O
that O
_RARE_ I-GENE
can O
be O
evoked O
also O
in O
the O
case O
when O
the O
_RARE_ I-GENE
dopaminergic O
tone O
is O
normal O
or O
even O
below O
normal O
: O
it O
is O
the O
equilibrium O
of O
the O
_RARE_ I-GENE
cholinergic O
- I-GENE
dopaminergic O
systems O
which O
must O
be O
shifted O
towards O
dopamine I-GENE
, O
which O
is O
necessary O
for O
the O
development O
of O
this O
behavioral O
manifestation O
. O

None O
of O
the O
_RARE_ I-GENE
showed O
_RARE_ I-GENE
_RARE_ I-GENE
contractions O
. O

In O
the O
_RARE_ I-GENE
a O
small I-GENE
part O
of O
the O
administered O
dose O
was O
transformed O
to O
3H O
- I-GENE
alpha I-GENE
- I-GENE
_RARE_ I-GENE
. O

Functional O
effects O
following O
subacute O
administration O
. O

Treatment O
of O
_RARE_ I-GENE
' O
disease O
. O

Although O
it O
has O
been O
shown O
that O
it O
is O
possible O
to O
use O
orally O
administered O
testosterone O
to O
maintain O
_RARE_ I-GENE
- I-GENE
T I-GENE
levels O
in O
the O
normal O
male O
range O
, O
the O
_RARE_ I-GENE
to O
the O
patient O
must O
be O
_RARE_ I-GENE
against O
the O
cost O
and O
possible O
side O
effects O
of O
the O
large O
doses O
required O
. O

_RARE_ I-GENE
to O
1 I-GENE
, O
8 O
- I-GENE
_RARE_ I-GENE
- I-GENE
9 O
- I-GENE
_RARE_ I-GENE
, O
1 I-GENE
, O
8 O
, O
9 O
- I-GENE
_RARE_ I-GENE
and O
1 I-GENE
, O
8 O
- I-GENE
_RARE_ I-GENE
- I-GENE
9 O
- I-GENE
_RARE_ I-GENE
are O
effective O
against O
_RARE_ I-GENE
lesions O
without O
accompanying O
_RARE_ I-GENE
of O
the O
skin O
. O

_RARE_ I-GENE
and O
therapeutic O
problems O
in O
acute O
_RARE_ I-GENE
inflammation O

_RARE_ I-GENE
of O
patients O
with O
_RARE_ I-GENE
diseases O

We O
measured O
basal O
plasma I-GENE
prolactin I-GENE
concentrations O
( O
in O
samples O
obtained O
during O
the O
early I-GENE
follicular O
phase O
) O
in O
25 O
normal O
( O
control O
) O
women O
and O
in O
a O
similar O
group O
of O
40 I-GENE
patients O
with O
a O
long O
- I-GENE
_RARE_ I-GENE
history O
of O
infertility O
. O

_RARE_ I-GENE
_RARE_ I-GENE
in O
human I-GENE
. O

_RARE_ I-GENE
reaction O
to O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
during O
_RARE_ I-GENE
. O

_RARE_ I-GENE
of O
asthma O
patients O
by O
determination O
of O
IgE I-GENE
and O
by O
_RARE_ I-GENE
of O
spectrum O
of O
_RARE_ I-GENE
IgE I-GENE
antibodies I-GENE

The O
induction O
of O
seizures O
in O
" O
_RARE_ I-GENE
_RARE_ I-GENE
" O
following O
_RARE_ I-GENE
alone O
or O
in O
combination O
with O
intermittent O
_RARE_ I-GENE
stimulation O

A I-GENE
highly O
significant O
correlation O
was O
found O
between O
the O
presence O
of O
_RARE_ I-GENE
degradation O
products I-GENE
( O
_RARE_ I-GENE
) O
and O
the O
incidence O
of O
nephropathy O
and O
renal O
insufficiency O
, O
as O
well O
as O
between O
the O
presence O
of O
fibrin I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
' O
s O
ethanol O
- I-GENE
_RARE_ I-GENE
test O
) O
and O
the O
_RARE_ I-GENE
signs O
of O
the O
primary O
disease O
( O
fever O
, O
accelerated O
_RARE_ I-GENE
). O

One O
- I-GENE
third O
of O
the O
men O
with O
_RARE_ I-GENE
and O
with O
sperm O
density I-GENE
of O
less O
than O
10 O
million O
had O
marked O
FSH I-GENE
elevation O
and O
our O
experience O
_RARE_ I-GENE
the O
work O
of O
others O
that O
this O
indicates O
a O
poor O
prognosis O
. O

In O
girls O
prolactin I-GENE
levels O
rise O
at O
stage O
2 I-GENE
, O
and O
are O
higher O
after O
_RARE_ I-GENE
; O
in O
boys O
there O
is O
no O
change O
in O
prolactin I-GENE
levels O
. O

It O
was O
concluded O
that O
both O
of O
these O
surgical O
procedures O
were O
as O
effective O
as O
_RARE_ I-GENE
in O
_RARE_ I-GENE
the O
pineal O
- I-GENE
induced O
alterations O
in O
the O
reproductive O
physiology O
of O
the O
blind O
- I-GENE
_RARE_ I-GENE
female O
rat I-GENE
. O

2 I-GENE
cases O
of O
toxic O
_RARE_ I-GENE

Such O
an O
hemoglobin I-GENE
solution O
was O
shown O
to O
exhibit O
a O
high O
affinity O
for O
oxygen O
and O
a O
low O
_RARE_ I-GENE
effect O
( O
assessed O
from O
the O
delta I-GENE
log O
_RARE_ I-GENE
/ I-GENE
delta I-GENE
pH O
ratio O
). O

A I-GENE
one O
- I-GENE
week O
ulcer O
therapy O
with O
atropine O
and O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
led O
to O
a O
significant O
( O
p O
less O
than O
0 O
. O
01 O
) O
reduction O
of O
the O
_RARE_ I-GENE
proteolytic O
activity O
. O

In O
one O
patient O
with O
severe O
_RARE_ I-GENE
the O
_RARE_ I-GENE
concentration O
in O
serum I-GENE
was O
low O
until O
the O
intestinal O
function O
_RARE_ I-GENE
and O
the O
_RARE_ I-GENE
concentration O
_RARE_ I-GENE
up O
_RARE_ I-GENE
when O
the O
_RARE_ I-GENE
stopped O
. O

Serum I-GENE
levels O
of O
IgG I-GENE
and O
IgM I-GENE
were O
also O
raised O
, O
but O
_RARE_ I-GENE
to O
the O
findings O
of O
other O
_RARE_ I-GENE
IgA I-GENE
levels O
were O
normal O
. O

Experimental O
ischemic O
heart O
disease O
induced O
by O
thromboxane I-GENE
A2 I-GENE
in O
rabbits O
. O

_RARE_ I-GENE
in O
ocular O
_RARE_ I-GENE

To O
study O
the O
sensitivity O
of O
some O
central O
brain O
structures O
to O
the O
action O
of O
an O
_RARE_ I-GENE
field O
of O
_RARE_ I-GENE
waves O
( O
_RARE_ I-GENE
of O
_RARE_ I-GENE
) O
a O
dynamic O
investigation O
of O
single O
unit I-GENE
activity O
was O
undertaken O
. O

No O
systematic O
L I-GENE
- I-GENE
R I-GENE
differences O
were O
observed O
. O

A I-GENE
decrease O
of O
the O
lysozyme I-GENE
activity O
_RARE_ I-GENE
with O
the O
clinical O
improvement O
of O
the O
bacterial I-GENE
meningitis O
. O

This O
_RARE_ I-GENE
that O
the O
groups O
do O
not O
just O
differ O
along O
one O
_RARE_ I-GENE
, O
but O
along O
three O
dimensions O
. O

_RARE_ I-GENE
_RARE_ I-GENE
were O
induced O
over O
the O
_RARE_ I-GENE
of O
volunteers O
with O
repeated O
exposure O
to O
_RARE_ I-GENE
_RARE_ I-GENE
radiation O
( O
UV O
- I-GENE
A I-GENE
). O

1 I-GENE
The O
effects O
in O
normal O
subjects O
of O
a O
single O
oral O
dose O
of O
_RARE_ I-GENE
( O
one O
tablet O
, O
containing O
_RARE_ I-GENE
0 O
. O
5 I-GENE
mg O
and O
_RARE_ I-GENE
10 O
mg O
) O
on O
the O
_RARE_ I-GENE
negative O
variation O
( O
CNV O
), O
reaction O
time O
, O
heart O
rate O
, O
blood O
pressure O
and O
self O
- I-GENE
rating O
_RARE_ I-GENE
for O
_RARE_ I-GENE
, O
anxiety O
, O
tension O
, O
_RARE_ I-GENE
and O
depression O
were O
compared O
with O
those O
of O
diazepam I-GENE
( O
5 I-GENE
mg O
and O
7 O
. O
5 I-GENE
mg O
) O
and O
placebo O
or O
propranolol O
( O
60 O
mg O
). O

_RARE_ I-GENE
effects O
on O
_RARE_ I-GENE
_RARE_ I-GENE
among O
subjects O
_RARE_ I-GENE
the O
type I-GENE
A I-GENE
coronary O
- I-GENE
prone O
behavior O
pattern O
. O

These O
show O
that O
the O
collagen I-GENE
in O
this O
tissue I-GENE
is O
modified O
compared O
with O
that O
in O
tendon O
. O

_RARE_ I-GENE
was O
regarded O
as O
the O
major I-GENE
contribution O
to O
pulmonary O
dysfunction O
. O

The O
_RARE_ I-GENE
of O
_RARE_ I-GENE
_RARE_ I-GENE
. O

Elimination O
of O
_RARE_ I-GENE
in O
_RARE_ I-GENE
paper O
_RARE_ I-GENE
plant O
workers O
. O

These O
responses O
were O
compared O
with O
others O
in O
the O
same O
subjects O
under O
the O
same O
conditions O
and O
it O
was O
concluded O
that O
the O
antihypertensive O
effect O
of O
_RARE_ I-GENE
is O
explained O
by O
concurrent O
blockade O
of O
alpha I-GENE
- I-GENE
and O
beta I-GENE
- I-GENE
adrenoceptors I-GENE
. O

_RARE_ I-GENE
: O
basic I-GENE
clinical O
_RARE_ I-GENE
and O
therapeutic O
use O
. O

Three O
patients O
with O
four O
_RARE_ I-GENE
units O
have O
undergone O
single O
- I-GENE
stage O
reconstruction O
involving O
_RARE_ I-GENE
and O
ipsilateral O
_RARE_ I-GENE
following O
temporary O
loop I-GENE
cutaneous O
_RARE_ I-GENE
. O

Evaluation O
of O
the O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
ammonia I-GENE
procedure O
. O

_RARE_ I-GENE
_RARE_ I-GENE
patients O
' O
scores O
on O
_RARE_ I-GENE
' O
s O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
of O
Control O
Scale O
remained O
the O
same O
over O
treatment O
but O
those O
of O
_RARE_ I-GENE
_RARE_ I-GENE
patients O
shifted O
toward O
greater O
internal O
control O
. O

_RARE_ I-GENE
of O
_RARE_ I-GENE
- I-GENE
90 O
and O
_RARE_ I-GENE
on O
_RARE_ I-GENE
_RARE_ I-GENE

_RARE_ I-GENE
_RARE_ I-GENE
- I-GENE
2 I-GENE
_RARE_ I-GENE
is O
_RARE_ I-GENE
around O
a O
_RARE_ I-GENE
water O
- I-GENE
filled O
_RARE_ I-GENE
and O
the O
dose O
distribution O
is O
recorded O
. O

Diagnosis O
and O
differential O
diagnosis O

The O
multiple O
factors I-GENE
affecting O
plasma I-GENE
renin I-GENE
activity O
in O
essential O
hypertension O
. O

_RARE_ I-GENE
induced O
bone O
changes O
and O
its O
response O
to O
lipid O
_RARE_ I-GENE
agents O
. O

2 I-GENE
) O
The O
time O
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
was O
applied O
to O
gain O
high O
stability O
. O

When O
blood O
samples O
of O
patients O
with O
hyperbilirubinemia O
were O
analyzed O
, O
direct O
measurement O
of O
_RARE_ I-GENE
by O
this O
_RARE_ I-GENE
yielded O
significantly O
higher O
levels O
than O
did O
an O
alternate O
extraction O
method O
. O

_RARE_ I-GENE
hypersensitivity O
in O
man O
: O
effects O
of O
systemic O
_RARE_ I-GENE
. O

In O
three O
of O
the O
seven O
, O
inhalation O
of O
2 I-GENE
ml O
normal O
saline O
produced O
FEV1 O
_RARE_ I-GENE
of O
25 O
% O
to O
30 O
%, O
but O
these O
_RARE_ I-GENE
were O
not O
as O
great O
as O
each O
subject O
' O
s O
reactions O
to O
the O
test O
solutions O
. O

Experimental O
studies O
on O
virus I-GENE
excretion O
and O
non O
- I-GENE
_RARE_ I-GENE
transmission O
. O

_RARE_ I-GENE
of O
_RARE_ I-GENE
in O
dogs O
: O
comparison O
with O
halothane O
and O
isoflurane O
. O

Prevention O
of O
acute O
_RARE_ I-GENE
toxicity O
in O
rats O
by O
superoxide I-GENE
dismutase I-GENE
. O

Measurement O
of O
magnesium O
absorption O
in O
man O
using O
stable O
_RARE_ I-GENE
as O
a O
tracer O
. O

Increased O
urinary O
_RARE_ I-GENE
excretion O
resulting O
from O
_RARE_ I-GENE
acid I-GENE
ingestion O
. O

_RARE_ I-GENE
angiography O
and O
_RARE_ I-GENE
whole O
body O
imaging O
performed O
with O
technetium O
- I-GENE
99m O
- I-GENE
labeled O
_RARE_ I-GENE
can O
clearly O
demonstrate O
differential O
_RARE_ I-GENE
in O
patients O
with O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
with O
_RARE_ I-GENE
physiology O
. O

_RARE_ I-GENE
_RARE_ I-GENE
in O
the O
human I-GENE
visual O
pathway O
. O

Escherichia I-GENE
of O
a O
single O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
type I-GENE
( O
_RARE_ I-GENE
: O
_RARE_ I-GENE
: O
H1 I-GENE
) O
were O
isolated O
in O
a O
group O
_RARE_ I-GENE
. O

The O
method O
described O
may O
prove O
useful O
in O
studying O
the O
physiology O
of O
the O
nasal O
cycle O
. O

At O
the O
same O
time O
we O
obtained O
easily O
_RARE_ I-GENE
EEG O
- I-GENE
information O
which O
has O
never O
previously O
been O
available O
to O
us O
. O

Analysis O
of O
liver O
biopsy O
specimens O
from O
patients O
with O
hepatitis I-GENE
showed O
a O
large O
variation O
in O
the O
mean O
iron O
content O
of O
the O
liver O
ferritin I-GENE
molecules I-GENE
. O

Female O
mice O
were O
significantly O
more O
resistant O
to O
infection O
than O
males O
. O

During O
the O
following O
9 O
1 I-GENE
/ I-GENE
2 I-GENE
years O
three O
sequential O
liver O
biopsies O
were O
performed O
. O

_RARE_ I-GENE
effect O
in O
the O
human I-GENE
kidney O
. O

_RARE_ I-GENE
yellow O
dye O
was O
injected O
_RARE_ I-GENE
into O
large O
auditory O
fibers O
of O
_RARE_ I-GENE
to O
investigate O
the O
relationship O
between O
the O
response O
type I-GENE
of O
these O
fibers O
and O
their O
site I-GENE
of O
termination O
in O
the O
_RARE_ I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
findings O
in O
the O
_RARE_ I-GENE
and O
in O
the O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
duct O
units O
. O

_RARE_ I-GENE
mortality O

These O
consisted O
of O
_RARE_ I-GENE
and O
_RARE_ I-GENE
mainly O
of O
the O
intrahepatic O
biliary O
_RARE_ I-GENE
( O
_RARE_ I-GENE
). O

_RARE_ I-GENE
and O
_RARE_ I-GENE
, O
which O
arise O
during O
lipid O
peroxidation O
in O
vivo O
, O
were O
measured O
by O
gas O
chromatography O
in O
_RARE_ I-GENE
samples O
of O
rats O
fed O
for O
8 O
weeks O
a O
vitamin O
E I-GENE
- I-GENE
deficient O
diet O
to O
which O
had O
been O
added O
0 O
, O
11 O
, O
or O
40 I-GENE
IU O
vitamin O
E I-GENE
acetate O
per O
kg O
. O

_RARE_ I-GENE
and O
_RARE_ I-GENE
activity O
of O
the O
blood O
after O
administration O
of O
_RARE_ I-GENE
in O
men O
with O
history O
of O
myocardial O
infarction O
up O
to O
45 O
year O
of O
life O

The O
authors O
report O
the O
_RARE_ I-GENE
findings O
in O
four O
cases O
of O
adult O
women O
with O
_RARE_ I-GENE
that O
_RARE_ I-GENE
in O
the O
_RARE_ I-GENE
or O
cervix O
, O
or O
both O
. O

The O
effect O
of O
pure O
natural O
porcine I-GENE
_RARE_ I-GENE
on O
endocrine O
and O
_RARE_ I-GENE
pancreatic O
secretion O
was O
studied O
in O
the O
_RARE_ I-GENE
isolated O
perfused O
porcine I-GENE
pancreas O
. O

_RARE_ I-GENE
analysis O
of O
_RARE_ I-GENE
lens O
power O
required O
to O
produce O
_RARE_ I-GENE
: O
results O
of O
450 I-GENE
implants O
. O

_RARE_ I-GENE
antibodies I-GENE
could O
not O
be O
demonstrated O
in O
any O
other O
cases O
. O

_RARE_ I-GENE
_RARE_ I-GENE
tended O
to O
increase O
after O
the O
therapy O
, O
there O
was O
no O
statistically O
significant O
change O
in O
_RARE_ I-GENE
, O
GFR O
and O
cardiac O
output O
. O

99mTc O
_RARE_ I-GENE
, O
_RARE_ I-GENE
colloid O
, O
and O
99mTc O
_RARE_ I-GENE
_RARE_ I-GENE
have O
been O
used O
; O
the O
last O
appears O
to O
have O
been O
the O
most O
satisfactory O
. O

Six O
patients O
with O
glomerulonephritis O
in O
association O
with O
a O
_RARE_ I-GENE
shunt O
were O
treated O
with O
three O
basic I-GENE
modes O
of O
therapy O
. O

The O
mass O
of O
_RARE_ I-GENE
in O
the O
_RARE_ I-GENE
_RARE_ I-GENE
and O
first O
_RARE_ I-GENE
decreased O
more O
slowly O
over O
0 O
-- O
8 O
d O
after O
inhalation O
than O
the O
corresponding O
mass O
on O
the O
_RARE_ I-GENE
. O

_RARE_ I-GENE
cysts O
of O
the O
hip O
joint O

A I-GENE
suspected O
_RARE_ I-GENE
dysfunction O
and O
a O
slightly O
impaired O
pituitary I-GENE
function O
manifested O
as O
GH I-GENE
deficiency O
were O
their O
common O
_RARE_ I-GENE
features O
. O

A I-GENE
_RARE_ I-GENE
outbreak O
of O
influenza I-GENE
A I-GENE
occurred O
on O
the O
base O
during O
_RARE_ I-GENE
that O
was O
due O
to O
an O
A I-GENE
/ I-GENE
_RARE_ I-GENE
/ I-GENE
1 I-GENE
/ I-GENE
77 O
- I-GENE
like I-GENE
virus I-GENE
, O
a O
variant I-GENE
of O
the O
A I-GENE
/ I-GENE
_RARE_ I-GENE
/ I-GENE
3 I-GENE
/ I-GENE
75 O
_RARE_ I-GENE
. O

Because O
decreases O
in O
the O
_RARE_ I-GENE
rates O
of O
_RARE_ I-GENE
were O
observed O
during O
the O
presentation O
of O
all O
three O
stimulus O
_RARE_ I-GENE
, O
the O
data O
failed O
to O
support O
the O
_RARE_ I-GENE
model O
. O

Effect O
of O
time O
and O
dose O
on O
alterations O
following O
inhalation O
of O
plutonium O
- I-GENE
239 O
dioxide O
_RARE_ I-GENE
in O
rat I-GENE
. O

In O
biopsies O
CK I-GENE
- I-GENE
MB I-GENE
fraction O
of O
total O
myocardial O
CPK I-GENE
was O
37 O
%, O
the O
total O
- I-GENE
CPK I-GENE
activity O
of O
human I-GENE
skeletal I-GENE
muscles O
still O
shows O
a O
5 I-GENE
% O
fraction O
of O
CK I-GENE
- I-GENE
MB I-GENE
. O

Value O
of O
determination O
of O
alkaline I-GENE
phosphatase I-GENE
isoenzymes I-GENE
for O
differential O
diagnosis O
of O
_RARE_ I-GENE
jaundice O
and O
biliary O
liver O
cirrhosis O

A I-GENE
one O
- I-GENE
way O
analysis O
of O
_RARE_ I-GENE
, O
performed O
separately O
for O
men O
and O
women O
for O
differences O
among O
the O
three O
_RARE_ I-GENE
groups O
on O
field O
dependence O
, O
showed O
significance O
( O
rho I-GENE
less O
than O
. O
05 O
) O
for O
the O
females O
, O
with O
the O
_RARE_ I-GENE
_RARE_ I-GENE
being O
more O
field O
dependent I-GENE
than O
the O
female O
simple O
_RARE_ I-GENE
groups O
, O
but O
not O
for O
the O
males O
. O

Several O
free O
_RARE_ I-GENE
- I-GENE
generation O
_RARE_ I-GENE
, O
which O
varied O
in O
diameter O
from O
11 O
to O
21 O
. O
6 I-GENE
_RARE_ I-GENE
, O
were O
found O
on O
the O
epithelial O
surface O
of O
the O
_RARE_ I-GENE
. O

The O
calculated O
_RARE_ I-GENE
values O
were O
8 O
. O
8 O
for O
E I-GENE
, O
8 O
. O
6 I-GENE
for O
_RARE_ I-GENE
and O
6 I-GENE
. O
6 I-GENE
for O
M I-GENE
. O

_RARE_ I-GENE
disease O
virus I-GENE
_RARE_ I-GENE
in O
_RARE_ I-GENE
_RARE_ I-GENE
on O
local O
and O
_RARE_ I-GENE
_RARE_ I-GENE
. O

It O
was O
postulated O
that O
persistent O
challenge O
by O
M I-GENE
. O
_RARE_ I-GENE
or O
its O
antigens I-GENE
to O
the O
IgA I-GENE
_RARE_ I-GENE
of O
the O
intestinal O
epithelium O
might O
have O
induced O
tolerance O
leading O
to O
IgA I-GENE
deficiency O
and O
subsequent O
subtotal O
atrophy O
of O
the O
intestinal O
_RARE_ I-GENE
in O
the O
patients O
with O
_RARE_ I-GENE
_RARE_ I-GENE
. O

Treatment O
of O
hypertension O
with O
a O
combination O
of O
the O
adrenergic I-GENE
beta I-GENE
receptor I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
and O
the O
vasodilator O
, O
_RARE_ I-GENE

_RARE_ I-GENE
. O

_RARE_ I-GENE
disease O
and O
pregnancy O
. O

_RARE_ I-GENE
removed O
from O
transcripts I-GENE
by O
splicing O
were O
identified O
. O

To O
_RARE_ I-GENE
reflux O
into O
the O
blind O
loop I-GENE
, O
a O
number O
of O
_RARE_ I-GENE
steps O
are O
considered O
_RARE_ I-GENE
: O
1 I-GENE
) O
_RARE_ I-GENE
section O
of O
the O
_RARE_ I-GENE
_RARE_ I-GENE
; O
2 I-GENE
) O
_RARE_ I-GENE
construction I-GENE
of O
the O
anastomosis O
and O
, O
particularly O
, O
3 I-GENE
) O
the O
_RARE_ I-GENE
of O
a O
single O
or O
double O
valve O
system O
upstream O
from O
the O
anastomosis O
by O
_RARE_ I-GENE
_RARE_ I-GENE
of O
the O
mucosa O
using O
_RARE_ I-GENE
_RARE_ I-GENE
parallel O
and O
_RARE_ I-GENE
to O
the O
_RARE_ I-GENE
_RARE_ I-GENE
. O

At O
this O
stage O
, O
the O
_RARE_ I-GENE
high O
mortality O
of O
acute O
ischemia O
is O
established O
_RARE_ I-GENE
the O
_RARE_ I-GENE
of O
the O
operation O
or O
the O
_RARE_ I-GENE
with O
which O
it O
is O
performed O
. O

_RARE_ I-GENE
( O
Staphylococcus I-GENE
aureus I-GENE
or O
Gram O
- I-GENE
negative O
bacilli O
) O
were O
isolated O
from O
only O
one O
member O
of O
_RARE_ I-GENE
in O
small I-GENE
numbers O
and O
_RARE_ I-GENE
and O
rarely O
in O
large O
numbers O
from O
patients O
. O

The O
_RARE_ I-GENE
and O
_RARE_ I-GENE
of O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
described O
by O
_RARE_ I-GENE
et O
al O
. O

A I-GENE
36 O
year O
- I-GENE
old O
woman O
was O
given O
_RARE_ I-GENE
_RARE_ I-GENE
4 I-GENE
. O
5 I-GENE
mg O
p O
. O
d O
. O
during O
seven O
days O
, O
after O
an O
abortion O
( O
a O
still O
birth O
). O

_RARE_ I-GENE
times O
to O
_RARE_ I-GENE
presented O
stimuli O
in O
_RARE_ I-GENE

Two O
out O
of O
five O
patients O
undergoing O
selective O
spinal O
_RARE_ I-GENE
developed O
transient O
neurological O
complications O
during O
the O
injection O
of O
_RARE_ I-GENE
_RARE_ I-GENE
M I-GENE
. O

The O
data O
indicate O
a O
three O
- I-GENE
phase O
reaction O
after O
B1 I-GENE
injection O
: O
Phase O
1 I-GENE
-- O
_RARE_ I-GENE
after O
injection O
there O
is O
a O
drop O
of O
all O
parameters O
lasting O
for O
30 O
sec O
. O

Serum I-GENE
_RARE_ I-GENE
levels O
in O
prostaglandin I-GENE
E2 I-GENE
induced O
_RARE_ I-GENE
. O

A I-GENE
-- O
A I-GENE
natural O
_RARE_ I-GENE
phenomenon O
, O
at O
the O
level O
of O
the O
ends O
of O
the O
_RARE_ I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
body O
weight O
, O
as O
_RARE_ I-GENE
plays O
the O
role O
of O
_RARE_ I-GENE
( O
_RARE_ I-GENE
_RARE_ I-GENE
1 I-GENE
) O
( O
5 I-GENE
); O
B I-GENE
-- O
_RARE_ I-GENE
_RARE_ I-GENE
ulceration O
( O
_RARE_ I-GENE
) O
is O
caused O
by O
a O
combination O
of O
_RARE_ I-GENE
and O
_RARE_ I-GENE
( O
1 I-GENE
); O
C I-GENE
-- O
The O
patient O
_RARE_ I-GENE
, O
as O
body O
weight O
( O
_RARE_ I-GENE
) O
effects O
_RARE_ I-GENE
, O
_RARE_ I-GENE
process O
can O
be O
easily O
observed O
; O
D I-GENE
-- O
_RARE_ I-GENE
_RARE_ I-GENE
, O
being O
elastic O
, O
_RARE_ I-GENE
localized O
compression O
at O
the O
ends O
of O
the O
_RARE_ I-GENE
_RARE_ I-GENE
, O
reduces O
_RARE_ I-GENE
, O
makes O
_RARE_ I-GENE
blood O
circulation O
, O
as O
well O
as O
cure O
and O
prophylaxis O
of O
_RARE_ I-GENE
( O
_RARE_ I-GENE
_RARE_ I-GENE
6 I-GENE
) O
( O
3 I-GENE
). O

Effect O
of O
_RARE_ I-GENE
in O
small I-GENE
doses O
on O
the O
central O
_RARE_ I-GENE
loci I-GENE
has O
been O
studied O
in O
_RARE_ I-GENE
anesthetized O
cats O
by O
_RARE_ I-GENE
it O
to O
the O
central O
sites I-GENE
. O

As O
expected O
, O
the O
heparin O
did O
produce O
increased O
_RARE_ I-GENE
times O
and O
the O
development O
of O
_RARE_ I-GENE
subcutaneous O
_RARE_ I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
between O
_RARE_ I-GENE
and O
their O
parents O
/ I-GENE
_RARE_ I-GENE
was O
used O
to O
_RARE_ I-GENE
consequences O
for O
daily O
self O
- I-GENE
monitoring O
, O
reduced O
_RARE_ I-GENE
intake O
, O
weight O
loss O
, O
and O
exercise O
. O

_RARE_ I-GENE
of O
childhood O
- I-GENE
and O
juvenile O
diabetes O

The O
results O
of O
a O
quantitative O
study O
of O
_RARE_ I-GENE
membranes O
in O
123 O
_RARE_ I-GENE
are O
presented O
. O

The O
_RARE_ I-GENE
uses O
_RARE_ I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
for O
the O
_RARE_ I-GENE
_RARE_ I-GENE
of O
the O
_RARE_ I-GENE
. O

Platelet I-GENE
serotonin I-GENE
( O
5 I-GENE
- I-GENE
HT O
) O
and O
5 I-GENE
- I-GENE
HT O
releasing I-GENE
factor I-GENE
in O
plasma I-GENE
of O
_RARE_ I-GENE
patients O
. O

The O
overall O
incidence O
of O
_RARE_ I-GENE
was O
1 I-GENE
. O
43 I-GENE
per O
1 I-GENE
, O
000 O
live O
births O
. O

The O
_RARE_ I-GENE
task O
and O
the O
measurement O
of O
_RARE_ I-GENE
deficits O
. O

The O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
in O
_RARE_ I-GENE
and O
the O
_RARE_ I-GENE
_RARE_ I-GENE

Significant O
increases O
in O
mean O
serum I-GENE
E2 I-GENE
concentration O
( O
100 O
to O
150 O
pg O
/ I-GENE
ml O
) O
were O
noted O
at O
6 I-GENE
and O
8 O
hours O
after O
administration O
on O
day O
1 I-GENE
and O
at O
8 O
hours O
on O
day O
4 I-GENE
. O

The O
motor O
unit I-GENE
_RARE_ I-GENE
from O
above O
. O

_RARE_ I-GENE
reproductive O
system O
: O
daily O
variations O
in O
responses O
to O
hormones O
. O

Biological O
properties O
of O
_RARE_ I-GENE
. O

_RARE_ I-GENE
studies O
of O
antibodies I-GENE
to O
Epstein I-GENE
- I-GENE
Barr I-GENE
virus I-GENE
in O
infectious O
_RARE_ I-GENE

_RARE_ I-GENE
antigen I-GENE
( O
CEA I-GENE
) O
procedures O
and O
clinical O
evaluation O
. O

We O
_RARE_ I-GENE
_RARE_ I-GENE
that O
_RARE_ I-GENE
globulin I-GENE
( O
_RARE_ I-GENE
) O
is O
a O
potent O
immunosuppressive O
agent O
in O
humans O
. O

On O
the O
basis O
of O
a O
global O
assessment O
patients O
showed O
a O
highly O
significant O
preference O
for O
_RARE_ I-GENE
compared O
with O
placebo O
as O
_RARE_ I-GENE
therapy O
. O

39 O
- I-GENE
47 O
. O

Patients O
were O
_RARE_ I-GENE
into O
age O
- I-GENE
matched O
groups O
of O
primary O
untreated O
cancer O
( O
21 O
), O
recurrent O
cancer O
( O
18 O
), O
and O
" O
_RARE_ I-GENE
" O
patients O
who O
had O
been O
free O
of O
disease O
for O
at O
least O
9 O
months O
( O
16 O
). O

_RARE_ I-GENE
varied O
between O
65 O
and O
95 O
per O
cent O
, O
with O
a O
mean O
absorption O
of O
80 O
per O
cent O
, O
in O
both O
pregnant O
and O
non O
- I-GENE
pregnant O
subjects O
. O

_RARE_ I-GENE
and O
_RARE_ I-GENE
activity O
of O
hydroxy I-GENE
- I-GENE
9 O
_RARE_ I-GENE
in O
vitro O

_RARE_ I-GENE
in O
the O
management O
of O
gynecologic O
cancer O
-- O
radiation O
therapy O
. O

The O
_RARE_ I-GENE
- I-GENE
pathological O
data O
from O
a O
patient O
with O
irreversible O
post O
- I-GENE
_RARE_ I-GENE
renal O
failure O
( O
_RARE_ I-GENE
) O
are O
presented O
. O

_RARE_ I-GENE
_RARE_ I-GENE
in O
nursing O
: O
an O
_RARE_ I-GENE
with O
extremely O
_RARE_ I-GENE
patients O

_RARE_ I-GENE
transfer I-GENE
factor I-GENE
. O

19 O
- I-GENE
32 O
. O

_RARE_ I-GENE
factor I-GENE
and O
_RARE_ I-GENE
antibody I-GENE
tests O
were O
frequently O
positive O
, O
and O
reactions O
to O
_RARE_ I-GENE
therapy O
were O
more O
frequent O
than O
in O
other O
rheumatoid I-GENE
populations O
. O

The O
effect O
of O
_RARE_ I-GENE
pressure O
on O
the O
swimming O
activity O
of O
three O
_RARE_ I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
_RARE_ I-GENE

This O
report O
presents O
an O
analysis O
of O
the O
_RARE_ I-GENE
_RARE_ I-GENE
of O
_RARE_ I-GENE
monkeys O
( O
_RARE_ I-GENE
_RARE_ I-GENE
) O
observed O
during O
a O
field O
study O
in O
_RARE_ I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
to O
now O
the O
number O
of O
patients O
examined O
is O
about O
300 O
, O
additionally O
6 I-GENE
persons O
who O
underwent O
_RARE_ I-GENE
. O

_RARE_ I-GENE
was O
well O
tolerated O
by O
25 O
patients O
, O
very O
well O
tolerated O
by O
2 I-GENE
. O

III I-GENE
. O

A I-GENE
new O
instrument O
has O
been O
designed O
for O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
of O
biological O
material O
in O
_RARE_ I-GENE
high O
_RARE_ I-GENE
. O

_RARE_ I-GENE
and O
biliary O
secretion O
and O
gastric O
emptying O
rates O
of O
a O
liquid O
test O
meal I-GENE
( O
_RARE_ I-GENE
) O
were O
determined O
in O
normal O
persons O
, O
in O
patients O
with O
subtotal O
_RARE_ I-GENE
with O
_RARE_ I-GENE
( O
_RARE_ I-GENE
- I-GENE
BI I-GENE
) O
or O
with O
_RARE_ I-GENE
( O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
), O
and O
in O
patients O
with O
_RARE_ I-GENE
vagotomy O
and O
_RARE_ I-GENE
( O
V I-GENE
& O
P I-GENE
). O

Abnormal O
calcium O
metabolism O
in O
_RARE_ I-GENE
_RARE_ I-GENE
. O

Also O
, O
except O
in O
one O
patient O
who O
developed O
_RARE_ I-GENE
following O
_RARE_ I-GENE
of O
_RARE_ I-GENE
, O
saturation O
of O
gallbladder O
bile O
with O
cholesterol I-GENE
was O
not O
markedly O
increased O
by O
this O
drug O
alone O
. O

A I-GENE
five O
- I-GENE
phase O
experiment O
was O
designed O
to O
investigate O
( O
a O
) O
whether O
_RARE_ I-GENE
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
would O
act O
as O
a O
_RARE_ I-GENE
to O
increase O
_RARE_ I-GENE
performance O
of O
_RARE_ I-GENE
children O
and O
( O
b I-GENE
) O
whether O
this O
_RARE_ I-GENE
_RARE_ I-GENE
would O
affect O
preference O
for O
that O
_RARE_ I-GENE
. O

The O
responsiveness O
of O
visual O
cortex O
( O
_RARE_ I-GENE
) O
and O
superior O
_RARE_ I-GENE
( O
SC O
) O
was O
simultaneously O
compared O
following O
conditioning O
" O
_RARE_ I-GENE
" O
or O
" O
_RARE_ I-GENE
" O
stimulation O
, O
in O
the O
rabbit I-GENE
. O

A I-GENE
diagnosis O
of O
MS O
was O
made O
based O
on O
_RARE_ I-GENE
neurologic O
signs O
, O
spinal O
fluid O
gamma I-GENE
globulin I-GENE
elevations O
, O
and O
abnormalities O
in O
_RARE_ I-GENE
testing O
. O

If O
, O
however O
, O
the O
mean O
temperature O
rise O
was O
higher O
( O
0 O
. O
57 O
degrees O
C I-GENE
or O
0 O
. O
69 O
degrees O
C I-GENE
), O
such O
a O
selection O
_RARE_ I-GENE
resulted O
in O
the O
disappearance O
of O
' O
_RARE_ I-GENE
' O
_RARE_ I-GENE
in O
the O
triplet O
groups O
and O
a O
great O
_RARE_ I-GENE
of O
' O
to O
be O
_RARE_ I-GENE
' O
_RARE_ I-GENE
in O
the O
large O
groups O
. O

The O
elevated O
_RARE_ I-GENE
V I-GENE
in O
the O
_RARE_ I-GENE
group O
suggests O
an O
increase O
in O
small I-GENE
airway O
resistance O
secondary O
to O
the O
disease O
or O
to O
its O
therapy O
. O

The O
psychological O
tests O
consisted O
of O
a O
free O
- I-GENE
_RARE_ I-GENE
task O
, O
a O
test O
for O
_RARE_ I-GENE
coordination O
and O
a O
recognition I-GENE
task O
. O

Selective O
bronchial O
_RARE_ I-GENE
in O
the O
management O
of O
unilateral O
pulmonary O
interstitial O
emphysema O
. O

The O
background O
processes O
depending O
on O
the O
_RARE_ I-GENE
factor I-GENE
and O
the O
character O
of O
lesion O
of O
the O
epithelium O
are O
divided O
into O
_RARE_ I-GENE
, O
inflammatory O
, O
and O
_RARE_ I-GENE
. O

The O
sense O
of O
self O
. O

_RARE_ I-GENE
strains O
of O
_RARE_ I-GENE
_RARE_ I-GENE
and O
F I-GENE
. O
_RARE_ I-GENE
from O
the O
U O
. O
S I-GENE
. O
S I-GENE
. O
R I-GENE
. O
and O
7 O
strains O
of O
these O
species O
and O
one O
of O
F I-GENE
. O
_RARE_ I-GENE
var I-GENE
. O
_RARE_ I-GENE
from O
U O
. O
S I-GENE
. O
A I-GENE
. O
and O
_RARE_ I-GENE
have O
been O
compared O
as O
to O
their O
capacity O
to O
yield O
T I-GENE
- I-GENE
2 I-GENE
toxin I-GENE
. O

Current O
diagnostic O
uses O
of O
computerized O
tomography O
in O
clinical O
medicine O
. O

A I-GENE
follow O
- I-GENE
up O
study O
of O
22 O
patients O
with O
_RARE_ I-GENE
' O
s O
_RARE_ I-GENE
has O
been O
performed O
. O

_RARE_ I-GENE
stopped O
11 O
hours O
after O
copper I-GENE
concentrations O
decreased O
below O
0 O
. O
2 I-GENE
ppm O
and O
signs O
of O
distress O
stopped O
in O
_RARE_ I-GENE
_RARE_ I-GENE
by O
approximately O
6 I-GENE
hours O
after O
the O
last O
death O
. O

_RARE_ I-GENE
of O
bladder O
tumors O
among O
the O
original O
9 O
cases O
has O
occurred O
only O
among O
the O
5 I-GENE
whose O
_RARE_ I-GENE
levels O
remained O
below O
the O
median O
. O

_RARE_ I-GENE
of O
_RARE_ I-GENE
transport O
maximum O
to O
increased O
secretory I-GENE
load O
in O
the O
rat I-GENE
. O

_RARE_ I-GENE
in O
use O
of O
live O
- I-GENE
virus I-GENE
vaccines O
. O

Treatment O
with O
heparin O
, O
plasminogen I-GENE
activators I-GENE
and O
_RARE_ I-GENE
agents O
was O
_RARE_ I-GENE
although O
renal O
function O
has O
stabilized O
in O
one O
patient O
on O
long O
term O
oral O
anticoagulant I-GENE
therapy O
. O

In O
_RARE_ I-GENE
ether O
solution O
the O
main O
peak O
is O
that O
of O
2 I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
1 I-GENE
- I-GENE
_RARE_ I-GENE
, O
which O
has O
a O
retention O
time O
of O
23 O
, O
2 I-GENE
minutes O
under O
the O
condition O
_RARE_ I-GENE
. O

_RARE_ I-GENE
was O
used O
in O
the O
treatment O
of O
56 O
serious O
gram O
- I-GENE
negative O
infections O
in O
54 I-GENE
patients O
of O
whom O
47 O
_RARE_ I-GENE
. O

The O
data O
normally O
available O
are O
insufficient O
and O
take O
no O
account O
of O
the O
direction O
of O
_RARE_ I-GENE
, O
which O
may O
be O
a O
determining O
factor I-GENE
. O

During O
activity O
III I-GENE
, O
one O
patient O
developed O
angina O
. O

_RARE_ I-GENE
of O
L I-GENE
- I-GENE
alanine I-GENE
in O
serum I-GENE
or O
plasma I-GENE
using O
the O
_RARE_ I-GENE
reaction O
rate O
_RARE_ I-GENE
. O

The O
acids O
were O
obtained O
by O
hydrolysis O
of O
the O
corresponding O
esters O
, O
and O
their O
anti I-GENE
- I-GENE
inflammatory O
activity O
was O
tested O
. O

_RARE_ I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
: O
a O
preliminary O
report O
. O

Evaluation O
of O
the O
new O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
meningitis O
secondary O
to O
abscess O
of O
the O
nasal O
_RARE_ I-GENE
. O

Serum I-GENE
amylase I-GENE
became O
markedly O
elevated O
( O
2 I-GENE
, O
_RARE_ I-GENE
_RARE_ I-GENE
/ I-GENE
100 O
ml O
), O
as O
did O
the O
serum I-GENE
_RARE_ I-GENE
( O
29 O
. O
19 O
mEq O
/ I-GENE
liter O
). O

In O
the O
control O
preparation O
before O
weight O
was O
allowed O
to O
increase O
, O
_RARE_ I-GENE
capillary O
pressure O
( O
_RARE_ I-GENE
) O
averaged O
8 O
mmHg O
lower O
than O
colloid O
osmotic O
pressure O
of O
the O
plasma I-GENE
( O
_RARE_ I-GENE
). O

_RARE_ I-GENE
who O
died O
in O
the O
first O
12 O
hours O
from O
' O
_RARE_ I-GENE
only O
' O
had O
_RARE_ I-GENE
severe O
birth O
_RARE_ I-GENE
but O
in O
those O
who O
died O
later O
the O
main O
_RARE_ I-GENE
was O
recurrent O
_RARE_ I-GENE
. O

The O
morphological O
effects O
of O
two O
_RARE_ I-GENE
_RARE_ I-GENE
, O
N I-GENE
. O
_RARE_ I-GENE
and O
A I-GENE
. O
_RARE_ I-GENE
, O
and O
of O
the O
Direct I-GENE
_RARE_ I-GENE
Factor I-GENE
and O
_RARE_ I-GENE
- I-GENE
A I-GENE
, O
compounds O
purified O
from O
N I-GENE
. O
_RARE_ I-GENE
crude O
_RARE_ I-GENE
, O
were O
investigated O
on O
lung O
and O
_RARE_ I-GENE
vessels O
of O
rats O
. O

Since O
_RARE_ I-GENE
are O
the O
components O
of O
cartilage O
matrix I-GENE
, O
the O
depletion O
of O
which O
is O
associated I-GENE
with O
_RARE_ I-GENE
, O
a O
method O
for O
measuring O
_RARE_ I-GENE
_RARE_ I-GENE
synthesis O
in O
culture O
has O
been O
investigated O
. O

The O
length I-GENE
_RARE_ I-GENE
of O
the O
_RARE_ I-GENE
were O
also O
estimated O
: O
at O
a O
_RARE_ I-GENE
number O
near O
4 I-GENE
, O
000 O
the O
_RARE_ I-GENE
is O
about O
1 I-GENE
. O
25 O
mm O
, O
the O
_RARE_ I-GENE
_RARE_ I-GENE
is O
about O
0 O
. O
85 O
mm O
, O
and O
the O
_RARE_ I-GENE
scale O
is O
near O
0 O
. O
_RARE_ I-GENE
mm O
. O

_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
of O
the O
_RARE_ I-GENE
can O
be O
obtained O
by O
_RARE_ I-GENE
after O
rapid O
_RARE_ I-GENE
injection O
of O
contrast O
- I-GENE
medium O
into O
an O
arm O
vein O
, O
as O
demonstrated O
in O
28 O
patients O
. O

No O
hypotension O
was O
noted O
in O
patients O
with O
_RARE_ I-GENE
and O
only O
2 I-GENE
_RARE_ I-GENE
a O
fever O
above O
37 O
. O
5 I-GENE
degrees O
C I-GENE
. O

The O
sera O
and O
nasal O
_RARE_ I-GENE
of O
142 O
patients O
, O
who O
were O
positive O
in O
HD I-GENE
or O
_RARE_ I-GENE
skin O
test O
, O
were O
subjected O
to O
a O
_RARE_ I-GENE
test O
( O
RAST O
) O
for O
estimating O
the O
specific I-GENE
IgE I-GENE
antibody I-GENE
activity O
to O
_RARE_ I-GENE
. O

_RARE_ I-GENE
the O
site I-GENE
of O
the O
conditioning O
stimulation O
, O
these O
modifications O
disappeared O
after O
ischaemia O
of O
the O
leg O
. O

_RARE_ I-GENE
( O
_RARE_ I-GENE
), O
one O
of O
the O
few O
_RARE_ I-GENE
tested O
thus O
far O
that O
has O
not O
induced O
neoplasms O
in O
rats O
, O
caused O
a O
high O
incidence O
of O
respiratory O
tract O
tumors O
in O
Syrian I-GENE
_RARE_ I-GENE
hamsters O
treated O
sc O
with O
single O
or O
weekly O
doses O
of O
the O
compound O
. O

_RARE_ I-GENE
term O
, O
under O
experimental O
conditions O
, O
maternal I-GENE
and O
fetal O
blood O
gases O
, O
pH O
, O
uterine O
and O
_RARE_ I-GENE
blood O
_RARE_ I-GENE
were O
measured O
or O
calculated O
. O

_RARE_ I-GENE
responses O
to O
_RARE_ I-GENE
of O
_RARE_ I-GENE
block O
with O
atropine O
- I-GENE
_RARE_ I-GENE
mixture O
in O
children O
. O

The O
mechanism O
by O
which O
large O
molecules I-GENE
, O
such O
as O
the O
_RARE_ I-GENE
99mTc O
- I-GENE
labeled O
_RARE_ I-GENE
or O
99mTc O
- I-GENE
labeled O
_RARE_ I-GENE
, O
_RARE_ I-GENE
through O
capillaries O
in O
bone O
is O
by O
passive O
diffusion O
. O

Twenty O
- I-GENE
nine O
days O
after O
injection O
of O
5 I-GENE
. O
8 O
mCi O
of O
Tc O
- I-GENE
99m O
, O
which O
gives O
28 O
_RARE_ I-GENE
to O
the O
testis I-GENE
, O
the O
number O
of O
sperm O
_RARE_ I-GENE
decreased O
to O
70 I-GENE
% O
of O
control O
. O

_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
is O
the O
end O
result O
of O
an O
unusual O
psychiatric O
disorder O
, O
which O
initially O
requires O
surgical O
treatment O
. O

_RARE_ I-GENE
of O
a O
TSH I-GENE
- I-GENE
_RARE_ I-GENE
method O
for O
detection O
of O
hypothyroidism O
in O
the O
newborn O

Thus O
analysis O
indicated O
no O
reliable O
evidence O
that O
conscious O
_RARE_ I-GENE
_RARE_ I-GENE
become O
incorporated O
into O
_RARE_ I-GENE
content O
. O

The O
prevalence O
of O
hepatitis I-GENE
B I-GENE
surface O
antigen I-GENE
( O
HBsAg I-GENE
) O
and O
anti I-GENE
- I-GENE
HBs I-GENE
was O
determined O
by O
a O
sensitive O
double O
- I-GENE
antibody I-GENE
_RARE_ I-GENE
- I-GENE
immunoassay O
technique O
in O
a O
series O
of O
patients O
with O
chronic O
liver O
diseases O
. O

It O
was O
concluded O
that O
patients O
with O
acute O
respiratory O
failure O
requiring O
artificial O
ventilation O
have O
two O
_RARE_ I-GENE
of O
the O
pulmonary O
shunt O
, O
one O
parallel O
with O
and O
the O
other O
inversely O
related I-GENE
with O
the O
_RARE_ I-GENE
. O

_RARE_ I-GENE
cardiac O
glycogen I-GENE
following O
_RARE_ I-GENE
injection O
in O
_RARE_ I-GENE
, O
_RARE_ I-GENE
_RARE_ I-GENE
rats O
. O

Biological O
evaluation O
of O
_RARE_ I-GENE
in O
the O
female O
_RARE_ I-GENE
. O

_RARE_ I-GENE
of O
both O
_RARE_ I-GENE
and O
_RARE_ I-GENE
were O
significantly O
higher O
during O
early I-GENE
spontaneous O
labour O
, O
at O
a O
cervical O
dilatation O
of O
less O
than O
4 I-GENE
cm O
, O
than O
before O
the O
onset O
of O
labour O
. O

The O
most O
common O
cause O
of O
renal O
deterioration O
in O
the O
spinal O
cord O
_RARE_ I-GENE
patient O
is O
irreversible O
_RARE_ I-GENE
reflux O
. O

_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
administered O
in O
a O
dose O
which O
blocks O
the O
beta I-GENE
- I-GENE
adrenergic I-GENE
apparatus O
of O
the O
heart O
prevents O
the O
development O
of O
the O
positive O
inotropic O
effect O
of O
therapeutic O
doses O
of O
_RARE_ I-GENE
K I-GENE
on O
a O
_RARE_ I-GENE
left O
ventricular O
myocardium O
. O

Recent O
studies O
have O
shown O
the O
rat I-GENE
larynx O
to O
be O
an O
important O
organ O
in O
the O
evaluation O
of O
_RARE_ I-GENE
of O
inhaled O
materials O
. O

_RARE_ I-GENE
electron O
microscopic O
investigations O
on O
the O
formation O
of O
_RARE_ I-GENE
' O
s O
fiber O
in O
_RARE_ I-GENE
_RARE_ I-GENE

_RARE_ I-GENE
behavior O
, O
_RARE_ I-GENE
body O
weight O
and O
_RARE_ I-GENE
_RARE_ I-GENE
in O
European O
hamsters O
lesioned O
in O
the O
noradrenergic O
ascending O
_RARE_ I-GENE

Role O
of O
the O
infectious O
- I-GENE
disease O
_RARE_ I-GENE
of O
a O
_RARE_ I-GENE
in O
reducing O
the O
incidence O
of O
_RARE_ I-GENE
diseases O

These O
observed O
drug O
interactions O
, O
plus O
the O
known O
effect O
of O
_RARE_ I-GENE
to O
block O
secretion O
of O
_RARE_ I-GENE
, O
have O
to O
be O
considered O
in O
evaluating O
the O
effect O
of O
the O
two O
drugs O
given O
together O
, O
compared O
to O
the O
effect O
of O
each O
drug O
given O
separately O
. O

_RARE_ I-GENE
arrest O
in O
the O
operating O
room O
. O

At O
a O
systolic O
blood O
pressure O
( O
BP I-GENE
) O
of O
60 O
mmHg O
, O
_RARE_ I-GENE
responsiveness O
was O
abolished O
, O
but O
was O
maintained O
at O
higher O
levels O
of O
BP I-GENE
. O

_RARE_ I-GENE
- I-GENE
123 O
was O
_RARE_ I-GENE
_RARE_ I-GENE
only O
with O
the O
_RARE_ I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
, O
which O
in O
turn I-GENE
yielded O
_RARE_ I-GENE
values O
comparable O
to O
those O
measured O
for O
99mTc O
. O

_RARE_ I-GENE
_RARE_ I-GENE
en I-GENE
plaque O
presenting O
as O
a O
right O
middle I-GENE
ear O
tumor I-GENE
. O

The O
_RARE_ I-GENE
to O
_RARE_ I-GENE
prostaglandins O
( O
_RARE_ I-GENE
) O
by O
gas O
- I-GENE
liquid O
chromatography O
are O
mainly O
due O
to O
the O
lack O
of O
sensitivity O
of O
the O
gas O
- I-GENE
_RARE_ I-GENE
itself O
( O
higher O
than O
200 O
ng O
) O
and O
to O
the O
poor O
resolution O
of O
the O
_RARE_ I-GENE
_RARE_ I-GENE
. O

On O
cessation O
of O
steroid I-GENE
therapy O
the O
patient O
was O
noted O
to O
have O
_RARE_ I-GENE
manifestations O
of O
_RARE_ I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
as O
well O
as O
clinical O
and O
laboratory O
features O
of O
rheumatoid I-GENE
arthritis O
( O
RA O
). O

The O
effect O
of O
food O
on O
_RARE_ I-GENE
absorption O
. O

After O
giving O
a O
survey O
on O
the O
_RARE_ I-GENE
of O
antibiotic O
resistance O
in O
the O
region O
of O
Northern O
_RARE_ I-GENE
during O
_RARE_ I-GENE
/ I-GENE
74 O
and O
comparing O
the O
activity O
of O
a O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
combination O
to O
other O
commonly O
used O
antibiotics O
and O
chemotherapeutic O
agents O
, O
the O
results O
of O
tests O
with O
the O
new O
combination O
of O
N1 O
-( O
4 I-GENE
, O
5 I-GENE
- I-GENE
dimethyl O
- I-GENE
2 I-GENE
- I-GENE
_RARE_ I-GENE
)- I-GENE
_RARE_ I-GENE
) O
( O
_RARE_ I-GENE
) O
and O
2 I-GENE
, O
4 I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
5 I-GENE
-( O
3 I-GENE
, O
4 I-GENE
, O
5 I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
)- I-GENE
pyrimidine O
( O
_RARE_ I-GENE
) O
at O
a O
ratio O
of O
5 I-GENE
: O
1 I-GENE
( O
_RARE_ I-GENE
_RARE_ I-GENE
; O
_RARE_ I-GENE
, O
_RARE_ I-GENE
) O
are O
compared O
to O
those O
of O
tests O
with O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
. O

RESULTS O
: O
Total O
IgE I-GENE
levels O
showed O
a O
tendency O
to O
_RARE_ I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
loop I-GENE
syndrome O
exist O
_RARE_ I-GENE
It O
is O
the O
author O
' O
s O
_RARE_ I-GENE
that O
diagnosis O
of O
the O
" O
_RARE_ I-GENE
loop I-GENE
syndrome O
" O
is O
unlikely O
to O
be O
correct O
in O
patients O
subjected O
to O
_RARE_ I-GENE
- I-GENE
II I-GENE
_RARE_ I-GENE
. O

Letter O
: O
Is O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
damage O
the O
_RARE_ I-GENE
cause O
of O
' O
post O
- I-GENE
inflammatory O
_RARE_ I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
_RARE_ I-GENE

These O
data O
suggest O
that O
spontaneous O
recovery O
of O
central O
respiratory O
function O
after O
_RARE_ I-GENE
with O
_RARE_ I-GENE
or O
_RARE_ I-GENE
may O
not O
be O
related I-GENE
to O
the O
return O
of O
_RARE_ I-GENE
activity O
. O

_RARE_ I-GENE
cultures O
of O
S I-GENE
. O
_RARE_ I-GENE
serotype I-GENE
a O
demonstrated O
no O
growth I-GENE
on O
_RARE_ I-GENE
agar O
. O

Also O
, O
samples O
of O
serum I-GENE
were O
absorbed O
with O
the O
various O
solid O
- I-GENE
phase O
allergens O
and O
the O
reactivity O
of O
the O
remaining O
IgE I-GENE
antibodies I-GENE
was O
determined O
. O

_RARE_ I-GENE
of O
the O
therapeutic O
community O
in O
_RARE_ I-GENE
_RARE_ I-GENE

_RARE_ I-GENE
women O
at O
term O
had O
the O
lowest O
levels O
of O
antithrombin I-GENE
III I-GENE
. O

_RARE_ I-GENE
problem O
of O
the O
month O
: O
band O
or O
_RARE_ I-GENE
? O

It O
is O
possible O
that O
cyclic I-GENE
variations O
in O
heme O
turnover O
are O
related I-GENE
to O
changes O
in O
erythrocyte I-GENE
characteristics O
during O
the O
progesterone I-GENE
phase O
. O

_RARE_ I-GENE
in O
cardiopulmonary O
bypass O
using O
a O
_RARE_ I-GENE
derivative O
for O
_RARE_ I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
of O
the O
_RARE_ I-GENE
gland O

I I-GENE
. O

The O
recovered O
calves O
were O
tested O
for O
immunity O
to O
homologous O
severe O
challenge O
, O
50 O
or O
73 O
days O
after O
the O
first O
infection O
. O

The O
performance O
of O
three O
commonly O
used O
chemical O
_RARE_ I-GENE
_RARE_ I-GENE
for O
_RARE_ I-GENE
was O
measured O
under O
working O
conditions O
in O
a O
copper I-GENE
_RARE_ I-GENE
. O

The O
neuroleptic O
- I-GENE
induced O
increase O
in O
central O
DA I-GENE
turnover O
( O
an O
indicator O
for O
the O
degree O
of O
DA I-GENE
receptor I-GENE
blocking O
) O
was O
found O
to O
be O
positively O
correlated O
with O
the O
therapeutic O
effect O
of O
_RARE_ I-GENE
and O
the O
development O
of O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
symptoms O
. O

_RARE_ I-GENE
trout I-GENE
were O
obtained O
from O
a O
commercial O
trout I-GENE
_RARE_ I-GENE
, O
kept O
in O
_RARE_ I-GENE
water O
and O
feeding O
in O
experimental O
pellets O
for O
4 I-GENE
to O
8 O
weeks O
. O

_RARE_ I-GENE
of O
macrophage I-GENE
function O
by O
killed O
_RARE_ I-GENE
pertussis I-GENE
cells O
did O
not O
show O
any O
beneficial O
effect O
as O
an O
increased O
susceptibility I-GENE
became O
apparent O
. O

Primary O
_RARE_ I-GENE
in O
a O
_RARE_ I-GENE
female O
individual O
with O
a O
_RARE_ I-GENE
46 O
, O
_RARE_ I-GENE
and O
bilateral O
_RARE_ I-GENE

_RARE_ I-GENE
absolute O
methods O
in O
clinical O
chemistry O
: O
application O
of O
mass O
_RARE_ I-GENE
to O
high O
- I-GENE
accuracy O
analyses O
. O

_RARE_ I-GENE
of O
the O
2 I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
D I-GENE
- I-GENE
glucose O
method O
to O
the O
coupling O
of O
cerebral O
metabolism O
and O
blood O
flow O
. O

Serum I-GENE
gastrin I-GENE
levels O
did O
not O
change O
in O
either O
group O
; O
however O
, O
background O
serum I-GENE
gastrin I-GENE
concentrations O
were O
significantly O
greater O
for O
V I-GENE
& O
P I-GENE
patients O
than O
V I-GENE
& O
A I-GENE
patients O
throughout O
the O
study O
. O

_RARE_ I-GENE
projections O
of O
the O
ventral O
portion O
of O
the O
_RARE_ I-GENE
to O
the O
frontal O
, O
_RARE_ I-GENE
and O
temporal O
regions O
of O
the O
cat O
cerebral O
cortex O

_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
exercise O
response O
tests O
were O
conducted O
on O
the O
_RARE_ I-GENE
of O
the O
second O
_RARE_ I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
3 I-GENE
) O
as O
part O
of O
an O
evaluation O
of O
physiological O
adaptation O
to O
long O
- I-GENE
term O
_RARE_ I-GENE
. O

Mean O
_RARE_ I-GENE
hemoglobin I-GENE
concentrations O
remained O
normal O
for O
48 O
h O
and O
then O
decreased O
in O
both O
groups O
, O
the O
CO2 O
group O
showing O
the O
larger O
decrease O
. O

All O
Cu I-GENE
values O
obtained O
from O
the O
organs O
investigated O
had O
reached O
a O
saturation O
level O
at O
8 O
_RARE_ I-GENE
Cu I-GENE
/ I-GENE
g O
diet O
with O
the O
exception O
of O
the O
values O
for O
body O
Cu I-GENE
found O
in O
the O
_RARE_ I-GENE
that O
were O
killed O
on O
the O
day O
of O
delivery O
. O

The O
effect O
of O
calcitonin I-GENE
, O
a O
large O
amount O
of O
calcium O
given O
orally O
, O
_RARE_ I-GENE
and O
glucagon I-GENE
on O
plasma I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
curves O
in O
subjects O
pretreated O
with O
_RARE_ I-GENE
was O
examined O
. O

State O
of O
the O
body O
in O
disorders O
of O
_RARE_ I-GENE
physiological O
_RARE_ I-GENE
and O
long O
- I-GENE
term O
_RARE_ I-GENE

_RARE_ I-GENE
tension O
of O
the O
small I-GENE
lymph O
vessels O
( O
_RARE_ I-GENE
) O
of O
the O
rabbit I-GENE
_RARE_ I-GENE
limb O
was O
measured O
with O
both O
a O
flow O
- I-GENE
through O
micro O
chamber O
and O
a O
_RARE_ I-GENE
catheter O
- I-GENE
tip O
oxygen O
electrode O
to O
obtain O
experimental O
data O
on O
the O
source O
of O
oxygen O
in O
the O
lymph O
. O

The O
response O
of O
the O
plasma I-GENE
fibrinogen I-GENE
level O
to O
the O
_RARE_ I-GENE
injection O
of O
_RARE_ I-GENE
and O
to O
the O
intravenous O
injection O
of O
endotoxin I-GENE
was O
measured O
in O
normal O
rabbits O
and O
in O
rabbits O
made O
_RARE_ I-GENE
and O
_RARE_ I-GENE
with O
_RARE_ I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
pressure O
curves O
without O
uterine O
activities O
are O
interpreted O
as O
characteristic O
_RARE_ I-GENE
criteria O
of O
an O
advanced O
ectopic O
_RARE_ I-GENE
. O

Since O
myoglobin I-GENE
is O
co O
- I-GENE
extracted O
with O
the O
hemoglobin I-GENE
, O
the O
2 I-GENE
heme O
_RARE_ I-GENE
are O
separated O
in O
one O
portion O
of O
the O
extract O
by O
precipitating O
the O
hemoglobin I-GENE
in O
an O
85 O
% O
( O
_RARE_ I-GENE
) O
_RARE_ I-GENE
solution O
. O

_RARE_ I-GENE
these O
sources O
of O
error O
some O
of O
the O
variability O
in O
the O
present O
investigation O
might O
be O
_RARE_ I-GENE
by O
systematic O
_RARE_ I-GENE
. O

E I-GENE
50 O
, O
_RARE_ I-GENE
( O
1994 O
)]. O

Six O
patients O
with O
the O
diagnosis O
of O
acute O
_RARE_ I-GENE
were O
treated O
with O
high O
doses O
of O
the O
beta I-GENE
- I-GENE
adrenergic I-GENE
blocking O
agent O
propranolol O
. O

Effect O
of O
trauma O
on O
plasma I-GENE
glucagon I-GENE
and O
insulin I-GENE
concentrations O
in O
sheep O
. O

With O
the O
help O
of O
a O
_RARE_ I-GENE
one O
can O
_RARE_ I-GENE
off O
the O
_RARE_ I-GENE
, O
when O
axis O
length I-GENE
and O
corneal O
_RARE_ I-GENE
are O
known O
. O

This O
up O
- I-GENE
_RARE_ I-GENE
of O
the O
final O
score O
by O
the O
CA I-GENE
component O
is O
greater O
( O
3 I-GENE
- I-GENE
8 O
%) O
in O
the O
less O
able O
students O
with O
scores O
below O
the O
mean O
level O
. O

_RARE_ I-GENE
to O
controls O
, O
both O
_RARE_ I-GENE
and O
_RARE_ I-GENE
rats O
showed O
a O
small I-GENE
but O
significant O
post O
- I-GENE
operative O
reduction O
in O
the O
_RARE_ I-GENE
of O
drinking O
. O

Effect O
of O
indomethacin O
on O
coronary O
circulation O
: O
effect O
on O
ECG O
_RARE_ I-GENE

_RARE_ I-GENE
_RARE_ I-GENE
of O
fast O
fibers O
in O
trunk O
muscles O
of O
_RARE_ I-GENE
larvae O

The O
feed O
_RARE_ I-GENE
which O
was O
lowered O
by O
25 O
% O
initially O
, O
did O
not O
alter O
later O
. O

_RARE_ I-GENE
characteristics O
of O
eye O
changes O
in O
patients O
with O
_RARE_ I-GENE
including O
_RARE_ I-GENE
' O
s O
syndrome O

The O
color O
- I-GENE
_RARE_ I-GENE
interference O
effect O
previously O
reported O
with O
normal O
populations O
when O
given O
the O
Stroop O
test O
was O
demonstrated O
for O
this O
retarded O
sample O
using O
a O
special O
_RARE_ I-GENE
. O

It O
was O
found O
that O
under O
the O
selected O
conditions O
a O
linear O
dependence O
exists O
between O
the O
_RARE_ I-GENE
% O
value O
and O
_RARE_ I-GENE
within O
the O
range O
of O
0 O
. O
5 I-GENE
-- O
10 O
_RARE_ I-GENE
_RARE_ I-GENE
. O

The O
influence O
of O
adrenergic I-GENE
nerves O
of O
the O
response O
of O
blood O
vessels O
in O
the O
rabbit I-GENE
ear O
to O
2 I-GENE
-- O
phenylalanine I-GENE
- I-GENE
8 O
- I-GENE
lysine O
vasopressin I-GENE
( O
_RARE_ I-GENE
). O

_RARE_ I-GENE
test O

I I-GENE
. O

When O
a O
tumour I-GENE
is O
present O
_RARE_ I-GENE
discharge O
is O
of O
little O
importance O
for O
the O
diagnosis O
and O
treatment O
. O

Studies O
of O
biochemical O
and O
morphological O
changes O
( O
between O
normal O
and O
treated O
animals O
) O
show O
that O
_RARE_ I-GENE
induces O
an O
increase O
in O
the O
lung O
free O
cell O
population O
and O
pulmonary O
surfactant I-GENE
levels O
. O

_RARE_ I-GENE
measurements O
of O
temperature O
changes O
and O
estimates O
of O
the O
_RARE_ I-GENE
produced O
at O
the O
_RARE_ I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
' O
National O
Health O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
'. O

Is O
_RARE_ I-GENE
of O
patient O
care O
_RARE_ I-GENE
and O
does O
it O
have O
_RARE_ I-GENE
value O
? O
Patients O
' O
_RARE_ I-GENE
contributes O
to O
improved O
patient O
care O

_RARE_ I-GENE
of O
" O
_RARE_ I-GENE
Effects O
of O
Test O
_RARE_ I-GENE
and O
_RARE_ I-GENE
/ I-GENE
No O
_RARE_ I-GENE
or O
A I-GENE
- I-GENE
F I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
upon O
Short O
- I-GENE
term O
and O
_RARE_ I-GENE
- I-GENE
term O
_RARE_ I-GENE
of O
_RARE_ I-GENE
_RARE_ I-GENE
. O

These O
studies O
have O
shown O
that O
the O
majority O
of O
tested O
_RARE_ I-GENE
were O
resistant O
to O
penicillin I-GENE
G I-GENE
, O
_RARE_ I-GENE
, O
and O
produced O
beta I-GENE
- I-GENE
lactamase I-GENE
. O

Since O
_RARE_ I-GENE
, O
a O
_RARE_ I-GENE
decrease O
in O
the O
number O
of O
strains O
resistant O
to O
three O
or O
more O
antibiotics O
( O
multiple O
- I-GENE
resistant O
) O
and O
in O
strains O
of O
the O
_RARE_ I-GENE
complex I-GENE
was O
_RARE_ I-GENE
. O

_RARE_ I-GENE
of O
nursing O
_RARE_ I-GENE
to O
be O
given O
at O
the O
time O
of O
discharge O
from O
the O
_RARE_ I-GENE
for O
premature O
infants O

No O
difference O
in O
the O
clinical O
_RARE_ I-GENE
could O
be O
_RARE_ I-GENE
between O
the O
two O
groups O
. O

After O
90 O
d O
a O
_RARE_ I-GENE
, O
_RARE_ I-GENE
_RARE_ I-GENE
- I-GENE
like I-GENE
lesion O
was O
observed O
in O
two O
specimens O
only O
. O

The O
_RARE_ I-GENE
pattern O
of O
_RARE_ I-GENE
women O
was O
analysed O
and O
13 O
. O
8 O
percent O
were O
using O
inefficient O
methods O
. O

_RARE_ I-GENE
technique O
and O
indirect O
blood O
pressure O
recordings O
were O
used O
. O

I I-GENE
. O

The O
second O
and O
third O
responded O
similarly O
to O
either O
a O
combined O
cyclophosphamide O
+ I-GENE
_RARE_ I-GENE
globulin I-GENE
( O
_RARE_ I-GENE
) O
treatment O
or O
to O
_RARE_ I-GENE
administration O
_RARE_ I-GENE
by O
a O
small I-GENE
dosage O
of O
cyclophosphamide O
, O
which O
had O
proved O
_RARE_ I-GENE
when O
administered O
alone O
. O

Evidence O
is O
presented O
that O
_RARE_ I-GENE
' O
s O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
is O
not O
a O
separate O
_RARE_ I-GENE
but O
a O
special O
form O
of O
_RARE_ I-GENE
' O
disease O
. O

_RARE_ I-GENE
_RARE_ I-GENE
along O
the O
catheter O
was O
found O
in O
20 O
patients O
studied O
by O
_RARE_ I-GENE
- I-GENE
out O
_RARE_ I-GENE
and O
was O
_RARE_ I-GENE
with O
clinical O
symptoms O
. O

The O
influence O
of O
a O
mobile O
_RARE_ I-GENE
on O
the O
response O
in O
the O
DC O
- I-GENE
_RARE_ I-GENE
is O
demonstrated O
. O

A I-GENE
newly O
synthesized O
anti I-GENE
- I-GENE
inflammatory O
agent O
, O
Y I-GENE
- I-GENE
_RARE_ I-GENE
demonstrated O
a O
greater O
inhibition O
than O
did O
indomethacin O
( O
IM O
). O
on O
inflammatory O
response O
such O
as O
_RARE_ I-GENE
_RARE_ I-GENE
in O
guinea O
pigs O
, O
_RARE_ I-GENE
edema O
, O
_RARE_ I-GENE
blue O
and O
_RARE_ I-GENE
- I-GENE
induced O
_RARE_ I-GENE
and O
_RARE_ I-GENE
acid I-GENE
- I-GENE
induced O
_RARE_ I-GENE
in O
rats O
. O

As O
_RARE_ I-GENE
shifted O
in O
_RARE_ I-GENE
from O
_RARE_ I-GENE
to O
_RARE_ I-GENE
with O
age O
, O
_RARE_ I-GENE
_RARE_ I-GENE
appeared O
to O
maintain O
gradually O
increasing O
rates O
of O
whole O
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
until O
_RARE_ I-GENE
were O
approximately O
400 O
years O
old O
. O

_RARE_ I-GENE
- I-GENE
1 I-GENE
antitrypsin I-GENE
and O
_RARE_ I-GENE
childhood O
cirrhosis O
. O

_RARE_ I-GENE
_RARE_ I-GENE
, O
serum I-GENE
IgE I-GENE
and O
total O
eosinophil O
counts O
in O
patients O
with O
bronchial O
asthma O
. O

A I-GENE
range O
of O
normal O
ventricular O
measurements O
for O
the O
_RARE_ I-GENE
scan O
is O
suggested O
. O

A I-GENE
comparison O
of O
physical O
and O
cytogenetic O
estimates O
of O
radiation O
dose O
in O
patients O
treated O
with O
iodine O
- I-GENE
131 O
for O
thyroid I-GENE
carcinoma O
. O

_RARE_ I-GENE
for O
obtaining O
_RARE_ I-GENE
_RARE_ I-GENE
with O
_RARE_ I-GENE
mass O

Mean O
total O
lung O
capacity O
, O
functional O
residual O
capacity O
, O
and O
residual O
volume O
increased O
significantly O
, O
and O
the O
mean O
_RARE_ I-GENE
volume O
, O
the O
lung O
volume O
above O
residual O
volume O
at O
which O
phase O
IV I-GENE
begins O
, O
decreased O
significantly O
with O
11 O
cm O
_RARE_ I-GENE
continuous O
positive O
airway O
pressure O
; O
differences O
at O
5 I-GENE
cm O
_RARE_ I-GENE
were O
not O
significant O
. O

Current O
status O
of O
zinc I-GENE
deficiency O
in O
the O
pathogenesis O
of O
neurological O
, O
_RARE_ I-GENE
and O
_RARE_ I-GENE
disorders O
. O

_RARE_ I-GENE
and O
phosphorus O
metabolism O
in O
chronic O
_RARE_ I-GENE
. O

_RARE_ I-GENE
studies O
, O
conducted O
with O
Delta I-GENE
- I-GENE
9 O
- I-GENE
_RARE_ I-GENE
, O
in O
healthy O
_RARE_ I-GENE
, O
again O
suggest O
the O
comparison O
or O
even O
the O
identity O
of O
the O
modifications O
caused O
by O
_RARE_ I-GENE
with O
sleep O
and O
_RARE_ I-GENE
. O

The O
_RARE_ I-GENE
action O
of O
_RARE_ I-GENE
_RARE_ I-GENE
upon O
the O
_RARE_ I-GENE
effects O
induced O
by O
_RARE_ I-GENE
has O
been O
studied O
in O
32 O
acute O
_RARE_ I-GENE
states O
. O

_RARE_ I-GENE
growth I-GENE
was O
retarded O
in O
animals O
maintained O
solely O
on O
_RARE_ I-GENE
_RARE_ I-GENE
and O
improved O
with O
supplementation O
. O

Two O
patients O
were O
treated O
with O
both O
regimens O
. O

Results O
obtained O
for O
chloramphenicol I-GENE
- I-GENE
containing O
preparations O
are O
presented O
, O
and O
both O
dissolution O
curves O
and O
_RARE_ I-GENE
- I-GENE
plate I-GENE
assays O
demonstrate O
that O
chloramphenicol I-GENE
has O
far O
superior O
release O
( O
and O
hence O
activity O
) O
from O
_RARE_ I-GENE
than O
from O
ophthalmic O
_RARE_ I-GENE
. O

IgG I-GENE
levels O
of O
1 I-GENE
/ I-GENE
100 O
were O
present O
in O
only O
four O
out O
of O
ten O
samples O
obtained O
150 O
days O
after O
the O
clinical O
onset O
. O

Letter O
: O
_RARE_ I-GENE
in O
bone O
marrow O
transplantation O
. O

Assessment O
of O
the O
_RARE_ I-GENE
of O
non O
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
II I-GENE
: O
_RARE_ I-GENE
and O
_RARE_ I-GENE
. O

The O
_RARE_ I-GENE
behaviour O
in O
weakly O
infected O
mice O
was O
due O
to O
the O
occurrence O
in O
some O
animals O
of O
a O
second O
phase O
of O
more O
rapid O
increase O
of O
the O
_RARE_ I-GENE
. O

_RARE_ I-GENE
amphotericin O
B I-GENE
was O
detected O
in O
the O
_RARE_ I-GENE
of O
the O
mice O
only O
while O
they O
were O
receiving O
the O
0 O
. O
3 I-GENE
mg O
/ I-GENE
ml O
dose O
level O
. O

There O
was O
a O
slight O
increase O
in O
total O
transferrin I-GENE
2 I-GENE
hr O
after O
1 I-GENE
tablet O
and O
values O
remained O
high O
throughout O
the O
experiment O
. O

Following O
intravenous O
administration O
, O
the O
myocardial O
concentration O
of O
tracer O
thallium O
- I-GENE
201 O
, O
potassium O
- I-GENE
43 I-GENE
, O
and O
_RARE_ I-GENE
- I-GENE
81 O
were O
determined O
in O
mice O
; O
thallium O
was O
present O
in O
the O
greatest O
concentration O
in O
the O
myocardium O
( O
2 I-GENE
. O
_RARE_ I-GENE
% O
compared O
1 I-GENE
. O
25 O
% O
for O
potassium O
and O
1 I-GENE
. O
15 O
% O
for O
_RARE_ I-GENE
at O
10 O
minutes O
). O

_RARE_ I-GENE
time O
, O
partial O
thromboplastin I-GENE
time O
, O
thrombin I-GENE
time O
, O
heat I-GENE
- I-GENE
dependent I-GENE
fibrin I-GENE
, O
_RARE_ I-GENE
_RARE_ I-GENE
, O
and O
clotting I-GENE
factors I-GENE
II I-GENE
, O
V I-GENE
, O
VIII I-GENE
, O
IX I-GENE
, O
X I-GENE
, O
and O
the O
platelet I-GENE
count O
were O
determined O
. O

The O
data O
support O
the O
notion O
that O
suppression O
of O
images O
during O
_RARE_ I-GENE
_RARE_ I-GENE
is O
independent O
in O
both O
eyes O
. O

_RARE_ I-GENE
utilization O
was O
increased O
, O
but O
tissue I-GENE
levels O
of O
creatine I-GENE
phosphate I-GENE
, O
ATP I-GENE
, O
and O
lactate I-GENE
were O
similar O
to O
those O
in O
hearts O
receiving O
normal O
flow O
. O

The O
records O
from O
_RARE_ I-GENE
through O
_RARE_ I-GENE
of O
_RARE_ I-GENE
previously O
untreated O
patients O
with O
squamous O
cell O
carcinoma O
of O
the O
oral O
cavity O
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
larynx O
and O
_RARE_ I-GENE
who O
had O
clinically O
positive O
cervical O
lymph O
node O
metastases O
_RARE_ I-GENE
N1 O
, O
_RARE_ I-GENE
, O
or O
_RARE_ I-GENE
, O
and O
whose O
initial O
neck O
treatment O
consisted O
of O
external O
radiation O
therapy O
alone O
were O
reviewed O
. O

With O
0 O
. O
5 I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
the O
corresponding O
values O
were O
_RARE_ I-GENE
mumol O
/ I-GENE
1 I-GENE
( O
5 I-GENE
. O
72 O
mg O
/ I-GENE
100 O
ml O
) O
and O
_RARE_ I-GENE
mumol O
/ I-GENE
1 I-GENE
( O
2 I-GENE
. O
25 O
mg O
/ I-GENE
100 O
ml O
) O
respectively O
. O

The O
authors O
describe O
the O
technique O
of O
transverse O
axial O
tomography O
of O
the O
spine O
and O
give O
a O
detailed O
description O
of O
the O
axial O
_RARE_ I-GENE
of O
the O
normal O
lumbar O
spine O
from O
L I-GENE
- I-GENE
4 I-GENE
to O
the O
_RARE_ I-GENE
. O

_RARE_ I-GENE
to O
parental O
_RARE_ I-GENE
, O
a O
low O
protein I-GENE
diet O
( O
1 I-GENE
- I-GENE
5 I-GENE
g O
/ I-GENE
kg O
) O
was O
introduced O
only O
late O
. O

In O
none O
of O
the O
44 I-GENE
type I-GENE
I I-GENE
attacks O
and O
29 O
type I-GENE
II I-GENE
attacks O
which O
were O
recorded O
did O
circulatory O
changes O
; O
the O
latter O
were O
different O
in O
the O
two O
groups O
. O

A I-GENE
clinically O
useful O
diagnostic O
method O
has O
been O
developed O
for O
detecting O
and O
_RARE_ I-GENE
periods O
of O
apnea O
in O
pediatric O
patients O
. O

The O
other O
_RARE_ I-GENE
patient O
showed O
an O
_RARE_ I-GENE
insulin I-GENE
release O
in O
response O
to O
_RARE_ I-GENE
. O

_RARE_ I-GENE
stimulation O
( O
1 I-GENE
. O
5 I-GENE
- I-GENE
12 O
cycles O
/ I-GENE
s O
) O
produced O
frequency O
- I-GENE
dependent I-GENE
reductions O
in O
CBF I-GENE
, O
a O
decrease O
of O
50 O
percent O
occurring O
with O
the O
highest O
frequency O
. O

Effect O
of O
ingestion O
of O
_RARE_ I-GENE
during O
the O
_RARE_ I-GENE
period O
of O
the O
genital O
organs O

Risk O
of O
infection O
in O
the O
treatment O
of O
_RARE_ I-GENE

_RARE_ I-GENE
_RARE_ I-GENE
were O
perfused O
with O
solutions O
of O
0 O
. O
9 O
% O
Na I-GENE
C1 I-GENE
, O
0 O
. O
1 I-GENE
N I-GENE
_RARE_ I-GENE
, O
40 I-GENE
% O
glucose O
, O
40 I-GENE
% O
_RARE_ I-GENE
, O
and O
40 I-GENE
% O
_RARE_ I-GENE
or O
with O
0 O
. O
1 I-GENE
% O
solutions O
of O
acetylcholine I-GENE
chloride O
. O

Liver O
_RARE_ I-GENE
of O
the O
_RARE_ I-GENE
showed O
smaller O
than O
8 O
% O
of O
the O
_RARE_ I-GENE
_RARE_ I-GENE
activity O
and O
smaller O
than O
14 O
% O
of O
the O
_RARE_ I-GENE
capacity O
of O
liver O
_RARE_ I-GENE
from O
the O
rat I-GENE
. O

_RARE_ I-GENE
heavy I-GENE
work O
_RARE_ I-GENE
an O
increase O
of O
10 O
. O
3 I-GENE
plus O
or O
minus O
0 O
. O
9 O
mmHg O
in O
in O
vivo O
_RARE_ I-GENE
( O
7 O
. O
30 O
PH I-GENE
- I-GENE
v I-GENE
, O
41 O
degrees O
C I-GENE
- I-GENE
v I-GENE
, O
and O
45 O
_RARE_ I-GENE
- I-GENE
CO2 O
); O
due O
entirely O
to O
the O
additive O
effects O
of O
increased O
venous O
temperature O
and O
[ O
H I-GENE
_RARE_ I-GENE

A I-GENE
clinical O
, O
serological O
and O
prognostic O
study O

The O
American O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
: O
a O
progress O
report O
. O

_RARE_ I-GENE
with O
an O
alternative O
instrument O
system O
. O

The O
metabolic O
clearance O
rate O
of O
progesterone I-GENE
was O
_RARE_ I-GENE
+/- O
49 O
( O
S I-GENE
. O
E I-GENE
.) O
1 I-GENE
/ I-GENE
day O
. O

This O
sequence I-GENE
is O
almost O
identical O
with O
that O
of O
human I-GENE
_RARE_ I-GENE
hormone I-GENE
( O
_RARE_ I-GENE
, O
M I-GENE
. O

The O
mean O
plasma I-GENE
sodium O
concentration O
which O
was O
135 O
. O
95 O
(+/- O
SD O
4 I-GENE
. O
14 O
) O
mEq O
/ I-GENE
kg O
before O
diuretic O
treatment O
was O
significantly O
decreased O
during O
treatment O
to O
_RARE_ I-GENE
. O
19 O
(+/- O
SD O
2 I-GENE
. O
77 O
) O
mEq O
/ I-GENE
kg O
, O
P I-GENE
less O
than O
0 O
. O
001 O
. O

_RARE_ I-GENE
: O
Low O
- I-GENE
dose O
heparin O
and O
the O
prevention O
of O
venous O
_RARE_ I-GENE
disease O
. O

At O
the O
very O
high O
dose O
levels O
used O
, O
sodium O
saccharin O
and O
sodium O
_RARE_ I-GENE
were O
weak O
_RARE_ I-GENE
_RARE_ I-GENE
producing O
4 I-GENE
/ I-GENE
_RARE_ I-GENE
and O
3 I-GENE
/ I-GENE
_RARE_ I-GENE
bladder O
tumours O
respectively O
, O
and O
the O
first O
of O
these O
tumours O
did O
not O
appear O
for O
more O
than O
80 O
weeks O
. O

Effects O
of O
_RARE_ I-GENE
_RARE_ I-GENE
on O
the O
matrix I-GENE
task O
performance O
of O
four O
- I-GENE
and O
six O
- I-GENE
year O
- I-GENE
old O
children O
. O

_RARE_ I-GENE
- I-GENE
6 I-GENE
- I-GENE
phosphate I-GENE
dehydrogenase I-GENE
( O
G I-GENE
- I-GENE
6 I-GENE
- I-GENE
PD I-GENE
) O
deficiency O
in O
the O
newborn O
. O

The O
_RARE_ I-GENE
solvent O
was O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
( O
10 O
+ I-GENE
90 O
) O
at O
a O
flow O
rate O
of O
2 I-GENE
. O
0 O
ml O
/ I-GENE
min O
. O

The O
bronchial O
_RARE_ I-GENE
of O
all O
smoke O
- I-GENE
exposed O
animals O
were O
_RARE_ I-GENE
, O
and O
their O
_RARE_ I-GENE
showed O
_RARE_ I-GENE
, O
tilt O
of O
nuclear I-GENE
_RARE_ I-GENE
, O
an O
increase O
in O
the O
number O
and O
size O
of O
_RARE_ I-GENE
and O
_RARE_ I-GENE
bodies O
, O
and O
increased O
numbers O
of O
_RARE_ I-GENE
_RARE_ I-GENE
granules O
. O

The O
routine O
administration O
of O
fat O
- I-GENE
soluble I-GENE
_RARE_ I-GENE
appears O
_RARE_ I-GENE
but O
it O
is O
_RARE_ I-GENE
to O
measure O
prothrombin I-GENE
time O
and O
serum I-GENE
_RARE_ I-GENE
A I-GENE
and O
E I-GENE
at O
intervals O
. O

_RARE_ I-GENE
F I-GENE
( O
_RARE_ I-GENE
) O
were O
measured O
in O
uterine O
vein O
, O
ovarian O
artery O
, O
and O
_RARE_ I-GENE
vein O
plasma I-GENE
and O
in O
the O
endometrial O
tissues O
at O
various O
times O
during O
the O
bovine I-GENE
_RARE_ I-GENE
cycle O
, O
and O
were O
compared O
to O
peripheral O
plasma I-GENE
progesterone I-GENE
levels O
. O

_RARE_ I-GENE
this O
date O
, O
the O
drug O
directly O
inhibits O
fetal O
weight O
gain O
, O
whereas O
the O
sensitivity O
of O
the O
placenta O
is O
only O
transient O
at O
day O
16 O
resulting O
in O
maximum O
weight O
decrease O
of O
this O
organ O
24 O
h O
later O
. O

_RARE_ I-GENE
of O
ten O
dependent I-GENE
and O
ten O
saline O
mice O
were O
_RARE_ I-GENE
tested O
in O
both O
light I-GENE
and O
dark O
conditions O
in O
each O
of O
five O
_RARE_ I-GENE
_RARE_ I-GENE
( O
2 I-GENE
- I-GENE
23 O
in O
high O
). O

The O
effects O
initiated O
from O
the O
nucleus O
_RARE_ I-GENE
_RARE_ I-GENE
were O
most O
marked O
. O

The O
appearance O
of O
_RARE_ I-GENE
movement O
disorders O
in O
humans O
following O
the O
chronic O
use O
of O
_RARE_ I-GENE
or O
amphetamine O
may O
be O
a O
manifestation O
of O
similarly O
increased O
dopamine I-GENE
receptor I-GENE
site I-GENE
sensitivity O
within O
the O
striatum I-GENE
. O

Association O
with O
HL I-GENE
- I-GENE
A I-GENE
W I-GENE
- I-GENE
27 O
. O

Letter O
: O
_RARE_ I-GENE
tolerance O
tests O
as O
a O
predictor O
of O
milk O
tolerance O
. O

_RARE_ I-GENE
: O
a O
study O
of O
natural O
history O
and O
prognosis O
of O
_RARE_ I-GENE
cases O
. O

Like O
pineal O
melatonin O
, O
serum I-GENE
melatonin O
was O
high O
at O
mid O
- I-GENE
dark O
and O
low O
at O
mid O
- I-GENE
light I-GENE
. O

D I-GENE
. O

_RARE_ I-GENE

The O
authors O
concluded O
that O
_RARE_ I-GENE
Doppler O
- I-GENE
_RARE_ I-GENE
can O
be O
used O
for O
measuring O
the O
relative O
changes O
in O
the O
stroke O
volume O
. O

The O
_RARE_ I-GENE
of O
sexual O
_RARE_ I-GENE
in O
terms O
of O
secondary O
sexual O
characteristics O
, O
the O
production O
of O
spermatozoa O
in O
the O
male O
, O
and O
the O
_RARE_ I-GENE
female O
pattern O
with O
release O
of O
_RARE_ I-GENE
are O
end O
- I-GENE
points O
of O
the O
developmental O
process O
. O

However O
, O
a O
10 O
-- O
15 O
% O
_RARE_ I-GENE
of O
the O
partial O
thromboplastin I-GENE
time O
is O
evident O
after O
24 O
hours O
of O
storage O
. O

_RARE_ I-GENE
should O
be O
_RARE_ I-GENE
in O
the O
use O
of O
these O
_RARE_ I-GENE
for O
_RARE_ I-GENE
. O

This O
reveals O
a O
new O
test O
for O
short O
_RARE_ I-GENE
_RARE_ I-GENE
and O
shows O
that O
14 O
per O
cent O
of O
_RARE_ I-GENE
stem O
from O
a O
_RARE_ I-GENE
reflux O
. O

Three O
groups O
of O
patients O
who O
had O
undergone O
subtotal O
_RARE_ I-GENE
for O
_RARE_ I-GENE
' O
s O
disease O
, O
toxic O
_RARE_ I-GENE
_RARE_ I-GENE
, O
or O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
12 O
to O
15 O
years O
before O
and O
in O
whom O
a O
normal O
serum I-GENE
thyroxine O
( O
T I-GENE
- I-GENE
4 I-GENE
) O
level O
was O
found O
were O
each O
divided O
into O
two O
subgroups O
on O
the O
basis O
of O
a O
normal O
or O
a O
raised O
serum I-GENE
_RARE_ I-GENE
concentration O
. O

_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
using O
_RARE_ I-GENE
Tc O
sulfur O
colloid O
for O
detection O
and O
follow O
- I-GENE
up O
of O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
reflux O

_RARE_ I-GENE
ion O
action O
on O
bacteria O
. O

No O
evidence O
of O
either O
positive O
or O
negative O
_RARE_ I-GENE
was O
found O
. O

The O
interpretation O
of O
antibiotic O
disc O
_RARE_ I-GENE
. O

Following O
_RARE_ I-GENE
, O
the O
affected O
epithelial O
_RARE_ I-GENE
appeared O
greatly O
_RARE_ I-GENE
over O
the O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
, O
with O
almost O
complete O
loss O
of O
structural O
detail O
. O

A I-GENE
study O
of O
chromosomes O
of O
lymphocytes O
from O
patients O
treated O
with O
_RARE_ I-GENE
. O

_RARE_ I-GENE
of O
anesthesia O
and O
resuscitation O
in O
_RARE_ I-GENE
lung O
surgery O

Study O
of O
the O
_RARE_ I-GENE
- I-GENE
chemical O
state O
of O
plutonium O
- I-GENE
239 O
in O
a O
citrate I-GENE
solution O
- I-GENE
blood O
system O

_RARE_ I-GENE
60 O
mg O
did O
not O
show O
any O
remarkable O
effect O
, O
but O
_RARE_ I-GENE
100 O
mg O
produced O
a O
slight O
_RARE_ I-GENE
effect O
on O
the O
action O
of O
d O
- I-GENE
_RARE_ I-GENE
. O

In O
about O
one O
third O
of O
the O
cases O
this O
operation O
results O
in O
_RARE_ I-GENE
and O
_RARE_ I-GENE
improvement O
for O
patients O
suffering O
from O
progressive O
_RARE_ I-GENE
_RARE_ I-GENE
. O

The O
specific I-GENE
electrical O
resistance O
of O
the O
cerebrospinal O
fluid O
was O
measured O
by O
means O
of O
_RARE_ I-GENE
in O
14 O
cases O
of O
meningitis O
_RARE_ I-GENE
, O
17 O
cases O
of O
meningitis O
_RARE_ I-GENE
, O
10 O
cases O
of O
_RARE_ I-GENE
and O
in O
32 O
control O
subjects O
. O

2 I-GENE
- I-GENE
Chemical O
occlusion O
of O
vas O
is O
quite O
effective O
in O
producing O
a O
block O
in O
the O
vas O
deferens O
of O
dogs O
. O

_RARE_ I-GENE
, O
we O
found O
in O
3 I-GENE
patients O
increased O
serum I-GENE
immunoglobulins I-GENE
, O
_RARE_ I-GENE
IgG I-GENE
, O
as O
first O
_RARE_ I-GENE
, O
_RARE_ I-GENE
and O
_RARE_ I-GENE
demonstrated O
in O
a O
large O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
family I-GENE
. O

We O
suggest O
that O
such O
_RARE_ I-GENE
occurred O
at O
the O
time O
of O
the O
infarction O
. O

_RARE_ I-GENE
preparation O
( O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
), O
a O
new O
type I-GENE
of O
anti I-GENE
- I-GENE
cancer O
agent O
, O
was O
given O
to O
the O
patients O
with O
advanced O
cancer O
in O
combination O
with O
_RARE_ I-GENE
- I-GENE
C I-GENE
, O
5 I-GENE
- I-GENE
FU O
and O
_RARE_ I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
, O
a O
correlation O
was O
observed O
between O
highest O
concentrations O
of O
CSF I-GENE
immunoglobulins I-GENE
and O
degree O
of O
_RARE_ I-GENE
inflammatory O
response O
, O
even O
if O
this O
was O
a O
component O
of O
other O
neurological O
diseases O
. O

_RARE_ I-GENE
_RARE_ I-GENE

Experimental O
_RARE_ I-GENE
of O
_RARE_ I-GENE

_RARE_ I-GENE
pathology O

_RARE_ I-GENE
of O
the O
agent O
was O
performed O
from O
the O
_RARE_ I-GENE
to O
the O
_RARE_ I-GENE
day O
p O
. O
i O
. O
by O
direct O
microscopic O
methods O
( O
_RARE_ I-GENE
and O
_RARE_ I-GENE
staining O
, O
fluorescent O
antibody I-GENE
technique O
); O
the O
_RARE_ I-GENE
content O
was O
determined O
by O
titration O
in O
_RARE_ I-GENE
_RARE_ I-GENE
' O
s O
eggs O
. O

The O
patients O
were O
divided O
into O
4 I-GENE
groups O
receiving O
_RARE_ I-GENE
II I-GENE
with O
or O
without O
_RARE_ I-GENE
, O
morphine O
or O
_RARE_ I-GENE
. O

The O
alterations O
of O
5 I-GENE
- I-GENE
HT O
and O
5 I-GENE
- I-GENE
_RARE_ I-GENE
levels O
in O
several O
regions O
of O
the O
brain O
under O
the O
conditions O
examined O
may O
indicate O
that O
_RARE_ I-GENE
' O
s O
neurotoxicity O
primarily O
affects O
5 I-GENE
- I-GENE
HT O
- I-GENE
containing O
neurones O
. O

( O
5 I-GENE
) O
An O
increase O
in O
leukocyte I-GENE
- I-GENE
counts O
occurred O
on O
the O
administration O
of O
serum I-GENE
obtained O
from O
rabbit I-GENE
during O
phase O
- I-GENE
2 I-GENE
. O

The O
results O
obtained O
_RARE_ I-GENE
to O
prove O
that O
the O
_RARE_ I-GENE
system O
mainly O
_RARE_ I-GENE
in O
_RARE_ I-GENE
retention O
. O

In O
both O
cases O
, O
at O
the O
end O
of O
exposure O
the O
same O
level O
of O
blood O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
( O
about O
50 O
%) O
was O
reached O
. O

The O
results O
indicate O
that O
increased O
pulmonary O
blood O
flow O
and O
decreased O
pulmonary O
vascular I-GENE
resistance O
with O
_RARE_ I-GENE
gestation O
are O
due O
to O
an O
increase O
in O
the O
total O
number O
of O
vessels O
and O
increased O
_RARE_ I-GENE
reactivity O
is O
related I-GENE
to O
an O
increase O
in O
the O
total O
amount O
of O
smooth I-GENE
muscle O
while O
the O
thickness O
of O
muscle O
in O
individual O
vessels O
remains O
constant O
. O

_RARE_ I-GENE
in O
dosage O
restored O
normal O
taste O
sense O
in O
all O
three O
, O
but O
in O
two O
the O
drug O
had O
to O
be O
_RARE_ I-GENE
because O
of O
_RARE_ I-GENE
high O
_RARE_ I-GENE
levels O
. O

The O
calcium O
ratio O
( O
mean O
ratio O
of O
the O
predicted O
to O
measured O
_RARE_ I-GENE
) O
in O
men O
was O
1 I-GENE
. O
000 O
+/- O
7 O
. O
8 O
% O
and O
in O
women O
0 O
. O
_RARE_ I-GENE
+/- O
7 O
. O
1 I-GENE
%. O

A I-GENE
late O
diagnosis O
of O
retinoblastoma I-GENE
is O
an O
_RARE_ I-GENE
fact O
that O
allows O
its O
growth I-GENE
and O
leads O
to O
a O
deterioration O
in O
the O
_RARE_ I-GENE
. O

Total O
cholesterol I-GENE
was O
measured O
in O
amniotic I-GENE
fluids O
collected O
at O
different O
stages O
of O
gestation O
. O

_RARE_ I-GENE
serum I-GENE
_RARE_ I-GENE
concentration O
was O
, O
however O
, O
much O
higher O
than O
the O
_RARE_ I-GENE
in O
normal O
pregnancy O
or O
in O
_RARE_ I-GENE
patients O
without O
clinical O
_RARE_ I-GENE
. O

The O
authors O
found O
that O
except O
for O
_RARE_ I-GENE
and O
_RARE_ I-GENE
all O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
correlations O
were O
positive O
, O
in O
contrast O
to O
_RARE_ I-GENE
' O
s O
_RARE_ I-GENE
of O
type I-GENE
I I-GENE
complementarity I-GENE
. O

A I-GENE
_RARE_ I-GENE
on O
the O
phase O
- I-GENE
_RARE_ I-GENE
technique O
_RARE_ I-GENE
of O
cardiac O
action O
potentials O
. O

3 I-GENE
activities O
of O
the O
factor I-GENE
II I-GENE
molecule I-GENE
in O
the O
newborn O
infant O
at O
term O

The O
concept O
of O
" O
structural O
_RARE_ I-GENE
" O
is O
employed O
in O
this O
analysis O
to O
determine O
which O
model O
parameters O
can O
be O
and O
which O
cannot O
be O
determined O
" O
_RARE_ I-GENE
" O
from O
given O
input O
- I-GENE
output O
data O
; O
a O
step O
- I-GENE
by O
- I-GENE
step O
procedure O
based O
on O
an O
extension O
of O
this O
concept O
is O
presented O
for O
adapting O
the O
overall O
approach O
to O
the O
experimental O
design O
problem O
. O

However O
, O
we O
did O
detect O
_RARE_ I-GENE
- I-GENE
to O
- I-GENE
_RARE_ I-GENE
variation O
and O
differences O
in O
performance O
between O
narrow O
_RARE_ I-GENE
and O
wide O
_RARE_ I-GENE
_RARE_ I-GENE
. O

The O
cochlear O
_RARE_ I-GENE
. O

A I-GENE
case O
observed O
in O
_RARE_ I-GENE

_RARE_ I-GENE
glucose O
administered O
_RARE_ I-GENE
in O
_RARE_ I-GENE
_RARE_ I-GENE
dogs O
resulted O
in O
an O
equal O
inhibition O
of O
_RARE_ I-GENE
- I-GENE
induced O
acid I-GENE
secretion O
from O
the O
_RARE_ I-GENE
and O
the O
main O
stomach O
, O
whereas O
_RARE_ I-GENE
saline O
had O
no O
effect O
. O

_RARE_ I-GENE
factor I-GENE
VIII I-GENE
inhibitor I-GENE
in O
non O
- I-GENE
_RARE_ I-GENE
patients O

_RARE_ I-GENE
of O
_RARE_ I-GENE
acid I-GENE
into O
_RARE_ I-GENE
acid I-GENE
was O
observed O
. O

The O
study O
of O
calcium O
metabolism O
in O
ten O
_RARE_ I-GENE
children O
_RARE_ I-GENE
with O
controls O
after O
oral O
administration O
of O
_RARE_ I-GENE
has O
shown O
diminished O
intestinal O
absorption O
. O

_RARE_ I-GENE
agents O
were O
isolated O
from O
the O
semen O
near O
the O
end O
of O
the O
_RARE_ I-GENE
phase O
. O

Because O
of O
the O
increased O
CPK I-GENE
activity O
found O
in O
normal O
newborns O
, O
screening O
for O
_RARE_ I-GENE
- I-GENE
type I-GENE
muscular O
dystrophy I-GENE
should O
be O
_RARE_ I-GENE
for O
a O
few O
weeks O
after O
delivery O
. O

In O
contrast O
, O
the O
insulin I-GENE
response O
had O
returned O
to O
the O
non O
- I-GENE
pregnant O
value O
by O
the O
second O
day O
of O
the O
_RARE_ I-GENE
. O

The O
authors O
report O
the O
results O
of O
a O
series O
of O
toxicological O
tests O
conducted O
on O
_RARE_ I-GENE
materials O
( O
_RARE_ I-GENE
) O
activated I-GENE
with O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
an O
additive O
recently O
proposed O
as O
a O
_RARE_ I-GENE
capable O
of O
_RARE_ I-GENE
_RARE_ I-GENE
materials O
. O

Mutational O
analysis O
of O
the O
major I-GENE
homology I-GENE
region O
of O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
monkey I-GENE
virus I-GENE
by O
use O
of O
saturation O
mutagenesis O
. O

One O
site I-GENE
, O
PAL I-GENE
, O
occurs O
within O
the O
10 O
bp O
sequence I-GENE
_RARE_ I-GENE
. O

Nuclear I-GENE
extracts O
prepared O
from O
both O
neural O
and O
non O
- I-GENE
neural O
cell O
lines O
, O
mouse I-GENE
brain O
, O
and O
mouse I-GENE
liver O
contain O
proteins I-GENE
that O
recognize O
and O
bind O
to O
the O
_RARE_ I-GENE
and O
PAL I-GENE
sequences I-GENE
indicating O
that O
proteins I-GENE
which O
bind O
to O
these O
target O
sequences I-GENE
are O
_RARE_ I-GENE
. O

To O
determine O
if O
the O
NF I-GENE
( O
H I-GENE
) O
promoter I-GENE
can O
be O
activated I-GENE
in O
a O
tissue I-GENE
specific I-GENE
manner O
during O
development O
transgenic O
mice O
containing O
the O
promoter I-GENE
region O
linked O
to O
a O
beta I-GENE
- I-GENE
galactosidase I-GENE
reporter I-GENE
gene I-GENE
were O
generated O
. O

Here O
we O
describe O
and O
map O
two O
more O
new O
genes I-GENE
identified O
as O
allele I-GENE
- I-GENE
specific I-GENE
suppressors O
that O
_RARE_ I-GENE
for O
carboxy I-GENE
- I-GENE
terminal I-GENE
_RARE_ I-GENE
of O
_RARE_ I-GENE
. O

Previous O
studies O
have O
shown O
[ O
_RARE_ I-GENE
, O
S I-GENE
., O
_RARE_ I-GENE
, O
M I-GENE
., O
_RARE_ I-GENE
, O
E I-GENE
. O
& O
_RARE_ I-GENE
, O
T I-GENE
. O

Treatment O
and O
staining O
of O
smears O
and O
sections O
for O
detection O
of O
_RARE_ I-GENE

The O
apparent O
_RARE_ I-GENE
of O
the O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
operator I-GENE
complex I-GENE
is O
one O
order O
magnitude O
higher O
than O
that O
of O
the O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
operator I-GENE
complex I-GENE
. O

A I-GENE
significant O
direct O
relationship O
was O
observed O
between O
the O
percent O
area O
density I-GENE
of O
smooth I-GENE
muscle O
and O
the O
percent O
change O
in O
peak O
urinary O
flow O
rate O
. O

_RARE_ I-GENE
skeletal I-GENE
muscle O
_RARE_ I-GENE
. O

Characterization O
of O
the O
human I-GENE
gene I-GENE
encoding O
_RARE_ I-GENE
17 O
and O
its O
expression O
pattern O
. O

Animals O
that O
received O
_RARE_ I-GENE
- I-GENE
4 I-GENE
were O
significantly O
retarded O
in O
motor O
recovery O
compared O
with O
the O
saline O
group O
. O

The O
prophylactic O
use O
of O
new O
medication O
for O
patients O
between O
the O
first O
and O
second O
cycle O
of O
chemotherapy O
, O
in O
agreement O
with O
the O
estimates O
calculated O
, O
does O
not O
_RARE_ I-GENE
health O
care O
costs O
but O
may O
improve O
the O
quality O
of O
life O
in O
these O
patients O
and O
permit O
the O
_RARE_ I-GENE
of O
a O
therapeutic O
schedule O
without O
_RARE_ I-GENE
which O
may O
improve O
the O
life O
_RARE_ I-GENE
of O
the O
patient O
. O

AP I-GENE
was O
induced O
by O
_RARE_ I-GENE
infusion O
of O
two O
different O
concentrations O
of O
_RARE_ I-GENE
acid I-GENE
( O
_RARE_ I-GENE
17 O
mmol O
and O
34 O
mmol O
). O

The O
isolation O
of O
this O
gene I-GENE
was O
based O
on O
the O
identification O
of O
the O
Y I-GENE
- I-GENE
231 O
cosmid O
that O
contains O
CpG O
rich O
sequences I-GENE
( O
_RARE_ I-GENE
_RARE_ I-GENE
) O
in O
its O
human I-GENE
insert O
. O

Tissue I-GENE
plasminogen I-GENE
activator I-GENE
, O
its O
inhibitor I-GENE
and O
other O
parameters O
of O
_RARE_ I-GENE
in O
blood O
of O
patients O
operated O
for O
mild O
hypertrophy O
of O
the O
prostate O

Gene I-GENE
constructs I-GENE
consisting O
of O
human I-GENE
growth I-GENE
hormone I-GENE
( O
hGH I-GENE
) O
gene I-GENE
driven O
by O
promoter I-GENE
/ I-GENE
regulatory I-GENE
sequence I-GENE
of O
mouse I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
), O
viral I-GENE
thymidine I-GENE
kinase I-GENE
( O
_RARE_ I-GENE
), O
rat I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
), O
or O
chicken I-GENE
beta I-GENE
- I-GENE
actin I-GENE
( O
_RARE_ I-GENE
) O
gene I-GENE
were O
injected O
into O
the O
cytoplasm O
of O
_RARE_ I-GENE
_RARE_ I-GENE
eggs O
via O
the O
_RARE_ I-GENE
. O

Serum I-GENE
gastrin I-GENE
and O
AFP I-GENE
levels O
had O
the O
same O
evolution O
and O
appear O
to O
have O
the O
same O
interest O
to O
follow O
the O
course O
of O
the O
disease O
. O

_RARE_ I-GENE
for O
controlled O
- I-GENE
delivery O
systems O
. O

The O
mean O
(+/- O
SD O
) O
PaO2 O
increased O
from O
80 O
. O
8 O
+/- O
26 O
. O
9 O
mmHg O
before O
to O
89 I-GENE
. O
8 O
+/- O
27 O
. O
3 I-GENE
mmHg O
after O
the O
infusion O
( O
P I-GENE
< O
0 O
. O
05 O
) O
and O
the O
PaCO2 O
decreased O
from O
42 O
. O
4 I-GENE
+/- O
8 O
. O
3 I-GENE
to O
39 O
. O
6 I-GENE
+/- O
7 O
. O
9 O
mmHg O
( O
P I-GENE
< O
0 O
. O
05 O
). O

_RARE_ I-GENE
_RARE_ I-GENE
and O
mild O
elevation O
of O
enzymes O
can O
be O
observed O
in O
a O
significant O
proportion O
of O
patients O
, O
involvement O
of O
liver O
leading O
to O
acute O
hepatitis I-GENE
or O
liver O
cell O
necrosis I-GENE
is O
a O
relatively O
_RARE_ I-GENE
complication O
in O
P I-GENE
. O
falciparum O
malaria O
. O

For O
the O
first O
group O
, O
the O
maximal O
decrease O
in O
plasma I-GENE
potassium O
elicited O
by O
_RARE_ I-GENE
was O
0 O
. O
80 O
+/- O
0 O
. O
19 O
, O
0 O
. O
48 O
+/- O
0 O
. O
22 O
, O
and O
0 O
. O
78 O
+/- O
0 O
. O
46 O
mmol O
/ I-GENE
l O
, O
and O
for O
the O
second O
group O
, O
maximal O
_RARE_ I-GENE
was O
1 I-GENE
. O
31 O
+/- O
0 O
. O
37 O
, O
0 O
. O
70 I-GENE
+/- O
0 O
. O
24 O
, O
and O
0 O
. O
84 O
+/- O
0 O
. O
17 O
mmol O
/ I-GENE
l O
for O
the O
iv O
, O
_RARE_ I-GENE
, O
and O
it O
routes O
, O
respectively O
. O

The O
two O
drugs O
increase O
the O
rate O
of O
early I-GENE
diastolic O
filling O
. O

A I-GENE
statistically O
significant O
improvement O
due O
to O
the O
administration O
of O
_RARE_ I-GENE
was O
observed O
in O
symptoms O
associated I-GENE
with O
_RARE_ I-GENE
to O
normal O
prolactin I-GENE
levels O
, O
i O
. O
e O
. O
abdominal O
tension O
, O
edema O
, O
weight O
gain O
and O
breast O
_RARE_ I-GENE
. O

The O
magnitude O
of O
the O
early I-GENE
response O
was O
_RARE_ I-GENE
+/- O
51 O
% O
in O
A I-GENE
_RARE_ I-GENE
baseline O
_RARE_ I-GENE
; O
mean O
+/- O
SE O
), O
and O
significantly O
less O
in O
B I-GENE
( O
119 O
+/- O
7 O
%) O
and O
C I-GENE
( O
131 O
+/- O
16 O
%) O
( O
p O
< O
0 O
. O
01 O
). O

Most O
of O
the O
patients O
presented O
with O
Transient O
Ischemic O
_RARE_ I-GENE
( O
64 O
%) O
or O
_RARE_ I-GENE
Ischemic O
_RARE_ I-GENE
_RARE_ I-GENE
( O
19 O
%). O

We O
cloned O
the O
third O
human I-GENE
gene I-GENE
for O
the O
_RARE_ I-GENE
, O
termed O
_RARE_ I-GENE
gamma I-GENE
and O
the O
sequence I-GENE
analysis O
showed O
that O
it O
is O
a O
5 I-GENE
'- O
truncated I-GENE
pseudogene I-GENE
. O

This O
analysis O
, O
together O
with O
a O
_RARE_ I-GENE
of O
the O
_RARE_ I-GENE
found O
upstream O
of O
known O
SWI4 I-GENE
, O
6 I-GENE
- I-GENE
dependent I-GENE
genes I-GENE
, O
leads O
to O
the O
_RARE_ I-GENE
of O
a O
revised O
consensus I-GENE
sequence I-GENE
for O
this O
important O
regulatory I-GENE
element I-GENE
. O

Mutational O
analysis O
of O
a O
DNA I-GENE
sequence I-GENE
involved O
in O
linking O
gene I-GENE
expression O
to O
the O
cell O
cycle O
. O

The O
natural O
history O
of O
these O
lesions O
, O
_RARE_ I-GENE
efficiency O
of O
the O
different O
treatments O
used O
, O
the O
part O
played O
by O
chemotherapy O
, O
survival O
, O
causes O
of O
death O
and O
therapeutic O
modalities O
used O
as O
a O
last O
measure O
, O
have O
been O
analysed O
. O

The O
method O
was O
adapted O
for O
the O
determination O
of O
_RARE_ I-GENE
_RARE_ I-GENE
A I-GENE
by O
a O
change O
in O
mobile O
phase O
composition O
. O

In O
general O
, O
however O
, O
this O
study O
provided O
little O
evidence O
of O
any O
effect O
of O
supplementation O
to O
_RARE_ I-GENE
performance O
for O
_RARE_ I-GENE
_RARE_ I-GENE
the O
dietary O
_RARE_ I-GENE
. O

In O
the O
absence O
of O
histological O
criteria O
, O
which O
it O
is O
difficult O
to O
demand O
in O
view O
of O
the O
variability O
of O
results O
and O
potential O
_RARE_ I-GENE
of O
_RARE_ I-GENE
biopsy O
involving O
such O
thin O
and O
_RARE_ I-GENE
ventricular O
_RARE_ I-GENE
, O
the O
diagnosis O
of O
_RARE_ I-GENE
is O
based O
upon O
the O
concomitant O
existence O
of O
: O
( O
1 I-GENE
) O
_RARE_ I-GENE
criteria O
: O
ventricular O
arrhythmias O
, O
in O
particular O
sustained O
_RARE_ I-GENE
VT O
, O
with O
the O
particular O
feature O
of O
a O
very O
high O
degree O
of O
sensitivity O
to O
adrenergic I-GENE
stimulation O
( O
exercise O
), O
the O
existence O
of O
late O
potentials O
on O
the O
high O
amplification O
ECG O
, O
a O
highly O
specific I-GENE
sign O
, O
though O
_RARE_ I-GENE
of O
poor O
sensitivity O
in O
localized O
_RARE_ I-GENE
, O
those O
which O
are O
most O
difficult O
to O
identify O
( O
2 I-GENE
); O
_RARE_ I-GENE
morphological O
and O
kinetic O
RV O
abnormalities O
, O
most O
often O
resulting O
in O
localized O
_RARE_ I-GENE
or O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
, O
with O
_RARE_ I-GENE
" O
in O
situ O
". O

In O
7 O
of O
9 O
cases O
, O
the O
enhancer I-GENE
is O
fused O
to O
the O
c I-GENE
- I-GENE
myc I-GENE
bearing O
sequences I-GENE
of O
chromosome O
8 O
. O

These O
components O
both O
had O
a O
median O
R2 I-GENE
of O
0 O
. O
84 O
, O
compared O
to O
median O
_RARE_ I-GENE
ranging O
from O
0 O
. O
37 O
to O
0 O
. O
83 O
for O
five O
commonly O
used O
_RARE_ I-GENE
_RARE_ I-GENE
EEG O
components O
. O

The O
obtained O
results O
were O
compared O
with O
control O
group O
( O
10 O
female O
volunteers O
). O

100 O
years O
of O
_RARE_ I-GENE
at O
the O
_RARE_ I-GENE
_RARE_ I-GENE
University O
in O
_RARE_ I-GENE

The O
target O
contained O
between O
positions O
- I-GENE
_RARE_ I-GENE
and O
- I-GENE
125 I-GENE
acts O
independently O
of O
orientation O
, O
in O
different O
cell O
types O
and O
species O
, O
and O
in O
the O
context O
of O
a O
heterologous O
promoter I-GENE
. O

66 O
: O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
, O
1992 O
). O

_RARE_ I-GENE
transactivation O
of O
the O
_RARE_ I-GENE
promoter I-GENE
by O
the O
Z I-GENE
/ I-GENE
c I-GENE
- I-GENE
myb I-GENE
combination O
appears O
to O
involve O
direct O
binding I-GENE
by O
the O
Z I-GENE
protein I-GENE
but O
not O
the O
c I-GENE
- I-GENE
myb I-GENE
protein I-GENE
. O

The O
_RARE_ I-GENE
core I-GENE
sequence I-GENE
, O
_RARE_ I-GENE
, O
binds O
a O
ubiquitous O
nuclear I-GENE
factor I-GENE
and O
mediates O
negative O
regulation O
of O
MuLV O
promoter I-GENE
activity O
. O

These O
studies O
show O
that O
_RARE_ I-GENE
binds O
to O
various O
target O
motifs O
that O
are O
distinct O
from O
the O
_RARE_ I-GENE
motif I-GENE
: O
the O
_RARE_ I-GENE
- I-GENE
associated I-GENE
virus I-GENE
_RARE_ I-GENE
promoter I-GENE
and O
elements O
in O
the O
immunoglobulin I-GENE
light I-GENE
- I-GENE
and O
heavy I-GENE
- I-GENE
chain I-GENE
genes I-GENE
, O
as O
well O
as O
elements O
in O
ribosomal I-GENE
protein I-GENE
genes I-GENE
. O

_RARE_ I-GENE
, O
the O
_RARE_ I-GENE
- I-GENE
1 I-GENE
mutation I-GENE
does O
not O
affect O
signal I-GENE
recognition I-GENE
or O
translational O
arrest O
but O
instead O
results O
in O
maintenance O
of O
translational O
arrest O
of O
_RARE_ I-GENE
synthesis O
. O

The O
cellular O
sequences I-GENE
5 I-GENE
' O
to O
the O
viral I-GENE
integration O
site I-GENE
exhibited O
85 O
to O
97 O
% O
identity O
to O
several O
sequences I-GENE
belonging O
to O
the O
mouse I-GENE
L1 I-GENE
family I-GENE
of O
long O
interspersed O
repetitive O
sequences I-GENE
. O

Both O
_RARE_ I-GENE
and O
_RARE_ I-GENE
cut I-GENE
the O
terminal I-GENE
AAV I-GENE
sequence I-GENE
at O
the O
same O
site I-GENE
( O
nucleotide I-GENE
124 I-GENE
). O

Nucleotide O
sequence I-GENE
analysis O
revealed O
that O
TAR I-GENE
- I-GENE
binding I-GENE
protein I-GENE
is O
very O
similar O
to O
the O
_RARE_ I-GENE
protein I-GENE
. O

These O
results O
indicate O
that O
both O
N I-GENE
- I-GENE
and O
C I-GENE
- I-GENE
terminal I-GENE
mutations O
are O
required O
to O
inhibit O
_RARE_ I-GENE
by O
_RARE_ I-GENE
protein I-GENE
and O
that O
multiple O
structural O
mutations O
accompanied O
by O
posttranslational O
protein I-GENE
modification O
alter O
gene I-GENE
regulation O
by O
_RARE_ I-GENE
protein I-GENE
. O

The O
_RARE_ I-GENE
mutation I-GENE
changes O
_RARE_ I-GENE
in O
_RARE_ I-GENE
. O
7 O
to O
an O
_RARE_ I-GENE
codon O
, O
which O
_RARE_ I-GENE
the O
production O
of O
the O
truncated I-GENE
, O
30 O
- I-GENE
kDa I-GENE
_RARE_ I-GENE
. O
7 O
- I-GENE
related I-GENE
polypeptide I-GENE
, O
and O
_RARE_ I-GENE
the O
11 O
- I-GENE
kDa I-GENE
C I-GENE
- I-GENE
terminal I-GENE
domain I-GENE
in O
host O
transcription I-GENE
_RARE_ I-GENE
- I-GENE
off O
. O

A I-GENE
patient O
suffering O
from O
heparin O
- I-GENE
associated I-GENE
thrombocytopenia O
( O
_RARE_ I-GENE
), O
recurrent O
_RARE_ I-GENE
, O
and O
acute O
renal O
failure O
after O
treatment O
with O
standard O
heparin O
is O
described O
. O

The O
predicted O
receptor I-GENE
structure O
includes O
a O
cysteine I-GENE
- I-GENE
rich O
extracellular I-GENE
domain I-GENE
, O
a O
single O
hydrophobic O
transmembrane I-GENE
domain I-GENE
, O
and O
a O
predicted O
cytoplasmic I-GENE
serine I-GENE
/ I-GENE
threonine I-GENE
kinase I-GENE
domain I-GENE
. O

Drosophila I-GENE
_RARE_ I-GENE
encodes O
a O
highly O
conserved O
ubiquitin I-GENE
- I-GENE
_RARE_ I-GENE
enzyme I-GENE
involved O
in O
selective O
protein I-GENE
degradation O
. O

Analysis O
of O
the O
entire O
16 O
. O
7 O
- I-GENE
kb O
_RARE_ I-GENE
genome O
determined O
that O
a O
_RARE_ I-GENE
mediates O
cleavage O
of O
chick I-GENE
_RARE_ I-GENE
in O
vitro O
at O
three O
H I-GENE
- I-GENE
and O
two O
L I-GENE
- I-GENE
strand O
sequence I-GENE
- I-GENE
specific I-GENE
target O
sites I-GENE
located O
within O
a O
90 O
- I-GENE
bp O
A I-GENE
+ I-GENE
T I-GENE
- I-GENE
rich O
genomic O
tract O
, O
_RARE_ I-GENE
capable O
of O
forming O
stable O
secondary O
structures O
, O
approximately O
200 O
bases O
upstream O
from O
the O
H I-GENE
- I-GENE
strand O
origin O
( O
OH O
) O
of O
replication O
. O

The O
goal O
of O
the O
present O
study O
was O
to O
determine O
the O
feasibility O
of O
retrovirus O
mediated O
expression O
of O
_RARE_ I-GENE
in O
the O
_RARE_ I-GENE
and O
U937 O
human I-GENE
hematopoietic I-GENE
cell O
lines O
, O
and O
in O
an O
Epstein I-GENE
- I-GENE
Barr I-GENE
virus I-GENE
transformed O
B I-GENE
- I-GENE
lymphocyte I-GENE
cell O
line O
( O
EBV I-GENE
- I-GENE
BCL I-GENE
) O
derived O
from O
a O
_RARE_ I-GENE
- I-GENE
deficient O
_RARE_ I-GENE
patient O
. O

Comparison O
with O
the O
sequence I-GENE
_RARE_ I-GENE
show O
that O
_RARE_ I-GENE
is O
a O
member O
of O
the O
immunoglobulin I-GENE
gene I-GENE
superfamily I-GENE
, O
with O
similarity O
to O
Drosophila I-GENE
_RARE_ I-GENE
, O
the O
melanoma O
Ag I-GENE
_RARE_ I-GENE
- I-GENE
18 O
, O
members O
of O
the O
_RARE_ I-GENE
Ag I-GENE
family I-GENE
, O
the O
_RARE_ I-GENE
receptor I-GENE
, O
and O
the O
neural O
cell O
adhesion I-GENE
molecule I-GENE
. O

A I-GENE
rather O
similar O
pattern O
of O
results O
was O
obtained O
with O
respect O
to O
_RARE_ I-GENE
mRNA I-GENE
expression O
, O
such O
transcripts I-GENE
being O
detectable O
only O
in O
a O
subset O
of O
tumors O
, O
and O
then O
at O
apparently O
low O
levels O
. O

The O
phenotypes O
of O
the O
_RARE_ I-GENE
nonsense O
mutants I-GENE
were O
intermediate O
between O
those O
of O
the O
wild I-GENE
- I-GENE
type I-GENE
virus I-GENE
and O
_RARE_ I-GENE
in O
that O
the O
more O
_RARE_ I-GENE
- I-GENE
coding O
sequence I-GENE
expressed O
by O
a O
given O
nonsense O
mutant I-GENE
, O
the O
more O
wild I-GENE
type I-GENE
- I-GENE
like I-GENE
was O
its O
phenotype O
. O

Analysis O
of O
nucleotide I-GENE
sequence I-GENE
of O
the O
_RARE_ I-GENE
43 I-GENE
kbp O
of O
herpesvirus I-GENE
_RARE_ I-GENE
( O
HVS O
) O
L I-GENE
- I-GENE
DNA I-GENE
: O
general O
conservation O
of O
genetic O
organization O
between O
HVS O
and O
Epstein I-GENE
- I-GENE
Barr I-GENE
virus I-GENE
. O

Treatment O
with O
MK O
- I-GENE
801 O
induced O
a O
burst O
suppression O
in O
the O
EEG O
and O
a O
transient O
drop O
( O
11 O
. O
4 I-GENE
+/- O
6 I-GENE
. O
5 I-GENE
mm O
Hg O
) O
in O
the O
mean O
arterial O
pressure O
. O

In O
contrast O
, O
gel O
mobility I-GENE
shift O
experiments O
have O
failed O
to O
reveal O
that O
_RARE_ I-GENE
or O
_RARE_ I-GENE
binds O
to O
domain I-GENE
1 I-GENE
or O
that O
_RARE_ I-GENE
mutations O
affect O
the O
complexes I-GENE
bound O
to O
it O
. O

_RARE_ I-GENE
differentiation O
can O
be O
inhibited O
by O
the O
adenovirus I-GENE
E1a I-GENE
protein I-GENE
in O
the O
rat I-GENE
_RARE_ I-GENE
muscle O
cell O
line O
. O

The O
experiment O
results O
showed O
: O
( O
i O
) O
not O
only O
_RARE_ I-GENE
, O
but O
also O
free O
radicals O
( O
O2 O
-. O
. O
OH O
and O
YHPD O
_RARE_ I-GENE
can O
be O
formed O
by O
the O
aid O
of O
YHPD O
; O
and O
( O
ii O
) O
as O
to O
the O
ability O
of O
producing O
_RARE_ I-GENE
, O
YHPD O
less O
than O
_RARE_ I-GENE
, O
while O
for O
generating O
O2 O
-. O
and O
. O
OH O
, O
YHPD O
greater O
than O
_RARE_ I-GENE
. O

Two O
points O
are O
indicated O
: O
first O
, O
the O
_RARE_ I-GENE
damage O
of O
YHPD O
is O
_RARE_ I-GENE
to O
not O
only O
_RARE_ I-GENE
, O
but O
also O
free O
radicals O
( O
O2 O
-. O
. O
OH O
and O
YHPD O
_RARE_ I-GENE
second O
, O
although O
the O
_RARE_ I-GENE
damage O
of O
YHPD O
is O
stronger O
than O
that O
of O
_RARE_ I-GENE
, O
yet O
the O
_RARE_ I-GENE
damage O
is O
negatively O
correlated O
to O
the O
yield O
of O
_RARE_ I-GENE
but O
positively O
correlated O
to O
those O
of O
O2 O
-. O
and O
OH O
. O

_RARE_ I-GENE
. O

Both O
in O
vitro O
- I-GENE
synthesized O
S2 I-GENE
protein I-GENE
and O
synthetic O
peptides I-GENE
corresponding O
to O
S2 I-GENE
are O
shown O
to O
_RARE_ I-GENE
positively O
with O
sera O
obtained O
from O
_RARE_ I-GENE
- I-GENE
infected O
horses O
, O
providing O
the O
first O
direct O
evidence O
of O
expression O
of O
this O
protein I-GENE
in O
infected O
animals O
. O

Many O
canonical O
TATA I-GENE
sequences I-GENE
are O
present O
upstream O
from O
these O
VZV I-GENE
transcriptional O
start O
sites I-GENE
but O
, O
apparently O
, O
are O
not O
used O
. O

The O
ORF I-GENE
4 I-GENE
gene I-GENE
was O
_RARE_ I-GENE
active O
, O
whereas O
the O
ORF I-GENE
62 O
gene I-GENE
gave O
twofold O
induction O
; O
both O
genes I-GENE
, O
acting O
together O
, O
gave O
_RARE_ I-GENE
induction O
. O

Interestingly O
, O
the O
_RARE_ I-GENE
ORF I-GENE
of O
EHV I-GENE
- I-GENE
1 I-GENE
possesses O
a O
sequence I-GENE
of O
13 O
amino O
acids O
( O
_RARE_ I-GENE
) O
that O
is O
a O
perfect O
match O
to O
the O
consensus I-GENE
zinc I-GENE
finger I-GENE
motif I-GENE
( O
C I-GENE
- I-GENE
X2 O
- I-GENE
4 I-GENE
- I-GENE
C I-GENE
- I-GENE
X2 O
- I-GENE
15 O
- I-GENE
C I-GENE
/ I-GENE
H I-GENE
- I-GENE
X2 O
- I-GENE
4 I-GENE
- I-GENE
C I-GENE
/ I-GENE
H I-GENE
). O

The O
DNA I-GENE
sequence I-GENE
of O
the O
sulfate I-GENE
activation O
locus I-GENE
from O
Escherichia I-GENE
coli I-GENE
K I-GENE
- I-GENE
12 O
has O
been O
determined O
. O

The O
_RARE_ I-GENE
form O
of O
RNA I-GENE
polymerase I-GENE
II I-GENE
is O
designated O
IIA I-GENE
, O
whereas O
the O
phosphorylated O
form O
is O
designated O
_RARE_ I-GENE
. O

RNA I-GENE
polymerase I-GENE
IIA I-GENE
was O
recovered O
in O
transcriptionally O
active O
complexes I-GENE
in O
reactions O
in O
which O
the O
input O
enzyme I-GENE
was O
RNA I-GENE
polymerase I-GENE
IIA I-GENE
. O

_RARE_ I-GENE
activity O
is O
elevated O
up O
to O
twofold O
when O
Z I-GENE
. O
_RARE_ I-GENE
was O
grown O
on O
fructose I-GENE
instead O
of O
glucose O
, O
and O
there O
was O
a O
parallel O
increase O
in O
_RARE_ I-GENE
mRNA I-GENE
levels O
. O

Plasma I-GENE
membranes O
of O
cultured O
cells O
contain O
high O
affinity O
receptors I-GENE
for O
high O
density I-GENE
lipoprotein I-GENE
( O
HDL I-GENE
) O
that O
appear O
to O
mediate O
removal O
of O
excess O
intracellular O
cholesterol I-GENE
. O

After O
the O
first O
28 O
patients O
vincristine O
was O
replaced O
by O
_RARE_ I-GENE
( O
_RARE_ I-GENE
- I-GENE
26 O
) O
due O
to O
neurotoxicity O
. O

These O
results O
indicate O
that O
an O
internal O
short O
element I-GENE
located O
at O
the O
very O
5 I-GENE
' O
terminal I-GENE
of O
L1 I-GENE
sequence I-GENE
and O
the O
nuclear I-GENE
factor I-GENE
binding I-GENE
to O
the O
element I-GENE
play O
a O
crucial O
role O
in O
the O
transcription I-GENE
of O
human I-GENE
L1 I-GENE
. O

Tumor I-GENE
cells O
were O
_RARE_ I-GENE
immunoreactive I-GENE
for O
neuron I-GENE
- I-GENE
specific I-GENE
_RARE_ I-GENE
, O
insulin I-GENE
, O
glucagon I-GENE
and O
_RARE_ I-GENE
. O

A I-GENE
recombinant I-GENE
with O
a O
5 I-GENE
' O
end O
from O
src I-GENE
and O
a O
3 I-GENE
' O
end O
from O
_RARE_ I-GENE
, O
called O
SRC I-GENE
x O
ROS I-GENE
, O
transformed O
chicken I-GENE
embryo O
fibroblasts O
( O
_RARE_ I-GENE
) O
to O
a O
spindle O
shape O
morphology O
, O
_RARE_ I-GENE
that O
of O
_RARE_ I-GENE
. O

ROS I-GENE
x O
SRC I-GENE
( O
R I-GENE
) O
contains O
a O
16 O
- I-GENE
amino O
- I-GENE
acid I-GENE
deletion O
that O
includes O
the O
3 I-GENE
' O
half O
of O
the O
transmembrane I-GENE
domain I-GENE
of O
_RARE_ I-GENE
. O

To O
define O
the O
number O
and O
nature O
of O
the O
E6 I-GENE
and O
E7 I-GENE
gene I-GENE
products I-GENE
expressed O
in O
BPV I-GENE
- I-GENE
1 I-GENE
- I-GENE
transformed O
cells O
, O
we O
performed O
immunoprecipitation O
experiments O
with O
antisera O
raised O
to O
bacterially O
expressed O
BPV I-GENE
- I-GENE
1 I-GENE
E6 I-GENE
and O
E7 I-GENE
fusion I-GENE
proteins I-GENE
. O

Transient O
transfection O
assays O
showed O
that O
site I-GENE
A I-GENE
is O
necessary O
and O
sufficient O
for O
RXR I-GENE
alpha I-GENE
- I-GENE
mediated O
transactivation O
of O
the O
_RARE_ I-GENE
gene I-GENE
basal O
promoter I-GENE
in O
human I-GENE
hepatoma O
HepG2 O
cells O
in O
the O
presence O
of O
RA O
and O
that O
this O
transactivation O
is O
abolished O
by O
increasing O
amounts O
of O
cotransfected O
_RARE_ I-GENE
- I-GENE
1 I-GENE
. O

The O
enhancer I-GENE
region O
of O
_RARE_ I-GENE
murine I-GENE
leukemia I-GENE
virus I-GENE
contains O
the O
sequence I-GENE
motif I-GENE
_RARE_ I-GENE
. O

Two O
splice O
variants I-GENE
of O
_RARE_ I-GENE
cDNA I-GENE
have O
been O
found O
, O
_RARE_ I-GENE
by O
a O
72 O
- I-GENE
bp O
insertion O
, O
coding O
for O
putative O
proteins I-GENE
of O
_RARE_ I-GENE
and O
_RARE_ I-GENE
amino O
acids O
. O

A I-GENE
third O
prominent O
component O
of O
apparent O
molecular O
mass O
16 O
kDa I-GENE
displayed O
several O
properties O
, O
including O
ability O
to O
bind O
_RARE_ I-GENE
+, I-GENE
that O
are O
characteristic O
of O
the O
regulatory I-GENE
( O
B I-GENE
) O
subunit I-GENE
of O
mammalian I-GENE
_RARE_ I-GENE
and O
was O
recognized O
by O
an O
antiserum O
raised O
against O
bovine I-GENE
_RARE_ I-GENE
. O

As O
was O
observed O
previously O
for O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
double O
mutants I-GENE
, O
_RARE_ I-GENE
_RARE_ I-GENE
mutants I-GENE
were O
defective O
in O
their O
ability O
to O
_RARE_ I-GENE
from O
alpha I-GENE
- I-GENE
factor I-GENE
- I-GENE
induced O
growth I-GENE
arrest O
. O

Antibodies O
against O
this O
purified O
protein I-GENE
localize O
_RARE_ I-GENE
to O
mitochondria O
. O

METHODS O
: O
IgG I-GENE
antibodies I-GENE
vs O
_RARE_ I-GENE
- I-GENE
6 I-GENE
( O
anti I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
6 I-GENE
- I-GENE
IgG I-GENE
) O
were O
determined O
by O
indirect O
immunofluorescence O
in O
100 O
_RARE_ I-GENE
( O
29 O
_RARE_ I-GENE
and O
71 O
seropositive O
for O
HIV I-GENE
- I-GENE
1 I-GENE
of O
which O
45 O
were O
in O
stage O
II I-GENE
and O
26 O
in O
IV I-GENE
- I-GENE
C1 I-GENE
of O
_RARE_ I-GENE
) O
as O
well O
as O
in O
100 O
healthy O
subjects O
of O
a O
similar O
age O
( O
control O
group O
). O

A I-GENE
position O
- I-GENE
independent O
activation O
domain I-GENE
which O
contained O
conserved O
regions O
II I-GENE
and O
III I-GENE
was O
identified O
at O
the O
carboxyl O
terminus O
of O
the O
HNF I-GENE
- I-GENE
3 I-GENE
beta I-GENE
protein I-GENE
( O
amino O
acids O
_RARE_ I-GENE
to O
_RARE_ I-GENE
). O

HNF I-GENE
- I-GENE
3 I-GENE
beta I-GENE
amino O
- I-GENE
terminal I-GENE
sequences I-GENE
defined O
by O
conserved O
region O
IV I-GENE
also O
contributed O
to O
transactivation O
, O
but O
region O
IV I-GENE
activity O
required O
the O
participation O
of O
the O
region O
II I-GENE
- I-GENE
III I-GENE
domain I-GENE
. O

_RARE_ I-GENE
roles O
of O
_RARE_ I-GENE
putative O
ATPase I-GENE
/ I-GENE
DNA I-GENE
helicase I-GENE
activity O
in O
DNA I-GENE
repair I-GENE
and O
in O
the O
maintenance O
of O
wild I-GENE
- I-GENE
type I-GENE
rates O
of O
_RARE_ I-GENE
of O
simple O
repetitive O
sequences I-GENE
are O
discussed O
. O

_RARE_ I-GENE
of O
_RARE_ I-GENE
anaerobic O
gram O
- I-GENE
negative O
bacilli O
to O
amoxicillin O
, O
amoxicillin O
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
, O
amoxicillin O
- I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
and O
clindamycin O
. O

_RARE_ I-GENE
arrest O
of O
_RARE_ I-GENE
cells O
was O
_RARE_ I-GENE
for O
the O
detection O
of O
an O
M I-GENE
- I-GENE
phase O
- I-GENE
activated I-GENE
MBP I-GENE
kinase I-GENE
that O
was O
resolved O
from O
_RARE_ I-GENE
MAP I-GENE
kinase I-GENE
by O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
chromatography O
. O

The O
_RARE_ I-GENE
- I-GENE
1 I-GENE
mutation I-GENE
caused O
a O
defect O
in O
synthesis O
of O
a O
74 O
- I-GENE
kD I-GENE
heat I-GENE
shock I-GENE
protein I-GENE
. O

The O
_RARE_ I-GENE
base O
pair O
region O
immediately O
upstream O
of O
the O
CAP I-GENE
site I-GENE
is O
characterized O
by O
the O
lack O
of O
a O
proximal I-GENE
TATA I-GENE
box I-GENE
and O
the O
presence O
of O
sequences I-GENE
similar O
to O
GC I-GENE
boxes O
, O
_RARE_ I-GENE
boxes O
, O
CCAAT I-GENE
boxes O
, O
activator I-GENE
protein I-GENE
2 I-GENE
( O
_RARE_ I-GENE
- I-GENE
2 I-GENE
) O
sites I-GENE
, O
partial O
glucocorticoid I-GENE
response O
elements O
( O
_RARE_ I-GENE
), O
and O
partial O
cyclic I-GENE
AMP I-GENE
response O
elements O
( O
_RARE_ I-GENE
). O

Cloning O
and O
primary O
structure O
of O
_RARE_ I-GENE
, O
a O
developmentally O
regulated O
, O
_RARE_ I-GENE
_RARE_ I-GENE
sulfate I-GENE
proteoglycan I-GENE
of O
brain O
. O

In O
rats O
_RARE_ I-GENE
with O
+- I-GENE
_RARE_ I-GENE
the O
changes O
in O
extracellular I-GENE
pH O
and O
K I-GENE
+ I-GENE
in O
spinal O
cord O
dorsal O
_RARE_ I-GENE
were O
studied O
using O
pH O
and O
K I-GENE
+ I-GENE
ion O
- I-GENE
selective O
electrodes O
. O

_RARE_ I-GENE
of O
bovine I-GENE
papillomavirus I-GENE
- I-GENE
1 I-GENE
( O
BPV I-GENE
- I-GENE
1 I-GENE
) O
DNA I-GENE
requires O
two O
viral I-GENE
gene I-GENE
products I-GENE
, O
the O
E1 I-GENE
protein I-GENE
and O
the O
full I-GENE
- I-GENE
length I-GENE
E2 I-GENE
protein I-GENE
. O

_RARE_ I-GENE
inactivation O
of O
_RARE_ I-GENE
led O
to O
increased O
sensitivity O
to O
the O
_RARE_ I-GENE
agent O
_RARE_ I-GENE
_RARE_ I-GENE
, O
but O
not O
to O
a O
requirement O
for O
serine I-GENE
or O
other O
metabolites O
. O

These O
findings O
suggest O
that O
the O
MAP I-GENE
kinase I-GENE
activator I-GENE
/ I-GENE
MAP I-GENE
kinase I-GENE
system O
may O
be O
the O
downstream O
components O
of O
ras I-GENE
signal I-GENE
transduction O
pathways O
. O

_RARE_ I-GENE
- I-GENE
1 I-GENE
is O
expressed O
in O
a O
larger O
number O
of O
these O
cell O
lines O
. O

_RARE_ I-GENE
LTR I-GENE
- I-GENE
binding I-GENE
proteins I-GENE
appear O
to O
be O
essential O
for O
c I-GENE
- I-GENE
myc I-GENE
_RARE_ I-GENE
, O
since O
both O
LTR I-GENE
- I-GENE
enhanced O
transcription I-GENE
and O
the O
activities O
of O
LTR I-GENE
- I-GENE
binding I-GENE
proteins I-GENE
are O
specifically O
decreased O
after O
inhibition O
of O
protein I-GENE
synthesis O
( O
A I-GENE
. O

_RARE_ I-GENE
, O
M I-GENE
. O

A I-GENE
single O
MEF I-GENE
- I-GENE
2 I-GENE
site I-GENE
is O
a O
major I-GENE
positive O
regulatory I-GENE
element I-GENE
required O
for O
transcription I-GENE
of O
the O
muscle O
- I-GENE
specific I-GENE
subunit I-GENE
of O
the O
human I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
gene I-GENE
in O
skeletal I-GENE
and O
cardiac O
muscle O
cells O
. O

_RARE_ I-GENE
variants I-GENE
of O
peptides I-GENE
isolated O
from O
MHC I-GENE
class I-GENE
II I-GENE
molecules I-GENE
suggest O
sequence I-GENE
motifs O
. O

Although O
the O
E I-GENE
- I-GENE
box I-GENE
consensus I-GENE
is O
_RARE_ I-GENE
defined O
as O
_RARE_ I-GENE
, O
the O
adjacent O
nucleotides O
of O
functional O
E I-GENE
- I-GENE
boxes O
are O
variable O
for O
genes I-GENE
regulated O
by O
the O
bHLH I-GENE
proteins I-GENE
. O

_RARE_ I-GENE
levels O
of O
gene I-GENE
activity O
were O
observed O
for O
TnI I-GENE
enhancers I-GENE
containing O
E I-GENE
- I-GENE
boxes O
derived O
from O
the O
_RARE_ I-GENE
left O
E I-GENE
- I-GENE
box I-GENE
site I-GENE
or O
from O
the O
Ig I-GENE
kappa I-GENE
E2 I-GENE
E I-GENE
- I-GENE
box I-GENE
. O

T I-GENE
- I-GENE
cell O
receptor I-GENE
beta I-GENE
( O
TCR I-GENE
beta I-GENE
) O
gene I-GENE
rearrangements O
occur O
in O
a O
third O
of O
early I-GENE
B I-GENE
- I-GENE
cell O
acute O
_RARE_ I-GENE
leukemias O
( O
_RARE_ I-GENE
). O

The O
_RARE_ I-GENE
motifs O
were O
found O
to O
bind O
MyoD I-GENE
and O
myogenin I-GENE
fusion I-GENE
proteins I-GENE
and O
to O
interact O
with O
proteins I-GENE
in O
nuclear I-GENE
extracts O
from O
cultured O
myotubes O
. O

_RARE_ I-GENE
_RARE_ I-GENE
associated I-GENE
with O
multiple O
myeloma O
. O

We O
have O
cloned O
and O
sequenced O
_RARE_ I-GENE
, O
the O
nuclear I-GENE
gene I-GENE
for O
subunit I-GENE
_RARE_ I-GENE
of O
Saccharomyces I-GENE
cerevisiae I-GENE
cytochrome I-GENE
c I-GENE
oxidase I-GENE
. O

The O
structure O
of O
the O
_RARE_ I-GENE
A I-GENE
gene I-GENE
was O
determined O
by O
comparison O
of O
the O
genomic O
and O
cDNA I-GENE
sequences I-GENE
. O

The O
basal O
promoter I-GENE
elements O
of O
murine I-GENE
cytochrome I-GENE
c I-GENE
oxidase I-GENE
subunit I-GENE
IV I-GENE
gene I-GENE
consist O
of O
tandemly O
duplicated O
ets I-GENE
motifs O
that O
bind O
to O
GABP I-GENE
- I-GENE
related I-GENE
transcription I-GENE
factors I-GENE
. O

_RARE_ I-GENE
, O
there O
are O
multiple O
instances O
in O
which O
short O
oligonucleotide I-GENE
direct O
repeats I-GENE
flank O
a O
region O
absent O
from O
either O
_RARE_ I-GENE
or O
vaccinia I-GENE
virus I-GENE
. O

Here O
we O
show O
that O
short O
synthetic O
peptides I-GENE
containing O
the O
_RARE_ I-GENE
- I-GENE
binding I-GENE
sequences I-GENE
of O
E1A I-GENE
are O
sufficient O
for O
interaction O
with O
p107 I-GENE
, O
cyclin I-GENE
A I-GENE
, O
and O
p130 I-GENE
. O

These O
mutants I-GENE
grow O
normally O
in O
_RARE_ I-GENE
mouse I-GENE
fibroblast I-GENE
cells O
, O
and O
they O
do O
not O
complement I-GENE
the O
wild I-GENE
- I-GENE
type I-GENE
virus I-GENE
in O
_RARE_ I-GENE
experiments O
of O
C2 I-GENE
myoblasts O
. O

The O
MICs O
of O
this O
compound O
against O
90 O
% O
of O
these O
organisms O
, O
except O
for O
_RARE_ I-GENE
- I-GENE
resistant O
S I-GENE
. O
aureus I-GENE
, O
ranged O
from O
less O
than O
or O
equal O
to O
0 O
. O
_RARE_ I-GENE
to O
3 I-GENE
. O
13 O
micrograms O
/ I-GENE
ml O
. O

The O
minimal I-GENE
promoter I-GENE
of O
the O
RII I-GENE
beta I-GENE
gene I-GENE
was O
composed O
of O
two O
adjacent O
functional O
elements O
. O

Mapping O
the O
cAMP I-GENE
receptor I-GENE
protein I-GENE
contact O
site I-GENE
on O
the O
alpha I-GENE
subunit I-GENE
of O
Escherichia I-GENE
coli I-GENE
RNA I-GENE
polymerase I-GENE
. O

Here O
we O
show O
that O
epidermal I-GENE
growth I-GENE
factor I-GENE
or O
platelet I-GENE
- I-GENE
derived O
growth I-GENE
factor I-GENE
stimulation O
of O
intact O
human I-GENE
or O
murine I-GENE
cells O
leads O
to O
phosphorylation O
of O
_RARE_ I-GENE
protein I-GENE
on O
tyrosine I-GENE
, O
serine I-GENE
, O
and O
threonine I-GENE
residues O
. O

A I-GENE
major I-GENE
mechanism O
_RARE_ I-GENE
steroid I-GENE
hydroxylase I-GENE
gene I-GENE
transcription I-GENE
is O
regulated O
in O
the O
adrenal O
cortex O
requires O
the O
pituitary I-GENE
peptide I-GENE
hormone I-GENE
, O
ACTH I-GENE
, O
which O
acts O
via O
cAMP I-GENE
. O

A I-GENE
combination O
of O
comparative O
sequence I-GENE
analysis O
and O
_RARE_ I-GENE
methods O
reveals O
the O
conservation O
of O
tertiary O
structure O
elements O
in O
the O
5 I-GENE
' O
untranslated O
region O
( O
UTR I-GENE
) O
of O
human I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
. O

The O
- I-GENE
64 O
/- O
37 O
region O
interacted O
with O
purified O
Sp1 I-GENE
and O
an O
unidentified O
protein I-GENE
( O
s O
), O
proximal I-GENE
regulatory I-GENE
factor I-GENE
( O
s O
) O
I I-GENE
( O
_RARE_ I-GENE
- I-GENE
I I-GENE
). O

_RARE_ I-GENE
and O
Vmax O
for O
two O
substrates O
, O
src I-GENE
- I-GENE
related I-GENE
peptide I-GENE
and O
poly O
( O
Glu O
, O
Tyr I-GENE
) O
( O
4 I-GENE
: O
1 I-GENE
), O
were O
2 I-GENE
. O
4 I-GENE
mM O
and O
2 I-GENE
. O
5 I-GENE
mumol O
min O
- I-GENE
1 I-GENE
mg O
- I-GENE
1 I-GENE
and O
0 O
. O
26 O
mM O
and O
1 I-GENE
. O
2 I-GENE
mumol O
min O
- I-GENE
1 I-GENE
mg O
- I-GENE
1 I-GENE
, O
respectively O
. O

This O
soluble I-GENE
form O
of O
the O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
bound O
HGF I-GENE
with O
an O
affinity O
similar O
to O
that O
of O
the O
_RARE_ I-GENE
, O
membrane I-GENE
- I-GENE
associated I-GENE
receptor I-GENE
. O

_RARE_ I-GENE
for O
blood O
screening O
for O
the O
hepatitis I-GENE
C I-GENE
virus I-GENE
and O
for O
the O
human I-GENE
immunodeficiency I-GENE
virus I-GENE
in O
high O
risk O
groups O
. O

Also O
, O
the O
human I-GENE
glycoprotein I-GENE
alpha I-GENE
- I-GENE
subunit I-GENE
promoter I-GENE
was O
induced O
10 O
- I-GENE
fold O
by O
_RARE_ I-GENE
in O
_RARE_ I-GENE
rat I-GENE
pituitary I-GENE
cells O
.( O
ABSTRACT O
TRUNCATED O
AT I-GENE
400 O
WORDS O
) O

Comparison O
of O
data O
obtained O
with O
the O
results O
of O
chronic O
treatment O
with O
the O
opioid I-GENE
antagonist O
permits O
to O
conclude O
that O
the O
chronic O
blockade O
increases O
the O
_RARE_ I-GENE
to O
a O
great O
extent O
than O
chronic O
activation O
of O
opioid I-GENE
system O
. O

Laboratory O
studies O
using O
_RARE_ I-GENE
labeled O
teeth O
and O
biologically O
stained O
teeth O
confirmed O
that O
the O
_RARE_ I-GENE
did O
not O
_RARE_ I-GENE
_RARE_ I-GENE
or O
_RARE_ I-GENE
teeth O
. O

Structure O
and O
expression O
of O
a O
gene I-GENE
from O
Arabidopsis I-GENE
thaliana O
encoding O
a O
protein I-GENE
related I-GENE
to O
_RARE_ I-GENE
protein I-GENE
kinase I-GENE
. O

We O
have O
cloned O
and O
characterized O
a O
55 O
- I-GENE
kb O
region O
of O
DNA I-GENE
surrounding O
_RARE_ I-GENE
. O

The O
ORF1 O
protein I-GENE
was O
found O
to O
be O
highly O
homologous O
to O
the O
putative O
_RARE_ I-GENE
RNA I-GENE
_RARE_ I-GENE
; O
ORF2 O
, O
- I-GENE
3 I-GENE
, O
- I-GENE
5 I-GENE
and O
- I-GENE
6 I-GENE
proteins I-GENE
also O
have O
analogues O
among O
the O
_RARE_ I-GENE
- I-GENE
and O
/ I-GENE
or O
_RARE_ I-GENE
- I-GENE
encoded I-GENE
proteins I-GENE
. O

A I-GENE
total O
of O
_RARE_ I-GENE
patients O
were O
divided O
into O
groups O
according O
to O
their O
clinical O
diagnosis O
and O
were O
examined O
using O
_RARE_ I-GENE
, O
_RARE_ I-GENE
and O
blood O
- I-GENE
gas O
analysis O
. O

The O
relationships O
between O
the O
partial O
pressures O
of O
O2 O
and O
CO2 O
as O
well O
as O
between O
their O
_RARE_ I-GENE
, O
become O
stronger O
with O
the O
increase O
of O
the O
ventilation O
- I-GENE
perfusion O
ratio O
. O

No O
significant O
correlations O
of O
peak O
VO2 O
were O
observed O
between O
the O
3 I-GENE
tests O
. O

An O
RNA I-GENE
- I-GENE
binding I-GENE
protein I-GENE
gene I-GENE
( O
_RARE_ I-GENE
) O
from O
Drosophila I-GENE
melanogaster I-GENE
, O
encoding O
an O
RNA I-GENE
recognition I-GENE
motif I-GENE
and O
an O
Arg O
- I-GENE
Ser O
rich O
( O
RS I-GENE
) O
domain I-GENE
, O
has O
been O
characterized O
. O

Some O
research O
studies O
have O
related I-GENE
this O
_RARE_ I-GENE
of O
tumors O
with O
prolonged O
ingestion O
of O
H2 I-GENE
inhibitors O
and O
others O
_RARE_ I-GENE
. O

A I-GENE
comparative O
study O
of O
the O
total O
protein I-GENE
profiles O
of O
wild I-GENE
- I-GENE
type I-GENE
S I-GENE
. O
_RARE_ I-GENE
_RARE_ I-GENE
and O
mutant I-GENE
_RARE_ I-GENE
revealed O
that O
the O
mutant I-GENE
lacked O
an O
approximately O
44 I-GENE
- I-GENE
kDa I-GENE
protein I-GENE
and O
overexpressed O
an O
approximately O
20 O
- I-GENE
kDa I-GENE
protein I-GENE
. O

Characterization O
of O
the O
_RARE_ I-GENE
controlled O
by O
the O
leucine I-GENE
- I-GENE
responsive I-GENE
regulatory I-GENE
protein I-GENE
in O
Escherichia I-GENE
coli I-GENE
. O

Mapping O
of O
the O
mouse I-GENE
_RARE_ I-GENE
decarboxylase I-GENE
- I-GENE
related I-GENE
sequence I-GENE
family I-GENE
. O

This O
mutation I-GENE
also O
results O
in O
markedly O
decreased O
levels O
of O
CAD I-GENE
mRNA I-GENE
and O
protein I-GENE
in O
the O
mutant I-GENE
. O

The O
_RARE_ I-GENE
for O
continuous O
dopaminergic O
stimulation O
in O
patients O
with O
Parkinson O
' O
s O
disease O
. O

Mutational O
studies O
revealed O
that O
it O
was O
the O
homeodomain I-GENE
binding I-GENE
site I-GENE
II I-GENE
sequence I-GENE
that O
was O
required O
for O
this O
regulation O
. O

Thus O
, O
the O
pol I-GENE
alpha I-GENE
- I-GENE
primase I-GENE
complex I-GENE
appears O
to O
act O
_RARE_ I-GENE
for O
only O
a O
short O
distance O
. O

Interestingly O
, O
the O
positions O
of O
these O
introns O
have O
been O
conserved O
in O
comparison O
with O
the O
genes I-GENE
of O
two O
other O
_RARE_ I-GENE
- I-GENE
like I-GENE
activities O
described O
in O
the O
literature O
, O
but O
the O
_RARE_ I-GENE
gene I-GENE
is O
by O
far O
the O
smallest O
characterized O
to O
date O
because O
its O
introns O
are O
relatively O
smaller O
. O

In O
a O
retrospective O
analysis O
of O
data O
from O
35 O
cases O
with O
malignant O
lymphoma O
from O
a O
cohort O
of O
_RARE_ I-GENE
HIV I-GENE
- I-GENE
infected O
patients O
, O
the O
stage O
of O
HIV I-GENE
- I-GENE
disease O
, O
the O
CD4 I-GENE
counts O
at O
the O
time O
of O
diagnosis O
, O
and O
the O
use O
of O
_RARE_ I-GENE
agents O
or O
radiotherapy O
were O
correlated O
with O
outcome O
. O

1 I-GENE
. O

Effects O
of O
_RARE_ I-GENE
on O
thyroid I-GENE
function O
in O
newborn O
babies O
. O

cDNA I-GENE
clones O
encoding O
Arabidopsis I-GENE
thaliana O
and O
_RARE_ I-GENE
_RARE_ I-GENE
mitochondrial I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
and O
gene I-GENE
expression O
during O
seed I-GENE
_RARE_ I-GENE
and O
heat I-GENE
shock I-GENE
. O

Amino O
acid I-GENE
sequence I-GENE
comparison O
revealed O
significant O
homology I-GENE
between O
the O
yeast I-GENE
and O
Escherichia I-GENE
coli I-GENE
gamma I-GENE
- I-GENE
glutamyl I-GENE
kinases I-GENE
throughout O
their O
lengths O
. O

The O
single O
site I-GENE
of O
glycosylation O
is O
located O
near O
the O
C I-GENE
- I-GENE
terminus O
in O
the O
N I-GENE
- I-GENE
glycosylation O
_RARE_ I-GENE
- I-GENE
Asn O
- I-GENE
Cys I-GENE
- I-GENE
Ser O
- I-GENE
in O
which O
Cys I-GENE
forms O
part O
of O
a O
_RARE_ I-GENE
_RARE_ I-GENE
. O

The O
pulmonary O
toxic O
events O
induced O
by O
acute O
nitrogen O
dioxide O
( O
NO O
) O
2 I-GENE
exposure O
were O
studied O
in O
the O
rat I-GENE
to O
develop O
an O
inhalation O
model O
to O
investigate O
therapeutic O
measures O
. O

The O
pulmonary O
effects O
observed O
, O
became O
more O
pronounced O
with O
increasing O
NO2 O
concentrations O
( O
0 O
, O
25 O
, O
75 O
, O
125 I-GENE
, O
175 O
or O
200 O
ppm O
, O
1 I-GENE
ppm O
NO2 O
= O
1 I-GENE
. O
88 O
mg O
m I-GENE
- I-GENE
3 I-GENE
NO2 O
) O
and O
exposure O
times O
( O
5 I-GENE
, O
10 O
, O
20 O
or O
30 O
min O
). O

Interaction O
of O
H I-GENE
- I-GENE
_RARE_ I-GENE
with O
an O
_RARE_ I-GENE
retrotransposon I-GENE
in O
the O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
B I-GENE
cell O
lymphoma O
. O

_RARE_ I-GENE
_RARE_ I-GENE
diseases O
: O
recent O
_RARE_ I-GENE
in O
the O
understanding O
of O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
and O
natural O
history O
. O

With O
the O
exception O
of O
mutants I-GENE
that O
_RARE_ I-GENE
the O
membrane I-GENE
anchor I-GENE
domain I-GENE
, O
all O
of O
the O
mutant I-GENE
glycoproteins I-GENE
retained O
the O
ability O
to O
cause O
fusion I-GENE
of O
CD4 I-GENE
- I-GENE
bearing O
cells O
. O

The O
subunit I-GENE
protein I-GENE
of O
_RARE_ I-GENE
was O
highly O
homologous O
at O
its O
amino O
terminus O
to O
_RARE_ I-GENE
- I-GENE
17 O
, O
the O
subunit I-GENE
protein I-GENE
of O
thin O
, O
_RARE_ I-GENE
_RARE_ I-GENE
of O
Salmonella I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
strain O
_RARE_ I-GENE
, O
suggesting O
that O
these O
fibres O
form O
a O
novel O
class I-GENE
of O
surface O
_RARE_ I-GENE
on O
_RARE_ I-GENE
. O

Substitution O
of O
the O
DR1 I-GENE
beta I-GENE
chain I-GENE
with O
H I-GENE
- I-GENE
_RARE_ I-GENE
beta I-GENE
_RARE_ I-GENE
led O
to O
a O
dramatic O
loss O
of O
recognition I-GENE
; O
alpha I-GENE
chain I-GENE
substitution O
had O
a O
less O
marked O
effect O
. O

This O
negative O
regulatory I-GENE
pathway O
may O
be O
important O
for O
determining O
cell O
fate O
or O
maintaining O
an O
inducible I-GENE
state O
in O
the O
_RARE_ I-GENE
region O
of O
the O
embryo O
. O

The O
distal O
portion O
of O
the O
rat I-GENE
insulin I-GENE
I I-GENE
gene I-GENE
5 I-GENE
'- O
flanking O
DNA I-GENE
contains O
two O
sequence I-GENE
elements O
, O
the O
_RARE_ I-GENE
and O
_RARE_ I-GENE
elements O
, O
that O
can O
function O
in O
combination O
, O
but O
not O
separately O
, O
as O
a O
beta I-GENE
- I-GENE
cell O
- I-GENE
specific I-GENE
transcriptional O
enhancer I-GENE
. O

The O
deduced O
amino O
acid I-GENE
sequence I-GENE
exhibited O
98 O
% O
identity O
to O
the O
human I-GENE
cellular O
_RARE_ I-GENE
sequence I-GENE
. O

This O
_RARE_ I-GENE
is O
performed O
by O
a O
parallel O
network O
of O
locally O
connected O
neuron I-GENE
- I-GENE
like I-GENE
elements O
. O

_RARE_ I-GENE
_RARE_ I-GENE
to O
isolate O
recombinant I-GENE
_RARE_ I-GENE
containing O
a O
wild I-GENE
- I-GENE
type I-GENE
kinase I-GENE
failed O
, O
whereas O
recombinants I-GENE
expressing O
a O
_RARE_ I-GENE
kinase I-GENE
with O
a O
catalytic O
domain I-GENE
II I-GENE
mutation I-GENE
were O
readily O
isolated O
. O

Finally O
, O
we O
determined O
that O
the O
_RARE_ I-GENE
amino O
terminus O
was O
both O
necessary O
and O
sufficient O
for O
binding I-GENE
dsRNA I-GENE
as O
we O
were O
able O
to O
transfer I-GENE
dsRNA I-GENE
- I-GENE
binding I-GENE
properties O
to O
a O
reporter I-GENE
gene I-GENE
product I-GENE
previously O
unable O
to O
bind O
RNA I-GENE
. O

From O
August O
1989 O
to O
_RARE_ I-GENE
1990 O
, O
83 O
pregnant O
Chinese O
women O
were O
the O
subjects O
for O
measuring O
the O
levels O
of O
plasma I-GENE
functional O
antithrombin I-GENE
III I-GENE
( O
AT I-GENE
III I-GENE
) O
activity O
. O

_RARE_ I-GENE
_RARE_ I-GENE
may O
be O
decreased O
by O
transient O
changes O
in O
_RARE_ I-GENE
error O
caused O
by O
_RARE_ I-GENE
, O
the O
_RARE_ I-GENE
agent O
_RARE_ I-GENE
, O
_RARE_ I-GENE
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
anhydrase I-GENE
inhibitors O
. O

_RARE_ I-GENE
aspects O
of O
H2 I-GENE
receptor I-GENE
antagonists O
in O
the O
treatment O
of O
ulcers O

In O
addition O
, O
a O
21 O
- I-GENE
mer I-GENE
_RARE_ I-GENE
structure O
is O
also O
present O
in O
each O
unit I-GENE
. O

Sequencing O
revealed O
one O
large O
open O
reading O
frame O
encoding O
a O
39 O
- I-GENE
kDa I-GENE
protein I-GENE
. O

These O
sites I-GENE
are O
also O
potential O
_RARE_ I-GENE
sulfate I-GENE
attachment O
sites I-GENE
. O

We O
propose O
that O
plasmids O
of O
the O
_RARE_ I-GENE
family I-GENE
( O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
) O
share O
functional O
and O
structural O
characteristics O
for O
the O
regulation O
of O
their O
copy O
numbers O
. O

_RARE_ I-GENE
of O
_RARE_ I-GENE
_RARE_ I-GENE
also O
affected O
the O
frameshift O
fidelity I-GENE
of O
the O
replicative O
yeast I-GENE
DNA I-GENE
polymerase I-GENE
alpha I-GENE
. O

Differential O
expression O
of O
the O
" O
B I-GENE
" O
subunit I-GENE
of O
the O
vacuolar I-GENE
H I-GENE
(+)- I-GENE
ATPase I-GENE
in O
bovine I-GENE
tissues O
. O

In O
addition O
, O
the O
_RARE_ I-GENE
gene I-GENE
was O
_RARE_ I-GENE
localized O
by O
Southern O
blot O
analysis O
of O
its O
segregation O
pattern O
in O
a O
panel O
of O
rodent O
- I-GENE
human I-GENE
hybrid O
DNAs O
using O
the O
radiolabeled O
cDNA I-GENE
probe O
. O

We O
have O
isolated O
and O
_RARE_ I-GENE
a O
differentially O
- I-GENE
regulated O
gene I-GENE
family I-GENE
in O
the O
_RARE_ I-GENE
parasite O
Leishmania I-GENE
major I-GENE
. O

At O
some O
sites I-GENE
, O
% O
T I-GENE
is O
greatly O
increased O
by O
Cl O
- I-GENE
concentrations O
up O
to O
1 I-GENE
M I-GENE
, O
while O
at O
other O
sites I-GENE
% O
T I-GENE
is O
reduced O
or O
unaffected O
by O
these O
conditions O
. O

_RARE_ I-GENE
appears O
6 I-GENE
h O
after O
TA O
infusion O
, O
being O
5 I-GENE
. O
77 O
% O
in O
extent O
after O
12 O
h O
, O
14 O
. O
9 O
% O
after O
24 O
h O
and O
animals O
_RARE_ I-GENE
with O
an O
area O
of O
29 O
. O
5 I-GENE
% O
necrosis I-GENE
. O

In O
summary O
, O
the O
segments O
of O
C3 I-GENE
represented O
by O
amino O
acid I-GENE
residues O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
C3 I-GENE
( O
D I-GENE
) O
epitopes I-GENE
that O
are O
expressed O
by O
erythrocyte I-GENE
- I-GENE
bound O
C3 I-GENE
fragments I-GENE
, O
but O
not O
by O
the O
corresponding O
fluid O
- I-GENE
phase O
fragment I-GENE
, O
whereas O
the O
segments O
spanning O
residues O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
contain O
C3 I-GENE
( O
D I-GENE
) O
epitopes I-GENE
that O
are O
exposed O
exclusively O
in O
_RARE_ I-GENE
C3 I-GENE
and O
therefore O
_RARE_ I-GENE
in O
physiological O
fragments I-GENE
of O
the O
protein I-GENE
. O

These O
exons O
, O
further O
identified O
as O
exons O
9 O
, O
10 O
, O
and O
11 O
, O
together O
encode O
the O
37 O
amino O
acid I-GENE
residues O
present O
in O
alpha I-GENE
_RARE_ I-GENE
- I-GENE
casein I-GENE
variant I-GENE
A I-GENE
but O
missing O
in O
variant I-GENE
F I-GENE
. O

We O
also O
report O
here O
the O
complete O
structural O
organization O
of O
the O
_RARE_ I-GENE
alpha I-GENE
_RARE_ I-GENE
- I-GENE
casein I-GENE
transcription I-GENE
unit I-GENE
, O
deduced O
from O
polymerase I-GENE
chain I-GENE
reaction O
experiments O
. O

_RARE_ I-GENE
of O
the O
three O
proteins I-GENE
specifically O
recognize O
the O
G I-GENE
- I-GENE
box I-GENE
motif I-GENE
, O
with O
_RARE_ I-GENE
and O
_RARE_ I-GENE
binding I-GENE
_RARE_ I-GENE
to O
this O
palindromic O
sequence I-GENE
. O

Neither O
gene I-GENE
possesses O
a O
distinct O
transcriptional O
start O
site I-GENE
as O
shown O
by O
nuclease I-GENE
S1 I-GENE
analysis O
. O

The O
_RARE_ I-GENE
_RARE_ I-GENE
of O
_RARE_ I-GENE
- I-GENE
3 I-GENE
is O
very O
similar O
to O
that O
of O
_RARE_ I-GENE
- I-GENE
1 I-GENE
and O
_RARE_ I-GENE
- I-GENE
2 I-GENE
. O

The O
initial O
translation I-GENE
protein I-GENE
encoded I-GENE
by O
the O
cDNA I-GENE
is O
53 O
, O
_RARE_ I-GENE
kDa I-GENE
and O
possesses O
a O
hydrophilic O
amino O
acid I-GENE
composition O
with O
_RARE_ I-GENE
acid I-GENE
_RARE_ I-GENE
22 O
% O
of O
the O
total O
amino O
acid I-GENE
residues O
. O

Each O
group O
received O
15 O
ml O
/ I-GENE
kg O
of O
either O
6 I-GENE
% O
_RARE_ I-GENE
, O
6 I-GENE
% O
_RARE_ I-GENE
, O
or O
plasma I-GENE
followed O
two O
hours O
later O
by O
1 I-GENE
. O
5 I-GENE
micrograms O
/ I-GENE
kg O
/ I-GENE
0 O
. O
5 I-GENE
hr O
E I-GENE
. O

Genetic O
and O
biochemical O
evidence O
suggests O
that O
v I-GENE
- I-GENE
Crk I-GENE
can O
induce O
transformation O
of O
chicken I-GENE
embryo O
fibroblasts O
by O
influencing O
the O
activity O
of O
cellular O
proteins I-GENE
involved O
in O
growth I-GENE
regulation O
. O

We O
have O
constructed O
, O
using O
synthetic O
DNA I-GENE
oligonucleotides O
, O
a O
U14 I-GENE
snRNA I-GENE
gene I-GENE
which O
has O
been O
positioned O
behind O
a O
T7 I-GENE
RNA I-GENE
polymerase I-GENE
promoter I-GENE
site I-GENE
and O
then O
inserted O
into O
a O
plasmid O
. O

Gene I-GENE
and O
pseudogene I-GENE
of O
the O
mouse I-GENE
_RARE_ I-GENE
- I-GENE
dependent I-GENE
_RARE_ I-GENE
6 I-GENE
- I-GENE
phosphate I-GENE
receptor I-GENE
. O

The O
chick I-GENE
_RARE_ I-GENE
- I-GENE
associated I-GENE
surface O
glycoprotein I-GENE
_RARE_ I-GENE
is O
implicated O
in O
_RARE_ I-GENE
growth I-GENE
and O
_RARE_ I-GENE
as O
revealed O
by O
antibody I-GENE
_RARE_ I-GENE
experiments O
. O

The O
carcinoma O
was O
restricted O
within O
the O
epithelium O
in O
one O
, O
the O
mucosal I-GENE
layer O
in O
five O
, O
and O
the O
_RARE_ I-GENE
layer O
in O
two O
. O

In O
addition O
, O
C I-GENE
/ I-GENE
EBP I-GENE
beta I-GENE
and O
C I-GENE
/ I-GENE
EBP I-GENE
gamma I-GENE
readily O
_RARE_ I-GENE
with O
each O
other O
as O
well O
as O
with O
C I-GENE
/ I-GENE
EBP I-GENE
alpha I-GENE
. O

In O
contrast O
, O
tobacco I-GENE
GS I-GENE
- I-GENE
2 I-GENE
is O
composed O
of O
subunits I-GENE
of O
identical O
size O
in O
all O
organs O
examined O
. O

_RARE_ I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
, O
two O
different O
types O
of O
sequences I-GENE
with O
dual O
_RARE_ I-GENE
_RARE_ I-GENE
[ O
_RARE_ I-GENE
-( O
_RARE_ I-GENE
to O
_RARE_ I-GENE
)- I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
-( O
_RARE_ I-GENE
to O
_RARE_ I-GENE
)- I-GENE
ACA I-GENE
] O
were O
found O
; O
these O
sequences I-GENE
are O
similar O
to O
_RARE_ I-GENE
and O
_RARE_ I-GENE
upstream O
activator I-GENE
sequences I-GENE
, O
respectively O
. O

Although O
the O
effects O
of O
the O
calcium O
_RARE_ I-GENE
or O
calcium O
antagonist O
alone O
were O
significant O
, O
such O
hypotensive O
responses O
were O
not O
optimal O
or O
_RARE_ I-GENE
or O
clearly O
dose O
- I-GENE
dependent I-GENE
. O

C I-GENE
., O
_RARE_ I-GENE
, O
J O
., O
_RARE_ I-GENE
, O
M I-GENE
_RARE_ I-GENE
Y I-GENE
., O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
, O
J O
., O
_RARE_ I-GENE
, O
S I-GENE
., O
and O
_RARE_ I-GENE
, O
M I-GENE
. O

Surprisingly O
, O
the O
full I-GENE
- I-GENE
deletion O
mutant I-GENE
showed O
a O
strong O
block O
in O
virus I-GENE
release O
, O
suggesting O
that O
_RARE_ I-GENE
is O
involved O
in O
virus I-GENE
assembly O
. O

Furthermore O
it O
was O
suggested O
that O
FK506 O
plasma I-GENE
levels O
were O
_RARE_ I-GENE
with O
the O
appearance O
of O
side O
effect O
. O

Thirty O
percent O
of O
patients O
were O
_RARE_ I-GENE
off O
all O
steroids O
, O
and O
the O
average O
steroid I-GENE
dose O
in O
the O
group O
who O
received O
steroids O
was O
8 O
. O
6 I-GENE
mg O
of O
prednisone O
per O
day O
. O

Thus O
, O
_RARE_ I-GENE
is O
an O
effective O
antiarrhythmic O
agent O
with O
a O
favourable O
pharmacokinetic O
profile O
that O
may O
be O
considered O
with O
other O
class I-GENE
I I-GENE
drugs O
in O
patients O
requiring O
therapy O
for O
high O
risk O
arrhythmias O
. O

T I-GENE
antigen I-GENE
contains O
four O
H I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
restricted O
cytotoxic O
T I-GENE
lymphocyte I-GENE
( O
CTL O
) O
recognition I-GENE
epitopes I-GENE
that O
are O
targets O
for O
CTL O
clones O
Y I-GENE
- I-GENE
1 I-GENE
, O
Y I-GENE
- I-GENE
2 I-GENE
, O
Y I-GENE
- I-GENE
3 I-GENE
, O
and O
Y I-GENE
- I-GENE
5 I-GENE
. O

The O
method O
requires O
a O
reversed O
- I-GENE
phase O
column O
and O
a O
paired I-GENE
- I-GENE
ion O
technique O
to O
separate O
_RARE_ I-GENE
sodium O
from O
other O
components O
. O

Here O
we O
demonstrate O
that O
the O
protein I-GENE
product I-GENE
of O
the O
_RARE_ I-GENE
- I-GENE
1 I-GENE
gene I-GENE
stimulates O
the O
DNA I-GENE
binding I-GENE
activity O
of O
Fos I-GENE
- I-GENE
Jun I-GENE
heterodimers I-GENE
, O
Jun I-GENE
- I-GENE
Jun I-GENE
homodimers I-GENE
and O
_RARE_ I-GENE
cell O
AP I-GENE
- I-GENE
1 I-GENE
proteins I-GENE
as O
well O
as O
that O
of O
several O
other O
transcription I-GENE
factors I-GENE
including O
NF I-GENE
- I-GENE
kappa I-GENE
B I-GENE
, O
Myb I-GENE
and O
members O
of O
the O
ATF I-GENE
/ I-GENE
CREB I-GENE
family I-GENE
. O

The O
_RARE_ I-GENE
tissues O
of O
the O
permanent O
mandibular O
_RARE_ I-GENE
were O
_RARE_ I-GENE
and O
then O
_RARE_ I-GENE
with O
calcium O
_RARE_ I-GENE
. O

Northern O
blot O
analyses O
demonstrate O
that O
3 I-GENE
. O
9 O
- I-GENE
and O
5 I-GENE
- I-GENE
kilobase O
mRNAs I-GENE
corresponding O
to O
the O
cDNA I-GENE
were O
present O
in O
all O
tissues O
examined O
, O
suggesting O
that O
the O
protein I-GENE
it O
encodes O
_RARE_ I-GENE
a O
housekeeping O
function O
. O

The O
_RARE_ I-GENE
SH2 I-GENE
domain I-GENE
exhibited O
relatively O
weak O
affinity O
for O
BCR I-GENE
and O
was O
determined O
to O
bind O
about O
10 O
- I-GENE
fold O
less O
strongly O
than O
the O
ABL I-GENE
SH2 I-GENE
domain I-GENE
. O

We O
analyzed O
an O
EBV I-GENE
B I-GENE
- I-GENE
cell O
clone O
, O
_RARE_ I-GENE
. O
1 I-GENE
, O
derived O
from O
an O
11 O
week O
- I-GENE
old O
embryo O
, O
and O
secreting O
both O
IgM I-GENE
kappa I-GENE
and O
IgM I-GENE
lambda I-GENE
. O

Interestingly O
, O
this O
activation O
occurred O
only O
when O
the O
regions O
were O
cloned O
in O
the O
same O
relative O
orientation O
in O
which O
they O
exist O
on O
wild I-GENE
- I-GENE
type I-GENE
_RARE_ I-GENE
. O

In O
rats O
, O
we O
examined O
the O
effect O
of O
an O
_RARE_ I-GENE
_RARE_ I-GENE
on O
the O
_RARE_ I-GENE
of O
the O
_RARE_ I-GENE
and O
on O
regeneration O
of O
the O
mucosal I-GENE
epithelium O
in O
the O
very O
early I-GENE
stage O
after O
free O
tracheal O
_RARE_ I-GENE
. O

To O
study O
a O
possible O
functional O
role O
of O
this O
putative O
chicken I-GENE
_RARE_ I-GENE
, O
an O
oligonucleotide I-GENE
spanning O
the O
upstream O
sequences I-GENE
of O
the O
BF I-GENE
- I-GENE
IV I-GENE
gene I-GENE
(- O
_RARE_ I-GENE
/- O
_RARE_ I-GENE
) O
was O
cloned O
_RARE_ I-GENE
or O
in O
multiple O
copies O
before O
the O
herpes I-GENE
TK I-GENE
promoter I-GENE
controlling O
the O
chloramphenicol I-GENE
acetyl I-GENE
transferase I-GENE
( O
CAT I-GENE
) O
gene I-GENE
( O
_RARE_ I-GENE
). O

In O
general O
, O
two O
separate O
high O
- I-GENE
performance O
liquid O
chromatographic O
_RARE_ I-GENE
were O
performed O
, O
one O
for O
the O
gamma I-GENE
- I-GENE
_RARE_ I-GENE
acid I-GENE
determination O
and O
one O
for O
the O
determination O
of O
the O
_RARE_ I-GENE
. O

We O
report O
the O
successful O
use O
of O
_RARE_ I-GENE
therapy O
for O
treatment O
of O
severe O
depression O
in O
a O
young O
man O
with O
adult O
_RARE_ I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
of O
yeast I-GENE
cells O
into O
the O
mitotic O
cell O
cycle O
( O
_RARE_ I-GENE
) O
involves O
a O
form O
of O
the O
_RARE_ I-GENE
kinase I-GENE
that O
associates O
with O
G1 I-GENE
- I-GENE
specific I-GENE
_RARE_ I-GENE
encoded I-GENE
by O
_RARE_ I-GENE
and O
_RARE_ I-GENE
( O
_RARE_ I-GENE
. O

_RARE_ I-GENE
Southern O
blot O
analyses O
of O
DNA I-GENE
from O
backcross O
and O
_RARE_ I-GENE
mice O
, O
recombinant I-GENE
_RARE_ I-GENE
strains O
, O
and O
somatic O
cell O
hybrids O
, O
the O
genetic O
loci I-GENE
that O
produce O
the O
cyclin I-GENE
B1 I-GENE
- I-GENE
related I-GENE
sequences I-GENE
( O
designated O
loci I-GENE
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
to O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
) O
were O
mapped O
on O
mouse I-GENE
chromosomes O
5 I-GENE
, O
1 I-GENE
, O
17 O
, O
4 I-GENE
, O
14 O
, O
13 O
, O
7 O
, O
X I-GENE
, O
and O
8 O
, O
respectively O
. O

_RARE_ I-GENE
residue O
Glu O
- I-GENE
_RARE_ I-GENE
of O
beta I-GENE
was O
_RARE_ I-GENE
reduced O
and O
no O
missing O
residue O
from O
the O
epsilon I-GENE
peptide I-GENE
could O
be O
identified O
, O
but O
the O
peptide I-GENE
sequence I-GENE
limited O
the O
possible O
_RARE_ I-GENE
to O
Ser O
- I-GENE
_RARE_ I-GENE
, O
Ser O
- I-GENE
_RARE_ I-GENE
, O
or O
Ser O
- I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
to O
dentin O
bond O
strength O
with O
a O
dentin O
adhesive O
. O

_RARE_ I-GENE
is O
defined O
as O
a O
_RARE_ I-GENE
of O
the O
difference O
of O
the O
first O
and O
the O
second O
measurement O
: O
_RARE_ I-GENE
= O
( O
P1 I-GENE
- I-GENE
P2 I-GENE
_RARE_ I-GENE
A1 I-GENE
- I-GENE
A2 I-GENE
). O

It O
was O
concluded O
that O
_RARE_ I-GENE
2 I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
2 I-GENE
are O
effective O
and O
are O
the O
_RARE_ I-GENE
_RARE_ I-GENE
agents O
of O
choice O
. O

From O
all O
clinically O
important O
_RARE_ I-GENE
species O
, O
a O
total O
of O
96 O
% O
were O
identified O
by O
_RARE_ I-GENE
method O
according O
to O
conventional O
methods O
. O

The O
_RARE_ I-GENE
vasopressin I-GENE
and O
_RARE_ I-GENE
content O
was O
_RARE_ I-GENE
by O
pressor O
effect O
following O
_RARE_ I-GENE
or O
milk O
- I-GENE
ejection O
activity O
in O
vitro O
following O
_RARE_ I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
, O
respectively O
. O

_RARE_ I-GENE
are O
given O
on O
the O
present O
status O
of O
_RARE_ I-GENE
concerning O
water O
in O
swimming O
_RARE_ I-GENE
and O
_RARE_ I-GENE
-- O
1991 O
_RARE_ I-GENE
in O
_RARE_ I-GENE
with O
the O
_RARE_ I-GENE
_RARE_ I-GENE
-- O
1972 O
-- O
and O
the O
_RARE_ I-GENE
_RARE_ I-GENE
standard O
[ O
_RARE_ I-GENE
] O
No O
. O

If O
no O
_RARE_ I-GENE
was O
received O
, O
_RARE_ I-GENE
contact O
or O
home O
_RARE_ I-GENE
were O
made O
. O

The O
treatment O
group O
also O
showed O
in O
vivo O
T I-GENE
- I-GENE
cell O
activation O
with O
an O
initial O
_RARE_ I-GENE
followed O
by O
a O
_RARE_ I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
of O
the O
subset O
markers O
_RARE_ I-GENE
( O
interleukin I-GENE
2 I-GENE
receptor I-GENE
) O
and O
_RARE_ I-GENE
( O
T I-GENE
- I-GENE
memory O
cells O
). O

_RARE_ I-GENE
activity O
, O
judged O
as O
the O
amount O
of O
ammonia I-GENE
production O
from O
urea O
, O
could O
be O
measured O
at O
25 O
ng O
per O
tube O
( O
S I-GENE
/ I-GENE
N I-GENE
= O
1 I-GENE
. O
5 I-GENE
) O
with O
_RARE_ I-GENE
bean I-GENE
meal I-GENE
urease I-GENE
. O

_RARE_ I-GENE
, O
significant O
differences O
between O
the O
measured O
and O
calculated O
methods O
were O
noted O
in O
oxygen O
uptake O
( O
_RARE_ I-GENE
+/- O
41 O
ml O
/ I-GENE
min O
vs O
193 O
+/- O
25 O
ml O
/ I-GENE
min O
, O
p O
< O
0 O
. O
001 O
), O
oxygen O
delivery O
( O
_RARE_ I-GENE
+/- O
_RARE_ I-GENE
ml O
/ I-GENE
min O
vs O
_RARE_ I-GENE
+/- O
296 O
ml O
/ I-GENE
min O
, O
p O
< O
0 O
. O
001 O
), O
and O
cardiac O
output O
( O
5 I-GENE
. O
8 O
+/- O
2 I-GENE
. O
2 I-GENE
L I-GENE
/ I-GENE
min O
vs O
5 I-GENE
. O
3 I-GENE
+/- O
1 I-GENE
. O
8 O
L I-GENE
/ I-GENE
min O
, O
p O
< O
0 O
. O
001 O
). O

Although O
a O
wide O
range O
of O
cognitive O
functions O
had O
been O
tested O
, O
all O
but O
one O
seizure O
occurred O
during O
assessment O
of O
memory O
performance O
. O

The O
experiments O
show O
that O
it O
is O
the O
_RARE_ I-GENE
of O
the O
_RARE_ I-GENE
and O
the O
condition O
of O
the O
AM I-GENE
( O
certain O
physiological O
activation O
states O
, O
such O
as O
phagocytic O
activity O
) O
that O
essentially O
determine O
the O
degree O
of O
recovery O
. O

_RARE_ I-GENE
_RARE_ I-GENE
plasmid O
_RARE_ I-GENE
did O
not O
compete O
, O
whereas O
an O
otherwise O
identical O
plasmid O
_RARE_ I-GENE
( O
CG I-GENE
), O
which O
contained O
a O
( O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
) O
7 O
segment O
in O
the O
Z I-GENE
- I-GENE
form O
was O
an O
excellent O
competitor O
. O

A I-GENE
cDNA I-GENE
library O
of O
tumour I-GENE
cells O
was O
screened O
with O
an O
interleukin I-GENE
2 I-GENE
gene I-GENE
- I-GENE
specific I-GENE
probe O
. O

Our O
experiments O
suggest O
that O
the O
_RARE_ I-GENE
gene I-GENE
can O
be O
a O
target O
for O
the O
erythroid I-GENE
transcription I-GENE
factor I-GENE
GATA I-GENE
- I-GENE
1 I-GENE
and O
that O
the O
_RARE_ I-GENE
gene I-GENE
product I-GENE
serves O
as O
a O
positive O
regulator I-GENE
of O
erythroid I-GENE
differentiation O
. O

In O
contrast O
, O
the O
_RARE_ I-GENE
domains I-GENE
of O
_RARE_ I-GENE
, O
_RARE_ I-GENE
and O
_RARE_ I-GENE
are O
very O
different O
in O
size O
and O
do O
not O
show O
any O
_RARE_ I-GENE
homology I-GENE
. O

_RARE_ I-GENE
containing O
wild I-GENE
- I-GENE
type I-GENE
and O
either O
_RARE_ I-GENE
or O
_RARE_ I-GENE
mutant I-GENE
p53 I-GENE
proteins I-GENE
are O
completely O
unable O
to O
bind O
to O
the O
_RARE_ I-GENE
DNA I-GENE
sequence I-GENE
. O

These O
temperature O
- I-GENE
and O
cold O
- I-GENE
sensitive O
strains O
were O
used O
to O
_RARE_ I-GENE
extracts O
deficient O
in O
_RARE_ I-GENE
activity O
and O
were O
tested O
for O
transcriptional O
activity O
by O
RNA I-GENE
polymerases I-GENE
I I-GENE
, O
II I-GENE
, O
and O
III I-GENE
in O
vitro O
. O

These O
results O
lead O
us O
to O
_RARE_ I-GENE
that O
a O
single O
multisubunit I-GENE
TFIID I-GENE
protein I-GENE
supports O
transcriptional O
stimulation O
by O
diverse O
activation O
domains I-GENE
and O
from O
a O
TATA I-GENE
- I-GENE
less O
promoter I-GENE
. O

The O
gene I-GENE
sequence I-GENE
also O
identified O
a O
_RARE_ I-GENE
- I-GENE
nucleotide I-GENE
RNA I-GENE
in O
total O
yeast I-GENE
RNA I-GENE
and O
in O
purified O
RNase I-GENE
MRP I-GENE
enzyme I-GENE
preparations O
. O

The O
RNase I-GENE
MRP I-GENE
RNA I-GENE
gene I-GENE
was O
deleted O
by O
insertional I-GENE
replacement O
and O
found O
to O
be O
essential O
for O
cellular O
viability O
, O
indicating O
a O
critical O
nuclear I-GENE
role O
for O
RNase I-GENE
MRP I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
hybrid O
selected O
an O
mRNA I-GENE
that O
on O
cell O
- I-GENE
free O
translation I-GENE
produced O
a O
38 O
- I-GENE
kDa I-GENE
polypeptide I-GENE
. O

From O
these O
results O
, O
CBF I-GENE
- I-GENE
A I-GENE
is O
a O
novel O
CArG I-GENE
box I-GENE
-, I-GENE
ssDNA I-GENE
- I-GENE
and O
RNA I-GENE
- I-GENE
binding I-GENE
protein I-GENE
, O
as O
well O
as O
a O
repressive O
transcriptional O
factor I-GENE
. O

_RARE_ I-GENE
by O
the O
intron O
- I-GENE
encoded I-GENE
enzyme I-GENE
( O
I I-GENE
- I-GENE
_RARE_ I-GENE
) O
occurs O
5 I-GENE
bp O
and O
1 I-GENE
bp O
3 I-GENE
' O
to O
the O
intron O
insertion O
site I-GENE
( O
in O
the O
3 I-GENE
'- O
exon O
) O
in O
the O
top O
_RARE_ I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
, O
respectively O
, O
resulting O
in O
4 I-GENE
- I-GENE
nt O
single O
- I-GENE
stranded I-GENE
_RARE_ I-GENE
with O
3 I-GENE
'- O
OH O
termini O
. O

Surprisingly O
, O
the O
Xenopus I-GENE
_RARE_ I-GENE
gene I-GENE
contains O
two O
adjacent O
octamer O
- I-GENE
binding I-GENE
motifs O
located O
only O
12 O
and O
24 O
bp O
upstream O
from O
the O
_RARE_ I-GENE
, O
instead O
of O
the O
_RARE_ I-GENE
location O
around O
150 O
- I-GENE
200 O
bp O
upstream O
. O

The O
results O
support O
earlier O
reports O
that O
_RARE_ I-GENE
inhibitors O
are O
useful O
in O
controlling O
_RARE_ I-GENE
formation O
in O
recessive O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
. O

Mutational O
analysis O
of O
essential O
_RARE_ I-GENE
alpha I-GENE
plasmid O
transfer I-GENE
genes I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
and O
involvement O
of O
_RARE_ I-GENE
in O
phage I-GENE
sensitivity O
. O

The O
promoter I-GENE
was O
stimulated O
8 O
- I-GENE
20 O
- I-GENE
fold O
by O
phorbol O
esters O
_RARE_ I-GENE
for O
the O
previously O
observed O
transcriptional O
activation O
of O
protein I-GENE
kinase I-GENE
C I-GENE
beta I-GENE
. O

In O
humans O
, O
four O
AMP I-GENE
deaminase I-GENE
variants I-GENE
, O
termed O
M I-GENE
( O
muscle O
), O
L I-GENE
( O
liver O
), O
E1 I-GENE
, O
and O
E2 I-GENE
( O
erythrocyte I-GENE
) O
can O
be O
distinguished O
by O
a O
variety O
of O
biochemical O
and O
_RARE_ I-GENE
criteria O
. O

Western O
blot O
analyses O
detect O
anti I-GENE
- I-GENE
E I-GENE
- I-GENE
specific I-GENE
immunoreactivity O
in O
affinity O
- I-GENE
purified O
extracts O
derived O
from O
the O
bacterial I-GENE
expression O
of O
a O
truncated I-GENE
_RARE_ I-GENE
cDNA I-GENE
. O

These O
results O
demonstrate O
that O
endogenous I-GENE
N I-GENE
- I-GENE
methylation O
of O
_RARE_ I-GENE
into O
N I-GENE
- I-GENE
_RARE_ I-GENE
occurs O
in O
the O
brain O
in O
vivo O
. O

DR1 I-GENE
molecules I-GENE
purified O
from O
human I-GENE
_RARE_ I-GENE
cell O
lines O
could O
specifically O
bind O
to O
these O
peptide I-GENE
sequences I-GENE
expressed O
on O
the O
phage I-GENE
surface O
. O

This O
article O
describes O
the O
_RARE_ I-GENE
care O
of O
the O
woman O
_RARE_ I-GENE
in O
maternal I-GENE
blood O
_RARE_ I-GENE
for O
intrauterine O
transfusion O
. O

Chronic O
hepatitis I-GENE
B I-GENE
in O
adopted O
_RARE_ I-GENE
children O
. O

_RARE_ I-GENE
the O
ATPase I-GENE
cluster I-GENE
, O
two O
open O
reading O
frames O
were O
detected O
that O
are O
not O
homologous O
to O
any O
known O
chloroplast I-GENE
gene I-GENE
. O

Therefore O
, O
recombinant I-GENE
human I-GENE
_RARE_ I-GENE
that O
express O
_RARE_ I-GENE
HIV I-GENE
or O
other O
microbial I-GENE
proteins I-GENE
are O
_RARE_ I-GENE
vaccine O
_RARE_ I-GENE
. O

_RARE_ I-GENE
of O
the O
selected O
sequences I-GENE
allowed O
us O
to O
predict O
a O
consensus I-GENE
sequence I-GENE
for O
binding I-GENE
of O
the O
individual O
_RARE_ I-GENE
Rel I-GENE
- I-GENE
related I-GENE
proteins I-GENE
, O
and O
DNA I-GENE
- I-GENE
protein I-GENE
binding I-GENE
analysis O
of O
the O
selected O
DNA I-GENE
sequences I-GENE
revealed O
sequence I-GENE
specificity O
of O
the O
proteins I-GENE
. O

Using O
either O
a O
p50 I-GENE
- I-GENE
or O
p65 I-GENE
- I-GENE
selected O
kappa I-GENE
B I-GENE
motif I-GENE
, O
which O
displayed O
differential O
binding I-GENE
with O
respect O
to O
the O
other O
protein I-GENE
, O
little O
to O
no O
binding I-GENE
was O
observed O
with O
the O
heterodimeric I-GENE
NF I-GENE
- I-GENE
kappa I-GENE
B I-GENE
complex I-GENE
. O

However O
, O
a O
cosmid O
clone O
containing O
the O
entire O
mouse I-GENE
alpha I-GENE
1 I-GENE
( O
I I-GENE
) O
gene I-GENE
, O
including O
3 I-GENE
. O
7 O
kb O
of O
5 I-GENE
'- O
and O
4 I-GENE
kb O
of O
3 I-GENE
'- O
flanking O
DNA I-GENE
, O
was O
expressed O
at O
reduced O
levels O
in O
fibroblasts O
overexpressing O
oncogenic I-GENE
ras I-GENE
. O

To O
define O
transcriptional O
control O
elements O
responsible O
for O
muscle O
- I-GENE
specific I-GENE
expression O
of O
the O
human I-GENE
myoglobin I-GENE
gene I-GENE
, O
we O
performed O
mutational O
analysis O
of O
upstream O
sequences I-GENE
( O
nucleotide I-GENE
positions O
- I-GENE
_RARE_ I-GENE
to O
+ I-GENE
7 O
relative O
to O
the O
transcriptional O
start O
site I-GENE
) O
linked O
to O
a O
_RARE_ I-GENE
luciferase I-GENE
gene I-GENE
. O

Sequencing O
analysis O
has O
shown O
that O
each O
_RARE_ I-GENE
allele I-GENE
contains O
a O
nonsense O
mutation I-GENE
within O
a O
discrete O
region O
between O
amino O
acids O
_RARE_ I-GENE
and O
_RARE_ I-GENE
. O

By O
screening O
a O
_RARE_ I-GENE
cell O
cDNA I-GENE
library O
with O
the O
DNA I-GENE
- I-GENE
binding I-GENE
region O
of O
the O
H I-GENE
- I-GENE
_RARE_ I-GENE
nuclear I-GENE
hormone I-GENE
receptor I-GENE
cDNA I-GENE
, O
we O
isolated O
a O
cDNA I-GENE
that O
is O
selectively O
expressed O
in O
_RARE_ I-GENE
cells O
. O

_RARE_ I-GENE
demonstrated O
good O
survival O
of O
the O
_RARE_ I-GENE
cells O
with O
good O
integration O
with O
the O
brain O
of O
the O
recipient O
and O
_RARE_ I-GENE
of O
positive O
_RARE_ I-GENE
reaction O
for O
tyrosine I-GENE
hydroxylase I-GENE
. O

The O
technique O
of O
the O
_RARE_ I-GENE
visualization O
of O
the O
proximal I-GENE
coronary O
arteries O
is O
described O
. O

The O
sequence I-GENE
of O
this O
region O
shows O
high O
G I-GENE
+ I-GENE
C I-GENE
content O
( O
62 O
%), O
which O
is O
particularly O
_RARE_ I-GENE
in O
the O
200 O
bp O
upstream O
from O
the O
mRNA I-GENE
start O
( O
80 O
% O
G I-GENE
+ I-GENE
C I-GENE
). O

In O
the O
eight O
patients O
with O
persistent O
generalized O
lymph O
- I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
and O
_RARE_ I-GENE
, O
_RARE_ I-GENE
nodes O
, O
pathologic O
analysis O
revealed O
lymphoid I-GENE
hyperplasia O
. O

PaO2 O
threshold O
was O
determined O
through O
an O
_RARE_ I-GENE
O2 O
_RARE_ I-GENE
catheter O
. O

We O
found O
that O
both O
the O
_RARE_ I-GENE
virus I-GENE
- I-GENE
encoded I-GENE
v I-GENE
- I-GENE
ets I-GENE
and O
the O
myeloid O
/ I-GENE
B I-GENE
- I-GENE
cell O
- I-GENE
specific I-GENE
factor I-GENE
PU I-GENE
. O
1 I-GENE
bind O
efficiently O
to O
this O
site I-GENE
in O
vitro O
. O

By O
using O
lambda I-GENE
gt11 O
expression O
cloning O
with O
oligonucleotides O
corresponding O
to O
the O
human I-GENE
immunodeficiency I-GENE
virus I-GENE
1 I-GENE
TATA I-GENE
element I-GENE
, O
we O
report O
the O
identification O
of O
a O
cellular O
protein I-GENE
with O
a O
calculated O
molecular O
mass O
of O
123 O
kDa I-GENE
that O
we O
_RARE_ I-GENE
TATA I-GENE
element I-GENE
_RARE_ I-GENE
factor I-GENE
( O
_RARE_ I-GENE
). O

Blood O
levels O
of O
melatonin O
, O
serotonin I-GENE
, O
cortisol O
, O
and O
prolactin I-GENE
in O
relation O
to O
the O
circadian O
rhythm O
of O
platelet I-GENE
serotonin I-GENE
uptake O
. O

We O
_RARE_ I-GENE
' O
t I-GENE
detect O
any O
effect O
of O
n O
- I-GENE
3 I-GENE
_RARE_ I-GENE
supplementation O
on O
total O
cholesterol I-GENE
, O
HDL I-GENE
cholesterol I-GENE
, O
LDL I-GENE
cholesterol I-GENE
, O
apo I-GENE
A1 I-GENE
, O
_RARE_ I-GENE
( O
a O
), O
_RARE_ I-GENE
, O
glucose O
, O
fibrinogen I-GENE
, O
factor I-GENE
VIII I-GENE
, O
antithrombin I-GENE
III I-GENE
, O
plasminogen I-GENE
activator I-GENE
inhibitor I-GENE
, O
tissue I-GENE
plasminogen I-GENE
activator I-GENE
and O
von I-GENE
Willebrand I-GENE
factor I-GENE
concentration O
, O
on O
bleeding O
time O
or O
on O
systolic O
or O
diastolic O
blood O
pressure O
. O

In O
8 O
healthy O
volunteers O
there O
were O
no O
significant O
differences O
in O
AUC O
, O
peak O
plasma I-GENE
concentrations O
or O
time O
to O
peak O
concentration O
when O
_RARE_ I-GENE
was O
administered O
either O
with O
or O
without O
_RARE_ I-GENE
. O

Using O
5 I-GENE
ng O
/ I-GENE
mL O
as O
the O
cutoff O
, O
the O
sensitivity O
of O
CEA I-GENE
was O
68 O
%. O

_RARE_ I-GENE
spikes O
and O
cognitive O
function O
. O

The O
effect O
of O
sodium O
18 O
beta I-GENE
- I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
on O
experimental O
_RARE_ I-GENE
was O
investigated O
. O

Thus O
, O
chronic O
hematocrit O
decrease O
induced O
by O
H I-GENE
or O
P I-GENE
resulted O
in O
a O
significant O
fall O
in O
blood O
pressure O
compared O
to O
control O
( O
201 O
+/- O
3 I-GENE
v I-GENE
175 O
+/- O
4 I-GENE
, O
_RARE_ I-GENE
+/- O
4 I-GENE
mm O
Hg O
, O
respectively O
; O
P I-GENE
< O
. O
05 O
). O

The O
effects O
of O
diltiazem O
were O
_RARE_ I-GENE
, O
thus O
the O
potentiation O
induced O
by O
d O
- I-GENE
cis O
diltiazem O
was O
significantly O
greater O
in O
all O
cases O
than O
that O
induced O
by O
l O
- I-GENE
cis O
diltiazem O
, O
which O
suggests O
that O
calcium O
channel O
blockade O
plays O
a O
role O
in O
these O
interactions O
. O

Localization O
of O
the O
_RARE_ I-GENE
_RARE_ I-GENE
with O
the O
nerve I-GENE
_RARE_ I-GENE
is O
equally O
effective O
at O
the O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
sites I-GENE
. O

Substitution O
of O
either O
_RARE_ I-GENE
( O
by O
Gly O
) O
or O
_RARE_ I-GENE
( O
by O
Ser O
), O
two O
of O
the O
most O
conserved O
residues O
in O
all O
protein I-GENE
kinases I-GENE
, O
resulted O
in O
enzyme I-GENE
with O
_RARE_ I-GENE
detectable O
activity O
. O

Significance O
of O
the O
biopsy O
site I-GENE
of O
the O
_RARE_ I-GENE
_RARE_ I-GENE
muscle O
for O
fiber O
_RARE_ I-GENE
. O

The O
TIMP I-GENE
(- O
59 O
/ I-GENE
- I-GENE
53 O
) O
AP1 I-GENE
site I-GENE
is O
a O
_RARE_ I-GENE
motif I-GENE
that O
binds O
c I-GENE
- I-GENE
Fos I-GENE
/ I-GENE
c I-GENE
- I-GENE
Jun I-GENE
AP1 I-GENE
translated O
in O
vitro O
and O
is O
an O
effective O
competitor O
for O
binding I-GENE
of O
nuclear I-GENE
AP1 I-GENE
factors I-GENE
to O
the O
consensus I-GENE
TRE I-GENE
, O
but O
in O
addition O
it O
binds O
factors I-GENE
that O
do O
not O
associate O
with O
the O
consensus I-GENE
TRE I-GENE
. O

_RARE_ I-GENE
of O
AP1 I-GENE
and O
PEA3 I-GENE
binding I-GENE
sites I-GENE
in O
the O
regulation O
of O
murine I-GENE
tissue I-GENE
inhibitor I-GENE
of O
_RARE_ I-GENE
- I-GENE
1 I-GENE
( O
TIMP I-GENE
- I-GENE
1 I-GENE
) O
transcription I-GENE
. O

Of O
the O
serum I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
antibody I-GENE
negative O
calves O
89 I-GENE
. O
7 O
% O
( O
26 O
/ I-GENE
29 O
) O
and O
92 O
. O
8 O
% O
( O
90 O
/ I-GENE
97 O
) O
developed O
_RARE_ I-GENE
antibody I-GENE
1 I-GENE
month O
after O
_RARE_ I-GENE
and O
_RARE_ I-GENE
vaccination O
, O
respectively O
. O

_RARE_ I-GENE
of O
crude O
nuclear I-GENE
extracts O
by O
heparin O
- I-GENE
agarose O
chromatography O
indicates O
that O
_RARE_ I-GENE
- I-GENE
1 I-GENE
is O
more O
_RARE_ I-GENE
in O
extracts O
prepared O
from O
salt O
- I-GENE
stressed O
leaf O
tissue I-GENE
. O

A I-GENE
controlled O
trial O
of O
recombinant I-GENE
human I-GENE
granulocyte I-GENE
- I-GENE
macrophage I-GENE
colony I-GENE
- I-GENE
stimulating I-GENE
factor I-GENE
after O
total O
body O
irradiation O
, O
high O
- I-GENE
dose O
chemotherapy O
, O
and O
autologous O
bone O
marrow O
transplantation O
for O
acute O
_RARE_ I-GENE
leukemia I-GENE
or O
malignant O
lymphoma O
. O

These O
data O
demonstrate O
that O
_RARE_ I-GENE
does O
not O
cause O
more O
myocardial O
trauma O
than O
CPB O
when O
used O
to O
provide O
_RARE_ I-GENE
circulatory O
support O
. O

The O
IgG I-GENE
_RARE_ I-GENE
profile O
of O
untreated O
_RARE_ I-GENE
disease O
was O
found O
to O
be O
the O
same O
as O
in O
healthy O
controls O
( O
_RARE_ I-GENE
approximately O
_RARE_ I-GENE
> O
_RARE_ I-GENE
> O
_RARE_ I-GENE
), O
with O
only O
the O
magnitude O
of O
the O
individual O
_RARE_ I-GENE
responses O
being O
increased O
in O
_RARE_ I-GENE
patients O
. O

Examination O
of O
_RARE_ I-GENE
is O
not O
only O
a O
significant O
contribution O
towards O
a O
more O
accurate O
diagnosis O
of O
renal O
vasculitis O
, O
but O
also O
an O
indicator O
of O
the O
activity O
of O
the O
disease O
and O
thus O
of O
the O
effectiveness O
of O
immunosuppressive O
treatment O
. O

On O
the O
other O
hand O
, O
total O
_RARE_ I-GENE
in O
these O
already O
_RARE_ I-GENE
_RARE_ I-GENE
rabbits O
always O
resulted O
in O
a O
substantial O
_RARE_ I-GENE
of O
the O
_RARE_ I-GENE
( O
mean O
delta I-GENE
tau I-GENE
= O
+ I-GENE
0 O
. O
23 O
h O
). O

_RARE_ I-GENE
_RARE_ I-GENE
is O
an O
_RARE_ I-GENE
systemic O
disease O
characterized O
by O
chronic O
_RARE_ I-GENE
_RARE_ I-GENE
. O

The O
effects O
of O
two O
levels O
of O
caffeine O
ingestion O
on O
excess O
_RARE_ I-GENE
oxygen O
consumption O
in O
_RARE_ I-GENE
women O
. O

The O
_RARE_ I-GENE
features O
involved O
eight O
amino O
acid I-GENE
changes O
, O
including O
a O
single O
lysine O
deletion O
relative O
to O
a O
primate O
consensus I-GENE
sequence I-GENE
in O
the O
first O
complementary O
- I-GENE
_RARE_ I-GENE
region O
of O
_RARE_ I-GENE
. O

4 I-GENE
. O

The O
in O
vivo O
profile O
of O
_RARE_ I-GENE
- I-GENE
2 I-GENE
in O
the O
larval I-GENE
CNS O
shows O
_RARE_ I-GENE
overlap O
with O
_RARE_ I-GENE
in O
specific I-GENE
serotonin I-GENE
and O
dopamine I-GENE
neurons O
. O

Unlike O
the O
introns O
of O
other O
duplicated O
ribosomal I-GENE
protein I-GENE
genes I-GENE
which O
are O
highly O
diverged O
, O
the O
duplicated O
_RARE_ I-GENE
genes I-GENE
have O
two O
nearly O
identical O
DNA I-GENE
sequences I-GENE
of O
25 O
and O
31 O
bp O
in O
length I-GENE
within O
their O
introns O
. O

In O
a O
prospective O
, O
randomized O
clinical O
trial O
we O
compared O
the O
efficacy O
of O
subcutaneously O
( O
SC O
) O
administered O
( O
every O
8 O
h O
) O
calcium O
heparin O
to O
intravenous O
( O
IV I-GENE
) O
sodium O
heparin O
in O
the O
treatment O
of O
proximal I-GENE
deep O
- I-GENE
vein O
thrombosis O
( O
_RARE_ I-GENE
). O

The O
highest O
prevalence O
of O
reported O
_RARE_ I-GENE
allergy O
, O
chronic O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
attacks O
of O
_RARE_ I-GENE
of O
_RARE_ I-GENE
with O
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
- I-GENE
diagnosed O
asthma O
was O
found O
in O
children O
who O
had O
_RARE_ I-GENE
in O
the O
past O
but O
not O
_RARE_ I-GENE
. O

Therefore O
, O
it O
would O
be O
_RARE_ I-GENE
to O
identify O
such O
persons O
and O
treat O
them O
preferentially O
. O

On O
the O
basis O
of O
these O
unique O
properties O
, O
the O
newly O
characterized O
hemagglutinin I-GENE
has O
been O
termed O
_RARE_ I-GENE
_RARE_ I-GENE
agglutination I-GENE
- I-GENE
aggregation O
factor I-GENE
( O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
). O

The O
shift O
to O
the O
_RARE_ I-GENE
temperature O
is O
accompanied O
by O
the O
loss O
of O
_RARE_ I-GENE
nucleotide I-GENE
- I-GENE
dependent I-GENE
activity O
of O
_RARE_ I-GENE
in O
vitro O
. O

_RARE_ I-GENE
. O

The O
data O
indicate O
that O
the O
minimal I-GENE
catalytic O
domain I-GENE
of O
_RARE_ I-GENE
is O
located O
between O
_RARE_ I-GENE
--> I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
--> I-GENE
_RARE_ I-GENE
. O

It O
corresponds O
to O
the O
complete O
mitochondrial I-GENE
_RARE_ I-GENE
and O
the O
_RARE_ I-GENE
- I-GENE
bearing O
domain I-GENE
that O
are O
encoded I-GENE
by O
exons O
I I-GENE
through O
IV I-GENE
of O
the O
functional O
E2 I-GENE
gene I-GENE
. O

Human I-GENE
neutrophil I-GENE
response O
to O
short O
- I-GENE
term O
exposure O
to O
F I-GENE
- I-GENE
75 O
_RARE_ I-GENE
- I-GENE
based O
_RARE_ I-GENE
. O

Disruption O
of O
_RARE_ I-GENE
did O
not O
affect O
the O
fidelity I-GENE
or O
kinetics O
of O
vacuolar I-GENE
protein I-GENE
sorting I-GENE
, O
indicating O
that O
_RARE_ I-GENE
function O
is O
not O
dependent I-GENE
on O
_RARE_ I-GENE
. O

A I-GENE
mutant I-GENE
form O
of O
_RARE_ I-GENE
lacking O
the O
entire O
GTP I-GENE
- I-GENE
binding I-GENE
domain I-GENE
_RARE_ I-GENE
with O
vacuolar I-GENE
protein I-GENE
sorting I-GENE
in O
wild I-GENE
- I-GENE
type I-GENE
cells O
. O

According O
to O
out O
field O
research O
, O
the O
_RARE_ I-GENE
_RARE_ I-GENE
was O
very O
rich O
throughout O
that O
area O
, O
and O
it O
was O
_RARE_ I-GENE
enough O
to O
determine O
ticks O
as O
the O
vectors O
, O
based O
on O
arising O
of O
anti I-GENE
- I-GENE
SF I-GENE
group O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
antibody I-GENE
in O
mice O
inoculated O
with O
some O
_RARE_ I-GENE
_RARE_ I-GENE
, O
findings O
of O
_RARE_ I-GENE
reactive I-GENE
to O
patient O
sera O
or O
a O
species O
- I-GENE
specific I-GENE
monoclonal I-GENE
antibody I-GENE
to O
_RARE_ I-GENE
in O
the O
_RARE_ I-GENE
cells O
of O
some O
ticks O
, O
and O
electron O
_RARE_ I-GENE
observations O
of O
_RARE_ I-GENE
in O
various O
internal O
organs O
including O
the O
salivary I-GENE
gland O
of O
ticks O
. O

The O
second O
method O
, O
the O
" O
_RARE_ I-GENE
" O
assay O
, O
has O
a O
sensitivity O
range O
of O
0 O
. O
03 O
- I-GENE
5 I-GENE
. O
0 O
micrograms O
phosphorus O
with O
100 O
- I-GENE
500 O
_RARE_ I-GENE
_RARE_ I-GENE
. O

Nucleotide O
sequence I-GENE
and O
transcriptional O
analysis O
of O
the O
_RARE_ I-GENE
gene I-GENE
of O
_RARE_ I-GENE
_RARE_ I-GENE
nuclear I-GENE
_RARE_ I-GENE
virus I-GENE
. O

_RARE_ I-GENE
of O
automated O
systems O
-- O
system O
definition O
. O

As O
a O
consequence O
of O
dark O
_RARE_ I-GENE
, O
the O
_RARE_ I-GENE
density I-GENE
of O
cortical O
neurons O
in O
area O
17 O
_RARE_ I-GENE
to O
about O
double O
of O
the O
value O
observed O
in O
normally O
_RARE_ I-GENE
_RARE_ I-GENE
and O
was O
also O
significantly O
higher O
in O
area O
18 O
. O

These O
results O
suggest O
that O
decreased O
class I-GENE
I I-GENE
enhancer I-GENE
activity O
in O
_RARE_ I-GENE
- I-GENE
transformed O
cells O
may O
, O
at O
least O
in O
part O
, O
be O
due O
to O
the O
higher O
levels O
of O
an O
enhancer I-GENE
- I-GENE
specific I-GENE
factor I-GENE
, O
possibly O
acting O
as O
a O
repressor I-GENE
. O

A I-GENE
second O
domain I-GENE
, O
located O
in O
the O
C I-GENE
- I-GENE
terminal I-GENE
_RARE_ I-GENE
amino O
acids O
of O
IE1 I-GENE
, O
is O
required O
for O
inhibitory I-GENE
and O
DNA I-GENE
- I-GENE
binding I-GENE
activities O
. O

In O
order O
to O
investigate O
the O
blood O
compatibility O
of O
_RARE_ I-GENE
vein O
graft O
( O
_RARE_ I-GENE
), O
changes O
in O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
production O
following O
_RARE_ I-GENE
and O
arterial O
implantation O
were O
studied O
experimentally O
. O

_RARE_ I-GENE
administration O
of O
the O
somatostatin I-GENE
analogue O
, O
_RARE_ I-GENE
, O
100 O
micrograms O
_RARE_ I-GENE
daily O
, O
resulted O
in O
a O
sustained O
improvement O
in O
_RARE_ I-GENE
and O
disappearance O
of O
_RARE_ I-GENE
_RARE_ I-GENE
without O
reducing O
calcitonin I-GENE
levels O
. O

Anti I-GENE
- I-GENE
_RARE_ I-GENE
antibodies I-GENE
detect O
a O
_RARE_ I-GENE
protein I-GENE
in O
extracts O
of O
C I-GENE
. O
_RARE_ I-GENE
in O
agreement O
with O
the O
size O
predicted O
from O
the O
nucleotide I-GENE
sequence I-GENE
of O
the O
cloned O
gene I-GENE
. O

_RARE_ I-GENE
, O
285 O
- I-GENE
_RARE_ I-GENE
] O
and O
was O
subsequently O
cloned O
and O
sequenced O
[ O
J O
. O

_RARE_ I-GENE
vaccinia I-GENE
vector O
efficiently O
_RARE_ I-GENE
recombinant I-GENE
genes I-GENE
. O

Use O
of O
free O
- I-GENE
access O
_RARE_ I-GENE
. O

Interferon I-GENE
type I-GENE
I I-GENE
in O
protective O
body O
reactions O
in O
an O
experimental O
Klebsiella I-GENE
infection O

No O
other O
changes O
in O
hematopoietic I-GENE
differentiation O
status O
were O
observed O
in O
association O
with O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
expression O
. O

_RARE_ I-GENE
interaction O
after O
spinal O
anesthesia O
and O
sedation O
with O
midazolam O
. O

For O
pressure O
greater O
than O
121 I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
, O
an O
increased O
_RARE_ I-GENE
of O
the O
_RARE_ I-GENE
made O
it O
difficult O
to O
_RARE_ I-GENE
the O
_RARE_ I-GENE
reflex O
from O
_RARE_ I-GENE
movements O
. O

One O
air O
_RARE_ I-GENE
occurred O
; O
this O
was O
the O
only O
filter O
- I-GENE
or O
_RARE_ I-GENE
- I-GENE
related I-GENE
complication O
. O

The O
5 I-GENE
' O
region O
of O
_RARE_ I-GENE
contains O
consensus I-GENE
binding I-GENE
sites I-GENE
for O
the O
transcriptional O
regulatory I-GENE
proteins I-GENE
, O
Sp1 I-GENE
, O
AP2 I-GENE
, O
_RARE_ I-GENE
- I-GENE
A1 I-GENE
, O
NF I-GENE
- I-GENE
1 I-GENE
, O
NF I-GENE
- I-GENE
A2 I-GENE
, O
and O
NF I-GENE
- I-GENE
E1 I-GENE
. O

V I-GENE
. O

These O
data O
indicate O
that O
_RARE_ I-GENE
- I-GENE
Met I-GENE
- I-GENE
1 I-GENE
is O
a O
serine I-GENE
protease I-GENE
with O
unique O
activity O
that O
is O
expressed O
in O
the O
granules O
of O
large O
_RARE_ I-GENE
lymphocytes O
. O

_RARE_ I-GENE
and O
cloning O
of O
a O
novel O
serine I-GENE
protease I-GENE
, O
_RARE_ I-GENE
- I-GENE
Met I-GENE
- I-GENE
1 I-GENE
, O
from O
the O
granules O
of O
a O
rat I-GENE
natural O
killer O
cell O
leukemia I-GENE
. O

We O
describe O
here O
17 O
dominant I-GENE
GCN2 I-GENE
mutations O
that O
lead O
to O
derepression O
of O
GCN4 I-GENE
expression O
in O
the O
absence O
of O
amino O
acid I-GENE
starvation O
. O

Administration O
of O
growth I-GENE
hormone I-GENE
leads O
to O
faster O
growth I-GENE
, O
but O
also O
faster O
bone O
maturation O
. O

_RARE_ I-GENE
with O
the O
available O
amino O
acid I-GENE
residue O
( O
aa O
) O
sequence I-GENE
information O
from O
the O
complete O
_RARE_ I-GENE
RNA I-GENE
1 I-GENE
sequence I-GENE
and O
the O
partial O
sequence I-GENE
of O
red I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
virus I-GENE
RNA I-GENE
1 I-GENE
suggest O
that O
_RARE_ I-GENE
RNA I-GENE
1 I-GENE
specifies O
the O
expected O
set O
of O
five O
mature O
proteins I-GENE
: O
_RARE_ I-GENE
proteinase I-GENE
cofactor I-GENE
, O
_RARE_ I-GENE
presumed I-GENE
helicase I-GENE
, O
_RARE_ I-GENE
5 I-GENE
'- O
linked O
protein I-GENE
of O
the O
genomic O
RNAs I-GENE
, O
_RARE_ I-GENE
proteinase I-GENE
, O
and O
_RARE_ I-GENE
presumed I-GENE
polymerase I-GENE
, O
separated O
by O
four O
cleavage O
sites I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
segment O
_RARE_ I-GENE
transcript I-GENE
is O
_RARE_ I-GENE
in O
vitro O
. O

In O
addition O
, O
the O
_RARE_ I-GENE
of O
beta I-GENE
2 I-GENE
transferrin I-GENE
assay O
in O
the O
diagnosis O
of O
cerebrospinal O
fluid O
_RARE_ I-GENE
is O
presented O
. O

_RARE_ I-GENE
_RARE_ I-GENE
was O
administered O
at O
45 O
mm O
Hg O
every O
20 O
minutes O
for O
2 I-GENE
hours O
. O

The O
addition O
of O
_RARE_ I-GENE
to O
the O
_RARE_ I-GENE
led O
to O
a O
dose O
- I-GENE
dependent I-GENE
biphasic O
change O
in O
_RARE_ I-GENE
and O
GFR O
characterized O
by O
an O
initial O
transient O
increase O
followed O
by O
a O
marked O
and O
sustained O
decrease O
. O

To O
_RARE_ I-GENE
for O
analyses O
with O
the O
family I-GENE
variables O
, O
we O
next O
present O
_RARE_ I-GENE
data O
based O
on O
separate O
principal O
components O
analysis O
( O
_RARE_ I-GENE
) O
and O
_RARE_ I-GENE
_RARE_ I-GENE
analysis O
( O
_RARE_ I-GENE
) O
of O
14 O
self O
- I-GENE
reported O
health O
scores O
for O
_RARE_ I-GENE
and O
for O
_RARE_ I-GENE
. O

The O
structural O
genes I-GENE
encoding O
_RARE_ I-GENE
- I-GENE
3 I-GENE
- I-GENE
phosphate I-GENE
dehydrogenase I-GENE
( O
_RARE_ I-GENE
), O
3 I-GENE
- I-GENE
_RARE_ I-GENE
kinase I-GENE
( O
_RARE_ I-GENE
) O
and O
the O
N I-GENE
- I-GENE
terminal I-GENE
part O
of O
_RARE_ I-GENE
isomerase I-GENE
( O
_RARE_ I-GENE
) O
from O
_RARE_ I-GENE
Bacillus I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
have O
been O
cloned O
as O
a O
gene I-GENE
cluster I-GENE
( O
_RARE_ I-GENE
operon I-GENE
) O
by O
complementation O
of O
an O
Escherichia I-GENE
coli I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
mutant I-GENE
. O

Pseudomonas I-GENE
aeruginosa I-GENE
_RARE_ I-GENE
A I-GENE
: O
its O
role O
in O
retardation O
of O
wound O
healing O
: O
the O
1992 O
_RARE_ I-GENE
_RARE_ I-GENE
. O

Laboratory O
studies O
showed O
that O
the O
direct O
fluorescent O
- I-GENE
antibody I-GENE
_RARE_ I-GENE
were O
the O
least O
sensitive O
in O
this O
case O
and O
did O
not O
detect O
fewer O
than O
10 O
( O
4 I-GENE
) O
_RARE_ I-GENE
bodies O
per O
ml O
, O
while O
most O
ELISA O
_RARE_ I-GENE
detected O
between O
130 I-GENE
and O
600 O
_RARE_ I-GENE
bodies O
per O
ml O
. O

To O
study O
the O
significance O
of O
these O
domains I-GENE
and O
the O
overall O
evolutionary O
conservation O
of O
the O
gene I-GENE
, O
the O
homolog I-GENE
from O
Drosophila I-GENE
melanogaster I-GENE
was O
isolated O
by O
low O
_RARE_ I-GENE
_RARE_ I-GENE
using O
two O
flanking O
probes O
of O
the O
human I-GENE
_RARE_ I-GENE
cDNA I-GENE
. O

_RARE_ I-GENE
- I-GENE
ADP I-GENE
- I-GENE
_RARE_ I-GENE
is O
a O
reversible O
modification O
of O
proteins I-GENE
, O
with O
NAD I-GENE
: O
arginine I-GENE
ADP I-GENE
- I-GENE
_RARE_ I-GENE
( O
EC I-GENE
2 I-GENE
. O
4 I-GENE
. O
2 I-GENE
. O
31 O
) O
and O
ADP I-GENE
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
( O
EC I-GENE
3 I-GENE
. O
2 I-GENE
. O
2 I-GENE
. O
19 O
) O
_RARE_ I-GENE
the O
_RARE_ I-GENE
reactions O
in O
an O
ADP I-GENE
- I-GENE
_RARE_ I-GENE
cycle O
. O

For O
this O
_RARE_ I-GENE
, O
the O
particle I-GENE
forming O
capacity O
of O
derivatives O
of O
the O
HIV I-GENE
- I-GENE
1 I-GENE
group O
specific I-GENE
core I-GENE
antigen I-GENE
p55 I-GENE
gag I-GENE
was O
assayed O
and O
compared O
dependent I-GENE
on O
various O
expression O
systems O
: O
recombinant I-GENE
bacteria O
, O
vaccinia I-GENE
- I-GENE
and O
_RARE_ I-GENE
were O
established O
encoding O
the O
entire O
core I-GENE
protein I-GENE
p55 I-GENE
either O
in O
its O
_RARE_ I-GENE
sequence I-GENE
or O
lacking O
the O
_RARE_ I-GENE
consensus I-GENE
signal I-GENE
. O

The O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
gene I-GENE
of O
Drosophila I-GENE
encodes O
69 O
- I-GENE
kDa I-GENE
and O
88 O
- I-GENE
kDa I-GENE
proteins I-GENE
through O
alternative O
splicing O
of O
the O
primary O
_RARE_ I-GENE
transcript I-GENE
. O

Removal O
of O
beta I-GENE
2 I-GENE
- I-GENE
microglobulin I-GENE
by O
hemodialysis O
and O
_RARE_ I-GENE
: O
a O
four O
year O
follow O
up O
. O

Removal O
of O
beta I-GENE
2 I-GENE
- I-GENE
microglobulin I-GENE
by O
hemodialysis O
and O
_RARE_ I-GENE
: O
a O
four O
year O
follow O
up O
. O

_RARE_ I-GENE
was O
established O
to O
_RARE_ I-GENE
a O
decrease O
of O
the O
amplitude O
of O
the O
dominant I-GENE
peak O
and O
dominant I-GENE
_RARE_ I-GENE
- I-GENE
activity O
in O
power O
spectra O
of O
the O
EEG O
in O
the O
cortex O
and O
_RARE_ I-GENE
, O
with O
an O
increase O
of O
rapid O
wave O
activity O
in O
the O
beta I-GENE
2 I-GENE
range O
in O
the O
right O
cortex O
and O
_RARE_ I-GENE
. O

These O
sequences I-GENE
were O
then O
used O
to O
clone O
the O
full I-GENE
- I-GENE
length I-GENE
genes I-GENE
from O
a O
yeast I-GENE
genomic O
library O
. O

GAL4 I-GENE
- I-GENE
VP16 I-GENE
- I-GENE
mediated O
_RARE_ I-GENE
required O
an O
auxiliary I-GENE
factor I-GENE
, O
_RARE_ I-GENE
as O
a O
co O
- I-GENE
_RARE_ I-GENE
, O
which O
was O
partially O
purified O
from O
Drosophila I-GENE
embryos O
. O

After O
28 O
days O
of O
haloperidol O
treatment O
, O
similar O
changes O
were O
observed O
for O
delta I-GENE
, O
together O
with O
an O
increase O
of O
alpha I-GENE
1 I-GENE
, O
and O
a O
decrease O
of O
fast O
beta I-GENE
. O

Four O
_RARE_ I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
were O
used O
in O
a O
4 I-GENE
x O
4 I-GENE
_RARE_ I-GENE
square O
experiment O
to O
determine O
whether O
_RARE_ I-GENE
methionine O
and O
calcium O
_RARE_ I-GENE
would O
increase O
duodenal O
flow O
of O
_RARE_ I-GENE
fatty I-GENE
acids O
( O
C18 O
: O
2 I-GENE
+ I-GENE
cis O
C18 O
: O
1 I-GENE
). O

_RARE_ I-GENE
_RARE_ I-GENE
lacking O
the O
first O
33 O
amino O
- I-GENE
terminal I-GENE
amino O
acids O
fails O
to O
bind O
to O
the O
_RARE_ I-GENE
, O
indicating O
that O
at O
least O
part O
of O
the O
DNA I-GENE
binding I-GENE
domain I-GENE
is O
located O
within O
the O
well O
conserved O
amino O
terminus O
. O

Therefore O
, O
_RARE_ I-GENE
may O
be O
involved O
in O
maintaining O
_RARE_ I-GENE
transcriptional O
activity O
of O
IFN I-GENE
- I-GENE
inducible I-GENE
genes I-GENE
in O
hematopoietic I-GENE
cells O
. O

A I-GENE
case O
of O
chronic O
hepatitis I-GENE
C I-GENE
with O
primary O
hypothyroidism O
manifested O
during O
interferon I-GENE
treatment O

_RARE_ I-GENE
_RARE_ I-GENE
making O
: O
human I-GENE
control O
of O
complex I-GENE
systems O
. O

A I-GENE
coiled O
- I-GENE
coil O
related I-GENE
protein I-GENE
specific I-GENE
for O
_RARE_ I-GENE
regions O
of O
meiotic I-GENE
_RARE_ I-GENE
chromosomes O
. O

_RARE_ I-GENE
amounts O
of O
alpha I-GENE
5 I-GENE
beta I-GENE
1 I-GENE
integrin I-GENE
were O
isolated O
from O
these O
cells O
by O
chromatography O
of O
detergent O
extracts O
on O
a O
fibronectin I-GENE
cell O
- I-GENE
binding I-GENE
fragment I-GENE
affinity O
column O
and O
_RARE_ I-GENE
with O
EDTA O
. O

_RARE_ I-GENE
. O

These O
results O
indicate O
a O
possible O
involvement O
of O
endogenous I-GENE
opioid I-GENE
peptides I-GENE
in O
the O
cardiac O
effects O
due O
to O
myocardial O
ischaemia O
and O
reperfusion O
, O
mediated O
by O
opiate I-GENE
receptors I-GENE
through O
opiate I-GENE
_RARE_ I-GENE
. O

From O
this O
library O
, O
LEU2 I-GENE
and O
HIS3 I-GENE
cDNAs I-GENE
were O
recovered O
at O
a O
frequency O
of O
about O
1 I-GENE
in O
10 O
( O
4 I-GENE
) O
and O
in O
12 O
out O
of O
13 O
cases O
these O
were O
expressed O
in O
a O
galactose I-GENE
- I-GENE
dependent I-GENE
manner O
. O

Among O
these O
, O
_RARE_ I-GENE
was O
isolated O
four O
times O
, O
and O
_RARE_ I-GENE
three O
times O
. O

Since O
_RARE_ I-GENE
- I-GENE
B I-GENE
gene I-GENE
is O
conserved O
in O
mammalian I-GENE
species O
and O
_RARE_ I-GENE
- I-GENE
B I-GENE
boxes O
are O
found O
also O
in O
mouse I-GENE
centromere O
satellite I-GENE
DNA I-GENE
( O
minor O
satellite I-GENE
), O
this O
sequence I-GENE
- I-GENE
specific I-GENE
DNA I-GENE
- I-GENE
protein I-GENE
interaction O
may O
be O
important O
for O
some O
_RARE_ I-GENE
of O
common O
centromere O
function O
. O

Interestingly O
, O
a O
portion O
of O
the O
tail O
domain I-GENE
( O
aa O
, O
1 I-GENE
, O
_RARE_ I-GENE
- I-GENE
1 I-GENE
, O
_RARE_ I-GENE
) O
shares O
58 O
% O
amino O
acid I-GENE
sequence I-GENE
identity O
with O
a O
_RARE_ I-GENE
- I-GENE
aa O
protein I-GENE
from O
mouse I-GENE
brain O
reported O
to O
be O
a O
_RARE_ I-GENE
acid I-GENE
decarboxylase I-GENE
. O

However O
, O
in O
the O
subgroup O
with O
normal O
_RARE_ I-GENE
(< O
0 O
. O
45 O
l O
/ I-GENE
l O
; O
n O
= O
201 O
) O
there O
was O
a O
significant O
reduction O
( O
p O
< O
0 O
. O
05 O
) O
of O
the O
mortality O
after O
3 I-GENE
months O
( O
27 O
% O
and O
16 O
%, O
respectively O
) O
and O
an O
increase O
of O
_RARE_ I-GENE
at O
home O
( O
35 O
% O
and O
48 O
%, O
respectively O
) O
due O
to O
a O
reduction O
of O
the O
viscosity O
by O
means O
of O
_RARE_ I-GENE
with O
albumin I-GENE
( O
a O
specific I-GENE
viscosity O
effect O
in O
the O
_RARE_ I-GENE
group O
). O

_RARE_ I-GENE
and O
changing O
morphological O
course O

The O
appropriate O
use O
and O
benefits O
of O
bile O
acid I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
acid I-GENE
, O
_RARE_ I-GENE
acids O
, O
3 I-GENE
- I-GENE
hydroxy I-GENE
- I-GENE
3 I-GENE
- I-GENE
_RARE_ I-GENE
coenzyme I-GENE
A I-GENE
( O
HMG I-GENE
- I-GENE
CoA I-GENE
) O
reductase I-GENE
inhibitors O
, O
and O
_RARE_ I-GENE
are O
individually O
discussed O
, O
whereas O
_RARE_ I-GENE
approaches O
used O
in O
conjunction O
with O
the O
drugs O
are O
recommended O
_RARE_ I-GENE
. O

This O
may O
result O
in O
more O
_RARE_ I-GENE
and O
hence O
reduced O
renal O
clearance O
. O

The O
major I-GENE
pathological O
findings O
of O
the O
placenta O
were O
_RARE_ I-GENE
and O
_RARE_ I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
significantly O
inhibited O
N I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
acid I-GENE
formation O
relative O
to O
_RARE_ I-GENE
acid I-GENE
alone O
. O

A I-GENE
genomic O
clone O
, O
_RARE_ I-GENE
, O
containing O
DNA I-GENE
apparently O
transcribed O
specifically O
in O
Trypanosoma O
_RARE_ I-GENE
_RARE_ I-GENE
, O
was O
obtained O
by O
differentially O
screening O
a O
genomic O
library O
with O
_RARE_ I-GENE
and O
_RARE_ I-GENE
cDNA I-GENE
. O

_RARE_ I-GENE
-- O
1990 O

_RARE_ I-GENE
of O
urea O
by O
_RARE_ I-GENE
urease I-GENE
coupled I-GENE
to O
a O
differential O
pH O
- I-GENE
_RARE_ I-GENE
. O

RESULTS O
: O
In O
the O
_RARE_ I-GENE
group O
, O
both O
fetal O
and O
maternal I-GENE
serum I-GENE
prolactin I-GENE
concentration O
increased O
significantly O
with O
gestation O
( O
P I-GENE
< O
0 O
. O
001 O
and O
P I-GENE
< O
0 O
. O
01 O
, O
respectively O
). O

One O
phage I-GENE
clone O
contains O
a O
junction O
between O
alpha I-GENE
satellite I-GENE
DNA I-GENE
and O
a O
novel O
low O
- I-GENE
copy O
repeated O
sequence I-GENE
. O

The O
5 I-GENE
'- O
flanking O
region O
of O
the O
human I-GENE
_RARE_ I-GENE
gene I-GENE
was O
isolated O
from O
a O
human I-GENE
placental I-GENE
genomic O
library O
. O

Therefore O
, O
the O
molecular O
mechanisms O
of O
the O
estrogen I-GENE
action O
that O
govern O
the O
_RARE_ I-GENE
gene I-GENE
expression O
differ O
between O
mouse I-GENE
and O
human I-GENE
. O

_RARE_ I-GENE
retains O
basal O
and O
Ca2 I-GENE
+ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
- I-GENE
inducible I-GENE
activities O
. O

The O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
via O
an O
_RARE_ I-GENE
message I-GENE
and O
_RARE_ I-GENE
data O
_RARE_ I-GENE
in O
_RARE_ I-GENE
via O
an O
interface O
to O
the O
_RARE_ I-GENE
database O
. O

Magnetic O
resonance O
spectroscopy O
( O
MRS O
) O
and O
imaging O
( O
MRI O
) O
are O
now O
well O
established O
techniques O
for O
the O
study O
of O
cellular O
metabolism O
and O
gross O
structure O
of O
muscle O
. O

_RARE_ I-GENE
a O
greater O
NA O
was O
found O
with O
no O
change O
in O
plasma I-GENE
epinephrine O
response O
. O

We O
investigated O
the O
diagnostic O
value O
of O
a O
new O
in O
vitro O
test O
, O
Pharmacia O
CAP I-GENE
_RARE_ I-GENE
( O
Pharmacia O
_RARE_ I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
), O
for O
the O
quantitative O
measurement O
of O
allergen I-GENE
- I-GENE
specific I-GENE
IgE I-GENE
antibodies I-GENE
by O
comparison O
with O
RAST O
in O
2 I-GENE
groups O
of O
patients O
, O
71 O
atopic O
and O
48 O
non O
- I-GENE
atopic O
. O

Patients O
receiving O
_RARE_ I-GENE
showed O
differences O
in O
attention O
, O
_RARE_ I-GENE
performance O
, O
_RARE_ I-GENE
span O
and O
sensory O
discrimination O
tasks O
at O
T1 O
, O
in O
_RARE_ I-GENE
performance O
at O
T2 I-GENE
and O
in O
spatial O
span O
at O
T3 O
, O
whereas O
no O
differences O
were O
detected O
at O
T4 I-GENE
. O

We O
found O
that O
the O
gene I-GENE
segment O
containing O
the O
mu I-GENE
m I-GENE
poly O
( O
A I-GENE
) O
signals O
, O
along O
with O
_RARE_ I-GENE
bp O
of O
downstream O
flanking O
sequence I-GENE
, O
_RARE_ I-GENE
as O
a O
transcription I-GENE
terminator O
in O
both O
myeloma O
cells O
and O
L I-GENE
cell O
fibroblasts O
. O

As O
a O
part O
of O
a O
large O
examination O
, O
total O
and O
free O
serum I-GENE
cholesterol I-GENE
, O
total O
lipid O
and O
_RARE_ I-GENE
levels O
were O
determined O
. O

_RARE_ I-GENE
is O
a O
nurse O
in O
_RARE_ I-GENE
-- O
_RARE_ I-GENE
_RARE_ I-GENE
of O
higher O
_RARE_ I-GENE
and O
a O
_RARE_ I-GENE
across O
the O
_RARE_ I-GENE

Dopamine I-GENE
neurons O
in O
subjects O
that O
received O
6 I-GENE
- I-GENE
_RARE_ I-GENE
were O
protected O
by O
pre I-GENE
- I-GENE
treatment O
with O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
was O
more O
sensitive O
and O
had O
a O
better O
negative O
predictive O
value O
and O
a O
lower O
false O
negative O
percentage O
than O
_RARE_ I-GENE
. O

_RARE_ I-GENE
and O
_RARE_ I-GENE
have O
been O
one O
of O
the O
most O
spread O
diseases O
of O
_RARE_ I-GENE
. O

The O
results O
of O
this O
study O
demonstrate O
that O
_RARE_ I-GENE
was O
the O
cause O
of O
_RARE_ I-GENE
death O
. O

A I-GENE
second O
large O
group O
of O
disorders O
in O
pregnancy O
is O
caused O
by O
effects O
of O
infections O
of O
the O
_RARE_ I-GENE
without O
pathogens O
being O
transmitted O
to O
the O
embryo O
or O
the O
placenta O
. O

Four O
short O
nucleotide I-GENE
sequences I-GENE
( O
boxes O
I I-GENE
to O
IV I-GENE
) O
contribute O
to O
the O
light I-GENE
responsiveness O
of O
the O
_RARE_ I-GENE
_RARE_ I-GENE
synthase I-GENE
promoter I-GENE
. O

The O
case O
described O
is O
that O
of O
a O
72 O
- I-GENE
year O
- I-GENE
old O
man O
with O
_RARE_ I-GENE
who O
_RARE_ I-GENE
a O
_RARE_ I-GENE
injury O
to O
his O
spine O
in O
a O
fall O
, O
resulting O
in O
a O
fracture O
through O
an O
_RARE_ I-GENE
L2 O
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
space O
. O

The O
mean O
blood O
flow O
in O
the O
_RARE_ I-GENE
_RARE_ I-GENE
was O
estimated O
to O
be O
15 O
ml O
/ I-GENE
min O
/ I-GENE
100 O
g O
and O
it O
increased O
to O
150 O
- I-GENE
200 O
% O
after O
the O
induction O
of O
anesthesia O
, O
and O
then O
decreased O
to O
72 O
% O
at O
the O
tip O
of O
the O
created O
_RARE_ I-GENE
_RARE_ I-GENE
flap O
. O

_RARE_ I-GENE
, O
a O
16 O
- I-GENE
base O
- I-GENE
pair O
nuclear I-GENE
factor I-GENE
binding I-GENE
site I-GENE
_RARE_ I-GENE
between O
the O
c I-GENE
- I-GENE
_RARE_ I-GENE
P1 I-GENE
and O
P2 I-GENE
transcription I-GENE
initiation I-GENE
sites I-GENE
, O
is O
required O
for O
P2 I-GENE
activity O
. O

The O
next O
_RARE_ I-GENE
years O
of O
prevention O
in O
_RARE_ I-GENE
_RARE_ I-GENE
: O
_RARE_ I-GENE
, O
complex I-GENE
, O
and O
_RARE_ I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
is O
also O
known O
to O
facilitate O
mating I-GENE
behavior O
in O
several O
species O
. O

The O
first O
_RARE_ I-GENE
consecutive O
patients O
treated O
with O
_RARE_ I-GENE
during O
the O
period O
from O
August O
, O
1986 O
to O
_RARE_ I-GENE
, O
1989 O
are O
reported O
. O

_RARE_ I-GENE
the O
_RARE_ I-GENE
acid I-GENE
with O
a O
lysine O
but O
not O
with O
an O
alanine I-GENE
or O
_RARE_ I-GENE
residue O
allowed O
formation O
of O
disulfide O
- I-GENE
linked O
dimers I-GENE
. O

During O
V I-GENE
- I-GENE
A I-GENE
bypass O
, O
hemodynamics O
were O
stable O
. O

_RARE_ I-GENE
_RARE_ I-GENE
force O
was O
required O
in O
the O
adult O
pigs O
than O
in O
the O
young O
pigs O
. O

At O
rest O
_RARE_ I-GENE
was O
significantly O
higher O
in O
UT O
( O
29 O
%) O
as O
compared O
to O
AT I-GENE
( O
25 O
%) O
and O
_RARE_ I-GENE
( O
25 O
%). O

We O
investigated O
the O
smoking O
_RARE_ I-GENE
of O
_RARE_ I-GENE
1 I-GENE
year O
after O
_RARE_ I-GENE
in O
a O
smoking O
cessation O
trial O
using O
nicotine O
or O
placebo O
_RARE_ I-GENE
. O

_RARE_ I-GENE
to O
hepatitis I-GENE
B I-GENE
virus I-GENE
in O
the O
general O
population O
of O
_RARE_ I-GENE
, O
Japan O
: O
significance O
of O
isolated O
antibody I-GENE
to O
hepatitis I-GENE
B I-GENE
surface O
antigen I-GENE
in O
general O
population O
. O

Because O
of O
this O
latter O
phenomenon O
, O
we O
were O
able O
to O
identify O
a O
particular O
cysteine I-GENE
motif I-GENE
that O
was O
repeated O
multiple O
times O
in O
_RARE_ I-GENE
but O
present O
only O
twice O
in O
mammalian I-GENE
_RARE_ I-GENE
. O

On O
the O
other O
hand O
, O
neither O
phosphate I-GENE
_RARE_ I-GENE
saline O
injection O
into O
the O
ES O
nor O
primary O
_RARE_ I-GENE
_RARE_ I-GENE
of O
the O
ES O
were O
capable O
of O
_RARE_ I-GENE
the O
threshold O
level O
and O
changing O
the O
latency O
. O

A I-GENE
newly O
developed O
broad O
- I-GENE
spectrum O
_RARE_ I-GENE
, O
_RARE_ I-GENE
( O
_RARE_ I-GENE
, O
DR I-GENE
- I-GENE
_RARE_ I-GENE
), O
was O
evaluated O
in O
vitro O
and O
in O
vivo O
in O
comparison O
with O
_RARE_ I-GENE
( O
_RARE_ I-GENE
), O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
and O
_RARE_ I-GENE
( O
_RARE_ I-GENE
). O

The O
mean O
serum I-GENE
creatinine O
levels O
were O
similar O
at O
one O
year O
( O
SPK I-GENE
1 I-GENE
. O
8 O
, O
_RARE_ I-GENE
1 I-GENE
. O
9 O
mg O
/ I-GENE
d O
_RARE_ I-GENE
ABSTRACT O
TRUNCATED O
AT I-GENE
250 O
WORDS O
) O

_RARE_ I-GENE
predictions O
were O
in O
_RARE_ I-GENE
with O
the O
nine O
- I-GENE
year O
survival O
experience O
of O
women O
in O
the O
_RARE_ I-GENE
trial O
, O
and O
, O
with O
the O
exception O
of O
women O
40 I-GENE
- I-GENE
44 I-GENE
years O
old O
, O
with O
_RARE_ I-GENE
data O
on O
18 O
- I-GENE
year O
survival O
. O

High O
- I-GENE
resolution O
computed O
tomography O
in O
the O
diagnosis O
of O
_RARE_ I-GENE
tuberculosis O
. O

Previously O
, O
we O
showed O
that O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
function O
_RARE_ I-GENE
in O
transcriptional O
activation O
, O
possibly O
forming O
a O
_RARE_ I-GENE
complex I-GENE
. O

We O
show O
that O
LexA I-GENE
- I-GENE
GAL4 I-GENE
and O
LexA I-GENE
- I-GENE
_RARE_ I-GENE
fusion I-GENE
proteins I-GENE
are O
both O
dependent I-GENE
on O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
for O
activation O
of O
target O
genes I-GENE
containing O
one O
or O
multiple O
_RARE_ I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
T I-GENE
. O

A I-GENE
lambda I-GENE
_RARE_ I-GENE
cDNA I-GENE
library O
was O
constructed O
from O
poly O
( O
A I-GENE
)+ O
RNA I-GENE
of O
young O
green I-GENE
leaves O
of O
_RARE_ I-GENE
. O

NE O
and O
_RARE_ I-GENE
_RARE_ I-GENE
in O
the O
_RARE_ I-GENE
of O
_RARE_ I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
the O
important O
connective O
- I-GENE
tissue I-GENE
protein I-GENE
elastin I-GENE
, O
and O
generate O
chemotactic O
activities O
by O
forming O
alpha I-GENE
1 I-GENE
- I-GENE
proteinase I-GENE
inhibitor I-GENE
complexes I-GENE
and O
elastin I-GENE
peptides I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
in O
pediatric O
ultrasonography O
-- O
1992 O
. O

_RARE_ I-GENE
included O
24 O
- I-GENE
hour O
dietary O
_RARE_ I-GENE
, O
_RARE_ I-GENE
weights O
, O
and O
_RARE_ I-GENE
analysis O
. O

Factors O
associated I-GENE
with O
_RARE_ I-GENE
included O
age O
, O
end O
- I-GENE
of O
- I-GENE
surgery O
temperature O
( O
both O
positively O
) O
and O
body O
mass O
( O
negatively O
). O

Both O
GH I-GENE
deficiency O
and O
impaired O
spinal O
growth I-GENE
may O
result O
in O
short O
_RARE_ I-GENE
, O
whereas O
the O
occurrence O
of O
early I-GENE
_RARE_ I-GENE
in O
association O
with O
GH I-GENE
deficiency O
reduces O
the O
time O
available O
for O
GH I-GENE
therapy O
. O

By O
contrast O
, O
d O
( O
_RARE_ I-GENE
) O
and O
d O
( O
_RARE_ I-GENE
) O
form O
only O
the O
G I-GENE
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
structures O
independent O
of O
K I-GENE
_RARE_ I-GENE
concentration O
as O
reported O
previously O
[ O
_RARE_ I-GENE
, O
D I-GENE
., O
& O
_RARE_ I-GENE
, O
W I-GENE
. O

_RARE_ I-GENE
among O
renal O
_RARE_ I-GENE
. O

_RARE_ I-GENE
16 O
mRNA I-GENE
was O
found O
to O
be O
constitutively O
expressed O
in O
lymphoid I-GENE
cells O
and O
in O
cell O
lines O
of O
both O
the O
T I-GENE
and O
B I-GENE
lineages O
. O

_RARE_ I-GENE
- I-GENE
lytic O
action O
of O
_RARE_ I-GENE
in O
lymphocytes O
. O

_RARE_ I-GENE
- I-GENE
intron O
junctions O
in O
the O
human I-GENE
and O
rat I-GENE
_RARE_ I-GENE
decarboxylase I-GENE
genes I-GENE
were O
in O
identical O
positions O
except O
that O
exons O
6 I-GENE
and O
7 O
of O
the O
human I-GENE
gene I-GENE
formed O
a O
single O
exon O
in O
the O
rat I-GENE
gene I-GENE
. O

Interferon I-GENE
- I-GENE
alpha I-GENE
- I-GENE
induced O
gene I-GENE
expression O
: O
evidence O
for O
a O
selective O
effect O
of O
_RARE_ I-GENE
on O
activation O
of O
the O
_RARE_ I-GENE
transcription I-GENE
complex I-GENE
. O

The O
cDNA I-GENE
has O
an O
open O
reading O
frame O
of O
_RARE_ I-GENE
amino O
acids O
capable O
of O
encoding O
a O
97 O
- I-GENE
kDa I-GENE
protein I-GENE
. O

Moreover O
, O
LD50 O
in O
mice O
of O
RP I-GENE
- I-GENE
170 I-GENE
( O
4 I-GENE
. O
3 I-GENE
g O
/ I-GENE
kg O
on O
i O
. O
v I-GENE
.) O
was O
increased O
to O
5 I-GENE
. O
2 I-GENE
g O
/ I-GENE
kg O
by O
oral O
administration O
. O

Among O
the O
few O
proteins I-GENE
of O
the O
eukaryotic I-GENE
_RARE_ I-GENE
that O
have O
been O
characterized O
, O
four O
proteins I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
and O
_RARE_ I-GENE
, O
possess O
a O
common O
structural O
motif I-GENE
, O
the O
_RARE_ I-GENE
domain I-GENE
, O
which O
is O
rich O
in O
glycine O
and O
arginine I-GENE
residues O
. O

Thus O
, O
this O
study O
provides O
evidence O
that O
a O
novel O
, O
ubiquitous O
factor I-GENE
( O
HF I-GENE
- I-GENE
1a I-GENE
) O
and O
a O
muscle O
factor I-GENE
( O
HF I-GENE
- I-GENE
1b I-GENE
/ I-GENE
MEF I-GENE
- I-GENE
2 I-GENE
) O
can O
form O
a O
novel O
, O
E I-GENE
- I-GENE
box I-GENE
- I-GENE
independent O
pathway O
for O
muscle O
- I-GENE
specific I-GENE
expression O
in O
ventricular O
cardiac O
muscle O
cells O
. O

Mutations O
in O
either O
gene I-GENE
block O
some O
crucial O
late O
step O
in O
assembly O
of O
F1 I-GENE
, O
causing O
the O
alpha I-GENE
and O
beta I-GENE
subunits I-GENE
to O
accumulate O
in O
mitochondria O
as O
inactive O
aggregates O
( O
_RARE_ I-GENE
, O
S I-GENE
. O

_RARE_ I-GENE
limits O
the O
use O
of O
hepatitis I-GENE
B I-GENE
vaccines O
, O
but O
low O
- I-GENE
dose O
_RARE_ I-GENE
immunization O
has O
been O
evaluated O
as O
a O
cost O
- I-GENE
_RARE_ I-GENE
strategy O
in O
numerous O
studies O
. O

_RARE_ I-GENE
replacement O
therapy O
and O
risk O
of O
breast O
cancer O
: O
results O
of O
two O
_RARE_ I-GENE
- I-GENE
analyses O
. O

_RARE_ I-GENE
_RARE_ I-GENE
- I-GENE
P1 I-GENE
/ I-GENE
_RARE_ I-GENE
cells O
from O
growth I-GENE
in O
M I-GENE
- I-GENE
CSF I-GENE
to O
GM I-GENE
- I-GENE
CSF I-GENE
caused O
the O
selective O
degradation O
of O
c I-GENE
- I-GENE
fms I-GENE
mRNA I-GENE
within O
6 I-GENE
h O
after O
factor I-GENE
switching O
. O

There O
was O
however O
, O
no O
significant O
difference O
in O
the O
prevalence O
of O
chronic O
respiratory O
symptoms O
between O
animal O
food O
workers O
with O
positive O
and O
negative O
skin O
tests O
to O
_RARE_ I-GENE
dust O
or O
to O
fish O
_RARE_ I-GENE
or O
among O
those O
with O
increased O
or O
normal O
IgE I-GENE
( O
except O
for O
_RARE_ I-GENE
). O

An O
_RARE_ I-GENE
finding O
was O
the O
presence O
at O
position O
- I-GENE
_RARE_ I-GENE
to O
- I-GENE
_RARE_ I-GENE
of O
a O
putative O
dioxin I-GENE
responsive I-GENE
element I-GENE
, O
a O
sequence I-GENE
found O
to O
be O
responsible O
for O
the O
induction O
of O
transcription I-GENE
of O
the O
cytochrome I-GENE
_RARE_ I-GENE
gene I-GENE
( O
_RARE_ I-GENE
) O
and O
other O
genes I-GENE
involved O
in O
_RARE_ I-GENE
/ I-GENE
activation O
of O
_RARE_ I-GENE
aromatic O
_RARE_ I-GENE
. O

The O
gene I-GENE
encoding O
_RARE_ I-GENE
- I-GENE
2 I-GENE
maps O
to O
mouse I-GENE
chromosome O
14 O
, O
in O
the O
region O
of O
the O
coat I-GENE
colour I-GENE
mutation I-GENE
_RARE_ I-GENE
. O

Using O
bovine I-GENE
and O
murine I-GENE
c I-GENE
- I-GENE
myb I-GENE
clones O
, O
no O
change O
in O
the O
rate O
of O
c I-GENE
- I-GENE
myb I-GENE
gene I-GENE
transcription I-GENE
or O
mRNA I-GENE
stability O
was O
detected O
during O
the O
cell O
cycle O
. O

A I-GENE
13 O
base O
- I-GENE
pair O
oligonucleotide I-GENE
spanning O
nucleotides O
+ I-GENE
80 O
to O
+ I-GENE
92 O
of O
the O
5 I-GENE
S I-GENE
RNA I-GENE
gene I-GENE
retained O
specific I-GENE
and O
high O
- I-GENE
affinity O
binding I-GENE
, O
although O
the O
latter O
was O
reduced O
_RARE_ I-GENE
relative O
to O
longer O
DNA I-GENE
fragments I-GENE
. O

Moreover O
, O
the O
_RARE_ I-GENE
of O
_RARE_ I-GENE
and O
TFIID I-GENE
- I-GENE
depleted O
transcription I-GENE
complexes I-GENE
with O
purified O
protein I-GENE
fractions O
demonstrate O
that O
not O
only O
TFIID I-GENE
but O
also O
_RARE_ I-GENE
essentially O
participates O
in O
complex I-GENE
formation O
even O
on O
_RARE_ I-GENE
promoter I-GENE
mutations O
lacking O
the O
TATA I-GENE
- I-GENE
box I-GENE
. O

A I-GENE
comparison O
of O
the O
amino O
acid I-GENE
sequence I-GENE
of O
the O
T I-GENE
. O
_RARE_ I-GENE
enzyme I-GENE
with O
that O
of O
the O
Escherichia I-GENE
coli I-GENE
enzyme I-GENE
showed O
( O
i O
) O
a O
37 O
% O
overall O
similarity O
; O
( O
ii O
) O
the O
conservation O
of O
the O
Ser O
residue O
, O
which O
is O
known O
to O
be O
phosphorylated O
in O
the O
E I-GENE
. O
coli I-GENE
enzyme I-GENE
, O
and O
of O
the O
surrounding O
sequence I-GENE
; O
and O
( O
iii O
) O
the O
presence O
of O
_RARE_ I-GENE
extra I-GENE
residues O
at O
the O
C I-GENE
terminus O
of O
the O
T I-GENE
. O
_RARE_ I-GENE
enzyme I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
was O
not O
incorporated O
into O
the O
mutated O
protein I-GENE
, O
showing O
that O
lipid O
modification O
occurs O
at O
the O
Cys I-GENE
- I-GENE
22 O
residue O
. O

17 O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
were O
compared O
with O
18 O
_RARE_ I-GENE
hearing O
_RARE_ I-GENE
on O
the O
_RARE_ I-GENE
_RARE_ I-GENE
Clinical O
Scale O
( O
_RARE_ I-GENE
) O
of O
_RARE_ I-GENE
and O
J O
. O

_RARE_ I-GENE
tobacco I-GENE
L12 I-GENE
protein I-GENE
has O
44 I-GENE
% O
amino O
acid I-GENE
identity O
with O
ribosomal I-GENE
protein I-GENE
_RARE_ I-GENE
/ I-GENE
L12 I-GENE
of O
Escherichia I-GENE
coli I-GENE
. O

Nuclear I-GENE
- I-GENE
encoded I-GENE
chloroplast I-GENE
ribosomal I-GENE
protein I-GENE
L12 I-GENE
of O
_RARE_ I-GENE
_RARE_ I-GENE
: O
characterization O
of O
mature O
protein I-GENE
and O
isolation O
and O
sequence I-GENE
analysis O
of O
cDNA I-GENE
clones O
encoding O
its O
cytoplasmic I-GENE
precursor I-GENE
. O

The O
gene I-GENE
encoding O
IFN I-GENE
- I-GENE
gamma I-GENE
was O
previously O
found O
to O
contain O
an O
intronic I-GENE
enhancer I-GENE
element I-GENE
that O
was O
not O
tissue I-GENE
- I-GENE
specific I-GENE
in O
its O
activity O
, O
despite O
the O
restricted O
expression O
of O
the O
intact O
IFN I-GENE
- I-GENE
gamma I-GENE
- I-GENE
encoding O
gene I-GENE
. O

Molecular O
cloning O
of O
the O
polypeptide I-GENE
component O
of O
the O
Rel I-GENE
- I-GENE
related I-GENE
human I-GENE
_RARE_ I-GENE
nucleoprotein I-GENE
complex I-GENE
has O
revealed O
its O
identity O
with O
the O
65 O
- I-GENE
kDa I-GENE
( O
p65 I-GENE
) O
subunit I-GENE
of O
NF I-GENE
- I-GENE
kappa I-GENE
B I-GENE
. O

Because O
single O
- I-GENE
chamber O
rate O
- I-GENE
adaptive O
atrial I-GENE
pacing O
leaves O
the O
patient O
exposed O
to O
the O
risk O
of O
future O
development O
of O
AV O
block O
and O
_RARE_ I-GENE
pacing O
does O
not O
provide O
_RARE_ I-GENE
support O
, O
it O
is O
likely O
that O
the O
new O
rate O
- I-GENE
adaptive O
dual O
- I-GENE
chamber O
( O
_RARE_ I-GENE
) O
_RARE_ I-GENE
will O
be O
used O
in O
a O
significant O
number O
of O
these O
patients O
.( O
ABSTRACT O
TRUNCATED O
AT I-GENE
250 O
WORDS O
) O

When O
transiently O
transfected O
into O
K562 O
cells O
, O
this O
_RARE_ I-GENE
genomic O
clone O
is O
actively O
transcribed O
, O
suggesting O
that O
, O
although O
it O
possesses O
the O
characteristics O
of O
a O
processed O
pseudogene I-GENE
, O
it O
is O
likely O
to O
correspond O
to O
the O
gene I-GENE
encoding O
this O
new O
ferritin I-GENE
subunit I-GENE
. O

Of O
the O
drugs O
orally O
administered O
, O
WR O
- I-GENE
_RARE_ I-GENE
was O
the O
best O
_RARE_ I-GENE
with O
a O
_RARE_ I-GENE
of O
1 I-GENE
. O
51 O
. O

Characterization O
of O
these O
R I-GENE
subunits I-GENE
by O
their O
8 O
- I-GENE
_RARE_ I-GENE
- I-GENE
cAMP I-GENE
_RARE_ I-GENE
labeling O
and O
immunoreactivity O
, O
as O
well O
as O
by O
a O
phosphorylation O
- I-GENE
dependent I-GENE
mobility I-GENE
shift O
on O
sodium O
dodecyl O
sulfate I-GENE
- I-GENE
polyacrylamide O
gel O
electrophoresis O
( O
SDS O
- I-GENE
PAGE O
), O
indicated O
subunit I-GENE
sizes O
of O
RII I-GENE
beta I-GENE
( O
53 O
kDa I-GENE
) O
greater O
than O
RII I-GENE
alpha I-GENE
_RARE_ I-GENE
( O
51 O
kDa I-GENE
) O
greater O
than O
RI I-GENE
alpha I-GENE
( O
49 O
kDa I-GENE
). O

Comparison O
of O
the O
genomic O
DNA I-GENE
sequence I-GENE
with O
that O
of O
the O
four O
different O
mRNAs I-GENE
indicates O
that O
these O
transcripts I-GENE
are O
produced O
by O
alternative O
splicing O
of O
the O
murine I-GENE
pre I-GENE
- I-GENE
mRNA I-GENE
according O
to O
a O
cassette I-GENE
model O
. O

During O
the O
1980 O
' O
s O
, O
_RARE_ I-GENE
of O
_RARE_ I-GENE
_RARE_ I-GENE
, O
especially O
C I-GENE
reactive I-GENE
protein I-GENE
, O
rheumatoid I-GENE
factor I-GENE
and O
_RARE_ I-GENE
O O
, O
progressed O
rapidly O
. O

Within O
the O
human I-GENE
enhancer I-GENE
, O
these O
two O
sites I-GENE
are O
located O
within O
the O
previously O
defined O
DNase I-GENE
I I-GENE
_RARE_ I-GENE
, O
NFAT I-GENE
- I-GENE
1 I-GENE
and O
_RARE_ I-GENE
- I-GENE
2B I-GENE
, O
respectively O
. O

The O
cardiac O
myosin I-GENE
light I-GENE
chain I-GENE
- I-GENE
2 I-GENE
( O
_RARE_ I-GENE
- I-GENE
2 I-GENE
) O
gene I-GENE
promoter I-GENE
contains O
several O
positive O
and O
negative O
cis O
- I-GENE
acting O
sequences I-GENE
that O
are O
involved O
in O
the O
regulation O
of O
its O
expression O
. O

Deletion O
mutagenesis O
demonstrated O
that O
these O
two O
elements O
are O
involved O
in O
the O
positive O
regulation O
of O
_RARE_ I-GENE
- I-GENE
2 I-GENE
gene I-GENE
transcription I-GENE
. O

Disruption O
mutations O
have O
been O
constructed O
in O
the O
_RARE_ I-GENE
gene I-GENE
. O
_RARE_ I-GENE
null I-GENE
mutants I-GENE
cannot O
grow O
at O
37 O
degrees O
C I-GENE
, O
but O
many O
cells O
can O
grow O
at O
30 O
, O
24 O
, O
and O
17 O
degrees O
C I-GENE
. O

Molecular O
and O
genetic O
analysis O
of O
the O
yeast I-GENE
early I-GENE
meiotic I-GENE
recombination O
genes I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
. O

The O
p130 I-GENE
and O
p62 I-GENE
tyrosine I-GENE
- I-GENE
phosphorylated O
proteins I-GENE
that O
complexed O
v I-GENE
- I-GENE
Src I-GENE
SH2 I-GENE
in O
vitro O
also O
associated I-GENE
with O
v I-GENE
- I-GENE
Src I-GENE
in O
v I-GENE
- I-GENE
src I-GENE
- I-GENE
transformed O
Rat I-GENE
- I-GENE
2 I-GENE
cells O
; O
this O
in O
vivo O
binding I-GENE
was O
dependent I-GENE
on O
the O
v I-GENE
- I-GENE
Src I-GENE
SH2 I-GENE
domain I-GENE
. O

_RARE_ I-GENE
progressive O
_RARE_ I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
was O
diagnosed O
on O
the O
basis O
of O
clinical O
picture O
and O
magnetic O
resonance O
imaging O
in O
a O
63 O
- I-GENE
year O
- I-GENE
old O
man O
with O
a O
complete O
remission O
of O
a O
non O
- I-GENE
Hodgkin O
' O
s O
lymphoma O
. O

These O
data O
support O
a O
possible O
biological O
significance O
of O
the O
frameshift O
to O
occur O
at O
this O
position O
of O
the O
large O
overlap O
by O
including O
the O
putative O
RNA I-GENE
template O
- I-GENE
binding I-GENE
site I-GENE
of O
the O
_RARE_ I-GENE
_RARE_ I-GENE
in O
the O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
protein I-GENE
. O

_RARE_ I-GENE
processing O
occurs O
_RARE_ I-GENE
. O

A I-GENE
32P O
- I-GENE
labeled O
_RARE_ I-GENE
DNA I-GENE
- I-GENE
binding I-GENE
and O
dimerization O
domain I-GENE
" O
zipper I-GENE
probe O
" O
was O
used O
to O
isolate O
a O
clone O
that O
encodes O
a O
new O
C I-GENE
/ I-GENE
EBP I-GENE
- I-GENE
homologous O
protein I-GENE
: O
CHOP I-GENE
- I-GENE
10 O
. O

Using O
a O
degenerate O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
based O
on O
the O
N I-GENE
- I-GENE
terminal I-GENE
aa O
sequence I-GENE
, O
plus O
an O
internal O
_RARE_ I-GENE
homologous O
to O
a O
conserved O
region O
within O
the O
portion O
of O
_RARE_ I-GENE
and O
_RARE_ I-GENE
that O
had O
been O
deleted O
in O
the O
genome O
, O
a O
_RARE_ I-GENE
- I-GENE
specific I-GENE
DNA I-GENE
fragment I-GENE
was O
generated O
by O
the O
polymerase I-GENE
chain I-GENE
reaction O
( O
PCR O
) O
using O
_RARE_ I-GENE
genomic O
DNA I-GENE
as O
a O
substrate I-GENE
. O

_RARE_ I-GENE
hybridization O
of O
_RARE_ I-GENE
- I-GENE
1 I-GENE
back O
to O
primate O
genomic O
DNA I-GENE
indicates O
two O
distinct O
_RARE_ I-GENE
- I-GENE
1 I-GENE
loci I-GENE
in O
normal O
human I-GENE
DNA I-GENE
, O
an O
identical O
band O
pattern O
in O
_RARE_ I-GENE
DNA I-GENE
, O
and O
a O
single O
locus I-GENE
in O
rhesus I-GENE
monkey I-GENE
DNA I-GENE
. O

The O
level O
of O
carboxyl O
- I-GENE
terminal I-GENE
parathyroid I-GENE
hormone I-GENE
in O
the O
patients O
with O
thyroid I-GENE
carcinoma O
was O
higher O
than O
that O
in O
the O
patients O
without O
thyroid I-GENE
carcinoma O
( O
P I-GENE
less O
than O
0 O
. O
05 O
). O

The O
Caenorhabditis I-GENE
elegans I-GENE
_RARE_ I-GENE
genes I-GENE
are O
subject O
to O
sex I-GENE
-, I-GENE
stage O
-, I-GENE
and O
tissue I-GENE
- I-GENE
specific I-GENE
regulation O
: O
they O
are O
expressed O
solely O
in O
the O
adult O
_RARE_ I-GENE
intestine O
. O

The O
_RARE_ I-GENE
gene I-GENE
was O
cloned O
, O
and O
its O
sequence I-GENE
reveals O
that O
it O
encodes O
a O
protein I-GENE
related I-GENE
to O
the O
family I-GENE
of O
the O
bZIP I-GENE
transcriptional O
activators I-GENE
. O

The O
functions O
of O
isolated O
portions O
of O
the O
insulin I-GENE
, O
_RARE_ I-GENE
, O
and O
beta I-GENE
_RARE_ I-GENE
promoters I-GENE
were O
studied O
by O
using O
transient O
expression O
and O
DNA I-GENE
binding I-GENE
assays O
. O

It O
is O
believed O
that O
these O
domains I-GENE
are O
important O
for O
_RARE_ I-GENE
specific I-GENE
protein I-GENE
- I-GENE
protein I-GENE
interactions O
necessary O
for O
the O
proper O
functioning O
of O
Src I-GENE
. O

The O
c I-GENE
- I-GENE
Ets I-GENE
- I-GENE
1 I-GENE
oncoprotein I-GENE
is O
a O
transcription I-GENE
activator I-GENE
that O
specifically O
binds O
to O
DNA I-GENE
. O

Previous O
transactivation O
experiments O
indicated O
that O
three O
amino O
acids O
_RARE_ I-GENE
in O
this O
region O
, O
Gly O
, O
Ser O
and O
Val I-GENE
, O
appear O
to O
be O
critical O
for O
target O
- I-GENE
site I-GENE
discrimination O
. O

_RARE_ I-GENE
is O
a O
water O
- I-GENE
soluble I-GENE
analogue O
of O
_RARE_ I-GENE
, O
a O
_RARE_ I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
rescue O
analysis O
has O
localized O
_RARE_ I-GENE
to O
a O
_RARE_ I-GENE
- I-GENE
bp O
internal O
segment O
of O
_RARE_ I-GENE
that O
encodes O
the O
_RARE_ I-GENE
domain I-GENE
. O

This O
vector O
transfected O
into O
the O
yeast I-GENE
Saccharomyces I-GENE
cerevisiae I-GENE
directs O
expression O
of O
a O
secreted O
mature O
protein I-GENE
at O
levels O
up O
to O
200 O
mg O
of O
_RARE_ I-GENE
/ I-GENE
liter O
of O
culture O
medium O
. O

Competition O
analysis O
by O
gel O
mobility I-GENE
shift O
electrophoresis O
indicates O
that O
this O
DNA I-GENE
- I-GENE
protein I-GENE
interaction O
is O
novel O
and O
not O
related I-GENE
to O
many O
transcription I-GENE
factors I-GENE
previously O
reported O
. O

This O
DNA I-GENE
motif I-GENE
represents O
a O
novel O
protein I-GENE
- I-GENE
binding I-GENE
sequence I-GENE
. O

OBJECTIVE O
: O
The O
study O
was O
designed O
to O
investigate O
the O
frequency O
of O
alterations O
in O
serum I-GENE
creatinine O
in O
patients O
with O
psoriasis O
receiving O
5 I-GENE
mg O
/ I-GENE
kg O
/ I-GENE
day O
of O
cyclosporine O
. O

_RARE_ I-GENE
chemotherapy O
in O
adult O
_RARE_ I-GENE
using O
a O
new O
controlled O
- I-GENE
release O
insert O
containing O
_RARE_ I-GENE
( O
PT O
- I-GENE
01 O
). O

_RARE_ I-GENE
blood O
flow O
( O
BF I-GENE
) O
probe O
was O
applied O
on O
the O
left O
anterior O
_RARE_ I-GENE
artery O
( O
LAD O
). O

Hence O
temperature O
and O
_RARE_ I-GENE
are O
both O
required O
for O
the O
induction O
of O
the O
_RARE_ I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
to O
be O
resolved O
in O
the O
area O
of O
quantitative O
risk O
assessment O
. O

The O
recently O
developed O
gamma I-GENE
- I-GENE
interferon I-GENE
( O
IFN I-GENE
- I-GENE
gamma I-GENE
) O
assay O
system O
for O
the O
diagnosis O
of O
bovine I-GENE
tuberculosis O
in O
cattle O
has O
been O
_RARE_ I-GENE
by O
the O
_RARE_ I-GENE
Committee O
on O
_RARE_ I-GENE
for O
use O
in O
_RARE_ I-GENE
. O

Control O
_RARE_ I-GENE
was O
35 O
. O
8 O
+/- O
0 O
. O
7 O
degrees O
C I-GENE
, O
with O
control O
_RARE_ I-GENE
, O
max O
being O
51 O
. O
6 I-GENE
( O
SD O
8 O
. O
7 O
) O
W I-GENE
. O
kg O
- I-GENE
1 I-GENE
. O

The O
Klebsiella I-GENE
_RARE_ I-GENE
gene I-GENE
_RARE_ I-GENE
, O
which O
is O
involved O
in O
the O
synthesis O
of O
monoamine I-GENE
oxidase I-GENE
, O
was O
induced O
by O
_RARE_ I-GENE
and O
the O
related I-GENE
compounds O
, O
subjected O
to O
catabolite I-GENE
and O
_RARE_ I-GENE
ion O
repression O
, O
and O
cloned O
. O

However O
, O
other O
regions O
of O
the O
plasmid O
are O
also O
efficiently O
_RARE_ I-GENE
. O

Eight O
of O
14 O
infectious O
or O
inflammatory O
lesions O
could O
be O
detected O
in O
the O
early I-GENE
scan O
( O
4 I-GENE
- I-GENE
6 I-GENE
h O
p O
. O
i O
.). O

Thus O
, O
the O
human I-GENE
_RARE_ I-GENE
gene I-GENE
belongs O
to O
the O
category O
of O
tissue I-GENE
- I-GENE
specific I-GENE
, O
regulated O
genes I-GENE
that O
have O
housekeeping O
- I-GENE
type I-GENE
promoters I-GENE
. O

Similar O
observations O
have O
been O
made O
previously O
for O
other O
genes I-GENE
. O

_RARE_ I-GENE
of O
CNS O
students O
: O
an O
_RARE_ I-GENE
study O
. O

To O
determine O
the O
genetic O
basis O
for O
the O
differences O
between O
the O
cardiac O
and O
brain O
_RARE_ I-GENE
variants I-GENE
, O
we O
isolated O
and O
characterized O
the O
rat I-GENE
gene I-GENE
. O

The O
1 I-GENE
. O
7 O
kb O
cloned O
fragment I-GENE
was O
sequenced O
and O
shown O
to O
contain O
the O
entire O
_RARE_ I-GENE
gene I-GENE
. O

_RARE_ I-GENE
of O
both O
intravenous O
and O
_RARE_ I-GENE
administration O
of O
amphotericin O
B I-GENE
and O
possibly O
concomitant O
intravenous O
administration O
of O
dexamethasone O
may O
be O
warranted O
in O
situations O
in O
which O
the O
association O
of O
C I-GENE
. O
_RARE_ I-GENE
with O
CNS O
vasculitis O
or O
_RARE_ I-GENE
appears O
likely O
before O
serologic O
or O
_RARE_ I-GENE
_RARE_ I-GENE
of O
C I-GENE
. O
_RARE_ I-GENE
infection O
involving O
the O
CNS O
is O
available O
. O

_RARE_ I-GENE
_RARE_ I-GENE
were O
introduced O
into O
several O
positions O
within O
the O
_RARE_ I-GENE
promoter I-GENE
and O
operator I-GENE
- I-GENE
free O
plasmid O
was O
used O
as O
control O
. O

_RARE_ I-GENE
, O
purification O
and O
characterization O
of O
M I-GENE
. O
_RARE_ I-GENE
methyltransferase I-GENE
and O
its O
deletion O
mutant I-GENE
. O

Various O
_RARE_ I-GENE
produce O
this O
type I-GENE
of O
lens O
. O

From O
_RARE_ I-GENE
5 I-GENE
through O
_RARE_ I-GENE
26 O
, O
1991 O
, O
eight O
persons O
were O
diagnosed O
with O
elevated O
blood O
lead O
levels O
( O
_RARE_ I-GENE
) O
at O
a O
local O
hospital O
and O
were O
reported O
to O
the O
_RARE_ I-GENE
disease O
_RARE_ I-GENE
system O
maintained O
by O
the O
_RARE_ I-GENE
_RARE_ I-GENE
of O
_RARE_ I-GENE
Health O
( O
_RARE_ I-GENE
). O

According O
to O
the O
changes O
of O
perfusion O
defects O
between O
_RARE_ I-GENE
, O
RD I-GENE
and O
_RARE_ I-GENE
images O
, O
they O
were O
classified O
into O
3 I-GENE
types O
: O
Type O
I I-GENE
; O
perfusion O
defect O
on O
the O
RD I-GENE
image O
was O
identical O
to O
_RARE_ I-GENE
image O
( O
75 O
%) O
Type O
I I-GENE
was O
divided O
into O
2 I-GENE
subgroups O
whether O
perfusion O
defect O
at O
_RARE_ I-GENE
was O
unchanged O
( O
_RARE_ I-GENE
, O
42 O
%) O
or O
improved O
( O
_RARE_ I-GENE
, O
33 O
%) O
on O
the O
RD I-GENE
image O
. O

_RARE_ I-GENE
, O
C I-GENE
. O
J O
. O

Twenty O
- I-GENE
eight O
( O
7 O
. O
0 O
%) O
infants O
without O
_RARE_ I-GENE
hemorrhage O
were O
revealed O
as O
having O
_RARE_ I-GENE
cerebral O
_RARE_ I-GENE
by O
_RARE_ I-GENE
evaluation O
in O
later O
_RARE_ I-GENE
. O

A I-GENE
possible O
mechanism O
is O
that O
elevated O
alveolar O
pressure O
and O
decreased O
cardiac O
output O
_RARE_ I-GENE
blood O
flow O
from O
_RARE_ I-GENE
vessels O
in O
_RARE_ I-GENE
high O
VA O
/ I-GENE
Q I-GENE
regions O
. O

_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
" O
_RARE_ I-GENE
" O
analysis O
revealed O
four O
possible O
open O
reading O
frames O
( O
ORFs O
), O
three O
in O
one O
direction O
and O
one O
in O
the O
opposite O
direction O
. O

_RARE_ I-GENE
II I-GENE
is O
highly O
homologous O
to O
the O
LDL I-GENE
receptor I-GENE
and O
contains O
four O
repeats I-GENE
with O
perfect O
conservation O
of O
all O
6 I-GENE
consecutive O
_RARE_ I-GENE
. O

In O
both O
_RARE_ I-GENE
, O
HTLV I-GENE
- I-GENE
I I-GENE
/ I-GENE
II I-GENE
prevalence O
increased O
significantly O
with O
age O
, O
and O
the O
New O
_RARE_ I-GENE
age O
- I-GENE
and O
sex I-GENE
- I-GENE
adjusted O
HTLV I-GENE
- I-GENE
I I-GENE
/ I-GENE
II I-GENE
prevalence O
was O
significantly O
higher O
than O
that O
of O
_RARE_ I-GENE
( O
P I-GENE
less O
than O
. O
001 O
). O

Here O
, O
we O
present O
evidence O
for O
a O
model O
in O
which O
mRNA I-GENE
sequences I-GENE
up O
to O
around O
100 O
nucleotides O
downstream O
from O
the O
start O
codon O
of O
_RARE_ I-GENE
fold O
back O
and O
base O
- I-GENE
pair O
to O
the O
_RARE_ I-GENE
translation I-GENE
initiation I-GENE
region O
, O
thereby O
decreasing O
the O
translation I-GENE
initiation I-GENE
frequency O
. O

Hybridization O
data O
indicate O
that O
_RARE_ I-GENE
. O
2 I-GENE
corresponds O
to O
the O
previously O
characterized O
_RARE_ I-GENE
cDNA I-GENE
clone O
and O
that O
_RARE_ I-GENE
. O
1 I-GENE
and O
_RARE_ I-GENE
. O
3 I-GENE
, O
but O
not O
_RARE_ I-GENE
. O
2 I-GENE
, O
are O
adjacent O
to O
alpha I-GENE
- I-GENE
type I-GENE
genes I-GENE
. O

The O
_RARE_ I-GENE
gene I-GENE
corresponds O
to O
a O
6 I-GENE
, O
_RARE_ I-GENE
- I-GENE
bp O
open O
reading O
frame O
coding O
for O
a O
2 I-GENE
, O
112 O
- I-GENE
amino O
- I-GENE
acid I-GENE
protein I-GENE
( O
molecular O
mass O
, O
239 O
kDa I-GENE
). O

Protein I-GENE
tyrosine I-GENE
kinases I-GENE
( O
_RARE_ I-GENE
) O
are O
implicated O
in O
the O
control O
of O
cell O
growth I-GENE
by O
_RARE_ I-GENE
of O
their O
frequent O
appearance O
as O
products I-GENE
of O
retroviral I-GENE
oncogenes I-GENE
, O
as O
intracellular O
signal I-GENE
_RARE_ I-GENE
, O
and O
as O
growth I-GENE
factor I-GENE
receptors I-GENE
or O
components O
_RARE_ I-GENE
. O

The O
_RARE_ I-GENE
mAb I-GENE
was O
identified O
among O
a O
series O
of O
antibodies I-GENE
raised O
in O
BALB O
/ I-GENE
c I-GENE
mice O
after O
immunization O
against O
a O
HLA I-GENE
class I-GENE
I I-GENE
- I-GENE
deficient O
, O
_RARE_ I-GENE
- I-GENE
activated I-GENE
killer O
( O
_RARE_ I-GENE
)- I-GENE
susceptible O
EBV I-GENE
- I-GENE
B I-GENE
lymphocyte I-GENE
line O
. O

In O
a O
randomized O
double O
- I-GENE
blind O
cross O
- I-GENE
over O
study O
, O
the O
subjects O
received O
theophylline O
5 I-GENE
mg O
. O
kg O
- I-GENE
1 I-GENE
per O
day O
with O
omeprazole O
20 O
mg O
per O
day O
or O
identical O
placebo O
during O
two O
periods O
, O
each O
of O
7 O
days O
, O
separated O
by O
a O
washout O
period O
of O
7 O
days O
. O

Primer O
extension O
and O
_RARE_ I-GENE
bean I-GENE
and O
S1 I-GENE
nuclease I-GENE
mapping O
indicated O
multiple O
transcription I-GENE
initiation I-GENE
sites I-GENE
and O
were O
consistent O
with O
Northern O
analyses O
. O

Two O
variant I-GENE
_RARE_ I-GENE
- I-GENE
precursor I-GENE
alleles I-GENE
occur O
which O
slightly O
differ O
in O
the O
number O
of O
repeats I-GENE
in O
domain I-GENE
C I-GENE
. O

Unlike O
the O
typical O
enhancer I-GENE
element I-GENE
, O
this O
region O
functions O
in O
an O
orientation O
- I-GENE
dependent I-GENE
manner O
. O

In O
the O
last O
20 O
years O
, O
the O
therapeutic O
uses O
of O
botulinum I-GENE
toxin I-GENE
, O
a O
potent O
_RARE_ I-GENE
, O
have O
been O
investigated O
. O

_RARE_ I-GENE
' O
s O
syndrome O
associated I-GENE
with O
_RARE_ I-GENE
_RARE_ I-GENE

_RARE_ I-GENE
and O
specificity O
was O
established O
for O
the O
Pharmacia O
CAP I-GENE
_RARE_ I-GENE
and O
the O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
by O
comparison O
with O
results O
of O
the O
skin O
_RARE_ I-GENE
test O
. O

PSI I-GENE
- I-GENE
G I-GENE
and O
PSI I-GENE
- I-GENE
K I-GENE
probably O
have O
evolved O
from O
a O
gene I-GENE
duplication O
of O
an O
ancestral O
gene I-GENE
. O

At O
the O
C I-GENE
- I-GENE
terminus O
of O
the O
protein I-GENE
is O
a O
domain I-GENE
that O
contains O
sequences I-GENE
very O
similar O
to O
those O
found O
in O
the O
breakpoint I-GENE
cluster I-GENE
region O
gene I-GENE
product I-GENE
, O
n O
- I-GENE
_RARE_ I-GENE
, O
and O
rho I-GENE
GAP I-GENE
, O
all O
of O
which O
have O
been O
shown O
to O
possess O
intrinsic O
GAP I-GENE
activity O
on O
small I-GENE
GTPases I-GENE
. O

Site I-GENE
- I-GENE
directed O
mutagenesis O
revealed O
that O
two O
clusters O
of O
basic I-GENE
amino O
acids O
within O
a O
conserved O
basic I-GENE
region O
and O
two O
_RARE_ I-GENE
helices O
within O
the O
adjacent O
_RARE_ I-GENE
domain I-GENE
are O
essential O
for O
sequence I-GENE
- I-GENE
specific I-GENE
DNA I-GENE
binding I-GENE
and O
_RARE_ I-GENE
- I-GENE
oligomerization O
, O
respectively O
. O

_RARE_ I-GENE
of O
_RARE_ I-GENE
- I-GENE
5 I-GENE
with O
the O
ubiquitously O
expressed O
bHLH I-GENE
protein I-GENE
E12 I-GENE
not O
only O
increases O
the O
affinity O
for O
DNA I-GENE
but O
also O
stimulates O
transactivation O
independently O
of O
DNA I-GENE
binding I-GENE
. O

The O
circadian O
_RARE_ I-GENE
of O
sleep O
was O
pronounced O
. O

_RARE_ I-GENE
was O
recorded O
with O
_RARE_ I-GENE
_RARE_ I-GENE
at O
25 O
- I-GENE
250 O
_RARE_ I-GENE
and O
40 I-GENE
- I-GENE
250 O
Hz O
using O
_RARE_ I-GENE
method O
. O

_RARE_ I-GENE
- I-GENE
specific I-GENE
expression O
, O
genomic O
structure O
, O
and O
chromosomal I-GENE
localization O
of O
the O
gene I-GENE
encoding O
the O
zinc I-GENE
- I-GENE
finger I-GENE
transcription I-GENE
factor I-GENE
_RARE_ I-GENE
- I-GENE
C I-GENE
. O

An O
experiment O
examined O
the O
effects O
of O
treatment O
with O
_RARE_ I-GENE
releasing I-GENE
hormone I-GENE
( O
100 O
micrograms O
GnRH I-GENE
injected O
24 O
h O
after O
_RARE_ I-GENE
_RARE_ I-GENE
removal O
), O
season O
of O
treatment O
( O
_RARE_ I-GENE
v I-GENE
. O
_RARE_ I-GENE
), O
the O
effect O
of O
supplementary O
feeding O
with O
_RARE_ I-GENE
_RARE_ I-GENE
( O
in O
_RARE_ I-GENE
only O
, O
from O
12 O
days O
before O
until O
8 O
days O
after O
_RARE_ I-GENE
removal O
) O
on O
the O
time O
of O
ovulation O
in O
182 O
mature O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
with O
a O
combination O
of O
400 O
I I-GENE
. O
U O
. O
pregnant O
_RARE_ I-GENE
serum I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
and O
12 O
mg O
follicle I-GENE
stimulating I-GENE
hormone I-GENE
( O
FSH I-GENE
- I-GENE
P I-GENE
). O

Drug O
- I-GENE
drug O
interactions O
are O
most O
likely O
to O
occur O
in O
patients O
receiving O
multiple O
_RARE_ I-GENE
and O
with O
drugs O
that O
have O
a O
narrow O
therapeutic O
_RARE_ I-GENE
. O

The O
sequence I-GENE
data O
now O
permit O
a O
detailed O
interpretation O
of O
the O
X I-GENE
- I-GENE
ray O
_RARE_ I-GENE
structure O
of O
the O
enzyme I-GENE
and O
the O
cloning O
and O
expression O
of O
the O
_RARE_ I-GENE
gene I-GENE
will O
facilitate O
site I-GENE
- I-GENE
directed O
mutagenesis O
. O

Total O
body O
irradiation O
was O
delivered O
according O
to O
a O
_RARE_ I-GENE
_RARE_ I-GENE
of O
12 O
fractions O
given O
three O
per O
day O
5 I-GENE
hr O
apart O
for O
4 I-GENE
days O
. O

A I-GENE
reduction O
in O
blood O
pressure O
was O
only O
observed O
at O
the O
end O
of O
the O
study O
, O
from O
142 O
+/- O
17 O
/ I-GENE
86 I-GENE
. O
6 I-GENE
+/- O
9 O
. O
1 I-GENE
to O
139 O
+/- O
13 O
/ I-GENE
82 O
. O
9 O
+/- O
8 O
. O
9 O
mmHg O
( O
P I-GENE
less O
than O
0 O
. O
05 O
for O
DBP I-GENE
). O

_RARE_ I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
are O
similar O
in O
terms O
of O
promoter I-GENE
structure O
and O
_RARE_ I-GENE
primary O
sequence I-GENE
, O
and O
the O
_RARE_ I-GENE
gene I-GENE
of O
both O
viruses O
is O
transcribed O
in O
the O
anti I-GENE
- I-GENE
_RARE_ I-GENE
direction O
in O
relation O
to O
their O
physical O
maps O
. O

A I-GENE
gene I-GENE
homologous O
to O
the O
Escherichia I-GENE
coli I-GENE
_RARE_ I-GENE
gene I-GENE
was O
isolated O
from O
Pseudomonas I-GENE
putida I-GENE
and O
its O
transcription I-GENE
was O
investigated O
in O
E I-GENE
. O
coli I-GENE
as O
well O
as O
in O
P I-GENE
. O
putida I-GENE
. O

_RARE_ I-GENE
is O
an O
_RARE_ I-GENE
yeast I-GENE
gene I-GENE
involved O
in O
the O
removal O
of O
intervening O
sequences I-GENE
from O
some O
, O
but O
not O
all O
, O
families O
of O
intervening O
sequence I-GENE
- I-GENE
containing O
pre I-GENE
- I-GENE
_RARE_ I-GENE
. O

Using O
these O
antibodies I-GENE
, O
we O
were O
able O
to O
define O
the O
conditions O
to O
completely O
_RARE_ I-GENE
the O
_RARE_ I-GENE
protein I-GENE
. O

_RARE_ I-GENE
gene I-GENE
function O
is O
required O
for O
high O
- I-GENE
level O
_RARE_ I-GENE
gene I-GENE
expression O
in O
Saccharomyces I-GENE
cerevisiae I-GENE
. O

The O
decay O
curves O
of O
_RARE_ I-GENE
fluorescence O
showed O
a O
_RARE_ I-GENE
of O
three O
_RARE_ I-GENE
_RARE_ I-GENE
components O
with O
time O
constants O
of O
T1 O
= O
100 O
- I-GENE
200 O
ps I-GENE
, O
T2 I-GENE
= O
300 O
- I-GENE
500 O
ps I-GENE
and O
T3 O
= O
2 I-GENE
. O
0 O
- I-GENE
3 I-GENE
. O
5 I-GENE
_RARE_ I-GENE
. O

After O
_RARE_ I-GENE
, O
systolic O
blood O
pressure O
fell O
an O
average O
of O
17 O
% O
in O
patients O
who O
_RARE_ I-GENE
_RARE_ I-GENE
( O
p O
= O
0 O
. O
_RARE_ I-GENE
) O
but O
only O
10 O
% O
in O
frequently O
_RARE_ I-GENE
patients O
. O

These O
results O
are O
consistent O
with O
the O
roles O
that O
_RARE_ I-GENE
and O
trypsin I-GENE
inhibitors O
are O
believed O
to O
play O
in O
the O
negative O
_RARE_ I-GENE
control O
of O
pancreatic O
_RARE_ I-GENE
function O
. O

Most O
_RARE_ I-GENE
events O
occurred O
during O
_RARE_ I-GENE
I I-GENE
and O
II I-GENE
, O
and O
REM O
, O
but O
this O
proportion O
was O
less O
during O
the O
gamma I-GENE
OH O
study O
( O
77 O
. O
9 O
+/- O
8 O
. O
9 O
%) O
than O
during O
the O
control O
studies O
( O
92 O
. O
3 I-GENE
+/- O
1 I-GENE
. O
9 O
and O
95 O
. O
9 O
+/- O
2 I-GENE
. O
2 I-GENE
%), O
_RARE_ I-GENE
occurring O
even O
during O
_RARE_ I-GENE
with O
gamma I-GENE
OH O
.( O
ABSTRACT O
TRUNCATED O
AT I-GENE
250 O
WORDS O
) O

Eight O
rabbits O
were O
exposed O
to O
0 O
. O
7 O
+/- O
0 O
. O
4 I-GENE
mg O
/ I-GENE
m3 O
_RARE_ I-GENE
+ I-GENE
as O
_RARE_ I-GENE
and O
1 I-GENE
. O
2 I-GENE
+/- O
0 O
. O
7 O
mg O
/ I-GENE
m3 O
_RARE_ I-GENE
+ I-GENE
as O
Cr I-GENE
( O
_RARE_ I-GENE
) O
3 I-GENE
( O
group O
Co O
+ I-GENE
Cr I-GENE
), O
eight O
to O
0 O
. O
6 I-GENE
+/- O
0 O
. O
5 I-GENE
mg O
/ I-GENE
m3 O
_RARE_ I-GENE
+ I-GENE
( O
group O
Co O
), O
and O
eight O
to O
_RARE_ I-GENE
air O
( O
control O
group O
), O
for O
4 I-GENE
months O
, O
5 I-GENE
days O
/ I-GENE
week O
, O
and O
6 I-GENE
hr O
/ I-GENE
day O
. O

16 O
women O
were O
treated O
with O
_RARE_ I-GENE
to O
prevent O
withdrawal O
symptoms O
. O

Disruption O
demonstrates O
that O
_RARE_ I-GENE
is O
an O
essential O
gene I-GENE
. O

Coronary O
flow O
was O
reduced O
by O
10 O
% O
in O
the O
_RARE_ I-GENE
and O
by O
18 O
% O
in O
the O
control O
group O
. O

The O
_RARE_ I-GENE
transcripts I-GENE
and O
protein I-GENE
are O
first O
detected O
at O
the O
onset O
of O
_RARE_ I-GENE
, O
primarily O
in O
the O
mesoderm O
of O
the O
extending O
germ I-GENE
band O
. O

A I-GENE
_RARE_ I-GENE
- I-GENE
bp O
segment O
of O
the O
5 I-GENE
'- O
flanking O
region O
consisting O
of O
the O
proximal I-GENE
E I-GENE
- I-GENE
box I-GENE
flanked O
upstream O
by O
a O
mammalian I-GENE
- I-GENE
specific I-GENE
_RARE_ I-GENE
- I-GENE
bp O
region O
was O
sufficient O
for O
maximal O
transcriptional O
activation O
in O
_RARE_ I-GENE
_RARE_ I-GENE
myoblasts O
. O

These O
results O
indicate O
that O
baculovirus O
- I-GENE
expressed O
TR I-GENE
mediates O
transcriptional O
activation O
and O
repression O
in O
a O
promoter I-GENE
- I-GENE
specific I-GENE
manner O
in O
vitro O
. O

Influence O
of O
neural O
regulation O
on O
anti I-GENE
- I-GENE
_RARE_ I-GENE
effects O
of O
GABA I-GENE
in O
rats O

Recent O
investigations O
have O
detailed O
a O
selective O
dye O
release O
technique O
in O
which O
a O
pulse O
of O
laser O
light I-GENE
induces O
the O
release O
of O
a O
fluorescent O
dye O
from O
temperature O
- I-GENE
sensitive O
liposomes O
circulating O
in O
the O
retinal O
_RARE_ I-GENE
. O

_RARE_ I-GENE
the O
natural O
_RARE_ I-GENE
? O

Three O
_RARE_ I-GENE
derivatives O
have O
been O
isolated O
from O
the O
fresh O
stem O
_RARE_ I-GENE
of O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE

The O
serum I-GENE
erythropoietin I-GENE
( O
EPO I-GENE
) O
concentrations O
of O
15 O
male O
_RARE_ I-GENE
( O
26 O
. O
3 I-GENE
U O
. O
ml O
- I-GENE
1 I-GENE
) O
were O
significantly O
lower O
than O
those O
of O
45 O
male O
distance O
_RARE_ I-GENE
( O
31 O
. O
6 I-GENE
U O
. O
ml O
- I-GENE
1 I-GENE
; O
P I-GENE
less O
than O
0 O
. O
05 O
). O

The O
_RARE_ I-GENE
materials O
were O
_RARE_ I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
35 O
. O

The O
_RARE_ I-GENE
and O
drinking O
patterns O
of O
_RARE_ I-GENE
goats O
fed O
_RARE_ I-GENE
_RARE_ I-GENE
and O
kept O
on O
a O
12 O
h O
light I-GENE
/ I-GENE
12 O
h O
dark O
cycle O
were O
recorded O
and O
analyzed O
. O

The O
present O
study O
_RARE_ I-GENE
the O
improvement O
in O
sputum I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
levels O
when O
a O
combination O
tablet O
, O
_RARE_ I-GENE
500 O
mg O
plus O
_RARE_ I-GENE
8 O
mg O
, O
is O
administered O
as O
compared O
to O
_RARE_ I-GENE
_RARE_ I-GENE
500 O
mg O
. O

His O
_RARE_ I-GENE
II I-GENE
activity O
and O
antigen I-GENE
levels O
were O
49 O
% O
and O
50 O
%, O
respectively O
, O
and O
his O
daughter O
also O
showed O
similar O
low O
levels O
. O

_RARE_ I-GENE
may O
be O
more O
effective O
under O
low O
_RARE_ I-GENE
II I-GENE
conditions O
because O
of O
its O
potent O
inhibition O
of O
thrombin I-GENE
activity O
at O
sites I-GENE
of O
vascular I-GENE
wall O
damage O
. O

These O
results O
support O
the O
diagnostic O
validity O
of O
_RARE_ I-GENE
in O
CP I-GENE
/ I-GENE
_RARE_ I-GENE
patients O
, O
because O
such O
patients O
had O
a O
family I-GENE
history O
of O
_RARE_ I-GENE
disorder O
similar O
to O
patients O
with O
a O
more O
classical O
_RARE_ I-GENE
disorder O
presentation O
. O

_RARE_ I-GENE
_RARE_ I-GENE
for O
growth I-GENE
factors I-GENE
and O
related I-GENE
products I-GENE
. O

Because O
the O
adrenergic I-GENE
nervous O
system O
influences O
cardiac O
arrhythmias O
and O
myocardial O
infarction O
can O
directly O
affect O
sympathetic O
_RARE_ I-GENE
in O
the O
heart O
, O
we O
investigated O
the O
role O
of O
the O
sympathetic O
nervous O
system O
on O
_RARE_ I-GENE
in O
the O
canine O
heart O
4 I-GENE
days O
after O
infarction O
. O

DESIGN O
: O
Serum I-GENE
aldosterone O
and O
plasma I-GENE
renin I-GENE
activity O
were O
measured O
supine O
prior O
to O
and O
60 O
, O
90 O
, O
120 O
minutes O
after O
oral O
captopril O
, O
25 O
mg O
. O

Furthermore O
, O
no O
transcripts I-GENE
of O
the O
same O
size O
and O
having O
the O
same O
developmental O
profile O
as O
those O
generated O
by O
the O
wild I-GENE
- I-GENE
type I-GENE
_RARE_ I-GENE
fragment I-GENE
were O
identified O
by O
probes O
covering O
the O
_RARE_ I-GENE
of O
the O
cloned O
region O
. O

Intravenous O
amine I-GENE
pressor O
tests O
in O
healthy O
volunteers O
. O

The O
mean O
minimum O
steady O
- I-GENE
state O
concentration O
after O
the O
oral O
regimen O
( O
23 O
micrograms O
. O
l O
- I-GENE
1 I-GENE
) O
was O
78 O
% O
of O
that O
after O
the O
_RARE_ I-GENE
_RARE_ I-GENE
( O
29 O
micrograms O
. O
l O
- I-GENE
1 I-GENE
). O

In O
an O
_RARE_ I-GENE
study O
the O
performance O
of O
the O
_RARE_ I-GENE
is O
being O
compared O
with O
that O
of O
the O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
). O

Both O
parents O
are O
clinically O
normal O
and O
unrelated O
. O

These O
mutant I-GENE
proteins I-GENE
retained O
the O
ability O
to O
_RARE_ I-GENE
inhibit O
kappa I-GENE
B I-GENE
- I-GENE
mediated O
transcriptional O
activation O
of O
the O
human I-GENE
immunodeficiency I-GENE
virus I-GENE
long O
terminal I-GENE
repeat I-GENE
but O
failed O
to O
efficiently O
transform O
chicken I-GENE
lymphoid I-GENE
cells O
both O
in O
vitro O
and O
in O
vivo O
. O

The O
sequence I-GENE
- I-GENE
specific I-GENE
interaction O
of O
nuclear I-GENE
factor I-GENE
_RARE_ I-GENE
- I-GENE
D I-GENE
with O
this O
key O
proximal I-GENE
promoter I-GENE
element I-GENE
of O
the O
H4 I-GENE
- I-GENE
_RARE_ I-GENE
gene I-GENE
is O
cell O
cycle O
regulated O
in O
normal O
diploid O
cells O
( O
J O
. O

In O
conclusion O
, O
to O
study O
and O
overcome O
_RARE_ I-GENE
region O
- I-GENE
based O
expression O
problems O
it O
is O
_RARE_ I-GENE
to O
start O
out O
with O
a O
_RARE_ I-GENE
vector O
containing O
_RARE_ I-GENE
mutations O
in O
the O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
sequences I-GENE
; O
as O
a O
_RARE_ I-GENE
the O
coding O
_RARE_ I-GENE
_RARE_ I-GENE
can O
be O
kept O
unchanged O
. O

Four O
of O
these O
five O
subjects O
also O
performed O
mixed O
sequences I-GENE
under O
conditional O
control O
of O
the O
_RARE_ I-GENE
( O
e O
. O
g O
., O
A1 I-GENE
---- I-GENE
B2 I-GENE
---- I-GENE
A3 I-GENE
---- I-GENE
_RARE_ I-GENE
---- I-GENE
_RARE_ I-GENE
and O
its O
reversal O
), O
_RARE_ I-GENE
that O
the O
stimuli O
which O
occupied O
the O
same O
position O
in O
each O
sequence I-GENE
were O
members O
of O
the O
same O
class I-GENE
. O

_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
ophthalmic O
solution O
( O
0 O
. O
03 O
to O
0 O
. O
24 O
%), O
when O
_RARE_ I-GENE
applied O
to O
the O
eyes O
of O
rabbits O
, O
caused O
dose O
- I-GENE
dependent I-GENE
IOP O
reduction O
( O
2 I-GENE
. O
8 O
to O
5 I-GENE
. O
2 I-GENE
mmHg O
), O
without O
transient O
IOP O
rise O
. O

While O
blood O
pressure O
and O
noradrenergic O
activity O
, O
assessed O
as O
changes O
in O
the O
plasma I-GENE
levels O
and O
urinary O
excretion O
of O
norepinephrine O
, O
remained O
unaffected O
in O
the O
_RARE_ I-GENE
group O
, O
a O
significant O
drop O
in O
the O
supine O
systolic O
and O
diastolic O
blood O
pressures O
, O
as O
well O
as O
in O
the O
resting O
venous O
norepinephrine O
level O
and O
in O
urinary O
norepinephrine O
excretion O
was O
found O
after O
the O
first O
month O
of O
_RARE_ I-GENE
administration O
. O

Wild I-GENE
- I-GENE
type I-GENE
protein I-GENE
bound O
_RARE_ I-GENE
- I-GENE
ATP I-GENE
well O
, O
but O
mutants I-GENE
with O
substitutions O
in O
the O
consensus I-GENE
amino O
acids O
were O
unable O
to O
bind O
_RARE_ I-GENE
- I-GENE
ATP I-GENE
. O

Therefore O
, O
with O
a O
biopsy O
from O
the O
_RARE_ I-GENE
site I-GENE
there O
is O
a O
risk O
of O
missing O
early I-GENE
rejection O
. O

_RARE_ I-GENE
blood O
serotonin I-GENE
levels O
were O
investigated O
in O
a O
control O
group O
( O
n O
= O
35 O
) O
and O
in O
a O
group O
of O
chronic O
renal O
failure O
patients O
( O
n O
= O
_RARE_ I-GENE
) O
on O
various O
treatment O
regimen O
i O
. O
e O
. O
conservative O
treatment O
( O
n O
= O
39 O
), O
maintenance O
haemodialysis O
( O
n O
= O
35 O
) O
and O
after O
renal O
transplantation O
( O
n O
= O
53 O
). O

_RARE_ I-GENE
and O
_RARE_ I-GENE
contain O
sufficient O
thymidine I-GENE
for O
growth I-GENE
of O
anaerobic O
bacteria O
in O
the O
presence O
of O
inhibitory I-GENE
levels O
of O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
. O

The O
homologies O
between O
_RARE_ I-GENE
, O
_RARE_ I-GENE
and O
_RARE_ I-GENE
are O
also O
shared O
by O
several O
additional O
, O
recently O
isolated O
yeast I-GENE
and O
Drosophila I-GENE
genes I-GENE
. O

_RARE_ I-GENE
the O
application O
solutions O
of O
instrument O
_RARE_ I-GENE
should O
not O
be O
used O
longer O
than O
one O
day O
. O

In O
the O
_RARE_ I-GENE
syndrome O
we O
, O
therefore O
, O
_RARE_ I-GENE
there O
are O
disturbances O
in O
the O
brain O
stem O
functions O
especially O
in O
the O
ascending O
_RARE_ I-GENE
activating I-GENE
system O
which O
is O
related I-GENE
to O
elevation O
of O
the O
conscious O
level O
. O

In O
a O
similar O
experiment O
, O
simultaneous O
_RARE_ I-GENE
administration O
and O
S I-GENE
. O
_RARE_ I-GENE
challenge O
resulted O
in O
no O
significant O
differences O
in O
S I-GENE
. O
_RARE_ I-GENE
isolation O
frequency O
. O

In O
agreement O
with O
this O
southern O
blotting O
of O
mouse I-GENE
DNA I-GENE
with O
_RARE_ I-GENE
probes O
reveals O
bands O
, O
additional O
to O
those O
derived O
from O
the O
pseudogene I-GENE
, O
which O
are O
characteristic O
of O
an O
intron O
- I-GENE
containing O
_RARE_ I-GENE
gene I-GENE
. O

Two O
cDNAs I-GENE
encoding O
casein I-GENE
kinase I-GENE
- I-GENE
1 I-GENE
have O
been O
isolated O
from O
a O
yeast I-GENE
cDNA I-GENE
library O
and O
termed O
_RARE_ I-GENE
and O
_RARE_ I-GENE
. O

_RARE_ I-GENE
rate O
ranging O
between O
122 O
/ I-GENE
100 O
, O
000 O
/ I-GENE
year O
and O
190 O
/ I-GENE
100 O
, O
000 O
/ I-GENE
year O
were O
found O
( O
minimum O
, O
estimated O
and O
_RARE_ I-GENE
_RARE_ I-GENE
). O

The O
observed O
sequence I-GENE
variation O
_RARE_ I-GENE
the O
first O
ORF I-GENE
in O
many O
Y I-GENE
' O
s O
while O
most O
of O
the O
second O
ORF I-GENE
including O
the O
putative O
helicase I-GENE
region O
is O
unaffected O
. O

The O
final O
screening O
yielded O
a O
clone O
containing O
a O
2 I-GENE
kilobase O
( O
kb O
) O
insert O
. O

_RARE_ I-GENE
were O
made O
by O
pressure O
injection O
of O
_RARE_ I-GENE
acid I-GENE
into O
the O
_RARE_ I-GENE
through O
a O
_RARE_ I-GENE
positioned O
glass O
_RARE_ I-GENE
. O

A I-GENE
38 O
- I-GENE
bp O
poly O
( O
_RARE_ I-GENE
- I-GENE
dT O
) O
region O
was O
found O
to O
be O
a O
positive O
regulator I-GENE
of O
_RARE_ I-GENE
promoter I-GENE
activity O
. O

We O
identified O
a O
protein I-GENE
, O
termed O
_RARE_ I-GENE
- I-GENE
1 I-GENE
beta I-GENE
A I-GENE
( O
NF I-GENE
beta I-GENE
A I-GENE
), O
that O
binds O
to O
a O
highly O
conserved O
12 O
- I-GENE
bp O
DNA I-GENE
sequence I-GENE
(- O
49 O
to O
- I-GENE
38 O
) O
located O
upstream O
of O
the O
TATA I-GENE
box I-GENE
motif I-GENE
in O
both O
the O
human I-GENE
and O
murine I-GENE
IL I-GENE
- I-GENE
1 I-GENE
beta I-GENE
genes I-GENE
. O

We O
_RARE_ I-GENE
amphotericin O
B I-GENE
( O
_RARE_ I-GENE
), O
and O
remission O
of O
the O
tumor I-GENE
was O
obtained O
. O

_RARE_ I-GENE
_RARE_ I-GENE
. O

The O
_RARE_ I-GENE
- I-GENE
2 I-GENE
nuclear I-GENE
protein I-GENE
has O
characteristics O
similar O
to O
those O
of O
the O
muscle O
- I-GENE
specific I-GENE
regulatory I-GENE
factor I-GENE
, O
MEF I-GENE
- I-GENE
2 I-GENE
( O
_RARE_ I-GENE
and O
_RARE_ I-GENE
1989 O
; O
_RARE_ I-GENE
et O
al O
., O
1989 O
). O

From O
the O
15 O
- I-GENE
kb O
clone O
a O
4 I-GENE
- I-GENE
kb O
EcoRI I-GENE
fragment I-GENE
containing O
the O
first O
two O
exons O
and O
2 I-GENE
. O
6 I-GENE
kb O
of O
the O
5 I-GENE
' O
flanking O
region O
of O
the O
_RARE_ I-GENE
gene I-GENE
was O
sequenced O
, O
and O
the O
transcriptional O
start O
site I-GENE
determined O
by O
primer O
extension O
analysis O
and O
S1 I-GENE
nuclease I-GENE
mapping O
. O

_RARE_ I-GENE
risk O
factors I-GENE
were O
measured O
by O
standardized O
techniques O
. O

_RARE_ I-GENE
costs O
included O
feed O
, O
non O
- I-GENE
feed O
operating O
, O
fixed O
, O
and O
replacement O
_RARE_ I-GENE
costs O
. O

We O
report O
a O
patient O
developing O
factor I-GENE
VII I-GENE
inhibitor I-GENE
possibly O
as O
a O
reaction O
to O
penicillin I-GENE
administration O
; O
it O
gave O
rise O
to O
fatal O
_RARE_ I-GENE
. O

This O
is O
in O
contrast O
with O
the O
classical O
' O
oxygen O
_RARE_ I-GENE
hypothesis O
', O
which O
states O
that O
the O
oxygen O
_RARE_ I-GENE
and O
lactate I-GENE
clearance O
are O
linked O
. O

_RARE_ I-GENE
was O
taken O
of O
_RARE_ I-GENE
and O
_RARE_ I-GENE
elements O
in O
the O
smears O
; O
they O
included O
mucus O
, O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
, O
pollen O
_RARE_ I-GENE
, O
_RARE_ I-GENE
fragments I-GENE
and O
_RARE_ I-GENE
. O

The O
results O
indicate O
that O
the O
carbon O
- I-GENE
perfused O
areas O
and O
_RARE_ I-GENE
in O
the O
liver O
, O
renal O
cortex O
, O
spleen O
, O
and O
small I-GENE
intestinal O
_RARE_ I-GENE
( O
only O
_RARE_ I-GENE
) O
increased O
significantly O
5 I-GENE
h O
after O
_RARE_ I-GENE
. O

In O
addition O
a O
greater O
proportion O
of O
women O
in O
the O
_RARE_ I-GENE
group O
had O
a O
cervical O
dilatation O
of O
4 I-GENE
cm O
or O
more O
at O
the O
first O
vaginal O
examination O
in O
the O
labour O
_RARE_ I-GENE
( O
16 O
/ I-GENE
33 O
( O
49 O
%) O
vs O
5 I-GENE
/ I-GENE
32 O
( O
16 O
_RARE_ I-GENE
OR O
4 I-GENE
. O
39 O
; O
95 O
% O
CI O
1 I-GENE
. O
56 O
to O
12 O
. O
32 O
; O
P I-GENE
= O
0 O
. O
005 O
). O

_RARE_ I-GENE
, O
N I-GENE
. O

A I-GENE
control O
group O
of O
nine O
women O
( O
age O
23 O
- I-GENE
40 I-GENE
years O
) O
on O
oral O
_RARE_ I-GENE
( O
_RARE_ I-GENE
- I-GENE
28 O
) O
was O
also O
studied O
four O
times O
during O
a O
_RARE_ I-GENE
cycle O
. O

This O
accurate O
and O
rapid O
method O
makes O
the O
_RARE_ I-GENE
test O
_RARE_ I-GENE
_RARE_ I-GENE
for O
large O
- I-GENE
scale O
screening O
. O

The O
modalities O
for O
using O
reference O
values O
for O
individual O
subjects O
as O
well O
as O
for O
groups O
are O
then O
discussed O
and O
the O
main O
points O
of O
research O
which O
must O
be O
_RARE_ I-GENE
in O
the O
near O
future O
regarding O
reference O
values O
are O
_RARE_ I-GENE
. O

The O
clinical O
application O
of O
the O
antibody I-GENE
- I-GENE
targeted O
_RARE_ I-GENE
was O
performed O
in O
3 I-GENE
patients O
suffering O
from O
an O
advanced O
ovarian O
carcinoma O
( O
_RARE_ I-GENE
III I-GENE
). O

We O
found O
that O
lung O
cancer O
tissues O
of O
positive O
_RARE_ I-GENE
scan O
expressed O
_RARE_ I-GENE
, O
but O
those O
of O
a O
negative O
scan O
did O
not O
. O

This O
open O
reading O
frame O
was O
confirmed O
the O
correct O
one O
by O
direct O
amino O
- I-GENE
terminal I-GENE
sequence I-GENE
analysis O
of O
the O
_RARE_ I-GENE
_RARE_ I-GENE
gene I-GENE
product I-GENE
. O

In O
this O
study O
, O
we O
purified O
and O
characterized O
the O
recombinant I-GENE
_RARE_ I-GENE
from O
the O
conditioned O
medium O
of O
these O
cells O
. O

The O
virus I-GENE
encodes O
a O
40 I-GENE
- I-GENE
kDa I-GENE
protein I-GENE
, O
_RARE_ I-GENE
, O
that O
is O
important O
for O
the O
_RARE_ I-GENE
of O
T I-GENE
cells O
. O

However O
, O
_RARE_ I-GENE
was O
at O
least O
2 I-GENE
- I-GENE
fold O
more O
effective O
in O
stimulating I-GENE
CAT I-GENE
activity O
of O
fusion I-GENE
genes I-GENE
containing O
upstream O
sequences I-GENE
(- O
_RARE_ I-GENE
to O
- I-GENE
_RARE_ I-GENE
) O
than O
those O
containing O
proximal I-GENE
sequences I-GENE
(- O
_RARE_ I-GENE
to O
- I-GENE
_RARE_ I-GENE
), O
suggesting O
two O
regions O
in O
the O
_RARE_ I-GENE
- I-GENE
I I-GENE
gene I-GENE
that O
mediate O
the O
_RARE_ I-GENE
response O
. O

An O
examination O
of O
the O
role O
of O
the O
carboxyl O
terminus O
in O
regulating O
_RARE_ I-GENE
- I-GENE
B I-GENE
transcriptional O
activity O
revealed O
that O
, O
in O
_RARE_ I-GENE
with O
other O
nuclear I-GENE
receptors I-GENE
, O
mutants I-GENE
lacking O
portions O
of O
the O
carboxyl O
terminus O
had O
greatly O
decreased O
activity O
. O

Altogether O
these O
results O
indicate O
that O
the O
_RARE_ I-GENE
5 I-GENE
locus I-GENE
_RARE_ I-GENE
from O
the O
gene I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
, O
to O
a O
region O
encompassing O
portions O
of O
the O
TK I-GENE
and O
_RARE_ I-GENE
24 O
genes I-GENE
, O
and O
that O
the O
_RARE_ I-GENE
mutation I-GENE
does O
not O
affect O
the O
expression O
or O
activity O
of O
TK I-GENE
. O

_RARE_ I-GENE
( O
N I-GENE
) O
expressed O
by O
both O
recombinant I-GENE
vaccinia I-GENE
virus I-GENE
and O
_RARE_ I-GENE
had O
a O
relative O
molecular O
mass O
( O
Mr O
) O
of O
47 O
, O
000 O
and O
was O
susceptible O
to O
degradation O
at O
the O
C I-GENE
- I-GENE
terminus O
_RARE_ I-GENE
discrete O
_RARE_ I-GENE
products I-GENE
. O

Recently O
, O
the O
3 I-GENE
. O
6 I-GENE
- I-GENE
kb O
full I-GENE
- I-GENE
length I-GENE
alpha I-GENE
- I-GENE
_RARE_ I-GENE
cDNA I-GENE
sequence I-GENE
was O
isolated O
and O
found O
to O
have O
remarkable O
nucleotide I-GENE
and O
predicted O
amino O
acid I-GENE
homology I-GENE
( O
55 O
. O
8 O
and O
46 O
. O
9 O
%, O
respectively O
) O
with O
the O
human I-GENE
alpha I-GENE
- I-GENE
galactosidase I-GENE
A I-GENE
( O
alpha I-GENE
- I-GENE
Gal I-GENE
A I-GENE
) O
cDNA I-GENE
. O

Patients O
with O
an O
enzymatic O
activity O
below O
X I-GENE
-- O
1 I-GENE
manifested O
a O
decrease O
of O
the O
content O
of O
IgA I-GENE
, O
IgG I-GENE
, O
IgM I-GENE
, O
T I-GENE
and O
B I-GENE
lymphocytes O
, O
and O
of O
phagocytic O
activity O
of O
neutrophils O
as O
compared O
to O
patients O
exhibiting O
a O
high O
enzymatic O
activity O
. O

The O
_RARE_ I-GENE
that O
_RARE_ I-GENE
oxide I-GENE
does O
not O
produce O
_RARE_ I-GENE
radicals O
readily O
might O
be O
that O
the O
one O
- I-GENE
electron O
reduction O
_RARE_ I-GENE
through O
an O
N2O O
- I-GENE
intermediate O
which O
is O
_RARE_ I-GENE
very O
_RARE_ I-GENE
: O
_RARE_ I-GENE
( O
N2O O
/ I-GENE
N2O O
-) I-GENE
= O
- I-GENE
1 I-GENE
. O
1 I-GENE
V I-GENE
. O

All O
mutant I-GENE
_RARE_ I-GENE
T I-GENE
antigens I-GENE
bound O
to O
_RARE_ I-GENE
and O
SV40 I-GENE
origins O
of O
DNA I-GENE
replication O
. O

The O
relation O
between O
myocardial O
beta I-GENE
- I-GENE
adrenergic I-GENE
receptor I-GENE
and O
left O
ventricular O
( O
LV O
) O
function O
was O
studied O
in O
10 O
patients O
, O
aged O
41 O
to O
61 O
years O
( O
average O
51 O
), O
with O
LV O
volume O
overload O
mainly O
due O
to O
chronic O
mitral O
_RARE_ I-GENE
. O

Since O
each O
transcript I-GENE
appears O
to O
encode O
the O
same O
protein I-GENE
, O
this O
complexity O
may O
reflect O
the O
need O
for O
lineage O
- I-GENE
specific I-GENE
or O
differentiation O
- I-GENE
dependent I-GENE
control O
of O
expression O
. O

In O
patients O
with O
limited O
disease O
, O
the O
survival O
in O
the O
_RARE_ I-GENE
arm O
was O
significantly O
superior O
to O
the O
survival O
in O
the O
_RARE_ I-GENE
arm O
( O
P I-GENE
= O
. O
_RARE_ I-GENE
) O
or O
the O
survival O
in O
the O
PE I-GENE
arm O
( O
P I-GENE
= O
. O
_RARE_ I-GENE
). O

We O
identify O
the O
" O
M I-GENE
region O
" O
of O
the O
muscle O
- I-GENE
specific I-GENE
Xenopus I-GENE
cardiac O
actin I-GENE
gene I-GENE
promoter I-GENE
from O
- I-GENE
_RARE_ I-GENE
to O
- I-GENE
_RARE_ I-GENE
as O
necessary O
for O
the O
embryonic O
expression O
of O
a O
cardiac O
actin I-GENE
- I-GENE
beta I-GENE
- I-GENE
globin I-GENE
reporter I-GENE
gene I-GENE
injected O
into O
_RARE_ I-GENE
eggs O
. O

In O
addition O
to O
the O
previously O
identified O
and O
characterized O
_RARE_ I-GENE
1 I-GENE
situated O
93 O
nucleotides O
downstream O
from O
the O
major I-GENE
late O
transcription I-GENE
start O
site I-GENE
, O
a O
second O
_RARE_ I-GENE
, O
_RARE_ I-GENE
2 I-GENE
, O
situated O
55 O
nucleotides O
downstream O
from O
it O
, O
has O
been O
identified O
. O

EBNA I-GENE
- I-GENE
2 I-GENE
and O
the O
cis O
- I-GENE
acting O
CD23 I-GENE
element I-GENE
increased O
TK I-GENE
- I-GENE
promoted O
mRNA I-GENE
and O
did O
not O
alter O
the O
herpes I-GENE
simplex I-GENE
virus I-GENE
TK I-GENE
promoter I-GENE
transcription I-GENE
start O
site I-GENE
. O

These O
experiments O
_RARE_ I-GENE
a O
186 I-GENE
- I-GENE
bp O
, O
EBNA I-GENE
- I-GENE
2 I-GENE
- I-GENE
responsive I-GENE
cell O
DNA I-GENE
fragment I-GENE
and O
provide O
_RARE_ I-GENE
evidence O
that O
EBNA I-GENE
- I-GENE
2 I-GENE
transactivates O
transcription I-GENE
of O
cell O
genes I-GENE
. O

Plasma I-GENE
vitamin O
E I-GENE
, O
total O
lipids O
and O
_RARE_ I-GENE
levels O
during O
spinal O
surgery O
. O

_RARE_ I-GENE
the O
cloned O
bovine I-GENE
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
cDNA I-GENE
into O
COS O
- I-GENE
7 O
cells O
resulted O
in O
an O
11 O
- I-GENE
fold O
increase O
in O
the O
density I-GENE
of O
high O
affinity O
[ O
3H O
] O
PK I-GENE
_RARE_ I-GENE
binding I-GENE
sites I-GENE
which O
had O
only O
low O
affinity O
for O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
. O

The O
initial O
phase O
of O
increased O
vascular I-GENE
permeability I-GENE
in O
the O
peritoneal O
cavity O
and O
_RARE_ I-GENE
production O
was O
dose O
dependently O
inhibited O
by O
the O
5 I-GENE
- I-GENE
_RARE_ I-GENE
inhibitors O
_RARE_ I-GENE
, O
_RARE_ I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
but O
not O
by O
dexamethasone O
or O
_RARE_ I-GENE
. O

_RARE_ I-GENE
results O
with O
a O
latex O
agglutination I-GENE
test O
in O
the O
assessment O
of O
cytomegalovirus I-GENE
antibody I-GENE
status O
of O
cardiac O
transplant O
donors O
. O

Each O
mRNA I-GENE
contained O
five O
or O
six O
internal O
_RARE_ I-GENE
residues O
, O
which O
were O
transcribed O
using O
a O
mixture O
of O
_RARE_ I-GENE
and O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
. O

We O
have O
isolated O
and O
sequenced O
two O
overlapping O
cDNA I-GENE
fragments I-GENE
which O
could O
encode O
the O
complete O
amino O
acid I-GENE
sequence I-GENE
of O
rat I-GENE
testis I-GENE
fructose I-GENE
- I-GENE
6 I-GENE
- I-GENE
phosphate I-GENE
, O
2 I-GENE
- I-GENE
kinase I-GENE
: O
fructose I-GENE
- I-GENE
2 I-GENE
, O
6 I-GENE
- I-GENE
_RARE_ I-GENE
. O

We O
have O
identified O
_RARE_ I-GENE
' O
s O
nuclear I-GENE
localization O
signal I-GENE
( O
NLS O
) O
and O
show O
that O
it O
can O
confer O
cell O
cycle O
- I-GENE
dependent I-GENE
nuclear I-GENE
entry O
to O
a O
heterologous O
protein I-GENE
. O

In O
contrast O
to O
behavioral O
deviation O
( O
the O
_RARE_ I-GENE
conditioning O
lost O
), O
the O
haloperidol O
_RARE_ I-GENE
_RARE_ I-GENE
did O
not O
affect O
the O
DA I-GENE
synaptic O
level O
in O
_RARE_ I-GENE
_RARE_ I-GENE
. O

In O
similar O
transient O
transfection O
experiments O
in O
HeLa O
cells O
, O
overexpression O
of O
the O
wt I-GENE
human I-GENE
retinoblastoma I-GENE
susceptibility I-GENE
gene I-GENE
product I-GENE
, O
RB I-GENE
, O
was O
found O
to O
repress O
the O
serum I-GENE
- I-GENE
induced O
IL I-GENE
- I-GENE
6 I-GENE
(- O
_RARE_ I-GENE
to O
+ I-GENE
13 O
), O
c I-GENE
- I-GENE
fos I-GENE
(- O
_RARE_ I-GENE
to O
+ I-GENE
42 O
), O
and O
beta I-GENE
- I-GENE
actin I-GENE
(- O
_RARE_ I-GENE
to O
+ I-GENE
_RARE_ I-GENE
) O
promoters I-GENE
but O
not O
the O
_RARE_ I-GENE
- I-GENE
induced O
IL I-GENE
- I-GENE
6 I-GENE
(- O
110 I-GENE
to O
+ I-GENE
13 O
) O
or O
the O
serum I-GENE
- I-GENE
induced O
MHC I-GENE
(- O
_RARE_ I-GENE
to O
- I-GENE
38 O
) O
promoters I-GENE
. O

This O
repression O
was O
mediated O
through O
binding I-GENE
to O
the O
E2 I-GENE
DNA I-GENE
- I-GENE
binding I-GENE
site I-GENE
immediately O
upstream O
of O
the O
_RARE_ I-GENE
promoter I-GENE
TATA I-GENE
box I-GENE
and O
could O
be O
abrogated O
by O
_RARE_ I-GENE
of O
the O
HPV I-GENE
- I-GENE
18 O
_RARE_ I-GENE
promoter I-GENE
template O
with O
the O
nuclear I-GENE
extract O
allowing O
the O
formation O
of O
the O
_RARE_ I-GENE
complex I-GENE
. O

We O
did O
not O
detect O
p50 I-GENE
in O
association O
with O
native O
glucocorticoid I-GENE
receptor I-GENE
in O
L I-GENE
cells O
or O
with O
the O
overexpressed O
glucocorticoid I-GENE
receptor I-GENE
in O
Chinese O
hamster I-GENE
ovary O
cells O
. O

Two O
putative O
12 O
- I-GENE
O O
- I-GENE
_RARE_ I-GENE
- I-GENE
phorbol O
- I-GENE
13 O
- I-GENE
acetate O
( O
TPA O
) O
response O
elements O
, O
that O
might O
serve O
as O
binding I-GENE
sites I-GENE
for O
the O
transcription I-GENE
factor I-GENE
AP I-GENE
- I-GENE
1 I-GENE
and O
a O
consensus I-GENE
sequence I-GENE
of O
a O
transforming I-GENE
growth I-GENE
factor I-GENE
beta I-GENE
1 I-GENE
( O
TGF I-GENE
- I-GENE
beta I-GENE
1 I-GENE
) O
inhibitory I-GENE
element I-GENE
were O
found O
in O
the O
promoter I-GENE
region O
. O

TPA O
and O
TGF I-GENE
- I-GENE
beta I-GENE
1 I-GENE
did O
not O
markedly O
affect O
the O
activities O
of O
the O
72 O
- I-GENE
kDa I-GENE
enzyme I-GENE
. O

They O
were O
almost O
_RARE_ I-GENE
_RARE_ I-GENE
by O
pressure O
to O
the O
ipsilateral O
_RARE_ I-GENE
or O
to O
both O
_RARE_ I-GENE
at O
a O
strength O
well O
above O
the O
human I-GENE
corneal O
pain O
threshold O
. O

_RARE_ I-GENE
intake O
was O
not O
affected O
by O
dietary O
_RARE_ I-GENE
or O
_RARE_ I-GENE
supplementation O
, O
but O
average O
daily O
gain O
increased O
with O
increased O
K I-GENE
and O
tended O
to O
be O
reduced O
by O
dietary O
_RARE_ I-GENE
. O

_RARE_ I-GENE
procedure O
for O
the O
measurement O
of O
_RARE_ I-GENE
compounds O
in O
biological O
tissues O
using O
toluene O
, O
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
. O

In O
this O
study O
, O
we O
have O
cloned O
a O
region O
that O
_RARE_ I-GENE
the O
_RARE_ I-GENE
S I-GENE
- I-GENE
deficient O
phenotype O
of O
strain O
_RARE_ I-GENE
_RARE_ I-GENE
:: O
_RARE_ I-GENE
, O
a O
chromosomal I-GENE
_RARE_ I-GENE
insertional I-GENE
mutation I-GENE
. O

_RARE_ I-GENE
, O
a O
transforming I-GENE
gene I-GENE
isolated O
from O
primary O
human I-GENE
myeloid O
leukemia I-GENE
cells O
, O
encodes O
a O
novel O
receptor I-GENE
tyrosine I-GENE
kinase I-GENE
. O

_RARE_ I-GENE
of O
the O
amino O
acid I-GENE
sequences I-GENE
surrounding O
Tyr I-GENE
- I-GENE
_RARE_ I-GENE
with O
corresponding O
regions O
of O
other O
_RARE_ I-GENE
revealed O
conserved O
tyrosine I-GENE
residues O
in O
all O
known O
members O
of O
the O
FGFR I-GENE
family I-GENE
. O

The O
single O
most O
important O
element I-GENE
, O
by O
linker I-GENE
- I-GENE
scanning O
analysis O
, O
is O
a O
10 O
- I-GENE
bp O
region O
that O
contains O
a O
CCAAT I-GENE
motif I-GENE
. O

_RARE_ I-GENE
curves O
of O
40 I-GENE
HVS O
patients O
, O
40 I-GENE
non O
- I-GENE
HVS O
patients O
with O
_RARE_ I-GENE
- I-GENE
somatic O
_RARE_ I-GENE
and O
26 O
healthy O
controls O
were O
analyzed O
. O

The O
transcription I-GENE
initiation I-GENE
site I-GENE
was O
determined O
to O
occur O
66 O
bp O
upstream O
of O
the O
initiating O
Met I-GENE
. O

All O
anti I-GENE
- I-GENE
I I-GENE
and O
anti I-GENE
- I-GENE
i O
CA I-GENE
were O
shown O
to O
express O
_RARE_ I-GENE
heavy I-GENE
chains I-GENE
, O
and O
14 O
of O
17 O
CA I-GENE
expressed O
a O
previously O
described O
_RARE_ I-GENE
second O
_RARE_ I-GENE
region O
determinant O
, O
termed O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
. O

Intron I-GENE
K1 I-GENE
_RARE_ I-GENE
. O
2 I-GENE
is O
not O
found O
in O
S I-GENE
. O
cerevisiae I-GENE
and O
appears O
at O
an O
unique O
location O
in O
K I-GENE
. O
lactis O
. O

We O
have O
determined O
that O
the O
mutants I-GENE
define O
two O
complementation O
groups O
, O
designated O
_RARE_ I-GENE
+ I-GENE
and O
_RARE_ I-GENE
+ I-GENE
( O
_RARE_ I-GENE
to O
grow O
in O
stationary O
). O

However O
, O
alterations O
in O
_RARE_ I-GENE
and O
hydrophobic O
interactions O
created O
by O
the O
three O
amino O
acid I-GENE
substitutions O
prevent O
the O
conformational O
change O
in O
the O
enzyme I-GENE
usually O
produced O
by O
calmodulin I-GENE
binding I-GENE
. O

The O
results O
of O
induced O
coexpression O
were O
also O
supported O
by O
rapid O
generation O
of O
_RARE_ I-GENE
recombinants I-GENE
when O
_RARE_ I-GENE
- I-GENE
C I-GENE
was O
used O
to O
_RARE_ I-GENE
the O
feline I-GENE
_RARE_ I-GENE
cell O
line O
that O
constitutively O
_RARE_ I-GENE
high O
levels O
of O
endogenous I-GENE
_RARE_ I-GENE
- I-GENE
specific I-GENE
mRNAs I-GENE
. O

_RARE_ I-GENE
between O
feline I-GENE
leukemia I-GENE
virus I-GENE
subgroup O
B I-GENE
or O
C I-GENE
and O
endogenous I-GENE
env I-GENE
elements O
alters O
the O
in O
vitro O
biological O
activities O
of O
the O
viruses O
. O

The O
nucleotide I-GENE
sequences I-GENE
at O
the O
5 I-GENE
' O
and O
3 I-GENE
' O
ends O
of O
these O
introns O
are O
characteristic O
of O
spliced O
transcripts I-GENE
from O
eukaryotic I-GENE
protein I-GENE
- I-GENE
encoding O
genes I-GENE
, O
with O
one O
significant O
difference O
; O
i O
. O
e O
., O
the O
5 I-GENE
' O
end O
of O
the O
_RARE_ I-GENE
intron O
is O
GC I-GENE
instead O
of O
the O
consensus I-GENE
sequence I-GENE
GT I-GENE
. O

At O
1 I-GENE
, O
5 I-GENE
, O
and O
9 O
months O
after O
initial O
isolation O
of O
C I-GENE
. O
_RARE_ I-GENE
from O
the O
oral O
cavity O
, O
hamsters O
were O
_RARE_ I-GENE
, O
and O
attempts O
were O
made O
to O
culture O
C I-GENE
. O
_RARE_ I-GENE
from O
13 O
additional O
sites I-GENE
. O

The O
strategy O
has O
been O
used O
to O
determine O
2 I-GENE
. O
6 I-GENE
kilobases O
of O
nucleotide I-GENE
sequence I-GENE
in O
the O
Saccharomyces I-GENE
cerevisiae I-GENE
_RARE_ I-GENE
1 I-GENE
locus I-GENE
. O

Two O
independent O
promoters I-GENE
as O
well O
as O
5 I-GENE
' O
untranslated O
regions O
regulate O
_RARE_ I-GENE
ras I-GENE
expression O
in O
Dictyostelium O
. O

The O
results O
suggested O
that O
, O
depending O
upon O
the O
cell O
type I-GENE
, O
gene I-GENE
_RARE_ I-GENE
using O
_RARE_ I-GENE
resistance O
as O
a O
selectable O
marker O
may O
_RARE_ I-GENE
_RARE_ I-GENE
important O
cellular O
control O
mechanisms O
such O
as O
the O
PKC I-GENE
pathway O
leading O
to O
activation O
of O
gene I-GENE
expression O
. O

_RARE_ I-GENE
RNA I-GENE
genes I-GENE
from O
Dictyostelium O
_RARE_ I-GENE
are O
frequently O
associated I-GENE
with O
repetitive O
elements O
and O
contain O
consensus I-GENE
boxes O
in O
their O
5 I-GENE
' O
and O
3 I-GENE
'- O
flanking O
regions O
. O

Therefore O
, O
the O
_RARE_ I-GENE
and O
_RARE_ I-GENE
genes I-GENE
could O
serve O
as O
_RARE_ I-GENE
probes O
indicative O
of O
the O
presence O
of O
biosynthetic O
capacity O
for O
6 I-GENE
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
. O

The O
two O
genes I-GENE
code O
for O
polypeptides I-GENE
of O
_RARE_ I-GENE
amino O
acids O
( O
M I-GENE
. O
_RARE_ I-GENE
) O
and O
_RARE_ I-GENE
amino O
acids O
( O
R I-GENE
. O
_RARE_ I-GENE
). O

Expression O
of O
the O
_RARE_ I-GENE
gene I-GENE
via O
transient O
transfection O
in O
COS O
- I-GENE
1 I-GENE
cells O
revealed O
a O
52 O
kDa I-GENE
protein I-GENE
which O
was O
immunoprecipitated O
by O
both O
the O
N I-GENE
- I-GENE
terminal I-GENE
- I-GENE
and O
C I-GENE
- I-GENE
terminal I-GENE
- I-GENE
specific I-GENE
antisera O
. O

The O
factor I-GENE
which O
binds O
to O
the O
TR I-GENE
promoter I-GENE
co O
- I-GENE
_RARE_ I-GENE
with O
SV40 I-GENE
chromosomes O
extracted O
late O
in O
infection O
. O

_RARE_ I-GENE
400 O
mg O
b I-GENE
. O
i O
. O
d O
. O
administered O
orally O
for O
28 O
days O
represents O
a O
safe O
and O
effective O
treatment O
for O
chronic O
bacterial I-GENE
_RARE_ I-GENE
. O

Its O
neuromuscular O
effects O
are O
similar O
to O
a O
single O
_RARE_ I-GENE
dose O
of O
_RARE_ I-GENE
. O

The O
patient O
with O
a O
prolonged O
fever O
caused O
by O
_RARE_ I-GENE
_RARE_ I-GENE
of O
the O
aorta O
in O
whom O
_RARE_ I-GENE
_RARE_ I-GENE
the O
real O
diseases O
has O
been O
presented O
. O

The O
resulting O
clone O
_RARE_ I-GENE
, O
which O
has O
a O
_RARE_ I-GENE
- I-GENE
base O
pair O
( O
bp O
) O
cDNA I-GENE
insert O
, O
overlapping O
_RARE_ I-GENE
by O
_RARE_ I-GENE
bp O
, O
was O
identified O
by O
hybridization O
methods O
and O
sequence I-GENE
analysis O
and O
found O
to O
contain O
the O
entire O
cDNA I-GENE
sequence I-GENE
for O
the O
amino O
end O
of O
the O
CAD I-GENE
polypeptide I-GENE
. O

This O
conclusion O
was O
confirmed O
by O
Northern O
blotting O
analysis O
of O
the O
5 I-GENE
'- O
flanking O
region O
of O
CAD I-GENE
gene I-GENE
. O

We O
report O
the O
isolation O
of O
genomic O
and O
cDNA I-GENE
clones O
of O
the O
light I-GENE
- I-GENE
independent O
_RARE_ I-GENE
: O
_RARE_ I-GENE
allele I-GENE
. O

_RARE_ I-GENE
- I-GENE
2 I-GENE
blockade O
in O
psoriasis O

Its O
clearance O
has O
been O
found O
to O
be O
decreased O
( O
typically O
by O
around O
25 O
%, O
but O
often O
by O
far O
more O
) O
by O
_RARE_ I-GENE
, O
_RARE_ I-GENE
( O
_RARE_ I-GENE
), O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
T I-GENE
- I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
acid I-GENE
, O
cimetidine O
, O
_RARE_ I-GENE
, O
propranolol O
, O
verapamil O
, O
diltiazem O
, O
nifedipine O
, O
furosemide O
( O
_RARE_ I-GENE
), O
at O
least O
some O
_RARE_ I-GENE
agents O
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
influenza I-GENE
- I-GENE
and O
BCG O
- I-GENE
vaccination O
, O
interferon I-GENE
, O
and O
caffeine O
( O
half O
- I-GENE
life O
increase O
). O

A I-GENE
third O
is O
a O
partial O
element I-GENE
_RARE_ I-GENE
at O
a O
probable O
internal O
restriction I-GENE
site I-GENE
used O
for O
cloning O
. O

We O
enrolled O
_RARE_ I-GENE
HIV I-GENE
- I-GENE
antibody I-GENE
positive O
_RARE_ I-GENE
addicts O
without O
HIV I-GENE
- I-GENE
related I-GENE
disease O
( O
n O
= O
81 O
) O
or O
with O
persistent O
generalized O
_RARE_ I-GENE
( O
n O
= O
_RARE_ I-GENE
) O
in O
a O
prospective O
study O
to O
evaluate O
clinical O
progression O
to O
AIDS O
related I-GENE
complex I-GENE
( O
ARC I-GENE
) O
or O
AIDS O
and O
to O
identify O
factors I-GENE
of O
possible O
prognostic O
relevance O
. O

No O
homology I-GENE
was O
found O
between O
_RARE_ I-GENE
and O
_RARE_ I-GENE
or O
between O
_RARE_ I-GENE
and O
other O
proteins I-GENE
contained O
in O
data O
_RARE_ I-GENE
. O

Mutations O
in O
the O
yeast I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
genes I-GENE
result O
in O
an O
abnormal O
mRNA I-GENE
decay O
rate O
; O
sequence I-GENE
analysis O
reveals O
an O
RNA I-GENE
- I-GENE
binding I-GENE
domain I-GENE
in O
the O
_RARE_ I-GENE
protein I-GENE
. O

Myocardial O
infarction O
in O
patients O
with O
previous O
bypass O
surgery O
. O

The O
most O
striking O
difference O
in O
the O
_RARE_ I-GENE
NAD I-GENE
( O
P I-GENE
) O
H I-GENE
- I-GENE
_RARE_ I-GENE
sequence I-GENE
in O
comparison O
to O
NADH I-GENE
- I-GENE
_RARE_ I-GENE
sequences I-GENE
was O
found O
at O
the O
putative O
_RARE_ I-GENE
nucleotide I-GENE
binding I-GENE
site I-GENE
. O

A I-GENE
single O
amino O
acid I-GENE
difference O
in O
the O
C I-GENE
- I-GENE
terminal I-GENE
region O
influences O
dominant I-GENE
negative O
activity O
and O
receptor I-GENE
dimer O
formation O
. O

No O
such O
benefits O
were O
seen O
for O
children O
with O
CD4 I-GENE
+ I-GENE
counts O
below O
0 O
. O
2 I-GENE
x O
10 O
( O
9 O
) O
per O
liter O
at O
entry O
. O

Because O
the O
human I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
binding I-GENE
protein I-GENE
is O
expressed O
in O
both O
lymphoid I-GENE
and O
non O
- I-GENE
lymphoid I-GENE
cells O
, O
we O
suggest O
that O
this O
homeobox I-GENE
gene I-GENE
has O
evolved O
a O
more O
general O
transcriptional O
regulatory I-GENE
function O
in O
higher O
eukaryotic I-GENE
cells O
. O

The O
95 O
% O
confidence O
values O
( O
_RARE_ I-GENE
) O
for O
the O
change O
in O
_RARE_ I-GENE
required O
to O
_RARE_ I-GENE
natural O
variability O
were O
0 O
. O
39 O
, O
0 O
. O
50 O
and O
0 O
. O
53 O
cmH2O O
l O
- I-GENE
1 I-GENE
s O
, O
respectively O
. O

Among O
_RARE_ I-GENE
infants O
in O
22 O
neonatal O
care O
units O
studied O
, O
23 O
% O
( O
median O
value O
, O
range O
0 O
- I-GENE
78 O
) O
were O
found O
to O
be O
_RARE_ I-GENE
_RARE_ I-GENE
with O
one O
of O
21 O
distinct O
_RARE_ I-GENE
strains O
of O
Escherichia I-GENE
coli I-GENE
, O
Klebsiella I-GENE
or O
_RARE_ I-GENE
_RARE_ I-GENE
. O

Biochemical O
studies O
revealed O
the O
expected O
loss O
of O
_RARE_ I-GENE
activity O
in O
the O
dorsal O
and O
ventral O
_RARE_ I-GENE
of O
lesioned O
animals O
along O
with O
elevated O
levels O
of O
norepinephrine O
( O
NE O
) O
in O
the O
dorsal O
hippocampus O
of O
MS O
/ I-GENE
_RARE_ I-GENE
animals O
.( O
ABSTRACT O
TRUNCATED O
AT I-GENE
250 O
WORDS O
) O

The O
localization O
of O
this O
proteoglycan I-GENE
locus I-GENE
in O
the O
human I-GENE
genome O
and O
the O
availability O
of O
new O
_RARE_ I-GENE
provide O
the O
tools O
for O
future O
studies O
of O
human I-GENE
diseases O
where O
the O
_RARE_ I-GENE
proteoglycan I-GENE
gene I-GENE
is O
suspected O
to O
be O
involved O
. O

After O
2 I-GENE
min O
of O
_RARE_ I-GENE
injection O
, O
or O
after O
20 O
min O
of O
_RARE_ I-GENE
injection O
, O
the O
myocardium O
was O
removed O
, O
and O
used O
for O
determination O
of O
the O
tissue I-GENE
levels O
of O
metabolites O
of O
energy O
and O
carbohydrate O
metabolism O
. O

During O
coronary O
stenosis O
, O
on O
the O
_RARE_ I-GENE
, O
_RARE_ I-GENE
_RARE_ I-GENE
at O
the O
same O
dose O
significantly O
_RARE_ I-GENE
regional O
myocardial O
dysfunction O
without O
changing O
_RARE_ I-GENE
flow O
, O
global O
hemodynamics O
and O
cardiac O
lactate I-GENE
metabolism O
. O

Here O
we O
present O
evidence O
that O
major I-GENE
IE I-GENE
proteins I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
are O
capable O
of O
trans O
- I-GENE
activating I-GENE
the O
HIV I-GENE
LTR I-GENE
in O
a O
T I-GENE
- I-GENE
cell O
line O
, O
_RARE_ I-GENE
- I-GENE
78 O
. O

In O
a O
_RARE_ I-GENE
where O
general O
HIV I-GENE
prevalence O
is O
low O
, O
the O
strategy O
is O
cost O
- I-GENE
effective O
for O
location O
and O
_RARE_ I-GENE
of O
_RARE_ I-GENE
seropositive O
individuals O
. O

The O
cis O
- I-GENE
acting O
element I-GENE
mediating O
glucocorticoid I-GENE
inducibility O
of O
the O
chicken I-GENE
glutamine I-GENE
synthetase I-GENE
gene I-GENE
has O
been O
identified O
. O

However O
, O
the O
increase O
in O
biliary O
excretion O
did O
not O
_RARE_ I-GENE
for O
the O
reduced O
elimination O
of O
_RARE_ I-GENE
and O
_RARE_ I-GENE
acid I-GENE
via O
the O
kidney O
. O

Diagnostic O
value O
of O
cerebrospinal O
fluid O
immunoglobulin I-GENE
G I-GENE
( O
IgG I-GENE
) O
in O
pediatric O
neurological O
diseases O
. O

Expression O
of O
six O
genes I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
, O
was O
apparently O
regulated O
by O
the O
positive O
regulator I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
VT O
was O
suppressed O
entirely O
in O
one O
patient O
. O

_RARE_ I-GENE
, O
and O
D I-GENE
. O

The O
presence O
of O
the O
corresponding O
mature O
mRNA I-GENE
transcripts I-GENE
( O
3 I-GENE
. O
2 I-GENE
- I-GENE
3 I-GENE
. O
5 I-GENE
kilobase O
pairs O
( O
kb O
] O
in O
human I-GENE
fibroblasts O
was O
shown O
by O
Northern O
blot O
hybridization O
, O
S1 I-GENE
nuclease I-GENE
protection O
assay O
, O
and O
the O
polymerase I-GENE
chain I-GENE
reaction O
. O

Approximately O
50 O
% O
of O
the O
ribosomal I-GENE
DNA I-GENE
( O
rDNA I-GENE
) O
units O
of O
Drosophila I-GENE
melanogaster I-GENE
are O
inactivated O
by O
two O
different O
28 O
S I-GENE
RNA I-GENE
ribosomal I-GENE
gene I-GENE
insertions O
( O
type I-GENE
I I-GENE
and O
type I-GENE
II I-GENE
). O

_RARE_ I-GENE
_RARE_ I-GENE
consists O
of O
two O
polypeptide I-GENE
chains I-GENE
( O
Mr O
= O
110 I-GENE
, O
000 O
and O
30 O
, O
000 O
), O
which O
seem O
to O
be O
proteolytic O
cleavage O
products I-GENE
connected O
by O
disulfide O
bonds O
from O
a O
precursor I-GENE
protein I-GENE
. O

However O
, O
the O
_RARE_ I-GENE
gamma I-GENE
R I-GENE
alpha I-GENE
cDNA I-GENE
clone O
is O
complementary O
to O
at O
least O
two O
different O
- I-GENE
sized O
mRNAs I-GENE
expressed O
by O
_RARE_ I-GENE
- I-GENE
16 O
cells O
, O
_RARE_ I-GENE
the O
single O
Fc I-GENE
gamma I-GENE
R I-GENE
- I-GENE
related I-GENE
mRNA I-GENE
species O
expressed O
by O
human I-GENE
and O
mouse I-GENE
natural O
killer O
cells O
. O

Both O
genes I-GENE
comprise O
three O
exons O
, O
two O
introns O
and O
an O
unusually O
long O
3 I-GENE
'- O
untranslated O
region O
( O
3 I-GENE
. O
2 I-GENE
kilobase O
pairs O
), O
_RARE_ I-GENE
a O
mRNA I-GENE
of O
approximately O
4 I-GENE
. O
1 I-GENE
kilobases O
. O

Stable O
expression O
of O
the O
chimeric I-GENE
alpha I-GENE
i O
( O
54 I-GENE
)/ O
s O
polypeptide I-GENE
in O
Chinese O
hamster I-GENE
ovary O
( O
CHO O
) O
cells O
constitutively O
increased O
both O
cAMP I-GENE
synthesis O
and O
cAMP I-GENE
- I-GENE
dependent I-GENE
protein I-GENE
kinase I-GENE
activity O
. O

This O
exon O
, O
here O
named O
exon O
0 O
, O
contained O
the O
entire O
5 I-GENE
' O
untranslated O
region O
and O
the O
N I-GENE
- I-GENE
terminal I-GENE
signal I-GENE
sequence I-GENE
of O
the O
polypeptide I-GENE
. O

Treatment O
of O
human I-GENE
myeloid O
cell O
lines O
HL I-GENE
- I-GENE
60 O
and O
U937 O
with O
phorbol O
12 O
- I-GENE
myristate O
13 O
- I-GENE
acetate O
( O
PMA O
) O
increased O
within O
2 I-GENE
h O
cellular O
levels O
of O
the O
RNA I-GENE
_RARE_ I-GENE
to O
_RARE_ I-GENE
cDNA I-GENE
. O

A I-GENE
new O
, O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
for O
observation O
of O
the O
ventricles O
and O
major I-GENE
_RARE_ I-GENE
is O
reported O
. O

_RARE_ I-GENE
N I-GENE
isomerase I-GENE
( O
_RARE_ I-GENE
) O
has O
been O
purified O
from O
Streptomyces I-GENE
_RARE_ I-GENE
, O
and O
the O
amino O
acid I-GENE
sequence I-GENE
of O
the O
N I-GENE
- I-GENE
terminus O
has O
been O
determined O
. O

Serum I-GENE
IgG I-GENE
was O
initially O
elevated O
in O
6 I-GENE
patients O
. O

The O
patient O
initially O
_RARE_ I-GENE
complete O
remission O
( O
_RARE_ I-GENE
) O
with O
conventional O
chemotherapy O
and O
then O
_RARE_ I-GENE
14 O
months O
later O
. O

_RARE_ I-GENE
+/- O
16 O
mg O
/ I-GENE
dl O
; O
NS I-GENE
), O
glucose O
levels O
, O
and O
basal O
( O
17 O
+/- O
4 I-GENE
vs O
. O

Platelet I-GENE
aggregation O
and O
metabolic O
control O
are O
not O
affected O
by O
calcium O
antagonist O
treatment O
in O
type I-GENE
II I-GENE
diabetes O
mellitus O
. O

Wnt I-GENE
- I-GENE
1 I-GENE
( O
int I-GENE
- I-GENE
1 I-GENE
) O
is O
a O
cellular O
oncogene I-GENE
often O
activated I-GENE
by O
insertion O
of O
proviral I-GENE
DNA I-GENE
of O
the O
mouse I-GENE
mammary O
tumor I-GENE
virus I-GENE
. O

Induction O
of O
Jurkat O
_RARE_ I-GENE
T I-GENE
cells O
with O
phorbol O
12 O
- I-GENE
myristate O
13 O
- I-GENE
acetate O
and O
_RARE_ I-GENE
did O
not O
affect O
the O
level O
of O
_RARE_ I-GENE
mRNA I-GENE
. O

_RARE_ I-GENE
mRNA I-GENE
is O
expressed O
at O
highest O
levels O
in O
small I-GENE
intestine O
and O
at O
much O
lower O
levels O
in O
kidney O
, O
skeletal I-GENE
muscle O
, O
and O
adipose I-GENE
tissue I-GENE
. O

e O
. O

We O
_RARE_ I-GENE
that O
these O
tumors O
may O
represent O
congenital O
_RARE_ I-GENE
_RARE_ I-GENE
. O

Identification O
and O
characterization O
of O
the O
promoter I-GENE
for O
the O
_RARE_ I-GENE
gene I-GENE
. O

Surprisingly O
, O
there O
is O
no O
sequence I-GENE
homology I-GENE
between O
this O
region O
of O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
and O
the O
established O
consensus I-GENE
for O
the O
interferon I-GENE
- I-GENE
stimulated O
response O
element I-GENE
, O
which O
has O
been O
shown O
functionally O
important O
to O
all O
previously O
characterized O
alpha I-GENE
/ I-GENE
beta I-GENE
interferon I-GENE
- I-GENE
inducible I-GENE
promoters I-GENE
. O

_RARE_ I-GENE
large O
DNA I-GENE
rearrangements O
spanning O
the O
region O
with O
tandem O
direct O
repeats I-GENE
encoding O
the O
carboxy I-GENE
- I-GENE
terminal I-GENE
histone I-GENE
H1 I-GENE
- I-GENE
like I-GENE
structure O
of O
_RARE_ I-GENE
were O
detected O
in O
several O
strains O
upon O
conversion O
from O
the O
_RARE_ I-GENE
to O
the O
_RARE_ I-GENE
phenotype O
. O

( O
1988 O
) O
J O
. O

These O
results O
strongly O
suggested O
that O
similar O
, O
if O
not O
identical O
, O
the O
CArG I-GENE
box I-GENE
binding I-GENE
proteins I-GENE
interact O
with O
the O
functionally O
different O
promoter I-GENE
element I-GENE
in O
the O
_RARE_ I-GENE
, O
cardiac O
alpha I-GENE
- I-GENE
actin I-GENE
, O
and O
c I-GENE
- I-GENE
fos I-GENE
genes I-GENE
. O

_RARE_ I-GENE
of O
_RARE_ I-GENE
RNA I-GENE
, O
which O
occurs O
very O
early I-GENE
during O
maturation O
, O
is O
limited O
to O
150 O
residues O
, O
and O
it O
is O
this O
number O
that O
is O
required O
for O
_RARE_ I-GENE
recruitment O
. O

Co O
- I-GENE
existence O
of O
these O
regulatory I-GENE
elements O
with O
other O
elements O
, O
such O
as O
the O
AP I-GENE
- I-GENE
2 I-GENE
element I-GENE
or O
CCAAT I-GENE
box I-GENE
, O
was O
also O
found O
. O

Recently O
, O
studies O
of O
agents O
that O
disrupt O
collagen I-GENE
synthesis O
and O
deposition O
have O
yielded O
several O
new O
angiogenesis O
inhibitors O
. O

Since O
the O
5 I-GENE
'- O
flanking O
region O
of O
this O
gene I-GENE
is O
likely O
involved O
in O
hormonal O
regulation O
of O
its O
expression O
, O
we O
have O
isolated O
and O
partially O
characterized O
an O
avian I-GENE
fatty I-GENE
acid I-GENE
synthase I-GENE
gene I-GENE
. O

A I-GENE
new O
set O
of O
cDNA I-GENE
clones O
spanning O
approximately O
3 I-GENE
. O
2 I-GENE
kb O
was O
isolated O
from O
a O
lambda I-GENE
- I-GENE
ZAP I-GENE
_RARE_ I-GENE
liver O
cDNA I-GENE
library O
using O
the O
5 I-GENE
'- O
most O
exon O
- I-GENE
containing O
fragment I-GENE
of O
the O
5 I-GENE
'- O
most O
genomic O
DNA I-GENE
clone O
. O

Northern O
blotting O
analysis O
indicates O
that O
expression O
of O
the O
genes I-GENE
corresponding O
to O
these O
clones O
is O
confined O
to O
pollen O
tissue I-GENE
. O

Whereas O
cDNA I-GENE
hybridization O
to O
genomic O
DNA I-GENE
blots O
indicated O
a O
small I-GENE
subfamily I-GENE
of O
_RARE_ I-GENE
genes I-GENE
, O
simple O
patterns O
of O
bands O
indicated O
that O
most O
cDNAs I-GENE
, O
including O
_RARE_ I-GENE
cDNA I-GENE
, O
corresponded O
to O
single O
- I-GENE
copy O
genes I-GENE
. O

_RARE_ I-GENE
disorders O
arising O
under O
_RARE_ I-GENE
with O
FK O
_RARE_ I-GENE
: O
initial O
observations O
in O
a O
large O
transplant O
population O
. O

The O
Drosophila I-GENE
suppressor I-GENE
of O
_RARE_ I-GENE
gene I-GENE
encodes O
a O
polypeptide I-GENE
with O
regions O
similar O
to O
those O
of O
RNA I-GENE
- I-GENE
binding I-GENE
proteins I-GENE
. O

2 I-GENE
: O
121 I-GENE
- I-GENE
133 I-GENE
, O
1988 O
). O

It O
is O
, O
however O
, O
extremely O
homologous O
to O
a O
third O
' O
non O
- I-GENE
classical O
' O
gene I-GENE
, O
HLA I-GENE
- I-GENE
5 I-GENE
. O
4 I-GENE
, O
and O
to O
the O
_RARE_ I-GENE
gene I-GENE
, O
_RARE_ I-GENE
. O

Although O
the O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
interval O
remained O
stable O
because O
of O
the O
parallel O
shift O
of O
the O
2 I-GENE
peaks O
, O
the O
central O
conduction O
time O
measured O
from O
onset O
_RARE_ I-GENE
of O
_RARE_ I-GENE
and O
_RARE_ I-GENE
significantly O
increased O
. O

Using O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
complex I-GENE
DNA I-GENE
binding I-GENE
assays O
, O
a O
series O
of O
overlapping O
alpha I-GENE
promoter I-GENE
DNA I-GENE
sequences I-GENE
between O
- I-GENE
170 I-GENE
to O
29 O
_RARE_ I-GENE
were O
tested O
, O
but O
each O
failed O
to O
bind O
GR I-GENE
, O
whereas O
a O
control O
GRE I-GENE
_RARE_ I-GENE
bound O
receptor I-GENE
. O

Sequence O
determination O
of O
isolated O
peptides I-GENE
suggested O
that O
_RARE_ I-GENE
is O
glycosylated O
, O
_RARE_ I-GENE
and O
_RARE_ I-GENE
glycosylated O
in O
some O
molecules I-GENE
but O
not O
in O
others O
, O
and O
_RARE_ I-GENE
not O
glycosylated O
. O

The O
DNA I-GENE
sequence I-GENE
conferring O
AP I-GENE
- I-GENE
1 I-GENE
activity O
was O
located O
in O
the O
proximal I-GENE
promoter I-GENE
region O
. O

The O
murine I-GENE
mutation I-GENE
dominant I-GENE
white O
_RARE_ I-GENE
( O
W I-GENE
) O
is O
in O
the O
proto I-GENE
- I-GENE
oncogene I-GENE
, O
c I-GENE
- I-GENE
kit I-GENE
. O

Isolation O
and O
characterization O
of O
the O
rat I-GENE
chromosomal I-GENE
gene I-GENE
for O
a O
polypeptide I-GENE
( O
_RARE_ I-GENE
) O
_RARE_ I-GENE
related I-GENE
to O
_RARE_ I-GENE
. O

The O
proteins I-GENE
differ O
in O
the O
presence O
or O
absence O
of O
a O
21 O
- I-GENE
amino O
- I-GENE
acid I-GENE
sequence I-GENE
located O
24 O
amino O
acids O
C I-GENE
terminal I-GENE
of O
the O
translational O
initiation I-GENE
codon O
. O

Our O
results O
also O
indicate O
the O
existence O
of O
sequences I-GENE
downstream O
of O
- I-GENE
0 O
. O
11 O
kb O
which O
can O
influence O
the O
pattern O
of O
tissue I-GENE
- I-GENE
specific I-GENE
expression O
of O
the O
HLA I-GENE
- I-GENE
B7 I-GENE
gene I-GENE
and O
the O
ability O
of O
this O
gene I-GENE
to O
respond O
to O
gamma I-GENE
interferon I-GENE
. O

The O
SH2 I-GENE
and O
SH3 I-GENE
domains I-GENE
of O
_RARE_ I-GENE
direct O
stable O
association O
with O
tyrosine I-GENE
phosphorylated O
proteins I-GENE
p130 I-GENE
and O
_RARE_ I-GENE
. O

Chem O
. O

These O
clones O
_RARE_ I-GENE
and O
contained O
the O
structural O
gene I-GENE
encoding O
the O
complete O
_RARE_ I-GENE
alpha I-GENE
- I-GENE
chain I-GENE
and O
90 O
% O
of O
the O
beta I-GENE
- I-GENE
chain I-GENE
. O

The O
_RARE_ I-GENE
alpha I-GENE
- I-GENE
chain I-GENE
was O
encoded I-GENE
by O
49 O
kilobases O
containing O
26 O
exons O
; O
the O
beta I-GENE
- I-GENE
chain I-GENE
was O
encoded I-GENE
by O
29 O
kilobases O
containing O
16 O
exons O
. O

_RARE_ I-GENE
mutation I-GENE
in O
the O
G I-GENE
+ I-GENE
5 I-GENE
position O
of O
intron O
33 O
of O
the O
pro I-GENE
- I-GENE
alpha I-GENE
2 I-GENE
( O
I I-GENE
) O
gene I-GENE
( O
_RARE_ I-GENE
) O
that O
causes O
aberrant O
RNA I-GENE
splicing O
and O
lethal O
_RARE_ I-GENE
_RARE_ I-GENE
. O

The O
nucleotide I-GENE
sequences I-GENE
of O
these O
genes I-GENE
differ O
at O
only O
nine O
positions O
, O
resulting O
in O
three O
amino O
acid I-GENE
differences O
. O

The O
protein I-GENE
predicted O
by O
the O
sequence I-GENE
of O
the O
human I-GENE
_RARE_ I-GENE
- I-GENE
1 I-GENE
proto I-GENE
- I-GENE
oncogene I-GENE
shares O
extensive O
homology I-GENE
with O
known O
serine I-GENE
/ I-GENE
threonine I-GENE
protein I-GENE
kinases I-GENE
, O
and O
yet O
the O
human I-GENE
_RARE_ I-GENE
- I-GENE
1 I-GENE
enzyme I-GENE
has O
previously O
been O
reported O
to O
exhibit O
protein I-GENE
tyrosine I-GENE
kinase I-GENE
activity O
both O
in O
vitro O
and O
in O
vivo O
. O

A I-GENE
full I-GENE
- I-GENE
length I-GENE
human I-GENE
_RARE_ I-GENE
- I-GENE
1 I-GENE
cDNA I-GENE
was O
subcloned O
into O
the O
bacterial I-GENE
vector O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
and O
the O
_RARE_ I-GENE
- I-GENE
1 I-GENE
protein I-GENE
expressed O
as O
a O
fusion I-GENE
product I-GENE
with O
bacterial I-GENE
glutathione I-GENE
S I-GENE
- I-GENE
transferase I-GENE
( O
GST I-GENE
). O

This O
report O
_RARE_ I-GENE
that O
at O
least O
two O
of O
the O
18 O
kDa I-GENE
_RARE_ I-GENE
in O
maize I-GENE
are O
products I-GENE
of O
different O
but O
related I-GENE
genes I-GENE
. O

The O
10 O
kDa I-GENE
polypeptide I-GENE
was O
phosphorylated O
in O
vitro O
by O
_RARE_ I-GENE
wheat I-GENE
_RARE_ I-GENE
membranes O
with O
[ O
gamma I-GENE
32P O
] O
ATP I-GENE
. O

_RARE_ I-GENE
with O
the O
human I-GENE
protein I-GENE
is O
only O
34 O
% O
in O
the O
tandem O
repeat I-GENE
domain I-GENE
, O
mainly O
showing O
conservation O
of O
_RARE_ I-GENE
and O
_RARE_ I-GENE
, O
presumed I-GENE
sites I-GENE
of O
O O
- I-GENE
linked O
carbohydrate O
attachment O
. O

In O
addition O
to O
targeting O
partially O
assembled O
_RARE_ I-GENE
alpha I-GENE
- I-GENE
beta I-GENE
CD3 I-GENE
gamma I-GENE
delta I-GENE
epsilon I-GENE
TCR I-GENE
complexes I-GENE
to O
the O
cell O
surface O
, O
CD3 I-GENE
zeta I-GENE
appears O
to O
be O
essential O
for O
interleukin I-GENE
- I-GENE
2 I-GENE
production O
after O
TCR I-GENE
stimulation O
with O
antigen I-GENE
/ I-GENE
major I-GENE
histocompatibility I-GENE
complex I-GENE
. O

When O
desipramine O
was O
injected O
16 O
hrs O
after O
_RARE_ I-GENE
injection O
, O
brain O
levels O
of O
desipramine O
were O
no O
longer O
elevated O
. O

_RARE_ I-GENE
effects O
of O
_RARE_ I-GENE
are O
observed O
in O
aerobic O
, O
heme O
- I-GENE
sufficient O
cells O
. O

A I-GENE
segmental O
analysis O
of O
the O
key O
regions O
of O
HLA I-GENE
- I-GENE
DR1 I-GENE
that O
control O
T I-GENE
cell O
_RARE_ I-GENE
was O
performed O
by O
using O
a O
series O
of O
transfected O
cell O
lines O
expressing O
the O
products I-GENE
of O
recombinant I-GENE
_RARE_ I-GENE
/ I-GENE
H I-GENE
- I-GENE
_RARE_ I-GENE
genes I-GENE
, O
paired I-GENE
with O
either O
DR I-GENE
alpha I-GENE
or O
H I-GENE
- I-GENE
_RARE_ I-GENE
alpha I-GENE
. O

We O
characterized O
cDNA I-GENE
clones O
specific I-GENE
for O
the O
extracellular I-GENE
matrix I-GENE
glycoprotein I-GENE
_RARE_ I-GENE
. O

Finally O
, O
some O
point O
mutations O
in O
the O
Gag I-GENE
- I-GENE
Pol I-GENE
PR I-GENE
domain I-GENE
inhibited O
activation O
of O
RT I-GENE
in O
trans O
by O
a O
wild I-GENE
- I-GENE
type I-GENE
PR I-GENE
, O
suggesting O
that O
the O
correct O
conformation O
of O
the O
PR I-GENE
domain I-GENE
in O
Gag I-GENE
- I-GENE
Pol I-GENE
is O
prerequisite O
for O
activation O
of O
RT I-GENE
. O

The O
alpha I-GENE
_RARE_ I-GENE
promoter I-GENE
containing O
a O
mutated O
CRE O
was O
not O
regulated O
by O
forskolin O
in O
_RARE_ I-GENE
cells O
and O
did O
not O
bind O
the O
CREB I-GENE
protein I-GENE
. O

Regulation O
of O
the O
alpha I-GENE
_RARE_ I-GENE
gene I-GENE
by O
cyclic I-GENE
adenosine I-GENE
3 I-GENE
', O
5 I-GENE
'- O
monophosphate O
after O
transfection O
into O
rat I-GENE
_RARE_ I-GENE
cells O
. O

Comparison O
of O
the O
nucleotide I-GENE
sequences I-GENE
between O
the O
human I-GENE
and O
bovine I-GENE
DNA I-GENE
showed O
that O
the O
sequence I-GENE
similarity O
extended O
_RARE_ I-GENE
bp O
downstream O
from O
the O
coding O
region O
. O

Cloning O
of O
a O
human I-GENE
cDNA I-GENE
encoding O
a O
_RARE_ I-GENE
- I-GENE
related I-GENE
kinase I-GENE
by O
complementation O
of O
a O
budding I-GENE
yeast I-GENE
_RARE_ I-GENE
mutation I-GENE
. O

In O
patients O
with O
_RARE_ I-GENE
and O
joint O
_RARE_ I-GENE
( O
n O
= O
48 O
) O
PMN I-GENE
elastase I-GENE
had O
a O
sensitivity O
of O
77 O
%, O
which O
was O
only O
_RARE_ I-GENE
by O
that O
of O
the O
_RARE_ I-GENE
erythrocyte I-GENE
sedimentation O
rate O
( O
sensitivity O
89 I-GENE
%). O

E I-GENE
., O
_RARE_ I-GENE
, O
C I-GENE
., O
_RARE_ I-GENE
, O
D I-GENE
., O
_RARE_ I-GENE
, O
B I-GENE
., O
_RARE_ I-GENE
, O
R I-GENE
., O
_RARE_ I-GENE
, O
B I-GENE
., O
Chi O
- I-GENE
_RARE_ I-GENE
, O
G I-GENE
., O
and O
_RARE_ I-GENE
, O
R I-GENE
., O
( O
1990 O
) O
Cell O
63 O
, O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
). O

The O
above O
results O
mean O
that O
the O
increase O
in O
alpha I-GENE
- I-GENE
adrenergic I-GENE
receptors I-GENE
makes O
the O
prostate O
, O
which O
has O
been O
already O
_RARE_ I-GENE
, O
less O
elastic O
, O
inhibiting O
external O
urinary O
_RARE_ I-GENE
function O
. O

An O
approximately O
2 I-GENE
- I-GENE
kilobase O
B2 I-GENE
transcript I-GENE
was O
expressed O
in O
all O
_RARE_ I-GENE
organs O
tested O
. O

These O
results O
indicate O
that O
the O
_RARE_ I-GENE
group O
of O
certain O
angiotensin I-GENE
converting I-GENE
enzyme I-GENE
inhibitors O
can O
_RARE_ I-GENE
their O
effect O
on O
the O
endogenous I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
of O
FK O
_RARE_ I-GENE
in O
transplant O
patients O
. O

A I-GENE
second O
even O
more O
significant O
match O
to O
this O
E I-GENE
. O
coli I-GENE
region O
was O
found O
in O
the O
retroviral I-GENE
ribonuclease I-GENE
H I-GENE
( O
RNase I-GENE
H I-GENE
) O
domain I-GENE
, O
and O
corresponds O
precisely O
to O
a O
region O
that O
has O
been O
_RARE_ I-GENE
by O
previous O
_RARE_ I-GENE
with O
the O
E I-GENE
. O
coli I-GENE
RNase I-GENE
H I-GENE
, O
suggesting O
that O
Pol I-GENE
I I-GENE
helices O
O O
and O
P I-GENE
are O
homologous O
to O
helices O
A I-GENE
and O
D I-GENE
of O
the O
RNase I-GENE
H I-GENE
crystal O
structure O
, O
respectively O
. O

Analysis O
of O
the O
deduced O
amino O
acid I-GENE
sequence I-GENE
suggests O
that O
_RARE_ I-GENE
protein I-GENE
contains O
six O
_RARE_ I-GENE
- I-GENE
spanning O
domains I-GENE
, O
two O
_RARE_ I-GENE
potential O
N I-GENE
- I-GENE
glycosylation O
sites I-GENE
, O
and O
intracellular O
N I-GENE
and O
C I-GENE
termini O
. O

The O
qualitative O
concentrations O
of O
_RARE_ I-GENE
had O
a O
sensitivity O
of O
37 O
. O
5 I-GENE
% O
and O
a O
specificity O
of O
100 O
%. O

The O
reduced O
rate O
of O
F I-GENE
absorption O
and O
slower O
rise O
in O
plasma I-GENE
F I-GENE
concentration O
accompanying O
delayed O
gastric O
emptying O
indicate O
that O
passage O
of O
F I-GENE
into O
the O
small I-GENE
intestine O
is O
the O
major I-GENE
factor I-GENE
in O
rapid O
F I-GENE
absorption O
. O

The O
activity O
of O
serum I-GENE
lipase I-GENE
and O
amylase I-GENE
distinctly O
increased O
at O
3 I-GENE
h O
and O
_RARE_ I-GENE
up O
to O
the O
maximum O
at O
12 O
h O
after O
injection O
of O
Na I-GENE
- I-GENE
Tc O
. O

They O
were O
_RARE_ I-GENE
for O
anti I-GENE
- I-GENE
HCV I-GENE
( O
anti I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
3 I-GENE
) O
with O
HCV I-GENE
EIA I-GENE
kit I-GENE
( O
_RARE_ I-GENE
_RARE_ I-GENE
., O
_RARE_ I-GENE
_RARE_ I-GENE
, O
IL I-GENE
). O

_RARE_ I-GENE
resulted O
in O
a O
significant O
increase O
in O
_RARE_ I-GENE
diameter O
(+ O
10 O
%; O
p O
= O
0 O
. O
001 O
) O
and O
in O
coronary O
blood O
flow O
( O
CBF I-GENE
) O
(+ O
30 O
%; O
p O
= O
0 O
. O
0001 O
). O

The O
first O
transfusion O
resulted O
in O
a O
platelet I-GENE
_RARE_ I-GENE
to O
32 O
_RARE_ I-GENE
/ I-GENE
l O
( O
_RARE_ I-GENE
11 O
). O

These O
risk O
factors I-GENE
can O
be O
divided O
into O
2 I-GENE
groups O
: O
local O
vessel O
wall O
- I-GENE
related I-GENE
factors I-GENE
, O
and O
local O
( O
focal I-GENE
action O
) O
systemic O
factors I-GENE
. O

_RARE_ I-GENE
and O
prevention O
of O
hospital O
infections O
in O
the O
_RARE_ I-GENE
Health O
_RARE_ I-GENE
of O
_RARE_ I-GENE
: O
profile O
of O
bacterial I-GENE
resistance O
and O
antimicrobial O
agents O
of O
large O
usage O
. O

_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
derived O
cDNAs I-GENE
did O
not O
result O
in O
stimulation O
of O
either O
basal O
or O
tat I-GENE
- I-GENE
induced O
activated I-GENE
gene I-GENE
expression O
. O

_RARE_ I-GENE
virus I-GENE
( O
_RARE_ I-GENE
) O
is O
a O
potent O
_RARE_ I-GENE
, O
but O
the O
nature O
of O
_RARE_ I-GENE
proteins I-GENE
involved O
in O
the O
activation O
of O
the O
immune I-GENE
response O
of O
the O
host O
is O
not O
yet O
known O
. O

Max I-GENE
: O
functional O
domains I-GENE
and O
interaction O
with O
c I-GENE
- I-GENE
Myc I-GENE
. O

86 I-GENE
: O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
) O
or O
G1 I-GENE
to O
S I-GENE
phase O
( O
_RARE_ I-GENE
, O
C I-GENE
. O

_RARE_ I-GENE
introduced O
at O
bases O
surrounding O
the O
_RARE_ I-GENE
motif I-GENE
yielded O
levels O
of O
_RARE_ I-GENE
replication O
that O
differed O
, O
depending O
on O
the O
maintenance O
of O
a O
putative O
5 I-GENE
' O
stem O
- I-GENE
loop I-GENE
structure O
in O
the O
positive O
strand O
of O
the O
viral I-GENE
genome O
. O

Zn I-GENE
( O
II I-GENE
) O
coordination O
domain I-GENE
mutants I-GENE
of O
T4 I-GENE
gene I-GENE
32 O
protein I-GENE
. O

Zn I-GENE
( O
II I-GENE
) O
coordination O
domain I-GENE
mutants I-GENE
of O
T4 I-GENE
gene I-GENE
32 O
protein I-GENE
. O

The O
tissue I-GENE
specificity O
of O
gene I-GENE
expression O
was O
identical O
to O
that O
described O
previously O
for O
the O
_RARE_ I-GENE
35S I-GENE
domain I-GENE
B I-GENE
enhancer I-GENE
element I-GENE
. O

The O
pathophysiology O
and O
clinical O
management O
of O
acute O
brain O
injury O
in O
_RARE_ I-GENE
and O
childhood O
are O
presented O
using O
acute O
_RARE_ I-GENE
brain O
injury O
as O
a O
model O
. O

_RARE_ I-GENE
from O
a O
second O
POU I-GENE
- I-GENE
domain I-GENE
gene I-GENE
, O
Oct I-GENE
- I-GENE
25 O
, O
were O
present O
at O
low O
levels O
in O
oocytes O
and O
early I-GENE
embryos O
and O
were O
dramatically O
_RARE_ I-GENE
during O
early I-GENE
_RARE_ I-GENE
. O

In O
some O
early I-GENE
B I-GENE
cells O
and O
_RARE_ I-GENE
murine I-GENE
leukemia I-GENE
virus I-GENE
- I-GENE
transformed O
pre I-GENE
- I-GENE
B I-GENE
- I-GENE
cell O
lines O
, O
_RARE_ I-GENE
mRNA I-GENE
is O
constitutively O
expressed O
. O

The O
genome O
of O
_RARE_ I-GENE
virus I-GENE
comprises O
six O
segments O
of O
single O
- I-GENE
stranded I-GENE
, O
negative O
sense O
RNA I-GENE
. O

These O
tumors O
were O
classified O
into O
three O
broad O
groups O
: O
I I-GENE
, O
_RARE_ I-GENE
; O
II I-GENE
, O
_RARE_ I-GENE
; O
and O
III I-GENE
, O
adenocarcinoma O
with O
_RARE_ I-GENE
production O
or O
an O
associated I-GENE
cyst O
. O

_RARE_ I-GENE
of O
cells O
transfected O
with O
these O
constructs I-GENE
revealed O
that O
both O
the O
_RARE_ I-GENE
and O
_RARE_ I-GENE
mutants I-GENE
were O
localized O
in O
nuclei O
, O
whereas O
wild I-GENE
- I-GENE
type I-GENE
PKC I-GENE
alpha I-GENE
was O
primarily O
cytoplasmic I-GENE
and O
_RARE_ I-GENE
. O

We O
have O
partially O
sequenced O
the O
_RARE_ I-GENE
protein I-GENE
from O
purified O
HeLa O
cells O
, O
cloned O
its O
complementary O
DNA I-GENE
and O
shown O
that O
its O
translation I-GENE
product I-GENE
can O
interact O
with O
_RARE_ I-GENE
in O
vitro O
as O
well O
as O
in O
vivo O
. O

Effects O
of O
thromboxane I-GENE
synthetase I-GENE
inhibition O
on O
_RARE_ I-GENE
_RARE_ I-GENE
vascular I-GENE
resistance O
and O
the O
rate O
of O
bacterial I-GENE
translocation O
in O
a O
chronic O
porcine I-GENE
model O
. O

The O
primary O
pancreatic O
_RARE_ I-GENE
_RARE_ I-GENE
to O
be O
unaffected O
by O
the O
treatment O
, O
because O
neither O
the O
rise O
in O
plasma I-GENE
lipase I-GENE
nor O
the O
development O
of O
_RARE_ I-GENE
or O
the O
extension O
of O
the O
pancreatic O
necrosis I-GENE
were O
diminished O
. O

The O
size O
of O
the O
mutant I-GENE
molecule I-GENE
corresponds O
to O
the O
_RARE_ I-GENE
cytoplasmic I-GENE
precursor I-GENE
( O
pre I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
pro I-GENE
- I-GENE
_RARE_ I-GENE
), O
as O
detected O
in O
_RARE_ I-GENE
mutants I-GENE
, O
when O
translocation O
into O
the O
endoplasmic O
reticulum O
is O
blocked O
. O

Thus O
, O
the O
active O
- I-GENE
site I-GENE
mutation I-GENE
prevents O
the O
wild I-GENE
- I-GENE
type I-GENE
processing O
of O
the O
N I-GENE
- I-GENE
glycosylated O
73 O
- I-GENE
kDa I-GENE
precursor I-GENE
of O
_RARE_ I-GENE
to O
the O
41 O
. O
5 I-GENE
kDa I-GENE
pro I-GENE
- I-GENE
_RARE_ I-GENE
in O
the O
endoplasmic O
reticulum O
. O

The O
predicted O
amino O
acid I-GENE
sequence I-GENE
exhibited O
70 I-GENE
% O
identity O
to O
that O
of O
Bacillus I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
and O
55 O
% O
identity O
to O
that O
of O
E I-GENE
. O
coli I-GENE
_RARE_ I-GENE
, O
while O
identity O
to O
a O
second O
_RARE_ I-GENE
B I-GENE
. O
subtilis I-GENE
_RARE_ I-GENE
gene I-GENE
, O
designated O
_RARE_ I-GENE
, O
was O
only O
27 O
%. O

_RARE_ I-GENE
- I-GENE
inducible I-GENE
CAT I-GENE
activity O
was O
detectable O
when O
additional O
sequences I-GENE
from O
the O
native O
promoter I-GENE
containing O
three O
CCAAT I-GENE
boxes O
and O
a O
single O
HSE O
were O
present O
in O
the O
_RARE_ I-GENE
. O

SETTING O
-- O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
and O
Children O
_RARE_ I-GENE
in O
_RARE_ I-GENE
, O
_RARE_ I-GENE
. O

_RARE_ I-GENE
, O
free O
testosterone O
, O
non O
- I-GENE
sex I-GENE
hormone I-GENE
- I-GENE
binding I-GENE
globulin I-GENE
- I-GENE
bound O
testosterone O
, O
and O
free O
androgen O
index O
: O
which O
testosterone O
measurement O
is O
most O
relevant O
to O
reproductive O
and O
sexual O
function O
in O
men O
with O
epilepsy O
? O

BACKGROUND O
: O
The O
effectiveness O
of O
monoamine I-GENE
oxidase I-GENE
inhibitors O
( O
_RARE_ I-GENE
) O
in O
_RARE_ I-GENE
resistant O
depression O
has O
received O
_RARE_ I-GENE
little O
systematic O
study O
. O

The O
upstream O
delta I-GENE
- I-GENE
alpha I-GENE
breakpoint I-GENE
is O
flanked O
by O
the O
direct O
repeats I-GENE
of O
the O
acceptor O
splice O
site I-GENE
, O
whereas O
the O
down O
- I-GENE
_RARE_ I-GENE
alpha I-GENE
- I-GENE
delta I-GENE
breakpoint I-GENE
is O
located O
in O
the O
adjacent O
intron O
. O

Patients O
with O
moderate O
_RARE_ I-GENE
were O
impaired O
on O
all O
serial O
positions O
for O
both O
spatial O
order O
and O
spatial O
recognition I-GENE
memory O
. O

_RARE_ I-GENE
and O
_RARE_ I-GENE
. O

One O
patients O
had O
plasma I-GENE
C I-GENE
- I-GENE
peptide I-GENE
greater O
than O
3 I-GENE
_RARE_ I-GENE
and O
was O
therefore O
excluded O
from O
analysis O
. O

_RARE_ I-GENE
repetitive O
_RARE_ I-GENE
were O
observed O
in O
muscles O
of O
_RARE_ I-GENE
mice O
but O
no O
complex I-GENE
repetitive O
_RARE_ I-GENE
or O
other O
abnormalities O
were O
observed O
in O
muscles O
of O
normal O
control O
mice O
. O

_RARE_ I-GENE
often O
involves O
beta I-GENE
- I-GENE
and O
calcium O
channel O
blocking O
drugs O
or O
type I-GENE
_RARE_ I-GENE
antiarrhythmic O
drugs O
. O

To O
overcome O
this O
problem O
, O
we O
have O
overexpressed O
_RARE_ I-GENE
using O
the O
baculovirus O
/ I-GENE
insect O
cell O
expression O
system O
. O

J O
. O

The O
major I-GENE
49 O
- I-GENE
kDa I-GENE
core I-GENE
protein I-GENE
in O
the O
liver O
_RARE_ I-GENE
preparation O
was O
found O
to O
be O
reactive I-GENE
to O
an O
antibody I-GENE
that O
specifically O
recognizes O
the O
cytoplasmic I-GENE
domain I-GENE
of O
_RARE_ I-GENE
. O

While O
no O
_RARE_ I-GENE
transmembrane I-GENE
regions O
were O
identified O
, O
several O
short O
hydrophobic O
amino O
acid I-GENE
stretches O
were O
found O
to O
be O
localized O
in O
and O
around O
the O
Pro I-GENE
II I-GENE
region O
, O
and O
these O
may O
be O
responsible O
for O
attachment O
of O
precursors I-GENE
to O
membranes O
. O

_RARE_ I-GENE
was O
mild O
, O
mainly O
consisting O
of O
_RARE_ I-GENE
( O
81 O
% O
of O
the O
patients O
; O
66 O
% O
of O
the O
courses O
), O
_RARE_ I-GENE
of O
_RARE_ I-GENE
Health O
Organization O
( O
_RARE_ I-GENE
) O
grade O
1 I-GENE
to O
2 I-GENE
( O
47 O
% O
of O
the O
patients O
; O
18 O
% O
of O
the O
courses O
), O
and O
thrombocytopenia O
( O
12 O
% O
of O
the O
patients O
; O
3 I-GENE
% O
of O
the O
courses O
). O

W I-GENE
. O
G I-GENE
. O

This O
study O
_RARE_ I-GENE
, O
although O
individual O
reaction O
is O
remarkably O
different O
, O
_RARE_ I-GENE
as O
a O
potent O
_RARE_ I-GENE
for O
_RARE_ I-GENE
dogs O
. O

A I-GENE
mouse I-GENE
brain O
beta I-GENE
- I-GENE
spectrin I-GENE
of O
cDNA I-GENE
was O
identified O
within O
a O
lambda I-GENE
_RARE_ I-GENE
expression O
library O
using O
an O
antibody I-GENE
which O
specifically O
binds O
with O
the O
_RARE_ I-GENE
kDa I-GENE
spectrin I-GENE
beta I-GENE
- I-GENE
subunit I-GENE
. O

RESULTS O
: O
Plasma I-GENE
AVP I-GENE
responses O
to O
osmotic O
stimulation O
, O
and O
non O
- I-GENE
osmotic O
inhibition O
by O
drinking O
, O
were O
normal O
in O
patients O
with O
_RARE_ I-GENE
water O
drinking O
. O

The O
fragments I-GENE
of O
each O
region O
were O
amplified O
by O
polymerase I-GENE
chain I-GENE
reaction O
and O
analyzed O
by O
gel O
electrophoresis O
to O
detect O
single O
- I-GENE
strand O
conformation O
polymorphism O
. O

The O
_RARE_ I-GENE
fusion I-GENE
was O
_RARE_ I-GENE
expressed O
during O
early I-GENE
stationary O
phase O
in O
cells O
grown O
in O
_RARE_ I-GENE
_RARE_ I-GENE
containing O
5 I-GENE
% O
glucose O
and O
0 O
. O
2 I-GENE
% O
glutamine I-GENE
. O

The O
_RARE_ I-GENE
of O
primase I-GENE
recognition I-GENE
sequences I-GENE
, O
nucleotide I-GENE
substrate I-GENE
requirements O
, O
and O
the O
effects O
of O
additional O
proteins I-GENE
on O
_RARE_ I-GENE
synthesis O
by O
the O
63 O
- I-GENE
kDa I-GENE
gene I-GENE
4 I-GENE
protein I-GENE
have O
been O
examined O
using O
templates O
of O
defined O
sequence I-GENE
. O

_RARE_ I-GENE
therapy O
in O
spontaneous O
coronary O
artery O
dissection O
. O

A I-GENE
prospective O
trial O
was O
carried O
out O
in O
156 I-GENE
_RARE_ I-GENE
patients O
( O
41 O
men O
, O
mean O
age O
67 O
. O
5 I-GENE
years O
, O
115 I-GENE
women O
, O
mean O
age O
71 O
. O
4 I-GENE
years O
) O
who O
had O
undergone O
total O
hip O
joint O
replacement O
because O
of O
_RARE_ I-GENE
or O
inflammatory O
arthritis O
or O
fracture O
of O
the O
neck O
of O
the O
femur O
. O

When O
both O
lesions O
were O
complete O
lateral O
_RARE_ I-GENE
in O
_RARE_ I-GENE
_RARE_ I-GENE
, O
little O
behavioral O
recovery O
was O
observed O
, O
similar O
to O
complete O
spinal O
cord O
_RARE_ I-GENE
( O
N I-GENE
= O
3 I-GENE
). O

Human I-GENE
SRF I-GENE
- I-GENE
related I-GENE
proteins I-GENE
: O
DNA I-GENE
- I-GENE
binding I-GENE
properties O
and O
potential O
regulatory I-GENE
targets O
. O

We O
have O
isolated O
cDNAs I-GENE
for O
a O
gene I-GENE
coding O
for O
a O
G I-GENE
protein I-GENE
alpha I-GENE
subunit I-GENE
from O
tomato I-GENE
( O
_RARE_ I-GENE
_RARE_ I-GENE
, O
cv O
. O

Growth I-GENE
factor I-GENE
stimulation O
of O
cells O
causes O
the O
phosphorylation O
of O
the O
c I-GENE
- I-GENE
Myc I-GENE
transcriptional O
activation O
domain I-GENE
at O
_RARE_ I-GENE
within O
a O
proline O
- I-GENE
rich O
region O
that O
is O
highly O
conserved O
among O
members O
of O
the O
Myc I-GENE
family I-GENE
( O
_RARE_ I-GENE
, O
E I-GENE
., O
_RARE_ I-GENE
, O
I I-GENE
. O
C I-GENE
., O
_RARE_ I-GENE
, O
F I-GENE
. O

The O
authors O
evaluated O
the O
potential O
for O
thrombotic O
complications O
arising O
from O
implantation O
of O
a O
ventricular O
_RARE_ I-GENE
device O
( O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
) O
in O
four O
calves O
. O

Cardiac I-GENE
output O
( O
CO I-GENE
) O
was O
significantly O
higher O
( O
p O
less O
than O
0 O
. O
_RARE_ I-GENE
) O
in O
the O
_RARE_ I-GENE
group O
. O

Amino O
acid I-GENE
residues O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
of O
the O
previously O
reported O
sequence I-GENE
are O
replaced O
by O
new O
residues O
_RARE_ I-GENE
to O
150 O
. O

Transcriptional O
activation O
by O
the O
HIV I-GENE
- I-GENE
1 I-GENE
Tat I-GENE
protein I-GENE
requires O
specific I-GENE
residues O
in O
the O
_RARE_ I-GENE
loop I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
of O
the O
TAR I-GENE
RNA I-GENE
stem O
- I-GENE
loop I-GENE
structure O
found O
in O
the O
5 I-GENE
'- O
untranslated O
leader O
of O
all O
viral I-GENE
transcripts I-GENE
. O

We O
obtained O
quantitative O
evidence O
on O
the O
coding O
of O
_RARE_ I-GENE
time O
differences O
( O
_RARE_ I-GENE
) O
of O
_RARE_ I-GENE
stimuli O
by O
40 I-GENE
single O
neurons O
in O
the O
auditory O
cortex O
of O
anesthetized O
_RARE_ I-GENE
rats O
. O

These O
results O
strongly O
suggest O
that O
locally O
- I-GENE
applied O
_RARE_ I-GENE
in O
combination O
with O
_RARE_ I-GENE
enhances O
new O
bone O
formation O
in O
experimental O
alveolar O
bone O
defects O
. O

As O
an O
initial O
step O
towards O
the O
characterization O
of O
replicative O
DNA I-GENE
polymerases I-GENE
of O
_RARE_ I-GENE
, O
we O
have O
cloned O
, O
sequenced O
and O
examined O
the O
expression O
of O
the O
Trypanosoma O
( O
_RARE_ I-GENE
) O
_RARE_ I-GENE
_RARE_ I-GENE
gene I-GENE
that O
encodes O
the O
DNA I-GENE
polymerase I-GENE
alpha I-GENE
catalytic O
core I-GENE
( O
pol I-GENE
alpha I-GENE
). O

In O
addition O
, O
there O
was O
a O
significant O
increase O
in O
_RARE_ I-GENE
cortical O
concentrations O
with O
age O
( O
p O
less O
than O
0 O
. O
01 O
; O
r O
= O
0 O
. O
31 O
). O

_RARE_ I-GENE
hypertension O
, O
with O
or O
without O
coronary O
arterial O
_RARE_ I-GENE
, O
is O
the O
major I-GENE
condition O
leading O
to O
isolated O
atrial I-GENE
infarction O
. O

The O
volume O
fraction O
( O
_RARE_ I-GENE
) O
and O
number O
/ I-GENE
mm2 O
( O
Na I-GENE
) O
of O
all O
capillaries O
( O
perfused O
and O
_RARE_ I-GENE
) O
in O
a O
given O
area O
of O
brain O
were O
determined O
after O
staining O
for O
alkaline I-GENE
phosphatase I-GENE
. O

_RARE_ I-GENE
pressure O
and O
air O
flow O
were O
measured O
at O
the O
_RARE_ I-GENE
tube O
in O
13 O
children O
on O
a O
variety O
of O
_RARE_ I-GENE
. O

_RARE_ I-GENE
. O

_RARE_ I-GENE
of O
distribution O
of O
kinetic O
energy O
of O
_RARE_ I-GENE
_RARE_ I-GENE
in O
direct O
contact O
interaction O
with O
head I-GENE
during O
impact O
are O
discussed O
from O
position O
of O
_RARE_ I-GENE
. O

CONCLUSION O
: O
_RARE_ I-GENE
_RARE_ I-GENE
at O
the O
nasal O
_RARE_ I-GENE
site I-GENE
is O
more O
reliable O
than O
monitoring O
it O
at O
the O
finger I-GENE
site I-GENE
in O
_RARE_ I-GENE
patients O
. O

_RARE_ I-GENE
decreased O
the O
total O
body O
clearance O
from O
34 O
. O
0 O
+/- O
8 O
. O
0 O
to O
28 O
. O
6 I-GENE
+/- O
6 I-GENE
. O
1 I-GENE
mL O
/ I-GENE
min O
( O
P I-GENE
less O
than O
. O
01 O
), O
and O
prolonged O
the O
elimination O
half O
- I-GENE
life O
from O
12 O
. O
6 I-GENE
+/- O
3 I-GENE
. O
0 O
to O
14 O
. O
3 I-GENE
+/- O
2 I-GENE
. O
5 I-GENE
hours O
( O
P I-GENE
less O
than O
. O
01 O
) O
of O
_RARE_ I-GENE
without O
any O
changes O
in O
volume O
of O
distribution O
. O

The O
granules O
_RARE_ I-GENE
as O
the O
_RARE_ I-GENE
material O
_RARE_ I-GENE
into O
the O
_RARE_ I-GENE
space O
among O
the O
_RARE_ I-GENE
particles O
. O

Hence O
, O
the O
uPA I-GENE
promoter I-GENE
contains O
multiple O
weak O
cis O
- I-GENE
acting O
elements O
distributed O
over O
7 O
. O
0 O
kb O
5 I-GENE
' O
to O
the O
translation I-GENE
start O
site I-GENE
. O

_RARE_ I-GENE
a O
Ser O
for O
_RARE_ I-GENE
or O
a O
Glu O
for O
Lys O
71 O
in O
the O
conserved O
_RARE_ I-GENE
_RARE_ I-GENE
in O
finger I-GENE
II I-GENE
of O
_RARE_ I-GENE
resulted O
in O
the O
loss O
of O
DNA I-GENE
binding I-GENE
. O

P I-GENE
. O

In O
one O
, O
_RARE_ I-GENE
behavior O
( O
assessed O
by O
_RARE_ I-GENE
_RARE_ I-GENE
) O
and O
_RARE_ I-GENE
were O
assessed O
during O
a O
10 O
- I-GENE
min O
test O
session O
. O

The O
model O
is O
able O
to O
_RARE_ I-GENE
_RARE_ I-GENE
the O
effect O
of O
water O
_RARE_ I-GENE
on O
_RARE_ I-GENE
prevalence O
is O
most O
pronounced O
when O
_RARE_ I-GENE
is O
diagnosed O
at O
cavity O
level O
. O

12 O
- I-GENE
O O
- I-GENE
_RARE_ I-GENE
13 O
- I-GENE
acetate O
was O
found O
to O
inhibit O
rapidly O
and O
_RARE_ I-GENE
the O
expression O
of O
mRNAs I-GENE
coding O
for O
the O
myogenic I-GENE
regulators O
_RARE_ I-GENE
and O
myogenin I-GENE
. O

In O
Xenopus I-GENE
laevis I-GENE
, O
the O
gene I-GENE
encoding O
the O
elongation I-GENE
factor I-GENE
1 I-GENE
- I-GENE
alpha I-GENE
variant I-GENE
EF I-GENE
- I-GENE
1 I-GENE
alpha I-GENE
O O
, O
where O
O O
_RARE_ I-GENE
for O
oocyte O
, O
is O
expressed O
in O
oocytes O
and O
early I-GENE
embryos O
. O

These O
introns O
belong O
to O
the O
class I-GENE
of O
nuclear I-GENE
pre I-GENE
- I-GENE
mRNA I-GENE
introns O
and O
contain O
typical O
5 I-GENE
'- O
and O
3 I-GENE
'- O
consensus I-GENE
sequences I-GENE
, O
as O
well O
as O
unique O
features O
. O

The O
mRNA I-GENE
identified O
in O
both O
human I-GENE
and O
rat I-GENE
cells O
with O
the O
human I-GENE
clathrin I-GENE
clone O
revealed O
transcripts I-GENE
of O
approximately O
6 I-GENE
. O
5 I-GENE
kb O
, O
which O
is O
consistent O
with O
the O
predicted O
180 O
kDa I-GENE
molecular O
weight O
of O
the O
clathrin I-GENE
heavy I-GENE
chain I-GENE
. O

In O
this O
report O
, O
almost O
6 I-GENE
kb O
of O
DNA I-GENE
sequence I-GENE
is O
presented O
, O
including O
_RARE_ I-GENE
bp O
5 I-GENE
' O
to O
the O
gene I-GENE
, O
over O
4 I-GENE
kb O
of O
exon O
and O
exon O
- I-GENE
intron O
junctions O
, O
and O
_RARE_ I-GENE
bp O
3 I-GENE
' O
to O
the O
gene I-GENE
. O

An O
8 O
- I-GENE
h O
exposure O
to O
10 O
mg O
_RARE_ I-GENE
/ I-GENE
m3 O
corresponds O
to O
a O
postexposure O
plasma I-GENE
concentration O
and O
2 I-GENE
- I-GENE
h O
postexposure O
urinary O
excretion O
of O
4 I-GENE
. O
9 O
mumol O
/ I-GENE
l O
and O
75 O
mmol O
/ I-GENE
mol O
creatinine O
, O
respectively O
. O

Antibodies O
specific I-GENE
to O
_RARE_ I-GENE
and O
_RARE_ I-GENE
- I-GENE
6 I-GENE
disrupt O
nucleoprotein I-GENE
complexes I-GENE
with O
these O
DNA I-GENE
- I-GENE
binding I-GENE
sites I-GENE
, O
confirming O
the O
interaction O
of O
native O
in O
vivo O
factors I-GENE
. O

A I-GENE
method O
is O
described O
for O
detecting O
targeted O
events O
at O
the O
mu I-GENE
heavy I-GENE
chain I-GENE
gene I-GENE
which O
_RARE_ I-GENE
on O
co O
- I-GENE
conversion O
( O
or O
co O
- I-GENE
exchange I-GENE
) O
of O
a O
point O
mutation I-GENE
with O
a O
selectable O
marker O
contained O
on O
a O
replacement O
vector O
. O

_RARE_ I-GENE
activity O
of O
allergen I-GENE
extract O
_RARE_ I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
was O
tested O
in O
_RARE_ I-GENE
volunteers O
extremely O
sensitive O
to O
the O
allergen I-GENE
. O

This O
study O
was O
aimed O
at O
assessing O
whether O
c I-GENE
- I-GENE
DDP O
administration O
immediately O
before O
radiotherapy O
could O
increase O
frequency O
and O
duration O
of O
objective O
responses O
, O
as O
well O
as O
survival O
, O
in O
patients O
affected O
with O
locally O
advanced O
stages O
of O
squamous O
carcinomas O
of O
the O
head I-GENE
and O
neck O
. O

Two O
potential O
regulatory I-GENE
sequences I-GENE
for O
DNA I-GENE
binding I-GENE
proteins I-GENE
were O
found O
in O
the O
non O
- I-GENE
coding O
5 I-GENE
' O
region O
: O
a O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
consensus I-GENE
recognition I-GENE
sequence I-GENE
at O
nucleotide I-GENE
- I-GENE
154 O
and O
a O
_RARE_ I-GENE
consensus I-GENE
recognition I-GENE
sequence I-GENE
at O
nucleotide I-GENE
- I-GENE
136 O
. O

Marked O
thrombocytopenia O
, O
depletion O
of O
serum I-GENE
fibrinogen I-GENE
and O
prolonged O
prothrombin I-GENE
and O
activated I-GENE
partial O
thromboplastin I-GENE
time O
, O
were O
recorded O
at O
5 I-GENE
to O
10 O
and O
30 O
to O
40 I-GENE
minutes O
after O
intravenous O
_RARE_ I-GENE
. O

We O
_RARE_ I-GENE
the O
properties O
of O
LexA I-GENE
fusion I-GENE
proteins I-GENE
to O
study O
the O
dimerization O
and O
DNA I-GENE
- I-GENE
_RARE_ I-GENE
domains I-GENE
of O
_RARE_ I-GENE
. O

Plasma I-GENE
lipid O
and O
lipoprotein I-GENE
profiles O
were O
compared O
in O
elderly O
female O
_RARE_ I-GENE
( O
_RARE_ I-GENE
: O
n O
= O
15 O
, O
aged O
66 O
+/- O
5 I-GENE
years O
, O
body O
fat O
20 O
+/- O
4 I-GENE
%, O
training O
distance O
35 O
+/- O
15 O
_RARE_ I-GENE
week O
- I-GENE
1 I-GENE
, O
_RARE_ I-GENE
36 O
+/- O
4 I-GENE
ml O
kg O
- I-GENE
1 I-GENE
min O
- I-GENE
1 I-GENE
, O
mean O
+/- O
SD O
) O
and O
age O
- I-GENE
matched O
_RARE_ I-GENE
women O
( O
UT O
: O
n O
= O
28 O
, O
66 O
+/- O
4 I-GENE
years O
, O
body O
fat O
26 O
+/- O
6 I-GENE
%, O
_RARE_ I-GENE
26 O
+/- O
3 I-GENE
ml O
kg O
- I-GENE
1 I-GENE
min O
- I-GENE
1 I-GENE
). O

_RARE_ I-GENE
threshold O
shifts O
, O
as O
measured O
by O
the O
auditory O
evoked O
_RARE_ I-GENE
response O
, O
were O
measured O
at O
2 I-GENE
, O
4 I-GENE
, O
8 O
, O
12 O
, O
16 O
, O
20 O
and O
24 O
_RARE_ I-GENE
. O

_RARE_ I-GENE
and O
clinical O
evaluation O
of O
equilibrium O
dialysis O
-- O
radioimmunoassay O
system O
for O
measurement O
of O
serum I-GENE
free O
thyroxine O

We O
conclude O
that O
TA O
caused O
a O
specific I-GENE
decrease O
in O
_RARE_ I-GENE
on O
_RARE_ I-GENE
20 O
that O
was O
largely O
reversed O
by O
_RARE_ I-GENE
23 O
. O

When O
examined O
as O
adults O
( O
8 O
weeks O
old O
), O
the O
external O
_RARE_ I-GENE
of O
TA O
- I-GENE
exposed O
_RARE_ I-GENE
were O
normal O
. O

After O
PTCA O
, O
ejection O
fraction O
increased O
from O
54 I-GENE
+/- O
8 O
% O
to O
59 O
+/- O
8 O
% O
( O
p O
less O
than O
0 O
. O
05 O
) O
and O
regional O
function O
improved O
significantly O
( O
maximal O
standard O
deviation O
before O
PTCA O
: O
2 I-GENE
. O
8 O
+/- O
0 O
. O
8 O
; O
after O
PTCA O
: O
1 I-GENE
. O
9 O
+/- O
0 O
. O
9 O
- I-GENE
segments O
below O
the O
first O
standard O
deviation O
before O
PTCA O
: O
31 O
+/- O
16 O
; O
after O
PTCA O
: O
19 O
+/- O
17 O
). O

The O
alcoholic O
patient O
, O
his O
work O
and O
the O
_RARE_ I-GENE
of O
the O
period O

These O
data O
suggest O
that O
the O
combined O
treatment O
with O
a O
thromboxane I-GENE
synthetase I-GENE
inhibitor I-GENE
and O
a O
thromboxane I-GENE
receptor I-GENE
antagonist O
provides O
a O
better O
protection O
against O
_RARE_ I-GENE
_RARE_ I-GENE
than O
with O
either O
agent O
alone O
. O

A I-GENE
_RARE_ I-GENE
- I-GENE
kb O
YAC O
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
from O
the O
HLA I-GENE
- I-GENE
_RARE_ I-GENE
locus I-GENE
through O
the O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
4 I-GENE
locus I-GENE
and O
extended O
at O
least O
130 I-GENE
kb O
_RARE_ I-GENE
of O
YAC O
_RARE_ I-GENE
. O

_RARE_ I-GENE
backcross O
analysis O
using O
_RARE_ I-GENE
derived O
from O
_RARE_ I-GENE
of O
( O
C57BL O
/ I-GENE
_RARE_ I-GENE
x O
_RARE_ I-GENE
_RARE_ I-GENE
) O
F1 I-GENE
x O
C57BL O
/ I-GENE
_RARE_ I-GENE
mice O
indicates O
that O
the O
_RARE_ I-GENE
gene I-GENE
is O
tightly O
linked O
to O
the O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
loci I-GENE
on O
murine I-GENE
chromosome O
2 I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
outcome O
in O
specific I-GENE
IgM I-GENE
positive O
Chlamydia O
_RARE_ I-GENE
infection O
in O
pregnancy O
. O

Using O
an O
image O
- I-GENE
processing O
computer O
, O
regional O
LV O
time O
- I-GENE
density I-GENE
curves O
were O
constructed O
for O
one O
cardiac O
cycle O
. O

In O
a O
second O
patient O
the O
VT O
became O
_RARE_ I-GENE
. O

If O
delay O
has O
occurred O
between O
_RARE_ I-GENE
and O
the O
measurement O
, O
causing O
substantial O
loss O
of O
CO2 O
, O
_RARE_ I-GENE
of O
the O
sample O
with O
a O
gas O
mixture O
corresponding O
to O
PCO2 O
= O
5 I-GENE
. O
3 I-GENE
_RARE_ I-GENE
prior O
to O
the O
measurement O
is O
recommended O
. O

The O
possible O
mechanisms O
underlying O
differences O
in O
post O
- I-GENE
_RARE_ I-GENE
effects O
from O
muscle O
and O
cutaneous O
afferents O
in O
adults O
and O
neonates O
are O
discussed O
. O

We O
examined O
behavioral O
alterations O
in O
the O
brown O
_RARE_ I-GENE
, O
_RARE_ I-GENE
_RARE_ I-GENE
, O
infected O
with O
the O
_RARE_ I-GENE
, O
_RARE_ I-GENE
_RARE_ I-GENE
. O

First O
, O
the O
finding O
of O
a O
monomeric I-GENE
Alu I-GENE
family I-GENE
repeat I-GENE
at O
the O
junction O
between O
_RARE_ I-GENE
block O
I I-GENE
and O
homology I-GENE
block O
Y I-GENE
of O
the O
alpha I-GENE
2 I-GENE
gene I-GENE
- I-GENE
containing O
unit I-GENE
in O
rhesus I-GENE
_RARE_ I-GENE
suggests O
that O
the O
dimeric I-GENE
Alu I-GENE
family I-GENE
repeat I-GENE
, O
Alu I-GENE
3 I-GENE
, O
at O
the O
_RARE_ I-GENE
position O
in O
human I-GENE
was O
generated O
by O
insertion O
of O
a O
monomeric I-GENE
Alu I-GENE
family I-GENE
repeat I-GENE
into O
the O
3 I-GENE
' O
end O
of O
another O
_RARE_ I-GENE
Alu I-GENE
family I-GENE
repeat I-GENE
. O

The O
sequence I-GENE
of O
the O
repressor I-GENE
locus I-GENE
, O
c I-GENE
, O
of O
the O
Streptomyces I-GENE
_RARE_ I-GENE
phage I-GENE
, O
phi I-GENE
_RARE_ I-GENE
, O
was O
shown O
previously O
to O
contain O
an O
open O
reading O
frame O
encoding O
a O
74 O
kDa I-GENE
protein I-GENE
. O

The O
EPO I-GENE
levels O
were O
distinctly O
increased O
before O
transfusion O
; O
they O
did O
not O
significantly O
change O
just O
after O
transfusion O
, O
but O
subsequently O
decreased O
. O

This O
differential O
sensitivity O
to O
_RARE_ I-GENE
, O
as O
measured O
by O
a O
lower O
concentration O
of O
_RARE_ I-GENE
which O
caused O
loss O
of O
_RARE_ I-GENE
in O
_RARE_ I-GENE
, O
was O
accompanied O
by O
an O
equal O
rate O
of O
water O
- I-GENE
soluble I-GENE
_RARE_ I-GENE
brain O
distribution O
and O
elimination O
in O
the O
two O
lines O
. O

The O
existence O
of O
threshold O
concentrations O
, O
above O
which O
certain O
phenomena O
may O
occur O
, O
_RARE_ I-GENE
the O
role O
of O
_RARE_ I-GENE
. O

However O
, O
it O
was O
synthesized O
at O
both O
temperatures O
after O
addition O
of O
_RARE_ I-GENE
. O

_RARE_ I-GENE
did O
not O
alter O
the O
baseline O
FEV1 O
, O
but O
showed O
a O
small I-GENE
significant O
inhibitory I-GENE
effect O
upon O
histamine O
and O
AMP I-GENE
induced O
_RARE_ I-GENE
. O

Ten O
out O
of O
10 O
patients O
with O
progressive O
disease O
had O
mast I-GENE
cells O
greater O
than O
or O
equal O
to O
0 O
. O
5 I-GENE
%, O
_RARE_ I-GENE
greater O
than O
or O
equal O
to O
50 O
micrograms O
. O
l O
- I-GENE
1 I-GENE
and O
fibronectin I-GENE
greater O
than O
or O
equal O
to O
350 O
micrograms O
. O
l O
- I-GENE
1 I-GENE
compared O
to O
eight O
out O
of O
41 O
patients O
with O
stable O
or O
_RARE_ I-GENE
disease O
.( O
ABSTRACT O
TRUNCATED O
AT I-GENE
250 O
WORDS O
) O

Our O
mapping O
results O
did O
not O
suggest O
involvement O
of O
this O
gene I-GENE
in O
previously O
mapped O
genetic O
disorders O
or O
in O
known O
_RARE_ I-GENE
- I-GENE
associated I-GENE
translocation O
breakpoints O
. O

_RARE_ I-GENE
little O
is O
known O
regarding O
the O
role O
of O
5 I-GENE
- I-GENE
HT2 I-GENE
receptor I-GENE
activity O
in O
male O
rat I-GENE
sexual O
behavior O
. O

These O
changes O
_RARE_ I-GENE
' O
t I-GENE
so O
significant O
in O
the O
group O
of O
obese O
children O
who O
_RARE_ I-GENE
' O
t I-GENE
_RARE_ I-GENE
weight O
. O

_RARE_ I-GENE
contents O
in O
native O
copper I-GENE

In O
ten O
other O
experiments O
( O
5 I-GENE
experimental O
and O
5 I-GENE
control O
rats O
) O
99mTc O
- I-GENE
sulfur O
colloid O
was O
injected O
intravenously O
. O

_RARE_ I-GENE
of O
hepatitis I-GENE
A I-GENE
and O
B I-GENE
in O
children O

These O
results O
were O
superior O
to O
those O
in O
24 O
patients O
with O
conventional O
end O
- I-GENE
to O
- I-GENE
end O
_RARE_ I-GENE
on O
clinical O
testing O
. O

Mutational O
analysis O
supports O
a O
role O
for O
multiple O
structural O
features O
in O
the O
C I-GENE
- I-GENE
terminal I-GENE
secretion O
signal I-GENE
of O
Escherichia I-GENE
coli I-GENE
_RARE_ I-GENE
. O

Among O
blood O
donors O
in O
the O
_RARE_ I-GENE
of O
_RARE_ I-GENE
, O
regardless O
the O
number O
of O
blood O
_RARE_ I-GENE
, O
the O
percentage O
of O
female O
donors O
is O
significantly O
lower O
compared O
to O
the O
percentage O
of O
male O
blood O
donors O
. O

_RARE_ I-GENE
relapse O
in O
childhood O
leukemia I-GENE
. O

_RARE_ I-GENE
pneumoniae I-GENE
was O
isolated O
from O
the O
pleural I-GENE
fluid O
of O
this O
patient O
. O

_RARE_ I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
in O
combination O
have O
been O
shown O
to O
be O
effective O
in O
early I-GENE
termination O
of O
pregnancy O
. O

The O
presence O
of O
local O
abnormalities O
in O
both O
patients O
can O
support O
the O
hypothesis O
that O
the O
cortex O
, O
especially O
of O
the O
temporal O
anterior O
lobe O
, O
is O
involved O
in O
the O
origin O
of O
the O
_RARE_ I-GENE
seizures O
. O

In O
line O
with O
the O
small I-GENE
values O
for O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
, O
our O
results O
further O
indicate O
that O
even O
large O
, O
well O
- I-GENE
perfused O
, O
occluded O
air O
_RARE_ I-GENE
in O
the O
lung O
will O
_RARE_ I-GENE
affect O
the O
recovered O
ventilation O
/ I-GENE
perfusion O
distribution O
obtained O
from O
_RARE_ I-GENE
gas O
data O
when O
_RARE_ I-GENE
_RARE_ I-GENE
0 O
. O
1 I-GENE
ml O
. O
min O
- I-GENE
1 I-GENE
. O
mmHg O
- I-GENE
1 I-GENE
. O

Many O
cells O
were O
negative O
for O
endothelial I-GENE
- I-GENE
cell O
markers O
, O
and O
they O
reacted O
with O
a O
monoclonal I-GENE
antibody I-GENE
against O
muscle O
actin I-GENE
. O

CT I-GENE
abnormalities O
noted O
in O
term O
babies O
included O
hemorrhage O
( O
_RARE_ I-GENE
5 I-GENE
. O
8 O
%, O
_RARE_ I-GENE
11 O
. O
6 I-GENE
%), O
_RARE_ I-GENE
( O
mild O
23 O
. O
2 I-GENE
%, O
moderate O
11 O
. O
6 I-GENE
% O
severe O
5 I-GENE
. O
8 O
_RARE_ I-GENE
_RARE_ I-GENE
with O
hemorrhage O
5 I-GENE
. O
8 O
% O
and O
cerebral O
atrophy O
5 I-GENE
. O
8 O
%. O

The O
effects O
of O
contrast O
media O
on O
coagulation I-GENE
factor I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
were O
_RARE_ I-GENE
from O
the O
growing O
to O
the O
_RARE_ I-GENE
diet O
at O
57 O
and O
61 O
kg O
in O
_RARE_ I-GENE
. O

In O
_RARE_ I-GENE
patients O
with O
moderate O
essential O
hypertension O
the O
effects O
of O
10 O
- I-GENE
day O
nifedipine O
treatment O
on O
serum I-GENE
uric O
acid I-GENE
and O
renal O
excretion O
of O
uric O
acid I-GENE
were O
evaluated O
. O

_RARE_ I-GENE
produced O
brain O
_RARE_ I-GENE
, O
and O
hepatic I-GENE
and O
pulmonary O
_RARE_ I-GENE
and O
generalized O
_RARE_ I-GENE
. O

_RARE_ I-GENE
are O
using O
more O
subjects O
or O
an O
improved O
research O
design O
, O
developing O
consensus I-GENE
_RARE_ I-GENE
or O
using O
_RARE_ I-GENE
- I-GENE
analysis O
. O

A I-GENE
two O
phase O
_RARE_ I-GENE
flow O
tubular O
heat I-GENE
_RARE_ I-GENE
was O
used O
for O
the O
thermal O
inactivation O
of O
_RARE_ I-GENE
monocytogenes O
in O
natural O
infected O
milk O
from O
seven O
cows O
. O

_RARE_ I-GENE
far O
15 O
children O
have O
been O
studied O
. O

_RARE_ I-GENE
cerebral O
blood O
flow O
( O
rCBF O
) O
measurements O
and O
psychiatric O
_RARE_ I-GENE
were O
performed O
on O
seven O
schizophrenic O
patients O
( O
mean O
age O
= O
41 O
. O
4 I-GENE
years O
) O
who O
had O
been O
examined O
18 O
years O
previously O
in O
a O
study O
that O
used O
similar O
psychiatric O
_RARE_ I-GENE
and O
a O
comparable O
rCBF O
technique O
. O

In O
the O
present O
study O
, O
we O
identified O
a O
strong O
positive O
cis O
- I-GENE
regulatory I-GENE
element I-GENE
at O
- I-GENE
70 I-GENE
bp O
to O
- I-GENE
75 O
bp O
in O
the O
_RARE_ I-GENE
beta I-GENE
promoter I-GENE
with O
the O
sequence I-GENE
( O
G I-GENE
) O
6 I-GENE
and O
a O
similar O
, O
more O
distal O
cis O
- I-GENE
element I-GENE
at O
- I-GENE
_RARE_ I-GENE
bp O
to O
- I-GENE
_RARE_ I-GENE
bp O
. O

The O
present O
study O
reports O
visual O
evoked O
potential O
responses O
to O
pattern O
reversal O
( O
_RARE_ I-GENE
- I-GENE
P I-GENE
) O
in O
ten O
third O
_RARE_ I-GENE
pregnant O
women O
and O
changes O
in O
latency O
of O
_RARE_ I-GENE
complex I-GENE
when O
compared O
with O
these O
responses O
in O
the O
non O
pregnant O
state O
. O

No O
case O
of O
_RARE_ I-GENE
demonstrated O
_RARE_ I-GENE
_RARE_ I-GENE
growth I-GENE
. O

_RARE_ I-GENE
doses O
of O
15 O
- I-GENE
methyl O
- I-GENE
PGF2 O
alpha I-GENE
( O
0 O
. O
125 I-GENE
- I-GENE
10 O
mg O
) O
were O
used O
to O
induce O
_RARE_ I-GENE
and O
_RARE_ I-GENE
in O
7 O
heifers O
with O
28 O
treatments O
on O
day O
8 O
- I-GENE
12 O
of O
the O
_RARE_ I-GENE
cycle O
. O

_RARE_ I-GENE
of O
the O
literature O
and O
report O
of O
a O
case O
of O
a O
_RARE_ I-GENE
cyst O
. O

_RARE_ I-GENE
of O
_RARE_ I-GENE
asymmetry O
and O
/ I-GENE
or O
decrease O
in O
Delta I-GENE
T I-GENE
was O
demonstrated O
in O
approximately O
81 O
% O
of O
the O
post O
- I-GENE
treatment O
population O
. O

In O
all O
instances O
the O
apparent O
alcohol O
responses O
were O
very O
small I-GENE
and O
never O
_RARE_ I-GENE
a O
reading O
of O
1 I-GENE
microgram O
/ I-GENE
_RARE_ I-GENE
for O
_RARE_ I-GENE
samples O
more O
than O
_RARE_ I-GENE
post O
- I-GENE
exposure O
. O

_RARE_ I-GENE
_RARE_ I-GENE
promoter I-GENE
activity O
depends O
on O
sequence I-GENE
elements O
not O
found O
in O
_RARE_ I-GENE
_RARE_ I-GENE
promoters I-GENE
. O

Measurements O
were O
done O
with O
a O
commercial O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
which O
was O
_RARE_ I-GENE
to O
the O
average O
_RARE_ I-GENE
value O
of O
0 O
. O
42 O
. O

The O
relatively O
_RARE_ I-GENE
number O
of O
examples O
, O
which O
could O
be O
_RARE_ I-GENE
by O
the O
variety O
and O
complexity O
of O
combined O
exposure O
, O
allows O
to O
conclude O
that O
life O
- I-GENE
_RARE_ I-GENE
factors I-GENE
have O
considerable O
influence O
on O
_RARE_ I-GENE
differences O
in O
susceptibility I-GENE
to O
_RARE_ I-GENE
toxicity O
. O

The O
_RARE_ I-GENE
E1A I-GENE
product I-GENE
does O
not O
activate O
a O
TRE I-GENE
sequence I-GENE
, O
but O
cotransfection O
with O
c I-GENE
- I-GENE
jun I-GENE
_RARE_ I-GENE
this O
lack O
of O
stimulation O
. O

After O
treatment O
with O
_RARE_ I-GENE
, O
the O
transfectants O
secreted O
_RARE_ I-GENE
18 O
- I-GENE
kDa I-GENE
polypeptides I-GENE
which O
could O
also O
bind O
IgE I-GENE
. O

_RARE_ I-GENE
, O
a O
yeast I-GENE
gene I-GENE
required O
for O
peroxisome I-GENE
biogenesis O
, O
encodes O
a O
member O
of O
a O
novel O
family I-GENE
of O
putative O
_RARE_ I-GENE
. O

The O
gene I-GENE
is O
1 I-GENE
, O
139 O
base O
pairs O
( O
bp O
) O
long O
, O
and O
, O
like I-GENE
other O
members O
of O
the O
_RARE_ I-GENE
family I-GENE
, O
the O
beta I-GENE
TG I-GENE
gene I-GENE
is O
divided O
into O
3 I-GENE
exons O
. O

The O
_RARE_ I-GENE
- I-GENE
protein I-GENE
kinase I-GENE
activity O
( O
referred O
to O
as O
_RARE_ I-GENE
- I-GENE
kinase I-GENE
) O
is O
also O
not O
related I-GENE
to O
cofactor I-GENE
- I-GENE
dependent I-GENE
signal I-GENE
_RARE_ I-GENE
protein I-GENE
kinases I-GENE
such O
as O
the O
cyclic I-GENE
AMP I-GENE
- I-GENE
dependent I-GENE
protein I-GENE
kinases I-GENE
, O
members O
of O
the O
protein I-GENE
kinase I-GENE
C I-GENE
family I-GENE
, O
or O
other O
Ca2 I-GENE
(+)- I-GENE
dependent I-GENE
protein I-GENE
kinases I-GENE
. O

Human I-GENE
GATA I-GENE
- I-GENE
3 I-GENE
: O
a O
lineage O
- I-GENE
restricted O
transcription I-GENE
factor I-GENE
that O
regulates O
the O
expression O
of O
the O
T I-GENE
cell O
receptor I-GENE
alpha I-GENE
gene I-GENE
. O

Like O
many O
eukaryotic I-GENE
transcription I-GENE
factors I-GENE
, O
these O
proteins I-GENE
bind O
to O
DNA I-GENE
as O
dimers I-GENE
. O

Furthermore O
, O
the O
_RARE_ I-GENE
protein I-GENE
interacts O
with O
the O
_RARE_ I-GENE
protein I-GENE
to O
modulate O
its O
activities O
, O
both O
in O
solution O
and O
in O
association O
with O
DNA I-GENE
, O
where O
the O
_RARE_ I-GENE
complex I-GENE
possesses O
a O
helicase I-GENE
activity O
. O

The O
_RARE_ I-GENE
values O
were O
2 I-GENE
. O
4 I-GENE
and O
2 I-GENE
. O
2 I-GENE
mg O
/ I-GENE
kg O
and O
similar O
to O
the O
respective O
values O
of O
nifedipine O
( O
_RARE_ I-GENE
30 O
: O
2 I-GENE
. O
4 I-GENE
, O
2 I-GENE
. O
1 I-GENE
mg O
/ I-GENE
kg O
). O

_RARE_ I-GENE
blot O
analysis O
demonstrated O
that O
this O
phosphoprotein I-GENE
can O
bind O
the O
kappa I-GENE
B I-GENE
element I-GENE
directly O
and O
specifically O
. O

Thus O
, O
the O
positive O
effect O
of O
NS1 I-GENE
on O
the O
steady O
- I-GENE
state O
levels O
of O
P4 I-GENE
transcripts I-GENE
depends O
on O
the O
amplification O
of O
gene I-GENE
copy O
number O
and O
the O
integrity O
of O
the O
terminal I-GENE
repeats I-GENE
. O

The O
minus O
- I-GENE
end O
- I-GENE
directed O
microtubule I-GENE
_RARE_ I-GENE
, O
the O
_RARE_ I-GENE
, O
may O
also O
constitute O
a O
superfamily I-GENE
of O
force O
- I-GENE
generating O
proteins I-GENE
with O
distinct O
attachment O
domains I-GENE
. O

It O
is O
_RARE_ I-GENE
, O
_RARE_ I-GENE
to O
be O
made O
, O
and O
_RARE_ I-GENE
to O
_RARE_ I-GENE
and O
was O
tested O
in O
118 O
animals O
for O
two O
and O
four O
weeks O
. O

The O
_RARE_ I-GENE
group O
W I-GENE
plasmid O
_RARE_ I-GENE
suppresses O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
( O
J O
. O

_RARE_ I-GENE
translational O
start O
signals O
are O
upstream O
of O
ORF1 O
and O
ORF2 O
. O

_RARE_ I-GENE
of O
D2 I-GENE
dopamine I-GENE
receptor I-GENE

The O
_RARE_ I-GENE
mutation I-GENE
causes O
a O
lethal O
phenotype O
in O
the O
fission I-GENE
yeast I-GENE
Schizosaccharomyces I-GENE
pombe I-GENE
, O
while O
replacement O
of O
_RARE_ I-GENE
with O
_RARE_ I-GENE
acid I-GENE
, O
potentially O
_RARE_ I-GENE
phosphorylation O
, O
causes O
_RARE_ I-GENE
of O
mitosis O
and O
multiple O
_RARE_ I-GENE
. O

The O
abundance O
of O
transcripts I-GENE
from O
several O
unrelated O
genes I-GENE
is O
decreased O
in O
_RARE_ I-GENE
- I-GENE
1 I-GENE
mutant I-GENE
cells O
after O
transfer I-GENE
to O
the O
restrictive O
temperature O
, O
while O
at O
least O
one O
transcript I-GENE
, O
from O
the O
_RARE_ I-GENE
gene I-GENE
, O
_RARE_ I-GENE
in O
an O
aberrant O
fashion O
. O

_RARE_ I-GENE
of O
their O
expression O
may O
contribute O
to O
malignant O
transformation O
associated I-GENE
with O
HTLV I-GENE
- I-GENE
1 I-GENE
infection O
. O

The O
murine I-GENE
_RARE_ I-GENE
- I-GENE
34 O
gene I-GENE
: O
full I-GENE
- I-GENE
length I-GENE
cDNA I-GENE
and O
genomic O
organization O
. O

CREB I-GENE
was O
identified O
as O
one O
of O
the O
protein I-GENE
components O
in O
several O
of O
the O
gel O
shift O
complexes I-GENE
formed O
with O
the O
variant I-GENE
CRE O
. O

The O
spectrum O
of O
histologically O
diagnosed O
malignant O
neoplasms O
in O
_RARE_ I-GENE
, O
1983 O
- I-GENE
1988 O
. O

When O
transfected O
into O
Drosophila I-GENE
_RARE_ I-GENE
- I-GENE
2 I-GENE
cells O
, O
_RARE_ I-GENE
plasmid O
containing O
2 I-GENE
, O
_RARE_ I-GENE
bp O
of O
5 I-GENE
'- O
flanking O
region O
shows O
a O
3 I-GENE
. O
0 O
- I-GENE
to O
3 I-GENE
. O
5 I-GENE
- I-GENE
fold O
increase O
in O
chloramphenicol I-GENE
acetyltransferase I-GENE
activity O
after O
induction O
with O
retinoic I-GENE
acid I-GENE
and O
/ I-GENE
or O
8 O
- I-GENE
_RARE_ I-GENE
- I-GENE
cAMP I-GENE
. O

Two O
alternatively O
spliced O
5 I-GENE
' O
_RARE_ I-GENE
, O
designated O
type I-GENE
I I-GENE
and O
type I-GENE
II I-GENE
, O
of O
_RARE_ I-GENE
and O
115 I-GENE
bp O
, O
respectively O
, O
were O
found O
associated I-GENE
with O
_RARE_ I-GENE
. O

The O
N I-GENE
- I-GENE
terminus O
of O
another O
open O
reading O
frame O
was O
found O
3 I-GENE
' O
from O
_RARE_ I-GENE
and O
tentatively O
identified O
as O
_RARE_ I-GENE
by O
amino O
acid I-GENE
sequence I-GENE
comparison O
. O

The O
RNA I-GENE
genome O
of O
rabbit I-GENE
hemorrhagic O
disease O
virus I-GENE
( O
_RARE_ I-GENE
) O
was O
molecularly O
cloned O
. O

Therefore O
, O
we O
have O
developed O
a O
system O
to O
study O
nuclear I-GENE
targeting O
in O
plants O
and O
have O
established O
that O
the O
nuclear I-GENE
transport O
machinery O
is O
similar O
in O
_RARE_ I-GENE
and O
_RARE_ I-GENE
. O

A I-GENE
novel O
cDNA I-GENE
clone O
termed O
R2 I-GENE
was O
isolated O
by O
_RARE_ I-GENE
hybridization O
of O
a O
cDNA I-GENE
library O
of O
phytohemagglutinin I-GENE
( O
PHA I-GENE
)/ O
phorbol O
myristate O
acetate O
- I-GENE
stimulated O
Jurkat O
cells O
and O
by O
_RARE_ I-GENE
a O
cDNA I-GENE
library O
of O
PHA I-GENE
- I-GENE
stimulated O
peripheral O
blood O
lymphocytes O
. O

In O
conclusion O
, O
we O
observed O
a O
great O
regeneration O
ability O
following O
mechanical O
injury O
in O
the O
nasal O
mucosa O
. O

There O
occurred O
a O
linear O
relationship O
between O
the O
drop O
in O
glucose O
- I-GENE
6 I-GENE
- I-GENE
phosphatase I-GENE
dehydrogenase I-GENE
activity O
and O
in O
vitamin O
E I-GENE
level O
, O
on O
one O
hand O
, O
and O
the O
duration O
of O
poisoning O
with O
sodium O
nitrite I-GENE
. O

A I-GENE
vector O
containing O
a O
transcriptionally O
inactive O
neomycin I-GENE
phosphotransferase I-GENE
II I-GENE
gene I-GENE
was O
used O
to O
select O
promoter I-GENE
sequences I-GENE
from O
a O
pool O
of O
random O
genomic O
DNA I-GENE
fragments I-GENE
. O

_RARE_ I-GENE
' O
disease O
, O
visceral O
_RARE_ I-GENE
, O
anti I-GENE
- I-GENE
nuclear I-GENE
factor I-GENE
, O
_RARE_ I-GENE
, O
rheumatoid I-GENE
factor I-GENE
and O
normal O
controls O
. O

Previous O
analysis O
of O
the O
98 O
- I-GENE
bp O
sequence I-GENE
has O
_RARE_ I-GENE
several O
protein I-GENE
- I-GENE
binding I-GENE
domains I-GENE
that O
are O
recognized O
by O
nuclear I-GENE
factors I-GENE
present O
in O
human I-GENE
brain O
cells O
. O

The O
second O
transcriptional O
unit I-GENE
, O
designated O
UL26 I-GENE
. O
5 I-GENE
, O
predicted O
to O
_RARE_ I-GENE
a O
protein I-GENE
of O
_RARE_ I-GENE
amino O
acids O
, O
encodes O
the O
family I-GENE
35 O
proteins I-GENE
; O
it O
is O
transcribed O
by O
an O
mRNA I-GENE
which O
_RARE_ I-GENE
at O
approximately O
nucleotide I-GENE
+ I-GENE
1000 O
of O
the O
UL26 I-GENE
transcription I-GENE
initiation I-GENE
site I-GENE
and O
is O
translated O
from O
the O
methionine O
initiation I-GENE
codon O
located O
at O
position O
+ I-GENE
_RARE_ I-GENE
of O
the O
UL26 I-GENE
transcriptional O
unit I-GENE
. O

The O
_RARE_ I-GENE
- I-GENE
associated I-GENE
virus I-GENE
( O
AAV I-GENE
) O
_RARE_ I-GENE
gene I-GENE
encodes O
four O
proteins I-GENE
( O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
) O
required O
for O
AAV I-GENE
DNA I-GENE
replication O
and O
AAV I-GENE
gene I-GENE
regulation O
. O

A I-GENE
larger O
region O
upstream O
of O
human I-GENE
CMV O
_RARE_ I-GENE
also O
mediated O
replication O
in O
transient O
assays O
. O

It O
also O
contains O
a O
_RARE_ I-GENE
3C I-GENE
- I-GENE
like I-GENE
protease I-GENE
domain I-GENE
and O
two O
_RARE_ I-GENE
- I-GENE
like I-GENE
protease I-GENE
domains I-GENE
. O

However O
, O
the O
relative O
positions O
of O
the O
_RARE_ I-GENE
genes I-GENE
( O
genus O
_RARE_ I-GENE
) O
are O
different O
than O
those O
of O
the O
corresponding O
ORFs O
in O
SFV I-GENE
( O
genus O
_RARE_ I-GENE
), O
indicating O
complex I-GENE
rearrangements O
of O
DNA I-GENE
in O
the O
genome O
of O
one O
or O
both O
of O
these O
viruses O
subsequent O
to O
their O
divergence O
from O
a O
common O
ancestor O
. O

This O
result O
suggests O
that O
phosphorylation O
of O
Thr I-GENE
14 O
and O
/ I-GENE
or O
Tyr I-GENE
15 O
inhibits O
p34cdc2 I-GENE
kinase I-GENE
activity O
, O
in O
line O
with O
the O
location O
of O
these O
residues O
within O
the O
putative O
ATP I-GENE
binding I-GENE
site I-GENE
of O
the O
kinase I-GENE
. O

In O
short O
- I-GENE
term O
_RARE_ I-GENE
, O
a O
_RARE_ I-GENE
- I-GENE
CAT I-GENE
target O
containing O
EBNA I-GENE
- I-GENE
1 I-GENE
- I-GENE
binding I-GENE
sites I-GENE
from O
the O
EBV I-GENE
origin O
of O
plasmid O
replication O
, O
_RARE_ I-GENE
- I-GENE
P I-GENE
, O
was O
transactivated O
by O
a O
carboxy I-GENE
- I-GENE
terminal I-GENE
EBNA I-GENE
- I-GENE
1 I-GENE
construction I-GENE
( O
amino O
acids O
450 I-GENE
to O
_RARE_ I-GENE
) O
that O
also O
carried O
a O
c I-GENE
- I-GENE
myc I-GENE
nuclear I-GENE
localization O
signal I-GENE
. O

The O
findings O
are O
compatible O
with O
the O
idea O
that O
the O
genes I-GENE
encoding O
PDGF I-GENE
receptors I-GENE
in O
glioma O
cells O
are O
regulated O
in O
_RARE_ I-GENE
with O
other O
genes I-GENE
, O
the O
expression O
of O
which O
may O
reflect O
the O
developmental O
program O
of O
normal O
_RARE_ I-GENE
cell O
lineages O
. O

_RARE_ I-GENE
evidence O
was O
obtained O
that O
_RARE_ I-GENE
is O
involved O
in O
peptide I-GENE
utilization O
. O

This O
study O
tested O
the O
hypothesis O
that O
sodium O
channel O
blocking O
drugs O
selectively O
_RARE_ I-GENE
the O
late O
potential O
, O
or O
terminal I-GENE
low O
amplitude O
signal I-GENE
, O
portion O
of O
the O
signal I-GENE
- I-GENE
averaged O
QRS O
complex I-GENE
and O
that O
prolongation O
of O
the O
late O
potential O
would O
correlate O
with O
_RARE_ I-GENE
of O
ventricular O
tachycardia O
. O

Identification O
and O
nucleotide I-GENE
sequence I-GENE
of O
Rhizobium I-GENE
_RARE_ I-GENE
insertion O
sequence I-GENE
_RARE_ I-GENE
: O
similarity O
between O
the O
putative O
_RARE_ I-GENE
encoded I-GENE
by O
_RARE_ I-GENE
and O
those O
encoded I-GENE
by O
Staphylococcus I-GENE
aureus I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
. O

To O
determine O
the O
relationship O
of O
these O
viruses O
, O
the O
complete O
DNA I-GENE
sequence I-GENE
of O
_RARE_ I-GENE
consisting O
of O
_RARE_ I-GENE
bp O
was O
determined O
. O

Whereas O
a O
_RARE_ I-GENE
beta I-GENE
transcript I-GENE
of O
about O
2 I-GENE
. O
3 I-GENE
kb O
was O
detected O
at O
high O
levels O
in O
the O
neuroblastoma O
derived O
cell O
line O
LA O
- I-GENE
N I-GENE
- I-GENE
1 I-GENE
, O
the O
level O
of O
the O
mRNA I-GENE
was O
very O
low O
in O
the O
other O
human I-GENE
cell O
lines O
analyzed O
. O

_RARE_ I-GENE
of O
myogenin I-GENE
and O
E12 I-GENE
( O
or O
MyoD I-GENE
and O
E12 I-GENE
) O
specifically O
bound O
a O
restriction I-GENE
fragment I-GENE
extending O
from O
- I-GENE
200 O
to O
- I-GENE
_RARE_ I-GENE
relative O
to O
the O
start O
of O
cardiac O
alpha I-GENE
- I-GENE
actin I-GENE
transcription I-GENE
. O

The O
effects O
of O
c I-GENE
- I-GENE
myc I-GENE
were O
further O
_RARE_ I-GENE
by O
showing O
that O
c I-GENE
- I-GENE
myc I-GENE
can O
inhibit O
differentiation O
independently O
of O
_RARE_ I-GENE
, O
a O
negative O
regulator I-GENE
of O
muscle O
differentiation O
. O

Stable O
association O
of O
U2 I-GENE
snRNP I-GENE
with O
the O
branchpoint O
sequence I-GENE
of O
mammalian I-GENE
pre I-GENE
- I-GENE
mRNAs I-GENE
requires O
binding I-GENE
of O
a O
non O
- I-GENE
snRNP I-GENE
protein I-GENE
to O
the O
_RARE_ I-GENE
tract O
. O

_RARE_ I-GENE
acquired O
antibodies I-GENE
were O
demonstrated O
in O
some O
rabbits O
kept O
on O
commercial O
_RARE_ I-GENE
. O

The O
Italian O
Lung O
Cancer O
_RARE_ I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
). O

The O
promoter I-GENE
activity O
of O
the O
gene I-GENE
encoding O
Alzheimer I-GENE
beta I-GENE
- I-GENE
_RARE_ I-GENE
precursor I-GENE
protein I-GENE
( O
_RARE_ I-GENE
) O
is O
regulated O
by O
two O
blocks O
of O
upstream O
sequences I-GENE
. O

Biol O
. O

Nucleotide O
sequences I-GENE
between O
the O
env I-GENE
gene I-GENE
and O
the O
LTR I-GENE
of O
SFV I-GENE
- I-GENE
1 I-GENE
were O
determined O
. O

This O
element I-GENE
was O
used O
to O
screen O
an O
_RARE_ I-GENE
mouse I-GENE
genomic O
library O
. O

The O
_RARE_ I-GENE
- I-GENE
value O
is O
under O
the O
predicted O
level O
in O
the O
case O
of O
67 O
- I-GENE
76 I-GENE
percent O
. O

The O
_RARE_ I-GENE
. O
192 I-GENE
DNA I-GENE
repair I-GENE
mutant I-GENE
from O
the O
fission I-GENE
yeast I-GENE
, O
Schizosaccharomyces I-GENE
pombe I-GENE
, O
is O
sensitive O
to O
both O
UV O
and O
_RARE_ I-GENE
radiation O
. O

_RARE_ I-GENE
: O
deterioration O
of O
glucose O
tolerance O
with O
age O
: O
the O
role O
of O
insulin I-GENE
resistance O
. O

The O
5 I-GENE
' O
region O
shows O
strong O
sequence I-GENE
similarity O
to O
Escherichia I-GENE
coli I-GENE
consensus I-GENE
promoters I-GENE
and O
ribosome I-GENE
- I-GENE
binding I-GENE
sequences I-GENE
and O
allows O
high O
levels O
of O
expression O
in O
E I-GENE
. O
coli I-GENE
. O

_RARE_ I-GENE
initiation I-GENE
of O
mitosis O
in O
yeast I-GENE
lacking O
_RARE_ I-GENE
or O
an O
interacting I-GENE
GTPase I-GENE
. O

The O
method O
has O
been O
_RARE_ I-GENE
used O
in O
our O
laboratory O
for O
1 I-GENE
year O
and O
has O
proven O
to O
be O
a O
reliable O
procedure O
for O
the O
biological O
control O
of O
_RARE_ I-GENE
exposure O
to O
toluene O
and O
/ I-GENE
or O
xylene O
. O

The O
patient O
was O
a O
78 O
- I-GENE
year O
- I-GENE
old O
male O
in O
whom O
skin O
lesions O
_RARE_ I-GENE
the O
diagnosis O
of O
_RARE_ I-GENE
. O

_RARE_ I-GENE
- I-GENE
500 O
is O
a O
group O
of O
high O
resolution O
imaging O
_RARE_ I-GENE
for O
use O
with O
_RARE_ I-GENE
- I-GENE
AT I-GENE
and O
compatible O
_RARE_ I-GENE
. O

The O
human I-GENE
cDNA I-GENE
was O
used O
to O
demonstrate O
that O
tumor I-GENE
necrosis I-GENE
factor I-GENE
- I-GENE
alpha I-GENE
could O
rapidly O
stimulate O
_RARE_ I-GENE
gene I-GENE
transcription I-GENE
in O
the O
human I-GENE
_RARE_ I-GENE
leukemia I-GENE
cell O
line O
_RARE_ I-GENE
. O

After O
resection O
of O
the O
proximal I-GENE
fragment I-GENE
, O
all O
_RARE_ I-GENE
contact O
area O
and O
pressure O
was O
born O
by O
the O
distal O
_RARE_ I-GENE
fragment I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
, O
a O
technique O
that O
uses O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
_RARE_ I-GENE
between O
the O
plate I-GENE
and O
the O
bone O
, O
as O
well O
as O
between O
the O
_RARE_ I-GENE
_RARE_ I-GENE
and O
the O
plate I-GENE
, O
to O
improve O
the O
stability O
of O
internal O
fixation O
was O
tested O
in O
vitro O
using O
20 O
paired I-GENE
equine I-GENE
third O
_RARE_ I-GENE
_RARE_ I-GENE
with O
mid O
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
with O
six O
- I-GENE
_RARE_ I-GENE
broad O
_RARE_ I-GENE
compression O
plates O
. O

These O
features O
were O
considered O
consistent O
with O
a O
diagnosis O
of O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
syndrome O
. O

_RARE_ I-GENE
lymphoma O
and O
its O
management O
. O

The O
protein I-GENE
encoded I-GENE
by O
_RARE_ I-GENE
contains O
a O
transmembrane I-GENE
domain I-GENE
. O

_RARE_ I-GENE
limitations O
prevent O
an O
_RARE_ I-GENE
review O
of O
all O
_RARE_ I-GENE
_RARE_ I-GENE
, O
such O
as O
tissue I-GENE
plasminogen I-GENE
activating I-GENE
_RARE_ I-GENE
, O
hormones O
( O
e O
. O
g O
., O
thyroid I-GENE
, O
insulin I-GENE
, O
growth I-GENE
hormone I-GENE
, O
erythropoietin I-GENE
), O
clotting I-GENE
factors I-GENE
, O
and O
blood O
products I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
RNA I-GENE
decreases O
after O
6 I-GENE
h O
of O
starvation O
to O
re O
- I-GENE
accumulate O
once O
the O
cells O
have O
_RARE_ I-GENE
. O

The O
various O
forms O
of O
_RARE_ I-GENE
cell O
disease O
share O
the O
common O
feature O
of O
an O
abnormal O
globin I-GENE
chain I-GENE
that O
, O
under O
certain O
conditions O
such O
as O
hypoxia O
, O
results O
in O
the O
_RARE_ I-GENE
of O
red I-GENE
blood O
cells O
and O
obstruction O
of O
blood O
vessels O
. O

The O
primary O
structure O
of O
each O
of O
the O
three O
proteins I-GENE
has O
about O
70 I-GENE
% O
homology I-GENE
with O
that O
of O
mouse I-GENE
_RARE_ I-GENE
, O
in O
contrast O
to O
43 I-GENE
- I-GENE
46 O
% O
homology I-GENE
with O
that O
of O
rat I-GENE
alpha I-GENE
1 I-GENE
- I-GENE
protease I-GENE
inhibitor I-GENE
. O

_RARE_ I-GENE
of O
_RARE_ I-GENE
underlying O
cross O
- I-GENE
modality O
integration O
were O
studied O
by O
injecting O
_RARE_ I-GENE
, O
_RARE_ I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
yellow O
) O
in O
_RARE_ I-GENE
manner O
into O
different O
sensory O
_RARE_ I-GENE
( O
visual O
, O
_RARE_ I-GENE
, O
and O
auditory O
) O
in O
the O
cerebral O
cortex O
of O
the O
rat I-GENE
. O

_RARE_ I-GENE
CD O
- I-GENE
1 I-GENE
mice O
, O
4 I-GENE
days O
old O
, O
exposed O
to O
0 O
. O
1 I-GENE
% O
nicotine O
sulfate I-GENE
on O
gestational O
days O
6 I-GENE
- I-GENE
20 O
were O
compared O
with O
untreated O
_RARE_ I-GENE
of O
the O
same O
age O
to O
determine O
its O
effect O
on O
the O
development O
of O
mandibular O
first O
_RARE_ I-GENE
. O

USF I-GENE
synthesized O
in O
an O
in O
vitro O
transcription I-GENE
and O
translation I-GENE
system O
also O
binds O
to O
the O
ADH I-GENE
promoter I-GENE
as O
well O
as O
to O
the O
_RARE_ I-GENE
. O

The O
across O
- I-GENE
fiber O
pattern O
of O
the O
responses O
to O
_RARE_ I-GENE
NaCl O
solutions O
correlated O
strongly O
to O
that O
elicited O
by O
_RARE_ I-GENE
_RARE_ I-GENE
.( O
ABSTRACT O
TRUNCATED O
AT I-GENE
400 O
WORDS O
) O

_RARE_ I-GENE
_RARE_ I-GENE
content O
after O
the O
intravenous O
administration O
of O
HMPAO O
in O
seven O
human I-GENE
subjects O
was O
analyzed O
. O

_RARE_ I-GENE
regression O
analysis O
was O
performed O
and O
the O
following O
result O
was O
obtained O
: O
clearance O
( O
HMPAO O
) O
= O
0 O
. O
07 O
+ I-GENE
0 O
. O
43 I-GENE
. O
rCBF O
with O
a O
high O
significance O
( O
p O
less O
than O
0 O
. O
001 O
). O

Human I-GENE
immunodeficiency I-GENE
virus I-GENE
type I-GENE
1 I-GENE
( O
HIV I-GENE
- I-GENE
1 I-GENE
) O
_RARE_ I-GENE
, O
expressed O
in O
Escherichia I-GENE
coli I-GENE
, O
was O
purified O
to O
near O
_RARE_ I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
correlated O
positively O
with O
HDL I-GENE
and O
HDL2 I-GENE
- I-GENE
C I-GENE
and O
mass O
, O
and O
with O
LDL I-GENE
particle I-GENE
size O
among O
women O
. O

_RARE_ I-GENE
from O
pairs O
of O
source O
and O
target O
volume O
elements O
are O
_RARE_ I-GENE
for O
the O
S I-GENE
values O
between O
the O
tumor I-GENE
and O
itself O
, O
between O
the O
remaining O
healthy O
host O
organ O
and O
itself O
, O
and O
between O
the O
tumor I-GENE
and O
the O
remaining O
healthy O
host O
organ O
, O
with O
the O
_RARE_ I-GENE
_RARE_ I-GENE
assumed O
for O
the O
last O
. O

_RARE_ I-GENE
showed O
that O
an O
overall O
_RARE_ I-GENE
of O
the O
force O
applied O
could O
be O
obtained O
from O
a O
laboratory O
_RARE_ I-GENE
, O
but O
that O
_RARE_ I-GENE
_RARE_ I-GENE
and O
testing O
_RARE_ I-GENE
were O
not O
_RARE_ I-GENE
by O
this O
method O
. O

The O
cDNA I-GENE
contained O
an O
open O
reading O
frame O
of O
_RARE_ I-GENE
bp O
that O
predicted O
a O
protein I-GENE
of O
_RARE_ I-GENE
amino O
acids O
and O
a O
molecular O
mass O
of O
52 O
kDa I-GENE
; O
this O
protein I-GENE
has O
97 O
% O
identity O
to O
rat I-GENE
liver O
_RARE_ I-GENE
. O

Analysis O
of O
viral I-GENE
mutants I-GENE
in O
vivo O
demonstrated O
that O
the O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
- I-GENE
1 I-GENE
binding I-GENE
site I-GENE
and O
a O
conserved O
ATF I-GENE
motif I-GENE
were O
important O
for O
efficient O
viral I-GENE
growth I-GENE
. O

_RARE_ I-GENE
of O
_RARE_ I-GENE
_RARE_ I-GENE
through O
urine O
( O
28 O
%) O
and O
_RARE_ I-GENE
( O
22 O
%) O
up O
to O
96 O
hrs O
averaged O
50 O
%, O
whereas O
residual O
_RARE_ I-GENE
in O
liver O
and O
testis I-GENE
experienced O
a O
recovery O
of O
29 O
% O
in O
_RARE_ I-GENE
animals O
. O

Saccharomyces I-GENE
cerevisiae I-GENE
has O
been O
used O
widely O
both O
as O
a O
model O
system O
for O
_RARE_ I-GENE
the O
biochemical O
, O
genetic O
, O
and O
molecular O
_RARE_ I-GENE
of O
gene I-GENE
expression O
and O
the O
secretion O
process O
, O
and O
as O
a O
host O
for O
the O
production O
of O
heterologous O
proteins I-GENE
of O
_RARE_ I-GENE
interest O
. O

_RARE_ I-GENE
, O
however O
, O
the O
GH I-GENE
receptor I-GENE
cloned O
from O
liver O
exhibits O
no O
sequence I-GENE
similarity O
to O
receptors I-GENE
with O
known O
signal I-GENE
transduction O
mechanisms O
, O
including O
those O
exhibiting O
ligand O
- I-GENE
activated I-GENE
tyrosine I-GENE
kinase I-GENE
activity O
. O

This O
indicates O
that O
under O
certain O
experimental O
conditions O
cdc2 I-GENE
/ I-GENE
_RARE_ I-GENE
and O
cdc2 I-GENE
/ I-GENE
p62 I-GENE
may O
express O
some O
differences O
in O
their O
catalytic O
activity O
. O

Mutation O
analysis O
implicated O
multiple O
segments O
of O
the O
5 I-GENE
' O
untranslated O
region O
as O
_RARE_ I-GENE
to O
the O
inhibitory I-GENE
effect O
. O

Identification O
of O
Ets I-GENE
- I-GENE
and O
_RARE_ I-GENE
- I-GENE
related I-GENE
subunits I-GENE
in O
GA I-GENE
binding I-GENE
protein I-GENE
. O

The O
enzymatic O
response O
of O
neutrophils O
and O
monocytes O
was O
similar O
although O
the O
magnitude O
of O
the O
_RARE_ I-GENE
oxidase I-GENE
activity O
was O
significantly O
higher O
in O
neutrophils O
than O
in O
monocytes O
. O

In O
the O
_RARE_ I-GENE
, O
enterotoxin I-GENE
increased O
the O
luminal O
disappearance O
( O
P I-GENE
less O
than O
0 O
. O
05 O
) O
and O
peripheral O
blood O
appearance O
( O
P I-GENE
less O
than O
0 O
. O
001 O
) O
of O
_RARE_ I-GENE
. O

_RARE_ I-GENE
activated I-GENE
both O
_RARE_ I-GENE
NS I-GENE
and O
_RARE_ I-GENE
neurones O
, O
but O
, O
when O
they O
responded O
, O
NS I-GENE
neurones O
( O
n O
= O
5 I-GENE
) O
showed O
only O
the O
first O
phase O
of O
activity O
while O
_RARE_ I-GENE
neurones O
showed O
either O
one O
( O
n O
= O
13 O
) O
or O
two O
phases O
( O
n O
= O
6 I-GENE
). O

_RARE_ I-GENE
of O
_RARE_ I-GENE
by O
Escherichia I-GENE
coli I-GENE

It O
is O
concluded O
that O
attention O
to O
these O
issues O
can O
substantially O
improve O
the O
quality O
of O
research O
on O
AIDS O
related I-GENE
_RARE_ I-GENE
on O
_RARE_ I-GENE
_RARE_ I-GENE
. O

The O
effectiveness O
of O
alpha I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
beta I-GENE
-( O
2 I-GENE
- I-GENE
_RARE_ I-GENE
) O
_RARE_ I-GENE
acid I-GENE
( O
_RARE_ I-GENE
) O
and O
N I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
N I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
D I-GENE
- I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
), O
used O
in O
combination O
, O
in O
the O
_RARE_ I-GENE
and O
excretion O
of O
lead O
was O
investigated O
in O
rats O
. O

These O
results O
suggest O
that O
beta I-GENE
- I-GENE
1 I-GENE
may O
act O
as O
a O
tissue I-GENE
- I-GENE
specific I-GENE
, O
trans O
- I-GENE
acting O
regulator I-GENE
of O
the O
expression O
of O
the O
beta I-GENE
- I-GENE
_RARE_ I-GENE
gene I-GENE
in O
developing O
maize I-GENE
_RARE_ I-GENE
. O

This O
study O
_RARE_ I-GENE
the O
effects O
of O
_RARE_ I-GENE
on O
the O
extracellular I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
at O
multiple O
tissue I-GENE
sites I-GENE
using O
a O
recently O
developed O
_RARE_ I-GENE
_RARE_ I-GENE
, O
that O
provides O
simultaneous O
measurements O
of O
_RARE_ I-GENE
and O
_RARE_ I-GENE
. O

All O
members O
are O
also O
capable O
of O
activating I-GENE
in O
vivo O
transcription I-GENE
from O
promoters I-GENE
that O
contain O
a O
C I-GENE
/ I-GENE
EBP I-GENE
- I-GENE
binding I-GENE
site I-GENE
. O

The O
domains I-GENE
involved O
in O
_RARE_ I-GENE
appear O
to O
be O
a O
subset O
of O
those O
necessary O
to O
achieve O
synergistic O
activation O
. O

_RARE_ I-GENE
on O
conserved O
noncoding O
sequences I-GENE
will O
help O
in O
studies O
on O
the O
regulation O
of O
the O
pro I-GENE
alpha I-GENE
1 I-GENE
( O
II I-GENE
) O
collagen I-GENE
gene I-GENE
. O

Chlamydia O
_RARE_ I-GENE
and O
Chlamydia O
_RARE_ I-GENE
were O
not O
affected O
by O
_RARE_ I-GENE
fixation O
. O

Although O
human I-GENE
infections O
with O
_RARE_ I-GENE
due O
to O
_RARE_ I-GENE
_RARE_ I-GENE
are O
not O
_RARE_ I-GENE
, O
_RARE_ I-GENE
associated I-GENE
with O
P I-GENE
. O
_RARE_ I-GENE
is O
rare O
. O

For O
_RARE_ I-GENE
at O
pH O
7 O
. O
0 O
, O
a O
1 I-GENE
: O
1 I-GENE
complex I-GENE
is O
formed O
, O
but O
at O
pH O
7 O
. O
5 I-GENE
_RARE_ I-GENE
has O
little O
effect O
on O
the O
_RARE_ I-GENE
of O
the O
highly O
_RARE_ I-GENE
_RARE_ I-GENE
, O
presumably O
since O
only O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
molecules I-GENE
can O
form O
inclusion O
complexes I-GENE
with O
the O
_RARE_ I-GENE
. O

PO2 O
measurements O
using O
a O
double O
_RARE_ I-GENE
_RARE_ I-GENE
type I-GENE
_RARE_ I-GENE
were O
measured O
in O
the O
optic O
nerve I-GENE
head I-GENE
of O
_RARE_ I-GENE
pigs O
in O
_RARE_ I-GENE
and O
_RARE_ I-GENE
. O

POU I-GENE
- I-GENE
specific I-GENE
and O
POU I-GENE
- I-GENE
_RARE_ I-GENE
domains I-GENE
of O
_RARE_ I-GENE
were O
produced O
in O
_RARE_ I-GENE
coli I-GENE
for O
characterization O
of O
DNA I-GENE
binding I-GENE
to O
the O
octamer O
sequence I-GENE
. O

A I-GENE
deletion O
series O
of O
the O
5 I-GENE
' O
flanking O
region O
was O
created O
from O
position O
- I-GENE
_RARE_ I-GENE
to O
- I-GENE
74 O
relative O
to O
the O
transcriptional O
initiation I-GENE
site I-GENE
and O
similarly O
examined O
in O
transgenic O
tobacco I-GENE
. O

The O
nucleotide I-GENE
( O
nt O
) O
sequences I-GENE
of O
the O
exons O
, O
exon O
/ I-GENE
intron O
boundaries O
and O
5 I-GENE
'- O
and O
3 I-GENE
'- O
untranslated O
regions O
were O
determined O
. O

_RARE_ I-GENE
of O
40 I-GENE
patients O
, O
who O
initially O
did O
not O
show O
eye O
complications O
due O
to O
_RARE_ I-GENE
, O
37 O
patients O
were O
essentially O
the O
same O
10 O
years O
later O
. O

Thus O
, O
two O
very O
different O
regulatory I-GENE
elements O
are O
used O
to O
mediate O
estrogen I-GENE
induction O
of O
related I-GENE
genes I-GENE
in O
chickens O
and O
_RARE_ I-GENE
. O

_RARE_ I-GENE
was O
very O
mild O
with O
both O
regimens O
, O
although O
sedation O
was O
significantly O
higher O
in O
arm O
B I-GENE
( O
p O
less O
than O
0 O
. O
001 O
). O

_RARE_ I-GENE
in O
green I-GENE
monkeys O
, O
Syrian I-GENE
hamsters O
and O
white O
mice O
the O
authors O
studied O
the O
pathogenic O
properties O
of O
a O
new O
virus I-GENE
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
. O

Increasing O
mean O
arterial O
pressure O
by O
_RARE_ I-GENE
infusion O
to O
levels O
much O
greater O
than O
produced O
by O
_RARE_ I-GENE
and O
_RARE_ I-GENE
caused O
only O
small I-GENE
reductions O
in O
cardiac O
output O
. O

J O
. O

_RARE_ I-GENE
of O
energy O
turnover O
in O
relation O
to O
physical O
performance O
were O
addressed O
in O
terms O
of O
upper O
and O
lower O
limit O
, O
changes O
during O
a O
training O
_RARE_ I-GENE
and O
how O
to O
regulate O
energy O
balance O
at O
a O
changing O
energy O
turnover O
. O

With O
_RARE_ I-GENE
reductions O
in O
flow O
, O
the O
peak O
( O
S I-GENE
) O
and O
trough O
( O
D I-GENE
) O
points O
of O
the O
maximum O
shifted O
- I-GENE
frequency O
envelope I-GENE
fell O
in O
parallel O
in O
a O
linear O
fashion O
until O
D I-GENE
reached O
zero O
. O

The O
_RARE_ I-GENE
gene I-GENE
product I-GENE
also O
transactivated O
the O
IE1 I-GENE
promoter I-GENE
but O
did O
not O
affect O
expression O
from O
its O
own O
promoter I-GENE
. O

Moreover O
, O
promoters I-GENE
containing O
a O
TATA I-GENE
box I-GENE
in O
the O
absence O
of O
Sp1 I-GENE
sites I-GENE
or O
Sp1 I-GENE
sites I-GENE
in O
the O
absence O
of O
a O
TATA I-GENE
box I-GENE
were O
equally O
inducible I-GENE
in O
vitro O
, O
as O
was O
an O
RNA I-GENE
polymerase I-GENE
III I-GENE
promoter I-GENE
. O

Evaluation O
of O
left O
ventricular O
function O
using O
gated O
_RARE_ I-GENE
myocardial O
imaging O
with O
Tc O
- I-GENE
99m O
- I-GENE
_RARE_ I-GENE

_RARE_ I-GENE
uptake O
and O
distribution O
in O
the O
plasma I-GENE
and O
tissue I-GENE
of O
_RARE_ I-GENE
and O
_RARE_ I-GENE
patients O
infected O
with O
_RARE_ I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
marrow O
abnormalities O
in O
Hodgkin O
' O
s O
disease O
are O
reviewed O
and O
the O
current O
understanding O
of O
the O
pathological O
mechanisms O
leading O
to O
_RARE_ I-GENE
anemia I-GENE
is O
discussed O
. O

The O
smaller O
uptake O
rate O
and O
faster O
clearance O
rate O
resulted O
in O
the O
lower O
_RARE_ I-GENE
for O
_RARE_ I-GENE
_RARE_ I-GENE
. O

The O
currently O
proposed O
extended O
_RARE_ I-GENE
repair I-GENE
should O
be O
_RARE_ I-GENE
for O
the O
small I-GENE
group O
of O
infants O
with O
transverse O
aortic O
_RARE_ I-GENE
to O
ascending O
aorta O
diameter O
ratios O
( O
_RARE_ I-GENE
indices O
) O
of O
less O
than O
0 O
. O
25 O
. O

DNA I-GENE
hybridization O
analysis O
revealed O
that O
both O
_RARE_ I-GENE
and O
_RARE_ I-GENE
cells O
of O
Y I-GENE
. O
_RARE_ I-GENE
possess O
a O
DNA I-GENE
locus I-GENE
homologous O
to O
the O
Escherichia I-GENE
coli I-GENE
_RARE_ I-GENE
gene I-GENE
. O

_RARE_ I-GENE
in O
the O
_RARE_ I-GENE
PCO2 O
but O
not O
in O
the O
_RARE_ I-GENE
H I-GENE
+ I-GENE
were O
highly O
correlated O
with O
decreases O
in O
both O
myocardial O
contractility O
and O
oxygen O
consumption O
( O
_RARE_ I-GENE
= O
. O
88 O
). O

Expression O
was O
cell O
cycle O
controlled O
, O
with O
steady O
- I-GENE
state O
RNA I-GENE
levels O
significantly O
higher O
in O
growth I-GENE
- I-GENE
arrested O
than O
in O
growth I-GENE
- I-GENE
stimulated O
cells O
. O

_RARE_ I-GENE
of O
recurrent O
ischaemia O
and O
_RARE_ I-GENE
procedures O
after O
_RARE_ I-GENE
with O
recombinant I-GENE
tissue I-GENE
plasminogen I-GENE
activator I-GENE
in O
primary O
coronary O
occlusion O
. O

Therefore O
, O
the O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
locus I-GENE
seems O
to O
be O
_RARE_ I-GENE
expressed O
under O
a O
standard O
condition O
for O
_RARE_ I-GENE
growth I-GENE
. O

_RARE_ I-GENE
between O
mitochondrial I-GENE
NADH I-GENE
- I-GENE
_RARE_ I-GENE
reductase I-GENE
and O
a O
bacterial I-GENE
NAD I-GENE
- I-GENE
reducing O
_RARE_ I-GENE
. O

Analysis O
of O
mRNA I-GENE
expression O
shows O
that O
AT I-GENE
- I-GENE
_RARE_ I-GENE
and O
AT I-GENE
- I-GENE
_RARE_ I-GENE
are O
expressed O
in O
all O
the O
tissues O
examined O
. O

We O
report O
two O
patients O
receiving O
maintenance O
_RARE_ I-GENE
, O
one O
with O
_RARE_ I-GENE
acute O
hepatitis I-GENE
C I-GENE
and O
the O
other O
with O
chronic O
persistent O
hepatitis I-GENE
C I-GENE
, O
with O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
demonstrated O
on O
oil O
- I-GENE
red I-GENE
O O
_RARE_ I-GENE
. O

3 I-GENE
cases O

_RARE_ I-GENE
- I-GENE
Gal I-GENE
: O
Gal I-GENE
beta I-GENE
1 I-GENE
---- I-GENE
_RARE_ I-GENE
alpha I-GENE
1 I-GENE
---- I-GENE
3 I-GENE
- I-GENE
_RARE_ I-GENE
is O
a O
terminal I-GENE
_RARE_ I-GENE
that O
is O
widely O
expressed O
in O
a O
variety O
of O
mammalian I-GENE
species O
, O
with O
the O
_RARE_ I-GENE
exception O
of O
man O
, O
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
_RARE_ I-GENE
monkeys O
. O

A I-GENE
synthetic O
oligonucleotide I-GENE
containing O
the O
SRE O
sequence I-GENE
from O
the O
mouse I-GENE
c I-GENE
- I-GENE
fos I-GENE
gene I-GENE
promoter I-GENE
(- O
_RARE_ I-GENE
to O
- I-GENE
_RARE_ I-GENE
) O
was O
_RARE_ I-GENE
labeled O
, O
used O
as O
a O
probe O
for O
the O
mobility I-GENE
shift O
assay O
and O
_RARE_ I-GENE
( O
DNA I-GENE
- I-GENE
protein I-GENE
) O
blotting O
, O
and O
also O
used O
for O
sequence I-GENE
- I-GENE
specific I-GENE
affinity O
chromatography O
. O

Sequence O
requirements O
for O
premature O
transcription I-GENE
arrest O
within O
the O
first O
intron O
of O
the O
mouse I-GENE
c I-GENE
- I-GENE
fos I-GENE
gene I-GENE
. O

_RARE_ I-GENE
regional O
ejection O
fraction O
improved O
by O
10 O
. O
1 I-GENE
+/- O
2 I-GENE
. O
1 I-GENE
% O
between O
early I-GENE
and O
late O
studies O
when O
the O
infarct O
- I-GENE
related I-GENE
artery O
was O
_RARE_ I-GENE
and O
by O
4 I-GENE
. O
8 O
+/- O
1 I-GENE
. O
4 I-GENE
% O
if O
it O
was O
occluded O
( O
p O
= O
0 O
. O
_RARE_ I-GENE
); O
changes O
in O
global O
and O
_RARE_ I-GENE
regional O
ejection O
fraction O
were O
similar O
irrespective O
of O
perfusion O
status O
. O

One O
of O
its O
lysine O
residues O
is O
modified O
by O
_RARE_ I-GENE
to O
form O
_RARE_ I-GENE
, O
a O
posttranslational O
modification O
unique O
to O
eIF I-GENE
- I-GENE
_RARE_ I-GENE
. O

The O
plasmid O
_RARE_ I-GENE
technique O
was O
used O
to O
replace O
the O
wild I-GENE
- I-GENE
type I-GENE
gene I-GENE
with O
the O
mutant I-GENE
form O
, O
resulting O
in O
failure O
of O
the O
yeast I-GENE
cells O
to O
grow O
. O

If O
this O
is O
the O
case O
, O
identification O
and O
characterization O
of O
transcripts I-GENE
from O
the O
Ig I-GENE
loci I-GENE
should O
permit O
a O
better O
understanding O
of O
the O
gene I-GENE
rearrangement O
process O
. O

Transcription O
of O
the O
_RARE_ I-GENE
gene I-GENE
in O
Salmonella I-GENE
_RARE_ I-GENE
and O
Escherichia I-GENE
coli I-GENE
is O
positively O
regulated O
by O
the O
_RARE_ I-GENE
gene I-GENE
product I-GENE
, O
a O
DNA I-GENE
binding I-GENE
protein I-GENE
. O

Disruption O
of O
the O
chromosomal I-GENE
_RARE_ I-GENE
gene I-GENE
in O
alpha I-GENE
and O
a O
/ I-GENE
alpha I-GENE
cells O
conferred O
the O
_RARE_ I-GENE
phenotype O
, O
and O
the O
a O
/ I-GENE
alpha I-GENE
_RARE_ I-GENE
could O
not O
_RARE_ I-GENE
. O

The O
effect O
of O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
on O
the O
_RARE_ I-GENE
response O
induced O
by O
the O
combination O
of O
ADR O
and O
_RARE_ I-GENE
was O
also O
investigated O
in O
order O
to O
assess O
alterations O
in O
the O
therapeutic O
index O
of O
this O
combined O
therapeutic O
modality O
treatment O
. O

The O
ORF I-GENE
was O
analyzed O
for O
secondary O
structural O
features O
, O
and O
the O
sequence I-GENE
data O
bases O
were O
_RARE_ I-GENE
for O
homologies O
. O

This O
study O
indicates O
that O
this O
dose O
- I-GENE
intense O
regimen O
can O
be O
_RARE_ I-GENE
administered O
, O
even O
with O
the O
use O
of O
_RARE_ I-GENE
marrow O
, O
with O
an O
acceptable O
toxicity O
profile O
. O

_RARE_ I-GENE
- I-GENE
C I-GENE
can O
cause O
severe O
necrosis I-GENE
and O
ulceration O
when O
_RARE_ I-GENE
_RARE_ I-GENE
into O
skin O
and O
soft O
tissues O
following O
IV I-GENE
drug O
administration O
. O

In O
this O
study O
, O
we O
have O
cloned O
the O
5 I-GENE
'- O
flanking O
region O
of O
the O
human I-GENE
_RARE_ I-GENE
gene I-GENE
. O

_RARE_ I-GENE
: O
Patients O
received O
_RARE_ I-GENE
- I-GENE
PA I-GENE
, O
heparin O
, O
and O
aspirin I-GENE
. O

Consistent O
with O
the O
in O
vivo O
result O
, O
the O
_RARE_ I-GENE
_RARE_ I-GENE
in O
the O
crude O
cell O
extract O
display O
site I-GENE
- I-GENE
specific I-GENE
partial O
DNA I-GENE
cleavage O
activity O
. O

Additionally O
, O
I I-GENE
kappa I-GENE
B I-GENE
beta I-GENE
, O
but O
not O
I I-GENE
kappa I-GENE
B I-GENE
alpha I-GENE
, O
also O
prevented O
the O
binding I-GENE
of O
Rel I-GENE
to O
the O
kappa I-GENE
B I-GENE
site I-GENE
. O

Sequence O
analysis O
reveals O
that O
the O
DNA I-GENE
binding I-GENE
domain I-GENE
of O
_RARE_ I-GENE
has O
strong O
homology I-GENE
to O
the O
recently O
described O
fork I-GENE
head I-GENE
DNA I-GENE
binding I-GENE
domain I-GENE
found O
in O
the O
Drosophila I-GENE
homeotic I-GENE
protein I-GENE
fork I-GENE
head I-GENE
and O
a O
family I-GENE
of O
hepatocyte I-GENE
nuclear I-GENE
factors I-GENE
, O
HNF I-GENE
- I-GENE
3 I-GENE
. O

_RARE_ I-GENE
and O
repeated O
_RARE_ I-GENE
were O
required O
to O
lower O
_RARE_ I-GENE
to O
_RARE_ I-GENE
_RARE_ I-GENE
. O

A I-GENE
single O
i O
. O
p O
. O
injection O
of O
d O
, O
l O
- I-GENE
_RARE_ I-GENE
10 O
mg O
/ I-GENE
kg O
both O
reduced O
noradrenaline O
( O
NA O
) O
biosynthesis O
in O
vivo O
( O
31 O
%) O
and O
the O
endogenous I-GENE
concentration O
of O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
( O
32 O
%) O
and O
increased O
NA O
levels O
( O
28 O
%). O

_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
have O
strong O
_RARE_ I-GENE
effect O
on O
cyclophosphamide O
induced O
_RARE_ I-GENE
in O
mice O
. O

Mutations O
in O
the O
small I-GENE
subunit I-GENE
of O
_RARE_ I-GENE
_RARE_ I-GENE
affect O
subunit I-GENE
binding I-GENE
and O
_RARE_ I-GENE
. O

The O
structural O
changes O
in O
intra O
- I-GENE
_RARE_ I-GENE
artery O
manifested O
mainly O
by O
an O
increase O
in O
number O
of O
muscular O
artery O
resulting O
from O
_RARE_ I-GENE
of O
precursor I-GENE
cells O
( O
_RARE_ I-GENE
and O
intermediate O
cells O
) O
located O
within O
partially O
muscular O
and O
_RARE_ I-GENE
arterial O
wall O
to O
smooth I-GENE
muscle O
cell O
, O
and O
by O
the O
medial O
wall O
_RARE_ I-GENE
due O
to O
hypertrophy O
and O
hyperplasia O
of O
smooth I-GENE
muscle O
cells O
as O
well O
as O
accumulation O
of O
a O
large O
amount O
of O
collagen I-GENE
, O
especially O
the O
type I-GENE
1 I-GENE
collagen I-GENE
. O

These O
results O
suggest O
that O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
may O
be O
a O
useful O
drug O
for O
the O
treatment O
of O
bronchial O
asthma O
by O
reducing O
late O
- I-GENE
phase O
airway O
responses O
and O
airway O
_RARE_ I-GENE
. O

In O
study O
2 I-GENE
, O
the O
correlation O
coefficients O
between O
the O
_RARE_ I-GENE
measurements O
obtained O
at O
the O
ulcer O
margin O
and O
at O
the O
adjacent O
normal O
mucosa O
, O
and O
delta I-GENE
_RARE_ I-GENE
obtained O
by O
the O
experienced O
_RARE_ I-GENE
and O
one O
of O
the O
three O
_RARE_ I-GENE
were O
0 O
. O
94 O
, O
0 O
. O
97 O
, O
and O
0 O
. O
94 O
, O
respectively O
. O

_RARE_ I-GENE
mucosa O
_RARE_ I-GENE
in O
persons O
exposed O
to O
different O
_RARE_ I-GENE
_RARE_ I-GENE
did O
not O
depend O
on O
the O
forms O
of O
PC I-GENE
, O
_RARE_ I-GENE
and O
the O
diseases O
' O
stages O
. O

Anti I-GENE
- I-GENE
_RARE_ I-GENE
production O
of O
_RARE_ I-GENE
was O
enhanced O
remarkably O
in O
this O
case O
. O

Sequence O
analysis O
of O
the O
_RARE_ I-GENE
genomic O
upstream O
sequences I-GENE
reveals O
a O
typical O
_RARE_ I-GENE
box I-GENE
within O
the O
80 O
base O
pairs O
( O
bp O
) O
that O
, O
by O
transfection O
experiments O
, O
are O
sufficient O
to O
promote O
expression O
of O
chimeric I-GENE
plasmids O
with O
the O
chloramphenicol I-GENE
acetyltransferase I-GENE
reporter I-GENE
. O

Sequence O
analysis O
of O
the O
_RARE_ I-GENE
genomic O
upstream O
sequences I-GENE
reveals O
a O
typical O
_RARE_ I-GENE
box I-GENE
within O
the O
80 O
base O
pairs O
( O
bp O
) O
that O
, O
by O
transfection O
experiments O
, O
are O
sufficient O
to O
promote O
expression O
of O
chimeric I-GENE
plasmids O
with O
the O
chloramphenicol I-GENE
acetyltransferase I-GENE
reporter I-GENE
. O

The O
cDNA I-GENE
segment O
is O
flanked O
by O
the O
immunoglobulin I-GENE
gene I-GENE
recombination O
signal I-GENE
sequences I-GENE
so O
that O
the O
cDNA I-GENE
segment O
can O
_RARE_ I-GENE
and O
the O
human I-GENE
IL I-GENE
- I-GENE
2R I-GENE
L I-GENE
chain I-GENE
is O
subsequently O
expressed O
under O
the O
control O
of O
the O
SV40 I-GENE
promoter I-GENE
. O

_RARE_ I-GENE
lipase I-GENE
( O
_RARE_ I-GENE
), O
a O
key O
enzyme I-GENE
in O
normal O
lipoprotein I-GENE
metabolism O
, O
has O
a O
complex I-GENE
pattern O
of O
regulation O
and O
tissue I-GENE
- I-GENE
specific I-GENE
expression O
. O

Deletion O
of O
the O
proximal I-GENE
_RARE_ I-GENE
motif I-GENE
from O
the O
plasmid O
containing O
the O
- I-GENE
_RARE_ I-GENE
fragment I-GENE
of O
the O
_RARE_ I-GENE
promoter I-GENE
, O
resulted O
in O
a O
79 O
and O
76 I-GENE
% O
decrease O
in O
the O
level O
of O
expression O
in O
transfected O
3T3 O
- I-GENE
L1 I-GENE
adipocytes O
and O
HepG2 O
hepatocytes O
, O
respectively O
. O

We O
examined O
the O
binding I-GENE
of O
purified O
T3 O
receptor I-GENE
alpha I-GENE
( O
T3R I-GENE
alpha I-GENE
), O
overexpressed O
in O
Escherichia I-GENE
coli I-GENE
, O
to O
wild I-GENE
- I-GENE
type I-GENE
and O
up O
and O
down O
mutations O
of O
the O
_RARE_ I-GENE
_RARE_ I-GENE
to O
evaluate O
whether O
transcriptional O
potency O
correlates O
with O
changes O
in O
T3R I-GENE
binding I-GENE
. O

Comparison O
of O
the O
cDNA I-GENE
- I-GENE
predicted O
avian I-GENE
_RARE_ I-GENE
amino O
acid I-GENE
sequences I-GENE
with O
known O
TnI I-GENE
sequences I-GENE
indicated O
1 I-GENE
) O
that O
the O
presence O
of O
an O
N I-GENE
- I-GENE
terminal I-GENE
extension O
sequence I-GENE
carrying O
a O
dual O
protein I-GENE
kinase I-GENE
A I-GENE
phosphorylation O
target O
site I-GENE
and O
an O
adjacent O
proline O
- I-GENE
rich O
segment O
is O
an O
_RARE_ I-GENE
cardiac O
- I-GENE
specific I-GENE
feature O
of O
TnI I-GENE
which O
has O
been O
conserved O
since O
the O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
divergence O
, O
2 I-GENE
) O
that O
features O
of O
the O
near O
- I-GENE
N I-GENE
- I-GENE
terminal I-GENE
_RARE_ I-GENE
C I-GENE
( O
_RARE_ I-GENE
)- I-GENE
binding I-GENE
site I-GENE
sequence I-GENE
suggest O
isoform I-GENE
- I-GENE
specific I-GENE
adaptation O
of O
TnI I-GENE
and O
_RARE_ I-GENE
, O
and O
3 I-GENE
) O
that O
the O
avian I-GENE
_RARE_ I-GENE
internal O
actin I-GENE
/ I-GENE
_RARE_ I-GENE
- I-GENE
binding I-GENE
, O
_RARE_ I-GENE
- I-GENE
inhibitory I-GENE
, O
domain I-GENE
shows O
significant O
sequence I-GENE
divergence O
from O
mammalian I-GENE
_RARE_ I-GENE
sequences I-GENE
, O
including O
the O
absence O
of O
a O
protein I-GENE
kinase I-GENE
C I-GENE
target O
site I-GENE
which O
is O
a O
cardiac O
- I-GENE
specific I-GENE
feature O
of O
TnI I-GENE
in O
mammals O
. O

_RARE_ I-GENE
management O
_RARE_ I-GENE
. O

An O
_RARE_ I-GENE
routine O
for O
on O
- I-GENE
line O
_RARE_ I-GENE
display O
and O
_RARE_ I-GENE
of O
data O
acquired O
on O
a O
personal O
_RARE_ I-GENE
. O

Expression O
of O
the O
mouse I-GENE
TSH I-GENE
beta I-GENE
gene I-GENE
, O
therefore O
, O
gives O
rise O
to O
multiple O
mRNAs I-GENE
, O
each O
with O
a O
unique O
5 I-GENE
'- O
untranslated O
region O
. O

_RARE_ I-GENE
of O
completely O
isolated O
neurons O
of O
the O
_RARE_ I-GENE
_RARE_ I-GENE
to O
electrical O
stimulation O
. O

It O
was O
found O
that O
the O
_RARE_ I-GENE
undergoes O
a O
number O
of O
fluctuations O
in O
the O
negative O
and O
positive O
_RARE_ I-GENE
with O
a O
gradually O
decreasing O
amplitude O
in O
the O
course O
of O
5 I-GENE
- I-GENE
25 O
days O
following O
the O
operation O
, O
after O
which O
relatively O
stable O
negative O
values O
of O
the O
_RARE_ I-GENE
are O
established O
on O
the O
average O
in O
electrodes O
implanted O
to O
the O
level O
of O
the O
_RARE_ I-GENE
_RARE_ I-GENE
, O
and O
positive O
values O
in O
electrodes O
implanted O
to O
the O
level O
of O
the O
_RARE_ I-GENE
_RARE_ I-GENE
. O

Blood O
flow O
velocity O
_RARE_ I-GENE
were O
recorded O
by O
pulsed O
Doppler O
examination O
of O
the O
fetal O
internal O
carotid O
and O
middle I-GENE
cerebral O
arteries O
using O
the O
established O
_RARE_ I-GENE
route O
as O
well O
as O
a O
new O
_RARE_ I-GENE
approach O
. O

Quantitative O
analysis O
of O
DNA I-GENE
using O
flow O
_RARE_ I-GENE
and O
_RARE_ I-GENE
findings O
in O
16 O
cases O
of O
cardiac O
_RARE_ I-GENE

Sequence O
analysis O
revealed O
that O
in O
addition O
to O
the O
non O
- I-GENE
spliced O
variant I-GENE
, O
multiple O
mRNA I-GENE
species O
were O
generated O
by O
alternative O
splicing O
resulting O
in O
the O
exclusion O
of O
92 O
, O
_RARE_ I-GENE
, O
170 I-GENE
, O
_RARE_ I-GENE
and O
_RARE_ I-GENE
nucleotides O
( O
nt O
), O
respectively O
, O
from O
exon O
1 I-GENE
. O

_RARE_ I-GENE
22 O
is O
an O
_RARE_ I-GENE
in O
the O
complete O
_RARE_ I-GENE
protein I-GENE
sequence I-GENE
, O
coded O
by O
an O
_RARE_ I-GENE
codon O
. O

_RARE_ I-GENE
due O
to O
the O
action O
of O
_RARE_ I-GENE
_RARE_ I-GENE
were O
observed O
. O

In O
the O
yeast I-GENE
Saccharomyces I-GENE
cerevisiae I-GENE
, O
copper I-GENE
levels O
exert O
some O
control O
over O
the O
level O
of O
_RARE_ I-GENE
expression O
. O

Of O
these O
_RARE_ I-GENE
samples O
, O
_RARE_ I-GENE
SP I-GENE
was O
observed O
in O
35 O
( O
19 O
. O
6 I-GENE
%) O
using O
Gram O
staining O
and O
in O
18 O
( O
10 O
. O
1 I-GENE
%) O
this O
_RARE_ I-GENE
was O
isolated O
in O
agar O
_RARE_ I-GENE
and O
anaerobic O
_RARE_ I-GENE
. O

Previous O
_RARE_ I-GENE
have O
suggested O
that O
subretinal O
blood O
_RARE_ I-GENE
the O
retina O
in O
part O
because O
of O
its O
solid O
fibrin I-GENE
_RARE_ I-GENE
. O

Twenty O
- I-GENE
four O
hours O
later O
, O
the O
animals O
were O
randomized O
to O
subretinal O
treatment O
with O
2 I-GENE
. O
5 I-GENE
micrograms O
of O
tissue I-GENE
plasminogen I-GENE
activator I-GENE
or O
a O
similar O
volume O
of O
_RARE_ I-GENE
saline O
. O

_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
examinations O
revealed O
spontaneous O
_RARE_ I-GENE
nystagmus O
, O
bilateral O
_RARE_ I-GENE
nystagmus O
and O
_RARE_ I-GENE
nystagmus O
. O

Since O
the O
morphology O
of O
the O
lesions O
can O
mimic O
that O
of O
other O
cutaneous O
disorders O
, O
_RARE_ I-GENE
' O
s O
disease O
is O
often O
not O
recognized O
initially O
. O

_RARE_ I-GENE
_RARE_ I-GENE
and O
live O
yeast I-GENE
cell O
derivative O
were O
evaluated O
as O
a O
biological O
_RARE_ I-GENE
and O
as O
a O
_RARE_ I-GENE
wound O
_RARE_ I-GENE
respectively O
, O
in O
the O
treatment O
of O
_RARE_ I-GENE
_RARE_ I-GENE
of O
the O
distal O
portion O
of O
the O
_RARE_ I-GENE
of O
horses O
. O

To O
lower O
the O
current O
high O
incidence O
of O
NANB O
- I-GENE
induced O
PTH I-GENE
, O
in O
1986 O
, O
the O
American O
Association O
of O
Blood O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
recommended O
testing O
for O
these O
PTH I-GENE
- I-GENE
associated I-GENE
" O
_RARE_ I-GENE
" O
markers O
on O
all O
_RARE_ I-GENE
units O
of O
blood O
. O

Insulin I-GENE
- I-GENE
like I-GENE
growth I-GENE
factor I-GENE
1 I-GENE
( O
IGF I-GENE
- I-GENE
1 I-GENE
) O
in O
burn O
patients O
. O

_RARE_ I-GENE
of O
ubiquitin I-GENE
to O
_RARE_ I-GENE
increased O
the O
yield O
of O
_RARE_ I-GENE
approximately O
10 O
- I-GENE
fold O
compared O
to O
that O
of O
the O
_RARE_ I-GENE
enzyme I-GENE
. O

In O
group O
III I-GENE
, O
patients O
also O
received O
their O
own O
_RARE_ I-GENE
drainage O
blood O
, O
_RARE_ I-GENE
for O
6 I-GENE
hours O
after O
operation O
, O
after O
concentration O
and O
_RARE_ I-GENE
in O
a O
_RARE_ I-GENE
. O

The O
suppression O
was O
also O
demonstrated O
in O
a O
transient O
expression O
assay O
in O
vivo O
using O
isolated O
barley I-GENE
_RARE_ I-GENE
. O

The O
effect O
of O
_RARE_ I-GENE
calcitonin I-GENE
nasal O
_RARE_ I-GENE
in O
women O
with O
established O
_RARE_ I-GENE
has O
also O
been O
studied O
. O

_RARE_ I-GENE
muscle O
_RARE_ I-GENE
responses O
are O
impaired O
in O
heart O
failure O
. O

_RARE_ I-GENE
muscle O
_RARE_ I-GENE
exercise O
responses O
are O
attenuated O
in O
heart O
failure O
. O

Evaluation O
of O
_RARE_ I-GENE
drug O
effect O
on O
membrane I-GENE
_RARE_ I-GENE
. O

The O
examinations O
were O
performed O
on O
two O
groups O
of O
20 O
( O
using O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
. O

RNA I-GENE
gel O
retardation O
and O
competition O
analyses O
indicate O
that O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
binding I-GENE
is O
strongly O
dependent I-GENE
on O
the O
TAR I-GENE
RNA I-GENE
loop I-GENE
sequences I-GENE
. O

The O
vaccine O
used O
was O
known O
to O
be O
_RARE_ I-GENE
for O
older O
children O
and O
adults O
. O

Both O
groups O
then O
underwent O
_RARE_ I-GENE
induction O
, O
and O
completed O
the O
test O
again O
( O
R2 I-GENE
). O

_RARE_ I-GENE
of O
three O
- I-GENE
dimensional O
analysis O
to O
the O
auditory O
_RARE_ I-GENE
. O

The O
construct I-GENE
was O
introduced O
into O
_RARE_ I-GENE
( O
_RARE_ I-GENE
- I-GENE
11 O
, O
_RARE_ I-GENE
- I-GENE
2 I-GENE
) O
strain O
cells O
of O
Escherichia I-GENE
coli I-GENE
. O

Recombinant I-GENE
human I-GENE
TFIID I-GENE
supported O
weak O
basal O
transcription I-GENE
in O
heat I-GENE
- I-GENE
treated O
nuclear I-GENE
extracts O
whereas O
a O
partially O
purified O
TFIID I-GENE
fraction O
from O
HeLa O
cells O
reconstituted O
a O
maximal O
level O
of O
transcription I-GENE
. O

Only O
after O
a O
pretreatment O
aimed O
at O
increasing O
its O
oxide I-GENE
surface O
layer O
was O
_RARE_ I-GENE
_RARE_ I-GENE
found O
to O
_RARE_ I-GENE
the O
precipitation O
from O
solutions O
containing O
2 I-GENE
mmol O
/ I-GENE
L I-GENE
_RARE_ I-GENE
, O
2 I-GENE
mmol O
/ I-GENE
L I-GENE
_RARE_ I-GENE
, O
50 O
mmol O
/ I-GENE
L I-GENE
_RARE_ I-GENE
, O
pH O
7 O
. O
2 I-GENE
, O
and O
to O
induce O
precipitation O
from O
_RARE_ I-GENE
solutions O
containing O
1 I-GENE
. O
2 I-GENE
mmol O
/ I-GENE
L I-GENE
_RARE_ I-GENE
, O
1 I-GENE
. O
2 I-GENE
mmol O
/ I-GENE
L I-GENE
_RARE_ I-GENE
, O
50 O
mmol O
/ I-GENE
L I-GENE
_RARE_ I-GENE
, O
pH O
7 O
. O
2 I-GENE
, O
at O
37 O
degrees O
C I-GENE
. O

We O
conclude O
that O
_RARE_ I-GENE
could O
occur O
in O
all O
_RARE_ I-GENE
containing O
casein I-GENE
and O
that O
alternative O
_RARE_ I-GENE
should O
be O
considered O
in O
patients O
with O
increased O
gastric O
_RARE_ I-GENE
. O

Neither O
model O
, O
as O
applied O
, O
provided O
a O
satisfactory O
account O
of O
the O
effects O
of O
the O
main O
variables O
of O
number O
of O
_RARE_ I-GENE
and O
amount O
of O
_RARE_ I-GENE
.( O
ABSTRACT O
TRUNCATED O
AT I-GENE
400 O
WORDS O
) O

This O
_RARE_ I-GENE
of O
_RARE_ I-GENE
involves O
_RARE_ I-GENE
an O
appropriate O
high O
- I-GENE
resolution O
cost O
function O
, O
_RARE_ I-GENE
the O
search O
space O
of O
the O
environment O
and O
source O
, O
_RARE_ I-GENE
solutions O
of O
the O
wave O
equation O
, O
and O
utilizing O
a O
_RARE_ I-GENE
_RARE_ I-GENE
method O
to O
search O
the O
parameter O
_RARE_ I-GENE
for O
the O
global O
minimum O
of O
the O
cost O
function O
. O

Determination O
of O
an O
RNA I-GENE
structure O
involved O
in O
splicing O
inhibition O
of O
a O
muscle O
- I-GENE
specific I-GENE
exon O
. O

_RARE_ I-GENE
cells O
stored O
with O
University O
of O
_RARE_ I-GENE
solution O
excluded O
_RARE_ I-GENE
blue O
better O
( O
1 I-GENE
. O
0 O
% O
+/- O
0 O
. O
5 I-GENE
% O
cells O
stained O
, O
p O
less O
than O
0 O
. O
001 O
. O

The O
original O
technique O
was O
developed O
in O
the O
_RARE_ I-GENE
' O
s O
to O
analyze O
the O
inner O
ear O
fluid O
as O
a O
diagnostic O
procedure O
( O
i O
. O
e O
., O
diagnostic O
_RARE_ I-GENE
) O
in O
acoustic O
_RARE_ I-GENE
_RARE_ I-GENE
. O

The O
effect O
of O
diffusion O
limitation O
was O
_RARE_ I-GENE
in O
terms O
of O
the O
ratio O
O2 O
uptake O
/ I-GENE
O2 O
requirement O
_RARE_ I-GENE
fraction O
of O
cross O
- I-GENE
sectional O
area O
supplied O
with O
O2 O
), O
_RARE_ I-GENE
local O
O2 O
requirement O
per O
unit I-GENE
volume O
to O
be O
constant O
and O
independent O
of O
PO2 O
at O
PO2 O
greater O
than O
0 O
. O

( O
2 I-GENE
) O
_RARE_ I-GENE
limitation O
in O
the O
heterogeneous I-GENE
model O
sets O
in O
at O
a O
lower O
O2 O
requirement O
value O
, O
and O
increases O
more O
gradually O
with O
increasing O
O2 O
requirement O
, O
than O
in O
the O
corresponding O
_RARE_ I-GENE
models O
with O
the O
same O
average O
_RARE_ I-GENE
diameter O
. O

The O
antihypertensive O
effect O
of O
_RARE_ I-GENE
has O
been O
examined O
over O
a O
12 O
- I-GENE
month O
period O
in O
101 I-GENE
hypertensive O
patients O
. O

At O
the O
time O
of O
the O
seizure O
, O
the O
patient O
was O
_RARE_ I-GENE
to O
_RARE_ I-GENE
a O
test O
_RARE_ I-GENE
_RARE_ I-GENE
until O
it O
was O
_RARE_ I-GENE
correctly O
and O
clearly O
. O

_RARE_ I-GENE
patients O
with O
acute O
leukemia I-GENE
for O
IL I-GENE
- I-GENE
1 I-GENE
and O
TNF I-GENE
levels O
throughout O
the O
clinical O
course O
of O
disease O
may O
help O
clarify O
the O
causes O
of O
_RARE_ I-GENE
episodes O
. O

_RARE_ I-GENE
_RARE_ I-GENE
was O
diagnosed O
by O
fine O
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
of O
a O
lung O
cyst O
in O
a O
6 I-GENE
- I-GENE
yr O
- I-GENE
old O
white O
female O
in O
central O
_RARE_ I-GENE
. O

The O
sequence I-GENE
was O
determined O
of O
_RARE_ I-GENE
nucleotides O
encompassing O
the O
_RARE_ I-GENE
genes I-GENE
of O
Escherichia I-GENE
coli I-GENE
which O
encode O
the O
_RARE_ I-GENE
_RARE_ I-GENE
- I-GENE
glycine O
_RARE_ I-GENE
pathway O
. O

A I-GENE
7 O
- I-GENE
day O
treatment O
of O
amphotericin O
B I-GENE
( O
5 I-GENE
mg O
/ I-GENE
kg O
/ I-GENE
day O
i O
. O
p O
.) O
significantly O
reduced O
the O
glomerular O
filtration O
rate O
( O
GFR O
) O
measured O
as O
_RARE_ I-GENE
clearance O
and O
creatinine O
clearance O
( O
0 O
. O
74 O
+/- O
0 O
. O
29 O
and O
0 O
. O
16 O
+/- O
0 O
. O
04 O
ml O
/ I-GENE
min O
, O
respectively O
) O
in O
comparison O
to O
vehicle O
- I-GENE
treated O
rats O
( O
2 I-GENE
. O
04 O
+/- O
0 O
. O
23 O
and O
1 I-GENE
. O
29 O
+/- O
0 O
. O
19 O
ml O
/ I-GENE
min O
, O
respectively O
). O

_RARE_ I-GENE
of O
lesions O
did O
not O
necessarily O
follow O
a O
regular O
progression O
through O
the O
later O
stages O
of O
the O
_RARE_ I-GENE
classification O
. O

_RARE_ I-GENE
fluorescence O
microscopy O
in O
modern O
cell O
_RARE_ I-GENE
. O

_RARE_ I-GENE
is O
the O
chemical O
most O
frequently O
present O
in O
cases O
involving O
volatile O
_RARE_ I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
-, I-GENE
_RARE_ I-GENE
- I-GENE
and O
HCB O
- I-GENE
levels O
decreased O
in O
breast O
milk O
during O
the O
last O
years O
. O

A I-GENE
herpesvirus I-GENE
proteinase I-GENE
activity O
has O
been O
identified O
and O
partially O
characterized O
by O
using O
the O
cloned O
enzyme I-GENE
and O
substrate I-GENE
genes I-GENE
in O
transient O
transfection O
assays O
. O

Adult O
H I-GENE
, O
but O
not O
R I-GENE
, O
manifested O
the O
_RARE_ I-GENE
preference O
_RARE_ I-GENE
offered O
the O
_RARE_ I-GENE
. O

The O
_RARE_ I-GENE
silver O
liquid O
chamber O
was O
threefold O
thick O
to O
17 O
_RARE_ I-GENE
_RARE_ I-GENE
in O
water O
and O
it O
efficiently O
produced O
either O
_RARE_ I-GENE
by O
the O
_RARE_ I-GENE
( O
p O
, O
alpha I-GENE
) O
_RARE_ I-GENE
reaction O
or O
[ O
18F O
] O
fluoride O
ion O
by O
the O
_RARE_ I-GENE
( O
p O
, O
n O
) O
18F O
reaction O
. O

_RARE_ I-GENE
electron O
transfer I-GENE
of O
cytochrome I-GENE
c I-GENE
facilitated O
by O
_RARE_ I-GENE
and O
methylene O
blue O
_RARE_ I-GENE
_RARE_ I-GENE
modified O
electrodes O
. O

Selective O
activation O
of O
adrenaline O
secretion O
by O
the O
rat I-GENE
adrenal O
in O
_RARE_ I-GENE
detected O
via O
_RARE_ I-GENE

_RARE_ I-GENE
specimens O
containing O
either O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
or O
11 O
- I-GENE
nor O
- I-GENE
delta I-GENE
9 O
- I-GENE
_RARE_ I-GENE
- I-GENE
9 O
- I-GENE
_RARE_ I-GENE
acid I-GENE
( O
9 O
- I-GENE
_RARE_ I-GENE
- I-GENE
COOH O
) O
were O
_RARE_ I-GENE
with O
sodium O
chloride O
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
potassium O
_RARE_ I-GENE
, O
liquid O
_RARE_ I-GENE
, O
2 I-GENE
- I-GENE
_RARE_ I-GENE
, O
and O
ammonia I-GENE
. O

The O
_RARE_ I-GENE
- I-GENE
base O
pair O
EFIA I-GENE
cDNA I-GENE
encodes O
a O
_RARE_ I-GENE
- I-GENE
amino O
acid I-GENE
protein I-GENE
which O
is O
nearly O
identical O
to O
two O
previously O
described O
human I-GENE
DNA I-GENE
binding I-GENE
proteins I-GENE
. O

Four O
putative O
positive O
cDNA I-GENE
clones O
were O
isolated O
, O
and O
the O
largest O
insert O
( O
_RARE_ I-GENE
- I-GENE
1 I-GENE
) O
was O
sequenced O
in O
both O
_RARE_ I-GENE
. O

_RARE_ I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
of O
botulinum I-GENE
toxin I-GENE
. O

The O
coding O
sequence I-GENE
for O
a O
260 O
- I-GENE
amino O
- I-GENE
acid I-GENE
residue O
polypeptide I-GENE
was O
interrupted O
by O
a O
single O
short O
intron O
of O
60 O
base O
pairs O
( O
bp O
), O
and O
about O
70 I-GENE
% O
of O
the O
deduced O
amino O
acid I-GENE
sequence I-GENE
of O
the O
Drosophila I-GENE
PCNA I-GENE
was O
identical O
to O
the O
rat I-GENE
and O
human I-GENE
PCNA I-GENE
polypeptides I-GENE
, O
with O
conserved O
unique O
repeats I-GENE
of O
leucine I-GENE
in O
the O
C I-GENE
- I-GENE
terminal I-GENE
region O
. O

_RARE_ I-GENE
fusions I-GENE
of O
the O
_RARE_ I-GENE
regulatory I-GENE
regions O
to O
lacZ I-GENE
were O
constructed O
and O
then O
introduced O
in O
single O
copy O
into O
the O
E I-GENE
. O
coli I-GENE
chromosome O
. O
beta I-GENE
- I-GENE
_RARE_ I-GENE
assays O
for O
_RARE_ I-GENE
- I-GENE
mediated O
regulation O
of O
_RARE_ I-GENE
- I-GENE
lacZ I-GENE
expression O
revealed O
that O
the O
E I-GENE
. O
coli I-GENE
_RARE_ I-GENE
repressor I-GENE
apparently O
recognizes O
the O
_RARE_ I-GENE
of O
both O
organisms O
with O
about O
equal O
efficiency O
. O

_RARE_ I-GENE
with O
previously O
mapped O
genes I-GENE
including O
_RARE_ I-GENE
- I-GENE
1 I-GENE
and O
_RARE_ I-GENE
, O
_RARE_ I-GENE
defines O
a O
new O
conserved O
_RARE_ I-GENE
group O
on O
the O
long O
arm O
of O
chromosome O
11 O
in O
the O
human I-GENE
and O
the O
proximal I-GENE
end O
of O
chromosome O
19 O
in O
the O
mouse I-GENE
. O

During O
exercise O
K I-GENE
+ I-GENE
is O
released O
from O
_RARE_ I-GENE
muscle O
and O
plasma I-GENE
K I-GENE
+ I-GENE
concentration O
_RARE_ I-GENE
. O

Following O
treatment O
, O
serum I-GENE
estradiol O
levels O
were O
higher O
in O
groups O
E I-GENE
+ I-GENE
T I-GENE
and O
E I-GENE
than O
in O
group O
C I-GENE
. O

We O
conclude O
that O
the O
beta I-GENE
- I-GENE
adrenergic I-GENE
agonist O
, O
isoproterenol O
, O
has O
little O
influence O
on O
vascular I-GENE
_RARE_ I-GENE
or O
liver O
volume O
of O
dogs O
, O
unless O
the O
hepatic I-GENE
outflow O
resistance O
is O
elevated O
by O
agents O
such O
as O
histamine O
. O

DNA I-GENE
sequence I-GENE
and O
evolution O
of O
the O
_RARE_ I-GENE
domain I-GENE
of O
the O
Syrian I-GENE
hamster I-GENE
_RARE_ I-GENE
protein I-GENE
CAD I-GENE
. O

Here O
we O
show O
that O
these O
synthetic O
binding I-GENE
sites I-GENE
have O
a O
more O
restricted O
and O
specific I-GENE
ability O
to O
enhance O
transcription I-GENE
when O
assayed O
in O
transformed O
embryos O
. O

After O
base O
- I-GENE
line O
CBF I-GENE
was O
established O
, O
_RARE_ I-GENE
bromide O
( O
2 I-GENE
mg O
/ I-GENE
kg O
iv O
), O
_RARE_ I-GENE
bromide O
( O
0 O
. O
5 I-GENE
microgram O
/ I-GENE
kg O
iv O
), O
indomethacin O
( O
2 I-GENE
mg O
/ I-GENE
kg O
iv O
), O
or O
intravenous O
0 O
. O
9 O
% O
saline O
was O
administered O
. O

A I-GENE
high O
- I-GENE
frequency O
restriction I-GENE
fragment I-GENE
length I-GENE
polymorphism O
was O
evident O
in O
the O
DNA I-GENE
from O
29 O
unrelated O
individuals O
using O
the O
enzyme I-GENE
_RARE_ I-GENE
. O

The O
_RARE_ I-GENE
transformation O
of O
pH O
did O
not O
improve O
the O
results O
. O

_RARE_ I-GENE
prevent O
end O
- I-GENE
to O
- I-GENE
end O
fusions I-GENE
and O
_RARE_ I-GENE
degradation O
, O
_RARE_ I-GENE
the O
end O
of O
the O
linear O
DNA I-GENE
molecule I-GENE
to O
_RARE_ I-GENE
, O
and O
function O
in O
cell O
division O
. O

One O
of O
these O
is O
located O
in O
the O
5 I-GENE
'- O
untranslated O
region O
, O
and O
may O
encode O
regulatory I-GENE
sequences I-GENE
. O

The O
native O
enzyme I-GENE
purified O
from O
protease I-GENE
- I-GENE
B I-GENE
- I-GENE
deficient O
_RARE_ I-GENE
- I-GENE
transformed O
cells O
, O
was O
phosphorylated O
in O
vitro O
using O
catalytic O
subunits I-GENE
of O
pure O
cAMP I-GENE
- I-GENE
dependent I-GENE
protein I-GENE
kinase I-GENE
. O

This O
study O
suggests O
that O
_RARE_ I-GENE
are O
useful O
in O
the O
assessment O
of O
AMI O
in O
terms O
of O
diagnosis O
, O
location O
and O
extent O
of O
myocardial O
infarct O
. O

A I-GENE
bovine I-GENE
_RARE_ I-GENE
lambda I-GENE
gt11 O
cDNA I-GENE
library O
was O
screened O
with O
a O
monoclonal I-GENE
antibody I-GENE
raised O
against O
the O
rabbit I-GENE
H I-GENE
, O
K I-GENE
- I-GENE
ATPase I-GENE
beta I-GENE
subunit I-GENE
. O

_RARE_ I-GENE
use O
of O
laboratory O
testing O
, O
including O
monitoring O
of O
CD4 I-GENE
cell O
counts O
, O
is O
recommended O
. O

There O
is O
no O
TATA I-GENE
box I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
upstream O
from O
the O
transcription I-GENE
initiation I-GENE
site I-GENE
. O

Characterization O
of O
the O
5 I-GENE
' O
end O
of O
the O
growth I-GENE
- I-GENE
regulated O
Syrian I-GENE
hamster I-GENE
CAD I-GENE
gene I-GENE
. O

Early O
cirrhosis O
, O
an O
early I-GENE
modality O
of O
the O
evolution O
of O
acute O
hepatitis I-GENE
. O

Examination O
of O
immediate I-GENE
- I-GENE
early I-GENE
transcription I-GENE
factor I-GENE
expression O
during O
the O
_RARE_ I-GENE
regimen O
revealed O
that O
RA O
mediated O
an O
elevated O
, O
prolonged O
expression O
of O
c I-GENE
- I-GENE
Jun I-GENE
mRNA I-GENE
accompanied O
by O
diminished O
expression O
of O
c I-GENE
- I-GENE
Fos I-GENE
and O
Jun I-GENE
- I-GENE
B I-GENE
mRNAs I-GENE
. O

Although O
heart O
rate O
and O
diastolic O
pressure O
rose O
in O
some O
degree O
1 I-GENE
min O
after O
_RARE_ I-GENE
, O
free O
and O
total O
CA I-GENE
concentrations O
did O
not O
increase O
during O
study O
period O
. O

_RARE_ I-GENE
, O
secretion O
, O
and O
immunoreactivity O
of O
carboxy I-GENE
terminally I-GENE
truncated I-GENE
_RARE_ I-GENE
- I-GENE
2 I-GENE
virus I-GENE
envelope I-GENE
proteins I-GENE
expressed O
in O
insect O
cells O
by O
recombinant I-GENE
_RARE_ I-GENE
. O

Combined O
therapy O
with O
MK O
- I-GENE
801 O
and O
_RARE_ I-GENE
for O
protection O
of O
ischemic O
brain O
damage O
. O

Initial O
screening O
of O
a O
rat I-GENE
liver O
cDNA I-GENE
library O
with O
an O
oligonucleotide I-GENE
probe O
derived O
from O
the O
rat I-GENE
_RARE_ I-GENE
protein I-GENE
sequence I-GENE
revealed O
an O
_RARE_ I-GENE
- I-GENE
base O
pair O
cDNA I-GENE
clone O
coding O
for O
the O
complete O
_RARE_ I-GENE
protein I-GENE
sequence I-GENE
. O

Cloning O
, O
expression O
, O
and O
nucleotide I-GENE
sequence I-GENE
of O
rat I-GENE
liver O
sterol I-GENE
carrier I-GENE
protein I-GENE
2 I-GENE
cDNAs I-GENE
. O

The O
addition O
of O
an O
_RARE_ I-GENE
complex I-GENE
of O
the O
fourth O
and O
_RARE_ I-GENE
largest O
subunits I-GENE
, O
purified O
from O
pol I-GENE
II I-GENE
holoenzyme I-GENE
by O
ion O
- I-GENE
exchange I-GENE
chromatography O
in O
the O
presence O
of O
urea O
, O
restored O
promoter I-GENE
- I-GENE
directed O
initiation I-GENE
activity O
to O
pol I-GENE
II I-GENE
delta I-GENE
4 I-GENE
/ I-GENE
7 O
. O

We O
report O
here O
the O
identification O
of O
HSF I-GENE
in O
the O
fission I-GENE
yeast I-GENE
Schizosaccharomyces I-GENE
pombe I-GENE
. O

Induction O
requires O
the O
_RARE_ I-GENE
gene I-GENE
product I-GENE
, O
which O
binds O
to O
specific I-GENE
sites I-GENE
in O
the O
promoter I-GENE
region O
of O
the O
_RARE_ I-GENE
gene I-GENE
. O

Gel O
mobility I-GENE
shift O
assays O
using O
a O
synthetic O
E6 I-GENE
motif I-GENE
detected O
a O
B I-GENE
- I-GENE
cell O
- I-GENE
specific I-GENE
complex I-GENE
in O
addition O
to O
a O
ubiquitous O
band O
found O
also O
in O
T I-GENE
cells O
and O
HeLa O
cells O
. O

_RARE_ I-GENE
clones O
encoding O
interferon I-GENE
response O
element I-GENE
binding I-GENE
factors I-GENE
have O
been O
isolated O
from O
a O
mouse I-GENE
fibroblast I-GENE
lambda I-GENE
gt11 O
cDNA I-GENE
library O
by O
using O
a O
32P O
end O
- I-GENE
labeled O
tandem O
_RARE_ I-GENE
of O
the O
mouse I-GENE
( O
2 I-GENE
'- O
5 I-GENE
') I-GENE
_RARE_ I-GENE
synthetase I-GENE
gene I-GENE
interferon I-GENE
response O
element I-GENE
as O
a O
probe O
. O

The O
sequence I-GENE
of O
four O
clones O
was O
sufficient O
to O
construct I-GENE
a O
_RARE_ I-GENE
- I-GENE
bp O
BAL I-GENE
cDNA I-GENE
structure O
. O

The O
application O
of O
these O
instruments O
allows O
occlusion O
of O
the O
ascending O
aorta O
_RARE_ I-GENE
by O
the O
perfusion O
_RARE_ I-GENE
inserted O
directly O
or O
through O
the O
apex O
of O
the O
heart O
as O
well O
as O
simultaneous O
left O
ventricular O
_RARE_ I-GENE
. O

_RARE_ I-GENE
synthetase I-GENE
( O
_RARE_ I-GENE
: O
L I-GENE
- I-GENE
aspartate I-GENE
ligase I-GENE
( O
GDP I-GENE
), O
EC I-GENE
6 I-GENE
. O
3 I-GENE
. O
4 I-GENE
. O
4 I-GENE
) O
plays O
an O
important O
role O
in O
_RARE_ I-GENE
biosynthesis O
_RARE_ I-GENE
the O
GTP I-GENE
- I-GENE
dependent I-GENE
conversion O
of O
_RARE_ I-GENE
to O
AMP I-GENE
. O

_RARE_ I-GENE
in O
four O
cases O
, O
demonstrated O
non O
- I-GENE
B I-GENE
, O
non O
- I-GENE
T I-GENE
cell O
origin O
in O
three O
and O
pre I-GENE
- I-GENE
B I-GENE
cell O
origin O
in O
one O
. O

DNA I-GENE
- I-GENE
protein I-GENE
UV O
cross O
- I-GENE
linking O
studies O
indicated O
that O
_RARE_ I-GENE
- I-GENE
1 I-GENE
has O
an O
electrophoretic O
mobility I-GENE
on O
sodium O
dodecyl O
sulfate I-GENE
- I-GENE
_RARE_ I-GENE
gels O
of O
approximately O
85 O
kDa I-GENE
and O
suggested O
that O
additional O
proteins I-GENE
, O
specific I-GENE
to O
each O
promoter I-GENE
, O
bind O
to O
each O
site I-GENE
. O

The O
results O
_RARE_ I-GENE
the O
conclusion O
that O
predominantly O
dynamic O
activity O
increases O
the O
_RARE_ I-GENE
content O
of O
mature O
_RARE_ I-GENE
fast O
muscles O
. O

The O
specific I-GENE
interaction O
between O
a O
defined O
structural O
element I-GENE
of O
the O
human I-GENE
immunodeficiency I-GENE
virus I-GENE
mRNA I-GENE
( O
_RARE_ I-GENE
, O
the O
Rev I-GENE
response O
element I-GENE
) O
and O
the O
virus I-GENE
- I-GENE
encoded I-GENE
protein I-GENE
Rev I-GENE
has O
been O
implicated O
in O
the O
regulation O
of O
the O
export O
of O
unspliced O
or O
_RARE_ I-GENE
spliced O
mRNA I-GENE
from O
the O
nucleus O
to O
the O
cytoplasm O
. O

We O
reviewed O
the O
records O
of O
151 O
patients O
with O
optic O
_RARE_ I-GENE
examined O
over O
an O
eight O
- I-GENE
year O
period O
. O

_RARE_ I-GENE
- I-GENE
off O
levels O
that O
define O
abnormality O
are O
rather O
_RARE_ I-GENE
and O
this O
decreases O
the O
specificity O
of O
the O
test O
in O
apparently O
healthy O
patients O
. O

_RARE_ I-GENE
aminotransferase I-GENE
in O
clinical O
practice O
. O

Nucleotide O
sequence I-GENE
analysis O
of O
the O
Pseudomonas I-GENE
putida I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
hydroxylase I-GENE
gene I-GENE
( O
_RARE_ I-GENE
) O
and O
its O
3 I-GENE
'- O
flanking O
region O
. O

All O
six O
ARF I-GENE
cDNAs I-GENE
are O
more O
similar O
to O
each O
other O
than O
to O
other O
approximately O
20 O
- I-GENE
kDa I-GENE
guanine I-GENE
nucleotide I-GENE
- I-GENE
binding I-GENE
proteins I-GENE
. O

The O
long O
terminal I-GENE
repeat I-GENE
( O
LTR I-GENE
) O
of O
the O
human I-GENE
immunodeficiency I-GENE
virus I-GENE
( O
HIV I-GENE
) O
contains O
three O
binding I-GENE
sites I-GENE
for O
the O
transcriptional O
factor I-GENE
Sp1 I-GENE
. O

DNA I-GENE
from O
PCR O
was O
labeled O
and O
used O
to O
isolate O
several O
lambda I-GENE
gt11 O
cDNA I-GENE
clones O
, O
including O
one O
full I-GENE
- I-GENE
length I-GENE
one O
( O
_RARE_ I-GENE
kinase I-GENE
- I-GENE
2 I-GENE
). O

_RARE_ I-GENE
- I-GENE
induced O
changes O
in O
the O
area O
of O
_RARE_ I-GENE
and O
_RARE_ I-GENE
as O
well O
as O
collagen I-GENE
content O
were O
seen O
11 O
weeks O
after O
irradiation O
. O

The O
first O
follow O
- I-GENE
up O
was O
at O
a O
nearly O
constant O
interval O
of O
5 I-GENE
. O
1 I-GENE
years O
in O
_RARE_ I-GENE
and O
3 I-GENE
. O
2 I-GENE
years O
in O
_RARE_ I-GENE
; O
_RARE_ I-GENE
major I-GENE
_RARE_ I-GENE
events O
had O
occurred O
. O

A I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
-- O
an O
unusual O
injury O
_RARE_ I-GENE
immediate I-GENE
and O
correct O
treatment O

_RARE_ I-GENE
( O
La I-GENE
- I-GENE
O O
) O
and O
cv O
. O

In O
summary O
, O
at O
_RARE_ I-GENE
concentrations O
, O
_RARE_ I-GENE
and O
isoflurane O
produced O
similar O
hemodynamic O
effects O
; O
however O
, O
in O
the O
absence O
of O
drugs O
that O
inhibit O
_RARE_ I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
had O
less O
negative O
inotropic O
activity O
and O
produced O
less O
decrease O
in O
arterial O
pressure O
. O

We O
report O
here O
the O
isolation O
of O
a O
full I-GENE
- I-GENE
length I-GENE
cDNA I-GENE
clone O
coding O
for O
a O
hitherto O
_RARE_ I-GENE
isoform I-GENE
of O
the O
bovine I-GENE
C I-GENE
- I-GENE
subunit I-GENE
. O

_RARE_ I-GENE
C I-GENE
beta I-GENE
2 I-GENE
, O
an O
unusual O
form O
of O
the O
bovine I-GENE
catalytic O
subunit I-GENE
of O
cAMP I-GENE
- I-GENE
dependent I-GENE
protein I-GENE
kinase I-GENE
. O

_RARE_ I-GENE
applications O
of O
_RARE_ I-GENE
- I-GENE
PK I-GENE
_RARE_ I-GENE
to O
toxicological O
problems O
are O
_RARE_ I-GENE
with O
examples O
. O

Patients O
with O
apparently O
minor O
CT I-GENE
abnormalities O
may O
have O
significant O
_RARE_ I-GENE
disease O
. O

The O
_RARE_ I-GENE
sequence I-GENE
includes O
an O
additional O
_RARE_ I-GENE
amino O
acids O
of O
the O
contiguous O
fragment I-GENE
and O
encodes O
a O
product I-GENE
of O
predicted O
Mr O
67 O
, O
000 O
. O

_RARE_ I-GENE
with O
a O
clear O
understanding O
of O
the O
_RARE_ I-GENE
pathways O
that O
may O
cause O
and O
/ I-GENE
or O
contribute O
to O
the O
development O
of O
_RARE_ I-GENE
hyperbilirubinemia O
and O
the O
associated I-GENE
jaundice O
, O
the O
_RARE_ I-GENE
will O
be O
successful O
in O
_RARE_ I-GENE
the O
family I-GENE
understand O
their O
child O
' O
s O
illness O
. O

_RARE_ I-GENE
_RARE_ I-GENE
of O
peripheral O
sites I-GENE
in O
_RARE_ I-GENE
human I-GENE
vision O
were O
obtained O
. O

The O
authors O
report O
a O
case O
in O
which O
_RARE_ I-GENE
irrigation O
of O
a O
brain O
cyst O
was O
temporally O
associated I-GENE
with O
respiratory O
distress O
. O

ELISA O
was O
found O
to O
make O
a O
contribution O
to O
the O
diagnosis O
of O
tuberculosis O
similar O
to O
that O
of O
sputum I-GENE
_RARE_ I-GENE
. O

In O
this O
paper O
, O
we O
report O
a O
detailed O
study O
of O
the O
structure O
and O
the O
functional O
role O
of O
the O
_RARE_ I-GENE
binding I-GENE
sites I-GENE
located O
in O
the O
adjacent O
and O
divergent O
_RARE_ I-GENE
and O
_RARE_ I-GENE
promoters I-GENE
. O

Despite O
the O
small I-GENE
number O
of O
patients O
, O
on O
the O
basis O
of O
this O
report O
, O
we O
can O
confirm O
that O
1 I-GENE
. O
5 I-GENE
_RARE_ I-GENE
/ I-GENE
day O
of O
alpha I-GENE
- I-GENE
IFN I-GENE
is O
an O
adequate O
treatment O
for O
patients O
with O
_RARE_ I-GENE
cell O
leukemia I-GENE
. O

_RARE_ I-GENE
fluctuations O
in O
observed O
_RARE_ I-GENE
in O
_RARE_ I-GENE
falciparum O
malaria O
. O

No O
positive O
family I-GENE
history O
was O
obtained O
. O

_RARE_ I-GENE
asthma O
and O
_RARE_ I-GENE
from O
inhalation O
of O
crystalline O
bovine I-GENE
serum I-GENE
albumin I-GENE
_RARE_ I-GENE
. O

A I-GENE
further O
_RARE_ I-GENE
of O
_RARE_ I-GENE
_RARE_ I-GENE
into O
_RARE_ I-GENE
( O
metastasis O
in O
single O
node O
) O
and O
_RARE_ I-GENE
( O
two O
or O
more O
nodes O
) O
is O
recommended O
. O

Amino O
acid I-GENE
sequence I-GENE
comparisons O
of O
the O
_RARE_ I-GENE
protein I-GENE
reveal O
a O
highly O
conserved O
C I-GENE
- I-GENE
terminal I-GENE
region O
that O
is O
rich O
in O
basic I-GENE
amino O
acid I-GENE
residues O
and O
which O
has O
been O
proposed O
to O
possess O
sequence I-GENE
- I-GENE
specific I-GENE
DNA I-GENE
binding I-GENE
activity O
. O

We O
found O
that O
the O
relative O
strengths O
of O
the O
promoters I-GENE
were O
similar O
in O
different O
_RARE_ I-GENE
. O

_RARE_ I-GENE
, O
and O
A I-GENE
. O

After O
6 I-GENE
months O
, O
definite O
improvement O
in O
strength O
occurred O
in O
4 I-GENE
of O
7 O
_RARE_ I-GENE
- I-GENE
treated O
patients O
and O
in O
none O
of O
7 O
controls O
. O

_RARE_ I-GENE
at O
_RARE_ I-GENE
and O
_RARE_ I-GENE
were O
achieved O
later O
for O
_RARE_ I-GENE
_RARE_ I-GENE
than O
for O
_RARE_ I-GENE
F I-GENE
. O

To O
identify O
the O
DNA I-GENE
sequences I-GENE
that O
cis O
- I-GENE
regulate O
the O
expression O
of O
the O
rat I-GENE
liver O
_RARE_ I-GENE
kinase I-GENE
( O
L I-GENE
- I-GENE
PK I-GENE
) O
genes I-GENE
, O
a O
series O
of O
constructs I-GENE
in O
which O
the O
chloramphenicol I-GENE
acetyltransferase I-GENE
reporter I-GENE
genes I-GENE
is O
driven O
by O
various O
deleted O
fragments I-GENE
of O
the O
_RARE_ I-GENE
base O
pairs O
( O
bp O
) O
upstream O
of O
the O
L I-GENE
- I-GENE
PK I-GENE
gene I-GENE
cap I-GENE
site I-GENE
have O
been O
assayed O
for O
transient O
expression O
after O
introduction O
into O
hepatoma O
HepG2 O
cells O
, O
rat I-GENE
hepatocytes O
in O
primary O
culture O
, O
fibroblast I-GENE
_RARE_ I-GENE
- I-GENE
cells O
, O
myogenic I-GENE
C2C12 O
cells O
, O
and O
CHO O
cells O
. O

The O
disturbance O
of O
pulmonary O
gas O
exchange I-GENE
, O
as O
revealed O
by O
the O
high O
value O
of O
_RARE_ I-GENE
, O
existed O
without O
left O
ventricular O
dysfunction O
, O
and O
_RARE_ I-GENE
had O
no O
significant O
relationship O
with O
any O
of O
the O
hemodynamic O
parameters O
including O
the O
difference O
between O
plasma I-GENE
colloid O
osmotic O
pressure O
and O
_RARE_ I-GENE
. O

A I-GENE
dose O
of O
3 I-GENE
and O
6 I-GENE
micrograms O
/ I-GENE
kg O
/ I-GENE
day O
GM I-GENE
- I-GENE
CSF I-GENE
reduces O
the O
severity O
of O
neutropenia O
and O
thrombocytopenia O
after O
_RARE_ I-GENE
- I-GENE
cyclophosphamide O
chemotherapy O
, O
which O
may O
lead O
to O
more O
effective O
chemotherapy O
for O
ovarian O
cancer O
in O
the O
future O
. O

These O
differences O
involve O
specific I-GENE
hydrogen O
- I-GENE
_RARE_ I-GENE
interactions O
between O
the O
protein I-GENE
and O
DNA I-GENE
, O
including O
guanine I-GENE
_RARE_ I-GENE
sites I-GENE
in O
the O
major I-GENE
groove I-GENE
of O
DNA I-GENE
, O
and O
alterations O
in O
DNA I-GENE
_RARE_ I-GENE
conformation O
induced O
by O
protein I-GENE
binding I-GENE
. O

Biochemical O
analysis O
demonstrates O
that O
the O
_RARE_ I-GENE
protein I-GENE
is O
associated I-GENE
with O
_RARE_ I-GENE
and O
is O
released O
from O
chromatin O
by O
agents O
which O
_RARE_ I-GENE
into O
DNA I-GENE
, O
as O
previously O
shown O
for O
the O
high O
mobility I-GENE
group O
proteins I-GENE
( O
_RARE_ I-GENE
). O

I I-GENE
propose O
that O
their O
gene I-GENE
products I-GENE
bind O
to O
the O
chromatin O
to O
establish O
or O
maintain O
a O
proper O
higher O
order O
structure O
as O
a O
prerequisite O
for O
a O
regulated O
gene I-GENE
expression O
. O

The O
_RARE_ I-GENE
alpha I-GENE
gene I-GENE
is O
organized O
as O
follows O
: O
the O
first O
exon O
codes O
for O
the O
first O
198 O
nucleotides O
of O
the O
5 I-GENE
' O
UTR I-GENE
. O

The O
human I-GENE
immunodeficiency I-GENE
virus I-GENE
type I-GENE
1 I-GENE
( O
HIV I-GENE
- I-GENE
1 I-GENE
) O
Rev I-GENE
protein I-GENE
is O
a O
positive O
posttranscriptional O
regulator I-GENE
of O
viral I-GENE
structural O
gene I-GENE
expression O
and O
essential O
for O
virus I-GENE
replication O
. O

Once O
the O
proliferation O
of O
fibroblasts O
and O
collagen I-GENE
synthesis O
had O
led O
to O
an O
increase O
of O
mechanical O
strength O
, O
no O
negative O
effect O
on O
wound O
healing O
could O
be O
detected O
applying O
the O
same O
chemotherapeutic O
agents O
. O

The O
_RARE_ I-GENE
gene I-GENE
has O
two O
in O
- I-GENE
frame O
AUG O
codons O
as O
possible O
translation I-GENE
start O
sites I-GENE
, O
which O
would O
produce O
58 O
- I-GENE
and O
56 O
- I-GENE
kDa I-GENE
proteins I-GENE
, O
respectively O
. O

During O
the O
years O
1980 O
- I-GENE
87 O
a O
total O
of O
_RARE_ I-GENE
persons O
received O
_RARE_ I-GENE
_RARE_ I-GENE
in O
the O
_RARE_ I-GENE
of O
_RARE_ I-GENE
in O
northern O
_RARE_ I-GENE
. O

HeLa O
and O
Jurkat O
cell O
lines O
carrying O
the O
nef I-GENE
gene I-GENE
linked O
to O
the O
CMV O
promoter I-GENE
or O
the O
HIV I-GENE
- I-GENE
1 I-GENE
LTR I-GENE
were O
isolated O
by O
_RARE_ I-GENE
for O
neomycin I-GENE
resistance O
. O

_RARE_ I-GENE
in O
the O
clinical O
presentation O
and O
the O
gross O
appearance O
of O
the O
two O
cases O
are O
described O
, O
and O
similarities O
in O
the O
microscopic O
features O
are O
discussed O
. O

_RARE_ I-GENE
AND O
MAIN O
RESULTS O
: O
The O
two O
groups O
were O
similar O
on O
entry O
into O
the O
study O
, O
including O
mean O
FEV1 O
measurements O
( O
0 O
. O
70 I-GENE
L I-GENE
atropine O
/ I-GENE
0 O
. O
60 O
L I-GENE
_RARE_ I-GENE
, O
P I-GENE
greater O
than O
. O
05 O
). O

Using O
an O
ELISA O
, O
we O
found O
that O
surfactant I-GENE
protein I-GENE
A I-GENE
( O
SP I-GENE
- I-GENE
A I-GENE
) O
was O
markedly O
elevated O
in O
the O
pneumonia O
patients O
. O

In O
view O
of O
the O
short O
t1 O
/ I-GENE
2 I-GENE
, O
we O
used O
three O
doses O
/ I-GENE
day O
. O

_RARE_ I-GENE
control O
of O
GUS I-GENE
expression O
was O
found O
to O
involve O
two O
negative O
regulatory I-GENE
sequences I-GENE
, O
_RARE_ I-GENE
(- O
_RARE_ I-GENE
to O
- I-GENE
_RARE_ I-GENE
) O
and O
_RARE_ I-GENE
(- O
_RARE_ I-GENE
to O
- I-GENE
_RARE_ I-GENE
), O
as O
well O
as O
the O
positive O
domain I-GENE
UAS1 O
. O

We O
purified O
a O
Ca2 I-GENE
+/ I-GENE
calmodulin I-GENE
( O
CaM I-GENE
)- I-GENE
dependent I-GENE
protein I-GENE
kinase I-GENE
( O
CaM I-GENE
kinase I-GENE
) O
from O
the O
yeast I-GENE
Saccharomyces I-GENE
cerevisiae I-GENE
with O
properties O
similar O
to O
mammalian I-GENE
type I-GENE
II I-GENE
CaM I-GENE
kinases I-GENE
. O

In O
most O
cases O
, O
_RARE_ I-GENE
- I-GENE
homozygous O
, O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
individuals O
could O
be O
_RARE_ I-GENE
with O
the O
panel O
of O
probes O
. O

Two O
patients O
had O
immediate I-GENE
adverse O
effects O
from O
_RARE_ I-GENE
; O
one O
had O
a O
_RARE_ I-GENE
_RARE_ I-GENE
seizure O
and O
the O
other O
developed O
severe O
abdominal O
pain O
. O

The O
muscles O
from O
the O
ischemic O
group O
had O
significantly O
lower O
( O
P I-GENE
less O
than O
. O
05 O
) O
values O
for O
capillary O
density I-GENE
and O
capillary O
to O
fiber O
ratio O
and O
significantly O
higher O
_RARE_ I-GENE
distance O
than O
those O
from O
the O
normal O
group O
. O

The O
prevalence O
of O
_RARE_ I-GENE
infection O
among O
_RARE_ I-GENE
AIDS O
patients O
and O
the O
_RARE_ I-GENE
of O
being O
in O
tumour I-GENE
response O
following O
cancer O
therapy O
conditional O
on O
being O
_RARE_ I-GENE
are O
two O
examples O
of O
such O
functions O
. O

Serum I-GENE
TNF I-GENE
concentrations O
were O
elevated O
at O
diagnosis O
and O
gradually O
decreased O
toward O
the O
reference O
limits O
by O
week O
16 O
. O

Genomic O
clones O
encompassing O
the O
human I-GENE
_RARE_ I-GENE
gene I-GENE
were O
isolated O
and O
utilized O
to O
define O
its O
molecular O
organization O
. O

_RARE_ I-GENE
chain I-GENE
reaction O
analysis O
of O
_RARE_ I-GENE
cDNA I-GENE
identified O
several O
amplified O
products I-GENE
, O
indicating O
alternative O
splicing O
. O

Most O
of O
the O
expressed O
human I-GENE
E3 I-GENE
polypeptides I-GENE
( O
five O
bands O
) O
were O
found O
in O
the O
_RARE_ I-GENE
_RARE_ I-GENE
while O
primarily O
full I-GENE
- I-GENE
length I-GENE
mature O
E3 I-GENE
was O
found O
in O
the O
soluble I-GENE
fraction O
. O

To O
test O
_RARE_ I-GENE
function O
, O
chimeric I-GENE
genes I-GENE
were O
constructed O
linking O
fragments I-GENE
of O
chicken I-GENE
IGF I-GENE
- I-GENE
I I-GENE
5 I-GENE
'- O
flanking O
DNA I-GENE
to O
a O
promoterless O
reporter I-GENE
plasmid O
. O

The O
alpha I-GENE
4 I-GENE
gene I-GENE
5 I-GENE
' O
flanking O
region O
_RARE_ I-GENE
as O
a O
promoter I-GENE
in O
transfection O
assays O
. O

Characterization O
of O
the O
alpha I-GENE
4 I-GENE
integrin I-GENE
gene I-GENE
promoter I-GENE
. O

Only O
the O
3 I-GENE
. O
0 O
- I-GENE
kb O
transcript I-GENE
was O
detected O
in O
adult O
tissues O
, O
where O
its O
expression O
was O
restricted O
almost O
exclusively O
to O
the O
central O
nervous O
system O
. O

Two O
homologues O
of O
the O
_RARE_ I-GENE
gene I-GENE
have O
now O
been O
isolated O
. O

_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
causing O
respiratory O
obstruction O
postoperatively O
. O

We O
examined O
the O
effects O
of O
long O
- I-GENE
term O
perfusion O
with O
_RARE_ I-GENE
hemoglobin I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
solution O
on O
cardiac O
function O
of O
isolated O
rat I-GENE
hearts O
. O

_RARE_ I-GENE
: O
_RARE_ I-GENE
type I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
type I-GENE
TOF O
have O
anatomic O
features O
in O
which O
the O
proximal I-GENE
His O
bundle O
_RARE_ I-GENE
to O
be O
_RARE_ I-GENE
by O
_RARE_ I-GENE
for O
_RARE_ I-GENE
closure O
. O

The O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
mutation I-GENE
also O
results O
in O
_RARE_ I-GENE
_RARE_ I-GENE
, O
accumulation O
of O
inactive O
_RARE_ I-GENE
ribosomal I-GENE
_RARE_ I-GENE
, O
and O
accumulation O
of O
at O
least O
one O
of O
the O
subunits I-GENE
of O
the O
general O
translation I-GENE
initiation I-GENE
factor I-GENE
2 I-GENE
( O
eIF I-GENE
- I-GENE
2 I-GENE
alpha I-GENE
) O
in O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
particles O
following O
a O
shift O
to O
the O
restrictive O
temperature O
. O

Eight O
patients O
with O
ARC I-GENE
and O
renal O
failure O
were O
recently O
evaluated O
. O

To O
measure O
the O
enhancer I-GENE
activity O
of O
_RARE_ I-GENE
, O
a O
reporter I-GENE
plasmid O
was O
constructed O
that O
contained O
_RARE_ I-GENE
cloned O
upstream O
of O
the O
reporter I-GENE
chloramphenicol I-GENE
acetyltransferase I-GENE
gene I-GENE
under O
the O
control O
of O
the O
delayed O
- I-GENE
early I-GENE
_RARE_ I-GENE
promoter I-GENE
. O

A I-GENE
single O
case O
of O
an O
adenocarcinoma O
, O
arising O
in O
a O
_RARE_ I-GENE
_RARE_ I-GENE
cyst O
and O
which O
presented O
as O
a O
left O
renal O
cyst O
, O
is O
reported O
. O

Using O
the O
polymerase I-GENE
chain I-GENE
reaction O
, O
we O
analyzed O
the O
U6 I-GENE
RNA I-GENE
genes I-GENE
of O
52 O
organisms O
. O

Both O
tear I-GENE
volume O
and O
tear I-GENE
flow O
were O
found O
to O
be O
significantly O
( O
P I-GENE
less O
than O
0 O
. O
001 O
) O
decreased O
up O
to O
6 I-GENE
h O
after O
_RARE_ I-GENE
, O
_RARE_ I-GENE
a O
minimum O
90 O
min O
after O
application O
( O
tear I-GENE
volume O
: O
- I-GENE
63 O
%; O
tear I-GENE
flow O
: O
- I-GENE
71 O
%). O

_RARE_ I-GENE
analysis O
indicated O
that O
the O
_RARE_ I-GENE
and O
_RARE_ I-GENE
polypeptides I-GENE
are O
likely O
to O
be O
soluble I-GENE
, O
whereas O
the O
_RARE_ I-GENE
polypeptide I-GENE
was O
predicted O
to O
have O
four O
potential O
membrane I-GENE
- I-GENE
spanning O
domains I-GENE
. O

To O
facilitate O
the O
availability O
of O
important O
new O
therapeutic O
agents O
, O
the O
_RARE_ I-GENE
and O
Drug O
Administration O
( O
_RARE_ I-GENE
) O
in O
the O
mid O
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
therapeutic O
_RARE_ I-GENE
to O
_RARE_ I-GENE
new O
drugs O
and O
_RARE_ I-GENE
end O
- I-GENE
of O
- I-GENE
phase O
II I-GENE
_RARE_ I-GENE
with O
drug O
_RARE_ I-GENE
. O

In O
contrast O
, O
similar O
rates O
of O
B I-GENE
. O
_RARE_ I-GENE
products I-GENE
, O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
and O
BSP I-GENE
- I-GENE
2 I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
, O
produced O
no O
significant O
reduction O
. O

The O
_RARE_ I-GENE
( O
18 O
. O
4 I-GENE
%) O
was O
with O
IgA I-GENE
nephropathy O
, O
which O
was O
histologically O
mild O
. O

_RARE_ I-GENE
, O
the O
experimental O
_RARE_ I-GENE
was O
identical O
to O
the O
field O
condition O
, O
and O
bacteria O
indistinguishable O
from O
the O
inoculated O
strains O
were O
_RARE_ I-GENE
. O

3 I-GENE
. O

Furthermore O
, O
the O
DNA I-GENE
polymerase I-GENE
II I-GENE
complex I-GENE
was O
difficult O
to O
obtain O
from O
_RARE_ I-GENE
- I-GENE
1 I-GENE
mutant I-GENE
cells O
, O
suggesting O
that O
a O
stable O
DNA I-GENE
polymerase I-GENE
II I-GENE
complex I-GENE
requires O
_RARE_ I-GENE
and O
is O
essential O
for O
chromosomal I-GENE
replication O
. O

To O
determine O
whether O
mononuclear O
cell O
secretory I-GENE
products I-GENE
contribute O
to O
the O
changes O
in O
bone O
turnover O
that O
characterize O
the O
development O
of O
_RARE_ I-GENE
_RARE_ I-GENE
, O
we O
evaluated O
the O
effects O
of O
_RARE_ I-GENE
and O
subsequent O
estrogen I-GENE
replacement O
on O
the O
spontaneous O
secretion O
of O
interleukin I-GENE
1 I-GENE
( O
IL I-GENE
- I-GENE
1 I-GENE
) O
and O
tumor I-GENE
necrosis I-GENE
factor I-GENE
alpha I-GENE
( O
TNF I-GENE
- I-GENE
alpha I-GENE
) O
and O
on O
the O
phytohemagglutinin I-GENE
A I-GENE
- I-GENE
induced O
secretion O
of O
granulocyte I-GENE
- I-GENE
macrophage I-GENE
colony I-GENE
- I-GENE
stimulating I-GENE
factor I-GENE
( O
GM I-GENE
- I-GENE
CSF I-GENE
) O
from O
peripheral O
blood O
mononuclear O
cells O
. O

There O
were O
45 O
to O
56 O
nt O
differences O
between O
the O
virulent O
and O
_RARE_ I-GENE
groups O
while O
there O
were O
6 I-GENE
to O
14 O
nt O
differences O
among O
four O
_RARE_ I-GENE
strains O
. O

The O
standard O
_RARE_ I-GENE
of O
surgical O
management O
must O
be O
_RARE_ I-GENE
to O
when O
using O
_RARE_ I-GENE
to O
treat O
patients O
with O
these O
disorders O
. O

Some O
of O
the O
PCR O
products I-GENE
contained O
mutations O
in O
_RARE_ I-GENE
and O
/ I-GENE
or O
_RARE_ I-GENE
. O

_RARE_ I-GENE
shock I-GENE
and O
bacterial I-GENE
translocation O
in O
a O
swine O
model O
. O

These O
data O
suggest O
that O
the O
levels O
of O
oxygen O
free O
radicals O
were O
increased O
in O
hepatocytes O
and O
mitochondria O
. O

The O
sequence I-GENE
of O
the O
_RARE_ I-GENE
plasmid O
containing O
the O
_RARE_ I-GENE
region O
contains O
a O
perfect O
tandem O
repeat I-GENE
of O
19 O
bp O
in O
the O
orientation O
1 I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
gene I-GENE
at O
the O
middle I-GENE
of O
the O
recombination O
junction O
site I-GENE
. O

No O
evidence O
for O
the O
presence O
of O
introns O
within O
the O
_RARE_ I-GENE
gene I-GENE
has O
been O
found O
. O

These O
observations O
, O
together O
with O
the O
occurrence O
of O
putative O
4 I-GENE
'- O
_RARE_ I-GENE
- I-GENE
attachment O
sites I-GENE
and O
a O
putative O
_RARE_ I-GENE
site I-GENE
, O
are O
discussed O
with O
reference O
to O
the O
reaction O
sequence I-GENE
leading O
to O
production O
of O
the O
_RARE_ I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
, O
a O
monoamine I-GENE
oxidase I-GENE
inhibitor I-GENE
, O
reduces O
peak O
3 I-GENE
transiently O
( O
max O
. O

When O
given O
the O
choice O
between O
an O
_RARE_ I-GENE
female O
and O
a O
_RARE_ I-GENE
active O
male O
in O
the O
_RARE_ I-GENE
, O
_RARE_ I-GENE
females O
, O
as O
well O
as O
controls O
, O
preferred O
the O
male O
partner I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
responses O
were O
- I-GENE
1 I-GENE
. O
99 O
+/- O
0 O
. O
37 O
L I-GENE
/ I-GENE
min O
_RARE_ I-GENE
SaO2 O
in O
the O
_RARE_ I-GENE
and O
- I-GENE
1 I-GENE
. O
54 I-GENE
+/- O
0 O
. O
25 O
L I-GENE
/ I-GENE
min O
_RARE_ I-GENE
SaO2 O
in O
the O
control O
subjects O
.( O
ABSTRACT O
TRUNCATED O
AT I-GENE
250 O
WORDS O
) O

_RARE_ I-GENE
small I-GENE
deletions O
within O
the O
conserved O
region O
completely O
abolished O
transforming I-GENE
activity O
of O
_RARE_ I-GENE
, O
while O
extensive O
deletion O
outside O
of O
this O
region O
had O
no O
effect O
. O

This O
computerized O
_RARE_ I-GENE
was O
linked O
to O
the O
central O
_RARE_ I-GENE
of O
the O
_RARE_ I-GENE
Cancer O
_RARE_ I-GENE
and O
cases O
diagnosed O
between O
1982 O
and O
1988 O
were O
identified O
. O

We O
also O
present O
evidence O
for O
a O
negative O
regulatory I-GENE
element I-GENE
in O
the O
5 I-GENE
' O
flanking O
region O
of O
the O
_RARE_ I-GENE
I I-GENE
upstream O
activation O
sequence I-GENE
. O

A I-GENE
method O
for O
_RARE_ I-GENE
stimulus O
control O
of O
ethanol O
responding O
was O
developed O
. O

Mechanism O
of O
activation O
of O
the O
_RARE_ I-GENE
protooncogene I-GENE
. O
_RARE_ I-GENE
is O
a O
human I-GENE
locus I-GENE
that O
appears O
to O
be O
specifically O
expressed O
in O
cells O
of O
hematopoietic I-GENE
origin O
regardless O
of O
their O
differentiation O
lineage O
. O

_RARE_ I-GENE
cell O
_RARE_ I-GENE
. O

_RARE_ I-GENE
disease O
in O
a O
child O
. O

After O
hemodynamic O
stabilization O
, O
the O
goal O
of O
therapy O
is O
to O
_RARE_ I-GENE
the O
_RARE_ I-GENE
that O
an O
ulcer O
will O
_RARE_ I-GENE
to O
_RARE_ I-GENE
or O
will O
_RARE_ I-GENE
. O

Thirty O
seven O
patients O
( O
_RARE_ I-GENE
n O
= O
16 O
, O
_RARE_ I-GENE
n O
= O
21 O
) O
completed O
the O
six O
week O
protocol O
, O
which O
was O
conducted O
under O
double O
blind O
conditions O
. O

The O
stimulus O
threshold O
for O
_RARE_ I-GENE
showed O
a O
less O
individual O
variation O
than O
amplitude O
. O

Analysis O
of O
electrically O
evoked O
response O
( O
_RARE_ I-GENE
) O
in O
relation O
to O
the O
central O
visual O
pathway O
of O
the O
cat O
( O
1 I-GENE
). O

Furthermore O
, O
plasma I-GENE
fibrinogen I-GENE
levels O
increased O
by O
a O
mean O
of O
17 O
. O
6 I-GENE
%, O
a O
potentially O
adverse O
effect O
of O
_RARE_ I-GENE
that O
has O
not O
been O
previously O
reported O
. O

_RARE_ I-GENE
in O
_RARE_ I-GENE
patients O
with O
peripheral O
arterial O
disease O
: O
some O
_RARE_ I-GENE
actions O
. O

An O
_RARE_ I-GENE
- I-GENE
independent O
pathway O
for O
sporulation I-GENE
control O
in O
Saccharomyces I-GENE
cerevisiae I-GENE
acts O
through O
IME1 I-GENE
transcript I-GENE
accumulation O
. O

The O
role O
of O
pharmacological O
_RARE_ I-GENE
in O
safety O
assessment O
. O

Its O
application O
in O
_RARE_ I-GENE
: O
advantages O
and O
_RARE_ I-GENE

In O
all O
cases O
, O
high O
- I-GENE
level O
expression O
of O
the O
truncated I-GENE
avian I-GENE
_RARE_ I-GENE
was O
obtained O
. O

The O
authors O
evaluate O
the O
clinical O
efficacy O
of O
_RARE_ I-GENE
_RARE_ I-GENE
in O
recurrent O
ulcer O
after O
operation O
on O
the O
stomach O
caused O
by O
a O
high O
level O
of O
acid I-GENE
production O
and O
_RARE_ I-GENE
_RARE_ I-GENE
bleeding O
. O

In O
_RARE_ I-GENE
these O
rats O
were O
_RARE_ I-GENE
and O
_RARE_ I-GENE
the O
active O
_RARE_ I-GENE
response O
later O
than O
the O
controls O
. O

To O
investigate O
the O
regulation O
of O
_RARE_ I-GENE
gene I-GENE
activity O
, O
the O
region O
around O
the O
_RARE_ I-GENE
transcriptional O
initiation I-GENE
site I-GENE
was O
analyzed O
for O
sites I-GENE
of O
protein I-GENE
- I-GENE
DNA I-GENE
interaction O
. O

_RARE_ I-GENE
mapping O
revealed O
the O
same O
autophosphorylation O
sites I-GENE
utilized O
by O
EGFR I-GENE
- I-GENE
_RARE_ I-GENE
as O
those O
identified O
in O
wild I-GENE
- I-GENE
type I-GENE
EGFR I-GENE
. O

The O
encoded I-GENE
sequence I-GENE
revealed O
a O
typical O
signal I-GENE
peptide I-GENE
, O
a O
predominantly O
hydrophilic O
_RARE_ I-GENE
amino O
acid I-GENE
residue O
domain I-GENE
with O
8 O
N I-GENE
- I-GENE
glycosylation O
sites I-GENE
, O
a O
transmembrane I-GENE
domain I-GENE
, O
and O
a O
C I-GENE
- I-GENE
terminal I-GENE
domain I-GENE
of O
52 O
amino O
acids O
. O

The O
TCF I-GENE
- I-GENE
1 I-GENE
alpha I-GENE
binding I-GENE
site I-GENE
was O
also O
required O
for O
TCR I-GENE
alpha I-GENE
enhancer I-GENE
activity O
in O
transcriptionally O
active O
extracts O
from O
Jurkat O
but O
not O
HeLa O
cells O
, O
confirming O
that O
TCF I-GENE
- I-GENE
1 I-GENE
alpha I-GENE
is O
a O
T I-GENE
- I-GENE
cell O
- I-GENE
specific I-GENE
transcription I-GENE
factor I-GENE
. O

A I-GENE
new O
_RARE_ I-GENE
- I-GENE
automatic O
method O
for O
_RARE_ I-GENE
regional O
cerebral O
uptake O
of O
99m O
technetium O
- I-GENE
_RARE_ I-GENE
amine I-GENE
_RARE_ I-GENE
( O
99mTc O
- I-GENE
HMPAO O
) O
was O
used O
to O
assess O
single O
photon O
emission O
_RARE_ I-GENE
from O
5 I-GENE
normal O
subjects O
, O
14 O
patients O
with O
Alzheimer I-GENE
' O
s O
disease O
, O
14 O
patients O
with O
dementia O
of O
frontal O
lobe O
type I-GENE
and O
4 I-GENE
patients O
with O
dementia O
with O
motor O
_RARE_ I-GENE
disease O
. O

The O
results O
showed O
that O
_RARE_ I-GENE
, O
up O
to O
a O
level O
of O
base O
plus O
_RARE_ I-GENE
of O
0 O
. O
6 I-GENE
optical O
density I-GENE
units O
, O
had O
no O
influence O
on O
the O
diagnostic O
accuracy O
in O
the O
absence O
of O
any O
_RARE_ I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
was O
first O
extracted O
by O
liquid O
- I-GENE
solid O
_RARE_ I-GENE
and O
the O
extracts O
were O
_RARE_ I-GENE
and O
analysed O
on O
a O
reversed O
- I-GENE
phase O
column O
under O
_RARE_ I-GENE
conditions O
, O
using O
either O
an O
_RARE_ I-GENE
or O
a O
UV O
detector O
. O

In O
this O
model O
, O
_RARE_ I-GENE
has O
a O
very O
specific I-GENE
anti I-GENE
- I-GENE
aggressive O
( O
_RARE_ I-GENE
) O
profile O
, O
inhibiting O
aggression O
while O
social O
interaction O
and O
_RARE_ I-GENE
are O
not O
decreased O
but O
even O
enhanced O
; O
_RARE_ I-GENE
, O
a O
measure O
for O
sedation O
, O
is O
not O
affected O
. O

A I-GENE
new O
method O
for O
the O
in O
vitro O
transfer I-GENE
of O
delayed O
hypersensitivity O
by O
_RARE_ I-GENE
transfer I-GENE
factor I-GENE
. O

Effect O
of O
separate O
and O
combined O
effects O
of O
plutonium O
- I-GENE
239 O
, O
_RARE_ I-GENE
and O
_RARE_ I-GENE
phosphate I-GENE
on O
the O
_RARE_ I-GENE
gland O
of O
rats O

Data O
collection O
was O
made O
with O
a O
_RARE_ I-GENE
language O
, O
and O
data O
analysis O
performed O
with O
an O
_RARE_ I-GENE
knowledge O
- I-GENE
based O
statistical O
tool O
, O
_RARE_ I-GENE
, O
employing O
a O
multivariate O
_RARE_ I-GENE
analysis O
technique O
. O

_RARE_ I-GENE
has O
been O
_RARE_ I-GENE
by O
using O
a O
_RARE_ I-GENE
_RARE_ I-GENE
, O
very O
_RARE_ I-GENE
and O
highly O
_RARE_ I-GENE
on O
personal O
_RARE_ I-GENE
. O

_RARE_ I-GENE
was O
induced O
by O
_RARE_ I-GENE
drinking O
of O
_RARE_ I-GENE
( O
150 O
ml O
/ I-GENE
h O
). O

Diagnostic O
value O
of O
adenosine I-GENE
deaminase I-GENE
activity O
in O
tuberculous O
_RARE_ I-GENE
. O

_RARE_ I-GENE
strain O
adaptation O
after O
total O
hip O
replacement O
: O
a O
comparison O
of O
_RARE_ I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
components O
in O
_RARE_ I-GENE
. O

_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
, O
using O
antisera O
against O
_RARE_ I-GENE
_RARE_ I-GENE
, O
showed O
that O
the O
positive O
staining O
in O
altered O
epithelial O
cells O
were O
restricted O
to O
intracellular O
organisms O
having O
a O
structure O
resembling O
_RARE_ I-GENE
_RARE_ I-GENE
. O

Promoter O
activities O
were O
estimated O
using O
beta I-GENE
- I-GENE
glucuronidase I-GENE
and O
neomycin I-GENE
phosphotransferase I-GENE
II I-GENE
reporter I-GENE
gene I-GENE
systems O
. O

The O
5 I-GENE
' O
regions O
of O
these O
two O
soybean I-GENE
actin I-GENE
genes I-GENE
contain O
many O
unusual O
features O
including O
( O
CT I-GENE
) O
repeats I-GENE
and O
long O
stretches O
of O
pyrimidine O
- I-GENE
rich O
DNA I-GENE
. O

All O
8 O
( O
100 O
%) O
patients O
with O
_RARE_ I-GENE
hepatic I-GENE
failure O
who O
received O
grafts O
_RARE_ I-GENE
, O
including O
3 I-GENE
who O
received O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
grafts O
, O
though O
2 I-GENE
of O
these O
subsequently O
required O
_RARE_ I-GENE
. O

No O
patient O
had O
a O
history O
of O
excess O
alcohol O
intake O
, O
or O
prolonged O
intake O
of O
_RARE_ I-GENE
drugs O
and O
steroids O
, O
and O
were O
not O
obese O
or O
_RARE_ I-GENE
. O

An O
evolutionary O
comparison O
of O
amino O
acid I-GENE
sequences I-GENE
of O
34 O
HSP70 I-GENE
proteins I-GENE
from O
17 O
species O
suggests O
that O
_RARE_ I-GENE
genes I-GENE
share O
a O
common O
ancestor O
, O
which O
diverged O
from O
other O
HSP70 I-GENE
genes I-GENE
near O
the O
time O
when O
eukaryotes O
first O
appeared O
. O

_RARE_ I-GENE
_RARE_ I-GENE
( O
approximately O
10 O
( O
6 I-GENE
)/ O
_RARE_ I-GENE
) O
were O
_RARE_ I-GENE
onto O
0 O
. O
5 I-GENE
- I-GENE
in O
. O

However O
, O
overexpression O
of O
both O
the O
_RARE_ I-GENE
and O
_RARE_ I-GENE
proteins I-GENE
did O
not O
generate O
a O
stronger O
pheromone O
response O
than O
overexpression O
of O
_RARE_ I-GENE
in O
the O
presence O
of O
wild I-GENE
- I-GENE
type I-GENE
levels O
of O
_RARE_ I-GENE
. O

Reverse I-GENE
transcription I-GENE
- I-GENE
PCR O
was O
then O
used O
to O
clone O
from O
human I-GENE
poly O
( O
A I-GENE
)+ O
RNA I-GENE
the O
cDNA I-GENE
corresponding O
to O
the O
expressed O
homolog I-GENE
of O
psi I-GENE
ARF I-GENE
4 I-GENE
, O
referred O
to O
as O
human I-GENE
ARF I-GENE
4 I-GENE
. O

To O
evaluate O
the O
cost O
and O
benefits O
of O
screening O
tests O
for O
Chlamydia O
_RARE_ I-GENE
in O
adolescent O
males O
, O
we O
developed O
a O
_RARE_ I-GENE
analysis O
model O
and O
compared O
the O
leukocyte I-GENE
esterase I-GENE
urine O
_RARE_ I-GENE
test O
with O
culture O
, O
with O
direct O
- I-GENE
_RARE_ I-GENE
fluorescent O
antibody I-GENE
( O
_RARE_ I-GENE
), O
and O
with O
the O
_RARE_ I-GENE
of O
no O
screening O
( O
no O
treatment O
). O

Sequencing O
the O
gene I-GENE
for O
an O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
enzyme I-GENE
( O
_RARE_ I-GENE
) O
from O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
reveals O
strong O
similarity O
between O
_RARE_ I-GENE
and O
Bacillus I-GENE
_RARE_ I-GENE
beta I-GENE
- I-GENE
lactamase I-GENE
II I-GENE
. O

The O
cloned O
HindIII I-GENE
fragment I-GENE
, O
which O
was O
shown O
by O
DNA I-GENE
sequence I-GENE
analysis O
to O
encode O
the O
N I-GENE
- I-GENE
terminal I-GENE
half O
of O
the O
B I-GENE
. O
subtilis I-GENE
_RARE_ I-GENE
protein I-GENE
and O
0 O
. O
2 I-GENE
kb O
of O
upstream O
flanking O
sequence I-GENE
, O
was O
utilized O
as O
a O
homologous O
probe O
to O
clone O
an O
overlapping O
2 I-GENE
. O
76 I-GENE
- I-GENE
kb O
_RARE_ I-GENE
chromosomal I-GENE
fragment I-GENE
containing O
the O
entire O
_RARE_ I-GENE
structural O
gene I-GENE
. O

The O
N I-GENE
- I-GENE
terminal I-GENE
115 I-GENE
amino O
acids O
correspond O
to O
a O
putative O
DNA I-GENE
- I-GENE
binding I-GENE
domain I-GENE
and O
show O
significant O
sequence I-GENE
similarity O
with O
other O
cloned O
IFN I-GENE
response O
factors I-GENE
( O
IRF I-GENE
- I-GENE
1 I-GENE
and O
IRF I-GENE
- I-GENE
2 I-GENE
). O

_RARE_ I-GENE
seizures O
had O
occurred O
during O
pregnancy O
in O
52 O
per O
cent O
. O

It O
encodes O
a O
protein I-GENE
with O
three O
zinc I-GENE
fingers O
similar O
to O
those O
of O
the O
transcription I-GENE
factor I-GENE
Sp1 I-GENE
. O

Krox I-GENE
- I-GENE
24 O
is O
therefore O
a O
sequence I-GENE
- I-GENE
specific I-GENE
transcriptional O
activator I-GENE
. O

The O
_RARE_ I-GENE
variability O
of O
the O
parameters O
is O
taken O
into O
_RARE_ I-GENE
by O
_RARE_ I-GENE
determining O
the O
threshold O
levels O
. O

The O
patients O
were O
divided O
into O
3 I-GENE
subgroups O
: O
1 I-GENE
) O
13 O
N I-GENE
+ I-GENE
patients O
with O
multiple O
hot O
spots O
( O
greater O
than O
2 I-GENE
) O
( O
N I-GENE
+ I-GENE
IM O
); O
2 I-GENE
) O
24 O
N I-GENE
+ I-GENE
patients O
with O
single O
hot O
spots O
( O
less O
than O
or O
equal O
to O
2 I-GENE
) O
( O
N I-GENE
+ I-GENE
_RARE_ I-GENE
); O
3 I-GENE
) O
12 O
N I-GENE
- I-GENE
patients O
with O
single O
hot O
spots O
( O
less O
than O
or O
equal O
to O
2 I-GENE
) O
( O
N I-GENE
- I-GENE
_RARE_ I-GENE
). O

_RARE_ I-GENE
CO2 O
causing O
changes O
from O
_RARE_ I-GENE
- I-GENE
to O
_RARE_ I-GENE
has O
previously O
been O
shown O
to O
improve O
arterial O
O2 O
tension O
( O
PaO2 O
) O
and O
to O
reduce O
alveolar O
- I-GENE
arterial O
O2 O
difference O
. O

Expression O
, O
nucleotide I-GENE
sequence I-GENE
and O
mutational O
analysis O
of O
two O
open O
reading O
frames O
in O
the O
_RARE_ I-GENE
gene I-GENE
region O
of O
_RARE_ I-GENE
sp O
. O
strain O
_RARE_ I-GENE
. O

Further O
, O
they O
are O
consistent O
with O
the O
_RARE_ I-GENE
that O
sites I-GENE
homologous O
to O
the O
_RARE_ I-GENE
_RARE_ I-GENE
may O
be O
situated O
in O
the O
5 I-GENE
'- O
flanking O
regions O
of O
multiple O
unrelated O
yeast I-GENE
genes I-GENE
. O

Our O
results O
suggest O
that O
a O
sequence I-GENE
match O
between O
enhancers I-GENE
and O
certain O
promoter I-GENE
elements O
is O
critical O
. O

This O
Mr O
is O
similar O
to O
those O
of O
the O
purified O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
estimated O
by O
sodium O
dodecyl O
sulfate I-GENE
- I-GENE
polyacrylamide O
gel O
electrophoresis O
and O
sucrose O
density I-GENE
gradient O
_RARE_ I-GENE
, O
which O
are O
about O
54 I-GENE
, O
000 O
and O
65 O
, O
000 O
, O
respectively O
. O

Yeast I-GENE
mutants I-GENE
assigned O
to O
the O
_RARE_ I-GENE
complementation O
group O
_RARE_ I-GENE
were O
found O
to O
lack O
alpha I-GENE
- I-GENE
_RARE_ I-GENE
dehydrogenase I-GENE
activity O
as O
a O
result O
of O
mutations O
in O
the O
_RARE_ I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
component O
of O
the O
complex I-GENE
. O

_RARE_ I-GENE
residues O
required O
for O
repression O
are O
located O
within O
the O
C I-GENE
- I-GENE
terminal I-GENE
27 O
amino O
acids O
of O
c I-GENE
- I-GENE
Fos I-GENE
, O
since O
v I-GENE
- I-GENE
Fos I-GENE
and O
C I-GENE
- I-GENE
terminal I-GENE
_RARE_ I-GENE
of O
c I-GENE
- I-GENE
Fos I-GENE
did O
not O
down O
regulate O
. O

We O
also O
discovered O
a O
V I-GENE
lambda I-GENE
pseudogene I-GENE
, O
called O
psi I-GENE
V I-GENE
lambda I-GENE
1 I-GENE
, O
3 I-GENE
kb O
upstream O
of O
the O
_RARE_ I-GENE
lambda I-GENE
gene I-GENE
. O

In O
this O
paper O
, O
we O
have O
analyzed O
the O
structure O
of O
human I-GENE
gene I-GENE
for O
_RARE_ I-GENE
alpha I-GENE
, O
which O
spans O
more O
than O
60 O
kilobases O
. O

A I-GENE
long O
follow O
- I-GENE
up O
study O
revealed O
that O
_RARE_ I-GENE
stage O
children O
still O
have O
the O
potency O
to O
have O
an O
immediate I-GENE
type I-GENE
hypersensitivity O
reaction O
on O
exposure O
to O
mite I-GENE
antigen I-GENE
, O
with O
a O
high O
titer O
of O
mite I-GENE
specific I-GENE
IgE I-GENE
in O
their O
sera O
, O
but O
they O
are O
free O
from O
asthmatic O
attacks O
because O
of O
the O
reduction O
in O
the O
amount O
of O
mite I-GENE
antigen I-GENE
in O
the O
body O
, O
as O
shown O
by O
the O
reduction O
in O
the O
amount O
of O
mite I-GENE
specific I-GENE
IgG I-GENE
. O

_RARE_ I-GENE
no O
influence O
was O
observed O
at O
lower O
concentrations O
than O
1 I-GENE
/ I-GENE
4 I-GENE
_RARE_ I-GENE
of O
_RARE_ I-GENE
. O

_RARE_ I-GENE
of O
_RARE_ I-GENE
_RARE_ I-GENE
for O
prophylaxis O
of O
rejection O
and O
induction O
in O
initial O
_RARE_ I-GENE
in O
kidney O
transplantation O
. O

_RARE_ I-GENE
of O
_RARE_ I-GENE
_RARE_ I-GENE
for O
prophylaxis O
of O
rejection O
and O
induction O
in O
initial O
_RARE_ I-GENE
in O
kidney O
transplantation O
. O

Furthermore O
, O
we O
_RARE_ I-GENE
two O
potential O
consensus I-GENE
motifs O
which O
are O
also O
found O
in O
corresponding O
positions O
in O
the O
genes I-GENE
for O
the O
nerve I-GENE
growth I-GENE
factor I-GENE
receptor I-GENE
and O
the O
68 O
- I-GENE
kDa I-GENE
_RARE_ I-GENE
protein I-GENE
. O

In O
addition O
, O
the O
- I-GENE
119 O
to O
- I-GENE
81 O
fragment I-GENE
of O
the O
_RARE_ I-GENE
promoter I-GENE
contains O
a O
transcriptional O
enhancer I-GENE
that O
potentiates O
the O
transcription I-GENE
from O
the O
herpes I-GENE
simplex I-GENE
virus I-GENE
thymidine I-GENE
kinase I-GENE
promoter I-GENE
in O
a O
position O
- I-GENE
and O
orientation O
- I-GENE
independent O
manner O
. O

Thirty O
minutes O
of O
supine O
_RARE_ I-GENE
decreased O
_RARE_ I-GENE
concentrations O
in O
the O
median O
_RARE_ I-GENE
of O
female O
rats O
that O
were O
not O
exposed O
to O
ether O
, O
and O
brief O
exposure O
to O
ether O
enhanced O
this O
effect O
. O

Influence O
of O
_RARE_ I-GENE
treatment O
on O
_RARE_ I-GENE
- I-GENE
adrenal O
activation O
of O
_RARE_ I-GENE
. O

Five O
of O
10 O
_RARE_ I-GENE
studied O
decreased O
at O
least O
50 O
% O
in O
linear O
dimensions O
. O

_RARE_ I-GENE
_RARE_ I-GENE
in O
a O
chronic O
care O
setting O
: O
an O
introduction O
. O

Gel O
- I-GENE
mobility I-GENE
- I-GENE
shift O
assays O
confirmed O
that O
the O
_RARE_ I-GENE
nuclear I-GENE
proteins I-GENE
that O
bound O
to O
W I-GENE
and O
V I-GENE
elements O
were O
_RARE_ I-GENE
with O
by O
an O
HLA I-GENE
- I-GENE
_RARE_ I-GENE
X I-GENE
- I-GENE
box I-GENE
oligonucleotide I-GENE
. O

In O
_RARE_ I-GENE
only O
1 I-GENE
- I-GENE
3 I-GENE
cases O
of O
transfusion O
- I-GENE
associated I-GENE
hepatitis I-GENE
NANB O
( O
_RARE_ I-GENE
- I-GENE
NANB O
) O
are O
_RARE_ I-GENE
_RARE_ I-GENE
or O
about O
1 I-GENE
case O
per O
100 O
, O
000 O
units O
_RARE_ I-GENE
. O

The O
NF1 I-GENE
locus I-GENE
encodes O
a O
protein I-GENE
functionally O
related I-GENE
to O
mammalian I-GENE
GAP I-GENE
and O
yeast I-GENE
_RARE_ I-GENE
proteins I-GENE
. O

Hence O
, O
the O
replacement O
of O
Phe I-GENE
- I-GENE
62 O
with O
Ser O
specifically O
affects O
a O
determinant O
on O
the O
lambda I-GENE
I I-GENE
light I-GENE
chain I-GENE
that O
is O
necessary O
for O
the O
intracellular O
transport O
of O
this O
molecule I-GENE
. O

A I-GENE
second O
_RARE_ I-GENE
of O
_RARE_ I-GENE
immunoglobulin I-GENE
heavy I-GENE
chain I-GENE
genes I-GENE
has O
been O
detected O
by O
screening O
a O
spleen O
cDNA I-GENE
library O
with O
homologous O
_RARE_ I-GENE
VH I-GENE
- I-GENE
and O
_RARE_ I-GENE
- I-GENE
specific I-GENE
probes O
_RARE_ I-GENE
the O
respective O
regions O
of O
the O
mu I-GENE
- I-GENE
like I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
, O
and O
S I-GENE
. O

Disruption O
of O
_RARE_ I-GENE
causes O
no O
detectable O
phenotype O
. O

Human I-GENE
recombinant I-GENE
DNA I-GENE
- I-GENE
derived O
_RARE_ I-GENE
factor I-GENE
( O
factor I-GENE
VIII I-GENE
) O
in O
the O
treatment O
of O
_RARE_ I-GENE
A I-GENE
. O
recombinant I-GENE
Factor I-GENE
VIII I-GENE
Study O
Group O
. O

Like O
other O
members O
of O
this O
family I-GENE
, O
the O
AP I-GENE
- I-GENE
4 I-GENE
_RARE_ I-GENE
motif I-GENE
and O
the O
adjacent O
basic I-GENE
domain I-GENE
are O
necessary O
and O
sufficient O
to O
confer O
site I-GENE
- I-GENE
specific I-GENE
DNA I-GENE
binding I-GENE
. O

Furthermore O
, O
expression O
of O
the O
promoter I-GENE
in O
embryonic O
Drosophila I-GENE
melanogaster I-GENE
cells O
that O
lack O
_RARE_ I-GENE
and O
Sp1 I-GENE
is O
strictly O
dependent I-GENE
on O
all O
three O
sites I-GENE
remaining O
intact O
and O
on O
the O
presence O
of O
_RARE_ I-GENE
supplied O
Sp1 I-GENE
and O
_RARE_ I-GENE
. O

Effects O
of O
a O
selective O
monoamine I-GENE
oxidase I-GENE
( O
MAO I-GENE
_RARE_ I-GENE
A I-GENE
inhibitor I-GENE
, O
_RARE_ I-GENE
, O
a O
selective O
MAO I-GENE
- I-GENE
B I-GENE
inhibitor I-GENE
, O
_RARE_ I-GENE
, O
and O
a O
non O
- I-GENE
selective O
MAO I-GENE
inhibitor I-GENE
, O
_RARE_ I-GENE
, O
were O
investigated O
on O
_RARE_ I-GENE
- I-GENE
induced O
aggression O
( O
_RARE_ I-GENE
) O
in O
paired I-GENE
rats O
. O

To O
identify O
structural O
features O
of O
residues O
flanking O
the O
c I-GENE
- I-GENE
region O
that O
influence O
the O
fidelity I-GENE
and O
efficiency O
of O
signal I-GENE
_RARE_ I-GENE
cleavage O
as O
well O
as O
co O
- I-GENE
translational O
translocation O
, O
we O
introduced O
six O
amino O
acid I-GENE
substitutions O
into O
the O
COOH O
terminus O
of O
the O
hydrophobic O
core I-GENE
and O
seven O
substitutions O
at O
the O
NH2 I-GENE
terminus O
of O
the O
mature O
region O
( O
the O
+ I-GENE
1 I-GENE
position O
) O
of O
a O
model O
eukaryotic I-GENE
_RARE_ I-GENE
- I-GENE
human I-GENE
pre I-GENE
( O
delta I-GENE
pro I-GENE
) O
_RARE_ I-GENE
- I-GENE
II I-GENE
. O

Additionally O
, O
although O
c I-GENE
- I-GENE
fos I-GENE
and O
_RARE_ I-GENE
- I-GENE
1 I-GENE
mRNAs I-GENE
are O
expressed O
at O
elevated O
levels O
in O
stimulated O
liver O
cells O
, O
fos I-GENE
- I-GENE
B I-GENE
, O
_RARE_ I-GENE
- I-GENE
1 I-GENE
, O
and O
_RARE_ I-GENE
- I-GENE
2 I-GENE
are O
not O
, O
which O
suggests O
that O
factors I-GENE
in O
addition O
to O
the O
serum I-GENE
response O
factor I-GENE
participate O
in O
the O
regulation O
of O
immediate I-GENE
- I-GENE
early I-GENE
gene I-GENE
induction O
. O

Of O
_RARE_ I-GENE
patients O
, O
_RARE_ I-GENE
cases O
with O
complete O
description O
of O
patient O
' O
s O
background O
were O
evaluable O
: O
Group O
A I-GENE
( O
surgery O
+ I-GENE
MMC O
+ I-GENE
5 I-GENE
- I-GENE
FU O
: O
chemotherapy O
) O
_RARE_ I-GENE
cases O
, O
group O
B I-GENE
( O
surgery O
+ I-GENE
MMC O
+ I-GENE
5 I-GENE
- I-GENE
FU O
+ I-GENE
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
or O
_RARE_ I-GENE
: O
_RARE_ I-GENE
) O
_RARE_ I-GENE
and O
group O
C I-GENE
( O
surgery O
alone O
) O
_RARE_ I-GENE
. O

The O
nuclear I-GENE
proteins I-GENE
encoded I-GENE
by O
the O
c I-GENE
- I-GENE
fos I-GENE
and O
c I-GENE
- I-GENE
jun I-GENE
_RARE_ I-GENE
are O
expressed O
during O
the O
proliferation O
period O
of O
_RARE_ I-GENE
phenotype O
development O
. O

This O
model O
is O
further O
supported O
by O
binding I-GENE
of O
the O
Fos I-GENE
- I-GENE
Jun I-GENE
complex I-GENE
at O
an O
AP I-GENE
- I-GENE
1 I-GENE
site I-GENE
in O
the O
type I-GENE
alpha I-GENE
I I-GENE
collagen I-GENE
promoter I-GENE
that O
is O
contiguous O
with O
, O
but O
not O
overlapping O
, O
the O
VDRE I-GENE
. O

_RARE_ I-GENE
is O
induced O
by O
agents O
which O
elicit O
the O
_RARE_ I-GENE
response O
. O

A I-GENE
_RARE_ I-GENE
relapse O
requiring O
treatment O
occurred O
by O
5 I-GENE
years O
in O
16 O
. O
8 O
% O
of O
113 I-GENE
_RARE_ I-GENE
, O
5 I-GENE
. O
2 I-GENE
% O
of O
97 O
_RARE_ I-GENE
, O
and O
20 O
. O
0 O
% O
of O
115 I-GENE
_RARE_ I-GENE
patients O
with O
organisms O
sensitive O
to O
_RARE_ I-GENE
and O
_RARE_ I-GENE
initially O
. O

In O
the O
controls O
, O
it O
was O
found O
that O
all O
right O
- I-GENE
_RARE_ I-GENE
and O
10 O
out O
of O
14 O
left O
- I-GENE
_RARE_ I-GENE
control O
subjects O
showed O
a O
right O
_RARE_ I-GENE
( O
i O
. O
e O
., O
left O
hemisphere O
) O
advantage O
. O

Although O
no O
_RARE_ I-GENE
- I-GENE
antibodies I-GENE
were O
_RARE_ I-GENE
, O
a O
similar O
mechanism O
can O
be O
postulated O
for O
the O
_RARE_ I-GENE
- I-GENE
system O
. O

The O
deduced O
amino O
acid I-GENE
sequence I-GENE
has O
the O
greatest O
homology I-GENE
( O
61 O
%) O
to O
the O
green I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
fasting O
serum I-GENE
gastrin I-GENE
concentration O
( O
_RARE_ I-GENE
. O
0 O
+/- O
21 O
. O
1 I-GENE
vs O
63 O
. O
3 I-GENE
+/- O
8 O
. O
3 I-GENE
ng O
. O
l O
- I-GENE
1 I-GENE
), O
and O
greater O
_RARE_ I-GENE
gastrin I-GENE
release O
( O
_RARE_ I-GENE
- I-GENE
120 O
: O
_RARE_ I-GENE
+/- O
_RARE_ I-GENE
vs O
_RARE_ I-GENE
+/- O
_RARE_ I-GENE
ng O
. O
l O
- I-GENE
1 I-GENE
min O
) O
were O
observed O
after O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
than O
after O
_RARE_ I-GENE
- I-GENE
Cas I-GENE
. O

The O
experimental O
group O
consisted O
of O
61 O
_RARE_ I-GENE
class I-GENE
II I-GENE
/ I-GENE
2 I-GENE
_RARE_ I-GENE
anomalies O
. O

This O
study O
was O
performed O
to O
clarify O
the O
location O
of O
a O
_RARE_ I-GENE
echocardiographic O
( O
_RARE_ I-GENE
) O
_RARE_ I-GENE
when O
obtaining O
the O
short O
- I-GENE
axis O
view O
of O
the O
left O
ventricle O
( O
S I-GENE
- I-GENE
LV O
). O

_RARE_ I-GENE
were O
16 O
male O
chronic O
_RARE_ I-GENE
consisting O
of O
8 O
_RARE_ I-GENE
suppressors O
and O
8 O
_RARE_ I-GENE
. O

From O
_RARE_ I-GENE
( O
CBF I-GENE
: O
79 O
- I-GENE
60 O
%) O
to O
_RARE_ I-GENE
( O
CBF I-GENE
: O
39 O
- I-GENE
0 O
%), O
% O
_RARE_ I-GENE
, O
1 I-GENE
/ I-GENE
_RARE_ I-GENE
and O
1 I-GENE
/ I-GENE
T I-GENE
were O
significantly O
decreased O
from O
those O
of O
the O
control O
levels O
( O
all O
p O
less O
than O
0 O
. O
01 O
). O

In O
this O
article O
we O
propose O
to O
find O
out O
the O
percentage O
of O
normal O
occlusion O
and O
the O
distribution O
of O
_RARE_ I-GENE
, O
according O
to O
the O
anteroposterior O
relationship O
between O
the O
dental O
_RARE_ I-GENE
( O
following O
the O
_RARE_ I-GENE
classification O
). O

In O
that O
case O
, O
the O
ratio O
of O
_RARE_ I-GENE
_RARE_ I-GENE
was O
0 O
. O
_RARE_ I-GENE
, O
_RARE_ I-GENE
and O
transverse O
strength O
, O
124 I-GENE
. O
3 I-GENE
and O
86 I-GENE
. O
3 I-GENE
_RARE_ I-GENE
respectively O
, O
_RARE_ I-GENE
, O
43 I-GENE
. O
2 I-GENE
_RARE_ I-GENE
, O
water O
absorption O
14 O
. O
2 I-GENE
micrograms O
/ I-GENE
_RARE_ I-GENE
and O
thermal O
expansion O
coefficient O
, O
47 O
. O
4 I-GENE
x O
10 O
(- O
6 I-GENE
)/ O
degrees O
C I-GENE
. O

9 O
, O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
). O

In O
a O
highly O
select O
group O
of O
stable O
hypertensive O
patients O
, O
we O
have O
assessed O
the O
strength O
of O
association O
between O
various O
blood O
pressure O
measurements O
( O
24 O
h O
average O
automated O
ambulatory O
blood O
pressure O
, O
4 I-GENE
h O
automated O
ambulatory O
_RARE_ I-GENE
average O
blood O
pressure O
, O
multiple O
_RARE_ I-GENE
_RARE_ I-GENE
average O
blood O
pressure O
, O
and O
a O
single O
_RARE_ I-GENE
_RARE_ I-GENE
average O
blood O
pressure O
) O
and O
various O
echocardiographic O
indices O
of O
hypertensive O
cardiac O
target O
organ O
damage O
( O
left O
atrial I-GENE
diameter O
, O
left O
ventricular O
end O
diastolic O
diameter O
, O
posterior O
wall O
thickness O
, O
combined O
wall O
thickness O
, O
relative O
wall O
thickness O
, O
left O
ventricular O
mass O
and O
mass O
index O
, O
and O
combined O
wall O
thickness O
/ I-GENE
left O
ventricular O
diastolic O
diameter O
ratio O
). O

We O
have O
previously O
identified O
, O
by O
screening O
a O
lambda I-GENE
gt11 O
expression O
library O
, O
murine I-GENE
protein I-GENE
_RARE_ I-GENE
, O
which O
binds O
to O
a O
sequence I-GENE
which O
_RARE_ I-GENE
the O
3 I-GENE
' O
end O
of O
the O
murine I-GENE
class I-GENE
II I-GENE
major I-GENE
histocompatibility I-GENE
complex I-GENE
A I-GENE
alpha I-GENE
gene I-GENE
X I-GENE
box I-GENE
, O
a O
conserved O
transcription I-GENE
element I-GENE
found O
upstream O
of O
all O
class I-GENE
II I-GENE
genes I-GENE
. O

The O
_RARE_ I-GENE
gene I-GENE
is O
at O
least O
22 O
kb O
in O
length I-GENE
and O
has O
a O
coding O
sequence I-GENE
of O
approximately O
1 I-GENE
kb O
, O
representing O
only O
4 I-GENE
. O
5 I-GENE
% O
of O
the O
gene I-GENE
.( O
ABSTRACT O
TRUNCATED O
AT I-GENE
250 O
WORDS O
) O

This O
_RARE_ I-GENE
treatment O
for O
locally O
advanced O
gynecologic O
tumors O
appears O
_RARE_ I-GENE
with O
modification O
, O
and O
continued O
work O
_RARE_ I-GENE
this O
approach O
is O
_RARE_ I-GENE
. O

A I-GENE
contiguous O
and O
_RARE_ I-GENE
occupied O
secondary O
Fur I-GENE
- I-GENE
binding I-GENE
site I-GENE
in O
_RARE_ I-GENE
was O
protected O
at O
higher O
Fur I-GENE
concentrations O
, O
extending O
the O
protected O
region O
to O
+ I-GENE
49 O
, O
and O
_RARE_ I-GENE
the O
putative O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
sequence I-GENE
. O

The O
major I-GENE
promoter I-GENE
_RARE_ I-GENE
strongly O
to O
virus I-GENE
- I-GENE
encoded I-GENE
trans O
activators I-GENE
EIA I-GENE
and O
_RARE_ I-GENE
and O
contains O
four O
elements O
: O
a O
_RARE_ I-GENE
motif I-GENE
analogous O
to O
the O
TATA I-GENE
box I-GENE
, O
two O
_RARE_ I-GENE
sites I-GENE
present O
in O
an O
inverted O
orientation O
, O
and O
an O
ATF I-GENE
/ I-GENE
CREB I-GENE
site I-GENE
. O

With O
the O
modified O
_RARE_ I-GENE
- I-GENE
to O
- I-GENE
floor I-GENE
( O
_RARE_ I-GENE
) O
method O
, O
patients O
_RARE_ I-GENE
on O
a O
_RARE_ I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
so O
that O
measurements O
can O
be O
taken O
on O
patients O
who O
are O
able O
to O
_RARE_ I-GENE
the O
floor I-GENE
or O
reach O
beyond O
the O
level O
of O
the O
floor I-GENE
. O

No O
significant O
differences O
could O
be O
seen O
in O
response O
rates O
according O
to O
the O
concentration O
of O
estrogen I-GENE
receptors I-GENE
or O
presence O
of O
_RARE_ I-GENE
receptors I-GENE
in O
this O
group O
of O
patients O
. O

_RARE_ I-GENE
was O
given O
most O
often O
because O
of O
persistent O
fever O
or O
initial O
Gram O
- I-GENE
positive O
_RARE_ I-GENE
and O
only O
one O
- I-GENE
third O
of O
these O
cases O
responded O
. O

_RARE_ I-GENE
hormone I-GENE
- I-GENE
releasing I-GENE
hormone I-GENE
analog O
therapy O
of O
uterine O
_RARE_ I-GENE
: O
analysis O
of O
results O
obtained O
with O
_RARE_ I-GENE
administered O
_RARE_ I-GENE
and O
_RARE_ I-GENE
administered O
subcutaneously O
as O
a O
monthly O
_RARE_ I-GENE
. O

In O
Experiments O
1 I-GENE
and O
2 I-GENE
, O
infants O
, O
like I-GENE
adults O
, O
initially O
_RARE_ I-GENE
novel O
objects O
on O
the O
basis O
of O
physical O
appearance O
, O
but O
only O
if O
_RARE_ I-GENE
with O
multiple O
_RARE_ I-GENE
, O
after O
_RARE_ I-GENE
of O
1 I-GENE
and O
7 O
days O
. O

The O
clinical O
picture O
of O
the O
disease O
was O
significantly O
different O
from O
_RARE_ I-GENE
cutaneous O
_RARE_ I-GENE
caused O
by O
L I-GENE
. O
_RARE_ I-GENE
but O
similar O
to O
cutaneous O
patterns O
caused O
by O
L I-GENE
. O
_RARE_ I-GENE
which O
was O
a O
_RARE_ I-GENE
pattern O
in O
the O
southern O
_RARE_ I-GENE
. O

Although O
there O
are O
no O
octamer O
elements O
in O
the O
adenovirus I-GENE
genome O
that O
are O
known O
to O
be O
important O
for O
transcription I-GENE
, O
there O
are O
octamer O
elements O
in O
the O
viral I-GENE
terminal I-GENE
repeat I-GENE
sequences I-GENE
. O

In O
comparison O
with O
the O
16 O
introns O
reported O
in O
_RARE_ I-GENE
, O
_RARE_ I-GENE
is O
missing O
one O
intron O
in O
the O
5 I-GENE
'- O
untranslated O
region O
and O
a O
second O
intron O
in O
the O
C I-GENE
- I-GENE
terminal I-GENE
coding O
region O
. O

Northern O
blot O
analysis O
indicates O
that O
_RARE_ I-GENE
mRNA I-GENE
relative O
to O
total O
cellular O
RNA I-GENE
is O
expressed O
at O
significantly O
higher O
levels O
in O
root O
tissue I-GENE
as O
compared O
with O
_RARE_ I-GENE
tissue I-GENE
. O

_RARE_ I-GENE
of O
_RARE_ I-GENE
tube O
in O
the O
abdominal O
wall O
. O

Both O
_RARE_ I-GENE
elevated O
the O
pain O
threshold O
_RARE_ I-GENE
, O
while O
pretreatment O
with O
_RARE_ I-GENE
largely O
blocked O
the O
analgesia O
. O

_RARE_ I-GENE
. O

A I-GENE
needs O
assessment O
of O
these O
families O
was O
also O
done O
. O

TCR I-GENE
alpha I-GENE
and O
beta I-GENE
gene I-GENE
expression O
may O
be O
regulated O
by O
a O
common O
set O
of O
T I-GENE
- I-GENE
cell O
nuclear I-GENE
proteins I-GENE
in O
that O
the O
T I-GENE
beta I-GENE
2 I-GENE
element I-GENE
binding I-GENE
a O
set O
of O
cyclic I-GENE
AMP I-GENE
response O
element I-GENE
- I-GENE
binding I-GENE
proteins I-GENE
that O
are O
also O
bound O
by O
the O
T I-GENE
alpha I-GENE
1 I-GENE
element I-GENE
of O
the O
human I-GENE
TCR I-GENE
alpha I-GENE
enhancer I-GENE
and O
the O
_RARE_ I-GENE
element I-GENE
present O
in O
a O
large O
number O
of O
human I-GENE
and O
murine I-GENE
TCR I-GENE
beta I-GENE
promoters I-GENE
. O

The O
3 I-GENE
' O
stem O
- I-GENE
loop I-GENE
is O
highly O
divergent O
in O
structure O
among O
species O
and O
lies O
immediately O
upstream O
of O
the O
binding I-GENE
site I-GENE
for O
_RARE_ I-GENE
proteins I-GENE
. O

The O
deleted O
nucleotide I-GENE
sequence I-GENE
corresponded O
to O
sequences I-GENE
that O
, O
by O
_RARE_ I-GENE
to O
the O
organization O
of O
the O
type I-GENE
I I-GENE
collagen I-GENE
genes I-GENE
, O
should O
be O
precisely O
encoded I-GENE
by O
exon O
41 O
of O
the O
_RARE_ I-GENE
gene I-GENE
. O

These O
_RARE_ I-GENE
account O
for O
the O
resistance O
of O
_RARE_ I-GENE
- I-GENE
IV I-GENE
collagen I-GENE
to O
_RARE_ I-GENE
bromide O
and O
mammalian I-GENE
_RARE_ I-GENE
digestion O
. O

A I-GENE
4 I-GENE
. O
8 O
- I-GENE
kilobase O
BamHI I-GENE
- I-GENE
HindIII I-GENE
fragment I-GENE
encoding O
the O
entire O
Neurospora I-GENE
crassa I-GENE
_RARE_ I-GENE
superoxide I-GENE
dismutase I-GENE
gene I-GENE
( O
_RARE_ I-GENE
designated O
_RARE_ I-GENE
- I-GENE
1 I-GENE
) O
was O
isolated O
from O
a O
genomic O
library O
using O
two O
60 O
- I-GENE
base O
_RARE_ I-GENE
probes O
corresponding O
to O
the O
published O
N I-GENE
. O
crassa I-GENE
amino O
acid I-GENE
sequence I-GENE
. O

Two O
other O
peptides I-GENE
, O
either O
partially O
or O
_RARE_ I-GENE
lacking O
the O
basic I-GENE
region O
, O
but O
containing O
the O
intact O
leucine I-GENE
zipper I-GENE
domain I-GENE
, O
readily O
form O
dimers I-GENE
but O
do O
not O
bind O
to O
the O
CRE O
. O

In O
contrast O
, O
the O
CRE O
of O
the O
human I-GENE
c I-GENE
- I-GENE
fos I-GENE
promoter I-GENE
located O
at O
- I-GENE
60 O
was O
weakly O
induced O
by O
cAMP I-GENE
and O
E1a I-GENE
in O
both O
HeLa O
and O
PC12 O
cells O
. O

We O
have O
isolated O
and O
sequenced O
the O
gene I-GENE
encoding O
the O
human I-GENE
U1 I-GENE
- I-GENE
_RARE_ I-GENE
snRNP I-GENE
protein I-GENE
. O

Although O
_RARE_ I-GENE
this O
hypothesis O
is O
far O
from O
_RARE_ I-GENE
all O
the O
clinical O
_RARE_ I-GENE
, O
namely O
that O
_RARE_ I-GENE
is O
equal O
in O
_RARE_ I-GENE
and O
_RARE_ I-GENE
, O
proximal I-GENE
and O
distal O
muscles O
. O

Using O
appropriate O
synthetic O
HSE O
oligonucleotides O
, O
three O
types O
of O
clones O
with O
potential O
HSE O
binding I-GENE
domains I-GENE
were O
isolated O
from O
a O
tomato I-GENE
lambda I-GENE
gt11 O
expression O
library O
by O
DNA I-GENE
- I-GENE
ligand O
screening O
. O

_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
31 O
. O

The O
results O
supported O
the O
therapeutic O
_RARE_ I-GENE
of O
_RARE_ I-GENE
: O
_RARE_ I-GENE
patients O
according O
to O
their O
_RARE_ I-GENE
patterns O
. O

The O
_RARE_ I-GENE
gene I-GENE
is O
the O
major I-GENE
negative O
regulatory I-GENE
gene I-GENE
in O
the O
nitrogen O
control O
circuit O
of O
Neurospora I-GENE
crassa I-GENE
, O
which O
, O
together O
with O
positive O
regulatory I-GENE
genes I-GENE
, O
_RARE_ I-GENE
the O
expression O
of O
multiple O
_RARE_ I-GENE
structural O
genes I-GENE
of O
the O
circuit O
. O

The O
4 I-GENE
days O
dexamethasone O
suppression O
test O
showed O
more O
than O
80 O
% O
suppression O
of O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
and O
a O
variable O
( O
40 I-GENE
- I-GENE
60 O
%) O
reduction O
of O
testosterone O
and O
_RARE_ I-GENE
levels O
. O

The O
ratio O
of O
P I-GENE
- I-GENE
31 O
NMR O
- I-GENE
S I-GENE
derived O
inorganic O
_RARE_ I-GENE
[ O
_RARE_ I-GENE
] O
to O
_RARE_ I-GENE
[ O
_RARE_ I-GENE
] O
was O
significantly O
greater O
at O
rest O
in O
_RARE_ I-GENE
_RARE_ I-GENE
[ O
0 O
. O
53 O
+/- O
0 O
. O
06 O
versus O
controls O
= O
0 O
. O
41 O
+/- O
0 O
. O
17 O
; O
P I-GENE
less O
than O
0 O
. O
05 O
]. O

_RARE_ I-GENE
necrosis I-GENE
associated I-GENE
with O
protein I-GENE
S I-GENE
deficiency O
. O

_RARE_ I-GENE
study O

_RARE_ I-GENE
cerebral O
blood O
flow O
was O
measured O
using O
N I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
with O
single O
- I-GENE
photon O
emission O
computed O
tomography O
( O
CT I-GENE
) O
in O
16 O
aged O
patients O
with O
_RARE_ I-GENE
- I-GENE
dependent I-GENE
diabetes O
mellitus O
( O
_RARE_ I-GENE
, O
average O
age O
72 O
. O
8 O
years O
, O
average O
fasting O
plasma I-GENE
glucose O
7 O
. O
7 O
mmol O
/ I-GENE
L I-GENE
), O
and O
12 O
_RARE_ I-GENE
subjects O
( O
71 O
. O
6 I-GENE
years O
, O
5 I-GENE
. O
3 I-GENE
mmol O
/ I-GENE
L I-GENE
). O

Mean O
_RARE_ I-GENE
- I-GENE
A I-GENE
/ I-GENE
B I-GENE
ratio O
was O
49 O
. O
6 I-GENE
+/- O
1 I-GENE
. O
7 O
% O
in O
the O
diabetic O
group O
, O
significantly O
lower O
than O
the O
57 O
. O
9 O
+/- O
1 I-GENE
. O
6 I-GENE
% O
at O
the O
_RARE_ I-GENE
group O
( O
p O
less O
than O
0 O
. O
005 O
). O

These O
data O
strongly O
_RARE_ I-GENE
the O
normal O
product I-GENE
of O
the O
int I-GENE
- I-GENE
2 I-GENE
gene I-GENE
, O
which O
is O
related I-GENE
to O
the O
fibroblast I-GENE
growth I-GENE
factor I-GENE
family I-GENE
, O
as O
a O
_RARE_ I-GENE
factor I-GENE
in O
_RARE_ I-GENE
induced O
mammary O
tumors O
. O

This O
result O
indicates O
that O
separate O
complexes I-GENE
exist O
containing O
_RARE_ I-GENE
and O
_RARE_ I-GENE
with O
either O
_RARE_ I-GENE
or O
Na I-GENE
+, I-GENE
K I-GENE
+- I-GENE
ATPase I-GENE
. O

These O
genes I-GENE
are O
expressed O
within O
a O
few O
hours O
of O
the O
initiation I-GENE
of O
development O
; O
their O
mRNAs I-GENE
accumulate O
to O
a O
peak O
at O
12 O
hr O
and O
_RARE_ I-GENE
until O
_RARE_ I-GENE
. O

The O
_RARE_ I-GENE
protein I-GENE
also O
shows O
great O
similarity O
to O
the O
incomplete O
NH2 I-GENE
- I-GENE
terminal I-GENE
sequence I-GENE
of O
the O
human I-GENE
_RARE_ I-GENE
gene I-GENE
product I-GENE
, O
a O
putative O
membrane I-GENE
- I-GENE
inserted O
receptor I-GENE
- I-GENE
like I-GENE
molecule I-GENE
. O

_RARE_ I-GENE
or O
not O
there O
are O
sequences I-GENE
conferring O
cAMP I-GENE
responsiveness O
which O
are O
common O
both O
to O
P I-GENE
- I-GENE
_RARE_ I-GENE
and O
the O
other O
_RARE_ I-GENE
P I-GENE
- I-GENE
450 I-GENE
genes I-GENE
remains O
to O
be O
established O
. O

In O
this O
study O
, O
we O
used O
footprinting O
and O
gel O
mobility I-GENE
retardation O
assays O
to O
reveal O
that O
bacterially O
synthesized O
Zta I-GENE
fusion I-GENE
proteins I-GENE
bound O
directly O
to O
six O
_RARE_ I-GENE
- I-GENE
like I-GENE
motifs O
within O
_RARE_ I-GENE
. O

The O
_RARE_ I-GENE
transactivator I-GENE
involved O
in O
induction O
of O
lytic O
cycle O
gene I-GENE
expression O
in O
Epstein I-GENE
- I-GENE
Barr I-GENE
virus I-GENE
- I-GENE
infected O
lymphocytes O
binds O
to O
both O
AP I-GENE
- I-GENE
1 I-GENE
and O
_RARE_ I-GENE
sites I-GENE
in O
target O
promoter I-GENE
and O
enhancer I-GENE
regions O
. O

It O
is O
the O
human I-GENE
homolog I-GENE
of O
the O
mouse I-GENE
_RARE_ I-GENE
protein I-GENE
involved O
in O
resistance O
to O
influenza I-GENE
virus I-GENE
. O

_RARE_ I-GENE
containing O
the O
21 O
- I-GENE
base O
- I-GENE
pair O
repeat I-GENE
region O
, O
the O
enhancer I-GENE
of O
simian I-GENE
virus I-GENE
40 I-GENE
or O
both O
strongly O
stimulated O
beta I-GENE
- I-GENE
galactosidase I-GENE
synthesis O
, O
and O
three O
fragments I-GENE
from O
the O
_RARE_ I-GENE
enhancer I-GENE
region O
stimulated O
moderate O
levels O
. O

The O
sites I-GENE
targeted O
for O
mutagenesis O
, O
residues O
60 O
, O
61 O
, O
and O
66 O
, O
are O
located O
within O
a O
putative O
helical O
loop I-GENE
structure O
which O
may O
be O
involved O
in O
substrate I-GENE
recognition I-GENE
by O
the O
enzyme I-GENE
. O

The O
possible O
benefits O
of O
_RARE_ I-GENE
heparin O
( O
reduced O
frequency O
of O
bleeding O
, O
_RARE_ I-GENE
of O
_RARE_ I-GENE
) O
were O
not O
, O
however O
, O
apparent O
, O
possibly O
because O
of O
the O
short O
observation O
period O
and O
the O
low O
incidence O
of O
hemorrhagic O
complications O
in O
routine O
_RARE_ I-GENE
. O

The O
deduced O
amino O
acid I-GENE
sequence I-GENE
of O
_RARE_ I-GENE
is O
165 O
residues O
long O
and O
is O
very O
similar O
( O
71 O
% O
identical O
) O
to O
that O
of O
_RARE_ I-GENE
, O
a O
widely O
distributed O
, O
pH O
- I-GENE
sensitive O
actin I-GENE
- I-GENE
_RARE_ I-GENE
protein I-GENE
. O

_RARE_ I-GENE
, O
_RARE_ I-GENE
89 I-GENE
: O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
). O

With O
only O
purified O
T I-GENE
antigen I-GENE
in O
the O
presence O
of O
topoisomerase I-GENE
I I-GENE
to O
_RARE_ I-GENE
purified O
DNA I-GENE
, O
_RARE_ I-GENE
- I-GENE
auxiliary I-GENE
sequences I-GENE
strongly O
facilitated O
T I-GENE
- I-GENE
antigen I-GENE
- I-GENE
dependent I-GENE
DNA I-GENE
conformational O
changes O
consistent O
with O
_RARE_ I-GENE
the O
first O
50 O
base O
pairs O
. O

A I-GENE
rabbit I-GENE
antiserum O
was O
raised O
against O
a O
synthetic O
peptide I-GENE
corresponding O
to O
a O
hydrophilic O
portion O
of O
the O
translated O
murine I-GENE
cDNA I-GENE
sequence I-GENE
. O

_RARE_ I-GENE
of O
function O
of O
Drosophila I-GENE
melanogaster I-GENE
abl I-GENE
and O
murine I-GENE
v I-GENE
- I-GENE
abl I-GENE
proteins I-GENE
in O
transformation O
of O
mammalian I-GENE
cells O
. O

In O
transient O
cotransfection O
assays O
using O
_RARE_ I-GENE
liver O
cells O
( O
_RARE_ I-GENE
13 O
), O
_RARE_ I-GENE
DNA I-GENE
exerts O
a O
6 I-GENE
- I-GENE
to O
10 O
- I-GENE
fold O
trans O
- I-GENE
activating I-GENE
effect O
on O
the O
expression O
of O
the O
_RARE_ I-GENE
reporter I-GENE
plasmid O
. O

We O
have O
determined O
the O
nucleotide I-GENE
( O
nt O
) O
sequence I-GENE
of O
the O
7 O
. O
5 I-GENE
- I-GENE
kb O
_RARE_ I-GENE
segment O
that O
_RARE_ I-GENE
a O
cluster I-GENE
of O
six O
genes I-GENE
( O
CYC1 I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
tRNA I-GENE
( O
Gly O
) O
and O
_RARE_ I-GENE
) O
located O
on O
chromosome O
X I-GENE
of O
the O
yeast I-GENE
Saccharomyces I-GENE
cerevisiae I-GENE
. O

Specific O
binding I-GENE
of O
the O
protein I-GENE
factors I-GENE
to O
the O
sites I-GENE
, O
possibly O
to O
the O
three O
_RARE_ I-GENE
sequences I-GENE
, O
may O
play O
an O
important O
role O
in O
the O
coordinate O
regulation O
of O
the O
transcription I-GENE
of O
nuclear I-GENE
genes I-GENE
encoding O
subunits I-GENE
responsible O
for O
mitochondrial I-GENE
oxidative O
phosphorylation O
. O

This O
points O
to O
a O
specific I-GENE
interference O
with O
HSV I-GENE
- I-GENE
induced O
DNA I-GENE
amplification O
. O

No O
recombination O
signal I-GENE
sequences I-GENE
have O
been O
found O
contiguous O
to O
the O
recombination O
point O
. O

The O
_RARE_ I-GENE
properties O
, O
as O
measured O
by O
the O
tail O
- I-GENE
_RARE_ I-GENE
and O
hot O
- I-GENE
plate I-GENE
tests O
, O
and O
the O
motor O
effects O
of O
an O
_RARE_ I-GENE
- I-GENE
administered O
_RARE_ I-GENE
agonist O
midazolam O
, O
alone O
, O
and O
in O
combination O
with O
morphine O
, O
was O
examined O
in O
rats O
. O

_RARE_ I-GENE
were O
made O
in O
which O
an O
_RARE_ I-GENE
and O
the O
GT I-GENE
- I-GENE
rich O
region O
were O
separated O
by O
various O
distances O
ranging O
from O
7 O
to O
43 I-GENE
bp O
. O

To O
address O
this O
_RARE_ I-GENE
, O
the O
gene I-GENE
for O
factor I-GENE
Y I-GENE
has O
been O
cloned O
molecularly O
and O
its O
DNA I-GENE
sequence I-GENE
has O
been O
determined O
. O

We O
cloned O
and O
sequenced O
the O
cDNAs I-GENE
against O
genomic O
RNA I-GENE
and O
mRNA I-GENE
for O
phosphoprotein I-GENE
( O
P I-GENE
) O
of O
human I-GENE
_RARE_ I-GENE
type I-GENE
2 I-GENE
virus I-GENE
( O
_RARE_ I-GENE
- I-GENE
2 I-GENE
). O
cDNA I-GENE
clone O
from O
genomic O
RNA I-GENE
was O
_RARE_ I-GENE
nucleotides O
in O
length I-GENE
excluding O
poly O
( O
A I-GENE
) O
and O
was O
found O
to O
have O
two O
small I-GENE
open O
reading O
frames O
encoding O
proteins I-GENE
of O
233 I-GENE
and O
_RARE_ I-GENE
amino O
acids O
. O

We O
show O
that O
_RARE_ I-GENE
expression O
is O
negatively O
controlled O
by O
the O
_RARE_ I-GENE
protein I-GENE
and O
positively O
affected O
by O
the O
cAMP I-GENE
/ I-GENE
CAP I-GENE
complex I-GENE
. O

To O
identify O
these O
sites I-GENE
, O
the O
deduced O
amino O
acid I-GENE
sequence I-GENE
of O
the O
3T3 O
- I-GENE
L1 I-GENE
_RARE_ I-GENE
insulin I-GENE
receptor I-GENE
of O
the O
mouse I-GENE
was O
determined O
. O

_RARE_ I-GENE
blocks O
turnover O
of O
the O
_RARE_ I-GENE
group O
of O
_RARE_ I-GENE
, O
causing O
its O
accumulation O
, O
and O
thereby O
appears O
to O
_RARE_ I-GENE
signal I-GENE
transmission O
from O
the O
receptor I-GENE
to O
the O
glucose O
- I-GENE
transport O
system O
. O

It O
is O
likely O
that O
the O
sequence I-GENE
similarities O
reflect O
a O
common O
molecular O
architecture O
of O
the O
two O
heme O
binding I-GENE
sites I-GENE
and O
of O
a O
copper I-GENE
binding I-GENE
site I-GENE
in O
these O
enzymes O
. O

The O
cDNA I-GENE
sequence I-GENE
has O
an O
_RARE_ I-GENE
- I-GENE
bp O
open O
reading O
frame O
( O
ORF I-GENE
) O
whose O
predicted O
amino O
acid I-GENE
sequence I-GENE
is O
97 O
. O
6 I-GENE
% O
identical O
to O
the O
272 O
carboxy I-GENE
- I-GENE
terminal I-GENE
amino O
acids O
of O
the O
human I-GENE
ets I-GENE
- I-GENE
1 I-GENE
protein I-GENE
. O

To O
characterize O
the O
_RARE_ I-GENE
- I-GENE
LPS I-GENE
region O
, O
the O
recombinant I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
were O
_RARE_ I-GENE
by O
transposon I-GENE
mutagenesis O
with O
_RARE_ I-GENE
, O
which O
carries O
a O
promoterless O
lac I-GENE
operon I-GENE
and O
can O
therefore O
generate O
lacZ I-GENE
transcriptional O
fusions I-GENE
with O
target O
DNA I-GENE
sequences I-GENE
. O

The O
_RARE_ I-GENE
gene I-GENE
regulating O
the O
_RARE_ I-GENE
operon I-GENE
in O
Bacillus I-GENE
subtilis I-GENE
shares O
strong O
homology I-GENE
with O
transcriptional O
_RARE_ I-GENE
. O

The O
_RARE_ I-GENE
protein I-GENE
( O
83 O
, O
_RARE_ I-GENE
Da I-GENE
) O
contains O
three O
hydrophobic O
regions O
, O
of O
which O
two O
are O
located O
near O
the O
amino O
- I-GENE
terminal I-GENE
region O
. O

The O
protein I-GENE
product I-GENE
of O
_RARE_ I-GENE
, O
which O
is O
probably O
a O
new O
_RARE_ I-GENE
gene I-GENE
( O
named O
_RARE_ I-GENE
), O
contains O
65 O
% O
hydrophobic O
amino O
acids O
, O
especially O
rich O
in O
alanine I-GENE
and O
leucine I-GENE
. O

Various O
mutant I-GENE
_RARE_ I-GENE
genes I-GENE
were O
constructed O
to O
examine O
the O
role O
of O
residues O
flanking O
the O
signal I-GENE
- I-GENE
anchor I-GENE
domain I-GENE
, O
including O
the O
cytoplasmic I-GENE
tail O
, O
on O
assembly O
and O
intracellular O
transport O
of O
the O
_RARE_ I-GENE
glycoprotein I-GENE
. O

Our O
studies O
extend O
these O
findings O
and O
show O
that O
the O
E2 I-GENE
transactivation O
gene I-GENE
is O
expressed O
from O
multiple O
promoters I-GENE
. O

Furthermore O
, O
analysis O
of O
the O
E2 I-GENE
proteins I-GENE
present O
in O
various O
cell O
lines O
harboring O
specific I-GENE
BPV I-GENE
- I-GENE
1 I-GENE
mutants I-GENE
, O
including O
the O
_RARE_ I-GENE
acceptor O
mutant I-GENE
, O
_RARE_ I-GENE
that O
alternate O
modes O
of O
E2 I-GENE
expression O
exist O
. O

Disruption O
of O
the O
_RARE_ I-GENE
gene I-GENE
resulted O
in O
( O
i O
) O
increased O
sensitivity O
to O
heat I-GENE
shock I-GENE
and O
nitrogen O
starvation O
, O
( O
ii O
) O
sporulation I-GENE
defects O
, O
and O
( O
iii O
) O
suppression O
of O
the O
lethality O
of O
the O
_RARE_ I-GENE
mutant I-GENE
. O

This O
cohort O
of O
patients O
was O
selected O
on O
the O
basis O
of O
clinical O
stage O
. O

A I-GENE
gene I-GENE
in O
Drosophila I-GENE
melanogaster I-GENE
that O
maps O
_RARE_ I-GENE
to O
_RARE_ I-GENE
- I-GENE
3 I-GENE
on O
the O
distal O
portion O
of O
the O
X I-GENE
- I-GENE
chromosome O
encodes O
a O
member O
of O
the O
steroid I-GENE
/ I-GENE
thyroid I-GENE
hormone I-GENE
receptor I-GENE
superfamily I-GENE
. O

A I-GENE
portion O
of O
_RARE_ I-GENE
II I-GENE
also O
resembles O
part O
of O
the O
human I-GENE
c I-GENE
- I-GENE
jun I-GENE
oncoprotein I-GENE
' O
s O
leucine I-GENE
zipper I-GENE
, O
which O
in O
turn I-GENE
, O
has O
been O
demonstrated O
to O
be O
the O
heterodimerization O
site I-GENE
between O
the O
jun I-GENE
and O
fos I-GENE
oncoproteins I-GENE
. O

To O
determine O
whether O
_RARE_ I-GENE
could O
inhibit O
PEPCK I-GENE
gene I-GENE
transcription I-GENE
, O
a O
series O
of O
chimeric I-GENE
genes I-GENE
containing O
several O
deletions O
in O
the O
P I-GENE
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
promoter I-GENE
between O
- I-GENE
_RARE_ I-GENE
and O
- I-GENE
68 O
was O
linked O
to O
the O
structural O
genes I-GENE
for O
either O
amino O
- I-GENE
3 I-GENE
- I-GENE
_RARE_ I-GENE
phosphotransferase I-GENE
( O
neo I-GENE
) O
or O
chloramphenicol I-GENE
acetyltransferase I-GENE
and O
introduced O
into O
hepatoma O
cells O
using O
three O
methods O
: O
( O
a O
) O
infection O
with O
a O
Moloney O
murine I-GENE
leukemia I-GENE
virus I-GENE
- I-GENE
based O
retrovirus O
, O
( O
b I-GENE
) O
transfection O
and O
stable O
selection O
for O
neo I-GENE
expression O
, O
or O
( O
c I-GENE
) O
transient O
expression O
of O
_RARE_ I-GENE
acetyltransferase I-GENE
. O

The O
diagnosis O
of O
_RARE_ I-GENE
tuberculosis O
should O
be O
systematically O
considered O
in O
ARDS O
of O
unknown O
origin O
. O

In O
order O
to O
characterize O
the O
functional O
elements O
of O
the O
promoter I-GENE
that O
in O
some O
way O
must O
respond O
to O
these O
regulatory I-GENE
signals O
, O
a O
number O
of O
promoter I-GENE
mutations O
were O
constructed O
, O
including O
a O
set O
of O
linker I-GENE
- I-GENE
scanning O
mutations O
across O
the O
entire O
promoter I-GENE
region O
. O

A I-GENE
DNA I-GENE
motif I-GENE
related I-GENE
to O
the O
cAMP I-GENE
- I-GENE
responsive I-GENE
element I-GENE
and O
an O
exon O
- I-GENE
located O
activator I-GENE
protein I-GENE
- I-GENE
2 I-GENE
binding I-GENE
site I-GENE
in O
the O
human I-GENE
tissue I-GENE
- I-GENE
type I-GENE
plasminogen I-GENE
activator I-GENE
gene I-GENE
promoter I-GENE
cooperate O
in O
basal O
expression O
and O
_RARE_ I-GENE
activation O
by O
phorbol O
ester O
and O
cAMP I-GENE
. O

The O
_RARE_ I-GENE
rRNA I-GENE
binding I-GENE
ribosomal I-GENE
protein I-GENE
equivalent O
to O
bacterial I-GENE
protein I-GENE
_RARE_ I-GENE
is O
encoded I-GENE
by O
unspliced O
duplicated O
genes I-GENE
in O
Saccharomyces I-GENE
cerevisiae I-GENE
. O

Five O
healthy O
male O
subjects O
_RARE_ I-GENE
air O
for O
20 O
min O
and O
then O
5 I-GENE
% O
CO2 O
/ I-GENE
95 O
% O
O2 O
for O
30 O
min O
, O
of O
which O
the O
first O
10 O
min O
was O
used O
to O
achieve O
a O
steady O
- I-GENE
state O
end O
- I-GENE
tidal O
CO2 O
measurement O
. O

Significant O
correlations O
were O
obtained O
between O
changes O
in O
_RARE_ I-GENE
in O
response O
to O
AS I-GENE
and O
the O
presence O
of O
not O
deep O
residual O
- I-GENE
organic O
disturbances O
, O
so O
- I-GENE
called O
" O
_RARE_ I-GENE
" O
in O
_RARE_ I-GENE
disorders O
. O

The O
transcripts I-GENE
were O
equally O
active O
with O
or O
without O
a O
5 I-GENE
' O
_RARE_ I-GENE
_RARE_ I-GENE
as O
expected O
, O
since O
_RARE_ I-GENE
- I-GENE
RNA I-GENE
is O
one O
of O
the O
mRNAs I-GENE
capable O
of O
internal O
initiation I-GENE
. O

The O
E6 I-GENE
/ I-GENE
E7 I-GENE
promoter I-GENE
of O
all O
genital O
human I-GENE
_RARE_ I-GENE
is O
responsible O
for O
expression O
of O
the O
viral I-GENE
transforming I-GENE
genes I-GENE
. O

A I-GENE
case O
of O
_RARE_ I-GENE
' O
s O
syndrome O
. O

Seventy O
- I-GENE
two O
of O
73 O
negative O
controls O
and O
all O
positive O
blocks O
as O
seen O
on O
soft O
tissue I-GENE
radiographs O
( O
_RARE_ I-GENE
) O
were O
correctly O
coded O
( O
specificity O
98 O
. O
6 I-GENE
%, O
sensitivity O
100 O
%). O

No O
symptomatic O
abnormality O
has O
been O
noted O
in O
the O
neonatal O
period O
except O
_RARE_ I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
analysis O
of O
several O
rat I-GENE
organs O
also O
showed O
staining O
in O
epithelial O
cells O
. O

Both O
strains O
_RARE_ I-GENE
very O
poorly O
, O
or O
not O
at O
all O
, O
on O
_RARE_ I-GENE
carbon O
sources O
and O
exhibited O
, O
at O
most O
, O
only O
5 I-GENE
% O
of O
wild I-GENE
- I-GENE
type I-GENE
_RARE_ I-GENE
- I-GENE
cytochrome I-GENE
c I-GENE
oxidoreductase I-GENE
activity O
. O

Regulation O
of O
_RARE_ I-GENE
by O
iron O
in O
V I-GENE
. O
cholerae I-GENE
occurs O
at O
the O
transcriptional O
level O
, O
and O
there O
is O
an O
interrupted O
_RARE_ I-GENE
_RARE_ I-GENE
sequence I-GENE
in O
the O
vicinity O
of O
the O
promoter I-GENE
that O
is O
homologous O
to O
Fur I-GENE
binding I-GENE
sites I-GENE
of O
E I-GENE
. O
coli I-GENE
. O

Transcription O
of O
the O
first O
operon I-GENE
coding O
for O
m I-GENE
- I-GENE
xylene O
- I-GENE
_RARE_ I-GENE
enzymes O
on O
the O
_RARE_ I-GENE
plasmid O
of O
Pseudomonas I-GENE
putida I-GENE
is O
activated I-GENE
by O
the O
_RARE_ I-GENE
gene I-GENE
product I-GENE
in O
the O
presence O
of O
m I-GENE
- I-GENE
xylene O
. O

The O
recombinant I-GENE
contains O
the O
normal O
beta I-GENE
A I-GENE
- I-GENE
globin I-GENE
gene I-GENE
, O
the O
mutant I-GENE
gene I-GENE
and O
_RARE_ I-GENE
vector O
sequences I-GENE
between O
the O
two O
copies O
. O

Some O
of O
the O
mutations O
obtained O
do O
not O
contain O
a O
copy O
of O
the O
_RARE_ I-GENE
element I-GENE
at O
the O
mutant I-GENE
locus I-GENE
, O
suggesting O
that O
a O
different O
_RARE_ I-GENE
element I-GENE
may O
be O
responsible O
for O
the O
mutation I-GENE
. O

Determination O
of O
_RARE_ I-GENE
in O
biological O
materials O
by O
electron O
spin O
resonance O
spectroscopy O
. O

We O
show O
also O
that O
RA O
represses O
the O
transcriptional O
activity O
of O
a O
reporter I-GENE
gene I-GENE
containing O
a O
TPA O
responding O
AP1 I-GENE
binding I-GENE
site I-GENE
_RARE_ I-GENE
the O
HSV I-GENE
tk I-GENE
promoter I-GENE
. O

Moreover O
, O
radiolabeled O
_RARE_ I-GENE
, O
NF I-GENE
- I-GENE
Y I-GENE
, O
or O
CBF I-GENE
DNAs O
give O
rise O
to O
identical O
gel O
retardation O
patterns O
in O
extracts O
from O
a O
variety O
of O
different O
cell O
types O
. O

Risk O
factors I-GENE
influencing O
lymph O
nodes O
metastasis O
in O
lung O
cancer O
with O
stage O
I I-GENE
, O
II I-GENE
or O
_RARE_ I-GENE

_RARE_ I-GENE
protein I-GENE
kinase I-GENE
( O
_RARE_ I-GENE
) O
phosphorylates O
ATP I-GENE
- I-GENE
citrate I-GENE
lyase I-GENE
on O
peptide I-GENE
B I-GENE
on O
two O
sites I-GENE
, O
_RARE_ I-GENE
and O
_RARE_ I-GENE
, O
on O
threonine I-GENE
and O
serine I-GENE
, O
respectively O
, O
inhibitor I-GENE
2 I-GENE
on O
a O
_RARE_ I-GENE
residue O
, O
and O
glycogen I-GENE
synthase I-GENE
at O
sites I-GENE
2 I-GENE
and O
3 I-GENE
. O

The O
characterized O
Y I-GENE
' O
repeated O
sequence I-GENE
families O
provide O
an O
experimental O
system O
in O
which O
repeated O
sequence I-GENE
interactions O
and O
subsequent O
evolution O
can O
be O
studied O
. O

The O
electrically O
induced O
_RARE_ I-GENE
responses O
were O
not O
suppressed O
in O
the O
presence O
of O
_RARE_ I-GENE
or O
_RARE_ I-GENE
B I-GENE
. O

Unlike O
_RARE_ I-GENE
- I-GENE
rel I-GENE
, O
which O
is O
a O
nuclear I-GENE
protein I-GENE
in O
_RARE_ I-GENE
, O
indirect O
immunofluorescence O
showed O
that O
_RARE_ I-GENE
- I-GENE
rel I-GENE
in O
_RARE_ I-GENE
- I-GENE
rel I-GENE
infected O
_RARE_ I-GENE
is O
located O
exclusively O
in O
the O
cytoplasm O
of O
these O
cells O
, O
even O
though O
the O
sequence I-GENE
of O
_RARE_ I-GENE
- I-GENE
rel I-GENE
showed O
that O
it O
contains O
a O
nuclear I-GENE
_RARE_ I-GENE
sequence I-GENE
identical O
to O
the O
one O
previously O
identified O
in O
_RARE_ I-GENE
- I-GENE
rel I-GENE
. O

_RARE_ I-GENE
experiments O
revealed O
that O
within O
10 O
min O
this O
radiolabeled O
precursor I-GENE
protein I-GENE
was O
converted O
in O
HL I-GENE
- I-GENE
60 O
cells O
into O
an O
Mr O
approximately O
150 O
, O
000 O
_RARE_ I-GENE
sulfate I-GENE
proteoglycan I-GENE
intermediate O
. O

Blood O
flow O
and O
velocity O
( O
measured O
using O
Doppler O
ultrasound O
) O
gradually O
decreased O
during O
_RARE_ I-GENE
and O
_RARE_ I-GENE
reversed O
in O
direction O
as O
_RARE_ I-GENE
resistance O
was O
increased O
up O
to O
14 O
fold O
. O

A I-GENE
total O
of O
112 O
patients O
received O
_RARE_ I-GENE
and O
119 O
received O
heparin O
within O
a O
mean O
period O
of O
_RARE_ I-GENE
+/- O
62 O
min O
following O
the O
onset O
of O
symptoms O
. O

However O
, O
primary O
transcripts I-GENE
of O
a O
variant I-GENE
tRNA I-GENE
( O
Val I-GENE
)( I-GENE
_RARE_ I-GENE
) O
gene I-GENE
are O
processing O
deficient O
under O
standard O
growth I-GENE
conditions O
( O
30 O
degrees O
C I-GENE
), O
due O
to O
a O
slightly O
altered O
5 I-GENE
' O
flanking O
region O
. O

The O
promoter I-GENE
activity O
was O
measured O
by O
a O
transient O
expression O
of O
a O
chloramphenicol I-GENE
acetyltransferase I-GENE
( O
CAT I-GENE
) O
gene I-GENE
connected O
with O
various O
5 I-GENE
'- O
deletion O
mutants I-GENE
of O
the O
5 I-GENE
'- O
flanking O
region O
. O

Three O
of O
the O
short O
ORFs O
in O
the O
central O
region O
of O
_RARE_ I-GENE
have O
been O
identified O
by O
location O
and O
structural O
similarity O
to O
the O
_RARE_ I-GENE
/ I-GENE
regulatory I-GENE
genes I-GENE
( O
_RARE_ I-GENE
, O
tat I-GENE
, O
and O
rev I-GENE
) O
of O
other O
_RARE_ I-GENE
; O
we O
also O
discovered O
two O
unique O
ORFs O
, O
termed O
W I-GENE
and O
Y I-GENE
, O
which O
may O
serve O
as O
exons O
for O
novel O
genes I-GENE
. O

The O
Saccharomyces I-GENE
cerevisiae I-GENE
_RARE_ I-GENE
gene I-GENE
, O
encoding O
cytochrome I-GENE
P450 I-GENE
_RARE_ I-GENE
14 O
alpha I-GENE
- I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
), O
was O
overexpressed O
in O
various O
S I-GENE
. O
cerevisiae I-GENE
strains O
under O
the O
control O
of O
three O
strong O
heterologous O
yeast I-GENE
transcription I-GENE
promoters I-GENE
( O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
) O
and O
under O
the O
control O
of O
its O
own O
promoter I-GENE
. O

_RARE_ I-GENE
composed O
of O
78 O
and O
64 O
amino O
acids O
were O
_RARE_ I-GENE
across O
the O
endoplasmic O
reticulum O
membrane I-GENE
, O
and O
translocation O
was O
found O
to O
be O
strictly O
co O
- I-GENE
translational O
and O
SRP I-GENE
- I-GENE
dependent I-GENE
. O

_RARE_ I-GENE
vascular I-GENE
resistance O
was O
not O
altered O
, O
ejection O
fraction O
remained O
unchanged O
and O
_RARE_ I-GENE
relaxation O
period O
was O
_RARE_ I-GENE
( O
119 O
+/- O
20 O
. O
1 I-GENE
to O
_RARE_ I-GENE
. O
39 O
+/- O
21 O
. O
15 O
, O
P I-GENE
less O
than O
0 O
. O
05 O
). O

The O
_RARE_ I-GENE
locus I-GENE
of O
Saccharomyces I-GENE
cerevisiae I-GENE
encodes O
the O
protein I-GENE
synthesis O
initiation I-GENE
factor I-GENE
eIF I-GENE
- I-GENE
_RARE_ I-GENE
. O

The O
contribution O
that O
alternative O
splicing O
events O
in O
c I-GENE
- I-GENE
myb I-GENE
expression O
may O
make O
on O
c I-GENE
- I-GENE
myb I-GENE
function O
remains O
to O
be O
_RARE_ I-GENE
. O

Serum I-GENE
beta I-GENE
2 I-GENE
- I-GENE
microglobulin I-GENE
levels O
( O
beta I-GENE
- I-GENE
2 I-GENE
- I-GENE
M I-GENE
) O
were O
studied O
in O
150 O
drug O
addicts O
, O
50 O
of O
them O
asymptomatic O
carriers O
of O
anti I-GENE
HIV I-GENE
- I-GENE
1 I-GENE
antibodies I-GENE
, O
50 O
symptomatic O
carriers O
with O
persistent O
generalized O
_RARE_ I-GENE
( O
P I-GENE
. O
G I-GENE
. O
L I-GENE
.) O
and O
50 O
serum I-GENE
negative O
patients O
who O
had O
been O
living O
in O
a O
closed O
community O
for O
at O
least O
2 I-GENE
years O
. O

This O
_RARE_ I-GENE
of O
the O
ability O
to O
_RARE_ I-GENE
from O
hormonal O
influence O
makes O
female O
sexual O
_RARE_ I-GENE
the O
primary O
regulator I-GENE
of O
mating I-GENE
in O
primates O
. O

No O
therapy O
exists O
for O
_RARE_ I-GENE
the O
progression O
of O
the O
disease O
with O
the O
possible O
exception O
of O
laser O
_RARE_ I-GENE
treatment O
used O
to O
_RARE_ I-GENE
subretinal O
_RARE_ I-GENE
membranes O
in O
an O
attempt O
to O
avoid O
complications O
of O
subretinal O
_RARE_ I-GENE
. O

R I-GENE
. O

Specific O
_RARE_ I-GENE
_RARE_ I-GENE
to O
pathogens O
such O
as O
Haemophilus O
influenzae O
and O
Streptococcus I-GENE
pneumoniae I-GENE
have O
also O
been O
studied O
. O

_RARE_ I-GENE
effects O
of O
_RARE_ I-GENE
( O
HR O
_RARE_ I-GENE
) O
on O
experimental O
mixed O
infections O
with O
_RARE_ I-GENE
_RARE_ I-GENE
and O
Escherichia I-GENE
coli I-GENE
in O
mice O
. O

Regulation O
of O
yeast I-GENE
LEU2 I-GENE
. O

Homozygous O
individuals O
usually O
develop O
purpura O
_RARE_ I-GENE
as O
newborns O
; O
_RARE_ I-GENE
protein I-GENE
C I-GENE
- I-GENE
deficient O
individuals O
are O
at O
increased O
risk O
for O
venous O
thrombosis O
and O
pulmonary O
_RARE_ I-GENE
. O

Ischemic O
stroke O
due O
to O
protein I-GENE
C I-GENE
deficiency O
. O

_RARE_ I-GENE
and O
_RARE_ I-GENE
protected O
all O
three O
repeats I-GENE
of O
the O
21 O
bp O
, O
but O
_RARE_ I-GENE
protected O
only O
the O
second O
repeat I-GENE
. O

These O
results O
suggest O
that O
5 I-GENE
_RARE_ I-GENE
X I-GENE
3 I-GENE
/ I-GENE
W I-GENE
may O
be O
the O
optimal O
regimen O
to O
_RARE_ I-GENE
the O
_RARE_ I-GENE
immunity O
of O
_RARE_ I-GENE
. O

Analysis O
of O
various O
deletion O
mutants I-GENE
indicates O
that O
the O
sequence I-GENE
requirements O
for O
binding I-GENE
by O
_RARE_ I-GENE
in O
vitro O
are O
indistinguishable O
from O
those O
necessary O
for O
Q I-GENE
activity O
in O
vivo O
, O
strongly O
suggesting O
that O
_RARE_ I-GENE
is O
required O
for O
the O
function O
of O
this O
TATA I-GENE
- I-GENE
independent O
promoter I-GENE
. O

Since O
general O
regulatory I-GENE
factor I-GENE
I I-GENE
( O
_RARE_ I-GENE
)/ O
repressor I-GENE
/ I-GENE
activator I-GENE
site I-GENE
binding I-GENE
protein I-GENE
1 I-GENE
( O
_RARE_ I-GENE
)/ O
translation I-GENE
upstream O
factor I-GENE
( O
_RARE_ I-GENE
) O
is O
believed O
to O
be O
an O
activator I-GENE
of O
_RARE_ I-GENE
alpha I-GENE
expression O
, O
we O
examined O
whether O
_RARE_ I-GENE
, O
which O
is O
known O
to O
be O
regulated O
by O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
, O
is O
also O
affected O
by O
the O
_RARE_ I-GENE
mutation I-GENE
. O

Yeast I-GENE
_RARE_ I-GENE
protein I-GENE
mediates O
the O
transcriptional O
activation O
signal I-GENE
of O
two O
different O
_RARE_ I-GENE
factors I-GENE
, O
Gal4 I-GENE
and O
general O
regulatory I-GENE
factor I-GENE
I I-GENE
/ I-GENE
repressor I-GENE
/ I-GENE
activator I-GENE
site I-GENE
binding I-GENE
protein I-GENE
1 I-GENE
/ I-GENE
translation I-GENE
upstream O
factor I-GENE
. O

Deletion O
from O
either O
the O
N I-GENE
- I-GENE
or O
C I-GENE
- I-GENE
terminal I-GENE
ends O
of O
_RARE_ I-GENE
( O
28 O
and O
69 O
codons O
, O
respectively O
, O
out O
of O
the O
_RARE_ I-GENE
- I-GENE
codon O
open O
reading O
frame O
) O
affected O
the O
initiator O
but O
not O
the O
inhibitory I-GENE
activity O
. O

The O
two O
larger O
peptides I-GENE
, O
one O
containing O
amino O
acids O
1 I-GENE
- I-GENE
_RARE_ I-GENE
and O
the O
other O
containing O
amino O
acids O
85 O
- I-GENE
_RARE_ I-GENE
, O
formed O
dimers I-GENE
in O
solution O
and O
bound O
DNA I-GENE
specifically O
as O
a O
dimer O
. O

In O
vitro O
transcription I-GENE
extracts O
from O
_RARE_ I-GENE
- I-GENE
1 I-GENE
cells O
terminate O
less O
efficiently O
at O
weak O
transcription I-GENE
termination O
signals O
than O
those O
from O
_RARE_ I-GENE
cells O
, O
using O
a O
variety O
of O
tRNA I-GENE
templates O
. O

_RARE_ I-GENE
patients O
in O
the O
_RARE_ I-GENE
should O
involve O
a O
_RARE_ I-GENE
_RARE_ I-GENE
composed O
of O
a O
surgical O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
. O

IgG I-GENE
and O
IgM I-GENE
antibody I-GENE
activity O
was O
determined O
by O
adding O
a O
1 I-GENE
: O
100 O
dilution O
of O
serum I-GENE
to O
plates O
_RARE_ I-GENE
with O
_RARE_ I-GENE
antigen I-GENE
. O

These O
factors I-GENE
belong O
to O
a O
set O
of O
genetically O
distinct O
molecules I-GENE
, O
including O
AP I-GENE
- I-GENE
4 I-GENE
and O
_RARE_ I-GENE
, O
that O
bind O
to O
the O
_RARE_ I-GENE
motif I-GENE
or O
related I-GENE
sequences I-GENE
. O

Among O
known O
_RARE_ I-GENE
larvae O
, O
the O
genus O
_RARE_ I-GENE
( O
_RARE_ I-GENE
, O
_RARE_ I-GENE
) O
is O
as O
distinctive O
in O
larval I-GENE
form O
as O
are O
the O
adults O
. O

Here O
, O
we O
have O
used O
specific I-GENE
antibody I-GENE
to O
identify O
and O
characterize O
the O
_RARE_ I-GENE
protein I-GENE
. O

These O
latter O
results O
showed O
that O
the O
_RARE_ I-GENE
protein I-GENE
, O
like I-GENE
the O
_RARE_ I-GENE
protein I-GENE
, O
bound O
sequences I-GENE
required O
for O
positive O
as O
well O
as O
negative O
regulation O
of O
gene I-GENE
expression O
. O

Clinical O
nutrition O
of O
adult O
horses O
. O

The O
computer O
- I-GENE
programmed O
_RARE_ I-GENE
is O
currently O
most O
_RARE_ I-GENE
. O

RNase I-GENE
protection O
assays O
reveal O
that O
this O
gene I-GENE
, O
_RARE_ I-GENE
, O
is O
transcribed O
in O
the O
same O
direction O
as O
N I-GENE
- I-GENE
ras I-GENE
and O
that O
its O
3 I-GENE
' O
end O
is O
located O
just O
130 I-GENE
base O
pairs O
_RARE_ I-GENE
from O
the O
point O
at O
which O
N I-GENE
- I-GENE
ras I-GENE
transcription I-GENE
begins O
. O

Isolation O
of O
a O
temperature O
- I-GENE
sensitive O
mutant I-GENE
with O
an O
altered O
tRNA I-GENE
_RARE_ I-GENE
and O
cloning O
of O
the O
gene I-GENE
encoding O
tRNA I-GENE
_RARE_ I-GENE
in O
the O
yeast I-GENE
Saccharomyces I-GENE
cerevisiae I-GENE
. O

The O
juxtamembrane I-GENE
region O
of O
the O
insulin I-GENE
receptor I-GENE
( O
IR I-GENE
) O
beta I-GENE
- I-GENE
subunit I-GENE
contains O
an O
_RARE_ I-GENE
_RARE_ I-GENE
residue O
( O
_RARE_ I-GENE
) O
that O
is O
essential O
for O
insulin I-GENE
- I-GENE
stimulated O
_RARE_ I-GENE
phosphorylation O
of O
some O
endogenous I-GENE
substrates O
and O
certain O
biological O
responses O
( O
_RARE_ I-GENE
, O
M I-GENE
. O
F I-GENE
., O
_RARE_ I-GENE
, O
J O
. O
N I-GENE
., O
_RARE_ I-GENE
, O
J O
. O
M I-GENE
., O
_RARE_ I-GENE
, O
V I-GENE
., O
_RARE_ I-GENE
, O
T I-GENE
. O
J O
., O
_RARE_ I-GENE
, O
A I-GENE
., O
and O
_RARE_ I-GENE
, O
C I-GENE
. O
R I-GENE
. O

This O
gene I-GENE
joins O
the O
group O
of O
genes I-GENE
whose O
members O
are O
rapidly O
transcribed O
in O
response O
to O
insulin I-GENE
and O
other O
_RARE_ I-GENE
. O

The O
3 I-GENE
' O
region O
, O
_RARE_ I-GENE
, O
is O
necessary O
for O
maximal O
expression O
. O

1 I-GENE
, O
among O
which O
nine O
have O
been O
cloned O
and O
two O
( O
potentially O
functional O
) O
sequenced O
. O

_RARE_ I-GENE
placed O
into O
the O
novel O
environment O
with O
their O
mothers O
exhibited O
an O
intermediate O
level O
of O
DA I-GENE
turnover O
. O

The O
efficacy O
and O
safety O
of O
a O
novel O
_RARE_ I-GENE
_RARE_ I-GENE
preparation O
based O
on O
_RARE_ I-GENE
has O
been O
investigated O
in O
the O
_RARE_ I-GENE
clinical O
environment O
. O

Homozygous O
protein I-GENE
C I-GENE
( O
PC I-GENE
) O
deficiency O
is O
reported O
in O
two O
_RARE_ I-GENE
( O
_RARE_ I-GENE
and O
_RARE_ I-GENE
) O
who O
received O
their O
proper O
_RARE_ I-GENE
at O
the O
ages O
of O
7 O
4 I-GENE
/ I-GENE
12 O
and O
1 I-GENE
3 I-GENE
/ I-GENE
12 O
years O
respectively O
. O

The O
_RARE_ I-GENE
and O
the O
_RARE_ I-GENE
both O
had O
_RARE_ I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
, O
whereas O
the O
daughter O
had O
a O
normal O
outer I-GENE
ear O
except O
for O
a O
narrow O
_RARE_ I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
. O

Abnormal O
_RARE_ I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
), O
which O
was O
proved O
in O
4 I-GENE
cases O
by O
whole O
- I-GENE
body O
_RARE_ I-GENE
scanning O
with O
99mTc O
- I-GENE
_RARE_ I-GENE
, O
is O
suggested O
as O
the O
major I-GENE
cause O
of O
_RARE_ I-GENE
in O
liver O
cirrhosis O
. O

The O
urinary O
protein I-GENE
, O
serum I-GENE
albumin I-GENE
, O
_RARE_ I-GENE
and O
_RARE_ I-GENE
all O
had O
very O
significant O
improvement O
. O

More O
generally O
, O
_RARE_ I-GENE
and O
_RARE_ I-GENE
could O
regulate O
transcription I-GENE
of O
cellular O
genes I-GENE
. O

Within O
this O
sequence I-GENE
the O
_RARE_ I-GENE
gene I-GENE
was O
identified O
as O
a O
_RARE_ I-GENE
- I-GENE
bp O
- I-GENE
long O
open O
reading O
frame O
coding O
for O
a O
protein I-GENE
of O
_RARE_ I-GENE
amino O
acids O
and O
190 O
, O
_RARE_ I-GENE
Da I-GENE
molecular O
mass O
. O

_RARE_ I-GENE
peroxidase I-GENE
as O
a O
permeability I-GENE
marker O
in O
_RARE_ I-GENE
rat I-GENE
_RARE_ I-GENE
and O
iliac O
arteries O
. O

_RARE_ I-GENE
gastric O
wall O
specimens O
from O
the O
area O
of O
_RARE_ I-GENE
_RARE_ I-GENE
ulcers O
were O
obtained O
, O
processed O
, O
and O
evaluated O
by O
light I-GENE
microscopy O
and O
by O
transmission O
electron O
microscopy O
. O

2 I-GENE
. O

The O
effects O
of O
coenzyme I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
and O
captopril O
on O
functional O
capacity O
, O
hemodynamics O
and O
survival O
were O
studied O
in O
154 O
rats O
that O
recovered O
after O
experimental O
myocardial O
infarction O
. O

Evidence O
that O
therapeutic O
alterations O
of O
a O
circadian O
rhythm O
for O
gastric O
emptying O
response O
may O
be O
possible O
. O

The O
_RARE_ I-GENE
of O
the O
levels O
of O
glucocorticoids O
and O
insulin I-GENE
in O
the O
blood O
of O
irradiated O
animals O

This O
last O
includes O
tissue I-GENE
O2 O
transfer I-GENE
( O
Ft O
') I-GENE
and O
mitochondrial I-GENE
O2 O
utilization O
( O
_RARE_ I-GENE
_RARE_ I-GENE

_RARE_ I-GENE
_RARE_ I-GENE
, O
therefore O
, O
can O
be O
distinguished O
from O
other O
_RARE_ I-GENE
on O
the O
basis O
of O
_RARE_ I-GENE
. O

_RARE_ I-GENE
correlated O
with O
the O
grade O
of O
oral O
_RARE_ I-GENE
_RARE_ I-GENE
periodontal O
disease O
. O

Our O
study O
shows O
that O
the O
area O
of O
_RARE_ I-GENE
is O
a O
medium O
MS O
risk O
region O
according O
to O
the O
_RARE_ I-GENE
of O
_RARE_ I-GENE
, O
although O
high O
MS O
areas O
may O
be O
found O
, O
thus O
confirming O
that O
MS O
distribution O
in O
southern O
_RARE_ I-GENE
is O
not O
uniform O
. O

On O
an O
antithrombin I-GENE
unit I-GENE
basis O
, O
_RARE_ I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
were O
equivalent O
and O
more O
potent O
than O
_RARE_ I-GENE
. O

_RARE_ I-GENE
brain O
actin I-GENE
_RARE_ I-GENE
factor I-GENE
( O
_RARE_ I-GENE
) O
is O
a O
19 O
- I-GENE
kDa I-GENE
protein I-GENE
that O
_RARE_ I-GENE
actin I-GENE
_RARE_ I-GENE
and O
binds O
actin I-GENE
_RARE_ I-GENE
. O

Initial O
experience O
with O
a O
serotonin I-GENE
agonist O
. O

_RARE_ I-GENE
care O
of O
the O
patient O
exposed O
to O
a O
human I-GENE
_RARE_ I-GENE
may O
also O
include O
discussion O
of O
_RARE_ I-GENE
diagnostic O
procedures O
and O
other O
pregnancy O
management O
_RARE_ I-GENE
. O

Primer O
extension O
analysis O
and O
RNA I-GENE
sequencing O
demonstrates O
that O
the O
transcription I-GENE
start O
point O
of O
rat I-GENE
_RARE_ I-GENE
mRNA I-GENE
is O
located O
_RARE_ I-GENE
nt O
upstream O
from O
the O
A I-GENE
residue O
in O
the O
start O
codon O
. O

For O
_RARE_ I-GENE
, O
larger O
- I-GENE
than O
- I-GENE
expected O
distribution O
coefficients O
were O
obtained O
in O
the O
_RARE_ I-GENE
experiments O
, O
an O
indication O
of O
the O
irreversible O
formation O
of O
metal O
- I-GENE
_RARE_ I-GENE
during O
a O
slow O
reaction O
. O

Gene I-GENE
constructs I-GENE
_RARE_ I-GENE
the O
complete O
tat I-GENE
, O
rev I-GENE
( O
tat I-GENE
+ I-GENE
rev I-GENE
+) O
and O
env I-GENE
genes I-GENE
were O
transiently O
expressed O
in O
COS O
- I-GENE
1 I-GENE
cells O
as O
precursor I-GENE
SU I-GENE
- I-GENE
TM I-GENE
( O
_RARE_ I-GENE
), O
SU I-GENE
. O
TM I-GENE
( O
gp120 I-GENE
x O
41 O
), O
and O
nucleolar I-GENE
rev I-GENE
protein I-GENE
. O

This O
growth I-GENE
arrest O
is O
partly O
suppressed O
on O
minimal I-GENE
medium O
or O
under O
conditions O
in O
which O
the O
cells O
are O
less O
dependent I-GENE
on O
mitochondrial I-GENE
metabolism O
. O

Patients O
with O
detectable O
serum I-GENE
TNF I-GENE
levels O
had O
significantly O
lower O
serum I-GENE
T3 O
concentrations O
compared O
to O
those O
with O
undetectable O
levels O
[ O
1 I-GENE
. O
_RARE_ I-GENE
+/- O
0 O
. O
_RARE_ I-GENE
vs O
. O

_RARE_ I-GENE
_RARE_ I-GENE
carcinoma O
: O
report O
and O
review O
of O
the O
literature O
. O

Further O
studies O
of O
mandibular O
movement O
at O
initial O
tooth O
contact O
. O

Each O
_RARE_ I-GENE
interacted O
with O
their O
4 I-GENE
- I-GENE
or O
5 I-GENE
- I-GENE
year O
- I-GENE
old O
_RARE_ I-GENE
or O
daughter O
in O
each O
of O
two O
_RARE_ I-GENE
-- O
_RARE_ I-GENE
( O
social O
_RARE_ I-GENE
) O
and O
structured O
( O
task O
activity O
). O

_RARE_ I-GENE
- I-GENE
induced O
_RARE_ I-GENE
symptoms O
in O
an O
adolescent O
following O
_RARE_ I-GENE
surgery O
. O

These O
results O
indicate O
that O
the O
cis O
- I-GENE
regulatory I-GENE
elements O
required O
for O
developmental O
control O
of O
the O
_RARE_ I-GENE
- I-GENE
A I-GENE
_RARE_ I-GENE
gene I-GENE
are O
located O
in O
a O
2 I-GENE
. O
4 I-GENE
kb O
upstream O
region O
of O
this O
gene I-GENE
. O

The O
induction O
by O
pseudorabies O
virus I-GENE
of O
an O
IL I-GENE
- I-GENE
6 I-GENE
construct I-GENE
containing O
the O
IL I-GENE
- I-GENE
6 I-GENE
TATA I-GENE
box I-GENE
and O
the O
RNA I-GENE
start O
site I-GENE
(" O
initiator O
" O
or O
_RARE_ I-GENE
element I-GENE
) O
but O
not O
the O
_RARE_ I-GENE
region O
was O
also O
repressed O
by O
_RARE_ I-GENE
in O
the O
presence O
of O
wild I-GENE
- I-GENE
type I-GENE
GR I-GENE
. O

Some O
mutations O
affected O
_RARE_ I-GENE
in O
a O
qualitative O
manner O
, O
such O
as O
by O
changing O
the O
_RARE_ I-GENE
of O
one O
of O
the O
major I-GENE
_RARE_ I-GENE
transcripts I-GENE
or O
changing O
the O
relative O
abundance O
of O
the O
two O
major I-GENE
_RARE_ I-GENE
transcripts I-GENE
. O

The O
_RARE_ I-GENE
cyst O
wall O
was O
_RARE_ I-GENE
in O
part O
by O
_RARE_ I-GENE
or O
_RARE_ I-GENE
epithelium O
. O

We O
conclude O
that O
class I-GENE
I I-GENE
_RARE_ I-GENE
smears O
with O
moderate O
to O
severe O
inflammation O
may O
be O
associated I-GENE
with O
findings O
of O
_RARE_ I-GENE
and O
cervical O
dysplasia O
. O

As O
in O
mammals O
, O
considerable O
nucleotide I-GENE
diversity O
was O
observed O
at O
the O
junctions O
of O
the O
variable O
, O
diversity O
, O
and O
joining O
elements O
in O
chicken I-GENE
TCR I-GENE
beta I-GENE
cDNAs I-GENE
. O

The O
protooncogene I-GENE
c I-GENE
- I-GENE
myb I-GENE
encodes O
a O
nuclear I-GENE
transcription I-GENE
factor I-GENE
that O
binds O
to O
DNA I-GENE
in O
a O
sequence I-GENE
- I-GENE
specific I-GENE
manner O
and O
transactivates O
transcription I-GENE
of O
several O
viral I-GENE
and O
cellular O
genes I-GENE
. O

_RARE_ I-GENE
by O
this O
latter O
compound O
was O
so O
extensive O
that O
the O
amount O
of O
membrane I-GENE
- I-GENE
associated I-GENE
N I-GENE
- I-GENE
_RARE_ I-GENE
protein I-GENE
was O
decreased O
. O

S6 I-GENE
kinase I-GENE
activation O
requires O
displacement I-GENE
of O
this O
inhibitory I-GENE
segment O
, O
which O
is O
proposed O
to O
occur O
_RARE_ I-GENE
to O
its O
multiple O
phosphorylation O
. O

Rats I-GENE
with O
one O
olfactory O
bulb O
removed O
and O
the O
contralateral O
_RARE_ I-GENE
closed O
can O
detect O
_RARE_ I-GENE
. O

Expression O
of O
the O
human I-GENE
T I-GENE
cell O
receptor I-GENE
( O
TCR I-GENE
) O
alpha I-GENE
gene I-GENE
is O
regulated O
by O
a O
T I-GENE
cell O
- I-GENE
specific I-GENE
transcriptional O
enhancer I-GENE
that O
is O
located O
4 I-GENE
. O
5 I-GENE
kilobases O
( O
kb O
) O
3 I-GENE
' O
to O
the O
C I-GENE
alpha I-GENE
gene I-GENE
segment O
. O

The O
Ets I-GENE
- I-GENE
1 I-GENE
binding I-GENE
site I-GENE
was O
localized O
to O
a O
17 O
- I-GENE
base O
pair O
( O
bp O
) O
region O
from O
the O
3 I-GENE
' O
end O
of O
T I-GENE
alpha I-GENE
2 I-GENE
. O

_RARE_ I-GENE
flow O
and O
resistance O
showed O
minor O
reductions O
with O
HD I-GENE
. O

_RARE_ I-GENE
of O
alternative O
polyadenylation O
signals O
was O
previously O
shown O
to O
generate O
two O
_RARE_ I-GENE
mRNAs I-GENE
of O
1 I-GENE
. O
9 O
and O
4 I-GENE
. O
3 I-GENE
kb O
, O
which O
differ O
in O
the O
length I-GENE
of O
their O
3 I-GENE
' O
untranslated O
regions O
. O

_RARE_ I-GENE
address O
1990 O
-- O
_RARE_ I-GENE
in O
from O
the O
cold O
. O

Human I-GENE
T I-GENE
- I-GENE
cell O
leukemia I-GENE
virus I-GENE
type I-GENE
I I-GENE
( O
HTLV I-GENE
- I-GENE
I I-GENE
) O
encodes O
a O
40 I-GENE
- I-GENE
kDa I-GENE
nuclear I-GENE
protein I-GENE
, O
Tax I-GENE
, O
which O
stimulates O
transcription I-GENE
from O
three O
21 O
- I-GENE
base O
pair O
( O
bp O
) O
repeats I-GENE
in O
its O
U3 I-GENE
region O
. O

We O
have O
now O
identified O
, O
after O
21 O
serial O
_RARE_ I-GENE
_RARE_ I-GENE
of O
_RARE_ I-GENE
, O
a O
small I-GENE
_RARE_ I-GENE
RNA I-GENE
, O
_RARE_ I-GENE
, O
which O
is O
efficiently O
_RARE_ I-GENE
into O
virions O
. O

The O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
and O
the O
_RARE_ I-GENE
- I-GENE
revised O
: O
further O
evidence O
of O
adaptive O
and O
_RARE_ I-GENE
type I-GENE
A I-GENE
_RARE_ I-GENE
. O

There O
was O
evidence O
of O
attenuated O
regression O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
to O
observed O
portion O
sizes O
for O
4 I-GENE
of O
the O
10 O
food O
groups O
; O
adjusted O
_RARE_ I-GENE
values O
for O
the O
_RARE_ I-GENE
portion O
sizes O
ranged O
from O
0 O
. O
02 O
to O
0 O
. O
94 O
. O

The O
result O
suggests O
that O
this O
non O
- I-GENE
invasive O
_RARE_ I-GENE
method O
is O
easily O
available O
and O
useful O
in O
monitoring O
the O
_RARE_ I-GENE
cardiac O
output O
. O

The O
_RARE_ I-GENE
gene I-GENE
was O
isolated O
in O
a O
screen O
for O
genes I-GENE
that O
regulate O
mating I-GENE
type I-GENE
( O
V I-GENE
. O
L I-GENE
. O

The O
_RARE_ I-GENE
suppressor I-GENE
mutation I-GENE
occurs O
near O
a O
region O
of O
the O
protein I-GENE
that O
corresponds O
to O
the O
known O
positions O
of O
alterations O
in O
E I-GENE
. O
coli I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
mutations O
. O

Interestingly O
, O
disruption O
of O
the O
_RARE_ I-GENE
locus I-GENE
resulted O
in O
a O
temperature O
- I-GENE
sensitive O
growth I-GENE
defect O
, O
indicating O
that O
the O
_RARE_ I-GENE
gene I-GENE
is O
essential O
for O
_RARE_ I-GENE
growth I-GENE
only O
at O
elevated O
growth I-GENE
temperatures O
. O

We O
describe O
a O
case O
of O
a O
_RARE_ I-GENE
abscess O
treated O
with O
amphotericin O
B I-GENE
and O
_RARE_ I-GENE
. O

This O
, O
together O
with O
the O
data O
obtained O
with O
haloperidol O
, O
suggests O
that O
a O
minimal I-GENE
increase O
in O
the O
_RARE_ I-GENE
rate O
of O
_RARE_ I-GENE
cells O
(+ O
140 I-GENE
%) O
is O
required O
before O
it O
could O
influence O
the O
turnover O
of O
NA O
, O
as O
measured O
by O
_RARE_ I-GENE
changes O
. O

This O
interaction O
occurs O
over O
a O
wide O
range O
of O
both O
parameters O
; O
for O
charge I-GENE
density I-GENE
from O
at O
least O
10 O
to O
800 O
_RARE_ I-GENE
/ I-GENE
cm2 O
and O
, O
for O
charge I-GENE
per O
phase O
, O
from O
at O
least O
0 O
. O
05 O
to O
5 I-GENE
. O
0 O
_RARE_ I-GENE
per O
phase O
. O

_RARE_ I-GENE
of O
illness O
_RARE_ I-GENE
were O
significantly O
higher O
when O
both O
muscle O
_RARE_ I-GENE
and O
headache O
symptoms O
occurred O
during O
one O
or O
more O
assessment O
intervals O
as O
compared O
to O
when O
muscle O
_RARE_ I-GENE
or O
_RARE_ I-GENE
, O
only O
, O
occurred O
. O

Results O
have O
_RARE_ I-GENE
revealed O
the O
presence O
of O
three O
U14 I-GENE
snRNA I-GENE
- I-GENE
homologous O
regions O
positioned O
within O
introns O
5 I-GENE
, O
6 I-GENE
, O
and O
8 O
of O
the O
mouse I-GENE
cognate I-GENE
_RARE_ I-GENE
heat I-GENE
shock I-GENE
gene I-GENE
. O

65 O
- I-GENE
kilodalton I-GENE
protein I-GENE
phosphorylated O
by O
interleukin I-GENE
2 I-GENE
stimulation O
_RARE_ I-GENE
two O
putative O
actin I-GENE
- I-GENE
binding I-GENE
sites I-GENE
and O
two O
calcium O
- I-GENE
binding I-GENE
sites I-GENE
. O

The O
highly O
_RARE_ I-GENE
girls O
had O
a O
significantly O
higher O
_RARE_ I-GENE
score O
than O
the O
low O
- I-GENE
_RARE_ I-GENE
girls O
, O
and O
shared O
with O
their O
mothers O
a O
susceptibility I-GENE
to O
the O
_RARE_ I-GENE
effects O
of O
negative O
_RARE_ I-GENE
states O
on O
their O
_RARE_ I-GENE
behaviour O
. O

The O
_RARE_ I-GENE
and O
_RARE_ I-GENE
mitochondrial I-GENE
plasmids O
are O
closely O
related I-GENE
, O
closed O
- I-GENE
circular O
DNAs O
( O
3 I-GENE
. O
6 I-GENE
and O
3 I-GENE
. O
7 O
kb O
, O
respectively O
) O
that O
have O
characteristics O
of O
_RARE_ I-GENE
introns O
and O
_RARE_ I-GENE
elements O
. O

The O
circadian O
rhythm O
, O
however O
, O
was O
not O
affected O
and O
the O
difference O
between O
minimum O
( O
12 O
. O
00 O
h O
) O
and O
maximum O
( O
18 O
. O
50 O
h O
) O
serum I-GENE
concentrations O
was O
31 O
. O
3 I-GENE
%. O

Sequence O
and O
genetic O
organization O
of O
a O
_RARE_ I-GENE
_RARE_ I-GENE
gene I-GENE
cluster I-GENE
that O
encodes O
several O
enzymes O
of O
glucose O
metabolism O
. O

Most O
strains O
( O
95 O
%) O
of O
S I-GENE
. O
_RARE_ I-GENE
produced O
a O
delta I-GENE
_RARE_ I-GENE
like I-GENE
that O
seen O
with O
nine O
other O
species O
of O
CNS O
. O

For O
this O
, O
cDNAs I-GENE
containing O
the O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
and O
_RARE_ I-GENE
protein I-GENE
coding O
sequences I-GENE
were O
each O
provided O
with O
an O
ATG O
start O
codon O
and O
the O
cDNA I-GENE
containing O
the O
_RARE_ I-GENE
coding O
sequence I-GENE
with O
a O
_RARE_ I-GENE
stop O
codon O
immediately O
downstream O
of O
the O
coding O
sequence I-GENE
. O

Finally O
, O
a O
complementary O
footprinting O
analysis O
of O
the O
upstream O
region O
of O
the O
constitutively O
expressed O
_RARE_ I-GENE
gene I-GENE
reveals O
the O
presence O
of O
three O
discrete O
protein I-GENE
complexes I-GENE
. O

_RARE_ I-GENE
of O
bone O
loss O
in O
_RARE_ I-GENE
animals O
. O

_RARE_ I-GENE
- I-GENE
visual O
interaction O
in O
the O
generation O
of O
_RARE_ I-GENE
in O
man O
. O

First O
, O
each O
lung O
was O
cut I-GENE
into O
_RARE_ I-GENE
, O
from O
which O
primary O
_RARE_ I-GENE
were O
_RARE_ I-GENE
systematically O
with O
a O
known O
sampling O
fraction O
. O

The O
upstream O
promoter I-GENE
is O
located O
within O
the O
coding O
sequence I-GENE
of O
a O
divergent O
gene I-GENE
expressing O
a O
protein I-GENE
of O
Mr O
39 O
kDa I-GENE
of O
unknown O
function O
. O

_RARE_ I-GENE
O2 O
consumption O
of O
the O
isolated O
skin O
to O
be O
same O
as O
in O
situ O
, O
_RARE_ I-GENE
showed O
that O
when O
water O
PO2 O
was O
high O
( O
150 O
mm O
Hg O
), O
about O
40 I-GENE
% O
of O
total O
cutaneous O
O2 O
uptake O
was O
_RARE_ I-GENE
by O
the O
skin O
. O

Experiments O
showed O
that O
temporary O
arrest O
of O
pulmonary O
circulation O
under O
conditions O
of O
_RARE_ I-GENE
circulation O
is O
_RARE_ I-GENE
by O
the O
development O
of O
ischemia O
of O
the O
respiratory O
pulmonary O
tissue I-GENE
. O

_RARE_ I-GENE
infusion O
caused O
a O
concentration O
- I-GENE
dependent I-GENE
increase O
in O
airway O
resistance O
at O
constant O
_RARE_ I-GENE
. O

_RARE_ I-GENE
reactivity O
tests O
were O
used O
to O
examine O
the O
_RARE_ I-GENE
responses O
of O
alcohol O
_RARE_ I-GENE
( O
P I-GENE
) O
rats O
and O
alcohol O
_RARE_ I-GENE
( O
NP I-GENE
) O
rats O
to O
the O
taste O
of O
alcohol O
. O

Plasma I-GENE
concentrations O
of O
_RARE_ I-GENE
and O
_RARE_ I-GENE
were O
0 O
. O
73 O
- I-GENE
3 I-GENE
. O
11 O
micrograms O
ml O
- I-GENE
1 I-GENE
and O
0 O
. O
48 O
- I-GENE
8 O
. O
65 O
micrograms O
ml O
- I-GENE
1 I-GENE
, O
respectively O
; O
CSF I-GENE
concentration O
of O
_RARE_ I-GENE
was O
70 I-GENE
- I-GENE
440 O
ng O
ml O
- I-GENE
1 I-GENE
. O

Plasma I-GENE
Al O
was O
obtained O
during O
each O
baseline O
and O
drug O
course O
. O

The O
survival O
in O
the O
case O
of O
these O
patients O
was O
studied O
five O
years O
later O
. O

The O
occurrence O
, O
maintenance O
and O
possible O
involvement O
of O
these O
repeated O
sequences I-GENE
, O
capable O
of O
forming O
stable O
secondary O
structures O
, O
are O
discussed O
in O
relation O
to O
their O
location O
in O
the O
region O
of O
control O
signals O
. O

_RARE_ I-GENE
is O
not O
the O
RNA I-GENE
target O
( O
TAR I-GENE
) O
for O
Tat I-GENE
trans O
- I-GENE
activation O
; O
however O
, O
because O
it O
_RARE_ I-GENE
entirely O
on O
cellular O
factors I-GENE
for O
activity O
, O
_RARE_ I-GENE
may O
serve O
to O
provide O
abundant O
RNA I-GENE
targets O
for O
Tat I-GENE
trans O
- I-GENE
activation O
without O
a O
requirement O
for O
full I-GENE
- I-GENE
length I-GENE
viral I-GENE
mRNA I-GENE
expression O
. O

_RARE_ I-GENE
activity O
of O
a O
tobacco I-GENE
- I-GENE
specific I-GENE
_RARE_ I-GENE
. O

The O
_RARE_ I-GENE
treatment O
need O
has O
been O
forming O
a O
clinical O
order O
of O
magnitude O
. O

1 I-GENE
(" O
long O
method O
_RARE_ I-GENE
and O
the O
HML I-GENE
method O
. O

These O
results O
may O
suggest O
involvement O
of O
peripheral O
_RARE_ I-GENE
in O
pain O
modulation O
in O
patients O
with O
_RARE_ I-GENE
cluster I-GENE
headache O
. O

Effects O
of O
_RARE_ I-GENE
on O
upper O
- I-GENE
gastrointestinal O
motility O
and O
_RARE_ I-GENE
hormones O

_RARE_ I-GENE
foot O
_RARE_ I-GENE
are O
_RARE_ I-GENE
pain O
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
and O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
and O
_RARE_ I-GENE
, O
_RARE_ I-GENE
_RARE_ I-GENE
, O
arthritis O
, O
and O
_RARE_ I-GENE
. O

Liver O
dysfunction O
in O
the O
presence O
of O
different O
adverse O
reactions O
presented O
with O
a O
higher O
activity O
in O
the O
blood O
serum I-GENE
of O
indicator O
liver O
enzymes O
and O
its O
impaired O
protein I-GENE
- I-GENE
forming O
function O
. O

_RARE_ I-GENE
_RARE_ I-GENE
: O
blood O
levels O
and O
metabolic O
demand O
. O

The O
CT I-GENE
characteristics O
are O
discussed O
and O
the O
recent O
literature O
is O
reviewed O
. O

_RARE_ I-GENE
, O
these O
_RARE_ I-GENE
may O
also O
_RARE_ I-GENE
with O
_RARE_ I-GENE
assays O
used O
to O
determine O
product I-GENE
_RARE_ I-GENE
or O
_RARE_ I-GENE
levels O
. O

In O
26 O
patients O
with O
angina O
pectoris O
, O
the O
changes O
of O
LVEF O
, O
_RARE_ I-GENE
and O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
were O
more O
sensitive O
for O
the O
detection O
of O
exercise O
- I-GENE
induced O
ischemia O
than O
the O
appearance O
of O
chest O
pain O
and O
the O
changes O
of O
ECG O
. O

In O
both O
groups O
there O
were O
5 I-GENE
management O
failure O
of O
therapy O
, O
so O
that O
alternative O
medication O
or O
a O
_RARE_ I-GENE
section O
lead O
to O
delivery O
. O

Serum I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
were O
determined O
in O
50 O
oral O
cancer O
patients O
and O
50 O
normal O
individuals O
prior O
to O
any O
_RARE_ I-GENE
of O
treatment O
. O

The O
_RARE_ I-GENE
promoter I-GENE
contains O
a O
_RARE_ I-GENE
estrogen I-GENE
responsive I-GENE
element I-GENE
. O

_RARE_ I-GENE
synthesis O
inhibitors O
have O
been O
shown O
to O
delay O
healing O
of O
bone O
and O
this O
has O
led O
to O
limitations O
on O
their O
use O
clinically O
in O
some O
situations O
. O

The O
inspiratory O
oxygen O
concentration O
needed O
( O
_RARE_ I-GENE
) O
and O
the O
_RARE_ I-GENE
_RARE_ I-GENE
differed O
in O
a O
highly O
significant O
manner O
beginning O
on O
the O
_RARE_ I-GENE
day O
after O
trauma O
. O

The O
_RARE_ I-GENE
and O
mineral O
oil O
_RARE_ I-GENE
were O
almost O
as O
effective O
as O
milk O
but O
less O
effective O
than O
sucrose O
( O
0 O
. O
_RARE_ I-GENE
) O
in O
stimulating I-GENE
ingestion O
. O

Significance O
of O
thin O
glomerular O
_RARE_ I-GENE
membranes O
in O
_RARE_ I-GENE
children O
. O

Significance O
of O
cytokine O
production O
and O
adhesion I-GENE
molecules I-GENE
in O
_RARE_ I-GENE
_RARE_ I-GENE
. O

The O
former O
procedure O
is O
_RARE_ I-GENE
but O
complicated O
, O
whereas O
the O
latter O
is O
simple O
and O
labour O
- I-GENE
_RARE_ I-GENE
, O
but O
a O
special O
_RARE_ I-GENE
tube O
is O
required O
. O

_RARE_ I-GENE
method O
for O
determination O
of O
the O
_RARE_ I-GENE
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
in O
biological O
fluids O
by O
high O
- I-GENE
performance O
liquid O
chromatography O
. O

Since O
one O
group O
of O
_RARE_ I-GENE
more O
difficult O
to O
influence O
are O
those O
whose O
parents O
smoke O
, O
parental O
involvement O
in O
smoking O
prevention O
may O
be O
a O
_RARE_ I-GENE
enhancer I-GENE
. O

Further O
research O
is O
recommended O
to O
identify O
the O
_RARE_ I-GENE
_RARE_ I-GENE
associated I-GENE
with O
the O
high O
_RARE_ I-GENE
/ I-GENE
low O
_RARE_ I-GENE
research O
classification O
. O

_RARE_ I-GENE
with O
IF O
_RARE_ I-GENE
alone O
of O
BAL I-GENE
fluid O
only O
_RARE_ I-GENE
to O
be O
even O
more O
sensitive O
than O
silver O
_RARE_ I-GENE
staining O
of O
BAL I-GENE
, O
_RARE_ I-GENE
and O
_RARE_ I-GENE
material O
. O

_RARE_ I-GENE
and O
_RARE_ I-GENE
study O
of O
the O
myeloid O
parenchyma O
cells O
of O
mice O
prior O
and O
after O
X I-GENE
- I-GENE
ray O
exposure O

Using O
an O
_RARE_ I-GENE
cassette I-GENE
and O
_RARE_ I-GENE
the O
duration O
of O
the O
_RARE_ I-GENE
decreased O
significantly O
. O

The O
mean O
change O
in O
_RARE_ I-GENE
, O
adjusted O
for O
the O
initial O
value O
, O
was O
- I-GENE
0 O
. O
4 I-GENE
% O
in O
the O
experimental O
and O
+ I-GENE
0 O
. O
5 I-GENE
% O
in O
the O
control O
group O
( O
p O
less O
than O
0 O
. O
05 O
). O

Effect O
of O
biliary O
obstruction O
and O
_RARE_ I-GENE
on O
serum I-GENE
_RARE_ I-GENE
- I-GENE
1 I-GENE
level O

_RARE_ I-GENE
good O
accuracy O
( O
r O
greater O
than O
0 O
. O
9 O
) O
was O
found O
when O
except O
comparing O
H I-GENE
* I-GENE
2 I-GENE
with O
the O
other O
machine O
and O
the O
reference O
methods O
, O
except O
for O
_RARE_ I-GENE
and O
_RARE_ I-GENE
count O
. O

The O
second O
part O
of O
this O
paper O
shows O
some O
medical O
applications O
of O
these O
two O
aspects O
of O
NMR O
, O
with O
help O
of O
some O
examples O
, O
taken O
from O
the O
literature O
, O
according O
to O
what O
is O
_RARE_ I-GENE
with O
_RARE_ I-GENE
. O

_RARE_ I-GENE
coordination O
during O
_RARE_ I-GENE
_RARE_ I-GENE
in O
the O
_RARE_ I-GENE
cat O
. O

_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
is O
a O
low O
mol O
wt I-GENE
mucosal I-GENE
secretory I-GENE
protein I-GENE
which O
, O
in O
human I-GENE
tissues O
, O
inhibits O
the O
activities O
of O
the O
neutral O
serine I-GENE
lysosomal I-GENE
_RARE_ I-GENE
elastase I-GENE
and O
_RARE_ I-GENE
- I-GENE
G I-GENE
. O

By O
_RARE_ I-GENE
a O
series O
of O
deletions O
in O
the O
_RARE_ I-GENE
promoter I-GENE
, O
we O
further O
_RARE_ I-GENE
these O
sequences I-GENE
to O
30 O
base O
pairs O
, O
located O
between O
_RARE_ I-GENE
and O
210 O
base O
pairs O
upstream O
of O
the O
mRNA I-GENE
cap I-GENE
site I-GENE
. O

In O
particular O
, O
71 O
and O
69 O
% O
amino O
acid I-GENE
sequence I-GENE
similarities O
were O
identified O
with O
hsp70 I-GENE
of O
Escherichia I-GENE
coli I-GENE
and O
Bacillus I-GENE
_RARE_ I-GENE
, O
respectively O
. O

No O
_RARE_ I-GENE
relations O
may O
be O
_RARE_ I-GENE
from O
the O
correlation O
between O
the O
level O
of O
_RARE_ I-GENE
activity O
and O
_RARE_ I-GENE
, O
though O
it O
indicates O
that O
individual O
, O
_RARE_ I-GENE
muscle O
activity O
patterns O
may O
constitute O
an O
important O
risk O
factor I-GENE
for O
development O
of O
_RARE_ I-GENE
- I-GENE
skeletal I-GENE
_RARE_ I-GENE
. O

All O
89 I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
members O
were O
anti I-GENE
- I-GENE
HIV I-GENE
_RARE_ I-GENE
, O
and O
78 O
who O
were O
tested O
were O
serum I-GENE
_RARE_ I-GENE
antigen I-GENE
negative O
. O

Analysis O
with O
additional O
anti I-GENE
- I-GENE
peptide I-GENE
antibodies I-GENE
specific I-GENE
for O
alpha I-GENE
, O
beta I-GENE
, O
or O
gamma I-GENE
PKC I-GENE
indicated O
that O
all O
three O
types O
of O
PKC I-GENE
are O
expressed O
in O
_RARE_ I-GENE
cells O
; O
however O
, O
_RARE_ I-GENE
cells O
lost O
a O
major I-GENE
approximately O
82 O
kDa I-GENE
immunoreactive I-GENE
cytosolic I-GENE
protein I-GENE
detectable O
with O
anti I-GENE
- I-GENE
PKC I-GENE
alpha I-GENE
antibody I-GENE
. O

To O
those O
of O
us O
who O
are O
not O
_RARE_ I-GENE
with O
the O
present O
_RARE_ I-GENE
there O
is O
much O
to O
be O
investigated O
and O
much O
to O
be O
contributed O
. O

To O
determine O
the O
effects O
on O
the O
pulmonary O
barrier O
of O
several O
surface O
active O
agents O
, O
a O
series O
of O
_RARE_ I-GENE
dose O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
was O
prepared O
and O
used O
to O
dose O
_RARE_ I-GENE
surfactant I-GENE
to O
the O
_RARE_ I-GENE
of O
isolated O
perfused O
rat I-GENE
lungs O
. O

The O
beta I-GENE
chain I-GENE
contains O
five O
potential O
N I-GENE
- I-GENE
linked O
glycosylation O
sites I-GENE
, O
and O
_RARE_ I-GENE
digestion O
suggested O
that O
the O
beta I-GENE
chain I-GENE
contained O
multiple O
complex I-GENE
carbohydrate O
side O
chains I-GENE
. O

The O
therapeutic O
_RARE_ I-GENE
used O
at O
the O
_RARE_ I-GENE
_RARE_ I-GENE
Institute O
for O
invasive O
_RARE_ I-GENE
of O
the O
uterine O
cervix O
_RARE_ I-GENE
, O
for O
limited O
forms O
( O
_RARE_ I-GENE
- I-GENE
T2 I-GENE
proximal I-GENE
), O
on O
combined O
_RARE_ I-GENE
and O
surgery O
. O

_RARE_ I-GENE
- I-GENE
induced O
expression O
of O
a O
gene I-GENE
for O
a O
ribosomal I-GENE
protein I-GENE
related I-GENE
to O
the O
trk I-GENE
oncogene I-GENE
. O

The O
introns O
are O
1 I-GENE
. O
6 I-GENE
- I-GENE
1 I-GENE
. O
9 O
kbp O
long O
. O

After O
an O
initial O
titration O
period O
and O
adjustment O
of O
the O
therapeutic O
dose O
, O
the O
individual O
doses O
were O
from O
21 O
to O
500 O
micrograms O
/ I-GENE
24 O
hrs O
( O
mean O
160 I-GENE
micrograms O
/ I-GENE
24 O
hrs O
). O

In O
the O
first O
series O
of O
experiments O
, O
Sprague O
- I-GENE
Dawley O
male O
rats O
were O
implanted O
_RARE_ I-GENE
with O
_RARE_ I-GENE
_RARE_ I-GENE
aimed O
at O
the O
lateral O
ventricle O
. O

Use O
of O
_RARE_ I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
as O
food O
for O
_RARE_ I-GENE
_RARE_ I-GENE
. O

The O
_RARE_ I-GENE
of O
members O
of O
the O
_RARE_ I-GENE
families O
_RARE_ I-GENE
, O
_RARE_ I-GENE
and O
_RARE_ I-GENE
in O
the O
_RARE_ I-GENE
- I-GENE
deficient O
90 O
_RARE_ I-GENE
concentration O
treatments O
supports O
previous O
evidence O
of O
_RARE_ I-GENE
to O
low O
- I-GENE
water O
- I-GENE
content O
_RARE_ I-GENE
. O

To O
define O
the O
mechanism O
responsible O
for O
the O
loss O
of O
transcription I-GENE
elongation I-GENE
_RARE_ I-GENE
and O
resulting O
c I-GENE
- I-GENE
myc I-GENE
_RARE_ I-GENE
in O
_RARE_ I-GENE
' O
s O
lymphoma O
, O
we O
analyzed O
transcription I-GENE
patterns O
after O
transfer I-GENE
of O
normal O
and O
_RARE_ I-GENE
' O
s O
lymphoma O
c I-GENE
- I-GENE
myc I-GENE
alleles I-GENE
into O
murine I-GENE
cells O
and O
Xenopus I-GENE
oocyte O
_RARE_ I-GENE
vesicles O
. O

_RARE_ I-GENE
_RARE_ I-GENE
concentration O
increased O
significantly O
( O
P I-GENE
less O
than O
0 O
. O
05 O
) O
by O
14 O
days O
in O
dogs O
fed O
the O
basal O
diet O
, O
and O
remained O
significantly O
high O
relative O
to O
that O
in O
dogs O
of O
the O
other O
dietary O
groups O
for O
the O
_RARE_ I-GENE
of O
the O
study O
. O

The O
coding O
sequences I-GENE
of O
the O
_RARE_ I-GENE
gene I-GENE
_RARE_ I-GENE
over O
25 O
kb O
of O
DNA I-GENE
, O
whereas O
the O
_RARE_ I-GENE
- I-GENE
ps I-GENE
sequences I-GENE
are O
included O
within O
a O
single O
5 I-GENE
. O
6 I-GENE
- I-GENE
kb O
_RARE_ I-GENE
- I-GENE
R1 I-GENE
fragment I-GENE
. O

The O
genomic O
and O
transcriptional O
complexity O
of O
the O
_RARE_ I-GENE
and O
_RARE_ I-GENE
- I-GENE
ps I-GENE
genes I-GENE
. O

From O
an O
_RARE_ I-GENE
- I-GENE
16 O
lambda I-GENE
- I-GENE
gt11 O
library O
, O
we O
have O
isolated O
and O
sequenced O
a O
novel O
cDNA I-GENE
rat I-GENE
NK I-GENE
cell O
protease I-GENE
1 I-GENE
( O
_RARE_ I-GENE
- I-GENE
1 I-GENE
) O
that O
has O
characteristics O
unique O
to O
serine I-GENE
proteases I-GENE
. O

The O
induction O
of O
_RARE_ I-GENE
- I-GENE
1 I-GENE
expression O
in O
the O
_RARE_ I-GENE
A I-GENE
- I-GENE
cultured O
spleen O
cells O
is O
accompanied O
by O
increases O
in O
both O
NK I-GENE
and O
_RARE_ I-GENE
- I-GENE
activated I-GENE
killer O
lymphocyte I-GENE
activities O
. O

The O
paper O
is O
_RARE_ I-GENE
with O
the O
data O
on O
change O
in O
the O
blood O
level O
of O
ACTH I-GENE
, O
_RARE_ I-GENE
, O
TSH I-GENE
, O
cortisol O
, O
T3 O
, O
insulin I-GENE
, O
C I-GENE
- I-GENE
peptide I-GENE
during O
a O
25 O
- I-GENE
minute O
session O
of O
respiration O
using O
a O
_RARE_ I-GENE
hypoxic O
mixture O
with O
10 O
% O
oxygen O
( O
_RARE_ I-GENE
- I-GENE
10 O
). O

The O
abscess O
was O
_RARE_ I-GENE
and O
the O
_RARE_ I-GENE
was O
_RARE_ I-GENE
with O
a O
single O
layer O
of O
autologous O
_RARE_ I-GENE
. O

In O
18 O
% O
_RARE_ I-GENE
was O
clearly O
positive O
and O
CT I-GENE
negative O
. O

The O
present O
study O
examined O
the O
effect O
of O
intensity O
, O
rate O
, O
and O
polarity O
on O
the O
spectral O
content O
of O
_RARE_ I-GENE
of O
15 O
normal O
- I-GENE
hearing O
subjects O
. O

Similar O
memory O
_RARE_ I-GENE
found O
in O
medial O
septal O
- I-GENE
vertical O
_RARE_ I-GENE
band O
of O
_RARE_ I-GENE
and O
nucleus O
_RARE_ I-GENE
lesioned O
rats O
: O
are O
memory O
defects O
induced O
by O
nucleus O
_RARE_ I-GENE
lesions O
related I-GENE
to O
the O
degree O
of O
non O
- I-GENE
specific I-GENE
_RARE_ I-GENE
cell O
loss O
? O
The O
function O
of O
nucleus O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
and O
medial O
septal O
- I-GENE
vertical O
_RARE_ I-GENE
band O
of O
_RARE_ I-GENE
( O
MS O
- I-GENE
_RARE_ I-GENE
) O
in O
a O
place O
_RARE_ I-GENE
task O
requiring O
reference O
memory O
was O
investigated O
. O

Studies O
also O
have O
_RARE_ I-GENE
to O
a O
relationship O
between O
the O
_RARE_ I-GENE
cyst O
and O
certain O
signs O
or O
symptoms O
of O
disease O
. O

The O
BAL I-GENE
- I-GENE
to O
- I-GENE
plasma I-GENE
specific I-GENE
activity O
of O
urea O
was O
about O
twice O
that O
of O
Na I-GENE
+, I-GENE
indicating O
that O
urea O
_RARE_ I-GENE
into O
the O
_RARE_ I-GENE
more O
rapidly O
than O
Na I-GENE
+ I-GENE
during O
the O
70 I-GENE
s O
that O
_RARE_ I-GENE
between O
the O
time O
the O
_RARE_ I-GENE
urea O
and O
Na I-GENE
+ I-GENE
were O
injected O
into O
the O
circulation O
and O
the O
time O
when O
_RARE_ I-GENE
was O
complete O
. O

The O
kappa I-GENE
coefficient O
of O
agreement O
between O
the O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
and O
the O
standard O
method O
was O
0 O
. O
_RARE_ I-GENE
. O

_RARE_ I-GENE
systems O
-- O
45 O
; O
_RARE_ I-GENE
health O
and O
illness O
in O
old O
age O
-- O
3 I-GENE
. O

When O
normalized O
for O
imaging O
time O
, O
all O
parameters O
are O
significantly O
higher O
with O
_RARE_ I-GENE
, O
with O
a O
C I-GENE
/ I-GENE
A I-GENE
per O
unit I-GENE
time O
that O
was O
_RARE_ I-GENE
% O
higher O
. O

Patients O
with O
acute O
myocardial O
infarction O
had O
higher O
plasma I-GENE
concentrations O
of O
neutrophil I-GENE
elastase I-GENE
and O
the O
non O
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
conjugated O
_RARE_ I-GENE
of O
_RARE_ I-GENE
acid I-GENE
than O
normal O
volunteers O
or O
patients O
with O
stable O
ischaemic O
heart O
disease O
. O

Determination O
of O
three O
- I-GENE
dimensional O
imaging O
properties O
of O
a O
light I-GENE
_RARE_ I-GENE
system O
. O

The O
cis O
- I-GENE
acting O
element I-GENE
, O
identified O
as O
_RARE_ I-GENE
, O
is O
located O
34 O
bp O
upstream O
from O
the O
transcription I-GENE
initiation I-GENE
site I-GENE
, O
and O
contains O
the O
core I-GENE
sequence I-GENE
of O
the O
upstream O
promoter I-GENE
sequence I-GENE
of O
_RARE_ I-GENE
. O

The O
clinical O
relevance O
of O
these O
findings O
is O
_RARE_ I-GENE
by O
the O
observation O
that O
similar O
results O
were O
obtained O
when O
P I-GENE
. O
_RARE_ I-GENE
was O
given O
by O
the O
intravenous O
route O
. O

_RARE_ I-GENE
- I-GENE
1 I-GENE
is O
identical O
to O
_RARE_ I-GENE
muscle O
alpha I-GENE
- I-GENE
_RARE_ I-GENE
from O
amino O
acids O
1 I-GENE
through O
258 O
but O
contains O
a O
novel O
COOH O
- I-GENE
terminal I-GENE
region O
from O
amino O
acids O
_RARE_ I-GENE
through O
_RARE_ I-GENE
. O

The O
procedure O
has O
been O
applied O
to O
three O
materials O
: O
particle I-GENE
_RARE_ I-GENE
with O
_RARE_ I-GENE
; O
_RARE_ I-GENE
_RARE_ I-GENE
with O
_RARE_ I-GENE
; O
and O
_RARE_ I-GENE
with O
_RARE_ I-GENE
_RARE_ I-GENE
, O
for O
which O
the O
steady O
- I-GENE
state O
emission O
factors I-GENE
( O
mg O
m I-GENE
- I-GENE
2 I-GENE
h O
- I-GENE
1 I-GENE
) O
of O
several O
compounds O
are O
given O
. O

Intron I-GENE
1 I-GENE
is O
6 I-GENE
. O
5 I-GENE
kb O
long O
, O
and O
the O
minimal I-GENE
sizes O
of O
introns O
2 I-GENE
and O
3 I-GENE
are O
estimated O
to O
be O
32 O
kb O
each O
. O

After O
4 I-GENE
h O
, O
lesions O
in O
the O
secretory I-GENE
part O
of O
the O
stomach O
were O
_RARE_ I-GENE
and O
mucosal I-GENE
prostaglandin I-GENE
E2 I-GENE
synthesis O
was O
determined O
by O
the O
_RARE_ I-GENE
vivo O
prostaglandin I-GENE
generation O
technique O
. O

Comparison O
of O
transmembrane I-GENE
and O
cytoplasmic I-GENE
domains I-GENE
to O
a O
third O
cell O
- I-GENE
surface O
proteoglycan I-GENE
, O
_RARE_ I-GENE
from O
human I-GENE
lung O
fibroblasts O
( O
_RARE_ I-GENE
, O
P I-GENE
., O
_RARE_ I-GENE
, O
J O
., O
_RARE_ I-GENE
, O
J O
., O
_RARE_ I-GENE
_RARE_ I-GENE
, O
H I-GENE
., O
and O
_RARE_ I-GENE
, O
C I-GENE
. O

Approximately O
65 O
% O
of O
the O
total O
cAMP I-GENE
- I-GENE
dependent I-GENE
phosphotransferase I-GENE
activity O
is O
recovered O
in O
particulate O
fractions O
of O
_RARE_ I-GENE
prepared O
from O
_RARE_ I-GENE
populations O
of O
C I-GENE
. O
elegans I-GENE
. O

High O
levels O
of O
C I-GENE
subunits I-GENE
are O
observed O
in O
several O
subsequent O
larval I-GENE
and O
adult O
stages O
of O
development O
. O

A I-GENE
second O
, O
novel O
C I-GENE
subunit I-GENE
( O
_RARE_ I-GENE
alpha I-GENE
', O
_RARE_ I-GENE
residues O
) O
has O
a O
unique O
56 O
- I-GENE
residue O
carboxyl O
- I-GENE
terminal I-GENE
region O
that O
is O
generated O
by O
the O
alternative O
splicing O
of O
the O
C I-GENE
pre I-GENE
- I-GENE
mRNA I-GENE
. O

The O
alternative O
exon O
_RARE_ I-GENE
the O
novel O
carboxyl O
terminus O
and O
a O
new O
translation I-GENE
stop O
signal I-GENE
, O
while O
simultaneously O
converting I-GENE
the O
coding O
sequence I-GENE
for O
40 I-GENE
carboxyl O
- I-GENE
terminal I-GENE
residues O
in O
_RARE_ I-GENE
alpha I-GENE
into O
3 I-GENE
'- O
untranslated O
nucleotides O
. O

_RARE_ I-GENE
, O
M I-GENE
. O

_RARE_ I-GENE
adapting O
type I-GENE
I I-GENE
_RARE_ I-GENE
discharge O
as O
a O
function O
of O
dynamic O
force O
versus O
dynamic O
displacement I-GENE
of O
_RARE_ I-GENE
skin O
of O
_RARE_ I-GENE
and O
_RARE_ I-GENE
monkey I-GENE
hand O
. O

_RARE_ I-GENE
used O
include O
_RARE_ I-GENE
angle O
and O
a O
segmental O
evaluation O
( O
T7 I-GENE
- I-GENE
_RARE_ I-GENE
) O
of O
each O
of O
_RARE_ I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
), O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
angle O
differences O
( O
_RARE_ I-GENE
), O
vertebral O
_RARE_ I-GENE
, O
tilt O
and O
displacement I-GENE
. O

Plasma I-GENE
_RARE_ I-GENE
/ I-GENE
cholesterol I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
activity O
in O
multiple O
- I-GENE
organ O
donors O
: O
a O
predictor O
of O
_RARE_ I-GENE
viability O
in O
clinical O
liver O
transplantation O
. O

_RARE_ I-GENE
has O
AIDS O
-- O
a O
more O
_RARE_ I-GENE
life O
with O
care O
at O
home O
. O

_RARE_ I-GENE
nodal O
status O
, O
tumour I-GENE
progesterone I-GENE
receptor I-GENE
status O
, O
and O
season O
of O
tumour I-GENE
detection O
significantly O
influenced O
survival O
in O
both O
older O
( O
greater O
than O
50 O
_RARE_ I-GENE
) O
and O
_RARE_ I-GENE
( O
less O
than O
50 O
_RARE_ I-GENE
) O
patients O
. O

The O
application O
of O
these O
_RARE_ I-GENE
to O
the O
measurement O
of O
rapid O
, O
transient O
changes O
in O
retinal O
[ O
K I-GENE
_RARE_ I-GENE
o I-GENE
is O
presented O
. O

Expression O
, O
cellular O
localization O
and O
in O
vitro O
transcription I-GENE
studies O
establish O
that O
cloned O
_RARE_ I-GENE
encodes O
a O
nucleolar I-GENE
factor I-GENE
that O
binds O
specifically O
to O
the O
upstream O
control O
element I-GENE
and O
core I-GENE
of O
the O
rRNA I-GENE
gene I-GENE
promoter I-GENE
to O
activate O
transcription I-GENE
in O
a O
binding I-GENE
site I-GENE
- I-GENE
dependent I-GENE
manner O
. O

_RARE_ I-GENE
multiple O
laboratory O
studies O
may O
be O
of O
value O
in O
_RARE_ I-GENE
the O
_RARE_ I-GENE
outcome O
in O
near O
- I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
of O
Tl O
+ I-GENE
1 I-GENE
( O
_RARE_ I-GENE
_RARE_ I-GENE
) O
were O
6 I-GENE
times O
those O
for O
Ga O
or O
In O
in O
the O
brain O
and O
muscles O
, O
and O
. O
1 I-GENE
times O
in O
plasma I-GENE
. O

There O
was O
a O
_RARE_ I-GENE
increase O
in O
the O
myocyte I-GENE
diameter O
according O
to O
age O
in O
the O
biopsy O
and O
autopsy O
specimens O
. O

Despite O
the O
absence O
of O
exercise O
- I-GENE
induced O
asthma O
( O
EIA I-GENE
) O
while O
breathing O
_RARE_ I-GENE
air O
, O
asthmatic O
patients O
still O
had O
significantly O
higher O
mean O
GH I-GENE
_RARE_ I-GENE
than O
normal O
subjects O
( O
9 O
. O
2 I-GENE
vs O
2 I-GENE
. O
3 I-GENE
ng O
/ I-GENE
ml O
, O
P I-GENE
less O
than O
0 O
. O
05 O
). O

The O
afferents O
' O
phase O
of O
response O
was O
_RARE_ I-GENE
by O
electrical O
_RARE_ I-GENE
stimulation O
. O

_RARE_ I-GENE
an O
age O
old O
problem O
. O

The O
distribution O
of O
their O
fibrinogen I-GENE
levels O
was O
_RARE_ I-GENE
, O
but O
more O
wide O
- I-GENE
based O
than O
the O
distribution O
of O
our O
normal O
controls O
. O

In O
a O
_RARE_ I-GENE
_RARE_ I-GENE
regression O
analysis O
of O
_RARE_ I-GENE
and O
RAST O
data O
, O
the O
occurrence O
of O
serum I-GENE
IgE I-GENE
antibodies I-GENE
to O
P I-GENE
. O
_RARE_ I-GENE
had O
the O
highest O
_RARE_ I-GENE
value O
for O
current O
_RARE_ I-GENE
. O

The O
examination O
was O
focused O
on O
assessment O
of O
different O
types O
of O
_RARE_ I-GENE
, O
on O
evaluation O
of O
the O
development O
and O
incidence O
of O
risk O
factors I-GENE
leading O
to O
complications O
and O
loss O
of O
central O
vision O
. O

They O
were O
then O
subjected O
to O
whole O
- I-GENE
body O
heat I-GENE
stress O
( O
water O
- I-GENE
perfused O
_RARE_ I-GENE
), O
and O
the O
3 I-GENE
minutes O
of O
_RARE_ I-GENE
was O
repeated O
. O

An O
NF1 I-GENE
- I-GENE
related I-GENE
_RARE_ I-GENE
activator I-GENE
element I-GENE
mediates O
transcription I-GENE
from O
the O
estrogen I-GENE
- I-GENE
regulated O
Xenopus I-GENE
laevis I-GENE
_RARE_ I-GENE
promoter I-GENE
. O

A I-GENE
poor O
correlation O
was O
also O
observed O
between O
_RARE_ I-GENE
and O
_RARE_ I-GENE
activity O
of O
the O
_RARE_ I-GENE
workers O
. O

At O
the O
carboxyl O
terminus O
, O
deletion O
as O
far O
as O
residue O
_RARE_ I-GENE
did O
not O
affect O
in O
vitro O
_RARE_ I-GENE
. O
C I-GENE
assembly O
, O
although O
trans O
- I-GENE
activating I-GENE
activity O
was O
abolished O
. O

The O
effects O
of O
mean O
_RARE_ I-GENE
were O
also O
measured O
and O
a O
general O
expression O
that O
would O
take O
them O
into O
account O
was O
derived O
. O

Effect O
of O
_RARE_ I-GENE
on O
pain O
threshold O
in O
_RARE_ I-GENE
- I-GENE
diabetic O
rats O
. O

We O
have O
synthesized O
[ O
7 O
, O
7 O
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
19 O
- I-GENE
_RARE_ I-GENE
with O
high O
_RARE_ I-GENE
content O
and O
, O
together O
with O
[ O
7 O
, O
7 O
- I-GENE
_RARE_ I-GENE
] O
A I-GENE
and O
[ O
9 O
, O
11 O
- I-GENE
_RARE_ I-GENE
] O
_RARE_ I-GENE
( O
E1 I-GENE
), O
have O
developed O
a O
quantitative O
assay O
of O
serum I-GENE
level O
19 O
- I-GENE
_RARE_ I-GENE
, O
A I-GENE
, O
and O
E1 I-GENE
using O
the O
gas O
chromatography O
/ I-GENE
mass O
spectrometry O
- I-GENE
mass O
_RARE_ I-GENE
method O
to O
monitor O
individual O
subjects O
throughout O
pregnancy O
. O

Sequence O
analysis O
of O
these O
genes I-GENE
and O
their O
surrounding O
sequences I-GENE
are O
presented O
and O
compared O
with O
other O
known O
tRNA I-GENE
genes I-GENE
from O
plant O
mitochondria O
. O

Experiments O
were O
performed O
in O
which O
brain O
- I-GENE
stem O
auditory O
- I-GENE
evoked O
responses O
( O
_RARE_ I-GENE
) O
were O
elicited O
by O
two O
types O
of O
_RARE_ I-GENE
pulse O
_RARE_ I-GENE
: O
maximum O
length I-GENE
sequences I-GENE
( O
_RARE_ I-GENE
) O
and O
_RARE_ I-GENE
sequences I-GENE
( O
_RARE_ I-GENE
). O

Since O
the O
_RARE_ I-GENE
and O
_RARE_ I-GENE
share O
many O
biosynthetic O
and O
structural O
features O
that O
include O
site I-GENE
of O
biosynthesis O
in O
the O
_RARE_ I-GENE
, O
P4 I-GENE
- I-GENE
responsiveness O
, O
the O
presence O
of O
the O
_RARE_ I-GENE
6 I-GENE
- I-GENE
phosphate I-GENE
lysosomal I-GENE
recognition I-GENE
marker O
, O
and O
considerable O
sequence I-GENE
similarity O
, O
the O
_RARE_ I-GENE
and O
the O
_RARE_ I-GENE
may O
have O
homologous O
function O
which O
for O
both O
still O
remains O
_RARE_ I-GENE
. O

_RARE_ I-GENE
light I-GENE
for O
_RARE_ I-GENE
infants O
and O
their O
_RARE_ I-GENE
were O
compared O
to O
15 O
well O
- I-GENE
grown O
infants O
and O
their O
_RARE_ I-GENE
. O

_RARE_ I-GENE
renal O
_RARE_ I-GENE
with O
recombinant I-GENE
human I-GENE
erythropoietin I-GENE
. O

The O
_RARE_ I-GENE
syndrome O
is O
a O
reversible O
reactive I-GENE
condition O
consisting O
of O
fever O
, O
_RARE_ I-GENE
and O
generalized O
rash O
. O

In O
the O
local O
_RARE_ I-GENE
field O
, O
the O
animals O
preferred O
the O
SE O
- I-GENE
_RARE_ I-GENE
. O

In O
the O
artificial O
lung O
, O
like I-GENE
in O
the O
natural O
lung O
and O
peripheral O
tissues O
, O
gas O
_RARE_ I-GENE
depend O
on O
several O
parameters O
: O
blood O
_RARE_ I-GENE
conditions O
, O
blood O
flow O
rate O
, O
temperature O
, O
composition O
of O
the O
gas O
mixture O
used O
for O
ventilation O
, O
blood O
tissue I-GENE
perfusion O
, O
O2 O
consumption O
, O
etc O
. O

Mean O
(+/- O
SE O
) O
measurements O
of O
clearance O
( O
24 O
. O
5 I-GENE
+/- O
2 I-GENE
. O
06 O
v I-GENE
26 O
. O
5 I-GENE
+/- O
2 I-GENE
. O
05 O
mL O
/ I-GENE
min O
/ I-GENE
m2 O
), O
half O
- I-GENE
life O
( O
5 I-GENE
. O
7 O
+/- O
0 O
. O
5 I-GENE
v I-GENE
6 I-GENE
. O
4 I-GENE
+/- O
0 O
. O
5 I-GENE
hours O
), O
and O
volume O
of O
distribution O
( O
12 O
. O
4 I-GENE
+/- O
1 I-GENE
. O
1 I-GENE
v I-GENE
13 O
. O
7 O
+/- O
1 I-GENE
. O
6 I-GENE
L I-GENE
/ I-GENE
m2 O
) O
were O
not O
significantly O
different O
in O
patients O
with O
jaundice O
when O
compared O
with O
controls O
. O

_RARE_ I-GENE
were O
found O
to O
be O
_RARE_ I-GENE
, O
with O
similar O
dimensions O
being O
identified O
in O
both O
samples O
. O

We O
conclude O
that O
DNA I-GENE
_RARE_ I-GENE
is O
a O
major I-GENE
objective O
prognostic O
factor I-GENE
and O
therapeutic O
determinant O
for O
endometrial O
carcinoma O
. O

A I-GENE
_RARE_ I-GENE
digital O
system O
( O
_RARE_ I-GENE
2 I-GENE
) O
was O
used O
. O

_RARE_ I-GENE
factors I-GENE
were O
more O
important O
in O
the O
older O
_RARE_ I-GENE
( O
perhaps O
because O
of O
less O
reliable O
_RARE_ I-GENE
). O

Dopamine I-GENE
_RARE_ I-GENE
spectra O
from O
these O
electrodes O
are O
similar O
to O
those O
obtained O
at O
_RARE_ I-GENE
electrodes O
. O

These O
findings O
indicate O
that O
_RARE_ I-GENE
induced O
by O
surgical O
removal O
of O
acid I-GENE
- I-GENE
producing O
mucosa O
in O
the O
rat I-GENE
has O
the O
same O
effects O
on O
_RARE_ I-GENE
mucosal I-GENE
_RARE_ I-GENE
activity O
, O
histamine O
concentration O
and O
_RARE_ I-GENE
cell O
density I-GENE
as O
_RARE_ I-GENE
induced O
by O
continuous O
gastrin I-GENE
infusion O
or O
by O
long O
- I-GENE
term O
treatment O
with O
effective O
_RARE_ I-GENE
. O

_RARE_ I-GENE
on O
experimental O
toxicity O
research O
it O
was O
established O
that O
, O
out O
of O
50 O
_RARE_ I-GENE
metal O
_RARE_ I-GENE
inhibitors O
, O
some O
14 O
per O
cent O
were O
found O
extremely O
hazardous O
, O
42 O
per O
cent O
-- O
of O
high O
level O
hazardous O
, O
33 O
percent O
-- O
of O
moderate O
and O
11 O
per O
cent O
-- O
of O
low O
hazardous O
. O

The O
order O
of O
the O
helicase I-GENE
motif I-GENE
and O
the O
_RARE_ I-GENE
homology I-GENE
region O
in O
the O
_RARE_ I-GENE
genome O
is O
reversed O
with O
respect O
to O
the O
_RARE_ I-GENE
genome O
indicating O
that O
a O
genetic O
rearrangement O
has O
occurred O
during O
the O
evolution O
of O
these O
viruses O
. O

The O
results O
suggest O
_RARE_ I-GENE
-- O
1 I-GENE
) O
both O
eosinophils O
and O
neutrophils O
participate O
in O
_RARE_ I-GENE
of O
type I-GENE
_RARE_ I-GENE
in O
atopic O
cases O
, O
and O
only O
eosinophils O
in O
non O
- I-GENE
atopic O
cases O
. O

There O
were O
5 I-GENE
treatments O
: O
control O
( O
C I-GENE
); O
a O
_RARE_ I-GENE
_RARE_ I-GENE
in O
one O
_RARE_ I-GENE
_RARE_ I-GENE
of O
the O
_RARE_ I-GENE
( O
S I-GENE
); O
a O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
in O
one O
_RARE_ I-GENE
_RARE_ I-GENE
of O
the O
_RARE_ I-GENE
( O
H I-GENE
); O
a O
_RARE_ I-GENE
and O
a O
_RARE_ I-GENE
( O
H I-GENE
/ I-GENE
S I-GENE
); O
a O
_RARE_ I-GENE
box I-GENE
attached O
to O
the O
back O
of O
the O
_RARE_ I-GENE
, O
containing O
a O
_RARE_ I-GENE
( O
N I-GENE
). O

While O
no O
significant O
differences O
in O
the O
_RARE_ I-GENE
responses O
or O
failure O
characteristics O
were O
noted O
for O
irradiated O
and O
_RARE_ I-GENE
grafts O
in O
the O
_RARE_ I-GENE
, O
in O
the O
_RARE_ I-GENE
environment O
the O
_RARE_ I-GENE
tissues O
had O
greater O
strength O
and O
_RARE_ I-GENE
. O

The O
patient O
was O
treated O
with O
_RARE_ I-GENE
penicillin I-GENE
, O
2 I-GENE
, O
400 O
, O
000 O
U O
weekly O
for O
three O
weeks O
. O

A I-GENE
consensus I-GENE
binding I-GENE
site I-GENE
for O
the O
transcription I-GENE
factor I-GENE
SP1 I-GENE
was O
identified O
in O
intron O
As O
downstream O
of O
the O
_RARE_ I-GENE
germ I-GENE
cell O
cap I-GENE
site I-GENE
region O
. O

This O
proposed O
method O
is O
similar O
in O
_RARE_ I-GENE
to O
the O
sets O
technique O
but O
is O
shown O
to O
have O
much O
better O
expected O
time O
to O
_RARE_ I-GENE
properties O
. O

The O
effects O
on O
reflex O
_RARE_ I-GENE
but O
not O
on O
_RARE_ I-GENE
or O
_RARE_ I-GENE
were O
blocked O
by O
naloxone O
( O
2 I-GENE
mg O
/ I-GENE
kg O
), O
and O
were O
not O
present O
in O
morphine O
- I-GENE
_RARE_ I-GENE
animals O
. O

Of O
the O
remaining O
seven O
, O
five O
reacted O
either O
with O
immediate I-GENE
and O
strong O
symptoms O
or O
had O
spontaneously O
reduced O
_RARE_ I-GENE
intake O
, O
or O
had O
an O
acquired O
IgA I-GENE
deficiency O
. O

Drug O
and O
_RARE_ I-GENE
costs O
were O
reduced O
when O
_RARE_ I-GENE
_RARE_ I-GENE
with O
40 I-GENE
- I-GENE
mL O
_RARE_ I-GENE
_RARE_ I-GENE
was O
compared O
with O
_RARE_ I-GENE
_RARE_ I-GENE
with O
unit I-GENE
- I-GENE
dose O
_RARE_ I-GENE
. O

Changes O
in O
prognosis O
of O
_RARE_ I-GENE
births O
over O
20 O
years O
. O

_RARE_ I-GENE
toxicity O
and O
_RARE_ I-GENE
of O
4 I-GENE
- I-GENE
vinyl O
- I-GENE
1 I-GENE
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
in O
_RARE_ I-GENE
rats O
and O
_RARE_ I-GENE
mice O
. O

_RARE_ I-GENE
kg O
_RARE_ I-GENE
_RARE_ I-GENE
was O
almost O
restored O
to O
baseline O
values O
for O
the O
_RARE_ I-GENE
group O
, O
whereas O
the O
non O
- I-GENE
_RARE_ I-GENE
subjects O
still O
showed O
depressed O
values O
( O
_RARE_ I-GENE
3 I-GENE
. O
7 O
per O
cent O
and O
D I-GENE
+ I-GENE
_RARE_ I-GENE
15 O
. O
8 O
per O
cent O
lower O
than O
before O
treatment O
; O
P I-GENE
less O
than O
0 O
. O
05 O
). O

MK O
- I-GENE
_RARE_ I-GENE
: O
a O
_RARE_ I-GENE
active O
ocular O
hypotensive O
_RARE_ I-GENE
anhydrase I-GENE
inhibitor I-GENE
. O

PCR O
- I-GENE
derived O
fragments I-GENE
were O
used O
as O
probes O
for O
the O
isolation O
of O
the O
U3 I-GENE
snRNA I-GENE
genes I-GENE
from O
a O
genomic O
library O
of O
Arabidopsis I-GENE
. O

In O
addition O
serum I-GENE
IgE I-GENE
concentrations O
were O
not O
statistically O
different O
. O

The O
findings O
suggest O
that O
, O
although O
iodine O
deficiency O
is O
the O
most O
probable O
cause O
of O
_RARE_ I-GENE
among O
_RARE_ I-GENE
of O
the O
_RARE_ I-GENE
cohort O
, O
where O
the O
native O
population O
is O
_RARE_ I-GENE
( O
both O
men O
and O
women O
), O
some O
other O
_RARE_ I-GENE
factor I-GENE
( O
s O
) O
must O
be O
involved O
. O

The O
transcriptional O
unit I-GENE
spans O
a O
chromosomal I-GENE
region O
of O
about O
55 O
kilobase O
pairs O
( O
kbp O
). O

100 O
of O
the O
patients O
who O
would O
have O
died O
_RARE_ I-GENE
. O

Co O
- I-GENE
administration O
of O
_RARE_ I-GENE
, O
angiotensin I-GENE
II I-GENE
and O
microspheres O
via O
the O
hepatic I-GENE
artery O
may O
reduce O
drug O
exposure O
in O
the O
systemic O
compartment O
and O
therefore O
may O
increase O
the O
therapeutic O
ratio O
of O
_RARE_ I-GENE
administration O
via O
the O
hepatic I-GENE
artery O
. O

The O
effects O
of O
tap I-GENE
( O
_RARE_ I-GENE
) O
or O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
water O
on O
arterial O
pH O
, O
partial O
pressure O
of O
carbon O
dioxide O
( O
PCO2 O
) O
and O
plasma I-GENE
lactate I-GENE
were O
determined O
in O
heat I-GENE
- I-GENE
stressed O
_RARE_ I-GENE
. O

Transient O
expression O
of O
human I-GENE
and O
chicken I-GENE
progesterone I-GENE
receptors I-GENE
does O
not O
support O
alternative O
translational O
initiation I-GENE
from O
a O
single O
mRNA I-GENE
as O
the O
mechanism O
generating O
two O
receptor I-GENE
isoforms I-GENE
. O

In O
contrast O
, O
2 I-GENE
, O
_RARE_ I-GENE
( O
74 O
%) O
had O
one O
or O
more O
risk O
factors I-GENE
( O
not O
low O
risk O
); O
of O
these O
, O
5 I-GENE
. O
3 I-GENE
% O
died O
in O
6 I-GENE
weeks O
( O
p O
less O
than O
0 O
. O
001 O
). O

The O
_RARE_ I-GENE
_RARE_ I-GENE
Scale O
provided O
outcome O
data O
related I-GENE
to O
the O
subjects O
' O
degree O
of O
_RARE_ I-GENE
, O
ability O
to O
maintain O
close O
relationships O
, O
and O
presence O
/ I-GENE
absence O
of O
_RARE_ I-GENE
an O
average O
of O
32 O
years O
after O
initial O
admission O
. O

However O
, O
at O
18 O
months O
of O
age O
, O
significantly O
higher O
levels O
of O
_RARE_ I-GENE
( O
P I-GENE
less O
than O
0 O
. O
05 O
) O
and O
of O
_RARE_ I-GENE
( O
P I-GENE
less O
than O
0 O
. O
01 O
) O
were O
found O
in O
infants O
with O
an O
elevated O
IgE I-GENE
( O
greater O
than O
or O
equal O
to O
8 O
. O
0 O
_RARE_ I-GENE
/ I-GENE
l O
) O
than O
in O
those O
with O
a O
lower O
level O
. O

The O
protein I-GENE
sequence I-GENE
contains O
seven O
potential O
N I-GENE
- I-GENE
linked O
glycosylation O
sites I-GENE
and O
a O
threonine I-GENE
/ I-GENE
serine I-GENE
- I-GENE
rich O
region O
which O
is O
a O
potential O
site I-GENE
for O
attachment O
of O
O O
- I-GENE
linked O
carbohydrate O
. O

Thus O
adaptation O
to O
continuous O
mild O
stress O
has O
a O
potent O
antiarrhythmic O
effect O
which O
occurs O
due O
to O
the O
increased O
_RARE_ I-GENE
tone O
. O

The O
_RARE_ I-GENE
from O
the O
column O
was O
mixed O
with O
the O
_RARE_ I-GENE
solution O
containing O
_RARE_ I-GENE
and O
_RARE_ I-GENE
X I-GENE
- I-GENE
100 O
and O
a O
0 O
. O
28 O
M I-GENE
_RARE_ I-GENE
solution O
by O
_RARE_ I-GENE
and O
monitored O
by O
a O
_RARE_ I-GENE
detector O
. O

On O
histologic O
examination O
the O
_RARE_ I-GENE
epithelium O
of O
the O
_RARE_ I-GENE
membrane I-GENE
was O
found O
to O
be O
changed O
into O
_RARE_ I-GENE
epithelium O
, O
with O
_RARE_ I-GENE
distribution O
of O
_RARE_ I-GENE
nuclei O
in O
the O
_RARE_ I-GENE
cytoplasm O
. O

These O
results O
suggest O
an O
increased O
risk O
of O
developing O
cancer O
among O
_RARE_ I-GENE
patients O
and O
the O
possibility O
of O
prophylactic O
effect O
of O
_RARE_ I-GENE
against O
subsequent O
cancer O
. O

The O
same O
trend O
was O
noted O
between O
_RARE_ I-GENE
4 I-GENE
. O
5 I-GENE
heifers O
and O
_RARE_ I-GENE
5 I-GENE
. O
5 I-GENE
steers O
, O
indicating O
a O
sex I-GENE
- I-GENE
related I-GENE
deposition O
of O
_RARE_ I-GENE
fat O
in O
fed O
cattle O
. O

The O
nucleotide I-GENE
sequence I-GENE
consists O
of O
48 O
bp O
of O
5 I-GENE
'- O
end O
non O
- I-GENE
coding O
region O
, O
_RARE_ I-GENE
bp O
of O
coding O
region O
and O
_RARE_ I-GENE
bp O
of O
3 I-GENE
'- O
end O
non O
- I-GENE
coding O
region O
including O
a O
20 O
bp O
poly O
( O
A I-GENE
) O
tail O
. O

_RARE_ I-GENE
included O
: O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
( O
69 O
%), O
headache O
( O
25 O
%), O
_RARE_ I-GENE
( O
69 O
%), O
pain O
at O
tumor I-GENE
sites I-GENE
( O
63 O
%), O
hypotension O
( O
31 O
%), O
and O
hypertension O
( O
38 O
%). O

The O
results O
also O
showed O
that O
although O
_RARE_ I-GENE
_RARE_ I-GENE
supplementation O
generally O
increased O
alkaline I-GENE
phosphatase I-GENE
activity O
, O
bone O
_RARE_ I-GENE
was O
relatively O
_RARE_ I-GENE
as O
judged O
by O
the O
low O
coefficients O
of O
variation O
( O
_RARE_ I-GENE
) O
of O
3 I-GENE
. O
14 O
- I-GENE
3 I-GENE
. O
51 O
% O
and O
3 I-GENE
. O
39 O
- I-GENE
4 I-GENE
. O
82 O
% O
for O
calcium O
and O
phosphorus O
content O
in O
the O
femur O
and O
_RARE_ I-GENE
respectively O
. O

In O
6 I-GENE
of O
24 O
infants O
studied O
( O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
weeks O
of O
gestation O
), O
acquired O
and O
congenital O
structural O
anomalies O
of O
the O
_RARE_ I-GENE
were O
detected O
with O
an O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
_RARE_ I-GENE
S I-GENE
, O
1 I-GENE
. O
8 O
mm O
). O

_RARE_ I-GENE
_RARE_ I-GENE
in O
a O
patient O
with O
chronic O
graft O
- I-GENE
versus O
- I-GENE
host O
disease O
. O

_RARE_ I-GENE
to O
its O
counterpart O
in O
the O
_RARE_ I-GENE
gene I-GENE
, O
exon O
3 I-GENE
of O
the O
_RARE_ I-GENE
gene I-GENE
contains O
several O
point O
mutations O
, O
an O
insertion O
of O
24 O
bp O
, O
and O
a O
stop O
codon O
which O
_RARE_ I-GENE
the O
reading O
frame O
. O

Molecular O
cloning O
of O
a O
cDNA I-GENE
encoding O
rat I-GENE
NADH I-GENE
- I-GENE
cytochrome I-GENE
_RARE_ I-GENE
reductase I-GENE
and O
the O
corresponding O
gene I-GENE
. O

The O
results O
_RARE_ I-GENE
the O
idea O
that O
the O
structure O
of O
relaxation O
curves O
contains O
information O
on O
the O
distance O
scale O
and O
on O
the O
architecture O
of O
the O
pore I-GENE
space O
, O
even O
if O
it O
is O
difficult O
to O
extract O
it O
without O
_RARE_ I-GENE
. O

_RARE_ I-GENE
5 I-GENE
- I-GENE
HT2 I-GENE
receptor I-GENE
binding I-GENE
on O
blood O
platelets O
as O
a O
state O
dependent I-GENE
marker O
in O
major I-GENE
affective O
disorder O
. O

Although O
% O
BF I-GENE
was O
correlated O
with O
all O
the O
_RARE_ I-GENE
( O
r O
= O
0 O
. O
60 O
- I-GENE
0 O
. O
82 O
), O
applying O
objective O
_RARE_ I-GENE
of O
obesity O
based O
on O
_RARE_ I-GENE
or O
% O
BF I-GENE
by O
_RARE_ I-GENE
often O
produced O
_RARE_ I-GENE
results O
. O

The O
_RARE_ I-GENE
values O
correlated O
well O
with O
the O
angiographic O
_RARE_ I-GENE
scale O
of O
severity O
of O
_RARE_ I-GENE
insufficiency O
( O
r O
= O
0 O
. O
_RARE_ I-GENE
; O
p O
less O
than O
0 O
. O
001 O
), O
although O
they O
_RARE_ I-GENE
the O
authors O
only O
to O
make O
a O
partial O
differentiation O
of O
_RARE_ I-GENE
severe O
_RARE_ I-GENE
and O
mild O
or O
_RARE_ I-GENE
ones O
. O

Promoter O
elements O
include O
an O
atypical O
TATA I-GENE
box I-GENE
( O
_RARE_ I-GENE
), O
one O
CCAAT I-GENE
box I-GENE
much O
further O
from O
the O
initiation I-GENE
site I-GENE
, O
three O
reverse I-GENE
_RARE_ I-GENE
of O
CCAAT I-GENE
( O
_RARE_ I-GENE
), O
and O
two O
pyrimidine O
- I-GENE
rich O
nucleotide I-GENE
stretches O
. O

The O
cloned O
genes I-GENE
were O
identified O
in O
genetic O
libraries O
by O
hybridization O
screening O
using O
four O
_RARE_ I-GENE
probes O
which O
corresponded O
to O
the O
partial O
amino O
acid I-GENE
sequence I-GENE
of O
the O
purified O
enzyme I-GENE
. O

The O
pattern O
for O
catalytic O
zinc I-GENE
sites I-GENE
included O
two O
ligands O
close O
in O
sequence I-GENE
, O
a O
sequence I-GENE
- I-GENE
distant O
ligand O
, O
and O
a O
main O
- I-GENE
chain I-GENE
hydrogen O
bond O
joining O
two O
ligands O
. O

Results O
of O
the O
long O
- I-GENE
term O
observation O
and O
treatment O
of O
patients O
with O
arterial O
hypertension O

_RARE_ I-GENE
transcription I-GENE
factors I-GENE
that O
stimulate O
RNA I-GENE
polymerase I-GENE
II I-GENE
by O
increasing O
the O
efficiency O
of O
elongation I-GENE
of O
specifically O
or O
randomly O
initiated O
RNA I-GENE
chains I-GENE
have O
been O
isolated O
and O
characterized O
. O

Sprague O
- I-GENE
Dawley O
newborn O
rats O
( O
n O
= O
85 O
) O
_RARE_ I-GENE
100 O
% O
oxygen O
( O
O2 O
) O
or O
room O
air O
( O
RA O
) O
during O
the O
first O
8 O
days O
of O
life O
, O
and O
then O
RA O
. O

The O
_RARE_ I-GENE
increased O
and O
the O
_RARE_ I-GENE
/ I-GENE
mm2 O
and O
elastic O
_RARE_ I-GENE
pressure O
decreased O
. O

Comparison O
of O
_RARE_ I-GENE
and O
_RARE_ I-GENE
as O
_RARE_ I-GENE
agents O
for O
_RARE_ I-GENE
therapy O
. O

In O
Experiment O
II I-GENE
, O
as O
_RARE_ I-GENE
moderate O
supine O
_RARE_ I-GENE
( O
55 O
% O
VO2 O
max O
) O
for O
50 O
minutes O
under O
several O
_RARE_ I-GENE
conditions O
in O
5 I-GENE
_RARE_ I-GENE
women O
, O
there O
were O
_RARE_ I-GENE
similar O
changing O
_RARE_ I-GENE
of O
the O
cardiovascular O
_RARE_ I-GENE
to O
each O
of O
the O
phases O
given O
in O
Experiment O
I I-GENE
. O

_RARE_ I-GENE
available O
_RARE_ I-GENE
of O
2 I-GENE
. O
5 I-GENE
% O
and O
5 I-GENE
% O
_RARE_ I-GENE
can O
be O
_RARE_ I-GENE
either O
with O
water O
for O
_RARE_ I-GENE
cold O
_RARE_ I-GENE
space O
- I-GENE
_RARE_ I-GENE
or O
with O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
for O
thermal O
_RARE_ I-GENE
at O
recommended O
application O
rates O
of O
0 O
. O
5 I-GENE
- I-GENE
1 I-GENE
g O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
for O
_RARE_ I-GENE
control O
and O
2 I-GENE
g O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
for O
_RARE_ I-GENE
control O
. O

Thus O
, O
this O
reading O
frame O
was O
concluded O
to O
encode O
the O
precursor I-GENE
of O
mitochondrial I-GENE
_RARE_ I-GENE
. O

Sequence O
analysis O
indicates O
that O
in O
addition O
to O
an O
_RARE_ I-GENE
and O
GC I-GENE
box I-GENE
, O
this O
region O
contains O
domains I-GENE
that O
have O
been O
implicated O
in O
the O
regulation O
of O
other O
muscle O
- I-GENE
specific I-GENE
genes I-GENE
: O
a O
CArG I-GENE
box I-GENE
at O
- I-GENE
91 O
bp O
; O
myocyte I-GENE
- I-GENE
specific I-GENE
enhancer I-GENE
- I-GENE
binding I-GENE
nuclear I-GENE
factor I-GENE
1 I-GENE
binding I-GENE
site I-GENE
homologies O
at O
- I-GENE
58 O
, O
- I-GENE
_RARE_ I-GENE
, O
and O
- I-GENE
_RARE_ I-GENE
bp O
; O
and O
a O
muscle O
- I-GENE
CAAT I-GENE
consensus I-GENE
sequence I-GENE
at O
- I-GENE
_RARE_ I-GENE
bp O
relative O
to O
the O
cap I-GENE
site I-GENE
. O

The O
trk I-GENE
- I-GENE
_RARE_ I-GENE
oncogene I-GENE
, O
isolated O
from O
the O
human I-GENE
breast O
carcinoma O
cell O
line O
_RARE_ I-GENE
- I-GENE
MB I-GENE
231 O
by O
genomic O
DNA I-GENE
- I-GENE
transfection O
into O
NIH3T3 O
cells O
, O
consists O
of O
the O
trk I-GENE
proto I-GENE
- I-GENE
oncogene I-GENE
receptor I-GENE
kinase I-GENE
domain I-GENE
fused O
to O
a O
N I-GENE
- I-GENE
terminal I-GENE
41 O
amino O
acid I-GENE
activating I-GENE
sequence I-GENE
( O
_RARE_ I-GENE
, O
S I-GENE
. O
C I-GENE
., O
_RARE_ I-GENE
, O
S I-GENE
. O
M I-GENE
. O
S I-GENE
., O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
, O
F I-GENE
., O
_RARE_ I-GENE
, O
S I-GENE
. O
M I-GENE
., O
_RARE_ I-GENE
, O
B I-GENE
. O
and O
_RARE_ I-GENE
, O
N I-GENE
. O
E I-GENE
. O

Antibodies O
raised O
against O
a O
bacterially O
produced O
beta I-GENE
_RARE_ I-GENE
- I-GENE
trk I-GENE
receptor I-GENE
kinase I-GENE
fusion I-GENE
protein I-GENE
recognized O
a O
44 I-GENE
_RARE_ I-GENE
phosphoprotein I-GENE
phosphorylated O
on O
serine I-GENE
, O
threonine I-GENE
and O
tyrosine I-GENE
in O
extracts O
of O
trk I-GENE
- I-GENE
_RARE_ I-GENE
transformed O
NIH3T3 O
cells O
. O

Since O
very O
recent O
scanning O
- I-GENE
deletion O
analysis O
indicates O
that O
there O
is O
a O
critical O
region O
for O
activity O
near O
Cys I-GENE
- I-GENE
118 O
and O
that O
Cys I-GENE
- I-GENE
118 O
is O
necessary O
for O
maximal O
activity O
, O
we O
conclude O
that O
the O
Cys I-GENE
- I-GENE
118 O
residue O
is O
necessary O
for O
proper O
glycosylation O
and O
maximal O
_RARE_ I-GENE
activity O
of O
GM I-GENE
- I-GENE
CSF I-GENE
. O

Molecular O
and O
functional O
characterization O
of O
the O
promoter I-GENE
of O
_RARE_ I-GENE
, O
the O
human I-GENE
c I-GENE
- I-GENE
ets I-GENE
- I-GENE
2 I-GENE
gene I-GENE
. O

_RARE_ I-GENE
about O
immunologic O
drug O
interactions O
is O
needed O
by O
_RARE_ I-GENE
to O
make O
_RARE_ I-GENE
drug O
- I-GENE
use O
_RARE_ I-GENE
. O

_RARE_ I-GENE
occlusion O
of O
_RARE_ I-GENE
' O
s O
artery O
, O
or O
_RARE_ I-GENE
from O
the O
proximal I-GENE
anterior O
or O
middle I-GENE
cerebral O
arteries O
were O
the O
_RARE_ I-GENE
mechanism O
of O
infarction O
. O

All O
_RARE_ I-GENE
- I-GENE
binding I-GENE
sites I-GENE
, O
regardless O
of O
origin O
, O
provided O
weak O
UAS O
function O
in O
vivo O
when O
examined O
in O
test O
plasmids O
. O

An O
examination O
of O
the O
properties O
of O
sequences I-GENE
surrounding O
_RARE_ I-GENE
left O
open O
the O
possibility O
that O
_RARE_ I-GENE
enhances O
the O
initiation I-GENE
of O
DNA I-GENE
replication O
at O
_RARE_ I-GENE
by O
transcriptional O
activation O
. O

_RARE_ I-GENE
ophthalmic O
and O
neurologic O
disorders O
that O
can O
be O
_RARE_ I-GENE
with O
_RARE_ I-GENE
_RARE_ I-GENE
are O
_RARE_ I-GENE
, O
and O
an O
algorithm O
for O
evaluation O
( O
which O
includes O
ophthalmic O
examination O
, O
laboratory O
studies O
, O
and O
_RARE_ I-GENE
carotid O
artery O
studies O
) O
is O
given O
. O

_RARE_ I-GENE
, O
whether O
or O
not O
the O
hypotensive O
action O
of O
converting I-GENE
enzyme I-GENE
inhibitors O
is O
age O
- I-GENE
related I-GENE
is O
as O
yet O
unknown O
. O

_RARE_ I-GENE
antiserum O
generated O
to O
the O
fusion I-GENE
protein I-GENE
was O
capable O
of O
detecting O
42 O
- I-GENE
and O
46 O
- I-GENE
kilodalton I-GENE
polypeptides I-GENE
from O
virus I-GENE
particles O
; O
both O
polypeptides I-GENE
were O
also O
shown O
to O
contain O
HBsAg I-GENE
determinants I-GENE
. O

These O
characteristics O
of O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
indicate O
that O
it O
is O
a O
localized O
_RARE_ I-GENE
dependent I-GENE
event O
_RARE_ I-GENE
to O
a O
transverse O
_RARE_ I-GENE
with O
dorsal O
_RARE_ I-GENE
and O
a O
simultaneous O
anterior O
_RARE_ I-GENE
. O

Role O
of O
superoxide I-GENE
dismutase I-GENE
in O
cellular O
oxidative O
processes O
and O
method O
of O
its O
determination O
in O
biological O
materials O

At O
maximum O
_RARE_ I-GENE
the O
inhibitory I-GENE
amino O
acids O
gamma I-GENE
- I-GENE
_RARE_ I-GENE
acid I-GENE
and O
_RARE_ I-GENE
were O
lower O
, O
and O
those O
of O
_RARE_ I-GENE
( O
metabolite O
of O
the O
_RARE_ I-GENE
amino O
acid I-GENE
aspartate I-GENE
) O
were O
higher O
, O
than O
when O
the O
animals O
were O
not O
_RARE_ I-GENE
. O

We O
evaluated O
the O
likelihood O
of O
tissues O
to O
be O
positive O
for O
_RARE_ I-GENE
antigen I-GENE
and O
the O
intensity O
of O
_RARE_ I-GENE
antigen I-GENE
staining O
in O
specimens O
of O
_RARE_ I-GENE
_RARE_ I-GENE
, O
mixed O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
using O
the O
peroxidase I-GENE
- I-GENE
_RARE_ I-GENE
technique O
. O

The O
_RARE_ I-GENE
activity O
of O
DNA I-GENE
_RARE_ I-GENE
by O
either O
of O
the O
Drosophila I-GENE
enzymes O
can O
be O
enhanced O
, O
however O
, O
by O
an O
additional O
incubation O
with O
E I-GENE
. O
coli I-GENE
endonuclease I-GENE
IV I-GENE
, O
which O
is O
known O
to O
_RARE_ I-GENE
_RARE_ I-GENE
DNA I-GENE
on O
the O
5 I-GENE
'- O
side O
of O
an O
_RARE_ I-GENE
site I-GENE
. O

A I-GENE
. O

Therefore O
, O
in O
conjunction O
with O
a O
positive O
pregnancy O
test O
and O
the O
patient O
' O
s O
clinical O
history O
, O
a O
severely O
depressed O
or O
absent O
serum I-GENE
_RARE_ I-GENE
- I-GENE
A I-GENE
level O
may O
aid O
in O
the O
diagnosis O
of O
_RARE_ I-GENE
pregnancy O
. O

The O
levels O
of O
both O
_RARE_ I-GENE
- I-GENE
specific I-GENE
and O
_RARE_ I-GENE
- I-GENE
specific I-GENE
mRNAs I-GENE
decline O
in O
the O
postnatal O
developing O
brain O
; O
the O
level O
of O
_RARE_ I-GENE
- I-GENE
specific I-GENE
mRNA I-GENE
also O
increases O
slightly O
in O
rat I-GENE
PC12 O
cells O
upon O
exposure O
to O
nerve I-GENE
growth I-GENE
factor I-GENE
. O

The O
cDNAs I-GENE
cross O
- I-GENE
_RARE_ I-GENE
with O
genomic O
sequences I-GENE
in O
rat I-GENE
, O
human I-GENE
, O
and O
chicken I-GENE
DNA I-GENE
, O
but O
not O
with O
DNA I-GENE
from O
_RARE_ I-GENE
, O
Drosophila I-GENE
, O
or O
sea O
urchin I-GENE
. O

_RARE_ I-GENE
method O
of O
determining O
_RARE_ I-GENE
in O
the O
blood O

Deletion O
analysis O
was O
carried O
out O
within O
a O
part O
of O
the O
5 I-GENE
'- O
flanking O
region O
showing O
homology I-GENE
to O
the O
upstream O
region O
of O
the O
yeast I-GENE
CYC1 I-GENE
gene I-GENE
. O

The O
N1 O
and O
P2 I-GENE
were O
comparable O
in O
amplitude O
and O
both O
had O
prolonged O
refractory O
periods O
. O

_RARE_ I-GENE
to O
_RARE_ I-GENE
_RARE_ I-GENE
: O
fact O
or O
_RARE_ I-GENE
? O
Recent O
findings O
in O
this O
laboratory O
with O
regard O
to O
tolerance O
to O
_RARE_ I-GENE
_RARE_ I-GENE
are O
reviewed O
with O
respect O
to O
_RARE_ I-GENE
of O
the O
_RARE_ I-GENE
phenomenon O
. O

In O
30 O
dogs O
the O
left O
limb O
( O
tail O
) O
of O
the O
pancreas O
was O
removed O
but O
left O
in O
the O
abdominal O
cavity O
after O
cessation O
of O
blood O
flow O
to O
produce O
_RARE_ I-GENE
ischemia O
for O
30 O
, O
60 O
, O
and O
120 O
min O
( O
10 O
dogs O
at O
each O
time O
point O
), O
and O
then O
was O
_RARE_ I-GENE
with O
cold O
_RARE_ I-GENE
' O
lactate I-GENE
and O
_RARE_ I-GENE
to O
the O
iliac O
vessels O
. O

These O
results O
support O
the O
view O
that O
_RARE_ I-GENE
and O
6 I-GENE
- I-GENE
_RARE_ I-GENE
, O
but O
not O
alpha I-GENE
- I-GENE
_RARE_ I-GENE
, O
have O
central O
pressor O
actions O
in O
the O
rat I-GENE
that O
_RARE_ I-GENE
their O
antihypertensive O
action O
. O

Furthermore O
, O
beta I-GENE
2 I-GENE
- I-GENE
adrenoceptor I-GENE
sensitivity O
appears O
to O
be O
unaltered O
in O
_RARE_ I-GENE
. O

We O
conclude O
that O
_RARE_ I-GENE
' O
s O
stain O
substantially O
_RARE_ I-GENE
the O
recognition I-GENE
of O
_RARE_ I-GENE
as O
compared O
with O
_RARE_ I-GENE
' O
s O
stain O
. O

These O
results O
suggest O
that O
the O
negative O
inotropic O
action O
of O
_RARE_ I-GENE
is O
caused O
by O
inhibition O
of O
Ca I-GENE
_RARE_ I-GENE
and O
intracellular O
_RARE_ I-GENE
of O
Ca I-GENE
. O

The O
study O
included O
139 O
eyes O
with O
presumed I-GENE
ocular O
_RARE_ I-GENE
syndrome O
( O
_RARE_ I-GENE
) O
and O
age O
- I-GENE
related I-GENE
_RARE_ I-GENE
degeneration O
( O
_RARE_ I-GENE
). O

Comparison O
of O
elastase I-GENE
- I-GENE
1 I-GENE
with O
amylase I-GENE
, O
lipase I-GENE
, O
and O
trypsin I-GENE
- I-GENE
like I-GENE
immunoreactivity O
in O
the O
diagnosis O
of O
acute O
pancreatitis O
. O

A I-GENE
probe O
evoked O
potentials O
procedure O
was O
used O
to O
assess O
the O
relative O
_RARE_ I-GENE
of O
both O
cerebral O
_RARE_ I-GENE
during O
a O
language O
task O
in O
the O
following O
four O
groups O
of O
_RARE_ I-GENE
adults O
: O
left O
hemisphere O
( O
LH I-GENE
)- I-GENE
damaged O
_RARE_ I-GENE
_RARE_ I-GENE
from O
stroke O
, O
_RARE_ I-GENE
, O
right O
hemisphere O
( O
RH O
)- I-GENE
damaged O
_RARE_ I-GENE
patients O
, O
and O
normal O
control O
subjects O
. O

_RARE_ I-GENE
type I-GENE
IV I-GENE
: O
clinical O
spectrum O
and O
natural O
history O
. O

Two O
of O
the O
three O
groups O
were O
administered O
_RARE_ I-GENE
, O
as O
a O
new O
calcium O
channel O
blocker O
, O
and O
verapamil O
, O
as O
a O
generally O
recognized O
calcium O
channel O
blocker O
, O
respectively O
, O
from O
15 O
minutes O
pre I-GENE
- I-GENE
bypass O
to O
the O
end O
of O
the O
bypass O
procedure O
( O
a O
period O
of O
95 O
minutes O
). O

No O
_RARE_ I-GENE
occurred O
in O
approximately O
30 O
percent O
of O
the O
muscle O
_RARE_ I-GENE
upon O
reperfusion O
. O

_RARE_ I-GENE
, O
patients O
with O
locally O
advanced O
, O
_RARE_ I-GENE
, O
non O
- I-GENE
metastatic O
prostatic I-GENE
cancer O
_RARE_ I-GENE
prolonged O
survival O
. O

_RARE_ I-GENE
activity O
was O
_RARE_ I-GENE
increased O
as O
well O
in O
_RARE_ I-GENE
as O
in O
_RARE_ I-GENE
sera O
in O
all O
our O
tested O
patients O
. O

The O
first O
involved O
measurements O
of O
the O
steady O
state O
levels O
of O
mRNAs I-GENE
for O
subunit I-GENE
5 I-GENE
of O
cytochrome I-GENE
oxidase I-GENE
and O
the O
beta I-GENE
subunit I-GENE
of O
F1 I-GENE
ATPase I-GENE
in O
wild I-GENE
type I-GENE
and O
in O
a O
_RARE_ I-GENE
mutant I-GENE
. O

A I-GENE
5 I-GENE
. O
_RARE_ I-GENE
- I-GENE
like I-GENE
structure O
is O
present O
within O
the O
5 I-GENE
'- O
terminal I-GENE
region O
of O
all O
three O
fungal I-GENE
mitochondrial I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
; O
in O
contrast O
, O
no O
4 I-GENE
. O
5S I-GENE
- I-GENE
like I-GENE
structure O
is O
evident O
at O
the O
3 I-GENE
' O
end O
of O
these O
molecules I-GENE
. O

ATP I-GENE
gamma I-GENE
S I-GENE
inhibition O
can O
be O
overcome O
by O
high O
concentrations O
of O
ATP I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
or O
_RARE_ I-GENE
. O

The O
recovery O
of O
labelled O
_RARE_ I-GENE
is O
98 O
+/- O
7 O
%. O

_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
demonstrated O
weak O
competitive O
beta I-GENE
- I-GENE
_RARE_ I-GENE
blocking O
activity O
in O
isolated O
guinea O
pig O
right O
_RARE_ I-GENE
with O
a O
_RARE_ I-GENE
of O
3 I-GENE
. O
73 O
+/- O
0 O
. O
07 O
; O
no O
agonist O
- I-GENE
like I-GENE
activity O
was O
observed O
in O
this O
tissue I-GENE
at O
concentrations O
of O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
from O
3 I-GENE
X I-GENE
10 O
(- O
5 I-GENE
) O
to O
1 I-GENE
X I-GENE
10 O
(- O
2 I-GENE
) O
M I-GENE
. O

_RARE_ I-GENE
and O
promoter I-GENE
elements O
_RARE_ I-GENE
activation O
and O
glucocorticoid I-GENE
repression O
of O
the O
alpha I-GENE
1 I-GENE
- I-GENE
fetoprotein I-GENE
gene I-GENE
in O
hepatocytes O
. O

We O
discuss O
the O
results O
in O
relation O
to O
previous O
systems O
for O
_RARE_ I-GENE
the O
posterior O
_RARE_ I-GENE
gyrus O
of O
the O
cat O
and O
consider O
the O
possibility O
that O
_RARE_ I-GENE
of O
the O
feline I-GENE
posterior O
_RARE_ I-GENE
gyrus O
correspond O
directly O
to O
areas O
making O
up O
the O
superior O
temporal O
gyrus O
in O
primates O
. O

The O
gene I-GENE
is O
contained O
within O
a O
1 I-GENE
. O
8 O
- I-GENE
kilobase O
_RARE_ I-GENE
- I-GENE
EcoRI I-GENE
restriction I-GENE
fragment I-GENE
mapping O
at O
map O
_RARE_ I-GENE
0 O
. O
136 O
to O
0 O
. O
_RARE_ I-GENE
in O
the O
_RARE_ I-GENE
region O
of O
the O
EHV I-GENE
- I-GENE
1 I-GENE
genome O
and O
is O
transcribed O
from O
right O
to O
left O
. O

The O
4 I-GENE
- I-GENE
AP I-GENE
( O
4 I-GENE
- I-GENE
20 O
mM O
) O
effect O
resulted O
in O
a O
decrease O
of O
the O
sensory O
activity O
, O
which O
was O
fully O
restored O
by O
_RARE_ I-GENE
or O
_RARE_ I-GENE
_RARE_ I-GENE

Hybridization O
of O
a O
probe O
from O
this O
region O
to O
electrophoretic O
blots O
of O
RNAs I-GENE
from O
different O
human I-GENE
tissues O
showed O
a O
predominant O
2 I-GENE
. O
8 O
- I-GENE
kilobase O
( O
kb O
) O
message I-GENE
accompanied O
by O
_RARE_ I-GENE
bands O
4 I-GENE
. O
1 I-GENE
and O
2 I-GENE
. O
1 I-GENE
kb O
in O
size O
. O

_RARE_ I-GENE
of O
asymptomatic O
multiple O
myeloma O
. O

A I-GENE
new O
method O
for O
the O
quantitative O
analysis O
of O
sleep O
_RARE_ I-GENE
during O
continuous O
_RARE_ I-GENE
EEG O
recordings O
. O

_RARE_ I-GENE
et O
al O
. O

_RARE_ I-GENE
release O
of O
neuronal O
serotonin I-GENE
and O
5 I-GENE
- I-GENE
_RARE_ I-GENE
acid I-GENE
in O
the O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
of O
the O
rat I-GENE
as O
revealed O
by O
_RARE_ I-GENE
dialysis O
coupled I-GENE
to O
high O
- I-GENE
performance O
liquid O
chromatography O
with O
_RARE_ I-GENE
detection O
. O

In O
this O
report O
we O
describe O
for O
the O
first O
time O
the O
complete O
primary O
structure O
of O
type I-GENE
X I-GENE
collagen I-GENE
, O
based O
on O
cloning O
and O
sequencing O
of O
cDNA I-GENE
and O
genomic O
DNA I-GENE
. O

_RARE_ I-GENE
flap O
areas O
were O
established O
following O
vascular I-GENE
_RARE_ I-GENE
ligation O
( O
both O
vessels O
or O
only O
artery O
or O
vein O
), O
on O
the O
third O
day O
after O
flap O
_RARE_ I-GENE
in O
both O
island O
and O
free O
_RARE_ I-GENE
. O

The O
size O
_RARE_ I-GENE
is O
not O
due O
to O
glycosylation O
or O
phosphorylation O
of O
_RARE_ I-GENE
but O
may O
result O
from O
a O
proline O
- I-GENE
rich O
sequence I-GENE
which O
occurs O
in O
this O
polypeptide I-GENE
. O

A I-GENE
9 O
. O
5 I-GENE
- I-GENE
kb O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
fragment I-GENE
, O
where O
all O
the O
DNA I-GENE
changes O
associated I-GENE
with O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
mutations O
were O
mapped O
, O
was O
able O
to O
rescue O
the O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
mutant I-GENE
phenotype O
after O
P I-GENE
- I-GENE
element I-GENE
- I-GENE
mediated O
germ I-GENE
- I-GENE
line O
transformation O
. O

The O
corticosterone O
synthesis O
inhibitor I-GENE
_RARE_ I-GENE
( O
75 O
mg O
/ I-GENE
kg O
i O
. O
p O
.) O
was O
given O
to O
_RARE_ I-GENE
the O
rise O
of O
corticosterone O
to O
a O
level O
typical O
of O
stressed O
males O
. O

The O
effects O
of O
_RARE_ I-GENE
, O
240 O
, O
a O
selective O
thromboxane I-GENE
and O
prostaglandin I-GENE
_RARE_ I-GENE
antagonist O
, O
on O
ischemia O
- I-GENE
and O
reperfusion O
- I-GENE
induced O
cardiac O
arrhythmias O
. O

In O
10 O
_RARE_ I-GENE
dogs O
, O
plasma I-GENE
viscosity O
( O
_RARE_ I-GENE
) O
was O
raised O
fourfold O
while O
apparent O
blood O
viscosity O
( O
_RARE_ I-GENE
) O
increased O
about O
twofold O
by O
two O
steps O
of O
exchange I-GENE
transfusion O
of O
200 O
ml O
of O
plasma I-GENE
with O
plasma I-GENE
containing O
high O
molecular O
weight O
_RARE_ I-GENE
( O
mol O
wt I-GENE
500 O
, O
000 O
, O
20 O
% O
wt I-GENE
/ I-GENE
_RARE_ I-GENE
). O

The O
small I-GENE
IGF I-GENE
- I-GENE
binding I-GENE
protein I-GENE
is O
abundant O
in O
human I-GENE
amniotic I-GENE
fluid O
. O

Serum I-GENE
prostatic I-GENE
acid I-GENE
phosphatase I-GENE
levels O
showed O
a O
significantly O
_RARE_ I-GENE
correlation O
with O
cancer O
volume O
( O
r O
_RARE_ I-GENE
0 O
. O
51 O
) O
and O
every O
other O
pathological O
parameter O
. O

The O
investigation O
was O
thereafter O
continued O
in O
an O
open O
fashion O
by O
_RARE_ I-GENE
a O
single O
10 O
mg O
dose O
of O
the O
MAO I-GENE
- I-GENE
B I-GENE
inhibitor I-GENE
_RARE_ I-GENE
to O
the O
same O
subjects O
. O

Their O
studies O
have O
revealed O
a O
considerable O
increase O
of O
CSF I-GENE
AP I-GENE
activity O
in O
_RARE_ I-GENE
_RARE_ I-GENE
whereas O
in O
_RARE_ I-GENE
_RARE_ I-GENE
it O
_RARE_ I-GENE
_RARE_ I-GENE
. O

A I-GENE
cDNA I-GENE
encoding O
a O
new O
human I-GENE
lymphocyte I-GENE
cell O
surface O
molecule I-GENE
has O
been O
isolated O
and O
shown O
to O
identify O
a O
fourth O
member O
of O
a O
recently O
discovered O
family I-GENE
of O
adhesion I-GENE
proteins I-GENE
. O

Dopamine I-GENE
caused O
a O
prominent O
potassium O
_RARE_ I-GENE
measured O
as O
_RARE_ I-GENE
+ I-GENE
_RARE_ I-GENE
from O
control O
glands O
, O
but O
was O
without O
effect O
in O
_RARE_ I-GENE
glands O
. O

_RARE_ I-GENE
sensitization O
to O
cross O
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
in O
a O
proportion O
of O
control O
animals O
is O
strongly O
suggested O
, O
_RARE_ I-GENE
_RARE_ I-GENE
to O
spontaneous O
sensitization O
in O
patients O
with O
_RARE_ I-GENE
reactions O
to O
neuromuscular O
blockers O
on O
first O
exposure O
, O
and O
in O
whom O
IgE I-GENE
antibodies I-GENE
are O
detected O
. O

This O
approach O
was O
examined O
utilizing O
the O
fetal O
protein I-GENE
, O
_RARE_ I-GENE
F I-GENE
. O

The O
investigation O
was O
_RARE_ I-GENE
at O
studying O
the O
relationship O
between O
urinary O
metabolites O
of O
serotonin I-GENE
and O
_RARE_ I-GENE
( O
5 I-GENE
- I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
), O
T I-GENE
- I-GENE
cells O
( O
_RARE_ I-GENE
+), O
T I-GENE
- I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
+), O
T I-GENE
- I-GENE
suppressor I-GENE
( O
_RARE_ I-GENE
+) O
and O
B I-GENE
- I-GENE
cells O
( O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
forming O
cells O
) O
in O
normal O
( O
10 O
subjects O
, O
1 I-GENE
female O
, O
9 O
male O
, O
age O
21 O
+/- O
5 I-GENE
years O
) O
and O
stress O
administered O
subjects O
( O
20 O
subjects O
, O
3 I-GENE
female O
, O
17 O
male O
, O
age O
20 O
+/- O
4 I-GENE
years O
). O

The O
84 O
. O
_RARE_ I-GENE
mAb I-GENE
recognizes O
a O
site I-GENE
on O
IgE I-GENE
which O
is O
identical O
or O
very O
close O
to O
the O
Fc I-GENE
epsilon I-GENE
R I-GENE
binding I-GENE
site I-GENE
, O
and O
95 O
. O
3 I-GENE
recognizes O
a O
site I-GENE
on O
IgE I-GENE
which O
is O
related I-GENE
, O
but O
not O
identical O
to O
the O
Fc I-GENE
epsilon I-GENE
R I-GENE
binding I-GENE
site I-GENE
. O

Their O
_RARE_ I-GENE
_RARE_ I-GENE
are O
very O
similar O
and O
both O
possess O
three O
hydrophobic O
segments O
that O
are O
likely O
alpha I-GENE
- I-GENE
helical O
transmembrane I-GENE
segments O
. O

_RARE_ I-GENE
converting I-GENE
enzyme I-GENE
inhibitors O
enhance O
the O
antihypertensive O
efficacy O
of O
_RARE_ I-GENE
and O
_RARE_ I-GENE
or O
prevent O
adverse O
metabolic O
effects O
. O

In O
addition O
to O
the O
significant O
reduction O
in O
blood O
pressure O
, O
the O
angiotensin I-GENE
converting I-GENE
enzyme I-GENE
( O
ACE I-GENE
) O
inhibitor I-GENE
_RARE_ I-GENE
caused O
a O
significant O
regression O
of O
pathologic O
left O
ventricular O
hypertrophy O
demonstrated O
by O
magnetic O
resonance O
imaging O
and O
echocardiography O
. O

_RARE_ I-GENE
cells O
were O
studied O
by O
means O
of O
_RARE_ I-GENE
' O
silver O
staining O
and O
_RARE_ I-GENE
for O
_RARE_ I-GENE
, O
a O
general O
marker O
of O
endocrine O
cells O
. O

The O
ratio O
of O
_RARE_ I-GENE
in O
tumour I-GENE
compared O
with O
normal O
tissue I-GENE
( O
T I-GENE
: O
N I-GENE
ratio O
) O
was O
determined O
after O
simultaneously O
injecting O
microspheres O
into O
the O
portal I-GENE
and O
arterial O
circulation O
of O
each O
animal O
. O

The O
mRNA I-GENE
was O
converted O
to O
cDNA I-GENE
and O
amplified O
by O
the O
polymerase I-GENE
chain I-GENE
reaction O
technique O
. O

Tissue I-GENE
necrosis I-GENE
was O
evaluated O
using O
_RARE_ I-GENE
staining O
and O
was O
related I-GENE
to O
two O
major I-GENE
baseline O
predictors O
of O
infarct O
size O
: O
anatomic O
risk O
zone O
size O
and O
coronary O
collateral O
flow O
. O

To O
study O
the O
retinal O
surface O
in O
the O
human I-GENE
eye O
in O
normal O
and O
diseased O
states O
we O
used O
laser O
scanning O
tomography O
. O

Previously O
, O
we O
reported O
the O
sequence I-GENE
of O
the O
gene I-GENE
encoding O
human I-GENE
_RARE_ I-GENE
( O
D I-GENE
. O

A I-GENE
potential O
TATA I-GENE
box I-GENE
is O
located O
29 O
base O
pairs O
upstream O
of O
the O
first O
transcription I-GENE
initiation I-GENE
site I-GENE
. O

Cotransfection O
of O
either O
construct I-GENE
with O
plasmids O
encoding O
_RARE_ I-GENE
( O
1 I-GENE
- I-GENE
31 O
) O
inhibits O
cAMP I-GENE
- I-GENE
stimulated O
but O
not O
basal O
- I-GENE
or O
phorbol O
ester O
- I-GENE
stimulated O
expression O
. O

Sequence O
analysis O
of O
the O
5 I-GENE
' O
flanking O
region O
revealed O
several O
GC I-GENE
boxes O
but O
no O
_RARE_ I-GENE
TATA I-GENE
box I-GENE
. O

The O
underlying O
cirrhosis O
was O
alcoholic O
in O
11 O
( O
53 O
. O
3 I-GENE
%), O
_RARE_ I-GENE
in O
5 I-GENE
( O
23 O
. O
8 O
%), O
and O
hepatitis I-GENE
B I-GENE
chronic O
infection O
related I-GENE
in O
5 I-GENE
( O
23 O
. O
8 O
%). O

Once O
P I-GENE
- I-GENE
_RARE_ I-GENE
mRNA I-GENE
is O
induced O
as O
a O
consequence O
of O
the O
LH I-GENE
/ I-GENE
hCG I-GENE
_RARE_ I-GENE
it O
is O
constitutively O
maintained O
by O
_RARE_ I-GENE
cells O
in O
vivo O
( O
0 O
- I-GENE
4 I-GENE
days O
) O
and O
in O
vitro O
( O
0 O
- I-GENE
9 O
days O
) O
in O
the O
absence O
of O
_RARE_ I-GENE
, O
is O
susceptible O
to O
modulation O
by O
prolactin I-GENE
and O
is O
no O
longer O
regulated O
by O
cAMP I-GENE
. O

Similarly O
, O
a O
human I-GENE
but O
not O
a O
bovine I-GENE
alpha I-GENE
_RARE_ I-GENE
was O
expressed O
in O
placenta O
in O
transgenic O
mice O
. O

A I-GENE
rapid O
staining O
technique O
for O
Leishmania I-GENE
parasites O
in O
splenic O
_RARE_ I-GENE
smears O
. O

_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
suppressed O
coronary O
ligation O
- I-GENE
and O
_RARE_ I-GENE
- I-GENE
induced O
arrhythmias O
, O
and O
the O
minimum O
effective O
plasma I-GENE
concentrations O
for O
arrhythmias O
induced O
by O
24 O
- I-GENE
h O
and O
48 O
- I-GENE
h O
coronary O
ligation O
and O
_RARE_ I-GENE
were O
0 O
. O
41 O
+/- O
0 O
. O
10 O
( O
by O
1 I-GENE
mg O
/ I-GENE
kg O
i O
. O
v I-GENE
_RARE_ I-GENE
0 O
. O
70 I-GENE
+/- O
0 O
. O
13 O
( O
by O
1 I-GENE
mg O
/ I-GENE
kg O
i O
. O
v I-GENE
_RARE_ I-GENE
and O
0 O
. O
21 O
+/- O
0 O
. O
_RARE_ I-GENE
( O
by O
0 O
. O
5 I-GENE
mg O
/ I-GENE
kg O
i O
. O
v I-GENE
.) O
microgram O
/ I-GENE
ml O
, O
respectively O
( O
mean O
+/- O
SD O
of O
the O
mean O
, O
n O
= O
6 I-GENE
). O

In O
TNF I-GENE
- I-GENE
resistant O
_RARE_ I-GENE
bladder O
carcinoma O
cells O
, O
TNF I-GENE
failed O
to O
alter O
EGF I-GENE
- I-GENE
R I-GENE
tyrosine I-GENE
protein I-GENE
kinase I-GENE
activity O
although O
both O
EGF I-GENE
and O
phorbol O
ester O
were O
shown O
to O
modulate O
the O
enzymatic O
activity O
of O
the O
receptor I-GENE
in O
these O
cells O
. O

Thus O
, O
phosphodiesterase I-GENE
inhibitors O
that O
produce O
an O
opiate I-GENE
_RARE_ I-GENE
- I-GENE
withdrawal O
syndrome O
_RARE_ I-GENE
_RARE_ I-GENE
stimuli O
and O
weight O
loss O
associated I-GENE
with O
the O
withdrawal O
syndrome O
precipitated O
by O
naltrexone O
in O
morphine O
- I-GENE
dependent I-GENE
rats O
. O

The O
diagnostic O
value O
of O
blood O
serum I-GENE
and O
urinary O
amylase I-GENE
, O
lipase I-GENE
, O
and O
trypsin I-GENE
in O
_RARE_ I-GENE
of O
chronic O
_RARE_ I-GENE
pancreatitis O
is O
discussed O
. O

On O
the O
basis O
of O
the O
mechanism O
of O
action O
, O
two O
groups O
of O
_RARE_ I-GENE
are O
distinguished O
, O
the O
phosphodiesterase I-GENE
inhibitors O
and O
the O
dopaminergic O
agents O
. O

Structural O
organization O
and O
expression O
of O
the O
mouse I-GENE
estrogen I-GENE
receptor I-GENE
. O

Intravenous O
gamma I-GENE
_RARE_ I-GENE

Following O
_RARE_ I-GENE
AC I-GENE
and O
_RARE_ I-GENE
digestion O
, O
staining O
reactions O
suggested O
that O
the O
highest O
levels O
of O
_RARE_ I-GENE
sulfate I-GENE
were O
in O
the O
diabetes O
resistant O
group O
( O
p O
less O
than O
0 O
. O
001 O
compared O
to O
diabetic O
, O
p O
less O
than O
0 O
. O
001 O
compared O
to O
diabetes O
prone O
) O
and O
the O
highest O
levels O
of O
_RARE_ I-GENE
_RARE_ I-GENE
were O
in O
the O
diabetes O
prone O
group O
( O
p O
less O
than O
0 O
. O
001 O
). O

Myocardial O
perfusion O
was O
evaluated O
using O
the O
enhanced O
gray O
level O
after O
contrast O
injection O
, O
and O
the O
level O
was O
compared O
with O
the O
morphology O
and O
degree O
of O
collateral O
development O
. O

Once O
_RARE_ I-GENE
administration O
is O
proven O
effective O
it O
will O
be O
possible O
to O
develop O
alternative O
ways O
of O
_RARE_ I-GENE
administration O
. O

During O
the O
program O
' O
s O
use O
at O
the O
_RARE_ I-GENE
_RARE_ I-GENE
, O
the O
program O
selected O
the O
correct O
diagnosis O
in O
the O
top O
five O
22 O
% O
of O
the O
time O
. O

_RARE_ I-GENE
light I-GENE
chain I-GENE
( O
_RARE_ I-GENE
) O
diversity O
is O
generated O
in O
the O
chicken I-GENE
by O
recombination O
between O
the O
single O
functional O
variable O
( O
_RARE_ I-GENE
) O
and O
joining O
( O
_RARE_ I-GENE
) O
gene I-GENE
segments O
and O
subsequent O
somatic O
_RARE_ I-GENE
of O
the O
rearranged I-GENE
_RARE_ I-GENE
region O
. O

The O
results O
were O
as O
follows O
: O
1 I-GENE
) O
Total O
integrated O
EMG O
activity O
of O
FB O
group O
was O
approximately O
equal O
in O
any O
occluded O
position O
, O
whereas O
that O
of O
CG I-GENE
and O
_RARE_ I-GENE
group O
varied O
from O
position O
to O
position O
. O

_RARE_ I-GENE
action O
potential O
and O
_RARE_ I-GENE
rhythm O
of O
anterior O
temporal O
and O
_RARE_ I-GENE
muscles O
in O
children O
and O
adults O

In O
76 I-GENE
% O
of O
59 O
lead O
- I-GENE
toxic O
children O
, O
bone O
lead O
values O
measured O
by O
_RARE_ I-GENE
were O
equal O
to O
or O
greater O
than O
those O
measured O
in O
normal O
and O
_RARE_ I-GENE
exposed O
adults O
. O

When O
considered O
with O
the O
known O
_RARE_ I-GENE
effects O
on O
children O
of O
" O
low O
levels O
" O
of O
exposure O
to O
lead O
, O
these O
results O
also O
suggest O
that O
either O
an O
_RARE_ I-GENE
narrow O
margin O
of O
safety O
or O
insufficient O
safety O
is O
provided O
by O
present O
U O
. O
S I-GENE
. O
guidelines O
, O
which O
_RARE_ I-GENE
an O
elevated O
blood O
lead O
concentration O
as O
25 O
micrograms O
/ I-GENE
dl O
or O
greater O
. O

In O
resting O
3T3 O
cells O
, O
jun I-GENE
- I-GENE
D I-GENE
is O
expressed O
at O
a O
higher O
level O
compared O
to O
c I-GENE
- I-GENE
jun I-GENE
and O
jun I-GENE
- I-GENE
B I-GENE
, O
and O
its O
transcription I-GENE
is O
stimulated O
only O
slightly O
by O
serum I-GENE
growth I-GENE
factors I-GENE
. O

The O
_RARE_ I-GENE
effects O
of O
native O
tissue I-GENE
- I-GENE
type I-GENE
plasminogen I-GENE
activator I-GENE
( O
_RARE_ I-GENE
- I-GENE
124 I-GENE
) O
on O
experimental O
canine O
coronary O
thrombosis O
. O

O2 O
and O
CO2 O
in O
the O
_RARE_ I-GENE
tube O
were O
continuously O
monitored O
by O
mass O
spectrometry O
using O
a O
special O
sample O
- I-GENE
_RARE_ I-GENE
phase O
- I-GENE
_RARE_ I-GENE
sampling O
technique O
. O

_RARE_ I-GENE
- I-GENE
linked O
immunosorbent O
assay O
for O
screening O
_RARE_ I-GENE
B1 I-GENE
in O
_RARE_ I-GENE
products I-GENE
and O
mixed O
feed O
: O
_RARE_ I-GENE
study O
. O

However O
, O
experiments O
with O
S1 I-GENE
mapping O
of O
in O
vivo O
transcripts I-GENE
, O
gene I-GENE
_RARE_ I-GENE
in O
the O
alpha I-GENE
region O
, O
and O
a O
single O
- I-GENE
copy O
transcriptional O
fusion I-GENE
vector O
all O
suggested O
that O
these O
possible O
promoters I-GENE
were O
largely O
inactive O
during O
_RARE_ I-GENE
growth I-GENE
, O
that O
the O
major I-GENE
promoter I-GENE
for O
the O
alpha I-GENE
operon I-GENE
_RARE_ I-GENE
upstream O
from O
the O
region O
cloned O
, O
and O
that O
the O
genes I-GENE
in O
the O
_RARE_ I-GENE
to O
_RARE_ I-GENE
interval O
were O
cotranscribed O
. O

Functional O
rearranged I-GENE
antibody I-GENE
genes I-GENE
were O
detected O
with O
_RARE_ I-GENE
and O
VH I-GENE
heavy I-GENE
chain I-GENE
probes O
and O
with O
_RARE_ I-GENE
and O
_RARE_ I-GENE
light I-GENE
chain I-GENE
probes O
. O

Two O
specific I-GENE
DNA I-GENE
- I-GENE
protein I-GENE
complexes I-GENE
were O
identified O
in O
gel O
retardation O
assays O
using O
HeLa O
cell O
nuclear I-GENE
extracts O
and O
an O
oligonucleotide I-GENE
probe O
spanning O
the O
_RARE_ I-GENE
region O
. O

After O
transfection O
, O
specific I-GENE
TSH I-GENE
beta I-GENE
promoter I-GENE
activity O
was O
evident O
in O
both O
TRH I-GENE
- I-GENE
responsive I-GENE
pituitary I-GENE
- I-GENE
derived O
_RARE_ I-GENE
and O
primary O
pituitary I-GENE
cell O
cultures O
. O

In O
transformed O
E I-GENE
. O
coli I-GENE
, O
constitutive O
CAT I-GENE
expression O
is O
maintained O
when O
as O
little O
as O
0 O
. O
3 I-GENE
kilobase O
of O
DNA I-GENE
from O
the O
3 I-GENE
' O
end O
of O
the O
1 I-GENE
. O
6 I-GENE
- I-GENE
kilobase O
segment O
is O
inserted O
in O
the O
correct O
orientation O
in O
front O
of O
the O
CAT I-GENE
gene I-GENE
. O

_RARE_ I-GENE
of O
the O
renal O
blood O
flow O
alters O
the O
glomerular O
and O
tubular O
excretion O
processes O
. O

_RARE_ I-GENE
of O
blood O
samples O
from O
patients O
may O
also O
be O
used O
in O
the O
determination O
of O
acid I-GENE
- I-GENE
base O
_RARE_ I-GENE
and O
hemoglobin I-GENE
- I-GENE
oxygen O
affinity O
e O
. O
g O
. O
p50 I-GENE
. O

100 O
and O
14 O
p O
. O

Isolation O
of O
_RARE_ I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
_RARE_ I-GENE
group O
_RARE_ I-GENE
) O
from O
a O
vaginal O
sample O
. O

Here O
, O
we O
alter O
the O
dimerization O
specificity O
of O
Fos I-GENE
by O
precisely O
replacing O
its O
leucine I-GENE
zipper I-GENE
with O
that O
from O
GCN4 I-GENE
. O

Growth I-GENE
of O
tracheal O
_RARE_ I-GENE
in O
growing O
animals O

_RARE_ I-GENE
, O
_RARE_ I-GENE
between O
4 I-GENE
and O
24 O
hours O
of O
recovery O
is O
necessary O
to O
reverse I-GENE
the O
effect O
of O
chronic O
hypoxia O
on O
cerebral O
blood O
flow O
. O

The O
ORF1 O
product I-GENE
was O
required O
for O
_RARE_ I-GENE
, O
while O
ORF2 O
, O
which O
was O
cotranscribed O
with O
ORF1 O
and O
encoded I-GENE
a O
predicted O
protein I-GENE
of O
126 O
amino O
acids O
, O
was O
not O
. O

_RARE_ I-GENE
of O
the O
primary O
visual O
cortex O
( O
_RARE_ I-GENE
) O
was O
compared O
with O
that O
of O
the O
amygdala O
in O
cats O
. O

_RARE_ I-GENE
_RARE_ I-GENE
of O
lymphocytes O
and O
plasma I-GENE
cells O
was O
also O
wide O
- I-GENE
spread O
_RARE_ I-GENE
the O
carcinoma O
in O
situ O
, O
together O
with O
the O
lymphoid I-GENE
_RARE_ I-GENE
. O

These O
case O
reports O
provide O
further O
evidence O
that O
_RARE_ I-GENE
can O
be O
a O
useful O
medication O
in O
the O
treatment O
of O
aggressive O
behavior O
and O
affective O
_RARE_ I-GENE
after O
brain O
injury O
, O
but O
that O
it O
has O
significant O
potential O
for O
neurotoxicity O
in O
this O
population O
, O
particularly O
when O
used O
in O
conjunction O
with O
neuroleptic O
agents O
. O

In O
all O
_RARE_ I-GENE
under O
IFN I-GENE
, O
the O
latency O
of O
the O
_RARE_ I-GENE
component O
of O
the O
_RARE_ I-GENE
was O
shortened O
as O
compared O
to O
baseline O
conditions O
. O

Among O
100 O
cases O
of O
post O
- I-GENE
transfusion O
hepatitis I-GENE
, O
10 O
are O
due O
to O
the O
hepatitis I-GENE
B I-GENE
virus I-GENE
( O
despite O
systematic O
search O
for O
HBs I-GENE
Ag I-GENE
), O
89 I-GENE
are O
due O
to O
one O
of O
the O
non O
- I-GENE
A I-GENE
non O
- I-GENE
B I-GENE
viruses O
( O
not O
detectable O
by O
specific I-GENE
serological O
tests O
) O
and O
1 I-GENE
to O
several O
viruses O
, O
_RARE_ I-GENE
CMV O
. O

_RARE_ I-GENE
lethal O
mutations O
were O
isolated O
based O
upon O
failure O
to O
complement I-GENE
the O
recessive O
lethality O
of O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
_RARE_ I-GENE
, O
a O
deletion O
of O
the O
DRE I-GENE
region O
that O
_RARE_ I-GENE
16 O
- I-GENE
18 O
_RARE_ I-GENE
chromosome O
bands O
. O

Current O
status O
and O
future O
_RARE_ I-GENE

K I-GENE
. O

A I-GENE
215 O
- I-GENE
base O
- I-GENE
pair O
( O
bp O
) O
region O
of O
the O
mouse I-GENE
_RARE_ I-GENE
41 O
kappa I-GENE
light I-GENE
- I-GENE
chain I-GENE
immunoglobulin I-GENE
gene I-GENE
enhancer I-GENE
has O
been O
analyzed O
for O
specific I-GENE
binding I-GENE
of O
lymphoid I-GENE
and O
_RARE_ I-GENE
nuclear I-GENE
factors I-GENE
. O

This O
paper O
presents O
the O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
to O
which O
_RARE_ I-GENE
disease O
is O
_RARE_ I-GENE
should O
carry O
out O
the O
relevant O
research O
themselves O
. O

The O
_RARE_ I-GENE
measurement O
during O
_RARE_ I-GENE
compression O
predicted O
the O
success O
of O
_RARE_ I-GENE
with O
return O
of O
spontaneous O
circulation O
. O

_RARE_ I-GENE
CO2 O
/ I-GENE
HCO3 O
was O
determined O
in O
absence O
of O
simultaneous O
inhibition O
of O
acid I-GENE
secretion O
by O
intra O
- I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
/ I-GENE
pH O
measurements O
in O
23 O
persons O
and O
calculated O
using O
the O
equation O
of O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
. O
_RARE_ I-GENE
was O
measured O
with O
use O
of O
a O
new O
electrode O
. O

_RARE_ I-GENE
- I-GENE
up O
study O
showed O
85 O
% O
of O
these O
patients O
with O
effectiveness O
. O

The O
other O
patients O
continued O
the O
trial O
with O
single O
daily O
doses O
of O
_RARE_ I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
disease O
: O
laboratory O
diagnosis O
during O
the O
first O
year O
of O
life O

Using O
mutated O
_RARE_ I-GENE
alpha I-GENE
promoter I-GENE
constructs I-GENE
in O
transient O
transfection O
and O
DNA I-GENE
binding I-GENE
assays O
, O
we O
now O
demonstrate O
that O
sequences I-GENE
located O
immediately O
upstream O
and O
downstream O
of O
the O
kappa I-GENE
B I-GENE
enhancer I-GENE
also O
contribute O
to O
the O
regulation O
of O
_RARE_ I-GENE
alpha I-GENE
gene I-GENE
expression O
. O

_RARE_ I-GENE
_RARE_ I-GENE

_RARE_ I-GENE
of O
_RARE_ I-GENE
_RARE_ I-GENE
against O
ticks O
. O

Forty O
patients O
, O
divided O
according O
to O
their O
initial O
total O
gastrointestinal O
transit O
times O
and O
presenting O
symptoms O
, O
were O
treated O
with O
_RARE_ I-GENE
bromide O
50 O
mg O
t I-GENE
. O
d O
. O
s O
. O
or O
placebo O
for O
1 I-GENE
month O
according O
to O
a O
double O
- I-GENE
blind O
, O
parallel O
group O
design O
. O

An O
_RARE_ I-GENE
related I-GENE
protein I-GENE
was O
detected O
in O
ribosome I-GENE
and O
membrane I-GENE
fractions O
of O
mitochondria O
from O
Saccharomyces I-GENE
cerevisiae I-GENE
. O

Mapping O
of O
RNA I-GENE
- I-GENE
temperature O
- I-GENE
sensitive O
mutants I-GENE
of O
_RARE_ I-GENE
virus I-GENE
: O
complementation O
group O
F I-GENE
mutants I-GENE
have O
lesions O
in O
_RARE_ I-GENE
. O

The O
effect O
of O
the O
thromboxane I-GENE
A2 I-GENE
( O
_RARE_ I-GENE
)/ O
prostaglandin I-GENE
_RARE_ I-GENE
receptor I-GENE
antagonist O
, O
_RARE_ I-GENE
29 O
, O
_RARE_ I-GENE
on O
pacing O
- I-GENE
induced O
ischemia O
was O
determined O
in O
anesthetized O
open O
- I-GENE
chest O
dogs O
. O

According O
to O
the O
published O
sequence I-GENE
of O
the O
_RARE_ I-GENE
gene I-GENE
, O
this O
fragment I-GENE
contains O
four O
repeats I-GENE
of O
a O
_RARE_ I-GENE
consensus I-GENE
sequence I-GENE
previously O
identified O
in O
the O
alpha I-GENE
- I-GENE
factor I-GENE
- I-GENE
inducible I-GENE
_RARE_ I-GENE
promoter I-GENE
[ O
_RARE_ I-GENE
, O
J O
. O

The O
recovery O
index O
( O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
) O
after O
the O
infusion O
stopped O
was O
similar O
in O
patients O
who O
received O
_RARE_ I-GENE
and O
those O
who O
received O
_RARE_ I-GENE
. O

The O
sign O
of O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
: O
does O
it O
exist O
? O
The O
sign O
of O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
is O
usually O
regarded O
as O
a O
reliable O
cutaneous O
marker O
of O
internal O
malignancy O
. O

Xenopus I-GENE
homolog I-GENE
of O
the O
mos I-GENE
protooncogene I-GENE
_RARE_ I-GENE
mammalian I-GENE
fibroblasts O
and O
induces O
maturation O
of O
Xenopus I-GENE
oocytes O
. O

Southern O
blot O
analyses O
demonstrated O
a O
low O
, O
if O
not O
single O
, O
copy O
number O
for O
this O
gene I-GENE
and O
conservation O
of O
this O
domain I-GENE
in O
other O
_RARE_ I-GENE
. O

Three O
missense O
mutants I-GENE
in O
subunit I-GENE
a O
of O
the O
Escherichia I-GENE
coli I-GENE
_RARE_ I-GENE
- I-GENE
ATPase I-GENE
were O
isolated O
and O
characterized O
after O
_RARE_ I-GENE
mutagenesis O
of O
a O
plasmid O
carrying O
the O
_RARE_ I-GENE
( O
subunit I-GENE
a O
) O
gene I-GENE
. O

Moreover O
, O
exons O
_RARE_ I-GENE
and O
2b I-GENE
share O
the O
same O
5 I-GENE
' O
sequence I-GENE
but O
differ O
from O
each O
other O
by O
the O
use O
of O
two O
distinct O
donor O
splice O
sites I-GENE
_RARE_ I-GENE
bp O
apart O
in O
the O
gene I-GENE
. O

S1 I-GENE
nuclease I-GENE
analysis O
of O
RNA I-GENE
prepared O
after O
transfection O
of O
these O
HIV I-GENE
constructs I-GENE
into O
HeLa O
cells O
infected O
with O
wild I-GENE
- I-GENE
type I-GENE
adenovirus I-GENE
indicated O
that O
the O
enhancer I-GENE
, O
SP1 I-GENE
, O
TATA I-GENE
, O
and O
a O
portion O
of O
the O
transactivation O
- I-GENE
responsive I-GENE
element I-GENE
were O
each O
required O
for O
complete O
E1A I-GENE
/ I-GENE
E1B I-GENE
- I-GENE
mediated O
activation O
of O
the O
HIV I-GENE
LTR I-GENE
. O

In O
supine O
position O
, O
plasma I-GENE
ANP I-GENE
levels O
ranged O
from O
12 O
pg O
/ I-GENE
ml O
to O
51 O
. O
5 I-GENE
pg O
/ I-GENE
ml O
, O
with O
an O
average O
level O
of O
35 O
. O
3 I-GENE
+/- O
11 O
. O
5 I-GENE
pg O
/ I-GENE
ml O
. O

The O
overall O
prevalence O
of O
HBV O
markers O
was O
higher O
among O
_RARE_ I-GENE
members O
than O
in O
the O
blood O
donors O
of O
our O
area O
. O

Quantitative O
predictions O
are O
confirmed O
for O
the O
positive O
responses O
, O
but O
not O
for O
the O
_RARE_ I-GENE
, O
suggesting O
that O
the O
_RARE_ I-GENE
model O
is O
_RARE_ I-GENE
. O

Plasma I-GENE
concentrations O
of O
_RARE_ I-GENE
( O
_RARE_ I-GENE
), O
aldosterone O
( O
_RARE_ I-GENE
) O
and O
renin I-GENE
( O
_RARE_ I-GENE
) O
were O
measured O
daily O
, O
as O
were O
hemodynamic O
parameters O
. O

The O
adenovirus I-GENE
E1A I-GENE
gene I-GENE
encodes O
a O
protein I-GENE
that O
transcriptionally O
activates O
viral I-GENE
early I-GENE
genes I-GENE
. O

Administration O
of O
dexamethasone O
was O
associated I-GENE
with O
progressive O
_RARE_ I-GENE
in O
plasma I-GENE
17 O
alpha I-GENE
OH O
progesterone I-GENE
, O
11 O
beta I-GENE
- I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
and O
testosterone O
, O
together O
with O
increased O
urinary O
excretion O
of O
_RARE_ I-GENE
, O
11 O
beta I-GENE
OH O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
and O
16 O
alpha I-GENE
OH O
_RARE_ I-GENE
. O

RNA I-GENE
transcripts I-GENE
that O
_RARE_ I-GENE
to O
the O
introduced O
foreign O
gene I-GENE
have O
been O
identified O
. O

In O
HeLa O
cells O
, O
it O
activated I-GENE
transcription I-GENE
from O
the O
herpes I-GENE
simplex I-GENE
virus I-GENE
type I-GENE
1 I-GENE
thymidine I-GENE
kinase I-GENE
promoter I-GENE
linked O
to O
the O
chloramphenicol I-GENE
acetyltransferase I-GENE
gene I-GENE
when O
located O
in O
inverted O
orientation O
upstream O
of O
the O
thymidine I-GENE
kinase I-GENE
promoter I-GENE
or O
downstream O
of O
the O
chloramphenicol I-GENE
acetyltransferase I-GENE
gene I-GENE
coding O
sequence I-GENE
. O

At O
the O
basal O
unstimulated O
condition O
, O
_RARE_ I-GENE
5 I-GENE
' O
flanking O
sequence I-GENE
in O
the O
sense O
orientation O
inhibited O
basal O
CAT I-GENE
expression O
from O
the O
TK I-GENE
promoter I-GENE
of O
_RARE_ I-GENE
, O
whereas O
the O
same O
sequence I-GENE
in O
the O
antisense I-GENE
orientation O
did O
not O
. O

None O
were O
restricted O
from O
clinical O
_RARE_ I-GENE
, O
were O
given O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
immune I-GENE
globulin I-GENE
, O
or O
developed O
disease O
. O

In O
the O
formalin O
test O
, O
however O
, O
naloxone O
attenuated O
morphine O
analgesia O
at O
the O
lower O
doses O
( O
0 O
. O
1 I-GENE
and O
0 O
. O
3 I-GENE
mg O
/ I-GENE
kg O
) O
and O
_RARE_ I-GENE
morphine O
analgesia O
at O
the O
highest O
dose O
( O
10 O
mg O
/ I-GENE
kg O
). O

We O
have O
isolated O
cDNA I-GENE
clones O
from O
rat I-GENE
brain O
and O
human I-GENE
liver O
encoding O
a O
putative O
isoform I-GENE
of O
the O
Na I-GENE
, O
K I-GENE
- I-GENE
ATPase I-GENE
beta I-GENE
subunit I-GENE
. O

We O
have O
determined O
that O
several O
E1 I-GENE
mutants I-GENE
mapping O
in O
both O
the O
M I-GENE
and O
R I-GENE
regions O
and O
a O
single O
mutant I-GENE
of O
the O
upstream O
regulatory I-GENE
region O
have O
a O
higher O
transforming I-GENE
activity O
on O
mouse I-GENE
_RARE_ I-GENE
cells O
than O
the O
wild I-GENE
- I-GENE
type I-GENE
genome O
does O
. O

_RARE_ I-GENE
is O
also O
unique O
among O
known O
_RARE_ I-GENE
genes I-GENE
in O
containing O
four O
cis O
- I-GENE
spliced O
introns O
within O
its O
coding O
sequence I-GENE
. O

_RARE_ I-GENE
of O
the O
T2 I-GENE
gene I-GENE
contains O
numerous O
potential O
sites I-GENE
for O
binding I-GENE
the O
mammalian I-GENE
transcription I-GENE
factor I-GENE
SP1 I-GENE
, O
but O
no O
TATA I-GENE
or O
CCAAT I-GENE
sequences I-GENE
are O
evident O
near O
to O
its O
5 I-GENE
' O
end O
, O
although O
these O
latter O
features O
are O
associated I-GENE
with O
the O
human I-GENE
T1 O
gene I-GENE
. O

_RARE_ I-GENE
therapy O
was O
effective O
in O
controlling O
symptomatic O
metastasis O
in O
all O
three O
patients O
. O

These O
results O
indicate O
that O
patients O
who O
undergo O
postoperative O
irradiation O
for O
low O
grade O
spinal O
_RARE_ I-GENE
and O
localized O
spinal O
_RARE_ I-GENE
achieve O
excellent O
survival O
. O

The O
methylation O
of O
nuclear I-GENE
and O
chloroplast I-GENE
DNAs O
has O
been O
examined O
in O
relation O
to O
the O
known O
differential O
expression O
of O
C4 I-GENE
_RARE_ I-GENE
genes I-GENE
in O
the O
bundle O
_RARE_ I-GENE
and O
_RARE_ I-GENE
cells O
of O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
and O
fully O
green I-GENE
maize I-GENE
leaves O
. O

S1 I-GENE
nuclease I-GENE
analysis O
of O
RNA I-GENE
from O
_RARE_ I-GENE
induced O
_RARE_ I-GENE
- I-GENE
8 O
cells O
and O
from O
_RARE_ I-GENE
cells O
cotransfected O
with O
_RARE_ I-GENE
repeat I-GENE
promoter I-GENE
- I-GENE
CAT I-GENE
and O
Z I-GENE
showed O
that O
Z I-GENE
transactivation O
increased O
the O
level O
of O
correctly O
initiated O
, O
stable O
RNA I-GENE
transcripts I-GENE
. O

We O
conclude O
that O
( O
a O
) O
the O
likelihood O
of O
detecting O
carcinoma O
or O
atypical O
hyperplasia O
exclusively O
in O
the O
adipose I-GENE
tissue I-GENE
component O
of O
_RARE_ I-GENE
benign O
breast O
biopsies O
is O
extremely O
low O
, O
and O
( O
b I-GENE
) O
a O
possible O
cost O
- I-GENE
effective O
method O
of O
sampling O
_RARE_ I-GENE
benign O
breast O
biopsies O
consists O
of O
initially O
_RARE_ I-GENE
a O
maximum O
of O
10 O
blocks O
of O
_RARE_ I-GENE
parenchyma O
for O
each O
case O
, O
then O
examining O
the O
remaining O
tissue I-GENE
histologically O
only O
if O
carcinoma O
or O
atypical O
hyperplasia O
is O
found O
among O
these O
blocks O
. O

Analysis O
of O
the O
DNA I-GENE
from O
15 O
cases O
of O
_RARE_ I-GENE
and O
familial O
_RARE_ I-GENE
' O
tumor I-GENE
did O
not O
reveal O
any O
changes O
, O
indicating O
that O
the O
translocation O
breakpoint I-GENE
does O
not O
reside O
in O
this O
gene I-GENE
. O

We O
also O
provide O
evidence O
that O
neither O
the O
lambda I-GENE
O O
and O
P I-GENE
_RARE_ I-GENE
nor O
the O
E I-GENE
. O
coli I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
heat I-GENE
shock I-GENE
proteins I-GENE
play O
a O
direct O
role O
in O
the O
_RARE_ I-GENE
of O
lambda I-GENE
replication O
_RARE_ I-GENE
in O
vitro O
. O

_RARE_ I-GENE
oligonucleotides O
representing O
the O
19 O
bp O
repeat I-GENE
unit I-GENE
strongly O
reduced O
the O
activity O
of O
the O
IE1 I-GENE
/ I-GENE
2 I-GENE
enhancer I-GENE
/ I-GENE
promoter I-GENE
in O
cotransfection O
assays O
after O
transient O
expression O
. O

Effects O
of O
nitrogen O
( O
_RARE_ I-GENE
: O
5 I-GENE
and O
14 O
_RARE_ I-GENE
) O
and O
_RARE_ I-GENE
( O
_RARE_ I-GENE
: O
13 O
and O
14 O
_RARE_ I-GENE
) O
were O
also O
tested O
. O

The O
_RARE_ I-GENE
chloroplast I-GENE
gene I-GENE
_RARE_ I-GENE
is O
_RARE_ I-GENE
by O
an O
_RARE_ I-GENE
bp O
group O
II I-GENE
( O
or O
III I-GENE
) O
intron O
. O

Antibodies O
raised O
to O
the O
expressed O
NS3 I-GENE
by O
immunization O
of O
mice O
detected O
both O
NS3 I-GENE
and O
_RARE_ I-GENE
in O
_RARE_ I-GENE
- I-GENE
10 O
- I-GENE
infected O
_RARE_ I-GENE
cells O
but O
not O
in O
purified O
_RARE_ I-GENE
- I-GENE
10 O
virus I-GENE
particles O
. O

Similarly O
, O
_RARE_ I-GENE
_RARE_ I-GENE
following O
_RARE_ I-GENE
_RARE_ I-GENE
appeared O
to O
be O
associated I-GENE
with O
a O
negative O
outcome O
. O

The O
negative O
calcium O
balance O
with O
_RARE_ I-GENE
occurred O
after O
continuous O
oral O
administration O
of O
Cd O
and O
developed O
via O
increased O
urinary O
excretion O
of O
calcium O
. O

_RARE_ I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
bp O
) O
had O
a O
coding O
region O
identical O
to O
that O
of O
clone O
_RARE_ I-GENE
but O
it O
included O
a O
putative O
intron O
of O
_RARE_ I-GENE
bp O
. O

The O
application O
of O
_RARE_ I-GENE
and O
_RARE_ I-GENE
did O
not O
change O
significantly O
the O
routine O
histologic O
classification O
of O
_RARE_ I-GENE
into O
CMV O
- I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
. O

_RARE_ I-GENE
of O
_RARE_ I-GENE
and O
in O
situ O
hybridization O
in O
the O
differential O
diagnosis O
of O
cytomegalovirus I-GENE
pneumonia O
and O
idiopathic O
interstitial O
pneumonia O
after O
_RARE_ I-GENE
bone O
marrow O
transplantation O

The O
unique O
nature O
and O
arrangement O
of O
the O
_RARE_ I-GENE
transcriptional O
control O
elements O
may O
account O
for O
this O
differential O
expression O
. O

A I-GENE
brief O
account O
of O
the O
1988 O
_RARE_ I-GENE
in O
_RARE_ I-GENE
on O
viral I-GENE
hepatitis I-GENE
A I-GENE

The O
Bacillus I-GENE
subtilis I-GENE
phage I-GENE
phi I-GENE
105 I-GENE
repressor I-GENE
, O
a O
lambda I-GENE
repressor I-GENE
- I-GENE
like I-GENE
transcriptional O
regulatory I-GENE
protein I-GENE
, O
was O
_RARE_ I-GENE
in O
Escherichia I-GENE
coli I-GENE
and O
purified O
to O
near O
_RARE_ I-GENE
in O
order O
to O
examine O
its O
in O
vitro O
DNA I-GENE
- I-GENE
binding I-GENE
properties O
. O

In O
consequence O
, O
the O
_RARE_ I-GENE
derived O
from O
cells O
infected O
with O
_RARE_ I-GENE
showed O
antigenic I-GENE
characteristics O
similar O
to O
those O
of O
_RARE_ I-GENE
from O
VZV I-GENE
- I-GENE
infected O
cells O
as O
determined O
from O
the O
immunoprecipitation O
pattern O
, O
although O
the O
molecular O
weight O
of O
each O
polypeptide I-GENE
was O
different O
, O
and O
antibody I-GENE
produced O
in O
rabbits O
infected O
with O
recombinant I-GENE
virus I-GENE
had O
a O
high O
_RARE_ I-GENE
activity O
, O
when O
the O
reaction O
was O
performed O
with O
complement I-GENE
. O

_RARE_ I-GENE
stages O
of O
mammalian I-GENE
_RARE_ I-GENE
parasites O
contain O
_RARE_ I-GENE
mitochondria O
whose O
functions O
are O
not O
well O
understood O
. O

However O
, O
bilateral O
diffuse O
pulmonary O
_RARE_ I-GENE
developed O
21 O
days O
later O
. O

_RARE_ I-GENE
, O
the O
incidence O
of O
a O
type I-GENE
_RARE_ I-GENE
carcinoma O
was O
46 O
. O
5 I-GENE
% O
and O
that O
of O
a O
_RARE_ I-GENE
+ I-GENE
III I-GENE
type I-GENE
was O
20 O
. O
5 I-GENE
%, O
respectively O
. O

Restriction O
maps O
of O
the O
cloned O
plasmids O
revealed O
that O
their O
chromosomal I-GENE
inserts O
consisted O
of O
overlapping O
fragments I-GENE
. O

_RARE_ I-GENE
, O
which O
encodes O
the O
major I-GENE
capsid I-GENE
protein I-GENE
, O
each O
fused O
to O
the O
chloramphenicol I-GENE
acetyltransferase I-GENE
gene I-GENE
. O

Of O
_RARE_ I-GENE
initially O
_RARE_ I-GENE
_RARE_ I-GENE
( O
observed O
for O
an O
average O
of O
_RARE_ I-GENE
days O
per O
woman O
), O
19 O
_RARE_ I-GENE
, O
for O
an O
annual O
_RARE_ I-GENE
rate O
of O
11 O
percent O
. O

In O
contrast O
, O
a O
similar O
fragment I-GENE
lacking O
the O
38 O
- I-GENE
base O
- I-GENE
pair O
region O
had O
no O
such O
_RARE_ I-GENE
effect O
. O

First O
, O
a O
_RARE_ I-GENE
:: O
LEU2 I-GENE
_RARE_ I-GENE
bearing O
the O
' O
short O
' O
mitochondrial I-GENE
genome O
that O
lacks O
both O
_RARE_ I-GENE
introns O
_RARE_ I-GENE
alpha I-GENE
and O
_RARE_ I-GENE
beta I-GENE
is O
defective O
only O
in O
_RARE_ I-GENE
gene I-GENE
expression O
and O
not O
in O
_RARE_ I-GENE
mRNA I-GENE
splicing O
or O
mRNA I-GENE
translation I-GENE
. O

_RARE_ I-GENE
contains O
repetitive O
non O
- I-GENE
Ig I-GENE
- I-GENE
related I-GENE
sequences I-GENE
and O
a O
small I-GENE
Ig I-GENE
- I-GENE
related I-GENE
sequence I-GENE
. O

Since O
considerable O
variations O
in O
length I-GENE
and O
primary O
sequence I-GENE
in O
the O
_RARE_ I-GENE
( O
complementarity I-GENE
determining O
region O
) O
peptides I-GENE
of O
all O
the O
H I-GENE
- I-GENE
chains I-GENE
are O
evident O
, O
conservation O
of O
the O
D I-GENE
- I-GENE
region O
structure O
does O
not O
appear O
to O
be O
necessary O
for O
effective O
_RARE_ I-GENE
binding I-GENE
. O

Tyrosine I-GENE
kinase I-GENE
oncogenes I-GENE
abrogate O
interleukin I-GENE
- I-GENE
3 I-GENE
dependence O
of O
murine I-GENE
myeloid O
cells O
through O
signaling O
pathways O
involving O
c I-GENE
- I-GENE
myc I-GENE
: O
conditional O
regulation O
of O
c I-GENE
- I-GENE
myc I-GENE
transcription I-GENE
by O
temperature O
- I-GENE
sensitive O
v I-GENE
- I-GENE
abl I-GENE
. O

This O
_RARE_ I-GENE
- I-GENE
II I-GENE
_RARE_ I-GENE
, O
which O
is O
identical O
to O
the O
kappa I-GENE
B I-GENE
motif I-GENE
from O
the O
kappa I-GENE
chain I-GENE
enhancer I-GENE
, O
was O
active O
in O
both O
lymphoid I-GENE
and O
non O
- I-GENE
lymphoid I-GENE
cells O
, O
which O
_RARE_ I-GENE
with O
the O
previously O
reported O
lymphoid I-GENE
cell O
specificity O
of O
the O
kappa I-GENE
B I-GENE
motif I-GENE
. O

The O
DNA I-GENE
helix I-GENE
at O
the O
tandemly O
repeated O
, O
_RARE_ I-GENE
sequence I-GENE
is O
_RARE_ I-GENE
unstable O
, O
as O
_RARE_ I-GENE
by O
hypersensitivity O
to O
single O
- I-GENE
strand O
- I-GENE
specific I-GENE
nuclease I-GENE
in O
a O
negatively O
_RARE_ I-GENE
plasmid O
, O
and O
demonstrated O
by O
stable O
DNA I-GENE
_RARE_ I-GENE
seen O
after O
two O
- I-GENE
dimensional O
gel O
electrophoresis O
of O
_RARE_ I-GENE
. O

There O
has O
been O
similar O
improvement O
in O
_RARE_ I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
cancer O
, O
gallbladder O
cancer O
, O
or O
_RARE_ I-GENE
bile O
duct O
cancer O
. O

_RARE_ I-GENE
- I-GENE
endorphin I-GENE
, O
ACTH I-GENE
and O
cortisol O
secretion O
were O
measured O
in O
_RARE_ I-GENE
healthy O
adult O
males O
after O
nasal O
_RARE_ I-GENE
administration O
200 O
IU O
_RARE_ I-GENE
calcitonin I-GENE
. O

The O
data O
indicate O
that O
calcitonin I-GENE
induced O
a O
beta I-GENE
- I-GENE
endorphin I-GENE
increase O
independent O
of O
enhanced O
_RARE_ I-GENE
- I-GENE
cortisol O
release O
. O

The O
DNA I-GENE
sequences I-GENE
predict O
proteins I-GENE
for O
_RARE_ I-GENE
and O
_RARE_ I-GENE
that O
are O
47 O
% O
and O
52 O
% O
identical O
to O
_RARE_ I-GENE
, O
respectively O
. O

Other O
_RARE_ I-GENE
values O
evaluated O
were O
activated I-GENE
partial O
thromboplastin I-GENE
times O
, O
prothrombin I-GENE
times O
, O
thrombin I-GENE
times O
, O
fibrinogen I-GENE
, O
platelet I-GENE
counts O
, O
and O
fibrin I-GENE
/ I-GENE
fibrinogen I-GENE
degradation O
products I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
tumor I-GENE
with O
metastasis O
to O
mouth O
, O
jaw O
and O
face O
regions O

We O
have O
designated O
the O
protein I-GENE
" O
cellular O
_RARE_ I-GENE
" O
( O
_RARE_ I-GENE
). O

_RARE_ I-GENE
to O
beta I-GENE
- I-GENE
2 I-GENE
agonist O
therapy O
was O
retained O
with O
both O
agents O
( O
p O
less O
than O
0 O
. O
05 O
). O

Drug O
use O
in O
trauma O
victims O
. O

A I-GENE
critical O
heart O
rate O
and O
/ I-GENE
or O
appropriate O
sympathetic O
state O
was O
found O
to O
_RARE_ I-GENE
all O
instances O
of O
_RARE_ I-GENE
or O
automatic O
atrial I-GENE
tachycardia O
and O
atypical O
_RARE_ I-GENE
tachycardia O
. O

In O
contrast O
, O
the O
neu I-GENE
proto I-GENE
- I-GENE
oncogene I-GENE
did O
not O
show O
kinase I-GENE
activity O
or O
transforming I-GENE
properties O
when O
expressed O
at O
similar O
levels O
in O
NIH O
3T3 O
cells O
.( O
ABSTRACT O
TRUNCATED O
AT I-GENE
250 O
WORDS O
) O

The O
65 O
- I-GENE
bp O
sequence I-GENE
contains O
the O
_RARE_ I-GENE
cAMP I-GENE
- I-GENE
responsive I-GENE
enhancer I-GENE
( O
CRE O
) O
_RARE_ I-GENE
( O
nucleotides O
- I-GENE
48 O
to O
- I-GENE
41 O
). O

_RARE_ I-GENE
gene I-GENE
expression O
in O
pancreatic O
islet O
cells O
is O
directed O
by O
cell O
- I-GENE
specific I-GENE
DNA I-GENE
control O
elements O
and O
DNA I-GENE
- I-GENE
binding I-GENE
proteins I-GENE
. O

In O
contrast O
, O
the O
full I-GENE
mu I-GENE
- I-GENE
opioid I-GENE
agonists O
fentanyl O
, O
morphine O
, O
I I-GENE
- I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
produced O
50 O
% O
fentanyl O
- I-GENE
appropriate O
responding O
at O
doses O
only O
1 I-GENE
. O
3 I-GENE
to O
10 O
. O
9 O
times O
smaller O
than O
those O
required O
to O
decrease O
response O
rates O
by O
50 O
%. O

After O
_RARE_ I-GENE
on O
the O
original O
discrimination O
, O
the O
controls O
showed O
the O
normal O
_RARE_ I-GENE
in O
learning O
the O
first O
reversal O
. O

Isolation O
and O
characterization O
of O
a O
cDNA I-GENE
encoding O
a O
putative O
cytokine O
which O
is O
induced O
by O
stimulation O
via O
the O
_RARE_ I-GENE
structure O
on O
human I-GENE
T I-GENE
lymphocytes O
. O

After O
termination O
of O
medication O
the O
animals O
were O
_RARE_ I-GENE
electrically O
in O
the O
nucleus O
amygdala O
. O

_RARE_ I-GENE
cells O
of O
mating I-GENE
type I-GENE
A I-GENE
of O
the O
_RARE_ I-GENE
yeast I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
a O
mating I-GENE
pheromone O
, O
_RARE_ I-GENE
A I-GENE
, O
which O
is O
an O
_RARE_ I-GENE
containing O
S I-GENE
- I-GENE
_RARE_ I-GENE
cysteine I-GENE
at O
its O
carboxy I-GENE
terminus O
. O

_RARE_ I-GENE
necrosis I-GENE
factor I-GENE
and O
adult O
respiratory O
distress O
syndrome O
. O

_RARE_ I-GENE
of O
rheumatoid I-GENE
arthritis O
. O

The O
decrease O
in O
left O
ventricular O
( O
LV O
) O
stroke O
volume O
during O
positive O
end O
- I-GENE
expiratory O
pressure O
( O
_RARE_ I-GENE
) O
has O
been O
attributed O
to O
reduced O
LV O
filling O
and O
a O
decreased O
contractile O
state O
. O

An O
experiment O
on O
the O
return O
- I-GENE
of O
- I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
was O
carried O
out O
on O
40 I-GENE
_RARE_ I-GENE
- I-GENE
or O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
subjects O
in O
order O
to O
determine O
whether O
an O
_RARE_ I-GENE
event O
that O
occurs O
_RARE_ I-GENE
before O
_RARE_ I-GENE
influences O
the O
magnitude O
of O
the O
_RARE_ I-GENE
. O

_RARE_ I-GENE
conservation O
of O
homeodomain I-GENE
- I-GENE
binding I-GENE
sites I-GENE
and O
other O
sequences I-GENE
upstream O
and O
within O
the O
major I-GENE
transcription I-GENE
unit I-GENE
of O
the O
Drosophila I-GENE
segmentation I-GENE
gene I-GENE
_RARE_ I-GENE
. O

To O
assess O
the O
functional O
importance O
of O
these O
_RARE_ I-GENE
in O
the O
overall O
drug O
resistance O
phenotype O
conferred O
by O
_RARE_ I-GENE
, O
we O
introduced O
amino O
acid I-GENE
substitutions O
in O
the O
core I-GENE
consensus I-GENE
sequence I-GENE
for O
nucleotide I-GENE
binding I-GENE
, O
_RARE_ I-GENE
. O

When O
the O
first O
_RARE_ I-GENE
of O
TOF O
spontaneously O
recovered O
to O
10 O
% O
of O
control O
value O
, O
_RARE_ I-GENE
was O
injected O
( O
40 I-GENE
micrograms O
/ I-GENE
kg O
in O
adults O
, O
30 O
micrograms O
/ I-GENE
kg O
in O
infants O
and O
children O
). O

No O
significant O
differences O
were O
found O
in O
relation O
to O
Type O
A I-GENE
behaviour O
and O
beta I-GENE
- I-GENE
adrenoceptor I-GENE
blockade O
. O

_RARE_ I-GENE
of O
the O
22 O
_RARE_ I-GENE
of O
the O
Clinical O
Institute O
_RARE_ I-GENE
Assessment O
- I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
- I-GENE
B I-GENE
) O
was O
based O
on O
statistically O
significant O
differences O
between O
baseline O
and O
critical O
withdrawal O
periods O
in O
high O
- I-GENE
dose O
subjects O
and O
between O
symptoms O
associated I-GENE
with O
placebo O
and O
diazepam I-GENE
in O
low O
- I-GENE
dose O
subjects O
, O
using O
_RARE_ I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
regression O
analysis O
. O

_RARE_ I-GENE
in O
asthma O
. O

We O
have O
therefore O
evaluated O
the O
efficacy O
and O
safety O
of O
_RARE_ I-GENE
, O
a O
new O
orally O
active O
selective O
alpha I-GENE
1 I-GENE
blocker O
, O
in O
patients O
with O
systemic O
hypertension O
with O
concomitant O
_RARE_ I-GENE
limitation O
. O

Northern O
blot O
analysis O
revealed O
multiple O
_RARE_ I-GENE
- I-GENE
I I-GENE
transcripts I-GENE
in O
a O
broad O
band O
at O
800 O
- I-GENE
1 I-GENE
, O
100 O
nucleotides O
and O
other O
transcripts I-GENE
of O
higher O
molecular O
weight O
in O
liver O
. O

_RARE_ I-GENE
_RARE_ I-GENE
studies O
on O
the O
_RARE_ I-GENE
of O
different O
_RARE_ I-GENE
_RARE_ I-GENE

The O
latency O
time O
for O
the O
lactate I-GENE
concentration O
to O
reach O
the O
top O
values O
was O
reduced O
by O
aerobic O
training O
( O
T2 I-GENE
). O

In O
patients O
resistant O
to O
_RARE_ I-GENE
, O
high O
- I-GENE
dose O
_RARE_ I-GENE
with O
intravenous O
_RARE_ I-GENE
, O
a O
_RARE_ I-GENE
combination O
( O
cyclophosphamide O
- I-GENE
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
16 O
) O
or O
an O
_RARE_ I-GENE
regimen O
( O
_RARE_ I-GENE
- I-GENE
16 O
- I-GENE
_RARE_ I-GENE
) O
produced O
responses O
in O
about O
40 I-GENE
% O
of O
patients O
. O

The O
discussion O
_RARE_ I-GENE
primarily O
on O
the O
_RARE_ I-GENE
drugs O
like I-GENE
angiotensin I-GENE
converting I-GENE
enzyme I-GENE
inhibitors O
, O
alpha I-GENE
- I-GENE
adrenergic I-GENE
receptor I-GENE
blockers O
, O
and O
calcium O
antagonists O
. O

The O
avian I-GENE
cellular O
homolog I-GENE
of O
the O
oncogene I-GENE
jun I-GENE
. O

A I-GENE
_RARE_ I-GENE
- I-GENE
bp O
sequence I-GENE
of O
the O
5 I-GENE
' O
flanking O
region O
adjacent O
to O
the O
cap I-GENE
site I-GENE
of O
the O
human I-GENE
AFP I-GENE
gene I-GENE
shows O
a O
61 O
% O
similarity O
with O
the O
corresponding O
region O
of O
the O
mouse I-GENE
AFP I-GENE
gene I-GENE
. O

High O
ATP I-GENE
/ I-GENE
GTP I-GENE
ratios O
promoted O
initiation I-GENE
of O
RNA I-GENE
primer O
synthesis O
at O
3 I-GENE
'- O
_RARE_ I-GENE
sites I-GENE
, O
whereas O
low O
ATP I-GENE
/ I-GENE
GTP I-GENE
ratios O
promoted O
initiation I-GENE
at O
3 I-GENE
'- O
_RARE_ I-GENE
sites I-GENE
. O

After O
hepatitis I-GENE
B I-GENE
vaccine O
immunization O
, O
serum I-GENE
antibody I-GENE
response O
was O
of O
primary O
type I-GENE
in O
33 O
cases O
with O
anti I-GENE
- I-GENE
HBs I-GENE
less O
than O
2 I-GENE
. O
1 I-GENE
S I-GENE
/ I-GENE
N I-GENE
( O
S I-GENE
/ I-GENE
N I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
) O
at O
_RARE_ I-GENE
, O
the O
anti I-GENE
- I-GENE
HBs I-GENE
positive O
rate O
was O
39 O
. O
4 I-GENE
%, O
84 O
. O
8 O
%, O
96 O
. O
7 O
% O
and O
96 O
. O
7 O
% O
in O
T1 O
, O
T2 I-GENE
, O
_RARE_ I-GENE
and O
_RARE_ I-GENE
respectively O
. O

The O
experimental O
design O
incorporated O
a O
multiple O
regression O
model O
, O
sequential O
treatments O
and O
a O
_RARE_ I-GENE
end O
point O
( O
95 O
%) O
for O
protection O
time O
. O

_RARE_ I-GENE
complementation O
tests O
showed O
that O
the O
P7 I-GENE
proteins I-GENE
are O
unable O
to O
complement I-GENE
P1 I-GENE
_RARE_ I-GENE
or O
_RARE_ I-GENE
mutants I-GENE
, O
and O
the O
P1 I-GENE
proteins I-GENE
fail O
to O
complement I-GENE
the O
P7 I-GENE
mutations O
. O

_RARE_ I-GENE
, O
_RARE_ I-GENE
- I-GENE
9 O
, O
and O
_RARE_ I-GENE
. O

Analysis O
of O
the O
_RARE_ I-GENE
1 I-GENE
, O
_RARE_ I-GENE
- I-GENE
residue O
_RARE_ I-GENE
- I-GENE
1 I-GENE
product I-GENE
showed O
considerable O
identity O
with O
the O
largest O
subunit I-GENE
of O
RNAP I-GENE
II I-GENE
from O
other O
organisms O
, O
including O
the O
presence O
of O
a O
zinc I-GENE
finger I-GENE
motif I-GENE
near O
the O
amino O
terminus O
, O
and O
a O
carboxyl O
- I-GENE
terminal I-GENE
domain I-GENE
of O
42 O
tandemly O
_RARE_ I-GENE
_RARE_ I-GENE
with O
the O
consensus I-GENE
Tyr I-GENE
Ser O
Pro I-GENE
Thr I-GENE
Ser O
Pro I-GENE
Ser O
. O

_RARE_ I-GENE
involvement O
of O
the O
left O
lung O
and O
_RARE_ I-GENE
of O
the O
mucosa O
of O
the O
left O
lower O
lobe O
_RARE_ I-GENE
followed O
very O
gradually O
and O
a O
monoclonal I-GENE
_RARE_ I-GENE
( O
IgA I-GENE
-- O
Type O
_RARE_ I-GENE
) O
was O
demonstrated O
. O

5 I-GENE
. O

None O
of O
the O
measured O
parameters O
( O
heart O
contents O
of O
neutral O
lipids O
, O
total O
phospholipids O
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
and O
fatty I-GENE
acid I-GENE
composition O
of O
each O
phospholipid I-GENE
class I-GENE
) O
appeared O
to O
be O
related I-GENE
with O
the O
_RARE_ I-GENE
of O
the O
lesions O
. O

Of O
165 O
women O
with O
non O
- I-GENE
malignant O
_RARE_ I-GENE
26 O
( O
16 O
%) O
had O
CA I-GENE
125 I-GENE
levels O
in O
excess O
of O
35 O
U O
/ I-GENE
ml O
and O
8 O
( O
5 I-GENE
%) O
greater O
than O
65 O
U O
/ I-GENE
ml O
. O

We O
conclude O
that O
at O
steady O
state O
the O
timing O
of O
a O
light I-GENE
meal I-GENE
is O
unlikely O
to O
alter O
in O
any O
clinically O
important O
manner O
the O
pharmacokinetics O
of O
nifedipine O
released O
from O
' O
biphasic O
' O
_RARE_ I-GENE
. O

The O
_RARE_ I-GENE
- I-GENE
primed O
calves O
had O
increased O
serum I-GENE
IgG I-GENE
, O
_RARE_ I-GENE
IgG I-GENE
and O
IgA I-GENE
and O
increased O
_RARE_ I-GENE
_RARE_ I-GENE
in O
both O
_RARE_ I-GENE
fluids O
and O
serum I-GENE
following O
the O
SC O
dose O
of O
killed O
bacteria O
. O

Recent O
investigations O
have O
shown O
that O
_RARE_ I-GENE
rays O
can O
suppress O
the O
allergic O
contact O
dermatitis O
reaction O
completely O
and O
that O
_RARE_ I-GENE
cells O
, O
identified O
by O
_RARE_ I-GENE
antibodies I-GENE
and O
electron O
microscopy O
, O
_RARE_ I-GENE
from O
the O
_RARE_ I-GENE
at O
the O
same O
time O
. O

The O
elements O
responsible O
for O
glucocorticoid I-GENE
stimulation O
of O
ADH I-GENE
gene I-GENE
transcription I-GENE
appear O
to O
reside O
outside O
of O
this O
region O
. O

1 I-GENE
. O

The O
present O
studies O
compare O
the O
biochemical O
characteristics O
, O
_RARE_ I-GENE
_RARE_ I-GENE
reactions O
, O
and O
plasmid O
profiles O
of O
13 O
patient O
and O
_RARE_ I-GENE
environmental O
isolates O
of O
the O
organism O
. O

High O
values O
of O
both O
retinol I-GENE
and O
beta I-GENE
- I-GENE
_RARE_ I-GENE
were O
found O
in O
full I-GENE
fat O
_RARE_ I-GENE
and O
_RARE_ I-GENE
cream O
: O
from O
_RARE_ I-GENE
. O
0 O
( O
_RARE_ I-GENE
, O
_RARE_ I-GENE
- I-GENE
type I-GENE
) O
to O
_RARE_ I-GENE
. O
7 O
micrograms O
/ I-GENE
100 O
g O
( O
_RARE_ I-GENE
cream O
) O
and O
from O
86 I-GENE
. O
7 O
( O
_RARE_ I-GENE
, O
_RARE_ I-GENE
- I-GENE
type I-GENE
) O
to O
186 I-GENE
. O
5 I-GENE
micrograms O
/ I-GENE
100 O
g O
( O
_RARE_ I-GENE
cream O
) O
for O
all O
- I-GENE
trans O
retinol I-GENE
and O
total O
beta I-GENE
- I-GENE
_RARE_ I-GENE
, O
respectively O
. O

_RARE_ I-GENE
includes O
measures O
of O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
performance O
. O

These O
data O
_RARE_ I-GENE
the O
_RARE_ I-GENE
gene I-GENE
( O
_RARE_ I-GENE
) O
and O
a O
recurrent O
T I-GENE
- I-GENE
cell O
leukemia I-GENE
breakpoint I-GENE
( O
_RARE_ I-GENE
) O
in O
the O
marker O
sequence I-GENE
, O
on O
opposite O
sides O
of O
_RARE_ I-GENE
. O

A I-GENE
fine O
- I-GENE
structure O
deletion O
map O
of O
human I-GENE
chromosome O
_RARE_ I-GENE
: O
analysis O
of O
_RARE_ I-GENE
series O
hybrids O
. O

With O
respect O
to O
effective O
_RARE_ I-GENE
of O
platelets O
( O
_RARE_ I-GENE
) O
and O
the O
surface O
reactivity O
constant O
( O
K I-GENE
), O
less O
significant O
differences O
were O
found O
among O
artificial O
materials O
. O

The O
two O
most O
recent O
patients O
( O
35 O
and O
132 O
days O
) O
received O
only O
oral O
_RARE_ I-GENE
( O
75 O
mg O
X I-GENE
3 I-GENE
/ I-GENE
day O
) O
and O
aspirin I-GENE
( O
80 O
mg O
/ I-GENE
day O
) O
after O
the O
early I-GENE
recovery O
period O
( O
four O
- I-GENE
six O
days O
), O
resulting O
in O
normal O
prothrombin I-GENE
and O
partial O
thromboplastin I-GENE
times O
. O

_RARE_ I-GENE
- I-GENE
latency O
auditory O
evoked O
potentials O
( O
_RARE_ I-GENE
) O
were O
recorded O
in O
controls O
and O
patients O
with O
focal I-GENE
lesions O
in O
_RARE_ I-GENE
_RARE_ I-GENE
cortex O
. O

Most O
of O
them O
were O
situated O
at O
_RARE_ I-GENE
_RARE_ I-GENE
( O
13 O
cases O
). O

_RARE_ I-GENE
activity O
studies O
indicated O
that O
, O
at O
ten O
times O
_RARE_ I-GENE
, O
only O
penicillin I-GENE
had O
any O
significant O
activity O
against O
intracellular O
_RARE_ I-GENE
, O
reducing O
survival O
by O
28 O
%. O

Specifically O
, O
they O
were O
performed O
to O
determine O
whether O
detection O
of O
envelope I-GENE
phase O
_RARE_ I-GENE
was O
consistent O
with O
processing O
within O
a O
single O
channel O
in O
which O
the O
AM I-GENE
_RARE_ I-GENE
were O
_RARE_ I-GENE
added O
. O

Gel O
retardation O
assays O
combined O
with O
DNase I-GENE
I I-GENE
footprinting O
and O
_RARE_ I-GENE
_RARE_ I-GENE
interference O
showed O
that O
a O
nuclear I-GENE
factor I-GENE
from O
differentiated O
C2 I-GENE
myotubes O
and O
_RARE_ I-GENE
_RARE_ I-GENE
recognized O
a O
conserved O
A I-GENE
+ I-GENE
T I-GENE
- I-GENE
rich O
sequence I-GENE
within O
the O
peripheral O
activating I-GENE
region O
. O

Such O
transgenic O
plants O
should O
_RARE_ I-GENE
not O
only O
the O
mutational O
analysis O
of O
sequence I-GENE
elements O
within O
the O
replication O
origin O
region O
, O
but O
also O
the O
construction I-GENE
of O
a O
new O
generation O
of O
vectors O
for O
gene I-GENE
amplification O
in O
plants O
, O
based O
on O
a O
minimal I-GENE
virus I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
is O
no O
more O
difficult O
than O
dorsal O
_RARE_ I-GENE
, O
has O
less O
patient O
morbidity O
and O
fewer O
postoperative O
complications O
, O
and O
is O
more O
_RARE_ I-GENE
acceptable O
. O

Four O
full I-GENE
- I-GENE
thickness O
skin O
_RARE_ I-GENE
were O
made O
in O
the O
back O
of O
10 O
female O
pigs O
that O
treated O
twice O
a O
day O
for O
14 O
days O
with O
2 I-GENE
ml O
of O
epidermal I-GENE
growth I-GENE
factor I-GENE
( O
300 O
ng O
/ I-GENE
ml O
) O
or O
2 I-GENE
ml O
of O
_RARE_ I-GENE
' O
s O
lactate I-GENE
solution O
in O
a O
single O
- I-GENE
blind O
, O
randomized O
fashion O
. O

During O
challenge O
, O
_RARE_ I-GENE
was O
done O
when O
_RARE_ I-GENE
antibodies I-GENE
turned O
positive O
( O
mean O
0 O
. O
6 I-GENE
years O
, O
range O
0 O
. O
2 I-GENE
- I-GENE
2 I-GENE
. O
0 O
) O
or O
at O
the O
end O
of O
the O
two O
year O
study O
. O

The O
effect O
of O
iron O
intake O
on O
_RARE_ I-GENE
absorption O
throughout O
pregnancy O
, O
and O
on O
maternal I-GENE
and O
fetal O
_RARE_ I-GENE
status O
towards O
the O
end O
of O
pregnancy O
, O
was O
investigated O
in O
rats O
. O

The O
deduced O
protein I-GENE
sequence I-GENE
is O
characterized O
by O
a O
putative O
16 O
- I-GENE
residue O
amino O
- I-GENE
terminal I-GENE
signal I-GENE
peptide I-GENE
that O
is O
cleaved O
, O
resulting O
in O
a O
239 O
- I-GENE
residue O
polypeptide I-GENE
. O

Analysis O
of O
the O
rate O
constants O
indicated O
that O
the O
_RARE_ I-GENE
rate O
_RARE_ I-GENE
was O
approximately O
equal O
to O
the O
apparent O
degradation O
rate O
of O
the O
delta I-GENE
3 I-GENE
ester O
_RARE_ I-GENE
, O
and O
slower O
than O
the O
hydrolysis O
rate O
of O
the O
delta I-GENE
2 I-GENE
ester O
_RARE_ I-GENE
. O

A I-GENE
protocol O
is O
_RARE_ I-GENE
for O
the O
preparation O
and O
characterization O
of O
a O
quality O
control O
material O
( O
_RARE_ I-GENE
) O
containing O
intrinsic O
concentration O
of O
cadmium O
( O
Cd O
) O
( O
0 O
. O
8 O
microgram O
/ I-GENE
L I-GENE
) O
and O
lead O
( O
_RARE_ I-GENE
) O
( O
13 O
. O
4 I-GENE
micrograms O
/ I-GENE
dL O
) O
from O
bovine I-GENE
blood O
and O
an O
elevated O
_RARE_ I-GENE
containing O
Cd O
( O
5 I-GENE
. O
0 O
micrograms O
/ I-GENE
L I-GENE
), O
_RARE_ I-GENE
( O
Hg O
) O
( O
11 O
. O
2 I-GENE
micrograms O
/ I-GENE
L I-GENE
), O
and O
_RARE_ I-GENE
( O
34 O
. O
5 I-GENE
micrograms O
/ I-GENE
dL O
) O
from O
bovine I-GENE
blood O
_RARE_ I-GENE
with O
aqueous O
_RARE_ I-GENE
- I-GENE
solutions O
prepared O
with O
_RARE_ I-GENE
of O
Cd O
, O
Hg O
, O
and O
_RARE_ I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
are O
frequently O
used O
in O
the O
practice O
of O
laboratory O
medicine O
as O
well O
as O
outside O
the O
_RARE_ I-GENE
laboratories O
. O

The O
lowest O
detectable O
concentration O
was O
1 I-GENE
. O
0 O
ng O
/ I-GENE
ml O
in O
the O
serum I-GENE
. O

_RARE_ I-GENE
antibodies I-GENE
for O
_RARE_ I-GENE
_RARE_ I-GENE
and O
M I-GENE
. O
f I-GENE
. O
were O
negative O
. O

_RARE_ I-GENE
- I-GENE
72 O
( O
34 O
isolates O
), O
_RARE_ I-GENE
- I-GENE
73 O
( O
1 I-GENE
), O
_RARE_ I-GENE
- I-GENE
71 O
( O
2 I-GENE
) O
and O
_RARE_ I-GENE
- I-GENE
10 O
( O
2 I-GENE
) O
were O
found O
at O
_RARE_ I-GENE
around O
2000 O
m I-GENE
, O
3 I-GENE
of O
them O
in O
a O
single O
_RARE_ I-GENE
. O

_RARE_ I-GENE
experimental O
and O
clinical O
applications O
of O
plates O
, O
_RARE_ I-GENE
and O
spinal O
segmental O
replacement O
implants O
made O
of O
this O
composite O
material O
have O
shown O
good O
results O
so O
far O
. O

Significance O
of O
delta I-GENE
- I-GENE
_RARE_ I-GENE
acid I-GENE
analysis O
in O
clinical O
tests O

No O
changes O
were O
evident O
in O
the O
FR I-GENE
- I-GENE
task O
performance O
of O
controls O
that O
received O
daily O
saline O
injections O
. O

The O
antigen I-GENE
- I-GENE
specific I-GENE
_RARE_ I-GENE
antibody I-GENE
seems O
to O
be O
an O
index O
in O
evaluating O
immunotherapy O
_RARE_ I-GENE
. O

Although O
the O
fertility O
decline O
in O
the O
black O
population O
in O
the O
_RARE_ I-GENE
Delta I-GENE
between O
the O
late O
_RARE_ I-GENE
' O
s O
and O
early I-GENE
_RARE_ I-GENE
' O
s O
closely O
_RARE_ I-GENE
that O
of O
the O
national O
black O
population O
, O
it O
rose O
much O
more O
dramatically O
in O
the O
_RARE_ I-GENE
' O
s O
and O
_RARE_ I-GENE
' O
s O
to O
almost O
_RARE_ I-GENE
levels O
. O

According O
to O
their O
staining O
affinity O
for O
anti I-GENE
- I-GENE
T I-GENE
antibodies I-GENE
, O
the O
_RARE_ I-GENE
tissue I-GENE
cells O
were O
classified O
as O
T I-GENE
-, I-GENE
T I-GENE
+, I-GENE
T I-GENE
_RARE_ I-GENE
and O
T I-GENE
and O
the O
annual O
changes O
in O
the O
numbers O
of O
these O
cell O
populations O
, O
as O
well O
as O
in O
the O
volume O
occupied O
by O
the O
_RARE_ I-GENE
tissue I-GENE
, O
were O
calculated O
. O

_RARE_ I-GENE
( O
AMP I-GENE
) O
alone O
or O
with O
an O
_RARE_ I-GENE
( O
AMI O
) O
was O
the O
treatment O
in O
9 O
and O
16 O
cases O
, O
respectively O
. O

_RARE_ I-GENE
- I-GENE
3 I-GENE
, O
4 I-GENE
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
were O
_RARE_ I-GENE
by O
_RARE_ I-GENE
3 I-GENE
, O
4 I-GENE
- I-GENE
_RARE_ I-GENE
with O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
, O
while O
1 I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
3 I-GENE
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
were O
obtained O
in O
reactions O
of O
1 I-GENE
- I-GENE
_RARE_ I-GENE
with O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
. O

We O
investigated O
the O
incidence O
of O
congenital O
color O
deficiency O
among O
_RARE_ I-GENE
by O
the O
use O
of O
H I-GENE
- I-GENE
R I-GENE
- I-GENE
R I-GENE
_RARE_ I-GENE
plates O
. O

_RARE_ I-GENE
patients O
presenting O
to O
_RARE_ I-GENE
with O
non O
- I-GENE
Hodgkin O
' O
s O
lymphomas O
between O
_RARE_ I-GENE
and O
1986 O
, O
were O
reviewed O
. O

The O
relation O
between O
VE O
/ I-GENE
VO2 O
and O
Q I-GENE
/ I-GENE
VO2 O
showed O
a O
significant O
negative O
correlation O
( O
r O
= O
- I-GENE
0 O
. O
93 O
, O
p O
less O
than O
0 O
. O
01 O
). O

The O
differential O
diagnosis O
of O
both O
_RARE_ I-GENE
is O
based O
on O
the O
clinical O
course O
, O
_RARE_ I-GENE
and O
CT I-GENE
examination O
which O
along O
with O
modern O
_RARE_ I-GENE
treatment O
significantly O
modify O
hitherto O
used O
surgical O
therapy O
. O

_RARE_ I-GENE
filling O
consists O
in O
_RARE_ I-GENE
_RARE_ I-GENE
system O
directly O
at O
the O
_RARE_ I-GENE
zone O
after O
surgical O
approach O
. O

_RARE_ I-GENE
study O
of O
Japanese O
_RARE_ I-GENE
Heparin O
Sodium O
_RARE_ I-GENE
_RARE_ I-GENE

_RARE_ I-GENE
studies O
at O
the O
early I-GENE
relapse O
stage O
of O
this O
disease O
showed O
increased O
serum I-GENE
_RARE_ I-GENE
, O
IgA I-GENE
and O
IgM I-GENE
level O
with O
normal O
IgG I-GENE
and O
decrease O
of O
C3 I-GENE
and O
C4 I-GENE
. O

The O
maximum O
stress O
due O
to O
the O
_RARE_ I-GENE
examination O
of O
the O
composite O
was O
0 O
. O
74 O
kg O
/ I-GENE
mm2 O
at O
equilibrium O
of O
the O
water O
absorbed O
of O
the O
composite O
. O

Ischemic O
heart O
disease O
evaluated O
by O
exercise O
stress O
thallium O
- I-GENE
201 O
myocardial O
scintigraphy O
: O
a O
comparison O
of O
SPECT O
and O
_RARE_ I-GENE
' O
s O
eye O
display O

Sequence O
analysis O
of O
the O
47 O
- I-GENE
kilodalton I-GENE
major I-GENE
integral I-GENE
membrane I-GENE
_RARE_ I-GENE
of O
_RARE_ I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
consensus I-GENE
sequences I-GENE
for O
early I-GENE
and O
late O
regulatory I-GENE
elements O
were O
identified O
. O

An O
_RARE_ I-GENE
mutant I-GENE
, O
_RARE_ I-GENE
- I-GENE
2 I-GENE
, O
had O
a O
1 I-GENE
. O
6 I-GENE
- I-GENE
kbp O
insertion O
of O
S I-GENE
. O
_RARE_ I-GENE
DNA I-GENE
near O
the O
5 I-GENE
' O
end O
of O
these O
transcripts I-GENE
which O
by O
S1 I-GENE
analysis O
were O
shown O
to O
initiate O
within O
the O
host O
cell O
sequence I-GENE
. O

_RARE_ I-GENE
of O
a O
_RARE_ I-GENE
deletion O
strain O
and O
isolation O
of O
temperature O
- I-GENE
sensitive O
mutants I-GENE
. O

These O
data O
suggest O
that O
_RARE_ I-GENE
in O
type I-GENE
I I-GENE
renal O
tubular O
acidosis O
may O
be O
due O
to O
a O
defect O
in O
proximal I-GENE
_RARE_ I-GENE
function O
. O

_RARE_ I-GENE
chronic O
_RARE_ I-GENE
leukemia I-GENE
, O
acute O
myeloid O
leukemia I-GENE
, O
and O
thrombosis O
with O
protein I-GENE
C I-GENE
deficiency O
. O

_RARE_ I-GENE
visual O
_RARE_ I-GENE
without O
other O
_RARE_ I-GENE
have O
been O
reported O
for O
several O
hundred O
years O
. O

In O
the O
whole O
group O
, O
basal O
GH I-GENE
and O
_RARE_ I-GENE
- I-GENE
C I-GENE
levels O
decreased O
from O
a O
mean O
(+/- O
standard O
error O
of O
the O
mean O
) O
of O
52 O
. O
3 I-GENE
+/- O
12 O
. O
7 O
to O
11 O
. O
1 I-GENE
+/- O
6 I-GENE
. O
3 I-GENE
ng O
/ I-GENE
ml O
and O
from O
7 O
. O
6 I-GENE
+/- O
0 O
. O
7 O
to O
2 I-GENE
. O
5 I-GENE
+/- O
0 O
. O
5 I-GENE
U O
/ I-GENE
ml O
, O
respectively O
. O

_RARE_ I-GENE
of O
different O
criteria O
of O
cure O
revealed O
that O
19 O
patients O
( O
66 O
%) O
had O
basal O
GH I-GENE
levels O
below O
5 I-GENE
ng O
/ I-GENE
ml O
, O
17 O
patients O
( O
59 O
%) O
had O
normal O
_RARE_ I-GENE
- I-GENE
C I-GENE
values O
, O
16 O
patients O
( O
55 O
%) O
had O
complete O
GH I-GENE
suppression O
( O
less O
than O
1 I-GENE
ng O
/ I-GENE
ml O
) O
during O
_RARE_ I-GENE
, O
and O
13 O
patients O
( O
45 O
%) O
met I-GENE
the O
above O
- I-GENE
mentioned O
criteria O
with O
disappearance O
of O
the O
_RARE_ I-GENE
GH I-GENE
response O
to O
TRH I-GENE
/ I-GENE
GnRH I-GENE
test O
. O

It O
suggests O
a O
sequence I-GENE
of O
surgical O
planning O
that O
can O
prevent O
them O
and O
also O
offers O
ways O
of O
_RARE_ I-GENE
with O
the O
problems O
should O
they O
occur O
. O

In O
Rat I-GENE
- I-GENE
1a I-GENE
cells O
the O
expression O
of O
human I-GENE
c I-GENE
- I-GENE
jun I-GENE
mRNA I-GENE
was O
associated I-GENE
with O
the O
ability O
to O
clone O
in O
soft O
agarose O
and O
form O
tumors O
in O
nude O
mice O
. O

Furthermore O
, O
formation O
of O
_RARE_ I-GENE
of O
transformed O
_RARE_ I-GENE
by O
the O
c I-GENE
- I-GENE
jun I-GENE
/ I-GENE
ras I-GENE
combination O
was O
augmented O
3 I-GENE
- I-GENE
fold O
by O
the O
tumor I-GENE
promoter I-GENE
phorbol O
12 O
- I-GENE
_RARE_ I-GENE
13 O
- I-GENE
acetate O
. O

Platelet I-GENE
activating I-GENE
factor I-GENE
was O
given O
in O
six O
doses O
at O
15 O
minute O
intervals O
and O
airway O
response O
measured O
as O
change O
in O
partial O
expiratory O
flow O
at O
30 O
% O
of O
vital O
capacity O
( O
_RARE_ I-GENE
). O

There O
was O
no O
significant O
correlation O
between O
baseline O
_RARE_ I-GENE
_RARE_ I-GENE
and O
the O
maximal O
fall O
in O
_RARE_ I-GENE
after O
either O
the O
first O
( O
12 O
micrograms O
) O
or O
the O
second O
dose O
( O
24 O
micrograms O
) O
of O
platelet I-GENE
activating I-GENE
factor I-GENE
. O

Both O
_RARE_ I-GENE
and O
_RARE_ I-GENE
concentrations O
during O
the O
_RARE_ I-GENE
were O
the O
lowest O
in O
body O
_RARE_ I-GENE
, O
medium O
in O
controls O
, O
and O
the O
highest O
in O
obese O
men O
. O

_RARE_ I-GENE
_RARE_ I-GENE
: O
a O
family I-GENE
planning O
study O
. O

A I-GENE
0 O
. O
5 I-GENE
rating O
was O
_RARE_ I-GENE
to O
characterize O
subjects O
in O
whom O
mild O
cognitive O
impairment O
due O
to O
senile O
dementia O
of O
the O
Alzheimer I-GENE
type I-GENE
was O
suspected O
but O
was O
insufficient O
in O
degree O
to O
_RARE_ I-GENE
a O
diagnosis O
of O
definite O
dementia O
. O

An O
implant O
may O
release O
a O
drug O
either O
by O
diffusion O
concurrent O
with O
dissolution O
of O
the O
_RARE_ I-GENE
implant O
material O
without O
_RARE_ I-GENE
( O
Type O
A I-GENE
) O
or O
by O
_RARE_ I-GENE
involving O
_RARE_ I-GENE
( O
Type O
B I-GENE
). O

Although O
it O
is O
well O
known O
that O
calcium O
channel O
blockers O
can O
influence O
contraction O
of O
vascular I-GENE
smooth I-GENE
muscle O
, O
there O
is O
less O
knowledge O
on O
its O
effect O
on O
_RARE_ I-GENE
contraction O
coupling O
in O
the O
endocrine O
glands O
and O
more O
specifically O
on O
insulin I-GENE
and O
glucagon I-GENE
release O
. O

Many O
studies O
have O
_RARE_ I-GENE
out O
the O
possibility O
of O
" O
_RARE_ I-GENE
" O
organic O
factors I-GENE
in O
_RARE_ I-GENE
_RARE_ I-GENE
, O
detectable O
only O
by O
means O
of O
laboratory O
investigations O
: O
mild O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
selectively O
located O
at O
the O
site I-GENE
of O
the O
sexual O
arteries O
, O
venous O
_RARE_ I-GENE
, O
subclinical O
_RARE_ I-GENE
. O

The O
site I-GENE
- I-GENE
specific I-GENE
DNA I-GENE
inversion O
system O
_RARE_ I-GENE
encoded I-GENE
by O
the O
bacteriophage I-GENE
P1 I-GENE
consists O
of O
a O
_RARE_ I-GENE
, O
two O
inverted O
_RARE_ I-GENE
- I-GENE
over O
sites I-GENE
and O
a O
_RARE_ I-GENE
enhancer I-GENE
. O

The O
terminator O
region O
supported O
termination O
of O
transcripts I-GENE
initiated O
by O
RNA I-GENE
polymerase I-GENE
I I-GENE
in O
vivo O
. O

US O
- I-GENE
Doppler O
has O
recently O
_RARE_ I-GENE
attention O
as O
a O
_RARE_ I-GENE
method O
for O
the O
functional O
evaluation O
of O
_RARE_ I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
). O

Doppler O
echo O
in O
evaluating O
_RARE_ I-GENE
_RARE_ I-GENE
for O
dialysis O

_RARE_ I-GENE
_RARE_ I-GENE
, O
extension O
of O
the O
_RARE_ I-GENE
of O
the O
problems O
that O
can O
be O
addressed O
with O
this O
repair I-GENE
( O
including O
treatment O
of O
a O
distal O
_RARE_ I-GENE
_RARE_ I-GENE
) O
and O
the O
_RARE_ I-GENE
with O
which O
the O
_RARE_ I-GENE
procedure O
can O
be O
performed O
are O
the O
advantages O
that O
this O
operation O
has O
over O
other O
1 I-GENE
- I-GENE
stage O
distal O
_RARE_ I-GENE
_RARE_ I-GENE
. O

Following O
the O
patients O
during O
a O
course O
of O
therapy O
with O
a O
selective O
vasodilator O
calcium O
antagonist O
, O
the O
beta I-GENE
- I-GENE
adrenergic I-GENE
reflex O
vasodilation O
became O
substantially O
attenuated O
but O
was O
_RARE_ I-GENE
during O
a O
placebo O
course O
of O
therapy O
. O

The O
galactose I-GENE
transporter I-GENE
shows O
both O
sequence I-GENE
and O
structural O
homology I-GENE
with O
a O
superfamily I-GENE
of O
sugar I-GENE
transporters I-GENE
which O
includes O
the O
human I-GENE
HepG2 O
- I-GENE
erythrocyte I-GENE
and O
fetal O
muscle O
glucose O
transporters I-GENE
, O
the O
rat I-GENE
brain O
and O
liver O
glucose O
transporters I-GENE
, O
the O
Escherichia I-GENE
coli I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
, O
and O
the O
S I-GENE
. O
cerevisiae I-GENE
glucose O
, O
_RARE_ I-GENE
, O
and O
galactose I-GENE
transporters I-GENE
. O

Of O
110 I-GENE
previously O
untreated O
patients O
who O
had O
_RARE_ I-GENE
the O
study O
of O
protocol O
_RARE_ I-GENE
, O
96 O
were O
evaluable O
. O

There O
were O
3 I-GENE
/ I-GENE
32 O
( O
9 O
. O
4 I-GENE
per O
cent O
) O
adverse O
reactions O
( O
_RARE_ I-GENE
), O
and O
one O
case O
each O
of O
_RARE_ I-GENE
, O
_RARE_ I-GENE
and O
increased O
menstrual O
flow O
. O

More O
mRNA I-GENE
corresponding O
to O
_RARE_ I-GENE
and O
_RARE_ I-GENE
is O
detected O
than O
that O
corresponding O
to O
the O
distal O
genes I-GENE
, O
_RARE_ I-GENE
and O
_RARE_ I-GENE
. O

Tumor I-GENE
necrosis I-GENE
factor I-GENE
( O
TNF I-GENE
) O
is O
reported O
to O
cause O
a O
shock I-GENE
syndrome O
similar O
to O
that O
produced O
by O
endotoxin I-GENE
( O
LPS I-GENE
). O

The O
calcium O
requirement O
for O
_RARE_ I-GENE
storage O
of O
the O
cardiac O
_RARE_ I-GENE
. O

The O
_RARE_ I-GENE
cysteine I-GENE
residue O
of O
_RARE_ I-GENE
is O
located O
within O
the O
activation O
peptide I-GENE
region O
of O
the O
_RARE_ I-GENE
. O

The O
_RARE_ I-GENE
. O
8 O
gene I-GENE
has O
a O
strong O
codon O
usage O
_RARE_ I-GENE
which O
is O
strikingly O
different O
from O
that O
of O
the O
_RARE_ I-GENE
gene I-GENE
. O

Of O
the O
single O
- I-GENE
stranded I-GENE
DNA I-GENE
transformants O
, O
65 O
% O
resulted O
from O
replacement O
of O
the O
_RARE_ I-GENE
_RARE_ I-GENE
mutation I-GENE
by O
the O
exogenous O
wild I-GENE
- I-GENE
type I-GENE
allele I-GENE
. O

The O
results O
strongly O
support O
the O
notion O
that O
the O
_RARE_ I-GENE
- I-GENE
binding I-GENE
sites I-GENE
and O
the O
_RARE_ I-GENE
protein I-GENE
are O
important O
for O
normal O
ARS I-GENE
function O
as O
an O
origin O
of O
replication O
. O

On O
the O
basis O
of O
S1 I-GENE
nuclease I-GENE
protection O
analysis O
of O
RNA I-GENE
preparations O
from O
several O
mouse I-GENE
tissues O
, O
both O
_RARE_ I-GENE
and O
divergent O
genes I-GENE
showed O
similar O
levels O
of O
expression O
but O
did O
show O
some O
specificity O
in O
start O
site I-GENE
utilization O
. O

Four O
out O
of O
10 O
patients O
showed O
clinical O
improvement O
according O
to O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
, O
pain O
score O
, O
_RARE_ I-GENE
and O
CRP I-GENE
. O

62 O
: O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
, O
1987 O
). O

With O
both O
wild I-GENE
- I-GENE
type I-GENE
and O
the O
mutant I-GENE
enzymes O
, O
ATP I-GENE
activates O
both O
[ O
14C O
] O
Asp I-GENE
in O
equilibrium O
N I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
L I-GENE
- I-GENE
aspartate I-GENE
( O
C I-GENE
- I-GENE
Asp I-GENE
) O
and O
the O
[ O
32P O
] O
_RARE_ I-GENE
phosphate I-GENE
( O
C I-GENE
- I-GENE
P I-GENE
) O
in O
equilibrium O
_RARE_ I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
rates O
for O
the O
original O
treatment O
group O
were O
84 O
. O
5 I-GENE
% O
and O
57 O
. O
6 I-GENE
% O
at O
12 O
and O
21 O
months O
, O
respectively O
; O
for O
the O
delayed O
treatment O
group O
, O
78 O
. O
8 O
% O
and O
64 O
. O
6 I-GENE
% O
at O
12 O
and O
21 O
months O
, O
respectively O
, O
and O
78 O
. O
8 O
% O
and O
47 O
. O
5 I-GENE
% O
at O
12 O
and O
21 O
months O
, O
respectively O
, O
for O
77 O
subjects O
with O
AIDS O
and O
93 O
. O
0 O
% O
and O
71 O
. O
8 O
%, O
respectively O
, O
for O
50 O
subjects O
with O
AIDS O
- I-GENE
related I-GENE
complex I-GENE
in O
the O
original O
treatment O
group O
. O

Mapping O
results O
suggested O
that O
the O
complementation O
group O
identified O
by O
these O
mutants I-GENE
is O
allelic O
to O
the O
_RARE_ I-GENE
alpha I-GENE
1 I-GENE
mutation I-GENE
identified O
previously O
. O

The O
products I-GENE
of O
genes I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
are O
proposed O
to O
participate O
in O
the O
_RARE_ I-GENE
of O
_RARE_ I-GENE
monophosphate O
. O

After O
the O
application O
of O
RS I-GENE
86 I-GENE
, O
REM O
latency O
was O
shortened O
in O
all O
groups O
under O
investigation O
. O

Hybridization O
analysis O
showed O
that O
the O
size O
of O
the O
mRNA I-GENE
is O
about O
1 I-GENE
. O
4 I-GENE
kilobases O
. O

_RARE_ I-GENE
treatment O
with O
_RARE_ I-GENE
- I-GENE
CSF I-GENE

The O
R I-GENE
. O
_RARE_ I-GENE
_RARE_ I-GENE
promoter I-GENE
but O
not O
the O
K I-GENE
. O
pneumoniae I-GENE
_RARE_ I-GENE
promoter I-GENE
showed O
sigma I-GENE
54 I-GENE
- I-GENE
dependent I-GENE
methylation O
protection O
of O
guanine I-GENE
residues O
at O
- I-GENE
14 O
, O
- I-GENE
25 O
and O
- I-GENE
26 O
, O
the O
most O
conserved O
nucleotides O
characteristic O
of O
sigma I-GENE
54 I-GENE
- I-GENE
dependent I-GENE
promoters I-GENE
. O

_RARE_ I-GENE
clinical O
symptoms O
of O
the O
disease O
were O
defined O
in O
this O
group O
of O
patients O
. O

Recently O
, O
an O
alternatively O
spliced O
form O
of O
c I-GENE
- I-GENE
myb I-GENE
- I-GENE
encoded I-GENE
mRNA I-GENE
has O
been O
identified O
in O
murine I-GENE
cells O
containing O
either O
normal O
or O
rearranged I-GENE
c I-GENE
- I-GENE
myb I-GENE
genes I-GENE
. O

_RARE_ I-GENE
clinical O
analysis O
revealed O
lower O
hematocrit O
and O
hemoglobin I-GENE
, O
and O
elevated O
_RARE_ I-GENE
and O
alkaline I-GENE
phosphatase I-GENE
in O
the O
treated O
group O
. O

To O
assess O
the O
health O
significance O
of O
the O
early I-GENE
renal O
changes O
after O
chronic O
exposure O
to O
cadmium O
, O
23 O
workers O
removed O
from O
exposure O
because O
of O
the O
discovery O
of O
an O
increased O
urinary O
excretion O
of O
beta I-GENE
2 I-GENE
- I-GENE
microglobulin I-GENE
or O
retinol I-GENE
binding I-GENE
protein I-GENE
, O
or O
both O
, O
have O
been O
examined O
once O
a O
year O
for O
five O
years O
. O

In O
order O
to O
study O
the O
structural O
and O
functional O
organization O
of O
the O
eukaryotic I-GENE
_RARE_ I-GENE
, O
we O
have O
started O
to O
isolate O
and O
characterize O
nucleolar I-GENE
components O
of O
the O
yeast I-GENE
Saccharomyces I-GENE
cerevisiae I-GENE
. O

A I-GENE
transcription I-GENE
factor I-GENE
exclusion O
assay O
was O
used O
to O
show O
that O
the O
_RARE_ I-GENE
mutation I-GENE
affects O
two O
distinct O
stages O
in O
transcription I-GENE
: O
one O
prior O
to O
and O
one O
after O
stable O
complex I-GENE
formation O
; O
and O
that O
these O
effects O
are O
mediated O
by O
a O
component O
of O
the O
stable O
complex I-GENE
. O

_RARE_ I-GENE
and O
the O
skin O
. O

These O
adverse O
effects O
usually O
_RARE_ I-GENE
with O
time O
. O

The O
cytosolic I-GENE
glutathione I-GENE
S I-GENE
- I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
, O
EC I-GENE
2 I-GENE
. O
5 I-GENE
. O
1 I-GENE
. O
18 O
) O
are O
a O
superfamily I-GENE
of O
dimeric I-GENE
isoenzymes I-GENE
which O
_RARE_ I-GENE
the O
conjugation O
of O
_RARE_ I-GENE
substrates O
with O
glutathione I-GENE
. O

Furthermore O
, O
the O
3 I-GENE
'- O
untranslated O
regions O
of O
_RARE_ I-GENE
display O
a O
marked O
degree O
of O
homology I-GENE
to O
the O
3 I-GENE
' O
region O
of O
the O
rat I-GENE
_RARE_ I-GENE
gene I-GENE
, O
while O
this O
region O
of O
_RARE_ I-GENE
displays O
marked O
homology I-GENE
to O
the O
corresponding O
region O
of O
the O
rat I-GENE
_RARE_ I-GENE
gene I-GENE
. O

_RARE_ I-GENE
IV I-GENE
: O
primary O
_RARE_ I-GENE
with O
the O
lateral O
_RARE_ I-GENE
and O
the O
second O
_RARE_ I-GENE
as O
secondary O
_RARE_ I-GENE
. O

The O
incidence O
of O
fetal O
breathing O
movements O
( O
06 O
. O
00 O
- I-GENE
10 O
. O
00 O
h O
) O
decreased O
with O
increasing O
gestational O
age O
while O
fetal O
arterial O
concentrations O
of O
plasma I-GENE
_RARE_ I-GENE
increased O
significantly O
over O
the O
same O
period O
of O
gestation O
. O

During O
the O
first O
3 I-GENE
min O
of O
recovery O
, O
plasma I-GENE
potassium O
fell O
rapidly O
in O
_RARE_ I-GENE
of O
nearly O
unchanged O
blood O
acidosis O
and O
significantly O
decreasing O
_RARE_ I-GENE
concentration O
. O

The O
present O
data O
also O
suggest O
that O
when O
compared O
to O
the O
systemic O
vascular I-GENE
_RARE_ I-GENE
, O
the O
pulmonary O
vascular I-GENE
_RARE_ I-GENE
is O
less O
responsive I-GENE
to O
bolus O
administration O
of O
ET I-GENE
- I-GENE
1 I-GENE
. O

In O
comparison O
with O
normal O
pregnant O
women O
and O
normal O
non O
- I-GENE
pregnant O
women O
, O
women O
with O
_RARE_ I-GENE
showed O
an O
increase O
in O
heart O
rate O
, O
suggesting O
an O
increased O
peripheral O
sympathetic O
tone O
, O
and O
an O
initial O
_RARE_ I-GENE
in O
renal O
function O
as O
shown O
by O
the O
increase O
in O
serum I-GENE
uric O
acid I-GENE
and O
reduction O
in O
sodium O
excretion O
and O
total O
and O
fractional O
calcium O
excretion O
at O
any O
given O
level O
of O
sodium O
excretion O
. O

We O
have O
examined O
the O
role O
of O
two O
recombination O
- I-GENE
and O
repair I-GENE
- I-GENE
defective O
mutations O
, O
_RARE_ I-GENE
and O
_RARE_ I-GENE
, O
on O
direct O
repeat I-GENE
recombination O
in O
transcriptionally O
active O
and O
inactive O
sequences I-GENE
. O

The O
encoded I-GENE
protein I-GENE
has O
a O
leader O
sequence I-GENE
of O
27 O
amino O
acids O
. O

On O
the O
other O
hand O
, O
knowledge O
of O
the O
_RARE_ I-GENE
of O
Parkinson O
' O
s O
disease O
is O
necessary O
in O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
, O
since O
only O
_RARE_ I-GENE
consistent O
with O
the O
epidemiological O
profile O
_RARE_ I-GENE
_RARE_ I-GENE
testing O
. O

The O
_RARE_ I-GENE
of O
drug O
action O
. O

_RARE_ I-GENE
2 I-GENE
showed O
the O
least O
dye O
penetration O
but O
not O
statistically O
less O
than O
the O
_RARE_ I-GENE
bond O
/ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
combination O
. O

A I-GENE
combination O
of O
cisplatin O
and O
5 I-GENE
- I-GENE
fluorouracil O
, O
both O
administered O
4 I-GENE
days O
continuously O
as O
infusion O
, O
was O
assessed O
in O
advanced O
head I-GENE
and O
neck O
cancer O
. O

_RARE_ I-GENE
plasma I-GENE
concentrations O
remained O
unchanged O
except O
for O
patients O
transferred O
from O
1 I-GENE
. O
5 I-GENE
to O
2 I-GENE
. O
0 O
g O
daily O
to O
_RARE_ I-GENE
mg O
twice O
daily O
; O
in O
these O
patients O
plasma I-GENE
concentrations O
increased O
from O
1 I-GENE
. O
83 O
+/- O
0 O
. O
87 O
to O
2 I-GENE
. O
50 O
+/- O
0 O
. O
89 I-GENE
micrograms O
/ I-GENE
l O
( O
p O
less O
than O
0 O
. O
01 O
). O

Diagnosis O
of O
primary O
_RARE_ I-GENE
_RARE_ I-GENE
in O
a O
blood O
donor O
with O
elevated O
serum I-GENE
alanine I-GENE
aminotransferase I-GENE
. O

When O
statistically O
analyzed O
in O
various O
_RARE_ I-GENE
, O
the O
obtained O
average O
sedimentation O
coefficients O
and O
_RARE_ I-GENE
profiles O
supported O
the O
following O
conclusions O
: O
( O
a O
) O
loss O
of O
proteoglycan I-GENE
aggregation O
and O
_RARE_ I-GENE
is O
confirmed O
to O
be O
a O
primary O
sign O
of O
cartilage O
matrix I-GENE
degradation O
; O
( O
b I-GENE
) O
higher O
S I-GENE
values O
for O
_RARE_ I-GENE
of O
the O
high O
weight O
( O
_RARE_ I-GENE
)- I-GENE
bearing O
areas O
and O
lower O
values O
for O
those O
of O
the O
low O
weight O
( O
_RARE_ I-GENE
)- I-GENE
bearing O
areas O
were O
a O
typical O
finding O
in O
normal O
cartilage O
samples O
; O
( O
c I-GENE
) O
inversion O
of O
this O
pattern O
was O
indicative O
of O
matrix I-GENE
degradation O
, O
suggesting O
that O
the O
_RARE_ I-GENE
regions O
are O
more O
affected O
than O
the O
_RARE_ I-GENE
- I-GENE
bearing O
areas O
; O
( O
d O
) O
the O
average O
S I-GENE
value O
distribution O
across O
cartilage O
thickness O
tended O
to O
_RARE_ I-GENE
the O
corresponding O
proteoglycan I-GENE
content O
versus O
distance O
from O
_RARE_ I-GENE
surface O
; O
and O
( O
e O
) O
the O
_RARE_ I-GENE
cartilage O
layer O
had O
, O
in O
most O
cases O
, O
the O
smallest O
amount O
of O
aggregates O
while O
the O
highest O
average O
_RARE_ I-GENE
was O
observed O
at O
the O
middle I-GENE
zone O
of O
the O
normal O
samples O
. O

A I-GENE
significant O
relationship O
existed O
during O
the O
evolution O
of O
the O
disease O
between O
CRS I-GENE
/ I-GENE
_RARE_ I-GENE
and O
gas O
exchange I-GENE
parameters O
( O
_RARE_ I-GENE
and O
a O
/ I-GENE
_RARE_ I-GENE
ratio O
) O
( O
P I-GENE
less O
than O
0 O
. O
01 O
), O
but O
gas O
exchange I-GENE
improved O
earlier O
than O
lung O
_RARE_ I-GENE
. O

_RARE_ I-GENE
points O
measured O
were O
_RARE_ I-GENE
( O
30 O
- I-GENE
day O
) O
myocardial O
infarction O
( O
MI O
) O
rate O
and O
death O
. O

The O
predicted O
molecular O
weight O
of O
the O
_RARE_ I-GENE
encoded I-GENE
by O
ORF1 O
is O
33 O
_RARE_ I-GENE
( O
kDa I-GENE
). O

Thus O
RV O
O2 O
demand O
fell O
when O
_RARE_ I-GENE
O2 O
supply O
was O
reduced O
, O
although O
a O
flow O
reserve O
was O
available O
. O

An O
alternative O
method O
of O
_RARE_ I-GENE
is O
proposed O
based O
on O
_RARE_ I-GENE
a O
small I-GENE
fraction O
of O
_RARE_ I-GENE
_RARE_ I-GENE
flow O
for O
3 I-GENE
consecutive O
_RARE_ I-GENE
. O

_RARE_ I-GENE
chromatography O
with O
_RARE_ I-GENE
detection O
( O
_RARE_ I-GENE
/ I-GENE
AD O
) O
is O
used O
to O
determine O
_RARE_ I-GENE
acid I-GENE
produced O
from O
the O
metabolism O
or O
base O
hydrolysis O
of O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
in O
_RARE_ I-GENE
and O
soybean I-GENE
oil O
. O

The O
_RARE_ I-GENE
is O
removed O
, O
mobile O
phase O
solvent O
is O
added O
, O
and O
_RARE_ I-GENE
are O
injected O
onto O
a O
_RARE_ I-GENE
- I-GENE
1 I-GENE
liquid O
chromatographic O
column O
; O
_RARE_ I-GENE
acid I-GENE
is O
separated O
from O
_RARE_ I-GENE
compounds O
and O
detected O
at O
an O
applied O
potential O
of O
+ I-GENE
1 I-GENE
. O
25 O
V I-GENE
, O
using O
an O
_RARE_ I-GENE
_RARE_ I-GENE
detector O
in O
the O
oxidation O
mode O
. O

Primer O
extension O
experiments O
indicated O
that O
the O
transcription I-GENE
initiation I-GENE
site I-GENE
mapped O
to O
a O
position O
on O
gene I-GENE
IV I-GENE
that O
was O
analogous O
to O
that O
reported O
for O
the O
structurally O
similar O
P I-GENE
- I-GENE
_RARE_ I-GENE
gene I-GENE
. O

Significantly O
, O
the O
polymerase I-GENE
chain I-GENE
reaction O
results O
demonstrated O
that O
gene I-GENE
IV I-GENE
transcripts I-GENE
were O
associated I-GENE
with O
hepatic I-GENE
_RARE_ I-GENE
fractions O
, O
indicating O
their O
active O
utilization O
in O
this O
tissue I-GENE
. O

_RARE_ I-GENE
of O
the O
survey O
of O
work O
_RARE_ I-GENE
: O
a O
profile O
measure O
of O
the O
type I-GENE
A I-GENE
behaviour O
pattern O
. O

Only O
one O
ADR O
was O
related I-GENE
_RARE_ I-GENE
to O
_RARE_ I-GENE
therapy O
. O

HIV I-GENE
_RARE_ I-GENE
and O
the O
AIDS O
epidemic O
. O

From O
day O
30 O
after O
_RARE_ I-GENE
, O
the O
_RARE_ I-GENE
- I-GENE
group O
had O
significantly O
lower O
serum I-GENE
_RARE_ I-GENE
levels O
, O
which O
_RARE_ I-GENE
the O
low O
degree O
of O
_RARE_ I-GENE
damage O
in O
these O
animals O
. O

The O
corresponding O
inhibition O
of O
acid I-GENE
phosphatase I-GENE
activity O
in O
control O
male O
and O
female O
guinea O
pigs O
was O
15 O
. O
91 O
% O
and O
20 O
. O
33 O
% O
respectively O
. O

Its O
clinical O
and O
_RARE_ I-GENE
characteristics O
. O

_RARE_ I-GENE
( O
_RARE_ I-GENE
= O
40 I-GENE
mm O
Hg O
) O
_RARE_ I-GENE
drive O
increased O
significantly O
( O
p O
less O
than O
0 O
. O
05 O
) O
in O
six O
subjects O
( O
Type O
1 I-GENE
response O
) O
and O
decreased O
substantially O
in O
the O
others O
( O
Type O
2 I-GENE
response O
); O
with O
hypercapnia O
, O
the O
changes O
in O
drive O
were O
attenuated O
in O
both O
groups O
. O

_RARE_ I-GENE
changes O
in O
( O
type I-GENE
II I-GENE
) O
_RARE_ I-GENE
glomerulonephritis O
_RARE_ I-GENE
_RARE_ I-GENE
: O
a O
histopathological O
report O
. O

Chronic O
dose O
effects O
of O
methyl O
_RARE_ I-GENE
on O
_RARE_ I-GENE
: O
cholinesterase I-GENE
and O
_RARE_ I-GENE
. O

The O
titer O
of O
anti I-GENE
HSV I-GENE
type I-GENE
1 I-GENE
and O
anti I-GENE
HSV I-GENE
type I-GENE
2 I-GENE
antibodies I-GENE
in O
the O
mothers O
' O
and O
cord O
blood O
was O
determined O
and O
compared O
. O

_RARE_ I-GENE
weight O
and O
kidney O
- I-GENE
to O
- I-GENE
body O
weight O
ratio O
were O
significantly O
elevated O
at O
the O
highest O
dose O
level O
after O
10 O
weeks O
and O
at O
the O
two O
higher O
dose O
levels O
after O
15 O
weeks O
of O
exposure O
. O

_RARE_ I-GENE
variation O
in O
HLA I-GENE
- I-GENE
B I-GENE
and O
HLA I-GENE
- I-GENE
C I-GENE
sequences I-GENE
and O
the O
evolution O
of O
the O
HLA I-GENE
- I-GENE
B I-GENE
alleles I-GENE
. O

A I-GENE
method O
for O
determining O
optimal O
development O
conditions O
by O
summary O
oxygen O
consumption O

_RARE_ I-GENE
were O
more O
positive O
about O
their O
physical O
fitness O
than O
women O
. O

_RARE_ I-GENE
_RARE_ I-GENE
was O
also O
carried O
out O
in O
_RARE_ I-GENE
of O
the O
patients O
. O

In O
cerebrospinal O
fluid O
, O
an O
_RARE_ I-GENE
catalytic O
concentration O
above O
0 O
. O
15 O
mu I-GENE
_RARE_ I-GENE
/ I-GENE
L I-GENE
strongly O
suggests O
tuberculous O
meningitis O
in O
patients O
older O
than O
7 O
years O
( O
sensitivity O
1 I-GENE
. O
00 O
, O
specificity O
0 O
. O
99 O
and O
efficiency O
0 O
. O
99 O
). O

_RARE_ I-GENE
contains O
_RARE_ I-GENE
anatomical O
data O
_RARE_ I-GENE
arranged O
in O
a O
_RARE_ I-GENE
- I-GENE
like I-GENE
manner O
reflecting O
structural O
and O
functional O
relationships O
. O

_RARE_ I-GENE
- I-GENE
over O
: O
an O
alternative O
method O
for O
_RARE_ I-GENE
_RARE_ I-GENE
spermatozoa O
. O

_RARE_ I-GENE
washout O
: O
increasing O
a O
microvascular O
free O
flap O
tolerance O
to O
ischemia O
. O

Similarly O
, O
the O
sequence I-GENE
of O
the O
U2 I-GENE
RNA I-GENE
region O
shown O
to O
be O
involved O
in O
pre I-GENE
- I-GENE
mRNA I-GENE
branchpoint O
recognition I-GENE
in O
yeast I-GENE
, O
and O
_RARE_ I-GENE
conserved O
in O
metazoan I-GENE
U2 I-GENE
RNAs I-GENE
, O
was O
_RARE_ I-GENE
divergent O
in O
_RARE_ I-GENE
. O

It O
is O
striking O
that O
the O
active O
CHO O
spacer O
promoter I-GENE
_RARE_ I-GENE
the O
otherwise O
_RARE_ I-GENE
_RARE_ I-GENE
that O
metazoan I-GENE
RNA I-GENE
polymerase I-GENE
I I-GENE
promoters I-GENE
all O
have O
a O
G I-GENE
residue O
at O
position O
- I-GENE
16 O
. O

A I-GENE
raised O
amplitude O
of O
the O
aggregation O
of O
plates O
and O
a O
decrease O
in O
the O
threshold O
of O
their O
sensitivity O
to O
ADP I-GENE
were O
established O
in O
the O
persons O
with O
types O
_RARE_ I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
and O
in O
_RARE_ I-GENE
without O
_RARE_ I-GENE
. O

Significant O
_RARE_ I-GENE
differences O
are O
_RARE_ I-GENE
for O
both O
selected O
_RARE_ I-GENE
and O
soft O
tissue I-GENE
profile O
variables O
. O

The O
author O
provides O
a O
_RARE_ I-GENE
for O
an O
_RARE_ I-GENE
view O
and O
presents O
a O
case O
in O
which O
post O
- I-GENE
surgical O
_RARE_ I-GENE
were O
successfully O
treated O
, O
using O
_RARE_ I-GENE
developed O
by O
the O
_RARE_ I-GENE
Research O
Institute O
. O

The O
relative O
toxicity O
of O
nickel O
oxide I-GENE
( O
_RARE_ I-GENE
), O
nickel O
sulfate I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
. O
_RARE_ I-GENE
), O
and O
nickel O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
was O
studied O
in O
_RARE_ I-GENE
/ I-GENE
N I-GENE
rats O
and O
_RARE_ I-GENE
mice O
after O
inhalation O
exposure O
for O
6 I-GENE
hr O
/ I-GENE
day O
, O
5 I-GENE
days O
/ I-GENE
week O
, O
for O
13 O
weeks O
. O

_RARE_ I-GENE
_RARE_ I-GENE
and O
routine O
immunohistochemical O
studies O
of O
a O
cervical O
_RARE_ I-GENE
in O
a O
32 O
year O
old O
woman O
initially O
suggested O
a O
_RARE_ I-GENE
lymphoma O
, O
but O
_RARE_ I-GENE
staining O
for O
_RARE_ I-GENE
esterase I-GENE
established O
the O
correct O
diagnosis O
. O

From O
the O
National O
_RARE_ I-GENE
of O
Health O
. O

Molecular O
cloning O
and O
_RARE_ I-GENE
of O
the O
two O
homologous O
genes I-GENE
coding O
for O
nitrate I-GENE
reductase I-GENE
in O
tobacco I-GENE
. O

In O
the O
final O
model O
, O
grade O
( O
p O
= O
0 O
. O
_RARE_ I-GENE
), O
peritoneal O
_RARE_ I-GENE
results O
( O
p O
= O
0 O
. O
_RARE_ I-GENE
), O
progesterone I-GENE
receptor I-GENE
status O
( O
p O
= O
0 O
. O
_RARE_ I-GENE
), O
and O
age O
as O
a O
continuous O
variable O
( O
p O
= O
0 O
. O
_RARE_ I-GENE
) O
were O
most O
closely O
associated I-GENE
with O
disease O
- I-GENE
free O
survival O
. O

In O
contrast O
, O
despite O
external O
radiation O
therapy O
, O
brain O
metastases O
proved O
fatal O
. O

COUP I-GENE
transcription I-GENE
factor I-GENE
is O
a O
member O
of O
the O
steroid I-GENE
receptor I-GENE
superfamily I-GENE
. O

In O
Experiment O
2 I-GENE
, O
we O
again O
used O
classification O
, O
but O
the O
fixed O
standard O
75 O
was O
not O
at O
the O
center I-GENE
of O
the O
range O
of O
target O
numbers O
( O
20 O
, O
21 O
, O
_RARE_ I-GENE

_RARE_ I-GENE
clones O
containing O
both O
_RARE_ I-GENE
sequences I-GENE
were O
identified O
, O
and O
restriction I-GENE
mapping O
showed O
them O
to O
be O
less O
than O
15 O
kb O
apart O
. O

The O
oxygen O
uptake O
( O
VO2 O
), O
carbon O
dioxide O
output O
( O
_RARE_ I-GENE
), O
respiratory O
rate O
( O
_RARE_ I-GENE
), O
minute O
ventilation O
( O
VE O
), O
alveolar O
ventilation O
( O
VA O
), O
alveolar O
oxygen O
pressure O
( O
_RARE_ I-GENE
), O
and O
VE O
/ I-GENE
VO2 O
ratio O
were O
higher O
in O
the O
cows O
, O
while O
the O
tidal O
volume O
( O
VT O
) O
and O
physiological O
_RARE_ I-GENE
space O
( O
_RARE_ I-GENE
) O
were O
larger O
in O
the O
horses O
. O

_RARE_ I-GENE
damage O
was O
not O
observed O
in O
any O
controls O
but O
was O
in O
all O
tissues O
exposed O
to O
_RARE_ I-GENE
. O

Among O
_RARE_ I-GENE
patients O
the O
maternal I-GENE
mortality O
rate O
was O
0 O
. O
32 O
and O
among O
_RARE_ I-GENE
patients O
11 O
. O
13 O
per O
1000 O
_RARE_ I-GENE
. O

The O
present O
study O
_RARE_ I-GENE
whether O
prostaglandins O
" O
_RARE_ I-GENE
" O
the O
gastric O
mucosa O
against O
hemorrhage O
- I-GENE
induced O
stress O
ulceration O
by O
assessing O
the O
influence O
of O
16 O
, O
16 O
- I-GENE
dimethyl O
prostaglandin I-GENE
E2 I-GENE
( O
16 O
, O
16 O
- I-GENE
_RARE_ I-GENE
PGE2 O
) O
on O
gross O
and O
microscopic O
lesion O
formation O
, O
_RARE_ I-GENE
tissue I-GENE
pH O
, O
H I-GENE
+ I-GENE
back O
- I-GENE
diffusion O
, O
and O
mucosal I-GENE
blood O
flow O
in O
rat I-GENE
gastric O
mucosa O
exposed O
to O
luminal O
acid I-GENE
( O
100 O
mM O
_RARE_ I-GENE
) O
during O
hemorrhagic O
shock I-GENE
( O
13 O
ml O
/ I-GENE
kg O
for O
20 O
min O
). O

_RARE_ I-GENE
characterized O
include O
( O
i O
) O
abundant O
_RARE_ I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
transcripts I-GENE
; O
( O
ii O
) O
less O
abundant O
_RARE_ I-GENE
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
transcripts I-GENE
and O
( O
iii O
) O
a O
very O
rare O
ORF I-GENE
_RARE_ I-GENE
transcript I-GENE
. O

_RARE_ I-GENE
, O
the O
results O
are O
similar O
for O
the O
two O
species O
: O
Both O
rhesus I-GENE
monkey I-GENE
and O
man O
have O
_RARE_ I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
, O
which O
cross O
at O
approximately O
the O
same O
time O
in O
the O
dark O
and O
at O
approximately O
the O
same O
background O
_RARE_ I-GENE
. O

Evidence O
from O
the O
structure O
of O
a O
number O
of O
cDNA I-GENE
clones O
, O
as O
well O
as O
S1 I-GENE
nuclease I-GENE
and O
primer O
extension O
studies O
supports O
the O
hypothesis O
that O
the O
_RARE_ I-GENE
gene I-GENE
contains O
at O
least O
two O
mRNA I-GENE
transcription I-GENE
start O
points O
that O
define O
two O
putative O
regulatory I-GENE
domains I-GENE
. O

At O
each O
level O
of O
PaO2 O
we O
obtained O
simultaneous O
measures O
of O
arterial O
and O
venous O
blood O
gases O
, O
venous O
lactate I-GENE
concentration O
, O
and O
changes O
in O
the O
relative O
concentrations O
of O
inorganic O
phosphate I-GENE
, O
_RARE_ I-GENE
, O
and O
ATP I-GENE
measured O
with O
_RARE_ I-GENE
magnetic O
resonance O
spectroscopy O
. O

The O
transcription I-GENE
initiation I-GENE
site I-GENE
was O
determined O
by O
S1 I-GENE
nuclease I-GENE
mapping O
. O

_RARE_ I-GENE
biopsies O
and O
plasma I-GENE
oestradiol O
( O
E2 I-GENE
) O
and O
progesterone I-GENE
( O
P4 I-GENE
) O
levels O
in O
23 O
patients O
were O
evaluated O
during O
26 O
replacement O
therapy O
cycles O
for O
premature O
ovarian O
failure O
. O

The O
mobility I-GENE
of O
the O
upper O
and O
lower O
_RARE_ I-GENE
under O
load O
was O
investigated O
in O
relation O
to O
the O
_RARE_ I-GENE
contact O
and O
_RARE_ I-GENE
_RARE_ I-GENE
. O

A I-GENE
larval I-GENE
albumin I-GENE
- I-GENE
like I-GENE
protein I-GENE
was O
not O
detectable O
by O
silver O
staining O
in O
serum I-GENE
of O
_RARE_ I-GENE
before O
the O
beginning O
of O
_RARE_ I-GENE
at O
stage O
48 O
. O

_RARE_ I-GENE
, O
a O
pain O
- I-GENE
_RARE_ I-GENE
group O
( O
PT O
= O
29 O
_RARE_ I-GENE
) O
tolerated O
the O
entire O
3 I-GENE
- I-GENE
min O
test O
( O
means O
= O
180 O
+/- O
0 O
sec O
), O
while O
a O
pain O
- I-GENE
sensitive O
group O
( O
PS I-GENE
= O
13 O
_RARE_ I-GENE
) O
averaged O
only O
50 O
. O
31 O
+/- O
20 O
. O
81 O
sec O
of O
the O
cold O
- I-GENE
pressor O
test O
( O
t I-GENE
= O
16 O
. O
75 O
, O
P I-GENE
less O
than O
0 O
. O
0001 O
), O
replicating I-GENE
our O
earlier O
studies O
. O

This O
suggested O
that O
_RARE_ I-GENE
liver O
class I-GENE
I I-GENE
ADH I-GENE
is O
of O
the O
same O
ancestral O
lineage O
as O
the O
human I-GENE
ADH I-GENE
- I-GENE
beta I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
( O
i O
. O
e O
. O
without O
_RARE_ I-GENE
and O
/ I-GENE
or O
_RARE_ I-GENE
) O
is O
a O
frequent O
finding O
. O

Each O
individual O
_RARE_ I-GENE
25 O
_RARE_ I-GENE
in O
about O
5 I-GENE
minutes O
, O
at O
an O
intensity O
level O
calculated O
at O
_RARE_ I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
the O
circadian O
rhythm O
of O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
in O
Syrian I-GENE
hamsters O
at O
plasma I-GENE
concentrations O
( O
0 O
. O
59 O
- I-GENE
0 O
. O
74 O
mM O
) O
that O
also O
cause O
toxic O
weight O
loss O
. O

_RARE_ I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
, O
using O
_RARE_ I-GENE
methylene O
_RARE_ I-GENE
, O
were O
obtained O
at O
zero O
, O
six O
, O
and O
12 O
weeks O
after O
fracture O
. O

On O
admission O
to O
our O
_RARE_ I-GENE
in O
_RARE_ I-GENE
, O
1987 O
, O
the O
patient O
was O
_RARE_ I-GENE
and O
had O
_RARE_ I-GENE
_RARE_ I-GENE
, O
the O
impairment O
of O
all O
sensory O
modalities O
below O
the O
level O
of O
_RARE_ I-GENE
10 O
and O
urinary O
disturbance O
. O

_RARE_ I-GENE
and O
_RARE_ I-GENE

The O
nature O
of O
the O
process O
formed O
by O
the O
successive O
_RARE_ I-GENE
of O
this O
_RARE_ I-GENE
was O
studied O
in O
8 O
patients O
with O
a O
history O
of O
symptomatic O
_RARE_ I-GENE
AF I-GENE
. O

This O
would O
have O
had O
the O
effect O
of O
positioning O
the O
genes I-GENE
currently O
on O
the O
long O
arm O
adjacent O
to O
the O
_RARE_ I-GENE
_RARE_ I-GENE
, O
perhaps O
resulting O
in O
a O
" O
position O
effect O
" O
on O
transcription I-GENE
of O
these O
genes I-GENE
. O

Initial O
experience O
with O
a O
_RARE_ I-GENE
controlled O
current O
based O
_RARE_ I-GENE
. O

_RARE_ I-GENE
was O
strongly O
associated I-GENE
with O
the O
_RARE_ I-GENE
of O
_RARE_ I-GENE
- I-GENE
bound O
and O
albumin I-GENE
- I-GENE
bound O
estradiol O
, O
and O
inversely O
associated I-GENE
with O
sex I-GENE
hormone I-GENE
binding I-GENE
globulin I-GENE
( O
SHBG I-GENE
) O
levels O
and O
the O
proportion O
of O
SHBG I-GENE
- I-GENE
bound O
estradiol O
. O

_RARE_ I-GENE
nuclear I-GENE
ribonucleoprotein I-GENE
( O
hnRNP I-GENE
) O
core I-GENE
protein I-GENE
A1 I-GENE
is O
a O
major I-GENE
component O
of O
mammalian I-GENE
hnRNP I-GENE
40 I-GENE
S I-GENE
particles O
. O

_RARE_ I-GENE
cholinesterase I-GENE
activity O
of O
_RARE_ I-GENE
great O
_RARE_ I-GENE
, O
_RARE_ I-GENE
_RARE_ I-GENE
and O
black O
- I-GENE
_RARE_ I-GENE
night O
- I-GENE
_RARE_ I-GENE
. O
inhibition O
of O
brain O
cholinesterase I-GENE
( O
_RARE_ I-GENE
) O
activity O
in O
birds O
is O
often O
used O
to O
_RARE_ I-GENE
exposure O
or O
death O
from O
_RARE_ I-GENE
or O
_RARE_ I-GENE
_RARE_ I-GENE
. O

The O
effect O
of O
zinc I-GENE
deficiency O
on O
_RARE_ I-GENE
_RARE_ I-GENE
in O
the O
liver O
, O
spleen O
, O
kidney O
, O
pancreas O
and O
_RARE_ I-GENE
was O
investigated O
in O
the O
control O
and O
zinc I-GENE
- I-GENE
deficient O
rats O
at O
17 O
days O
and O
20 O
days O
of O
pregnancy O
. O

Our O
findings O
support O
the O
view O
of O
a O
_RARE_ I-GENE
_RARE_ I-GENE
of O
the O
cardiac O
involvement O
in O
_RARE_ I-GENE
patients O
. O

_RARE_ I-GENE
cells O
to O
43 I-GENE
degrees O
C I-GENE
decreased O
the O
amount O
of O
newly O
synthesized O
rRNA I-GENE
to O
less O
than O
5 I-GENE
% O
of O
the O
control O
level O
and O
led O
to O
greater O
than O
95 O
% O
inhibition O
of O
transcription I-GENE
termination O
at O
a O
region O
_RARE_ I-GENE
to O
_RARE_ I-GENE
nucleotides O
downstream O
of O
the O
3 I-GENE
' O
end O
of O
28S I-GENE
rRNA I-GENE
, O
with O
readthrough O
_RARE_ I-GENE
into O
the O
next O
transcription I-GENE
unit I-GENE
. O

Deletion O
analysis O
showed O
that O
the O
NF I-GENE
- I-GENE
_RARE_ I-GENE
, O
NF I-GENE
- I-GENE
_RARE_ I-GENE
, O
and O
AP I-GENE
- I-GENE
1 I-GENE
sequences I-GENE
are O
each O
necessary O
for O
full I-GENE
enhancer I-GENE
activity O
. O

_RARE_ I-GENE
swelling O
was O
observed O
in O
2 I-GENE
patients O
who O
developed O
complete O
lesions O
. O

_RARE_ I-GENE
' O
s O
syndrome O
: O
reports O
of O
7 O
cases O
in O
the O
period O
1982 O
- I-GENE
1987 O

When O
two O
- I-GENE
dimensional O
polyacrylamide O
gel O
electrophoretic O
patterns O
of O
[ O
35S I-GENE
] O
methionine O
- I-GENE
labeled O
proteins I-GENE
secreted O
from O
cells O
infected O
with O
parental O
and O
recombinant I-GENE
viruses O
were O
compared O
, O
a O
_RARE_ I-GENE
missing O
from O
the O
latter O
corresponded O
in O
molecular O
_RARE_ I-GENE
and O
_RARE_ I-GENE
point O
with O
that O
predicted O
from O
the O
_RARE_ I-GENE
ORF I-GENE
. O

_RARE_ I-GENE
is O
used O
to O
set O
such O
NMR O
_RARE_ I-GENE
parameters O
as O
the O
delay O
and O
duration O
of O
_RARE_ I-GENE
_RARE_ I-GENE
and O
receive O
_RARE_ I-GENE
, O
_RARE_ I-GENE
phase O
, O
sampling O
times O
, O
and O
such O
imaging O
parameters O
as O
_RARE_ I-GENE
pulse O
shape O
and O
gradient O
_RARE_ I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
( O
24 O
patients O
) O
was O
defined O
as O
arthritis O
associated I-GENE
, O
but O
not O
necessarily O
_RARE_ I-GENE
, O
with O
a O
typical O
_RARE_ I-GENE
rash O
, O
or O
arthritis O
plus O
at O
least O
3 I-GENE
of O
4 I-GENE
minor O
criteria O
: O
_RARE_ I-GENE
, O
_RARE_ I-GENE
_RARE_ I-GENE
, O
psoriasis O
- I-GENE
like I-GENE
rash O
, O
or O
family I-GENE
history O
of O
psoriasis O
. O

Hence O
follows O
_RARE_ I-GENE
' O
s O
demand O
to O
_RARE_ I-GENE
out O
appropriate O
importance O
to O
the O
_RARE_ I-GENE
. O

The O
author O
gives O
an O
account O
of O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
and O
_RARE_ I-GENE
effects O
of O
some O
calcium O
antagonists O
, O
and O
their O
clinical O
application O
is O
discussed O
. O

A I-GENE
correlation O
coefficient O
was O
used O
for O
assessing O
the O
similarity O
of O
each O
map O
pattern O
with O
the O
normal O
mean O
_RARE_ I-GENE
map O
. O

A I-GENE
hospital O
- I-GENE
based O
study O
of O
the O
relationship O
between O
retained O
placenta O
and O
_RARE_ I-GENE
in O
_RARE_ I-GENE
cows O
. O

This O
indicates O
that O
lipid O
peroxidation O
may O
be O
involved O
in O
the O
development O
of O
senile O
_RARE_ I-GENE
and O
, O
as O
a O
direct O
consequence O
of O
retinal O
damage O
, O
also O
in O
the O
pathogenesis O
of O
_RARE_ I-GENE
in O
diabetes O
and O
in O
severe O
_RARE_ I-GENE
. O

The O
histological O
_RARE_ I-GENE
was O
_RARE_ I-GENE
in O
68 O
cases O
: O
12 O
G1 I-GENE
, O
39 O
G2 I-GENE
, O
17 O
_RARE_ I-GENE
; O
_RARE_ I-GENE
spread O
was O
found O
in O
20 O
/ I-GENE
54 I-GENE
cases O
( O
37 O
%). O

_RARE_ I-GENE
was O
significantly O
more O
often O
associated I-GENE
with O
ASA I-GENE
group O
( O
91 O
%) O
vs O
46 O
% O
at O
AT I-GENE
and O
in O
only O
16 O
% O
at O
_RARE_ I-GENE
group O
. O

A I-GENE
value O
of O
1 I-GENE
. O
1 I-GENE
l O
/ I-GENE
kg O
was O
used O
for O
V I-GENE
in O
_RARE_ I-GENE
all O
single O
sample O
estimates O
of O
clearance O
( O
CL O
), O
and O
a O
value O
of O
4 I-GENE
. O
3 I-GENE
l O
/ I-GENE
kg O
was O
used O
to O
_RARE_ I-GENE
single O
sample O
estimates O
of O
clearance O
of O
plasma I-GENE
_RARE_ I-GENE
drug O
( O
_RARE_ I-GENE
). O

The O
_RARE_ I-GENE
kidney O
: O
a O
model O
of O
chronic O
_RARE_ I-GENE
in O
humans O
. O

_RARE_ I-GENE
is O
_RARE_ I-GENE
by O
an O
oxidative O
pathway O
to O
stable O
, O
_RARE_ I-GENE
end O
products I-GENE
, O
_RARE_ I-GENE
acid I-GENE
( O
_RARE_ I-GENE
) O
and O
bromide O
( O
Br O
_RARE_ I-GENE
and O
by O
_RARE_ I-GENE
pathways O
to O
Br O
- I-GENE
and O
inorganic O
fluoride O
( O
F I-GENE
_RARE_ I-GENE

The O
values O
were O
consistently O
lower O
( O
P I-GENE
less O
than O
0 O
. O
01 O
) O
during O
summer O
( O
3 I-GENE
. O
79 O
+/- O
0 O
. O
13 O
micrograms O
/ I-GENE
100 O
ml O
), O
as O
compared O
to O
_RARE_ I-GENE
( O
5 I-GENE
. O
06 O
+/- O
0 O
. O
27 O
). O

These O
results O
suggest O
that O
_RARE_ I-GENE
- I-GENE
S I-GENE
- I-GENE
S I-GENE
are O
prone O
to O
_RARE_ I-GENE
_RARE_ I-GENE
breathing O
patterns O
at O
high O
altitude O
, O
which O
is O
associated I-GENE
with O
the O
development O
of O
_RARE_ I-GENE
, O
but O
it O
was O
not O
possible O
to O
determine O
whether O
these O
abnormal O
breathing O
patterns O
are O
a O
cause O
or O
an O
effect O
of O
_RARE_ I-GENE
. O

_RARE_ I-GENE
( O
i O
. O
v I-GENE
.) O
induced O
a O
dose O
- I-GENE
dependent I-GENE
increase O
of O
cardiac O
output O
at O
0 O
. O
16 O
- I-GENE
0 O
. O
64 O
mg O
/ I-GENE
kg O
, O
biphasic O
changes O
at O
1 I-GENE
. O
28 O
and O
2 I-GENE
. O
56 O
mg O
/ I-GENE
kg O
and O
a O
marked O
decrease O
and O
subsequent O
slight O
increase O
at O
a O
large O
dose O
of O
5 I-GENE
. O
12 O
mg O
/ I-GENE
kg O
. O

It O
was O
possible O
to O
_RARE_ I-GENE
the O
animals O
into O
high O
and O
low O
responders O
according O
to O
the O
pattern O
of O
_RARE_ I-GENE
immune I-GENE
response O
. O

_RARE_ I-GENE
rate O
( O
HR O
), O
rectal O
temperature O
( O
_RARE_ I-GENE
), O
blood O
pressure O
, O
temperature O
and O
relative O
_RARE_ I-GENE
changes O
_RARE_ I-GENE
_RARE_ I-GENE
were O
measured O
on O
18 O
_RARE_ I-GENE
_RARE_ I-GENE
( O
mean O
age O
29 O
. O
4 I-GENE
+/- O
7 O
. O
4 I-GENE
yr O
, O
VO2 O
max O
41 O
. O
4 I-GENE
+ I-GENE
8 O
. O
8 O
ml O
kg O
- I-GENE
1 I-GENE
min O
- I-GENE
1 I-GENE
) O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
' O
s O
_RARE_ I-GENE
( O
SU I-GENE
) O
or O
_RARE_ I-GENE
, O
_RARE_ I-GENE
resistant O
, O
_RARE_ I-GENE
_RARE_ I-GENE
with O
self O
contained O
breathing O
apparatus O
( O
_RARE_ I-GENE
). O

The O
clinical O
tolerance O
and O
pharmacokinetics O
of O
_RARE_ I-GENE
_RARE_ I-GENE
( O
sodium O
( O
_RARE_ I-GENE
, O
_RARE_ I-GENE
)- I-GENE
6 I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
)- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
2 I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
2 I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
3 I-GENE
- I-GENE
_RARE_ I-GENE
), O
a O
new O
_RARE_ I-GENE
antibiotic O
, O
have O
been O
studied O
after O
giving O
a O
single O
i O
. O
v I-GENE
. O
dose O
of O
4 I-GENE
mg O
. O
kg O
- I-GENE
1 I-GENE
to O
ten O
healthy O
male O
volunteers O
. O

DNA I-GENE
blot O
hybridization O
suggests O
that O
the O
rat I-GENE
genome O
may O
contain O
more O
than O
one O
gene I-GENE
encoding O
_RARE_ I-GENE
transfer I-GENE
protein I-GENE
. O

We O
use O
the O
term O
corticosteroid I-GENE
- I-GENE
dependent I-GENE
IA O
to O
_RARE_ I-GENE
to O
the O
serious O
problem O
of O
chronic O
IA O
requiring O
maintenance O
prednisone O
therapy O
. O

Another O
segment O
of O
_RARE_ I-GENE
(- O
296 O
to O
- I-GENE
_RARE_ I-GENE
), O
also O
_RARE_ I-GENE
enhancer I-GENE
function O
, O
contained O
tandem O
repeated O
sequences I-GENE
( O
DR I-GENE
- I-GENE
A1 I-GENE
and O
DR I-GENE
- I-GENE
A2 I-GENE
). O

1 I-GENE
-( O
1 I-GENE
- I-GENE
_RARE_ I-GENE
) O
_RARE_ I-GENE
( O
1 I-GENE
- I-GENE
NP I-GENE
) O
has O
been O
reported O
to O
have O
serotonin I-GENE
antagonist O
properties O
at O
the O
5 I-GENE
- I-GENE
HT2 I-GENE
subtype I-GENE
of O
receptor I-GENE
, O
and O
it O
has O
been O
suggested O
that O
it O
may O
have O
agonist O
actions O
at O
the O
5 I-GENE
- I-GENE
_RARE_ I-GENE
site I-GENE
. O

1 I-GENE
-( O
m I-GENE
- I-GENE
_RARE_ I-GENE
) O
_RARE_ I-GENE
( O
_RARE_ I-GENE
, O
0 O
. O
1 I-GENE
- I-GENE
3 I-GENE
. O
0 O
mg O
/ I-GENE
kg O
) O
and O
1 I-GENE
-( O
m I-GENE
- I-GENE
_RARE_ I-GENE
) O
_RARE_ I-GENE
( O
_RARE_ I-GENE
, O
0 O
. O
1 I-GENE
- I-GENE
3 I-GENE
. O
0 O
mg O
/ I-GENE
kg O
), O
both O
thought O
to O
act O
primarily O
at O
5 I-GENE
- I-GENE
_RARE_ I-GENE
sites I-GENE
, O
also O
decreased O
responding O
and O
this O
effect O
was O
blocked O
by O
_RARE_ I-GENE
and O
by O
1 I-GENE
- I-GENE
NP I-GENE
, O
but O
not O
by O
_RARE_ I-GENE
. O

The O
characteristic O
feature O
of O
liver O
and O
spleen O
MP I-GENE
function O
in O
patients O
with O
_RARE_ I-GENE
associated I-GENE
with O
HBsAg I-GENE
_RARE_ I-GENE
consisted O
in O
the O
lack O
of O
the O
_RARE_ I-GENE
reaction O
on O
the O
part O
of O
spleen O
MP I-GENE
, O
which O
was O
likely O
to O
be O
connected O
with O
_RARE_ I-GENE
of O
long O
_RARE_ I-GENE
and O
depletion O
of O
the O
MP I-GENE
system O
due O
to O
permanent O
antigenic I-GENE
stimulation O
of O
HBsAg I-GENE
. O

Changes O
in O
_RARE_ I-GENE
oxidase I-GENE
activity O
in O
patients O
with O
circulatory O
failure O

A I-GENE
_RARE_ I-GENE
and O
water O
( O
1 I-GENE
: O
1 I-GENE
, O
v I-GENE
/ I-GENE
v I-GENE
) O
solution O
effectively O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
. O

The O
_RARE_ I-GENE
and O
_RARE_ I-GENE
activities O
of O
the O
_RARE_ I-GENE
_RARE_ I-GENE
( O
ES O
_RARE_ I-GENE
) O
as O
well O
as O
its O
effects O
on O
gastric O
mucosal I-GENE
blood O
flow O
and O
mucus O
_RARE_ I-GENE
, O
were O
determined O
in O
the O
rat I-GENE
. O

The O
human I-GENE
immunodeficiency I-GENE
virus I-GENE
type I-GENE
1 I-GENE
( O
HIV I-GENE
- I-GENE
1 I-GENE
) O
preferentially O
_RARE_ I-GENE
CD4 I-GENE
+ I-GENE
T I-GENE
lymphocytes O
and O
may O
exist O
as O
a O
latent I-GENE
provirus O
within O
these O
cells O
for O
extended O
periods O
. O

_RARE_ I-GENE
_RARE_ I-GENE
was O
observed O
in O
biopsy O
specimens O
with O
_RARE_ I-GENE
. O

We O
have O
utilized O
the O
human I-GENE
_RARE_ I-GENE
heavy I-GENE
chain I-GENE
( O
_RARE_ I-GENE
) O
gene I-GENE
as O
a O
model O
system O
in O
studies O
designed O
to O
elucidate O
the O
molecular O
events O
involved O
in O
regulating O
inducible I-GENE
gene I-GENE
expression O
during O
normal O
human I-GENE
T I-GENE
- I-GENE
cell O
activation O
. O

A I-GENE
cDNA I-GENE
encoding O
the O
NF I-GENE
- I-GENE
_RARE_ I-GENE
enhancer I-GENE
binding I-GENE
protein I-GENE
has O
been O
cloned O
by O
screening O
a O
lambda I-GENE
gt11 O
cDNA I-GENE
library O
with O
a O
_RARE_ I-GENE
oligonucleotide I-GENE
corresponding O
to O
the O
NF I-GENE
- I-GENE
_RARE_ I-GENE
recognition I-GENE
sequence I-GENE
. O

_RARE_ I-GENE
right O
ventricular O
hypertrophy O
was O
seen O
in O
4 I-GENE
, O
and O
_RARE_ I-GENE
hypertrophy O
in O
5 I-GENE
patients O
. O

The O
two O
IL6 I-GENE
mRNA I-GENE
species O
are O
generated O
by O
alternative O
polyadenylation O
at O
sites I-GENE
separated O
by O
a O
distance O
of O
1 I-GENE
. O
2 I-GENE
kilobases O
. O

Sequencing O
analysis O
revealed O
that O
the O
0 O
. O
54 I-GENE
- I-GENE
and O
0 O
. O
4 I-GENE
- I-GENE
kb O
fragments I-GENE
are O
identical O
except O
for O
150 O
nucleotides O
missing O
at O
the O
5 I-GENE
' O
region O
of O
the O
0 O
. O
4 I-GENE
- I-GENE
kb O
fragment I-GENE
. O

The O
mature O
protein I-GENE
also O
contains O
a O
cysteine I-GENE
- I-GENE
rich O
, O
highly O
hydrophilic O
region O
homologous O
to O
the O
_RARE_ I-GENE
serine I-GENE
protease I-GENE
inhibitors O
( O
residues O
76 I-GENE
- I-GENE
132 O
). O

_RARE_ I-GENE
_RARE_ I-GENE
components O
were O
consistently O
modulated O
only O
in O
the O
superficial O
_RARE_ I-GENE
responses O
in O
_RARE_ I-GENE
_RARE_ I-GENE
, O
which O
exhibited O
enhanced O
amplitude O
during O
the O
_RARE_ I-GENE
phase O
. O

Experiments O
on O
23 O
white O
rats O
and O
10 O
guinea O
pigs O
have O
shown O
that O
_RARE_ I-GENE
indomethacin O
- I-GENE
induced O
inhibition O
of O
prostaglandins O
synthesis O
prevented O
development O
of O
pulmonary O
_RARE_ I-GENE
, O
evoked O
by O
heterologous O
serum I-GENE
in O
rats O
and O
by O
vagotomy O
in O
guinea O
pigs O
. O

On O
the O
other O
hand O
, O
lack O
of O
conservation O
of O
the O
membrane I-GENE
attachment O
sequence I-GENE
arginine I-GENE
- I-GENE
glycine O
- I-GENE
_RARE_ I-GENE
acid I-GENE
_RARE_ I-GENE
against O
its O
functional O
importance O
in O
_RARE_ I-GENE
. O

_RARE_ I-GENE
- I-GENE
and O
later O
- I-GENE
_RARE_ I-GENE
cows O
were O
randomly O
assigned O
after O
each O
_RARE_ I-GENE
to O
_RARE_ I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
in O
multiple O
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
. O

Within O
each O
lobe O
, O
the O
PA I-GENE
dispersion O
was O
up O
to O
10 O
cmH2O O
at O
_RARE_ I-GENE
of O
90 O
l O
/ I-GENE
min O
; O
when O
flow O
decreased O
, O
PA I-GENE
at O
all O
sites I-GENE
decreased O
, O
as O
did O
the O
_RARE_ I-GENE
dispersion O
. O

The O
system O
consisted O
of O
the O
intact O
canine O
heart O
connected O
to O
a O
_RARE_ I-GENE
that O
operated O
as O
the O
modulated O
_RARE_ I-GENE
_RARE_ I-GENE
. O

In O
order O
to O
identify O
and O
_RARE_ I-GENE
the O
basic I-GENE
CT I-GENE
_RARE_ I-GENE
of O
interstitial O
pneumonia O
, O
_RARE_ I-GENE
- I-GENE
pathologic O
_RARE_ I-GENE
study O
was O
performed O
using O
_RARE_ I-GENE
and O
fixed O
lungs O
from O
autopsy O
and O
surgery O
. O

The O
disease O
_RARE_ I-GENE
an O
atypical O
course O
; O
with O
early I-GENE
jaundice O
syndrome O
, O
severe O
_RARE_ I-GENE
and O
late O
appearance O
of O
_RARE_ I-GENE
. O

The O
transcription I-GENE
factor I-GENE
Sp1 I-GENE
bound O
to O
eight O
sites I-GENE
, O
as O
demonstrated O
by O
footprinting O
assays O
and O
gel O
shift O
analysis O
with O
purified O
Sp1 I-GENE
. O

The O
combination O
_RARE_ I-GENE
64 O
micrograms O
- I-GENE
_RARE_ I-GENE
4 I-GENE
micrograms O
prevents O
the O
frequent O
secondary O
_RARE_ I-GENE
seen O
after O
6 I-GENE
hours O
with O
the O
antibiotics O
used O
alone O
. O

With O
a O
sample O
of O
mothers O
of O
healthy O
infants O
, O
all O
three O
_RARE_ I-GENE
of O
the O
revised O
instrument O
, O
_RARE_ I-GENE
- I-GENE
R I-GENE
, O
had O
acceptable O
levels O
of O
internal O
_RARE_ I-GENE
at O
7 O
, O
30 O
, O
and O
90 O
days O
_RARE_ I-GENE
, O
and O
stability O
across O
_RARE_ I-GENE
. O

Since O
_RARE_ I-GENE
, O
the O
use O
of O
saline O
- I-GENE
_RARE_ I-GENE
red I-GENE
cells O
( O
_RARE_ I-GENE
) O
has O
been O
_RARE_ I-GENE
to O
_RARE_ I-GENE
_RARE_ I-GENE
after O
transfusion O
to O
patients O
with O
_RARE_ I-GENE
. O

In O
the O
group O
of O
_RARE_ I-GENE
statistically O
significant O
correlation O
was O
found O
between O
_RARE_ I-GENE
PGF2 O
alpha I-GENE
and O
histamine O
values O
( O
r O
= O
0 O
. O
_RARE_ I-GENE
, O
p O
less O
than O
0 O
. O
05 O
). O

Acute O
experiments O
on O
_RARE_ I-GENE
- I-GENE
anesthetized O
cats O
( O
50 O
mg O
/ I-GENE
kg O
) O
were O
employed O
to O
investigate O
the O
effect O
of O
1 I-GENE
T I-GENE
_RARE_ I-GENE
magnetic O
field O
( O
_RARE_ I-GENE
) O
on O
neuromuscular O
system O
of O
the O
leg O
. O

No O
significant O
differences O
were O
found O
between O
the O
_RARE_ I-GENE
and O
the O
_RARE_ I-GENE
. O

The O
_RARE_ I-GENE
of O
formed O
cysts O
and O
growth I-GENE
rates O
were O
monthly O
estimated O
and O
analyzed O
_RARE_ I-GENE
by O
_RARE_ I-GENE
for O
5 I-GENE
_RARE_ I-GENE
cultures O
of O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
grown O
for O
2 I-GENE
years O
under O
laboratory O
conditions O
, O
_RARE_ I-GENE
as O
constant O
as O
possible O
from O
the O
view O
point O
of O
environmental O
temperature O
( O
24 O
+/- O
1 I-GENE
degree O
C I-GENE
), O
_RARE_ I-GENE
( O
25 O
_RARE_ I-GENE
m I-GENE
- I-GENE
2 I-GENE
s O
- I-GENE
1 I-GENE
), O
and O
artificial O
_RARE_ I-GENE
. O

A I-GENE
genomic O
DNA I-GENE
clone O
encoding O
_RARE_ I-GENE
( O
_RARE_ I-GENE
), O
a O
cysteine I-GENE
proteinase I-GENE
inhibitor I-GENE
( O
_RARE_ I-GENE
) O
of O
rice I-GENE
, O
was O
isolated O
from O
a O
lambda I-GENE
_RARE_ I-GENE
phage I-GENE
library O
constructed O
with O
_RARE_ I-GENE
partial O
_RARE_ I-GENE
of O
rice I-GENE
chromosomal I-GENE
DNA I-GENE
, O
by O
screening O
with O
an O
_RARE_ I-GENE
cDNA I-GENE
as O
a O
probe O
. O

The O
use O
of O
an O
appropriate O
solution O
of O
methylene O
blue O
( O
0 O
. O
2 I-GENE
% O
in O
0 O
. O
9 O
M I-GENE
NaCl O
for O
15 O
min O
) O
permits O
the O
staining O
of O
_RARE_ I-GENE
areas O
and O
_RARE_ I-GENE
, O
and O
their O
early I-GENE
diagnosis O
. O

_RARE_ I-GENE
limits O
( O
to O
10 O
micrograms O
/ I-GENE
kg O
) O
were O
detectable O
, O
but O
with O
lower O
reliability O
( O
60 O
%). O

Instead O
, O
some O
small I-GENE
negative O
effects O
are O
observed O
, O
particularly O
involving O
effects O
of O
_RARE_ I-GENE
' O
_RARE_ I-GENE
on O
the O
_RARE_ I-GENE
_RARE_ I-GENE
of O
employed O
_RARE_ I-GENE
. O

This O
in O
turn I-GENE
will O
further O
enhance O
the O
role O
of O
_RARE_ I-GENE
- I-GENE
analysis O
in O
_RARE_ I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
clinical O
questions O
. O

In O
one O
_RARE_ I-GENE
patient O
visual O
improvement O
was O
obtained O
while O
the O
abnormal O
GH I-GENE
secretion O
remained O
unaltered O
. O

In O
contrast O
, O
the O
_RARE_ I-GENE
+ I-GENE
DBP I-GENE
side O
showed O
large O
amounts O
of O
bone O
formation O
, O
and O
bone O
almost O
_RARE_ I-GENE
the O
implant O
. O

The O
_RARE_ I-GENE
of O
presence O
or O
absence O
of O
neuroblastoma O
were O
compared O
between O
131I O
- I-GENE
_RARE_ I-GENE
imaging O
and O
several O
tumor I-GENE
markers O
. O

The O
congenital O
forms O
( O
7 O
cases O
) O
all O
occurred O
in O
female O
infants O
and O
involved O
the O
mucosa O
_RARE_ I-GENE
either O
the O
anterior O
_RARE_ I-GENE
of O
the O
_RARE_ I-GENE
or O
the O
_RARE_ I-GENE
. O

_RARE_ I-GENE
studies O
revealed O
positive O
staining O
for O
_RARE_ I-GENE
protein I-GENE
in O
all O
the O
_RARE_ I-GENE
cell O
tumors O
of O
the O
adult O
but O
in O
none O
of O
the O
congenital O
_RARE_ I-GENE
cell O
_RARE_ I-GENE
. O

We O
also O
found O
that O
the O
same O
males O
, O
_RARE_ I-GENE
in O
different O
years O
on O
the O
same O
_RARE_ I-GENE
, O
had O
significantly O
larger O
_RARE_ I-GENE
in O
the O
years O
they O
had O
_RARE_ I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
- I-GENE
enhanced O
antigen I-GENE
gene I-GENE
is O
_RARE_ I-GENE
conserved O
and O
expressed O
at O
late O
stages O
of O
_RARE_ I-GENE
. O

In O
rats O
bearing O
_RARE_ I-GENE
- I-GENE
256 O
- I-GENE
_RARE_ I-GENE
4 I-GENE
- I-GENE
_RARE_ I-GENE
was O
effective O
.( O
ABSTRACT O
TRUNCATED O
AT I-GENE
250 O
WORDS O
) O

_RARE_ I-GENE
the O
_RARE_ I-GENE
limb O
abolished O
the O
ectopic O
_RARE_ I-GENE
, O
restored O
the O
slow O
emptying O
of O
_RARE_ I-GENE
to O
the O
more O
rapid O
rate O
found O
in O
the O
_RARE_ I-GENE
dogs O
( O
t1 O
/ I-GENE
2 I-GENE
: O
_RARE_ I-GENE
_RARE_ I-GENE
, O
72 O
+/- O
15 O
minutes O
; O
_RARE_ I-GENE
, O
43 I-GENE
+/- O
9 O
minutes O
; O
p O
greater O
than O
0 O
. O
05 O
) O
and O
did O
not O
change O
emptying O
of O
_RARE_ I-GENE
. O

The O
treatments O
were O
60 O
mg O
t I-GENE
. O
i O
. O
d O
. O
and O
120 O
mg O
t I-GENE
. O
i O
. O
d O
. O
during O
14 O
days O
' O
treatment O
, O
with O
the O
last O
dose O
pulsed O
with O
1 I-GENE
. O
85 O
MBq O
[ O
14C O
] O
diltiazem O
. O

The O
_RARE_ I-GENE
_RARE_ I-GENE
capillaries O
were O
_RARE_ I-GENE
and O
_RARE_ I-GENE
with O
each O
other O
to O
form O
a O
relatively O
_RARE_ I-GENE
network O
which O
extended O
over O
the O
entire O
surface O
of O
both O
ventricles O
. O

The O
examination O
must O
include O
T1 O
and O
T2 I-GENE
sequences I-GENE
and O
scans O
in O
three O
_RARE_ I-GENE
. O

A I-GENE
great O
_RARE_ I-GENE
of O
information O
is O
available O
on O
the O
morphology O
of O
the O
_RARE_ I-GENE
in O
various O
animal O
species O
, O
as O
well O
as O
on O
its O
neuronal O
distribution O
and O
relationships O
with O
the O
cerebral O
cortex O
and O
other O
nuclei O
. O

Low O
- I-GENE
grade O
glioma O
. O

In O
terms O
of O
sequence I-GENE
_RARE_ I-GENE
, O
seven O
tandemly O
repeated O
copies O
of O
the O
_RARE_ I-GENE
_RARE_ I-GENE
and O
three O
flanking O
regions O
of O
_RARE_ I-GENE
_RARE_ I-GENE
were O
detected O
, O
all O
in O
ORF I-GENE
_RARE_ I-GENE
. O

The O
significance O
of O
these O
palindromic O
domains I-GENE
in O
this O
ORF I-GENE
is O
unclear O
but O
the O
_RARE_ I-GENE
of O
the O
end O
of O
one O
larger O
palindrome O
with O
the O
end O
of O
the O
translated O
protein I-GENE
sequence I-GENE
that O
has O
homology I-GENE
with O
the O
B I-GENE
chain I-GENE
of O
insulin I-GENE
suggests O
that O
the O
_RARE_ I-GENE
may O
_RARE_ I-GENE
the O
T2 I-GENE
protein I-GENE
into O
several O
functional O
units O
. O

During O
sub O
- I-GENE
maximal O
exercise O
, O
_RARE_ I-GENE
in O
the O
UT O
dogs O
decreased O
from O
a O
resting O
value O
of O
4 I-GENE
. O
_RARE_ I-GENE
+/- O
0 O
. O
18 O
mm O
Hg O
X I-GENE
ml O
- I-GENE
1 I-GENE
X I-GENE
min O
- I-GENE
1 I-GENE
to O
1 I-GENE
. O
91 O
+/- O
0 O
. O
17 O
mm O
Hg O
X I-GENE
ml O
- I-GENE
1 I-GENE
X I-GENE
min O
- I-GENE
1 I-GENE
at O
a O
_RARE_ I-GENE
of O
6 I-GENE
. O
4 I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
)/ O
16 O
% O
( O
grade O
). O

7 O
. O

These O
data O
suggest O
that O
the O
G I-GENE
- I-GENE
protein I-GENE
gene I-GENE
family I-GENE
may O
be O
distributed O
over O
at O
least O
two O
human I-GENE
chromosomes O
. O

The O
major I-GENE
inserted O
DNA I-GENE
has O
no O
significant O
homology I-GENE
to O
published O
human I-GENE
nucleic O
acid I-GENE
sequences I-GENE
. O

In O
44 I-GENE
evaluable O
patients O
the O
response O
rate O
was O
50 O
%, O
with O
one O
complete O
response O
. O

We O
have O
also O
found O
that O
the O
in O
vitro O
interaction O
between O
the O
SV40 I-GENE
octamer O
motif I-GENE
and O
the O
lymphoid I-GENE
cell O
- I-GENE
specific I-GENE
protein I-GENE
_RARE_ I-GENE
- I-GENE
B2 I-GENE
was O
negatively O
modulated O
by O
a O
component O
present O
in O
the O
nuclear I-GENE
extracts O
from O
several O
lymphoid I-GENE
cell O
lines O
. O

_RARE_ I-GENE
was O
introduced O
by O
_RARE_ I-GENE
the O
_RARE_ I-GENE
with O
water O
deprived O
of O
oxygen O
or O
by O
_RARE_ I-GENE
the O
water O
flow O
to O
the O
_RARE_ I-GENE
. O

Growth I-GENE
, O
4 I-GENE
- I-GENE
PA I-GENE
and O
14C O
turnover O
data O
indicated O
that O
_RARE_ I-GENE
contributed O
to O
B I-GENE
- I-GENE
6 I-GENE
intake O
of O
these O
rats O
. O

Thus O
, O
multiple O
myogenic I-GENE
factors I-GENE
that O
vary O
_RARE_ I-GENE
and O
_RARE_ I-GENE
may O
be O
responsible O
for O
the O
different O
and O
complex I-GENE
_RARE_ I-GENE
programs O
of O
actin I-GENE
gene I-GENE
expression O
observed O
during O
in O
vivo O
muscle O
differentiation O
. O

DNA I-GENE
sequence I-GENE
analysis O
revealed O
that O
these O
clones O
encode O
two O
distinct O
forms O
of O
_RARE_ I-GENE
. O

The O
effect O
of O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
on O
HCO3 O
- I-GENE
and O
Cl O
- I-GENE
activities O
in O
inner O
ear O
fluid O
was O
investigated O
by O
ion O
- I-GENE
selective O
_RARE_ I-GENE
methods O
. O

_RARE_ I-GENE
encodes O
a O
polypeptide I-GENE
chain I-GENE
of O
186 I-GENE
, O
270 O
_RARE_ I-GENE
in O
a O
large O
_RARE_ I-GENE
reading O
frame O
. O

Both O
the O
intact O
A1 I-GENE
protein I-GENE
and O
its O
proteolytic O
fragment I-GENE
, O
the O
_RARE_ I-GENE
protein I-GENE
, O
can O
be O
cleaved O
by O
Staphylococcus I-GENE
aureus I-GENE
V I-GENE
- I-GENE
8 O
protease I-GENE
to O
produce O
two O
polypeptides I-GENE
of O
92 O
amino O
acids O
. O

_RARE_ I-GENE
, O
and O
W I-GENE
. O

These O
_RARE_ I-GENE
of O
the O
alpha I-GENE
- I-GENE
MSH I-GENE
treated O
mothers O
were O
less O
sensitive O
to O
pain O
and O
as O
adults O
showed O
a O
reduced O
analgesic O
response O
to O
morphine O
. O

_RARE_ I-GENE
immunodeficiency I-GENE
virus I-GENE
( O
SIV O
) O
is O
a O
_RARE_ I-GENE
with O
morphological O
and O
antigenic I-GENE
similarities O
to O
human I-GENE
immunodeficiency I-GENE
virus I-GENE
, O
the O
_RARE_ I-GENE
agent O
of O
acquired O
immunodeficiency I-GENE
syndrome O
( O
AIDS O
) O
of O
humans O
. O

The O
lack O
of O
change O
in O
the O
ratio O
of O
the O
two O
spliced O
products I-GENE
expressed O
from O
either O
the O
normal O
or O
the O
5 I-GENE
'- O
rearranged I-GENE
myb I-GENE
further O
indicates O
that O
the O
insertion O
of O
the O
unique O
121 I-GENE
amino O
acids O
in O
the O
larger O
myb I-GENE
transcripts I-GENE
is O
not O
a O
consequence O
of O
tumor I-GENE
- I-GENE
specific I-GENE
activation O
of O
the O
mouse I-GENE
myb I-GENE
oncogene I-GENE
. O

The O
use O
of O
CRF I-GENE
- I-GENE
41 O
in O
the O
differential O
diagnosis O
of O
_RARE_ I-GENE
' O
s O
syndrome O
and O
obesity O
. O

We O
detected O
mos I-GENE
transcripts I-GENE
by O
Northern O
( O
RNA I-GENE
) O
analyses O
in O
RNA I-GENE
prepared O
from O
chicken I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
and O
testes O
. O

The O
predicted O
L I-GENE
mRNA I-GENE
was O
_RARE_ I-GENE
nucleotides O
long O
and O
contained O
a O
single O
open O
reading O
frame O
corresponding O
to O
an O
L I-GENE
protein I-GENE
encompassing O
_RARE_ I-GENE
amino O
acids O
with O
a O
_RARE_ I-GENE
of O
_RARE_ I-GENE
, O
_RARE_ I-GENE
. O

The O
results O
suggest O
that O
the O
organization O
of O
functional O
units O
of O
the O
72 O
- I-GENE
bp O
repeat I-GENE
required O
for O
transcriptional O
enhancement O
of O
the O
early I-GENE
promoter I-GENE
is O
different O
from O
that O
required O
for O
late O
promoter I-GENE
function O
. O

_RARE_ I-GENE
in O
the O
5 I-GENE
' O
half O
of O
U3 I-GENE
were O
primarily O
due O
to O
insertions O
and O
deletions O
. O

An O
analysis O
of O
the O
steady O
state O
RNA I-GENE
levels O
in O
T I-GENE
- I-GENE
lymphoid I-GENE
cell O
lines O
showed O
that O
at O
least O
three O
different O
incomplete O
proviral I-GENE
transcripts I-GENE
and O
their O
spliced O
products I-GENE
made O
up O
the O
majority O
of O
expressed O
RD I-GENE
- I-GENE
114 I-GENE
mRNA I-GENE
, O
and O
further O
demonstrated O
that O
partially O
deleted O
proviral I-GENE
loci I-GENE
have O
the O
potential O
to O
be O
transcriptionally O
_RARE_ I-GENE
in O
certain O
feline I-GENE
cell O
types O
. O

_RARE_ I-GENE
_RARE_ I-GENE
in O
_RARE_ I-GENE
cell O
disorders O
: O
bone O
marrow O
necrosis I-GENE
and O
human I-GENE
_RARE_ I-GENE
infection O
. O

_RARE_ I-GENE
two O
or O
more O
different O
sequences I-GENE
can O
promote O
cleavage O
, O
or O
a O
single O
element I-GENE
exists O
which O
is O
long O
and O
diffuse O
. O

Low O
molecular O
weight O
_RARE_ I-GENE
have O
stimulated O
much O
interest O
because O
of O
their O
_RARE_ I-GENE
more O
selective O
action O
on O
_RARE_ I-GENE
factor I-GENE
. O

The O
bactericidal O
activity O
of O
six O
new O
_RARE_ I-GENE
derivatives O
-- O
_RARE_ I-GENE
( O
_RARE_ I-GENE
), O
_RARE_ I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
), O
_RARE_ I-GENE
( O
_RARE_ I-GENE
), O
CGP I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
), O
CGP I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
and O
CGP I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
and O
_RARE_ I-GENE
( O
_RARE_ I-GENE
_RARE_ I-GENE
have O
been O
measured O
against O
log O
phase O
and O
, O
as O
a O
better O
test O
of O
_RARE_ I-GENE
activity O
, O
against O
stationary O
phase O
cultures O
of O
Mycobacterium O
tuberculosis O
, O
_RARE_ I-GENE
. O

_RARE_ I-GENE
+ I-GENE
SV O
M I-GENE
- I-GENE
MuLV O
- I-GENE
inoculated O
animals O
became O
_RARE_ I-GENE
at O
3 I-GENE
to O
13 O
months O
_RARE_ I-GENE
, O
whereas O
delta I-GENE
_RARE_ I-GENE
+ I-GENE
SV O
M I-GENE
- I-GENE
MuLV O
- I-GENE
inoculated O
animals O
became O
_RARE_ I-GENE
at O
6 I-GENE
to O
24 O
months O
_RARE_ I-GENE
. O

Sodium O
dodecyl O
_RARE_ I-GENE
- I-GENE
induced O
cleavage O
by O
eukaryotic I-GENE
topoisomerase I-GENE
I I-GENE
is O
known O
to O
yield O
enzyme I-GENE
covalently O
attached O
to O
the O
3 I-GENE
' O
cut I-GENE
end O
of O
the O
DNA I-GENE
. O

Amino O
acid I-GENE
sequence I-GENE
of O
one O
human I-GENE
liver O
clone O
( O
HL I-GENE
- I-GENE
14 O
) O
was O
identical O
to O
the O
rabbit I-GENE
skeletal I-GENE
muscle O
phosphatase I-GENE
2A I-GENE
cDNA I-GENE
( O
with O
97 O
% O
nucleotide I-GENE
identity O
). O

_RARE_ I-GENE
virus I-GENE
infection O
was O
characterized O
by O
inversion O
of O
the O
T4 I-GENE
/ I-GENE
_RARE_ I-GENE
ratio O
below O
1 I-GENE
. O
0 O
( O
sensitivity O
90 O
%, O
specificity O
88 O
%), O
caused O
by O
proliferation O
of O
the O
_RARE_ I-GENE
_RARE_ I-GENE
, O
which O
-- O
compared O
with O
the O
findings O
in O
patients O
with O
rejection O
_RARE_ I-GENE
-- O
was O
significantly O
raised O
( O
P I-GENE
less O
than O
0 O
. O
001 O
). O

_RARE_ I-GENE
and O
LVEF O
both O
increased O
by O
about O
14 O
% O
( O
p O
less O
than O
0 O
. O
05 O
and O
p O
less O
than O
0 O
. O
01 O
). O

The O
levels O
of O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
in O
the O
rat I-GENE
vas O
deferens O
were O
not O
affected O
by O
either O
surgical O
or O
pharmacological O
treatment O
. O

Quantitative O
assays O
in O
which O
the O
activity O
of O
the O
synthetic O
alpha I-GENE
s O
- I-GENE
1 I-GENE
was O
compared O
to O
that O
of O
native O
purified O
human I-GENE
erythrocyte I-GENE
type I-GENE
- I-GENE
1 I-GENE
Gs I-GENE
, O
indicated O
that O
the O
two O
products I-GENE
are O
_RARE_ I-GENE
within O
a O
2 I-GENE
- I-GENE
fold O
margin O
of O
error O
. O

In O
these O
cells O
, O
E2 I-GENE
proteins I-GENE
had O
little O
or O
no O
stimulatory I-GENE
effect O
on O
the O
transcriptional O
activity O
of O
the O
HPV I-GENE
- I-GENE
11 O
enhancer I-GENE
- I-GENE
SV40 I-GENE
promoter I-GENE
. O

The O
mechanism O
by O
which O
E2 I-GENE
- I-GENE
C I-GENE
represses O
E2 I-GENE
- I-GENE
dependent I-GENE
enhancer I-GENE
activity O
most O
likely O
involves O
competition O
with O
E2 I-GENE
for O
binding I-GENE
to O
a O
common O
transcriptional O
regulatory I-GENE
site I-GENE
.( O
ABSTRACT O
TRUNCATED O
AT I-GENE
400 O
WORDS O
) O

_RARE_ I-GENE
evaluation O
of O
the O
treatment O
results O
in O
_RARE_ I-GENE
lung O
cancer O
patients O
must O
take O
the O
strong O
prognostic O
factors I-GENE
into O
account O
. O

( O
anti I-GENE
- I-GENE
_RARE_ I-GENE
) O
and O
_RARE_ I-GENE
et O
al O
. O

_RARE_ I-GENE
of O
v I-GENE
- I-GENE
fms I-GENE
into O
a O
CSF I-GENE
- I-GENE
1 I-GENE
dependent I-GENE
murine I-GENE
macrophage I-GENE
cell O
line O
induced O
factor I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
by O
a O
_RARE_ I-GENE
mechanism O
. O

Chronic O
E I-GENE
- I-GENE
B I-GENE
virus I-GENE
infection O
_RARE_ I-GENE
in O
malignant O
lymphoma O
: O
a O
case O
report O

The O
primary O
structure O
and O
_RARE_ I-GENE
of O
the O
_RARE_ I-GENE
genes I-GENE
encoding O
the O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
( O
nuclear I-GENE
encoded I-GENE
in O
plants O
) O
and O
_RARE_ I-GENE
f I-GENE
proteins I-GENE
has O
been O
described O
previously O
( O
_RARE_ I-GENE
, O
T I-GENE
., O
_RARE_ I-GENE
, O
S I-GENE
., O
and O
_RARE_ I-GENE
, O
R I-GENE
. O

The O
_RARE_ I-GENE
_RARE_ I-GENE
genes I-GENE
are O
not O
closely O
linked O
to O
the O
_RARE_ I-GENE
gene I-GENE
( O
encoding O
the O
51 O
- I-GENE
kDa I-GENE
_RARE_ I-GENE
II I-GENE
polypeptide I-GENE
) O
and O
do O
not O
contain O
introns O
as O
do O
the O
closely O
related I-GENE
chloroplast I-GENE
genes I-GENE
. O

RNA I-GENE
blot O
_RARE_ I-GENE
identified O
an O
1 I-GENE
. O
8 O
- I-GENE
kb O
mRNA I-GENE
common O
to O
cytochrome I-GENE
_RARE_ I-GENE
and O
subunit I-GENE
IV I-GENE
, O
and O
an O
_RARE_ I-GENE
_RARE_ I-GENE
0 O
. O
8 O
- I-GENE
kb O
mRNA I-GENE
specific I-GENE
to O
the O
subunit I-GENE
IV I-GENE
gene I-GENE
probe O
. O

Whereas O
the O
muscle O
isoform I-GENE
consists O
of O
_RARE_ I-GENE
amino O
acids O
and O
_RARE_ I-GENE
with O
the O
sequence I-GENE
Ala I-GENE
- I-GENE
Ile O
- I-GENE
Leu I-GENE
- I-GENE
Glu O
, O
the O
second O
isoform I-GENE
is O
_RARE_ I-GENE
amino O
acids O
in O
length I-GENE
due O
to O
the O
replacement O
of O
these O
last O
4 I-GENE
amino O
acids O
with O
a O
50 O
- I-GENE
amino O
acid I-GENE
sequence I-GENE
that O
contains O
a O
potential O
transmembrane I-GENE
domain I-GENE
followed O
by O
a O
consensus I-GENE
sequence I-GENE
for O
an O
N I-GENE
- I-GENE
linked O
glycosylation O
site I-GENE
. O

Substitution O
of O
a O
threonine I-GENE
residue O
by O
an O
alanine I-GENE
residue O
at O
position O
- I-GENE
2 I-GENE
( O
P2 I-GENE
) O
of O
this O
cleavage O
site I-GENE
abolished O
cleavage O
, O
whereas O
substitution O
of O
a O
tyrosine I-GENE
residue O
by O
a O
phenylalanine I-GENE
residue O
at O
amino O
acid I-GENE
position O
- I-GENE
1 I-GENE
( O
P1 I-GENE
) O
of O
the O
cleavage O
site I-GENE
did O
not O
influence O
processing O
. O

All O
of O
the O
_RARE_ I-GENE
- I-GENE
producing O
bacteria O
had O
an O
_RARE_ I-GENE
phosphatase I-GENE
with O
a O
_RARE_ I-GENE
of O
6 I-GENE
. O
4 I-GENE
. O

The O
number O
of O
polymerases I-GENE
active O
in O
vitro O
at O
the O
E I-GENE
strand O
promoter I-GENE
was O
similar O
to O
the O
number O
of O
polymerases I-GENE
at O
the O
L I-GENE
strand O
promoter I-GENE
. O

A I-GENE
family I-GENE
of O
RNA I-GENE
molecules I-GENE
in O
the O
2 I-GENE
. O
0 O
- I-GENE
2 I-GENE
. O
2 I-GENE
- I-GENE
kilobase O
range O
identified O
with O
a O
probe O
from O
this O
gene I-GENE
was O
overexpressed O
in O
the O
resistant O
cells O
. O

A I-GENE
highly O
hydrophobic O
sequence I-GENE
located O
near O
the O
carboxyl O
- I-GENE
terminal I-GENE
_RARE_ I-GENE
of O
the O
molecule I-GENE
most O
likely O
constitutes O
the O
anchor I-GENE
to O
the O
plasma I-GENE
membrane I-GENE
. O

The O
SV40 I-GENE
enhancer I-GENE
augmented O
replication O
1 I-GENE
. O
5 I-GENE
- I-GENE
10 O
fold O
. O

One O
of O
these O
, O
the O
origin O
core I-GENE
, O
is O
required O
only O
for O
DNA I-GENE
replication O
. O

Induction O
of O
proto I-GENE
- I-GENE
oncogene I-GENE
fos I-GENE
transcription I-GENE
through O
the O
adenylate I-GENE
cyclase I-GENE
pathway O
: O
characterization O
of O
a O
cAMP I-GENE
- I-GENE
responsive I-GENE
element I-GENE
. O

A I-GENE
17 O
- I-GENE
mer I-GENE
_RARE_ I-GENE
, O
corresponding O
to O
a O
region O
of O
the O
_RARE_ I-GENE
amino O
acid I-GENE
sequence I-GENE
was O
used O
as O
a O
hybridization O
probe O
to O
screen O
a O
_RARE_ I-GENE
genomic O
library O
constructed O
in O
broad O
- I-GENE
host O
- I-GENE
range O
cosmid O
vector O
_RARE_ I-GENE
. O

( O
total O
soluble I-GENE
_RARE_ I-GENE
) O
and O
_RARE_ I-GENE
characteristics O
under O
the O
influence O
of O
different O
treatments O
. O

_RARE_ I-GENE
of O
death O
found O
in O
an O
epidemiological O
study O
of O
native O
chickens O
in O
_RARE_ I-GENE
_RARE_ I-GENE
. O

The O
progression O
of O
non O
- I-GENE
A I-GENE
, O
non O
- I-GENE
B I-GENE
hepatitis I-GENE
to O
chronic O
diseases O
, O
and O
the O
transformation O
to O
_RARE_ I-GENE
carcinoma O

_RARE_ I-GENE
IOP O
developed O
in O
35 O
patients O
( O
44 I-GENE
eyes O
) O
during O
the O
study O
. O

Use O
of O
serum I-GENE
_RARE_ I-GENE
determination O
in O
the O
follow O
- I-GENE
up O
of O
differentiated O
carcinomas O
of O
the O
thyroid I-GENE

_RARE_ I-GENE
response O
when O
laboratory O
recommended O
range O
for O
serum I-GENE
lithium O
is O
changed O
. O

The O
aim O
of O
this O
study O
was O
to O
investigate O
the O
effects O
of O
_RARE_ I-GENE
_RARE_ I-GENE
in O
patients O
with O
acute O
asthma O
in O
order O
to O
determine O
whether O
it O
_RARE_ I-GENE
the O
_RARE_ I-GENE
effect O
of O
a O
beta I-GENE
agonist O
drug O
. O

Further O
analysis O
of O
this O
DNA I-GENE
fragment I-GENE
showed O
that O
four O
genes I-GENE
are O
present O
encoding O
proteins I-GENE
of O
16 O
, O
18 O
. O
5 I-GENE
, O
21 O
and O
89 I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
virus I-GENE
. O

Changes O
in O
dopamine I-GENE
receptor I-GENE
sensitivity O
in O
humans O
after O
heavy I-GENE
alcohol O
intake O
. O

No O
significant O
differences O
between O
the O
two O
treatment O
groups O
were O
found O
, O
but O
rapid O
responders O
had O
a O
smaller O
mean O
initial O
platelet I-GENE
- I-GENE
associated I-GENE
IgG I-GENE
index O
which O
returned O
more O
rapidly O
and O
more O
_RARE_ I-GENE
to O
normal O
than O
that O
of O
slow O
responders O
. O

Replacement I-GENE
variant I-GENE
histone I-GENE
genes I-GENE
contain O
intervening O
sequences I-GENE
. O

Double O
- I-GENE
blind O
randomised O
trial O
of O
intravenous O
tissue I-GENE
- I-GENE
type I-GENE
plasminogen I-GENE
activator I-GENE
versus O
placebo O
in O
acute O
myocardial O
infarction O
. O

The O
C I-GENE
- I-GENE
terminal I-GENE
domains I-GENE
( O
_RARE_ I-GENE
) O
of O
the O
_RARE_ I-GENE
beta I-GENE
subunit I-GENE
and O
DNA I-GENE
primase I-GENE
( O
_RARE_ I-GENE
protein I-GENE
) O
were O
not O
only O
strongly O
homologous O
to O
each O
other O
but O
also O
considerably O
homologous O
to O
the O
_RARE_ I-GENE
alpha I-GENE
, O
suggesting O
that O
an O
alpha I-GENE
subunit I-GENE
- I-GENE
like I-GENE
enzyme I-GENE
must O
have O
been O
commonly O
ancestral O
to O
core I-GENE
enzyme I-GENE
subunits I-GENE
and O
primase I-GENE
. O

However O
, O
vancomycin O
and O
_RARE_ I-GENE
, O
which O
revealed O
_RARE_ I-GENE
in O
vitro O
bactericidal O
activity O
, O
proved O
as O
_RARE_ I-GENE
as O
penicillin I-GENE
G I-GENE
and O
_RARE_ I-GENE
in O
an O
experimental O
mode O
of O
murine I-GENE
gas O
_RARE_ I-GENE
. O

_RARE_ I-GENE
, O
a O
_RARE_ I-GENE
mu I-GENE
- I-GENE
opiate I-GENE
receptor I-GENE
agonist O
, O
has O
been O
previously O
shown O
to O
produce O
a O
syndrome O
characterized O
by O
marked O
analgesia O
and O
locomotor O
stimulation O
as O
well O
as O
tachycardia O
, O
_RARE_ I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
chemotherapy O
. O

_RARE_ I-GENE
was O
found O
to O
be O
an O
effective O
beta I-GENE
- I-GENE
adrenoceptor I-GENE
antagonist O
, O
the O
_RARE_ I-GENE
values O
determined O
against O
_RARE_ I-GENE
in O
guinea O
pig O
_RARE_ I-GENE
and O
tracheal O
muscle O
being O
7 O
. O
45 O
and O
6 I-GENE
. O
41 O
, O
respectively O
. O

_RARE_ I-GENE
of O
_RARE_ I-GENE
- I-GENE
4 I-GENE
by O
the O
_RARE_ I-GENE
gland O
closely O
mimicked O
fluctuations O
in O
_RARE_ I-GENE
_RARE_ I-GENE
flow O
rate O
. O

The O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
equation O
is O
used O
to O
assess O
the O
effects O
of O
attached O
parasites O
in O
the O
_RARE_ I-GENE
of O
Leishmania I-GENE
- I-GENE
infected O
_RARE_ I-GENE
on O
blood O
flow O
. O

Moreover O
, O
in O
rats O
allowed O
to O
_RARE_ I-GENE
in O
a O
T I-GENE
- I-GENE
_RARE_ I-GENE
between O
immediate I-GENE
- I-GENE
but O
- I-GENE
small I-GENE
vs O
. O
delayed O
- I-GENE
but O
- I-GENE
large O
_RARE_ I-GENE
, O
_RARE_ I-GENE
significantly O
decreased O
the O
frequency O
with O
which O
the O
delayed O
_RARE_ I-GENE
was O
chosen O
, O
with O
5 I-GENE
- I-GENE
HT O
uptake O
blockers O
producing O
opposite O
effects O
. O

An O
endometrial O
luteal O
phase O
deficiency O
was O
detected O
in O
15 O
( O
30 O
%) O
of O
_RARE_ I-GENE
patients O
. O

_RARE_ I-GENE
exposure O
to O
the O
_RARE_ I-GENE
_RARE_ I-GENE
causes O
behavioral O
_RARE_ I-GENE
, O
_RARE_ I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
in O
mice O
, O
but O
not O
rats O
or O
hamsters O
. O

_RARE_ I-GENE
with O
normal O
blood O
in O
the O
_RARE_ I-GENE
, O
working O
hearts O
caused O
extensive O
structural O
damage O
, O
reduced O
_RARE_ I-GENE
, O
and O
failed O
to O
_RARE_ I-GENE
contractility O
in O
any O
_RARE_ I-GENE
(- O
27 O
% O
systolic O
shortening O
, O
p O
less O
than O
0 O
. O
05 O
). O

The O
sensitivity O
of O
the O
vas O
deferens O
to O
adrenaline O
was O
also O
reduced O
in O
_RARE_ I-GENE
guinea O
pigs O
, O
thus O
decreasing O
their O
fertility O
rate O
. O

In O
metabolic O
acidosis O
there O
was O
a O
marked O
stimulation O
when O
_RARE_ I-GENE
at O
- I-GENE
10 O
to O
- I-GENE
100 O
_RARE_ I-GENE
. O

On O
_RARE_ I-GENE
1 I-GENE
and O
14 O
, O
most O
young O
and O
elderly O
subjects O
exhibited O
_RARE_ I-GENE
decline O
in O
_RARE_ I-GENE
plasma I-GENE
concentrations O
after O
absorption O
phase O
. O

_RARE_ I-GENE
and O
old O
_RARE_ I-GENE
and O
_RARE_ I-GENE
mice O
were O
given O
_RARE_ I-GENE
tap I-GENE
water O
or O
_RARE_ I-GENE
_RARE_ I-GENE
( O
a O
_RARE_ I-GENE
with O
H1 I-GENE
receptor I-GENE
blocking O
activity O
), O
_RARE_ I-GENE
( O
an O
H1 I-GENE
blocker O
) O
or O
_RARE_ I-GENE
( O
a O
_RARE_ I-GENE
with O
no O
H1 I-GENE
blocking O
activity O
) O
in O
their O
drinking O
water O
, O
and O
the O
effects O
of O
these O
agents O
on O
bone O
mineral O
content O
were O
assessed O
by O
_RARE_ I-GENE
measuring O
the O
24 O
- I-GENE
h O
whole O
body O
retention O
of O
Tc O
99m O
methylene O
_RARE_ I-GENE
( O
Tc O
99m O
_RARE_ I-GENE
, O
an O
indicator O
of O
bone O
metabolism O
) O
and O
at O
the O
end O
of O
the O
studies O
by O
determining O
_RARE_ I-GENE
weights O
of O
femur O
, O
_RARE_ I-GENE
and O
_RARE_ I-GENE
. O

_RARE_ I-GENE
results O
reveal O
a O
frequency O
- I-GENE
dependent I-GENE
inhibition O
of O
_RARE_ I-GENE
transmission O
by O
diltiazem O
, O
and O
suggest O
that O
diltiazem O
may O
_RARE_ I-GENE
excessive O
sympathetic O
activity O
without O
affecting O
normal O
_RARE_ I-GENE
transmission O
. O

Studies O
were O
performed O
on O
several O
superficial O
_RARE_ I-GENE
from O
the O
rabbit I-GENE
face O
to O
examine O
the O
relationship O
between O
beta I-GENE
adrenoceptor I-GENE
subtype I-GENE
distribution O
, O
intrinsic O
myogenic I-GENE
tone O
and O
sympathetic O
nerve I-GENE
_RARE_ I-GENE
. O

Effects O
of O
a O
new O
antihypertensive O
agent O
, O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
, O
on O
rat I-GENE
platelet I-GENE
aggregation O
. O

Since O
the O
stability O
of O
_RARE_ I-GENE
resides O
in O
its O
primary O
structure O
, O
we O
cloned O
a O
gene I-GENE
coding O
for O
_RARE_ I-GENE
, O
and O
the O
primary O
structure O
of O
the O
beta I-GENE
subunit I-GENE
was O
deduced O
from O
the O
nucleotide I-GENE
sequence I-GENE
of O
the O
gene I-GENE
to O
compare O
the O
sequence I-GENE
with O
those O
of O
beta I-GENE
' O
s O
of O
three O
major I-GENE
categories O
of O
F1 I-GENE
' O
s O
; O
prokaryotic I-GENE
membranes O
, O
_RARE_ I-GENE
, O
and O
mitochondria O
. O

_RARE_ I-GENE
temperature O
and O
overall O
conductance I-GENE
in O
the O
cold O
appear O
to O
be O
more O
variable O
in O
P I-GENE
. O
s O
. O
_RARE_ I-GENE
than O
in O
_RARE_ I-GENE
sp O
. O

Two O
polyadenylation O
sites I-GENE
were O
used O
, O
one O
at O
the O
end O
of O
the O
early I-GENE
( O
E I-GENE
) O
region O
of O
the O
viral I-GENE
DNA I-GENE
, O
the O
other O
at O
the O
end O
of O
the O
late O
( O
L I-GENE
) O
region O
. O

A I-GENE
drug O
with O
_RARE_ I-GENE
" O
down O
regulates O
" O
beta I-GENE
receptors I-GENE
; O
thus O
, O
when O
the O
drug O
is O
_RARE_ I-GENE
there O
is O
no O
post O
- I-GENE
beta I-GENE
- I-GENE
blocking O
drug O
hypersensitivity O
in O
contrast O
to O
agents O
without O
_RARE_ I-GENE
. O

Six O
patients O
with O
human I-GENE
T I-GENE
- I-GENE
cell O
_RARE_ I-GENE
virus I-GENE
type I-GENE
I I-GENE
( O
HTLV I-GENE
- I-GENE
I I-GENE
)- I-GENE
associated I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
were O
studied O
by O
_RARE_ I-GENE
methods O
. O

_RARE_ I-GENE
, O
a O
structural O
analog O
of O
_RARE_ I-GENE
, O
also O
inhibits O
alpha I-GENE
1 I-GENE
adrenoceptors I-GENE
and O
is O
recommended O
as O
once O
or O
twice O
- I-GENE
daily O
therapy O
. O

_RARE_ I-GENE
blood O
donors O
for O
non O
- I-GENE
A I-GENE
, O
non O
- I-GENE
B I-GENE
hepatitis I-GENE
: O
_RARE_ I-GENE
, O
perhaps O
, O
but O
_RARE_ I-GENE
. O

Most O
patients O
with O
high O
blood O
pressure O
( O
BP I-GENE
) O
can O
be O
_RARE_ I-GENE
by O
using O
one O
of O
4 I-GENE
classes O
of O
compounds O
: O
a O
diuretic O
, O
beta I-GENE
blocker O
, O
converting I-GENE
enzyme I-GENE
inhibitor I-GENE
or O
calcium O
antagonist O
. O

In O
a O
randomised O
double O
- I-GENE
blind O
study O
, O
46 O
first O
_RARE_ I-GENE
_RARE_ I-GENE
were O
given O
_RARE_ I-GENE
or O
_RARE_ I-GENE
for O
up O
to O
5 I-GENE
weeks O
; O
the O
mean O
daily O
dose O
at O
the O
end O
was O
18 O
. O
8 O
mg O
_RARE_ I-GENE
and O
20 O
mg O
_RARE_ I-GENE
. O

_RARE_ I-GENE
- I-GENE
producing O
endocrine O
pancreatic O
tumor I-GENE
in O
_RARE_ I-GENE
' O
s O
_RARE_ I-GENE
. O

Direct I-GENE
and O
inverted O
repeat I-GENE
elements O
of O
10 O
, O
11 O
, O
16 O
, O
19 O
, O
and O
22 O
nucleotides O
( O
nt O
) O
flank O
the O
promoter I-GENE
site I-GENE
. O

We O
have O
been O
able O
to O
map O
specific I-GENE
DNA I-GENE
fragments I-GENE
at O
the O
bases O
of O
chromatin O
loops O
with O
the O
help O
of O
a O
novel O
extraction O
procedure O
by O
using O
lithium O
- I-GENE
3 I-GENE
', O
5 I-GENE
'- O
_RARE_ I-GENE
. O

Seventy O
- I-GENE
one O
supplementary O
doses O
of O
_RARE_ I-GENE
were O
used O
for O
muscle O
relaxation O
during O
a O
22 O
- I-GENE
h O
- I-GENE
long O
_RARE_ I-GENE
II I-GENE
anaesthesia O
. O

Finally O
, O
the O
recovery O
_RARE_ I-GENE
represented O
by O
the O
times O
required O
for O
T1 O
/ I-GENE
_RARE_ I-GENE
and O
T4 I-GENE
/ I-GENE
T1 O
to O
rise O
from O
25 O
% O
to O
75 O
% O
respectively O
were O
studied O
. O

_RARE_ I-GENE
bacterial I-GENE
colonies O
were O
screened O
for O
recombinant I-GENE
plasmids O
containing O
cDNA I-GENE
coding O
for O
_RARE_ I-GENE
by O
hybrid O
- I-GENE
selected O
mRNA I-GENE
translation I-GENE
. O

_RARE_ I-GENE
attenuated O
the O
increase O
of O
the O
intensity O
of O
the O
ischemic O
and O
pressure O
pain O
components O
with O
increasing O
ischemia O
duration O
, O
but O
only O
the O
effect O
on O
the O
pressure O
pain O
component O
was O
significant O
. O

_RARE_ I-GENE
1 I-GENE
percent O
isoproterenol O
in O
the O
presence O
of O
the O
phosphodiesterase I-GENE
inhibitor I-GENE
theophylline O
was O
tested O
for O
its O
ability O
to O
stimulate O
the O
rate O
of O
aqueous O
_RARE_ I-GENE
flow O
through O
the O
anterior O
chamber O
of O
the O
normal O
and O
the O
partially O
_RARE_ I-GENE
_RARE_ I-GENE
human I-GENE
eye O
( O
_RARE_ I-GENE
' O
s O
syndrome O
). O

_RARE_ I-GENE
is O
one O
of O
the O
numerous O
causes O
of O
infertility O
and O
recurrent O
abortion O
. O

A I-GENE
strong O
correlation O
exists O
between O
the O
numbers O
of O
_RARE_ I-GENE
- I-GENE
GM I-GENE
_RARE_ I-GENE
and O
the O
rate O
of O
_RARE_ I-GENE
and O
platelets O
recovery O
. O

We O
propose O
that O
the O
technique O
of O
low O
- I-GENE
frequency O
kindling O
is O
a O
useful O
experimental O
model O
in O
assessing O
the O
effects O
of O
_RARE_ I-GENE
or O
_RARE_ I-GENE
drugs O
on O
the O
_RARE_ I-GENE
of O
the O
_RARE_ I-GENE
regions O
. O

_RARE_ I-GENE
implant O
_RARE_ I-GENE
. O

Three O
sequence I-GENE
elements O
are O
shown O
to O
be O
required O
for O
accurate O
and O
efficient O
transcription I-GENE
termination O
by O
RNA I-GENE
polymerase I-GENE
I I-GENE
( O
pol I-GENE
I I-GENE
) O
assayed O
both O
in O
a O
cell O
- I-GENE
free O
transcription I-GENE
system O
and O
in O
vivo O
after O
transfection O
of O
rDNA I-GENE
_RARE_ I-GENE
constructs I-GENE
into O
_RARE_ I-GENE
cells O
. O

The O
biosynthesis O
and O
stability O
of O
the O
three O
mutant I-GENE
proteins I-GENE
were O
similar O
to O
those O
of O
the O
wild I-GENE
- I-GENE
type I-GENE
erbB I-GENE
protein I-GENE
, O
and O
all O
three O
retained O
the O
ability O
to O
transform O
chicken I-GENE
embryo O
fibroblasts O
. O

_RARE_ I-GENE
usage O
in O
C I-GENE
. O
_RARE_ I-GENE
mitochondria O
is O
highly O
_RARE_ I-GENE
, O
with O
eight O
codons O
entirely O
absent O
from O
all O
protein I-GENE
- I-GENE
coding O
genes I-GENE
; O
however O
, O
even O
though O
codon O
usage O
is O
restricted O
, O
it O
appears O
that O
C I-GENE
. O
_RARE_ I-GENE
_RARE_ I-GENE
cannot O
encode O
the O
minimum O
number O
of O
_RARE_ I-GENE
needed O
to O
support O
mitochondrial I-GENE
protein I-GENE
synthesis O
. O

A I-GENE
new O
_RARE_ I-GENE
treatment O
of O
HBV O
- I-GENE
related I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
by O
_RARE_ I-GENE
in O
the O
treatment O
of O
chronic O
active O
hepatitis I-GENE
B I-GENE
was O
tested O
in O
7 O
patients O
. O

Like O
_RARE_ I-GENE
testes O
, O
_RARE_ I-GENE
testes O
were O
_RARE_ I-GENE
to O
fat O
on O
sequences I-GENE
with O
a O
short O
_RARE_ I-GENE
time O
( O
TR I-GENE
) O
and O
echo O
time O
( O
_RARE_ I-GENE
) O
in O
all O
cases O
, O
and O
_RARE_ I-GENE
or O
_RARE_ I-GENE
to O
fat O
on O
long O
TR I-GENE
/ I-GENE
_RARE_ I-GENE
sequences I-GENE
in O
all O
but O
two O
cases O
. O

The O
subunit I-GENE
- I-GENE
a O
gene I-GENE
is O
_RARE_ I-GENE
by O
a O
gene I-GENE
coding O
for O
a O
small I-GENE
hydrophobic O
protein I-GENE
, O
as O
has O
been O
observed O
previously O
in O
the O
_RARE_ I-GENE
operons I-GENE
in O
E I-GENE
. O
coli I-GENE
, O
bacterium O
_RARE_ I-GENE
and O
_RARE_ I-GENE
. O

Here O
, O
we O
describe O
the O
isolation O
of O
bovine I-GENE
and O
rat I-GENE
_RARE_ I-GENE
- I-GENE
1 I-GENE
cDNA I-GENE
clones O
. O

To O
explore O
the O
functional O
properties O
of O
the O
protein I-GENE
encoded I-GENE
by O
neu I-GENE
, O
we O
created O
a O
fusion I-GENE
gene I-GENE
that O
joins O
the O
cytoplasmic I-GENE
domain I-GENE
of O
neu I-GENE
to O
the O
extracellular I-GENE
portion O
of O
an O
immunoglobulin I-GENE
heavy I-GENE
chain I-GENE
. O

The O
_RARE_ I-GENE
African O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
represents O
a O
_RARE_ I-GENE
model O
_RARE_ I-GENE
for O
comparative O
studies O
. O

By O
sequence I-GENE
comparison O
, O
42 O
blocks O
of O
homology I-GENE
are O
defined O
in O
the O
5 I-GENE
'- O
terminal I-GENE
region O
, O
of O
which O
36 O
appear O
in O
the O
CpG O
island O
and O
contain O
numerous O
conserved O
CpG O
_RARE_ I-GENE
. O

Among O
unusual O
features O
, O
we O
report O
numerous O
large O
G I-GENE
+ I-GENE
C I-GENE
- I-GENE
rich O
conserved O
sequences I-GENE
located O
in O
the O
first O
intron O
. O

In O
the O
first O
group O
, O
0 O
. O
02 O
% O
_RARE_ I-GENE
( O
0 O
. O
5 I-GENE
mg O
/ I-GENE
kg O
) O
was O
administered O
intravenously O
for O
1 I-GENE
. O
5 I-GENE
hours O
before O
the O
application O
of O
_RARE_ I-GENE
- I-GENE
Hb I-GENE
or O
PGF2 O
alpha I-GENE
. O

_RARE_ I-GENE
and O
field O
evaluation O
of O
Bacillus I-GENE
_RARE_ I-GENE
( O
H I-GENE
- I-GENE
14 O
) O
and O
B I-GENE
. O
_RARE_ I-GENE
against O
_RARE_ I-GENE
_RARE_ I-GENE
in O
_RARE_ I-GENE
. O

2 I-GENE
cases O
of O
type I-GENE
II I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
syndrome O
) O

This O
loss O
was O
independent O
of O
drug O
concentration O
and O
a O
correction O
factor I-GENE
was O
employed O
to O
_RARE_ I-GENE
the O
true O
free O
diazepam I-GENE
concentration O
. O

Effects O
of O
a O
_RARE_ I-GENE
blood O
substitute O
on O
diazepam I-GENE
binding I-GENE
by O
human I-GENE
albumin I-GENE
. O

A I-GENE
second O
promoter I-GENE
activity O
was O
identified O
in O
the O
region O
between O
the O
two O
major I-GENE
transcriptional O
start O
sites I-GENE
. O

A I-GENE
_RARE_ I-GENE
sequence I-GENE
, O
5 I-GENE
'- O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
3 I-GENE
', O
complementary O
to O
a O
conserved O
sequence I-GENE
adjacent O
to O
the O
enzymatic O
cleavage O
site I-GENE
on O
the O
mitochondrial I-GENE
RNA I-GENE
substrate I-GENE
, O
is O
present O
in O
the O
_RARE_ I-GENE
MRP I-GENE
RNA I-GENE
. O

Effects O
of O
aging O
and O
beta I-GENE
- I-GENE
adrenergic I-GENE
- I-GENE
blockade O
on O
_RARE_ I-GENE
- I-GENE
induced O
QT O
/ I-GENE
_RARE_ I-GENE
changes O
. O

A I-GENE
patient O
with O
an O
infected O
wound O
or O
one O
on O
a O
primary O
area O
( O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
face O
, O
or O
_RARE_ I-GENE
) O
may O
have O
to O
be O
hospitalized O
to O
_RARE_ I-GENE
proper O
care O
. O

_RARE_ I-GENE
studies O
with O
potassium O
chloride O
and O
acetylcholine I-GENE
suggest O
that O
_RARE_ I-GENE
acts O
as O
a O
calcium O
antagonist O
by O
blocking O
the O
_RARE_ I-GENE
of O
extracellular I-GENE
calcium O
. O

_RARE_ I-GENE
analysis O
included O
digital O
_RARE_ I-GENE
, O
followed O
by O
digital O
_RARE_ I-GENE
in O
different O
frequency O
bands O
in O
order O
to O
determine O
the O
frequency O
range O
corresponding O
to O
_RARE_ I-GENE
and O
_RARE_ I-GENE
. O

On O
admission O
to O
the O
_RARE_ I-GENE
, O
117 O
patients O
( O
61 O
percent O
) O
had O
_RARE_ I-GENE
( O
serum I-GENE
Mg I-GENE
less O
than O
1 I-GENE
. O
5 I-GENE
mEq O
/ I-GENE
dl O
), O
66 O
patients O
( O
34 O
percent O
) O
had O
_RARE_ I-GENE
( O
1 I-GENE
. O
5 I-GENE
to O
2 I-GENE
. O
0 O
mEq O
/ I-GENE
dl O
), O
and O
ten O
patients O
( O
5 I-GENE
percent O
) O
had O
_RARE_ I-GENE
( O
greater O
than O
2 I-GENE
. O
0 O
mEq O
/ I-GENE
dl O
). O

The O
risk O
factors I-GENE
studied O
were O
male O
sex I-GENE
, O
hypertension O
, O
diabetes O
mellitus O
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
smoking O
, O
_RARE_ I-GENE
life O
- I-GENE
_RARE_ I-GENE
, O
and O
family I-GENE
history O
. O

Neither O
verapamil O
nor O
nifedipine O
changed O
collateral O
myocardial O
blood O
flow O
from O
0 O
. O
10 O
+/- O
0 O
. O
02 O
in O
the O
_RARE_ I-GENE
and O
0 O
. O
17 O
+/- O
0 O
. O
03 O
ml O
/ I-GENE
min O
/ I-GENE
g O
in O
the O
_RARE_ I-GENE
. O

There O
were O
35 O
boys O
and O
15 O
girls O
, O
with O
a O
mean O
age O
of O
five O
and O
a O
half O
years O
. O

_RARE_ I-GENE
versus O
_RARE_ I-GENE
reperfusion O
of O
ischemic O
myocardium O
after O
experimental O
coronary O
artery O
occlusion O
was O
studied O
to O
determine O
the O
effect O
on O
regional O
ventricular O
wall O
motion O
and O
associated I-GENE
biochemical O
alterations O
. O

Cardiac I-GENE
disease O
was O
not O
detected O
with O
M I-GENE
- I-GENE
mode O
, O
2 I-GENE
- I-GENE
dimensional O
real O
- I-GENE
time O
or O
pulsed O
- I-GENE
wave O
Doppler O
echocardiography O
. O

_RARE_ I-GENE
assessment O
was O
obtained O
before O
and O
following O
administration O
of O
_RARE_ I-GENE
10 O
micrograms O
/ I-GENE
kg O
IV I-GENE
or O
dopamine I-GENE
, O
5 I-GENE
to O
12 O
micrograms O
/ I-GENE
kg O
/ I-GENE
min O
IV I-GENE
. O

We O
also O
examined O
the O
relationship O
between O
the O
side O
of O
_RARE_ I-GENE
and O
the O
_RARE_ I-GENE
side O
in O
patients O
with O
unilateral O
_RARE_ I-GENE
_RARE_ I-GENE
. O

We O
conclude O
that O
at O
these O
low O
levels O
studied O
, O
aluminum O
accumulates O
in O
intestinal O
tissue I-GENE
, O
and O
that O
this O
accumulation O
is O
enhanced O
by O
citrate I-GENE
ligand O
. O

Thus O
, O
the O
effects O
of O
_RARE_ I-GENE
absence O
under O
routine O
conditions O
in O
relatively O
healthy O
samples O
may O
exert O
no O
significant O
effects O
independent O
of O
intervening O
family I-GENE
_RARE_ I-GENE
or O
maternal I-GENE
_RARE_ I-GENE
. O

Recently O
, O
an O
electrical O
- I-GENE
mechanical O
analog O
model O
of O
heat I-GENE
flow O
within O
the O
brain O
has O
been O
developed O
from O
which O
an O
expression O
for O
CBF I-GENE
has O
been O
derived O
: O
CBF I-GENE
= O
_RARE_ I-GENE
_RARE_ I-GENE
tau I-GENE
rho I-GENE
c I-GENE
) O
where O
tau I-GENE
is O
the O
thermal O
decay O
constant O
, O
rho I-GENE
is O
the O
density I-GENE
of O
blood O
, O
and O
c I-GENE
is O
its O
specific I-GENE
heat I-GENE
. O

All O
of O
the O
newly O
acquired O
_RARE_ I-GENE
identified O
in O
mosaic O
_RARE_ I-GENE
_RARE_ I-GENE
/ I-GENE
J O
- I-GENE
_RARE_ I-GENE
/ I-GENE
J O
mice O
that O
could O
be O
transmitted O
through O
the O
germ I-GENE
line O
were O
also O
present O
in O
somatic O
tissues O
, O
demonstrating O
that O
viral I-GENE
integration O
occurred O
before O
the O
germ I-GENE
line O
was O
set O
_RARE_ I-GENE
from O
the O
somatic O
lineages O
. O

Molecular O
cloning O
of O
the O
cDNA I-GENE
for O
the O
human I-GENE
U2 I-GENE
snRNA I-GENE
- I-GENE
specific I-GENE
A I-GENE
' O
protein I-GENE
. O

For O
the O
present O
work O
we O
used O
water O
_RARE_ I-GENE
with O
a O
50 O
/ I-GENE
50 O
mixture O
of O
H2 I-GENE
and O
O2 O
gases O
, O
for O
which O
the O
heat I-GENE
defect O
is O
calculated O
to O
be O
- I-GENE
2 I-GENE
. O
1 I-GENE
%. O

_RARE_ I-GENE
use O
of O
_RARE_ I-GENE
to O
_RARE_ I-GENE
_RARE_ I-GENE
after O
_RARE_ I-GENE
failure O
. O

During O
_RARE_ I-GENE
_RARE_ I-GENE
, O
the O
_RARE_ I-GENE
at O
the O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
its O
direction O
at O
about O
25 O
ms O
after O
impact O
. O

The O
data O
indicates O
the O
presence O
of O
5 I-GENE
- I-GENE
HT2 I-GENE
_RARE_ I-GENE
receptors I-GENE
in O
the O
bronchial O
artery O
of O
these O
species O
. O

_RARE_ I-GENE
, O
which O
was O
active O
for O
the O
_RARE_ I-GENE
time O
( O
about O
65 O
days O
) O
from O
the O
start O
of O
_RARE_ I-GENE
( O
_RARE_ I-GENE
1 I-GENE
), O
produced O
a O
78 O
. O
1 I-GENE
per O
cent O
reduction O
in O
_RARE_ I-GENE
species O
and O
an O
84 O
. O
4 I-GENE
per O
cent O
reduction O
in O
D I-GENE
_RARE_ I-GENE
. O

By O
adapting O
a O
method O
for O
DNA I-GENE
- I-GENE
footprinting O
using O
_RARE_ I-GENE
extracts O
of O
_RARE_ I-GENE
_RARE_ I-GENE
cells O
, O
we O
were O
able O
to O
determine O
that O
the O
_RARE_ I-GENE
- I-GENE
binding I-GENE
sites I-GENE
are O
located O
between O
nucleotides O
_RARE_ I-GENE
and O
_RARE_ I-GENE
from O
the O
_RARE_ I-GENE
left O
end O
. O

We O
have O
identified O
and O
characterized O
the O
structure O
of O
the O
_RARE_ I-GENE
gene I-GENE
in O
the O
sea O
urchin I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
. O

Platelet I-GENE
function O
and O
platelet I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
neutrophil I-GENE
interaction O
in O
patients O
with O
deficient O
platelet I-GENE
_RARE_ I-GENE
activity O
. O

_RARE_ I-GENE
degradation O
of O
_RARE_ I-GENE
in O
plasma I-GENE
is O
the O
major I-GENE
route O
of O
elimination O
in O
man O
and O
contributes O
to O
a O
short O
elimination O
half O
- I-GENE
life O
( O
_RARE_ I-GENE
20 O
min O
). O

_RARE_ I-GENE
cell O
lines O
expressing O
solely O
E1a I-GENE
or O
E1a I-GENE
and O
_RARE_ I-GENE
gene I-GENE
products I-GENE
derived O
from O
these O
viruses O
display O
enhanced O
anchorage O
- I-GENE
independent O
growth I-GENE
at O
37 O
degrees O
C I-GENE
versus O
32 O
degrees O
C I-GENE
and O
display O
a O
cytoskeletal O
architecture O
resembling O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
cells O
. O

Partial O
N I-GENE
- I-GENE
terminal I-GENE
amino O
acid I-GENE
sequence I-GENE
analysis O
showed O
that O
the O
_RARE_ I-GENE
and O
_RARE_ I-GENE
T I-GENE
antigens I-GENE
contain O
methionine O
at O
residues O
1 I-GENE
and O
5 I-GENE
, O
as O
predicted O
from O
the O
DNA I-GENE
sequence I-GENE
, O
whereas O
no O
methionine O
was O
released O
from O
the O
_RARE_ I-GENE
T I-GENE
antigen I-GENE
during O
the O
first O
six O
cycles O
of O
_RARE_ I-GENE
degradation O
. O

Group O
A I-GENE
was O
treated O
with O
three O
or O
four O
doses O
of O
hepatitis I-GENE
B I-GENE
immune I-GENE
globulin I-GENE
( O
_RARE_ I-GENE
) O
in O
one O
of O
three O
different O
_RARE_ I-GENE
. O

In O
the O
former O
_RARE_ I-GENE
, O
in O
addition O
to O
serum I-GENE
calcium O
and O
_RARE_ I-GENE
ion O
concentrations O
, O
tissue I-GENE
pH O
, O
blood O
supply O
, O
hormones O
, O
i O
. O
e O
., O
vitamin O
D I-GENE
, O
vitamin O
A I-GENE
, O
and O
various O
enzymes O
( O
e O
. O
g O
., O
alkaline I-GENE
phosphatase I-GENE
and O
_RARE_ I-GENE
) O
may O
all O
play O
significant O
, O
_RARE_ I-GENE
, O
time O
- I-GENE
dependent I-GENE
, O
but O
as O
yet O
_RARE_ I-GENE
roles O
. O

_RARE_ I-GENE
production O
in O
Staphylococcus I-GENE
aureus I-GENE
strains O
of O
clinical O
importance O
. O

Thus O
, O
quantitative O
analysis O
of O
thallium O
- I-GENE
201 O
uptake O
and O
washout O
provided O
objective O
evidence O
for O
improved O
myocardial O
perfusion O
after O
coronary O
_RARE_ I-GENE
. O

This O
study O
reports O
the O
effects O
of O
a O
preparation O
with O
50 O
micrograms O
_RARE_ I-GENE
estradiol O
and O
2 I-GENE
mg O
_RARE_ I-GENE
acetate O
on O
_RARE_ I-GENE
, O
prolactin I-GENE
, O
testosterone O
, O
sex I-GENE
hormone I-GENE
binding I-GENE
globulin I-GENE
( O
SHBG I-GENE
), O
_RARE_ I-GENE
, O
and O
calculated O
free O
testosterone O
index O
before O
and O
after O
six O
months O
of O
treatment O
. O

Functional O
flow O
was O
evaluated O
using O
laser O
Doppler O
_RARE_ I-GENE
( O
_RARE_ I-GENE
), O
for O
which O
the O
output O
signal I-GENE
, O
blood O
cell O
_RARE_ I-GENE
( O
_RARE_ I-GENE
), O
is O
expressed O
in O
terms O
of O
_RARE_ I-GENE
. O

In O
nine O
patients O
with O
renal O
failure O
routine O
haemodialysis O
was O
accompanied O
by O
a O
30 O
per O
cent O
reduction O
in O
plasma I-GENE
ANP I-GENE
concentration O
. O

To O
investigate O
the O
effects O
of O
_RARE_ I-GENE
on O
HDL I-GENE
, O
we O
measured O
HDL I-GENE
- I-GENE
C I-GENE
, O
HDL I-GENE
phospholipids O
( O
HDL I-GENE
- I-GENE
PL I-GENE
), O
_RARE_ I-GENE
A1 I-GENE
( O
apo I-GENE
A I-GENE
- I-GENE
1 I-GENE
), O
and O
HDL I-GENE
- I-GENE
C I-GENE
_RARE_ I-GENE
( O
HDL2 I-GENE
- I-GENE
C I-GENE
and O
_RARE_ I-GENE
- I-GENE
C I-GENE
) O
in O
24 O
healthy O
, O
male O
patients O
receiving O
a O
16 O
- I-GENE
week O
course O
of O
_RARE_ I-GENE
( O
1 I-GENE
. O
0 O
mg O
/ I-GENE
kg O
/ I-GENE
day O
) O
for O
treatment O
of O
severe O
_RARE_ I-GENE
_RARE_ I-GENE
. O

The O
clinical O
picture O
and O
laboratory O
parameters O
were O
consistent O
with O
a O
serum I-GENE
_RARE_ I-GENE
reaction O
. O

Our O
data O
, O
however O
, O
did O
not O
suggest O
the O
existence O
of O
a O
conversion O
factor I-GENE
for O
_RARE_ I-GENE
signal I-GENE
to O
absolute O
flow O
values O
from O
experiment O
to O
experiment O
. O

_RARE_ I-GENE
effect O
of O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
on O
thrombosis O
and O
_RARE_ I-GENE
in O
vitro O
and O
in O
vivo O
. O

The O
frequency O
of O
_RARE_ I-GENE
strains O
increased O
from O
1 I-GENE
. O
7 O
% O
in O
_RARE_ I-GENE
to O
6 I-GENE
. O
7 O
% O
in O
1985 O
. O

_RARE_ I-GENE
antibodies I-GENE
, O
_RARE_ I-GENE
from O
the O
beta I-GENE
- I-GENE
galactosidase I-GENE
fusion I-GENE
protein I-GENE
of O
either O
clone O
reacted O
with O
the O
U1 I-GENE
snRNP I-GENE
- I-GENE
specific I-GENE
A I-GENE
antigen I-GENE
. O

Quantitative O
analysis O
of O
the O
coronary O
stenosis O
was O
assessed O
before O
and O
after O
PTCA O
, O
and O
the O
dilatation O
resulted O
in O
an O
increase O
in O
minimal I-GENE
luminal O
cross O
- I-GENE
sectional O
area O
from O
1 I-GENE
. O
1 I-GENE
+/- O
0 O
. O
8 O
to O
2 I-GENE
. O
7 O
+/- O
1 I-GENE
. O
2 I-GENE
mm2 O
. O

The O
pathogenesis O
of O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
in O
diabetes O
is O
unknown O
, O
but O
the O
abnormality O
is O
_RARE_ I-GENE
to O
be O
associated I-GENE
with O
an O
increased O
incidence O
of O
_RARE_ I-GENE
. O

In O
a O
previous O
study O
( O
_RARE_ I-GENE
, O
C I-GENE
. O

The O
experimental O
end O
points O
were O
the O
time O
required O
for O
treated O
tumors O
to O
reach O
3 I-GENE
times O
their O
treatment O
size O
, O
the O
survival O
of O
stem O
cells O
in O
the O
duodenal O
_RARE_ I-GENE
, O
and O
the O
breathing O
rate O
measured O
early I-GENE
( O
19 O
- I-GENE
23 O
weeks O
) O
and O
late O
( O
41 O
- I-GENE
46 O
weeks O
) O
after O
treatment O
. O

_RARE_ I-GENE
2 I-GENE
, O
in O
which O
2 I-GENE
. O
4 I-GENE
mg O
/ I-GENE
kg O
c I-GENE
- I-GENE
DDP O
was O
administered O
immediately O
before O
X I-GENE
- I-GENE
ray O
on O
5 I-GENE
consecutive O
days O
produced O
the O
highest O
degree O
of O
enhancement O
of O
radiation O
effect O
( O
expressed O
as O
dose O
- I-GENE
effect O
factor I-GENE
); O
and O
the O
next O
greatest O
enhancement O
was O
produced O
by O
12 O
mg O
/ I-GENE
kg O
c I-GENE
- I-GENE
DDP O
administered O
24 O
h O
before O
the O
start O
of O
_RARE_ I-GENE
daily O
radiotherapy O
. O

The O
_RARE_ I-GENE
- I-GENE
1 I-GENE
- I-GENE
encoded I-GENE
transcript I-GENE
contains O
three O
open O
reading O
frames O
, O
two O
of O
which O
are O
located O
in O
the O
_RARE_ I-GENE
- I-GENE
nucleotide I-GENE
leader O
segment O
preceding O
the O
_RARE_ I-GENE
- I-GENE
1 I-GENE
coding O
region O
. O

The O
_RARE_ I-GENE
- I-GENE
steroid I-GENE
hormone I-GENE
1 I-GENE
, O
25 O
- I-GENE
_RARE_ I-GENE
D3 I-GENE
is O
known O
to O
induce O
the O
expression O
of O
a O
calcium O
binding I-GENE
protein I-GENE
termed O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
in O
a O
variety O
of O
target O
tissues O
. O

In O
addition O
, O
the O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
promoter I-GENE
is O
composed O
of O
a O
variety O
of O
simple O
repeated O
sequences I-GENE
, O
some O
of O
which O
are O
components O
of O
putative O
regulatory I-GENE
signals O
. O

The O
_RARE_ I-GENE
induced O
a O
nearly O
fourfold O
increase O
in O
_RARE_ I-GENE
in O
the O
elderly O
, O
whereas O
that O
for O
the O
young O
was O
threefold O
. O

To O
assess O
the O
ability O
of O
the O
_RARE_ I-GENE
to O
maintain O
elevated O
plasma I-GENE
concentrations O
of O
atrial I-GENE
_RARE_ I-GENE
peptide I-GENE
( O
ANP I-GENE
), O
the O
temporal O
changes O
in O
plasma I-GENE
ANP I-GENE
concentrations O
were O
studied O
in O
seven O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
dogs O
during O
4 I-GENE
h O
of O
sustained O
rapid O
cardiac O
pacing O
. O

Ig I-GENE
D I-GENE
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
may O
_RARE_ I-GENE
_RARE_ I-GENE
gene I-GENE
recombination O
in O
these O
early I-GENE
T I-GENE
cell O
lines O
, O
and O
some O
but O
not O
all O
express O
_RARE_ I-GENE
_RARE_ I-GENE
transcripts I-GENE
. O

The O
_RARE_ I-GENE
gene I-GENE
open O
reading O
frame O
encodes O
a O
protein I-GENE
of O
_RARE_ I-GENE
amino O
acids O
, O
with O
a O
calculated O
molecular O
weight O
of O
55 O
, O
_RARE_ I-GENE
. O

_RARE_ I-GENE
absorption O
_RARE_ I-GENE
applied O
to O
bacterially O
expressed O
E1A I-GENE
proteins I-GENE
revealed O
that O
the O
_RARE_ I-GENE
- I-GENE
amino O
acid I-GENE
protein I-GENE
binds O
one O
zinc I-GENE
ion O
, O
whereas O
the O
_RARE_ I-GENE
- I-GENE
amino O
acid I-GENE
protein I-GENE
binds O
no O
zinc I-GENE
. O

Most O
patients O
preferred O
_RARE_ I-GENE
to O
injection O
both O
on O
day O
1 I-GENE
( O
_RARE_ I-GENE
v I-GENE
200 O
) O
and O
at O
follow O
up O
( O
_RARE_ I-GENE
v I-GENE
104 O
). O

_RARE_ I-GENE
of O
RV O
, O
LV O
+ I-GENE
S I-GENE
and O
2A I-GENE
weight O
vs O
real O
hematocrit O
showed O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
at O
real O
hematocrit O
65 O
%, O
suggesting O
a O
possible O
role O
of O
increased O
viscosity O
in O
CO I-GENE
_RARE_ I-GENE
at O
the O
higher O
hematocrit O
. O

The O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
is O
an O
important O
improvement O
, O
and O
in O
some O
cases O
it O
may O
replace O
other O
techniques O
for O
_RARE_ I-GENE
splenic O
bleeding O
. O

A I-GENE
rare O
chronic O
course O
of O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
syndrome O
associated I-GENE
with O
thrombosis O
of O
the O
portal I-GENE
vein O
was O
observed O
in O
a O
30 O
- I-GENE
year O
- I-GENE
old O
male O
patient O
suffering O
from O
_RARE_ I-GENE
_RARE_ I-GENE
. O

After O
one O
_RARE_ I-GENE
night O
, O
sleep O
EEG O
recordings O
were O
performed O
during O
three O
consecutive O
_RARE_ I-GENE
in O
ten O
drug O
- I-GENE
free O
_RARE_ I-GENE
presenting O
generalized O
anxiety O
disorder O
( O
_RARE_ I-GENE
) O
with O
significant O
depression O
, O
compared O
with O
a O
age O
- I-GENE
and O
sex I-GENE
- I-GENE
matched O
group O
of O
patients O
with O
_RARE_ I-GENE
and O
a O
group O
of O
primary O
major I-GENE
_RARE_ I-GENE
disorder O
( O
_RARE_ I-GENE
) O
patients O
. O

_RARE_ I-GENE
mutagenesis O
of O
these O
binding I-GENE
domains I-GENE
indicated O
their O
importance O
in O
the O
transcriptional O
regulation O
of O
the O
E3 I-GENE
promoter I-GENE
in O
yeast I-GENE
cells O
. O

The O
concentration O
of O
_RARE_ I-GENE
on O
the O
newly O
- I-GENE
formed O
luminal O
surface O
remained O
low O
. O

_RARE_ I-GENE
transplantation O
in O
_RARE_ I-GENE
. O

Effects O
of O
single O
and O
combined O
_RARE_ I-GENE
_RARE_ I-GENE
immunotherapy O
, O
cyclophosphamide O
chemotherapy O
and O
radiotherapy O
on O
ethyl O
_RARE_ I-GENE
accelerated O
primary O
lung O
cancer O
in O
A I-GENE
/ I-GENE
J O
mice O
. O

D I-GENE
. O

A I-GENE
114 I-GENE
- I-GENE
base O
pair O
sequence I-GENE
of O
predominantly O
repeating O
_RARE_ I-GENE
- I-GENE
pyrimidine O
nucleotides O
_RARE_ I-GENE
these O
two O
d O
( O
AC I-GENE
) O
repeats I-GENE
. O

Phase O
II I-GENE
study O
of O
_RARE_ I-GENE
- I-GENE
16 O
( O
_RARE_ I-GENE
) O
in O
solid O
tumors O
. O

When O
the O
coding O
segments O
, O
including O
both O
_RARE_ I-GENE
and O
complementarity I-GENE
- I-GENE
determining O
regions O
, O
of O
these O
genes I-GENE
and O
the O
murine I-GENE
probe O
sequences I-GENE
are O
compared O
by O
_RARE_ I-GENE
analysis O
, O
it O
is O
apparent O
that O
the O
_RARE_ I-GENE
genes I-GENE
are O
only O
slightly O
more O
related I-GENE
to O
each O
other O
than O
to O
the O
mammalian I-GENE
sequence I-GENE
, O
consistent O
with O
significant O
preservation O
of O
nucleotide I-GENE
sequence I-GENE
over O
an O
extended O
period O
of O
phylogenetic O
time O
. O

Evidence O
for O
a O
role O
of O
endogenous I-GENE
_RARE_ I-GENE
- I-GENE
releasing I-GENE
factor I-GENE
in O
cold O
, O
ether O
, O
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
stress O
. O

An O
unusual O
feature O
of O
these O
replicative O
genes I-GENE
is O
that O
the O
smaller O
mRNA I-GENE
begins O
within O
a O
long O
open O
reading O
frame O
of O
the O
larger O
mRNA I-GENE
. O

_RARE_ I-GENE
sequence I-GENE
elements O
of O
both O
the O
retroviral I-GENE
vectors O
and O
the O
c I-GENE
- I-GENE
myc I-GENE
gene I-GENE
_RARE_ I-GENE
during O
_RARE_ I-GENE
of O
highly O
oncogenic I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
or O
_RARE_ I-GENE
. O

81 O
milk O
samples O
collected O
from O
35 O
donors O
3 I-GENE
days O
to O
7 O
months O
after O
delivery O
were O
examined O
for O
the O
occurrence O
of O
cytomegalovirus I-GENE
( O
CMV O
). O

_RARE_ I-GENE
of O
DNA I-GENE
fragments I-GENE
from O
the O
8 O
. O
5 I-GENE
- I-GENE
kilobase O
( O
kb O
) O
insert O
of O
_RARE_ I-GENE
defined O
a O
4 I-GENE
- I-GENE
kb O
DNA I-GENE
fragment I-GENE
which O
contained O
the O
functional O
_RARE_ I-GENE
+ I-GENE
gene I-GENE
and O
its O
regulatory I-GENE
region O
. O

Three O
cases O
of O
primary O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
cell O
carcinoma O
of O
the O
_RARE_ I-GENE
are O
described O
. O

The O
data O
obtained O
up O
to O
now O
only O
suggest O
the O
future O
_RARE_ I-GENE
of O
_RARE_ I-GENE
treatment O
for O
these O
types O
of O
malignancy O
. O

These O
data O
suggest O
that O
dopaminergic O
regulation O
of O
adrenal O
_RARE_ I-GENE
_RARE_ I-GENE
corticosteroid I-GENE
and O
renal O
renin I-GENE
secretion O
is O
absent O
in O
patients O
with O
high O
spinal O
cord O
_RARE_ I-GENE
, O
suggesting O
that O
intact O
neural O
pathways O
from O
the O
central O
nervous O
system O
are O
necessary O
for O
_RARE_ I-GENE
stimulation O
of O
aldosterone O
and O
renin I-GENE
secretion O
in O
men O
. O

In O
the O
absence O
of O
enhancer I-GENE
sequences I-GENE
, O
the O
adenovirus I-GENE
E1A I-GENE
gene I-GENE
can O
not O
stimulate O
_RARE_ I-GENE
synthesis O
. O

These O
IgG I-GENE
antibodies I-GENE
in O
the O
babies O
diminished O
rapidly O
after O
delivery O
, O
and O
were O
detectable O
only O
in O
3 I-GENE
cases O
at O
2 I-GENE
, O
3 I-GENE
, O
and O
5 I-GENE
months O
of O
ages O
out O
of O
38 O
babies O
up O
to O
21 O
months O
. O

_RARE_ I-GENE
analysis O
at O
the O
nucleotide I-GENE
level O
of O
the O
early I-GENE
events O
in O
the O
digestion O
with O
nuclease I-GENE
S1 I-GENE
shows O
that O
the O
enzyme I-GENE
attacks O
preferentially O
the O
sequence I-GENE
( O
G I-GENE
- I-GENE
A I-GENE
) O
12 O
on O
the O
message I-GENE
complementary O
strand O
. O

_RARE_ I-GENE
_RARE_ I-GENE
that O
inhibited O
mean O
_RARE_ I-GENE
activity O
in O
spinal O
cord O
greater O
than O
or O
equal O
to O
72 O
% O
and O
brain O
greater O
than O
or O
equal O
to O
66 O
% O
of O
control O
values O
within O
44 I-GENE
hr O
postexposure O
produced O
marked O
spinal O
cord O
pathology O
14 O
days O
postexposure O
in O
greater O
than O
or O
equal O
to O
90 O
% O
of O
similarly O
_RARE_ I-GENE
animals O
. O

FK O
33 O
- I-GENE
_RARE_ I-GENE
, O
a O
methionine O
- I-GENE
_RARE_ I-GENE
analogue O
, O
suppressed O
plasma I-GENE
ACTH I-GENE
to O
85 O
% O
of O
basal O
level O
, O
while O
_RARE_ I-GENE
( O
_RARE_ I-GENE
- I-GENE
154 O
) O
caused O
no O
significant O
change O
. O

A I-GENE
v I-GENE
- I-GENE
erbB I-GENE
- I-GENE
related I-GENE
protooncogene I-GENE
, O
c I-GENE
- I-GENE
erbB I-GENE
- I-GENE
2 I-GENE
, O
is O
distinct O
from O
the O
c I-GENE
- I-GENE
erbB I-GENE
- I-GENE
1 I-GENE
/ I-GENE
epidermal I-GENE
growth I-GENE
factor I-GENE
- I-GENE
receptor I-GENE
gene I-GENE
and O
is O
amplified O
in O
a O
human I-GENE
salivary I-GENE
gland O
adenocarcinoma O
. O

The O
sequence I-GENE
analysis O
of O
both O
products I-GENE
of O
individual O
phi I-GENE
80 O
site I-GENE
- I-GENE
specific I-GENE
recombination O
events O
in O
vivo O
shows O
that O
recombination O
with O
a O
secondary O
attachment O
( O
_RARE_ I-GENE
) O
site I-GENE
generates O
several O
different O
novel O
_RARE_ I-GENE
at O
the O
_RARE_ I-GENE
position O
: O
one O
recombination O
event O
resulted O
in O
a O
single O
base O
- I-GENE
pair O
deletion O
and O
two O
other O
recombination O
events O
resulted O
in O
two O
different O
single O
base O
- I-GENE
pair O
substitutions O
. O

This O
L I-GENE
- I-GENE
myc I-GENE
sequence I-GENE
is O
amplified O
10 O
- I-GENE
20 O
- I-GENE
fold O
in O
four O
_RARE_ I-GENE
cell O
line O
DNAs O
and O
in O
one O
_RARE_ I-GENE
tumour I-GENE
_RARE_ I-GENE
taken O
directly O
from O
a O
patient O
. O

_RARE_ I-GENE
- I-GENE
shift O
experiments O
using O
_RARE_ I-GENE
grown O
cells O
of O
a O
delta I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
temperature O
- I-GENE
sensitive O
( O
ts I-GENE
) O
double O
mutant I-GENE
and O
its O
_RARE_ I-GENE
_RARE_ I-GENE
ts I-GENE
strain O
show O
that O
, O
whereas O
mitotic O
blocks O
can O
prevent O
_RARE_ I-GENE
of O
the O
_RARE_ I-GENE
ts I-GENE
mutant I-GENE
at O
a O
_RARE_ I-GENE
temperature O
, O
the O
same O
treatments O
are O
_RARE_ I-GENE
in O
preventing O
cell O
death O
of O
the O
delta I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
ts I-GENE
double O
mutant I-GENE
. O

The O
homology I-GENE
to O
v I-GENE
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
within O
the O
coding O
sequence I-GENE
of O
exon O
1 I-GENE
and O
ends O
within O
the O
3 I-GENE
' O
untranslated O
region O
of O
exon O
11 O
, O
12 O
nucleotides O
downstream O
from O
the O
nonsense O
codon O
_RARE_ I-GENE
the O
large O
open O
reading O
frame O
shared O
between O
c I-GENE
- I-GENE
_RARE_ I-GENE
and O
v I-GENE
- I-GENE
_RARE_ I-GENE
. O

Examination O
of O
the O
sequence I-GENE
of O
the O
_RARE_ I-GENE
_RARE_ I-GENE
M I-GENE
gene I-GENE
product I-GENE
reveals O
the O
presence O
of O
multiple O
hydrophobic O
sequences I-GENE
including O
a O
19 O
- I-GENE
amino O
acid I-GENE
, O
carboxy I-GENE
- I-GENE
proximal I-GENE
, O
hydrophobic O
region O
( O
G2 I-GENE
). O

Six O
( O
four O
_RARE_ I-GENE
; O
two O
primary O
_RARE_ I-GENE
) O
also O
had O
_RARE_ I-GENE
positive O
myocardial O
_RARE_ I-GENE
, O
but O
the O
intensity O
was O
less O
than O
that O
of O
the O
_RARE_ I-GENE
. O

The O
intensity O
of O
myocardial O
uptake O
of O
Tc O
- I-GENE
99m O
- I-GENE
_RARE_ I-GENE
in O
patients O
with O
echocardiographic O
left O
ventricular O
hypertrophy O
and O
/ I-GENE
or O
highly O
_RARE_ I-GENE
myocardial O
_RARE_ I-GENE
, O
so O
- I-GENE
called O
_RARE_ I-GENE
_RARE_ I-GENE
appearance O
( O
GS I-GENE
) O
was O
slightly O
greater O
than O
that O
in O
patients O
with O
neither O
myocardial O
hypertrophy O
nor O
GS I-GENE
. O

The O
210 O
kDa I-GENE
precursor I-GENE
is O
converted O
slowly O
( O
t I-GENE
1 I-GENE
/ I-GENE
2 I-GENE
= O
2 I-GENE
h O
) O
by O
proteolytic O
processing O
into O
a O
125 I-GENE
kDa I-GENE
( O
alpha I-GENE
') I-GENE
and O
83 O
kDa I-GENE
( O
beta I-GENE
') I-GENE
species O
. O

_RARE_ I-GENE
lymphocytes O
were O
_RARE_ I-GENE
increased O
in O
most O
patients O
with O
AIDS O
( O
mean O
26 O
. O
1 I-GENE
+/- O
21 O
. O
9 O
%; O
range O
1 I-GENE
- I-GENE
76 I-GENE
%) O
and O
_RARE_ I-GENE
( O
mean O
26 O
. O
6 I-GENE
+/- O
22 O
. O
6 I-GENE
%; O
range O
3 I-GENE
- I-GENE
76 I-GENE
%) O
with O
criteria O
of O
activation O
_RARE_ I-GENE
with O
the O
blood O
_RARE_ I-GENE
. O

We O
have O
determined O
that O
these O
_RARE_ I-GENE
occur O
in O
both O
the O
wild I-GENE
- I-GENE
type I-GENE
and O
the O
mutant I-GENE
sites I-GENE
. O

The O
sequence I-GENE
was O
determined O
for O
a O
_RARE_ I-GENE
- I-GENE
base O
pair O
( O
bp O
) O
segment O
that O
_RARE_ I-GENE
from O
_RARE_ I-GENE
bp O
5 I-GENE
' O
to O
the O
cap I-GENE
site I-GENE
of O
alpha I-GENE
1 I-GENE
to O
_RARE_ I-GENE
bp O
3 I-GENE
' O
to O
psi I-GENE
alpha I-GENE
. O

Its O
predicted O
amino O
acid I-GENE
sequence I-GENE
shows O
extensive O
homology I-GENE
to O
those O
of O
Drosophila I-GENE
hsp70 I-GENE
, O
trout I-GENE
hsp70 I-GENE
, O
Xenopus I-GENE
hsp70 I-GENE
, O
yeast I-GENE
hsp70 I-GENE
, O
and O
some O
homology I-GENE
to O
the O
heat I-GENE
- I-GENE
inducible I-GENE
_RARE_ I-GENE
gene I-GENE
product I-GENE
of O
Escherichia I-GENE
coli I-GENE
. O

When O
phosphorylation O
of O
exogenous O
peptide I-GENE
substrates O
was O
measured O
as O
a O
function O
of O
receptor I-GENE
self O
- I-GENE
phosphorylation O
, O
tyrosine I-GENE
kinase I-GENE
activity O
was O
found O
to O
be O
enhanced O
two O
to O
threefold O
at O
1 I-GENE
- I-GENE
2 I-GENE
mol O
of O
phosphate I-GENE
per O
mol O
of O
receptor I-GENE
. O

At O
temperatures O
permissive O
for O
transformation O
, O
_RARE_ I-GENE
cells O
contain O
_RARE_ I-GENE
produced O
from O
the O
4 I-GENE
. O
0 O
- I-GENE
kilobase O
( O
kb O
) O
viral I-GENE
RNA I-GENE
genome O
and O
_RARE_ I-GENE
- I-GENE
mos I-GENE
translated O
from O
a O
3 I-GENE
. O
5 I-GENE
- I-GENE
kb O
spliced O
mRNA I-GENE
. O

The O
_RARE_ I-GENE
and O
_RARE_ I-GENE
genes I-GENE
are O
transcribed O
divergently O
from O
initiation I-GENE
sites I-GENE
that O
are O
separated O
by O
only O
192 I-GENE
bp O
. O

_RARE_ I-GENE
transformation O
by O
defined O
fragments I-GENE
of O
herpes I-GENE
simplex I-GENE
virus I-GENE
type I-GENE
2 I-GENE
DNA I-GENE
: O
oncogenic I-GENE
region O
and O
its O
gene I-GENE
product I-GENE
. O

It O
is O
concluded O
that O
in O
patients O
with O
first O
- I-GENE
_RARE_ I-GENE
genital O
herpes I-GENE
, O
the O
type I-GENE
of O
HSV I-GENE
is O
the O
most O
important O
determinant O
of O
subsequent O
_RARE_ I-GENE
and O
that O
intravenous O
_RARE_ I-GENE
has O
little O
effect O
on O
subsequent O
_RARE_ I-GENE
. O

Comparison O
of O
sequences I-GENE
of O
_RARE_ I-GENE
and O
bovine I-GENE
, O
rat I-GENE
and O
guinea O
- I-GENE
pig O
alpha I-GENE
_RARE_ I-GENE
- I-GENE
casein I-GENE
mRNAs I-GENE
has O
revealed O
a O
greater O
homology I-GENE
in O
the O
3 I-GENE
' O
and O
especially O
5 I-GENE
' O
non O
coding O
regions O
. O

One O
group O
( O
n O
= O
9 O
) O
was O
_RARE_ I-GENE
with O
midazolam O
, O
0 O
. O
1 I-GENE
mg O
kg O
- I-GENE
1 I-GENE
, O
and O
atropine O
0 O
. O
2 I-GENE
- I-GENE
0 O
. O
4 I-GENE
mg O
i O
. O
m I-GENE
. O

Comparison O
with O
a O
recently O
described O
c I-GENE
- I-GENE
_RARE_ I-GENE
cDNA I-GENE
clone O
( O
_RARE_ I-GENE
et O
al O
., O
_RARE_ I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
- I-GENE
750 O
( O
1985 O
)) O
revealed O
that O
the O
1 I-GENE
. O
9 O
kbp O
DNA I-GENE
region O
contained O
a O
large O
5 I-GENE
' O
c I-GENE
- I-GENE
_RARE_ I-GENE
exon O
of O
at O
least O
_RARE_ I-GENE
bp O
. O

It O
was O
also O
suggested O
that O
the O
biological O
activities O
of O
5 I-GENE
- I-GENE
FU O
, O
_RARE_ I-GENE
and O
MMC O
in O
_RARE_ I-GENE
were O
stable O
in O
_RARE_ I-GENE
, O
_RARE_ I-GENE
and O
_RARE_ I-GENE
. O

Surprisingly O
, O
a O
C I-GENE
to O
G I-GENE
transversion O
at O
the O
first O
residue O
of O
the O
CAT I-GENE
_RARE_ I-GENE
, O
which O
severely O
_RARE_ I-GENE
the O
activity O
of O
both O
promoters I-GENE
, O
appears O
to O
increase O
affinity O
of O
the O
CAT I-GENE
binding I-GENE
protein I-GENE
. O

The O
nucleotide I-GENE
sequence I-GENE
of O
_RARE_ I-GENE
bp O
of O
cloned O
R I-GENE
. O
_RARE_ I-GENE
chromosomal I-GENE
DNA I-GENE
, O
including O
the O
three O
structural O
genes I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
and O
_RARE_ I-GENE
has O
been O
determined O
. O

The O
N I-GENE
- I-GENE
terminal I-GENE
sequence I-GENE
of O
one O
hydrophilic O
peptide I-GENE
of O
the O
_RARE_ I-GENE
protein I-GENE
has O
been O
also O
obtained O
confirming O
the O
_RARE_ I-GENE
reading O
frame O
. O

The O
5 I-GENE
' O
and O
3 I-GENE
' O
untranslated O
sequences I-GENE
contain O
characteristic O
sequences I-GENE
that O
are O
involved O
in O
the O
initiation I-GENE
and O
termination O
of O
transcription I-GENE
, O
including O
two O
possible O
promoters I-GENE
, O
one O
of O
which O
may O
contain O
two O
overlapping O
- I-GENE
10 O
sequences I-GENE
. O

Unlike O
_RARE_ I-GENE
- I-GENE
myb I-GENE
- I-GENE
ets I-GENE
and O
the O
Mr O
75 O
, O
000 O
translation I-GENE
product I-GENE
of O
c I-GENE
- I-GENE
myb I-GENE
( O
_RARE_ I-GENE
- I-GENE
myb I-GENE
), O
which O
are O
nuclear I-GENE
proteins I-GENE
, O
_RARE_ I-GENE
- I-GENE
ets I-GENE
was O
found O
to O
be O
predominantly O
cytoplasmic I-GENE
. O

The O
_RARE_ I-GENE
- I-GENE
A2 I-GENE
locus I-GENE
is O
within O
3 I-GENE
. O
4 I-GENE
to O
4 I-GENE
. O
4 I-GENE
kb O
of O
the O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
_RARE_ I-GENE
breakpoint I-GENE
, O
_RARE_ I-GENE
four O
of O
the O
vital O
loci I-GENE
within O
a O
maximum O
of O
15 O
. O
5 I-GENE
kb O
. O

The O
C I-GENE
- I-GENE
terminal I-GENE
end O
of O
this O
polypeptide I-GENE
_RARE_ I-GENE
three O
types O
of O
repeated O
sequences I-GENE
. O

Further O
_RARE_ I-GENE
of O
ocular O
disease O
in O
_RARE_ I-GENE
red I-GENE
_RARE_ I-GENE
calves O
caused O
by O
_RARE_ I-GENE
- I-GENE
1 I-GENE
were O
investigated O
. O

From O
our O
_RARE_ I-GENE
and O
biochemical O
studies O
, O
it O
is O
evident O
that O
Type O
II I-GENE
_RARE_ I-GENE
are O
an O
early I-GENE
target O
of O
radiation O
and O
the O
release O
of O
surfactant I-GENE
into O
the O
_RARE_ I-GENE
_RARE_ I-GENE
after O
exposure O
_RARE_ I-GENE
for O
days O
and O
weeks O
. O

Thirty O
of O
the O
clones O
contained O
a O
complete O
_RARE_ I-GENE
base O
- I-GENE
pair O
dimer O
unit I-GENE
of O
the O
repeat I-GENE
. O

Two O
copies O
of O
the O
72 O
- I-GENE
bp O
repeat I-GENE
provided O
efficient O
activation O
of O
gene I-GENE
expression O
. O

The O
open O
reading O
frames O
of O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
encode O
proteins I-GENE
of O
139 O
, O
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
amino O
acid I-GENE
residues O
, O
respectively O
. O

In O
order O
to O
study O
the O
influence O
of O
iron O
overload O
on O
the O
_RARE_ I-GENE
_RARE_ I-GENE
( O
PMN I-GENE
) O
metabolism O
of O
patients O
on O
chronic O
hemodialysis O
, O
generation O
of O
superoxide I-GENE
_RARE_ I-GENE
( O
O2 O
-) I-GENE
by O
PMN I-GENE
in O
whole O
blood O
was O
compared O
in O
two O
groups O
of O
_RARE_ I-GENE
patients O
: O
group O
A I-GENE
consisted O
of O
_RARE_ I-GENE
- I-GENE
one O
individuals O
with O
serum I-GENE
ferritin I-GENE
levels O
above O
1000 O
ng O
/ I-GENE
ml O
and O
group O
B I-GENE
of O
_RARE_ I-GENE
individuals O
with O
serum I-GENE
ferritin I-GENE
levels O
below O
1000 O
ng O
/ I-GENE
ml O
. O

_RARE_ I-GENE
, O
and O
J O
. O

Human I-GENE
alpha I-GENE
- I-GENE
galactosidase I-GENE
A I-GENE
: O
nucleotide I-GENE
sequence I-GENE
of O
a O
cDNA I-GENE
clone O
encoding O
the O
mature O
enzyme I-GENE
. O

_RARE_ I-GENE
( O
3 I-GENE
mg O
/ I-GENE
kg O
) O
generalized O
to O
Ro I-GENE
11 O
- I-GENE
_RARE_ I-GENE
whereas O
the O
structurally O
related I-GENE
Ro I-GENE
5 I-GENE
- I-GENE
_RARE_ I-GENE
( O
3 I-GENE
mg O
/ I-GENE
kg O
and O
30 O
mg O
/ I-GENE
kg O
) O
did O
not O
. O

The O
amino O
acid I-GENE
sequence I-GENE
was O
determined O
to O
be O
residues O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
and O
hence O
lysine O
residue O
_RARE_ I-GENE
is O
located O
within O
the O
ATP I-GENE
- I-GENE
binding I-GENE
site I-GENE
. O

_RARE_ I-GENE
( O
and O
urinary O
_RARE_ I-GENE
) O
were O
not O
elevated O
in O
isolated O
_RARE_ I-GENE
, O
indicating O
that O
mechanisms O
other O
than O
increased O
bone O
turnover O
may O
account O
for O
the O
markedly O
elevated O
serum I-GENE
alkaline I-GENE
phosphatase I-GENE
activity O
in O
these O
subjects O
. O

Analysis O
of O
glucocorticoid I-GENE
_RARE_ I-GENE
cell O
variants I-GENE
using O
a O
mouse I-GENE
glucocorticoid I-GENE
receptor I-GENE
complementary O
DNA I-GENE
clone O
. O

Among O
the O
v I-GENE
- I-GENE
myc I-GENE
codons O
, O
the O
first O
5 I-GENE
are O
derived O
from O
the O
noncoding O
5 I-GENE
' O
terminus O
of O
the O
second O
c I-GENE
- I-GENE
myc I-GENE
exon O
, O
and O
_RARE_ I-GENE
codons O
correspond O
to O
the O
c I-GENE
- I-GENE
myc I-GENE
coding O
region O
. O

A I-GENE
recombinant I-GENE
vector O
, O
_RARE_ I-GENE
+, I-GENE
was O
constructed O
which O
carried O
the O
BamHI I-GENE
- I-GENE
K I-GENE
fragment I-GENE
( O
nucleotides O
_RARE_ I-GENE
to O
_RARE_ I-GENE
of O
the O
_RARE_ I-GENE
- I-GENE
8 O
strain O
, O
encoding O
the O
EBV I-GENE
- I-GENE
associated I-GENE
nuclear I-GENE
antigen I-GENE
EBNA I-GENE
- I-GENE
1 I-GENE
), O
the O
cis O
- I-GENE
acting O
sequence I-GENE
from O
the O
BamHI I-GENE
- I-GENE
C I-GENE
fragment I-GENE
, O
and O
a O
dominant I-GENE
selectable O
marker O
gene I-GENE
encoding O
G I-GENE
- I-GENE
_RARE_ I-GENE
resistance O
in O
animal O
cells O
. O

13 O
men O
with O
a O
history O
of O
recurrent O
genital O
herpes I-GENE
simplex I-GENE
virus I-GENE
type I-GENE
2 I-GENE
( O
HSV I-GENE
- I-GENE
2 I-GENE
) O
infection O
were O
followed O
daily O
for O
4 I-GENE
weeks O
with O
samples O
taken O
from O
the O
_RARE_ I-GENE
for O
virus I-GENE
isolation O
. O

_RARE_ I-GENE
, O
with O
carcinoma O
presenting O
a O
_RARE_ I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
_RARE_ I-GENE
type I-GENE
) O
of O
the O
stomach O
itself O
, O
the O
II I-GENE
c I-GENE
portion O
of O
the O
stomach O
consisted O
of O
_RARE_ I-GENE
glands O
( O
undifferentiated O
carcinoma O
) O
_RARE_ I-GENE
become O
the O
primary O
focus O
supporting O
_RARE_ I-GENE
' O
s O
theory O
. O

During O
the O
biosynthesis O
of O
all O
three O
mutant I-GENE
polypeptides I-GENE
, O
the O
signal I-GENE
peptide I-GENE
is O
efficiently O
and O
accurately O
cleaved O
from O
the O
_RARE_ I-GENE
protein I-GENE
, O
even O
though O
in O
mutants I-GENE
X2 O
and O
_RARE_ I-GENE
the O
cleavage O
site I-GENE
itself O
has O
been O
altered O
. O

The O
_RARE_ I-GENE
5 I-GENE
'- O
_RARE_ I-GENE
- I-GENE
3 I-GENE
', O
thought O
to O
be O
important O
for O
GRE I-GENE
activity O
, O
not O
only O
was O
found O
in O
this O
sequence I-GENE
and O
in O
the O
5 I-GENE
'- O
flanking O
region O
, O
but O
also O
was O
present O
twice O
in O
the O
3 I-GENE
' O
end O
of O
the O
gene I-GENE
that O
did O
not O
show O
specific I-GENE
receptor I-GENE
binding I-GENE
. O

Five O
patients O
developed O
metastatic O
spread O
, O
and O
all O
of O
them O
died O
of O
tumor I-GENE
. O

The O
smallest O
of O
the O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
elements O
is O
only O
7 O
. O
9 O
kilobase O
pairs O
long O
, O
allowing O
the O
cloning O
of O
DNA I-GENE
fragments I-GENE
of O
up O
to O
31 O
. O
1 I-GENE
kilobase O
pairs O
, O
and O
the O
largest O
of O
them O
is O
21 O
. O
7 O
kilobase O
pairs O
, O
requiring O
that O
clones O
carry O
insertions O
of O
less O
than O
17 O
. O
3 I-GENE
kilobase O
pairs O
. O

The O
52 O
- I-GENE
protein I-GENE
subunit I-GENE
of O
T4 I-GENE
DNA I-GENE
topoisomerase I-GENE
is O
homologous O
to O
the O
_RARE_ I-GENE
- I-GENE
protein I-GENE
of O
_RARE_ I-GENE
. O

There O
were O
no O
interfering O
peaks O
in O
the O
_RARE_ I-GENE
of O
_RARE_ I-GENE
. O

The O
latent I-GENE
periods O
from O
the O
_RARE_ I-GENE
exclusion O
to O
the O
occurrence O
of O
_RARE_ I-GENE
ulcers O
after O
a O
subtotal O
_RARE_ I-GENE
with O
_RARE_ I-GENE
' O
s O
type I-GENE
II I-GENE
reconstruction O
varied O
from O
a O
few O
days O
to O
19 O
years O
, O
with O
an O
average O
of O
2 I-GENE
. O
8 O
years O
. O

The O
_RARE_ I-GENE
arrays O
detected O
by O
_RARE_ I-GENE
X I-GENE
_RARE_ I-GENE
( O
II I-GENE
) O
were O
characterized O
by O
a O
considerable O
loss O
of O
detail O
and O
significantly O
enhanced O
_RARE_ I-GENE
, O
the O
extent O
of O
which O
probably O
reflected O
the O
relative O
transcription I-GENE
rate O
of O
each O
gene I-GENE
. O

_RARE_ I-GENE
of O
specific I-GENE
cellular O
genes I-GENE
from O
the O
chimeric I-GENE
viral I-GENE
- I-GENE
cellular O
transcripts I-GENE
seems O
to O
be O
unlikely O
. O

The O
molecular O
weight O
of O
in O
vivo O
- I-GENE
labeled O
proteins I-GENE
was O
increased O
relative O
to O
that O
of O
in O
vitro O
- I-GENE
translated O
proteins I-GENE
, O
indicating O
that O
a O
posttranslational O
modification O
had O
occurred O
. O

_RARE_ I-GENE
of O
4 I-GENE
bp O
reduced O
SV40 I-GENE
early I-GENE
promoter I-GENE
- I-GENE
dependent I-GENE
chloramphenicol I-GENE
acetyltransferase I-GENE
( O
CAT I-GENE
) O
expression O
by O
six O
- I-GENE
to O
_RARE_ I-GENE
. O

In O
the O
DNAs O
of O
all O
_RARE_ I-GENE
- I-GENE
positive O
chronic O
_RARE_ I-GENE
leukemia I-GENE
patients O
studied O
to O
date O
, O
a O
breakpoint I-GENE
on O
chromosome O
22 O
( O
the O
_RARE_ I-GENE
chromosome O
) O
can O
be O
demonstrated O
with O
a O
probe O
from O
the O
_RARE_ I-GENE
( O
breakpoint I-GENE
cluster I-GENE
region O
). O

_RARE_ I-GENE
footprinting O
revealed O
that O
purified O
glucocorticoid I-GENE
receptor I-GENE
bound O
at O
multiple O
discrete O
sites I-GENE
within O
and O
at O
the O
_RARE_ I-GENE
of O
the O
tandemly O
repeated O
sequence I-GENE
motif I-GENE
that O
defines O
_RARE_ I-GENE
. O

The O
96 O
- I-GENE
bp O
insert O
contained O
a O
termination O
signal I-GENE
which O
caused O
the O
premature O
termination O
of O
the O
protein I-GENE
, O
leading O
to O
the O
generation O
of O
a O
p53 I-GENE
product I-GENE
9 O
amino O
acids O
shorter O
than O
_RARE_ I-GENE
. O

All O
tumors O
proved O
histologically O
to O
be O
_RARE_ I-GENE
in O
origin O
. O

The O
coding O
region O
of O
_RARE_ I-GENE
nucleotides O
corresponds O
to O
a O
polypeptide I-GENE
chain I-GENE
of O
_RARE_ I-GENE
amino O
acids O
, O
giving O
a O
molecular O
weight O
of O
91 O
, O
_RARE_ I-GENE
for O
the O
_RARE_ I-GENE
protein I-GENE
. O

Transcriptional O
control O
signals O
of O
a O
herpes I-GENE
simplex I-GENE
virus I-GENE
type I-GENE
1 I-GENE
late O
( O
gamma I-GENE
2 I-GENE
) O
gene I-GENE
_RARE_ I-GENE
within O
bases O
- I-GENE
34 O
to O
+ I-GENE
124 I-GENE
relative O
to O
the O
5 I-GENE
' O
terminus O
of O
the O
mRNA I-GENE
. O

A I-GENE
_RARE_ I-GENE
domain I-GENE
conserved O
among O
cytoplasmic I-GENE
protein I-GENE
- I-GENE
tyrosine I-GENE
kinases I-GENE
_RARE_ I-GENE
the O
kinase I-GENE
function O
and O
transforming I-GENE
activity O
of O
_RARE_ I-GENE
sarcoma I-GENE
virus I-GENE
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
, O
_RARE_ I-GENE
J O
. O

A I-GENE
single O
exon O
encodes O
the O
carboxyl O
- I-GENE
terminal I-GENE
26 O
amino O
acids O
of O
the O
_RARE_ I-GENE
chain I-GENE
and O
the O
3 I-GENE
' O
untranslated O
region O
of O
its O
mRNA I-GENE
, O
_RARE_ I-GENE
with O
a O
poly O
( O
A I-GENE
)- I-GENE
addition O
site I-GENE
. O

The O
5 I-GENE
'- O
_RARE_ I-GENE
sequences I-GENE
and O
parts O
of O
the O
coding O
sequences I-GENE
of O
various O
yeast I-GENE
genes I-GENE
have O
been O
cloned O
into O
representative O
lacZ I-GENE
fusion I-GENE
vectors O
. O

Two O
activities O
of O
the O
D I-GENE
protein I-GENE
of O
the O
_RARE_ I-GENE
plasmid O
have O
been O
found O
. O

SPECT O
examination O
of O
the O
_RARE_ I-GENE
using O
99m O
Tc O
- I-GENE
_RARE_ I-GENE
was O
performed O
in O
43 I-GENE
patients O
with O
_RARE_ I-GENE
proven O
anterior O
dislocation O
of O
the O
disc O
and O
in O
30 O
normals O
. O

Plasma I-GENE
renin I-GENE
activity O
rose O
and O
the O
plasma I-GENE
aldosterone O
level O
fell O
after O
taking O
_RARE_ I-GENE
. O

Two O
mutants I-GENE
, O
each O
representative O
of O
a O
separate O
_RARE_ I-GENE
complementation O
group O
, O
have O
been O
analyzed O
. O

The O
second O
group O
of O
homologous O
elements O
is O
present O
in O
the O
upstream O
region O
of O
both O
genes I-GENE
. O

A I-GENE
centromere O
in O
S I-GENE
. O
cerevisiae I-GENE
consists O
of O
a O
region O
of O
DNA I-GENE
, O
approximately O
150 O
bp O
in O
length I-GENE
, O
containing O
three O
important O
sequence I-GENE
elements O
, O
which O
are O
folded O
with O
proteins I-GENE
into O
a O
specific I-GENE
conformation O
in O
the O
chromatin O
( O
the O
yeast I-GENE
_RARE_ I-GENE
). O

_RARE_ I-GENE
function O
of O
a O
positively O
regulated O
promoter I-GENE
reveals O
new O
sequences I-GENE
essential O
for O
activity O
. O

Two O
separate O
NF1 I-GENE
- I-GENE
binding I-GENE
loci I-GENE
were O
also O
found O
in O
the O
equivalent O
_RARE_ I-GENE
gene I-GENE
of O
HCMV I-GENE
( O
_RARE_ I-GENE
) O
DNA I-GENE
, O
but O
in O
this O
case O
the O
DNA I-GENE
sequence I-GENE
and O
competition O
filter O
binding I-GENE
experiments O
indicated O
a O
maximum O
of O
only O
four O
to O
five O
consensus I-GENE
binding I-GENE
sites I-GENE
encompassing O
the O
promoter I-GENE
- I-GENE
enhancer I-GENE
region O
. O

The O
previously O
described O
four O
sets O
of O
13 O
- I-GENE
to O
18 O
- I-GENE
base O
- I-GENE
pair O
interspersed O
repeat I-GENE
elements O
between O
- I-GENE
55 O
and O
- I-GENE
_RARE_ I-GENE
provide O
most O
of O
the O
high O
basal O
transcriptional O
strength O
, O
whereas O
the O
arrangement O
of O
further O
upstream O
tandemly O
repeated O
NF1 I-GENE
- I-GENE
binding I-GENE
sites I-GENE
may O
contribute O
significantly O
to O
the O
_RARE_ I-GENE
biological O
host O
range O
for O
expression O
of O
_RARE_ I-GENE
_RARE_ I-GENE
compared O
with O
HCMV I-GENE
_RARE_ I-GENE
. O

We O
inserted O
genes I-GENE
or O
gene I-GENE
segments O
, O
that O
code O
for O
the O
bacterial I-GENE
chloramphenicol I-GENE
acetyltransferase I-GENE
, O
the O
bacterial I-GENE
gene I-GENE
conferring O
resistance O
against O
_RARE_ I-GENE
, O
and O
the O
ORF I-GENE
E7 I-GENE
of O
the O
human I-GENE
papillomavirus I-GENE
type I-GENE
18 O
into O
these O
vectors O
. O

By O
contrast O
, O
their O
basal O
adrenal O
androgen O
levels O
were O
significantly O
decreased O
compared O
to O
those O
in O
normal O
subjects O
on O
both O
the O
day O
on O
and O
the O
day O
off O
prednisone O
( O
P I-GENE
less O
than O
0 O
. O
05 O
). O

_RARE_ I-GENE
lambda I-GENE
and O
kappa I-GENE
antibody I-GENE
gene I-GENE
rearrangement O
in O
_RARE_ I-GENE
murine I-GENE
leukemia I-GENE
virus I-GENE
- I-GENE
transformed O
pre I-GENE
- I-GENE
B I-GENE
cell O
lines O
. O

Identification O
of O
_RARE_ I-GENE
- I-GENE
responsive I-GENE
regulatory I-GENE
sequences I-GENE
within O
the O
human I-GENE
T I-GENE
- I-GENE
cell O
leukemia I-GENE
virus I-GENE
type I-GENE
I I-GENE
long O
terminal I-GENE
repeat I-GENE
. O

During O
_RARE_ I-GENE
anesthesia O
, O
the O
basal O
VO2 O
was O
5 I-GENE
. O
26 O
ml O
/ I-GENE
kg O
/ I-GENE
min O
and O
was O
increased O
by O
epinephrine O
in O
a O
dose O
dependent I-GENE
manner O
at O
plasma I-GENE
concentrations O
between O
3 I-GENE
. O
9 O
ng O
/ I-GENE
ml O
( O
VO2 O
= O
5 I-GENE
. O
68 O
ml O
/ I-GENE
kg O
/ I-GENE
min O
) O
and O
36 O
. O
5 I-GENE
ng O
/ I-GENE
ml O
( O
VO2 O
= O
6 I-GENE
. O
47 O
ml O
/ I-GENE
kg O
/ I-GENE
min O
). O

Influence O
of O
_RARE_ I-GENE
- I-GENE
oxygenase I-GENE
inhibition O
and O
of O
_RARE_ I-GENE
receptor I-GENE
blockade O
on O
pulmonary O
vascular I-GENE
pressure O
/ I-GENE
cardiac O
index O
relationships O
in O
_RARE_ I-GENE
and O
in O
hypoxic O
dogs O
. O

_RARE_ I-GENE
- I-GENE
directed O
mutagenesis O
was O
used O
to O
create O
an O
_RARE_ I-GENE
restriction I-GENE
site I-GENE
at O
the O
natural O
ATG O
of O
the O
yeast I-GENE
R I-GENE
. O

ACTH I-GENE
release O
is O
transiently O
suppressed O
in O
some O
children O
after O
exogenous O
ACTH I-GENE
treatment O
. O

We O
previously O
showed O
that O
the O
upstream O
promoter I-GENE
element I-GENE
of O
the O
yeast I-GENE
_RARE_ I-GENE
gene I-GENE
consists O
of O
these O
identical O
sequence I-GENE
motifs O
. O

These O
data O
suggest O
that O
mammalian I-GENE
erythroid I-GENE
alpha I-GENE
- I-GENE
spectrin I-GENE
evolved O
by O
duplication O
and O
rapid O
divergence O
from O
an O
ancestral O
alpha I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
like I-GENE
gene I-GENE
. O

Northern O
analyses O
of O
RNAs I-GENE
from O
mouse I-GENE
tissues O
and O
cell O
lines O
indicated O
that O
_RARE_ I-GENE
mRNA I-GENE
levels O
vary O
widely O
. O

One O
group O
of O
six O
cDNA I-GENE
clones O
was O
derived O
from O
a O
2 I-GENE
. O
9 O
- I-GENE
kilobase O
early I-GENE
transcript I-GENE
encoded I-GENE
by O
the O
_RARE_ I-GENE
repeat I-GENE
element I-GENE
and O
showed O
restriction I-GENE
site I-GENE
polymorphism O
for O
the O
enzyme I-GENE
_RARE_ I-GENE
. O

Combined O
_RARE_ I-GENE
with O
cyclophosphamide O
plus O
BCG O
gave O
a O
better O
enhancement O
of O
the O
_RARE_ I-GENE
effect O
of O
the O
_RARE_ I-GENE
than O
that O
of O
the O
combination O
of O
methotrexate O
plus O
BCG O
and O
cyclophosphamide O
plus O
_RARE_ I-GENE
. O

_RARE_ I-GENE
produced O
a O
dose O
- I-GENE
dependent I-GENE
_RARE_ I-GENE
followed O
by O
tachycardia O
. O

The O
_RARE_ I-GENE
gene I-GENE
was O
subcloned O
into O
a O
1 I-GENE
. O
1 I-GENE
- I-GENE
kb O
fragment I-GENE
of O
the O
yeast I-GENE
DNA I-GENE
on O
the O
_RARE_ I-GENE
vector O
. O

Indeed O
, O
A I-GENE
- I-GENE
MuLV O
_RARE_ I-GENE
with O
some O
viruses O
, O
such O
as O
the O
Moloney O
MuLV O
, O
has O
been O
shown O
to O
be O
highly O
_RARE_ I-GENE
, O
whereas O
A I-GENE
- I-GENE
MuLV O
_RARE_ I-GENE
with O
other O
viruses O
, O
such O
as O
the O
BALB O
/ I-GENE
c I-GENE
endogenous I-GENE
N I-GENE
- I-GENE
_RARE_ I-GENE
MuLV O
, O
has O
been O
shown O
to O
be O
_RARE_ I-GENE
of O
_RARE_ I-GENE
potential O
( O
N I-GENE
. O

The O
presence O
of O
circulating O
platelet I-GENE
aggregates O
and O
elevated O
levels O
of O
_RARE_ I-GENE
A I-GENE
( O
a O
cleavage O
product I-GENE
of O
fibrin I-GENE
) O
suggests O
that O
platelet I-GENE
activation O
and O
fibrin I-GENE
deposition O
may O
play O
a O
role O
in O
the O
pathogenesis O
of O
this O
disorder O
. O

The O
gene I-GENE
is O
essential O
for O
yeast I-GENE
_RARE_ I-GENE
growth I-GENE
. O

4 I-GENE
. O

In O
general O
, O
the O
values O
obtained O
by O
the O
two O
methods O
were O
in O
agreement O
for O
each O
species O
of O
epidermal I-GENE
growth I-GENE
factor I-GENE
and O
followed O
the O
order O
: O
wild I-GENE
type I-GENE
greater O
than O
_RARE_ I-GENE
---- I-GENE
Gly O
greater O
than O
_RARE_ I-GENE
---- I-GENE
Gly O
much O
greater O
than O
_RARE_ I-GENE
---- I-GENE
Thr I-GENE
greater O
than O
_RARE_ I-GENE
---- I-GENE
Gly O
greater O
than O
_RARE_ I-GENE
---- I-GENE
His O
. O

It O
is O
concluded O
that O
suppression O
of O
elevated O
prolactin I-GENE
levels O
in O
progressive O
metastatic O
breast O
cancer O
patients O
is O
not O
effective O
in O
_RARE_ I-GENE
tumor I-GENE
sensitivity O
to O
chemotherapy O
. O

We O
report O
a O
prevalence O
study O
of O
the O
best O
visual O
_RARE_ I-GENE
in O
the O
affected O
eye O
of O
100 O
selected O
patients O
with O
_RARE_ I-GENE
_RARE_ I-GENE
seen O
during O
a O
two O
- I-GENE
year O
period O
. O

We O
also O
found O
an O
eIF I-GENE
- I-GENE
_RARE_ I-GENE
intronless O
_RARE_ I-GENE
which O
, O
when O
compared O
to O
the O
cDNA I-GENE
, O
contains O
a O
single O
nucleotide I-GENE
difference O
. O

_RARE_ I-GENE
culture O
of O
pancreatic O
tissue I-GENE
was O
positive O
in O
6 I-GENE
/ I-GENE
8 O
_RARE_ I-GENE
and O
3 I-GENE
/ I-GENE
17 O
_RARE_ I-GENE
rats O
( O
p O
less O
than O
0 O
. O
01 O
). O

These O
similarities O
suggest O
that O
these O
E2 I-GENE
proteins I-GENE
are O
structurally O
and O
evolutionarily O
related I-GENE
. O

After O
infection O
of O
293 O
cells O
( O
which O
provide O
complementary O
E1a I-GENE
- I-GENE
_RARE_ I-GENE
functions O
), O
both O
viruses O
directed O
equal O
amounts O
of O
P I-GENE
/ I-GENE
C I-GENE
- I-GENE
specific I-GENE
mRNA I-GENE
transcription I-GENE
. O

This O
observation O
cannot O
be O
explained O
by O
the O
scanning O
model O
for O
ribosomal I-GENE
initiation I-GENE
and O
suggests O
that O
_RARE_ I-GENE
may O
be O
binding I-GENE
directly O
at O
an O
internal O
mRNA I-GENE
site I-GENE
at O
or O
near O
the O
initiator O
AUG O
codon O
for O
the O
C I-GENE
protein I-GENE
. O

In O
view O
of O
these O
results O
, O
simultaneous O
pancreas O
- I-GENE
kidney O
transplantation O
appears O
to O
be O
the O
treatment O
of O
choice O
for O
Type O
I I-GENE
diabetic O
patients O
. O

This O
makes O
these O
compounds O
_RARE_ I-GENE
as O
_RARE_ I-GENE
for O
these O
and O
other O
gases O
in O
- I-GENE
vivo O
and O
in O
- I-GENE
vitro O
. O

DNA I-GENE
sequencing O
of O
the O
_RARE_ I-GENE
gene I-GENE
revealed O
an O
open O
reading O
frame O
of O
801 O
bases O
. O

The O
relationship O
between O
primary O
malignant O
lymphoma O
of O
the O
thyroid I-GENE
and O
chronic O
thyroiditis O
is O
discussed O
. O

Administration O
of O
_RARE_ I-GENE
, O
i O
. O
e O
., O
heparin O
, O
prostaglandin I-GENE
E1 I-GENE
and O
_RARE_ I-GENE
seems O
to O
be O
effective O
in O
_RARE_ I-GENE
symptoms O
and O
might O
prevent O
further O
deterioration O
. O

Mutational O
analysis O
of O
the O
L1 I-GENE
binding I-GENE
site I-GENE
of O
_RARE_ I-GENE
rRNA I-GENE
in O
Escherichia I-GENE
coli I-GENE
. O

Animals O
may O
be O
immunized O
by O
oral O
vaccination O
, O
but O
natural O
mechanisms O
that O
also O
can O
terminate O
_RARE_ I-GENE
are O
discussed O
. O

_RARE_ I-GENE
formation O
, O
reflected O
by O
the O
excretion O
rate O
of O
its O
stable O
metabolite O
6 I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
prostaglandin I-GENE
F1 I-GENE
alpha I-GENE
, O
was O
measured O
by O
means O
of O
radioimmunoassay O
in O
4 I-GENE
- I-GENE
hour O
urine O
specimens O
obtained O
during O
a O
smoking O
- I-GENE
free O
period O
and O
after O
_RARE_ I-GENE
had O
inhaled O
smoke O
from O
four O
high O
- I-GENE
nicotine O
_RARE_ I-GENE
. O

However O
, O
excretion O
of O
6 I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
prostaglandin I-GENE
F1 I-GENE
alpha I-GENE
was O
further O
reduced O
in O
the O
smokers O
who O
used O
oral O
_RARE_ I-GENE
( O
133 I-GENE
+/- O
20 O
to O
86 I-GENE
+/- O
9 O
ng O
/ I-GENE
_RARE_ I-GENE
of O
creatinine O
, O
p O
less O
than O
0 O
. O
05 O
). O

The O
in O
vitro O
activity O
of O
_RARE_ I-GENE
and O
amoxicillin O
/ I-GENE
_RARE_ I-GENE
acid I-GENE
against O
Escherichia I-GENE
coli I-GENE
strains O
producing O
beta I-GENE
- I-GENE
_RARE_ I-GENE
of O
the O
_RARE_ I-GENE
- I-GENE
1 I-GENE
, O
_RARE_ I-GENE
- I-GENE
1 I-GENE
and O
chromosomal I-GENE
type I-GENE
were O
studied O
using O
the O
_RARE_ I-GENE
and O
agar O
dilution O
technique O
. O

GCN4 I-GENE
encodes O
a O
transcriptional O
activator I-GENE
of O
amino O
acid I-GENE
biosynthetic O
genes I-GENE
in O
Saccharomyces I-GENE
cerevisiae I-GENE
. O

These O
results O
imply O
that O
the O
_RARE_ I-GENE
product I-GENE
can O
promote O
either O
repression O
or O
activation O
of O
GCN4 I-GENE
expression O
depending O
on O
amino O
acid I-GENE
availability O
. O

The O
efficacy O
of O
these O
immunosuppressive O
drugs O
is O
clinical O
proven O
. O

The O
amino O
acid I-GENE
sequence I-GENE
of O
the O
S I-GENE
. O
aureus I-GENE
peptide I-GENE
carrying O
the O
_RARE_ I-GENE
group O
was O
found O
to O
be O
Gln O
- I-GENE
Val I-GENE
- I-GENE
Val I-GENE
- I-GENE
Ser O
- I-GENE
Thr I-GENE
- I-GENE
Phe I-GENE
- I-GENE
Met I-GENE
- I-GENE
Gly O
- I-GENE
Asn O
- I-GENE
Gly O
- I-GENE
Leu I-GENE
- I-GENE
Ala I-GENE
- I-GENE
Ile O
- I-GENE
Pro I-GENE
- I-GENE
His O
- I-GENE
Gly O
- I-GENE
Thr I-GENE
- I-GENE
Asp I-GENE
- I-GENE
Asp I-GENE
. O

These O
mutations O
alter O
two O
regions O
of O
GAL4 I-GENE
protein I-GENE
: O
the O
DNA I-GENE
binding I-GENE
domain I-GENE
, O
and O
the O
transcription I-GENE
activation O
domain I-GENE
. O

The O
results O
indicated O
that O
two O
genes I-GENE
( O
_RARE_ I-GENE
and O
_RARE_ I-GENE
) O
have O
separate O
promoters I-GENE
, O
and O
the O
location O
of O
the O
promoter I-GENE
for O
the O
_RARE_ I-GENE
gene I-GENE
in O
the O
_RARE_ I-GENE
nucleotide I-GENE
sequence I-GENE
was O
different O
from O
that O
in O
_RARE_ I-GENE
. O

The O
_RARE_ I-GENE
gene I-GENE
was O
fused O
with O
lacZ I-GENE
and O
its O
gene I-GENE
product I-GENE
was O
identified O
by O
Western O
blot O
analysis O
. O

Structure O
and O
regulation O
of O
a O
nuclear I-GENE
gene I-GENE
in O
Saccharomyces I-GENE
cerevisiae I-GENE
that O
specifies O
_RARE_ I-GENE
, O
a O
protein I-GENE
of O
the O
small I-GENE
subunit I-GENE
of O
the O
mitochondrial I-GENE
ribosome I-GENE
. O

After O
a O
survey O
of O
the O
anatomical O
and O
physiological O
basis O
of O
operative O
treatment O
of O
behaviour O
disorders O
by O
_RARE_ I-GENE
lesions O
in O
the O
amygdala O
and O
the O
posterior O
medial O
hypothalamus O
the O
author O
describes O
his O
own O
_RARE_ I-GENE
with O
_RARE_ I-GENE
_RARE_ I-GENE
for O
control O
of O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
. O

Histological O
examination O
revealed O
a O
small I-GENE
simple O
renal O
cyst O
associated I-GENE
with O
renal O
cell O
carcinoma O
. O

Although O
large O
_RARE_ I-GENE
studies O
are O
best O
able O
to O
identify O
the O
relative O
_RARE_ I-GENE
of O
specific I-GENE
risk O
factors I-GENE
while O
controlling O
for O
other O
risk O
factors I-GENE
, O
new O
studies O
need O
to O
focus O
on O
important O
_RARE_ I-GENE
questions O
. O

Thus O
, O
_RARE_ I-GENE
enhanced O
the O
_RARE_ I-GENE
_RARE_ I-GENE
of O
the O
inner O
ear O
vessels O
. O

The O
method O
is O
accurate O
, O
with O
good O
_RARE_ I-GENE
and O
adequate O
sensitivity O
. O

Factors O
influencing O
the O
bond O
strength O
between O
glass O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
_RARE_ I-GENE
and O
_RARE_ I-GENE
. O

The O
amino O
acid I-GENE
sequences I-GENE
of O
the O
yeast I-GENE
and O
mammalian I-GENE
mitochondrial I-GENE
targeting O
sequences I-GENE
are O
similar O
but O
less O
related I-GENE
than O
the O
mature O
polypeptides I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
, O
R I-GENE
. O

During O
insulin I-GENE
infusion O
, O
a O
20 O
% O
_RARE_ I-GENE
solution O
was O
infused O
by O
a O
_RARE_ I-GENE
in O
order O
to O
maintain O
the O
patient O
' O
s O
_RARE_ I-GENE
at O
90 O
mg O
/ I-GENE
dl O
. O

_RARE_ I-GENE
of O
glucose O
infused O
during O
the O
last O
20 O
min O
of O
each O
2 I-GENE
hour O
insulin I-GENE
infusion O
were O
( O
at O
1 I-GENE
and O
10 O
m I-GENE
/ I-GENE
kg O
/ I-GENE
min O
respectively O
): O
before O
treatment O
( O
K I-GENE
+ I-GENE
= O
2 I-GENE
. O
7 O
mmol O
/ I-GENE
l O
): O
2 I-GENE
. O
4 I-GENE
and O
8 O
. O
4 I-GENE
mg O
/ I-GENE
kg O
/ I-GENE
min O
; O
after O
_RARE_ I-GENE
( O
K I-GENE
+ I-GENE
= O
3 I-GENE
. O
9 O
mmol O
/ I-GENE
l O
): O
3 I-GENE
. O
3 I-GENE
and O
15 O
. O
4 I-GENE
mg O
/ I-GENE
kg O
/ I-GENE
min O
; O
after O
_RARE_ I-GENE
( O
K I-GENE
+ I-GENE
= O
3 I-GENE
. O
7 O
mmol O
/ I-GENE
l O
): O
5 I-GENE
and O
19 O
mg O
/ I-GENE
kg O
/ I-GENE
min O
after O
_RARE_ I-GENE
drugs O
( O
K I-GENE
+ I-GENE
= O
2 I-GENE
. O
9 O
mmol O
/ I-GENE
l O
): O
2 I-GENE
. O
5 I-GENE
and O
5 I-GENE
. O
3 I-GENE
mg O
/ I-GENE
kg O
/ I-GENE
min O
. O

Mycobacterium O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
complex I-GENE
infections O
in O
the O
acquired O
immunodeficiency I-GENE
syndrome O
. O

_RARE_ I-GENE
of O
_RARE_ I-GENE
deposition O
in O
a O
renal O
transplant O
during O
_RARE_ I-GENE
A I-GENE
therapy O
. O

The O
bile O
acid I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
and O
_RARE_ I-GENE
), O
_RARE_ I-GENE
acid I-GENE
, O
_RARE_ I-GENE
and O
inhibitors O
of O
_RARE_ I-GENE
coenzyme I-GENE
A I-GENE
( O
HMG I-GENE
CoA I-GENE
) O
reductase I-GENE
( O
e O
. O
g O
. O
_RARE_ I-GENE
or O
_RARE_ I-GENE
) O
are O
the O
most O
effective O
drugs O
for O
use O
in O
patients O
with O
primary O
_RARE_ I-GENE
; O
these O
agents O
reduce O
plasma I-GENE
concentrations O
of O
total O
and O
LDL I-GENE
- I-GENE
cholesterol I-GENE
by O
15 O
to O
45 O
%. O

Finally O
, O
the O
_RARE_ I-GENE
aspects O
of O
urinary O
acidification O
are O
discussed O
, O
focusing O
on O
renal O
tubular O
acidosis O
models O
( O
induced O
by O
_RARE_ I-GENE
and O
amphotericin O
B I-GENE
treatment O
) O
and O
their O
cellular O
mechanisms O
, O
as O
well O
as O
the O
role O
of O
adrenal O
steroids O
in O
urinary O
acidification O
. O

Analysis O
in O
3 I-GENE
groups O
of O
patients O
suffering O
from O
simple O
acute O
and O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE

_RARE_ I-GENE
on O
the O
development O
of O
guidelines O
for O
the O
prevention O
of O
AIDS O
transmission O
in O
the O
_RARE_ I-GENE
. O

_RARE_ I-GENE
of O
the O
_RARE_ I-GENE
_RARE_ I-GENE
in O
diseased O
people O
. O

_RARE_ I-GENE
- I-GENE
treated O
rats O
acquired O
a O
preference O
for O
cocaine O
- I-GENE
associated I-GENE
_RARE_ I-GENE
stimuli O
( O
CS I-GENE
) O
relative O
to O
saline O
- I-GENE
injected O
control O
rats O
. O

Under O
these O
_RARE_ I-GENE
, O
a O
reinforced O
response O
run O
consisted O
of O
responding O
between O
eight O
and O
12 O
times O
on O
one O
response O
key O
( O
work O
key O
) O
and O
then O
responding O
once O
on O
a O
second O
response O
key O
( O
reinforced O
key O
). O

Intravenous O
glucose O
tolerance O
tests O
were O
performed O
before O
operation O
, O
before O
starting O
_RARE_ I-GENE
and O
after O
3 I-GENE
weeks O
. O

The O
effects O
of O
_RARE_ I-GENE
on O
dimensions O
and O
_RARE_ I-GENE
of O
microvascular O
_RARE_ I-GENE
in O
rat I-GENE
_RARE_ I-GENE
were O
studied O
in O
two O
_RARE_ I-GENE
of O
experiment O
, O
_RARE_ I-GENE
the O
_RARE_ I-GENE
by O
intra O
- I-GENE
arterial O
perfusion O
at O
a O
pressure O
of O
80 O
mm O
Hg O
and O
by O
_RARE_ I-GENE
of O
the O
_RARE_ I-GENE
_RARE_ I-GENE
membrane I-GENE
. O

This O
gave O
rise O
to O
RNA I-GENE
molecules I-GENE
with O
3 I-GENE
'- O
untranslated O
regions O
of O
_RARE_ I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
base O
pairs O
. O

Also O
, O
the O
BALB O
/ I-GENE
c I-GENE
gene I-GENE
contains O
a O
single O
substitution O
in O
a O
conserved O
octamer O
sequence I-GENE
approximately O
equal O
to O
100 O
nucleotides O
upstream O
of O
the O
coding O
region O
, O
which O
could O
affect O
its O
expression O
. O

Clinical O
findings O
were O
: O
height O
_RARE_ I-GENE
cm O
, O
weight O
62 O
kg O
, O
increased O
length I-GENE
of O
lower O
_RARE_ I-GENE
, O
P2 I-GENE
- I-GENE
A2 I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
. O

Our O
data O
suggest O
that O
it O
may O
be O
possible O
to O
_RARE_ I-GENE
hCG I-GENE
administration O
at O
_RARE_ I-GENE
by O
determining O
the O
number O
of O
_RARE_ I-GENE
greater O
than O
1 I-GENE
cm O
by O
ultrasound O
on O
cycle O
day O
12 O
or O
13 O
and O
giving O
hCG I-GENE
when O
serum I-GENE
E2 I-GENE
levels O
reach O
_RARE_ I-GENE
to O
_RARE_ I-GENE
_RARE_ I-GENE
/ I-GENE
l O
per O
follicle I-GENE
. O

The O
8 O
patients O
receiving O
_RARE_ I-GENE
implant O
in O
addition O
to O
external O
radiation O
showed O
improved O
( O
p O
= O
0 O
. O
06 O
) O
survival O
compared O
to O
the O
9 O
receiving O
external O
only O
: O
median O
15 O
months O
( O
range O
1 I-GENE
. O
5 I-GENE
- I-GENE
34 O
+ I-GENE
months O
) O
versus O
7 O
months O
( O
range O
2 I-GENE
. O
5 I-GENE
- I-GENE
21 O
months O
). O

Within O
Stage O
IA O
, O
_RARE_ I-GENE
patients O
had O
well O
differentiated O
tumor I-GENE
( O
G1 I-GENE
), O
20 O
had O
moderately O
well O
differentiated O
tumor I-GENE
( O
G2 I-GENE
), O
and O
12 O
patients O
had O
poorly O
differentiated O
( O
_RARE_ I-GENE
). O

Mechanism O
of O
the O
t I-GENE
( O
14 O
; O
18 O
) O
chromosomal I-GENE
translocation O
: O
structural O
analysis O
of O
both O
derivative O
14 O
and O
18 O
reciprocal O
partners O
. O

After O
age O
30 O
, O
mean O
hemoglobin I-GENE
levels O
for O
men O
gradually O
declined O
, O
while O
those O
in O
women O
rose O
, O
so O
that O
the O
sex I-GENE
difference O
diminished O
after O
60 O
years O
of O
age O
. O

_RARE_ I-GENE
is O
a O
new O
_RARE_ I-GENE
with O
highly O
selective O
blocking O
activity O
on O
S2 I-GENE
receptors I-GENE
for O
5 I-GENE
- I-GENE
HT O
in O
the O
central O
nervous O
system O
. O

_RARE_ I-GENE
glycol O
and O
_RARE_ I-GENE
glycol O
were O
each O
administered O
once O
weekly O
subcutaneously O
to O
groups O
of O
100 O
female O
_RARE_ I-GENE
mice O
at O
3 I-GENE
_RARE_ I-GENE
( O
30 O
; O
10 O
_RARE_ I-GENE
3 I-GENE
mg O
single O
dose O
per O
mouse I-GENE
). O

Research O
on O
ethylene O
glycol O
and O
_RARE_ I-GENE
glycol O
for O
_RARE_ I-GENE
effects O

The O
results O
suggest O
that O
the O
greater O
_RARE_ I-GENE
influence O
associated I-GENE
with O
the O
_RARE_ I-GENE
estradiol O
- I-GENE
containing O
OC I-GENE
resulted O
in O
inhibition O
of O
coronary O
artery O
atherosclerosis O
despite O
a O
pronounced O
_RARE_ I-GENE
- I-GENE
induced O
lowering O
of O
plasma I-GENE
HDL I-GENE
cholesterol I-GENE
concentration O
and O
, O
further O
, O
that O
hormonal O
balance O
may O
have O
a O
marked O
influence O
on O
the O
relationship O
between O
plasma I-GENE
lipids O
and O
_RARE_ I-GENE
. O

During O
_RARE_ I-GENE
the O
_RARE_ I-GENE
was O
_RARE_ I-GENE
and O
a O
_RARE_ I-GENE
flow O
of O
50 O
% O
O2 O
at O
4 I-GENE
- I-GENE
5 I-GENE
l O
/ I-GENE
min O
was O
delivered O
through O
the O
side O
_RARE_ I-GENE
of O
a O
small I-GENE
catheter O
whose O
tip O
was O
positioned O
1 I-GENE
cm O
_RARE_ I-GENE
of O
the O
_RARE_ I-GENE
. O

Comparison O
of O
beta I-GENE
2 I-GENE
- I-GENE
microglobulin I-GENE
removal O
using O
the O
same O
_RARE_ I-GENE
membrane I-GENE
for O
haemodialysis O
and O
_RARE_ I-GENE
shows O
that O
beta I-GENE
2 I-GENE
- I-GENE
microglobulin I-GENE
is O
more O
effectively O
removed O
by O
_RARE_ I-GENE
than O
by O
diffusion O
when O
both O
treatment O
modes O
are O
matched O
for O
blood O
flow O
and O
urea O
clearance O
. O

40 I-GENE
. O
3 I-GENE
+/- O
10 O
. O
1 I-GENE
mg O
/ I-GENE
l O
( O
SD O
) O
vs O
31 O
. O
2 I-GENE
+/- O
8 O
. O
0 O
, O
P I-GENE
less O
than O
0 O
. O
01 O
). O
beta I-GENE
_RARE_ I-GENE
was O
not O
significantly O
higher O
in O
patients O
with O
bone O
cysts O
( O
37 O
. O
7 O
+/- O
11 O
. O
4 I-GENE
mg O
/ I-GENE
l O
vs O
37 O
. O
0 O
+/- O
10 O
. O
0 O
), O
but O
median O
duration O
of O
dialysis O
was O
significantly O
( O
P I-GENE
less O
than O
0 O
. O
01 O
) O
longer O
in O
patients O
with O
bone O
cysts O
( O
90 O
vs O
57 O
months O
). O
beta I-GENE
_RARE_ I-GENE
was O
lower O
in O
patients O
maintained O
on O
dialysis O
for O
less O
than O
1 I-GENE
year O
and O
whose O
residual O
urine O
volume O
was O
greater O
than O
0 O
. O
1 I-GENE
_RARE_ I-GENE
per O
day O
. O

The O
mean O
percentage O
of O
_RARE_ I-GENE
acid I-GENE
in O
the O
triglycerides I-GENE
of O
the O
subcutaneous O
adipose I-GENE
tissue I-GENE
( O
_RARE_ I-GENE
) O
of O
these O
subjects O
was O
substantially O
higher O
than O
that O
in O
a O
similar O
group O
examined O
in O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
. O

In O
_RARE_ I-GENE
up O
to O
2 I-GENE
g O
_RARE_ I-GENE
no O
lasting O
toxic O
effects O
were O
observed O
. O

It O
is O
concluded O
that O
the O
plasma I-GENE
prolactin I-GENE
response O
to O
12 O
. O
5 I-GENE
micrograms O
i O
. O
v I-GENE
. O

No O
effect O
was O
found O
on O
_RARE_ I-GENE
behavior O
. O

The O
remaining O
six O
patients O
had O
slightly O
decreased O
( O
n O
= O
3 I-GENE
) O
or O
normal O
( O
n O
= O
3 I-GENE
) O
seminal I-GENE
parameters O
. O

In O
addition O
, O
a O
wild I-GENE
- I-GENE
type I-GENE
strain O
containing O
a O
temperature O
- I-GENE
sensitive O
_RARE_ I-GENE
- I-GENE
tRNA I-GENE
synthetase I-GENE
mutation I-GENE
showed O
increased O
_RARE_ I-GENE
operon I-GENE
expression O
at O
the O
non O
- I-GENE
permissive O
temperature O
, O
whereas O
none O
of O
the O
mutants I-GENE
showed O
any O
change O
. O

Significant O
treatment O
- I-GENE
related I-GENE
problems O
appeared O
during O
the O
second O
_RARE_ I-GENE
in O
5 I-GENE
patients O
, O
including O
one O
chest O
wall O
sarcoma I-GENE
; O
all O
of O
these O
patients O
had O
received O
at O
least O
60 O
Gy O
to O
breast O
and O
regional O
nodal O
areas O
. O

Clinical O
and O
biological O
correlates O
of O
_RARE_ I-GENE
states O
. O

Effects O
of O
long O
- I-GENE
term O
_RARE_ I-GENE
nutrition O
on O
gastrin I-GENE
release O
in O
dogs O
. O

The O
mean O
weight O
and O
height O
_RARE_ I-GENE
were O
_RARE_ I-GENE
% O
and O
122 O
% O
of O
the O
standard O
, O
respectively O
. O

Of O
7 O
patients O
treated O
with O
cyclophosphamide O
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
and O
cisplatin O
( O
_RARE_ I-GENE
- I-GENE
5 I-GENE
), O
6 I-GENE
had O
_RARE_ I-GENE
disease O
, O
of O
whom O
5 I-GENE
yielded O
a O
response O
( O
2 I-GENE
complete O
responses O
for O
19 O
+ I-GENE
and O
40 I-GENE
months O
and O
3 I-GENE
partial O
responses O
for O
4 I-GENE
, O
7 O
and O
8 O
months O
). O

Isolation O
and O
characterization O
of O
a O
_RARE_ I-GENE
cDNA I-GENE
from O
chick I-GENE
- I-GENE
embryo O
fibroblasts O
. O

A I-GENE
complementary O
study O
, O
showing O
a O
good O
agreement O
between O
surface O
and O
_RARE_ I-GENE
_RARE_ I-GENE
seems O
to O
confirm O
that O
surface O
_RARE_ I-GENE
is O
a O
useful O
and O
_RARE_ I-GENE
tool O
for O
clinical O
investigation O
. O

No O
differences O
in O
fixation O
quality O
were O
observed O
between O
_RARE_ I-GENE
fixed O
by O
intravascular O
perfusion O
and O
_RARE_ I-GENE
fixed O
by O
_RARE_ I-GENE
perfusion O
. O

The O
DNA I-GENE
sequence I-GENE
encodes O
a O
protein I-GENE
of O
_RARE_ I-GENE
amino O
acids O
with O
sequence I-GENE
homology I-GENE
to O
the O
human I-GENE
c I-GENE
- I-GENE
abl I-GENE
proto I-GENE
- I-GENE
oncogene I-GENE
product I-GENE
, O
beginning O
at O
the O
amino O
terminus O
and O
extending O
_RARE_ I-GENE
amino O
acids O
through O
the O
region O
essential O
for O
tyrosine I-GENE
kinase I-GENE
activity O
. O

The O
requirement O
of O
different O
essential O
fatty I-GENE
acids O
in O
patients O
with O
total O
_RARE_ I-GENE
nutrition O
after O
heavy I-GENE
injury O
is O
of O
special O
interest O
with O
respect O
to O
the O
development O
and O
prognosis O
of O
shock I-GENE
, O
sepsis O
or O
adult O
respiratory O
distress O
syndrome O
. O

In O
64 O
% O
a O
small I-GENE
cardiac O
vein O
does O
not O
exist O
, O
but O
its O
origin O
, O
the O
right O
_RARE_ I-GENE
vein O
, O
joins O
the O
system O
of O
anterior O
cardiac O
_RARE_ I-GENE
. O

The O
Drosophila I-GENE
melanogaster I-GENE
_RARE_ I-GENE
gene I-GENE
encodes O
three O
enzymatic O
activities O
in O
the O
pathway O
for O
_RARE_ I-GENE
de O
novo I-GENE
synthesis O
. O

The O
role O
of O
_RARE_ I-GENE
in O
the O
response O
to O
drugs O
. O

Biol O
. O

The O
results O
of O
these O
experiments O
indicate O
that O
at O
least O
two O
upstream O
activator I-GENE
sequences I-GENE
( O
UAS O
) O
mediate O
maximum O
induction O
by O
galactose I-GENE
. O

_RARE_ I-GENE
of O
the O
increase O
in O
_RARE_ I-GENE
- I-GENE
induced O
_RARE_ I-GENE
and O
aggression O
in O
REM O
sleep O
deprived O
rats O
by O
dopamine I-GENE
agonist O
_RARE_ I-GENE
. O

The O
heart O
rate O
, O
respiratory O
rate O
, O
arterial O
O2 O
and O
systemic O
vascular I-GENE
resistance O
were O
not O
significantly O
altered O
. O

Human I-GENE
_RARE_ I-GENE
- I-GENE
3 I-GENE
expressed O
in O
_RARE_ I-GENE
cells O
has O
_RARE_ I-GENE
CSF I-GENE
activity O
in O
_RARE_ I-GENE
cultures O
of O
bone O
marrow O
cells O
, O
and O
selectively O
induced O
the O
proliferation O
of O
_RARE_ I-GENE
- I-GENE
10 O
+ I-GENE
marrow O
or O
cord O
blood O
cells O
in O
liquid O
cultures O
. O

In O
14 O
patients O
whose O
PaCO2 O
was O
greater O
than O
or O
equal O
to O
39 O
torr O
( O
range O
39 O
to O
58 O
torr O
) O
and O
clinical O
asthma O
score O
was O
6 I-GENE
or O
greater O
, O
PaCO2 O
decreased O
a O
mean O
of O
11 O
. O
7 O
torr O
during O
a O
mean O
of O
8 O
. O
1 I-GENE
hours O
. O

A I-GENE
randomized O
, O
prospective O
study O
was O
conducted O
to O
compare O
ovarian O
stimulation O
with O
human I-GENE
menopausal I-GENE
gonadotropin I-GENE
( O
_RARE_ I-GENE
) O
and O
human I-GENE
follicle I-GENE
- I-GENE
stimulating I-GENE
hormone I-GENE
( O
_RARE_ I-GENE
) O
in O
an O
in O
vitro O
fertilization O
and O
embryo O
transfer I-GENE
( O
_RARE_ I-GENE
- I-GENE
ET I-GENE
) O
program O
. O

Our O
findings O
suggest O
that O
the O
_RARE_ I-GENE
product I-GENE
causes O
both O
transcription I-GENE
attenuation O
and O
inhibition O
of O
translation I-GENE
of O
_RARE_ I-GENE
mRNA I-GENE
. O

_RARE_ I-GENE
of O
a O
case O

A I-GENE
prostaglandin I-GENE
analogue O
given O
in O
early I-GENE
pregnancy O
and O
human I-GENE
_RARE_ I-GENE
gonadotropin I-GENE
given O
near O
the O
end O
of O
the O
_RARE_ I-GENE
follicular O
phase O
were O
used O
for O
controlling O
the O
reproductive O
cycle O
, O
timing O
oocyte O
collection O
, O
and O
_RARE_ I-GENE
the O
cycles O
of O
oocyte O
donors O
and O
embryo O
recipients O
. O

The O
_RARE_ I-GENE
gene I-GENE
_RARE_ I-GENE
over O
_RARE_ I-GENE
base O
- I-GENE
pairs O
and O
is O
_RARE_ I-GENE
into O
14 O
exons O
that O
encode O
the O
_RARE_ I-GENE
amino O
acid I-GENE
residues O
of O
the O
protein I-GENE
. O

Although O
L I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
), O
an O
artificial O
norepinephrine O
( O
NE O
) O
precursor I-GENE
, O
did O
not O
change O
_RARE_ I-GENE
in O
intact O
mice O
, O
_RARE_ I-GENE
significantly O
reduced O
_RARE_ I-GENE
in O
mice O
pretreated O
with O
the O
selective O
NE O
_RARE_ I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
amounts O
of O
_RARE_ I-GENE
_RARE_ I-GENE
were O
recovered O
from O
isolated O
_RARE_ I-GENE
cells O
, O
the O
target O
cells O
of O
L I-GENE
. O
monocytogenes O
after O
intravenous O
_RARE_ I-GENE
. O

This O
suggested O
that O
delta I-GENE
6 I-GENE
and O
delta I-GENE
5 I-GENE
_RARE_ I-GENE
activities O
are O
normal O
in O
these O
conditions O
with O
this O
C18 O
: O
_RARE_ I-GENE
supply O
. O

The O
genetic O
basis O
for O
the O
expression O
of O
a O
latent I-GENE
VH I-GENE
_RARE_ I-GENE
in O
the O
rabbit I-GENE
was O
investigated O
. O

Here O
we O
report O
the O
complete O
6 I-GENE
- I-GENE
kilobase O
cDNA I-GENE
sequence I-GENE
coding O
for O
a O
chain I-GENE
of O
_RARE_ I-GENE
amino O
acids O
, O
as O
well O
as O
the O
genomic O
structure O
. O

HDL I-GENE
- I-GENE
cholesterol I-GENE
(+ O
6 I-GENE
%, O
P I-GENE
less O
than O
. O
01 O
) O
and O
apolipoprotein I-GENE
A I-GENE
- I-GENE
I I-GENE
(+ O
6 I-GENE
%, O
P I-GENE
less O
than O
. O
01 O
) O
concentrations O
increased O
significantly O
only O
in O
the O
young O
. O

The O
_RARE_ I-GENE
ribosomal I-GENE
protein I-GENE
gene I-GENE
cluster I-GENE
resembles O
the O
S I-GENE
- I-GENE
10 O
ribosomal I-GENE
protein I-GENE
operon I-GENE
of O
Escherichia I-GENE
coli I-GENE
in O
gene I-GENE
organization O
and O
follows O
the O
_RARE_ I-GENE
linear O
order O
of O
the O
analogous O
genes I-GENE
in O
the O
tobacco I-GENE
and O
_RARE_ I-GENE
chloroplast I-GENE
genomes O
. O

The O
distribution O
of O
the O
sites I-GENE
of O
_RARE_ I-GENE
resolution O
is O
inversely O
correlated O
with O
that O
of O
the O
gradient O
of O
sequence I-GENE
divergence O
, O
with O
only O
approximately O
7 O
% O
of O
the O
X I-GENE
recombinants I-GENE
resolved O
within O
the O
3 I-GENE
' O
third O
of O
the O
X I-GENE
blocks O
where O
two O
diverged O
Alu I-GENE
family I-GENE
repeats I-GENE
reside O
. O

The O
nucleotide I-GENE
sequence I-GENE
of O
the O
region O
upstream O
from O
M I-GENE
. O
_RARE_ I-GENE
_RARE_ I-GENE
was O
determined O
and O
revealed O
the O
presence O
of O
an O
ORF I-GENE
of O
_RARE_ I-GENE
nucleotides O
( O
_RARE_ I-GENE
) O
encoding O
a O
_RARE_ I-GENE
amino O
acid I-GENE
polypeptide I-GENE
of O
mol O
. O
wt I-GENE
. O

_RARE_ I-GENE
of O
the O
_RARE_ I-GENE
efficacy O
of O
single O
- I-GENE
chain I-GENE
urokinase I-GENE
( O
Pro I-GENE
- I-GENE
urokinase I-GENE
) O
by O
heparin O
. O

Of O
49 O
receptors I-GENE
which O
_RARE_ I-GENE
in O
phase O
with O
ventilation O
, O
13 O
_RARE_ I-GENE
like I-GENE
mammalian I-GENE
rapidly O
adapting O
pulmonary O
stretch O
receptors I-GENE
, O
19 O
like I-GENE
mammalian I-GENE
slowly O
adapting O
pulmonary O
stretch O
receptors I-GENE
( O
_RARE_ I-GENE
), O
and O
17 O
like I-GENE
avian I-GENE
_RARE_ I-GENE
CO2 O
- I-GENE
sensitive O
_RARE_ I-GENE
( O
_RARE_ I-GENE
). O

_RARE_ I-GENE
_RARE_ I-GENE
had O
a O
larger O
number O
of O
_RARE_ I-GENE
and O
_RARE_ I-GENE
wide O
fluctuations O
in O
baseline O
for O
inspiratory O
time O
, O
expiratory O
time O
, O
and O
_RARE_ I-GENE
. O

In O
the O
IA O
task O
, O
post O
- I-GENE
training O
_RARE_ I-GENE
injections O
of O
_RARE_ I-GENE
and O
_RARE_ I-GENE
induced O
a O
dose O
- I-GENE
dependent I-GENE
enhancement O
of O
retention O
measured O
24 O
h O
after O
the O
training O
, O
while O
retention O
was O
not O
affected O
by O
_RARE_ I-GENE
_RARE_ I-GENE
( O
a O
GABA I-GENE
receptor I-GENE
antagonist O
that O
does O
not O
readily O
cross O
the O
blood O
- I-GENE
brain O
barrier O
). O

Clinical O
research O
of O
non O
- I-GENE
A I-GENE
, O
non O
- I-GENE
B I-GENE
post O
- I-GENE
transfusion O
hepatitis I-GENE

It O
is O
suggested O
that O
the O
use O
of O
endogenous I-GENE
creatinine O
clearance O
to O
estimate O
the O
glomerular O
filtration O
rate O
( O
GFR O
) O
requires O
_RARE_ I-GENE
and O
the O
recognition I-GENE
of O
the O
limitations O
of O
the O
method O
, O
and O
that O
_RARE_ I-GENE
techniques O
( O
serum I-GENE
creatinine O
or O
estimated O
endogenous I-GENE
creatinine O
clearance O
) O
are O
_RARE_ I-GENE
in O
routine O
practice O
. O

The O
protein I-GENE
_RARE_ I-GENE
of O
_RARE_ I-GENE
_RARE_ I-GENE
and O
soybean I-GENE
_RARE_ I-GENE
were O
well O
accepted O
. O

The O
5 I-GENE
' O
end O
of O
the O
coding O
region O
was O
located O
precisely O
by O
comparing O
the O
deduced O
amino O
acid I-GENE
sequence I-GENE
to O
the O
actual O
N I-GENE
- I-GENE
terminal I-GENE
amino O
acid I-GENE
sequence I-GENE
of O
_RARE_ I-GENE
. O

A I-GENE
protein I-GENE
footprint O
also O
was O
identified O
for O
a O
GC I-GENE
box I-GENE
element I-GENE
at O
nucleotides O
- I-GENE
59 O
to O
- I-GENE
45 O
. O

Insulin I-GENE
- I-GENE
like I-GENE
growth I-GENE
factor I-GENE
II I-GENE
( O
_RARE_ I-GENE
) O
is O
a O
mitogenic O
polypeptide I-GENE
, O
the O
mRNAs I-GENE
of O
which O
are O
present O
in O
multiple O
forms O
, O
despite O
_RARE_ I-GENE
from O
a O
single O
gene I-GENE
. O

The O
central O
visual O
fields O
of O
_RARE_ I-GENE
normal O
and O
_RARE_ I-GENE
glaucoma O
eyes O
were O
measured O
using O
a O
threshold O
related I-GENE
_RARE_ I-GENE
strategy O
. O

The O
variability O
is O
most O
likely O
a O
result O
of O
alternative O
splicing O
of O
exons O
from O
the O
primary O
elastin I-GENE
transcripts I-GENE
. O

This O
led O
to O
the O
conclusion O
that O
the O
_RARE_ I-GENE
artery O
should O
be O
used O
for O
toe O
MP I-GENE
joint O
grafts O
, O
while O
the O
unilateral O
proper O
digital O
artery O
is O
suitable O
for O
toe O
_RARE_ I-GENE
joint O
grafts O
, O
together O
with O
concomitant O
or O
dorsal O
cutaneous O
vein O
. O

Effect O
of O
chronic O
_RARE_ I-GENE
on O
susceptibility I-GENE
to O
cold O
stress O
in O
young O
adult O
and O
aged O
rats O
. O

This O
effect O
and O
the O
fact O
that O
all O
three O
doses O
were O
toxic O
to O
the O
_RARE_ I-GENE
_RARE_ I-GENE
that O
a O
second O
experiment O
be O
carried O
out O
at O
lower O
doses O
. O

The O
_RARE_ I-GENE
association O
is O
a O
collection O
of O
_RARE_ I-GENE
congenital O
anomalies O
including O
_RARE_ I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
screening O
was O
undertaken O
and O
blood O
concentrations O
of O
_RARE_ I-GENE
( O
vitamin O
A I-GENE
, O
E I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
acid I-GENE
and O
methionine O
) O
determined O
from O
adults O
at O
risk O
for O
esophageal O
carcinoma O
( O
EC I-GENE
) O
in O
_RARE_ I-GENE
and O
_RARE_ I-GENE
, O
Southern O
_RARE_ I-GENE
. O

_RARE_ I-GENE
from O
the O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
were O
_RARE_ I-GENE
and O
the O
results O
were O
_RARE_ I-GENE
by O
_RARE_ I-GENE
type I-GENE
. O

Evaluation O
of O
human I-GENE
and O
bovine I-GENE
modified O
- I-GENE
hemoglobin I-GENE
solution O
as O
oxygen O
- I-GENE
carrying O
fluid O
for O
blood O
volume O
replacement O
. O

_RARE_ I-GENE
gallbladder O
visualization O
and O
reduction O
in O
ejection O
fraction O
were O
sensitive O
but O
nonspecific O
indicators O
of O
biliary O
disease O
. O

26 O
micrograms O
_RARE_ I-GENE
or O
placebo O
was O
_RARE_ I-GENE
into O
each O
nasal O
cavity O
8 O
h O
and O
1 I-GENE
h O
before O
a O
nasal O
allergen I-GENE
challenge O
. O

_RARE_ I-GENE
. O

Chem O
. O

_RARE_ I-GENE
MR O
examinations O
of O
the O
nasal O
cavity O
and O
_RARE_ I-GENE
_RARE_ I-GENE
were O
performed O
within O
a O
6 I-GENE
- I-GENE
8 O
h O
period O
in O
five O
normal O
volunteers O
. O

Comparison O
was O
made O
with O
other O
_RARE_ I-GENE
imaging O
modalities O
including O
CT I-GENE
, O
_RARE_ I-GENE
, O
CT I-GENE
_RARE_ I-GENE
, O
and O
CT I-GENE
_RARE_ I-GENE
. O

The O
feed O
given O
to O
young O
_RARE_ I-GENE
chickens O
was O
contaminated O
artificially O
with O
Salmonella I-GENE
_RARE_ I-GENE
, O
a O
serotype I-GENE
associated I-GENE
with O
both O
subclinical O
infections O
in O
_RARE_ I-GENE
_RARE_ I-GENE
chickens O
and O
food O
poisoning O
in O
humans O
. O

A I-GENE
poor O
correlation O
was O
found O
between O
a O
_RARE_ I-GENE
- I-GENE
atypical O
( O
inflammatory O
) O
_RARE_ I-GENE
result O
( O
class I-GENE
2 I-GENE
) O
and O
a O
benign O
histological O
diagnosis O
: O
48 O
% O
of O
class I-GENE
- I-GENE
2 I-GENE
smears O
were O
diagnosed O
histologically O
as O
dysplasia O
or O
_RARE_ I-GENE
. O

Factors O
involved O
in O
specific I-GENE
transcription I-GENE
by O
mammalian I-GENE
RNA I-GENE
polymerase I-GENE
II I-GENE
: O
purification O
, O
genetic O
specificity O
, O
and O
TATA I-GENE
box I-GENE
- I-GENE
promoter I-GENE
interactions O
of O
TFIID I-GENE
. O

_RARE_ I-GENE
in O
plasma I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
between O
30 O
- I-GENE
34 O
weeks O
' O
gestation O
as O
a O
predictor O
of O
pregnancy O
- I-GENE
induced O
hypertension O
. O

_RARE_ I-GENE
make O
the O
diagnosis O
. O

The O
test O
for O
alpha I-GENE
- I-GENE
_RARE_ I-GENE
esterase I-GENE
and O
_RARE_ I-GENE
of O
macrophages O
( O
absolute O
number O
) O
per O
_RARE_ I-GENE
area O
unit I-GENE
adjacent O
to O
the O
abscess O
suggest O
a O
direct O
correlation O
between O
the O
absolute O
number O
of O
macrophages O
and O
the O
_RARE_ I-GENE
of O
the O
_RARE_ I-GENE
. O

_RARE_ I-GENE
as O
migration O
_RARE_ I-GENE
, O
chemotactic O
and O
_RARE_ I-GENE
responsiveness O
tended O
to O
be O
higher O
in O
the O
_RARE_ I-GENE
group O
. O

The O
deduced O
96 O
- I-GENE
residue O
amino O
acid I-GENE
coding O
sequence I-GENE
of O
the O
murine I-GENE
HMG I-GENE
- I-GENE
I I-GENE
( O
Y I-GENE
) O
cDNA I-GENE
is O
very O
similar O
to O
the O
reported O
amino O
acid I-GENE
sequence I-GENE
of O
human I-GENE
HMG I-GENE
- I-GENE
I I-GENE
, O
except O
that O
it O
lacks O
11 O
internal O
amino O
acids O
reported O
in O
the O
human I-GENE
protein I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
differences O
among O
drug O
_RARE_ I-GENE
were O
explored O
using O
_RARE_ I-GENE
' O
s O
( O
_RARE_ I-GENE
) O
_RARE_ I-GENE
system O
of O
_RARE_ I-GENE
- I-GENE
B I-GENE
interpretation O
. O

_RARE_ I-GENE
of O
the O
American O
_RARE_ I-GENE
of O
_RARE_ I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
from O
_RARE_ I-GENE
post O
- I-GENE
menopausal I-GENE
or O
pregnant O
women O
yielded O
TSH I-GENE
levels O
within O
the O
normal O
range O
. O

No O
_RARE_ I-GENE
mRNA I-GENE
was O
detected O
in O
11 O
_RARE_ I-GENE
tissues O
of O
rat I-GENE
, O
suggesting O
tissue I-GENE
specificity O
of O
expression O
of O
this O
_RARE_ I-GENE
gene I-GENE
. O

The O
platelet I-GENE
adhesion I-GENE
rate O
on O
these O
_RARE_ I-GENE
were O
tested O
concerning O
the O
_RARE_ I-GENE
of O
the O
_RARE_ I-GENE
of O
the O
basic I-GENE
- I-GENE
polymers O
_RARE_ I-GENE
( O
_RARE_ I-GENE
), O
_RARE_ I-GENE
( O
_RARE_ I-GENE
), O
and O
_RARE_ I-GENE
( O
PS I-GENE
) O
in O
two O
different O
_RARE_ I-GENE
test O
_RARE_ I-GENE
. O

_RARE_ I-GENE
treatment O
of O
bladder O
carcinoma O
by O
partial O
_RARE_ I-GENE
and O
interstitial O
_RARE_ I-GENE
192 I-GENE
. O

In O
a O
112 O
- I-GENE
d O
_RARE_ I-GENE
trial O
, O
105 I-GENE
heifers O
were O
assigned O
to O
light I-GENE
, O
medium O
and O
heavy I-GENE
weight O
blocks O
on O
five O
treatments O
: O
dietary O
MGA O
_RARE_ I-GENE
5 I-GENE
mg O
. O
_RARE_ I-GENE
- I-GENE
1 I-GENE
. O
d O
- I-GENE
1 I-GENE
), O
control O
( O
no O
MGA O
) O
or O
_RARE_ I-GENE
- I-GENE
MGA O
on O
d O
1 I-GENE
at O
. O
5 I-GENE
, O
1 I-GENE
. O
0 O
or O
1 I-GENE
. O
5 I-GENE
ml O
/ I-GENE
_RARE_ I-GENE
( O
30 O
, O
60 O
or O
90 O
mg O
MGA O
/ I-GENE
_RARE_ I-GENE
, O
respectively O
). O

_RARE_ I-GENE
and O
_RARE_ I-GENE
of O
solutions O
of O
the O
appropriate O
boundary O
value O
problems O
are O
established O
, O
in O
the O
case O
of O
small I-GENE
permeability I-GENE
coefficients O
and O
transport O
rates O
, O
or O
large O
diffusion O
coefficients O
and O
small I-GENE
resistance O
to O
flow O
constants O
. O

There O
were O
gene I-GENE
clusters O
encoding O
_RARE_ I-GENE
components O
such O
as O
the O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
and O
the O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
clusters O
. O

The O
results O
presented O
suggest O
that O
_RARE_ I-GENE
reduces O
the O
turnover O
rate O
of O
the O
_RARE_ I-GENE
dopamine I-GENE
neurons O
after O
repeated O
administration O
for O
a O
long O
period O
in O
mice O
. O

The O
partial O
sequence I-GENE
of O
the O
62 O
- I-GENE
kDa I-GENE
nuclear I-GENE
pore I-GENE
glycoprotein I-GENE
shows O
little O
similarity O
to O
other O
characterized O
proteins I-GENE
and O
_RARE_ I-GENE
structural O
features O
of O
a O
member O
of O
the O
family I-GENE
of O
nuclear I-GENE
pore I-GENE
glycoproteins I-GENE
. O

Seventy O
- I-GENE
two O
hours O
after O
administration O
of O
vitamin O
K1 I-GENE
, O
plasma I-GENE
concentrations O
of O
the O
vitamin O
were O
not O
different O
from O
normal O
. O

The O
glomerular O
filtration O
rate O
did O
not O
change O
but O
lithium O
clearance O
fell O
by O
30 O
%. O

During O
a O
28 O
- I-GENE
week O
_RARE_ I-GENE
_RARE_ I-GENE
, O
groups O
of O
30 O
male O
CD O
- I-GENE
1 I-GENE
mice O
were O
treated O
once O
with O
50 O
_RARE_ I-GENE
of O
either O
_RARE_ I-GENE
( O
1 I-GENE
. O
0 O
mg O
/ I-GENE
ml O
) O
or O
_RARE_ I-GENE
, O
_RARE_ I-GENE
for O
2 I-GENE
weeks O
, O
and O
then O
treated O
twice O
per O
week O
with O
test O
material O
for O
the O
remaining O
25 O
weeks O
. O

The O
pathogenesis O
of O
_RARE_ I-GENE
' O
s O
_RARE_ I-GENE

An O
ELISA O
procedure O
was O
developed O
for O
monitoring O
the O
specific I-GENE
IgE I-GENE
response O
in O
dogs O
to O
_RARE_ I-GENE
_RARE_ I-GENE
infection O
. O

Fifty O
min O
after O
release O
from O
stress O
, O
increases O
in O
plasma I-GENE
corticosterone O
levels O
induced O
by O
stress O
recovered O
in O
the O
_RARE_ I-GENE
group O
but O
remained O
high O
in O
the O
non O
- I-GENE
_RARE_ I-GENE
group O
. O

The O
only O
isolate O
of O
_RARE_ I-GENE
_RARE_ I-GENE
produced O
cytotoxic O
enterotoxin I-GENE
and O
was O
invasive O
. O

An O
11 O
- I-GENE
month O
- I-GENE
old O
_RARE_ I-GENE
suffering O
from O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
associated I-GENE
with O
_RARE_ I-GENE
of O
_RARE_ I-GENE
( O
TOF O
) O
is O
presented O
. O

The O
incidence O
of O
early I-GENE
neonatal O
_RARE_ I-GENE
for O
_RARE_ I-GENE
babies O
was O
3 I-GENE
. O
0 O
/ I-GENE
1000 O
live O
births O
. O

The O
median O
survival O
is O
not O
reached O
with O
a O
median O
follow O
- I-GENE
up O
time O
of O
9 O
. O
6 I-GENE
years O
. O

_RARE_ I-GENE
evaluation O
of O
various O
methods O
of O
determining O
markers O
of O
fetal O
_RARE_ I-GENE
in O
amniotic I-GENE
fluid O

Of O
the O
43 I-GENE
infants O
with O
a O
( O
probable O
) O
loss O
18 O
were O
examined O
again O
at O
3 I-GENE
months O
corrected O
age O
. O

_RARE_ I-GENE
of O
cows O
and O
_RARE_ I-GENE
according O
to O
types O
of O
_RARE_ I-GENE
( O
patterns O
) O
of O
the O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
of O
cattle O

Although O
not O
consistently O
identified O
in O
all O
samples O
, O
secondary O
Academic O
, O
_RARE_ I-GENE
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
dimensions O
were O
also O
identified O
. O

_RARE_ I-GENE
was O
characterized O
by O
rapid O
improvement O
such O
that O
all O
measured O
parameters O
normalized O
by O
1 I-GENE
week O
, O
except O
for O
cross O
- I-GENE
sectional O
cardiac O
area O
which O
remained O
_RARE_ I-GENE
up O
to O
4 I-GENE
weeks O
( O
14 O
+/- O
3 I-GENE
cm2 O
, O
p O
less O
than O
0 O
. O
05 O
versus O
control O
_RARE_ I-GENE
ABSTRACT O
TRUNCATED O
AT I-GENE
250 O
WORDS O
) O

_RARE_ I-GENE
even O
extensive O
pancreatic O
resection O
could O
prevent O
pancreatic O
_RARE_ I-GENE
infection O
. O

It O
has O
been O
calculated O
that O
600 O
, O
000 O
new O
cases O
of O
lung O
cancer O
occur O
_RARE_ I-GENE
every O
year O
, O
most O
of O
them O
due O
to O
smoking O
. O

_RARE_ I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
' O
s O
syndrome O
): O
not O
always O
multiple O
sclerosis O
. O

Effect O
of O
the O
methods O
of O
cutaneous O
administration O
of O
methyl O
_RARE_ I-GENE
_RARE_ I-GENE
on O
its O
toxicity O

_RARE_ I-GENE
of O
0 O
. O
1 I-GENE
or O
0 O
. O
2 I-GENE
M I-GENE
sodium O
_RARE_ I-GENE
phosphate I-GENE
in O
the O
sugar I-GENE
solutions O
resulted O
in O
a O
decrease O
in O
the O
_RARE_ I-GENE
- I-GENE
life O
of O
diltiazem O
. O

None O
had O
a O
past O
history O
of O
_RARE_ I-GENE
infections O
; O
neither O
did O
any O
have O
_RARE_ I-GENE
. O

Increasing O
the O
phosphorus O
content O
of O
the O
diet O
improved O
the O
_RARE_ I-GENE
of O
calcium O
and O
magnesium O
. O

Post O
- I-GENE
transcriptional O
regulation O
of O
ribosomal I-GENE
protein I-GENE
gene I-GENE
expression O
during O
development O
in O
Dictyostelium O
_RARE_ I-GENE
. O

The O
temporal O
and O
_RARE_ I-GENE
plasma I-GENE
concentration O
- I-GENE
effect O
relationships O
were O
evaluated O
by O
_RARE_ I-GENE
_RARE_ I-GENE
and O
linear O
regression O
. O

The O
increase O
in O
amplitudes O
of O
the O
b I-GENE
- I-GENE
wave O
during O
the O
adaptation O
period O
was O
more O
prominent O
in O
lead O
- I-GENE
exposed O
subjects O
than O
in O
controls O
. O

_RARE_ I-GENE
factors I-GENE
for O
the O
development O
of O
_RARE_ I-GENE
_RARE_ I-GENE
during O
group O
activities O
and O
the O
role O
of O
group O
dynamics O
acting O
as O
stress O
factors I-GENE
precipitating O
functional O
_RARE_ I-GENE
, O
especially O
bipolar O
manifestations O
, O
are O
discussed O
. O

_RARE_ I-GENE
measurements O
of O
_RARE_ I-GENE
expiratory O
volume O
in O
1 I-GENE
s O
( O
FEV1 O
), O
specific I-GENE
airway O
conductance I-GENE
( O
_RARE_ I-GENE
) O
and O
the O
_RARE_ I-GENE
dose O
of O
carbachol O
causing O
a O
35 O
% O
reduction O
in O
_RARE_ I-GENE
( O
_RARE_ I-GENE
), O
and O
a O
20 O
% O
reduction O
in O
FEV1 O
( O
_RARE_ I-GENE
) O
were O
established O
on O
entry O
while O
each O
subject O
was O
still O
smoking O
. O

Many O
children O
with O
_RARE_ I-GENE
are O
delayed O
in O
their O
development O
, O
but O
_RARE_ I-GENE
are O
not O
directly O
related I-GENE
to O
specific I-GENE
forms O
of O
neurologic O
dysfunction O
. O

R I-GENE
- I-GENE
wave O
voltage O
in O
the O
right O
_RARE_ I-GENE
leads O
in O
_RARE_ I-GENE
cardiomyopathy O
: O
a O
clinical O
study O
. O

The O
results O
indicate O
that O
the O
_RARE_ I-GENE
requirements O
are O
task O
dependent I-GENE
. O

These O
results O
indicate O
that O
_RARE_ I-GENE
can O
increase O
neutrophil I-GENE
counts O
by O
increasing O
the O
number O
and O
_RARE_ I-GENE
of O
the O
marrow O
neutrophil I-GENE
precursors I-GENE
in O
some O
types O
of O
childhood O
chronic O
neutropenia O
. O

The O
_RARE_ I-GENE
of O
this O
study O
were O
1 I-GENE
) O
to O
examine O
the O
effect O
of O
high O
intensity O
, O
low O
frequency O
_RARE_ I-GENE
electrical O
nerve I-GENE
stimulation O
at O
_RARE_ I-GENE
_RARE_ I-GENE
points O
on O
experimental O
pain O
threshold O
measured O
at O
the O
wrist O
and O
2 I-GENE
) O
to O
determine O
the O
changes O
in O
effect O
over O
time O
. O

In O
the O
infected O
neonates O
serum I-GENE
alpha I-GENE
- I-GENE
amylase I-GENE
value O
, O
as O
determined O
by O
the O
blue O
_RARE_ I-GENE
method O
, O
was O
only O
40 I-GENE
% O
that O
of O
healthy O
controls O
; O
the O
mean O
value O
of O
175 O
. O
1 I-GENE
+/- O
64 O
. O
9 O
IU O
/ I-GENE
l O
for O
healthy O
neonates O
was O
significantly O
higher O
( O
p O
less O
than O
0 O
. O
_RARE_ I-GENE
) O
than O
the O
value O
of O
82 O
. O
8 O
+/- O
44 I-GENE
. O
4 I-GENE
IU O
/ I-GENE
l O
for O
the O
infected O
neonates O
. O

_RARE_ I-GENE
of O
31 O
children O
with O
AIDS O
or O
AIDS O
- I-GENE
related I-GENE
complex I-GENE
_RARE_ I-GENE
to O
the O
pediatric O
intensive O
care O
unit I-GENE
for O
acute O
respiratory O
failure O
throughout O
a O
46 O
- I-GENE
month O
period O
were O
reviewed O
. O

_RARE_ I-GENE
patients O
were O
in O
the O
_RARE_ I-GENE
disease O
group O
; O
13 O
were O
detected O
by O
SPECT O
and O
10 O
by O
_RARE_ I-GENE
. O

SPECT O
is O
an O
important O
aid O
in O
the O
diagnosis O
of O
AIDS O
dementia O
complex I-GENE
and O
contributes O
to O
the O
understanding O
of O
the O
_RARE_ I-GENE
mechanisms O
of O
this O
disorder O
. O

We O
were O
_RARE_ I-GENE
in O
studying O
the O
relationship O
between O
the O
circadian O
rhythm O
in O
body O
temperature O
and O
24 O
- I-GENE
h O
variations O
in O
plasma I-GENE
concentrations O
of O
iron O
, O
zinc I-GENE
, O
circulating O
leukocyte I-GENE
counts O
, O
and O
plasma I-GENE
interleukin I-GENE
1 I-GENE
( O
IL I-GENE
- I-GENE
1 I-GENE
) O
activity O
. O

The O
murine I-GENE
MHC I-GENE
class I-GENE
I I-GENE
genes I-GENE
, O
H I-GENE
- I-GENE
_RARE_ I-GENE
and O
H I-GENE
- I-GENE
_RARE_ I-GENE
, O
are O
strikingly O
homologous O
to O
each O
other O
, O
H I-GENE
- I-GENE
_RARE_ I-GENE
, O
and O
two O
genes I-GENE
reported O
to O
encode O
tumor I-GENE
- I-GENE
specific I-GENE
antigens I-GENE
. O

The O
active O
derivatives O
of O
the O
present O
series O
were O
also O
tested O
for O
their O
analgesic O
activity O
against O
_RARE_ I-GENE
- I-GENE
induced O
_RARE_ I-GENE
in O
_RARE_ I-GENE
mice O
and O
_RARE_ I-GENE
activity O
in O
_RARE_ I-GENE
rats O
. O

In O
untreated O
mice O
, O
bactericidal O
activity O
of O
peritoneal O
macrophages O
decreased O
from O
one O
day O
to O
3 I-GENE
days O
after O
_RARE_ I-GENE
injection O
of O
killed O
L I-GENE
. O
monocytogenes O
. O

Among O
a O
population O
of O
18 O
, O
175 O
children O
below O
7 O
years O
of O
age O
in O
medium O
sized O
_RARE_ I-GENE
and O
_RARE_ I-GENE
areas O
in O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
( O
3 I-GENE
. O
03 O
%) O
cases O
of O
_RARE_ I-GENE
were O
_RARE_ I-GENE
during O
a O
12 O
months O
period O
in O
_RARE_ I-GENE
- I-GENE
85 O
by O
their O
physicians O
. O

We O
concluded O
that O
Ga O
- I-GENE
_RARE_ I-GENE
scintigraphy O
is O
a O
very O
simple O
method O
and O
_RARE_ I-GENE
useful O
for O
detecting O
active O
left O
ventricular O
_RARE_ I-GENE
and O
for O
monitoring O
the O
effect O
of O
anticoagulant I-GENE
therapy O
. O

In O
vitro O
assessment O
of O
the O
_RARE_ I-GENE
of O
dental O
materials O
-- O
the O
_RARE_ I-GENE
filter O
method O
. O

_RARE_ I-GENE
was O
due O
to O
magnesium O
_RARE_ I-GENE
by O
the O
kidney O
. O

_RARE_ I-GENE
was O
controlled O
by O
the O
oral O
_RARE_ I-GENE
index O
of O
the O
whole O
_RARE_ I-GENE
daily O
, O
after O
staining O
with O
1 I-GENE
per O
cent O
alkaline I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
bound O
to O
sequences I-GENE
at O
the O
negative O
regulatory I-GENE
elements O
( O
_RARE_ I-GENE
) O
of O
the O
silent I-GENE
mating I-GENE
type I-GENE
loci I-GENE
HML I-GENE
E I-GENE
and O
HMR I-GENE
E I-GENE
and O
to O
the O
upstream O
activating I-GENE
sequence I-GENE
( O
UAS O
) O
required O
for O
transcription I-GENE
of O
the O
_RARE_ I-GENE
alpha I-GENE
genes I-GENE
. O

The O
effects O
of O
these O
mutations O
on O
RNA I-GENE
polymerase I-GENE
II I-GENE
activity O
were O
assayed O
by O
measuring O
the O
ability O
of O
mutant I-GENE
genes I-GENE
to O
confer O
alpha I-GENE
- I-GENE
_RARE_ I-GENE
resistance O
after O
transfection O
of O
susceptible O
rodent O
cells O
. O

We O
report O
the O
use O
of O
a O
new O
technetium O
- I-GENE
99m O
- I-GENE
albumin I-GENE
colloid O
white O
blood O
cell O
( O
_RARE_ I-GENE
- I-GENE
WBC O
) O
scan O
in O
the O
evaluation O
of O
_RARE_ I-GENE
. O

In O
one O
of O
these O
tumors O
the O
observed O
rearrangement O
was O
not O
due O
to O
the O
insertion O
of O
an O
intact O
_RARE_ I-GENE
provirus O
. O

The O
_RARE_ I-GENE
for O
its O
use O
include O
every O
primary O
and O
secondary O
_RARE_ I-GENE
candidate O
unless O
tip O
grafts O
are O
_RARE_ I-GENE
to O
be O
under O
tension O
or O
if O
the O
_RARE_ I-GENE
is O
minor O
. O

The O
SSB I-GENE
- I-GENE
poly O
( O
dT O
) O
affinity O
is O
_RARE_ I-GENE
high O
to O
measure O
in O
_RARE_ I-GENE
containing O
even O
5 I-GENE
M I-GENE
NaCl O
; O
however O
, O
in O
1 I-GENE
. O
8 O
- I-GENE
2 I-GENE
. O
5 I-GENE
M I-GENE
_RARE_ I-GENE
, O
we O
measure O
alpha I-GENE
log O
_RARE_ I-GENE
/ I-GENE
alpha I-GENE
log O
[ O
_RARE_ I-GENE
] O
= O
- I-GENE
5 I-GENE
. O
7 O
+/- O
0 O
. O
7 O
, O
with O
a O
lower O
value O
of O
omega I-GENE
T I-GENE
/ I-GENE
O O
= O
130 I-GENE
+/- O
70 I-GENE
. O

Mutations O
at O
the O
_RARE_ I-GENE
locus I-GENE
were O
isolated O
in O
Saccharomyces I-GENE
cerevisiae I-GENE
as O
_RARE_ I-GENE
suppressors O
of O
+ I-GENE
1 I-GENE
frameshift O
mutations O
in O
glycine O
( O
_RARE_ I-GENE
) O
and O
proline O
( O
_RARE_ I-GENE
) O
codons O
, O
as O
well O
as O
UGA O
and O
_RARE_ I-GENE
nonsense O
mutations O
. O

The O
behavior O
of O
_RARE_ I-GENE
- I-GENE
null I-GENE
/ I-GENE
_RARE_ I-GENE
+ I-GENE
_RARE_ I-GENE
indicates O
that O
_RARE_ I-GENE
is O
co O
- I-GENE
_RARE_ I-GENE
expressed O
and O
suggests O
that O
_RARE_ I-GENE
allele I-GENE
- I-GENE
specific I-GENE
suppression O
may O
result O
from O
functionally O
distinct O
mutant I-GENE
proteins I-GENE
rather O
than O
variation O
in O
residual O
wild I-GENE
- I-GENE
type I-GENE
_RARE_ I-GENE
+ I-GENE
activity O
. O

_RARE_ I-GENE
agents O
. O

The O
putative O
immunity O
protein I-GENE
was O
detected O
among O
the O
[ O
35S I-GENE
] O
methionine O
- I-GENE
labelled O
proteins I-GENE
produced O
by O
_RARE_ I-GENE
carrying O
_RARE_ I-GENE
cloned O
under O
lac I-GENE
promoter I-GENE
control O
, O
and O
when O
the O
gene I-GENE
was O
subcloned O
into O
expression O
vectors O
under O
the O
control O
of O
a O
bacteriophage I-GENE
T7 I-GENE
promoter I-GENE
. O

Antibodies O
made O
against O
fusion I-GENE
protein I-GENE
produced O
by O
the O
_RARE_ I-GENE
clone O
reacted O
specifically O
with O
DP I-GENE
- I-GENE
I I-GENE
and O
- I-GENE
II I-GENE
on O
_RARE_ I-GENE
. O

Finally O
, O
over O
a O
similar O
range O
of O
_RARE_ I-GENE
, O
oxygen O
extraction O
was O
greater O
in O
patients O
with O
ARDS O
compared O
to O
patients O
with O
non O
- I-GENE
ARDS O
respiratory O
failure O
( O
r O
= O
- I-GENE
0 O
. O
67 O
and O
slope O
= O
- I-GENE
0 O
. O
62 O
vs O
r O
= O
- I-GENE
0 O
. O
45 O
and O
slope O
= O
- I-GENE
0 O
. O
35 O
; O
p O
less O
than O
0 O
. O
05 O
). O

Stable O
patients O
have O
_RARE_ I-GENE
_RARE_ I-GENE
and O
little O
evidence O
of O
acute O
inflammation O
. O

_RARE_ I-GENE
, O
moderate O
_RARE_ I-GENE
, O
_RARE_ I-GENE
_RARE_ I-GENE
, O
arterial O
_RARE_ I-GENE
and O
moderate O
venous O
_RARE_ I-GENE
seem O
to O
play O
a O
partial O
role O
of O
organic O
_RARE_ I-GENE
or O
cofactor I-GENE
, O
the O
sexual O
consequences O
of O
which O
are O
amplified O
by O
psychological O
factors I-GENE
, O
partly O
secondary O
to O
the O
initial O
sexual O
_RARE_ I-GENE
. O

_RARE_ I-GENE
and O
H I-GENE
. O

_RARE_ I-GENE
function O
of O
the O
prostate O
gland O
. O

Chronic O
_RARE_ I-GENE
appears O
to O
be O
associated I-GENE
with O
an O
elevated O
pulmonary O
microvascular O
permeability I-GENE
and O
a O
tendency O
toward O
a O
_RARE_ I-GENE
circulation O
but O
with O
an O
_RARE_ I-GENE
degree O
of O
_RARE_ I-GENE
associated I-GENE
with O
regional O
hemodynamics O
and O
_RARE_ I-GENE
biosynthesis O
. O

In O
contrast O
, O
we O
observed O
high O
concentrations O
in O
29 O
of O
75 O
patients O
with O
tumors O
of O
the O
central O
nervous O
system O
, O
especially O
in O
_RARE_ I-GENE
( O
6 I-GENE
/ I-GENE
9 O
), O
_RARE_ I-GENE
( O
9 O
/ I-GENE
23 O
), O
and O
_RARE_ I-GENE
( O
5 I-GENE
/ I-GENE
5 I-GENE
). O

_RARE_ I-GENE
and O
atopic O
_RARE_ I-GENE
. O

_RARE_ I-GENE
delay O
effects O
on O
the O
_RARE_ I-GENE
bond O
strength O
developed O
by O
the O
_RARE_ I-GENE
. O

The O
future O
of O
research O
with O
interferon I-GENE
may O
be O
divided O
into O
three O
areas O
: O
_RARE_ I-GENE
must O
be O
made O
to O
determine O
how O
best O
to O
_RARE_ I-GENE
the O
in O
vitro O
_RARE_ I-GENE
into O
clinically O
_RARE_ I-GENE
terms O
; O
in O
order O
to O
_RARE_ I-GENE
the O
_RARE_ I-GENE
potential O
of O
IFN I-GENE
, O
research O
is O
_RARE_ I-GENE
toward O
using O
this O
agent O
earlier O
in O
disease O
either O
as O
an O
adjuvant O
after O
tumor I-GENE
_RARE_ I-GENE
or O
after O
initial O
diagnosis O
; O
the O
medical O
community O
must O
_RARE_ I-GENE
the O
natural O
history O
of O
some O
diseases O
, O
because O
the O
_RARE_ I-GENE
potential O
of O
the O
_RARE_ I-GENE
agents O
will O
most O
likely O
manifest O
itself O
when O
these O
agents O
are O
used O
together O
. O

_RARE_ I-GENE
differences O
were O
noted O
with O
_RARE_ I-GENE
producing O
mild O
_RARE_ I-GENE
elevation O
of O
prothrombin I-GENE
time O
( O
0 O
. O
7 O
second O
) O
associated I-GENE
with O
depression O
of O
factor I-GENE
II I-GENE
and O
factor I-GENE
VII I-GENE
. O

Six O
healthy O
male O
subjects O
received O
single O
oral O
doses O
of O
regular O
release O
( O
RR O
) O
_RARE_ I-GENE
sulfate I-GENE
, O
sustained O
release O
( O
SR I-GENE
) O
_RARE_ I-GENE
_RARE_ I-GENE
and O
the O
same O
dose O
of O
the O
SR I-GENE
product I-GENE
with O
food O
( O
SR I-GENE
- I-GENE
F I-GENE
). O

This O
report O
_RARE_ I-GENE
on O
previous O
work O
with O
interferon I-GENE
_RARE_ I-GENE
- I-GENE
2b I-GENE
( O
Intron I-GENE
A I-GENE
; O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
) O
in O
the O
treatment O
of O
_RARE_ I-GENE
cell O
leukemia I-GENE
( O
_RARE_ I-GENE
). O

_RARE_ I-GENE
delivery O
and O
base O
excess O
decreased O
significantly O
and O
four O
pigs O
died O
. O

Clinical O
chemistry O
. O

_RARE_ I-GENE
after O
anterior O
_RARE_ I-GENE
and O
mandibular O
_RARE_ I-GENE

_RARE_ I-GENE
_RARE_ I-GENE
for O
the O
management O
of O
_RARE_ I-GENE
. O

The O
_RARE_ I-GENE
spread O
of O
the O
carcinoma O
correlated O
with O
portal I-GENE
invasion O
of O
carcinoma O
, O
_RARE_ I-GENE
of O
the O
body O
and O
tail O
, O
obstruction O
of O
main O
pancreatic O
duct O
and O
_RARE_ I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
enzymes O
that O
_RARE_ I-GENE
cartilage O
are O
released O
. O

_RARE_ I-GENE
to O
the O
observation O
made O
with O
other O
S I-GENE
. O
pombe I-GENE
genes I-GENE
transcribed O
in O
the O
budding I-GENE
yeast I-GENE
, O
the O
heterologous O
actin I-GENE
gene I-GENE
transcript I-GENE
is O
initiated O
39 O
nucleotides O
upstream O
of O
the O
initiation I-GENE
start O
site I-GENE
used O
in O
the O
homologous O
yeast I-GENE
. O

A I-GENE
_RARE_ I-GENE
study O
involving O
9 O
Italian O
_RARE_ I-GENE
was O
carried O
out O
to O
compare O
the O
efficacy O
and O
safety O
of O
ranitidine O
150 O
mg O
b I-GENE
. O
i O
. O
d O
. O
and O
ranitidine O
300 O
mg O
_RARE_ I-GENE
in O
the O
treatment O
of O
reflux O
_RARE_ I-GENE
. O

_RARE_ I-GENE
with O
_RARE_ I-GENE
was O
clinically O
and O
_RARE_ I-GENE
as O
effective O
as O
a O
combination O
therapy O
with O
_RARE_ I-GENE
and O
_RARE_ I-GENE
. O

The O
_RARE_ I-GENE
wave O
of O
the O
_RARE_ I-GENE
' O
s O
, O
which O
has O
been O
found O
to O
correlate O
best O
with O
neurological O
recovery O
, O
returned O
to O
65 O
% O
+/- O
48 O
% O
of O
the O
_RARE_ I-GENE
amplitude O
in O
the O
insulin I-GENE
- I-GENE
treated O
animals O
, O
compared O
to O
40 I-GENE
% O
+/- O
34 O
% O
in O
the O
fasted O
group O
and O
26 O
% O
+/- O
24 O
% O
in O
the O
control O
animals O
. O

_RARE_ I-GENE
and O
_RARE_ I-GENE
studies O
may O
be O
an O
important O
part O
of O
evaluation O
, O
especially O
in O
patients O
who O
present O
with O
_RARE_ I-GENE
_RARE_ I-GENE
, O
masses O
, O
or O
_RARE_ I-GENE
_RARE_ I-GENE
. O

In O
the O
control O
group O
the O
histological O
picture O
_RARE_ I-GENE
_RARE_ I-GENE
. O

In O
contrast O
to O
this O
mRNA I-GENE
, O
90 O
% O
of O
alpha I-GENE
and O
beta I-GENE
actin I-GENE
mRNAs I-GENE
were O
translated O
in O
both O
myoblasts O
and O
myotubes O
. O

Plasma I-GENE
renin I-GENE
activity O
does O
not O
predict O
the O
antihypertensive O
efficacy O
of O
_RARE_ I-GENE
. O

_RARE_ I-GENE
250 O
mg O
at O
night O
for O
12 O
months O
was O
given O
as O
a O
prophylactic O
measure O
to O
33 O
female O
patients O
of O
mean O
age O
41 O
. O
6 I-GENE
years O
, O
who O
had O
a O
history O
in O
the O
preceding O
12 O
months O
of O
between O
three O
and O
24 O
( O
median O
= O
7 O
) O
episodes O
of O
frequency O
and O
/ I-GENE
or O
_RARE_ I-GENE
. O

If O
this O
is O
_RARE_ I-GENE
, O
then O
_RARE_ I-GENE
has O
a O
proven O
record O
for O
good O
tissue I-GENE
compatibility O
and O
resistance O
to O
infection O
. O

The O
size O
of O
the O
group O
allocated O
to O
the O
good O
compliance O
category O
by O
the O
use O
of O
the O
_RARE_ I-GENE
marker O
was O
equivalent O
in O
size O
to O
a O
group O
of O
patients O
who O
had O
returned O
less O
than O
15 O
% O
of O
their O
_RARE_ I-GENE
dose O
or O
reported O
a O
deviation O
of O
less O
than O
6 I-GENE
% O
from O
their O
_RARE_ I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
was O
usually O
_RARE_ I-GENE
in O
origin O
in O
1982 O
, O
but O
after O
1983 O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
was O
the O
most O
common O
cause O
of O
_RARE_ I-GENE
_RARE_ I-GENE
. O

The O
_RARE_ I-GENE
findings O
, O
as O
well O
as O
the O
urinary O
C I-GENE
- I-GENE
peptide I-GENE
excretion O
, O
confirmed O
that O
the O
_RARE_ I-GENE
effects O
should O
not O
be O
thought O
to O
be O
due O
to O
a O
direct O
action O
of O
the O
drugs O
used O
on O
the O
endocrine O
pancreas O
. O

The O
activity O
of O
the O
EGF I-GENE
receptor I-GENE
promoter I-GENE
can O
be O
modulated O
by O
E1A I-GENE
protein I-GENE
and O
receptor I-GENE
RNA I-GENE
levels O
increased O
by O
stimulation O
with O
phorbol O
ester O
or O
fetal O
calf I-GENE
serum I-GENE
. O

In O
vitro O
_RARE_ I-GENE
activity O
of O
_RARE_ I-GENE
( O
_RARE_ I-GENE
_RARE_ I-GENE
A I-GENE
. O

" O
In O
vitro O
" O
study O
of O
dentin O
adhesion I-GENE
to O
_RARE_ I-GENE
made O
from O
_RARE_ I-GENE
molecules I-GENE
with O
free O
groups O
of O
_RARE_ I-GENE

By O
_RARE_ I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
. O

There O
is O
a O
cysteine I-GENE
_RARE_ I-GENE
region O
in O
an O
N I-GENE
- I-GENE
terminal I-GENE
region O
of O
the O
c I-GENE
- I-GENE
raf I-GENE
(- O
1 I-GENE
) O
product I-GENE
deduced O
from O
the O
nucleotide I-GENE
sequence I-GENE
, O
and O
this O
cysteine I-GENE
_RARE_ I-GENE
region O
was O
found O
to O
be O
highly O
homologous O
to O
that O
present O
in O
an O
N I-GENE
- I-GENE
terminal I-GENE
region O
of O
protein I-GENE
kinase I-GENE
C I-GENE
, O
although O
, O
in O
the O
latter O
cysteine I-GENE
clusters O
are O
present O
in O
_RARE_ I-GENE
. O

_RARE_ I-GENE
- I-GENE
held O
, O
continuous O
- I-GENE
wave O
Doppler O
probes O
, O
coupled I-GENE
with O
sound O
spectral O
analysis O
, O
can O
successfully O
predict O
carotid O
artery O
stenosis O
. O

The O
_RARE_ I-GENE
_RARE_ I-GENE
of O
_RARE_ I-GENE
_RARE_ I-GENE
in O
_RARE_ I-GENE
initiated O
the O
_RARE_ I-GENE
_RARE_ I-GENE
' O
s O
_RARE_ I-GENE
Study O
( O
_RARE_ I-GENE
81 O
) O
using O
a O
four O
- I-GENE
drug O
combination O
of O
chemotherapy O
prior O
to O
definitive O
local O
control O
with O
surgery O
and O
/ I-GENE
or O
radiation O
. O

The O
program O
has O
been O
_RARE_ I-GENE
in O
a O
_RARE_ I-GENE
_RARE_ I-GENE
in O
order O
to O
make O
the O
procedure O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
. O

Since O
high O
levels O
of O
immunoglobulin I-GENE
G I-GENE
were O
demonstrated O
against O
the O
surface O
of O
the O
_RARE_ I-GENE
after O
immunization O
, O
passive O
transfer I-GENE
experiments O
were O
initiated O
. O

A I-GENE
study O
was O
conducted O
of O
a O
human I-GENE
male O
who O
had O
inhaled O
a O
mixture O
of O
_RARE_ I-GENE
and O
_RARE_ I-GENE
. O

An O
_RARE_ I-GENE
method O
for O
comparative O
parameter O
_RARE_ I-GENE
in O
magnetic O
resonance O
( O
MR O
) O
imaging O
has O
been O
developed O
using O
the O
concept O
of O
" O
fractional O
sensitivity O
." I-GENE
This O
new O
approach O
results O
in O
easily O
calculated O
_RARE_ I-GENE
for O
T1 O
, O
T2 I-GENE
, O
and O
hydrogen O
_RARE_ I-GENE
. O

Fifty O
- I-GENE
four O
patients O
were O
divided O
into O
groups O
according O
to O
their O
clinical O
presentation O
; O
seven O
asymptomatic O
volunteers O
, O
20 O
patients O
with O
duodenal O
- I-GENE
gastric O
reflux O
_RARE_ I-GENE
( O
_RARE_ I-GENE
), O
16 O
patients O
with O
recurrent O
ulcers O
of O
the O
duodenal O
bulb O
( O
_RARE_ I-GENE
), O
and O
11 O
patients O
with O
_RARE_ I-GENE
' O
s O
disease O
. O

No O
previous O
studies O
have O
determined O
the O
_RARE_ I-GENE
- I-GENE
dynamics O
of O
intravenous O
_RARE_ I-GENE
when O
administered O
in O
a O
dose O
of O
15 O
mg O
/ I-GENE
kg O
and O
at O
a O
rate O
of O
50 O
mg O
/ I-GENE
min O
, O
as O
is O
common O
practice O
during O
_RARE_ I-GENE
testing O
. O

High O
concentrations O
of O
tumor I-GENE
- I-GENE
associated I-GENE
trypsin I-GENE
inhibitor I-GENE
in O
_RARE_ I-GENE
patients O
. O

In O
the O
chicken I-GENE
liver O
, O
levels O
of O
chicken I-GENE
_RARE_ I-GENE
mRNA I-GENE
were O
rapidly O
induced O
by O
_RARE_ I-GENE
( O
_RARE_ I-GENE
+, I-GENE
_RARE_ I-GENE
+, I-GENE
_RARE_ I-GENE
+), O
glucocorticoids O
and O
lipopolysaccharide O
. O

With O
_RARE_ I-GENE
and O
_RARE_ I-GENE
blue O
injections O
, O
blood O
- I-GENE
brain O
barrier O
alterations O
were O
seen O
as O
early I-GENE
as O
4 I-GENE
days O
after O
a O
dose O
of O
50 O
Gy O
. O

_RARE_ I-GENE
estimates O
for O
these O
organs O
were O
2 I-GENE
. O
3 I-GENE
+/- O
1 I-GENE
. O
1 I-GENE
and O
2 I-GENE
. O
3 I-GENE
+/- O
1 I-GENE
. O
4 I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
02 O
+/- O
. O
01 O
Gy O
), O
respectively O
, O
with O
a O
whole O
- I-GENE
body O
estimate O
of O
0 O
. O
28 O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
Gy O
). O

A I-GENE
significant O
association O
between O
a O
family I-GENE
history O
and O
a O
higher O
urinary O
pH O
was O
observed O
among O
the O
female O
calcium O
stone O
patients O
. O

New O
_RARE_ I-GENE
in O
diagnosis O
and O
classification O
of O
malignancy O
. O

Thus O
the O
present O
data O
also O
suggest O
that O
BP I-GENE
and O
HR O
measurements O
are O
influenced O
not O
only O
by O
state O
- I-GENE
dependent I-GENE
factors I-GENE
but O
also O
by O
at O
least O
three O
different O
factors I-GENE
that O
are O
each O
independent O
of O
the O
state O
: O
one O
leads O
to O
BP I-GENE
and O
HR O
values O
that O
are O
influenced O
by O
the O
cycle O
the O
animal O
is O
in O
and O
the O
other O
two O
influence O
, O
respectively O
, O
the O
_RARE_ I-GENE
of O
the O
individual O
' O
s O
BP I-GENE
and O
HR O
levels O
within O
the O
population O
. O

The O
correlation O
between O
PaCO2 O
and O
_RARE_ I-GENE
in O
_RARE_ I-GENE
was O
insufficient O
to O
make O
clinical O
_RARE_ I-GENE
. O

Since O
_RARE_ I-GENE
at O
the O
times O
of O
their O
_RARE_ I-GENE
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
examinations O
, O
all O
Adult O
Health O
Study O
( O
_RARE_ I-GENE
) O
subjects O
have O
been O
_RARE_ I-GENE
to O
determine O
the O
exposures O
to O
medical O
x O
- I-GENE
rays O
they O
experienced O
in O
_RARE_ I-GENE
other O
than O
_RARE_ I-GENE
in O
order O
to O
estimate O
the O
numbers O
of O
examinations O
and O
corresponding O
doses O
which O
they O
received O
. O

The O
epidermal I-GENE
growth I-GENE
factor I-GENE
( O
EGF I-GENE
) O
receptor I-GENE
, O
which O
exhibits O
intrinsic O
protein I-GENE
tyrosine I-GENE
kinase I-GENE
activity O
, O
undergoes O
a O
rapid O
, O
_RARE_ I-GENE
self O
- I-GENE
phosphorylation O
reaction O
following O
EGF I-GENE
activation O
. O

One O
_RARE_ I-GENE
_RARE_ I-GENE
completely O
inhibited O
_RARE_ I-GENE
HCO3 O
- I-GENE
secretion O
. O

There O
are O
regions O
with O
long O
_RARE_ I-GENE
of O
up O
to O
45 O
% O
C I-GENE
or O
35 O
% O
G I-GENE
residues O
. O

The O
same O
_RARE_ I-GENE
structure O
enables O
a O
prediction O
to O
be O
made O
concerning O
when O
_RARE_ I-GENE
of O
stressed O
_RARE_ I-GENE
will O
be O
_RARE_ I-GENE
perceived O
. O

_RARE_ I-GENE
cord O
_RARE_ I-GENE
_RARE_ I-GENE
by O
nervous O
selective O
anastomosis O
. O

_RARE_ I-GENE
' O
s O
_RARE_ I-GENE
lacking O
_RARE_ I-GENE
. O

A I-GENE
case O
of O
AIDS O
- I-GENE
related I-GENE
complex I-GENE
( O
ARC I-GENE
/ I-GENE
_RARE_ I-GENE
) O
in O
a O
health O
_RARE_ I-GENE

_RARE_ I-GENE
spread O
was O
found O
in O
46 O
patients O
( O
34 O
%), O
42 O
of O
whom O
had O
serum I-GENE
_RARE_ I-GENE
greater O
than O
10 O
micrograms O
/ I-GENE
l O
. O

The O
glomerular O
filtration O
rate O
and O
effective O
renal O
plasma I-GENE
flow O
were O
determined O
by O
a O
standard O
clearance O
method O
, O
employing O
continuous O
infusion O
of O
_RARE_ I-GENE
and O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
acid I-GENE
. O

After O
the O
meal I-GENE
containing O
_RARE_ I-GENE
, O
plasma I-GENE
glucose O
levels O
rose O
sharply O
, O
_RARE_ I-GENE
at O
30 O
- I-GENE
45 O
min O
and O
fell O
below O
initial O
levels O
2 I-GENE
to O
3 I-GENE
h O
later O
. O

The O
relations O
among O
various O
negative O
_RARE_ I-GENE
and O
behavioral O
characteristics O
( O
e O
. O
g O
., O
aggression O
, O
anxiety O
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
_RARE_ I-GENE
) O
and O
adjustment O
were O
examined O
through O
use O
of O
data O
from O
the O
31 O
- I-GENE
year O
- I-GENE
old O
New O
York O
_RARE_ I-GENE
Study O
. O

To O
evaluate O
the O
effect O
of O
altitude O
on O
adolescent O
growth I-GENE
and O
development O
, O
three O
groups O
of O
healthy O
, O
well O
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
of O
similar O
_RARE_ I-GENE
status O
and O
_RARE_ I-GENE
_RARE_ I-GENE
who O
_RARE_ I-GENE
at O
sea O
level O
( O
n O
= O
_RARE_ I-GENE
subjects O
), O
mid O
- I-GENE
altitude O
( O
n O
= O
_RARE_ I-GENE
subjects O
), O
and O
high O
altitude O
( O
n O
= O
_RARE_ I-GENE
subjects O
) O
were O
studied O
. O

Because O
the O
CAP I-GENE
measures O
variables O
predictive O
of O
_RARE_ I-GENE
behavior O
, O
a O
substantial O
relationship O
was O
expected O
between O
the O
CAP I-GENE
and O
the O
_RARE_ I-GENE
_RARE_ I-GENE
of O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
Control O
scale O
. O

We O
have O
improved O
our O
system O
for O
nuclear I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
and O
determined O
its O
_RARE_ I-GENE
limitations O
by O
_RARE_ I-GENE
standardized O
objects O
. O

Such O
a O
change O
may O
involve O
increased O
mammary O
utilization O
of O
pre I-GENE
- I-GENE
formed O
long O
- I-GENE
chain I-GENE
fatty I-GENE
acid I-GENE
and O
increased O
metabolism O
of O
glucose O
via O
_RARE_ I-GENE
. O

The O
skin O
site I-GENE
, O
6 I-GENE
- I-GENE
cm O
- I-GENE
distal O
and O
- I-GENE
proximal I-GENE
subcutaneous O
segments O
of O
the O
catheter O
, O
_RARE_ I-GENE
, O
and O
blood O
were O
cultured O
. O

Because O
of O
its O
great O
reliability O
, O
conventional O
_RARE_ I-GENE
_RARE_ I-GENE
a O
place O
of O
choice O
among O
the O
medical O
imaging O
techniques O
. O

_RARE_ I-GENE
detection O
of O
_RARE_ I-GENE
contaminated O
test O
serum I-GENE
before O
_RARE_ I-GENE
of O
vitamin O
_RARE_ I-GENE
. O

The O
former O
group O
did O
_RARE_ I-GENE
less O
_RARE_ I-GENE
fecal O
material O
compared O
to O
both O
other O
groups O
. O

_RARE_ I-GENE
data O
processing O
( O
_RARE_ I-GENE
) O
latex O
immunoassay O
using O
anti I-GENE
- I-GENE
human I-GENE
seminal I-GENE
acid I-GENE
phosphatase I-GENE
( O
anti I-GENE
- I-GENE
_RARE_ I-GENE
) O
immune I-GENE
serum I-GENE
was O
applied O
for O
the O
species O
and O
organ O
identification O
of O
human I-GENE
seminal I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
was O
noted O
in O
the O
undifferentiated O
and O
_RARE_ I-GENE
components O
. O

The O
maximum O
_RARE_ I-GENE
of O
phase O
IV I-GENE
for O
_RARE_ I-GENE
and O
N2 O
from O
_RARE_ I-GENE
phase O
III I-GENE
_RARE_ I-GENE
were O
smaller O
in O
the O
prone O
position O
, O
suggesting O
more O
uniform O
tracer O
gas O
concentrations O
across O
the O
lungs O
. O

Recent O
_RARE_ I-GENE
in O
drugs O
antagonistic O
to O
factors I-GENE
causing O
_RARE_ I-GENE
ulcer O
-- O
clinical O
efficacy O
and O
problems O
; O
gastrin I-GENE
receptor I-GENE
_RARE_ I-GENE

The O
_RARE_ I-GENE
_RARE_ I-GENE
- I-GENE
9 O
is O
a O
member O
of O
a O
homologous O
series O
of O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
of O
general O
formula O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
O O
-( O
_RARE_ I-GENE
) O
n O
- I-GENE
1 I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
magnetic O
fields O
affect O
the O
diffusion O
of O
biological O
particles O
in O
solutions O
through O
the O
_RARE_ I-GENE
force O
and O
_RARE_ I-GENE
stress O
. O

_RARE_ I-GENE
disturbance O
was O
greater O
in O
the O
high O
life O
stress O
group O
as O
indicated O
by O
significant O
elevations O
on O
the O
global O
severity O
index O
of O
the O
_RARE_ I-GENE
_RARE_ I-GENE
- I-GENE
90 O
and O
elevations O
on O
_RARE_ I-GENE
, O
_RARE_ I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
sensitivity O
, O
depression O
, O
anxiety O
and O
_RARE_ I-GENE
_RARE_ I-GENE
. O

Chronic O
administration O
of O
sodium O
_RARE_ I-GENE
decreases O
O2 O
extraction O
ratio O
in O
dogs O
. O

Nucleotide O
sequencing O
indicates O
that O
this O
E1 I-GENE
alpha I-GENE
cDNA I-GENE
clone O
is O
_RARE_ I-GENE
base O
pairs O
( O
bp O
) O
in O
length I-GENE
with O
an O
open O
reading O
frame O
of O
_RARE_ I-GENE
bp O
and O
a O
3 I-GENE
'- O
untranslated O
region O
of O
_RARE_ I-GENE
bp O
. O

_RARE_ I-GENE
from O
_RARE_ I-GENE
sites I-GENE
was O
associated I-GENE
with O
_RARE_ I-GENE
. O

In O
contrast O
, O
the O
_RARE_ I-GENE
showed O
a O
_RARE_ I-GENE
, O
_RARE_ I-GENE
distribution O
, O
with O
a O
range O
from O
approximately O
1 I-GENE
to O
14 O
micron O
and O
a O
maximum O
at O
3 I-GENE
- I-GENE
4 I-GENE
micron O
. O

Abnormal O
technetium O
Tc O
99m O
_RARE_ I-GENE
scans O
in O
patients O
with O
previously O
_RARE_ I-GENE
_RARE_ I-GENE
suggested O
inflammatory O
_RARE_ I-GENE
and O
influenced O
management O
_RARE_ I-GENE
with O
_RARE_ I-GENE
therapeutic O
outcomes O
. O

_RARE_ I-GENE
interest O
of O
such O
studies O
is O
limited O
since O
the O
pharmacokinetic O
parameters O
are O
systematically O
evaluated O
in O
man O
during O
phase O
I I-GENE
trials O
. O

The O
artery O
_RARE_ I-GENE
was O
slightly O
superior O
to O
the O
fat O
_RARE_ I-GENE
, O
particularly O
in O
having O
fewer O
adhesions O
and O
a O
better O
histological O
picture O
. O

_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
action O
during O
radiation O
therapy O
has O
been O
studied O
, O
_RARE_ I-GENE
the O
positive O
effect O
on O
_RARE_ I-GENE
and O
the O
_RARE_ I-GENE
better O
clinical O
conditions O
of O
the O
patients O
in O
course O
of O
treatment O
. O

Of O
the O
53 O
units O
tested O
during O
_RARE_ I-GENE
motion O
at O
0 O
. O
05 O
Hz O
( O
9 O
. O
1 I-GENE
cm O
/ I-GENE
s O
), O
1 I-GENE
( O
1 I-GENE
. O
9 O
%) O
was O
responsive I-GENE
to O
the O
_RARE_ I-GENE
input O
only O
, O
13 O
( O
24 O
. O
5 I-GENE
%) O
were O
influenced O
by O
the O
visual O
input O
only O
and O
23 O
( O
43 I-GENE
. O
4 I-GENE
%) O
responded O
to O
both O
modalities O
. O

_RARE_ I-GENE
on O
the O
location O
and O
size O
of O
the O
mass O
, O
a O
wide O
range O
of O
clinical O
_RARE_ I-GENE
is O
associated I-GENE
with O
the O
lesion O
. O

The O
development O
and O
distribution O
of O
Trypanosoma O
_RARE_ I-GENE
, O
T I-GENE
_RARE_ I-GENE
and O
T I-GENE
_RARE_ I-GENE
in O
the O
skin O
of O
goats O
was O
examined O
after O
the O
animals O
were O
_RARE_ I-GENE
by O
infected O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
is O
a O
useful O
, O
non O
- I-GENE
invasive O
technique O
that O
can O
_RARE_ I-GENE
in O
the O
assessment O
of O
_RARE_ I-GENE
fold O
dysfunction O
. O

_RARE_ I-GENE
analysis O
of O
the O
degrees O
of O
secondary O
spinal O
cord O
compression O
was O
performed O
in O
group O
- I-GENE
1 I-GENE
dogs O
by O
measuring O
and O
comparing O
ratios O
of O
the O
vertical O
to O
the O
horizontal O
diameters O
of O
the O
transverse O
spinal O
cord O
sections O
from O
locations O
within O
( O
_RARE_ I-GENE
to O
L1 I-GENE
) O
and O
out O
of O
( O
_RARE_ I-GENE
, O
_RARE_ I-GENE
- I-GENE
12 O
, O
L1 I-GENE
- I-GENE
2 I-GENE
, O
and O
L2 O
) O
the O
region O
of O
surgical O
intervention O
. O

The O
pharmacological O
effects O
of O
the O
novel O
compound O
_RARE_ I-GENE
_RARE_ I-GENE
FU O
( O
4 I-GENE
- I-GENE
amino O
- I-GENE
methyl O
- I-GENE
1 I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
2 I-GENE
- I-GENE
one O
- I-GENE
_RARE_ I-GENE
) O
were O
investigated O
. O

_RARE_ I-GENE
examination O
revealed O
dose O
- I-GENE
related I-GENE
proliferation O
of O
type I-GENE
II I-GENE
_RARE_ I-GENE
in O
_RARE_ I-GENE
and O
proliferation O
of O
interstitial O
cells O
and O
delayed O
septal O
/ I-GENE
capillary O
development O
in O
neonates O
.( O
ABSTRACT O
TRUNCATED O
AT I-GENE
250 O
WORDS O
) O

_RARE_ I-GENE
far O
no O
problems O
with O
_RARE_ I-GENE
resistant O
strains O
have O
developed O
. O

During O
the O
observation O
period O
of O
0 O
. O
4 I-GENE
- I-GENE
30 O
weeks O
, O
cardiac O
white O
spots O
on O
the O
right O
ventricle O
of O
BALB O
/ I-GENE
c I-GENE
mice O
were O
first O
detected O
at O
three O
weeks O
( O
6 I-GENE
of O
20 O
mice O
; O
30 O
%), O
and O
the O
maximal O
incidence O
of O
cardiac O
white O
spots O
was O
obtained O
at O
nine O
weeks O
( O
39 O
of O
44 I-GENE
mice O
; O
88 O
%). O

The O
state O
of O
the O
liver O
in O
generalized O
forms O
of O
_RARE_ I-GENE
infection O

Increasing O
the O
RH O
beyond O
32 O
% O
resulted O
in O
_RARE_ I-GENE
of O
the O
_RARE_ I-GENE
radical O
, O
_RARE_ I-GENE
_RARE_ I-GENE
the O
radical O
from O
_RARE_ I-GENE
the O
_RARE_ I-GENE
transition O
state O
. O

The O
effects O
produced O
by O
oral O
administration O
of O
500 O
mg O
/ I-GENE
kg O
p O
- I-GENE
xylene O
or O
toluene O
_RARE_ I-GENE
at O
least O
8 O
hr O
, O
while O
the O
effect O
of O
inhaled O
p O
- I-GENE
xylene O
_RARE_ I-GENE
within O
75 O
min O
of O
removal O
from O
the O
exposure O
. O

PATIENTS O
and O
METHODS O
: O
_RARE_ I-GENE
- I-GENE
201 O
myocardial O
scintigraphy O
was O
performed O
at O
rest O
and O
after O
0 O
. O
56 O
mg O
/ I-GENE
kg O
intravenous O
_RARE_ I-GENE
during O
four O
minutes O
in O
16 O
patients O
with O
_RARE_ I-GENE
. O

_RARE_ I-GENE
melanomas O
can O
_RARE_ I-GENE
and O
be O
lethal O
. O

The O
TA O
muscle O
was O
_RARE_ I-GENE
by O
four O
forms O
of O
repeated O
_RARE_ I-GENE
contractions O
: O
( O
1 I-GENE
) O
maximal O
_RARE_ I-GENE
contractions O
( O
_RARE_ I-GENE
), O
( O
2 I-GENE
) O
_RARE_ I-GENE
with O
circulation O
occluded O
, O
( O
3 I-GENE
) O
electrically O
evoked O
contractions O
with O
20 O
Hz O
_RARE_ I-GENE
voltage O
stimulation O
and O
( O
4 I-GENE
) O
electrically O
evoked O
contractions O
with O
circulation O
occluded O
. O

The O
_RARE_ I-GENE
local O
control O
rates O
at O
10 O
years O
for O
the O
three O
treatment O
groups O
were O
as O
follows O
: O
subtotal O
excision O
alone O
, O
18 O
%; O
subtotal O
excision O
plus O
postoperative O
radiation O
therapy O
, O
82 O
%; O
and O
total O
excision O
alone O
, O
77 O
%. O

The O
effects O
of O
_RARE_ I-GENE
implants O
on O
rate O
, O
composition O
and O
_RARE_ I-GENE
efficiency O
of O
growth I-GENE
were O
determined O
in O
steers O
fed O
diets O
varying O
in O
_RARE_ I-GENE
and O
_RARE_ I-GENE
content O
. O

_RARE_ I-GENE
_RARE_ I-GENE
induced O
a O
significant O
change O
in O
the O
_RARE_ I-GENE
configuration O
of O
the O
femur O
_RARE_ I-GENE
by O
increasing O
the O
minimum O
diameter O
( O
12 O
%) O
without O
any O
significant O
alterations O
in O
cortical O
area O
, O
density I-GENE
, O
mineral O
, O
and O
collagen I-GENE
concentrations O
. O

_RARE_ I-GENE
_RARE_ I-GENE
assessed O
anatomic O
variable O
correlates O
best O
with O
functional O
measurements O
of O
stenosis O
severity O
? O
A I-GENE
comparison O
of O
quantitative O
analysis O
of O
the O
coronary O
_RARE_ I-GENE
with O
measured O
coronary O
flow O
reserve O
and O
exercise O
/ I-GENE
_RARE_ I-GENE
thallium O
- I-GENE
201 O
scintigraphy O
. O

_RARE_ I-GENE
content O
and O
equilibrium O
water O
_RARE_ I-GENE
in O
immature O
cartilage O
. O

_RARE_ I-GENE
function O
tests O
were O
performed O
on O
300 O
_RARE_ I-GENE
, O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
. O

Data O
on O
the O
line O
spread O
function O
( O
_RARE_ I-GENE
) O
were O
obtained O
from O
the O
image O
of O
a O
0 O
. O
2 I-GENE
mm O
wide O
_RARE_ I-GENE
between O
_RARE_ I-GENE
blocks O
that O
were O
positioned O
at O
the O
_RARE_ I-GENE
in O
front O
of O
a O
_RARE_ I-GENE
_RARE_ I-GENE
. O

Primary O
infection O
is O
usually O
_RARE_ I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
of O
the O
_RARE_ I-GENE
for O
Clinical O
_RARE_ I-GENE
_RARE_ I-GENE
. O

Ischemic O
heart O
disease O
, O
age O
of O
more O
than O
75 O
years O
, O
and O
the O
fact O
that O
the O
patient O
was O
a O
woman O
were O
independent O
predictors O
of O
poor O
cardiac O
function O
. O

_RARE_ I-GENE
in O
_RARE_ I-GENE
' O
s O
disease O
localized O
to O
the O
_RARE_ I-GENE
- I-GENE
genital O
region O
. O

Taken O
together O
, O
the O
results O
suggest O
that O
_RARE_ I-GENE
may O
be O
capable O
of O
producing O
dual O
stimulus O
effects O
in O
animals O
. O

_RARE_ I-GENE
chromatographic O
method O
for O
determination O
of O
_RARE_ I-GENE
in O
_RARE_ I-GENE
and O
rice I-GENE
. O

These O
findings O
indicate O
that O
autophosphorylation O
of O
_RARE_ I-GENE
( O
alpha I-GENE
subunit I-GENE
) O
and O
_RARE_ I-GENE
( O
beta I-GENE
subunit I-GENE
) O
is O
responsible O
for O
transition O
of O
CaM I-GENE
- I-GENE
kinase I-GENE
II I-GENE
to O
the O
Ca2 I-GENE
+- I-GENE
independent O
form O
. O

This O
rapid O
and O
extensive O
penetration O
of O
_RARE_ I-GENE
administered O
chemotherapy O
may O
offer O
insight O
into O
the O
_RARE_ I-GENE
observed O
with O
these O
treatments O
. O

The O
interaction O
of O
radiation O
and O
_RARE_ I-GENE
was O
systematically O
studied O
in O
the O
_RARE_ I-GENE
_RARE_ I-GENE
prostatic I-GENE
adenocarcinoma O
, O
the O
_RARE_ I-GENE
animal O
model O
for O
human I-GENE
prostatic I-GENE
cancer O
. O

_RARE_ I-GENE
rats O
were O
exposed O
to O
one O
of O
the O
following O
: O
( O
1 I-GENE
) O
10 O
% O
O2 O
in O
N2 O
or O
100 O
% O
O2 O
for O
2 I-GENE
days O
beginning O
at O
day O
7 O
, O
11 O
, O
14 O
, O
or O
18 O
of O
pregnancy O
; O
( O
2 I-GENE
) O
10 O
% O
O2 O
in O
N2 O
or O
100 O
% O
O2 O
for O
10 O
h O
/ I-GENE
day O
beginning O
at O
day O
7 O
; O
or O
( O
3 I-GENE
) O
14 O
- I-GENE
11 O
% O
O2 O
in O
N2 O
continuously O
beginning O
at O
day O
14 O
_RARE_ I-GENE
day O
21 O
when O
they O
were O
_RARE_ I-GENE
. O

The O
incidence O
of O
_RARE_ I-GENE
in O
young O
children O
was O
determined O
by O
staining O
of O
_RARE_ I-GENE
specimens O
with O
a O
modified O
_RARE_ I-GENE
stain O
. O

_RARE_ I-GENE
patients O
( O
8 O
. O
3 I-GENE
percent O
) O
had O
latent I-GENE
hypothyroidism O
only O
discovered O
by O
hormonal O
determinations O
. O

Addition O
of O
_RARE_ I-GENE
or O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
resulted O
in O
_RARE_ I-GENE
of O
gastric O
HCO3 O
secretion O
, O
_RARE_ I-GENE
about O
45 O
% O
and O
59 O
%, O
respectively O
, O
of O
the O
maximal O
HCO3 O
response O
to O
16 O
, O
16 O
- I-GENE
dimethyl O
PGE2 O
( O
_RARE_ I-GENE
). O

Moreover O
, O
unlike O
control O
rats O
operated O
animals O
did O
not O
show O
_RARE_ I-GENE
to O
the O
highest O
concentrations O
of O
saccharin O
solutions O
. O

In O
_RARE_ I-GENE
_RARE_ I-GENE
, O
no O
specialized O
system O
of O
portal I-GENE
vessels O
appears O
to O
exist O
between O
the O
pineal O
organ O
and O
other O
portions O
of O
the O
brain O
. O

The O
4 I-GENE
degrees O
stimuli O
were O
found O
to O
elicit O
_RARE_ I-GENE
_RARE_ I-GENE
for O
the O
pattern O
reversal O
_RARE_ I-GENE
and O
the O
pattern O
onset O
C1 I-GENE
consistent O
with O
_RARE_ I-GENE
and O
_RARE_ I-GENE
visual O
cortical O
origins O
respectively O
. O

Nuclear I-GENE
factor I-GENE
III I-GENE
( O
_RARE_ I-GENE
) O
is O
a O
protein I-GENE
from O
HeLa O
cells O
that O
stimulates O
the O
initiation I-GENE
of O
adenovirus I-GENE
type I-GENE
2 I-GENE
( O
_RARE_ I-GENE
) O
DNA I-GENE
replication O
by O
binding I-GENE
to O
a O
specific I-GENE
nucleotide I-GENE
sequence I-GENE
in O
the O
origin O
, O
adjacent O
to O
the O
nuclear I-GENE
factor I-GENE
I I-GENE
recognition I-GENE
site I-GENE
. O

A I-GENE
Golgi I-GENE
study O
of O
the O
_RARE_ I-GENE
layer O
of O
the O
cerebral O
cortex O
. O

We O
conclude O
that O
_RARE_ I-GENE
clearance O
of O
S I-GENE
. O
aureus I-GENE
from O
a O
site I-GENE
_RARE_ I-GENE
to O
_RARE_ I-GENE
was O
delayed O
when O
compared O
to O
a O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
site I-GENE
. O

The O
findings O
are O
discussed O
in O
the O
context O
of O
known O
properties O
of O
cortical O
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
. O

Mean O
rCBF O
increased O
in O
some O
patients O
4 I-GENE
- I-GENE
8 O
weeks O
after O
surgery O
on O
the O
ipsilateral O
side O
. O

Quantitative O
computed O
tomography O
for O
measuring O
vertebral O
bone O
mineral O
content O
offers O
high O
sensitivity O
and O
reproducibility O
. O

The O
structure O
of O
the O
enhancer I-GENE
was O
also O
_RARE_ I-GENE
by O
inserting O
a O
pair O
of O
complementary O
synthetic O
_RARE_ I-GENE
which O
represented O
the O
region O
between O
nt O
positions O
- I-GENE
_RARE_ I-GENE
and O
- I-GENE
215 O
into O
a O
truncated I-GENE
template O
which O
lacked O
the O
enhancer I-GENE
. O

_RARE_ I-GENE
, O
c I-GENE
and O
CT I-GENE
( O
_RARE_ I-GENE
to O
the O
initial O
lung O
mass O
) O
decreased O
_RARE_ I-GENE
with O
reductions O
in O
lung O
mass O
% O
delta I-GENE
_RARE_ I-GENE
, O
c I-GENE
= O
1 I-GENE
. O
26 O
- I-GENE
0 O
. O
98 O
% O
mass O
removed O
( O
r O
= O
0 O
. O
90 O
, O
P I-GENE
less O
than O
0 O
. O
01 O
) O
and O
% O
delta I-GENE
CT I-GENE
= O
- I-GENE
3 I-GENE
. O
99 O
- I-GENE
0 O
. O
98 O
% O
mass O
removed O
( O
r O
= O
0 O
. O
82 O
, O
P I-GENE
less O
than O
0 O
. O
01 O
) O
relationships O
that O
were O
not O
altered O
by O
blocker O
pretreatment O
.( O
ABSTRACT O
TRUNCATED O
AT I-GENE
250 O
WORDS O
) O

Two O
_RARE_ I-GENE
methods O
, O
resting O
_RARE_ I-GENE
and O
exercise O
thallium O
- I-GENE
201 O
myocardial O
perfusion O
imaging O
, O
to O
detect O
and O
localize O
coronary O
artery O
stenosis O
were O
compared O
in O
32 O
patients O
suffering O
from O
coronary O
artery O
disease O
. O

From O
these O
results O
, O
it O
is O
concluded O
that O
_RARE_ I-GENE
has O
clear O
_RARE_ I-GENE
properties O
which O
are O
not O
due O
to O
adrenergic I-GENE
or O
calcium O
entry O
mechanisms O
and O
that O
there O
are O
differences O
in O
the O
_RARE_ I-GENE
effects O
of O
_RARE_ I-GENE
with O
respect O
to O
different O
vascular I-GENE
_RARE_ I-GENE
. O

Research O
was O
carried O
out O
on O
the O
rheumatoid I-GENE
factors I-GENE
in O
the O
serum I-GENE
of O
_RARE_ I-GENE
patients O
by O
means O
of O
two O
tests O
( O
one O
using O
_RARE_ I-GENE
and O
one O
with O
_RARE_ I-GENE
) O
and O
the O
results O
obtained O
were O
compared O
using O
a O
method O
of O
reference O
. O

A I-GENE
low O
aspirin I-GENE
esterase I-GENE
activity O
may O
be O
a O
_RARE_ I-GENE
factor I-GENE
in O
precipitating O
these O
aspirin I-GENE
sensitive O
reactions O
. O

In O
both O
experiments O
, O
average O
daily O
gain O
and O
gain O
- I-GENE
to O
- I-GENE
feed O
ratio O
were O
similar O
for O
TR I-GENE
and O
CR I-GENE
. O

Overall O
least O
- I-GENE
_RARE_ I-GENE
means O
for O
_RARE_ I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
muscle O
and O
subcutaneous O
fat O
were O
63 O
. O
32 O
, O
80 O
. O
27 O
and O
98 O
. O
90 O
mg O
of O
cholesterol I-GENE
/ I-GENE
100 O
g O
of O
tissue I-GENE
, O
respectively O
. O

The O
role O
of O
_RARE_ I-GENE
fluid O
chromatography O
( O
_RARE_ I-GENE
) O
as O
a O
viable O
technique O
for O
analyzing O
_RARE_ I-GENE
products I-GENE
has O
been O
investigated O
using O
_RARE_ I-GENE
and O
capillary O
column O
_RARE_ I-GENE
. O

_RARE_ I-GENE
significantly O
reduced O
the O
rise O
in O
LH I-GENE
induced O
by O
_RARE_ I-GENE
. O

_RARE_ I-GENE
tumors O
in O
pregnancy O
. O

_RARE_ I-GENE
study O
of O
_RARE_ I-GENE

X2 O
test O
, O
with O
_RARE_ I-GENE
correction O
if O
need O
, O
was O
used O
as O
statistical O
. O
method O
. O

After O
a O
baseline O
study O
, O
_RARE_ I-GENE
syndrome O
was O
simulated O
by O
stimulation O
at O
seven O
different O
sites I-GENE
around O
the O
base O
of O
the O
ventricles O
, O
and O
_RARE_ I-GENE
' O
s O
were O
obtained O
. O

_RARE_ I-GENE
and O
insect O
, O
past O
, O
present O
, O
future O

All O
patients O
had O
the O
CA I-GENE
125 I-GENE
assay O
performed O
within O
one O
week O
before O
their O
second O
- I-GENE
_RARE_ I-GENE
operation O
. O

_RARE_ I-GENE
and O
_RARE_ I-GENE
' O
s O
syndrome O
. O

The O
criterion O
was O
reached O
after O
two O
_RARE_ I-GENE
and O
_RARE_ I-GENE
to O
a O
variety O
of O
_RARE_ I-GENE
and O
capsules O
occurred O
. O

Clinical O
method O
for O
the O
treatment O
of O
Class I-GENE
II I-GENE
_RARE_ I-GENE
anomalies O
with O
open O
_RARE_ I-GENE

_RARE_ I-GENE
appears O
to O
be O
well O
_RARE_ I-GENE
for O
the O
treatment O
of O
complicated O
_RARE_ I-GENE
. O

Mean O
_RARE_ I-GENE
scores O
, O
however O
, O
were O
similar O
. O

_RARE_ I-GENE
_RARE_ I-GENE
were O
restricted O
to O
_RARE_ I-GENE
_RARE_ I-GENE
. O

An O
_RARE_ I-GENE
- I-GENE
wide O
retrospective O
cohort O
mortality O
study O
was O
conducted O
on O
6 I-GENE
, O
_RARE_ I-GENE
chemical O
workers O
( O
2 I-GENE
, O
_RARE_ I-GENE
exposed O
and O
3 I-GENE
, O
_RARE_ I-GENE
_RARE_ I-GENE
) O
_RARE_ I-GENE
in O
_RARE_ I-GENE
ether O
_RARE_ I-GENE
at O
7 O
major I-GENE
U O
. O
S I-GENE
. O
_RARE_ I-GENE
between O
_RARE_ I-GENE
and O
1980 O
. O

The O
diagnosis O
of O
_RARE_ I-GENE
was O
determined O
from O
a O
_RARE_ I-GENE
salivary I-GENE
gland O
biopsy O
. O

_RARE_ I-GENE
and O
blood O
samples O
were O
taken O
before O
vitamin O
C I-GENE
or O
placebo O
supplementation O
was O
started O
and O
at O
monthly O
intervals O
thereafter O
for O
three O
months O
. O

In O
treated O
_RARE_ I-GENE
, O
cows O
more O
than O
40 I-GENE
d O
_RARE_ I-GENE
with O
a O
_RARE_ I-GENE
_RARE_ I-GENE
received O
prostaglandin I-GENE
F2 O
alpha I-GENE
. O

On O
the O
other O
hand O
, O
if O
the O
measured O
angle O
_RARE_ I-GENE
is O
smaller O
than O
the O
calculated O
angle O
, O
the O
skeletal I-GENE
relation O
is O
Class I-GENE
III I-GENE
. O

_RARE_ I-GENE
treatment O
of O
facial O
and O
_RARE_ I-GENE
/ I-GENE
mandibular O
injuries O

In O
14 O
cases O
, O
isolates O
were O
_RARE_ I-GENE
_RARE_ I-GENE
eight O
with O
_RARE_ I-GENE
II I-GENE
, O
four O
with O
_RARE_ I-GENE
III I-GENE
, O
and O
one O
each O
with O
_RARE_ I-GENE
IV I-GENE
and O
V I-GENE
. O

A I-GENE
total O
of O
117 O
_RARE_ I-GENE
treatments O
were O
performed O
on O
34 O
patients O
. O

Most O
of O
the O
_RARE_ I-GENE
portion O
of O
the O
precursor I-GENE
polypeptide I-GENE
is O
encoded I-GENE
by O
the O
next O
three O
exons O
, O
and O
the O
mature O
form O
of O
IL I-GENE
- I-GENE
1 I-GENE
alpha I-GENE
is O
encoded I-GENE
by O
the O
remaining O
three O
exons O
. O

A I-GENE
_RARE_ I-GENE
version O
of O
_RARE_ I-GENE
' O
s O
( O
_RARE_ I-GENE
, O
1972 O
) O
model O
with O
cumulative O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
was O
simulated O
. O

In O
a O
previous O
_RARE_ I-GENE
report O
we O
noted O
more O
_RARE_ I-GENE
resolution O
of O
_RARE_ I-GENE
signs O
and O
symptoms O
with O
_RARE_ I-GENE
treatment O
. O

The O
_RARE_ I-GENE
of O
the O
defects O
in O
_RARE_ I-GENE
or O
LAD O
region O
was O
80 O
% O
in O
single O
- I-GENE
position O
scans O
in O
stress O
studies O
. O

_RARE_ I-GENE
properties O
of O
_RARE_ I-GENE
agents O
and O
_RARE_ I-GENE
drugs O
. O

This O
brief O
_RARE_ I-GENE
challenge O
induced O
a O
rapid O
increase O
in O
CBF I-GENE
in O
the O
absence O
of O
any O
change O
in O
_RARE_ I-GENE
. O

These O
data O
should O
be O
useful O
in O
developing O
_RARE_ I-GENE
for O
_RARE_ I-GENE
detection O
and O
_RARE_ I-GENE
diagnosis O
of O
11 O
beta I-GENE
- I-GENE
hydroxylase I-GENE
deficiency O
, O
the O
second O
most O
frequent O
cause O
of O
congenital O
adrenal O
hyperplasia O
. O

_RARE_ I-GENE
( O
serum I-GENE
bone O
- I-GENE
_RARE_ I-GENE
protein I-GENE
, O
_RARE_ I-GENE
), O
serum I-GENE
alkaline I-GENE
phosphatase I-GENE
( O
_RARE_ I-GENE
) O
and O
urinary O
_RARE_ I-GENE
/ I-GENE
creatinine O
ratio O
( O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
/ I-GENE
creatinine O
) O
have O
been O
measured O
in O
21 O
patients O
with O
primary O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
and O
in O
nine O
patients O
with O
_RARE_ I-GENE
of O
malignancy O
( O
_RARE_ I-GENE
). O

_RARE_ I-GENE
_RARE_ I-GENE
regression O
analysis O
indicated O
that O
_RARE_ I-GENE
was O
strongly O
associated I-GENE
with O
the O
prevalence O
of O
hepatitis I-GENE
B I-GENE
in O
an O
_RARE_ I-GENE
' O
s O
_RARE_ I-GENE
of O
birth O
and O
with O
age O
. O

_RARE_ I-GENE
is O
the O
_RARE_ I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
for O
a O
_RARE_ I-GENE
_RARE_ I-GENE
synthesized O
from O
1 I-GENE
- I-GENE
_RARE_ I-GENE
with O
3 I-GENE
- I-GENE
5 I-GENE
% O
_RARE_ I-GENE
as O
the O
source O
of O
residual O
double O
bonds O
for O
_RARE_ I-GENE
. O

_RARE_ I-GENE
phage I-GENE
- I-GENE
plasmid O
expression O
vectors O
were O
constructed O
from O
_RARE_ I-GENE
/ I-GENE
19 O
plasmids O
by O
cloning O
a O
single O
- I-GENE
stranded I-GENE
DNA I-GENE
( O
ssDNA I-GENE
) O
origin O
of O
replication O
from O
bacteriophage I-GENE
f1 I-GENE
and O
inserting O
a O
bacteriophage I-GENE
T7 I-GENE
promoter I-GENE
within O
the O
beta I-GENE
- I-GENE
galactosidase I-GENE
gene I-GENE
. O

By O
order O
of O
decreasing O
rate O
, O
finger I-GENE
_RARE_ I-GENE
, O
jaw O
, O
_RARE_ I-GENE
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
_RARE_ I-GENE
were O
less O
frequently O
elicited O
in O
both O
groups O
. O

_RARE_ I-GENE
. O

Neither O
ethanol O
nor O
estrogen I-GENE
has O
been O
shown O
to O
cause O
_RARE_ I-GENE
- I-GENE
deficiency O
in O
animals O
. O

Although O
not O
common O
, O
the O
disorder O
is O
the O
most O
frequently O
diagnosed O
disturbance O
of O
porphyrin O
metabolism O
in O
many O
_RARE_ I-GENE
, O
and O
further O
insight O
into O
its O
unusual O
pathogenesis O
may O
clarify O
the O
_RARE_ I-GENE
effects O
of O
the O
4 I-GENE
_RARE_ I-GENE
agents O
. O

Five O
out O
of O
eight O
consecutive O
cases O
with O
initial O
symptoms O
of O
a O
' O
_RARE_ I-GENE
granuloma O
' O
were O
identified O
as O
malignant O
_RARE_ I-GENE
( O
_RARE_ I-GENE
sarcoma I-GENE
) O
which O
within O
5 I-GENE
months O
to O
4 I-GENE
years O
led O
to O
_RARE_ I-GENE
and O
death O
. O

All O
patients O
then O
received O
_RARE_ I-GENE
1 I-GENE
. O
5 I-GENE
mg O
kg O
- I-GENE
1 I-GENE
i O
. O
v I-GENE
. O

The O
highest O
postoperative O
CK I-GENE
- I-GENE
MB I-GENE
level O
was O
less O
after O
_RARE_ I-GENE
( O
_RARE_ I-GENE
, O
31 O
+/- O
17 O
U O
/ I-GENE
L I-GENE
; O
CC O
, O
56 O
+/- O
13 O
U O
/ I-GENE
L I-GENE
; O
p O
less O
than O
0 O
. O
05 O
). O

No O
relevant O
changes O
in O
heart O
rate O
, O
body O
weight O
, O
and O
plasma I-GENE
levels O
of O
renin I-GENE
activity O
and O
aldosterone O
concentration O
were O
observed O
. O

High O
trough O
serum I-GENE
_RARE_ I-GENE
concentrations O
were O
associated I-GENE
with O
death O
and O
very O
low O
levels O
with O
recovery O
. O

State O
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
of O
nursing O
R I-GENE
. O
N I-GENE
. O

In O
a O
_RARE_ I-GENE
system O
a O
protein I-GENE
with O
an O
_RARE_ I-GENE
molecular O
weight O
of O
36 O
, O
000 O
was O
synthesized O
. O

This O
means O
that O
the O
loss O
of O
_RARE_ I-GENE
must O
be O
calculated O
by O
using O
a O
_RARE_ I-GENE
and O
not O
a O
_RARE_ I-GENE
model O
as O
_RARE_ I-GENE
did O
. O

The O
incidence O
of O
second O
malignant O
neoplasms O
was O
lower O
( O
1 I-GENE
. O
3 I-GENE
%) O
in O
the O
group O
treated O
with O
5 I-GENE
- I-GENE
fluorouracil O
, O
_RARE_ I-GENE
, O
and O
cyclophosphamide O
than O
in O
the O
_RARE_ I-GENE
control O
group O
( O
4 I-GENE
. O
8 O
%). O

_RARE_ I-GENE
was O
induced O
in O
8 O
( O
56 O
. O
7 O
%) O
patients O
who O
_RARE_ I-GENE
. O

In O
previous O
work O
( O
E I-GENE
. O

The O
small I-GENE
size O
and O
placement O
of O
the O
mutagenesis O
marker O
( O
the O
_RARE_ I-GENE
suppressor I-GENE
tRNA I-GENE
gene I-GENE
from O
Escherichia I-GENE
coli I-GENE
) O
within O
the O
vector O
substantially O
reduced O
the O
frequency O
of O
spontaneous O
mutations O
normally O
observed O
after O
transfection O
of O
mammalian I-GENE
cells O
with O
plasmid O
DNA I-GENE
; O
hence O
, O
UV O
- I-GENE
induced O
mutations O
were O
easily O
identified O
above O
the O
spontaneous O
background O
. O

W I-GENE
. O

_RARE_ I-GENE
analysis O
and O
mitotic O
recombination O
experiments O
localized O
the O
_RARE_ I-GENE
gene I-GENE
proximal I-GENE
to O
GAL4 I-GENE
on O
chromosome O
_RARE_ I-GENE
. O

Based O
on O
our O
observations O
, O
we O
propose O
a O
model O
_RARE_ I-GENE
inactive O
precursor I-GENE
molecules I-GENE
produced O
from O
the O
_RARE_ I-GENE
gene I-GENE
self O
- I-GENE
activate O
within O
the O
yeast I-GENE
_RARE_ I-GENE
and O
subsequently O
activate O
other O
vacuolar I-GENE
_RARE_ I-GENE
. O

The O
poly O
( O
A I-GENE
) O
segment O
of O
the O
RNA I-GENE
was O
selectively O
cross O
- I-GENE
linked O
to O
the O
72 O
, O
000 O
- I-GENE
molecular O
- I-GENE
weight O
protein I-GENE
( O
_RARE_ I-GENE
protein I-GENE
). O

In O
vitro O
translation I-GENE
of O
RNA I-GENE
synthesized O
from O
the O
cloned O
cDNAs I-GENE
predicts O
that O
_RARE_ I-GENE
transcripts I-GENE
are O
translated O
into O
a O
novel O
12 O
. O
5 I-GENE
- I-GENE
kilodalton I-GENE
protein I-GENE
corresponding O
to O
the O
first O
open O
reading O
frame O
. O

The O
N I-GENE
- I-GENE
terminal I-GENE
amino O
acid I-GENE
sequence I-GENE
of O
_RARE_ I-GENE
has O
sequence I-GENE
homology I-GENE
with O
DNA I-GENE
binding I-GENE
proteins I-GENE
. O

Several O
new O
techniques O
are O
available O
for O
monitoring O
control O
of O
diabetes O
. O

_RARE_ I-GENE
: O
an O
_RARE_ I-GENE
of O
adverse O
_RARE_ I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
mechanisms O
of O
_RARE_ I-GENE
changes O
in O
response O
to O
space O
_RARE_ I-GENE
effects O
are O
described O
. O

The O
rho I-GENE
genes I-GENE
comprise O
an O
evolutionarily O
conserved O
family I-GENE
with O
significant O
homology I-GENE
to O
the O
ras I-GENE
oncogene I-GENE
family I-GENE
. O

Also O
, O
component O
I I-GENE
significantly O
correlated O
with O
fasting O
insulin I-GENE
and O
VO2 O
max O
for O
both O
_RARE_ I-GENE
and O
with O
basal O
metabolism O
and O
HDL I-GENE
- I-GENE
cholesterol I-GENE
for O
females O
and O
males O
, O
respectively O
. O

The O
glucose O
areas O
following O
the O
ingestion O
of O
the O
_RARE_ I-GENE
were O
: O
Study O
1 I-GENE
: O
glucose O
11 O
. O
7 O
, O
_RARE_ I-GENE
juice O
7 O
. O
3 I-GENE
, O
sucrose O
5 I-GENE
. O
2 I-GENE
, O
glucose O
+ I-GENE
fructose I-GENE
6 I-GENE
. O
3 I-GENE
, O
and O
fructose I-GENE
0 O
. O
7 O
mmol O
X I-GENE
h O
/ I-GENE
l O
; O
Study O
2 I-GENE
: O
glucose O
14 O
. O
6 I-GENE
, O
_RARE_ I-GENE
juice O
7 O
. O
3 I-GENE
, O
_RARE_ I-GENE
5 I-GENE
. O
5 I-GENE
, O
and O
_RARE_ I-GENE
juice O
4 I-GENE
. O
7 O
mmol O
X I-GENE
h O
/ I-GENE
l O
; O
Study O
3 I-GENE
: O
glucose O
12 O
. O
6 I-GENE
, O
_RARE_ I-GENE
cream O
8 O
. O
1 I-GENE
, O
milk O
3 I-GENE
. O
7 O
, O
and O
_RARE_ I-GENE
4 I-GENE
. O
1 I-GENE
mmol O
X I-GENE
h O
/ I-GENE
l O
. O

The O
serum I-GENE
insulin I-GENE
response O
cannot O
. O

_RARE_ I-GENE
prolonged O
_RARE_ I-GENE
after O
verapamil O
, O
and O
sinus O
arrest O
developed O
in O
two O
of O
10 O
group O
2 I-GENE
and O
two O
of O
five O
group O
3 I-GENE
animals O
. O

_RARE_ I-GENE
of O
a O
yeast I-GENE
system O
to O
assay O
mutational O
specificity O
. O

_RARE_ I-GENE
serum I-GENE
insulin I-GENE
levels O
showed O
no O
significant O
correlations O
with O
systolic O
or O
diastolic O
blood O
pressure O
levels O
in O
men O
, O
but O
in O
female O
diabetic O
and O
non O
- I-GENE
diabetic O
subjects O
significant O
correlations O
were O
found O
in O
particular O
with O
systolic O
blood O
pressure O
level O
. O

We O
used O
oligonucleotide I-GENE
- I-GENE
directed O
mutagenesis O
to O
alter O
a O
site I-GENE
in O
_RARE_ I-GENE
homologous O
to O
the O
Ala I-GENE
- I-GENE
Gly O
cleavage O
site I-GENE
of O
LexA I-GENE
. O

The O
latter O
was O
determined O
as O
follows O
: O
Type O
I I-GENE
- I-GENE
solid O
tumor I-GENE
tissue I-GENE
without O
significant O
peripheral O
isolated O
tumor I-GENE
cells O
; O
Type O
II I-GENE
- I-GENE
solid O
tumor I-GENE
tissue I-GENE
associated I-GENE
with O
peripheral O
isolated O
tumor I-GENE
cells O
; O
Type O
III I-GENE
- I-GENE
isolated O
tumor I-GENE
cells O
only O
. O

The O
_RARE_ I-GENE
of O
_RARE_ I-GENE
. O

Acute O
inhalation O
toxicity O
of O
T I-GENE
- I-GENE
2 I-GENE
_RARE_ I-GENE
in O
mice O
. O

The O
present O
investigation O
sought O
to O
identify O
the O
principal O
dimensions O
of O
the O
_RARE_ I-GENE
Type O
A I-GENE
scale O
( O
_RARE_ I-GENE
) O
and O
then O
to O
examine O
their O
physiological O
and O
psychological O
correlates O
. O

A I-GENE
preliminary O
study O
on O
_RARE_ I-GENE
arthritis O
. O

_RARE_ I-GENE
, O
microbial I-GENE
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
consumption O
. O

_RARE_ I-GENE
in O
the O
aorta O
of O
rats O
treated O
with O
a O
_RARE_ I-GENE
- I-GENE
bean I-GENE
oil O
extract O
( O
_RARE_ I-GENE
). O

As O
a O
last O
_RARE_ I-GENE
, O
it O
may O
be O
possible O
to O
maintain O
a O
patient O
on O
dialysis O
in O
reasonable O
health O
with O
a O
_RARE_ I-GENE
_RARE_ I-GENE
graft O
complex I-GENE
infected O
with O
Staphylococcus I-GENE
_RARE_ I-GENE
and O
intermittent O
positive O
blood O
cultures O
using O
long O
term O
vancomycin O
therapy O
. O

For O
signal I-GENE
durations O
less O
than O
10 O
ms O
, O
however O
, O
the O
_RARE_ I-GENE
and O
S I-GENE
pi I-GENE
No O
threshold O
functions O
_RARE_ I-GENE
and O
the O
_RARE_ I-GENE
- I-GENE
level O
difference O
decreased O
. O

The O
spleen O
rate O
of O
about O
600 O
_RARE_ I-GENE
of O
_RARE_ I-GENE
I I-GENE
examined O
was O
54 I-GENE
. O
3 I-GENE
% O
and O
the O
parasite O
rate O
13 O
. O
2 I-GENE
% O
before O
the O
drug O
intervention O
. O

Multiple O
_RARE_ I-GENE
four O
times O
daily O
for O
7 O
days O
of O
_RARE_ I-GENE
200 O
mg O
, O
a O
non O
- I-GENE
_RARE_ I-GENE
anti I-GENE
- I-GENE
inflammatory O
drug O
with O
a O
short O
half O
- I-GENE
life O
( O
t1 O
/ I-GENE
2 I-GENE
), O
revealed O
drug O
accumulation O
in O
eight O
elderly O
subjects O
. O

In O
10 O
patients O
with O
subacute O
cardiac O
_RARE_ I-GENE
, O
pulmonary O
_RARE_ I-GENE
pressure O
( O
_RARE_ I-GENE
), O
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
were O
measured O
along O
with O
_RARE_ I-GENE
of O
systolic O
function O
. O

_RARE_ I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
data O
, O
left O
ventricular O
stroke O
work O
index O
showed O
positive O
correlation O
with O
_RARE_ I-GENE
( O
r O
= O
. O
59 O
) O
and O
_RARE_ I-GENE
( O
r O
= O
. O
52 O
) O
but O
not O
with O
_RARE_ I-GENE
. O

_RARE_ I-GENE
developed O
profound O
_RARE_ I-GENE
, O
with O
levels O
_RARE_ I-GENE
from O
15 O
. O
5 I-GENE
+/- O
0 O
. O
2 I-GENE
to O
7 O
. O
6 I-GENE
+/- O
0 O
. O
4 I-GENE
mg O
/ I-GENE
dl O
under O
the O
influence O
of O
_RARE_ I-GENE
- I-GENE
1 I-GENE
. O

_RARE_ I-GENE
value O
of O
_RARE_ I-GENE
features O
of O
language O
for O
_RARE_ I-GENE
, O
_RARE_ I-GENE
retarded O
, O
and O
normal O
children O
. O

Similarly O
, O
_RARE_ I-GENE
_RARE_ I-GENE
for O
the O
second O
_RARE_ I-GENE
were O
not O
more O
frequently O
selected O
by O
_RARE_ I-GENE
as O
more O
_RARE_ I-GENE
, O
regardless O
of O
treatment O
condition O
and O
elevation O
of O
the O
F I-GENE
and O
F I-GENE
- I-GENE
K I-GENE
indices O
on O
the O
first O
MMPI O
profile O
. O

_RARE_ I-GENE
to O
its O
relatively O
soluble I-GENE
chemical O
form O
, O
_RARE_ I-GENE
was O
rapidly O
_RARE_ I-GENE
from O
lung O
to O
bone O
where O
a O
substantial O
portion O
was O
retained O
for O
a O
long O
period O
of O
time O
. O

The O
study O
_RARE_ I-GENE
generalized O
atrophy O
and O
diffuse O
_RARE_ I-GENE
white O
matter O
_RARE_ I-GENE
. O

The O
diagnosis O
of O
_RARE_ I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
was O
confirmed O
by O
the O
finding O
of O
low O
_RARE_ I-GENE
A I-GENE
( O
ASA I-GENE
) O
levels O
in O
cultured O
fibroblasts O
in O
both O
_RARE_ I-GENE
. O

_RARE_ I-GENE
ventilation O
was O
conducted O
using O
a O
tidal O
volume O
of O
10 O
ml O
X I-GENE
kg O
- I-GENE
1 I-GENE
and O
a O
rate O
of O
10 O
to O
12 O
c I-GENE
X I-GENE
min O
- I-GENE
1 I-GENE
. O

Significantly O
lower O
heart O
rate O
reactivity O
and O
significantly O
less O
pronounced O
left O
temporal O
artery O
pulse O
amplitude O
responses O
were O
found O
in O
non O
- I-GENE
_RARE_ I-GENE
TH I-GENE
subjects O
than O
in O
controls O
. O

An O
epidemiological O
survey O
of O
_RARE_ I-GENE
valve O
disease O
and O
_RARE_ I-GENE
fever O
in O
primary O
and O
secondary O
_RARE_ I-GENE
students O
in O
_RARE_ I-GENE
_RARE_ I-GENE

_RARE_ I-GENE
that O
are O
transformed O
via O
phase O
II I-GENE
reactions O
usually O
do O
not O
require O
dosage O
adjustment O
. O

A I-GENE
study O
of O
human I-GENE
genes I-GENE
coding O
for O
U4 I-GENE
small I-GENE
nuclear I-GENE
RNA I-GENE
is O
presented O
. O

Using O
the O
_RARE_ I-GENE
- I-GENE
gas O
procedure O
with O
a O
single O
gas O
injection O
, O
a O
_RARE_ I-GENE
was O
obtained O
that O
was O
large O
enough O
to O
_RARE_ I-GENE
a O
_RARE_ I-GENE
tear I-GENE
without O
prior O
drainage O
of O
subretinal O
fluid O
or O
_RARE_ I-GENE
. O

_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
like I-GENE
enterotoxin I-GENE
( O
_RARE_ I-GENE
) O
was O
produced O
by O
26 O
of O
42 O
_RARE_ I-GENE
isolates O
( O
62 O
%), O
while O
only O
1 I-GENE
of O
the O
42 O
isolates O
( O
2 I-GENE
%) O
produced O
_RARE_ I-GENE
activity O
in O
_RARE_ I-GENE
mice O
; O
65 O
% O
of O
the O
_RARE_ I-GENE
- I-GENE
producing O
strains O
also O
produced O
an O
_RARE_ I-GENE
- I-GENE
like I-GENE
material O
. O

_RARE_ I-GENE
of O
a O
_RARE_ I-GENE
information O
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
language O
for O
" O
_RARE_ I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
" O
for O
use O
in O
the O
_RARE_ I-GENE
system O

_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
with O
increased O
light I-GENE
sensitivity O

Thus O
, O
a O
negative O
test O
is O
compatible O
with O
low O
disease O
activity O
and O
/ I-GENE
or O
efficacy O
of O
calcium O
antagonist O
treatment O
. O

Thus O
, O
a O
negative O
test O
is O
compatible O
with O
low O
disease O
activity O
and O
/ I-GENE
or O
efficacy O
of O
calcium O
antagonist O
treatment O
. O

_RARE_ I-GENE
foot O
_RARE_ I-GENE
was O
measured O
by O
using O
oxygen O
- I-GENE
_RARE_ I-GENE
electrodes O
with O
surface O
temperatures O
of O
42 O
degrees O
C I-GENE
and O
45 O
degrees O
C I-GENE
; O
in O
theory O
, O
changes O
in O
sympathetic O
activity O
should O
affect O
_RARE_ I-GENE
tone O
and O
_RARE_ I-GENE
in O
skin O
_RARE_ I-GENE
an O
electrode O
at O
42 O
degrees O
C I-GENE
( O
_RARE_ I-GENE
vasodilation O
), O
but O
not O
at O
45 O
degrees O
C I-GENE
( O
maximal O
vasodilation O
). O

In O
subjects O
( O
n O
= O
5 I-GENE
) O
with O
_RARE_ I-GENE
and O
reduced O
sympathetic O
tone O
secondary O
to O
cervical O
cord O
trauma O
, O
_RARE_ I-GENE
at O
42 O
degrees O
C I-GENE
and O
vasodilation O
index O
were O
increased O
( O
45 O
. O
0 O
mmHg O
and O
0 O
. O
61 O
); O
_RARE_ I-GENE
at O
45 O
degrees O
C I-GENE
did O
not O
change O
. O

The O
nucleotide I-GENE
sequences I-GENE
of O
the O
human I-GENE
and O
murine I-GENE
_RARE_ I-GENE
decarboxylase I-GENE
mRNAs I-GENE
share O
an O
85 O
% O
homology I-GENE
, O
even O
in O
their O
3 I-GENE
'- O
noncoding O
regions O
. O

The O
absolute O
concentrations O
of O
alpha I-GENE
2 I-GENE
- I-GENE
_RARE_ I-GENE
inhibitor I-GENE
, O
alpha I-GENE
2 I-GENE
- I-GENE
_RARE_ I-GENE
, O
and O
antithrombin I-GENE
III I-GENE
increased O
with O
exercise O
( O
all O
P I-GENE
less O
than O
0 O
. O
005 O
), O
but O
when O
concentrations O
were O
corrected O
for O
acute O
shifts O
of O
plasma I-GENE
water O
during O
exercise O
, O
the O
_RARE_ I-GENE
of O
these O
inhibitors O
_RARE_ I-GENE
decreased O
( O
all O
P I-GENE
less O
than O
0 O
. O
005 O
). O

The O
other O
model O
was O
a O
continuous O
_RARE_ I-GENE
plus O
constant O
of O
the O
form O
La I-GENE
- I-GENE
= O
a O
+ I-GENE
b I-GENE
[ O
_RARE_ I-GENE
( O
_RARE_ I-GENE
)]. O

Cell O
. O

_RARE_ I-GENE
of O
symptoms O
and O
_RARE_ I-GENE
excretion O
in O
human I-GENE
_RARE_ I-GENE
. O

After O
dopamine I-GENE
infusion O
in O
women O
with O
_RARE_ I-GENE
ovary O
syndrome O
and O
in O
matched O
controls O
, O
steady O
state O
levels O
of O
plasma I-GENE
dopamine I-GENE
, O
norepinephrine O
, O
and O
the O
ratio O
of O
dopamine I-GENE
/ I-GENE
norepinephrine O
were O
similar O
in O
the O
two O
groups O
. O

Diagnostic O
importance O
of O
determining O
the O
complement I-GENE
_RARE_ I-GENE
in O
children O
with O
_RARE_ I-GENE
thyroiditis O

In O
the O
normal O
, O
basal O
( O
unstimulated O
) O
condition O
there O
were O
no O
significant O
correlations O
( O
p O
greater O
than O
0 O
. O
05 O
) O
between O
the O
systolic O
blood O
pressure O
and O
dopamine I-GENE
( O
r O
= O
0 O
. O
09 O
), O
norepinephrine O
( O
r O
= O
0 O
. O
26 O
), O
or O
epinephrine O
( O
r O
= O
0 O
. O
27 O
), O
nor O
were O
there O
significant O
correlations O
between O
melatonin O
and O
dopamine I-GENE
( O
r O
= O
- I-GENE
0 O
. O
01 O
), O
norepinephrine O
( O
r O
= O
- I-GENE
0 O
. O
26 O
), O
or O
growth I-GENE
hormone I-GENE
( O
r O
= O
0 O
. O
17 O
). O

The O
4 I-GENE
patients O
with O
_RARE_ I-GENE
levels O
in O
excess O
of O
10 O
% O
may O
represent O
_RARE_ I-GENE
carbon O
_RARE_ I-GENE
poisoning O
in O
this O
population O
. O

All O
these O
processes O
were O
fully O
developed O
during O
the O
last O
month O
of O
pregnancy O
, O
_RARE_ I-GENE
the O
same O
picture O
as O
the O
controls O
. O

_RARE_ I-GENE
action O
of O
" O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
" O
and O
its O
mechanism O
on O
diabetes O
mellitus O

In O
cases O
of O
1 I-GENE
degrees O
_RARE_ I-GENE
, O
the O
plasma I-GENE
1 I-GENE
, O
25 O
-( O
OH O
) O
_RARE_ I-GENE
level O
rose O
significantly O
in O
all O
cases O
( O
P I-GENE
less O
than O
0 O
. O
05 O
), O
although O
the O
pattern O
of O
the O
increase O
was O
not O
uniform O
. O

This O
region O
of O
60 O
amino O
acids O
may O
be O
involved O
in O
coiled O
- I-GENE
coil O
interactions O
similar O
to O
those O
that O
facilitate O
the O
_RARE_ I-GENE
formation O
in O
the O
_RARE_ I-GENE
region O
. O

This O
approach O
enables O
the O
sources O
of O
error O
in O
the O
_RARE_ I-GENE
of O
nutrient O
utilization O
to O
be O
readily O
identified O
, O
and O
their O
effect O
on O
_RARE_ I-GENE
to O
be O
assessed O
in O
different O
nutritional O
and O
metabolic O
states O
. O

The O
effect O
of O
dietary O
zinc I-GENE
deficiency O
on O
the O
_RARE_ I-GENE
fiber O
zinc I-GENE
content O
of O
the O
rat I-GENE
hippocampus O
. O

_RARE_ I-GENE
rats O
were O
fed O
a O
normal O
diet O
or O
a O
low O
- I-GENE
protein I-GENE
, O
low O
- I-GENE
energy O
diet O
, O
and O
injected O
with O
saline O
or O
thyroxine O
( O
5 I-GENE
micrograms O
/ I-GENE
100 O
g O
_RARE_ I-GENE
) O
for O
22 O
days O
. O

It O
is O
largely O
predicted O
by O
lupus O
anticoagulant I-GENE
( O
estimated O
by O
activated I-GENE
partial O
thromboplastin I-GENE
time O
) O
and O
/ I-GENE
or O
antibody I-GENE
to O
_RARE_ I-GENE
. O

The O
effects O
of O
several O
opioid I-GENE
agonists O
and O
the O
opioid I-GENE
antagonist O
naloxone O
were O
examined O
in O
rats O
responding O
under O
a O
fixed O
- I-GENE
consecutive O
- I-GENE
number O
( O
_RARE_ I-GENE
) O
schedule O
. O

The O
rate O
- I-GENE
decreasing O
effects O
of O
morphine O
and O
_RARE_ I-GENE
were O
reversed O
completely O
by O
a O
0 O
. O
01 O
and O
1 I-GENE
. O
0 O
mg O
/ I-GENE
kg O
dose O
of O
naloxone O
, O
respectively O
. O

Data O
from O
119 O
men O
and O
40 I-GENE
women O
undergoing O
coronary O
angiography O
provide O
an O
_RARE_ I-GENE
to O
compare O
these O
associations O
in O
relation O
to O
a O
direct O
and O
continuous O
measure O
of O
atherosclerosis O
while O
controlling O
for O
age O
, O
sex I-GENE
, O
_RARE_ I-GENE
, O
hypertension O
, O
serum I-GENE
cholesterol I-GENE
, O
smoking O
, O
angina O
, O
diabetes O
, O
family I-GENE
history O
of O
heart O
disease O
, O
Type O
A I-GENE
behavior O
pattern O
, O
and O
_RARE_ I-GENE
. O

An O
_RARE_ I-GENE
change O
in O
temperature O
above O
or O
below O
36 O
degrees O
C I-GENE
decreases O
only O
the O
_RARE_ I-GENE
bronchial O
blood O
flow O
and O
does O
not O
influence O
blood O
flow O
to O
other O
_RARE_ I-GENE
tissues O
including O
those O
_RARE_ I-GENE
by O
the O
bronchial O
circulation O
. O

_RARE_ I-GENE
status O
_RARE_ I-GENE
after O
infusion O
of O
cisplatin O

The O
presence O
in O
such O
patients O
of O
antibodies I-GENE
to O
adrenaline O
and O
noradrenaline O
is O
indicative O
of O
considerable O
disruption O
of O
_RARE_ I-GENE
_RARE_ I-GENE
. O

The O
following O
markers O
were O
_RARE_ I-GENE
for O
in O
the O
serum I-GENE
, O
skin O
and O
liver O
of O
all O
patients O
with O
chronic O
hepatitis I-GENE
: O
HBV O
( O
HBs I-GENE
Ag I-GENE
and O
_RARE_ I-GENE
Ag I-GENE
, O
anti I-GENE
- I-GENE
HBs I-GENE
, O
anti I-GENE
- I-GENE
_RARE_ I-GENE
and O
anti I-GENE
- I-GENE
_RARE_ I-GENE
in O
the O
serum I-GENE
, O
HBs I-GENE
and O
_RARE_ I-GENE
Ag I-GENE
in O
the O
liver O
); O
non O
- I-GENE
A I-GENE
non O
- I-GENE
B I-GENE
( O
non O
- I-GENE
A I-GENE
, O
non O
- I-GENE
B I-GENE
Ag I-GENE
and O
antibody I-GENE
, O
anti I-GENE
non O
- I-GENE
A I-GENE
non O
- I-GENE
_RARE_ I-GENE
in O
the O
serum I-GENE
, O
non O
- I-GENE
A I-GENE
, O
non O
- I-GENE
_RARE_ I-GENE
Ag I-GENE
in O
the O
liver O
). O

_RARE_ I-GENE
of O
male O
and O
female O
_RARE_ I-GENE
_RARE_ I-GENE
rats O
, O
_RARE_ I-GENE
mice O
, O
and O
_RARE_ I-GENE
guinea O
pigs O
were O
exposed O
once O
for O
6 I-GENE
hr O
to O
mean O
concentrations O
of O
10 O
. O
5 I-GENE
, O
5 I-GENE
. O
4 I-GENE
, O
2 I-GENE
. O
4 I-GENE
, O
1 I-GENE
. O
0 O
, O
or O
0 O
( O
control O
) O
ppm O
of O
methyl O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
_RARE_ I-GENE
. O

_RARE_ I-GENE
study O
and O
_RARE_ I-GENE
biopsy O
revealed O
remarkable O
degeneration O
of O
myocardium O
. O

_RARE_ I-GENE
of O
the O
fracture O
in O
a O
_RARE_ I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
was O
as O
effective O
as O
more O
_RARE_ I-GENE
methods O
. O

Comparison O
of O
patients O
receiving O
phenytoin O
and O
those O
who O
were O
not O
showed O
significantly O
lower O
serum I-GENE
folate I-GENE
in O
the O
sub O
- I-GENE
group O
receiving O
phenytoin O
, O
but O
there O
was O
no O
significant O
difference O
between O
the O
sub O
- I-GENE
groups O
with O
respect O
to O
vitamin O
_RARE_ I-GENE
or O
behaviour O
problem O
rating O
. O

Effects O
of O
a O
low O
- I-GENE
energy O
laser O
beam O
on O
the O
cells O
of O
the O
_RARE_ I-GENE
embryo O

_RARE_ I-GENE
and O
atypical O
clinical O
features O
of O
this O
_RARE_ I-GENE
_RARE_ I-GENE
cyst O
are O
_RARE_ I-GENE
. O

The O
role O
of O
_RARE_ I-GENE
in O
_RARE_ I-GENE
taste O
_RARE_ I-GENE
was O
investigated O
in O
a O
series O
of O
4 I-GENE
experiments O
. O

_RARE_ I-GENE
from O
_RARE_ I-GENE
neurological O
patients O
were O
used O
to O
study O
the O
diagnostic O
value O
of O
acid I-GENE
alpha I-GENE
1 I-GENE
- I-GENE
glycoprotein I-GENE
in O
the O
lumbar O
cerebrospinal O
fluid O
. O

_RARE_ I-GENE
experiments O
measured O
_RARE_ I-GENE
and O
_RARE_ I-GENE
uptake O
in O
_RARE_ I-GENE
- I-GENE
10 O
cells O
in O
vitro O
1 I-GENE
and O
2 I-GENE
days O
following O
20 O
Gy O
irradiation O
to O
assess O
whether O
this O
radiation O
dose O
reduced O
the O
capacity O
of O
tumor I-GENE
cells O
to O
_RARE_ I-GENE
_RARE_ I-GENE
or O
Rb I-GENE
_RARE_ I-GENE

For O
patients O
with O
recurrent O
or O
metastatic O
disease O
, O
the O
data O
suggest O
that O
I I-GENE
- I-GENE
131 O
_RARE_ I-GENE
scintigraphy O
is O
the O
examination O
of O
choice O
. O

W I-GENE
. O

Comparison O
of O
the O
amino O
acid I-GENE
sequence I-GENE
of O
the O
M I-GENE
RNA I-GENE
product I-GENE
of O
_RARE_ I-GENE
virus I-GENE
with O
that O
of O
_RARE_ I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
fever O
viruses O
showed O
in O
both O
cases O
a O
weak O
homology I-GENE
that O
was O
more O
pronounced O
for O
the O
proteins I-GENE
located O
at O
the O
COOH O
- I-GENE
terminal I-GENE
end O
of O
the O
precursor I-GENE
. O

_RARE_ I-GENE
treatment O
for O
_RARE_ I-GENE
_RARE_ I-GENE
. O

In O
addition O
, O
on O
the O
_RARE_ I-GENE
' O
s O
maternal I-GENE
scale O
, O
_RARE_ I-GENE
mothers O
were O
found O
to O
view O
their O
infants O
as O
more O
passive O
and O
dependent I-GENE
than O
American O
mothers O
did O
( O
P I-GENE
less O
than O
0 O
. O
00 O
). O

A I-GENE
preoperative O
_RARE_ I-GENE
_RARE_ I-GENE
for O
pediatric O
patients O
. O

_RARE_ I-GENE

We O
conclude O
that O
for O
mono O
- I-GENE
intronic I-GENE
precursors I-GENE
in O
which O
there O
is O
only O
one O
choice O
of O
splice O
sites I-GENE
, O
most O
of O
the O
exon O
sequences I-GENE
are O
not O
_RARE_ I-GENE
involved O
in O
the O
splicing O
process O
. O

_RARE_ I-GENE
- I-GENE
induced O
_RARE_ I-GENE
lesions O
. O

_RARE_ I-GENE
vivo O
MAO I-GENE
inhibition O
data O
indicated O
_RARE_ I-GENE
to O
be O
an O
inhibitor I-GENE
of O
MAO I-GENE
- I-GENE
B I-GENE
, O
although O
the O
effect O
was O
much O
_RARE_ I-GENE
than O
seen O
with O
_RARE_ I-GENE
or O
_RARE_ I-GENE
. O

Thus O
in O
this O
region O
of O
the O
vessel O
_RARE_ I-GENE
represents O
the O
major I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
of O
collagen I-GENE
. O

A I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
tissue I-GENE
- I-GENE
distribution O
study O
is O
warranted O
to O
elucidate O
the O
complicated O
metabolic O
fate O
of O
_RARE_ I-GENE
. O

_RARE_ I-GENE
lupus O
erythematosus O
was O
diagnosed O
. O

In O
the O
_RARE_ I-GENE
, O
the O
amplitude O
of O
the O
responses O
to O
both O
O2 O
and O
CO2 O
increased O
but O
the O
increase O
in O
CO2 O
sensitivity O
was O
_RARE_ I-GENE
more O
important O
. O

The O
statistical O
significance O
of O
the O
prognosis O
factors I-GENE
was O
studied O
by O
_RARE_ I-GENE
- I-GENE
and O
_RARE_ I-GENE
methods O
, O
according O
to O
the O
model O
of O
Cox O
, O
with O
the O
help O
of O
an O
_RARE_ I-GENE
computer O
. O

These O
changes O
at O
the O
site I-GENE
of O
injection O
consist O
of O
a O
focal I-GENE
abnormality O
characterized O
by O
a O
slight O
increase O
in O
signal I-GENE
intensity O
on O
T1 O
weighted O
images O
and O
markedly O
increased O
signal I-GENE
intensity O
on O
T2 I-GENE
weighted O
images O
. O

These O
results O
suggest O
that O
less O
_RARE_ I-GENE
activity O
of O
_RARE_ I-GENE
in O
this O
neuroleptic O
test O
might O
be O
explained O
by O
the O
lesser O
conversion O
of O
_RARE_ I-GENE
to O
_RARE_ I-GENE
. O

The O
purpose O
of O
this O
study O
is O
twofold O
: O
( O
1 I-GENE
) O
to O
present O
a O
parallel O
form O
of O
the O
_RARE_ I-GENE
_RARE_ I-GENE
Scale O
( O
_RARE_ I-GENE
, O
_RARE_ I-GENE
1 I-GENE
); O
( O
2 I-GENE
) O
to O
study O
test O
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
of O
_RARE_ I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
were O
recovered O
from O
the O
_RARE_ I-GENE
for O
several O
weeks O
, O
and O
persistent O
genital O
and O
gastrointestinal O
infection O
also O
resulted O
from O
the O
ocular O
infection O
in O
some O
cats O
. O

In O
vivo O
_RARE_ I-GENE
microscopy O
of O
_RARE_ I-GENE
skin O
lesions O
. O

These O
equilibrium O
solutions O
are O
then O
shown O
to O
arise O
from O
the O
_RARE_ I-GENE
of O
a O
particular O
_RARE_ I-GENE
_RARE_ I-GENE
. O

The O
average O
_RARE_ I-GENE
in O
the O
X I-GENE
- I-GENE
ray O
counts O
of O
the O
constant O
elements O
from O
the O
series O
means O
were O
used O
to O
correct O
the O
recorded O
count O
of O
the O
variable O
element I-GENE
in O
each O
block O
. O

_RARE_ I-GENE
significant O
effects O
were O
noted O
at O
doses O
which O
did O
not O
appear O
to O
be O
_RARE_ I-GENE
toxic O
. O

Low O
MAO I-GENE
subjects O
showed O
a O
pattern O
of O
higher O
scores O
in O
_RARE_ I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
and O
lower O
scores O
in O
_RARE_ I-GENE
_RARE_ I-GENE
, O
in O
line O
with O
_RARE_ I-GENE
profiles O
found O
in O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
and O
suicide O
_RARE_ I-GENE
who O
also O
_RARE_ I-GENE
to O
have O
low O
platelet I-GENE
MAO I-GENE
activity O
. O

To O
evaluate O
the O
relative O
accuracy O
of O
continuous O
wave O
( O
_RARE_ I-GENE
) O
and O
high O
pulse O
_RARE_ I-GENE
frequency O
( O
_RARE_ I-GENE
) O
Doppler O
for O
estimating O
aortic O
_RARE_ I-GENE
pressure O
_RARE_ I-GENE
, O
Doppler O
examinations O
with O
both O
_RARE_ I-GENE
were O
obtained O
in O
87 O
consecutive O
patients O
with O
aortic O
valve O
disease O
. O

In O
group O
I I-GENE
, O
_RARE_ I-GENE
, O
delta I-GENE
V I-GENE
, O
PaO2 O
, O
_RARE_ I-GENE
and O
VT O
significantly O
decreased O
whereas O
operating O
pressure O
and O
E I-GENE
significantly O
increased O
when O
the O
internal O
diameter O
of O
the O
_RARE_ I-GENE
_RARE_ I-GENE
was O
reduced O
. O

In O
calves O
receiving O
milk O
- I-GENE
substitute O
diets O
containing O
80 O
- I-GENE
260 O
g O
DM O
/ I-GENE
kg O
, O
milk O
_RARE_ I-GENE
were O
reduced O
by O
up O
to O
30 O
% O
on O
the O
_RARE_ I-GENE
day O
that O
calves O
were O
fed O
once O
daily O
instead O
of O
twice O
daily O
. O

_RARE_ I-GENE
there O
is O
no O
_RARE_ I-GENE
that O
elevated O
plasma I-GENE
cholesterol I-GENE
levels O
should O
be O
lowered O
first O
by O
dietary O
modification O
even O
in O
early I-GENE
childhood O
, O
beginning O
at O
the O
age O
of O
two O
years O
. O

The O
number O
of O
fecal O
pellets O
_RARE_ I-GENE
_RARE_ I-GENE
at O
5 I-GENE
to O
6 I-GENE
weeks O
old O
( O
13 O
pellets O
/ I-GENE
day O
) O
and O
gradually O
decreased O
, O
thereafter O
( O
2 I-GENE
. O
1 I-GENE
pellets O
at O
78 O
weeks O
old O
, O
1 I-GENE
. O
5 I-GENE
pellets O
at O
104 O
weeks O
old O
). O

These O
results O
suggest O
that O
N I-GENE
- I-GENE
_RARE_ I-GENE
compounds O
can O
be O
formed O
in O
vivo O
in O
the O
infected O
bladder O
, O
which O
could O
explain O
the O
association O
between O
urinary O
- I-GENE
tract O
infections O
and O
increased O
risk O
for O
bladder O
cancer O
. O

_RARE_ I-GENE
nerve I-GENE
fiber O
defects O
included O
absence O
or O
_RARE_ I-GENE
architecture O
of O
the O
basal O
epithelial O
_RARE_ I-GENE
and O
intra O
- I-GENE
epithelial O
_RARE_ I-GENE
. O

The O
histologic O
grade O
for O
the O
same O
anatomic O
site I-GENE
varied O
among O
hearts O
and O
among O
different O
anatomic O
sites I-GENE
in O
the O
same O
heart O
. O

Serum I-GENE
levels O
of O
albumin I-GENE
, O
globulin I-GENE
, O
and O
coagulation I-GENE
protein I-GENE
activity O
were O
measured O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
and O
daily O
for O
3 I-GENE
days O
; O
skin O
lymph O
levels O
were O
measured O
on O
Day O
3 I-GENE
. O

For O
_RARE_ I-GENE
milk O
there O
was O
a O
significant O
correlation O
of O
vitamin O
K1 I-GENE
to O
cholesterol I-GENE
( O
r O
= O
0 O
. O
62 O
) O
but O
not O
to O
total O
lipid O
or O
phospholipid I-GENE
suggesting O
a O
role O
for O
cholesterol I-GENE
in O
the O
secretion O
of O
vitamin O
K1 I-GENE
into O
_RARE_ I-GENE
milk O
. O

_RARE_ I-GENE
training O
resulted O
in O
an O
increase O
of O
stiffness O
associated I-GENE
with O
a O
decrease O
of O
type I-GENE
II I-GENE
fibers O
. O

A I-GENE
rate O
- I-GENE
decreasing O
dose O
of O
_RARE_ I-GENE
, O
an O
_RARE_ I-GENE
inhibitor I-GENE
, O
was O
studied O
in O
combination O
with O
the O
range O
of O
atropine O
doses O
. O

_RARE_ I-GENE
for O
_RARE_ I-GENE
fitness O
of O
_RARE_ I-GENE
with O
diseases O
of O
the O
respiratory O
tract O
and O
lungs O

_RARE_ I-GENE
, O
9 O
- I-GENE
12 O
_RARE_ I-GENE
1987 O
. O

Two O
new O
_RARE_ I-GENE
inhibitors O
( O
_RARE_ I-GENE
m I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
o I-GENE
_RARE_ I-GENE
) O
were O
studied O
in O
volunteers O
and O
type I-GENE
II I-GENE
_RARE_ I-GENE
under O
various O
conditions O
. O

The O
models O
accurately O
localized O
the O
common O
boundaries O
between O
the O
_RARE_ I-GENE
and O
_RARE_ I-GENE
. O

Two O
of O
these O
six O
cases O
showed O
mucosal I-GENE
spread O
without O
_RARE_ I-GENE
invasion O
( O
type I-GENE
A I-GENE
); O
the O
remaining O
four O
cases O
presented O
a O
direct O
extension O
( O
type I-GENE
B I-GENE
) O
from O
muscle O
- I-GENE
invasive O
carcinomas O
of O
the O
bladder O
. O

However O
, O
_RARE_ I-GENE
of O
12 O
mm O
or O
more O
from O
a O
_RARE_ I-GENE
negative O
result O
indicated O
spread O
of O
infection O
. O

The O
maximum O
amplitude O
of O
evoked O
responses O
in O
the O
cervical O
sympathetic O
trunk O
was O
obtained O
when O
the O
T2 I-GENE
white O
_RARE_ I-GENE
was O
stimulated O
and O
decreased O
gradually O
when O
followed O
by O
the O
stimulation O
of O
T1 O
, O
T3 O
, O
T4 I-GENE
and O
_RARE_ I-GENE
white O
_RARE_ I-GENE
. O

It O
is O
concluded O
that O
contact O
allergy O
to O
K I-GENE
- I-GENE
CG I-GENE
is O
common O
. O

The O
effect O
of O
a O
beta I-GENE
- I-GENE
adrenoceptor I-GENE
antagonist O
, O
_RARE_ I-GENE
, O
on O
uterine O
smooth I-GENE
muscle O
in O
term O
pregnant O
women O
was O
studied O
in O
vitro O
and O
in O
vivo O
( O
in O
hypertensive O
women O
). O

The O
less O
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
acid I-GENE
- I-GENE
containing O
_RARE_ I-GENE
species O
showed O
chromatographic O
patterns O
that O
partially O
_RARE_ I-GENE
( O
in O
_RARE_ I-GENE
times O
) O
the O
patterns O
of O
_RARE_ I-GENE
_RARE_ I-GENE
, O
N I-GENE
. O
_RARE_ I-GENE
, O
and O
N I-GENE
. O
_RARE_ I-GENE
, O
but O
the O
larger O
number O
of O
peaks O
in O
the O
last O
species O
made O
separation O
between O
the O
_RARE_ I-GENE
possible O
. O

The O
development O
of O
a O
data O
base O
is O
described O
which O
can O
be O
used O
as O
common O
reference O
for O
ECG O
computer O
programs O
analyzing O
12 O
or O
15 O
simultaneously O
recorded O
leads O
. O

Blood O
serum I-GENE
erythropoietin I-GENE
level O
and O
basic I-GENE
_RARE_ I-GENE
indices O
during O
the O
adaptation O
of O
healthy O
newborn O
infants O

49 O
, O
_RARE_ I-GENE
chromosome O
_RARE_ I-GENE
: O
an O
unusual O
variant I-GENE
of O
_RARE_ I-GENE
' O
s O
syndrome O
. O

_RARE_ I-GENE
of O
the O
tracheal O
muscle O
and O
the O
activity O
of O
stretch O
receptors I-GENE
in O
the O
_RARE_ I-GENE

The O
selenium O
level O
and O
glutathione I-GENE
peroxidase I-GENE
activity O
in O
the O
blood O
, O
liver O
, O
and O
stomach O
mucosa O
were O
significantly O
higher O
in O
the O
high O
- I-GENE
selenium O
diet O
group O
than O
in O
the O
low O
- I-GENE
selenium O
diet O
group O
. O

_RARE_ I-GENE
delivery O
and O
consumption O
and O
_RARE_ I-GENE
in O
patients O
with O
acute O
myocardial O
infarction O
. O

_RARE_ I-GENE
of O
this O
sample O
had O
_RARE_ I-GENE
PL I-GENE
visual O
_RARE_ I-GENE
similar O
to O
those O
established O
by O
_RARE_ I-GENE
et O
al O
. O
in O
a O
laboratory O
setting O
. O

These O
results O
indicate O
that O
the O
effect O
of O
the O
_RARE_ I-GENE
of O
_RARE_ I-GENE
and O
_RARE_ I-GENE
on O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
responding O
and O
on O
suppressed O
responding O
are O
_RARE_ I-GENE
similar O
.( O
ABSTRACT O
TRUNCATED O
AT I-GENE
250 O
WORDS O
) O

The O
number O
of O
crystalline O
_RARE_ I-GENE
is O
less O
in O
the O
advanced O
_RARE_ I-GENE
areas O
of O
the O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
complex I-GENE
. O

All O
33 O
subjects O
were O
given O
_RARE_ I-GENE
instruments O
for O
measuring O
various O
components O
of O
_RARE_ I-GENE
and O
anxiety O
: O
_RARE_ I-GENE
' O
s O
State O
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
, O
the O
_RARE_ I-GENE
Expression O
Scale O
, O
and O
the O
State O
_RARE_ I-GENE
_RARE_ I-GENE
Scale O
. O

It O
was O
found O
that O
the O
primary O
visual O
cortex O
of O
the O
rat I-GENE
is O
_RARE_ I-GENE
in O
volume O
, O
and O
that O
the O
asymmetry O
_RARE_ I-GENE
side O
differences O
in O
the O
number O
of O
neurons O
. O

The O
subjects O
received O
a O
single O
500 O
mg O
dose O
of O
_RARE_ I-GENE
i O
. O
v I-GENE
. O
and O
concentrations O
in O
plasma I-GENE
were O
measured O
for O
_RARE_ I-GENE
minutes O
and O
in O
urine O
for O
24 O
h O
in O
order O
to O
estimate O
the O
production O
of O
metabolites O
. O

Mean O
weighted O
skin O
temperature O
( O
_RARE_ I-GENE
) O
was O
lower O
( O
P I-GENE
less O
than O
0 O
. O
01 O
) O
following O
_RARE_ I-GENE
than O
before O
, O
and O
_RARE_ I-GENE
resulted O
in O
a O
larger O
( O
P I-GENE
less O
than O
0 O
. O
02 O
) O
_RARE_ I-GENE
- I-GENE
to O
- I-GENE
_RARE_ I-GENE
gradient O
. O

_RARE_ I-GENE
- I-GENE
111 O
leukocyte I-GENE
imaging O
in O
patients O
with O
rheumatoid I-GENE
arthritis O
. O

The O
effect O
of O
L I-GENE
- I-GENE
methionine O
supplementation O
on O
the O
utilization O
of O
a O
_RARE_ I-GENE
protein I-GENE
isolate O
( O
_RARE_ I-GENE
) O
was O
evaluated O
by O
short O
- I-GENE
term O
nitrogen O
balance O
studies O
in O
young O
women O
. O

Primary O
invasive O
Haemophilus O
influenzae O
type I-GENE
b I-GENE
disease O
: O
a O
population O
- I-GENE
based O
assessment O
of O
risk O
factors I-GENE
. O

Overall O
, O
lesions O
_RARE_ I-GENE
the O
deep O
_RARE_ I-GENE
_RARE_ I-GENE
do O
not O
exhibit O
a O
reduced O
frequency O
of O
occurrence O
compared O
to O
lesions O
_RARE_ I-GENE
the O
skeletal I-GENE
muscle O
; O
however O
, O
carcinomas O
affecting O
other O
oral O
sites I-GENE
showed O
a O
reduced O
frequency O
of O
_RARE_ I-GENE
_RARE_ I-GENE
lesions O
in O
comparison O
to O
more O
superficial O
lesions O
. O

Factors O
that O
showed O
significant O
correlation O
to O
elevated O
CIC I-GENE
' O
s O
in O
the O
highly O
elevated O
portion O
of O
our O
CIC I-GENE
population O
were O
poor O
NIH O
score O
, O
increased O
patient O
age O
, O
low O
peak O
expiratory O
flow O
rate O
, O
and O
elevated O
total O
serum I-GENE
IgG I-GENE
. O

Induction O
of O
both O
potential O
transcripts I-GENE
follows O
heat I-GENE
shock I-GENE
in O
vivo O
. O

New O
and O
successful O
steps O
have O
been O
made O
in O
_RARE_ I-GENE
, O
immunotherapy O
, O
and O
_RARE_ I-GENE
of O
_RARE_ I-GENE
conditioned O
infertility O
. O

_RARE_ I-GENE
was O
the O
most O
stable O
and O
_RARE_ I-GENE
was O
the O
least O
stable O
_RARE_ I-GENE
under O
the O
conditions O
tested O
. O

This O
may O
explain O
in O
part O
a O
_RARE_ I-GENE
trend O
towards O
reduced O
_RARE_ I-GENE
for O
gestation O
in O
preterm O
infants O
. O

_RARE_ I-GENE
nucleic O
acid I-GENE
N I-GENE
absorption O
is O
7 O
- I-GENE
8 O
% O
of O
N I-GENE
intake O
. O

_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
chemotactic O
and O
random O
migration O
, O
_RARE_ I-GENE
_RARE_ I-GENE
dye O
reduction O
of O
peritoneal O
_RARE_ I-GENE
neutrophils O
and O
macrophages O
, O
fibrinogen I-GENE
level O
, O
_RARE_ I-GENE
of O
soluble I-GENE
fibrin I-GENE
and O
serial O
dilution O
_RARE_ I-GENE
sulfate I-GENE
test O
were O
investigated O
in O
115 I-GENE
New O
_RARE_ I-GENE
white O
rabbits O
with O
experimentally O
induced O
_RARE_ I-GENE
phenomenon O
in O
the O
colon O
, O
and O
in O
control O
animals O
. O

_RARE_ I-GENE
is O
the O
most O
common O
cause O
of O
allergic O
contact O
dermatitis O
in O
_RARE_ I-GENE
, O
resulting O
in O
positive O
reactions O
in O
patch O
tests O
between O
7 O
and O
14 O
%. O

The O
_RARE_ I-GENE
levels O
were O
not O
affected O
( O
P I-GENE
greater O
than O
. O
1 I-GENE
) O
by O
meal I-GENE
interval O
. O

He O
_RARE_ I-GENE
our O
hospital O
and O
left O
_RARE_ I-GENE
renal O
cyst O
was O
suspected O
. O

However O
, O
further O
analyses O
of O
the O
data O
indicate O
that O
increasing O
VO2 O
AT I-GENE
( O
r O
= O
- I-GENE
0 O
. O
63 O
, O
P I-GENE
less O
than O
0 O
. O
05 O
) O
rather O
than O
_RARE_ I-GENE
( O
r O
= O
- I-GENE
0 O
. O
15 O
) O
could O
result O
in O
_RARE_ I-GENE
the O
10 O
, O
000 O
m I-GENE
_RARE_ I-GENE
performance O
to O
a O
larger O
extent O
, O
and O
that O
the O
absolute O
amount O
of O
change O
( O
delta I-GENE
) O
in O
the O
10 O
, O
000 O
m I-GENE
run O
time O
is O
best O
_RARE_ I-GENE
for O
by O
a O
combination O
of O
delta I-GENE
VO2 O
AT I-GENE
and O
delta I-GENE
5 I-GENE
, O
000 O
m I-GENE
run O
time O
. O

A I-GENE
significant O
herd O
X I-GENE
period O
interaction O
existed O
for O
liver O
TG I-GENE
and O
serum I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
cholesterol I-GENE
concentrations O
. O

Liver O
TG I-GENE
and O
serum I-GENE
_RARE_ I-GENE
concentrations O
were O
positively O
correlated O
. O

The O
results O
show O
that O
nerve I-GENE
and O
roots O
differ O
considerably O
both O
in O
the O
force O
they O
_RARE_ I-GENE
before O
failure O
and O
in O
the O
other O
_RARE_ I-GENE
they O
exhibit O
. O

When O
the O
coronary O
sinus O
pressure O
reached O
15 O
torr O
, O
there O
was O
a O
significant O
decrease O
in O
cardiac O
index O
( O
3 I-GENE
. O
60 O
+/- O
0 O
. O
5 I-GENE
to O
2 I-GENE
. O
70 I-GENE
+/- O
0 O
. O
6 I-GENE
L I-GENE
/ I-GENE
min O
/ I-GENE
m2 O
, O
p O
less O
than O
0 O
. O
001 O
), O
coronary O
blood O
flow O
( O
13 O
. O
7 O
+/- O
3 I-GENE
. O
1 I-GENE
to O
7 O
. O
0 O
+/- O
2 I-GENE
. O
1 I-GENE
ml O
/ I-GENE
min O
, O
p O
less O
than O
0 O
. O
001 O
), O
rate O
of O
rise O
of O
left O
ventricular O
pressure O
( O
1 I-GENE
, O
_RARE_ I-GENE
+/- O
_RARE_ I-GENE
to O
1 I-GENE
, O
_RARE_ I-GENE
+/- O
_RARE_ I-GENE
, O
p O
less O
than O
0 O
. O
05 O
), O
and O
an O
increase O
in O
coronary O
_RARE_ I-GENE
difference O
( O
62 O
. O
8 O
% O
+/- O
9 O
. O
3 I-GENE
% O
to O
70 I-GENE
. O
5 I-GENE
% O
+/- O
5 I-GENE
. O
4 I-GENE
% O
saturation O
, O
p O
less O
than O
0 O
. O
03 O
). O

_RARE_ I-GENE
in O
the O
_RARE_ I-GENE
aorta O
at O
the O
level O
of O
the O
_RARE_ I-GENE
and O
the O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
in O
_RARE_ I-GENE
men O
and O
_RARE_ I-GENE
women O
were O
studied O
using O
computed O
tomography O
. O

In O
a O
series O
of O
_RARE_ I-GENE
consecutive O
_RARE_ I-GENE
, O
_RARE_ I-GENE
pleural I-GENE
_RARE_ I-GENE
( O
PP I-GENE
) O
were O
found O
in O
68 O
individuals O
above O
40 I-GENE
years O
of O
age O
. O

Approximately O
60 O
% O
of O
cell O
bodies O
of O
primary O
neurons O
_RARE_ I-GENE
the O
intra O
and O
_RARE_ I-GENE
structures O
through O
the O
inferior O
alveolar O
, O
_RARE_ I-GENE
, O
mental O
, O
and O
_RARE_ I-GENE
nerves O
were O
in O
the O
range O
between O
300 O
and O
600 O
micron O
2 I-GENE
in O
cross O
- I-GENE
sectional O
area O
: O
mean O
+/- O
SD O
_RARE_ I-GENE
+/- O
_RARE_ I-GENE
micron O
2 I-GENE
, O
_RARE_ I-GENE
+/- O
_RARE_ I-GENE
micron O
2 I-GENE
, O
_RARE_ I-GENE
+/- O
200 O
micron O
2 I-GENE
, O
and O
_RARE_ I-GENE
+/- O
186 I-GENE
micron O
2 I-GENE
, O
respectively O
. O

_RARE_ I-GENE
action O
of O
_RARE_ I-GENE
( O
l O
- I-GENE
1 I-GENE
, O
4 I-GENE
- I-GENE
dimethyl O
- I-GENE
10 O
- I-GENE
hydroxy I-GENE
- I-GENE
2 I-GENE
, O
3 I-GENE
, O
4 I-GENE
, O
5 I-GENE
, O
6 I-GENE
, O
7 O
- I-GENE
_RARE_ I-GENE
- I-GENE
1 I-GENE
, O
6 I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
4 I-GENE
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
). O

On O
transition O
from O
high O
to O
low O
voltage O
there O
was O
a O
significant O
fall O
in O
arterial O
pressure O
( O
7 O
%) O
and O
an O
increase O
in O
flow O
( O
19 O
- I-GENE
38 O
%) O
to O
areas O
of O
the O
brain O
corresponding O
to O
the O
_RARE_ I-GENE
of O
the O
_RARE_ I-GENE
formation O
, O
i O
. O
e O
. O
excluding O
the O
_RARE_ I-GENE
and O
_RARE_ I-GENE
. O

_RARE_ I-GENE
of O
positive O
potentials O
showed O
that O
N1 O
_RARE_ I-GENE
in O
the O
area O
of O
ventral O
gray O
matter O
through O
the O
_RARE_ I-GENE
- I-GENE
lateral O
column O
and O
N2 O
through O
the O
dorsal O
column O
. O

One O
hundred O
and O
four O
( O
14 O
per O
cent O
) O
second O
primary O
tumours O
were O
reported O
. O

_RARE_ I-GENE
of O
_RARE_ I-GENE
_RARE_ I-GENE
under O
these O
experimental O
conditions O
are O
discussed O
. O

There O
have O
been O
five O
problems O
( O
_RARE_ I-GENE
2 I-GENE
, O
suspected O
sepsis O
1 I-GENE
, O
and O
_RARE_ I-GENE
2 I-GENE
) O
during O
a O
total O
of O
2 I-GENE
, O
_RARE_ I-GENE
days O
of O
exposure O
. O

It O
is O
suggested O
that O
these O
results O
may O
_RARE_ I-GENE
the O
_RARE_ I-GENE
possibility O
of O
providing O
a O
means O
of O
identifying O
greater O
or O
lesser O
susceptibility I-GENE
to O
the O
coronary O
effects O
of O
Type O
A I-GENE
behavior O
. O

Two O
studies O
assessed O
two O
types O
of O
reliability O
of O
the O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
; O
a O
questionnaire O
measure O
of O
Type O
A I-GENE
behavior O
). O

_RARE_ I-GENE
patients O
are O
_RARE_ I-GENE
toward O
developing O
_RARE_ I-GENE
bacterial I-GENE
infections O
. O

When O
_RARE_ I-GENE
was O
administered O
alone O
, O
overall O
response O
rate O
decreased O
and O
percent O
_RARE_ I-GENE
increased O
with O
increasing O
doses O
. O

_RARE_ I-GENE
and O
_RARE_ I-GENE
for O
wrist O
joint O
_RARE_ I-GENE

Study O
of O
the O
energy O
metabolism O
of O
the O
_RARE_ I-GENE
cortex O
and O
hippocampus O
by O
the O
( O
14C O
) O
2 I-GENE
- I-GENE
_RARE_ I-GENE
method O
during O
the O
development O
of O
_RARE_ I-GENE
states O

_RARE_ I-GENE
lymphoma O
is O
very O
heterogeneous I-GENE
in O
terms O
of O
its O
biological O
behavior O
. O

Further O
investigations O
are O
necessary O
to O
elucidate O
the O
biochemical O
and O
physiological O
properties O
of O
_RARE_ I-GENE
. O

Among O
them O
, O
26 O
cases O
were O
benign O
and O
34 O
malignant O
. O

Of O
the O
cases O
with O
_RARE_ I-GENE
, O
50 O
% O
had O
associated I-GENE
renal O
cysts O
and O
10 O
% O
of O
the O
cases O
with O
_RARE_ I-GENE
had O
associated I-GENE
liver O
cysts O
. O

_RARE_ I-GENE
goal O
- I-GENE
directed O
_RARE_ I-GENE
movements O
of O
the O
human I-GENE
upper O
_RARE_ I-GENE
are O
known O
to O
be O
associated I-GENE
with O
three O
distinct O
_RARE_ I-GENE
of O
EMG O
activity O
in O
antagonistic O
muscles O
. O

The O
combination O
of O
F1 I-GENE
and O
F2 O
which O
was O
the O
best O
predictor O
of O
_RARE_ I-GENE
in O
this O
population O
( O
G1 I-GENE
) O
might O
be O
interpreted O
as O
reflecting O
trunk O
_RARE_ I-GENE
mainly O
abdominal O
. O

Renal O
clearance O
fell O
from O
19 O
. O
0 O
+/- O
4 I-GENE
. O
9 O
ml O
/ I-GENE
min O
/ I-GENE
1 I-GENE
. O
73 O
m2 O
( O
group O
I I-GENE
) O
to O
1 I-GENE
. O
0 O
+/- O
0 O
. O
4 I-GENE
ml O
/ I-GENE
min O
/ I-GENE
1 I-GENE
. O
73 O
m2 O
( O
group O
IV I-GENE
). O

The O
relations O
between O
type I-GENE
A I-GENE
behavior O
, O
clinically O
relevant O
behavior O
, O
_RARE_ I-GENE
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
in O
children O
. O

The O
rats O
were O
used O
for O
the O
study O
of O
the O
effects O
of O
sepsis O
on O
the O
utilization O
of O
exogenous O
fat O
_RARE_ I-GENE
. O

_RARE_ I-GENE
also O
had O
slight O
_RARE_ I-GENE
of O
the O
upper O
_RARE_ I-GENE
. O

Results O
of O
electron O
therapy O
of O
tumors O
in O
different O
sites I-GENE

The O
mechanism O
of O
action O
is O
explored O
in O
some O
detail O
, O
specifically O
as O
it O
_RARE_ I-GENE
to O
_RARE_ I-GENE
system O
( O
_RARE_ I-GENE
) O
Fc I-GENE
receptor I-GENE
blockade O
and O
suppression O
of O
_RARE_ I-GENE
antibody I-GENE
synthesis O
. O

_RARE_ I-GENE
of O
_RARE_ I-GENE
stroke O
, O
myocardial O
infarction O
, O
angina O
pectoris O
_RARE_ I-GENE
left O
ventricular O
hypertrophy O
could O
also O
be O
lowered O
. O

High O
_RARE_ I-GENE
r O
values O
with O
small I-GENE
standard O
_RARE_ I-GENE
were O
observed O
in O
normal O
LV O
( O
0 O
. O
_RARE_ I-GENE
+/- O
0 O
. O
_RARE_ I-GENE
) O
and O
in O
non O
- I-GENE
MI O
regions O
( O
0 O
. O
_RARE_ I-GENE
+/- O
0 O
. O
_RARE_ I-GENE
), O
indicating O
temporally O
_RARE_ I-GENE
_RARE_ I-GENE
shortening O
. O

These O
results O
indicate O
that O
during O
pregnancy O
there O
are O
increases O
in O
bone O
formation O
rates O
_RARE_ I-GENE
to O
the O
increases O
in O
skeletal I-GENE
mass O
. O

We O
analyzed O
data O
from O
56 O
patients O
with O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
( O
SLE O
) O
in O
whom O
renal O
biopsies O
were O
done O
systematically O
. O

The O
possibility O
of O
a O
hereditary I-GENE
disorder O
leading O
to O
a O
minor O
defect O
in O
elastic O
fibre O
structure O
which O
could O
be O
responsible O
for O
the O
spontaneous O
lesions O
is O
discussed O
. O

Prevention O
by O
a O
heparin O
- I-GENE
antithrombin I-GENE
III I-GENE
combination O

N I-GENE
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
were O
tested O
as O
_RARE_ I-GENE
_RARE_ I-GENE
for O
gas O
chromatographic O
analysis O
. O

MICs O
of O
four O
_RARE_ I-GENE
agents O
( O
5 I-GENE
- I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
and O
amphotericin O
B I-GENE
) O
for O
84 O
clinical O
isolates O
of O
various O
Candida I-GENE
species O
were O
then O
determined O
with O
both O
media O
in O
agar O
dilution O
and O
_RARE_ I-GENE
_RARE_ I-GENE
dilution O
systems O
. O

There O
were O
18 O
patients O
with O
Group O
II I-GENE
( O
a O
) O
tumors O
; O
although O
tumor I-GENE
biopsy O
was O
_RARE_ I-GENE
on O
eight O
of O
these O
, O
pathological O
diagnosis O
at O
the O
time O
of O
surgery O
was O
made O
in O
only O
one O
case O
. O

Evidence O
that O
opiate I-GENE
_RARE_ I-GENE
is O
in O
part O
an O
immune I-GENE
response O
. O

_RARE_ I-GENE
post O
- I-GENE
_RARE_ I-GENE
examination O
of O
all O
seropositive O
animals O
showed O
five O
and O
seven O
false O
- I-GENE
positive O
animals O
when O
E I-GENE
/ I-GENE
S I-GENE
and O
_RARE_ I-GENE
antigens I-GENE
were O
used O
, O
respectively O
. O

_RARE_ I-GENE
induced O
hypertension O
has O
been O
regarded O
as O
independent O
of O
sodium O
( O
Na I-GENE
), O
in O
contrast O
to O
_RARE_ I-GENE
induced O
hypertension O
, O
which O
is O
Na I-GENE
+- I-GENE
dependent I-GENE
. O

_RARE_ I-GENE
of O
them O
were O
on O
treatment O
with O
systemic O
steroids O
. O

_RARE_ I-GENE
of O
its O
use O
in O
the O
intensive O
therapy O
unit I-GENE
are O
described O
. O

The O
growing O
drug O
problem O
is O
also O
reflected O
in O
the O
increasing O
number O
of O
cases O
of O
hepatitis I-GENE
B I-GENE
and O
of O
drug O
- I-GENE
related I-GENE
deaths O
. O

Only O
seven O
patients O
, O
five O
of O
whom O
have O
metastatic O
disease O
, O
_RARE_ I-GENE
more O
than O
10 O
years O
after O
first O
presentation O
; O
nine O
patients O
, O
one O
of O
whom O
has O
_RARE_ I-GENE
, O
_RARE_ I-GENE
for O
5 I-GENE
years O
or O
less O
. O

Although O
differences O
were O
not O
significant O
, O
infants O
in O
the O
experimental O
group O
had O
more O
changes O
in O
the O
intermittent O
_RARE_ I-GENE
ventilation O
( O
_RARE_ I-GENE
) O
_RARE_ I-GENE
during O
transport O
, O
and O
more O
such O
infants O
_RARE_ I-GENE
at O
the O
receiving O
hospital O
with O
acceptable O
pH O
and O
PCO2 O
values O
. O

_RARE_ I-GENE
sequences I-GENE
are O
present O
in O
at O
least O
three O
introns O
of O
the O
cytochrome I-GENE
P I-GENE
- I-GENE
_RARE_ I-GENE
gene I-GENE
, O
but O
not O
in O
exons O
or O
the O
5 I-GENE
'- O
flanking O
region O
. O

A I-GENE
large O
increase O
of O
serum I-GENE
_RARE_ I-GENE
occurred O
under O
all O
conditions O
, O
and O
the O
exercise O
respiratory O
_RARE_ I-GENE
suggested O
some O
increase O
of O
fat O
utilization O
, O
_RARE_ I-GENE
( O
0 O
. O
85 O
) O
through O
_RARE_ I-GENE
( O
0 O
. O
84 O
) O
to O
CC O
( O
0 O
. O
83 O
). O

This O
lack O
of O
correlation O
may O
be O
due O
to O
variations O
in O
the O
metabolic O
activity O
of O
the O
_RARE_ I-GENE
implants O
present O
at O
different O
stages O
of O
the O
disease O
. O

_RARE_ I-GENE
adaptation O
to O
chronic O
hypoxia O
in O
newborn O
rats O
. O

_RARE_ I-GENE
1 I-GENE
is O
either O
21 O
- I-GENE
O O
- I-GENE
_RARE_ I-GENE
, O
22 O
- I-GENE
O O
- I-GENE
_RARE_ I-GENE
R1 I-GENE
- I-GENE
_RARE_ I-GENE
, O
or O
21 O
- I-GENE
O O
- I-GENE
_RARE_ I-GENE
, O
22 O
- I-GENE
O O
- I-GENE
_RARE_ I-GENE
R1 I-GENE
- I-GENE
_RARE_ I-GENE
. O

Human I-GENE
and O
Chinese O
hamster I-GENE
_RARE_ I-GENE
protein I-GENE
sequences I-GENE
deduced O
from O
the O
cDNAs I-GENE
are O
identical O
. O

_RARE_ I-GENE
introns O
3 I-GENE
and O
4 I-GENE
both O
contain O
Alu I-GENE
sequences I-GENE
. O

One O
of O
the O
most O
relevant O
aspects O
in O
_RARE_ I-GENE
the O
consistent O
survival O
of O
an O
animal O
undergoing O
the O
experimental O
implantation O
of O
a O
total O
artificial O
heart O
is O
_RARE_ I-GENE
related I-GENE
to O
the O
correct O
anatomic O
placement O
of O
_RARE_ I-GENE
ventricles O
_RARE_ I-GENE
the O
chest O
. O

An O
_RARE_ I-GENE
tissue I-GENE
response O
adjacent O
to O
the O
_RARE_ I-GENE
site I-GENE
suggested O
a O
potential O
toxic O
chemical O
or O
thermal O
reaction O
, O
or O
both O
, O
to O
the O
tissue I-GENE
adhesive O
, O
but O
there O
was O
no O
evidence O
of O
any O
distant O
ocular O
effects O
. O

These O
findings O
suggest O
that O
there O
may O
be O
a O
relationship O
between O
the O
pathogenesis O
of O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
. O

Among O
82 O
superficial O
lesions O
34 O
were O
classified O
as O
showing O
CR I-GENE
and O
another O
23 O
as O
showing O
PR I-GENE
, O
with O
a O
response O
rate O
of O
69 O
. O
5 I-GENE
%. O

Under O
the O
same O
hematocrit O
and O
flow O
conditions O
, O
the O
rate O
of O
oxygen O
saturation O
decrease O
was O
significantly O
higher O
for O
the O
_RARE_ I-GENE
cells O
than O
for O
normal O
cells O
. O

While O
the O
_RARE_ I-GENE
observed O
the O
_RARE_ I-GENE
of O
the O
eye O
with O
indirect O
_RARE_ I-GENE
, O
the O
point O
source O
of O
light I-GENE
from O
the O
_RARE_ I-GENE
light I-GENE
_RARE_ I-GENE
was O
_RARE_ I-GENE
along O
the O
_RARE_ I-GENE
of O
the O
_RARE_ I-GENE
plaque O
. O

These O
fusion I-GENE
proteins I-GENE
also O
allowed O
the O
localization O
of O
the O
transcriptional O
activation O
and O
DNA I-GENE
binding I-GENE
domains I-GENE
of O
the O
_RARE_ I-GENE
protein I-GENE
to O
its O
_RARE_ I-GENE
located O
N I-GENE
- I-GENE
terminal I-GENE
portion O
. O

From O
life O
- I-GENE
_RARE_ I-GENE
analyses O
of O
these O
patients O
, O
we O
estimated O
that O
the O
incidence O
of O
secondary O
_RARE_ I-GENE
in O
patients O
who O
have O
_RARE_ I-GENE
disease O
is O
about O
25 O
per O
cent O
at O
the O
age O
of O
_RARE_ I-GENE
years O
, O
and O
that O
malignant O
degeneration O
is O
almost O
a O
_RARE_ I-GENE
in O
patients O
who O
have O
_RARE_ I-GENE
syndrome O
. O

The O
lethal O
toxicity O
of O
inorganic O
( O
_RARE_ I-GENE
) O
and O
organic O
( O
_RARE_ I-GENE
) O
_RARE_ I-GENE
chloride O
was O
compared O
for O
_RARE_ I-GENE
( O
Japanese O
_RARE_ I-GENE
, O
_RARE_ I-GENE
_RARE_ I-GENE
) O
of O
different O
ages O
from O
_RARE_ I-GENE
through O
_RARE_ I-GENE
by O
single O
- I-GENE
dose O
acute O
oral O
and O
_RARE_ I-GENE
injections O
and O
by O
a O
5 I-GENE
- I-GENE
d O
dietary O
trial O
. O

Since O
the O
integrated O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
plasma I-GENE
cortisol O
estimation O
is O
_RARE_ I-GENE
and O
_RARE_ I-GENE
than O
the O
mean O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
plasma I-GENE
cortisol O
estimation O
, O
we O
_RARE_ I-GENE
it O
as O
an O
_RARE_ I-GENE
in O
the O
diagnosis O
of O
_RARE_ I-GENE
' O
s O
syndrome O
. O

Most O
of O
the O
patients O
had O
locally O
advanced O
lesions O
( O
63 O
T3 O
- I-GENE
4 I-GENE
: O
91 O
. O
5 I-GENE
%) O
according O
to O
the O
adopted O
_RARE_ I-GENE
system O
( O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
). O

The O
risk O
for O
these O
complications O
is O
increased O
by O
the O
following O
factors I-GENE
: O
multiple O
gestation O
, O
the O
combination O
of O
magnesium O
sulfate I-GENE
and O
beta I-GENE
- I-GENE
adrenergic I-GENE
agonist O
, O
and O
the O
use O
of O
_RARE_ I-GENE
- I-GENE
steroids O
to O
_RARE_ I-GENE
fetal O
pulmonary O
_RARE_ I-GENE
. O

_RARE_ I-GENE
and O
interferon I-GENE
for O
low O
grade O
non O
- I-GENE
Hodgkin O
' O
s O
lymphoma O
. O

_RARE_ I-GENE
_RARE_ I-GENE
1 I-GENE
ppm O
) O
and O
E I-GENE
( O
50 O
IU O
/ I-GENE
kg O
) O
supplementation O
of O
the O
diet O
of O
the O
_RARE_ I-GENE
increased O
plasma I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
concentrations O
, O
but O
did O
not O
increase O
plasma I-GENE
glutathione I-GENE
peroxidase I-GENE
( O
_RARE_ I-GENE
- I-GENE
Px I-GENE
) O
activity O
. O

_RARE_ I-GENE
Type O
A I-GENE
behavior O
was O
positively O
associated I-GENE
with O
diastolic O
blood O
pressure O
( O
r O
= O
0 O
. O
17 O
, O
p O
less O
than O
0 O
. O
05 O
) O
among O
the O
women O
. O

The O
in O
vitro O
_RARE_ I-GENE
potency O
is O
greatest O
when O
the O
1 I-GENE
- I-GENE
_RARE_ I-GENE
is O
2 I-GENE
, O
4 I-GENE
- I-GENE
_RARE_ I-GENE
and O
the O
7 O
- I-GENE
_RARE_ I-GENE
is O
a O
3 I-GENE
- I-GENE
amino O
- I-GENE
1 I-GENE
- I-GENE
_RARE_ I-GENE
group O
. O

The O
M I-GENE
reading O
frame O
differed O
from O
the O
reported O
sequence I-GENE
by O
a O
single O
nucleotide I-GENE
corresponding O
to O
a O
conservative O
lysine O
to O
arginine I-GENE
amino O
acid I-GENE
substitution O
near O
the O
carboxy I-GENE
- I-GENE
terminus O
conserved O
among O
the O
M I-GENE
proteins I-GENE
of O
_RARE_ I-GENE
. O

An O
ion O
chromatographic O
method O
was O
used O
to O
determine O
Br O
ion O
in O
the O
urine O
of O
_RARE_ I-GENE
. O

II I-GENE
. O

_RARE_ I-GENE
changes O
following O
_RARE_ I-GENE
_RARE_ I-GENE
in O
adults O
. O

_RARE_ I-GENE
of O
human I-GENE
myocardial O
contractile O
activity O
as O
affected O
by O
blood O
serum I-GENE

_RARE_ I-GENE
of O
a O
vein O
segment O
with O
valve O
in O
the O
treatment O
of O
deep O
vein O
_RARE_ I-GENE
insufficiency O
of O
the O
lower O
_RARE_ I-GENE

The O
relationships O
among O
four O
_RARE_ I-GENE
of O
lactate I-GENE
increase O
: O
lactate I-GENE
threshold O
( O
_RARE_ I-GENE
) O
( O
the O
VO2 O
at O
which O
blood O
lactate I-GENE
concentration O
begins O
to O
increase O
above O
the O
resting O
level O
during O
an O
_RARE_ I-GENE
exercise O
test O
), O
_RARE_ I-GENE
( O
the O
VO2 O
at O
which O
blood O
lactate I-GENE
increases O
1 I-GENE
mM O
above O
the O
resting O
level O
), O
_RARE_ I-GENE
( O
the O
VO2 O
at O
which O
blood O
lactate I-GENE
concentration O
_RARE_ I-GENE
a O
fixed O
value O
of O
2 I-GENE
mM O
), O
onset O
of O
blood O
lactate I-GENE
accumulation O
( O
_RARE_ I-GENE
; O
the O
VO2 O
at O
which O
blood O
lactate I-GENE
_RARE_ I-GENE
a O
concentration O
of O
4 I-GENE
mM O
), O
were O
compared O
with O
aerobic O
capacity O
( O
_RARE_ I-GENE
) O
and O
12 O
min O
_RARE_ I-GENE
performance O
in O
19 O
_RARE_ I-GENE
female O
students O
. O

This O
is O
based O
on O
_RARE_ I-GENE
an O
underlying O
multivariate O
normal O
distribution O
. O

The O
observation O
of O
late O
effects O
after O
_RARE_ I-GENE
or O
after O
space O
_RARE_ I-GENE
show O
the O
_RARE_ I-GENE
_RARE_ I-GENE
in O
assessing O
_RARE_ I-GENE
_RARE_ I-GENE
during O
long O
duration O
space O
_RARE_ I-GENE
. O

_RARE_ I-GENE
use O
and O
interpretation O
of O
viral I-GENE
hepatitis I-GENE
B I-GENE
markers O
and O
hepatic I-GENE
biopsy O
in O
HBs I-GENE
Ag I-GENE
carriers O
and O
at O
the O
chronic O
hepatitis I-GENE
stage O

The O
1 I-GENE
, O
2 I-GENE
, O
3 I-GENE
and O
4 I-GENE
year O
survival O
rates O
were O
94 O
%, O
84 O
%, O
76 I-GENE
% O
and O
63 O
%, O
respectively O
. O

Inhibition O
of O
_RARE_ I-GENE
- I-GENE
stimulated O
gastric O
secretion O
by O
40 I-GENE
_RARE_ I-GENE
RP I-GENE
, O
a O
new O
long O
- I-GENE
acting O
gastric O
_RARE_ I-GENE
agent O
. O

Five O
- I-GENE
year O
prospective O
study O
of O
peripheral O
white O
blood O
cells O
in O
infectious O
_RARE_ I-GENE
. O

Northern O
blotting O
with O
a O
unique O
17 O
- I-GENE
mer I-GENE
oligonucleotide I-GENE
demonstrated O
the O
absence O
of O
the O
mutant I-GENE
sequence I-GENE
in O
the O
mRNA I-GENE
from O
which O
the O
cDNA I-GENE
library O
giving O
rise O
to O
the O
mutant I-GENE
cDNA I-GENE
was O
constructed O
. O

_RARE_ I-GENE
_RARE_ I-GENE
families O
encoding O
highly O
repetitive O
peptide I-GENE
sequences I-GENE
. O

_RARE_ I-GENE
of O
_RARE_ I-GENE
breast O
cancer O

In O
recent O
years O
, O
successful O
physiological O
models O
have O
been O
developed O
for O
a O
variety O
of O
volatile O
and O
_RARE_ I-GENE
_RARE_ I-GENE
, O
and O
their O
ability O
to O
perform O
the O
_RARE_ I-GENE
needed O
in O
risk O
assessment O
has O
been O
demonstrated O
. O

_RARE_ I-GENE
_RARE_ I-GENE
is O
used O
below O
the O
experimental O
data O
range O
to O
establish O
an O
upper O
bound O
on O
_RARE_ I-GENE
risk O
at O
low O
doses O
. O

_RARE_ I-GENE
_RARE_ I-GENE
who O
has O
_RARE_ I-GENE
as O
a O
psychiatric O
_RARE_ I-GENE
in O
_RARE_ I-GENE
for O
the O
past O
20 O
years O

Deletion O
mapping O
studies O
revealed O
that O
the O
upstream O
DNA I-GENE
sequences I-GENE
up O
to O
- I-GENE
86 I-GENE
were O
sufficient O
for O
the O
optimal O
basal O
level O
transcription I-GENE
in O
HeLa O
cells O
and O
also O
for O
the O
EIA I-GENE
- I-GENE
induced O
transcription I-GENE
. O

_RARE_ I-GENE
of O
the O
_RARE_ I-GENE
antibiotic O
amphotericin O
B I-GENE
( O
_RARE_ I-GENE
) O
in O
liposomes O
results O
in O
a O
marked O
reduction O
in O
drug O
toxicity O
with O
no O
loss O
of O
_RARE_ I-GENE
potency O
. O

_RARE_ I-GENE
healthy O
, O
_RARE_ I-GENE
males O
undergoing O
routine O
_RARE_ I-GENE
dental O
care O
were O
evaluated O
during O
treatment O
for O
possible O
hemodynamic O
alterations O
in O
response O
to O
potential O
sympathetic O
nervous O
system O
stimulation O
. O

Serum I-GENE
IgM I-GENE
and O
IgE I-GENE
concentrations O
, O
allergen I-GENE
- I-GENE
specific I-GENE
IgE I-GENE
scores O
, O
and O
the O
tumor I-GENE
_RARE_ I-GENE
status O
were O
combined O
to O
construct I-GENE
a O
three O
- I-GENE
level O
risk O
classification O
that O
was O
more O
prognostic O
than O
any O
of O
the O
individual O
components O
. O

The O
M I-GENE
- I-GENE
3 I-GENE
subtype I-GENE
was O
an O
adverse O
prognostic O
factor I-GENE
. O

Within O
the O
_RARE_ I-GENE
. O
_RARE_ I-GENE
group O
there O
was O
a O
highly O
- I-GENE
significant O
difference O
between O
_RARE_ I-GENE
. O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
. O
_RARE_ I-GENE
( O
p O
less O
than O
0 O
. O
01 O
) O
with O
respect O
to O
mean O
_RARE_ I-GENE
size O
. O

These O
results O
indicate O
that O
T I-GENE
. O
C I-GENE
., O
LDL I-GENE
- I-GENE
C I-GENE
., O
HDL I-GENE
- I-GENE
C I-GENE
., O
HDL2 I-GENE
- I-GENE
C I-GENE
., O
apo I-GENE
B I-GENE
, O
apo I-GENE
A I-GENE
- I-GENE
I I-GENE
/ I-GENE
B I-GENE
ratio O
and O
apo I-GENE
A I-GENE
- I-GENE
II I-GENE
/ I-GENE
B I-GENE
ratio O
are O
predictive O
risk O
factors I-GENE
of O
the O
coronary O
heart O
disease O
. O

It O
is O
concluded O
that O
the O
unique O
_RARE_ I-GENE
formulation O
of O
_RARE_ I-GENE
- I-GENE
S I-GENE
is O
useful O
in O
the O
treatment O
of O
infections O
in O
children O
with O
heavy I-GENE
_RARE_ I-GENE
disorders O
and O
in O
children O
who O
cannot O
take O
oral O
drugs O
because O
of O
severe O
_RARE_ I-GENE
. O

In O
addition O
, O
marked O
hypertension O
accompanied O
this O
disorder O
and O
all O
abnormalities O
, O
including O
the O
hypertension O
, O
responded O
to O
1 I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
8 O
- I-GENE
D I-GENE
- I-GENE
arginine I-GENE
vasopressin I-GENE
therapy O
. O

_RARE_ I-GENE
photon O
emission O
computerized O
tomography O
( O
SPECT O
), O
by O
providing O
three O
- I-GENE
dimensional O
_RARE_ I-GENE
of O
myocardial O
Tl O
- I-GENE
201 O
, O
offers O
_RARE_ I-GENE
for O
improved O
localization O
of O
CAD I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
mapping O
in O
quantitative O
analysis O
of O
cerebral O
_RARE_ I-GENE
emission O
_RARE_ I-GENE
. O

In O
19 O
patients O
vagotomy O
not O
only O
_RARE_ I-GENE
the O
bleeding O
but O
provided O
definitive O
therapy O
( O
_RARE_ I-GENE
I I-GENE
- I-GENE
II I-GENE
); O
4 I-GENE
patients O
died O
( O
mortality O
rate O
16 O
%). O

_RARE_ I-GENE
of O
a O
successful O
intrauterine O
fertilization O
with O
delivery O
of O
a O
term O
_RARE_ I-GENE
supports O
the O
_RARE_ I-GENE
feasibility O
of O
the O
_RARE_ I-GENE
; O
however O
, O
_RARE_ I-GENE
_RARE_ I-GENE
by O
our O
procedure O
appears O
to O
be O
the O
major I-GENE
_RARE_ I-GENE
. O

MRI O
_RARE_ I-GENE
one O
or O
more O
of O
the O
following O
abnormalities O
in O
24 O
( O
63 O
%) O
of O
38 O
treated O
kidneys O
: O
( O
1 I-GENE
) O
loss O
of O
_RARE_ I-GENE
differentiation O
, O
( O
2 I-GENE
) O
_RARE_ I-GENE
fluid O
, O
( O
3 I-GENE
) O
_RARE_ I-GENE
_RARE_ I-GENE
, O
( O
4 I-GENE
) O
hemorrhage O
into O
a O
renal O
cyst O
, O
and O
( O
5 I-GENE
) O
_RARE_ I-GENE
abnormalities O
. O

The O
results O
obtained O
are O
similar O
to O
those O
described O
with O
the O
previous O
_RARE_ I-GENE
formulation O
although O
greater O
variability O
in O
induction O
and O
recovery O
times O
was O
noted O
with O
the O
_RARE_ I-GENE
formulation O
. O

The O
percentage O
_RARE_ I-GENE
reduction O
at O
the O
end O
of O
CPB O
showed O
significant O
correlation O
with O
1 I-GENE
) O
CPB O
duration O
( O
r O
= O
0 O
. O
49 O
), O
2 I-GENE
) O
oxygen O
flow O
rate O
index O
( O
_RARE_ I-GENE
), O
i O
. O
e O
. O
flow O
/ I-GENE
min O
in O
the O
_RARE_ I-GENE
_RARE_ I-GENE
/ I-GENE
m2 O
_RARE_ I-GENE
( O
r O
= O
0 O
. O
38 O
), O
and O
3 I-GENE
) O
blood O
flow O
rate O
index O
( O
_RARE_ I-GENE
), O
i O
. O
e O
. O
average O
volume O
of O
blood O
_RARE_ I-GENE
through O
the O
heart O
- I-GENE
lung O
machine O
/ I-GENE
min O
CPB O
time O
/ I-GENE
m2 O
_RARE_ I-GENE
( O
r O
= O
0 O
. O
51 O
). O

Diagnosis O
of O
unilateral O
renal O
artery O
lesions O
after O
captopril O
administration O
. O

A I-GENE
yeast I-GENE
DNA I-GENE
fragment I-GENE
carrying O
the O
gene I-GENE
CP I-GENE
A1 I-GENE
encoding O
the O
small I-GENE
subunit I-GENE
of O
the O
arginine I-GENE
pathway O
_RARE_ I-GENE
- I-GENE
phosphate I-GENE
synthetase I-GENE
has O
been O
sequenced O
. O

A I-GENE
retrospective O
study O
of O
_RARE_ I-GENE
sera O
from O
19 O
cats O
with O
the O
_RARE_ I-GENE
granuloma O
complex I-GENE
revealed O
that O
68 O
% O
of O
affected O
cats O
had O
circulating O
antibodies I-GENE
to O
components O
of O
normal O
cat O
epithelium O
. O

In O
memory O
of O
_RARE_ I-GENE
_RARE_ I-GENE

The O
H2 I-GENE
receptor I-GENE
antagonists O
and O
_RARE_ I-GENE
cost O
about O
the O
same O
and O
have O
few O
side O
effects O
. O

These O
results O
suggest O
that O
_RARE_ I-GENE
may O
have O
Class I-GENE
III I-GENE
antiarrhythmic O
activity O
. O

A I-GENE
high O
efficacy O
of O
the O
combined O
use O
of O
_RARE_ I-GENE
doses O
of O
two O
_RARE_ I-GENE
: O
_RARE_ I-GENE
( O
50 O
mg O
/ I-GENE
kg O
) O
and O
_RARE_ I-GENE
( O
25 O
mg O
/ I-GENE
kg O
) O
under O
the O
conditions O
of O
short O
- I-GENE
term O
exogenous O
hypoxia O
( O
7 O
. O
5 I-GENE
% O
O2 O
) O
was O
found O
in O
( O
_RARE_ I-GENE
X I-GENE
_RARE_ I-GENE
) O
F1 I-GENE
mice O
. O

The O
Mean O
was O
74 O
, O
3 I-GENE
+/- O
53 O
, O
6 I-GENE
micrograms O
J O
/ I-GENE
g O
Cr I-GENE
, O
the O
_RARE_ I-GENE
61 O
micrograms O
J O
/ I-GENE
g O
Cr I-GENE
. O

In O
the O
region O
_RARE_ I-GENE
with O
mixed O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
population O
an O
iodine O
deficiency O
I I-GENE
was O
found O
in O
81 O
% O
and O
an O
iodine O
deficiency O
II I-GENE
in O
45 O
%. O

The O
structural O
gene I-GENE
for O
_RARE_ I-GENE
encodes O
a O
protein I-GENE
product I-GENE
of O
molecular O
mass O
_RARE_ I-GENE
Da I-GENE
. O

_RARE_ I-GENE
lymph O
node O
enlargement O
, O
regardless O
of O
cause O
, O
has O
been O
a O
source O
of O
imaging O
_RARE_ I-GENE
because O
of O
its O
propensity O
to O
mimic O
pancreatic O
malignancy O
yet O
not O
cause O
biliary O
obstruction O
. O

_RARE_ I-GENE
with O
rheumatoid I-GENE
factor I-GENE
was O
only O
observed O
in O
the O
ELISA O
_RARE_ I-GENE
if O
sera O
were O
not O
pretreated O
with O
latex O
_RARE_ I-GENE
. O

All O
patients O
had O
elevated O
levels O
of O
serum I-GENE
IgE I-GENE
antibodies I-GENE
to O
the O
crude O
soybean I-GENE
extract O
; O
binding I-GENE
values O
ranged O
from O
2 I-GENE
. O
3 I-GENE
to O
28 O
. O
1 I-GENE
times O
that O
of O
a O
negative O
control O
serum I-GENE
. O

New O
techniques O
for O
the O
mass O
spectrometry O
of O
natural O
products I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
imaging O
of O
the O
spleen O
using O
_RARE_ I-GENE
citrate I-GENE
and O
99mTc O
is O
useful O
in O
further O
_RARE_ I-GENE
lesions O
that O
are O
identified O
on O
either O
a O
routine O
_RARE_ I-GENE
survey O
or O
on O
a O
conventional O
sulfur O
colloid O
liver O
- I-GENE
spleen O
image O
. O

Such O
studied O
acquired O
with O
low O
energy O
or O
medium O
energy O
_RARE_ I-GENE
and O
a O
_RARE_ I-GENE
centered O
on O
the O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
contain O
_RARE_ I-GENE
septal O
_RARE_ I-GENE
signals O
_RARE_ I-GENE
from O
_RARE_ I-GENE
_RARE_ I-GENE
of O
high O
energy O
_RARE_ I-GENE
primarily O
from O
_RARE_ I-GENE
. O

_RARE_ I-GENE
education O
-- O
the O
computer O
_RARE_ I-GENE
. O

_RARE_ I-GENE
bond O
strength O
of O
a O
composite O
resin O
to O
an O
_RARE_ I-GENE
glass O
_RARE_ I-GENE
. O

An O
additional O
advantage O
is O
that O
the O
resin O
can O
be O
removed O
and O
the O
_RARE_ I-GENE
technique O
carried O
out O
on O
thin O
sections O
. O

Such O
a O
concept O
is O
crucial O
to O
our O
understanding O
of O
the O
pathology O
of O
_RARE_ I-GENE
in O
general O
. O

We O
consider O
that O
_RARE_ I-GENE
- I-GENE
CP I-GENE
is O
a O
safe O
and O
excellent O
CP I-GENE
in O
_RARE_ I-GENE
surgery O
and O
we O
are O
now O
utilizing O
this O
CP I-GENE
in O
all O
patients O
requiring O
_RARE_ I-GENE
surgery O
. O

We O
have O
earlier O
evolved O
an O
experimental O
model O
by O
means O
of O
which O
changes O
identical O
to O
the O
_RARE_ I-GENE
syndrome O
can O
be O
induced O
from O
a O
_RARE_ I-GENE
_RARE_ I-GENE
- I-GENE
skeletal I-GENE
trauma O
in O
pigs O
observed O
under O
long O
- I-GENE
term O
anesthesia O
under O
standardized O
conditions O
. O

Although O
no O
statistical O
significance O
was O
achieved O
, O
it O
is O
remarkable O
that O
there O
was O
a O
clear O
trend O
for O
the O
_RARE_ I-GENE
of O
_RARE_ I-GENE
_RARE_ I-GENE
while O
the O
_RARE_ I-GENE
dilution O
10 O
(- O
6 I-GENE
) O
was O
about O
equally O
effective O
compared O
with O
placebo O
. O

The O
volume O
of O
blood O
to O
the O
flap O
_RARE_ I-GENE
from O
1 I-GENE
to O
2 I-GENE
ml O
/ I-GENE
min O
, O
collateral O
circulation O
to O
the O
flap O
exists O
, O
but O
is O
_RARE_ I-GENE
, O
and O
there O
is O
little O
change O
in O
the O
capillary O
blood O
flow O
as O
the O
flap O
ages O
. O

With O
aging O
, O
many O
aspects O
of O
immune I-GENE
function O
change O
. O

_RARE_ I-GENE
candidiasis O

In O
addition O
, O
the O
_RARE_ I-GENE
- I-GENE
101 I-GENE
mutation I-GENE
suppressed O
the O
low O
translational O
efficiency O
of O
GCN4 I-GENE
- I-GENE
lacZ I-GENE
mRNA I-GENE
observed O
in O
_RARE_ I-GENE
- I-GENE
and O
_RARE_ I-GENE
- I-GENE
cells O
. O

This O
suggests O
that O
_RARE_ I-GENE
_RARE_ I-GENE
increases O
the O
responsiveness O
of O
_RARE_ I-GENE
_RARE_ I-GENE
and O
alpha I-GENE
1 I-GENE
adrenoceptors I-GENE
. O

The O
concentrations O
of O
apo I-GENE
A I-GENE
- I-GENE
I I-GENE
and O
apo I-GENE
A I-GENE
- I-GENE
II I-GENE
of O
_RARE_ I-GENE
decreased O
significantly O
compared O
with O
the O
corresponding O
changes O
in O
controls O
. O

The O
distribution O
of O
patients O
was O
as O
follows O
: O
group O
1 I-GENE
-- O
complex I-GENE
gamma I-GENE
- I-GENE
therapy O
( O
55 O
cases O
), O
group O
2 I-GENE
-- O
complex I-GENE
gamma I-GENE
- I-GENE
therapy O
plus O
iliac O
_RARE_ I-GENE
( O
50 O
cases O
) O
and O
group O
3 I-GENE
-- O
complex I-GENE
radiation O
treatment O
with O
_RARE_ I-GENE
_RARE_ I-GENE
beam O
from O
the O
_RARE_ I-GENE
type I-GENE
_RARE_ I-GENE
and O
iliac O
_RARE_ I-GENE
( O
50 O
cases O
). O

The O
availability O
of O
_RARE_ I-GENE
and O
_RARE_ I-GENE
offers O
an O
alternative O
and O
effective O
treatment O
for O
the O
temporary O
reversal O
of O
_RARE_ I-GENE
bleeding O
in O
patients O
who O
require O
_RARE_ I-GENE
invasive O
procedures O
. O

_RARE_ I-GENE
and O
pulmonary O
_RARE_ I-GENE
in O
congenital O
factor I-GENE
_RARE_ I-GENE
deficiency O

_RARE_ I-GENE
of O
the O
_RARE_ I-GENE
mucosa O
have O
shown O
abnormal O
enzyme I-GENE
activity O
or O
deficiencies O
in O
transport O
mechanisms O
. O

Laboratory O
_RARE_ I-GENE
have O
indeed O
shown O
that O
_RARE_ I-GENE
give O
significant O
yields O
of O
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
give O
both O
_RARE_ I-GENE
and O
_RARE_ I-GENE
. O

A I-GENE
significant O
degree O
of O
homology I-GENE
was O
also O
found O
among O
these O
genes I-GENE
and O
the O
_RARE_ I-GENE
gene I-GENE
of O
related I-GENE
phage I-GENE
_RARE_ I-GENE
, O
which O
codes O
for O
an O
enzyme I-GENE
with O
different O
modification O
specificity O
. O

_RARE_ I-GENE
- I-GENE
releasing I-GENE
hormone I-GENE
- I-GENE
induced O
contraction O
of O
_RARE_ I-GENE
and O
vaginal O
muscle O
. O

In O
a O
blind O
controlled O
trial O
, O
15 O
patients O
with O
_RARE_ I-GENE
( O
_RARE_ I-GENE
II I-GENE
- I-GENE
III I-GENE
) O
with O
sinus O
rhythm O
and O
a O
left O
ventricular O
ejection O
fraction O
( O
LV O
- I-GENE
EF I-GENE
) O
of O
34 O
. O
5 I-GENE
+/- O
2 I-GENE
. O
6 I-GENE
% O
received O
_RARE_ I-GENE
D I-GENE
( O
0 O
. O
25 O
- I-GENE
0 O
. O
5 I-GENE
mg O
/ I-GENE
d O
), O
placebo O
( O
_RARE_ I-GENE
), O
P I-GENE
( O
slow O
_RARE_ I-GENE
= O
SR I-GENE
) O
( O
80 O
mg O
/ I-GENE
d O
SR I-GENE
) O
and O
both O
drugs O
combined O
in O
respective O
doses O
. O

_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
occurred O
in O
some O
patients O
. O

The O
sample O
is O
_RARE_ I-GENE
and O
after O
_RARE_ I-GENE
_RARE_ I-GENE
acid I-GENE
in O
the O
supernatant O
is O
measured O
in O
the O
free O
form O
by O
direct O
injection O
into O
the O
gas O
_RARE_ I-GENE
. O

Changes O
in O
_RARE_ I-GENE
acetylcholine I-GENE
receptors I-GENE
in O
guinea O
- I-GENE
pig O
lung O
: O
effects O
of O
aging O
, O
inhalation O
of O
an O
allergen I-GENE
, O
administration O
of O
drugs O
, O
and O
vagotomy O
. O

In O
the O
absence O
of O
other O
_RARE_ I-GENE
, O
increased O
sucrose O
can O
provide O
increased O
_RARE_ I-GENE
to O
the O
virus I-GENE
in O
2 I-GENE
. O
5 I-GENE
% O
albumin I-GENE
. O

The O
overall O
prevalence O
of O
psoriasis O
was O
4 I-GENE
. O
79 O
% O
in O
men O
and O
4 I-GENE
. O
85 O
% O
in O
women O
. O

_RARE_ I-GENE
_RARE_ I-GENE
in O
living O
structure O
? O
Some O
_RARE_ I-GENE
pathways O
in O
animal O
morphology O
. O

The O
possible O
origin O
and O
role O
of O
CSF I-GENE
prolactin I-GENE
are O
discussed O
. O

Three O
chromosomal I-GENE
_RARE_ I-GENE
mutations O
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
, O
were O
transferred O
by O
the O
" O
gene I-GENE
conversion O
" O
process O
to O
B I-GENE
. O
subtilis I-GENE
plasmid O
_RARE_ I-GENE
, O
which O
consists O
of O
the O
entire O
wild I-GENE
- I-GENE
type I-GENE
_RARE_ I-GENE
coding O
sequence I-GENE
, O
encoding O
the O
major I-GENE
sigma I-GENE
43 I-GENE
factor I-GENE
of O
B I-GENE
. O
subtilis I-GENE
RNA I-GENE
polymerase I-GENE
, O
and O
_RARE_ I-GENE
. O

Selective O
effect O
of O
pulmonary O
_RARE_ I-GENE
on O
prostaglandin I-GENE
E2 I-GENE
pharmacokinetics O
in O
rat I-GENE
lung O
. O

This O
article O
will O
_RARE_ I-GENE
review O
the O
published O
data O
on O
the O
morphology O
, O
function O
, O
and O
_RARE_ I-GENE
of O
the O
normal O
renal O
_RARE_ I-GENE
and O
the O
pathology O
associated I-GENE
with O
_RARE_ I-GENE
, O
together O
with O
the O
secondary O
changes O
which O
give O
rise O
to O
cortical O
degeneration O
or O
epithelial O
carcinoma O
. O

The O
data O
indicate O
that O
the O
five O
different O
( O
and O
partially O
overlapping O
) O
_RARE_ I-GENE
messenger I-GENE
RNAs I-GENE
detectable O
in O
early I-GENE
embryos O
are O
initiated O
at O
three O
separate O
sites I-GENE
, O
each O
directly O
upstream O
from O
one O
of O
the O
three O
protein I-GENE
- I-GENE
coding O
regions O
, O
designated O
( O
in O
5 I-GENE
' O
to O
3 I-GENE
' O
order O
) O
beta I-GENE
, O
alpha I-GENE
and O
delta I-GENE
. O

Chronic O
thyroiditis O
as O
a O
risk O
factor I-GENE
of O
B I-GENE
- I-GENE
cell O
lymphoma O
in O
the O
thyroid I-GENE
gland O
. O

Plasma I-GENE
_RARE_ I-GENE
levels O
also O
augmented O
after O
the O
administration O
of O
ethanol O
solutions O
, O
with O
a O
delay O
of O
about O
one O
hour O
after O
the O
onset O
of O
acid I-GENE
secretion O
. O

_RARE_ I-GENE
_RARE_ I-GENE
of O
_RARE_ I-GENE
acid I-GENE
in O
_RARE_ I-GENE
preparations O

A I-GENE
comparison O
among O
the O
5 I-GENE
' O
flanking O
regions O
encompassing O
the O
_RARE_ I-GENE
HS I-GENE
promoter I-GENE
of O
the O
soybean I-GENE
HS I-GENE
- I-GENE
protein I-GENE
genes I-GENE
demonstrated O
this O
region O
to O
be O
extremely O
homologous O
. O

Results O
of O
this O
study O
indicate O
that O
_RARE_ I-GENE
of O
short O
chain I-GENE
fatty I-GENE
acids O
produced O
on O
agar O
medium O
by O
_RARE_ I-GENE
, O
combined O
with O
simple O
tests O
such O
as O
Gram O
' O
s O
stain O
and O
_RARE_ I-GENE
morphology O
, O
may O
allow O
_RARE_ I-GENE
direct O
_RARE_ I-GENE
genus O
identification O
from O
an O
initial O
pure O
agar O
culture O
. O

Using O
this O
method O
, O
we O
measured O
absorption O
of O
low O
doses O
of O
vitamin O
A I-GENE
, O
which O
may O
provide O
a O
more O
physiological O
approach O
to O
assessment O
of O
fat O
_RARE_ I-GENE
. O

_RARE_ I-GENE
hepatitis I-GENE
A I-GENE
in O
chronic O
HBV O
carrier I-GENE
. O

Tissue I-GENE
pressure O
, O
rCBF O
, O
and O
water O
content O
were O
measured O
from O
gray O
matter O
in O
the O
central O
core I-GENE
and O
the O
peripheral O
margin O
of O
the O
_RARE_ I-GENE
_RARE_ I-GENE
over O
6 I-GENE
h O
after O
_RARE_ I-GENE
. O

During O
this O
time O
, O
the O
patients O
all O
had O
the O
characteristic O
plasma I-GENE
thyroid I-GENE
hormone I-GENE
changes O
associated I-GENE
with O
_RARE_ I-GENE
therapy O
, O
i O
. O
e O
. O
increased O
T4 I-GENE
, O
free O
T4 I-GENE
, O
and O
_RARE_ I-GENE
and O
decreased O
T3 O
, O
while O
remaining O
clinically O
_RARE_ I-GENE
. O

Drug O
and O
nutrient O
interactions O
. O

In O
each O
compartment O
O2 O
is O
removed O
by O
the O
tissues O
as O
a O
chemical O
reaction O
_RARE_ I-GENE
place O
between O
O2 O
and O
_RARE_ I-GENE
( O
_RARE_ I-GENE
). O

To O
evaluate O
the O
effects O
of O
propranolol O
on O
myocardial O
metabolism O
after O
coronary O
reperfusion O
, O
serial O
measurements O
of O
myocardial O
creatine I-GENE
kinase I-GENE
( O
CK I-GENE
) O
and O
calcium O
( O
Ca I-GENE
) O
contents O
and O
CK I-GENE
and O
_RARE_ I-GENE
acid I-GENE
( O
LA O
) O
concentrations O
in O
coronary O
sinus O
blood O
were O
carried O
out O
in O
33 O
open O
- I-GENE
chest O
dogs O
. O

_RARE_ I-GENE
of O
the O
_RARE_ I-GENE
- I-GENE
30 O
% O
_RARE_ I-GENE
_RARE_ I-GENE
tip O
was O
observed O
by O
scanning O
electron O
microscopy O
at O
charge I-GENE
_RARE_ I-GENE
as O
low O
as O
200 O
_RARE_ I-GENE
/ I-GENE
cm2 O
X I-GENE
_RARE_ I-GENE
( O
1 I-GENE
A I-GENE
/ I-GENE
cm2 O
), O
whereas O
_RARE_ I-GENE
of O
activated I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
occurred O
only O
at O
the O
highest O
charge I-GENE
and O
current O
_RARE_ I-GENE
( O
_RARE_ I-GENE
_RARE_ I-GENE
/ I-GENE
cm2 O
X I-GENE
_RARE_ I-GENE
, O
16 O
A I-GENE
/ I-GENE
cm2 O
). O

_RARE_ I-GENE
excretion O
, O
appeared O
to O
be O
markedly O
affected O
by O
the O
season O
although O
other O
factors I-GENE
such O
as O
social O
and O
environmental O
stress O
cannot O
be O
_RARE_ I-GENE
. O

Two O
studies O
on O
the O
relationship O
between O
taking O
a O
commercial O
_RARE_ I-GENE
course O
and O
performance O
on O
the O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
Test O
( O
_RARE_ I-GENE
) O
are O
reported O
. O

A I-GENE
total O
of O
90 O
patients O
were O
randomly O
allocated O
either O
to O
an O
_RARE_ I-GENE
- I-GENE
1 I-GENE
treated O
or O
an O
untreated O
group O
. O

_RARE_ I-GENE
50 O
% O
decrease O
of O
PaO2 O
, O
NADH I-GENE
was O
reduced O
largely O
. O

_RARE_ I-GENE
was O
performed O
following O
the O
rCBF O
study O
and O
the O
degree O
of O
_RARE_ I-GENE
was O
measured O
on O
the O
_RARE_ I-GENE
. O

The O
results O
from O
the O
first O
five O
years O
of O
follow O
up O
in O
1972 O
showed O
a O
4 I-GENE
. O
7 O
- I-GENE
fold O
excess O
mortality O
for O
ischaemic O
and O
other O
heart O
diseases O
( O
_RARE_ I-GENE
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
) O
compared O
with O
a O
comparable O
reference O
cohort O
of O
paper O
_RARE_ I-GENE
workers O
. O

The O
_RARE_ I-GENE
impact O
of O
childhood O
asthma O
has O
not O
been O
assessed O
since O
_RARE_ I-GENE
and O
_RARE_ I-GENE
reported O
their O
data O
in O
_RARE_ I-GENE
of O
_RARE_ I-GENE
13 O
years O
_RARE_ I-GENE
. O

_RARE_ I-GENE

_RARE_ I-GENE
activity O
was O
evaluated O
by O
monitoring O
the O
general O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
as O
well O
as O
local O
DC O
steady O
potential O
( O
two O
sites I-GENE
). O

The O
_RARE_ I-GENE
and O
_RARE_ I-GENE
of O
the O
_RARE_ I-GENE
fibers O
of O
the O
superior O
temporal O
region O
( O
_RARE_ I-GENE
) O
are O
studied O
using O
the O
_RARE_ I-GENE
technique O
. O

The O
diabetic O
state O
was O
characterized O
by O
mild O
insulin I-GENE
deficiency O
, O
plasma I-GENE
levels O
being O
73 O
% O
of O
controls O
, O
and O
mild O
_RARE_ I-GENE
, O
with O
_RARE_ I-GENE
plasma I-GENE
glucose O
levels O
of O
1 I-GENE
. O
5 I-GENE
times O
normal O
. O

The O
primary O
CT I-GENE
findings O
were O
_RARE_ I-GENE
as O
a O
brain O
infarct O
or O
possibly O
a O
tumour I-GENE
. O

No O
consistent O
correlation O
between O
blood O
pressure O
change O
and O
_RARE_ I-GENE
- I-GENE
change O
was O
seen O
. O

_RARE_ I-GENE
_RARE_ I-GENE
support O
for O
the O
_RARE_ I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
produced O
a O
lower O
incidence O
of O
gastric O
ulcers O
than O
equivalent O
doses O
of O
indomethacin O
. O

These O
findings O
suggest O
that O
both O
in O
the O
early I-GENE
stages O
( O
_RARE_ I-GENE
, O
_RARE_ I-GENE
) O
and O
in O
more O
severe O
stages O
of O
_RARE_ I-GENE
( O
stages O
1 I-GENE
- I-GENE
2 I-GENE
) O
cold O
induced O
_RARE_ I-GENE
in O
the O
digital O
vessels O
and O
_RARE_ I-GENE
' O
s O
syndrome O
are O
vascular I-GENE
disorders O
of O
functional O
origin O
occurring O
without O
any O
_RARE_ I-GENE
alterations O
. O

In O
_RARE_ I-GENE
functions O
of O
the O
source O
emission O
, O
surface O
_RARE_ I-GENE
, O
_RARE_ I-GENE
sensitivity O
are O
_RARE_ I-GENE
by O
the O
normal O
distribution O
curves O
. O

However O
, O
kidneys O
perfused O
for O
72 O
hr O
demonstrated O
more O
similar O
renal O
functions O
when O
tested O
by O
either O
_RARE_ I-GENE
or O
_RARE_ I-GENE
. O

To O
assess O
the O
effects O
of O
alveolar O
hypoxia O
and O
angiotensin I-GENE
II I-GENE
infusion O
on O
distribution O
of O
blood O
flow O
to O
the O
lung O
we O
performed O
perfusion O
lung O
scans O
on O
anesthetized O
_RARE_ I-GENE
ventilated O
lambs O
. O

A I-GENE
flow O
rate O
of O
at O
least O
5 I-GENE
mL O
/ I-GENE
h O
is O
required O
through O
the O
receptor I-GENE
( O
volume O
, O
0 O
. O
4 I-GENE
mL O
) O
for O
accurate O
results O
. O

We O
have O
now O
located O
the O
5 I-GENE
' O
ends O
of O
the O
two O
remaining O
late O
mRNAs I-GENE
. O

The O
efficacy O
of O
quantitative O
and O
qualitative O
chloride O
_RARE_ I-GENE
in O
the O
estimation O
of O
human I-GENE
salt O
intake O
. O

_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
members O
of O
_RARE_ I-GENE
_RARE_ I-GENE
. O

Acute O
appearance O
of O
_RARE_ I-GENE
or O
_RARE_ I-GENE
with O
initial O
marked O
_RARE_ I-GENE
was O
observed O
in O
8 O
stroke O
patients O
. O

_RARE_ I-GENE
acute O
_RARE_ I-GENE
was O
common O
in O
both O
groups O
of O
patients O
, O
but O
the O
development O
of O
chronic O
_RARE_ I-GENE
was O
only O
found O
in O
patients O
with O
_RARE_ I-GENE
, O
indicating O
the O
more O
severe O
nature O
of O
this O
condition O
compared O
with O
selective O
IgA I-GENE
deficiency O
. O

These O
data O
suggest O
that O
AP I-GENE
- I-GENE
A I-GENE
may O
be O
potentially O
useful O
in O
the O
management O
of O
heart O
failure O
. O

The O
various O
muscles O
of O
the O
_RARE_ I-GENE
floor I-GENE
region O
could O
be O
_RARE_ I-GENE
activated I-GENE
either O
individually O
or O
as O
a O
mass O
unit I-GENE
depending O
on O
the O
intensity O
of O
stimulation O
. O

It O
has O
been O
reported O
that O
rat I-GENE
blood O
_RARE_ I-GENE
levels O
were O
significantly O
decreased O
after O
treatment O
with O
_RARE_ I-GENE
. O

The O
frequency O
of O
_RARE_ I-GENE
phenotypes O
in O
_RARE_ I-GENE
children O
. O

_RARE_ I-GENE
of O
hepatic I-GENE
cytochrome I-GENE
P I-GENE
- I-GENE
450 I-GENE
- I-GENE
dependent I-GENE
_RARE_ I-GENE
enzymes O
such O
as O
_RARE_ I-GENE
- I-GENE
and O
_RARE_ I-GENE
N I-GENE
- I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
hydroxylase I-GENE
activity O
were O
decreased O
by O
pretreatment O
of O
rats O
with O
cimetidine O
, O
whereas O
in O
the O
rats O
pretreated O
with O
ranitidine O
, O
these O
enzyme I-GENE
activities O
were O
not O
changed O
. O

_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
vincristine O
, O
and O
cyclophosphamide O
in O
the O
treatment O
of O
advanced O
gastrointestinal O
_RARE_ I-GENE
. O

The O
effect O
of O
the O
opiate I-GENE
antagonist O
naloxone O
was O
evaluated O
in O
11 O
_RARE_ I-GENE
patients O
with O
cerebral O
ischemia O
. O

_RARE_ I-GENE
detection O
of O
depressed O
circulating O
levels O
of O
vitamin O
K1 I-GENE
in O
_RARE_ I-GENE
. O

In O
the O
present O
experiments O
, O
we O
investigate O
the O
role O
played O
by O
the O
temporal O
pattern O
of O
neural O
activity O
during O
the O
_RARE_ I-GENE
of O
frequency O
_RARE_ I-GENE
in O
the O
mouse I-GENE
central O
auditory O
system O
. O

_RARE_ I-GENE
of O
the O
tumor I-GENE
in O
1 I-GENE
patient O
in O
whom O
_RARE_ I-GENE
resection O
was O
performed O
2 I-GENE
weeks O
after O
_RARE_ I-GENE
irrigation O
revealed O
well O
_RARE_ I-GENE
nuclear I-GENE
chromatin O
, O
thus O
, O
suggesting O
that O
_RARE_ I-GENE
changes O
occur O
after O
_RARE_ I-GENE
irrigation O
are O
short O
- I-GENE
_RARE_ I-GENE
. O

The O
generally O
adopted O
criteria O
_RARE_ I-GENE
to O
_RARE_ I-GENE
the O
examined O
persons O
into O
the O
following O
3 I-GENE
groups O
have O
been O
used O
: O
( O
a O
) O
diseased O
of O
_RARE_ I-GENE
; O
( O
b I-GENE
) O
_RARE_ I-GENE
to O
be O
diseased O
of O
_RARE_ I-GENE
, O
and O
( O
c I-GENE
) O
individuals O
without O
signs O
of O
a O
renal O
disease O
. O

For O
this O
purpose O
, O
a O
simple O
respiration O
- I-GENE
control O
device O
has O
been O
developed O
that O
enables O
the O
patient O
to O
monitor O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
during O
successive O
scans O
. O

The O
_RARE_ I-GENE
syndrome O
( O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
component O
, O
_RARE_ I-GENE
). O

During O
a O
disease O
remission O
there O
was O
an O
increase O
in O
_RARE_ I-GENE
secretion O
with O
urine O
, O
linked O
with O
_RARE_ I-GENE
( O
13 O
. O
1 I-GENE
- I-GENE
fold O
, O
P I-GENE
less O
than O
0 O
. O
001 O
). O

In O
metastasis O
- I-GENE
free O
patients O
, O
the O
best O
results O
were O
obtained O
with O
tumor I-GENE
diameters O
under O
2 I-GENE
cm O
regardless O
of O
their O
localization O
in O
lung O
tissue I-GENE
and O
with O
2 I-GENE
-- O
4 I-GENE
. O
9 O
cm O
tumors O
embedded O
in O
lung O
parenchyma O
. O

Two O
_RARE_ I-GENE
with O
_RARE_ I-GENE
anemia I-GENE
caused O
by O
_RARE_ I-GENE
isomerase I-GENE
deficiency O
developed O
a O
progressive O
neurological O
syndrome O
_RARE_ I-GENE
_RARE_ I-GENE
movements O
, O
tremor O
, O
pyramidal O
tract O
signs O
, O
and O
evidence O
of O
spinal O
motor O
neuron I-GENE
involvement O
. O

One O
extract O
with O
the O
lowest O
_RARE_ I-GENE
content O
was O
non O
- I-GENE
_RARE_ I-GENE
. O

In O
the O
10 O
patients O
with O
a O
more O
severe O
degree O
of O
_RARE_ I-GENE
the O
decrease O
in O
fat O
loss O
_RARE_ I-GENE
20 O
% O
and O
a O
close O
relationship O
was O
found O
( O
r O
= O
0 O
. O
84 O
, O
p O
less O
than O
0 O
. O
01 O
) O
between O
the O
extent O
of O
the O
fatty I-GENE
acid I-GENE
loss O
on O
placebo O
and O
the O
decrease O
of O
this O
loss O
on O
_RARE_ I-GENE
. O

_RARE_ I-GENE
diameters O
in O
infants O
and O
young O
children O
: O
_RARE_ I-GENE
angiographic O
data O
. O

The O
present O
investigation O
has O
revealed O
that O
the O
distribution O
of O
the O
main O
fatty I-GENE
acids O
in O
_RARE_ I-GENE
phospholipids O
is O
similar O
to O
their O
distribution O
in O
_RARE_ I-GENE
neutral O
lipids O
with O
the O
exception O
of O
_RARE_ I-GENE
fatty I-GENE
acid I-GENE
with O
14 O
carbon O
_RARE_ I-GENE
, O
occurring O
mainly O
in O
phospholipids O
. O

Since O
_RARE_ I-GENE
the O
frequency O
of O
potassium O
- I-GENE
induced O
ulceration O
has O
been O
low O
-- O
3 I-GENE
cases O
per O
100 O
000 O
patient O
- I-GENE
years O
of O
slow O
- I-GENE
release O
tablet O
use O
. O

_RARE_ I-GENE
caused O
_RARE_ I-GENE
and O
inhibited O
the O
_RARE_ I-GENE
response O
of O
peripheral O
blood O
lymphocytes O
to O
phytohemagglutinin I-GENE
and O
_RARE_ I-GENE
A I-GENE
_RARE_ I-GENE
. O

To O
test O
the O
feasibility O
of O
using O
liposomes O
to O
_RARE_ I-GENE
therapeutic O
agents O
to O
the O
lungs O
, O
the O
effect O
of O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
superoxide I-GENE
dismutase I-GENE
( O
SOD I-GENE
) O
or O
catalase I-GENE
on O
pulmonary O
oxygen O
toxicity O
was O
studied O
in O
rats O
. O

_RARE_ I-GENE
cell O
necrosis I-GENE
in O
_RARE_ I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
starvation O
. O

For O
comparison O
conventional O
heparin O
was O
used O
during O
18 O
_RARE_ I-GENE
in O
the O
same O
patients O
. O

_RARE_ I-GENE
acid I-GENE
( O
_RARE_ I-GENE
) O
and O
_RARE_ I-GENE
acid I-GENE
( O
_RARE_ I-GENE
) O
_RARE_ I-GENE
cholesterol I-GENE
_RARE_ I-GENE
in O
man O
. O

_RARE_ I-GENE
evoked O
field O
potentials O
were O
recorded O
from O
the O
_RARE_ I-GENE
_RARE_ I-GENE
formation O
( O
_RARE_ I-GENE
), O
central O
gray O
( O
CG I-GENE
) O
and O
_RARE_ I-GENE
cortex O
( O
_RARE_ I-GENE
), O
following O
_RARE_ I-GENE
doses O
of O
halothane O
in O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
rats O
. O

_RARE_ I-GENE
of O
the O
heart O
muscle O
in O
experimental O
myocardial O
infarct O
following O
physical O
training O

_RARE_ I-GENE
_RARE_ I-GENE
leads O
to O
the O
development O
of O
_RARE_ I-GENE
- I-GENE
reactivity O
of O
the O
true O
_RARE_ I-GENE
to O
noradrenaline O
and O
dopamine I-GENE
and O
triggers O
off O
changes O
in O
the O
regulation O
of O
the O
_RARE_ I-GENE
activity O
of O
these O
cells O
by O
catecholamines O
. O

_RARE_ I-GENE
is O
a O
diagnostic O
method O
_RARE_ I-GENE
assessment O
of O
ocular O
pulse O
curves O
and O
objective O
determination O
of O
blood O
pressures O
in O
the O
ophthalmic O
circulatory O
system O
( O
retinal O
and O
_RARE_ I-GENE
arterial O
blood O
pressures O
) O
simultaneously O
for O
both O
eyes O
, O
without O
dilatation O
of O
the O
_RARE_ I-GENE
. O

_RARE_ I-GENE
infections O
have O
long O
been O
suspected O
to O
be O
_RARE_ I-GENE
agents O
in O
a O
number O
of O
inner O
ear O
_RARE_ I-GENE
. O

55 O
+/- O
11 O
%), O
all O
other O
parameters O
showed O
a O
significant O
increase O
: O
RS I-GENE
index O
5 I-GENE
. O
4 I-GENE
+/- O
1 I-GENE
. O
4 I-GENE
_RARE_ I-GENE
to O
6 I-GENE
. O
0 O
+/- O
1 I-GENE
. O
7 O
_RARE_ I-GENE
( O
p O
less O
than O
0 O
. O
01 O
); O
_RARE_ I-GENE
6 I-GENE
. O
3 I-GENE
+/- O
0 O
. O
7 O
to O
6 I-GENE
. O
8 O
+/- O
0 O
. O
9 O
cm O
( O
p O
less O
than O
0 O
. O
001 O
); O
_RARE_ I-GENE
_RARE_ I-GENE
+/- O
151 O
ml O
to O
_RARE_ I-GENE
+/- O
_RARE_ I-GENE
ml O
( O
p O
less O
than O
0 O
. O
01 O
); O
_RARE_ I-GENE
_RARE_ I-GENE
+/- O
131 O
ml O
to O
_RARE_ I-GENE
+/- O
175 O
ml O
( O
p O
less O
than O
0 O
. O
001 O
); O
_RARE_ I-GENE
117 O
+/- O
57 O
ml O
to O
151 O
+/- O
77 O
ml O
( O
p O
less O
than O
0 O
. O
001 O
). O

_RARE_ I-GENE
analyses O
of O
this O
death O
revealed O
a O
significant O
decrease O
of O
the O
left O
ventricular O
( O
LV O
) O
end O
- I-GENE
diastolic O
volume O
index O
( O
_RARE_ I-GENE
) O
of O
21 O
ml O
/ I-GENE
m2 O
( O
36 O
% O
of O
normal O
). O

In O
group O
I I-GENE
adults O
both O
of O
these O
variables O
increased O
. O

_RARE_ I-GENE
80 O
did O
not O
have O
a O
direct O
_RARE_ I-GENE
or O
_RARE_ I-GENE
effect O
on O
either O
guinea O
pig O
_RARE_ I-GENE
or O
rat I-GENE
_RARE_ I-GENE
, O
however O
, O
it O
_RARE_ I-GENE
the O
contractions O
induced O
by O
acetylcholine I-GENE
, O
histamine O
, O
_RARE_ I-GENE
, O
5 I-GENE
- I-GENE
_RARE_ I-GENE
and O
carbachol O
in O
a O
dose O
- I-GENE
dependent I-GENE
manner O
. O

_RARE_ I-GENE
alcohol O
reaction O
profiles O
. O

_RARE_ I-GENE
in O
diabetes O
mellitus O
. O

The O
pharmacokinetics O
of O
each O
_RARE_ I-GENE
in O
serum I-GENE
and O
dermal O
, O
_RARE_ I-GENE
_RARE_ I-GENE
fluid O
were O
determined O
after O
oral O
doses O
of O
300 O
mg O
_RARE_ I-GENE
or O
100 O
mg O
_RARE_ I-GENE
on O
the O
_RARE_ I-GENE
day O
. O

A I-GENE
high O
degree O
of O
correlation O
in O
the O
sense O
of O
the O
_RARE_ I-GENE
_RARE_ I-GENE
of O
brain O
localization O
of O
_RARE_ I-GENE
syndromes O
was O
found O
. O

_RARE_ I-GENE
a O
UV O
detector O
set O
at O
_RARE_ I-GENE
nm O
or O
an O
_RARE_ I-GENE
( O
EC I-GENE
) O
detector O
set O
at O
a O
potential O
of O
+ I-GENE
0 O
. O
9 O
V I-GENE
( O
versus O
Ag I-GENE
/ I-GENE
_RARE_ I-GENE
/ I-GENE
3 I-GENE
M I-GENE
NaCl O
) O
was O
used O
to O
monitor O
the O
drug O
. O

35 O
patients O
with O
acute O
arterial O
_RARE_ I-GENE
[ O
27 O
] O
and O
graft O
_RARE_ I-GENE
[ O
8 O
], O
responsible O
for O
severe O
and O
recent O
ischemia O
, O
were O
treated O
by O
_RARE_ I-GENE
therapy O
( O
_RARE_ I-GENE
: O
1 I-GENE
000 O
units O
/ I-GENE
kg O
/ I-GENE
hour O
, O
and O
Lys O
_RARE_ I-GENE
). O

The O
mean O
transfer I-GENE
ratios O
of O
the O
drug O
into O
the O
genital O
tissues O
to O
the O
concentration O
in O
the O
uterine O
arterial O
blood O
were O
such O
that O
the O
transfer I-GENE
ratio O
into O
the O
_RARE_ I-GENE
_RARE_ I-GENE
was O
the O
highest O
, O
followed O
by O
the O
uterine O
cervix O
and O
the O
_RARE_ I-GENE
, O
and O
that O
into O
the O
_RARE_ I-GENE
was O
the O
lowest O
with O
about O
1 I-GENE
/ I-GENE
2 I-GENE
that O
into O
the O
_RARE_ I-GENE
_RARE_ I-GENE
. O

We O
conclude O
that O
_RARE_ I-GENE
hormones O
reduce O
HDL I-GENE
- I-GENE
cholesterol I-GENE
concentrations O
and O
the O
HDL2 I-GENE
- I-GENE
cholesterol I-GENE
_RARE_ I-GENE
, O
possibly O
by O
enhancing O
hepatic I-GENE
_RARE_ I-GENE
lipase I-GENE
activity O
. O

Because O
of O
its O
wide O
spectrum O
of O
activity O
particularly O
against O
_RARE_ I-GENE
resistant O
strains O
of O
H I-GENE
. O
influenzae O
and O
because O
of O
its O
good O
tolerance O
_RARE_ I-GENE
is O
very O
useful O
in O
treatment O
of O
respiratory O
tract O
infections O
in O
children O
. O

_RARE_ I-GENE
_RARE_ I-GENE
weight O
bearing O
under O
various O
_RARE_ I-GENE
conditions O
in O
independently O
ambulatory O
patients O
with O
_RARE_ I-GENE
. O

_RARE_ I-GENE
factor I-GENE
correlated O
well O
with O
hemodynamic O
data O
for O
RV O
/ I-GENE
LV O
systolic O
pressure O
ratios O
( O
r O
= O
0 O
. O
93 O
, O
p O
less O
than O
0 O
. O
001 O
) O
for O
normalized O
_RARE_ I-GENE
pressure O
differences O
( O
r O
= O
- I-GENE
0 O
. O
95 O
, O
p O
less O
than O
0 O
. O
001 O
). O

The O
effective O
and O
low O
toxic O
dose O
_RARE_ I-GENE
of O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
should O
be O
investigated O
further O
. O

Furthermore O
, O
the O
initial O
plasma I-GENE
retinol I-GENE
level O
in O
conjunction O
with O
_RARE_ I-GENE
was O
found O
to O
be O
even O
lower O
in O
12 O
patients O
( O
35 O
. O
1 I-GENE
micrograms O
dl O
- I-GENE
1 I-GENE
, O
3 I-GENE
. O
7 O
mg O
dl O
- I-GENE
1 I-GENE
) O
who O
subsequently O
had O
cancer O
recurrence O
than O
in O
those O
who O
remained O
free O
of O
apparent O
cancer O
( O
44 I-GENE
. O
5 I-GENE
micrograms O
dl O
- I-GENE
1 I-GENE
, O
4 I-GENE
. O
6 I-GENE
mg O
dl O
- I-GENE
1 I-GENE
). O

The O
results O
indicate O
that O
: O
1 I-GENE
) O
the O
initial O
response O
to O
_RARE_ I-GENE
_RARE_ I-GENE
according O
to O
previous O
_RARE_ I-GENE
and O
_RARE_ I-GENE
experience O
, O
2 I-GENE
) O
although O
the O
circadian O
rhythm O
of O
cortisol O
was O
either O
altered O
or O
disrupted O
during O
_RARE_ I-GENE
, O
such O
_RARE_ I-GENE
were O
not O
influenced O
by O
type I-GENE
of O
_RARE_ I-GENE
and O
3 I-GENE
) O
_RARE_ I-GENE
_RARE_ I-GENE
may O
_RARE_ I-GENE
increase O
cortisol O
concentrations O
in O
_RARE_ I-GENE
. O

This O
laser O
provided O
sufficient O
power O
in O
an O
amniotic I-GENE
fluid O
medium O
to O
_RARE_ I-GENE
placental I-GENE
vessels O
as O
large O
as O
7 O
mm O
in O
diameter O
within O
6 I-GENE
_RARE_ I-GENE
at O
a O
power O
density I-GENE
of O
2000 O
W I-GENE
/ I-GENE
cm2 O
. O

On O
d O
112 O
, O
progesterone I-GENE
was O
higher O
( O
P I-GENE
less O
than O
. O
05 O
) O
in O
_RARE_ I-GENE
heifers O
than O
in O
other O
treatment O
groups O
. O

_RARE_ I-GENE
Japanese O
_RARE_ I-GENE
were O
_RARE_ I-GENE
exposed O
to O
_RARE_ I-GENE
ppm O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
as O
particulate O
_RARE_ I-GENE
oxide I-GENE
( O
_RARE_ I-GENE
) O
in O
their O
diet O
from O
_RARE_ I-GENE
to O
75 O
days O
of O
age O
. O

This O
study O
indicated O
that O
the O
Japanese O
_RARE_ I-GENE
was O
less O
sensitive O
to O
particulate O
_RARE_ I-GENE
exposure O
than O
_RARE_ I-GENE
treated O
_RARE_ I-GENE
. O

Plasma I-GENE
and O
bladder O
_RARE_ I-GENE
concentration O
were O
measured O
following O
_RARE_ I-GENE
DDP O
, O
and O
also O
histopathological O
examination O
, O
_RARE_ I-GENE
, O
complete O
blood O
count O
and O
blood O
chemistry O
were O
performed O
in O
order O
to O
_RARE_ I-GENE
the O
toxicity O
of O
_RARE_ I-GENE
DDP O
. O

_RARE_ I-GENE
_RARE_ I-GENE
of O
_RARE_ I-GENE
carcinoma O
- I-GENE
256 O
in O
Sprague O
- I-GENE
Dawley O
rats O
by O
means O
of O
99mTc O
- I-GENE
labelled O
monocytes O
. O

These O
results O
were O
compared O
with O
those O
obtained O
in O
- I-GENE
D I-GENE
mothers O
and O
_RARE_ I-GENE
, O
after O
giving O
the O
mothers O
an O
oral O
_RARE_ I-GENE
( O
10 O
i O
. O
_RARE_ I-GENE
. O
vitamin O
D3 I-GENE
/ I-GENE
day O
) O
during O
the O
period O
of O
_RARE_ I-GENE
( O
20 O
days O
). O

_RARE_ I-GENE
eyes O
were O
removed O
and O
held O
in O
temperature O
- I-GENE
regulated O
_RARE_ I-GENE
and O
_RARE_ I-GENE
with O
saline O
. O

_RARE_ I-GENE
birth O
, O
there O
were O
a O
few O
_RARE_ I-GENE
adrenergic I-GENE
nerves O
and O
_RARE_ I-GENE
low O
ovarian O
NE O
levels O
. O

_RARE_ I-GENE
changes O
in O
the O
heart O
rate O
of O
the O
premature O
fetus O
during O
_RARE_ I-GENE
with O
the O
beta I-GENE
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE

Since O
_RARE_ I-GENE
1980 O
to O
_RARE_ I-GENE
1983 O
we O
have O
treated O
32 O
patients O
with O
ovarian O
cancer O
. O

The O
results O
suggest O
that O
the O
calcium O
antagonist O
, O
diltiazem O
, O
may O
modify O
the O
effects O
of O
isoflurane O
on O
myocardial O
function O
. O

_RARE_ I-GENE
arrhythmias O
-- O
_RARE_ I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
I I-GENE
is O
_RARE_ I-GENE
for O
storage O
and O
re O
- I-GENE
reading O
. O

Treatment O
with O
_RARE_ I-GENE
and O
_RARE_ I-GENE
failed O
to O
inhibit O
the O
raised O
serum I-GENE
_RARE_ I-GENE
levels O
. O

40 I-GENE
, O
000 O
). O

The O
Cox O
_RARE_ I-GENE
_RARE_ I-GENE
model O
was O
applied O
to O
the O
data O
in O
order O
to O
determine O
the O
prognostic O
factors I-GENE
for O
long O
- I-GENE
term O
survival O
. O

This O
suggests O
that O
mechanisms O
other O
than O
an O
excessive O
increase O
in O
myocardial O
oxygen O
demand O
may O
be O
responsible O
for O
the O
many O
episodes O
occurring O
outside O
the O
hospital O
. O

_RARE_ I-GENE
of O
remission O
in O
advanced O
gastric O
cancer O
patients O
responding O
to O
sequential O
dose O
of O
_RARE_ I-GENE
and O
5 I-GENE
- I-GENE
FU O

These O
data O
showed O
: O
that O
progesterone I-GENE
secretion O
is O
_RARE_ I-GENE
throughout O
the O
human I-GENE
luteal O
phase O
, O
with O
maximum O
frequency O
in O
the O
mid O
- I-GENE
luteal O
phase O
; O
that O
during O
the O
mid O
- I-GENE
luteal O
phase O
most O
subjects O
had O
progesterone I-GENE
levels O
both O
above O
and O
below O
currently O
accepted O
_RARE_ I-GENE
_RARE_ I-GENE
; O
the O
use O
of O
a O
single O
measurement O
of O
progesterone I-GENE
in O
the O
mid O
- I-GENE
luteal O
phase O
is O
not O
always O
a O
reliable O
indicator O
of O
ovulation O
; O
a O
threshold O
greater O
than O
20 O
nmol O
/ I-GENE
l O
may O
yield O
an O
_RARE_ I-GENE
number O
of O
false O
negative O
results O
. O

The O
fast O
real O
- I-GENE
time O
digital O
processing O
of O
the O
N2 O
and O
flow O
signals O
incorporated O
_RARE_ I-GENE
, O
delay O
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
for O
the O
effects O
of O
changes O
in O
gas O
composition O
and O
temperature O
. O

This O
slope O
tended O
to O
be O
higher O
( O
approximately O
1 I-GENE
. O
6 I-GENE
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
) O
for O
L1 I-GENE
= O
L2 O
greater O
than O
80 O
_RARE_ I-GENE
. O

_RARE_ I-GENE
reactivity O
was O
significantly O
reduced O
after O
the O
nifedipine O
_RARE_ I-GENE
, O
the O
_RARE_ I-GENE
mean O
_RARE_ I-GENE
concentration O
causing O
a O
35 O
% O
fall O
in O
specific I-GENE
airway O
conductance I-GENE
, O
_RARE_ I-GENE
from O
5 I-GENE
. O
0 O
to O
10 O
. O
9 O
mg O
/ I-GENE
ml O
of O
histamine O
( O
p O
less O
than O
0 O
. O
05 O
). O

_RARE_ I-GENE
doses O
of O
vitamin O
B6 I-GENE
administered O
to O
_RARE_ I-GENE
women O
have O
been O
reported O
to O
suppress O
plasma I-GENE
prolactin I-GENE
. O

There O
was O
a O
significant O
but O
similar O
elevation O
of O
mean O
O2 O
uptake O
during O
40 I-GENE
min O
_RARE_ I-GENE
by O
13 O
. O
6 I-GENE
% O
in O
both O
the O
fasted O
( O
p O
less O
than O
0 O
. O
001 O
) O
and O
fed O
state O
( O
p O
less O
than O
0 O
. O
001 O
). O

National O
_RARE_ I-GENE
of O
Health O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
. O

In O
controls O
, O
most O
of O
the O
output O
from O
the O
_RARE_ I-GENE
occurred O
during O
type I-GENE
I I-GENE
activity O
( O
73 O
+/- O
14 O
%). O

_RARE_ I-GENE
attenuation O
of O
the O
N1 O
- I-GENE
P2 I-GENE
and O
baseline O
- I-GENE
P2 I-GENE
amplitude O
of O
the O
probe O
_RARE_ I-GENE
was O
observed O
when O
the O
probe O
stimulus O
was O
presented O
to O
the O
right O
ear O
and O
the O
_RARE_ I-GENE
material O
presented O
to O
the O
left O
ear O
than O
when O
the O
opposite O
stimulation O
arrangement O
was O
used O
. O

Twenty O
- I-GENE
five O
patients O
( O
80 O
, O
6 I-GENE
%) O
with O
mixed O
neoplasms O
were O
operated O
on O
by O
total O
conservative O
_RARE_ I-GENE
( O
T I-GENE
. O
C I-GENE
. O
P I-GENE
_RARE_ I-GENE
3 I-GENE
( O
9 O
, O
7 O
%) O
by O
S I-GENE
. O
P I-GENE
. O
and O
3 I-GENE
( O
9 O
, O
7 O
%) O
by O
_RARE_ I-GENE
. O

The O
comparisons O
revealed O
that O
female O
_RARE_ I-GENE
- I-GENE
suicide O
_RARE_ I-GENE
were O
more O
likely O
than O
female O
_RARE_ I-GENE
- I-GENE
suicide O
victims O
to O
live O
in O
mobile O
_RARE_ I-GENE
, O
_RARE_ I-GENE
their O
_RARE_ I-GENE
or O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
, O
have O
their O
_RARE_ I-GENE
_RARE_ I-GENE
discovered O
, O
_RARE_ I-GENE
a O
suicide O
_RARE_ I-GENE
, O
_RARE_ I-GENE
on O
a O
_RARE_ I-GENE
, O
and O
be O
depressed O
, O
but O
are O
less O
likely O
than O
female O
_RARE_ I-GENE
- I-GENE
suicide O
victims O
to O
live O
with O
a O
_RARE_ I-GENE
. O

_RARE_ I-GENE
- I-GENE
free O
rabbits O
given O
mouse I-GENE
CRF I-GENE
- I-GENE
_RARE_ I-GENE
showed O
values O
quite O
different O
from O
control O
animals O
for O
most O
parameters O
, O
indicating O
_RARE_ I-GENE
of O
mouse I-GENE
CRF I-GENE
_RARE_ I-GENE
to O
' O
_RARE_ I-GENE
' O
rabbits O
. O

The O
weak O
relationships O
between O
F I-GENE
and O
Zn I-GENE
to O
Mg I-GENE
clearly O
have O
no O
significant O
effect O
on O
the O
contents O
of O
these O
elements O
in O
bone O
. O

_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
load O
was O
calculated O
using O
a O
model O
of O
the O
_RARE_ I-GENE
of O
the O
trunk O
_RARE_ I-GENE
system O
. O

Diagnosis O
: O
progressive O
_RARE_ I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
was O
associated I-GENE
with O
a O
frontal O
_RARE_ I-GENE
of O
similar O
latency O
_RARE_ I-GENE
the O
hypothesis O
of O
a O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
. O

Although O
no O
differences O
were O
noted O
in O
the O
decrease O
in O
platelet I-GENE
counts O
between O
the O
two O
groups O
, O
fibrinogen I-GENE
levels O
and O
alpha I-GENE
2 I-GENE
- I-GENE
_RARE_ I-GENE
levels O
declined O
less O
_RARE_ I-GENE
in O
the O
antithrombin I-GENE
- I-GENE
treated O
group O
. O

_RARE_ I-GENE
of O
_RARE_ I-GENE
_RARE_ I-GENE
in O
the O
diagnosis O
of O
_RARE_ I-GENE
_RARE_ I-GENE
. O

Factors O
influencing O
semen O
characteristics O
in O
young O
_RARE_ I-GENE
_RARE_ I-GENE
in O
a O
_RARE_ I-GENE
environment O
were O
studied O
. O

[ O
14C O
_RARE_ I-GENE
beta I-GENE
- I-GENE
_RARE_ I-GENE
, O
its O
distribution O
after O
administration O
by O
various O
routes O
to O
cats O
, O
and O
the O
effects O
of O
monoamine I-GENE
oxidase I-GENE
inhibitors O
. O

All O
_RARE_ I-GENE
_RARE_ I-GENE
a O
total O
of O
1 I-GENE
. O
4 I-GENE
L I-GENE
of O
water O
during O
the O
_RARE_ I-GENE
. O

The O
rates O
of O
total O
energy O
use O
( O
mean O
+/- O
SD O
= O
39 O
. O
3 I-GENE
+/- O
1 I-GENE
. O
2 I-GENE
vs O
35 O
. O
7 O
+/- O
1 I-GENE
. O
3 I-GENE
_RARE_ I-GENE
X I-GENE
min O
- I-GENE
1 I-GENE
; O
P I-GENE
less O
than O
0 O
. O
05 O
) O
were O
significantly O
higher O
at O
- I-GENE
10 O
degrees O
C I-GENE
than O
at O
22 O
degrees O
C I-GENE
. O

Clinical O
aspects O
and O
therapy O

Following O
seven O
days O
' O
incubation O
both O
at O
20 O
degrees O
C I-GENE
and O
28 O
degrees O
C I-GENE
, O
_RARE_ I-GENE
. O
_RARE_ I-GENE
_RARE_ I-GENE
. O
was O
capable O
of O
_RARE_ I-GENE
the O
virus I-GENE
. O

Blood O
eosinophils O
in O
patients O
with O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
. O

The O
_RARE_ I-GENE
proton I-GENE
of O
T3 O
in O
the O
_RARE_ I-GENE
. O
T I-GENE
12 O
- I-GENE
mer I-GENE
and O
_RARE_ I-GENE
in O
the O
_RARE_ I-GENE
. O
N I-GENE
12 O
- I-GENE
mer I-GENE
helix I-GENE
, O
which O
are O
associated I-GENE
with O
the O
modification O
site I-GENE
, O
_RARE_ I-GENE
at O
unusually O
high O
field O
( O
8 O
. O
5 I-GENE
to O
9 O
. O
0 O
ppm O
) O
compared O
to O
_RARE_ I-GENE
_RARE_ I-GENE
in O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
base O
pairs O
( O
12 O
. O
5 I-GENE
to O
14 O
. O
5 I-GENE
ppm O
). O

The O
_RARE_ I-GENE
is O
made O
that O
specific I-GENE
sub O
- I-GENE
groups O
of O
_RARE_ I-GENE
need O
to O
be O
identified O
and O
may O
_RARE_ I-GENE
specialized O
intervention O
strategies O
. O

There O
was O
no O
correlation O
between O
_RARE_ I-GENE
status O
and O
clinical O
status O
, O
_RARE_ I-GENE
measurements O
, O
salivary I-GENE
and O
serum I-GENE
lysozyme I-GENE
levels O
or O
rates O
of O
respiratory O
tract O
_RARE_ I-GENE
with O
P I-GENE
. O
aeruginosa I-GENE
and O
S I-GENE
. O
aureus I-GENE
. O

There O
was O
no O
correlation O
between O
_RARE_ I-GENE
status O
and O
clinical O
status O
, O
_RARE_ I-GENE
measurements O
, O
salivary I-GENE
and O
serum I-GENE
lysozyme I-GENE
levels O
or O
rates O
of O
respiratory O
tract O
_RARE_ I-GENE
with O
P I-GENE
. O
aeruginosa I-GENE
and O
S I-GENE
. O
aureus I-GENE
. O

_RARE_ I-GENE
increased O
3 I-GENE
. O
5 I-GENE
% O
( O
P I-GENE
less O
than O
. O
10 O
) O
and O
feed O
conversion O
improved O
5 I-GENE
. O
9 O
% O
( O
P I-GENE
less O
than O
. O
07 O
) O
in O
steers O
fed O
. O
28 O
% O
AS I-GENE
- I-GENE
_RARE_ I-GENE
compared O
with O
gain O
and O
feed O
conversion O
of O
the O
control O
steers O
. O

_RARE_ I-GENE
_RARE_ I-GENE
development O
of O
the O
_RARE_ I-GENE
cortex O
in O
the O
rat I-GENE
. O

_RARE_ I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
in O
the O
methylation O
of O
pineal O
_RARE_ I-GENE
compounds O
in O
adult O
male O
_RARE_ I-GENE
hamsters O
, O
kept O
under O
natural O
conditions O
. O

The O
transit O
time O
was O
significantly O
shortened O
. O

Among O
the O
patients O
_RARE_ I-GENE
1 I-GENE
- I-GENE
2 I-GENE
- I-GENE
3 I-GENE
, O
81 O
% O
had O
a O
good O
out O
_RARE_ I-GENE
without O
any O
neurological O
abnormality O
, O
among O
the O
patients O
_RARE_ I-GENE
4 I-GENE
- I-GENE
5 I-GENE
, O
only O
27 O
% O
had O
a O
_RARE_ I-GENE
out O
_RARE_ I-GENE
. O

_RARE_ I-GENE
of O
acid I-GENE
_RARE_ I-GENE
of O
peripheral O
blood O
_RARE_ I-GENE
in O
focal I-GENE
and O
segmental O
pneumonia O
in O
children O

Comparative O
studies O
of O
the O
antithrombin I-GENE
III I-GENE
level O
and O
plasminogen I-GENE
activator I-GENE
activity O
in O
patients O
with O
_RARE_ I-GENE

We O
also O
observed O
that O
the O
predictive O
ability O
of O
the O
selected O
_RARE_ I-GENE
and O
_RARE_ I-GENE
increased O
considerably O
from O
_RARE_ I-GENE
to O
1982 O
. O

_RARE_ I-GENE
between O
cellular O
electrical O
activity O
and O
cardiac O
mechanical O
activity O
in O
man O
, O
the O
dog O
and O
the O
rabbit I-GENE

Treatment O
of O
_RARE_ I-GENE
' O
s O
disease O
. O

_RARE_ I-GENE
of O
the O
_RARE_ I-GENE
display O
of O
an O
_RARE_ I-GENE
. O

Is O
_RARE_ I-GENE
' O
for O
_RARE_ I-GENE
_RARE_ I-GENE
fever O
_RARE_ I-GENE
specific I-GENE
? O

Renal O
excretion O
of O
_RARE_ I-GENE
in O
normal O
and O
_RARE_ I-GENE
subjects O
. O

_RARE_ I-GENE
with O
the O
clinical O
and O
experimental O
use O
of O
_RARE_ I-GENE
- I-GENE
I I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
of O
_RARE_ I-GENE
and O
_RARE_ I-GENE
by O
_RARE_ I-GENE
_RARE_ I-GENE
. O

Evaluation O
of O
thyroid I-GENE
function O
. O

The O
effect O
of O
a O
tissue I-GENE
_RARE_ I-GENE
, O
vitamin O
A I-GENE
and O
nonspecific O
gamma I-GENE
- I-GENE
globulin I-GENE
on O
the O
blood O
clearance O
in O
rabbits O

HL I-GENE
- I-GENE
A I-GENE
antibodies I-GENE
in O
_RARE_ I-GENE
patients O

_RARE_ I-GENE
of O
fine O
structure O
of O
the O
guinea O
pig O
organ O
of O
_RARE_ I-GENE
after O
electron O
microscopic O
silver O
staining O

_RARE_ I-GENE
metabolism O
in O
hemorrhagic O
- I-GENE
hypotensive O
shock I-GENE

They O
also O
discuss O
the O
existing O
_RARE_ I-GENE
. O

_RARE_ I-GENE
of O
_RARE_ I-GENE
in O
a O
_RARE_ I-GENE
smooth I-GENE
muscle O
. O

Studies O
on O
alcoholic O
liver O
injury O
. O

_RARE_ I-GENE
control O
of O
coronary O
circulation O
in O
the O
dog O
. O

Evidence O
for O
two O
distinctive O
clinical O
, O
epidemiological O
, O
and O
_RARE_ I-GENE
types O
of O
infection O
. O

_RARE_ I-GENE
light I-GENE
- I-GENE
induced O
_RARE_ I-GENE
formation O
in O
human I-GENE
skin O
. O

_RARE_ I-GENE
from O
a O
vaccine O
. O

To O
the O
problem O
of O
the O
stimulation O
of O
the O
growth I-GENE
of O
_RARE_ I-GENE
tumors O
of O
animals O
previously O
treated O
with O
_RARE_ I-GENE
antibiotics O

Assessment O
of O
nutrient O
media O
in O
the O
diagnosis O
of O
_RARE_ I-GENE

_RARE_ I-GENE
resin O
for O
the O
treatment O
of O
the O
_RARE_ I-GENE
of O
renal O
failure O
. O

Value O
of O
the O
EMG O
in O
the O
diagnosis O
of O
a O
cardiomyopathy O
associated I-GENE
with O
a O
_RARE_ I-GENE
_RARE_ I-GENE
. O

D I-GENE
. O

Prevention O
of O
maternal I-GENE
_RARE_ I-GENE
sensitization O
: O
anti I-GENE
- I-GENE
_RARE_ I-GENE
immune I-GENE
globulin I-GENE
. O

_RARE_ I-GENE
levels O
in O
infant O
hypothyroidism O
. O

_RARE_ I-GENE
fluid O
transferrin I-GENE
II I-GENE
studies O
in O
ischemic O
disorders O
of O
the O
central O
nervous O
system O
. O

High O
_RARE_ I-GENE
of O
D I-GENE
- I-GENE
_RARE_ I-GENE
in O
pulmonary O
_RARE_ I-GENE

_RARE_ I-GENE
relation O
between O
serum I-GENE
IgG I-GENE
concentration O
and O
glucose O
and O
_RARE_ I-GENE
absorption O
in O
_RARE_ I-GENE
African O
adults O
. O

_RARE_ I-GENE
of O
platelet I-GENE
function O
in O
chronic O
myeloid O
leukemias O

The O
effect O
of O
_RARE_ I-GENE
on O
sodium O
- I-GENE
potassium O
- I-GENE
activated I-GENE
ATPase I-GENE
, O
sodium O
, O
and O
_RARE_ I-GENE
in O
cortex O
. O

Effect O
of O
immune I-GENE
lymphocytes O
and O
of O
rabbit I-GENE
- I-GENE
anti I-GENE
- I-GENE
lymphocyte I-GENE
globulin I-GENE
( O
_RARE_ I-GENE
) O
on O
infected O
macrophages O
exposed O
to O
increased O
incubation O
temperature O
in O
vitro O
. O

_RARE_ I-GENE
cycle O
in O
white O
rats O
in O
the O
low O
and O
high O
_RARE_ I-GENE
of O
_RARE_ I-GENE

_RARE_ I-GENE
of O
_RARE_ I-GENE
fed O
a O
low O
protein I-GENE
maintenance O
diet O
. O

Studies O
on O
the O
organic O
matrix I-GENE
of O
human I-GENE
ear O
_RARE_ I-GENE

A I-GENE
medical O
- I-GENE
_RARE_ I-GENE
review O

_RARE_ I-GENE
and O
sex I-GENE
structure O
of O
the O
natural O
population O
of O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
to O
_RARE_ I-GENE
induced O
by O
_RARE_ I-GENE
after O
subtotal O
ablation O
of O
the O
pancreas O
. O

_RARE_ I-GENE
D3 I-GENE
and O
calcium O
absorption O
in O
the O
chick I-GENE
. O

The O
incidence O
of O
tumours O
in O
young O
chickens O
. O

Laboratory O
aspects O
with O
particular O
reference O
to O
chemotherapy O
and O
control O
. O

Their O
effect O
on O
the O
guinea O
pig O
vas O
deferens O
. O

_RARE_ I-GENE
and O
growth I-GENE
. O

Effect O
of O
variations O
in O
time O
interval O
between O
treatment O
with O
BCG O
and O
_RARE_ I-GENE
dust O
on O
translocation O
of O
_RARE_ I-GENE
dust O
from O
the O
lungs O
to O
their O
regional O
lymph O
nodes O
. O

_RARE_ I-GENE
action O
of O
a O
new O
antibiotic O
- I-GENE
_RARE_ I-GENE
association O
used O
for O
_RARE_ I-GENE
in O
_RARE_ I-GENE

_RARE_ I-GENE
- I-GENE
physiological O
experiment O

_RARE_ I-GENE
_RARE_ I-GENE
findings O
in O
the O
_RARE_ I-GENE
body O
of O
the O
horse I-GENE

_RARE_ I-GENE
glutathione I-GENE
reductase I-GENE
deficiency O
and O
disorder O
of O
glutathione I-GENE
synthesis O
in O
the O
erythrocyte I-GENE

Studies O
on O
swine O
_RARE_ I-GENE
. O

_RARE_ I-GENE
of O
_RARE_ I-GENE
in O
laboratory O
mice O

_RARE_ I-GENE
effect O
on O
the O
cytochrome I-GENE
oxidase I-GENE
activity O

_RARE_ I-GENE
of O
colon O
carcinoma O
to O
the O
_RARE_ I-GENE
. O

_RARE_ I-GENE
of O
_RARE_ I-GENE
cells O
: O
study O
in O
rats O
after O
administration O
of O
_RARE_ I-GENE
. O

_RARE_ I-GENE
- I-GENE
beta I-GENE
- I-GENE
1 I-GENE
lipoprotein I-GENE
and O
early I-GENE
detection O
of O
risk O
factors I-GENE
for O
coronary O
heart O
disease O
. O

_RARE_ I-GENE
influencing O
inhibitors O
of O
the O
colony I-GENE
- I-GENE
stimulating I-GENE
factor I-GENE
( O
CSF I-GENE
). O

_RARE_ I-GENE
of O
action O
potentials O
in O
_RARE_ I-GENE
slow O
muscle O
fibres O
_RARE_ I-GENE
by O
botulinum I-GENE
toxin I-GENE
. O

An O
automated O
method O
for O
the O
quantitative O
analysis O
of O
the O
_RARE_ I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
and O
_RARE_ I-GENE
in O
cerebrospinal O
fluid O
( O
CSF I-GENE
) O
was O
used O
to O
analyze O
CSF I-GENE
samples O
from O
37 O
patients O
with O
central O
nervous O
system O
( O
CNS O
) O
tumors O
and O
from O
13 O
patients O
without O
tumors O
. O

I I-GENE
. O

_RARE_ I-GENE
and O
the O
drug O
- I-GENE
induced O
effects O
on O
motility O
. O

_RARE_ I-GENE
resembling O
_RARE_ I-GENE
in O
normal O
and O
neoplastic O
_RARE_ I-GENE
glands O
of O
dogs O
. O

_RARE_ I-GENE
and O
induced O
_RARE_ I-GENE
in O
_RARE_ I-GENE
hemisphere O
monkeys O
. O

A I-GENE
study O
in O
vivo O
of O
adrenergic I-GENE
receptors I-GENE
in O
the O
_RARE_ I-GENE
and O
in O
the O
internal O
and O
_RARE_ I-GENE
of O
the O
cat O
. O

_RARE_ I-GENE
_RARE_ I-GENE
cyst O
of O
the O
middle I-GENE
_RARE_ I-GENE
demonstrated O
by O
positive O
99mTc O
_RARE_ I-GENE
. O

Effects O
of O
estrogen I-GENE
and O
glucocorticoids O
on O
the O
adrenal O
development O
of O
the O
fetus O
. O

_RARE_ I-GENE
and O
_RARE_ I-GENE
content O
in O
pregnant O
women O
and O
in O
women O
with O
certain O
_RARE_ I-GENE
diseases O

Effect O
of O
noise O
on O
CO I-GENE
- I-GENE
induced O
increases O
of O
_RARE_ I-GENE
and O
_RARE_ I-GENE
activity O
in O
the O
plasma I-GENE
of O
rats O

_RARE_ I-GENE
of O
calcium O
metabolism O
. O

On O
the O
transport O
of O
mucus O
and O
its O
_RARE_ I-GENE
_RARE_ I-GENE
in O
_RARE_ I-GENE
systems O
. O

A I-GENE
_RARE_ I-GENE
description O
of O
the O
osmotic O
_RARE_ I-GENE
coefficient O
with O
application O
to O
the O
pore I-GENE
theory O
of O
_RARE_ I-GENE
exchange I-GENE
. O

_RARE_ I-GENE
of O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
in O
the O
horse I-GENE

Abnormal O
characteristics O
and O
_RARE_ I-GENE
in O
_RARE_ I-GENE
_RARE_ I-GENE

_RARE_ I-GENE
_RARE_ I-GENE
in O
laboratory O
animal O
medicine O
. O

_RARE_ I-GENE
common O
to O
_RARE_ I-GENE
and O
_RARE_ I-GENE

Clinical O
course O
and O
nursing O
care O
of O
patients O
with O
_RARE_ I-GENE
ulcer O
-- O
use O
of O
_RARE_ I-GENE
_RARE_ I-GENE
with O
_RARE_ I-GENE
_RARE_ I-GENE

On O
parents O

From O
the O
_RARE_ I-GENE
_RARE_ I-GENE
Cross O
activities O

Effects O
of O
_RARE_ I-GENE
on O
the O
family I-GENE

Treatment O
and O
care O
of O
adult O
diabetes O
mellitus O
without O
_RARE_ I-GENE

Re O
- I-GENE
examining O
_RARE_ I-GENE
( O
toluene O
) O
as O
a O
treatment O
for O
_RARE_ I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
between O
cells O
of O
the O
human I-GENE
_RARE_ I-GENE
organ O
. O

_RARE_ I-GENE
of O
the O
month O
. O

_RARE_ I-GENE
as O
_RARE_ I-GENE
materials O

Hodgkin O
' O
s O
disease O
. O

Value O
of O
_RARE_ I-GENE
and O
antithrombin I-GENE
3 I-GENE
in O
the O
assessment O
of O
liver O
function O
. O

_RARE_ I-GENE
peroxidase I-GENE
in O
human I-GENE
red I-GENE
cells O
in O
health O
and O
disease O
. O

_RARE_ I-GENE
response O
of O
_RARE_ I-GENE
tissues O
to O
_RARE_ I-GENE
and O
aluminum O
chloride O
solutions O
as O
tissue I-GENE
displacement I-GENE
materials O
. O

Changes O
following O
periodontal O
surgery O
. O

_RARE_ I-GENE
pH O
, O
H I-GENE
ion O
_RARE_ I-GENE
and O
H I-GENE
ion O
permeability I-GENE
coefficient O
in O
_RARE_ I-GENE
toe O
muscle O
. O

_RARE_ I-GENE
studies O
on O
SF I-GENE
- I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
concerning O
medical O
care O

_RARE_ I-GENE
: O
_RARE_ I-GENE
complete O
heart O
block O
following O
surgery O
of O
congenital O
heart O
defects O

_RARE_ I-GENE
of O
synthesis O
of O
the O
rheumatoid I-GENE
factor I-GENE
in O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
studies O

_RARE_ I-GENE
of O
the O
timing O
of O
_RARE_ I-GENE
in O
the O
His O
bundle O
recordings O
. O

_RARE_ I-GENE
_RARE_ I-GENE
formation O
by O
_RARE_ I-GENE
cells O
at O
the O
_RARE_ I-GENE
junction O
of O
the O
human I-GENE
eye O
. O

Blood O
platelets O
, O
coagulation I-GENE
factors I-GENE
and O
morphologic O
organ O
changes O
following O
_RARE_ I-GENE
shock I-GENE
in O
rhesus I-GENE
monkeys O

Cell O
viability O
and O
lysosomal I-GENE
enzymes O

State O
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
of O
nursing O
-- O
R I-GENE
. O
N I-GENE
., O
1972 O
. O

Further O
investigation O
on O
the O
chemotactic O
influence O
of O
thymic I-GENE
hormone I-GENE
on O
lymphocytes O

1 I-GENE
, O
3 I-GENE
- I-GENE
_RARE_ I-GENE
( O
2 I-GENE
- I-GENE
_RARE_ I-GENE
)- I-GENE
1 I-GENE
- I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
and O
other O
_RARE_ I-GENE
in O
cancer O
treatment O
: O
a O
review O
. O

_RARE_ I-GENE
following O
lung O
abscess O
in O
the O
renal O
transplant O
patient O
. O

_RARE_ I-GENE
significant O
colour I-GENE
changes O
in O
_RARE_ I-GENE
_RARE_ I-GENE
probably O
associated I-GENE
with O
a O
_RARE_ I-GENE
- I-GENE
like I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
relationships O
and O
the O
development O
phase O
affected O
. O

A I-GENE
short O
history O
of O
_RARE_ I-GENE
in O
_RARE_ I-GENE
, O
_RARE_ I-GENE
. O

_RARE_ I-GENE
graft O
irradiation O
as O
an O
_RARE_ I-GENE
to O
_RARE_ I-GENE
_RARE_ I-GENE
. O

Letter O
: O
Salmonella I-GENE
detection O

Role O
of O
_RARE_ I-GENE
in O
the O
manifestation O
of O
_RARE_ I-GENE
virulence I-GENE

The O
effect O
of O
_RARE_ I-GENE
sera O
on O
formation O
of O
transplantation O
and O
anti I-GENE
- I-GENE
infection O
immunity O
in O
mice O

_RARE_ I-GENE
_RARE_ I-GENE
of O
_RARE_ I-GENE
_RARE_ I-GENE
. O
e O
. O
_RARE_ I-GENE
m I-GENE
. O
d O
. O

_RARE_ I-GENE
of O
_RARE_ I-GENE
of O
Klebsiella I-GENE
bacilli O
. O

_RARE_ I-GENE
afferents O
to O
the O
_RARE_ I-GENE
cortex O
of O
the O
_RARE_ I-GENE
monkey I-GENE
. O

Mechanism O
of O
_RARE_ I-GENE
in O
vaccination O
with O
_RARE_ I-GENE
- I-GENE
dependent I-GENE
mutants I-GENE
of O
_RARE_ I-GENE
and O
_RARE_ I-GENE
. O

Resistance O
pattern O
of O
Mycobacterium O
tuberculosis O
( O
H I-GENE
37 O
_RARE_ I-GENE
) O
to O
a O
new O
antibiotic O
, O
_RARE_ I-GENE

_RARE_ I-GENE
arterial O
pressure O
and O
structure O
in O
the O
_RARE_ I-GENE
monkey I-GENE
after O
prolonged O
administration O
of O
_RARE_ I-GENE
_RARE_ I-GENE
. O

Effect O
of O
_RARE_ I-GENE
and O
_RARE_ I-GENE
on O
hippocampal O
_RARE_ I-GENE
activity O

_RARE_ I-GENE
ratio O
at O
birth O
. O

_RARE_ I-GENE
processes O
in O
the O
cervix O
_RARE_ I-GENE

_RARE_ I-GENE
_RARE_ I-GENE
tumors O
of O
the O
_RARE_ I-GENE

_RARE_ I-GENE
_RARE_ I-GENE
for O
estimating O
_RARE_ I-GENE
in O
a O
population O
with O
related I-GENE
parents O
. O

Measurement O
of O
open O
- I-GENE
loop I-GENE
responses O
to O
electrical O
stimulation O
in O
olfactory O
bulb O
of O
cat O
. O

_RARE_ I-GENE
disappearance O
rate O
and O
changes O
in O
plasma I-GENE
_RARE_ I-GENE
after O
_RARE_ I-GENE
injected O
glucose O
in O
_RARE_ I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
newborns O
. O

_RARE_ I-GENE
values O
for O
the O
peripheral O
blood O
and O
bone O
marrow O
of O
the O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
hamster I-GENE

The O
relationship O
of O
human I-GENE
_RARE_ I-GENE
arterial O
and O
venous O
plasma I-GENE
levels O
of O
corticosteroids O
to O
gestational O
age O
. O

_RARE_ I-GENE
effect O
of O
the O
_RARE_ I-GENE
from O
_RARE_ I-GENE

_RARE_ I-GENE
acid I-GENE
concentration O
in O
the O
catalyzed O
_RARE_ I-GENE
_RARE_ I-GENE
. O

Role O
of O
_RARE_ I-GENE
studies O
in O
the O
prophylaxis O
of O
spontaneous O
_RARE_ I-GENE

_RARE_ I-GENE
behavior O
of O
_RARE_ I-GENE
, O
_RARE_ I-GENE
x O
_RARE_ I-GENE
and O
_RARE_ I-GENE
non O
- I-GENE
_RARE_ I-GENE
heifers O
. O

Chemical O
_RARE_ I-GENE
of O
the O
_RARE_ I-GENE
V I-GENE
: O
_RARE_ I-GENE
_RARE_ I-GENE
of O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
in O
rat I-GENE
kidneys O
. O

_RARE_ I-GENE
of O
_RARE_ I-GENE
steroids O
by O
double O
_RARE_ I-GENE
method O
. O

_RARE_ I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
among O
Japanese O
, O
Chinese O
, O
and O
_RARE_ I-GENE
. O

Effects O
of O
_RARE_ I-GENE
, O
starvation O
, O
and O
_RARE_ I-GENE
on O
oxidative O
enzyme I-GENE
activities O
of O
_RARE_ I-GENE
cartilage O
from O
rats O
. O

_RARE_ I-GENE
coordination O
compounds O
of O
_RARE_ I-GENE
. O

_RARE_ I-GENE
of O
renin I-GENE
secretion O
rate O
and O
renal O
plasma I-GENE
flow O
from O
peripheral O
and O
renal O
vein O
renin I-GENE
levels O
. O

_RARE_ I-GENE
_RARE_ I-GENE
under O
social O
_RARE_ I-GENE
. O

_RARE_ I-GENE
of O
vessel O
. O

_RARE_ I-GENE
of O
food O
intake O
in O
the O
rat I-GENE
by O
_RARE_ I-GENE
oil O
. O

Studies O
of O
lipoprotein I-GENE
- I-GENE
X I-GENE
( O
_RARE_ I-GENE
- I-GENE
X I-GENE
) O
and O
bile O
acids O
in O
familial O
_RARE_ I-GENE
deficiency O
. O

_RARE_ I-GENE
complicated O
by O
chronic O
steroid I-GENE
treatment O
. O

_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
anxiety O
of O
_RARE_ I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
. O

_RARE_ I-GENE
juvenile O
_RARE_ I-GENE

Early O
heparin O
therapy O
in O
60 O
children O
with O
acute O
_RARE_ I-GENE
. O

9 O
, O
11 O
- I-GENE
_RARE_ I-GENE
steroids O
derived O
from O
estradiol O
3 I-GENE
- I-GENE
methyl O
ether O
. O

_RARE_ I-GENE
examinations O
in O
patients O
with O
chronic O
kidney O
insufficiency O

_RARE_ I-GENE
of O
_RARE_ I-GENE
administration O
of O
various O
substances O
to O
animals O

_RARE_ I-GENE
in O
the O
_RARE_ I-GENE
of O
the O
blood O
following O
a O
short O
- I-GENE
term O
local O
action O
of O
a O
permanent O
magnetic O
field O
on O
the O
human I-GENE
body O

_RARE_ I-GENE
on O
the O
_RARE_ I-GENE
activities O
of O
_RARE_ I-GENE
_RARE_ I-GENE
L I-GENE
. O

_RARE_ I-GENE
of O
3 I-GENE
multiple O
primary O
malignant O
and O
benign O
tumors O
of O
the O
_RARE_ I-GENE
and O
_RARE_ I-GENE

Analysis O
of O
clearance O
curve O
of O
rose O
_RARE_ I-GENE
- I-GENE
I I-GENE
- I-GENE
131 O

_RARE_ I-GENE
: O
_RARE_ I-GENE
and O
_RARE_ I-GENE
in O
S I-GENE
I I-GENE
_RARE_ I-GENE
of O
the O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
K I-GENE
agents O

_RARE_ I-GENE
_RARE_ I-GENE
: O
effects O
of O
a O
single O
injection O
of O
_RARE_ I-GENE
acetate O
on O
the O
reproductive O
organs O
of O
the O
_RARE_ I-GENE
. O

3 I-GENE
. O

_RARE_ I-GENE
and O
_RARE_ I-GENE
properties O

_RARE_ I-GENE
system O
in O
streptococcal I-GENE
allergy O
. O

Letter O
: O
_RARE_ I-GENE
hydrocarbon I-GENE
hydroxylase I-GENE
and O
smoking O
. O

Evaluation O
of O
1 I-GENE
, O
10 O
- I-GENE
_RARE_ I-GENE
as O
a O
_RARE_ I-GENE
for O
_RARE_ I-GENE
acid I-GENE
determinations O
. O

Delta I-GENE
- I-GENE
_RARE_ I-GENE
acid I-GENE
in O
physiological O
conditions O
and O
some O
diseases O
in O
children O

_RARE_ I-GENE
in O
rats O
of O
_RARE_ I-GENE
_RARE_ I-GENE
and O
compounds O
contained O
in O
them O
. O

VII I-GENE
. O

Isolation O
of O
_RARE_ I-GENE
avian I-GENE
_RARE_ I-GENE
virus I-GENE
( O
strain O
T I-GENE
). O

_RARE_ I-GENE
on O
_RARE_ I-GENE
of O
rats O
exposed O
to O
long O
- I-GENE
term O
_RARE_ I-GENE
. O

Effect O
of O
a O
high O
- I-GENE
intensity O
_RARE_ I-GENE
field O
on O
the O
blood O
coagulation I-GENE
system O

The O
levels O
of O
_RARE_ I-GENE
activity O
in O
sera O
from O
normal O
children O
and O
patients O
with O
cystic I-GENE
fibrosis I-GENE
. O

_RARE_ I-GENE
of O
effect O
of O
the O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
105 I-GENE
) O
on O
the O
absorption O
of O
_RARE_ I-GENE
. O

_RARE_ I-GENE
between O
gross O
lesions O
and O
Escherichia I-GENE
coli I-GENE
_RARE_ I-GENE
in O
chronic O
respiratory O
disease O
( O
_RARE_ I-GENE
) O
of O
_RARE_ I-GENE
. O

_RARE_ I-GENE
solution O
of O
_RARE_ I-GENE
joint O
_RARE_ I-GENE
with O
a O
_RARE_ I-GENE
_RARE_ I-GENE
flap O

Effects O
of O
_RARE_ I-GENE
radiation O
in O
the O
human I-GENE
oral O
cavity O
and O
_RARE_ I-GENE
: O
results O
of O
a O
survey O
. O

The O
_RARE_ I-GENE
_RARE_ I-GENE
of O
the O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
pattern O
of O
_RARE_ I-GENE
_RARE_ I-GENE
and O
comparison O
of O
the O
appearance O
time O
between O
_RARE_ I-GENE
and O
_RARE_ I-GENE
antibodies I-GENE

_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
QRS O
complexes I-GENE
and O
_RARE_ I-GENE
QRS O
loop I-GENE

Study O
of O
_RARE_ I-GENE
autoantibodies O
by O
immunofluorescence O
_RARE_ I-GENE
in O
collagen I-GENE
diseases O

Cardiac I-GENE
preservation O
. O

_RARE_ I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
L I-GENE
. O
R I-GENE
. O
C I-GENE
. O
P I-GENE
. O

_RARE_ I-GENE
. O

The O
metabolism O
and O
_RARE_ I-GENE
of O
5 I-GENE
- I-GENE
fluorouracil O
. O

_RARE_ I-GENE
weight O
in O
rats O
during O
tumour I-GENE
growth I-GENE
and O
in O
_RARE_ I-GENE
rejection O
. O

Isolation O
of O
_RARE_ I-GENE
_RARE_ I-GENE
MC O
- I-GENE
63 O
from O
carcinoma O
63 O
and O
its O
_RARE_ I-GENE
effect O
on O
_RARE_ I-GENE
sarcoma I-GENE
180 O
and O
_RARE_ I-GENE
carcinoma O
. O

Human I-GENE
synovial O
fluid O
: O
detection O
of O
a O
new O
component O
. O

Effects O
of O
temperature O
and O
_RARE_ I-GENE
cycle O
on O
_RARE_ I-GENE
synthesis O
in O
the O
_RARE_ I-GENE
, O
_RARE_ I-GENE
_RARE_ I-GENE
. O

Some O
_RARE_ I-GENE
_RARE_ I-GENE
of O
a O
personal O
statistical O
study O
of O
_RARE_ I-GENE
arterial O
_RARE_ I-GENE

LA O
- I-GENE
_RARE_ I-GENE
- I-GENE
MS O
. O

_RARE_ I-GENE
studies O
with O
_RARE_ I-GENE
antigens I-GENE
. O

_RARE_ I-GENE
and O
functional O
alterations O
noted O
after O
_RARE_ I-GENE
renal O
_RARE_ I-GENE
. O

_RARE_ I-GENE
of O
human I-GENE
serum I-GENE
albumin I-GENE
. O

Analysis O
of O
corticosteroids O
. O

_RARE_ I-GENE
to O
horse I-GENE
anti I-GENE
- I-GENE
lymphocyte I-GENE
globulin I-GENE
. O

Plasma I-GENE
_RARE_ I-GENE
in O
patients O
of O
bronchial O
asthma O
and O
the O
effect O
of O
_RARE_ I-GENE
administration O
on O
it O
. O

A I-GENE
comparative O
study O
of O
the O
cortical O
end O
of O
the O
auditory O
_RARE_ I-GENE
during O
postnatal O
_RARE_ I-GENE
in O
lower O
monkeys O
and O
man O

The O
effect O
of O
osmotic O
flow O
on O
the O
distribution O
of O
_RARE_ I-GENE
peroxidase I-GENE
within O
the O
_RARE_ I-GENE
_RARE_ I-GENE
of O
_RARE_ I-GENE
bladder O
epithelium O
. O

_RARE_ I-GENE
of O
various O
mycobacteria O
and O
the O
corresponding O
levels O
of O
cross O
- I-GENE
protection O
developed O
between O
species O
. O

Ten O
- I-GENE
year O
experience O
with O
one O
- I-GENE
stage O
_RARE_ I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
- I-GENE
hydrogen O
_RARE_ I-GENE
in O
_RARE_ I-GENE
and O
_RARE_ I-GENE
. O

Factors O
affecting O
the O
inhibition O
of O
_RARE_ I-GENE
by O
_RARE_ I-GENE
. O

_RARE_ I-GENE
spectral O
sensitivity O
determined O
_RARE_ I-GENE
for O
the O
_RARE_ I-GENE
eye O
. O

_RARE_ I-GENE
of O
_RARE_ I-GENE
bone O
cyst O
. O

_RARE_ I-GENE

Sodium O
restriction I-GENE
in O
cardiac O
failure O
. O

Clinical O
and O
angiographic O
examinations O
in O
occlusion O
disease O
of O
the O
great O
intestinal O
arteries O

Serum I-GENE
lipid O
changes O
during O
pregnancy O
due O
to O
oral O
calcium O
administration O

_RARE_ I-GENE
treatment O
of O
candidiasis O
with O
transfer I-GENE
factor I-GENE
. O

A I-GENE
possible O
role O
for O
the O
mixed O
function O
oxidase I-GENE
enzyme I-GENE
system O
in O
the O
requirement O
for O
selenium O
in O
the O
rat I-GENE
. O

_RARE_ I-GENE
breathing O
and O
apnea O
in O
preterm O
infants O
. O

_RARE_ I-GENE
session O
report O
: O
in O
vivo O
- I-GENE
in O
vitro O
screening O
. O

_RARE_ I-GENE
studies O
in O
_RARE_ I-GENE
tumors O
of O
the O
ovary O
. O

On O
the O
_RARE_ I-GENE
of O
_RARE_ I-GENE
_RARE_ I-GENE

_RARE_ I-GENE
between O
_RARE_ I-GENE
ratio O
of O
_RARE_ I-GENE
materials O
and O
composition O
of O
products I-GENE
in O
the O
synthesis O
of O
_RARE_ I-GENE

Influence O
of O
diet O
on O
urinary O
_RARE_ I-GENE
excretion O
. O

_RARE_ I-GENE
_RARE_ I-GENE
circuit O
for O
recording O
long O
_RARE_ I-GENE
at O
fast O
_RARE_ I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
of O
_RARE_ I-GENE
acids O
. O

The O
status O
of O
education O
and O
training O
programs O
in O
speech O
pathology O
and O
_RARE_ I-GENE
-- O
_RARE_ I-GENE
- I-GENE
72 O
. O

Coronary O
arteries O
-- O
old O
and O
new O
. O

_RARE_ I-GENE
agents O
. O

_RARE_ I-GENE
of O
_RARE_ I-GENE
- I-GENE
positive O
compounds O
in O
urine O
by O
the O
combined O
methods O
of O
medium O
- I-GENE
tension O
_RARE_ I-GENE
and O
_RARE_ I-GENE
chromatography O

_RARE_ I-GENE
treatment O
of O
central O
nervous O
system O
injuries O

_RARE_ I-GENE
_RARE_ I-GENE
: O
a O
syndrome O
of O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
. O

6 I-GENE
. O

_RARE_ I-GENE
data O
on O
the O
immunosuppressive O
therapy O
of O
_RARE_ I-GENE

_RARE_ I-GENE
lysosomal I-GENE
enzyme I-GENE
release O
and O
its O
_RARE_ I-GENE
by O
drugs O
in O
adjuvant O
- I-GENE
induced O
_RARE_ I-GENE
. O

Treatment O
of O
ovarian O
neoplasms O

Experimental O
pancreatitis O
in O
pigs O
. O

_RARE_ I-GENE
metabolism O
of O
4 I-GENE
- I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
of O
hospital O
_RARE_ I-GENE
in O
_RARE_ I-GENE
ulcer O
patients O

I I-GENE
. O

_RARE_ I-GENE
treatment O
of O
pathologic O
_RARE_ I-GENE
of O
myocardial O
infarct O

The O
interaction O
of O
caffeine O
, O
theophylline O
and O
_RARE_ I-GENE
with O
monoamine I-GENE
oxidase I-GENE
inhibitors O
. O

Effect O
of O
_RARE_ I-GENE
on O
_RARE_ I-GENE
in O
perfused O
rat I-GENE
liver O
. O

New O
_RARE_ I-GENE
from O
_RARE_ I-GENE
of O
_RARE_ I-GENE
_RARE_ I-GENE
. O

A I-GENE
case O
of O
M I-GENE
_RARE_ I-GENE

_RARE_ I-GENE
nature O
of O
_RARE_ I-GENE
_RARE_ I-GENE
- I-GENE
producing O
potential O
of O
parental O
spleen O
cells O
. O

_RARE_ I-GENE
_RARE_ I-GENE
of O
a O
gas O
dilution O
indicator O

The O
value O
of O
different O
sources O
of O
nitrogen O
in O
diets O
for O
the O
early I-GENE
- I-GENE
_RARE_ I-GENE
calf I-GENE
. O

1 I-GENE
. O

_RARE_ I-GENE
tumors O
in O
childhood O
. O

Results O
of O
the O
_RARE_ I-GENE
_RARE_ I-GENE
of O
the O
commercial O
anti I-GENE
- I-GENE
inflammatory O
enzyme I-GENE
preparations O
containing O
_RARE_ I-GENE
and O
trypsin I-GENE
by O
means O
of O
modified O
NF I-GENE
13 O
methods O

Studies O
on O
the O
hereditary I-GENE
nature O
of O
_RARE_ I-GENE
_RARE_ I-GENE
-- O
with O
special O
reference O
to O
_RARE_ I-GENE
and O
_RARE_ I-GENE

The O
problem O
of O
_RARE_ I-GENE
due O
to O
pulmonary O
tuberculosis O
, O
on O
the O
basis O
of O
an O
analysis O
of O
the O
history O
of O
_RARE_ I-GENE
cases O
as O
observed O
in O
_RARE_ I-GENE
in O
the O
years O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE

_RARE_ I-GENE
_RARE_ I-GENE

_RARE_ I-GENE
on O
_RARE_ I-GENE
; O
by O
a O
group O
of O
_RARE_ I-GENE
from O
psychiatric O
hospitals O

_RARE_ I-GENE
abdominal O
_RARE_ I-GENE
with O
131 O
- I-GENE
I I-GENE
- I-GENE
tagged O
BSP I-GENE
-- O
description O
of O
the O
thyroid I-GENE
gland O
, O
kidney O
and O
spleen O
( O
comparison O
with O
131 O
- I-GENE
I I-GENE
- I-GENE
RB I-GENE
) O

_RARE_ I-GENE
in O
children O

_RARE_ I-GENE
caused O
by O
3 I-GENE
, O
4 I-GENE
- I-GENE
_RARE_ I-GENE

The O
content O
of O
_RARE_ I-GENE
and O
_RARE_ I-GENE
in O
_RARE_ I-GENE

_RARE_ I-GENE
of O
leukemia I-GENE
after O
prolonged O
remission O
. O

Influence O
of O
_RARE_ I-GENE
smoking O
on O
some O
blood O
coagulation I-GENE
tests O
. O

The O
non O
- I-GENE
role O
of O
fluoride O
in O
the O
control O
of O
plasma I-GENE
calcium O
in O
the O
_RARE_ I-GENE
rat I-GENE
. O

Second O
report O
of O
the O
_RARE_ I-GENE
Cancer O
_RARE_ I-GENE
. O

_RARE_ I-GENE
of O
the O
growth I-GENE
of O
_RARE_ I-GENE
by O
compounds O
which O
affect O
the O
adrenergic I-GENE
mechanism O
. O

_RARE_ I-GENE
- I-GENE
TR I-GENE
- I-GENE
68 O
- I-GENE
54 I-GENE
. O

A I-GENE
brief O
discussion O
of O
color O
deficiencies O
. O

_RARE_ I-GENE
130 I-GENE
. O

_RARE_ I-GENE
in O
the O
determination O
of O
the O
antigenic I-GENE
content O
of O
influenza I-GENE
vaccines O
. O

_RARE_ I-GENE
_RARE_ I-GENE
( O
L I-GENE
.) O
and O
_RARE_ I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
in O
_RARE_ I-GENE
City O
. O

_RARE_ I-GENE
response O
and O
hemagglutinin I-GENE
production O
by O
_RARE_ I-GENE
_RARE_ I-GENE
irradiated O
adult O
mice O
. O

Comparative O
study O
on O
acute O
oral O
overload O
using O
_RARE_ I-GENE
and O
_RARE_ I-GENE
in O
normal O
and O
diabetic O
subjects O
. O

_RARE_ I-GENE
in O
_RARE_ I-GENE
and O
_RARE_ I-GENE
. O

Factors O
influencing O
in O
vitro O
skin O
permeability I-GENE
factor I-GENE
production O
by O
Vibrio I-GENE
cholerae I-GENE
. O

_RARE_ I-GENE
cord O
_RARE_ I-GENE
of O
the O
_RARE_ I-GENE
reflex O
. O

Biological O
action O
and O
kinetics O
of O
the O
elimination O
of O
_RARE_ I-GENE
oxide I-GENE
in O
dogs O

_RARE_ I-GENE
- I-GENE
and O
_RARE_ I-GENE
of O
the O
_RARE_ I-GENE

IX I-GENE
. O

_RARE_ I-GENE
in O
the O
use O
of O
chromosome O
_RARE_ I-GENE
analysis O
for O
biological O
radiation O
_RARE_ I-GENE
. O

_RARE_ I-GENE
secretion O
in O
essential O
and O
accelerated O
hypertension O
. O

The O
need O
for O
including O
_RARE_ I-GENE
medical O
_RARE_ I-GENE
in O
the O
_RARE_ I-GENE
of O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
actions O

_RARE_ I-GENE
and O
pathogenesis O
of O
_RARE_ I-GENE
_RARE_ I-GENE

CNS O
effects O
of O
local O
_RARE_ I-GENE
only O
partially O
dependent I-GENE
on O
_RARE_ I-GENE
amine I-GENE
mechanisms O
. O

_RARE_ I-GENE
_RARE_ I-GENE

_RARE_ I-GENE
control O
in O
_RARE_ I-GENE
channels I-GENE
. O

The O
effects O
of O
_RARE_ I-GENE
and O
_RARE_ I-GENE
on O
isolated O
human I-GENE
smooth I-GENE
muscle O
. O

The O
_RARE_ I-GENE
behaviour O
in O
normal O
and O
aggressive O
mice O
. O

_RARE_ I-GENE
in O
_RARE_ I-GENE
states O
. O

_RARE_ I-GENE
test O
of O
HB I-GENE
_RARE_ I-GENE
in O
animal O
experiments O

The O
role O
of O
_RARE_ I-GENE
acid I-GENE
in O
the O
prevention O
of O
bladder O
tumor I-GENE
formation O
. O

The O
" O
28 O
percent O
" O
_RARE_ I-GENE
_RARE_ I-GENE
in O
_RARE_ I-GENE
airway O
disease O
. O

3 I-GENE
'- O
_RARE_ I-GENE
, O
8 O
- I-GENE
methyl O
, O
and O
8 O
- I-GENE
_RARE_ I-GENE
derivatives O
of O
5 I-GENE
, O
9 O
- I-GENE
dimethyl O
- I-GENE
6 I-GENE
, O
7 O
- I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
invasion O
of O
_RARE_ I-GENE
and O
recurrent O
collateral O
inhibition O
in O
pyramidal O
tract O
neurones O
. O

The O
distribution O
of O
body O
fluids O
following O
hemorrhage O
and O
resuscitation O
in O
_RARE_ I-GENE
_RARE_ I-GENE
. O

Once O
more O
_RARE_ I-GENE
_RARE_ I-GENE
influenza I-GENE
in O
the O
_RARE_ I-GENE

Early O
_RARE_ I-GENE
of O
cancer O
-- O
50 O
per O
cent O
of O
all O
patients O
could O
be O
_RARE_ I-GENE

_RARE_ I-GENE
bound O
to O
measuring O
of O
sputum I-GENE
viscosity O

_RARE_ I-GENE
concentration O
and O
lipase I-GENE
activity O
in O
the O
_RARE_ I-GENE
of O
_RARE_ I-GENE
rats O
_RARE_ I-GENE
food O
with O
different O
sodium O
content O

_RARE_ I-GENE
of O
aspartate I-GENE
aminotransferase I-GENE
( O
EC I-GENE
2 I-GENE
. O
6 I-GENE
. O
1 I-GENE
. O
1 I-GENE
) O
and O
alanine I-GENE
aminotransferase I-GENE
( O
EC I-GENE
2 I-GENE
. O
6 I-GENE
. O
1 I-GENE
. O
2 I-GENE
) O
in O
rat I-GENE
serum I-GENE
during O
the O
course O
of O
acute O
radiation O
syndrome O
following O
whole O
body O
X I-GENE
- I-GENE
irradiation O

_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
capacity O
produced O
by O
_RARE_ I-GENE
- I-GENE
induced O
salt O
retention O
in O
man O
. O

Studies O
on O
the O
_RARE_ I-GENE
of O
ECHO O
9 O
( O
_RARE_ I-GENE
) O
virus I-GENE
and O
its O
mutants I-GENE
for O
_RARE_ I-GENE
mice O

_RARE_ I-GENE
- I-GENE
current O
heat I-GENE
exchange I-GENE
in O
the O
respiratory O
_RARE_ I-GENE
: O
effect O
on O
water O
and O
heat I-GENE
balance O
. O

_RARE_ I-GENE
and O
a O
correction O
of O
blood O
O2 O
content O
measured O
by O
_RARE_ I-GENE
and O
CO I-GENE
saturation O
. O

_RARE_ I-GENE
_RARE_ I-GENE
and O
the O
_RARE_ I-GENE
_RARE_ I-GENE
. O

Elimination O
of O
gamma I-GENE
- I-GENE
irradiation O
induced O
oxidation O
in O
aqueous O
drug O
preparations O

The O
absolute O
configuration O
at O
C I-GENE
- I-GENE
2 I-GENE
in O
_RARE_ I-GENE
acid I-GENE
. O

_RARE_ I-GENE
effects O
of O
_RARE_ I-GENE
D I-GENE
in O
rats O

The O
plasma I-GENE
growth I-GENE
hormone I-GENE
concentration O
of O
the O
_RARE_ I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
cochlear O
response O
curves O
in O
_RARE_ I-GENE
. O

A I-GENE
new O
_RARE_ I-GENE
test O
for O
the O
on O
- I-GENE
_RARE_ I-GENE
assay O
of O
rheumatoid I-GENE
factor I-GENE

CO2 O
_RARE_ I-GENE
by O
_RARE_ I-GENE
_RARE_ I-GENE
on O
filter O
paper O
. O

The O
_RARE_ I-GENE
of O
_RARE_ I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
profiles O
in O
air O
_RARE_ I-GENE
control O
activities O
. O

Effects O
of O
chronic O
_RARE_ I-GENE
treatment O
on O
the O
sympathetic O
activity O
of O
intact O
and O
adrenal O
_RARE_ I-GENE
rats O
kept O
in O
_RARE_ I-GENE
or O
cold O
_RARE_ I-GENE
. O

The O
association O
of O
_RARE_ I-GENE
and O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
in O
the O
treatment O
of O
the O
_RARE_ I-GENE
- I-GENE
renal O
syndromes O
of O
pregnancy O

The O
effect O
of O
low O
dosage O
radiation O
on O
metabolism O
and O
function O
of O
the O
rat I-GENE
kidney O
damaged O
by O
ischemia O

_RARE_ I-GENE
in O
_RARE_ I-GENE
: O
world O
- I-GENE
wide O
review O
of O
clinical O
cases O
. O

_RARE_ I-GENE
report O
. O

_RARE_ I-GENE
of O
_RARE_ I-GENE
IgA I-GENE
in O
human I-GENE
serum I-GENE
in O
health O
and O
disease O
. O

_RARE_ I-GENE
manifestations O
of O
systemic O
sclerosis O

_RARE_ I-GENE
metabolism O
in O
chronic O
thyroiditis O
. O

Total O
body O
water O
, O
_RARE_ I-GENE
space O
and O
I I-GENE
- I-GENE
131 O
- I-GENE
albumin I-GENE
space O
under O
the O
acute O
effect O
of O
furosemide O

V I-GENE
. O

18F O
and O
_RARE_ I-GENE
_RARE_ I-GENE
in O
the O
study O
of O
primary O
_RARE_ I-GENE
. O

_RARE_ I-GENE
and O
hormone I-GENE
production O
by O
human I-GENE
normal O
and O
malignant O
_RARE_ I-GENE
in O
rats O
. O

Health O
: O
an O
_RARE_ I-GENE
reticulum O
. O

_RARE_ I-GENE
_RARE_ I-GENE
method O
of O
determining O
SH I-GENE
- I-GENE
and O
S I-GENE
- I-GENE
S I-GENE
- I-GENE
groups O
when O
_RARE_ I-GENE
present O

_RARE_ I-GENE
of O
the O
_RARE_ I-GENE
produced O
by O
femoral O
regeneration O
in O
the O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
Br O

_RARE_ I-GENE
and O
_RARE_ I-GENE
expression O
of O
natural O
sleep O
and O
_RARE_ I-GENE
in O
_RARE_ I-GENE

_RARE_ I-GENE
of O
_RARE_ I-GENE
to O
factor I-GENE
VII I-GENE
deficiency O
. O

3 I-GENE
. O

_RARE_ I-GENE
venous O
catheter O
used O
for O
recording O
_RARE_ I-GENE
electrocardiogram O
. O

Two O
_RARE_ I-GENE
8 O
computer O
_RARE_ I-GENE
for O
use O
in O
the O
study O
of O
the O
_RARE_ I-GENE
and O
_RARE_ I-GENE
contractile O
characteristics O
of O
skeletal I-GENE
muscle O
. O

_RARE_ I-GENE
head I-GENE
- I-GENE
brain O
injuries O

The O
modification O
of O
_RARE_ I-GENE
uptake O
into O
the O
_RARE_ I-GENE
sarcoma I-GENE
in O
vitro O
by O
adding O
of O
_RARE_ I-GENE
to O
the O
_RARE_ I-GENE
medium O

_RARE_ I-GENE
, O
parents O
, O
_RARE_ I-GENE
and O
hearing O
disorders O

_RARE_ I-GENE
and O
predicting O
doses O
of O
_RARE_ I-GENE
irradiation O

_RARE_ I-GENE
shifts O
of O
basal O
skin O
potentials O
during O
human I-GENE
sleep O
. O

_RARE_ I-GENE
dietary O
_RARE_ I-GENE
management O
. O

5 I-GENE
-( O
_RARE_ I-GENE
)- I-GENE
19 O
, O
11 O
- I-GENE
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
[ O
2 I-GENE
, O
3 I-GENE
] O
_RARE_ I-GENE
[ O
6 I-GENE
, O
7 O
- I-GENE
b I-GENE
] O
_RARE_ I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE

_RARE_ I-GENE
on O
the O
exchange I-GENE
of O
_RARE_ I-GENE
in O
intact O
and O
_RARE_ I-GENE
rats O
by O
the O
kinetic O
analysis O
method O

Effect O
of O
thrombotic O
and O
_RARE_ I-GENE
drugs O
on O
the O
surface O
charge I-GENE
characteristics O
of O
canine O
blood O
vessels O
: O
in O
vivo O
and O
in O
vitro O
studies O
. O

Measurements O
of O
activity O
with O
the O
_RARE_ I-GENE
chamber O
VA O
- I-GENE
K I-GENE
- I-GENE
_RARE_ I-GENE
of O
the O
_RARE_ I-GENE
VA O
- I-GENE
_RARE_ I-GENE

3 I-GENE
-( O
N I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
N I-GENE
- I-GENE
2 I-GENE
- I-GENE
_RARE_ I-GENE
)- I-GENE
5 I-GENE
- I-GENE
or O
7 O
- I-GENE
_RARE_ I-GENE
[ O
b I-GENE
] O
_RARE_ I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
applied O
to O
cattle O

Evaluation O
of O
automatic O
blood O
cell O
_RARE_ I-GENE
. O

Determination O
of O
_RARE_ I-GENE
with O
an O
_RARE_ I-GENE

_RARE_ I-GENE
in O
pollen O
. O

_RARE_ I-GENE
cyst O
in O
a O
free O
skin O
flap O
as O
the O
complication O
after O
treatment O
of O
_RARE_ I-GENE
_RARE_ I-GENE

Histological O
observations O
on O
the O
_RARE_ I-GENE
in O
the O
second O
half O
of O
pregnancy O

_RARE_ I-GENE
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
, O
mitral O
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
of O
abdominal O
aorta O
. O

Studies O
on O
the O
method O
of O
size O
reduction O
of O
_RARE_ I-GENE
compounds O
. O

Children O
with O
defective O
vision O

Identification O
and O
estimation O
of O
_RARE_ I-GENE
and O
_RARE_ I-GENE
in O
urine O
by O
gas O
- I-GENE
liquid O
chromatography O
. O

_RARE_ I-GENE
in O
_RARE_ I-GENE
and O
conventional O
rats O
. O

The O
effects O
of O
loading O
the O
respiratory O
_RARE_ I-GENE
on O
the O
oxygen O
consumption O
of O
_RARE_ I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
of O
_RARE_ I-GENE
activity O
against O
_RARE_ I-GENE
larvae O

The O
significance O
of O
structural O
integrity O
of O
lymphoid I-GENE
tissue I-GENE
for O
antibody I-GENE
production O
in O
culture O
in O
vivo O

The O
effect O
of O
a O
constant O
magnetic O
field O
on O
the O
phagocytic O
activity O
of O
_RARE_ I-GENE

Studies O
carried O
out O
with O
the O
_RARE_ I-GENE
_RARE_ I-GENE
colony I-GENE
of O
_RARE_ I-GENE
. O

_RARE_ I-GENE
between O
adrenergic I-GENE
mechanisms O
and O
analgesic O
effects O

_RARE_ I-GENE
in O
the O
morphine O
series O
. O

_RARE_ I-GENE
_RARE_ I-GENE
2 I-GENE
-( O
o I-GENE
- I-GENE
_RARE_ I-GENE
)- I-GENE
2 I-GENE
- I-GENE
methyl O
- I-GENE
amino O
_RARE_ I-GENE
_RARE_ I-GENE
( O
CI O
- I-GENE
_RARE_ I-GENE
) O

_RARE_ I-GENE
and O
_RARE_ I-GENE
abilities O
of O
androgen O
- I-GENE
_RARE_ I-GENE
rats O

The O
bearing O
of O
season O
and O
sequence I-GENE
of O
_RARE_ I-GENE
on O
frequency O
of O
male O
, O
female O
and O
total O
_RARE_ I-GENE
in O
_RARE_ I-GENE
cows O
. O

_RARE_ I-GENE
changes O
in O
man O
during O
_RARE_ I-GENE

_RARE_ I-GENE
prevention O
in O
the O
dental O
_RARE_ I-GENE
. O

I I-GENE
. O

Clinical O
applications O
of O
inhibition O
of O
beta I-GENE
- I-GENE
adrenergic I-GENE
receptors I-GENE
with O
propranolol O
. O

_RARE_ I-GENE
view O
box I-GENE
. O

Measurement O
of O
gastric O
acid I-GENE
secretion O
by O
_RARE_ I-GENE
. O

Effect O
of O
_RARE_ I-GENE
on O
pituitary I-GENE
and O
serum I-GENE
LH I-GENE
and O
FSH I-GENE
in O
testosterone O
- I-GENE
_RARE_ I-GENE
rats O
. O

The O
significance O
of O
the O
_RARE_ I-GENE
_RARE_ I-GENE
test O
for O
the O
differentiation O
and O
identification O
of O
_RARE_ I-GENE
species O
. O

_RARE_ I-GENE
of O
mast I-GENE
cells O
to O
_RARE_ I-GENE
granuloma O
of O
the O
skin O

_RARE_ I-GENE
- I-GENE
term O
effects O
of O
_RARE_ I-GENE
( O
_RARE_ I-GENE
- I-GENE
S I-GENE
) O
on O
serum I-GENE
lipids O
in O
man O
. O

_RARE_ I-GENE
glucose O
dehydrogenase I-GENE
deficiency O
causing O
hyperbilirubinemia O
in O
the O
newborn O

Evidence O
_RARE_ I-GENE
_RARE_ I-GENE
theory O
of O
transport O
in O
the O
_RARE_ I-GENE
. O

Effects O
of O
beta I-GENE
- I-GENE
adrenergic I-GENE
receptor I-GENE
blockade O
on O
airway O
conductance I-GENE
and O
lung O
volume O
in O
normal O
and O
asthmatic O
subjects O
. O

Effect O
of O
heparin O
on O
the O
inactivation O
of O
serum I-GENE
lipoprotein I-GENE
lipase I-GENE
by O
the O
liver O
in O
_RARE_ I-GENE
dogs O
. O

Experimental O
_RARE_ I-GENE
_RARE_ I-GENE
. O

I I-GENE
. O

_RARE_ I-GENE
in O
family I-GENE
practice O
-- O
prototype O
of O
a O
_RARE_ I-GENE
. O

The O
possibility O
of O
selective O
chemotherapy O
of O
progressive O
_RARE_ I-GENE
ovarian O
carcinoma O
with O
the O
aid O
of O
_RARE_ I-GENE
and O
incorporation O
of O
tagged O
_RARE_ I-GENE

_RARE_ I-GENE
in O
the O
temporal O
- I-GENE
spatial O
distribution O
of O
_RARE_ I-GENE
and O
_RARE_ I-GENE
in O
the O
_RARE_ I-GENE
and O
marrow O
- I-GENE
free O
_RARE_ I-GENE
after O
incorporation O
of O
_RARE_ I-GENE
_RARE_ I-GENE

_RARE_ I-GENE
degradation O
of O
adrenaline O
solutions O
: O
study O
of O
the O
intermediate O
stages O
and O
their O
_RARE_ I-GENE
value O
for O
the O
control O
of O
this O
_RARE_ I-GENE

_RARE_ I-GENE
of O
_RARE_ I-GENE
from O
the O
colon O
in O
cases O
of O
_RARE_ I-GENE
_RARE_ I-GENE
and O
in O
control O
subjects O
. O

_RARE_ I-GENE
injection O
. O

_RARE_ I-GENE
alcohol O
as O
a O
solution O
_RARE_ I-GENE

_RARE_ I-GENE
the O
diagnostic O
iron O
_RARE_ I-GENE
. O

The O
structure O
of O
_RARE_ I-GENE
. O

The O
need O
in O
the O
small I-GENE
hospital O
. O

I I-GENE
. O

On O
the O
character O
of O
changes O
in O
the O
enzyme I-GENE
activity O
in O
the O
brain O
tissue I-GENE
during O
reflex O
epilepsy O

A I-GENE
malignant O
true O
_RARE_ I-GENE
of O
liver O
in O
childhood O
. O

_RARE_ I-GENE
and O
renal O
function O

_RARE_ I-GENE
and O
electron O
microscopy O
of O
acute O
liver O
lesions O
induced O
by O
_RARE_ I-GENE
B1 I-GENE
in O
_RARE_ I-GENE
. O

Functional O
disorders O
of O
the O
_RARE_ I-GENE
following O
gynecologic O
surgery O

Study O
of O
the O
alterations O
of O
intestinal O
absorption O
, O
by O
means O
of O
I I-GENE
- I-GENE
131 O
- I-GENE
_RARE_ I-GENE
, O
in O
the O
whole O
body O
irradiated O
rat I-GENE

Chemical O
histologic O
and O
immunologic O
responses O
in O
rats O
to O
_RARE_ I-GENE
- I-GENE
4 I-GENE
by O
different O
routes O
of O
administration O
. O

Clinical O
trials O
with O
1 I-GENE
, O
3 I-GENE
- I-GENE
_RARE_ I-GENE
( O
2 I-GENE
- I-GENE
_RARE_ I-GENE
)- I-GENE
1 I-GENE
- I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
, O
a O
new O
water O
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
medium O
for O
electron O
microscopy O
. O

_RARE_ I-GENE
of O
the O
past O
5 I-GENE
years O

On O
the O
diagnosis O
of O
bovine I-GENE
_RARE_ I-GENE
and O
its O
control O
in O
southern O
_RARE_ I-GENE
_RARE_ I-GENE

_RARE_ I-GENE
with O
the O
_RARE_ I-GENE
of O
agglutination I-GENE
properties O
of O
non O
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
cultures O
with O
the O
use O
of O
_RARE_ I-GENE
' O
s O
method O

Study O
on O
_RARE_ I-GENE
in O
the O
mouse I-GENE
fetus O
caused O
by O
x O
- I-GENE
radiation O
, O
hypoxia O
, O
_RARE_ I-GENE
blue O
injection O
of O
_RARE_ I-GENE
- I-GENE
A I-GENE
upon O
_RARE_ I-GENE
animals O
during O
pregnancy O
. O

Human I-GENE
_RARE_ I-GENE
serum I-GENE
: O
an O
_RARE_ I-GENE
_RARE_ I-GENE

( O
3 I-GENE
). O

Studies O
on O
the O
_RARE_ I-GENE
infection O
of O
rabbits O
by O
Staphylococcus I-GENE
aureus I-GENE
. O

On O
catabolism O
of O
_RARE_ I-GENE
in O
_RARE_ I-GENE
age O

The O
effect O
of O
feeding O
patterns O
on O
fat O
deposition O
in O
mice O
. O

_RARE_ I-GENE
and O
_RARE_ I-GENE
in O
clinical O
_RARE_ I-GENE

IV I-GENE
. O

Studies O
on O
_RARE_ I-GENE
preparations O
. O

A I-GENE
case O
report O
with O
angiographic O
follow O
- I-GENE
up O
study O
. O

_RARE_ I-GENE
between O
_RARE_ I-GENE
, O
_RARE_ I-GENE
and O
monoamine I-GENE
oxidase I-GENE
inhibitors O

Further O
studies O
on O
a O
" O
new O
" O
human I-GENE
_RARE_ I-GENE
system O
( O
_RARE_ I-GENE
antigen I-GENE
). O

_RARE_ I-GENE
_RARE_ I-GENE
as O
indicators O
of O
_RARE_ I-GENE
. O

_RARE_ I-GENE
of O
a O
hospital O
that O
_RARE_ I-GENE
its O
_RARE_ I-GENE
orientation O
program O
. O

When O
the O
cervical O
_RARE_ I-GENE
_RARE_ I-GENE
is O
positive O
. O

I I-GENE
. O

The O
3 I-GENE
- I-GENE
hour O
test O
iodine O
( O
I I-GENE
- I-GENE
132 O
) O
uptake O
by O
the O
thyroid I-GENE
in O
children O
with O
growth I-GENE
deficiency O

_RARE_ I-GENE
of O
_RARE_ I-GENE
in O
treated O
_RARE_ I-GENE
. O

Studies O
on O
_RARE_ I-GENE
B I-GENE
Type O
5 I-GENE
virus I-GENE
infections O
. O

Value O
of O
the O
method O
of O
passive O
_RARE_ I-GENE
with O
_RARE_ I-GENE
C I-GENE
in O
detecting O
C I-GENE
- I-GENE
reactive I-GENE
protein I-GENE
as O
compared O
to O
precipitation O
in O
capillaries O
and O
_RARE_ I-GENE
latex O
test O
with O
anti I-GENE
- I-GENE
CRP I-GENE
serum I-GENE

_RARE_ I-GENE
nerve I-GENE
function O
, O
noradrenaline O
level O
and O
noradrenaline O
uptake O
in O
cat O
_RARE_ I-GENE
membrane I-GENE
after O
_RARE_ I-GENE
treatment O
. O

_RARE_ I-GENE
of O
the O
spinal O
cord O

Study O
on O
the O
_RARE_ I-GENE
of O
_RARE_ I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
isolated O
from O
an O
_RARE_ I-GENE
extract O
. O

The O
_RARE_ I-GENE
of O
_RARE_ I-GENE
_RARE_ I-GENE
for O
cold O
_RARE_ I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
animals O

_RARE_ I-GENE
and O
migration O
in O
the O
_RARE_ I-GENE
of O
the O
region O
of O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE

On O
the O
amount O
and O
significance O
of O
the O
effective O
glucose O
level O
in O
tumors O
. O

Studies O
of O
_RARE_ I-GENE
by O
labelled O
precursors I-GENE
in O
the O
pregnant O
rat I-GENE
. O

_RARE_ I-GENE
studies O
on O
the O
cardiovascular O
system O
of O
spontaneously O
hypertensive O
rats O
. O

Nuclear I-GENE
spin O
of O
_RARE_ I-GENE
from O
the O
_RARE_ I-GENE
structure O
in O
its O
emission O
spectrum O
. O

Further O
observations O
on O
resorption O
in O
guinea O
pigs O
following O
injections O
of O
_RARE_ I-GENE
blue O
. O

_RARE_ I-GENE
of O
_RARE_ I-GENE
. O

_RARE_ I-GENE
on O
_RARE_ I-GENE
' O
s O
method O
for O
the O
specific I-GENE
determination O
of O
creatinine O
. O

_RARE_ I-GENE
behavior O
of O
steroids O
in O
gas O
chromatography O
with O
a O
series O
of O
combination O
_RARE_ I-GENE
. O

_RARE_ I-GENE
renal O
hypertrophy O
in O
_RARE_ I-GENE
rats O
. O

( O
3 I-GENE
). O

_RARE_ I-GENE
. O

In O
vitro O
evaluation O
of O
the O
_RARE_ I-GENE
action O
of O
urea O
. O

Electrophoretic O
_RARE_ I-GENE
of O
virus I-GENE
- I-GENE
induced O
interferon I-GENE
of O
the O
blood O
and O
urine O
in O
rabbits O

_RARE_ I-GENE
and O
folate I-GENE
deficiency O
in O
pregnancy O

_RARE_ I-GENE
on O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
. O

Twenty O
- I-GENE
two O
of O
the O
24 O
patients O
had O
a O
rise O
in O
the O
total O
serum I-GENE
amylase I-GENE
following O
_RARE_ I-GENE
. O

The O
_RARE_ I-GENE
- I-GENE
purified O
mRNA I-GENE
in O
the O
_RARE_ I-GENE
complex I-GENE
was O
used O
to O
_RARE_ I-GENE
cDNA I-GENE
with O
which O
to O
probe O
a O
D I-GENE
. O
melanogaster I-GENE
genomic O
library O
. O

_RARE_ I-GENE
maternal I-GENE
alpha I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
: O
fetal O
prognosis O

Also O
discussed O
is O
the O
possibility O
of O
a O
combined O
genetic O
and O
environmental O
etiology O
. O

_RARE_ I-GENE
were O
repeated O
monthly O
upon O
recovery O
of O
_RARE_ I-GENE
. O

_RARE_ I-GENE
with O
_RARE_ I-GENE
produced O
a O
Ca I-GENE
- I-GENE
dependent I-GENE
transient O
elevation O
of O
cGMP I-GENE
level O
from O
10 O
to O
80 O
_RARE_ I-GENE
/ I-GENE
gland O
, O
_RARE_ I-GENE
at O
1 I-GENE
- I-GENE
2 I-GENE
min O
but O
_RARE_ I-GENE
to O
the O
basal O
level O
by O
5 I-GENE
min O
. O

Two O
hundred O
_RARE_ I-GENE
- I-GENE
three O
patients O
have O
received O
WR O
- I-GENE
2721 O
in O
Phase O
I I-GENE
- I-GENE
II I-GENE
studies O
. O

The O
PEPCK I-GENE
promoter I-GENE
fragment I-GENE
was O
introduced O
either O
in O
the O
proper O
orientation O
for O
transcription I-GENE
of O
the O
TK I-GENE
gene I-GENE
or O
in O
the O
opposite O
orientation O
. O

Many O
mammary O
tumors O
induced O
by O
mouse I-GENE
mammary O
tumor I-GENE
virus I-GENE
( O
MMTV I-GENE
) O
contain O
a O
provirus O
in O
the O
same O
region O
of O
the O
host O
- I-GENE
cell O
genome O
, O
leading O
to O
expression O
of O
a O
putative O
cellular O
oncogene I-GENE
called O
int I-GENE
- I-GENE
1 I-GENE
. O

In O
these O
cases O
, O
_RARE_ I-GENE
or O
_RARE_ I-GENE
- I-GENE
tissue I-GENE
burden O
followed O
by O
fibrosis I-GENE
was O
frequently O
observed O
. O

Hepatitis I-GENE
B I-GENE
virus I-GENE
and O
hepatoma O
. O

Eight O
recombinant I-GENE
DNA I-GENE
clones O
of O
endogenous I-GENE
murine I-GENE
leukemia I-GENE
virus I-GENE
( O
MuLV O
)- I-GENE
related I-GENE
DNA I-GENE
sequences I-GENE
have O
been O
isolated O
from O
a O
_RARE_ I-GENE
genomic O
library O
of O
_RARE_ I-GENE
/ I-GENE
c I-GENE
mouse I-GENE
DNA I-GENE
. O

_RARE_ I-GENE
80 O
, O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
) O
The O
two O
proteins I-GENE
show O
36 O
% O
identities O
in O
their O
amino O
acid I-GENE
sequence I-GENE
, O
in O
an O
alignment O
requiring O
six O
_RARE_ I-GENE
. O

The O
envelope I-GENE
glycoproteins I-GENE
of O
Rous I-GENE
sarcoma I-GENE
virus I-GENE
( O
_RARE_ I-GENE
), O
_RARE_ I-GENE
and O
_RARE_ I-GENE
, O
are O
anchored I-GENE
in O
the O
membrane I-GENE
by O
a O
27 O
- I-GENE
amino O
acid I-GENE
, O
hydrophobic O
domain I-GENE
that O
lies O
adjacent O
to O
a O
22 O
- I-GENE
amino O
acid I-GENE
, O
cytoplasmic I-GENE
domain I-GENE
at O
the O
carboxy I-GENE
terminus O
of O
_RARE_ I-GENE
. O

The O
drug O
was O
given O
in O
a O
daily O
oral O
dose O
of O
0 O
. O
5 I-GENE
g O
/ I-GENE
m2 O
, O
3 I-GENE
. O
5 I-GENE
h O
prior O
to O
each O
radiation O
treatment O
. O

_RARE_ I-GENE
aspects O
of O
_RARE_ I-GENE
_RARE_ I-GENE
. O

Effect O
of O
acute O
and O
chronic O
_RARE_ I-GENE
stress O
on O
_RARE_ I-GENE
and O
pituitary I-GENE
- I-GENE
thyroid I-GENE
hormones O
in O
male O
rats O
. O

_RARE_ I-GENE
mRNA I-GENE
for O
cytosolic I-GENE
phosphoenolpyruvate I-GENE
_RARE_ I-GENE
of O
the O
chicken I-GENE
is O
2 I-GENE
. O
8 O
kilobases O
in O
length I-GENE
, O
similar O
to O
that O
previously O
noted O
for O
mRNA I-GENE
coding O
for O
the O
same O
enzyme I-GENE
in O
the O
rat I-GENE
. O

Upstream O
activation O
sites I-GENE
of O
the O
CYC1 I-GENE
gene I-GENE
of O
Saccharomyces I-GENE
cerevisiae I-GENE
are O
active O
when O
inverted O
but O
not O
when O
placed O
downstream O
of O
the O
" O
TATA I-GENE
box I-GENE
". O

An O
intact O
5 I-GENE
. O
7 O
- I-GENE
kb O
provirus O
of O
the O
avian I-GENE
_RARE_ I-GENE
virus I-GENE
_RARE_ I-GENE
has O
been O
molecularly O
cloned O
for O
comparisons O
with O
avian I-GENE
_RARE_ I-GENE
virus I-GENE
( O
_RARE_ I-GENE
) O
and O
other O
avian I-GENE
tumor I-GENE
viruses O
. O

It O
is O
concluded O
that O
haloperidol O
selectively O
reduced O
the O
animal O
' O
s O
capacity O
to O
' O
_RARE_ I-GENE
non O
- I-GENE
stimulus O
directed O
motor O
behaviour O
'. O

Neither O
side O
effect O
nor O
abnormal O
laboratory O
findings O
due O
to O
this O
drug O
were O
observed O
. O

The O
results O
presented O
in O
this O
report O
suggest O
that O
the O
SV40 I-GENE
G I-GENE
- I-GENE
C I-GENE
- I-GENE
rich O
sequences I-GENE
can O
function O
as O
independent O
RNA I-GENE
polymerase I-GENE
II I-GENE
transcriptional O
- I-GENE
control O
elements O
. O

_RARE_ I-GENE
of O
human I-GENE
cell O
lines O
which O
contain O
and O
express O
the O
adenovirus I-GENE
DNA I-GENE
binding I-GENE
protein I-GENE
gene I-GENE
by O
_RARE_ I-GENE
with O
the O
HSV I-GENE
- I-GENE
1 I-GENE
tk I-GENE
gene I-GENE
. O

Diagnosis O
and O
treatment O
of O
insulin I-GENE
- I-GENE
secreting O
tumours O
. O

_RARE_ I-GENE
_RARE_ I-GENE
to O
account O
for O
the O
modality O
shift O
effect O
are O
_RARE_ I-GENE
evaluated O
. O

The O
effects O
of O
_RARE_ I-GENE
beta I-GENE
- I-GENE
1 I-GENE
adrenergic I-GENE
agonist O
, O
1 I-GENE
-( O
4 I-GENE
- I-GENE
_RARE_ I-GENE
)- I-GENE
_RARE_ I-GENE
- I-GENE
2 I-GENE
- I-GENE
_RARE_ I-GENE
), O
i O
. O
e O
., O
_RARE_ I-GENE
, O
were O
examined O
on O
direct O
and O
continuous O
measurements O
of O
left O
ventricular O
( O
LV O
) O
pressure O
, O
diameter O
, O
_RARE_ I-GENE
/ I-GENE
dt O
, O
velocity O
of O
shortening O
, O
arterial O
pressure O
, O
iliac O
blood O
flow O
and O
heart O
rate O
in O
10 O
conscious O
dogs O
. O

_RARE_ I-GENE
at O
the O
approach O
of O
death O
. O

_RARE_ I-GENE
treatment O
of O
schizophrenia O
with O
_RARE_ I-GENE
- I-GENE
Tyr I-GENE
- I-GENE
gamma I-GENE
- I-GENE
endorphin I-GENE

Cardiac I-GENE
_RARE_ I-GENE
levels O
and O
_RARE_ I-GENE
calcium O
binding I-GENE
activity O
in O
_RARE_ I-GENE
- I-GENE
induced O
cardiomyopathy O
. O

_RARE_ I-GENE
of O
malaria O
- I-GENE
infected O
_RARE_ I-GENE
from O
whole O
blood O
: O
use O
of O
a O
selective O
high O
- I-GENE
gradient O
magnetic O
separation O
technique O
. O

The O
_RARE_ I-GENE
- I-GENE
over O
test O
to O
predict O
_RARE_ I-GENE
in O
pregnancy O
. O

_RARE_ I-GENE
_RARE_ I-GENE
assay O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
scans O
in O
patients O
with O
differentiated O
thyroid I-GENE
cancer O
? O

3 I-GENE
Significant O
reductions O
in O
_RARE_ I-GENE
mean O
arterial O
blood O
pressure O
were O
observed O
with O
daily O
doses O
of O
200 O
mg O
(- O
9 O
%), O
400 O
mg O
(- O
10 O
%) O
and O
800 O
mg O
(- O
14 O
%), O
and O
were O
associated I-GENE
with O
significant O
decreases O
in O
heart O
rate O
and O
plasma I-GENE
renin I-GENE
activity O
. O

Isolation O
of O
_RARE_ I-GENE
from O
_RARE_ I-GENE
. O

Plasma I-GENE
and O
_RARE_ I-GENE
lipid O
profile O
and O
lipoprotein I-GENE
lipase I-GENE
activity O
in O
_RARE_ I-GENE
plasma I-GENE
on O
_RARE_ I-GENE
rabbits O
were O
studied O
and O
also O
the O
incidence O
of O
atherosclerosis O
in O
different O
arterial O
_RARE_ I-GENE
. O

( O
iii O
) O
The O
mRNA I-GENE
is O
not O
efficiently O
polyadenylated O
at O
sequences I-GENE
in O
the O
3 I-GENE
' O
end O
of O
the O
DHFR I-GENE
cDNA I-GENE
but O
rather O
uses O
polyadenylation O
signals O
downstream O
from O
the O
DHFR I-GENE
cDNA I-GENE
. O

At O
both O
water O
temperatures O
, O
VO2 O
increased O
_RARE_ I-GENE
with O
increasing O
swimming O
velocity O
. O

_RARE_ I-GENE
also O
effectively O
controlled O
her I-GENE
familial O
tremor O
. O

_RARE_ I-GENE
report O
. O

The O
distribution O
phase O
is O
followed O
by O
an O
elimination O
phase O
with O
a O
much O
longer O
half O
- I-GENE
life O
( O
mean O
value O
_RARE_ I-GENE
min O
) O
and O
a O
volume O
of O
distribution O
of O
approximately O
200 O
- I-GENE
400 O
l O
. O

_RARE_ I-GENE
- I-GENE
selection O
experiments O
against O
total O
_RARE_ I-GENE
- I-GENE
inducible I-GENE
RNA I-GENE
were O
performed O
with O
plasmid O
DNA I-GENE
derived O
from O
clones O
enriched O
in O
_RARE_ I-GENE
- I-GENE
inducible I-GENE
information O
. O

Risk O
of O
HTLV I-GENE
infection O
in O
patients O
on O
haemodialysis O
. O

In O
vitro O
metabolism O
of O
progesterone I-GENE
by O
the O
human I-GENE
_RARE_ I-GENE
testis I-GENE
. O

Two O
patients O
_RARE_ I-GENE
from O
therapy O
, O
one O
for O
personal O
_RARE_ I-GENE
and O
one O
because O
a O
_RARE_ I-GENE
mass O
developed O
. O

All O
patients O
received O
_RARE_ I-GENE
1 I-GENE
. O
0 O
mg O
/ I-GENE
m2 O
weekly O
for O
6 I-GENE
weeks O
with O
dose O
modification O
for O
neurotoxicity O
. O

_RARE_ I-GENE
acid I-GENE
in O
a O
dose O
of O
1 I-GENE
/ I-GENE
100 O
of O
the O
LD50 O
was O
injected O
in O
the O
form O
of O
sodium O
salt O
into O
male O
and O
female O
_RARE_ I-GENE
rats O
for O
7 O
days O
after O
8 O
- I-GENE
and O
12 O
- I-GENE
day O
injections O
of O
_RARE_ I-GENE
. O

Serum I-GENE
_RARE_ I-GENE
acid I-GENE
had O
an O
_RARE_ I-GENE
and O
the O
strongest O
association O
with O
systolic O
blood O
pressure O
among O
the O
risk O
factors I-GENE
including O
blood O
pressure O
, O
total O
cholesterol I-GENE
, O
_RARE_ I-GENE
, O
gamma I-GENE
- I-GENE
GTP I-GENE
and O
obesity O
. O

Plasma I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
and O
somatostatin I-GENE
- I-GENE
like I-GENE
hormone I-GENE
in O
chronic O
renal O
failure O
patients O
. O

Effect O
of O
_RARE_ I-GENE
on O
growth I-GENE
hormone I-GENE
and O
prolactin I-GENE
secretion O
in O
normal O
subjects O
. O

In O
several O
cases O
of O
definite O
_RARE_ I-GENE
, O
_RARE_ I-GENE
salivary I-GENE
gland O
examinations O
after O
more O
than O
a O
one O
year O
interval O
were O
performed O
on O
two O
_RARE_ I-GENE
, O
and O
the O
clinical O
and O
histopathological O
changes O
were O
investigated O
. O

All O
_RARE_ I-GENE
using O
the O
machine O
found O
that O
the O
_RARE_ I-GENE
terminal I-GENE
was O
simple O
to O
_RARE_ I-GENE
, O
but O
found O
that O
_RARE_ I-GENE
abnormalities O
caused O
an O
increased O
effort O
and O
_RARE_ I-GENE
a O
longer O
time O
. O

_RARE_ I-GENE
_RARE_ I-GENE
at O
the O
CM I-GENE
- I-GENE
_RARE_ I-GENE
complex I-GENE
and O
using O
_RARE_ I-GENE
gamma I-GENE
irradiation O
has O
been O
performed O
in O
a O
series O
of O
52 O
patients O
with O
severe O
pain O
due O
to O
malignancy O
. O

2 I-GENE
_RARE_ I-GENE
capsules O
, O
each O
containing O
22 O
- I-GENE
23 O
mg O
of O
_RARE_ I-GENE
estradiol O
, O
were O
inserted O
subcutaneously O
in O
5 I-GENE
men O
with O
benign O
prostatic I-GENE
hypertrophy O
. O

When O
used O
subcutaneously O
or O
intravenously O
in O
maximum O
tolerated O
doses O
the O
antibiotic O
inhibited O
the O
development O
of O
_RARE_ I-GENE
NK I-GENE
/ I-GENE
Li O
by O
90 O
and O
70 I-GENE
per O
cent O
respectively O
. O

Effect O
of O
2 I-GENE
-( O
p O
- I-GENE
_RARE_ I-GENE
) O
_RARE_ I-GENE
on O
5 I-GENE
- I-GENE
_RARE_ I-GENE
concentration O
and O
monoamine I-GENE
oxidase I-GENE
activity O
in O
rat I-GENE
brain O
. O

_RARE_ I-GENE
, O
pure O
pancreatic O
juice O
was O
infused O
into O
the O
_RARE_ I-GENE
. O

An O
experiment O
was O
carried O
on O
133 I-GENE
grown O
up O
_RARE_ I-GENE
and O
_RARE_ I-GENE
from O
4 I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
with O
_RARE_ I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
vaccines O
for O
_RARE_ I-GENE
the O
immunity O
against O
_RARE_ I-GENE
through O
_RARE_ I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
with O
a O
pathogenic O
virus I-GENE
. O

( O
2 I-GENE
) O
The O
_RARE_ I-GENE
of O
adaptive O
segmentation I-GENE
for O
the O
isolation O
of O
spikes O
and O
_RARE_ I-GENE
waves O
, O
which O
had O
been O
_RARE_ I-GENE
in O
view O
of O
the O
short O
duration O
of O
such O
_RARE_ I-GENE
in O
relation O
to O
the O
length I-GENE
of O
the O
_RARE_ I-GENE
( O
1 I-GENE
. O
2 I-GENE
sec O
) O
used O
for O
the O
_RARE_ I-GENE
functions O
employed O
in O
the O
segmentation I-GENE
algorithm O
, O
was O
confirmed O
. O

The O
ability O
of O
chronic O
_RARE_ I-GENE
- I-GENE
272 O
( O
_RARE_ I-GENE
) O
treatment O
to O
prevent O
the O
induction O
of O
_RARE_ I-GENE
ventricular O
_RARE_ I-GENE
was O
assessed O
in O
the O
conscious O
dog O
subjected O
to O
serial O
programmed O
electrical O
stimulation O
on O
days O
3 I-GENE
-- O
5 I-GENE
after O
myocardial O
infarction O
. O

The O
effect O
of O
_RARE_ I-GENE
on O
the O
biphasic O
response O
of O
rabbit I-GENE
ocular O
pressure O
to O
_RARE_ I-GENE
. O

In O
most O
cases O
of O
acute O
_RARE_ I-GENE
infarction O
, O
the O
reciprocal O
ST O
segment O
_RARE_ I-GENE
observed O
in O
contralateral O
leads O
are O
less O
marked O
than O
the O
primary O
ST O
segment O
elevations O
. O

Bacillus I-GENE
_RARE_ I-GENE
cross O
- I-GENE
infection O
in O
a O
_RARE_ I-GENE
- I-GENE
unit I-GENE
. O

We O
have O
followed O
37 O
phenytoin O
- I-GENE
treated O
patients O
with O
reduced O
serum I-GENE
IgA I-GENE
concentrations O
for O
2 I-GENE
- I-GENE
7 O
years O
. O

In O
the O
latter O
category O
particular O
_RARE_ I-GENE
is O
being O
placed O
on O
new O
_RARE_ I-GENE
analogues O
of O
_RARE_ I-GENE
and O
analogues O
of O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
course O
of O
_RARE_ I-GENE
. O

_RARE_ I-GENE
mRNA I-GENE
selected O
by O
a O
cDNA I-GENE
homologous O
to O
the O
HindIII I-GENE
- I-GENE
P I-GENE
/ I-GENE
EcoRI I-GENE
- I-GENE
B I-GENE
region O
of O
the O
_RARE_ I-GENE
map O
directed O
the O
synthesis O
of O
_RARE_ I-GENE
and O
_RARE_ I-GENE
proteins I-GENE
which O
_RARE_ I-GENE
with O
the O
_RARE_ I-GENE
and O
_RARE_ I-GENE
proteins I-GENE
translated O
from O
RNA I-GENE
selected O
by O
the O
HindIII I-GENE
- I-GENE
A I-GENE
/ I-GENE
EcoRI I-GENE
- I-GENE
C I-GENE
/ I-GENE
_RARE_ I-GENE
- I-GENE
G I-GENE
cDNA I-GENE
. O

_RARE_ I-GENE
the O
complement I-GENE
factor I-GENE
_RARE_ I-GENE
decreased O
by O
20 O
%, O
while O
alpha I-GENE
1 I-GENE
- I-GENE
antitrypsin I-GENE
showed O
postoperatively O
an O
increase O
by O
30 O
%. O

A I-GENE
polypeptide I-GENE
chain I-GENE
of O
34 O
residues O
of O
the O
deduced O
yeast I-GENE
amino O
acid I-GENE
sequence I-GENE
closely O
resembles O
a O
peptide I-GENE
sequence I-GENE
at O
the O
ADP I-GENE
binding I-GENE
site I-GENE
of O
bovine I-GENE
muscle O
_RARE_ I-GENE
kinase I-GENE
. O

The O
_RARE_ I-GENE
component O
, O
however O
, O
could O
be O
differentiated O
from O
the O
two O
later O
components O
since O
it O
increased O
in O
amplitude O
with O
increased O
task O
_RARE_ I-GENE
while O
the O
N2 O
and O
P3 I-GENE
amplitudes O
remained O
constant O
. O

Differential O
_RARE_ I-GENE
size O
associated I-GENE
with O
unilateral O
brain O
damage O
. O

The O
_RARE_ I-GENE
administration O
of O
both O
drugs O
markedly O
reduced O
the O
incidence O
of O
VF O
induced O
by O
the O
release O
of O
a O
40 I-GENE
- I-GENE
min O
coronary O
artery O
occlusion O
. O

These O
fusions I-GENE
are O
contained O
on O
plasmids O
which O
have O
both O
yeast I-GENE
and O
E I-GENE
. O
coli I-GENE
replication O
origins O
and O
selectable O
markers O
and O
, O
therefore O
, O
can O
be O
used O
to O
transform O
either O
yeast I-GENE
or O
E I-GENE
. O
coli I-GENE
cells O
. O

Therefore O
, O
it O
was O
concluded O
that O
thrombotic O
tendency O
_RARE_ I-GENE
existed O
in O
patients O
with O
MS O
compared O
to O
those O
with O
non O
_RARE_ I-GENE
and O
that O
it O
was O
one O
of O
the O
causes O
of O
the O
significantly O
high O
incidence O
of O
_RARE_ I-GENE
in O
comparison O
with O
non O
_RARE_ I-GENE
. O

_RARE_ I-GENE
was O
significant O
in O
selected O
cases O
; O
three O
patients O
developed O
WBC O
counts O
less O
than O
1 I-GENE
, O
000 O
/ I-GENE
_RARE_ I-GENE
and O
one O
of O
these O
patients O
died O
with O
sepsis O
. O

_RARE_ I-GENE
electrodes O
may O
yield O
larger O
_RARE_ I-GENE
amplitudes O
than O
_RARE_ I-GENE
or O
_RARE_ I-GENE
electrodes O
. O

_RARE_ I-GENE
of O
immune I-GENE
cells O
such O
as O
transfer I-GENE
factor I-GENE
and O
_RARE_ I-GENE
form O
the O
third O
and O
possibly O
most O
important O
group O
of O
immune I-GENE
- I-GENE
stimulating I-GENE
agents O
. O

Use O
of O
the O
immunofluorescence O
method O
for O
identification O
of O
_RARE_ I-GENE
in O
cell O
cultures O

This O
fraction O
is O
resistant O
to O
_RARE_ I-GENE
by O
DNase I-GENE
I I-GENE
and O
RNase I-GENE
T1 O
and O
_RARE_ I-GENE
completely O
upon O
_RARE_ I-GENE
hydrolysis O
. O

The O
construction I-GENE
of O
a O
small I-GENE
library O
of O
mouse I-GENE
repetitive O
DNA I-GENE
has O
been O
previously O
reported O
( O
_RARE_ I-GENE
et O
al O
., O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
. O

No O
direct O
repeats I-GENE
flank O
the O
pseudogene I-GENE
in O
the O
U2 I-GENE
/ I-GENE
4 I-GENE
locus I-GENE
. O

The O
direct O
effects O
of O
_RARE_ I-GENE
release O
were O
( O
a O
) O
an O
early I-GENE
fall O
in O
MAP I-GENE
followed O
by O
a O
late O
pressor O
effect O
; O
and O
( O
b I-GENE
) O
an O
early I-GENE
_RARE_ I-GENE
followed O
by O
a O
late O
tachycardia O
. O

At O
_RARE_ I-GENE
( O
_RARE_ I-GENE
), O
a O
_RARE_ I-GENE
characterized O
by O
a O
high O
incidence O
of O
_RARE_ I-GENE
and O
_RARE_ I-GENE
deficiency O
less O
than O
half O
the O
people O
between O
18 O
and O
35 O
have O
a O
_RARE_ I-GENE
knowledge O
of O
genetic O
diseases O
and O
of O
their O
prevention O
. O

The O
number O
of O
elements O
and O
their O
sizes O
relative O
to O
the O
configuration O
were O
varied O
in O
a O
series O
of O
five O
experiments O
. O

In O
addition O
, O
the O
overall O
_RARE_ I-GENE
that O
a O
patient O
would O
undergo O
ET I-GENE
was O
greater O
in O
a O
cycle O
in O
which O
more O
than O
one O
follicle I-GENE
20 O
mm O
or O
larger O
was O
developing O
than O
in O
a O
cycle O
in O
which O
a O
single O
large O
follicle I-GENE
was O
developing O
. O

_RARE_ I-GENE
with O
the O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
free O
flap O
. O

Five O
of O
the O
patients O
with O
increased O
L I-GENE
- I-GENE
L I-GENE
size O
had O
a O
normal O
A I-GENE
- I-GENE
P I-GENE
diameter O
. O

_RARE_ I-GENE
with O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
combined O
with O
chemotherapeutic O
agents O
was O
evaluated O
in O
two O
_RARE_ I-GENE
tumor I-GENE
- I-GENE
C3H O
/ I-GENE
He O
mouse I-GENE
systems O
. O

However O
, O
when O
combined O
with O
_RARE_ I-GENE
C I-GENE
given O
with O
1 I-GENE
to O
5 I-GENE
- I-GENE
days O
interval O
, O
the O
concurrent O
administration O
of O
_RARE_ I-GENE
prolonged O
significantly O
the O
life O
- I-GENE
span O
of O
the O
tumor I-GENE
- I-GENE
bearing O
mice O
. O

Data O
are O
presented O
_RARE_ I-GENE
that O
the O
15 O
beta I-GENE
- I-GENE
hydroxy I-GENE
-, I-GENE
metabolite O
of O
_RARE_ I-GENE
may O
_RARE_ I-GENE
be O
the O
biologically O
active O
agent O
. O

The O
_RARE_ I-GENE
surface O
is O
often O
almost O
entirely O
_RARE_ I-GENE
by O
a O
thick O
layer O
of O
_RARE_ I-GENE
connective O
tissue I-GENE
. O

In O
contrast O
, O
in O
_RARE_ I-GENE
patients O
during O
_RARE_ I-GENE
the O
_RARE_ I-GENE
- I-GENE
induced O
suppressor I-GENE
response O
was O
markedly O
reduced O
. O

Functional O
characterization O
of O
a O
fraction O
identified O
by O
its O
activity O
in O
a O
second O
template O
rescue O
assay O
. O

It O
has O
been O
established O
that O
preoperative O
irradiation O
in O
the O
form O
of O
the O
fractionation O
of O
a O
single O
focal I-GENE
dose O
of O
6 I-GENE
Gy O
every O
other O
day O
, O
the O
summary O
dose O
of O
24 O
Gy O
within O
8 O
- I-GENE
10 O
days O
followed O
by O
surgery O
1 I-GENE
- I-GENE
3 I-GENE
days O
after O
irradiation O
does O
not O
either O
_RARE_ I-GENE
its O
performance O
or O
the O
course O
of O
the O
postoperative O
period O
, O
and O
by O
the O
short O
- I-GENE
and O
long O
- I-GENE
term O
results O
it O
is O
no O
_RARE_ I-GENE
than O
the O
routine O
dose O
fractionation O
. O

_RARE_ I-GENE
gels O
and O
their O
possible O
_RARE_ I-GENE
for O
surface O
_RARE_ I-GENE
in O
health O
and O
disease O
. O

Hepatitis I-GENE
- I-GENE
B I-GENE
vaccination O
in O
the O
elderly O
. O

_RARE_ I-GENE
imaging O
is O
thus O
of O
limited O
use O
in O
evaluation O
of O
suspected O
_RARE_ I-GENE
cell O
tumors O
of O
bone O
. O

The O
_RARE_ I-GENE
coupling O
_RARE_ I-GENE
_RARE_ I-GENE
acid I-GENE
has O
been O
replaced O
by O
1 I-GENE
, O
3 I-GENE
- I-GENE
_RARE_ I-GENE
acid I-GENE
; O
_RARE_ I-GENE
is O
produced O
in O
the O
flow O
through O
system O
directly O
from O
_RARE_ I-GENE
and O
_RARE_ I-GENE
T I-GENE
. O

_RARE_ I-GENE
volume O
stiffness O
vs O
. O
the O
mean O
wall O
stress O
relationship O
of O
_RARE_ I-GENE
shifted O
_RARE_ I-GENE
, O
whereas O
the O
normalized O
wall O
muscle O
stiffness O
vs O
. O
the O
mean O
wall O
stress O
relationship O
of O
_RARE_ I-GENE
showed O
a O
smaller O
slope O
. O

_RARE_ I-GENE
of O
(+)- I-GENE
_RARE_ I-GENE
acid I-GENE
_RARE_ I-GENE
_RARE_ I-GENE

_RARE_ I-GENE
loss O
reduces O
arterial O
pressure O
by O
a O
decrease O
in O
intravascular O
volume O
and O
cardiac O
output O
associated I-GENE
with O
a O
fall O
in O
sympathetic O
activity O
. O

The O
effect O
of O
treatment O
may O
thus O
be O
divided O
into O
two O
main O
phases O
-- O
an O
initial O
phase O
with O
a O
reduction O
in O
LV O
mass O
and O
a O
reduction O
in O
cardiac O
output O
and O
no O
change O
in O
total O
peripheral O
resistance O
-- O
and O
a O
second O
phase O
with O
a O
constant O
LV O
mass O
but O
an O
increase O
in O
cardiac O
output O
to O
the O
pretreatment O
level O
again O
and O
a O
concomitant O
decrease O
in O
total O
peripheral O
resistance O
. O

This O
study O
was O
undertaken O
to O
assess O
the O
effects O
of O
hypothermia O
and O
chemical O
_RARE_ I-GENE
on O
the O
functional O
recovery O
of O
_RARE_ I-GENE
non O
- I-GENE
_RARE_ I-GENE
rat I-GENE
hearts O
subjected O
to O
an O
extended O
period O
of O
global O
ischaemia O
. O

_RARE_ I-GENE
profiles O
calculated O
for O
the O
_RARE_ I-GENE
model O
with O
_RARE_ I-GENE
diffusion O
were O
similar O
to O
those O
derived O
for O
the O
two O
models O
of O
_RARE_ I-GENE
diffusion O
. O

_RARE_ I-GENE
_RARE_ I-GENE
for O
_RARE_ I-GENE
_RARE_ I-GENE

_RARE_ I-GENE
of O
serum I-GENE
creatine I-GENE
kinase I-GENE
B I-GENE
_RARE_ I-GENE
in O
the O
diagnosis O
of O
acute O
myocardial O
infarction O
. O

Selective O
macrophage I-GENE
inhibition O
abolishes O
_RARE_ I-GENE
- I-GENE
induced O
reduction O
of O
metastasis O
. O

Restriction O
enzyme I-GENE
and O
_RARE_ I-GENE
analyses O
confirmed O
that O
sequences I-GENE
unique O
to O
_RARE_ I-GENE
( O
src I-GENE
sequences I-GENE
) O
are O
located O
at O
the O
center I-GENE
of O
the O
_RARE_ I-GENE
genome O
and O
are O
approximately O
1 I-GENE
. O
5 I-GENE
kilobase O
pairs O
in O
length I-GENE
. O

Among O
six O
different O
library O
isolates O
containing O
6 I-GENE
. O
5 I-GENE
- I-GENE
to O
7 O
- I-GENE
kb O
_RARE_ I-GENE
units O
, O
some O
restriction I-GENE
sites I-GENE
were O
highly O
conserved O
whereas O
others O
varied O
in O
both O
occurrence O
and O
position O
. O

_RARE_ I-GENE
and O
_RARE_ I-GENE
learning O
: O
a O
review O
. O

A I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
strain O
of O
E I-GENE
. O
coli I-GENE
( O
_RARE_ I-GENE
: O
_RARE_ I-GENE
: O
_RARE_ I-GENE
) O
was O
_RARE_ I-GENE
recovered O
from O
_RARE_ I-GENE
with O
_RARE_ I-GENE
while O
_RARE_ I-GENE
was O
demonstrated O
on O
a O
number O
of O
_RARE_ I-GENE
. O

The O
antibody I-GENE
titer O
of O
_RARE_ I-GENE
chickens O
to O
SA O
- I-GENE
11 O
_RARE_ I-GENE
was O
determined O
by O
enzyme I-GENE
- I-GENE
linked O
immunosorbent O
blocking O
assay O
. O

_RARE_ I-GENE
( O
dT O
) O
and O
_RARE_ I-GENE
calf I-GENE
_RARE_ I-GENE
DNA I-GENE
were O
more O
effective O
than O
were O
other O
_RARE_ I-GENE
tested O
in O
promoting I-GENE
accumulation O
of O
19 O
_RARE_ I-GENE
_RARE_ I-GENE
( O
dT O
) O
8 O
was O
as O
effective O
as O
were O
longer O
molecules I-GENE
of O
( O
dT O
) O
n O
, O
but O
( O
dT O
) O
4 I-GENE
and O
( O
dT O
) O
6 I-GENE
were O
much O
less O
effective O
, O
indicating O
that O
the O
binding I-GENE
site I-GENE
involved O
in O
19 O
_RARE_ I-GENE
* I-GENE
accumulation O
_RARE_ I-GENE
between O
6 I-GENE
and O
8 O
residues O
of O
( O
dT O
) O
n O
. O

A I-GENE
double O
- I-GENE
blind O
trial O
of O
half O
- I-GENE
strength O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
bladder O
irrigation O
in O
_RARE_ I-GENE
. O

Thus O
it O
appears O
that O
insertion O
of O
a O
_RARE_ I-GENE
element I-GENE
near O
the O
5 I-GENE
' O
terminus O
of O
the O
structural O
gene I-GENE
can O
produce O
constitutive O
expression O
of O
a O
normally O
glucose O
- I-GENE
repressed O
enzyme I-GENE
. O

Five O
experiments O
examined O
the O
influence O
of O
opiate I-GENE
antagonists O
on O
both O
the O
short O
- I-GENE
term O
analgesic O
reaction O
resulting O
30 O
min O
after O
exposure O
to O
_RARE_ I-GENE
shock I-GENE
and O
the O
long O
- I-GENE
term O
analgesic O
reaction O
resulting O
after O
_RARE_ I-GENE
to O
shock I-GENE
24 O
hr O
after O
_RARE_ I-GENE
shock I-GENE
exposure O
. O

Experiment O
3 I-GENE
showed O
that O
the O
long O
- I-GENE
term O
analgesic O
reaction O
could O
also O
be O
reduced O
by O
administration O
of O
naltrexone O
prior O
to O
_RARE_ I-GENE
to O
shock I-GENE
. O

During O
the O
period O
from O
_RARE_ I-GENE
to O
August O
, O
_RARE_ I-GENE
, O
an O
epidemic O
of O
hand O
, O
foot O
and O
mouth O
disease O
( O
_RARE_ I-GENE
) O
occurred O
in O
_RARE_ I-GENE
_RARE_ I-GENE
. O

A I-GENE
_RARE_ I-GENE
polypeptide I-GENE
was O
detected O
as O
a O
translation I-GENE
product I-GENE
of O
late O
RNA I-GENE
that O
hybridized O
to O
this O
DNA I-GENE
fragment I-GENE
. O

_RARE_ I-GENE
simian I-GENE
virus I-GENE
40 I-GENE
( O
SV40 I-GENE
) O
chromosomes O
were O
found O
to O
be O
similar O
to O
other O
eukaryotic I-GENE
chromosomes O
in O
that O
the O
rate O
and O
extent O
of O
_RARE_ I-GENE
nuclease I-GENE
( O
_RARE_ I-GENE
) O
digestion O
were O
greater O
with O
replicating I-GENE
than O
with O
_RARE_ I-GENE
mature O
SV40 I-GENE
chromatin O
. O

A I-GENE
hypothesis O
. O

We O
have O
investigated O
the O
requirements O
of O
the O
_RARE_ I-GENE
gene I-GENE
switch O
by O
characterizing O
two O
rearranged I-GENE
gamma I-GENE
2b I-GENE
genes I-GENE
from O
a O
gamma I-GENE
2b I-GENE
producing O
mouse I-GENE
myeloma O
( O
_RARE_ I-GENE
- I-GENE
11 O
). O

_RARE_ I-GENE
and O
_RARE_ I-GENE

The O
genome O
of O
avian I-GENE
_RARE_ I-GENE
virus I-GENE
contains O
two O
independently O
expressed O
genetic O
loci I-GENE
( O
v I-GENE
- I-GENE
erbA I-GENE
and O
v I-GENE
- I-GENE
erbB I-GENE
) O
whose O
activities O
are O
probably O
responsible O
for O
_RARE_ I-GENE
by O
the O
virus I-GENE
. O

Because O
RNase I-GENE
III I-GENE
host O
mutants I-GENE
are O
defective O
in O
_RARE_ I-GENE
regulation O
, O
processing O
of O
the O
PL I-GENE
mRNA I-GENE
at O
_RARE_ I-GENE
by O
this O
_RARE_ I-GENE
may O
cause O
int I-GENE
mRNA I-GENE
decay O
and O
decrease O
int I-GENE
synthesis O
. O

At O
least O
one O
clone O
, O
lambda I-GENE
_RARE_ I-GENE
41 O
, O
contains O
, O
in O
addition O
to O
the O
histone I-GENE
genes I-GENE
, O
a O
region O
that O
_RARE_ I-GENE
with O
a O
cytoplasmic I-GENE
RNA I-GENE
approximately O
_RARE_ I-GENE
nucleotides O
in O
length I-GENE
. O

Both O
neural O
and O
hormonal O
pathways O
and O
both O
opiate I-GENE
and O
_RARE_ I-GENE
substances O
play O
roles O
in O
the O
complex I-GENE
modulation O
of O
pain O
transmission O
. O

_RARE_ I-GENE
of O
impaired O
immune I-GENE
functions O
in O
aging O
animals O
. O

_RARE_ I-GENE
serum I-GENE
ACTH I-GENE
levels O
were O
normal O
. O

WR O
- I-GENE
2721 O
( O
S I-GENE
- I-GENE
2 I-GENE
-( O
3 I-GENE
_RARE_ I-GENE
) O
_RARE_ I-GENE
acid I-GENE
) O
has O
been O
investigated O
for O
its O
ability O
to O
protect O
gut O
, O
lung O
, O
and O
testis I-GENE
, O
as O
well O
as O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
tumor I-GENE
nodules O
, O
in O
the O
lungs O
of O
mice O
from O
gamma I-GENE
- I-GENE
radiation O
injury O
. O

In O
fact O
, O
families O
of O
polypeptides I-GENE
were O
produced O
by O
initiation I-GENE
of O
translation I-GENE
at O
AUG O
codons O
within O
sequences I-GENE
coding O
for O
_RARE_ I-GENE
and O
T I-GENE
, O
presumably O
as O
a O
result O
of O
transcription I-GENE
initiation I-GENE
events O
that O
generated O
5 I-GENE
' O
ends O
immediately O
upstream O
from O
these O
_RARE_ I-GENE
. O

In O
addition O
, O
_RARE_ I-GENE
RI I-GENE
_RARE_ I-GENE
DNA I-GENE
is O
organized O
into O
_RARE_ I-GENE
whose O
size O
and O
_RARE_ I-GENE
are O
indistinguishable O
from O
that O
of O
bulk O
yeast I-GENE
chromatin O
. O

The O
frequency O
of O
previous O
transfusion O
in O
chronic O
hepatitis I-GENE
, O
cirrhosis O
and O
_RARE_ I-GENE
carcinoma O
of O
type I-GENE
NANB O
was O
42 O
. O
8 O
, O
37 O
. O
1 I-GENE
and O
15 O
. O
1 I-GENE
%, O
respectively O
, O
whereas O
the O
incidence O
of O
early I-GENE
_RARE_ I-GENE
hepatitis I-GENE
was O
8 O
. O
5 I-GENE
, O
8 O
. O
6 I-GENE
and O
7 O
. O
5 I-GENE
%, O
respectively O
. O
in O
chronic O
liver O
diseases O
with O
a O
history O
of O
jaundice O
and O
/ I-GENE
or O
hepatitis I-GENE
, O
previous O
_RARE_ I-GENE
are O
more O
frequently O
associated I-GENE
with O
type I-GENE
NANB O
than O
with O
type I-GENE
B I-GENE
disease O
. O

Of O
115 I-GENE
hepatitis I-GENE
B I-GENE
patients O
seen O
at O
12 O
months O
, O
6 I-GENE
% O
had O
chronic O
hepatitis I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
, O
60 O
% O
had O
developed O
anti I-GENE
- I-GENE
HBs I-GENE
antibodies I-GENE
, O
and O
7 O
. O
3 I-GENE
% O
still O
had O
abnormal O
liver O
function O
. O

_RARE_ I-GENE
on O
antibody I-GENE
against O
egg I-GENE
drop O
syndrome O
- I-GENE
_RARE_ I-GENE
virus I-GENE
among O
chicken I-GENE
_RARE_ I-GENE
in O
Japan O
. O

In O
49 O
patients O
in O
whom O
gated O
equilibrium O
_RARE_ I-GENE
and O
cardiac O
_RARE_ I-GENE
were O
performed O
within O
a O
6 I-GENE
day O
interval O
, O
total O
and O
fractional O
portions O
of O
global O
and O
regional O
right O
ventricular O
ejection O
fraction O
( O
_RARE_ I-GENE
) O
were O
correlated O
with O
pulmonary O
arterial O
systolic O
pressure O
. O

74 O
, O
193 O
- I-GENE
_RARE_ I-GENE
). O

The O
combination O
of O
_RARE_ I-GENE
and O
WR O
- I-GENE
2721 O
gave O
an O
intermediate O
response O
compared O
with O
either O
drug O
used O
alone O
, O
resulting O
in O
some O
sensitization O
with O
single O
doses O
and O
an O
overall O
protection O
with O
repeated O
small I-GENE
doses O
. O

Two O
mutations O
that O
affect O
larval I-GENE
_RARE_ I-GENE
protein I-GENE
gene I-GENE
expression O
in O
the O
2 I-GENE
/ I-GENE
3 I-GENE
variant I-GENE
Drosophila I-GENE
melanogaster I-GENE
strain O
were O
investigated O
. O

The O
_RARE_ I-GENE
are O
considered O
to O
be O
one O
of O
the O
forms O
of O
activity O
of O
the O
structured O
_RARE_ I-GENE
cortical O
units O
, O
i O
. O
e O
. O
the O
_RARE_ I-GENE
. O

The O
strong O
conservation O
of O
the O
inverted O
terminal I-GENE
repeat I-GENE
sequence I-GENE
may O
reflect O
a O
common O
integration O
mechanism O
for O
_RARE_ I-GENE
elements O
and O
MuLV O
_RARE_ I-GENE
. O

A I-GENE
cDNA I-GENE
cloning O
vector O
that O
permits O
expression O
of O
cDNA I-GENE
inserts O
in O
mammalian I-GENE
cells O
. O

Hybridization O
of O
plasmid O
- I-GENE
transformed O
Escherichia I-GENE
coli I-GENE
_RARE_ I-GENE
colonies O
with O
32P O
- I-GENE
labeled O
viral I-GENE
genome O
RNAs I-GENE
demonstrated O
the O
presence O
of O
DNA I-GENE
clones O
representative O
of O
each O
of O
the O
10 O
_RARE_ I-GENE
RNAs I-GENE
and O
10 O
of O
the O
11 O
_RARE_ I-GENE
segments O
of O
the O
_RARE_ I-GENE
genome O
. O

Another O
sequence I-GENE
, O
_RARE_ I-GENE
, O
which O
is O
repeated O
several O
times O
in O
many O
_RARE_ I-GENE
and O
_RARE_ I-GENE
, O
and O
which O
is O
thought O
to O
play O
a O
role O
in O
DNA I-GENE
replication O
and O
/ I-GENE
or O
transcription I-GENE
, O
is O
not O
found O
in O
the O
_RARE_ I-GENE
sequence I-GENE
presented O
. O

In O
conclusion O
, O
these O
studies O
indicate O
that O
_RARE_ I-GENE
( O
1 I-GENE
) O
decreases O
histamine O
- I-GENE
stimulated O
gastric O
acid I-GENE
secretion O
, O
and O
( O
2 I-GENE
) O
_RARE_ I-GENE
bile O
- I-GENE
induced O
disruption O
of O
the O
gastric O
mucosal I-GENE
barrier O
in O
the O
canine O
_RARE_ I-GENE
_RARE_ I-GENE
. O

Lung O
density I-GENE
increased O
in O
_RARE_ I-GENE
- I-GENE
exposed O
, O
but O
not O
in O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
exposed O
animals O
. O

The O
hepatitis I-GENE
A I-GENE
virus I-GENE
antibody I-GENE
( O
anti I-GENE
- I-GENE
_RARE_ I-GENE
) O
in O
chronic O
diffuse O
liver O
diseases O

The O
junctions O
between O
viral I-GENE
and O
cellular O
sequences I-GENE
were O
determined O
by O
DNA I-GENE
sequence I-GENE
analysis O
to O
be O
_RARE_ I-GENE
nucleotides O
into O
the O
_RARE_ I-GENE
sequence I-GENE
and O
1 I-GENE
, O
_RARE_ I-GENE
nucleotides O
into O
the O
polymerase I-GENE
sequence I-GENE
. O

_RARE_ I-GENE
( O
2 I-GENE
mg O
/ I-GENE
kg O
bolus O
+ I-GENE
2 I-GENE
mg O
X I-GENE
kg O
- I-GENE
1 I-GENE
X I-GENE
h O
- I-GENE
1 I-GENE
) O
was O
given O
with O
one O
of O
the O
two O
doses O
of O
the O
lipopolysaccharide O
. O

Gel O
route O
preparation O
of O
low O
_RARE_ I-GENE
dental O
_RARE_ I-GENE
_RARE_ I-GENE
. O

I I-GENE
. O

_RARE_ I-GENE
RNA I-GENE
, O
molecularly O
cloned O
proviral I-GENE
DNA I-GENE
, O
and O
virus I-GENE
- I-GENE
specific I-GENE
protein I-GENE
of O
avian I-GENE
retrovirus O
_RARE_ I-GENE
were O
analyzed O
. O

_RARE_ I-GENE
recordings O
were O
performed O
on O
the O
optic O
_RARE_ I-GENE
of O
the O
_RARE_ I-GENE
in O
vitro O
. O

Molecular O
structure O
and O
evolutionary O
origin O
of O
human I-GENE
cardiac O
muscle O
actin I-GENE
gene I-GENE
. O

The O
mutants I-GENE
were O
obtained O
by O
substitution O
into O
a O
molecular O
clone O
of O
M I-GENE
- I-GENE
MuLV O
DNA I-GENE
by O
DNA I-GENE
from O
two O
_RARE_ I-GENE
transforming I-GENE
viruses O
, O
_RARE_ I-GENE
MuLV O
( O
Ab I-GENE
- I-GENE
MuLV O
) O
and O
Moloney O
murine I-GENE
sarcoma I-GENE
virus I-GENE
( O
M I-GENE
- I-GENE
_RARE_ I-GENE
). O

_RARE_ I-GENE
for O
the O
cloning O
and O
expression O
of O
full I-GENE
- I-GENE
length I-GENE
double O
- I-GENE
stranded I-GENE
cDNAs I-GENE
under O
control O
of O
the O
SV40 I-GENE
early I-GENE
or O
late O
gene I-GENE
promoter I-GENE
. O

_RARE_ I-GENE
a O
soybean I-GENE
protein I-GENE
and O
sucrose O
- I-GENE
based O
diet O
with O
levels O
of O
2 I-GENE
. O
2 I-GENE
, O
11 O
, O
and O
55 O
ppm O
of O
the O
antibiotic O
, O
from O
the O
two O
sources O
each O
with O
two O
different O
_RARE_ I-GENE
, O
improved O
weight O
gain O
of O
chicks O
an O
average O
of O
23 O
% O
and O
improved O
feed O
efficiency O
an O
average O
of O
13 O
% O
at O
the O
higher O
levels O
( O
all O
P I-GENE
less O
than O
. O
01 O
). O

The O
_RARE_ I-GENE
- I-GENE
lacZ I-GENE
and O
the O
_RARE_ I-GENE
- I-GENE
lacZ I-GENE
fused O
genes I-GENE
were O
constructed O
and O
hybrid O
proteins I-GENE
with O
beta I-GENE
- I-GENE
galactosidase I-GENE
activity O
were O
produced O
. O

Overall O
_RARE_ I-GENE
of O
antibody I-GENE
were O
70 I-GENE
per O
cent O
in O
cattle O
, O
67 O
per O
cent O
in O
sheep O
and O
76 I-GENE
per O
cent O
in O
goats O
as O
assessed O
by O
an O
_RARE_ I-GENE
test O
. O

Expression O
of O
herpes I-GENE
simplex I-GENE
virus I-GENE
beta I-GENE
and O
gamma I-GENE
genes I-GENE
integrated O
in O
mammalian I-GENE
cells O
and O
their O
induction O
by O
an O
alpha I-GENE
gene I-GENE
product I-GENE
. O

The O
splice O
acceptor O
site I-GENE
is O
_RARE_ I-GENE
. O

This O
is O
consistent O
with O
a O
model O
_RARE_ I-GENE
that O
_RARE_ I-GENE
was O
generated O
by O
recombination O
between O
proviral I-GENE
DNA I-GENE
of O
a O
simian I-GENE
sarcoma I-GENE
associated I-GENE
virus I-GENE
and O
proto I-GENE
- I-GENE
_RARE_ I-GENE
and O
that O
introns O
were O
spliced O
out O
subsequently O
from O
a O
fused O
viral I-GENE
- I-GENE
_RARE_ I-GENE
messenger I-GENE
RNA I-GENE
. O

We O
conclude O
that O
, O
with O
_RARE_ I-GENE
nervous O
system O
activity O
intact O
, O
carotid O
_RARE_ I-GENE
reflex O
activation O
can O
elicit O
an O
absolute O
_RARE_ I-GENE
mediated O
reduction O
in O
coronary O
blood O
flow O
in O
the O
normal O
, O
conscious O
dog O
, O
despite O
an O
increase O
in O
arterial O
pressure O
. O

Female O
subjects O
, O
including O
both O
normal O
subjects O
and O
idiopathic O
calcium O
stone O
- I-GENE
_RARE_ I-GENE
, O
have O
higher O
urinary O
cyclic I-GENE
AMP I-GENE
levels O
than O
their O
male O
counterparts O
, O
and O
this O
difference O
is O
significant O
when O
urinary O
cyclic I-GENE
AMP I-GENE
is O
expressed O
in O
the O
units O
mumol O
/ I-GENE
g O
of O
creatinine O
. O

We O
conclude O
that O
the O
' O
_RARE_ I-GENE
_RARE_ I-GENE
' O
observed O
in O
asthmatic O
patients O
cannot O
_RARE_ I-GENE
be O
explained O
by O
changes O
in O
cell O
receptor I-GENE
number O
or O
affinity O
, O
as O
our O
results O
suggest O
that O
both O
groups O
have O
intact O
beta I-GENE
- I-GENE
adrenoceptor I-GENE
function O
. O

The O
effect O
of O
desipramine O
probably O
represents O
inhibition O
of O
neuronal O
uptake O
and O
that O
of O
_RARE_ I-GENE
and O
_RARE_ I-GENE
blockade O
of O
neuronal O
uptake O
and O
_RARE_ I-GENE
alpha I-GENE
2 I-GENE
- I-GENE
_RARE_ I-GENE
. O

We O
conclude O
that O
the O
_RARE_ I-GENE
structural O
gene I-GENE
is O
required O
for O
initiation I-GENE
or O
amplification O
of O
the O
splenic O
_RARE_ I-GENE
hyperplasia O
which O
_RARE_ I-GENE
the O
_RARE_ I-GENE
phase O
of O
_RARE_ I-GENE
disease O
. O

_RARE_ I-GENE
treatment O
of O
pulmonary O
metastases O
. O

A I-GENE
promoter I-GENE
sequence I-GENE
( O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
or O
TATA I-GENE
box I-GENE
) O
is O
situated O
28 O
base O
pairs O
upstream O
from O
the O
point O
of O
initiation I-GENE
of O
transcription I-GENE
which O
was O
found O
by O
S1 I-GENE
nuclease I-GENE
mapping O
and O
by O
oligonucleotide I-GENE
- I-GENE
primed O
reverse I-GENE
transcription I-GENE
of O
rat I-GENE
PTH I-GENE
mRNA I-GENE
. O

Each O
of O
these O
spliced O
mRNAs I-GENE
has O
an O
untranslated O
leader O
sequence I-GENE
of O
_RARE_ I-GENE
bases O
and O
a O
single O
intron O
of O
approximately O
_RARE_ I-GENE
bases O
which O
are O
contained O
entirely O
within O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
sequences I-GENE
. O

The O
expression O
of O
chloramphenicol I-GENE
acetyltransferase I-GENE
was O
detected O
within O
1 I-GENE
h O
after O
infection O
of O
cells O
with O
recombinant I-GENE
virus I-GENE
, O
reflecting O
the O
early I-GENE
nature O
of O
the O
promoters I-GENE
used O
. O

_RARE_ I-GENE
II I-GENE
synthesis O
, O
measured O
by O
agar O
plate I-GENE
assays O
of O
_RARE_ I-GENE
resistance O
and O
by O
immunoprecipitation O
of O
the O
_RARE_ I-GENE
II I-GENE
protein I-GENE
, O
was O
repressed O
in O
the O
presence O
of O
cysteine I-GENE
and O
_RARE_ I-GENE
in O
its O
absence O
. O

A I-GENE
computed O
_RARE_ I-GENE
scan O
obtained O
after O
_RARE_ I-GENE
- I-GENE
13 O
infusion O
accurately O
showed O
the O
perfusion O
pattern O
of O
the O
implanted O
catheter O
. O

The O
primary O
structure O
of O
the O
_RARE_ I-GENE
5 I-GENE
' O
flanking O
region O
has O
many O
features O
common O
to O
those O
of O
_RARE_ I-GENE
eukaryotic I-GENE
genes I-GENE
. O

The O
12 O
, O
000 O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
IE I-GENE
polypeptide I-GENE
encoded I-GENE
by O
_RARE_ I-GENE
- I-GENE
5 I-GENE
is O
translated O
from O
an O
88 O
codon O
open O
reading O
frame O
, O
_RARE_ I-GENE
a O
_RARE_ I-GENE
base O
3 I-GENE
' O
non O
- I-GENE
translated O
region O
. O

The O
greatest O
difference O
between O
the O
_RARE_ I-GENE
and O
Ad5 I-GENE
_RARE_ I-GENE
is O
the O
absence O
, O
in O
the O
_RARE_ I-GENE
protein I-GENE
, O
of O
12 O
amino O
acids O
located O
between O
the O
two O
functional O
domains I-GENE
in O
the O
Ad5 I-GENE
protein I-GENE
( O
amino O
acids O
151 O
- I-GENE
_RARE_ I-GENE
). O

No O
significant O
correlation O
was O
found O
between O
_RARE_ I-GENE
or O
wall O
thickness O
and O
body O
surface O
area O
, O
age O
, O
blood O
pressure O
, O
heart O
rate O
, O
cardiac O
output O
, O
total O
peripheral O
resistance O
and O
left O
ventricular O
systolic O
wall O
stress O
, O
whereas O
_RARE_ I-GENE
was O
correlated O
with O
urinary O
catecholamines O
only O
in O
hypertensive O
patients O
( O
r O
= O
0 O
. O
_RARE_ I-GENE
, O
p O
less O
than O
0 O
. O
001 O
). O

Furthermore O
, O
no O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
sequences I-GENE
are O
present O
upstream O
of O
the O
presumed I-GENE
translational O
start O
codons O
. O

The O
gene I-GENE
cat O
- I-GENE
86 I-GENE
, O
_RARE_ I-GENE
chloramphenicol I-GENE
- I-GENE
inducible I-GENE
chloramphenicol I-GENE
acetyltransferase I-GENE
, O
is O
located O
on O
the O
1 I-GENE
. O
1 I-GENE
- I-GENE
kilobase O
cloned O
DNA I-GENE
. O

The O
_RARE_ I-GENE
sarcoma I-GENE
virus I-GENE
( O
_RARE_ I-GENE
) O
was O
derived O
by O
passage O
of O
Moloney O
sarcoma I-GENE
virus I-GENE
( O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
) O
in O
adult O
mice O
. O

The O
same O
- I-GENE
sized O
EBNA I-GENE
protein I-GENE
( O
approximately O
78 O
, O
000 O
) O
was O
made O
after O
transfection O
with O
BamHI I-GENE
- I-GENE
K I-GENE
( O
5 I-GENE
. O
2 I-GENE
kilobase O
pairs O
[ O
kbp O
]) I-GENE
or O
the O
_RARE_ I-GENE
_RARE_ I-GENE
( O
2 I-GENE
. O
9 O
kbp O
). O

They O
generated O
_RARE_ I-GENE
. O

Here O
we O
have O
determined O
the O
nucleotide I-GENE
sequence I-GENE
of O
3 I-GENE
. O
5 I-GENE
kb O
from O
the O
3 I-GENE
' O
end O
of O
delta I-GENE
gag I-GENE
to O
the O
3 I-GENE
' O
end O
of O
molecularly O
cloned O
proviral I-GENE
_RARE_ I-GENE
DNA I-GENE
, O
in O
order O
to O
elucidate O
the O
genetic O
structure O
of O
the O
virus I-GENE
and O
to O
compare O
it O
with O
other O
_RARE_ I-GENE
- I-GENE
and O
myc I-GENE
- I-GENE
containing O
oncogenic I-GENE
viruses O
as O
well O
as O
with O
the O
chicken I-GENE
proto I-GENE
- I-GENE
myc I-GENE
gene I-GENE
. O

_RARE_ I-GENE
80 O
, O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
] O
was O
used O
to O
isolate O
a O
genomic O
clone O
lambda I-GENE
_RARE_ I-GENE
- I-GENE
1 I-GENE
containing O
a O
portion O
of O
an O
_RARE_ I-GENE
locus I-GENE
for O
_RARE_ I-GENE
kinase I-GENE
( O
_RARE_ I-GENE
). O

A I-GENE
. O

_RARE_ I-GENE
patients O
received O
cimetidine O
400 O
mg O
q I-GENE
. O
i O
. O
d O
. O
intravenously O
and O
1 I-GENE
, O
000 O
mg O
daily O
orally O
in O
divided O
doses O
. O

An O
immunologic O
test O
using O
stomach O
and O
tumor I-GENE
antigens I-GENE
for O
screening O
of O
those O
at O
high O
risk O
for O
stomach O
cancer O
is O
suggested O
. O

Thirty O
isolates O
of O
Haemophilus O
influenzae O
type I-GENE
b I-GENE
were O
obtained O
during O
an O
outbreak O
of O
invasive O
H I-GENE
. O
influenzae O
type I-GENE
b I-GENE
disease O
and O
were O
classified O
by O
the O
electrophoretic O
profile O
of O
their O
lipopolysaccharide O
( O
LPS I-GENE
). O

_RARE_ I-GENE
acid I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
type I-GENE
I I-GENE
( O
Ft O
I I-GENE
) O
and O
_RARE_ I-GENE
type I-GENE
II I-GENE
( O
Ft O
II I-GENE
) O
slowly O
adapting O
( O
SA O
) O
units O
produced O
spikes O
only O
at O
the O
_RARE_ I-GENE
phase O
, O
and O
the O
threshold O
response O
phase O
( O
_RARE_ I-GENE
), O
i O
. O
e O
_RARE_ I-GENE
the O
phase O
of O
the O
first O
_RARE_ I-GENE
was O
for O
_RARE_ I-GENE
. O

_RARE_ I-GENE
type I-GENE
I I-GENE
( O
Ft O
I I-GENE
) O
and O
_RARE_ I-GENE
type I-GENE
II I-GENE
( O
Ft O
II I-GENE
) O
slowly O
adapting O
( O
SA O
) O
units O
produced O
spikes O
only O
at O
the O
_RARE_ I-GENE
phase O
, O
and O
the O
threshold O
response O
phase O
( O
_RARE_ I-GENE
), O
i O
. O
e O
_RARE_ I-GENE
the O
phase O
of O
the O
first O
_RARE_ I-GENE
was O
for O
_RARE_ I-GENE
. O

_RARE_ I-GENE
also O
permits O
extension O
of O
the O
possibilities O
of O
obtaining O
and O
_RARE_ I-GENE
donor O
organs O
. O

_RARE_ I-GENE
stain O
was O
positive O
, O
_RARE_ I-GENE
_RARE_ I-GENE
stain O
negative O
. O

Blood O
glucose O
and O
plasma I-GENE
insulin I-GENE
were O
measured O
at O
zero O
time O
and O
then O
at O
15 O
, O
30 O
, O
60 O
, O
90 O
and O
120 O
min O
after O
ingestion O
of O
25 O
g O
glucose O
, O
fructose I-GENE
or O
_RARE_ I-GENE
, O
or O
30 O
g O
_RARE_ I-GENE
, O
50 O
g O
white O
_RARE_ I-GENE
, O
125 I-GENE
g O
white O
rice I-GENE
or O
_RARE_ I-GENE
, O
150 O
g O
_RARE_ I-GENE
or O
260 O
g O
_RARE_ I-GENE
. O

Clinical O
use O
of O
_RARE_ I-GENE
_RARE_ I-GENE
acid I-GENE
_RARE_ I-GENE
in O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
' O
s O
operation O

Among O
these O
are O
: O
( O
1 I-GENE
) O
Is O
there O
sufficient O
understanding O
of O
family I-GENE
pathophysiology O
, O
of O
the O
sensitivity O
and O
specificity O
of O
diagnostic O
techniques O
and O
of O
the O
safety O
and O
efficacy O
of O
therapeutic O
modalities O
to O
make O
true O
family I-GENE
health O
care O
possible O
? O
( O
2 I-GENE
) O
If O
this O
type I-GENE
of O
care O
is O
possible O
, O
how O
are O
the O
needs O
of O
the O
family I-GENE
and O
its O
individual O
members O
met I-GENE
, O
or O
value O
_RARE_ I-GENE
made O
about O
their O
relative O
importance O
? O
and O
( O
3 I-GENE
) O
_RARE_ I-GENE
are O
the O
consequences O
for O
the O
health O
care O
delivery O
system O
of O
this O
type I-GENE
of O
care O
? O
An O
extensive O
literature O
review O
is O
used O
in O
an O
attempt O
to O
_RARE_ I-GENE
these O
_RARE_ I-GENE
, O
from O
which O
questions O
for O
further O
study O
are O
_RARE_ I-GENE
. O

In O
patients O
in O
group O
A I-GENE
(" O
normal O
" O
CI O
), O
the O
CI O
, O
heart O
rate O
and O
the O
mean O
_RARE_ I-GENE
fiber O
shortening O
velocity O
( O
_RARE_ I-GENE
) O
were O
normal O
, O
but O
the O
TPR O
was O
increased O
significantly O
. O

_RARE_ I-GENE
reactive I-GENE
insulin I-GENE
levels O
were O
determined O
in O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
normal O
rats O
offered O
three O
different O
test O
- I-GENE
_RARE_ I-GENE
. O

These O
results O
indicate O
that O
both O
naturally O
acquired O
and O
passive O
( O
modified O
immune I-GENE
serum I-GENE
globulin I-GENE
) O
antibodies I-GENE
to O
type I-GENE
III I-GENE
group O
B I-GENE
Streptococcus I-GENE
antigen I-GENE
are O
partially O
protective O
against O
intra O
- I-GENE
amniotic I-GENE
infection O
. O

In O
the O
_RARE_ I-GENE
phase O
of O
AMI O
, O
as O
well O
as O
in O
_RARE_ I-GENE
, O
the O
occurrence O
of O
high O
- I-GENE
grade O
_RARE_ I-GENE
usually O
indicates O
more O
advanced O
degrees O
of O
both O
coronary O
and O
left O
ventricular O
disease O
as O
well O
as O
the O
possibility O
of O
cardiac O
and O
/ I-GENE
or O
_RARE_ I-GENE
death O
. O

_RARE_ I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
are O
generally O
used O
for O
processing O
. O

The O
genes I-GENE
at O
each O
locus I-GENE
are O
divergently O
transcribed O
and O
the O
coding O
sequences I-GENE
are O
separated O
by O
_RARE_ I-GENE
base O
- I-GENE
pairs O
at O
one O
locus I-GENE
and O
_RARE_ I-GENE
base O
- I-GENE
pairs O
at O
the O
other O
. O

The O
_RARE_ I-GENE
hydrolysis O
of O
urea O
produces O
ammonia I-GENE
which O
causes O
a O
_RARE_ I-GENE
yellow O
to O
_RARE_ I-GENE
colour I-GENE
change O
in O
the O
pH O
indicator O
. O

The O
clinical O
efficacy O
rates O
evaluated O
in O
151 O
cases O
( O
KS O
- I-GENE
R1 I-GENE
group O
in O
77 O
cases O
, O
oral O
group O
in O
74 O
cases O
) O
on O
standard O
criteria O
of O
_RARE_ I-GENE
members O
were O
88 O
. O
3 I-GENE
% O
for O
the O
KS O
- I-GENE
R1 I-GENE
group O
and O
86 I-GENE
. O
5 I-GENE
% O
for O
the O
oral O
group O
, O
respectively O
. O

_RARE_ I-GENE
effect O
including O
_RARE_ I-GENE
and O
objective O
symptoms O
were O
strictly O
evaluated O
in O
_RARE_ I-GENE
cases O
( O
KS O
- I-GENE
R1 I-GENE
group O
in O
83 O
cases O
, O
oral O
group O
in O
80 O
cases O
), O
but O
the O
incidence O
rate O
which O
was O
22 O
. O
9 O
% O
for O
the O
KS O
- I-GENE
R1 I-GENE
group O
and O
23 O
. O
8 O
% O
for O
the O
oral O
group O
showed O
no O
significant O
difference O
. O

Plasma I-GENE
renin I-GENE
activity O
did O
not O
change O
in O
response O
to O
head I-GENE
- I-GENE
up O
tilt O
or O
_RARE_ I-GENE
infusion O
in O
the O
patients O
. O

_RARE_ I-GENE
_RARE_ I-GENE
and O
his O
physicians O
. O

_RARE_ I-GENE
of O
the O
immune I-GENE
response O
by O
_RARE_ I-GENE
action O
of O
vaccine O
_RARE_ I-GENE
in O
the O
_RARE_ I-GENE
immunization O
of O
swine O
against O
swine O
_RARE_ I-GENE

_RARE_ I-GENE
gamma I-GENE
- I-GENE
ray O
spectroscopy O

_RARE_ I-GENE
, O
a O
calcium O
antagonist O
with O
a O
half O
- I-GENE
life O
of O
approximately O
42 O
hours O
, O
was O
compared O
with O
placebo O
in O
a O
double O
- I-GENE
blind O
, O
randomized O
, O
_RARE_ I-GENE
trial O
. O

Analysis O
of O
proteins I-GENE
synthesized O
by O
plasmids O
containing O
deleted O
forms O
of O
the O
_RARE_ I-GENE
region O
indicates O
that O
the O
A2 I-GENE
protein I-GENE
is O
the O
essential O
_RARE_ I-GENE
- I-GENE
encoded I-GENE
replication O
protein I-GENE
of O
plasmid O
_RARE_ I-GENE
. O

Effects O
of O
negative O
pleural I-GENE
pressure O
on O
left O
ventricular O
hemodynamics O
. O

_RARE_ I-GENE
plasma I-GENE
norepinephrine O
( O
NE O
) O
and O
epinephrine O
( O
E I-GENE
) O
levels O
were O
lower O
during O
active O
therapy O
than O
2 I-GENE
wk O
after O
withdrawal O
( O
_RARE_ I-GENE
and O
control O
: O
plasma I-GENE
NE O
, O
0 O
. O
27 O
+/- O
0 O
. O
03 O
/ I-GENE
0 O
. O
64 O
+/- O
0 O
. O
13 O
ng O
/ I-GENE
ml O
; O
plasma I-GENE
E I-GENE
, O
0 O
. O
09 O
+/- O
0 O
. O
02 O
/ I-GENE
0 O
. O
17 O
+/- O
0 O
. O
05 O
ng O
/ I-GENE
ml O
). O

Renal O
response O
to O
captopril O
in O
severe O
heart O
failure O
: O
role O
of O
furosemide O
in O
_RARE_ I-GENE
and O
reversal O
of O
_RARE_ I-GENE
. O

_RARE_ I-GENE
describes O
a O
technique O
for O
the O
placement O
of O
functionally O
generated O
_RARE_ I-GENE
_RARE_ I-GENE
as O
restorations O
within O
mandibular O
_RARE_ I-GENE
teeth O
. O

_RARE_ I-GENE
biopsy O
specimens O
( O
five O
_RARE_ I-GENE
and O
six O
_RARE_ I-GENE
or O
_RARE_ I-GENE
lesions O
) O
from O
four O
patients O
with O
_RARE_ I-GENE
_RARE_ I-GENE
et O
_RARE_ I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
were O
studied O
by O
direct O
immunofluorescence O
and O
_RARE_ I-GENE
_RARE_ I-GENE
. O

These O
data O
suggest O
that O
a O
major I-GENE
part O
of O
the O
reduction O
in O
food O
intake O
in O
_RARE_ I-GENE
rats O
_RARE_ I-GENE
a O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
diet O
is O
due O
to O
_RARE_ I-GENE
events O
. O

The O
_RARE_ I-GENE
from O
a O
parathyroid I-GENE
cyst O
was O
_RARE_ I-GENE
clear O
and O
contained O
high O
amount O
of O
parathyroid I-GENE
hormone I-GENE
. O

_RARE_ I-GENE
had O
no O
detectable O
effect O
on O
PP I-GENE
secretion O
under O
basal O
or O
stimulated O
conditions O
. O

The O
numerous O
tests O
demonstrate O
that O
the O
HDL I-GENE
- I-GENE
_RARE_ I-GENE
can O
be O
extensively O
and O
successfully O
used O
for O
therapy O
of O
insulin I-GENE
- I-GENE
dependent I-GENE
diabetes O
mellitus O
in O
clinical O
practice O
. O

Lung O
_RARE_ I-GENE
production O
may O
be O
related I-GENE
to O
flow O
. O

For O
the O
first O
30 O
min O
following O
insulin I-GENE
administration O
, O
the O
rate O
of O
change O
in O
glucose O
levels O
was O
significantly O
less O
among O
the O
patients O
with O
major I-GENE
_RARE_ I-GENE
disorder O
than O
among O
either O
the O
patients O
with O
_RARE_ I-GENE
disorder O
or O
the O
normal O
control O
subjects O
. O

_RARE_ I-GENE
of O
hypertension O
in O
the O
elderly O
. O

_RARE_ I-GENE
treatment O
of O
children O
with O
respiratory O
allergy O

_RARE_ I-GENE
of O
kidneys O
of O
juvenile O
donors O
in O
adult O
recipients O
. O

Ten O
patients O
with O
advanced O
, O
diffuse O
Hodgkin O
' O
s O
and O
non O
- I-GENE
Hodgkin O
' O
s O
lymphomas O
responding O
poorly O
to O
the O
most O
widely O
employed O
primary O
chemotherapy O
regimens O
were O
treated O
with O
a O
high O
- I-GENE
dose O
chemotherapy O
( O
_RARE_ I-GENE
) O
followed O
by O
rescue O
with O
non O
- I-GENE
_RARE_ I-GENE
autologous O
bone O
marrow O
infusion O
( O
_RARE_ I-GENE
). O

Effect O
of O
proteolytic O
enzymes O
and O
polypeptides I-GENE
on O
the O
_RARE_ I-GENE
activity O
of O
_RARE_ I-GENE
and O
other O
_RARE_ I-GENE
. O

Results O
of O
a O
controlled O
study O

_RARE_ I-GENE
also O
caused O
a O
slight O
increase O
in O
plasma I-GENE
renin I-GENE
activity O
and O
urinary O
excretion O
of O
noradrenaline O
. O

_RARE_ I-GENE
activity O
of O
97 O
% O
of O
these O
organisms O
became O
evident O
within O
30 O
min O
. O

After O
description O
of O
his O
short O
life O
and O
an O
explanation O
of O
the O
light I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
' O
s O
_RARE_ I-GENE
is O
_RARE_ I-GENE
, O
by O
his O
_RARE_ I-GENE
as O
first O
_RARE_ I-GENE
to O
have O
made O
_RARE_ I-GENE
to O
medicine O
_RARE_ I-GENE
diagnostic O
possibilities O
. O

The O
effect O
of O
lithium O
on O
the O
_RARE_ I-GENE
of O
arginine I-GENE
vasopressin I-GENE
secretion O
. O

The O
susceptibility I-GENE
of O
the O
_RARE_ I-GENE
strains O
to O
clinically O
relevant O
antibiotics O
varied O
with O
the O
plasmid O
pattern O
; O
this O
stresses O
the O
_RARE_ I-GENE
of O
permanent O
_RARE_ I-GENE
of O
_RARE_ I-GENE
infections O
and O
of O
regular O
evaluation O
of O
the O
_RARE_ I-GENE
for O
antimicrobial O
treatment O
. O

_RARE_ I-GENE
III I-GENE
( O
AT I-GENE
III I-GENE
) O
is O
a O
plasma I-GENE
protein I-GENE
which O
acts O
as O
the O
principal O
inhibitor I-GENE
of O
thrombin I-GENE
and O
is O
a O
major I-GENE
_RARE_ I-GENE
of O
intravascular O
coagulation I-GENE
. O

_RARE_ I-GENE
patients O
were O
untreated O
, O
and O
8 O
had O
been O
given O
previous O
treatment O
with O
_RARE_ I-GENE
testosterone O
100 O
mg O
_RARE_ I-GENE
every O
2 I-GENE
- I-GENE
3 I-GENE
weeks O
for O
an O
average O
duration O
of O
4 I-GENE
. O
7 O
years O
. O

_RARE_ I-GENE
- I-GENE
labeled O
cisplatin O
was O
administered O
iv O
and O
_RARE_ I-GENE
to O
control O
mice O
and O
to O
mice O
bearing O
_RARE_ I-GENE
180 O
. O

New O
beta I-GENE
- I-GENE
blocking O
drugs O
have O
been O
introduced O
which O
may O
prove O
beneficial O
in O
certain O
clinical O
situations O
since O
they O
exert O
more O
selective O
blockade O
of O
the O
cardiac O
receptors I-GENE
( O
beta1 I-GENE
) O
as O
opposed O
to O
smooth I-GENE
muscle O
receptors I-GENE
( O
beta2 I-GENE
). O

If O
_RARE_ I-GENE
for O
measurements O
of O
O2 O
consumption O
and O
hence O
metabolic O
rate O
are O
available O
, O
these O
should O
be O
utilized O
. O

This O
generally O
means O
an O
energy O
intake O
of O
1 I-GENE
. O
4 I-GENE
to O
1 I-GENE
. O
6 I-GENE
times O
the O
energy O
expenditure O
, O
with O
a O
N I-GENE
intake O
of O
250 O
to O
400 O
mg O
/ I-GENE
kg O
/ I-GENE
day O
. O

In O
the O
37 O
patients O
without O
lung O
disease O
respiratory O
muscle O
_RARE_ I-GENE
was O
accompanied O
by O
significant O
decreases O
in O
vital O
capacity O
, O
total O
lung O
capacity O
, O
and O
maximum O
_RARE_ I-GENE
ventilation O
; O
by O
significant O
increases O
in O
residual O
volume O
and O
arterial O
carbon O
dioxide O
tension O
( O
PaCO2 O
); O
and O
greater O
likelihood O
of O
dependence O
on O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
and O
pneumonia O
. O

_RARE_ I-GENE
. O

The O
statistical O
analysis O
of O
data O
of O
TRH I-GENE
test O
on O
a O
sample O
of O
57 O
healthy O
volunteers O
has O
permitted O
an O
evaluation O
of O
the O
upper O
limits O
of O
the O
normal O
thyrotropin I-GENE
response O
; O
the O
secretory I-GENE
area O
( O
As O
) O
was O
shown O
to O
be O
more O
_RARE_ I-GENE
. O

Total O
cumulative O
doses O
of O
_RARE_ I-GENE
ranged O
from O
_RARE_ I-GENE
to O
_RARE_ I-GENE
mg O
_RARE_ I-GENE
m I-GENE
. O
2 I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
depends O
on O
understanding O
of O
behavioral O
requirements O
. O

Following O
20 O
min O
of O
steady O
state O
anaesthesia O
during O
which O
measurements O
of O
IOP O
, O
arterial O
pressure O
, O
heart O
rate O
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
' O
CO2 O
and O
_RARE_ I-GENE
were O
recorded O
, O
one O
group O
of O
patients O
received O
_RARE_ I-GENE
0 O
. O
45 O
mg O
kg O
- I-GENE
1 I-GENE
and O
the O
other O
_RARE_ I-GENE
0 O
. O
1 I-GENE
mg O
kg O
- I-GENE
1 I-GENE
. O

_RARE_ I-GENE
subclinical O
and O
permanent O
hypothyroidism O
in O
the O
course O
of O
subacute O
thyroiditis O
( O
de O
_RARE_ I-GENE
). O

_RARE_ I-GENE
levels O
in O
mothers O
who O
have O
had O
two O
sets O
of O
_RARE_ I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
of O
plasma I-GENE
to O
obtain O
better O
yield O
of O
factor I-GENE
VIII I-GENE
: O
C I-GENE
. O

These O
children O
were O
_RARE_ I-GENE
into O
four O
diagnostic O
categories O
: O
1 I-GENE
) O
idiopathic O
GH I-GENE
deficiency O
( O
n O
= O
10 O
); O
2 I-GENE
) O
organic O
_RARE_ I-GENE
( O
n O
= O
7 O
); O
3 I-GENE
) O
intrauterine O
growth I-GENE
retardation O
( O
n O
= O
5 I-GENE
); O
and O
4 I-GENE
) O
_RARE_ I-GENE
delay O
of O
growth I-GENE
and O
/ I-GENE
or O
familial O
short O
_RARE_ I-GENE
( O
n O
= O
18 O
), O
by O
standard O
clinical O
criteria O
and O
physiological O
and O
pharmacological O
tests O
of O
GH I-GENE
reserve O
. O

Each O
patient O
had O
_RARE_ I-GENE
LH I-GENE
and O
FSH I-GENE
levels O
, O
with O
pulsed O
_RARE_ I-GENE
secretion O
, O
and O
_RARE_ I-GENE
LH I-GENE
and O
FSH I-GENE
responses O
to O
_RARE_ I-GENE
. O

These O
changes O
were O
the O
result O
of O
a O
decrease O
in O
_RARE_ I-GENE
: O
mean O
aortic O
pressure O
fell O
from O
85 O
+/- O
11 O
. O
8 O
to O
68 O
+/- O
19 O
. O
6 I-GENE
mmHg O
( O
p O
less O
than O
0 O
. O
01 O
) O
and O
systemic O
arterial O
resistance O
fell O
from O
2 I-GENE
_RARE_ I-GENE
+/- O
_RARE_ I-GENE
to O
2 I-GENE
_RARE_ I-GENE
+/- O
_RARE_ I-GENE
_RARE_ I-GENE
/ I-GENE
cm O
- I-GENE
5 I-GENE
/ I-GENE
sec O
/ I-GENE
m I-GENE
- I-GENE
2 I-GENE
( O
p O
less O
than O
0 O
. O
01 O
). O

_RARE_ I-GENE
800 O
mg O
given O
at O
night O
is O
as O
effective O
as O
400 O
mg O
twice O
daily O
; O
the O
single O
dose O
regimen O
may O
improve O
patient O
compliance O
, O
thus O
facilitating O
treatment O
. O

_RARE_ I-GENE
shows O
_RARE_ I-GENE
as O
single O
- I-GENE
agent O
therapy O
for O
serious O
gram O
- I-GENE
negative O
_RARE_ I-GENE
infections O
. O

_RARE_ I-GENE
CBF I-GENE
was O
determined O
by O
clearance O
of O
_RARE_ I-GENE
133 I-GENE
in O
67 O
patients O
undergoing O
coronary O
bypass O
_RARE_ I-GENE
procedures O
. O

Our O
results O
indicate O
that O
serum I-GENE
_RARE_ I-GENE
is O
a O
valuable O
measurement O
of O
bone O
metabolism O
. O

The O
management O
of O
the O
" O
chronic O
" O
patient O
. O

Study O
of O
bacterial I-GENE
motility O
and O
rate O
of O
movement O
using O
a O
closed O
circuit O
_RARE_ I-GENE

_RARE_ I-GENE
of O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
in O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE

Each O
_RARE_ I-GENE
organism O
has O
a O
species O
- I-GENE
specific I-GENE
preference O
and O
requirement O
for O
temperature O
, O
_RARE_ I-GENE
, O
pH O
, O
the O
basic I-GENE
_RARE_ I-GENE
, O
and O
growth I-GENE
factors I-GENE
, O
and O
the O
toxin I-GENE
formation O
is O
affected O
by O
these O
environmental O
factors I-GENE
. O

It O
is O
concluded O
that O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
by O
- I-GENE
_RARE_ I-GENE
is O
a O
simple O
solution O
for O
a O
complex I-GENE
_RARE_ I-GENE
, O
clinical O
and O
therapeutic O
problem O
. O

_RARE_ I-GENE
of O
the O
tip O
of O
the O
_RARE_ I-GENE
and O
of O
the O
_RARE_ I-GENE
process O
are O
also O
described O
( O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
_RARE_ I-GENE
). O

There O
was O
significant O
correlation O
of O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
for O
pre I-GENE
- I-GENE
_RARE_ I-GENE
and O
post O
_RARE_ I-GENE
studies O
. O

_RARE_ I-GENE
recording O
in O
_RARE_ I-GENE
_RARE_ I-GENE

The O
development O
and O
_RARE_ I-GENE
organization O
of O
intrahepatic O
biliary O
_RARE_ I-GENE
were O
studied O
on O
a O
human I-GENE
_RARE_ I-GENE
material O
6 I-GENE
to O
32 O
weeks O
old O
. O

It O
has O
been O
shown O
in O
an O
animal O
experiment O
that O
alterations O
of O
the O
renal O
_RARE_ I-GENE
and O
parenchyma O
after O
hemostasis O
performed O
by O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
are O
best O
shown O
by O
_RARE_ I-GENE
magnification O
angiography O
( O
magnification O
factor I-GENE
2 I-GENE
. O
22 O
). O

_RARE_ I-GENE
and O
adrenal O
_RARE_ I-GENE
- I-GENE
sympathetic O
reactions O
to O
acute O
tobacco I-GENE
poisoning O

Intravenous O
injections O
of O
SG I-GENE
- I-GENE
75 O
( O
0 O
. O
03 O
- I-GENE
1 I-GENE
mg O
/ I-GENE
kg O
) O
decreased O
systemic O
blood O
pressure O
( O
_RARE_ I-GENE
) O
and O
increased O
peripheral O
( O
coronary O
, O
renal O
, O
_RARE_ I-GENE
and O
femoral O
) O
blood O
flow O
( O
_RARE_ I-GENE
) O
dose O
- I-GENE
dependently O
. O

In O
doses O
of O
0 O
. O
03 O
- I-GENE
0 O
. O
3 I-GENE
mg O
/ I-GENE
kg O
i O
. O
v I-GENE
., O
SG I-GENE
- I-GENE
75 O
did O
not O
significantly O
affect O
pulse O
pressure O
, O
heart O
rate O
, O
aortic O
blood O
flow O
, O
left O
ventricular O
pressure O
( O
_RARE_ I-GENE
) O
and O
_RARE_ I-GENE
/ I-GENE
dt O
max O
. O

_RARE_ I-GENE
VE O
in O
the O
luteal O
phase O
was O
7 O
. O
8 O
% O
greater O
than O
that O
in O
the O
follicular O
phase O
. O

_RARE_ I-GENE
of O
endothelium O
to O
_RARE_ I-GENE
shear O
stresses O
that O
followed O
a O
_RARE_ I-GENE
recording O
of O
physiological O
flow O
_RARE_ I-GENE
( O
_RARE_ I-GENE
_RARE_ I-GENE
) O
did O
not O
cause O
gross O
injury O
or O
_RARE_ I-GENE
even O
when O
peak O
shear O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
/ I-GENE
cm2 O
. O

_RARE_ I-GENE
cancer O
therapy O
has O
included O
surgery O
, O
radiotherapy O
, O
chemotherapy O
, O
and O
most O
recently O
, O
immunotherapy O
and O
_RARE_ I-GENE
. O

There O
was O
a O
close O
correlation O
between O
plasma I-GENE
clearance O
of O
_RARE_ I-GENE
by O
10 O
- I-GENE
_RARE_ I-GENE
and O
the O
D I-GENE
metabolic O
ratio O
( O
D I-GENE
/ I-GENE
4 I-GENE
- I-GENE
OH O
- I-GENE
D I-GENE
in O
urine O
) O
in O
the O
_RARE_ I-GENE
( O
rs O
= O
- I-GENE
0 O
. O
95 O
; O
P I-GENE
less O
than O
0 O
. O
01 O
) O
and O
_RARE_ I-GENE
( O
rs O
= O
- I-GENE
0 O
. O
84 O
; O
P I-GENE
less O
than O
0 O
. O
01 O
). O

The O
response O
properties O
of O
cat O
horizontal O
_RARE_ I-GENE
afferents O
( O
N I-GENE
= O
81 O
) O
were O
characterized O
by O
three O
parameters O
: O
their O
long O
time O
constants O
( O
tau I-GENE
), O
low O
frequency O
gain O
constants O
( O
G1 I-GENE
), O
and O
middle I-GENE
frequency O
gain O
constants O
( O
_RARE_ I-GENE
). O

_RARE_ I-GENE
of O
the O
central O
ear O
artery O
of O
an O
anesthetized O
rabbit I-GENE
is O
damaged O
by O
_RARE_ I-GENE
artery O
_RARE_ I-GENE
on O
the O
ear O
directly O
over O
the O
vessel O
. O

Despite O
_RARE_ I-GENE
E2 I-GENE
concentrations O
, O
however O
, O
cervical O
mucus O
scores O
were O
significantly O
reduced O
in O
the O
CC O
- I-GENE
treated O
group O
( O
P I-GENE
less O
than O
0 O
. O
01 O
). O

_RARE_ I-GENE
of O
the O
_RARE_ I-GENE
nucleus O
' O
_RARE_ I-GENE
- I-GENE
reactive I-GENE
system O
in O
dogs O
by O
means O
of O
administration O
of O
_RARE_ I-GENE
( O
60 O
micrograms O
) O
and O
_RARE_ I-GENE
led O
to O
deterioration O
of O
conditioned O
and O
_RARE_ I-GENE
components O
of O
feeding O
behaviour O
. O

Value O
of O
urine O
glucose O
tests O
in O
the O
management O
of O
type I-GENE
II I-GENE
diabetes O
mellitus O
. O

This O
experiment O
was O
conducted O
to O
determine O
if O
the O
sex I-GENE
or O
actual O
egg I-GENE
production O
was O
the O
important O
factor I-GENE
.( O
ABSTRACT O
TRUNCATED O
AT I-GENE
250 O
WORDS O
) O

_RARE_ I-GENE
seems O
to O
be O
unable O
to O
_RARE_ I-GENE
the O
_RARE_ I-GENE
changes O
in O
the O
muscle O
membrane I-GENE
whereas O
high O
doses O
of O
the O
hormone I-GENE
are O
able O
to O
induce O
changes O
in O
the O
muscle O
membrane I-GENE
. O

Significant O
clinical O
differences O
between O
the O
patients O
treated O
with O
and O
without O
_RARE_ I-GENE
were O
longer O
survival O
time O
following O
diagnosis O
of O
illness O
( O
P I-GENE
less O
than O
0 O
. O
05 O
) O
and O
more O
frequent O
_RARE_ I-GENE
nerve I-GENE
signs O
in O
the O
treated O
patients O
( O
P I-GENE
= O
0 O
. O
_RARE_ I-GENE
). O

A I-GENE
pharmacokinetic O
study O
of O
_RARE_ I-GENE
was O
performed O
in O
12 O
patients O
in O
an O
intensive O
- I-GENE
care O
unit I-GENE
. O

_RARE_ I-GENE
- I-GENE
up O
growth I-GENE
was O
observed O
only O
for O
a O
12 O
- I-GENE
month O
period O
in O
4 I-GENE
children O
with O
a O
bone O
age O
of O
7 O
to O
8 O
years O
. O

_RARE_ I-GENE
function O
was O
impaired O
in O
all O
patients O
, O
characterized O
by O
a O
diminished O
platelet I-GENE
shape O
change O
. O

The O
findings O
demonstrate O
that O
_RARE_ I-GENE
administration O
induces O
a O
significant O
increase O
in O
the O
height O
of O
a O
major I-GENE
_RARE_ I-GENE
peak O
in O
the O
_RARE_ I-GENE
nucleus O
of O
_RARE_ I-GENE
monkeys O
, O
and O
further O
that O
such O
amphetamine O
- I-GENE
induced O
increases O
can O
be O
_RARE_ I-GENE
by O
altering O
the O
affective O
and O
/ I-GENE
or O
_RARE_ I-GENE
state O
of O
the O
animal O
. O

In O
two O
experiments O
, O
neonatal O
female O
BALB O
/ I-GENE
_RARE_ I-GENE
or O
BALB O
/ I-GENE
_RARE_ I-GENE
mice O
were O
given O
subcutaneous O
injections O
of O
5 I-GENE
micrograms O
17 O
beta I-GENE
- I-GENE
estradiol O
or O
_RARE_ I-GENE
oil O
for O
the O
first O
3 I-GENE
days O
of O
life O
and O
were O
_RARE_ I-GENE
at O
60 O
days O
of O
age O
, O
at O
which O
time O
vaginal O
_RARE_ I-GENE
( O
Experiments O
I I-GENE
and O
II I-GENE
) O
or O
_RARE_ I-GENE
( O
Experiment O
II I-GENE
) O
were O
implanted O
_RARE_ I-GENE
. O

For O
_RARE_ I-GENE
of O
_RARE_ I-GENE
deaths O
( O
54 I-GENE
%) O
occurring O
among O
26 O
100 O
people O
of O
known O
age O
in O
the O
_RARE_ I-GENE
area O
of O
northern O
_RARE_ I-GENE
, O
data O
were O
collected O
on O
symptoms O
present O
prior O
to O
death O
. O

_RARE_ I-GENE
estradiol O
17 O
beta I-GENE
( O
E2 I-GENE
- I-GENE
17 O
beta I-GENE
) O
and O
progesterone I-GENE
( O
P I-GENE
) O
were O
determined O
by O
using O
radioimmunoassay O
techniques O
in O
30 O
pregnant O
females O
in O
the O
first O
, O
second O
and O
third O
_RARE_ I-GENE
as O
well O
as O
in O
10 O
non O
- I-GENE
pregnant O
controls O
during O
the O
luteal O
phase O
of O
the O
menstrual O
cycle O
. O

Other O
than O
d O
7 O
, O
there O
was O
no O
significant O
effect O
on O
the O
number O
of O
implants O
. O

_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
or O
_RARE_ I-GENE
were O
_RARE_ I-GENE
on O
95 O
_RARE_ I-GENE
tests O
( O
18 O
. O
8 O
%) O
in O
80 O
( O
33 O
. O
5 I-GENE
%) O
_RARE_ I-GENE
patients O
. O

The O
response O
chain I-GENE
in O
each O
component O
was O
maintained O
by O
food O
presentation O
under O
a O
fixed O
- I-GENE
ratio O
schedule O
. O

The O
results O
imply O
that O
kindling O
does O
not O
produce O
its O
facilitating O
effect O
on O
acquisition O
of O
_RARE_ I-GENE
SS I-GENE
by O
removing O
a O
_RARE_ I-GENE
effect O
of O
the O
stimulation O
. O

The O
persistent O
fetal O
dispersion O
of O
nodal O
and O
_RARE_ I-GENE
bundle O
fragments I-GENE
within O
the O
ventricular O
_RARE_ I-GENE
is O
proposed O
as O
a O
possible O
explanation O
. O

According O
to O
the O
biochemical O
tests O
, O
high O
activity O
( O
over O
200 O
U O
/ I-GENE
l O
) O
of O
alkaline I-GENE
phosphatase I-GENE
was O
recorded O
exclusively O
in O
patients O
with O
the O
_RARE_ I-GENE
- I-GENE
induced O
liver O
damage O
. O

Changes O
of O
plasma I-GENE
cortisol O
level O
in O
late O
asthmatic O
responses O

Significant O
alterations O
in O
the O
_RARE_ I-GENE
rats O
from O
sham O
rats O
included O
: O
testicular I-GENE
and O
_RARE_ I-GENE
hypertrophy O
, O
formation O
of O
pathologic O
vas O
deferens O
_RARE_ I-GENE
, O
decreased O
total O
serum I-GENE
protein I-GENE
, O
lowered O
alpha I-GENE
- I-GENE
globulin I-GENE
levels O
as O
shown O
by O
serum I-GENE
electrophoresis O
, O
and O
increased O
sperm O
_RARE_ I-GENE
antibody I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
was O
significantly O
elevated O
in O
_RARE_ I-GENE
( O
s O
). O

The O
average O
birth O
mass O
of O
these O
newborns O
was O
_RARE_ I-GENE
. O
9 O
+/- O
2 I-GENE
SD O
_RARE_ I-GENE
. O
5 I-GENE
g O
and O
that O
in O
the O
control O
group O
3 I-GENE
, O
_RARE_ I-GENE
. O
5 I-GENE
+/- O
2 I-GENE
SD O
_RARE_ I-GENE
. O
2 I-GENE
g O
( O
P I-GENE
less O
than O
0 O
. O
05 O
). O

This O
machine O
_RARE_ I-GENE
, O
which O
was O
not O
associated I-GENE
with O
a O
rise O
in O
water O
_RARE_ I-GENE
temperature O
and O
did O
not O
consistently O
correlate O
with O
estimated O
x O
- I-GENE
ray O
tube O
heat I-GENE
, O
could O
result O
in O
a O
significant O
_RARE_ I-GENE
of O
regional O
cerebral O
blood O
flow O
( O
rCBF O
) O
for O
a O
_RARE_ I-GENE
/ I-GENE
CT I-GENE
rCBF O
protocol O
involving O
5 I-GENE
- I-GENE
7 O
sequential O
scans O
obtained O
at O
1 I-GENE
- I-GENE
min O
_RARE_ I-GENE
intervals O
. O

Other O
_RARE_ I-GENE
in O
the O
_RARE_ I-GENE
at O
Y I-GENE
- I-GENE
12 O
and O
_RARE_ I-GENE
are O
unaltered O
. O

E2 I-GENE
treatments O
elevated O
_RARE_ I-GENE
plasma I-GENE
TG I-GENE
7 O
. O
_RARE_ I-GENE
, O
PL I-GENE
5 I-GENE
. O
_RARE_ I-GENE
, O
and O
C I-GENE
7 O
. O
_RARE_ I-GENE
; O
and O
_RARE_ I-GENE
plasma I-GENE
TG I-GENE
6 I-GENE
. O
_RARE_ I-GENE
, O
PL I-GENE
3 I-GENE
. O
_RARE_ I-GENE
, O
and O
C I-GENE
2 I-GENE
. O
_RARE_ I-GENE
. O

By O
contrast O
, O
kidneys O
from O
rats O
with O
chronic O
metabolic O
acidosis O
produced O
significantly O
more O
_RARE_ I-GENE
than O
both O
these O
groups O
( O
2 I-GENE
. O
73 O
+/- O
0 O
. O
29 O
mumol O
X I-GENE
min O
- I-GENE
1 I-GENE
X I-GENE
g O
- I-GENE
1 I-GENE
). O

_RARE_ I-GENE
of O
_RARE_ I-GENE
in O
_RARE_ I-GENE
_RARE_ I-GENE
using O
a O
_RARE_ I-GENE
agglutination I-GENE
test O
set O
( O
_RARE_ I-GENE
_RARE_ I-GENE
). O

_RARE_ I-GENE
cyclase I-GENE
activity O
of O
gastric O
mucosa O
in O
patients O
with O
duodenal O
ulcer O
before O
and O
after O
treatment O

_RARE_ I-GENE
-- O
selected O
_RARE_ I-GENE
and O
clinical O
problems O

However O
, O
subcutaneously O
administered O
_RARE_ I-GENE
gave O
a O
lower O
mortality O
than O
_RARE_ I-GENE
given O
intravenously O
or O
_RARE_ I-GENE
. O

_RARE_ I-GENE
of O
human I-GENE
organism O
to O
exercise O
. O

HA I-GENE
resulted O
in O
decreased O
( O
p O
less O
than O
0 O
. O
05 O
) O
_RARE_ I-GENE
( O
0 O
. O
4 I-GENE
degrees O
C I-GENE
) O
and O
HR O
( O
17 O
b I-GENE
X I-GENE
min O
- I-GENE
1 I-GENE
), O
and O
increased O
( O
p O
less O
than O
0 O
. O
05 O
) O
_RARE_ I-GENE
( O
16 O
g O
X I-GENE
m I-GENE
- I-GENE
2 I-GENE
X I-GENE
h O
- I-GENE
1 I-GENE
) O
during O
the O
saline O
experiments O
. O

The O
results O
obtained O
were O
as O
follows O
: O
The O
mitral O
valve O
_RARE_ I-GENE
area O
( O
_RARE_ I-GENE
) O
was O
significantly O
smaller O
in O
patients O
with O
type I-GENE
III I-GENE
of O
the O
_RARE_ I-GENE
flow O
velocity O
pattern O
than O
in O
patients O
with O
type I-GENE
I I-GENE
( O
p O
less O
than O
0 O
. O
001 O
). O

_RARE_ I-GENE
cooperation O
of O
_RARE_ I-GENE
member O
_RARE_ I-GENE
has O
been O
carried O
out O
since O
_RARE_ I-GENE
under O
the O
_RARE_ I-GENE
of O
the O
Cancer O
Research O
Institute O
, O
_RARE_ I-GENE
_RARE_ I-GENE
of O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
within O
the O
_RARE_ I-GENE
of O
_RARE_ I-GENE
. O

This O
_RARE_ I-GENE
_RARE_ I-GENE
to O
results O
of O
similarly O
sized O
melanomas O
treated O
by O
_RARE_ I-GENE
. O

A I-GENE
new O
variant I-GENE
of O
the O
EMG O
- I-GENE
_RARE_ I-GENE
method O
( O
_RARE_ I-GENE
) O
is O
offered O
which O
has O
made O
it O
possible O
to O
use O
the O
method O
not O
only O
for O
training O
_RARE_ I-GENE
muscles O
and O
reducing O
_RARE_ I-GENE
in O
their O
antagonists O
but O
also O
for O
_RARE_ I-GENE
motor O
coordination O
. O

_RARE_ I-GENE
from O
all O
3 I-GENE
species O
yielded O
maximum O
responses O
with O
a O
48 O
- I-GENE
hour O
_RARE_ I-GENE
and O
12 O
- I-GENE
to O
- I-GENE
16 O
hour O
_RARE_ I-GENE
incubation O
period O
at O
41 O
C I-GENE
and O
1 I-GENE
: O
20 O
blood O
dilution O
. O

However O
, O
there O
was O
a O
difference O
in O
the O
quality O
of O
immunity O
: O
fever O
and O
body O
weight O
loss O
were O
seen O
in O
hamsters O
_RARE_ I-GENE
with O
the O
killed O
- I-GENE
_RARE_ I-GENE
vaccine O
after O
they O
were O
challenge O
exposed O
with O
T I-GENE
- I-GENE
1 I-GENE
strain O
, O
whereas O
these O
changes O
were O
rarely O
seen O
in O
hamsters O
given O
the O
live O
- I-GENE
_RARE_ I-GENE
vaccine O
and O
then O
challenge O
exposed O
with O
RH O
strain O
. O

_RARE_ I-GENE
proline O
/ I-GENE
alanine I-GENE
sequence I-GENE
of O
beta I-GENE
B1 I-GENE
subunit I-GENE
_RARE_ I-GENE
from O
a O
repetitive O
DNA I-GENE
sequence I-GENE
. O

The O
segmental O
and O
regional O
projections O
of O
the O
_RARE_ I-GENE
, O
_RARE_ I-GENE
and O
common O
_RARE_ I-GENE
nerves O
to O
the O
_RARE_ I-GENE
_RARE_ I-GENE
of O
the O
spinal O
cord O
in O
rats O
-- O
an O
experimental O
study O
by O
means O
of O
an O
acid I-GENE
phosphatase I-GENE
( O
_RARE_ I-GENE
) O
method O
. O

Removal O
of O
lipid O
fractions O
of O
plant O
_RARE_ I-GENE
with O
_RARE_ I-GENE
is O
recommended O
to O
avoid O
damage O
to O
the O
HPLC O
column O
. O

In O
the O
_RARE_ I-GENE
_RARE_ I-GENE
one O
of O
the O
_RARE_ I-GENE
would O
not O
_RARE_ I-GENE
the O
_RARE_ I-GENE
_RARE_ I-GENE
shown O
while O
the O
last O
two O
_RARE_ I-GENE
offer O
very O
little O
possibility O
of O
success O
for O
all O
subjects O
.( O
ABSTRACT O
TRUNCATED O
AT I-GENE
250 O
WORDS O
) O

The O
toxicological O
evaluation O
of O
_RARE_ I-GENE
22 O
( O
_RARE_ I-GENE
22 O
). O

All O
patients O
were O
evaluable O
for O
toxicity O
and O
9 O
for O
response O
. O

_RARE_ I-GENE
of O
clinical O
and O
experimental O
_RARE_ I-GENE
are O
described O
that O
have O
been O
used O
to O
evaluate O
effects O
of O
_RARE_ I-GENE
and O
_RARE_ I-GENE
acting O
_RARE_ I-GENE
. O

The O
present O
paper O
_RARE_ I-GENE
the O
existing O
_RARE_ I-GENE
, O
and O
offers O
a O
consistent O
_RARE_ I-GENE
_RARE_ I-GENE
also O
such O
terms O
as O
" O
_RARE_ I-GENE
_RARE_ I-GENE
" O
potentiation O
_RARE_ I-GENE
and O
" O
simple O
similarity O
". O

We O
propose O
that O
the O
_RARE_ I-GENE
discrimination O
required O
a O
greater O
time O
for O
_RARE_ I-GENE
evaluation O
and O
that O
this O
was O
reflected O
in O
the O
delayed O
P3 I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
concentration O
_RARE_ I-GENE
significantly O
in O
all O
treatments O
, O
a O
finding O
which O
suggests O
a O
protective O
effect O
on O
protein I-GENE
nitrogen O
degradation O
to O
non O
- I-GENE
protein I-GENE
nitrogen O
( O
_RARE_ I-GENE
). O

In O
this O
respect O
C I-GENE
reactive I-GENE
protein I-GENE
concentrations O
are O
superior O
to O
white O
cell O
count O
, O
erythrocyte I-GENE
sedimentation O
rate O
, O
and O
temperature O
and O
the O
concentrations O
of O
_RARE_ I-GENE
. O

Human I-GENE
thyroid I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
in O
thyroid I-GENE
diseases O

We O
conclude O
that O
administration O
of O
the O
calcium O
antagonist O
_RARE_ I-GENE
is O
of O
no O
additional O
value O
in O
_RARE_ I-GENE
treatment O
with O
beta I-GENE
- I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
auditory O
evoked O
responses O
( O
_RARE_ I-GENE
) O
and O
quantitative O
_RARE_ I-GENE
eye O
movement O
studies O
provide O
information O
on O
the O
integrity O
of O
pathways O
_RARE_ I-GENE
the O
_RARE_ I-GENE
. O

Effects O
of O
_RARE_ I-GENE
on O
the O
circulatory O
functions O
and O
body O
tissue I-GENE
oxygenation O
in O
dogs O
under O
normal O
and O
_RARE_ I-GENE
conditions O
. O

The O
_RARE_ I-GENE
clinical O
features O
, O
the O
problems O
of O
management O
and O
the O
modern O
approaches O
to O
the O
reconstruction O
of O
facial O
_RARE_ I-GENE
seen O
in O
this O
disease O
are O
described O
. O

_RARE_ I-GENE
, O
it O
was O
considered O
that O
the O
_RARE_ I-GENE
was O
a O
useful O
tool O
for O
activation O
of O
_RARE_ I-GENE
activity O
by O
way O
of O
visual O
feed O
- I-GENE
back O
control O
. O

To O
evaluate O
the O
comparative O
safety O
of O
U O
- I-GENE
P I-GENE
and O
D I-GENE
& O
E I-GENE
, O
we O
analyzed O
2 I-GENE
, O
_RARE_ I-GENE
U O
- I-GENE
P I-GENE
and O
9 O
, O
_RARE_ I-GENE
D I-GENE
& O
E I-GENE
_RARE_ I-GENE
at O
13 O
to O
24 O
menstrual O
weeks O
' O
gestation O
. O

Three O
_RARE_ I-GENE
without O
knowledge O
of O
patients O
' O
data O
and O
treatment O
analyzed O
30 O
_RARE_ I-GENE
with O
and O
30 O
examinations O
without O
_RARE_ I-GENE
. O

In O
a O
man O
with O
_RARE_ I-GENE
leukemia I-GENE
, O
the O
association O
of O
increased O
prostatic I-GENE
acid I-GENE
phosphatase I-GENE
activity O
in O
serum I-GENE
and O
the O
presence O
of O
typical O
bone O
lesions O
on O
_RARE_ I-GENE
suggested O
the O
existence O
of O
_RARE_ I-GENE
prostatic I-GENE
carcinoma O
. O

The O
_RARE_ I-GENE
for O
the O
prophylactic O
treatment O
, O
the O
therapy O
of O
the O
_RARE_ I-GENE
and O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
are O
exposed O
. O

An O
experimental O
long O
- I-GENE
term O
study O
. O

No O
_RARE_ I-GENE
was O
recorded O
in O
a O
_RARE_ I-GENE
solution O
. O

Hepatitis I-GENE
B I-GENE
vaccine O

The O
calculated O
values O
of O
lambda I-GENE
_RARE_ I-GENE
at O
37 O
degrees O
C I-GENE
and O
50 O
per O
cent O
_RARE_ I-GENE
were O
0 O
. O
_RARE_ I-GENE
for O
the O
_RARE_ I-GENE
, O
0 O
. O
_RARE_ I-GENE
for O
the O
_RARE_ I-GENE
, O
0 O
. O
_RARE_ I-GENE
for O
the O
_RARE_ I-GENE
gland O
and O
0 O
. O
_RARE_ I-GENE
for O
the O
_RARE_ I-GENE
of O
the O
dog O
. O
lambda I-GENE
_RARE_ I-GENE
increased O
and O
lambda I-GENE
_RARE_ I-GENE
decreased O
as O
the O
temperature O
was O
reduced O
from O
37 O
to O
4 I-GENE
degrees O
C I-GENE
. O

As O
pleural I-GENE
_RARE_ I-GENE
is O
seen O
commonly O
in O
_RARE_ I-GENE
and O
may O
influence O
lung O
volumes O
and O
the O
ratio O
of O
transfer I-GENE
factor I-GENE
to O
effective O
alveolar O
volume O
, O
the O
results O
of O
these O
measurements O
were O
compared O
only O
in O
the O
cases O
showing O
absent O
or O
minimal I-GENE
pleural I-GENE
_RARE_ I-GENE
. O

The O
invasive O
pattern O
of O
squamous O
cell O
carcinoma O
in O
the O
mandibular O
_RARE_ I-GENE

_RARE_ I-GENE
vein O
_RARE_ I-GENE
the O
posterior O
wall O
of O
the O
right O
main O
and O
upper O
lobe O
_RARE_ I-GENE
: O
a O
normal O
CT I-GENE
variant I-GENE
. O

However O
, O
the O
history O
of O
acute O
severe O
complications O
from O
_RARE_ I-GENE
media O
revealed O
a O
higher O
frequency O
in O
those O
individuals O
with O
alpha I-GENE
1 I-GENE
- I-GENE
antitrypsin I-GENE
deficiency O
as O
compared O
to O
normals O
. O

The O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
the O
venous O
system O
as O
efficiently O
as O
the O
double O
_RARE_ I-GENE
_RARE_ I-GENE
. O

All O
other O
changes O
at O
the O
3 I-GENE
-, I-GENE
5 I-GENE
-, I-GENE
and O
6 I-GENE
- I-GENE
positions O
, O
as O
well O
as O
the O
replacement O
of O
the O
_RARE_ I-GENE
group O
at O
position O
2 I-GENE
, O
caused O
a O
marked O
decrease O
of O
activity O
. O

Three O
experiments O
_RARE_ I-GENE
the O
effects O
of O
6 I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
induced O
lesions O
of O
the O
ventral O
noradrenergic O
and O
dorsal O
noradrenergic O
projections O
, O
predominantly O
to O
hypothalamus O
and O
cortex O
, O
respectively O
, O
upon O
body O
weight O
changes O
and O
food O
- I-GENE
related I-GENE
behaviour O
in O
the O
rat I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
in O
rats O
_RARE_ I-GENE
with O
cyclosporin O
A I-GENE
. O

The O
method O
involved O
_RARE_ I-GENE
samples O
with O
two O
volumes O
of O
_RARE_ I-GENE
followed O
by O
injection O
of O
5 I-GENE
_RARE_ I-GENE
of O
_RARE_ I-GENE
supernatant O
onto O
a O
C18 O
reversed O
- I-GENE
phase O
column O
. O

_RARE_ I-GENE
periods O
of O
the O
AV O
junction O
were O
altered O
in O
a O
comparable O
fashion O
to O
conduction O
through O
the O
AV O
node O
. O

This O
paper O
_RARE_ I-GENE
together O
data O
, O
obtained O
from O
a O
variety O
of O
sources O
, O
on O
the O
extent O
of O
_RARE_ I-GENE
and O
use O
of O
_RARE_ I-GENE
drugs O
in O
the O
late O
_RARE_ I-GENE
and O
early I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
patients O
were O
studied O
within O
24 O
hours O
of O
resuscitation O
and O
all O
showed O
depressed O
right O
ventricular O
ejection O
( O
_RARE_ I-GENE
) O
and O
/ I-GENE
or O
an O
increased O
end O
- I-GENE
diastolic O
volume O
( O
_RARE_ I-GENE
). O

During O
a O
single O
LAD O
occlusion O
lasting O
35 O
minutes O
( O
series O
I I-GENE
, O
n O
= O
10 O
) O
9 O
microns O
_RARE_ I-GENE
were O
infused O
immediately O
and O
30 O
minutes O
after O
ligation O
, O
15 O
microns O
_RARE_ I-GENE
being O
infused O
after O
15 O
- I-GENE
20 O
minutes O
. O

The O
population O
of O
between O
75 O
, O
000 O
and O
100 O
, O
000 O
was O
largely O
unstable O
, O
and O
cost O
per O
_RARE_ I-GENE
was O
_RARE_ I-GENE
0 O
. O
95 O
to O
_RARE_ I-GENE
1 I-GENE
. O
21 O
. O

Female O
_RARE_ I-GENE
rats O
were O
fed O
a O
liquid O
diet O
, O
_RARE_ I-GENE
, O
which O
contained O
ethanol O
( O
40 I-GENE
% O
of O
_RARE_ I-GENE
) O
or O
_RARE_ I-GENE
sucrose O
. O

HL I-GENE
02 O
type I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
. O

Four O
patients O
( O
group O
1 I-GENE
) O
had O
type I-GENE
I I-GENE
_RARE_ I-GENE
membrane I-GENE
nephropathy O
, O
characterized O
by O
marked O
_RARE_ I-GENE
and O
_RARE_ I-GENE
of O
the O
_RARE_ I-GENE
membrane I-GENE
in O
a O
pattern O
resembling O
that O
of O
_RARE_ I-GENE
' O
s O
syndrome O
. O

_RARE_ I-GENE
pH O
following O
3 I-GENE
h O
of O
cerebral O
focal I-GENE
ischemia O
changed O
from O
a O
normal O
value O
of O
7 O
. O
0 O
to O
6 I-GENE
. O
5 I-GENE
and O
6 I-GENE
. O
2 I-GENE
in O
animals O
studied O
under O
_RARE_ I-GENE
and O
halothane O
anesthesia O
, O
respectively O
. O

Our O
results O
demonstrate O
the O
importance O
of O
phosphate I-GENE
and O
calcium O
in O
influencing O
the O
secretion O
of O
PTH I-GENE
and O
CT I-GENE
in O
_RARE_ I-GENE
. O

_RARE_ I-GENE
- I-GENE
layer O
chromatographic O
methods O
were O
up O
- I-GENE
_RARE_ I-GENE
for O
pharmacokinetic O
studies O
of O
_RARE_ I-GENE
in O
plasma I-GENE
and O
urine O
. O

_RARE_ I-GENE
_RARE_ I-GENE
. O

Increasing O
the O
cut I-GENE
- I-GENE
off O
point O
to O
3 I-GENE
positive O
responses O
decreased O
the O
sensitivity O
to O
81 O
% O
and O
increased O
the O
specificity O
to O
94 O
%. O

After O
_RARE_ I-GENE
administration O
the O
autoregulation O
_RARE_ I-GENE
shifted O
to O
the O
right O
i O
. O
e O
. O
towards O
higher O
AP I-GENE
levels O
. O

This O
phenomenon O
may O
be O
regarded O
as O
a O
variant I-GENE
of O
selective O
individual O
cell O
death O
, O
currently O
referred O
to O
as O
apoptosis O
, O
which O
has O
not O
been O
previously O
reported O
in O
a O
case O
of O
_RARE_ I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
of O
a O
_RARE_ I-GENE
syndrome O
and O
a O
complex I-GENE
granulocyte I-GENE
function O
disorder O
in O
a O
_RARE_ I-GENE

A I-GENE
combined O
series O
of O
patients O
experienced O
a O
_RARE_ I-GENE
after O
two O
or O
more O
previous O
_RARE_ I-GENE
_RARE_ I-GENE
; O
the O
rate O
of O
vaginal O
delivery O
was O
66 O
%, O
and O
there O
was O
virtually O
no O
morbidity O
. O

_RARE_ I-GENE
home O
_RARE_ I-GENE
in O
clinical O
practice O
. O

_RARE_ I-GENE
3 I-GENE
_RARE_ I-GENE
chickens O
were O
maintained O
on O
control O
feed O
until O
they O
reached O
3 I-GENE
weeks O
of O
age O
at O
which O
time O
they O
were O
taken O
off O
of O
feed O
for O
2 I-GENE
. O
5 I-GENE
hr O
and O
then O
placed O
on O
either O
control O
feed O
or O
feed O
containing O
4 I-GENE
. O
0 O
ppm O
_RARE_ I-GENE
A I-GENE
, O
and O
heart O
rate O
and O
blood O
pressure O
were O
measured O
every O
half O
hour O
through O
7 O
hr O
. O

The O
_RARE_ I-GENE
_RARE_ I-GENE
therefore O
is O
a O
very O
important O
component O
of O
the O
battery O
of O
toxicological O
tests O
used O
in O
_RARE_ I-GENE
evaluation O
. O

_RARE_ I-GENE
effects O
in O
animals O
and O
man O
may O
result O
from O
both O
deficient O
or O
excessive O
amounts O
of O
intake O
. O

_RARE_ I-GENE
in O
the O
diagnosis O
of O
diseases O
of O
the O
kidney O

The O
analysis O
of O
the O
structure O
of O
the O
sleep O
period O
as O
a O
whole O
reveals O
that O
with O
increasing O
of O
the O
age O
the O
delta I-GENE
- I-GENE
wave O
stage O
( O
_RARE_ I-GENE
) O
of O
the O
_RARE_ I-GENE
( O
determined O
by O
defined O
_RARE_ I-GENE
parameters O
) O
increases O
, O
while O
the O
_RARE_ I-GENE
phase O
of O
sleep O
( O
PS I-GENE
) O
decreases O
, O
this O
change O
being O
more O
pronounced O
during O
the O
first O
six O
months O
than O
during O
the O
second O
ones O
of O
the O
first O
year O
of O
the O
life O
. O

[ O
_RARE_ I-GENE
] O
_RARE_ I-GENE
was O
prepared O
by O
_RARE_ I-GENE
samples O
of O
Br O
- I-GENE
_RARE_ I-GENE
in O
a O
_RARE_ I-GENE
_RARE_ I-GENE
for O
2 I-GENE
h O
at O
a O
thermal O
_RARE_ I-GENE
_RARE_ I-GENE
of O
10 O
( O
12 O
) O
n O
cm O
- I-GENE
2 I-GENE
s O
- I-GENE
1 I-GENE
. O

While O
these O
findings O
may O
reflect O
the O
sensitivity O
of O
a O
thick O
myocardial O
wall O
to O
ischaemia O
during O
surgery O
, O
the O
postoperative O
recovery O
was O
not O
related I-GENE
to O
the O
serum I-GENE
CK I-GENE
- I-GENE
MB I-GENE
level O
. O

_RARE_ I-GENE
status O
of O
the O
formed O
elements O
of O
the O
blood O
in O
rats O
subjected O
to O
different O
variants I-GENE
of O
combined O
and O
isolated O
exposure O
to O
_RARE_ I-GENE
- I-GENE
1 I-GENE
_RARE_ I-GENE

Using O
a O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
reversed O
- I-GENE
phase O
column O
with O
a O
phosphate I-GENE
_RARE_ I-GENE
-- O
_RARE_ I-GENE
mobile O
phase O
, O
baseline O
separation O
of O
_RARE_ I-GENE
, O
its O
metabolites O
3 I-GENE
- I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
and O
4 I-GENE
- I-GENE
_RARE_ I-GENE
, O
and O
the O
internal O
standard O
, O
_RARE_ I-GENE
, O
was O
achieved O
within O
6 I-GENE
min O
. O

The O
liver O
in O
the O
severely O
_RARE_ I-GENE

In O
a O
randomized O
study O
on O
150 O
patients O
( O
ASA I-GENE
1 I-GENE
) O
undergoing O
induction O
of O
anaesthesia O
, O
the O
effects O
of O
_RARE_ I-GENE
( O
0 O
. O
1 I-GENE
mg O
), O
the O
combination O
of O
_RARE_ I-GENE
( O
0 O
. O
1 I-GENE
mg O
) O
and O
_RARE_ I-GENE
( O
5 I-GENE
mg O
) O
( O
_RARE_ I-GENE
, O
_RARE_ I-GENE
) O
and O
_RARE_ I-GENE
( O
0 O
. O
01 O
mg O
/ I-GENE
kg O
b I-GENE
. O
w O
.) O
alone O
on O
_RARE_ I-GENE
parameters O
were O
studied O
. O

These O
results O
confirming O
the O
high O
validity O
of O
_RARE_ I-GENE
inhibiting O
test O
in O
the O
diagnosis O
of O
_RARE_ I-GENE
_RARE_ I-GENE
states O
, O
reveal O
_RARE_ I-GENE
responses O
to O
CD O
/ I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
and O
_RARE_ I-GENE
, O
with O
_RARE_ I-GENE
the O
existence O
of O
2 I-GENE
sub O
- I-GENE
group O
of O
_RARE_ I-GENE
: O
with O
or O
without O
a O
maintained O
DA I-GENE
central O
_RARE_ I-GENE
supporting O
the O
possibility O
of O
different O
_RARE_ I-GENE
factors I-GENE
in O
inducing O
a O
_RARE_ I-GENE
_RARE_ I-GENE
states O
. O

Serum I-GENE
lipids O
and O
lipoproteins I-GENE
of O
29 O
insulin I-GENE
dependent I-GENE
diabetic O
children O
have O
been O
determined O
and O
related I-GENE
to O
the O
metabolic O
status O
of O
the O
patients O
. O

Low O
NA O
and O
A I-GENE
may O
participate O
in O
lowering O
the O
plasma I-GENE
renin I-GENE
activity O
which O
in O
PA I-GENE
in O
suppressed O
, O
_RARE_ I-GENE
_RARE_ I-GENE
to O
the O
actual O
body O
sodium O
content O
. O

_RARE_ I-GENE
concentrations O
in O
serum I-GENE
and O
_RARE_ I-GENE
fluid O
in O
healthy O
volunteers O
and O
in O
patients O
with O
renal O
impairment O
. O

The O
subgroup O
_RARE_ I-GENE
the O
medial O
_RARE_ I-GENE
lies O
exclusively O
along O
the O
medial O
face O
of O
the O
_RARE_ I-GENE
nucleus O
, O
with O
no O
aberrant O
neurons O
in O
the O
medial O
longitudinal O
_RARE_ I-GENE
, O
as O
have O
been O
found O
in O
other O
mammals O
. O

Hepatitis I-GENE
B I-GENE
vaccination O
strategy O
for O
health O
- I-GENE
care O
workers O
in O
a O
_RARE_ I-GENE
of O
intermediate O
hepatitis I-GENE
B I-GENE
_RARE_ I-GENE
. O

An O
intravenous O
_RARE_ I-GENE
infusion O
of O
_RARE_ I-GENE
in O
adequate O
dosage O
would O
be O
beneficial O
to O
use O
against O
some O
infectious O
diseases O
of O
_RARE_ I-GENE
field O
. O

_RARE_ I-GENE
of O
these O
families O
74 O
, O
3 I-GENE
% O
_RARE_ I-GENE
next O
pregnancy O
( O
_RARE_ I-GENE
IX I-GENE
), O
57 O
, O
6 I-GENE
% O
_RARE_ I-GENE
to O
have O
_RARE_ I-GENE
diagnosis O
( O
_RARE_ I-GENE
VI I-GENE
). O

The O
authors O
have O
tested O
the O
interference O
of O
the O
hemoglobin I-GENE
by O
two O
routine O
methods O
( O
_RARE_ I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
modified O
) O
for O
the O
determination O
of O
_RARE_ I-GENE
urea O
. O

_RARE_ I-GENE
patients O
had O
a O
significantly O
lower O
prevalence O
of O
alcohol O
use O
. O

These O
cells O
averaged O
17 O
microns O
in O
diameter O
and O
_RARE_ I-GENE
by O
fission I-GENE
, O
forming O
clusters O
of O
two O
or O
four O
daughter O
cells O
. O

Female O
but O
not O
male O
_RARE_ I-GENE
were O
significantly O
higher O
for O
_RARE_ I-GENE
- I-GENE
fed O
rats O
than O
for O
those O
fed O
diet O
_RARE_ I-GENE
. O

_RARE_ I-GENE
N I-GENE
- I-GENE
_RARE_ I-GENE
activity O
per O
mg O
creatinine O
did O
not O
differ O
significantly O
between O
groups O
. O

The O
associations O
between O
sex I-GENE
- I-GENE
hormone I-GENE
- I-GENE
binding I-GENE
globulin I-GENE
capacity O
( O
SHBG I-GENE
), O
age O
, O
body O
mass O
index O
( O
BMI O
), O
and O
physical O
fitness O
have O
been O
studied O
in O
34 O
men O
and O
36 O
women O
. O

_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
_RARE_ I-GENE
_RARE_ I-GENE
. O
et O
sp O
. O
n O
. O

After O
1 I-GENE
. O
5 I-GENE
years O
of O
such O
_RARE_ I-GENE
control O
, O
all O
_RARE_ I-GENE
were O
_RARE_ I-GENE
by O
bilateral O
_RARE_ I-GENE
_RARE_ I-GENE
. O

The O
concentrations O
of O
C4 I-GENE
and O
C1 I-GENE
- I-GENE
_RARE_ I-GENE
increased O
with O
_RARE_ I-GENE
stage O
of O
disease O
and O
were O
above O
normal O
mean O
values O
in O
all O
stages O
. O

_RARE_ I-GENE
_RARE_ I-GENE
activity O
was O
shown O
toward O
the O
Gram O
- I-GENE
negative O
bacilli O
, O
i O
. O
e O
., O
Pseudomonas I-GENE
, O
Klebsiella I-GENE
- I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
Escherichia I-GENE
coli I-GENE
, O
_RARE_ I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
. O

The O
mucosal I-GENE
_RARE_ I-GENE
capacity O
against O
proteolytic O
leukocyte I-GENE
enzymes O
. O

The O
apparatus O
consists O
of O
an O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
source O
( O
300 O
mCi O
) O
and O
pure O
_RARE_ I-GENE
detector O
( O
50 O
mm2 O
X I-GENE
5 I-GENE
mm O
) O
for O
measuring O
K I-GENE
alpha I-GENE
fluorescent O
x O
- I-GENE
rays O
( O
28 O
. O
3 I-GENE
and O
28 O
. O
6 I-GENE
_RARE_ I-GENE
) O
_RARE_ I-GENE
from O
_RARE_ I-GENE
iodine O
. O

_RARE_ I-GENE
studies O
of O
_RARE_ I-GENE
of O
premature O
infants O

The O
range O
of O
serum I-GENE
concentrations O
, O
mean O
values O
, O
median O
values O
, O
and O
standard O
_RARE_ I-GENE
for O
each O
_RARE_ I-GENE
are O
reported O
for O
males O
and O
females O
and O
for O
three O
age O
groups O
( O
25 O
- I-GENE
44 I-GENE
, O
45 O
- I-GENE
59 O
, O
60 O
- I-GENE
70 I-GENE
). O

The O
effects O
of O
_RARE_ I-GENE
drugs O
in O
patients O
with O
left O
ventricular O
_RARE_ I-GENE
: O
assessment O
with O
_RARE_ I-GENE
- I-GENE
111 O
platelet I-GENE
imaging O
and O
two O
- I-GENE
dimensional O
echocardiography O
. O

A I-GENE
stable O
interface O
depends O
on O
overall O
stress O
and O
_RARE_ I-GENE
distribution O
on O
the O
bone O
, O
particularly O
_RARE_ I-GENE
bone O
. O

Plasma I-GENE
NE O
was O
also O
low O
in O
the O
_RARE_ I-GENE
group O
( O
_RARE_ I-GENE
mg O
/ I-GENE
liter O
+/- O
126 O
( O
1 I-GENE
SD O
) O
vs O
_RARE_ I-GENE
+/- O
_RARE_ I-GENE
, O
P I-GENE
= O
0 O
. O
_RARE_ I-GENE
, O
resting O
_RARE_ I-GENE
ABSTRACT O
TRUNCATED O
AT I-GENE
250 O
WORDS O
) O

10 O
long O
- I-GENE
term O
hemodialysis O
patients O
had O
immediate I-GENE
and O
_RARE_ I-GENE
thallium O
- I-GENE
201 O
myocardial O
imaging O
performed O
after O
a O
course O
of O
hemodialysis O
. O

The O
_RARE_ I-GENE
levels O
were O
within O
the O
physiological O
_RARE_ I-GENE
; O
the O
responses O
to O
TRH I-GENE
were O
normal O
, O
and O
elevated O
only O
in O
a O
few O
cases O
. O

Despite O
total O
tumor I-GENE
resection O
, O
multiple O
_RARE_ I-GENE
tumor I-GENE
nodules O
of O
varying O
sizes O
were O
found O
and O
_RARE_ I-GENE
six O
months O
and O
one O
year O
later O
. O

_RARE_ I-GENE
hospital O
_RARE_ I-GENE
. O

_RARE_ I-GENE
III I-GENE
in O
hip O
surgery O

In O
14 O
of O
21 O
infant O
hearts O
( O
66 O
%) O
with O
aortic O
_RARE_ I-GENE
_RARE_ I-GENE
between O
the O
left O
common O
carotid O
and O
left O
_RARE_ I-GENE
arteries O
( O
type I-GENE
B I-GENE
of O
_RARE_ I-GENE
and O
_RARE_ I-GENE
), O
the O
right O
_RARE_ I-GENE
artery O
( O
SA O
) O
_RARE_ I-GENE
_RARE_ I-GENE
. O

We O
suggest O
that O
sensitivity O
to O
_RARE_ I-GENE
in O
_RARE_ I-GENE
_RARE_ I-GENE
, O
as O
in O
several O
other O
mammals O
, O
is O
mediated O
by O
the O
pineal O
gland O
. O

_RARE_ I-GENE
was O
rapid O
, O
with O
a O
mean O
time O
to O
peak O
of O
39 O
min O
. O

Additionally O
, O
observations O
that O
patients O
with O
mitral O
versus O
aortic O
_RARE_ I-GENE
respond O
differently O
to O
valve O
replacement O
suggest O
that O
differences O
exist O
_RARE_ I-GENE
between O
these O
two O
types O
of O
volume O
overload O
. O

A I-GENE
case O
of O
manifest O
latent I-GENE
nystagmus O
of O
late O
onset O
in O
a O
13 O
- I-GENE
year O
- I-GENE
old O
_RARE_ I-GENE
is O
reported O
. O

Within O
the O
compartment O
or O
_RARE_ I-GENE
of O
severity O
of O
depression O
a O
_RARE_ I-GENE
of O
the O
_RARE_ I-GENE
_RARE_ I-GENE
Scale O
( O
or O
the O
_RARE_ I-GENE
Scale O
) O
was O
shown O
to O
have O
reached O
an O
_RARE_ I-GENE
_RARE_ I-GENE
, O
e O
. O
g O
. O
as O
an O
outcome O
measure O
of O
_RARE_ I-GENE
treatment O
. O

Significant O
_RARE_ I-GENE
developed O
prior O
to O
the O
development O
of O
_RARE_ I-GENE
, O
significantly O
decreased O
creatinine O
clearance O
, O
significant O
_RARE_ I-GENE
( O
greater O
than O
or O
equal O
to O
3 I-GENE
+ I-GENE
_RARE_ I-GENE
or O
greater O
than O
or O
equal O
to O
5 I-GENE
_RARE_ I-GENE
per O
24 O
- I-GENE
hour O
urine O
collection O
), O
or O
_RARE_ I-GENE
. O

A I-GENE
total O
number O
of O
_RARE_ I-GENE
cases O
were O
collected O
from O
135 O
medical O
_RARE_ I-GENE
. O

_RARE_ I-GENE
activity O
recorded O
from O
superficial O
_RARE_ I-GENE
_RARE_ I-GENE
layer O
4 I-GENE
, O
and O
into O
which O
layer O
4 I-GENE
' O
s O
primary O
projections O
terminate O
, O
is O
suppressed O
preferentially O
by O
phenytoin O
. O

The O
AD O
components O
were O
markedly O
more O
dependent I-GENE
on O
the O
affective O
state O
of O
the O
rat I-GENE
then O
was O
the O
_RARE_ I-GENE
component O
. O

Is O
_RARE_ I-GENE
capable O
of O
reducing O
left O
ventricular O
_RARE_ I-GENE
? O
In O
ten O
anesthetized O
pigs O
, O
_RARE_ I-GENE
( O
2 I-GENE
- I-GENE
4 I-GENE
micrograms O
X I-GENE
kg O
- I-GENE
1 I-GENE
X I-GENE
min O
- I-GENE
1 I-GENE
), O
a O
calcium O
channel O
blocker O
structurally O
related I-GENE
to O
nifedipine O
, O
reduced O
left O
ventricular O
systolic O
pressure O
( O
40 I-GENE
%) O
and O
systemic O
vascular I-GENE
resistance O
( O
35 O
%), O
whereas O
_RARE_ I-GENE
/ I-GENE
dt O
decreased O
by O
20 O
% O
and O
cardiac O
output O
was O
unchanged O
. O

_RARE_ I-GENE
were O
evaluated O
before O
and O
after O
unilateral O
and O
serial O
bilateral O
removal O
of O
superior O
temporal O
cortex O
. O

_RARE_ I-GENE
concentration O
in O
the O
_RARE_ I-GENE
indicated O
little O
, O
if O
any O
accumulation O
. O

All O
samples O
exhibited O
a O
decline O
in O
ethanol O
concentration O
, O
with O
most O
_RARE_ I-GENE
_RARE_ I-GENE
within O
the O
expected O
20 O
to O
40 I-GENE
mg O
% O
range O
. O

Plasma I-GENE
_RARE_ I-GENE
and O
the O
blood O
count O
of O
_RARE_ I-GENE
neutrophils O

The O
importance O
of O
selective O
renal O
vein O
_RARE_ I-GENE
in O
the O
evaluation O
of O
_RARE_ I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
defects O
in O
the O
_RARE_ I-GENE
_RARE_ I-GENE
is O
_RARE_ I-GENE
. O

_RARE_ I-GENE
study O
of O
blood O
coagulation I-GENE
in O
_RARE_ I-GENE
patients O
. O

The O
statistical O
analysis O
consist O
of O
the O
F I-GENE
test O
followed O
by O
_RARE_ I-GENE
' O
s O
contrast O
test O
. O

The O
pyramidal O
tract O
and O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
were O
stimulated O
before O
and O
after O
the O
_RARE_ I-GENE
. O

Further O
, O
the O
reduction O
in O
5 I-GENE
- I-GENE
_RARE_ I-GENE
( O
5 I-GENE
- I-GENE
_RARE_ I-GENE
) O
accumulation O
by O
_RARE_ I-GENE
showed O
regional O
differences O
in O
inhibition O
by O
_RARE_ I-GENE
( O
hypothalamus O
greater O
than O
cortex O
greater O
than O
striatum I-GENE
) O
which O
_RARE_ I-GENE
the O
_RARE_ I-GENE
antagonist O
activity O
of O
_RARE_ I-GENE
in O
vitro O
.( O
ABSTRACT O
TRUNCATED O
AT I-GENE
250 O
WORDS O
) O

Effects O
of O
_RARE_ I-GENE
and O
_RARE_ I-GENE
acid I-GENE
_RARE_ I-GENE
on O
serotonin I-GENE
release O
in O
vitro O
and O
serotonin I-GENE
synthesis O
in O
vivo O
: O
possible O
relation O
to O
serotonin I-GENE
_RARE_ I-GENE
function O
. O

In O
a O
recent O
_RARE_ I-GENE
epidemic O
in O
_RARE_ I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
120 O
, O
000 O
records O
were O
screened O
using O
these O
criteria O
, O
and O
as O
a O
result O
13 O
, O
000 O
students O
were O
_RARE_ I-GENE
. O

No O
patient O
with O
_RARE_ I-GENE
- I-GENE
related I-GENE
_RARE_ I-GENE
had O
manifest O
_RARE_ I-GENE
block O
or O
bundle O
branch O
block O
. O

The O
measurement O
of O
the O
areas O
of O
fibrin I-GENE
, O
of O
tissue I-GENE
and O
_RARE_ I-GENE
, O
at O
the O
above O
mentioned O
times O
, O
has O
been O
_RARE_ I-GENE
at O
standard O
magnification O
( O
15 O
X I-GENE
) O
by O
an O
image O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
scale O
1 I-GENE
: O
8 O
. O

_RARE_ I-GENE
sodium O
- I-GENE
_RARE_ I-GENE
poisoning O
. O

_RARE_ I-GENE
plasma I-GENE
_RARE_ I-GENE
concentration O
after O
90 O
minutes O
in O
untreated O
patients O
correlated O
positively O
to O
the O
_RARE_ I-GENE
fat O
excretion O
( O
r O
= O
0 O
. O
58 O
, O
p O
less O
than O
0 O
. O
02 O
). O

Blood O
pressure O
in O
children O
. O

In O
this O
study O
the O
_RARE_ I-GENE
_RARE_ I-GENE
born O
_RARE_ I-GENE
appeared O
to O
be O
capable O
of O
_RARE_ I-GENE
rhesus I-GENE
as O
an O
_RARE_ I-GENE
drug O
testing O
model O
. O

The O
results O
showed O
that O
the O
sensitivity O
of O
the O
3 I-GENE
given O
guinea O
pig O
strains O
was O
comparable O
. O

Adult O
_RARE_ I-GENE
_RARE_ I-GENE
ticks O
fed O
as O
_RARE_ I-GENE
on O
this O
_RARE_ I-GENE
transmitted O
_RARE_ I-GENE
to O
a O
_RARE_ I-GENE
( O
_RARE_ I-GENE
_RARE_ I-GENE
) O
calf I-GENE
. O

Twenty O
- I-GENE
one O
percent O
of O
these O
patients O
had O
neurologic O
disease O
that O
appeared O
to O
be O
responsible O
for O
the O
_RARE_ I-GENE
. O

_RARE_ I-GENE
injected O
into O
the O
lateral O
ventricle O
of O
the O
rat I-GENE
produced O
unilateral O
analgesia O
in O
the O
formalin O
test O
, O
which O
involves O
continuous O
, O
moderate O
pain O
. O

The O
maps O
of O
_RARE_ I-GENE
2 I-GENE
showed O
that O
a O
maximum O
first O
appeared O
on O
the O
upper O
right O
back O
and O
then O
_RARE_ I-GENE
down O
the O
right O
side O
of O
the O
posterior O
_RARE_ I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
excretion O
, O
_RARE_ I-GENE
clearance O
, O
and O
fractional O
excretion O
of O
_RARE_ I-GENE
all O
increased O
significantly O
during O
water O
immersion O
, O
and O
decreased O
in O
the O
hour O
following O
water O
immersion O
. O

Mutations O
in O
seven O
other O
_RARE_ I-GENE
genes I-GENE
do O
not O
result O
in O
the O
_RARE_ I-GENE
- I-GENE
phenotype O
. O

Twenty O
- I-GENE
eight O
were O
excluded O
as O
_RARE_ I-GENE
were O
not O
proved O
: O
of O
the O
_RARE_ I-GENE
, O
21 O
patients O
received O
glucagon I-GENE
and O
22 O
placebo O
. O

4 I-GENE
Five O
patients O
died O
within O
one O
month O
of O
captopril O
and O
five O
between O
four O
and O
seven O
months O
, O
three O
of O
whom O
had O
improved O
to O
class I-GENE
_RARE_ I-GENE
and O
one O
to O
_RARE_ I-GENE
before O
death O
. O

_RARE_ I-GENE
_RARE_ I-GENE
hyperplasia O
with O
_RARE_ I-GENE

_RARE_ I-GENE
of O
the O
translated O
open O
reading O
frames O
of O
_RARE_ I-GENE
and O
the O
third O
intron O
of O
the O
_RARE_ I-GENE
gene I-GENE
in O
yeast I-GENE
show O
high O
amino O
acid I-GENE
homology I-GENE
. O

_RARE_ I-GENE
strains O
isolated O
from O
humans O
in O
_RARE_ I-GENE
_RARE_ I-GENE
- I-GENE
infections O
_RARE_ I-GENE
orally O
infected O
mice O
more O
frequently O
than O
strains O
isolated O
in O
hospital O
infections O
. O

_RARE_ I-GENE
tooth O
replacement O
with O
the O
aid O
of O
the O
_RARE_ I-GENE
( O
International O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
) O
type I-GENE
F I-GENE
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
implant O

The O
13 O
, O
14 O
- I-GENE
_RARE_ I-GENE
- I-GENE
15 O
- I-GENE
_RARE_ I-GENE
- I-GENE
metabolites O
of O
PGE2 O
and O
PGF2 O
alpha I-GENE
had O
no O
statistically O
significant O
antiarrhythmic O
effect O
. O

Nucleotide O
sequence I-GENE
of O
DNA I-GENE
controlling O
expression O
of O
genes I-GENE
for O
_RARE_ I-GENE
utilization O
in O
Streptococcus I-GENE
pneumoniae I-GENE
. O

The O
hypertension O
with O
elevated O
_RARE_ I-GENE
, O
however O
, O
was O
resistant O
to O
the O
angiotensin I-GENE
II I-GENE
( O
_RARE_ I-GENE
) O
analog O
[ O
_RARE_ I-GENE
, O
_RARE_ I-GENE
] O
ALL O
. O

_RARE_ I-GENE
determination O
of O
urinary O
iron O
, O
_RARE_ I-GENE
with O
_RARE_ I-GENE
B I-GENE
, O
using O
a O
single O
_RARE_ I-GENE

Measurements O
of O
perfusion O
also O
showed O
significantly O
higher O
values O
under O
active O
therapy O
. O

_RARE_ I-GENE
of O
distribution O
of O
total O
_RARE_ I-GENE
( O
range O
, O
1 I-GENE
. O
33 O
to O
6 I-GENE
. O
30 O
l O
/ I-GENE
kg O
) O
and O
of O
_RARE_ I-GENE
_RARE_ I-GENE
after O
correction O
for O
protein I-GENE
binding I-GENE
( O
range O
, O
43 I-GENE
to O
_RARE_ I-GENE
l O
/ I-GENE
kg O
) O
was O
larger O
in O
women O
than O
in O
men O
of O
all O
ages O
, O
and O
in O
the O
elderly O
as O
opposed O
to O
the O
young O
. O

Effects O
of O
dopamine I-GENE
and O
of O
a O
dopaminergic O
blocker O
, O
haloperidol O
, O
on O
the O
responses O
of O
carotid O
body O
_RARE_ I-GENE
to O
hypoxia O
and O
hypercapnia O
were O
investigated O
in O
16 O
anesthetized O
cats O
. O

HLA I-GENE
- I-GENE
A I-GENE
and O
B I-GENE
phenotypes O
of O
105 I-GENE
patients O
suffering O
from O
malignant O
melanomas O
were O
determined O
, O
with O
special O
regard O
for O
metastatic O
form O
or O
relapse O
. O

Trypanosoma O
_RARE_ I-GENE
. O

The O
subjects O
of O
the O
study O
were O
10 O
normal O
subjects O
and O
64 O
patients O
with O
_RARE_ I-GENE
disease O
. O

1 I-GENE
. O

This O
study O
represents O
the O
first O
published O
long O
- I-GENE
term O
follow O
- I-GENE
up O
regarding O
this O
mode O
of O
treatment O
in O
patients O
with O
alveolar O
_RARE_ I-GENE
. O

The O
alterations O
in O
differentiation O
of O
_RARE_ I-GENE
cells O
, O
together O
with O
the O
failure O
of O
_RARE_ I-GENE
, O
resulted O
in O
significantly O
lower O
rates O
of O
bone O
formation O
( O
as O
measured O
by O
_RARE_ I-GENE
labeling O
) O
in O
the O
magnesium O
- I-GENE
deficient O
rats O
. O

A I-GENE
_RARE_ I-GENE
measure O
of O
this O
impairment O
may O
be O
obtained O
using O
the O
ratio O
of O
urine O
volume O
( O
V I-GENE
) O
divided O
by O
lithium O
clearance O
( O
_RARE_ I-GENE
). O

_RARE_ I-GENE
balance O
was O
compared O
, O
and O
metabolic O
complications O
were O
monitored O
by O
evaluating O
_RARE_ I-GENE
, O
serum I-GENE
creatinine O
, O
creatinine O
clearance O
, O
serum I-GENE
CO2 O
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
serum I-GENE
_RARE_ I-GENE
, O
and O
serum I-GENE
alkaline I-GENE
phosphatase I-GENE
. O

_RARE_ I-GENE
of O
C I-GENE
mu I-GENE
RNAs I-GENE
, O
unlike O
mu I-GENE
mRNAs I-GENE
, O
does O
not O
require O
recombination O
with O
the O
joining O
region O
( O
_RARE_ I-GENE
) O
locus I-GENE
. O

The O
1 I-GENE
. O
9 O
- I-GENE
kb O
C I-GENE
mu I-GENE
RNA I-GENE
contains O
the O
3 I-GENE
' O
sequence I-GENE
characteristic O
of O
secreted O
mu I-GENE
chain I-GENE
, O
whereas O
the O
longer O
species O
_RARE_ I-GENE
that O
of O
membrane I-GENE
- I-GENE
bound O
mu I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
of O
the O
immunoglobulin I-GENE
C I-GENE
mu I-GENE
gene I-GENE
vary O
in O
structure O
and O
splicing O
during O
lymphoid I-GENE
development O
. O

Non O
- I-GENE
complement I-GENE
- I-GENE
dependent I-GENE
sperm O
- I-GENE
_RARE_ I-GENE
activity O
was O
also O
detected O
in O
the O
cervical O
mucus O
of O
several O
patients O
. O

The O
role O
of O
DNA I-GENE
rearrangement O
and O
alternative O
RNA I-GENE
processing O
in O
the O
expression O
of O
immunoglobulin I-GENE
delta I-GENE
genes I-GENE
. O

Although O
the O
mechanism O
of O
action O
of O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
has O
not O
been O
clearly O
defined O
, O
it O
is O
evident O
from O
both O
_RARE_ I-GENE
and O
early I-GENE
clinical O
studies O
that O
these O
compounds O
are O
of O
interest O
. O

All O
62 O
isolates O
were O
resistant O
to O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
amphotericin O
B I-GENE
, O
_RARE_ I-GENE
lactate I-GENE
, O
_RARE_ I-GENE
B I-GENE
, O
and O
_RARE_ I-GENE
. O

The O
evaluation O
of O
amniotic I-GENE
fluid O
delta I-GENE
_RARE_ I-GENE
is O
considered O
to O
be O
the O
_RARE_ I-GENE
of O
clinical O
management O
. O

_RARE_ I-GENE
lipids O
in O
tuberculous O
infection O
. O

There O
is O
now O
a O
_RARE_ I-GENE
difference O
between O
age O
group O
1 I-GENE
- I-GENE
5 I-GENE
and O
the O
others O
( O
p O
_RARE_ I-GENE
_RARE_ I-GENE
0 O
, O
02 O
). O

The O
sympathetic O
_RARE_ I-GENE
influence O
on O
the O
myocardium O
with O
_RARE_ I-GENE
depends O
to O
a O
large O
measure O
on O
the O
intensity O
of O
the O
_RARE_ I-GENE
biosynthesis O
and O
function O
of O
_RARE_ I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
reductase I-GENE
in O
diabetic O
and O
_RARE_ I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
( O
in O
doses O
ranging O
from O
0 O
. O
_RARE_ I-GENE
- I-GENE
4 I-GENE
. O
0 O
mg O
/ I-GENE
kg O
/ I-GENE
infusion O
) O
did O
not O
maintain O
self O
- I-GENE
administration O
behavior O
at O
or O
above O
the O
minimum O
requirement O
( O
FR I-GENE
30 O
). O

In O
the O
course O
of O
Hepatitis I-GENE
A I-GENE
HBs I-GENE
- I-GENE
and O
_RARE_ I-GENE
- I-GENE
antigen I-GENE
as O
well O
as O
_RARE_ I-GENE
( O
IgM I-GENE
and O
IgG I-GENE
_RARE_ I-GENE
HBs I-GENE
- I-GENE
and O
_RARE_ I-GENE
- I-GENE
antibodies I-GENE
can O
be O
detected O
. O

The O
effect O
of O
the O
fatty I-GENE
acid I-GENE
_RARE_ I-GENE
- I-GENE
oxygenase I-GENE
inhibitor I-GENE
indomethacin O
on O
cerebral O
blood O
flow O
( O
CBF I-GENE
) O
and O
the O
metabolic O
rate O
for O
oxygen O
( O
_RARE_ I-GENE
) O
was O
studied O
in O
_RARE_ I-GENE
and O
artificially O
ventilated O
rats O
. O

The O
rat I-GENE
_RARE_ I-GENE
is O
an O
excellent O
model O
system O
in O
which O
to O
study O
_RARE_ I-GENE
. O

The O
already O
elevated O
prolactin I-GENE
levels O
in O
nursing O
women O
were O
not O
influenced O
by O
chronic O
oestradiol O
administration O
. O

Factor I-GENE
VIII I-GENE
_RARE_ I-GENE
activity O
, O
antigen I-GENE
concentration O
and O
von I-GENE
Willebrand I-GENE
activity O
as O
_RARE_ I-GENE
cofactor I-GENE
were O
determined O
several O
times O
in O
10 O
patients O
with O
_RARE_ I-GENE
. O

_RARE_ I-GENE
- I-GENE
dependent I-GENE
and O
control O
rats O
in O
an O
oral O
free O
- I-GENE
choice O
protocol O
were O
treated O
with O
gamma I-GENE
- I-GENE
vinyl O
GABA I-GENE
( O
_RARE_ I-GENE
), O
60 O
, O
120 O
and O
240 O
mg O
/ I-GENE
kg O
_RARE_ I-GENE
, O
for O
3 I-GENE
days O
over O
three O
successive O
periods O
. O

Significance O
of O
the O
pulmonary O
gas O
exchange I-GENE
reaction O
to O
physical O
loading O
in O
evaluating O
the O
effectiveness O
of O
mitral O
_RARE_ I-GENE

_RARE_ I-GENE
_RARE_ I-GENE
in O
thyroid I-GENE
_RARE_ I-GENE

In O
_RARE_ I-GENE
, O
significant O
relationships O
between O
patients O
and O
_RARE_ I-GENE
were O
not O
seen O
with O
respect O
to O
arterial O
blood O
gas O
determinations O
and O
_RARE_ I-GENE
responses O
except O
for O
_RARE_ I-GENE
of O
patients O
and O
_RARE_ I-GENE
_RARE_ I-GENE
responses O
of O
_RARE_ I-GENE
. O

For O
steers O
the O
urinary O
N I-GENE
values O
were O
_RARE_ I-GENE
and O
_RARE_ I-GENE
mg O
/ I-GENE
kg O
_RARE_ I-GENE
. O
75 O
at O
200 O
and O
350 O
kg O
live O
weight O
respectively O
and O
total O
N I-GENE
excretion O
including O
_RARE_ I-GENE
N I-GENE
was O
_RARE_ I-GENE
and O
_RARE_ I-GENE
mg O
/ I-GENE
kg O
_RARE_ I-GENE
. O
75 O
. O

_RARE_ I-GENE
in O
_RARE_ I-GENE
treatment O
: O
a O
hepatitis I-GENE
- I-GENE
safe O
factor I-GENE
VIII I-GENE
_RARE_ I-GENE

This O
study O
was O
designed O
to O
assess O
and O
compare O
the O
ability O
of O
three O
different O
forms O
of O
_RARE_ I-GENE
to O
block O
_RARE_ I-GENE
. O

Comparison O
of O
three O
different O
preparations O
of O
_RARE_ I-GENE
_RARE_ I-GENE
in O
the O
prevention O
of O
exercise O
- I-GENE
induced O
_RARE_ I-GENE
: O
a O
double O
- I-GENE
blind O
study O
. O

_RARE_ I-GENE
in O
normal O
and O
hypoxic O
_RARE_ I-GENE
was O
correlated O
with O
local O
cerebral O
glucose O
utilization O
( O
_RARE_ I-GENE
) O
obtained O
under O
the O
same O
experimental O
conditions O
( O
_RARE_ I-GENE
et O
al O
, O
1982 O
). O

_RARE_ I-GENE
of O
_RARE_ I-GENE
bacilli O
by O
macrophages O
. O

Detection O
of O
_RARE_ I-GENE
A I-GENE
carriers O
. O

The O
stability O
of O
_RARE_ I-GENE
solutions O
increases O
markedly O
with O
increasing O
_RARE_ I-GENE
or O
EDTA O
concentration O
up O
to O
1 I-GENE
mmol O
/ I-GENE
l O
. O

_RARE_ I-GENE
bilirubin O
did O
not O
rise O
within O
12 O
h O
after O
_RARE_ I-GENE
infusion O
a O
finding O
which O
_RARE_ I-GENE
further O
investigation O
. O

_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
juvenile O
diabetes O
management O
. O

Other O
properties O
of O
Hg O
- I-GENE
and O
Cd O
- I-GENE
_RARE_ I-GENE
were O
similar O
to O
those O
of O
control O
_RARE_ I-GENE
. O

The O
decrease O
in O
HDL I-GENE
- I-GENE
cholesterol I-GENE
with O
increasing O
_RARE_ I-GENE
- I-GENE
triglycerides I-GENE
was O
relatively O
much O
larger O
than O
the O
concomitant O
decrease O
in O
apo I-GENE
A I-GENE
- I-GENE
I I-GENE
. O

_RARE_ I-GENE
A I-GENE
- I-GENE
I I-GENE
level O
was O
unrelated O
to O
age O
, O
but O
increased O
with O
ethanol O
consumption O
and O
decreased O
with O
_RARE_ I-GENE
. O

_RARE_ I-GENE
and O
_RARE_ I-GENE
were O
the O
most O
potent O
_RARE_ I-GENE
. O

The O
osmotic O
diuretic O
_RARE_ I-GENE
was O
administered O
to O
21 O
patients O
. O

Of O
270 O
patients O
with O
well O
- I-GENE
defined O
drug O
reactions O
, O
190 O
( O
70 I-GENE
per O
cent O
) O
gave O
a O
positive O
response O
to O
the O
mast I-GENE
cell O
test O
. O

_RARE_ I-GENE
, O
as O
a O
_RARE_ I-GENE
of O
glutathione I-GENE
peroxidase I-GENE
, O
plays O
a O
role O
in O
the O
antioxidant O
defense O
systems O
of O
the O
body O
, O
but O
other O
metabolic O
roles O
for O
selenium O
may O
yet O
be O
discovered O
. O

Diagnostic O
value O
of O
serum I-GENE
myoglobin I-GENE
in O
cases O
of O
neuromuscular O
disease O

At O
43 I-GENE
% O
blood O
pressure O
reduction O
, O
PCO2 O
fell O
by O
0 O
. O
53 O
_RARE_ I-GENE
, O
a O
decrease O
which O
could O
not O
explain O
the O
observed O
CBF I-GENE
fall O
of O
27 O
%. O

During O
the O
last O
6 I-GENE
months O
of O
the O
study O
a O
striking O
change O
in O
_RARE_ I-GENE
concerning O
hepatitis I-GENE
A I-GENE
was O
seen O
, O
apparently O
caused O
by O
a O
_RARE_ I-GENE
increase O
in O
the O
incidence O
of O
this O
type I-GENE
of O
hepatitis I-GENE
among O
drug O
addicts O
. O

_RARE_ I-GENE
patients O
showed O
greater O
responses O
of O
both O
parameters O
to O
adrenaline O
than O
controls O
indicating O
that O
long O
- I-GENE
term O
corticosteroid I-GENE
treatment O
enhances O
the O
acute O
responses O
of O
plasminogen I-GENE
activator I-GENE
and O
clotting I-GENE
factor I-GENE
VIII I-GENE
to O
adrenaline O
infusion O
. O

_RARE_ I-GENE
amino O
acids O
( O
g O
/ I-GENE
16 O
g O
N I-GENE
) O
were O
higher O
in O
the O
isolates O
than O
in O
the O
_RARE_ I-GENE
. O

_RARE_ I-GENE
shifts O
increase O
growth I-GENE
hormone I-GENE
release O
. O

It O
then O
_RARE_ I-GENE
with O
right O
ventricular O
_RARE_ I-GENE
_RARE_ I-GENE
along O
the O
right O
ventricular O
anterior O
_RARE_ I-GENE
groove I-GENE
and O
outflow O
tract O
. O

Many O
of O
these O
_RARE_ I-GENE
_RARE_ I-GENE
were O
undertaken O
in O
the O
early I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
, O
when O
knowledge O
regarding O
the O
safe O
and O
prolonged O
_RARE_ I-GENE
of O
the O
_RARE_ I-GENE
_RARE_ I-GENE
was O
_RARE_ I-GENE
or O
minimal I-GENE
at O
best O
. O

_RARE_ I-GENE
could O
be O
induced O
only O
with O
multiple O
exposures O
to O
_RARE_ I-GENE
. O

The O
level O
of O
contamination O
in O
the O
wound O
can O
be O
determined O
with O
the O
rapid O
biopsy O
fixation O
technique O
. O

_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
after O
deep O
hypothermia O
( O
20 O
degrees O
C I-GENE
) O
causes O
a O
considerable O
increase O
in O
the O
brain O
tissues O
_RARE_ I-GENE
activity O
at O
all O
studied O
incubation O
temperatures O
( O
37 O
, O
30 O
, O
20 O
and O
10 O
degrees O
C I-GENE
) O
as O
compared O
to O
control O
rats O
and O
rats O
under O
hypothermia O
. O

Similar O
observations O
were O
made O
with O
unilateral O
_RARE_ I-GENE
of O
15 O
cmH2O O
for O
30 O
min O
. O

According O
to O
_RARE_ I-GENE
' O
s O
classification O
, O
they O
consisted O
of O
Type O
_RARE_ I-GENE
in O
63 O
%, O
Type O
_RARE_ I-GENE
in O
11 O
%, O
Type O
II I-GENE
in O
11 O
%, O
and O
Type O
III I-GENE
in O
16 O
%. O

This O
study O
was O
undertaken O
to O
define O
the O
mechanism O
for O
the O
respiratory O
inhibition O
observed O
during O
high O
- I-GENE
frequency O
_RARE_ I-GENE
ventilation O
( O
_RARE_ I-GENE
). O

Determination O
of O
20 O
alpha I-GENE
- I-GENE
hydroxy I-GENE
- I-GENE
9 O
beta I-GENE
, O
10 O
alpha I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
4 I-GENE
, O
6 I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
3 I-GENE
- I-GENE
one O
in O
plasma I-GENE
by O
selected O
ion O
monitoring O
. O

A I-GENE
case O
of O
a O
_RARE_ I-GENE
_RARE_ I-GENE
cyst O
of O
the O
_RARE_ I-GENE
_RARE_ I-GENE
is O
presented O
. O

_RARE_ I-GENE
treatments O
were O
assigned O
to O
_RARE_ I-GENE
the O
different O
levels O
of O
copper I-GENE
intake O
that O
might O
result O
from O
differences O
in O
daily O
feed O
intake O
similar O
to O
the O
practice O
followed O
with O
commercial O
_RARE_ I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
was O
seen O
in O
the O
ascending O
and O
_RARE_ I-GENE
aorta O
of O
the O
swine O
fed O
62 O
, O
500 O
IU O
of O
vitamin O
D3 I-GENE
/ I-GENE
kg O
of O
diet O
for O
three O
months O
duration O
; O
and O
after O
3 I-GENE
months O
of O
vitamin O
D3 I-GENE
withdrawal O
, O
_RARE_ I-GENE
lesions O
were O
found O
. O

Because O
of O
a O
rapid O
development O
of O
the O
connective O
tissue I-GENE
_RARE_ I-GENE
, O
however O
, O
at O
the O
place O
of O
the O
_RARE_ I-GENE
_RARE_ I-GENE
parenchyma O
areas O
, O
there O
is O
no O
_RARE_ I-GENE
of O
the O
organ O
' O
s O
structure O
and O
function O
by O
the O
_RARE_ I-GENE
day O
. O

Histological O
signs O
of O
the O
_RARE_ I-GENE
- I-GENE
up O
reaction O
were O
already O
present O
at O
6 I-GENE
hr O
after O
i O
. O
v I-GENE
. O
challenge O
and O
_RARE_ I-GENE
for O
at O
least O
4 I-GENE
days O
. O

Significant O
_RARE_ I-GENE
reductions O
occurred O
in O
early I-GENE
shock I-GENE
in O
both O
treatment O
groups O
. O

Of O
_RARE_ I-GENE
children O
with O
neuroblastoma O
treated O
at O
_RARE_ I-GENE
. O

_RARE_ I-GENE
- I-GENE
G I-GENE
degradation O
products I-GENE
inhibit O
in O
vitro O
_RARE_ I-GENE
. O

Plasma I-GENE
fibrinogen I-GENE
was O
measured O
by O
the O
_RARE_ I-GENE
method O
in O
_RARE_ I-GENE
_RARE_ I-GENE
units O
. O

Five O
patients O
with O
type I-GENE
III I-GENE
_RARE_ I-GENE
infection O
from O
_RARE_ I-GENE
_RARE_ I-GENE
species O
were O
examined O
during O
a O
13 O
- I-GENE
month O
period O
. O

_RARE_ I-GENE
tubular O
acidification O
and O
the O
threshold O
for O
proximal I-GENE
tubular O
_RARE_ I-GENE
_RARE_ I-GENE
were O
normal O
, O
as O
was O
urine O
_RARE_ I-GENE
capacity O
. O

Detection O
of O
exercise O
- I-GENE
induced O
_RARE_ I-GENE
by O
M I-GENE
- I-GENE
mode O
echocardiography O
. O

The O
_RARE_ I-GENE
phenomenon O
, O
_RARE_ I-GENE
test O
, O
and O
_RARE_ I-GENE
' O
s O
sign O
: O
clinical O
significance O
. O

These O
results O
indicate O
that O
significant O
pulmonary O
metabolism O
of O
5 I-GENE
- I-GENE
HT O
followed O
by O
_RARE_ I-GENE
of O
5 I-GENE
- I-GENE
_RARE_ I-GENE
into O
venous O
output O
occurs O
during O
single O
- I-GENE
_RARE_ I-GENE
circulation O
. O

_RARE_ I-GENE
of O
placental I-GENE
maturation O
, O
2 I-GENE
. O

On O
the O
basis O
of O
histopathological O
findings O
, O
the O
origin O
of O
_RARE_ I-GENE
appeared O
to O
be O
closely O
related I-GENE
to O
the O
fibroblasts O
. O

Both O
groups O
were O
subjected O
to O
tests O
of O
delayed O
hypersensitivity O
with O
_RARE_ I-GENE
, O
_RARE_ I-GENE
and O
_RARE_ I-GENE
. O

Serum I-GENE
lactate I-GENE
dehydrogenase I-GENE
and O
_RARE_ I-GENE
levels O
were O
normal O
, O
and O
total O
bilirubin O
was O
only O
slightly O
elevated O
. O

Low O
- I-GENE
dose O
D I-GENE
( O
0 O
. O
4 I-GENE
- I-GENE
0 O
. O
8 O
mg O
) O
and O
_RARE_ I-GENE
( O
1 I-GENE
. O
0 O
- I-GENE
5 I-GENE
. O
0 O
mg O
) O
did O
not O
significantly O
alter O
any O
parameter O
from O
control O
. O

_RARE_ I-GENE
of O
cervical O
spine O
_RARE_ I-GENE
methods O
. O

_RARE_ I-GENE
from O
the O
_RARE_ I-GENE
. O

The O
presence O
of O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
in O
_RARE_ I-GENE
is O
reported O
for O
the O
first O
time O
. O

High O
levels O
of O
_RARE_ I-GENE
_RARE_ I-GENE
with O
relative O
_RARE_ I-GENE
. O

_RARE_ I-GENE
platelets O
may O
be O
activated I-GENE
by O
exposed O
triple O
- I-GENE
helical O
collagen I-GENE
in O
_RARE_ I-GENE
lesions O
in O
Mg I-GENE
- I-GENE
deficient O
_RARE_ I-GENE
. O

Acute O
type I-GENE
A I-GENE
hepatitis I-GENE
in O
three O
patients O
with O
chronic O
HBV O
infection O
. O

_RARE_ I-GENE
relationships O
between O
renal O
tubular O
acidosis O
and O
sodium O
metabolism O
alterations O
in O
liver O
cirrhosis O
. O

5 I-GENE
_RARE_ I-GENE
/ I-GENE
l O
thyrotropin I-GENE
: O
75 O
% O
( O
_RARE_ I-GENE
), O
45 O
% O
( O
_RARE_ I-GENE
) O
and O
20 O
% O
( O
1980 O
). O

_RARE_ I-GENE
enables O
to O
improve O
the O
diagnosis O
when O
compared O
with O
classical O
_RARE_ I-GENE
in O
about O
20 O
% O
of O
cases O
. O

_RARE_ I-GENE
with O
the O
acquired O
immune I-GENE
deficiency O
syndrome O
. O

The O
prevalence O
of O
_RARE_ I-GENE
was O
similar O
in O
type I-GENE
1 I-GENE
and O
type I-GENE
2 I-GENE
diabetes O
, O
was O
greater O
in O
women O
than O
in O
men O
, O
and O
was O
significantly O
greater O
after O
repeated O
_RARE_ I-GENE
than O
after O
one O
single O
administration O
of O
_RARE_ I-GENE
. O

A I-GENE
_RARE_ I-GENE
of O
the O
prevalence O
data O
was O
carried O
out O
in O
the O
southern O
_RARE_ I-GENE
of O
_RARE_ I-GENE
and O
in O
the O
_RARE_ I-GENE
_RARE_ I-GENE
of O
_RARE_ I-GENE
, O
the O
prevalence O
day O
being O
January O
1 I-GENE
, O
_RARE_ I-GENE
. O

The O
results O
confirm O
and O
extend O
previous O
work O
by O
other O
_RARE_ I-GENE
. O

In O
the O
_RARE_ I-GENE
_RARE_ I-GENE
the O
testosterone O
levels O
sharply O
rose O
at O
the O
beginning O
of O
the O
training O
session O
( O
from O
the O
7 O
, O
20 O
ng O
/ I-GENE
ml O
to O
11 O
, O
50 O
ng O
/ I-GENE
ml O
after O
20 O
' O
training O
), O
and O
subsequently O
decrease O
after O
3 I-GENE
hours O
( O
9 O
, O
20 O
ng O
/ I-GENE
ml O
) O
and O
at O
the O
end O
of O
the O
6 I-GENE
hours O
training O
( O
4 I-GENE
, O
60 O
ng O
/ I-GENE
ml O
). O

In O
patients O
with O
complete O
or O
partial O
remission O
of O
the O
tumor I-GENE
, O
the O
_RARE_ I-GENE
excretion O
_RARE_ I-GENE
to O
normal O
values O
. O

In O
_RARE_ I-GENE
tumours O
the O
best O
results O
were O
obtained O
with O
FB O
( O
85 O
%) O
while O
_RARE_ I-GENE
was O
positive O
in O
65 O
%. O

Total O
_RARE_ I-GENE
levels O
in O
synovial O
fluid O
remained O
significantly O
depressed O
in O
the O
patient O
group O
for O
24 O
hours O
after O
the O
400 O
- I-GENE
mg O
test O
dose O
of O
_RARE_ I-GENE
on O
day O
8 O
. O

_RARE_ I-GENE
rates O
of O
weight O
gain O
were O
seen O
once O
absorbed O
energy O
_RARE_ I-GENE
reached O
100 O
- I-GENE
110 I-GENE
% O
of O
requirements O
. O

Its O
_RARE_ I-GENE
, O
anti I-GENE
- I-GENE
_RARE_ I-GENE
, O
and O
platelet I-GENE
_RARE_ I-GENE
effects O
could O
be O
expected O
to O
_RARE_ I-GENE
the O
placental I-GENE
ischemia O
, O
hypertension O
and O
excessive O
coagulation I-GENE
that O
are O
seen O
in O
pre I-GENE
- I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
' O
s O
syndrome O

_RARE_ I-GENE
of O
111 O
_RARE_ I-GENE
- I-GENE
labelled O
autologous O
platelets O
was O
studied O
in O
2 I-GENE
patients O
after O
correction O
of O
platelet I-GENE
count O
and O
was O
still O
found O
shortened O
. O

The O
effect O
of O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
stress O
( O
_RARE_ I-GENE
) O
on O
myocardial O
_RARE_ I-GENE
and O
contractility O
was O
studied O
on O
an O
isolated O
rat I-GENE
atrium O
. O

_RARE_ I-GENE
; O
a O
beta2 I-GENE
- I-GENE
adrenergic I-GENE
agonist O
, O
and O
_RARE_ I-GENE
, O
a O
phosphodiesterase I-GENE
inhibitor I-GENE
, O
were O
given O
separately O
, O
or O
in O
combination O
, O
to O
rabbit I-GENE
_RARE_ I-GENE
on O
the O
_RARE_ I-GENE
day O
of O
gestation O
. O

When O
O2 O
therapy O
was O
controlled O
for O
, O
the O
association O
between O
_RARE_ I-GENE
and O
_RARE_ I-GENE
did O
not O
achieve O
statistical O
significance O
( O
P I-GENE
= O
. O
07 O
). O

This O
two O
- I-GENE
helix I-GENE
motif I-GENE
is O
thought O
to O
be O
involved O
in O
specific I-GENE
DNA I-GENE
sequence I-GENE
recognition I-GENE
by O
CAP I-GENE
. O

The O
_RARE_ I-GENE
phase O
of O
_RARE_ I-GENE
myocardial O
infarction O
. O

_RARE_ I-GENE
for O
nurse O
_RARE_ I-GENE
-- O
3 I-GENE
. O

The O
infection O
rate O
was O
five O
times O
greater O
in O
patients O
with O
_RARE_ I-GENE
_RARE_ I-GENE
than O
in O
those O
with O
_RARE_ I-GENE
_RARE_ I-GENE
( O
p O
= O
0 O
. O
01 O
). O

After O
a O
year O
of O
planning O
in O
the O
Laboratory O
_RARE_ I-GENE
' O
_RARE_ I-GENE
in O
_RARE_ I-GENE
: O
new O
education O
for O
laboratory O
_RARE_ I-GENE
is O
now O
arranged O

The O
electrocardiogram O
. O

_RARE_ I-GENE
_RARE_ I-GENE
place O
through O
complex I-GENE
formation O
of O
( O
_RARE_ I-GENE
_RARE_ I-GENE
. O
_RARE_ I-GENE
) O
n O
, O
excess O
_RARE_ I-GENE
, O
and O
water O
. O

The O
_RARE_ I-GENE
have O
proposed O
to O
develop O
this O
research O
employing O
a O
preparation O
containing O
exclusively O
a O
_RARE_ I-GENE
, O
the O
_RARE_ I-GENE
, O
in O
order O
to O
evaluate O
the O
alterations O
of O
the O
_RARE_ I-GENE
to O
be O
attributed O
to O
such O
component O
. O

_RARE_ I-GENE
IgA I-GENE
and O
serum I-GENE
immunoglobulins I-GENE
as O
indices O
of O
the O
local O
immunity O
of O
the O
intestinal O
mucosa O
in O
acute O
leukemias O

Serum I-GENE
IgE I-GENE
levels O
in O
_RARE_ I-GENE
children O
. O

Use O
of O
prostaglandin I-GENE
F2 O
alpha I-GENE
( O
PGF2 O
alpha I-GENE
) O
in O
cattle O
_RARE_ I-GENE
. O

Thus O
it O
appears O
that O
the O
management O
of O
blood O
, O
including O
_RARE_ I-GENE
is O
of O
great O
importance O
. O

_RARE_ I-GENE
, O
variations O
and O
neoplastic O
potential O
. O

The O
scores O
are O
dependent I-GENE
in O
part O
on O
the O
reliability O
of O
_RARE_ I-GENE
_RARE_ I-GENE
. O

Study O
on O
distribution O
of O
metal O
in O
the O
teeth O
treated O
by O
_RARE_ I-GENE
with O
_RARE_ I-GENE
specimens O

Whereas O
creatine I-GENE
kinase I-GENE
activity O
declined O
_RARE_ I-GENE
from O
a O
single O
peak O
, O
myoglobin I-GENE
appeared O
in O
multiple O
episodes O
_RARE_ I-GENE
represented O
by O
a O
single O
peak O
value O
and O
having O
no O
clear O
clinical O
correlation O
. O

_RARE_ I-GENE
- I-GENE
placental I-GENE
blood O
flow O
and O
the O
effect O
of O
beta I-GENE
2 I-GENE
- I-GENE
adrenoceptor I-GENE
stimulating I-GENE
drugs O
. O

_RARE_ I-GENE
of O
_RARE_ I-GENE
leukemia I-GENE
with O
_RARE_ I-GENE
8 O
and O
atypical O
_RARE_ I-GENE
in O
a O
patient O
with O
a O
history O
of O
_RARE_ I-GENE
anemia I-GENE
22 O
years O
earlier O

The O
_RARE_ I-GENE
peptide I-GENE
bonds O
that O
are O
cleaved O
in O
the O
conversion O
of O
human I-GENE
factor I-GENE
IX I-GENE
to O
factor I-GENE
_RARE_ I-GENE
by O
factor I-GENE
_RARE_ I-GENE
were O
identified O
as O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
growth I-GENE
, O
_RARE_ I-GENE
with O
dental O
_RARE_ I-GENE
, O
is O
sufficient O
to O
_RARE_ I-GENE
possible O
_RARE_ I-GENE
of O
_RARE_ I-GENE
bone O
bases O
. O

_RARE_ I-GENE
methods O
can O
also O
provide O
information O
about O
porphyrin O
binding I-GENE
sites I-GENE
that O
is O
useful O
in O
understanding O
porphyrin O
transport O
and O
clearance O
. O

Renal O
and O
_RARE_ I-GENE
arterial O
_RARE_ I-GENE
hyperplasia O
with O
hypertension O
. O

The O
_RARE_ I-GENE
rate O
of O
clearance O
of O
tracer O
-- O
obtained O
from O
the O
portion O
of O
the O
residue O
- I-GENE
detection O
curve O
reflecting O
metabolism O
of O
fatty I-GENE
acid I-GENE
incorporated O
into O
neutral O
lipids O
-- O
correlated O
directly O
with O
induced O
changes O
in O
tension O
- I-GENE
time O
index O
after O
injections O
into O
the O
left O
atrium O
( O
r O
= O
0 O
. O
96 O
, O
n O
= O
12 O
), O
right O
atrium O
( O
r O
= O
0 O
. O
86 I-GENE
, O
n O
= O
14 O
), O
and O
ear O
vein O
( O
r O
= O
0 O
. O
93 O
, O
n O
= O
14 O
). O

Both O
examinations O
are O
sensitive O
indicators O
of O
CNS O
abnormalities O
associated I-GENE
with O
bacterial I-GENE
_RARE_ I-GENE
infections O
and O
are O
important O
determinants I-GENE
of O
the O
therapy O
and O
_RARE_ I-GENE
prognosis O
of O
such O
complications O
. O

Specific O
IgE I-GENE
levels O
decreased O
slightly O
, O
but O
always O
remained O
within O
the O
pathological O
range O
. O

Similar O
clinical O
evaluation O
of O
an O
_RARE_ I-GENE
carrier I-GENE
revealed O
no O
ocular O
abnormalities O
. O

_RARE_ I-GENE
between O
_RARE_ I-GENE
involvement O
and O
systemic O
outcome O
was O
poor O
. O

A I-GENE
case O
of O
anterior O
cleavage O
syndrome O
in O
a O
27 O
- I-GENE
year O
- I-GENE
old O
female O
patient O
is O
described O
. O

The O
daily O
administration O
of O
_RARE_ I-GENE
for O
three O
weeks O
markedly O
reduced O
the O
absorption O
of O
calcium O
and O
phosphate I-GENE
as O
well O
as O
the O
growth I-GENE
rate O
. O

_RARE_ I-GENE
and O
_RARE_ I-GENE
issues O
. O

At O
_RARE_ I-GENE
28 O
days O
post O
- I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
rats O
had O
no O
gross O
lung O
lesions O
, O
even O
those O
given O
the O
maximum O
dose O
of O
1 I-GENE
. O
4 I-GENE
X I-GENE
10 O
( O
9 O
) O
colony I-GENE
- I-GENE
forming O
units O
of O
M I-GENE
. O
_RARE_ I-GENE
. O

_RARE_ I-GENE
and O
the O
performance O
of O
_RARE_ I-GENE
were O
not O
significantly O
associated I-GENE
with O
postoperative O
ECG O
changes O
, O
but O
more O
bypass O
grafts O
per O
patient O
_RARE_ I-GENE
appeared O
in O
the O
group O
with O
postoperative O
ECG O
changes O
, O
suggesting O
that O
coronary O
artery O
disease O
may O
be O
more O
severe O
in O
that O
group O
. O

_RARE_ I-GENE
I I-GENE
: O
All O
vessels O
up O
to O
50 O
% O
_RARE_ I-GENE
have O
a O
_RARE_ I-GENE
graft O
. O

_RARE_ I-GENE
sequences I-GENE
were O
obtained O
for O
the O
three O
large O
_RARE_ I-GENE
peptides I-GENE
, O
and O
these O
were O
_RARE_ I-GENE
by O
using O
peptides I-GENE
from O
the O
_RARE_ I-GENE
protease I-GENE
_RARE_ I-GENE
. O

The O
extraction O
measurements O
were O
used O
to O
test O
for O
_RARE_ I-GENE
contamination O
of O
venous O
outflow O
. O

_RARE_ I-GENE
responses O
to O
norepinephrine O
, O
serotonin I-GENE
and O
potassium O
( O
K I-GENE
+) O
and O
_RARE_ I-GENE
responses O
to O
isoproterenol O
and O
_RARE_ I-GENE
were O
studied O
in O
vitro O
with O
_RARE_ I-GENE
cut I-GENE
_RARE_ I-GENE
aortic O
_RARE_ I-GENE
from O
aortic O
_RARE_ I-GENE
hypertensive O
rats O
( O
_RARE_ I-GENE
) O
2 I-GENE
, O
6 I-GENE
, O
14 O
and O
28 O
days O
postoperatively O
and O
compared O
to O
time O
- I-GENE
matched O
, O
sham O
- I-GENE
operated O
_RARE_ I-GENE
controls O
. O

On O
line O
_RARE_ I-GENE
of O
steroid I-GENE
concentrations O
by O
radioimmunoassay O

Detection O
of O
congenital O
hypothyroidism O
in O
26 O
, O
_RARE_ I-GENE
newborn O
infants O

In O
_RARE_ I-GENE
patients O
with O
serologic O
_RARE_ I-GENE
by O
_RARE_ I-GENE
, O
the O
IF O
test O
detected O
significant O
_RARE_ I-GENE
in O
_RARE_ I-GENE
( O
99 O
. O
1 I-GENE
%) O
of O
_RARE_ I-GENE
patients O
and O
the O
PHA I-GENE
test O
detected O
antibody I-GENE
conversion O
in O
68 O
( O
93 O
%) O
of O
73 O
patients O
. O

The O
results O
indicate O
that O
folate I-GENE
compounds O
decrease O
formate O
accumulation O
after O
_RARE_ I-GENE
by O
stimulating I-GENE
formate O
oxidation O
or O
utilization O
and O
suggest O
a O
possible O
use O
for O
_RARE_ I-GENE
in O
the O
treatment O
of O
certain O
cases O
of O
human I-GENE
_RARE_ I-GENE
poisoning O
. O

The O
effect O
of O
sodium O
saccharin O
in O
the O
diet O
on O
_RARE_ I-GENE
_RARE_ I-GENE
. O

The O
residue O
functions O
, O
R I-GENE
( O
t I-GENE
), O
for O
C I-GENE
- I-GENE
11 O
_RARE_ I-GENE
and O
In O
- I-GENE
_RARE_ I-GENE
transferrin I-GENE
were O
_RARE_ I-GENE
against O
time O
for O
selected O
areas O
of O
interest O
, O
and O
the O
_RARE_ I-GENE
area O
- I-GENE
weighted O
extraction O
, O
E I-GENE
( O
t I-GENE
), O
was O
computed O
for O
the O
same O
areas O
every O
250 O
msec O
using O
the O
formula O
: O
E I-GENE
( O
t I-GENE
) O
= O
[ O
RT I-GENE
( O
t I-GENE
) O
- I-GENE
RR O
( O
t I-GENE
_RARE_ I-GENE
1 I-GENE
- I-GENE
RR O
( O
t I-GENE
_RARE_ I-GENE
where O
RT I-GENE
and O
RR O
are O
the O
normalized O
residue O
functions O
for O
_RARE_ I-GENE
and O
transferrin I-GENE
, O
respectively O
. O

_RARE_ I-GENE
extracts O
showed O
no O
significant O
migration O
inhibition O
in O
_RARE_ I-GENE
assays O
. O

Ten O
days O
of O
_RARE_ I-GENE
therapy O
was O
used O
to O
treat O
44 I-GENE
children O
with O
urinary O
tract O
infection O
and O
CRP I-GENE
values O
greater O
than O
or O
equal O
to O
28 O
microgram O
/ I-GENE
ml O
( O
CRP I-GENE
- I-GENE
positive O
group O
). O

Both O
resting O
blood O
flow O
( O
_RARE_ I-GENE
) O
and O
maximal O
blood O
flow O
( O
_RARE_ I-GENE
) O
were O
studied O
by O
_RARE_ I-GENE
133 I-GENE
clearance O
. O

Plasma I-GENE
renin I-GENE
concentration O
is O
significantly O
higher O
in O
the O
_RARE_ I-GENE
venous O
outflow O
, O
which O
_RARE_ I-GENE
the O
superficial O
cortex O
, O
than O
in O
the O
deep O
venous O
outflow O
, O
which O
_RARE_ I-GENE
the O
inner O
half O
of O
the O
cortex O
and O
_RARE_ I-GENE
of O
the O
cat O
kidney O
. O

After O
_RARE_ I-GENE
, O
resting O
supine O
and O
_RARE_ I-GENE
_RARE_ I-GENE
decreased O
( O
P I-GENE
less O
than O
0 O
. O
05 O
) O
by O
6 I-GENE
and O
9 O
mmHg O
, O
respectively O
. O

In O
the O
_RARE_ I-GENE
, O
Ca2 I-GENE
+ I-GENE
_RARE_ I-GENE
induced O
a O
rise O
of O
plasma I-GENE
Ca2 I-GENE
+ I-GENE
up O
to O
3 I-GENE
. O
2 I-GENE
+/- O
0 O
. O
1 I-GENE
mmol O
/ I-GENE
1 I-GENE
and O
a O
fall O
of O
circulating O
glucagon I-GENE
(- O
26 O
. O
4 I-GENE
+/- O
5 I-GENE
. O
7 O
%; O
p O
less O
than O
0 O
. O
001 O
) O
and O
glucose O
(- O
23 O
. O
3 I-GENE
+/- O
3 I-GENE
. O
6 I-GENE
%; O
p O
less O
than O
0 O
. O
05 O
). O

Fifty O
- I-GENE
eight O
_RARE_ I-GENE
' O
s O
occurred O
in O
the O
placebo O
group O
as O
compared O
to O
only O
_RARE_ I-GENE
in O
the O
AC I-GENE
group O
( O
p O
less O
than O
0 O
. O
01 O
). O

The O
" O
_RARE_ I-GENE
- I-GENE
tooth O
" O
syndrome O
. O

The O
_RARE_ I-GENE
results O
show O
that O
_RARE_ I-GENE
has O
high O
efficacy O
and O
safety O
and O
it O
can O
be O
_RARE_ I-GENE
that O
it O
is O
a O
drug O
required O
in O
the O
pediatric O
field O
. O

Based O
on O
peptide I-GENE
map O
similarities O
, O
partial O
amino O
- I-GENE
terminal I-GENE
sequence I-GENE
data O
, O
and O
common O
genetic O
origin O
, O
it O
is O
suggested O
that O
_RARE_ I-GENE
and O
p62 I-GENE
have O
identical O
amino O
acid I-GENE
sequences I-GENE
carboxy I-GENE
- I-GENE
terminal I-GENE
to O
the O
_RARE_ I-GENE
initiator O
methionine O
( O
residue O
21 O
of O
p62 I-GENE
). O

All O
patients O
in O
the O
control O
group O
showed O
a O
significant O
improvement O
in O
their O
_RARE_ I-GENE
while O
only O
3 I-GENE
patients O
in O
the O
treated O
group O
showed O
an O
improvement O
. O

_RARE_ I-GENE
on O
the O
_RARE_ I-GENE
_RARE_ I-GENE
Tax I-GENE
_RARE_ I-GENE
of O
_RARE_ I-GENE
for O
speech O
- I-GENE
language O
_RARE_ I-GENE
and O
_RARE_ I-GENE
. O

From O
_RARE_ I-GENE
to O
_RARE_ I-GENE
. O

The O
relationship O
between O
the O
rare O
complications O
mentioned O
above O
and O
the O
pathophysiology O
of O
_RARE_ I-GENE
' O
s O
syndrome O
is O
still O
_RARE_ I-GENE
. O

Using O
an O
_RARE_ I-GENE
bacterial I-GENE
assay O
and O
a O
_RARE_ I-GENE
rat I-GENE
model O
of O
_RARE_ I-GENE
sepsis O
, O
we O
analyzed O
a O
modified O
human I-GENE
immunoglobulin I-GENE
for O
_RARE_ I-GENE
and O
protective O
antibody I-GENE
. O

_RARE_ I-GENE
lesions O
in O
renal O
_RARE_ I-GENE
. O

_RARE_ I-GENE
observed O
systemic O
toxic O
effects O
( O
bone O
marrow O
, O
gastrointestinal O
tract O
, O
and O
heart O
) O
were O
not O
seen O
in O
this O
study O
. O

2 I-GENE
. O

When O
vascular I-GENE
pressure O
( O
_RARE_ I-GENE
) O
was O
raised O
_RARE_ I-GENE
from O
- I-GENE
5 I-GENE
to O
+ I-GENE
25 O
cmH2O O
by O
air O
_RARE_ I-GENE
for O
60 O
min O
, O
Px I-GENE
( O
f I-GENE
) O
became O
_RARE_ I-GENE
less O
negative O
, O
then O
remained O
stable O
. O

( O
1980 O
): O
_RARE_ I-GENE
210 O
, O
77 O
- I-GENE
72 O
) O
that O
stimulating I-GENE
the O
_RARE_ I-GENE
_RARE_ I-GENE
bundle O
( O
_RARE_ I-GENE
) O
can O
change O
the O
magnitude O
of O
the O
_RARE_ I-GENE
product I-GENE
( O
_RARE_ I-GENE
- I-GENE
f1 I-GENE
) O
in O
the O
ear O
- I-GENE
_RARE_ I-GENE
sound O
pressure O
. O

Rats I-GENE
underwent O
either O
a O
90 O
- I-GENE
95 O
% O
_RARE_ I-GENE
or O
a O
sham O
operation O
. O

When O
the O
l O
- I-GENE
_RARE_ I-GENE
- I-GENE
sensitive O
, O
opioid I-GENE
receptor I-GENE
is O
blocked O
by O
naloxone O
or O
tolerance O
has O
developed O
, O
than O
l O
- I-GENE
_RARE_ I-GENE
can O
produce O
behavioral O
effects O
by O
a O
_RARE_ I-GENE
mechanism O
. O

_RARE_ I-GENE
_RARE_ I-GENE
- I-GENE
induced O
blood O
- I-GENE
brain O
barrier O
alterations O
. O

Large I-GENE
and O
small I-GENE
_RARE_ I-GENE
lesions O
inhibited O
the O
occurrence O
of O
target O
fibres O
in O
the O
_RARE_ I-GENE
muscles O
, O
the O
smallest O
one O
being O
_RARE_ I-GENE
of O
the O
dorsal O
roots O
. O

Diagnosis O
of O
phenylalanine I-GENE
hydroxylase I-GENE
deficiency O
( O
_RARE_ I-GENE
). O

In O
10 O
control O
sheep O
mean O
plasma I-GENE
_RARE_ I-GENE
concentration O
increased O
from O
0 O
. O
39 O
ng O
/ I-GENE
ml O
_RARE_ I-GENE
to O
about O
1 I-GENE
. O
1 I-GENE
ng O
/ I-GENE
ml O
at O
8 O
and O
16 O
min O
of O
bypass O
. O

The O
respiratory O
rate O
was O
13 O
+/- O
1 I-GENE
_RARE_ I-GENE
/ I-GENE
min O
with O
52 O
+/- O
4 I-GENE
% O
of O
the O
respiratory O
cycle O
_RARE_ I-GENE
in O
_RARE_ I-GENE
; O
end O
- I-GENE
tidal O
CO2 O
pressure O
increased O
by O
3 I-GENE
. O
3 I-GENE
+/- O
1 I-GENE
. O
0 O
_RARE_ I-GENE
during O
_RARE_ I-GENE
at O
_RARE_ I-GENE
. O

There O
was O
no O
further O
increase O
in O
oxygen O
consumption O
when O
these O
subjects O
_RARE_ I-GENE
with O
inspiratory O
pressures O
above O
_RARE_ I-GENE
. O

We O
compared O
the O
volume O
of O
the O
pulmonary O
_RARE_ I-GENE
, O
extracellular I-GENE
water O
space O
using O
sodium O
and O
sucrose O
indicators O
in O
8 O
normal O
and O
11 O
_RARE_ I-GENE
rabbit I-GENE
lungs O
by O
steady O
- I-GENE
state O
techniques O
. O

_RARE_ I-GENE
the O
reliability O
, O
validity O
and O
_RARE_ I-GENE
of O
scores O
obtained O
by O
acute O
psychiatric O
_RARE_ I-GENE
( O
N I-GENE
= O
120 O
) O
on O
the O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
Test O
adapted O
to O
assess O
_RARE_ I-GENE
and O
current O
_RARE_ I-GENE
. O

A I-GENE
simple O
method O
for O
measuring O
urinary O
iron O
following O
the O
administration O
of O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
is O
described O
. O

During O
conventional O
_RARE_ I-GENE
using O
substitution O
fluid O
with O
a O
Na I-GENE
+ I-GENE
concentration O
of O
140 I-GENE
mEq O
/ I-GENE
L I-GENE
, O
a O
decrease O
in O
extracellular I-GENE
fluid O
volume O
was O
noted O
whereas O
the O
intracellular O
fluid O
volume O
was O
unaltered O
. O

The O
_RARE_ I-GENE
cases O
of O
_RARE_ I-GENE
fever O
were O
found O
to O
have O
an O
intact O
_RARE_ I-GENE
as O
compared O
to O
the O
complicated O
cases O
. O

_RARE_ I-GENE
serial O
_RARE_ I-GENE
. O

_RARE_ I-GENE
to O
_RARE_ I-GENE
with O
these O
and O
related I-GENE
issues O
are O
presented O
. O

Use O
of O
subcutaneous O
_RARE_ I-GENE
in O
a O
child O
with O
_RARE_ I-GENE
associated I-GENE
with O
congenital O
_RARE_ I-GENE
anemia I-GENE
, O
type I-GENE
I I-GENE
. O

There O
was O
a O
significant O
correlation O
between O
tubular O
diameter O
and O
_RARE_ I-GENE
( O
r O
= O
0 O
. O
68 O
, O
P I-GENE
less O
than O
0 O
. O
001 O
) O
suggesting O
that O
tubular O
diameter O
measurements O
in O
histological O
sections O
could O
be O
used O
to O
predict O
sperm O
production O
. O

The O
differential O
investigation O
of O
lipoproteins I-GENE
, O
however O
, O
showed O
that O
the O
high O
- I-GENE
density I-GENE
lipoprotein I-GENE
( O
HDL I-GENE
) O
fractions O
are O
_RARE_ I-GENE
or O
relatively O
decreased O
with O
respect O
to O
low O
- I-GENE
density I-GENE
lipoproteins I-GENE
( O
LDL I-GENE
) O
in O
cerebral O
_RARE_ I-GENE
and O
in O
transient O
ischaemic O
attacks O
. O

Although O
_RARE_ I-GENE
fluid O
had O
higher O
mean O
concentrations O
of O
phosphorus O
and O
zinc I-GENE
, O
these O
differences O
did O
not O
_RARE_ I-GENE
after O
_RARE_ I-GENE
- I-GENE
stained O
samples O
were O
excluded O
. O

_RARE_ I-GENE
status O
of O
_RARE_ I-GENE
in O
the O
United O
_RARE_ I-GENE
. O

During O
an O
8 O
- I-GENE
wk O
follow O
- I-GENE
up O
, O
parasites O
_RARE_ I-GENE
in O
10 O
patients O
, O
5 I-GENE
after O
each O
drug O
, O
between O
1 I-GENE
and O
7 O
wk O
after O
treatment O
. O

_RARE_ I-GENE
of O
a O
stable O
phospholipid I-GENE
_RARE_ I-GENE
for O
coagulation I-GENE
assays O
. O

A I-GENE
_RARE_ I-GENE
on O
some O
consequences O
of O
UV O
vision O
in O
birds O
. O

_RARE_ I-GENE
_RARE_ I-GENE
, O
a O
_RARE_ I-GENE
sustained O
release O
bolus O
( O
_RARE_ I-GENE
) O
was O
administered O
to O
each O
animal O
in O
the O
" O
treated O
" O
category O
. O

In O
a O
longitudinal O
study O
, O
14 O
low O
- I-GENE
risk O
_RARE_ I-GENE
were O
studied O
at O
2 I-GENE
- I-GENE
week O
intervals O
from O
32 O
weeks O
of O
gestation O
_RARE_ I-GENE
. O

Further O
, O
_RARE_ I-GENE
injections O
of O
_RARE_ I-GENE
resulted O
in O
the O
substantial O
loss O
of O
pyramidal O
cells O
in O
the O
whole O
CA3 O
field O
of O
the O
hippocampus O
. O

_RARE_ I-GENE
of O
the O
35 O
patients O
were O
randomly O
chosen O
to O
receive O
a O
training O
program O
( O
lasting O
approximately O
1 I-GENE
month O
) O
designed O
to O
establish O
a O
systematic O
strategy O
of O
_RARE_ I-GENE
complex I-GENE
visual O
material O
. O

The O
duration O
and O
the O
amplitude O
of O
the O
negative O
potential O
were O
greatest O
for O
completely O
_RARE_ I-GENE
ears O
with O
_RARE_ I-GENE
, O
smaller O
for O
partially O
_RARE_ I-GENE
ears O
, O
and O
smallest O
for O
the O
_RARE_ I-GENE
ears O
. O

_RARE_ I-GENE
obtained O
from O
normal O
volunteers O
and O
from O
the O
great O
majority O
of O
the O
patients O
, O
excluding O
those O
with O
asthma O
, O
had O
no O
effect O
on O
_RARE_ I-GENE
_RARE_ I-GENE
. O

These O
results O
suggested O
the O
possibility O
that O
the O
fetus O
played O
some O
role O
in O
the O
production O
of O
E3 I-GENE
- I-GENE
16 O
- I-GENE
G I-GENE
in O
early I-GENE
pregnancy O
. O

In O
this O
way O
it O
is O
possible O
to O
_RARE_ I-GENE
the O
growth I-GENE
function O
of O
the O
_RARE_ I-GENE
curve O
of O
the O
length I-GENE
' O
increase O
of O
man O
and O
the O
curve O
of O
the O
mass O
' O
increase O
of O
rat I-GENE
. O

The O
highest O
doses O
were O
found O
for O
_RARE_ I-GENE
who O
transported O
large O
numbers O
of O
_RARE_ I-GENE
_RARE_ I-GENE
. O

The O
_RARE_ I-GENE
of O
the O
standard O
O2 O
dissociation O
curve O
becomes O
greater O
during O
the O
training O
period O
( O
increase O
in O
_RARE_ I-GENE
' O
s O
n O
from O
2 I-GENE
. O
68 O
+/- O
0 O
. O
10 O
to O
2 I-GENE
. O
96 O
+/- O
0 O
. O
15 O
). O

_RARE_ I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
acid I-GENE
and O
m I-GENE
- I-GENE
and O
p O
- I-GENE
_RARE_ I-GENE
acid I-GENE
have O
been O
determined O
in O
the O
plasma I-GENE
of O
normal O
, O
healthy O
subjects O
after O
fasting O
, O
consumption O
of O
a O
meal I-GENE
and O
ingestion O
of O
_RARE_ I-GENE
labelled O
amine I-GENE
precursors I-GENE
, O
by O
high O
- I-GENE
resolution O
gas O
chromatography O
-- O
high O
resolution O
mass O
spectrometry O
with O
selected O
ion O
monitoring O
of O
their O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
derivatives O
. O

In O
concept O
II I-GENE
62 O
patients O
were O
treated O
with O
selective O
vagotomy O
and O
_RARE_ I-GENE
. O

They O
consisted O
of O
_RARE_ I-GENE
disorders O
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
. O

CSF I-GENE
adenosine I-GENE
deaminase I-GENE
activity O
( O
_RARE_ I-GENE
) O
was O
measured O
at O
the O
same O
time O
. O

_RARE_ I-GENE
reactivity O
had O
returned O
to O
normal O
in O
half O
the O
workers O
who O
had O
left O
their O
original O
_RARE_ I-GENE
, O
but O
in O
only O
one O
_RARE_ I-GENE
who O
had O
_RARE_ I-GENE
within O
her I-GENE
original O
_RARE_ I-GENE
. O

It O
was O
also O
found O
that O
there O
is O
no O
significant O
difference O
between O
the O
prevalence O
of O
nasal O
_RARE_ I-GENE
of O
S I-GENE
. O
aureus I-GENE
_RARE_ I-GENE
the O
hospital O
_RARE_ I-GENE
and O
the O
patients O
. O

_RARE_ I-GENE
and O
_RARE_ I-GENE
' O
s O
_RARE_ I-GENE
depth O
index O
and O
the O
_RARE_ I-GENE
- I-GENE
joint O
surface O
angle O
of O
_RARE_ I-GENE
are O
recommended O
as O
especially O
suitable O
methods O
of O
measurement O
. O

There O
were O
no O
significant O
differences O
in O
EF I-GENE
between O
the O
two O
studies O
, O
both O
at O
rest O
( O
56 O
. O
0 O
+/- O
13 O
. O
8 O
% O
vs O
58 O
. O
2 I-GENE
+/- O
11 O
. O
7 O
%, O
p O
= O
NS I-GENE
) O
and O
with O
exercise O
( O
51 O
. O
1 I-GENE
+/- O
17 O
. O
6 I-GENE
% O
vs O
54 I-GENE
. O
3 I-GENE
+/- O
17 O
. O
6 I-GENE
%, O
p O
= O
NS I-GENE
) O
and O
a O
highly O
significant O
correlation O
was O
shown O
between O
the O
two O
groups O
of O
values O
( O
rest O
r O
= O
0 O
. O
90 O
, O
exercise O
r O
= O
0 O
. O
93 O
, O
p O
less O
than O
0 O
. O
001 O
). O

After O
_RARE_ I-GENE
therapy O
, O
complete O
remission O
of O
Hodgkin O
' O
s O
disease O
was O
accompanied O
by O
_RARE_ I-GENE
of O
the O
_RARE_ I-GENE
level O
and O
disappearance O
of O
_RARE_ I-GENE
' O
s O
cells O
. O

Specifically O
, O
by O
the O
type I-GENE
of O
adjuvant O
therapy O
, O
the O
median O
disease O
- I-GENE
free O
interval O
and O
survival O
from O
stage O
_RARE_ I-GENE
for O
23 O
patients O
receiving O
_RARE_ I-GENE
_RARE_ I-GENE
were O
6 I-GENE
. O
9 O
and O
19 O
months O
; O
for O
39 O
patients O
receiving O
BCG O
, O
eight O
months O
and O
26 O
months O
; O
for O
24 O
patients O
receiving O
BCG O
+ I-GENE
_RARE_ I-GENE
, O
eight O
and O
17 O
. O
4 I-GENE
months O
; O
and O
for O
all O
51 O
_RARE_ I-GENE
treated O
patients O
6 I-GENE
. O
3 I-GENE
and O
17 O
. O
8 O
months O
, O
respectively O
. O

The O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
gradient O
was O
markedly O
decreased O
in O
both O
shock I-GENE
and O
non O
- I-GENE
shock I-GENE
patients O
with O
pulmonary O
edema O
. O

Re O
: O
A I-GENE
modified O
method O
for O
the O
in O
vivo O
labeling O
of O
red I-GENE
blood O
cells O
with O
Tc O
- I-GENE
99m O
. O

A I-GENE
limited O
study O
in O
a O
_RARE_ I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
exposure O
) O
involving O
the O
measurement O
of O
total O
_RARE_ I-GENE
_RARE_ I-GENE
, O
the O
determination O
of O
urinary O
_RARE_ I-GENE
, O
and O
the O
evaluation O
of O
hand O
and O
mouth O
contamination O
by O
_RARE_ I-GENE
before O
and O
after O
the O
_RARE_ I-GENE
suggests O
that O
the O
high O
urinary O
_RARE_ I-GENE
levels O
( O
300 O
microgram O
/ I-GENE
g O
creatinine O
) O
are O
likely O
to O
be O
more O
related I-GENE
to O
an O
increased O
oral O
intake O
from O
contaminated O
_RARE_ I-GENE
than O
to O
an O
increased O
absorption O
from O
the O
lungs O
. O

_RARE_ I-GENE
and O
pathological O
findings O
in O
_RARE_ I-GENE
monkeys O
infected O
with O
_RARE_ I-GENE
_RARE_ I-GENE
or O
_RARE_ I-GENE
_RARE_ I-GENE
. O

The O
_RARE_ I-GENE
_RARE_ I-GENE
at O
the O
site I-GENE
of O
the O
entry O
of O
blood O
vessels O
into O
the O
central O
nervous O
system O
. O

Experimental O
_RARE_ I-GENE
of O
malignant O
_RARE_ I-GENE
fever O
in O
_RARE_ I-GENE
cattle O

1 I-GENE
A I-GENE
_RARE_ I-GENE
delivery O
system O
is O
described O
to O
_RARE_ I-GENE
orally O
_RARE_ I-GENE
drugs O
to O
the O
colon O
and O
release O
them O
at O
that O
site I-GENE
by O
_RARE_ I-GENE
with O
an O
_RARE_ I-GENE
based O
resin O
( O
_RARE_ I-GENE
S I-GENE
). O

Administration O
of O
the O
dopamine I-GENE
agonist O
_RARE_ I-GENE
( O
2 I-GENE
. O
5 I-GENE
mg O
three O
times O
a O
day O
for O
4 I-GENE
days O
) O
suppressed O
( O
P I-GENE
less O
than O
0 O
. O
01 O
) O
mean O
24 O
- I-GENE
h O
plasma I-GENE
18 O
- I-GENE
_RARE_ I-GENE
levels O
from O
21 O
. O
9 O
+/- O
2 I-GENE
. O
0 O
to O
14 O
. O
8 O
+/- O
1 I-GENE
. O
4 I-GENE
ng O
/ I-GENE
dl O
. O

_RARE_ I-GENE
time O
was O
not O
affected O
by O
magnesium O
_RARE_ I-GENE
. O

The O
most O
common O
types O
of O
malformations O
were O
eye O
defects O
and O
open O
_RARE_ I-GENE
. O

_RARE_ I-GENE
of O
a O
_RARE_ I-GENE
defect O
of O
the O
lower O
leg O
with O
a O
_RARE_ I-GENE
free O
flap O
. O

According O
to O
the O
literature O
, O
second O
malignant O
epithelial O
tumours O
are O
, O
in O
contrast O
to O
mesenchymal O
tumours O
such O
as O
osteosarcoma O
, O
very O
rare O
in O
retinoblastoma I-GENE
_RARE_ I-GENE
. O

In O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
17 O
, O
_RARE_ I-GENE
_RARE_ I-GENE
children O
born O
in O
the O
years O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
were O
screened O
for O
_RARE_ I-GENE
once O
a O
year O
between O
the O
ages O
of O
7 O
and O
16 O
years O
, O
during O
_RARE_ I-GENE
- I-GENE
1980 O
. O

In O
the O
past O
, O
_RARE_ I-GENE
in O
_RARE_ I-GENE
was O
mainly O
confined O
to O
_RARE_ I-GENE
for O
the O
diagnosis O
of O
certain O
infectious O
diseases O
. O

_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
dislocation O
of O
the O
_RARE_ I-GENE
. O

This O
study O
demonstrates O
secretion O
of O
_RARE_ I-GENE
by O
the O
human I-GENE
stomach O
in O
vivo O
at O
a O
rate O
equivalent O
to O
10 O
-- O
20 O
% O
of O
basal O
acid I-GENE
secretion O
. O

Histological O
evaluation O
revealed O
a O
more O
than O
twofold O
increase O
in O
the O
number O
of O
_RARE_ I-GENE
mononuclear O
cells O
( O
p O
less O
than O
0 O
. O
005 O
), O
while O
the O
number O
of O
epithelial O
cells O
/ I-GENE
100 O
microns O
of O
_RARE_ I-GENE
mucosa O
and O
the O
mean O
height O
of O
the O
epithelial O
cells O
were O
comparable O
in O
both O
groups O
. O

_RARE_ I-GENE
in O
_RARE_ I-GENE
disorders O
. O

A I-GENE
suspected O
new O
storage O
disease O
in O
cattle O
. O

For O
various O
dog O
vessels O
in O
vivo O
, O
Q I-GENE
/ I-GENE
_RARE_ I-GENE
ranged O
from O
0 O
. O
15 O
to O
47 O
X I-GENE
10 O
( O
5 I-GENE
) O
_RARE_ I-GENE
/ I-GENE
cm2 O
. O

The O
_RARE_ I-GENE
action O
of O
lidocaine O
on O
CNS O
electrical O
activity O
and O
behavior O
in O
cats O
. O

_RARE_ I-GENE
of O
_RARE_ I-GENE
resorption O
by O
_RARE_ I-GENE
therapy O

_RARE_ I-GENE
_RARE_ I-GENE
and O
fertility O

_RARE_ I-GENE
of O
_RARE_ I-GENE
national O
_RARE_ I-GENE

The O
favourable O
effect O
of O
thymic I-GENE
_RARE_ I-GENE
was O
also O
reflected O
in O
a O
significant O
increase O
of O
LD50 O
/ I-GENE
30 O
, O
and O
the O
dose O
reduction O
factor I-GENE
was O
equal O
to O
2 I-GENE
. O

The O
application O
of O
_RARE_ I-GENE
to O
sample O
preparation O
in O
the O
detection O
and O
_RARE_ I-GENE
of O
ethylene O
glycol O
in O
plasma I-GENE
by O
gas O
chromatography O
is O
described O
. O

_RARE_ I-GENE
. O

A I-GENE
new O
_RARE_ I-GENE
species O
, O
a O
parasite O
of O
_RARE_ I-GENE
cattle O
, O
in O
_RARE_ I-GENE

It O
was O
suggested O
that O
the O
absence O
of O
pronounced O
differences O
between O
conditions O
may O
have O
been O
due O
to O
the O
complexity O
of O
the O
task O
or O
the O
type I-GENE
of O
_RARE_ I-GENE
employed O
. O

A I-GENE
limiting O
factor I-GENE
were O
disturbances O
in O
the O
system O
of O
energy O
transport O
( O
creatine I-GENE
phosphate I-GENE
, O
creatine I-GENE
_RARE_ I-GENE
) O
and O
of O
the O
calcium O
pump I-GENE
( O
Ca I-GENE
_RARE_ I-GENE
ATPase I-GENE
of O
the O
_RARE_ I-GENE
reticulum O
, O
_RARE_ I-GENE
), O
which O
_RARE_ I-GENE
led O
to O
a O
decrease O
of O
the O
inotropic O
properties O
of O
the O
myocardium O
at O
70 I-GENE
% O
restriction I-GENE
of O
coronary O
blood O
flow O
. O

In O
vitro O
penetration O
tests O
of O
human I-GENE
sperm O
into O
cervical O
mucus O
were O
introduced O
in O
order O
to O
study O
the O
interaction O
between O
sperm O
and O
cervical O
mucus O
. O

Vibrio I-GENE
_RARE_ I-GENE
( O
group O
F I-GENE
_RARE_ I-GENE
) O
in O
_RARE_ I-GENE
. O

Serum I-GENE
creatine I-GENE
kinase I-GENE
( O
_RARE_ I-GENE
) O
was O
measured O
in O
ten O
subjects O
in O
the O
laboratory O
before O
and O
after O
the O
performance O
of O
_RARE_ I-GENE
_RARE_ I-GENE
and O
a O
_RARE_ I-GENE
task O
. O

_RARE_ I-GENE
were O
not O
observed O
in O
the O
5 I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
in O
2 I-GENE
other O
_RARE_ I-GENE
. O

The O
cause O
of O
death O
is O
often O
quite O
apparent O
from O
the O
pathological O
and O
toxicological O
findings O
; O
however O
, O
the O
manner O
of O
death O
often O
gives O
the O
examining O
_RARE_ I-GENE
some O
_RARE_ I-GENE
. O

The O
average O
annual O
cost O
per O
head I-GENE
of O
population O
was O
US O
+ I-GENE
0 O
X I-GENE
46 O
. O

It O
is O
postulated O
that O
altered O
blood O
flow O
, O
mediated O
through O
the O
well O
- I-GENE
known O
prostaglandin I-GENE
synthetase I-GENE
inhibitory I-GENE
effects O
of O
_RARE_ I-GENE
, O
resulted O
in O
tubular O
necrosis I-GENE
. O

_RARE_ I-GENE
20 O
mg O
_RARE_ I-GENE
/ I-GENE
20 O
ml O
_RARE_ I-GENE
water O
or O
40 I-GENE
mg O
/ I-GENE
40 I-GENE
ml O
_RARE_ I-GENE
water O
was O
locally O
_RARE_ I-GENE
into O
the O
bladder O
with O
a O
catheter O
after O
emptying O
it O
and O
was O
left O
for O
about O
25 O
- I-GENE
_RARE_ I-GENE
min O
. O

Both O
groups O
_RARE_ I-GENE
_RARE_ I-GENE
with O
added O
_RARE_ I-GENE
, O
decreasing O
_RARE_ I-GENE
times O
as O
_RARE_ I-GENE
concentration O
increased O
. O

The O
mean O
extracted O
concentration O
of O
_RARE_ I-GENE
obtained O
at O
operation O
was O
12 O
. O
9 O
micrograms O
/ I-GENE
ml O
( O
SD O
5 I-GENE
. O
25 O
) O
in O
synovial O
fluid O
; O
2 I-GENE
. O
9 O
micrograms O
/ I-GENE
g O
( O
SD O
3 I-GENE
. O
59 O
) O
in O
_RARE_ I-GENE
; O
2 I-GENE
. O
0 O
micrograms O
/ I-GENE
g O
( O
SD O
1 I-GENE
. O
48 O
) O
in O
_RARE_ I-GENE
bone O
and O
1 I-GENE
. O
3 I-GENE
micrograms O
/ I-GENE
g O
( O
SD O
1 I-GENE
. O
25 O
) O
in O
cortical O
bone O
. O

A I-GENE
preliminary O
study O
of O
vincristine O
, O
methotrexate O
, O
and O
_RARE_ I-GENE
( O
_RARE_ I-GENE
* I-GENE
P I-GENE
) O
combination O
chemotherapy O
for O
advanced O
adult O
non O
- I-GENE
Hodgkin O
' O
s O
lymphoma O

_RARE_ I-GENE
secretion O
in O
_RARE_ I-GENE

Re O
- I-GENE
examination O
of O
the O
_RARE_ I-GENE
study O
. O

Based O
on O
_RARE_ I-GENE
determinations O
, O
the O
control O
mean O
serum I-GENE
CPK I-GENE
activity O
was O
_RARE_ I-GENE
+/- O
113 I-GENE
I I-GENE
. O
U O
_RARE_ I-GENE
liter O
. O

A I-GENE
further O
study O
on O
plasminogen I-GENE
activator I-GENE
release O
by O
_RARE_ I-GENE
agents O
in O
the O
isolated O
perfused O
dog O
leg O
. O

_RARE_ I-GENE
is O
active O
as O
a O
single O
agent O
in O
non O
- I-GENE
Hodgkin O
' O
s O
lymphoma O
. O

Treatment O
of O
meat O
muscle O
800 O
V I-GENE
for O
45 O
s O
reduced O
_RARE_ I-GENE
but O
increased O
slightly O
the O
rate O
of O
_RARE_ I-GENE
of O
lipids O
. O

The O
hormonal O
response O
to O
a O
standardized O
_RARE_ I-GENE
exercise O
test O
was O
studied O
in O
11 O
male O
_RARE_ I-GENE
exposed O
to O
a O
course O
of O
_RARE_ I-GENE
h O
of O
continuous O
activity O
with O
less O
than O
2 I-GENE
h O
sleep O
. O

At O
an O
_RARE_ I-GENE
temperature O
of O
25 O
degrees O
C I-GENE
, O
the O
responses O
to O
spinal O
_RARE_ I-GENE
are O
reduced O
during O
the O
dark O
phase O
. O

A I-GENE
method O
for O
determining O
cumulative O
behavioral O
toxicity O
after O
chronic O
oral O
administration O
of O
l O
- I-GENE
alpha I-GENE
- I-GENE
_RARE_ I-GENE
to O
female O
rats O
. O

After O
successful O
subtotal O
_RARE_ I-GENE
, O
evident O
by O
the O
decrease O
of O
serum I-GENE
_RARE_ I-GENE
levels O
, O
both O
the O
CL O
of O
group O
2 I-GENE
_RARE_ I-GENE
and O
the O
ability O
of O
group O
2 I-GENE
sera O
to O
induce O
augmented O
CL O
in O
normal O
_RARE_ I-GENE
decreased O
( O
p O
< O
0 O
. O
_RARE_ I-GENE
). O

_RARE_ I-GENE
provides O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
indication O
of O
tissue I-GENE
necrosis I-GENE
, O
moderate O
- I-GENE
to O
- I-GENE
severe O
_RARE_ I-GENE
hemorrhage O
, O
and O
delayed O
brain O
maturation O
. O

The O
number O
of O
_RARE_ I-GENE
rats O
increased O
with O
increase O
in O
the O
duration O
of O
Cd O
administration O
in O
association O
with O
greater O
accumulation O
of O
Cd O
in O
the O
olfactory O
bulb O
than O
in O
any O
other O
region O
of O
the O
brain O
. O

This O
test O
should O
provide O
another O
_RARE_ I-GENE
means O
to O
study O
_RARE_ I-GENE
. O

The O
_RARE_ I-GENE
were O
for O
intact O
_RARE_ I-GENE
- I-GENE
a O
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
males O
, O
though O
injections O
of O
_RARE_ I-GENE
restored O
the O
_RARE_ I-GENE
' O
_RARE_ I-GENE
to O
the O
females O
. O

Each O
trial O
consisted O
of O
light I-GENE
and O
_RARE_ I-GENE
for O
five O
_RARE_ I-GENE
as O
conditioned O
stimuli O
and O
_RARE_ I-GENE
shock I-GENE
for O
five O
_RARE_ I-GENE
as O
an O
_RARE_ I-GENE
stimulus O
. O

_RARE_ I-GENE
appeared O
on O
the O
_RARE_ I-GENE
of O
the O
stomach O
at O
the O
_RARE_ I-GENE
week O
and O
resulted O
in O
ulcer O
_RARE_ I-GENE
at O
the O
_RARE_ I-GENE
week O
. O

_RARE_ I-GENE
_RARE_ I-GENE
and O
involvement O
in O
treatment O
of O
patients O
at O
a O
state O
hospital O
. O

A I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
for O
assessing O
amplitude O
of O
ECG O
wave O
forms O
. O

_RARE_ I-GENE
reaction O
of O
the O
apparently O
healthy O
partner I-GENE
in O
response O
to O
improvement O
in O
the O
_RARE_ I-GENE
_RARE_ I-GENE
partner I-GENE
. O

_RARE_ I-GENE
scan O
with O
99mTc O
- I-GENE
labelled O
_RARE_ I-GENE
albumin I-GENE
( O
_RARE_ I-GENE
brain O
scan O
) O
and O
computed O
tomography O
studies O
( O
CT I-GENE
) O
were O
performed O
on O
78 O
patients O
with O
_RARE_ I-GENE
diseases O
. O

Inhibition O
of O
_RARE_ I-GENE
_RARE_ I-GENE
var I-GENE
. O
_RARE_ I-GENE
, O
the O
_RARE_ I-GENE
agent O
of O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
, O
by O
the O
_RARE_ I-GENE
bacterium O
_RARE_ I-GENE
sp O
. O

The O
five O
- I-GENE
drug O
combination O
of O
fluorouracil O
_RARE_ I-GENE
_RARE_ I-GENE
dimethyl O
_RARE_ I-GENE
, O
vincristine O
, O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
, O
and O
prednisone O
( O
_RARE_ I-GENE
+ I-GENE
P I-GENE
) O
was O
given O
to O
120 O
women O
with O
metastatic O
breast O
cancer O
. O

A I-GENE
method O
is O
described O
for O
the O
simultaneous O
determination O
of O
1 I-GENE
, O
alpha I-GENE
- I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
and O
five O
active O
metabolites O
-- O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
-- O
in O
_RARE_ I-GENE
by O
high O
- I-GENE
performance O
liquid O
chromatography O
using O
a O
normal O
- I-GENE
phase O
column O
and O
a O
UV O
detector O
at O
_RARE_ I-GENE
nm O
. O

Results O
of O
the O
recognition I-GENE
task O
revealed O
significant O
effects O
of O
_RARE_ I-GENE
_RARE_ I-GENE
, O
position O
and O
_RARE_ I-GENE
context O
on O
_RARE_ I-GENE
recognition I-GENE
. O

_RARE_ I-GENE
response O
properties O
of O
neurons O
in O
four O
_RARE_ I-GENE
visual O
areas O
of O
the O
_RARE_ I-GENE
monkey I-GENE
( O
_RARE_ I-GENE
_RARE_ I-GENE
): O
a O
quantitative O
comparison O
of O
medial O
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
and O
middle I-GENE
temporal O
areas O
. O

A I-GENE
_RARE_ I-GENE
approach O
to O
the O
_RARE_ I-GENE
of O
allergens O
. O

Clinical O
and O
anatomical O
_RARE_ I-GENE

A I-GENE
dose O
- I-GENE
dependent I-GENE
fall O
in O
GABA I-GENE
content O
was O
observed O
; O
GABA I-GENE
decrease O
was O
evident O
15 O
min O
after O
the O
administration O
, O
reached O
its O
_RARE_ I-GENE
at O
60 O
min O
and O
disappeared O
at O
120 O
minutes O
. O

_RARE_ I-GENE
and O
applications O
of O
pulse O
_RARE_ I-GENE
: O
a O
summary O
of O
the O
_RARE_ I-GENE
. O

These O
results O
show O
that O
the O
_RARE_ I-GENE
differs O
from O
the O
adult O
in O
respect O
of O
both O
the O
nature O
of O
effects O
of O
the O
drug O
and O
sensitivity O
to O
it O
. O

To O
evaluate O
the O
gas O
chromatographic O
electron O
_RARE_ I-GENE
detection O
method O
described O
earlier O
, O
23 O
plasma I-GENE
samples O
have O
been O
analysed O
by O
both O
techniques O
. O

The O
hemodynamics O
of O
isoproterenol O
- I-GENE
induced O
cardiac O
failure O
in O
the O
rat I-GENE
. O

Several O
authors O
have O
recently O
reported O
interference O
in O
theophylline O
analysis O
by O
_RARE_ I-GENE
( O
1 I-GENE
, O
7 O
- I-GENE
_RARE_ I-GENE
), O
an O
important O
metabolite O
of O
caffeine O
. O

_RARE_ I-GENE
drug O
regimens O
like I-GENE
C I-GENE
- I-GENE
_RARE_ I-GENE
, O
CHOP I-GENE
and O
_RARE_ I-GENE
led O
to O
high O
remission O
rates O
and O
in O
some O
cases O
probably O
also O
to O
a O
cure O
of O
the O
disease O
. O

For O
monocytes O
, O
as O
measured O
on O
the O
_RARE_ I-GENE
, O
it O
was O
13 O
. O
4 I-GENE
%. O

_RARE_ I-GENE
features O
of O
_RARE_ I-GENE
_RARE_ I-GENE
. O

Clinical O
accuracy O
of O
_RARE_ I-GENE
version O
of O
the O
_RARE_ I-GENE
RAST O
test O
. O

Five O
control O
subjects O
with O
COPD O
, O
who O
performed O
the O
same O
sequence I-GENE
of O
tests O
without O
breathing O
30 O
% O
O2 O
, O
showed O
no O
change O
in O
flow O
rates O
or O
density I-GENE
dependence O
. O

Following O
extended O
recovery O
hippocampal O
EEG O
was O
normal O
despite O
extensive O
cellular O
loss O
in O
areas O
CA3 O
and O
_RARE_ I-GENE
. O

_RARE_ I-GENE
potential O
and O
single O
unit I-GENE
responses O
to O
olfactory O
nerve I-GENE
_RARE_ I-GENE
in O
the O
isolated O
_RARE_ I-GENE
olfactory O
bulb O
. O

While O
all O
deletions O
within O
the O
sequence I-GENE
coding O
for O
the O
mature O
tRNA I-GENE
led O
to O
_RARE_ I-GENE
of O
the O
mutated O
genes I-GENE
, O
substitution O
of O
the O
central O
portion O
by O
_RARE_ I-GENE
_RARE_ I-GENE
III I-GENE
_RARE_ I-GENE
produced O
gene I-GENE
units O
active O
in O
transcription I-GENE
. O

Cross O
reactivity O
in O
theophylline O
_RARE_ I-GENE
kit I-GENE
decreased O
. O

_RARE_ I-GENE
- I-GENE
90 O
was O
_RARE_ I-GENE
i O
. O
v I-GENE
. O
into O
pregnant O
rats O
on O
day O
18 O
post O
_RARE_ I-GENE
( O
p O
. O
c I-GENE
.). O

_RARE_ I-GENE
of O
the O
digital O
_RARE_ I-GENE
activity O
in O
the O
lower O
_RARE_ I-GENE
with O
the O
_RARE_ I-GENE
and O
strain O
- I-GENE
_RARE_ I-GENE
methods O
. O

Eight O
hr O
of O
acidosis O
caused O
a O
significant O
( O
P I-GENE
less O
than O
0 O
. O
01 O
) O
decrease O
in O
_RARE_ I-GENE
in O
vitro O
which O
fell O
from O
29 O
. O
0 O
to O
24 O
. O
4 I-GENE
torr O
. O

_RARE_ I-GENE
transit O
_RARE_ I-GENE
the O
response O
to O
a O
step O
increase O
in O
concentration O
by O
about O
0 O
. O
13 O
s O
( O
from O
10 O
per O
cent O
- I-GENE
90 O
per O
cent O
) O
and O
_RARE_ I-GENE
the O
transit O
time O
through O
the O
catheter O
for O
a O
volatile O
_RARE_ I-GENE
by O
about O
0 O
. O
04 O
s O
more O
than O
N2 O
. O

These O
women O
should O
not O
be O
given O
the O
current O
estrogen I-GENE
_RARE_ I-GENE
, O
which O
was O
designed O
to O
_RARE_ I-GENE
women O
of O
the O
_RARE_ I-GENE
of O
long O
- I-GENE
term O
estrogen I-GENE
use O
; O
a O
_RARE_ I-GENE
should O
be O
_RARE_ I-GENE
specifically O
for O
patients O
receiving O
short O
courses O
. O

The O
oral O
temperature O
rose O
and O
the O
serum I-GENE
creatine I-GENE
kinase I-GENE
levels O
fell O
only O
in O
those O
patients O
who O
were O
actively O
_RARE_ I-GENE
. O

Determination O
of O
aortic O
_RARE_ I-GENE
and O
its O
variations O
in O
arterial O
hypertension O
. O

We O
studied O
the O
role O
of O
prostaglandins O
in O
acid I-GENE
- I-GENE
induced O
_RARE_ I-GENE
and O
the O
associated I-GENE
_RARE_ I-GENE
hypotension O
by O
simultaneous O
treatment O
of O
some O
animals O
with O
indomethacin O
( O
150 O
micrograms O
/ I-GENE
kg O
intravenous O
), O
a O
specific I-GENE
inhibitor I-GENE
of O
prostaglandin I-GENE
synthesis O
, O
either O
during O
production O
of O
_RARE_ I-GENE
or O
during O
recovery O
. O

Since O
only O
58 O
% O
of O
our O
sample O
could O
be O
_RARE_ I-GENE
classified O
with O
one O
diagnosis O
, O
we O
_RARE_ I-GENE
that O
the O
_RARE_ I-GENE
_RARE_ I-GENE
will O
need O
to O
_RARE_ I-GENE
further O
. O

A I-GENE
surgical O
technique O
for O
_RARE_ I-GENE
this O
problem O
is O
described O
. O

Effects O
of O
prostaglandin I-GENE
inhibitors O
on O
the O
onset O
of O
_RARE_ I-GENE
and O
stroke O
in O
stroke O
- I-GENE
prone O
spontaneously O
hypertensive O
rats O
. O

In O
this O
study O
, O
the O
general O
clinical O
criteria O
for O
inhalation O
injury O
-- O
presence O
of O
facial O
or O
_RARE_ I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
levels O
, O
_RARE_ I-GENE
sputum I-GENE
, O
or O
closed O
space O
injury O
-- O
did O
not O
differentiate O
patients O
with O
airway O
injury O
only O
from O
those O
with O
_RARE_ I-GENE
injury O
. O

_RARE_ I-GENE
was O
calculated O
both O
from O
the O
date O
of O
onset O
and O
from O
the O
date O
of O
diagnosis O
. O

_RARE_ I-GENE
( O
0 O
. O
5 I-GENE
mg O
/ I-GENE
kg O
, O
i O
. O
p O
_RARE_ I-GENE
a O
blocker O
of O
serotonin I-GENE
receptors I-GENE
, O
prevented O
the O
development O
of O
the O
_RARE_ I-GENE
effect O
of O
serotonin I-GENE
. O

The O
plasma I-GENE
half O
- I-GENE
life O
of O
slow O
_RARE_ I-GENE
phase O
t1 O
/ I-GENE
2 I-GENE
beta I-GENE
, O
increases O
from O
0 O
. O
26 O
hour O
in O
rabbits O
with O
normal O
renal O
function O
to O
5 I-GENE
. O
41 O
hours O
in O
rabbits O
with O
severe O
renal O
impairment O
. O

Effects O
of O
early I-GENE
_RARE_ I-GENE
deprivation O
on O
development O
of O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
projections O
in O
the O
cat O
. O

_RARE_ I-GENE
therapy O
is O
known O
to O
be O
hazardous O
in O
patients O
with O
_RARE_ I-GENE
infection O
but O
the O
mechanism O
by O
which O
the O
host O
parasite O
relationship O
is O
altered O
by O
steroids O
is O
not O
known O
. O
We O
have O
used O
an O
intestinal O
_RARE_ I-GENE
parasite O
, O
_RARE_ I-GENE
_RARE_ I-GENE
, O
to O
examine O
the O
effects O
of O
corticosteroids O
on O
the O
number O
of O
parasites O
in O
the O
intestine O
in O
the O
course O
of O
a O
primary O
infection O
. O

_RARE_ I-GENE
lung O
function O
in O
_RARE_ I-GENE
after O
_RARE_ I-GENE
. O

With O
_RARE_ I-GENE
and O
_RARE_ I-GENE
, O
mean O
vital O
capacity O
was O
reduced O
by O
44 I-GENE
% O
from O
control O
. O

_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
as O
a O
single O
procedure O
. O

Of O
the O
117 O
patients O
( O
out O
of O
the O
136 O
) O
with O
serologic O
evidence O
of O
chronic O
thyroiditis O
who O
could O
be O
studied O
, O
eight O
( O
7 O
%) O
had O
_RARE_ I-GENE
and O
45 O
( O
38 O
%) O
were O
_RARE_ I-GENE
. O

The O
relationship O
between O
_RARE_ I-GENE
properties O
of O
_RARE_ I-GENE
and O
breast O
cancer O
management O
is O
discussed O
. O

The O
new O
_RARE_ I-GENE
- I-GENE
synthetic O
oral O
_RARE_ I-GENE
, O
CGP I-GENE
9 O
, O
000 O
, O
has O
been O
evaluated O
in O
a O
large O
number O
of O
hospitalized O
patients O
with O
urinary O
infections O
. O

A I-GENE
_RARE_ I-GENE
for O
the O
determination O
of O
serum I-GENE
of O
plasma I-GENE
levels O
of O
propranolol O
was O
developed O
using O
antibodies I-GENE
to O
propranolol O
coupled I-GENE
to O
_RARE_ I-GENE
solid O
- I-GENE
phase O
particles O
and O
_RARE_ I-GENE
- I-GENE
labeled O
propranolol O
as O
tracer O
. O

The O
_RARE_ I-GENE
_RARE_ I-GENE
projections O
_RARE_ I-GENE
to O
be O
more O
numerous O
and O
longer O
in O
_RARE_ I-GENE
, O
otherwise O
the O
structure O
of O
the O
_RARE_ I-GENE
layer O
of O
the O
_RARE_ I-GENE
and O
the O
_RARE_ I-GENE
of O
the O
_RARE_ I-GENE
vessels O
were O
identical O
in O
_RARE_ I-GENE
and O
controls O
. O

When O
pollen O
allergen I-GENE
from O
three O
_RARE_ I-GENE
species O
were O
used O
, O
The O
RAST O
- I-GENE
test O
results O
did O
not O
differ O
from O
_RARE_ I-GENE
values O
either O
. O

_RARE_ I-GENE
and O
2 I-GENE
- I-GENE
OH O
- I-GENE
_RARE_ I-GENE
concentrations O
were O
determined O
in O
a O
similar O
group O
of O
61 O
_RARE_ I-GENE
- I-GENE
treated O
patients O
. O

It O
has O
been O
shown O
in O
experiments O
in O
vitro O
that O
the O
_RARE_ I-GENE
organic O
_RARE_ I-GENE
, O
the O
_RARE_ I-GENE
contrast O
agent O
( O
_RARE_ I-GENE
) O
_RARE_ I-GENE
used O
in O
_RARE_ I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
, O
have O
an O
affinity O
, O
unlike O
the O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
dye O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
, O
for O
the O
_RARE_ I-GENE
membranes O
( O
_RARE_ I-GENE
) O
of O
liver O
cells O
. O

33 O
out O
of O
90 O
neurons O
of O
the O
cat O
medial O
_RARE_ I-GENE
body O
revealed O
the O
selectivity O
of O
their O
_RARE_ I-GENE
to O
movement O
of O
sound O
when O
velocity O
of O
the O
movement O
changed O
from O
30 O
to O
180 O
_RARE_ I-GENE
/ I-GENE
s O
. O

In O
controls O
, O
only O
_RARE_ I-GENE
differences O
were O
observed O
. O

_RARE_ I-GENE
of O
serum I-GENE
immunoreactive I-GENE
trypsin I-GENE
in O
_RARE_ I-GENE
blood O
spots O
and O
the O
early I-GENE
detection O
of O
cystic I-GENE
fibrosis I-GENE
. O

Similar O
waves O
were O
seen O
on O
cross O
- I-GENE
_RARE_ I-GENE
a O
motor O
unit I-GENE
with O
an O
_RARE_ I-GENE
_RARE_ I-GENE
, O
confirming O
that O
their O
occurrence O
does O
not O
necessarily O
demonstrate O
the O
existence O
of O
active O
neural O
interactions O
. O

_RARE_ I-GENE
enzyme I-GENE
activity O
and O
blood O
lymphocyte I-GENE
_RARE_ I-GENE
transformation O
in O
chronic O
_RARE_ I-GENE

Current O
status O
of O
chemotherapy O
for O
Hodgkin O
' O
s O
disease O

In O
literature O
, O
the O
_RARE_ I-GENE
has O
been O
displayed O
by O
application O
of O
the O
_RARE_ I-GENE
method O
. O

Forty O
- I-GENE
five O
cases O
were O
surgically O
by O
direct O
approach O
to O
the O
tumour I-GENE
, O
while O
two O
cases O
were O
treated O
only O
with O
a O
shunt O
. O

In O
Group O
V I-GENE
, O
the O
_RARE_ I-GENE
tissue I-GENE
was O
primarily O
_RARE_ I-GENE
with O
virtually O
no O
lateral O
zone O
of O
_RARE_ I-GENE
tissue I-GENE
( O
ratio O
of O
_RARE_ I-GENE
_RARE_ I-GENE
to O
_RARE_ I-GENE
_RARE_ I-GENE
14 O
. O
8 O
+/- O
1 I-GENE
. O
9 O
to O
1 I-GENE
). O

_RARE_ I-GENE
100 O
- I-GENE
mmHg O
_RARE_ I-GENE
decreases O
in O
_RARE_ I-GENE
oxygen O
partial O
pressure O
( O
PO2 O
) O
from O
control O
( O
95 O
% O
O2 O
_RARE_ I-GENE
, O
PO2 O
, O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
mmHg O
) O
were O
produced O
, O
and O
subsequent O
changes O
in O
_RARE_ I-GENE
active O
and O
resting O
tension O
were O
measured O
. O

The O
known O
B1 I-GENE
- I-GENE
deficiency O
_RARE_ I-GENE
excessive O
high O
values O
with O
light I-GENE
exercise O
. O

Based O
on O
AUC O
_RARE_ I-GENE
analyses O
, O
the O
pharmacokinetics O
of O
_RARE_ I-GENE
were O
found O
to O
be O
linear O
within O
the O
dose O
_RARE_ I-GENE
studied O
( O
50 O
to O
200 O
mg O
for O
i O
. O
v I-GENE
. O
injection O
and O
150 O
to O
450 I-GENE
mg O
for O
oral O
administration O
). O

_RARE_ I-GENE
secretion O
during O
food O
stimulation O
in O
_RARE_ I-GENE
system O
diseases O

_RARE_ I-GENE
determination O
using O
the O
_RARE_ I-GENE
- I-GENE
1 I-GENE
_RARE_ I-GENE

_RARE_ I-GENE
a O
period O
of O
15 O
days O
16 O
% O
of O
the O
dose O
administered O
was O
_RARE_ I-GENE
with O
_RARE_ I-GENE
and O
0 O
. O
9 O
% O
in O
the O
urine O
. O

_RARE_ I-GENE
or O
_RARE_ I-GENE
emptying O
regions O
of O
the O
left O
ventricle O
were O
detected O
by O
a O
relatively O
new O
nuclear I-GENE
technique O
-- O
phase O
imaging O
. O

_RARE_ I-GENE
to O
_RARE_ I-GENE
of O
nuclei O
_RARE_ I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
posterior O
were O
of O
considerably O
longer O
latency O
. O

_RARE_ I-GENE
patients O
with O
non O
- I-GENE
_RARE_ I-GENE
gallbladder O
with O
_RARE_ I-GENE
subsequently O
had O
Tc O
- I-GENE
99m O
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
performed O
. O

One O
was O
allowed O
fresh O
drinking O
water O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
the O
other O
received O
_RARE_ I-GENE
in O
their O
drinking O
water O
. O

_RARE_ I-GENE
data O
were O
obtained O
from O
case O
history O
, O
smoking O
_RARE_ I-GENE
were O
not O
known O
in O
_RARE_ I-GENE
A I-GENE
and O
C I-GENE
. O

The O
determination O
of O
physical O
performance O
capacity O
was O
based O
on O
_RARE_ I-GENE
, O
_RARE_ I-GENE
% O
and O
on O
predicted O
VO2 O
max O
measured O
with O
continuously O
increasing O
work O
load O
on O
a O
_RARE_ I-GENE
_RARE_ I-GENE
. O

Determination O
of O
lead O
in O
blood O
. O

Effect O
of O
indomethacin O
and O
prostaglandin I-GENE
F2 O
alpha I-GENE
on O
_RARE_ I-GENE
in O
swine O
. O

LD50 O
values O
of O
terms O
of O
KP O
were O
84 O
mg O
/ I-GENE
kg O
in O
male O
rats O
and O
122 O
mg O
/ I-GENE
kg O
in O
female O
rats O
when O
KP O
- I-GENE
_RARE_ I-GENE
was O
administered O
_RARE_ I-GENE
, O
and O
117 O
mg O
/ I-GENE
kg O
in O
male O
and O
92 O
mg O
/ I-GENE
kg O
in O
female O
when O
KP O
- I-GENE
_RARE_ I-GENE
was O
administered O
_RARE_ I-GENE
., O
while O
_RARE_ I-GENE
administration O
of O
KP O
- I-GENE
_RARE_ I-GENE
showed O
LD50 O
values O
of O
68 O
mg O
/ I-GENE
kg O
in O
males O
and O
78 O
mg O
/ I-GENE
kg O
in O
females O
in O
terms O
of O
KP O
. O

_RARE_ I-GENE
was O
performed O
as O
follows O
: O
Heparin O
- I-GENE
_RARE_ I-GENE
- I-GENE
B I-GENE
- I-GENE
Heparin O
- I-GENE
_RARE_ I-GENE
- I-GENE
Heparin O
- I-GENE
_RARE_ I-GENE
- I-GENE
B I-GENE
etc O
. O

_RARE_ I-GENE
microscopic O
picture O
of O
the O
cerebral O
cortex O
in O
rats O
_RARE_ I-GENE
to O
22 O
degrees O
C I-GENE

_RARE_ I-GENE
the O
differences O
between O
short O
gut O
and O
sham O
operation O
animals O
disappeared O
when O
the O
data O
were O
_RARE_ I-GENE
for O
mucosal I-GENE
weight O
. O

A I-GENE
_RARE_ I-GENE
thin O
- I-GENE
layer O
chromatographic O
determination O
of O
_RARE_ I-GENE
acid I-GENE
and O
_RARE_ I-GENE
acids O
. O

The O
architecture O
of O
_RARE_ I-GENE
in O
these O
two O
regions O
was O
also O
examined O
by O
scanning O
electron O
microscopy O
, O
using O
the O
resin O
_RARE_ I-GENE
method O
. O

_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
new O
_RARE_ I-GENE
health O
_RARE_ I-GENE
. O

_RARE_ I-GENE
of O
the O
spinal O
cord O
in O
a O
_RARE_ I-GENE
rat I-GENE
. O

_RARE_ I-GENE
high O
- I-GENE
performance O
liquid O
chromatographic O
system O
with O
micro O
_RARE_ I-GENE
and O
dual O
_RARE_ I-GENE
detector O
for O
direct O
injection O
analysis O
of O
catecholamines O
in O
body O
fluids O
. O

Thirty O
- I-GENE
one O
age O
- I-GENE
matched O
, O
conscious O
, O
_RARE_ I-GENE
, O
male O
Sprague O
- I-GENE
Dawley O
rats O
and O
spontaneously O
hypertensive O
rats O
( O
_RARE_ I-GENE
) O
were O
individually O
injected O
with O
a O
single O
subcutaneous O
dose O
of O
85 O
mg O
/ I-GENE
kg O
dl O
- I-GENE
isoproterenol O
to O
determine O
the O
degree O
and O
time O
course O
of O
drug O
- I-GENE
induced O
cardiac O
failure O
and O
functional O
recovery O
. O

A I-GENE
narrow O
zone O
of O
myelin I-GENE
- I-GENE
_RARE_ I-GENE
dissociation O
was O
also O
observed O
. O

The O
IgA I-GENE
deficiency O
is O
combined O
with O
the O
IgE I-GENE
one O
. O

In O
_RARE_ I-GENE
mice O
, O
there O
was O
only O
a O
small I-GENE
deficit O
in O
the O
number O
of O
the O
hippocampal O
pyramidal O
neurons O
compared O
to O
controls O
( O
15 O
%, O
p O
less O
than O
0 O
. O
01 O
), O
and O
no O
deficit O
in O
the O
_RARE_ I-GENE
cells O
. O

_RARE_ I-GENE
_RARE_ I-GENE
in O
_RARE_ I-GENE
_RARE_ I-GENE
. O

Prevention O
of O
transfusion O
reactions O
by O
the O
use O
of O
saline O
_RARE_ I-GENE
red I-GENE
blood O
cells O
. O

The O
_RARE_ I-GENE
mean O
_RARE_ I-GENE
- I-GENE
inhibition O
antibody I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
of O
non O
- I-GENE
immunized O
, O
once O
- I-GENE
immunized O
, O
and O
twice O
- I-GENE
immunized O
chickens O
were O
compared O
at O
2 I-GENE
- I-GENE
week O
intervals O
following O
primary O
immunization O
, O
secondary O
immunization O
, O
and O
challenge O
. O

The O
quantitative O
determination O
of O
_RARE_ I-GENE
-- O
a O
valuable O
aid O
in O
evaluating O
the O
_RARE_ I-GENE
of O
hepatitis I-GENE
B I-GENE
virus I-GENE
carriers O

2 I-GENE
. O
numerous O
narrow O
shunt O
vessels O
_RARE_ I-GENE
continuously O
from O
the O
primary O
arteries O
to O
feed O
a O
secondary O
arterial O
system O
which O
_RARE_ I-GENE
the O
primary O
one O
. O

_RARE_ I-GENE
complications O
are O
frequent O
during O
and O
after O
the O
treatment O
of O
_RARE_ I-GENE
malignancy O
. O

_RARE_ I-GENE
cyst O
. O

100 O
more O
than O
in O
the O
summer O
coat I-GENE
). O

_RARE_ I-GENE
was O
produced O
by O
head I-GENE
up O
tilt O
. O

Therefore O
the O
procedure O
of O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
is O
not O
to O
be O
recommended O
in O
adults O
. O

_RARE_ I-GENE
and O
_RARE_ I-GENE
cell O
carcinomas O
of O
salivary I-GENE
tissues O
. O

Twenty O
patients O
aged O
45 O
or O
older O
with O
the O
diagnosis O
of O
endogenous I-GENE
depression O
were O
evaluated O
in O
terms O
of O
safety O
and O
efficacy O
in O
their O
response O
to O
multiple O
monitored O
_RARE_ I-GENE
therapy O
( O
_RARE_ I-GENE
) O
versus O
single O
_RARE_ I-GENE
therapy O
( O
_RARE_ I-GENE
). O

Two O
new O
_RARE_ I-GENE
in O
automated O
coagulation I-GENE
testing O
. O

This O
relatively O
simple O
and O
easily O
performed O
technique O
of O
measuring O
deep O
muscle O
temperature O
appears O
to O
be O
a O
useful O
_RARE_ I-GENE
in O
_RARE_ I-GENE
the O
_RARE_ I-GENE
level O
. O

_RARE_ I-GENE
force O
- I-GENE
length I-GENE
relationships O
of O
guinea O
pig O
_RARE_ I-GENE
were O
studied O
in O
vitro O
in O
animals O
3 I-GENE
weeks O
, O
3 I-GENE
months O
, O
and O
3 I-GENE
years O
of O
age O
. O

_RARE_ I-GENE
of O
the O
method O
indicate O
( O
1 I-GENE
) O
the O
_RARE_ I-GENE
source O
can O
be O
placed O
on O
the O
_RARE_ I-GENE
membrane I-GENE
without O
altering O
the O
signal I-GENE
- I-GENE
transmission O
properties O
of O
the O
_RARE_ I-GENE
, O
and O
( O
2 I-GENE
) O
the O
source O
_RARE_ I-GENE
to O
the O
_RARE_ I-GENE
membrane I-GENE
. O

_RARE_ I-GENE
work O
- I-GENE
up O
in O
a O
patient O
with O
late O
vaginal O
metastasis O
from O
a O
renal O
carcinoma O
. O

The O
authors O
conclude O
that O
_RARE_ I-GENE
of O
low O
platelet I-GENE
MAO I-GENE
as O
a O
possible O
correlate O
of O
bipolar O
affective O
disorder O
, O
as O
well O
as O
schizophrenia O
, O
increases O
the O
burden O
of O
_RARE_ I-GENE
necessary O
before O
findings O
of O
low O
platelet I-GENE
MAO I-GENE
can O
be O
accepted O
as O
primary O
. O

_RARE_ I-GENE
, O
a O
known O
disease O
, O
of O
which O
little O
is O
known O

_RARE_ I-GENE
replacement O
, O
either O
as O
17 O
beta I-GENE
- I-GENE
estradiol O
or O
beta I-GENE
- I-GENE
estradiol O
- I-GENE
3 I-GENE
- I-GENE
_RARE_ I-GENE
via O
subcutaneous O
_RARE_ I-GENE
capsules O
, O
was O
associated I-GENE
with O
elevated O
rates O
of O
heat I-GENE
production O
and O
_RARE_ I-GENE
heat I-GENE
loss O
relative O
to O
untreated O
_RARE_ I-GENE
controls O
. O

The O
following O
aspects O
were O
assessed O
: O
( O
1 I-GENE
) O
The O
effect O
on O
the O
cardiovascular O
system O
in O
terms O
of O
_RARE_ I-GENE
arterial O
pressure O
, O
pulse O
rate O
, O
and O
oxygen O
consumption O
( O
VO2 O
) O
during O
exercise O
in O
5 I-GENE
health O
volunteers O
; O
( O
2 I-GENE
) O
_RARE_ I-GENE
activity O
of O
the O
_RARE_ I-GENE
anterior O
and O
_RARE_ I-GENE
muscles O
during O
exercise O
in O
the O
same O
5 I-GENE
volunteers O
; O
and O
( O
3 I-GENE
) O
_RARE_ I-GENE
_RARE_ I-GENE
pressure O
changes O
in O
10 O
subjects O
with O
_RARE_ I-GENE
proven O
_RARE_ I-GENE
arterial O
diseases O
of O
the O
lower O
_RARE_ I-GENE
. O

Changes O
in O
immunologic O
reactivity O
in O
subjects O
receiving O
transfer I-GENE
factor I-GENE
could O
not O
be O
distinguished O
from O
those O
in O
subjects O
receiving O
placebo O
. O

It O
was O
_RARE_ I-GENE
that O
this O
_RARE_ I-GENE
from O
the O
possibility O
that O
the O
nature O
of O
blue O
_RARE_ I-GENE
_RARE_ I-GENE
was O
physical O
, O
and O
that O
loss O
of O
myocardial O
tissue I-GENE
might O
be O
expected O
to O
more O
markedly O
_RARE_ I-GENE
with O
their O
work O
efficiency O
( O
on O
_RARE_ I-GENE
to O
work O
) O
than O
it O
would O
the O
efficiency O
of O
the O
more O
_RARE_ I-GENE
_RARE_ I-GENE
of O
white O
_RARE_ I-GENE
workers O
. O

_RARE_ I-GENE
of O
determining O
the O
blood O
_RARE_ I-GENE
groups O
in O
_RARE_ I-GENE
of O
the O
long O
tubular O
_RARE_ I-GENE
complicated O
by O
infection O

The O
results O
revealed O
increased O
blood O
lead O
level O
associated I-GENE
with O
decreased O
blood O
_RARE_ I-GENE
and O
increased O
urinary O
excretion O
of O
delta I-GENE
amino O
_RARE_ I-GENE
acid I-GENE
. O

Following O
iv O
injection O
of O
0 O
. O
5 I-GENE
g O
galactose I-GENE
per O
kg O
body O
weight O
, O
together O
with O
2 I-GENE
mu I-GENE
_RARE_ I-GENE
generally O
14C O
- I-GENE
labelled O
galactose I-GENE
, O
_RARE_ I-GENE
is O
collected O
in O
regular O
intervals O
during O
one O
hour O
. O

Specific O
clotting I-GENE
factor I-GENE
assays O
showed O
an O
isolated O
deficiency O
of O
factor I-GENE
X I-GENE
ranging O
from O
7 O
to O
12 O
per O
cent O
on O
three O
determinations O
. O

_RARE_ I-GENE
- I-GENE
facilitated O
dialysis O
. O

Blood O
variables O
measured O
at O
eight O
intervals O
before O
, O
during O
, O
and O
after O
operation O
were O
as O
follows O
: O
seven O
plasma I-GENE
proteins I-GENE
, O
free O
hemoglobin I-GENE
, O
formed O
elements O
, O
and O
clotting I-GENE
functions O
. O

_RARE_ I-GENE
changes O
in O
_RARE_ I-GENE
_RARE_ I-GENE
in O
children O

As O
a O
result O
, O
beta I-GENE
- I-GENE
apo I-GENE
- I-GENE
8 O
'- O
_RARE_ I-GENE
acid I-GENE
ethyl O
ester O
( O
apo I-GENE
- I-GENE
_RARE_ I-GENE
) O
was O
used O
as O
a O
reference O
standard O
in O
Experiments O
4 I-GENE
to O
6 I-GENE
. O

The O
ability O
of O
sodium O
_RARE_ I-GENE
( O
60 O
mg O
/ I-GENE
kg O
) O
and O
sodium O
_RARE_ I-GENE
( O
80 O
mg O
/ I-GENE
kg O
) O
to O
produce O
a O
taste O
_RARE_ I-GENE
in O
23 O
hr O
fluid O
deprived O
rats O
was O
examined O
using O
a O
discrimination O
or O
two O
_RARE_ I-GENE
taste O
_RARE_ I-GENE
task O
( O
0 O
. O
125 I-GENE
% O
sodium O
saccharin O
solution O
or O
water O
). O

It O
appears O
that O
the O
pulmonary O
gas O
exchange I-GENE
parenchyma O
of O
these O
smallest O
mammals O
is O
well O
_RARE_ I-GENE
to O
supply O
the O
organism O
with O
the O
_RARE_ I-GENE
high O
levels O
of O
O2 O
required O
by O
the O
high O
metabolic O
rates O
, O
exhibiting O
a O
structural O
adaptation O
of O
the O
lung O
to O
higher O
VO2 O
. O

_RARE_ I-GENE
by O
as O
much O
as O
35 O
% O
may O
occur O
due O
to O
the O
problems O
in O
the O
existing O
_RARE_ I-GENE
. O

_RARE_ I-GENE
was O
administered O
without O
altering O
the O
course O
of O
the O
disorder O
. O

Drug O
inhibition O
of O
whole O
blood O
aspirin I-GENE
esterase I-GENE
. O

However O
, O
at O
lower O
temperature O
the O
positive O
_RARE_ I-GENE
was O
not O
clear O
and O
rather O
negative O
_RARE_ I-GENE
appeared O
( O
1 I-GENE
-- O
3 I-GENE
Hz O
). O

_RARE_ I-GENE
averaged O
evoked O
responses O
and O
platelet I-GENE
monoamine I-GENE
oxidase I-GENE
in O
patients O
suffering O
from O
_RARE_ I-GENE
. O

At O
the O
end O
of O
the O
experiment O
the O
urinary O
porphyrin O
excretion O
and O
the O
porphyrin O
content O
in O
_RARE_ I-GENE
and O
skin O
were O
diminished O
in O
HCB O
- I-GENE
_RARE_ I-GENE
- I-GENE
treated O
animals O
by O
about O
50 O
% O
compared O
to O
the O
HCB O
controls O
. O

Six O
hours O
after O
the O
last O
administration O
, O
_RARE_ I-GENE
of O
_RARE_ I-GENE
and O
_RARE_ I-GENE
mice O
were O
weight O
_RARE_ I-GENE
. O
6 I-GENE
mg O
% O
and O
_RARE_ I-GENE
. O
5 I-GENE
mg O
% O
respectively O
, O
the O
difference O
was O
statistically O
significant O
( O
p O
less O
than O
0 O
. O
01 O
). O

Although O
stone O
- I-GENE
_RARE_ I-GENE
were O
not O
found O
to O
display O
any O
features O
of O
magnesium O
metabolism O
that O
were O
different O
from O
those O
in O
the O
control O
group O
, O
their O
lower O
urinary O
excretion O
of O
magnesium O
in O
relation O
to O
calcium O
may O
be O
a O
factor I-GENE
in O
their O
increased O
stone O
- I-GENE
forming O
propensity O
. O

Analysis O
of O
an O
autopsy O
population O
. O

A I-GENE
16 O
- I-GENE
year O
follow O
- I-GENE
up O
study O
of O
69 O
_RARE_ I-GENE
with O
complete O
lesions O
from O
T1 O
- I-GENE
_RARE_ I-GENE
is O
presented O
. O

_RARE_ I-GENE
_RARE_ I-GENE
of O
its O
cellular O
distribution O
in O
the O
kidney O
. O

_RARE_ I-GENE
stimulation O
overlapping O
conditioned O
stimulus O
_RARE_ I-GENE
produced O
attenuation O
of O
latent I-GENE
inhibition O
, O
as O
did O
stimulation O
presented O
during O
conditioning O
after O
_RARE_ I-GENE
. O

The O
_RARE_ I-GENE
amygdala O
and O
gastric O
pathology O
in O
rats O
. O

_RARE_ I-GENE
extraction O
in O
primary O
glaucoma O

_RARE_ I-GENE
and O
size O
of O
the O
myelin I-GENE
structures O
in O
the O
_RARE_ I-GENE
_RARE_ I-GENE
II I-GENE
increased O
simultaneously O
. O

In O
the O
intact O
animal O
, O
_RARE_ I-GENE
potentiation O
_RARE_ I-GENE
on O
the O
basic I-GENE
pacing O
interval O
, O
_RARE_ I-GENE
, O
and O
the O
timing O
of O
the O
_RARE_ I-GENE
, O
t1 O
: O
when O
_RARE_ I-GENE
was O
held O
constant O
and O
t1 O
was O
increased O
, O
potentiation O
decreased O
; O
when O
t1 O
was O
held O
constant O
and O
_RARE_ I-GENE
was O
increased O
, O
potentiation O
increased O
. O

In O
_RARE_ I-GENE
of O
this O
and O
other O
complications O
of O
corticosteroids O
, O
_RARE_ I-GENE
made O
a O
full I-GENE
recovery O
from O
the O
fungal I-GENE
infection O
following O
treatment O
with O
amphotericin O
B I-GENE
and O
surgical O
excision O
of O
the O
lung O
abscess O
. O

_RARE_ I-GENE
of O
this O
observation O
for O
_RARE_ I-GENE
are O
discussed O
. O

For O
the O
study O
of O
the O
transition O
of O
long O
to O
short O
waves O
( O
deep O
- I-GENE
water O
waves O
) O
a O
closed O
- I-GENE
form O
solution O
is O
_RARE_ I-GENE
; O
this O
can O
, O
however O
, O
only O
be O
obtained O
at O
the O
cost O
of O
further O
_RARE_ I-GENE
. O

Treatment O
of O
_RARE_ I-GENE
_RARE_ I-GENE

We O
report O
a O
case O
of O
_RARE_ I-GENE
_RARE_ I-GENE
during O
the O
third O
_RARE_ I-GENE
of O
pregnancy O
. O

_RARE_ I-GENE
plasma I-GENE
and O
lipoprotein I-GENE
lipid O
concentrations O
, O
adipose I-GENE
tissue I-GENE
lipoprotein I-GENE
lipase I-GENE
activity O
, O
_RARE_ I-GENE
data O
, O
alcohol O
consumption O
, O
smoking O
_RARE_ I-GENE
, O
weekly O
_RARE_ I-GENE
run O
and O
performance O
on O
a O
_RARE_ I-GENE
_RARE_ I-GENE
were O
recorded O
before O
and O
after O
the O
training O
period O
. O

The O
C18 O
: O
1 I-GENE
: O
_RARE_ I-GENE
value O
is O
a O
_RARE_ I-GENE
measure O
of O
these O
changes O
and O
can O
be O
determined O
more O
rapidly O
than O
determining O
all O
the O
lower O
fatty I-GENE
acids O
. O

A I-GENE
progressive O
growth I-GENE
of O
blood O
erythrocyte I-GENE
membrane I-GENE
injury O
has O
been O
demonstrated O
after O
rats O
were O
exposed O
to O
gamma I-GENE
- I-GENE
_RARE_ I-GENE
at O
a O
dose O
of O
100 O
to O
500 O
Gy O
. O

Within O
the O
3 I-GENE
' O
terminal I-GENE
50 O
nucleotides O
, O
the O
mouse I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
rRNA I-GENE
contains O
a O
potential O
10 O
bp O
hairpin O
structure O
and O
a O
sequence I-GENE
of O
15 O
consecutive O
nucleotides O
common O
to O
the O
RNA I-GENE
of O
the O
small I-GENE
ribosomal I-GENE
subunit I-GENE
in O
all O
systems O
, O
but O
does O
not O
contain O
the O
mRNA I-GENE
binding I-GENE
site I-GENE
( O
_RARE_ I-GENE
) O
found O
in O
E I-GENE
. O
coli I-GENE
and O
_RARE_ I-GENE
chloroplast I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
and O
cell O
population O
dynamics O
. O

Thirty O
_RARE_ I-GENE
_RARE_ I-GENE
were O
examined O
under O
X I-GENE
6 I-GENE
to O
16 O
magnification O
in O
order O
to O
define O
the O
_RARE_ I-GENE
_RARE_ I-GENE
of O
the O
pineal O
region O
, O
particularly O
the O
relationship O
of O
the O
pineal O
body O
, O
posterior O
cerebral O
artery O
, O
superior O
_RARE_ I-GENE
artery O
, O
vein O
of O
_RARE_ I-GENE
, O
basal O
vein O
of O
_RARE_ I-GENE
, O
internal O
cerebral O
vein O
, O
_RARE_ I-GENE
sinus O
, O
_RARE_ I-GENE
vein O
, O
the O
size O
of O
the O
_RARE_ I-GENE
_RARE_ I-GENE
, O
and O
the O
third O
and O
the O
fourth O
_RARE_ I-GENE
nerves O
. O

Serum I-GENE
antibody I-GENE
_RARE_ I-GENE
was O
not O
significantly O
associated I-GENE
with O
the O
recurrence O
rate O
or O
the O
duration O
of O
infection O
. O

We O
propose O
that O
_RARE_ I-GENE
may O
be O
an O
important O
mechanism O
for O
activation O
of O
certain O
viral I-GENE
infections O
previously O
suppressed O
by O
_RARE_ I-GENE
. O

One O
hundred O
_RARE_ I-GENE
units O
of O
_RARE_ I-GENE
red I-GENE
blood O
cells O
, O
some O
with O
_RARE_ I-GENE
added O
so O
as O
to O
_RARE_ I-GENE
an O
acceptable O
1 I-GENE
% O
_RARE_ I-GENE
content O
, O
had O
measurements O
made O
of O
the O
post O
- I-GENE
_RARE_ I-GENE
supernatant O
fluid O
by O
_RARE_ I-GENE
index O
and O
_RARE_ I-GENE
. O

The O
symptoms O
and O
objective O
findings O
were O
caused O
by O
a O
malignant O
lymphoma O
, O
and O
the O
diagnosis O
was O
established O
from O
a O
_RARE_ I-GENE
biopsy O
. O

Our O
study O
differs O
from O
previous O
studies O
in O
that O
it O
is O
limited O
to O
one O
diagnostic O
_RARE_ I-GENE
, O
yet O
at O
the O
same O
time O
_RARE_ I-GENE
a O
broad O
range O
of O
social O
and O
work O
- I-GENE
related I-GENE
factors I-GENE
in O
_RARE_ I-GENE
. O

It O
is O
suggested O
that O
a O
raised O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
acid I-GENE
ratio O
does O
not O
necessarily O
indicate O
vitamin O
B6 I-GENE
deficiency O
but O
may O
represent O
a O
nonspecific O
response O
of O
tryptophan I-GENE
metabolism O
to O
stress O
. O

All O
control O
persons O
had O
a O
normal O
reaction O
to O
_RARE_ I-GENE
. O

In O
a O
control O
group O
both O
common O
carotid O
arteries O
( O
_RARE_ I-GENE
) O
were O
ligated O
. O

At O
pH O
6 I-GENE
. O
9 O
, O
the O
same O
lidocaine O
concentrations O
significantly O
reduced O
resting O
potential O
( O
3 I-GENE
- I-GENE
10 O
%), O
action O
potential O
amplitude O
( O
3 I-GENE
- I-GENE
8 O
%) O
and O
Vmax O
( O
14 O
- I-GENE
22 O
%). O

_RARE_ I-GENE
right O
and O
left O
adrenal O
and O
peripheral O
blood O
samples O
were O
collected O
for O
determination O
of O
_RARE_ I-GENE
( O
E1 I-GENE
) O
and O
oestradiol O
( O
E2 I-GENE
). O

_RARE_ I-GENE
function O
tests O
. O

All O
lambs O
with O
B I-GENE
_RARE_ I-GENE
had O
significantly O
higher O
Hb I-GENE
levels O
at O
the O
end O
of O
the O
experiment O
than O
did O
_RARE_ I-GENE
lambs O
. O
b I-GENE
and O
S I-GENE
x O
B I-GENE
lambs O
had O
higher O
( O
P I-GENE
< O
. O
05 O
) O
Hb I-GENE
levels O
than O
the O
D I-GENE
x O
B I-GENE
lambs O
, O
and O
B I-GENE
lambs O
had O
the O
highest O
( O
P I-GENE
< O
. O
05 O
) O
mean O
_RARE_ I-GENE
hemoglobin I-GENE
concentrations O
. O

The O
same O
response O
occurs O
whether O
_RARE_ I-GENE
is O
given O
immediately O
after O
nerve I-GENE
ligation O
or O
1 I-GENE
week O
later O
. O

The O
operation O
recommended O
is O
excision O
of O
3 I-GENE
mm O
of O
central O
_RARE_ I-GENE
followed O
by O
end O
- I-GENE
to O
- I-GENE
end O
repair I-GENE
of O
the O
tendon O
. O

In O
the O
_RARE_ I-GENE
group O
arterial O
pressure O
decreased O
50 O
mmHg O
to O
normal O
by O
24 O
h O
and O
was O
associated I-GENE
with O
increased O
_RARE_ I-GENE
and O
a O
small I-GENE
decrease O
in O
blood O
volume O
( O
9 O
. O
8 O
%). O

Marked O
_RARE_ I-GENE
activity O
was O
observed O
with O
9 O
- I-GENE
_RARE_ I-GENE
- I-GENE
5 I-GENE
- I-GENE
_RARE_ I-GENE
[ O
2 I-GENE
, O
1 I-GENE
- I-GENE
d O
_RARE_ I-GENE
1 I-GENE
, O
5 I-GENE
] O
_RARE_ I-GENE
- I-GENE
6 I-GENE
, O
6 I-GENE
- I-GENE
dioxide O
( O
_RARE_ I-GENE
) O
and O
9 O
- I-GENE
_RARE_ I-GENE
- I-GENE
5 I-GENE
- I-GENE
p O
- I-GENE
_RARE_ I-GENE
[ O
2 I-GENE
, O
1 I-GENE
- I-GENE
d O
_RARE_ I-GENE
1 I-GENE
, O
5 I-GENE
] O
_RARE_ I-GENE
- I-GENE
6 I-GENE
, O
6 I-GENE
- I-GENE
dioxide O
( O
_RARE_ I-GENE
). O

In O
patients O
, O
the O
effect O
of O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
on O
the O
movement O
of O
the O
terminal I-GENE
part O
of O
the O
bile O
duct O
was O
measured O
with O
a O
pressure O
_RARE_ I-GENE
using O
a O
_RARE_ I-GENE
. O

In O
11 O
patients O
with O
_RARE_ I-GENE
' O
s O
headache O
morphological O
investigations O
( O
differential O
white O
blood O
cell O
count O
), O
_RARE_ I-GENE
determinations O
( O
alkaline I-GENE
and O
acid I-GENE
phosphatase I-GENE
, O
non O
- I-GENE
specific I-GENE
esterase I-GENE
) O
and O
_RARE_ I-GENE
tests O
( O
IgM I-GENE
and O
IgG I-GENE
binding I-GENE
) O
were O
carried O
out O
on O
capillary O
blood O
neutrophils O
obtained O
from O
the O
area O
of O
pain O
, O
non O
- I-GENE
_RARE_ I-GENE
area O
of O
the O
skin O
on O
the O
head I-GENE
on O
the O
contralateral O
side O
, O
and O
from O
the O
finger I-GENE
. O

As O
high O
- I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
imaging O
, O
computed O
_RARE_ I-GENE
scan O
_RARE_ I-GENE
such O
as O
the O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
become O
available O
with O
higher O
density I-GENE
resolution O
, O
perhaps O
a O
single O
injection O
of O
contrast O
agent O
into O
the O
right O
atrium O
or O
even O
a O
peripheral O
vein O
may O
be O
adequate O
to O
obtain O
all O
these O
measurements O
. O

The O
_RARE_ I-GENE
' O
s O
are O
a O
direct O
result O
of O
the O
_RARE_ I-GENE
study O
. O

The O
potentially O
SLE O
- I-GENE
inducing O
drugs O
are O
reviewed O
. O

A I-GENE
third O
series O
of O
mice O
were O
given O
a O
single O
injection O
of O
5 I-GENE
- I-GENE
OH O
- I-GENE
DA I-GENE
, O
_RARE_ I-GENE
, O
and O
prepared O
for O
_RARE_ I-GENE
study O
. O

_RARE_ I-GENE
different O
species O
( O
eight O
_RARE_ I-GENE
, O
one O
_RARE_ I-GENE
and O
five O
_RARE_ I-GENE
) O
have O
been O
_RARE_ I-GENE
. O

No O
symptoms O
other O
than O
hot O
_RARE_ I-GENE
showed O
such O
significant O
correlation O
with O
plasma I-GENE
epinephrine O
or O
norepinephrine O
levels O
. O

The O
mean O
values O
of O
the O
concentrations O
of O
the O
components O
due O
to O
tobacco I-GENE
smoke O
are O
: O
CO I-GENE
= O
1 I-GENE
. O
1 I-GENE
ppm O
, O
NO O
= O
32 O
ppb O
, O
NO2 O
= O
24 O
ppb O
, O
nicotine O
= O
0 O
. O
9 O
micrograms O
/ I-GENE
m3 O
, O
particulate O
matter O
= O
133 I-GENE
micrograms O
/ I-GENE
m3 O
. O

The O
average O
_RARE_ I-GENE
coefficient O
was O
six O
time O
larger O
in O
regions O
of O
infarct O
studied O
8 O
-- O
10 O
weeks O
after O
occlusion O
than O
that O
in O
regions O
of O
infarct O
studied O
5 I-GENE
-- O
6 I-GENE
weeks O
after O
occlusion O
. O

At O
4 I-GENE
wk O
however O
, O
tumor I-GENE
relapse O
was O
noted O
in O
6 I-GENE
of O
7 O
group O
4 I-GENE
responders O
, O
10 O
of O
12 O
in O
group O
5 I-GENE
, O
13 O
of O
16 O
in O
group O
7 O
, O
but O
only O
4 I-GENE
of O
19 O
group O
8 O
responders O
( O
p O
less O
than O
. O
001 O
group O
8 O
versus O
4 I-GENE
, O
5 I-GENE
, O
7 O
). O

Early O
infection O
was O
detected O
in O
one O
of O
50 O
control O
women O
who O
gave O
birth O
to O
a O
healthy O
infant O
. O

_RARE_ I-GENE
_RARE_ I-GENE
the O
onset O
of O
HCB O
_RARE_ I-GENE
, O
in O
other O
_RARE_ I-GENE
it O
increases O
the O
total O
urinary O
porphyrin O
excretion O
and O
causes O
an O
earlier O
disturbance O
of O
the O
porphyrin O
pattern O
. O

_RARE_ I-GENE
planning O
_RARE_ I-GENE
to O
play O
a O
minor O
role O
, O
and O
only O
25 O
. O
3 I-GENE
per O
cent O
of O
all O
patients O
reviewed O
_RARE_ I-GENE
to O
oral O
_RARE_ I-GENE
for O
shorter O
or O
longer O
periods O
of O
time O
. O
- I-GENE
The O
_RARE_ I-GENE
of O
_RARE_ I-GENE
and O
_RARE_ I-GENE
in O
all O
births O
as O
well O
as O
the O
high O
percentage O
of O
_RARE_ I-GENE
are O
parameters O
by O
which O
the O
approach O
to O
_RARE_ I-GENE
differs O
_RARE_ I-GENE
from O
behaviour O
patterns O
in O
_RARE_ I-GENE
. O

The O
term O
_RARE_ I-GENE
is O
proposed O
for O
a O
_RARE_ I-GENE
bone O
disease O
with O
dominant I-GENE
_RARE_ I-GENE
that O
has O
been O
discovered O
in O
five O
members O
of O
four O
different O
families O
. O

The O
_RARE_ I-GENE
protein I-GENE
, O
together O
with O
proteins I-GENE
of O
105 I-GENE
, O
000 O
and O
75 O
, O
000 O
_RARE_ I-GENE
, O
are O
translated O
from O
_RARE_ I-GENE
transcribed O
( O
1 I-GENE
- I-GENE
strand O
) O
messenger I-GENE
RNAs I-GENE
that O
are O
complementary O
to O
the O
viral I-GENE
genome O
between O
positions O
11 O
. O
2 I-GENE
and O
31 O
. O
5 I-GENE
. O

The O
identification O
of O
viable O
myocardium O
with O
both O
99mTc O
- I-GENE
tetrofosmin O
and O
_RARE_ I-GENE
can O
be O
greatly O
enhanced O
to O
a O
similar O
degree O
if O
the O
severity O
of O
reduction O
in O
activity O
within O
_RARE_ I-GENE
defects O
is O
considered O
. O

The O
temporal O
component O
lacked O
a O
mandibular O
_RARE_ I-GENE
as O
well O
as O
_RARE_ I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
- I-GENE
8 O
is O
a O
novel O
, O
synthetic O
, O
low O
- I-GENE
molecular O
- I-GENE
weight O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
complex I-GENE
that O
exhibits O
both O
superoxide I-GENE
dismutase I-GENE
and O
catalase I-GENE
activities O
in O
vitro O
. O

The O
protein I-GENE
_RARE_ I-GENE
- I-GENE
1 I-GENE
, O
encoded I-GENE
by O
a O
single O
- I-GENE
copy O
gene I-GENE
homologous O
to O
the O
GATA I-GENE
family I-GENE
of O
vertebrate I-GENE
transcription I-GENE
factors I-GENE
, O
is O
potentially O
capable O
of O
interacting I-GENE
with O
this O
element I-GENE
. O

However O
, O
in O
contrast O
with O
previous O
in O
vitro O
cell O
- I-GENE
free O
integration O
studies O
, O
alteration O
of O
the O
highly O
conserved O
CA I-GENE
dinucleotide O
resulted O
in O
a O
mutant I-GENE
which O
still O
retained O
40 I-GENE
% O
of O
wild I-GENE
- I-GENE
type I-GENE
integration O
activity O
. O

The O
resulting O
R I-GENE
protein I-GENE
_RARE_ I-GENE
five O
codons O
downstream O
of O
the O
frameshift O
site I-GENE
at O
the O
V I-GENE
protein I-GENE
stop O
codon O
. O

These O
results O
demonstrate O
that O
although O
_RARE_ I-GENE
and O
_RARE_ I-GENE
viruses O
belong O
to O
the O
same O
_RARE_ I-GENE
virus I-GENE
genus O
, O
these O
viruses O
show O
marked O
differences O
with O
respect O
to O
functional O
requirements O
for O
the O
cytoplasmic I-GENE
tail O
of O
the O
F I-GENE
glycoprotein I-GENE
. O

By O
site I-GENE
- I-GENE
specific I-GENE
mutagenesis O
, O
we O
also O
show O
that O
individual O
_RARE_ I-GENE
C I-GENE
- I-GENE
terminal I-GENE
amino O
acid I-GENE
residues O
that O
are O
_RARE_ I-GENE
conserved O
in O
_RARE_ I-GENE
homologs I-GENE
in O
other O
_RARE_ I-GENE
( O
D I-GENE
- I-GENE
_RARE_ I-GENE
, O
E I-GENE
- I-GENE
_RARE_ I-GENE
, O
H I-GENE
- I-GENE
_RARE_ I-GENE
, O
C I-GENE
- I-GENE
400 O
, O
C I-GENE
- I-GENE
_RARE_ I-GENE
, O
and O
C I-GENE
- I-GENE
_RARE_ I-GENE
) O
are O
critical O
for O
trans O
- I-GENE
regulatory I-GENE
activity O
. O

Magnetic O
resonance O
imaging O
( O
MRI O
) O
has O
_RARE_ I-GENE
us O
to O
_RARE_ I-GENE
the O
spinal O
_RARE_ I-GENE
pathology O
as O
differences O
in O
signal I-GENE
intensity O
. O

Patients O
with O
_RARE_ I-GENE
drugs O
showed O
significantly O
higher O
PRL I-GENE
levels O
. O

The O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
enables O
a O
_RARE_ I-GENE
- I-GENE
based O
examination O
and O
therefore O
allows O
_RARE_ I-GENE
comparison O
between O
morphologic O
appearance O
and O
corresponding O
function O
. O

_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
and O
HIV I-GENE
- I-GENE
1 I-GENE
transmission O
in O
central O
_RARE_ I-GENE
. O

_RARE_ I-GENE
and O
_RARE_ I-GENE
. O

In O
addition O
, O
two O
- I-GENE
dimensional O
nuclear I-GENE
magnetic O
resonance O
studies O
with O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
and O
_RARE_ I-GENE
revealed O
that O
the O
mutants I-GENE
have O
the O
same O
overall O
structure O
as O
the O
wild I-GENE
- I-GENE
type I-GENE
_RARE_ I-GENE
protein I-GENE
. O

_RARE_ I-GENE
high O
levels O
of O
IgE I-GENE
antibodies I-GENE
was O
also O
established O
while O
other O
_RARE_ I-GENE
did O
not O
show O
such O
_RARE_ I-GENE
. O

_RARE_ I-GENE
proliferator I-GENE
- I-GENE
activated I-GENE
receptors I-GENE
( O
_RARE_ I-GENE
) O
and O
retinoid I-GENE
X I-GENE
receptors I-GENE
( O
_RARE_ I-GENE
) O
are O
nuclear I-GENE
hormone I-GENE
receptors I-GENE
that O
are O
activated I-GENE
by O
fatty I-GENE
acids O
and O
9 O
- I-GENE
cis O
- I-GENE
retinoic I-GENE
acid I-GENE
, O
respectively O
. O

This O
is O
particularly O
_RARE_ I-GENE
because O
_RARE_ I-GENE
- I-GENE
1B I-GENE
- I-GENE
20 O
cells O
lack O
the O
transcription I-GENE
factor I-GENE
Pit I-GENE
- I-GENE
1 I-GENE
. O

The O
number O
of O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
was O
not O
altered O
compared O
with O
controls O
, O
indicating O
that O
in O
the O
adult O
pituitary I-GENE
, O
_RARE_ I-GENE
products I-GENE
are O
not O
required O
to O
maintain O
the O
distribution O
of O
cell O
types O
. O

Some O
strains O
of O
A I-GENE
. O
_RARE_ I-GENE
produced O
all O
four O
_RARE_ I-GENE
B1 I-GENE
B2 I-GENE
G1 I-GENE
G2 I-GENE
, O
while O
the O
other O
ones O
produced O
AF I-GENE
B1 I-GENE
+ I-GENE
G1 I-GENE
only O
, O
with O
concentrations O
of O
_RARE_ I-GENE
from O
0 O
. O
1 I-GENE
to O
450 I-GENE
mg O
/ I-GENE
kg O
. O

We O
have O
isolated O
a O
new O
, O
larger O
rat I-GENE
B I-GENE
- I-GENE
myc I-GENE
genomic O
clone O
. O

In O
addition O
to O
the O
nine O
and O
51 O
terminal I-GENE
amino O
acid I-GENE
forms O
already O
known O
, O
we O
identified O
a O
third O
with O
43 I-GENE
terminal I-GENE
amino O
acids O
predicted O
to O
encode O
a O
novel O
RET I-GENE
protein I-GENE
isoform I-GENE
. O

Both O
classes O
of O
_RARE_ I-GENE
proteins I-GENE
were O
found O
to O
form O
dimers I-GENE
; O
an O
which O
is O
involved O
in O
mediating O
the O
dimerization O
. O

In O
electrophoretic O
mobility I-GENE
shift O
assays O
, O
the O
_RARE_ I-GENE
formed O
three O
major I-GENE
complexes I-GENE
( O
P1 I-GENE
, O
P2 I-GENE
and O
P3 I-GENE
) O
with O
proteins I-GENE
in O
nuclear I-GENE
extracts O
from O
HeLa O
or O
293 O
cells O
. O

_RARE_ I-GENE
had O
been O
receiving O
_RARE_ I-GENE
7 O
. O
5 I-GENE
mg O
/ I-GENE
week O
for O
2 I-GENE
. O
5 I-GENE
months O
because O
of O
her I-GENE
vasculitis O
symptoms O
. O

Analysis O
of O
the O
sequence I-GENE
identified O
four O
open O
reading O
frames O
( O
ORFs O
) O
which O
are O
designated O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
. O
5 I-GENE
based O
on O
their O
homology I-GENE
with O
proteins I-GENE
of O
herpes I-GENE
simplex I-GENE
virus I-GENE
- I-GENE
1 I-GENE
( O
HSV I-GENE
- I-GENE
1 I-GENE
), O
pseudorabies O
virus I-GENE
( O
_RARE_ I-GENE
), O
equine I-GENE
herpesvirus I-GENE
- I-GENE
1 I-GENE
, O
and O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
virus I-GENE
. O

These O
_RARE_ I-GENE
E6 I-GENE
/ I-GENE
E7 I-GENE
cDNAs I-GENE
were O
cloned O
under O
the O
SV40 I-GENE
enhancer I-GENE
/ I-GENE
promoter I-GENE
and O
the O
MMTV I-GENE
LTR I-GENE
to O
examine O
the O
activities O
of O
ras I-GENE
- I-GENE
_RARE_ I-GENE
transformation O
and O
induction O
of O
cellular O
DNA I-GENE
synthesis O
, O
both O
of O
which O
depend O
on O
the O
E7 I-GENE
gene I-GENE
product I-GENE
. O

_RARE_ I-GENE
coefficients O
between O
the O
reference O
methods O
and O
_RARE_ I-GENE
were O
> O
or O
= O
0 O
. O
95 O
for O
water O
, O
fat O
, O
crude O
protein I-GENE
and O
connective O
- I-GENE
tissue I-GENE
- I-GENE
protein I-GENE
_RARE_ I-GENE
meat O
protein I-GENE
, O
and O
> O
or O
= O
0 O
. O
86 I-GENE
for O
connective O
- I-GENE
tissue I-GENE
- I-GENE
protein I-GENE
. O

The O
translation I-GENE
products I-GENE
of O
both O
clones O
are O
highly O
homologous O
to O
_RARE_ I-GENE
( O
66 O
and O
86 I-GENE
% O
identity O
, O
respectively O
) O
over O
their O
entire O
lengths O
, O
including O
amino O
terminal I-GENE
sequences I-GENE
resembling O
transit O
peptides I-GENE
for O
_RARE_ I-GENE
localization O
. O

The O
serum I-GENE
levels O
of O
IgE I-GENE
, O
and O
_RARE_ I-GENE
and O
IgG I-GENE
- I-GENE
4 I-GENE
against O
14 O
common O
food O
allergens O
were O
determined O
. O

Two O
experiments O
_RARE_ I-GENE
the O
effects O
of O
short O
- I-GENE
term O
_RARE_ I-GENE
on O
_RARE_ I-GENE
bone O
turnover O
were O
carried O
out O
: O
_RARE_ I-GENE
_RARE_ I-GENE
Experiment O
- I-GENE
1 I-GENE
( O
_RARE_ I-GENE
- I-GENE
1 I-GENE
) O
( O
a O
4 I-GENE
- I-GENE
d O
_RARE_ I-GENE
_RARE_ I-GENE
) O
and O
_RARE_ I-GENE
- I-GENE
2 I-GENE
( O
a O
10 O
- I-GENE
d O
_RARE_ I-GENE
). O

_RARE_ I-GENE
sequence I-GENE
strongly O
promoted O
the O
transcription I-GENE
of O
the O
_RARE_ I-GENE
chloramphenicol I-GENE
_RARE_ I-GENE
( O
CAT I-GENE
) O
gene I-GENE
in O
cells O
of O
pancreatic O
origin O
( O
AR I-GENE
- I-GENE
_RARE_ I-GENE
) O
but O
not O
in O
cells O
of O
non O
- I-GENE
pancreatic O
origin O
( O
Rat I-GENE
2 I-GENE
and O
_RARE_ I-GENE
6 I-GENE
). O

Functional O
analysis O
of O
_RARE_ I-GENE
hydrocarbon I-GENE
receptor I-GENE
nuclear I-GENE
_RARE_ I-GENE
interactions O
with O
_RARE_ I-GENE
hydrocarbon I-GENE
receptor I-GENE
in O
the O
yeast I-GENE
two O
- I-GENE
hybrid O
system O
. O

_RARE_ I-GENE
observations O
showed O
that O
both O
somatostatin I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
reduced O
the O
inflammatory O
signs O
in O
the O
joint O
structures O
, O
although O
_RARE_ I-GENE
_RARE_ I-GENE
appeared O
to O
be O
more O
effective O
. O

An O
approach O
to O
a O
_RARE_ I-GENE
model O
of O
_RARE_ I-GENE
. O

The O
influenza I-GENE
virus I-GENE
NS1 I-GENE
protein I-GENE
is O
a O
unique O
posttranscriptional O
regulator I-GENE
that O
has O
two O
activities O
: O
inhibition O
of O
the O
nuclear I-GENE
export O
of O
poly O
A I-GENE
- I-GENE
containing O
mRNAs I-GENE
and O
inhibition O
of O
pre I-GENE
- I-GENE
mRNA I-GENE
splicing O
. O

These O
are O
two O
regions O
of O
known O
conserved O
_RARE_ I-GENE
, O
providing O
further O
evidence O
that O
the O
human I-GENE
_RARE_ I-GENE
is O
a O
true O
homolog I-GENE
of O
the O
murine I-GENE
_RARE_ I-GENE
gene I-GENE
. O

Molecular O
cloning O
of O
the O
human I-GENE
homolog I-GENE
of O
a O
striatum I-GENE
- I-GENE
enriched O
phosphatase I-GENE
( O
_RARE_ I-GENE
) O
gene I-GENE
and O
chromosomal I-GENE
mapping O
of O
the O
human I-GENE
and O
murine I-GENE
loci I-GENE
. O

_RARE_ I-GENE
anhydrase I-GENE
V I-GENE
( O
CA I-GENE
V I-GENE
) O
is O
expressed O
in O
mitochondrial I-GENE
matrix I-GENE
in O
liver O
and O
several O
other O
tissues O
. O

_RARE_ I-GENE
D3 I-GENE
plus O
nicotine O
treatment O
produced O
parallel O
increases O
in O
cardiac O
mass O
and O
elastic O
_RARE_ I-GENE
, O
with O
a O
significant O
correlation O
between O
the O
two O
. O

The O
latter O
domain I-GENE
appears O
to O
be O
involved O
in O
targeting O
_RARE_ I-GENE
to O
the O
_RARE_ I-GENE
cell O
cortex O
. O

This O
finding O
is O
consistent O
with O
the O
notion O
that O
the O
dsRNA I-GENE
binding I-GENE
domains I-GENE
may O
be O
composed O
of O
two O
separate O
functional O
subdomains O
. O

_RARE_ I-GENE
heterodimeric I-GENE
parallel O
coiled O
- I-GENE
coil O
formation O
by O
synthetic O
Max I-GENE
and O
c I-GENE
- I-GENE
Myc I-GENE
leucine I-GENE
zippers I-GENE
: O
a O
description O
of O
putative O
_RARE_ I-GENE
interactions O
responsible O
for O
the O
specificity O
of O
heterodimerization O
. O

Comparison O
to O
other O
_RARE_ I-GENE
genes I-GENE
revealed O
a O
_RARE_ I-GENE
- I-GENE
bp O
group O
I I-GENE
intron O
, O
which O
, O
based O
on O
homology I-GENE
with O
the O
related I-GENE
yeast I-GENE
_RARE_ I-GENE
intron O
_RARE_ I-GENE
, O
potentially O
encodes O
a O
_RARE_ I-GENE
- I-GENE
amino O
- I-GENE
acid I-GENE
site I-GENE
- I-GENE
specific I-GENE
DNA I-GENE
endonuclease I-GENE
. O

We O
studied O
the O
GR I-GENE
in O
_RARE_ I-GENE
- I-GENE
79 O
cells O
derived O
from O
a O
human I-GENE
ACTH I-GENE
- I-GENE
secreting O
small I-GENE
cell O
lung O
cancer O
. O

This O
study O
analyzed O
whether O
the O
localization O
of O
an O
accessory I-GENE
pathway O
could O
be O
predicted O
by O
using O
the O
polarity O
of O
the O
QRS O
complex I-GENE
during O
sinus O
rhythm O
on O
the O
surface O
ECG O
, O
instead O
of O
the O
delta I-GENE
wave O
polarity O
as O
used O
in O
many O
reports O
. O

The O
promoter I-GENE
mutation I-GENE
is O
complemented O
in O
trans O
by O
E1A I-GENE
products I-GENE
of O
the O
heterologous O
_RARE_ I-GENE
adenovirus I-GENE
type I-GENE
5 I-GENE
( O
Ad5 I-GENE
). O

Thus O
, O
as O
expected O
, O
trans O
- I-GENE
splicing O
depends O
on O
the O
integrity O
of O
U2 I-GENE
, O
U4 I-GENE
, O
and O
U6 I-GENE
_RARE_ I-GENE
. O

Treatment O
of O
_RARE_ I-GENE
. O
_RARE_ I-GENE
cells O
with O
an O
RAR I-GENE
- I-GENE
selective O
agonist O
also O
repressed O
the O
expression O
of O
EC I-GENE
- I-GENE
1 I-GENE
mRNA I-GENE
while O
treatment O
with O
an O
RXR I-GENE
- I-GENE
selective O
agonist O
reduced O
EC I-GENE
- I-GENE
1 I-GENE
expression O
slightly O
. O

In O
the O
absence O
of O
_RARE_ I-GENE
, O
YY1 I-GENE
represses O
CRE O
- I-GENE
dependent I-GENE
transcription I-GENE
of O
c I-GENE
- I-GENE
fos I-GENE
by O
physically O
interacting I-GENE
with O
ATF I-GENE
/ I-GENE
CREB I-GENE
proteins I-GENE
bound O
to O
the O
- I-GENE
67 O
CRE O
. O

_RARE_ I-GENE
- I-GENE
down O
experiments O
indicated O
that O
the O
10 O
( O
4 I-GENE
)- I-GENE
to O
10 O
( O
5 I-GENE
)- I-GENE
fold O
reduction O
in O
virus I-GENE
yield O
at O
the O
_RARE_ I-GENE
temperature O
was O
due O
to O
the O
_RARE_ I-GENE
of O
alpha I-GENE
TIF I-GENE
late O
in O
infection O
, O
presumably O
in O
virion O
maturation O
. O

These O
results O
demonstrate O
that O
tip O
acts O
at O
an O
early I-GENE
stage O
of O
the O
T I-GENE
- I-GENE
cell O
signal I-GENE
transduction O
cascade O
by O
_RARE_ I-GENE
with O
Lck I-GENE
and O
_RARE_ I-GENE
Lck I-GENE
- I-GENE
mediated O
activation O
. O

Human I-GENE
immunodeficiency I-GENE
virus I-GENE
type I-GENE
1 I-GENE
_RARE_ I-GENE
is O
a O
virion O
- I-GENE
associated I-GENE
, O
regulatory I-GENE
protein I-GENE
that O
is O
required O
for O
efficient O
viral I-GENE
replication O
in O
monocytes O
/ I-GENE
macrophages O
. O

Here O
we O
examine O
the O
potential O
for O
VP16 I-GENE
protein I-GENE
- I-GENE
protein I-GENE
interactions O
specific I-GENE
to O
virus I-GENE
- I-GENE
infected O
cells O
and O
show O
that O
VP16 I-GENE
_RARE_ I-GENE
in O
a O
highly O
enriched O
fraction O
with O
a O
single O
major I-GENE
polypeptide I-GENE
which O
we O
identify O
as O
the O
virus I-GENE
- I-GENE
encoded I-GENE
structural O
protein I-GENE
_RARE_ I-GENE
. O

Thus O
, O
transcriptional O
regulation O
, O
splicing O
, O
kinase I-GENE
interaction O
sites I-GENE
, O
and O
tyrosine I-GENE
phosphorylation O
of O
the O
_RARE_ I-GENE
homologs I-GENE
have O
been O
conserved O
despite O
significant O
sequences I-GENE
heterogeneity O
in O
the O
_RARE_ I-GENE
repeat I-GENE
regions O
of O
these O
human I-GENE
and O
_RARE_ I-GENE
primate O
_RARE_ I-GENE
. O

Results O
of O
the O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
Study O
Group O
. O

Therefore O
, O
a O
prospective O
Phase O
II I-GENE
trial O
was O
conducted O
to O
determine O
the O
safety O
and O
efficacy O
of O
_RARE_ I-GENE
following O
radiation O
therapy O
in O
men O
with O
local O
recurrence O
. O

These O
motifs O
include O
a O
Chi O
motif I-GENE
and O
a O
Chi O
- I-GENE
like I-GENE
element I-GENE
previously O
found O
in O
the O
recombination O
_RARE_ I-GENE
region O
of O
the O
Bcl I-GENE
- I-GENE
2 I-GENE
proto I-GENE
- I-GENE
oncogene I-GENE
and O
close O
to O
chromosomal I-GENE
breakpoints O
in O
T I-GENE
- I-GENE
ALL O
lines O
. O

_RARE_ I-GENE
history O
and O
_RARE_ I-GENE
in O
surgical O
_RARE_ I-GENE
of O
the O
_RARE_ I-GENE
and O
the O
_RARE_ I-GENE
University O
_RARE_ I-GENE

In O
contrast O
with O
the O
previously O
reported O
_RARE_ I-GENE
mRNA I-GENE
( O
_RARE_ I-GENE
mRNA I-GENE
), O
which O
is O
detected O
at O
high O
levels O
in O
all O
tissues O
of O
the O
plant O
, O
_RARE_ I-GENE
mRNA I-GENE
is O
present O
at O
relatively O
low O
levels O
and O
its O
expression O
is O
restricted O
mostly O
to O
seedlings O
, O
roots O
and O
_RARE_ I-GENE
. O

However O
, O
the O
requirement O
of O
_RARE_ I-GENE
for O
the O
production O
of O
G I-GENE
. O
C I-GENE
--> I-GENE
T I-GENE
. O
A I-GENE
_RARE_ I-GENE
by O
the O
_RARE_ I-GENE
_RARE_ I-GENE
, O
which O
induces O
only O
these O
substitutions O
, O
was O
similar O
to O
that O
for O
_RARE_ I-GENE
- I-GENE
mediated O
G I-GENE
. O
C I-GENE
--> I-GENE
T I-GENE
. O
A I-GENE
transversion O
. O

The O
second O
mutation I-GENE
present O
in O
the O
original O
mutant I-GENE
proved O
to O
be O
an O
allele I-GENE
of O
a O
known O
gene I-GENE
, O
_RARE_ I-GENE
, O
which O
encodes O
a O
putative O
protein I-GENE
kinase I-GENE
that O
functions O
in O
the O
high O
_RARE_ I-GENE
stress O
pathway O
. O

In O
adult O
tissues O
, O
it O
was O
less O
restricted O
, O
indicating O
that O
_RARE_ I-GENE
expression O
is O
developmentally O
up O
- I-GENE
regulated O
. O

As O
_RARE_ I-GENE
- I-GENE
CSF I-GENE
receptor I-GENE
( O
_RARE_ I-GENE
) O
does O
not O
contain O
a O
consensus I-GENE
sequence I-GENE
for O
binding I-GENE
of O
PI I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
, O
_RARE_ I-GENE
must O
use O
a O
distinct O
mechanism O
for O
its O
association O
with O
and O
activation O
of O
PI I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
. O

J O
. O

The O
identity O
between O
_RARE_ I-GENE
H I-GENE
and O
H I-GENE
' O
is O
96 O
%, O
between O
H I-GENE
and O
F I-GENE
78 O
%, O
and O
between O
H I-GENE
' O
and O
F I-GENE
75 O
%, O
respectively O
. O

_RARE_ I-GENE
has O
two O
potential O
coiled O
- I-GENE
coil O
regions O
, O
a O
basic I-GENE
region O
, O
a O
proline O
- I-GENE
rich O
region O
, O
a O
histidine O
- I-GENE
rich O
N I-GENE
terminus O
, O
and O
a O
nuclear I-GENE
targeting O
sequence I-GENE
. O

In O
the O
present O
study O
, O
we O
transiently O
expressed O
in O
primary O
cultures O
of O
rat I-GENE
hepatocytes O
plasmids O
consisting O
of O
_RARE_ I-GENE
5 I-GENE
'- O
flanking O
sequences I-GENE
fused O
to O
a O
chloramphenicol I-GENE
acetyltransferase I-GENE
reporter I-GENE
plasmid O
. O

We O
show O
that O
stimulation O
of O
resting O
splenic O
B I-GENE
cells O
with O
_RARE_ I-GENE
- I-GENE
expressing O
Sf9 O
cells O
induces O
germ I-GENE
- I-GENE
line O
gamma I-GENE
1 I-GENE
and O
epsilon I-GENE
transcripts I-GENE
independently O
of O
cytokines O
. O

To O
confirm O
the O
_RARE_ I-GENE
protein I-GENE
activity O
, O
constructs I-GENE
containing O
different O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
domains I-GENE
were O
transformed O
into O
_RARE_ I-GENE
mutant I-GENE
yeast I-GENE
to O
determine O
their O
relative O
ability O
to O
replace O
_RARE_ I-GENE
functionally O
. O

At O
the O
time O
of O
the O
13 O
_RARE_ I-GENE
_RARE_ I-GENE
, O
age O
ranged O
from O
three O
days O
to O
13 O
. O
1 I-GENE
years O
( O
mean O
5 I-GENE
. O
7 O
+/- O
SD O
4 I-GENE
. O
8 O
years O
). O

A I-GENE
tobacco I-GENE
homologue I-GENE
( O
_RARE_ I-GENE
) O
of O
the O
_RARE_ I-GENE
gene I-GENE
of O
the O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
- I-GENE
plasmid O
was O
cloned O
and O
sequenced O
from O
_RARE_ I-GENE
_RARE_ I-GENE
L I-GENE
. O
cv O
. O

High O
ADR1 I-GENE
gene I-GENE
dosage O
increased O
the O
transcription I-GENE
of O
genes I-GENE
encoding O
_RARE_ I-GENE
proteins I-GENE
as O
compared O
to O
one O
copy O
of O
the O
ADR1 I-GENE
gene I-GENE
. O

A I-GENE
water O
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
in O
the O
active O
_RARE_ I-GENE
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
. O

Of O
the O
three O
known O
C I-GENE
/ I-GENE
EBP I-GENE
family I-GENE
inhibitors O
, O
Ig I-GENE
/ I-GENE
EBP I-GENE
, O
_RARE_ I-GENE
and O
CHOP I-GENE
- I-GENE
10 O
, O
only O
Ig I-GENE
/ I-GENE
EBP I-GENE
is O
ubiquitously O
expressed O
. O

The O
effects O
of O
a O
1 I-GENE
- I-GENE
or O
24 O
- I-GENE
hour O
pretreatment O
regimen O
with O
_RARE_ I-GENE
lipid O
A I-GENE
( O
_RARE_ I-GENE
, O
35 O
micrograms O
/ I-GENE
kg O
i O
. O
v I-GENE
.) O
on O
myocardial O
_RARE_ I-GENE
produced O
by O
repetitive O
coronary O
_RARE_ I-GENE
were O
studied O
in O
_RARE_ I-GENE
- I-GENE
anesthetized O
dogs O
. O

These O
_RARE_ I-GENE
were O
studied O
by O
scanning O
electron O
microscopy O
- I-GENE
energy O
_RARE_ I-GENE
spectroscopy O
analysis O
( O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
) O
and O
light I-GENE
microscopy O
to O
examine O
the O
_RARE_ I-GENE
lines O
of O
_RARE_ I-GENE
in O
the O
rat I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
dentin O
. O

A I-GENE
platelet I-GENE
- I-GENE
derived O
growth I-GENE
factor I-GENE
receptor I-GENE
( O
PDGF I-GENE
- I-GENE
R I-GENE
) O
phosphopeptide I-GENE
containing O
Tyr I-GENE
- I-GENE
_RARE_ I-GENE
does O
not O
bind O
_RARE_ I-GENE
to O
the O
Src I-GENE
SH2 I-GENE
domain I-GENE
, O
suggesting O
it O
is O
not O
the O
PDGF I-GENE
- I-GENE
R I-GENE
binding I-GENE
site I-GENE
for O
Src I-GENE
as O
previously O
reported O
. O

We O
have O
also O
tested O
Src I-GENE
SH2 I-GENE
mutants I-GENE
for O
their O
binding I-GENE
properties O
and O
have O
interpreted O
our O
results O
in O
light I-GENE
of O
the O
recent O
crystal O
structure O
solution O
for O
the O
Src I-GENE
SH2 I-GENE
domain I-GENE
. O

These O
observations O
link I-GENE
actin I-GENE
plaque O
assembly O
to O
increased O
cell O
substrate I-GENE
adhesion I-GENE
. O

The O
early I-GENE
lethality O
of O
the O
left O
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
was O
0 O
% O
and O
the O
postoperative O
survival O
-- O
5 I-GENE
- I-GENE
10 O
months O
. O

There O
are O
two O
_RARE_ I-GENE
sites I-GENE
on O
the O
type I-GENE
A I-GENE
influenza I-GENE
A I-GENE
/ I-GENE
Japan O
/ I-GENE
57 O
( O
_RARE_ I-GENE
) O
hemagglutinin I-GENE
( O
HA I-GENE
) O
that O
can O
be O
recognized O
by O
class I-GENE
I I-GENE
major I-GENE
histocompatibility I-GENE
complex I-GENE
( O
MHC I-GENE
), O
H I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
restricted O
_RARE_ I-GENE
T I-GENE
lymphocytes O
( O
_RARE_ I-GENE
). O

This O
enhancer I-GENE
activates O
both O
the O
_RARE_ I-GENE
and O
TK I-GENE
basal O
promoters I-GENE
in O
HeLa O
cells O
. O

Mechanism O
of O
enhancement O
of O
DNA I-GENE
expression O
_RARE_ I-GENE
to O
_RARE_ I-GENE
of O
a O
replication O
- I-GENE
deficient O
adenovirus I-GENE
and O
_RARE_ I-GENE
plasmid O
DNA I-GENE
. O

Interestingly O
, O
one O
IRF I-GENE
binding I-GENE
site I-GENE
was O
found O
within O
the O
IRF I-GENE
- I-GENE
2 I-GENE
promoter I-GENE
, O
and O
expression O
of O
the O
IRF I-GENE
- I-GENE
2 I-GENE
gene I-GENE
was O
affected O
by O
both O
transient O
and O
stable O
IRF I-GENE
- I-GENE
1 I-GENE
expression O
. O

Therefore O
, O
we O
studied O
_RARE_ I-GENE
_RARE_ I-GENE
patients O
with O
the O
aim O
of O
determining O
the O
prevalence O
of O
hepatitis I-GENE
C I-GENE
virus I-GENE
( O
HCV I-GENE
) O
antibodies I-GENE
using O
the O
ELISA O
and O
_RARE_ I-GENE
methods O
. O

The O
highest O
decrease O
in O
_RARE_ I-GENE
activity O
was O
observed O
when O
enzymatic O
_RARE_ I-GENE
was O
used O
together O
with O
_RARE_ I-GENE
. O

Hepatitis I-GENE
B I-GENE
surface O
antigen I-GENE
was O
detected O
in O
2 I-GENE
patients O
, O
with O
negative O
hepatitis I-GENE
C I-GENE
virus I-GENE
antibody I-GENE
. O

There O
was O
also O
a O
highly O
significant O
correlation O
between O
total O
selenium O
intake O
and O
liver O
selenium O
concentration O
( O
r O
= O
0 O
. O
99 O
, O
p O
< O
0 O
. O
01 O
) O
after O
1 I-GENE
mo O
of O
treatment O
, O
but O
this O
time O
liver O
selenium O
did O
not O
change O
with O
time O
, O
and O
the O
correlation O
remained O
highly O
significant O
throughout O
the O
investigation O
. O

Antibodies O
affinity O
- I-GENE
purified O
using O
the O
bacterially O
expressed O
recombinant I-GENE
protein I-GENE
recognized O
the O
_RARE_ I-GENE
_RARE_ I-GENE
in O
a O
HeLa O
cell O
extract O
. O
cDNA I-GENE
sequencing O
revealed O
that O
the O
_RARE_ I-GENE
cDNA I-GENE
shares O
a O
high O
degree O
of O
homology I-GENE
in O
both O
nucleotide I-GENE
( O
87 O
%) O
and O
amino O
acid I-GENE
sequence I-GENE
( O
92 O
. O
5 I-GENE
%) O
with O
bovine I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
, O
indicating O
that O
the O
_RARE_ I-GENE
cDNA I-GENE
encodes O
the O
human I-GENE
homologue I-GENE
of O
_RARE_ I-GENE
_RARE_ I-GENE
, O
a O
member O
of O
the O
Ca I-GENE
( O
2 I-GENE
+)- I-GENE
dependent I-GENE
phospholipid I-GENE
binding I-GENE
protein I-GENE
family I-GENE
. O

The O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
complex I-GENE
peroxidase I-GENE
( O
_RARE_ I-GENE
- I-GENE
P I-GENE
) O
method O
was O
used O
to O
detect O
Mycobacterium O
_RARE_ I-GENE
, O
and O
the O
results O
were O
compared O
with O
those O
obtained O
by O
the O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
technique O
. O

Its O
role O
in O
these O
processes O
suggests O
that O
the O
function O
of O
c I-GENE
- I-GENE
Myb I-GENE
may O
be O
important O
early I-GENE
in O
the O
establishment O
of O
the O
hematopoietic I-GENE
lineage O
. O

The O
transforming I-GENE
gene I-GENE
of O
the O
avian I-GENE
sarcoma I-GENE
virus I-GENE
_RARE_ I-GENE
encodes O
a O
fusion I-GENE
protein I-GENE
( O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
or O
v I-GENE
- I-GENE
Crk I-GENE
) O
containing O
viral I-GENE
Gag I-GENE
sequences I-GENE
fused O
to O
cellular O
sequences I-GENE
consisting O
primarily O
of O
Src I-GENE
homology I-GENE
regions O
2 I-GENE
and O
3 I-GENE
( O
SH2 I-GENE
and O
SH3 I-GENE
sequences I-GENE
). O

This O
specific I-GENE
methylation O
pattern O
caused O
inactivation O
of O
the O
HSV I-GENE
tk I-GENE
gene I-GENE
, O
while O
methylation O
of O
the O
cytosine O
residues O
within O
the O
nucleotide I-GENE
sequence I-GENE
from O
+ I-GENE
_RARE_ I-GENE
to O
+ I-GENE
_RARE_ I-GENE
had O
no O
effect O
on O
HSV I-GENE
tk I-GENE
gene I-GENE
activity O
. O

CONCLUSION O
: O
This O
study O
_RARE_ I-GENE
that O
regression O
of O
_RARE_ I-GENE
_RARE_ I-GENE
that O
occurred O
with O
alpha I-GENE
interferon I-GENE
treatment O
was O
minimal I-GENE
. O

_RARE_ I-GENE
- I-GENE
range O
mapping O
of O
the O
_RARE_ I-GENE
region O
involved O
in O
chromosome O
_RARE_ I-GENE
in O
human I-GENE
tumors O
by O
pulsed O
- I-GENE
field O
gel O
electrophoresis O
with O
a O
yeast I-GENE
artificial O
chromosome O
. O

_RARE_ I-GENE
, O
TRE I-GENE
, O
and O
CRE O
oligonucleotides O
all O
compete O
more O
efficiently O
for O
protein I-GENE
binding I-GENE
to O
their O
labeled O
_RARE_ I-GENE
than O
for O
protein I-GENE
binding I-GENE
to O
either O
of O
the O
other O
labeled O
oligonucleotides O
, O
suggesting O
that O
the O
_RARE_ I-GENE
, O
TRE I-GENE
, O
and O
CRE O
oligonucleotides O
, O
suggesting O
that O
the O
_RARE_ I-GENE
, O
TRE I-GENE
, O
and O
CRE O
oligonucleotides O
each O
bind O
unique O
as O
well O
as O
common O
proteins I-GENE
, O
likely O
to O
be O
members O
of O
the O
Jun I-GENE
/ I-GENE
Fos I-GENE
and O
cAMP I-GENE
- I-GENE
responsive I-GENE
element I-GENE
- I-GENE
binding I-GENE
protein I-GENE
/ I-GENE
activating I-GENE
transcription I-GENE
factors I-GENE
( O
CREB I-GENE
/ I-GENE
ATF I-GENE
) O
families O
of O
transcription I-GENE
factors I-GENE
, O
in O
_RARE_ I-GENE
cells O
. O

One O
patient O
only O
had O
any O
test O
abnormalities O
. O

One O
antibody I-GENE
, O
_RARE_ I-GENE
, O
and O
a O
synthetic O
peptide I-GENE
_RARE_ I-GENE
its O
epitope O
selectively O
inhibited O
in O
vitro O
transcription I-GENE
from O
TATA I-GENE
- I-GENE
containing O
, O
but O
not O
from O
TATA I-GENE
- I-GENE
less O
promoters I-GENE
, O
irrespective O
of O
whether O
they O
were O
transcribed O
by O
Pol I-GENE
II I-GENE
or O
Pol I-GENE
III I-GENE
. O

The O
lymph O
nodes O
from O
two O
of O
the O
patients O
with O
rheumatoid I-GENE
arthritis O
contained O
numerous O
_RARE_ I-GENE
like I-GENE
_RARE_ I-GENE
, O
further O
indicating O
a O
possible O
association O
between O
_RARE_ I-GENE
and O
rheumatoid I-GENE
arthritis O
. O

HCV I-GENE
infection O
acquired O
during O
or O
after O
_RARE_ I-GENE
caused O
only O
mild O
acute O
hepatitis I-GENE
C I-GENE
, O
which O
progressed O
to O
chronic O
hepatitis I-GENE
C I-GENE
in O
one O
patient O
_RARE_ I-GENE
10 O
years O
after O
_RARE_ I-GENE
. O

Hepatitis I-GENE
C I-GENE
virus I-GENE
infection O
is O
a O
risk O
factor I-GENE
for O
liver O
failure O
from O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
disease O
after O
bone O
marrow O
transplantation O
. O

High O
plasma I-GENE
concentrations O
of O
soluble I-GENE
E I-GENE
- I-GENE
selectin I-GENE
were O
closely O
associated I-GENE
with O
multiple O
- I-GENE
organ O
dysfunction O
and O
death O
. O

These O
human I-GENE
IFN I-GENE
- I-GENE
beta I-GENE
- I-GENE
transformed O
cell O
populations O
have O
acquired O
a O
low O
, O
constitutive O
production O
of O
human I-GENE
IFN I-GENE
, O
while O
replicating I-GENE
at O
a O
rate O
similar O
to O
that O
of O
_RARE_ I-GENE
cells O
and O
of O
cells O
transformed O
with O
the O
control O
vector O
carrying O
a O
human I-GENE
IFN I-GENE
- I-GENE
beta I-GENE
sequence I-GENE
encoding O
an O
inactive O
, O
mutated O
protein I-GENE
. O

_RARE_ I-GENE
of O
the O
_RARE_ I-GENE
tract O
also O
increased O
the O
splicing O
efficiency O
, O
but O
to O
a O
degree O
slightly O
less O
than O
that O
obtained O
with O
the O
branchpoint O
mutation I-GENE
. O

Liver O
transplantation O
in O
one O
patient O
resolved O
metabolic O
complications O
but O
did O
not O
improve O
PMN I-GENE
count O
or O
the O
infectious O
status O
, O
while O
neutropenia O
was O
corrected O
by O
G I-GENE
- I-GENE
CSF I-GENE
. O

_RARE_ I-GENE
and O
F I-GENE
. O

Activation O
of O
the O
SH2 I-GENE
- I-GENE
containing O
protein I-GENE
tyrosine I-GENE
phosphatase I-GENE
, O
SH I-GENE
- I-GENE
_RARE_ I-GENE
, O
by O
phosphotyrosine I-GENE
- I-GENE
containing O
peptides I-GENE
derived O
from O
insulin I-GENE
receptor I-GENE
substrate I-GENE
- I-GENE
1 I-GENE
. O

Tyrosine I-GENE
phosphorylation O
of O
cellular O
proteins I-GENE
is O
the O
_RARE_ I-GENE
_RARE_ I-GENE
event O
following O
T I-GENE
- I-GENE
cell O
antigen I-GENE
receptor I-GENE
( O
TCR I-GENE
) O
stimulation O
and O
is O
essential O
for O
activating I-GENE
downstream O
signaling O
machinery O
. O

The O
interferon I-GENE
- I-GENE
induced O
RNA I-GENE
- I-GENE
dependent I-GENE
protein I-GENE
kinase I-GENE
( O
PKR I-GENE
) O
is O
considered O
to O
play O
an O
important O
role O
in O
the O
cellular O
defense O
against O
viral I-GENE
infection O
and O
, O
in O
addition O
, O
has O
been O
suggested O
to O
be O
a O
tumor I-GENE
suppressor I-GENE
gene I-GENE
because O
of O
its O
growth I-GENE
- I-GENE
_RARE_ I-GENE
properties O
. O

Moreover O
, O
Lck I-GENE
was O
_RARE_ I-GENE
co O
- I-GENE
immunoprecipitated O
with O
_RARE_ I-GENE
, O
and O
the O
_RARE_ I-GENE
of O
binding I-GENE
increased O
in O
anti I-GENE
- I-GENE
CD3 I-GENE
- I-GENE
treated O
Jurkat O
cells O
. O

In O
contrast O
, O
injection O
of O
a O
plasmid O
encoding O
simian I-GENE
virus I-GENE
40 I-GENE
small I-GENE
t I-GENE
antigen I-GENE
, O
which O
interacts O
with O
PP2A I-GENE
to O
inhibit O
its O
activity O
towards O
several O
phosphoprotein I-GENE
substrates O
, O
had O
no O
effect O
on O
the O
phosphorylation O
state O
of O
CREB I-GENE
in O
stimulated O
or O
unstimulated O
NIH O
3T3 O
cells O
. O

Several O
Src I-GENE
SH3 I-GENE
- I-GENE
binding I-GENE
proteins I-GENE
were O
phosphorylated O
in O
Src I-GENE
- I-GENE
transformed O
cells O
. O

We O
also O
examined O
the O
effect O
of O
proteolytic O
processing O
in O
the O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
segment O
mediated O
by O
the O
viral I-GENE
proteinase I-GENE
NS3 I-GENE
on O
antigen I-GENE
processing O
and O
presentation O
of O
the O
_RARE_ I-GENE
H I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
restricted O
T I-GENE
cell O
determinant O
. O

A I-GENE
full I-GENE
- I-GENE
length I-GENE
PRL I-GENE
receptor I-GENE
( O
_RARE_ I-GENE
) O
complementary O
DNA I-GENE
from O
_RARE_ I-GENE
was O
obtained O
by O
screening O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
libraries O
and O
by O
reverse I-GENE
transcription I-GENE
coupled I-GENE
with O
polymerase I-GENE
chain I-GENE
reaction O
. O

After O
7 O
days O
, O
a O
spontaneous O
regression O
of O
the O
morphologic O
alterations O
caused O
by O
_RARE_ I-GENE
- I-GENE
induced O
acute O
pancreatitis O
occurs O
; O
however O
, O
recovery O
of O
the O
secretory I-GENE
function O
of O
the O
pancreas O
was O
only O
reached O
after O
this O
period O
of O
time O
when O
L I-GENE
- I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
was O
administered O
_RARE_ I-GENE
( O
0 O
. O
1 I-GENE
mg O
/ I-GENE
kg O
/ I-GENE
day O
). O

We O
observed O
that O
_RARE_ I-GENE
severely O
inhibits O
the O
DNA I-GENE
- I-GENE
binding I-GENE
ability O
of O
C I-GENE
/ I-GENE
EBP I-GENE
- I-GENE
delta I-GENE
and O
its O
transactivating O
potential O
increases O
in O
the O
presence O
of O
cellular O
phosphatase I-GENE
inhibitors O
, O
such O
as O
_RARE_ I-GENE
acid I-GENE
and O
sodium O
_RARE_ I-GENE
. O

Two O
promoters I-GENE
were O
identified O
by O
S1 I-GENE
nuclease I-GENE
mapping O
: O
P1 I-GENE
, O
which O
lies O
about O
72 O
bp O
upstream O
from O
the O
structural O
gene I-GENE
; O
and O
P2 I-GENE
, O
which O
lies O
about O
35 O
bp O
upstream O
. O

Interleukin I-GENE
- I-GENE
8 O
( O
IL I-GENE
- I-GENE
8 O
) O
is O
a O
potent O
inflammatory O
_RARE_ I-GENE
that O
belongs O
to O
the O
family I-GENE
of O
C I-GENE
- I-GENE
X I-GENE
- I-GENE
C I-GENE
_RARE_ I-GENE
. O

On O
the O
other O
hand O
, O
cells O
containing O
a O
_RARE_ I-GENE
in O
which O
the O
catalytic O
site I-GENE
had O
been O
inactivated O
through O
mutagenesis O
, O
stably O
phosphorylated O
the O
phosphatase I-GENE
. O

We O
recently O
found O
that O
the O
_RARE_ I-GENE
protein I-GENE
tyrosine I-GENE
kinase I-GENE
is O
physically O
associated I-GENE
with O
the O
TCR I-GENE
/ I-GENE
CD3 I-GENE
complex I-GENE
and O
is O
rapidly O
tyrosine I-GENE
phosphorylated O
and O
activated I-GENE
by O
receptor I-GENE
_RARE_ I-GENE
also O
in O
T I-GENE
cells O
lacking O
_RARE_ I-GENE
. O

The O
transforming I-GENE
protein I-GENE
of O
Rous I-GENE
sarcoma I-GENE
virus I-GENE
, O
_RARE_ I-GENE
- I-GENE
src I-GENE
, O
and O
its O
normal O
cellular O
homolog I-GENE
, O
_RARE_ I-GENE
- I-GENE
src I-GENE
, O
differ O
not O
only O
in O
oncogenic I-GENE
potential O
but O
also O
in O
their O
subcellular O
localization O
and O
cytoskeletal O
binding I-GENE
ability O
. O
_RARE_ I-GENE
- I-GENE
src I-GENE
has O
been O
shown O
to O
stably O
associate O
with O
a O
detergent O
- I-GENE
_RARE_ I-GENE
cytoskeletal O
matrix I-GENE
, O
whereas O
_RARE_ I-GENE
- I-GENE
src I-GENE
does O
not O
. O

Organization O
of O
the O
bovine I-GENE
gene I-GENE
encoding O
the O
endothelial I-GENE
nitric I-GENE
oxide I-GENE
synthase I-GENE
. O

We O
determined O
whether O
regional O
myocardial O
work O
efficiency O
( O
segment O
work O
/ I-GENE
regional O
O2 O
consumption O
) O
would O
be O
elevated O
by O
surgically O
- I-GENE
augmented O
_RARE_ I-GENE
. O

In O
female O
_RARE_ I-GENE
( O
_RARE_ I-GENE
)/ O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
mice O
, O
ovarian O
follicle I-GENE
development O
is O
arrested O
at O
the O
one O
_RARE_ I-GENE
_RARE_ I-GENE
stage O
as O
a O
result O
of O
reduced O
_RARE_ I-GENE
expression O
in O
follicle I-GENE
cells O
, O
indicating O
a O
role O
for O
c I-GENE
- I-GENE
kit I-GENE
in O
oocyte O
growth I-GENE
. O

Anti I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
C I-GENE
also O
exclusively O
detected O
time O
- I-GENE
dependent I-GENE
_RARE_ I-GENE
of O
5 I-GENE
- I-GENE
10 O
- I-GENE
kDa I-GENE
_RARE_ I-GENE
- I-GENE
C I-GENE
forms O
in O
_RARE_ I-GENE
bodies O
and O
_RARE_ I-GENE
. O

In O
the O
B6 I-GENE
- I-GENE
derived O
_RARE_ I-GENE
mutant I-GENE
B6 I-GENE
. O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
strain O
, O
part O
of O
the O
class I-GENE
I I-GENE
_RARE_ I-GENE
antigen I-GENE
- I-GENE
presenting O
groove I-GENE
is O
shaped O
by O
a O
class I-GENE
I I-GENE
_RARE_ I-GENE
- I-GENE
encoded I-GENE
sequence I-GENE
. O

Three O
mutants I-GENE
( O
_RARE_ I-GENE
, O
_RARE_ I-GENE
and O
_RARE_ I-GENE
) O
isolated O
earlier O
from O
_RARE_ I-GENE
- I-GENE
1B I-GENE
were O
shown O
to O
correct O
in O
vitro O
constructed O
plasmids O
with O
defined O
DNA I-GENE
_RARE_ I-GENE
( O
G I-GENE
/ I-GENE
T I-GENE
, O
A I-GENE
/ I-GENE
C I-GENE
, O
G I-GENE
/ I-GENE
G I-GENE
, O
etc O
.) O
poorly O
( O
_RARE_ I-GENE
et O
al O
., O
_RARE_ I-GENE
). O

Our O
findings O
confirm O
the O
high O
frequency O
of O
proximal I-GENE
nerve I-GENE
lesions O
in O
early I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
, O
not O
all O
of O
which O
are O
associated I-GENE
with O
distal O
motor O
conduction O
abnormalities O
, O
and O
suggest O
that O
assessment O
of O
multiple O
F I-GENE
wave O
parameters O
, O
in O
particular O
_RARE_ I-GENE
, O
mean O
latency O
and O
mean O
amplitude O
( O
in O
addition O
to O
absence O
and O
minimum O
latency O
), O
increases O
the O
yield O
of O
F I-GENE
wave O
studies O
. O

_RARE_ I-GENE
growth I-GENE
factors I-GENE
are O
being O
used O
to O
_RARE_ I-GENE
the O
recovery O
of O
_RARE_ I-GENE
following O
high O
- I-GENE
dose O
chemotherapy O
in O
cancer O
patients O
. O

Effects O
of O
alterations O
of O
primer O
- I-GENE
binding I-GENE
site I-GENE
sequences I-GENE
on O
human I-GENE
immunodeficiency I-GENE
virus I-GENE
type I-GENE
1 I-GENE
replication O
. O

_RARE_ I-GENE
of O
a O
horse I-GENE
cytochrome I-GENE
c I-GENE
peptide I-GENE
by O
multiple O
H I-GENE
- I-GENE
2b I-GENE
class I-GENE
I I-GENE
major I-GENE
histocompatibility I-GENE
complex I-GENE
( O
MHC I-GENE
) O
molecules I-GENE
to O
C57BL O
/ I-GENE
6 I-GENE
- I-GENE
and O
_RARE_ I-GENE
- I-GENE
derived O
cytotoxic O
T I-GENE
lymphocytes O
: O
presence O
of O
a O
single O
MHC I-GENE
anchor I-GENE
residue O
may O
confer O
efficient O
peptide I-GENE
- I-GENE
specific I-GENE
CTL O
recognition I-GENE
. O

A I-GENE
particularly O
striking O
_RARE_ I-GENE
_RARE_ I-GENE
fragment I-GENE
island O
, O
extending O
over O
nearly O
2 I-GENE
, O
000 O
base O
pairs O
, O
_RARE_ I-GENE
the O
_RARE_ I-GENE
translation I-GENE
initiation I-GENE
site I-GENE
. O

Diagnosis O
of O
prostatic I-GENE
carcinoma O
: O
the O
yield O
of O
serum I-GENE
prostate O
specific I-GENE
antigen I-GENE
, O
digital O
rectal O
examination O
and O
_RARE_ I-GENE
ultrasonography O
. O

Increased O
granulocyte I-GENE
- I-GENE
colony I-GENE
stimulating I-GENE
factor I-GENE
( O
G I-GENE
- I-GENE
CSF I-GENE
) O
levels O
in O
neonates O
with O
_RARE_ I-GENE
complications O
. O

The O
results O
revealed O
a O
_RARE_ I-GENE
of O
ligand O
affinities O
that O
_RARE_ I-GENE
their O
adhesive O
activity O
( O
_RARE_ I-GENE
- I-GENE
1 I-GENE
> O
fibronectin I-GENE
variants I-GENE
containing O
_RARE_ I-GENE
_RARE_ I-GENE
other O
fibronectin I-GENE
variants I-GENE
). O

When O
expressed O
in O
and O
purified O
from O
Escherichia I-GENE
coli I-GENE
, O
both O
full I-GENE
- I-GENE
length I-GENE
_RARE_ I-GENE
and O
its O
isolated O
COOH O
- I-GENE
terminal I-GENE
domain I-GENE
exhibit O
readily O
detectable O
_RARE_ I-GENE
activity O
. O

_RARE_ I-GENE
of O
H I-GENE
- I-GENE
2b I-GENE
or O
H I-GENE
- I-GENE
_RARE_ I-GENE
NP I-GENE
peptides I-GENE
indicated O
that O
3 I-GENE
- I-GENE
4 I-GENE
_RARE_ I-GENE
less O
H I-GENE
- I-GENE
2b I-GENE
NP I-GENE
peptide I-GENE
was O
required O
to O
_RARE_ I-GENE
_RARE_ I-GENE
target O
cells O
for O
CTL O
- I-GENE
specific I-GENE
lysis O
, O
suggesting O
that O
the O
_RARE_ I-GENE
affinities O
of O
H I-GENE
- I-GENE
2b I-GENE
and O
H I-GENE
- I-GENE
_RARE_ I-GENE
major I-GENE
histocompatibility I-GENE
complex I-GENE
molecules I-GENE
for O
their O
peptides I-GENE
likely O
account O
for O
the O
total O
removal O
of O
NP I-GENE
CTL O
in O
the O
H I-GENE
- I-GENE
2b I-GENE
mice O
but O
only O
partial O
removal O
in O
H I-GENE
- I-GENE
_RARE_ I-GENE
mice O
made O
to O
express O
thymic I-GENE
NP I-GENE
. O

However O
, O
expression O
of O
sigma I-GENE
3 I-GENE
from O
S4 I-GENE
( O
3 I-GENE
' O
UTR I-GENE
/ I-GENE
S1 I-GENE
), O
which O
included O
the O
PKR I-GENE
activator I-GENE
sequence I-GENE
from O
S1 I-GENE
within O
the O
3 I-GENE
'- O
UTR I-GENE
of O
S4 I-GENE
, O
was O
comparable O
to O
that O
from O
wild I-GENE
- I-GENE
type I-GENE
S4 I-GENE
. O

_RARE_ I-GENE
were O
_RARE_ I-GENE
in O
a O
_RARE_ I-GENE
field O
( O
0 O
. O
_RARE_ I-GENE
mm2 O
) O
in O
the O
area O
of O
maximal O
angiogenesis O
. O

Although O
both O
transfected O
cell O
lines O
contain O
FGF I-GENE
- I-GENE
1 I-GENE
cell O
surface O
receptors I-GENE
as O
judged O
by O
_RARE_ I-GENE
studies O
, O
the O
wild I-GENE
- I-GENE
type I-GENE
transfectants O
are O
refractory O
to O
exogenous O
FGF I-GENE
- I-GENE
1 I-GENE
, O
whereas O
the O
mutant I-GENE
transfectants O
respond O
normally O
.( O
ABSTRACT O
TRUNCATED O
AT I-GENE
250 O
WORDS O
) O

Recent O
studies O
have O
demonstrated O
that O
the O
activated I-GENE
GH I-GENE
receptor I-GENE
can O
stimulate O
_RARE_ I-GENE
, O
a O
cytoplasmic I-GENE
transcription I-GENE
factor I-GENE
that O
becomes O
tyrosine I-GENE
phosphorylated O
and O
_RARE_ I-GENE
to O
the O
nucleus O
, O
where O
it O
can O
interact O
with O
specific I-GENE
DNA I-GENE
sequences I-GENE
to O
modulate O
gene I-GENE
expression O
. O

In O
viral I-GENE
infections O
, O
G I-GENE
- I-GENE
CSF I-GENE
was O
correlated O
with O
mononuclear O
cells O
( O
rs O
= O
0 O
. O
41 O
, O
P I-GENE
< O
0 O
. O
05 O
), O
white O
blood O
cell O
counts O
( O
rs O
= O
0 O
. O
56 O
, O
P I-GENE
< O
0 O
. O
01 O
), O
neutrophils O
( O
rs O
= O
0 O
. O
41 O
, O
P I-GENE
< O
0 O
. O
05 O
) O
and O
CRP I-GENE
( O
rs O
= O
0 O
. O
47 O
, O
P I-GENE
< O
0 O
. O
05 O
). O

_RARE_ I-GENE
initiation I-GENE
sites I-GENE
were O
found O
at O
positions O
- I-GENE
128 I-GENE
, O
- I-GENE
111 O
, O
- I-GENE
91 O
, O
and O
- I-GENE
74 O
. O

_RARE_ I-GENE
acid I-GENE
analysis O
of O
radiolabeled O
_RARE_ I-GENE
subunits I-GENE
identified O
Ser O
( O
P I-GENE
) O
as O
the O
predominant O
( O
approximately O
95 O
%) O
and O
Thr I-GENE
( O
P I-GENE
) O
as O
a O
minor O
( O
approximately O
5 I-GENE
%) O
_RARE_ I-GENE
acid I-GENE
in O
each O
polypeptide I-GENE
and O
confirmed O
the O
presence O
of O
Tyr I-GENE
( O
P I-GENE
) O
( O
approximately O
1 I-GENE
%) O
in O
_RARE_ I-GENE
. O

To O
further O
define O
the O
structural O
requirements O
for O
ZAP I-GENE
- I-GENE
70 I-GENE
interaction O
with O
the O
TCR I-GENE
, O
we O
developed O
a O
binding I-GENE
assay O
using O
_RARE_ I-GENE
glutathione I-GENE
S I-GENE
- I-GENE
transferase I-GENE
fusion I-GENE
proteins I-GENE
containing O
the O
NH2 I-GENE
- I-GENE
and O
/ I-GENE
or O
COOH O
- I-GENE
terminal I-GENE
SH2 I-GENE
domains I-GENE
of O
ZAP I-GENE
- I-GENE
70 I-GENE
, O
and O
soluble I-GENE
synthetic O
peptides I-GENE
with O
the O
sequence I-GENE
of O
the O
cytoplasmic I-GENE
region O
of O
the O
TCR I-GENE
zeta I-GENE
chain I-GENE
( O
TCR I-GENE
zeta I-GENE
cyt I-GENE
) O
or O
individual O
TCR I-GENE
zeta I-GENE
and O
CD3 I-GENE
epsilon I-GENE
_RARE_ I-GENE
motifs O
. O

All O
four O
_RARE_ I-GENE
tyrosine I-GENE
phosphorylated O
_RARE_ I-GENE
peptides I-GENE
cross O
- I-GENE
compete O
with O
each O
other O
for O
binding I-GENE
to O
the O
tandem O
SH2 I-GENE
domains I-GENE
of O
ZAP I-GENE
- I-GENE
70 I-GENE
. O

The O
three O
- I-GENE
dimensional O
structure O
of O
RT I-GENE
shows O
that O
it O
is O
a O
strikingly O
asymmetric O
heterodimer O
consisting O
of O
two O
differently O
folded O
subunits I-GENE
( O
molecular O
weights O
66 O
kDa I-GENE
and O
51 O
kDa I-GENE
) O
with O
identical O
amino O
- I-GENE
terminal I-GENE
amino O
acid I-GENE
sequences I-GENE
( O
residues O
1 I-GENE
- I-GENE
_RARE_ I-GENE
). O

_RARE_ I-GENE
and O
pharmacokinetic O
characteristics O
of O
the O
non O
- I-GENE
ionic O
monomeric I-GENE
X I-GENE
- I-GENE
ray O
contrast O
agent O
_RARE_ I-GENE
( O
_RARE_ I-GENE
, O
CAS I-GENE
_RARE_ I-GENE
- I-GENE
07 O
- I-GENE
3 I-GENE
) O
were O
evaluated O
in O
_RARE_ I-GENE
studies O
. O

All O
subsequent O
patients O
were O
treated O
at O
the O
maximal O
tolerated O
dose O
of O
_RARE_ I-GENE
( O
35 O
mg O
/ I-GENE
m2 O
/ I-GENE
day O
). O

The O
median O
post O
- I-GENE
treatment O
, O
pre I-GENE
- I-GENE
operative O
serum I-GENE
PSA I-GENE
was O
0 O
. O
4 I-GENE
ng O
/ I-GENE
ml O
. O

Addition O
of O
soluble I-GENE
recombinant I-GENE
human I-GENE
_RARE_ I-GENE
to O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
cultures O
enhanced O
reduction O
of O
cell O
- I-GENE
surface O
c I-GENE
- I-GENE
kit I-GENE
expression O
and O
its O
protein I-GENE
degradation O
. O

_RARE_ I-GENE
- I-GENE
bound O
_RARE_ I-GENE
factor I-GENE
induces O
more O
persistent O
tyrosine I-GENE
kinase I-GENE
activation O
and O
longer O
life O
span O
of O
c I-GENE
- I-GENE
kit I-GENE
gene I-GENE
- I-GENE
encoded I-GENE
protein I-GENE
than O
its O
soluble I-GENE
form O
. O

Analysis O
of O
the O
sequences I-GENE
with O
the O
_RARE_ I-GENE
and O
_RARE_ I-GENE
programs O
provided O
additional O
independent O
evidence O
that O
15 O
of O
these O
17 O
clones O
contain O
coding O
sequences I-GENE
and O
that O
nine O
other O
clones O
are O
likely O
to O
contain O
sequences I-GENE
coding O
for O
portions O
of O
new O
genes I-GENE
. O

Patients O
with O
more O
than O
250 O
_RARE_ I-GENE
/ I-GENE
24 O
hours O
were O
selected O
for O
distribution O
of O
_RARE_ I-GENE
and O
CI O
evaluation O
. O

_RARE_ I-GENE
, O
I I-GENE
. O

Cell O
lines O
derived O
from O
the O
tumors O
were O
examined O
by O
fluorescent O
in O
situ O
hybridization O
for O
the O
status O
of O
the O
transferred O
human I-GENE
chromosome O
and O
by O
PCR O
for O
marker O
loss O
. O

The O
amino O
acid I-GENE
sequences I-GENE
of O
the O
predicted O
_RARE_ I-GENE
and O
_RARE_ I-GENE
homologs I-GENE
showed O
identities O
of O
75 O
. O
7 O
% O
( O
87 O
. O
9 O
% O
total O
similarity O
) O
and O
78 O
. O
0 O
% O
( O
86 I-GENE
. O
5 I-GENE
% O
total O
similarity O
), O
respectively O
. O

However O
, O
multiple O
alanine I-GENE
substitutions O
or O
proline O
( O
helix I-GENE
- I-GENE
_RARE_ I-GENE
) O
substitutions O
disrupted O
both O
oligomerization O
and O
transport O
of O
_RARE_ I-GENE
_RARE_ I-GENE
. O

The O
_RARE_ I-GENE
protein I-GENE
of O
_RARE_ I-GENE
plasmids O
binds O
_RARE_ I-GENE
antisense I-GENE
RNA I-GENE
and O
its O
target O
, O
_RARE_ I-GENE
mRNA I-GENE
, O
and O
promotes O
duplex O
formation O
. O

In O
this O
paper O
we O
report O
that O
ligand O
binding I-GENE
induced O
tyrosine I-GENE
phosphorylation O
in O
_RARE_ I-GENE
cells O
engineered I-GENE
to O
express O
the O
murine I-GENE
_RARE_ I-GENE
receptor I-GENE
( O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
). O

A I-GENE
chicken I-GENE
paxillin I-GENE
cDNA I-GENE
was O
also O
cloned O
and O
is O
predicted O
to O
encode O
a O
protein I-GENE
approximately O
90 O
% O
identical O
to O
human I-GENE
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
. O

We O
linked O
a O
4 I-GENE
. O
1 I-GENE
- I-GENE
kilobase O
pair O
HindIII I-GENE
DNA I-GENE
fragment I-GENE
from O
the O
region O
upstream O
of O
the O
human I-GENE
AP I-GENE
endonuclease I-GENE
gene I-GENE
( O
_RARE_ I-GENE
) O
to O
the O
chloramphenicol I-GENE
acetyltransferase I-GENE
( O
CAT I-GENE
) O
gene I-GENE
. O

The O
overexpressed O
_RARE_ I-GENE
- I-GENE
tagged O
_RARE_ I-GENE
derivatives O
were O
affinity O
- I-GENE
purified O
, O
and O
the O
catalytic O
properties O
of O
the O
deletion O
mutants I-GENE
were O
examined O
by O
biochemical O
studies O
including O
ATP I-GENE
- I-GENE
dependent I-GENE
amino O
acid I-GENE
activation O
, O
carboxyl O
_RARE_ I-GENE
formation O
, O
and O
the O
ability O
to O
_RARE_ I-GENE
the O
covalently O
bound O
phenylalanine I-GENE
from O
L I-GENE
- I-GENE
to O
the O
D I-GENE
- I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
+/ I-GENE
CD3 I-GENE
- I-GENE
T I-GENE
- I-GENE
cell O
precursors I-GENE
exhibit O
V I-GENE
delta I-GENE
_RARE_ I-GENE
delta I-GENE
3 I-GENE
rearrangements O
. O

_RARE_ I-GENE
mRNA I-GENE
showed O
an O
expression O
pattern O
distinct O
from O
_RARE_ I-GENE
( O
human I-GENE
homologue I-GENE
of O
mouse I-GENE
_RARE_ I-GENE
) O
and O
_RARE_ I-GENE
, O
two O
previously O
identified O
MAP I-GENE
kinase I-GENE
phosphatases I-GENE
. O

These O
data O
suggest O
that O
these O
sequences I-GENE
located O
immediately O
3 I-GENE
' O
to O
the O
breakpoint I-GENE
of O
the O
_RARE_ I-GENE
- I-GENE
3 I-GENE
deletion O
, O
exhibit O
both O
the O
structure O
and O
the O
function O
of O
an O
enhancer I-GENE
, O
and O
can O
modify O
the O
developmental O
specificity O
of O
the O
fetal O
gamma I-GENE
- I-GENE
globin I-GENE
genes I-GENE
, O
resulting O
in O
their O
continued O
expression O
during O
adult O
life O
. O

In O
vivo O
association O
between O
_RARE_ I-GENE
- I-GENE
SH3 I-GENE
domain I-GENE
proteins I-GENE
v I-GENE
- I-GENE
Src I-GENE
and O
_RARE_ I-GENE
was O
detected O
by O
_RARE_ I-GENE
. O

Our O
results O
indicate O
that O
interaction O
between O
_RARE_ I-GENE
and O
_RARE_ I-GENE
requires O
a O
proline O
- I-GENE
rich O
sequence I-GENE
in O
the O
membrane I-GENE
proximal I-GENE
region O
of O
the O
receptor I-GENE
, O
which O
is O
conserved O
among O
the O
different O
members O
of O
the O
cytokine O
receptor I-GENE
superfamily I-GENE
. O

Transcription O
of O
the O
vascular I-GENE
cell O
adhesion I-GENE
molecule I-GENE
1 I-GENE
( O
_RARE_ I-GENE
- I-GENE
1 I-GENE
) O
gene I-GENE
in O
endothelial I-GENE
cells O
is O
induced O
by O
lipopolysaccharide O
and O
the O
inflammatory O
cytokines O
interleukin I-GENE
- I-GENE
1 I-GENE
beta I-GENE
and O
tumor I-GENE
necrosis I-GENE
factor I-GENE
alpha I-GENE
( O
TNF I-GENE
- I-GENE
alpha I-GENE
). O

Experiments O
with O
recombinant I-GENE
proteins I-GENE
showed O
that O
p50 I-GENE
/ I-GENE
p65 I-GENE
and O
high O
- I-GENE
mobility I-GENE
- I-GENE
group O
I I-GENE
( O
Y I-GENE
) O
protein I-GENE
_RARE_ I-GENE
facilitated O
the O
binding I-GENE
of O
IRF I-GENE
- I-GENE
1 I-GENE
to O
the O
_RARE_ I-GENE
IRF I-GENE
binding I-GENE
site I-GENE
and O
that O
IRF I-GENE
- I-GENE
1 I-GENE
physically O
interacted O
with O
p50 I-GENE
and O
with O
high O
- I-GENE
mobility I-GENE
- I-GENE
group O
I I-GENE
( O
Y I-GENE
) O
protein I-GENE
. O

Based O
on O
these O
results O
the O
minimal I-GENE
control O
element I-GENE
( O
_RARE_ I-GENE
_RARE_ I-GENE
) O
_RARE_ I-GENE
the O
anterior O
boundary O
of O
Hox I-GENE
expression O
was O
designated O
as O
_RARE_ I-GENE
- I-GENE
7 O
enhancer I-GENE
. O

In O
this O
report O
we O
describe O
the O
isolation O
of O
a O
_RARE_ I-GENE
fragment I-GENE
( O
_RARE_ I-GENE
_RARE_ I-GENE
) O
showing O
a O
high O
relative O
affinity O
for O
the O
receptor I-GENE
( O
0 O
. O
5 I-GENE
nM O
). O

MBP I-GENE
- I-GENE
_RARE_ I-GENE
delta I-GENE
- I-GENE
mediated O
DNA I-GENE
- I-GENE
RNA I-GENE
helicase I-GENE
activity O
required O
ATP I-GENE
hydrolysis O
and O
the O
presence O
of O
_RARE_ I-GENE
+ I-GENE
ions O
and O
was O
inhibited O
by O
high O
ionic O
strength O
. O

To O
identify O
critical O
regions O
mediating O
growth I-GENE
signal I-GENE
transduction O
by O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
, O
deletions O
or O
site I-GENE
- I-GENE
directed O
amino O
acid I-GENE
substitutions O
were O
introduced O
into O
the O
cytoplasmic I-GENE
domain I-GENE
of O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
, O
and O
the O
mutant I-GENE
cDNAs I-GENE
were O
transfected O
into O
the O
murine I-GENE
interleukin I-GENE
- I-GENE
3 I-GENE
( O
IL I-GENE
- I-GENE
3 I-GENE
)- I-GENE
dependent I-GENE
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
cell O
lines O
. O

When O
combined O
with O
independent O
activating I-GENE
mutations O
in O
the O
c I-GENE
- I-GENE
abl I-GENE
kinase I-GENE
domain I-GENE
or O
NH2 I-GENE
- I-GENE
terminus O
, O
the O
_RARE_ I-GENE
mutation I-GENE
blocked O
transformation O
by O
the O
double O
mutant I-GENE
, O
suggesting O
that O
the O
_RARE_ I-GENE
mutant I-GENE
was O
unable O
to O
transform O
cells O
for O
_RARE_ I-GENE
_RARE_ I-GENE
. O

Both O
mutations O
completely O
abolished O
binding I-GENE
of O
the O
Abl I-GENE
SH3 I-GENE
domain I-GENE
to O
proline O
- I-GENE
rich O
target O
proteins I-GENE
in O
a O
filter O
- I-GENE
binding I-GENE
assay O
. O

Changes O
induced O
in O
the O
_RARE_ I-GENE
of O
_RARE_ I-GENE
( O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
) O
_RARE_ I-GENE
after O
acute O
exposure O
to O
_RARE_ I-GENE
( O
_RARE_ I-GENE
; O
P I-GENE
- I-GENE
_RARE_ I-GENE
). O

_RARE_ I-GENE
of O
these O
2 I-GENE
dogs O
resulted O
in O
a O
similar O
, O
but O
_RARE_ I-GENE
, O
response O
to O
human I-GENE
immunoglobulin I-GENE
. O

The O
levels O
of O
_RARE_ I-GENE
and O
MBP I-GENE
in O
the O
_RARE_ I-GENE
were O
compared O
to O
those O
in O
the O
_RARE_ I-GENE
. O

As O
expected O
, O
the O
insulin I-GENE
effect O
to O
increase O
ras I-GENE
GTP I-GENE
formation O
and O
MAP I-GENE
kinase I-GENE
activity O
was O
_RARE_ I-GENE
in O
A I-GENE
/ I-GENE
_RARE_ I-GENE
cells O
but O
normal O
, O
or O
_RARE_ I-GENE
, O
in O
Y I-GENE
/ I-GENE
F2 O
cells O
. O

_RARE_ I-GENE
variables O
included O
cancer O
volume O
, O
histologic O
grade O
, O
_RARE_ I-GENE
penetration O
, O
seminal I-GENE
vesicle O
invasion O
, O
and O
lymph O
node O
metastasis O
. O

Sequence O
analysis O
of O
these O
regions O
showed O
a O
CAAT I-GENE
box I-GENE
upstream O
of O
exon O
1a I-GENE
and O
high O
G I-GENE
- I-GENE
C I-GENE
content O
regions O
within O
both O
P1 I-GENE
and O
P2 I-GENE
. O

The O
fusion I-GENE
proteins I-GENE
were O
tested O
by O
ELISA O
for O
reactivity O
with O
a O
panel O
of O
human I-GENE
anti I-GENE
- I-GENE
La I-GENE
sera O
in O
order O
to O
define O
the O
nature O
of O
the O
epitopes I-GENE
. O

_RARE_ I-GENE
was O
first O
identified O
genetically O
as O
a O
translational O
repressor I-GENE
of O
GCN4 I-GENE
. O

_RARE_ I-GENE
binds O
RNA I-GENE
in O
vitro O
and O
we O
present O
strong O
biochemical O
evidence O
that O
it O
is O
identical O
to O
the O
RNA I-GENE
- I-GENE
binding I-GENE
subunit I-GENE
of O
yeast I-GENE
initiation I-GENE
factor I-GENE
- I-GENE
3 I-GENE
( O
eIF I-GENE
- I-GENE
3 I-GENE
). O
eIF I-GENE
- I-GENE
3 I-GENE
is O
a O
multisubunit I-GENE
complex I-GENE
that O
stimulates O
translation I-GENE
initiation I-GENE
in O
vitro O
at O
several O
different O
steps O
. O

_RARE_ I-GENE
of O
noise O
in O
these O
signals O
were O
evaluated O
in O
preparations O
stained O
with O
the O
_RARE_ I-GENE
probe O
RH O
- I-GENE
_RARE_ I-GENE
. O

1993 O
. O

A I-GENE
transformation O
- I-GENE
competent O
mutant I-GENE
, O
like I-GENE
the O
wild I-GENE
- I-GENE
type I-GENE
_RARE_ I-GENE
protein I-GENE
, O
bound O
the O
receptor I-GENE
and O
induced O
receptor I-GENE
tyrosine I-GENE
phosphorylation O
and O
down O
- I-GENE
regulation O
. O

We O
conclude O
that O
cAMP I-GENE
, O
acting O
through O
PKA I-GENE
, O
is O
an O
essential O
regulator I-GENE
of O
basal O
CFTR I-GENE
gene I-GENE
expression O
and O
may O
mediate O
an O
induction O
of O
CFTR I-GENE
in O
responsive I-GENE
cell O
types O
. O

_RARE_ I-GENE
restriction I-GENE
sites I-GENE
allow O
one O
to O
insert O
virtually O
any O
_RARE_ I-GENE
cDNA I-GENE
fragment I-GENE
directly O
behind O
the O
epitope O
- I-GENE
specific I-GENE
sequence I-GENE
and O
before O
a O
long O
poly O
( O
A I-GENE
) O
tail O
. O

Both O
_RARE_ I-GENE
- I-GENE
1 I-GENE
and O
_RARE_ I-GENE
- I-GENE
31 O
cells O
display O
tumorigenesis O
and O
_RARE_ I-GENE
in O
nude O
mice O
, O
whereas O
_RARE_ I-GENE
cells O
exhibit O
a O
less O
malignant O
phenotype O
, O
suggesting O
a O
correlation O
between O
CD44 I-GENE
variant I-GENE
( O
_RARE_ I-GENE
) O
expression O
and O
aggressive O
prostate O
tumor I-GENE
behavior O
. O

The O
gene I-GENE
product I-GENE
of O
_RARE_ I-GENE
was O
confirmed O
to O
be O
identical O
to O
_RARE_ I-GENE
- I-GENE
2 I-GENE
by O
SDS O
- I-GENE
PAGE O
and O
_RARE_ I-GENE
from O
Escherichia I-GENE
coli I-GENE
transformed O
with O
a O
plasmid O
containing O
the O
_RARE_ I-GENE
region O
. O

Two O
such O
genes I-GENE
, O
designated O
_RARE_ I-GENE
and O
_RARE_ I-GENE
, O
were O
cloned O
and O
sequenced O
from O
genomic O
DNA I-GENE
. O

A I-GENE
retrospective O
epidemiological O
study O
is O
reported O
concerning O
burn O
injuries O
in O
_RARE_ I-GENE
children O
hospitalized O
at O
the O
unit I-GENE
of O
burn O
care O
of O
_RARE_ I-GENE
between O
1985 O
and O
1993 O
. O

Our O
results O
suggest O
that O
protein I-GENE
binding I-GENE
to O
the O
E2F I-GENE
- I-GENE
like I-GENE
sequences I-GENE
may O
act O
to O
reduce O
expression O
. O

The O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
gene I-GENE
from O
Saccharomyces I-GENE
cerevisiae I-GENE
encodes O
a O
ubiquitin I-GENE
- I-GENE
_RARE_ I-GENE
enzyme I-GENE
involved O
in O
DNA I-GENE
repair I-GENE
, O
induced O
mutagenesis O
, O
and O
sporulation I-GENE
. O

_RARE_ I-GENE
revealed O
right O
ventricular O
diastolic O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
without O
physical O
signs O
of O
cardiac O
_RARE_ I-GENE
. O

In O
on O
- I-GENE
_RARE_ I-GENE
screening O
_RARE_ I-GENE
, O
the O
_RARE_ I-GENE
test O
consists O
of O
six O
_RARE_ I-GENE
and O
a O
test O
is O
considered O
positive O
if O
at O
least O
one O
_RARE_ I-GENE
is O
_RARE_ I-GENE
. O

We O
showed O
previously O
that O
a O
fusion I-GENE
protein I-GENE
( O
GAL4 I-GENE
- I-GENE
p40 I-GENE
) O
containing O
the O
DNA I-GENE
- I-GENE
binding I-GENE
domain I-GENE
of O
GAL4 I-GENE
and O
sequences I-GENE
of O
chicken I-GENE
l O
kappa I-GENE
B I-GENE
- I-GENE
alpha I-GENE
( O
p40 I-GENE
) O
inhibits O
growth I-GENE
in O
the O
yeast I-GENE
Saccharomyces I-GENE
cerevisiae I-GENE
. O

We O
have O
demonstrated O
previously O
that O
two O
binding I-GENE
sites I-GENE
in O
the O
- I-GENE
_RARE_ I-GENE
HNF I-GENE
- I-GENE
3 I-GENE
beta I-GENE
promoter I-GENE
are O
recognized O
by O
widely O
distributed O
factors I-GENE
and O
that O
there O
is O
also O
a O
critical O
_RARE_ I-GENE
site I-GENE
, O
we O
identified O
a O
binding I-GENE
site I-GENE
for O
a O
cell O
- I-GENE
specific I-GENE
factor I-GENE
, O
_RARE_ I-GENE
- I-GENE
H3 I-GENE
beta I-GENE
, O
that O
may O
function O
in O
_RARE_ I-GENE
HNF I-GENE
- I-GENE
3 I-GENE
beta I-GENE
gene I-GENE
expression O
to O
hepatocytes O
. O

In O
4 I-GENE
_RARE_ I-GENE
cats O
, O
the O
effects O
of O
_RARE_ I-GENE
inputs O
from O
_RARE_ I-GENE
cutaneous O
nerves O
( O
_RARE_ I-GENE
cutaneous O
nerve I-GENE
: O
_RARE_ I-GENE
) O
on O
mono O
- I-GENE
and O
poly O
- I-GENE
synaptic O
reflex O
recorded O
from O
tail O
muscle O
_RARE_ I-GENE
were O
studied O
before O
and O
after O
spinal O
_RARE_ I-GENE
at O
S2 I-GENE
- I-GENE
3 I-GENE
level O
. O

The O
flow O
rate O
of O
phosphate I-GENE
_RARE_ I-GENE
saline O
through O
_RARE_ I-GENE
was O
measured O
as O
a O
function O
of O
applied O
pressure O
. O

However O
, O
_RARE_ I-GENE
measurements O
showed O
that O
at O
_RARE_ I-GENE
, O
_RARE_ I-GENE
of O
_RARE_ I-GENE
sections O
does O
not O
take O
place O
. O

Although O
within O
normal O
limits O
, O
latency O
was O
high O
. O

The O
outcome O
of O
the O
_RARE_ I-GENE
of O
the O
seven O
- I-GENE
field O
_RARE_ I-GENE
_RARE_ I-GENE
an O
investigation O
into O
the O
best O
results O
that O
could O
be O
achieved O
by O
an O
" O
_RARE_ I-GENE
" O
_RARE_ I-GENE
radiotherapy O
technique O
. O

Specific O
requirements O
for O
branched I-GENE
- I-GENE
chain I-GENE
amino O
acids O
, O
glutamine I-GENE
, O
and O
arginine I-GENE
are O
evaluated O
. O

The O
_RARE_ I-GENE
_RARE_ I-GENE
intron O
is O
homologous O
to O
introns O
in O
_RARE_ I-GENE
and O
_RARE_ I-GENE
in O
the O
_RARE_ I-GENE
mitochondrial I-GENE
genome O
, O
while O
the O
_RARE_ I-GENE
_RARE_ I-GENE
gene I-GENE
lacks O
an O
intron O
. O

The O
optimal O
care O
of O
_RARE_ I-GENE
patient O
includes O
the O
recognition I-GENE
and O
management O
of O
these O
_RARE_ I-GENE
disturbances O
. O

Serum I-GENE
magnesium O
in O
79 O
patients O
of O
gynecologic O
neoplasms O
treated O
with O
cisplatin O
and O
their O
controls O
was O
measured O
. O

METHODS O
: O
_RARE_ I-GENE
. O
1 I-GENE
or O
human I-GENE
serum I-GENE
albumin I-GENE
was O
administered O
intravenously O
to O
fasting O
male O
volunteers O
. O

_RARE_ I-GENE
aminotransferase I-GENE
( O
_RARE_ I-GENE
) O
levels O
had O
been O
elevated O
for O
six O
months O
in O
all O
patients O
and O
hepatitis I-GENE
B I-GENE
viral I-GENE
infection O
was O
replicative O
. O

In O
this O
study O
we O
have O
investigated O
the O
role O
of O
C I-GENE
/ I-GENE
EBP I-GENE
beta I-GENE
in O
initiating O
the O
_RARE_ I-GENE
program O
by O
overexpressing O
C I-GENE
/ I-GENE
EBP I-GENE
beta I-GENE
in O
_RARE_ I-GENE
NIH O
- I-GENE
3T3 O
fibroblasts O
. O

_RARE_ I-GENE
was O
isolated O
as O
a O
highly O
expressed O
fusion I-GENE
clone O
from O
a O
' O
lacZ I-GENE
translational O
fusion I-GENE
library O
. O

Various O
transcripts I-GENE
are O
generated O
from O
the O
_RARE_ I-GENE
gene I-GENE
by O
alternative O
splicing O
and O
poly O
( O
A I-GENE
) O
processing O
in O
the O
rat I-GENE
_RARE_ I-GENE
gland O
. O

However O
, O
division O
of O
the O
chest O
wall O
muscles O
, O
usually O
with O
_RARE_ I-GENE
, O
contributes O
to O
prolonged O
pain O
and O
morbidity O
. O

_RARE_ I-GENE
of O
an O
open O
high O
below O
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
wound O
using O
a O
skin O
- I-GENE
_RARE_ I-GENE
device O
. O

Our O
study O
was O
addressed O
to O
the O
synthesis O
of O
some O
derivatives O
of O
this O
sequence I-GENE
in O
order O
to O
obtain O
both O
peptide I-GENE
substrates O
suitable O
for O
the O
detection O
of O
the O
Src I-GENE
- I-GENE
like I-GENE
tyrosine I-GENE
kinase I-GENE
activity O
and O
active O
site I-GENE
- I-GENE
directed O
inhibitors O
specific I-GENE
for O
this O
class I-GENE
of O
enzymes O
. O

_RARE_ I-GENE
synthase I-GENE
activity O
was O
increased O
in O
the O
medial O
head I-GENE
( O
81 O
%, O
P I-GENE
< O
0 O
. O
001 O
) O
and O
the O
red I-GENE
long O
head I-GENE
( O
88 O
%, O
P I-GENE
< O
0 O
. O
001 O
) O
of O
the O
_RARE_ I-GENE
_RARE_ I-GENE
muscle O
in O
R I-GENE
rats O
but O
not O
in O
the O
white O
long O
head I-GENE
( O
25 O
%, O
P I-GENE
= O
0 O
. O
06 O
). O

The O
expression O
of O
the O
putative O
operon I-GENE
_RARE_ I-GENE
of O
Bacillus I-GENE
subtilis I-GENE
was O
studied O
by O
using O
_RARE_ I-GENE
'- O
lacZ I-GENE
transcriptional O
fusions I-GENE
. O

Although O
eight O
contiguous O
genes I-GENE
necessary O
for O
urease I-GENE
activity O
have O
been O
cloned O
and O
sequenced O
, O
the O
transcriptional O
organization O
and O
regulation O
of O
specific I-GENE
genes I-GENE
within O
the O
_RARE_ I-GENE
gene I-GENE
cluster I-GENE
has O
not O
been O
investigated O
in O
detail O
. O

The O
_RARE_ I-GENE
operon I-GENE
from O
Rhizobium I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
is O
expressed O
from O
an O
_RARE_ I-GENE
- I-GENE
type I-GENE
promoter I-GENE
that O
_RARE_ I-GENE
mutagenesis O
of O
the O
_RARE_ I-GENE
gene I-GENE
. O

We O
demonstrate O
that O
a O
VT O
+ I-GENE
peptide I-GENE
was O
specifically O
phosphorylated O
by O
protein I-GENE
kinase I-GENE
C I-GENE
( O
PKC I-GENE
) O
in O
vitro O
, O
but O
not O
by O
protein I-GENE
kinase I-GENE
A I-GENE
( O
PKA I-GENE
). O

R I-GENE
. O

15 O
, O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
; O
O O
' O
_RARE_ I-GENE
, O
T I-GENE
. O

Control O
experiments O
showed O
that O
each O
fusion I-GENE
protein I-GENE
had O
a O
high O
affinity O
binding I-GENE
site I-GENE
for O
estradiol O
- I-GENE
17 O
beta I-GENE
and O
could O
transactivate O
an O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
reporter I-GENE
gene I-GENE
in O
yeast I-GENE
similar O
to O
the O
wild I-GENE
type I-GENE
ER I-GENE
. O

Although O
_RARE_ I-GENE
_RARE_ I-GENE
UV O
endonuclease I-GENE
has O
been O
reported O
to O
be O
an O
18 O
- I-GENE
kDa I-GENE
enzyme I-GENE
with O
possible O
homology I-GENE
to O
the O
16 O
- I-GENE
kDa I-GENE
endonuclease I-GENE
V I-GENE
from O
bacteriophage I-GENE
T4 I-GENE
( O
_RARE_ I-GENE
, O
L I-GENE
. O

Several O
different O
oncogenes I-GENE
and O
growth I-GENE
factors I-GENE
promote O
G1 I-GENE
phase O
progression O
. O

Cyclin I-GENE
D1 I-GENE
promoter I-GENE
activity O
was O
stimulated O
by O
overexpression O
of O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
( O
_RARE_ I-GENE
) O
or O
c I-GENE
- I-GENE
Ets I-GENE
- I-GENE
2 I-GENE
through O
the O
proximal I-GENE
22 O
base O
pairs O
. O

Indeed O
, O
_RARE_ I-GENE
and O
c I-GENE
- I-GENE
Jun I-GENE
synergistically O
activated I-GENE
the O
_RARE_ I-GENE
- I-GENE
CRE O
without O
making O
an O
apparent O
ternary O
complex I-GENE
. O

A I-GENE
mutant I-GENE
( O
residues O
1 I-GENE
- I-GENE
_RARE_ I-GENE
) O
showed O
complete O
Ca2 I-GENE
+/ I-GENE
CaM I-GENE
- I-GENE
dependent I-GENE
activity O
. O

In O
addition O
, O
the O
_RARE_ I-GENE
HSF I-GENE
substitution O
exhibits O
constitutive O
transcriptional O
activation O
from O
a O
consensus I-GENE
HSE O
( O
_RARE_ I-GENE
). O

The O
two O
bases O
immediately O
flanking O
the O
5 I-GENE
' O
end O
of O
the O
element I-GENE
proved O
to O
be O
very O
important O
to O
its O
function O
as O
a O
UAS O
element I-GENE
as O
did O
the O
two O
bases O
immediately O
3 I-GENE
' O
of O
the O
bHLH I-GENE
core I-GENE
motif I-GENE
. O

These O
results O
indicate O
that O
the O
PCNA I-GENE
gene I-GENE
is O
a O
likely O
target O
gene I-GENE
of O
E2F I-GENE
. O

Differential O
sensitivity O
of O
the O
MMPI O
- I-GENE
2 I-GENE
depression O
_RARE_ I-GENE
and O
_RARE_ I-GENE
. O

After O
recovery O
, O
a O
_RARE_ I-GENE
saline O
challenge O
was O
performed O
. O

The O
range O
of O
eosinophils O
was O
22 O
- I-GENE
56 O
% O
of O
the O
number O
of O
peripheral O
white O
blood O
cells O
( O
mean O
_RARE_ I-GENE
33 O
%). O

_RARE_ I-GENE
of O
_RARE_ I-GENE
P1 I-GENE
- I-GENE
lacZ I-GENE
expression O
at O
different O
_RARE_ I-GENE
levels O
is O
interpreted O
for O
the O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
mutant I-GENE
as O
resulting O
from O
a O
hypersensitivity O
to O
_RARE_ I-GENE
. O

These O
intron O
_RARE_ I-GENE
show O
that O
peripheral O
sequences I-GENE
and O
the O
elements O
that O
define O
the O
splice O
sites I-GENE
are O
adequate O
for O
self O
- I-GENE
splicing O
activity O
but O
that O
the O
central O
portions O
containing O
the O
catalytic O
_RARE_ I-GENE
of O
_RARE_ I-GENE
and O
_RARE_ I-GENE
are O
deficient O
; O
these O
_RARE_ I-GENE
are O
the O
likely O
targets O
of O
the O
splicing O
proteins I-GENE
. O

Here O
we O
demonstrate O
genetically O
that O
plus O
- I-GENE
strand O
DNA I-GENE
synthesis O
of O
the O
yeast I-GENE
Ty1 I-GENE
element I-GENE
is O
initiated O
at O
two O
sites I-GENE
located O
at O
the O
5 I-GENE
' O
boundary O
of O
the O
3 I-GENE
' O
long O
terminal I-GENE
repeat I-GENE
( O
_RARE_ I-GENE
) O
and O
near O
the O
middle I-GENE
of O
the O
pol I-GENE
gene I-GENE
in O
the O
integrase I-GENE
coding O
sequence I-GENE
( O
_RARE_ I-GENE
). O

Characterization O
of O
the O
3 I-GENE
' O
ends O
of O
the O
plus O
- I-GENE
strand O
DNA I-GENE
fragments I-GENE
reveals O
( O
1 I-GENE
) O
that O
the O
upstream O
fragment I-GENE
is O
_RARE_ I-GENE
beyond O
_RARE_ I-GENE
_RARE_ I-GENE
a O
plus O
- I-GENE
strand O
overlap O
and O
( O
2 I-GENE
) O
that O
the O
majority O
of O
plus O
- I-GENE
strand O
strong O
- I-GENE
stop O
DNA I-GENE
fragments I-GENE
_RARE_ I-GENE
a O
copy O
of O
the O
minus O
- I-GENE
strand O
primer O
binding I-GENE
site I-GENE
in O
agreement O
with O
the O
accepted O
model O
of O
retroviral I-GENE
genomic O
RNA I-GENE
reverse I-GENE
transcription I-GENE
. O

The O
patients O
undergoing O
_RARE_ I-GENE
had O
significantly O
shorter O
operative O
times O
( O
_RARE_ I-GENE
, O
100 O
. O
2 I-GENE
+/- O
27 O
. O
2 I-GENE
min O
. O
vs O
_RARE_ I-GENE
, O
119 O
. O
8 O
+/- O
42 O
. O
6 I-GENE
min O
; O
p O
< O
0 O
. O
01 O
) O
and O
less O
blood O
loss O
( O
_RARE_ I-GENE
, O
4 I-GENE
. O
7 O
+/- O
14 O
. O
6 I-GENE
ml O
vs O
_RARE_ I-GENE
, O
65 O
. O
7 O
+/- O
77 O
. O
0 O
ml O
; O
p O
< O
0 O
. O
001 O
). O

By O
150 O
minutes O
after O
_RARE_ I-GENE
inhalation O
, O
FEV1 O
. O
0 O
had O
decreased O
by O
32 O
%. O

This O
combined O
intravenous O
_RARE_ I-GENE
regimen O
gave O
good O
anaesthesia O
and O
analgesia O
to O
pigs O
for O
up O
to O
2 I-GENE
h O
as O
monitored O
by O
clinical O
signs O
. O

Twenty O
food O
products I-GENE
were O
contaminated O
with O
V I-GENE
. O
cholerae I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
and O
not O
_RARE_ I-GENE
strains O
: O
_RARE_ I-GENE
, O
cream O
_RARE_ I-GENE
, O
_RARE_ I-GENE
_RARE_ I-GENE
, O
hip O
rose O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
_RARE_ I-GENE
for O
" O
_RARE_ I-GENE
_RARE_ I-GENE
" O
_RARE_ I-GENE
de O
_RARE_ I-GENE
_RARE_ I-GENE
meat O
_RARE_ I-GENE
, O
meat O
and O
_RARE_ I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
milk O
_RARE_ I-GENE
( O
made O
with O
_RARE_ I-GENE
, O
milk O
_RARE_ I-GENE
, O
_RARE_ I-GENE
and O
_RARE_ I-GENE
), O
_RARE_ I-GENE
, O
_RARE_ I-GENE
fish O
, O
_RARE_ I-GENE
and O
_RARE_ I-GENE
milk O
. O

It O
is O
_RARE_ I-GENE
to O
define O
only O
one O
clinical O
_RARE_ I-GENE
because O
both O
symptomatic O
and O
asymptomatic O
infected O
_RARE_ I-GENE
may O
be O
found O
with O
gestational O
age O
at O
term O
and O
pre I-GENE
- I-GENE
term O
and O
when O
born O
with O
a O
weight O
above O
or O
below O
2000 O
g O
. O

The O
expression O
of O
the O
_RARE_ I-GENE
gene I-GENE
, O
_RARE_ I-GENE
, O
is O
dependent I-GENE
upon O
_RARE_ I-GENE
and O
upon O
_RARE_ I-GENE
. O

The O
chloramphenicol I-GENE
- I-GENE
resistance O
transposon I-GENE
_RARE_ I-GENE
undergoes O
precise O
_RARE_ I-GENE
deletion O
from O
its O
_RARE_ I-GENE
plasmid O
_RARE_ I-GENE
in O
_RARE_ I-GENE
_RARE_ I-GENE
and O
precise O
spontaneous O
excision O
from O
multicopy O
plasmids O
in O
Escherichia I-GENE
coli I-GENE
. O

Ras I-GENE
_RARE_ I-GENE
inhibits O
_RARE_ I-GENE
without O
altering O
the O
DNA I-GENE
binding I-GENE
or O
transcriptional O
activities O
of O
the O
myogenic I-GENE
basic I-GENE
helix I-GENE
- I-GENE
loop I-GENE
- I-GENE
helix I-GENE
factors I-GENE
. O

In O
cells O
limited O
for O
His O
, O
increased O
expression O
of O
_RARE_ I-GENE
- I-GENE
2 I-GENE
and O
_RARE_ I-GENE
- I-GENE
1 I-GENE
, O
and O
decreased O
expression O
of O
_RARE_ I-GENE
- I-GENE
5 I-GENE
, O
also O
had O
translational O
and O
transcriptional O
components O
. O

The O
peptide I-GENE
sequences I-GENE
reveal O
that O
the O
factor I-GENE
consists O
of O
GABP I-GENE
alpha I-GENE
and O
GABP I-GENE
beta I-GENE
1 I-GENE
with O
Ets I-GENE
and O
Notch I-GENE
motifs O
, O
respectively O
. O

_RARE_ I-GENE
microscopy O
and O
cell O
fractionation O
analyses O
showed O
that O
the O
110 I-GENE
- I-GENE
kDa I-GENE
protein I-GENE
was O
exclusively O
nuclear I-GENE
, O
whereas O
the O
150 O
- I-GENE
kDa I-GENE
protein I-GENE
was O
present O
in O
both O
the O
cytoplasm O
and O
nucleus O
of O
human I-GENE
cells O
. O

Expression O
and O
regulation O
by O
interferon I-GENE
of O
a O
double O
- I-GENE
stranded I-GENE
- I-GENE
RNA I-GENE
- I-GENE
specific I-GENE
adenosine I-GENE
deaminase I-GENE
from O
human I-GENE
cells O
: O
evidence O
for O
two O
forms O
of O
the O
deaminase I-GENE
. O

T I-GENE
- I-GENE
cell O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
and O
T I-GENE
cells O
can O
be O
induced O
to O
undergo O
apoptotic O
cell O
death O
by O
activation O
through O
the O
T I-GENE
- I-GENE
cell O
receptor I-GENE
. O

_RARE_ I-GENE
were O
examined O
in O
the O
_RARE_ I-GENE
gene I-GENE
, O
using O
a O
set O
of O
31 O
- I-GENE
to O
156 I-GENE
- I-GENE
bp O
inserts O
that O
included O
inserts O
with O
no O
apparent O
potential O
for O
secondary O
structure O
as O
well O
as O
two O
_RARE_ I-GENE
. O

Overexpression O
of O
_RARE_ I-GENE
could O
not O
complement I-GENE
an O
_RARE_ I-GENE
- I-GENE
null I-GENE
allele I-GENE
, O
indicating O
that O
suppression O
was O
not O
due O
to O
the O
_RARE_ I-GENE
of O
_RARE_ I-GENE
activity O
. O

The O
DNA I-GENE
binding I-GENE
domain I-GENE
of O
_RARE_ I-GENE
was O
expressed O
as O
a O
fusion I-GENE
protein I-GENE
with O
the O
glutathione I-GENE
S I-GENE
- I-GENE
transferase I-GENE
of O
_RARE_ I-GENE
_RARE_ I-GENE
. O

The O
kinase I-GENE
is O
essential O
in O
vivo O
for O
normal O
phosphorylation O
of O
the O
CTD I-GENE
and O
for O
normal O
growth I-GENE
and O
differentiation O
. O

A I-GENE
general O
model O
for O
_RARE_ I-GENE
- I-GENE
mediated O
mRNA I-GENE
degradation O
involving O
a O
potential O
role O
for O
certain O
heterogeneous I-GENE
nuclear I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
- I-GENE
binding I-GENE
proteins I-GENE
is O
proposed O
. O

Finally O
, O
we O
demonstrate O
that O
C I-GENE
/ I-GENE
EBP I-GENE
alpha I-GENE
can O
also O
active O
the O
GM I-GENE
- I-GENE
CSF I-GENE
receptor I-GENE
alpha I-GENE
promoter I-GENE
in O
_RARE_ I-GENE
cells O
. O

_RARE_ I-GENE
and O
vacuolar I-GENE
degradation O
of O
the O
plasma I-GENE
membrane I-GENE
- I-GENE
localized O
_RARE_ I-GENE
ATP I-GENE
- I-GENE
binding I-GENE
cassette I-GENE
multidrug I-GENE
transporter I-GENE
in O
Saccharomyces I-GENE
cerevisiae I-GENE
. O

_RARE_ I-GENE
mutations O
in O
motifs O
III I-GENE
, O
IV I-GENE
, O
and O
V I-GENE
had O
distinctive O
effects O
on O
the O
affinity O
of O
enzyme I-GENE
for O
GTP I-GENE
, O
the O
rate O
of O
_RARE_ I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
formation O
), O
or O
the O
transfer I-GENE
of O
_RARE_ I-GENE
from O
enzyme I-GENE
to O
RNA I-GENE
. O

Mutational O
analysis O
of O
mRNA I-GENE
capping I-GENE
enzyme I-GENE
identifies O
amino O
acids O
involved O
in O
GTP I-GENE
binding I-GENE
, O
enzyme I-GENE
- I-GENE
_RARE_ I-GENE
formation O
, O
and O
_RARE_ I-GENE
transfer I-GENE
to O
RNA I-GENE
. O

Disruption O
of O
the O
_RARE_ I-GENE
and O
_RARE_ I-GENE
genes I-GENE
leads O
to O
a O
dramatic O
decrease O
of O
the O
_RARE_ I-GENE
inducibility O
in O
_RARE_ I-GENE
cells O
, O
whereas O
_RARE_ I-GENE
of O
_RARE_ I-GENE
produces O
a O
_RARE_ I-GENE
increase O
in O
wild I-GENE
- I-GENE
type I-GENE
induced O
levels O
upon O
a O
shift O
to O
a O
high O
salt O
concentration O
. O

Deletion O
or O
inactivation O
of O
_RARE_ I-GENE
leads O
to O
5 I-GENE
- I-GENE
to O
10 O
- I-GENE
fold O
- I-GENE
increased O
levels O
of O
_RARE_ I-GENE
mRNA I-GENE
. O

( O
1986 O
) O
method O
of O
separation O
of O
_RARE_ I-GENE
_RARE_ I-GENE
. O
_RARE_ I-GENE
from O
_RARE_ I-GENE
by O
using O
a O
_RARE_ I-GENE
_RARE_ I-GENE
density I-GENE
gradient O
appeared O
a O
method O
of O
choice O
for O
obtaining O
large O
numbers O
of O
_RARE_ I-GENE
of O
C I-GENE
. O
_RARE_ I-GENE
free O
of O
fecal O
contamination O
. O

_RARE_ I-GENE
enterotoxin I-GENE
A I-GENE
involvement O
in O
the O
illness O
of O
a O
20 O
- I-GENE
month O
- I-GENE
old O
burn O
patient O
. O

METHODS O
: O
We O
obtained O
maximal O
inspiratory O
and O
expiratory O
flow O
- I-GENE
volume O
curves O
in O
41 O
_RARE_ I-GENE
patients O
with O
essential O
tremor O
( O
14 O
males O
, O
27 O
females O
, O
age O
61 O
. O
7 O
+/- O
2 I-GENE
. O
14 O
years O
). O

Our O
findings O
also O
provide O
the O
basis O
for O
the O
development O
of O
assays O
to O
screen O
for O
the O
ligands O
to O
testis I-GENE
receptor I-GENE
2 I-GENE
and O
_RARE_ I-GENE
. O

Four O
p53 I-GENE
DNA I-GENE
- I-GENE
binding I-GENE
domain I-GENE
peptides I-GENE
bind O
natural O
p53 I-GENE
- I-GENE
response O
elements O
and O
_RARE_ I-GENE
the O
DNA I-GENE
. O

The O
_RARE_ I-GENE
mRNA I-GENE
has O
a O
size O
of O
5 I-GENE
. O
6 I-GENE
kb O
and O
encodes O
a O
protein I-GENE
of O
_RARE_ I-GENE
amino O
acids O
. O

The O
_RARE_ I-GENE
_RARE_ I-GENE
revealed O
a O
rather O
hydrophilic O
N I-GENE
- I-GENE
terminal I-GENE
region O
and O
the O
absence O
of O
a O
hydrophobic O
signal I-GENE
peptide I-GENE
. O

These O
results O
suggest O
that O
G I-GENE
beta I-GENE
gamma I-GENE
- I-GENE
stimulated O
Shc I-GENE
phosphorylation O
represents O
an O
early I-GENE
step O
in O
the O
pathway O
leading O
to O
p21ras I-GENE
activation O
, O
similar O
to O
the O
mechanism O
utilized O
by O
growth I-GENE
factor I-GENE
tyrosine I-GENE
kinase I-GENE
receptors I-GENE
. O

This O
report O
focused O
on O
the O
relationship O
between O
Type O
A I-GENE
behavior O
and O
eight O
basic I-GENE
_RARE_ I-GENE
dimensions O
. O

All O
_RARE_ I-GENE
resulted O
in O
contamination O
with O
aerobic O
_RARE_ I-GENE
bacteria O
in O
the O
range O
from O
6 I-GENE
x O
10 O
( O
3 I-GENE
) O
to O
1 I-GENE
. O
2 I-GENE
x O
10 O
( O
6 I-GENE
) O
_RARE_ I-GENE
/ I-GENE
ml O
liquid O
_RARE_ I-GENE
, O
and O
94 O
% O
them O
with O
_RARE_ I-GENE
bacteria O
, O
the O
threshold O
being O
under O
100 O
_RARE_ I-GENE
/ I-GENE
ml O
( O
_RARE_ I-GENE
1 I-GENE
). O

As O
for O
31 O
stage O
I I-GENE
- I-GENE
II I-GENE
lung O
cancer O
patients O
, O
CR I-GENE
has O
been O
observed O
in O
82 O
. O
8 O
% O
of O
them O
and O
PR I-GENE
in O
13 O
. O
8 O
%; O
the O
response O
was O
always O
assessed O
with O
chest O
_RARE_ I-GENE
, O
CT I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
and O
/ I-GENE
or O
_RARE_ I-GENE
. O

_RARE_ I-GENE
medical O
_RARE_ I-GENE
in O
a O
regional O
hospital O
: O
appropriate O
_RARE_ I-GENE
? O

Protein I-GENE
electrophoresis O
showed O
decreased O
albumin I-GENE
levels O
in O
both O
groups O
, O
with O
lower O
values O
in O
G2 I-GENE
. O

METHODS O
: O
All O
these O
30 O
non O
- I-GENE
responders O
received O
an O
extra I-GENE
dose O
of O
the O
same O
vaccine O
2 I-GENE
months O
after O
primary O
immunization O
and O
a O
_RARE_ I-GENE
dose O
with O
a O
yeast I-GENE
- I-GENE
derived O
vaccine O
6 I-GENE
years O
later O
. O

An O
_RARE_ I-GENE
high O
percentage O
of O
hypertensive O
patients O
( O
approximately O
30 O
%) O
undergoing O
cardiac O
_RARE_ I-GENE
because O
of O
_RARE_ I-GENE
pain O
and O
/ I-GENE
or O
exercise O
- I-GENE
induced O
ST O
- I-GENE
segment O
_RARE_ I-GENE
has O
_RARE_ I-GENE
normal O
coronary O
arteries O
. O

_RARE_ I-GENE
- I-GENE
staining O
, O
_RARE_ I-GENE
mycobacteria O
in O
_RARE_ I-GENE
- I-GENE
stained O
smears O
. O

_RARE_ I-GENE
( O
Ro I-GENE
40 I-GENE
- I-GENE
_RARE_ I-GENE
) O
is O
a O
novel O
calcium O
antagonist O
from O
a O
new O
chemical O
class I-GENE
and O
is O
the O
first O
that O
selectively O
blocks O
the O
T I-GENE
- I-GENE
type I-GENE
calcium O
channel O
. O

However O
, O
2 I-GENE
minimum O
alveolar O
concentration O
anesthesia O
did O
significantly O
decrease O
the O
calculated O
VE O
at O
a O
PCO2 O
of O
60 O
mmHg O
( O
from O
7 O
. O
4 I-GENE
+/- O
1 I-GENE
. O
2 I-GENE
to O
4 I-GENE
. O
0 O
+/- O
0 O
. O
6 I-GENE
l O
. O
min O
- I-GENE
1 I-GENE
), O
indicating O
a O
_RARE_ I-GENE
shift O
in O
the O
response O
relationship O
. O

cDNA I-GENE
encoding O
a O
functional O
feline I-GENE
liver O
/ I-GENE
bone O
/ I-GENE
kidney O
- I-GENE
type I-GENE
alkaline I-GENE
phosphatase I-GENE
. O

Protein I-GENE
kinase I-GENE
C I-GENE
( O
PKC I-GENE
), O
a O
widely O
- I-GENE
distributed O
enzyme I-GENE
implicated O
in O
the O
regulation O
of O
many O
physiological O
processes O
, O
consists O
of O
a O
family I-GENE
of O
at O
least O
_RARE_ I-GENE
isoenzymes I-GENE
which O
differ O
in O
tissue I-GENE
distribution O
, O
subcellular O
localization O
, O
regulatory I-GENE
properties O
, O
etc O
. O

This O
work O
, O
therefore O
, O
also O
emphasizes O
the O
importance O
of O
_RARE_ I-GENE
choice O
of O
oligonucleotide I-GENE
and O
cDNA I-GENE
probes O
to O
study O
PKC I-GENE
zeta I-GENE
mRNA I-GENE
. O

This O
action O
is O
dependent I-GENE
on O
helix I-GENE
- I-GENE
loop I-GENE
- I-GENE
helix I-GENE
factors I-GENE
bound O
to O
the O
E1 I-GENE
element I-GENE
. O

The O
_RARE_ I-GENE
over O
_RARE_ I-GENE
-- O
_RARE_ I-GENE
. O

_RARE_ I-GENE
growth I-GENE
factors I-GENE
and O
cytokines O
mediate O
their O
biochemical O
functions O
through O
their O
responsive I-GENE
receptors I-GENE
. O

However O
, O
a O
strongly O
increased O
frequency O
of O
CpG O
_RARE_ I-GENE
was O
found O
. O

Here O
we O
focused O
on O
the O
role O
of O
the O
5 I-GENE
' O
proximal I-GENE
regulatory I-GENE
cassette I-GENE
(- O
190 O
; O
+ I-GENE
53 O
bp O
) O
of O
the O
rat I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
gene I-GENE
in O
the O
developmental O
regulation O
of O
the O
_RARE_ I-GENE
phenotype O
. O

_RARE_ I-GENE
, O
all O
_RARE_ I-GENE
- I-GENE
specific I-GENE
motifs O
formed O
specific I-GENE
and O
highly O
abundant O
protein I-GENE
- I-GENE
DNA I-GENE
complexes I-GENE
when O
nuclear I-GENE
extracts O
from O
the O
human I-GENE
tumor I-GENE
cell O
line O
( O
HeLa O
), O
which O
does O
not O
express O
_RARE_ I-GENE
, O
were O
used O
. O

_RARE_ I-GENE
aged O
3 I-GENE
. O
5 I-GENE
years O
presents O
_RARE_ I-GENE
of O
_RARE_ I-GENE
vitreous O
body O
with O
crystalline O
dislocation O
in O
the O
_RARE_ I-GENE
_RARE_ I-GENE
and O
secondary O
_RARE_ I-GENE
of O
the O
left O
eye O
and O
_RARE_ I-GENE
with O
dislocation O
of O
the O
crystalline O
in O
the O
vitreous O
body O
of O
the O
right O
eye O
. O

During O
the O
dose O
- I-GENE
finding O
, O
two O
patients O
were O
_RARE_ I-GENE
_RARE_ I-GENE
from O
medication O
and O
one O
patient O
was O
excluded O
because O
of O
elevated O
levels O
of O
liver O
enzymes O
. O

In O
comparison O
of O
cDNA I-GENE
and O
genomic O
sequences I-GENE
four O
RNA I-GENE
_RARE_ I-GENE
events O
were O
found O
in O
both O
_RARE_ I-GENE
genes I-GENE
. O

_RARE_ I-GENE
- I-GENE
1 I-GENE
represses O
CAT I-GENE
reporter I-GENE
gene I-GENE
expression O
via O
GAL4 I-GENE
binding I-GENE
sites I-GENE
in O
the O
_RARE_ I-GENE
cell O
lines O
NIH O
3T3 O
and O
293 O
. O

As O
with O
the O
heterologous O
DNA I-GENE
binding I-GENE
domain I-GENE
, O
_RARE_ I-GENE
- I-GENE
1 I-GENE
represses O
reporter I-GENE
gene I-GENE
expression O
in O
_RARE_ I-GENE
cell O
lines O
and O
activates O
expression O
in O
hematopoietic I-GENE
cell O
lines O
. O

_RARE_ I-GENE
of O
_RARE_ I-GENE
beta I-GENE
subunit I-GENE
mutants I-GENE
revealed O
two O
cytoplasmic I-GENE
regions O
involved O
in O
activation O
of O
the O
c I-GENE
- I-GENE
myc I-GENE
promoter I-GENE
, O
one O
is O
essential O
and O
the O
other O
is O
dispensable O
but O
enhances O
the O
activity O
. O

Similarly O
, O
we O
observed O
synthetic O
phenotypes O
between O
mutations O
in O
_RARE_ I-GENE
and O
trans O
- I-GENE
acting O
mutations O
in O
three O
known O
yeast I-GENE
centromere O
protein I-GENE
genes I-GENE
- I-GENE
_RARE_ I-GENE
/ I-GENE
CBF1 I-GENE
/ I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
/ I-GENE
CBF2 I-GENE
, O
and O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
. O

Taken O
together O
, O
these O
data O
suggest O
that O
the O
_RARE_ I-GENE
protein I-GENE
interacts O
with O
_RARE_ I-GENE
at O
the O
centromere O
and O
that O
the O
yeast I-GENE
centromere O
indeed O
exists O
as O
a O
higher O
order O
protein I-GENE
- I-GENE
DNA I-GENE
complex I-GENE
. O

To O
_RARE_ I-GENE
this O
, O
actin I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
are O
_RARE_ I-GENE
during O
the O
cell O
cycle O
to O
direct O
secretory I-GENE
components O
to O
appropriate O
sites I-GENE
for O
cell O
growth I-GENE
. O

The O
effects O
of O
_RARE_ I-GENE
_RARE_ I-GENE
oral O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
on O
tissue I-GENE
- I-GENE
type I-GENE
plasminogen I-GENE
activator I-GENE
( O
t I-GENE
- I-GENE
PA I-GENE
) O
and O
plasminogen I-GENE
activator I-GENE
inhibitor I-GENE
( O
PAI I-GENE
) O
in O
the O
plasma I-GENE
of O
25 O
patients O
of O
coronary O
heart O
disease O
with O
blood O
_RARE_ I-GENE
were O
studied O
. O

_RARE_ I-GENE
daily O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
per O
_RARE_ I-GENE
were O
0 O
. O
56 O
microgram O
for O
total O
_RARE_ I-GENE
, O
0 O
. O
20 O
microgram O
for O
gamma I-GENE
- I-GENE
_RARE_ I-GENE
, O
0 O
. O
09 O
microgram O
for O
_RARE_ I-GENE
, O
1 I-GENE
. O
42 O
micrograms O
for O
total O
_RARE_ I-GENE
, O
and O
0 O
. O
15 O
microgram O
for O
HCB O
. O

_RARE_ I-GENE
features O
of O
splenic O
_RARE_ I-GENE
cyst O
with O
pathologic O
correlation O
. O

In O
two O
further O
cases O
( O
one O
type I-GENE
I I-GENE
and O
one O
type I-GENE
III I-GENE
_RARE_ I-GENE
), O
de O
novo I-GENE
deletions O
of O
only O
one O
copy O
of O
_RARE_ I-GENE
- I-GENE
CA I-GENE
and O
_RARE_ I-GENE
were O
found O
. O

With O
each O
of O
the O
three O
pairs O
of O
isolates O
( O
case O
and O
_RARE_ I-GENE
case O
), O
identical O
_RARE_ I-GENE
_RARE_ I-GENE
patterns O
were O
found O
suggesting O
identical O
_RARE_ I-GENE
strains O
. O

_RARE_ I-GENE
has O
been O
found O
to O
be O
clinically O
useful O
in O
assessing O
histologic O
damage O
following O
_RARE_ I-GENE
dilatation O
and O
in O
_RARE_ I-GENE
the O
_RARE_ I-GENE
during O
the O
administration O
of O
_RARE_ I-GENE
botulinum I-GENE
toxin I-GENE
injection O
in O
the O
treatment O
of O
_RARE_ I-GENE
. O

These O
early I-GENE
structural O
processes O
are O
assumed O
to O
be O
_RARE_ I-GENE
by O
the O
anterior O
parts O
of O
the O
left O
hemisphere O
, O
as O
event O
- I-GENE
related I-GENE
brain O
potentials O
show O
this O
area O
to O
be O
_RARE_ I-GENE
activated I-GENE
when O
_RARE_ I-GENE
structure O
_RARE_ I-GENE
are O
processed O
and O
as O
_RARE_ I-GENE
lesions O
in O
this O
area O
lead O
to O
an O
impairment O
of O
the O
on O
- I-GENE
line O
structural O
assignment O
. O

In O
men O
with O
BMI O
< O
30 O
, O
the O
OR O
was O
1 I-GENE
. O
83 O
for O
_RARE_ I-GENE
TG I-GENE
( O
P I-GENE
= O
. O
_RARE_ I-GENE
) O
and O
2 I-GENE
. O
77 O
for O
_RARE_ I-GENE
RP I-GENE
( O
P I-GENE
= O
. O
_RARE_ I-GENE
) O
in O
models O
that O
included O
fasting O
TG I-GENE
, O
LDL I-GENE
- I-GENE
C I-GENE
, O
and O
hypertension O
. O

_RARE_ I-GENE
trans O
- I-GENE
splicing O
specified O
by O
_RARE_ I-GENE
- I-GENE
rich O
synthetic O
RNA I-GENE
inserted O
at O
the O
5 I-GENE
' O
end O
of O
Caenorhabditis I-GENE
elegans I-GENE
pre I-GENE
- I-GENE
mRNA I-GENE
. O

A I-GENE
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
compound O
, O
6 I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
4 I-GENE
-[ I-GENE
2 I-GENE
_RARE_ I-GENE
2 I-GENE
- I-GENE
_RARE_ I-GENE
)- I-GENE
ethyl O
] O
amino O
_RARE_ I-GENE
3 I-GENE
- I-GENE
methyl O
- I-GENE
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
[ O
3 I-GENE
, O
4 I-GENE
- I-GENE
b I-GENE
] O
_RARE_ I-GENE
( O
_RARE_ I-GENE
_RARE_ I-GENE
), O
was O
identified O
based O
on O
its O
ability O
to O
_RARE_ I-GENE
human I-GENE
smooth I-GENE
muscle O
alpha I-GENE
- I-GENE
actin I-GENE
promoter I-GENE
activity O
in O
ras I-GENE
- I-GENE
transformed O
cells O
. O

On O
the O
basis O
of O
these O
relations O
, O
a O
risk O
factor I-GENE
- I-GENE
selection O
scale O
( O
_RARE_ I-GENE
) O
( O
range O
, O
0 O
to O
10 O
) O
was O
developed O
by O
_RARE_ I-GENE
appropriate O
weights O
for O
each O
risk O
factor I-GENE
. O

The O
Caenorhabditis I-GENE
elegans I-GENE
death O
susceptibility I-GENE
gene I-GENE
, O
_RARE_ I-GENE
- I-GENE
3 I-GENE
, O
has O
a O
number O
of O
homologs I-GENE
in O
vertebrate I-GENE
species O
, O
including O
interleukin I-GENE
- I-GENE
1 I-GENE
beta I-GENE
( O
IL I-GENE
- I-GENE
1 I-GENE
beta I-GENE
)- I-GENE
converting I-GENE
enzyme I-GENE
( O
ICE I-GENE
), O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
. O

_RARE_ I-GENE
of O
glucocorticoid I-GENE
receptor I-GENE
- I-GENE
mediated O
transcriptional O
activation O
by O
_RARE_ I-GENE
thyroid I-GENE
hormone I-GENE
receptor I-GENE
( O
TR I-GENE
) O
is O
TR I-GENE
isoform I-GENE
- I-GENE
specific I-GENE
. O

The O
results O
indicate O
considerable O
_RARE_ I-GENE
in O
the O
_RARE_ I-GENE
between O
_RARE_ I-GENE
regulatory I-GENE
sites I-GENE
. O

_RARE_ I-GENE
of O
the O
_RARE_ I-GENE
repressor I-GENE
function O
by O
the O
transactivating O
members O
of O
the O
ets I-GENE
family I-GENE
of O
genes I-GENE
( O
i O
. O
e O
. O
gag I-GENE
- I-GENE
myb I-GENE
- I-GENE
ets I-GENE
) O
may O
be O
essential O
for O
the O
control O
of O
genes I-GENE
involved O
in O
cell O
proliferation O
and O
may O
also O
_RARE_ I-GENE
their O
tumorigenic O
effects O
. O

Overexpression O
of O
wild I-GENE
- I-GENE
type I-GENE
p53 I-GENE
also O
induces O
apoptosis O
in O
an O
_RARE_ I-GENE
. O

We O
show O
that O
c I-GENE
- I-GENE
Fos I-GENE
( O
the O
c I-GENE
- I-GENE
fos I-GENE
protooncogene I-GENE
product I-GENE
), O
which O
is O
an O
_RARE_ I-GENE
unstable O
nuclear I-GENE
protein I-GENE
, O
is O
_RARE_ I-GENE
highly O
stabilized O
, O
and O
greatly O
enhances O
the O
transforming I-GENE
efficiency O
of O
NIH O
3T3 O
cells O
, O
by O
_RARE_ I-GENE
. O

Cloning O
, O
sequencing O
and O
expression O
of O
the O
3 I-GENE
- I-GENE
_RARE_ I-GENE
kinase I-GENE
gene I-GENE
of O
_RARE_ I-GENE
_RARE_ I-GENE
in O
Escherichia I-GENE
coli I-GENE
and O
characterization O
of O
the O
protein I-GENE
. O

These O
observations O
lead O
to O
the O
_RARE_ I-GENE
that O
the O
RNAP I-GENE
II I-GENE
CTD I-GENE
might O
be O
an O
in O
vivo O
target O
for O
the O
activated I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
MAP I-GENE
kinases I-GENE
. O

We O
also O
isolated O
two O
alternatively O
spliced O
forms O
of O
human I-GENE
_RARE_ I-GENE
cDNA I-GENE
lacking O
sequences I-GENE
encoding O
membrane I-GENE
- I-GENE
proximal I-GENE
regions O
of O
the O
cytoplasmic I-GENE
domain I-GENE
which O
maintain O
the O
same O
reading O
frame O
as O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
. O

We O
sought O
to O
determine O
whether O
such O
differences O
in O
polyadenylation O
affect O
the O
steady O
- I-GENE
state O
levels O
of O
DHFR I-GENE
and O
mRNAs I-GENE
expressed O
from O
either O
allele I-GENE
and O
, O
in O
a O
more O
general O
sense O
, O
to O
_RARE_ I-GENE
whether O
differences O
in O
3 I-GENE
' O
end O
RNA I-GENE
processing O
in O
a O
gene I-GENE
containing O
multiple O
poly O
( O
A I-GENE
) O
sites I-GENE
affects O
the O
final O
level O
of O
gene I-GENE
expression O
. O

We O
have O
isolated O
a O
Drosophila I-GENE
melanogaster I-GENE
( O
_RARE_ I-GENE
) O
cDNA I-GENE
encoding O
a O
polypeptide I-GENE
that O
has O
extensive O
sequence I-GENE
similarity O
to O
the O
mammalian I-GENE
_RARE_ I-GENE
- I-GENE
2 I-GENE
. O

A I-GENE
2 I-GENE
. O
4 I-GENE
- I-GENE
kb O
_RARE_ I-GENE
- I-GENE
2 I-GENE
message I-GENE
is O
expressed O
throughout O
development O
, O
while O
two O
shorter O
transcripts I-GENE
of O
2 I-GENE
. O
3 I-GENE
and O
1 I-GENE
. O
8 O
kb O
appear O
to O
be O
specifically O
expressed O
in O
the O
germline I-GENE
. O

The O
finding O
that O
the O
chimeric I-GENE
_RARE_ I-GENE
:: O
Pol I-GENE
beta I-GENE
protein I-GENE
possessed O
significant O
template O
- I-GENE
dependent I-GENE
polymerase I-GENE
activity O
suggests O
that O
aa O
1 I-GENE
- I-GENE
60 O
of O
Pol I-GENE
beta I-GENE
are O
involved O
in O
template O
utilization O
during O
the O
_RARE_ I-GENE
reaction O
, O
as O
suggested O
by O
the O
previous O
finding O
that O
the O
8 O
- I-GENE
kDa I-GENE
N I-GENE
- I-GENE
terminal I-GENE
domain I-GENE
of O
Pol I-GENE
beta I-GENE
possesses O
ssDNA I-GENE
- I-GENE
binding I-GENE
activity O
[ O
_RARE_ I-GENE
et O
al O
., O
J O
. O

The O
average O
values O
were O
_RARE_ I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
/ I-GENE
g O
for O
the O
_RARE_ I-GENE
and O
hot O
dogs O
, O
respectively O
. O

_RARE_ I-GENE
was O
performed O
in O
all O
cases O
and O
classified O
by O
a O
_RARE_ I-GENE
system O
specifically O
developed O
for O
pediatric O
patients O
. O

The O
integrity O
of O
the O
cDNA I-GENE
sequence I-GENE
was O
confirmed O
by O
analysis O
of O
several O
overlapping O
genomic O
clones O
that O
span O
the O
_RARE_ I-GENE
gene I-GENE
. O

In O
_RARE_ I-GENE
1 I-GENE
, O
eight O
_RARE_ I-GENE
were O
allowed O
to O
_RARE_ I-GENE
naturally O
( O
d O
114 I-GENE
, O
NF I-GENE
_RARE_ I-GENE
) O
and O
eight O
_RARE_ I-GENE
were O
induced O
to O
_RARE_ I-GENE
( O
IF O
_RARE_ I-GENE
) O
_RARE_ I-GENE
by O
injection O
of O
prostaglandin I-GENE
F2 O
alpha I-GENE
on O
d O
112 O
of O
gestation O
. O

_RARE_ I-GENE
- I-GENE
tidal O
PO2 O
and O
the O
ratio O
of O
minute O
ventilation O
to O
oxygen O
consumption O
( O
VE O
/ I-GENE
VO2 O
) O
were O
lower O
while O
_RARE_ I-GENE
was O
higher O
for O
_RARE_ I-GENE
( O
P I-GENE
< O
or O
= O
0 O
. O
01 O
). O

These O
results O
suggested O
that O
_RARE_ I-GENE
negatively O
_RARE_ I-GENE
the O
expression O
of O
_RARE_ I-GENE
itself O
. O

_RARE_ I-GENE
is O
a O
broad O
- I-GENE
host O
- I-GENE
range O
, O
virulent O
_RARE_ I-GENE
for O
_RARE_ I-GENE
monocytogenes O
. O

The O
mechanism O
of O
peroxisome I-GENE
proliferation O
is O
poorly O
understood O
. O

If O
NCR O
- I-GENE
sensitive O
gene I-GENE
expression O
occurs O
exclusively O
by O
this O
pathway O
, O
as O
has O
been O
thought O
to O
be O
the O
case O
, O
then O
the O
NCR O
sensitivity O
of O
a O
gene I-GENE
' O
s O
expression O
should O
be O
abolished O
by O
a O
_RARE_ I-GENE
delta I-GENE
mutation I-GENE
. O

The O
single O
- I-GENE
stranded I-GENE
DNA I-GENE
_RARE_ I-GENE
alpha I-GENE
recognition I-GENE
element I-GENE
_RARE_ I-GENE
these O
complexes I-GENE
. O

Association O
of O
human I-GENE
_RARE_ I-GENE
alpha I-GENE
with O
the O
retinoblastoma I-GENE
protein I-GENE
, O
Rb I-GENE
, O
regulates O
binding I-GENE
to O
the O
single O
- I-GENE
stranded I-GENE
DNA I-GENE
_RARE_ I-GENE
alpha I-GENE
recognition I-GENE
element I-GENE
. O

The O
insulin I-GENE
- I-GENE
induced O
DNA I-GENE
- I-GENE
binding I-GENE
complex I-GENE
was O
identified O
as O
the O
p50 I-GENE
/ I-GENE
p65 I-GENE
heterodimer O
. O

Using O
varying O
conditions O
, O
three O
distinct O
complexes I-GENE
were O
shown O
to O
interact O
specifically O
with O
the O
_RARE_ I-GENE
region O
, O
although O
only O
one O
correlates O
with O
repressor I-GENE
activity O
. O

_RARE_ I-GENE
of O
the O
_RARE_ I-GENE
and O
HL I-GENE
_RARE_ I-GENE
resulted O
in O
a O
reversal O
of O
the O
phospholipase I-GENE
/ I-GENE
neutral O
lipase I-GENE
ratio O
, O
_RARE_ I-GENE
the O
important O
role O
of O
this O
region O
in O
mediating O
substrate I-GENE
specificity O
. O

The O
interferon I-GENE
- I-GENE
inducible I-GENE
protein I-GENE
kinase I-GENE
PKR I-GENE
_RARE_ I-GENE
the O
transcriptional O
activation O
of O
immunoglobulin I-GENE
kappa I-GENE
gene I-GENE
. O

_RARE_ I-GENE
forms O
of O
a O
novel O
yeast I-GENE
protein I-GENE
suppress O
the O
lethality O
of O
a O
G I-GENE
protein I-GENE
alpha I-GENE
subunit I-GENE
deficiency O
by O
interacting I-GENE
with O
the O
beta I-GENE
subunit I-GENE
. O

Another O
common O
mutation I-GENE
involved O
amino O
acids O
that O
are O
thought O
to O
make O
specific I-GENE
contacts O
with O
DNA I-GENE
. O

_RARE_ I-GENE
esters O
stimulated O
phosphorylation O
of O
_RARE_ I-GENE
_RARE_ I-GENE
proteins I-GENE
, O
thus O
_RARE_ I-GENE
that O
sequences I-GENE
isolated O
according O
to O
PKC I-GENE
binding I-GENE
activity O
in O
vitro O
are O
also O
PKC I-GENE
substrates O
in O
vivo O
. O

_RARE_ I-GENE
of O
_RARE_ I-GENE
- I-GENE
14 O
protein I-GENE
( O
also O
termed O
_RARE_ I-GENE
- I-GENE
3 I-GENE
) O
become O
elevated O
in O
the O
serum I-GENE
of O
mice O
and O
humans O
after O
injection O
with O
bacterial I-GENE
lipopolysaccharide O
, O
but O
in O
contrast O
to O
conventional O
acute O
phase O
proteins I-GENE
, O
the O
bulk O
of O
_RARE_ I-GENE
- I-GENE
14 O
synthesis O
in O
the O
intact O
organism O
occurs O
outside O
the O
liver O
. O

The O
mouse I-GENE
beta I-GENE
2 I-GENE
- I-GENE
_RARE_ I-GENE
gene I-GENE
( O
> O
33 O
kilobases O
) O
contains O
seven O
exons O
, O
all O
of O
which O
have O
homologues O
at O
the O
corresponding O
position O
in O
the O
alpha I-GENE
1 I-GENE
- I-GENE
_RARE_ I-GENE
gene I-GENE
. O

Altogether O
our O
data O
indicate O
that O
_RARE_ I-GENE
belongs O
to O
the O
subgroup O
of O
_RARE_ I-GENE
_RARE_ I-GENE
and O
that O
its O
N I-GENE
- I-GENE
terminal I-GENE
region O
confers O
a O
_RARE_ I-GENE
- I-GENE
promoting I-GENE
activity O
to O
the O
protein I-GENE
. O

We O
report O
here O
the O
cloning O
of O
the O
murine I-GENE
p44 I-GENE
MAP I-GENE
kinase I-GENE
( O
extracellular I-GENE
signal I-GENE
- I-GENE
regulated O
kinase I-GENE
1 I-GENE
) O
gene I-GENE
, O
the O
determination O
of O
its O
intron O
/ I-GENE
exon O
boundaries O
, O
and O
the O
characterization O
of O
its O
promoter I-GENE
. O

It O
contains O
three O
putative O
TATA I-GENE
boxes O
far O
upstream O
of O
the O
main O
start O
sites I-GENE
region O
, O
one O
AP I-GENE
- I-GENE
1 I-GENE
box I-GENE
, O
one O
AP I-GENE
- I-GENE
2 I-GENE
box I-GENE
, O
one O
_RARE_ I-GENE
box I-GENE
, O
one O
_RARE_ I-GENE
box I-GENE
, O
one O
half O
serum I-GENE
- I-GENE
responsive I-GENE
element I-GENE
, O
and O
putative O
binding I-GENE
sites I-GENE
for O
Sp1 I-GENE
( O
five O
), O
GC I-GENE
- I-GENE
rich O
binding I-GENE
factor I-GENE
( O
five O
), O
_RARE_ I-GENE
- I-GENE
NF1 I-GENE
( O
one O
), O
Myb I-GENE
( O
one O
), O
p53 I-GENE
( O
two O
), O
Ets I-GENE
- I-GENE
1 I-GENE
( O
one O
), O
NF I-GENE
- I-GENE
IL6 I-GENE
( O
two O
), O
MyoD I-GENE
( O
two O
), O
_RARE_ I-GENE
( O
one O
), O
and O
hepatocyte I-GENE
nuclear I-GENE
factor I-GENE
- I-GENE
5 I-GENE
( O
one O
). O

One O
of O
these O
is O
_RARE_ I-GENE
by O
an O
adenine O
- I-GENE
_RARE_ I-GENE
rich O
region O
that O
can O
form O
an O
11 O
- I-GENE
base O
pair O
stem O
structure O
. O

We O
conclude O
that O
this O
new O
measurement O
technique O
provides O
an O
_RARE_ I-GENE
and O
accurate O
_RARE_ I-GENE
. O
1 I-GENE
measurement O
using O
standard O
respiratory O
_RARE_ I-GENE
when O
tested O
in O
a O
lung O
model O
. O

Effects O
of O
verapamil O
and O
propranolol O
on O
early I-GENE
_RARE_ I-GENE
and O
ventricular O
arrhythmias O
induced O
by O
epinephrine O
in O
congenital O
long O
QT O
syndrome O
. O

Deletion O
of O
the O
NF I-GENE
- I-GENE
IL6 I-GENE
beta I-GENE
leucine I-GENE
zipper I-GENE
domain I-GENE
also O
greatly O
diminished O
the O
interaction O
between O
these O
two O
proteins I-GENE
. O

After O
cells O
were O
stably O
transfected O
with O
_RARE_ I-GENE
, O
endogenous I-GENE
MHC I-GENE
class I-GENE
II I-GENE
genes I-GENE
were O
constitutively O
expressed O
, O
and O
MHC I-GENE
class I-GENE
II I-GENE
promoters I-GENE
, O
delivered O
by O
transfection O
, O
were O
actively O
transcribed O
in O
_RARE_ I-GENE
- I-GENE
expressing O
cells O
. O

Two O
domains I-GENE
of O
EBNA2 I-GENE
defined O
by O
deletion O
of O
amino O
acids O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
were O
found O
to O
be O
important O
for O
the O
activation O
of O
both O
promoters I-GENE
, O
while O
two O
different O
domains I-GENE
corresponding O
to O
residues O
4 I-GENE
- I-GENE
18 O
and O
118 O
- I-GENE
198 O
were O
required O
solely O
for O
the O
LMP1 I-GENE
promoter I-GENE
. O

The O
peak O
_RARE_ I-GENE
of O
the O
atrial I-GENE
systolic O
waves O
of O
the O
_RARE_ I-GENE
and O
pulmonary O
venous O
flow O
_RARE_ I-GENE
( O
A I-GENE
and O
_RARE_ I-GENE
, O
respectively O
) O
and O
first O
systolic O
wave O
( O
_RARE_ I-GENE
) O
of O
pulmonary O
venous O
flow O
, O
durations O
of O
both O
atrial I-GENE
systolic O
waves O
, O
and O
amplitude O
of O
_RARE_ I-GENE
septal O
motion O
during O
atrial I-GENE
_RARE_ I-GENE
increased O
significantly O
ten O
days O
after O
_RARE_ I-GENE
compared O
with O
those O
measured O
within O
a O
day O
of O
_RARE_ I-GENE
in O
all O
patients O
except O
the O
5 I-GENE
patients O
with O
_RARE_ I-GENE
cardiomyopathy O
. O

Additionally O
, O
the O
enzyme I-GENE
shows O
activity O
towards O
triglycerides I-GENE
such O
as O
_RARE_ I-GENE
oil O
and O
_RARE_ I-GENE
and O
towards O
egg I-GENE
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
. O

The O
nucleotide I-GENE
sequence I-GENE
directly O
upstream O
of O
_RARE_ I-GENE
contains O
two O
open O
reading O
frames O
, O
_RARE_ I-GENE
and O
ORF1 O
, O
whose O
deduced O
protein I-GENE
products I-GENE
are O
homologous O
to O
members O
of O
a O
superfamily I-GENE
of O
ATP I-GENE
- I-GENE
binding I-GENE
cassette I-GENE
membrane I-GENE
transport O
proteins I-GENE
, O
including O
both O
prokaryotic I-GENE
and O
eukaryotic I-GENE
uptake O
and O
export O
systems O
. O

The O
ORF3 O
probe O
also O
hybridized O
to O
a O
_RARE_ I-GENE
bp O
transcript I-GENE
consistent O
with O
the O
size O
of O
ORF3 O
alone O
and O
_RARE_ I-GENE
of O
the O
mutagenesis O
data O
of O
non O
- I-GENE
linkage O
. O

These O
results O
suggest O
that O
low O
concentrations O
of O
IL I-GENE
- I-GENE
1 I-GENE
beta I-GENE
may O
be O
useful O
for O
_RARE_ I-GENE
treatment O
of O
human I-GENE
vitreous O
hemorrhage O
. O

We O
conclude O
that O
pancreatic O
polypeptide I-GENE
and O
_RARE_ I-GENE
responses O
to O
a O
meal I-GENE
are O
different O
in O
_RARE_ I-GENE
children O
than O
in O
children O
in O
the O
control O
group O
. O

Here O
we O
report O
the O
cloning O
, O
expression O
, O
and O
biochemical O
characterization O
of O
the O
32 O
- I-GENE
kDa I-GENE
subunit I-GENE
of O
human I-GENE
( O
h O
) O
TFIID I-GENE
, O
termed O
_RARE_ I-GENE
. O

_RARE_ I-GENE
jaundice O
due O
to O
_RARE_ I-GENE
deficiency O
causing O
_RARE_ I-GENE
in O
a O
female O
newborn O
. O

Two O
transcripts I-GENE
of O
1 I-GENE
. O
6 I-GENE
kb O
and O
5 I-GENE
. O
8 O
kb O
are O
5 I-GENE
' O
_RARE_ I-GENE
and O
may O
both O
encode O
the O
novel O
glycoprotein I-GENE
gene I-GENE
_RARE_ I-GENE
. O

Mean O
growth I-GENE
changes O
in O
this O
Class I-GENE
II I-GENE
sample O
were O
comparable O
to O
those O
previously O
reported O
for O
male O
subjects O
with O
Class I-GENE
I I-GENE
_RARE_ I-GENE
over O
the O
same O
age O
period O
, O
suggesting O
a O
similarity O
in O
_RARE_ I-GENE
development O
between O
these O
two O
groups O
. O

However O
, O
the O
few O
studies O
that O
address O
antimicrobial O
prophylaxis O
in O
bone O
marrow O
transplantation O
have O
not O
always O
shown O
a O
survival O
benefit O
. O

The O
fracture O
groups O
were O
significantly O
older O
and O
had O
more O
years O
since O
_RARE_ I-GENE
than O
the O
control O
groups O
. O

In O
addition O
, O
we O
found O
differences O
in O
the O
binding I-GENE
of O
nuclear I-GENE
factors I-GENE
from O
_RARE_ I-GENE
versus O
from O
roots O
, O
in O
agreement O
with O
the O
different O
activities O
of O
the O
promoter I-GENE
in O
these O
two O
organs O
. O

The O
prevalence O
and O
incidence O
of O
human I-GENE
immunodeficiency I-GENE
virus I-GENE
types O
1 I-GENE
and O
2 I-GENE
( O
HIV I-GENE
- I-GENE
1 I-GENE
, O
HIV I-GENE
- I-GENE
2 I-GENE
), O
human I-GENE
T I-GENE
- I-GENE
_RARE_ I-GENE
virus I-GENE
types O
I I-GENE
and O
II I-GENE
( O
HTLV I-GENE
- I-GENE
I I-GENE
/ I-GENE
II I-GENE
), O
and O
_RARE_ I-GENE
infections O
and O
the O
association O
between O
these O
infections O
were O
determined O
in O
a O
cohort O
of O
_RARE_ I-GENE
_RARE_ I-GENE
in O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
. O

By O
in O
vitro O
_RARE_ I-GENE
and O
gel O
shift O
assays O
, O
we O
identified O
two O
classes O
of O
high O
affinity O
_RARE_ I-GENE
- I-GENE
binding I-GENE
sites I-GENE
upstream O
of O
each O
of O
the O
two O
_RARE_ I-GENE
transcription I-GENE
units O
. O

_RARE_ I-GENE
with O
a O
short O
postexposure O
time O
and O
a O
dioxin I-GENE
burden O
> O
0 O
. O
6 I-GENE
pg O
/ I-GENE
m3 O
had O
a O
significantly O
higher O
risk O
of O
_RARE_ I-GENE
than O
_RARE_ I-GENE
subjects O
( O
_RARE_ I-GENE
I I-GENE
: O
OR O
= O
9 O
. O
51 O
, O
95 O
% O
CI O
= O
1 I-GENE
. O
96 O
- I-GENE
42 O
. O
02 O
; O
_RARE_ I-GENE
II I-GENE
: O
OR O
= O
2 I-GENE
. O
92 O
, O
95 O
% O
CI O
= O
1 I-GENE
. O
14 O
- I-GENE
7 O
. O
5 I-GENE
). O

Analysis O
of O
this O
sequence I-GENE
combined O
with O
that O
previously O
reported O
for O
the O
5 I-GENE
'- O
flanking O
region O
directly O
proximal I-GENE
to O
the O
start O
of O
transcription I-GENE
revealed O
several O
putative O
regulatory I-GENE
sequences I-GENE
. O

We O
now O
show O
that O
the O
_RARE_ I-GENE
translation I-GENE
product I-GENE
is O
the O
homolog I-GENE
of O
the O
rat I-GENE
_RARE_ I-GENE
nuclear I-GENE
protein I-GENE
, O
the O
_RARE_ I-GENE
Drosophila I-GENE
gene I-GENE
product I-GENE
, O
and O
probably O
also O
_RARE_ I-GENE
of O
Caenorhabditis I-GENE
elegans I-GENE
, O
all O
members O
of O
the O
_RARE_ I-GENE
protein I-GENE
family I-GENE
of O
ATP I-GENE
- I-GENE
dependent I-GENE
RNA I-GENE
_RARE_ I-GENE
. O

By O
using O
lacZ I-GENE
fusions I-GENE
, O
it O
was O
possible O
to O
localize O
the O
DNA I-GENE
sequences I-GENE
required O
to O
mediate O
nitrate I-GENE
repression O
to O
the O
_RARE_ I-GENE
promoter I-GENE
- I-GENE
regulatory I-GENE
region O
. O

In O
this O
report O
, O
we O
describe O
the O
characterization O
of O
two O
early I-GENE
class I-GENE
II I-GENE
_RARE_ I-GENE
genes I-GENE
contained O
in O
the O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
locus I-GENE
. O

_RARE_ I-GENE
adaptation O
_RARE_ I-GENE
and O
recovery O
: O
acute O
stage O
after O
acoustic O
_RARE_ I-GENE
resection O
. O

The O
experimental O
design O
represents O
a O
2 I-GENE
x O
3 I-GENE
_RARE_ I-GENE
arrangement O
of O
treatments O
with O
three O
dietary O
levels O
of O
incorporation O
of O
_RARE_ I-GENE
( O
0 O
, O
50 O
, O
and O
100 O
%), O
and O
chickens O
either O
infected O
or O
_RARE_ I-GENE
. O

A I-GENE
cDNA I-GENE
clone O
corresponding O
to O
the O
putative O
GA I-GENE
20 O
- I-GENE
oxidase I-GENE
genomic O
sequence I-GENE
was O
constructed O
with O
the O
reverse I-GENE
transcription I-GENE
- I-GENE
PCR O
method O
, O
and O
the O
identity O
of O
the O
cDNA I-GENE
clone O
was O
confirmed O
by O
analyzing O
the O
_RARE_ I-GENE
of O
the O
fusion I-GENE
protein I-GENE
expressed O
in O
Escherichia I-GENE
coli I-GENE
to O
_RARE_ I-GENE
_RARE_ I-GENE
to O
_RARE_ I-GENE
and O
_RARE_ I-GENE
to O
_RARE_ I-GENE
. O

There O
were O
no O
significant O
changes O
in O
either O
the O
fatty I-GENE
acid I-GENE
composition O
of O
biliary O
_RARE_ I-GENE
or O
in O
the O
bile O
acid I-GENE
composition O
of O
bile O
. O

Total O
cholesterol I-GENE
was O
also O
reduced O
at O
week O
12 O
by O
17 O
. O
0 O
% O
( O
20 O
mg O
/ I-GENE
day O
) O
and O
15 O
. O
7 O
% O
( O
20 O
- I-GENE
30 O
mg O
/ I-GENE
day O
), O
and O
at O
week O
52 O
by O
20 O
. O
4 I-GENE
% O
(< O
or O
= O
20 O
mg O
/ I-GENE
day O
) O
and O
19 O
. O
2 I-GENE
% O
(> O
or O
= O
30 O
mg O
/ I-GENE
day O
). O

Although O
further O
studies O
are O
required O
to O
determine O
the O
precise O
role O
of O
_RARE_ I-GENE
in O
the O
GM I-GENE
- I-GENE
CSF I-GENE
promoter I-GENE
activity O
, O
the O
present O
findings O
suggested O
the O
importance O
of O
the O
relative O
ratio O
of O
different O
_RARE_ I-GENE
isoforms I-GENE
in O
regulating O
the O
levels O
of O
the O
promoter I-GENE
activity O
. O

_RARE_ I-GENE
of O
obtaining O
_RARE_ I-GENE
_RARE_ I-GENE
in O
_RARE_ I-GENE
. O

_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
can O
be O
used O
for O
the O
treatment O
of O
infections O
caused O
by O
gram O
- I-GENE
negative O
, O
gram O
- I-GENE
positive O
, O
aerobic O
, O
and O
anaerobic O
bacteria O
. O

Basal O
plasma I-GENE
renin I-GENE
activity O
( O
_RARE_ I-GENE
) O
was O
slightly O
raised O
prior O
to O
training O
( O
P I-GENE
< O
0 O
. O
07 O
) O
compared O
to O
the O
controls O
and O
post O
- I-GENE
training O
. O

This O
apparently O
_RARE_ I-GENE
structure O
/ I-GENE
activity O
relationship O
_RARE_ I-GENE
important O
issues O
for O
understanding O
the O
evolution O
of O
regulatory I-GENE
peptides I-GENE
and O
the O
mechanisms O
that O
control O
their O
expression O
. O

The O
structural O
gene I-GENE
encoding O
the O
novel O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
from O
Staphylococcus I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
was O
cloned O
and O
its O
nucleotide I-GENE
sequence I-GENE
was O
determined O
. O

This O
paper O
_RARE_ I-GENE
the O
experimental O
evidence O
upon O
which O
the O
clinical O
trials O
of O
_RARE_ I-GENE
reductase I-GENE
inhibitors O
in O
diabetic O
patients O
have O
been O
initiated O
and O
the O
results O
of O
published O
drug O
trials O
in O
these O
patients O
. O

The O
spectrum O
of O
phenotypes O
caused O
by O
these O
mutations O
was O
strikingly O
different O
than O
mutations O
in O
the O
adaptor I-GENE
for O
the O
VP16 I-GENE
activation O
domain I-GENE
. O

_RARE_ I-GENE
in O
urinary O
calcium O
and O
_RARE_ I-GENE
after O
fructose I-GENE
infusion O
. O

The O
5 I-GENE
' O
flanking O
region O
is O
highly O
GC I-GENE
rich O
, O
with O
multiple O
CpG O
_RARE_ I-GENE
, O
and O
contains O
multiple O
binding I-GENE
sites I-GENE
for O
Sp1 I-GENE
. O

To O
_RARE_ I-GENE
whether O
these O
disorders O
of O
GnRH I-GENE
deficiency O
are O
associated I-GENE
with O
altered O
melatonin O
secretion O
profiles O
, O
we O
compared O
untreated O
young O
males O
_RARE_ I-GENE
( O
n O
= O
7 O
) O
and O
DP I-GENE
( O
n O
= O
7 O
) O
to O
normal O
_RARE_ I-GENE
male O
controls O
( O
n O
= O
6 I-GENE
). O

Increased O
blood O
pressure O
during O
_RARE_ I-GENE
treatment O
was O
independent O
of O
circulating O
ET I-GENE
- I-GENE
1 I-GENE
levels O
. O

Analysis O
of O
several O
Tat I-GENE
mutants I-GENE
indicated O
that O
both O
the O
cysteine I-GENE
- I-GENE
rich O
and O
the O
core I-GENE
domains I-GENE
of O
this O
transactivator I-GENE
are O
necessary O
and O
sufficient O
to O
activate O
transcription I-GENE
when O
TBP I-GENE
is O
overexpressed O
. O

In O
addition O
, O
depletion O
of O
Oct I-GENE
- I-GENE
1 I-GENE
from O
the O
nuclear I-GENE
extract O
by O
using O
Oct I-GENE
- I-GENE
1 I-GENE
- I-GENE
specific I-GENE
antiserum O
or O
a O
sequence I-GENE
- I-GENE
specific I-GENE
DNA I-GENE
affinity O
resin O
decreased O
in O
vitro O
transcription I-GENE
from O
the O
wild I-GENE
- I-GENE
type I-GENE
MMTV I-GENE
promoter I-GENE
to O
a O
level O
identical O
to O
that O
obtained O
from O
a O
promoter I-GENE
in O
which O
all O
three O
octamer O
- I-GENE
related I-GENE
sequences I-GENE
were O
mutated O
. O

_RARE_ I-GENE
of O
the O
HIV I-GENE
- I-GENE
1 I-GENE
LTR I-GENE
by O
T3R I-GENE
alpha I-GENE
and O
several O
receptor I-GENE
mutants I-GENE
revealed O
that O
the O
50 O
- I-GENE
amino O
- I-GENE
acid I-GENE
N I-GENE
- I-GENE
terminal I-GENE
A I-GENE
/ I-GENE
B I-GENE
region O
of O
T3R I-GENE
alpha I-GENE
, O
known O
to O
interact O
with O
the O
basal O
transcription I-GENE
factor I-GENE
_RARE_ I-GENE
, O
is O
critical O
for O
activation O
of O
both O
Tat I-GENE
- I-GENE
dependent I-GENE
and O
Tat I-GENE
- I-GENE
independent O
responsive I-GENE
sequences I-GENE
of O
the O
LTR I-GENE
. O

M I-GENE
. O
M I-GENE
. O
C I-GENE
. O
was O
used O
for O
2 I-GENE
. O
5 I-GENE
minutes O
in O
44 I-GENE
cases O
( O
20 O
HR O
patients O
, O
24 O
_RARE_ I-GENE
patients O
), O
and O
for O
5 I-GENE
minutes O
in O
66 O
cases O
( O
46 O
HR O
patients O
, O
20 O
_RARE_ I-GENE
patients O
). O

Finally O
, O
we O
show O
that O
complexes I-GENE
similar O
to O
the O
_RARE_ I-GENE
, O
_RARE_ I-GENE
and O
_RARE_ I-GENE
complexes I-GENE
are O
formed O
by O
rat I-GENE
cortex O
nuclear I-GENE
extracts O
and O
the O
_RARE_ I-GENE
element I-GENE
in O
EMSA O
experiments O
, O
suggesting O
the O
relevance O
of O
our O
in O
vitro O
observations O
to O
the O
in O
vivo O
functioning O
of O
the O
rat I-GENE
_RARE_ I-GENE
promoter I-GENE
. O

_RARE_ I-GENE
, O
clinical O
and O
psychological O
aspects O
are O
evaluated O
according O
to O
experience O
accumulated O
in O
recent O
years O
, O
with O
immediate I-GENE
and O
delayed O
reconstruction O
, O
carried O
out O
in O
the O
most O
diverse O
specialized O
centers O
. O

The O
analysis O
of O
the O
prevalence O
values O
shows O
clearly O
that O
the O
global O
MS O
- I-GENE
frequency O
is O
_RARE_ I-GENE
related I-GENE
to O
the O
_RARE_ I-GENE
than O
to O
the O
_RARE_ I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
caused O
significant O
decrease O
in O
the O
ventricular O
response O
without O
conversion O
to O
sinus O
rhythm O
. O

_RARE_ I-GENE
primates O
appear O
to O
be O
more O
sensitive O
to O
reproductive O
and O
other O
adverse O
effects O
of O
_RARE_ I-GENE
than O
humans O
. O

When O
excluding O
children O
with O
ocular O
and O
cerebral O
pathology O
, O
32 O
matched O
pairs O
of O
premature O
and O
control O
children O
remained O
. O

The O
_RARE_ I-GENE
antigen I-GENE
test O
was O
positive O
at O
1 I-GENE
: O
125 I-GENE
by O
latex O
agglutination I-GENE
. O

Functional O
analysis O
of O
DNase I-GENE
- I-GENE
I I-GENE
hypersensitive I-GENE
sites I-GENE
at O
the O
mouse I-GENE
_RARE_ I-GENE
deaminase I-GENE
gene I-GENE
locus I-GENE
. O

These O
transcripts I-GENE
have O
a O
unique O
5 I-GENE
' O
untranslated O
region O
and O
NH2 I-GENE
- I-GENE
terminal I-GENE
sequence I-GENE
and O
encode O
a O
predicted O
protein I-GENE
of O
121 I-GENE
kD I-GENE
. O

Both O
mu I-GENE
and O
gamma I-GENE
2b I-GENE
heavy I-GENE
chain I-GENE
genes I-GENE
cause O
this O
_RARE_ I-GENE
inhibition O
of O
heavy I-GENE
chain I-GENE
gene I-GENE
rearrangement O
. O

Purified I-GENE
_RARE_ I-GENE
binds O
in O
vitro O
to O
the O
_RARE_ I-GENE
control O
region O
and O
_RARE_ I-GENE
against O
DNase I-GENE
I I-GENE
two O
approximately O
25 O
bp O
long O
stretches O
, O
one O
of O
which O
is O
located O
just O
downstream O
of O
the O
_RARE_ I-GENE
sequence I-GENE
. O

They O
include O
genes I-GENE
encoding O
three O
subunits I-GENE
of O
the O
cytochrome I-GENE
oxidase I-GENE
( O
_RARE_ I-GENE
to O
3 I-GENE
), O
_RARE_ I-GENE
b I-GENE
( O
_RARE_ I-GENE
), O
seven O
subunits I-GENE
of O
the O
NADH I-GENE
dehydrogenase I-GENE
complex I-GENE
( O
_RARE_ I-GENE
to O
6 I-GENE
, O
_RARE_ I-GENE
), O
two O
ATPase I-GENE
subunits I-GENE
( O
_RARE_ I-GENE
and O
_RARE_ I-GENE
), O
three O
ribosomal I-GENE
RNAs I-GENE
( O
_RARE_ I-GENE
, O
_RARE_ I-GENE
and O
_RARE_ I-GENE
), O
23 O
_RARE_ I-GENE
and O
four O
ribosomal I-GENE
proteins I-GENE
( O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
and O
_RARE_ I-GENE
). O

From O
day O
10 O
, O
a O
significant O
increase O
in O
platelet I-GENE
count O
was O
observed O
in O
eight O
of O
the O
ten O
patients O
treated O
with O
heparin O
( O
p O
< O
0 O
. O
05 O
), O
with O
return O
to O
the O
initial O
value O
after O
heparin O
cessation O
in O
six O
of O
the O
responders O
. O

These O
" O
_RARE_ I-GENE
- I-GENE
like I-GENE
" O
structures O
were O
readily O
purified O
by O
density I-GENE
gradient O
_RARE_ I-GENE
. O

The O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
for O
_RARE_ I-GENE
patients O
to O
_RARE_ I-GENE
smoking O
. O

The O
_RARE_ I-GENE
alpha I-GENE
proteins I-GENE
contain O
a O
128 I-GENE
- I-GENE
amino O
- I-GENE
acid I-GENE
( O
aa O
) O
region O
highly O
homologous O
to O
the O
Drosophila I-GENE
melanogaster I-GENE
segmentation I-GENE
gene I-GENE
_RARE_ I-GENE
. O

In O
human I-GENE
proliferative O
cells O
, O
the O
_RARE_ I-GENE
- I-GENE
dependent I-GENE
_RARE_ I-GENE
activity O
is O
poorly O
expressed O
and O
_RARE_ I-GENE
inducible I-GENE
by O
thyroid I-GENE
hormones O
. O

Based O
on O
previous O
mapping O
of O
the O
G I-GENE
beta I-GENE
gamma I-GENE
binding I-GENE
region O
of O
beta I-GENE
_RARE_ I-GENE
, O
and O
conserved O
residues O
within O
the O
PH I-GENE
domain I-GENE
, O
we O
have O
constructed O
a O
series O
of O
mutants I-GENE
in O
the O
carboxyl O
terminus O
of O
beta I-GENE
_RARE_ I-GENE
in O
order O
to O
determine O
important O
residues O
involved O
in O
G I-GENE
beta I-GENE
gamma I-GENE
and O
PIP2 O
binding I-GENE
. O

_RARE_ I-GENE
features O
of O
_RARE_ I-GENE
_RARE_ I-GENE
. O

To O
_RARE_ I-GENE
these O
mechanisms O
, O
wild I-GENE
- I-GENE
type I-GENE
and O
mutant I-GENE
Raf I-GENE
- I-GENE
1 I-GENE
proteins I-GENE
were O
studied O
in O
an O
in O
vitro O
system O
with O
purified O
plasma I-GENE
membranes O
from O
v I-GENE
- I-GENE
Ras I-GENE
- I-GENE
and O
v I-GENE
- I-GENE
Src I-GENE
- I-GENE
transformed O
cells O
( O
transformed O
membranes O
). O

In O
_RARE_ I-GENE
- I-GENE
1 I-GENE
cells O
, O
cotransfection O
of O
the O
retinoid I-GENE
and O
estrogen I-GENE
receptors I-GENE
led O
to O
_RARE_ I-GENE
inhibition O
of O
the O
other O
' O
s O
activity O
, O
while O
an O
RA O
- I-GENE
dependent I-GENE
inhibition O
of O
ER I-GENE
activity O
was O
observed O
in O
breast O
cancer O
cells O
. O

One O
of O
these O
factors I-GENE
, O
_RARE_ I-GENE
- I-GENE
1 I-GENE
, O
recognizes O
a O
cis O
element I-GENE
consisting O
of O
an O
inverted O
palindromic O
motif I-GENE
. O

Regulation O
of O
_RARE_ I-GENE
homeobox I-GENE
gene I-GENE
transcription I-GENE
by O
a O
combination O
of O
positive O
factors I-GENE
including O
myocyte I-GENE
- I-GENE
specific I-GENE
enhancer I-GENE
factor I-GENE
2 I-GENE
. O

The O
carboxyl O
- I-GENE
terminal I-GENE
transactivation O
domain I-GENE
of O
heat I-GENE
shock I-GENE
factor I-GENE
1 I-GENE
is O
negatively O
regulated O
and O
stress O
responsive I-GENE
. O

D I-GENE
. O

It O
was O
proposed O
that O
the O
synthetase I-GENE
- I-GENE
related I-GENE
sequences I-GENE
of O
GCN2 I-GENE
stimulate O
the O
activity O
of O
the O
kinase I-GENE
by O
interacting I-GENE
directly O
with O
_RARE_ I-GENE
tRNA I-GENE
that O
accumulates O
during O
amino O
acid I-GENE
limitation O
. O

However O
, O
unlike O
Bcl I-GENE
- I-GENE
2 I-GENE
and O
the O
E1B I-GENE
_RARE_ I-GENE
proteins I-GENE
, O
which O
completely O
block O
apoptosis O
but O
not O
p53 I-GENE
- I-GENE
dependent I-GENE
growth I-GENE
arrest O
, O
H I-GENE
- I-GENE
ras I-GENE
expression O
permitted O
DNA I-GENE
synthesis O
and O
cell O
proliferation O
in O
the O
presence O
of O
high O
levels O
of O
wild I-GENE
- I-GENE
type I-GENE
p53 I-GENE
. O

To O
compare O
the O
_RARE_ I-GENE
and O
putative O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
transactivation O
domains I-GENE
, O
we O
fused O
C I-GENE
- I-GENE
terminal I-GENE
test O
fragments I-GENE
to O
the O
heterologous O
GAL4 I-GENE
DNA I-GENE
- I-GENE
binding I-GENE
domain I-GENE
and O
tested O
activation O
of O
a O
reporter I-GENE
gene I-GENE
co O
- I-GENE
transfected O
into O
four O
cell O
types O
. O

All O
subjects O
were O
submitted O
to O
ECG O
and O
arterial O
blood O
pressure O
determination O
and O
were O
assayed O
for O
TSH I-GENE
, O
thyroid I-GENE
hormone I-GENE
, O
PRL I-GENE
, O
glucose O
, O
creatinine O
, O
nitrogen O
, O
glutamine I-GENE
_RARE_ I-GENE
, O
cholesterol I-GENE
and O
triglycerides I-GENE
plasma I-GENE
levels O
before O
therapy O
( O
_RARE_ I-GENE
), O
after O
30 O
treatment O
days O
( O
_RARE_ I-GENE
) O
and O
after O
a O
15 O
days O
washout O
( O
_RARE_ I-GENE
). O

Acute O
decrease O
in O
body O
temperature O
( O
TB I-GENE
) O
lowered O
PaCO2 O
( O
32 O
. O
5 I-GENE
to O
14 O
. O
5 I-GENE
mmHg O
) O
and O
[ O
HCO3 O
_RARE_ I-GENE
a O
( O
24 O
. O
20 O
mEq O
/ I-GENE
L I-GENE
to O
17 O
. O
56 O
mEq O
/ I-GENE
L I-GENE
), O
increased O
_RARE_ I-GENE
( O
7 O
. O
_RARE_ I-GENE
to O
7 O
. O
_RARE_ I-GENE
) O
and O
diminished O
the O
[ O
OH O
_RARE_ I-GENE
H I-GENE
_RARE_ I-GENE
ratio O
, O
but O
had O
no O
significant O
effect O
on O
[ O
_RARE_ I-GENE
] O
or O
[ O
_RARE_ I-GENE
], O
although O
both O
total O
phosphorus O
[ O
PT O
] O
and O
inorganic O
phosphate I-GENE
[ O
_RARE_ I-GENE
] O
increased O
. O

Hepatitis I-GENE
B I-GENE
vaccine O
: O
still O
has O
its O
problems O
. O

Basal O
promoter I-GENE
activity O
is O
enhanced O
by O
a O
functional O
M1 I-GENE
domain I-GENE
in O
LHR I-GENE
- I-GENE
expressing O
mouse I-GENE
_RARE_ I-GENE
tumor I-GENE
cells O
( O
_RARE_ I-GENE
) O
but O
not O
in O
non O
- I-GENE
expressing O
CHO O
cells O
. O

The O
_RARE_ I-GENE
gene I-GENE
encodes O
an O
_RARE_ I-GENE
- I-GENE
amino O
acid I-GENE
protein I-GENE
without O
similarity O
to O
other O
known O
proteins I-GENE
. O

For O
Al O
, O
the O
exposure O
to O
1 I-GENE
. O
36 O
mg O
/ I-GENE
m3 O
during O
the O
shift O
corresponded O
to O
a O
urinary O
concentration O
at O
the O
end O
of O
the O
shift O
of O
200 O
microgram O
/ I-GENE
g O
creatinine O
. O

Tumor I-GENE
necrosis I-GENE
factor I-GENE
- I-GENE
alpha I-GENE
( O
TNF I-GENE
alpha I-GENE
), O
a O
_RARE_ I-GENE
cytokine O
, O
inhibits O
cAMP I-GENE
- I-GENE
stimulated O
testosterone O
production O
in O
mouse I-GENE
_RARE_ I-GENE
cells O
. O

The O
Drosophila I-GENE
insulin I-GENE
receptor I-GENE
homolog I-GENE
: O
a O
gene I-GENE
essential O
for O
embryonic O
development O
encodes O
two O
receptor I-GENE
isoforms I-GENE
with O
different O
signaling O
potential O
. O

We O
show O
here O
that O
RA O
and O
E1A I-GENE
induce O
phosphorylation O
of O
the O
E1A I-GENE
- I-GENE
associated I-GENE
300 O
kDa I-GENE
protein I-GENE
( O
p300 I-GENE
) O
during O
the O
differentiation O
of O
F9 O
cells O
. O

The O
double O
- I-GENE
stranded I-GENE
RNA I-GENE
binding I-GENE
domain I-GENE
( O
_RARE_ I-GENE
) O
is O
an O
approximately O
65 O
amino O
acid I-GENE
motif I-GENE
that O
is O
found O
in O
a O
variety O
of O
proteins I-GENE
that O
interact O
with O
double O
- I-GENE
stranded I-GENE
( O
_RARE_ I-GENE
) O
RNA I-GENE
, O
such O
as O
Escherichia I-GENE
coli I-GENE
RNase I-GENE
III I-GENE
and O
the O
dsRNA I-GENE
- I-GENE
dependent I-GENE
kinase I-GENE
, O
PKR I-GENE
. O

CCAAT I-GENE
/ I-GENE
enhancer I-GENE
- I-GENE
binding I-GENE
protein I-GENE
isoforms I-GENE
beta I-GENE
and O
delta I-GENE
are O
expressed O
in O
mammary O
epithelial O
cells O
and O
bind O
to O
multiple O
sites I-GENE
in O
the O
beta I-GENE
- I-GENE
casein I-GENE
gene I-GENE
promoter I-GENE
. O

_RARE_ I-GENE
was O
resistant O
to O
inhibitors O
of O
serine I-GENE
, O
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
, O
but O
it O
was O
sensitive O
to O
N I-GENE
- I-GENE
_RARE_ I-GENE
. O

Mutational O
analysis O
of O
potential O
activating I-GENE
phosphorylation O
sites I-GENE
found O
in O
_RARE_ I-GENE
, O
_RARE_ I-GENE
- I-GENE
1 I-GENE
, O
and O
related I-GENE
protein I-GENE
kinases I-GENE
was O
performed O
on O
_RARE_ I-GENE
. O

However O
, O
a O
similar O
mutation I-GENE
of O
a O
leucine I-GENE
residue O
to O
arginine I-GENE
at O
position O
_RARE_ I-GENE
showed O
no O
alteration O
of O
heterodimerization O
, O
DNA I-GENE
binding I-GENE
, O
or O
transcriptional O
activation O
. O

Expression O
of O
the O
_RARE_ I-GENE
gene I-GENE
is O
increased O
by O
hormones O
, O
such O
as O
_RARE_ I-GENE
and O
_RARE_ I-GENE
hormone I-GENE
, O
as O
well O
as O
by O
a O
number O
of O
growth I-GENE
factors I-GENE
, O
suggesting O
that O
its O
promoter I-GENE
may O
contain O
regulatory I-GENE
elements O
that O
respond O
to O
multiple O
signal I-GENE
transduction O
pathways O
. O

NH2 I-GENE
- I-GENE
and O
COOH O
- I-GENE
terminal I-GENE
deletion O
analysis O
revealed O
that O
both O
the O
PH I-GENE
and O
putative O
guanine I-GENE
nucleotide I-GENE
exchange I-GENE
factor I-GENE
domains I-GENE
are O
required O
, O
but O
the O
zinc I-GENE
_RARE_ I-GENE
is O
dispensable O
, O
for O
transformation O
. O

We O
have O
found O
that O
the O
expression O
of O
GTPase I-GENE
- I-GENE
deficient O
mutants I-GENE
of O
alpha I-GENE
12 O
( O
alpha I-GENE
_RARE_ I-GENE
) O
or O
alpha I-GENE
13 O
( O
alpha I-GENE
_RARE_ I-GENE
) O
leads O
to O
_RARE_ I-GENE
activation O
of O
the O
Jun I-GENE
kinase I-GENE
/ I-GENE
stress O
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
( O
JNK I-GENE
/ I-GENE
SAPK I-GENE
) O
pathway O
. O

The O
objective O
of O
our O
study O
was O
to O
evaluate O
the O
age O
, O
sex I-GENE
, O
clinical O
conditions O
, O
family I-GENE
history O
, O
site I-GENE
, O
catheter O
association O
, O
means O
of O
_RARE_ I-GENE
evaluation O
, O
development O
of O
pulmonary O
involvement O
, O
prevalence O
of O
antithrombin I-GENE
III I-GENE
, O
protein I-GENE
C I-GENE
and O
protein I-GENE
S I-GENE
deficiencies O
, O
and O
lupus O
_RARE_ I-GENE
in O
children O
who O
_RARE_ I-GENE
a O
thrombotic O
event O
. O

_RARE_ I-GENE
, O
E I-GENE
. O
M I-GENE
. O

_RARE_ I-GENE
and O
early I-GENE
_RARE_ I-GENE
in O
stage O
D1 I-GENE
prostatic I-GENE
carcinoma O

Structural O
organization O
and O
developmental O
expression O
pattern O
of O
the O
mouse I-GENE
WD I-GENE
- I-GENE
repeat I-GENE
gene I-GENE
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
immediately O
upstream O
of O
the O
_RARE_ I-GENE
dystrophy I-GENE
locus I-GENE
. O

The O
_RARE_ I-GENE
procedure O
models O
the O
recorded O
signal I-GENE
as O
the O
sum O
of O
three O
signals O
: O
( O
a O
) O
the O
background O
EEG O
activity O
, O
_RARE_ I-GENE
as O
an O
_RARE_ I-GENE
process O
driven O
by O
a O
white O
noise O
; O
( O
b I-GENE
) O
a O
_RARE_ I-GENE
version O
of O
a O
reference O
signal I-GENE
carrying O
the O
average O
information O
contained O
in O
each O
_RARE_ I-GENE
; O
( O
c I-GENE
) O
a O
signal I-GENE
due O
to O
the O
ocular O
_RARE_ I-GENE
_RARE_ I-GENE
. O

The O
expression O
of O
the O
gene I-GENE
encoding O
the O
enzyme I-GENE
( O
_RARE_ I-GENE
) O
is O
regulated O
, O
in O
part O
, O
by O
tissue I-GENE
- I-GENE
specific I-GENE
promoters I-GENE
through O
the O
use O
of O
alternative O
- I-GENE
splicing O
mechanisms O
. O

Using O
mutagenesis O
, O
we O
have O
identified O
two O
mutations O
of O
the O
second O
actin I-GENE
- I-GENE
binding I-GENE
domain I-GENE
that O
can O
also O
suppress O
the O
_RARE_ I-GENE
mutations O
of O
interest O
. O

_RARE_ I-GENE
mRNA I-GENE
is O
normally O
inducible I-GENE
by O
IFN I-GENE
- I-GENE
gamma I-GENE
in O
class I-GENE
II I-GENE
non O
- I-GENE
inducible I-GENE
, O
RB I-GENE
- I-GENE
defective O
lines O
, O
and O
in O
one O
line O
, O
re O
- I-GENE
expression O
of O
RB I-GENE
has O
no O
effect O
on O
_RARE_ I-GENE
mRNA I-GENE
induction O
levels O
. O

The O
normal O
cell O
cycle O
is O
regulated O
by O
several O
molecules I-GENE
, O
such O
as O
the O
tumor I-GENE
- I-GENE
suppressor I-GENE
protein I-GENE
pRb I-GENE
, O
the O
G1 I-GENE
_RARE_ I-GENE
, O
the O
cyclin I-GENE
- I-GENE
dependent I-GENE
kinases I-GENE
, O
and O
their O
inhibitors O
. O

Consistent O
with O
the O
protein I-GENE
expression O
data O
, O
V I-GENE
beta I-GENE
8 O
. O
3 I-GENE
gene I-GENE
transcripts I-GENE
were O
found O
only O
in O
the O
transgenic O
lines O
with O
the O
wild I-GENE
- I-GENE
type I-GENE
promoter I-GENE
. O

These O
results O
are O
very O
useful O
for O
_RARE_ I-GENE
on O
the O
doses O
of O
hormones O
and O
the O
expected O
serum I-GENE
estradiol O
level O
in O
_RARE_ I-GENE
for O
Japanese O
women O
. O

Comparison O
of O
1 I-GENE
. O
5 I-GENE
_RARE_ I-GENE
and O
0 O
. O
35 O
_RARE_ I-GENE
field O
strength O
magnetic O
resonance O
imaging O
scans O
in O
the O
_RARE_ I-GENE
evaluation O
of O
the O
lumbar O
_RARE_ I-GENE
_RARE_ I-GENE
. O

One O
month O
after O
the O
_RARE_ I-GENE
_RARE_ I-GENE
vaccination O
, O
both O
groups O
had O
6 I-GENE
- I-GENE
to O
40 I-GENE
- I-GENE
fold O
increases O
in O
serum I-GENE
antibody I-GENE
concentrations O
to O
all O
antigens I-GENE
tested O
; O
the O
concentrations O
against O
the O
three O
pertussis I-GENE
antigens I-GENE
were O
higher O
in O
the O
_RARE_ I-GENE
- I-GENE
primed O
children O
( O
p O
< O
0 O
. O
05 O
). O

Interestingly O
, O
this O
amino O
- I-GENE
terminal I-GENE
determinant O
appears O
not O
to O
reside O
in O
the O
HSV I-GENE
- I-GENE
alpha I-GENE
TIF I-GENE
, O
which O
displays O
no O
independent O
amino O
- I-GENE
terminal I-GENE
activity O
. O

We O
also O
show O
that O
in O
fusions I-GENE
with O
the O
DNA I-GENE
binding I-GENE
domain I-GENE
of O
GAL4 I-GENE
, O
full I-GENE
activity O
requires O
the O
entire O
_RARE_ I-GENE
- I-GENE
alpha I-GENE
TIF I-GENE
, O
although O
both O
amino O
and O
carboxyl O
termini O
display O
some O
activity O
on O
their O
own O
. O

To O
investigate O
the O
potential O
role O
of O
SP1 I-GENE
, O
we O
examined O
nuclear I-GENE
extracts O
from O
HCMV I-GENE
- I-GENE
infected O
cells O
. O

Here O
we O
show O
that O
messenger I-GENE
RNAs I-GENE
encoding O
trans O
- I-GENE
_RARE_ I-GENE
containing O
the O
repeats I-GENE
are O
not O
present O
in O
_RARE_ I-GENE
but O
are O
abundant O
in O
_RARE_ I-GENE
. O

From O
_RARE_ I-GENE
1985 O
to O
_RARE_ I-GENE
1989 O
, O
126 O
_RARE_ I-GENE
were O
performed O
at O
the O
_RARE_ I-GENE
_RARE_ I-GENE
City O
_RARE_ I-GENE
on O
_RARE_ I-GENE
of O
individuals O
AIDS O
victims O
whose O
_RARE_ I-GENE
deaths O
had O
_RARE_ I-GENE
_RARE_ I-GENE
investigations O
. O

A I-GENE
model O
with O
age O
and O
weight O
described O
the O
best O
fit O
for O
_RARE_ I-GENE
, O
whereas O
age O
, O
weight O
, O
and O
height O
described O
the O
best O
fit O
for O
total O
body O
_RARE_ I-GENE
. O

As O
retinoic I-GENE
acid I-GENE
and O
thyroid I-GENE
hormone I-GENE
are O
frequently O
involved O
in O
developmental O
regulatory I-GENE
processes O
, O
it O
is O
possible O
that O
this O
element I-GENE
may O
be O
important O
in O
the O
process O
of O
islet O
cell O
differentiation O
. O

The O
C I-GENE
- I-GENE
terminal I-GENE
peptide I-GENE
sequences I-GENE
of O
the O
human I-GENE
lymphocyte I-GENE
- I-GENE
specific I-GENE
high O
mobility I-GENE
group O
( O
HMG I-GENE
)- I-GENE
box I-GENE
transcription I-GENE
factor I-GENE
TCF I-GENE
- I-GENE
1 I-GENE
are O
determined O
by O
alternative O
splice O
mechanisms O
affecting O
the O
exons O
VIII I-GENE
to O
X I-GENE
. O

_RARE_ I-GENE
B2 I-GENE
increased O
( O
97 O
+/- O
105 I-GENE
versus O
40 I-GENE
+/- O
26 O
pg O
/ I-GENE
ml O
) O
and O
was O
significantly O
higher O
during O
heparin O
free O
hemodialysis O
than O
during O
hemodialysis O
with O
heparin O
( O
p O
= O
0 O
. O
01 O
, O
_RARE_ I-GENE
matched O
pairs O
_RARE_ I-GENE
_RARE_ I-GENE
test O
). O

A I-GENE
new O
vector O
, O
_RARE_ I-GENE
, O
was O
designed O
to O
facilitate O
this O
analysis O
. O

To O
explore O
the O
mechanism O
of O
_RARE_ I-GENE
activation O
, O
a O
cloned O
human I-GENE
_RARE_ I-GENE
cDNA I-GENE
( O
_RARE_ I-GENE
) O
was O
used O
to O
generate O
and O
characterize O
several O
site I-GENE
- I-GENE
directed O
_RARE_ I-GENE
mutants I-GENE
; O
_RARE_ I-GENE
( O
N I-GENE
- I-GENE
Lys O
, O
NH2 I-GENE
- I-GENE
terminal I-GENE
ATP I-GENE
- I-GENE
binding I-GENE
mutant I-GENE
), O
_RARE_ I-GENE
( O
C I-GENE
- I-GENE
Lys O
, O
COOH O
- I-GENE
terminal I-GENE
ATP I-GENE
- I-GENE
binding I-GENE
mutant I-GENE
), O
N I-GENE
/ I-GENE
C I-GENE
- I-GENE
Lys O
( O
double O
ATP I-GENE
- I-GENE
binding I-GENE
mutant I-GENE
) O
_RARE_ I-GENE
( O
C I-GENE
- I-GENE
Thr I-GENE
, O
mutant I-GENE
of O
the O
putative O
MAPK I-GENE
phosphorylation O
site I-GENE
in O
subdomain I-GENE
VIII I-GENE
of O
the O
C I-GENE
- I-GENE
domain I-GENE
), O
_RARE_ I-GENE
( O
N I-GENE
- I-GENE
Ser O
, O
mutant I-GENE
of O
the O
corresponding O
NH2 I-GENE
- I-GENE
terminal I-GENE
residue O
). O

In O
contrast O
, O
both O
C I-GENE
- I-GENE
Lys O
and O
C I-GENE
- I-GENE
Thr I-GENE
retained O
high O
levels O
of O
kinase I-GENE
activity O
and O
were O
capable O
of O
responding O
to O
stimulation O
. O

Conversely O
, O
treatment O
of O
human I-GENE
protein I-GENE
- I-GENE
tyrosine I-GENE
phosphatase I-GENE
alpha I-GENE
- I-GENE
overexpressing O
cells O
with O
_RARE_ I-GENE
oxide I-GENE
led O
to O
a O
loss O
of O
the O
constitutive O
NF I-GENE
- I-GENE
kappa I-GENE
B I-GENE
activity O
. O

A I-GENE
TATA I-GENE
- I-GENE
less O
promoter I-GENE
containing O
binding I-GENE
sites I-GENE
for O
ubiquitous O
transcription I-GENE
factors I-GENE
mediates O
cell O
type I-GENE
- I-GENE
specific I-GENE
regulation O
of O
the O
gene I-GENE
for O
transcription I-GENE
enhancer I-GENE
factor I-GENE
- I-GENE
1 I-GENE
( O
TEF I-GENE
- I-GENE
1 I-GENE
). O

Since O
electrical O
stimulation O
of O
neurones O
may O
activate O
not O
only O
cell O
bodies O
but O
also O
neuronal O
fibres O
, O
this O
study O
aimed O
to O
test O
a O
selectively O
cholinergic O
_RARE_ I-GENE
stimulation O
of O
the O
rat I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
by O
the O
local O
microinjection O
of O
carbachol O
; O
the O
effects O
of O
this O
acetylcholine I-GENE
agonist O
were O
compared O
with O
glutamate I-GENE
. O

Here O
we O
describe O
an O
in O
vitro O
assay O
where O
the O
NS3 I-GENE
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
, O
NS3 I-GENE
, O
the O
serine I-GENE
proteinase I-GENE
domain I-GENE
( O
the O
N I-GENE
- I-GENE
terminal I-GENE
_RARE_ I-GENE
residues O
of O
NS3 I-GENE
), O
and O
the O
_RARE_ I-GENE
cofactor I-GENE
were O
produced O
by O
cell O
- I-GENE
free O
translation I-GENE
and O
tested O
for O
trans O
- I-GENE
processing O
of O
radiolabeled O
substrates O
. O

In O
contrast O
, O
over O
- I-GENE
expression O
of O
RAR I-GENE
beta I-GENE
only O
poorly O
restored O
differentiation O
, O
although O
it O
could O
replace O
RAR I-GENE
gamma I-GENE
for O
the O
activation O
of O
target O
genes I-GENE
. O

We O
purified O
both O
proteins I-GENE
from O
human I-GENE
platelet I-GENE
membranes O
using O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
chromatography O
followed O
by O
mAb I-GENE
_RARE_ I-GENE
affinity O
chromatography O
. O

The O
homeobox I-GENE
gene I-GENE
_RARE_ I-GENE
of O
Arabidopsis I-GENE
thaliana O
is O
expressed O
in O
the O
_RARE_ I-GENE
apex O
of O
the O
_RARE_ I-GENE
and O
in O
_RARE_ I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
of O
mature O
plants O
. O

The O
most O
likely O
explanation O
for O
this O
is O
that O
_RARE_ I-GENE
_RARE_ I-GENE
accumulates O
in O
the O
_RARE_ I-GENE
cells O
and O
renal O
cortex O
and O
these O
cells O
do O
not O
express O
Type O
I I-GENE
deiodinase I-GENE
. O

These O
results O
suggest O
that O
different O
models O
of O
intestinal O
ischemia O
have O
different O
cytokine O
profiles O
and O
that O
the O
early I-GENE
TNF I-GENE
response O
associated I-GENE
with O
_RARE_ I-GENE
occlusion O
model O
is O
primarily O
due O
to O
the O
_RARE_ I-GENE
. O

Our O
evidence O
_RARE_ I-GENE
from O
three O
principal O
observations O
: O
1 I-GENE
) O
a O
transfection O
construct I-GENE
containing O
only O
122 O
nucleotides O
( O
nt O
) O
of O
promoter I-GENE
1 I-GENE
and O
_RARE_ I-GENE
nt O
of O
the O
5 I-GENE
'- O
UTR I-GENE
retained O
full I-GENE
PGE2 O
- I-GENE
stimulated O
reporter I-GENE
expression O
; O
2 I-GENE
) O
maximal O
PGE2 O
- I-GENE
driven O
reporter I-GENE
expression O
required O
the O
presence O
of O
nt O
_RARE_ I-GENE
to O
_RARE_ I-GENE
of O
exon O
1 I-GENE
when O
tested O
within O
the O
context O
of O
IGF I-GENE
- I-GENE
I I-GENE
promoter I-GENE
1 I-GENE
; O
3 I-GENE
) O
cotransfection O
of O
IGF I-GENE
- I-GENE
I I-GENE
promoter I-GENE
- I-GENE
luciferase I-GENE
- I-GENE
reporter I-GENE
constructs I-GENE
with O
a O
plasmid O
encoding O
the O
alpha I-GENE
- I-GENE
isoform I-GENE
of O
the O
catalytic O
subunit I-GENE
of O
murine I-GENE
cAMP I-GENE
- I-GENE
dependent I-GENE
protein I-GENE
kinase I-GENE
( O
PKA I-GENE
) O
produced O
results O
comparable O
to O
those O
seen O
with O
PGE2 O
treatment O
, O
whereas O
cotransfection O
with O
a O
plasmid O
encoding O
a O
mutant I-GENE
regulatory I-GENE
subunit I-GENE
of O
PKA I-GENE
that O
cannot O
bind O
cAMP I-GENE
blocked O
PGE2 O
- I-GENE
induced O
reporter I-GENE
expression O
. O

The O
changes O
after O
treatment O
were O
observed O
_RARE_ I-GENE
by O
_RARE_ I-GENE
while O
sensory O
and O
motor O
improvement O
were O
also O
recorded O
as O
auxiliary I-GENE
indicators O
. O

_RARE_ I-GENE
- I-GENE
shift O
assays O
and O
DNase I-GENE
I I-GENE
footprinting O
experiments O
using O
purified O
42 O
kDa I-GENE
repressor I-GENE
isoform I-GENE
confirmed O
that O
_RARE_ I-GENE
5 I-GENE
and O
6 I-GENE
were O
indeed O
the O
targets O
for O
binding I-GENE
of O
this O
protein I-GENE
. O

The O
5 I-GENE
'- O
terminus O
of O
the O
p O
- I-GENE
_RARE_ I-GENE
- I-GENE
M I-GENE
mRNA I-GENE
was O
located O
_RARE_ I-GENE
nucleotides O
upstream O
of O
p O
- I-GENE
_RARE_ I-GENE
within O
p O
- I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
of O
_RARE_ I-GENE
mutants I-GENE
with O
the O
_RARE_ I-GENE
_RARE_ I-GENE
from O
the O
_RARE_ I-GENE
- I-GENE
resistant O
transformants O
resulted O
in O
_RARE_ I-GENE
of O
both O
UV O
and O
_RARE_ I-GENE
resistance O
to O
wild I-GENE
- I-GENE
type I-GENE
levels O
. O

Furthermore O
, O
this O
element I-GENE
confers O
p53 I-GENE
induction O
to O
the O
otherwise O
_RARE_ I-GENE
adenovirus I-GENE
major I-GENE
late O
promoter I-GENE
. O

In O
_RARE_ I-GENE
, O
the O
_RARE_ I-GENE
protein I-GENE
physically O
associates O
with O
the O
activated I-GENE
Drosophila I-GENE
epidermal I-GENE
growth I-GENE
factor I-GENE
receptor I-GENE
homolog I-GENE
( O
DER I-GENE
) O
and O
is O
_RARE_ I-GENE
phosphorylated O
on O
tyrosine I-GENE
by O
DER I-GENE
. O

A I-GENE
potential O
binding I-GENE
site I-GENE
for O
the O
_RARE_ I-GENE
PTB I-GENE
domain I-GENE
is O
located O
at O
Tyr I-GENE
- I-GENE
_RARE_ I-GENE
of O
DER I-GENE
. O

A I-GENE
Drosophila I-GENE
_RARE_ I-GENE
gene I-GENE
product I-GENE
is O
implicated O
in O
signaling O
by O
the O
DER I-GENE
receptor I-GENE
tyrosine I-GENE
kinase I-GENE
. O

This O
inhibition O
can O
be O
overcome O
by O
_RARE_ I-GENE
either O
the O
exon O
' O
s O
5 I-GENE
' O
or O
3 I-GENE
' O
splice O
site I-GENE
to O
make O
it O
correspond O
more O
closely O
to O
the O
relevant O
consensus I-GENE
sequence I-GENE
. O

Biochemical O
analysis O
shows O
that O
_RARE_ I-GENE
is O
a O
structural O
protein I-GENE
that O
forms O
part O
of O
the O
largest O
_RARE_ I-GENE
ribosomal I-GENE
subunit I-GENE
, O
which O
does O
not O
exist O
in O
a O
pool O
of O
free O
proteins I-GENE
. O

In O
wild I-GENE
- I-GENE
type I-GENE
cells O
, O
_RARE_ I-GENE
transcripts I-GENE
accumulate O
to O
twice O
the O
level O
of O
_RARE_ I-GENE
transcripts I-GENE
, O
suggesting O
that O
_RARE_ I-GENE
is O
responsible O
for O
the O
majority O
of O
the O
_RARE_ I-GENE
pool O
. O

Northern O
blot O
analysis O
revealed O
the O
expression O
of O
_RARE_ I-GENE
- I-GENE
1 I-GENE
mRNA I-GENE
predominantly O
in O
the O
brain O
and O
the O
expression O
of O
_RARE_ I-GENE
- I-GENE
2 I-GENE
mRNA I-GENE
in O
various O
tissues O
in O
the O
rat I-GENE
. O

However O
, O
the O
relative O
binding I-GENE
affinity O
for O
the O
motifs O
is O
different O
. O

On O
the O
basis O
of O
this O
anatomic O
concept O
, O
the O
_RARE_ I-GENE
procedure O
was O
modified O
to O
provide O
_RARE_ I-GENE
_RARE_ I-GENE
of O
the O
arm O
flap O
to O
the O
_RARE_ I-GENE
_RARE_ I-GENE
along O
with O
strong O
superficial O
_RARE_ I-GENE
system O
repair I-GENE
of O
_RARE_ I-GENE
, O
reducing O
the O
risk O
of O
_RARE_ I-GENE
or O
migration O
of O
_RARE_ I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
. O

Furthermore O
, O
microinjection O
of O
dominant I-GENE
negative O
forms O
of O
Rac I-GENE
and O
Cdc42 I-GENE
or O
of O
the O
Rho I-GENE
inhibitor I-GENE
C3 I-GENE
transferase I-GENE
blocked O
serum I-GENE
- I-GENE
induced O
DNA I-GENE
synthesis O
. O

_RARE_ I-GENE
- I-GENE
alpha I-GENE
therapy O
has O
been O
a O
major I-GENE
development O
in O
the O
treatment O
of O
CML O
. O

A I-GENE
series O
of O
amino O
terminal I-GENE
deletion O
mutants I-GENE
( O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
) O
were O
compared O
for O
processing O
, O
cell O
surface O
expression O
, O
and O
maintenance O
of O
their O
biological O
_RARE_ I-GENE
by O
recombinant I-GENE
expression O
of O
mutant I-GENE
genes I-GENE
using O
a O
plasmid O
vector O
( O
_RARE_ I-GENE
- I-GENE
SR I-GENE
alpha I-GENE
- I-GENE
296 O
) O
in O
_RARE_ I-GENE
- I-GENE
1 I-GENE
and O
HeLa O
cells O
. O

_RARE_ I-GENE
acetyl I-GENE
cholinesterase I-GENE
inhibitors O
produce O
analgesia O
that O
is O
synergistic O
with O
morphine O
and O
_RARE_ I-GENE
in O
rats O
. O

After O
determining O
isoflurane O
_RARE_ I-GENE
in O
_RARE_ I-GENE
, O
birds O
were O
given O
a O
mu I-GENE
- I-GENE
opioid I-GENE
agonist O
( O
morphine O
, O
n O
= O
9 O
) O
or O
a O
kappa I-GENE
- I-GENE
opioid I-GENE
agonist O
( O
_RARE_ I-GENE
, O
n O
= O
9 O
). O

Max I-GENE
was O
_RARE_ I-GENE
transcribed O
at O
a O
relatively O
low O
level O
during O
cell O
cycle O
progression O
. O

The O
yeast I-GENE
enzyme I-GENE
was O
6 I-GENE
- I-GENE
fold O
slower O
than O
the O
mammalian I-GENE
enzymes O
, O
which O
made O
it O
_RARE_ I-GENE
to O
pre I-GENE
- I-GENE
steady O
- I-GENE
state O
stopped O
- I-GENE
flow O
_RARE_ I-GENE
kinetic O
analysis O
at O
30 O
degrees O
C I-GENE
and O
pH O
6 I-GENE
. O
0 O
. O

_RARE_ I-GENE
areas O
of O
the O
selection O
process O
including O
medical O
and O
surgical O
_RARE_ I-GENE
to O
transplantation O
, O
the O
composition O
of O
the O
transplant O
work O
- I-GENE
up O
, O
specific I-GENE
inclusion O
criteria O
as O
well O
as O
specific I-GENE
_RARE_ I-GENE
factors I-GENE
and O
specific I-GENE
disease O
_RARE_ I-GENE
and O
co O
- I-GENE
_RARE_ I-GENE
that O
might O
represent O
_RARE_ I-GENE
were O
extensively O
reviewed O
. O

The O
transport O
of O
a O
genetically O
engineered I-GENE
chimeric I-GENE
transmembrane I-GENE
protein I-GENE
connected O
to O
this O
ER I-GENE
leader O
sequence I-GENE
was O
as O
efficient O
as O
that O
of O
the O
original O
protein I-GENE
from O
which O
the O
ER I-GENE
sequence I-GENE
has O
been O
derived O
. O

In O
both O
_RARE_ I-GENE
and O
roots O
, O
GT I-GENE
- I-GENE
2 I-GENE
protein I-GENE
is O
undetectable O
in O
_RARE_ I-GENE
tissue I-GENE
but O
becomes O
expressed O
at O
later O
stages O
of O
cellular O
development O
, O
consistent O
with O
a O
role O
in O
_RARE_ I-GENE
to O
the O
pattern O
of O
_RARE_ I-GENE
A I-GENE
gene I-GENE
expression O
. O

A I-GENE
polymorphic O
bipartite O
motif I-GENE
signals O
nuclear I-GENE
targeting O
of O
early I-GENE
_RARE_ I-GENE
- I-GENE
inducible I-GENE
proteins I-GENE
related I-GENE
to O
PS I-GENE
- I-GENE
_RARE_ I-GENE
from O
_RARE_ I-GENE
( O
_RARE_ I-GENE
_RARE_ I-GENE
). O

Comparative O
DNA I-GENE
sequence I-GENE
analysis O
showed O
the O
_RARE_ I-GENE
microsatellite I-GENE
_RARE_ I-GENE
lies O
2 I-GENE
. O
2 I-GENE
kb O
downstream O
of O
the O
coding O
region O
of O
_RARE_ I-GENE
, O
indicating O
that O
the O
cluster I-GENE
_RARE_ I-GENE
the O
closely O
linked O
_RARE_ I-GENE
and O
_RARE_ I-GENE
genes I-GENE
is O
located O
4 I-GENE
_RARE_ I-GENE
distal O
to O
_RARE_ I-GENE
( O
_RARE_ I-GENE
score O
13 O
. O
7 O
) O
and O
9 O
_RARE_ I-GENE
proximal I-GENE
to O
_RARE_ I-GENE
( O
_RARE_ I-GENE
score O
11 O
. O
7 O
). O

We O
conclude O
that O
transcription I-GENE
activation O
by O
_RARE_ I-GENE
- I-GENE
1 I-GENE
in O
vitro O
is O
a O
chromatin O
- I-GENE
dependent I-GENE
process O
that O
requires O
a O
functional O
trans O
- I-GENE
activation O
domain I-GENE
in O
addition O
to O
the O
HMG I-GENE
domain I-GENE
. O

TH I-GENE
- I-GENE
SH3 I-GENE
binding I-GENE
in O
vitro O
is O
abolished O
by O
specific I-GENE
, O
single O
amino O
acid I-GENE
substitutions O
within O
the O
_RARE_ I-GENE
TH I-GENE
domain I-GENE
or O
the O
Fyn I-GENE
SH3 I-GENE
domain I-GENE
. O

These O
results O
indicate O
that O
K I-GENE
- I-GENE
_RARE_ I-GENE
is O
a O
novel O
GPI I-GENE
- I-GENE
anchored I-GENE
_RARE_ I-GENE
involved O
in O
embryonic O
development O
. O

Protein I-GENE
S I-GENE
levels O
were O
virtually O
undetectable O
at O
the O
time O
of O
admission O
and O
failed O
to O
respond O
to O
_RARE_ I-GENE
of O
fresh O
_RARE_ I-GENE
plasma I-GENE
, O
despite O
correction O
of O
other O
_RARE_ I-GENE
and O
anticoagulant I-GENE
factors I-GENE
. O

The O
plant O
hormone I-GENE
_RARE_ I-GENE
transcriptionally O
activates O
early I-GENE
genes I-GENE
. O

The O
test O
was O
not O
performed O
in O
_RARE_ I-GENE
patients O
because O
of O
_RARE_ I-GENE
. O

The O
ubiquitous O
transcription I-GENE
factor I-GENE
Oct I-GENE
- I-GENE
1 I-GENE
forms O
complexes I-GENE
with O
an O
octamer O
motif I-GENE
present O
within O
_RARE_ I-GENE
by O
gel O
shift O
analysis O
with O
liver O
and O
kidney O
extracts O
, O
making O
Oct I-GENE
- I-GENE
1 I-GENE
an O
_RARE_ I-GENE
candidate O
for O
_RARE_ I-GENE
in O
androgen O
regulation O
. O

A I-GENE
new O
non O
- I-GENE
LTR I-GENE
retrotransposon I-GENE
provides O
evidence O
for O
multiple O
distinct O
site I-GENE
- I-GENE
specific I-GENE
elements O
in O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
arrays O
. O

We O
used O
deletion O
analysis O
and O
transfection O
assays O
with O
reporter I-GENE
gene I-GENE
constructs I-GENE
to O
examine O
the O
transcription I-GENE
control O
elements O
in O
the O
5 I-GENE
' O
flanking O
region O
of O
the O
human I-GENE
_RARE_ I-GENE
gene I-GENE
. O

The O
_RARE_ I-GENE
. O
4 I-GENE
_RARE_ I-GENE
transcript I-GENE
is O
the O
most O
_RARE_ I-GENE
of O
the O
two O
_RARE_ I-GENE
_RARE_ I-GENE
in O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
10 O
d O
post O
- I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
of O
the O
purified O
fusion I-GENE
proteins I-GENE
with O
[ O
gamma I-GENE
- I-GENE
32P O
] O
ATP I-GENE
in O
an O
in O
vitro O
assay O
showed O
that O
both O
proteins I-GENE
were O
capable O
of O
autophosphorylation O
. O

The O
character O
of O
specific I-GENE
immune I-GENE
response O
in O
101 I-GENE
immunized O
children O
and O
in O
12 O
adults O
belonging O
to O
a O
high O
risk O
group O
with O
respect O
to O
_RARE_ I-GENE
. O

After O
_RARE_ I-GENE
, O
heart O
rate O
decreased O
(- O
22 O
+/- O
8 O
%), O
and O
so O
did O
_RARE_ I-GENE
and O
_RARE_ I-GENE
( O
8 O
. O
8 O
+/- O
3 I-GENE
. O
4 I-GENE
vs O
. O

The O
synthetic O
DNA I-GENE
sequence I-GENE
was O
constructed O
to O
achieve O
efficient O
base O
_RARE_ I-GENE
with O
Escherichia I-GENE
coli I-GENE
_RARE_ I-GENE
ribosomal I-GENE
RNA I-GENE
, O
_RARE_ I-GENE
of O
internal O
secondary O
structure O
, O
and O
optimal O
codon O
usage O
for O
high O
- I-GENE
level O
protein I-GENE
expression O
in O
_RARE_ I-GENE
with O
the O
known O
_RARE_ I-GENE
in O
E I-GENE
. O
coli I-GENE
. O

_RARE_ I-GENE
system O
activation O
, O
indicated O
by O
_RARE_ I-GENE
/ I-GENE
epinephrine O
ratio O
, O
increased O
with O
time O
in O
_RARE_ I-GENE
males O
, O
except O
that O
after O
one O
month O
of O
_RARE_ I-GENE
, O
turnover O
returned O
to O
levels O
that O
_RARE_ I-GENE
those O
of O
control O
animals O
. O

_RARE_ I-GENE
repair I-GENE
of O
type I-GENE
IV I-GENE
_RARE_ I-GENE
- I-GENE
abdominal O
aortic O
_RARE_ I-GENE
. O

A I-GENE
. O

Transcription O
factors I-GENE
containing O
a O
basic I-GENE
helix I-GENE
- I-GENE
loop I-GENE
- I-GENE
helix I-GENE
( O
bHLH I-GENE
) O
motif I-GENE
regulate O
the O
expression O
of O
tissue I-GENE
- I-GENE
specific I-GENE
genes I-GENE
in O
a O
number O
of O
mammalian I-GENE
and O
insect O
systems O
. O

Primer O
extension O
and O
cDNA I-GENE
cloning O
were O
used O
to O
isolate O
the O
complete O
5 I-GENE
' O
end O
of O
the O
_RARE_ I-GENE
mRNA I-GENE
. O

Primer O
extension O
and O
S1 I-GENE
nuclease I-GENE
mapping O
experiments O
were O
used O
to O
_RARE_ I-GENE
the O
transcription I-GENE
initiation I-GENE
site I-GENE
of O
_RARE_ I-GENE
and O
revealed O
the O
presence O
of O
one O
major I-GENE
and O
several O
minor O
initiation I-GENE
sites I-GENE
. O

_RARE_ I-GENE
can O
repress O
its O
own O
expression O
but O
seems O
not O
to O
regulate O
the O
expression O
of O
_RARE_ I-GENE
. O

Sequence O
analysis O
of O
the O
5 I-GENE
'- O
flanking O
region O
of O
the O
_RARE_ I-GENE
gene I-GENE
revealed O
the O
presence O
of O
a O
potential O
TATA I-GENE
element I-GENE
30 O
base O
pairs O
upstream O
of O
the O
major I-GENE
transcription I-GENE
initiation I-GENE
site I-GENE
and O
several O
putative O
binding I-GENE
sequences I-GENE
for O
inducible I-GENE
transcription I-GENE
factors I-GENE
( O
NF I-GENE
- I-GENE
kappa I-GENE
B I-GENE
, O
_RARE_ I-GENE
- I-GENE
1 I-GENE
, O
AP I-GENE
- I-GENE
1 I-GENE
), O
which O
might O
mediate O
the O
inducible I-GENE
expression O
of O
this O
gene I-GENE
. O

The O
_RARE_ I-GENE
- I-GENE
derived O
D I-GENE
( O
approximately O
105 I-GENE
- I-GENE
kDa I-GENE
) O
product I-GENE
, O
however O
, O
could O
be O
cross O
- I-GENE
linked O
into O
_RARE_ I-GENE
dimers I-GENE
. O

All O
clinical O
isolates O
were O
_RARE_ I-GENE
tested O
by O
_RARE_ I-GENE
diffusion O
and O
agar O
dilution O
procedures O
as O
_RARE_ I-GENE
by O
the O
National O
Committee O
for O
Clinical O
Laboratory O
_RARE_ I-GENE
. O

IgE I-GENE
levels O
showed O
higher O
values O
compared O
to O
normal O
individuals O
and O
IgE I-GENE
levels O
were O
higher O
in O
children O
groups O
than O
in O
adults O
regardless O
of O
the O
intensity O
of O
infection O
. O

Tissue I-GENE
- I-GENE
specific I-GENE
expression O
of O
the O
_RARE_ I-GENE
- I-GENE
1 I-GENE
gene I-GENE
was O
determined O
by O
microinjection O
of O
a O
promoter I-GENE
/ I-GENE
lacZ I-GENE
fusion I-GENE
gene I-GENE
and O
with O
_RARE_ I-GENE
by O
using O
affinity O
- I-GENE
purified O
tissue I-GENE
- I-GENE
specific I-GENE
anti I-GENE
- I-GENE
_RARE_ I-GENE
. O

The O
nucleotide I-GENE
sequence I-GENE
of O
the O
chloroplast I-GENE
( O
_RARE_ I-GENE
) O
DNA I-GENE
from O
maize I-GENE
( O
_RARE_ I-GENE
_RARE_ I-GENE
) O
has O
been O
completed O
. O

_RARE_ I-GENE
of O
the O
control O
of O
coronavirus O
_RARE_ I-GENE
mRNA I-GENE
transcription I-GENE
by O
using O
T7 I-GENE
- I-GENE
generated O
negative O
- I-GENE
sense O
RNA I-GENE
transcripts I-GENE
. O

_RARE_ I-GENE
of O
translation I-GENE
of O
the O
human I-GENE
hepatitis I-GENE
C I-GENE
virus I-GENE
( O
HCV I-GENE
) O
RNA I-GENE
genome O
occurs O
by O
internal O
ribosome I-GENE
entry O
into O
the O
5 I-GENE
' O
noncoding O
region O
( O
5 I-GENE
' O
NCR O
) O
in O
a O
cap I-GENE
- I-GENE
independent O
manner O
. O

Mean O
longitudinal O
extension O
of O
the O
_RARE_ I-GENE
lesion O
was O
2 I-GENE
. O
6 I-GENE
vertebral O
segments O
. O

The O
association O
of O
_RARE_ I-GENE
with O
splicing O
complexes I-GENE
is O
suggested O
by O
the O
finding O
that O
mAb I-GENE
_RARE_ I-GENE
can O
inhibit O
in O
vitro O
splicing O
and O
_RARE_ I-GENE
pre I-GENE
- I-GENE
messenger I-GENE
RNA I-GENE
and O
splicing O
products I-GENE
. O

L I-GENE
- I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
free O
base O
or O
sulfate I-GENE
salt O
was O
administered O
orally O
as O
_RARE_ I-GENE
, O
solution O
or O
in O
solid O
dosage O
forms O
to O
fasted O
or O
fed O
_RARE_ I-GENE
dogs O
. O

Doppler O
ultrasound O
studies O
of O
long O
- I-GENE
term O
follow O
- I-GENE
up O
of O
children O
with O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
syndrome O

Thus O
, O
_RARE_ I-GENE
_RARE_ I-GENE
of O
hepatitis I-GENE
A I-GENE
diseases O
are O
possible O
. O

( O
1991 O
). O

The O
properties O
of O
the O
phi I-GENE
29 O
SSB I-GENE
- I-GENE
ssDNA I-GENE
complex I-GENE
are O
described O
. O

This O
shows O
that O
the O
_RARE_ I-GENE
diffuse O
_RARE_ I-GENE
pattern O
of O
plant O
nuclear I-GENE
proteins I-GENE
interacting I-GENE
with O
the O
G I-GENE
- I-GENE
box I-GENE
is O
also O
observed O
in O
a O
binding I-GENE
assay O
using O
only O
one O
recombinant I-GENE
_RARE_ I-GENE
. O

We O
studied O
120 O
male O
and O
42 O
female O
patients O
with O
early I-GENE
CAD I-GENE
who O
were O
unrelated O
to O
each O
other O
but O
were O
from O
families O
in O
which O
at O
least O
one O
other O
_RARE_ I-GENE
had O
early I-GENE
CAD I-GENE
. O

The O
physical O
linkage O
of O
the O
_RARE_ I-GENE
and O
the O
factor I-GENE
H I-GENE
genes I-GENE
provides O
additional O
evidence O
for O
a O
close O
_RARE_ I-GENE
of O
complement I-GENE
factor I-GENE
H I-GENE
and O
the O
factor I-GENE
H I-GENE
- I-GENE
related I-GENE
proteins I-GENE
. O

Genomic O
structure O
and O
chromosomal I-GENE
location O
of O
the O
mouse I-GENE
pre I-GENE
- I-GENE
T I-GENE
- I-GENE
cell O
receptor I-GENE
alpha I-GENE
gene I-GENE
. O

The O
third O
domain I-GENE
had O
the O
motif I-GENE
of O
a O
cAMP I-GENE
response O
element I-GENE
( O
CRE O
). O

The O
tyrosine I-GENE
- I-GENE
phosphorylated O
state O
of O
CAK I-GENE
beta I-GENE
was O
not O
reduced O
on O
_RARE_ I-GENE
, O
nor O
enhanced O
in O
response O
to O
_RARE_ I-GENE
_RARE_ I-GENE
cells O
onto O
fibronectin I-GENE
. O

Our O
results O
suggest O
that O
while O
many O
muscle O
gene I-GENE
E I-GENE
- I-GENE
boxes O
are O
capable O
of O
binding I-GENE
the O
previously O
characterized O
spectrum O
of O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
- I-GENE
L I-GENE
- I-GENE
H I-GENE
heterodimers I-GENE
in O
vitro O
, O
_RARE_ I-GENE
- I-GENE
L I-GENE
type I-GENE
E I-GENE
- I-GENE
boxes O
probably O
bind O
_RARE_ I-GENE
different O
factors I-GENE
in O
vivo O
. O

A I-GENE
single O
- I-GENE
case O
experimental O
_RARE_ I-GENE
multiple O
baseline O
design O
was O
employed O
to O
test O
for O
treatment O
effectiveness O
. O

These O
clones O
were O
found O
to O
share O
a O
common O
domain I-GENE
encoded I-GENE
by O
p O
( O
CA I-GENE
) O
n O
repeats I-GENE
; O
a O
simple O
sequence I-GENE
length I-GENE
polymorphism O
( O
_RARE_ I-GENE
). O

In O
one O
_RARE_ I-GENE
cell O
line O
, O
a O
Shc I-GENE
- I-GENE
associated I-GENE
p190 I-GENE
was O
identified O
as O
the O
activated I-GENE
_RARE_ I-GENE
. O

We O
conclude O
that O
, O
in O
comparison O
to O
reports O
from O
other O
regions O
, O
_RARE_ I-GENE
renal O
transplant O
recipients O
are O
at O
high O
risk O
of O
_RARE_ I-GENE
of O
_RARE_ I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
for O
_RARE_ I-GENE
export O
. O

The O
serum I-GENE
concentration O
of O
_RARE_ I-GENE
before O
dialysis O
( O
HD I-GENE
) O
was O
on O
average O
3 I-GENE
. O
06 O
(+/- O
0 O
. O
81 O
) O
mmol O
/ I-GENE
l O
and O
D I-GENE
was O
on O
average O
55 O
. O
6 I-GENE
(+/- O
10 O
. O
0 O
) O
mmol O
. O

A I-GENE
significant O
correlation O
between O
a O
number O
of O
functional O
parameters O
of O
gastric O
secretion O
, O
_RARE_ I-GENE
and O
histological O
changes O
of O
gastric O
mucosa O
was O
found O
in O
patients O
with O
chronic O
_RARE_ I-GENE
. O

The O
TAF I-GENE
factor I-GENE
appears O
to O
be O
particularly O
significant O
in O
_RARE_ I-GENE
. O

_RARE_ I-GENE
white O
matter O
injury O
can O
be O
attributed O
to O
radiation O
and O
associated I-GENE
with O
neurological O
deficits O
, O
but O
_RARE_ I-GENE
is O
rarely O
observed O
in O
the O
absence O
of O
chemotherapy O
. O

RNase I-GENE
protection O
analyses O
indicate O
that O
either O
61 O
- I-GENE
kDa I-GENE
CaM I-GENE
_RARE_ I-GENE
mRNA I-GENE
or O
structurally O
related I-GENE
transcripts I-GENE
encoding O
different O
CaM I-GENE
_RARE_ I-GENE
isoforms I-GENE
are O
expressed O
in O
a O
tissue I-GENE
- I-GENE
specific I-GENE
manner O
. O

_RARE_ I-GENE
or O
no O
protection O
was O
detected O
using O
adrenal O
cortex O
, O
adrenal O
_RARE_ I-GENE
, O
liver O
, O
kidney O
cortex O
, O
spleen O
, O
or O
T I-GENE
- I-GENE
lymphocyte I-GENE
total O
RNA I-GENE
. O

The O
_RARE_ I-GENE
mutants I-GENE
that O
failed O
to O
associate O
with O
PLC I-GENE
gamma I-GENE
were O
not O
able O
to O
mediate O
the O
PDGF I-GENE
- I-GENE
dependent I-GENE
production O
of O
inositol I-GENE
_RARE_ I-GENE
. O

We O
found O
a O
direct O
correlation O
between O
the O
levels O
of O
transcription I-GENE
of O
the O
_RARE_ I-GENE
genes I-GENE
and O
the O
rate O
of O
cellular O
growth I-GENE
. O

The O
_RARE_ I-GENE
clone O
of O
V I-GENE
. O
_RARE_ I-GENE
chromosomal I-GENE
DNA I-GENE
complemented O
a O
V I-GENE
. O
cholerae I-GENE
_RARE_ I-GENE
mutant I-GENE
. O

We O
generated O
transformed O
B I-GENE
_RARE_ I-GENE
cell O
lines O
from O
controls O
, O
from O
four O
patients O
with O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
deficient O
chronic O
_RARE_ I-GENE
disease O
, O
and O
from O
three O
parents O
. O

The O
ectopic O
expression O
of O
Oct I-GENE
- I-GENE
3 I-GENE
/ I-GENE
4 I-GENE
in O
hybrid O
cells O
under O
a O
constitutive O
promoter I-GENE
is O
sufficient O
for O
transcriptional O
activation O
of O
an O
octamer O
- I-GENE
dependent I-GENE
promoter I-GENE
. O

RNase I-GENE
protection O
and O
primer O
extension O
assays O
confirmed O
that O
the O
5 I-GENE
' O
non O
- I-GENE
coding O
exon O
is O
included O
in O
the O
_RARE_ I-GENE
_RARE_ I-GENE
mRNA I-GENE
and O
that O
a O
major I-GENE
transcription I-GENE
start O
site I-GENE
is O
approximately O
136 O
bp O
upstream O
of O
the O
5 I-GENE
' O
non O
- I-GENE
coding O
splice O
junction O
of O
this O
exon O
. O

These O
results O
suggest O
that O
FK O
_RARE_ I-GENE
is O
a O
useful O
immunosuppressive O
agent O
in O
kidney O
transplantation O
. O

The O
roles O
of O
phorbol O
esters O
and O
cyclic I-GENE
AMP I-GENE
in O
mediating O
the O
GnRH I-GENE
response O
were O
also O
investigated O
. O

RT I-GENE
- I-GENE
PCR O
using O
1 I-GENE
. O
D I-GENE
- I-GENE
specific I-GENE
primers O
showed O
that O
kidney O
, O
brain O
and O
prostate O
do O
not O
express O
1 I-GENE
. O
D I-GENE
mRNA I-GENE
even O
though O
kidney O
and O
brain O
are O
the O
most O
abundant O
source O
for O
_RARE_ I-GENE
protein I-GENE
. O

Molecular O
cloning O
and O
characterization O
of O
two O
genes I-GENE
encoding O
_RARE_ I-GENE
, O
a O
cell O
surface O
glycoprotein I-GENE
involved O
in O
the O
sexual O
cell O
fusion I-GENE
of O
Dictyostelium O
_RARE_ I-GENE
. O

Two O
- I-GENE
dimensional O
_RARE_ I-GENE
analyses O
indicate O
that O
phosphorylation O
on O
Ser O
- I-GENE
12 O
and O
Ser O
- I-GENE
48 O
in O
unstimulated O
cells O
is O
associated I-GENE
with O
the O
ability O
of O
overexpressed O
_RARE_ I-GENE
- I-GENE
src I-GENE
to O
_RARE_ I-GENE
beta I-GENE
- I-GENE
adrenergic I-GENE
signalling O
. O

_RARE_ I-GENE
is O
a O
new O
phosphodiesterase I-GENE
III I-GENE
inhibitor I-GENE
that O
_RARE_ I-GENE
inotropic O
and O
vasodilator O
properties O
. O

_RARE_ I-GENE
studies O
were O
performed O
in O
lymphocytes O
from O
hospital O
workers O
exposed O
to O
low O
doses O
of O
radiation O
( O
1 I-GENE
. O
6 I-GENE
- I-GENE
42 O
. O
71 O
_RARE_ I-GENE
). O

To O
study O
the O
origin O
of O
different O
_RARE_ I-GENE
- I-GENE
R I-GENE
transcripts I-GENE
, O
the O
genetic O
linkage O
of O
chemotactic O
receptor I-GENE
genes I-GENE
, O
and O
the O
regulation O
of O
_RARE_ I-GENE
- I-GENE
R I-GENE
gene I-GENE
expression O
, O
we O
determined O
the O
copy O
number O
, O
chromosomal I-GENE
location O
, O
structural O
organization O
, O
and O
5 I-GENE
'- O
flanking O
sequence I-GENE
of O
the O
human I-GENE
_RARE_ I-GENE
- I-GENE
R I-GENE
gene I-GENE
. O

The O
first O
exon O
encodes O
66 O
bp O
of O
the O
5 I-GENE
'- O
untranslated O
sequence I-GENE
, O
while O
exon O
2 I-GENE
encodes O
the O
coding O
and O
3 I-GENE
'- O
untranslated O
sequences I-GENE
. O

The O
genomic O
structure O
of O
four O
members O
of O
the O
SRC I-GENE
- I-GENE
family I-GENE
revealed O
nearly O
identical O
exon O
/ I-GENE
intron O
boundaries O
within O
the O
catalytic O
domain I-GENE
of O
this O
family I-GENE
. O

Since O
we O
have O
observed O
effects O
of O
growth I-GENE
factors I-GENE
and O
cAMP I-GENE
as O
well O
as O
estradiol O
( O
E2 I-GENE
) O
on O
regulation O
of O
expression O
of O
some O
genes I-GENE
stimulated O
by O
the O
estrogen I-GENE
receptor I-GENE
( O
ER I-GENE
), O
we O
have O
undertaken O
studies O
to O
examine O
directly O
whether O
activators I-GENE
of O
protein I-GENE
kinases I-GENE
can O
modulate O
transcriptional O
activity O
of O
the O
ER I-GENE
. O

Using O
the O
polymerase I-GENE
chain I-GENE
reaction O
, O
_RARE_ I-GENE
- I-GENE
specific I-GENE
DNA I-GENE
fragments I-GENE
of O
_RARE_ I-GENE
base O
pairs O
from O
the O
genome O
of O
the O
_RARE_ I-GENE
bacterium O
( O
_RARE_ I-GENE
_RARE_ I-GENE
) O
were O
demonstrated O
. O

RNA I-GENE
polymerase I-GENE
bound O
to O
the O
+ I-GENE
_RARE_ I-GENE
promoter I-GENE
partially O
_RARE_ I-GENE
a O
20 O
base O
- I-GENE
pair O
sequence I-GENE
from O
DNase I-GENE
I I-GENE
digestion O
upstream O
of O
the O
start O
site I-GENE
. O

_RARE_ I-GENE
sodium O
, O
calcium O
, O
and O
magnesium O
concentrations O
were O
significantly O
higher O
in O
the O
SLE O
patients O
with O
systemic O
lupus O
erythematosus O
, O
whereas O
potassium O
and O
total O
protein I-GENE
concentrations O
and O
amylase I-GENE
activity O
did O
not O
differ O
significantly O
from O
the O
controls O
. O

Chem O
. O

Recombinant I-GENE
plasmid O
_RARE_ I-GENE
was O
subsequently O
isolated O
by O
its O
ability O
to O
complement I-GENE
B I-GENE
- I-GENE
band O
expression O
in O
_RARE_ I-GENE
. O

We O
here O
demonstrate O
that O
a O
temperature O
- I-GENE
sensitive O
fission I-GENE
yeast I-GENE
mutant I-GENE
which O
has O
a O
mutation I-GENE
in O
a O
homologous O
gene I-GENE
, O
and O
two O
of O
three O
additional O
( O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
) O
mutants I-GENE
accumulate O
nuclear I-GENE
poly O
( O
A I-GENE
)+ O
RNA I-GENE
at O
37 O
degrees O
C I-GENE
. O

Since O
_RARE_ I-GENE
acts O
as O
_RARE_ I-GENE
for O
Ran I-GENE
, O
a O
small I-GENE
nuclear I-GENE
GTPase I-GENE
of O
the O
ras I-GENE
superfamily I-GENE
, O
we O
have O
identified O
two O
homologs I-GENE
of O
Ran I-GENE
in O
S I-GENE
. O
cerevisiae I-GENE
( O
_RARE_ I-GENE
and O
_RARE_ I-GENE
). O

The O
_RARE_ I-GENE
FK506 O
inhibits O
amino O
acid I-GENE
import O
in O
Saccharomyces I-GENE
cerevisiae I-GENE
. O

_RARE_ I-GENE
specific I-GENE
antigen I-GENE
shows O
the O
metastatic O
cases O
better O
[ O
correction O
of O
_RARE_ I-GENE
] O
than O
prostatic I-GENE
acid I-GENE
phosphatase I-GENE
. O

Protein I-GENE
phosphorylation O
appears O
to O
play O
a O
critical O
role O
in O
uPA I-GENE
gene I-GENE
expression O
in O
these O
cells O
; O
protein I-GENE
kinase I-GENE
C I-GENE
- I-GENE
activating I-GENE
phorbol O
esters O
cooperate O
with O
_RARE_ I-GENE
- I-GENE
src I-GENE
to O
synergistically O
increase O
uPA I-GENE
mRNA I-GENE
, O
whereas O
cyclic I-GENE
AMP I-GENE
( O
cAMP I-GENE
)- I-GENE
dependent I-GENE
protein I-GENE
kinase I-GENE
- I-GENE
activating I-GENE
agents O
( O
e O
. O
g O
., O
8 O
- I-GENE
_RARE_ I-GENE
cAMP I-GENE
) O
repress O
uPA I-GENE
mRNA I-GENE
levels O
. O

Of O
these O
carriers O
_RARE_ I-GENE
were O
diagnosed O
to O
be O
asymptomatic O
clinically O
, O
_RARE_ I-GENE
and O
_RARE_ I-GENE
. O

This O
300 O
bp O
5 I-GENE
'- O
upstream O
sequence I-GENE
of O
_RARE_ I-GENE
_RARE_ I-GENE
gene I-GENE
, O
which O
can O
function O
in O
vitro O
as O
a O
_RARE_ I-GENE
- I-GENE
specific I-GENE
promoter I-GENE
, O
contains O
two O
clusters O
of O
partially O
overlapping O
motifs O
, O
one O
with O
an O
_RARE_ I-GENE
consensus I-GENE
sequence I-GENE
and O
another O
with O
a O
GC I-GENE
box I-GENE
. O

Identification O
of O
mutations O
in O
the O
coding O
sequence I-GENE
of O
the O
proto I-GENE
- I-GENE
oncogene I-GENE
c I-GENE
- I-GENE
kit I-GENE
in O
a O
human I-GENE
mast I-GENE
cell O
leukemia I-GENE
cell O
line O
causing O
ligand O
- I-GENE
independent O
activation O
of O
c I-GENE
- I-GENE
kit I-GENE
product I-GENE
. O

BACKGROUND O
: O
_RARE_ I-GENE
of O
the O
morphologic O
aspects O
of O
age O
- I-GENE
related I-GENE
_RARE_ I-GENE
degeneration O
( O
_RARE_ I-GENE
) O
is O
helpful O
in O
correlation O
with O
the O
clinical O
features O
and O
may O
contribute O
to O
understanding O
the O
pathogenesis O
. O

An O
abundant O
1 I-GENE
. O
1 I-GENE
- I-GENE
kb O
virion O
- I-GENE
sense O
polyadenylated O
RNA I-GENE
and O
four O
complementary O
- I-GENE
sense O
polyadenylated O
RNAs I-GENE
of O
1 I-GENE
. O
7 O
, O
1 I-GENE
. O
5 I-GENE
, O
1 I-GENE
. O
3 I-GENE
, O
and O
0 O
. O
7 O
kb O
have O
been O
identified O
by O
northern O
blot O
hybridization O
, O
confirming O
the O
_RARE_ I-GENE
transcription I-GENE
strategy O
_RARE_ I-GENE
by O
the O
arrangement O
of O
ORFs O
. O

Risk O
factors I-GENE
associated I-GENE
with O
a O
high O
_RARE_ I-GENE
of O
hepatitis I-GENE
C I-GENE
virus I-GENE
infection O
in O
_RARE_ I-GENE
blood O
donors O
. O

Here O
the O
cloning O
and O
molecular O
analysis O
of O
the O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
genes I-GENE
is O
presented O
. O

This O
agent O
, O
isolated O
from O
the O
fungus I-GENE
Streptomyces I-GENE
_RARE_ I-GENE
, O
has O
a O
mechanism O
of O
action O
similar O
to O
that O
of O
cyclosporine O
. O

DNase I-GENE
I I-GENE
footprinting O
of O
the O
proximal I-GENE
promoter I-GENE
revealed O
four O
regions O
of O
protection O
. O

Finally O
, O
the O
stability O
of O
the O
nucleotide I-GENE
binding I-GENE
function O
of O
the O
two O
proteins I-GENE
is O
similar O
as O
assessed O
by O
sensitivity O
to O
urea O
. O

Insulin I-GENE
- I-GENE
like I-GENE
growth I-GENE
factor I-GENE
- I-GENE
binding I-GENE
protein I-GENE
- I-GENE
2 I-GENE
( O
IGF I-GENE
- I-GENE
BP I-GENE
- I-GENE
2 I-GENE
) O
transcription I-GENE
in O
rat I-GENE
liver O
_RARE_ I-GENE
with O
developmental O
age O
and O
fasting O
. O

The O
presence O
of O
the O
RV O
5 I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
sequence I-GENE
had O
the O
primary O
enhancing O
effect O
on O
translation I-GENE
. O

By O
contrast O
, O
all O
proteins I-GENE
initiated O
with O
a O
methionine O
placed O
one O
residue O
upstream O
of O
the O
natural O
N I-GENE
terminus O
of O
PR I-GENE
failed O
to O
show O
specific I-GENE
proteolysis O
. O

Reverse I-GENE
transcriptase I-GENE
and O
protease I-GENE
activities O
of O
avian I-GENE
_RARE_ I-GENE
virus I-GENE
Gag I-GENE
- I-GENE
Pol I-GENE
fusion I-GENE
proteins I-GENE
expressed O
in O
insect O
cells O
. O

In O
addition O
, O
an O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
triple O
_RARE_ I-GENE
was O
viable O
. O

However O
, O
there O
were O
some O
properties O
of O
_RARE_ I-GENE
that O
are O
distinct O
from O
Src I-GENE
- I-GENE
like I-GENE
kinases I-GENE
: O
( O
a O
) O
expression O
of O
_RARE_ I-GENE
was O
predominantly O
in O
epithelial O
- I-GENE
derived O
cell O
lines O
and O
tissues O
, O
especially O
normal O
liver O
and O
kidney O
, O
and O
cell O
lines O
of O
breast O
and O
colon O
origin O
; O
( O
b I-GENE
) O
_RARE_ I-GENE
does O
not O
harbor O
the O
NH2 I-GENE
- I-GENE
terminal I-GENE
glycine O
essential O
for O
_RARE_ I-GENE
and O
membrane I-GENE
localization O
; O
and O
( O
c I-GENE
) O
_RARE_ I-GENE
possesses O
a O
putative O
bipartite O
nuclear I-GENE
localization O
signal I-GENE
in O
the O
SH2 I-GENE
domain I-GENE
, O
and O
subcellular O
fractionation O
studies O
revealed O
that O
_RARE_ I-GENE
resides O
predominantly O
in O
the O
nucleus O
. O

PATIENTS O
AND O
METHODS O
: O
We O
report O
our O
experience O
with O
seven O
children O
with O
active O
small I-GENE
bowel O
Crohn O
' O
s O
disease O
given O
a O
casein I-GENE
- I-GENE
based O
, O
_RARE_ I-GENE
feed O
rich O
in O
TGF I-GENE
- I-GENE
beta I-GENE
2 I-GENE
( O
Specific O
_RARE_ I-GENE
_RARE_ I-GENE
; O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
; O
_RARE_ I-GENE
, O
_RARE_ I-GENE
) O
as O
complete O
nutrition O
for O
8 O
weeks O
. O

The O
leader O
sequence I-GENE
of O
the O
isolated O
cDNA I-GENE
clone O
contains O
several O
small I-GENE
open O
reading O
frames O
upstream O
of O
the O
initiation I-GENE
codon O
of O
the O
largest O
open O
reading O
frame O
coding O
for O
the O
homeodomain I-GENE
protein I-GENE
. O

A I-GENE
small I-GENE
amount O
of O
_RARE_ I-GENE
- I-GENE
1 I-GENE
mRNA I-GENE
was O
detected O
only O
in O
roots O
. O

Cell O
adhesion I-GENE
and O
migration O
assays O
demonstrate O
that O
alpha I-GENE
6 I-GENE
beta I-GENE
1 I-GENE
is O
the O
major I-GENE
_RARE_ I-GENE
receptor I-GENE
in O
undifferentiated O
F9 O
cells O
as O
well O
as O
F9 O
- I-GENE
derived O
PE I-GENE
cells O
. O

No O
local O
_RARE_ I-GENE
by O
tumor I-GENE
or O
infection O
could O
be O
demonstrated O
apart O
from O
HIV I-GENE
infection O
. O

Among O
the O
mixed O
_RARE_ I-GENE
persons O
one O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
had O
AS I-GENE
, O
one O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
had O
_RARE_ I-GENE
arthritis O
( O
_RARE_ I-GENE
). O

Our O
data O
complement I-GENE
other O
studies O
of O
_RARE_ I-GENE
populations O
and O
_RARE_ I-GENE
the O
reported O
high O
_RARE_ I-GENE
of O
_RARE_ I-GENE
and O
HLA I-GENE
- I-GENE
_RARE_ I-GENE
among O
those O
populations O
. O

Clinical O
studies O
_RARE_ I-GENE
was O
administered O
to O
45 O
patients O
with O
various O
infectious O
diseases O
( O
2 I-GENE
with O
acute O
_RARE_ I-GENE
, O
8 O
with O
acute O
_RARE_ I-GENE
, O
4 I-GENE
with O
_RARE_ I-GENE
_RARE_ I-GENE
, O
3 I-GENE
each O
with O
acute O
_RARE_ I-GENE
, O
pneumonia O
and O
pertussis I-GENE
, O
7 O
with O
_RARE_ I-GENE
fever O
, O
3 I-GENE
with O
_RARE_ I-GENE
_RARE_ I-GENE
, O
6 I-GENE
with O
acute O
urinary O
tract O
infections O
, O
2 I-GENE
with O
_RARE_ I-GENE
and O
1 I-GENE
each O
with O
cervical O
_RARE_ I-GENE
, O
S I-GENE
. O
S I-GENE
. O
S I-GENE
. O
S I-GENE
., O
_RARE_ I-GENE
and O
acute O
_RARE_ I-GENE
) O
at O
daily O
doses O
between O
3 I-GENE
. O
4 I-GENE
- I-GENE
10 O
mg O
/ I-GENE
kg O
, O
t I-GENE
. O
i O
. O
d O
., O
for O
3 I-GENE
- I-GENE
14 O
days O
. O

Although O
most O
SH2 I-GENE
- I-GENE
_RARE_ I-GENE
interactions O
occur O
between O
two O
different O
types O
of O
molecules I-GENE
, O
some O
appear O
to O
involve O
only O
a O
single O
molecular O
type I-GENE
. O

RESULTS O
: O
_RARE_ I-GENE
time O
of O
_RARE_ I-GENE
in O
patients O
receiving O
TPN O
+ I-GENE
somatostatin I-GENE
was O
significantly O
shorter O
( O
13 O
. O
86 I-GENE
+/- O
1 I-GENE
. O
84 O
versus O
20 O
. O
4 I-GENE
+/- O
2 I-GENE
. O
89 I-GENE
days O
) O
than O
in O
those O
receiving O
TPN O
alone O
. O

Experimental O
adhesion I-GENE
prophylaxis O
with O
recombinant I-GENE
tissue I-GENE
plasminogen I-GENE
activator I-GENE
. O

_RARE_ I-GENE
during O
sleep O
in O
children O
with O
atopic O
dermatitis O
is O
associated I-GENE
with O
increased O
VO2 O
. O

To O
determine O
which O
sequences I-GENE
in O
the O
rat I-GENE
_RARE_ I-GENE
promoter I-GENE
may O
be O
responsible O
for O
basal O
and O
cAMP I-GENE
- I-GENE
stimulated O
gene I-GENE
transcription I-GENE
, O
deletion O
constructs I-GENE
containing O
between O
- I-GENE
1 I-GENE
, O
_RARE_ I-GENE
and O
- I-GENE
53 O
base O
pairs O
of O
5 I-GENE
'- O
flanking O
DNA I-GENE
from O
the O
rat I-GENE
_RARE_ I-GENE
gene I-GENE
were O
ligated O
to O
plasmids O
expressing O
the O
reporter I-GENE
gene I-GENE
luciferase I-GENE
and O
transfected O
into O
two O
mouse I-GENE
cell O
lines O
, O
adrenal O
Y I-GENE
- I-GENE
1 I-GENE
cells O
, O
and O
testicular I-GENE
_RARE_ I-GENE
MA I-GENE
- I-GENE
10 O
cells O
. O

Within O
- I-GENE
subject O
BP I-GENE
differences O
between O
fish O
oil O
and O
_RARE_ I-GENE
oil O
treatment O
were O
similar O
for O
_RARE_ I-GENE
( O
3 I-GENE
. O
2 I-GENE
+/- O
1 I-GENE
. O
8 O
/ I-GENE
2 I-GENE
. O
5 I-GENE
+/- O
1 I-GENE
. O
0 O
mm O
Hg O
) O
and O
for O
24 O
- I-GENE
h O
_RARE_ I-GENE
( O
2 I-GENE
. O
5 I-GENE
+/- O
1 I-GENE
. O
0 O
/ I-GENE
2 I-GENE
. O
3 I-GENE
+/- O
0 O
. O
8 O
mm O
Hg O
), O
but O
were O
more O
significant O
with O
the O
latter O
. O

We O
have O
cloned O
and O
sequenced O
the O
mouse I-GENE
_RARE_ I-GENE
cDNA I-GENE
, O
which O
encodes O
the O
NAD I-GENE
( O
P I-GENE
) O
H I-GENE
: O
_RARE_ I-GENE
oxidoreductase I-GENE
[ O
also O
called O
NAD I-GENE
( O
P I-GENE
) O
H I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
acceptor O
) O
oxidoreductase I-GENE
; O
_RARE_ I-GENE
reductase I-GENE
; O
_RARE_ I-GENE
dye O
reductase I-GENE
; O
DT I-GENE
_RARE_ I-GENE
; O
EC I-GENE
1 I-GENE
. O
6 I-GENE
. O
99 O
. O
2 I-GENE
]. O

Escherichia I-GENE
coli I-GENE
_RARE_ I-GENE
is O
an O
_RARE_ I-GENE
_RARE_ I-GENE
deletion O
derivative O
of O
strain O
_RARE_ I-GENE
and O
_RARE_ I-GENE
it O
is O
_RARE_ I-GENE
for O
expression O
of O
the O
cloned O
inducible I-GENE
beta I-GENE
- I-GENE
lactamase I-GENE
gene I-GENE
of O
_RARE_ I-GENE
_RARE_ I-GENE
, O
carried O
on O
plasmid O
_RARE_ I-GENE
. O

Such O
a O
mechanism O
may O
allow O
_RARE_ I-GENE
of O
_RARE_ I-GENE
joint O
conditions O
, O
and O
may O
account O
for O
the O
increased O
prevalence O
of O
such O
conditions O
seen O
with O
_RARE_ I-GENE
subjects O
. O

_RARE_ I-GENE
thyroid I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
: O
_RARE_ I-GENE
for O
the O
future O
. O

While O
daily O
food O
intake O
was O
almost O
constant O
regardless O
of O
the O
dietary O
protein I-GENE
level O
, O
water O
intake O
and O
urine O
volume O
increased O
with O
increasing O
the O
dietary O
protein I-GENE
. O

We O
propose O
that O
_RARE_ I-GENE
and O
_RARE_ I-GENE
encode O
rate O
- I-GENE
limiting O
components O
integral I-GENE
to O
_RARE_ I-GENE
pathways O
throughout O
development O
. O

Transcriptional O
regulation O
of O
the O
vacuolar I-GENE
H I-GENE
(+)- I-GENE
ATPase I-GENE
B2 I-GENE
subunit I-GENE
gene I-GENE
in O
differentiating O
_RARE_ I-GENE
- I-GENE
1 I-GENE
cells O
. O

However O
, O
the O
_RARE_ I-GENE
to O
export O
RNA I-GENE
from O
the O
nucleus O
to O
the O
cytoplasm O
was O
not O
limited O
to O
a O
particular O
phase O
of O
the O
cell O
division O
cycle O
. O

An O
E I-GENE
box I-GENE
element I-GENE
is O
required O
for O
the O
expression O
of O
the O
_RARE_ I-GENE
gene I-GENE
, O
a O
mammalian I-GENE
homologue I-GENE
of O
_RARE_ I-GENE
- I-GENE
f1 I-GENE
gene I-GENE
, O
which O
is O
essential O
for O
adrenal O
and O
_RARE_ I-GENE
development O
. O

Inhibition O
assays O
performed O
with O
over O
30 O
different O
natural O
and O
synthetic O
_RARE_ I-GENE
and O
/ I-GENE
or O
_RARE_ I-GENE
compounds O
are O
utilized O
to O
define O
in O
greater O
detail O
specific I-GENE
structural O
features O
involved O
in O
_RARE_ I-GENE
- I-GENE
protein I-GENE
binding I-GENE
. O

The O
amino O
acid I-GENE
sequence I-GENE
of O
the O
protein I-GENE
in O
the O
region O
of O
the O
specificity O
pocket O
is O
similar O
to O
that O
of O
S I-GENE
. O
_RARE_ I-GENE
proteases I-GENE
A I-GENE
, O
B I-GENE
, O
and O
C I-GENE
. O

Mutations O
in O
the O
_RARE_ I-GENE
gene I-GENE
, O
a O
_RARE_ I-GENE
homologue I-GENE
, O
result O
in O
vacuolar I-GENE
protein I-GENE
sorting I-GENE
defects O
and O
accumulation O
of O
membrane I-GENE
vesicles O
. O

In O
293 O
cells O
, O
expression O
of O
the O
NF I-GENE
- I-GENE
kappa I-GENE
B I-GENE
inhibitor I-GENE
, O
I I-GENE
kappa I-GENE
B I-GENE
- I-GENE
alpha I-GENE
, O
reduced O
the O
stimulatory I-GENE
activity O
of O
LMP I-GENE
. O

This O
experimental O
design O
was O
used O
to O
determine O
the O
effect O
of O
displacement I-GENE
of O
the O
alpha I-GENE
4 I-GENE
- I-GENE
2 I-GENE
binding I-GENE
site I-GENE
on O
the O
repression O
of O
alpha I-GENE
4 I-GENE
gene I-GENE
transcription I-GENE
by O
ICP4 I-GENE
. O

_RARE_ I-GENE
- I-GENE
early I-GENE
transcription I-GENE
from O
the O
channel O
_RARE_ I-GENE
virus I-GENE
genome O
: O
characterization O
of O
two O
immediate I-GENE
- I-GENE
early I-GENE
transcripts I-GENE
. O

The O
GRE I-GENE
at O
nucleotide I-GENE
_RARE_ I-GENE
is O
a O
composite O
GRE I-GENE
( O
_RARE_ I-GENE
) O
containing O
an O
overlapping O
activator I-GENE
protein I-GENE
- I-GENE
1 I-GENE
( O
AP I-GENE
- I-GENE
1 I-GENE
) O
motif I-GENE
for O
the O
c I-GENE
- I-GENE
jun I-GENE
homodimer I-GENE
and O
c I-GENE
- I-GENE
jun I-GENE
/ I-GENE
c I-GENE
- I-GENE
fos I-GENE
heterodimer O
. O

In O
contrast O
to O
some O
results O
previously O
published O
for O
a O
very O
close O
sequence I-GENE
variant I-GENE
( O
_RARE_ I-GENE
_RARE_ I-GENE
. O

Transcriptional O
activation O
by O
thyroid I-GENE
hormone I-GENE
( O
T3 O
) O
requires O
interactions O
between O
the O
T3 O
receptor I-GENE
( O
TR I-GENE
) O
and O
T3 O
response O
elements O
( O
_RARE_ I-GENE
) O
composed O
of O
two O
copies O
of O
sequences I-GENE
related I-GENE
to O
_RARE_ I-GENE
. O

A I-GENE
multivariate O
analysis O
of O
risk O
factors I-GENE
for O
relapse O
examined O
age O
, O
WBC O
at O
diagnosis O
, O
_RARE_ I-GENE
count O
at O
diagnosis O
, O
percentage O
of O
marrow O
_RARE_ I-GENE
, O
_RARE_ I-GENE
subtype I-GENE
, O
the O
number O
of O
remission O
induction O
courses O
to O
achieve O
a O
remission O
, O
maintenance O
therapy O
, O
_RARE_ I-GENE
therapy O
, O
marrow O
cell O
dose O
, O
donor O
- I-GENE
recipient O
sex I-GENE
, O
_RARE_ I-GENE
prophylaxis O
regimen O
and O
isolation O
and O
_RARE_ I-GENE
in O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
( O
CPT I-GENE
) O
II I-GENE
deficiency O
is O
the O
most O
common O
inherited O
disorder O
of O
lipid O
metabolism O
affecting O
skeletal I-GENE
muscle O
. O

We O
show O
that O
these O
three O
gain O
- I-GENE
of O
- I-GENE
function O
mutants I-GENE
differ O
considerably O
in O
their O
ability O
to O
bypass O
the O
sex I-GENE
determination O
signal I-GENE
, O
with O
_RARE_ I-GENE
being O
the O
strongest O
and O
_RARE_ I-GENE
the O
_RARE_ I-GENE
. O

We O
show O
that O
these O
three O
gain O
- I-GENE
of O
- I-GENE
function O
mutants I-GENE
differ O
considerably O
in O
their O
ability O
to O
bypass O
the O
sex I-GENE
determination O
signal I-GENE
, O
with O
_RARE_ I-GENE
being O
the O
strongest O
and O
_RARE_ I-GENE
the O
_RARE_ I-GENE
. O

Binding O
of O
_RARE_ I-GENE
is O
necessary O
to O
activate O
transcription I-GENE
of O
the O
adaptive O
response O
genes I-GENE
; O
_RARE_ I-GENE
, O
in O
vitro O
transcription I-GENE
of O
_RARE_ I-GENE
is O
dependent I-GENE
on O
the O
presence O
of O
_RARE_ I-GENE
. O

No O
significant O
differences O
were O
identified O
between O
groups O
for O
pH O
, O
PaCO2 O
, O
_RARE_ I-GENE
pressure O
, O
heart O
rate O
, O
brain O
temperature O
, O
or O
glucose O
levels O
. O

Blood O
pressure O
also O
was O
increased O
by O
lidocaine O
( O
6 I-GENE
mg O
kg O
- I-GENE
1 I-GENE
). O

_RARE_ I-GENE
often O
use O
more O
than O
one O
drug O
in O
a O
patient O
to O
achieve O
a O
target O
response O
, O
such O
as O
a O
_RARE_ I-GENE
blood O
pressure O
. O

We O
suggest O
that O
this O
gene I-GENE
cluster I-GENE
codes O
for O
( O
parts O
of O
) O
a O
multisubunit I-GENE
cytochrome I-GENE
c I-GENE
_RARE_ I-GENE
lyase I-GENE
. O

In O
this O
paper O
, O
a O
comparison O
between O
the O
number O
and O
shape O
of O
corneal O
endothelial I-GENE
cells O
has O
been O
performed O
in O
25 O
patients O
before O
and O
6 I-GENE
months O
after O
PRK O
. O

_RARE_ I-GENE
reference O
sources O
indicate O
that O
an O
able O
- I-GENE
_RARE_ I-GENE
11 O
- I-GENE
year O
- I-GENE
old O
child O
of O
comparable O
height O
requires O
1 I-GENE
, O
_RARE_ I-GENE
_RARE_ I-GENE
/ I-GENE
d O
for O
support O
of O
basal O
metabolic O
functions O
. O

_RARE_ I-GENE
_RARE_ I-GENE
of O
recombinant I-GENE
_RARE_ I-GENE
CGP I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
in O
_RARE_ I-GENE
volunteers O
. O

In O
contrast O
to O
the O
myoD I-GENE
promoter I-GENE
, O
the O
myoD I-GENE
enhancer I-GENE
shows O
striking O
conservation O
between O
humans O
and O
mice O
both O
in O
its O
sequence I-GENE
and O
its O
distal O
position O
. O

However O
, O
a O
clear O
difference O
exists O
between O
myoblasts O
and O
_RARE_ I-GENE
/ I-GENE
2 I-GENE
cells O
( O
and O
other O
non O
- I-GENE
muscle O
cell O
types O
) O
in O
the O
chromatin O
structure O
of O
the O
chromosomal I-GENE
myoD I-GENE
core I-GENE
enhancer I-GENE
, O
suggesting O
that O
the O
myoD I-GENE
enhancer I-GENE
is O
repressed O
by O
_RARE_ I-GENE
mechanisms O
in O
_RARE_ I-GENE
/ I-GENE
2 I-GENE
cells O
. O

Using O
_RARE_ I-GENE
- I-GENE
ras I-GENE
- I-GENE
transformed O
3T3 O
cells O
as O
a O
model O
system O
, O
we O
show O
that O
both O
RA O
and O
the O
' O
_RARE_ I-GENE
' O
_RARE_ I-GENE
inhibit O
anchorage O
- I-GENE
independent O
cell O
proliferation O
, O
suggesting O
that O
retinoid I-GENE
- I-GENE
induced O
growth I-GENE
inhibition O
may O
be O
related I-GENE
to O
AP1 I-GENE
_RARE_ I-GENE
. O

The O
Oct I-GENE
and O
_RARE_ I-GENE
proteins I-GENE
also O
interact O
in O
vivo O
. O

_RARE_ I-GENE
dermatitis O
is O
an O
" O
_RARE_ I-GENE
which O
_RARE_ I-GENE
and O
not O
a O
rash O
which O
_RARE_ I-GENE
" O
and O
therefore O
, O
any O
patient O
treatment O
program O
should O
address O
the O
_RARE_ I-GENE
of O
potential O
_RARE_ I-GENE
factors I-GENE
that O
_RARE_ I-GENE
this O
_RARE_ I-GENE
. O

Primer O
extension O
experiments O
showed O
that O
there O
are O
two O
transcription I-GENE
initiation I-GENE
sites I-GENE
16 O
bp O
apart O
in O
the O
mouse I-GENE
type I-GENE
2 I-GENE
receptor I-GENE
gene I-GENE
. O

The O
beta I-GENE
subunit I-GENE
of O
the O
Fc I-GENE
epsilon I-GENE
R1 I-GENE
is O
a O
33 O
- I-GENE
kDa I-GENE
tyrosine I-GENE
phosphoprotein I-GENE
, O
but O
the O
_RARE_ I-GENE
Grb2 I-GENE
- I-GENE
binding I-GENE
protein I-GENE
described O
in O
the O
present O
report O
is O
not O
the O
Fc I-GENE
epsilon I-GENE
R1 I-GENE
beta I-GENE
chain I-GENE
and O
its O
identity O
is O
unknown O
. O

To O
study O
the O
mechanisms O
as O
well O
as O
magnitude O
of O
the O
transmembrane I-GENE
transfer I-GENE
of O
bacterial I-GENE
products I-GENE
from O
the O
_RARE_ I-GENE
, O
we O
developed O
a O
computerized O
in O
vitro O
dialysis O
model O
which O
provides O
continuous O
pressure O
recording O
from O
the O
arterial O
, O
venous O
, O
_RARE_ I-GENE
_RARE_ I-GENE
and O
outflow O
_RARE_ I-GENE
. O

After O
24 O
hour O
incubation O
, O
total O
cell O
- I-GENE
associated I-GENE
IL I-GENE
- I-GENE
_RARE_ I-GENE
and O
IL I-GENE
- I-GENE
1 I-GENE
beta I-GENE
were O
measured O
by O
specific I-GENE
radioimmunoassay O
. O

Each O
dietary O
treatment O
was O
fed O
to O
six O
_RARE_ I-GENE
_RARE_ I-GENE
of O
five O
chicks O
per O
_RARE_ I-GENE
for O
21 O
d O
. O

1972 O
. O

In O
contrast O
, O
recent O
evidence O
suggests O
that O
children O
with O
_RARE_ I-GENE
- I-GENE
hemoglobin I-GENE
C I-GENE
disease O
do O
not O
develop O
functional O
_RARE_ I-GENE
before O
3 I-GENE
to O
4 I-GENE
years O
of O
age O
and O
thus O
may O
not O
benefit O
from O
penicillin I-GENE
prophylaxis O
. O

Deletion O
analysis O
indicates O
that O
TBP I-GENE
and O
_RARE_ I-GENE
bind O
to O
distinct O
domains I-GENE
of O
_RARE_ I-GENE
. O
_RARE_ I-GENE
also O
interacts O
with O
TBP I-GENE
, O
but O
it O
interacts O
more O
strongly O
with O
_RARE_ I-GENE
and O
_RARE_ I-GENE
. O

The O
_RARE_ I-GENE
and O
_RARE_ I-GENE
proteins I-GENE
with O
amino O
acid I-GENE
substitutions O
at O
the O
first O
conserved O
histidine O
position O
were O
also O
unable O
to O
_RARE_ I-GENE
_RARE_ I-GENE
- I-GENE
phosphate I-GENE
in O
vitro O
. O

_RARE_ I-GENE
endothelial I-GENE
cells O
undergo O
profound O
changes O
upon O
cellular O
activation O
including O
expression O
of O
a O
spectrum O
of O
cell O
activation O
- I-GENE
associated I-GENE
genes I-GENE
. O

Because O
ATF I-GENE
- I-GENE
1 I-GENE
and O
_RARE_ I-GENE
are O
known O
to O
bind O
to O
cAMP I-GENE
response O
elements O
( O
CRE O
), O
this O
functional O
sequence I-GENE
was O
named O
the O
kappa I-GENE
E3 I-GENE
'- O
CRE O
. O

The O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
and O
PKC I-GENE
- I-GENE
gamma I-GENE
genes I-GENE
have O
a O
similar O
expression O
pattern O
in O
the O
brain O
during O
development O
. O

Structure O
and O
regulation O
of O
the O
gene I-GENE
encoding O
the O
neuron I-GENE
- I-GENE
specific I-GENE
protein I-GENE
kinase I-GENE
C I-GENE
substrate I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
protein I-GENE
). O

The O
amino O
acid I-GENE
sequences I-GENE
of O
the O
known O
largest O
subunits I-GENE
of O
_RARE_ I-GENE
from O
different O
species O
contain O
highly O
conserved O
regions O
. O

The O
_RARE_ I-GENE
- I-GENE
2 I-GENE
gene I-GENE
has O
been O
identified O
at O
the O
site I-GENE
of O
chromosomal I-GENE
_RARE_ I-GENE
in O
acute O
T I-GENE
- I-GENE
cell O
leukemia I-GENE
' O
s O
( O
T I-GENE
- I-GENE
ALL O
). O

In O
vitro O
studies O
with O
blood O
cells O
incubated O
with O
acetate O
or O
_RARE_ I-GENE
ions O
in O
concentrations O
, O
which O
are O
observed O
in O
vivo O
during O
hemodialysis O
, O
suggest O
that O
probably O
these O
ions O
do O
not O
directly O
affect O
superoxide I-GENE
_RARE_ I-GENE
generation O
, O
erythrocyte I-GENE
SOD I-GENE
- I-GENE
1 I-GENE
and O
catalase I-GENE
activities O
and O
erythrocyte I-GENE
membrane I-GENE
lipid O
peroxidation O
. O

Short O
therapy O
with O
omeprazole O
20 O
mg O
/ I-GENE
b I-GENE
. O
i O
. O
d O
., O
_RARE_ I-GENE
500 O
mg O
/ I-GENE
b I-GENE
. O
i O
. O
d O
., O
and O
_RARE_ I-GENE
120 O
mg O
/ I-GENE
q I-GENE
. O
i O
. O
d O
. O
is O
a O
safe O
, O
well O
tolerated O
combination O
that O
_RARE_ I-GENE
a O
80 O
. O
6 I-GENE
% O
eradication O
rate O
of O
H I-GENE
. O
pylori I-GENE
and O
duodenal O
ulcer O
healing O
rates O
as O
good O
as O
those O
achieved O
by O
omeprazole O
20 O
mg O
/ I-GENE
d O
when O
given O
for O
4 I-GENE
wk O
. O

The O
concentration O
of O
mite I-GENE
allergen I-GENE
was O
very O
low O
( O
mean O
0 O
. O
18 O
micrograms O
_RARE_ I-GENE
p O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
dust O
), O
whereas O
that O
of O
cat O
allergen I-GENE
was O
high O
in O
_RARE_ I-GENE
with O
a O
cat O
( O
80 O
. O
8 O
micrograms O
_RARE_ I-GENE
d O
_RARE_ I-GENE
) O
but O
also O
in O
_RARE_ I-GENE
with O
no O
cat O
( O
3 I-GENE
. O
2 I-GENE
micrograms O
_RARE_ I-GENE
d O
_RARE_ I-GENE
). O

CONCLUSIONS O
: O
A I-GENE
comparison O
of O
the O
_RARE_ I-GENE
crystal O
structure O
with O
the O
structures O
of O
_RARE_ I-GENE
- I-GENE
and O
_RARE_ I-GENE
- I-GENE
tRNA I-GENE
synthetases I-GENE
enables O
a O
conserved O
core I-GENE
to O
be O
identified O
. O

_RARE_ I-GENE
bowel O
irrigation O
is O
a O
recently O
described O
technique O
to O
enhance O
the O
passage O
of O
drugs O
already O
beyond O
the O
_RARE_ I-GENE
. O

The O
_RARE_ I-GENE
open O
reading O
frame O
has O
been O
fused O
to O
those O
that O
encode O
the O
LexA I-GENE
protein I-GENE
or O
the O
GST I-GENE
protein I-GENE
and O
both O
of O
these O
constructs I-GENE
function O
in O
yeast I-GENE
. O

As O
in O
_RARE_ I-GENE
, O
U6 I-GENE
is O
a O
single O
- I-GENE
copy O
gene I-GENE
and O
two O
tRNA I-GENE
genes I-GENE
, O
_RARE_ I-GENE
and O
_RARE_ I-GENE
, O
are O
found O
upstream O
to O
the O
gene I-GENE
. O

_RARE_ I-GENE
growth I-GENE
factors I-GENE
have O
already O
had O
an O
_RARE_ I-GENE
impact O
on O
transfusion O
practice O
by O
_RARE_ I-GENE
or O
reducing O
the O
need O
for O
red I-GENE
blood O
cell O
_RARE_ I-GENE
in O
a O
variety O
of O
_RARE_ I-GENE
states O
characterized O
by O
an O
absolute O
or O
relative O
decrease O
in O
erythropoietin I-GENE
. O

However O
, O
the O
mouse I-GENE
has O
previously O
been O
shown O
to O
possess O
only O
three O
forms O
of O
ADH I-GENE
. O

During O
_RARE_ I-GENE
_RARE_ I-GENE
and O
following O
EC I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
at O
rest O
, O
end O
- I-GENE
tidal O
CO2 O
pressure O
( O
PET O
, O
CO2 O
) O
fell O
by O
7 O
. O
5 I-GENE
, O
8 O
. O
5 I-GENE
and O
9 O
. O
5 I-GENE
mmHg O
, O
respectively O
. O

2 I-GENE
. O

_RARE_ I-GENE
analyses O
of O
19 O
amino O
acid I-GENE
sequences I-GENE
of O
6 I-GENE
related I-GENE
protein I-GENE
types O
indicate O
that O
actin I-GENE
- I-GENE
associated I-GENE
proteins I-GENE
related I-GENE
to O
_RARE_ I-GENE
are O
_RARE_ I-GENE
to O
a O
common O
ancestor O
and O
include O
_RARE_ I-GENE
proteins I-GENE
. O

No O
homologs I-GENE
of O
other O
members O
of O
the O
_RARE_ I-GENE
gene I-GENE
cluster I-GENE
were O
detected O
in O
close O
_RARE_ I-GENE
to O
the O
D I-GENE
. O
melanogaster I-GENE
Surf I-GENE
- I-GENE
3 I-GENE
/ I-GENE
_RARE_ I-GENE
gene I-GENE
. O

Moreover O
, O
we O
found O
that O
cyclin I-GENE
E I-GENE
, O
in O
contrast O
to O
cyclin I-GENE
D1 I-GENE
, O
was O
required O
for O
the O
G1 I-GENE
/ I-GENE
S I-GENE
transition O
even O
in O
cells O
lacking O
retinoblastoma I-GENE
protein I-GENE
function O
. O

The O
predicted O
amino O
acid I-GENE
sequence I-GENE
of O
the O
_RARE_ I-GENE
gene I-GENE
product I-GENE
includes O
a O
region O
with O
substantial O
similarity O
to O
the O
basic I-GENE
- I-GENE
helix I-GENE
- I-GENE
loop I-GENE
- I-GENE
helix I-GENE
domain I-GENE
of O
the O
Myc I-GENE
family I-GENE
of O
DNA I-GENE
- I-GENE
binding I-GENE
proteins I-GENE
. O

By O
_RARE_ I-GENE
Pax I-GENE
- I-GENE
6 I-GENE
- I-GENE
_RARE_ I-GENE
fusion I-GENE
proteins I-GENE
, O
we O
were O
able O
to O
identify O
a O
short O
amino O
acid I-GENE
stretch O
in O
the O
N I-GENE
- I-GENE
terminal I-GENE
part O
of O
the O
paired I-GENE
domain I-GENE
which O
is O
responsible O
for O
these O
differences O
in O
DNA I-GENE
- I-GENE
binding I-GENE
specificity O
. O

To O
establish O
a O
possible O
association O
between O
familial O
_RARE_ I-GENE
and O
_RARE_ I-GENE
, O
data O
on O
cases O
with O
both O
_RARE_ I-GENE
were O
collected O
in O
a O
study O
within O
the O
_RARE_ I-GENE
of O
the O
_RARE_ I-GENE
_RARE_ I-GENE
on O
_RARE_ I-GENE
of O
the O
International O
_RARE_ I-GENE
on O
_RARE_ I-GENE
and O
_RARE_ I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
bleeding O
time O
in O
_RARE_ I-GENE
: O
a O
possible O
role O
of O
serotonin I-GENE
? O

These O
six O
_RARE_ I-GENE
have O
an O
area O
of O
34 O
, O
000 O
_RARE_ I-GENE
and O
_RARE_ I-GENE
a O
population O
of O
30 O
million O
. O

According O
to O
symptoms O
, O
signs O
, O
imaging O
features O
, O
operation O
findings O
, O
the O
original O
_RARE_ I-GENE
and O
the O
_RARE_ I-GENE
_RARE_ I-GENE
of O
the O
tumor I-GENE
, O
they O
were O
divided O
into O
four O
clinical O
types O
: O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
- I-GENE
temporal O
and O
extent O
. O

Two O
mammalian I-GENE
enzymes O
, O
the O
_RARE_ I-GENE
- I-GENE
controlled O
repressor I-GENE
( O
_RARE_ I-GENE
) O
and O
the O
double O
- I-GENE
stranded I-GENE
RNA I-GENE
- I-GENE
activated I-GENE
inhibitor I-GENE
( O
_RARE_ I-GENE
), O
phosphorylate O
Ser O
- I-GENE
51 O
of O
the O
alpha I-GENE
subunit I-GENE
, O
thereby O
inhibiting O
the O
exchange I-GENE
of O
bound O
nucleotides O
on O
, O
and O
thus O
the O
_RARE_ I-GENE
of O
, O
eIF I-GENE
- I-GENE
2 I-GENE
. O

A I-GENE
triple O
Ser O
--> I-GENE
Ala I-GENE
mutant I-GENE
form O
of O
yeast I-GENE
eIF I-GENE
- I-GENE
2 I-GENE
alpha I-GENE
was O
found O
to O
be O
no O
longer O
phosphorylated O
by O
either O
of O
the O
yeast I-GENE
( O
or O
mammalian I-GENE
) O
casein I-GENE
kinase I-GENE
activities O
in O
vitro O
. O

The O
cases O
included O
35 O
de O
novo I-GENE
diffuse O
aggressive O
lymphomas O
( O
_RARE_ I-GENE
; O
19 O
large O
- I-GENE
cell O
, O
4 I-GENE
mixed O
- I-GENE
cell O
, O
and O
12 O
large O
- I-GENE
cell O
_RARE_ I-GENE
), O
52 O
transformed O
aggressive O
lymphomas O
derived O
from O
follicular O
lymphomas O
( O
_RARE_ I-GENE
), O
42 O
_RARE_ I-GENE
follicular O
lymphomas O
( O
FL I-GENE
), O
14 O
_RARE_ I-GENE
cell O
lymphomas O
( O
_RARE_ I-GENE
), O
and O
27 O
small I-GENE
_RARE_ I-GENE
cell O
lymphomas O
( O
_RARE_ I-GENE
). O

_RARE_ I-GENE
and O
beta I-GENE
- I-GENE
_RARE_ I-GENE
in O
_RARE_ I-GENE
children O
in O
_RARE_ I-GENE

Female O
patients O
with O
breast O
cancer O
diagnosed O
between O
1982 O
and O
1991 O
at O
_RARE_ I-GENE
_RARE_ I-GENE
Cancer O
Institute O
( O
_RARE_ I-GENE
) O
in O
_RARE_ I-GENE
, O
New O
York O
, O
who O
provided O
information O
on O
their O
_RARE_ I-GENE
smoking O
history O
at O
the O
time O
of O
their O
diagnosis O
were O
included O
. O

Upon O
analysis O
of O
the O
tissue I-GENE
distribution O
of O
_RARE_ I-GENE
, O
it O
was O
found O
to O
be O
expressed O
strongly O
in O
endothelial I-GENE
cells O
, O
_RARE_ I-GENE
, O
and O
poorly O
differentiated O
colon O
adenocarcinoma O
cells O
found O
in O
_RARE_ I-GENE
. O

Data O
from O
the O
V I-GENE
- I-GENE
_RARE_ I-GENE
II I-GENE
show O
that O
at O
2 I-GENE
- I-GENE
year O
follow O
- I-GENE
up O
, O
a O
progressive O
rise O
of O
plasma I-GENE
norepinephrine O
was O
observed O
in O
both O
treatment O
_RARE_ I-GENE
, O
suggesting O
that O
disease O
_RARE_ I-GENE
despite O
treatment O
with O
either O
an O
angiotensin I-GENE
- I-GENE
converting I-GENE
enzyme I-GENE
inhibitor I-GENE
, O
_RARE_ I-GENE
, O
or O
vasodilator O
therapy O
with O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
. O

Binding O
activity O
in O
rat I-GENE
liver O
nuclear I-GENE
extracts O
includes O
these O
orphan I-GENE
receptors I-GENE
as O
judged O
from O
_RARE_ I-GENE
supershift O
experiments O
and O
from O
results O
obtained O
with O
expressed O
receptors I-GENE
, O
although O
the O
element I-GENE
in O
_RARE_ I-GENE
did O
not O
bind O
HNF I-GENE
- I-GENE
4 I-GENE
. O

_RARE_ I-GENE
analysis O
reveals O
that O
lethal O
B I-GENE
block O
substitutions O
reduce O
U6 I-GENE
RNA I-GENE
synthesis O
at O
least O
10 O
- I-GENE
fold O
in O
vivo O
and O
20 O
- I-GENE
fold O
in O
vitro O
. O

Analysis O
of O
Bcl I-GENE
- I-GENE
2 I-GENE
/ I-GENE
Bcl I-GENE
- I-GENE
2 I-GENE
_RARE_ I-GENE
using O
both O
in O
vitro O
binding I-GENE
assays O
as O
well O
as O
a O
yeast I-GENE
two O
- I-GENE
hybrid O
method O
provided O
evidence O
in O
support O
of O
a O
head I-GENE
- I-GENE
to O
- I-GENE
tail O
model O
for O
Bcl I-GENE
- I-GENE
2 I-GENE
/ I-GENE
Bcl I-GENE
- I-GENE
2 I-GENE
_RARE_ I-GENE
and O
revealed O
that O
sequences I-GENE
within O
the O
NH2 I-GENE
- I-GENE
terminal I-GENE
A I-GENE
domain I-GENE
interact O
with O
a O
structure O
that O
requires O
the O
presence O
of O
both O
the O
carboxyl O
B I-GENE
and O
C I-GENE
domains I-GENE
in O
combination O
. O

The O
protein I-GENE
is O
composed O
of O
a O
central O
alpha I-GENE
- I-GENE
helical O
portion O
with O
globular O
domains I-GENE
at O
both O
NH2 I-GENE
and O
COOH O
termini O
, O
and O
the O
epitope O
to O
the O
monoclonal I-GENE
antibody I-GENE
resides O
in O
the O
central O
alpha I-GENE
- I-GENE
helical O
_RARE_ I-GENE
. O

_RARE_ I-GENE
binding I-GENE
was O
indistinguishable O
for O
both O
transiently O
expressed O
constructs I-GENE
. O

Diagnosis O
of O
_RARE_ I-GENE
has O
been O
_RARE_ I-GENE
upon O
laparoscopic O
findings O
. O

Human I-GENE
papillomavirus I-GENE
type I-GENE
_RARE_ I-GENE
late O
gene I-GENE
expression O
is O
regulated O
through O
protein I-GENE
kinase I-GENE
C I-GENE
- I-GENE
mediated O
changes O
in O
RNA I-GENE
processing O
. O

Interestingly O
, O
virions O
also O
contained O
smaller O
proteins I-GENE
that O
reacted O
with O
antibodies I-GENE
specific I-GENE
for O
the O
accessory I-GENE
proteins I-GENE
as O
well O
as O
_RARE_ I-GENE
and O
CAT I-GENE
fusion I-GENE
partners O
. O

Studies O
using O
an O
inhibitor I-GENE
or O
a O
mutant I-GENE
_RARE_ I-GENE
proteinase I-GENE
indicated O
that O
stimulation O
of O
_RARE_ I-GENE
- I-GENE
driven O
translation I-GENE
is O
mediated O
via O
proteolysis O
of O
some O
cellular O
component O
( O
s O
). O

Restriction O
mapping O
analysis O
localized O
this O
cDNA I-GENE
to O
the O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
genomic O
BamHI I-GENE
G I-GENE
fragment I-GENE
, O
at O
the O
right O
end O
of O
the O
unique O
long O
segment O
of O
the O
genome O
and O
to O
the O
_RARE_ I-GENE
L I-GENE
and O
_RARE_ I-GENE
O O
fragments I-GENE
within O
the O
left O
and O
right O
terminal I-GENE
direct O
repeat I-GENE
regions O
, O
respectively O
. O

For O
replication O
reporter I-GENE
constructs I-GENE
where O
E1 I-GENE
and O
E2 I-GENE
are O
supplied O
in O
trans O
by O
the O
respective O
expression O
vectors O
, O
distance O
between O
the O
half O
sites I-GENE
seems O
to O
play O
a O
major I-GENE
role O
, O
yet O
the O
_RARE_ I-GENE
relationships O
are O
_RARE_ I-GENE
. O

As O
it O
had O
been O
previously O
reported O
that O
the O
18 O
- I-GENE
bp O
palindrome O
contains O
sufficient O
nucleotide I-GENE
sequence I-GENE
information O
for O
E1 I-GENE
binding I-GENE
, O
we O
_RARE_ I-GENE
that O
a O
minimal I-GENE
E1 I-GENE
recognition I-GENE
motif I-GENE
is O
presented O
in O
each O
half O
site I-GENE
. O

METHODS O
: O
_RARE_ I-GENE
of O
_RARE_ I-GENE
patients O
receiving O
_RARE_ I-GENE
between O
_RARE_ I-GENE
1992 O
and O
_RARE_ I-GENE
1993 O
, O
83 O
patients O
with O
_RARE_ I-GENE
_RARE_ I-GENE
received O
heparin O
within O
72 O
hours O
from O
onset O
( O
activated I-GENE
partial O
thromboplastin I-GENE
time O
[ O
_RARE_ I-GENE
] O
1 I-GENE
. O
5 I-GENE
times O
control O
value O
). O

In O
the O
_RARE_ I-GENE
available O
intravenous O
formulation O
of O
_RARE_ I-GENE
A I-GENE
( O
_RARE_ I-GENE
), O
_RARE_ I-GENE
_RARE_ I-GENE
oil O
( O
_RARE_ I-GENE
_RARE_ I-GENE
) O
is O
used O
as O
a O
_RARE_ I-GENE
agent O
. O

Lung O
function O
tests O
( O
_RARE_ I-GENE
) O
were O
performed O
on O
these O
patients O
for O
a O
period O
of O
19 O
. O
2 I-GENE
+/- O
3 I-GENE
. O
4 I-GENE
months O
. O

Sequence O
comparisons O
of O
prokaryotic I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
has O
revealed O
a O
set O
of O
three O
common O
motifs O
, O
two O
of O
which O
, O
a O
putative O
metal O
coordination O
site I-GENE
and O
a O
downstream O
active O
- I-GENE
site I-GENE
tyrosine I-GENE
motif I-GENE
, O
could O
be O
tentatively O
identified O
in O
_RARE_ I-GENE
_RARE_ I-GENE
proteins I-GENE
. O

The O
mean O
_RARE_ I-GENE
_RARE_ I-GENE
of O
_RARE_ I-GENE
restorations O
was O
compared O
for O
restorations O
_RARE_ I-GENE
from O
stone O
, O
low O
- I-GENE
viscosity O
poly O
( O
vinyl O
_RARE_ I-GENE
), O
and O
medium O
- I-GENE
viscosity O
poly O
( O
vinyl O
_RARE_ I-GENE
). O

The O
characterized O
_RARE_ I-GENE
_RARE_ I-GENE
is O
a O
candidate O
PC I-GENE
that O
may O
play O
an O
important O
role O
in O
the O
processing O
of O
egg I-GENE
- I-GENE
_RARE_ I-GENE
hormone I-GENE
( O
_RARE_ I-GENE
)- I-GENE
related I-GENE
precursors I-GENE
in O
the O
secretory I-GENE
cells O
of O
the O
atrial I-GENE
gland O
. O

Rats I-GENE
treated O
with O
8 O
- I-GENE
OH O
- I-GENE
_RARE_ I-GENE
were O
not O
impaired O
in O
their O
ability O
to O
_RARE_ I-GENE
a O
visual O
discrimination O
in O
a O
water O
_RARE_ I-GENE
. O

The O
term O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
is O
suggested O
. O

In O
addition O
, O
two O
internal O
promoters I-GENE
, O
_RARE_ I-GENE
and O
_RARE_ I-GENE
were O
identified O
and O
mapped O
to O
201 O
and O
_RARE_ I-GENE
nucleotides O
upstream O
from O
the O
respective O
translation I-GENE
start O
sites I-GENE
. O

These O
results O
indicate O
that O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
expression O
could O
be O
regulated O
by O
multiple O
mechanisms O
, O
including O
degree O
of O
_RARE_ I-GENE
from O
upstream O
genes I-GENE
, O
modulation O
of O
internal O
promoter I-GENE
strength O
, O
and O
by O
RNase I-GENE
E I-GENE
activity O
. O

Coronary O
T1 O
and O
T2 I-GENE
weighted O
images O
were O
obtained O
. O

The O
2 I-GENE
kb O
of O
5 I-GENE
'- O
flanking O
region O
and O
the O
1 I-GENE
. O
1 I-GENE
kb O
of O
the O
entire O
_RARE_ I-GENE
alpha I-GENE
subunit I-GENE
coding O
region O
were O
sequenced O
from O
the O
genomic O
clone O
, O
_RARE_ I-GENE
alpha I-GENE
- I-GENE
G1 I-GENE
. O

Functional O
analysis O
of O
the O
_RARE_ I-GENE
alpha I-GENE
subunit I-GENE
promoter I-GENE
by O
the O
transient O
transfection O
of O
several O
_RARE_ I-GENE
alpha I-GENE
/ I-GENE
CAT I-GENE
chimeric I-GENE
plasmids O
into O
_RARE_ I-GENE
trout I-GENE
pituitary I-GENE
cells O
suggests O
that O
its O
pituitary I-GENE
- I-GENE
specific I-GENE
expression O
is O
_RARE_ I-GENE
- I-GENE
dependent I-GENE
. O

_RARE_ I-GENE
- I-GENE
111 O
_RARE_ I-GENE
CR I-GENE
/ I-GENE
_RARE_ I-GENE
and O
F I-GENE
- I-GENE
18 O
FDG O
in O
_RARE_ I-GENE
and O
ovarian O
carcinoma O
_RARE_ I-GENE
. O

His O
_RARE_ I-GENE
_RARE_ I-GENE
( O
CPT I-GENE
) O
I I-GENE
and O
II I-GENE
activities O
were O
0 O
. O
06 O
and O
0 O
. O
12 O
nmol O
/ I-GENE
min O
/ I-GENE
mg O
protein I-GENE
, O
as O
compared O
with O
a O
mean O
value O
of O
0 O
. O
22 O
+/- O
0 O
. O
14 O
and O
0 O
. O
27 O
+/- O
0 O
. O
07 O
nmol O
/ I-GENE
min O
/ I-GENE
mg O
protein I-GENE
, O
respectively O
, O
in O
control O
subjects O
. O

The O
Myc I-GENE
_RARE_ I-GENE
was O
found O
to O
prevent O
_RARE_ I-GENE
interactions O
, O
thus O
_RARE_ I-GENE
Myc I-GENE
_RARE_ I-GENE
to O
_RARE_ I-GENE
efficiently O
. O

Staphylococcus I-GENE
aureus I-GENE
and O
CNS O
showed O
high O
or O
moderate O
resistance O
rates O
to O
_RARE_ I-GENE
( O
_RARE_ I-GENE
). O

Thus O
, O
VF O
resistant O
to O
_RARE_ I-GENE
is O
not O
necessarily O
associated I-GENE
with O
both O
toxic O
plasma I-GENE
drug O
level O
and O
remarkably O
decreased O
conduction O
. O

The O
smallest O
active O
_RARE_ I-GENE
derivative O
contained O
59 O
amino O
acid I-GENE
residues O
as O
compared O
to O
the O
_RARE_ I-GENE
residues O
of O
wild I-GENE
- I-GENE
type I-GENE
_RARE_ I-GENE
. O

The O
gene I-GENE
pairs O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
are O
cotranscribed O
from O
opposite O
_RARE_ I-GENE
. O

Hybridization O
signals O
were O
also O
detected O
with O
total O
DNAs O
of O
Rhizobium I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
. O
_RARE_ I-GENE
, O
_RARE_ I-GENE
_RARE_ I-GENE
and O
Escherichia I-GENE
coli I-GENE
, O
but O
not O
those O
of O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
. O
_RARE_ I-GENE
and O
Pseudomonas I-GENE
putida I-GENE
. O

The O
predicted O
amino O
acid I-GENE
sequence I-GENE
contains O
regions O
identical O
to O
the O
sequences I-GENE
of O
peptides I-GENE
derived O
from O
bovine I-GENE
liver O
eIF I-GENE
- I-GENE
2B I-GENE
alpha I-GENE
subunit I-GENE
. O

Expression O
of O
this O
cDNA I-GENE
in O
vitro O
yields O
a O
peptide I-GENE
which O
_RARE_ I-GENE
with O
natural O
eIF I-GENE
- I-GENE
2B I-GENE
alpha I-GENE
in O
SDS O
/ I-GENE
polyacrylamide O
gels O
. O

When O
RNA I-GENE
encoding O
the O
tail O
domain I-GENE
of O
_RARE_ I-GENE
was O
_RARE_ I-GENE
with O
plakoglobin I-GENE
RNA I-GENE
, O
both O
the O
_RARE_ I-GENE
effect O
and O
nuclear I-GENE
accumulation O
of O
plakoglobin I-GENE
were O
suppressed O
. O

Six O
of O
them O
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
( O
also O
called O
_RARE_ I-GENE
), O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
the O
gene I-GENE
encoding O
the O
ribosomal I-GENE
protein I-GENE
_RARE_ I-GENE
and O
the O
gene I-GENE
coding O
for O
a O
_RARE_ I-GENE
protein I-GENE
of O
_RARE_ I-GENE
amino O
acids O
, O
have O
been O
sequenced O
previously O
. O

_RARE_ I-GENE
grafts O
of O
_RARE_ I-GENE
and O
adrenal O
tissues O
have O
been O
found O
to O
be O
effective O
in O
_RARE_ I-GENE
many O
of O
the O
simple O
motor O
and O
_RARE_ I-GENE
deficits O
associated I-GENE
with O
lesions O
of O
the O
_RARE_ I-GENE
dopamine I-GENE
system O
. O

OBJECTIVE O
: O
To O
determine O
the O
impact O
of O
the O
introduction O
of O
_RARE_ I-GENE
and O
_RARE_ I-GENE
on O
the O
treatment O
and O
survival O
of O
patients O
with O
AIDS O
and O
_RARE_ I-GENE
Mycobacterium O
_RARE_ I-GENE
complex I-GENE
( O
_RARE_ I-GENE
). O

_RARE_ I-GENE
, O
the O
aggregation O
rose O
to O
the O
initial O
100 O
% O
value O
4 I-GENE
h O
after O
drug O
application O
and O
remained O
at O
this O
level O
during O
the O
observation O
period O
.( O
ABSTRACT O
TRUNCATED O
AT I-GENE
250 O
WORDS O
) O

Growth I-GENE
curves O
indicated O
that O
proliferation O
of O
clone O
_RARE_ I-GENE
in O
the O
presence O
of O
10 O
% O
serum I-GENE
was O
reduced O
by O
60 O
% O
compared O
with O
clone O
_RARE_ I-GENE
. O

The O
protein I-GENE
coding O
region O
, O
1 I-GENE
, O
_RARE_ I-GENE
_RARE_ I-GENE
long O
, O
is O
divided O
by O
an O
intron O
into O
two O
exons O
. O

The O
UAS O
of O
the O
_RARE_ I-GENE
gene I-GENE
contains O
at O
least O
two O
distinct O
motifs O
for O
DNA I-GENE
- I-GENE
binding I-GENE
transcriptional O
activators I-GENE
, O
including O
one O
which O
is O
identical O
with O
the O
core I-GENE
_RARE_ I-GENE
/ I-GENE
3 I-GENE
/ I-GENE
4 I-GENE
binding I-GENE
motif I-GENE
, O
and O
a O
second O
one O
with O
the O
_RARE_ I-GENE
consensus I-GENE
binding I-GENE
sequence I-GENE
. O

The O
_RARE_ I-GENE
complexity O
of O
the O
5 I-GENE
' O
regulatory I-GENE
region O
of O
the O
GH I-GENE
receptor I-GENE
gene I-GENE
was O
_RARE_ I-GENE
by O
the O
observation O
that O
probes O
derived O
from O
exon O
1B I-GENE
and O
the O
distal O
3 I-GENE
' O
intron O
boundary O
do O
not O
_RARE_ I-GENE
with O
previously O
cloned O
genomic O
sequences I-GENE
that O
span O
the O
liver O
- I-GENE
specific I-GENE
P1 I-GENE
promoter I-GENE
and O
exon O
2 I-GENE
. O

A I-GENE
polymorphic O
dinucleotide O
( O
GT I-GENE
/ I-GENE
CA I-GENE
) O
n O
repeat I-GENE
contained O
in O
the O
_RARE_ I-GENE
cosmid O
was O
identified O
and O
developed O
into O
a O
microsatellite I-GENE
PCR O
marker O
. O

The O
proteins I-GENE
are O
more O
than O
90 O
% O
identical O
to O
each O
other O
within O
the O
protein I-GENE
kinase I-GENE
domain I-GENE
but O
only O
51 O
- I-GENE
59 O
% O
identical O
to O
other O
casein I-GENE
kinase I-GENE
I I-GENE
isoforms I-GENE
within O
this O
region O
. O

We O
used O
two O
approaches O
to O
_RARE_ I-GENE
whether O
CDP I-GENE
/ I-GENE
cut I-GENE
serves O
as O
a O
repressor I-GENE
of O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
gene I-GENE
expression O
. O

Serum I-GENE
induction O
of O
a O
MEF2 I-GENE
reporter I-GENE
gene I-GENE
was O
not O
observed O
in O
a O
line O
of O
NIH O
3T3 O
cells O
which O
contain O
low O
MEF2 I-GENE
site I-GENE
binding I-GENE
activity O
. O

Despite O
the O
activation O
of O
these O
intracellular O
signaling O
molecules I-GENE
, O
PDGF I-GENE
beta I-GENE
receptor I-GENE
activation O
elicited O
no O
detectable O
effect O
on O
cell O
proliferation O
or O
differentiation O
. O

UAS1 O
is O
the O
binding I-GENE
site I-GENE
for O
the O
transcriptional O
regulator I-GENE
_RARE_ I-GENE
. O

In O
the O
context O
of O
the O
_RARE_ I-GENE
upstream O
regulatory I-GENE
region O
, O
including O
UAS1 O
, O
working O
in O
_RARE_ I-GENE
with O
the O
_RARE_ I-GENE
basal O
promoter I-GENE
elements O
, O
_RARE_ I-GENE
- I-GENE
dependent I-GENE
gene I-GENE
activation O
was O
dependent I-GENE
on O
orientation O
, O
copy O
number O
, O
and O
helix I-GENE
phase O
. O

Induction O
in O
AP I-GENE
- I-GENE
1 I-GENE
DNA I-GENE
binding I-GENE
correlates O
with O
a O
concomitant O
GH I-GENE
trans O
- I-GENE
activation O
of O
c I-GENE
- I-GENE
jun I-GENE
and O
c I-GENE
- I-GENE
fos I-GENE
genes I-GENE
described O
previously O
. O

_RARE_ I-GENE
of O
MAP I-GENE
kinases I-GENE
occurs O
via O
a O
specific I-GENE
phosphatase I-GENE
, O
MKP I-GENE
- I-GENE
1 I-GENE
. O

Short O
- I-GENE
course O
amphotericin O
B I-GENE
therapy O
for O
_RARE_ I-GENE
in O
pediatric O
patients O
. O

Furthermore O
, O
_RARE_ I-GENE
- I-GENE
binding I-GENE
assays O
revealed O
that O
_RARE_ I-GENE
directly O
binds O
Ca2 I-GENE
_RARE_ I-GENE

Since O
AP I-GENE
- I-GENE
1 I-GENE
is O
an O
important O
_RARE_ I-GENE
of O
tumor I-GENE
promoter I-GENE
action O
, O
these O
findings O
may O
explain O
the O
anti I-GENE
- I-GENE
tumor I-GENE
- I-GENE
promoting I-GENE
activity O
of O
_RARE_ I-GENE
_RARE_ I-GENE
. O

The O
second O
complex I-GENE
, O
when O
purified O
, O
contained O
four O
protein I-GENE
components O
including O
the O
36 O
- I-GENE
kDa I-GENE
protein I-GENE
. O

The O
protein I-GENE
expressed O
from O
the O
cloned O
cDNA I-GENE
is O
secreted O
into O
the O
culture O
medium O
and O
yields O
of O
up O
to O
40 I-GENE
mg O
per O
_RARE_ I-GENE
have O
been O
obtained O
. O

The O
study O
was O
repeated O
after O
administration O
of O
oral O
_RARE_ I-GENE
, O
50 O
mg O
/ I-GENE
kg O
/ I-GENE
day O
for O
2 I-GENE
days O
in O
8 O
divided O
doses O
( O
mean O
dose O
6 I-GENE
. O
9 O
+/- O
0 O
. O
4 I-GENE
g O
). O

_RARE_ I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
and O
_RARE_ I-GENE
were O
transformed O
into O
a O
laboratory O
strain O
of O
Saccharomyces I-GENE
cerevisiae I-GENE
, O
whereas O
_RARE_ I-GENE
was O
stably O
introduced O
into O
two O
commercial O
_RARE_ I-GENE
yeast I-GENE
strains O
. O

The O
maximum O
induction O
of O
_RARE_ I-GENE
- I-GENE
oxidase I-GENE
transcripts I-GENE
occurred O
at O
about O
6 I-GENE
h O
after O
excision O
, O
while O
the O
maximum O
enzyme I-GENE
activity O
was O
observed O
at O
24 O
h O
. O

Within O
their O
polypeptide I-GENE
chain I-GENE
, O
they O
all O
contain O
those O
conserved O
features O
that O
define O
a O
plant O
_RARE_ I-GENE
; O
kinase I-GENE
catalytic O
sequences I-GENE
are O
linked O
to O
a O
calmodulin I-GENE
- I-GENE
like I-GENE
regulatory I-GENE
domain I-GENE
through O
a O
junction O
region O
. O

_RARE_ I-GENE
of O
this O
insertion O
by O
homologous O
recombination O
restores O
the O
activity O
of O
the O
_RARE_ I-GENE
locus I-GENE
, O
thus O
confirming O
the O
site I-GENE
of O
mutation I-GENE
. O

The O
timing O
of O
_RARE_ I-GENE
gene I-GENE
expression O
in O
the O
cell O
cycle O
is O
determined O
by O
specialized O
forms O
of O
RNA I-GENE
polymerase I-GENE
and O
the O
appearance O
and O
/ I-GENE
or O
activation O
of O
regulatory I-GENE
proteins I-GENE
. O

Primer O
extension O
experiments O
revealed O
a O
strong O
transcription I-GENE
initiation I-GENE
site I-GENE
_RARE_ I-GENE
bp O
upstream O
of O
the O
translational O
start O
site I-GENE
. O

_RARE_ I-GENE
of O
the O
same O
apparent O
sizes O
are O
detected O
in O
_RARE_ I-GENE
of O
a O
_RARE_ I-GENE
null I-GENE
mutant I-GENE
, O
on O
which O
basis O
we O
_RARE_ I-GENE
that O
the O
products I-GENE
of O
the O
_RARE_ I-GENE
operon I-GENE
are O
required O
for O
the O
normal O
formation O
of O
the O
inner O
_RARE_ I-GENE
of O
the O
coat I-GENE
or O
are O
themselves O
structural O
components O
of O
the O
coat I-GENE
. O

Based O
on O
the O
estimated O
values O
of O
divergence O
of O
_RARE_ I-GENE
sequences I-GENE
in O
terms O
of O
the O
numbers O
of O
_RARE_ I-GENE
and O
non O
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
per O
site I-GENE
, O
we O
found O
that O
_RARE_ I-GENE
is O
a O
_RARE_ I-GENE
rapidly O
_RARE_ I-GENE
protein I-GENE
. O

_RARE_ I-GENE
is O
a O
conserved O
alpha I-GENE
- I-GENE
helical O
peripheral O
membrane I-GENE
protein I-GENE
flanked O
by O
cysteine I-GENE
" O
fingers O
" O
and O
contains O
a O
calmodulin I-GENE
- I-GENE
binding I-GENE
_RARE_ I-GENE
motif I-GENE
. O

Nucleotide O
sequences I-GENE
of O
the O
clones O
revealed O
that O
one O
clone O
, O
_RARE_ I-GENE
, O
contained O
an O
open O
reading O
frame O
( O
ORF I-GENE
) O
that O
would O
code O
for O
a O
26 O
- I-GENE
amino O
acid I-GENE
, O
cysteine I-GENE
- I-GENE
rich O
peptide I-GENE
with O
significant O
homology I-GENE
to O
Neurospora I-GENE
crassa I-GENE
copper I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
with O
_RARE_ I-GENE
and O
biologically O
modified O
carbon O
electrodes O
. O

_RARE_ I-GENE
of O
the O
tissues O
of O
the O
face O
is O
essentially O
vertical O
and O
acts O
on O
the O
_RARE_ I-GENE
, O
temporal O
region O
, O
_RARE_ I-GENE
and O
_RARE_ I-GENE
. O

This O
region O
binds O
two O
ubiquitous O
nuclear I-GENE
factors I-GENE
, O
USF I-GENE
/ I-GENE
_RARE_ I-GENE
and O
the O
CAAT I-GENE
- I-GENE
binding I-GENE
transcription I-GENE
factor I-GENE
/ I-GENE
nuclear I-GENE
factor I-GENE
1 I-GENE
( O
_RARE_ I-GENE
/ I-GENE
NF1 I-GENE
). O

The O
potential O
impact O
of O
using O
a O
rapid O
diagnostic O
test O
( O
_RARE_ I-GENE
A I-GENE
_RARE_ I-GENE
) O
on O
detection O
and O
treatment O
of O
group O
A I-GENE
beta I-GENE
- I-GENE
_RARE_ I-GENE
streptococcal I-GENE
( O
_RARE_ I-GENE
) O
_RARE_ I-GENE
in O
a O
large O
- I-GENE
volume O
pediatric O
and O
adolescent O
_RARE_ I-GENE
was O
examined O
. O

The O
bHLH I-GENE
proteins I-GENE
function O
as O
potent O
transcriptional O
activators I-GENE
of O
tissue I-GENE
- I-GENE
specific I-GENE
genes I-GENE
by O
forming O
heterodimers I-GENE
between O
ubiquitous O
and O
cell O
- I-GENE
restricted O
family I-GENE
members O
. O

YAC O
and O
cosmid O
_RARE_ I-GENE
spanning O
the O
BRCA1 I-GENE
region O
were O
used O
to O
select O
cDNA I-GENE
clones O
from O
_RARE_ I-GENE
of O
cDNAs I-GENE
derived O
from O
human I-GENE
placenta O
, O
HeLa O
cells O
, O
activated I-GENE
T I-GENE
cells O
, O
and O
fetal O
head I-GENE
. O

The O
other O
two O
clones O
, O
_RARE_ I-GENE
- I-GENE
m I-GENE
and O
- I-GENE
s O
, O
had O
nucleotide I-GENE
sequences I-GENE
identical O
with O
_RARE_ I-GENE
- I-GENE
l O
cDNA I-GENE
in O
the O
amino O
- I-GENE
terminal I-GENE
region O
. O

This O
study O
_RARE_ I-GENE
the O
feasibility O
and O
toxicity O
of O
_RARE_ I-GENE
immunotherapy O
with O
tumor I-GENE
_RARE_ I-GENE
lymphocytes O
and O
recombinant I-GENE
interleukin I-GENE
- I-GENE
2 I-GENE
in O
29 O
patients O
who O
underwent O
resection O
for O
stage O
III I-GENE
non O
- I-GENE
small I-GENE
- I-GENE
cell O
lung O
cancer O
. O

_RARE_ I-GENE
AND O
METHODS O
: O
Of O
the O
17 O
men O
and O
17 O
women O
, O
who O
were O
21 O
to O
80 O
years O
of O
age O
, O
27 O
had O
hereditary I-GENE
motor O
and O
sensory O
neuropathy I-GENE
type I-GENE
I I-GENE
and O
7 O
had O
acquired O
_RARE_ I-GENE
_RARE_ I-GENE
. O

The O
present O
study O
describes O
the O
cell O
volume O
dynamics O
in O
intact O
rat I-GENE
hearts O
, O
during O
ischemia O
and O
after O
reperfusion O
. O

In O
contrast O
, O
COUP I-GENE
- I-GENE
TF I-GENE
alone O
had O
no O
effect O
on O
_RARE_ I-GENE
- I-GENE
dependent I-GENE
reporter I-GENE
gene I-GENE
activity O
. O

DNA I-GENE
sequencing O
and O
Southern O
blot O
analyses O
established O
that O
the O
cDNA I-GENE
clones O
are O
derived O
from O
two O
different O
genes I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
- I-GENE
Px I-GENE
activity O
after O
prolonged O
exercise O
, O
training O
, O
and O
selenium O
supplementation O
. O

Mutation O
of O
the O
Sp1 I-GENE
element I-GENE
, O
which O
abolishes O
Sp1 I-GENE
binding I-GENE
, O
results O
in O
a O
6 I-GENE
- I-GENE
10 O
- I-GENE
fold O
reduction O
in O
reporter I-GENE
activity O
. O

The O
c I-GENE
- I-GENE
myc I-GENE
gene I-GENE
is O
overexpressed O
in O
a O
variety O
of O
tumor I-GENE
types O
and O
appears O
to O
play O
an O
important O
role O
in O
the O
abnormal O
growth I-GENE
of O
a O
number O
of O
cell O
types O
. O

We O
found O
that O
_RARE_ I-GENE
was O
expressed O
at O
a O
lower O
level O
in O
S I-GENE
, O
G2 I-GENE
, O
and O
M I-GENE
phases O
and O
at O
a O
significantly O
higher O
level O
in O
G1 I-GENE
phase O
. O

_RARE_ I-GENE
is O
found O
to O
be O
related I-GENE
to O
good O
health O
even O
after O
controlling O
for O
differences O
in O
_RARE_ I-GENE
health O
inputs O
. O

With O
this O
_RARE_ I-GENE
diastolic O
_RARE_ I-GENE
, O
the O
abnormal O
echo O
disappeared O
completely O
. O

It O
acts O
on O
_RARE_ I-GENE
in O
the O
G1 I-GENE
and O
S I-GENE
phases O
of O
the O
cell O
cycle O
, O
and O
also O
binds O
to O
proliferating I-GENE
cell O
nuclear I-GENE
antigen I-GENE
( O
PCNA I-GENE
), O
blocking O
DNA I-GENE
replication O
in O
vitro O
. O

Two O
major I-GENE
and O
one O
minor O
transcription I-GENE
initiation I-GENE
sites I-GENE
were O
assigned O
to O
positions O
+ I-GENE
1 I-GENE
and O
+ I-GENE
24 O
and O
position O
+ I-GENE
14 O
, O
respectively O
, O
by O
a O
combination O
of O
ribonuclease I-GENE
protection O
, O
primer O
extension O
, O
and O
5 I-GENE
' O
RACE O
analyses O
. O

The O
_RARE_ I-GENE
doses O
that O
were O
chosen O
for O
these O
studies O
were O
less O
than O
_RARE_ I-GENE
blood O
levels O
. O

We O
demonstrate O
here O
that O
the O
- I-GENE
_RARE_ I-GENE
sequence I-GENE
stabilizes O
GDP I-GENE
binding I-GENE
to O
Ran I-GENE
, O
and O
that O
the O
domain I-GENE
is O
required O
for O
high O
affinity O
interaction O
with O
a O
Ran I-GENE
- I-GENE
binding I-GENE
protein I-GENE
, O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
. O

Further O
, O
the O
ORFs O
of O
components O
3 I-GENE
and O
5 I-GENE
potentially O
encoded I-GENE
proteins I-GENE
of O
about O
20 O
kDa I-GENE
, O
the O
size O
of O
the O
_RARE_ I-GENE
coat I-GENE
protein I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
strength O
data O
for O
2 I-GENE
patients O
were O
compared O
to O
change O
in O
creatinine O
kinase I-GENE
( O
CK I-GENE
) O
levels O
. O

_RARE_ I-GENE
does O
not O
have O
any O
homologues O
in O
the O
data O
- I-GENE
bases O
. O

OBJECTIVE O
: O
To O
investigate O
the O
incidence O
and O
presentation O
of O
acute O
_RARE_ I-GENE
or O
_RARE_ I-GENE
_RARE_ I-GENE
in O
a O
general O
_RARE_ I-GENE
hospital O
. O

Unlike O
most O
other O
small I-GENE
G I-GENE
proteins I-GENE
which O
are O
expressed O
ubiquitously O
, O
TTF I-GENE
was O
transcribed O
only O
in O
_RARE_ I-GENE
cells O
as O
a O
2 I-GENE
. O
2 I-GENE
kb O
transcript I-GENE
. O

An O
explanation O
explored O
for O
this O
lack O
of O
gene I-GENE
expression O
was O
that O
increased O
levels O
of O
RAR I-GENE
alpha I-GENE
or O
_RARE_ I-GENE
might O
suppress O
_RARE_ I-GENE
cell O
growth I-GENE
. O

Transfection O
of O
non O
- I-GENE
deleted O
expression O
vector O
into O
NIH3T3 O
cells O
results O
in O
acquisition O
of O
focus O
- I-GENE
forming O
activity O
while O
a O
deleted O
form O
of O
expression O
vector O
fails O
to O
show O
this O
activity O
even O
in O
the O
presence O
of O
basic I-GENE
FGF I-GENE
. O

_RARE_ I-GENE
extracts O
from O
a O
variety O
of O
mammalian I-GENE
cell O
lines O
( O
monkey I-GENE
_RARE_ I-GENE
, O
several O
mouse I-GENE
_RARE_ I-GENE
and O
human I-GENE
HeLa O
_RARE_ I-GENE
) O
demonstrated O
similar O
TGF I-GENE
- I-GENE
beta I-GENE
1 I-GENE
dependent I-GENE
RNA I-GENE
- I-GENE
protein I-GENE
band O
shifts O
as O
cell O
extract O
from O
BALB O
/ I-GENE
c I-GENE
3T3 O
mouse I-GENE
fibroblasts O
. O

All O
ribosomal I-GENE
protein I-GENE
( O
_RARE_ I-GENE
) O
gene I-GENE
promoters I-GENE
from O
Saccharomyces I-GENE
cerevisiae I-GENE
studied O
so O
far O
contain O
either O
( O
usually O
two O
) O
binding I-GENE
sites I-GENE
for O
the O
global O
gene I-GENE
regulator I-GENE
_RARE_ I-GENE
or O
one O
binding I-GENE
site I-GENE
for O
another O
global O
factor I-GENE
, O
_RARE_ I-GENE
. O

The O
_RARE_ I-GENE
reports O
are O
based O
mainly O
upon O
_RARE_ I-GENE
findings O
, O
whereas O
the O
final O
reports O
include O
the O
information O
provided O
by O
supplementary O
investigations O
such O
as O
microscopy O
, O
_RARE_ I-GENE
, O
more O
rarely O
electron O
microscopy O
, O
_RARE_ I-GENE
and O
/ I-GENE
or O
_RARE_ I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
: O
current O
knowledge O
and O
future O
_RARE_ I-GENE

CPT I-GENE
- I-GENE
11 O
was O
administered O
as O
a O
30 O
- I-GENE
minute O
i O
. O
v I-GENE
. O
infusion O
at O
a O
dose O
of O
350 O
mg O
/ I-GENE
m2 O
_RARE_ I-GENE
in O
250 O
ml O
normal O
saline O
every O
3 I-GENE
weeks O
. O

CONCLUSION O
: O
The O
_RARE_ I-GENE
for O
CPT I-GENE
- I-GENE
11 O
administered O
in O
a O
3 I-GENE
consecutive O
- I-GENE
days O
- I-GENE
every O
- I-GENE
3 I-GENE
weeks O
schedule O
in O
this O
patient O
population O
is O
115 I-GENE
mg O
/ I-GENE
m2 O
/ I-GENE
day O
. O

A I-GENE
73 O
bp O
fragment I-GENE
( O
_RARE_ I-GENE
region O
) O
of O
the O
_RARE_ I-GENE
- I-GENE
1b I-GENE
promoter I-GENE
, O
located O
between O
positions O
- I-GENE
_RARE_ I-GENE
and O
- I-GENE
_RARE_ I-GENE
, O
was O
sufficient O
to O
confer O
ethylene O
responsiveness O
to O
the O
reporter I-GENE
gene I-GENE
. O

To O
assess O
the O
function O
( O
s O
) O
of O
_RARE_ I-GENE
during O
_RARE_ I-GENE
, O
we O
have O
isolated O
and O
characterized O
recessive O
loss O
- I-GENE
of O
- I-GENE
function O
mutations O
specific I-GENE
to O
each O
transcription I-GENE
unit I-GENE
. O

Although O
the O
extracellular I-GENE
domain I-GENE
of O
the O
TSH I-GENE
- I-GENE
R I-GENE
is O
sufficient O
for O
high O
affinity O
binding I-GENE
of O
TSH I-GENE
, O
we O
conclude O
that O
the O
_RARE_ I-GENE
mutation I-GENE
in O
the O
fourth O
transmembrane I-GENE
domain I-GENE
_RARE_ I-GENE
TSH I-GENE
binding I-GENE
. O

_RARE_ I-GENE
was O
covalently O
conjugated O
with O
_RARE_ I-GENE
. O

Moreover O
, O
Western O
blots O
demonstrated O
at O
least O
six O
types O
of O
_RARE_ I-GENE
in O
both O
Cr I-GENE
and O
_RARE_ I-GENE
, O
suggesting O
that O
these O
_RARE_ I-GENE
are O
used O
for O
_RARE_ I-GENE
functions O
responsible O
for O
vesicle O
transport O
rather O
than O
for O
cellular O
differentiation O
. O

The O
absence O
of O
other O
regions O
of O
hybridization O
suggests O
that O
there O
are O
no O
closely O
related I-GENE
sequences I-GENE
( O
e O
. O
g O
., O
reverse I-GENE
transcribed O
_RARE_ I-GENE
) O
_RARE_ I-GENE
throughout O
the O
genome O
and O
that O
if O
there O
are O
closely O
related I-GENE
genes I-GENE
, O
they O
must O
be O
clustered O
near O
_RARE_ I-GENE
. O

However O
, O
the O
lens O
dose O
( O
3 I-GENE
. O
6 I-GENE
Gy O
/ I-GENE
25 O
fractions O
) O
was O
higher O
compared O
to O
the O
other O
techniques O
. O

Antibodies O
to O
the O
human I-GENE
_RARE_ I-GENE
recognize O
this O
protein I-GENE
in O
human I-GENE
, O
monkey I-GENE
, O
rat I-GENE
, O
and O
hamster I-GENE
cells O
. O

There O
is O
a O
national O
effort O
to O
begin O
to O
_RARE_ I-GENE
all O
female O
patients O
about O
family I-GENE
_RARE_ I-GENE
. O

GnRH I-GENE
treatment O
was O
found O
to O
increase O
the O
phosphorylation O
of O
tyrosine I-GENE
residues O
of O
MAPK I-GENE
and O
to O
increase O
MAPK I-GENE
activity O
, O
as O
determined O
by O
an O
immune I-GENE
complex I-GENE
kinase I-GENE
assay O
. O

Molecular O
cloning O
of O
an O
_RARE_ I-GENE
insulin I-GENE
receptor I-GENE
substrate I-GENE
1 I-GENE
- I-GENE
like I-GENE
cDNA I-GENE
and O
involvement O
of O
phosphatidylinositol I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
in O
insulin I-GENE
- I-GENE
induced O
Xenopus I-GENE
oocyte O
maturation O
. O

We O
report O
here O
that O
in O
cultured O
Jurkat O
T I-GENE
cells O
, O
Cbl I-GENE
is O
_RARE_ I-GENE
with O
antibody I-GENE
against O
the O
adapter I-GENE
protein I-GENE
Grb2 I-GENE
. O

The O
effect O
of O
these O
cell O
cycle O
regulators O
is O
not O
specific I-GENE
to O
the O
_RARE_ I-GENE
or O
_RARE_ I-GENE
delta I-GENE
A I-GENE
mutation I-GENE
, O
since O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
mutations O
also O
suppress O
mutations O
in O
_RARE_ I-GENE
, O
another O
gene I-GENE
implicated O
in O
the O
establishment O
of O
silencing O
. O

ICP4 I-GENE
has O
been O
shown O
to O
form O
_RARE_ I-GENE
complexes I-GENE
_RARE_ I-GENE
with O
the O
TATA I-GENE
box I-GENE
- I-GENE
binding I-GENE
protein I-GENE
and O
_RARE_ I-GENE
on O
DNA I-GENE
containing O
an O
ICP4 I-GENE
binding I-GENE
site I-GENE
and O
a O
TATA I-GENE
box I-GENE
( O
C I-GENE
. O

_RARE_ I-GENE
, O
_RARE_ I-GENE
. O

Characterization O
of O
_RARE_ I-GENE
of O
Schizosaccharomyces I-GENE
pombe I-GENE
: O
a O
developmentally O
controlled O
function O
needed O
for O
conjugation O
. O

_RARE_ I-GENE
- I-GENE
related I-GENE
cDNA I-GENE
encoding O
a O
protein I-GENE
with O
a O
high O
- I-GENE
mobility I-GENE
- I-GENE
group O
( O
HMG I-GENE
) O
box I-GENE
and O
a O
leucine I-GENE
zipper I-GENE
motif I-GENE
, O
which O
was O
designated O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
, O
was O
isolated O
from O
a O
_RARE_ I-GENE
trout I-GENE
testis I-GENE
cDNA I-GENE
library O
. O

_RARE_ I-GENE
_RARE_ I-GENE
can O
be O
_RARE_ I-GENE
just O
to O
the O
point O
of O
_RARE_ I-GENE
_RARE_ I-GENE
over O
4 I-GENE
to O
6 I-GENE
weeks O
followed O
by O
_RARE_ I-GENE
flap O
_RARE_ I-GENE
and O
_RARE_ I-GENE
closure O
of O
the O
donor O
site I-GENE
. O

In O
the O
_RARE_ I-GENE
for O
Human I-GENE
_RARE_ I-GENE
in O
_RARE_ I-GENE
, O
predictive O
DNA I-GENE
- I-GENE
testing O
for O
_RARE_ I-GENE
' O
s O
disease O
is O
available O
as O
a O
clinical O
_RARE_ I-GENE
since O
_RARE_ I-GENE
1987 O
, O
initially O
by O
DNA I-GENE
- I-GENE
linkage O
and O
since O
mid O
1993 O
by O
direct O
mutation I-GENE
analysis O
. O

_RARE_ I-GENE
of O
_RARE_ I-GENE
following O
acute O
hepatitis I-GENE
B I-GENE
virus I-GENE
infection O
: O
a O
review O
. O

Examination O
of O
_RARE_ I-GENE
factors I-GENE
revealed O
a O
_RARE_ I-GENE
sympathetic O
nervous O
system O
and O
an O
increase O
in O
plasma I-GENE
renin I-GENE
activity O
. O

We O
compared O
the O
inhibitory I-GENE
effect O
of O
naturally O
occurring O
mutant I-GENE
_RARE_ I-GENE
beta I-GENE
1 I-GENE
, O
artificially O
created O
_RARE_ I-GENE
alpha I-GENE
1 I-GENE
mutants I-GENE
, O
c I-GENE
- I-GENE
erbA I-GENE
alpha I-GENE
2 I-GENE
and O
the O
human I-GENE
peroxisome I-GENE
proliferator I-GENE
- I-GENE
activated I-GENE
receptor I-GENE
( O
_RARE_ I-GENE
) O
on O
three O
_RARE_ I-GENE
T3 O
- I-GENE
response O
elements O
( O
_RARE_ I-GENE
), O
TRE I-GENE
- I-GENE
PAL I-GENE
, O
DR I-GENE
+ I-GENE
4 I-GENE
and O
TRE I-GENE
- I-GENE
_RARE_ I-GENE
. O

The O
amino O
- I-GENE
terminal I-GENE
DNA I-GENE
- I-GENE
binding I-GENE
domain I-GENE
of O
_RARE_ I-GENE
exhibits O
a O
high O
degree O
of O
homology I-GENE
to O
the O
DNA I-GENE
- I-GENE
binding I-GENE
domains I-GENE
of O
members O
of O
the O
interferon I-GENE
regulatory I-GENE
factor I-GENE
( O
IRF I-GENE
) O
family I-GENE
, O
which O
includes O
IRF I-GENE
- I-GENE
1 I-GENE
, O
IRF I-GENE
- I-GENE
2 I-GENE
, O
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
gamma I-GENE
. O

An O
outbreak O
of O
hepatitis I-GENE
A I-GENE
among O
_RARE_ I-GENE
men O
in O
_RARE_ I-GENE
, O
1991 O
- I-GENE
1993 O
. O

The O
_RARE_ I-GENE
subunit I-GENE
of O
_RARE_ I-GENE
alone O
contained O
the O
stimulatory I-GENE
activity O
and O
the O
minimal I-GENE
region O
sufficient O
for O
stimulation O
corresponds O
to O
COOH O
- I-GENE
terminal I-GENE
residues O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
. O

We O
have O
generated O
various O
base O
substitutions O
and O
internal O
deletions O
in O
and O
around O
DRE I-GENE
( O
nucleotide I-GENE
positions O
- I-GENE
93 O
to O
- I-GENE
100 O
with O
respect O
to O
the O
transcription I-GENE
initiation I-GENE
site I-GENE
) O
of O
the O
PCNA I-GENE
gene I-GENE
in O
vitro O
and O
subsequently O
examined O
their O
effects O
on O
the O
binding I-GENE
to O
_RARE_ I-GENE
( O
DRE I-GENE
- I-GENE
binding I-GENE
factor I-GENE
) O
and O
PCNA I-GENE
gene I-GENE
promote O
activity O
in O
cultured O
Drosophila I-GENE
_RARE_ I-GENE
cells O
as O
well O
as O
in O
living O
_RARE_ I-GENE
. O

The O
hsp70 I-GENE
gene I-GENE
family I-GENE
of O
Neurospora I-GENE
crassa I-GENE
: O
cloning O
, O
sequence I-GENE
analysis O
, O
expression O
, O
and O
genetic O
mapping O
of O
the O
major I-GENE
stress O
- I-GENE
inducible I-GENE
member O
. O

The O
deduced O
amino O
acid I-GENE
sequences I-GENE
of O
each O
of O
the O
_RARE_ I-GENE
_RARE_ I-GENE
subunits I-GENE
exhibit O
only O
approximately O
30 O
% O
identity O
with O
the O
corresponding O
subunits I-GENE
of O
the O
_RARE_ I-GENE
from O
human I-GENE
, O
rat I-GENE
, O
and O
_RARE_ I-GENE
_RARE_ I-GENE
, O
which O
as O
a O
group O
are O
greater O
than O
50 O
% O
identical O
. O

A I-GENE
secondary O
phosphorylation O
of O
_RARE_ I-GENE
at O
_RARE_ I-GENE
is O
required O
for O
the O
cAMP I-GENE
- I-GENE
mediated O
control O
of O
gene I-GENE
expression O
. O

A I-GENE
role O
for O
glycogen I-GENE
synthase I-GENE
kinase I-GENE
- I-GENE
3 I-GENE
in O
the O
control O
of O
gene I-GENE
expression O
. O

This O
last O
region O
contains O
two O
sites I-GENE
that O
bind O
Ets I-GENE
- I-GENE
related I-GENE
proteins I-GENE
present O
in O
liver O
nuclear I-GENE
extracts O
as O
well O
as O
recombinant I-GENE
purified O
Ets I-GENE
- I-GENE
1 I-GENE
protein I-GENE
. O

Other O
assays O
also O
distinguished O
the O
_RARE_ I-GENE
replication O
of O
_RARE_ I-GENE
. O
Myc I-GENE
- I-GENE
2 I-GENE
. O
4 I-GENE
from O
the O
_RARE_ I-GENE
labeling O
of O
control O
plasmids O
. O

_RARE_ I-GENE
of O
complexes I-GENE
containing O
p62 I-GENE
and O
the O
src I-GENE
family I-GENE
kinase I-GENE
_RARE_ I-GENE
in O
HeLa O
cells O
demonstrated O
that O
complex I-GENE
formation O
resulted O
in O
tyrosine I-GENE
phosphorylation O
of O
p62 I-GENE
and O
was O
mediated O
by O
both O
the O
SH3 I-GENE
and O
SH2 I-GENE
domains I-GENE
of O
_RARE_ I-GENE
. O

Therefore O
, O
it O
is O
_RARE_ I-GENE
that O
by O
_RARE_ I-GENE
the O
transcriptional O
control O
of O
the O
_RARE_ I-GENE
gene I-GENE
_RARE_ I-GENE
into O
the O
mechanisms O
that O
control O
functional O
fate O
and O
organization O
in O
the O
nervous O
system O
can O
be O
_RARE_ I-GENE
. O

In O
contrast O
, O
a O
Maf I-GENE
- I-GENE
related I-GENE
protein I-GENE
, O
_RARE_ I-GENE
, O
completely O
mimicked O
c I-GENE
- I-GENE
Maf I-GENE
actions O
. O

The O
27 O
- I-GENE
base O
element I-GENE
interacts O
with O
a O
PDGF I-GENE
- I-GENE
activated I-GENE
serine I-GENE
/ I-GENE
threonine I-GENE
phosphoprotein I-GENE
that O
is O
detected O
only O
within O
the O
nucleus O
of O
PDGF I-GENE
- I-GENE
treated O
3T3 O
cells O
. O

By O
contrast O
, O
deletion O
of O
this O
Ras I-GENE
- I-GENE
binding I-GENE
site I-GENE
did O
not O
_RARE_ I-GENE
activation O
of O
Raf I-GENE
- I-GENE
1 I-GENE
kinase I-GENE
by O
Src I-GENE
, O
implying O
that O
Src I-GENE
and O
Ras I-GENE
can O
activate O
Raf I-GENE
- I-GENE
1 I-GENE
through O
independent O
mechanisms O
. O

In O
studies O
of O
many O
different O
_RARE_ I-GENE
distinct O
cells O
, O
the O
CRE O
of O
the O
somatostatin I-GENE
gene I-GENE
promoter I-GENE
is O
a O
prototype O
of O
a O
highly O
cAMP I-GENE
- I-GENE
responsive I-GENE
element I-GENE
regulated O
by O
CREB I-GENE
. O

The O
first O
gene I-GENE
, O
_RARE_ I-GENE
, O
a O
previously O
identified O
gene I-GENE
, O
encodes O
a O
protein I-GENE
involved O
in O
ribosomal I-GENE
RNA I-GENE
maturation O
and O
possibly O
in O
transport O
of O
proteins I-GENE
into O
the O
nucleus O
. O

Characterization O
of O
the O
promoter I-GENE
for O
the O
human I-GENE
85 O
kDa I-GENE
cytosolic I-GENE
phospholipase I-GENE
A2 I-GENE
gene I-GENE
. O

This O
paper O
describes O
the O
advantages O
and O
limitations O
of O
the O
main O
study O
approaches O
used O
. O

Comparative O
study O
of O
the O
differential O
white O
blood O
cell O
count O
using O
three O
automated O
_RARE_ I-GENE
: O
_RARE_ I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
NE O
_RARE_ I-GENE
and O
_RARE_ I-GENE
H I-GENE
- I-GENE
1 I-GENE
. O

Characterization O
of O
_RARE_ I-GENE
/ I-GENE
YY1 I-GENE
, O
a O
Xenopus I-GENE
laevis I-GENE
conserved O
zinc I-GENE
- I-GENE
finger I-GENE
protein I-GENE
binding I-GENE
to O
the O
first O
exon O
of O
L1 I-GENE
and O
_RARE_ I-GENE
ribosomal I-GENE
protein I-GENE
genes I-GENE
. O

Further O
studies O
established O
that O
the O
_RARE_ I-GENE
- I-GENE
induced O
increase O
in O
beta I-GENE
- I-GENE
globin I-GENE
mRNA I-GENE
could O
be O
inhibited O
by O
the O
tyrosine I-GENE
kinase I-GENE
inhibitor I-GENE
_RARE_ I-GENE
and O
the O
protein I-GENE
kinase I-GENE
C I-GENE
inhibitor I-GENE
_RARE_ I-GENE
3 I-GENE
.( O
ABSTRACT O
TRUNCATED O
AT I-GENE
250 O
WORDS O
) O

This O
structure O
of O
_RARE_ I-GENE
suggests O
that O
it O
is O
probably O
synthesized O
as O
an O
inactive O
precursor I-GENE
. O

Molecular O
dissection O
of O
the O
_RARE_ I-GENE
CD3 I-GENE
- I-GENE
TCR I-GENE
complex I-GENE
revealed O
that O
at O
least O
two O
associated I-GENE
polypeptides I-GENE
, O
CD3 I-GENE
zeta I-GENE
and O
CD3 I-GENE
epsilon I-GENE
, O
autonomously I-GENE
_RARE_ I-GENE
antigenic I-GENE
recognition I-GENE
event O
to O
early I-GENE
and O
late O
events O
of O
the O
_RARE_ I-GENE
activation O
cascade O
. O

Protein I-GENE
_RARE_ I-GENE
binds O
preferentially O
to O
AT I-GENE
- I-GENE
rich O
DNA I-GENE
with O
a O
half O
- I-GENE
saturation O
value O
of O
1 I-GENE
. O
1 I-GENE
nM O
. O

This O
study O
investigated O
the O
degree O
to O
which O
_RARE_ I-GENE
identity O
influences O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
' O
performance O
on O
the O
L I-GENE
, O
K I-GENE
, O
and O
_RARE_ I-GENE
_RARE_ I-GENE
of O
the O
MMPI O
- I-GENE
2 I-GENE
. O

Both O
can O
be O
elevated O
on O
a O
single O
vascular I-GENE
_RARE_ I-GENE
based O
on O
the O
superficial O
temporal O
artery O
, O
the O
double O
- I-GENE
_RARE_ I-GENE
temporal O
_RARE_ I-GENE
flap O
. O

To O
do O
this O
, O
segments O
of O
DNA I-GENE
from O
the O
5 I-GENE
' O
flank O
of O
the O
initiation I-GENE
sites I-GENE
for O
germline I-GENE
epsilon I-GENE
RNA I-GENE
were O
ligated O
to O
a O
luciferase I-GENE
reporter I-GENE
gene I-GENE
and O
transfected O
into O
two O
mouse I-GENE
B I-GENE
cell O
lines O
, O
one O
of O
which O
can O
be O
induced O
to O
switch O
to O
IgE I-GENE
. O

The O
negative O
predictive O
value O
is O
92 O
%, O
vs O
80 O
% O
for O
the O
_RARE_ I-GENE
I I-GENE
. O

_RARE_ I-GENE
capacity O
of O
the O
E2F1 I-GENE
gene I-GENE
. O

In O
some O
of O
the O
cases O
of O
_RARE_ I-GENE
lesion O
, O
serum I-GENE
TSH I-GENE
levels O
, O
serum I-GENE
_RARE_ I-GENE
values O
, O
and O
131I O
protein I-GENE
_RARE_ I-GENE
iodine O
( O
131I O
- I-GENE
_RARE_ I-GENE
) O
were O
measured O
, O
but O
there O
were O
no O
significant O
differences O
between O
successful O
and O
_RARE_ I-GENE
therapy O
. O

_RARE_ I-GENE
transcripts I-GENE
are O
confined O
to O
the O
definitive O
_RARE_ I-GENE
plate I-GENE
in O
_RARE_ I-GENE
stage O
embryos O
; O
at O
_RARE_ I-GENE
stage O
this O
gene I-GENE
is O
expressed O
throughout O
the O
_RARE_ I-GENE
, O
but O
later O
only O
in O
the O
_RARE_ I-GENE
. O

A I-GENE
unique O
leucine I-GENE
- I-GENE
proline O
repeat I-GENE
element I-GENE
found O
N I-GENE
- I-GENE
terminal I-GENE
to O
the O
DNA I-GENE
- I-GENE
binding I-GENE
domain I-GENE
of O
_RARE_ I-GENE
- I-GENE
1 I-GENE
does O
not O
appear O
to O
play O
a O
role O
in O
DNA I-GENE
- I-GENE
binding I-GENE
or O
dimerization O
. O

Another O
full I-GENE
ORF I-GENE
was O
found O
on O
the O
opposite O
strand O
downstream O
from O
the O
_RARE_ I-GENE
gene I-GENE
. O

The O
U14 I-GENE
genes I-GENE
of O
mouse I-GENE
as O
well O
as O
rat I-GENE
, O
hamster I-GENE
, O
human I-GENE
, O
Xenopus I-GENE
and O
trout I-GENE
are O
encoded I-GENE
within O
introns O
of O
the O
constitutively O
expressed O
70 I-GENE
- I-GENE
kDa I-GENE
- I-GENE
cognate I-GENE
- I-GENE
heat I-GENE
- I-GENE
shock I-GENE
protein I-GENE
gene I-GENE
( O
_RARE_ I-GENE
). O

Two O
related I-GENE
cDNAs I-GENE
were O
isolated O
that O
encode O
proteins I-GENE
that O
recognize O
the O
_RARE_ I-GENE
TATA I-GENE
motif I-GENE
. O

Deletion O
of O
both O
_RARE_ I-GENE
and O
_RARE_ I-GENE
resulted O
in O
extremely O
slow O
growth I-GENE
and O
a O
reduction O
in O
sporulation I-GENE
efficiency O
. O

_RARE_ I-GENE
in O
this O
family I-GENE
of O
proteins I-GENE
suggests O
that O
_RARE_ I-GENE
and O
_RARE_ I-GENE
may O
participate O
in O
an O
export O
pathway O
required O
for O
_RARE_ I-GENE
assembly O
. O

In O
_RARE_ I-GENE
L I-GENE
- I-GENE
cell O
membranes O
expressing O
wild I-GENE
type I-GENE
or O
mutant I-GENE
_RARE_ I-GENE
/ I-GENE
IGF I-GENE
II I-GENE
receptors I-GENE
, O
30 O
nM O
IGF I-GENE
II I-GENE
also O
failed O
to O
affect O
the O
pertussis I-GENE
toxin I-GENE
substrate I-GENE
activity O
. O

Chem O
. O

For O
the O
first O
time O
we O
describe O
deletion O
and O
point O
mutations O
within O
the O
plasma I-GENE
membrane I-GENE
family I-GENE
of O
_RARE_ I-GENE
cyclase I-GENE
receptors I-GENE
that O
result O
in O
the O
formation O
of O
effective O
dominant I-GENE
negative O
proteins I-GENE
. O

_RARE_ I-GENE
in O
blood O
_RARE_ I-GENE
was O
further O
augmented O
by O
fat O
plus O
AA O
supplementation O
, O
but O
no O
changes O
in O
concentrations O
of O
Lys O
or O
Met I-GENE
in O
blood O
were O
found O
. O

_RARE_ I-GENE
. O

Coronary O
_RARE_ I-GENE
caused O
by O
endothelin I-GENE
- I-GENE
1 I-GENE
is O
enhanced O
by O
ischemia O
- I-GENE
reperfusion O
and O
by O
norepinephrine O
present O
in O
concentrations O
typically O
observed O
after O
neonatal O
cardiopulmonary O
bypass O
. O

Comparison O
of O
the O
deduced O
amino O
acid I-GENE
sequence I-GENE
of O
gamma I-GENE
- I-GENE
_RARE_ I-GENE
with O
the O
published O
sequences I-GENE
of O
gamma I-GENE
- I-GENE
_RARE_ I-GENE
of O
maize I-GENE
, O
and O
_RARE_ I-GENE
revealed O
highly O
conserved O
domains I-GENE
. O

_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
and O
the O
ORF I-GENE
are O
very O
close O
to O
each O
other O
and O
organized O
in O
the O
same O
polarity O
; O
hence O
, O
the O
intergenic O
regions O
probably O
contain O
, O
within O
less O
than O
0 O
. O
5 I-GENE
kb O
, O
all O
the O
regulatory I-GENE
elements O
necessary O
to O
govern O
initiation I-GENE
and O
termination O
of O
transcription I-GENE
. O

Southern O
blot O
hybridization O
experiments O
suggest O
the O
presence O
of O
one O
copy O
of O
_RARE_ I-GENE
, O
_RARE_ I-GENE
and O
_RARE_ I-GENE
per O
_RARE_ I-GENE
genome O
, O
and O
Northern O
blot O
analysis O
demonstrates O
that O
the O
three O
genes I-GENE
are O
differentially O
expressed O
in O
roots O
, O
_RARE_ I-GENE
and O
leaves O
. O

These O
results O
suggest O
that O
_RARE_ I-GENE
may O
also O
be O
one O
of O
the O
meiotic I-GENE
genes I-GENE
. O

We O
characterized O
three O
Arabidopsis I-GENE
thaliana O
cDNA I-GENE
clones O
that O
could O
rescue O
the O
_RARE_ I-GENE
phenotype O
of O
the O
Schizosaccharomyces I-GENE
pombe I-GENE
_RARE_ I-GENE
mutant I-GENE
, O
which O
is O
defective O
in O
cAMP I-GENE
phosphodiesterase I-GENE
. O

Furthermore O
, O
the O
identification O
of O
a O
_RARE_ I-GENE
- I-GENE
like I-GENE
protein I-GENE
in O
A I-GENE
. O
thaliana O
strongly O
_RARE_ I-GENE
for O
the O
_RARE_ I-GENE
of O
this O
protein I-GENE
among O
eukaryotic I-GENE
_RARE_ I-GENE
and O
for O
a O
conserved O
mechanism O
to O
regulate O
transcription I-GENE
initiation I-GENE
that O
involves O
_RARE_ I-GENE
. O

Similarly O
approximately O
300 O
bp O
of O
sequence I-GENE
downstream O
of O
the O
translation I-GENE
terminator O
_RARE_ I-GENE
of O
the O
beta I-GENE
- I-GENE
_RARE_ I-GENE
2 I-GENE
( O
_RARE_ I-GENE
) O
gene I-GENE
could O
substitute O
for O
the O
3 I-GENE
' O
region O
of O
the O
H4 I-GENE
- I-GENE
I I-GENE
gene I-GENE
. O

These O
data O
demonstrate O
that O
the O
_RARE_ I-GENE
family I-GENE
of O
genes I-GENE
is O
represented O
in O
a O
nematode O
whose O
ancestor O
appeared O
well O
before O
the O
_RARE_ I-GENE
that O
gave O
rise O
to O
the O
_RARE_ I-GENE
and O
_RARE_ I-GENE
. O

The O
pre I-GENE
- I-GENE
and O
postoperative O
_RARE_ I-GENE
concentrations O
in O
the O
autologous O
group O
were O
lower O
by O
15 O
and O
10 O
g O
/ I-GENE
L I-GENE
, O
respectively O
, O
after O
primary O
_RARE_ I-GENE
and O
by O
10 O
g O
/ I-GENE
L I-GENE
in O
both O
instances O
after O
_RARE_ I-GENE
_RARE_ I-GENE
. O

The O
introduction O
of O
an O
acidic O
residue O
at O
the O
second O
site I-GENE
was O
essential O
for O
suppression O
of O
the O
Asn O
- I-GENE
285 O
mutation I-GENE
because O
Lys O
- I-GENE
220 O
and O
Gln O
- I-GENE
220 O
second O
- I-GENE
site I-GENE
mutants I-GENE
of O
the O
Asn O
- I-GENE
285 O
mutant I-GENE
showed O
very O
low O
_RARE_ I-GENE
resistance O
.( O
ABSTRACT O
TRUNCATED O
AT I-GENE
250 O
WORDS O
) O

Tumor I-GENE
necrosis I-GENE
factor I-GENE
alpha I-GENE
, O
the O
cytokine O
that O
participates O
in O
the O
autocrine O
growth I-GENE
control O
of O
_RARE_ I-GENE
cell O
leukemia I-GENE
has O
strong O
bone O
_RARE_ I-GENE
properties O
. O

( O
iv O
) O
Although O
_RARE_ I-GENE
has O
been O
previously O
shown O
to O
act O
as O
a O
transcriptional O
repressor I-GENE
, O
we O
show O
here O
that O
_RARE_ I-GENE
can O
also O
act O
as O
a O
positive O
transactivator I-GENE
of O
a O
reporter I-GENE
driven O
by O
_RARE_ I-GENE
elements O
when O
used O
in O
co O
- I-GENE
transfection O
assays O
. O

The O
sequence I-GENE
of O
monkey I-GENE
_RARE_ I-GENE
closely O
resembles O
the O
human I-GENE
sequence I-GENE
at O
the O
nucleotide I-GENE
and O
the O
amino O
acid I-GENE
levels O
, O
with O
the O
latter O
having O
only O
7 O
differences O
out O
of O
_RARE_ I-GENE
residues O
. O

One O
complex I-GENE
appears O
to O
be O
ubiquitous O
but O
enriched O
in O
lymphoid I-GENE
cells O
and O
represents O
the O
binding I-GENE
of O
a O
potentially O
novel O
factor I-GENE
with O
an O
apparent O
molecular O
mass O
of O
approximately O
50 O
kDa I-GENE
. O

Chem O
. O

Conversely O
, O
activation O
of O
Oct I-GENE
- I-GENE
3 I-GENE
/ I-GENE
4 I-GENE
promoter I-GENE
by O
RAR I-GENE
: O
RXR I-GENE
heterodimers I-GENE
was O
completely O
abolished O
by O
_RARE_ I-GENE
- I-GENE
3 I-GENE
/ I-GENE
COUP I-GENE
- I-GENE
TFI I-GENE
and O
by O
_RARE_ I-GENE
- I-GENE
1 I-GENE
/ I-GENE
COUP I-GENE
- I-GENE
_RARE_ I-GENE
. O

These O
results O
demonstrate O
that O
_RARE_ I-GENE
provides O
a O
crucial O
transactivation O
function O
for O
globin I-GENE
expression O
and O
further O
_RARE_ I-GENE
the O
idea O
that O
_RARE_ I-GENE
is O
an O
important O
regulator I-GENE
of O
_RARE_ I-GENE
element I-GENE
- I-GENE
directed O
transcription I-GENE
in O
erythroid I-GENE
cells O
. O

Using O
a O
battery O
of O
I I-GENE
kappa I-GENE
B I-GENE
alpha I-GENE
mutants I-GENE
, O
we O
show O
that O
( O
i O
) O
a O
dimer O
binds O
a O
single O
I I-GENE
kappa I-GENE
B I-GENE
alpha I-GENE
molecule I-GENE
, O
( O
ii O
) O
the O
acidic O
C I-GENE
- I-GENE
terminal I-GENE
region O
of O
I I-GENE
kappa I-GENE
B I-GENE
alpha I-GENE
is O
not O
required O
for O
protein I-GENE
- I-GENE
protein I-GENE
binding I-GENE
and O
does O
not O
_RARE_ I-GENE
the O
nuclear I-GENE
localization O
signal I-GENE
of O
the O
dimer O
, O
( O
iii O
) O
the O
same O
C I-GENE
- I-GENE
terminal I-GENE
region O
is O
required O
for O
inhibition O
of O
DNA I-GENE
binding I-GENE
, O
and O
( O
iv O
) O
this O
inhibition O
may O
be O
_RARE_ I-GENE
by O
direct O
interaction O
between O
the O
_RARE_ I-GENE
- I-GENE
like I-GENE
region O
and O
the O
DNA I-GENE
- I-GENE
binding I-GENE
region O
of O
one O
of O
the O
subunits I-GENE
of O
the O
dimer O
. O

The O
negative O
regulatory I-GENE
activity O
of O
the O
N I-GENE
- I-GENE
terminal I-GENE
domain I-GENE
was O
_RARE_ I-GENE
by O
a O
C I-GENE
- I-GENE
terminal I-GENE
segment O
of O
_RARE_ I-GENE
supplied O
in O
trans O
. O

At O
different O
times O
of O
the O
surgical O
procedures O
( O
_RARE_ I-GENE
_RARE_ I-GENE
and O
closure O
, O
period O
of O
cardiopulmonary O
bypass O
) O
67 O
to O
100 O
% O
of O
the O
patients O
in O
group O
1 I-GENE
had O
vancomycin O
concentrations O
in O
the O
studied O
tissues O
above O
the O
_RARE_ I-GENE
90 O
for O
Staphylococcus I-GENE
aureus I-GENE
( O
1 I-GENE
microgram O
/ I-GENE
g O
) O
and O
Staphylococcus I-GENE
_RARE_ I-GENE
( O
2 I-GENE
micrograms O
/ I-GENE
g O
). O

On O
- I-GENE
line O
_RARE_ I-GENE
images O
of O
tissue I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
in O
the O
_RARE_ I-GENE
, O
recent O
or O
structured O
_RARE_ I-GENE
, O
artery O
wall O
_RARE_ I-GENE
, O
plaque O
_RARE_ I-GENE
, O
deep O
_RARE_ I-GENE
and O
sub O
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
demonstrate O
, O
in O
live O
colour I-GENE
, O
the O
_RARE_ I-GENE
mechanisms O
of O
coronary O
artery O
stenosis O
. O

The O
enhanced O
cysteine I-GENE
formation O
in O
a O
_RARE_ I-GENE
plant O
responding O
to O
_RARE_ I-GENE
was O
also O
observed O
in O
leaf O
_RARE_ I-GENE
. O

Each O
type I-GENE
was O
divided O
into O
two O
subgroups O
on O
the O
basis O
of O
whether O
the O
body O
and O
tail O
of O
the O
pancreas O
showed O
intense O
fatty I-GENE
replacement O
( O
type I-GENE
a O
= O
negative O
for O
intense O
fatty I-GENE
replacement O
, O
type I-GENE
b I-GENE
= O
positive O
for O
intense O
fatty I-GENE
replacement O
). O

_RARE_ I-GENE
the O
subgroups O
of O
dementia O
disorders O
there O
were O
no O
significant O
differences O
in O
basal O
cortisol O
levels O
. O

A I-GENE
new O
hypothesis O
on O
mechanisms O
for O
inhibiting O
catalytic O
subunits I-GENE
by O
gamma I-GENE
- I-GENE
subunits I-GENE
and O
activation O
of O
a O
holoenzyme I-GENE
by O
_RARE_ I-GENE

Basal O
components O
of O
the O
transcription I-GENE
apparatus O
( O
RNA I-GENE
polymerase I-GENE
II I-GENE
, O
TATA I-GENE
- I-GENE
binding I-GENE
protein I-GENE
) O
contain O
activation O
domains I-GENE
: O
is O
the O
repetitive O
C I-GENE
- I-GENE
terminal I-GENE
domain I-GENE
( O
CTD I-GENE
) O
of O
RNA I-GENE
polymerase I-GENE
II I-GENE
a O
" O
_RARE_ I-GENE
enhancer I-GENE
domain I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
rich O
in O
serine I-GENE
, O
threonine I-GENE
, O
and O
proline O
residues O
can O
be O
found O
in O
transcriptional O
activation O
domains I-GENE
, O
as O
well O
as O
in O
the O
N I-GENE
- I-GENE
terminal I-GENE
parts O
of O
mammalian I-GENE
TATA I-GENE
- I-GENE
binding I-GENE
proteins I-GENE
, O
where O
they O
are O
interrupted O
by O
_RARE_ I-GENE
stretches O
. O

_RARE_ I-GENE
of O
_RARE_ I-GENE
enhances O
the O
ability O
of O
c I-GENE
- I-GENE
Fos I-GENE
to O
activate O
an O
AP1 I-GENE
bearing O
promoter I-GENE
. O

Binding O
of O
_RARE_ I-GENE
to O
the O
stage O
_RARE_ I-GENE
element I-GENE
( O
_RARE_ I-GENE
) O
in O
the O
proximal I-GENE
gamma I-GENE
- I-GENE
globin I-GENE
promoter I-GENE
is O
integral I-GENE
to O
the O
competitive O
silencing O
of O
a O
linked O
beta I-GENE
- I-GENE
promoter I-GENE
in O
embryonic O
/ I-GENE
fetal O
stage O
_RARE_ I-GENE
( O
K562 O
) O
cells O
. O

This O
failure O
to O
_RARE_ I-GENE
regulated O
G1 I-GENE
/ I-GENE
S I-GENE
arrest O
is O
correlated O
with O
enhanced O
_RARE_ I-GENE
of O
colony I-GENE
- I-GENE
forming O
ability O
. O

Mutations O
that O
alter O
_RARE_ I-GENE
cell O
structure O
and O
development O
were O
isolated O
that O
fail O
to O
complement I-GENE
these O
deletions O
. O

It O
is O
possible O
that O
the O
_RARE_ I-GENE
of O
the O
two O
nuclei O
have O
different O
functions O
. O

The O
marker O
_RARE_ I-GENE
from O
the O
genetic O
and O
RH O
maps O
were O
consistent O
. O

_RARE_ I-GENE
mapping O
analysis O
of O
the O
_RARE_ I-GENE
syndrome O
region O
of O
chromosome O
8 O
. O

The O
region O
between O
_RARE_ I-GENE
and O
Factor I-GENE
VIII I-GENE
gene I-GENE
in O
the O
human I-GENE
_RARE_ I-GENE
chromosomal I-GENE
band O
contains O
a O
G I-GENE
+ I-GENE
C I-GENE
- I-GENE
rich O
_RARE_ I-GENE
to O
which O
many O
genes I-GENE
have O
been O
mapped O
. O

_RARE_ I-GENE
mapping O
and O
sequence I-GENE
analysis O
of O
the O
mouse I-GENE
_RARE_ I-GENE
gene I-GENE
predict O
susceptibility I-GENE
to O
infection O
with O
intracellular O
parasites O
. O

This O
utilization O
of O
an O
intronic I-GENE
polyadenylation O
site I-GENE
without O
alternative O
exon O
usage O
is O
comparable O
to O
the O
mechanism O
_RARE_ I-GENE
both O
secreted O
and O
membrane I-GENE
- I-GENE
bound O
forms O
of O
the O
immunoglobulin I-GENE
mu I-GENE
heavy I-GENE
chain I-GENE
are O
made O
from O
a O
single O
genetic O
locus I-GENE
. O

To O
further O
our O
knowledge O
about O
the O
systemic O
_RARE_ I-GENE
immune I-GENE
system O
response O
to O
weak O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
or O
_RARE_ I-GENE
protein I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
and O
_RARE_ I-GENE
products I-GENE
of O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
), O
a O
sensitive O
enzyme I-GENE
- I-GENE
linked O
immunosorbent O
assay O
( O
ELISA O
) O
method O
for O
testing O
for O
antibody I-GENE
( O
_RARE_ I-GENE
immunity O
) O
to O
_RARE_ I-GENE
was O
developed O
. O

In O
contrast O
, O
peak O
filling O
rate O
( O
_RARE_ I-GENE
), O
normalized O
to O
end O
diastolic O
volume O
( O
_RARE_ I-GENE
), O
or O
stroke O
volume O
( O
SV O
), O
or O
expressed O
as O
the O
ratio O
of O
_RARE_ I-GENE
- I-GENE
to O
- I-GENE
_RARE_ I-GENE
was O
reduced O
( O
p O
< O
0 O
. O
01 O
), O
time O
to O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
was O
prolonged O
( O
p O
< O
0 O
. O
01 O
), O
and O
echocardiographic O
left O
ventricular O
mass O
index O
was O
higher O
( O
p O
< O
0 O
. O
001 O
) O
in O
patients O
with O
_RARE_ I-GENE
compared O
to O
normals O
. O

A I-GENE
genetic O
complementation O
system O
was O
developed O
in O
which O
tobacco I-GENE
_RARE_ I-GENE
virus I-GENE
( O
_RARE_ I-GENE
) O
polymerase I-GENE
( O
_RARE_ I-GENE
)- I-GENE
expressing O
transgenic O
plants O
or O
_RARE_ I-GENE
were O
inoculated O
with O
_RARE_ I-GENE
- I-GENE
defective O
_RARE_ I-GENE
mutants I-GENE
. O

Nucleotide O
sequence I-GENE
and O
transcriptional O
analysis O
of O
the O
DNA I-GENE
polymerase I-GENE
gene I-GENE
of O
_RARE_ I-GENE
_RARE_ I-GENE
nuclear I-GENE
_RARE_ I-GENE
virus I-GENE
. O

Comparison O
of O
the O
genomes O
of O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
shows O
that O
_RARE_ I-GENE
exhibit O
considerable O
heterogeneity O
in O
genome O
organization O
. O

The O
drug O
sensitivity O
was O
100 O
% O
for O
vancomycin O
( O
_RARE_ I-GENE
), O
30 O
% O
for O
_RARE_ I-GENE
( O
_RARE_ I-GENE
), O
31 O
% O
for O
_RARE_ I-GENE
( O
_RARE_ I-GENE
), O
31 O
% O
for O
_RARE_ I-GENE
( O
_RARE_ I-GENE
), O
and O
7 O
% O
for O
_RARE_ I-GENE
( O
_RARE_ I-GENE
). O

_RARE_ I-GENE
with O
_RARE_ I-GENE
H I-GENE
showed O
that O
the O
mutant I-GENE
receptors I-GENE
had O
mainly O
high O
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
chains I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
with O
fish O
oil O
and O
related I-GENE
n O
- I-GENE
3 I-GENE
_RARE_ I-GENE
has O
been O
used O
to O
study O
their O
antihypertensive O
_RARE_ I-GENE
in O
animals O
and O
humans O
with O
_RARE_ I-GENE
and O
essential O
hypertension O
. O

The O
_RARE_ I-GENE
and O
_RARE_ I-GENE
genes I-GENE
encoding O
the O
types O
I I-GENE
and O
II I-GENE
3 I-GENE
beta I-GENE
- I-GENE
_RARE_ I-GENE
isoenzymes I-GENE
, O
respectively O
, O
have O
been O
previously O
assigned O
by O
in O
situ O
hybridization O
to O
the O
chromosome O
_RARE_ I-GENE
. O
1 I-GENE
region O
. O

Therefore O
the O
_RARE_ I-GENE
of O
total O
diabetes O
and O
_RARE_ I-GENE
were O
1 I-GENE
. O
19 O
% O
and O
0 O
. O
56 O
%, O
respectively O
. O

Insulin I-GENE
- I-GENE
stimulated O
glucose O
transport O
in O
adipocytes O
is O
mediated O
by O
the O
insulin I-GENE
receptor I-GENE
. O

After O
selection O
and O
conversion O
to O
adipocytes O
, O
the O
level O
of O
EGFR I-GENE
expression O
was O
retained O
in O
_RARE_ I-GENE
adipocytes O
( O
150 O
, O
000 O
and O
250 O
, O
000 O
/ I-GENE
cell O
, O
respectively O
), O
but O
not O
in O
the O
parental O
3T3 O
- I-GENE
L1 I-GENE
adipocytes O
(< O
_RARE_ I-GENE
/ I-GENE
cell O
). O

Intron I-GENE
- I-GENE
exon O
structure O
of O
the O
porcine I-GENE
I I-GENE
kappa I-GENE
B I-GENE
alpha I-GENE
- I-GENE
encoding O
gene I-GENE
. O

_RARE_ I-GENE
2 I-GENE
contains O
1 I-GENE
, O
25 O
( O
OH O
) O
2 I-GENE
- I-GENE
vitamin O
D3 I-GENE
, O
vitamin O
D3 I-GENE
, O
25 O
( O
OH O
)- I-GENE
vitamin O
D3 I-GENE
and O
1 I-GENE
, O
24 O
, O
25 O
( O
OH O
) O
3 I-GENE
- I-GENE
vitamin O
D3 I-GENE
. O

The O
_RARE_ I-GENE
gene I-GENE
was O
localized O
by O
in O
situ O
hybridization O
to O
human I-GENE
chromosome O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
. O
1 I-GENE
, O
close O
to O
the O
_RARE_ I-GENE
genes I-GENE
encoding O
alpha I-GENE
1 I-GENE
- I-GENE
_RARE_ I-GENE
, O
protein I-GENE
C I-GENE
inhibitor I-GENE
, O
alpha I-GENE
1 I-GENE
- I-GENE
antitrypsin I-GENE
, O
and O
corticosteroid I-GENE
- I-GENE
binding I-GENE
globulin I-GENE
. O

The O
locus I-GENE
encoding O
the O
_RARE_ I-GENE
gene I-GENE
( O
designated O
_RARE_ I-GENE
) O
was O
mapped O
to O
the O
distal O
part O
of O
mouse I-GENE
chromosome O
17 O
by O
_RARE_ I-GENE
analysis O
of O
114 I-GENE
_RARE_ I-GENE
backcross O
mice O
. O

Some O
studies O
of O
exercise O
have O
associated I-GENE
beta I-GENE
- I-GENE
endorphin I-GENE
release O
with O
increased O
_RARE_ I-GENE
levels O
, O
but O
other O
evidence O
suggests O
that O
acidosis O
may O
stimulate O
the O
release O
of O
beta I-GENE
- I-GENE
endorphin I-GENE
. O

An O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
the O
impairment O
of O
LV O
function O
after O
an O
acute O
and O
sustained O
drop O
of O
_RARE_ I-GENE
pressure O
. O

_RARE_ I-GENE
or O
foreign O
cellular O
proteins I-GENE
provide O
peptides I-GENE
for O
presentation O
by O
major I-GENE
histocompatibility I-GENE
complex I-GENE
( O
MHC I-GENE
) O
class I-GENE
I I-GENE
molecules I-GENE
on O
the O
surface O
of O
antigen I-GENE
presenting O
cells O
( O
APC I-GENE
). O

The O
characteristics O
of O
the O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
- I-GENE
mediated O
cleavage O
reaction O
strongly O
_RARE_ I-GENE
those O
observed O
with O
_RARE_ I-GENE
of O
_RARE_ I-GENE
plasmids O
involved O
in O
initiation I-GENE
of O
transfer I-GENE
DNA I-GENE
replication O
during O
bacterial I-GENE
conjugation O
. O

_RARE_ I-GENE
focusing O
of O
_RARE_ I-GENE
peptides I-GENE
generated O
from O
MHC I-GENE
- I-GENE
B I-GENE
phosphorylated O
with O
cdc2 I-GENE
kinase I-GENE
revealed O
one O
major I-GENE
phosphopeptide I-GENE
that O
was O
purified O
by O
reverse I-GENE
- I-GENE
phase O
high O
performance O
liquid O
chromatography O
and O
sequenced O
. O

The O
deduced O
protein I-GENE
sequence I-GENE
was O
88 O
% O
homologous O
to O
that O
of O
_RARE_ I-GENE
I I-GENE
, O
isolated O
from O
human I-GENE
osteosarcoma O
cells O
. O

However O
, O
cotransfection O
studies O
indicate O
that O
_RARE_ I-GENE
does O
not O
activate O
transcription I-GENE
when O
this O
hormone I-GENE
response O
element I-GENE
is O
linked O
to O
a O
reporter I-GENE
gene I-GENE
but O
rather O
acts O
as O
a O
potent O
competitive O
repressor I-GENE
of O
_RARE_ I-GENE
alpha I-GENE
function O
. O

A I-GENE
comparison O
of O
the O
_RARE_ I-GENE
_RARE_ I-GENE
with O
a O
mammalian I-GENE
_RARE_ I-GENE
revealed O
30 O
% O
structural O
identity O
and O
60 O
% O
overall O
similarity O
between O
the O
prokaryotic I-GENE
and O
eukaryotic I-GENE
forms O
of O
the O
enzyme I-GENE
. O

_RARE_ I-GENE
and O
_RARE_ I-GENE
of O
the O
_RARE_ I-GENE
_RARE_ I-GENE
-- O
an O
_RARE_ I-GENE
. O

_RARE_ I-GENE
dismutase I-GENE
( O
SOD I-GENE
) O
activity O
decreased O
significantly O
in O
sperm O
subjected O
to O
direct O
_RARE_ I-GENE
current O
in O
comparison O
to O
the O
control O
or O
the O
sample O
incubated O
with O
_RARE_ I-GENE
medium O
. O

These O
studies O
indicate O
that O
in O
vitro O
and O
in O
vivo O
electrical O
stimulation O
generate O
reactive I-GENE
oxygen O
species O
and O
affect O
SOD I-GENE
activity O
, O
which O
in O
part O
are O
responsible O
for O
decreased O
sperm O
motion O
and O
viability O
. O

Molecular O
cloning O
and O
sequencing O
of O
a O
cDNA I-GENE
encoding O
SR I-GENE
beta I-GENE
revealed O
that O
SR I-GENE
beta I-GENE
is O
a O
transmembrane I-GENE
protein I-GENE
and O
, O
like I-GENE
SR I-GENE
alpha I-GENE
and O
_RARE_ I-GENE
, O
is O
a O
member O
of O
the O
GTPase I-GENE
superfamily I-GENE
. O

To O
understand O
the O
function O
of O
receptor I-GENE
- I-GENE
linked O
tyrosine I-GENE
phosphatases I-GENE
in O
neural O
development O
, O
we O
sought O
to O
identify O
_RARE_ I-GENE
isoforms I-GENE
preferentially O
expressed O
in O
the O
nervous O
system O
and O
cellular O
processes O
regulating O
_RARE_ I-GENE
alternative O
splicing O
. O

_RARE_ I-GENE
selection O
via O
albumin I-GENE
_RARE_ I-GENE
: O
20 O
years O
of O
results O
. O

135 O
students O
had O
a O
count O
of O
less O
than O
50 O
eggs O
/ I-GENE
10 O
ml O
. O
urine O
and O
56 O
had O
more O
than O
50 O
eggs O
/ I-GENE
_RARE_ I-GENE
. O

They O
also O
reported O
that O
E I-GENE
mu I-GENE
_RARE_ I-GENE
- I-GENE
1 I-GENE
transgenic O
mice O
show O
greatly O
accelerated O
lymphoma O
development O
when O
infected O
with O
wild I-GENE
- I-GENE
type I-GENE
M I-GENE
- I-GENE
MuLV O
at O
birth O
. O

Comparison O
of O
human I-GENE
and O
murine I-GENE
_RARE_ I-GENE
sequences I-GENE
indicated O
that O
they O
share O
86 I-GENE
% O
amino O
acid I-GENE
identity O
, O
the O
most O
conserved O
region O
being O
the O
catalytic O
domain I-GENE
( O
93 O
% O
identity O
). O

_RARE_ I-GENE
[ O
1993 O
] O
_RARE_ I-GENE
J O
12 O
: O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
). O

The O
mRNAs I-GENE
of O
the O
_RARE_ I-GENE
genes I-GENE
are O
encoded I-GENE
by O
six O
exons O
interrupted O
by O
five O
introns O
. O

The O
effect O
of O
ethanol O
on O
human I-GENE
_RARE_ I-GENE
reactivity O
was O
assessed O
by O
examining O
the O
acoustic O
_RARE_ I-GENE
response O
. O

_RARE_ I-GENE
_RARE_ I-GENE
or O
beta I-GENE
- I-GENE
receptor I-GENE
antagonists O
are O
not O
helpful O
in O
the O
therapy O
of O
this O
form O
of O
atrial I-GENE
fibrillation O
whereas O
class I-GENE
I I-GENE
antiarrhythmic O
drugs O
have O
been O
shown O
to O
be O
more O
effective O
. O

_RARE_ I-GENE
fibrillation O
and O
the O
_RARE_ I-GENE
nervous O
system O

VIII I-GENE
in O
doses O
2 I-GENE
- I-GENE
3 I-GENE
times O
higher O
than O
usually O
used O
in O
_RARE_ I-GENE
without O
inhibitor I-GENE
were O
successful O
. O

A I-GENE
reduction O
of O
the O
aspartate I-GENE
aminotransferase I-GENE
activity O
was O
observed O
from O
800 O
mg O
/ I-GENE
kg O
b I-GENE
. O
w O
_RARE_ I-GENE
d O
_RARE_ I-GENE
. O

Thus O
, O
these O
studies O
indicate O
that O
the O
104 O
- I-GENE
kDa I-GENE
isoform I-GENE
is O
required O
for O
normal O
proliferation O
of O
female O
germline I-GENE
cells O
and O
perhaps O
for O
oocyte O
differentiation O
. O

_RARE_ I-GENE
analysis O
maps O
_RARE_ I-GENE
to O
chromosome O
_RARE_ I-GENE
between O
_RARE_ I-GENE
and O
_RARE_ I-GENE
. O

The O
newly O
_RARE_ I-GENE
_RARE_ I-GENE
method O
yields O
reliable O
data O
in O
measuring O
_RARE_ I-GENE
. O

Removal O
of O
_RARE_ I-GENE
from O
the O
cell O
medium O
resulted O
in O
reversal O
of O
the O
cell O
cycle O
changes O
, O
with O
cells O
re O
- I-GENE
_RARE_ I-GENE
the O
S I-GENE
phase O
. O

Rho I-GENE
GDP I-GENE
/ I-GENE
GTP I-GENE
exchange I-GENE
inhibitor I-GENE
, O
Rho I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
with O
_RARE_ I-GENE
and O
RhoA I-GENE
, O
but O
not O
Rac1 I-GENE
. O

A I-GENE
major I-GENE
task O
for O
_RARE_ I-GENE
_RARE_ I-GENE
may O
be O
to O
_RARE_ I-GENE
_RARE_ I-GENE
the O
nature O
of O
an O
integrated O
model O
of O
the O
_RARE_ I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
, O
J O
. O

_RARE_ I-GENE
of O
_RARE_ I-GENE
_RARE_ I-GENE
encoding O
the O
complete O
human I-GENE
immunodeficiency I-GENE
virus I-GENE
type I-GENE
1 I-GENE
gag I-GENE
gene I-GENE
by O
using O
a O
complementation O
system O
which O
provides O
the O
P1 I-GENE
capsid I-GENE
protein I-GENE
in O
trans O
. O

Removal O
of O
the O
GST I-GENE
domain I-GENE
from O
GST I-GENE
- I-GENE
Tax I-GENE
by O
thrombin I-GENE
restores O
Tax I-GENE
' O
s O
ability O
to O
_RARE_ I-GENE
a O
ternary O
Tax I-GENE
- I-GENE
CREB I-GENE
- I-GENE
21 O
- I-GENE
bp O
- I-GENE
repeat I-GENE
complex I-GENE
.( O
ABSTRACT O
TRUNCATED O
AT I-GENE
400 O
WORDS O
) O

The O
requirement O
of O
_RARE_ I-GENE
in O
_RARE_ I-GENE
biogenesis O
was O
confirmed O
by O
demonstrating O
that O
chromosomal I-GENE
_RARE_ I-GENE
insertion O
mutants I-GENE
were O
_RARE_ I-GENE
- I-GENE
and O
_RARE_ I-GENE
- I-GENE
motility O
deficient O
. O

The O
_RARE_ I-GENE
gene I-GENE
product I-GENE
of O
Pseudomonas I-GENE
aeruginosa I-GENE
, O
required O
for O
_RARE_ I-GENE
biogenesis O
, O
shares O
amino O
acid I-GENE
sequence I-GENE
identity O
with O
the O
N I-GENE
- I-GENE
termini O
of O
type I-GENE
4 I-GENE
_RARE_ I-GENE
proteins I-GENE
. O

Because O
of O
the O
functional O
conservation O
of O
cell O
cycle O
control O
elements O
, O
the O
expression O
of O
a O
vertebrate I-GENE
_RARE_ I-GENE
or O
_RARE_ I-GENE
homolog I-GENE
would O
be O
expected O
to O
rescue O
such O
lethal O
mutations O
in O
yeast I-GENE
. O

The O
expression O
of O
this O
clone O
in O
a O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
- I-GENE
deficient O
mutant I-GENE
causes O
an O
_RARE_ I-GENE
cell O
phenotype O
under O
non O
- I-GENE
permissive O
growth I-GENE
conditions O
. O

These O
data O
indicate O
that O
phosphorylation O
of O
M I-GENE
protein I-GENE
at O
the O
major I-GENE
in O
vivo O
sites I-GENE
is O
not O
essential O
for O
virus I-GENE
assembly O
. O

_RARE_ I-GENE
a O
third O
( O
31 O
. O
6 I-GENE
%) O
of O
Insulin I-GENE
_RARE_ I-GENE
and O
a O
third O
( O
33 O
. O
41 O
%) O
for O
Non O
Insulin I-GENE
_RARE_ I-GENE
were O
of O
D I-GENE
, O
F I-GENE
, O
H I-GENE
_RARE_ I-GENE
' O
s O
Class I-GENE
. O

The O
activity O
of O
6 I-GENE
- I-GENE
_RARE_ I-GENE
and O
their O
_RARE_ I-GENE
derivatives O
is O
compared O
in O
general O
. O

As O
the O
half O
- I-GENE
life O
of O
the O
compound O
did O
never O
_RARE_ I-GENE
8 O
- I-GENE
9 O
h O
, O
the O
data O
do O
not O
support O
any O
change O
of O
_RARE_ I-GENE
administration O
schedule O
( O
every O
24 O
- I-GENE
12 O
h O
). O

The O
MAP I-GENE
kinase I-GENE
cascade O
is O
highly O
conserved O
in O
all O
eukaryotes O
and O
involved O
in O
numerous O
cellular O
responses O
. O

A I-GENE
comparative O
study O
by O
_RARE_ I-GENE
_RARE_ I-GENE
of O
ten O
porcine I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
( O
seven O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
, O
two O
_RARE_ I-GENE
and O
one O
_RARE_ I-GENE
) O
with O
five O
human I-GENE
aortic O
_RARE_ I-GENE
before O
and O
after O
_RARE_ I-GENE
treatment O
is O
presented O
. O

No O
serious O
side O
effects O
were O
observed O
. O

This O
region O
constitutes O
the O
DNA I-GENE
- I-GENE
binding I-GENE
domain I-GENE
with O
basic I-GENE
- I-GENE
helix I-GENE
- I-GENE
loop I-GENE
- I-GENE
helix I-GENE
and O
leucine I-GENE
- I-GENE
zipper I-GENE
motifs O
, O
features O
common O
to O
the O
myc I-GENE
- I-GENE
related I-GENE
transcription I-GENE
factor I-GENE
family I-GENE
. O

Specific O
binding I-GENE
was O
not O
observed O
with O
either O
the O
_RARE_ I-GENE
rat I-GENE
or O
mouse I-GENE
fragments I-GENE
using O
human I-GENE
or O
rodent O
extracts O
. O

The O
mean O
_RARE_ I-GENE
and O
the O
fiber O
density I-GENE
did O
not O
change O
significantly O
from O
day O
0 O
( O
30 O
. O
1 I-GENE
+/- O
3 I-GENE
. O
6 I-GENE
_RARE_ I-GENE
; O
1 I-GENE
. O
4 I-GENE
+/- O
0 O
. O
07 O
) O
to O
day O
30 O
( O
34 O
. O
5 I-GENE
+/- O
2 I-GENE
. O
7 O
_RARE_ I-GENE
; O
1 I-GENE
. O
6 I-GENE
+/- O
0 O
. O
13 O
). O

_RARE_ I-GENE
of O
cyclin I-GENE
D I-GENE
- I-GENE
Cdk I-GENE
complexes I-GENE
in O
Rb I-GENE
- I-GENE
negative O
cells O
correlates O
with O
high O
levels O
of O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
tumour I-GENE
suppressor I-GENE
gene I-GENE
product I-GENE
. O

Recombinant I-GENE
human I-GENE
serum I-GENE
albumin I-GENE
( O
_RARE_ I-GENE
) O
produced O
by O
cultured O
_RARE_ I-GENE
has O
been O
prepared O
in O
the O
form O
of O
_RARE_ I-GENE
_RARE_ I-GENE
3 I-GENE
- I-GENE
5 I-GENE
microns O
in O
diameter O
and O
_RARE_ I-GENE
with O
technetium O
- I-GENE
99m O
following O
reduction O
with O
_RARE_ I-GENE
chloride O
. O

We O
have O
measured O
the O
release O
of O
interleukin I-GENE
- I-GENE
1 I-GENE
beta I-GENE
( O
IL I-GENE
- I-GENE
1 I-GENE
) O
and O
tumour I-GENE
necrosis I-GENE
factor I-GENE
- I-GENE
alpha I-GENE
( O
TNF I-GENE
) O
by O
unstimulated O
monocytes O
and O
monocytes O
stimulated O
with O
lipopolysaccharide O
( O
LPS I-GENE
) O
isolated O
from O
the O
peripheral O
blood O
of O
two O
patients O
with O
acute O
_RARE_ I-GENE
glomerulonephritis O
( O
_RARE_ I-GENE
) O
and O
16 O
healthy O
controls O
. O

Such O
an O
intervention O
may O
be O
of O
considerable O
use O
for O
the O
treatment O
of O
angiogenesis O
- I-GENE
dependent I-GENE
diseases O
involving O
FGF I-GENE
- I-GENE
2 I-GENE
. O

We O
have O
_RARE_ I-GENE
to O
clone O
two O
recessive O
_RARE_ I-GENE
suppressors O
of O
such O
ts I-GENE
mutants I-GENE
( O
_RARE_ I-GENE
for O
mutation I-GENE
_RARE_ I-GENE
- I-GENE
14 O
and O
_RARE_ I-GENE
- I-GENE
1 I-GENE
for O
mutation I-GENE
_RARE_ I-GENE
- I-GENE
11 O
) O
by O
transforming I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
strains O
_RARE_ I-GENE
- I-GENE
14 O
_RARE_ I-GENE
and O
_RARE_ I-GENE
- I-GENE
11 O
_RARE_ I-GENE
- I-GENE
1 I-GENE
with O
wild I-GENE
- I-GENE
type I-GENE
genomic O
libraries O
in O
_RARE_ I-GENE
or O
multicopy O
vectors O
. O

UV O
cross O
- I-GENE
linking O
experiments O
show O
that O
_RARE_ I-GENE
has O
an O
apparent O
molecular O
mass O
of O
approximately O
65 O
kDa I-GENE
. O

In O
acute O
- I-GENE
phase O
_RARE_ I-GENE
, O
we O
observed O
a O
dramatic O
reduction O
in O
HNF I-GENE
- I-GENE
3 I-GENE
alpha I-GENE
expression O
which O
correlates O
with O
a O
decrease O
in O
the O
expression O
of O
its O
target O
gene I-GENE
, O
the O
_RARE_ I-GENE
gene I-GENE
. O

_RARE_ I-GENE
, O
loss O
- I-GENE
of O
- I-GENE
function O
alleles I-GENE
of O
genes I-GENE
that O
inhibit O
_RARE_ I-GENE
lead O
to O
the O
_RARE_ I-GENE
to O
undergo O
sexual O
differentiation O
. O

One O
member O
of O
this O
family I-GENE
, O
_RARE_ I-GENE
, O
is O
a O
transcription I-GENE
factor I-GENE
for O
a O
variety O
of O
viral I-GENE
and O
cellular O
genes I-GENE
. O

This O
mutant I-GENE
was O
identified O
by O
screening O
with O
a O
TGF I-GENE
- I-GENE
beta I-GENE
- I-GENE
inducible I-GENE
vector O
a O
series O
of O
_RARE_ I-GENE
lung O
epithelial O
cell O
clones O
that O
have O
normal O
TGF I-GENE
- I-GENE
beta I-GENE
binding I-GENE
activity O
but O
have O
lost O
_RARE_ I-GENE
and O
transcriptional O
responses O
to O
TGF I-GENE
- I-GENE
beta I-GENE
. O

Cloning O
by O
complementation O
and O
subsequent O
physical O
and O
genetic O
analysis O
revealed O
that O
it O
maps O
to O
_RARE_ I-GENE
. O

In O
the O
presence O
of O
inositol I-GENE
and O
_RARE_ I-GENE
( O
repressing O
), O
the O
product I-GENE
of O
the O
_RARE_ I-GENE
gene I-GENE
represses O
transcription I-GENE
_RARE_ I-GENE
by O
the O
_RARE_ I-GENE
element I-GENE
. O

By O
_RARE_ I-GENE
monkey I-GENE
COS O
cells O
with O
oligonucleotides O
linked O
to O
_RARE_ I-GENE
, O
we O
have O
generated O
targeted O
mutations O
in O
a O
simian I-GENE
virus I-GENE
40 I-GENE
( O
SV40 I-GENE
) O
vector O
contained O
within O
the O
cells O
via O
intracellular O
triple O
helix I-GENE
formation O
. O

The O
interleukin I-GENE
2 I-GENE
receptor I-GENE
alpha I-GENE
- I-GENE
chain I-GENE
( O
IL I-GENE
- I-GENE
2R I-GENE
alpha I-GENE
) O
gene I-GENE
is O
rapidly O
and O
_RARE_ I-GENE
induced O
in O
T I-GENE
cells O
in O
response O
to O
mitogenic O
stimuli O
. O

The O
_RARE_ I-GENE
' O
tumour I-GENE
suppressor I-GENE
protein I-GENE
( O
WT1 I-GENE
) O
is O
a O
putative O
transcriptional O
regulatory I-GENE
protein I-GENE
with O
four O
zinc I-GENE
fingers O
, O
the O
last O
three O
of O
which O
have O
extensive O
sequence I-GENE
homology I-GENE
to O
the O
early I-GENE
growth I-GENE
response O
- I-GENE
1 I-GENE
( O
_RARE_ I-GENE
- I-GENE
1 I-GENE
) O
protein I-GENE
. O

OBJECTIVES O
: O
1 I-GENE
) O
to O
determine O
serum I-GENE
ACE I-GENE
activity O
in O
patients O
with O
COPD O
treated O
with O
and O
without O
continuous O
ambulatory O
oxygen O
therapy O
( O
_RARE_ I-GENE
); O
2 I-GENE
) O
to O
_RARE_ I-GENE
whether O
there O
is O
a O
correlation O
between O
ACE I-GENE
and O
any O
_RARE_ I-GENE
, O
_RARE_ I-GENE
or O
_RARE_ I-GENE
parameter O
. O

In O
order O
to O
_RARE_ I-GENE
shape O
from O
_RARE_ I-GENE
, O
the O
human I-GENE
visual O
system O
must O
selectively O
_RARE_ I-GENE
fragments I-GENE
_RARE_ I-GENE
from O
a O
common O
_RARE_ I-GENE
while O
_RARE_ I-GENE
fragments I-GENE
from O
different O
objects O
separate O
. O

Among O
9 O
group O
I I-GENE
patients O
with O
a O
positive O
result O
on O
head I-GENE
- I-GENE
up O
tilt O
- I-GENE
_RARE_ I-GENE
testing O
and O
no O
evidence O
of O
structural O
heart O
disease O
( O
mean O
follow O
- I-GENE
up O
4 I-GENE
. O
3 I-GENE
years O
), O
7 O
are O
without O
further O
episodes O
of O
_RARE_ I-GENE
; O
3 I-GENE
have O
_RARE_ I-GENE
medication O
and O
5 I-GENE
have O
_RARE_ I-GENE
at O
least O
limited O
exercise O
. O

_RARE_ I-GENE
designed O
and O
expressed O
were O
_RARE_ I-GENE
( O
1 I-GENE
- I-GENE
98 O
), O
_RARE_ I-GENE
. O
H1 I-GENE
( O
1 I-GENE
- I-GENE
128 I-GENE
), O
_RARE_ I-GENE
( O
120 O
- I-GENE
233 I-GENE
), O
_RARE_ I-GENE
. O
L2 O
( O
98 O
- I-GENE
233 I-GENE
), O
and O
_RARE_ I-GENE
. O
H1 I-GENE
. O
L2 O
( O
1 I-GENE
- I-GENE
233 I-GENE
), O
where O
numbers O
in O
_RARE_ I-GENE
give O
the O
amino O
acid I-GENE
sequence I-GENE
for O
the O
portions O
of O
the O
E2 I-GENE
component O
incorporated O
into O
a O
construct I-GENE
. O

Thus O
, O
we O
have O
produced O
_RARE_ I-GENE
domain I-GENE
constructs I-GENE
that O
can O
be O
employed O
in O
sorting I-GENE
the O
specific I-GENE
roles O
of O
_RARE_ I-GENE
and O
_RARE_ I-GENE
in O
facilitating O
catalytic O
and O
regulatory I-GENE
processes O
. O

METHODS O
: O
Ten O
influenza I-GENE
A I-GENE
( O
_RARE_ I-GENE
) O
viruses O
isolated O
during O
the O
_RARE_ I-GENE
were O
examined O
for O
resistance O
to O
_RARE_ I-GENE
and O
_RARE_ I-GENE
by O
means O
of O
an O
enzyme I-GENE
immunoassay O
and O
by O
sequencing O
of O
the O
viral I-GENE
nucleic O
acid I-GENE
that O
encodes O
the O
transmembrane I-GENE
domain I-GENE
of O
the O
_RARE_ I-GENE
protein I-GENE
. O

The O
first O
contains O
ATF I-GENE
/ I-GENE
CRE O
and O
TBP I-GENE
/ I-GENE
TATA I-GENE
sequence I-GENE
motifs O
within O
an O
87 O
- I-GENE
bp O
region O
. O

Gene I-GENE
expression O
occurs O
in O
a O
circadian O
rhythm O
and O
induced O
by O
light I-GENE
in O
leaves O
of O
dark O
- I-GENE
adapted O
plants O
. O

Our O
results O
suggested O
that O
the O
hexamer O
and O
the O
octamer O
motifs O
may O
play O
important O
role O
( O
s O
) O
in O
regulation O
of O
replication O
- I-GENE
dependent I-GENE
but O
not O
of O
replication O
- I-GENE
independent O
expression O
of O
the O
wheat I-GENE
histone I-GENE
H3 I-GENE
gene I-GENE
. O

The O
tissue I-GENE
- I-GENE
specific I-GENE
expression O
of O
DP I-GENE
family I-GENE
members O
suggests O
that O
the O
combination O
of O
DP I-GENE
/ I-GENE
E2F I-GENE
heterodimers I-GENE
that O
constitute O
_RARE_ I-GENE
/ I-GENE
E2F I-GENE
is O
influenced O
by O
the O
phenotype O
of O
the O
cell O
. O

Similarly O
, O
in O
mammalian I-GENE
cells O
_RARE_ I-GENE
is O
synthesized O
as O
a O
pre I-GENE
- I-GENE
protein I-GENE
that O
requires O
membrane I-GENE
potential O
- I-GENE
dependent I-GENE
import O
into O
mitochondria O
for O
its O
maturation O
. O

In O
a O
second O
experiment O
involving O
an O
18 O
- I-GENE
h O
lung O
clearance O
assay O
, O
we O
used O
the O
mAb I-GENE
3 I-GENE
. O
2 I-GENE
. O
3 I-GENE
to O
_RARE_ I-GENE
rats O
of O
_RARE_ I-GENE
/ I-GENE
NK I-GENE
cells O
with O
the O
following O
_RARE_ I-GENE
: O
if O
_RARE_ I-GENE
/ I-GENE
NK I-GENE
cells O
are O
necessary O
to O
mediate O
an O
event O
, O
then O
in O
their O
absence O
, O
that O
event O
should O
not O
occur O
. O

Treatment O
of O
recurrent O
_RARE_ I-GENE
has O
included O
high O
- I-GENE
dose O
steroids O
, O
high O
- I-GENE
dose O
cyclosporine O
( O
_RARE_ I-GENE
), O
_RARE_ I-GENE
, O
and O
ACE I-GENE
inhibitors O
with O
mixed O
results O
. O

Our O
results O
concluded O
that O
1 I-GENE
) O
the O
two O
_RARE_ I-GENE
/ I-GENE
activin I-GENE
beta I-GENE
B I-GENE
- I-GENE
subunit I-GENE
mRNAs I-GENE
were O
transcribed O
from O
different O
initiation I-GENE
sites I-GENE
; O
2 I-GENE
) O
both O
promoters I-GENE
may O
be O
controlled O
by O
up O
- I-GENE
_RARE_ I-GENE
negative O
regulatory I-GENE
elements O
; O
and O
3 I-GENE
) O
neither O
of O
these O
promoters I-GENE
is O
responsive I-GENE
to O
cAMP I-GENE
and O
/ I-GENE
or O
phorbol O
esters O
under O
the O
conditions O
employed O
. O

Promoter O
region O
of O
the O
transcriptional O
unit I-GENE
for O
human I-GENE
alpha I-GENE
1 I-GENE
- I-GENE
_RARE_ I-GENE
, O
a O
neuron I-GENE
- I-GENE
specific I-GENE
GTPase I-GENE
- I-GENE
activating I-GENE
protein I-GENE
for O
_RARE_ I-GENE
. O
alpha I-GENE
1 I-GENE
- I-GENE
_RARE_ I-GENE
is O
a O
neuron I-GENE
- I-GENE
specific I-GENE
GTPase I-GENE
- I-GENE
activating I-GENE
protein I-GENE
for O
_RARE_ I-GENE
, O
a O
protein I-GENE
involved O
in O
morphological O
events O
. O

Upstream O
from O
the O
transcription I-GENE
start O
point O
( O
_RARE_ I-GENE
), O
a O
nucleotide I-GENE
sequence I-GENE
highly O
homologous O
to O
the O
consensus I-GENE
sequence I-GENE
motif I-GENE
for O
the O
sigma I-GENE
35 O
- I-GENE
recognized O
promoters I-GENE
was O
found O
. O

In O
this O
paper O
, O
an O
analysis O
of O
the O
dynamics O
in O
the O
_RARE_ I-GENE
phase O
of O
the O
_RARE_ I-GENE
of O
a O
mechanical O
_RARE_ I-GENE
heart O
valve O
_RARE_ I-GENE
is O
presented O
. O

During O
_RARE_ I-GENE
+ I-GENE
AT I-GENE
infusion O
, O
abdominal O
fat O
blood O
flow O
was O
still O
significantly O
increased O
as O
compared O
with O
control O
values O
in O
lean O
and O
obese O
subjects O
. O

When O
expressed O
per O
_RARE_ I-GENE
body O
weight O
, O
mean O
_RARE_ I-GENE
increased O
in O
the O
_RARE_ I-GENE
group O
from O
0 O
. O
14 O
% O
to O
0 O
. O
16 O
% O
above O
_RARE_ I-GENE
, O
with O
a O
significant O
decrease O
from O
0 O
. O
15 O
% O
to O
0 O
. O
13 O
% O
in O
the O
P I-GENE
group O
. O

In O
nucleus O
_RARE_ I-GENE
anterior O
_RARE_ I-GENE
- I-GENE
nucleus O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
neurons O
with O
an O
inhibitory I-GENE
input O
from O
nucleus O
_RARE_ I-GENE
, O
a O
shortening O
of O
inhibition O
from O
17 O
. O
5 I-GENE
+/- O
3 I-GENE
. O
6 I-GENE
to O
9 O
. O
1 I-GENE
+/- O
1 I-GENE
. O
8 O
ms O
( O
P I-GENE
< O
0 O
. O
05 O
) O
under O
the O
haloperidol O
influence O
was O
evident O
. O

However O
, O
inclusion O
of O
the O
_RARE_ I-GENE
_RARE_ I-GENE
motifs O
from O
the O
ICP4 I-GENE
promoter I-GENE
, O
which O
bind O
factors I-GENE
GABP I-GENE
alpha I-GENE
and O
beta I-GENE
, O
results O
in O
a O
strong O
synergistic O
activation O
. O

The O
first O
open O
reading O
frame O
of O
the O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
genome O
encodes O
a O
putative O
replication O
- I-GENE
associated I-GENE
protein I-GENE
of O
_RARE_ I-GENE
kDa I-GENE
( O
_RARE_ I-GENE
). O

From O
sequence I-GENE
_RARE_ I-GENE
with O
_RARE_ I-GENE
related I-GENE
viruses O
, O
including O
_RARE_ I-GENE
, O
we O
predicted O
that O
_RARE_ I-GENE
contained O
a O
_RARE_ I-GENE
- I-GENE
like I-GENE
proteinase I-GENE
domain I-GENE
with O
a O
putative O
catalytic O
_RARE_ I-GENE
and O
_RARE_ I-GENE
. O

This O
finding O
represents O
both O
a O
potentially O
important O
mechanism O
by O
which O
HPV I-GENE
gene I-GENE
expression O
can O
be O
regulated O
and O
an O
_RARE_ I-GENE
model O
for O
the O
study O
of O
transcriptional O
cooperativity O
. O

Using O
this O
method O
, O
_RARE_ I-GENE
were O
obtained O
in O
_RARE_ I-GENE
sufficient O
for O
further O
characterization O
. O

Analysis O
of O
the O
sequence I-GENE
upstream O
of O
this O
initiation I-GENE
codon O
reveals O
the O
presence O
of O
a O
_RARE_ I-GENE
sequence I-GENE
. O

_RARE_ I-GENE
is O
implicated O
in O
translation I-GENE
fidelity I-GENE
and O
encodes O
the O
ribosomal I-GENE
protein I-GENE
_RARE_ I-GENE
. O

To O
explore O
the O
functional O
relationship O
between O
c I-GENE
- I-GENE
fos I-GENE
and O
Rb I-GENE
, O
a O
eukaryotic I-GENE
expression O
plasmid O
was O
constructed O
containing O
the O
c I-GENE
- I-GENE
fos I-GENE
gene I-GENE
under O
control O
of O
the O
SV40 I-GENE
promoter I-GENE
complex I-GENE
. O

The O
high O
degree O
of O
sequence I-GENE
identity O
( O
96 O
%) O
between O
_RARE_ I-GENE
B I-GENE
and O
C I-GENE
, O
particularly O
in O
the O
3 I-GENE
' O
untranslated O
region O
, O
suggests O
that O
the O
genes I-GENE
encoding O
these O
two O
_RARE_ I-GENE
evolved O
by O
duplication O
and O
divergence O
of O
a O
common O
ancestral O
gene I-GENE
. O

The O
regions O
of O
the O
tooth O
fracture O
are O
determined O
. O

_RARE_ I-GENE
pancreatic O
involvement O
of O
_RARE_ I-GENE
_RARE_ I-GENE
detected O
by O
a O
clinically O
_RARE_ I-GENE
mass O
. O

The O
_RARE_ I-GENE
hybrid O
is O
a O
_RARE_ I-GENE
tool O
for O
the O
mapping O
of O
new O
probes O
of O
this O
region O
, O
as O
well O
as O
for O
obtaining O
new O
_RARE_ I-GENE
probes O
specific I-GENE
for O
the O
deletion O
by O
_RARE_ I-GENE
cloning O
of O
the O
region O
. O

_RARE_ I-GENE
at O
doses O
of O
200 O
to O
500 O
mg O
/ I-GENE
kg O
significantly O
suppressed O
_RARE_ I-GENE
oxidase I-GENE
( O
_RARE_ I-GENE
) O
activity O
in O
the O
stomach O
tissue I-GENE
following O
its O
oral O
administration O
. O

Like O
humans O
, O
the O
_RARE_ I-GENE
PK I-GENE
genes I-GENE
in O
chickens O
must O
be O
closely O
linked O
, O
based O
on O
fluorescent O
in O
situ O
hybridization O
( O
_RARE_ I-GENE
) O
localization O
of O
these O
genes I-GENE
to O
a O
single O
chicken I-GENE
_RARE_ I-GENE
. O

Here O
, O
we O
report O
the O
characterization O
of O
an O
alternatively O
processed O
form O
of O
_RARE_ I-GENE
- I-GENE
110 I-GENE
that O
encodes O
an O
additional O
258 O
base O
pair O
( O
bp O
) O
of O
open O
reading O
frame O
. O

Expression O
of O
class I-GENE
IV I-GENE
ADH I-GENE
mRNA I-GENE
was O
detected O
in O
human I-GENE
stomach O
but O
not O
liver O
. O

In O
ICE I-GENE
gamma I-GENE
, O
most O
of O
the O
_RARE_ I-GENE
( O
amino O
acids O
20 O
- I-GENE
112 O
) O
is O
deleted O
, O
which O
suggests O
that O
it O
may O
function O
as O
a O
_RARE_ I-GENE
for O
ICE I-GENE
_RARE_ I-GENE
in O
vivo O
. O

_RARE_ I-GENE
and O
lysosomal I-GENE
targeting O
of O
epidermal I-GENE
growth I-GENE
factor I-GENE
receptors I-GENE
are O
mediated O
by O
distinct O
sequences I-GENE
independent O
of O
the O
tyrosine I-GENE
kinase I-GENE
domain I-GENE
. O

It O
is O
now O
recognized O
that O
essentially O
all O
eukaryotic I-GENE
and O
prokaryotic I-GENE
genes I-GENE
whose O
5 I-GENE
'- O
flanking O
regions O
are O
known O
and O
that O
encode O
_RARE_ I-GENE
- I-GENE
inducible I-GENE
proteins I-GENE
contain O
the O
_RARE_ I-GENE
box I-GENE
element I-GENE
. O

Mutation O
of O
the O
_RARE_ I-GENE
- I-GENE
3 I-GENE
_RARE_ I-GENE
box I-GENE
significantly O
increased O
the O
expression O
of O
both O
_RARE_ I-GENE
- I-GENE
3 I-GENE
and O
_RARE_ I-GENE
( O
another O
small I-GENE
gene I-GENE
located O
upstream O
of O
the O
_RARE_ I-GENE
- I-GENE
3 I-GENE
gene I-GENE
that O
encodes O
a O
second O
putative O
regulatory I-GENE
protein I-GENE
) O
in O
response O
to O
_RARE_ I-GENE
induction O
but O
left O
the O
basal O
levels O
unaffected O
. O

The O
_RARE_ I-GENE
- I-GENE
depleted O
nuclei O
remained O
largely O
competent O
for O
nuclear I-GENE
protein I-GENE
import O
. O

A I-GENE
potential O
outcome O
of O
these O
biochemical O
effects O
may O
include O
the O
limited O
responsiveness O
of O
infected O
T I-GENE
cells O
to O
antigenic I-GENE
stimulation O
observed O
during O
HIV I-GENE
- I-GENE
1 I-GENE
infection O
. O

The O
full I-GENE
protocol O
was O
completed O
by O
33 O
patients O
( O
45 O
% O
of O
original O
cohort O
). O

In O
addition O
, O
we O
found O
that O
cell O
- I-GENE
specific I-GENE
suppression O
of O
RA O
- I-GENE
stimulated O
_RARE_ I-GENE
gene I-GENE
expression O
can O
be O
attributed O
to O
a O
29 O
base O
pair O
nucleotide I-GENE
sequence I-GENE
, O
located O
downstream O
of O
the O
RA O
- I-GENE
responsive I-GENE
region O
in O
the O
_RARE_ I-GENE
gene I-GENE
. O

We O
show O
that O
CBF I-GENE
- I-GENE
A I-GENE
and O
CBF I-GENE
- I-GENE
C I-GENE
interact O
with O
each O
other O
to O
form O
a O
CBF I-GENE
- I-GENE
A I-GENE
- I-GENE
CBF I-GENE
- I-GENE
C I-GENE
complex I-GENE
and O
that O
CBF I-GENE
- I-GENE
B I-GENE
does O
not O
interact O
with O
CBF I-GENE
- I-GENE
A I-GENE
or O
CBF I-GENE
- I-GENE
C I-GENE
individually O
but O
that O
it O
associates O
with O
the O
CBF I-GENE
- I-GENE
A I-GENE
- I-GENE
CBF I-GENE
- I-GENE
C I-GENE
complex I-GENE
. O

In O
the O
first O
, O
homologous O
sequences I-GENE
were O
deleted O
from O
a O
mouse I-GENE
enhancer I-GENE
, O
resulting O
in O
a O
tissue I-GENE
- I-GENE
specific I-GENE
loss O
of O
activity O
when O
assayed O
in O
transgenic O
mice O
. O

_RARE_ I-GENE
prophylaxis O
_RARE_ I-GENE
long O
- I-GENE
term O
renal O
graft O
survival O
in O
high O
- I-GENE
risk O
patients O
as O
compared O
to O
cyclosporine O
: O
combined O
results O
from O
the O
prospective O
, O
randomized O
_RARE_ I-GENE
and O
US O
studies O
. O

The O
major I-GENE
PKC I-GENE
beta I-GENE
transcription I-GENE
initiation I-GENE
site I-GENE
was O
identified O
by O
primer O
extension O
and O
S1 I-GENE
nuclease I-GENE
protection O
. O

In O
the O
course O
of O
a O
study O
of O
low O
dose O
X I-GENE
- I-GENE
rays O
effects O
, O
we O
found O
that O
male O
_RARE_ I-GENE
white O
_RARE_ I-GENE
mice O
showed O
remarkable O
suppression O
of O
_RARE_ I-GENE
behavior O
after O
whole O
body O
irradiation O
by O
5 I-GENE
to O
15 O
_RARE_ I-GENE
X I-GENE
- I-GENE
rays O
. O

A I-GENE
quantitative O
analysis O
of O
the O
_RARE_ I-GENE
intensity O
as O
function O
of O
the O
accumulated O
electron O
dose O
suggests O
the O
possibility O
of O
recording O
up O
to O
250 O
_RARE_ I-GENE
patterns O
with O
3 I-GENE
. O
5 I-GENE
A I-GENE
resolution O
from O
a O
single O
_RARE_ I-GENE
complex I-GENE
crystal O
128 I-GENE
A I-GENE
thick O
. O

_RARE_ I-GENE
Phase O
_RARE_ I-GENE
_RARE_ I-GENE
(" O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
sequences I-GENE
were O
carried O
out O
in O
29 O
patients O
. O

In O
yeast I-GENE
, O
the O
products I-GENE
of O
the O
_RARE_ I-GENE
and O
_RARE_ I-GENE
genes I-GENE
are O
required O
for O
this O
decay O
pathway O
, O
and O
in O
this O
report O
we O
focus O
on O
the O
identification O
and O
characterization O
of O
additional O
factors I-GENE
required O
for O
rapid O
decay O
of O
nonsense O
- I-GENE
containing O
mRNAs I-GENE
. O

Mutations O
in O
_RARE_ I-GENE
lead O
to O
the O
selective O
stabilization O
of O
mRNAs I-GENE
containing O
early I-GENE
nonsense O
mutations O
without O
affecting O
the O
decay O
rates O
of O
most O
other O
mRNAs I-GENE
. O

A I-GENE
DNA I-GENE
fragment I-GENE
encoding O
the O
DNA I-GENE
- I-GENE
binding I-GENE
domain I-GENE
( O
amino O
acids O
1 I-GENE
- I-GENE
60 O
) O
of O
the O
Escherichia I-GENE
coli I-GENE
_RARE_ I-GENE
transcriptional O
regulator I-GENE
was O
cloned O
into O
the O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
vector O
and O
expressed O
in O
frame O
with O
the O
fused O
gene I-GENE
encoding O
glutathione I-GENE
S I-GENE
- I-GENE
transferase I-GENE
. O

Using O
gel O
retardation O
assays O
with O
HepG2 O
nuclear I-GENE
extract O
, O
we O
demonstrated O
the O
presence O
of O
a O
specific I-GENE
protein I-GENE
which O
bound O
to O
the O
_RARE_ I-GENE
fragment I-GENE
. O

0 O
. O
61 O
+/- O
0 O
. O
04 O
). O

Several O
nuclear I-GENE
factors I-GENE
that O
interact O
with O
sequences I-GENE
in O
the O
5 I-GENE
' O
flanking O
region O
of O
the O
mouse I-GENE
_RARE_ I-GENE
gene I-GENE
were O
identified O
using O
band O
shift O
and O
methylation O
interference O
assays O
. O

With O
a O
population O
of O
_RARE_ I-GENE
million O
there O
should O
be O
51 O
, O
_RARE_ I-GENE
patients O
with O
_RARE_ I-GENE
A I-GENE
in O
_RARE_ I-GENE
_RARE_ I-GENE
a O
prevalence O
of O
6 I-GENE
/ I-GENE
100 O
, O
000 O
population O
. O

When O
combined O
with O
serum I-GENE
ferritin I-GENE
and O
hemoglobin I-GENE
determinations O
, O
the O
serum I-GENE
transferrin I-GENE
receptor I-GENE
assay O
is O
a O
valuable O
addition O
in O
_RARE_ I-GENE
_RARE_ I-GENE
because O
it O
provides O
a O
quantitative O
measure O
of O
functional O
iron O
deficiency O
and O
it O
_RARE_ I-GENE
true O
_RARE_ I-GENE
from O
the O
anemia I-GENE
of O
chronic O
disease O
. O

Twenty O
- I-GENE
two O
consecutive O
patients O
with O
ischaemic O
ulcers O
had O
_RARE_ I-GENE
measured O
and O
the O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
and O
toe O
/ I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
indices O
calculated O
. O

_RARE_ I-GENE
measurement O
appears O
to O
be O
a O
reliable O
technique O
that O
can O
influence O
ischaemic O
ulcer O
management O
. O

Since O
1990 O
the O
University O
_RARE_ I-GENE
of O
_RARE_ I-GENE
has O
provided O
local O
hospitals O
in O
northern O
_RARE_ I-GENE
with O
a O
_RARE_ I-GENE
_RARE_ I-GENE
section O
_RARE_ I-GENE
and O
with O
access O
to O
_RARE_ I-GENE
_RARE_ I-GENE
for O
the O
review O
of O
microscopic O
findings O
and O
for O
the O
discussion O
of O
major I-GENE
diagnostic O
issues O
. O

Current O
status O
of O
_RARE_ I-GENE
. O

Expression O
of O
_RARE_ I-GENE
. O
1 I-GENE
in O
COS O
- I-GENE
1 I-GENE
cells O
led O
to O
the O
production O
of O
a O
typical O
type I-GENE
IV I-GENE
_RARE_ I-GENE
activity O
in O
that O
cAMP I-GENE
, O
but O
not O
cGMP I-GENE
, O
_RARE_ I-GENE
as O
substrate I-GENE
and O
its O
activity O
was O
_RARE_ I-GENE
to O
either O
Ca2 I-GENE
+/ I-GENE
CaM I-GENE
or O
cGMP I-GENE
but O
was O
inhibited O
by O
low O
concentrations O
of O
_RARE_ I-GENE
.( O
ABSTRACT O
TRUNCATED O
AT I-GENE
400 O
WORDS O
) O

_RARE_ I-GENE
displays O
96 O
and O
80 O
% O
identity O
respectively O
with O
the O
tobacco I-GENE
_RARE_ I-GENE
and O
Arabidopsis I-GENE
_RARE_ I-GENE
kinases I-GENE
, O
and O
only O
50 O
% O
to O
the O
more O
distantly O
related I-GENE
plant O
MAP I-GENE
kinase I-GENE
_RARE_ I-GENE
from O
_RARE_ I-GENE
. O

_RARE_ I-GENE
of O
the O
coding O
segment O
, O
which O
was O
designated O
_RARE_ I-GENE
, O
suggested O
it O
encodes O
a O
chimeric I-GENE
40 I-GENE
, O
_RARE_ I-GENE
Da I-GENE
cell O
wall O
protein I-GENE
with O
an O
amino O
- I-GENE
terminal I-GENE
signal I-GENE
sequence I-GENE
, O
a O
repetitive O
proline O
- I-GENE
rich O
sequence I-GENE
, O
and O
a O
cysteine I-GENE
- I-GENE
rich O
carboxyl O
- I-GENE
terminal I-GENE
sequence I-GENE
homologous O
to O
nonspecific O
lipid O
transfer I-GENE
proteins I-GENE
. O

The O
presence O
of O
type I-GENE
I I-GENE
hypersensitivity O
in O
a O
subgroup O
of O
_RARE_ I-GENE
suggests O
an O
_RARE_ I-GENE
component O
to O
this O
disease O
which O
could O
contribute O
to O
a O
chronic O
inflammatory O
response O
to O
Aspergillus I-GENE
in O
some O
_RARE_ I-GENE
. O

This O
concept O
is O
supported O
by O
the O
identification O
of O
RH O
- I-GENE
like I-GENE
genes I-GENE
in O
non O
human I-GENE
primates O
. O

With O
steady O
_RARE_ I-GENE
, O
outer I-GENE
retinal O
( O
_RARE_ I-GENE
) O
_RARE_ I-GENE
decreased O
to O
1 I-GENE
. O
4 I-GENE
+/- O
0 O
. O
9 O
ml O
O2 O
_RARE_ I-GENE
100 O
g O
. O
min O
), O
but O
inner O
retinal O
_RARE_ I-GENE
remained O
unchanged O
at O
3 I-GENE
. O
7 O
+/- O
1 I-GENE
. O
5 I-GENE
ml O
O2 O
_RARE_ I-GENE
100 O
g O
. O
min O
) O
( O
5 I-GENE
cats O
). O

We O
have O
screened O
the O
mouse I-GENE
cDNA I-GENE
library O
of O
an O
_RARE_ I-GENE
cell O
line O
, O
derived O
from O
pancreatic O
beta I-GENE
cells O
, O
for O
its O
novel O
isoform I-GENE
and O
have O
identified O
a O
cDNA I-GENE
encoding O
a O
_RARE_ I-GENE
- I-GENE
amino O
acid I-GENE
protein I-GENE
having O
63 O
, O
53 O
, O
and O
30 O
% O
identity O
with O
_RARE_ I-GENE
- I-GENE
18 O
/ I-GENE
n O
- I-GENE
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
, O
Caenorhabditis I-GENE
elegans I-GENE
_RARE_ I-GENE
, O
and O
Saccharomyces I-GENE
cerevisiae I-GENE
_RARE_ I-GENE
, O
respectively O
. O

The O
_RARE_ I-GENE
bind O
to O
APC I-GENE
and O
E I-GENE
- I-GENE
cadherin I-GENE
in O
a O
similar O
fashion O
, O
but O
APC I-GENE
and O
E I-GENE
- I-GENE
cadherin I-GENE
do O
not O
associate O
with O
each O
other O
either O
in O
the O
presence O
or O
absence O
of O
_RARE_ I-GENE
. O

However O
, O
addition O
of O
core I-GENE
DNA I-GENE
polymerase I-GENE
III I-GENE
to O
_RARE_ I-GENE
complex I-GENE
, O
fully O
_RARE_ I-GENE
holoenzyme I-GENE
resulted O
in O
replacement O
of O
gamma I-GENE
by O
alpha I-GENE
at O
the O
primer O
terminus O
. O

The O
_RARE_ I-GENE
gene I-GENE
was O
_RARE_ I-GENE
expressed O
by O
infection O
of O
_RARE_ I-GENE
- I-GENE
9 O
insect O
cells O
with O
recombinant I-GENE
baculovirus O
, O
resulting O
in O
a O
10 O
- I-GENE
fold O
increase O
in O
_RARE_ I-GENE
activity O
. O

_RARE_ I-GENE
detection O
of O
abnormal O
asymmetry O
in O
digital O
chest O
radiographs O
. O

These O
results O
suggest O
that O
_RARE_ I-GENE
genes I-GENE
are O
_RARE_ I-GENE
upon O
binding I-GENE
of O
_RARE_ I-GENE
, O
whose O
synthesis O
depends O
on O
the O
release O
of O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
from O
the O
_RARE_ I-GENE
promoter I-GENE
. O

Like O
Epo I-GENE
, O
HNF I-GENE
- I-GENE
4 I-GENE
is O
expressed O
in O
kidney O
, O
liver O
, O
and O
_RARE_ I-GENE
cells O
but O
not O
in O
HeLa O
cells O
. O

Moreover O
, O
the O
hypoxia O
- I-GENE
induced O
expression O
of O
the O
endogenous I-GENE
Epo I-GENE
gene I-GENE
was O
significantly O
inhibited O
in O
_RARE_ I-GENE
cells O
stably O
transfected O
with O
HNF I-GENE
- I-GENE
4 I-GENE
delta I-GENE
C I-GENE
. O

These O
observations O
indicate O
that O
there O
are O
multiple O
mechanisms O
by O
which O
an O
individual O
transcript I-GENE
can O
be O
degraded O
following O
_RARE_ I-GENE
. O

_RARE_ I-GENE
Maf I-GENE
proteins I-GENE
_RARE_ I-GENE
with O
Fos I-GENE
and O
may O
act O
as O
competitive O
_RARE_ I-GENE
of O
the O
NF I-GENE
- I-GENE
E2 I-GENE
transcription I-GENE
factor I-GENE
. O

We O
show O
here O
that O
the O
binding I-GENE
of O
_RARE_ I-GENE
in O
vitro O
is O
sensitive O
to O
the O
concentration O
of O
calcium O
ions O
. O

_RARE_ I-GENE
after O
development O
of O
symptomatic O
infection O
( O
P I-GENE
- I-GENE
2 I-GENE
) O
did O
not O
differ O
by O
transmission O
mode O
. O

Both O
factors I-GENE
demonstrated O
significant O
correlations O
with O
rCBF O
in O
the O
medial O
_RARE_ I-GENE
cortex O
and O
frontal O
_RARE_ I-GENE
cortex O
while O
for O
each O
factor I-GENE
there O
were O
also O
unique O
patterns O
of O
correlations O
with O
posterior O
brain O
regions O
. O

These O
data O
suggest O
that O
the O
function O
of O
the O
_RARE_ I-GENE
may O
be O
the O
protection O
of O
the O
nuclear I-GENE
DNA I-GENE
from O
_RARE_ I-GENE
. O

_RARE_ I-GENE
hemodynamics O
during O
abortion O
induced O
by O
_RARE_ I-GENE
_RARE_ I-GENE
and O
sepsis O
in O
rats O
. O

The O
aim O
of O
this O
retrospective O
study O
was O
to O
demonstrate O
that O
in O
certain O
cases O
of O
_RARE_ I-GENE
_RARE_ I-GENE
hemorrhage O
( O
_RARE_ I-GENE
) O
anatomical O
success O
and O
useful O
vision O
can O
be O
obtained O
with O
repeated O
_RARE_ I-GENE
surgery O
. O

The O
function O
of O
the O
C I-GENE
- I-GENE
terminal I-GENE
tail O
in O
telomere I-GENE
maintenance O
is O
not O
mediated O
through O
the O
_RARE_ I-GENE
interacting I-GENE
factor I-GENE
_RARE_ I-GENE
: O
_RARE_ I-GENE
alleles I-GENE
defective O
in O
both O
the O
C I-GENE
- I-GENE
terminal I-GENE
tail O
and O
_RARE_ I-GENE
interaction O
domains I-GENE
have O
additive O
effects O
on O
telomere I-GENE
length I-GENE
. O

The O
resulting O
integrated O
physical O
, O
genetic O
, O
and O
cytogenetic O
map O
constitutes O
a O
resource O
for O
the O
characterization O
of O
genes I-GENE
that O
may O
be O
involved O
in O
the O
_RARE_ I-GENE
syndrome O
. O

The O
contribution O
of O
skin O
flow O
to O
the O
changes O
in O
_RARE_ I-GENE
- I-GENE
800 O
nm O
absorption O
was O
investigated O
by O
simultaneous O
measurement O
of O
skin O
flow O
by O
laser O
flow O
Doppler O
and O
_RARE_ I-GENE
recordings O
during O
hot O
water O
immersion O
. O

_RARE_ I-GENE
immunoprecipitated O
from O
lysates O
of O
control O
- I-GENE
and O
VEGF I-GENE
- I-GENE
stimulated O
_RARE_ I-GENE
with O
antisera O
to O
phospholipase I-GENE
C I-GENE
- I-GENE
gamma I-GENE
( O
PLC I-GENE
- I-GENE
gamma I-GENE
) O
were O
_RARE_ I-GENE
by O
SDS O
- I-GENE
polyacrylamide O
gel O
electrophoresis O
and O
transferred O
to O
_RARE_ I-GENE
- I-GENE
P I-GENE
. O

_RARE_ I-GENE
processed O
isoforms I-GENE
of O
cellular O
nucleic O
acid I-GENE
- I-GENE
binding I-GENE
protein I-GENE
interact O
with O
a O
suppressor I-GENE
region O
of O
the O
human I-GENE
beta I-GENE
- I-GENE
myosin I-GENE
heavy I-GENE
chain I-GENE
gene I-GENE
. O

_RARE_ I-GENE
of O
early I-GENE
growth I-GENE
response O
factor I-GENE
_RARE_ I-GENE
- I-GENE
1 I-GENE
in O
apolipoprotein I-GENE
_RARE_ I-GENE
gene I-GENE
transcription I-GENE
. O

The O
wild I-GENE
- I-GENE
type I-GENE
and O
altered O
forms O
of O
the O
F I-GENE
protein I-GENE
were O
expressed O
in O
_RARE_ I-GENE
- I-GENE
21 O
and O
HeLa O
T4 I-GENE
cells O
by O
use O
of O
the O
recombinant I-GENE
vaccinia I-GENE
virus I-GENE
- I-GENE
encoding O
T7 I-GENE
polymerase I-GENE
system O
. O

_RARE_ I-GENE
delta I-GENE
- I-GENE
_RARE_ I-GENE
acid I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
activity O
, O
erythrocyte I-GENE
zinc I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
)/ O
heme O
ratio O
, O
and O
urinary O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
concentration O
have O
been O
employed O
as O
biological O
indicators O
of O
moderate O
- I-GENE
to O
high O
- I-GENE
level O
lead O
exposure O
, O
corresponding O
to O
blood O
levels O
in O
excess O
of O
50 O
micrograms O
/ I-GENE
dl O
, O
in O
human I-GENE
subjects O
. O

The O
relative O
risk O
of O
graft O
loss O
after O
conversion O
to O
_RARE_ I-GENE
compared O
with O
graft O
loss O
after O
conversion O
to O
_RARE_ I-GENE
compared O
with O
cyclosporin O
maintenance O
was O
0 O
. O
71 O
( O
0 O
. O
37 O
- I-GENE
1 I-GENE
. O
38 O
) O
and O
the O
relative O
risk O
of O
patient O
death O
was O
0 O
. O
57 O
( O
0 O
. O
23 O
- I-GENE
1 I-GENE
. O
41 O
). O

Three O
classes O
of O
test O
objects O
were O
considered O
: O
( O
1 I-GENE
) O
a O
_RARE_ I-GENE
test O
_RARE_ I-GENE
for O
_RARE_ I-GENE
MRS O
measurements O
performed O
with O
_RARE_ I-GENE
- I-GENE
selective O
sequences I-GENE
; O
( O
2 I-GENE
) O
a O
two O
- I-GENE
compartment O
test O
_RARE_ I-GENE
for O
volume O
- I-GENE
selection O
_RARE_ I-GENE
MRS O
; O
and O
( O
3 I-GENE
) O
two O
- I-GENE
compartment O
test O
objects O
for O
assessing O
the O
performance O
of O
experimental O
systems O
using O
_RARE_ I-GENE
as O
volume O
localization O
sequence I-GENE
in O
_RARE_ I-GENE
MRS O
. O

The O
" O
tobacco I-GENE
_RARE_ I-GENE
". O

_RARE_ I-GENE
screening O
by O
uterine O
artery O
Doppler O
_RARE_ I-GENE
-- O
which O
criterion O
_RARE_ I-GENE
best O
? O
OBJECTIVE O
: O
To O
test O
whether O
repeating O
Doppler O
studies O
of O
the O
_RARE_ I-GENE
circulation O
late O
in O
gestation O
will O
improve O
the O
test O
' O
s O
power O
for O
predicting O
pregnancy O
- I-GENE
induced O
hypertension O
and O
fetal O
growth I-GENE
restriction I-GENE
( O
_RARE_ I-GENE
), O
and O
whether O
analysis O
based O
on O
a O
combination O
of O
quantitative O
and O
qualitative O
_RARE_ I-GENE
of O
the O
uterine O
arterial O
_RARE_ I-GENE
will O
yield O
better O
results O
than O
analysis O
based O
on O
either O
alone O
. O

The O
effect O
of O
the O
Ca I-GENE
entry O
blocker O
_RARE_ I-GENE
, O
the O
antioxidant O
superoxide I-GENE
dismutase I-GENE
( O
SOD I-GENE
), O
and O
a O
combination O
of O
_RARE_ I-GENE
and O
superoxide I-GENE
dismutase I-GENE
on O
_RARE_ I-GENE
renal O
function O
was O
studied O
in O
four O
groups O
( O
n O
= O
24 O
) O
of O
rats O
. O

PURPOSE O
: O
The O
aim O
of O
this O
study O
was O
to O
evaluate O
the O
_RARE_ I-GENE
anchorage O
of O
a O
new O
implant O
( O
_RARE_ I-GENE
_RARE_ I-GENE
surface O
effect O
with O
_RARE_ I-GENE
_RARE_ I-GENE
Al O
_RARE_ I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
of O
_RARE_ I-GENE
mu I-GENE
). O

To O
determine O
whether O
food O
and O
/ I-GENE
or O
water O
in O
the O
gastrointestinal O
tract O
affects O
_RARE_ I-GENE
of O
blood O
volume O
and O
plasma I-GENE
protein I-GENE
after O
hemorrhage O
, O
fed O
and O
24 O
- I-GENE
h O
- I-GENE
fasted O
_RARE_ I-GENE
rats O
received O
a O
20 O
ml O
. O
kg O
- I-GENE
1 I-GENE
x O
3 I-GENE
min O
- I-GENE
1 I-GENE
hemorrhage O
, O
and O
_RARE_ I-GENE
of O
blood O
volume O
was O
measured O
by O
_RARE_ I-GENE
blue O
dye O
and O
dilution O
of O
hematocrit O
. O

_RARE_ I-GENE
dimerization O
of O
paired I-GENE
class I-GENE
_RARE_ I-GENE
domains I-GENE
on O
DNA I-GENE
. O

We O
_RARE_ I-GENE
advantage O
of O
the O
high O
degree O
of O
aa O
sequence I-GENE
homology I-GENE
between O
_RARE_ I-GENE
from O
several O
species O
to O
isolate O
_RARE_ I-GENE
homologues O
from O
the O
pathogenic O
yeast I-GENE
Candida I-GENE
albicans I-GENE
. O

In O
this O
study O
, O
we O
demonstrate O
that O
_RARE_ I-GENE
DNA I-GENE
enhances O
transcription I-GENE
from O
the O
thymidine I-GENE
kinase I-GENE
( O
TK I-GENE
) O
promoter I-GENE
in O
various O
EC I-GENE
cells O
. O

Deletion O
analyses O
of O
the O
construct I-GENE
revealed O
that O
the O
transcription I-GENE
of O
_RARE_ I-GENE
gene I-GENE
is O
regulated O
by O
_RARE_ I-GENE
DNA I-GENE
, O
preferentially O
in O
undifferentiated O
EC I-GENE
cells O
versus O
differentiated O
cells O
. O

Analysis O
of O
_RARE_ I-GENE
rates O
indicates O
that O
the O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
DNA I-GENE
complex I-GENE
has O
a O
longer O
half O
- I-GENE
life O
than O
protein I-GENE
- I-GENE
DNA I-GENE
complexes I-GENE
that O
contain O
only O
_RARE_ I-GENE
or O
_RARE_ I-GENE
. O

The O
presence O
of O
an O
unusual O
transcript I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
beta I-GENE
1 I-GENE
at O
the O
5 I-GENE
' O
terminus O
suggests O
that O
cleavage O
of O
its O
splice O
acceptor O
is O
inefficient O
or O
negatively O
regulated O
. O

The O
mutant I-GENE
allele I-GENE
of O
the O
alpha I-GENE
1 I-GENE
- I-GENE
_RARE_ I-GENE
gene I-GENE
was O
designated O
_RARE_ I-GENE
- I-GENE
1 I-GENE
. O

During O
chronic O
treatment O
, O
when O
plasma I-GENE
concentrations O
_RARE_ I-GENE
between O
23 O
. O
5 I-GENE
ng O
. O
ml O
- I-GENE
1 I-GENE
at O
8 O
h O
and O
14 O
ng O
. O
ml O
- I-GENE
1 I-GENE
at O
24 O
h O
post O
- I-GENE
_RARE_ I-GENE
, O
ST O
segment O
depression O
at O
an O
individually O
comparable O
_RARE_ I-GENE
was O
significantly O
decreased O
by O
28 O
% O
compared O
with O
placebo O
( O
P I-GENE
< O
0 O
. O
005 O
) O
at O
both O
points O
in O
time O
. O

Results O
from O
in O
vitro O
transcription I-GENE
- I-GENE
translation I-GENE
analysis O
and O
_RARE_ I-GENE
experiments O
suggested O
that O
the O
_RARE_ I-GENE
- I-GENE
bp O
ORF I-GENE
was O
the O
one O
being O
actively O
expressed O
. O

_RARE_ I-GENE
experiments O
demonstrated O
that O
it O
was O
possible O
to O
produce O
_RARE_ I-GENE
mutants I-GENE
, O
whose O
products I-GENE
_RARE_ I-GENE
functional O
for O
_RARE_ I-GENE
export O
and O
assembly O
. O

_RARE_ I-GENE
_RARE_ I-GENE
response O
to O
indirect O
_RARE_ I-GENE
stimulation O
at O
1 I-GENE
Hz O
was O
monitored O
in O
ten O
adult O
goats O
under O
_RARE_ I-GENE
- I-GENE
halothane O
anaesthesia O
. O

_RARE_ I-GENE
, O
98 O
- I-GENE
_RARE_ I-GENE
). O

Group O
6 I-GENE
was O
given O
_RARE_ I-GENE
, O
0 O
. O
1 I-GENE
mg O
/ I-GENE
kg O
i O
. O
v I-GENE
., O
known O
to O
inhibit O
cholinesterase I-GENE
degradation O
, O
5 I-GENE
min O
before O
_RARE_ I-GENE
administration O
, O
and O
Group O
7 O
received O
a O
combination O
of O
_RARE_ I-GENE
pretreatment O
and O
electrical O
_RARE_ I-GENE
stimulation O
. O

To O
examine O
the O
possibility O
that O
_RARE_ I-GENE
performance O
of O
the O
schizophrenic O
groups O
may O
have O
been O
related I-GENE
to O
neuroleptic O
medication O
, O
analyses O
were O
completed O
on O
the O
relationship O
between O
medication O
levels O
and O
_RARE_ I-GENE
scores O
. O

_RARE_ I-GENE
5 I-GENE
possibilities O
. O

The O
use O
of O
specific I-GENE
antibodies I-GENE
allowed O
the O
identification O
of O
at O
least O
RAR I-GENE
beta I-GENE
in O
some O
of O
the O
DNA I-GENE
- I-GENE
protein I-GENE
complexes I-GENE
, O
although O
the O
four O
sequences I-GENE
bind O
single O
_RARE_ I-GENE
transfected O
in O
COS O
cells O
much O
less O
efficiently O
, O
or O
not O
at O
all O
, O
when O
compared O
to O
a O
canonical O
RAR I-GENE
responsive I-GENE
element I-GENE
. O

The O
present O
treatment O
strategy O
in O
progressive O
disorders O
is O
mainly O
based O
on O
the O
complementary O
effect O
of O
intensive O
_RARE_ I-GENE
, O
autologous O
stem O
- I-GENE
cell O
transplantation O
and O
the O
_RARE_ I-GENE
use O
of O
cytokines O
, O
mostly O
colony I-GENE
- I-GENE
stimulating I-GENE
factors I-GENE
. O

Our O
study O
_RARE_ I-GENE
consisted O
of O
15 O
patients O
who O
received O
SC O
_RARE_ I-GENE
- I-GENE
2 I-GENE
at O
doses O
of O
4 I-GENE
. O
8 O
- I-GENE
14 O
. O
4 I-GENE
million O
IU O
/ I-GENE
m2 O
/ I-GENE
day O
on O
5 I-GENE
days O
per O
week O
for O
a O
total O
of O
8 O
weeks O
, O
20 O
patients O
who O
received O
_RARE_ I-GENE
- I-GENE
alpha I-GENE
2b I-GENE
at O
3 I-GENE
. O
0 O
- I-GENE
6 I-GENE
. O
0 O
million O
U O
/ I-GENE
m2 O
/ I-GENE
day O
_RARE_ I-GENE
weekly O
for O
a O
total O
of O
6 I-GENE
weeks O
, O
and O
72 O
patients O
who O
were O
given O
SC O
_RARE_ I-GENE
- I-GENE
alpha I-GENE
2b I-GENE
at O
6 I-GENE
. O
0 O
million O
U O
/ I-GENE
m2 O
/ I-GENE
day O
_RARE_ I-GENE
weekly O
plus O
SC O
_RARE_ I-GENE
- I-GENE
2 I-GENE
at O
14 O
. O
4 I-GENE
- I-GENE
18 O
. O
0 O
million O
IU O
/ I-GENE
m2 O
/ I-GENE
day O
on O
days O
1 I-GENE
and O
2 I-GENE
, O
followed O
by O
4 I-GENE
. O
8 O
million O
IU O
/ I-GENE
m2 O
/ I-GENE
day O
, O
5 I-GENE
days O
per O
week O
for O
6 I-GENE
consecutive O
weeks O
. O

Analysis O
of O
a O
set O
of O
deletion O
constructs I-GENE
in O
transient O
transfection O
assays O
measuring O
heterologous O
reporter I-GENE
gene I-GENE
( O
luciferase I-GENE
) O
activity O
demonstrated O
that O
the O
182 O
- I-GENE
bp O
5 I-GENE
'- O
flanking O
region O
provides O
full I-GENE
promoter I-GENE
activity O
in O
IL I-GENE
- I-GENE
2 I-GENE
- I-GENE
stimulated O
L2 O
cells O
. O

At O
the O
_RARE_ I-GENE
( O
8 O
mg O
/ I-GENE
m2 O
/ I-GENE
day O
), O
the O
dose O
- I-GENE
limiting O
toxicity O
of O
this O
agent O
is O
_RARE_ I-GENE
. O

_RARE_ I-GENE
- I-GENE
induced O
lymphocyte I-GENE
proliferation O
was O
diminished O
. O

A I-GENE
_RARE_ I-GENE
promoter I-GENE
sequence I-GENE
homologous O
to O
those O
found O
in O
humans O
and O
mice O
was O
located O
in O
the O
5 I-GENE
' O
untranslated O
region O
of O
one O
horse I-GENE
gene I-GENE
. O

Some O
of O
these O
targets O
were O
reported O
to O
code O
for O
molecules I-GENE
involved O
in O
cell O
- I-GENE
cell O
interactions O
, O
whereas O
no O
relationship O
has O
yet O
been O
demonstrated O
between O
Hox I-GENE
genes I-GENE
and O
other O
transcription I-GENE
factors I-GENE
involved O
in O
determining O
and O
/ I-GENE
or O
maintaining O
tissue I-GENE
specificity O
. O

Northern O
analysis O
of O
RNA I-GENE
samples O
isolated O
from O
_RARE_ I-GENE
- I-GENE
grown O
cultures O
of O
the O
_RARE_ I-GENE
mutant I-GENE
showed O
reduced O
amounts O
of O
_RARE_ I-GENE
message I-GENE
and O
the O
absence O
of O
a O
1 I-GENE
. O
7 O
- I-GENE
kb O
transcript I-GENE
. O

_RARE_ I-GENE
overexpressing O
cells O
showed O
a O
single O
prominent O
DNase I-GENE
I I-GENE
hypersensitive I-GENE
site I-GENE
near O
a O
conserved O
and O
hitherto O
_RARE_ I-GENE
ets I-GENE
response O
element I-GENE
( O
_RARE_ I-GENE
), O
located O
38 O
bases O
down O
- I-GENE
_RARE_ I-GENE
from O
the O
CAAT I-GENE
box I-GENE
and O
directly O
5 I-GENE
' O
of O
the O
TATA I-GENE
box I-GENE
in O
the O
human I-GENE
_RARE_ I-GENE
promoter I-GENE
. O

Gel O
- I-GENE
shift O
assays O
with O
nuclear I-GENE
extracts O
and O
oligonucleotide I-GENE
sequences I-GENE
spanning O
the O
0 O
. O
125 I-GENE
- I-GENE
kb O
promoter I-GENE
region O
detected O
an O
ETS I-GENE
- I-GENE
immunoreactive I-GENE
complex I-GENE
, O
present O
most O
abundantly O
in O
cells O
overexpressing O
_RARE_ I-GENE
, O
whose O
high O
- I-GENE
affinity O
binding I-GENE
_RARE_ I-GENE
on O
the O
_RARE_ I-GENE
response O
element I-GENE
. O

Comparison O
of O
cDNA I-GENE
sequences I-GENE
revealed O
that O
the O
two O
mRNA I-GENE
species O
arise O
as O
a O
result O
of O
alternate O
use O
of O
poly O
( O
A I-GENE
)- I-GENE
addition O
sites I-GENE
. O

The O
gene I-GENE
for O
the O
RNA I-GENE
- I-GENE
dependent I-GENE
eIF I-GENE
- I-GENE
2 I-GENE
alpha I-GENE
protein I-GENE
kinase I-GENE
( O
PKR I-GENE
) O
was O
isolated O
from O
mouse I-GENE
genomic O
DNA I-GENE
and O
characterized O
. O

High O
- I-GENE
frequency O
electrical O
stimulation O
in O
the O
hippocampus O
leads O
to O
an O
increase O
in O
synaptic O
efficacy O
that O
_RARE_ I-GENE
for O
many O
hours O
. O

Similar O
to O
the O
mouse I-GENE
gene I-GENE
, O
the O
5 I-GENE
' O
flanking O
region O
of O
human I-GENE
_RARE_ I-GENE
alpha I-GENE
lacks O
a O
TATA I-GENE
box I-GENE
; O
however O
, O
unlike O
mouse I-GENE
_RARE_ I-GENE
alpha I-GENE
, O
a O
classical O
octamer O
motif I-GENE
could O
not O
be O
identified O
in O
the O
human I-GENE
gene I-GENE
. O

_RARE_ I-GENE
molecular O
organization O
of O
the O
coding O
and O
upstream O
regulatory I-GENE
regions O
of O
the O
murine I-GENE
homeodomain I-GENE
- I-GENE
containing O
gene I-GENE
, O
_RARE_ I-GENE
- I-GENE
1 I-GENE
, O
is O
reported O
. O

We O
report O
here O
the O
cloning O
of O
the O
human I-GENE
_RARE_ I-GENE
gene I-GENE
( O
_RARE_ I-GENE
) O
from O
a O
genomic O
library O
and O
the O
sequence I-GENE
of O
its O
encoded I-GENE
protein I-GENE
. O

In O
order O
to O
define O
potential O
candidate O
genes I-GENE
for O
inherited O
disorders O
characterized O
by O
aberrant O
gene I-GENE
expression O
, O
we O
utilized O
_RARE_ I-GENE
- I-GENE
related I-GENE
sequences I-GENE
to O
isolate O
zinc I-GENE
finger I-GENE
- I-GENE
containing O
cDNAs I-GENE
. O

This O
virus I-GENE
is O
not O
_RARE_ I-GENE
a O
_RARE_ I-GENE
African O
strain O
of O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
virus I-GENE
( O
_RARE_ I-GENE
): O
the O
deduced O
CP I-GENE
sequence I-GENE
is O
only O
distantly O
related I-GENE
to O
_RARE_ I-GENE
of O
other O
sequenced O
strains O
of O
_RARE_ I-GENE
, O
although O
it O
is O
part O
of O
a O
distinct O
subgroup O
of O
_RARE_ I-GENE
related I-GENE
to O
_RARE_ I-GENE
. O

The O
ratio O
of O
the O
activity O
of O
_RARE_ I-GENE
dehydrogenase I-GENE
to O
that O
of O
_RARE_ I-GENE
dehydrogenase I-GENE
( O
approximately O
3 I-GENE
: O
1 I-GENE
) O
remained O
constant O
throughout O
purification O
, O
and O
the O
two O
activities O
were O
therefore O
_RARE_ I-GENE
. O

The O
isolated O
_RARE_ I-GENE
clones O
hybridized O
to O
a O
1 I-GENE
. O
4 I-GENE
kb O
RNA I-GENE
species O
, O
which O
was O
induced O
approximately O
30 O
- I-GENE
fold O
when O
_RARE_ I-GENE
was O
the O
carbon O
source O
. O

The O
Y I-GENE
. O
_RARE_ I-GENE
genomic O
_RARE_ I-GENE
gene I-GENE
was O
disrupted O
by O
replacing O
120 O
bp O
of O
its O
coding O
sequence I-GENE
with O
2 I-GENE
. O
7 O
kbp O
of O
DNA I-GENE
including O
the O
Y I-GENE
. O
_RARE_ I-GENE
LEU2 I-GENE
gene I-GENE
. O

A I-GENE
leucine I-GENE
zipper I-GENE
domain I-GENE
of O
the O
suppressor I-GENE
of O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
protein I-GENE
mediates O
its O
repressive O
effect O
on O
enhancer I-GENE
function O
. O

It O
is O
concluded O
that O
CT I-GENE
should O
be O
_RARE_ I-GENE
employed O
in O
patients O
with O
N1 O
- I-GENE
_RARE_ I-GENE
neck O
disease O
to O
determine O
the O
proper O
electron O
- I-GENE
energy O
_RARE_ I-GENE
. O

The O
predicted O
DNA I-GENE
- I-GENE
binding I-GENE
, O
zinc I-GENE
finger I-GENE
domain I-GENE
protein I-GENE
sequence I-GENE
was O
strictly O
conserved O
. O

60 O
patients O
were O
_RARE_ I-GENE
into O
a O
randomised O
study O
comparing O
_RARE_ I-GENE
( O
3 I-GENE
mg O
/ I-GENE
m2 O
/ I-GENE
week O
) O
plus O
interferon I-GENE
- I-GENE
alpha I-GENE
2b I-GENE
( O
6 I-GENE
U O
/ I-GENE
m2 O
3 I-GENE
times O
per O
week O
) O
to O
_RARE_ I-GENE
alone O
or O
to O
interferon I-GENE
alone O
for O
the O
treatment O
of O
metastatic O
malignant O
melanoma O
. O

The O
novel O
Notch I-GENE
homologue I-GENE
mouse I-GENE
Notch I-GENE
3 I-GENE
lacks O
specific I-GENE
epidermal I-GENE
growth I-GENE
factor I-GENE
- I-GENE
repeats I-GENE
and O
is O
expressed O
in O
proliferating I-GENE
_RARE_ I-GENE
. O

BACKGROUND O
: O
We O
conducted O
a O
phase O
I I-GENE
study O
with O
_RARE_ I-GENE
73 O
, O
_RARE_ I-GENE
, O
a O
new O
5 I-GENE
_RARE_ I-GENE
3 I-GENE
( O
5 I-GENE
- I-GENE
HT3 I-GENE
) O
receptor I-GENE
antagonist O
, O
in O
25 O
patients O
requiring O
_RARE_ I-GENE
chemotherapy O
. O

In O
the O
presence O
of O
the O
in O
vivo O
reducing O
system O
( O
_RARE_ I-GENE
, O
_RARE_ I-GENE
reductase I-GENE
, O
and O
_RARE_ I-GENE
), O
however O
, O
each O
of O
these O
mutants I-GENE
catalyzed O
the O
formation O
of O
only O
0 O
. O
6 I-GENE
- I-GENE
0 O
. O
8 O
_RARE_ I-GENE
per O
_RARE_ I-GENE
of O
enzyme I-GENE
. O

These O
genetic O
alterations O
do O
not O
affect O
synthesis O
of O
the O
major I-GENE
c I-GENE
- I-GENE
myc I-GENE
protein I-GENE
, O
_RARE_ I-GENE
, O
which O
is O
initiated O
from O
the O
first O
AUG O
codon O
in O
exon O
2 I-GENE
. O

In O
addition O
, O
both O
the O
exon O
1 I-GENE
- I-GENE
and O
exon O
2 I-GENE
- I-GENE
initiated O
forms O
of O
the O
c I-GENE
- I-GENE
Myc I-GENE
protein I-GENE
stimulated O
transcription I-GENE
of O
a O
Myc I-GENE
/ I-GENE
Max I-GENE
- I-GENE
responsive I-GENE
reporter I-GENE
construct I-GENE
to O
a O
similar O
level O
. O

Biological O
activities O
of O
hematopoietic I-GENE
growth I-GENE
factors I-GENE
that O
lead O
to O
future O
clinical O
application O
. O

Expression O
is O
exclusively O
limited O
to O
the O
CNS O
at O
this O
and O
later O
stages O
. O

_RARE_ I-GENE
AR I-GENE
content O
in O
transfected O
COS O
- I-GENE
1 I-GENE
cells O
was O
not O
influenced O
by O
exposure O
to O
8 O
- I-GENE
Br O
- I-GENE
cAMP I-GENE
. O

Disruption O
of O
any O
one O
of O
the O
four O
genes I-GENE
encoding O
the O
newly O
identified O
SRP I-GENE
proteins I-GENE
results O
in O
slow O
cell O
growth I-GENE
and O
inefficient O
protein I-GENE
translocation O
across O
the O
ER I-GENE
membrane I-GENE
. O

Genetic O
alterations O
in O
elements O
of O
normal O
signal I-GENE
transduction O
mechanisms O
are O
known O
to O
be O
oncogenic I-GENE
events O
often O
resulting O
in O
aberrant O
activation O
of O
programs O
of O
gene I-GENE
transcription I-GENE
. O

The O
expression O
pattern O
of O
_RARE_ I-GENE
, O
as O
demonstrated O
by O
in O
situ O
hybridization O
, O
indicated O
that O
the O
gene I-GENE
is O
expressed O
in O
_RARE_ I-GENE
progenitor I-GENE
cells O
and O
at O
stages O
associated I-GENE
with O
_RARE_ I-GENE
development O
. O

_RARE_ I-GENE
interacts O
with O
_RARE_ I-GENE
and O
_RARE_ I-GENE
in O
the O
two O
- I-GENE
hybrid O
assay O
, O
and O
overexpression O
of O
_RARE_ I-GENE
or O
_RARE_ I-GENE
suppresses O
_RARE_ I-GENE
and O
_RARE_ I-GENE
mutations O
. O

Binding O
site I-GENE
selection O
using O
in O
vitro O
- I-GENE
synthesized O
proteins I-GENE
reveals O
that O
the O
_RARE_ I-GENE
alpha I-GENE
1 I-GENE
and O
_RARE_ I-GENE
alpha I-GENE
2 I-GENE
isoforms I-GENE
bind O
DNA I-GENE
as O
_RARE_ I-GENE
to O
hormone I-GENE
response O
elements O
composed O
of O
a O
6 I-GENE
- I-GENE
bp O
AT I-GENE
- I-GENE
rich O
sequence I-GENE
preceding O
a O
half O
- I-GENE
site I-GENE
core I-GENE
motif I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
). O

The O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
complex I-GENE
binds O
both O
in O
vitro O
and O
in O
vivo O
to O
_RARE_ I-GENE
but O
not O
_RARE_ I-GENE
or O
E2F I-GENE
sites I-GENE
. O

We O
show O
that O
the O
en I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
in O
_RARE_ I-GENE
mutant I-GENE
embryos O
and O
that O
_RARE_ I-GENE
activity O
is O
an O
absolute O
requirement O
for O
maintenance O
of O
_RARE_ I-GENE
expression O
at O
the O
same O
time O
that O
_RARE_ I-GENE
transcription I-GENE
is O
dependent I-GENE
on O
_RARE_ I-GENE
. O

The O
DNA I-GENE
sequence I-GENE
adjacent O
to O
the O
lacZ I-GENE
gene I-GENE
has O
been O
determined O
for O
91 O
_RARE_ I-GENE
fusion I-GENE
genes I-GENE
whose O
products I-GENE
have O
been O
localized O
and O
for O
43 I-GENE
_RARE_ I-GENE
induced O
fusions I-GENE
. O

CMV O
_RARE_ I-GENE
treatment O
( O
_RARE_ I-GENE
, O
_RARE_ I-GENE
) O
was O
started O
( O
2 I-GENE
ml O
/ I-GENE
kg O
_RARE_ I-GENE
on O
day O
1 I-GENE
and O
3 I-GENE
, O
and O
1 I-GENE
ml O
/ I-GENE
kg O
on O
days O
5 I-GENE
, O
7 O
and O
9 O
), O
which O
led O
to O
the O
eradication O
of O
the O
residual O
_RARE_ I-GENE
and O
CMV O
- I-GENE
DNA I-GENE
in O
the O
myocardium O
. O

_RARE_ I-GENE
biliary O
drainage O
, O
unlike O
external O
drainage O
, O
does O
not O
suppress O
the O
regeneration O
of O
_RARE_ I-GENE
rat I-GENE
liver O
after O
partial O
_RARE_ I-GENE
. O

ORF I-GENE
2 I-GENE
potentially O
encoded I-GENE
a O
hydrophobic O
protein I-GENE
of O
29 O
, O
_RARE_ I-GENE
Da I-GENE
with O
six O
potential O
membrane I-GENE
- I-GENE
spanning O
regions O
. O

In O
eight O
groups O
of O
subjects O
operating O
various O
hand O
- I-GENE
held O
_RARE_ I-GENE
tools O
and O
aged O
from O
30 O
to O
59 O
years O
, O
the O
prevalence O
rates O
of O
vibration O
- I-GENE
induced O
white O
finger I-GENE
( O
_RARE_ I-GENE
) O
and O
_RARE_ I-GENE
, O
pain O
, O
or O
stiffness O
in O
the O
upper O
and O
lower O
_RARE_ I-GENE
were O
investigated O
. O

DNA I-GENE
sequence I-GENE
analysis O
showed O
that O
the O
gene I-GENE
was O
_RARE_ I-GENE
bp O
long O
and O
encoded I-GENE
a O
175 O
- I-GENE
amino O
- I-GENE
acid I-GENE
protein I-GENE
with O
a O
molecular O
weight O
of O
19 O
, O
_RARE_ I-GENE
containing O
a O
21 O
- I-GENE
residue O
typical O
lipoprotein I-GENE
signal I-GENE
peptide I-GENE
and O
consensus I-GENE
_RARE_ I-GENE
processing O
site I-GENE
. O

DNA I-GENE
sequence I-GENE
and O
functions O
of O
the O
_RARE_ I-GENE
region O
of O
the O
_RARE_ I-GENE
biosynthetic O
gene I-GENE
cluster I-GENE
of O
Streptomyces I-GENE
_RARE_ I-GENE
A3 I-GENE
( O
2 I-GENE
). O

( O
1992 O
) O
_RARE_ I-GENE
12 O
, O
58 O
- I-GENE
62 O
). O

A I-GENE
comparison O
of O
the O
predicted O
polypeptide I-GENE
sequence I-GENE
of O
the O
Drosophila I-GENE
protein I-GENE
with O
the O
equivalent O
subunits I-GENE
from O
mouse I-GENE
and O
yeast I-GENE
suggests O
that O
they O
are O
closely O
related I-GENE
and O
defines O
three O
conserved O
regions O
which O
are O
likely O
to O
be O
important O
for O
enzyme I-GENE
activity O
. O

_RARE_ I-GENE
were O
constructed O
with O
the O
mouse I-GENE
promoter I-GENE
region O
linked O
to O
the O
reporter I-GENE
gene I-GENE
chloramphenicol I-GENE
acetyltransferase I-GENE
( O
CAT I-GENE
), O
and O
transiently O
and O
stably O
transfected O
in O
the O
_RARE_ I-GENE
- I-GENE
1 I-GENE
cells O
. O

_RARE_ I-GENE
dynein I-GENE
is O
a O
multisubunit I-GENE
, O
microtubule I-GENE
- I-GENE
dependent I-GENE
_RARE_ I-GENE
enzyme I-GENE
that O
has O
been O
proposed O
to O
function O
in O
a O
variety O
of O
intracellular O
movements O
, O
including O
minus O
- I-GENE
end O
- I-GENE
directed O
transport O
of O
_RARE_ I-GENE
. O

Identification O
of O
the O
plakoglobin I-GENE
- I-GENE
binding I-GENE
domain I-GENE
in O
_RARE_ I-GENE
and O
its O
role O
in O
plaque O
assembly O
and O
intermediate O
_RARE_ I-GENE
anchorage O
. O

PATIENTS O
AND O
METHODS O
: O
One O
hundred O
_RARE_ I-GENE
- I-GENE
four O
chemotherapy O
- I-GENE
_RARE_ I-GENE
patients O
receiving O
high O
- I-GENE
dose O
cisplatin O
( O
81 O
to O
120 O
mg O
/ I-GENE
m2 O
) O
were O
randomized O
to O
receive O
one O
of O
four O
_RARE_ I-GENE
doses O
( O
5 I-GENE
, O
10 O
, O
20 O
, O
or O
40 I-GENE
micrograms O
/ I-GENE
kg O
) O
administered O
before O
chemotherapy O
. O

_RARE_ I-GENE
new O
_RARE_ I-GENE
related I-GENE
compounds O
( O
I I-GENE
, O
IV I-GENE
, O
V I-GENE
, O
VII I-GENE
- I-GENE
_RARE_ I-GENE
) O
together O
with O
four O
known O
compounds O
( O
II I-GENE
, O
III I-GENE
, O
VI I-GENE
, O
_RARE_ I-GENE
) O
were O
isolated O
from O
the O
root O
_RARE_ I-GENE
of O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
. O

Specifically O
, O
this O
study O
determined O
the O
influence O
of O
: O
( O
1 I-GENE
) O
an O
_RARE_ I-GENE
strategy O
, O
( O
2 I-GENE
) O
a O
non O
- I-GENE
_RARE_ I-GENE
strategy O
, O
( O
3 I-GENE
) O
a O
Five O
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
strategy O
and O
( O
4 I-GENE
) O
a O
control O
condition O
. O

_RARE_ I-GENE
_RARE_ I-GENE
interaction O
of O
the O
adenovirus I-GENE
_RARE_ I-GENE
- I-GENE
6 I-GENE
/ I-GENE
7 O
protein I-GENE
and O
the O
retinoblastoma I-GENE
gene I-GENE
product I-GENE
with O
internal O
domains I-GENE
of O
E2F I-GENE
- I-GENE
1 I-GENE
and O
DP I-GENE
- I-GENE
1 I-GENE
. O

As O
shown O
previously O
, O
EBNA2 I-GENE
transactivates O
the O
promoters I-GENE
of O
the O
viral I-GENE
latent I-GENE
membrane I-GENE
proteins I-GENE
. O

We O
previously O
showed O
that O
v I-GENE
- I-GENE
Rel I-GENE
, O
the O
oncoprotein I-GENE
of O
the O
avian I-GENE
retrovirus O
Rev I-GENE
- I-GENE
T I-GENE
, O
can O
increase O
expression O
from O
promoters I-GENE
containing O
binding I-GENE
sites I-GENE
for O
the O
cellular O
transcription I-GENE
factor I-GENE
Sp1 I-GENE
in O
chicken I-GENE
embryo O
fibroblasts O
( O
S I-GENE
. O

Previous O
studies O
have O
demonstrated O
that O
the O
TATA I-GENE
element I-GENE
is O
critical O
for O
basal O
and O
Tat I-GENE
- I-GENE
induced O
HIV I-GENE
- I-GENE
1 I-GENE
gene I-GENE
expression O
. O

A I-GENE
comparison O
of O
the O
nucleotide I-GENE
sequence I-GENE
of O
the O
p54 I-GENE
gene I-GENE
carried O
by O
two O
virulent O
_RARE_ I-GENE
strains O
( O
_RARE_ I-GENE
and O
_RARE_ I-GENE
) O
with O
that O
obtained O
from O
virus I-GENE
_RARE_ I-GENE
showed O
100 O
% O
similarity O
. O

The O
p55 I-GENE
mRNA I-GENE
is O
undetectable O
in O
non O
- I-GENE
EBV I-GENE
- I-GENE
infected O
B I-GENE
- I-GENE
and O
T I-GENE
- I-GENE
cell O
lines O
or O
in O
a O
_RARE_ I-GENE
cell O
line O
( O
U937 O
). O

A I-GENE
simple O
_RARE_ I-GENE
as O
an O
_RARE_ I-GENE
for O
improvement O

The O
transverse O
_RARE_ I-GENE
_RARE_ I-GENE
mentioned O
above O
exhibited O
two O
components O
, O
a O
T2 I-GENE
fast O
( O
_RARE_ I-GENE
) O
and O
a O
T2 I-GENE
slow O
( O
_RARE_ I-GENE
) O
component O
. O

RESULTS O
: O
The O
diagnostic O
quality O
of O
FDG O
images O
was O
at O
least O
as O
good O
as O
that O
of O
their O
Tl O
- I-GENE
201 O
counterparts O
, O
with O
less O
liver O
background O
in O
all O
but O
one O
FDG O
study O
. O

The O
_RARE_ I-GENE
expression O
of O
CD4 I-GENE
and O
CD8 I-GENE
during O
T I-GENE
- I-GENE
cell O
development O
is O
tightly O
coupled I-GENE
with O
the O
maturation O
state O
of O
the O
T I-GENE
cell O
. O

Expression O
of O
a O
dominant I-GENE
- I-GENE
negative O
ras I-GENE
gene I-GENE
also O
blocks O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
induction O
by O
v I-GENE
- I-GENE
src I-GENE
. O

The O
_RARE_ I-GENE
_RARE_ I-GENE
- I-GENE
transfected O
cells O
exhibit O
both O
cytoplasmic I-GENE
and O
nuclear I-GENE
changes O
characteristic O
of O
cells O
undergoing O
apoptosis O
. O

Using O
an O
RNase I-GENE
H I-GENE
- I-GENE
mediated O
mapping O
technique O
, O
we O
show O
that O
the O
64 O
- I-GENE
kDa I-GENE
subunit I-GENE
of O
_RARE_ I-GENE
can O
be O
_RARE_ I-GENE
cross O
- I-GENE
linked O
to O
pre I-GENE
- I-GENE
mRNAs I-GENE
at O
U O
- I-GENE
rich O
regions O
located O
downstream O
of O
the O
cleavage O
site I-GENE
of O
the O
simian I-GENE
virus I-GENE
40 I-GENE
late O
and O
adenovirus I-GENE
_RARE_ I-GENE
pre I-GENE
- I-GENE
mRNAs I-GENE
. O

The O
protein I-GENE
encoded I-GENE
is O
114 I-GENE
kDa I-GENE
and O
contains O
eight O
zinc I-GENE
finger I-GENE
motifs O
, O
seven O
of O
which O
are O
present O
in O
two O
clusters O
at O
opposite O
ends O
of O
the O
molecule I-GENE
. O

Tissue I-GENE
- I-GENE
specific I-GENE
expression O
of O
the O
diazepam I-GENE
- I-GENE
binding I-GENE
inhibitor I-GENE
in O
Drosophila I-GENE
melanogaster I-GENE
: O
cloning O
, O
structure O
, O
and O
localization O
of O
the O
gene I-GENE
. O

Using O
a O
v I-GENE
- I-GENE
erbA I-GENE
probe O
, O
we O
obtained O
a O
cDNA I-GENE
which O
encodes O
a O
novel O
_RARE_ I-GENE
- I-GENE
amino O
- I-GENE
acid I-GENE
protein I-GENE
, O
_RARE_ I-GENE
- I-GENE
1 I-GENE
, O
that O
contains O
the O
characteristic O
domains I-GENE
of O
nuclear I-GENE
receptors I-GENE
. O

Only O
two O
of O
the O
isoforms I-GENE
possess O
the O
N I-GENE
- I-GENE
terminal I-GENE
zinc I-GENE
finger I-GENE
domain I-GENE
that O
is O
necessary O
and O
sufficient O
for O
_RARE_ I-GENE
promoter I-GENE
binding I-GENE
. O

This O
study O
provides O
direct O
evidence O
that O
USF I-GENE
, O
a O
member O
of O
the O
basic I-GENE
helix I-GENE
- I-GENE
loop I-GENE
- I-GENE
helix I-GENE
leucine I-GENE
zipper I-GENE
family I-GENE
, O
binds O
to O
_RARE_ I-GENE
, O
HF I-GENE
- I-GENE
1a I-GENE
, O
and O
_RARE_ I-GENE
B I-GENE
sites I-GENE
and O
suggests O
that O
it O
is O
a O
component O
of O
protein I-GENE
complexes I-GENE
that O
may O
_RARE_ I-GENE
control O
the O
expression O
of O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
and O
alpha I-GENE
- I-GENE
myosin I-GENE
heavy I-GENE
- I-GENE
chain I-GENE
genes I-GENE
. O

Human I-GENE
T I-GENE
- I-GENE
cell O
leukemia I-GENE
virus I-GENE
type I-GENE
I I-GENE
Tax I-GENE
activation O
of O
NF I-GENE
- I-GENE
kappa I-GENE
B I-GENE
/ I-GENE
Rel I-GENE
involves O
phosphorylation O
and O
degradation O
of O
I I-GENE
kappa I-GENE
B I-GENE
alpha I-GENE
and O
RelA I-GENE
( O
p65 I-GENE
)- I-GENE
mediated O
induction O
of O
the O
c I-GENE
- I-GENE
rel I-GENE
gene I-GENE
. O

Activation O
of O
c I-GENE
- I-GENE
fos I-GENE
gene I-GENE
expression O
by O
a O
kinase I-GENE
- I-GENE
deficient O
epidermal I-GENE
growth I-GENE
factor I-GENE
receptor I-GENE
. O

Because O
endogenous I-GENE
HSF I-GENE
DNA I-GENE
- I-GENE
binding I-GENE
activity O
is O
low O
and O
anti I-GENE
- I-GENE
_RARE_ I-GENE
antibody I-GENE
does O
not O
recognize O
Xenopus I-GENE
HSF I-GENE
, O
we O
employed O
this O
system O
for O
mapping O
regions O
in O
_RARE_ I-GENE
that O
are O
required O
for O
the O
maintenance O
of O
the O
monomeric I-GENE
state O
. O

_RARE_ I-GENE
containing O
disrupted O
Ets I-GENE
- I-GENE
1 I-GENE
binding I-GENE
sites I-GENE
were O
tested O
in O
transient O
expression O
assays O
in O
the O
murine I-GENE
T I-GENE
- I-GENE
cell O
line O
_RARE_ I-GENE
. O
E1 I-GENE
; O
alterations O
in O
the O
_RARE_ I-GENE
element I-GENE
affected O
constitutive O
enhancer I-GENE
activity O
, O
while O
mutation I-GENE
of O
either O
the O
_RARE_ I-GENE
or O
_RARE_ I-GENE
element I-GENE
disrupted O
phorbol O
ester O
- I-GENE
induced O
enhancer I-GENE
activity O
. O

The O
predominant O
binding I-GENE
activity O
was O
not O
Ets I-GENE
- I-GENE
1 I-GENE
but O
rather O
two O
independent O
DNA I-GENE
- I-GENE
protein I-GENE
complexes I-GENE
that O
_RARE_ I-GENE
in O
mobility I-GENE
shift O
assays O
. O

These O
_RARE_ I-GENE
subtypes O
represent O
members O
of O
a O
new O
family I-GENE
of O
orphan I-GENE
nuclear I-GENE
receptors I-GENE
that O
most O
likely O
regulate O
specific I-GENE
gene I-GENE
expression O
. O

Interestingly O
, O
these O
response O
elements O
display O
dramatically O
reduced O
affinity O
for O
retinoic I-GENE
acid I-GENE
receptor I-GENE
- I-GENE
retinoid I-GENE
- I-GENE
X I-GENE
receptor I-GENE
heterodimers I-GENE
. O

Treatment O
with O
amphotericin O
B I-GENE
and O
_RARE_ I-GENE
led O
to O
improvement O
of O
the O
symptoms O
but O
did O
not O
_RARE_ I-GENE
the O
micro O
- I-GENE
organisms O
from O
the O
cerebrospinal O
fluid O
( O
CSF I-GENE
). O

The O
_RARE_ I-GENE
presence O
of O
the O
tRNA I-GENE
( O
_RARE_ I-GENE
)( I-GENE
_RARE_ I-GENE
)- I-GENE
gene I-GENE
transcript I-GENE
in O
mitochondria O
is O
also O
reported O
. O

The O
parameters O
of O
nonspecific O
_RARE_ I-GENE
immunity O
-- O
serum I-GENE
immunoglobulins I-GENE
and O
immune I-GENE
complexes I-GENE
-- O
were O
evaluated O
in O
irradiated O
group O
of O
patients O
with O
uterine O
cervix O
carcinoma O
( O
_RARE_ I-GENE
_RARE_ I-GENE
and O
IIIB I-GENE
), O
during O
one O
year O
follow O
up O
. O

Mutation O
of O
_RARE_ I-GENE
to O
_RARE_ I-GENE
retains O
_RARE_ I-GENE
in O
the O
cytoplasmic I-GENE
compartment O
, O
_RARE_ I-GENE
the O
wild I-GENE
- I-GENE
type I-GENE
protein I-GENE
is O
detected O
exclusively O
in O
the O
nucleus O
. O

To O
confirm O
the O
binding I-GENE
of O
protein I-GENE
to O
these O
sites I-GENE
in O
cells O
, O
we O
carried O
out O
an O
in O
vivo O
genomic O
footprinting O
analysis O
of O
this O
portion O
of O
the O
TGF I-GENE
alpha I-GENE
promoter I-GENE
in O
normal O
and O
transformed O
rat I-GENE
liver O
epithelial O
cell O
lines O
that O
express O
the O
endogenous I-GENE
gene I-GENE
at O
varying O
levels O
. O

_RARE_ I-GENE
, O
this O
subdomain I-GENE
is O
also O
present O
in O
the O
otherwise O
unrelated O
N I-GENE
- I-GENE
terminal I-GENE
activating I-GENE
region O
of O
_RARE_ I-GENE
- I-GENE
ets I-GENE
- I-GENE
2 I-GENE
and O
was O
thus O
named O
_RARE_ I-GENE
for O
Ets I-GENE
- I-GENE
1 I-GENE
- I-GENE
beta I-GENE
/ I-GENE
Ets I-GENE
- I-GENE
2 I-GENE
- I-GENE
_RARE_ I-GENE
sequence I-GENE
. O

This O
work O
_RARE_ I-GENE
a O
new O
model O
for O
the O
ets I-GENE
- I-GENE
1 I-GENE
/ I-GENE
ets I-GENE
- I-GENE
2 I-GENE
gene I-GENE
' O
s O
evolution O
, O
based O
for O
the O
first O
time O
on O
both O
structural O
and O
functional O
_RARE_ I-GENE
. O

The O
v I-GENE
- I-GENE
ets I-GENE
oncogene I-GENE
of O
the O
avian I-GENE
retrovirus O
_RARE_ I-GENE
differs O
from O
its O
cellular O
progenitor I-GENE
_RARE_ I-GENE
- I-GENE
ets I-GENE
- I-GENE
1 I-GENE
by O
two O
amino O
acid I-GENE
substitutions O
( O
alanine I-GENE
285 O
and O
_RARE_ I-GENE
_RARE_ I-GENE
in O
c I-GENE
- I-GENE
ets I-GENE
- I-GENE
1 I-GENE
both O
substituted O
by O
_RARE_ I-GENE
in O
v I-GENE
- I-GENE
ets I-GENE
, O
mutations O
A I-GENE
and O
B I-GENE
respectively O
) O
and O
its O
carboxy I-GENE
- I-GENE
terminal I-GENE
end O
( O
mutation I-GENE
C I-GENE
). O

_RARE_ I-GENE
functional O
mRNAs I-GENE
can O
be O
produced O
by O
endogenous I-GENE
RNA I-GENE
polymerase I-GENE
I I-GENE
. O

The O
individual O
subunits I-GENE
of O
_RARE_ I-GENE
have O
been O
difficult O
to O
isolate O
from O
human I-GENE
cells O
without O
_RARE_ I-GENE
and O
attempts O
to O
produce O
functional O
recombinant I-GENE
_RARE_ I-GENE
have O
been O
largely O
_RARE_ I-GENE
. O

Using O
this O
method O
, O
we O
were O
able O
to O
select O
strong O
enhancer I-GENE
- I-GENE
type I-GENE
activation O
domains I-GENE
from O
the O
immediate I-GENE
early I-GENE
regions O
of O
two O
_RARE_ I-GENE
, O
namely O
pseudorabies O
virus I-GENE
and O
bovine I-GENE
herpesvirus I-GENE
1 I-GENE
. O

_RARE_ I-GENE
, O
_RARE_ I-GENE
contains O
a O
long O
stretch O
( O
13 O
nt O
.) O
of O
complementarity I-GENE
to O
a O
highly O
conserved O
sequence I-GENE
in O
28S I-GENE
rRNA I-GENE
. O

A I-GENE
genetic O
system O
was O
_RARE_ I-GENE
to O
select O
for O
pi I-GENE
protein I-GENE
mutants I-GENE
which O
_RARE_ I-GENE
between O
IR I-GENE
and O
DR I-GENE
( O
York O
et O
al O
., O
Gene I-GENE
( O
_RARE_ I-GENE
.) O
_RARE_ I-GENE
, O
7 O
- I-GENE
12 O
, O
1992 O
; O
York O
and O
_RARE_ I-GENE
, O
J O
. O

_RARE_ I-GENE
statistical O
analysis O
based O
on O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
estimates O
and O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
Test O
showed O
the O
following O
_RARE_ I-GENE
beneficial O
factors I-GENE
: O
_RARE_ I-GENE
disease O
stage O
( O
p O
= O
0 O
. O
_RARE_ I-GENE
), O
_RARE_ I-GENE
serum I-GENE
level O
less O
than O
25 O
micrograms O
/ I-GENE
l O
( O
p O
= O
0 O
. O
_RARE_ I-GENE
), O
serum I-GENE
alkaline I-GENE
phosphatase I-GENE
less O
than O
200 O
U O
/ I-GENE
l O
( O
p O
= O
0 O
. O
_RARE_ I-GENE
), O
normal O
serum I-GENE
albumin I-GENE
( O
p O
= O
0 O
. O
_RARE_ I-GENE
) O
and O
activity O
index O
of O
minimum O
of O
70 I-GENE
( O
p O
< O
0 O
. O
001 O
). O

These O
results O
provide O
evidence O
of O
a O
bypass O
of O
p53 I-GENE
- I-GENE
induced O
_RARE_ I-GENE
/ I-GENE
Cip1 I-GENE
- I-GENE
mediated O
cell O
cycle O
regulatory I-GENE
pathways O
by O
a O
member O
of O
the O
myb I-GENE
oncogene I-GENE
family I-GENE
. O

_RARE_ I-GENE
strongly O
_RARE_ I-GENE
levels O
of O
GTP I-GENE
- I-GENE
bound O
Ras I-GENE
, O
activated I-GENE
and O
phosphorylated O
Raf I-GENE
, O
and O
tyrosine I-GENE
- I-GENE
phosphorylated O
and O
activated I-GENE
MAP I-GENE
kinase I-GENE
. O

Role O
of O
c I-GENE
- I-GENE
myc I-GENE
in O
simian I-GENE
virus I-GENE
40 I-GENE
large O
tumor I-GENE
antigen I-GENE
- I-GENE
induced O
DNA I-GENE
synthesis O
in O
_RARE_ I-GENE
3T3 O
- I-GENE
L1 I-GENE
mouse I-GENE
fibroblasts O
. O

All O
groups O
were O
_RARE_ I-GENE
subsequently O
with O
naloxone O
( O
0 O
. O
4 I-GENE
mg O
/ I-GENE
kg O
) O
in O
the O
distinctive O
environment O
and O
then O
observed O
for O
signs O
of O
opiate I-GENE
withdrawal O
. O

_RARE_ I-GENE
therapy O
of O
_RARE_ I-GENE
carcinoma O

A I-GENE
15 O
. O
1 I-GENE
kb O
fragment I-GENE
of O
the O
yeast I-GENE
genome O
was O
allocated O
to O
the O
_RARE_ I-GENE
region O
of O
chromosome O
_RARE_ I-GENE
by O
genetic O
mapping O
. O

A I-GENE
third O
one O
is O
homologous O
in O
half O
of O
its O
length I-GENE
to O
the O
prokaryotic I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
and O
in O
the O
other O
half O
to O
_RARE_ I-GENE
_RARE_ I-GENE
. O

It O
was O
shown O
that O
estradiol O
concentrations O
obtained O
after O
estradiol O
_RARE_ I-GENE
and O
_RARE_ I-GENE
estradiol O
ingestion O
were O
dependent I-GENE
on O
the O
patient O
' O
s O
age O
as O
well O
as O
on O
the O
_RARE_ I-GENE
type I-GENE
. O

There O
were O
9 O
patients O
in O
_RARE_ I-GENE
class I-GENE
III I-GENE
and O
8 O
in O
class I-GENE
IV I-GENE
.( O
ABSTRACT O
TRUNCATED O
AT I-GENE
250 O
WORDS O
) O

_RARE_ I-GENE
is O
not O
a O
risk O
factor I-GENE
for O
_RARE_ I-GENE
: O
a O
case O
- I-GENE
control O
study O
of O
potential O
_RARE_ I-GENE
agents O
. O

Of O
_RARE_ I-GENE
persons O
_RARE_ I-GENE
, O
_RARE_ I-GENE
( O
49 O
. O
4 I-GENE
%) O
were O
antigen I-GENE
- I-GENE
positive O
with O
the O
_RARE_ I-GENE
assay O
. O

TG I-GENE
- I-GENE
day O
and O
TG I-GENE
- I-GENE
night O
were O
19 O
. O
4 I-GENE
+/- O
6 I-GENE
. O
1 I-GENE
%, O
26 O
. O
6 I-GENE
+/- O
5 I-GENE
. O
3 I-GENE
%, O
( O
750 O
_RARE_ I-GENE
< O
T I-GENE
. O

Vibrio I-GENE
cholerae I-GENE
_RARE_ I-GENE
in O
_RARE_ I-GENE
. O

Ten O
volunteers O
were O
tested O
at O
18 O
, O
000 O
_RARE_ I-GENE
( O
5 I-GENE
, O
_RARE_ I-GENE
m I-GENE
), O
and O
through O
12 O
, O
000 O
, O
8 O
, O
000 O
, O
and O
5 I-GENE
, O
000 O
_RARE_ I-GENE
( O
3 I-GENE
, O
_RARE_ I-GENE
, O
2 I-GENE
, O
_RARE_ I-GENE
, O
and O
1 I-GENE
, O
_RARE_ I-GENE
m I-GENE
) O
with O
_RARE_ I-GENE
_RARE_ I-GENE
recorded O
via O
a O
_RARE_ I-GENE
head I-GENE
_RARE_ I-GENE
and O
presented O
_RARE_ I-GENE
. O

Upon O
differentiation O
with O
retinoic I-GENE
acid I-GENE
( O
RA O
), O
transcription I-GENE
of O
the O
Rex I-GENE
- I-GENE
1 I-GENE
gene I-GENE
decreases O
rapidly O
. O

Sequence O
analysis O
of O
the O
_RARE_ I-GENE
_RARE_ I-GENE
coding O
region O
revealed O
a O
high O
level O
of O
homology I-GENE
to O
the O
mouse I-GENE
, O
rat I-GENE
, O
and O
human I-GENE
_RARE_ I-GENE
genes I-GENE
with O
the O
_RARE_ I-GENE
exception O
of O
a O
polymorphic O
, O
triplet O
nucleotide I-GENE
repeat I-GENE
sequence I-GENE
in O
the O
region O
coding O
for O
the O
amino O
terminus O
of O
the O
_RARE_ I-GENE
protein I-GENE
. O

The O
fibrinogen I-GENE
, O
serum I-GENE
proteins I-GENE
, O
sodium O
heparin O
and O
membrane I-GENE
contributed O
to O
_RARE_ I-GENE
by O
20 O
%, O
14 O
%, O
2 I-GENE
% O
and O
64 O
%, O
respectively O
. O

In O
these O
vectors O
the O
chimeric I-GENE
long O
terminal I-GENE
repeat I-GENE
( O
_RARE_ I-GENE
) O
_RARE_ I-GENE
the O
expression O
of O
the O
chloramphenicol I-GENE
acetyl I-GENE
transferase I-GENE
( O
CAT I-GENE
) O
reporter I-GENE
gene I-GENE
that O
is O
followed O
by O
an O
internal O
SV40 I-GENE
virus I-GENE
early I-GENE
region O
promoter I-GENE
linked O
to O
the O
neomycin I-GENE
phosphotransferase I-GENE
II I-GENE
( O
_RARE_ I-GENE
) O
gene I-GENE
. O

_RARE_ I-GENE
) O
genomic O
library O
by O
_RARE_ I-GENE
with O
_RARE_ I-GENE
- I-GENE
induced O
_RARE_ I-GENE
synthase I-GENE
cDNA I-GENE
as O
a O
probe O
. O

A I-GENE
total O
of O
125 I-GENE
acute O
leukemia I-GENE
adult O
patients O
were O
_RARE_ I-GENE
with O
bone O
marrow O
( O
_RARE_ I-GENE
) O
_RARE_ I-GENE
by O
_RARE_ I-GENE
( O
_RARE_ I-GENE
Z I-GENE
) O
during O
the O
period O
of O
January O
1983 O
to O
January O
1993 O
. O

The O
_RARE_ I-GENE
regimen O
consisted O
of O
cyclophosphamide O
( O
120 O
mg O
/ I-GENE
kg O
) O
and O
total O
body O
irradiation O
. O

The O
site I-GENE
- I-GENE
directed O
mutation I-GENE
of O
the O
kappa I-GENE
B I-GENE
motif I-GENE
in O
IL I-GENE
- I-GENE
6 I-GENE
/ I-GENE
CAT I-GENE
plasmid O
resulted O
in O
the O
complete O
_RARE_ I-GENE
of O
IL I-GENE
- I-GENE
6 I-GENE
promoter I-GENE
activity O
in O
these O
cells O
. O

_RARE_ I-GENE
, O
_RARE_ I-GENE
was O
earlier O
and O
more O
widely O
used O
than O
_RARE_ I-GENE
in O
_RARE_ I-GENE
advanced O
breast O
carcinoma O
. O

Use O
of O
the O
_RARE_ I-GENE
_RARE_ I-GENE
to O
extend O
the O
right O
renal O
vein O
for O
_RARE_ I-GENE
transplantation O
is O
_RARE_ I-GENE
. O

_RARE_ I-GENE
hepatic I-GENE
portal I-GENE
blood O
flow O
induced O
by O
prostaglandin I-GENE
E1 I-GENE
following O
liver O
transplantation O
in O
pigs O
. O

One O
gene I-GENE
appears O
ubiquitously O
expressed O
while O
the O
other O
is O
_RARE_ I-GENE
expressed O
in O
muscle O
. O

For O
HeLa O
, O
293 O
, O
U937 O
, O
and O
_RARE_ I-GENE
cells O
, O
participation O
of O
E2F I-GENE
- I-GENE
1 I-GENE
, O
DP I-GENE
- I-GENE
1 I-GENE
, O
cyclin I-GENE
A I-GENE
, O
and O
RB I-GENE
was O
involved O
in O
formation O
of O
some O
complexes I-GENE
only O
, O
_RARE_ I-GENE
participation O
of O
factors I-GENE
different O
from O
E2F I-GENE
- I-GENE
1 I-GENE
or O
DP I-GENE
- I-GENE
1 I-GENE
in O
others O
. O

E1A I-GENE
_RARE_ I-GENE
mediated O
by O
these O
sites I-GENE
was O
about O
twofold O
compared O
with O
a O
_RARE_ I-GENE
activation O
described O
for O
the O
complete O
E1A I-GENE
promoter I-GENE
. O

_RARE_ I-GENE
invasion O
in O
irradiated O
host O
organism O
increases O
the O
negative O
effect O
of O
_RARE_ I-GENE
radiation O
on O
the O
hamster I-GENE
immune I-GENE
system O
. O

During O
heat I-GENE
exposure O
, O
chicks O
that O
had O
been O
subjected O
to O
early I-GENE
60 O
% O
restriction I-GENE
with O
non O
- I-GENE
_RARE_ I-GENE
- I-GENE
treated O
food O
had O
lower O
H I-GENE
/ I-GENE
L I-GENE
ratios O
and O
improved O
resistance O
to O
_RARE_ I-GENE
spleen O
disease O
infection O
. O

_RARE_ I-GENE
of O
additional O
tumors O
induced O
in O
mice O
from O
two O
reciprocal O
_RARE_ I-GENE
, O
A I-GENE
/ I-GENE
J O
x O
C3H O
/ I-GENE
_RARE_ I-GENE
F1 I-GENE
( O
_RARE_ I-GENE
called O
_RARE_ I-GENE
) O
and O
C3H O
/ I-GENE
_RARE_ I-GENE
x O
A I-GENE
/ I-GENE
J O
F1 I-GENE
( O
_RARE_ I-GENE
called O
_RARE_ I-GENE
), O
provided O
evidence O
for O
the O
inactivation O
of O
one O
allele I-GENE
of O
the O
putative O
chromosome O
4 I-GENE
tumor I-GENE
suppressor I-GENE
gene I-GENE
by O
parental O
imprinting O
. O

_RARE_ I-GENE
is O
involved O
in O
the O
cell O
- I-GENE
division O
cycle O
and O
the O
maintenance O
of O
mitochondrial I-GENE
genomes O
in O
Saccharomyces I-GENE
cerevisiae I-GENE
. O

_RARE_ I-GENE
diameters O
of O
greater O
than O
20 O
mm O
and O
the O
large O
_RARE_ I-GENE
- I-GENE
type I-GENE
_RARE_ I-GENE
were O
factors I-GENE
that O
were O
associated I-GENE
with O
incomplete O
removal O
. O

_RARE_ I-GENE
collected O
, O
processed O
and O
stored O
breast O
cancer O
tissue I-GENE
blocks O
recovered O
from O
the O
_RARE_ I-GENE
of O
the O
_RARE_ I-GENE
laboratory O
in O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
after O
storage O
of O
up O
to O
3 I-GENE
years O
were O
analysed O
by O
a O
flow O
_RARE_ I-GENE
for O
DNA I-GENE
_RARE_ I-GENE
and O
S I-GENE
- I-GENE
phase O
fraction O
. O

_RARE_ I-GENE
contains O
three O
proteins I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
and O
_RARE_ I-GENE
. O

Such O
an O
interaction O
could O
be O
detected O
using O
a O
GST I-GENE
- I-GENE
POU I-GENE
fusion I-GENE
protein I-GENE
bound O
to O
glutathione I-GENE
- I-GENE
agarose O
_RARE_ I-GENE
. O

These O
mutations O
are O
localized O
in O
the O
same O
region O
where O
the O
HSV I-GENE
transactivator I-GENE
VP16 I-GENE
binds O
, O
but O
did O
not O
_RARE_ I-GENE
with O
the O
VP16 I-GENE
contacts O
. O

In O
general O
, O
the O
filtration O
rate O
in O
relevant O
areas O
appears O
to O
be O
an O
_RARE_ I-GENE
and O
easily O
determined O
parameter O
, O
reflecting O
hormonal O
and O
_RARE_ I-GENE
vascular I-GENE
as O
well O
as O
local O
interstitial O
control O
of O
the O
_RARE_ I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
, O
these O
residues O
are O
located O
in O
different O
domains I-GENE
. O

However O
, O
_RARE_ I-GENE
inhibited O
proliferation O
of O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
but O
not O
of O
_RARE_ I-GENE
cells O
despite O
inhibition O
of O
p70 I-GENE
S6 I-GENE
kinase I-GENE
activity O
in O
both O
cells O
. O

_RARE_ I-GENE
injection O
of O
( O
_RARE_ I-GENE
, O
1 I-GENE
' O
R I-GENE
, O
2 I-GENE
' O
R I-GENE
, O
3 I-GENE
' O
R I-GENE
)- I-GENE
2 I-GENE
-( O
2 I-GENE
, O
3 I-GENE
- I-GENE
_RARE_ I-GENE
) O
glycine O
( O
_RARE_ I-GENE
- I-GENE
IV I-GENE
), O
a O
potent O
agonist O
for O
_RARE_ I-GENE
glutamate I-GENE
receptors I-GENE
, O
to O
rats O
retarded O
dose O
- I-GENE
dependently O
the O
recovery O
from O
halothane O
anesthesia O
at O
a O
dose O
range O
from O
30 O
to O
300 O
_RARE_ I-GENE
/ I-GENE
rat I-GENE
. O

The O
hepatocyte I-GENE
nuclear I-GENE
factor I-GENE
- I-GENE
3 I-GENE
( O
HNF I-GENE
- I-GENE
3 I-GENE
)/ O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
proteins I-GENE
consist O
of O
an O
extensive O
family I-GENE
of O
tissue I-GENE
- I-GENE
specific I-GENE
and O
developmental O
gene I-GENE
regulators O
which O
share O
homology I-GENE
within O
the O
_RARE_ I-GENE
helix I-GENE
DNA I-GENE
binding I-GENE
motif I-GENE
. O

Homozygous O
null I-GENE
embryos O
also O
displayed O
abnormalities O
in O
heart O
development O
, O
consistent O
with O
the O
conclusion O
that O
_RARE_ I-GENE
is O
necessary O
for O
_RARE_ I-GENE
/ I-GENE
myocardial O
interactions O
during O
development O
. O

Interestingly O
, O
_RARE_ I-GENE
- I-GENE
L I-GENE
/ I-GENE
S I-GENE
is O
also O
able O
to O
significantly O
enhance O
transcriptional O
activation O
by O
upstream O
transcription I-GENE
factors I-GENE
including O
Sp1 I-GENE
, O
VP16 I-GENE
, O
and O
_RARE_ I-GENE
- I-GENE
1 I-GENE
. O

A I-GENE
strong O
_RARE_ I-GENE
binding I-GENE
site I-GENE
was O
found O
at O
the O
_RARE_ I-GENE
location O
of O
the O
fork I-GENE
head I-GENE
gene I-GENE
, O
a O
region O
- I-GENE
specific I-GENE
homeotic I-GENE
gene I-GENE
not O
located O
within O
a O
homeotic I-GENE
complex I-GENE
. O

In O
particular O
, O
changes O
in O
intracellular O
Ca2 I-GENE
+ I-GENE
have O
the O
potential O
to O
either O
inhibit O
or O
_RARE_ I-GENE
the O
ability O
of O
cAMP I-GENE
to O
stimulate O
transcription I-GENE
, O
depending O
on O
the O
presence O
of O
specific I-GENE
forms O
of O
Ca2 I-GENE
+/ I-GENE
calmodulin I-GENE
- I-GENE
dependent I-GENE
protein I-GENE
kinases I-GENE
. O

Antibodies O
directed O
against O
the O
_RARE_ I-GENE
protein I-GENE
immunoprecipitated O
RNase I-GENE
MRP I-GENE
RNA I-GENE
from O
whole O
- I-GENE
cell O
extracts O
without O
precipitating O
the O
structurally O
and O
functionally O
related I-GENE
RNase I-GENE
P I-GENE
RNA I-GENE
. O

C I-GENE
/ I-GENE
EBP I-GENE
alpha I-GENE
also O
activates O
the O
promoter I-GENE
of O
the O
rat I-GENE
class I-GENE
- I-GENE
I I-GENE
ADH I-GENE
gene I-GENE
in O
a O
sequence I-GENE
- I-GENE
specific I-GENE
manner O
[ O
_RARE_ I-GENE
et O
al O
., O
_RARE_ I-GENE
. O

C I-GENE
/ I-GENE
EBP I-GENE
alpha I-GENE
also O
activates O
the O
promoter I-GENE
of O
the O
rat I-GENE
class I-GENE
- I-GENE
I I-GENE
ADH I-GENE
gene I-GENE
in O
a O
sequence I-GENE
- I-GENE
specific I-GENE
manner O
[ O
_RARE_ I-GENE
et O
al O
., O
_RARE_ I-GENE
. O

Our O
results O
show O
that O
the O
ORF I-GENE
of O
_RARE_ I-GENE
encodes O
_RARE_ I-GENE
amino O
acids O
( O
aa O
) O
( O
62 O
. O
250 O
kDa I-GENE
) O
and O
is O
highly O
conserved O
with O
_RARE_ I-GENE
with O
identities O
of O
97 O
. O
3 I-GENE
and O
90 O
% O
at O
the O
aa O
and O
nt O
levels O
, O
respectively O
. O

In O
human I-GENE
brain O
, O
_RARE_ I-GENE
was O
first O
identified O
by O
amino O
terminal I-GENE
and O
peptide I-GENE
sequencing O
of O
the O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
binding I-GENE
glycoprotein I-GENE
_RARE_ I-GENE
. O

The O
_RARE_ I-GENE
YAC O
contig O
, O
which O
consists O
of O
23 O
overlapping O
YACs O
and O
_RARE_ I-GENE
19 O
sequence I-GENE
- I-GENE
tagged O
sites I-GENE
( O
_RARE_ I-GENE
), O
_RARE_ I-GENE
a O
minimum O
of O
2 I-GENE
. O
2 I-GENE
Mb O
and O
spans O
the O
_RARE_ I-GENE
sarcoma I-GENE
breakpoint I-GENE
. O
c I-GENE
- I-GENE
ets I-GENE
1 I-GENE
and O
_RARE_ I-GENE
- I-GENE
1 I-GENE
, O
two O
members O
of O
the O
ets I-GENE
family I-GENE
, O
have O
been O
linked O
within O
400 O
kb O
of O
intervening O
DNA I-GENE
within O
this O
contig O
, O
which O
also O
comprises O
a O
polymorphic O
microsatellite I-GENE
, O
_RARE_ I-GENE
( O
CA I-GENE
) O
n O
, O
which O
we O
have O
localized O
within O
the O
_RARE_ I-GENE
- I-GENE
1 I-GENE
gene I-GENE
. O

A I-GENE
cDNA I-GENE
for O
a O
newly O
discovered O
pseudogene I-GENE
, O
closely O
related I-GENE
to O
the O
mouse I-GENE
mast I-GENE
cell O
_RARE_ I-GENE
was O
isolated O
by O
polymerase I-GENE
chain I-GENE
reaction O
amplification O
from O
a O
mouse I-GENE
connective O
tissue I-GENE
- I-GENE
like I-GENE
mast I-GENE
cell O
line O
. O

_RARE_ I-GENE
consists O
of O
ten O
exons O
and O
nine O
intervening O
introns O
spanning O
at O
least O
28 O
kilobases O
( O
kb O
) O
of O
DNA I-GENE
. O

_RARE_ I-GENE
were O
repeated O
every O
four O
weeks O
. O

_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
the O
implications O
of O
the O
_RARE_ I-GENE
. O

Other O
adverse O
events O
with O
_RARE_ I-GENE
significantly O
higher O
than O
with O
placebo O
were O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
and O
abnormal O
_RARE_ I-GENE
. O

_RARE_ I-GENE
was O
also O
detected O
between O
the O
putative O
transit O
peptide I-GENE
sequence I-GENE
of O
cysteine I-GENE
synthase I-GENE
C I-GENE
and O
other O
_RARE_ I-GENE
- I-GENE
targeting O
leader O
sequences I-GENE
. O

Furthermore O
, O
our O
data O
also O
show O
that O
, O
in O
addition O
to O
TEF I-GENE
- I-GENE
1 I-GENE
, O
another O
HF I-GENE
- I-GENE
1a I-GENE
- I-GENE
related I-GENE
factor I-GENE
may O
be O
recognized O
by O
the O
alpha I-GENE
- I-GENE
MHC I-GENE
gene I-GENE
EM O
element I-GENE
. O

Rat I-GENE
kidney O
_RARE_ I-GENE
. O

Recombinant I-GENE
I I-GENE
- I-GENE
kappa I-GENE
B I-GENE
alpha I-GENE
inhibited O
kappa I-GENE
B I-GENE
motif I-GENE
binding I-GENE
by O
nuclear I-GENE
factor I-GENE
- I-GENE
kappa I-GENE
B1 I-GENE
, O
RelA I-GENE
, O
and O
c I-GENE
- I-GENE
Rel I-GENE
as O
indicated O
by O
studies O
using O
UV O
radiation O
- I-GENE
induced O
_RARE_ I-GENE
cross O
- I-GENE
linking O
to O
a O
_RARE_ I-GENE
- I-GENE
substituted O
kappa I-GENE
B I-GENE
oligonucleotide I-GENE
. O

The O
physical O
and O
chemical O
stability O
of O
a O
combination O
of O
drugs O
commonly O
administered O
into O
the O
_RARE_ I-GENE
or O
_RARE_ I-GENE
space O
for O
the O
treatment O
of O
chronic O
pain O
was O
investigated O
. O

Therefore O
, O
mechanisms O
that O
control O
activation O
of O
the O
MAP I-GENE
kinase I-GENE
cascade O
temporally O
and O
spatially O
may O
be O
important O
for O
_RARE_ I-GENE
of O
cellular O
responses O
. O

A I-GENE
candidate O
gene I-GENE
for O
_RARE_ I-GENE
, O
designated O
natural O
resistance O
- I-GENE
associated I-GENE
macrophage I-GENE
protein I-GENE
( O
_RARE_ I-GENE
), O
has O
been O
isolated O
and O
shown O
to O
encode O
a O
novel O
macrophage I-GENE
- I-GENE
specific I-GENE
membrane I-GENE
protein I-GENE
, O
which O
is O
altered O
in O
susceptible O
animals O
. O

This O
motif I-GENE
is O
similar O
to O
but O
distinct O
from O
the O
LIM I-GENE
domain I-GENE
and O
the O
RING I-GENE
finger I-GENE
family I-GENE
, O
and O
is O
_RARE_ I-GENE
of O
known O
metal O
- I-GENE
binding I-GENE
regions O
. O

The O
_RARE_ I-GENE
ORF I-GENE
is O
followed O
in O
- I-GENE
frame O
by O
a O
second O
ORF I-GENE
which O
is O
probably O
expressed O
by O
partial O
readthrough O
of O
the O
UGA O
termination O
codon O
of O
the O
_RARE_ I-GENE
ORF I-GENE
to O
produce O
a O
polypeptide I-GENE
of O
M I-GENE
( O
r O
) O
_RARE_ I-GENE
( O
_RARE_ I-GENE
). O

One O
hundred O
_RARE_ I-GENE
patients O
were O
reviewed O
at O
1 I-GENE
year O
after O
_RARE_ I-GENE
. O

_RARE_ I-GENE
visual O
_RARE_ I-GENE
in O
_RARE_ I-GENE
and O
epilepsy O
. O

The O
influence O
of O
patient O
- I-GENE
related I-GENE
factors I-GENE
on O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
variability O
in O
the O
evaluation O
of O
neurological O
signs O
was O
investigated O
. O

_RARE_ I-GENE
with O
more O
reduced O
_RARE_ I-GENE
uptake O
than O
_RARE_ I-GENE
uptake O
( O
_RARE_ I-GENE
) O
showed O
either O
normal O
wall O
motion O
or O
demonstrated O
inotropic O
reserve O
during O
_RARE_ I-GENE
stimulation O
. O

The O
defined O
length I-GENE
of O
the O
mRNA I-GENE
, O
1 I-GENE
, O
_RARE_ I-GENE
nucleotides O
, O
was O
in O
agreement O
with O
that O
of O
a O
1 I-GENE
. O
9 O
- I-GENE
kb O
RNA I-GENE
expressed O
throughout O
the O
replication O
cycle O
, O
starting O
at O
the O
early I-GENE
stages O
of O
infection O
. O

_RARE_ I-GENE
. O

Transient O
transfections O
of O
a O
construct I-GENE
expressing O
the O
RNA I-GENE
transcript I-GENE
defined O
by O
clone O
B1 I-GENE
. O
1 I-GENE
into O
_RARE_ I-GENE
cells O
led O
to O
the O
expression O
of O
an O
Env I-GENE
/ I-GENE
_RARE_ I-GENE
- I-GENE
4 I-GENE
fusion I-GENE
protein I-GENE
with O
an O
apparent O
molecular O
mass O
of O
33 O
kDa I-GENE
. O

_RARE_ I-GENE
, O
J O
. O

_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
heart O
disease O
or O
heart O
failure O
secondary O
to O
acute O
myocardial O
infarction O
or O
_RARE_ I-GENE
' O
disease O
were O
excluded O
. O

The O
present O
data O
also O
indicate O
that O
patients O
with O
_RARE_ I-GENE
nephropathy O
often O
have O
concomitant O
IgA I-GENE
nephropathy O
and O
_RARE_ I-GENE
proliferative O
glomerulonephritis O
. O

All O
nuclear I-GENE
receptors I-GENE
have O
several O
well O
- I-GENE
characterized O
structural O
domains I-GENE
, O
including O
a O
conserved O
DNA I-GENE
- I-GENE
binding I-GENE
domain I-GENE
, O
and O
a O
ligand O
binding I-GENE
domain I-GENE
at O
the O
carboxyl O
terminus O
of O
the O
receptor I-GENE
. O

The O
sample O
includes O
all O
the O
HIV I-GENE
- I-GENE
infected O
- I-GENE
patients O
continuously O
referred O
to O
the O
_RARE_ I-GENE
_RARE_ I-GENE
of O
the O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
. O
of O
_RARE_ I-GENE
' O
s O
" O
_RARE_ I-GENE
_RARE_ I-GENE
" O
_RARE_ I-GENE
_RARE_ I-GENE
during O
some O
five O
days O
( O
19 O
- I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
1993 O
). O

Using O
in O
_RARE_ I-GENE
footprint O
analysis O
, O
we O
demonstrate O
that O
within O
human I-GENE
placental I-GENE
mitochondria O
there O
is O
a O
high O
level O
of O
protein I-GENE
- I-GENE
DNA I-GENE
binding I-GENE
at O
_RARE_ I-GENE
_RARE_ I-GENE
intervals O
throughout O
a O
500 O
- I-GENE
bp O
region O
encompassing O
the O
D I-GENE
- I-GENE
loop I-GENE
DNA I-GENE
origins O
and O
two O
promoter I-GENE
regions O
. O

The O
_RARE_ I-GENE
protein I-GENE
can O
act O
as O
a O
potent O
transcription I-GENE
activator I-GENE
and O
may O
function O
to O
regulate O
the O
expression O
of O
downstream O
genes I-GENE
in O
response O
to O
extracellular I-GENE
stimuli O
. O

One O
class I-GENE
of O
plasmids O
contained O
tRNA I-GENE
( O
His O
) O
genes I-GENE
and O
conferred O
efficient O
suppression O
only O
when O
cells O
were O
_RARE_ I-GENE
for O
histidine O
; O
these O
plasmids O
suppressed O
a O
_RARE_ I-GENE
deletion O
much O
less O
efficiently O
than O
they O
suppressed O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
. O

Thus O
, O
the O
presence O
of O
the O
_RARE_ I-GENE
_RARE_ I-GENE
domain I-GENE
was O
sufficient O
to O
_RARE_ I-GENE
a O
heterologous O
protein I-GENE
. O

Electrophoretic O
mobility I-GENE
shift O
assays O
with O
each O
of O
these O
sequences I-GENE
demonstrated O
complexes I-GENE
with O
_RARE_ I-GENE
identical O
to O
those O
of O
the O
NF I-GENE
- I-GENE
kappa I-GENE
B I-GENE
site I-GENE
from O
the O
kappa I-GENE
light I-GENE
- I-GENE
chain I-GENE
gene I-GENE
. O

Although O
a O
carboxyl O
- I-GENE
terminal I-GENE
HSF I-GENE
transcriptional O
activation O
domain I-GENE
is O
critical O
for O
the O
activation O
of O
_RARE_ I-GENE
transcription I-GENE
in O
response O
to O
both O
heat I-GENE
shock I-GENE
stress O
and O
glucose O
starvation O
, O
this O
region O
is O
dispensable O
for O
transient O
heat I-GENE
shock I-GENE
activation O
of O
at O
least O
two O
genes I-GENE
encoding O
members O
of O
the O
S I-GENE
. O
cerevisiae I-GENE
hsp70 I-GENE
family I-GENE
. O

We O
have O
recently O
detected O
high O
levels O
of O
_RARE_ I-GENE
mRNA I-GENE
in O
HeLa O
cells O
and O
, O
in O
this O
study O
, O
have O
tested O
whether O
this O
may O
be O
due O
to O
the O
extremely O
low O
amounts O
of O
p53 I-GENE
protein I-GENE
present O
in O
HeLa O
cells O
. O

_RARE_ I-GENE
lower O
motor O
neuron I-GENE
syndrome O
with O
high O
- I-GENE
titer O
serum I-GENE
IgM I-GENE
anti I-GENE
- I-GENE
_RARE_ I-GENE
antibodies I-GENE
: O
improvement O
following O
immunotherapy O
with O
monthly O
plasma I-GENE
exchange I-GENE
and O
intravenous O
cyclophosphamide O
. O

_RARE_ I-GENE
responsible O
for O
the O
_RARE_ I-GENE
, O
_RARE_ I-GENE
- I-GENE
specific I-GENE
alternative O
pre I-GENE
- I-GENE
mRNA I-GENE
splicing O
characteristic O
of O
_RARE_ I-GENE
are O
almost O
entirely O
unknown O
or O
_RARE_ I-GENE
. O

A I-GENE
normal O
systemic O
response O
was O
obtained O
after O
IF O
, O
indicating O
that O
_RARE_ I-GENE
- I-GENE
CSF I-GENE
retains O
activity O
in O
the O
solid O
state O
. O

A I-GENE
full I-GENE
- I-GENE
length I-GENE
cDNA I-GENE
clone O
isolated O
from O
a O
rat I-GENE
lung O
library O
was O
predicted O
to O
encode O
a O
55 O
- I-GENE
kDa I-GENE
protein I-GENE
containing O
at O
its O
amino O
terminus O
a O
targeting O
domain I-GENE
that O
binds O
to O
the O
ANP I-GENE
- I-GENE
receptor I-GENE
kinase I-GENE
- I-GENE
like I-GENE
domain I-GENE
and O
containing O
at O
its O
carboxyl O
terminus O
a O
putative O
protein I-GENE
- I-GENE
serine I-GENE
phosphatase I-GENE
domain I-GENE
. O

A I-GENE
high O
- I-GENE
resolution O
restriction I-GENE
map O
of O
over O
200 O
kb O
of O
contiguous O
DNA I-GENE
containing O
N I-GENE
- I-GENE
myc I-GENE
has O
been O
generated O
by O
_RARE_ I-GENE
YACs O
into O
_RARE_ I-GENE
. O

PAI I-GENE
- I-GENE
1 I-GENE
levels O
increased O
significantly O
in O
patients O
who O
received O
_RARE_ I-GENE
but O
not O
in O
those O
who O
received O
_RARE_ I-GENE
. O

In O
the O
present O
article O
, O
the O
causes O
of O
death O
or O
_RARE_ I-GENE
- I-GENE
being O
as O
found O
in O
10 O
consecutive O
_RARE_ I-GENE
studies O
-- O
5 I-GENE
studies O
with O
_RARE_ I-GENE
_RARE_ I-GENE
( O
Sprague O
- I-GENE
Dawley O
- I-GENE
derived O
) O
and O
_RARE_ I-GENE
rats O
and O
5 I-GENE
studies O
with O
_RARE_ I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
mice O
-- O
were O
re O
- I-GENE
examined O
. O

Determination O
of O
potassium O
_RARE_ I-GENE
in O
_RARE_ I-GENE
_RARE_ I-GENE
salt O

The O
recovery O
value O
of O
systolic O
pressure O
was O
higher O
than O
diastolic O
pressure O
and O
pulse O
pressure O
increased O
. O

The O
importance O
of O
hepatitis I-GENE
C I-GENE
virus I-GENE
( O
HCV I-GENE
) O
infection O
as O
a O
cause O
of O
chronic O
liver O
disease O
has O
become O
clear O
with O
the O
introduction O
of O
serologic O
detection O
methods O
. O

Human I-GENE
adenovirus I-GENE
type I-GENE
41 O
contains O
two O
fibers O
. O

_RARE_ I-GENE
obstruction O
of O
pancreatic O
juice O
, O
i O
. O
e O
., O
" O
relative O
stenosis O
of O
the O
minor O
_RARE_ I-GENE
," O
was O
considered O
to O
be O
present O
in O
the O
patients O
with O
type I-GENE
II I-GENE
_RARE_ I-GENE
, O
and O
, O
therefore O
, O
the O
patients O
with O
type I-GENE
II I-GENE
_RARE_ I-GENE
might O
_RARE_ I-GENE
from O
acute O
pancreatitis O
resulting O
from O
poor O
drainage O
of O
pancreatic O
juice O
and O
excessive O
pressure O
in O
the O
dorsal O
duct O
. O

Sequencing O
of O
the O
_RARE_ I-GENE
transcripts I-GENE
from O
exons O
2 I-GENE
to O
10 O
, O
however O
, O
did O
not O
reveal O
mutations O
of O
the O
remaining O
allele I-GENE
in O
any O
of O
these O
tumors O
. O

An O
unusual O
complication O
in O
an O
_RARE_ I-GENE
patient O
. O

In O
the O
_RARE_ I-GENE
group O
, O
at O
pre I-GENE
- I-GENE
_RARE_ I-GENE
, O
CBF I-GENE
increased O
from O
86 I-GENE
+/- O
8 O
to O
_RARE_ I-GENE
+/- O
19 O
mL O
. O
min O
- I-GENE
1 I-GENE
. O
100 O
g O
- I-GENE
1 I-GENE
in O
response O
to O
hypercapnia O
( O
PCO2 O
approximately O
90 O
mmHg O
_RARE_ I-GENE
ABSTRACT O
TRUNCATED O
AT I-GENE
250 O
WORDS O
) O

All O
other O
_RARE_ I-GENE
parameters O
( O
density I-GENE
, O
motility O
, O
swelling O
test O
, O
penetration O
test O
) O
remained O
unchanged O
, O
and O
there O
was O
only O
one O
post O
- I-GENE
therapeutic O
pregnancy O
. O

_RARE_ I-GENE
and O
_RARE_ I-GENE
produced O
a O
dose O
- I-GENE
dependent I-GENE
increase O
in O
aortic O
and O
coronary O
blood O
flow O
. O

In O
_RARE_ I-GENE
rat I-GENE
hepatoma O
cells O
, O
glucocorticoids O
, O
retinoic I-GENE
acid I-GENE
and O
cyclic I-GENE
AMP I-GENE
( O
cAMP I-GENE
) O
increase O
PEPCK I-GENE
gene I-GENE
transcription I-GENE
whereas O
insulin I-GENE
and O
phorbol O
esters O
have O
the O
opposite O
effect O
. O

_RARE_ I-GENE
_RARE_ I-GENE
, O
113 I-GENE
- I-GENE
120 O
]. O

Basal O
plasma I-GENE
AVP I-GENE
levels O
and O
AVP I-GENE
release O
after O
_RARE_ I-GENE
change O
were O
assessed O
, O
and O
plasma I-GENE
_RARE_ I-GENE
levels O
were O
measured O
in O
the O
same O
samples O
. O

A I-GENE
stretch O
of O
16 O
nucleotides O
just O
upstream O
of O
the O
IL I-GENE
- I-GENE
_RARE_ I-GENE
contributed O
to O
IL I-GENE
- I-GENE
4 I-GENE
inducibility O
and O
formed O
nucleoprotein I-GENE
complexes I-GENE
with O
constitutive O
factors I-GENE
. O

Our O
previous O
study O
suggested O
that O
pertussis I-GENE
toxin I-GENE
( O
_RARE_ I-GENE
)- I-GENE
sensitive O
GTP I-GENE
- I-GENE
binding I-GENE
protein I-GENE
( O
s O
) O
( O
G I-GENE
- I-GENE
protein I-GENE
) O
is O
involved O
in O
the O
process O
of O
differentiation O
by O
hormones O
/ I-GENE
_RARE_ I-GENE
, O
accompanied O
by O
c I-GENE
- I-GENE
fos I-GENE
induction O
. O

_RARE_ I-GENE
, O
like I-GENE
PC I-GENE
- I-GENE
1 I-GENE
, O
was O
found O
to O
_RARE_ I-GENE
the O
type I-GENE
I I-GENE
phosphodiesterase I-GENE
substrate I-GENE
p O
- I-GENE
_RARE_ I-GENE
thymidine I-GENE
- I-GENE
5 I-GENE
'- O
monophosphate O
. O

The O
effect O
of O
site I-GENE
- I-GENE
specific I-GENE
mutations O
in O
the O
mouse I-GENE
platelet I-GENE
- I-GENE
derived O
growth I-GENE
factor I-GENE
( O
PDGF I-GENE
) O
beta I-GENE
- I-GENE
receptor I-GENE
on O
activation O
of O
the O
Na I-GENE
+/ I-GENE
H I-GENE
+ I-GENE
_RARE_ I-GENE
was O
examined O
in O
normal O
murine I-GENE
mammary O
gland O
epithelial O
( O
_RARE_ I-GENE
) O
and O
Chinese O
hamster I-GENE
ovary O
( O
CHO O
) O
cells O
. O

Sequence O
analysis O
revealed O
: O
1 I-GENE
) O
a O
kinase I-GENE
catalytic O
domain I-GENE
most O
characteristic O
of O
serine I-GENE
/ I-GENE
threonine I-GENE
kinases I-GENE
but O
hybrid O
between O
members O
of O
the O
family I-GENE
of O
microtubule I-GENE
- I-GENE
associated I-GENE
protein I-GENE
kinase I-GENE
kinase I-GENE
kinases I-GENE
and O
the O
fibroblast I-GENE
growth I-GENE
factor I-GENE
receptor I-GENE
family I-GENE
; O
2 I-GENE
) O
two O
putative O
alpha I-GENE
- I-GENE
helical O
leucine I-GENE
zipper I-GENE
motifs O
separated O
by O
a O
25 O
- I-GENE
amino O
acid I-GENE
charged O
intermediate O
segment O
but O
lacking O
an O
NH2 I-GENE
- I-GENE
terminal I-GENE
basic I-GENE
domain I-GENE
; O
and O
3 I-GENE
) O
COOH O
- I-GENE
terminal I-GENE
and O
NH2 I-GENE
- I-GENE
terminal I-GENE
proline O
- I-GENE
rich O
domains I-GENE
suggestive O
of O
src I-GENE
homology I-GENE
3 I-GENE
( O
SH3 I-GENE
) O
domain I-GENE
binding I-GENE
regions O
. O

Type O
2 I-GENE
genomes O
containing O
this O
sequence I-GENE
presumably O
more O
closely O
reflect O
the O
structure O
of O
the O
infectious O
, O
replication O
- I-GENE
competent O
retrovirus O
_RARE_ I-GENE
of O
the O
_RARE_ I-GENE
- I-GENE
K I-GENE
family I-GENE
than O
do O
type I-GENE
1 I-GENE
genomes O
that O
lack O
the O
sequence I-GENE
. O

However O
, O
when O
domain I-GENE
I I-GENE
and O
domain I-GENE
II I-GENE
were O
linked O
on O
the O
same O
plasmid O
, O
high O
levels O
of O
replication O
were O
observed O
. O

_RARE_ I-GENE
mutations O
that O
suppressed O
the O
in O
vitro O
binding I-GENE
of O
NF I-GENE
- I-GENE
Y I-GENE
to O
the O
internal O
palindromic O
arm O
reduced O
the O
activity O
of O
the O
_RARE_ I-GENE
P4 I-GENE
promoter I-GENE
, O
while O
those O
preventing O
complex I-GENE
formation O
with O
USF I-GENE
did O
not O
, O
as O
determined O
by O
transient O
expression O
assays O
using O
the O
luciferase I-GENE
reporter I-GENE
gene I-GENE
. O

Surprisingly O
, O
Northern O
( O
RNA I-GENE
) O
blot O
analysis O
and O
reverse I-GENE
transcriptase I-GENE
- I-GENE
_RARE_ I-GENE
performed O
after O
transfection O
of O
COS O
- I-GENE
7 O
or O
HeLa O
cells O
with O
these O
viral I-GENE
RNAs I-GENE
revealed O
that O
_RARE_ I-GENE
and O
_RARE_ I-GENE
RNAs I-GENE
_RARE_ I-GENE
at O
only O
very O
low O
levels O
. O

Surprisingly O
, O
nuclear I-GENE
forms O
of O
_RARE_ I-GENE
were O
found O
to O
_RARE_ I-GENE
a O
cytoplasmic I-GENE
form O
of O
_RARE_ I-GENE
into O
nuclear I-GENE
_RARE_ I-GENE
structures O
, O
and O
a O
cytoplasmic I-GENE
form O
of O
_RARE_ I-GENE
was O
able O
to O
_RARE_ I-GENE
nuclear I-GENE
forms O
of O
_RARE_ I-GENE
in O
cytoplasmic I-GENE
_RARE_ I-GENE
structures O
. O

Transcription O
of O
the O
gene I-GENE
for O
_RARE_ I-GENE
O O
and O
expression O
of O
other O
genes I-GENE
of O
the O
virulence I-GENE
gene I-GENE
cluster I-GENE
in O
L I-GENE
. O
_RARE_ I-GENE
were O
dependent I-GENE
on O
_RARE_ I-GENE
. O

Moreover O
, O
by O
complementation O
of O
the O
_RARE_ I-GENE
_RARE_ I-GENE
mutant I-GENE
by O
the O
cloned O
_RARE_ I-GENE
gene I-GENE
, O
_RARE_ I-GENE
uptake O
and O
mouse I-GENE
virulence I-GENE
were O
restored O
. O

The O
_RARE_ I-GENE
in O
the O
ischaemic O
cortex O
revealed O
a O
_RARE_ I-GENE
reduction O
from O
the O
ischaemic O
_RARE_ I-GENE
to O
the O
surrounding O
tissues O
. O

The O
treatment O
of O
_RARE_ I-GENE
in O
children O

The O
_RARE_ I-GENE
_RARE_ I-GENE
of O
the O
probe O
is O
_RARE_ I-GENE
by O
_RARE_ I-GENE
a O
standard O
_RARE_ I-GENE
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
Y I-GENE
adaptor I-GENE
and O
_RARE_ I-GENE
this O
to O
the O
_RARE_ I-GENE
probe O
_RARE_ I-GENE
. O

The O
other O
element I-GENE
bound O
_RARE_ I-GENE
- I-GENE
J O
kappa I-GENE
with O
low O
affinity O
. O

The O
basal O
promoter I-GENE
strength O
of O
constructs I-GENE
that O
contained O
deletions O
in O
the O
U5 I-GENE
region O
of O
the O
LTR I-GENE
was O
analyzed O
by O
chloramphenicol I-GENE
acetyltransferase I-GENE
( O
CAT I-GENE
) O
assays O
following O
transfection O
of O
HeLa O
cells O
or O
Jurkat O
T I-GENE
- I-GENE
cells O
in O
the O
presence O
or O
absence O
of O
viral I-GENE
transactivator I-GENE
_RARE_ I-GENE
protein I-GENE
. O

In O
_RARE_ I-GENE
a O
number O
of O
the O
most O
_RARE_ I-GENE
studied O
_RARE_ I-GENE
inducible I-GENE
promoters I-GENE
it O
becomes O
clear O
that O
the O
presence O
of O
two O
cis O
- I-GENE
acting O
elements O
are O
critical O
for O
promoter I-GENE
activity O
, O
one O
of O
which O
is O
the O
G I-GENE
- I-GENE
box I-GENE
( O
_RARE_ I-GENE
). O

Recently O
, O
a O
protein I-GENE
designated O
_RARE_ I-GENE
has O
been O
isolated O
that O
is O
associated I-GENE
with O
the O
_RARE_ I-GENE
protein I-GENE
complex I-GENE
. O

New O
diagnostic O
strategies O
for O
lupus O
_RARE_ I-GENE
and O
_RARE_ I-GENE
antibodies I-GENE
. O

Moreover O
, O
the O
ability O
to O
selectivity O
arrest O
elongation I-GENE
by O
_RARE_ I-GENE
at O
defined O
positions O
within O
the O
tRNA I-GENE
gene I-GENE
transcription I-GENE
unit I-GENE
has O
permitted O
the O
identification O
of O
discrete O
functional O
properties O
of O
_RARE_ I-GENE
mammalian I-GENE
_RARE_ I-GENE
ternary O
complexes I-GENE
. O

_RARE_ I-GENE
is O
well O
tolerated O
in O
the O
majority O
of O
young O
patients O
. O

Mutational O
analysis O
of O
yeast I-GENE
_RARE_ I-GENE
demonstrated O
that O
four O
of O
the O
five O
conserved O
motifs O
are O
essential O
for O
capping I-GENE
enzyme I-GENE
function O
in O
vivo O
. O

2 I-GENE
patients O
( O
11 O
%) O
had O
significant O
morbidity O
_RARE_ I-GENE
and O
_RARE_ I-GENE
days O
respectively O
after O
transplantation O
. O

A I-GENE
recent O
index O
( O
_RARE_ I-GENE
Risk O
_RARE_ I-GENE
) O
developed O
by O
_RARE_ I-GENE
( O
1990 O
) O
is O
also O
included O
in O
this O
review O
. O

Alternative O
splicing O
of O
the O
cytoplasmic I-GENE
tail O
appears O
to O
generate O
multiple O
_RARE_ I-GENE
- I-GENE
1 I-GENE
isoforms I-GENE
that O
may O
regulate O
phosphorylation O
, O
cytoskeletal O
association O
, O
and O
affinity O
modulation O
of O
the O
mature O
protein I-GENE
. O

_RARE_ I-GENE
also O
correlated O
inversely O
with O
gastric O
juice O
pH O
( O
r O
= O
- I-GENE
0 O
. O
_RARE_ I-GENE
, O
P I-GENE
< O
0 O
. O
02 O
). O

This O
technique O
has O
a O
sensitivity O
and O
a O
specificity O
of O
almost O
100 O
%, O
and O
is O
currently O
the O
best O
way O
to O
_RARE_ I-GENE
nodal O
involvement O
, O
apart O
from O
_RARE_ I-GENE
. O

The O
data O
show O
_RARE_ I-GENE
that O
phosphorylation O
of O
His O
- I-GENE
_RARE_ I-GENE
is O
not O
essential O
for O
any O
of O
the O
known O
functions O
of O
A I-GENE
. O
_RARE_ I-GENE
_RARE_ I-GENE
. O

The O
role O
of O
HIV I-GENE
tat I-GENE
, O
which O
is O
the O
main O
enhancing O
factor I-GENE
for O
viral I-GENE
LTR I-GENE
, O
in O
the O
regulation O
of O
IL I-GENE
- I-GENE
2 I-GENE
gene I-GENE
transcription I-GENE
has O
been O
studied O
following O
transient O
expression O
of O
the O
tat I-GENE
gene I-GENE
in O
phorbol O
ester O
and O
calcium O
_RARE_ I-GENE
- I-GENE
activated I-GENE
Jurkat O
cells O
transfected O
with O
IL I-GENE
- I-GENE
2 I-GENE
promoter I-GENE
- I-GENE
chloramphenicol I-GENE
acetyltransferase I-GENE
reporter I-GENE
constructs I-GENE
. O

_RARE_ I-GENE
variations O
in O
genes I-GENE
coding O
for O
the O
transmembrane I-GENE
FGF I-GENE
receptor I-GENE
( O
FGFR I-GENE
) O
result O
in O
isoforms I-GENE
that O
vary O
in O
the O
_RARE_ I-GENE
, O
intracellular O
juxtamembrane I-GENE
domain I-GENE
, O
and O
the O
intracellular O
kinase I-GENE
domain I-GENE
. O

If O
this O
is O
present O
, O
such O
patients O
should O
be O
closely O
monitored O
, O
and O
any O
atypical O
lesions O
_RARE_ I-GENE
. O

_RARE_ I-GENE
maximum O
_RARE_ I-GENE
scores O
between O
_RARE_ I-GENE
and O
_RARE_ I-GENE
and O
between O
_RARE_ I-GENE
and O
_RARE_ I-GENE
are O
above O
36 O
and O
61 O
, O
respectively O
, O
at O
a O
recombination O
fraction O
of O
0 O
, O
indicating O
that O
recombination O
events O
needed O
to O
_RARE_ I-GENE
the O
search O
of O
the O
gene I-GENE
are O
very O
difficult O
to O
identify O
and O
_RARE_ I-GENE
. O

A I-GENE
receptor I-GENE
- I-GENE
like I-GENE
protein I-GENE
kinase I-GENE
, O
_RARE_ I-GENE
, O
has O
been O
cloned O
from O
rice I-GENE
( O
_RARE_ I-GENE
_RARE_ I-GENE
). O

A I-GENE
sequence I-GENE
representing O
about O
50 O
% O
of O
the O
expected O
complete O
sequence I-GENE
was O
obtained O
by O
translation I-GENE
of O
the O
two O
open O
reading O
frames O
present O
on O
a O
1 I-GENE
. O
6 I-GENE
kb O
DNA I-GENE
genomic O
fragment I-GENE
. O

_RARE_ I-GENE
' O
s O
- I-GENE
like I-GENE
syndrome O
and O
effect O
of O
_RARE_ I-GENE
membrane I-GENE
_RARE_ I-GENE
support O
. O

A I-GENE
cDNA I-GENE
clone O
_RARE_ I-GENE
, O
with O
a O
1 I-GENE
. O
1 I-GENE
kb O
insert O
, O
was O
isolated O
from O
a O
NaCl O
- I-GENE
adapted O
tobacco I-GENE
cell O
cDNA I-GENE
library O
that O
encodes O
an O
apparently O
full I-GENE
- I-GENE
length I-GENE
29 O
kDa I-GENE
protein I-GENE
( O
_RARE_ I-GENE
amino O
acids O
) O
with O
a O
calculated O
_RARE_ I-GENE
of O
5 I-GENE
. O
7 O
. O

METHODS O
-- O
16 O
_RARE_ I-GENE
for O
_RARE_ I-GENE
with O
_RARE_ I-GENE
_RARE_ I-GENE
test O
including O
a O
test O
for O
small I-GENE
_RARE_ I-GENE
function O
by O
volume O
of O
_RARE_ I-GENE
gas O
( O
_RARE_ I-GENE
). O

_RARE_ I-GENE
of O
CDK I-GENE
- I-GENE
activating I-GENE
kinase I-GENE
and O
RNA I-GENE
polymerase I-GENE
II I-GENE
CTD I-GENE
kinase I-GENE
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
. O

The O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
and O
_RARE_ I-GENE
genes I-GENE
act O
upstream O
of O
adenylate I-GENE
cyclase I-GENE
, O
presumably O
encoding O
an O
adenylate I-GENE
cyclase I-GENE
activation O
pathway O
. O

These O
same O
regions O
showed O
remarkable O
homology I-GENE
to O
two O
_RARE_ I-GENE
proteins I-GENE
, O
_RARE_ I-GENE
and O
skin O
- I-GENE
1 I-GENE
, O
postulated O
to O
regulate O
embryonic O
development O
in O
Drosophila I-GENE
melanogaster I-GENE
and O
Caenorhabditis I-GENE
elegans I-GENE
, O
respectively O
. O

DNA I-GENE
sequence I-GENE
analysis O
has O
confirmed O
that O
this O
mutation I-GENE
affects O
the O
C I-GENE
- I-GENE
terminal I-GENE
region O
of O
the O
alpha I-GENE
subunit I-GENE
, O
changing O
a O
leucine I-GENE
residue O
at O
position O
_RARE_ I-GENE
to O
a O
histidine O
( O
_RARE_ I-GENE
). O

CONCLUSIONS O
: O
These O
findings O
indicate O
a O
physical O
barrier O
of O
_RARE_ I-GENE
surfactant I-GENE
which O
could O
offer O
some O
degree O
of O
protection O
against O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
reflux O
but O
one O
which O
is O
particularly O
prone O
to O
_RARE_ I-GENE
by O
bile O
. O

Differential O
screening O
of O
mitochondrial I-GENE
cDNA I-GENE
libraries O
from O
male O
- I-GENE
_RARE_ I-GENE
and O
cytoplasmic I-GENE
male O
- I-GENE
_RARE_ I-GENE
sugar I-GENE
- I-GENE
_RARE_ I-GENE
reveals O
genome O
rearrangements O
at O
_RARE_ I-GENE
and O
_RARE_ I-GENE
loci I-GENE
. O

The O
effects O
of O
social O
isolation O
on O
morphine O
- I-GENE
induced O
locomotor O
activity O
were O
compared O
in O
: O
( O
i O
) O
animals O
with O
an O
intact O
_RARE_ I-GENE
- I-GENE
pituitary I-GENE
- I-GENE
adrenal O
( O
_RARE_ I-GENE
) O
axis O
; O
( O
ii O
) O
animals O
in O
which O
stress O
- I-GENE
induced O
corticosterone O
secretion O
was O
blocked O
by O
_RARE_ I-GENE
. O

Using O
this O
reporter I-GENE
gene I-GENE
system O
, O
we O
previously O
showed O
that O
EPO I-GENE
- I-GENE
induced O
activation O
of O
the O
c I-GENE
- I-GENE
fos I-GENE
promoter I-GENE
can O
be O
detected O
rapidly O
and O
_RARE_ I-GENE
as O
an O
elevation O
of O
cellular O
luciferase I-GENE
activity O
. O

I I-GENE
_RARE_ I-GENE
that O
white O
gene I-GENE
expression O
from O
P I-GENE
[ O
en I-GENE
] O
is O
repressed O
by O
the O
formation O
of O
a O
protein I-GENE
complex I-GENE
which O
is O
initiated O
at O
the O
_RARE_ I-GENE
PS I-GENE
sites I-GENE
and O
also O
requires O
interactions O
with O
flanking O
genomic O
DNA I-GENE
. O

_RARE_ I-GENE
was O
cloned O
and O
sequenced O
and O
found O
to O
be O
essential O
. O
_RARE_ I-GENE
is O
allelic O
to O
the O
previously O
identified O
suppressor I-GENE
_RARE_ I-GENE
, O
which O
encodes O
a O
negative O
regulator I-GENE
of O
gene I-GENE
expression O
. O

_RARE_ I-GENE
curve O
correlation O
coefficients O
of O
0 O
. O
_RARE_ I-GENE
or O
greater O
were O
obtained O
during O
_RARE_ I-GENE
experiments O
and O
analysis O
of O
study O
samples O
. O

To O
_RARE_ I-GENE
if O
a O
pulse O
_RARE_ I-GENE
can O
monitor O
the O
fetus O
during O
labour O
we O
recruited O
100 O
_RARE_ I-GENE
women O
in O
normal O
_RARE_ I-GENE
labour O
. O

There O
was O
no O
difference O
in O
plasma I-GENE
concentrations O
of O
_RARE_ I-GENE
( O
_RARE_ I-GENE
4 I-GENE
) O
and O
_RARE_ I-GENE
in O
patients O
with O
normal O
blood O
pressure O
, O
mild O
_RARE_ I-GENE
and O
hypotension O
, O
whereas O
in O
severe O
_RARE_ I-GENE
, O
the O
plasma I-GENE
concentration O
of O
_RARE_ I-GENE
was O
significantly O
lower O
( O
p O
< O
0 O
. O
001 O
) O
and O
of O
_RARE_ I-GENE
significantly O
higher O
( O
p O
< O
0 O
. O
001 O
). O

A I-GENE
_RARE_ I-GENE
analysis O
of O
secondary O
variables O
showed O
that O
the O
formation O
of O
FB O
_RARE_ I-GENE
was O
primarily O
associated I-GENE
with O
the O
level O
of O
importance O
attached O
to O
the O
event O
and O
level O
of O
affective O
response O
to O
the O
_RARE_ I-GENE
. O

Deletion O
studies O
identified O
a O
distal O
response O
element I-GENE
that O
is O
responsible O
for O
the O
cytokine O
response O
and O
has O
properties O
of O
an O
inducible I-GENE
transcriptional O
enhancer I-GENE
. O

The O
_RARE_ I-GENE
gene I-GENE
is O
required O
for O
high O
- I-GENE
fidelity I-GENE
chromosome O
segregation O
in O
the O
budding I-GENE
yeast I-GENE
Saccharomyces I-GENE
cerevisiae I-GENE
. O

2 I-GENE
. O

No O
drop O
in O
oxygen O
saturation O
( O
SaO2 O
) O
or O
visual O
evidence O
of O
transient O
_RARE_ I-GENE
( O
EEG O
) O
_RARE_ I-GENE
can O
be O
found O
at O
repeat I-GENE
_RARE_ I-GENE
. O

The O
complete O
gene I-GENE
organization O
was O
obtained O
by O
_RARE_ I-GENE
the O
results O
of O
the O
sequence I-GENE
of O
these O
clones O
and O
those O
of O
the O
characterization O
of O
polymerase I-GENE
chain I-GENE
reaction O
- I-GENE
amplified O
genomic O
segments O
. O

_RARE_ I-GENE
, O
a O
regulatory I-GENE
gene I-GENE
in O
yeast I-GENE
phospholipid I-GENE
biosynthesis O
, O
affects O
nuclear I-GENE
segregation O
and O
_RARE_ I-GENE
pattern O
formation O
. O

The O
_RARE_ I-GENE
derivative O
of O
_RARE_ I-GENE
yields O
an O
intense O
ion O
fragment I-GENE
at O
m I-GENE
/ I-GENE
z O
_RARE_ I-GENE
, O
and O
the O
lower O
limit O
of O
detection O
is O
0 O
. O
_RARE_ I-GENE
ng O
/ I-GENE
ml O
for O
a O
1 I-GENE
- I-GENE
ml O
plasma I-GENE
sample O
. O

_RARE_ I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
bind O
sex I-GENE
steroids O
with O
high O
affinity O
, O
but O
some O
binding I-GENE
properties O
differ O
among O
species O
. O

Src I-GENE
homology I-GENE
( O
SH I-GENE
) O
domain I-GENE
dependent I-GENE
protein I-GENE
- I-GENE
protein I-GENE
interactions O
are O
important O
to O
tyrosine I-GENE
kinase I-GENE
receptor I-GENE
signal I-GENE
transduction O
. O

_RARE_ I-GENE
treatment O
was O
_RARE_ I-GENE
in O
order O
to O
achieve O
a O
complete O
extraction O
of O
_RARE_ I-GENE
_RARE_ I-GENE
and O
to O
avoid O
_RARE_ I-GENE
during O
extraction O
. O

Under O
resting O
conditions O
, O
activity O
levels O
of O
cardiac O
_RARE_ I-GENE
and O
sympathetic O
_RARE_ I-GENE
are O
not O
related I-GENE
across O
young O
, O
healthy O
human I-GENE
subjects O
and O
peripheral O
interaction O
is O
not O
manifest O
between O
the O
_RARE_ I-GENE
_RARE_ I-GENE
. O

Both O
_RARE_ I-GENE
and O
_RARE_ I-GENE
units O
showed O
a O
progression O
of O
_RARE_ I-GENE
fields O
from O
anterior O
to O
posterior O
body O
in O
the O
_RARE_ I-GENE
to O
_RARE_ I-GENE
direction O
along O
the O
length I-GENE
of O
_RARE_ I-GENE
. O

In O
control O
patients O
, O
baseline O
images O
presented O
Type O
I I-GENE
in O
25 O
, O
Type O
II I-GENE
in O
7 O
, O
and O
the O
Type O
III I-GENE
& O
IV I-GENE
in O
0 O
, O
and O
the O
Type O
after O
loading O
was O
the O
same O
as O
the O
Type O
at O
baseline O
. O

A I-GENE
more O
complete O
analysis O
of O
dose O
response O
, O
time O
and O
mode O
of O
Ga O
administration O
( O
_RARE_ I-GENE
or O
_RARE_ I-GENE
), O
and O
availability O
of O
Ga O
across O
the O
blood O
- I-GENE
brain O
barrier O
is O
needed O
to O
further O
evaluate O
the O
efficacy O
of O
this O
compound O
. O

The O
presence O
of O
regulatory I-GENE
sequences I-GENE
for O
the O
binding I-GENE
of O
transcription I-GENE
factors I-GENE
such O
as O
NF I-GENE
- I-GENE
kappa I-GENE
B I-GENE
and O
AP I-GENE
- I-GENE
2 I-GENE
, O
whose O
activation O
is O
associated I-GENE
with O
the O
immediate I-GENE
response O
of O
the O
cell O
to O
an O
injury O
, O
may O
be O
an O
indication O
of O
the O
important O
role O
which O
_RARE_ I-GENE
- I-GENE
1 I-GENE
may O
play O
in O
defense O
mechanisms O
against O
tissue I-GENE
injury O
. O

_RARE_ I-GENE
, O
but O
not O
saline O
, O
abolished O
_RARE_ I-GENE
and O
_RARE_ I-GENE
when O
given O
as O
intervention O
after O
this O
combined O
_RARE_ I-GENE
regimen O
. O

The O
_RARE_ I-GENE
coronary O
sinus O
difference O
in O
lactate I-GENE
turned O
negative O
, O
and O
pH O
, O
PCO2 O
and O
potassium O
differences O
increased O
in O
group O
2 I-GENE
during O
pacing O
. O

This O
was O
obtained O
with O
the O
thermal O
_RARE_ I-GENE
_RARE_ I-GENE
2 I-GENE
. O
0 O
x O
10 O
( O
10 O
) O
n O
/ I-GENE
cm2 O
. O

_RARE_ I-GENE
induced O
by O
gram O
- I-GENE
negative O
bacteria O
leads O
to O
_RARE_ I-GENE
shock I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
from O
the O
integral I-GENE
component O
of O
the O
bacterial I-GENE
wall O
-- O
lipid O
A I-GENE
. O

The O
study O
made O
to O
define O
the O
ability O
of O
lipid O
A I-GENE
monoclonal I-GENE
antibodies I-GENE
to O
correct O
hemodynamic O
disturbances O
due O
to O
_RARE_ I-GENE
in O
dog O
experiments O
showed O
the O
efficacy O
of O
the O
antibodies I-GENE
administration O
. O

A I-GENE
randomised O
, O
controlled O
trial O
was O
undertaken O
in O
40 I-GENE
patients O
with O
active O
Crohn O
' O
s O
disease O
to O
evaluate O
clinical O
and O
nutritional O
outcomes O
after O
an O
amino O
acid I-GENE
based O
diet O
containing O
3 I-GENE
% O
fat O
was O
given O
by O
a O
feeding O
tube O
compared O
with O
a O
peptide I-GENE
based O
diet O
containing O
33 O
% O
fat O
. O

This O
sequenced O
region O
of O
the O
V I-GENE
beta I-GENE
locus I-GENE
contains O
an O
average O
number O
of O
repetitive O
DNA I-GENE
elements O
( O
21 O
Alu I-GENE
, O
three O
L1 I-GENE
, O
three O
_RARE_ I-GENE
, O
and O
three O
retrovirus O
- I-GENE
related I-GENE
elements O
. O

The O
sequenced O
genomic O
region O
thus O
_RARE_ I-GENE
for O
essentially O
all O
of O
the O
_RARE_ I-GENE
known O
transcript I-GENE
( O
4 I-GENE
. O
5 I-GENE
kb O
), O
although O
the O
precise O
ends O
of O
this O
transcript I-GENE
have O
not O
been O
defined O
. O

The O
_RARE_ I-GENE
upstream O
region O
contained O
_RARE_ I-GENE
nucleotides O
within O
which O
sequences I-GENE
_RARE_ I-GENE
the O
consensus I-GENE
for O
cyclic I-GENE
AMP I-GENE
receptor I-GENE
protein I-GENE
and O
integration O
host O
factor I-GENE
binding I-GENE
sites I-GENE
were O
_RARE_ I-GENE
. O

The O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
operons I-GENE
in O
the O
_RARE_ I-GENE
synthesis O
and O
transport O
system O
are O
divergently O
transcribed O
from O
overlapping O
promoters I-GENE
, O
and O
both O
are O
inhibited O
by O
the O
Fur I-GENE
repressor I-GENE
protein I-GENE
under O
iron O
- I-GENE
_RARE_ I-GENE
conditions O
. O

Sequence O
analysis O
of O
a O
6 I-GENE
. O
3 I-GENE
- I-GENE
kbp O
genomic O
EcoRI I-GENE
- I-GENE
fragment I-GENE
of O
_RARE_ I-GENE
_RARE_ I-GENE
, O
which O
was O
recently O
identified O
by O
using O
a O
_RARE_ I-GENE
dehydrogenase I-GENE
- I-GENE
specific I-GENE
DNA I-GENE
probe O
( O
A I-GENE
. O

Using O
a O
previously O
published O
two O
- I-GENE
frequency O
( O
AC I-GENE
_RARE_ I-GENE
) O
three O
- I-GENE
electrode O
method O
, O
the O
_RARE_ I-GENE
locus I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
in O
the O
low O
- I-GENE
frequency O
region O
(< O
1000 O
Hz O
) O
has O
been O
shown O
to O
be O
very O
well O
_RARE_ I-GENE
by O
a O
_RARE_ I-GENE
line O
and O
can O
be O
described O
with O
frequency O
- I-GENE
independent O
parameters O
; O
phase O
angle O
alpha I-GENE
pi I-GENE
/ I-GENE
2 I-GENE
, O
conductance I-GENE
at O
_RARE_ I-GENE
zero O
frequency O
_RARE_ I-GENE
= O
1 I-GENE
/ I-GENE
_RARE_ I-GENE
, O
and O
ion O
relaxation O
time O
tau I-GENE
. O

_RARE_ I-GENE
measurement O
of O
activated I-GENE
partial O
thromboplastin I-GENE
time O
and O
prothrombin I-GENE
time O
with O
a O
new O
_RARE_ I-GENE
monitor O
. O

In O
addition O
, O
we O
sought O
to O
test O
the O
hypothesis O
that O
, O
when O
equal O
volumes O
are O
administered O
_RARE_ I-GENE
, O
significant O
differences O
exist O
in O
the O
potential O
to O
three O
commonly O
used O
_RARE_ I-GENE
solutions O
to O
induce O
sensory O
impairment O
. O

In O
an O
in O
vitro O
study O
, O
10 O
/ I-GENE
0 O
_RARE_ I-GENE
was O
found O
to O
require O
a O
significantly O
lower O
laser O
energy O
density I-GENE
to O
produce O
_RARE_ I-GENE
lysis O
following O
a O
single O
_RARE_ I-GENE
than O
either O
10 O
/ I-GENE
0 O
_RARE_ I-GENE
or O
10 O
/ I-GENE
0 O
_RARE_ I-GENE
. O

The O
proteins I-GENE
encoded I-GENE
downstream O
of O
_RARE_ I-GENE
are O
known O
to O
negatively O
regulate O
sigma I-GENE
54 I-GENE
activity O
. O

We O
report O
here O
that O
microinjection O
of O
an O
anti I-GENE
- I-GENE
CBP I-GENE
antiserum O
into O
fibroblasts O
can O
inhibit O
transcription I-GENE
from O
a O
cAMP I-GENE
responsive I-GENE
promoter I-GENE
. O

These O
results O
demonstrate O
that O
a O
class I-GENE
of O
proline O
- I-GENE
rich O
activator I-GENE
proteins I-GENE
and O
RNA I-GENE
polymerase I-GENE
II I-GENE
possess O
a O
common O
structural O
and O
functional O
component O
which O
can O
interact O
with O
the O
same O
target O
in O
the O
general O
transcription I-GENE
machinery O
. O

Cloning O
of O
higher O
plant O
omega I-GENE
- I-GENE
3 I-GENE
fatty I-GENE
acid I-GENE
_RARE_ I-GENE
. O

65 O
, O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
, O
1991 O
), O
a O
truncated I-GENE
form O
of O
the O
IE I-GENE
polypeptide I-GENE
lacking O
IE I-GENE
amino O
acid I-GENE
residues O
1 I-GENE
- I-GENE
_RARE_ I-GENE
( O
and O
, O
therefore O
lacks O
the O
deduced O
transcriptional O
activation O
domain I-GENE
), O
fails O
to O
transactivate O
the O
EHV I-GENE
- I-GENE
1 I-GENE
tk I-GENE
promoter I-GENE
, O
but O
retains O
the O
ability O
to O
down O
- I-GENE
regulate O
the O
EHV I-GENE
- I-GENE
1 I-GENE
IE I-GENE
promoter I-GENE
. O

However O
, O
by O
an O
_RARE_ I-GENE
- I-GENE
specific I-GENE
RNA I-GENE
_RARE_ I-GENE
assay O
, O
the O
_RARE_ I-GENE
were O
shown O
to O
possess O
the O
RNA I-GENE
- I-GENE
binding I-GENE
activity O
previously O
demonstrated O
for O
_RARE_ I-GENE
. O

CONCLUSION O
: O
Human I-GENE
preterm O
birth O
is O
associated I-GENE
with O
significantly O
lower O
progesterone I-GENE
/ I-GENE
17 O
beta I-GENE
- I-GENE
estradiol O
ratios O
than O
those O
of O
women O
with O
preterm O
_RARE_ I-GENE
delivered O
at O
term O
. O

_RARE_ I-GENE
in O
the O
treatment O
of O
_RARE_ I-GENE
during O
mechanical O
ventilation O
. O

In O
conclusion O
, O
the O
_RARE_ I-GENE
of O
_RARE_ I-GENE
and O
O O
- I-GENE
_RARE_ I-GENE
is O
markedly O
altered O
in O
renal O
disease O
; O
therefore O
dosage O
adjustment O
is O
warranted O
for O
patients O
with O
creatinine O
clearance O
values O
below O
30 O
ml O
/ I-GENE
min O
. O

The O
availability O
of O
sequence I-GENE
from O
multiple O
species O
has O
permitted O
us O
to O
determine O
that O
the O
_RARE_ I-GENE
site I-GENE
has O
close O
similarity O
to O
motifs O
that O
bind O
members O
of O
the O
NF I-GENE
- I-GENE
1 I-GENE
family I-GENE
of O
transcription I-GENE
factors I-GENE
. O

The O
incidence O
of O
HSV I-GENE
- I-GENE
2 I-GENE
positive O
subjects O
( O
HSV I-GENE
- I-GENE
2 I-GENE
/ I-GENE
HSV I-GENE
- I-GENE
1 I-GENE
antibody I-GENE
ratio O
> O
or O
= O
1 I-GENE
) O
was O
low O
in O
the O
_RARE_ I-GENE
_RARE_ I-GENE
population O
, O
compared O
to O
other O
_RARE_ I-GENE
areas O
. O

The O
mechanism O
_RARE_ I-GENE
zeta I-GENE
PKC I-GENE
regulates O
NF I-GENE
- I-GENE
kappa I-GENE
B I-GENE
most O
probably O
involves O
the O
activation O
of O
a O
putative O
I I-GENE
kappa I-GENE
B I-GENE
kinase I-GENE
of O
molecular O
mass O
approximately O
50 O
kDa I-GENE
, O
which O
phosphorylates O
and O
_RARE_ I-GENE
I I-GENE
kappa I-GENE
B I-GENE
. O

Stable O
expression O
of O
truncated I-GENE
inositol I-GENE
1 I-GENE
, O
4 I-GENE
, O
5 I-GENE
- I-GENE
_RARE_ I-GENE
receptor I-GENE
subunits I-GENE
in O
3T3 O
fibroblasts O
. O

The O
molecular O
basis O
for O
_RARE_ I-GENE
of O
_RARE_ I-GENE
to O
the O
eosinophil O
lineage O
and O
mechanisms O
by O
which O
eosinophil O
- I-GENE
specific I-GENE
genes I-GENE
are O
expressed O
and O
regulated O
during O
differentiation O
is O
unknown O
. O

We O
report O
the O
identification O
and O
characterization O
of O
_RARE_ I-GENE
4 I-GENE
( O
myosin I-GENE
from O
rat I-GENE
), O
the O
first O
mammalian I-GENE
myosin I-GENE
I I-GENE
that O
is O
not O
closely O
related I-GENE
to O
_RARE_ I-GENE
_RARE_ I-GENE
myosin I-GENE
I I-GENE
. O

M I-GENE
., O
and O
D I-GENE
. O

In O
addition O
, O
computer O
analysis O
suggests O
that O
sequences I-GENE
similar O
to O
the O
A I-GENE
stem O
element I-GENE
are O
present O
within O
the O
three O
AAV I-GENE
promoter I-GENE
regions O
. O

At O
least O
some O
of O
the O
difference O
in O
stability O
of O
the O
two O
_RARE_ I-GENE
of O
complexes I-GENE
was O
due O
to O
the O
fact O
that O
the O
dissociation O
rate O
of O
the O
A I-GENE
stem O
substrate I-GENE
from O
the O
protein I-GENE
- I-GENE
DNA I-GENE
complexes I-GENE
was O
approximately O
fourfold O
faster O
than O
that O
of O
the O
complete O
TR I-GENE
. O

_RARE_ I-GENE
of O
the O
NS3 I-GENE
'- O
_RARE_ I-GENE
_RARE_ I-GENE
was O
complex I-GENE
and O
occurred O
rapidly O
. O

However O
, O
each O
promoter I-GENE
activated I-GENE
by O
_RARE_ I-GENE
was O
synergistically O
affected O
by O
the O
addition O
of O
_RARE_ I-GENE
. O

_RARE_ I-GENE
labeling O
or O
_RARE_ I-GENE
focusing O
analysis O
of O
eIF I-GENE
- I-GENE
2 I-GENE
alpha I-GENE
from O
conditional O
casein I-GENE
kinase I-GENE
II I-GENE
mutants I-GENE
indicated O
that O
phosphorylation O
of O
eIF I-GENE
- I-GENE
2 I-GENE
alpha I-GENE
is O
abolished O
or O
_RARE_ I-GENE
forms O
of O
eIF I-GENE
- I-GENE
2 I-GENE
alpha I-GENE
are O
detected O
when O
these O
strains O
are O
grown O
at O
the O
restrictive O
growth I-GENE
conditions O
. O

Thus O
, O
_RARE_ I-GENE
is O
a O
functional O
homolog I-GENE
of O
_RARE_ I-GENE
and O
represents O
a O
new O
component O
of O
the O
yeast I-GENE
mitochondrial I-GENE
import O
machinery O
. O

The O
R2 I-GENE
region O
within O
the O
class I-GENE
I I-GENE
enhancer I-GENE
acts O
as O
a O
negative O
element I-GENE
in O
_RARE_ I-GENE
- I-GENE
transformed O
cells O
and O
exhibits O
a O
stronger O
binding I-GENE
activity O
than O
is O
observed O
in O
_RARE_ I-GENE
Ad5 I-GENE
- I-GENE
transformed O
cells O
, O
which O
are O
not O
reduced O
in O
class I-GENE
I I-GENE
expression O
. O

PURPOSE O
: O
To O
evaluate O
the O
kinetics O
of O
erythropoietin I-GENE
( O
EPO I-GENE
) O
production O
and O
address O
the O
pathogenesis O
of O
anemia I-GENE
of O
_RARE_ I-GENE
, O
we O
measured O
EPO I-GENE
levels O
in O
infants O
during O
the O
first O
year O
of O
life O
. O

The O
nerve I-GENE
growth I-GENE
factor I-GENE
beta I-GENE
gene I-GENE
( O
_RARE_ I-GENE
) O
belongs O
to O
a O
conserved O
_RARE_ I-GENE
group O
on O
human I-GENE
chromosome O
1 I-GENE
and O
mouse I-GENE
_RARE_ I-GENE
3 I-GENE
. O

Furthermore O
, O
an O
upstream O
element I-GENE
, O
collagen I-GENE
element I-GENE
I I-GENE
(- O
_RARE_ I-GENE
/- O
_RARE_ I-GENE
), O
which O
shares O
homology I-GENE
with O
the O
_RARE_ I-GENE
binding I-GENE
cis O
- I-GENE
element I-GENE
of O
the O
albumin I-GENE
promoter I-GENE
( O
9 O
of O
13 O
bp O
) O
is O
described O
. O

_RARE_ I-GENE
and O
size O
of O
silver O
- I-GENE
stained O
_RARE_ I-GENE
( O
Ag I-GENE
- I-GENE
_RARE_ I-GENE
clusters O
) O
in O
canine O
_RARE_ I-GENE
: O
correlation O
with O
histological O
features O
and O
tumour I-GENE
behaviour O
. O

We O
_RARE_ I-GENE
that O
mast I-GENE
cell O
_RARE_ I-GENE
may O
be O
involved O
in O
the O
pathogenesis O
of O
_RARE_ I-GENE
by O
altering O
fibroblast I-GENE
enzyme I-GENE
activity O
and O
/ I-GENE
or O
producing O
prolonged O
inflammatory O
reactions O
. O

Molecular O
cloning O
of O
a O
cysteine I-GENE
synthase I-GENE
cDNA I-GENE
from O
_RARE_ I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
by O
genetic O
complementation O
in O
an O
Escherichia I-GENE
coli I-GENE
Cys I-GENE
- I-GENE
_RARE_ I-GENE
. O

In O
earlier O
studies O
we O
identified O
several O
regulatory I-GENE
elements O
that O
control O
transcriptional O
activation O
and O
aerobic O
repression O
of O
one O
of O
these O
genes I-GENE
, O
_RARE_ I-GENE
. O

Although O
elevated O
serum I-GENE
levels O
of O
antibodies I-GENE
to O
the O
_RARE_ I-GENE
acetylcholine I-GENE
receptor I-GENE
( O
_RARE_ I-GENE
) O
have O
been O
reported O
in O
neuroleptic O
treated O
patients O
with O
_RARE_ I-GENE
_RARE_ I-GENE
, O
such O
antibodies I-GENE
have O
not O
been O
determined O
in O
comparable O
_RARE_ I-GENE
patients O
. O

The O
tumor I-GENE
suppressor I-GENE
and O
transcriptional O
factor I-GENE
p53 I-GENE
is O
a O
phosphorylated O
protein I-GENE
. O

This O
DNA I-GENE
containing O
promoter I-GENE
activity O
has O
been O
sequenced O
in O
its O
_RARE_ I-GENE
and O
found O
to O
contain O
multiple O
putative O
regulatory I-GENE
sites I-GENE
. O

However O
, O
Southern O
blot O
and O
_RARE_ I-GENE
analyses O
did O
not O
reveal O
any O
significant O
changes O
in O
copy O
number O
or O
gross O
rearrangements O
of O
the O
p53 I-GENE
gene I-GENE
in O
any O
of O
the O
p53 I-GENE
- I-GENE
cell O
lines O
. O

_RARE_ I-GENE
showed O
strong O
identity O
to O
_RARE_ I-GENE
and O
_RARE_ I-GENE
- I-GENE
like I-GENE
proteins I-GENE
from O
many O
other O
bacteria O
. O

The O
_RARE_ I-GENE
_RARE_ I-GENE
rate O
( O
P I-GENE
< O
0 O
. O
01 O
) O
and O
the O
effective O
maximal O
rate O
of O
mitochondrial I-GENE
ATP I-GENE
synthesis O
( O
P I-GENE
< O
0 O
. O
05 O
) O
also O
improved O
. O

An O
examination O
was O
performed O
in O
15 O
patients O
who O
had O
developed O
pronounced O
_RARE_ I-GENE
following O
gastric O
resection O
. O

However O
, O
regional O
_RARE_ I-GENE
increased O
to O
about O
the O
same O
extent O
in O
the O
_RARE_ I-GENE
( O
from O
6 I-GENE
. O
0 O
+/- O
0 O
. O
7 O
to O
12 O
. O
4 I-GENE
+/- O
0 O
. O
9 O
ml O
O2 O
. O
min O
- I-GENE
1 I-GENE
times O
100 O
g O
- I-GENE
1 I-GENE
) O
and O
the O
LAD O
region O
( O
from O
7 O
. O
0 O
+/- O
0 O
. O
6 I-GENE
to O
14 O
. O
5 I-GENE
+/- O
1 I-GENE
. O
3 I-GENE
ml O
O2 O
. O
min O
- I-GENE
1 I-GENE
times O
100 O
g O
- I-GENE
1 I-GENE
). O

IGF I-GENE
I I-GENE
and O
insulin I-GENE
receptors I-GENE
are O
homologous O
proteins I-GENE
that O
function O
in O
distinct O
physiological O
pathways O
. O

_RARE_ I-GENE
was O
combined O
with O
the O
increase O
of O
glucocorticoid I-GENE
activity O
of O
adrenal O
cortex O
, O
while O
no O
significant O
changes O
in O
thyroid I-GENE
hormones O
were O
_RARE_ I-GENE
. O

_RARE_ I-GENE
cleavage O
and O
peptide I-GENE
sequence I-GENE
analysis O
demonstrated O
that O
the O
98 O
- I-GENE
kD I-GENE
protein I-GENE
is O
identical O
to O
a O
recently O
cloned O
protein I-GENE
, O
special O
A I-GENE
- I-GENE
T I-GENE
- I-GENE
rich O
binding I-GENE
protein I-GENE
1 I-GENE
( O
_RARE_ I-GENE
), O
that O
binds O
selectively O
to O
nuclear I-GENE
matrix I-GENE
/ I-GENE
_RARE_ I-GENE
- I-GENE
associated I-GENE
regions O
of O
DNA I-GENE
( O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
). O

_RARE_ I-GENE
protein I-GENE
phosphorylation O
at O
tyrosine I-GENE
is O
responsible O
for O
the O
growth I-GENE
- I-GENE
inhibitory I-GENE
action O
of O
_RARE_ I-GENE
- I-GENE
src I-GENE
expressed O
in O
the O
yeast I-GENE
Saccharomyces I-GENE
cerevisiae I-GENE
. O

Acute O
pancreatitis O
: O
a O
_RARE_ I-GENE
disease O
. O

_RARE_ I-GENE
biosynthesis O
is O
controlled O
by O
a O
complex I-GENE
regulatory I-GENE
mechanism O
. O

The O
sequence I-GENE
upstream O
of O
the O
_RARE_ I-GENE
promoter I-GENE
contains O
two O
inverted O
repeats I-GENE
which O
define O
putative O
binding I-GENE
sites I-GENE
for O
the O
_RARE_ I-GENE
regulator I-GENE
. O

We O
have O
examined O
by O
in O
vitro O
footprinting O
a O
region O
located O
downstream O
of O
the O
human I-GENE
immunodeficiency I-GENE
virus I-GENE
, O
type I-GENE
1 I-GENE
( O
HIV I-GENE
- I-GENE
1 I-GENE
) O
promoter I-GENE
found O
to O
be O
hypersensitive I-GENE
to O
DNase I-GENE
I I-GENE
digestion O
in O
vivo O
. O

Heparin O
had O
no O
effect O
on O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
myosin I-GENE
light I-GENE
chain I-GENE
phosphatase I-GENE
activity O
, O
while O
the O
B I-GENE
subunit I-GENE
- I-GENE
containing O
forms O
were O
stimulated O
2 I-GENE
- I-GENE
3 I-GENE
- I-GENE
fold O
. O

The O
relative O
abundance O
of O
each O
alternatively O
spliced O
mRNA I-GENE
was O
determined O
by O
reverse I-GENE
transcription I-GENE
- I-GENE
polymerase I-GENE
chain I-GENE
reaction O
in O
various O
human I-GENE
tissues O
and O
cell O
lines O
. O

BACKGROUND O
AND O
DESIGN O
: O
Fifty O
- I-GENE
nine O
_RARE_ I-GENE
_RARE_ I-GENE
with O
_RARE_ I-GENE
_RARE_ I-GENE
of O
_RARE_ I-GENE
(" O
small I-GENE
dark O
_RARE_ I-GENE
_RARE_ I-GENE
that O
measured O
primarily O
1 I-GENE
to O
2 I-GENE
mm O
in O
diameter O
were O
_RARE_ I-GENE
examined O
to O
determine O
the O
histologic O
correlates O
of O
the O
dark O
_RARE_ I-GENE
. O

The O
retention O
index O
of O
_RARE_ I-GENE
SPECT O
is O
a O
useful O
indicator O
of O
metastatic O
potential O
, O
thereby O
facilitating O
the O
prediction O
of O
prognosis O
, O
and O
provides O
insight O
into O
the O
relationship O
between O
_RARE_ I-GENE
uptake O
and O
malignancy O
. O

The O
central O
globular O
domain I-GENE
is O
highly O
similar O
to O
those O
regions O
from O
other O
H1 I-GENE
molecules I-GENE
, O
and O
the O
carboxyl O
- I-GENE
terminal I-GENE
domain I-GENE
contains O
a O
repeating O
_RARE_ I-GENE
motif I-GENE
, O
variants I-GENE
of O
which O
are O
conserved O
among O
H1 I-GENE
molecules I-GENE
. O

The O
location O
and O
_RARE_ I-GENE
length I-GENE
of O
the O
intron O
are O
conserved O
in O
both O
the O
tomato I-GENE
and O
Arabidopsis I-GENE
genes I-GENE
, O
with O
the O
intron O
_RARE_ I-GENE
the O
' O
_RARE_ I-GENE
' O
region O
( O
encoded I-GENE
by O
exon O
1 I-GENE
) O
from O
the O
central O
globular O
domain I-GENE
( O
exon O
2 I-GENE
). O

The O
topology O
and O
chain I-GENE
folding O
of O
the O
beta I-GENE
subunits I-GENE
in O
the O
_RARE_ I-GENE
beta I-GENE
60 O
capsid I-GENE
are O
similar O
to O
the O
native O
alpha I-GENE
3 I-GENE
beta I-GENE
60 O
enzyme I-GENE
. O

A I-GENE
single O
_RARE_ I-GENE
was O
present O
in O
69 O
. O
4 I-GENE
%, O
two O
in O
16 O
%, O
three O
in O
6 I-GENE
. O
4 I-GENE
%, O
four O
in O
3 I-GENE
. O
5 I-GENE
%, O
five O
to O
nine O
in O
4 I-GENE
. O
2 I-GENE
%, O
and O
0 O
. O
5 I-GENE
% O
had O
ten O
or O
more O
. O

A I-GENE
constitutive O
mutant I-GENE
form O
with O
a O
single O
substitution O
( O
_RARE_ I-GENE
) O
in O
the O
amino O
- I-GENE
terminal I-GENE
( O
response O
regulator I-GENE
) O
region O
was O
used O
. O

_RARE_ I-GENE
of O
the O
four O
operon I-GENE
control O
regions O
studied O
indicate O
that O
the O
_RARE_ I-GENE
_RARE_ I-GENE
are O
arranged O
with O
diverse O
_RARE_ I-GENE
and O
_RARE_ I-GENE
. O

Direct I-GENE
binding I-GENE
and O
competition O
assays O
using O
30 O
- I-GENE
mer I-GENE
oligonucleotide I-GENE
probes O
representing O
the O
individual O
CBF1 I-GENE
binding I-GENE
sites I-GENE
indicated O
that O
CBF1 I-GENE
bound O
less O
efficiently O
to O
the O
CD23 I-GENE
promoter I-GENE
and O
the O
EBV I-GENE
LMP I-GENE
- I-GENE
1 I-GENE
promoter I-GENE
sites I-GENE
than O
to O
the O
Cp I-GENE
site I-GENE
. O

We O
have O
found O
a O
satisfactory O
reproducibility O
in O
vitro O
( O
T1 O
: O
1 I-GENE
. O
9 O
%; O
T2 I-GENE
: O
6 I-GENE
. O
2 I-GENE
%), O
while O
the O
reproducibility O
was O
less O
satisfactory O
in O
vivo O
( O
T1 O
: O
16 O
. O
4 I-GENE
%; O
T2 I-GENE
: O
13 O
. O
4 I-GENE
%). O

The O
two O
_RARE_ I-GENE
proteins I-GENE
that O
are O
produced O
as O
a O
result O
of O
independent O
translation I-GENE
initiation I-GENE
at O
two O
different O
start O
codons O
within O
the O
same O
open O
reading O
frame O
were O
overexpressed O
in O
Escherichia I-GENE
coli I-GENE
and O
partially O
purified O
. O

To O
_RARE_ I-GENE
further O
_RARE_ I-GENE
into O
the O
molecular O
mechanisms O
that O
control O
tal I-GENE
- I-GENE
1 I-GENE
expression O
, O
we O
have O
isolated O
5 I-GENE
' O
sequences I-GENE
of O
the O
murine I-GENE
gene I-GENE
and O
compared O
them O
to O
their O
human I-GENE
counterparts O
. O

CONCLUSION O
: O
_RARE_ I-GENE
angiography O
has O
a O
possible O
role O
in O
the O
detection O
of O
small I-GENE
nodules O
in O
patients O
with O
CRF I-GENE
. O

Each O
expressed O
domain I-GENE
, O
as O
well O
as O
_RARE_ I-GENE
- I-GENE
33 O
itself O
, O
possesses O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
cis O
- I-GENE
trans O
isomerase I-GENE
activity O
, O
though O
with O
much O
lower O
specific I-GENE
activities O
than O
_RARE_ I-GENE
- I-GENE
12 O
. O

The O
first O
85 O
nt O
upstream O
of O
the O
transcription I-GENE
initiation I-GENE
site I-GENE
of O
the O
mouse I-GENE
_RARE_ I-GENE
gene I-GENE
, O
which O
contain O
an O
E I-GENE
box I-GENE
( O
E1 I-GENE
), O
the O
binding I-GENE
site I-GENE
of O
the O
helix I-GENE
- I-GENE
loop I-GENE
- I-GENE
helix I-GENE
myogenic I-GENE
regulators O
, O
are O
sufficient O
to O
confer O
low O
level O
muscle O
- I-GENE
specific I-GENE
expression O
. O

The O
_RARE_ I-GENE
gene I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
nt O
that O
are O
predicted O
to O
encode O
an O
88 O
- I-GENE
amino O
- I-GENE
acid I-GENE
( O
aa O
) O
protein I-GENE
. O

We O
find O
that O
beta I-GENE
II I-GENE
PKC I-GENE
phosphorylates O
nuclear I-GENE
envelope I-GENE
_RARE_ I-GENE
B I-GENE
at O
10 O
- I-GENE
20 O
times O
the O
rate O
of O
alpha I-GENE
PKC I-GENE
, O
whereas O
both O
kinases I-GENE
phosphorylate O
soluble I-GENE
_RARE_ I-GENE
B I-GENE
at O
similar O
rates O
. O

Regulation O
of O
parathyroid I-GENE
hormone I-GENE
- I-GENE
related I-GENE
protein I-GENE
( O
_RARE_ I-GENE
) O
gene I-GENE
expression O
. O

These O
results O
demonstrate O
that O
a O
diverse O
set O
of O
carboxyl O
- I-GENE
terminal I-GENE
sequence I-GENE
motifs O
and O
posttranslational O
modifications O
lead O
to O
functional O
Ras I-GENE
proteins I-GENE
in O
yeast I-GENE
. O

We O
conclude O
that O
c I-GENE
- I-GENE
Abl I-GENE
activates O
c I-GENE
- I-GENE
myc I-GENE
transcription I-GENE
indirectly O
with O
no O
requirement O
for O
DNA I-GENE
binding I-GENE
by O
c I-GENE
- I-GENE
Abl I-GENE
. O

_RARE_ I-GENE
- I-GENE
latency O
: O
_RARE_ I-GENE
units O
responded O
to O
_RARE_ I-GENE
with O
little O
_RARE_ I-GENE
and O
long O
latency O
( O
4 I-GENE
- I-GENE
11 O
ms O
). O

The O
highly O
conserved O
_RARE_ I-GENE
heptad I-GENE
, O
which O
is O
involved O
in O
heterodimerization O
, O
appears O
to O
participate O
in O
the O
receptor I-GENE
- I-GENE
inhibitor I-GENE
interaction O
, O
suggesting O
that O
the O
inhibitor I-GENE
is O
a O
related I-GENE
member O
of O
the O
receptor I-GENE
gene I-GENE
family I-GENE
. O

Here O
we O
show O
that O
for O
expression O
of O
snRNA I-GENE
genes I-GENE
in O
maize I-GENE
, O
a O
_RARE_ I-GENE
plant O
, O
the O
_RARE_ I-GENE
and O
TATA I-GENE
elements O
are O
essential O
, O
but O
not O
sufficient O
, O
for O
transcription I-GENE
. O

_RARE_ I-GENE
DNA I-GENE
rearrangement O
occurs O
during O
the O
development O
of O
the O
somatic O
_RARE_ I-GENE
from O
the O
germ I-GENE
line O
_RARE_ I-GENE
in O
_RARE_ I-GENE
_RARE_ I-GENE
. O

An O
in O
vitro O
binding I-GENE
site I-GENE
selection O
procedure O
was O
used O
to O
determine O
DNA I-GENE
sequences I-GENE
preferentially O
bound O
by O
wild I-GENE
- I-GENE
type I-GENE
_RARE_ I-GENE
and O
chimeric I-GENE
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
proteins I-GENE
isolated O
from O
various O
t I-GENE
( O
17 O
; O
19 O
)- I-GENE
bearing O
leukemias O
. O

The O
Oct I-GENE
- I-GENE
2 I-GENE
glutamine I-GENE
- I-GENE
rich O
and O
proline O
- I-GENE
rich O
activation O
domains I-GENE
can O
_RARE_ I-GENE
with O
each O
other O
or O
_RARE_ I-GENE
of O
themselves O
to O
activate O
transcription I-GENE
. O

Binding O
of O
U2 I-GENE
small I-GENE
nuclear I-GENE
ribonucleoprotein I-GENE
( O
snRNP I-GENE
) O
to O
the O
pre I-GENE
- I-GENE
mRNA I-GENE
is O
an O
early I-GENE
and O
important O
step O
in O
spliceosome O
assembly O
. O

Taken O
together O
, O
our O
data O
suggest O
that O
_RARE_ I-GENE
plays O
an O
essential O
role O
in O
chromosome O
segregation O
. O

_RARE_ I-GENE
, O
_RARE_ I-GENE
. O

Our O
results O
indicate O
that O
the O
KRAB I-GENE
domain I-GENE
present O
in O
the O
non O
- I-GENE
finger I-GENE
region O
of O
many O
_RARE_ I-GENE
genes I-GENE
_RARE_ I-GENE
transcription I-GENE
possibly O
due O
to O
specific I-GENE
protein I-GENE
- I-GENE
protein I-GENE
interactions O
between O
the O
KRAB I-GENE
- I-GENE
A I-GENE
domain I-GENE
and O
components O
of O
the O
proximal I-GENE
transcriptional O
apparatus O
. O

_RARE_ I-GENE
_RARE_ I-GENE
and O
cardiovascular O
reactivity O
. O

The O
diagnostic O
significance O
of O
creatine I-GENE
_RARE_ I-GENE
antibodies I-GENE
in O
the O
cardiac O
muscle O
in O
non O
- I-GENE
_RARE_ I-GENE
myocardial O
diseases O

According O
to O
the O
results O
of O
assays O
obtained O
with O
the O
use O
of O
assay O
systems O
_RARE_ I-GENE
ELISA O
and O
_RARE_ I-GENE
HCV I-GENE
EIA I-GENE
( O
_RARE_ I-GENE
), O
the O
detection O
rate O
of O
anti I-GENE
- I-GENE
HCV I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
3 I-GENE
among O
primary O
blood O
donors O
in O
_RARE_ I-GENE
was O
1 I-GENE
. O
37 O
% O
and O
was O
not O
different O
from O
that O
among O
HBsAg I-GENE
carriers O
( O
1 I-GENE
. O
8 O
%) O
and O
among O
donors O
with O
anti I-GENE
- I-GENE
HCV I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
3 I-GENE
in O
the O
blood O
( O
1 I-GENE
. O
6 I-GENE
%) O
( O
p O
< O
0 O
. O
01 O
). O

We O
examined O
the O
hypothesis O
that O
the O
coronary O
_RARE_ I-GENE
responses O
to O
_RARE_ I-GENE
( O
_RARE_ I-GENE
), O
_RARE_ I-GENE
( O
_RARE_ I-GENE
), O
and O
sodium O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
are O
mediated O
through O
_RARE_ I-GENE
effects O
on O
the O
resting O
nitric I-GENE
oxide I-GENE
( O
NO O
)- I-GENE
dependent I-GENE
vasodilator O
tone O
that O
_RARE_ I-GENE
adrenergic I-GENE
_RARE_ I-GENE
activity O
in O
the O
intact O
dog O
. O

Significant O
alterations O
in O
_RARE_ I-GENE
results O
and O
serum I-GENE
CRP I-GENE
concentration O
, O
compared O
with O
baseline O
values O
, O
were O
lacking O
in O
dogs O
of O
the O
control O
group O
. O

These O
alternative O
splice O
variants I-GENE
were O
detected O
in O
RNA I-GENE
isolated O
from O
several O
sources O
, O
including O
primary O
_RARE_ I-GENE
tissue I-GENE
and O
an O
established O
line O
of O
_RARE_ I-GENE
cells O
( O
_RARE_ I-GENE
). O

_RARE_ I-GENE
- I-GENE
en I-GENE
- I-GENE
Y I-GENE
_RARE_ I-GENE
severely O
_RARE_ I-GENE
emptying O
of O
the O
gallbladder O
. O

_RARE_ I-GENE
- I-GENE
coil O
experiments O
on O
_RARE_ I-GENE
and O
on O
human I-GENE
calf I-GENE
muscles O
in O
vivo O
are O
presented O
. O

Large I-GENE
_RARE_ I-GENE
variation O
in O
peak O
_RARE_ I-GENE
plasma I-GENE
levels O
( O
91 O
- I-GENE
_RARE_ I-GENE
ng O
/ I-GENE
ml O
) O
was O
seen O
, O
with O
the O
plasma I-GENE
half O
- I-GENE
life O
( O
t1 O
/ I-GENE
2 I-GENE
alpha I-GENE
) O
being O
approximately O
57 O
min O
in O
patients O
given O
135 O
- I-GENE
180 O
mg O
/ I-GENE
m2 O
_RARE_ I-GENE
. O

The O
maximal O
effect O
was O
seen O
at O
100 O
ng O
/ I-GENE
ml O
EGF I-GENE
, O
with O
a O
time O
_RARE_ I-GENE
of O
about O
5 I-GENE
h O
. O

_RARE_ I-GENE
encodes O
an O
essential O
component O
of O
the O
yeast I-GENE
spindle O
pole O
body O
( O
SPB O
) O
that O
is O
required O
for O
_RARE_ I-GENE
and O
SPB O
duplication O
. O

_RARE_ I-GENE
is O
required O
for O
SPB O
duplication O
and O
encodes O
a O
calmodulin I-GENE
- I-GENE
like I-GENE
protein I-GENE
that O
is O
most O
closely O
related I-GENE
to O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
, O
a O
protein I-GENE
associated I-GENE
with O
the O
_RARE_ I-GENE
basal O
body O
. O

During O
transcript I-GENE
elongation I-GENE
, O
the O
sizes O
of O
the O
DNA I-GENE
footprint O
and O
the O
single O
- I-GENE
stranded I-GENE
transcription I-GENE
_RARE_ I-GENE
vary O
markedly O
among O
transcription I-GENE
complexes I-GENE
_RARE_ I-GENE
at O
different O
template O
positions O
. O

The O
newly O
_RARE_ I-GENE
_RARE_ I-GENE
syndrome O
. O

All O
our O
patients O
had O
polyps O
, O
23 O
( O
54 I-GENE
%) O
had O
asthma O
, O
12 O
( O
27 O
%) O
had O
aspirin I-GENE
sensitivity O
, O
20 O
( O
65 O
%) O
had O
_RARE_ I-GENE
, O
and O
9 O
( O
69 O
%) O
had O
increased O
total O
IgE I-GENE
levels O
. O

Ras I-GENE
- I-GENE
and O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
responsive I-GENE
protein I-GENE
kinases I-GENE
that O
phosphorylate O
c I-GENE
- I-GENE
Jun I-GENE
on O
serine I-GENE
residues O
at O
positions O
63 O
and O
73 O
and O
stimulate O
its O
transcriptional O
activity O
have O
been O
identified O
. O

A I-GENE
short O
sequence I-GENE
surrounding O
the O
major I-GENE
JNK I-GENE
phosphorylation O
site I-GENE
of O
c I-GENE
- I-GENE
Jun I-GENE
is O
conserved O
in O
c I-GENE
- I-GENE
Fos I-GENE
and O
is O
part O
of O
its O
activation O
domain I-GENE
, O
suggesting O
that O
c I-GENE
- I-GENE
Fos I-GENE
may O
be O
similarly O
regulated O
. O

c I-GENE
- I-GENE
Fos I-GENE
transcriptional O
activity O
stimulated O
by O
H I-GENE
- I-GENE
Ras I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
distinct O
from O
JNK I-GENE
and O
ERK I-GENE
. O

A I-GENE
new O
generation O
of O
information O
_RARE_ I-GENE
tools O
for O
_RARE_ I-GENE
: O
the O
example O
of O
the O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
features O
of O
this O
model O
are O
_RARE_ I-GENE
of O
the O
DNA I-GENE
double O
helix I-GENE
and O
contact O
of O
operator I-GENE
sites I-GENE
with O
repressor I-GENE
domains I-GENE
bearing O
sequence I-GENE
homologies O
with O
the O
helix I-GENE
- I-GENE
turn I-GENE
- I-GENE
helix I-GENE
( O
_RARE_ I-GENE
) O
motifs O
of O
other O
DNA I-GENE
- I-GENE
binding I-GENE
proteins I-GENE
. O

The O
partial O
ORF I-GENE
was O
found O
to O
be O
identical O
to O
the O
C I-GENE
terminus O
of O
_RARE_ I-GENE
. O

The O
partial O
ORF I-GENE
was O
found O
to O
be O
identical O
to O
the O
C I-GENE
terminus O
of O
_RARE_ I-GENE
. O

The O
binding I-GENE
of O
transcription I-GENE
factor I-GENE
AP I-GENE
- I-GENE
1 I-GENE
and O
vitamin O
D I-GENE
receptor I-GENE
( O
VDR I-GENE
) O
to O
the O
composite O
AP I-GENE
- I-GENE
1 I-GENE
plus O
vitamin O
- I-GENE
D I-GENE
- I-GENE
responsive I-GENE
promoter I-GENE
region O
( O
AP I-GENE
- I-GENE
1 I-GENE
+ I-GENE
VDRE I-GENE
) O
of O
the O
human I-GENE
_RARE_ I-GENE
gene I-GENE
was O
characterized O
in O
_RARE_ I-GENE
- I-GENE
producing O
( O
_RARE_ I-GENE
- I-GENE
63 O
) O
and O
non O
- I-GENE
producing O
( O
U2 I-GENE
- I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
- I-GENE
2 I-GENE
) O
human I-GENE
osteosarcoma O
cell O
lines O
. O

_RARE_ I-GENE
detection O
of O
this O
mutation I-GENE
is O
achieved O
by O
restriction I-GENE
digestion O
of O
PCR O
- I-GENE
amplified O
genomic O
DNA I-GENE
; O
a O
_RARE_ I-GENE
primer O
combined O
with O
the O
point O
mutation I-GENE
_RARE_ I-GENE
a O
_RARE_ I-GENE
restriction I-GENE
site I-GENE
. O

Wild I-GENE
type I-GENE
and O
mutant I-GENE
Epo I-GENE
cDNAs I-GENE
were O
transiently O
expressed O
at O
high O
levels O
in O
_RARE_ I-GENE
and O
_RARE_ I-GENE
cells O
. O

OBJECTIVE O
-- O
To O
assess O
the O
risk O
of O
hepatitis I-GENE
A I-GENE
in O
_RARE_ I-GENE
_RARE_ I-GENE
and O
to O
_RARE_ I-GENE
_RARE_ I-GENE
measures O
. O

The O
bactericidal O
effect O
of O
_RARE_ I-GENE
against O
_RARE_ I-GENE
cells O
was O
found O
to O
be O
considerably O
enhanced O
by O
increasing O
the O
concentrations O
of O
the O
_RARE_ I-GENE
. O

Expression O
of O
_RARE_ I-GENE
cDNA I-GENE
in O
S I-GENE
. O
pombe I-GENE
suppresses O
the O
_RARE_ I-GENE
mutation I-GENE
. O

Use O
of O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
for O
anesthesia O
in O
minor O
surgery O

2 I-GENE
. O

The O
immune I-GENE
response O
of O
past O
- I-GENE
infection O
of O
cytomegalovirus I-GENE
in O
the O
patients O
of O
_RARE_ I-GENE
is O
rather O
remarkable O
. O

_RARE_ I-GENE
effect O
on O
deep O
receptors I-GENE
was O
not O
limited O
to O
one O
point O
but O
within O
a O
certain O
area O
, O
namely O
distant O
effect O
existed O
. O

_RARE_ I-GENE
NK I-GENE
activity O
correlates O
with O
active O
disease O
in O
HIV I-GENE
- I-GENE
patients O
with O
multidrug I-GENE
- I-GENE
resistant O
pulmonary O
tuberculosis O
. O

_RARE_ I-GENE
history O
and O
_RARE_ I-GENE
oxygen O
saturation O
( O
SaO2 O
) O
was O
recorded O
in O
all O
of O
them O
. O

( O
LH I-GENE
P I-GENE
< O
0 O
. O
05 O
, O
LH I-GENE
/ I-GENE
FSH I-GENE
P I-GENE
< O
0 O
. O
01 O
). O

The O
relative O
R I-GENE
- I-GENE
and O
L I-GENE
- I-GENE
brain O
weights O
were O
found O
to O
be O
inversely O
related I-GENE
to O
the O
relative O
R I-GENE
- I-GENE
L I-GENE
brain O
weight O
only O
in O
the O
RH O
female O
cats O
with O
R I-GENE
- I-GENE
L I-GENE
brain O
weight O
smaller O
than O
zero O
( O
testosterone O
in O
males O
, O
estrogen I-GENE
in O
females O
). O

This O
mode O
of O
ternary O
complex I-GENE
formation O
is O
in O
contrast O
to O
the O
one O
seen O
in O
the O
promoter I-GENE
of O
the O
c I-GENE
- I-GENE
fos I-GENE
protooncogene I-GENE
, O
where O
formation O
of O
the O
ternary O
complex I-GENE
is O
dependent I-GENE
on O
the O
prior O
assembly O
of O
the O
serum I-GENE
response O
factor I-GENE
- I-GENE
DNA I-GENE
_RARE_ I-GENE
complex I-GENE
. O

The O
LTR I-GENE
- I-GENE
binding I-GENE
activities O
of O
_RARE_ I-GENE
, O
_RARE_ I-GENE
/ I-GENE
EBP I-GENE
, O
and O
B I-GENE
- I-GENE
cell O
nuclear I-GENE
extract O
protein I-GENE
were O
compared O
and O
mapped O
by O
gel O
shift O
, O
DNase I-GENE
I I-GENE
footprinting O
, O
and O
methylation O
interference O
assays O
. O

These O
results O
suggest O
that O
leader O
- I-GENE
mRNA I-GENE
fusion I-GENE
in O
coronavirus O
transcription I-GENE
does O
not O
require O
direct O
RNA I-GENE
- I-GENE
RNA I-GENE
interaction O
between O
complementary O
sequences I-GENE
. O

These O
results O
suggest O
that O
leader O
- I-GENE
mRNA I-GENE
fusion I-GENE
in O
coronavirus O
transcription I-GENE
does O
not O
require O
direct O
RNA I-GENE
- I-GENE
RNA I-GENE
interaction O
between O
complementary O
sequences I-GENE
. O

_RARE_ I-GENE
virus I-GENE
- I-GENE
expressed O
, O
purified O
full I-GENE
- I-GENE
length I-GENE
HPV I-GENE
- I-GENE
16 O
and O
BPV I-GENE
- I-GENE
1 I-GENE
E2 I-GENE
proteins I-GENE
bound O
a O
consensus I-GENE
E2 I-GENE
site I-GENE
with O
high O
specific I-GENE
affinities O
( O
_RARE_ I-GENE
= O
approximately O
10 O
(- O
9 O
) O
M I-GENE
) O
and O
stimulated O
in O
vitro O
transcription I-GENE
up O
to O
six O
- I-GENE
to O
_RARE_ I-GENE
. O

This O
alternatively O
spliced O
transcript I-GENE
contained O
an O
open O
reading O
frame O
extending O
from O
the O
upstream O
J O
alpha I-GENE
11 O
- I-GENE
2 I-GENE
region O
to O
82 O
nucleotides O
downstream O
of O
the O
beginning O
of O
the O
TCR I-GENE
C I-GENE
alpha I-GENE
region O
, O
and O
potentially O
encoded I-GENE
a O
36 O
amino O
acid I-GENE
polypeptide I-GENE
. O

In O
HeLa O
x O
fibroblast I-GENE
cell O
hybrids O
its O
expression O
correlates O
with O
_RARE_ I-GENE
. O

_RARE_ I-GENE
characteristics O
and O
risk O
factor I-GENE
data O
for O
76 I-GENE
, O
_RARE_ I-GENE
_RARE_ I-GENE
were O
studied O
to O
characterize O
the O
distribution O
of O
infection O
with O
human I-GENE
immunodeficiency I-GENE
virus I-GENE
( O
HIV I-GENE
) O
and O
the O
use O
of O
_RARE_ I-GENE
and O
testing O
_RARE_ I-GENE
in O
_RARE_ I-GENE
, O
_RARE_ I-GENE
. O

Results O
indicate O
that O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
differs O
from O
both O
human I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
in O
relative O
distances O
( O
measured O
in O
three O
dimensions O
) O
between O
_RARE_ I-GENE
_RARE_ I-GENE
termini O
. O

We O
describe O
49 O
cases O
with O
_RARE_ I-GENE
tumor I-GENE
< O
1 I-GENE
cm O
. O

Comparison O
with O
the O
bovine I-GENE
gene I-GENE
showed O
that O
the O
5 I-GENE
'- O
flanking O
region O
of O
the O
_RARE_ I-GENE
gene I-GENE
has O
an O
_RARE_ I-GENE
guanine I-GENE
- I-GENE
cytosine O
( O
GC I-GENE
) O
rich O
region O
, O
including O
several O
binding I-GENE
motifs O
of O
transcriptional O
factors I-GENE
, O
such O
as O
Sp1 I-GENE
, O
AP I-GENE
- I-GENE
2 I-GENE
, O
and O
_RARE_ I-GENE
. O

Structure O
, O
promoter I-GENE
analysis O
and O
chromosomal I-GENE
assignment O
of O
the O
human I-GENE
_RARE_ I-GENE
gene I-GENE
. O

The O
_RARE_ I-GENE
gene I-GENE
was O
transcribed O
throughout O
the O
_RARE_ I-GENE
life O
cycle O
with O
peaks O
in O
the O
1 I-GENE
. O
6 I-GENE
- I-GENE
kb O
mRNA I-GENE
levels O
during O
pre I-GENE
- I-GENE
cleavage O
, O
cleavage O
, O
and O
post O
- I-GENE
inversion O
. O

Thus O
, O
in O
stress O
- I-GENE
induced O
_RARE_ I-GENE
disease O
as O
well O
as O
in O
ischemic O
heart O
disease O
, O
the O
main O
_RARE_ I-GENE
links O
are O
outside O
the O
heart O
, O
but O
they O
differ O
from O
those O
observed O
in O
ischemia O
. O

Here O
, O
we O
present O
genetic O
evidence O
in O
Saccharomyces I-GENE
cerevisiae I-GENE
for O
a O
functional O
interaction O
between O
the O
_RARE_ I-GENE
protein I-GENE
_RARE_ I-GENE
, O
and O
the O
U6 I-GENE
and O
U2 I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
. O

The O
consensus I-GENE
gene I-GENE
order O
deduced O
by O
_RARE_ I-GENE
data O
from O
both O
_RARE_ I-GENE
is O
_RARE_ I-GENE
-( O
_RARE_ I-GENE
, O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
)- I-GENE
_RARE_ I-GENE
- I-GENE
Ab I-GENE
l O
-( O
_RARE_ I-GENE
, O
_RARE_ I-GENE
)- I-GENE
( O
_RARE_ I-GENE
, O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
. O
2 I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
)- I-GENE
_RARE_ I-GENE
. O

The O
high O
level O
of O
transformation O
- I-GENE
associated I-GENE
deletions O
in O
the O
human I-GENE
YACs O
was O
reduced O
over O
10 O
- I-GENE
fold O
when O
the O
host O
was O
a O
recombination O
- I-GENE
deficient O
strain O
deleted O
for O
the O
_RARE_ I-GENE
gene I-GENE
. O

In O
addition O
, O
the O
_RARE_ I-GENE
region O
surrounding O
the O
_RARE_ I-GENE
locus I-GENE
was O
mapped O
. O

These O
mutants I-GENE
had O
deletions O
of O
the O
extreme O
amino O
- I-GENE
terminal I-GENE
residues O
as O
far O
as O
amino O
acid I-GENE
residue O
30 O
. O

_RARE_ I-GENE
OUTCOME O
_RARE_ I-GENE
-- O
Double O
- I-GENE
blind O
caffeine O
- I-GENE
withdrawal O
evaluation O
. O

Elimination O
of O
natural O
antibodies I-GENE
in O
_RARE_ I-GENE
_RARE_ I-GENE

An O
8 O
- I-GENE
bp O
sequence I-GENE
( O
_RARE_ I-GENE
) O
within O
the O
protected O
region O
shares O
significant O
homology I-GENE
with O
promoter I-GENE
sequences I-GENE
required O
for O
ethylene O
responsiveness O
from O
the O
tomato I-GENE
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
gene I-GENE
. O

We O
present O
evidence O
that O
DNA I-GENE
polymerase I-GENE
delta I-GENE
of O
Saccharomyces I-GENE
cerevisiae I-GENE
, O
an O
enzyme I-GENE
that O
is O
essential O
for O
viability O
and O
chromosomal I-GENE
replication O
, O
is O
also O
required O
for O
base O
excision O
repair I-GENE
of O
exogenous O
DNA I-GENE
methylation O
damage O
. O

We O
have O
identified O
two O
_RARE_ I-GENE
' O
s O
_RARE_ I-GENE
_RARE_ I-GENE
( O
MDV I-GENE
) O
genes I-GENE
within O
the O
EcoRI I-GENE
- I-GENE
B I-GENE
fragment I-GENE
of O
MDV I-GENE
- I-GENE
GA I-GENE
genomic O
DNA I-GENE
. O

_RARE_ I-GENE
virus I-GENE
contains O
two O
copies O
of O
an O
early I-GENE
gene I-GENE
encoding O
a O
soluble I-GENE
secreted O
form O
of O
the O
type I-GENE
II I-GENE
TNF I-GENE
receptor I-GENE
. O

To O
determine O
whether O
_RARE_ I-GENE
could O
activate O
the O
_RARE_ I-GENE
promoter I-GENE
in O
the O
absence O
of O
IE1 I-GENE
, O
the O
_RARE_ I-GENE
open O
reading O
frame O
was O
cloned O
under O
the O
control O
of O
the O
_RARE_ I-GENE
promoter I-GENE
. O

_RARE_ I-GENE
of O
each O
_RARE_ I-GENE
- I-GENE
1 I-GENE
motif I-GENE
in O
the O
_RARE_ I-GENE
promoter I-GENE
gave O
substantially O
lowered O
levels O
of O
chloramphenicol I-GENE
acetyltransferase I-GENE
expression O
, O
whereas O
mutagenesis O
of O
both O
_RARE_ I-GENE
- I-GENE
1 I-GENE
motifs O
resulted O
in O
the O
almost O
complete O
loss O
of O
expression O
. O

DNase I-GENE
I I-GENE
footprinting O
analysis O
indicated O
that O
_RARE_ I-GENE
binds O
to O
the O
24 O
- I-GENE
bp O
DRE I-GENE
region O
of O
the O
DNA I-GENE
polymerase I-GENE
alpha I-GENE
gene I-GENE
in O
which O
8 O
- I-GENE
bp O
palindromic O
sequences I-GENE
are O
centered O
. O

_RARE_ I-GENE
8 O
- I-GENE
base O
pair O
sequence I-GENE
( O
Drosophila I-GENE
DNA I-GENE
replication O
- I-GENE
related I-GENE
element I-GENE
) O
and O
specific I-GENE
binding I-GENE
factor I-GENE
involved O
in O
the O
expression O
of O
Drosophila I-GENE
genes I-GENE
for O
DNA I-GENE
polymerase I-GENE
alpha I-GENE
and O
proliferating I-GENE
cell O
nuclear I-GENE
antigen I-GENE
. O

In O
addition O
, O
a O
microsatellite I-GENE
repeat I-GENE
polymorphism O
with O
a O
heterozygosity O
of O
71 O
% O
at O
the O
RET I-GENE
locus I-GENE
and O
a O
restriction I-GENE
fragment I-GENE
length I-GENE
polymorphism O
with O
a O
heterozygosity O
of O
42 O
% O
detected O
by O
a O
lambda I-GENE
clone O
from O
the O
_RARE_ I-GENE
locus I-GENE
have O
been O
developed O
for O
high O
- I-GENE
resolution O
genetic O
linkage O
mapping O
and O
predictive O
diagnostic O
testing O
. O

However O
, O
_RARE_ I-GENE
can O
be O
expressed O
efficiently O
from O
an O
internal O
promoter I-GENE
which O
appears O
to O
_RARE_ I-GENE
within O
the O
3 I-GENE
' O
portion O
of O
_RARE_ I-GENE
. O

Within O
the O
span O
of O
_RARE_ I-GENE
region O
encoding O
the O
three O
stem O
- I-GENE
loop I-GENE
structures O
of O
mRNA I-GENE
secondary O
configuration O
, O
hot O
spots O
of O
base O
- I-GENE
residue O
divergence O
were O
localized O
to O
_RARE_ I-GENE
- I-GENE
out O
regions O
. O

Most O
, O
however O
, O
would O
_RARE_ I-GENE
the O
_RARE_ I-GENE
the O
full I-GENE
_RARE_ I-GENE
about O
both O
diagnosis O
and O
prognosis O
. O

Previous O
studies O
showed O
that O
mutations O
in O
the O
_RARE_ I-GENE
protein I-GENE
led O
to O
the O
slow O
release O
of O
aberrant O
, O
multi I-GENE
- I-GENE
_RARE_ I-GENE
infectious O
virions O
. O

_RARE_ I-GENE
of O
calcium O
and O
vitamin O
D3 I-GENE
in O
patients O
with O
acute O
_RARE_ I-GENE
_RARE_ I-GENE
: O
a O
study O
of O
41 O
patients O
with O
_RARE_ I-GENE
_RARE_ I-GENE
. O

Furthermore O
, O
this O
study O
demonstrates O
that O
reduced O
_RARE_ I-GENE
with O
_RARE_ I-GENE
_RARE_ I-GENE
uniform O
local O
contraction O
as O
estimated O
by O
the O
increased O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
ratio O
, O
a O
transition O
that O
could O
improve O
contraction O
efficacy O
. O

Effects O
of O
moderate O
hypercapnia O
on O
hypothermia O
induced O
by O
cold O
He O
- I-GENE
O2 O
in O
rats O
. O

The O
_RARE_ I-GENE
patterns O
of O
the O
isolates O
from O
six O
of O
these O
patients O
remained O
essentially O
unchanged O
( O
two O
strains O
showed O
one O
additional O
band O
) O
despite O
the O
development O
of O
drug O
resistance O
. O

We O
_RARE_ I-GENE
that O
ovarian O
stimulation O
is O
done O
only O
if O
there O
is O
a O
_RARE_ I-GENE
indication O
after O
proper O
assessment O
of O
the O
_RARE_ I-GENE
, O
and O
that O
women O
who O
have O
had O
ovarian O
stimulation O
are O
followed O
for O
longer O
than O
at O
present O
. O

_RARE_ I-GENE
did O
not O
induce O
any O
modifications O
of O
the O
_RARE_ I-GENE
potential O
, O
the O
_RARE_ I-GENE
direct O
current O
or O
the O
frequency O
of O
the O
evoked O
_RARE_ I-GENE
spikes O
. O

Activation O
of O
the O
_RARE_ I-GENE
_RARE_ I-GENE
- I-GENE
specific I-GENE
_RARE_ I-GENE
gene I-GENE
in O
_RARE_ I-GENE
- I-GENE
stage O
sea O
urchin I-GENE
embryos O
requires O
an O
upstream O
regulatory I-GENE
region O
that O
is O
part O
of O
a O
repetitive O
sequence I-GENE
element I-GENE
( O
_RARE_ I-GENE
) O
associated I-GENE
with O
all O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
genes I-GENE
. O

A I-GENE
transcript I-GENE
of O
about O
2 I-GENE
kb O
is O
expected O
for O
each O
_RARE_ I-GENE
. O

Mutations O
in O
a O
region O
located O
15 O
to O
30 O
bp O
downstream O
from O
the O
major I-GENE
transcription I-GENE
start O
site I-GENE
that O
shows O
good O
homology I-GENE
to O
a O
sequence I-GENE
in O
the O
first O
exon O
of O
c I-GENE
- I-GENE
fos I-GENE
implicated O
as O
a O
negative O
regulatory I-GENE
element I-GENE
resulted O
in O
a O
significant O
increase O
in O
basal O
gene I-GENE
expression O
but O
did O
not O
affect O
regulation O
. O

_RARE_ I-GENE
_RARE_ I-GENE

During O
exercise O
, O
the O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
relation O
was O
shifted O
toward O
the O
left O
and O
the O
slope O
[ O
end O
- I-GENE
systolic O
_RARE_ I-GENE
( O
_RARE_ I-GENE
)] O
increased O
from O
7 O
. O
7 O
+/- O
2 I-GENE
. O
8 O
to O
12 O
. O
7 O
+/- O
4 I-GENE
. O
2 I-GENE
( O
SD O
) O
mmHg O
/ I-GENE
ml O
( O
P I-GENE
< O
0 O
. O
05 O
). O

We O
show O
that O
_RARE_ I-GENE
and O
dsRNA I-GENE
- I-GENE
PK I-GENE
phosphorylate O
yeast I-GENE
eIF I-GENE
- I-GENE
2 I-GENE
alpha I-GENE
in O
vitro O
and O
in O
vivo O
and O
functionally O
substitute O
for O
GCN2 I-GENE
protein I-GENE
to O
stimulate O
GCN4 I-GENE
translation I-GENE
in O
yeast I-GENE
. O

Double O
- I-GENE
staining O
confirmed O
that O
there O
were O
separate O
populations O
of O
_RARE_ I-GENE
- I-GENE
positive O
macrophages O
and O
_RARE_ I-GENE
- I-GENE
positive O
_RARE_ I-GENE
. O

Interestingly O
, O
in O
the O
adult O
, O
_RARE_ I-GENE
expression O
patterns O
within O
the O
_RARE_ I-GENE
in O
two O
lines O
appeared O
to O
_RARE_ I-GENE
distinct O
anterior O
- I-GENE
posterior O
_RARE_ I-GENE
. O

Southern O
analysis O
on O
genomic O
DNA I-GENE
isolated O
from O
tissues O
and O
cell O
lines O
from O
several O
mouse I-GENE
strains O
using O
_RARE_ I-GENE
cDNA I-GENE
demonstrated O
that O
the O
_RARE_ I-GENE
locus I-GENE
encoding O
_RARE_ I-GENE
is O
a O
single O
copy O
gene I-GENE
of O
< O
or O
= O
30 O
kb O
. O

The O
concentrations O
of O
plasma I-GENE
ACTH I-GENE
and O
cortisol O
increased O
by O
40 I-GENE
% O
and O
60 O
% O
after O
_RARE_ I-GENE
treatment O
, O
respectively O
. O

Instead O
, O
the O
results O
support O
the O
idea O
that O
_RARE_ I-GENE
group O
products I-GENE
provide O
stable O
memory O
or O
imprinting O
of O
boundaries O
which O
are O
initially O
specified O
by O
_RARE_ I-GENE
and O
pair O
- I-GENE
_RARE_ I-GENE
regulators O
. O

To O
investigate O
the O
regulation O
of O
expression O
of O
the O
human I-GENE
_RARE_ I-GENE
gene I-GENE
, O
the O
response O
of O
the O
_RARE_ I-GENE
promoter I-GENE
to O
signals O
involved O
in O
cell O
proliferation O
was O
examined O
. O

The O
tyrosine I-GENE
hydroxylase I-GENE
gene I-GENE
( O
TH I-GENE
) O
contains O
a O
single O
copy O
of O
a O
consensus I-GENE
CRE O
at O
- I-GENE
45 O
to O
- I-GENE
38 O
base O
pair O
( O
bp O
) O
upstream O
of O
the O
transcription I-GENE
initiation I-GENE
site I-GENE
. O

_RARE_ I-GENE
mosaic O
virus I-GENE
- I-GENE
infected O
tobacco I-GENE
( O
_RARE_ I-GENE
_RARE_ I-GENE
var I-GENE
. O

_RARE_ I-GENE
a O
stretch O
of O
56 O
amino O
acids O
, O
_RARE_ I-GENE
the O
MADS I-GENE
domain I-GENE
, O
the O
two O
proteins I-GENE
are O
identical O
except O
for O
two O
conservative O
amino O
acid I-GENE
substitutions O
. O

Isolation O
and O
characterization O
of O
SRF I-GENE
accessory I-GENE
proteins I-GENE
. O

These O
data O
suggest O
that O
: O
( O
a O
) O
_RARE_ I-GENE
cleavage O
is O
initiated O
in O
the O
_RARE_ I-GENE
, O
and O
( O
b I-GENE
) O
this O
reaction O
requires O
an O
acidic O
pH O
which O
is O
facilitated O
by O
a O
Golgi I-GENE
- I-GENE
associated I-GENE
vacuolar I-GENE
- I-GENE
type I-GENE
ATPase I-GENE
. O

_RARE_ I-GENE
, O
a O
dopamine I-GENE
receptor I-GENE
agonist O
, O
has O
been O
shown O
, O
in O
animal O
experiments O
, O
to O
improve O
renal O
perfusion O
. O

Clinical O
aspects O
of O
early I-GENE
increase O
in O
serum I-GENE
gamma I-GENE
- I-GENE
glutamyl I-GENE
transferase I-GENE
in O
cerebral O
infarction O
. O

In O
the O
3 I-GENE
' O
flanking O
region O
of O
the O
27 O
kDa I-GENE
_RARE_ I-GENE
gene I-GENE
, O
several O
_RARE_ I-GENE
- I-GENE
like I-GENE
sequences I-GENE
and O
a O
sequence I-GENE
resembling O
the O
mammalian I-GENE
GT I-GENE
- I-GENE
rich O
sequence I-GENE
are O
present O
around O
the O
polyadenylation O
sites I-GENE
. O

The O
_RARE_ I-GENE
_RARE_ I-GENE
concentration O
in O
the O
summer O
( O
1990 O
) O
period O
ranged O
between O
8 O
and O
81 O
_RARE_ I-GENE
m I-GENE
- I-GENE
3 I-GENE
, O
while O
in O
the O
_RARE_ I-GENE
( O
1989 O
- I-GENE
1990 O
) O
it O
ranged O
between O
20 O
and O
143 I-GENE
_RARE_ I-GENE
m I-GENE
- I-GENE
3 I-GENE
for O
the O
first O
year O
of O
measurements O
or O
between O
8 O
and O
92 O
_RARE_ I-GENE
m I-GENE
- I-GENE
3 I-GENE
in O
the O
summer O
( O
1991 O
) O
period O
and O
between O
12 O
and O
119 O
_RARE_ I-GENE
m I-GENE
- I-GENE
3 I-GENE
in O
the O
_RARE_ I-GENE
( O
1990 O
- I-GENE
1991 O
) O
for O
the O
second O
year O
of O
measurements O
. O

The O
results O
indicate O
that O
_RARE_ I-GENE
and O
_RARE_ I-GENE
are O
part O
of O
a O
regulatory I-GENE
cascade O
in O
which O
_RARE_ I-GENE
and O
_RARE_ I-GENE
activate O
expression O
of O
_RARE_ I-GENE
and O
_RARE_ I-GENE
, O
a O
putative O
sigma I-GENE
factor I-GENE
, O
induces O
expression O
of O
_RARE_ I-GENE
- I-GENE
responsive I-GENE
genes I-GENE
. O

_RARE_ I-GENE
is O
an O
iron O
- I-GENE
dependent I-GENE
sequence I-GENE
- I-GENE
specific I-GENE
DNA I-GENE
- I-GENE
binding I-GENE
protein I-GENE
that O
binds O
to O
the O
_RARE_ I-GENE
operator I-GENE
, O
an O
inverted O
- I-GENE
repeat I-GENE
nucleotide I-GENE
sequence I-GENE
located O
upstream O
from O
the O
_RARE_ I-GENE
toxin I-GENE
gene I-GENE
. O

_RARE_ I-GENE
( O
AVP I-GENE
), O
the O
_RARE_ I-GENE
hormone I-GENE
, O
is O
a O
cyclic I-GENE
_RARE_ I-GENE
that O
acts O
through O
binding I-GENE
to O
G I-GENE
protein I-GENE
- I-GENE
coupled I-GENE
specific I-GENE
membrane I-GENE
receptors I-GENE
_RARE_ I-GENE
divided O
into O
three O
subtypes O
( O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
and O
V2 I-GENE
) O
linked O
to O
distinct O
second O
_RARE_ I-GENE
. O

These O
results O
confirmed O
that O
cleavage O
of O
the O
leader O
peptide I-GENE
is O
the O
last O
step O
in O
_RARE_ I-GENE
maturation O
and O
is O
necessary O
to O
generate O
a O
biologically O
active O
peptide I-GENE
. O

When O
the O
promoter I-GENE
region O
was O
linked O
with O
a O
heterologous O
reporter I-GENE
gene I-GENE
, O
we O
found O
that O
the O
promoter I-GENE
region O
is O
inducible I-GENE
by O
both O
_RARE_ I-GENE
( O
interferon I-GENE
- I-GENE
alpha I-GENE
and O
- I-GENE
gamma I-GENE
) O
and O
interferon I-GENE
regulatory I-GENE
factor I-GENE
1 I-GENE
. O

Anti I-GENE
- I-GENE
B I-GENE
. O
_RARE_ I-GENE
, O
anti I-GENE
- I-GENE
B I-GENE
. O
_RARE_ I-GENE
and O
anti I-GENE
- I-GENE
B I-GENE
. O
_RARE_ I-GENE
antibodies I-GENE
, O
tested O
by O
the O
indirect O
_RARE_ I-GENE
assay O
( O
_RARE_ I-GENE
), O
were O
detected O
in O
10 O
. O
8 O
, O
16 O
. O
1 I-GENE
and O
8 O
. O
2 I-GENE
% O
of O
the O
serum I-GENE
samples O
tested O
, O
and O
confirmed O
by O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
in O
1 I-GENE
. O
3 I-GENE
, O
1 I-GENE
. O
3 I-GENE
and O
1 I-GENE
. O
0 O
%, O
respectively O
. O

The O
approach O
_RARE_ I-GENE
from O
a O
recently O
described O
strategy O
for O
making O
recombinants I-GENE
from O
five O
overlapping O
EBV I-GENE
cosmid O
- I-GENE
cloned O
DNAs O
( O
B I-GENE
. O

Evaluation O
of O
_RARE_ I-GENE
for O
dental O
_RARE_ I-GENE
in O
patients O
with O
_RARE_ I-GENE
disorders O
. O

Comparative O
analysis O
with O
an O
_RARE_ I-GENE
_RARE_ I-GENE
and O
synthetic O
GnRH I-GENE
was O
carried O
out O
in O
22 O
normal O
subjects O
, O
14 O
patients O
with O
primary O
and O
20 O
ones O
with O
secondary O
_RARE_ I-GENE
, O
and O
in O
5 I-GENE
patients O
with O
clinical O
signs O
of O
_RARE_ I-GENE
insufficiency O
and O
_RARE_ I-GENE
diagnosis O
in O
order O
to O
elucidate O
the O
pituitary I-GENE
gonadotropin I-GENE
_RARE_ I-GENE
. O

All O
other O
normal O
and O
transformed O
lymphoid I-GENE
and O
_RARE_ I-GENE
cell O
lines O
and O
normal O
tissues O
were O
negative O
for O
_RARE_ I-GENE
expression O
except O
for O
the O
brain O
, O
_RARE_ I-GENE
unique O
4 I-GENE
. O
0 O
- I-GENE
and O
6 I-GENE
. O
1 I-GENE
- I-GENE
kb O
transcripts I-GENE
were O
detected O
. O

The O
cis O
- I-GENE
acting O
regulatory I-GENE
properties O
of O
an O
_RARE_ I-GENE
bp O
promoter I-GENE
fragment I-GENE
of O
a O
B I-GENE
. O
napus I-GENE
_RARE_ I-GENE
gene I-GENE
were O
examined O
by O
analysis O
of O
beta I-GENE
- I-GENE
glucuronidase I-GENE
( O
GUS I-GENE
) O
expression O
in O
transgenic O
tobacco I-GENE
plants O
containing O
an O
_RARE_ I-GENE
promoter I-GENE
- I-GENE
GUS I-GENE
transcriptional O
fusion I-GENE
. O

This O
indicates O
that O
the O
mechanism O
by O
which O
_RARE_ I-GENE
blocks O
rapid O
degradation O
of O
_RARE_ I-GENE
mRNA I-GENE
in O
vivo O
is O
not O
_RARE_ I-GENE
by O
preventing O
its O
translation I-GENE
and O
suggests O
the O
involvement O
of O
an O
altered O
trans O
- I-GENE
factor I-GENE
. O

L I-GENE
., O
_RARE_ I-GENE
, O
J O
. O
& O
_RARE_ I-GENE
, O
G I-GENE
. O

Increasing O
the O
extracellular I-GENE
calcium O
concentration O
enhanced O
_RARE_ I-GENE
contractility O
in O
a O
dose O
- I-GENE
dependent I-GENE
manner O
in O
both O
control O
and O
_RARE_ I-GENE
_RARE_ I-GENE
. O

Structural O
organization O
of O
the O
gene I-GENE
encoding O
the O
human I-GENE
_RARE_ I-GENE
tear I-GENE
_RARE_ I-GENE
and O
synthesis O
of O
the O
recombinant I-GENE
protein I-GENE
in O
Escherichia I-GENE
coli I-GENE
. O

The O
sequence I-GENE
has O
a O
_RARE_ I-GENE
- I-GENE
bp O
open O
reading O
frame O
encoding O
a O
protein I-GENE
of O
_RARE_ I-GENE
amino O
acids O
. O

Western O
blotting O
( O
_RARE_ I-GENE
) O
with O
an O
antiserum O
to O
a O
partial O
SOD I-GENE
expressed O
in O
Escherichia I-GENE
coli I-GENE
revealed O
two O
proteins I-GENE
with O
estimated O
molecular O
masses O
of O
19 O
and O
29 O
kDa I-GENE
. O

The O
gene I-GENE
organization O
of O
_RARE_ I-GENE
RNA I-GENE
- I-GENE
1 I-GENE
is O
similar O
to O
those O
of O
red I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
mosaic O
( O
_RARE_ I-GENE
) O
and O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
mosaic O
( O
_RARE_ I-GENE
) O
_RARE_ I-GENE
with O
the O
exception O
that O
_RARE_ I-GENE
RNA I-GENE
- I-GENE
1 I-GENE
contains O
the O
additional O
3 I-GENE
'- O
terminal I-GENE
ORF I-GENE
. O

Members O
of O
the O
myocyte I-GENE
- I-GENE
specific I-GENE
enhancer I-GENE
- I-GENE
binding I-GENE
factor I-GENE
2 I-GENE
( O
MEF2 I-GENE
) O
family I-GENE
of O
transcription I-GENE
factors I-GENE
bind O
a O
conserved O
A I-GENE
/ I-GENE
T I-GENE
- I-GENE
rich O
sequence I-GENE
in O
the O
control O
regions O
of O
numerous O
muscle O
- I-GENE
specific I-GENE
genes I-GENE
. O

We O
have O
previously O
shown O
that O
_RARE_ I-GENE
- I-GENE
1 I-GENE
represses O
HIV I-GENE
- I-GENE
1 I-GENE
transcription I-GENE
by O
inhibiting O
the O
binding I-GENE
of O
TFIID I-GENE
to O
the O
TATA I-GENE
box I-GENE
. O

These O
results O
_RARE_ I-GENE
an O
important O
role O
for O
La I-GENE
in O
RNA I-GENE
production O
by O
demonstrating O
its O
ability O
to O
clear O
the O
termination O
sites I-GENE
of O
class I-GENE
III I-GENE
templates O
, O
thereby O
promoting I-GENE
efficient O
use O
of O
transcription I-GENE
complexes I-GENE
by O
pol I-GENE
III I-GENE
. O

The O
films O
were O
analyzed O
using O
a O
scanning O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
laser O
_RARE_ I-GENE
with O
a O
small I-GENE
_RARE_ I-GENE
of O
5 I-GENE
- I-GENE
10 O
microns O
. O

The O
_RARE_ I-GENE
method O
has O
proven O
to O
be O
an O
accurate O
and O
rapid O
method O
of O
analysis O
and O
could O
be O
easily O
incorporated O
into O
a O
quality O
_RARE_ I-GENE
program O
. O

_RARE_ I-GENE
genomic O
RNA I-GENE
for O
these O
reactions O
was O
obtained O
directly O
from O
fecal O
specimens O
of O
infected O
infant O
rats O
. O

GATA I-GENE
- I-GENE
1 I-GENE
mRNA I-GENE
was O
present O
in O
equivalent O
levels O
in O
both O
erythroid I-GENE
cell O
lines O
, O
but O
at O
a O
low O
level O
in O
_RARE_ I-GENE
- I-GENE
P1 I-GENE
cells O
. O

Tumor I-GENE
necrosis I-GENE
factor I-GENE
- I-GENE
alpha I-GENE
( O
TNF I-GENE
alpha I-GENE
) O
is O
one O
of O
several O
autocrine O
/ I-GENE
_RARE_ I-GENE
factors I-GENE
known O
to O
exert O
potent O
inhibitory I-GENE
effects O
on O
bone O
. O

We O
have O
investigated O
the O
role O
of O
cellular O
p21ras I-GENE
protein I-GENE
in O
insulin I-GENE
and O
insulin I-GENE
- I-GENE
like I-GENE
growth I-GENE
factor I-GENE
- I-GENE
I I-GENE
( O
IGF I-GENE
- I-GENE
I I-GENE
) O
signaling O
pathways O
. O

The O
lack O
of O
the O
C2 I-GENE
domain I-GENE
of O
the O
Ca I-GENE
( O
2 I-GENE
+)- I-GENE
dependent I-GENE
_RARE_ I-GENE
and O
the O
presence O
of O
a O
unique O
NH2 I-GENE
- I-GENE
terminal I-GENE
sequence I-GENE
with O
a O
potential O
signal I-GENE
peptide I-GENE
and O
a O
transmembrane I-GENE
domain I-GENE
suggest O
that O
PKC I-GENE
mu I-GENE
is O
a O
novel O
member O
of O
the O
subgroup O
of O
atypical O
_RARE_ I-GENE
. O

Moreover O
, O
we O
observed O
that O
the O
function O
of O
T3R I-GENE
- I-GENE
RXR I-GENE
heterodimers I-GENE
on O
response O
elements O
composed O
of O
two O
half O
- I-GENE
sites I-GENE
in O
a O
directly O
repeated O
orientation O
_RARE_ I-GENE
by O
4 I-GENE
nucleotides O
is O
determined O
in O
major I-GENE
parts O
by O
the O
5 I-GENE
'- O
flanking O
sequence I-GENE
of O
the O
upstream O
half O
- I-GENE
site I-GENE
. O

However O
, O
three O
_RARE_ I-GENE
mutants I-GENE
that O
were O
moderately O
deficient O
in O
stimulating I-GENE
PI I-GENE
turnover O
displayed O
normal O
_RARE_ I-GENE
, O
suggesting O
distinct O
mechanisms O
. O

Furthermore O
, O
in O
vitro O
decay O
reaction O
_RARE_ I-GENE
supplemented O
with O
the O
20 O
- I-GENE
nt O
sense O
RNA I-GENE
transcript I-GENE
resulted O
in O
stabilization O
of O
R2 I-GENE
message I-GENE
. O

Deletion O
analyses O
of O
the O
_RARE_ I-GENE
ORF I-GENE
- I-GENE
A I-GENE
and O
the O
use O
of O
promoter I-GENE
constructs I-GENE
further O
mapped O
an O
internal O
functional O
promoter I-GENE
within O
the O
_RARE_ I-GENE
sequence I-GENE
that O
can O
direct O
the O
synthesis O
of O
the O
trans O
- I-GENE
activating I-GENE
protein I-GENE
. O

_RARE_ I-GENE
of O
these O
had O
counterparts O
in O
the O
US O
of O
herpes I-GENE
simplex I-GENE
type I-GENE
1 I-GENE
( O
HSV I-GENE
- I-GENE
1 I-GENE
), O
pseudorabies O
virus I-GENE
( O
_RARE_ I-GENE
), O
and O
equine I-GENE
herpesvirus I-GENE
type I-GENE
1 I-GENE
( O
EHV I-GENE
- I-GENE
1 I-GENE
). O

The O
_RARE_ I-GENE
amino O
acid I-GENE
sequence I-GENE
of O
the O
_RARE_ I-GENE
_RARE_ I-GENE
protein I-GENE
indicates O
a O
significant O
difference O
in O
the O
metal O
cofactor I-GENE
requirement O
from O
the O
higher O
- I-GENE
plant O
enzymes O
, O
which O
was O
confirmed O
by O
overexpression O
and O
biochemical O
analysis O
. O

METHODS O
AND O
RESULTS O
: O
In O
25 O
open O
- I-GENE
chest O
, O
anesthetized O
dogs O
, O
progressive O
_RARE_ I-GENE
artery O
stenosis O
led O
to O
a O
_RARE_ I-GENE
decrease O
of O
_RARE_ I-GENE
artery O
resting O
and O
_RARE_ I-GENE
flow O
, O
coronary O
flow O
reserve O
, O
and O
_RARE_ I-GENE
angiographic O
mean O
transit O
time O
_RARE_ I-GENE
- I-GENE
1 I-GENE
( O
P I-GENE
< O
. O
01 O
). O

However O
, O
a O
correlation O
was O
observed O
between O
SF I-GENE
levels O
of O
IL I-GENE
- I-GENE
8 O
with O
those O
of O
lactate I-GENE
, O
_RARE_ I-GENE
, O
beta I-GENE
2 I-GENE
- I-GENE
microglobulin I-GENE
and O
glucose O
. O

Sodium O
- I-GENE
_RARE_ I-GENE
- I-GENE
induced O
acute O
_RARE_ I-GENE
pancreatitis O
does O
not O
affect O
_RARE_ I-GENE
oxygenation O
in O
pigs O
. O

Although O
inactive O
in O
cells O
under O
normal O
conditions O
, O
the O
CHOP I-GENE
gene I-GENE
is O
markedly O
induced O
by O
a O
variety O
of O
cellular O
stresses O
, O
including O
nutrient O
deprivation O
and O
metabolic O
_RARE_ I-GENE
. O

The O
_RARE_ I-GENE
genes I-GENE
code O
for O
two O
almost O
identical O
_RARE_ I-GENE
- I-GENE
aa O
proteins I-GENE
which O
do O
not O
have O
any O
homology I-GENE
with O
sequences I-GENE
present O
in O
data O
libraries O
. O

_RARE_ I-GENE
analysis O
of O
the O
disrupted O
mutant I-GENE
demonstrated O
the O
accumulation O
of O
_RARE_ I-GENE
, O
indicating O
a O
loss O
of O
_RARE_ I-GENE
activity O
. O

The O
previously O
described O
enhanced O
translation I-GENE
of O
_RARE_ I-GENE
L12 I-GENE
mRNA I-GENE
from O
its O
two O
tandem O
AUG O
codons O
and O
the O
two O
functional O
_RARE_ I-GENE
genes I-GENE
in O
Arabidopsis I-GENE
probably O
provide O
two O
mechanisms O
for O
generating O
the O
four O
copies O
of O
L12 I-GENE
/ I-GENE
chloroplast I-GENE
ribosome I-GENE
, O
_RARE_ I-GENE
different O
from O
those O
_RARE_ I-GENE
in O
_RARE_ I-GENE
. O

In O
these O
experiments O
we O
begin O
to O
study O
the O
potential O
functions O
of O
the O
alpha I-GENE
7 O
cytoplasmic I-GENE
domain I-GENE
by O
analyzing O
homologies O
between O
the O
rat I-GENE
and O
human I-GENE
sequences I-GENE
, O
by O
immunologic O
studies O
using O
an O
anti I-GENE
- I-GENE
cytoplasmic I-GENE
domain I-GENE
antiserum O
, O
and O
by O
identifying O
two O
alternate O
forms O
. O

The O
alpha I-GENE
_RARE_ I-GENE
form O
RNA I-GENE
contains O
an O
additional O
113 I-GENE
nucleotides O
compared O
to O
the O
B I-GENE
form O
, O
and O
a O
common O
coding O
region O
in O
the O
A I-GENE
and O
B I-GENE
form O
RNAs I-GENE
is O
used O
in O
alternate O
reading O
frames O
. O

In O
order O
to O
evaluate O
the O
function O
of O
the O
_RARE_ I-GENE
- I-GENE
pituitary I-GENE
- I-GENE
thyroid I-GENE
( O
_RARE_ I-GENE
)- I-GENE
axis O
in O
_RARE_ I-GENE
depression O
, O
the O
authors O
measured O
basal O
_RARE_ I-GENE
plasma I-GENE
levels O
of O
free O
thyroxine O
( O
_RARE_ I-GENE
), O
free O
_RARE_ I-GENE
( O
_RARE_ I-GENE
), O
and O
thyroid I-GENE
stimulating I-GENE
hormone I-GENE
( O
TSH I-GENE
) O
by O
means O
of O
the O
new O
, O
_RARE_ I-GENE
assays O
( O
TSH I-GENE
- I-GENE
_RARE_ I-GENE
) O
in O
69 O
healthy O
controls O
, O
62 O
minor O
, O
101 I-GENE
simple O
major I-GENE
, O
and O
57 O
_RARE_ I-GENE
depressed O
subjects O
. O

CRS I-GENE
function O
in O
a O
5 I-GENE
' O
LTR I-GENE
- I-GENE
linked O
gene I-GENE
expression O
assay O
correlates O
with O
the O
ability O
of O
both O
_RARE_ I-GENE
and O
_RARE_ I-GENE
to O
interact O
with O
5 I-GENE
' O
LTR I-GENE
RNA I-GENE
in O
vitro O
. O

_RARE_ I-GENE
levels O
of O
_RARE_ I-GENE
T I-GENE
and O
the O
activity O
of O
CK I-GENE
- I-GENE
MB I-GENE
were O
measured O
6 I-GENE
, O
12 O
, O
24 O
and O
48 O
h O
after O
aortic O
_RARE_ I-GENE
. O

_RARE_ I-GENE
of O
drug O
delivery O
is O
a O
potential O
method O
to O
avoid O
this O
problem O
. O

The O
epidemic O
occurred O
in O
a O
group O
of O
26 O
community O
members O
( O
23 O
men O
and O
3 I-GENE
women O
, O
mean O
age O
, O
28 O
. O
9 O
-- O
3 I-GENE
years O
) O
living O
and O
working O
together O
, O
who O
underwent O
acute O
and O
_RARE_ I-GENE
serologic O
tests O
for O
_RARE_ I-GENE
pneumoniae I-GENE
, O
_RARE_ I-GENE
_RARE_ I-GENE
, O
cytomegalovirus I-GENE
, O
adenovirus I-GENE
, O
_RARE_ I-GENE
_RARE_ I-GENE
, O
and O
Chlamydia O
pneumoniae I-GENE
. O

MEK I-GENE
itself O
is O
activated I-GENE
via O
serine I-GENE
phosphorylation O
by O
upstream O
activator I-GENE
kinases I-GENE
, O
including O
c I-GENE
- I-GENE
raf I-GENE
, O
mos I-GENE
and O
MEK I-GENE
kinase I-GENE
. O

Genomic O
DNA I-GENE
clones O
containing O
the O
T I-GENE
- I-GENE
cell O
- I-GENE
specific I-GENE
human I-GENE
_RARE_ I-GENE
gene I-GENE
were O
isolated O
. O

Members O
of O
_RARE_ I-GENE
are O
also O
present O
in O
the O
complement I-GENE
C2 I-GENE
gene I-GENE
located O
about O
20 O
kilobases O
upstream O
of O
_RARE_ I-GENE
in O
the O
HLA I-GENE
and O
in O
the O
cytochrome I-GENE
_RARE_ I-GENE
gene I-GENE
. O

Expression O
of O
the O
_RARE_ I-GENE
_RARE_ I-GENE
processing O
enzyme I-GENE
_RARE_ I-GENE
is O
directed O
by O
multiple O
promoters I-GENE
. O

European O
_RARE_ I-GENE
_RARE_ I-GENE
' O
s O
_RARE_ I-GENE
_RARE_ I-GENE
Study O
Group O
. O

The O
c I-GENE
- I-GENE
myc I-GENE
and O
skeletal I-GENE
alpha I-GENE
- I-GENE
actin I-GENE
gene I-GENE
promoters I-GENE
contain O
YY1 I-GENE
binding I-GENE
sites I-GENE
thought O
to O
act O
either O
as O
positive O
or O
negative O
cis O
- I-GENE
acting O
elements O
. O

_RARE_ I-GENE
- I-GENE
1 I-GENE
produced O
in O
E I-GENE
. O
coli I-GENE
as O
a O
fusion I-GENE
protein I-GENE
with O
GST I-GENE
specifically O
interacted O
with O
single O
- I-GENE
stranded I-GENE
_RARE_ I-GENE
( O
plus O
myc I-GENE
( O
H I-GENE
- I-GENE
P I-GENE
) O
21 O
) O
and O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
( O
in O
minus O
myc I-GENE
( O
H I-GENE
- I-GENE
P I-GENE
) O
21 O
), O
the O
consensus I-GENE
of O
which O
can O
be O
referred O
to O
as O
A I-GENE
/ I-GENE
_RARE_ I-GENE
/ I-GENE
TA O
/ I-GENE
_RARE_ I-GENE
. O

Within O
12 O
hours O
after O
MR O
tomography O
the O
patients O
were O
surgically O
explored O
, O
_RARE_ I-GENE
and O
if O
necessary O
_RARE_ I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
spontaneous O
alleles I-GENE
are O
good O
suppressors O
but O
have O
a O
normal O
growth I-GENE
rate O
, O
suggesting O
that O
the O
_RARE_ I-GENE
protein I-GENE
may O
have O
two O
distinct O
functions O
. O

_RARE_ I-GENE
of O
_RARE_ I-GENE
experience O
. O

The O
results O
show O
that O
both O
the O
amino O
and O
carboxy I-GENE
termini O
of O
the O
NS1 I-GENE
protein I-GENE
molecule I-GENE
and O
the O
_RARE_ I-GENE
at O
residues O
_RARE_ I-GENE
and O
_RARE_ I-GENE
are O
essential O
for O
_RARE_ I-GENE
formation O
. O

The O
3 I-GENE
' O
UTR I-GENE
has O
several O
stable O
_RARE_ I-GENE
that O
are O
flanked O
by O
single O
- I-GENE
stranded I-GENE
( O
A I-GENE
/ I-GENE
U O
) O
_RARE_ I-GENE
sequences I-GENE
. O

Moreover O
, O
the O
major I-GENE
site I-GENE
of O
transcriptional O
initiation I-GENE
, O
which O
was O
localized O
by O
primer O
extension O
250 O
bp O
upstream O
of O
the O
5 I-GENE
' O
end O
of O
the O
Ets I-GENE
- I-GENE
1 I-GENE
cDNA I-GENE
clone O
, O
was O
shown O
to O
be O
identical O
in O
normal O
cells O
and O
tumors O
carrying O
a O
provirus O
in O
the O
_RARE_ I-GENE
- I-GENE
1 I-GENE
locus I-GENE
. O

Specifically O
, O
by O
oligonucleotide I-GENE
- I-GENE
directed O
site I-GENE
- I-GENE
specific I-GENE
mutagenesis O
, O
we O
demonstrate O
that O
of O
10 O
cysteine I-GENE
residues O
in O
the O
_RARE_ I-GENE
polypeptide I-GENE
, O
only O
C I-GENE
- I-GENE
_RARE_ I-GENE
and O
C I-GENE
- I-GENE
_RARE_ I-GENE
are O
essential O
for O
transactivator I-GENE
function O
and O
suggest O
that O
these O
cysteine I-GENE
residues O
may O
participate O
in O
critical O
protein I-GENE
- I-GENE
protein I-GENE
interactions O
rather O
than O
protein I-GENE
- I-GENE
nucleic O
acid I-GENE
interactions O
to O
mediate O
_RARE_ I-GENE
inducibility O
. O

In O
Rat I-GENE
1a I-GENE
cells O
, O
_RARE_ I-GENE
stimulation O
of O
phospholipase I-GENE
C I-GENE
beta I-GENE
and O
the O
marked O
rise O
in O
intracellular O
calcium O
stimulated O
cyclic I-GENE
AMP I-GENE
( O
cAMP I-GENE
) O
synthesis O
, O
resulting O
in O
the O
activation O
of O
protein I-GENE
kinase I-GENE
A I-GENE
. O

The O
mutations O
did O
not O
affect O
the O
repression O
of O
_RARE_ I-GENE
by O
arginine I-GENE
. O

A I-GENE
segment O
of O
mRNA I-GENE
encoding O
the O
leader O
peptide I-GENE
of O
the O
_RARE_ I-GENE
gene I-GENE
confers O
repression O
by O
arginine I-GENE
on O
a O
heterologous O
yeast I-GENE
gene I-GENE
transcript I-GENE
. O

To O
search O
for O
genes I-GENE
that O
interact O
with O
the O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
pathway O
, O
a O
synthetic O
lethal O
suppression O
screen O
was O
carried O
out O
. O

Genetic O
and O
_RARE_ I-GENE
analysis O
indicates O
that O
_RARE_ I-GENE
and O
_RARE_ I-GENE
function O
downstream O
of O
_RARE_ I-GENE
. O

In O
this O
report O
, O
we O
present O
two O
lines O
of O
evidence O
that O
all O
_RARE_ I-GENE
which O
_RARE_ I-GENE
GCN4 I-GENE
have O
previously O
translated O
_RARE_ I-GENE
, O
_RARE_ I-GENE
scanning O
, O
and O
_RARE_ I-GENE
at O
the O
GCN4 I-GENE
start O
site I-GENE
. O

_RARE_ I-GENE
components O
of O
yeast I-GENE
transcription I-GENE
factor I-GENE
IIIB I-GENE
are O
required O
and O
sufficient O
for O
transcription I-GENE
of O
TATA I-GENE
box I-GENE
- I-GENE
containing O
and O
TATA I-GENE
- I-GENE
less O
genes I-GENE
. O

_RARE_ I-GENE
, O
it O
was O
shown O
that O
the O
_RARE_ I-GENE
protein I-GENE
_RARE_ I-GENE
inhibits O
differentiation O
of O
muscle O
and O
myeloid O
cells O
in O
vitro O
. O

_RARE_ I-GENE
, O
a O
new O
ribonucleoprotein I-GENE
gene I-GENE
of O
the O
yeast I-GENE
Saccharomyces I-GENE
cerevisiae I-GENE
. O

Crohn O
' O
s O
disease O
in O
prolonged O
remission O
: O
should O
one O
_RARE_ I-GENE
protein I-GENE
- I-GENE
_RARE_ I-GENE
intake O
as O
compared O
to O
healthy O
subjects O
_RARE_ I-GENE
The O
aim O
of O
our O
two O
year O
prospective O
study O
was O
to O
evaluate O
whether O
adult O
Crohn O
' O
s O
disease O
patients O
in O
prolonged O
remission O
( O
_RARE_ I-GENE
< O
150 O
), O
in O
order O
to O
maintain O
their O
body O
weight O
as O
close O
as O
possible O
to O
the O
_RARE_ I-GENE
one O
, O
need O
a O
protein I-GENE
- I-GENE
_RARE_ I-GENE
intake O
higher O
than O
the O
predicted O
one O
and O
that O
of O
healthy O
controls O
. O

To O
achieve O
complete O
dissection O
of O
the O
anterior O
vitreous O
, O
we O
_RARE_ I-GENE
even O
a O
clear O
lens O
during O
the O
first O
surgical O
intervention O
in O
selected O
cases O
. O

_RARE_ I-GENE
of O
_RARE_ I-GENE
function O
with O
transplantation O
of O
free O
_RARE_ I-GENE
dorsal O
_RARE_ I-GENE
skin O
flap O
containing O
m I-GENE
. O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE

Neither O
ethanol O
regimen O
impaired O
spontaneous O
_RARE_ I-GENE
, O
but O
the O
4 I-GENE
g O
ethanol O
. O
kg O
- I-GENE
1 I-GENE
x O
day O
- I-GENE
1 I-GENE
regimen O
increased O
the O
percent O
completed O
trials O
. O

The O
mean O
(+/- O
_RARE_ I-GENE
) O
intra O
- I-GENE
vesicular O
pressure O
( O
_RARE_ I-GENE
) O
and O
maximal O
_RARE_ I-GENE
closure O
pressures O
( O
_RARE_ I-GENE
) O
were O
10 O
. O
3 I-GENE
(+/- O
1 I-GENE
. O
7 O
) O
and O
_RARE_ I-GENE
. O
8 O
(+/- O
19 O
. O
6 I-GENE
) O
cmH2O O
, O
respectively O
, O
and O
the O
ratio O
between O
_RARE_ I-GENE
and O
_RARE_ I-GENE
was O
13 O
. O
2 I-GENE
(+/- O
2 I-GENE
. O
5 I-GENE
). O

Several O
highly O
conserved O
regions O
were O
identified O
at O
the O
near O
N I-GENE
terminus O
, O
middle I-GENE
and O
C I-GENE
terminus O
. O

_RARE_ I-GENE
( O
TR I-GENE
) O
is O
a O
small I-GENE
ubiquitous O
_RARE_ I-GENE
- I-GENE
reductase I-GENE
enzyme I-GENE
first O
identified O
in O
bacteria O
and O
plants O
. O

The O
mutation I-GENE
within O
the O
_RARE_ I-GENE
allele I-GENE
was O
identified O
as O
an O
A I-GENE
- I-GENE
to O
- I-GENE
G I-GENE
transition O
that O
results O
in O
a O
threonine I-GENE
- I-GENE
to O
- I-GENE
alanine I-GENE
substitution O
in O
the O
predicted O
protein I-GENE
product I-GENE
. O

The O
cysteine I-GENE
- I-GENE
rich O
region O
of O
raf I-GENE
- I-GENE
1 I-GENE
kinase I-GENE
contains O
zinc I-GENE
, O
_RARE_ I-GENE
to O
liposomes O
, O
and O
is O
adjacent O
to O
a O
segment O
that O
binds O
GTP I-GENE
- I-GENE
ras I-GENE
. O

_RARE_ I-GENE
coupling O
and O
requirement O
for O
ATP I-GENE
hydrolysis O
. O

ATP I-GENE
by O
itself O
also O
reduced O
polypeptide I-GENE
binding I-GENE
to O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
to O
a O
level O
that O
was O
intermediate O
between O
that O
observed O
for O
the O
_RARE_ I-GENE
_RARE_ I-GENE
proteins I-GENE
tested O
and O
_RARE_ I-GENE
and O
_RARE_ I-GENE
. O

_RARE_ I-GENE
of O
NF I-GENE
- I-GENE
IL6 I-GENE
with O
_RARE_ I-GENE
Asp I-GENE
- I-GENE
N I-GENE
produced O
a O
domain I-GENE
smaller O
than O
the O
_RARE_ I-GENE
( O
NF I-GENE
- I-GENE
IL6 I-GENE
bZIP I-GENE
domains I-GENE
( O
_RARE_ I-GENE
) O
( O
272 O
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
a O
domain I-GENE
identified O
either O
in O
the O
absence O
or O
the O
presence O
of O
DNA I-GENE
. O

_RARE_ I-GENE
by O
tyrosine I-GENE
kinases I-GENE
involves O
direct O
associations O
between O
proteins I-GENE
with O
Src I-GENE
homology I-GENE
2 I-GENE
( O
SH2 I-GENE
) O
domains I-GENE
and O
sites I-GENE
of O
tyrosine I-GENE
phosphorylation O
. O

_RARE_ I-GENE
, O
complete O
_RARE_ I-GENE
of O
exon O
V I-GENE
and O
subsequent O
joining O
of O
exon O
IV I-GENE
to O
exon O
VI I-GENE
caused O
a O
shift O
in O
the O
open O
reading O
frame O
, O
which O
_RARE_ I-GENE
_RARE_ I-GENE
( O
P2 I-GENE
) O
with O
an O
_RARE_ I-GENE
new O
hydrophobic O
sequence I-GENE
for O
membrane I-GENE
_RARE_ I-GENE
. O

The O
responses O
of O
the O
" O
stress O
hormones O
" O
cortisol O
, O
11 O
- I-GENE
_RARE_ I-GENE
, O
ACTH I-GENE
, O
vasopressin I-GENE
( O
AVP I-GENE
), O
and O
_RARE_ I-GENE
releasing I-GENE
factor I-GENE
( O
CRF I-GENE
) O
were O
studied O
in O
6 I-GENE
normal O
males O
in O
response O
to O
acute O
cortisol O
deficiency O
induced O
by O
the O
11 O
- I-GENE
beta I-GENE
- I-GENE
hydroxylase I-GENE
inhibitor I-GENE
, O
_RARE_ I-GENE
. O

Structure O
and O
expression O
of O
the O
alternative O
sigma I-GENE
factor I-GENE
, O
_RARE_ I-GENE
, O
in O
_RARE_ I-GENE
_RARE_ I-GENE
; O
physiological O
relevance O
of O
an O
_RARE_ I-GENE
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
. O

Thus O
our O
observations O
establish O
a O
functional O
link I-GENE
between O
the O
PKC I-GENE
and O
retinoid I-GENE
pathways O
, O
which O
are O
generally O
considered O
to O
have O
antagonistic O
activities O
on O
differentiation O
processes O
. O

The O
colony I-GENE
- I-GENE
stimulating I-GENE
factors I-GENE
( O
_RARE_ I-GENE
) O
_RARE_ I-GENE
involved O
in O
the O
production O
of O
neutrophils O
and O
monocytes O
are O
granulocyte I-GENE
CSF I-GENE
, O
granulocyte I-GENE
- I-GENE
macrophage I-GENE
CSF I-GENE
, O
macrophage I-GENE
CSF I-GENE
, O
and O
interleukin I-GENE
3 I-GENE
( O
_RARE_ I-GENE
called O
multi I-GENE
- I-GENE
CSF I-GENE
). O

The O
degree O
of O
lung O
_RARE_ I-GENE
, O
reflected O
by O
interstitial O
hemorrhage O
was O
assessed O
by O
measuring O
hemoglobin I-GENE
content O
in O
the O
fluid O
of O
the O
_RARE_ I-GENE
lungs O
. O

Expression O
plasmids O
harboring O
full I-GENE
- I-GENE
length I-GENE
or O
kinase I-GENE
domain I-GENE
of O
PKC I-GENE
alpha I-GENE
and O
PKC I-GENE
delta I-GENE
( O
PKC I-GENE
alpha I-GENE
K I-GENE
and O
PKC I-GENE
delta I-GENE
K I-GENE
) O
were O
constructed O
. O

These O
results O
indicate O
that O
both O
PKC I-GENE
alpha I-GENE
( O
calcium O
dependent I-GENE
) O
and O
PKC I-GENE
delta I-GENE
( O
calcium O
independent O
) O
may O
mediate O
the O
transcription I-GENE
of O
TPA O
- I-GENE
inducible I-GENE
genes I-GENE
through O
both O
AP I-GENE
- I-GENE
1 I-GENE
and O
non O
- I-GENE
AP I-GENE
- I-GENE
1 I-GENE
sequences I-GENE
. O

With O
a O
cutoff O
level O
for O
_RARE_ I-GENE
- I-GENE
1 I-GENE
of O
less O
than O
100 O
pg O
/ I-GENE
ml O
, O
28 O
samples O
obtained O
from O
12 O
patients O
were O
positive O
for O
_RARE_ I-GENE
- I-GENE
1 I-GENE
. O

_RARE_ I-GENE
of O
short O
oligonucleotides O
encoding O
the O
basic I-GENE
amino O
acid I-GENE
motifs O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
from O
_RARE_ I-GENE
and O
500 O
- I-GENE
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
from O
_RARE_ I-GENE
into O
deleted O
cytoplasmic I-GENE
forms O
of O
the O
two O
proteins I-GENE
restored O
the O
_RARE_ I-GENE
phenotype O
and O
confirmed O
that O
these O
motifs O
are O
both O
necessary O
and O
sufficient O
for O
proper O
nuclear I-GENE
localization O
. O

Mapping O
of O
intracellular O
localization O
domains I-GENE
and O
evidence O
for O
_RARE_ I-GENE
interactions O
between O
the O
_RARE_ I-GENE
and O
_RARE_ I-GENE
nuclear I-GENE
transactivator I-GENE
proteins I-GENE
of O
herpes I-GENE
simplex I-GENE
virus I-GENE
. O

The O
_RARE_ I-GENE
TATA I-GENE
boxes O
accelerated O
the O
kinetics O
of O
HIV I-GENE
replication O
when O
present O
in O
the O
context O
of O
an O
LTR I-GENE
containing O
a O
Sp1 I-GENE
mutation I-GENE
( O
deletion O
or O
site I-GENE
specific I-GENE
); O
no O
effect O
was O
observed O
on O
the O
_RARE_ I-GENE
of O
wild I-GENE
- I-GENE
type I-GENE
HIV I-GENE
. O

_RARE_ I-GENE
emphysema O

Since O
the O
ETS I-GENE
domain I-GENE
, O
which O
is O
localized O
in O
the O
carboxy I-GENE
terminal I-GENE
region O
of O
the O
encoded I-GENE
protein I-GENE
, O
is O
95 O
% O
and O
96 O
% O
identical O
to O
that O
of O
PEA3 I-GENE
and O
_RARE_ I-GENE
, O
respectively O
, O
we O
named O
this O
new O
member O
' O
Ets I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
PEA3 I-GENE
- I-GENE
like I-GENE
' O
( O
_RARE_ I-GENE
). O

Gel O
shift O
analysis O
indicates O
that O
the O
full I-GENE
- I-GENE
length I-GENE
_RARE_ I-GENE
protein I-GENE
is O
able O
to O
bind O
specifically O
to O
an O
oligonucleotide I-GENE
containing O
the O
consensus I-GENE
nucleotide I-GENE
core I-GENE
sequence I-GENE
_RARE_ I-GENE
recognized O
by O
the O
Ets I-GENE
proteins I-GENE
. O

Effects O
of O
estradiol O
on O
_RARE_ I-GENE
burden O
and O
peripheral O
_RARE_ I-GENE
in O
_RARE_ I-GENE
_RARE_ I-GENE
- I-GENE
infected O
rats O
. O

_RARE_ I-GENE
produced O
arterial O
_RARE_ I-GENE
in O
both O
systemic O
and O
pulmonary O
circulation O
: O
the O
total O
peripheral O
resistance O
_RARE_ I-GENE
, O
and O
femoral O
artery O
flow O
rose O
; O
aortic O
and O
pulmonary O
artery O
mean O
and O
diastolic O
pressures O
declined O
, O
and O
systolic O
pressures O
remained O
almost O
stable O
. O

These O
issues O
include O
the O
use O
of O
_RARE_ I-GENE
in O
patients O
with O
arterial O
thrombosis O
or O
myocardial O
infarction O
( O
e O
. O
g O
. O
in O
conjunction O
with O
_RARE_ I-GENE
treatment O
), O
and O
in O
patients O
with O
pulmonary O
_RARE_ I-GENE
. O

The O
_RARE_ I-GENE
of O
the O
lambda I-GENE
_RARE_ I-GENE
and O
the O
lambda I-GENE
_RARE_ I-GENE
cloning O
vectors O
was O
demonstrated O
by O
_RARE_ I-GENE
large O
Neurospora I-GENE
crassa I-GENE
cDNA I-GENE
libraries O
. O

_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
as O
adjuvant O
treatment O
for O
critical O
upper O
- I-GENE
limb O
ischaemia O
. O

Sequence O
comparisons O
have O
shown O
that O
_RARE_ I-GENE
is O
more O
similar O
to O
the O
sigma I-GENE
subunit I-GENE
of O
the O
Golgi I-GENE
- I-GENE
localized O
mammalian I-GENE
AP I-GENE
- I-GENE
1 I-GENE
complex I-GENE
than O
_RARE_ I-GENE
, O
which O
is O
more O
related I-GENE
to O
the O
plasma I-GENE
membrane I-GENE
AP I-GENE
- I-GENE
2 I-GENE
sigma I-GENE
subunit I-GENE
. O

The O
Saccharomyces I-GENE
cerevisiae I-GENE
_RARE_ I-GENE
gene I-GENE
encodes O
a O
homolog I-GENE
of O
the O
small I-GENE
subunit I-GENE
of O
the O
mammalian I-GENE
clathrin I-GENE
AP I-GENE
- I-GENE
1 I-GENE
complex I-GENE
: O
evidence O
for O
functional O
interaction O
with O
clathrin I-GENE
at O
the O
Golgi I-GENE
complex I-GENE
. O

These O
results O
are O
the O
first O
to O
demonstrate O
the O
structural O
organization O
of O
a O
vertebrate I-GENE
gene I-GENE
encoding O
an O
integral I-GENE
membrane I-GENE
protein I-GENE
of O
the O
nuclear I-GENE
envelope I-GENE
that O
may O
be O
a O
member O
of O
a O
family I-GENE
of O
polypeptides I-GENE
conserved O
in O
evolution O
. O

Biochemical O
characterization O
of O
_RARE_ I-GENE
- I-GENE
containing O
protein I-GENE
, O
a O
protein I-GENE
tyrosine I-GENE
kinase I-GENE
substrate I-GENE
in O
hematopoietic I-GENE
cells O
. O

The O
presence O
of O
the O
foreign O
gene I-GENE
was O
confirmed O
by O
Southern O
analysis O
. O

All O
patients O
with O
_RARE_ I-GENE
in O
mental O
status O
showed O
a O
marked O
increase O
in O
liver O
enzymes O
( O
aspartate I-GENE
and O
alanine I-GENE
_RARE_ I-GENE
) O
and O
severe O
_RARE_ I-GENE
. O

Functional O
postnatal O
development O
of O
the O
rat I-GENE
primary O
visual O
cortex O
and O
the O
role O
of O
visual O
experience O
: O
dark O
_RARE_ I-GENE
and O
_RARE_ I-GENE
deprivation O
. O

_RARE_ I-GENE
patients O
tested O
positive O
for O
the O
hepatitis I-GENE
B I-GENE
surface O
antigen I-GENE
( O
HBsAg I-GENE
). O

The O
_RARE_ I-GENE
isomerase I-GENE
- I-GENE
encoding O
gene I-GENE
( O
_RARE_ I-GENE
) O
of O
_RARE_ I-GENE
_RARE_ I-GENE
: O
cloning O
, O
sequencing O
and O
_RARE_ I-GENE
of O
_RARE_ I-GENE
enzymes O
. O

Two O
phosphopeptides O
, O
identified O
as O
RS I-GENE
-[ I-GENE
32P O
] O
_RARE_ I-GENE
and O
S I-GENE
-[ I-GENE
32P O
] O
_RARE_ I-GENE
, O
were O
obtained O
after O
_RARE_ I-GENE
phosphorylation O
and O
_RARE_ I-GENE
of O
the O
peptide I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
signal I-GENE
anchor I-GENE
sequence I-GENE
. O

Altogether O
, O
these O
data O
suggest O
that O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
are O
required O
for O
transport O
in O
the O
endocytic O
pathway O
and O
for O
correct O
sorting I-GENE
of O
vacuolar I-GENE
_RARE_ I-GENE
suggesting O
a O
possible O
_RARE_ I-GENE
of O
the O
endocytic O
with O
the O
vacuolar I-GENE
sorting I-GENE
pathway O
. O

All O
of O
the O
basal O
TPN O
solutions O
were O
_RARE_ I-GENE
and O
identical O
in O
nutrient O
composition O
, O
except O
for O
the O
difference O
in O
energy O
level O
, O
which O
was O
adjusted O
with O
glucose O
. O

Surprisingly O
, O
_RARE_ I-GENE
alpha I-GENE
has O
no O
homology I-GENE
to O
any O
of O
the O
yeast I-GENE
_RARE_ I-GENE
subunits I-GENE
already O
cloned O
, O
suggesting O
a O
significant O
degree O
of O
evolutionary O
divergence O
for O
RNA I-GENE
polymerase I-GENE
III I-GENE
factors I-GENE
. O

_RARE_ I-GENE
domain I-GENE
is O
located O
downstream O
of O
the O
128 I-GENE
- I-GENE
amino O
- I-GENE
acid I-GENE
_RARE_ I-GENE
homology I-GENE
region O
, O
referred O
to O
as O
the O
_RARE_ I-GENE
domain I-GENE
. O

We O
estimate O
that O
the O
protease I-GENE
activity O
is O
at O
least O
35 O
- I-GENE
fold O
greater O
in O
mature O
B I-GENE
cells O
than O
in O
pre I-GENE
- I-GENE
B I-GENE
cells O
. O

The O
ligand O
for O
RXR I-GENE
, O
9 O
- I-GENE
cis O
retinoic I-GENE
acid I-GENE
, O
has O
the O
opposite O
effect O
of O
_RARE_ I-GENE
the O
heterodimeric I-GENE
- I-GENE
DNA I-GENE
complex I-GENE
. O

_RARE_ I-GENE
albumin I-GENE
was O
increased O
to O
similar O
_RARE_ I-GENE
in O
those O
groups O
submitted O
to O
_RARE_ I-GENE
. O

_RARE_ I-GENE
labelled O
neurons O
significantly O
_RARE_ I-GENE
in O
the O
ipsilateral O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
. O

Response O
to O
treatment O
was O
better O
in O
patients O
with O
less O
pretreatment O
( O
one O
- I-GENE
two O
prior O
treatments O
) O
than O
in O
_RARE_ I-GENE
pretreated O
ones O
( O
more O
than O
three O
) O
and O
this O
relation O
was O
found O
to O
be O
statistically O
significant O
( O
p O
< O
0 O
. O
05 O
). O

Therefore O
, O
the O
amino O
- I-GENE
terminal I-GENE
sequence I-GENE
of O
the O
purified O
_RARE_ I-GENE
product I-GENE
is O
identical O
to O
that O
derived O
from O
the O
nucleotide I-GENE
sequence I-GENE
in O
both O
organisms O
, O
P I-GENE
. O
_RARE_ I-GENE
having O
four O
additional O
amino O
acids O
. O

_RARE_ I-GENE
bone O
cyst O
of O
the O
_RARE_ I-GENE
: O
analysis O
of O
11 O
cases O
. O

_RARE_ I-GENE
and O
orientation O
of O
an O
activating I-GENE
region O
in O
the O
Escherichia I-GENE
coli I-GENE
transcription I-GENE
factor I-GENE
, O
_RARE_ I-GENE
. O

_RARE_ I-GENE
( O
at O
3 I-GENE
times O
the O
therapeutic O
dose O
) O
did O
not O
have O
_RARE_ I-GENE
effects O
on O
_RARE_ I-GENE
reproductive O
performance O
as O
examined O
( O
_RARE_ I-GENE
, O
at O
_RARE_ I-GENE
, O
ovulation O
, O
and O
the O
early I-GENE
embryonic O
phase O
of O
development O
). O

Northern O
- I-GENE
blot O
analysis O
of O
mRNA I-GENE
from O
_RARE_ I-GENE
- I-GENE
grown O
N I-GENE
. O
_RARE_ I-GENE
showed O
that O
_RARE_ I-GENE
hybridized O
to O
a O
3 I-GENE
. O
4 I-GENE
kb O
mRNA I-GENE
species O
. O

The O
variable O
regions O
of O
vertebrate I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
isoforms I-GENE
reflect O
the O
subsequent O
addition O
and O
modification O
of O
genomic O
sequences I-GENE
to O
give O
rise O
to O
members O
of O
the O
_RARE_ I-GENE
_RARE_ I-GENE
family I-GENE
. O

The O
class I-GENE
II I-GENE
Escherichia I-GENE
coli I-GENE
alanine I-GENE
tRNA I-GENE
synthetase I-GENE
_RARE_ I-GENE
RNA I-GENE
_RARE_ I-GENE
, O
which O
_RARE_ I-GENE
the O
acceptor O
end O
of O
alanine I-GENE
tRNA I-GENE
with O
the O
critical O
_RARE_ I-GENE
: O
_RARE_ I-GENE
base O
pair O
. O

_RARE_ I-GENE
reaction O
time O
( O
RT I-GENE
) O
to O
a O
peripheral O
visual O
target O
( O
S2 I-GENE
) O
is O
shortened O
when O
a O
non O
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
( O
S1 I-GENE
) O
is O
_RARE_ I-GENE
at O
the O
S2 I-GENE
location O
100 O
- I-GENE
150 O
ms O
before O
target O
onset O
( O
early I-GENE
_RARE_ I-GENE
). O

A I-GENE
second O
study O
group O
, O
with O
intact O
cardiac O
_RARE_ I-GENE
, O
consisted O
of O
19 O
patients O
with O
stable O
angina O
pectoris O
class I-GENE
I I-GENE
to O
III I-GENE
. O

These O
viruses O
depend O
on O
the O
host O
cell O
machinery O
for O
their O
existence O
, O
and O
interference O
with O
these O
processes O
typically O
_RARE_ I-GENE
with O
other O
important O
host O
physiology O
. O

Treatment O
was O
well O
- I-GENE
tolerated O
. O

A I-GENE
concentration O
of O
12 O
. O
5 I-GENE
ppm O
_RARE_ I-GENE
induced O
a O
decrease O
from O
baseline O
values O
of O
approximately O
80 O
% O
in O
mean O
_RARE_ I-GENE
and O
of O
_RARE_ I-GENE
70 I-GENE
% O
in O
mean O
CBF I-GENE
. O

We O
have O
used O
these O
modified O
assay O
conditions O
to O
extend O
studies O
on O
the O
_RARE_ I-GENE
pathway O
. O

Renal O
cell O
carcinoma O
in O
children O
: O
a O
single O
_RARE_ I-GENE
' O
s O
experience O
. O

The O
data O
suggest O
that O
_RARE_ I-GENE
constitutively O
increases O
ras I-GENE
activity O
, O
and O
its O
TM I-GENE
segment O
plays O
a O
critical O
role O
in O
transformation O
- I-GENE
related I-GENE
signaling O
pathways O
. O

Thus O
, O
we O
have O
separated O
the O
signal I-GENE
function O
from O
the O
anchor I-GENE
function O
of O
the O
6 I-GENE
. O
_RARE_ I-GENE
SA O
domain I-GENE
. O

Five O
_RARE_ I-GENE
poly O
A I-GENE
addition O
sites I-GENE
are O
located O
in O
the O
350 O
base O
pairs O
immediately O
following O
the O
protein I-GENE
IX I-GENE
coding O
region O
. O

Factors O
associated I-GENE
with O
_RARE_ I-GENE
transmission O
of O
hepatitis I-GENE
B I-GENE
virus I-GENE
infection O
in O
_RARE_ I-GENE
. O

_RARE_ I-GENE
to O
higher O
TPA O
concentrations O
decreased O
the O
content O
of O
these O
transcripts I-GENE
. O

Northern O
analysis O
, O
to O
search O
for O
a O
_RARE_ I-GENE
transcript I-GENE
, O
showed O
no O
distinct O
transcript I-GENE
and O
indicated O
severely O
degraded O
mRNA I-GENE
. O

Our O
results O
indicate O
that O
the O
minimal I-GENE
requirements O
for O
induction O
of O
PEPCK I-GENE
by O
PKA I-GENE
and O
inhibition O
by O
insulin I-GENE
include O
: O
1 I-GENE
) O
the O
CREB I-GENE
activation O
domain I-GENE
, O
2 I-GENE
) O
the O
PEPCK I-GENE
TATA I-GENE
sequence I-GENE
, O
and O
3 I-GENE
) O
insulin I-GENE
- I-GENE
responsive I-GENE
hepatoma O
cells O
. O

The O
high O
degree O
of O
conservation O
between O
_RARE_ I-GENE
and O
_RARE_ I-GENE
gene I-GENE
organization O
and O
sequence I-GENE
confirmed O
that O
_RARE_ I-GENE
gene I-GENE
encodes O
for O
a O
second O
member O
of O
the O
_RARE_ I-GENE
gene I-GENE
family I-GENE
in O
human I-GENE
. O

The O
efficacy O
of O
a O
_RARE_ I-GENE
_RARE_ I-GENE
product I-GENE
for O
treatment O
of O
_RARE_ I-GENE
_RARE_ I-GENE
was O
evaluated O
following O
_RARE_ I-GENE
infusion O
of O
Escherichia I-GENE
coli I-GENE
. O

The O
human I-GENE
_RARE_ I-GENE
gene I-GENE
, O
encoding O
a O
tyrosine I-GENE
kinase I-GENE
substrate I-GENE
, O
is O
conserved O
in O
evolution O
and O
maps O
to O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
. O

The O
gene I-GENE
encoding O
the O
105 I-GENE
- I-GENE
kDa I-GENE
protein I-GENE
( O
_RARE_ I-GENE
) O
precursor I-GENE
of O
the O
p50 I-GENE
subunit I-GENE
of O
transcription I-GENE
factor I-GENE
NF I-GENE
- I-GENE
kappa I-GENE
B I-GENE
also O
encodes O
a O
p70 I-GENE
I I-GENE
kappa I-GENE
B I-GENE
protein I-GENE
, O
I I-GENE
kappa I-GENE
B I-GENE
gamma I-GENE
, O
which O
is O
identical O
to O
the O
C I-GENE
- I-GENE
terminal I-GENE
_RARE_ I-GENE
amino O
acids O
of O
_RARE_ I-GENE
. O

Alternative O
splicing O
of O
RNA I-GENE
transcripts I-GENE
encoded I-GENE
by O
the O
murine I-GENE
_RARE_ I-GENE
NF I-GENE
- I-GENE
kappa I-GENE
B I-GENE
gene I-GENE
generates O
I I-GENE
kappa I-GENE
B I-GENE
gamma I-GENE
isoforms I-GENE
with O
different O
inhibitory I-GENE
activities O
. O

_RARE_ I-GENE
L I-GENE
- I-GENE
_RARE_ I-GENE
attenuated O
the O
_RARE_ I-GENE
increase O
of O
_RARE_ I-GENE
by O
52 O
+/- O
6 I-GENE
% O
and O
_RARE_ I-GENE
by O
29 O
+/- O
5 I-GENE
% O
after O
45 O
- I-GENE
min O
exposure O
. O

The O
experiment O
included O
6 I-GENE
male O
and O
4 I-GENE
female O
healthy O
subjects O
who O
, O
during O
a O
24 O
- I-GENE
hour O
_RARE_ I-GENE
in O
the O
respiration O
_RARE_ I-GENE
, O
performed O
, O
in O
the O
_RARE_ I-GENE
and O
_RARE_ I-GENE
, O
15 O
min O
_RARE_ I-GENE
with O
the O
total O
work O
of O
6 I-GENE
, O
750 O
kg O
m I-GENE
. O

These O
rearrangements O
result O
in O
the O
formation O
of O
chimeric I-GENE
genes I-GENE
showing O
the O
tyrosine I-GENE
kinase I-GENE
domain I-GENE
of O
_RARE_ I-GENE
fused O
with O
the O
5 I-GENE
' O
end O
sequences I-GENE
of O
different O
genes I-GENE
. O

_RARE_ I-GENE
loss O
of O
heterozygosity O
( O
_RARE_ I-GENE
) O
of O
> O
30 O
% O
of O
the O
_RARE_ I-GENE
cases O
was O
observed O
on O
chromosomes O
_RARE_ I-GENE
( O
41 O
. O
1 I-GENE
%), O
_RARE_ I-GENE
( O
52 O
. O
6 I-GENE
%), O
_RARE_ I-GENE
( O
30 O
. O
4 I-GENE
%), O
_RARE_ I-GENE
( O
33 O
. O
3 I-GENE
%), O
_RARE_ I-GENE
( O
35 O
. O
7 O
%), O
_RARE_ I-GENE
( O
30 O
. O
8 O
%), O
_RARE_ I-GENE
( O
32 O
. O
4 I-GENE
%), O
_RARE_ I-GENE
( O
52 O
. O
7 O
%), O
_RARE_ I-GENE
( O
55 O
. O
2 I-GENE
%), O
_RARE_ I-GENE
( O
33 O
. O
3 I-GENE
%), O
_RARE_ I-GENE
( O
45 O
. O
7 O
%), O
and O
_RARE_ I-GENE
( O
30 O
. O
4 I-GENE
%). O

A I-GENE
single O
amino O
acid I-GENE
change O
in O
the O
_RARE_ I-GENE
vacuolar I-GENE
sorting I-GENE
signal I-GENE
prevents O
this O
interaction O
. O

_RARE_ I-GENE
- I-GENE
tRNA I-GENE
synthetase I-GENE
and O
_RARE_ I-GENE
- I-GENE
tRNA I-GENE
synthetase I-GENE
belong O
to O
different O
classes O
of O
_RARE_ I-GENE
- I-GENE
tRNA I-GENE
synthetases I-GENE
that O
are O
thought O
to O
have O
evolved O
along O
independent O
evolutionary O
pathways O
. O

Using O
the O
sequence I-GENE
data O
obtained O
from O
the O
human I-GENE
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
region O
, O
we O
have O
extended O
a O
polymerase I-GENE
chain I-GENE
reaction O
- I-GENE
based O
assay O
to O
test O
for O
the O
expression O
of O
the O
individual O
_RARE_ I-GENE
gene I-GENE
segments O
. O

This O
analysis O
revealed O
an O
intact O
gene I-GENE
( O
_RARE_ I-GENE
) O
showing O
a O
high O
degree O
of O
homology I-GENE
with O
the O
Saccharomyces I-GENE
cerevisiae I-GENE
_RARE_ I-GENE
gene I-GENE
encoding O
the O
large O
subunit I-GENE
of O
_RARE_ I-GENE
- I-GENE
phosphate I-GENE
synthetase I-GENE
( O
_RARE_ I-GENE
- I-GENE
A I-GENE
). O

Restriction O
analysis O
and O
Southern O
hybridization O
revealed O
the O
presence O
of O
_RARE_ I-GENE
in O
all O
the O
plasmid O
- I-GENE
mediated O
cadmium O
- I-GENE
resistant O
L I-GENE
. O
monocytogenes O
strains O
tested O
but O
not O
in O
strains O
encoding O
cadmium O
resistance O
on O
the O
chromosome O
. O

The O
_RARE_ I-GENE
latency O
( O
from O
the O
ECG O
R I-GENE
- I-GENE
wave O
to O
the O
integrated O
_RARE_ I-GENE
burst O
peak O
) O
was O
constant O
at O
approximately O
1 I-GENE
. O
20 O
s O
during O
sleep O
, O
suggesting O
that O
pulse O
- I-GENE
_RARE_ I-GENE
was O
maintained O
. O

DESIGN O
-- O
A I-GENE
randomised O
study O
was O
conducted O
in O
all O
women O
aged O
50 O
- I-GENE
70 I-GENE
years O
who O
were O
_RARE_ I-GENE
for O
breast O
cancer O
screening O
and O
living O
in O
the O
_RARE_ I-GENE
of O
_RARE_ I-GENE
. O

Identification O
of O
an O
immediate I-GENE
- I-GENE
early I-GENE
gene I-GENE
in O
the O
_RARE_ I-GENE
' O
s O
disease O
virus I-GENE
long O
internal O
repeat I-GENE
region O
which O
encodes O
a O
unique O
14 O
- I-GENE
kilodalton I-GENE
polypeptide I-GENE
. O

We O
have O
used O
a O
full I-GENE
- I-GENE
length I-GENE
cDNA I-GENE
clone O
of O
a O
mouse I-GENE
hepatitis I-GENE
virus I-GENE
strain O
_RARE_ I-GENE
defective O
interfering O
( O
_RARE_ I-GENE
) O
RNA I-GENE
, O
_RARE_ I-GENE
- I-GENE
C I-GENE
, O
and O
cassette I-GENE
mutagenesis O
to O
study O
the O
mechanism O
of O
coronavirus O
_RARE_ I-GENE
mRNA I-GENE
synthesis O
. O

To O
study O
the O
structure O
- I-GENE
function O
of O
the O
gene I-GENE
5 I-GENE
product I-GENE
, O
wild I-GENE
- I-GENE
type I-GENE
and O
mutant I-GENE
forms O
of O
_RARE_ I-GENE
were O
produced O
by O
using O
a O
recombinant I-GENE
baculovirus O
expression O
system O
and O
a O
recombinant I-GENE
vaccinia I-GENE
virus I-GENE
/ I-GENE
T7 I-GENE
( O
_RARE_ I-GENE
- I-GENE
3 I-GENE
) O
expression O
system O
. O

Gel O
electrophoresis O
and O
Western O
_RARE_ I-GENE
analyses O
of O
intracellular O
fractions O
derived O
from O
infected O
cells O
revealed O
that O
large O
amounts O
of O
_RARE_ I-GENE
were O
present O
in O
the O
cytosol O
and O
in O
association O
with O
the O
cytoskeletal O
matrix I-GENE
. O

The O
transcription I-GENE
factor I-GENE
AP I-GENE
- I-GENE
2 I-GENE
is O
encoded I-GENE
by O
a O
gene I-GENE
located O
on O
chromosome O
6 I-GENE
near O
the O
HLA I-GENE
locus I-GENE
. O

The O
mature O
AP I-GENE
- I-GENE
2 I-GENE
mRNA I-GENE
is O
spliced O
from O
7 O
exons O
distributed O
over O
a O
region O
of O
18 O
kb O
genomic O
DNA I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
' O
s O
psychological O
_RARE_ I-GENE
coupled I-GENE
to O
his O
work O
with O
_RARE_ I-GENE
_RARE_ I-GENE
that O
allowed O
_RARE_ I-GENE
to O
display O
his O
abilities O
as O
_RARE_ I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
. O

The O
_RARE_ I-GENE
were O
_RARE_ I-GENE
men O
in O
hepatitis I-GENE
B I-GENE
vaccine O
trials O
in O
_RARE_ I-GENE
( O
n O
= O
74 O
), O
New O
York O
City O
( O
n O
= O
120 O
), O
and O
_RARE_ I-GENE
_RARE_ I-GENE
( O
n O
= O
_RARE_ I-GENE
). O

The O
7 O
- I-GENE
day O
treatment O
resulted O
in O
a O
decrease O
in O
mitochondrial I-GENE
uptake O
of O
_RARE_ I-GENE
and O
an O
increase O
in O
_RARE_ I-GENE
uptake O
. O

_RARE_ I-GENE
_RARE_ I-GENE
purpura O
in O
systemic O
lupus O
erythematosus O
. O

Comparison O
with O
the O
crystal O
structure O
of O
_RARE_ I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
( O
_RARE_ I-GENE
et O
al O
., O
1991 O
) O
reveals O
a O
very O
similar O
folding O
topology O
, O
although O
several O
secondary O
structural O
elements O
are O
extended O
in O
_RARE_ I-GENE
relative O
to O
_RARE_ I-GENE
_RARE_ I-GENE
. O

CONCLUSIONS O
: O
Serum I-GENE
prolactin I-GENE
concentrations O
show O
age O
related I-GENE
variations O
in O
presumably O
_RARE_ I-GENE
men O
. O

Eight O
highly O
_RARE_ I-GENE
male O
_RARE_ I-GENE
were O
studied O
to O
determine O
the O
relationship O
between O
critical O
power O
( O
CP I-GENE
) O
and O
the O
onset O
of O
blood O
lactate I-GENE
accumulation O
( O
_RARE_ I-GENE
). O

As O
in O
S I-GENE
. O
cerevisiae I-GENE
, O
the O
sequence I-GENE
of O
_RARE_ I-GENE
+ I-GENE
showed O
two O
_RARE_ I-GENE
cell O
- I-GENE
cycle O
boxes O
and O
a O
putative O
DNA I-GENE
damage O
- I-GENE
responsive I-GENE
element I-GENE
in O
its O
upstream O
region O
. O

_RARE_ I-GENE
' O
s O
_RARE_ I-GENE
for O
_RARE_ I-GENE
work O
outside O
the O
home O
are O
_RARE_ I-GENE
by O
their O
role O
as O
primary O
_RARE_ I-GENE
within O
the O
family I-GENE
, O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
. O

A I-GENE
partial O
cDNA I-GENE
sequence I-GENE
indicated O
that O
the O
T I-GENE
lymphocyte I-GENE
early I-GENE
- I-GENE
activation O
gene I-GENE
( O
_RARE_ I-GENE
) O
encodes O
a O
protein I-GENE
related I-GENE
to O
the O
dual O
- I-GENE
function O
_RARE_ I-GENE
retrovirus O
receptor I-GENE
/ I-GENE
_RARE_ I-GENE
amino O
acid I-GENE
transporter I-GENE
( O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
), O
and O
RNA I-GENE
blots O
suggested O
highest O
_RARE_ I-GENE
expression O
in O
T I-GENE
lymphocytes O
and O
liver O
( O
_RARE_ I-GENE
, O
C I-GENE
. O
L I-GENE
., O
_RARE_ I-GENE
, O
K I-GENE
., O
_RARE_ I-GENE
, O
D I-GENE
. O

Furthermore O
, O
unlike O
the O
case O
for O
HIS3 I-GENE
where O
only O
a O
limited O
subset O
of O
TATA I-GENE
- I-GENE
like I-GENE
sequences I-GENE
can O
activate O
transcription I-GENE
in O
conjunction O
with O
_RARE_ I-GENE
, O
many O
divergent O
TATA I-GENE
- I-GENE
like I-GENE
sequences I-GENE
allowed O
_RARE_ I-GENE
activation O
of O
_RARE_ I-GENE
. O

_RARE_ I-GENE
expressed O
protein I-GENE
, O
as O
well O
as O
the O
in O
vitro O
_RARE_ I-GENE
_RARE_ I-GENE
translation I-GENE
product I-GENE
, O
_RARE_ I-GENE
with O
the O
purified O
37 O
- I-GENE
kDa I-GENE
protein I-GENE
on O
sodium O
dodecyl O
sulfate I-GENE
- I-GENE
polyacrylamide O
gels O
. O

In O
addition O
, O
this O
kinase I-GENE
is O
well O
conserved O
evolutionarily O
, O
ubiquitously O
expressed O
, O
and O
its O
genes I-GENE
map O
to O
a O
position O
on O
human I-GENE
chromosome O
1 I-GENE
frequently O
deleted O
in O
the O
late O
stages O
of O
tumorigenesis O
. O

Deletion O
analysis O
of O
the O
_RARE_ I-GENE
promoter I-GENE
led O
to O
the O
identification O
of O
an O
upstream O
activating I-GENE
sequence I-GENE
element I-GENE
, O
_RARE_ I-GENE
( O
5 I-GENE
' O
_RARE_ I-GENE
3 I-GENE
_RARE_ I-GENE
necessary O
and O
sufficient O
for O
conferring O
carbon O
source O
- I-GENE
dependent I-GENE
regulation O
on O
a O
heterologous O
reporter I-GENE
gene I-GENE
. O

Interestingly O
, O
the O
interaction O
of O
ZAP I-GENE
- I-GENE
70 I-GENE
with O
the O
motif I-GENE
was O
dependent I-GENE
on O
the O
presence O
of O
both O
ZAP I-GENE
- I-GENE
70 I-GENE
SH2 I-GENE
domains I-GENE
and O
both O
of O
the O
tyrosine I-GENE
residues O
in O
the O
motif I-GENE
, O
suggesting O
that O
ZAP I-GENE
- I-GENE
70 I-GENE
interacts O
with O
two O
phosphotyrosine I-GENE
residues O
and O
that O
the O
binding I-GENE
of O
the O
two O
SH2 I-GENE
domains I-GENE
is O
cooperative O
. O

PRL I-GENE
- I-GENE
1 I-GENE
is O
able O
to O
_RARE_ I-GENE
phosphotyrosine I-GENE
substrates O
, O
and O
mutation I-GENE
of O
the O
active O
- I-GENE
site I-GENE
cysteine I-GENE
residue O
abolishes O
this O
activity O
. O

In O
_RARE_ I-GENE
lung O
epithelial O
cells O
, O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
and O
T I-GENE
beta I-GENE
R I-GENE
- I-GENE
I I-GENE
signal I-GENE
a O
common O
set O
of O
growth I-GENE
- I-GENE
inhibitory I-GENE
and O
transcriptional O
responses O
in O
association O
with O
their O
corresponding O
ligands O
and O
type I-GENE
II I-GENE
receptors I-GENE
. O

50 O
kDa I-GENE
and O
130 I-GENE
- I-GENE
170 I-GENE
kDa I-GENE
were O
detected O
. O

H I-GENE
- I-GENE
7 O
, O
which O
specifically O
, O
although O
weakly O
, O
inhibited O
PKC I-GENE
activation O
, O
had O
no O
effect O
on O
tyrosine I-GENE
phosphorylation O
and O
_RARE_ I-GENE
( O
3 I-GENE
, O
4 I-GENE
) O
P2 I-GENE
production O
. O

The O
effects O
of O
systemic O
glucose O
concentration O
on O
brain O
metabolism O
following O
repeated O
brain O
ischemia O
. O

This O
strategy O
was O
used O
to O
place O
both O
the O
_RARE_ I-GENE
neo I-GENE
gene I-GENE
and O
the O
_RARE_ I-GENE
_RARE_ I-GENE
phenylalanine I-GENE
ammonia I-GENE
lyase I-GENE
( O
PAL I-GENE
)- I-GENE
encoding O
gene I-GENE
under O
the O
transcriptional O
control O
of O
_RARE_ I-GENE
:: O
_RARE_ I-GENE
. O

In O
the O
case O
of O
congenital O
protein I-GENE
C I-GENE
deficiency O
, O
vitamin O
K I-GENE
antagonists O
must O
be O
started O
_RARE_ I-GENE
due O
to O
the O
risk O
of O
skin O
necrosis I-GENE
. O

A I-GENE
- I-GENE
69 O
- I-GENE
year O
- I-GENE
old O
patient O
with O
postoperative O
small I-GENE
- I-GENE
bowel O
obstruction O
underwent O
_RARE_ I-GENE
three O
times O
. O

On O
physical O
examination O
a O
mild O
_RARE_ I-GENE
_RARE_ I-GENE
of O
small I-GENE
and O
large O
_RARE_ I-GENE
was O
seen O
. O

In O
addition O
, O
we O
observe O
that O
the O
_RARE_ I-GENE
- I-GENE
promoter I-GENE
interaction O
is O
highly O
sensitive O
to O
the O
antagonistic O
effects O
of O
cisplatin O
- I-GENE
DNA I-GENE
_RARE_ I-GENE
. O

We O
conclude O
that O
the O
_RARE_ I-GENE
is O
useful O
in O
_RARE_ I-GENE
neonates O
from O
the O
_RARE_ I-GENE
. O

_RARE_ I-GENE
- I-GENE
16 O
, O
_RARE_ I-GENE
and O
cisplatin O
( O
_RARE_ I-GENE
) O
for O
extensive O
small I-GENE
cell O
lung O
cancer O
. O

A I-GENE
total O
of O
7 O
( O
4 I-GENE
males O
and O
3 I-GENE
females O
) O
patients O
were O
included O
in O
this O
retrospective O
study O
to O
determine O
the O
sensitivity O
of O
_RARE_ I-GENE
with O
I I-GENE
- I-GENE
131 O
labeled O
anti I-GENE
CEA I-GENE
/ I-GENE
CA I-GENE
19 O
- I-GENE
9 O
monoclonal I-GENE
antibodies I-GENE
. O

_RARE_ I-GENE
, O
bilateral O
and O
permanent O
ventilation O
with O
a O
diaphragm O
pacing O
in O
childhood O
: O
the O
implantation O
technique O
and O
_RARE_ I-GENE

A I-GENE
genomic O
clone O
for O
the O
_RARE_ I-GENE
gene I-GENE
, O
which O
is O
expressed O
specifically O
at O
the O
S I-GENE
phase O
during O
the O
cell O
cycle O
in O
_RARE_ I-GENE
cultures O
of O
_RARE_ I-GENE
( O
_RARE_ I-GENE
_RARE_ I-GENE
) O
cells O
, O
was O
isolated O
. O

CONCLUSIONS O
: O
_RARE_ I-GENE
of O
bacteria O
or O
endotoxin I-GENE
from O
the O
gastrointestinal O
tract O
into O
the O
_RARE_ I-GENE
has O
been O
noted O
in O
animal O
experiments O
; O
however O
, O
translocation O
was O
not O
detected O
in O
our O
patients O
with O
hemorrhagic O
shock I-GENE
. O

The O
_RARE_ I-GENE
and O
_RARE_ I-GENE
genes I-GENE
encoded I-GENE
polypeptides I-GENE
with O
calculated O
molecular O
masses O
of O
19 O
. O
9 O
and O
45 O
. O
2 I-GENE
kDa I-GENE
, O
respectively O
. O

Southern O
blotting O
analysis O
_RARE_ I-GENE
the O
occurrence O
of O
multiple O
_RARE_ I-GENE
genes I-GENE
in O
the O
rat I-GENE
genome O
. O

_RARE_ I-GENE
with O
the O
_RARE_ I-GENE
analog O
was O
prevented O
when O
Gly O
- I-GENE
2 I-GENE
was O
mutated O
to O
alanine I-GENE
, O
implying O
that O
N I-GENE
- I-GENE
_RARE_ I-GENE
is O
required O
for O
_RARE_ I-GENE
, O
and O
when O
either O
Cys I-GENE
- I-GENE
3 I-GENE
or O
Cys I-GENE
- I-GENE
6 I-GENE
was O
mutated O
to O
serine I-GENE
. O

_RARE_ I-GENE
composition O
and O
domain I-GENE
structure O
of O
the O
_RARE_ I-GENE
sporulation I-GENE
transcription I-GENE
factor I-GENE
of O
Bacillus I-GENE
subtilis I-GENE
. O

Electrophoretic O
mobility I-GENE
shift O
analysis O
indicates O
that O
NF I-GENE
- I-GENE
IL I-GENE
- I-GENE
6 I-GENE
, O
as O
well O
as O
other O
related I-GENE
members O
of O
this O
family I-GENE
, O
bind O
specifically O
to O
the O
NF I-GENE
- I-GENE
IL I-GENE
- I-GENE
6 I-GENE
site I-GENE
in O
the O
IL I-GENE
- I-GENE
8 O
promoter I-GENE
. O

_RARE_ I-GENE
, O
_RARE_ I-GENE
_RARE_ I-GENE
virus I-GENE
( O
_RARE_ I-GENE
), O
_RARE_ I-GENE
yellow O
_RARE_ I-GENE
virus I-GENE
( O
_RARE_ I-GENE
) O
and O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
virus I-GENE
templates O
produced O
1 I-GENE
kb O
amplification O
products I-GENE
, O
which O
were O
shown O
by O
sequencing O
to O
represent O
fragments I-GENE
of O
the O
respective O
HSP70 I-GENE
genes I-GENE
. O

To O
identify O
the O
precise O
location O
of O
the O
phosphorylation O
site I-GENE
on O
the O
64 O
- I-GENE
kDa I-GENE
protein I-GENE
, O
a O
step O
- I-GENE
by O
- I-GENE
step O
mutagenesis O
procedures O
was O
followed O
. O

The O
p53 I-GENE
tumor I-GENE
suppressor I-GENE
gene I-GENE
product I-GENE
, O
a O
sequence I-GENE
- I-GENE
specific I-GENE
DNA I-GENE
- I-GENE
binding I-GENE
protein I-GENE
, O
has O
been O
shown O
to O
act O
as O
a O
transcriptional O
activator I-GENE
and O
repressor I-GENE
both O
in O
vitro O
and O
in O
vivo O
. O

Mutational O
analysis O
of O
chromosomal I-GENE
segment O
_RARE_ I-GENE
, O
a O
region O
containing O
the O
_RARE_ I-GENE
acid I-GENE
decarboxylase I-GENE
gene I-GENE
. O

_RARE_ I-GENE
of O
the O
_RARE_ I-GENE
gene I-GENE
are O
associated I-GENE
with O
lymphoid I-GENE
_RARE_ I-GENE
, O
but O
the O
functional O
significance O
of O
these O
alterations O
is O
not O
known O
. O

Cloning O
and O
sequencing O
of O
the O
corresponding O
cDNAs I-GENE
indicates O
that O
, O
via O
alternative O
splicing O
, O
the O
rearranged I-GENE
gene I-GENE
codes O
for O
two O
proteins I-GENE
of O
84 O
and O
85 O
kD I-GENE
( O
_RARE_ I-GENE
/ I-GENE
85 O
) O
which O
_RARE_ I-GENE
the O
DNA I-GENE
- I-GENE
binding I-GENE
rel I-GENE
domain I-GENE
and O
the O
first O
five O
_RARE_ I-GENE
repeats I-GENE
, O
but O
have O
lost O
their O
carboxy I-GENE
- I-GENE
terminus O
including O
the O
_RARE_ I-GENE
_RARE_ I-GENE
repeat I-GENE
. O

Transient O
co O
- I-GENE
transfection O
assays O
involving O
_RARE_ I-GENE
expression O
vectors O
and O
kappa I-GENE
B I-GENE
- I-GENE
driven O
reporter I-GENE
plasmids O
indicate O
that O
_RARE_ I-GENE
p85 I-GENE
has O
lost O
the O
transcriptional O
repressor I-GENE
functions O
typical O
of O
normal O
_RARE_ I-GENE
_RARE_ I-GENE
. O

Also O
, O
_RARE_ I-GENE
as O
well O
as O
_RARE_ I-GENE
are O
specific I-GENE
in O
their O
inhibition O
of O
Sp1 I-GENE
binding I-GENE
. O

Intravenous O
antibiotic O
therapy O
in O
cystic I-GENE
fibrosis I-GENE
: O
in O
hospital O
or O
at O
home O
? O

_RARE_ I-GENE
reading O
frames O
in O
a O
_RARE_ I-GENE
nucleotide I-GENE
sequence I-GENE
within O
MDV I-GENE
- I-GENE
1 I-GENE
BamHI I-GENE
- I-GENE
D I-GENE
DNA I-GENE
fragment I-GENE
: O
evidence O
for O
splicing O
of O
mRNA I-GENE
from O
a O
new O
viral I-GENE
glycoprotein I-GENE
gene I-GENE
. O

The O
_RARE_ I-GENE
gene I-GENE
comprises O
an O
open O
reading O
frame O
( O
ORF I-GENE
) O
encoding O
a O
putative O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
protein I-GENE
of O
_RARE_ I-GENE
amino O
acids O
with O
a O
predicted O
molecular O
mass O
of O
32 O
- I-GENE
kDa I-GENE
. O

Co O
- I-GENE
transfection O
of O
a O
tat I-GENE
expressing O
plasmid O
with O
these O
viruses O
containing O
the O
tat I-GENE
ORF I-GENE
mutations O
resulted O
in O
higher O
levels O
of O
virus I-GENE
production O
demonstrating O
that O
the O
effects O
of O
both O
mutants I-GENE
are O
tat I-GENE
specific I-GENE
. O

Analysis O
of O
the O
gag I-GENE
and O
rev I-GENE
proteins I-GENE
in O
the O
transfected O
cells O
demonstrated O
that O
these O
proteins I-GENE
were O
not O
detectable O
in O
cells O
transfected O
with O
the O
tat I-GENE
mutants I-GENE
but O
could O
be O
readily O
detected O
when O
the O
mutations O
were O
complemented O
in O
trans O
with O
a O
tat I-GENE
expression O
vector O
. O

The O
_RARE_ I-GENE
profile O
of O
the O
methyltransferase I-GENE
reveals O
the O
presence O
of O
at O
least O
five O
potential O
transmembrane I-GENE
domains I-GENE
. O

Measurement O
of O
SaO2 O
at O
moderate O
altitude O
can O
be O
helpful O
in O
the O
care O
of O
both O
healthy O
and O
_RARE_ I-GENE
newborns O
or O
infants O
. O

To O
determine O
whether O
the O
excess O
prevalence O
of O
human I-GENE
immunodeficiency I-GENE
virus I-GENE
type I-GENE
1 I-GENE
( O
HIV I-GENE
- I-GENE
1 I-GENE
) O
infection O
in O
US O
black O
and O
_RARE_ I-GENE
_RARE_ I-GENE
men O
relative O
to O
white O
men O
can O
be O
explained O
by O
differences O
in O
_RARE_ I-GENE
factors I-GENE
, O
history O
of O
_RARE_ I-GENE
transmitted O
diseases O
, O
or O
sexual O
and O
drug O
- I-GENE
use O
_RARE_ I-GENE
, O
the O
authors O
conducted O
a O
cross O
- I-GENE
sectional O
analysis O
of O
baseline O
HIV I-GENE
- I-GENE
1 I-GENE
_RARE_ I-GENE
and O
HIV I-GENE
- I-GENE
1 I-GENE
risk O
factors I-GENE
among O
4 I-GENE
, O
_RARE_ I-GENE
non O
- I-GENE
_RARE_ I-GENE
white O
, O
_RARE_ I-GENE
_RARE_ I-GENE
white O
, O
and O
_RARE_ I-GENE
black O
_RARE_ I-GENE
men O
from O
four O
centers O
in O
the O
United O
_RARE_ I-GENE
( O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
, O
DC O
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
_RARE_ I-GENE
). O

The O
patients O
in O
one O
group O
had O
intrauterine O
_RARE_ I-GENE
inserted O
and O
_RARE_ I-GENE
was O
_RARE_ I-GENE
to O
achieve O
the O
_RARE_ I-GENE
_RARE_ I-GENE
of O
uterine O
activity O
observed O
in O
spontaneous O
normal O
labour O
according O
to O
_RARE_ I-GENE
. O

_RARE_ I-GENE
development O
of O
the O
rat I-GENE
conditioning O
_RARE_ I-GENE
is O
especially O
warranted O
because O
of O
the O
ability O
to O
record O
sympathetic O
nerve I-GENE
activity O
in O
intact O
, O
_RARE_ I-GENE
subjects O
and O
the O
large O
number O
of O
readily O
available O
genetic O
strains O
, O
which O
model O
human I-GENE
pathological O
states O
. O

The O
_RARE_ I-GENE
of O
retinal O
vessels O
was O
examined O
in O
three O
eyes O
from O
diabetic O
patients O
and O
two O
eyes O
from O
control O
subjects O
. O

The O
regulatory I-GENE
region O
also O
has O
a O
sequence I-GENE
similar O
to O
the O
binding I-GENE
site I-GENE
for O
a O
liver O
- I-GENE
specific I-GENE
transcription I-GENE
factor I-GENE
, O
hepatocyte I-GENE
nuclear I-GENE
factor I-GENE
1 I-GENE
( O
HNF I-GENE
- I-GENE
1 I-GENE
), O
at O
positions O
- I-GENE
120 O
to O
- I-GENE
132 O
. O

Thus O
, O
we O
have O
identified O
a O
GRE I-GENE
sufficient O
to O
account O
for O
full I-GENE
glucocorticoid I-GENE
inducibility O
and O
an O
HNF I-GENE
- I-GENE
1 I-GENE
site I-GENE
close O
to O
the O
promoter I-GENE
that O
are O
major I-GENE
determinants I-GENE
of O
transcriptional O
control O
of O
the O
Xenopus I-GENE
fibrinogen I-GENE
B I-GENE
beta I-GENE
subunit I-GENE
gene I-GENE
in O
cells O
from O
normal O
liver O
tissue I-GENE
. O

_RARE_ I-GENE
. O

The O
_RARE_ I-GENE
- I-GENE
1b I-GENE
gene I-GENE
encodes O
for O
a O
basic I-GENE
- I-GENE
type I-GENE
component O
of O
the O
pathogenesis O
- I-GENE
related I-GENE
PR I-GENE
- I-GENE
1 I-GENE
protein I-GENE
family I-GENE
. O

Replacement I-GENE
of O
the O
CRE O
with O
a O
second O
copy O
of O
the O
AP I-GENE
- I-GENE
1 I-GENE
site I-GENE
results O
in O
a O
level O
of O
transcriptional O
activity O
comparable O
with O
that O
of O
the O
wild I-GENE
- I-GENE
type I-GENE
sequence I-GENE
, O
but O
replacement O
of O
the O
AP I-GENE
- I-GENE
1 I-GENE
site I-GENE
with O
a O
CRE O
abolishes O
activity O
. O

The O
T I-GENE
- I-GENE
cyt I-GENE
promoter I-GENE
, O
although O
of O
bacterial I-GENE
origin O
is O
active O
in O
_RARE_ I-GENE
and O
the O
30 O
bp O
cyt I-GENE
- I-GENE
1 I-GENE
element I-GENE
is O
located O
within O
a O
region O
that O
is O
essential O
for O
T I-GENE
- I-GENE
cyt I-GENE
_RARE_ I-GENE
activity O
in O
leaf O
, O
stem O
and O
root O
cells O
of O
tobacco I-GENE
plants O
. O

_RARE_ I-GENE
_RARE_ I-GENE
: O
developing O
an O
efficient O
system O
. O

We O
suggest O
that O
CT I-GENE
scan O
be O
_RARE_ I-GENE
in O
diagnosis O
of O
tumors O
in O
that O
area O
. O

_RARE_ I-GENE
- I-GENE
1 I-GENE
had O
no O
influence O
on O
either O
the O
ischemic O
parameters O
in O
the O
surface O
electrocardiogram O
( O
ECG O
) O
or O
the O
_RARE_ I-GENE
ECG O
. O

Effect O
of O
aging O
on O
respiratory O
skeletal I-GENE
muscles O
. O

Two O
_RARE_ I-GENE
computer O
programs O
using O
_RARE_ I-GENE
transformation O
for O
the O
analysis O
of O
S I-GENE
- I-GENE
shaped O
curves O
are O
presented O
. O

The O
yeast I-GENE
_RARE_ I-GENE
gene I-GENE
is O
essential O
for O
secretory I-GENE
protein I-GENE
translocation O
and O
encodes O
a O
conserved O
protein I-GENE
of O
the O
endoplasmic O
reticulum O
. O

The O
lengths O
of O
the O
complete O
polypeptide I-GENE
chain I-GENE
of O
the O
recombinant I-GENE
enzyme I-GENE
and O
its O
transit O
peptide I-GENE
are O
_RARE_ I-GENE
and O
53 O
residues O
, O
respectively O
. O

The O
absence O
of O
_RARE_ I-GENE
bound O
to O
the O
T I-GENE
protein I-GENE
in O
our O
experimental O
conditions O
demonstrates O
that O
_RARE_ I-GENE
is O
not O
covalently O
linked O
to O
the O
T I-GENE
protein I-GENE
. O

TATA I-GENE
and O
CCAAT I-GENE
boxes O
are O
located O
34 O
- I-GENE
bp O
and O
68 O
- I-GENE
bp O
, O
respectively O
, O
upstream O
of O
the O
transcription I-GENE
start O
site I-GENE
, O
the O
5 I-GENE
'- O
untranslated O
leader O
is O
78 O
nucleotides O
long O
, O
and O
the O
intronless O
gene I-GENE
has O
at O
least O
two O
different O
polyadenylation O
sites I-GENE
. O

_RARE_ I-GENE
is O
the O
same O
gene I-GENE
as O
_RARE_ I-GENE
which O
was O
identified O
as O
encoding O
a O
subunit I-GENE
of O
the O
_RARE_ I-GENE
- I-GENE
6 I-GENE
- I-GENE
phosphate I-GENE
synthase I-GENE
/ I-GENE
phosphatase I-GENE
complex I-GENE
and O
it O
is O
allelic O
to O
the O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
and O
_RARE_ I-GENE
mutations O
. O

We O
also O
compared O
the O
sequence I-GENE
with O
the O
partly O
homologous O
products I-GENE
of O
the O
S I-GENE
. O
cerevisiae I-GENE
genes I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
which O
code O
for O
the O
larger O
subunits I-GENE
of O
the O
_RARE_ I-GENE
synthase I-GENE
complex I-GENE
and O
with O
a O
_RARE_ I-GENE
homologue I-GENE
, O
_RARE_ I-GENE
, O
of O
unknown O
function O
. O

Stroop O
interference O
: O
aging O
effects O
assessed O
with O
the O
Stroop O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
Test O
. O

_RARE_ I-GENE
of O
[ O
3H O
] O
PA I-GENE
production O
upon O
CD3 I-GENE
cross O
- I-GENE
linking O
was O
77 O
% O
lower O
in O
_RARE_ I-GENE
_RARE_ I-GENE
- I-GENE
cells O
than O
in O
_RARE_ I-GENE
+ I-GENE
cells O
, O
consistent O
with O
the O
reduced O
activity O
of O
_RARE_ I-GENE
in O
_RARE_ I-GENE
- I-GENE
cells O
. O

CONCLUSION O
: O
The O
study O
demonstrates O
that O
_RARE_ I-GENE
ultrasonography O
has O
an O
efficiency O
of O
88 O
% O
in O
differentiating O
_RARE_ I-GENE
from O
other O
ovarian O
masses O
with O
a O
specificity O
of O
90 O
%. O

Genomic O
Southern O
blot O
analysis O
of O
rat I-GENE
EFIA I-GENE
( O
gene I-GENE
encoding O
enhancer I-GENE
factor I-GENE
I I-GENE
subunit I-GENE
A I-GENE
) O
reveals O
a O
complex I-GENE
band O
pattern O
when O
cDNA I-GENE
_RARE_ I-GENE
probes O
are O
used O
. O

The O
effect O
of O
_RARE_ I-GENE
and O
furosemide O
in O
130 I-GENE
patients O
with O
_RARE_ I-GENE
Class I-GENE
I I-GENE
and O
II I-GENE
heart O
failure O
were O
studied O
in O
a O
parallel O
, O
double O
- I-GENE
blind O
, O
randomized O
placebo O
- I-GENE
controlled O
multi I-GENE
- I-GENE
_RARE_ I-GENE
trial O
. O

The O
_RARE_ I-GENE
- I-GENE
3 I-GENE
gene I-GENE
of O
the O
filamentous I-GENE
fungus I-GENE
Neurospora I-GENE
crassa I-GENE
encodes O
nitrate I-GENE
reductase I-GENE
, O
the O
enzyme I-GENE
which O
catalyzes O
the O
first O
step O
in O
nitrate I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
can O
be O
described O
by O
a O
two O
- I-GENE
state O
process O
since O
a O
ratio O
of O
delta I-GENE
_RARE_ I-GENE
to O
delta I-GENE
_RARE_ I-GENE
' O
t I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
0 O
. O
96 O
. O

A I-GENE
Dictyostelium O
_RARE_ I-GENE
overexpressing O
_RARE_ I-GENE
does O
not O
develop O
normally O
. O

This O
motif I-GENE
has O
been O
shown O
to O
mediate O
protein I-GENE
interactions O
in O
the O
case O
of O
_RARE_ I-GENE
as O
well O
as O
several O
other O
repeat I-GENE
- I-GENE
bearing O
proteins I-GENE
. O

[ O
_RARE_ I-GENE
] O
_RARE_ I-GENE
( O
69 O
- I-GENE
85 O
) O
retains O
full I-GENE
biological O
activity O
. O

We O
_RARE_ I-GENE
that O
CaM I-GENE
binding I-GENE
by O
HIV I-GENE
envelope I-GENE
proteins I-GENE
is O
likely O
to O
exert O
diverse O
_RARE_ I-GENE
effects O
, O
and O
the O
mechanism O
for O
HIV I-GENE
- I-GENE
induced O
cytotoxicity O
may O
involve O
, O
in O
part O
, O
inhibition O
of O
CaM I-GENE
- I-GENE
regulated O
cellular O
functions O
. O

There O
was O
no O
apparent O
effect O
of O
growth I-GENE
temperature O
on O
the O
steady O
- I-GENE
state O
levels O
of O
_RARE_ I-GENE
mRNA I-GENE
in O
wild I-GENE
type I-GENE
plants O
. O

The O
major I-GENE
myosin I-GENE
- I-GENE
binding I-GENE
domain I-GENE
of O
skeletal I-GENE
muscle O
_RARE_ I-GENE
- I-GENE
C I-GENE
( O
C I-GENE
protein I-GENE
) O
resides O
in O
the O
COOH O
- I-GENE
terminal I-GENE
, O
immunoglobulin I-GENE
C2 I-GENE
motif I-GENE
. O

A I-GENE
second O
important O
molecule I-GENE
in O
TCR I-GENE
signal I-GENE
transduction O
is O
the O
guanine I-GENE
nucleotide I-GENE
binding I-GENE
protein I-GENE
, O
p21ras I-GENE
, O
which O
is O
coupled I-GENE
to O
the O
TCR I-GENE
by O
a O
protein I-GENE
tyrosine I-GENE
kinase I-GENE
dependent I-GENE
mechanism O
. O

Our O
results O
indicate O
that O
_RARE_ I-GENE
lipid O
accumulation O
is O
related I-GENE
to O
cortical O
oxygenation O
. O

We O
conclude O
that O
the O
_RARE_ I-GENE
questionnaire O
has O
good O
potential O
as O
an O
instrument O
for O
assessing O
_RARE_ I-GENE
in O
post O
- I-GENE
AMI O
patients O
and O
that O
it O
can O
be O
successfully O
self O
- I-GENE
administered O
. O

Most O
smokers O
would O
_RARE_ I-GENE
to O
_RARE_ I-GENE
smoking O
on O
their O
own O
. O

The O
inhibitory I-GENE
response O
to O
_RARE_ I-GENE
is O
essentially O
a O
protective O
reflex O
which O
probably O
serves O
to O
reduce O
the O
activity O
of O
the O
jaw O
- I-GENE
_RARE_ I-GENE
muscles O
when O
one O
_RARE_ I-GENE
_RARE_ I-GENE
on O
_RARE_ I-GENE
objects O
. O

The O
action O
of O
nef I-GENE
was O
specific I-GENE
to O
the O
LTR I-GENE
, O
as O
expression O
of O
nef I-GENE
had O
no O
effect O
on O
the O
activity O
of O
the O
simian I-GENE
virus I-GENE
40 I-GENE
, O
c I-GENE
- I-GENE
fms I-GENE
, O
urokinase I-GENE
plasminogen I-GENE
activator I-GENE
, O
or O
type I-GENE
5 I-GENE
acid I-GENE
phosphatase I-GENE
promoter I-GENE
. O
trans O
- I-GENE
activating I-GENE
activity O
was O
also O
manifested O
by O
a O
frameshift O
mutant I-GENE
expressing O
only O
the O
first O
35 O
amino O
acids O
of O
the O
protein I-GENE
. O

The O
product I-GENE
of O
the O
_RARE_ I-GENE
open O
reading O
frame O
of O
human I-GENE
immunodeficiency I-GENE
virus I-GENE
type I-GENE
1 I-GENE
( O
HIV I-GENE
- I-GENE
1 I-GENE
) O
is O
a O
15 O
- I-GENE
kDa I-GENE
, O
arginine I-GENE
- I-GENE
rich O
protein I-GENE
that O
is O
present O
in O
virions O
in O
_RARE_ I-GENE
_RARE_ I-GENE
equivalent O
to O
that O
of O
Gag I-GENE
. O

The O
recombinant I-GENE
vaccinia I-GENE
virus I-GENE
- I-GENE
expressed O
mutant I-GENE
P1 I-GENE
_RARE_ I-GENE
were O
analyzed O
for O
proteolytic O
processing O
defects O
in O
cells O
_RARE_ I-GENE
with O
a O
recombinant I-GENE
vaccinia I-GENE
virus I-GENE
( O
_RARE_ I-GENE
) O
that O
_RARE_ I-GENE
the O
_RARE_ I-GENE
_RARE_ I-GENE
protease I-GENE
and O
for O
processing O
and O
assembly O
defects O
by O
using O
a O
trans O
complementation O
system O
in O
which O
P1 I-GENE
- I-GENE
expressing O
recombinant I-GENE
vaccinia I-GENE
viruses O
provide O
capsid I-GENE
precursor I-GENE
to O
a O
defective O
_RARE_ I-GENE
genome O
that O
does O
not O
express O
functional O
capsid I-GENE
proteins I-GENE
( O
D I-GENE
. O

In O
contrast O
, O
capsid I-GENE
proteins I-GENE
derived O
from O
the O
P1 I-GENE
precursor I-GENE
with O
a O
_RARE_ I-GENE
substitution O
at O
the O
amino O
terminus O
of O
_RARE_ I-GENE
( O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
) O
assembled O
_RARE_ I-GENE
capsid I-GENE
particles O
but O
were O
deficient O
in O
_RARE_ I-GENE
RNA I-GENE
- I-GENE
containing O
virions O
. O

RESULTS O
: O
In O
an O
18 O
_RARE_ I-GENE
period O
and O
out O
of O
a O
total O
of O
_RARE_ I-GENE
positive O
blood O
cultures O
( O
154 O
significant O
_RARE_ I-GENE
) O
14 O
episodes O
of O
_RARE_ I-GENE
by O
M I-GENE
. O
tuberculosis O
were O
studied O
in O
12 O
_RARE_ I-GENE
patients O
_RARE_ I-GENE
by O
the O
human I-GENE
immunodeficiency I-GENE
virus I-GENE
with O
associated I-GENE
severe O
_RARE_ I-GENE
( O
mean O
of O
CD4 I-GENE
= O
0 O
. O
_RARE_ I-GENE
x O
10 O
( O
9 O
)/ O
l O
). O

_RARE_ I-GENE
_RARE_ I-GENE
on O
the O
larynx O
of O
_RARE_ I-GENE
rabbits O
resulted O
in O
significant O
_RARE_ I-GENE
, O
central O
, O
and O
mixed O
apnea O
. O

By O
using O
total O
- I-GENE
protein I-GENE
extracts O
from O
_RARE_ I-GENE
grown O
under O
penicillin I-GENE
producing O
conditions O
we O
have O
detected O
a O
DNA I-GENE
- I-GENE
binding I-GENE
activity O
that O
specifically O
shifts O
a O
promoter I-GENE
fragment I-GENE
located O
between O
- I-GENE
_RARE_ I-GENE
and O
- I-GENE
_RARE_ I-GENE
( O
relative O
to O
_RARE_ I-GENE
_RARE_ I-GENE
). O

A I-GENE
series O
of O
5 I-GENE
'- O
deletions O
revealed O
that O
the O
fragment I-GENE
- I-GENE
_RARE_ I-GENE
to O
+ I-GENE
4 I-GENE
from O
the O
_RARE_ I-GENE
had O
the O
highest O
promoter I-GENE
activity O
, O
nearly O
1000 O
- I-GENE
fold O
greater O
than O
the O
promoterless O
chloramphenicol I-GENE
acetyltransferase I-GENE
construct I-GENE
. O

The O
_RARE_ I-GENE
gene I-GENE
was O
cloned O
in O
the O
expression O
vector O
_RARE_ I-GENE
and O
transfected O
into O
wild I-GENE
- I-GENE
type I-GENE
L I-GENE
. O
_RARE_ I-GENE
and O
the O
resulting O
transfected O
cells O
were O
resistant O
to O
_RARE_ I-GENE
but O
at O
lower O
levels O
than O
in O
the O
selected O
mutant I-GENE
cells O
. O

The O
_RARE_ I-GENE
of O
_RARE_ I-GENE
from O
capsules O
exposed O
to O
stressed O
conditions O
was O
compared O
in O
both O
dogs O
and O
humans O
to O
capsules O
stored O
at O
RT I-GENE
conditions O
. O

Similar O
synergistic O
activation O
was O
observed O
in O
the O
IL I-GENE
- I-GENE
8 O
promoter I-GENE
, O
which O
also O
contains O
both O
NF I-GENE
- I-GENE
IL6 I-GENE
and O
NF I-GENE
- I-GENE
kappa I-GENE
B I-GENE
binding I-GENE
sites I-GENE
. O

_RARE_ I-GENE
of O
_RARE_ I-GENE
. O

No O
homology I-GENE
was O
found O
between O
the O
_RARE_ I-GENE
protein I-GENE
and O
known O
structures O
of O
proteins I-GENE
. O

We O
report O
an O
_RARE_ I-GENE
case O
of O
marked O
enlargement O
of O
_RARE_ I-GENE
_RARE_ I-GENE
in O
a O
patient O
with O
_RARE_ I-GENE
_RARE_ I-GENE
. O

As O
_RARE_ I-GENE
lipid O
metabolism O
, O
the O
mean O
values O
for O
total O
triglycerides I-GENE
, O
cholesterol I-GENE
, O
LDL I-GENE
- I-GENE
cholesterol I-GENE
and O
HDL I-GENE
- I-GENE
cholesterol I-GENE
seen O
at O
the O
end O
of O
five O
years O
of O
_RARE_ I-GENE
- I-GENE
2 I-GENE
_RARE_ I-GENE
use O
and O
six O
months O
_RARE_ I-GENE
were O
similar O
to O
the O
_RARE_ I-GENE
mean O
. O

At O
a O
PaCO2 O
of O
40 I-GENE
mmHg O
, O
baseline O
brain O
_RARE_ I-GENE
measured O
7 O
. O
03 O
+/- O
0 O
. O
04 O
, O
while O
regional O
cortical O
blood O
flow O
was O
47 O
. O
0 O
+/- O
4 I-GENE
. O
3 I-GENE
ml O
. O
100 O
g O
- I-GENE
1 I-GENE
. O
min O
- I-GENE
1 I-GENE
. O

_RARE_ I-GENE
reduced O
_RARE_ I-GENE
( O
defined O
as O
the O
last O
common O
minute O
of O
exercise O
) O
VO2 O
and O
_RARE_ I-GENE
in O
those O
patients O
with O
more O
severe O
lung O
disease O
, O
but O
these O
values O
tended O
to O
increase O
slightly O
in O
the O
patients O
with O
only O
mild O
lung O
disease O
. O

Effects O
of O
diltiazem O
on O
_RARE_ I-GENE
- I-GENE
induced O
_RARE_ I-GENE
in O
rabbits O
. O

Four O
forms O
of O
_RARE_ I-GENE
were O
_RARE_ I-GENE
in O
_RARE_ I-GENE
and O
during O
transport O
by O
sea O
: O
_RARE_ I-GENE
, O
and O
acute O
, O
subacute O
and O
chronic O
enteric O
. O

_RARE_ I-GENE
20 O
% O
of O
single O
- I-GENE
stranded I-GENE
DNA I-GENE
binding I-GENE
was O
observed O
in O
the O
presence O
of O
_RARE_ I-GENE
, O
but O
none O
was O
detectable O
in O
the O
absence O
of O
nucleotides O
. O

To O
our O
knowledge O
this O
is O
the O
first O
case O
in O
which O
a O
probable O
association O
between O
_RARE_ I-GENE
and O
_RARE_ I-GENE
' O
s O
syndrome O
has O
been O
recorded O
. O

Both O
4 I-GENE
, O
8 O
- I-GENE
_RARE_ I-GENE
and O
A I-GENE
alpha I-GENE
C I-GENE
were O
found O
at O
< O
1 I-GENE
p O
. O
p O
. O
b I-GENE
. O

Three O
cysteine I-GENE
and O
four O
tryptophan I-GENE
residues O
, O
previously O
identified O
as O
conserved O
_RARE_ I-GENE
_RARE_ I-GENE
- I-GENE
oxide I-GENE
_RARE_ I-GENE
, O
are O
found O
in O
the O
_RARE_ I-GENE
enzyme I-GENE
. O

Recombinant I-GENE
Leishmania I-GENE
surface O
glycoprotein I-GENE
_RARE_ I-GENE
is O
secreted O
in O
the O
baculovirus O
expression O
system O
as O
a O
latent I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
the O
molecular O
basis O
for O
agonist O
- I-GENE
induced O
_RARE_ I-GENE
of O
mRNA I-GENE
of O
G I-GENE
- I-GENE
protein I-GENE
- I-GENE
linked O
receptors I-GENE
that O
contributes O
to O
receptor I-GENE
down O
- I-GENE
regulation O
is O
_RARE_ I-GENE
to O
our O
understanding O
of O
long O
- I-GENE
term O
regulation O
of O
receptors I-GENE
by O
agonist O
. O

Addition O
of O
_RARE_ I-GENE
- I-GENE
stabilized O
F I-GENE
- I-GENE
actin I-GENE
nuclei O
and O
_RARE_ I-GENE
restored O
_RARE_ I-GENE
actin I-GENE
' O
s O
ability O
to O
_RARE_ I-GENE
at O
4 I-GENE
degrees O
C I-GENE
. O

These O
cells O
produce O
a O
low O
level O
of O
IL I-GENE
- I-GENE
5 I-GENE
when O
stimulated O
with O
PMA O
alone O
; O
however O
, O
_RARE_ I-GENE
, O
O2 O
- I-GENE
_RARE_ I-GENE
cAMP I-GENE
( O
_RARE_ I-GENE
), O
in O
combination O
with O
PMA O
, O
augmented O
by O
more O
than O
_RARE_ I-GENE
the O
IL I-GENE
- I-GENE
5 I-GENE
production O
at O
the O
mRNA I-GENE
and O
the O
protein I-GENE
levels O
. O

_RARE_ I-GENE
- I-GENE
Met I-GENE
- I-GENE
1 I-GENE
mRNA I-GENE
expression O
in O
a O
small I-GENE
number O
of O
human I-GENE
T I-GENE
cell O
tumor I-GENE
lines O
did O
not O
correlate O
with O
any O
particular O
phenotype O
or O
stage O
of O
development O
. O

Partial O
_RARE_ I-GENE
was O
higher O
in O
the O
treatments O
. O

Northern O
( O
RNA I-GENE
) O
analysis O
demonstrated O
expression O
of O
human I-GENE
PI I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
in O
all O
tissues O
and O
cell O
lines O
tested O
. O

These O
results O
demonstrate O
the O
existence O
of O
different O
PI I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
isoforms I-GENE
and O
define O
a O
family I-GENE
of O
genes I-GENE
encoding O
distinct O
PI I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
catalytic O
subunits I-GENE
that O
can O
associate O
with O
p85 I-GENE
. O

In O
addition O
to O
the O
protein I-GENE
- I-GENE
tyrosine I-GENE
kinase I-GENE
domain I-GENE
, O
_RARE_ I-GENE
possesses O
Src I-GENE
homology I-GENE
2 I-GENE
and O
3 I-GENE
( O
SH2 I-GENE
and O
SH3 I-GENE
) O
domains I-GENE
as O
well O
as O
a O
unique O
N I-GENE
- I-GENE
terminal I-GENE
region O
. O

_RARE_ I-GENE
bearing O
the O
_RARE_ I-GENE
mutation I-GENE
process O
the O
20S I-GENE
precursor I-GENE
of O
the O
mature O
_RARE_ I-GENE
rRNA I-GENE
slowly O
and O
are O
deficient O
in O
_RARE_ I-GENE
ribosomal I-GENE
subunits I-GENE
. O

Hepatitis I-GENE
B I-GENE
and O
liver O
transplantation O
. O

One O
complex I-GENE
most O
likely O
contained O
Sp1 I-GENE
, O
and O
another O
complex I-GENE
showed O
S I-GENE
- I-GENE
phase O
- I-GENE
specific I-GENE
binding I-GENE
, O
suggesting O
a O
direct O
role O
in O
the O
cell O
- I-GENE
cycle O
- I-GENE
dependent I-GENE
R1 I-GENE
gene I-GENE
expression O
. O

These O
combined O
observations O
define O
a O
promoter I-GENE
and O
an O
enhancer I-GENE
for O
the O
chicken I-GENE
L I-GENE
- I-GENE
_RARE_ I-GENE
gene I-GENE
. O

The O
rate O
of O
_RARE_ I-GENE
stimulation O
induced O
by O
a O
given O
nitrate I-GENE
correlates O
closely O
with O
the O
rate O
of O
measured O
NO O
production O
from O
the O
nitrate I-GENE
molecule I-GENE
. O

_RARE_ I-GENE
resulted O
in O
a O
serious O
_RARE_ I-GENE
of O
the O
position O
of O
the O
peak O
of O
the O
_RARE_ I-GENE
potential O
field O
. O

The O
duration O
of O
diabetes O
mellitus O
in O
these O
patients O
was O
from O
5 I-GENE
months O
to O
6 I-GENE
years O
, O
and O
in O
all O
patients O
this O
was O
the O
first O
myocardial O
infarction O
. O

The O
_RARE_ I-GENE
- I-GENE
kDa I-GENE
complex I-GENE
appears O
to O
contain O
two O
distinct O
protein I-GENE
- I-GENE
DNA I-GENE
complexes I-GENE
of O
approximately O
_RARE_ I-GENE
and O
256 O
kDa I-GENE
and O
represents O
two O
proteins I-GENE
covalently O
cross O
- I-GENE
linked O
to O
a O
single O
DRE I-GENE
oligonucleotide I-GENE
, O
while O
the O
97 O
, O
105 I-GENE
, O
and O
115 I-GENE
- I-GENE
kDa I-GENE
complexes I-GENE
represent O
single O
protein I-GENE
- I-GENE
DRE I-GENE
cross O
- I-GENE
links O
. O

The O
promoter I-GENE
and O
upstream O
region O
of O
the O
_RARE_ I-GENE
napus I-GENE
_RARE_ I-GENE
storage O
protein I-GENE
_RARE_ I-GENE
gene I-GENE
were O
studied O
to O
identify O
cis O
- I-GENE
acting O
sequences I-GENE
involved O
in O
developmental O
seed I-GENE
- I-GENE
specific I-GENE
expression O
. O

However O
, O
limited O
comparisons O
reveal O
domains I-GENE
in O
the O
NH2 I-GENE
and O
COOH O
termini O
that O
have O
a O
high O
degree O
of O
similarity O
suggesting O
functional O
conservation O
. O

_RARE_ I-GENE
_RARE_ I-GENE
the O
_RARE_ I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
represents O
the O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
pressure O
_RARE_ I-GENE
in O
the O
system O
. O

We O
have O
explored O
the O
mechanism O
of O
action O
of O
the O
fibronectin I-GENE
splicing O
enhancer I-GENE
and O
found O
that O
the O
SE O
element I-GENE
is O
required O
for O
efficient O
assembly O
of O
early I-GENE
splicing O
complexes I-GENE
, O
allowing O
a O
more O
efficient O
interaction O
of O
the O
U2 I-GENE
snRNP I-GENE
with O
branch O
site I-GENE
sequences I-GENE
. O

_RARE_ I-GENE
of O
enhancer I-GENE
mutants I-GENE
suggests O
that O
trans O
- I-GENE
activation O
by O
_RARE_ I-GENE
/ I-GENE
GAL4 I-GENE
is O
especially O
dependent I-GENE
on O
TCF I-GENE
- I-GENE
2 I-GENE
, O
a O
distinct O
T I-GENE
- I-GENE
cell O
- I-GENE
enriched O
protein I-GENE
that O
binds O
to O
sequences I-GENE
flanking O
the O
_RARE_ I-GENE
- I-GENE
binding I-GENE
site I-GENE
in O
the O
enhancer I-GENE
. O

We O
conclude O
that O
sequences I-GENE
outside O
of O
the O
_RARE_ I-GENE
HMG I-GENE
box I-GENE
mediate O
cell O
- I-GENE
and O
context O
- I-GENE
specific I-GENE
activation O
of O
the O
TCR I-GENE
alpha I-GENE
enhancer I-GENE
and O
may O
facilitate O
interactions O
between O
_RARE_ I-GENE
and O
other O
T I-GENE
- I-GENE
cell O
- I-GENE
specific I-GENE
factors I-GENE
recruited O
to O
the O
enhancer I-GENE
. O

A I-GENE
cAMP I-GENE
response O
element I-GENE
( O
CRE O
) O
consensus I-GENE
signal I-GENE
was O
identified O
in O
the O
5 I-GENE
'- O
noncoding O
region O
. O
cAMP I-GENE
regulates O
the O
expression O
of O
_RARE_ I-GENE
. O
5 I-GENE
gene I-GENE
in O
a O
cell O
- I-GENE
specific I-GENE
manner O
. O

A I-GENE
number O
of O
serological O
tests O
measuring O
the O
presence O
of O
_RARE_ I-GENE
pylori I-GENE
- I-GENE
specific I-GENE
serum I-GENE
immunoglobulin I-GENE
G I-GENE
( O
IgG I-GENE
) O
are O
now O
_RARE_ I-GENE
available O
. O

Using O
a O
series O
of O
mutant I-GENE
T I-GENE
antigens I-GENE
expressed O
by O
recombinant I-GENE
_RARE_ I-GENE
in O
Sf9 O
cells O
, O
we O
find O
that O
the O
origin O
_RARE_ I-GENE
activities O
of O
both O
_RARE_ I-GENE
--> I-GENE
A I-GENE
and O
_RARE_ I-GENE
, O
_RARE_ I-GENE
--> I-GENE
A I-GENE
are O
inhibited O
by O
the O
T I-GENE
- I-GENE
antigen I-GENE
kinase I-GENE
, O
as O
is O
wild I-GENE
- I-GENE
type I-GENE
T I-GENE
antigen I-GENE
. O

The O
degree O
of O
_RARE_ I-GENE
was O
slightly O
related I-GENE
to O
decrease O
in O
FEV1 O
. O
0 O
%, O
_RARE_ I-GENE
and O
PaO2 O
and O
increase O
in O
circulating O
blood O
volume O
and O
peripheral O
red I-GENE
blood O
cell O
counts O
. O

Two O
patients O
were O
treated O
successfully O
with O
a O
combination O
of O
_RARE_ I-GENE
( O
a O
tissue I-GENE
_RARE_ I-GENE
) O
and O
_RARE_ I-GENE
( O
a O
_RARE_ I-GENE
_RARE_ I-GENE
). O

We O
have O
identified O
in O
the O
5 I-GENE
' O
untranslated O
region O
of O
the O
Drosophila I-GENE
_RARE_ I-GENE
retrotransposon I-GENE
, O
3 I-GENE
' O
to O
the O
left O
LTR I-GENE
, O
a O
sequence I-GENE
for O
transcriptional O
regulation O
by O
_RARE_ I-GENE
. O

In O
the O
present O
study O
, O
lesions O
of O
the O
_RARE_ I-GENE
complex I-GENE
( O
the O
_RARE_ I-GENE
source O
of O
afferents O
to O
_RARE_ I-GENE
and O
HD I-GENE
) O
were O
found O
to O
have O
no O
effect O
on O
color O
- I-GENE
reversal O
learning O
performance O
. O

The O
fourth O
dose O
produced O
_RARE_ I-GENE
results O
( O
66 O
. O
7 O
%) O
in O
individuals O
with O
HB I-GENE
antibodies I-GENE
between O
10 O
and O
100 O
IU O
/ I-GENE
ml O
and O
_RARE_ I-GENE
ones O
( O
3 I-GENE
. O
8 O
%) O
where O
the O
HB I-GENE
antibodies I-GENE
were O
below O
10 O
IU O
/ I-GENE
ml O
. O

CONCLUSIONS O
: O
In O
our O
patients O
and O
within O
the O
range O
of O
treatment O
variables O
studied O
, O
age O
, O
_RARE_ I-GENE
index O
, O
and O
graft O
- I-GENE
versus O
- I-GENE
host O
disease O
are O
the O
most O
important O
factors I-GENE
related I-GENE
with O
early I-GENE
mortality O
. O

Nucleotide O
sequence I-GENE
analysis O
of O
the O
HA I-GENE
gene I-GENE
in O
these O
two O
mutants I-GENE
confirmed O
the O
HA I-GENE
- I-GENE
phenotype O
. O

This O
intron O
_RARE_ I-GENE
a O
conserved O
position O
corresponding O
to O
that O
of O
intron O
1 I-GENE
in O
the O
transit O
peptide I-GENE
region O
of O
chloroplast I-GENE
_RARE_ I-GENE
genes I-GENE
( O
_RARE_ I-GENE
and O
_RARE_ I-GENE
) O
of O
higher O
plants O
. O

The O
drug O
- I-GENE
resistant O
cell O
lines O
P388 O
/ I-GENE
ADR O
/ I-GENE
3 I-GENE
and O
P388 O
/ I-GENE
ADR O
/ I-GENE
7 O
express O
a O
shortened O
_RARE_ I-GENE
II I-GENE
alpha I-GENE
mRNA I-GENE
transcript I-GENE
in O
addition O
to O
the O
native O
transcript I-GENE
present O
in O
the O
drug O
- I-GENE
sensitive O
P388 O
/ I-GENE
4 I-GENE
cell O
line O
. O

Using O
a O
3 I-GENE
'- O
rapid O
amplification O
of O
cDNA I-GENE
ends O
strategy O
, O
we O
have O
cloned O
cDNAs I-GENE
representing O
the O
3 I-GENE
'- O
termini O
of O
both O
the O
native O
and O
mutant I-GENE
transcripts I-GENE
from O
both O
P388 O
/ I-GENE
ADR O
/ I-GENE
3 I-GENE
and O
P388 O
/ I-GENE
ADR O
/ I-GENE
7 O
cells O
. O

The O
phi I-GENE
_RARE_ I-GENE
factor I-GENE
is O
a O
nuclear I-GENE
phosphoprotein I-GENE
; O
the O
extent O
of O
its O
phosphorylation O
is O
regulated O
during O
the O
cell O
cycle O
. O

Similarly O
, O
the O
N I-GENE
- I-GENE
terminal I-GENE
cytoplasmic I-GENE
domain I-GENE
of O
the O
latent I-GENE
membrane I-GENE
protein I-GENE
2A I-GENE
( O
_RARE_ I-GENE
) O
of O
the O
Epstein I-GENE
- I-GENE
Barr I-GENE
virus I-GENE
( O
EBV I-GENE
) O
contains O
a O
single O
copy O
of O
the O
Tyr I-GENE
- I-GENE
X I-GENE
- I-GENE
X I-GENE
- I-GENE
Leu I-GENE
/ I-GENE
Ile O
- I-GENE
containing O
motif I-GENE
which O
could O
play O
a O
critical O
role O
in O
B I-GENE
cell O
transformation O
. O

The O
functional O
homology I-GENE
of O
_RARE_ I-GENE
with O
_RARE_ I-GENE
, O
which O
has O
been O
implicated O
in O
the O
control O
of O
cell O
polarity O
, O
suggests O
a O
link I-GENE
between O
two O
_RARE_ I-GENE
events O
such O
as O
establishment O
of O
cell O
polarity O
and O
cell O
wall O
biosynthesis O
. O

Molecular O
cloning O
of O
a O
P I-GENE
- I-GENE
type I-GENE
ATPase I-GENE
gene I-GENE
from O
the O
_RARE_ I-GENE
_RARE_ I-GENE
sp O
. O

The O
cloning O
of O
_RARE_ I-GENE
represents O
the O
first O
example O
of O
the O
molecular O
genetic O
characterization O
of O
a O
_RARE_ I-GENE
peptide I-GENE
transport O
gene I-GENE
. O

By O
using O
the O
full I-GENE
- I-GENE
length I-GENE
cytoplasmic I-GENE
domain I-GENE
and O
mutants I-GENE
with O
progressive O
carboxy I-GENE
- I-GENE
terminal I-GENE
deletions O
, O
internal O
deletions O
, O
or O
point O
mutations O
, O
we O
identified O
the O
first O
150 O
amino O
acid I-GENE
residues O
of O
_RARE_ I-GENE
as O
the O
minimal I-GENE
region O
necessary O
for O
signaling O
. O

To O
examine O
the O
biochemical O
basis O
of O
the O
end O
joining O
, O
nuclear I-GENE
extracts O
were O
prepared O
from O
a O
wide O
variety O
of O
mammalian I-GENE
cell O
lines O
and O
tested O
for O
their O
ability O
to O
_RARE_ I-GENE
test O
plasmid O
substrates O
. O

These O
data O
indicate O
that O
the O
largest O
subunit I-GENE
of O
RNA I-GENE
polymerase I-GENE
II I-GENE
and O
_RARE_ I-GENE
are O
important O
determinants I-GENE
of O
transcription I-GENE
start O
site I-GENE
selection O
in O
S I-GENE
. O
cerevisiae I-GENE
and O
suggest O
that O
this O
function O
might O
be O
conferred O
by O
interaction O
between O
these O
two O
proteins I-GENE
. O

Recombinant I-GENE
expression O
of O
a O
chimeric I-GENE
EGFR I-GENE
/ I-GENE
ErbB I-GENE
- I-GENE
3 I-GENE
receptor I-GENE
in O
NIH O
3T3 O
fibroblasts O
allowed O
us O
to O
investigate O
cytoplasmic I-GENE
events O
associated I-GENE
with O
ErbB I-GENE
- I-GENE
3 I-GENE
signal I-GENE
transduction O
upon O
ligand O
activation O
. O

_RARE_ I-GENE
_RARE_ I-GENE
were O
used O
to O
evaluate O
the O
_RARE_ I-GENE
of O
the O
TATA I-GENE
- I-GENE
binding I-GENE
site I-GENE
in O
TIF I-GENE
- I-GENE
_RARE_ I-GENE
, O
TFIID I-GENE
, O
and O
_RARE_ I-GENE
. O

The O
_RARE_ I-GENE
- I-GENE
to O
- I-GENE
239 O
region O
blocked O
ADR1 I-GENE
activity O
independently O
of O
the O
_RARE_ I-GENE
present O
on O
ADR1 I-GENE
, O
ADR1 I-GENE
DNA I-GENE
binding I-GENE
, O
and O
specific I-GENE
_RARE_ I-GENE
promoter I-GENE
sequences I-GENE
. O

Analysis O
of O
strains O
harboring O
an O
_RARE_ I-GENE
null I-GENE
mutation I-GENE
demonstrates O
that O
_RARE_ I-GENE
is O
not O
essential O
during O
normal O
_RARE_ I-GENE
growth I-GENE
but O
appears O
to O
be O
required O
for O
meiosis O
. O

TGF I-GENE
beta I-GENE
1 I-GENE
expression O
is O
largely O
_RARE_ I-GENE
by O
three O
AP I-GENE
- I-GENE
1 I-GENE
binding I-GENE
sites I-GENE
located O
in O
two O
different O
promoters I-GENE
of O
this O
gene I-GENE
. O

Val I-GENE
--> I-GENE
Ala I-GENE
mutations O
selectively O
alter O
helix I-GENE
- I-GENE
helix I-GENE
_RARE_ I-GENE
in O
the O
transmembrane I-GENE
segment O
of O
phage I-GENE
_RARE_ I-GENE
coat I-GENE
protein I-GENE
. O

_RARE_ I-GENE
change O
in O
the O
_RARE_ I-GENE
. O

A I-GENE
much O
less O
_RARE_ I-GENE
solution O
than O
_RARE_ I-GENE
, O
containing O
only O
K I-GENE
(+)- I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
and O
_RARE_ I-GENE
, O
can O
be O
used O
successfully O
for O
preservation O
of O
rat I-GENE
hepatocytes O
for O
24 O
hr O
for O
drug O
transport O
studies O
. O

_RARE_ I-GENE
administration O
of O
_RARE_ I-GENE
20 O
mg O
/ I-GENE
kg O
i O
. O
p O
. O
significantly O
improved O
the O
_RARE_ I-GENE
- I-GENE
induced O
_RARE_ I-GENE
deficits O
by O
increasing O
the O
_RARE_ I-GENE
- I-GENE
decreased O
rate O
from O
55 O
. O
8 O
+/- O
9 O
. O
6 I-GENE
to O
80 O
. O
8 O
+/- O
4 I-GENE
. O
2 I-GENE
in O
d O
3 I-GENE
learning O
acquisition O
( O
F I-GENE
( O
1 I-GENE
, O
14 O
) O
= O
5 I-GENE
. O
6 I-GENE
, O
p O
< O
0 O
. O
05 O
), O
from O
53 O
. O
4 I-GENE
+/- O
8 O
. O
4 I-GENE
to O
60 O
. O
0 O
+/- O
8 O
. O
2 I-GENE
in O
48 O
h O
memory O
acquisition O
( O
F I-GENE
( O
1 I-GENE
, O
14 O
) O
= O
7 O
. O
5 I-GENE
, O
p O
< O
0 O
. O
05 O
) O
and O
from O
55 O
. O
0 O
+/- O
5 I-GENE
. O
5 I-GENE
to O
88 O
. O
3 I-GENE
+/- O
2 I-GENE
. O
5 I-GENE
in O
24 O
h O
memory O
retention O
( O
F I-GENE
( O
1 I-GENE
, O
12 O
) O
27 O
. O
5 I-GENE
, O
p O
< O
0 O
. O
01 O
) O
as O
well O
as O
from O
60 O
. O
0 O
+/- O
6 I-GENE
. O
8 O
to O
85 O
. O
6 I-GENE
+/- O
6 I-GENE
. O
9 O
in O
48 O
h O
memory O
_RARE_ I-GENE
( O
F I-GENE
( O
1 I-GENE
, O
12 O
) O
= O
5 I-GENE
. O
2 I-GENE
, O
p O
< O
0 O
. O
05 O
), O
respectively O
. O

Human I-GENE
_RARE_ I-GENE
protein I-GENE
specifically O
_RARE_ I-GENE
( O
p50 I-GENE
) O
2 I-GENE
- I-GENE
DNA I-GENE
complexes I-GENE
. O

The O
therapeutic O
action O
of O
cyclosporin O
A I-GENE
( O
_RARE_ I-GENE
): O
its O
application O
in O
rheumatoid I-GENE
arthritis O
. O

In O
vitro O
translation I-GENE
experiments O
show O
that O
human I-GENE
cDNA I-GENE
derived O
RNA I-GENE
_RARE_ I-GENE
into O
a O
protein I-GENE
with O
a O
mobility I-GENE
of O
44 I-GENE
- I-GENE
46 O
kD I-GENE
on O
SDS O
polyacrylamide O
gels O
. O

After O
peripheral O
administration O
of O
both O
CRF I-GENE
and O
TRH I-GENE
, O
ACTH I-GENE
levels O
were O
significantly O
higher O
on O
the O
tumor I-GENE
side O
in O
all O
patients O
. O

_RARE_ I-GENE
analgesia O
: O
is O
there O
a O
_RARE_ I-GENE
for O
_RARE_ I-GENE
_RARE_ I-GENE
? O
_RARE_ I-GENE
can O
be O
a O
useful O
analgesic O
agent O
for O
the O
management O
of O
acute O
dental O
pain O
. O

A I-GENE
sequence I-GENE
homology I-GENE
analysis O
between O
human I-GENE
_RARE_ I-GENE
- I-GENE
H1 I-GENE
and O
the O
homolog I-GENE
gene I-GENE
of O
the O
rat I-GENE
( O
_RARE_ I-GENE
- I-GENE
K I-GENE
beta I-GENE
) O
shows O
that O
exon O
- I-GENE
intron O
boundaries O
are O
well O
conserved O
between O
these O
two O
species O
. O

A I-GENE
favourable O
response O
was O
achieved O
with O
a O
combination O
of O
amphotericin O
B I-GENE
and O
_RARE_ I-GENE
. O

Response O
durations O
were O
short O
. O

RESULTS O
: O
At O
the O
beginning O
of O
the O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
process O
, O
monitoring O
of O
blood O
administration O
_RARE_ I-GENE
revealed O
that O
a O
_RARE_ I-GENE
from O
_RARE_ I-GENE
blood O
administration O
_RARE_ I-GENE
occurred O
during O
50 O
percent O
of O
blood O
and O
component O
_RARE_ I-GENE
. O

In O
addition O
, O
_RARE_ I-GENE
plants O
were O
resistant O
to O
an O
unusually O
broad O
range O
of O
_RARE_ I-GENE
including O
tomato I-GENE
mosaic O
virus I-GENE
, O
tobacco I-GENE
mild O
green I-GENE
mosaic O
virus I-GENE
, O
_RARE_ I-GENE
- I-GENE
U5 I-GENE
, O
green I-GENE
tomato I-GENE
atypical O
mosaic O
virus I-GENE
, O
and O
_RARE_ I-GENE
mosaic O
virus I-GENE
. O

Drug O
effect O
, O
measured O
as O
_RARE_ I-GENE
_RARE_ I-GENE
, O
was O
also O
similar O
in O
the O
patients O
with O
cirrhosis O
and O
control O
subjects O
; O
therefore O
the O
ratio O
of O
effect O
area O
under O
the O
curve O
to O
concentration O
area O
under O
the O
curve O
, O
a O
measure O
of O
sensitivity O
, O
did O
not O
differ O
significantly O
between O
the O
patients O
with O
cirrhosis O
and O
the O
control O
subjects O
. O

We O
present O
evidence O
that O
YY1 I-GENE
, O
a O
ubiquitously O
expressed O
DNA I-GENE
- I-GENE
binding I-GENE
protein I-GENE
, O
regulates O
the O
activity O
of O
the O
c I-GENE
- I-GENE
fos I-GENE
promoter I-GENE
primarily O
through O
an O
effect O
on O
DNA I-GENE
structure O
. O

In O
a O
retrospective O
analysis O
of O
first O
- I-GENE
time O
total O
_RARE_ I-GENE
in O
_RARE_ I-GENE
patients O
, O
we O
investigated O
the O
relationship O
between O
_RARE_ I-GENE
and O
_RARE_ I-GENE
polyps O
. O

The O
rate O
of O
_RARE_ I-GENE
in O
_RARE_ I-GENE
amplitude O
over O
a O
_RARE_ I-GENE
time O
period O
was O
utilized O
as O
a O
measure O
of O
susceptibility I-GENE
to O
the O
acoustic O
trauma O
. O

Effect O
of O
single O
base O
substitutions O
at O
glycine O
- I-GENE
_RARE_ I-GENE
codon O
of O
_RARE_ I-GENE
S I-GENE
synthetase I-GENE
2 I-GENE
gene I-GENE
on O
proline O
activation O
. O

The O
predicted O
_RARE_ I-GENE
sequence I-GENE
contains O
two O
putative O
ATP I-GENE
- I-GENE
binding I-GENE
domains I-GENE
and O
shows O
structural O
relationships O
to O
other O
potential O
ATP I-GENE
- I-GENE
binding I-GENE
proteins I-GENE
involved O
in O
biological O
processes O
as O
diverse O
as O
peroxisome I-GENE
biogenesis O
, O
vesicle O
- I-GENE
mediated O
protein I-GENE
transport O
, O
cell O
cycle O
control O
, O
and O
transcriptional O
regulation O
. O

The O
results O
show O
that O
the O
structure O
of O
the O
_RARE_ I-GENE
gene I-GENE
promoter I-GENE
is O
different O
from O
that O
of O
any O
other O
proteoglycan I-GENE
promoter I-GENE
characterized O
so O
far O
and O
indicate O
that O
the O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
segment O
plays O
a O
role O
in O
the O
regulation O
of O
gene I-GENE
transcription I-GENE
. O

The O
kinase I-GENE
inhibitor I-GENE
_RARE_ I-GENE
( O
1 I-GENE
microM O
) O
blocks O
_RARE_ I-GENE
- I-GENE
induced O
, O
but O
not O
epidermal I-GENE
growth I-GENE
factor I-GENE
- I-GENE
induced O
, O
activation O
of O
p21ras I-GENE
and O
MAP I-GENE
kinase I-GENE
, O
consistent O
with O
an O
intermediate O
protein I-GENE
kinase I-GENE
linking O
the O
_RARE_ I-GENE
receptor I-GENE
to O
p21ras I-GENE
activation O
. O

_RARE_ I-GENE
, O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
)) O
indicates O
an O
overall O
identity O
of O
58 O
and O
56 O
%, O
respectively O
, O
with O
a O
91 O
and O
92 O
% O
identity O
in O
the O
highly O
conserved O
transmembrane I-GENE
and O
cytoplasmic I-GENE
domains I-GENE
. O

S I-GENE
., O
K I-GENE
. O

The O
survival O
rate O
at O
_RARE_ I-GENE
months O
in O
15 O
patients O
with O
N2 O
disease O
who O
underwent O
_RARE_ I-GENE
operation O
was O
51 O
%. O

_RARE_ I-GENE
with O
severe O
anatomical O
abnormalities O
, O
who O
are O
HIV I-GENE
positive O
, O
have O
active O
TB I-GENE
or O
whose O
children O
have O
inherited O
mono O
- I-GENE
or O
_RARE_ I-GENE
_RARE_ I-GENE
should O
not O
_RARE_ I-GENE
. O

G I-GENE
. O

The O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
products I-GENE
have O
two O
isoforms I-GENE
each O
that O
are O
distinguished O
by O
different O
_RARE_ I-GENE
in O
polyacrylamide O
gel O
electrophoresis O
, O
and O
the O
_RARE_ I-GENE
product I-GENE
has O
four O
isoforms I-GENE
. O

When O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
type I-GENE
V I-GENE
embryos O
were O
exposed O
to O
either O
0 O
. O
20 O
ml O
50 O
% O
ethanol O
in O
CRS I-GENE
or O
to O
0 O
. O
20 O
ml O
CRS I-GENE
( O
controls O
), O
ethanol O
- I-GENE
treated O
embryos O
showed O
a O
_RARE_ I-GENE
incidence O
of O
34 O
. O
1 I-GENE
% O
compared O
with O
a O
3 I-GENE
. O
6 I-GENE
% O
incidence O
in O
the O
controls O
( O
P I-GENE
= O
0 O
. O
_RARE_ I-GENE
). O

_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
in O
_RARE_ I-GENE
patients O

In O
our O
studies O
, O
we O
utilized O
HIV I-GENE
- I-GENE
1 I-GENE
_RARE_ I-GENE
and O
HIV I-GENE
- I-GENE
1 I-GENE
_RARE_ I-GENE
core I-GENE
enhancers I-GENE
because O
the O
_RARE_ I-GENE
strain O
has O
a O
single O
point O
mutation I-GENE
flanking O
the O
right O
ETS I-GENE
- I-GENE
binding I-GENE
site I-GENE
. O

The O
secondary O
, O
but O
not O
the O
primary O
, O
antibody I-GENE
responses O
of O
male O
_RARE_ I-GENE
/ I-GENE
6 I-GENE
mice O
were O
higher O
among O
mice O
_RARE_ I-GENE
alone O
compared O
to O
mice O
_RARE_ I-GENE
in O
groups O
; O
differences O
were O
observed O
for O
both O
IgM I-GENE
and O
IgG I-GENE
anti I-GENE
- I-GENE
_RARE_ I-GENE
antibodies I-GENE
. O

However O
, O
a O
_RARE_ I-GENE
high O
degree O
of O
conservation O
of O
intron O
sequences I-GENE
was O
observed O
between O
both O
species O
. O

Interleukin I-GENE
- I-GENE
6 I-GENE
may O
possibly O
_RARE_ I-GENE
metastasis O
of O
cardiac O
_RARE_ I-GENE
. O

Other O
parameters O
of O
iron O
metabolism O
, O
including O
ferritin I-GENE
, O
were O
not O
found O
to O
contribute O
to O
the O
risk O
. O

_RARE_ I-GENE
to O
the O
_RARE_ I-GENE
_RARE_ I-GENE
vaccine O
by O
43 I-GENE
calves O
and O
70 I-GENE
adult O
cattle O
in O
_RARE_ I-GENE
in O
1990 O
, O
through O
the O
production O
of O
IgG I-GENE
antibodies I-GENE
, O
were O
monitored O
for O
4 I-GENE
weeks O
using O
the O
ELISA O
assay O
. O

Because O
of O
the O
small I-GENE
number O
of O
visceral O
angiography O
procedures O
performed O
( O
38 O
), O
no O
definitive O
conclusions O
could O
be O
_RARE_ I-GENE
as O
to O
the O
differences O
between O
ionic O
and O
_RARE_ I-GENE
agents O
regarding O
grade O
- I-GENE
2 I-GENE
and O
grade O
- I-GENE
3 I-GENE
adverse O
events O
. O

_RARE_ I-GENE
of O
the O
_RARE_ I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
of O
T1 O
- I-GENE
stage O
are O
possible O
only O
in O
1 I-GENE
of O
3 I-GENE
cases O
. O

_RARE_ I-GENE
' O
_RARE_ I-GENE
solution O
( O
with O
95 O
% O
O2 O
: O
5 I-GENE
% O
CO2 O
) O
can O
_RARE_ I-GENE
the O
metabolic O
demand O
of O
the O
ischaemic O
myocardium O
and O
thus O
increase O
the O
safe O
duration O
of O
cardiac O
arrest O
. O

Plasma I-GENE
, O
LDL I-GENE
and O
liver O
cholesterol I-GENE
concentrations O
were O
higher O
in O
the O
_RARE_ I-GENE
control O
than O
the O
_RARE_ I-GENE
control O
and O
lower O
in O
the O
groups O
fed O
diets O
containing O
_RARE_ I-GENE
or O
_RARE_ I-GENE
fiber O
than O
in O
the O
_RARE_ I-GENE
control O
group O
. O

The O
_RARE_ I-GENE
frame O
modification O
to O
the O
standard O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
allows O
for O
improved O
visualization O
and O
_RARE_ I-GENE
localization O
of O
distal O
_RARE_ I-GENE
_RARE_ I-GENE
compared O
to O
the O
standard O
_RARE_ I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
cells O
expressed O
an O
abundant O
1 I-GENE
. O
1 I-GENE
kb O
mRNA I-GENE
transcript I-GENE
for O
_RARE_ I-GENE
, O
but O
in O
contrast O
to O
other O
cell O
types O
_RARE_ I-GENE
mRNA I-GENE
was O
expressed O
in O
both O
randomly O
_RARE_ I-GENE
cells O
and O
in O
serum I-GENE
- I-GENE
deprived O
, O
_RARE_ I-GENE
cultures O
. O

_RARE_ I-GENE
_RARE_ I-GENE
screening O
of O
_RARE_ I-GENE
patients O
may O
provide O
a O
cost O
- I-GENE
effective O
means O
of O
_RARE_ I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
to O
the O
relatively O
high O
levels O
of O
distress O
among O
their O
patients O
. O

A I-GENE
single O
1 I-GENE
. O
8 O
- I-GENE
kb O
transcript I-GENE
mRNA I-GENE
was O
detected O
by O
Northern O
( O
RNA I-GENE
) O
blot O
analysis O
, O
and O
its O
5 I-GENE
' O
end O
maps O
to O
a O
position O
51 O
bp O
upstream O
from O
the O
site I-GENE
of O
initiation I-GENE
of O
protein I-GENE
synthesis O
. O

_RARE_ I-GENE
this O
sequence I-GENE
information O
from O
_RARE_ I-GENE
/ I-GENE
1 I-GENE
, O
the O
_RARE_ I-GENE
/ I-GENE
1 I-GENE
- I-GENE
specific I-GENE
cDNA I-GENE
was O
generated O
from O
poly O
( O
A I-GENE
)+ O
RNA I-GENE
of O
bovine I-GENE
_RARE_ I-GENE
by O
reverse I-GENE
transcription I-GENE
and O
a O
combination O
of O
polymerase I-GENE
chain I-GENE
reaction O
( O
PCR O
) O
methods O
. O

The O
sequence I-GENE
similarity O
has O
suggested O
that O
_RARE_ I-GENE
and O
_RARE_ I-GENE
have O
been O
derived O
from O
structurally O
and O
evolutionarily O
related I-GENE
genes I-GENE
. O

These O
data O
are O
consistent O
with O
the O
idea O
that O
the O
neuron I-GENE
- I-GENE
specific I-GENE
_RARE_ I-GENE
gene I-GENE
evolved O
by O
duplication O
and O
modification O
of O
the O
more O
broadly O
expressed O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
gene I-GENE
. O

The O
deduced O
amino O
acid I-GENE
sequence I-GENE
of O
the O
mouse I-GENE
_RARE_ I-GENE
- I-GENE
1 I-GENE
gene I-GENE
is O
identical O
to O
that O
of O
_RARE_ I-GENE
, O
initially O
identified O
as O
a O
stress O
- I-GENE
induced O
protein I-GENE
in O
mouse I-GENE
_RARE_ I-GENE
/ I-GENE
3T3 O
cells O
. O

We O
found O
that O
T3 O
( O
10 O
(- O
8 O
) O
M I-GENE
) O
selectively O
stimulates O
transcription I-GENE
from O
_RARE_ I-GENE
- I-GENE
TRE I-GENE
- I-GENE
and O
_RARE_ I-GENE
-, I-GENE
but O
not O
_RARE_ I-GENE
- I-GENE
TRE I-GENE
- I-GENE
and O
F2 O
- I-GENE
TRE I-GENE
-, I-GENE
containing O
templates O
in O
which O
these O
_RARE_ I-GENE
are O
linked O
in O
front O
of O
the O
_RARE_ I-GENE
minimal I-GENE
promoter I-GENE
containing O
only O
the O
TATA I-GENE
box I-GENE
binding I-GENE
protein I-GENE
, O
but O
not O
any O
other O
proximal I-GENE
binding I-GENE
protein I-GENE
, O
sequence I-GENE
. O

Using O
a O
polymerase I-GENE
chain I-GENE
reaction O
- I-GENE
based O
approach O
, O
we O
cloned O
a O
150 O
- I-GENE
base O
pair O
fragment I-GENE
of O
a O
new O
_RARE_ I-GENE
from O
human I-GENE
placenta O
mRNA I-GENE
, O
which O
was O
then O
used O
as O
a O
probe O
to O
clone O
the O
complete O
coding O
sequence I-GENE
of O
the O
corresponding O
gene I-GENE
from O
a O
cDNA I-GENE
library O
. O

The O
structural O
analysis O
also O
demonstrated O
that O
the O
heterogeneity O
of O
the O
_RARE_ I-GENE
mRNA I-GENE
is O
caused O
by O
an O
insertion O
of O
the O
_RARE_ I-GENE
intron O
sequence I-GENE
and O
alternative O
use O
of O
the O
splicing O
acceptor O
site I-GENE
at O
the O
_RARE_ I-GENE
exon O
. O

A I-GENE
complementary O
DNA I-GENE
was O
isolated O
from O
Caenorhabditis I-GENE
elegans I-GENE
that O
encoded I-GENE
a O
polypeptide I-GENE
of O
_RARE_ I-GENE
amino O
acid I-GENE
residues O
, O
_RARE_ I-GENE
, O
which O
contains O
a O
domain I-GENE
with O
sequence I-GENE
similarity O
to O
the O
COOH O
- I-GENE
terminal I-GENE
segment O
( O
GTPase I-GENE
- I-GENE
activating I-GENE
protein I-GENE
region O
) O
of O
_RARE_ I-GENE
and O
other O
known O
GTPase I-GENE
- I-GENE
activating I-GENE
proteins I-GENE
of O
the O
Rho I-GENE
subfamily I-GENE
. O

_RARE_ I-GENE
exonuclease I-GENE
III I-GENE
protection O
was O
observed O
beyond O
the O
core I-GENE
region O
on O
both O
the O
5 I-GENE
' O
and O
3 I-GENE
' O
sides O
, O
suggesting O
that O
E1 I-GENE
interacted O
with O
more O
distal O
sequences I-GENE
as O
well O
. O

_RARE_ I-GENE
is O
_RARE_ I-GENE
when O
the O
two O
( O
for O
E2 I-GENE
) O
or O
three O
( O
for O
E2 I-GENE
- I-GENE
C I-GENE
) O
promoter I-GENE
- I-GENE
proximal I-GENE
copies O
of O
E2 I-GENE
- I-GENE
RS I-GENE
are O
mutated O
. O

A I-GENE
mutant I-GENE
in O
the O
AAV I-GENE
terminal I-GENE
resolution O
site I-GENE
( O
_RARE_ I-GENE
) O
was O
defective O
for O
DNA I-GENE
replication O
in O
the O
in O
vitro O
assay O
. O

The O
results O
indicate O
that O
_RARE_ I-GENE
strongly O
enhances O
the O
function O
of O
negative O
regulatory I-GENE
elements O
of O
the O
LTR I-GENE
. O

However O
, O
artificially O
ventilated O
rats O
, O
pretreated O
with O
MK O
- I-GENE
801 O
, O
were O
more O
sensitive O
( O
lethal O
cocaine O
dose O
, O
76 I-GENE
. O
6 I-GENE
+/- O
8 O
. O
0 O
mg O
/ I-GENE
kg O
, O
n O
= O
5 I-GENE
) O
than O
vehicle O
pretreated O
rats O
( O
_RARE_ I-GENE
. O
4 I-GENE
+/- O
15 O
. O
8 O
mg O
/ I-GENE
kg O
, O
n O
= O
6 I-GENE
), O
indicating O
that O
MK O
- I-GENE
801 O
may O
increase O
both O
the O
respiratory O
and O
the O
cardiac O
toxicity O
of O
cocaine O
in O
_RARE_ I-GENE
anesthetized O
rats O
. O

The O
Oct I-GENE
- I-GENE
3 I-GENE
/ I-GENE
4 I-GENE
gene I-GENE
product I-GENE
, O
which O
belongs O
to O
the O
POU I-GENE
family I-GENE
of O
transcription I-GENE
factors I-GENE
, O
is O
a O
good O
candidate O
for O
regulating O
initial O
differentiation O
_RARE_ I-GENE
. O

Using O
site I-GENE
- I-GENE
directed O
mutagenesis O
, O
we O
show O
that O
the O
_RARE_ I-GENE
contributes O
to O
the O
transcriptional O
activation O
of O
Oct I-GENE
- I-GENE
3 I-GENE
/ I-GENE
4 I-GENE
promoter I-GENE
in O
P19 O
cells O
and O
, O
most O
_RARE_ I-GENE
, O
mediates O
the O
RA O
- I-GENE
induced O
repression O
in O
RA O
- I-GENE
differentiated O
EC I-GENE
cells O
. O

_RARE_ I-GENE
: O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
, O
1992 O
; O
M I-GENE
. O

Furthermore O
, O
the O
negative O
transcriptional O
effect O
of O
COUP I-GENE
- I-GENE
_RARE_ I-GENE
is O
dominant I-GENE
over O
the O
activating I-GENE
effect O
of O
the O
_RARE_ I-GENE
embryonic O
stem O
cell O
- I-GENE
specific I-GENE
enhancer I-GENE
. O

Analysis O
of O
_RARE_ I-GENE
/ I-GENE
CAT I-GENE
chimeric I-GENE
constructs I-GENE
transiently O
transfected O
into O
the O
_RARE_ I-GENE
264 O
. O
7 O
mouse I-GENE
monocytic O
cell O
line O
revealed O
a O
unique O
IFN I-GENE
- I-GENE
gamma I-GENE
- I-GENE
responsive I-GENE
element I-GENE
( O
gamma I-GENE
_RARE_ I-GENE
- I-GENE
1 I-GENE
). O

When O
expressed O
alone O
in O
test O
cells O
, O
_RARE_ I-GENE
- I-GENE
I I-GENE
is O
unable O
to O
bind O
TGF I-GENE
- I-GENE
beta I-GENE
, O
activin I-GENE
, O
or O
bone O
_RARE_ I-GENE
protein I-GENE
2 I-GENE
. O

Therefore O
, O
_RARE_ I-GENE
and O
_RARE_ I-GENE
might O
_RARE_ I-GENE
Myc I-GENE
function O
and O
are O
candidate O
tumor I-GENE
suppressor I-GENE
genes I-GENE
. O

To O
our O
knowledge O
, O
type I-GENE
IV I-GENE
renal O
tubular O
acidosis O
has O
not O
been O
reported O
previously O
in O
association O
with O
_RARE_ I-GENE
' O
s O
syndrome O
in O
an O
adult O
patient O
. O

A I-GENE
cDNA I-GENE
clone O
was O
isolated O
from O
a O
chicken I-GENE
embryo O
cDNA I-GENE
library O
employing O
a O
PCR O
- I-GENE
generated O
radiolabeled O
probe O
specific I-GENE
for O
the O
U3 I-GENE
region O
of O
the O
Rous I-GENE
sarcoma I-GENE
virus I-GENE
LTR I-GENE
. O

Two O
basic I-GENE
patterns O
of O
locomotor O
behavior O
and O
corresponding O
_RARE_ I-GENE
morphology O
exist O
among O
_RARE_ I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
age O
and O
sex I-GENE
had O
no O
significant O
effects O
on O
CSF I-GENE
composition O
, O
but O
serum I-GENE
IgG I-GENE
concentration O
increased O
with O
age O
. O

_RARE_ I-GENE
continuous O
expansion O
. O

A I-GENE
randomized O
, O
_RARE_ I-GENE
study O
comparing O
the O
efficacy O
and O
_RARE_ I-GENE
of O
_RARE_ I-GENE
, O
a O
new O
5 I-GENE
- I-GENE
HT3 I-GENE
receptor I-GENE
antagonist O
, O
with O
a O
_RARE_ I-GENE
- I-GENE
containing O
_RARE_ I-GENE
_RARE_ I-GENE
in O
the O
prevention O
of O
cisplatin O
- I-GENE
induced O
_RARE_ I-GENE
. O

Each O
repeat I-GENE
consists O
of O
12 O
nt O
, O
coding O
for O
the O
_RARE_ I-GENE
sequence I-GENE
, O
K I-GENE
/ I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
also O
was O
secreted O
from O
P I-GENE
. O
_RARE_ I-GENE
using O
the O
S I-GENE
. O
cerevisiae I-GENE
alpha I-GENE
- I-GENE
factor I-GENE
_RARE_ I-GENE
secretion O
leader O
and O
the O
S I-GENE
. O
cerevisiae I-GENE
_RARE_ I-GENE
signal I-GENE
sequence I-GENE
. O

BACKGROUND O
: O
To O
determine O
the O
predictors O
of O
desipramine O
- I-GENE
refractory O
depression O
, O
the O
authors O
examined O
the O
outcome O
in O
patients O
with O
major I-GENE
depression O
who O
were O
_RARE_ I-GENE
to O
a O
general O
hospital O
and O
treated O
with O
desipramine O
adjusted O
to O
an O
adequate O
blood O
level O
. O

Analysis O
of O
the O
intact O
hGH I-GENE
gene I-GENE
or O
hGH I-GENE
5 I-GENE
'- O
flanking O
DNA I-GENE
( O
5 I-GENE
'- O
FR I-GENE
) O
coupled I-GENE
to O
the O
_RARE_ I-GENE
cDNA I-GENE
or O
chloramphenicol I-GENE
acetyltransferase I-GENE
or O
luciferase I-GENE
genes I-GENE
, O
indicated O
that O
cAMP I-GENE
primarily O
stimulated O
hGH I-GENE
promoter I-GENE
activity O
. O

The O
predicted O
amino O
acid I-GENE
sequence I-GENE
of O
the O
_RARE_ I-GENE
- I-GENE
1 I-GENE
cDNA I-GENE
showed O
that O
mature O
_RARE_ I-GENE
- I-GENE
1 I-GENE
consisted O
of O
_RARE_ I-GENE
amino O
acids O
and O
a O
transmembrane I-GENE
- I-GENE
type I-GENE
PTP I-GENE
, O
which O
possessed O
a O
single O
PTP I-GENE
- I-GENE
conserved O
domain I-GENE
in O
the O
cytoplasmic I-GENE
region O
. O

The O
following O
evidence O
indicates O
that O
the O
69 O
- I-GENE
kD I-GENE
protein I-GENE
is O
a O
common O
, O
rather O
than O
a O
U1 I-GENE
- I-GENE
specific I-GENE
, O
protein I-GENE
, O
possibly O
_RARE_ I-GENE
with O
the O
snRNP I-GENE
core I-GENE
particles O
by O
protein I-GENE
- I-GENE
protein I-GENE
interaction O
. O

Several O
features O
of O
10 O
. O
24 O
. O
6 I-GENE
cells O
suggest O
that O
the O
mutation I-GENE
_RARE_ I-GENE
normal O
intracellular O
formation O
of O
peptide I-GENE
/ I-GENE
DR I-GENE
complexes I-GENE
. O

This O
distribution O
_RARE_ I-GENE
that O
of O
the O
_RARE_ I-GENE
glutamate I-GENE
and O
aspartate I-GENE
; O
however O
, O
neither O
of O
these O
_RARE_ I-GENE
amino O
acids O
is O
a O
substrate I-GENE
for O
transport O
. O

The O
_RARE_ I-GENE
apparatus O
is O
a O
simple O
, O
useful O
, O
cost O
- I-GENE
effective O
_RARE_ I-GENE
to O
the O
diagnosis O
and O
treatment O
of O
this O
life O
- I-GENE
_RARE_ I-GENE
condition O
. O

Co O
- I-GENE
transfection O
of O
expression O
vectors O
for O
CCAAT I-GENE
/ I-GENE
enhancer I-GENE
binding I-GENE
protein I-GENE
( O
C I-GENE
/ I-GENE
EBP I-GENE
) O
alpha I-GENE
and O
C I-GENE
/ I-GENE
EBP I-GENE
beta I-GENE
trans O
- I-GENE
activated I-GENE
the O
rat I-GENE
_RARE_ I-GENE
protein I-GENE
gene I-GENE
promoter I-GENE
due O
to O
sequences I-GENE
in O
the O
5 I-GENE
' O
proximal I-GENE
region O
. O

It O
was O
not O
possible O
to O
study O
the O
basis O
for O
tissue I-GENE
- I-GENE
specific I-GENE
expression O
of O
this O
gene I-GENE
, O
because O
the O
beta I-GENE
3 I-GENE
gene I-GENE
promoter I-GENE
had O
not O
been O
isolated O
previously O
. O

Isolation O
and O
characterization O
of O
a O
TATA I-GENE
- I-GENE
less O
promoter I-GENE
for O
the O
human I-GENE
beta I-GENE
3 I-GENE
integrin I-GENE
gene I-GENE
. O

_RARE_ I-GENE
fluid O
was O
_RARE_ I-GENE
on O
the O
_RARE_ I-GENE
eye O
in O
19 O
eyes O
( O
52 O
. O
7 O
%) O
and O
on O
the O
better O
eye O
in O
7 O
eyes O
( O
19 O
. O
4 I-GENE
%). O

These O
data O
indicate O
that O
activation O
of O
these O
enzymes O
is O
not O
sufficient O
for O
the O
acute O
stimulation O
of O
glucose O
transport O
. O

The O
inserted O
region O
, O
which O
represents O
an O
intron O
in O
brain O
and O
muscle O
, O
is O
expressed O
in O
the O
tumor I-GENE
cell O
lines O
either O
as O
a O
" O
readthrough O
" O
form O
or O
with O
78 O
residues O
deleted O
from O
its O
5 I-GENE
' O
end O
. O

_RARE_ I-GENE
of O
_RARE_ I-GENE
scores O
was O
tested O
in O
_RARE_ I-GENE
stable O
subjects O
. O

_RARE_ I-GENE
line O
_RARE_ I-GENE
of O
_RARE_ I-GENE
scores O
were O
significantly O
different O
in O
patients O
who O
_RARE_ I-GENE
from O
those O
who O
remained O
stable O
_RARE_ I-GENE
b I-GENE
] O
< O
0 O
. O
15 O
; O
P I-GENE
< O
0 O
. O
0001 O
). O

_RARE_ I-GENE
and O
_RARE_ I-GENE
were O
found O
effective O
in O
the O
treatment O
of O
_RARE_ I-GENE
, O
but O
because O
of O
serious O
side O
effects O
_RARE_ I-GENE
in O
some O
cases O
, O
the O
drugs O
should O
be O
used O
_RARE_ I-GENE
in O
selected O
cases O
only O
. O

Inhibition O
of O
_RARE_ I-GENE
synthesis O
by O
disruption O
of O
_RARE_ I-GENE
- I-GENE
coenzyme I-GENE
A I-GENE
decarboxylase I-GENE
gene I-GENE
_RARE_ I-GENE
in O
_RARE_ I-GENE
_RARE_ I-GENE
. O

This O
region O
is O
required O
for O
activation O
of O
DNA I-GENE
binding I-GENE
of O
MyoD I-GENE
and O
E12 I-GENE
homodimers I-GENE
and O
E12 I-GENE
/ I-GENE
MyoD I-GENE
heterodimers I-GENE
. O

Transcriptional O
analysis O
of O
a O
series O
of O
deletion O
mutants I-GENE
of O
the O
gene I-GENE
in O
the O
nuclear I-GENE
extracts O
prepared O
from O
the O
middle I-GENE
_RARE_ I-GENE
gland O
of O
2 I-GENE
- I-GENE
day O
- I-GENE
old O
_RARE_ I-GENE
_RARE_ I-GENE
larvae O
revealed O
the O
presence O
of O
multiple O
cis O
- I-GENE
regulatory I-GENE
elements O
located O
both O
upstream O
and O
downstream O
of O
the O
initiation I-GENE
site I-GENE
. O

One O
of O
these O
elements O
, O
the O
homeodomain I-GENE
- I-GENE
binding I-GENE
element I-GENE
, O
was O
identified O
to O
mediate O
negative O
regulation O
. O

Site I-GENE
- I-GENE
directed O
mutagenesis O
of O
the O
_RARE_ I-GENE
structural O
gene I-GENE
and O
application O
of O
purified O
mutant I-GENE
_RARE_ I-GENE
proteins I-GENE
for O
in O
vitro O
assays O
_RARE_ I-GENE
to O
evaluate O
the O
functional O
importance O
of O
conserved O
amino O
acid I-GENE
residues O
. O

_RARE_ I-GENE
action O
of O
three O
distinct O
domains I-GENE
in O
the O
DNA I-GENE
_RARE_ I-GENE
- I-GENE
joining O
reaction O
catalyzed O
by O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
of O
_RARE_ I-GENE
plasmid O
_RARE_ I-GENE
. O

The O
COOH O
- I-GENE
terminal I-GENE
46 O
codons O
of O
_RARE_ I-GENE
encode O
a O
remarkable O
histidine O
- I-GENE
rich O
peptide I-GENE
sequence I-GENE
which O
is O
at O
least O
partly O
dispensable O
for O
_RARE_ I-GENE
function O
in O
E I-GENE
- I-GENE
mediated O
lysis O
. O

_RARE_ I-GENE
antibodies I-GENE
raised O
against O
rat I-GENE
cytochrome I-GENE
P I-GENE
- I-GENE
450 I-GENE
_RARE_ I-GENE
recognized O
a O
protein I-GENE
in O
the O
hepatic I-GENE
_RARE_ I-GENE
of O
the O
double O
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
, O
and O
also O
in O
those O
of O
the O
great O
blue O
_RARE_ I-GENE
( O
_RARE_ I-GENE
_RARE_ I-GENE
), O
using O
_RARE_ I-GENE
. O

We O
studied O
_RARE_ I-GENE
- I-GENE
Px I-GENE
enzyme I-GENE
activity O
in O
serum I-GENE
after O
acute O
myocardial O
infarction O
( O
AMI O
) O
and O
unstable O
angina O
pectoris O
( O
_RARE_ I-GENE
). O

The O
HGF I-GENE
- I-GENE
induced O
cell O
motility O
was O
mimicked O
by O
12 O
- I-GENE
0 O
- I-GENE
_RARE_ I-GENE
- I-GENE
phorbol O
- I-GENE
13 O
- I-GENE
acetate O
, O
a O
protein I-GENE
kinase I-GENE
C I-GENE
- I-GENE
activating I-GENE
phorbol O
ester O
, O
but O
not O
by O
Ca2 I-GENE
+ I-GENE
_RARE_ I-GENE
. O

In O
addition O
, O
_RARE_ I-GENE
_RARE_ I-GENE
was O
examined O
by O
presenting O
an O
identity O
_RARE_ I-GENE
earlier O
in O
the O
_RARE_ I-GENE
. O

METHODS O
: O
Forty O
- I-GENE
nine O
cases O
with O
intrahepatic O
multiple O
nodules O
of O
_RARE_ I-GENE
, O
by O
gross O
examination O
, O
among O
_RARE_ I-GENE
consecutive O
_RARE_ I-GENE
_RARE_ I-GENE
were O
examined O
_RARE_ I-GENE
. O

In O
the O
present O
report O
, O
66 O
_RARE_ I-GENE
families O
_RARE_ I-GENE
151 O
_RARE_ I-GENE
chromosomes O
and O
182 O
normal O
chromosomes O
were O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
with O
a O
battery O
of O
probes O
, O
including O
two O
newly O
derived O
polymorphic O
markers O
from O
the O
6 I-GENE
. O
7 O
and O
HLA I-GENE
- I-GENE
F I-GENE
loci I-GENE
located O
150 O
and O
250 O
kb O
telomeric O
to O
HLA I-GENE
- I-GENE
A I-GENE
, O
respectively O
. O

_RARE_ I-GENE
during O
laparoscopic O
dissection O
of O
the O
_RARE_ I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
cortical O
malformations O
were O
produced O
in O
rats O
by O
a O
single O
dose O
of O
X I-GENE
- I-GENE
rays O
( O
200 O
_RARE_ I-GENE
) O
given O
on O
different O
days O
during O
gestation O
. O

T2 I-GENE
cancers O
should O
not O
be O
excluded O
from O
the O
benefit O
of O
preoperative O
irradiation O
. O

IFN I-GENE
alpha I-GENE
and O
IFN I-GENE
gamma I-GENE
inducibility O
is O
mediated O
by O
a O
single O
element I-GENE
: O
a O
high O
affinity O
, O
nearly O
palindromic O
version O
of O
the O
IFN I-GENE
gamma I-GENE
activation O
site I-GENE
( O
_RARE_ I-GENE
). O

Mutations O
in O
the O
nuclear I-GENE
gene I-GENE
_RARE_ I-GENE
of O
Saccharomyces I-GENE
cerevisiae I-GENE
result O
in O
degradation O
of O
_RARE_ I-GENE
encoded I-GENE
cytochrome I-GENE
b I-GENE
( O
_RARE_ I-GENE
) O
RNA I-GENE
; O
thus O
, O
the O
cells O
are O
unable O
to O
_RARE_ I-GENE
. O

Twenty O
- I-GENE
three O
sequence I-GENE
- I-GENE
tagged O
sites I-GENE
( O
_RARE_ I-GENE
) O
were O
mapped O
within O
the O
contig O
, O
a O
density I-GENE
of O
approximately O
1 I-GENE
per O
200 O
kb O
. O

In O
this O
paper O
, O
we O
demonstrate O
that O
binding I-GENE
of O
the O
GA I-GENE
- I-GENE
binding I-GENE
protein I-GENE
( O
GABP I-GENE
) O
to O
ets I-GENE
sequence I-GENE
motifs O
within O
each O
repeated O
unit I-GENE
is O
required O
for O
transcriptional O
activation O
of O
the O
_RARE_ I-GENE
promoter I-GENE
. O

To O
gain O
further O
insight O
into O
the O
pathogenesis O
of O
the O
adult O
respiratory O
distress O
syndrome O
( O
ARDS O
), O
the O
authors O
studied O
possible O
relationships O
among O
the O
activation O
status O
of O
circulating O
_RARE_ I-GENE
neutrophils O
( O
PMN I-GENE
), O
cytokine O
levels O
, O
and O
the O
severity O
of O
lung O
injury O
in O
31 O
patients O
: O
15 O
with O
ARDS O
, O
9 O
with O
severe O
pneumonia O
_RARE_ I-GENE
by O
ARDS O
, O
and O
7 O
_RARE_ I-GENE
ventilated O
patients O
with O
neither O
ARDS O
nor O
pneumonia O
. O

_RARE_ I-GENE
, O
_RARE_ I-GENE
used O
as O
first O
- I-GENE
line O
treatment O
, O
appears O
to O
be O
the O
most O
effective O
drug O
. O

These O
results O
demonstrate O
that O
dopamine I-GENE
receptor I-GENE
stimulation O
by O
different O
dopamine I-GENE
agonists O
produces O
a O
different O
pattern O
of O
effects O
on O
the O
characteristics O
of O
the O
reaction O
time O
response O
. O

Two O
experiments O
were O
conducted O
to O
study O
the O
_RARE_ I-GENE
jaw O
movements O
induced O
in O
rats O
by O
acute O
administration O
of O
the O
monoamine I-GENE
- I-GENE
_RARE_ I-GENE
agent O
_RARE_ I-GENE
. O

_RARE_ I-GENE
of O
dopamine I-GENE
in O
the O
nucleus O
_RARE_ I-GENE
led O
to O
a O
dramatic O
shift O
in O
behavior O
in O
which O
there O
was O
a O
significant O
decrease O
in O
_RARE_ I-GENE
_RARE_ I-GENE
but O
a O
significant O
increase O
in O
consumption O
of O
_RARE_ I-GENE
_RARE_ I-GENE
. O

We O
have O
investigated O
the O
influence O
of O
_RARE_ I-GENE
+ I-GENE
EDTA O
, O
and O
of O
increasing O
dietary O
levels O
of O
_RARE_ I-GENE
, O
on O
Zn I-GENE
, O
Cu I-GENE
and O
Ca I-GENE
metabolism O
in O
rats O
fed O
on O
Zn I-GENE
- I-GENE
sufficient O
and O
Zn I-GENE
- I-GENE
deficient O
_RARE_ I-GENE
- I-GENE
bean I-GENE
- I-GENE
isolate O
- I-GENE
based O
diets O
. O

_RARE_ I-GENE
of O
_RARE_ I-GENE
- I-GENE
induced O
_RARE_ I-GENE
following O
recombinant I-GENE
granulocyte I-GENE
- I-GENE
macrophage I-GENE
colony I-GENE
stimulating I-GENE
factor I-GENE
( O
_RARE_ I-GENE
- I-GENE
CSF I-GENE
) O
administration O
. O

Thus O
, O
the O
system O
can O
be O
used O
to O
detect O
and O
study O
dynamic O
perfusion O
changes O
from O
the O
brain O
surface O
with O
minimal I-GENE
tissue I-GENE
damage O
. O

The O
_RARE_ I-GENE
of O
_RARE_ I-GENE
' O
s O
theory O
demonstrates O
the O
range O
of O
factors I-GENE
, O
other O
than O
the O
strictly O
_RARE_ I-GENE
, O
which O
can O
be O
important O
in O
determining O
the O
influence O
or O
otherwise O
of O
a O
psychological O
theory O
. O

The O
positive O
- I-GENE
acting O
global O
sulfur O
regulatory I-GENE
protein I-GENE
, O
_RARE_ I-GENE
, O
of O
Neurospora I-GENE
crassa I-GENE
_RARE_ I-GENE
on O
the O
expression O
of O
a O
family I-GENE
of O
_RARE_ I-GENE
structural O
genes I-GENE
that O
encode O
enzymes O
of O
sulfur O
catabolism O
. O

Analysis O
of O
the O
upstream O
untranslated O
region O
of O
_RARE_ I-GENE
revealed O
the O
presence O
of O
the O
hexamer O
element I-GENE
, O
_RARE_ I-GENE
( O
an O
_RARE_ I-GENE
restriction I-GENE
site I-GENE
) O
controlling O
both O
the O
periodic I-GENE
expression O
and O
coordinate O
regulation O
of O
the O
DNA I-GENE
synthesis O
genes I-GENE
in O
budding I-GENE
yeast I-GENE
. O

The O
C I-GENE
- I-GENE
terminal I-GENE
region O
of O
the O
150 O
- I-GENE
kDa I-GENE
protein I-GENE
contains O
an O
_RARE_ I-GENE
- I-GENE
binding I-GENE
helicase I-GENE
motif I-GENE
and O
the O
readthrough O
region O
, O
an O
RNA I-GENE
polymerase I-GENE
motif I-GENE
, O
indicating O
that O
these O
two O
overlapping O
proteins I-GENE
may O
form O
an O
RNA I-GENE
replication O
complex I-GENE
similar O
to O
those O
of O
_RARE_ I-GENE
- I-GENE
and O
_RARE_ I-GENE
. O

The O
5 I-GENE
' O
ends O
of O
_RARE_ I-GENE
late O
transcripts I-GENE
were O
located O
to O
an O
A I-GENE
within O
the O
sequence I-GENE
5 I-GENE
'- O
_RARE_ I-GENE
, O
41 O
nt O
downstream O
from O
the O
early I-GENE
promoter I-GENE
and O
17 O
nt O
upstream O
from O
the O
initiation I-GENE
codon O
. O

On O
T2 I-GENE
weighted O
images O
, O
low O
intensity O
areas O
in O
the O
_RARE_ I-GENE
, O
the O
striatum I-GENE
, O
the O
anterior O
limb O
of O
the O
internal O
_RARE_ I-GENE
, O
the O
_RARE_ I-GENE
of O
_RARE_ I-GENE
, O
high O
intensity O
areas O
in O
middle I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
, O
the O
posterior O
limb O
of O
the O
internal O
_RARE_ I-GENE
, O
the O
lateral O
part O
of O
the O
cerebral O
_RARE_ I-GENE
, O
and O
the O
cerebral O
white O
matter O
were O
noted O
. O

Using O
the O
_RARE_ I-GENE
alleles I-GENE
to O
generate O
wild I-GENE
- I-GENE
type I-GENE
cells O
_RARE_ I-GENE
only O
in O
telomere I-GENE
tract O
lengths O
, O
we O
also O
show O
that O
telomere I-GENE
position O
effects O
are O
highly O
sensitive O
to O
changes O
in O
the O
size O
( O
or O
structure O
) O
of O
the O
telomeric O
tract O
. O

_RARE_ I-GENE
_RARE_ I-GENE
characterized O
by O
_RARE_ I-GENE
fields O
, O
_RARE_ I-GENE
and O
_RARE_ I-GENE
capillaries O
and O
increased O
_RARE_ I-GENE
diffusion O
of O
sodium O
_RARE_ I-GENE
, O
was O
clearly O
_RARE_ I-GENE
in O
the O
area O
of O
the O
nodules O
. O

_RARE_ I-GENE
switching O
of O
transcriptional O
states O
: O
cis O
- I-GENE
and O
trans O
- I-GENE
acting O
factors I-GENE
affecting O
establishment O
of O
silencing O
at O
the O
HMR I-GENE
locus I-GENE
in O
Saccharomyces I-GENE
cerevisiae I-GENE
. O

NF I-GENE
- I-GENE
kappa I-GENE
B I-GENE
p65 I-GENE
, O
p50 I-GENE
, O
and O
Rel I-GENE
functionally O
_RARE_ I-GENE
with O
C I-GENE
/ I-GENE
EBP I-GENE
alpha I-GENE
, O
C I-GENE
/ I-GENE
EBP I-GENE
beta I-GENE
, O
and O
C I-GENE
/ I-GENE
EBP I-GENE
delta I-GENE
. O

It O
could O
be O
detected O
exclusively O
in O
the O
culture O
medium O
of O
cDNA I-GENE
- I-GENE
transfected O
COS O
cells O
. O

The O
first O
group O
of O
sequential O
_RARE_ I-GENE
showed O
a O
significant O
progress O
to O
_RARE_ I-GENE
in O
so O
- I-GENE
called O
" O
Chronic O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
-, I-GENE
which O
corresponds O
to O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
in O
72 O
. O
4 I-GENE
% O
( O
21 O
/ I-GENE
29 O
patients O
), O
as O
well O
as O
in O
CML O
with O
_RARE_ I-GENE
increase O
- I-GENE
CML O
. O
MI O
- I-GENE
in O
39 O
. O
2 I-GENE
% O
( O
20 O
/ I-GENE
51 O
). O

The O
two O
methods O
identify O
the O
same O
patients O
only O
if O
_RARE_ I-GENE
pressures O
are O
normal O
( O
40 I-GENE
to O
60 O
cmH2O O
) O
to O
high O
( O
over O
60 O
cmH2O O
) O
and O
the O
_RARE_ I-GENE
formula O
is O
used O
with O
a O
higher O
( O
_RARE_ I-GENE
_RARE_ I-GENE
) O
cutoff O
. O

There O
was O
no O
clear O
correlation O
between O
the O
_RARE_ I-GENE
and O
the O
severity O
of O
the O
_RARE_ I-GENE
phenotype O
. O

_RARE_ I-GENE
sterol I-GENE
carrier I-GENE
protein I-GENE
2 I-GENE
/ I-GENE
sterol I-GENE
carrier I-GENE
protein I-GENE
x O
: O
cDNA I-GENE
cloning O
reveals O
evolutionary O
conservation O
of O
structure O
and O
regulated O
expression O
. O

The O
_RARE_ I-GENE
albumin I-GENE
concentration O
( O
3 I-GENE
. O
5 I-GENE
- I-GENE
4 I-GENE
. O
5 I-GENE
g O
/ I-GENE
dl O
) O
represents O
about O
60 O
% O
of O
the O
total O
plasma I-GENE
protein I-GENE
. O

These O
lesions O
were O
asymptomatic O
, O
but O
both O
were O
characterized O
clinically O
by O
central O
ulceration O
. O

A I-GENE
single O
five O
minute O
period O
of O
rapid O
atrial I-GENE
pacing O
fails O
to O
limit O
infarct O
size O
in O
the O
in O
situ O
rabbit I-GENE
heart O
. O

Neither O
_RARE_ I-GENE
nor O
_RARE_ I-GENE
mRNA I-GENE
synthesis O
was O
responsive I-GENE
to O
cold O
or O
to O
heat I-GENE
stress O
. O

Previous O
studies O
indicated O
that O
the O
20S I-GENE
proteasome I-GENE
is O
a O
catalytic O
core I-GENE
of O
the O
_RARE_ I-GENE
proteolytic O
complex I-GENE
that O
possesses O
a O
latent I-GENE
_RARE_ I-GENE
proteinase I-GENE
activity O
and O
catalyzes O
an O
ATP I-GENE
- I-GENE
dependent I-GENE
, O
selective O
_RARE_ I-GENE
of O
proteins I-GENE
ligated O
to O
ubiquitin I-GENE
. O

The O
O2 O
deficit O
was O
not O
related I-GENE
to O
blood O
lactate I-GENE
during O
_RARE_ I-GENE
exercise O
, O
muscle O
enzyme I-GENE
activity O
( O
citrate I-GENE
synthase I-GENE
, O
3 I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
CoA I-GENE
- I-GENE
dehydrogenase I-GENE
, O
lactate I-GENE
dehydrogenase I-GENE
), O
number O
of O
muscle O
capillaries O
, O
% O
ST O
fibres O
or O
muscle O
_RARE_ I-GENE
capacity O
. O

The O
sequence I-GENE
of O
the O
putative O
_RARE_ I-GENE
protein I-GENE
contains O
two O
copies O
of O
an O
RNA I-GENE
recognition I-GENE
motif I-GENE
, O
two O
glutamine I-GENE
stretches O
, O
an O
_RARE_ I-GENE
- I-GENE
rich O
region O
, O
a O
methionine O
- I-GENE
rich O
region O
, O
and O
two O
long O
potential O
alpha I-GENE
- I-GENE
_RARE_ I-GENE
. O

One O
defective O
RNA I-GENE
with O
a O
large O
deletion O
in O
the O
p70 I-GENE
coding O
region O
was O
able O
to O
_RARE_ I-GENE
efficiently O
, O
both O
when O
inoculated O
with O
the O
_RARE_ I-GENE
genome O
and O
when O
inoculated O
with O
a O
second O
_RARE_ I-GENE
defective O
RNA I-GENE
that O
supplied O
a O
wild I-GENE
- I-GENE
type I-GENE
p70 I-GENE
. O

_RARE_ I-GENE
of O
this O
selective O
pressure O
, O
however O
, O
gave O
way O
to O
homologous O
resolution O
of O
the O
_RARE_ I-GENE
structures O
. O

_RARE_ I-GENE
nucleotide I-GENE
sequence I-GENE
of O
the O
bacteriophage I-GENE
_RARE_ I-GENE
tail O
gene I-GENE
encoding O
_RARE_ I-GENE
- I-GENE
N I-GENE
- I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
- I-GENE
N I-GENE
) O
and O
comparison O
to O
an O
_RARE_ I-GENE
- I-GENE
N I-GENE
homolog I-GENE
in O
bacteriophage I-GENE
_RARE_ I-GENE
. O

Binding O
of O
U2 I-GENE
small I-GENE
nuclear I-GENE
ribonucleoprotein I-GENE
was O
partially O
inhibited O
. O

_RARE_ I-GENE
_RARE_ I-GENE
of O
brain O
edema O
related I-GENE
to O
experimental O
multiple O
micro O
- I-GENE
_RARE_ I-GENE
in O
mice O
: O
assessment O
of O
_RARE_ I-GENE
effect O
. O

One O
member O
of O
this O
_RARE_ I-GENE
family I-GENE
, O
GATA I-GENE
- I-GENE
3 I-GENE
, O
is O
most O
abundantly O
expressed O
in O
T I-GENE
lymphocytes O
, O
a O
cellular O
target O
for O
human I-GENE
immunodeficiency I-GENE
virus I-GENE
type I-GENE
1 I-GENE
( O
HIV I-GENE
- I-GENE
1 I-GENE
) O
infection O
and O
replication O
. O

Indeed O
, O
significant O
level O
of O
CAT I-GENE
activity O
was O
observed O
in O
human I-GENE
lung O
adenocarcinoma O
( O
_RARE_ I-GENE
- I-GENE
1 I-GENE
) O
cells O
which O
had O
been O
incubated O
with O
a O
complex I-GENE
of O
T7 I-GENE
RNA I-GENE
polymerase I-GENE
, O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
CAT I-GENE
DNA I-GENE
and O
DC O
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
liposomes O
. O

_RARE_ I-GENE
is O
a O
rare O
condition O
that O
_RARE_ I-GENE
little O
discussion O
in O
standard O
_RARE_ I-GENE
of O
_RARE_ I-GENE
. O

The O
first O
gene I-GENE
codes O
for O
a O
protein I-GENE
containing O
11 O
_RARE_ I-GENE
residues O
in O
an O
arrangement O
typical O
for O
_RARE_ I-GENE
/ I-GENE
S I-GENE
proteins I-GENE
. O

_RARE_ I-GENE
- I-GENE
disrupted O
cells O
retained O
capacity O
for O
activation O
of O
the O
pathway O
by O
both O
peptide I-GENE
growth I-GENE
factors I-GENE
and O
by O
addition O
of O
GTP I-GENE
- I-GENE
_RARE_ I-GENE
p21 I-GENE
_RARE_ I-GENE
. O

To O
begin O
to O
examine O
the O
mechanism O
controlling O
expression O
of O
this O
gene I-GENE
during O
the O
cell O
- I-GENE
cycle O
, O
a O
mouse I-GENE
B I-GENE
- I-GENE
myb I-GENE
5 I-GENE
' O
flanking O
sequence I-GENE
was O
isolated O
from O
a O
cosmid O
library O
and O
shown O
to O
promote O
efficiently O
the O
transcription I-GENE
of O
a O
luciferase I-GENE
reporter I-GENE
gene I-GENE
when O
transfected O
into O
NIH3T3 O
fibroblasts O
. O

The O
influence O
of O
a O
high O
ionic O
strength O
on O
the O
resolution O
was O
clearly O
shown O
. O

The O
number O
of O
bacteria O
in O
the O
lung O
, O
peripheral O
white O
blood O
cell O
and O
BAL I-GENE
fluid O
cell O
also O
decreased O
by O
the O
administration O
of O
FN I-GENE
. O

In O
mice O
, O
three O
major I-GENE
families O
of O
L1 I-GENE
elements O
, O
termed O
" O
A I-GENE
," O
" O
F I-GENE
," O
and O
" O
V I-GENE
," O
have O
been O
defined O
on O
the O
basis O
of O
the O
sequence I-GENE
found O
at O
the O
5 I-GENE
' O
terminus O
. O

_RARE_ I-GENE
, O
a O
basic I-GENE
helix I-GENE
- I-GENE
loop I-GENE
- I-GENE
helix I-GENE
protein I-GENE
, O
forms O
heterodimers I-GENE
with O
_RARE_ I-GENE
and O
inhibits O
_RARE_ I-GENE
- I-GENE
dependent I-GENE
transcription I-GENE
activation O
. O

The O
equivalent O
of O
the O
third O
ligand O
, O
H I-GENE
- I-GENE
87 O
, O
is O
T I-GENE
- I-GENE
47 O
in O
the O
_RARE_ I-GENE
sequence I-GENE
motif I-GENE
. O

Similar O
results O
were O
seen O
on O
Western O
blots O
of O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
)- I-GENE
infected O
_RARE_ I-GENE
_RARE_ I-GENE
cells O
. O

In O
infected O
mammalian I-GENE
cells O
, O
the O
_RARE_ I-GENE
G I-GENE
and O
_RARE_ I-GENE
genes I-GENE
are O
transcribed O
primarily O
as O
a O
_RARE_ I-GENE
mRNA I-GENE
which O
appears O
to O
extend O
from O
the O
consensus I-GENE
sequence I-GENE
( O
_RARE_ I-GENE
) O
at O
the O
start O
of O
the O
G I-GENE
gene I-GENE
to O
the O
next O
recognized O
polyadenylation O
signal I-GENE
( O
_RARE_ I-GENE
[ O
A I-GENE
] O
7 O
) O
located O
_RARE_ I-GENE
nucleotides O
downstream O
of O
the O
_RARE_ I-GENE
protein I-GENE
termination O
codon O
. O

Molecular O
cloning O
and O
expression O
of O
_RARE_ I-GENE
, O
a O
novel O
retinal O
_RARE_ I-GENE
epithelium O
- I-GENE
specific I-GENE
_RARE_ I-GENE
protein I-GENE
that O
is O
post O
- I-GENE
transcriptionally O
regulated O
in O
vitro O
. O

The O
mean O
power O
( O
in O
mu I-GENE
W I-GENE
) O
required O
to O
produce O
the O
observed O
flow O
rate O
was O
estimated O
at O
each O
outflow O
pressure O
as O
the O
product I-GENE
of O
the O
flow O
rate O
and O
the O
pressure O
across O
the O
_RARE_ I-GENE
vessel O
. O

Although O
_RARE_ I-GENE
antibodies I-GENE
are O
associated I-GENE
with O
infertility O
, O
many O
hospital O
laboratories O
do O
not O
test O
for O
these O
antibodies I-GENE
. O

_RARE_ I-GENE
- I-GENE
specific I-GENE
IgG I-GENE
_RARE_ I-GENE
responses O
were O
evident O
to O
all O
four O
IgG I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
body O
pattern O
in O
Drosophila I-GENE
is O
specified O
by O
the O
_RARE_ I-GENE
distribution O
of O
the O
_RARE_ I-GENE
protein I-GENE
( O
_RARE_ I-GENE
), O
which O
activates O
_RARE_ I-GENE
genes I-GENE
in O
distinct O
anterior O
domains I-GENE
. O

GAP I-GENE
- I-GENE
N I-GENE
bound O
constitutively O
to O
p190 I-GENE
in O
both O
serum I-GENE
- I-GENE
deprived O
and O
growth I-GENE
factor I-GENE
- I-GENE
stimulated O
cells O
. O

The O
peptide I-GENE
sequence I-GENE
contains O
a O
region O
of O
80 O
amino O
acids O
that O
shows O
similarity O
to O
bcl I-GENE
- I-GENE
2 I-GENE
and O
to O
the O
recently O
described O
bcl I-GENE
- I-GENE
2 I-GENE
- I-GENE
related I-GENE
gene I-GENE
, O
_RARE_ I-GENE
. O

The O
phosphorylation O
efficiency O
is O
improved O
by O
increasing O
the O
number O
of O
N I-GENE
- I-GENE
terminal I-GENE
arginine I-GENE
residues O
and O
by O
_RARE_ I-GENE
the O
_RARE_ I-GENE
cluster I-GENE
one O
residue O
further O
_RARE_ I-GENE
from O
the O
serine I-GENE
, O
the O
_RARE_ I-GENE
( O
Arg O
) O
4 I-GENE
- I-GENE
Ala I-GENE
- I-GENE
Ala I-GENE
- I-GENE
Ser O
- I-GENE
Val I-GENE
- I-GENE
Ala I-GENE
being O
the O
best O
substrate I-GENE
among O
all O
the O
short O
peptides I-GENE
tested O
( O
_RARE_ I-GENE
= O
15 O
microM O
). O

_RARE_ I-GENE
toxin I-GENE
: O
preferred O
treatment O
for O
_RARE_ I-GENE
_RARE_ I-GENE
. O

The O
Saccharomyces I-GENE
cerevisiae I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
genes I-GENE
are O
controlled O
in O
response O
to O
the O
availability O
of O
galactose I-GENE
and O
glucose O
by O
multiple O
activating I-GENE
and O
repressing O
proteins I-GENE
bound O
at O
adjacent O
or O
overlapping O
sites I-GENE
in O
_RARE_ I-GENE
. O

Surprisingly O
, O
the O
results O
of O
several O
experiments O
suggest O
that O
the O
_RARE_ I-GENE
genes I-GENE
encode O
global O
regulatory I-GENE
factors I-GENE
. O
_RARE_ I-GENE
to O
_RARE_ I-GENE
mutations O
_RARE_ I-GENE
expression O
from O
yeast I-GENE
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
hybrid O
promoters I-GENE
( O
fused O
to O
lacZ I-GENE
) O
that O
harbor O
a O
variety O
of O
operator I-GENE
sequences I-GENE
, O
and O
caused O
pleiotropic O
defects O
in O
cell O
growth I-GENE
, O
mating I-GENE
, O
and O
sporulation I-GENE
. O

_RARE_ I-GENE
of O
calf I-GENE
( O
_RARE_ I-GENE
2 I-GENE
) O
was O
associated I-GENE
most O
closely O
with O
_RARE_ I-GENE
of O
_RARE_ I-GENE
and O
head I-GENE
. O

Sequence O
comparison O
indicates O
that O
exons O
5 I-GENE
_RARE_ I-GENE
L I-GENE
and O
L I-GENE
/ I-GENE
N I-GENE
in O
_RARE_ I-GENE
and O
_RARE_ I-GENE
psi I-GENE
are O
99 O
% O
identical O
, O
except O
that O
the O
L I-GENE
/ I-GENE
N I-GENE
exon O
in O
the O
_RARE_ I-GENE
psi I-GENE
gene I-GENE
contains O
a O
stop O
codon O
. O

The O
mechanisms O
that O
govern O
the O
activation O
or O
suppression O
of O
the O
CD8 I-GENE
gene I-GENE
are O
likely O
to O
be O
central O
to O
the O
T I-GENE
cell O
development O
program O
. O

We O
suggest O
that O
the O
ER I-GENE
_RARE_ I-GENE
variable O
domain I-GENE
of O
_RARE_ I-GENE
has O
a O
specific I-GENE
tertiary O
structure O
that O
is O
important O
for O
binding I-GENE
to O
the O
polymorphic O
alpha I-GENE
1 I-GENE
and O
alpha I-GENE
2 I-GENE
domains I-GENE
of O
class I-GENE
I I-GENE
heavy I-GENE
( O
alpha I-GENE
) O
chains I-GENE
. O

We O
recently O
found O
that O
17 O
beta I-GENE
- I-GENE
estradiol O
( O
E2 I-GENE
) O
not O
only O
suppresses O
bone O
resorption O
but O
also O
stimulates O
bone O
formation O
in O
the O
_RARE_ I-GENE
bone O
of O
female O
rats O
. O

Recombinant I-GENE
human I-GENE
erythropoietin I-GENE
( O
_RARE_ I-GENE
) O
is O
_RARE_ I-GENE
to O
be O
administered O
by O
the O
intravenous O
( O
i O
. O
v I-GENE
.) O
or O
subcutaneous O
( O
SC O
) O
route O
. O

_RARE_ I-GENE
- I-GENE
photon O
emission O
computed O
tomography O
( O
SPECT O
) O
with O
99mTc O
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
( O
HMPAO O
) O
was O
used O
to O
investigate O
changes O
in O
cerebral O
blood O
flow O
in O
seven O
patients O
with O
cortical O
visual O
impairment O
. O

The O
rCBF O
ratio O
was O
mainly O
reduced O
in O
frontal O
_RARE_ I-GENE
( O
65 O
%). O

METHODS O
: O
Twenty O
- I-GENE
two O
patients O
were O
_RARE_ I-GENE
according O
to O
their O
etiology O
based O
on O
the O
study O
of O
_RARE_ I-GENE
antibodies I-GENE
at O
diagnosis O
of O
the O
disease O
: O
7 O
were O
positive O
( O
_RARE_ I-GENE
etiology O
or O
_RARE_ I-GENE
), O
11 O
were O
negative O
( O
tuberculous O
etiology O
or O
_RARE_ I-GENE
) O
and O
in O
four O
serologic O
study O
was O
not O
available O
( O
_RARE_ I-GENE
etiology O
or O
_RARE_ I-GENE
). O

2 I-GENE
- I-GENE
AP I-GENE
induced O
marked O
, O
steady O
_RARE_ I-GENE
in O
mRNA I-GENE
accumulation O
from O
both O
transfected O
and O
_RARE_ I-GENE
integrated O
HIV I-GENE
- I-GENE
1 I-GENE
constructs I-GENE
but O
no O
increases O
from O
an O
endogenous I-GENE
gene I-GENE
encoding O
gamma I-GENE
- I-GENE
actin I-GENE
or O
glucose O
6 I-GENE
- I-GENE
phosphate I-GENE
dehydrogenase I-GENE
. O

The O
UV O
induction O
of O
c I-GENE
- I-GENE
jun I-GENE
is O
mediated O
by O
two O
UV O
response O
elements O
consisting O
of O
AP I-GENE
- I-GENE
1 I-GENE
- I-GENE
like I-GENE
sequences I-GENE
within O
its O
5 I-GENE
' O
control O
region O
. O

Protein I-GENE
tyrosine I-GENE
phosphatases I-GENE
( O
_RARE_ I-GENE
), O
together O
with O
protein I-GENE
tyrosine I-GENE
kinases I-GENE
( O
_RARE_ I-GENE
), O
are O
involved O
in O
the O
regulation O
of O
cell O
activation O
, O
growth I-GENE
, O
and O
differentiation O
. O

ST O
elevation O
occurs O
in O
5 I-GENE
patients O
( O
55 O
. O
5 I-GENE
%) O
of O
subgroup O
A I-GENE
and O
in O
no O
patient O
of O
the O
subgroup O
B I-GENE
. O

Furthermore O
, O
a O
_RARE_ I-GENE
protein I-GENE
lacking O
the O
N I-GENE
- I-GENE
terminus O
of O
_RARE_ I-GENE
was O
expressed O
at O
high O
levels O
; O
our O
data O
indicate O
that O
_RARE_ I-GENE
is O
translated O
from O
the O
1 I-GENE
. O
6 I-GENE
- I-GENE
kb O
mRNA I-GENE
which O
is O
derived O
primarily O
from O
deleted O
_RARE_ I-GENE
. O

HTLV I-GENE
- I-GENE
1 I-GENE
gene I-GENE
expression O
by O
defective O
_RARE_ I-GENE
in O
an O
infected O
T I-GENE
- I-GENE
cell O
line O
. O

Thus O
, O
it O
was O
confirmed O
that O
the O
sodium O
_RARE_ I-GENE
sulfate I-GENE
method O
of O
estimating O
hemoglobin I-GENE
concentration O
is O
an O
appropriate O
alternative O
to O
the O
_RARE_ I-GENE
method O
and O
_RARE_ I-GENE
the O
generation O
of O
toxic O
_RARE_ I-GENE
. O

A I-GENE
comparison O
of O
the O
predicted O
amino O
acid I-GENE
sequences I-GENE
of O
the O
two O
human I-GENE
PKC I-GENE
- I-GENE
delta I-GENE
clones O
with O
the O
rat I-GENE
and O
mouse I-GENE
homologues O
indicated O
a O
greater O
degree O
of O
sequence I-GENE
divergence O
( O
89 I-GENE
- I-GENE
90 O
% O
homology I-GENE
) O
compared O
to O
the O
high O
degree O
of O
sequence I-GENE
conservation O
observed O
with O
other O
human I-GENE
PKC I-GENE
family I-GENE
members O
and O
their O
mammalian I-GENE
counterparts O
. O

_RARE_ I-GENE
. O

When O
comparing O
the O
barley I-GENE
PSI I-GENE
- I-GENE
K I-GENE
and O
PSI I-GENE
- I-GENE
G I-GENE
with O
the O
reported O
PSI I-GENE
- I-GENE
K I-GENE
sequence I-GENE
from O
_RARE_ I-GENE
_RARE_ I-GENE
, O
the O
degree O
of O
similarity O
is O
equal O
, O
suggesting O
that O
an O
ancestral O
gene I-GENE
has O
been O
duplicated O
in O
a O
chloroplast I-GENE
progenitor I-GENE
but O
not O
in O
a O
_RARE_ I-GENE
. O

On O
the O
other O
hand O
, O
the O
structures O
of O
the O
b I-GENE
- I-GENE
Zip I-GENE
domain I-GENE
are O
well O
conserved O
among O
these O
Maf I-GENE
- I-GENE
related I-GENE
proteins I-GENE
. O

Under O
these O
conditions O
, O
transfections O
with O
cDNAs I-GENE
of O
the O
NF I-GENE
- I-GENE
kappa I-GENE
B I-GENE
p50 I-GENE
and O
serum I-GENE
response O
factor I-GENE
( O
SRF I-GENE
) O
produced O
a O
factor I-GENE
( O
s O
) O
that O
mediated O
Tax I-GENE
binding I-GENE
to O
the O
NF I-GENE
- I-GENE
kappa I-GENE
B I-GENE
site I-GENE
and O
the O
CArG I-GENE
box I-GENE
respectively O
. O

We O
show O
here O
that O
v I-GENE
- I-GENE
Rel I-GENE
specifically O
increased O
expression O
from O
a O
reporter I-GENE
plasmid O
containing O
multiple O
Sp1 I-GENE
binding I-GENE
sites I-GENE
approximately O
_RARE_ I-GENE
in O
chicken I-GENE
embryo O
fibroblasts O
( O
_RARE_ I-GENE
), O
even O
though O
v I-GENE
- I-GENE
Rel I-GENE
did O
not O
bind O
directly O
to O
these O
sites I-GENE
. O
v I-GENE
- I-GENE
Rel I-GENE
also O
increased O
expression O
from O
a O
reporter I-GENE
plasmid O
containing O
a O
human I-GENE
immunodeficiency I-GENE
virus I-GENE
type I-GENE
1 I-GENE
( O
HIV I-GENE
- I-GENE
1 I-GENE
) O
long O
terminal I-GENE
repeat I-GENE
( O
LTR I-GENE
) O
in O
which O
the O
kappa I-GENE
B I-GENE
binding I-GENE
sites I-GENE
were O
mutated O
but O
which O
still O
contained O
intact O
Sp1 I-GENE
binding I-GENE
sites I-GENE
. O

The O
simultaneous O
recording O
of O
electrical O
activity O
from O
the O
surface O
electrocardiogram O
, O
right O
ventricular O
apex O
, O
His O
bundle O
, O
high O
right O
atrium O
, O
coronary O
sinus O
, O
with O
or O
without O
a O
_RARE_ I-GENE
mapping O
catheter O
, O
enables O
us O
to O
precisely O
map O
the O
electrical O
activation O
sequence I-GENE
in O
the O
heart O
. O

CONCLUSION O
: O
This O
retrospective O
analysis O
does O
not O
confirm O
the O
efficacy O
of O
one O
course O
of O
simultaneous O
_RARE_ I-GENE
- I-GENE
C I-GENE
and O
5 I-GENE
- I-GENE
fluorouracil O
, O
at O
least O
in O
association O
with O
full I-GENE
- I-GENE
dose O
radiotherapy O
_RARE_ I-GENE
_RARE_ I-GENE
- I-GENE
192 I-GENE
_RARE_ I-GENE
. O

Despite O
the O
existence O
of O
30 O
cysteine I-GENE
residues O
, O
_RARE_ I-GENE
prevented O
the O
formation O
of O
most O
if O
not O
all O
disulfide O
bonds O
that O
otherwise O
occurred O
when O
the O
cells O
were O
_RARE_ I-GENE
. O

_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
syndrome O
( O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
syndrome O
II I-GENE
) O

Most O
_RARE_ I-GENE
, O
the O
addition O
of O
purified O
_RARE_ I-GENE
U2 I-GENE
snRNPs I-GENE
, O
but O
not O
of O
_RARE_ I-GENE
U2 I-GENE
snRNPs I-GENE
, O
to O
HeLa O
splicing O
extracts O
in O
which O
the O
_RARE_ I-GENE
U2 I-GENE
snRNPs I-GENE
have O
been O
functionally O
_RARE_ I-GENE
with O
anti I-GENE
- I-GENE
_RARE_ I-GENE
antibodies I-GENE
fully O
restores O
the O
mRNA I-GENE
- I-GENE
splicing O
activity O
of O
the O
extracts O
. O

_RARE_ I-GENE
in O
profiles O
of O
viscosity O
variables O
between O
subgroups O
of O
_RARE_ I-GENE
in O
RA O
patients O
were O
observed O
. O

These O
contain O
a O
single O
_RARE_ I-GENE
- I-GENE
bp O
exon O
that O
encodes O
_RARE_ I-GENE
bp O
of O
the O
5 I-GENE
' O
and O
3 I-GENE
' O
untranslated O
sequences I-GENE
in O
addition O
to O
a O
_RARE_ I-GENE
- I-GENE
bp O
open O
reading O
frame O
identical O
to O
that O
found O
in O
vascular I-GENE
smooth I-GENE
muscle O
cell O
_RARE_ I-GENE
receptor I-GENE
cDNAs I-GENE
. O

Deletion O
of O
a O
53 O
- I-GENE
bp O
early I-GENE
promoter I-GENE
region O
containing O
the O
transcription I-GENE
start O
site I-GENE
and O
a O
putative O
TATA I-GENE
box I-GENE
completely O
abolishes O
the O
ability O
of O
upstream O
elements O
to O
drive O
transcription I-GENE
of O
the O
luciferase I-GENE
cDNA I-GENE
. O

One O
_RARE_ I-GENE
_RARE_ I-GENE
selected O
the O
larger O
_RARE_ I-GENE
4 I-GENE
during O
testing O
with O
a O
_RARE_ I-GENE
pair O
( O
2 I-GENE
- I-GENE
4 I-GENE
), O
and O
2 I-GENE
_RARE_ I-GENE
showed O
no O
preference O
. O

_RARE_ I-GENE
of O
_RARE_ I-GENE
pain O
after O
_RARE_ I-GENE
: O
implications O
for O
_RARE_ I-GENE
training O
. O

Alternative O
transcript I-GENE
of O
the O
_RARE_ I-GENE
- I-GENE
type I-GENE
endothelin I-GENE
receptor I-GENE
from O
rat I-GENE
brain O
. O

The O
Functional O
_RARE_ I-GENE
_RARE_ I-GENE
: O
a O
comparative O
study O
of O
_RARE_ I-GENE
and O
self O
_RARE_ I-GENE
. O

_RARE_ I-GENE
B I-GENE
was O
given O
intravenously O
for O
1 I-GENE
week O
_RARE_ I-GENE
in O
doses O
designed O
to O
_RARE_ I-GENE
circulating O
_RARE_ I-GENE
. O

_RARE_ I-GENE
can O
be O
determined O
in O
vitro O
and O
in O
vivo O
. O

The O
transverse O
relaxation O
time O
( O
T2 I-GENE
) O
and O
apparent O
diffusion O
coefficient O
of O
water O
were O
determined O
. O

The O
Drosophila I-GENE
clathrin I-GENE
heavy I-GENE
chain I-GENE
gene I-GENE
: O
clathrin I-GENE
function O
is O
essential O
in O
a O
_RARE_ I-GENE
organism O
. O

The O
binding I-GENE
specificity O
of O
this O
protein I-GENE
was O
compared O
to O
that O
of O
human I-GENE
E2F I-GENE
using O
a O
number O
of O
mutant I-GENE
E2F I-GENE
sites I-GENE
as O
_RARE_ I-GENE
. O

To O
analyze O
the O
VH I-GENE
regions O
of O
_RARE_ I-GENE
antibodies I-GENE
, O
with O
particular O
attention O
at O
their O
_RARE_ I-GENE
mutated O
status O
, O
we O
generated O
five O
IgG I-GENE
( O
three O
_RARE_ I-GENE
and O
two O
_RARE_ I-GENE
) O
mAb I-GENE
( O
using O
B I-GENE
cells O
from O
a O
healthy O
subject O
, O
a O
patient O
with O
insulin I-GENE
- I-GENE
dependent I-GENE
diabetes O
mellitus O
and O
a O
patient O
with O
SLE O
), O
which O
bound O
with O
various O
_RARE_ I-GENE
a O
number O
of O
different O
self O
and O
foreign O
Ag I-GENE
. O

It O
is O
possible O
that O
the O
patch O
_RARE_ I-GENE
the O
proper O
conformation O
of O
the O
site I-GENE
and O
thereby O
contributes O
to O
recognition I-GENE
indirectly O
. O

These O
findings O
suggest O
a O
functional O
cross O
- I-GENE
_RARE_ I-GENE
between O
RB I-GENE
protein I-GENE
and O
p21ras I-GENE
, O
which O
_RARE_ I-GENE
the O
cell O
phenotype O
between O
normal O
and O
transformed O
states O
. O

The O
7 O
- I-GENE
kb O
mRNA I-GENE
differs O
by O
alternative O
splicing O
such O
that O
it O
encodes O
a O
protein I-GENE
with O
a O
distinct O
amino O
terminus O
. O

_RARE_ I-GENE
of O
the O
inhibition O
indicated O
that O
this O
polymerase I-GENE
domain I-GENE
can O
inhibit O
viral I-GENE
replication O
only O
during O
the O
_RARE_ I-GENE
stage O
. O

The O
other O
transmembrane I-GENE
regions O
as O
well O
as O
the O
_RARE_ I-GENE
domain I-GENE
are O
not O
required O
for O
sorting I-GENE
. O

3 I-GENE
. O

_RARE_ I-GENE
III I-GENE
, O
F I-GENE
. O

These O
cell O
lines O
, O
selected O
for O
the O
ability O
to O
support O
the O
replication O
of O
a O
temperature O
- I-GENE
sensitive O
_RARE_ I-GENE
mutant I-GENE
, O
were O
used O
to O
isolate O
_RARE_ I-GENE
and O
_RARE_ I-GENE
null I-GENE
mutants I-GENE
. O

The O
E1 I-GENE
nuclear I-GENE
transport O
motif I-GENE
is O
highly O
conserved O
in O
the O
animal O
and O
human I-GENE
_RARE_ I-GENE
and O
is O
encoded I-GENE
in O
a O
similar O
region O
in O
the O
related I-GENE
E1 I-GENE
genes I-GENE
. O

The O
E1 I-GENE
replication O
protein I-GENE
of O
bovine I-GENE
papillomavirus I-GENE
type I-GENE
1 I-GENE
contains O
an O
extended O
nuclear I-GENE
localization O
signal I-GENE
that O
includes O
a O
p34cdc2 I-GENE
phosphorylation O
site I-GENE
. O

In O
order O
to O
investigate O
to O
what O
extent O
this O
interaction O
might O
contribute O
to O
tumor I-GENE
induction O
by O
the O
virus I-GENE
, O
we O
have O
introduced O
two O
different O
point O
mutations O
within O
the O
putative O
pRb I-GENE
- I-GENE
binding I-GENE
sequence I-GENE
of O
large O
T I-GENE
antigen I-GENE
, O
and O
as O
a O
preliminary O
to O
in O
vivo O
experiments O
we O
have O
studied O
their O
effects O
in O
vitro O
on O
some O
biological O
activities O
relevant O
to O
tumor I-GENE
induction O
. O

We O
conclude O
that O
the O
conservation O
of O
nucleotides O
154 O
to O
156 I-GENE
is O
likely O
to O
be O
a O
consequence O
of O
their O
role O
as O
a O
sequence I-GENE
- I-GENE
specific I-GENE
recognition I-GENE
element I-GENE
for O
the O
_RARE_ I-GENE
protein I-GENE
. O

A I-GENE
region O
of O
the O
deduced O
protein I-GENE
shares O
extensive O
homology I-GENE
with O
a O
catalytic O
region O
of O
Raf I-GENE
kinases I-GENE
, O
a O
feature O
shared O
only O
with O
_RARE_ I-GENE
among O
transcription I-GENE
factors I-GENE
. O

The O
low O
molecular O
mass O
polypeptide I-GENE
complex I-GENE
is O
assumed O
to O
be O
involved O
in O
antigen I-GENE
presentation O
, O
generating O
peptides I-GENE
from O
cytosolic I-GENE
protein I-GENE
antigens I-GENE
, O
which O
are O
subsequently O
presented O
to O
cytotoxic O
T I-GENE
- I-GENE
lymphocytes O
on O
the O
cell O
surface O
. O

_RARE_ I-GENE
cleavage O
of O
RT I-GENE
at O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
Tyr I-GENE
- I-GENE
_RARE_ I-GENE
of O
Pol I-GENE
yields O
a O
truncated I-GENE
form O
lacking O
the O
C I-GENE
- I-GENE
terminal I-GENE
RNase I-GENE
H I-GENE
domain I-GENE
. O

The O
C I-GENE
- I-GENE
terminal I-GENE
approximately O
50 O
amino O
acids O
of O
_RARE_ I-GENE
- I-GENE
1 I-GENE
are O
shown O
to O
be O
essential O
for O
_RARE_ I-GENE
- I-GENE
1 I-GENE
activity O
but O
can O
be O
effectively O
substituted O
by O
the O
C I-GENE
- I-GENE
terminal I-GENE
activation O
domain I-GENE
of O
VP16 I-GENE
. O

Since O
the O
- I-GENE
_RARE_ I-GENE
/- O
_RARE_ I-GENE
element I-GENE
also O
conferred O
estrogen I-GENE
and O
thyroid I-GENE
hormone I-GENE
responsiveness O
, O
it O
can O
be O
considered O
a O
composite O
hormone I-GENE
response O
element I-GENE
. O

_RARE_ I-GENE
activation O
of O
T I-GENE
cells O
requires O
at O
least O
two O
signals O
. O

Together O
with O
a O
considerably O
shortened O
and O
interrupted O
aromatic O
aa O
stretch O
in O
this O
region O
, O
these O
differences O
are O
discussed O
in O
terms O
of O
the O
_RARE_ I-GENE
affinity O
of O
_RARE_ I-GENE
cytochrome I-GENE
_RARE_ I-GENE
for O
acidic O
c I-GENE
- I-GENE
type I-GENE
_RARE_ I-GENE
. O

All O
four O
of O
the O
genes I-GENE
have O
a O
similar O
structure O
, O
with O
the O
receptor I-GENE
protein I-GENE
encoded I-GENE
in O
a O
single O
exon O
. O

_RARE_ I-GENE
of O
GABP I-GENE
with O
_RARE_ I-GENE
- I-GENE
2 I-GENE
, O
a O
multisubunit I-GENE
activator I-GENE
of O
cytochrome I-GENE
oxidase I-GENE
expression O
, O
reveals O
a O
cellular O
role O
for O
an O
ETS I-GENE
domain I-GENE
activator I-GENE
of O
viral I-GENE
promoters I-GENE
. O

In O
the O
present O
study O
, O
beta I-GENE
- I-GENE
_RARE_ I-GENE
( O
beta I-GENE
- I-GENE
_RARE_ I-GENE
) O
and O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
( O
_RARE_ I-GENE
mu I-GENE
- I-GENE
and O
delta I-GENE
- I-GENE
antagonist O
, O
respectively O
) O
were O
used O
to O
_RARE_ I-GENE
withdrawal O
in O
_RARE_ I-GENE
- I-GENE
dependent I-GENE
rats O
. O

The O
intracellular O
basic I-GENE
region O
/ I-GENE
helix I-GENE
- I-GENE
loop I-GENE
- I-GENE
helix I-GENE
( O
bHLH I-GENE
) O
dioxin I-GENE
receptor I-GENE
mediates O
signal I-GENE
transduction O
by O
dioxin I-GENE
( O
2 I-GENE
, O
3 I-GENE
, O
7 O
, O
8 O
- I-GENE
_RARE_ I-GENE
- I-GENE
p O
- I-GENE
dioxin I-GENE
) O
and O
functions O
as O
a O
ligand O
- I-GENE
activated I-GENE
DNA I-GENE
binding I-GENE
protein I-GENE
directly O
interacting I-GENE
with O
target O
genes I-GENE
by O
binding I-GENE
to O
dioxin I-GENE
response O
elements O
. O

The O
alpha I-GENE
2A I-GENE
- I-GENE
adrenergic I-GENE
receptor I-GENE
( O
alpha I-GENE
_RARE_ I-GENE
) O
is O
coupled I-GENE
to O
a O
variety O
of O
effectors I-GENE
via O
pertussis I-GENE
toxin I-GENE
- I-GENE
sensitive O
GTP I-GENE
- I-GENE
binding I-GENE
proteins I-GENE
. O

A I-GENE
sequence I-GENE
comparison O
reveals O
two O
CCAAT I-GENE
/ I-GENE
enhancer I-GENE
binding I-GENE
protein I-GENE
( O
C I-GENE
/ I-GENE
EBP I-GENE
) O
consensus I-GENE
sequences I-GENE
, O
basic I-GENE
DNA I-GENE
binding I-GENE
region O
and O
leucine I-GENE
zippers I-GENE
1 I-GENE
and O
2 I-GENE
( O
_RARE_ I-GENE
and O
_RARE_ I-GENE
), O
within O
this O
region O
. O

One O
of O
these O
genes I-GENE
, O
_RARE_ I-GENE
, O
is O
described O
here O
, O
and O
the O
data O
confirm O
that O
_RARE_ I-GENE
is O
a O
meiosis O
- I-GENE
specific I-GENE
recombination O
gene I-GENE
with O
no O
detectable O
function O
in O
mitosis O
. O

The O
transactivation O
function O
of O
EBNA2 I-GENE
was O
also O
observed O
in O
the O
HeLa O
epithelial O
cell O
line O
, O
which O
suggests O
that O
EBV I-GENE
and O
HIV I-GENE
- I-GENE
1 I-GENE
infection O
of O
non O
- I-GENE
B I-GENE
cells O
may O
result O
in O
HIV I-GENE
- I-GENE
1 I-GENE
promoter I-GENE
activation O
. O

Mutation O
of O
the O
C I-GENE
/ I-GENE
EBP I-GENE
binding I-GENE
sites I-GENE
in O
the O
Rous I-GENE
sarcoma I-GENE
virus I-GENE
long O
terminal I-GENE
repeat I-GENE
and O
gag I-GENE
enhancers I-GENE
. O

Nuclear I-GENE
protein I-GENE
phosphatase I-GENE
2A I-GENE
_RARE_ I-GENE
protein I-GENE
kinase I-GENE
A I-GENE
- I-GENE
phosphorylated O
CREB I-GENE
and O
regulates O
CREB I-GENE
transcriptional O
stimulation O
. O

We O
show O
that O
IL I-GENE
- I-GENE
6 I-GENE
activates O
_RARE_ I-GENE
- I-GENE
IL6 I-GENE
through O
an O
_RARE_ I-GENE
- I-GENE
sensitive O
pathway O
that O
does O
not O
involve O
protein I-GENE
kinase I-GENE
C I-GENE
, O
cyclic I-GENE
AMP I-GENE
- I-GENE
dependent I-GENE
kinase I-GENE
, O
Ca I-GENE
( O
2 I-GENE
+)- I-GENE
or O
calmodulin I-GENE
- I-GENE
dependent I-GENE
kinases I-GENE
, O
Ras I-GENE
, O
Raf I-GENE
- I-GENE
1 I-GENE
, O
or O
NF I-GENE
- I-GENE
IL6 I-GENE
( O
C I-GENE
/ I-GENE
EBP I-GENE
beta I-GENE
). O

Mutation O
of O
the O
_RARE_ I-GENE
phosphorylated O
tyrosine I-GENE
and O
threonine I-GENE
residues O
of O
_RARE_ I-GENE
individually O
to O
phenylalanine I-GENE
and O
alanine I-GENE
, O
respectively O
, O
severely O
impaired O
_RARE_ I-GENE
function O
. O

Growth I-GENE
factor I-GENE
stimulation O
rapidly O
induces O
a O
reversible O
change O
in O
the O
electrophoretic O
mobility I-GENE
of O
the O
ternary O
complex I-GENE
, O
accompanied O
by O
increased O
phosphorylation O
of O
the O
Elk I-GENE
- I-GENE
1 I-GENE
C I-GENE
- I-GENE
terminal I-GENE
region O
and O
by O
the O
activation O
of O
a O
42 O
_RARE_ I-GENE
cellular O
Elk I-GENE
- I-GENE
1 I-GENE
kinase I-GENE
. O

In O
contrast O
to O
the O
_RARE_ I-GENE
in O
mammalian I-GENE
cells O
, O
prolonged O
exposure O
of O
the O
agonist O
( O
24 O
h O
) O
does O
not O
result O
in O
down O
regulation O
of O
the O
remaining O
70 I-GENE
% O
of O
the O
receptors I-GENE
. O

This O
stimulatory I-GENE
effect O
could O
also O
be O
elicited O
by O
c I-GENE
- I-GENE
Jun I-GENE
, O
which O
interacts O
with O
_RARE_ I-GENE
II I-GENE
, O
but O
not O
by O
c I-GENE
- I-GENE
Fos I-GENE
, O
which O
does O
not O
bind O
_RARE_ I-GENE
II I-GENE
in O
our O
in O
vitro O
assay O
. O

The O
regulation O
of O
_RARE_ I-GENE
- I-GENE
5 I-GENE
and O
MyoD I-GENE
function O
by O
a O
cAMP I-GENE
- I-GENE
dependent I-GENE
pathway O
may O
partly O
explain O
how O
external O
signals O
generated O
by O
serum I-GENE
and O
certain O
peptide I-GENE
growth I-GENE
factors I-GENE
can O
be O
_RARE_ I-GENE
to O
the O
nucleus O
and O
inhibit O
dominant I-GENE
- I-GENE
acting O
factors I-GENE
that O
are O
responsible O
for O
_RARE_ I-GENE
differentiation O
. O

16 O
, O
99 O
- I-GENE
104 O
). O

We O
have O
previously O
reported O
that O
high O
level O
human I-GENE
_RARE_ I-GENE
expression O
depends O
on O
a O
_RARE_ I-GENE
- I-GENE
base O
pair O
muscle O
- I-GENE
specific I-GENE
enhancer I-GENE
which O
can O
function O
not O
only O
in O
myotubes O
, O
but O
can O
also O
activate O
gene I-GENE
expression O
in O
myoblasts O
. O

After O
surgery O
, O
patients O
self O
administered O
one O
of O
three O
possible O
_RARE_ I-GENE
_RARE_ I-GENE
, O
which O
included O
placebo O
, O
_RARE_ I-GENE
60 O
mg O
, O
and O
_RARE_ I-GENE
400 O
mg O
, O
when O
their O
pain O
reached O
a O
moderate O
or O
severe O
intensity O
. O

Replacement I-GENE
of O
the O
wild I-GENE
- I-GENE
type I-GENE
5 I-GENE
'- O
regulatory I-GENE
region O
with O
either O
of O
the O
mutants I-GENE
' O
cis O
- I-GENE
acting O
regulatory I-GENE
element I-GENE
resulted O
in O
the O
anaerobic O
expression O
of O
active O
_RARE_ I-GENE
- I-GENE
superoxide I-GENE
dismutase I-GENE
. O

The O
_RARE_ I-GENE
gene I-GENE
product I-GENE
, O
when O
expressed O
from O
an O
exogenous O
promoter I-GENE
, O
inhibited O
int I-GENE
- I-GENE
mediated O
integration O
at O
the O
chromosomal I-GENE
_RARE_ I-GENE
site I-GENE
. O

Expression O
in O
established O
_RARE_ I-GENE
, O
occurring O
irrespective O
of O
virus I-GENE
_RARE_ I-GENE
status O
, O
was O
not O
a O
consequence O
of O
continued O
in O
vitro O
passage O
; O
thus O
, O
_RARE_ I-GENE
spliced O
BamHI I-GENE
- I-GENE
A I-GENE
transcripts I-GENE
could O
be O
amplified O
from O
normal O
B I-GENE
cells O
within O
1 I-GENE
day O
of O
their O
experimental O
infection O
in O
vitro O
, O
along O
with O
BamHI I-GENE
- I-GENE
C I-GENE
/ I-GENE
W I-GENE
promoter I-GENE
- I-GENE
initiated O
but O
not O
BamHI I-GENE
- I-GENE
F I-GENE
promoter I-GENE
- I-GENE
initiated O
mRNAs I-GENE
. O

Analysis O
by O
cell O
surface O
immunofluorescence O
showed O
that O
the O
_RARE_ I-GENE
gene I-GENE
is O
not O
required O
for O
expression O
of O
viral I-GENE
glycoproteins I-GENE
on O
the O
surface O
of O
infected O
cells O
. O

Furthermore O
, O
a O
mutant I-GENE
receptor I-GENE
( O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
[ O
PLC I-GENE
gamma I-GENE
- I-GENE
binding I-GENE
sites I-GENE
]) I-GENE
could O
fully O
activate O
Ras I-GENE
, O
and O
the O
direct O
activation O
of O
protein I-GENE
kinase I-GENE
C I-GENE
and O
calcium O
_RARE_ I-GENE
had O
almost O
no O
effect O
on O
the O
GDP I-GENE
/ I-GENE
GTP I-GENE
state O
of O
Ras I-GENE
in O
this O
cell O
line O
. O

_RARE_ I-GENE
treatment O
in O
high O
doses O
is O
effective O
in O
reducing O
adult O
_RARE_ I-GENE
in O
_RARE_ I-GENE
_RARE_ I-GENE
girls O
. O

Mutations O
at O
the O
extreme O
C I-GENE
- I-GENE
terminus O
of O
_RARE_ I-GENE
Tat I-GENE
impaired O
both O
RNA I-GENE
binding I-GENE
and O
activation O
domain I-GENE
functions O
, O
suggesting O
effects O
on O
secondary O
or O
tertiary O
structure O
. O

This O
observation O
suggests O
that O
the O
methyl O
- I-GENE
directed O
repair I-GENE
system O
_RARE_ I-GENE
the O
proximal I-GENE
d O
( O
_RARE_ I-GENE
) O
sequence I-GENE
to O
direct O
correction O
. O

_RARE_ I-GENE
DNA I-GENE
glycosylase I-GENE
catalyzes O
the O
initial O
step O
in O
the O
repair I-GENE
pathway O
that O
_RARE_ I-GENE
potentially O
_RARE_ I-GENE
_RARE_ I-GENE
from O
duplex O
DNA I-GENE
. O

Current O
clinical O
trials O
should O
_RARE_ I-GENE
the O
question O
of O
which O
of O
the O
therapeutic O
_RARE_ I-GENE
_RARE_ I-GENE
quality O
of O
life O
less O
. O

_RARE_ I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
is O
a O
prototype O
of O
another O
generation O
of O
synthetic O
, O
_RARE_ I-GENE
- I-GENE
organic O
, O
_RARE_ I-GENE
_RARE_ I-GENE
that O
appear O
very O
useful O
for O
in O
vitro O
and O
in O
vivo O
electron O
_RARE_ I-GENE
resonance O
_RARE_ I-GENE
. O

In O
this O
report O
, O
we O
focus O
on O
the O
_RARE_ I-GENE
of O
the O
region O
of O
the O
17 O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
gene I-GENE
that O
conferred O
both O
the O
_RARE_ I-GENE
and O
pathogenic O
phenotypes O
to O
17 O
_RARE_ I-GENE
_RARE_ I-GENE

_RARE_ I-GENE
with O
acute O
_RARE_ I-GENE
in O
first O
remission O
or O
chronic O
myeloid O
_RARE_ I-GENE
in O
first O
chronic O
phase O
were O
analysed O
as O
good O
risk O
, O
and O
those O
beyond O
these O
stages O
, O
as O
poor O
risk O
patients O
. O

_RARE_ I-GENE
, O
P I-GENE
. O

_RARE_ I-GENE
suppressed O
> O
or O
= O
75 O
% O
of O
the O
total O
premature O
ventricular O
contractions O
in O
all O
patients O
who O
had O
both O
use O
- I-GENE
dependent I-GENE
QRS O
prolongation O
and O
reverse I-GENE
use O
- I-GENE
dependent I-GENE
QT O
prolongation O
, O
in O
79 O
% O
of O
patients O
with O
use O
- I-GENE
dependent I-GENE
QRS O
prolongation O
alone O
, O
in O
70 I-GENE
% O
with O
reverse I-GENE
use O
- I-GENE
dependent I-GENE
QT O
prolongation O
alone O
, O
and O
in O
11 O
% O
with O
neither O
use O
- I-GENE
dependent I-GENE
QRS O
prolongation O
nor O
reverse I-GENE
use O
- I-GENE
dependent I-GENE
QT O
prolongation O
. O

_RARE_ I-GENE
during O
the O
complete O
procedure O
are O
corrected O
for O
using O
_RARE_ I-GENE
estrogen I-GENE
_RARE_ I-GENE
during O
the O
first O
steps O
and O
later O
by O
adding O
_RARE_ I-GENE
internal O
_RARE_ I-GENE
of O
all O
compounds O
measured O
( O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
O O
- I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
). O

IE2 I-GENE
- I-GENE
IE2 I-GENE
interactions O
were O
mapped O
to O
a O
domain I-GENE
containing O
a O
putative O
helix I-GENE
- I-GENE
turn I-GENE
- I-GENE
helix I-GENE
motif I-GENE
located O
near O
the O
C I-GENE
terminus O
of O
IE2 I-GENE
, O
between O
amino O
acids O
_RARE_ I-GENE
and O
_RARE_ I-GENE
. O

The O
Sp1 I-GENE
region O
, O
however O
, O
is O
converted O
to O
a O
functionally O
strong O
TRE I-GENE
by O
the O
viral I-GENE
tat I-GENE
factor I-GENE
. O

_RARE_ I-GENE
using O
GST I-GENE
fusion I-GENE
proteins I-GENE
containing O
Fyn I-GENE
SH2 I-GENE
, O
SH3 I-GENE
, O
and O
SH2 I-GENE
/ I-GENE
SH3 I-GENE
domains I-GENE
revealed O
that O
PI I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
bound O
_RARE_ I-GENE
to O
the O
SH3 I-GENE
domain I-GENE
of O
Fyn I-GENE
. O

A I-GENE
sheep O
testicular I-GENE
cDNA I-GENE
library O
constructed O
in O
_RARE_ I-GENE
vector O
was O
screened O
with O
a O
probe O
generated O
by O
polymerase I-GENE
chain I-GENE
reaction O
( O
PCR O
) O
and O
corresponding O
to O
a O
1 I-GENE
. O
6 I-GENE
kb O
fragment I-GENE
of O
the O
rat I-GENE
_RARE_ I-GENE
hormone I-GENE
receptor I-GENE
cDNA I-GENE
. O

Two O
putative O
Rev I-GENE
proteins I-GENE
with O
apparent O
molecular O
masses O
of O
18 O
and O
16 O
kDa I-GENE
were O
expressed O
by O
_RARE_ I-GENE
/ I-GENE
2 I-GENE
and O
_RARE_ I-GENE
, O
while O
_RARE_ I-GENE
expressed O
only O
a O
16 O
- I-GENE
kDa I-GENE
species O
. O

Three O
group O
1 I-GENE
patients O
developed O
CMV O
disease O
; O
1 I-GENE
group O
2 I-GENE
patient O
developed O
CMV O
hepatitis I-GENE
. O

The O
ability O
of O
_RARE_ I-GENE
mutations O
to O
suppress O
the O
transcriptional O
interference O
caused O
by O
the O
delta I-GENE
promoter I-GENE
insertion O
his O
- I-GENE
4 I-GENE
- I-GENE
_RARE_ I-GENE
delta I-GENE
correlates O
with O
an O
increase O
in O
wild I-GENE
- I-GENE
type I-GENE
_RARE_ I-GENE
mRNA I-GENE
levels O
. O

Nuclear I-GENE
localization O
and O
protein I-GENE
sequence I-GENE
similarities O
suggested O
that O
the O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
protein I-GENE
may O
be O
related I-GENE
to O
the O
_RARE_ I-GENE
chromosomal I-GENE
protein I-GENE
_RARE_ I-GENE
. O

The O
conserved O
_RARE_ I-GENE
C I-GENE
- I-GENE
terminal I-GENE
heptad I-GENE
in O
thyroid I-GENE
hormone I-GENE
and O
retinoic I-GENE
acid I-GENE
receptors I-GENE
mediates O
diverse O
responses O
by O
affecting O
heterodimer O
but O
not O
homodimer I-GENE
formation O
. O

Genetic O
interactions O
between O
_RARE_ I-GENE
and O
other O
pathway O
components O
suggested O
that O
_RARE_ I-GENE
functions O
on O
a O
common O
pathway O
branch O
with O
_RARE_ I-GENE
and O
_RARE_ I-GENE
. O

_RARE_ I-GENE
factor I-GENE
1 I-GENE
, O
an O
orphan I-GENE
nuclear I-GENE
receptor I-GENE
, O
regulates O
the O
expression O
of O
the O
rat I-GENE
aromatase I-GENE
gene I-GENE
in O
_RARE_ I-GENE
tissues O
. O

To O
study O
the O
functional O
differences O
between O
cutaneous O
_RARE_ I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
and O
genital O
_RARE_ I-GENE
E7 I-GENE
, O
we O
cloned O
each O
of O
the O
E7 I-GENE
open O
reading O
frames O
and O
tested O
their O
_RARE_ I-GENE
and O
transforming I-GENE
activities O
, O
the O
binding I-GENE
ability O
of O
their O
products I-GENE
with O
retinoblastoma I-GENE
protein I-GENE
( O
RB I-GENE
) O
and O
their O
complementation O
activity O
of O
a O
RB I-GENE
- I-GENE
_RARE_ I-GENE
adenovirus I-GENE
E1A I-GENE
mutant I-GENE
. O

The O
_RARE_ I-GENE
transcription I-GENE
start O
site I-GENE
was O
mapped O
to O
- I-GENE
24 O
relative O
to O
the O
start O
of O
translation I-GENE
. O

Several O
lines O
of O
evidence O
demonstrate O
that O
this O
growth I-GENE
inhibition O
requires O
active O
PKA I-GENE
subunits I-GENE
and O
cAMP I-GENE
: O
( O
i O
) O
this O
phenotype O
is O
dependent I-GENE
on O
cAMP I-GENE
since O
it O
is O
not O
seen O
in O
a O
strain O
lacking O
_RARE_ I-GENE
cyclase I-GENE
activity O
, O
but O
the O
growth I-GENE
rate O
of O
these O
transformants O
is O
slower O
when O
exogenous O
cAMP I-GENE
is O
added O
; O
( O
ii O
) O
normal O
growth I-GENE
occurs O
when O
wild I-GENE
- I-GENE
type I-GENE
RI I-GENE
cDNA I-GENE
is O
replaced O
by O
a O
mutant I-GENE
RI I-GENE
cDNA I-GENE
encoding O
a O
RI I-GENE
protein I-GENE
with O
reduced O
cAMP I-GENE
binding I-GENE
; O
and O
( O
iii O
) O
the O
growth I-GENE
- I-GENE
inhibited O
phenotype O
of O
the O
transformed O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
cells O
requires O
soluble I-GENE
, O
active O
C I-GENE
alpha I-GENE
protein I-GENE
. O

_RARE_ I-GENE
, O
B I-GENE
. O

BCR I-GENE
- I-GENE
ABL I-GENE
and O
v I-GENE
- I-GENE
abl I-GENE
oncogenes I-GENE
induce O
distinct O
patterns O
of O
thymic I-GENE
lymphoma O
involving O
different O
lymphocyte I-GENE
_RARE_ I-GENE
. O

These O
experiments O
confirm O
that O
the O
6 I-GENE
- I-GENE
S I-GENE
_RARE_ I-GENE
form O
of O
the O
receptor I-GENE
identified O
in O
nuclear I-GENE
extracts O
of O
cells O
treated O
with O
2 I-GENE
, O
3 I-GENE
, O
7 O
, O
8 O
- I-GENE
_RARE_ I-GENE
- I-GENE
p O
- I-GENE
dioxin I-GENE
( O
_RARE_ I-GENE
) O
contains O
the O
_RARE_ I-GENE
receptor I-GENE
protein I-GENE
and O
_RARE_ I-GENE
but O
not O
the O
90 O
- I-GENE
kDa I-GENE
heat I-GENE
shock I-GENE
protein I-GENE
. O

LDL I-GENE
cholesterol I-GENE
decreased O
from O
4 I-GENE
. O
74 O
+/- O
0 O
. O
87 O
to O
3 I-GENE
. O
78 O
+/- O
0 O
. O
78 O
mmol O
/ I-GENE
l O
after O
8 O
weeks O
on O
_RARE_ I-GENE
( O
P I-GENE
< O
0 O
. O
001 O
), O
and O
apo I-GENE
B I-GENE
fell O
from O
142 O
+/- O
31 O
to O
112 O
+/- O
22 O
mg O
/ I-GENE
dl O
( O
P I-GENE
< O
0 O
. O
001 O
). O

LDL I-GENE
cholesterol I-GENE
decreased O
from O
4 I-GENE
. O
74 O
+/- O
0 O
. O
87 O
to O
3 I-GENE
. O
78 O
+/- O
0 O
. O
78 O
mmol O
/ I-GENE
l O
after O
8 O
weeks O
on O
_RARE_ I-GENE
( O
P I-GENE
< O
0 O
. O
001 O
), O
and O
apo I-GENE
B I-GENE
fell O
from O
142 O
+/- O
31 O
to O
112 O
+/- O
22 O
mg O
/ I-GENE
dl O
( O
P I-GENE
< O
0 O
. O
001 O
). O

This O
negative O
element I-GENE
may O
, O
at O
least O
in O
part O
, O
be O
responsible O
for O
the O
cell O
type I-GENE
- I-GENE
specific I-GENE
expression O
of O
the O
_RARE_ I-GENE
gene I-GENE
. O

_RARE_ I-GENE
activity O
of O
the O
distal O
promoter I-GENE
- I-GENE
like I-GENE
element I-GENE
of O
the O
human I-GENE
_RARE_ I-GENE
- I-GENE
releasing I-GENE
hormone I-GENE
gene I-GENE
and O
secondary O
structural O
features O
of O
its O
corresponding O
transcripts I-GENE
. O

A I-GENE
new O
_RARE_ I-GENE
technology O
for O
microbial I-GENE
_RARE_ I-GENE
. O

We O
linked O
hypersensitivity O
site I-GENE
2 I-GENE
( O
_RARE_ I-GENE
) O
from O
the O
locus I-GENE
control O
region O
( O
LCR I-GENE
) O
to O
a O
A I-GENE
gamma I-GENE
- I-GENE
globin I-GENE
gene I-GENE
( O
A I-GENE
gamma I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
marked O
to O
allow O
its O
transcript I-GENE
to O
be O
distinguished O
from O
endogenous I-GENE
gamma I-GENE
- I-GENE
globin I-GENE
mRNA I-GENE
. O

_RARE_ I-GENE
-- O
Patients O
allocated O
to O
treatment O
with O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
decarboxylase I-GENE
inhibitor I-GENE
alone O
( O
arm O
1 I-GENE
), O
_RARE_ I-GENE
/ I-GENE
decarboxylase I-GENE
inhibitor I-GENE
/ I-GENE
_RARE_ I-GENE
in O
combination O
( O
arm O
2 I-GENE
), O
or O
_RARE_ I-GENE
( O
arm O
3 I-GENE
). O

It O
contains O
three O
putative O
binding I-GENE
sites I-GENE
for O
transcription I-GENE
factor I-GENE
Sp1 I-GENE
as O
well O
as O
several O
short O
sequences I-GENE
that O
are O
similar O
to O
known O
cis O
- I-GENE
acting O
enhancers I-GENE
or O
binding I-GENE
sites I-GENE
for O
transcription I-GENE
factors I-GENE
. O

_RARE_ I-GENE
bean I-GENE
contains O
a O
small I-GENE
family I-GENE
of O
genes I-GENE
encoding O
PAL I-GENE
and O
two O
of O
these O
genes I-GENE
, O
_RARE_ I-GENE
and O
_RARE_ I-GENE
, O
have O
been O
shown O
to O
be O
differentially O
expressed O
at O
the O
mRNA I-GENE
level O
in O
bean I-GENE
tissues O
. O

Plasma I-GENE
thromboxane I-GENE
B2 I-GENE
levels O
in O
the O
older O
group O
were O
about O
double O
those O
in O
_RARE_ I-GENE
_RARE_ I-GENE
. O

By O
_RARE_ I-GENE
linear O
multiple O
regression O
analysis O
, O
_RARE_ I-GENE
magnesium O
was O
significantly O
related I-GENE
to O
cyclosporin O
trough O
level O
and O
total O
cholesterol I-GENE
but O
not O
to O
serum I-GENE
creatinine O
, O
time O
after O
transplant O
or O
the O
dose O
of O
cyclosporin O
. O

The O
human I-GENE
insulin I-GENE
- I-GENE
like I-GENE
growth I-GENE
factor I-GENE
II I-GENE
( O
IGF I-GENE
- I-GENE
II I-GENE
) O
gene I-GENE
contains O
four O
promoters I-GENE
( O
P1 I-GENE
, O
P2 I-GENE
, O
P3 I-GENE
and O
P4 I-GENE
). O

Moreover O
, O
in O
transient O
transfection O
assays O
, O
PU I-GENE
. O
1 I-GENE
alone O
activated I-GENE
reporter I-GENE
constructs I-GENE
containing O
the O
_RARE_ I-GENE
cis O
- I-GENE
element I-GENE
, O
and O
the O
activation O
was O
shown O
to O
be O
dependent I-GENE
on O
a O
glutamine I-GENE
- I-GENE
rich O
sequence I-GENE
in O
the O
amino O
- I-GENE
terminal I-GENE
portion O
of O
PU I-GENE
. O
1 I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
given O
yellow O
fever O
vaccine O
contaminated O
with O
hepatitis I-GENE
B I-GENE
virus I-GENE
in O
_RARE_ I-GENE
and O
controls O
and O
( O
b I-GENE
) O
a O
case O
- I-GENE
control O
study O
comparing O
_RARE_ I-GENE
with O
_RARE_ I-GENE
carcinoma O
in O
_RARE_ I-GENE
_RARE_ I-GENE
hospitals O
with O
matched O
controls O
with O
respect O
to O
_RARE_ I-GENE
of O
contaminated O
vaccine O
in O
_RARE_ I-GENE
. O

They O
were O
found O
to O
be O
seropositive O
for O
antibodies I-GENE
to O
hepatitis I-GENE
C I-GENE
virus I-GENE
by O
second O
- I-GENE
generation O
testing O
( O
_RARE_ I-GENE
2 I-GENE
, O
_RARE_ I-GENE
Diagnostic O
_RARE_ I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
MA I-GENE
). O

_RARE_ I-GENE
of O
_RARE_ I-GENE
( O
_RARE_ I-GENE
), O
a O
glycoprotein I-GENE
component O
of O
the O
extracellular I-GENE
_RARE_ I-GENE
, O
cause O
_RARE_ I-GENE
syndrome O
. O

When O
introduced O
into O
_RARE_ I-GENE
+ I-GENE
strains O
, O
_RARE_ I-GENE
mutations O
conferred O
_RARE_ I-GENE
and O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
phenotypes O
. O

_RARE_ I-GENE
roles O
of O
the O
membrane I-GENE
- I-GENE
cytoskeleton I-GENE
and O
cadherin I-GENE
mediated O
cell O
- I-GENE
cell O
adhesion I-GENE
in O
generating O
different O
Na I-GENE
+, I-GENE
K I-GENE
(+)- I-GENE
ATPase I-GENE
_RARE_ I-GENE
in O
_RARE_ I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
lupus O
erythematosus O
is O
most O
often O
associated I-GENE
with O
autoantibodies O
against O
Ro I-GENE
and O
La I-GENE
antigens I-GENE
. O

Genetic O
abnormalities O
that O
could O
lead O
to O
mutagenesis O
include O
chromosomal I-GENE
abnormalities O
and O
single O
- I-GENE
gene I-GENE
mutations O
. O

_RARE_ I-GENE
, O
and O
L I-GENE
. O

_RARE_ I-GENE
absorption O
of O
amino O
acids O
by O
the O
_RARE_ I-GENE
carrier I-GENE
( O
for O
neutral O
amino O
acids O
), O
the O
Y I-GENE
+ I-GENE
system O
( O
for O
_RARE_ I-GENE
amino O
acids O
), O
and O
the O
_RARE_ I-GENE
carrier I-GENE
were O
operative O
even O
during O
the O
actively O
_RARE_ I-GENE
stage O
of O
_RARE_ I-GENE
_RARE_ I-GENE
due O
to O
_RARE_ I-GENE
. O

1 I-GENE
) O
_RARE_ I-GENE
, O
_RARE_ I-GENE
and O
_RARE_ I-GENE
showed O
a O
potent O
antimicrobial O
activity O
against O
H I-GENE
. O
pylori I-GENE
, O
and O
especially O
, O
_RARE_ I-GENE
showed O
a O
marked O
bactericidal O
activity O
in O
a O
short O
time O
. O

_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
disease O
and O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
grafts O
: O
report O
of O
two O
cases O
. O

A I-GENE
high O
mean O
intensity O
of O
_RARE_ I-GENE
( O
standardized O
multivariate O
regression O
coefficient O
beta I-GENE
- I-GENE
0 O
. O
_RARE_ I-GENE
, O
p O
= O
0 O
. O
_RARE_ I-GENE
) O
and O
a O
high O
maximal O
oxygen O
uptake O
( O
beta I-GENE
- I-GENE
0 O
. O
_RARE_ I-GENE
, O
p O
< O
0 O
. O
001 O
) O
were O
associated I-GENE
with O
reduced O
plasma I-GENE
fibrinogen I-GENE
when O
_RARE_ I-GENE
for O
the O
strongest O
_RARE_ I-GENE
. O

_RARE_ I-GENE
young O
people O
_RARE_ I-GENE
and O
do O
when O
the O
_RARE_ I-GENE
for O
cystic I-GENE
fibrosis I-GENE
carrier I-GENE
testing O
is O
available O
. O

A I-GENE
patient O
matches O
a O
_RARE_ I-GENE
patient O
if O
both O
have O
the O
same O
mechanism O
of O
injury O
, O
the O
same O
coding O
of O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
variables O
( O
_RARE_ I-GENE
_RARE_ I-GENE
Scale O
score O
, O
systolic O
blood O
pressure O
, O
respiratory O
rate O
), O
the O
same O
coded O
age O
per O
A I-GENE
_RARE_ I-GENE
Characterization O
of O
_RARE_ I-GENE
) O
( O
_RARE_ I-GENE
), O
and O
if O
they O
differ O
by O
no O
more O
than O
0 O
. O
5 I-GENE
for O
A I-GENE
, O
B I-GENE
, O
and O
C I-GENE
( O
the O
_RARE_ I-GENE
components O
for O
serious O
injuries O
). O

_RARE_ I-GENE
and O
bowel O
_RARE_ I-GENE
varied O
with O
_RARE_ I-GENE
and O
each O
other O
( O
P I-GENE
< O
0 O
. O
05 O
). O

A I-GENE
region O
approximately O
100 O
bp O
upstream O
from O
the O
transcription I-GENE
start O
point O
of O
_RARE_ I-GENE
was O
identified O
as O
being O
necessary O
for O
full I-GENE
activation O
of O
this O
promoter I-GENE
by O
_RARE_ I-GENE
. O

We O
have O
isolated O
a O
cosmid O
containing O
DNA I-GENE
that O
corresponds O
to O
the O
site I-GENE
of O
transposon I-GENE
insertion O
in O
_RARE_ I-GENE
and O
have O
localized O
_RARE_ I-GENE
on O
an O
8 O
. O
0 O
kb O
EcoRI I-GENE
fragment I-GENE
. O

The O
_RARE_ I-GENE
_RARE_ I-GENE
of O
_RARE_ I-GENE
and O
the O
_RARE_ I-GENE
encoded I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
of O
Klebsiella I-GENE
pneumoniae I-GENE
_RARE_ I-GENE
are O
both O
negatively O
controlled O
by O
a O
specific I-GENE
repressor I-GENE
( O
_RARE_ I-GENE
). O

Although O
the O
molecular O
mechanisms O
involved O
in O
this O
regulation O
are O
currently O
being O
_RARE_ I-GENE
, O
very O
little O
is O
known O
about O
the O
trans O
- I-GENE
acting O
factors I-GENE
that O
allow O
expression O
of O
the O
nitrate I-GENE
and O
nitrite I-GENE
reductase I-GENE
genes I-GENE
which O
code O
for O
the O
first O
enzymes O
in O
the O
pathway O
. O

The O
_RARE_ I-GENE
gene I-GENE
is O
present O
as O
a O
unique O
copy O
in O
the O
diploid O
N I-GENE
. O
_RARE_ I-GENE
species O
. O

Transient O
transfection O
experiments O
revealed O
that O
Pax I-GENE
- I-GENE
8 O
isoforms I-GENE
a O
and O
b I-GENE
, O
but O
not O
c I-GENE
and O
d O
, O
strongly O
stimulate O
transcription I-GENE
from O
a O
promoter I-GENE
containing O
six O
copies O
of O
a O
paired I-GENE
- I-GENE
domain I-GENE
recognition I-GENE
sequence I-GENE
. O

The O
amino O
- I-GENE
terminal I-GENE
third O
of O
the O
protein I-GENE
contains O
a O
high O
- I-GENE
mobility I-GENE
- I-GENE
group O
motif I-GENE
characteristic O
of O
DNA I-GENE
- I-GENE
binding I-GENE
proteins I-GENE
. O

We O
have O
examined O
the O
ability O
of O
various O
NF I-GENE
- I-GENE
kappa I-GENE
B I-GENE
subunits I-GENE
to O
bind O
to O
, O
and O
activate O
transcription I-GENE
from O
, O
the O
IL I-GENE
- I-GENE
8 O
promoter I-GENE
. O

When O
multiple O
copies O
of O
the O
IL I-GENE
- I-GENE
1 I-GENE
beta I-GENE
NF I-GENE
- I-GENE
kappa I-GENE
B I-GENE
site I-GENE
were O
linked O
to O
an O
_RARE_ I-GENE
simian I-GENE
virus I-GENE
40 I-GENE
promoter I-GENE
, O
this O
element I-GENE
was O
able O
to O
mediate O
phorbol O
ester O
- I-GENE
or O
lipopolysaccharide O
- I-GENE
inducible I-GENE
gene I-GENE
expression O
. O

We O
found O
that O
the O
3 I-GENE
'- O
end O
- I-GENE
adjacent O
sequence I-GENE
CA I-GENE
( O
N I-GENE
) O
3 I-GENE
- I-GENE
_RARE_ I-GENE
, O
conserved O
in O
plant O
Pol I-GENE
II I-GENE
- I-GENE
specific I-GENE
U O
snRNA I-GENE
genes I-GENE
, O
is O
essential O
for O
the O
3 I-GENE
'- O
end O
formation O
of O
U2 I-GENE
transcripts I-GENE
and O
, O
similar O
to O
the O
vertebrate I-GENE
3 I-GENE
' O
box I-GENE
, O
is O
highly O
_RARE_ I-GENE
to O
mutation I-GENE
. O

These O
results O
indicate O
that O
Rb I-GENE
protein I-GENE
is O
interacting I-GENE
with O
some O
component O
( O
s O
) O
of O
the O
cell O
cycle O
- I-GENE
regulatory I-GENE
machinery O
during O
G2 I-GENE
phase O
. O

_RARE_ I-GENE
from O
HeLa O
and O
_RARE_ I-GENE
cells O
formed O
DNA I-GENE
- I-GENE
protein I-GENE
complexes I-GENE
with O
X I-GENE
- I-GENE
box I-GENE
oligonucleotides O
that O
_RARE_ I-GENE
with O
those O
containing O
standard O
_RARE_ I-GENE
sites I-GENE
. O

_RARE_ I-GENE
mice O
harboring O
the O
rat I-GENE
TnI I-GENE
- I-GENE
CAT I-GENE
fusion I-GENE
gene I-GENE
expressed O
the O
reporter I-GENE
specifically O
in O
the O
skeletal I-GENE
muscle O
. O

METHODS O
: O
Fifty O
- I-GENE
one O
healthy O
eyes O
, O
_RARE_ I-GENE
ocular O
hypertensive O
eyes O
with O
normal O
visual O
fields O
, O
and O
132 O
_RARE_ I-GENE
eyes O
with O
early I-GENE
visual O
field O
defects O
were O
evaluated O
with O
qualitative O
and O
quantitative O
measures O
of O
structural O
damage O
to O
the O
optic O
nerve I-GENE
and O
nerve I-GENE
fiber O
layer O
. O

Consistent O
with O
the O
hypothesis O
that O
it O
acts O
as O
transcriptional O
regulator I-GENE
, O
wild I-GENE
- I-GENE
type I-GENE
p53 I-GENE
protein I-GENE
binds O
DNA I-GENE
and O
activates O
transcription I-GENE
of O
several O
promoters I-GENE
. O

The O
ADP I-GENE
- I-GENE
_RARE_ I-GENE
factor I-GENE
( O
ARF I-GENE
) O
family I-GENE
is O
one O
of O
four O
_RARE_ I-GENE
of O
the O
_RARE_ I-GENE
superfamily I-GENE
of O
low O
molecular O
weight O
GTP I-GENE
- I-GENE
binding I-GENE
proteins I-GENE
( O
G I-GENE
proteins I-GENE
). O

The O
E1 I-GENE
gene I-GENE
is O
located O
within O
the O
first O
intron O
of O
the O
gene I-GENE
for O
_RARE_ I-GENE
, O
a O
protein I-GENE
that O
regulates O
onset O
of O
mitosis O
. O

Genomic O
Southern O
blot O
analysis O
and O
chromosome O
mapping O
showed O
that O
_RARE_ I-GENE
_RARE_ I-GENE
to O
two O
closely O
related I-GENE
genes I-GENE
located O
on O
chromosomes O
5 I-GENE
and O
13 O
and O
are O
, O
therefore O
, O
distinct O
from O
the O
_RARE_ I-GENE
located O
near O
the O
_RARE_ I-GENE
disease O
locus I-GENE
on O
chromosome O
4 I-GENE
. O

_RARE_ I-GENE
labeling O
studies O
in O
S I-GENE
. O
cerevisiae I-GENE
and O
co O
- I-GENE
expression O
of O
_RARE_ I-GENE
with O
several O
protein I-GENE
substrates O
of O
_RARE_ I-GENE
in O
Escherichia I-GENE
coli I-GENE
indicate O
that O
the O
_RARE_ I-GENE
--> I-GENE
Pro I-GENE
substitution O
causes O
a O
reduction O
in O
the O
_RARE_ I-GENE
of O
some O
but O
not O
all O
protein I-GENE
substrates O
. O

These O
CTD I-GENE
kinases I-GENE
, O
designated O
_RARE_ I-GENE
and O
_RARE_ I-GENE
, O
are O
_RARE_ I-GENE
by O
chromatography O
on O
_RARE_ I-GENE
Q I-GENE
. O

Instead O
, O
mRNA I-GENE
of O
2 I-GENE
. O
0 O
and O
2 I-GENE
. O
8 O
kb O
are O
detected O
in O
varying O
abundance O
. O

Previously O
, O
we O
identified O
a O
51 O
- I-GENE
bp O
promoter I-GENE
fragment I-GENE
, O
_RARE_ I-GENE
/ I-GENE
32 O
, O
which O
conferred O
heat I-GENE
shock I-GENE
inducibility O
on O
the O
heterologous O
CYC1 I-GENE
- I-GENE
lacZ I-GENE
reporter I-GENE
gene I-GENE
in O
S I-GENE
. O
cerevisiae I-GENE
( O
N I-GENE
. O

The O
sequence I-GENE
of O
the O
_RARE_ I-GENE
gene I-GENE
predicts O
an O
88 O
- I-GENE
kDa I-GENE
protein I-GENE
with O
three O
repeats I-GENE
of O
a O
motif I-GENE
found O
in O
the O
G I-GENE
beta I-GENE
subunit I-GENE
of O
retinal O
_RARE_ I-GENE
and O
in O
a O
yeast I-GENE
transcriptional O
repressor I-GENE
, O
_RARE_ I-GENE
. O

All O
of O
these O
data O
suggest O
that O
replication O
of O
UV O
- I-GENE
damaged O
templates O
occurs O
in O
vitro O
as O
it O
does O
in O
vivo O
and O
that O
this O
replication O
results O
in O
mutation I-GENE
fixation O
. O

To O
identify O
factors I-GENE
that O
may O
modify O
the O
_RARE_ I-GENE
transmission O
of O
human I-GENE
T I-GENE
cell O
leukemia I-GENE
/ I-GENE
lymphoma O
virus I-GENE
type I-GENE
I I-GENE
( O
HTLV I-GENE
- I-GENE
I I-GENE
), O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
enrolled O
in O
the O
_RARE_ I-GENE
_RARE_ I-GENE
Study O
between O
_RARE_ I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
1989 O
were O
studied O
: O
95 O
_RARE_ I-GENE
HTLV I-GENE
- I-GENE
I I-GENE
- I-GENE
seropositive O
( O
H I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
seropositive O
( O
W I-GENE
+), O
33 O
H I-GENE
+/ I-GENE
W I-GENE
-, I-GENE
64 O
H I-GENE
_RARE_ I-GENE
W I-GENE
+, I-GENE
and O
_RARE_ I-GENE
H I-GENE
_RARE_ I-GENE
W I-GENE
-. O

Biol O
. O

To O
characterize O
the O
expression O
of O
this O
DNA I-GENE
repair I-GENE
enzyme I-GENE
, O
we O
have O
isolated O
the O
corresponding O
genomic O
clone O
. O

L I-GENE
., O
_RARE_ I-GENE
, O
G I-GENE
., O
_RARE_ I-GENE
, O
D I-GENE
., O
_RARE_ I-GENE
, O
J O
., O
_RARE_ I-GENE
, O
X I-GENE
., O
_RARE_ I-GENE
, O
A I-GENE
., O
_RARE_ I-GENE
, O
M I-GENE
., O
and O
_RARE_ I-GENE
, O
H I-GENE
. O

The O
nucleotide I-GENE
sequence I-GENE
of O
the O
gene I-GENE
predicts O
a O
polypeptide I-GENE
of O
215 O
amino O
acids O
( O
25 O
. O
2 I-GENE
kDa I-GENE
) O
with O
two O
putative O
membrane I-GENE
- I-GENE
spanning O
domains I-GENE
. O

_RARE_ I-GENE
, O
echocardiography O
and O
thallium O
- I-GENE
201 O
imaging O
were O
performed O
before O
and O
1 I-GENE
month O
after O
_RARE_ I-GENE
_RARE_ I-GENE
. O

They O
were O
called O
_RARE_ I-GENE
and O
_RARE_ I-GENE
. O

_RARE_ I-GENE
, O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
). O

Both O
fusion I-GENE
proteins I-GENE
form O
stable O
specific I-GENE
complexes I-GENE
with O
a O
short O
DNA I-GENE
duplex O
harboring O
the O
_RARE_ I-GENE
( O
at O
) O
_RARE_ I-GENE
consensus I-GENE
sequence I-GENE
of O
the O
LexA I-GENE
repressor I-GENE
. O

Ten O
selenocysteine I-GENE
residues O
( O
deduced O
) O
are O
present O
. O

CONCLUSIONS O
: O
_RARE_ I-GENE
protein I-GENE
S I-GENE
deficiency O
is O
common O
among O
hospitalized O
patients O
, O
even O
in O
the O
absence O
of O
a O
recognized O
_RARE_ I-GENE
condition O
. O

During O
the O
past O
_RARE_ I-GENE
, O
different O
types O
of O
endogenous I-GENE
retroviral I-GENE
sequences I-GENE
have O
been O
defined O
in O
the O
human I-GENE
genome O
usually O
by O
low O
_RARE_ I-GENE
hybridization O
employing O
DNA I-GENE
probes O
of O
evolutionary O
conserved O
animal O
retrovirus O
genes I-GENE
. O

As O
the O
components O
of O
these O
complexes I-GENE
, O
at O
least O
five O
_RARE_ I-GENE
( O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
p50 I-GENE
, O
and O
_RARE_ I-GENE
) O
showing O
specific I-GENE
binding I-GENE
to O
the O
TAR I-GENE
RNA I-GENE
were O
detected O
in O
the O
_RARE_ I-GENE
cross O
- I-GENE
linking O
assay O
. O

The O
_RARE_ I-GENE
functional O
_RARE_ I-GENE
for O
_RARE_ I-GENE
in O
_RARE_ I-GENE
mitochondria O
is O
the O
formation O
of O
_RARE_ I-GENE
mRNAs I-GENE
. O

The O
use O
of O
this O
model O
for O
_RARE_ I-GENE
_RARE_ I-GENE
significant O
issues O
in O
_RARE_ I-GENE
diseases O
is O
_RARE_ I-GENE
with O
five O
different O
sets O
of O
parameters O
. O

An O
extensive O
inverted O
repeat I-GENE
is O
present O
3 I-GENE
' O
of O
_RARE_ I-GENE
; O
inverted O
repeats I-GENE
are O
found O
downstream O
of O
all O
PE I-GENE
operons I-GENE
sequenced O
to O
date O
, O
although O
the O
sequence I-GENE
is O
not O
conserved O
. O

We O
describe O
a O
novel O
cytoplasmic I-GENE
tyrosine I-GENE
kinase I-GENE
, O
termed O
_RARE_ I-GENE
( O
B I-GENE
cell O
progenitor I-GENE
kinase I-GENE
), O
which O
is O
expressed O
in O
all O
stages O
of O
the O
B I-GENE
lineage O
and O
in O
myeloid O
cells O
. O

Large I-GENE
differences O
between O
the O
groups O
were O
not O
observed O
in O
HA I-GENE
- I-GENE
_RARE_ I-GENE
enzyme I-GENE
activity O
, O
but O
_RARE_ I-GENE
enzyme I-GENE
activity O
was O
much O
higher O
in O
aspirin I-GENE
- I-GENE
induced O
asthma O
- I-GENE
related I-GENE
polyps O
than O
in O
other O
types O
of O
nasal O
polyps O
tested O
. O

In O
the O
multivariate O
analysis O
, O
six O
variables O
were O
independently O
correlated O
with O
survival O
: O
blood O
urea O
nitrogen O
level O
, O
serum I-GENE
aspartate I-GENE
aminotransferase I-GENE
level O
, O
community O
- I-GENE
acquired O
vs O
. O
hospital O
- I-GENE
acquired O
_RARE_ I-GENE
, O
age O
, O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
score O
and O
_RARE_ I-GENE
. O

Localization O
of O
the O
intronless O
gene I-GENE
coding O
for O
calmodulin I-GENE
- I-GENE
like I-GENE
protein I-GENE
_RARE_ I-GENE
to O
human I-GENE
chromosome O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
. O

In O
_RARE_ I-GENE
stage O
larvae O
, O
the O
_RARE_ I-GENE
transcript I-GENE
appeared O
to O
be O
at O
least O
250 O
- I-GENE
fold O
less O
abundant O
than O
ribosomal I-GENE
RNA I-GENE
. O

One O
such O
mutant I-GENE
also O
affects O
the O
overlapping O
- I-GENE
10 O
hexamer O
of O
PR I-GENE
and O
results O
in O
reduced O
_RARE_ I-GENE
by O
both O
_RARE_ I-GENE
and O
RNA I-GENE
polymerase I-GENE
, O
likely O
as O
a O
result O
of O
inefficient O
transcriptional O
initiation I-GENE
of O
_RARE_ I-GENE
mRNA I-GENE
. O

However O
, O
L I-GENE
- I-GENE
plastin I-GENE
has O
been O
found O
in O
many O
types O
of O
malignant O
human I-GENE
cells O
of O
non O
- I-GENE
_RARE_ I-GENE
origin O
suggesting O
that O
its O
expression O
is O
induced O
accompanying O
tumorigenesis O
in O
solid O
tissues O
. O

Finally O
, O
we O
present O
evidence O
that O
_RARE_ I-GENE
is O
a O
third O
distinct O
plastin I-GENE
isoform I-GENE
which O
is O
specifically O
expressed O
at O
high O
levels O
in O
the O
small I-GENE
intestine O
. O

This O
promoter I-GENE
could O
direct O
the O
constitutive O
expression O
of O
the O
reporter I-GENE
beta I-GENE
- I-GENE
galactosidase I-GENE
at O
high O
frequency O
in O
transfected O
colonies O
of O
transformed O
cells O
that O
express O
L I-GENE
- I-GENE
plastin I-GENE
constitutively O
; O
by O
contrast O
, O
this O
promoter I-GENE
was O
virtually O
inactive O
in O
transfected O
colonies O
of O
normal O
fibroblasts O
and O
it O
exhibited O
a O
low O
frequency O
of O
constitutive O
activation O
in O
transfected O
colonies O
of O
in O
vitro O
SV40 I-GENE
- I-GENE
transformed O
fibroblasts O
which O
did O
not O
exhibit O
L I-GENE
- I-GENE
plastin I-GENE
expression O
. O

The O
half O
- I-GENE
life O
of O
the O
serum I-GENE
- I-GENE
induced O
CBP I-GENE
/ I-GENE
tk I-GENE
binding I-GENE
activity O
was O
estimated O
to O
be O
less O
than O
1 I-GENE
h O
.( O
ABSTRACT O
TRUNCATED O
AT I-GENE
400 O
WORDS O
) O

The O
DNase I-GENE
I I-GENE
footprint O
extended O
5 I-GENE
' O
in O
the O
silencer I-GENE
region O
to O
include O
an O
inverted O
repeat I-GENE
of O
a O
six O
- I-GENE
nucleotide I-GENE
motif I-GENE
( O
epsilon I-GENE
- I-GENE
_RARE_ I-GENE
to O
- I-GENE
_RARE_ I-GENE
bp O
) O
which O
shares O
5 I-GENE
of O
6 I-GENE
bases O
with O
the O
GATA I-GENE
- I-GENE
1 I-GENE
consensus I-GENE
sequence I-GENE
. O

Furthermore O
, O
competitor O
containing O
the O
YY1 I-GENE
consensus I-GENE
sequence I-GENE
_RARE_ I-GENE
for O
protein I-GENE
B I-GENE
binding I-GENE
, O
whereas O
competitor O
containing O
a O
perfect O
yeast I-GENE
_RARE_ I-GENE
- I-GENE
1 I-GENE
consensus I-GENE
sequence I-GENE
did O
not O
.( O
ABSTRACT O
TRUNCATED O
AT I-GENE
400 O
WORDS O
) O

The O
gene I-GENE
includes O
three O
exons O
and O
two O
introns O
within O
1 I-GENE
. O
6 I-GENE
kilobases O
of O
DNA I-GENE
, O
and O
the O
entire O
open O
reading O
frame O
for O
glycoprotein I-GENE
IX I-GENE
is O
included O
within O
the O
third O
exon O
. O

Rhizobium I-GENE
_RARE_ I-GENE
large O
plasmid O
_RARE_ I-GENE
carries O
the O
_RARE_ I-GENE
_RARE_ I-GENE
locus I-GENE
_RARE_ I-GENE
responsible O
for O
the O
_RARE_ I-GENE
efficiency O
and O
competitive O
ability O
of O
strain O
_RARE_ I-GENE
on O
_RARE_ I-GENE
roots O
. O

Further O
, O
the O
ability O
of O
recombinant I-GENE
beta I-GENE
and O
/ I-GENE
or O
gamma I-GENE
chains I-GENE
to O
function O
in O
defined O
biochemical O
assays O
of O
beta I-GENE
gamma I-GENE
activity O
was O
assessed O
for O
membrane I-GENE
extracts O
and O
supernatant O
fractions O
from O
infected O
Sf9 O
cells O
. O

This O
report O
describes O
the O
identification O
of O
a O
gene I-GENE
of O
related I-GENE
function O
, O
_RARE_ I-GENE
, O
located O
immediately O
3 I-GENE
' O
to O
_RARE_ I-GENE
. O

These O
data O
establish O
_RARE_ I-GENE
as O
a O
required O
component O
of O
the O
cellular O
splicing O
apparatus O
and O
a O
factor I-GENE
in O
snRNA I-GENE
maturation O
and O
stability O
. O

This O
study O
compared O
the O
gross O
and O
fine O
motor O
performance O
of O
14 O
_RARE_ I-GENE
brain O
- I-GENE
_RARE_ I-GENE
children O
( O
five O
to O
15 O
years O
old O
, O
with O
loss O
of O
_RARE_ I-GENE
for O
at O
least O
24 O
hours O
) O
to O
14 O
normal O
children O
group O
matched O
for O
age O
and O
sex I-GENE
. O

We O
compared O
the O
parameters O
pleural I-GENE
adenosine I-GENE
deaminase I-GENE
( O
_RARE_ I-GENE
, O
determined O
in O
_RARE_ I-GENE
patients O
), O
the O
_RARE_ I-GENE
/ I-GENE
serum I-GENE
_RARE_ I-GENE
ratio O
( O
P I-GENE
/ I-GENE
_RARE_ I-GENE
; O
_RARE_ I-GENE
cases O
), O
pleural I-GENE
lysozyme I-GENE
( O
_RARE_ I-GENE
, O
_RARE_ I-GENE
cases O
), O
the O
_RARE_ I-GENE
/ I-GENE
serum I-GENE
_RARE_ I-GENE
ratio O
( O
P I-GENE
/ I-GENE
_RARE_ I-GENE
; O
_RARE_ I-GENE
cases O
), O
and O
pleural I-GENE
interferon I-GENE
gamma I-GENE
( O
IFN I-GENE
, O
_RARE_ I-GENE
cases O
) O
regarding O
their O
ability O
to O
differentiate O
tuberculous O
pleural I-GENE
_RARE_ I-GENE
from O
others O
. O

These O
exons O
were O
identified O
by O
cloning O
and O
sequencing O
cDNAs I-GENE
obtained O
by O
polymerase I-GENE
chain I-GENE
reaction O
amplification O
of O
a O
fibroblast I-GENE
cDNA I-GENE
library O
. O

Deletion O
of O
the O
_RARE_ I-GENE
gene I-GENE
, O
either O
with O
or O
without O
deletion O
of O
other O
_RARE_ I-GENE
( O
protease I-GENE
IV I-GENE
and O
_RARE_ I-GENE
N I-GENE
), O
did O
not O
have O
any O
effect O
on O
cell O
growth I-GENE
in O
the O
various O
media O
tested O
. O

In O
Experiment O
2 I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
, O
0 O
. O
5 I-GENE
and O
1 I-GENE
. O
0 O
mg O
/ I-GENE
kg O
i O
. O
p O
., O
was O
administered O
1 I-GENE
h O
before O
each O
electrical O
stimulation O
until O
each O
rat I-GENE
showed O
the O
stage O
- I-GENE
3 I-GENE
seizure O
. O

_RARE_ I-GENE
, O
_RARE_ I-GENE
and O
_RARE_ I-GENE
in O
the O
initial O
stage O
of O
kindling O
, O
kindling O
rate O
for O
the O
stage O
- I-GENE
3 I-GENE
and O
- I-GENE
5 I-GENE
seizures O
, O
seizure O
parameters O
at O
the O
first O
stage O
- I-GENE
3 I-GENE
and O
- I-GENE
5 I-GENE
were O
recorded O
and O
compared O
to O
the O
values O
of O
saline O
- I-GENE
treated O
, O
control O
group O
. O

CONCLUSIONS O
. O

There O
was O
a O
positive O
correlation O
between O
_RARE_ I-GENE
cross O
- I-GENE
link I-GENE
excretion O
and O
thyroid I-GENE
hormone I-GENE
concentrations O
. O

Mutations O
_RARE_ I-GENE
as O
many O
as O
143 I-GENE
C I-GENE
- I-GENE
terminal I-GENE
residues O
from O
the O
transcriptional O
activator I-GENE
encoded I-GENE
by O
the O
_RARE_ I-GENE
gene I-GENE
, O
mediating O
nitrogen O
metabolite O
repression O
in O
Aspergillus I-GENE
_RARE_ I-GENE
, O
do O
not O
significantly O
reduce O
the O
ability O
of O
the O
_RARE_ I-GENE
product I-GENE
to O
activate O
expression O
of O
most O
genes I-GENE
under O
_RARE_ I-GENE
control O
. O

_RARE_ I-GENE
_RARE_ I-GENE
who O
_RARE_ I-GENE
_RARE_ I-GENE
for O
% O
BF I-GENE
can O
be O
separated O
from O
active O
_RARE_ I-GENE
. O

_RARE_ I-GENE
promoter I-GENE
activity O
was O
observed O
for O
the O
promoter I-GENE
of O
the O
C1 I-GENE
and O
C2 I-GENE
ORFs O
( O
C1 I-GENE
- I-GENE
C2 I-GENE
gene I-GENE
) O
and O
for O
the O
promoter I-GENE
of O
the O
_RARE_ I-GENE
ORF I-GENE
. O

The O
activity O
of O
the O
coat I-GENE
protein I-GENE
promoter I-GENE
of O
_RARE_ I-GENE
_RARE_ I-GENE
mosaic O
virus I-GENE
is O
enhanced O
by O
its O
own O
and O
C1 I-GENE
- I-GENE
C2 I-GENE
gene I-GENE
products I-GENE
. O

The O
amino O
acid I-GENE
sequence I-GENE
alignment O
of O
_RARE_ I-GENE
II I-GENE
with O
that O
of O
other O
Cbl I-GENE
binding I-GENE
proteins I-GENE
( O
rat I-GENE
intrinsic O
factor I-GENE
, O
human I-GENE
_RARE_ I-GENE
I I-GENE
and O
porcine I-GENE
_RARE_ I-GENE
) O
revealed O
only O
33 O
% O
overall O
homology I-GENE
. O

This O
short O
_RARE_ I-GENE
_RARE_ I-GENE
a O
novel O
_RARE_ I-GENE
_RARE_ I-GENE
enzyme I-GENE
immunoassay O
( O
_RARE_ I-GENE
) O
with O
a O
commercial O
time O
- I-GENE
resolved O
_RARE_ I-GENE
for O
the O
determination O
of O
thyrotropin I-GENE
in O
_RARE_ I-GENE
blood O
spots O
. O

The O
evaluation O
was O
performed O
using O
a O
retrospective O
study O
design O
with O
newborn O
blood O
samples O
from O
three O
screening O
_RARE_ I-GENE
. O

A I-GENE
region O
in O
the O
C I-GENE
- I-GENE
terminus O
of O
adenovirus I-GENE
2 I-GENE
/ I-GENE
5 I-GENE
E1a I-GENE
protein I-GENE
is O
required O
for O
association O
with O
a O
cellular O
phosphoprotein I-GENE
and O
important O
for O
the O
negative O
modulation O
of O
_RARE_ I-GENE
- I-GENE
ras I-GENE
mediated O
transformation O
, O
tumorigenesis O
and O
metastasis O
. O

These O
studies O
demonstrate O
that O
both O
G I-GENE
alpha I-GENE
i O
genes I-GENE
are O
_RARE_ I-GENE
regulated O
in O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
cells O
by O
both O
growth I-GENE
, O
differentiation O
, O
and O
hormone I-GENE
signals O
. O

_RARE_ I-GENE
containing O
the O
full I-GENE
- I-GENE
length I-GENE
_RARE_ I-GENE
cDNA I-GENE
have O
been O
expressed O
in O
Escherichia I-GENE
coli I-GENE
at O
a O
high O
level O
to O
generate O
a O
60 O
- I-GENE
kDa I-GENE
recombinant I-GENE
protein I-GENE
. O

When O
ligated O
to O
the O
_RARE_ I-GENE
- I-GENE
1 I-GENE
beta I-GENE
cap I-GENE
site I-GENE
- I-GENE
proximal I-GENE
region O
( O
located O
between O
- I-GENE
131 O
to O
+ I-GENE
12 O
), O
both O
the O
_RARE_ I-GENE
- I-GENE
1 I-GENE
beta I-GENE
and O
the O
simian I-GENE
virus I-GENE
40 I-GENE
enhancer I-GENE
elements O
functioned O
more O
efficiently O
in O
monocytes O
than O
in O
HeLa O
cells O
, O
which O
are O
not O
normally O
competent O
for O
IL I-GENE
- I-GENE
1 I-GENE
beta I-GENE
expression O
. O

Therefore O
, O
PC I-GENE
- I-GENE
PLC I-GENE
is O
a O
component O
of O
a O
signal I-GENE
transduction O
pathway O
leading O
to O
transcription I-GENE
of O
c I-GENE
- I-GENE
fos I-GENE
and O
junB I-GENE
that O
_RARE_ I-GENE
with O
c I-GENE
- I-GENE
myc I-GENE
and O
is O
independent O
of O
PKC I-GENE
- I-GENE
delta I-GENE
and O
Ras I-GENE
activation O
. O

In O
mitogen I-GENE
- I-GENE
stimulated O
_RARE_ I-GENE
, O
_RARE_ I-GENE
- I-GENE
1 I-GENE
expression O
begins O
to O
rise O
at O
12 O
h O
after O
stimulation O
and O
_RARE_ I-GENE
very O
high O
levels O
after O
50 O
h O
, O
suggesting O
that O
it O
may O
be O
functionally O
involved O
in O
events O
occurring O
after O
the O
interaction O
of O
IL I-GENE
- I-GENE
2 I-GENE
with O
its O
receptor I-GENE
, O
perhaps O
during O
the O
transition O
from O
the O
G1 I-GENE
to O
the O
S I-GENE
phase O
of O
the O
cell O
cycle O
. O

We O
have O
isolated O
and O
characterized O
the O
_RARE_ I-GENE
and O
_RARE_ I-GENE
genes I-GENE
and O
shown O
that O
their O
products I-GENE
are O
required O
to O
repress O
GCN4 I-GENE
translation I-GENE
under O
_RARE_ I-GENE
conditions O
. O

The O
_RARE_ I-GENE
_RARE_ I-GENE
value O
was O
that O
predicted O
by O
_RARE_ I-GENE
relation O
. O

While O
the O
latter O
corresponded O
to O
a O
protein I-GENE
of O
_RARE_ I-GENE
amino O
acids O
, O
an O
upstream O
open O
reading O
frame O
( O
uORF I-GENE
) O
within O
the O
5 I-GENE
' O
leader O
could O
potentially O
encode O
a O
54 I-GENE
amino O
acid I-GENE
peptide I-GENE
. O

The O
_RARE_ I-GENE
protein I-GENE
kinase I-GENE
mRNA I-GENE
contains O
a O
long O
5 I-GENE
' O
leader O
with O
a O
small I-GENE
open O
reading O
frame O
. O

In O
contrast O
to O
T I-GENE
cells O
, O
in O
fibroblasts O
_RARE_ I-GENE
gene I-GENE
expression O
requires O
only O
one O
signal I-GENE
( O
PMA O
) O
and O
is O
not O
affected O
by O
_RARE_ I-GENE
. O

_RARE_ I-GENE
localization O
of O
GUS I-GENE
revealed O
promoter I-GENE
function O
in O
leaf O
_RARE_ I-GENE
, O
_RARE_ I-GENE
and O
vascular I-GENE
_RARE_ I-GENE
, O
in O
the O
cortex O
and O
vascular I-GENE
_RARE_ I-GENE
of O
the O
root O
. O

In O
order O
to O
investigate O
how O
these O
expression O
patterns O
are O
established O
, O
we O
fused O
promoter I-GENE
regions O
of O
an O
acidic O
and O
a O
basic I-GENE
_RARE_ I-GENE
gene I-GENE
to O
the O
beta I-GENE
- I-GENE
glucuronidase I-GENE
( O
GUS I-GENE
) O
reporter I-GENE
gene I-GENE
and O
examined O
expression O
of O
these O
constructs I-GENE
in O
transgenic O
tobacco I-GENE
plants O
. O

Southern O
blot O
analysis O
using O
probes O
from O
the O
3 I-GENE
' O
portions O
of O
the O
genomic O
and O
B I-GENE
. O
napus I-GENE
MA I-GENE
and O
MB I-GENE
cDNA I-GENE
clones O
showed O
that O
MA I-GENE
type I-GENE
_RARE_ I-GENE
are O
encoded I-GENE
by O
approximately O
4 I-GENE
genes I-GENE
, O
while O
MB I-GENE
type I-GENE
_RARE_ I-GENE
are O
encoded I-GENE
by O
more O
than O
10 O
genes I-GENE
in O
B I-GENE
. O
napus I-GENE
. O

_RARE_ I-GENE
, O
A I-GENE
. O

_RARE_ I-GENE
fingers O
( O
_RARE_ I-GENE
) O
are O
a O
common O
structural O
motif I-GENE
found O
in O
many O
nucleic O
acid I-GENE
- I-GENE
binding I-GENE
proteins I-GENE
. O

The O
deduced O
bovine I-GENE
EFIA I-GENE
_RARE_ I-GENE
1 I-GENE
amino O
acid I-GENE
( O
aa O
) O
sequence I-GENE
is O
98 O
% O
identical O
to O
rat I-GENE
EFIA I-GENE
and O
100 O
% O
identical O
to O
human I-GENE
EFIA I-GENE
/ I-GENE
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
- I-GENE
1 I-GENE
family I-GENE
member O
DNA I-GENE
- I-GENE
binding I-GENE
protein I-GENE
B I-GENE
( O
_RARE_ I-GENE
). O

Effect O
of O
tracheal O
_RARE_ I-GENE
of O
_RARE_ I-GENE
on O
acute O
_RARE_ I-GENE
toxicity O
in O
rats O
. O

Localization O
of O
the O
insertion O
locus I-GENE
in O
the O
yeast I-GENE
genome O
and O
complementation O
studies O
with O
the O
temperature O
- I-GENE
sensitive O
mutant I-GENE
indicate O
that O
the O
two O
mutations O
are O
allelic O
. O

Replacement I-GENE
of O
the O
spacer O
sequence I-GENE
between O
the O
two O
_RARE_ I-GENE
with O
a O
shorter O
stretch O
of O
sequence I-GENE
also O
reduced O
RNA I-GENE
binding I-GENE
in O
vitro O
. O

Type O
II I-GENE
could O
be O
divided O
further O
into O
two O
forms O
( O
IIA I-GENE
and O
_RARE_ I-GENE
) O
that O
may O
represent O
two O
_RARE_ I-GENE
species O
or O
developmental O
stages O
of O
the O
same O
species O
. O

Second O
, O
the O
transcription I-GENE
factor I-GENE
Gal I-GENE
- I-GENE
ER I-GENE
was O
_RARE_ I-GENE
more O
potent O
and O
less O
susceptible O
to O
cell O
type I-GENE
- I-GENE
specific I-GENE
variation O
by O
_RARE_ I-GENE
the O
strong O
activating I-GENE
domain I-GENE
of O
the O
herpesvirus I-GENE
protein I-GENE
VP16 I-GENE
onto O
its O
C I-GENE
terminus O
. O

The O
exogenous O
fos I-GENE
gene I-GENE
was O
rapidly O
induced O
to O
maximal O
levels O
within O
1 I-GENE
- I-GENE
2 I-GENE
hr O
of O
estrogen I-GENE
addition O
. O

Elimination O
of O
Haemophilus O
influenzae O
type I-GENE
b I-GENE
meningitis O
after O
introduction O
of O
vaccination O

_RARE_ I-GENE
accurately O
assessed O
tumor I-GENE
extension O
in O
two O
T2 I-GENE
tumors O
, O
14 O
T3 O
tumors O
, O
and O
seven O
T4 I-GENE
tumors O
. O

In O
the O
present O
study O
we O
demonstrated O
a O
unique O
mechanism O
of O
action O
of O
8 O
- I-GENE
Cl O
- I-GENE
cAMP I-GENE
in O
the O
regulation O
of O
these O
kinase I-GENE
_RARE_ I-GENE
in O
HL I-GENE
- I-GENE
60 O
human I-GENE
_RARE_ I-GENE
leukemia I-GENE
cells O
. O

Analysis O
of O
cell O
cycle O
regulation O
in O
the O
budding I-GENE
yeast I-GENE
Saccharomyces I-GENE
cerevisiae I-GENE
has O
shown O
that O
a O
central O
regulatory I-GENE
protein I-GENE
kinase I-GENE
, O
Cdc28 I-GENE
, O
undergoes O
changes O
in O
activity O
through O
the O
cell O
cycle O
by O
_RARE_ I-GENE
with O
distinct O
groups O
of O
_RARE_ I-GENE
that O
accumulate O
at O
different O
times O
. O

_RARE_ I-GENE
clones O
representing O
full I-GENE
- I-GENE
length I-GENE
cDNAs I-GENE
for O
_RARE_ I-GENE
alpha I-GENE
were O
obtained O
from O
mouse I-GENE
brain O
. O

The O
method O
involves O
preliminary O
isolation O
of O
_RARE_ I-GENE
and O
internal O
standard O
from O
plasma I-GENE
by O
solid O
- I-GENE
phase O
extraction O
prior O
to O
the O
formation O
of O
their O
n O
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
derivatives O
. O

There O
are O
, O
however O
, O
several O
differences O
between O
the O
two O
new O
_RARE_ I-GENE
sequences I-GENE
. O

_RARE_ I-GENE
linking O
the O
olfactory O
_RARE_ I-GENE
with O
the O
medial O
_RARE_ I-GENE
anterior O
hypothalamus O
are O
important O
for O
_RARE_ I-GENE
aggression O
in O
mice O
. O

_RARE_ I-GENE
mitogen I-GENE
( O
_RARE_ I-GENE
) O
or O
anti I-GENE
- I-GENE
CD3 I-GENE
significantly O
increases O
c I-GENE
- I-GENE
jun I-GENE
messenger I-GENE
RNA I-GENE
( O
mRNA I-GENE
) O
levels O
in O
T I-GENE
cells O
. O

Following O
seizure O
induction O
, O
_RARE_ I-GENE
increased O
to O
105 I-GENE
mm O
Hg O
and O
brain O
_RARE_ I-GENE
fell O
to O
6 I-GENE
. O
79 O
+/- O
0 O
. O
03 O
within O
15 O
min O
and O
remained O
at O
this O
level O
for O
1 I-GENE
h O
( O
P I-GENE
< O
0 O
. O
001 O
). O

In O
contrast O
, O
rats O
receiving O
_RARE_ I-GENE
( O
2 I-GENE
mg O
/ I-GENE
kg O
i O
. O
v I-GENE
. O
infusion O
_RARE_ I-GENE
30 O
min O
prior O
to O
_RARE_ I-GENE
) O
exhibited O
enhanced O
_RARE_ I-GENE
throughout O
reperfusion O
[ O
PI I-GENE
10 O
min O
: O
3 I-GENE
. O
26 O
( O
2 I-GENE
. O
56 O
- I-GENE
3 I-GENE
. O
63 O
); O
120 O
min O
: O
2 I-GENE
. O
03 O
( O
1 I-GENE
. O
73 O
- I-GENE
2 I-GENE
. O
25 O
); O
240 O
min O
: O
2 I-GENE
. O
13 O
( O
1 I-GENE
. O
75 O
- I-GENE
2 I-GENE
. O
44 I-GENE
), O
p O
< O
0 O
. O
01 O
vs O
. O
controls O
and O
normals O
] O
with O
complete O
muscle O
_RARE_ I-GENE
[ O
_RARE_ I-GENE
100 O
% O
in O
all O
_RARE_ I-GENE
muscles O
, O
p O
< O
0 O
. O
01 O
vs O
. O
controls O
, O
not O
significant O
( O
NS I-GENE
) O
vs O
. O
normals O
and O
6 I-GENE
h O
ischaemia O
_RARE_ I-GENE
ABSTRACT O
TRUNCATED O
AT I-GENE
250 O
WORDS O
) O

Sequencing O
of O
a O
1 I-GENE
. O
3 I-GENE
- I-GENE
kilobase O
fragment I-GENE
of O
the O
5 I-GENE
'- O
flanking O
region O
of O
the O
_RARE_ I-GENE
gene I-GENE
identified O
TATA I-GENE
- I-GENE
like I-GENE
and O
CAAT I-GENE
sequences I-GENE
near O
the O
transcription I-GENE
start O
site I-GENE
. O

The O
region O
that O
_RARE_ I-GENE
inducibility O
by O
IL I-GENE
- I-GENE
1 I-GENE
or O
TNF I-GENE
( O
positions O
- I-GENE
165 O
to O
- I-GENE
58 O
) O
contains O
potential O
binding I-GENE
sites I-GENE
for O
IRF I-GENE
- I-GENE
1 I-GENE
and O
- I-GENE
2 I-GENE
, O
AP I-GENE
- I-GENE
1 I-GENE
, O
and O
NF I-GENE
- I-GENE
IL I-GENE
- I-GENE
6 I-GENE
. O

Ig I-GENE
- I-GENE
alpha I-GENE
and O
Ig I-GENE
- I-GENE
beta I-GENE
contain O
extended O
cytoplasmic I-GENE
structure O
( O
61 O
and O
48 O
amino O
acids O
, O
respectively O
) O
and O
associate O
with O
cytoplasmic I-GENE
effectors I-GENE
indicating O
that O
they O
are O
directly O
involved O
in O
signal I-GENE
transduction O
. O

_RARE_ I-GENE
mutants I-GENE
of O
Saccharomyces I-GENE
cerevisiae I-GENE
were O
isolated O
from O
alpha I-GENE
* I-GENE
cells O
having O
the O
a O
/ I-GENE
alpha I-GENE
_RARE_ I-GENE
- I-GENE
6 I-GENE
_RARE_ I-GENE
( O
exhibiting O
alpha I-GENE
mating I-GENE
ability O
and O
weak O
a O
mating I-GENE
ability O
as O
a O
result O
of O
a O
defect O
in O
_RARE_ I-GENE
- I-GENE
alpha I-GENE
2 I-GENE
repression O
). O

We O
studied O
the O
functional O
interaction O
between O
human I-GENE
embryonic O
zeta I-GENE
2 I-GENE
globin I-GENE
promoter I-GENE
and O
the O
alpha I-GENE
globin I-GENE
regulatory I-GENE
element I-GENE
( O
HS I-GENE
- I-GENE
40 I-GENE
) O
located O
40 I-GENE
kb O
upstream O
of O
the O
zeta I-GENE
2 I-GENE
globin I-GENE
gene I-GENE
. O

It O
was O
shown O
by O
transient O
expression O
assay O
that O
HS I-GENE
- I-GENE
40 I-GENE
_RARE_ I-GENE
as O
an O
_RARE_ I-GENE
enhancer I-GENE
for O
high O
- I-GENE
level O
zeta I-GENE
2 I-GENE
globin I-GENE
promoter I-GENE
activity O
in O
K562 O
cells O
, O
an O
erythroid I-GENE
cell O
line O
of O
embryonic O
and O
/ I-GENE
or O
fetal O
origin O
. O

Initial O
results O
indicate O
that O
this O
_RARE_ I-GENE
pre I-GENE
- I-GENE
rRNA I-GENE
is O
the O
same O
as O
the O
species O
detected O
on O
depletion O
of O
the O
small I-GENE
nucleolar I-GENE
RNA I-GENE
- I-GENE
associated I-GENE
proteins I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
and O
in O
an O
_RARE_ I-GENE
mutant I-GENE
strain O
. O

_RARE_ I-GENE
, O
L I-GENE
. O

This O
study O
_RARE_ I-GENE
the O
feasibility O
of O
indirect O
_RARE_ I-GENE
_RARE_ I-GENE
as O
a O
_RARE_ I-GENE
technique O
in O
a O
canine O
model O
. O

OBJECTIVE O
: O
Our O
purpose O
was O
to O
determine O
the O
simultaneous O
concentrations O
of O
serum I-GENE
_RARE_ I-GENE
in O
both O
fetal O
and O
maternal I-GENE
blood O
. O

_RARE_ I-GENE
amino O
acid I-GENE
sequence I-GENE
has O
now O
been O
obtained O
from O
this O
protein I-GENE
which O
shares O
50 O
- I-GENE
100 O
% O
sequence I-GENE
identity O
with O
sequences I-GENE
encoded I-GENE
by O
mammalian I-GENE
G I-GENE
alpha I-GENE
11 O
and O
G I-GENE
alpha I-GENE
q I-GENE
cDNAs I-GENE
. O

_RARE_ I-GENE
is O
known O
to O
induce O
expression O
of O
certain O
proto I-GENE
- I-GENE
oncogenes I-GENE
, O
and O
this O
led O
us O
to O
examine O
potential O
regulatory I-GENE
regions O
of O
the O
cellular O
c I-GENE
- I-GENE
fos I-GENE
oncogene I-GENE
. O

_RARE_ I-GENE
lead O
was O
not O
a O
significant O
_RARE_ I-GENE
variable O
. O

We O
now O
show O
that O
regulation O
of O
_RARE_ I-GENE
transcription I-GENE
in O
vivo O
depends O
on O
a O
sigma I-GENE
54 I-GENE
promoter I-GENE
and O
two O
_RARE_ I-GENE
elements O
located O
downstream O
of O
the O
transcription I-GENE
start O
site I-GENE
at O
+ I-GENE
86 I-GENE
( O
_RARE_ I-GENE
) O
and O
+ I-GENE
120 O
( O
_RARE_ I-GENE
). O

5 I-GENE
micrograms O
/ I-GENE
l O
was O
detected O
in O
urine O
from O
some O
non O
- I-GENE
_RARE_ I-GENE
exposed O
persons O
. O

_RARE_ I-GENE
_RARE_ I-GENE
with O
deficiency O
of O
the O
_RARE_ I-GENE
. O

This O
prospective O
study O
compared O
the O
measured O
energy O
_RARE_ I-GENE
of O
30 O
patients O
using O
indirect O
_RARE_ I-GENE
with O
their O
predicted O
basal O
energy O
expenditure O
according O
to O
the O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
equation O
, O
or O
their O
calculated O
energy O
expenditure O
derived O
from O
basal O
energy O
expenditure O
times O
, O
an O
activity O
factor I-GENE
, O
and O
a O
stress O
factor I-GENE
. O

However O
, O
after O
repeated O
infections O
, O
_RARE_ I-GENE
larvae O
were O
numerous O
. O

This O
was O
performed O
in O
a O
double O
_RARE_ I-GENE
, O
randomized O
, O
placebo O
- I-GENE
controlled O
study O
. O

Group O
I I-GENE
consisted O
of O
six O
_RARE_ I-GENE
patients O
; O
group O
II I-GENE
consisted O
of O
nine O
_RARE_ I-GENE
_RARE_ I-GENE
patients O
with O
mild O
hepatic I-GENE
impairment O
( O
conjugated O
bilirubin O
, O
47 O
mumol O
liter O
- I-GENE
1 I-GENE
; O
alkaline I-GENE
phosphatase I-GENE
, O
_RARE_ I-GENE
IU O
liter O
- I-GENE
1 I-GENE
; O
gamma I-GENE
- I-GENE
_RARE_ I-GENE
, O
190 O
IU O
liter O
- I-GENE
1 I-GENE
); O
group O
III I-GENE
consisted O
of O
six O
benign O
intrahepatic O
_RARE_ I-GENE
patients O
with O
high O
isolated O
conjugated O
hyperbilirubinemia O
( O
98 O
. O
1 I-GENE
mumol O
liter O
- I-GENE
1 I-GENE
). O

There O
was O
either O
no O
change O
or O
an O
improvement O
in O
_RARE_ I-GENE
findings O
( O
t1 O
/ I-GENE
2 I-GENE
time O
and O
/ I-GENE
or O
_RARE_ I-GENE
function O
) O
in O
40 I-GENE
patients O
( O
93 O
%). O

We O
discuss O
the O
need O
to O
use O
animals O
older O
than O
3 I-GENE
months O
for O
the O
study O
of O
' O
adult O
' O
regeneration O
phenomena O
since O
3 I-GENE
- I-GENE
month O
- I-GENE
old O
rats O
may O
be O
_RARE_ I-GENE
immature O
. O

Nuclear I-GENE
beta I-GENE
II I-GENE
PKC I-GENE
, O
like I-GENE
p34cdc2 I-GENE
kinase I-GENE
, O
may O
function O
to O
regulate O
nuclear I-GENE
_RARE_ I-GENE
structural O
stability O
during O
cell O
cycle O
. O

In O
situ O
copper I-GENE
- I-GENE
_RARE_ I-GENE
footprinting O
of O
individual O
gel O
shift O
assembly O
_RARE_ I-GENE
shows O
that O
on O
the O
_RARE_ I-GENE
- I-GENE
nucleotide I-GENE
_RARE_ I-GENE
, O
the O
first O
two O
SSB I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
at O
random O
, O
but O
the O
addition O
of O
more O
SSB I-GENE
_RARE_ I-GENE
results O
in O
formation O
of O
a O
unique O
structure O
. O

Effects O
of O
_RARE_ I-GENE
endotoxin I-GENE
infusion O
on O
_RARE_ I-GENE
- I-GENE
induced O
_RARE_ I-GENE
release O
. O

_RARE_ I-GENE
associated I-GENE
box I-GENE
- I-GENE
zinc I-GENE
finger I-GENE
proteins I-GENE
( O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
) O
constitute O
a O
subfamily I-GENE
of O
the O
many O
_RARE_ I-GENE
type I-GENE
_RARE_ I-GENE
in O
Xenopus I-GENE
laevis I-GENE
. O

Further O
evidence O
for O
a O
clustered O
organization O
of O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
transcription I-GENE
units O
is O
provided O
by O
Southern O
blot O
analysis O
of O
large O
genomic O
restriction I-GENE
fragments I-GENE
separated O
by O
transverse O
field O
gel O
electrophoresis O
, O
and O
by O
in O
situ O
hybridization O
on O
intact O
chromosomes O
. O

A I-GENE
rat I-GENE
cDNA I-GENE
that O
encodes O
eIF I-GENE
- I-GENE
5 I-GENE
has O
been O
isolated O
and O
expressed O
in O
Escherichia I-GENE
coli I-GENE
to O
yield O
a O
catalytically O
active O
eIF I-GENE
- I-GENE
5 I-GENE
protein I-GENE
. O

Mutational O
analyses O
have O
demonstrated O
the O
importance O
of O
sequences I-GENE
within O
the O
_RARE_ I-GENE
bp O
segment O
that O
contain O
a O
putative O
cyclic I-GENE
AMP I-GENE
responsive I-GENE
element I-GENE
binding I-GENE
protein I-GENE
( O
CREB I-GENE
) O
binding I-GENE
site I-GENE
for O
TGF I-GENE
- I-GENE
beta I-GENE
1 I-GENE
and O
PMA O
responsiveness O
and O
putative O
PU I-GENE
- I-GENE
1 I-GENE
and O
Sp1 I-GENE
binding I-GENE
sites I-GENE
for O
basal O
promoter I-GENE
activity O
. O

( O
1992 O
) O
J O
. O

In O
_RARE_ I-GENE
- I-GENE
stimulated O
internalization O
assays O
on O
forskolin O
- I-GENE
induced O
_RARE_ I-GENE
- I-GENE
1 I-GENE
cells O
, O
the O
IL I-GENE
- I-GENE
2R I-GENE
alpha I-GENE
chain I-GENE
is O
consistently O
_RARE_ I-GENE
together O
with O
the O
IL I-GENE
- I-GENE
2R I-GENE
beta I-GENE
subunit I-GENE
indicating O
that O
IL I-GENE
- I-GENE
2R I-GENE
alpha I-GENE
is O
stably O
associated I-GENE
with O
the O
_RARE_ I-GENE
- I-GENE
IL I-GENE
- I-GENE
2R I-GENE
beta I-GENE
complex I-GENE
even O
though O
the O
alpha I-GENE
- I-GENE
subunit I-GENE
contributes O
little O
if O
any O
affinity O
to O
the O
_RARE_ I-GENE
binding I-GENE
reaction O
. O

The O
_RARE_ I-GENE
dynamics O
of O
prostaglandin I-GENE
E1 I-GENE
and O
/ I-GENE
or O
_RARE_ I-GENE
and O
their O
different O
reactions O
in O
the O
_RARE_ I-GENE
- I-GENE
and O
_RARE_ I-GENE
state O
of O
_RARE_ I-GENE
shock I-GENE
in O
a O
rat I-GENE
model O

We O
obtained O
the O
prevalence O
of O
IgG I-GENE
antibodies I-GENE
against O
Trypanosoma O
_RARE_ I-GENE
among O
_RARE_ I-GENE
blood O
donors O
at O
the O
_RARE_ I-GENE
_RARE_ I-GENE
de O
_RARE_ I-GENE
" O
_RARE_ I-GENE
_RARE_ I-GENE
" O
in O
_RARE_ I-GENE
City O
. O

Examination O
of O
the O
immediate I-GENE
sequence I-GENE
5 I-GENE
' O
to O
the O
mRNA I-GENE
start O
site I-GENE
reveals O
no O
TATA I-GENE
box I-GENE
and O
multiple O
known O
enhancer I-GENE
sequences I-GENE
. O

The O
short O
- I-GENE
term O
synthesis O
and O
infant O
- I-GENE
regulated O
removal O
of O
milk O
in O
_RARE_ I-GENE
women O
. O

_RARE_ I-GENE
( O
19 O
- I-GENE
36 O
), O
derived O
from O
the O
C I-GENE
- I-GENE
terminus O
of O
Ca I-GENE
- I-GENE
dependent I-GENE
PKC I-GENE
_RARE_ I-GENE
, O
inhibited O
beta I-GENE
- I-GENE
PKC I-GENE
but O
not O
_RARE_ I-GENE
activity O
using O
either O
_RARE_ I-GENE
_RARE_ I-GENE
or O
peptide I-GENE
( O
19 O
- I-GENE
31 O
) O
as O
substrate I-GENE
. O

Based O
on O
these O
results O
, O
a O
new O
model O
for O
the O
regulation O
of O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
gene I-GENE
expression O
in O
A I-GENE
. O
_RARE_ I-GENE
is O
proposed O
. O

_RARE_ I-GENE
oxide I-GENE
inhalation O
selectively O
reduces O
pulmonary O
hypertension O
in O
porcine I-GENE
endotoxin I-GENE
shock I-GENE
and O
_RARE_ I-GENE
arterial O
oxygenation O
and O
pH O
with O
a O
marked O
attenuation O
of O
sympathetic O
activation O
. O

B I-GENE
cell O
- I-GENE
specific I-GENE
_RARE_ I-GENE
- I-GENE
1 I-GENE
and O
_RARE_ I-GENE
genes I-GENE
encode O
the O
alpha I-GENE
/ I-GENE
beta I-GENE
components O
of O
the O
BCR I-GENE
- I-GENE
associated I-GENE
complex I-GENE
in O
mature O
_RARE_ I-GENE
+ I-GENE
B I-GENE
cells O
. O

_RARE_ I-GENE
in O
_RARE_ I-GENE
type I-GENE
theory O
and O
the O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
Type O
_RARE_ I-GENE
. O

A I-GENE
variety O
of O
nuclear I-GENE
_RARE_ I-GENE
are O
believed O
to O
associate O
directly O
with O
_RARE_ I-GENE
RNA I-GENE
polymerase I-GENE
II I-GENE
transcripts I-GENE
and O
_RARE_ I-GENE
associated I-GENE
during O
subsequent O
nuclear I-GENE
RNA I-GENE
processing O
reactions O
, O
including O
pre I-GENE
- I-GENE
mRNA I-GENE
polyadenylation O
and O
splicing O
as O
well O
as O
_RARE_ I-GENE
mRNA I-GENE
transport O
. O

Mutations O
at O
three O
sites I-GENE
have O
larger O
effects O
in O
muscle O
than O
_RARE_ I-GENE
cells O
; O
an O
A I-GENE
/ I-GENE
T I-GENE
- I-GENE
rich O
site I-GENE
mutation I-GENE
has O
a O
pronounced O
effect O
in O
both O
_RARE_ I-GENE
muscle O
types O
, O
mutations O
at O
the O
_RARE_ I-GENE
( O
_RARE_ I-GENE
E I-GENE
- I-GENE
box I-GENE
) O
site I-GENE
are O
relatively O
specific I-GENE
to O
expression O
in O
skeletal I-GENE
muscle O
, O
and O
mutations O
at O
the O
CArG I-GENE
site I-GENE
are O
relatively O
specific I-GENE
to O
expression O
in O
cardiac O
muscle O
. O

Transient O
transfection O
analysis O
with O
these O
mutations O
revealed O
that O
only O
a O
10 O
- I-GENE
bp O
region O
, O
containing O
precisely O
the O
Ets I-GENE
and O
proximal I-GENE
_RARE_ I-GENE
- I-GENE
1 I-GENE
binding I-GENE
sites I-GENE
, O
was O
needed O
for O
D I-GENE
' O
activity O
. O

However O
, O
despite O
its O
relationship O
to O
the O
TR I-GENE
, O
Rev I-GENE
- I-GENE
_RARE_ I-GENE
bound O
poorly O
to O
TR I-GENE
binding I-GENE
sites I-GENE
. O

We O
report O
here O
that O
a O
25 O
- I-GENE
bp O
promoter I-GENE
element I-GENE
previously O
shown O
to O
be O
important O
for O
the O
G1 I-GENE
- I-GENE
S I-GENE
activation O
of O
the O
human I-GENE
thymidine I-GENE
kinase I-GENE
( O
_RARE_ I-GENE
) O
promoter I-GENE
in O
growth I-GENE
- I-GENE
stimulated O
cells O
is O
a O
cellular O
target O
of O
cyclin I-GENE
A I-GENE
and O
the O
_RARE_ I-GENE
complexes I-GENE
. O

These O
protective O
influences O
were O
observed O
throughout O
the O
range O
of O
filling O
pressures O
measured O
, O
from O
0 O
to O
30 O
mmHg O
. O

DNase I-GENE
I I-GENE
footprinting O
with O
rat I-GENE
liver O
nuclear I-GENE
extracts O
identified O
7 O
major I-GENE
protein I-GENE
- I-GENE
binding I-GENE
domains I-GENE
termed O
P1 I-GENE
through O
P7 I-GENE
in O
a O
_RARE_ I-GENE
base O
pair O
DNA I-GENE
fragment I-GENE
( O
base O
pairs O
- I-GENE
_RARE_ I-GENE
to O
+ I-GENE
33 O
). O

This O
may O
account O
, O
at O
least O
in O
part O
, O
for O
the O
ability O
of O
excess O
wt I-GENE
p53 I-GENE
to O
inhibit O
cell O
proliferation O
and O
to O
_RARE_ I-GENE
with O
neoplastic O
processes O
. O

Neither O
clone O
encoded I-GENE
the O
cognate I-GENE
endonuclease I-GENE
. O

Northern O
blot O
analysis O
of O
total O
cellular O
RNA I-GENE
indicated O
that O
_RARE_ I-GENE
encodes O
a O
1 I-GENE
. O
3 I-GENE
- I-GENE
kb O
transcript I-GENE
which O
is O
induced O
by O
_RARE_ I-GENE
. O

The O
_RARE_ I-GENE
and O
_RARE_ I-GENE
promoters I-GENE
of O
Klebsiella I-GENE
pneumoniae I-GENE
are O
divergently O
transcribed O
sigma I-GENE
54 I-GENE
- I-GENE
dependent I-GENE
promoters I-GENE
that O
are O
positively O
activated I-GENE
by O
the O
_RARE_ I-GENE
protein I-GENE
. O

These O
data O
show O
that O
PTH I-GENE
and O
cAMP I-GENE
can O
repress O
collagen I-GENE
promoter I-GENE
activity O
in O
_RARE_ I-GENE
from O
transgenic O
mice O
, O
suggesting O
that O
the O
alpha I-GENE
1 I-GENE
( O
I I-GENE
) O
collagen I-GENE
promoter I-GENE
may O
contain O
cis O
elements O
down O
- I-GENE
_RARE_ I-GENE
of O
- I-GENE
2 I-GENE
. O
3 I-GENE
kilobases O
that O
mediate O
PTH I-GENE
and O
cAMP I-GENE
repression O
of O
collagen I-GENE
gene I-GENE
expression O
in O
bone O
. O

Both O
inhaled O
and O
_RARE_ I-GENE
isoflurane O
_RARE_ I-GENE
the O
baseline O
vein O
diameter O
before O
stimulation O
. O

_RARE_ I-GENE
of O
rheumatoid I-GENE
arthritis O
and O
rheumatoid I-GENE
factor I-GENE
in O
women O
: O
evidence O
for O
a O
_RARE_ I-GENE
decline O
. O

Although O
olfactory O
_RARE_ I-GENE
conditioning O
in O
newborn O
rats O
produces O
marked O
structural O
and O
functional O
changes O
in O
the O
olfactory O
bulb O
, O
recent O
evidence O
suggests O
that O
_RARE_ I-GENE
_RARE_ I-GENE
must O
be O
involved O
in O
_RARE_ I-GENE
these O
early I-GENE
_RARE_ I-GENE
. O

The O
fission I-GENE
yeast I-GENE
_RARE_ I-GENE
+ I-GENE
gene I-GENE
, O
a O
multicopy O
suppressor I-GENE
for O
cold O
- I-GENE
sensitive O
_RARE_ I-GENE
mutants I-GENE
, O
encodes O
a O
novel O
61 O
- I-GENE
_RARE_ I-GENE
protein I-GENE
kinase I-GENE
. O

_RARE_ I-GENE
of O
the O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
with O
a O
_RARE_ I-GENE
through O
a O
_RARE_ I-GENE
. O

Sequence O
comparison O
between O
the O
translated O
ORF I-GENE
and O
a O
protein I-GENE
database O
reveal O
between O
26 O
. O
5 I-GENE
and O
23 O
. O
4 I-GENE
% O
aa O
sequence I-GENE
homology I-GENE
to O
bacterial I-GENE
transmembrane I-GENE
( O
TM I-GENE
) O
proteins I-GENE
including O
those O
mediating O
chloramphenicol I-GENE
( O
_RARE_ I-GENE
) O
and O
_RARE_ I-GENE
( O
Tc O
) O
resistance O
and O
an O
_RARE_ I-GENE
- I-GENE
proton I-GENE
_RARE_ I-GENE
protein I-GENE
. O

The O
yeast I-GENE
gene I-GENE
that O
encodes O
eIF I-GENE
- I-GENE
5 I-GENE
, O
designated O
_RARE_ I-GENE
, O
has O
been O
isolated O
and O
expressed O
in O
Escherichia I-GENE
coli I-GENE
to O
yield O
a O
catalytically O
active O
eIF I-GENE
- I-GENE
5 I-GENE
protein I-GENE
. O

The O
strategies O
by O
which O
hepatitis I-GENE
B I-GENE
and O
hepatitis I-GENE
D I-GENE
can O
be O
diminished O
and O
_RARE_ I-GENE
_RARE_ I-GENE
are O
: O
immunization O
, O
measures O
to O
prevent O
exposure O
to O
_RARE_ I-GENE
blood O
or O
blood O
derivatives O
and O
education O
( O
in O
particular O
_RARE_ I-GENE
that O
hepatitis I-GENE
B I-GENE
is O
a O
_RARE_ I-GENE
transmitted O
disease O
). O

_RARE_ I-GENE
- I-GENE
and O
_RARE_ I-GENE
- I-GENE
containing O
polymers O
were O
better O
_RARE_ I-GENE
than O
was O
_RARE_ I-GENE
for O
both O
_RARE_ I-GENE
. O

The O
_RARE_ I-GENE
construction I-GENE
of O
the O
mouth O
_RARE_ I-GENE
is O
_RARE_ I-GENE
, O
as O
is O
the O
need O
for O
_RARE_ I-GENE
and O
its O
costs O
and O
the O
materials O
required O
to O
_RARE_ I-GENE
these O
mouth O
_RARE_ I-GENE
. O

The O
alpha I-GENE
- I-GENE
subunit I-GENE
by O
itself O
binds O
to O
telomeric O
DNA I-GENE
. O

We O
conclude O
that O
the O
alpha I-GENE
- I-GENE
subunit I-GENE
of O
the O
telomere I-GENE
- I-GENE
binding I-GENE
protein I-GENE
, O
like I-GENE
many O
transcription I-GENE
factors I-GENE
, O
has O
_RARE_ I-GENE
DNA I-GENE
- I-GENE
binding I-GENE
and O
protein I-GENE
- I-GENE
protein I-GENE
interaction O
domains I-GENE
. O

Three O
patients O
had O
well O
-, I-GENE
6 I-GENE
patients O
had O
moderately O
-, I-GENE
and O
5 I-GENE
patients O
had O
poorly O
- I-GENE
differentiated O
adenocarcinoma O
of O
the O
prostate O
. O

_RARE_ I-GENE
burst O
_RARE_ I-GENE
in O
cat O
primary O
auditory O
cortex O
: O
age O
and O
depth O
dependence O
and O
its O
effect O
on O
neural O
interaction O
measures O
. O

By O
applying O
the O
_RARE_ I-GENE
method O
, O
in O
aqueous O
medium O
of O
ionic O
strength O
mu I-GENE
= O
0 O
. O
2 I-GENE
, O
the O
stability O
constants O
, O
log O
beta I-GENE
1 I-GENE
= O
4 I-GENE
. O
42 O
and O
log O
beta I-GENE
2 I-GENE
= O
8 O
. O
57 O
were O
obtained O
. O

_RARE_ I-GENE
_RARE_ I-GENE
filled O
with O
media O
plus O
additive O
are O
_RARE_ I-GENE
below O
the O
surface O
of O
an O
_RARE_ I-GENE
donor O
_RARE_ I-GENE
. O

The O
bcl I-GENE
- I-GENE
2 I-GENE
gene I-GENE
can O
potentially O
encode O
26 O
- I-GENE
and O
22 O
- I-GENE
kDa I-GENE
proteins I-GENE
that O
differ O
only O
in O
their O
carboxyl O
tails O
because O
of O
an O
alternative O
splicing O
mechanism O
. O

The O
active O
open O
reading O
frame O
in O
the O
clone O
maps O
at O
27 O
min O
on O
the O
E I-GENE
. O
coli I-GENE
chromosome O
and O
is O
identical O
in O
sequence I-GENE
to O
a O
wild I-GENE
type I-GENE
counterpart O
. O

_RARE_ I-GENE
cloning O
and O
nucleotide I-GENE
sequence I-GENE
analysis O
of O
the O
S I-GENE
. O
pombe I-GENE
adenylate I-GENE
kinase I-GENE
gene I-GENE
, O
_RARE_ I-GENE
, O
revealed O
a O
coding O
region O
of O
_RARE_ I-GENE
nucleotides O
. O

_RARE_ I-GENE
of O
a O
_RARE_ I-GENE
Streptococcus I-GENE
and O
of O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
_RARE_ I-GENE
. O

As O
a O
result O
of O
alternative O
splicing O
, O
the O
_RARE_ I-GENE
gene I-GENE
is O
transcribed O
into O
at O
least O
seven O
distinct O
mRNA I-GENE
species O
. O

A I-GENE
comparison O
of O
the O
promoters I-GENE
for O
_RARE_ I-GENE
- I-GENE
1 I-GENE
beta I-GENE
and O
_RARE_ I-GENE
- I-GENE
1 I-GENE
alpha I-GENE
reveals O
a O
conserved O
CK I-GENE
- I-GENE
1 I-GENE
element I-GENE
, O
but O
transient O
expression O
studies O
in O
_RARE_ I-GENE
264 O
. O
7 O
macrophages O
with O
proximal I-GENE
fragments I-GENE
of O
either O
the O
_RARE_ I-GENE
- I-GENE
1 I-GENE
beta I-GENE
or O
the O
_RARE_ I-GENE
- I-GENE
1 I-GENE
alpha I-GENE
5 I-GENE
' O
promoter I-GENE
fused O
to O
a O
human I-GENE
growth I-GENE
hormone I-GENE
reporter I-GENE
gene I-GENE
link I-GENE
LPS I-GENE
- I-GENE
inducibility O
in O
both O
to O
promoter I-GENE
segments O
near O
to O
, O
but O
not O
identical O
with O
, O
the O
consensus I-GENE
CK I-GENE
- I-GENE
1 I-GENE
sequence I-GENE
. O

However O
, O
essential O
contrast O
differences O
existing O
between O
the O
_RARE_ I-GENE
sequences I-GENE
and O
their O
routine O
asymmetric O
dual O
SE O
counterpart O
can O
be O
identified O
. O

Sequence O
analysis O
and O
identification O
of O
two O
_RARE_ I-GENE
regulatory I-GENE
mutants I-GENE
. O

The O
gene I-GENE
encoding O
the O
receptor I-GENE
for O
macrophage I-GENE
colony I-GENE
- I-GENE
stimulating I-GENE
factor I-GENE
1 I-GENE
( O
CSF I-GENE
- I-GENE
1 I-GENE
), O
the O
c I-GENE
- I-GENE
fms I-GENE
protooncogene I-GENE
, O
is O
selectively O
expressed O
in O
immature O
and O
mature O
mononuclear O
_RARE_ I-GENE
and O
_RARE_ I-GENE
. O

The O
level O
of O
the O
_RARE_ I-GENE
transcript I-GENE
was O
threefold O
higher O
in O
the O
_RARE_ I-GENE
- I-GENE
1 I-GENE
mutant I-GENE
than O
in O
the O
wild I-GENE
type I-GENE
. O

This O
sequence I-GENE
similarity O
_RARE_ I-GENE
the O
possibility O
that O
_RARE_ I-GENE
interacts O
with O
_RARE_ I-GENE
or O
tRNA I-GENE
molecules I-GENE
and O
functions O
in O
conjunction O
with O
GCN2 I-GENE
in O
monitoring O
_RARE_ I-GENE
tRNA I-GENE
levels O
during O
the O
process O
of O
translation I-GENE
elongation I-GENE
. O

NF I-GENE
- I-GENE
HB I-GENE
( O
_RARE_ I-GENE
) O
is O
a O
repressor I-GENE
of O
the O
murine I-GENE
immunoglobulin I-GENE
heavy I-GENE
- I-GENE
chain I-GENE
3 I-GENE
' O
alpha I-GENE
enhancer I-GENE
at O
early I-GENE
stages O
of O
B I-GENE
- I-GENE
cell O
differentiation O
. O

Since O
the O
regulation O
of O
SWI4 I-GENE
is O
required O
for O
normal O
cell O
cycle O
progression O
, O
we O
have O
characterized O
cis O
- I-GENE
and O
trans O
- I-GENE
acting O
regulators O
of O
SWI4 I-GENE
transcription I-GENE
. O

It O
also O
suggests O
that O
there O
is O
another O
pathway O
which O
can O
activate O
SWI4 I-GENE
transcription I-GENE
in O
the O
absence O
of O
_RARE_ I-GENE
. O

Multiple O
_RARE_ I-GENE
- I-GENE
dependent I-GENE
cis O
- I-GENE
acting O
elements O
control O
SWI4 I-GENE
transcription I-GENE
through O
the O
cell O
cycle O
. O

In O
conclusion O
, O
changes O
in O
carotid O
sinus O
stimulation O
alters O
blood O
flow O
to O
the O
_RARE_ I-GENE
through O
changes O
in O
both O
_RARE_ I-GENE
and O
_RARE_ I-GENE
. O

_RARE_ I-GENE
PRK O
has O
been O
suggested O
to O
increase O
the O
_RARE_ I-GENE
of O
higher O
_RARE_ I-GENE
_RARE_ I-GENE
. O

In O
17 O
patients O
with O
deletions O
, O
the O
parental O
origin O
of O
deletion O
was O
determined O
. O

The O
_RARE_ I-GENE
gene I-GENE
, O
which O
encodes O
type I-GENE
VII I-GENE
collagen I-GENE
, O
has O
been O
implicated O
as O
a O
candidate O
gene I-GENE
for O
_RARE_ I-GENE
and O
_RARE_ I-GENE
inherited O
forms O
of O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
. O

However O
, O
study O
of O
the O
_RARE_ I-GENE
gamma I-GENE
gene I-GENE
showed O
that O
the O
_RARE_ I-GENE
variable O
exon O
was O
_RARE_ I-GENE
by O
normal O
splicing O
signals O
and O
that O
the O
adjacent O
intron O
organization O
was O
not O
altered O
. O

We O
conclude O
that O
grade O
III I-GENE
_RARE_ I-GENE
can O
be O
treated O
by O
modified O
_RARE_ I-GENE
excision O
provided O
the O
_RARE_ I-GENE
_RARE_ I-GENE
and O
part O
of O
the O
_RARE_ I-GENE
are O
intact O
. O

Second O
, O
nitrate I-GENE
induction O
of O
_RARE_ I-GENE
- I-GENE
46 O
. O
5 I-GENE
operon I-GENE
expression O
is O
substantially O
enhanced O
in O
_RARE_ I-GENE
null I-GENE
strains O
( O
M I-GENE
. O
H I-GENE
. O

This O
new O
knowledge O
has O
contributed O
to O
the O
development O
of O
a O
successful O
_RARE_ I-GENE
strategy O
for O
_RARE_ I-GENE
_RARE_ I-GENE
disease O
. O

The O
HMG I-GENE
CoA I-GENE
reductase I-GENE
inhibitors O
are O
the O
most O
effective O
cholesterol I-GENE
- I-GENE
lowering O
agents O
currently O
available O
. O

The O
etiology O
, O
pathology O
, O
brain O
CT I-GENE
scan O
features O
, O
clinical O
manifestations O
and O
treatment O
of O
these O
_RARE_ I-GENE
were O
discussed O
. O

Drosophila I-GENE
_RARE_ I-GENE
- I-GENE
kD I-GENE
TFIID I-GENE
subunit I-GENE
, O
a O
functional O
homolog I-GENE
of O
the O
human I-GENE
cell O
cycle O
gene I-GENE
product I-GENE
, O
negatively O
regulates O
DNA I-GENE
binding I-GENE
of O
the O
TATA I-GENE
box I-GENE
- I-GENE
binding I-GENE
subunit I-GENE
of O
TFIID I-GENE
. O

One O
_RARE_ I-GENE
_RARE_ I-GENE
of O
GATA I-GENE
factor I-GENE
expression O
is O
that O
several O
GATA I-GENE
proteins I-GENE
, O
which O
_RARE_ I-GENE
share O
the O
same O
DNA I-GENE
- I-GENE
binding I-GENE
site I-GENE
specificity O
, O
are O
coexpressed O
in O
erythroid I-GENE
cells O
. O

Pit I-GENE
- I-GENE
1 I-GENE
is O
a O
tissue I-GENE
- I-GENE
specific I-GENE
POU I-GENE
domain I-GENE
factor I-GENE
_RARE_ I-GENE
for O
the O
appearance O
of O
three O
cell O
phenotypes O
in O
the O
anterior O
pituitary I-GENE
gland O
. O

_RARE_ I-GENE
number O
of O
strains O
( O
39 O
. O
1 I-GENE
%) O
were O
resistant O
in O
S I-GENE
. O
_RARE_ I-GENE
serotype I-GENE
, O
followed O
by O
S I-GENE
. O
_RARE_ I-GENE
( O
21 O
. O
7 O
%) O
and O
least O
in O
S I-GENE
. O
_RARE_ I-GENE
( O
17 O
. O
4 I-GENE
%). O

Biol O
. O

Characterization O
and O
hormonal O
regulation O
of O
the O
promoter I-GENE
of O
the O
rat I-GENE
prostaglandin I-GENE
_RARE_ I-GENE
synthase I-GENE
2 I-GENE
gene I-GENE
in O
_RARE_ I-GENE
cells O
. O

The O
retention O
of O
_RARE_ I-GENE
was O
low O
. O

_RARE_ I-GENE
characteristics O
associated I-GENE
with O
deep O
_RARE_ I-GENE
as O
well O
as O
patient O
and O
wound O
characteristics O
predictive O
of O
the O
extent O
of O
healing O
and O
time O
required O
for O
healing O
were O
identified O
. O

Members O
of O
the O
C I-GENE
/ I-GENE
EBP I-GENE
family I-GENE
of O
basic I-GENE
- I-GENE
leucine I-GENE
zipper I-GENE
( O
_RARE_ I-GENE
) O
transcription I-GENE
factors I-GENE
form O
heterodimers I-GENE
and O
bind O
to O
the O
CAAT I-GENE
box I-GENE
and O
other O
sequence I-GENE
- I-GENE
related I-GENE
enhancer I-GENE
motifs O
. O

In O
mammalian I-GENE
cells O
, O
phosphorylation O
of O
eIF I-GENE
- I-GENE
2 I-GENE
alpha I-GENE
inhibits O
the O
activity O
of O
eIF I-GENE
- I-GENE
2B I-GENE
, O
the O
GDP I-GENE
- I-GENE
GTP I-GENE
exchange I-GENE
factor I-GENE
for O
eIF I-GENE
- I-GENE
2 I-GENE
. O

In O
conclusion O
, O
these O
observations O
demonstrated O
that O
_RARE_ I-GENE
of O
acute O
MI O
patients O
by O
plasma I-GENE
_RARE_ I-GENE
level O
is O
a O
useful O
non O
- I-GENE
invasive O
method O
for O
predicting O
prognosis O
and O
for O
identifying O
individuals O
at O
high O
risk O
of O
cardiac O
death O
. O

Analysis O
of O
the O
binding I-GENE
of O
_RARE_ I-GENE
to O
a O
set O
of O
_RARE_ I-GENE
_RARE_ I-GENE
DNA I-GENE
fragments I-GENE
from O
this O
region O
indicates O
that O
_RARE_ I-GENE
induces O
DNA I-GENE
_RARE_ I-GENE
. O

Yeast I-GENE
mutants I-GENE
lacking O
a O
functional O
_RARE_ I-GENE
gene I-GENE
can O
be O
complemented O
by O
human I-GENE
_RARE_ I-GENE
but O
are O
temperature O
sensitive O
for O
growth I-GENE
and O
impaired O
in O
pre I-GENE
- I-GENE
rRNA I-GENE
processing O
. O

The O
patients O
were O
divided O
into O
ischaemia O
and O
non O
- I-GENE
ischaemia O
groups O
on O
the O
basis O
of O
the O
change O
in O
lactate I-GENE
extraction O
ratio O
during O
_RARE_ I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
out O
of O
34 O
patients O
died O
, O
giving O
a O
mortality O
rate O
of O
21 O
%. O

A I-GENE
36 O
- I-GENE
kDa I-GENE
protein I-GENE
that O
was O
localized O
to O
the O
membrane I-GENE
fraction O
was O
detected O
in O
_RARE_ I-GENE
containing O
plasmids O
with O
the O
_RARE_ I-GENE
gene I-GENE
, O
confirming O
that O
_RARE_ I-GENE
was O
a O
membrane I-GENE
protein I-GENE
. O

_RARE_ I-GENE
, O
a O
gene I-GENE
encoding O
a O
sporulation I-GENE
- I-GENE
specific I-GENE
1 I-GENE
, O
3 I-GENE
- I-GENE
beta I-GENE
- I-GENE
_RARE_ I-GENE
in O
Saccharomyces I-GENE
cerevisiae I-GENE
. O

Expression O
of O
this O
protein I-GENE
in O
E I-GENE
. O
coli I-GENE
demonstrated O
that O
tyrosine I-GENE
was O
incorporated O
during O
suppression O
and O
that O
yeast I-GENE
cytoplasmic I-GENE
_RARE_ I-GENE
activity O
was O
produced O
. O

The O
first O
involved O
complementation O
of O
a O
_RARE_ I-GENE
mutant I-GENE
of O
_RARE_ I-GENE
, O
CC O
- I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
g O
- I-GENE
2 I-GENE
. O
3 I-GENE
), O
which O
has O
a O
frameshift O
mutation I-GENE
in O
the O
_RARE_ I-GENE
gene I-GENE
, O
and O
selection O
of O
_RARE_ I-GENE
transformants O
on O
minimal I-GENE
medium O
. O

_RARE_ I-GENE
200 O
strains O
of O
_RARE_ I-GENE
- I-GENE
resistant O
Staphylococcus I-GENE
aureus I-GENE
( O
_RARE_ I-GENE
) O
isolated O
from O
1990 O
to O
1991 O
, O
minimum O
inhibitory I-GENE
concentrations O
( O
MICs O
) O
of O
a O
total O
of O
15 O
_RARE_ I-GENE
agents O
including O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
were O
determined O
. O

It O
is O
reported O
that O
, O
at O
present O
, O
most O
of O
the O
_RARE_ I-GENE
_RARE_ I-GENE
in O
Japan O
are O
_RARE_ I-GENE
_RARE_ I-GENE
resistance O
to O
many O
drugs O
, O
and O
especially O
, O
they O
are O
developing O
high O
resistance O
against O
beta I-GENE
- I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
and O
_RARE_ I-GENE
are O
regulated O
differently O
which O
may O
indicate O
variation O
in O
storage O
or O
utilization O
properties O
among O
the O
barley I-GENE
_RARE_ I-GENE
. O

Here O
, O
we O
have O
more O
closely O
investigated O
transactivation O
of O
the O
human I-GENE
HSP70 I-GENE
promoter I-GENE
by O
Myb I-GENE
proteins I-GENE
. O

We O
have O
found O
out O
that O
one O
- I-GENE
year O
- I-GENE
old O
_RARE_ I-GENE
are O
extremely O
sensitive O
to O
_RARE_ I-GENE
in O
concentrations O
between O
25 O
- I-GENE
125 I-GENE
micrograms O
/ I-GENE
_RARE_ I-GENE
. O

RESULTS O
: O
_RARE_ I-GENE
significant O
differences O
were O
obtained O
between O
group O
I I-GENE
and O
II I-GENE
concerning O
the O
number O
of O
patients O
in O
whom O
induced O
atrial I-GENE
fibrillation O
with O
conduction O
by O
the O
accessory I-GENE
pathway O
and O
RR O
< O
or O
= O
250 O
msec O
was O
found O
( O
0 O
vs O
6 I-GENE
, O
p O
= O
0 O
. O
_RARE_ I-GENE
). O

We O
studied O
the O
effect O
of O
_RARE_ I-GENE
thickness O
on O
the O
correlation O
between O
serum I-GENE
total O
bilirubin O
level O
and O
_RARE_ I-GENE
bilirubin O
( O
_RARE_ I-GENE
) O
_RARE_ I-GENE
. O

Both O
_RARE_ I-GENE
may O
have O
important O
roles O
in O
receptor I-GENE
assembly O
and O
may O
represent O
a O
new O
category O
of O
ligand O
- I-GENE
and O
calcium O
- I-GENE
dependent I-GENE
_RARE_ I-GENE
of O
protein I-GENE
function O
. O

The O
GTPase I-GENE
activity O
of O
_RARE_ I-GENE
is O
moderately O
stimulated O
by O
human I-GENE
n O
- I-GENE
_RARE_ I-GENE
, O
a O
GTPase I-GENE
- I-GENE
activating I-GENE
protein I-GENE
for O
the O
related I-GENE
p21 I-GENE
_RARE_ I-GENE
. O

Tl O
- I-GENE
201 O
uptake O
ratio O
of O
the O
right O
ventricle O
, O
which O
represents O
the O
ratio O
of O
total O
counts O
of O
the O
right O
ventricle O
to O
counts O
of O
the O
administered O
dose O
of O
Tl O
- I-GENE
201 O
, O
was O
higher O
in O
COPD O
, O
especially O
in O
pulmonary O
emphysema O
and O
B I-GENE
type I-GENE
COPD O
by O
_RARE_ I-GENE
classification O
than O
in O
controls O
. O

A I-GENE
second O
hydrophobic O
domain I-GENE
, O
_RARE_ I-GENE
by O
two O
hydrophilic O
regions O
strongly O
suggests O
a O
transmembrane I-GENE
region O
. O

This O
gene I-GENE
spans O
23 O
kb O
and O
is O
composed O
of O
five O
exons O
and O
four O
introns O
. O

The O
remaining O
_RARE_ I-GENE
+ I-GENE
cells O
progressed O
to O
form O
_RARE_ I-GENE
(< O
30 O
cells O
) O
containing O
_RARE_ I-GENE
shaped O
_RARE_ I-GENE
cells O
. O

The O
11 O
; O
22 O
chromosomal I-GENE
translocation O
specifically O
linked O
to O
_RARE_ I-GENE
sarcoma I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
tumor I-GENE
results O
in O
a O
chimeric I-GENE
molecule I-GENE
_RARE_ I-GENE
the O
amino O
- I-GENE
terminal I-GENE
- I-GENE
encoding O
portion O
of O
the O
EWS I-GENE
gene I-GENE
to O
the O
carboxyl O
- I-GENE
terminal I-GENE
DNA I-GENE
- I-GENE
binding I-GENE
domain I-GENE
encoded I-GENE
by O
the O
FLI1 I-GENE
gene I-GENE
. O

These O
findings O
suggest O
that O
a O
range O
of O
_RARE_ I-GENE
conditions O
exist O
within O
purified O
water O
systems O
, O
leading O
to O
variable O
populations O
of O
bacteria O
. O

X I-GENE
- I-GENE
linked O
liver O
_RARE_ I-GENE
: O
localization O
and O
isolation O
of O
a O
candidate O
gene I-GENE
. O

This O
conclusion O
is O
based O
on O
the O
observations O
of O
the O
immunologic O
changes O
that O
characterize O
the O
acute O
stages O
of O
illness O
as O
well O
as O
on O
the O
demonstrated O
association O
with O
toxin I-GENE
- I-GENE
producing O
bacteria O
in O
the O
_RARE_ I-GENE
and O
gastrointestinal O
tract O
. O

Measurement O
of O
anti I-GENE
- I-GENE
HCV I-GENE
IgM I-GENE
antibodies I-GENE
with O
an O
experimental O
kit I-GENE

_RARE_ I-GENE
_RARE_ I-GENE
system O
may O
contribute O
to O
understand O
the O
mechanisms O
underlying O
the O
decrease O
of O
fertility O
with O
aging O
. O

These O
cell O
lines O
displayed O
methylation O
of O
the O
CpG O
island O
surrounding O
the O
first O
exon O
of O
_RARE_ I-GENE
and O
expressed O
abundant O
levels O
of O
a O
_RARE_ I-GENE
mRNA I-GENE
containing O
an O
alternative O
first O
exon O
( O
E1 I-GENE
beta I-GENE
), O
as O
did O
all O
other O
cell O
lines O
in O
which O
the O
_RARE_ I-GENE
locus I-GENE
was O
not O
deleted O
. O

An O
_RARE_ I-GENE
reaction O
, O
_RARE_ I-GENE
method O
, O
with O
the O
antiserum O
of O
Factor I-GENE
VIII I-GENE
as O
the O
primary O
antibody I-GENE
, O
was O
carried O
out O
in O
the O
endometrial O
biopsies O
to O
detect O
the O
Factor I-GENE
VIII I-GENE
activity O
in O
the O
endometrial O
endothelium O
before O
and O
after O
insertion O
of O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
20 O
. O

_RARE_ I-GENE
. O

_RARE_ I-GENE
is O
homologous O
to O
human I-GENE
_RARE_ I-GENE
, O
recently O
identified O
as O
the O
beta I-GENE
subunit I-GENE
of O
the O
heterodimeric I-GENE
_RARE_ I-GENE
- I-GENE
polypeptide I-GENE
- I-GENE
associated I-GENE
complex I-GENE
( O
_RARE_ I-GENE
) O
involved O
in O
_RARE_ I-GENE
signal I-GENE
- I-GENE
sequence I-GENE
- I-GENE
specific I-GENE
protein I-GENE
sorting I-GENE
and O
translocation O
[ O
_RARE_ I-GENE
et O
al O
., O
_RARE_ I-GENE
_RARE_ I-GENE
( O
1994 O
) O
_RARE_ I-GENE
- I-GENE
440 O
]. O

Purified I-GENE
_RARE_ I-GENE
showed O
optimal O
lyase I-GENE
activity O
at O
pH O
10 O
. O
0 O
. O

The O
5 I-GENE
' O
flanking O
regions O
of O
both O
_RARE_ I-GENE
and O
_RARE_ I-GENE
were O
_RARE_ I-GENE
fused O
to O
the O
beta I-GENE
- I-GENE
glucuronidase I-GENE
gene I-GENE
and O
introduced O
into O
F I-GENE
. O
_RARE_ I-GENE
f I-GENE
. O
sp O
. O
_RARE_ I-GENE
, O
and O
beta I-GENE
- I-GENE
glucuronidase I-GENE
activities O
of O
the O
transformants O
were O
measured O
. O

When O
_RARE_ I-GENE
mRNA I-GENE
5 I-GENE
' O
start O
points O
were O
mapped O
by O
primer O
extension O
, O
both O
a O
minor O
upstream O
transcript I-GENE
( O
s O
) O
starting O
45 O
bp O
distal O
to O
the O
_RARE_ I-GENE
and O
a O
major I-GENE
downstream O
transcript I-GENE
starting O
10 O
bp O
distal O
to O
the O
sigma I-GENE
54 I-GENE
box I-GENE
were O
observed O
. O

We O
failed O
to O
find O
these O
data O
to O
be O
useful O
in O
predicting O
the O
time O
of O
onset O
of O
initial O
seizures O
after O
acute O
ischemic O
stroke O
and O
recurrence O
. O

The O
human I-GENE
papillomavirus I-GENE
type I-GENE
16 O
E7 I-GENE
protein I-GENE
_RARE_ I-GENE
adenovirus I-GENE
type I-GENE
5 I-GENE
E1A I-GENE
amino O
- I-GENE
terminus O
- I-GENE
dependent I-GENE
transactivation O
of O
adenovirus I-GENE
type I-GENE
5 I-GENE
early I-GENE
genes I-GENE
and O
increases O
ATF I-GENE
and O
Oct I-GENE
- I-GENE
1 I-GENE
DNA I-GENE
binding I-GENE
activity O
. O

A I-GENE
_RARE_ I-GENE
detergent O
, O
0 O
. O
1 I-GENE
% O
_RARE_ I-GENE
P I-GENE
- I-GENE
40 I-GENE
, O
also O
abolished O
the O
interaction O
, O
further O
supporting O
the O
hydrophobic O
nature O
of O
the O
interaction O
. O

_RARE_ I-GENE
to O
_RARE_ I-GENE
, O
we O
find O
a O
relatively O
high O
level O
of O
variation O
in O
the O
_RARE_ I-GENE
2 I-GENE
enhancer I-GENE
region O
, O
including O
point O
substitutions O
and O
insertion O
/ I-GENE
deletions O
in O
binding I-GENE
sites I-GENE
, O
and O
a O
comparable O
level O
of O
variation O
in O
the O
other O
noncoding O
regions O
. O

_RARE_ I-GENE
of O
the O
soybean I-GENE
_RARE_ I-GENE
- I-GENE
1 I-GENE
, O
5 I-GENE
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
small I-GENE
- I-GENE
subunit I-GENE
mRNA I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
with O
_RARE_ I-GENE
cleavage O
. O

Cloning O
and O
sequencing O
revealed O
that O
_RARE_ I-GENE
contains O
a O
deletion O
spanning O
the O
basic I-GENE
region O
and O
helix I-GENE
1 I-GENE
and O
the O
loop I-GENE
of O
the O
helix I-GENE
- I-GENE
loop I-GENE
- I-GENE
helix I-GENE
region O
, O
presumably O
as O
a O
result O
of O
alternative O
splicing O
of O
max O
RNA I-GENE
. O

I I-GENE
report O
here O
that O
induction O
of O
_RARE_ I-GENE
is O
regulated O
by O
the O
early I-GENE
meiotic I-GENE
IME1 I-GENE
- I-GENE
_RARE_ I-GENE
transcriptional O
cascade O
. O

The O
domain I-GENE
structure O
of O
bovine I-GENE
_RARE_ I-GENE
- I-GENE
2 I-GENE
is O
very O
similar O
to O
that O
of O
the O
human I-GENE
_RARE_ I-GENE
- I-GENE
2 I-GENE
, O
containing O
20 O
examples O
of O
6 I-GENE
- I-GENE
cysteine I-GENE
epidermal I-GENE
growth I-GENE
factor I-GENE
- I-GENE
like I-GENE
repeats I-GENE
, O
16 O
of O
which O
have O
the O
consensus I-GENE
sequence I-GENE
for O
calcium O
binding I-GENE
, O
together O
with O
4 I-GENE
examples O
of O
8 O
- I-GENE
cysteine I-GENE
motifs O
characteristic O
of O
_RARE_ I-GENE
and O
_RARE_ I-GENE
- I-GENE
1 I-GENE
. O

Similarly O
, O
expression O
of O
a O
transiently O
transfected O
wild I-GENE
- I-GENE
type I-GENE
_RARE_ I-GENE
alpha I-GENE
gene I-GENE
as O
the O
reporter I-GENE
was O
not O
affected O
by O
a O
_RARE_ I-GENE
of O
myc I-GENE
- I-GENE
derived O
genes I-GENE
, O
including O
myc I-GENE
itself O
and O
dominant I-GENE
or O
recessive O
negative O
myc I-GENE
mutants I-GENE
. O

Differential O
regulation O
of O
the O
alpha I-GENE
/ I-GENE
beta I-GENE
interferon I-GENE
- I-GENE
stimulated O
Jak I-GENE
/ I-GENE
Stat I-GENE
pathway O
by O
the O
SH2 I-GENE
domain I-GENE
- I-GENE
containing O
tyrosine I-GENE
phosphatase I-GENE
_RARE_ I-GENE
. O

We O
now O
report O
the O
isolation O
and O
expression O
of O
cDNAs I-GENE
encoding O
_RARE_ I-GENE
gamma I-GENE
and O
_RARE_ I-GENE
delta I-GENE
, O
as O
well O
as O
functional O
studies O
with O
cognate I-GENE
antibodies I-GENE
that O
recognize O
the O
native O
_RARE_ I-GENE
complex I-GENE
in O
HeLa O
extracts O
. O

Results O
from O
the O
mechanism O
study O
have O
revealed O
that O
YY1 I-GENE
is O
able O
to O
inhibit O
transactivation O
mediated O
by O
either O
AP1 I-GENE
or O
the O
Sp1 I-GENE
- I-GENE
related I-GENE
protein I-GENE
, O
and O
YY1 I-GENE
_RARE_ I-GENE
activity O
is O
DNA I-GENE
binding I-GENE
dependent I-GENE
. O

The O
_RARE_ I-GENE
+ I-GENE
gene I-GENE
is O
not O
essential O
. O

The O
_RARE_ I-GENE
( O
_RARE_ I-GENE
enhancer I-GENE
activator I-GENE
) O
gene I-GENE
sequence I-GENE
predicts O
a O
protein I-GENE
of O
86 I-GENE
. O
9 O
kDa I-GENE
whose O
N I-GENE
terminus O
contains O
a O
zinc I-GENE
cluster I-GENE
and O
dimerization O
motif I-GENE
typical O
of O
the O
Gal4 I-GENE
- I-GENE
type I-GENE
family I-GENE
of O
DNA I-GENE
- I-GENE
binding I-GENE
proteins I-GENE
. O

_RARE_ I-GENE
living O
in O
_RARE_ I-GENE
and O
_RARE_ I-GENE
to O
_RARE_ I-GENE
considered O
their O
health O
as O
_RARE_ I-GENE
in O
a O
higher O
proportion O
than O
their O
_RARE_ I-GENE
counterparts O
, O
with O
an O
odds O
ratio O
of O
3 I-GENE
. O
48 O
( O
2 I-GENE
. O
03 O
- I-GENE
5 I-GENE
. O
66 O
) O
and O
4 I-GENE
. O
78 O
( O
2 I-GENE
. O
1 I-GENE
- I-GENE
10 O
. O
25 O
) O
respectively O
. O

This O
study O
_RARE_ I-GENE
the O
importance O
of O
terminal I-GENE
_RARE_ I-GENE
- I-GENE
9 O
complement I-GENE
complex I-GENE
as O
a O
suitable O
marker O
in O
the O
evaluation O
of O
complement I-GENE
activation O
during O
cardiopulmonary O
bypass O
. O

_RARE_ I-GENE
has O
been O
used O
to O
_RARE_ I-GENE
observe O
the O
responses O
of O
the O
vestibular O
system O
in O
a O
population O
of O
patients O
with O
vestibular O
deficits O
. O

The O
_RARE_ I-GENE
and O
_RARE_ I-GENE
PI I-GENE
values O
showed O
the O
greatest O
deviation O
for O
any O
single O
- I-GENE
vessel O
parameter O
. O

_RARE_ I-GENE
sequence I-GENE
similarities O
( O
57 O
and O
53 O
%) O
were O
observed O
with O
yeast I-GENE
mitochondrial I-GENE
proteins I-GENE
, O
_RARE_ I-GENE
and O
_RARE_ I-GENE
, O
especially O
within O
putative O
functional O
domains I-GENE
: O
exon O
6 I-GENE
encoding O
the O
second O
transmembrane I-GENE
spanning O
domain I-GENE
, O
site I-GENE
of O
the O
murine I-GENE
susceptibility I-GENE
mutation I-GENE
; O
and O
exon O
11 O
encoding O
a O
conserved O
transport O
motif I-GENE
. O

_RARE_ I-GENE
contain O
distinctly O
less O
P I-GENE
protein I-GENE
mRNA I-GENE
and O
the O
relative O
level O
in O
roots O
is O
very O
low O
but O
still O
clearly O
detectable O
. O

The O
B I-GENE
. O
_RARE_ I-GENE
_RARE_ I-GENE
amino O
acid I-GENE
sequence I-GENE
shares O
83 O
% O
identity O
with O
the O
cytosolic I-GENE
_RARE_ I-GENE
isoform I-GENE
from O
Drosophila I-GENE
melanogaster I-GENE
( O
_RARE_ I-GENE
- I-GENE
1 I-GENE
). O

Furthermore O
, O
we O
have O
identified O
a O
soluble I-GENE
form O
of O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
by O
Western O
blotting O
and O
biosynthetic O
labeling O
. O

The O
minimal I-GENE
region O
of O
overlap O
of O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
syndrome O
deletions O
, O
previously O
identified O
by O
analysis O
of O
15 O
patients O
, O
was O
placed O
on O
the O
map O
by O
analysis O
of O
2 I-GENE
patients O
whose O
deletions O
define O
the O
_RARE_ I-GENE
. O

Consistent O
with O
the O
hepatic I-GENE
and O
epidermal I-GENE
expression O
of O
_RARE_ I-GENE
, O
this O
finding O
suggests O
that O
_RARE_ I-GENE
transcription I-GENE
may O
be O
regulated O
by O
these O
factors I-GENE
. O

Comparison O
of O
promoters I-GENE
repressed O
by O
c I-GENE
- I-GENE
myc I-GENE
reveals O
a O
weak O
consensus I-GENE
sequence I-GENE
of O
the O
initiator O
( O
_RARE_ I-GENE
) O
element I-GENE
: O
_RARE_ I-GENE
(+ O
1 I-GENE
) O
_RARE_ I-GENE
. O

The O
human I-GENE
_RARE_ I-GENE
promoter I-GENE
. O

Transfection O
analyses O
indicate O
that O
mutation I-GENE
of O
any O
one O
of O
these O
_RARE_ I-GENE
motifs O
or O
_RARE_ I-GENE
of O
the O
entire O
HD I-GENE
_RARE_ I-GENE
into O
a O
separate O
DR1 I-GENE
and O
_RARE_ I-GENE
element I-GENE
significantly O
reduced O
the O
transcriptional O
response O
of O
HD I-GENE
_RARE_ I-GENE
to O
peroxisome I-GENE
_RARE_ I-GENE
. O

The O
site I-GENE
of O
autophosphorylation O
is O
_RARE_ I-GENE
which O
corresponds O
to O
the O
consensus I-GENE
autophosphorylation O
site I-GENE
of O
other O
Src I-GENE
family I-GENE
tyrosine I-GENE
kinases I-GENE
. O

This O
protein I-GENE
- I-GENE
protein I-GENE
interaction O
does O
not O
require O
the O
simultaneous O
binding I-GENE
of O
Oct I-GENE
proteins I-GENE
to O
DNA I-GENE
, O
and O
high O
resolution O
footprinting O
of O
the O
Oct I-GENE
- I-GENE
DNA I-GENE
interaction O
reveals O
that O
binding I-GENE
of O
_RARE_ I-GENE
. O
1 I-GENE
/ I-GENE
_RARE_ I-GENE
. O
1 I-GENE
to O
_RARE_ I-GENE
or O
_RARE_ I-GENE
does O
not O
alter O
the O
interaction O
with O
DNA I-GENE
. O

Together O
, O
our O
data O
suggest O
that O
the O
_RARE_ I-GENE
orphan I-GENE
receptor I-GENE
may O
be O
a O
_RARE_ I-GENE
regulator I-GENE
in O
_RARE_ I-GENE
the O
activation O
of O
two O
key O
_RARE_ I-GENE
, O
_RARE_ I-GENE
beta I-GENE
and O
_RARE_ I-GENE
, O
involved O
in O
the O
retinoic I-GENE
acid I-GENE
signal I-GENE
transduction O
pathway O
. O

Using O
a O
series O
of O
mutant I-GENE
proteins I-GENE
, O
we O
have O
characterized O
domains I-GENE
responsible O
for O
activation O
or O
repression O
. O

Unlike O
ARF I-GENE
, O
the O
_RARE_ I-GENE
immunoreactivity O
was O
detected O
in O
plasma I-GENE
membranes O
but O
not O
in O
cytosol O
of O
_RARE_ I-GENE
3T3 O
- I-GENE
L1 I-GENE
cells O
. O

It O
is O
considered O
that O
the O
recurrent O
_RARE_ I-GENE
_RARE_ I-GENE
is O
a O
specific I-GENE
skin O
manifestation O
of O
_RARE_ I-GENE
with O
anti I-GENE
SS I-GENE
- I-GENE
A I-GENE
/ I-GENE
SS I-GENE
- I-GENE
B I-GENE
antibodies I-GENE
. O

Competition O
needs O
to O
be O
better O
studied O
, O
since O
in O
_RARE_ I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
this O
_RARE_ I-GENE
of O
study O
has O
_RARE_ I-GENE
the O
biological O
control O
of O
_RARE_ I-GENE
species O
. O

In O
this O
paper O
we O
describe O
properties O
of O
the O
_RARE_ I-GENE
- I-GENE
C4 I-GENE
mutant I-GENE
of O
the O
fission I-GENE
yeast I-GENE
Schizosaccharomyces I-GENE
pombe I-GENE
. O

_RARE_ I-GENE
expression O
in O
_RARE_ I-GENE
cells O
was O
highly O
induced O
by O
TGF I-GENE
- I-GENE
beta I-GENE
and O
bone O
_RARE_ I-GENE
protein I-GENE
- I-GENE
2 I-GENE
( O
BMP I-GENE
- I-GENE
2 I-GENE
), O
with O
a O
moderate O
induction O
by O
epidermal I-GENE
growth I-GENE
factor I-GENE
( O
EGF I-GENE
), O
but O
no O
induction O
by O
other O
growth I-GENE
factors I-GENE
/ I-GENE
cytokines O
was O
observed O
. O

An O
infectious O
origin O
should O
always O
be O
excluded O
since O
specific I-GENE
_RARE_ I-GENE
therapy O
may O
be O
_RARE_ I-GENE
. O

The O
predicted O
protein I-GENE
products I-GENE
of O
ORFs O
_RARE_ I-GENE
and O
_RARE_ I-GENE
present O
similarities O
with O
domains I-GENE
from O
proteins I-GENE
of O
other O
organisms O
: O
the O
Candida I-GENE
_RARE_ I-GENE
cycloheximide I-GENE
- I-GENE
resistance O
protein I-GENE
, O
the O
human I-GENE
interleukin I-GENE
enhancer I-GENE
- I-GENE
binding I-GENE
factor I-GENE
( O
_RARE_ I-GENE
- I-GENE
2 I-GENE
). O

In O
particular O
, O
the O
highly O
expressed O
_RARE_ I-GENE
gene I-GENE
is O
represented O
in O
this O
database O
by O
no O
less O
than O
20 O
EST I-GENE
sequences I-GENE
. O

Five O
families O
of O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
carried O
the O
_RARE_ I-GENE
mutation I-GENE
and O
shared O
the O
same O
_RARE_ I-GENE
at O
eight O
polymorphic O
markers O
spanning O
approximately O
_RARE_ I-GENE
kb O
at O
BRCA1 I-GENE
. O

The O
subjects O
from O
the O
two O
regions O
with O
a O
higher O
_RARE_ I-GENE
level O
had O
lower O
_RARE_ I-GENE
and O
FEV1 O
values O
than O
those O
from O
the O
_RARE_ I-GENE
region O
. O

PTP I-GENE
- I-GENE
_RARE_ I-GENE
differs O
from O
PTP I-GENE
- I-GENE
S4 I-GENE
in O
having O
a O
deletion O
of O
19 O
amino O
acids O
corresponding O
to O
exon O
E1 I-GENE
. O

All O
three O
_RARE_ I-GENE
isoforms I-GENE
are O
expressed O
in O
cv O
. O

All O
three O
_RARE_ I-GENE
isoforms I-GENE
are O
expressed O
in O
cv O
. O

The O
Arabidopsis I-GENE
_RARE_ I-GENE
gene I-GENE
encodes O
a O
chloroplast I-GENE
omega I-GENE
- I-GENE
3 I-GENE
fatty I-GENE
acid I-GENE
_RARE_ I-GENE
that O
catalyzes O
the O
_RARE_ I-GENE
of O
lipid O
- I-GENE
linked O
_RARE_ I-GENE
fatty I-GENE
acids O
( O
18 O
: O
2 I-GENE
and O
16 O
: O
2 I-GENE
). O

When O
differentiated O
_RARE_ I-GENE
- I-GENE
arrested O
leaf O
cells O
were O
induced O
to O
_RARE_ I-GENE
cell O
division O
by O
treatment O
with O
plant O
hormones O
, O
_RARE_ I-GENE
transcription I-GENE
was O
induced O
before O
the O
onset O
of O
DNA I-GENE
synthesis O
. O

A I-GENE
survey O
is O
given O
of O
the O
pharmacological O
_RARE_ I-GENE
that O
are O
relevant O
for O
the O
drug O
treatment O
of O
essential O
hypertension O
in O
the O
elderly O
. O

Protein I-GENE
kinases I-GENE
play O
pivotal O
roles O
in O
the O
control O
of O
many O
cellular O
processes O
. O

Interestingly O
, O
internal O
and O
5 I-GENE
' O
deletions O
revealed O
_RARE_ I-GENE
the O
distal O
promoter I-GENE
was O
not O
required O
for O
full I-GENE
transcriptional O
activity O
and O
that O
the O
first O
_RARE_ I-GENE
base O
pairs O
of O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
the O
strongest O
promoter I-GENE
activity O
. O

The O
protein I-GENE
kinase I-GENE
domains I-GENE
of O
_RARE_ I-GENE
and O
_RARE_ I-GENE
are O
unique O
in O
that O
they O
contain O
an O
unusual O
sequence I-GENE
motif I-GENE
Asp I-GENE
- I-GENE
Leu I-GENE
- I-GENE
Asn O
- I-GENE
Ser O
- I-GENE
His O
- I-GENE
Asn O
in O
subdomain I-GENE
_RARE_ I-GENE
and O
a O
highly O
basic I-GENE
insert O
between O
subdomains O
VII I-GENE
and O
VIII I-GENE
. O

A I-GENE
human I-GENE
recombinant I-GENE
cDNA I-GENE
clone O
that O
encoded I-GENE
_RARE_ I-GENE
amino O
acids O
residues O
of O
a O
zinc I-GENE
- I-GENE
finger I-GENE
protein I-GENE
( O
_RARE_ I-GENE
- I-GENE
1 I-GENE
) O
was O
cloned O
by O
screening O
a O
cDNA I-GENE
library O
prepared O
from O
human I-GENE
_RARE_ I-GENE
leukemia I-GENE
_RARE_ I-GENE
cells O
with O
synthetic O
_RARE_ I-GENE
probes O
that O
corresponded O
to O
the O
amino O
acid I-GENE
sequences I-GENE
of O
_RARE_ I-GENE
peptides I-GENE
derived O
from O
the O
DNA I-GENE
- I-GENE
binding I-GENE
protein I-GENE
specific I-GENE
for O
the O
nuclease I-GENE
- I-GENE
hypersensitive I-GENE
element I-GENE
( O
_RARE_ I-GENE
) O
of O
the O
human I-GENE
c I-GENE
- I-GENE
myc I-GENE
gene I-GENE
. O

_RARE_ I-GENE
AA O
in O
_RARE_ I-GENE
+ I-GENE
EPO I-GENE
- I-GENE
supplemented O
infants O
remained O
low O
and O
below O
breast O
- I-GENE
and O
placebo O
formula O
- I-GENE
fed O
levels O
. O

_RARE_ I-GENE
into O
_RARE_ I-GENE
weight O
and O
_RARE_ I-GENE
changes O
in O
bone O
mass O
, O
total O
( O
_RARE_ I-GENE
) O
and O
regional O
body O
bone O
mineral O
content O
were O
measured O
in O
38 O
women O
treated O
with O
GnRH I-GENE
agonists O
for O
6 I-GENE
months O
for O
_RARE_ I-GENE
or O
_RARE_ I-GENE
. O

The O
encoded I-GENE
polypeptide I-GENE
is O
similar O
in O
sequence I-GENE
to O
the O
ABA I-GENE
- I-GENE
1 I-GENE
allergen I-GENE
of O
_RARE_ I-GENE
, O
the O
_RARE_ I-GENE
/ I-GENE
400 O
' O
_RARE_ I-GENE
' O
protein I-GENE
of O
_RARE_ I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
, O
and O
a O
15 O
- I-GENE
kDa I-GENE
antigen I-GENE
of O
_RARE_ I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
transcript I-GENE
patterns O
in O
_RARE_ I-GENE
_RARE_ I-GENE
are O
highly O
complex I-GENE
and O
similar O
to O
those O
of O
tobacco I-GENE
operons I-GENE
. O

_RARE_ I-GENE
recovery O
occurs O
within O
30 O
min O
to O
2 I-GENE
hrs O
. O

_RARE_ I-GENE
is O
a O
70 I-GENE
kD I-GENE
glycoprotein I-GENE
containing O
complement I-GENE
regulatory I-GENE
short O
consensus I-GENE
repeats I-GENE
( O
_RARE_ I-GENE
); O
its O
gene I-GENE
is O
located O
in O
the O
regulation O
of O
complement I-GENE
activation O
( O
_RARE_ I-GENE
) O
gene I-GENE
cluster I-GENE
on O
chromosome O
1 I-GENE
and O
is O
about O
40 I-GENE
kb O
in O
size O
. O

The O
_RARE_ I-GENE
gene I-GENE
down O
- I-GENE
regulates O
but O
does O
not O
_RARE_ I-GENE
expression O
of O
_RARE_ I-GENE
genes I-GENE
and O
does O
not O
affect O
expression O
of O
CD44 I-GENE
. O

_RARE_ I-GENE
care O
: O
a O
_RARE_ I-GENE
to O
the O
_RARE_ I-GENE
needed O
to O
support O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
. O

There O
is O
no O
TATA I-GENE
box I-GENE
around O
the O
transcriptional O
start O
points O
( O
_RARE_ I-GENE
), O
as O
determined O
by O
primer O
extension O
analysis O
. O

According O
to O
the O
investigation O
, O
the O
recent O
burst O
of O
_RARE_ I-GENE
in O
this O
area O
can O
be O
attributed O
to O
the O
increased O
presence O
of O
sea O
_RARE_ I-GENE
, O
which O
_RARE_ I-GENE
in O
the O
_RARE_ I-GENE
region O
, O
then O
_RARE_ I-GENE
to O
the O
northern O
Japan O
_RARE_ I-GENE
and O
_RARE_ I-GENE
the O
intermediate O
host O
fish O
. O

In O
summary O
, O
the O
_RARE_ I-GENE
of O
adjuvant O
_RARE_ I-GENE
and O
of O
abdominal O
radiotherapy O
seem O
to O
be O
identical O
. O

To O
identify O
some O
of O
the O
genes I-GENE
expressed O
in O
LPS I-GENE
- I-GENE
activated I-GENE
_RARE_ I-GENE
, O
we O
sequenced O
randomly O
chosen O
clones O
from O
a O
_RARE_ I-GENE
constructed O
cDNA I-GENE
library O
to O
produce O
a O
set O
of O
expressed O
sequence I-GENE
tags O
( O
ESTs I-GENE
). O

Characterization O
of O
an O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
heterodimer O
target O
site I-GENE
that O
mediates O
ecdysone O
responsiveness O
of O
the O
Drosophila I-GENE
_RARE_ I-GENE
- I-GENE
2 I-GENE
gene I-GENE
. O

Thus O
, O
SPECT O
was O
not O
as O
sensitive O
as O
PET O
in O
this O
activation O
task O
. O

Transcriptional O
activation O
of O
the O
chicken I-GENE
lysozyme I-GENE
gene I-GENE
by O
NF I-GENE
- I-GENE
kappa I-GENE
_RARE_ I-GENE
( O
RelA I-GENE
) O
and O
c I-GENE
- I-GENE
Rel I-GENE
, O
but O
not O
by O
NF I-GENE
- I-GENE
kappa I-GENE
_RARE_ I-GENE
. O

The O
results O
indicate O
that O
the O
_RARE_ I-GENE
agents O
_RARE_ I-GENE
and O
_RARE_ I-GENE
do O
not O
exert O
antiarrhythmic O
efficacy O
against O
_RARE_ I-GENE
induced O
during O
subacute O
myocardial O
infarction O
in O
conscious O
dogs O
. O

In O
vivo O
, O
selective O
activation O
of O
_RARE_ I-GENE
stimulates O
formation O
of O
the O
ternary O
complex I-GENE
containing O
Elk I-GENE
- I-GENE
1 I-GENE
, O
serum I-GENE
response O
factor I-GENE
and O
the O
serum I-GENE
response O
element I-GENE
, O
and O
enhances O
Elk I-GENE
- I-GENE
1 I-GENE
- I-GENE
dependent I-GENE
transcription I-GENE
. O

An O
epidemic O
of O
hepatitis I-GENE
B I-GENE
virus I-GENE
infection O
among O
intravenous O
drug O
users O
in O
_RARE_ I-GENE
. O

The O
gene I-GENE
was O
_RARE_ I-GENE
mapped O
with O
odds O
> O
1 I-GENE
, O
000 O
: O
1 I-GENE
on O
chromosome O
_RARE_ I-GENE
in O
_RARE_ I-GENE
d O
' O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
. O

Three O
of O
these O
subunits I-GENE
are O
also O
homologous O
to O
the O
dimeric I-GENE
_RARE_ I-GENE
from O
a O
_RARE_ I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
_RARE_ I-GENE
( O
21 O
% O
identity O
). O

The O
transposon I-GENE
- I-GENE
inactivated O
gene I-GENE
, O
designated O
_RARE_ I-GENE
, O
is O
_RARE_ I-GENE
bp O
long O
, O
potentially O
encoding O
a O
19 O
. O
1 I-GENE
- I-GENE
kDa I-GENE
protein I-GENE
precursor I-GENE
that O
contains O
a O
typical O
membrane I-GENE
lipoprotein I-GENE
leader O
sequence I-GENE
. O

_RARE_ I-GENE
and O
S I-GENE
. O

Upstream O
of O
the O
_RARE_ I-GENE
gene I-GENE
an O
open O
reading O
frame O
of O
_RARE_ I-GENE
amino O
acids O
was O
identified O
. O

_RARE_ I-GENE
- I-GENE
specific I-GENE
regulation O
of O
_RARE_ I-GENE
was O
also O
lost O
upon O
deletion O
of O
4 I-GENE
bp O
of O
a O
palindromic O
sequence I-GENE
( O
_RARE_ I-GENE
) O
covering O
positions O
+ I-GENE
6 I-GENE
to O
+ I-GENE
21 O
downstream O
of O
the O
_RARE_ I-GENE
transcriptional O
start O
site I-GENE
. O

In O
E I-GENE
. O
coli I-GENE
, O
_RARE_ I-GENE
mediates O
the O
physical O
coupling O
of O
the O
receptors I-GENE
to O
the O
kinase I-GENE
_RARE_ I-GENE
. O

The O
promoter I-GENE
of O
the O
first O
gene I-GENE
, O
_RARE_ I-GENE
, O
responded O
to O
the O
activator I-GENE
protein I-GENE
_RARE_ I-GENE
and O
contained O
a O
palindromic O
sequence I-GENE
similar O
to O
the O
_RARE_ I-GENE
binding I-GENE
site I-GENE
of O
the O
_RARE_ I-GENE
promoter I-GENE
, O
which O
is O
also O
activated I-GENE
by O
_RARE_ I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
bind O
to O
unique O
sets O
of O
selectivity O
determinants I-GENE
that O
can O
function O
independently O
and O
are O
broadly O
distributed O
on O
multiple O
domains I-GENE
of O
human I-GENE
interleukin I-GENE
- I-GENE
8 O
receptor I-GENE
B I-GENE
. O

_RARE_ I-GENE
antisense I-GENE
to O
the O
predicted O
translation I-GENE
initiation I-GENE
regions O
of O
ICP4 I-GENE
and O
_RARE_ I-GENE
mRNAs I-GENE
inhibited O
proliferation O
of O
_RARE_ I-GENE
cells O
but O
not O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
_RARE_ I-GENE
virus I-GENE
- I-GENE
transformed O
cells O
. O

_RARE_ I-GENE
replication O
requires O
that O
a O
portion O
of O
the O
primary O
transcripts I-GENE
generated O
from O
proviral I-GENE
DNA I-GENE
be O
spliced O
to O
serve O
as O
mRNA I-GENE
for O
the O
envelope I-GENE
protein I-GENE
and O
in O
Rous I-GENE
sarcoma I-GENE
virus I-GENE
as O
src I-GENE
mRNA I-GENE
. O

In O
this O
case O
the O
degree O
of O
promoter I-GENE
methylation O
, O
which O
could O
extend O
beyond O
the O
T I-GENE
- I-GENE
DNA I-GENE
_RARE_ I-GENE
, O
was O
not O
correlated O
with O
the O
reduction O
in O
steady O
- I-GENE
state O
poly O
( O
A I-GENE
)+ O
mRNA I-GENE
levels O
, O
the O
_RARE_ I-GENE
state O
was O
transmitted O
through O
meiosis O
and O
_RARE_ I-GENE
_RARE_ I-GENE
several O
_RARE_ I-GENE
. O

Thus O
, O
the O
consensus I-GENE
sequences I-GENE
for O
phosphatase I-GENE
regulation O
are O
5 I-GENE
'- O
_RARE_ I-GENE
- I-GENE
3 I-GENE
' O
and O
5 I-GENE
'- O
_RARE_ I-GENE
- I-GENE
3 I-GENE
' O
which O
differ O
from O
the O
binding I-GENE
sequences I-GENE
for O
the O
_RARE_ I-GENE
protein I-GENE
required O
for O
transcription I-GENE
of O
the O
genes I-GENE
in O
methionine O
biosynthesis O
and O
for O
centromere O
function O
. O

Here O
we O
report O
that O
the O
proline O
- I-GENE
rich O
region O
of O
CAP I-GENE
is O
recognized O
by O
the O
SH3 I-GENE
domains I-GENE
of O
several O
proteins I-GENE
, O
including O
the O
yeast I-GENE
actin I-GENE
- I-GENE
associated I-GENE
protein I-GENE
_RARE_ I-GENE
. O

We O
have O
identified O
and O
characterized O
a O
vitamin O
D I-GENE
response O
element I-GENE
( O
VDRE I-GENE
) O
in O
the O
promoter I-GENE
of O
c I-GENE
- I-GENE
fos I-GENE
. O

In O
addition O
to O
protein I-GENE
binding I-GENE
at O
sequences I-GENE
known O
to O
be O
involved O
in O
the O
regulation O
of O
transcription I-GENE
, O
genomic O
footprinting O
of O
the O
entire O
promoter I-GENE
region O
also O
showed O
that O
a O
protein I-GENE
factor I-GENE
is O
constitutively O
bound O
to O
the O
first O
intron O
of O
the O
_RARE_ I-GENE
gene I-GENE
. O

_RARE_ I-GENE
was O
not O
observed O
after O
cellular O
expression O
of O
GTPase I-GENE
- I-GENE
deficient O
forms O
of O
alpha I-GENE
_RARE_ I-GENE
or O
alpha I-GENE
0 O
, O
indicating O
selectivity O
for O
the O
_RARE_ I-GENE
family I-GENE
of O
G I-GENE
proteins I-GENE
. O

Consistent O
with O
a O
possible O
role O
in O
transcription I-GENE
, O
_RARE_ I-GENE
is O
localized O
to O
the O
nucleus O
. O

By O
comparing O
the O
_RARE_ I-GENE
of O
many O
yeast I-GENE
transcripts I-GENE
in O
_RARE_ I-GENE
wild I-GENE
- I-GENE
type I-GENE
and O
_RARE_ I-GENE
mutant I-GENE
strains O
, O
we O
have O
identified O
genes I-GENE
whose O
expression O
is O
affected O
by O
_RARE_ I-GENE
. O

_RARE_ I-GENE
may O
therefore O
be O
required O
for O
both O
positive O
and O
negative O
regulation O
of O
_RARE_ I-GENE
of O
yeast I-GENE
genes I-GENE
. O

Using O
a O
high O
- I-GENE
copy O
suppression O
strategy O
, O
we O
have O
identified O
a O
yeast I-GENE
gene I-GENE
( O
_RARE_ I-GENE
) O
whose O
elevated O
expression O
suppresses O
the O
conditional O
cell O
cycle O
defects O
associated I-GENE
with O
_RARE_ I-GENE
mutations O
. O

Molecular O
characterization O
of O
malignant O
melanoma O
of O
soft O
parts O
or O
soft O
tissue I-GENE
clear O
cell O
sarcoma I-GENE
which O
shares O
t I-GENE
( O
12 O
; O
22 O
) O
chromosome O
translocation O
revealed O
fusion I-GENE
of O
EWS I-GENE
with O
a O
transcriptional O
factor I-GENE
gene I-GENE
ATF I-GENE
- I-GENE
1 I-GENE
. O

_RARE_ I-GENE
that O
expressed O
_RARE_ I-GENE
exhibited O
a O
dominant I-GENE
negative O
phenotype O
and O
did O
not O
elicit O
_RARE_ I-GENE
activity O
against O
vesicular O
stomatitis I-GENE
virus I-GENE
( O
_RARE_ I-GENE
) O
infection O
upon O
IFN I-GENE
treatment O
. O

_RARE_ I-GENE
preferentially O
binds O
to O
multiple O
sites I-GENE
in O
ARS I-GENE
_RARE_ I-GENE
and O
to O
the O
DNA I-GENE
_RARE_ I-GENE
poly O
[ O
d O
( O
A I-GENE
. O
T I-GENE
)]. O

Identification O
, O
purification O
, O
and O
molecular O
cloning O
of O
autonomously I-GENE
replicating I-GENE
sequence I-GENE
- I-GENE
binding I-GENE
protein I-GENE
1 I-GENE
from O
fission I-GENE
yeast I-GENE
Schizosaccharomyces I-GENE
pombe I-GENE
. O

A I-GENE
short O
open O
reading O
frame O
( O
ORF2 O
), O
of O
unknown O
function O
, O
is O
present O
in O
all O
_RARE_ I-GENE
isolates O
. O

The O
patient O
was O
homozygous O
for O
the O
underlying O
mutation I-GENE
, O
which O
was O
found O
to O
be O
a O
G I-GENE
--> I-GENE
T I-GENE
transversion O
within O
the O
acceptor O
splice O
site I-GENE
between O
intron O
e O
and O
exon O
6 I-GENE
, O
_RARE_ I-GENE
normal O
RNA I-GENE
splicing O
. O

These O
regions O
overlap O
with O
the O
_RARE_ I-GENE
protein I-GENE
similarity O
regions O
. O

We O
tested O
10 O
rats O
with O
_RARE_ I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
acid I-GENE
lesions O
of O
the O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
to O
determine O
whether O
they O
could O
_RARE_ I-GENE
a O
_RARE_ I-GENE
- I-GENE
induced O
_RARE_ I-GENE
to O
l O
- I-GENE
alanine I-GENE
( O
0 O
. O
3 I-GENE
M I-GENE
) O
or O
demonstrate O
a O
sodium O
_RARE_ I-GENE
following O
furosemide O
treatment O
and O
_RARE_ I-GENE
access O
to O
sodium O
deficient O
_RARE_ I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
- I-GENE
B I-GENE
failed O
in O
6 I-GENE
/ I-GENE
7 O
patients O
with O
culture O
- I-GENE
proven O
_RARE_ I-GENE
who O
died O
from O
infection O
with O
Aspergillus I-GENE
( O
n O
= O
2 I-GENE
) O
and O
Candida I-GENE
( O
n O
= O
4 I-GENE
), O
respectively O
. O

_RARE_ I-GENE
+ I-GENE
and O
_RARE_ I-GENE
+ I-GENE
compete O
for O
binding I-GENE
sites I-GENE
, O
with O
the O
former O
having O
lower O
affinity O
. O

Magnetic O
_RARE_ I-GENE
indicators O
could O
be O
used O
in O
medicine O
, O
in O
_RARE_ I-GENE
and O
for O
special O
_RARE_ I-GENE
. O

_RARE_ I-GENE
tobacco I-GENE
plants O
( O
_RARE_ I-GENE
- I-GENE
1 I-GENE
) O
constitutively O
expressing O
Escherichia I-GENE
coli I-GENE
_RARE_ I-GENE
behind O
the O
35S I-GENE
_RARE_ I-GENE
promoter I-GENE
accumulate O
high O
levels O
of O
soluble I-GENE
sugars O
in O
their O
leaves O
[ O
27 O
]. O

Human I-GENE
_RARE_ I-GENE
- I-GENE
4 I-GENE
readily O
hybridized O
with O
genes I-GENE
in O
mouse I-GENE
and O
chicken I-GENE
, O
thus O
showing O
that O
this O
gene I-GENE
family I-GENE
has O
been O
highly O
conserved O
during O
vertebrate I-GENE
evolution O
. O

Hb I-GENE
levels O
remained O
adequate O
( O
Hb I-GENE
= O
10 O
. O
68 O
+/- O
0 O
. O
77 O
g O
/ I-GENE
dl O
) O
after O
14 O
. O
6 I-GENE
+/- O
7 O
. O
64 O
months O
. O

_RARE_ I-GENE
is O
discussed O
in O
comparison O
with O
the O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
Test O
as O
a O
potential O
cognitive O
activation O
task O
for O
functional O
_RARE_ I-GENE
of O
the O
frontal O
_RARE_ I-GENE
. O

These O
data O
indicate O
that O
although O
_RARE_ I-GENE
retains O
normal O
transactivation O
activity O
on O
a O
p53 I-GENE
promoter I-GENE
in O
yeast I-GENE
at O
physiological O
temperatures O
, O
it O
is O
not O
capable O
of O
normal O
p53 I-GENE
function O
in O
the O
presence O
of O
a O
_RARE_ I-GENE
allele I-GENE
in O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
cells O
. O

_RARE_ I-GENE
were O
repeated O
every O
3 I-GENE
weeks O
. O

Neither O
class I-GENE
II I-GENE
nor O
IV I-GENE
infections O
_RARE_ I-GENE
transplantation O
. O

Although O
a O
great O
_RARE_ I-GENE
is O
understood O
about O
how O
bHLH I-GENE
factors I-GENE
activate O
gene I-GENE
transcription I-GENE
via O
E I-GENE
- I-GENE
box I-GENE
DNA I-GENE
consensus I-GENE
sequences I-GENE
, O
studies O
of O
bHLH I-GENE
factor I-GENE
function O
in O
higher O
eukaryotes O
often O
have O
been O
_RARE_ I-GENE
by O
the O
presence O
of O
multiple O
family I-GENE
members O
. O

_RARE_ I-GENE
and O
supershift O
assays O
demonstrated O
that O
upstream O
stimulatory I-GENE
factor I-GENE
( O
USF I-GENE
) O
and O
Sp1 I-GENE
bind O
to O
the O
former O
elements O
and O
competition O
experiments O
confirmed O
that O
CREB I-GENE
/ I-GENE
ATF I-GENE
and O
AP I-GENE
- I-GENE
1 I-GENE
bind O
to O
the O
CRE O
/ I-GENE
TRE I-GENE
element I-GENE
. O

Upstream O
of O
- I-GENE
37 O
, O
the O
5 I-GENE
' O
untranslated O
sequences I-GENE
of O
the O
isolates O
differ O
in O
both O
length I-GENE
and O
sequence I-GENE
. O

In O
these O
cases O
, O
greatly O
increased O
human I-GENE
_RARE_ I-GENE
gonadotropin I-GENE
( O
hCG I-GENE
) O
levels O
and O
suppressed O
TSH I-GENE
levels O
suggest O
that O
hCG I-GENE
has O
_RARE_ I-GENE
activity O
. O

High O
fibrinogen I-GENE
levels O
could O
thus O
be O
a O
risk O
for O
_RARE_ I-GENE
thrombosis O
. O

_RARE_ I-GENE
chloride O
_RARE_ I-GENE
89 I-GENE
is O
_RARE_ I-GENE
, O
but O
preliminary O
analysis O
indicates O
that O
it O
may O
reduce O
management O
_RARE_ I-GENE
overall O
.( O
ABSTRACT O
TRUNCATED O
AT I-GENE
250 O
WORDS O
) O

We O
propose O
that O
_RARE_ I-GENE
features O
of O
tissue I-GENE
- I-GENE
specific I-GENE
control O
and O
of O
the O
control O
of O
allelic O
expression O
are O
_RARE_ I-GENE
linked O
. O

This O
study O
determined O
the O
_RARE_ I-GENE
potential O
of O
_RARE_ I-GENE
gel O
by O
either O
_RARE_ I-GENE
it O
with O
bovine I-GENE
collagen I-GENE
II I-GENE
( O
_RARE_ I-GENE
) O
or O
by O
injecting O
_RARE_ I-GENE
gel O
alone O
in O
DA I-GENE
rats O
. O

SBF I-GENE
binds O
to O
the O
promoter I-GENE
prior O
to O
the O
activation O
of O
transcription I-GENE
in O
late O
G1 I-GENE
, O
suggesting O
that O
_RARE_ I-GENE
/ I-GENE
Cdc28 I-GENE
kinase I-GENE
regulates O
the O
ability O
of O
previously O
bound O
SBF I-GENE
to O
activate O
transcription I-GENE
. O

However O
, O
it O
remains O
an O
open O
question O
whether O
vertebrate I-GENE
Hox I-GENE
genes I-GENE
expressed O
under O
the O
control O
of O
Drosophila I-GENE
regulatory I-GENE
sequences I-GENE
can O
substitute O
the O
function O
of O
Drosophila I-GENE
Hox I-GENE
genes I-GENE
. O

This O
approach O
_RARE_ I-GENE
_RARE_ I-GENE
- I-GENE
1 I-GENE
into O
the O
normal O
embryonic O
_RARE_ I-GENE
context O
in O
which O
_RARE_ I-GENE
acts O
. O

This O
5 I-GENE
' O
splice O
site I-GENE
sequence I-GENE
was O
required O
for O
enhanced O
polyadenylation O
and O
was O
recognized O
by O
both O
U1 I-GENE
small I-GENE
nuclear I-GENE
_RARE_ I-GENE
( O
snRNPs I-GENE
) O
and O
alternative O
splicing O
factor I-GENE
/ I-GENE
splicing O
factor I-GENE
2 I-GENE
( O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
). O

This O
analysis O
revealed O
that O
_RARE_ I-GENE
_RARE_ I-GENE
, O
together O
with O
four O
other O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
subunits I-GENE
, O
UV O
cross O
- I-GENE
links O
to O
pre I-GENE
- I-GENE
mRNA I-GENE
in O
a O
20 O
- I-GENE
nucleotide I-GENE
region O
upstream O
of O
the O
_RARE_ I-GENE
. O

We O
propose O
that O
_RARE_ I-GENE
and O
_RARE_ I-GENE
of O
_RARE_ I-GENE
are O
members O
of O
two O
distinct O
classes O
of O
fungal I-GENE
_RARE_ I-GENE
, O
an O
observation O
not O
previously O
reported O
for O
a O
single O
fungus I-GENE
. O

Although O
the O
consumption O
of O
myoglobin I-GENE
- I-GENE
bound O
O2 O
( O
_RARE_ I-GENE
) O
_RARE_ I-GENE
in O
_RARE_ I-GENE
muscles O
has O
been O
demonstrated O
in O
_RARE_ I-GENE
muscles O
during O
laboratory O
_RARE_ I-GENE
of O
_RARE_ I-GENE
, O
this O
may O
not O
be O
a O
feature O
of O
normal O
field O
_RARE_ I-GENE
in O
which O
measurements O
of O
heart O
rate O
and O
lactate I-GENE
production O
show O
marked O
differences O
from O
the O
profound O
_RARE_ I-GENE
response O
induced O
by O
_RARE_ I-GENE
immersion O
. O

The O
human I-GENE
_RARE_ I-GENE
cDNA I-GENE
is O
_RARE_ I-GENE
base O
pairs O
in O
length I-GENE
encoding O
for O
a O
_RARE_ I-GENE
- I-GENE
amino O
acid I-GENE
_RARE_ I-GENE
( O
Mr O
= O
64 O
, O
_RARE_ I-GENE
). O

The O
Saccharomyces I-GENE
cerevisiae I-GENE
spindle O
pole O
body O
duplication O
gene I-GENE
_RARE_ I-GENE
is O
part O
of O
a O
mitotic O
checkpoint I-GENE
. O

In O
our O
_RARE_ I-GENE
, O
the O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
system O
is O
, O
despite O
some O
_RARE_ I-GENE
in O
its O
_RARE_ I-GENE
- I-GENE
interface O
, O
a O
useful O
and O
_RARE_ I-GENE
instrument O
for O
examination O
of O
human I-GENE
semen O
samples O
, O
with O
_RARE_ I-GENE
features O
. O

The O
purpose O
of O
the O
study O
reported O
here O
was O
to O
investigate O
whether O
differences O
in O
T1 O
and O
T2 I-GENE
between O
tumors O
are O
mainly O
a O
consequence O
of O
differences O
in O
the O
fractional O
volume O
of O
the O
extracellular I-GENE
compartment O
. O

A I-GENE
mutant I-GENE
_RARE_ I-GENE
product I-GENE
truncated I-GENE
immediately O
after O
the O
last O
residue O
of O
the O
highly O
conserved O
GATA I-GENE
( O
DNA I-GENE
- I-GENE
binding I-GENE
) O
domain I-GENE
retains O
partial O
function O
. O

_RARE_ I-GENE
, O
designed O
on O
the O
basis O
of O
conserved O
flanking O
amino O
acid I-GENE
sequence I-GENE
segments O
within O
the O
catalytic O
domain I-GENE
of O
eukaryotic I-GENE
protein I-GENE
kinase I-GENE
C I-GENE
( O
PKC I-GENE
) O
proteins I-GENE
, O
were O
used O
as O
primers O
for O
polymerase I-GENE
chain I-GENE
reactions O
to O
_RARE_ I-GENE
a O
_RARE_ I-GENE
- I-GENE
bp O
chromosomal I-GENE
DNA I-GENE
fragment I-GENE
from O
the O
filamentous I-GENE
fungus I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
. O

Disruption O
of O
RB I-GENE
/ I-GENE
E2F I-GENE
- I-GENE
1 I-GENE
interaction O
by O
single O
point O
mutations O
in O
E2F I-GENE
- I-GENE
1 I-GENE
enhances O
S I-GENE
- I-GENE
phase O
entry O
and O
apoptosis O
. O

_RARE_ I-GENE
loss O
of O
differentiation O
markers O
_RARE_ I-GENE
advanced O
malignant O
neoplasms O
. O

This O
region O
contains O
a O
motif I-GENE
with O
partial O
identity O
with O
the O
binding I-GENE
site I-GENE
for O
the O
ubiquitous O
transcription I-GENE
factor I-GENE
upstream O
stimulatory I-GENE
factor I-GENE
( O
USF I-GENE
), O
which O
binds O
to O
the O
human I-GENE
insulin I-GENE
promoter I-GENE
. O

The O
method O
has O
been O
_RARE_ I-GENE
applied O
to O
the O
determination O
of O
_RARE_ I-GENE
in O
_RARE_ I-GENE
_RARE_ I-GENE
and O
biological O
fluids O
. O

These O
primers O
yielded O
a O
PCR O
product I-GENE
of O
a O
characteristic O
length I-GENE
within O
most O
_RARE_ I-GENE
species O
and O
_RARE_ I-GENE
tested O
. O

The O
_RARE_ I-GENE
kinase I-GENE
, O
which O
promotes O
S I-GENE
phase O
, O
remains O
active O
during O
the O
G2 I-GENE
- I-GENE
phase O
arrest O
of O
cells O
of O
the O
parental O
strain O
, O
but O
its O
activity O
_RARE_ I-GENE
rapidly O
in O
_RARE_ I-GENE
mutants I-GENE
. O

The O
C I-GENE
/ I-GENE
D I-GENE
ratio O
was O
equal O
to O
or O
over O
0 O
. O
6 I-GENE
in O
9 O
cases O
( O
16 O
eyes O
), O
and O
the O
values O
were O
_RARE_ I-GENE
between O
both O
eyes O
in O
55 O
% O
of O
the O
patients O
. O

_RARE_ I-GENE
mutants I-GENE
display O
a O
remarkably O
pleiotropic O
phenotype O
, O
_RARE_ I-GENE
the O
protein I-GENE
in O
DNA I-GENE
damage O
- I-GENE
induced O
mutagenesis O
, O
_RARE_ I-GENE
repair I-GENE
, O
repression O
of O
_RARE_ I-GENE
, O
and O
sporulation I-GENE
. O

RNase I-GENE
protection O
assays O
revealed O
a O
correlation O
between O
the O
levels O
of O
dorsal O
and O
ventral O
skin O
expression O
with O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
phenotypes O
. O

Molecular O
cloning O
, O
expression O
pattern O
, O
and O
chromosomal I-GENE
localization O
of O
human I-GENE
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
, O
an O
inhibitor I-GENE
of O
cyclin I-GENE
D I-GENE
- I-GENE
dependent I-GENE
kinases I-GENE
. O

_RARE_ I-GENE
of O
_RARE_ I-GENE
protein I-GENE
from O
a O
second O
copy O
of O
_RARE_ I-GENE
derived O
from O
a O
plasmid O
( O
_RARE_ I-GENE
+) O
in O
B I-GENE
. O
subtilis I-GENE
wild I-GENE
- I-GENE
type I-GENE
and O
delta I-GENE
_RARE_ I-GENE
strains O
prevented O
heat I-GENE
shock I-GENE
induction O
of O
the O
_RARE_ I-GENE
and O
_RARE_ I-GENE
operons I-GENE
at O
the O
level O
of O
transcription I-GENE
almost O
completely O
and O
strongly O
reduced O
the O
amounts O
of O
mRNA I-GENE
at O
a O
low O
temperature O
as O
well O
. O

We O
report O
the O
molecular O
cloning O
and O
functional O
characterization O
of O
_RARE_ I-GENE
isoforms I-GENE
, O
corresponding O
to O
a O
44 I-GENE
- I-GENE
kDa I-GENE
subunit I-GENE
, O
_RARE_ I-GENE
, O
and O
a O
new O
38 O
- I-GENE
kDa I-GENE
subunit I-GENE
, O
_RARE_ I-GENE
, O
generated O
by O
differential O
splicing O
. O

The O
preferential O
heterodimerization O
of O
USF I-GENE
subunits I-GENE
was O
_RARE_ I-GENE
_RARE_ I-GENE
vivo O
, O
while O
the O
in O
vitro O
association O
of O
_RARE_ I-GENE
subunits I-GENE
, O
or O
recombinant I-GENE
USF I-GENE
proteins I-GENE
, O
appeared O
to O
be O
random O
. O

_RARE_ I-GENE
PKR I-GENE
may O
exist O
as O
a O
dimer O
and O
phosphorylates O
the O
eukaryotic I-GENE
translation I-GENE
initiation I-GENE
factor I-GENE
2 I-GENE
alpha I-GENE
subunit I-GENE
( O
_RARE_ I-GENE
- I-GENE
2 I-GENE
alpha I-GENE
) O
to O
inhibit O
polypeptide I-GENE
chain I-GENE
initiation I-GENE
. O

_RARE_ I-GENE
, O
a O
molecular O
_RARE_ I-GENE
expressed O
in O
the O
endoplasmic O
reticulum O
, O
is O
a O
" O
glucose O
- I-GENE
regulated O
protein I-GENE
" O
induced O
by O
stress O
responses O
that O
_RARE_ I-GENE
glucose O
or O
_RARE_ I-GENE
calcium O
or O
otherwise O
disrupt O
glycoprotein I-GENE
trafficking O
. O

The O
IL I-GENE
- I-GENE
8 O
receptor I-GENE
is O
a O
seven O
- I-GENE
transmembrane I-GENE
spanning O
receptor I-GENE
coupled I-GENE
to O
specific I-GENE
heterotrimeric I-GENE
G I-GENE
proteins I-GENE
including O
_RARE_ I-GENE
and O
_RARE_ I-GENE
. O

In O
a O
second O
series O
of O
experiments O
, O
the O
efficacy O
of O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
Ac I-GENE
was O
evaluated O
in O
both O
single O
and O
multiple O
dose O
_RARE_ I-GENE
. O

To O
elucidate O
the O
functional O
significance O
of O
Fyn I-GENE
in O
the O
expression O
of O
viral I-GENE
promoters I-GENE
, O
we O
transfected O
a O
Fyn I-GENE
- I-GENE
expression O
vector O
together O
with O
a O
reporter I-GENE
plasmid O
containing O
the O
chloramphenicol I-GENE
acetyltransferase I-GENE
gene I-GENE
driven O
by O
HIV I-GENE
LTR I-GENE
into O
a O
human I-GENE
T I-GENE
cell O
line O
, O
Jurkat O
. O

We O
conducted O
a O
prospective O
, O
randomized O
controlled O
trial O
of O
_RARE_ I-GENE
, O
a O
selective O
beta I-GENE
- I-GENE
blocker O
for O
prevention O
of O
gastrointestinal O
bleeding O
from O
portal I-GENE
hypertension O
in O
29 O
non O
- I-GENE
selected O
patients O
with O
liver O
disease O
and O
previous O
gastrointestinal O
bleeding O
. O

A I-GENE
genetic O
and O
molecular O
analysis O
of O
non O
- I-GENE
inducible I-GENE
_RARE_ I-GENE
mutants I-GENE
showed O
that O
all O
23 O
mutations O
analysed O
map O
within O
the O
N I-GENE
- I-GENE
terminal I-GENE
half O
of O
the O
encoded I-GENE
_RARE_ I-GENE
protein I-GENE
. O

These O
studies O
indicate O
that O
the O
_RARE_ I-GENE
test O
was O
less O
sensitive O
than O
the O
_RARE_ I-GENE
_RARE_ I-GENE
substrates O
and O
that O
_RARE_ I-GENE
and O
S1 I-GENE
could O
be O
used O
to O
screen O
for O
beta I-GENE
- I-GENE
lactamase I-GENE
production O
in O
these O
tested O
species O
. O

_RARE_ I-GENE
of O
defective O
silencing O
in O
yeast I-GENE
: O
effects O
on O
transcriptional O
repression O
at O
the O
HMR I-GENE
locus I-GENE
, O
cell O
growth I-GENE
and O
telomere I-GENE
structure O
. O

Although O
ANP I-GENE
induced O
systemic O
capillary O
filtration O
, O
in O
the O
calf I-GENE
, O
filtration O
was O
reduced O
with O
ANP I-GENE
. O

Recent O
literature O
has O
suggested O
that O
beta I-GENE
- I-GENE
2 I-GENE
transferrin I-GENE
can O
also O
be O
used O
as O
a O
clinical O
marker O
for O
_RARE_ I-GENE
. O

With O
current O
_RARE_ I-GENE
beta I-GENE
- I-GENE
2 I-GENE
transferrin I-GENE
does O
not O
appear O
to O
be O
a O
reliable O
clinical O
marker O
for O
_RARE_ I-GENE
in O
the O
operative O
setting O
. O

The O
_RARE_ I-GENE
- I-GENE
I I-GENE
gene I-GENE
has O
two O
promoters I-GENE
, O
P1 I-GENE
and O
P2 I-GENE
. O

Gel O
mobility I-GENE
shift O
assays O
indicated O
that O
at O
least O
four O
nuclear I-GENE
proteins I-GENE
with O
distinct O
biochemical O
and O
binding I-GENE
properties O
possess O
the O
ability O
to O
bind O
the O
3 I-GENE
beta I-GENE
I I-GENE
- I-GENE
A I-GENE
element I-GENE
to O
produce O
four O
DNA I-GENE
- I-GENE
protein I-GENE
complexes I-GENE
( O
R1 I-GENE
to O
_RARE_ I-GENE
). O

_RARE_ I-GENE
- I-GENE
five O
patients O
( O
aged O
between O
3 I-GENE
years O
5 I-GENE
months O
and O
60 O
years O
) O
suffering O
from O
_RARE_ I-GENE
resistant O
temporal O
lobe O
epilepsy O
( O
_RARE_ I-GENE
) O
were O
operated O
on O
over O
a O
period O
of O
33 O
months O
in O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
. O

Significant O
correlations O
existed O
between O
FEV1 O
and O
the O
corresponding O
values O
of O
_RARE_ I-GENE
, O
_RARE_ I-GENE
and O
_RARE_ I-GENE
, O
although O
there O
were O
considerable O
individual O
differences O
between O
test O
results O
. O

( O
1989 O
), O
which O
is O
identical O
to O
the O
_RARE_ I-GENE
gene I-GENE
( O
_RARE_ I-GENE
et O
al O
., O
1988 O
). O

This O
region O
also O
contains O
a O
gene I-GENE
_RARE_ I-GENE
a O
Leu I-GENE
- I-GENE
tRNA I-GENE
precursor I-GENE
and O
a O
_RARE_ I-GENE
of O
a O
tau I-GENE
element I-GENE
. O

_RARE_ I-GENE
exposure O
to O
hepatitis I-GENE
B I-GENE
virus I-GENE
and O
human I-GENE
immunodeficiency I-GENE
virus I-GENE
: O
a O
comparative O
risk O
analysis O
. O

_RARE_ I-GENE
female O
mice O
( O
C57BL O
x O
_RARE_ I-GENE
) O
were O
paired I-GENE
with O
_RARE_ I-GENE
males O
( O
CD O
- I-GENE
1 I-GENE
) O
and O
_RARE_ I-GENE
pellets O
were O
implanted O
on O
day O
0 O
, O
the O
day O
on O
which O
_RARE_ I-GENE
_RARE_ I-GENE
were O
found O
, O
or O
on O
day O
2 I-GENE
or O
day O
3 I-GENE
in O
the O
_RARE_ I-GENE
period O
. O

This O
gene I-GENE
encodes O
a O
putative O
transcription I-GENE
factor I-GENE
with O
regions O
of O
homology I-GENE
to O
several O
other O
proteins I-GENE
including O
the O
zinc I-GENE
fingers O
and O
other O
domains I-GENE
of O
the O
Drosophila I-GENE
_RARE_ I-GENE
gene I-GENE
product I-GENE
, O
and O
the O
" O
AT I-GENE
- I-GENE
_RARE_ I-GENE
" O
DNA I-GENE
- I-GENE
binding I-GENE
motif I-GENE
of O
high O
mobility I-GENE
group O
proteins I-GENE
. O

Using O
reference O
probes O
as O
internal O
_RARE_ I-GENE
, O
we O
show O
that O
the O
_RARE_ I-GENE
transcription I-GENE
unit I-GENE
is O
located O
within O
the O
cytogenetic O
band O
interval O
_RARE_ I-GENE
, O
2 I-GENE
on O
the O
right O
arm O
of O
the O
third O
chromosome O
, O
and O
that O
it O
exerts O
diagnostic O
segmentation I-GENE
gene I-GENE
expression O
patterns O
in O
the O
embryo O
. O

The O
purified O
recombinant I-GENE
enzyme I-GENE
catalyzed O
specific I-GENE
_RARE_ I-GENE
transfer I-GENE
from O
ATP I-GENE
to O
_RARE_ I-GENE
and O
_RARE_ I-GENE
. O

Studies O
on O
the O
life O
cycle O
of O
_RARE_ I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
, O
_RARE_ I-GENE
) O
_RARE_ I-GENE
, O
_RARE_ I-GENE
with O
morphological O
_RARE_ I-GENE
of O
larval I-GENE
and O
adult O
stages O
. O

_RARE_ I-GENE
_RARE_ I-GENE
in O
5 I-GENE
cases O
of O
hepatitis I-GENE
B I-GENE
virus I-GENE
related I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
. O

During O
the O
following O
pregnancy O
_RARE_ I-GENE
studies O
of O
the O
male O
fetus O
in O
the O
_RARE_ I-GENE
week O
of O
gestation O
revealed O
severe O
_RARE_ I-GENE
, O
short O
and O
wide O
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
_RARE_ I-GENE
. O

Despite O
an O
overall O
survival O
rate O
of O
43 I-GENE
%, O
survival O
to O
discharge O
varied O
greatly O
( O
0 O
to O
100 O
%) O
among O
the O
24 O
diagnostic O
groups O
: O
tumor I-GENE
lysis O
syndrome O
and O
systemic O
lupus O
erythematosus O
( O
3 I-GENE
/ I-GENE
3 I-GENE
patients O
each O
, O
100 O
%), O
_RARE_ I-GENE
_RARE_ I-GENE
syndrome O
( O
8 O
/ I-GENE
9 O
patients O
, O
89 I-GENE
%). O

One O
hundred O
units O
/ I-GENE
kg O
of O
recombinant I-GENE
human I-GENE
erythropoietin I-GENE
( O
_RARE_ I-GENE
) O
was O
given O
subcutaneously O
3 I-GENE
times O
a O
week O
for O
3 I-GENE
weeks O
. O

A I-GENE
3 I-GENE
- I-GENE
week O
regimen O
of O
erythropoietin I-GENE
may O
help O
prevent O
the O
donor O
' O
s O
need O
to O
receive O
_RARE_ I-GENE
blood O
transfusion O
, O
when O
the O
initial O
Hb I-GENE
levels O
were O
below O
130 I-GENE
_RARE_ I-GENE
. O

In O
these O
constructs I-GENE
, O
GUS I-GENE
expression O
was O
driven O
by O
promoter I-GENE
regions O
derived O
from O
the O
Arabidopsis I-GENE
alcohol O
dehydrogenase I-GENE
( O
_RARE_ I-GENE
), O
maize I-GENE
ubiquitin I-GENE
( O
_RARE_ I-GENE
), O
rice I-GENE
actin I-GENE
( O
_RARE_ I-GENE
) O
and O
_RARE_ I-GENE
35S I-GENE
genes I-GENE
. O

Its O
organization O
and O
regulation O
indicate O
that O
the O
S I-GENE
. O
pombe I-GENE
_RARE_ I-GENE
gene I-GENE
product I-GENE
appears O
very O
similar O
to O
the O
S I-GENE
. O
cerevisiae I-GENE
_RARE_ I-GENE
gene I-GENE
product I-GENE
. O

The O
mean O
body O
mass O
index O
( O
BMI O
) O
was O
31 O
. O
8 O
+/- O
6 I-GENE
. O
3 I-GENE
kg O
/ I-GENE
m2 O
and O
28 O
. O
5 I-GENE
+/- O
6 I-GENE
. O
3 I-GENE
kg O
/ I-GENE
m2 O
in O
women O
and O
men O
, O
respectively O
. O

These O
findings O
demonstrate O
that O
haemodialysis O
patients O
with O
chronic O
hepatitis I-GENE
C I-GENE
respond O
well O
to O
interferon I-GENE
treatment O
and O
that O
a O
long O
- I-GENE
term O
response O
is O
achieved O
in O
a O
high O
proportion O
of O
patients O
. O

_RARE_ I-GENE
_RARE_ I-GENE
of O
drugs O

_RARE_ I-GENE
analysis O
further O
indicated O
that O
these O
germ I-GENE
cell O
- I-GENE
specific I-GENE
Sp1 I-GENE
mRNAs I-GENE
are O
translated O
, O
_RARE_ I-GENE
with O
a O
lower O
efficiency O
than O
the O
somatic O
transcript I-GENE
. O

In O
_RARE_ I-GENE
the O
response O
of O
_RARE_ I-GENE
but O
not O
of O
_RARE_ I-GENE
was O
influenced O
by O
the O
values O
at O
rest O
. O

This O
study O
_RARE_ I-GENE
an O
_RARE_ I-GENE
for O
such O
global O
_RARE_ I-GENE
effects O
upon O
unit I-GENE
- I-GENE
pair O
correlations O
based O
on O
local O
field O
potentials O
( O
_RARE_ I-GENE
). O

The O
assembly O
of O
sequence I-GENE
_RARE_ I-GENE
, O
high O
- I-GENE
resolution O
physical O
maps O
and O
construction I-GENE
of O
_RARE_ I-GENE
overlapping O
_RARE_ I-GENE
for O
the O
human I-GENE
as O
well O
as O
model O
genomes O
requires O
accurate O
determination O
of O
the O
extent O
of O
overlap O
between O
adjacent O
clones O
as O
well O
as O
their O
relative O
orientation O
. O

( O
ii O
) O
_RARE_ I-GENE
of O
_RARE_ I-GENE
attenuates O
, O
inhibition O
of O
the O
channel O
_RARE_ I-GENE
functional O
consequences O
of O
coronary O
occlusion O
, O
and O
( O
iii O
) O
_RARE_ I-GENE
_RARE_ I-GENE
attenuates O
reperfusion O
- I-GENE
induced O
VF O
, O
but O
it O
triggers O
ischemia O
- I-GENE
induced O
VF O
. O

The O
DNA I-GENE
sequences I-GENE
upstream O
of O
these O
termini O
exhibit O
homology I-GENE
to O
plant O
mitochondrial I-GENE
- I-GENE
processing O
sites I-GENE
, O
therefore O
the O
proximal I-GENE
5 I-GENE
' O
ends O
are O
most O
probably O
generated O
by O
RNA I-GENE
processing O
. O

_RARE_ I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
changes O
of O
resin O
- I-GENE
modified O
glass O
_RARE_ I-GENE
_RARE_ I-GENE
materials O
. O

Here O
we O
present O
genetic O
evidence O
suggesting O
that O
PP2A I-GENE
functions O
downstream O
of O
_RARE_ I-GENE
in O
the O
_RARE_ I-GENE
receptor I-GENE
tyrosine I-GENE
kinase I-GENE
( O
_RARE_ I-GENE
) O
signal I-GENE
transduction O
pathway O
that O
specifies O
_RARE_ I-GENE
_RARE_ I-GENE
cell O
fate O
in O
the O
developing O
Drosophila I-GENE
eye O
. O

_RARE_ I-GENE
for O
a O
5 I-GENE
% O
change O
in O
response O
( O
_RARE_ I-GENE
) O
were O
6 I-GENE
- I-GENE
fold O
lower O
, O
on O
average O
, O
than O
the O
corresponding O
_RARE_ I-GENE
. O

Effects O
of O
repeated O
exposures O
of O
hydrogen O
_RARE_ I-GENE
on O
rat I-GENE
hippocampal O
EEG O
. O

The O
gene I-GENE
encodes O
an O
ATP I-GENE
- I-GENE
binding I-GENE
cassette I-GENE
, O
_RARE_ I-GENE
transporter I-GENE
. O

The O
T I-GENE
- I-GENE
box I-GENE
motif I-GENE
is O
present O
in O
a O
family I-GENE
of O
genes I-GENE
whose O
structural O
features O
and O
expression O
patterns O
support O
their O
involvement O
in O
developmental O
gene I-GENE
regulation O
. O

Molecular O
analysis O
of O
a O
novel O
_RARE_ I-GENE
pombe I-GENE
gene I-GENE
containing O
two O
RNP I-GENE
consensus I-GENE
- I-GENE
sequence I-GENE
RNA I-GENE
- I-GENE
binding I-GENE
domains I-GENE
. O

_RARE_ I-GENE
overall O
treatment O
time O
, O
field O
size O
, O
and O
treatment O
energy O
influence O
local O
control O
of O
T1 O
- I-GENE
T2 I-GENE
squamous O
cell O
carcinomas O
of O
the O
_RARE_ I-GENE
larynx O
? O
PURPOSE O
: O
To O
evaluate O
treatment O
and O
patient O
related I-GENE
prognostic O
factors I-GENE
that O
may O
influence O
local O
control O
in O
the O
treatment O
of O
T1 O
- I-GENE
T2 I-GENE
squamous O
cell O
carcinoma O
of O
the O
_RARE_ I-GENE
larynx O
. O

In O
contrast O
to O
the O
signaling O
triggered O
by O
surface O
Ig I-GENE
_RARE_ I-GENE
in O
B I-GENE
lymphocytes O
, O
_RARE_ I-GENE
ligation O
did O
not O
appear O
to O
induce O
tyrosine I-GENE
phosphorylation O
of O
the O
src I-GENE
- I-GENE
like I-GENE
protein I-GENE
tyrosine I-GENE
kinases I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
, O
or O
of O
_RARE_ I-GENE
- I-GENE
and O
ras I-GENE
- I-GENE
GTPase I-GENE
- I-GENE
activating I-GENE
protein I-GENE
, O
nor O
did O
it O
induce O
detectable O
changes O
in O
cytosolic I-GENE
_RARE_ I-GENE
+ I-GENE
concentrations O
. O

Mutations O
in O
the O
alpha I-GENE
- I-GENE
_RARE_ I-GENE
conserved O
domain I-GENE
of O
the O
largest O
subunit I-GENE
of O
yeast I-GENE
RNA I-GENE
polymerase I-GENE
III I-GENE
affect O
_RARE_ I-GENE
, O
RNA I-GENE
cleavage O
and O
transcriptional O
_RARE_ I-GENE
. O

The O
evidence O
presented O
here O
suggests O
that O
the O
p40 I-GENE
complex I-GENE
is O
a O
ribonucleoprotein I-GENE
complex I-GENE
containing O
_RARE_ I-GENE
RNA I-GENE
( O
s O
) O
and O
that O
protein I-GENE
- I-GENE
protein I-GENE
interactions O
in O
which O
alpha I-GENE
- I-GENE
helix I-GENE
structures O
participate O
, O
for O
example O
coiled O
- I-GENE
_RARE_ I-GENE
, O
may O
occur O
in O
the O
complex I-GENE
. O

Our O
data O
suggest O
that O
trans O
- I-GENE
activation O
from O
the O
_RARE_ I-GENE
intron O
enhancer I-GENE
is O
a O
_RARE_ I-GENE
_RARE_ I-GENE
of O
the O
transforming I-GENE
properties O
of O
the O
Myc I-GENE
protein I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
following O
bone O
marrow O
transplantation O
: O
_RARE_ I-GENE
and O
_RARE_ I-GENE
study O
of O
one O
case O
. O

In O
view O
of O
the O
presence O
of O
SECIS O
elements O
in O
the O
open O
reading O
frames O
( O
ORFs O
) O
of O
bacterial I-GENE
_RARE_ I-GENE
, O
we O
examine O
the O
effects O
in O
the O
type I-GENE
1 I-GENE
deiodinase I-GENE
of O
extending O
the O
ORF I-GENE
into O
the O
SECIS O
element I-GENE
, O
and O
find O
that O
this O
dramatically O
inhibits O
SECIS O
function O
. O

The O
5 I-GENE
' O
external O
transcribed O
spacer O
( O
ETS I-GENE
) O
region O
of O
the O
pre I-GENE
- I-GENE
rRNA I-GENE
in O
Saccharomyces I-GENE
cerevisiae I-GENE
contains O
a O
sequence I-GENE
with O
10 O
bp O
of O
perfect O
complementarity I-GENE
to O
the O
U3 I-GENE
_RARE_ I-GENE
. O

These O
animals O
were O
viable O
and O
_RARE_ I-GENE
. O

This O
spindle O
defect O
of O
_RARE_ I-GENE
mutants I-GENE
results O
from O
a O
temperature O
- I-GENE
sensitive O
step O
that O
occurs O
around O
the O
G1 I-GENE
/ I-GENE
S I-GENE
boundary O
about O
the O
time O
of O
spindle O
assembly O
. O

These O
data O
suggest O
that O
_RARE_ I-GENE
- I-GENE
1 I-GENE
is O
likely O
to O
be O
involved O
in O
early I-GENE
steps O
in O
the O
differentiation O
of O
_RARE_ I-GENE
and O
_RARE_ I-GENE
cells O
. O

In O
the O
point O
mutant I-GENE
we O
observed O
normal O
repair I-GENE
of O
endonuclease I-GENE
III I-GENE
site I-GENE
( O
i O
. O
e O
. O
as O
wild I-GENE
type I-GENE
), O
but O
no O
removal O
of O
_RARE_ I-GENE
at O
the O
_RARE_ I-GENE
alpha I-GENE
and O
HML I-GENE
alpha I-GENE
loci I-GENE
. O

However O
, O
for O
the O
evaluable O
cases O
, O
the O
_RARE_ I-GENE
of O
the O
_RARE_ I-GENE
and O
the O
_RARE_ I-GENE
were O
broadly O
similar O
and O
generally O
correlated O
well O
with O
the O
_RARE_ I-GENE
reference O
procedure O
. O

_RARE_ I-GENE
- I-GENE
terminal I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
lacking O
the O
calmodulin I-GENE
binding I-GENE
site I-GENE
can O
support O
growth I-GENE
and O
are O
also O
phosphorylated O
in O
a O
cell O
cycle O
- I-GENE
specific I-GENE
manner O
. O

Both O
EWS I-GENE
- I-GENE
FLI I-GENE
- I-GENE
1 I-GENE
and O
FLI I-GENE
- I-GENE
1 I-GENE
proteins I-GENE
function O
as O
transcription I-GENE
factors I-GENE
that O
bind O
specifically O
to O
ets I-GENE
sequences I-GENE
( O
the O
ets I-GENE
boxes O
) O
present O
in O
promoter I-GENE
elements O
. O

In O
_RARE_ I-GENE
shift O
assays O
, O
EWS I-GENE
- I-GENE
FLI I-GENE
- I-GENE
1 I-GENE
binding I-GENE
to O
the O
SRE O
is O
detectable O
in O
the O
absence O
of O
SRF I-GENE
whereas O
the O
binding I-GENE
of O
FLI I-GENE
- I-GENE
1 I-GENE
is O
not O
, O
suggesting O
that O
the O
interaction O
with O
DNA I-GENE
is O
the O
step O
which O
limits O
ternary O
complex I-GENE
formation O
by O
FLI I-GENE
- I-GENE
1 I-GENE
. O

_RARE_ I-GENE
studies O
with O
new O
and O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
comparing O
450 I-GENE
and O
220 O
mL O
/ I-GENE
min O
blood O
flow O
rates O
at O
10 O
minutes O
showed O
no O
change O
in O
_RARE_ I-GENE
. O

DNA I-GENE
methylation O
, O
especially O
of O
either O
one O
or O
both O
of O
the O
_RARE_ I-GENE
at O
the O
two O
_RARE_ I-GENE
motifs O
( O
one O
in O
the O
first O
exon O
and O
the O
other O
in O
the O
first O
intron O
of O
the O
rice I-GENE
_RARE_ I-GENE
gene I-GENE
), O
appeared O
to O
be O
responsible O
for O
the O
_RARE_ I-GENE
promoter I-GENE
activity O
identified O
in O
the O
transient O
assay O
. O

The O
viral I-GENE
LTR I-GENE
was O
used O
as O
the O
promoter I-GENE
. O

_RARE_ I-GENE
cDNA I-GENE
clones O
were O
isolated O
and O
sequenced O
. O

In O
conclusion O
, O
IgM I-GENE
class I-GENE
CIC I-GENE
is O
the O
predominant O
CIC I-GENE
in O
acute O
hepatitis I-GENE
A I-GENE
and O
correlated O
with O
disease O
activity O
. O

_RARE_ I-GENE
mapping O
revealed O
that O
these O
three O
clones O
appear O
to O
recognize O
an O
identical O
epitope O
domain I-GENE
present O
on O
the O
C I-GENE
- I-GENE
terminal I-GENE
RNP I-GENE
motif I-GENE
of O
the O
_RARE_ I-GENE
protein I-GENE
. O

_RARE_ I-GENE
evaluated O
were O
number O
of O
weekly O
_RARE_ I-GENE
events O
, O
data O
from O
_RARE_ I-GENE
exercise O
testing O
with O
simultaneous O
_RARE_ I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
evaluation O
of O
Tc O
- I-GENE
99m O
2 I-GENE
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
scans O
and O
_RARE_ I-GENE
variables O
. O

As O
the O
length I-GENE
of O
the O
fatty I-GENE
acid I-GENE
decreased O
, O
the O
binding I-GENE
affinity O
was O
reduced O
; O
_RARE_ I-GENE
acid I-GENE
( O
14 O
: O
0 O
) O
bound O
with O
a O
K I-GENE
( O
d O
) O
of O
_RARE_ I-GENE
+/- O
_RARE_ I-GENE
nM O
, O
but O
medium O
- I-GENE
chain I-GENE
( O
_RARE_ I-GENE
acid I-GENE
, O
10 O
: O
0 O
) O
and O
short O
- I-GENE
chain I-GENE
( O
_RARE_ I-GENE
acid I-GENE
, O
8 O
: O
0 O
) O
lipids O
were O
not O
bound O
at O
all O
. O

The O
membrane I-GENE
- I-GENE
distal O
cytoplasmic I-GENE
region O
of O
human I-GENE
granulocyte I-GENE
colony I-GENE
- I-GENE
stimulating I-GENE
factor I-GENE
receptor I-GENE
is O
required O
for O
STAT3 I-GENE
but O
not O
STAT1 I-GENE
homodimer I-GENE
formation O
. O

However O
, O
whether O
or O
not O
nonsense O
codon O
recognition I-GENE
within O
_RARE_ I-GENE
transcripts I-GENE
_RARE_ I-GENE
place O
prior O
to O
or O
after O
splicing O
remained O
_RARE_ I-GENE
. O

Although O
some O
residues O
are O
found O
reactive I-GENE
toward O
_RARE_ I-GENE
and O
_RARE_ I-GENE
in O
regions O
predicted O
to O
be O
_RARE_ I-GENE
by O
the O
phylogenetic O
secondary O
structure O
model O
of O
4 I-GENE
. O
5S I-GENE
RNA I-GENE
, O
generally O
the O
reactivity O
is O
low O
, O
and O
some O
residues O
in O
internal O
loops O
are O
not O
reactive I-GENE
at O
all O
. O

_RARE_ I-GENE
and O
future O
investigations O
may O
better O
define O
the O
optimal O
approach O
for O
local O
control O
, O
the O
optimal O
duration O
of O
maintenance O
chemotherapy O
, O
and O
the O
possible O
role O
of O
_RARE_ I-GENE
response O
_RARE_ I-GENE
and O
growth I-GENE
factors I-GENE
in O
further O
_RARE_ I-GENE
the O
outcome O
for O
patients O
with O
this O
disease O
. O

_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
: O
We O
discuss O
the O
criteria O
that O
make O
such O
studies O
comparable O
, O
_RARE_ I-GENE
on O
the O
_RARE_ I-GENE
of O
recent O
studies O
performed O
around O
the O
world O
. O

Forty O
- I-GENE
five O
patients O
with O
pleural I-GENE
lesions O
identified O
on O
CT I-GENE
scans O
were O
subsequently O
examined O
by O
MR O
imaging O
at O
0 O
. O
5 I-GENE
T I-GENE
. O

_RARE_ I-GENE
atrial I-GENE
volumes O
were O
greater O
in O
old O
compared O
with O
young O
subjects O
( O
maximal O
: O
31 O
+/- O
10 O
cm3 O
/ I-GENE
m2 O
vs O
24 O
+/- O
8 O
cm3 O
/ I-GENE
m2 O
, O
p O
= O
0 O
. O
02 O
; O
at O
onset O
of O
atrial I-GENE
_RARE_ I-GENE
: O
23 O
+/- O
8 O
cm3 O
/ I-GENE
m2 O
vs O
15 O
+/- O
5 I-GENE
cm3 O
/ I-GENE
m2 O
, O
p O
= O
0 O
. O
_RARE_ I-GENE
; O
minimal I-GENE
: O
13 O
+/- O
5 I-GENE
cm3 O
/ I-GENE
m2 O
vs O
9 O
+/- O
4 I-GENE
cm3 O
/ I-GENE
m2 O
, O
p O
= O
0 O
. O
001 O
). O

RESULTS O
: O
Basal O
plasma I-GENE
IGF I-GENE
- I-GENE
I I-GENE
levels O
as O
well O
as O
body O
mass O
index O
( O
BMI O
) O
were O
lower O
in O
_RARE_ I-GENE
patients O
than O
in O
healthy O
controls O
. O

We O
observed O
abundant O
levels O
of O
Rev I-GENE
- I-GENE
erbA I-GENE
alpha I-GENE
mRNA I-GENE
in O
_RARE_ I-GENE
C2C12 O
myoblasts O
, O
which O
were O
suppressed O
when O
the O
cells O
differentiated O
into O
_RARE_ I-GENE
_RARE_ I-GENE
myotubes O
. O

We O
then O
demonstrated O
that O
1 I-GENE
) O
GAL4 I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
erbA I-GENE
alpha I-GENE
_RARE_ I-GENE
that O
contain O
the O
' O
_RARE_ I-GENE
' O
region O
and O
lack O
the O
' O
E I-GENE
' O
region O
activated I-GENE
transcription I-GENE
of O
GAL4 I-GENE
response O
elements O
in O
the O
presence O
of O
8 O
- I-GENE
Br O
- I-GENE
cAMP I-GENE
and O
2 I-GENE
) O
the O
ligand O
- I-GENE
binding I-GENE
domain I-GENE
( O
_RARE_ I-GENE
) O
contains O
an O
active O
transcriptional O
silencer I-GENE
. O

The O
alpha I-GENE
T3 O
- I-GENE
1 I-GENE
cell O
line O
, O
a O
GnRH I-GENE
- I-GENE
responsive I-GENE
_RARE_ I-GENE
cell O
line O
developed O
by O
targeted O
_RARE_ I-GENE
in O
transgenic O
mice O
, O
was O
used O
to O
study O
regulation O
of O
the O
glycoprotein I-GENE
hormone I-GENE
alpha I-GENE
- I-GENE
subunit I-GENE
by O
activin I-GENE
. O

Cotransfection O
with O
the O
_RARE_ I-GENE
gene I-GENE
resulted O
in O
a O
dramatic O
increase O
in O
the O
amount O
of O
the O
two O
enzymes O
expressed O
in O
the O
transfected O
cells O
. O

As O
expected O
, O
glycosylation O
of O
Env I-GENE
produced O
from O
mutants I-GENE
was O
affected O
but O
, O
irrespective O
of O
the O
glycosylation O
phenotype O
, O
( O
i O
) O
similar O
_RARE_ I-GENE
of O
Env I-GENE
were O
synthesized O
, O
( O
ii O
) O
the O
immunoreactivity O
of O
_RARE_ I-GENE
was O
similar O
, O
( O
iii O
) O
_RARE_ I-GENE
was O
efficiently O
cleaved O
into O
gp120 I-GENE
and O
_RARE_ I-GENE
, O
( O
_RARE_ I-GENE
) O
Env I-GENE
was O
exposed O
at O
the O
cell O
membrane I-GENE
, O
( O
v I-GENE
) O
secreted O
gp120 I-GENE
bound O
CD4 I-GENE
, O
and O
( O
_RARE_ I-GENE
) O
membrane I-GENE
_RARE_ I-GENE
was O
able O
to O
induce O
membrane I-GENE
fusion I-GENE
with O
CD4 I-GENE
+ I-GENE
cells O
. O

Effects O
of O
_RARE_ I-GENE
_RARE_ I-GENE
on O
Parkinson O
' O
s O
disease O
. O

On O
the O
_RARE_ I-GENE
of O
_RARE_ I-GENE
. O

However O
, O
only O
complete O
_RARE_ I-GENE
can O
cooperate O
with O
_RARE_ I-GENE
and O
a O
third O
protein I-GENE
, O
_RARE_ I-GENE
, O
in O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
luciferase I-GENE
. O

The O
two O
different O
_RARE_ I-GENE
of O
STAT5 I-GENE
have O
identical O
in O
vitro O
DNA I-GENE
binding I-GENE
specificity O
and O
reactivity O
with O
tyrosine I-GENE
phosphopeptides O
, O
but O
differ O
in O
their O
cellular O
localization O
. O

TNF I-GENE
Treatment O
of O
cell O
activated I-GENE
the O
p38 I-GENE
MAP I-GENE
kinase I-GENE
pathway O
, O
as O
revealed O
by O
increased O
phosphorylation O
of O
p38 I-GENE
MAP I-GENE
kinase I-GENE
itself O
, O
activation O
of O
the O
substrate I-GENE
protein I-GENE
_RARE_ I-GENE
kinase I-GENE
- I-GENE
2 I-GENE
, O
and O
_RARE_ I-GENE
in O
the O
phosphorylation O
of O
the O
heat I-GENE
shock I-GENE
protein I-GENE
27 O
( O
_RARE_ I-GENE
). O

We O
have O
isolated O
a O
novel O
protein I-GENE
from O
Drosophila I-GENE
nuclear I-GENE
extracts O
which O
binds O
specifically O
to O
a O
site I-GENE
in O
this O
second O
region O
. O

However O
, O
while O
the O
sequence I-GENE
similarity O
between O
the O
membrane I-GENE
exons O
of O
avian I-GENE
_RARE_ I-GENE
and O
mammalian I-GENE
_RARE_ I-GENE
and O
IgE I-GENE
is O
striking O
, O
the O
overall O
similarity O
with O
Xenopus I-GENE
_RARE_ I-GENE
is O
very O
low O
. O

Control O
of O
transcription I-GENE
of O
the O
erbB I-GENE
- I-GENE
2 I-GENE
gene I-GENE
is O
an O
important O
determinant O
of O
receptor I-GENE
expression O
. O

DNase I-GENE
I I-GENE
footprinting O
and O
electrophoretic O
mobility I-GENE
shift O
assays O
indicate O
that O
_RARE_ I-GENE
binds O
to O
the O
half O
- I-GENE
site I-GENE
of O
each O
palindrome O
with O
the O
core I-GENE
recognition I-GENE
sequence I-GENE
_RARE_ I-GENE
. O

These O
results O
demonstrate O
that O
sequences I-GENE
in O
the O
SH2 I-GENE
/ I-GENE
SH3 I-GENE
/ I-GENE
SH2 I-GENE
region O
of O
_RARE_ I-GENE
GAP I-GENE
are O
required O
for O
full I-GENE
catalytic O
activity O
toward O
Ras I-GENE
. O

The O
novel O
hematopoietic I-GENE
growth I-GENE
factor I-GENE
_RARE_ I-GENE
ligand O
( O
FL I-GENE
) O
is O
the O
cognate I-GENE
ligand O
for O
the O
_RARE_ I-GENE
, O
tyrosine I-GENE
kinase I-GENE
receptor I-GENE
( O
R I-GENE
), O
also O
referred O
to O
as O
_RARE_ I-GENE
- I-GENE
2 I-GENE
and O
STK I-GENE
- I-GENE
1 I-GENE
. O

In O
contrast O
to O
the O
selective O
expression O
of O
the O
receptor I-GENE
, O
FL I-GENE
expression O
was O
detected O
in O
90 O
- I-GENE
100 O
% O
of O
the O
various O
cell O
types O
of O
leukemia I-GENE
cell O
lines O
from O
all O
hematopoietic I-GENE
cell O
lineages O
. O

Further O
analysis O
of O
this O
domain I-GENE
by O
in O
vitro O
mutagenesis O
_RARE_ I-GENE
to O
a O
core I-GENE
of O
hydrophobic O
and O
acidic O
residues O
as O
critical O
for O
the O
activity O
. O

Analysis O
of O
RAR I-GENE
alpha I-GENE
mutants I-GENE
in O
transfection O
studies O
reveals O
that O
the O
DNA I-GENE
binding I-GENE
domain I-GENE
is O
sufficient O
for O
inhibition O
of O
_RARE_ I-GENE
activity O
. O

We O
measured O
serum I-GENE
hepatocyte I-GENE
growth I-GENE
factor I-GENE
( O
HGF I-GENE
) O
in O
patients O
with O
acute O
myocardial O
infarction O
, O
angina O
pectoris O
, O
and O
other O
heart O
diseases O
. O

The O
neural O
mechanism O
of O
_RARE_ I-GENE
motor O
symptoms O
, O
i O
. O
e O
., O
_RARE_ I-GENE
, O
tremor O
and O
_RARE_ I-GENE
, O
which O
are O
the O
result O
of O
_RARE_ I-GENE
dopamine I-GENE
deficiency O
, O
is O
interpreted O
from O
long O
- I-GENE
term O
observations O
on O
the O
effect O
of O
surgical O
and O
pharmacological O
treatment O
of O
the O
disease O
in O
relation O
to O
the O
_RARE_ I-GENE
findings O
within O
the O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
). O

Protein I-GENE
splicing O
: O
evidence O
for O
an O
N I-GENE
- I-GENE
O O
_RARE_ I-GENE
rearrangement O
as O
the O
initial O
step O
in O
the O
splicing O
process O
. O

In O
agreement O
with O
these O
data O
, O
_RARE_ I-GENE
blot O
experiments O
using O
an O
antibody I-GENE
directed O
against O
the O
carboxy I-GENE
- I-GENE
terminal I-GENE
portion O
of O
the O
mouse I-GENE
c I-GENE
- I-GENE
kit I-GENE
protein I-GENE
showed O
that O
a O
polypeptide I-GENE
, O
of O
the O
size O
predicted O
by O
the O
open O
reading O
frame O
of O
the O
_RARE_ I-GENE
- I-GENE
specific I-GENE
c I-GENE
- I-GENE
kit I-GENE
cDNA I-GENE
, O
accumulates O
in O
the O
_RARE_ I-GENE
stages O
of O
_RARE_ I-GENE
and O
in O
_RARE_ I-GENE
spermatozoa O
. O

It O
is O
shown O
that O
the O
( O
G I-GENE
+ I-GENE
C I-GENE
)- I-GENE
rich O
element I-GENE
of O
the O
_RARE_ I-GENE
C I-GENE
promoter I-GENE
directs O
transcription I-GENE
in O
neuronal O
as O
well O
as O
in O
_RARE_ I-GENE
cells O
. O

_RARE_ I-GENE
appears O
to O
inhibit O
uPA I-GENE
promoter I-GENE
activation O
by O
blocking O
phorbol O
ester O
- I-GENE
stimulated O
binding I-GENE
of O
nuclear I-GENE
proteins I-GENE
to O
the O
uPA I-GENE
PEA3 I-GENE
/ I-GENE
12 O
- I-GENE
0 O
- I-GENE
_RARE_ I-GENE
13 O
- I-GENE
acetate O
responsive I-GENE
element I-GENE
( O
TRE I-GENE
). O

Treatment O
of O
_RARE_ I-GENE
expressing O
a O
normal O
epidermal I-GENE
growth I-GENE
factor I-GENE
receptor I-GENE
( O
EGFR I-GENE
) O
with O
_RARE_ I-GENE
or O
epidermal I-GENE
growth I-GENE
factor I-GENE
for O
5 I-GENE
min O
induced O
_RARE_ I-GENE
tyrosine I-GENE
phosphorylation O
. O

Only O
one O
of O
these O
bands O
was O
_RARE_ I-GENE
by O
antibody I-GENE
to O
p50 I-GENE
, O
whereas O
antibodies I-GENE
to O
p65 I-GENE
or O
other O
NF I-GENE
- I-GENE
kappaB I-GENE
proteins I-GENE
had O
no O
effect O
. O

We O
isolated O
a O
complementary O
DNA I-GENE
( O
cDNA I-GENE
) O
clone O
from O
an O
_RARE_ I-GENE
- I-GENE
2 I-GENE
expression O
library O
that O
encodes O
the O
C1 I-GENE
site I-GENE
- I-GENE
binding I-GENE
protein I-GENE
. O

Biol O
. O

In O
addition O
, O
anti I-GENE
- I-GENE
phosphotyrosine I-GENE
antibodies I-GENE
immunoprecipitated O
_RARE_ I-GENE
- I-GENE
H I-GENE
from O
cell O
lysates O
of O
FGF I-GENE
- I-GENE
stimulated O
but O
not O
from O
control O
fibroblasts O
. O

The O
novel O
protein I-GENE
kinases I-GENE
, O
c I-GENE
- I-GENE
Jun I-GENE
NH2 I-GENE
- I-GENE
terminal I-GENE
kinases I-GENE
( O
_RARE_ I-GENE
)/ O
stress O
- I-GENE
activated I-GENE
protein I-GENE
kinases I-GENE
, O
are O
also O
activated I-GENE
by O
TNF I-GENE
- I-GENE
alpha I-GENE
, O
IL I-GENE
- I-GENE
1 I-GENE
, O
and O
_RARE_ I-GENE
_RARE_ I-GENE
. O

Thus O
, O
_RARE_ I-GENE
potentially O
functions O
as O
a O
dominant I-GENE
negative O
inhibitor I-GENE
of O
_RARE_ I-GENE
activity O
. O

_RARE_ I-GENE
contains O
an O
NH2 I-GENE
- I-GENE
terminal I-GENE
_RARE_ I-GENE
domain I-GENE
followed O
by O
four O
epidermal I-GENE
growth I-GENE
factor I-GENE
- I-GENE
like I-GENE
repeats I-GENE
and O
tandem O
globular O
( O
G I-GENE
) O
domains I-GENE
. O

Both O
_RARE_ I-GENE
cDNA I-GENE
clones O
detect O
a O
single O
3 I-GENE
. O
2 I-GENE
- I-GENE
kb O
transcript I-GENE
on O
Northern O
blots O
of O
multiple O
human I-GENE
tissues O
, O
indicating O
the O
long O
cDNA I-GENE
containing O
the O
3 I-GENE
'- O
untranslated O
intron O
represents O
the O
predominant O
transcript I-GENE
. O

_RARE_ I-GENE
of O
_RARE_ I-GENE
L I-GENE
protein I-GENE
in O
vitro O
was O
inhibited O
by O
phosphorylation O
of O
_RARE_ I-GENE
L I-GENE
protein I-GENE
by O
PKN I-GENE
. O

The O
protein I-GENE
_RARE_ I-GENE
correctly O
with O
two O
disulfide O
bonds O
and O
a O
free O
_RARE_ I-GENE
group O
at O
_RARE_ I-GENE
. O

We O
and O
others O
have O
demonstrated O
that O
the O
c I-GENE
- I-GENE
cbl I-GENE
proto I-GENE
- I-GENE
oncogene I-GENE
product I-GENE
is O
one O
of O
the O
_RARE_ I-GENE
targets O
of O
tyrosine I-GENE
phosphorylation O
upon O
T I-GENE
cell O
receptor I-GENE
stimulation O
. O

A I-GENE
substantial O
fraction O
of O
Cbl I-GENE
was O
constitutively O
associated I-GENE
with O
Grb2 I-GENE
and O
this O
interaction O
was O
mediated O
by O
Grb2 I-GENE
SH3 I-GENE
domains I-GENE
. O

An O
AP I-GENE
- I-GENE
1 I-GENE
binding I-GENE
sequence I-GENE
is O
essential O
for O
regulation O
of O
the O
human I-GENE
alpha2 I-GENE
( O
I I-GENE
) O
collagen I-GENE
( O
_RARE_ I-GENE
) O
promoter I-GENE
activity O
by O
transforming I-GENE
growth I-GENE
factor I-GENE
- I-GENE
beta I-GENE
. O

No O
significant O
differences O
existed O
between O
the O
two O
age O
groups O
in O
baseline O
characteristics O
, O
including O
treatment O
protocol O
, O
performance O
status O
, O
and O
serum I-GENE
lactate I-GENE
dehydrogenase I-GENE
( O
_RARE_ I-GENE
) O
level O
. O

Only O
two O
patients O
( O
0 O
. O
3 I-GENE
%) O
had O
a O
CA I-GENE
125 I-GENE
response O
at O
the O
time O
of O
clinical O
progression O
. O

The O
men O
self O
- I-GENE
selected O
a O
_RARE_ I-GENE
diet O
at O
home O
_RARE_ I-GENE
_RARE_ I-GENE
fat O
as O
the O
_RARE_ I-GENE
fat O
for O
1 I-GENE
week O
. O

Conversely O
, O
when O
VDR I-GENE
is O
overexpressed O
, O
vitamin O
D3 I-GENE
attenuates O
9 O
- I-GENE
cis O
RA O
induction O
from O
an O
RXR I-GENE
- I-GENE
responsive I-GENE
element I-GENE
. O

These O
results O
_RARE_ I-GENE
a O
hitherto O
_RARE_ I-GENE
function O
of O
U6 I-GENE
RNA I-GENE
: O
the O
modulation O
of O
a O
phosphorylation O
- I-GENE
_RARE_ I-GENE
cycle O
of O
C1 I-GENE
hnRNP I-GENE
protein I-GENE
that O
influences O
the O
binding I-GENE
affinity O
of O
this O
protein I-GENE
for O
pre I-GENE
- I-GENE
mRNA I-GENE
. O

_RARE_ I-GENE
of O
the O
extended O
N I-GENE
terminus O
into O
the O
_RARE_ I-GENE
reported O
protein I-GENE
resulted O
in O
a O
striking O
similarity O
to O
the O
lymphoid I-GENE
factor I-GENE
_RARE_ I-GENE
- I-GENE
1 I-GENE
. O

_RARE_ I-GENE
mammalian I-GENE
_RARE_ I-GENE
activates O
CBF1 I-GENE
/ I-GENE
_RARE_ I-GENE
- I-GENE
repressed O
genes I-GENE
by O
a O
mechanism O
resembling O
that O
of O
Epstein I-GENE
- I-GENE
Barr I-GENE
virus I-GENE
EBNA2 I-GENE
. O

Electrophoretic O
mobility I-GENE
shift O
assays O
( O
_RARE_ I-GENE
) O
using O
purified O
glucocorticoid I-GENE
receptor I-GENE
DNA I-GENE
binding I-GENE
domain I-GENE
( O
_RARE_ I-GENE
) O
demonstrated O
that O
both O
GRE I-GENE
- I-GENE
2 I-GENE
and O
- I-GENE
3 I-GENE
motifs O
interact O
with O
_RARE_ I-GENE
and O
oligonucleotide I-GENE
competition O
experiments O
established O
that O
these O
have O
different O
affinities O
for O
_RARE_ I-GENE
. O

The O
large O
subfamily I-GENE
of O
receptor I-GENE
tyrosine I-GENE
kinases I-GENE
( O
_RARE_ I-GENE
) O
for O
which O
_RARE_ I-GENE
is O
the O
prototype O
have O
likely O
roles O
in O
_RARE_ I-GENE
_RARE_ I-GENE
during O
normal O
mammalian I-GENE
development O
, O
but O
the O
biochemical O
signalling O
pathways O
_RARE_ I-GENE
by O
this O
family I-GENE
are O
poorly O
_RARE_ I-GENE
. O

The O
17 O
- I-GENE
kDa I-GENE
protein I-GENE
is O
required O
for O
the O
systemic O
infection O
of O
plants O
. O

We O
present O
here O
a O
detailed O
genomic O
sequencing O
analysis O
of O
the O
cytosine O
methylation O
patterns O
of O
the O
_RARE_ I-GENE
binding I-GENE
sites I-GENE
within O
both O
Ac I-GENE
ends O
in O
the O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
:: O
Ac I-GENE
allele I-GENE
, O
where O
Ac I-GENE
is O
inserted O
into O
the O
_RARE_ I-GENE
exon O
of O
the O
_RARE_ I-GENE
gene I-GENE
. O

Krox I-GENE
- I-GENE
20 O
, O
a O
zinc I-GENE
finger I-GENE
gene I-GENE
, O
has O
a O
highly O
conserved O
pattern O
of O
expression O
in O
_RARE_ I-GENE
and O
_RARE_ I-GENE
and O
is O
functionally O
required O
for O
their O
maintenance O
in O
mouse I-GENE
embryos O
. O

_RARE_ I-GENE
adenylate I-GENE
cyclase I-GENE
- I-GENE
activating I-GENE
polypeptide I-GENE
regulates O
prolactin I-GENE
promoter I-GENE
activity O
via O
a O
protein I-GENE
kinase I-GENE
A I-GENE
- I-GENE
mediated O
pathway O
that O
is O
independent O
of O
the O
transcriptional O
pathway O
employed O
by O
thyrotropin I-GENE
- I-GENE
releasing I-GENE
hormone I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
encoded I-GENE
identical O
aromatase I-GENE
proteins I-GENE
of O
_RARE_ I-GENE
amino O
acids O
, O
but O
differed O
in O
size O
due O
to O
alternative O
polyadenylation O
signal I-GENE
usage O
for O
the O
corresponding O
mRNAs I-GENE
. O

In O
_RARE_ I-GENE
bone O
marrow O
cells O
expression O
of O
both O
_RARE_ I-GENE
genes I-GENE
was O
detected O
in O
pro I-GENE
- I-GENE
B I-GENE
/ I-GENE
pre I-GENE
- I-GENE
BI I-GENE
and O
large O
pre I-GENE
- I-GENE
_RARE_ I-GENE
cells O
, O
while O
the O
RNA I-GENE
steady O
state O
levels O
were O
at O
least O
100 O
- I-GENE
fold O
lower O
in O
small I-GENE
pre I-GENE
- I-GENE
_RARE_ I-GENE
and O
immature O
/ I-GENE
mature O
B I-GENE
cells O
. O

We O
have O
cloned O
and O
sequenced O
a O
_RARE_ I-GENE
- I-GENE
bp O
Bacillus I-GENE
subtilis I-GENE
( O
_RARE_ I-GENE
) O
DNA I-GENE
fragment I-GENE
located O
between O
the O
_RARE_ I-GENE
and O
_RARE_ I-GENE
genes I-GENE
at O
about O
_RARE_ I-GENE
degrees O
on O
the O
chromosome O
. O

_RARE_ I-GENE
_RARE_ I-GENE
possesses O
two O
genes I-GENE
encoding O
homologs I-GENE
of O
the O
major I-GENE
outer I-GENE
membrane I-GENE
protein I-GENE
, O
_RARE_ I-GENE
. O

Expression O
of O
_RARE_ I-GENE
was O
toxic O
to O
E I-GENE
. O
coli I-GENE
when O
the O
entire O
_RARE_ I-GENE
gene I-GENE
was O
present O
. O

In O
agreement O
with O
previous O
in O
vitro O
data O
, O
we O
have O
shown O
that O
UmuD I-GENE
and O
UmuD I-GENE
' O
are O
able O
to O
form O
both O
homodimers I-GENE
( O
UmuD I-GENE
- I-GENE
UmuD I-GENE
and O
UmuD I-GENE
'- O
UmuD I-GENE
') I-GENE
and O
a O
heterodimer O
( O
UmuD I-GENE
- I-GENE
UmuD I-GENE
_RARE_ I-GENE

Lyn I-GENE
kinase I-GENE
immunoprecipitated O
from O
lysates O
of O
irradiated O
_RARE_ I-GENE
as O
well O
as O
a O
full I-GENE
- I-GENE
length I-GENE
glutathione I-GENE
S I-GENE
- I-GENE
transferase I-GENE
( O
GST I-GENE
)- I-GENE
Lyn I-GENE
fusion I-GENE
protein I-GENE
- I-GENE
phosphorylated O
recombinant I-GENE
human I-GENE
p34cdc2 I-GENE
on O
tyrosine I-GENE
15 O
. O

Mutations O
within O
conserved O
region O
2 I-GENE
( O
_RARE_ I-GENE
) O
of O
E1A I-GENE
that O
inhibit O
the O
binding I-GENE
of O
E1A I-GENE
to O
the O
retinoblastoma I-GENE
gene I-GENE
product I-GENE
( O
pRb I-GENE
) O
further O
enhanced O
the O
stimulation O
of O
transcription I-GENE
from O
the O
PEPCK I-GENE
promoter I-GENE
by O
2 I-GENE
3 I-GENE
- I-GENE
fold O
compared O
with O
wild I-GENE
type I-GENE
E1A I-GENE
. O

Using O
autoantibodies O
from O
a O
_RARE_ I-GENE
' O
s O
syndrome O
patient O
, O
we O
have O
previously O
identified O
a O
_RARE_ I-GENE
- I-GENE
kDa I-GENE
peripheral O
membrane I-GENE
protein I-GENE
associated I-GENE
with O
the O
cytosolic I-GENE
face O
of O
the O
trans O
- I-GENE
Golgi I-GENE
( O
_RARE_ I-GENE
, O
J O
., O
_RARE_ I-GENE
, O
B I-GENE
. O

_RARE_ I-GENE
from O
two O
proline O
- I-GENE
rich O
regions O
( O
amino O
acids O
1 I-GENE
- I-GENE
117 O
and O
239 O
- I-GENE
270 O
), O
_RARE_ I-GENE
contains O
a O
very O
high O
frequency O
of O
heptad I-GENE
repeats I-GENE
, O
characteristic O
of O
alpha I-GENE
- I-GENE
helices O
that O
form O
dimeric I-GENE
coiled O
- I-GENE
coil O
structures O
. O
_RARE_ I-GENE
also O
includes O
the O
sequence I-GENE
_RARE_ I-GENE
( O
amino O
acids O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
), O
a O
motif I-GENE
found O
in O
the O
_RARE_ I-GENE
family I-GENE
of O
acidic O
proteins I-GENE
present O
in O
secretory I-GENE
granules O
of O
_RARE_ I-GENE
cells O
. O

Binding O
specificity O
and O
modulation O
of O
the O
_RARE_ I-GENE
- I-GENE
I I-GENE
promoter I-GENE
activity O
by O
_RARE_ I-GENE
- I-GENE
and O
heterodimers I-GENE
of O
nuclear I-GENE
receptors I-GENE
. O

They O
were O
found O
to O
stimulate O
at O
_RARE_ I-GENE
concentrations O
the O
turnover O
of O
_RARE_ I-GENE
labeled O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
. O

There O
is O
growing O
evidence O
that O
mammalian I-GENE
AMP I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
( O
_RARE_ I-GENE
) O
plays O
a O
role O
in O
_RARE_ I-GENE
cells O
from O
stresses O
that O
cause O
ATP I-GENE
depletion O
by O
switching O
off O
ATP I-GENE
- I-GENE
_RARE_ I-GENE
biosynthetic O
pathways O
. O

_RARE_ I-GENE
- I-GENE
mediated O
suppression O
of O
cleavage O
of O
SREBP I-GENE
- I-GENE
1 I-GENE
was O
found O
to O
be O
dependent I-GENE
on O
the O
extreme O
COOH O
- I-GENE
terminal I-GENE
region O
( O
residue O
_RARE_ I-GENE
to O
the O
COOH O
terminus O
), O
which O
exists O
in O
two O
forms O
as O
a O
result O
of O
alternative O
splicing O
. O

_RARE_ I-GENE
. O

EMSA O
competition O
experiments O
showed O
that O
mutations O
within O
the O
direct O
repeats I-GENE
failed O
to O
compete O
for O
binding I-GENE
of O
the O
nuclear I-GENE
proteins I-GENE
to O
labeled O
wild I-GENE
type I-GENE
oligonucleotide I-GENE
. O

Transcription O
from O
the O
promoter I-GENE
containing O
the O
mutated O
direct O
repeats I-GENE
was O
increased O
greatly O
, O
consistent O
with O
the O
conclusion O
that O
these O
motifs O
functions O
in O
vivo O
to O
repress O
_RARE_ I-GENE
gene I-GENE
expression O
. O

However O
, O
a O
> O
10 O
- I-GENE
fold O
increase O
in O
_RARE_ I-GENE
activity O
in O
each O
PKC I-GENE
beta I-GENE
_RARE_ I-GENE
was O
shown O
by O
immunoprecipitation O
with O
anti I-GENE
- I-GENE
_RARE_ I-GENE
monoclonal I-GENE
antibody I-GENE
followed O
by O
either O
immune I-GENE
complex I-GENE
kinase I-GENE
assay O
or O
by O
in O
gel O
kinase I-GENE
assay O
. O

Sequence O
analysis O
of O
this O
100 O
- I-GENE
bp O
_RARE_ I-GENE
enhancer I-GENE
revealed O
several O
sequence I-GENE
motifs O
similar O
to O
motifs O
present O
within O
the O
regulatory I-GENE
region O
of O
the O
link I-GENE
protein I-GENE
gene I-GENE
, O
another O
cartilage O
gene I-GENE
. O

_RARE_ I-GENE
- I-GENE
dependent I-GENE
activation O
of O
the O
tissue I-GENE
_RARE_ I-GENE
promoter I-GENE
depends O
on O
both O
a O
proximal I-GENE
regulatory I-GENE
region O
containing O
sequences I-GENE
highly O
conserved O
between O
the O
human I-GENE
and O
the O
mouse I-GENE
tissue I-GENE
_RARE_ I-GENE
promoters I-GENE
and O
a O
distal O
region O
that O
includes O
a O
30 O
- I-GENE
base O
pair O
retinoid I-GENE
response O
element I-GENE
( O
_RARE_ I-GENE
). O
_RARE_ I-GENE
contains O
three O
_RARE_ I-GENE
half O
- I-GENE
sites I-GENE
( O
two O
canonical O
and O
one O
non O
- I-GENE
canonical O
) O
in O
a O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
motif I-GENE
that O
bind O
both O
RAR I-GENE
* I-GENE
RXR I-GENE
heterodimers I-GENE
and O
RXR I-GENE
homodimers I-GENE
. O

Significantly O
, O
_RARE_ I-GENE
is O
capable O
of O
specifically O
_RARE_ I-GENE
_RARE_ I-GENE
in O
a O
synthetic O
eIF I-GENE
- I-GENE
2alpha I-GENE
peptide I-GENE
, O
a O
key O
characteristic O
of O
the O
eIF I-GENE
- I-GENE
2alpha I-GENE
kinase I-GENE
family I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
constitute O
a O
family I-GENE
of O
synaptic O
proteins I-GENE
that O
participate O
in O
the O
regulation O
of O
_RARE_ I-GENE
release O
. O

Electrophoretic O
mobility I-GENE
shift O
assays O
using O
crude O
extracts O
from O
_RARE_ I-GENE
cells O
revealed O
the O
binding I-GENE
of O
a O
member O
( O
s O
) O
of O
the O
Ets I-GENE
family I-GENE
of O
transcription I-GENE
factors I-GENE
to O
the O
P4 I-GENE
_RARE_ I-GENE
, O
as O
well O
as O
the O
interaction O
of O
two O
members O
of O
the O
Sp1 I-GENE
family I-GENE
, O
Sp1 I-GENE
and O
Sp3 I-GENE
, O
with O
the O
adjacent O
GC I-GENE
box I-GENE
. O

_RARE_ I-GENE
and O
cellular O
AP I-GENE
- I-GENE
1 I-GENE
_RARE_ I-GENE
activators I-GENE
, O
such O
as O
c I-GENE
- I-GENE
Fos I-GENE
, O
have O
homologous O
DNA I-GENE
- I-GENE
binding I-GENE
domains I-GENE
, O
and O
their O
DNA I-GENE
- I-GENE
binding I-GENE
_RARE_ I-GENE
overlap O
. O

This O
result O
suggested O
that O
mutant I-GENE
_RARE_ I-GENE
has O
diminished O
cap I-GENE
- I-GENE
binding I-GENE
activity O
. O

UV O
cross O
- I-GENE
linking O
experiments O
demonstrated O
that O
HSV I-GENE
infection O
caused O
enhanced O
binding I-GENE
of O
protein I-GENE
factors I-GENE
, O
including O
the O
64 O
- I-GENE
kDa I-GENE
component O
of O
cleavage O
stimulation O
factor I-GENE
( O
_RARE_ I-GENE
), O
to O
poly O
( O
A I-GENE
) O
site I-GENE
RNAs I-GENE
from O
virus I-GENE
genes I-GENE
of O
all O
temporal O
classes O
and O
that O
this O
enhanced O
binding I-GENE
required O
expression O
of O
_RARE_ I-GENE
. O

CM I-GENE
- I-GENE
_RARE_ I-GENE
is O
expressed O
in O
_RARE_ I-GENE
and O
is O
not O
induced O
by O
any O
of O
the O
stimuli O
tested O
. O

We O
show O
here O
that O
these O
Jun I-GENE
/ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
are O
potent O
_RARE_ I-GENE
of O
AP1 I-GENE
sites I-GENE
and O
that O
they O
can O
cooperate O
with O
c I-GENE
- I-GENE
Ha I-GENE
- I-GENE
Ras I-GENE
to O
induce O
_RARE_ I-GENE
. O

In O
_RARE_ I-GENE
HeLa O
cells O
, O
expression O
of O
luciferase I-GENE
activity O
was O
induced O
at O
the O
beginning O
of O
DNA I-GENE
synthesis O
and O
was O
dependent I-GENE
on O
the O
presence O
of O
an O
E2F I-GENE
- I-GENE
binding I-GENE
site I-GENE
in O
the O
_RARE_ I-GENE
. O
1 I-GENE
promoter I-GENE
. O

_RARE_ I-GENE
transient O
transfection O
studies O
in O
HepG2 O
cells O
, O
we O
have O
shown O
that O
deletion O
of O
the O
factor I-GENE
VIII I-GENE
promoter I-GENE
sequences I-GENE
distal O
to O
nucleotide I-GENE
- I-GENE
44 I-GENE
results O
in O
a O
significant O
but O
small I-GENE
increase O
in O
promoter I-GENE
activity O
. O

We O
constructed O
a O
yeast I-GENE
reporter I-GENE
strain O
containing O
the O
lacZ I-GENE
gene I-GENE
under O
the O
control O
of O
the O
CYC1 I-GENE
promoter I-GENE
associated I-GENE
with O
three O
copies O
of O
TRE I-GENE
- I-GENE
1 I-GENE
. O

If O
hnRNP I-GENE
K I-GENE
is O
a O
transcription I-GENE
factor I-GENE
, O
then O
interactions O
with O
the O
RNA I-GENE
polymerase I-GENE
II I-GENE
transcription I-GENE
apparatus O
are O
predicted O
. O

A I-GENE
developmentally O
regulated O
4 I-GENE
. O
6 I-GENE
kb O
mRNA I-GENE
is O
recognized O
on O
Northern O
blots O
of O
oocyte O
RNA I-GENE
using O
the O
X I-GENE
. O
laevis I-GENE
cDNA I-GENE
. O

Sequence O
conservation O
is O
greatest O
for O
residues O
located O
near O
the O
active O
centers O
of O
the O
_RARE_ I-GENE
and O
pol I-GENE
domains I-GENE
of O
the O
E I-GENE
. O
coli I-GENE
DNA I-GENE
polymerase I-GENE
I I-GENE
structure O
. O

Despite O
the O
favourable O
natural O
history O
of O
acute O
BI I-GENE
, O
mild O
, O
moderate O
, O
and O
severe O
_RARE_ I-GENE
changes O
were O
shown O
to O
appear O
as O
_RARE_ I-GENE
- I-GENE
adhesive O
and O
_RARE_ I-GENE
processes O
, O
_RARE_ I-GENE
cysts O
, O
_RARE_ I-GENE
, O
which O
result O
in O
_RARE_ I-GENE
epilepsy O
, O
_RARE_ I-GENE
, O
etc O
. O

These O
findings O
suggest O
that O
the O
increase O
in O
V I-GENE
O2 O
may O
have O
been O
a O
consequence O
of O
the O
increase O
in O
Q I-GENE
O2 O
rather O
than O
a O
response O
to O
the O
procedure O
itself O
. O

Several O
cytokines O
exhibit O
a O
high O
degree O
of O
temporal O
regulation O
as O
well O
as O
_RARE_ I-GENE
potency O
( O
e O
. O
g O
., O
interleukin I-GENE
- I-GENE
1 I-GENE
[ O
IL I-GENE
- I-GENE
1 I-GENE
], O
tumor I-GENE
necrosis I-GENE
factor I-GENE
- I-GENE
alpha I-GENE
[ O
TNF I-GENE
- I-GENE
alpha I-GENE
_RARE_ I-GENE

As O
pH O
and O
Hb I-GENE
can O
also O
affect O
mixed O
venous O
CO2 O
content O
, O
the O
effect O
on O
Q I-GENE
was O
also O
assessed O
. O

No O
difference O
in O
elastin I-GENE
peptide I-GENE
concentration O
was O
observed O
between O
_RARE_ I-GENE
patients O
and O
control O
subjects O
( O
mean O
+/- O
SD O
= O
2 I-GENE
. O
39 O
+/- O
1 I-GENE
. O
18 O
micrograms O
/ I-GENE
ml O
in O
patients O
versus O
2 I-GENE
. O
55 O
+/- O
1 I-GENE
. O
34 O
micrograms O
/ I-GENE
ml O
in O
_RARE_ I-GENE
and O
2 I-GENE
. O
59 O
+/- O
1 I-GENE
. O
20 O
micrograms O
/ I-GENE
ml O
in O
_RARE_ I-GENE
_RARE_ I-GENE
). O

Identification O
of O
this O
region O
as O
the O
E I-GENE
. O
coli I-GENE
_RARE_ I-GENE
gene I-GENE
was O
confirmed O
by O
functional O
complementation O
of O
a O
yeast I-GENE
_RARE_ I-GENE
kinase I-GENE
temperature O
- I-GENE
sensitive O
mutant I-GENE
and O
by O
in O
vitro O
enzyme I-GENE
assay O
of O
the O
_RARE_ I-GENE
kinase I-GENE
activity O
in O
cell O
extracts O
of O
E I-GENE
. O
coli I-GENE
by O
use O
of O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
plasmids O
. O

The O
structural O
gene I-GENE
for O
copper I-GENE
- I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
- I-GENE
containing O
monoamine I-GENE
oxidase I-GENE
( O
_RARE_ I-GENE
) O
and O
an O
unknown O
amine I-GENE
oxidase I-GENE
gene I-GENE
have O
been O
located O
at O
30 O
. O
9 O
min O
on O
the O
Escherichia I-GENE
coli I-GENE
chromosome O
. O

This O
interaction O
is O
mediated O
by O
the O
SH2 I-GENE
domain I-GENE
of O
Crk I-GENE
and O
can O
be O
inhibited O
with O
a O
phosphopeptide I-GENE
containing O
the O
Crk I-GENE
- I-GENE
SH2 I-GENE
binding I-GENE
motif I-GENE
. O

Consistent O
with O
ErbB I-GENE
- I-GENE
2 I-GENE
being O
a O
shared O
receptor I-GENE
subunit I-GENE
, O
its O
tyrosine I-GENE
phosphorylation O
was O
increased O
by O
both O
heterologous O
ligands O
and O
it O
mediated O
a O
trans O
- I-GENE
inhibitory I-GENE
effect O
of O
_RARE_ I-GENE
on O
EGF I-GENE
binding I-GENE
. O

Identification O
of O
a O
consensus I-GENE
cyclin I-GENE
- I-GENE
dependent I-GENE
kinase I-GENE
phosphorylation O
site I-GENE
unique O
to O
the O
nuclear I-GENE
form O
of O
human I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
. O

The O
cDNA I-GENE
corresponding O
to O
the O
_RARE_ I-GENE
gene I-GENE
was O
isolated O
by O
functional O
complementation O
of O
a O
mutant I-GENE
yeast I-GENE
strain O
defective O
in O
_RARE_ I-GENE
activity O
( O
_RARE_ I-GENE
, O
D I-GENE
., O
_RARE_ I-GENE
, O
F I-GENE
., O
and O
_RARE_ I-GENE
, O
F I-GENE
. O

The O
isolated O
_RARE_ I-GENE
fragments I-GENE
of O
VEGF I-GENE
were O
compared O
with O
respect O
to O
heparin O
binding I-GENE
, O
interaction O
with O
soluble I-GENE
VEGF I-GENE
receptors I-GENE
, O
and O
ability O
to O
promote O
endothelial I-GENE
cell O
_RARE_ I-GENE
. O

VDR I-GENE
/ I-GENE
RXR I-GENE
bound O
well O
to O
the O
_RARE_ I-GENE
and O
to O
_RARE_ I-GENE
and O
_RARE_ I-GENE
using O
the O
electrophoretic O
mobility I-GENE
shift O
assay O
. O

The O
members O
of O
the O
Myb I-GENE
family I-GENE
of O
transcription I-GENE
factors I-GENE
are O
defined O
by O
homology I-GENE
in O
the O
DNA I-GENE
- I-GENE
binding I-GENE
domain I-GENE
; O
all O
bind O
the O
Myb I-GENE
- I-GENE
binding I-GENE
site I-GENE
( O
_RARE_ I-GENE
) O
sequence I-GENE
( O
_RARE_ I-GENE
( O
A I-GENE
/ I-GENE
G I-GENE
) O
C I-GENE
( O
A I-GENE
/ I-GENE
C I-GENE
/ I-GENE
G I-GENE
) O
_RARE_ I-GENE
( O
G I-GENE
/ I-GENE
A I-GENE
_RARE_ I-GENE

In O
contrast O
, O
when O
the O
isoform I-GENE
containing O
the O
C I-GENE
_RARE_ I-GENE
domain I-GENE
_RARE_ I-GENE
directly O
to O
the O
_RARE_ I-GENE
exon O
( O
IgE I-GENE
_RARE_ I-GENE
) O
is O
expressed O
in O
the O
_RARE_ I-GENE
cell O
line O
, O
it O
is O
degraded O
_RARE_ I-GENE
, O
suggesting O
a O
cell O
line O
- I-GENE
dependent I-GENE
regulation O
of O
secretion O
. O

Human I-GENE
cytomegalovirus I-GENE
immediate I-GENE
- I-GENE
early I-GENE
protein I-GENE
IE2 I-GENE
_RARE_ I-GENE
a O
transcriptional O
repression O
domain I-GENE
to O
p53 I-GENE
. O

The O
specificity O
of O
action O
of O
C I-GENE
/ I-GENE
EBP I-GENE
family I-GENE
members O
may O
be O
derived O
from O
the O
characteristics O
of O
each O
factor I-GENE
, O
including O
the O
expression O
profiles O
, O
the O
DNA I-GENE
binding I-GENE
affinities O
, O
the O
_RARE_ I-GENE
, O
and O
so O
on O
, O
in O
addition O
to O
the O
DNA I-GENE
binding I-GENE
_RARE_ I-GENE
. O

The O
antibodies I-GENE
inhibited O
specifically O
the O
transcription I-GENE
of O
DNA I-GENE
polymerase I-GENE
alpha I-GENE
promoter I-GENE
in O
vitro O
. O

_RARE_ I-GENE
analysis O
demonstrated O
the O
presence O
of O
_RARE_ I-GENE
polypeptide I-GENE
in O
nuclei O
after O
the O
_RARE_ I-GENE
nuclear I-GENE
division O
cycle O
, O
suggesting O
that O
nuclear I-GENE
accumulation O
of O
_RARE_ I-GENE
is O
important O
for O
the O
coordinate O
_RARE_ I-GENE
expression O
of O
DNA I-GENE
replication O
- I-GENE
related I-GENE
genes I-GENE
carrying O
DRE I-GENE
sequences I-GENE
. O

A I-GENE
DNA I-GENE
fragment I-GENE
carrying O
1 I-GENE
, O
100 O
nucleotides O
derived O
from O
the O
5 I-GENE
'- O
flanking O
region O
of O
the O
_RARE_ I-GENE
gene I-GENE
was O
enough O
for O
MC O
induction O
. O

This O
result O
supports O
the O
_RARE_ I-GENE
that O
the O
beta I-GENE
' O
subunit I-GENE
plays O
an O
essential O
role O
in O
determining O
the O
progress O
of O
transcription I-GENE
elongation I-GENE
. O

Two O
_RARE_ I-GENE
regions O
with O
putative O
NLS O
[ O
amino O
acid I-GENE
( O
AA O
) O
_RARE_ I-GENE
: O
NLS O
- I-GENE
B I-GENE
( O
AA O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
) O
and O
NLS O
- I-GENE
C I-GENE
( O
AA O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
)] O
were O
each O
shown O
to O
independently O
localize O
the O
beta I-GENE
- I-GENE
_RARE_ I-GENE
extensively O
(> O
80 O
%) O
to O
the O
nucleus O
of O
HeLa O
cells O
. O

The O
_RARE_ I-GENE
gene I-GENE
was O
cloned O
in O
an O
E I-GENE
. O
coli I-GENE
- I-GENE
Streptococcus I-GENE
_RARE_ I-GENE
vector O
and O
was O
expressed O
both O
in O
a O
_RARE_ I-GENE
deletion O
derivative O
of O
S I-GENE
. O
_RARE_ I-GENE
and O
in O
a O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
strain O
, O
L I-GENE
. O
lactis O
_RARE_ I-GENE
. O

The O
genome O
of O
all O
_RARE_ I-GENE
consists O
of O
two O
identical O
RNAs I-GENE
_RARE_ I-GENE
linked O
near O
their O
5 I-GENE
' O
end O
. O

The O
extraction O
recovery O
of O
_RARE_ I-GENE
B I-GENE
from O
the O
cerebrospinal O
fluid O
is O
higher O
than O
90 O
% O
over O
the O
entire O
linear O
range O
. O

_RARE_ I-GENE
- I-GENE
R I-GENE
Ab I-GENE
inhibited O
Epo I-GENE
- I-GENE
induced O
parental O
UT O
- I-GENE
7 O
cell O
growth I-GENE
, O
but O
not O
that O
of O
cells O
of O
clone O
12 O
, O
suggesting O
that O
the O
_RARE_ I-GENE
- I-GENE
R I-GENE
is O
able O
to O
induce O
human I-GENE
UT O
- I-GENE
7 O
cell O
proliferation O
. O

The O
frequency O
of O
_RARE_ I-GENE
that O
led O
to O
transcription I-GENE
of O
the O
lacZ I-GENE
gene I-GENE
was O
estimated O
to O
be O
0 O
. O
5 I-GENE
% O
of O
all O
_RARE_ I-GENE
, O
of O
which O
14 O
% O
were O
_RARE_ I-GENE
on O
differentiation O
of O
_RARE_ I-GENE
cells O
towards O
neutrophils O
. O

The O
sequence I-GENE
and O
isolated O
cDNAs I-GENE
will O
provide O
useful O
_RARE_ I-GENE
for O
studying O
the O
expression O
of O
_RARE_ I-GENE
in O
the O
mouse I-GENE
, O
and O
for O
testing O
the O
importance O
of O
the O
evolutionarily O
conserved O
domains I-GENE
. O

A I-GENE
study O
was O
performed O
to O
compare O
the O
_RARE_ I-GENE
and O
_RARE_ I-GENE
II I-GENE
_RARE_ I-GENE
with O
gas O
chromatographic O
/ I-GENE
mass O
_RARE_ I-GENE
( O
GC I-GENE
/ I-GENE
MS O
) O
analysis O
of O
_RARE_ I-GENE
metabolites O
on O
urine O
using O
samples O
obtained O
from O
a O
clinical O
study O
. O

Interaction O
of O
the O
Fur I-GENE
repressor I-GENE
with O
a O
150 O
- I-GENE
bp O
fragment I-GENE
encompassing O
the O
_RARE_ I-GENE
promoter I-GENE
was O
demonstrated O
in O
vivo O
by O
the O
Fur I-GENE
titration O
assay O
and O
confirmed O
in O
vitro O
by O
gel O
retardation O
experiments O
with O
a O
partially O
purified O
Fur I-GENE
preparation O
. O

This O
protein I-GENE
encoded I-GENE
by O
this O
cDNA I-GENE
, O
which O
we O
have O
termed O
_RARE_ I-GENE
( O
for O
TPR O
- I-GENE
containing O
, O
SH2 I-GENE
- I-GENE
binding I-GENE
phosphoprotein I-GENE
), O
is O
located O
predominantly O
in O
the O
nucleus O
and O
is O
highly O
conserved O
in O
evolution O
. O

Both O
mutant I-GENE
receptors I-GENE
were O
expressed O
on O
the O
cell O
surface O
and O
bound O
insulin I-GENE
normally O
, O
but O
showed O
markedly O
impaired O
autophosphorylation O
in O
response O
to O
insulin I-GENE
. O

_RARE_ I-GENE
J O
. O

Taken O
together O
, O
our O
results O
indicate O
that O
thrombin I-GENE
- I-GENE
stimulated O
vascular I-GENE
smooth I-GENE
muscle O
proliferation O
is O
delayed O
and O
requires O
the O
de O
novo I-GENE
expression O
of O
one O
or O
more O
autocrine O
_RARE_ I-GENE
. O

Transcription O
from O
adenovirus I-GENE
E2 I-GENE
- I-GENE
early I-GENE
promoter I-GENE
is O
controlled O
by O
a O
unique O
_RARE_ I-GENE
of O
four O
cis O
- I-GENE
acting O
elements O
which O
include O
an O
atypical O
TBP I-GENE
site I-GENE
, O
two O
E2F I-GENE
sites I-GENE
present O
in O
an O
inverted O
orientation O
relative O
to O
each O
other O
, O
and O
an O
ATF I-GENE
site I-GENE
. O

Furthermore O
, O
we O
showed O
that O
the O
IL I-GENE
- I-GENE
6 I-GENE
/ I-GENE
interferon I-GENE
gamma I-GENE
( O
IFN I-GENE
gamma I-GENE
) O
response O
element I-GENE
in O
the O
IRF I-GENE
- I-GENE
1 I-GENE
promoter I-GENE
( O
IR I-GENE
/ I-GENE
IRF I-GENE
- I-GENE
1 I-GENE
), O
which O
contains O
a O
Stat I-GENE
- I-GENE
binding I-GENE
site I-GENE
and O
an O
adjacent O
CRE O
- I-GENE
like I-GENE
site I-GENE
, O
also O
makes O
IL I-GENE
- I-GENE
6 I-GENE
- I-GENE
induced O
binding I-GENE
complexes I-GENE
similar O
to O
_RARE_ I-GENE
- I-GENE
IL6 I-GENE
- I-GENE
_RARE_ I-GENE
. O

A I-GENE
second O
peptide I-GENE
( O
amino O
acids O
58 O
- I-GENE
77 O
) O
also O
_RARE_ I-GENE
p21 I-GENE
- I-GENE
activity O
, O
but O
this O
peptide I-GENE
did O
not O
affect O
the O
ability O
of O
p21 I-GENE
to O
interact O
with O
cyclin I-GENE
E I-GENE
/ I-GENE
Cdk2 I-GENE
. O

A I-GENE
p21 I-GENE
peptide I-GENE
spanning O
amino O
acids O
139 O
- I-GENE
_RARE_ I-GENE
was O
found O
to O
bind O
PCNA I-GENE
in O
a O
filter O
binding I-GENE
assay O
and O
this O
peptide I-GENE
suppressed O
recombinant I-GENE
p21 I-GENE
- I-GENE
PCNA I-GENE
interaction O
. O

Results O
were O
supported O
by O
the O
agar O
diffusion O
method O
for O
Y I-GENE
. O
_RARE_ I-GENE
, O
whereas O
inhibition O
activity O
was O
not O
found O
for O
A I-GENE
. O
_RARE_ I-GENE
. O

_RARE_ I-GENE
8 O
mg O
_RARE_ I-GENE
days O
2 I-GENE
- I-GENE
3 I-GENE
, O
and O
8 O
mg O
_RARE_ I-GENE
_RARE_ I-GENE
days O
4 I-GENE
- I-GENE
5 I-GENE
and O
_RARE_ I-GENE
75 O
- I-GENE
100 O
mg O
_RARE_ I-GENE
days O
2 I-GENE
- I-GENE
5 I-GENE
and O
2 I-GENE
) O
_RARE_ I-GENE
30 O
mg O
/ I-GENE
_RARE_ I-GENE
80 O
mg O
i O
. O
v I-GENE
. O
before O
CT I-GENE
and O
_RARE_ I-GENE
20 O
mg O
p O
. O
r O
. O
after O
4 I-GENE
and O
8 O
h O
respectively O
. O

The O
dynamic O
properties O
of O
this O
protein I-GENE
fragment I-GENE
were O
measured O
and O
analyzed O
using O
both O
_RARE_ I-GENE
and O
_RARE_ I-GENE
models O
of O
molecular O
motion O
. O

_RARE_ I-GENE
of O
the O
human I-GENE
N I-GENE
- I-GENE
ras I-GENE
codon O
61 O
sequence I-GENE
with O
_RARE_ I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
)- I-GENE
7 O
, O
8 O
- I-GENE
_RARE_ I-GENE
- I-GENE
9 O
, O
10 O
- I-GENE
_RARE_ I-GENE
- I-GENE
7 O
, O
8 O
, O
9 O
, O
10 O
- I-GENE
_RARE_ I-GENE
[ O
a O
] O
_RARE_ I-GENE
: O
structural O
_RARE_ I-GENE
of O
the O
_RARE_ I-GENE
_RARE_ I-GENE
( O
61 O
, O
2 I-GENE
) O
_RARE_ I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
)- I-GENE
_RARE_ I-GENE
-[ I-GENE
10 O
-( O
7 O
, O
8 O
, O
9 O
, O
10 O
- I-GENE
_RARE_ I-GENE
[ O
a O
] O
_RARE_ I-GENE
_RARE_ I-GENE
2 I-GENE
'- O
_RARE_ I-GENE
_RARE_ I-GENE
from O
_RARE_ I-GENE
NMR O
. O

Isolation O
by O
PCR O
of O
a O
cDNA I-GENE
clone O
from O
_RARE_ I-GENE
_RARE_ I-GENE
with O
similarity O
to O
_RARE_ I-GENE
and O
wheat I-GENE
zinc I-GENE
finger I-GENE
proteins I-GENE
. O

This O
fragment I-GENE
can O
bind O
several O
trans O
- I-GENE
acting O
factors I-GENE
in O
vitro O
, O
including O
GATA I-GENE
- I-GENE
1 I-GENE
and O
members O
of O
the O
Ets I-GENE
family I-GENE
. O

_RARE_ I-GENE
of O
peripheral O
blood O
T I-GENE
cells O
from O
young O
subjects O
to O
PHA I-GENE
or O
cross O
- I-GENE
linked O
anti I-GENE
- I-GENE
CD3 I-GENE
monoclonal I-GENE
antibodies I-GENE
stimulated O
rapid O
increases O
in O
MAPK I-GENE
and O
MEK I-GENE
enzymatic O
activity O
. O

These O
different O
observations O
_RARE_ I-GENE
a O
heterozygosity O
of O
the O
A I-GENE
--> I-GENE
G I-GENE
mutation I-GENE
at O
codon O
beta I-GENE
77 O
, O
as O
well O
as O
a O
deletion O
comparable O
to O
that O
of O
_RARE_ I-GENE
_RARE_ I-GENE
or O
_RARE_ I-GENE
, O
or O
a O
beta I-GENE
- I-GENE
globin I-GENE
gene I-GENE
duplication O
, O
and O
point O
to O
a O
_RARE_ I-GENE
_RARE_ I-GENE
of O
Hb I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
. O

This O
is O
the O
first O
description O
, O
to O
our O
knowledge O
, O
of O
regulatory I-GENE
elements O
that O
control O
expression O
of O
a O
gene I-GENE
encoding O
a O
B7 I-GENE
_RARE_ I-GENE
molecule I-GENE
. O

DNA I-GENE
- I-GENE
STAT I-GENE
complexes I-GENE
were O
detected O
in O
all O
_RARE_ I-GENE
/ I-GENE
Abl I-GENE
- I-GENE
transformed O
cell O
lines O
and O
they O
were O
_RARE_ I-GENE
by O
antibodies I-GENE
against O
STAT1 I-GENE
and O
STAT5 I-GENE
. O

When O
overexpressed O
in O
an O
appropriate O
cell O
line O
, O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
prevented O
kappa I-GENE
B I-GENE
- I-GENE
dependent I-GENE
transactivation O
in O
transient O
reporter I-GENE
gene I-GENE
assays O
in O
a O
fashion O
similar O
to O
the O
structurally O
related I-GENE
protein I-GENE
, O
Bcl I-GENE
- I-GENE
3 I-GENE
. O

T I-GENE
cell O
leukemia I-GENE
- I-GENE
associated I-GENE
human I-GENE
Notch I-GENE
/ I-GENE
translocation O
- I-GENE
associated I-GENE
Notch I-GENE
homologue I-GENE
has O
I I-GENE
kappa I-GENE
B I-GENE
- I-GENE
like I-GENE
activity O
and O
physically O
interacts O
with O
nuclear I-GENE
factor I-GENE
- I-GENE
kappa I-GENE
B I-GENE
proteins I-GENE
in O
T I-GENE
cells O
. O

_RARE_ I-GENE
processing O
in O
_RARE_ I-GENE
virus I-GENE
: O
identification O
of O
3C I-GENE
- I-GENE
like I-GENE
protease I-GENE
cleavage O
sites I-GENE
by O
in O
vitro O
mutagenesis O
. O

The O
_RARE_ I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
), O
lacking O
light I-GENE
chain I-GENE
variable O
region O
glycosylation O
, O
exhibited O
_RARE_ I-GENE
that O
were O
comparable O
to O
that O
of O
chimeric I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
), O
which O
was O
shown O
previously O
to O
have O
antigen I-GENE
- I-GENE
binding I-GENE
properties O
similar O
to O
its O
murine I-GENE
counterpart O
, O
suggesting O
that O
the O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
found O
in O
_RARE_ I-GENE
are O
not O
necessary O
for O
antigen I-GENE
binding I-GENE
. O

An O
apparent O
N I-GENE
- I-GENE
terminal I-GENE
transit O
peptide I-GENE
in O
the O
coding O
region O
and O
a O
3 I-GENE
' O
poly O
( O
A I-GENE
) O
tail O
exist O
in O
the O
cDNA I-GENE
clone O
indicated O
that O
this O
chloroplast I-GENE
protein I-GENE
as O
nuclear I-GENE
encoded I-GENE
. O

Deletion O
analysis O
of O
_RARE_ I-GENE
promoter I-GENE
- I-GENE
chloramphenicol I-GENE
acetyltransferase I-GENE
constructs I-GENE
demonstrates O
that O
an O
_RARE_ I-GENE
- I-GENE
1 I-GENE
- I-GENE
binding I-GENE
sequence I-GENE
within O
the O
proximal I-GENE
promoter I-GENE
(- O
_RARE_ I-GENE
to O
- I-GENE
130 I-GENE
nt O
) O
contributes O
to O
75 O
% O
of O
the O
level O
of O
_RARE_ I-GENE
gene I-GENE
expression O
. O

Thus O
, O
a O
critical O
question O
is O
how O
_RARE_ I-GENE
proteins I-GENE
select O
the O
correct O
sets O
of O
target O
genes I-GENE
in O
vivo O
. O

_RARE_ I-GENE
, O
a O
dominant I-GENE
activated I-GENE
form O
of O
Saccharomyces I-GENE
cerevisiae I-GENE
_RARE_ I-GENE
, O
stimulates O
both O
filamentous I-GENE
growth I-GENE
and O
expression O
of O
a O
transcriptional O
reporter I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
_RARE_ I-GENE
lacZ I-GENE
but O
does O
not O
induce O
the O
mating I-GENE
pathway O
reporter I-GENE
_RARE_ I-GENE
:: O
lacZ I-GENE
. O

Moreover O
, O
the O
Rho I-GENE
family I-GENE
protein I-GENE
Cdc42 I-GENE
, O
a O
conserved O
_RARE_ I-GENE
G I-GENE
protein I-GENE
, O
is O
also O
a O
potent O
regulator I-GENE
of O
filamentous I-GENE
growth I-GENE
and O
_RARE_ I-GENE
( O
_RARE_ I-GENE
_RARE_ I-GENE
lacZ I-GENE
expression O
in O
S I-GENE
. O
cerevisiae I-GENE
. O

Each O
_RARE_ I-GENE
contained O
a O
complex I-GENE
of O
N1 O
( O
_RARE_ I-GENE
) O
and O
CBF1 I-GENE
. O

This O
region O
includes O
_RARE_ I-GENE
, O
a O
structural O
gene I-GENE
previously O
shown O
to O
be O
required O
for O
ST O
biosynthesis O
, O
and O
24 O
additional O
closely O
_RARE_ I-GENE
transcripts I-GENE
ranging O
in O
size O
from O
0 O
. O
6 I-GENE
to O
7 O
. O
2 I-GENE
kb O
that O
are O
_RARE_ I-GENE
induced O
only O
under O
ST O
- I-GENE
producing O
conditions O
. O

_RARE_ I-GENE
_RARE_ I-GENE
of O
the O
wild I-GENE
- I-GENE
type I-GENE
_RARE_ I-GENE
and O
the O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
fusion I-GENE
protein I-GENE
were O
determined O
by O
immunofluorescence O
of O
NIH O
3T3 O
cells O
that O
_RARE_ I-GENE
wild I-GENE
- I-GENE
type I-GENE
or O
fusion I-GENE
protein I-GENE
. O

_RARE_ I-GENE
- I-GENE
cycle O
phase O
did O
not O
significantly O
affect O
_RARE_ I-GENE
variables O
in O
either O
group O
. O

We O
report O
the O
isolation O
of O
human I-GENE
cDNAs I-GENE
homologous O
to O
the O
Drosophila I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
segment O
- I-GENE
polarity O
gene I-GENE
. O

Escherichia I-GENE
coli I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
_RARE_ I-GENE
, O
_RARE_ I-GENE
a O
recombinant I-GENE
plasmid O
containing O
the O
catalase I-GENE
- I-GENE
peroxidase I-GENE
gene I-GENE
, O
produced O
a O
large O
amount O
of O
proteins I-GENE
that O
co O
- I-GENE
_RARE_ I-GENE
on O
SDS O
/ I-GENE
PAGE O
with O
the O
native O
enzyme I-GENE
. O

Ca2 I-GENE
+ I-GENE
decreased O
_RARE_ I-GENE
+ I-GENE
binding I-GENE
in O
_RARE_ I-GENE
beta I-GENE
but O
it O
did O
not O
influence O
binding I-GENE
to O
_RARE_ I-GENE
, O
suggesting O
that O
the O
_RARE_ I-GENE
+ I-GENE
binding I-GENE
site I-GENE
was O
distinct O
from O
and O
independent O
of O
the O
two O
Ca2 I-GENE
+ I-GENE
binding I-GENE
domains I-GENE
. O

Cdk2 I-GENE
formed O
a O
complex I-GENE
with O
cyclin I-GENE
D1 I-GENE
in O
this O
system O
. O

The O
Cdk2 I-GENE
- I-GENE
cyclin I-GENE
- I-GENE
D1 I-GENE
complex I-GENE
did O
not O
phosphorylate O
any O
tested O
substrates O
, O
such O
as O
H1 I-GENE
histone I-GENE
, O
_RARE_ I-GENE
, O
SV40 I-GENE
large O
T I-GENE
antigen I-GENE
, O
p53 I-GENE
, O
E2F I-GENE
- I-GENE
1 I-GENE
or O
a O
preparation O
of O
nuclear I-GENE
proteins I-GENE
from O
HeLa O
cells O
; O
in O
contrast O
, O
Cdk2 I-GENE
- I-GENE
cyclin I-GENE
- I-GENE
E I-GENE
and O
Cdk2 I-GENE
- I-GENE
cyclin I-GENE
- I-GENE
A I-GENE
phosphorylated O
these O
proteins I-GENE
. O

Cyclin I-GENE
- I-GENE
dependent I-GENE
kinase I-GENE
- I-GENE
2 I-GENE
( O
Cdk2 I-GENE
) O
forms O
an O
inactive O
complex I-GENE
with O
cyclin I-GENE
D1 I-GENE
since O
Cdk2 I-GENE
associated I-GENE
with O
cyclin I-GENE
D1 I-GENE
is O
not O
phosphorylated O
by O
_RARE_ I-GENE
- I-GENE
cyclin I-GENE
- I-GENE
H I-GENE
. O

Two O
overlapping O
clones O
contained O
the O
complete O
_RARE_ I-GENE
- I-GENE
2 I-GENE
gene I-GENE
composed O
of O
nine O
exons O
in O
a O
12 O
- I-GENE
kb O
region O
, O
with O
the O
placement O
of O
introns O
_RARE_ I-GENE
that O
observed O
in O
other O
mammalian I-GENE
ADH I-GENE
genes I-GENE
. O

_RARE_ I-GENE
of O
CD40 I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
lymphoma O
B I-GENE
cells O
from O
calcium O
_RARE_ I-GENE
- I-GENE
and O
antigen I-GENE
receptor I-GENE
- I-GENE
triggered O
apoptosis O
by O
inhibiting O
activation O
of O
the O
cysteine I-GENE
protease I-GENE
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
and O
cleavage O
of O
its O
substrate I-GENE
_RARE_ I-GENE
. O

Large I-GENE
T I-GENE
antigen I-GENE
was O
_RARE_ I-GENE
by O
antibodies I-GENE
to O
epitope O
- I-GENE
tagged O
TBP I-GENE
, O
endogenous I-GENE
TBP I-GENE
, O
_RARE_ I-GENE
( O
II I-GENE
) O
100 O
, O
_RARE_ I-GENE
( O
II I-GENE
) O
130 I-GENE
, O
and O
_RARE_ I-GENE
( O
II I-GENE
) O
250 O
, O
under O
conditions O
where O
_RARE_ I-GENE
- I-GENE
TFIID I-GENE
would O
be O
precipitated O
. O

Northern O
blot O
hybridization O
demonstrated O
that O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
was O
expressed O
in O
a O
wide O
range O
of O
human I-GENE
adult O
and O
fetal O
tissues O
. O

A I-GENE
human I-GENE
cytoplasmic I-GENE
signaling O
protein I-GENE
has O
been O
cloned O
that O
possesses O
the O
same O
structural O
arrangement O
of O
SH3 I-GENE
- I-GENE
SH2 I-GENE
- I-GENE
SH3 I-GENE
domains I-GENE
as O
Grb2 I-GENE
. O

A I-GENE
direct O
role O
for O
sterol I-GENE
regulatory I-GENE
element I-GENE
binding I-GENE
protein I-GENE
in O
activation O
of O
3 I-GENE
- I-GENE
hydroxy I-GENE
- I-GENE
3 I-GENE
- I-GENE
_RARE_ I-GENE
coenzyme I-GENE
A I-GENE
reductase I-GENE
gene I-GENE
. O

E3 I-GENE
/ I-GENE
_RARE_ I-GENE
resides O
in O
the O
endoplasmic O
reticulum O
where O
it O
binds O
to O
MHC I-GENE
class I-GENE
I I-GENE
molecules I-GENE
, O
thereby O
preventing O
their O
transport O
to O
the O
cell O
surface O
. O

When O
the O
_RARE_ I-GENE
and O
_RARE_ I-GENE
groups O
were O
compared O
, O
_RARE_ I-GENE
levels O
were O
significantly O
higher O
in O
the O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
+ I-GENE
group O
than O
in O
the O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
+ I-GENE
group O
. O

Among O
the O
_RARE_ I-GENE
deletions O
, O
only O
one O
had O
a O
reduced O
transformation O
efficiency O
, O
while O
seven O
transformed O
cells O
at O
least O
as O
efficiently O
as O
wild I-GENE
- I-GENE
type I-GENE
_RARE_ I-GENE
. O

ORF I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
with O
ORF I-GENE
E6 I-GENE
, O
which O
could O
generate O
a O
50 O
- I-GENE
amino O
- I-GENE
acid I-GENE
protein I-GENE
with O
a O
hydrophobic O
segment O
, O
did O
not O
transform O
cells O
when O
cloned O
into O
the O
_RARE_ I-GENE
vector O
. O

Cloning O
of O
individual O
_RARE_ I-GENE
domains I-GENE
upstream O
of O
a O
minimal I-GENE
promoter I-GENE
demonstrated O
that O
the O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
domains I-GENE
, O
but O
not O
the O
_RARE_ I-GENE
domain I-GENE
, O
are O
TPA O
responsive I-GENE
. O

_RARE_ I-GENE
/ I-GENE
Cdc28 I-GENE
kinase I-GENE
is O
not O
required O
for O
the O
repression O
of O
_RARE_ I-GENE
- I-GENE
binding I-GENE
factor I-GENE
transcriptional O
activity O
in O
G2 I-GENE
and O
M I-GENE
phase O
. O

The O
carboxy I-GENE
terminus O
of O
_RARE_ I-GENE
is O
sufficient O
for O
interaction O
with O
_RARE_ I-GENE
, O
and O
the O
carboxy I-GENE
terminus O
of O
_RARE_ I-GENE
is O
required O
for O
interaction O
with O
_RARE_ I-GENE
. O

Multiple O
single O
- I-GENE
stranded I-GENE
cis O
elements O
are O
associated I-GENE
with O
activated I-GENE
chromatin O
of O
the O
human I-GENE
c I-GENE
- I-GENE
myc I-GENE
gene I-GENE
in O
vivo O
. O

A I-GENE
new O
_RARE_ I-GENE
consensus I-GENE
sequence I-GENE
derived O
from O
this O
mutational O
analysis O
closely O
matches O
a O
consensus I-GENE
_RARE_ I-GENE
binding I-GENE
site I-GENE
. O

We O
have O
isolated O
and O
analyzed O
human I-GENE
CTCF I-GENE
cDNA I-GENE
clones O
and O
show O
here O
that O
the O
ubiquitously O
expressed O
11 O
- I-GENE
zinc I-GENE
- I-GENE
finger I-GENE
factor I-GENE
CTCF I-GENE
is O
an O
_RARE_ I-GENE
highly O
conserved O
protein I-GENE
_RARE_ I-GENE
93 O
% O
identity O
between O
avian I-GENE
and O
human I-GENE
amino O
acid I-GENE
sequences I-GENE
. O

Mutational O
analysis O
of O
the O
P2 I-GENE
- I-GENE
proximal I-GENE
CTCF I-GENE
binding I-GENE
site I-GENE
and O
transient O
- I-GENE
cotransfection O
experiments O
demonstrate O
that O
CTCF I-GENE
is O
a O
transcriptional O
repressor I-GENE
of O
the O
human I-GENE
c I-GENE
- I-GENE
myc I-GENE
gene I-GENE
. O

A I-GENE
chromosome O
transmission O
fidelity I-GENE
( O
_RARE_ I-GENE
) O
mutant I-GENE
, O
_RARE_ I-GENE
, O
of O
Saccharomyces I-GENE
cerevisiae I-GENE
was O
identified O
by O
its O
centromere O
( O
_RARE_ I-GENE
) O
transcriptional O
readthrough O
phenotype O
, O
suggesting O
_RARE_ I-GENE
_RARE_ I-GENE
integrity O
in O
vivo O
. O

The O
growth I-GENE
defect O
of O
a O
_RARE_ I-GENE
_RARE_ I-GENE
double O
mutant I-GENE
is O
_RARE_ I-GENE
by O
a O
loss O
- I-GENE
of O
- I-GENE
function O
mutation I-GENE
in O
the O
_RARE_ I-GENE
- I-GENE
encoded I-GENE
protein I-GENE
kinase I-GENE
. O

Sp1 I-GENE
binds O
two O
sites I-GENE
in O
the O
_RARE_ I-GENE
promoter I-GENE
in O
vivo O
specifically O
in O
myeloid O
cells O
and O
_RARE_ I-GENE
with O
AP1 I-GENE
to O
activate O
transcription I-GENE
. O

Expression O
of O
the O
phenylalanine I-GENE
hydroxylase I-GENE
gene I-GENE
in O
_RARE_ I-GENE
and O
kidneys O
of O
_RARE_ I-GENE
is O
activated I-GENE
at O
birth O
and O
is O
induced O
by O
glucocorticoids O
and O
cyclic I-GENE
AMP I-GENE
in O
the O
liver O
. O

We O
found O
that O
120 O
bp O
of O
the O
enhancer I-GENE
' O
s O
transcriptional O
core I-GENE
becomes O
DNase I-GENE
I I-GENE
hypersensitive I-GENE
early I-GENE
in O
B I-GENE
- I-GENE
cell O
development O
. O

A I-GENE
developmentally O
modulated O
chromatin O
structure O
at O
the O
mouse I-GENE
immunoglobulin I-GENE
kappa I-GENE
3 I-GENE
' O
enhancer I-GENE
. O

We O
report O
here O
the O
identification O
of O
a O
cDNA I-GENE
that O
encodes O
a O
new O
member O
of O
the O
GTPase I-GENE
- I-GENE
activating I-GENE
protein I-GENE
( O
GAP I-GENE
) O
family I-GENE
of O
GTPase I-GENE
regulators O
. O

In O
this O
study O
, O
we O
further O
investigated O
the O
regulation O
of O
the O
synthesis O
of O
the O
c I-GENE
- I-GENE
mos I-GENE
oncogene I-GENE
product I-GENE
, O
which O
is O
necessary O
for O
the O
activation O
of O
Cdc2 I-GENE
. O

The O
heterogeneity O
of O
bovine I-GENE
_RARE_ I-GENE
-- O
VIII I-GENE
. O

The O
ability O
of O
BCL I-GENE
- I-GENE
6 I-GENE
to O
function O
as O
a O
transcriptional O
repressor I-GENE
may O
contribute O
to O
its O
ability O
to O
transform O
B I-GENE
lymphocytes O
in O
diffuse O
large O
cell O
lymphoma O
. O

_RARE_ I-GENE
this O
uORF I-GENE
, O
together O
with O
its O
accompanying O
_RARE_ I-GENE
sequences I-GENE
, O
between O
a O
heterologous O
promoter I-GENE
from O
SV40 I-GENE
and O
a O
CAT I-GENE
reporter I-GENE
gene I-GENE
resulted O
in O
marked O
inhibition O
of O
CAT I-GENE
protein I-GENE
production O
without O
a O
decrease O
in O
CAT I-GENE
mRNA I-GENE
. O

A I-GENE
secondary O
spread O
of O
an O
_RARE_ I-GENE
_RARE_ I-GENE
- I-GENE
resistant O
Staphylococcus I-GENE
aureus I-GENE
strain O
( O
_RARE_ I-GENE
) O
to O
two O
other O
patients O
occurred O
within O
a O
_RARE_ I-GENE
surgical O
_RARE_ I-GENE
in O
_RARE_ I-GENE
of O
isolation O
of O
a O
_RARE_ I-GENE
index O
- I-GENE
patient O
immediately O
after O
_RARE_ I-GENE
from O
a O
hospital O
in O
the O
_RARE_ I-GENE
area O
. O

_RARE_ I-GENE
temporal O
sclerosis O
was O
characterized O
by O
severe O
neuronal O
loss O
accompanied O
by O
_RARE_ I-GENE
occurring O
in O
the O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
( O
27 O
patients O
, O
100 O
%), O
_RARE_ I-GENE
in O
the O
_RARE_ I-GENE
gyrus O
( O
12 O
patients O
, O
44 I-GENE
%), O
and O
in O
the O
_RARE_ I-GENE
region O
( O
11 O
patients O
, O
41 O
%). O

_RARE_ I-GENE
temporal O
sclerosis O
. O

More O
specific I-GENE
adverse O
events O
, O
also O
frequently O
considered O
as O
dose O
- I-GENE
limiting O
_RARE_ I-GENE
, O
include O
hypotension O
with O
IL I-GENE
- I-GENE
1 I-GENE
, O
severe O
headache O
or O
skin O
rash O
with O
IL I-GENE
- I-GENE
3 I-GENE
, O
and O
nasal O
_RARE_ I-GENE
and O
_RARE_ I-GENE
lesions O
with O
IL I-GENE
- I-GENE
4 I-GENE
. O

Therefore O
, O
magnetic O
resonance O
imaging O
was O
used O
to O
determine O
liver O
volume O
in O
pediatric O
and O
adolescent O
patients O
, O
in O
whom O
systemic O
clearance O
of O
three O
model O
substrates O
[ O
_RARE_ I-GENE
( O
0 O
. O
03 O
mg O
/ I-GENE
kg O
), O
_RARE_ I-GENE
( O
10 O
mg O
/ I-GENE
kg O
), O
and O
_RARE_ I-GENE
green I-GENE
( O
_RARE_ I-GENE
; O
0 O
. O
5 I-GENE
mg O
/ I-GENE
kg O
)] O
was O
also O
determined O
. O

A I-GENE
mutational O
analysis O
has O
resolved O
a O
region O
of O
seven O
amino O
acids O
( O
amino O
acids O
26 O
- I-GENE
32 O
) O
in O
the O
N I-GENE
- I-GENE
terminus O
of O
_RARE_ I-GENE
that O
are O
important O
for O
_RARE_ I-GENE
the O
DNA I-GENE
binding I-GENE
POU I-GENE
domain I-GENE
of O
Oct I-GENE
- I-GENE
1 I-GENE
or O
Oct I-GENE
- I-GENE
2 I-GENE
. O

_RARE_ I-GENE
oxygenase I-GENE
1 I-GENE
is O
an O
essential O
enzyme I-GENE
in O
heme O
catabolism O
that O
_RARE_ I-GENE
heme O
to O
form O
_RARE_ I-GENE
, O
iron O
, O
and O
carbon O
_RARE_ I-GENE
. O

An O
inactive O
analog O
of O
wortmannin O
, O
_RARE_ I-GENE
, O
did O
not O
affect O
TCR I-GENE
/ I-GENE
CD3 I-GENE
- I-GENE
induced O
_RARE_ I-GENE
activation O
, O
and O
wortmannin O
had O
no O
effect O
on O
the O
activity O
of O
_RARE_ I-GENE
when O
added O
directly O
to O
the O
in O
vitro O
assays O
. O

_RARE_ I-GENE
aa O
, O
shares O
78 O
% O
identity O
with O
the O
analogous O
region O
of O
Xenopus I-GENE
laevis I-GENE
_RARE_ I-GENE
and O
72 O
% O
identity O
with O
the O
product I-GENE
of O
the O
more O
distantly O
related I-GENE
human I-GENE
gene I-GENE
. O

The O
transcription I-GENE
start O
point O
of O
the O
proximal I-GENE
promoter I-GENE
_RARE_ I-GENE
to O
that O
of O
mouse I-GENE
promoter I-GENE
P3 I-GENE
and O
lies O
within O
a O
conserved O
region O
of O
sequence I-GENE
. O

_RARE_ I-GENE
in O
the O
Schizosaccharomyces I-GENE
pombe I-GENE
( O
_RARE_ I-GENE
) O
cell O
cycle O
- I-GENE
controlling O
genes I-GENE
prevent O
the O
cell O
cycle O
progression O
. O

To O
determine O
the O
signal I-GENE
recognition I-GENE
particle I-GENE
( O
SRP I-GENE
)- I-GENE
SRP I-GENE
receptor I-GENE
( O
_RARE_ I-GENE
) O
system O
in O
Bacillus I-GENE
subtilis I-GENE
( O
_RARE_ I-GENE
), O
we O
cloned O
the O
_RARE_ I-GENE
_RARE_ I-GENE
gene I-GENE
, O
which O
encodes O
a O
homologue I-GENE
of O
the O
mammalian I-GENE
SRP I-GENE
receptor I-GENE
alpha I-GENE
- I-GENE
subunit I-GENE
[ O
_RARE_ I-GENE
et O
al O
., O
DNA I-GENE
_RARE_ I-GENE
. O

A I-GENE
novel O
gene I-GENE
designated O
_RARE_ I-GENE
, O
which O
mapped O
to O
18 O
. O
8 O
min O
of O
the O
Escherichia I-GENE
coli I-GENE
K I-GENE
- I-GENE
12 O
genome O
, O
was O
shown O
to O
mediate O
resistance O
to O
chloramphenicol I-GENE
when O
it O
was O
expressed O
from O
a O
multicopy O
vector O
. O

In O
addition O
, O
5 I-GENE
' O
deletions O
removing O
all O
but O
34 O
bp O
upstream O
of O
the O
transcription I-GENE
start O
point O
retained O
greater O
than O
90 O
% O
promoter I-GENE
activity O
, O
suggesting O
that O
the O
- I-GENE
35 O
hexamer O
was O
not O
essential O
for O
promoter I-GENE
activity O
. O

The O
DNA I-GENE
sequence I-GENE
immediately O
upstream O
from O
the O
- I-GENE
10 O
hexamer O
contained O
the O
_RARE_ I-GENE
motif I-GENE
described O
as O
an O
extended O
- I-GENE
10 O
region O
in O
prokaryotic I-GENE
promoters I-GENE
. O

An O
apparent O
_RARE_ I-GENE
mRNA I-GENE
overexpression O
was O
not O
found O
in O
any O
of O
the O
positive O
leukemia I-GENE
cell O
lines O
, O
but O
was O
identified O
in O
the O
drug O
- I-GENE
resistant O
_RARE_ I-GENE
of O
the O
cervix O
carcinoma O
cell O
line O
HeLa O
. O

We O
conclude O
from O
these O
studies O
that O
_RARE_ I-GENE
may O
act O
as O
a O
positive O
regulator I-GENE
of O
_RARE_ I-GENE
by O
preventing O
E I-GENE
protein I-GENE
homodimers I-GENE
from O
binding I-GENE
to O
muscle O
gene I-GENE
regulatory I-GENE
elements O
. O

The O
role O
of O
negative O
regulators O
such O
as O
_RARE_ I-GENE
, O
as O
well O
as O
the O
previously O
described O
_RARE_ I-GENE
gene I-GENE
, O
in O
determining O
the O
promoter I-GENE
specificity O
of O
homologous O
activators I-GENE
is O
discussed O
. O

Transcriptional O
regulators O
utilizing O
the O
POU I-GENE
domain I-GENE
DNA I-GENE
- I-GENE
binding I-GENE
motif I-GENE
have O
been O
shown O
to O
form O
multi I-GENE
- I-GENE
protein I-GENE
complexes I-GENE
dependent I-GENE
on O
the O
POU I-GENE
domain I-GENE
itself O
and O
its O
_RARE_ I-GENE
recognition I-GENE
of O
various O
octamer O
sequence I-GENE
elements O
. O

We O
found O
strand O
selective O
repair I-GENE
in O
DNA I-GENE
fragments I-GENE
within O
two O
active O
genes I-GENE
, O
DHFR I-GENE
and O
an O
unknown O
gene I-GENE
adjacent O
to O
DHFR I-GENE
. O

_RARE_ I-GENE
AND O
METHODS O
: O
_RARE_ I-GENE
_RARE_ I-GENE
GRE I-GENE
imaging O
was O
used O
to O
study O
the O
_RARE_ I-GENE
, O
middle I-GENE
, O
and O
dorsal O
portions O
of O
the O
_RARE_ I-GENE
in O
14 O
patients O
with O
an O
_RARE_ I-GENE
normal O
_RARE_ I-GENE
and O
in O
five O
_RARE_ I-GENE
_RARE_ I-GENE
that O
had O
a O
normal O
_RARE_ I-GENE
proved O
with O
dissection O
. O

In O
an O
effort O
to O
contribute O
to O
the O
transcript I-GENE
map O
of O
human I-GENE
chromosome O
21 O
and O
the O
understanding O
of O
the O
pathophysiology O
of O
_RARE_ I-GENE
21 O
, O
we O
have O
used O
exon O
_RARE_ I-GENE
to O
identify O
fragments I-GENE
of O
chromosome O
21 O
genes I-GENE
. O

_RARE_ I-GENE
populations O
of O
this O
_RARE_ I-GENE
were O
first O
detected O
in O
_RARE_ I-GENE
_RARE_ I-GENE
in O
_RARE_ I-GENE
1992 O
. O

The O
model O
_RARE_ I-GENE
the O
_RARE_ I-GENE
of O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
dynamics O
to O
provide O
reasonable O
predictions O
of O
population O
patterns O
. O

At O
_RARE_ I-GENE
positions O
exhibiting O
the O
_RARE_ I-GENE
_RARE_ I-GENE
loss O
phenotype O
, O
we O
have O
found O
that O
the O
_RARE_ I-GENE
of O
the O
_RARE_ I-GENE
_RARE_ I-GENE
develop O
_RARE_ I-GENE
, O
in O
that O
neurons O
and O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
cells O
appear O
but O
not O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
and O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
cells O
. O

Transcriptional O
blockade O
was O
reversed O
by O
co O
- I-GENE
transfections O
of O
a O
wild I-GENE
- I-GENE
type I-GENE
SRF I-GENE
expression O
vector O
, O
but O
was O
not O
_RARE_ I-GENE
by O
the O
expression O
of O
other O
myogenic I-GENE
factors I-GENE
, O
such O
as O
MyoD I-GENE
and O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
. O

The O
_RARE_ I-GENE
promoter I-GENE
was O
identified O
and O
contained O
TATA I-GENE
, O
CAAT I-GENE
, O
GATA I-GENE
, O
and O
AP I-GENE
- I-GENE
2 I-GENE
elements O
; O
primer O
extension O
revealed O
_RARE_ I-GENE
transcription I-GENE
initiation I-GENE
at O
_RARE_ I-GENE
bp O
upstream O
from O
the O
_RARE_ I-GENE
translational O
initiation I-GENE
site I-GENE
. O

Human I-GENE
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
gene I-GENE
, O
a O
novel O
member O
of O
the O
_RARE_ I-GENE
anhydrase I-GENE
family I-GENE
: O
structure O
and O
exon O
to O
protein I-GENE
domain I-GENE
relationships O
. O

The O
exon O
- I-GENE
intron O
distribution O
of O
_RARE_ I-GENE
appears O
strikingly O
similar O
to O
that O
of O
the O
_RARE_ I-GENE
gene I-GENE
in O
the O
regions O
encoding O
the O
conserved O
domains I-GENE
, O
with O
a O
divergent O
structure O
in O
the O
other O
parts O
. O

DNA I-GENE
sequence I-GENE
analysis O
reveals O
that O
the O
gene I-GENE
encodes O
a O
protein I-GENE
highly O
homologous O
to O
rat I-GENE
_RARE_ I-GENE
. O

The O
gene I-GENE
was O
expressed O
as O
an O
approximately O
1 I-GENE
. O
5 I-GENE
- I-GENE
kb O
mRNA I-GENE
in O
most O
_RARE_ I-GENE
human I-GENE
cells O
/ I-GENE
tissues O
including O
prostate O
, O
lung O
, O
liver O
, O
and O
colon O
. O

Both O
of O
these O
domains I-GENE
have O
striking O
sequence I-GENE
homology I-GENE
with O
human I-GENE
_RARE_ I-GENE
and O
Drosophila I-GENE
_RARE_ I-GENE
proteins I-GENE
. O

Promoter O
activity O
was O
high O
in O
cell O
lines O
that O
expressed O
high O
levels O
of O
endogenous I-GENE
D3 I-GENE
mRNA I-GENE
, O
as O
indicated O
by O
Northern O
blot O
analyses O
, O
and O
was O
significantly O
reduced O
when O
the O
promoter I-GENE
was O
truncated I-GENE
to O
- I-GENE
122 O
bp O
. O

We O
have O
obtained O
the O
human I-GENE
_RARE_ I-GENE
receptor I-GENE
gene I-GENE
sequence I-GENE
and O
determined O
its O
structure O
relative O
to O
_RARE_ I-GENE
cDNA I-GENE
synthesized O
from O
peripheral O
blood O
lymphocytes O
. O

Some O
users O
will O
_RARE_ I-GENE
_RARE_ I-GENE
with O
management O
measures O
, O
other O
users O
will O
_RARE_ I-GENE
in O
response O
to O
education O
, O
but O
there O
will O
be O
another O
group O
who O
will O
only O
respond O
to O
_RARE_ I-GENE
activities O
. O

Three O
separate O
activation O
subdomains O
, O
and O
one O
negative O
- I-GENE
acting O
region O
, O
which O
function O
in O
yeast I-GENE
were O
located O
in O
the O
carboxyl O
- I-GENE
terminal I-GENE
region O
of O
_RARE_ I-GENE
. O

The O
front O
( O
F I-GENE
) O
interaction O
occurs O
_RARE_ I-GENE
of O
the O
growing O
end O
of O
RNA I-GENE
. O

Collectively O
, O
these O
data O
indicate O
that O
_RARE_ I-GENE
is O
a O
membrane I-GENE
- I-GENE
associated I-GENE
_RARE_ I-GENE
- I-GENE
binding I-GENE
protein I-GENE
expressed O
on O
the O
surface O
of O
normal O
human I-GENE
uterine O
_RARE_ I-GENE
and O
uterine O
epithelial O
cell O
lines O
. O

The O
corresponding O
gene I-GENE
was O
identified O
in O
the O
_RARE_ I-GENE
data O
base O
by O
sequence I-GENE
alignment O
and O
termed O
_RARE_ I-GENE
. O

The O
location O
of O
multiple O
_RARE_ I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
sites I-GENE
at O
the O
extreme O
carboxyl O
terminus O
of O
the O
_RARE_ I-GENE
is O
highly O
_RARE_ I-GENE
of O
_RARE_ I-GENE
- I-GENE
mediated O
phosphorylation O
of O
_RARE_ I-GENE
. O

This O
regulation O
could O
not O
be O
_RARE_ I-GENE
modified O
by O
enhanced O
expression O
of O
STAT I-GENE
proteins I-GENE
. O

_RARE_ I-GENE
for O
interleukin I-GENE
( O
IL I-GENE
)- I-GENE
10 O
and O
IL I-GENE
- I-GENE
6 I-GENE
- I-GENE
type I-GENE
cytokines O
use O
similar O
signaling O
mechanisms O
for O
inducing O
transcription I-GENE
through O
IL I-GENE
- I-GENE
6 I-GENE
response O
elements O
. O

Specifically O
, O
the O
deduced O
FR I-GENE
- I-GENE
19 O
amino O
acid I-GENE
sequence I-GENE
has O
_RARE_ I-GENE
, O
77 O
, O
and O
68 O
% O
overall O
identity O
to O
chicken I-GENE
TEF I-GENE
- I-GENE
_RARE_ I-GENE
, O
mouse I-GENE
TEF I-GENE
- I-GENE
1 I-GENE
, O
and O
mouse I-GENE
embryonic O
_RARE_ I-GENE
domain I-GENE
- I-GENE
containing O
factor I-GENE
, O
respectively O
. O

This O
phenomenon O
did O
not O
require O
DNA I-GENE
binding I-GENE
by O
the O
" O
interfering O
" O
receptor I-GENE
but O
required O
it O
to O
be O
hormone I-GENE
- I-GENE
bound O
, O
indicating O
that O
a O
transcriptionally O
active O
form O
of O
the O
interfering O
receptor I-GENE
is O
essential O
for O
the O
interfering O
effect O
. O

The O
receptor I-GENE
for O
_RARE_ I-GENE
mediated O
motility O
( O
_RARE_ I-GENE
) O
gene I-GENE
expression O
is O
markedly O
elevated O
in O
_RARE_ I-GENE
exposed O
to O
transforming I-GENE
growth I-GENE
factor I-GENE
- I-GENE
beta1 I-GENE
( O
TGF I-GENE
- I-GENE
beta1 I-GENE
). O

_RARE_ I-GENE
Raf I-GENE
- I-GENE
1 I-GENE
activates O
p70 I-GENE
S6 I-GENE
kinase I-GENE
via O
a O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
- I-GENE
independent O
pathway O
. O

_RARE_ I-GENE
analysis O
of O
_RARE_ I-GENE
indicates O
structural O
homology I-GENE
to O
_RARE_ I-GENE
, O
including O
12 O
transmembrane I-GENE
domains I-GENE
, O
a O
large O
extracellular I-GENE
loop I-GENE
with O
potential O
N I-GENE
- I-GENE
linked O
glycosylation O
sites I-GENE
, O
and O
cytoplasmic I-GENE
N I-GENE
- I-GENE
and O
C I-GENE
- I-GENE
terminal I-GENE
regions O
. O

A I-GENE
cis O
- I-GENE
acting O
DNA I-GENE
element I-GENE
located O
between O
TATA I-GENE
box I-GENE
and O
transcription I-GENE
initiation I-GENE
site I-GENE
is O
critical O
in O
response O
to O
regulatory I-GENE
sequences I-GENE
in O
human I-GENE
_RARE_ I-GENE
gene I-GENE
. O

This O
protein I-GENE
with O
a O
hydrophobic O
amino O
terminus O
appears O
to O
be O
a O
secreted O
protein I-GENE
. O

The O
promoter I-GENE
of O
the O
rat I-GENE
_RARE_ I-GENE
- I-GENE
2 I-GENE
gene I-GENE
contains O
a O
CAAT I-GENE
enhancer I-GENE
- I-GENE
binding I-GENE
protein I-GENE
consensus I-GENE
site I-GENE
( O
CAAT I-GENE
box I-GENE
) O
which O
can O
confer O
hormone I-GENE
inducibility O
to O
a O
_RARE_ I-GENE
- I-GENE
2 I-GENE
. O
CAT I-GENE
reporter I-GENE
gene I-GENE
, O
as O
well O
as O
a O
putative O
E I-GENE
- I-GENE
box I-GENE
region O
. O

_RARE_ I-GENE
, O
SRF I-GENE
has O
been O
found O
to O
be O
a O
key O
regulator I-GENE
of O
members O
of O
a O
class I-GENE
of O
cellular O
response O
genes I-GENE
termed O
immediate I-GENE
- I-GENE
early I-GENE
genes I-GENE
( O
_RARE_ I-GENE
), O
many O
of O
which O
are O
believed O
to O
be O
involved O
in O
regulating O
cell O
growth I-GENE
and O
differentiation O
. O

The O
final O
_RARE_ I-GENE
- I-GENE
dependent I-GENE
_RARE_ I-GENE
activator I-GENE
regulates O
transcription I-GENE
of O
the O
_RARE_ I-GENE
operon I-GENE
that O
encodes O
the O
enzymes O
for O
catabolism O
of O
( O
methyl O
) O
_RARE_ I-GENE
. O

In O
this O
study O
, O
we O
have O
cloned O
the O
human I-GENE
_RARE_ I-GENE
gene I-GENE
and O
examined O
the O
transcriptional O
regulation O
of O
its O
expression O
. O

Clinical O
evaluation O
of O
the O
_RARE_ I-GENE
_RARE_ I-GENE
500 O
_RARE_ I-GENE
and O
the O
_RARE_ I-GENE
AR I-GENE
- I-GENE
1000 O
_RARE_ I-GENE
. O

None O
of O
the O
five O
_RARE_ I-GENE
processing O
proteases I-GENE
tested O
were O
capable O
of O
_RARE_ I-GENE
human I-GENE
pro I-GENE
- I-GENE
_RARE_ I-GENE
, O
strongly O
suggesting O
that O
they O
are O
not O
involved O
in O
the O
maturation O
of O
this O
enzyme I-GENE
. O

These O
changes O
may O
be O
the O
result O
of O
, O
on O
the O
one O
hand O
, O
an O
increased O
sensitivity O
of O
the O
neuromuscular O
transmission O
and O
/ I-GENE
or O
decreased O
muscle O
contractility O
and O
, O
on O
the O
other O
hand O
, O
the O
result O
of O
a O
reduced O
plasma I-GENE
clearance O
during O
hypothermia O
. O

SETTING O
-- O
_RARE_ I-GENE
, O
_RARE_ I-GENE
_RARE_ I-GENE
, O
1985 O
- I-GENE
6 I-GENE
. O

By O
using O
interleukin I-GENE
- I-GENE
3 I-GENE
- I-GENE
dependent I-GENE
cells O
that O
_RARE_ I-GENE
express O
the O
three O
ErbB I-GENE
proteins I-GENE
or O
their O
combinations O
, O
we O
found O
that O
ErbB I-GENE
- I-GENE
3 I-GENE
is O
_RARE_ I-GENE
of O
any O
biological O
activity O
but O
both O
ErbB I-GENE
- I-GENE
1 I-GENE
and O
ErbB I-GENE
- I-GENE
2 I-GENE
can O
_RARE_ I-GENE
its O
extremely O
potent O
mitogenic O
activity O
. O

_RARE_ I-GENE
was O
significantly O
more O
sensitive O
than O
all O
subsequent O
methods O
, O
and O
_RARE_ I-GENE
, O
O2 O
was O
significantly O
more O
sensitive O
than O
FEV1 O
. O

Selective O
translation I-GENE
initiation I-GENE
by O
ribosome I-GENE
_RARE_ I-GENE
in O
adenovirus I-GENE
- I-GENE
infected O
and O
heat I-GENE
- I-GENE
_RARE_ I-GENE
cells O
. O

Furthermore O
, O
we O
have O
identified O
a O
43 I-GENE
- I-GENE
bp O
region O
of O
the O
_RARE_ I-GENE
promoter I-GENE
required O
for O
the O
_RARE_ I-GENE
responsiveness O
. O

These O
findings O
suggest O
that O
direct O
cDNA I-GENE
mapping O
using O
fluorescence O
in O
situ O
hybridization O
provides O
an O
accurate O
and O
rapid O
approach O
to O
the O
definition O
of O
a O
transcribed O
map O
of O
the O
human I-GENE
genome O
. O

YAC O
and O
cosmid O
_RARE_ I-GENE
spanning O
the O
_RARE_ I-GENE
disease O
( O
_RARE_ I-GENE
) O
region O
at O
_RARE_ I-GENE
. O
1 I-GENE
- I-GENE
_RARE_ I-GENE
. O
2 I-GENE
. O

Isolation O
of O
a O
near O
full I-GENE
- I-GENE
length I-GENE
cDNA I-GENE
from O
a O
human I-GENE
fetal O
brain O
cDNA I-GENE
library O
revealed O
a O
protein I-GENE
serine I-GENE
- I-GENE
threonine I-GENE
phosphatase I-GENE
with O
a O
_RARE_ I-GENE
motif I-GENE
, O
almost O
identical O
to O
human I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
and O
highly O
homologous O
to O
rat I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
- I-GENE
49 O
is O
a O
family I-GENE
type I-GENE
II I-GENE
transmembrane I-GENE
proteins I-GENE
encoded I-GENE
by O
a O
gene I-GENE
cluster I-GENE
on O
murine I-GENE
chromosome O
6 I-GENE
. O

The O
_RARE_ I-GENE
- I-GENE
A2 I-GENE
ORF I-GENE
driven O
by O
the O
_RARE_ I-GENE
promoter I-GENE
complemented O
the O
phenotype O
of O
a O
strain O
deleted O
for O
_RARE_ I-GENE
. O

The O
introduction O
of O
_RARE_ I-GENE
to O
the O
cells O
maintained O
the O
balance O
between O
cytosolic I-GENE
and O
membrane I-GENE
- I-GENE
associated I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
. O

Our O
data O
demonstrate O
directly O
that O
_RARE_ I-GENE
is O
transcribed O
with O
its O
substrates O
, O
tRNA I-GENE
met I-GENE
f I-GENE
and O
_RARE_ I-GENE
, O
from O
a O
promoter I-GENE
located O
upstream O
of O
the O
tRNA I-GENE
met I-GENE
f I-GENE
gene I-GENE
and O
suggest O
that O
a O
portion O
also O
_RARE_ I-GENE
from O
a O
second O
promoter I-GENE
, O
located O
between O
the O
tRNA I-GENE
met I-GENE
f I-GENE
gene I-GENE
and O
_RARE_ I-GENE
. O

Furthermore O
, O
strains O
with O
mutant I-GENE
_RARE_ I-GENE
genes I-GENE
also O
accumulate O
precursor I-GENE
_RARE_ I-GENE
, O
suggesting O
that O
mutations O
in O
either O
gene I-GENE
can O
lead O
to O
similar O
biogenesis O
defects O
. O

_RARE_ I-GENE
membrane I-GENE
vesicles O
from O
_RARE_ I-GENE
mutants I-GENE
lack O
all O
Ca2 I-GENE
+/ I-GENE
H I-GENE
+ I-GENE
_RARE_ I-GENE
activity O
, O
demonstrating O
that O
_RARE_ I-GENE
catalyzes O
the O
exchange I-GENE
of O
Ca2 I-GENE
+ I-GENE
for O
H I-GENE
+ I-GENE
across O
the O
yeast I-GENE
vacuolar I-GENE
membrane I-GENE
. O

_RARE_ I-GENE
mutagenesis O
of O
the O
element I-GENE
' O
s O
rare O
- I-GENE
codon O
/ I-GENE
_RARE_ I-GENE
- I-GENE
rich O
sequence I-GENE
boundary O
revealed O
that O
the O
_RARE_ I-GENE
activity O
of O
the O
_RARE_ I-GENE
IE I-GENE
is O
observed O
when O
the O
terminal I-GENE
codon O
of O
the O
element I-GENE
' O
s O
rare O
- I-GENE
codon O
interval O
is O
translated O
. O

_RARE_ I-GENE
is O
also O
abundantly O
expressed O
in O
the O
pancreas O
and O
may O
exert O
differentiation O
functions O
in O
_RARE_ I-GENE
_RARE_ I-GENE
, O
similar O
to O
SF I-GENE
- I-GENE
1 I-GENE
in O
_RARE_ I-GENE
tissues O
. O

_RARE_ I-GENE
, O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
evidence O
supports O
a O
critical O
role O
for O
the O
activation O
of O
the O
Raf I-GENE
- I-GENE
1 I-GENE
/ I-GENE
MEK I-GENE
/ I-GENE
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
pathway O
in O
oncogenic I-GENE
Ras I-GENE
- I-GENE
mediated O
transformation O
. O

_RARE_ I-GENE
chain I-GENE
_RARE_ I-GENE
: O
choice O
of O
the O
surgical O
approach O
. O

The O
incidence O
of O
cardiac O
death O
( O
one O
per O
group O
), O
Q I-GENE
wave O
MI O
( O
_RARE_ I-GENE
, O
n O
= O
7 O
; O
midazolam O
, O
n O
= O
3 I-GENE
; O
P I-GENE
= O
0 O
. O
27 O
), O
or O
non O
Q I-GENE
wave O
MI O
( O
_RARE_ I-GENE
, O
n O
= O
16 O
; O
midazolam O
, O
n O
= O
18 O
; O
P I-GENE
= O
0 O
. O
81 O
) O
did O
not O
differ O
between O
treatment O
groups O
. O

63 O
. O
3 I-GENE
_RARE_ I-GENE
/ I-GENE
1 I-GENE
, O
p O
< O
0 O
. O
01 O
) O
and O
area O
under O
the O
plasma I-GENE
concentration O
- I-GENE
time O
curve O
_RARE_ I-GENE
to O
_RARE_ I-GENE
AUC O
9 O
( O
0 O
- I-GENE
_RARE_ I-GENE
)( I-GENE
_RARE_ I-GENE
. O
7 O
vs O
. O

_RARE_ I-GENE
formation O
of O
E I-GENE
- I-GENE
cadherin I-GENE
on O
the O
cell O
surface O
is O
believed O
to O
be O
of O
major I-GENE
importance O
for O
cell O
- I-GENE
cell O
adhesion I-GENE
. O

DNA I-GENE
polymerase I-GENE
E I-GENE
, O
DNA I-GENE
ligase I-GENE
III I-GENE
and O
a O
DNA I-GENE
structure O
- I-GENE
specific I-GENE
endonuclease I-GENE
co O
- I-GENE
_RARE_ I-GENE
with O
the O
five O
polypeptide I-GENE
complex I-GENE
. O

By O
using O
reporter I-GENE
gene I-GENE
constructs I-GENE
, O
it O
is O
shown O
that O
upstream O
sequences I-GENE
of O
the O
P1 I-GENE
promoter I-GENE
contain O
several O
regions O
that O
modulate O
the O
expression O
either O
positively O
or O
negatively O
. O

The O
factor I-GENE
structure O
of O
" O
_RARE_ I-GENE
' O
_RARE_ I-GENE
: O
a O
large O
replication O
study O
. O

Interestingly O
, O
however O
, O
it O
is O
homologous O
to O
several O
expressed O
sequence I-GENE
tags O
( O
EST I-GENE
) O
of O
unknown O
function O
from O
Caenorhabditis I-GENE
elegans I-GENE
, O
_RARE_ I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
. O

RESULTS O
: O
The O
_RARE_ I-GENE
model O
provided O
a O
significantly O
better O
fit O
to O
the O
_RARE_ I-GENE
outcome O
data O
. O

_RARE_ I-GENE
of O
severe O
congenital O
hypothyroidism O
. O

Mean O
increase O
of O
milk O
protein I-GENE
yield O
was O
46 O
g O
/ I-GENE
d O
with O
Met I-GENE
plus O
Lys O
, O
and O
mean O
increase O
of O
true O
protein I-GENE
content O
was O
1 I-GENE
. O
1 I-GENE
g O
/ I-GENE
kg O
of O
milk O
. O

_RARE_ I-GENE
rates O
can O
be O
used O
to O
_RARE_ I-GENE
more O
_RARE_ I-GENE
biological O
measures O
for O
reproductive O
efficiency O
, O
such O
as O
_RARE_ I-GENE
rate O
and O
_RARE_ I-GENE
rate O
, O
which O
separately O
might O
be O
more O
reliable O
than O
_RARE_ I-GENE
rate O
itself O
to O
evaluate O
the O
fertility O
of O
a O
_RARE_ I-GENE
or O
the O
performance O
of O
an O
_RARE_ I-GENE
_RARE_ I-GENE
. O

However O
, O
if O
_RARE_ I-GENE
involves O
the O
_RARE_ I-GENE
_RARE_ I-GENE
or O
_RARE_ I-GENE
area O
, O
a O
search O
for O
internal O
malignancy O
is O
still O
warranted O
. O

The O
mean O
values O
of O
protease I-GENE
activity O
were O
significantly O
higher O
in O
the O
test O
groups O
than O
in O
the O
control O
group O
at O
baseline O
. O

Each O
half O
molecule I-GENE
contains O
four O
disulfide O
_RARE_ I-GENE
and O
four O
cis O
peptides I-GENE
. O

Only O
fully O
processed O
Pra I-GENE
( O
_RARE_ I-GENE
and O
_RARE_ I-GENE
) O
and O
_RARE_ I-GENE
( O
_RARE_ I-GENE
e O
, O
f I-GENE
) O
are O
present O
in O
B I-GENE
_RARE_ I-GENE
, O
which O
are O
believed O
to O
be O
precursors I-GENE
of O
mature O
virions O
. O

A I-GENE
chimeric I-GENE
VP16 I-GENE
- I-GENE
Tat I-GENE
construct I-GENE
containing O
the O
leucine I-GENE
mutations O
showed O
no O
increased O
AP I-GENE
- I-GENE
1 I-GENE
responsiveness O
in O
comparison O
with O
that O
of O
the O
VP16 I-GENE
activation O
domain I-GENE
alone O
. O

However O
, O
one O
3 I-GENE
' O
splice O
site I-GENE
, O
located O
at O
nucleotide I-GENE
( O
nt O
) O
_RARE_ I-GENE
, O
is O
used O
for O
the O
processing O
of O
most O
BPV I-GENE
- I-GENE
1 I-GENE
pre I-GENE
- I-GENE
mRNAs I-GENE
in O
BPV I-GENE
- I-GENE
1 I-GENE
- I-GENE
transformed O
_RARE_ I-GENE
cells O
and O
at O
early I-GENE
to O
intermediate O
times O
in O
_RARE_ I-GENE
infected O
_RARE_ I-GENE
. O

Here O
, O
the O
cloning O
and O
characterization O
of O
S I-GENE
- I-GENE
RNase I-GENE
genes I-GENE
from O
two O
species O
of O
_RARE_ I-GENE
, O
_RARE_ I-GENE
( O
_RARE_ I-GENE
x O
_RARE_ I-GENE
) O
and O
Japanese O
_RARE_ I-GENE
( O
_RARE_ I-GENE
_RARE_ I-GENE
) O
is O
described O
and O
these O
sequences I-GENE
are O
compared O
with O
those O
of O
other O
T2 I-GENE
- I-GENE
type I-GENE
_RARE_ I-GENE
. O

A I-GENE
phylogenetic O
_RARE_ I-GENE
of O
members O
of O
the O
T2 I-GENE
/ I-GENE
S I-GENE
- I-GENE
RNase I-GENE
superfamily I-GENE
in O
plants O
was O
obtained O
. O

In O
a O
_RARE_ I-GENE
_RARE_ I-GENE
Group O
randomized O
study O
involving O
extensive O
- I-GENE
disease O
_RARE_ I-GENE
patients O
, O
_RARE_ I-GENE
was O
superior O
to O
_RARE_ I-GENE
/ I-GENE
cisplatin O
with O
regard O
to O
median O
time O
to O
progression O
( O
6 I-GENE
. O
6 I-GENE
v I-GENE
5 I-GENE
. O
8 O
months O
), O
median O
survival O
times O
( O
9 O
. O
1 I-GENE
v I-GENE
7 O
. O
3 I-GENE
months O
), O
and O
2 I-GENE
- I-GENE
and O
3 I-GENE
- I-GENE
year O
survival O
rates O
( O
13 O
% O
v I-GENE
5 I-GENE
% O
and O
5 I-GENE
% O
v I-GENE
0 O
%, O
respectively O
). O

It O
was O
shown O
that O
administration O
of O
_RARE_ I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
results O
in O
more O
steady O
_RARE_ I-GENE
and O
retention O
of O
feeding O
and O
_RARE_ I-GENE
behavior O
, O
and O
some O
_RARE_ I-GENE
mechanisms O
of O
that O
phenomena O
were O
revealed O
. O

_RARE_ I-GENE
scintigraphy O
, O
performed O
in O
70 I-GENE
patients O
, O
was O
less O
sensitive O
than O
ultrasonography O
( O
80 O
%). O

_RARE_ I-GENE
allergy O
and O
other O
_RARE_ I-GENE
. O

Despite O
significant O
lethality O
and O
cardiovascular O
dysfunction O
, O
in O
the O
_RARE_ I-GENE
group O
on O
_RARE_ I-GENE
1 I-GENE
and O
2 I-GENE
, O
_RARE_ I-GENE
versus O
control O
animals O
had O
no O
significant O
differences O
in O
mean O
metabolic O
_RARE_ I-GENE
measured O
( O
_RARE_ I-GENE
, O
ml O
/ I-GENE
kg O
/ I-GENE
min O
; O
Day O
1 I-GENE
: O
11 O
. O
9 O
versus O
12 O
. O
4 I-GENE
, O
p O
= O
0 O
. O
81 O
; O
Day O
2 I-GENE
: O
14 O
. O
2 I-GENE
versus O
13 O
. O
5 I-GENE
, O
p O
= O
0 O
. O
72 O
, O
respectively O
) O
and O
intravascular O
catheter O
calculated O
( O
_RARE_ I-GENE
, O
ml O
/ I-GENE
kg O
/ I-GENE
min O
; O
Day O
1 I-GENE
: O
11 O
. O
2 I-GENE
versus O
11 O
. O
2 I-GENE
, O
p O
= O
0 O
. O
99 O
; O
Day O
2 I-GENE
: O
12 O
. O
8 O
versus O
15 O
. O
4 I-GENE
, O
p O
= O
0 O
. O
49 O
, O
respectively O
). O

After O
6 I-GENE
h O
of O
reperfusion O
, O
PO2 O
/ I-GENE
_RARE_ I-GENE
ratio O
was O
significantly O
better O
after O
Combined O
_RARE_ I-GENE
( O
_RARE_ I-GENE
+/- O
52 O
mm O
Hg O
) O
than O
in O
the O
_RARE_ I-GENE
_RARE_ I-GENE
( O
117 O
+/- O
47 O
mm O
Hg O
) O
and O
Control O
groups O
( O
87 O
+/- O
26 O
mm O
Hg O
), O
with O
intermediate O
values O
in O
_RARE_ I-GENE
_RARE_ I-GENE
dogs O
( O
_RARE_ I-GENE
+/- O
64 O
mm O
Hg O
). O

The O
_RARE_ I-GENE
_RARE_ I-GENE
lysis O
time O
was O
slightly O
longer O
in O
the O
smokers O
than O
in O
the O
non O
- I-GENE
smokers O
in O
all O
three O
experimental O
situations O
, O
but O
the O
differences O
were O
not O
significant O
. O

HS I-GENE
inducibility O
required O
the O
HSE O
which O
was O
bound O
by O
HS I-GENE
transcription I-GENE
factor I-GENE
- I-GENE
1 I-GENE
( O
HSF I-GENE
- I-GENE
1 I-GENE
) O
present O
in O
extracts O
prepared O
from O
cells O
exposed O
to O
HS I-GENE
. O

Although O
the O
_RARE_ I-GENE
- I-GENE
1 I-GENE
mutation I-GENE
alters O
a O
conserved O
residue O
in O
the O
_RARE_ I-GENE
ubiquitin I-GENE
- I-GENE
like I-GENE
domain I-GENE
, O
we O
detect O
no O
differences O
in O
_RARE_ I-GENE
or O
_RARE_ I-GENE
stability O
. O

Although O
IL I-GENE
- I-GENE
2 I-GENE
and O
IFN I-GENE
- I-GENE
alpha I-GENE
activated I-GENE
STAT1 I-GENE
alpha I-GENE
and O
STAT5 I-GENE
, O
IL I-GENE
- I-GENE
2 I-GENE
predominantly O
activated I-GENE
STAT5 I-GENE
, O
while O
IFN I-GENE
- I-GENE
alpha I-GENE
predominantly O
activated I-GENE
STAT1 I-GENE
alpha I-GENE
. O

Consistent O
with O
this O
interpretation O
, O
recombinant I-GENE
CREB I-GENE
and O
activating I-GENE
transcription I-GENE
factor I-GENE
proteins I-GENE
bound O
the O
junB I-GENE
CRE O
- I-GENE
like I-GENE
site I-GENE
, O
but O
did O
not O
interact O
with O
a O
mutant I-GENE
CRE O
- I-GENE
like I-GENE
site I-GENE
. O

Collectively O
, O
these O
results O
suggest O
that O
components O
of O
the O
protein I-GENE
kinase I-GENE
A I-GENE
signaling O
pathway O
are O
recruited O
by O
_RARE_ I-GENE
to O
induce O
junB I-GENE
transcription I-GENE
. O

One O
complex I-GENE
containing O
a O
70 I-GENE
D I-GENE
protein I-GENE
was O
found O
to O
be O
associated I-GENE
specifically O
with O
transcriptionally O
active O
leukemia I-GENE
cells O
. O

Our O
results O
confirm O
the O
participation O
of O
intron O
1 I-GENE
in O
transcriptional O
regulation O
of O
the O
c I-GENE
- I-GENE
myb I-GENE
gene I-GENE
( O
in O
mouse I-GENE
and O
human I-GENE
) O
and O
_RARE_ I-GENE
multiple O
and O
complex I-GENE
regulatory I-GENE
mechanisms O
of O
activation O
during O
_RARE_ I-GENE
differentiation O
and O
_RARE_ I-GENE
cell O
growth I-GENE
control O
. O

_RARE_ I-GENE
microscopy O
revealed O
extensive O
deposition O
of O
such O
extracellular I-GENE
_RARE_ I-GENE
as O
type I-GENE
IV I-GENE
collagen I-GENE
and O
_RARE_ I-GENE
in O
the O
vascular I-GENE
wall O
. O

OBJECTIVE O
: O
To O
compare O
pregnancy O
complications O
in O
women O
having O
genetic O
_RARE_ I-GENE
at O
11 O
- I-GENE
14 O
weeks O
versus O
those O
undergoing O
_RARE_ I-GENE
at O
16 O
- I-GENE
19 O
weeks O
' O
gestation O
. O

Three O
ORFs O
( O
_RARE_ I-GENE
, O
_RARE_ I-GENE
and O
_RARE_ I-GENE
) O
were O
found O
to O
be O
homologous O
with O
Schizosaccharomyces I-GENE
pombe I-GENE
_RARE_ I-GENE
binding I-GENE
protein I-GENE
, O
Escherichia I-GENE
coli I-GENE
_RARE_ I-GENE
38 O
. O
1 I-GENE
- I-GENE
kDa I-GENE
protein I-GENE
in O
the O
BCR I-GENE
5 I-GENE
' O
region O
, O
and O
transcription I-GENE
regulatory I-GENE
protein I-GENE
_RARE_ I-GENE
, O
respectively O
. O

Two O
new O
_RARE_ I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
5 I-GENE
- I-GENE
O O
- I-GENE
beta I-GENE
- I-GENE
D I-GENE
- I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
5 I-GENE
- I-GENE
O O
- I-GENE
beta I-GENE
- I-GENE
D I-GENE
- I-GENE
_RARE_ I-GENE
( O
1 I-GENE
--> I-GENE
6 I-GENE
) O
beta I-GENE
- I-GENE
D I-GENE
- I-GENE
_RARE_ I-GENE
, O
have O
been O
isolated O
from O
the O
_RARE_ I-GENE
parts O
of O
_RARE_ I-GENE
_RARE_ I-GENE
. O

Recently O
, O
our O
laboratory O
developed O
a O
screen O
that O
identified O
five O
multicopy O
suppressors O
that O
can O
rescue O
lethal O
strains O
of O
clathrin I-GENE
heavy I-GENE
chain I-GENE
- I-GENE
deficient O
yeast I-GENE
( O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
i O
) O
to O
viability O
. O

_RARE_ I-GENE
period O
affects O
water O
intake O
in O
heat I-GENE
- I-GENE
stressed O
_RARE_ I-GENE
goats O
. O

The O
_RARE_ I-GENE
regression O
analysis O
of O
the O
_RARE_ I-GENE
method O
( O
percentage O
normal O
morphology O
) O
and O
_RARE_ I-GENE
indicated O
that O
both O
were O
predictors O
of O
fertilization O
. O

METHODS O
: O
Rats I-GENE
received O
continuous O
_RARE_ I-GENE
infusion O
of O
_RARE_ I-GENE
diet O
or O
with O
supplementation O
of O
_RARE_ I-GENE
, O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
, O
with O
and O
without O
_RARE_ I-GENE
, O
from O
the O
beginning O
of O
the O
study O
. O

However O
, O
_RARE_ I-GENE
binding I-GENE
was O
observed O
by O
nuclease I-GENE
protection O
with O
_RARE_ I-GENE
- I-GENE
as O
well O
as O
_RARE_ I-GENE
- I-GENE
like I-GENE
cell O
nuclear I-GENE
protein I-GENE
. O

_RARE_ I-GENE
role O
for O
PCR O
- I-GENE
based O
diagnosis O
of O
_RARE_ I-GENE
' O
s O
disease O
from O
peripheral O
blood O
mononuclear O
cells O
. O

The O
ability O
of O
_RARE_ I-GENE
to O
block O
NF I-GENE
- I-GENE
kappaB I-GENE
activation O
was O
mapped O
to O
its O
C I-GENE
- I-GENE
terminal I-GENE
zinc I-GENE
finger I-GENE
domain I-GENE
. O

The O
Pro I-GENE
- I-GENE
258 O
--> I-GENE
Leu I-GENE
( O
_RARE_ I-GENE
) O
mutation I-GENE
caused O
constitutive O
receptor I-GENE
signaling O
that O
was O
equivalent O
to O
about O
45 O
% O
of O
the O
maximum O
level O
observed O
in O
wild I-GENE
- I-GENE
type I-GENE
cells O
stimulated O
with O
alpha I-GENE
- I-GENE
factor I-GENE
. O

By O
using O
a O
DNA I-GENE
sequence I-GENE
selected O
for O
its O
ability O
to O
bind O
recombinant I-GENE
BCL I-GENE
- I-GENE
6 I-GENE
in O
vitro O
, O
we O
show O
here O
that O
BCL I-GENE
- I-GENE
6 I-GENE
is O
present O
in O
DNA I-GENE
- I-GENE
binding I-GENE
complexes I-GENE
in O
nuclear I-GENE
extracts O
from O
various O
B I-GENE
- I-GENE
cell O
lines O
. O

The O
predictive O
value O
of O
a O
positive O
_RARE_ I-GENE
was O
77 O
. O
7 O
%. O

CONCLUSIONS O
: O
Our O
findings O
suggest O
that O
pre I-GENE
- I-GENE
treatment O
with O
coenzyme I-GENE
_RARE_ I-GENE
may O
play O
a O
protective O
role O
during O
routine O
vascular I-GENE
procedures O
requiring O
abdominal O
aortic O
cross O
_RARE_ I-GENE
by O
_RARE_ I-GENE
the O
degree O
of O
_RARE_ I-GENE
damage O
. O

Because O
chromosome O
X I-GENE
is O
frequently O
involved O
in O
structural O
alterations O
in O
neoplastic O
Syrian I-GENE
hamster I-GENE
cells O
transformed O
by O
chemical O
_RARE_ I-GENE
and O
oncogenic I-GENE
viruses O
, O
the O
localization O
of O
the O
_RARE_ I-GENE
locus I-GENE
on O
this O
chromosome O
supports O
the O
notion O
that O
the O
_RARE_ I-GENE
oncogene I-GENE
plays O
a O
role O
in O
the O
malignant O
conversion O
of O
_RARE_ I-GENE
transformed O
hamster I-GENE
fibroblasts O
. O

In O
a O
screen O
for O
genes I-GENE
with O
oncogenic I-GENE
potential O
expressed O
by O
the O
murine I-GENE
_RARE_ I-GENE
myeloid O
progenitor I-GENE
cell O
line O
, O
we O
isolated O
a O
2 I-GENE
. O

_RARE_ I-GENE
( O
_RARE_ I-GENE
), O
one O
of O
a O
member O
of O
Ras I-GENE
GTPase I-GENE
- I-GENE
activating I-GENE
proteins I-GENE
, O
has O
been O
identified O
as O
a O
specific I-GENE
inositol I-GENE
1 I-GENE
, O
3 I-GENE
, O
4 I-GENE
, O
5 I-GENE
- I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
)- I-GENE
binding I-GENE
protein I-GENE
( O
_RARE_ I-GENE
, O
P I-GENE
. O

We O
previously O
described O
the O
purification O
of O
an O
83 O
- I-GENE
kDa I-GENE
_RARE_ I-GENE
acid I-GENE
phosphatase I-GENE
( O
_RARE_ I-GENE
) O
from O
the O
porcine I-GENE
_RARE_ I-GENE
membranes O
( O
_RARE_ I-GENE
, O
H I-GENE
., O
_RARE_ I-GENE
, O
S I-GENE
_RARE_ I-GENE
i O
., O
_RARE_ I-GENE
, O
K I-GENE
. O
and O
_RARE_ I-GENE
, O
F I-GENE
.( O
1992 O
) O
J O
. O

The O
mechanism O
involves O
Gbetagamma I-GENE
subunit I-GENE
- I-GENE
mediated O
increases O
in O
tyrosine I-GENE
phosphorylation O
of O
the O
Shc I-GENE
adapter I-GENE
protein I-GENE
, O
Shc I-GENE
* I-GENE
Grb2 I-GENE
complex I-GENE
formation O
, O
and O
recruitment O
of O
Ras I-GENE
guanine I-GENE
nucleotide I-GENE
exchange I-GENE
factor I-GENE
activity O
. O

A I-GENE
cDNA I-GENE
encoding O
the O
amino O
- I-GENE
terminal I-GENE
17 O
% O
of O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
was O
fused O
to O
a O
cDNA I-GENE
coding O
for O
the O
last O
37 O
amino O
acids O
of O
decay O
- I-GENE
_RARE_ I-GENE
factor I-GENE
( O
_RARE_ I-GENE
), O
which O
contains O
the O
signal I-GENE
for O
_RARE_ I-GENE
anchor I-GENE
attachment O
. O

_RARE_ I-GENE
, O
we O
stably O
overexpressed O
wild I-GENE
- I-GENE
type I-GENE
Shc I-GENE
or O
_RARE_ I-GENE
mutant I-GENE
Shc I-GENE
into O
_RARE_ I-GENE
cells O
. O

The O
small I-GENE
GTPase I-GENE
Rho I-GENE
is O
implicated O
in O
physiological O
functions O
associated I-GENE
with O
actin I-GENE
- I-GENE
myosin I-GENE
_RARE_ I-GENE
such O
as O
_RARE_ I-GENE
, O
cell O
motility O
, O
and O
smooth I-GENE
muscle O
contraction O
. O

Conversely O
, O
activation O
of O
this O
signaling O
pathway O
by O
expression O
of O
a O
constitutively O
active O
_RARE_ I-GENE
mutant I-GENE
dramatically O
increased O
cyclin I-GENE
D1 I-GENE
promoter I-GENE
activity O
and O
cyclin I-GENE
D1 I-GENE
protein I-GENE
expression O
, O
in O
a O
growth I-GENE
factor I-GENE
- I-GENE
independent O
manner O
. O

Furthermore O
, O
upstream O
insertion O
of O
the O
_RARE_ I-GENE
silencer I-GENE
element I-GENE
failed O
to O
inhibit O
activity O
of O
a O
heterologous O
promoter I-GENE
in O
_RARE_ I-GENE
cells O
. O

In O
order O
to O
_RARE_ I-GENE
structural O
motifs O
regulating O
substrate I-GENE
affinity O
and O
recognition I-GENE
for O
the O
human I-GENE
dopamine I-GENE
transporter I-GENE
( O
_RARE_ I-GENE
), O
we O
assessed O
[ O
3H O
] O
dopamine I-GENE
uptake O
kinetics O
and O
[ O
3H O
] O
_RARE_ I-GENE
binding I-GENE
characteristics O
of O
COS O
- I-GENE
7 O
cells O
transiently O
expressing O
mutant I-GENE
_RARE_ I-GENE
in O
which O
the O
COOH O
terminus O
was O
truncated I-GENE
or O
substituted O
. O

An O
expression O
library O
was O
constructed O
by O
inserting O
5 I-GENE
' O
portion O
- I-GENE
enriched O
cDNAs I-GENE
from O
phytohemagglutinin I-GENE
- I-GENE
stimulated O
peripheral O
blood O
mononuclear O
cells O
into O
upstream O
of O
signal I-GENE
sequence I-GENE
- I-GENE
deleted O
CD4 I-GENE
cDNA I-GENE
in O
an O
Epstein I-GENE
- I-GENE
Barr I-GENE
virus I-GENE
_RARE_ I-GENE
vector O
. O

_RARE_ I-GENE
recombinant I-GENE
_RARE_ I-GENE
specifically O
bound O
to O
T I-GENE
cell O
lines O
and O
peripheral O
T I-GENE
cells O
but O
not O
to O
monocytes O
or O
_RARE_ I-GENE
. O

The O
cis O
- I-GENE
acting O
elements O
that O
control O
promoter I-GENE
activity O
include O
binding I-GENE
sites I-GENE
for O
transcription I-GENE
factors I-GENE
Sp1 I-GENE
and O
_RARE_ I-GENE
, O
a O
60 O
- I-GENE
kDa I-GENE
CCAAT I-GENE
box I-GENE
- I-GENE
binding I-GENE
protein I-GENE
. O

Therefore O
, O
we O
have O
identified O
a O
cis O
- I-GENE
acting O
element I-GENE
, O
the O
E1 I-GENE
E I-GENE
- I-GENE
box I-GENE
, O
located O
in O
the O
GAP I-GENE
- I-GENE
43 I-GENE
promoter I-GENE
region O
that O
_RARE_ I-GENE
either O
positively O
or O
negatively O
the O
expression O
of O
the O
GAP I-GENE
- I-GENE
43 I-GENE
gene I-GENE
depending O
on O
which O
E I-GENE
- I-GENE
box I-GENE
- I-GENE
binding I-GENE
proteins I-GENE
_RARE_ I-GENE
this O
site I-GENE
. O

Collectively O
, O
our O
findings O
demonstrate O
that O
SF I-GENE
- I-GENE
1 I-GENE
plays O
a O
key O
role O
in O
controlling O
the O
basal O
and O
cAMP I-GENE
- I-GENE
stimulated O
expression O
of O
the O
_RARE_ I-GENE
gene I-GENE
. O

There O
was O
a O
general O
_RARE_ I-GENE
of O
proton I-GENE
_RARE_ I-GENE
for O
a O
three O
- I-GENE
nucleotide I-GENE
segment O
centered O
about O
the O
lesion O
site I-GENE
which O
resulted O
in O
a O
_RARE_ I-GENE
assignment O
for O
the O
sugar I-GENE
_RARE_ I-GENE
of O
the O
_RARE_ I-GENE
residue O
in O
the O
spectrum O
of O
the O
_RARE_ I-GENE
duplex O
. O

Using O
one O
of O
the O
six O
fragments I-GENE
( O
_RARE_ I-GENE
- I-GENE
8 O
), O
we O
isolated O
a O
_RARE_ I-GENE
bp O
cDNA I-GENE
( O
_RARE_ I-GENE
- I-GENE
1 I-GENE
) O
from O
a O
_RARE_ I-GENE
_RARE_ I-GENE
lambda I-GENE
gt11 O
library O
. O

However O
, O
in O
TF I-GENE
- I-GENE
1 I-GENE
cells O
grown O
on O
GM I-GENE
- I-GENE
CSF I-GENE
before O
starvation O
, O
CREB I-GENE
phosphorylation O
was O
observed O
10 O
minutes O
after O
_RARE_ I-GENE
stimulation O
. O

_RARE_ I-GENE
_RARE_ I-GENE
-- O
_RARE_ I-GENE
at O
risk O
. O

RESULTS O
: O
The O
LV O
maximum O
_RARE_ I-GENE
and O
area O
under O
the O
curve O
showed O
significant O
negative O
correlations O
( O
p O
= O
< O
0 O
. O
_RARE_ I-GENE
) O
with O
the O
_RARE_ I-GENE
, O
while O
the O
minimum O
_RARE_ I-GENE
showed O
a O
significant O
positive O
correlation O
( O
p O
= O
< O
0 O
. O
_RARE_ I-GENE
). O

The O
results O
also O
imply O
that O
the O
absence O
of O
_RARE_ I-GENE
expression O
in O
non O
- I-GENE
cytotoxic O
cells O
may O
be O
due O
to O
the O
suppression O
of O
the O
induction O
of O
the O
killer O
- I-GENE
cell O
- I-GENE
specific I-GENE
trans O
- I-GENE
acting O
factor I-GENE
NF I-GENE
- I-GENE
P2 I-GENE
. O

We O
identify O
considerable O
_RARE_ I-GENE
- I-GENE
temporal O
similarities O
between O
reported O
expression O
patterns O
of O
_RARE_ I-GENE
genes I-GENE
and O
ribonuclease I-GENE
genes I-GENE
, O
which O
, O
together O
with O
the O
significant O
sequence I-GENE
similarity O
to O
the O
_RARE_ I-GENE
ribonuclease I-GENE
, O
support O
the O
hypothesis O
of O
a O
ribonuclease I-GENE
function O
for O
PR I-GENE
- I-GENE
10 O
proteins I-GENE
and O
allow O
the O
prediction O
of O
possible O
biological O
roles O
. O

The O
expression O
of O
_RARE_ I-GENE
env I-GENE
mRNA I-GENE
was O
found O
to O
be O
differentiation O
- I-GENE
associated I-GENE
, O
with O
high O
expression O
detected O
in O
the O
late O
stages O
of O
monocytic O
development O
. O

Initial O
estimates O
indicate O
that O
27 O
, O
193 O
people O
are O
either O
in O
_RARE_ I-GENE
of O
or O
in O
need O
of O
mental O
_RARE_ I-GENE
_RARE_ I-GENE
. O

It O
is O
exclusively O
observed O
in O
smooth I-GENE
muscle O
cells O
by O
Northern O
blotting O
and O
immunohistochemical O
analysis O
and O
therefore O
designated O
" O
_RARE_ I-GENE
." I-GENE
A I-GENE
human I-GENE
smooth I-GENE
muscle O
cDNA I-GENE
library O
was O
screened O
with O
the O
monoclonal I-GENE
antibody I-GENE
_RARE_ I-GENE
, O
and O
a O
full I-GENE
- I-GENE
size O
cDNA I-GENE
of O
the O
protein I-GENE
was O
selected O
. O

Using O
_RARE_ I-GENE
electron O
microscopy O
, O
we O
found O
that O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
and O
p54 I-GENE
are O
localized O
on O
both O
sides O
of O
the O
nuclear I-GENE
pore I-GENE
complex I-GENE
, O
like I-GENE
p62 I-GENE
. O

_RARE_ I-GENE
with O
ligand O
- I-GENE
dependent I-GENE
uptake O
, O
we O
now O
show O
that O
the O
receptor I-GENE
undergoes O
ligand O
- I-GENE
induced O
ubiquitination O
, O
suggesting O
that O
receptor I-GENE
ubiquitination O
may O
function O
in O
the O
ligand O
- I-GENE
dependent I-GENE
_RARE_ I-GENE
of O
the O
a O
- I-GENE
factor I-GENE
receptor I-GENE
as O
well O
as O
in O
its O
constitutive O
_RARE_ I-GENE
. O

Transcription O
initiation I-GENE
sites I-GENE
of O
the O
rat I-GENE
II I-GENE
beta I-GENE
-, I-GENE
III I-GENE
beta I-GENE
, O
and O
O O
beta I-GENE
- I-GENE
globin I-GENE
genes I-GENE
were O
determined O
to O
be O
52 O
base O
pairs O
( O
bp O
) O
5 I-GENE
'- O
upstream O
of O
the O
translation I-GENE
initiation I-GENE
codon O
( O
ATG O
), O
in O
each O
gene I-GENE
by O
primer O
extension O
analysis O
. O

_RARE_ I-GENE
process O
induced O
by O
indomethacin O
on O
chronic O
gastric O
lesion O
in O
rat I-GENE
. O

Epstein I-GENE
- I-GENE
Barr I-GENE
virus I-GENE
nuclear I-GENE
protein I-GENE
2 I-GENE
( O
EBNA2 I-GENE
) O
binds O
to O
a O
component O
of O
the O
human I-GENE
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
complex I-GENE
, O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
. O

Our O
studies O
also O
excluded O
the O
possibility O
that O
the O
phosphorylation O
of O
Ser O
- I-GENE
2 I-GENE
, O
Ser O
- I-GENE
123 O
, O
or O
Ser O
- I-GENE
210 O
, O
had O
roles O
in O
the O
trans O
- I-GENE
suppression O
activity O
of O
the O
large O
_RARE_ I-GENE
, O
in O
the O
assembly O
of O
_RARE_ I-GENE
virus I-GENE
- I-GENE
like I-GENE
_RARE_ I-GENE
particle I-GENE
, O
and O
in O
the O
nuclear I-GENE
transport O
of O
_RARE_ I-GENE
. O

_RARE_ I-GENE
recombination O
between O
the O
_RARE_ I-GENE
_RARE_ I-GENE
nuclear I-GENE
_RARE_ I-GENE
virus I-GENE
( O
_RARE_ I-GENE
) O
genome O
and O
a O
0 O
. O
6 I-GENE
- I-GENE
kbp O
- I-GENE
long O
DNA I-GENE
fragment I-GENE
derived O
from O
the O
putative O
DNA I-GENE
helicase I-GENE
gene I-GENE
of O
_RARE_ I-GENE
_RARE_ I-GENE
nuclear I-GENE
_RARE_ I-GENE
virus I-GENE
generates O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
, O
an O
_RARE_ I-GENE
- I-GENE
host O
- I-GENE
range O
_RARE_ I-GENE
mutant I-GENE
( O
S I-GENE
. O

The O
data O
further O
indicate O
that O
the O
IL I-GENE
- I-GENE
_RARE_ I-GENE
alpha I-GENE
chains I-GENE
are O
directly O
involved O
in O
the O
activation O
of O
_RARE_ I-GENE
and O
_RARE_ I-GENE
and O
have O
a O
major I-GENE
role O
in O
proliferative O
signaling O
in O
precursor I-GENE
B I-GENE
cells O
. O

Furthermore O
, O
the O
potency O
of O
_RARE_ I-GENE
in O
the O
treatment O
of O
_RARE_ I-GENE
tumors O
seems O
to O
be O
_RARE_ I-GENE
up O
to O
now O
. O

5 I-GENE
) O
We O
' O
_RARE_ I-GENE
_RARE_ I-GENE
that O
the O
mean O
value O
of O
the O
cost O
for O
_RARE_ I-GENE
of O
_RARE_ I-GENE
s O
. O
in O
class I-GENE
A I-GENE
was O
more O
than O
15 O
% O
compared O
to O
class I-GENE
B I-GENE
and O
the O
cost O
for O
patient O
in O
class I-GENE
A I-GENE
was O
nearly O
double O
than O
in O
class I-GENE
B I-GENE
. O

We O
have O
been O
studying O
the O
interaction O
of O
the O
oncogenic I-GENE
human I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
with O
the O
tumor I-GENE
- I-GENE
suppressor I-GENE
protein I-GENE
p53 I-GENE
to O
understand O
the O
_RARE_ I-GENE
of O
this O
virus I-GENE
as O
well O
as O
to O
understand O
the O
basic I-GENE
mechanisms O
of O
p53 I-GENE
transactivation O
. O

Site I-GENE
S I-GENE
- I-GENE
II I-GENE
also O
spans O
a O
23 O
bp O
sequence I-GENE
containing O
two O
tandem O
consensus I-GENE
binding I-GENE
sites I-GENE
with O
three O
base O
pair O
_RARE_ I-GENE
in O
each O
and O
a O
one O
base O
pair O
deletion O
. O

Cbl I-GENE
constitutively O
interacts O
with O
the O
SH3 I-GENE
domains I-GENE
of O
Grb2 I-GENE
, O
with O
a O
preference O
for O
the O
amino O
- I-GENE
terminal I-GENE
domain I-GENE
, O
and O
is O
in O
this O
way O
recruited O
to O
Shc I-GENE
upon O
BCR I-GENE
stimulation O
. O

Activation O
mediated O
by O
_RARE_ I-GENE
was O
no O
longer O
detectable O
in O
a O
_RARE_ I-GENE
mutant I-GENE
. O

Treatment O
is O
_RARE_ I-GENE
with O
prednisone O
and O
cyclophosphamide O
. O

_RARE_ I-GENE
attempts O
to O
_RARE_ I-GENE
smoking O
are O
generally O
_RARE_ I-GENE
. O

Laboratory O
evaluation O
was O
normal O
, O
and O
_RARE_ I-GENE
failed O
to O
confirm O
obstruction O
of O
venous O
or O
_RARE_ I-GENE
drainage O
. O

_RARE_ I-GENE
management O
of O
chronic O
hepatitis I-GENE
B I-GENE
virus I-GENE
asymptomatic O
patients O

While O
fusion I-GENE
to O
the O
N I-GENE
- I-GENE
terminus O
required O
a O
linker I-GENE
to O
become O
surface O
_RARE_ I-GENE
, O
both O
fusion I-GENE
to O
the O
N I-GENE
- I-GENE
terminus O
and O
to O
the O
C I-GENE
- I-GENE
terminus O
was O
compatible O
with O
particle I-GENE
assembly O
and O
_RARE_ I-GENE
the O
native O
_RARE_ I-GENE
and O
_RARE_ I-GENE
of O
_RARE_ I-GENE
. O

The O
standard O
dosage O
of O
anti I-GENE
- I-GENE
D I-GENE
currently O
given O
at O
all O
gestational O
ages O
is O
1 I-GENE
_RARE_ I-GENE
containing O
125 I-GENE
micrograms O
of O
anti I-GENE
- I-GENE
D I-GENE
. O

We O
report O
here O
the O
molecular O
cloning O
of O
a O
putative O
adhesive O
molecule I-GENE
from O
P I-GENE
. O
falciparum O
that O
shares O
both O
sequence I-GENE
and O
structural O
similarities O
with O
a O
_RARE_ I-GENE
surface O
molecule I-GENE
from O
_RARE_ I-GENE
termed O
the O
_RARE_ I-GENE
- I-GENE
related I-GENE
_RARE_ I-GENE
protein I-GENE
( O
_RARE_ I-GENE
) O
and O
, O
to O
a O
lesser O
extent O
, O
with O
the O
_RARE_ I-GENE
( O
CS I-GENE
) O
protein I-GENE
. O

There O
are O
no O
introns O
within O
the O
gene I-GENE
, O
which O
contains O
a O
_RARE_ I-GENE
- I-GENE
bp O
open O
reading O
frame O
and O
encodes O
a O
_RARE_ I-GENE
- I-GENE
kDa I-GENE
protein I-GENE
. O

METHODS O
: O
_RARE_ I-GENE
was O
_RARE_ I-GENE
in O
one O
eye O
chosen O
at O
random O
and O
_RARE_ I-GENE
in O
the O
_RARE_ I-GENE
eye O
of O
13 O
normal O
subjects O
and O
in O
13 O
patients O
with O
KCS I-GENE
. O

The O
experience O
of O
the O
lateral O
_RARE_ I-GENE
approach O
in O
_RARE_ I-GENE
surgery O
of O
_RARE_ I-GENE
has O
been O
favourable O
. O

CONCLUSION O
: O
The O
results O
demonstrate O
that O
at O
the O
site I-GENE
of O
lumbar O
disc O
_RARE_ I-GENE
, O
inflammatory O
cytokines O
such O
as O
interleukin I-GENE
- I-GENE
1 I-GENE
alpha I-GENE
are O
produced O
, O
which O
increases O
prostaglandin I-GENE
E2 I-GENE
production O
. O

The O
predominant O
_RARE_ I-GENE
allergens O
in O
_RARE_ I-GENE
asthmatic O
children O
are O
_RARE_ I-GENE
_RARE_ I-GENE
animals O
. O

Our O
results O
demonstrate O
that O
distinct O
cytoplasmic I-GENE
domains I-GENE
of O
these O
cytokine O
receptors I-GENE
elicit O
_RARE_ I-GENE
signaling O
pathways O
and O
provide O
evidence O
that O
beta I-GENE
c I-GENE
and O
IL I-GENE
- I-GENE
2R I-GENE
beta I-GENE
function O
as O
a O
complete O
signal I-GENE
_RARE_ I-GENE
. O

In O
addition O
, O
they O
display O
common O
features O
that O
make O
them O
strikingly O
related I-GENE
to O
_RARE_ I-GENE
U14 I-GENE
. O

_RARE_ I-GENE
has O
two O
separate O
12 O
nt O
long O
_RARE_ I-GENE
to O
a O
highly O
conserved O
tract O
of O
28S I-GENE
rRNA I-GENE
. O

This O
complex I-GENE
interacts O
at O
the O
GTPase I-GENE
domain I-GENE
in O
the O
large O
subunit I-GENE
rRNA I-GENE
, O
overlapping O
the O
binding I-GENE
site I-GENE
of O
the O
protein I-GENE
_RARE_ I-GENE
- I-GENE
like I-GENE
eukaryotic I-GENE
counterpart O
( O
Saccharomyces I-GENE
cerevisiae I-GENE
protein I-GENE
_RARE_ I-GENE
and O
mammalian I-GENE
protein I-GENE
L12 I-GENE
). O

_RARE_ I-GENE
repression O
of O
these O
replacement O
genes I-GENE
would O
be O
_RARE_ I-GENE
, O
consistent O
with O
the O
high O
, O
constitutive O
expression O
of O
replacement O
H3 I-GENE
histone I-GENE
genes I-GENE
in O
plants O
. O

This O
transition O
is O
regulated O
positively O
by O
G1 I-GENE
- I-GENE
specific I-GENE
cyclin I-GENE
- I-GENE
dependent I-GENE
kinases I-GENE
( O
_RARE_ I-GENE
) O
and O
negatively O
by O
the O
product I-GENE
of O
the O
retinoblastoma I-GENE
tumour I-GENE
suppressor I-GENE
gene I-GENE
, O
pRb I-GENE
. O

_RARE_ I-GENE
relationship O
between O
_RARE_ I-GENE
and O
glomerular O
hypertrophy O
in O
_RARE_ I-GENE
. O

Blood O
_RARE_ I-GENE
- I-GENE
Px I-GENE
activity O
was O
measured O
with O
a O
_RARE_ I-GENE
, O
using O
a O
modification O
of O
a O
previously O
described O
assay O
. O

The O
concentrations O
of O
vitamin O
A I-GENE
precursors I-GENE
and O
vitamin O
E I-GENE
in O
the O
_RARE_ I-GENE
were O
below O
currently O
recommended O
dietary O
levels O
for O
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
_RARE_ I-GENE
appears O
to O
provide O
an O
_RARE_ I-GENE
source O
of O
_RARE_ I-GENE
A I-GENE
and O
E I-GENE
in O
this O
species O
. O

Eight O
cats O
infected O
with O
H I-GENE
. O
pylori I-GENE
were O
used O
in O
the O
study O
. O

However O
, O
as O
determined O
by O
PCR O
with O
primers O
specific I-GENE
for O
the O
26 O
- I-GENE
kDa I-GENE
product I-GENE
, O
the O
majority O
of O
cats O
at O
2 I-GENE
and O
4 I-GENE
weeks O
p O
. O
t I-GENE
. O
had O
gastric O
fluid O
samples O
which O
were O
positive O
for O
H I-GENE
. O
pylori I-GENE
and O
three O
of O
three O
cats O
at O
2 I-GENE
weeks O
p O
. O
t I-GENE
. O
had O
dental O
plaque O
which O
was O
positive O
for O
H I-GENE
. O
pylori I-GENE
. O

To O
_RARE_ I-GENE
quantitative O
concentration O
changes O
from O
measurements O
of O
light I-GENE
attenuation O
, O
the O
optical O
_RARE_ I-GENE
length I-GENE
must O
be O
known O
. O

_RARE_ I-GENE
DESIGN O
. O

Following O
the O
injection O
of O
PGF2 O
alpha I-GENE
, O
heifers O
were O
observed O
_RARE_ I-GENE
for O
signs O
of O
_RARE_ I-GENE
at O
_RARE_ I-GENE
and O
_RARE_ I-GENE
( O
45 O
min O
each O
). O

Differential O
activation O
of O
the O
extracellular I-GENE
signal I-GENE
- I-GENE
regulated O
kinase I-GENE
, O
Jun I-GENE
kinase I-GENE
and O
Janus I-GENE
kinase I-GENE
- I-GENE
Stat I-GENE
pathways O
by O
_RARE_ I-GENE
M I-GENE
and O
basic I-GENE
fibroblast I-GENE
growth I-GENE
factor I-GENE
in O
AIDS O
- I-GENE
derived O
Kaposi O
' O
s O
sarcoma I-GENE
cells O
. O

There O
is O
general O
agreement O
that O
the O
hepatitis I-GENE
C I-GENE
virus I-GENE
is O
efficiently O
transmitted O
_RARE_ I-GENE
, O
while O
data O
on O
viral I-GENE
transmission O
from O
mothers O
to O
babies O
or O
by O
sexual O
or O
non O
- I-GENE
sexual O
_RARE_ I-GENE
contact O
are O
_RARE_ I-GENE
. O

Ten O
weeks O
after O
reconstruction O
, O
the O
_RARE_ I-GENE
nerves O
already O
_RARE_ I-GENE
normal O
nerves O
. O

The O
distribution O
and O
organization O
of O
projections O
from O
the O
spinal O
cervical O
enlargement O
to O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
and O
the O
_RARE_ I-GENE
_RARE_ I-GENE
nucleus O
( O
Cu I-GENE
) O
area O
was O
studied O
in O
the O
rat I-GENE
by O
using O
_RARE_ I-GENE
of O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
( O
PHA I-GENE
- I-GENE
L I-GENE
) O
into O
different O
_RARE_ I-GENE
around O
the O
_RARE_ I-GENE
level O
. O

The O
levels O
of O
fibrinogen I-GENE
as O
well O
as O
antithrombin I-GENE
III I-GENE
( O
_RARE_ I-GENE
) O
and O
heparin O
cofactor I-GENE
II I-GENE
( O
_RARE_ I-GENE
) O
activities O
were O
_RARE_ I-GENE
increased O
in O
loop I-GENE
- I-GENE
bearing O
animals O
. O

_RARE_ I-GENE
and O
overexpression O
of O
the O
c I-GENE
- I-GENE
erbB I-GENE
- I-GENE
2 I-GENE
gene I-GENE
in O
_RARE_ I-GENE
- I-GENE
2 I-GENE
and O
_RARE_ I-GENE
- I-GENE
1 I-GENE
human I-GENE
breast O
carcinoma O
cells O
results O
in O
_RARE_ I-GENE
elevated O
levels O
of O
constitutively O
tyrosine I-GENE
- I-GENE
phosphorylated O
_RARE_ I-GENE
- I-GENE
2 I-GENE
and O
is O
associated I-GENE
with O
progressive O
insulin I-GENE
- I-GENE
like I-GENE
growth I-GENE
factor I-GENE
( O
IGF I-GENE
) O
and O
combined O
IGF I-GENE
/ I-GENE
epidermal I-GENE
growth I-GENE
factor I-GENE
( O
EGF I-GENE
) O
_RARE_ I-GENE
in O
culture O
. O

_RARE_ I-GENE
muscular O
dystrophy I-GENE
( O
_RARE_ I-GENE
) O
is O
an O
_RARE_ I-GENE
dominant I-GENE
, O
neuromuscular O
disorder O
characterized O
by O
progressive O
_RARE_ I-GENE
of O
muscles O
in O
the O
face O
, O
_RARE_ I-GENE
and O
upper O
arm O
. O

The O
mature O
chromosome O
4 I-GENE
_RARE_ I-GENE
transcript I-GENE
is O
_RARE_ I-GENE
bp O
in O
length I-GENE
and O
contains O
nine O
exons O
which O
encode O
a O
putative O
protein I-GENE
of O
258 O
amino O
acid I-GENE
residues O
. O

Patients O
who O
have O
undergone O
_RARE_ I-GENE
for O
thyroid I-GENE
carcinoma O
are O
frequently O
subjected O
to O
periods O
of O
induced O
severe O
hypothyroidism O
in O
preparation O
for O
131I O
whole O
body O
scanning O
and O
measurement O
of O
serum I-GENE
TG I-GENE
. O

_RARE_ I-GENE
thyroid I-GENE
function O
testing O
was O
performed O
on O
600 O
randomly O
selected O
samples O
with O
normal O
TSH I-GENE
values O
and O
also O
on O
subjects O
with O
abnormal O
TSH I-GENE
levels O
. O

In O
a O
third O
experiment O
, O
_RARE_ I-GENE
AM I-GENE
between O
_RARE_ I-GENE
_RARE_ I-GENE
was O
investigated O
, O
and O
it O
was O
found O
that O
the O
more O
_RARE_ I-GENE
_RARE_ I-GENE
carried O
the O
AM I-GENE
. O

The O
relative O
tumor I-GENE
FDG O
- I-GENE
uptake O
( O
Q I-GENE
- I-GENE
_RARE_ I-GENE
) O
( O
tumor I-GENE
/ I-GENE
contralateral O
cortex O
) O
of O
all O
_RARE_ I-GENE
was O
calculated O
with O
0 O
. O
73 O
+/- O
0 O
. O
37 O
( O
0 O
. O
24 O
- I-GENE
1 I-GENE
. O
79 O
). O

_RARE_ I-GENE
weakly O
depressed O
the O
ectopic O
ventricular O
rate O
but O
not O
the O
_RARE_ I-GENE
ratio O
of O
the O
ventricular O
arrhythmias O
induced O
by O
two O
- I-GENE
stage O
coronary O
ligation O
24 O
h O
after O
the O
ligation O
in O
conscious O
dogs O
. O

_RARE_ I-GENE
_RARE_ I-GENE
, O
a O
plant O
that O
has O
amphetamine O
effects O
. O

The O
predicted O
protein I-GENE
, O
_RARE_ I-GENE
, O
consists O
of O
82 O
amino O
acids O
and O
contains O
one O
potential O
membrane I-GENE
- I-GENE
spanning O
region O
at O
the O
C I-GENE
- I-GENE
terminus O
but O
no O
N I-GENE
- I-GENE
terminal I-GENE
signal I-GENE
sequence I-GENE
. O

The O
_RARE_ I-GENE
homologue I-GENE
thus O
isolated O
, O
_RARE_ I-GENE
, O
encodes O
a O
protein I-GENE
53 O
% O
identical O
to O
_RARE_ I-GENE
. O

_RARE_ I-GENE
, O
that O
ventricular O
afferents O
, O
in O
certain O
special O
_RARE_ I-GENE
, O
are O
able O
to O
induce O
e O
. O
g O
. O
_RARE_ I-GENE
vasodilation O
and O
hypotension O
cannot O
be O
excluded O
. O

Large I-GENE
ones O
were O
similar O
in O
size O
to O
the O
main O
lobe O
and O
small I-GENE
ones O
were O
approximately O
1 I-GENE
/ I-GENE
4 I-GENE
of O
the O
length I-GENE
of O
the O
main O
lobe O
. O

_RARE_ I-GENE
and O
_RARE_ I-GENE
of O
the O
hormone I-GENE
ACTH I-GENE
were O
previously O
shown O
to O
have O
beneficial O
effect O
on O
the O
outcome O
of O
head I-GENE
injury O
, O
while O
elevated O
levels O
of O
corticosterone O
( O
CS I-GENE
) O
_RARE_ I-GENE
it O
. O

The O
most O
frequent O
causes O
of O
the O
meningitis O
was O
the O
external O
ventricular O
drainage O
( O
14 O
. O
8 O
%), O
post O
- I-GENE
_RARE_ I-GENE
( O
0 O
. O
8 O
%) O
and O
head I-GENE
injury O
( O
0 O
. O
_RARE_ I-GENE
%). O

Fifty O
- I-GENE
one O
patients O
with O
primary O
refractory O
or O
_RARE_ I-GENE
malignant O
lymphoma O
( O
47 O
non O
- I-GENE
Hodgkin O
' O
s O
lymphoma O
and O
four O
Hodgkin O
' O
s O
disease O
) O
were O
treated O
with O
a O
new O
chemotherapeutic O
regimen O
( O
_RARE_ I-GENE
, O
methyl O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
methyl O
_RARE_ I-GENE
). O

With O
the O
increasing O
use O
of O
ACE I-GENE
inhibitors O
, O
the O
incidence O
of O
rare O
adverse O
effects O
such O
as O
potentially O
lethal O
pancreatitis O
is O
likely O
to O
increase O
. O

In O
3 I-GENE
treatments O
the O
diet O
was O
supplemented O
with O
0 O
, O
100 O
and O
150 O
mg O
_RARE_ I-GENE
/ I-GENE
kg O
food O
. O

Low O
- I-GENE
dose O
aspirin I-GENE
and O
recurrent O
_RARE_ I-GENE
. O

Protein I-GENE
films O
are O
distinctly O
different O
in O
mechanical O
profiles O
from O
those O
films O
made O
of O
other O
materials O
. O

Furthermore O
, O
_RARE_ I-GENE
* I-GENE
mutations O
suppress O
the O
toxicity O
conferred O
by O
the O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
hybrid O
protein I-GENE
, O
which O
exerts O
its O
effects O
in O
the O
cytoplasm O
, O
_RARE_ I-GENE
from O
_RARE_ I-GENE
. O

The O
_RARE_ I-GENE
cDNA I-GENE
encodes O
a O
protein I-GENE
of O
210 O
kDa I-GENE
, O
which O
lacks O
sequences I-GENE
implicated O
in O
linking O
_RARE_ I-GENE
PI I-GENE
3 I-GENE
- I-GENE
kinases I-GENE
to O
p85 I-GENE
adaptor I-GENE
proteins I-GENE
, O
but O
contains O
an O
amino O
- I-GENE
terminal I-GENE
proline O
- I-GENE
rich O
sequence I-GENE
, O
which O
could O
bind O
to O
SH3 I-GENE
domains I-GENE
, O
and O
a O
carboxy I-GENE
- I-GENE
terminal I-GENE
C2 I-GENE
domain I-GENE
. O

In O
vitro O
interaction O
studies O
, O
using O
proteins I-GENE
fused O
to O
glutathione I-GENE
- I-GENE
S I-GENE
- I-GENE
transferase I-GENE
, O
showed O
that O
_RARE_ I-GENE
- I-GENE
J O
kappa I-GENE
and O
_RARE_ I-GENE
( O
H I-GENE
) O
bind O
directly O
to O
the O
_RARE_ I-GENE
regions O
of O
mouse I-GENE
_RARE_ I-GENE
and O
Drosophila I-GENE
Notch I-GENE
, O
respectively O
. O

_RARE_ I-GENE
/ I-GENE
METHODS O
: O
_RARE_ I-GENE
system O
function O
, O
as O
assessed O
by O
clearance O
of O
_RARE_ I-GENE
bacteria O
, O
was O
evaluated O
in O
acute O
liver O
injury O
induced O
by O
D I-GENE
- I-GENE
_RARE_ I-GENE
in O
rats O
, O
and O
compared O
with O
that O
after O
70 I-GENE
% O
liver O
resection O
model O
. O

Our O
laboratory O
and O
others O
have O
shown O
alternative O
splicing O
of O
up O
to O
ten O
exons O
at O
a O
discrete O
extracellular I-GENE
site I-GENE
to O
be O
primarily O
responsible O
for O
the O
generation O
of O
CD44 I-GENE
variant I-GENE
( O
_RARE_ I-GENE
) O
isoforms I-GENE
. O

Study O
groups O
were O
control O
, O
and O
those O
treated O
with O
the O
alpha1 I-GENE
- I-GENE
adrenoceptor I-GENE
- I-GENE
subtype I-GENE
blockers O
_RARE_ I-GENE
( O
0 O
. O
5 I-GENE
mg O
/ I-GENE
kg O
i O
. O
v I-GENE
.) O
or O
_RARE_ I-GENE
( O
1 I-GENE
. O
9 O
mg O
/ I-GENE
kg O
i O
. O
v I-GENE
.). O

This O
caused O
severe O
cortical O
damage O
and O
neuronal O
loss O
in O
hippocampus O
_RARE_ I-GENE
_RARE_ I-GENE
, O
CA3 O
, O
and O
_RARE_ I-GENE
. O

The O
occurrence O
of O
multiple O
malignancy O
was O
studied O
in O
_RARE_ I-GENE
patients O
with O
_RARE_ I-GENE
_RARE_ I-GENE
who O
were O
_RARE_ I-GENE
to O
this O
_RARE_ I-GENE
during O
the O
past O
10 O
years O
. O

The O
_RARE_ I-GENE
binds O
more O
T3R I-GENE
homodimers I-GENE
and O
less O
T3R I-GENE
- I-GENE
RXR I-GENE
heterodimers I-GENE
than O
the O
_RARE_ I-GENE
, O
and O
T3 O
more O
readily O
_RARE_ I-GENE
heterodimer O
binding I-GENE
to O
the O
_RARE_ I-GENE
- I-GENE
than O
to O
the O
_RARE_ I-GENE
. O

Transcriptional O
control O
of O
a O
nuclear I-GENE
gene I-GENE
encoding O
a O
mitochondrial I-GENE
fatty I-GENE
acid I-GENE
oxidation O
enzyme I-GENE
in O
transgenic O
mice O
: O
role O
for O
nuclear I-GENE
receptors I-GENE
in O
cardiac O
and O
brown O
adipose I-GENE
expression O
. O

_RARE_ I-GENE
, O
F I-GENE
. O
J O
. O

_RARE_ I-GENE
genomic O
fragments I-GENE
containing O
novel O
response O
elements O
are O
described O
, O
and O
the O
transcription I-GENE
unit I-GENE
associated I-GENE
with O
one O
of O
them O
, O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
, O
was O
characterized O
in O
detail O
. O

Moreover O
, O
_RARE_ I-GENE
synthase I-GENE
activity O
, O
which O
is O
activated I-GENE
by O
_RARE_ I-GENE
, O
was O
significantly O
reduced O
in O
the O
_RARE_ I-GENE
mutant I-GENE
. O

In O
gel O
retardation O
assays O
, O
an O
_RARE_ I-GENE
cell O
- I-GENE
specific I-GENE
protein I-GENE
and O
another O
closely O
related I-GENE
protein I-GENE
expressed O
only O
in O
_RARE_ I-GENE
cells O
and O
primary O
_RARE_ I-GENE
bound O
to O
a O
10 O
- I-GENE
bp O
sequence I-GENE
within O
the O
18 O
- I-GENE
mer I-GENE
. O

Two O
classes O
of O
_RARE_ I-GENE
pathogens O
_RARE_ I-GENE
_RARE_ I-GENE
host O
resistance O
and O
_RARE_ I-GENE
reduced O
fitness O
were O
found O
to O
be O
specifically O
mutated O
in O
_RARE_ I-GENE
. O

Members O
of O
the O
Ras I-GENE
subfamily I-GENE
of O
small I-GENE
GTP I-GENE
- I-GENE
binding I-GENE
proteins I-GENE
have O
been O
shown O
to O
be O
_RARE_ I-GENE
towards O
a O
variety O
of O
putative O
effector O
molecules I-GENE
such O
as O
the O
protein I-GENE
kinase I-GENE
c I-GENE
- I-GENE
Raf I-GENE
and O
the O
_RARE_ I-GENE
- I-GENE
specific I-GENE
guanine I-GENE
nucleotide I-GENE
exchange I-GENE
factor I-GENE
( O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
). O

Thus O
, O
the O
characterization O
of O
the O
promoter I-GENE
region O
should O
help O
to O
define O
regulatory I-GENE
elements O
that O
control O
neuron I-GENE
- I-GENE
specific I-GENE
and O
developmental O
expression O
of O
the O
_RARE_ I-GENE
gene I-GENE
. O

The O
cDNA I-GENE
encoded I-GENE
a O
mature O
protein I-GENE
of O
240 O
amino O
acids O
, O
including O
a O
29 O
- I-GENE
amino O
acid I-GENE
signal I-GENE
sequence I-GENE
. O

_RARE_ I-GENE
lacking O
the O
3 I-GENE
' O
stem O
- I-GENE
loop I-GENE
exhibited O
a O
75 O
% O
reduction O
in O
the O
level O
of O
_RARE_ I-GENE
mRNA I-GENE
. O

The O
deduced O
amino O
acid I-GENE
sequence I-GENE
was O
highly O
conserved O
across O
the O
wide O
range O
of O
eukaryotes O
( O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
plants O
and O
_RARE_ I-GENE
) O
in O
which O
this O
gene I-GENE
has O
now O
been O
identified O
. O

Biol O
. O

_RARE_ I-GENE
mutations O
in O
the O
yeast I-GENE
_RARE_ I-GENE
protein I-GENE
and O
their O
relationships O
with O
the O
_RARE_ I-GENE
helicase I-GENE
. O

_RARE_ I-GENE
of O
the O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
interval O
are O
frequently O
observed O
in O
_RARE_ I-GENE
and O
myeloid O
leukemia I-GENE
. O

Previous O
studies O
have O
suggested O
that O
the O
_RARE_ I-GENE
amino O
acid I-GENE
, O
70 I-GENE
- I-GENE
kDa I-GENE
subunit I-GENE
of O
RPA I-GENE
( O
RPA I-GENE
70 I-GENE
) O
is O
composed O
of O
multiple O
structural O
/ I-GENE
functional O
domains I-GENE
. O

_RARE_ I-GENE
were O
held O
at O
- I-GENE
67 O
_RARE_ I-GENE
to O
_RARE_ I-GENE
voltage O
- I-GENE
dependent I-GENE
effects O
. O

This O
site I-GENE
acts O
as O
a O
negative O
element I-GENE
when O
transferred O
to O
the O
thymidine I-GENE
kinase I-GENE
promoter I-GENE
, O
but O
does O
not O
confer O
inducibility O
. O

The O
extent O
of O
the O
_RARE_ I-GENE
operator I-GENE
sequence I-GENE
( O
42 O
bp O
), O
as O
defined O
by O
our O
footprinting O
analysis O
, O
would O
suggest O
the O
binding I-GENE
of O
two O
Fur I-GENE
repressor I-GENE
dimers I-GENE
. O

The O
structural O
similarity O
between O
_RARE_ I-GENE
and O
other O
guanine I-GENE
nucleotide I-GENE
exchange I-GENE
factors I-GENE
for O
small I-GENE
GTP I-GENE
- I-GENE
binding I-GENE
proteins I-GENE
, O
together O
with O
the O
recent O
identification O
of O
biochemical O
routes O
specific I-GENE
for O
members O
of O
the O
Ras I-GENE
and O
Rho I-GENE
family I-GENE
of O
GTPases I-GENE
, O
_RARE_ I-GENE
us O
to O
explore O
whether O
MAPK I-GENE
or O
JNK I-GENE
are O
downstream O
components O
of O
the O
_RARE_ I-GENE
signaling O
pathways O
. O

CONCLUSION O
: O
_RARE_ I-GENE
daily O
treatment O
with O
inhaled O
_RARE_ I-GENE
_RARE_ I-GENE
50 O
micrograms O
or O
100 O
micrograms O
was O
significantly O
more O
effective O
than O
theophylline O
in O
the O
treatment O
of O
mild O
- I-GENE
to O
- I-GENE
moderate O
asthma O
. O

Our O
results O
support O
a O
model O
where O
both O
E2F I-GENE
- I-GENE
and O
_RARE_ I-GENE
- I-GENE
mediated O
repression O
, O
acting O
at O
different O
stages O
in O
the O
cell O
cycle O
, O
are O
dependent I-GENE
on O
promoter I-GENE
- I-GENE
specific I-GENE
_RARE_ I-GENE
elements O
. O

The O
cDNA I-GENE
clone O
was O
used O
as O
a O
homologous O
probe O
to O
isolate O
a O
truncated I-GENE
genomic O
clone O
encoding O
_RARE_ I-GENE
. O

Comparison O
of O
the O
deduced O
amino O
acid I-GENE
sequences I-GENE
with O
protein I-GENE
sequences I-GENE
of O
T I-GENE
. O
_RARE_ I-GENE
_RARE_ I-GENE
showed O
only O
two O
and O
three O
differences O
respectively O
, O
in O
a O
total O
of O
_RARE_ I-GENE
amino O
acids O
for O
_RARE_ I-GENE
, O
and O
132 O
amino O
acids O
for O
_RARE_ I-GENE
, O
indicating O
the O
two O
genes I-GENE
_RARE_ I-GENE
before O
the O
divergence O
of O
these O
two O
species O
. O

_RARE_ I-GENE
visual O
dysfunction O
in O
a O
child O
with O
cerebral O
damage O
. O

Interaction O
was O
apparently O
determined O
by O
the O
N I-GENE
- I-GENE
terminal I-GENE
splice O
region O
of O
_RARE_ I-GENE
- I-GENE
6 I-GENE
, O
as O
the O
_RARE_ I-GENE
splice O
variant I-GENE
_RARE_ I-GENE
- I-GENE
39 O
, O
which O
differs O
from O
_RARE_ I-GENE
- I-GENE
6 I-GENE
at O
the O
extreme O
N I-GENE
- I-GENE
terminus O
, O
failed O
to O
associate O
with O
v I-GENE
- I-GENE
Src I-GENE
- I-GENE
SH3 I-GENE
; O
_RARE_ I-GENE
( O
where O
_RARE_ I-GENE
is O
rat I-GENE
' O
_RARE_ I-GENE
- I-GENE
like I-GENE
' O
_RARE_ I-GENE
), O
which O
has O
the O
N I-GENE
- I-GENE
terminal I-GENE
splice O
region O
deleted O
, O
failed O
to O
associate O
with O
v I-GENE
- I-GENE
Src I-GENE
- I-GENE
SH3 I-GENE
, O
and O
the O
association O
of O
_RARE_ I-GENE
- I-GENE
6 I-GENE
and O
v I-GENE
- I-GENE
Src I-GENE
- I-GENE
SH3 I-GENE
was O
blocked O
by O
a O
fusion I-GENE
protein I-GENE
formed O
from O
the O
N I-GENE
- I-GENE
terminal I-GENE
splice O
region O
. O

_RARE_ I-GENE
load O
- I-GENE
_RARE_ I-GENE
measures O
of O
ventricular O
performance O
were O
therefore O
evaluated O
in O
10 O
open O
- I-GENE
and O
closed O
- I-GENE
_RARE_ I-GENE
, O
anesthetized O
rabbits O
. O

Large I-GENE
strain O
differences O
were O
found O
for O
all O
variables O
recorded O
, O
i O
. O
e O
., O
the O
proportion O
of O
_RARE_ I-GENE
males O
, O
the O
time O
_RARE_ I-GENE
in O
the O
_RARE_ I-GENE
_RARE_ I-GENE
box I-GENE
, O
and O
the O
number O
of O
_RARE_ I-GENE
between O
the O
_RARE_ I-GENE
and O
the O
dark O
boxes O
. O

The O
effect O
of O
_RARE_ I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
on O
_RARE_ I-GENE
pulmonary O
artery O
hypertension O
has O
been O
proved O
in O
recent O
studies O
. O

It O
is O
the O
oxidation O
peak O
of O
this O
product I-GENE
, O
arising O
in O
acidic O
media O
at O
0 O
. O
42 O
V I-GENE
, O
which O
was O
analysed O
using O
_RARE_ I-GENE
, O
again O
following O
the O
accumulation O
of O
_RARE_ I-GENE
at O
the O
_RARE_ I-GENE
- I-GENE
modified O
_RARE_ I-GENE
. O

_RARE_ I-GENE
is O
a O
pure O
alpha I-GENE
- I-GENE
1 I-GENE
_RARE_ I-GENE
agonist O
known O
to O
produce O
marked O
systemic O
_RARE_ I-GENE
and O
associated I-GENE
hypertension O
with O
_RARE_ I-GENE
profound O
reflex O
_RARE_ I-GENE
. O

The O
expression O
of O
the O
first O
two O
genes I-GENE
located O
in O
this O
unit I-GENE
( O
c I-GENE
- I-GENE
_RARE_ I-GENE
and O
c I-GENE
- I-GENE
_RARE_ I-GENE
) O
was O
also O
monitored O
by O
Western O
blot O
( O
_RARE_ I-GENE
) O
analyses O
using O
antisera O
raised O
against O
these O
proteins I-GENE
synthesized O
in O
Escherichia I-GENE
coli I-GENE
. O

One O
unit I-GENE
encodes O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
, O
while O
the O
second O
encodes O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
. O

A I-GENE
. O

In O
an O
effort O
to O
isolate O
genes I-GENE
with O
down O
- I-GENE
regulated O
expression O
at O
the O
mRNA I-GENE
level O
during O
oncogenic I-GENE
transformation O
of O
human I-GENE
mammary O
epithelial O
cells O
( O
_RARE_ I-GENE
), O
we O
performed O
_RARE_ I-GENE
hybridization O
between O
normal O
_RARE_ I-GENE
strain O
_RARE_ I-GENE
and O
its O
radiation O
- I-GENE
transformed O
tumorigenic O
derivative O
_RARE_ I-GENE
- I-GENE
30 O
. O

_RARE_ I-GENE
_RARE_ I-GENE
: O
_RARE_ I-GENE
because O
of O
a O
right O
corneal O
_RARE_ I-GENE
with O
cellular O
reaction O
in O
anterior O
chamber O
, O
a O
patient O
was O
_RARE_ I-GENE
and O
treated O
with O
a O
single O
_RARE_ I-GENE
injection O
of O
0 O
. O
2 I-GENE
ml O
( O
1 I-GENE
mg O
) O
_RARE_ I-GENE
and O
0 O
. O
2 I-GENE
ml O
( O
1 I-GENE
mg O
) O
_RARE_ I-GENE
. O

In O
the O
same O
period O
we O
_RARE_ I-GENE
out O
an O
increase O
of O
hematocrit O
( O
from O
29 O
% O
to O
35 O
%) O
and O
of O
the O
Hb I-GENE
( O
from O
9 O
. O
3 I-GENE
to O
11 O
. O
2 I-GENE
g O
/ I-GENE
dl O
). O

The O
P I-GENE
- I-GENE
_RARE_ I-GENE
and O
P I-GENE
- I-GENE
_RARE_ I-GENE
cDNA I-GENE
sequences I-GENE
are O
very O
similar O
in O
their O
5 I-GENE
' O
regions O
. O

Because O
the O
_RARE_ I-GENE
locus I-GENE
was O
mapped O
at O
a O
distance O
< O
0 O
. O
1 I-GENE
_RARE_ I-GENE
from O
the O
_RARE_ I-GENE
C I-GENE
gene I-GENE
, O
its O
molecular O
characterization O
by O
_RARE_ I-GENE
cloning O
is O
possible O
. O

The O
human I-GENE
MSH I-GENE
- I-GENE
2 I-GENE
gene I-GENE
product I-GENE
is O
a O
member O
of O
a O
highly O
conserved O
family I-GENE
of O
proteins I-GENE
which O
are O
involved O
in O
post O
- I-GENE
replication O
_RARE_ I-GENE
repair I-GENE
. O
_RARE_ I-GENE
- I-GENE
2 I-GENE
is O
homologous O
to O
Escherichia I-GENE
coli I-GENE
( O
E I-GENE
. O
coli I-GENE
) O
_RARE_ I-GENE
and O
_RARE_ I-GENE
cerevisiae I-GENE
MSH I-GENE
- I-GENE
1 I-GENE
and O
MSH I-GENE
- I-GENE
2 I-GENE
proteins I-GENE
, O
which O
_RARE_ I-GENE
_RARE_ I-GENE
DNA I-GENE
at O
the O
sites I-GENE
of O
all O
single O
base O
_RARE_ I-GENE
and O
deletions O
or O
insertions O
up O
to O
4 I-GENE
base O
pairs O
. O
_RARE_ I-GENE
- I-GENE
2 I-GENE
is O
one O
of O
the O
hereditary I-GENE
non O
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
cancer O
( O
_RARE_ I-GENE
) O
tumor I-GENE
suppressor I-GENE
genes I-GENE
, O
and O
maps O
to O
human I-GENE
chromosome O
_RARE_ I-GENE
. O

We O
have O
recently O
shown O
that O
the O
tissue I-GENE
- I-GENE
specific I-GENE
expression O
of O
the O
RAR I-GENE
beta I-GENE
2 I-GENE
gene I-GENE
in O
mouse I-GENE
embryos O
is O
regulated O
at O
the O
translational O
level O
by O
short O
upstream O
open O
reading O
frames O
( O
_RARE_ I-GENE
) O
In O
the O
5 I-GENE
'- O
untranslated O
region O
( O
_RARE_ I-GENE
, O
A I-GENE
., O
A I-GENE
. O
M I-GENE
. O

We O
have O
previously O
isolated O
a O
cDNA I-GENE
for O
a O
transcription I-GENE
factor I-GENE
referred O
to O
as O
_RARE_ I-GENE
( O
zinc I-GENE
finger I-GENE
homeodomain I-GENE
enhancer I-GENE
- I-GENE
binding I-GENE
protein I-GENE
) O
containing O
two O
separate O
zinc I-GENE
finger I-GENE
domains I-GENE
, O
_RARE_ I-GENE
and O
_RARE_ I-GENE
, O
each O
of O
which O
binds O
DNA I-GENE
, O
and O
a O
homeodomain I-GENE
. O

The O
structure O
of O
these O
genes I-GENE
suggests O
a O
common O
ancestor O
for O
all O
_RARE_ I-GENE
_RARE_ I-GENE
genes I-GENE
. O

Increased O
_RARE_ I-GENE
production O
by O
a O
tyrosine I-GENE
kinase I-GENE
oncogene I-GENE
, O
_RARE_ I-GENE
- I-GENE
Met I-GENE
: O
role O
of O
the O
Ras I-GENE
signaling O
pathway O
. O

_RARE_ I-GENE
to O
their O
secretion O
, O
the O
IGF I-GENE
- I-GENE
II I-GENE
in O
_RARE_ I-GENE
and O
_RARE_ I-GENE
cells O
accumulated O
in O
the O
conditioned O
medium O
mostly O
as O
two O
partially O
processed O
species O
with O
_RARE_ I-GENE
, O
of O
_RARE_ I-GENE
and O
_RARE_ I-GENE
, O
respectively O
. O

_RARE_ I-GENE
, O
coexpression O
of O
the O
transcriptionally O
inactive O
, O
amino O
- I-GENE
terminally I-GENE
deleted O
_RARE_ I-GENE
- I-GENE
1 I-GENE
mutant I-GENE
proteins I-GENE
, O
either O
with O
the O
wild I-GENE
- I-GENE
type I-GENE
_RARE_ I-GENE
- I-GENE
1 I-GENE
or O
with O
themselves O
, O
results O
in O
a O
marked O
enhancement O
of O
transactivation O
of O
the O
transcriptional O
_RARE_ I-GENE
- I-GENE
1 I-GENE
element I-GENE
reporter I-GENE
. O

All O
patients O
had O
abnormal O
von I-GENE
Willebrand I-GENE
factor I-GENE
( O
vWF I-GENE
) O
_RARE_ I-GENE
as O
reflected O
by O
decreased O
high O
molecular O
weight O
and O
increased O
low O
molecular O
weight O
vWF I-GENE
_RARE_ I-GENE
in O
the O
circulation O
. O

In O
an O
attempt O
to O
investigate O
whether O
the O
intergenic O
region O
between O
the O
_RARE_ I-GENE
and O
a O
second O
open O
reading O
frame O
( O
_RARE_ I-GENE
) O
in O
_RARE_ I-GENE
napus I-GENE
( O
L I-GENE
.) O
is O
a O
divergent O
promoter I-GENE
, O
and O
also O
to O
characterize O
the O
_RARE_ I-GENE
, O
cDNA I-GENE
clones O
homologous O
to O
_RARE_ I-GENE
were O
isolated O
from O
a O
leaf O
cDNA I-GENE
library O
. O

The O
_RARE_ I-GENE
gene I-GENE
product I-GENE
is O
targeted O
to O
the O
chloroplast I-GENE
, O
which O
is O
consistent O
with O
previous O
data O
indicating O
the O
presence O
of O
_RARE_ I-GENE
activity O
in O
the O
chloroplast I-GENE
. O

Characterization O
of O
_RARE_ I-GENE
, O
a O
leucine I-GENE
- I-GENE
rich O
repeat I-GENE
( O
_RARE_ I-GENE
) O
protein I-GENE
from O
tomato I-GENE
plants O
that O
is O
processed O
during O
pathogenesis O
. O

To O
test O
whether O
Sp1 I-GENE
and O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
- I-GENE
1 I-GENE
interact O
with O
this O
motif I-GENE
, O
gel O
retardation O
assays O
were O
performed O
. O

OBJECTIVES O
: O
The O
aim O
of O
the O
study O
was O
to O
analyze O
the O
clinical O
characteristics O
, O
treatment O
and O
outcome O
of O
_RARE_ I-GENE
patients O
with O
_RARE_ I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
transfected O
human I-GENE
kidney O
293 O
cells O
expressing O
the O
wild I-GENE
type I-GENE
rat I-GENE
LH I-GENE
/ I-GENE
CG I-GENE
receptor I-GENE
( O
_RARE_ I-GENE
) O
or O
receptors I-GENE
with O
C I-GENE
- I-GENE
terminal I-GENE
tails O
truncated I-GENE
at O
residues O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
or O
_RARE_ I-GENE
( O
designated O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
) O
were O
used O
to O
probe O
the O
importance O
of O
this O
region O
on O
the O
regulation O
of O
hormonal O
responsiveness O
. O

_RARE_ I-GENE
low O
_RARE_ I-GENE
amplitudes O
a O
marker O
for O
schizophrenia O
. O

_RARE_ I-GENE
was O
determined O
again O
for O
an O
additional O
3 I-GENE
days O
and O
6 I-GENE
hours O
. O

The O
patients O
are O
two O
healthy O
adult O
males O
. O

_RARE_ I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
of O
Arabidopsis I-GENE
is O
a O
recessive O
nuclear I-GENE
mutation I-GENE
that O
causes O
green I-GENE
and O
white O
_RARE_ I-GENE
in O
leaves O
and O
is O
inherited O
in O
a O
non O
- I-GENE
_RARE_ I-GENE
fashion O
. O

_RARE_ I-GENE
concentrations O
were O
only O
weakly O
correlated O
with O
_RARE_ I-GENE
concentrations O
, O
however O
, O
and O
personal O
exposures O
were O
even O
more O
poorly O
correlated O
with O
_RARE_ I-GENE
concentrations O
. O

A I-GENE
_RARE_ I-GENE
test O
battery O
was O
used O
that O
contained O
the O
_RARE_ I-GENE
_RARE_ I-GENE
sorting I-GENE
test O
, O
_RARE_ I-GENE
_RARE_ I-GENE
test O
, O
Stroop O
test O
, O
a O
_RARE_ I-GENE
memory O
_RARE_ I-GENE
test O
, O
and O
a O
facial O
recognition I-GENE
test O
. O

We O
present O
this O
case O
because O
of O
the O
_RARE_ I-GENE
of O
left O
ventricular O
involvement O
associated I-GENE
with O
_RARE_ I-GENE
. O

In O
a O
randomized O
single O
- I-GENE
blind O
3 I-GENE
x O
3 I-GENE
_RARE_ I-GENE
- I-GENE
square O
study O
with O
_RARE_ I-GENE
for O
any O
_RARE_ I-GENE
effects O
, O
27 O
males O
and O
30 O
females O
_RARE_ I-GENE
_RARE_ I-GENE
containing O
glucose O
or O
resistant O
_RARE_ I-GENE
( O
RS I-GENE
) O
from O
_RARE_ I-GENE
high O
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
or O
from O
_RARE_ I-GENE
high O
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
). O

The O
5 I-GENE
' O
flanking O
region O
of O
the O
mouse I-GENE
Met I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
1 I-GENE
gene I-GENE
also O
shares O
considerable O
regions O
of O
identity O
with O
the O
5 I-GENE
' O
flanking O
region O
of O
the O
rat I-GENE
Met I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
1 I-GENE
gene I-GENE
. O

The O
[ O
18F O
] O
_RARE_ I-GENE
_RARE_ I-GENE
is O
a O
simple O
and O
clinically O
useful O
index O
for O
detecting O
tumour I-GENE
hypoxia O
in O
_RARE_ I-GENE
. O

_RARE_ I-GENE
methods O
have O
been O
developed O
for O
maintaining O
and O
_RARE_ I-GENE
the O
_RARE_ I-GENE
short O
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
_RARE_ I-GENE
, O
in O
an O
easily O
- I-GENE
_RARE_ I-GENE
, O
laboratory O
setting O
. O

In O
addition O
, O
the O
time O
to O
_RARE_ I-GENE
was O
significantly O
shorter O
in O
the O
_RARE_ I-GENE
arm O
in O
both O
_RARE_ I-GENE
. O

Also O
like I-GENE
the O
thrombin I-GENE
receptor I-GENE
, O
_RARE_ I-GENE
can O
be O
activated I-GENE
by O
the O
_RARE_ I-GENE
corresponding O
to O
its O
_RARE_ I-GENE
ligand O
sequence I-GENE
independent O
of O
receptor I-GENE
cleavage O
. O

We O
conclude O
that O
_RARE_ I-GENE
is O
a O
useful O
investigation O
in O
the O
management O
of O
patients O
with O
cardiopulmonary O
disease O
and O
_RARE_ I-GENE
the O
various O
other O
investigations O
offered O
by O
a O
pulmonary O
function O
laboratory O
. O

Using O
fluorescence O
in O
situ O
hybridization O
, O
we O
mapped O
the O
chromosome O
- I-GENE
17 O
breakpoint I-GENE
in O
a O
patient O
with O
_RARE_ I-GENE
_RARE_ I-GENE
and O
sex I-GENE
reversal O
, O
who O
carries O
a O
de O
novo I-GENE
_RARE_ I-GENE
t I-GENE
( O
12 O
; O
17 O
) O
translocation O
, O
between O
two O
known O
cosmid O
markers O
in O
the O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
region O
. O

This O
is O
concluded O
from O
the O
isolation O
of O
cDNAs I-GENE
from O
_RARE_ I-GENE
( O
_RARE_ I-GENE
_RARE_ I-GENE
) O
and O
barley I-GENE
( O
_RARE_ I-GENE
_RARE_ I-GENE
cv O
. O

The O
data O
presented O
in O
this O
work O
indicate O
that O
_RARE_ I-GENE
may O
also O
be O
involved O
in O
DNA I-GENE
damage O
tolerance O
in O
plant O
cells O
. O

In O
the O
rat I-GENE
_RARE_ I-GENE
allele I-GENE
described O
here O
, O
a O
nonsense O
mutation I-GENE
in O
exon O
8 O
of O
the O
_RARE_ I-GENE
gene I-GENE
was O
identified O
. O

Such O
an O
increase O
in O
the O
steady O
- I-GENE
state O
testicular I-GENE
TIMP I-GENE
- I-GENE
2 I-GENE
mRNA I-GENE
level O
apparently O
is O
not O
the O
result O
of O
an O
up O
- I-GENE
regulation O
by O
germ I-GENE
cells O
because O
germ I-GENE
cells O
_RARE_ I-GENE
with O
_RARE_ I-GENE
cells O
failed O
to O
elicit O
an O
increase O
in O
the O
_RARE_ I-GENE
cell O
steady O
- I-GENE
state O
TIMP I-GENE
- I-GENE
2 I-GENE
mRNA I-GENE
level O
. O

Control O
intact O
rats O
were O
age O
- I-GENE
matched O
to O
the O
different O
treated O
groups O
. O

DESIGN O
: O
A I-GENE
cross O
- I-GENE
sectional O
study O
. O

In O
the O
SPK I-GENE
and O
_RARE_ I-GENE
category O
, O
anti I-GENE
- I-GENE
T I-GENE
- I-GENE
cell O
therapy O
significantly O
lowered O
the O
risk O
of O
graft O
loss O
. O

We O
have O
identified O
a O
strong O
_RARE_ I-GENE
- I-GENE
responsive I-GENE
element I-GENE
, O
designated O
TRE I-GENE
( O
_RARE_ I-GENE
), O
near O
the O
3 I-GENE
' O
end O
of O
the O
gag I-GENE
gene I-GENE
and O
preceding O
the O
pol I-GENE
gene I-GENE
of O
SFV I-GENE
- I-GENE
1 I-GENE
. O

Although O
the O
binding I-GENE
of O
IE2 I-GENE
86 I-GENE
to O
_RARE_ I-GENE
full I-GENE
- I-GENE
length I-GENE
CREB I-GENE
or O
_RARE_ I-GENE
is O
minimal I-GENE
, O
IE2 I-GENE
86 I-GENE
does O
form O
complexes I-GENE
with O
p300 I-GENE
and O
the O
CREB I-GENE
- I-GENE
binding I-GENE
protein I-GENE
( O
CBP I-GENE
), O
which O
in O
turn I-GENE
bind O
to O
CREB I-GENE
and O
can O
serve O
as O
adaptor I-GENE
proteins I-GENE
for O
CREB I-GENE
function O
. O

A I-GENE
transgenic O
complementation O
assay O
was O
used O
to O
test O
whether O
_RARE_ I-GENE
supplied O
in O
trans O
could O
rescue O
amplification O
- I-GENE
defective O
viral I-GENE
genomes O
encoding O
altered O
_RARE_ I-GENE
proteins I-GENE
. O

On O
the O
basis O
of O
its O
bZIP I-GENE
structural O
homology I-GENE
, O
_RARE_ I-GENE
is O
perhaps O
the O
only O
member O
of O
the O
jun I-GENE
- I-GENE
fos I-GENE
gene I-GENE
family I-GENE
completely O
viral I-GENE
in O
origin O
. O

The O
rCBF O
and O
_RARE_ I-GENE
were O
recorded O
by O
laser O
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
. O

Although O
basal O
vessels O
may O
_RARE_ I-GENE
distal O
_RARE_ I-GENE
vessels O
_RARE_ I-GENE
to O
_RARE_ I-GENE
after O
_RARE_ I-GENE
. O

The O
triple O
combination O
of O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
_RARE_ I-GENE
resulted O
in O
an O
ulcer O
healing O
rate O
of O
98 O
% O
and O
an O
H I-GENE
. O
pylori I-GENE
eradication O
rate O
of O
90 O
%. O

Several O
lines O
of O
evidence O
presented O
here O
suggest O
that O
PKC I-GENE
- I-GENE
zeta I-GENE
plays O
a O
role O
in O
alpha I-GENE
2 I-GENE
integrin I-GENE
gene I-GENE
expression O
. O

Plasma I-GENE
_RARE_ I-GENE
: O
a O
marker O
for O
microvascular O
complications O
in O
diabetes O
mellitus O
. O

_RARE_ I-GENE
: O
_RARE_ I-GENE
epidemic O
in O
the O
newly O
independent O
states O
of O
the O
former O
_RARE_ I-GENE
, O
January O
1995 O
- I-GENE
_RARE_ I-GENE
1996 O
. O

The O
characterization O
of O
the O
promoter I-GENE
region O
indicated O
that O
three O
distinct O
regulatory I-GENE
elements O
corresponding O
to O
an O
AP I-GENE
- I-GENE
1 I-GENE
binding I-GENE
site I-GENE
( O
or O
TRE I-GENE
), O
a O
_RARE_ I-GENE
/ I-GENE
kappaB I-GENE
domain I-GENE
, O
and O
a O
CAAT I-GENE
box I-GENE
are O
involved O
in O
the O
activation O
by O
_RARE_ I-GENE
( O
v I-GENE
-) I-GENE
src I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
is O
phosphorylated O
in O
vivo O
in O
several O
cell O
lines O
, O
and O
substitution O
of O
serine I-GENE
_RARE_ I-GENE
to O
alanine I-GENE
( O
_RARE_ I-GENE
) O
resulted O
in O
an O
increased O
ability O
of O
Myb I-GENE
to O
transactivate O
a O
synthetic O
promoter I-GENE
containing O
five O
copies O
of O
the O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
Myb I-GENE
- I-GENE
responsive I-GENE
element I-GENE
and O
a O
minimal I-GENE
herpes I-GENE
tk I-GENE
promoter I-GENE
. O

The O
DNA I-GENE
binding I-GENE
and O
_RARE_ I-GENE
activities O
of O
c I-GENE
- I-GENE
Myb I-GENE
appear O
to O
be O
unaffected O
by O
the O
_RARE_ I-GENE
substitution O
, O
suggesting O
that O
phosphorylation O
of O
serine I-GENE
_RARE_ I-GENE
may O
mediate O
its O
effect O
on O
the O
transcription I-GENE
transactivating O
activity O
of O
c I-GENE
- I-GENE
Myb I-GENE
by O
regulating O
interactions O
with O
other O
proteins I-GENE
. O

The O
amount O
of O
these O
factors I-GENE
was O
reduced O
in O
_RARE_ I-GENE
cells O
in O
which O
the O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
gene I-GENE
is O
only O
weakly O
transcriptionally O
activated I-GENE
. O

PIP2 O
, O
when O
incorporated O
into O
_RARE_ I-GENE
carrier I-GENE
vesicles O
, O
binds O
tightly O
to O
the O
guanine I-GENE
nucleotide I-GENE
- I-GENE
depleted O
form O
of O
_RARE_ I-GENE
and O
weakly O
to O
the O
GDP I-GENE
- I-GENE
bound O
form O
of O
the O
GTP I-GENE
- I-GENE
binding I-GENE
protein I-GENE
but O
does O
not O
bind O
to O
GTP I-GENE
- I-GENE
bound O
_RARE_ I-GENE
, O
similar O
to O
what O
was O
observed O
for O
the O
_RARE_ I-GENE
oncoprotein I-GENE
. O

Purified I-GENE
spleen O
GAP I-GENE
accelerated O
hydrolysis O
of O
GTP I-GENE
bound O
to O
recombinant I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
; O
no O
effect O
of O
NH2 I-GENE
- I-GENE
terminal I-GENE
_RARE_ I-GENE
was O
observed O
. O

Biol O
. O

A I-GENE
novel O
phosphotyrosine I-GENE
- I-GENE
binding I-GENE
domain I-GENE
in O
the O
N I-GENE
- I-GENE
terminal I-GENE
transforming I-GENE
region O
of O
Cbl I-GENE
interacts O
directly O
and O
selectively O
with O
ZAP I-GENE
- I-GENE
70 I-GENE
in O
T I-GENE
cells O
. O

Cys I-GENE
- I-GENE
_RARE_ I-GENE
within O
the O
( O
_RARE_ I-GENE
)- I-GENE
_RARE_ I-GENE
- I-GENE
binding I-GENE
domain I-GENE
was O
essential O
for O
native O
enzyme I-GENE
activity O
. O

Its O
transcription I-GENE
has O
been O
shown O
to O
be O
induced O
40 I-GENE
- I-GENE
50 O
- I-GENE
fold O
in O
response O
to O
oxygen O
or O
heme O
deficiency O
, O
in O
part O
through O
_RARE_ I-GENE
of O
repression O
_RARE_ I-GENE
by O
_RARE_ I-GENE
and O
in O
part O
by O
activation O
mediated O
by O
an O
upstream O
activation O
sequence I-GENE
( O
UAS O
). O

Altogether O
, O
our O
results O
indicate O
that O
the O
transcriptional O
activity O
of O
_RARE_ I-GENE
proteins I-GENE
is O
modulated O
by O
PKC I-GENE
. O

Lck I-GENE
has O
been O
postulated O
to O
_RARE_ I-GENE
through O
the O
SH2 I-GENE
and O
SH3 I-GENE
domains I-GENE
. O

Furthermore O
, O
_RARE_ I-GENE
in O
the O
presence O
of O
bovine I-GENE
_RARE_ I-GENE
resulted O
in O
a O
good O
maintenance O
of O
the O
cellular O
viability O
and O
of O
the O
_RARE_ I-GENE
heterogeneity O
in O
respect O
to O
fresh O
cells O
. O

_RARE_ I-GENE
pleural I-GENE
_RARE_ I-GENE
as O
presentation O
form O
of O
multiple O
myeloma O

Five O
- I-GENE
year O
_RARE_ I-GENE
_RARE_ I-GENE
to O
100 O
%, O
86 I-GENE
. O
2 I-GENE
%, O
59 O
. O
4 I-GENE
%, O
29 O
. O
8 O
%, O
and O
20 O
% O
for O
stages O
I I-GENE
, O
II I-GENE
, O
III I-GENE
, O
_RARE_ I-GENE
and O
_RARE_ I-GENE
respectively O
. O

The O
presence O
of O
unidentified O
_RARE_ I-GENE
or O
microscopic O
clusters O
of O
neoplastic O
cells O
, O
_RARE_ I-GENE
around O
, O
more O
or O
less O
close O
to O
, O
the O
line O
of O
insertion O
of O
lesion O
, O
could O
_RARE_ I-GENE
any O
attempt O
to O
gain O
a O
" O
radical O
" O
excision O
_RARE_ I-GENE
. O

The O
partial O
categories O
of O
the O
_RARE_ I-GENE
that O
were O
more O
affected O
were O
work O
, O
_RARE_ I-GENE
and O
_RARE_ I-GENE
, O
home O
management O
, O
and O
sleep O
and O
rest O
. O

Northern O
blot O
analysis O
, O
using O
the O
_RARE_ I-GENE
- I-GENE
specific I-GENE
probe O
, O
indicated O
that O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
. O
_RARE_ I-GENE
induced O
an O
increase O
over O
basal O
levels O
of O
_RARE_ I-GENE
mRNA I-GENE
, O
while O
Pseudomonas I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
. O
_RARE_ I-GENE
caused O
a O
decrease O
. O

_RARE_ I-GENE
disruption O
of O
the O
_RARE_ I-GENE
gene I-GENE
in O
yeast I-GENE
revealed O
a O
second O
_RARE_ I-GENE
glycosylase I-GENE
/ I-GENE
lyase I-GENE
protein I-GENE
, O
tentatively O
named O
_RARE_ I-GENE
, O
which O
differs O
from O
_RARE_ I-GENE
in O
that O
it O
preferentially O
acts O
on O
_RARE_ I-GENE
: O
G I-GENE
. O

Furthermore O
, O
the O
use O
of O
zero O
- I-GENE
loss O
_RARE_ I-GENE
in O
combination O
with O
_RARE_ I-GENE
_RARE_ I-GENE
reconstruction O
is O
considerably O
more O
effective O
at O
removing O
the O
effects O
of O
multiple O
elastic O
and O
_RARE_ I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
objective O
lens O
_RARE_ I-GENE
than O
either O
technique O
by O
itself O
. O

_RARE_ I-GENE
for O
both O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
initiate O
from O
conserved O
_RARE_ I-GENE
motifs O
, O
and O
transcripts I-GENE
are O
detected O
from O
16 O
through O
72 O
hr O
p O
. O
i O
. O

In O
order O
to O
determine O
which O
sequences I-GENE
in O
the O
GATA I-GENE
- I-GENE
1 I-GENE
promoter I-GENE
are O
crucial O
for O
activation O
by O
the O
_RARE_ I-GENE
viral I-GENE
protein I-GENE
, O
we O
made O
deletions O
of O
the O
promoter I-GENE
, O
cloned O
them O
into O
a O
luciferase I-GENE
expression O
vector O
and O
tested O
their O
activity O
in O
mouse I-GENE
fibroblasts O
, O
which O
do O
not O
express O
GATA I-GENE
- I-GENE
1 I-GENE
. O

Sequence O
analysis O
of O
the O
isolated O
genomic O
clone O
revealed O
that O
the O
DNA I-GENE
binding I-GENE
domain I-GENE
of O
this O
orphan I-GENE
receptor I-GENE
is O
most O
homologous O
to O
the O
human I-GENE
_RARE_ I-GENE
receptor I-GENE
. O

Genomic O
DNA I-GENE
hybridization O
suggests O
that O
_RARE_ I-GENE
is O
a O
single O
- I-GENE
copy O
gene I-GENE
in O
the O
S I-GENE
. O
_RARE_ I-GENE
genome O
. O

A I-GENE
3 I-GENE
- I-GENE
yr O
retrospective O
review O
is O
effective O
and O
_RARE_ I-GENE
94 O
% O
of O
the O
_RARE_ I-GENE
. O

Isolation O
and O
identification O
of O
genes I-GENE
activating I-GENE
_RARE_ I-GENE
- I-GENE
dependent I-GENE
_RARE_ I-GENE
expression O
in O
Saccharomyces I-GENE
cerevisiae I-GENE
. O

METHODS O
AND O
RESULTS O
: O
A I-GENE
64 O
- I-GENE
year O
- I-GENE
old O
woman O
with O
confirmed O
AV O
nodal O
_RARE_ I-GENE
tachycardia O
underwent O
a O
successful O
" O
slow O
pathway O
" O
AV O
modification O
with O
a O
single O
_RARE_ I-GENE
application O
. O

Patients O
with O
low O
_RARE_ I-GENE
of O
having O
aluminum O
overload O
( O
serum I-GENE
iron O
levels O
< O
40 I-GENE
micrograms O
/ I-GENE
L I-GENE
and O
_RARE_ I-GENE
< O
150 O
micrograms O
/ I-GENE
L I-GENE
) O
had O
significantly O
higher O
values O
of O
serum I-GENE
iron O
, O
iron O
transferrin I-GENE
saturation O
, O
and O
serum I-GENE
ferritin I-GENE
levels O
compared O
with O
those O
patients O
with O
a O
high O
_RARE_ I-GENE
of O
having O
aluminum O
overload O
( O
serum I-GENE
aluminum O
levels O
> O
40 I-GENE
micrograms O
/ I-GENE
L I-GENE
and O
_RARE_ I-GENE
> O
150 O
micrograms O
/ I-GENE
L I-GENE
). O

Although O
the O
_RARE_ I-GENE
_RARE_ I-GENE
are O
well O
conserved O
during O
evolution O
, O
the O
mammalian I-GENE
genes I-GENE
did O
not O
express O
the O
UV O
- I-GENE
inducible I-GENE
phenotype O
of O
their O
yeast I-GENE
counterpart O
. O

Ha I-GENE
- I-GENE
_RARE_ I-GENE
and O
activated I-GENE
proteins I-GENE
in O
both O
the O
extra I-GENE
- I-GENE
cellular O
regulated O
kinase I-GENE
( O
ERK I-GENE
) O
and O
the O
stress O
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
( O
SAPK I-GENE
) O
or O
Jun I-GENE
N I-GENE
- I-GENE
terminal I-GENE
kinase I-GENE
( O
JNK I-GENE
) O
cascades I-GENE
independently O
stimulated O
PEA3 I-GENE
- I-GENE
mediated O
gene I-GENE
expression O
. O

Sequence O
analysis O
of O
reverse I-GENE
transcribed O
, O
amplified O
cDNA I-GENE
generated O
from O
total O
RNA I-GENE
isolated O
from O
transfected O
cells O
demonstrated O
the O
presence O
of O
_RARE_ I-GENE
spliced O
products I-GENE
containing O
13 O
and O
78 O
additional O
bases O
as O
well O
as O
the O
accumulation O
of O
unspliced O
mRNA I-GENE
. O

Its O
_RARE_ I-GENE
profile O
predicts O
seven O
transmembrane I-GENE
spans O
and O
a O
hydrophilic O
amino O
terminus O
of O
approximately O
100 O
residues O
, O
and O
it O
suggests O
the O
presence O
of O
an O
_RARE_ I-GENE
alpha I-GENE
- I-GENE
helix I-GENE
( O
L I-GENE
- I-GENE
61 O
to O
F I-GENE
- I-GENE
97 O
) O
in O
close O
_RARE_ I-GENE
to O
the O
first O
strongly O
hydrophobic O
segment O
of O
_RARE_ I-GENE
. O

A I-GENE
1 I-GENE
. O
5 I-GENE
- I-GENE
kb O
HindIII I-GENE
genomic O
fragment I-GENE
carrying O
the O
_RARE_ I-GENE
gene I-GENE
from O
M I-GENE
. O
_RARE_ I-GENE
_RARE_ I-GENE
was O
cloned O
and O
sequenced O
. O

_RARE_ I-GENE
catabolite I-GENE
repression O
of O
the O
_RARE_ I-GENE
operon I-GENE
of O
Bacillus I-GENE
subtilis I-GENE
is O
mediated O
by O
the O
catabolite I-GENE
control O
protein I-GENE
_RARE_ I-GENE
and O
by O
_RARE_ I-GENE
, O
a O
_RARE_ I-GENE
protein I-GENE
of O
the O
phosphotransferase I-GENE
system O
. O

_RARE_ I-GENE
and O
_RARE_ I-GENE
: O
filling O
the O
_RARE_ I-GENE
. O

A I-GENE
subsequent O
screen O
for O
the O
loss O
of O
the O
positively O
selectable O
target O
locus I-GENE
marker O
_RARE_ I-GENE
the O
_RARE_ I-GENE
replacement O
at O
_RARE_ I-GENE
frequency O
(> O
2 I-GENE
%). O

Here O
we O
demonstrate O
that O
another O
cellular O
protein I-GENE
linked O
to O
BCR I-GENE
/ I-GENE
ABL I-GENE
through O
the O
_RARE_ I-GENE
- I-GENE
SH2 I-GENE
domain I-GENE
is O
p130 I-GENE
( O
CAS I-GENE
). O
p130 I-GENE
( O
CAS I-GENE
) O
was O
found O
to O
be O
tyrosine I-GENE
phosphorylated O
and O
associated I-GENE
with O
_RARE_ I-GENE
in O
BCR I-GENE
/ I-GENE
ABL I-GENE
expressing O
cell O
lines O
and O
in O
samples O
obtained O
from O
CML O
and O
ALL O
patients O
, O
but O
not O
in O
samples O
from O
controls O
. O

There O
are O
four O
_RARE_ I-GENE
motifs O
interspersed O
with O
histidine O
- I-GENE
rich O
regions O
. O

The O
effects O
of O
_RARE_ I-GENE
variations O
on O
_RARE_ I-GENE
Stroop O
effects O
. O

In O
a O
third O
experiment O
, O
a O
_RARE_ I-GENE
gradually O
increases O
the O
number O
of O
_RARE_ I-GENE
_RARE_ I-GENE
can O
_RARE_ I-GENE
with O
higher O
than O
70 I-GENE
% O
average O
accuracy O
to O
nine O
, O
replacing O
as O
many O
as O
160 I-GENE
_RARE_ I-GENE
correctly O
. O

PCNA I-GENE
mRNA I-GENE
has O
a O
3 I-GENE
' O
UTR I-GENE
antisense I-GENE
to O
yellow O
_RARE_ I-GENE
RNA I-GENE
and O
is O
localized O
in O
_RARE_ I-GENE
eggs O
and O
embryos O
. O

A I-GENE
1 I-GENE
. O
8 O
- I-GENE
kb O
cDNA I-GENE
clone O
( O
designed O
_RARE_ I-GENE
, O
gene I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
) O
with O
homology I-GENE
to O
the O
_RARE_ I-GENE
was O
isolated O
from O
a O
human I-GENE
kidney O
cDNA I-GENE
library O
. O

PCR O
/ I-GENE
Southern O
blot O
analysis O
of O
human I-GENE
kidney O
cDNA I-GENE
using O
primers O
flanking O
the O
_RARE_ I-GENE
coding O
sequence I-GENE
revealed O
expression O
of O
a O
full I-GENE
- I-GENE
length I-GENE
mRNA I-GENE
and O
short O
transcripts I-GENE
with O
partial O
exon O
1 I-GENE
and O
partial O
exon O
4 I-GENE
deletions O
. O

The O
high O
sequence I-GENE
homology I-GENE
, O
similar O
genomic O
structure O
, O
and O
identical O
chromosomal I-GENE
loci I-GENE
of O
_RARE_ I-GENE
, O
MIP I-GENE
, O
and O
_RARE_ I-GENE
- I-GENE
2 I-GENE
suggest O
a O
MIP I-GENE
family I-GENE
gene I-GENE
cluster I-GENE
at O
chromosome O
locus I-GENE
_RARE_ I-GENE
. O

The O
third O
ORF I-GENE
generates O
a O
transcript I-GENE
of O
1 I-GENE
. O
6 I-GENE
kb O
and O
encodes O
a O
protein I-GENE
of O
_RARE_ I-GENE
residues O
including O
a O
perfect O
match O
to O
the O
consensus I-GENE
sequence I-GENE
of O
a O
_RARE_ I-GENE
zinc I-GENE
finger I-GENE
domain I-GENE
; O
it O
shares O
a O
strong O
homology I-GENE
with O
yeast I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
- I-GENE
A I-GENE
from O
Aspergillus I-GENE
, O
_RARE_ I-GENE
and O
E I-GENE
. O
coli I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
improved O
the O
_RARE_ I-GENE
of O
development O
, O
_RARE_ I-GENE
and O
arrangement O
of O
cartilage O
and O
bone O
cells O
, O
and O
_RARE_ I-GENE
the O
effects O
of O
P I-GENE
deficiency O
on O
the O
histological O
and O
gross O
structure O
of O
the O
_RARE_ I-GENE
. O

The O
importance O
of O
temporal O
factors I-GENE
on O
the O
presence O
and O
severity O
of O
ethanol O
withdrawal O
signs O
in O
the O
rat I-GENE
was O
_RARE_ I-GENE
using O
rating O
scale O
, O
tremor O
, O
and O
acoustic O
_RARE_ I-GENE
_RARE_ I-GENE
. O

Data O
supported O
the O
_RARE_ I-GENE
of O
the O
_RARE_ I-GENE
- I-GENE
III I-GENE
short O
form O
and O
the O
criterion O
- I-GENE
related I-GENE
validity O
of O
both O
the O
K I-GENE
- I-GENE
_RARE_ I-GENE
and O
and O
_RARE_ I-GENE
Short O
_RARE_ I-GENE
Assessment O
_RARE_ I-GENE
( O
K I-GENE
- I-GENE
_RARE_ I-GENE
). O

Quantitative O
analysis O
of O
plasmid O
loss O
rates O
in O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
strains O
carrying O
plasmids O
with O
multiple O
replication O
origins O
suggests O
that O
a O
defect O
in O
initiating O
DNA I-GENE
replication O
probably O
causes O
this O
plasmid O
loss O
phenotype O
. O

Thus O
, O
the O
_RARE_ I-GENE
_RARE_ I-GENE
alpha I-GENE
appears O
to O
be O
involved O
in O
_RARE_ I-GENE
of O
the O
cytoskeleton I-GENE
, O
with O
the O
N I-GENE
and O
C I-GENE
termini O
acting O
as O
positive O
and O
negative O
regulators O
, O
respectively O
, O
of O
the O
kinase I-GENE
domain I-GENE
whose O
activity O
is O
crucial O
for O
formation O
of O
stress O
fibers O
and O
focal I-GENE
adhesion I-GENE
complexes I-GENE
. O

These O
findings O
and O
the O
differential O
tissue I-GENE
distribution O
of O
p54 I-GENE
suggest O
that O
this O
novel O
SR I-GENE
protein I-GENE
may O
participate O
in O
regulation O
of O
alternative O
splicing O
in O
a O
tissue I-GENE
- I-GENE
and O
substrate I-GENE
- I-GENE
dependent I-GENE
manner O
. O

The O
elevation O
of O
cyclic I-GENE
AMP I-GENE
( O
cAMP I-GENE
) O
levels O
in O
the O
cell O
_RARE_ I-GENE
the O
activity O
of O
the O
Raf I-GENE
- I-GENE
1 I-GENE
kinase I-GENE
. O

An O
interaction O
screen O
with O
the O
repression O
domain I-GENE
of O
the O
orphan I-GENE
receptor I-GENE
_RARE_ I-GENE
identified O
N I-GENE
- I-GENE
_RARE_ I-GENE
, O
the O
_RARE_ I-GENE
for O
thyroid I-GENE
hormone I-GENE
receptor I-GENE
( O
TR I-GENE
) O
and O
retinoic I-GENE
acid I-GENE
receptor I-GENE
( O
RAR I-GENE
). O

These O
results O
indicate O
that O
inhibition O
of O
Jun I-GENE
kinase I-GENE
activation O
was O
sufficient O
to O
inhibit O
Ras I-GENE
transformation O
even O
in O
the O
presence O
of O
activated I-GENE
_RARE_ I-GENE
- I-GENE
2 I-GENE
. O

Our O
analysis O
suggests O
that O
_RARE_ I-GENE
is O
a O
_RARE_ I-GENE
protein I-GENE
with O
_RARE_ I-GENE
activities O
that O
can O
affect O
mRNA I-GENE
turnover O
and O
nonsense O
suppression O
. O

Identification O
of O
_RARE_ I-GENE
as O
a O
potential O
regulator I-GENE
of O
_RARE_ I-GENE
in O
the O
sexual O
response O
pathway O
of O
Schizosaccharomyces I-GENE
pombe I-GENE
. O

Two O
closely O
related I-GENE
variants I-GENE
of O
Stat5 I-GENE
, O
Stat5a I-GENE
and O
_RARE_ I-GENE
, O
are O
encoded I-GENE
by O
distinct O
genes I-GENE
. O

Mutations O
in O
three O
loci I-GENE
( O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
) O
were O
identified O
. O

The O
serine I-GENE
/ I-GENE
threonine I-GENE
kinase I-GENE
Raf I-GENE
- I-GENE
1 I-GENE
functions O
downstream O
of O
Rats I-GENE
in O
a O
signal I-GENE
transduction O
cascade O
which O
_RARE_ I-GENE
mitogenic O
stimuli O
from O
the O
plasma I-GENE
membrane I-GENE
to O
the O
nucleus O
. O

Platelet I-GENE
- I-GENE
derived O
growth I-GENE
factor I-GENE
- I-GENE
dependent I-GENE
activation O
of O
phosphatidylinositol I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
is O
regulated O
by O
receptor I-GENE
binding I-GENE
of O
SH2 I-GENE
- I-GENE
domain I-GENE
- I-GENE
containing O
proteins I-GENE
which O
influence O
Ras I-GENE
activity O
. O

In O
transient O
_RARE_ I-GENE
E1A I-GENE
could O
induce O
the O
activity O
of O
the O
p53 I-GENE
promoter I-GENE
to O
a O
high O
level O
; O
_RARE_ I-GENE
E1A I-GENE
was O
threefold O
as O
efficient O
as O
_RARE_ I-GENE
E1A I-GENE
in O
this O
activity O
, O
and O
YY1 I-GENE
bound O
to O
the O
composite O
element I-GENE
was O
shown O
to O
mediate O
55 O
% O
of O
this O
induction O
. O

The O
retinoid I-GENE
Z I-GENE
receptor I-GENE
beta I-GENE
( O
_RARE_ I-GENE
beta I-GENE
), O
an O
orphan I-GENE
receptor I-GENE
, O
is O
a O
member O
of O
the O
retinoic I-GENE
acid I-GENE
receptor I-GENE
( O
RAR I-GENE
)/ O
thyroid I-GENE
hormone I-GENE
receptor I-GENE
( O
TR I-GENE
) O
subfamily I-GENE
of O
nuclear I-GENE
receptors I-GENE
. O

DNA I-GENE
- I-GENE
dependent I-GENE
protein I-GENE
kinase I-GENE
( O
DNA I-GENE
- I-GENE
PK I-GENE
) O
consists O
of O
a O
heterodimeric I-GENE
protein I-GENE
( O
_RARE_ I-GENE
) O
and O
a O
large O
catalytic O
subunit I-GENE
( O
DNA I-GENE
- I-GENE
_RARE_ I-GENE
). O

_RARE_ I-GENE
complete O
sequence I-GENE
identity O
was O
found O
between O
the O
3 I-GENE
' O
end O
of O
the O
_RARE_ I-GENE
gene I-GENE
and O
two O
expressed O
sequence I-GENE
tags O
( O
ESTs I-GENE
) O
and O
between O
the O
5 I-GENE
' O
end O
of O
the O
_RARE_ I-GENE
gene I-GENE
and O
a O
third O
EST I-GENE
. O

Sequencing O
of O
the O
_RARE_ I-GENE
11 O
. O
1 I-GENE
/ I-GENE
_RARE_ I-GENE
duplication O
breakpoints O
has O
revealed O
the O
presence O
of O
repetitive O
immunoglobulin I-GENE
- I-GENE
like I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
sequences I-GENE
at O
or O
near O
the O
_RARE_ I-GENE
boundaries O
. O

However O
, O
in O
a O
multivariate O
analysis O
_RARE_ I-GENE
age O
, O
gender O
, O
and O
a O
previous O
history O
of O
cardiovascular O
diseases O
, O
female O
gender O
was O
not O
independently O
associated I-GENE
with O
death O
. O

Moreover O
, O
following O
a O
single O
intravenous O
injection O
of O
the O
_RARE_ I-GENE
vector O
complexed O
to O
_RARE_ I-GENE
liposomes O
into O
recipient O
mice O
, O
delivery O
of O
_RARE_ I-GENE
and O
GC I-GENE
cDNAs I-GENE
was O
achieved O
in O
all O
the O
organs O
we O
tested O
. O

The O
limits O
of O
agreement O
between O
_RARE_ I-GENE
and O
TOF O
responses O
were O
so O
wide O
that O
they O
cannot O
be O
used O
_RARE_ I-GENE
. O

The O
_RARE_ I-GENE
- I-GENE
encoding O
_RARE_ I-GENE
gene I-GENE
is O
located O
in O
an O
operon I-GENE
that O
also O
encodes O
_RARE_ I-GENE
secretion O
pathway O
components O
and O
is O
part O
of O
the O
functional O
cluster I-GENE
of O
_RARE_ I-GENE
genes I-GENE
carried O
on O
cosmid O
_RARE_ I-GENE
that O
enables O
_RARE_ I-GENE
bacteria O
like I-GENE
Escherichia I-GENE
coli I-GENE
and O
Pseudomonas I-GENE
_RARE_ I-GENE
to O
elicit O
the O
HR O
in O
tobacco I-GENE
leaves O
. O

Despite O
the O
presence O
of O
one O
additional O
_RARE_ I-GENE
reductase I-GENE
, O
the O
_RARE_ I-GENE
- I-GENE
encoded I-GENE
enzyme I-GENE
is O
essential O
to O
the O
aerobic O
growth I-GENE
of O
the O
cell O
because O
_RARE_ I-GENE
- I-GENE
defective O
mutants I-GENE
of O
both O
species O
are O
not O
viable O
in O
the O
presence O
of O
oxygen O
. O

Altogether O
, O
the O
results O
demonstrate O
that O
the O
two O
isoforms I-GENE
elicit O
similar O
responses O
in O
vivo O
despite O
differences O
in O
their O
regulation O
. O

_RARE_ I-GENE
factors I-GENE
focusing O
on O
_RARE_ I-GENE
, O
perceived O
susceptibility I-GENE
to O
pregnancy O
, O
and O
_RARE_ I-GENE
factors I-GENE
were O
also O
relevant O
. O

High O
- I-GENE
resolution O
structure O
of O
the O
_RARE_ I-GENE
toxin I-GENE
repressor I-GENE
complexed O
with O
_RARE_ I-GENE
and O
_RARE_ I-GENE
reveals O
an O
SH3 I-GENE
- I-GENE
like I-GENE
third O
domain I-GENE
and O
suggests O
a O
possible O
role O
of O
phosphate I-GENE
as O
co O
- I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
of O
the O
human I-GENE
and O
porcine I-GENE
proteins I-GENE
with O
2 I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
5 I-GENE
- I-GENE
_RARE_ I-GENE
indicates O
that O
membrane I-GENE
_RARE_ I-GENE
additionally O
possesses O
two O
_RARE_ I-GENE
disulfide O
bonds O
. O

FEV1 O
did O
not O
fall O
significantly O
in O
patients O
without O
acute O
or O
chronic O
_RARE_ I-GENE
and O
recovered O
earlier O
than O
in O
patients O
without O
_RARE_ I-GENE
pulmonary O
infection O
. O

Administration O
of O
adrenaline O
resulted O
in O
a O
large O
_RARE_ I-GENE
of O
the O
SaO2 O
in O
6 I-GENE
of O
the O
7 O
measurements O
. O

_RARE_ I-GENE
with O
dietary O
modification O
and O
_RARE_ I-GENE
lowering O
drugs O
resulted O
in O
resolution O
of O
symptoms O
and O
_RARE_ I-GENE
swelling O
in O
one O
patient O
. O

_RARE_ I-GENE
, O
submitted O
for O
_RARE_ I-GENE
). O

We O
have O
cloned O
a O
novel O
protein I-GENE
kinase I-GENE
, O
termed O
hematopoietic I-GENE
progenitor I-GENE
kinase I-GENE
1 I-GENE
( O
_RARE_ I-GENE
), O
that O
is O
expressed O
predominantly O
in O
hematopoietic I-GENE
cells O
, O
including O
early I-GENE
progenitor I-GENE
cells O
. O

Human I-GENE
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
protein I-GENE
has O
two O
LIM I-GENE
domains I-GENE
, O
and O
each O
shares O
35 O
. O
1 I-GENE
% O
and O
77 O
or O
79 O
% O
identical O
residues O
with O
human I-GENE
cysteine I-GENE
- I-GENE
rich O
protein I-GENE
( O
CRP I-GENE
) O
and O
rat I-GENE
_RARE_ I-GENE
, O
respectively O
. O

The O
fragments I-GENE
are O
separated O
and O
directly O
sized O
by O
agarose O
gel O
electrophoresis O
. O

Several O
of O
the O
exon O
boundaries O
correspond O
to O
the O
boundaries O
of O
functional O
domains I-GENE
in O
the O
p55 I-GENE
protein I-GENE
. O

_RARE_ I-GENE
studies O
have O
shown O
locus I-GENE
heterogeneity O
with O
one O
_RARE_ I-GENE
gene I-GENE
mapped O
to O
chromosome O
_RARE_ I-GENE
and O
a O
second O
to O
_RARE_ I-GENE
. O
3 I-GENE
. O

The O
cytogenetic O
expression O
of O
the O
folate I-GENE
sensitive O
_RARE_ I-GENE
site I-GENE
, O
_RARE_ I-GENE
, O
is O
due O
to O
the O
expansion O
of O
a O
_RARE_ I-GENE
repeat I-GENE
in O
proximal I-GENE
_RARE_ I-GENE
of O
the O
human I-GENE
X I-GENE
chromosome O
and O
is O
associated I-GENE
with O
a O
mild O
form O
of O
mental O
_RARE_ I-GENE
. O

DNA I-GENE
sequence I-GENE
analysis O
of O
a O
_RARE_ I-GENE
bp O
BamHI I-GENE
- I-GENE
_RARE_ I-GENE
fragment I-GENE
revealed O
that O
three O
open O
reading O
frames O
( O
ORFs O
) O
were O
encoded I-GENE
in O
the O
same O
orientation O
. O

The O
initial O
_RARE_ I-GENE
experience O
for O
individuals O
with O
HIV I-GENE
- I-GENE
related I-GENE
TB I-GENE
may O
be O
pivotal O
to O
the O
_RARE_ I-GENE
of O
and O
participation O
in O
_RARE_ I-GENE
TB I-GENE
care O
. O

_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
is O
the O
prototype O
of O
a O
group O
of O
potential O
transcription I-GENE
factors I-GENE
that O
contain O
two O
or O
more O
unusual O
_RARE_ I-GENE
zinc I-GENE
fingers O
. O

This O
element I-GENE
, O
termed O
_RARE_ I-GENE
- I-GENE
a O
( O
_RARE_ I-GENE
), O
differs O
by O
one O
nucleotide I-GENE
from O
a O
palindromic O
CRE O
( O
_RARE_ I-GENE
, O
_RARE_ I-GENE
), O
which O
is O
known O
to O
bind O
CREB I-GENE
as O
a O
homodimer I-GENE
. O

Analysis O
of O
human I-GENE
genomic O
DNA I-GENE
reveals O
an O
intronless O
sequence I-GENE
with O
strong O
homology I-GENE
to O
human I-GENE
G I-GENE
alpha I-GENE
q I-GENE
cDNA I-GENE
. O

The O
complete O
exon O
- I-GENE
intron O
structure O
of O
the O
156 I-GENE
- I-GENE
kb O
human I-GENE
gene I-GENE
_RARE_ I-GENE
, O
which O
encodes O
the O
_RARE_ I-GENE
and O
p50 I-GENE
proteins I-GENE
of O
transcription I-GENE
factors I-GENE
NF I-GENE
- I-GENE
kappa I-GENE
B I-GENE
and O
I I-GENE
kappa I-GENE
B I-GENE
- I-GENE
gamma I-GENE
: O
implications O
for O
NF I-GENE
- I-GENE
kappa I-GENE
B I-GENE
- I-GENE
mediated O
signal I-GENE
transduction O
. O

An O
inverted O
Alu I-GENE
repeat I-GENE
element I-GENE
, O
flanked O
by O
_RARE_ I-GENE
direct O
repeats I-GENE
, O
was O
identified O
within O
the O
region O
- I-GENE
_RARE_ I-GENE
/- O
_RARE_ I-GENE
, O
relative O
to O
the O
cap I-GENE
site I-GENE
. O

The O
_RARE_ I-GENE
were O
returned O
to O
_RARE_ I-GENE
, O
and O
monitoring O
was O
continued O
for O
1 I-GENE
h O
. O

_RARE_ I-GENE
leukemia I-GENE
viruses O
( O
_RARE_ I-GENE
), O
which O
are O
replication O
- I-GENE
competent O
_RARE_ I-GENE
of O
the O
_RARE_ I-GENE
cat O
species O
, O
are O
_RARE_ I-GENE
transmitted O
in O
natural O
_RARE_ I-GENE
. O

Comparison O
of O
the O
amino O
acid I-GENE
sequences I-GENE
of O
the O
_RARE_ I-GENE
polypeptides I-GENE
of O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
- I-GENE
1 I-GENE
with O
the O
corresponding O
prokaryotic I-GENE
, O
eukaryotic I-GENE
, O
and O
viral I-GENE
proteins I-GENE
revealed O
differences O
in O
amino O
acid I-GENE
similarity O
and O
phylogenetic O
relationships O
. O

The O
_RARE_ I-GENE
of O
_RARE_ I-GENE
shows O
the O
highest O
similarity O
to O
the O
_RARE_ I-GENE
of O
_RARE_ I-GENE
and O
significant O
lower O
similarity O
to O
the O
eukaryotic I-GENE
polymerases I-GENE
II I-GENE
and O
III I-GENE
as O
well O
as O
to O
the O
_RARE_ I-GENE
subunit I-GENE
. O

The O
use O
of O
primary O
_RARE_ I-GENE
cells O
thus O
provides O
a O
_RARE_ I-GENE
in O
vitro O
system O
for O
further O
study O
of O
the O
endocrine O
, O
_RARE_ I-GENE
, O
and O
autocrine O
factors I-GENE
regulating O
endometrial O
gene I-GENE
expression O
during O
pregnancy O
. O

We O
performed O
_RARE_ I-GENE
estimation O
of O
spikes O
and O
_RARE_ I-GENE
components O
in O
identical O
patients O
. O

Both O
verapamil O
and O
propranolol O
can O
exhibit O
additive O
effects O
with O
adenosine I-GENE
in O
_RARE_ I-GENE
AV O
nodal O
conduction O
time O
; O
however O
, O
only O
verapamil O
can O
reduce O
the O
dose O
of O
adenosine I-GENE
required O
to O
produce O
AV O
nodal O
block O
. O

_RARE_ I-GENE
_RARE_ I-GENE
was O
inversely O
correlated O
with O
bone O
alkaline I-GENE
phosphatase I-GENE
( O
r O
= O
- I-GENE
0 O
. O
71 O
, O
p O
< O
0 O
. O
01 O
) O
and O
intact O
PTH I-GENE
( O
r O
= O
- I-GENE
0 O
. O
59 O
, O
p O
< O
0 O
. O
05 O
). O

In O
addition O
, O
a O
comparison O
of O
the O
_RARE_ I-GENE
gene I-GENE
sequences I-GENE
with O
available O
_RARE_ I-GENE
indicates O
that O
a O
large O
portion O
of O
these O
genes I-GENE
, O
including O
exons O
encoding O
two O
functional O
domains I-GENE
of O
the O
carboxyl O
- I-GENE
terminal I-GENE
region O
of O
these O
proteins I-GENE
, O
has O
been O
duplicated O
as O
part O
of O
a O
larger O
human I-GENE
telomeric O
repeat I-GENE
sequence I-GENE
found O
on O
many O
human I-GENE
chromosomes O
. O

We O
show O
here O
that O
the O
LIM I-GENE
domain I-GENE
homeobox I-GENE
protein I-GENE
_RARE_ I-GENE
- I-GENE
1 I-GENE
activates O
the O
rat I-GENE
_RARE_ I-GENE
promoter I-GENE
in O
both O
fibroblast I-GENE
and O
islet O
cell O
lines O
. O

Although O
_RARE_ I-GENE
- I-GENE
1 I-GENE
binds O
to O
both O
the O
insulin I-GENE
and O
_RARE_ I-GENE
gene I-GENE
promoter I-GENE
elements O
in O
vitro O
, O
these O
sequences I-GENE
display O
marked O
differences O
in O
their O
relative O
transcriptional O
properties O
when O
ligated O
adjacent O
to O
a O
heterologous O
promoter I-GENE
and O
transfected O
into O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
islet O
cells O
. O

It O
is O
likely O
that O
other O
pathways O
involve O
alternate O
signal I-GENE
transduction O
events O
( O
e O
. O
g O
., O
calcium O
_RARE_ I-GENE
) O
and O
promoter I-GENE
response O
elements O
( O
e O
. O
g O
., O
SRE O
). O

The O
CD4 I-GENE
count O
at O
which O
remission O
occurs O
may O
reflect O
severe O
immunodeficiency I-GENE
such O
that O
risk O
for O
AIDS O
- I-GENE
related I-GENE
infection O
is O
high O
. O

Although O
diagnostic O
_RARE_ I-GENE
is O
still O
considered O
the O
standard O
reference O
in O
the O
diagnosis O
of O
ectopic O
pregnancy O
( O
_RARE_ I-GENE
), O
use O
of O
high O
- I-GENE
resolution O
_RARE_ I-GENE
_RARE_ I-GENE
, O
in O
conjunction O
with O
qualitative O
serum I-GENE
assays O
of O
the O
beta I-GENE
subunit I-GENE
of O
human I-GENE
_RARE_ I-GENE
gonadotropin I-GENE
( O
beta I-GENE
- I-GENE
hCG I-GENE
), O
allows O
detection O
of O
earlier O
and O
smaller O
_RARE_ I-GENE
. O

_RARE_ I-GENE
of O
the O
_RARE_ I-GENE
homologous O
region O
sequence I-GENE
( O
_RARE_ I-GENE
): O
enhancer I-GENE
and O
_RARE_ I-GENE
functions O
have O
different O
sequence I-GENE
requirements O
. O

_RARE_ I-GENE
' O
loss O
of O
function O
' O
studies O
by O
constitutive O
over O
- I-GENE
expression O
of O
a O
dominant I-GENE
negative O
_RARE_ I-GENE
delta I-GENE
E I-GENE
resulted O
in O
increased O
levels O
of O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
and O
myogenin I-GENE
mRNAs I-GENE
after O
serum I-GENE
withdrawal O
. O

Neither O
_RARE_ I-GENE
nor O
_RARE_ I-GENE
is O
essential O
for O
cell O
growth I-GENE
, O
and O
a O
double O
deletion O
mutant I-GENE
is O
viable O
. O

These O
two O
repeat I-GENE
motifs O
are O
organized O
in O
an O
extremely O
well O
- I-GENE
_RARE_ I-GENE
pattern O
in O
each O
domain I-GENE
, O
which O
suggests O
that O
_RARE_ I-GENE
belongs O
to O
a O
new O
group O
of O
proteins I-GENE
having O
the O
repeat I-GENE
motifs O
of O
two O
distinct O
groups O
of O
_RARE_ I-GENE
_RARE_ I-GENE
. O

Their O
use O
established O
that O
the O
_RARE_ I-GENE
activity O
catalyzed O
both O
a O
_RARE_ I-GENE
and O
a O
_RARE_ I-GENE
cleavage O
and O
therefore O
has O
a O
_RARE_ I-GENE
specificity O
than O
previously O
recognized O
. O

To O
explore O
the O
functional O
significance O
of O
these O
subdomains O
in O
PRL I-GENE
binding I-GENE
and O
signal I-GENE
transduction O
, O
deletion O
mutants I-GENE
of O
S1 I-GENE
or O
/ I-GENE
and O
S2 I-GENE
subdomains O
were O
constructed O
. O

A I-GENE
stable O
heterologous O
cell O
line O
containing O
the O
mouse I-GENE
TRH I-GENE
receptor I-GENE
was O
constructed O
by O
transfection O
of O
_RARE_ I-GENE
293 O
cells O
, O
which O
lack O
L I-GENE
channel O
activity O
. O

To O
understand O
further O
the O
expression O
and O
regulation O
of O
the O
_RARE_ I-GENE
, O
we O
now O
describe O
the O
genomic O
characteristics O
, O
tissue I-GENE
expression O
, O
chromosomal I-GENE
localization O
, O
and O
regional O
mapping O
of O
the O
human I-GENE
_RARE_ I-GENE
gene I-GENE
, O
_RARE_ I-GENE
. O

The O
final O
predicted O
structure O
has O
an O
overall O
_RARE_ I-GENE
deviation O
of O
0 O
. O
7 O
A I-GENE
from O
that O
of O
ras I-GENE
- I-GENE
p21 I-GENE
. O

Genomic O
organization O
of O
the O
human I-GENE
beta I-GENE
- I-GENE
catenin I-GENE
gene I-GENE
( O
_RARE_ I-GENE
). O

Furthermore O
, O
although O
the O
regional O
distribution O
of O
lean O
tissue I-GENE
mass O
in O
the O
trunk O
and O
_RARE_ I-GENE
remained O
_RARE_ I-GENE
constant O
at O
different O
_RARE_ I-GENE
stages O
, O
the O
regional O
distribution O
of O
fat O
was O
altered O
significantly O
, O
_RARE_ I-GENE
more O
central O
and O
less O
peripheral O
. O

Thus O
, O
the O
predicted O
_RARE_ I-GENE
protein I-GENE
retains O
most O
of O
the O
cytoplasmic I-GENE
region O
, O
but O
lacks O
the O
extracellular I-GENE
and O
transmembrane I-GENE
domains I-GENE
. O

_RARE_ I-GENE
phosphorylation O
of O
the O
_RARE_ I-GENE
protein I-GENE
was O
demonstrated O
by O
in O
vitro O
labeling O
with O
[ O
32P O
]. O

17 O
. O
5 I-GENE
% O
of O
cycles O
). O

We O
report O
here O
the O
discovery O
of O
a O
new O
actin I-GENE
- I-GENE
related I-GENE
gene I-GENE
in O
this O
organism O
, O
which O
we O
have O
named O
_RARE_ I-GENE
. O

Two O
of O
the O
ORFs O
are O
completely O
internal O
to O
longer O
ones O
and O
a O
third O
is O
partially O
embedded O
in O
_RARE_ I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
of O
rare O
- I-GENE
length I-GENE
alleles I-GENE
indicates O
that O
they O
are O
comprised O
of O
_RARE_ I-GENE
sequences I-GENE
, O
although O
they O
usually O
_RARE_ I-GENE
a O
_RARE_ I-GENE
to O
one O
of O
the O
common O
alleles I-GENE
at O
the O
5 I-GENE
'- O
most O
end O
. O

_RARE_ I-GENE
_RARE_ I-GENE
contains O
the O
genetic O
determinants I-GENE
for O
H2 I-GENE
uptake O
( O
_RARE_ I-GENE
) O
from O
Rhizobium I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
. O
_RARE_ I-GENE
, O
including O
a O
cluster I-GENE
of O
17 O
genes I-GENE
named O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
. O

Two O
classes O
of O
inactive O
receptors I-GENE
were O
identified O
: O
one O
in O
which O
both O
transcriptional O
activation O
and O
dimerization O
were O
_RARE_ I-GENE
and O
a O
second O
in O
which O
only O
transcriptional O
activation O
was O
abolished O
. O

Here O
we O
localize O
a O
_RARE_ I-GENE
40 I-GENE
- I-GENE
amino O
acid I-GENE
region O
within O
the O
_RARE_ I-GENE
of O
RXR I-GENE
, O
RAR I-GENE
, O
TR I-GENE
, O
and O
chicken I-GENE
_RARE_ I-GENE
upstream O
promoter I-GENE
transcription I-GENE
factor I-GENE
that O
is O
critical O
for O
determining O
identity O
in O
the O
heterodimeric I-GENE
interaction O
and O
for O
high O
- I-GENE
affinity O
DNA I-GENE
binding I-GENE
. O

_RARE_ I-GENE
and O
_RARE_ I-GENE
A I-GENE
do O
not O
decrease O
_RARE_ I-GENE
DNA I-GENE
- I-GENE
protein I-GENE
interactions O
, O
suggesting O
that O
important O
protein I-GENE
- I-GENE
protein I-GENE
interactions O
are O
phosphatase I-GENE
regulated O
. O

An O
open O
- I-GENE
_RARE_ I-GENE
, O
placebo O
- I-GENE
controlled O
, O
randomized O
, O
two O
- I-GENE
way O
_RARE_ I-GENE
study O
was O
performed O
in O
12 O
healthy O
volunteers O
( O
between O
20 O
and O
44 I-GENE
years O
of O
age O
) O
to O
assess O
the O
effect O
of O
_RARE_ I-GENE
, O
a O
gastrointestinal O
lipase I-GENE
inhibitor I-GENE
that O
reduces O
dietary O
fat O
absorption O
and O
is O
being O
developed O
for O
weight O
control O
in O
obesity O
, O
on O
the O
absorption O
of O
_RARE_ I-GENE
A I-GENE
and O
E I-GENE
. O

_RARE_ I-GENE
is O
a O
novel O
_RARE_ I-GENE
antibiotic O
developed O
for O
_RARE_ I-GENE
use O
in O
_RARE_ I-GENE
medicine O
. O

Effect O
of O
_RARE_ I-GENE
oxide I-GENE
( O
N2O O
) O
on O
the O
_RARE_ I-GENE
A I-GENE
- I-GENE
and O
C I-GENE
- I-GENE
_RARE_ I-GENE
was O
investigated O
using O
artificially O
ventilated O
rats O
anesthetized O
with O
alpha I-GENE
- I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
. O

Restriction O
enzyme I-GENE
mapping O
and O
Southern O
analysis O
indicated O
further O
that O
the O
human I-GENE
_RARE_ I-GENE
- I-GENE
1 I-GENE
gene I-GENE
is O
a O
single O
- I-GENE
copy O
gene I-GENE
. O

In O
the O
absence O
of O
_RARE_ I-GENE
and O
_RARE_ I-GENE
cell O
viability O
is O
lost O
, O
but O
can O
be O
_RARE_ I-GENE
by O
ectopic O
expression O
of O
the O
G1 I-GENE
cyclin I-GENE
encoding O
genes I-GENE
, O
_RARE_ I-GENE
or O
_RARE_ I-GENE
. O

The O
detection O
ratio O
_RARE_ I-GENE
at O
ages O
30 O
to O
34 O
and O
decreased O
_RARE_ I-GENE
during O
the O
next O
15 O
years O
of O
age O
. O

_RARE_ I-GENE
many O
embryos O
to O
transfer I-GENE
in O
patients O
undergoing O
_RARE_ I-GENE
? O

_RARE_ I-GENE
: O
_RARE_ I-GENE
the O
small I-GENE
size O
of O
this O
study O
and O
the O
_RARE_ I-GENE
of O
results O
among O
the O
few O
prospective O
studies O
of O
ovarian O
cancer O
conducted O
to O
test O
these O
associations O
, O
_RARE_ I-GENE
of O
these O
findings O
are O
highly O
_RARE_ I-GENE
. O

The O
_RARE_ I-GENE
TATA I-GENE
box I-GENE
in O
promoter I-GENE
B I-GENE
plays O
a O
more O
important O
role O
in O
promoter I-GENE
activity O
than O
the O
TATA I-GENE
box I-GENE
in O
promoter I-GENE
A I-GENE
. O

These O
properties O
indicate O
that O
_RARE_ I-GENE
is O
an O
RNA I-GENE
- I-GENE
export O
factor I-GENE
and O
that O
Rev I-GENE
may O
mediate O
viral I-GENE
RNA I-GENE
export O
by O
_RARE_ I-GENE
the O
function O
of O
_RARE_ I-GENE
. O

_RARE_ I-GENE
is O
a O
reliable O
and O
_RARE_ I-GENE
measure O
of O
_RARE_ I-GENE
in O
the O
elderly O
. O

Two O
techniques O
based O
on O
assay O
coefficients O
of O
variation O
were O
employed O
to O
characterize O
a O
normal O
circadian O
pattern O
of O
cortisol O
. O

We O
have O
performed O
_RARE_ I-GENE
analyses O
on O
_RARE_ I-GENE
mRNA I-GENE
of O
plasmid O
R1 I-GENE
, O
both O
free O
and O
in O
duplex O
with O
the O
antisense I-GENE
RNA I-GENE
, O
_RARE_ I-GENE
. O

Previous O
work O
showed O
that O
_RARE_ I-GENE
( O
initiator O
protein I-GENE
) O
expression O
requires O
tap I-GENE
( O
leader O
peptide I-GENE
) O
translation I-GENE
. O

A I-GENE
system O
is O
described O
in O
which O
the O
volume O
flow O
rate O
of O
blood O
in O
a O
vessel O
is O
determined O
using O
transverse O
colour I-GENE
Doppler O
ultrasound O
imaging O
. O

The O
enzyme I-GENE
activities O
studied O
are O
important O
elements O
in O
the O
pathophysiology O
of O
dental O
_RARE_ I-GENE
and O
may O
even O
be O
addressed O
as O
virulence I-GENE
factors I-GENE
. O

_RARE_ I-GENE
is O
an O
effective O
means O
of O
prophylaxis O
for O
upper O
respiratory O
infection O
in O
_RARE_ I-GENE
angina O
patients O
. O

In O
lean O
mice O
, O
the O
fat O
/ I-GENE
water O
intensity O
ratio O
was O
about O
1 I-GENE
: O
4 I-GENE
, O
about O
half O
that O
in O
normal O
mice O
. O

_RARE_ I-GENE
parameters O
were O
similar O
to O
values O
given O
in O
the O
literature O
for O
intravenous O
( O
IV I-GENE
) O
or O
_RARE_ I-GENE
( O
IA O
) O
bolus O
MMC O
injections O
( O
_RARE_ I-GENE
= O
7 O
. O
0 O
min O
following O
the O
beginning O
of O
MMC O
infusion O
, O
_RARE_ I-GENE
= O
0 O
. O
57 O
1 I-GENE
/ I-GENE
kg O
, O
C1 I-GENE
= O
8 O
. O
9 O
ml O
/ I-GENE
min O
. O
kg O
, O
T1 O
/ I-GENE
2 I-GENE
alpha I-GENE
= O
8 O
. O
3 I-GENE
min O
, O
T1 O
/ I-GENE
2 I-GENE
beta I-GENE
= O
58 O
. O
6 I-GENE
min O
). O

In O
this O
study O
, O
we O
identified O
four O
distinct O
E2F I-GENE
complexes I-GENE
present O
in O
aged O
and O
_RARE_ I-GENE
normal O
, O
human I-GENE
diploid O
fibroblasts O
. O

This O
paper O
gives O
an O
_RARE_ I-GENE
of O
the O
global O
pattern O
of O
_RARE_ I-GENE
in O
_RARE_ I-GENE
which O
occurred O
during O
the O
30 O
- I-GENE
month O
period O
from O
1 I-GENE
_RARE_ I-GENE
1993 O
to O
29 O
_RARE_ I-GENE
1996 O
. O

If O
we O
_RARE_ I-GENE
the O
finding O
of O
non O
- I-GENE
visualization O
of O
the O
_RARE_ I-GENE
at O
4 I-GENE
h O
post O
injection O
as O
the O
criterion O
for O
the O
diagnosis O
of O
AC I-GENE
, O
the O
diagnostic O
accuracy O
was O
only O
40 I-GENE
. O
7 O
% O
( O
11 O
/ I-GENE
27 O
). O

These O
results O
were O
_RARE_ I-GENE
in O
a O
subsequent O
study O
in O
which O
30 O
_RARE_ I-GENE
men O
were O
supplemented O
with O
_RARE_ I-GENE
5 I-GENE
mg O
three O
times O
daily O
for O
6 I-GENE
months O
. O

Alternative O
processing O
of O
the O
_RARE_ I-GENE
- I-GENE
tRNA I-GENE
synthetase I-GENE
mRNA I-GENE
from O
interferon I-GENE
- I-GENE
treated O
human I-GENE
cells O
. O

Evidence O
for O
the O
promoting I-GENE
role O
of O
the O
intra O
- I-GENE
uterine O
_RARE_ I-GENE
release O
in O
the O
development O
of O
late O
_RARE_ I-GENE
saline O
- I-GENE
induced O
abortion O
. O

This O
GAP I-GENE
activity O
was O
observed O
in O
3T3 O
- I-GENE
L1 I-GENE
_RARE_ I-GENE
lysates O
, O
and O
was O
able O
to O
_RARE_ I-GENE
the O
hydrolysis O
of O
the O
[ O
alpha I-GENE
- I-GENE
32P O
] O
GTP I-GENE
bound O
to O
GST I-GENE
- I-GENE
_RARE_ I-GENE
into O
[ O
alpha I-GENE
- I-GENE
32P O
] O
GDP I-GENE
. O

CONCLUSION O
: O
During O
chronic O
treatment O
, O
the O
_RARE_ I-GENE
response O
to O
oral O
_RARE_ I-GENE
was O
attenuated O
, O
indicating O
that O
continued O
clinical O
improvement O
in O
patients O
with O
_RARE_ I-GENE
on O
_RARE_ I-GENE
is O
independent O
of O
to O
its O
acute O
_RARE_ I-GENE
effects O
. O

We O
conclude O
that O
, O
in O
AIDS O
patients O
with O
_RARE_ I-GENE
, O
tolerance O
to O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
was O
acceptable O
when O
the O
daily O
dosage O
did O
not O
_RARE_ I-GENE
1 I-GENE
mg O
/ I-GENE
kg O
, O
but O
the O
higher O
1 I-GENE
. O
5 I-GENE
mg O
/ I-GENE
kg O
daily O
dosage O
was O
associated I-GENE
with O
an O
_RARE_ I-GENE
rate O
of O
_RARE_ I-GENE
. O

Moreover O
, O
the O
second O
_RARE_ I-GENE
- I-GENE
like I-GENE
motif I-GENE
located O
at O
the O
amino O
- I-GENE
terminus O
of O
_RARE_ I-GENE
stimulates O
guanine I-GENE
nucleotide I-GENE
exchange I-GENE
on O
_RARE_ I-GENE
and O
on O
members O
of O
the O
related I-GENE
_RARE_ I-GENE
proteins I-GENE
, O
but O
not O
on O
other O
small I-GENE
GTP I-GENE
binding I-GENE
proteins I-GENE
such O
as O
Ran I-GENE
or O
R I-GENE
- I-GENE
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
. O

The O
reconstituted O
RNA I-GENE
polymerases I-GENE
containing O
the O
mutant I-GENE
alpha I-GENE
subunits I-GENE
were O
examined O
for O
their O
response O
to O
transcription I-GENE
activation O
by O
cAMP I-GENE
- I-GENE
CRP I-GENE
and O
the O
_RARE_ I-GENE
_RARE_ I-GENE
element I-GENE
. O

Transcription O
factor I-GENE
recognition I-GENE
surface O
on O
the O
RNA I-GENE
polymerase I-GENE
alpha I-GENE
subunit I-GENE
is O
involved O
in O
contact O
with O
the O
DNA I-GENE
enhancer I-GENE
element I-GENE
. O

Consistent O
with O
this O
similarity O
, O
the O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
mutant I-GENE
accumulates O
unspliced O
precursors I-GENE
at O
the O
restrictive O
temperature O
. O

A I-GENE
decrease O
of O
erythrocyte I-GENE
_RARE_ I-GENE
with O
age O
, O
expressed O
in O
nmol O
/ I-GENE
L I-GENE
, O
was O
noted O
( O
p O
< O
0 O
. O
02 O
). O

Cloning O
and O
sequence I-GENE
analyses O
revealed O
a O
second O
cDNA I-GENE
with O
a O
95 O
- I-GENE
nt O
deletion O
in O
the O
region O
coding O
for O
the O
putative O
second O
intracellular O
loop I-GENE
and O
the O
fourth O
transmembrane I-GENE
domain I-GENE
of O
the O
5 I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
R I-GENE
. O

Expression O
of O
thymidine I-GENE
kinase I-GENE
gene I-GENE
in O
normal O
human I-GENE
diploid O
cells O
is O
both O
cell O
cycle O
- I-GENE
and O
age O
- I-GENE
dependent I-GENE
and O
appears O
to O
be O
transcriptionally O
regulated O
. O

The O
minimum O
inhibitory I-GENE
concentrations O
( O
MICs O
) O
of O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
and O
amphotericin O
B I-GENE
were O
significantly O
influenced O
by O
the O
_RARE_ I-GENE
size O
, O
regardless O
of O
the O
techniques O
used O
. O

These O
bacteria O
produce O
and O
export O
proteins I-GENE
capable O
of O
specific I-GENE
interactions O
with O
key O
mammalian I-GENE
cell O
regulatory I-GENE
molecules I-GENE
in O
order O
to O
_RARE_ I-GENE
the O
normal O
functions O
of O
the O
cells O
. O

The O
elevations O
achieved O
by O
_RARE_ I-GENE
given O
s O
. O
c I-GENE
. O
were O
higher O
than O
those O
achieved O
after O
i O
. O
p O
. O
administration O
and O
_RARE_ I-GENE
for O
longer O
periods O
. O

Thus O
, O
although O
_RARE_ I-GENE
may O
play O
only O
a O
limited O
role O
during O
the O
early I-GENE
embryonic O
_RARE_ I-GENE
, O
it O
may O
function O
later O
in O
development O
to O
establish O
a O
somatic O
type I-GENE
of O
cell O
cycle O
. O

The O
main O
aim O
of O
the O
contribution O
, O
which O
_RARE_ I-GENE
an O
_RARE_ I-GENE
for O
discussion O
on O
the O
_RARE_ I-GENE
_RARE_ I-GENE
' O
_RARE_ I-GENE
is O
to O
_RARE_ I-GENE
_RARE_ I-GENE
published O
research O
_RARE_ I-GENE
focusing O
both O
on O
strengths O
and O
_RARE_ I-GENE
and O
_RARE_ I-GENE
in O
the O
hypothesis O
formulation O
, O
methods O
and O
instruments O
used O
, O
discussion O
of O
results O
. O

Moreover O
, O
it O
also O
_RARE_ I-GENE
the O
effects O
of O
antihypertensive O
drugs O
currently O
regarded O
as O
first O
- I-GENE
choice O
agents O
, O
i O
. O
e O
. O
calcium O
antagonists O
and O
the O
angiotensin I-GENE
converting I-GENE
enzyme I-GENE
inhibitors O
, O
on O
_RARE_ I-GENE
hemodynamics O
. O

Many O
human I-GENE
viruses O
are O
able O
to O
develop O
suitable O
strategies O
for O
_RARE_ I-GENE
apoptosis O
in O
virus I-GENE
- I-GENE
infected O
cells O
and O
in O
virus I-GENE
- I-GENE
primed O
T I-GENE
cells O
. O

It O
is O
suggested O
that O
the O
observed O
clinical O
phenomena O
in O
response O
to O
morphine O
can O
be O
explained O
by O
differences O
in O
expression O
and O
sensitivity O
of O
some O
opioid I-GENE
receptor I-GENE
subtypes O
in O
_RARE_ I-GENE
. O

Previous O
studies O
demonstrated O
that O
the O
_RARE_ I-GENE
- I-GENE
containing O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
are O
expressed O
in O
a O
tissue I-GENE
- I-GENE
specific I-GENE
manner O
. O

Taken O
together O
, O
these O
observations O
indicate O
that O
the O
C I-GENE
- I-GENE
terminal I-GENE
24 O
amino O
acids O
are O
sufficient O
for O
_RARE_ I-GENE
secretion O
although O
the O
region O
adjacent O
to O
this O
domain I-GENE
appears O
to O
affect O
secretion O
efficiency O
. O

Thus O
, O
despite O
the O
potential O
for O
common O
regulatory I-GENE
mechanisms O
, O
the O
available O
evidence O
indicates O
that O
the O
_RARE_ I-GENE
minimal I-GENE
promoter I-GENE
does O
not O
significantly O
affect O
_RARE_ I-GENE
gene I-GENE
expression O
. O

_RARE_ I-GENE
proteins I-GENE
have O
been O
identified O
by O
their O
binding I-GENE
to O
an O
upstream O
element I-GENE
of O
c I-GENE
- I-GENE
myc I-GENE
. O

Gene I-GENE
1 I-GENE
has O
been O
completely O
sequenced O
. O

B I-GENE
cell O
antigen I-GENE
receptor I-GENE
( O
BCR I-GENE
)- I-GENE
induced O
apoptosis O
in O
the O
_RARE_ I-GENE
- I-GENE
231 O
B I-GENE
lymphoma O
cell O
line O
can O
be O
prevented O
by O
_RARE_ I-GENE
CD40 I-GENE
. O

Both O
alleles I-GENE
are O
functionally O
expressed O
and O
are O
distributed O
within O
CD4 I-GENE
+/ I-GENE
CD8 I-GENE
+ I-GENE
T I-GENE
cell O
_RARE_ I-GENE
. O

The O
model O
also O
predicts O
that O
blood O
flow O
shunt O
fraction O
( O
_RARE_ I-GENE
/ I-GENE
QT O
) O
is O
directly O
related I-GENE
to O
the O
oxygen O
_RARE_ I-GENE
- I-GENE
wave O
amplitude O
_RARE_ I-GENE
transmitted O
to O
end O
- I-GENE
_RARE_ I-GENE
air O
and O
arterial O
and O
mixed O
- I-GENE
venous O
blood O
through O
two O
simple O
_RARE_ I-GENE
. O

The O
deduced O
amino O
acid I-GENE
sequence I-GENE
of O
_RARE_ I-GENE
is O
nearly O
identical O
to O
_RARE_ I-GENE
except O
at O
the O
amino O
end O
, O
where O
they O
are O
sharply O
divergent O
. O

_RARE_ I-GENE
disruption O
in O
_RARE_ I-GENE
embryos O
caused O
a O
relative O
drop O
in O
USF I-GENE
RNA I-GENE
accumulation O
levels O
to O
approximately O
60 O
% O
of O
control O
embryos O
, O
while O
_RARE_ I-GENE
RNA I-GENE
accumulation O
levels O
_RARE_ I-GENE
to O
less O
than O
5 I-GENE
%. O

Five O
of O
these O
eight O
patients O
in O
group O
II I-GENE
also O
received O
8 O
- I-GENE
in O
- I-GENE
1 I-GENE
chemotherapy O
. O

_RARE_ I-GENE
days O
after O
the O
intervention O
, O
_RARE_ I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
remained O
dependent I-GENE
upon O
the O
extracellular I-GENE
Ca2 I-GENE
+ I-GENE
concentration O
_RARE_ I-GENE
Ca I-GENE
] O
o I-GENE
) O
both O
in O
groups O
A I-GENE
and O
B I-GENE
. O

_RARE_ I-GENE
between O
HIV I-GENE
- I-GENE
1 I-GENE
and O
HIV I-GENE
- I-GENE
2 I-GENE
showed O
evidence O
for O
the O
presence O
of O
HIV I-GENE
- I-GENE
1 I-GENE
only O
. O

However O
, O
an O
intrinsic O
DNA I-GENE
- I-GENE
binding I-GENE
subunit I-GENE
for O
_RARE_ I-GENE
- I-GENE
D I-GENE
was O
not O
identified O
. O

The O
_RARE_ I-GENE
- I-GENE
D I-GENE
( O
CDP I-GENE
/ I-GENE
cut I-GENE
) O
complex I-GENE
with O
the O
H4 I-GENE
promoter I-GENE
is O
immunoreactive I-GENE
with O
antibodies I-GENE
against O
CDP I-GENE
/ I-GENE
cut I-GENE
and O
_RARE_ I-GENE
but O
not O
p107 I-GENE
, O
whereas O
the O
CDP I-GENE
/ I-GENE
cut I-GENE
complex I-GENE
with O
a O
_RARE_ I-GENE
promoter I-GENE
( O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
) O
_RARE_ I-GENE
only O
with O
CDP I-GENE
and O
p107 I-GENE
antibodies I-GENE
. O

Recently O
, O
a O
distantly O
related I-GENE
_RARE_ I-GENE
- I-GENE
homolog I-GENE
, O
_RARE_ I-GENE
, O
has O
also O
been O
identified O
in O
E I-GENE
. O
coli I-GENE
. O

To O
study O
the O
regulation O
of O
_RARE_ I-GENE
expression O
, O
the O
promoter I-GENE
of O
the O
_RARE_ I-GENE
gene I-GENE
has O
been O
isolated O
from O
a O
murine I-GENE
_RARE_ I-GENE
- I-GENE
resistant O
cell O
line O
, O
_RARE_ I-GENE
. O
V2 I-GENE
- I-GENE
1 I-GENE
, O
and O
characterized O
. O

The O
amplification O
was O
achieved O
using O
two O
primers O
which O
correspond O
to O
TRH I-GENE
progenitor I-GENE
sequence I-GENE
( O
Lys O
/ I-GENE
Arg O
- I-GENE
Arg O
- I-GENE
Gln O
- I-GENE
His O
- I-GENE
Pro I-GENE
- I-GENE
Gly O
- I-GENE
Lys O
/ I-GENE
Arg O
- I-GENE
Arg O
). O

The O
_RARE_ I-GENE
_RARE_ I-GENE
cells O
occupied O
the O
_RARE_ I-GENE
of O
the O
lymph O
nodes O
and O
were O
initially O
suspected O
of O
being O
metastatic O
from O
the O
ovarian O
tumor I-GENE
in O
each O
case O
. O

The O
gene I-GENE
_RARE_ I-GENE
encoding O
the O
catabolite I-GENE
control O
protein I-GENE
_RARE_ I-GENE
of O
Staphylococcus I-GENE
_RARE_ I-GENE
has O
been O
cloned O
and O
characterized O
. O

An O
_RARE_ I-GENE
deletion O
mutant I-GENE
shows O
reduced O
virulence I-GENE
when O
tested O
in O
an O
intravenous O
mouse I-GENE
model O
, O
but O
intracellular O
replication O
of O
the O
mutant I-GENE
in O
_RARE_ I-GENE
- I-GENE
2 I-GENE
and O
_RARE_ I-GENE
cells O
appears O
to O
be O
comparable O
with O
that O
of O
the O
wild I-GENE
- I-GENE
type I-GENE
strain O
. O

Thus O
, O
the O
N I-GENE
- I-GENE
_RARE_ I-GENE
complex I-GENE
may O
be O
affected O
through O
contacts O
with O
the O
CTD I-GENE
of O
the O
alpha I-GENE
subunit I-GENE
of O
RNA I-GENE
polymerase I-GENE
, O
as O
is O
a O
group O
of O
regulatory I-GENE
proteins I-GENE
that O
influences O
initiation I-GENE
of O
transcription I-GENE
. O

Administration O
of O
_RARE_ I-GENE
at O
200 O
mg O
/ I-GENE
kg O
/ I-GENE
day O
in O
combination O
with O
_RARE_ I-GENE
at O
100 O
mg O
/ I-GENE
kg O
/ I-GENE
day O
resulted O
in O
a O
marked O
prolongation O
of O
survival O
compared O
with O
that O
for O
mice O
that O
received O
_RARE_ I-GENE
or O
_RARE_ I-GENE
alone O
. O

Eight O
- I-GENE
four O
_RARE_ I-GENE
were O
tested O
in O
order O
to O
examine O
the O
fit O
of O
the O
model O
to O
the O
data O
by O
_RARE_ I-GENE
analysis O
with O
_RARE_ I-GENE
VII I-GENE
. O

Two O
of O
seven O
initiation I-GENE
sites I-GENE
were O
flanked O
by O
a O
sequence I-GENE
homologous O
to O
the O
consensus I-GENE
promoter I-GENE
motif I-GENE
that O
includes O
the O
_RARE_ I-GENE
motif I-GENE
( O
where O
R I-GENE
is O
A I-GENE
or O
G I-GENE
) O
of O
the O
rice I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
using O
SC O
_RARE_ I-GENE
was O
more O
effective O
than O
_RARE_ I-GENE
selection O
in O
reducing O
age O
at O
_RARE_ I-GENE
in O
_RARE_ I-GENE
. O

Using O
anchored I-GENE
PCR O
, O
a O
_RARE_ I-GENE
element I-GENE
rearranged I-GENE
to O
_RARE_ I-GENE
was O
isolated O
. O

Sodium O
_RARE_ I-GENE
_RARE_ I-GENE
treatment O
for O
lithium O
toxicity O
: O
effects O
on O
serum I-GENE
potassium O
concentrations O
. O

The O
mammalian I-GENE
homeodomain I-GENE
proteins I-GENE
encoded I-GENE
by O
Hox I-GENE
genes I-GENE
play O
an O
important O
role O
in O
embryonic O
development O
by O
providing O
_RARE_ I-GENE
_RARE_ I-GENE
which O
define O
developmental O
identities O
along O
the O
anteroposterior O
axis O
of O
developing O
organisms O
. O

Interferon I-GENE
stimulated O
gene I-GENE
factor I-GENE
3 I-GENE
( O
_RARE_ I-GENE
) O
is O
a O
_RARE_ I-GENE
transcription I-GENE
factor I-GENE
activated I-GENE
on O
treatment O
of O
cells O
with O
interferon I-GENE
- I-GENE
alpha I-GENE
and O
beta I-GENE
( O
type I-GENE
I I-GENE
_RARE_ I-GENE
). O

The O
_RARE_ I-GENE
/ I-GENE
P1 I-GENE
resource O
, O
derivative O
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
constitute O
an O
_RARE_ I-GENE
resource O
to O
further O
studies O
of O
telomere I-GENE
structure O
and O
function O
and O
a O
means O
for O
physical O
and O
genetic O
map O
integration O
and O
closure O
. O

_RARE_ I-GENE
_RARE_ I-GENE
included O
_RARE_ I-GENE
2 I-GENE
of O
the O
Clinical O
_RARE_ I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
), O
the O
total O
score O
of O
the O
_RARE_ I-GENE
Clinical O
Assessment O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
scale O
, O
the O
_RARE_ I-GENE
' O
need O
for O
help O
' O
of O
the O
nurse O
' O
s O
rating O
of O
_RARE_ I-GENE
patients O
( O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
; O
_RARE_ I-GENE
) O
and O
the O
total O
score O
of O
the O
Short O
_RARE_ I-GENE
_RARE_ I-GENE
Test O
( O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
; O
_RARE_ I-GENE
). O

Three O
mutants I-GENE
were O
isolated O
from O
the O
widely O
used O
strain O
, O
_RARE_ I-GENE
. O

As O
extensively O
examined O
with O
the O
myogenin I-GENE
promoter I-GENE
, O
presence O
of O
one O
or O
multiple O
copies O
of O
_RARE_ I-GENE
in O
the O
vectors O
elevated O
the O
expression O
activity O
in O
myotubes O
by O
4 I-GENE
. O
5 I-GENE
- I-GENE
to O
19 O
- I-GENE
fold O
over O
those O
without O
_RARE_ I-GENE
, O
but O
not O
significantly O
in O
myoblasts O
. O

We O
conclude O
that O
common O
upstream O
signals O
cause O
activation O
of O
Ras I-GENE
and O
_RARE_ I-GENE
, O
but O
activated I-GENE
_RARE_ I-GENE
controls O
cell O
growth I-GENE
via O
distinct O
Raf I-GENE
- I-GENE
independent O
downstream O
signaling O
pathways O
. O

_RARE_ I-GENE
yeast I-GENE
_RARE_ I-GENE
+ I-GENE
is O
required O
for O
chromosome O
segregation O
. O

_RARE_ I-GENE
was O
based O
on O
expression O
of O
an O
integrated O
DNA I-GENE
fragment I-GENE
containing O
the O
_RARE_ I-GENE
- I-GENE
10 O
promoter I-GENE
- I-GENE
regulatory I-GENE
region O
followed O
by O
the O
initial O
segment O
of O
the O
_RARE_ I-GENE
- I-GENE
10 O
open O
reading O
frame O
fused O
in O
frame O
with O
the O
bacterial I-GENE
_RARE_ I-GENE
B I-GENE
phosphotransferase I-GENE
structural O
gene I-GENE
( O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
). O

Mutations O
at O
two O
_RARE_ I-GENE
sites I-GENE
, O
serine I-GENE
_RARE_ I-GENE
and O
threonine I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
the O
effect O
. O

IRF I-GENE
- I-GENE
1 I-GENE
acts O
as O
a O
transcriptional O
activator I-GENE
, O
while O
IRF I-GENE
- I-GENE
2 I-GENE
acts O
as O
a O
repressor I-GENE
. O

In O
contrast O
, O
cotransfection O
of O
_RARE_ I-GENE
and O
IRF I-GENE
- I-GENE
1 I-GENE
into O
NIH O
3T3 O
cells O
resulted O
in O
a O
dose O
- I-GENE
dependent I-GENE
repression O
of O
promoter I-GENE
activation O
which O
occurred O
in O
a O
TATA I-GENE
- I-GENE
dependent I-GENE
manner O
. O

The O
requirement O
of O
Tyr I-GENE
- I-GENE
19 O
_RARE_ I-GENE
for O
spindle O
assembly O
is O
also O
observed O
under O
conditions O
in O
which O
spindle O
formation O
is O
independent O
of O
mitosis O
, O
suggesting O
that O
the O
involvement O
of O
Cdc28 I-GENE
/ I-GENE
_RARE_ I-GENE
kinase I-GENE
in O
SPB O
separation O
is O
direct O
. O

A I-GENE
subset O
of O
these O
_RARE_ I-GENE
recognition I-GENE
sequences I-GENE
containing O
a O
_RARE_ I-GENE
_RARE_ I-GENE
core I-GENE
can O
also O
function O
as O
Ets I-GENE
- I-GENE
responsive I-GENE
elements O
. O

In O
both O
_RARE_ I-GENE
, O
it O
can O
be O
phosphorylated O
by O
cyclin I-GENE
D I-GENE
- I-GENE
dependent I-GENE
kinases I-GENE
, O
suggesting O
that O
its O
transcriptional O
activity O
may O
normally O
be O
regulated O
through O
such O
mechanisms O
. O

Expression O
of O
the O
_RARE_ I-GENE
protein I-GENE
_RARE_ I-GENE
under O
the O
control O
of O
a O
_RARE_ I-GENE
promoter I-GENE
in O
Saccharomyces I-GENE
cerevisiae I-GENE
resulted O
in O
galactose I-GENE
- I-GENE
inducible I-GENE
cell O
death O
. O

This O
technique O
was O
employed O
in O
12 O
patients O
with O
a O
_RARE_ I-GENE
bone O
cyst O
. O

_RARE_ I-GENE
_RARE_ I-GENE
strains O
with O
_RARE_ I-GENE
- I-GENE
mediated O
_RARE_ I-GENE
resistance O
were O
isolated O
by O
_RARE_ I-GENE
culture O
from O
the O
_RARE_ I-GENE
and O
_RARE_ I-GENE
of O
several O
animal O
species O
, O
mainly O
horses O
and O
dogs O
( O
8 O
% O
positive O
), O
chickens O
( O
7 O
% O
positive O
), O
and O
pigs O
( O
6 I-GENE
% O
positive O
). O

The O
amino O
- I-GENE
terminal I-GENE
region O
of O
E1A I-GENE
binds O
several O
high O
molecular O
weight O
proteins I-GENE
and O
inhibits O
the O
transcriptional O
coactivator I-GENE
function O
of O
p300 I-GENE
and O
the O
homologous O
cAMP I-GENE
response O
element I-GENE
( O
CRE O
)- I-GENE
binding I-GENE
protein I-GENE
. O

Transient O
transfection O
assays O
using O
reporter I-GENE
gene I-GENE
constructs I-GENE
containing O
various O
lengths O
of O
the O
5 I-GENE
' O
_RARE_ I-GENE
sequences I-GENE
revealed O
that O
the O
sequence I-GENE
located O
between O
- I-GENE
_RARE_ I-GENE
to O
- I-GENE
126 O
bp O
was O
important O
for O
the O
expression O
of O
the O
reporter I-GENE
gene I-GENE
in O
many O
different O
cell O
lines O
. O

We O
show O
that O
the O
5 I-GENE
' O
UTR I-GENE
characteristic O
of O
testis I-GENE
- I-GENE
specific I-GENE
c I-GENE
- I-GENE
mos I-GENE
mRNA I-GENE
strongly O
represses O
translation I-GENE
relative O
to O
the O
translation I-GENE
of O
transcripts I-GENE
that O
contain O
a O
5 I-GENE
' O
UTR I-GENE
derived O
from O
beta I-GENE
- I-GENE
globin I-GENE
mRNA I-GENE
, O
and O
this O
is O
mainly O
due O
to O
the O
four O
_RARE_ I-GENE
. O

To O
address O
the O
biological O
effect O
of O
specific I-GENE
isoform I-GENE
expression O
, O
NIH3T3 O
cells O
were O
transfected O
with O
a O
eukaryotic I-GENE
expression O
vector O
containing O
cDNA I-GENE
for O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
or O
_RARE_ I-GENE
. O

These O
findings O
suggest O
that O
the O
F I-GENE
- I-GENE
wave O
may O
be O
elicited O
in O
_RARE_ I-GENE
of O
different O
_RARE_ I-GENE
threshold O
but O
primarily O
in O
larger O
and O
faster O
nerve I-GENE
fibers O
, O
with O
a O
lower O
threshold O
of O
_RARE_ I-GENE
. O

In O
addition O
, O
_RARE_ I-GENE
_RARE_ I-GENE
shows O
higher O
sequence I-GENE
homology I-GENE
to O
mammalian I-GENE
_RARE_ I-GENE
in O
both O
the O
kinase I-GENE
- I-GENE
like I-GENE
( O
_RARE_ I-GENE
) O
and O
kinase I-GENE
( O
_RARE_ I-GENE
) O
domains I-GENE
( O
approximately O
70 I-GENE
% O
identity O
). O

When O
this O
DNA I-GENE
fragment I-GENE
was O
placed O
upstream O
of O
the O
chloramphenicol I-GENE
acetyltransferase I-GENE
( O
CAT I-GENE
) O
reporter I-GENE
gene I-GENE
and O
transfected O
into O
a O
_RARE_ I-GENE
_RARE_ I-GENE
cell O
line O
, O
it O
could O
drive O
the O
synthesis O
of O
CAT I-GENE
enzyme I-GENE
16 O
times O
more O
efficiently O
than O
the O
promoterless O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
. O

Molecular O
cloning O
of O
Elk I-GENE
- I-GENE
3 I-GENE
, O
a O
new O
member O
of O
the O
Ets I-GENE
family I-GENE
expressed O
during O
mouse I-GENE
embryogenesis O
and O
analysis O
of O
its O
transcriptional O
repression O
activity O
. O

We O
report O
an O
example O
of O
an O
MDV I-GENE
- I-GENE
transformed O
T I-GENE
- I-GENE
_RARE_ I-GENE
cell O
line O
( O
_RARE_ I-GENE
) O
expressing O
high O
levels O
of O
a O
truncated I-GENE
C I-GENE
- I-GENE
_RARE_ I-GENE
protein I-GENE
as O
a O
result O
of O
_RARE_ I-GENE
integration O
within O
one O
c I-GENE
- I-GENE
myb I-GENE
allele I-GENE
. O

_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
muscle O
tendon O
units O
had O
significantly O
lower O
values O
for O
load O
to O
failure O
( O
p O
< O
0 O
. O
01 O
), O
energy O
absorbed O
to O
failure O
( O
p O
< O
0 O
. O
01 O
), O
and O
strain O
at O
failure O
( O
p O
< O
0 O
. O
01 O
), O
and O
they O
tended O
to O
fail O
at O
a O
different O
anatomic O
location O
( O
p O
< O
0 O
. O
01 O
) O
( O
broadly O
at O
the O
_RARE_ I-GENE
- I-GENE
muscle O
interface O
as O
compared O
with O
_RARE_ I-GENE
at O
the O
_RARE_ I-GENE
junction O
) O
than O
fresh O
units O
. O

Northern O
analysis O
of O
the O
3 I-GENE
. O
1 I-GENE
- I-GENE
kb O
_RARE_ I-GENE
cDNA I-GENE
revealed O
that O
a O
3 I-GENE
. O
3 I-GENE
- I-GENE
kb O
major I-GENE
transcript I-GENE
is O
ubiquitously O
expressed O
in O
human I-GENE
adult O
tissues O
. O

Forty O
- I-GENE
eight O
10 O
- I-GENE
12 O
- I-GENE
week O
- I-GENE
old O
male O
Sprague O
- I-GENE
Dawley O
rats O
were O
randomized O
to O
receive O
, O
daily O
for O
28 O
days O
: O
( O
1 I-GENE
) O
CsA O
vehicle O
p O
. O
o I-GENE
. O
plus O
FB O
vehicle O
sc O
; O
( O
2 I-GENE
) O
CsA O
( O
15 O
mg O
/ I-GENE
kg O
) O
p O
. O
o I-GENE
. O
plus O
FB O
vehicle O
sc O
, O
( O
3 I-GENE
) O
CsA O
vehicle O
p O
. O
o I-GENE
. O
plus O
FB O
( O
1 I-GENE
. O
5 I-GENE
mg O
/ I-GENE
kg O
) O
sc O
; O
and O
( O
4 I-GENE
) O
CsA O
( O
15 O
mg O
/ I-GENE
kg O
) O
p O
. O
o I-GENE
. O
plus O
FB O
( O
1 I-GENE
. O
5 I-GENE
mg O
/ I-GENE
kg O
) O
sc O
. O

CsA O
alone O
resulted O
in O
elevated O
bone O
turnover O
. O

_RARE_ I-GENE
_RARE_ I-GENE
the O
_RARE_ I-GENE
_RARE_ I-GENE
in O
the O
_RARE_ I-GENE
_RARE_ I-GENE
of O
_RARE_ I-GENE
between O
1990 O
and O
1994 O
with O
the O
diagnosis O
of O
HIV I-GENE
infection O
, O
genital O
_RARE_ I-GENE
, O
genital O
herpes I-GENE
, O
non O
- I-GENE
specific I-GENE
genital O
infection O
( O
_RARE_ I-GENE
), O
_RARE_ I-GENE
and O
_RARE_ I-GENE
were O
included O
in O
the O
study O
. O

_RARE_ I-GENE
activation O
of O
the O
tyrosine I-GENE
kinase I-GENE
domain I-GENE
of O
the O
human I-GENE
trk I-GENE
proto I-GENE
- I-GENE
oncogene I-GENE
by O
fusion I-GENE
to O
a O
cell O
adhesion I-GENE
molecule I-GENE
. O

Northern O
blotting O
showed O
that O
_RARE_ I-GENE
, O
like I-GENE
_RARE_ I-GENE
, O
is O
expressed O
in O
all O
tissues O
tested O
, O
and O
that O
several O
mRNAs I-GENE
for O
_RARE_ I-GENE
can O
be O
detected O
. O

_RARE_ I-GENE
. O

The O
nucleotide I-GENE
sequence I-GENE
of O
22 O
, O
_RARE_ I-GENE
bp O
of O
the O
left O
arm O
of O
chromosome O
IV I-GENE
is O
described O
. O

They O
suggest O
that O
decreased O
steady O
- I-GENE
state O
levels O
of O
IME1 I-GENE
and O
_RARE_ I-GENE
mRNA I-GENE
were O
not O
_RARE_ I-GENE
the O
result O
of O
non O
- I-GENE
specific I-GENE
adverse O
affects O
on O
nucleic O
acid I-GENE
metabolism O
caused O
by O
the O
_RARE_ I-GENE
disruption O
. O

_RARE_ I-GENE
FL I-GENE
protein I-GENE
has O
been O
purified O
from O
a O
_RARE_ I-GENE
cell O
line O
and O
shown O
to O
be O
a O
65 O
kD I-GENE
_RARE_ I-GENE
- I-GENE
linked O
_RARE_ I-GENE
glycoprotein I-GENE
comprised O
of O
30 O
kD I-GENE
subunits I-GENE
, O
each O
containing O
12 O
kD I-GENE
of O
N I-GENE
- I-GENE
and O
O O
- I-GENE
linked O
sugars O
. O

The O
objective O
of O
this O
study O
was O
to O
examine O
the O
influence O
of O
_RARE_ I-GENE
and O
other O
serological O
factors I-GENE
upon O
the O
development O
of O
_RARE_ I-GENE
. O

_RARE_ I-GENE
exons O
of O
adenovirus I-GENE
late O
RNAs I-GENE
_RARE_ I-GENE
with O
snRNP I-GENE
in O
a O
specific I-GENE
nuclear I-GENE
domain I-GENE
. O

Using O
_RARE_ I-GENE
' O
s O
resin O
as O
a O
_RARE_ I-GENE
medium O
, O
we O
could O
observe O
thick O
specimens O
with O
oil O
immersion O
objective O
lens O
without O
the O
use O
of O
_RARE_ I-GENE
, O
then O
avoid O
air O
_RARE_ I-GENE
near O
the O
_RARE_ I-GENE
. O

The O
present O
study O
investigated O
dose O
dependence O
and O
time O
course O
effects O
of O
the O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
partial O
_RARE_ I-GENE
agonist O
, O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
( O
0 O
. O
005 O
- I-GENE
0 O
. O
30 O
mg O
/ I-GENE
kg O
) O
alone O
, O
and O
in O
combination O
with O
the O
_RARE_ I-GENE
receptor I-GENE
antagonists O
_RARE_ I-GENE
, O
_RARE_ I-GENE
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
_RARE_ I-GENE
( O
20 O
mg O
/ I-GENE
kg O
) O
in O
selectively O
_RARE_ I-GENE
alcohol O
- I-GENE
_RARE_ I-GENE
( O
P I-GENE
) O
rats O
provided O
a O
two O
- I-GENE
_RARE_ I-GENE
choice O
test O
between O
ethanol O
( O
_RARE_ I-GENE
) O
( O
10 O
% O
v I-GENE
/ I-GENE
v I-GENE
), O
and O
a O
_RARE_ I-GENE
saccharin O
( O
0 O
. O
_RARE_ I-GENE
% O
g O
/ I-GENE
v I-GENE
) O
solution O
. O

_RARE_ I-GENE
the O
_RARE_ I-GENE
of O
_RARE_ I-GENE
: O
a O
_RARE_ I-GENE
for O
_RARE_ I-GENE
. O

_RARE_ I-GENE
with O
_RARE_ I-GENE
_RARE_ I-GENE
group O
B I-GENE
has O
been O
difficult O
to O
detect O
, O
partly O
because O
this O
bacterial I-GENE
group O
' O
s O
_RARE_ I-GENE
is O
a O
weak O
_RARE_ I-GENE
. O

RNase I-GENE
protection O
analysis O
of O
two O
rRNA I-GENE
fragments I-GENE
whose O
genes I-GENE
are O
adjacent O
provided O
evidence O
for O
a O
_RARE_ I-GENE
transcript I-GENE
containing O
sequences I-GENE
from O
both O
, O
as O
well O
as O
separate O
small I-GENE
RNAs I-GENE
. O

_RARE_ I-GENE
encodes O
a O
novel O
essential O
protein I-GENE
of O
_RARE_ I-GENE
amino O
acids O
, O
which O
contains O
an O
extended O
predicted O
coiled O
- I-GENE
coil O
domain I-GENE
and O
is O
located O
both O
at O
nuclear I-GENE
pore I-GENE
complexes I-GENE
( O
_RARE_ I-GENE
) O
and O
in O
the O
cytoplasm O
. O

To O
map O
this O
regulatory I-GENE
serine I-GENE
phosphorylation O
site I-GENE
we O
developed O
a O
baculovirus O
- I-GENE
mediated O
expression O
system O
for O
wild I-GENE
- I-GENE
type I-GENE
_RARE_ I-GENE
II I-GENE
and O
for O
a O
series O
of O
_RARE_ I-GENE
II I-GENE
mutants I-GENE
which O
contained O
substitutions O
in O
one O
or O
more O
serine I-GENE
residues O
present O
in O
the O
N I-GENE
- I-GENE
terminal I-GENE
domain I-GENE
. O

The O
PAI I-GENE
- I-GENE
2 I-GENE
gene I-GENE
is O
one O
of O
the O
most O
TNF I-GENE
- I-GENE
responsive I-GENE
genes I-GENE
known O
and O
is O
also O
highly O
induced O
by O
the O
phorbol O
ester O
phorbol O
12 O
- I-GENE
myristate O
13 O
- I-GENE
acetate O
( O
PMA O
) O
and O
the O
phosphatase I-GENE
inhibitor I-GENE
, O
_RARE_ I-GENE
acid I-GENE
, O
in O
both O
HT O
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
and O
U O
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
cells O
. O

220 O
, O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
). O

These O
two O
_RARE_ I-GENE
contain O
a O
total O
of O
_RARE_ I-GENE
open O
reading O
frames O
( O
ORFs O
) O
in O
26 O
- I-GENE
29 O
putative O
operons I-GENE
; O
56 O
ORFs O
could O
be O
identified O
with O
reasonable O
_RARE_ I-GENE
. O

T I-GENE
., O
_RARE_ I-GENE
, O
S I-GENE
. O

Growth I-GENE
factors I-GENE
induce O
the O
expression O
of O
the O
immediate I-GENE
early I-GENE
gene I-GENE
products I-GENE
MAP I-GENE
kinase I-GENE
phosphatase I-GENE
- I-GENE
1 I-GENE
( O
MKP I-GENE
- I-GENE
1 I-GENE
), O
c I-GENE
- I-GENE
Fos I-GENE
and O
c I-GENE
- I-GENE
Jun I-GENE
. O

The O
up O
- I-GENE
regulation O
of O
E I-GENE
- I-GENE
selectin I-GENE
, O
one O
of O
the O
adhesion I-GENE
molecules I-GENE
on O
the O
endothelium O
, O
is O
an O
important O
event O
in O
the O
_RARE_ I-GENE
of O
the O
inflammatory O
response O
. O

The O
_RARE_ I-GENE
protein I-GENE
is O
_RARE_ I-GENE
in O
nuclei O
and O
could O
not O
be O
detected O
in O
the O
cytoplasmic I-GENE
fraction O
of O
cells O
subjected O
to O
nitrogen O
derepression O
or O
nitrogen O
repression O
, O
indicating O
that O
the O
nuclear I-GENE
import O
of O
_RARE_ I-GENE
is O
not O
regulated O
. O

In O
_RARE_ I-GENE
of O
much O
effort O
, O
no O
one O
has O
_RARE_ I-GENE
in O
_RARE_ I-GENE
and O
characterizing O
the O
enzyme I-GENE
( O
s O
) O
responsible O
for O
synthesis O
of O
_RARE_ I-GENE
, O
the O
major I-GENE
cell O
wall O
_RARE_ I-GENE
of O
plants O
. O

_RARE_ I-GENE
responses O
to O
reactive I-GENE
_RARE_ I-GENE
( O
with O
flow O
increase O
leading O
to O
endothelium O
- I-GENE
dependent I-GENE
_RARE_ I-GENE
) O
and O
to O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
; O
endothelium O
- I-GENE
independent O
_RARE_ I-GENE
) O
were O
recorded O
. O

During O
this O
period O
, O
administration O
of O
additional O
exogenous O
PRL I-GENE
did O
not O
stimulate O
further O
activation O
( O
binding I-GENE
) O
of O
the O
Stat I-GENE
factors I-GENE
. O

_RARE_ I-GENE
administration O
of O
L I-GENE
- I-GENE
5 I-GENE
- I-GENE
_RARE_ I-GENE
( O
L I-GENE
- I-GENE
5 I-GENE
- I-GENE
_RARE_ I-GENE
) O
at O
doses O
of O
25 O
to O
100 O
mg O
/ I-GENE
kg O
dramatically O
increase O
_RARE_ I-GENE
in O
mice O
. O

In O
the O
VA O
- I-GENE
_RARE_ I-GENE
mode O
, O
the O
_RARE_ I-GENE
was O
made O
with O
_RARE_ I-GENE
_RARE_ I-GENE
from O
the O
LV O
apex O
( O
_RARE_ I-GENE
) O
to O
the O
ascending O
aorta O
( O
outflow O
) O
( O
n O
= O
11 O
) O
or O
to O
the O
_RARE_ I-GENE
( O
n O
= O
12 O
). O

The O
evidence O
in O
support O
of O
this O
was O
derived O
from O
the O
fact O
that O
the O
affinity O
or O
interaction O
between O
the O
two O
subunits I-GENE
was O
impaired O
as O
indicated O
by O
the O
first O
order O
rate O
constant O
of O
hCG I-GENE
alpha I-GENE
1 I-GENE
beta I-GENE
( O
_RARE_ I-GENE
= O
4 I-GENE
. O
1 I-GENE
x O
10 O
(- O
2 I-GENE
) O
min O
- I-GENE
1 I-GENE
) O
at O
pH O
3 I-GENE
. O
0 O
at O
23 O
degrees O
C I-GENE
which O
is O
one O
order O
of O
magnitude O
greater O
relative O
to O
_RARE_ I-GENE
( O
_RARE_ I-GENE
= O
4 I-GENE
. O
6 I-GENE
x O
10 O
(- O
3 I-GENE
) O
min O
- I-GENE
1 I-GENE
). O

Factor I-GENE
V I-GENE
_RARE_ I-GENE
is O
a O
genetic O
disorder O
associated I-GENE
with O
an O
increased O
risk O
of O
venous O
thrombosis O
. O

This O
is O
the O
first O
determination O
of O
the O
complete O
secondary O
structure O
of O
an O
RNA I-GENE
spliced O
in O
a O
spliceosome O
. O

The O
majority O
of O
the O
cases O
with O
0 O
- I-GENE
I I-GENE
or O
0 O
- I-GENE
III I-GENE
components O
were O
_RARE_ I-GENE
. O
cancer O
. O

These O
patients O
appear O
to O
have O
slightly O
better O
pulmonary O
function O
and O
nutritional O
status O
; O
yet O
, O
they O
seem O
to O
have O
a O
higher O
degree O
of O
health O
care O
utilization O
. O

This O
observation O
_RARE_ I-GENE
for O
_RARE_ I-GENE
monitoring O
of O
calcium O
and O
alkaline I-GENE
phosphatase I-GENE
values O
and O
possible O
_RARE_ I-GENE
of O
vitamin O
D I-GENE
intake O
when O
_RARE_ I-GENE
are O
used O
for O
extended O
periods O
. O

We O
have O
found O
that O
_RARE_ I-GENE
is O
also O
required O
for O
the O
bipolar O
budding I-GENE
pattern O
and O
that O
it O
encodes O
a O
novel O
protein I-GENE
with O
a O
predicted O
coiled O
- I-GENE
coil O
domain I-GENE
. O

_RARE_ I-GENE
from O
the O
small I-GENE
GTP I-GENE
- I-GENE
binding I-GENE
proteins I-GENE
Rac1 I-GENE
and O
Cdc42 I-GENE
to O
the O
c I-GENE
- I-GENE
Jun I-GENE
N I-GENE
- I-GENE
terminal I-GENE
kinase I-GENE
/ I-GENE
stress O
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
pathway O
. O

_RARE_ I-GENE
identities O
of O
the O
mouse I-GENE
_RARE_ I-GENE
to O
mouse I-GENE
_RARE_ I-GENE
, O
mouse I-GENE
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
and O
human I-GENE
_RARE_ I-GENE
receptors I-GENE
are O
53 O
, O
42 O
, O
and O
31 O
, O
respectively O
. O

_RARE_ I-GENE
with O
the O
previous O
observation O
that O
CBF I-GENE
binding I-GENE
to O
the O
_RARE_ I-GENE
site I-GENE
is O
enhanced O
by O
_RARE_ I-GENE
and O
EDTA O
, O
these O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
specifically O
stimulate O
_RARE_ I-GENE
- I-GENE
directed O
transcription I-GENE
. O

The O
human I-GENE
gene I-GENE
fragment I-GENE
ligated O
to O
the O
minimal I-GENE
rat I-GENE
liver O
_RARE_ I-GENE
promoter I-GENE
was O
shown O
to O
work O
as O
an O
enhancer I-GENE
in O
the O
hepatocyte I-GENE
transfection O
system O
. O

To O
test O
the O
role O
of O
_RARE_ I-GENE
in O
human I-GENE
reproductive O
axis O
, O
128 I-GENE
healthy O
children O
, O
68 O
boys O
and O
60 O
girls O
, O
were O
studied O
. O

However O
, O
the O
truncated I-GENE
_RARE_ I-GENE
receptor I-GENE
lacks O
the O
most O
C I-GENE
- I-GENE
terminal I-GENE
tyrosine I-GENE
residue O
in O
the O
intracellular O
domain I-GENE
which O
is O
believed O
to O
be O
essential O
for O
activation O
of O
the O
beta I-GENE
- I-GENE
casein I-GENE
promoter I-GENE
. O

This O
report O
provides O
further O
evidence O
for O
the O
_RARE_ I-GENE
in O
the O
control O
of O
_RARE_ I-GENE
, O
and O
a O
_RARE_ I-GENE
is O
postulated O
for O
the O
development O
of O
the O
_RARE_ I-GENE
_RARE_ I-GENE
nystagmus O
. O

_RARE_ I-GENE
has O
substantial O
efficacy O
when O
combined O
with O
other O
agents O
. O

_RARE_ I-GENE
- I-GENE
four O
percent O
of O
the O
_RARE_ I-GENE
were O
_RARE_ I-GENE
, O
and O
90 O
% O
of O
the O
_RARE_ I-GENE
exhibited O
some O
pathologic O
changes O
, O
including O
chronic O
_RARE_ I-GENE
( O
49 O
. O
5 I-GENE
%) O
and O
follicular O
_RARE_ I-GENE
( O
10 O
%), O
among O
others O
. O

The O
assessment O
using O
7 O
H I-GENE
9 O
liquid O
medium O
by O
the O
former O
author O
demonstrated O
the O
potent O
activities O
of O
both O
CS I-GENE
- I-GENE
_RARE_ I-GENE
* I-GENE
and O
_RARE_ I-GENE
( O
_RARE_ I-GENE
), O
followed O
by O
AM I-GENE
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
), O
_RARE_ I-GENE
( O
_RARE_ I-GENE
), O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
* I-GENE
in O
sequence I-GENE
. O

The O
_RARE_ I-GENE
gene I-GENE
, O
encoding O
a O
protein I-GENE
kinase I-GENE
required O
for O
pheromone O
signal I-GENE
transduction O
, O
has O
recently O
been O
identified O
in O
a O
genetic O
screen O
for O
high O
- I-GENE
gene I-GENE
- I-GENE
dosage O
suppressors O
of O
a O
partly O
defective O
G I-GENE
beta I-GENE
mutation I-GENE
. O

This O
enzyme I-GENE
is O
designated O
( O
1 I-GENE
--> I-GENE
4 I-GENE
)- I-GENE
beta I-GENE
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
X I-GENE
- I-GENE
I I-GENE
. O

Magnetic O
resonance O
imaging O
in O
_RARE_ I-GENE
arthritis O
. O

Moloney O
murine I-GENE
leukemia I-GENE
virus I-GENE
( O
_RARE_ I-GENE
)- I-GENE
derived O
_RARE_ I-GENE
- I-GENE
based O
retroviral I-GENE
vectors O
were O
engineered I-GENE
to O
allow O
constitutive O
and O
Tat I-GENE
( O
trans O
- I-GENE
activator I-GENE
of O
transcription I-GENE
)- I-GENE
inducible I-GENE
expression O
of O
five O
_RARE_ I-GENE
_RARE_ I-GENE
targeted O
against O
highly O
conserved O
sequences I-GENE
within O
the O
group O
antigen I-GENE
( O
Gag I-GENE
), O
protease I-GENE
( O
Pro I-GENE
), O
reverse I-GENE
transcriptase I-GENE
( O
RT I-GENE
), O
tat I-GENE
, O
and O
envelope I-GENE
( O
Env I-GENE
) O
coding O
regions O
of O
human I-GENE
immunodeficiency I-GENE
virus I-GENE
type I-GENE
- I-GENE
1 I-GENE
( O
HIV I-GENE
- I-GENE
1 I-GENE
) O
RNA I-GENE
. O

REM O
sleep O
deprivation O
was O
performed O
using O
the O
_RARE_ I-GENE
technique O
. O

The O
same O
ligands O
also O
exhibit O
a O
similar O
inhibitory I-GENE
effect O
on O
PDGF I-GENE
- I-GENE
BB I-GENE
- I-GENE
dependent I-GENE
[ O
3H O
] O
thymidine I-GENE
incorporation O
in O
_RARE_ I-GENE
cells O
expressing O
the O
PDGF I-GENE
beta I-GENE
- I-GENE
receptors I-GENE
. O

We O
analyzed O
serial O
biopsy O
specimens O
from O
eight O
patients O
with O
FL I-GENE
for O
secondary O
alterations O
of O
the O
rearranged I-GENE
bcl I-GENE
- I-GENE
2 I-GENE
gene I-GENE
in O
the O
breakpoint I-GENE
and O
open O
reading O
frame O
( O
ORF I-GENE
) O
regions O
. O

In O
all O
eight O
cases O
, O
neither O
FL I-GENE
nor O
_RARE_ I-GENE
cells O
showed O
alterations O
of O
bcl I-GENE
- I-GENE
2 I-GENE
gene I-GENE
sequences I-GENE
in O
the O
breakpoint I-GENE
region O
, O
suggesting O
high O
conservation O
of O
the O
bcl I-GENE
- I-GENE
2 I-GENE
gene I-GENE
during O
both O
t I-GENE
( O
14 O
; O
18 O
) O
translocation O
and O
morphologic O
transformation O
of O
the O
FL I-GENE
cells O
. O

BACKGROUND O
: O
The O
_RARE_ I-GENE
- I-GENE
corrected O
QT O
( O
_RARE_ I-GENE
) O
interval O
during O
exercise O
has O
been O
used O
as O
a O
marker O
for O
ischemic O
disease O
, O
_RARE_ I-GENE
substrate I-GENE
and O
the O
long O
QT O
syndrome O
. O

An O
essential O
role O
of O
c I-GENE
- I-GENE
Jun I-GENE
and O
c I-GENE
- I-GENE
Fos I-GENE
in O
basal O
and O
PMA O
- I-GENE
stimulated O
transcription I-GENE
of O
the O
PAI I-GENE
- I-GENE
1 I-GENE
gene I-GENE
is O
demonstrated O
by O
our O
finding O
that O
antisense I-GENE
c I-GENE
- I-GENE
jun I-GENE
and O
c I-GENE
- I-GENE
fos I-GENE
_RARE_ I-GENE
both O
strongly O
reduced O
basal O
and O
PMA O
- I-GENE
stimulated O
PAI I-GENE
- I-GENE
1 I-GENE
synthesis O
. O

_RARE_ I-GENE
- I-GENE
inhibitory I-GENE
factor I-GENE
( O
_RARE_ I-GENE
) O
is O
a O
_RARE_ I-GENE
able O
to O
regulate O
the O
differentiation O
and O
the O
survival O
of O
many O
cell O
types O
, O
which O
include O
some O
neuronal O
populations O
. O

To O
analyze O
the O
mechanism O
of O
fos I-GENE
/ I-GENE
jun I-GENE
activation O
by O
_RARE_ I-GENE
we O
have O
used O
electrophoretic O
mobility I-GENE
shift O
and O
transient O
expression O
assays O
of O
reporter I-GENE
gene I-GENE
constructs I-GENE
containing O
response O
elements O
for O
12 O
- I-GENE
O O
- I-GENE
_RARE_ I-GENE
- I-GENE
phorbol O
- I-GENE
13 O
- I-GENE
acetate O
( O
TRE I-GENE
), O
serum I-GENE
( O
SRE O
), O
cAMP I-GENE
( O
CRE O
), O
and O
aromatic O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
from O
the O
fos I-GENE
and O
jun I-GENE
genes I-GENE
fused O
to O
the O
_RARE_ I-GENE
luciferase I-GENE
gene I-GENE
under O
the O
control O
of O
the O
SV40 I-GENE
minimal I-GENE
promoter I-GENE
. O

The O
optimal O
sequence I-GENE
for O
interaction O
with O
mu I-GENE
2 I-GENE
and O
with O
AP I-GENE
- I-GENE
2 I-GENE
has O
tyrosine I-GENE
as O
an O
anchor I-GENE
and O
_RARE_ I-GENE
arginine I-GENE
at O
position O
Y I-GENE
+ I-GENE
2 I-GENE
and O
leucine I-GENE
at O
position O
Y I-GENE
+ I-GENE
3 I-GENE
. O

STK I-GENE
/ I-GENE
_RARE_ I-GENE
- I-GENE
expressing O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
pro I-GENE
- I-GENE
B I-GENE
cells O
( O
_RARE_ I-GENE
/ I-GENE
STK I-GENE
) O
exhibited O
_RARE_ I-GENE
- I-GENE
dependent I-GENE
growth I-GENE
, O
whereas O
STK I-GENE
/ I-GENE
_RARE_ I-GENE
- I-GENE
expressing O
mouse I-GENE
_RARE_ I-GENE
cells O
( O
_RARE_ I-GENE
/ I-GENE
STK I-GENE
) O
displayed O
_RARE_ I-GENE
- I-GENE
induced O
apoptosis O
. O

In O
vitro O
DNase I-GENE
I I-GENE
footprinting O
showed O
that O
OxyR I-GENE
- I-GENE
_RARE_ I-GENE
protected O
_RARE_ I-GENE
from O
- I-GENE
104 O
to O
- I-GENE
46 O
on O
the O
top O
strand O
and O
produced O
a O
protection O
pattern O
characteristic O
of O
reduced O
wild I-GENE
- I-GENE
type I-GENE
OxyR I-GENE
. O

_RARE_ I-GENE
binds O
specifically O
to O
a O
GST I-GENE
- I-GENE
_RARE_ I-GENE
fusion I-GENE
in O
the O
absence O
of O
any O
other O
yeast I-GENE
protein I-GENE
. O

In O
contrast O
, O
_RARE_ I-GENE
_RARE_ I-GENE
cells O
constitutively O
_RARE_ I-GENE
agar O
medium O
, O
whereas O
a O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
triple O
mutant I-GENE
does O
not O
, O
indicating O
that O
_RARE_ I-GENE
and O
_RARE_ I-GENE
share O
a O
role O
in O
negatively O
regulating O
the O
invasive O
growth I-GENE
pathway O
. O

_RARE_ I-GENE
activation O
of O
the O
HIV I-GENE
- I-GENE
1 I-GENE
LTR I-GENE
promoter I-GENE
by O
the O
viral I-GENE
Tat I-GENE
protein I-GENE
is O
_RARE_ I-GENE
similar O
to O
trans O
- I-GENE
activation O
within O
a O
cell O
. O

Comparison O
of O
the O
sequences I-GENE
of O
the O
_RARE_ I-GENE
repeat I-GENE
regions O
of O
p62 I-GENE
and O
_RARE_ I-GENE
indicated O
that O
_RARE_ I-GENE
was O
probably O
interacting I-GENE
with O
the O
phenylalanine I-GENE
- I-GENE
containing O
core I-GENE
of O
these O
repeats I-GENE
and O
not O
the O
intervening O
hydrophilic O
_RARE_ I-GENE
. O

This O
is O
the O
first O
report O
of O
the O
successful O
resection O
of O
a O
_RARE_ I-GENE
_RARE_ I-GENE
in O
the O
renal O
_RARE_ I-GENE
tissue I-GENE
and O
extending O
into O
the O
inferior O
_RARE_ I-GENE
_RARE_ I-GENE
. O

Transient O
expression O
of O
_RARE_ I-GENE
- I-GENE
1 I-GENE
in O
_RARE_ I-GENE
stimulated O
vs O
- I-GENE
1 I-GENE
dependent I-GENE
activation O
of O
the O
- I-GENE
76 I-GENE
/ I-GENE
_RARE_ I-GENE
. O
8 O
minimal I-GENE
promoter I-GENE
. O

_RARE_ I-GENE
in O
_RARE_ I-GENE
the O
limited O
range O
of O
age O
and O
_RARE_ I-GENE
, O
advantages O
and O
_RARE_ I-GENE
of O
the O
drug O
are O
discussed O
, O
comparing O
the O
experimental O
results O
with O
those O
derived O
from O
the O
literature O
. O

Blood O
sampling O
procedures O
were O
_RARE_ I-GENE
. O

Analysis O
of O
one O
cDNA I-GENE
revealed O
an O
unusual O
splicing O
event O
involving O
_RARE_ I-GENE
and O
a O
tandemly O
linked O
gene I-GENE
_RARE_ I-GENE
and O
suggests O
a O
potential O
mechanism O
for O
_RARE_ I-GENE
the O
_RARE_ I-GENE
protein I-GENE
in O
the O
conserved O
C I-GENE
- I-GENE
terminal I-GENE
domain I-GENE
. O

A I-GENE
given O
standard O
input O
function O
and O
a O
given O
value O
of O
distribution O
volume O
( O
_RARE_ I-GENE
) O
used O
for O
the O
rCBF O
measurement O
of O
this O
method O
were O
calculated O
from O
the O
dynamic O
study O
by O
six O
normal O
volunteers O
. O

They O
lack O
a O
predicted O
single O
stranded I-GENE
( O
_RARE_ I-GENE
) O
DNA I-GENE
binding I-GENE
motif I-GENE
that O
is O
unique O
the O
large O
terminase I-GENE
proteins I-GENE
in O
T4 I-GENE
_RARE_ I-GENE
, O
and O
that O
has O
been O
implicated O
in O
_RARE_ I-GENE
ssDNA I-GENE
regions O
in O
replicating I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
to O
be O
_RARE_ I-GENE
. O

It O
can O
be O
concluded O
that O
in O
_RARE_ I-GENE
subjects O
, O
uric O
acid I-GENE
and O
_RARE_ I-GENE
oxidase I-GENE
have O
significant O
association O
with O
blood O
pressure O
and O
thus O
are O
one O
of O
the O
many O
factors I-GENE
which O
are O
involved O
in O
the O
cause O
or O
effect O
of O
hypertension O
. O

_RARE_ I-GENE
of O
expressed O
recombinant I-GENE
proteins I-GENE
with O
the O
monoclonal I-GENE
_RARE_ I-GENE
antibody I-GENE
localized O
the O
_RARE_ I-GENE
epitope O
to O
the O
carboxyl O
end O
of O
the O
protein I-GENE
. O

We O
_RARE_ I-GENE
that O
the O
dominant I-GENE
negative O
inhibition O
results O
from O
both O
direct O
proteolysis O
of O
the O
beta I-GENE
- I-GENE
galactosidase I-GENE
tetramer I-GENE
by O
the O
fusion I-GENE
subunit I-GENE
and O
_RARE_ I-GENE
of O
the O
tetramer I-GENE
to O
the O
_RARE_ I-GENE
. O

The O
current O
study O
defines O
the O
_RARE_ I-GENE
- I-GENE
and O
FAK I-GENE
- I-GENE
interaction O
domains I-GENE
on O
paxillin I-GENE
and O
identifies O
the O
principal O
paxillin I-GENE
focal I-GENE
adhesion I-GENE
targeting O
motif I-GENE
. O

These O
data O
demonstrate O
the O
presence O
of O
a O
single O
binding I-GENE
site I-GENE
for O
_RARE_ I-GENE
, O
and O
at O
least O
two O
binding I-GENE
sites I-GENE
for O
FAK I-GENE
that O
are O
separated O
by O
an O
intervening O
stretch O
of O
100 O
amino O
acids O
. O

These O
data O
demonstrate O
that O
paxillin I-GENE
localizes O
to O
focal I-GENE
adhesions O
independent O
of O
interactions O
with O
_RARE_ I-GENE
and O
/ I-GENE
or O
FAK I-GENE
, O
and O
represents O
the O
first O
definitive O
_RARE_ I-GENE
of O
LIM I-GENE
domains I-GENE
functioning O
as O
a O
primary O
determinant O
of O
protein I-GENE
subcellular O
localization O
to O
focal I-GENE
adhesions O
. O

A I-GENE
single O
protease I-GENE
- I-GENE
resistant O
structure O
formed O
by O
the O
_RARE_ I-GENE
of O
both O
PDZ I-GENE
repeats I-GENE
1 I-GENE
and O
2 I-GENE
( O
_RARE_ I-GENE
- I-GENE
2 I-GENE
) O
contains O
the O
protein I-GENE
4 I-GENE
. O
1 I-GENE
- I-GENE
binding I-GENE
site I-GENE
. O

Several O
agents O
have O
been O
_RARE_ I-GENE
for O
treatment O
, O
often O
limited O
by O
toxic O
side O
effects O
. O

_RARE_ I-GENE
had O
higher O
hepatic I-GENE
Cu I-GENE
concentrations O
than O
did O
_RARE_ I-GENE
on O
d O
60 O
( O
_RARE_ I-GENE
vs O
. O

_RARE_ I-GENE
- I-GENE
1 I-GENE
beta I-GENE
is O
a O
95 O
- I-GENE
kDa I-GENE
truncated I-GENE
version O
of O
_RARE_ I-GENE
- I-GENE
1 I-GENE
alpha I-GENE
that O
results O
from O
alternative O
splicing O
of O
a O
57 O
- I-GENE
bp O
exon O
as O
confirmed O
by O
genomic O
cloning O
. O

These O
results O
are O
consistent O
with O
the O
well O
established O
polarity O
of O
RXR I-GENE
heterodimer O
binding I-GENE
to O
bipartite O
hormone I-GENE
response O
elements O
, O
with O
the O
VDR I-GENE
_RARE_ I-GENE
the O
3 I-GENE
'- O
half O
- I-GENE
element I-GENE
. O

_RARE_ I-GENE
gamma I-GENE
mRNA I-GENE
levels O
were O
reduced O
by O
95 O
% O
with O
3 I-GENE
nM O
TNF I-GENE
alpha I-GENE
treatment O
for O
24 O
h O
. O

_RARE_ I-GENE
III I-GENE
to O
VIII I-GENE
, O
which O
_RARE_ I-GENE
the O
coding O
region O
and O
the O
3 I-GENE
' O
untranslated O
region O
, O
are O
almost O
identical O
in O
all O
types O
of O
_RARE_ I-GENE
or O
_RARE_ I-GENE
cDNAs I-GENE
. O

Growth I-GENE
factor I-GENE
allows O
effective O
dose O
- I-GENE
intensive O
regimen O
in O
advanced O
breast O
cancer O
patients O
. O

Recombinant I-GENE
erythropoietin I-GENE
( O
r O
- I-GENE
_RARE_ I-GENE
) O
in O
the O
treatment O
of O
anemia I-GENE
in O
multiple O
myeloma O

In O
1993 O
and O
1994 O
and O
infection O
with O
body O
_RARE_ I-GENE
was O
_RARE_ I-GENE
41 O
times O
in O
31 O
patients O
at O
the O
_RARE_ I-GENE
for O
_RARE_ I-GENE
of O
the O
_RARE_ I-GENE
Health O
_RARE_ I-GENE
of O
_RARE_ I-GENE
. O

_RARE_ I-GENE
- I-GENE
ras I-GENE
and O
p53 I-GENE
mutations O
in O
pancreatic O
_RARE_ I-GENE
adenocarcinoma O
. O

_RARE_ I-GENE
data O
are O
quite O
_RARE_ I-GENE
but O
_RARE_ I-GENE
death O
occurring O
during O
_RARE_ I-GENE
activity O
is O
probably O
not O
a O
rare O
occurrence O
. O

However O
, O
the O
ratio O
M I-GENE
/ I-GENE
_RARE_ I-GENE
provides O
a O
useful O
index O
that O
seems O
to O
be O
independent O
of O
the O
metabolic O
demand O
. O

Rat I-GENE
liver O
catalase I-GENE
is O
_RARE_ I-GENE
to O
_RARE_ I-GENE
by O
its O
C I-GENE
- I-GENE
terminal I-GENE
_RARE_ I-GENE
Ala I-GENE
- I-GENE
Asn O
- I-GENE
Leu I-GENE
, O
not O
by O
the O
internal O
Ser O
- I-GENE
Lys O
- I-GENE
Leu I-GENE
motif I-GENE
. O

The O
mobility I-GENE
shift O
assay O
of O
the O
65 O
bp O
(- O
_RARE_ I-GENE
/ I-GENE
- I-GENE
_RARE_ I-GENE
) O
fragment I-GENE
with O
nuclear I-GENE
extract O
from O
the O
dark O
- I-GENE
adapted O
sample O
showed O
an O
additional O
band O
, O
not O
seen O
with O
the O
light I-GENE
- I-GENE
grown O
sample O
. O

These O
data O
provide O
strong O
evidence O
that O
E2F I-GENE
or O
an O
E2F I-GENE
- I-GENE
related I-GENE
transcription I-GENE
factor I-GENE
is O
involved O
in O
the O
regulation O
of O
_RARE_ I-GENE
myosin I-GENE
expression O
. O

When O
the O
E1A I-GENE
N I-GENE
- I-GENE
terminus O
is O
used O
as O
a O
competitor O
in O
_RARE_ I-GENE
experiments O
it O
abolishes O
CBP I-GENE
- I-GENE
induced O
activation O
of O
E2F1 I-GENE
/ I-GENE
_RARE_ I-GENE
, O
whereas O
an O
E1A I-GENE
mutant I-GENE
lacking O
CBP I-GENE
binding I-GENE
ability O
fails O
to O
do O
so O
. O

_RARE_ I-GENE
Maf I-GENE
proteins I-GENE
interact O
with O
the O
human I-GENE
transcription I-GENE
factor I-GENE
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
/ I-GENE
LCR I-GENE
- I-GENE
F1 I-GENE
. O

On O
the O
third O
_RARE_ I-GENE
water O
( O
W I-GENE
) O
was O
_RARE_ I-GENE
throughout O
the O
run O
. O

The O
effect O
of O
maternal I-GENE
ingestion O
of O
the O
reduced O
energy O
_RARE_ I-GENE
_RARE_ I-GENE
was O
investigated O
in O
_RARE_ I-GENE
: O
_RARE_ I-GENE
strain O
pregnant O
rabbits O
. O

Moreover O
, O
the O
same O
mutations O
alter O
the O
structure O
of O
junB I-GENE
5 I-GENE
' O
flanking O
DNA I-GENE
within O
chromatin O
. O

The O
_RARE_ I-GENE
- I-GENE
H1 I-GENE
/ I-GENE
_RARE_ I-GENE
- I-GENE
H2 I-GENE
gene I-GENE
transcriptional O
activity O
ratio O
varied O
depending O
on O
the O
cell O
line O
. O

CONCLUSION O
: O
Intravenous O
diazepam I-GENE
administration O
before O
_RARE_ I-GENE
produces O
a O
significant O
fall O
in O
_RARE_ I-GENE
during O
the O
procedure O
, O
and O
so O
should O
be O
_RARE_ I-GENE
; O
continuous O
monitoring O
of O
_RARE_ I-GENE
should O
be O
done O
during O
_RARE_ I-GENE
. O

The O
nucleotide I-GENE
sequence I-GENE
alignment O
between O
mouse I-GENE
and O
human I-GENE
CA I-GENE
IV I-GENE
shows O
69 O
% O
identity O
in O
the O
coding O
region O
and O
all O
of O
the O
exon O
- I-GENE
intron O
boundaries O
are O
conserved O
, O
as O
are O
the O
sizes O
of O
the O
introns O
. O

_RARE_ I-GENE
on O
the O
cost O
_RARE_ I-GENE
correlated O
negatively O
with O
G I-GENE
Hb I-GENE
, O
suggesting O
better O
_RARE_ I-GENE
control O
with O
greater O
_RARE_ I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
: O
_RARE_ I-GENE
studies O
, O
research O
studies O
, O
review O
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
reports O
_RARE_ I-GENE
to O
_RARE_ I-GENE
of O
lung O
cancer O
. O

RESULTS O
: O
The O
age O
distribution O
was O
28 O
to O
83 O
years O
old O
( O
mean O
was O
54 I-GENE
. O
1 I-GENE
years O
). O

Histological O
changes O
, O
including O
cortical O
cell O
_RARE_ I-GENE
and O
hemorrhage O
occurring O
during O
the O
neonatal O
period O
, O
would O
seem O
to O
have O
crucial O
relevance O
to O
the O
remodeling O
of O
the O
adrenal O
_RARE_ I-GENE
. O

Furthermore O
, O
co O
- I-GENE
expression O
of O
both O
_RARE_ I-GENE
and O
p54 I-GENE
subunits I-GENE
markedly O
altered O
the O
subcellular O
distribution O
of O
_RARE_ I-GENE
; O
co O
- I-GENE
expressed O
_RARE_ I-GENE
was O
transported O
into O
the O
nucleus O
as O
efficiently O
as O
p54 I-GENE
. O

The O
results O
suggest O
that O
, O
although O
both O
the O
N I-GENE
- I-GENE
and O
C I-GENE
- I-GENE
terminal I-GENE
regions O
of O
_RARE_ I-GENE
bind O
actin I-GENE
, O
the O
properties O
of O
these O
two O
regions O
of O
the O
protein I-GENE
are O
distinct O
. O

_RARE_ I-GENE
.) O
embryo O
library O
. O

The O
accumulation O
of O
both O
_RARE_ I-GENE
and O
_RARE_ I-GENE
mRNAs I-GENE
is O
induced O
by O
the O
addition O
of O
exogenous O
sugars O
and O
this O
induction O
appears O
to O
be O
dependent I-GENE
on O
sugar I-GENE
uptake O
and O
metabolism O
, O
because O
_RARE_ I-GENE
and O
3 I-GENE
- I-GENE
O O
- I-GENE
_RARE_ I-GENE
do O
not O
stimulate O
mRNA I-GENE
accumulation O
. O

Using O
the O
yeast I-GENE
one O
- I-GENE
hybrid O
screen O
with O
integrated O
_RARE_ I-GENE
and O
flanking O
DNA I-GENE
as O
_RARE_ I-GENE
, O
the O
predominant O
clone O
obtained O
was O
bovine I-GENE
_RARE_ I-GENE
. O

As O
the O
rate O
of O
protein I-GENE
synthesis O
decreases O
during O
late O
embryogenesis O
, O
levels O
of O
_RARE_ I-GENE
- I-GENE
1 I-GENE
and O
its O
cognate I-GENE
mRNA I-GENE
decline O
_RARE_ I-GENE
. O

These O
findings O
suggest O
that O
_RARE_ I-GENE
proteolysis O
in O
vivo O
may O
reflect O
the O
activity O
of O
multiple O
ICE I-GENE
/ I-GENE
_RARE_ I-GENE
- I-GENE
3 I-GENE
proteases I-GENE
whose O
partial O
sensitivity O
to O
_RARE_ I-GENE
- I-GENE
CHO O
_RARE_ I-GENE
a O
limited O
contribution O
from O
_RARE_ I-GENE
, O
or O
an O
ICE I-GENE
/ I-GENE
_RARE_ I-GENE
- I-GENE
3 I-GENE
protease I-GENE
less O
sensitive O
than O
_RARE_ I-GENE
to O
_RARE_ I-GENE
- I-GENE
CHO O
inhibition O
. O

In O
_RARE_ I-GENE
and O
_RARE_ I-GENE
v I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
transformed O
fibroblasts O
, O
almost O
all O
of O
the O
total O
_RARE_ I-GENE
and O
about O
40 I-GENE
% O
of O
total O
p130 I-GENE
( O
Cas I-GENE
) O
co O
- I-GENE
_RARE_ I-GENE
with O
membranes O
composed O
primarily O
of O
endoplasmic O
reticulum O
. O

_RARE_ I-GENE
residues O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
on O
_RARE_ I-GENE
with O
the O
conserved O
AF I-GENE
- I-GENE
2 I-GENE
domain I-GENE
from O
the O
vitamin O
D3 I-GENE
receptor I-GENE
or O
the O
estrogen I-GENE
receptor I-GENE
results O
in O
a O
receptor I-GENE
with O
wild I-GENE
- I-GENE
type I-GENE
or O
low O
transcriptional O
activity O
, O
respectively O
. O

_RARE_ I-GENE
G I-GENE
- I-GENE
to O
- I-GENE
A I-GENE
substitution O
in O
a O
single O
codon O
of O
SREBP I-GENE
cleavage O
- I-GENE
activating I-GENE
protein I-GENE
causes O
sterol I-GENE
resistance O
in O
three O
mutant I-GENE
Chinese O
hamster I-GENE
ovary O
cell O
lines O
. O

The O
Escherichia I-GENE
coli I-GENE
_RARE_ I-GENE
- I-GENE
repressor I-GENE
( O
_RARE_ I-GENE
) O
operator I-GENE
system O
was O
used O
to O
develop O
a O
variation O
of O
the O
yeast I-GENE
two O
- I-GENE
hybrid O
assay O
in O
which O
_RARE_ I-GENE
of O
protein I-GENE
- I-GENE
protein I-GENE
interactions O
can O
be O
identified O
by O
a O
positive O
selection O
. O

Recent O
studies O
have O
suggested O
that O
SHP I-GENE
- I-GENE
1 I-GENE
regulates O
the O
function O
of O
Jak I-GENE
family I-GENE
tyrosine I-GENE
kinases I-GENE
, O
as O
shown O
by O
its O
constitutive O
association O
with O
the O
_RARE_ I-GENE
kinase I-GENE
and O
the O
_RARE_ I-GENE
of O
Jak I-GENE
kinases I-GENE
in O
the O
_RARE_ I-GENE
cells O
that O
lack O
functional O
SHP I-GENE
- I-GENE
1 I-GENE
. O

Administration O
of O
a O
second O
dose O
of O
vaccine O
during O
the O
outbreak O
was O
not O
protective O
. O

_RARE_ I-GENE
, O
as O
_RARE_ I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
in O
assessing O
exposure O
have O
not O
yet O
translated O
into O
clear O
and O
consistent O
findings O
. O

Biol O
. O

Structural O
basis O
for O
activation O
of O
human I-GENE
lymphocyte I-GENE
kinase I-GENE
Lck I-GENE
upon O
tyrosine I-GENE
phosphorylation O
. O

_RARE_ I-GENE
morphology O
of O
the O
olfactory O
bulb O
in O
man O
and O
certain O
non O
- I-GENE
human I-GENE
mammals O

From O
these O
results O
, O
we O
concluded O
that O
this O
ORF I-GENE
is O
the O
_RARE_ I-GENE
gene I-GENE
. O

FK506 O
is O
10 O
- I-GENE
to O
100 O
- I-GENE
fold O
more O
potent O
than O
cyclosporin O
A I-GENE
in O
preventing O
organ O
rejection O
and O
in O
toxicity O
. O

These O
results O
suggest O
that O
_RARE_ I-GENE
regulates O
cytoskeletal O
_RARE_ I-GENE
at O
least O
through O
_RARE_ I-GENE
and O
_RARE_ I-GENE
. O

The O
_RARE_ I-GENE
expression O
profile O
is O
similar O
, O
to O
that O
of O
_RARE_ I-GENE
, O
which O
localizes O
to O
the O
animal O
hemisphere O
of O
oocytes O
and O
is O
abundantly O
expressed O
in O
the O
embryo O
. O

_RARE_ I-GENE
N1 O
, O
P3 I-GENE
and O
CNV O
were O
recorded O
during O
a O
CNV O
_RARE_ I-GENE
in O
a O
simple O
reaction O
time O
task O
with O
a O
constant O
_RARE_ I-GENE
interval O
( O
_RARE_ I-GENE
) O
of O
1 I-GENE
sec O
. O

Therefore O
, O
both O
the O
_RARE_ I-GENE
and O
the O
Japanese O
samples O
collected O
in O
high O
- I-GENE
risk O
areas O
showed O
higher O
_RARE_ I-GENE
rates O
than O
the O
Japanese O
ones O
in O
a O
low O
- I-GENE
risk O
area O
, O
with O
a O
statistical O
significance O
( O
p O
< O
0 O
. O
001 O
), O
_RARE_ I-GENE
- I-GENE
square O
test O
). O

Regulation O
of O
_RARE_ I-GENE
and O
_RARE_ I-GENE
expression O
was O
studied O
using O
lacZ I-GENE
fusions I-GENE
and O
both O
genes I-GENE
were O
found O
to O
be O
several O
times O
less O
expressed O
in O
the O
absence O
of O
the O
transcription I-GENE
activator I-GENE
_RARE_ I-GENE
. O

Several O
particular O
features O
of O
this O
polypeptide I-GENE
fragment I-GENE
from O
the O
hamster I-GENE
_RARE_ I-GENE
- I-GENE
tRNA I-GENE
synthetase I-GENE
suggest O
that O
it O
is O
implicated O
in O
the O
assembly O
of O
that O
enzyme I-GENE
within O
the O
_RARE_ I-GENE
complex I-GENE
. O

He O
is O
well O
, O
five O
years O
after O
relapse O
. O

Comparison O
of O
the O
proportion O
of O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
and O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
substitutions O
occurring O
per O
site I-GENE
within O
_RARE_ I-GENE
variable O
region O
genes I-GENE
demonstrated O
a O
reduction O
in O
_RARE_ I-GENE
in O
the O
_RARE_ I-GENE
regions O
compared O
with O
_RARE_ I-GENE
in O
the O
presumed I-GENE
MHC I-GENE
contact O
regions O
( O
_RARE_ I-GENE
and O
_RARE_ I-GENE
). O

The O
effects O
of O
oral O
_RARE_ I-GENE
sulfate I-GENE
( O
_RARE_ I-GENE
) O
( O
0 O
. O
5 I-GENE
mg O
/ I-GENE
kg O
/ I-GENE
day O
) O
on O
_RARE_ I-GENE
, O
body O
composition O
, O
and O
performance O
were O
investigated O
in O
a O
12 O
- I-GENE
week O
, O
double O
- I-GENE
blind O
, O
placebo O
- I-GENE
controlled O
trial O
involving O
weight O
- I-GENE
training O
volunteers O
. O

_RARE_ I-GENE
in O
development O
, O
_RARE_ I-GENE
expression O
is O
restricted O
to O
_RARE_ I-GENE
, O
_RARE_ I-GENE
mesoderm O
and O
to O
the O
tail O
_RARE_ I-GENE
, O
which O
_RARE_ I-GENE
the O
_RARE_ I-GENE
as O
the O
source O
of O
mesoderm O
. O

Disruption O
of O
re O
- I-GENE
replication O
control O
by O
overexpression O
of O
human I-GENE
_RARE_ I-GENE
in O
fission I-GENE
yeast I-GENE
. O

Our O
results O
demonstrate O
that O
the O
promoter I-GENE
and O
enhancer I-GENE
regions O
identified O
here O
are O
essential O
for O
maintaining O
the O
efficient O
promoter I-GENE
activity O
of O
the O
human I-GENE
activin I-GENE
_RARE_ I-GENE
subunit I-GENE
gene I-GENE
. O

Recombinant I-GENE
, O
bacterially O
expressed O
_RARE_ I-GENE
possessed O
_RARE_ I-GENE
activity O
and O
was O
immunoreactive I-GENE
with O
erythroid I-GENE
_RARE_ I-GENE
antibodies I-GENE
. O

Human I-GENE
acid I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
AC I-GENE
) O
N I-GENE
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
, O
EC I-GENE
3 I-GENE
. O
5 I-GENE
. O

The O
0 O
. O
22 O
- I-GENE
kb O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
promoter I-GENE
exhibited O
PMA O
inducibility O
in O
myeloid O
cells O
and O
contained O
a O
PMA O
- I-GENE
responsive I-GENE
element I-GENE
recognized O
by O
Sp1 I-GENE
and O
_RARE_ I-GENE
- I-GENE
1 I-GENE
transcription I-GENE
factors I-GENE
. O

Northern O
( O
RNA I-GENE
) O
blot O
analyses O
indicated O
that O
the O
_RARE_ I-GENE
genes I-GENE
encoding O
the O
five O
subunits I-GENE
and O
an O
open O
reading O
frame O
( O
ORF1 O
) O
with O
unknown O
function O
are O
cotranscribed O
during O
growth I-GENE
on O
acetate O
. O

Two O
classes O
of O
mutations O
were O
obtained O
: O
( O
i O
) O
those O
that O
altered O
the O
coding O
region O
of O
_RARE_ I-GENE
, O
conferring O
the O
ability O
to O
take O
up O
_RARE_ I-GENE
; O
and O
( O
ii O
) O
cis O
- I-GENE
acting O
mutations O
( O
selected O
in O
a O
mutant I-GENE
_RARE_ I-GENE
- I-GENE
1 I-GENE
background O
) O
that O
increased O
expression O
of O
the O
_RARE_ I-GENE
protein I-GENE
. O

_RARE_ I-GENE
to O
the O
_RARE_ I-GENE
was O
judged O
by O
_RARE_ I-GENE
of O
_RARE_ I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
dye O
, O
which O
was O
administered O
either O
2 I-GENE
, O
3 I-GENE
, O
24 O
or O
48 O
h O
after O
onset O
of O
_RARE_ I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
levels O
in O
plasma I-GENE
and O
LDL I-GENE
remained O
unchanged O
throughout O
the O
study O
. O

When O
the O
degree O
of O
exercise O
was O
maximal O
, O
_RARE_ I-GENE
was O
maintained O
, O
_RARE_ I-GENE
decreased O
, O
HR O
was O
unchanged O
, O
and O
CO I-GENE
and O
VO2 O
decreased O
. O

We O
report O
a O
case O
of O
vasculitis O
( O
cutaneous O
and O
neurologic O
) O
which O
led O
to O
the O
discovery O
of O
a O
selective O
_RARE_ I-GENE
towards O
EBV I-GENE
, O
similar O
to O
_RARE_ I-GENE
' O
s O
syndrome O
. O

To O
elucidate O
whether O
potential O
endocrine O
changes O
resulted O
from O
acute O
_RARE_ I-GENE
alone O
, O
the O
underlying O
disease O
, O
or O
_RARE_ I-GENE
influences O
connected O
with O
the O
_RARE_ I-GENE
setting O
, O
all O
measurements O
were O
compared O
to O
those O
of O
a O
completely O
healthy O
reference O
group O
( O
_RARE_ I-GENE
) O
with O
comparable O
acute O
experimental O
_RARE_ I-GENE
. O

There O
were O
no O
significant O
differences O
in O
graft O
survival O
between O
groups O
with O
early I-GENE
graft O
function O
( O
EGF I-GENE
) O
and O
_RARE_ I-GENE
, O
either O
in O
first O
_RARE_ I-GENE
or O
_RARE_ I-GENE
. O

These O
results O
suggested O
that O
the O
_RARE_ I-GENE
motifs O
contributed O
to O
the O
cell O
- I-GENE
specific I-GENE
transcription I-GENE
of O
the O
human I-GENE
insulin I-GENE
gene I-GENE
in O
association O
with O
the O
binding I-GENE
of O
the O
sequence I-GENE
- I-GENE
specific I-GENE
nuclear I-GENE
factor I-GENE
. O

Abnormal O
urinary O
_RARE_ I-GENE
levels O
in O
patients O
infected O
by O
hepatitis I-GENE
C I-GENE
virus I-GENE
with O
or O
without O
human I-GENE
immunodeficiency I-GENE
virus I-GENE
. O

The O
determination O
of O
immunoglobulin I-GENE
E I-GENE
( O
IgE I-GENE
) O
antibodies I-GENE
by O
one O
of O
several O
laboratory O
tests O
, O
by O
skin O
- I-GENE
_RARE_ I-GENE
tests O
or O
by O
appropriate O
challenge O
procedures O
is O
useful O
either O
to O
identify O
atopic O
individuals O
or O
as O
outcome O
predictors O
in O
_RARE_ I-GENE
children O
. O

_RARE_ I-GENE
of O
the O
renal O
vein O
may O
be O
dramatic O
and O
include O
renal O
failure O
. O

_RARE_ I-GENE
and O
_RARE_ I-GENE
preparations O
of O
the O
urine O
were O
studied O
and O
all O
cases O
displayed O
numerous O
_RARE_ I-GENE
aggregates O
or O
single O
tumor I-GENE
cells O
in O
an O
inflammatory O
background O
. O

_RARE_ I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
of O
_RARE_ I-GENE
examinations O
from O
_RARE_ I-GENE
hospitals O
N I-GENE
31 O
and O
57 O
, O
respectively O
, O
were O
evaluated O
statistically O
. O

The O
promoter I-GENE
segment O
was O
inactive O
when O
introduced O
into O
the O
rat I-GENE
glioma O
cell O
line O
_RARE_ I-GENE
, O
the O
rat I-GENE
_RARE_ I-GENE
cell O
line O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
, O
and O
the O
rat I-GENE
pancreatic O
beta I-GENE
cell O
line O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
, O
all O
of O
which O
do O
not O
express O
the O
endogenous I-GENE
_RARE_ I-GENE
- I-GENE
AR I-GENE
gene I-GENE
. O

The O
sequencing O
of O
the O
conditional O
lethal O
mutation I-GENE
ts I-GENE
- I-GENE
_RARE_ I-GENE
, O
localized O
in O
the O
_RARE_ I-GENE
_RARE_ I-GENE
, O
and O
the O
lethality O
of O
insertional I-GENE
mutations O
targeted O
in O
the O
internal O
region O
of O
_RARE_ I-GENE
and O
_RARE_ I-GENE
, O
demonstrated O
the O
essential O
role O
of O
this O
locus I-GENE
. O

The O
_RARE_ I-GENE
scores O
and O
their O
side O
- I-GENE
to O
- I-GENE
side O
differences O
in O
patients O
correlated O
negatively O
with O
the O
serum I-GENE
25 O
- I-GENE
_RARE_ I-GENE
concentration O
and O
positively O
with O
the O
degree O
of O
_RARE_ I-GENE
. O

These O
data O
do O
not O
support O
the O
use O
of O
_RARE_ I-GENE
to O
reduce O
risk O
of O
progression O
to O
_RARE_ I-GENE
in O
sepsis O
. O

This O
correlated O
with O
reduced O
levels O
of O
secreted O
hepatitis I-GENE
B I-GENE
e O
antigen I-GENE
and O
increased O
intracellular O
levels O
of O
core I-GENE
and O
Pol I-GENE
proteins I-GENE
and O
replicative O
HBV O
DNA I-GENE
_RARE_ I-GENE
. O

In O
contrast O
, O
extracts O
of O
the O
mutant I-GENE
virions O
_RARE_ I-GENE
the O
wild I-GENE
- I-GENE
type I-GENE
level O
of O
transcription I-GENE
from O
an O
exogenous O
template O
containing O
an O
early I-GENE
promoter I-GENE
. O

The O
_RARE_ I-GENE
_RARE_ I-GENE
sites I-GENE
contain O
potential O
overlapping O
core I-GENE
recognition I-GENE
binding I-GENE
motifs O
for O
SRF I-GENE
, O
Rel I-GENE
/ I-GENE
_RARE_ I-GENE
, O
ETS I-GENE
, O
and O
YY1 I-GENE
class I-GENE
transcription I-GENE
factors I-GENE
but O
fail O
to O
respond O
to O
either O
serum I-GENE
or O
tumor I-GENE
necrosis I-GENE
factor I-GENE
alpha I-GENE
. O

Upon O
serum I-GENE
withdrawal O
at O
the O
permissive O
temperature O
, O
p53 I-GENE
- I-GENE
mediated O
apoptosis O
was O
induced O
in O
50 O
to O
60 O
% O
of O
the O
cells O
. O

To O
_RARE_ I-GENE
this O
problem O
, O
a O
simple O
two O
- I-GENE
step O
strategy O
was O
_RARE_ I-GENE
by O
which O
essential O
cis O
- I-GENE
acting O
sites I-GENE
like I-GENE
the O
a O
sequence I-GENE
can O
be O
readily O
deleted O
from O
their O
natural O
loci I-GENE
in O
large O
viral I-GENE
DNA I-GENE
genomes O
. O

On O
the O
basis O
of O
serological O
studies O
, O
the O
highly O
conserved O
A I-GENE
domain I-GENE
of O
_RARE_ I-GENE
was O
found O
to O
be O
the O
_RARE_ I-GENE
domain I-GENE
. O

In O
Group O
IV I-GENE
dogs O
that O
received O
alpha I-GENE
- I-GENE
MSH I-GENE
only O
during O
reperfusion O
, O
_RARE_ I-GENE
were O
increased O
approximately O
10 O
to O
14 O
% O
more O
than O
in O
Group O
II I-GENE
during O
the O
late O
reperfusion O
period O
. O

The O
Fas I-GENE
receptor I-GENE
mediates O
a O
signalling O
cascade O
resulting O
in O
programmed O
cell O
death O
( O
apoptosis O
) O
within O
hours O
of O
receptor I-GENE
cross O
- I-GENE
linking O
. O

Fas I-GENE
has O
been O
shown O
to O
require O
ICE I-GENE
( O
interleukin I-GENE
- I-GENE
1 I-GENE
beta I-GENE
- I-GENE
converting I-GENE
enzyme I-GENE
) O
family I-GENE
proteases I-GENE
to O
induce O
apoptosis O
from O
studies O
utilizing O
the O
_RARE_ I-GENE
ICE I-GENE
inhibitor I-GENE
protein I-GENE
_RARE_ I-GENE
, O
the O
synthetic O
_RARE_ I-GENE
ICE I-GENE
inhibitor I-GENE
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
, O
and O
the O
_RARE_ I-GENE
_RARE_ I-GENE
- I-GENE
ICE I-GENE
inhibitor I-GENE
Z I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
. O

The O
imprinted O
expression O
of O
the O
endogenous I-GENE
gene I-GENE
can O
be O
_RARE_ I-GENE
in O
mice O
by O
using O
a O
14 O
- I-GENE
kb O
_RARE_ I-GENE
encompassing O
4 I-GENE
kb O
of O
5 I-GENE
'- O
flanking O
sequence I-GENE
, O
8 O
kb O
of O
3 I-GENE
'- O
flanking O
sequence I-GENE
, O
which O
includes O
the O
two O
endoderm O
- I-GENE
specific I-GENE
enhancers I-GENE
, O
and O
an O
_RARE_ I-GENE
deleted O
structural O
gene I-GENE
. O

In O
this O
report O
, O
we O
demonstrate O
that O
_RARE_ I-GENE
is O
also O
an O
_RARE_ I-GENE
and O
has O
the O
same O
substrate I-GENE
specificity O
as O
_RARE_ I-GENE
. O

The O
effect O
of O
six O
arginine I-GENE
mutations O
of O
oxidative O
phosphorylation O
and O
_RARE_ I-GENE
expression O
. O

_RARE_ I-GENE
DNAs O
encompassing O
the O
coat I-GENE
protein I-GENE
coding O
and O
adjacent O
regions O
of O
_RARE_ I-GENE
mosaic O
virus I-GENE
( O
_RARE_ I-GENE
) O
and O
_RARE_ I-GENE
mosaic O
virus I-GENE
( O
_RARE_ I-GENE
) O
were O
cloned O
and O
sequenced O
. O

In O
some O
cases O
, O
factor I-GENE
- I-GENE
induced O
Rac I-GENE
activation O
results O
in O
Rho I-GENE
activation O
, O
and O
factor I-GENE
- I-GENE
induced O
Cdc42 I-GENE
activation O
leads O
to O
Rac I-GENE
activation O
, O
as O
determined O
by O
specific I-GENE
morphological O
changes O
. O

Several O
cDNAs I-GENE
corresponding O
to O
the O
human I-GENE
_RARE_ I-GENE
gene I-GENE
were O
identified O
and O
partially O
sequenced O
. O

Isolation O
and O
genomic O
structure O
of O
a O
human I-GENE
homolog I-GENE
of O
the O
yeast I-GENE
periodic I-GENE
tryptophan I-GENE
protein I-GENE
2 I-GENE
( O
_RARE_ I-GENE
) O
gene I-GENE
mapping O
to O
_RARE_ I-GENE
. O
3 I-GENE
. O

_RARE_ I-GENE
defined O
by O
combinations O
of O
normal O
and O
abnormal O
laboratory O
results O
had O
decreased O
the O
likelihood O
of O
_RARE_ I-GENE
from O
an O
all O
- I-GENE
2 I-GENE
to O
all O
- I-GENE
0 O
pattern O
. O

To O
examine O
whether O
_RARE_ I-GENE
( O
vitamin O
B1 I-GENE
) O
deficiency O
is O
associated I-GENE
with O
recurrent O
_RARE_ I-GENE
stomatitis I-GENE
, O
we O
studied O
vitamin O
B1 I-GENE
levels O
in O
70 I-GENE
patients O
with O
recurrent O
_RARE_ I-GENE
stomatitis I-GENE
and O
in O
50 O
members O
of O
a O
control O
group O
. O

Liver O
injuries O

By O
screening O
a O
cDNA I-GENE
library O
with O
a O
probe O
derived O
from O
sequences I-GENE
downstream O
of O
the O
_RARE_ I-GENE
start O
site I-GENE
, O
we O
have O
cloned O
and O
characterized O
a O
cDNA I-GENE
that O
represents O
a O
mRNA I-GENE
that O
appears O
to O
have O
been O
initiated O
from O
the O
_RARE_ I-GENE
promoter I-GENE
. O

However O
, O
we O
did O
not O
observe O
a O
correlation O
between O
serum I-GENE
and O
seminal I-GENE
plasma I-GENE
PSA I-GENE
levels O
. O

The O
implications O
for O
estimates O
of O
cortical O
magnification O
and O
possible O
differences O
in O
the O
_RARE_ I-GENE
of O
_RARE_ I-GENE
and O
peripheral O
vision O
are O
discussed O
. O

G I-GENE
- I-GENE
CSF I-GENE
activates O
multiple O
signaling O
molecules I-GENE
, O
including O
the O
_RARE_ I-GENE
and O
_RARE_ I-GENE
kinases I-GENE
and O
the O
STAT I-GENE
transcription I-GENE
factors I-GENE
. O

_RARE_ I-GENE
lacking O
any O
tyrosine I-GENE
residues O
in O
the O
cytoplasmic I-GENE
domain I-GENE
maintain O
their O
ability O
to O
activate O
STAT5 I-GENE
and O
STAT1 I-GENE
but O
cannot O
activate O
STAT3 I-GENE
, O
implying O
that O
STAT5 I-GENE
and O
STAT1 I-GENE
activation O
does O
not O
require O
receptor I-GENE
tyrosine I-GENE
phosphorylation O
. O

The O
RI I-GENE
alpha I-GENE
gene I-GENE
is O
composed O
of O
nine O
coding O
exons O
of O
varying O
lengths O
, O
separated O
by O
introns O
, O
giving O
the O
gene I-GENE
a O
total O
length I-GENE
of O
at O
least O
21 O
kb O
. O
our O
recent O
cloning O
of O
a O
processed O
RI I-GENE
alpha I-GENE
pseudogene I-GENE
with O
a O
5 I-GENE
'- O
noncoding O
region O
different O
from O
the O
previously O
reported O
RI I-GENE
alpha I-GENE
complementary O
RNA I-GENE
indicated O
that O
the O
RI I-GENE
alpha I-GENE
gene I-GENE
may O
have O
multiple O
leader O
exons O
giving O
rise O
to O
_RARE_ I-GENE
spliced O
messenger I-GENE
RNAs I-GENE
( O
mRNAs I-GENE
). O

This O
_RARE_ I-GENE
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
as O
the O
only O
conserved O
protein I-GENE
which O
is O
required O
for O
all O
the O
DNA I-GENE
structure O
_RARE_ I-GENE
in O
both O
yeast I-GENE
model O
systems O
. O

In O
addition O
, O
double O
mutants I-GENE
with O
either O
_RARE_ I-GENE
- I-GENE
delta I-GENE
or O
_RARE_ I-GENE
- I-GENE
1 I-GENE
and O
the O
_RARE_ I-GENE
mutants I-GENE
_RARE_ I-GENE
- I-GENE
1 I-GENE
or O
_RARE_ I-GENE
- I-GENE
1 I-GENE
displayed O
synthetic O
growth I-GENE
defects O
, O
indicating O
that O
the O
_RARE_ I-GENE
gene I-GENE
products I-GENE
function O
in O
a O
common O
or O
parallel O
endocytic O
pathway O
. O

The O
identification O
of O
the O
hepatitis I-GENE
C I-GENE
virus I-GENE
as O
the O
major I-GENE
cause O
of O
liver O
disease O
both O
in O
dialysis O
patients O
and O
in O
transplant O
patients O
has O
focused O
attention O
on O
the O
_RARE_ I-GENE
and O
the O
impact O
of O
_RARE_ I-GENE
infection O
in O
these O
patient O
groups O
. O

Stable O
transfection O
of O
the O
_RARE_ I-GENE
cell O
line O
_RARE_ I-GENE
with O
constructs I-GENE
containing O
core I-GENE
promoter I-GENE
mutations O
confirmed O
that O
the O
proximal I-GENE
Sp1 I-GENE
site I-GENE
and O
the O
TATA I-GENE
box I-GENE
are O
essential O
for O
the O
activation O
of O
promoter I-GENE
P1 I-GENE
by O
the O
Ig I-GENE
kappa I-GENE
enhancers I-GENE
. O

Such O
_RARE_ I-GENE
interactions O
can O
be O
significant O
for O
behavior O
. O

The O
_RARE_ I-GENE
and O
_RARE_ I-GENE
of O
_RARE_ I-GENE
had O
phase O
reversal O
relationship O
with O
the O
P2 I-GENE
and O
N2 O
recorded O
from O
the O
_RARE_ I-GENE
, O
respectively O
. O

The O
cDNA I-GENE
of O
_RARE_ I-GENE
encodes O
a O
closely O
related I-GENE
protein I-GENE
of O
36 O
. O
8 O
kDa I-GENE
. O

Finally O
, O
the O
C I-GENE
- I-GENE
terminal I-GENE
region O
of O
_RARE_ I-GENE
shows O
strong O
homology I-GENE
to O
a O
protein I-GENE
from O
rat I-GENE
that O
is O
specifically O
expressed O
in O
testis I-GENE
tissue I-GENE
. O

The O
conservation O
of O
both O
the O
G I-GENE
- I-GENE
box I-GENE
and O
H I-GENE
- I-GENE
box I-GENE
in O
different O
_RARE_ I-GENE
promoters I-GENE
emphasizes O
their O
importance O
as O
regulatory I-GENE
motifs O
. O

_RARE_ I-GENE
on O
the O
last O
_RARE_ I-GENE
was O
particularly O
severe O
among O
certain O
_RARE_ I-GENE
groups O
of O
_RARE_ I-GENE
that O
included O
_RARE_ I-GENE
, O
_RARE_ I-GENE
birds O
, O
and O
birds O
undergoing O
a O
_RARE_ I-GENE
event O
such O
as O
artificial O
_RARE_ I-GENE
. O

Further O
, O
the O
PIP2 O
content O
of O
the O
85 O
- I-GENE
90 O
kDa I-GENE
protein I-GENE
appeared O
to O
decrease O
with O
CSF I-GENE
- I-GENE
1 I-GENE
treatment O
. O

Further O
, O
the O
PIP2 O
content O
of O
the O
85 O
- I-GENE
90 O
kDa I-GENE
protein I-GENE
appeared O
to O
decrease O
with O
CSF I-GENE
- I-GENE
1 I-GENE
treatment O
. O

_RARE_ I-GENE
before O
inserting O
on O
the O
anterior O
margin O
and O
apex O
of O
the O
iliac O
_RARE_ I-GENE
it O
_RARE_ I-GENE
, O
_RARE_ I-GENE
the O
_RARE_ I-GENE
of O
a O
small I-GENE
_RARE_ I-GENE
. O

The O
first O
identification O
of O
the O
active O
_RARE_ I-GENE
/ I-GENE
p40 I-GENE
gene I-GENE
presented O
in O
this O
study O
is O
a O
critical O
step O
toward O
the O
isolation O
of O
the O
corresponding O
human I-GENE
gene I-GENE
and O
the O
understanding O
of O
the O
molecular O
mechanisms O
involved O
in O
the O
up O
- I-GENE
regulation O
of O
its O
expression O
during O
tumor I-GENE
invasion O
and O
metastasis O
. O

The O
promoter I-GENE
region O
( O
P1 I-GENE
) O
corresponding O
to O
the O
main O
group O
of O
transcription I-GENE
initiation I-GENE
sites I-GENE
is O
_RARE_ I-GENE
of O
TATA I-GENE
and O
CAAT I-GENE
boxes O
but O
has O
putative O
binding I-GENE
sites I-GENE
for O
the O
transcription I-GENE
factor I-GENE
SP1 I-GENE
and O
is O
embedded O
in O
a O
large O
G I-GENE
+ I-GENE
C I-GENE
- I-GENE
rich O
domain I-GENE
of O
a O
CpG O
island O
, O
features O
shared O
by O
the O
promoters I-GENE
of O
constitutively O
expressed O
housekeeping O
genes I-GENE
. O

The O
STAT I-GENE
- I-GENE
1 I-GENE
signaling O
pathway O
provides O
at O
least O
one O
mechanism O
for O
activation O
of O
the O
_RARE_ I-GENE
LTR I-GENE
by O
IFN I-GENE
- I-GENE
gamma I-GENE
in O
monocytes O
. O

_RARE_ I-GENE
caused O
a O
transient O
reduction O
in O
lactate I-GENE
production O
and O
a O
significant O
increase O
in O
_RARE_ I-GENE
release O
. O

To O
evaluate O
the O
hepatic I-GENE
_RARE_ I-GENE
response O
in O
patients O
with O
alcoholic O
liver O
disease O
, O
sera O
from O
_RARE_ I-GENE
patients O
with O
severe O
alcoholic O
hepatitis I-GENE
and O
/ I-GENE
or O
cirrhosis O
were O
analyzed O
for O
hepatocyte I-GENE
growth I-GENE
factor I-GENE
( O
HGF I-GENE
) O
and O
alpha I-GENE
- I-GENE
fetoprotein I-GENE
( O
AFP I-GENE
). O

Children O
born O
from O
chronic O
alcoholic O
mothers O
have O
shown O
behavioral O
_RARE_ I-GENE
effects O
more O
frequently O
than O
morphological O
malformations O
. O

_RARE_ I-GENE
( O
S I-GENE
): O
Twenty O
- I-GENE
six O
hemostasis O
parameters O
evaluated O
_RARE_ I-GENE
in O
patients O
undergoing O
_RARE_ I-GENE
- I-GENE
ET I-GENE
. O

Here O
we O
report O
that O
expression O
of O
the O
I I-GENE
- I-GENE
POU I-GENE
/ I-GENE
_RARE_ I-GENE
- I-GENE
POU I-GENE
message I-GENE
is O
maximal O
late O
in O
the O
embryonic O
phase O
of O
Drosophila I-GENE
development O
, O
and O
I I-GENE
- I-GENE
POU I-GENE
is O
the O
preferred O
splice O
variant I-GENE
. O

Unlike O
wild I-GENE
- I-GENE
type I-GENE
p53 I-GENE
, O
the O
delta I-GENE
_RARE_ I-GENE
mutant I-GENE
cDNA I-GENE
can O
be O
stably O
expressed O
in O
tumor I-GENE
derived O
cell O
lines O
with O
few O
immediate I-GENE
_RARE_ I-GENE
effects O
. O

The O
patient O
' O
s O
role O
, O
organized O
by O
the O
_RARE_ I-GENE
of O
_RARE_ I-GENE
_RARE_ I-GENE
, O
is O
_RARE_ I-GENE
_RARE_ I-GENE
with O
the O
_RARE_ I-GENE
' O
s O
, O
which O
is O
structured O
to O
_RARE_ I-GENE
_RARE_ I-GENE
and O
understanding O
. O

The O
most O
common O
risk O
factor I-GENE
reported O
for O
both O
recent O
and O
all O
other O
hepatitis I-GENE
C I-GENE
cases O
was O
a O
history O
of O
injecting O
drug O
use O
, O
although O
the O
proportion O
of O
cases O
with O
that O
history O
was O
different O
in O
_RARE_ I-GENE
from O
_RARE_ I-GENE
and O
_RARE_ I-GENE
. O

_RARE_ I-GENE
can O
be O
restored O
by O
_RARE_ I-GENE
of O
a O
telomere I-GENE
at O
13 O
kb O
from O
the O
reporter I-GENE
construct I-GENE
, O
or O
by O
insertion O
of O
_RARE_ I-GENE
bp O
of O
yeast I-GENE
telomeric O
repeat I-GENE
sequence I-GENE
at O
this O
site I-GENE
without O
chromosomal I-GENE
_RARE_ I-GENE
. O

In O
contrast O
with O
previous O
two O
- I-GENE
pool O
models O
, O
_RARE_ I-GENE
were O
made O
for O
folate I-GENE
turnover O
by O
urinary O
folate I-GENE
excretion O
( O
as O
measured O
here O
) O
and O
by O
fecal O
excretion O
and O
_RARE_ I-GENE
processes O
. O

When O
voltage O
- I-GENE
operated O
Ca2 I-GENE
+ I-GENE
channels I-GENE
( O
_RARE_ I-GENE
) O
were O
blocked O
by O
nifedipine O
, O
midazolam O
, O
in O
concentrations O
more O
than O
1 I-GENE
microM O
, O
attenuated O
both O
_RARE_ I-GENE
and O
_RARE_ I-GENE
responses O
. O

Several O
_RARE_ I-GENE
occurred O
that O
_RARE_ I-GENE
with O
visualization O
of O
the O
diaphragm O
. O

Although O
_RARE_ I-GENE
gene I-GENE
induction O
is O
dependent I-GENE
on O
STAT1 I-GENE
and O
_RARE_ I-GENE
, O
activated I-GENE
STAT1 I-GENE
does O
not O
bind O
to O
_RARE_ I-GENE
. O

The O
syndrome O
of O
resistance O
to O
thyroid I-GENE
hormone I-GENE
is O
characterized O
by O
elevated O
serum I-GENE
free O
thyroid I-GENE
hormones O
, O
failure O
to O
suppress O
pituitary I-GENE
thyrotropin I-GENE
secretion O
, O
and O
variable O
peripheral O
_RARE_ I-GENE
to O
hormone I-GENE
action O
. O

Finally O
, O
_RARE_ I-GENE
mutants I-GENE
, O
including O
the O
_RARE_ I-GENE
- I-GENE
lacking O
_RARE_ I-GENE
I I-GENE
mutant I-GENE
, O
_RARE_ I-GENE
, O
did O
not O
show O
evidence O
of O
light I-GENE
- I-GENE
stimulated O
RNA I-GENE
processing O
. O

The O
progression O
of O
acute O
_RARE_ I-GENE
is O
associated I-GENE
with O
elevated O
blood O
concentrations O
of O
acute O
- I-GENE
phase O
proteins I-GENE
, O
_RARE_ I-GENE
activation O
in O
the O
blood O
and O
high O
serotonin I-GENE
and O
_RARE_ I-GENE
acid I-GENE
content O
in O
the O
_RARE_ I-GENE
_RARE_ I-GENE
from O
the O
_RARE_ I-GENE
air O
. O

Because O
of O
the O
potential O
implications O
of O
these O
findings O
in O
human I-GENE
physiology O
, O
we O
cloned O
the O
_RARE_ I-GENE
- I-GENE
R I-GENE
gene I-GENE
. O

Differential O
signaling O
and O
immediate I-GENE
- I-GENE
early I-GENE
gene I-GENE
activation O
by O
four O
splice O
variants I-GENE
of O
the O
human I-GENE
pituitary I-GENE
adenylate I-GENE
cyclase I-GENE
- I-GENE
activating I-GENE
polypeptide I-GENE
receptor I-GENE
( O
_RARE_ I-GENE
- I-GENE
R I-GENE
). O

During O
skeletal I-GENE
muscle O
development O
, O
different O
types O
of O
muscle O
fibers O
are O
generated O
, O
which O
express O
different O
combinations O
of O
muscle O
- I-GENE
specific I-GENE
gene I-GENE
products I-GENE
. O

We O
discuss O
these O
results O
with O
respect O
to O
the O
transcriptional O
induction O
of O
the O
HNF I-GENE
- I-GENE
3 I-GENE
alpha I-GENE
gene I-GENE
in O
respiratory O
epithelium O
during O
embryogenesis O
. O

BACKGROUND O
: O
_RARE_ I-GENE
is O
regulated O
by O
_RARE_ I-GENE
( O
maturation O
promoting I-GENE
factor I-GENE
), O
the O
active O
form O
of O
Cdc2 I-GENE
/ I-GENE
28 O
- I-GENE
cyclin I-GENE
B I-GENE
complexes I-GENE
. O

_RARE_ I-GENE
expression O
of O
_RARE_ I-GENE
- I-GENE
3 I-GENE
in O
_RARE_ I-GENE
or O
HeLa O
cells O
induced O
marked O
apoptosis O
. O

An O
N I-GENE
- I-GENE
terminal I-GENE
arm O
from O
each O
subunit I-GENE
_RARE_ I-GENE
around O
the O
dinucleotide O
- I-GENE
binding I-GENE
domain I-GENE
of O
an O
adjacent O
subunit I-GENE
, O
covering O
the O
adenine O
_RARE_ I-GENE
of O
_RARE_ I-GENE
. O

_RARE_ I-GENE
is O
most O
striking O
in O
the O
zinc I-GENE
_RARE_ I-GENE
region O
, O
a O
region O
characteristic O
of O
gag I-GENE
genes I-GENE
of O
most O
replication O
- I-GENE
competent O
_RARE_ I-GENE
. O

D I-GENE
. O
melanogaster I-GENE
_RARE_ I-GENE
- I-GENE
A I-GENE
coding O
sequences I-GENE
have O
a O
polymorphic O
region O
with O
insertions O
/ I-GENE
deletions O
of O
1 I-GENE
- I-GENE
31 O
codons O
and O
many O
nucleotide I-GENE
changes O
. O

_RARE_ I-GENE
initiation I-GENE
factor I-GENE
3 I-GENE
( O
eIF3 I-GENE
) O
is O
a O
large O
multisubunit I-GENE
complex I-GENE
that O
stabilizes O
the O
ternary O
complex I-GENE
, O
_RARE_ I-GENE
x O
GTP I-GENE
x O
tRNA I-GENE
( O
Met I-GENE
) O
i O
and O
promotes O
mRNA I-GENE
binding I-GENE
to O
the O
40 I-GENE
S I-GENE
ribosomal I-GENE
subunit I-GENE
. O
eIF3 I-GENE
also O
functions O
as O
a O
ribosome I-GENE
subunit I-GENE
anti I-GENE
- I-GENE
association O
factor I-GENE
. O

Our O
data O
, O
combined O
with O
those O
of O
_RARE_ I-GENE
and O
co O
- I-GENE
workers O
, O
suggest O
that O
mammalian I-GENE
eIF3 I-GENE
is O
composed O
of O
at O
least O
10 O
subunits I-GENE
: O
_RARE_ I-GENE
, O
_RARE_ I-GENE
( O
_RARE_ I-GENE
), O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
p44 I-GENE
, O
p40 I-GENE
, O
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
. O

Identification O
of O
a O
cis O
- I-GENE
acting O
element I-GENE
in O
the O
class I-GENE
I I-GENE
major I-GENE
histocompatibility I-GENE
complex I-GENE
gene I-GENE
promoter I-GENE
responsive I-GENE
to O
activation O
by O
retroviral I-GENE
sequences I-GENE
. O

The O
results O
demonstrate O
that O
( O
i O
) O
no O
intact O
_RARE_ I-GENE
were O
assembled O
when O
the O
full I-GENE
- I-GENE
length I-GENE
or O
a O
truncated I-GENE
( O
missing O
the O
C I-GENE
- I-GENE
terminal I-GENE
65 O
amino O
acids O
) O
UL80 I-GENE
. O
5 I-GENE
protein I-GENE
was O
tested O
; O
( O
ii O
) O
when O
the O
C I-GENE
- I-GENE
terminal I-GENE
65 O
amino O
acids O
of O
the O
UL80 I-GENE
. O
5 I-GENE
protein I-GENE
were O
replaced O
with O
the O
C I-GENE
- I-GENE
terminal I-GENE
25 O
amino O
acids O
of O
the O
UL26 I-GENE
. O
5 I-GENE
protein I-GENE
, O
intact O
_RARE_ I-GENE
were O
made O
and O
direct O
interaction O
of O
the O
UL80 I-GENE
. O
5 I-GENE
protein I-GENE
with O
_RARE_ I-GENE
was O
detected O
; O
( O
iii O
) O
assembly O
of O
intact O
_RARE_ I-GENE
was O
demonstrated O
when O
the O
sequence I-GENE
of O
the O
last O
12 O
amino O
acids O
of O
the O
UL80 I-GENE
. O
5 I-GENE
protein I-GENE
was O
changed O
from O
_RARE_ I-GENE
_RARE_ I-GENE
to O
_RARE_ I-GENE
; O
( O
iv O
) O
self O
- I-GENE
interaction O
of O
the O
_RARE_ I-GENE
proteins I-GENE
is O
mediated O
by O
sequences I-GENE
N I-GENE
terminal I-GENE
to O
the O
maturation O
cleavage O
site I-GENE
; O
and O
( O
v I-GENE
) O
the O
UL26 I-GENE
. O
5 I-GENE
and O
UL80 I-GENE
. O
5 I-GENE
proteins I-GENE
will O
not O
_RARE_ I-GENE
into O
_RARE_ I-GENE
structures O
. O

_RARE_ I-GENE
, O
the O
3 I-GENE
'- O
region O
splice O
junctions O
of O
the O
_RARE_ I-GENE
during O
latent I-GENE
and O
_RARE_ I-GENE
infection O
were O
determined O
by O
sequencing O
RNA I-GENE
- I-GENE
PCR O
products I-GENE
generated O
with O
primers O
that O
flank O
the O
3 I-GENE
' O
splice O
region O
. O

( O
ii O
) O
_RARE_ I-GENE
binds O
preferentially O
to O
less O
modified O
forms O
of O
ICP4 I-GENE
, O
a O
protein I-GENE
that O
is O
extensively O
modified O
_RARE_ I-GENE
. O

_RARE_ I-GENE
of O
sufficient O
data O
on O
vibration O
measurements O
and O
_RARE_ I-GENE
durations O
_RARE_ I-GENE
to O
the O
_RARE_ I-GENE
, O
as O
do O
variations O
in O
tool O
conditions O
( O
_RARE_ I-GENE
_RARE_ I-GENE
, O
etc O
) O
and O
_RARE_ I-GENE
_RARE_ I-GENE
in O
measurement O
. O

C I-GENE
/ I-GENE
EBP I-GENE
beta I-GENE
V I-GENE
> O
A I-GENE
selectively O
binds O
only O
the O
subset O
of O
C I-GENE
/ I-GENE
EBP I-GENE
sites I-GENE
that O
are O
also O
DBP I-GENE
sites I-GENE
, O
both O
as O
oligonucleotides O
and O
within O
the O
natural O
_RARE_ I-GENE
of O
the O
albumin I-GENE
and O
cholesterol I-GENE
hydroxylase I-GENE
promoters I-GENE
. O

Specific O
IgG I-GENE
, O
specific I-GENE
IgE I-GENE
and O
total O
IgE I-GENE
immunoglobulins I-GENE
against O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
/ I-GENE
secretory I-GENE
antigens I-GENE
( O
_RARE_ I-GENE
) O
were O
detected O
by O
using O
ELISA O
technique O
. O

_RARE_ I-GENE
BACKGROUND O
_RARE_ I-GENE
: O
_RARE_ I-GENE
care O
has O
not O
changed O
significantly O
in O
the O
last O
20 O
years O
, O
and O
the O
_RARE_ I-GENE
of O
_RARE_ I-GENE
lymph O
node O
_RARE_ I-GENE
in O
this O
disease O
_RARE_ I-GENE
to O
be O
discussed O
. O

The O
differences O
among O
_RARE_ I-GENE
of O
the O
genus O
_RARE_ I-GENE
are O
more O
significant O
. O

_RARE_ I-GENE
the O
E I-GENE
- I-GENE
box I-GENE
in O
the O
context O
of O
the O
3 I-GENE
'- O
flanking O
region O
confirmed O
that O
it O
contributes O
to O
the O
enhancement O
of O
transcriptional O
activity O
of O
the O
alpha1 I-GENE
( O
I I-GENE
) O
collagen I-GENE
gene I-GENE
promoter I-GENE
. O

Expression O
of O
neuronal O
_RARE_ I-GENE
in O
pancreatic O
beta I-GENE
cells O
. O

We O
propose O
that O
_RARE_ I-GENE
: O
Max I-GENE
: O
_RARE_ I-GENE
complexes I-GENE
normally O
function O
to O
_RARE_ I-GENE
Myc I-GENE
: O
Max I-GENE
activities O
associated I-GENE
with O
cell O
proliferation O
. O

Its O
transcription I-GENE
product I-GENE
, O
a O
1 I-GENE
. O
3 I-GENE
kb O
mRNA I-GENE
, O
is O
polyadenylated O
at O
a O
site I-GENE
containing O
consensus I-GENE
eukaryotic I-GENE
polyadenylation O
signals O
and O
mapping O
87 O
bp O
downstream O
of O
the O
translation I-GENE
termination O
codon O
for O
_RARE_ I-GENE
. O

_RARE_ I-GENE
changes O
induced O
by O
wild I-GENE
type I-GENE
and O
variant I-GENE
c I-GENE
- I-GENE
src I-GENE
genes I-GENE
carrying O
C I-GENE
- I-GENE
terminal I-GENE
sequence I-GENE
alterations O
. O

The O
_RARE_ I-GENE
of O
drug O
- I-GENE
resistant O
malaria O
makes O
_RARE_ I-GENE
the O
evaluation O
of O
new O
_RARE_ I-GENE
agents O
. O

In O
the O
_RARE_ I-GENE
subunit I-GENE
, O
the O
_RARE_ I-GENE
side O
- I-GENE
chain I-GENE
is O
_RARE_ I-GENE
in O
a O
similar O
direction O
to O
the O
_RARE_ I-GENE
side O
- I-GENE
chain I-GENE
in O
the O
wild I-GENE
- I-GENE
type I-GENE
complex I-GENE
. O

The O
relatively O
high O
level O
transcription I-GENE
from O
this O
gene I-GENE
shows O
that O
the O
polymorphic O
chromosome O
ends O
of O
P I-GENE
. O
falciparum O
, O
which O
have O
been O
proposed O
to O
be O
transcriptionally O
silent I-GENE
, O
can O
be O
active O
expression O
sites I-GENE
for O
var I-GENE
genes I-GENE
. O

_RARE_ I-GENE
was O
previously O
identified O
by O
using O
a O
genetic O
synthetic O
lethal O
screen O
( O
E I-GENE
. O

_RARE_ I-GENE
of O
sleep O
- I-GENE
_RARE_ I-GENE
breathing O
( O
_RARE_ I-GENE
) O
is O
reported O
to O
increase O
in O
menopausal I-GENE
women O
. O

In O
all O
cases O
the O
_RARE_ I-GENE
was O
transient O
and O
_RARE_ I-GENE
by O
_RARE_ I-GENE
day O
post O
- I-GENE
vaccination O
. O

A I-GENE
total O
of O
_RARE_ I-GENE
men O
aged O
48 O
to O
84 O
years O
, O
who O
were O
diagnosed O
for O
the O
first O
time O
by O
physicians O
as O
having O
_RARE_ I-GENE
in O
1994 O
and O
who O
had O
not O
received O
treatment O
, O
_RARE_ I-GENE
in O
the O
study O
. O

BCL I-GENE
- I-GENE
2 I-GENE
, O
an O
inhibitor I-GENE
of O
apoptosis O
in O
a O
wide O
variety O
of O
cell O
types O
, O
has O
been O
reported O
to O
prevent O
oxidative O
stress O
- I-GENE
induced O
cell O
death O
. O

In O
vitro O
translation I-GENE
of O
the O
_RARE_ I-GENE
cDNA I-GENE
resulted O
in O
a O
56 O
kDa I-GENE
protein I-GENE
that O
binds O
to O
_RARE_ I-GENE
repeat I-GENE
arrays O
. O
_RARE_ I-GENE
displayed O
the O
same O
sequence I-GENE
specificity O
as O
_RARE_ I-GENE
, O
_RARE_ I-GENE
arrays O
of O
_RARE_ I-GENE
repeats I-GENE
as O
a O
binding I-GENE
substrate I-GENE
over O
_RARE_ I-GENE
and O
_RARE_ I-GENE
repeats I-GENE
. O

The O
ubiquitously O
expressed O
E12 I-GENE
bHLH I-GENE
protein I-GENE
_RARE_ I-GENE
with O
numerous O
cell O
- I-GENE
specific I-GENE
bHLH I-GENE
factors I-GENE
. O

The O
E I-GENE
- I-GENE
box I-GENE
sequence I-GENE
in O
the O
_RARE_ I-GENE
fragment I-GENE
of O
the O
transferrin I-GENE
promoter I-GENE
was O
_RARE_ I-GENE
and O
was O
similar O
in O
gel O
shifts O
to O
the O
consensus I-GENE
E I-GENE
- I-GENE
box I-GENE
elements O
( O
_RARE_ I-GENE
) O
previously O
characterized O
. O

A I-GENE
5 I-GENE
. O
3 I-GENE
- I-GENE
kb O
DNA I-GENE
fragment I-GENE
, O
which O
included O
the O
entire O
structural O
_RARE_ I-GENE
gene I-GENE
( O
named O
_RARE_ I-GENE
) O
and O
its O
flanking O
regions O
, O
was O
identified O
. O

_RARE_ I-GENE
- I-GENE
length I-GENE
AT I-GENE
- I-GENE
_RARE_ I-GENE
, O
and O
both O
AT I-GENE
- I-GENE
_RARE_ I-GENE
and O
AT I-GENE
- I-GENE
_RARE_ I-GENE
delta I-GENE
C I-GENE
- I-GENE
_RARE_ I-GENE
( O
truncated I-GENE
to O
be O
approximately O
the O
size O
of O
microbial I-GENE
_RARE_ I-GENE
genes I-GENE
) O
cDNAs I-GENE
, O
were O
overexpressed O
, O
respectively O
, O
in O
yeast I-GENE
and O
Escherichia I-GENE
coli I-GENE
mutants I-GENE
hypersensitive I-GENE
to O
_RARE_ I-GENE
light I-GENE
. O

The O
human I-GENE
_RARE_ I-GENE
protein I-GENE
was O
recently O
identified O
as O
a O
coactivator I-GENE
of O
the O
Epstein I-GENE
- I-GENE
Barr I-GENE
virus I-GENE
nuclear I-GENE
antigen I-GENE
2 I-GENE
. O

However O
, O
five O
new O
mutation I-GENE
sites I-GENE
( O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
and O
_RARE_ I-GENE
) O
are O
unique O
to O
the O
_RARE_ I-GENE
intron O
and O
disrupt O
self O
- I-GENE
splicing O
. O

This O
report O
presents O
the O
isolation O
and O
characterization O
of O
the O
5 I-GENE
'- O
flanking O
region O
( O
1 I-GENE
. O
2 I-GENE
kb O
) O
and O
exon O
1 I-GENE
of O
the O
human I-GENE
RII I-GENE
alpha I-GENE
gene I-GENE
. O

A I-GENE
cohort O
of O
_RARE_ I-GENE
children O
was O
monitored O
from O
6 I-GENE
months O
to O
11 O
years O
of O
age O
. O

The O
aim O
of O
this O
study O
was O
to O
assess O
the O
reproducibility O
of O
a O
number O
of O
_RARE_ I-GENE
clearance O
methods O
using O
_RARE_ I-GENE
- I-GENE
51 O
_RARE_ I-GENE
_RARE_ I-GENE
acid I-GENE
( O
_RARE_ I-GENE
- I-GENE
EDTA O
) O
and O
to O
compare O
these O
with O
the O
multiple O
blood O
sample O
technique O
. O

The O
primary O
structure O
of O
a O
_RARE_ I-GENE
bp O
DNA I-GENE
fragment I-GENE
between O
the O
_RARE_ I-GENE
gene I-GENE
( O
encoding O
plasminogen I-GENE
activator I-GENE
) O
and O
the O
origin O
of O
replication O
of O
the O
wild I-GENE
- I-GENE
type I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
plasmid O
_RARE_ I-GENE
was O
determined O
. O

_RARE_ I-GENE
concentration O
in O
the O
blood O
of O
patients O
with O
hemorrhagic O
fever O
with O
renal O
syndrome O

MAIN O
OUTCOME O
_RARE_ I-GENE
: O
_RARE_ I-GENE
of O
factor I-GENE
analysis O
- I-GENE
derived O
syndromes O
with O
risk O
factors I-GENE
for O
chemical O
interactions O
that O
inhibit O
_RARE_ I-GENE
and O
neuropathy I-GENE
target O
esterase I-GENE
. O

CONCLUSION O
: O
Some O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
may O
have O
delayed O
, O
chronic O
_RARE_ I-GENE
syndromes O
from O
_RARE_ I-GENE
exposure O
to O
combinations O
of O
_RARE_ I-GENE
that O
inhibit O
_RARE_ I-GENE
and O
neuropathy I-GENE
target O
esterase I-GENE
. O

Control O
examination O
was O
performed O
at O
the O
end O
of O
each O
period O
. O

No O
correlation O
between O
the O
age O
of O
the O
horses O
and O
the O
antibody I-GENE
level O
could O
be O
found O
. O

The O
_RARE_ I-GENE
mRNA I-GENE
: O
_RARE_ I-GENE
mRNA I-GENE
ratio O
was O
1 I-GENE
. O
1 I-GENE
+/- O
0 O
. O
12 O
and O
remained O
unchanged O
during O
differentiation O
. O

The O
results O
demonstrate O
( O
i O
) O
that O
the O
selenocysteine I-GENE
- I-GENE
specific I-GENE
UGA O
codon O
is O
readily O
suppressed O
under O
conditions O
where O
the O
homologous O
_RARE_ I-GENE
protein I-GENE
is O
absent O
and O
( O
ii O
) O
that O
apart O
from O
the O
specificity O
of O
the O
_RARE_ I-GENE
- I-GENE
mRNA I-GENE
interaction O
, O
a O
structural O
compatibility O
of O
the O
_RARE_ I-GENE
complex I-GENE
with O
the O
ribosome I-GENE
is O
required O
. O

One O
linker I-GENE
- I-GENE
peptide I-GENE
insertion O
in O
the O
_RARE_ I-GENE
C I-GENE
terminus O
( O
amino O
acid I-GENE
_RARE_ I-GENE
) O
had O
no O
effect O
on O
S I-GENE
- I-GENE
layer O
biogenesis O
, O
while O
another O
( O
amino O
acid I-GENE
_RARE_ I-GENE
) O
disrupted O
secretion O
of O
the O
protein I-GENE
, O
suggesting O
that O
_RARE_ I-GENE
possesses O
a O
secretion O
signal I-GENE
_RARE_ I-GENE
C I-GENE
terminal I-GENE
to O
amino O
acid I-GENE
_RARE_ I-GENE
, O
near O
or O
including O
amino O
acid I-GENE
_RARE_ I-GENE
. O

To O
characterize O
the O
gene I-GENE
products I-GENE
, O
the O
_RARE_ I-GENE
gene I-GENE
was O
subcloned O
and O
expressed O
under O
the O
control O
of O
T7 I-GENE
RNA I-GENE
polymerase I-GENE
promoter I-GENE
. O

_RARE_ I-GENE
showed O
homology I-GENE
to O
_RARE_ I-GENE
_RARE_ I-GENE
of O
Streptomyces I-GENE
_RARE_ I-GENE
and O
to O
its O
homolog I-GENE
in O
the O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
; O
_RARE_ I-GENE
was O
homologous O
to O
both O
_RARE_ I-GENE
and O
bacterial I-GENE
citrate I-GENE
_RARE_ I-GENE
; O
_RARE_ I-GENE
showed O
homology I-GENE
to O
yeast I-GENE
and O
Bacillus I-GENE
subtilis I-GENE
proteins I-GENE
of O
unknown O
function O
; O
_RARE_ I-GENE
showed O
homology I-GENE
to O
acetyl I-GENE
coenzyme I-GENE
A I-GENE
synthetases I-GENE
. O

MAIN O
OUTCOME O
_RARE_ I-GENE
: O
_RARE_ I-GENE
and O
pulmonary O
hemodynamics O
, O
arterial O
blood O
gas O
determination O
, O
_RARE_ I-GENE
_RARE_ I-GENE
protein I-GENE
and O
neutrophil I-GENE
content O
, O
neutrophil I-GENE
_RARE_ I-GENE
burst O
, O
lung O
_RARE_ I-GENE
content O
, O
and O
scanning O
electron O
_RARE_ I-GENE
studies O
. O

We O
have O
isolated O
a O
cDNA I-GENE
encoding O
human I-GENE
_RARE_ I-GENE
. O

To O
investigate O
the O
mechanisms O
involved O
in O
the O
transcriptional O
control O
of O
retinoid I-GENE
X I-GENE
receptor I-GENE
( O
RXR I-GENE
) O
gene I-GENE
expression O
, O
the O
5 I-GENE
'- O
flanking O
region O
of O
the O
human I-GENE
_RARE_ I-GENE
isoform I-GENE
was O
characterized O
. O

JNK I-GENE
and O
p38 I-GENE
are O
constitutively O
present O
in O
the O
nucleus O
, O
and O
DNA I-GENE
- I-GENE
bound O
c I-GENE
- I-GENE
_RARE_ I-GENE
and O
ATF I-GENE
- I-GENE
2 I-GENE
are O
stably O
_RARE_ I-GENE
by O
JNK I-GENE
and O
p38 I-GENE
, O
respectively O
. O

The O
effects O
of O
dominant I-GENE
interfering O
forms O
of O
the O
JNK I-GENE
/ I-GENE
p38 I-GENE
signaling O
pathway O
demonstrate O
that O
activation O
of O
these O
kinases I-GENE
is O
critical O
for O
cytokine O
- I-GENE
induced O
E I-GENE
- I-GENE
selectin I-GENE
gene I-GENE
expression O
. O

Sp1 I-GENE
binds O
the O
_RARE_ I-GENE
repeat I-GENE
with O
an O
affinity O
, O
_RARE_ I-GENE
= O
0 O
. O
37 O
nM O
, O
at O
least O
as O
high O
as O
the O
consensus I-GENE
GC I-GENE
box I-GENE
. O

Identification O
of O
the O
region O
in O
actin I-GENE
- I-GENE
binding I-GENE
protein I-GENE
that O
binds O
to O
the O
cytoplasmic I-GENE
domain I-GENE
of O
glycoprotein I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
enzyme I-GENE
forms O
were O
prepared O
to O
_RARE_ I-GENE
the O
initial O
_RARE_ I-GENE
site I-GENE
and O
thus O
form O
an O
active O
single O
- I-GENE
chain I-GENE
protein I-GENE
for O
structure O
- I-GENE
function O
studies O
. O

The O
primer O
is O
generated O
by O
a O
cleavage O
that O
occurs O
between O
bases O
11 O
and O
12 O
of O
the O
_RARE_ I-GENE
mRNA I-GENE
. O

Similarly O
, O
we O
examined O
whether O
the O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
FLI1 I-GENE
, O
EWS I-GENE
- I-GENE
FLI1 I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
PEA3 I-GENE
and O
PU I-GENE
. O
1 I-GENE
proteins I-GENE
can O
form O
ternary O
complexes I-GENE
with O
SRF I-GENE
on O
the O
_RARE_ I-GENE
_RARE_ I-GENE
and O
II I-GENE
. O

This O
R I-GENE
- I-GENE
domain I-GENE
may O
modulate O
the O
interaction O
with O
SRF I-GENE
, O
providing O
a O
mechanism O
that O
would O
be O
unique O
to O
FLI1 I-GENE
and O
EWS I-GENE
- I-GENE
FLI1 I-GENE
, O
thus O
_RARE_ I-GENE
a O
novel O
function O
for O
these O
ETS I-GENE
transcription I-GENE
factors I-GENE
in O
the O
regulation O
of O
the O
_RARE_ I-GENE
gene I-GENE
. O

The O
total O
number O
of O
specimens O
was O
131 O
with O
78 O
_RARE_ I-GENE
and O
53 O
smokers O
. O

The O
murine I-GENE
chromosomal I-GENE
locations O
of O
the O
five O
_RARE_ I-GENE
receptor I-GENE
channel O
subunits I-GENE
, O
the O
epsilon I-GENE
1 I-GENE
( O
_RARE_ I-GENE
), O
epsilon I-GENE
2 I-GENE
( O
_RARE_ I-GENE
), O
epsilon I-GENE
3 I-GENE
( O
_RARE_ I-GENE
), O
epsilon I-GENE
4 I-GENE
( O
_RARE_ I-GENE
) O
and O
zeta I-GENE
1 I-GENE
( O
_RARE_ I-GENE
) O
subunits I-GENE
, O
were O
determined O
using O
an O
_RARE_ I-GENE
backcross O
mapping O
panel O
derived O
from O
_RARE_ I-GENE
of O
_RARE_ I-GENE
C57BL O
/ I-GENE
_RARE_ I-GENE
. O
_RARE_ I-GENE
) O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
] O
mice O
. O

_RARE_ I-GENE
cloning O
of O
chick I-GENE
brain O
alpha I-GENE
- I-GENE
amino O
- I-GENE
3 I-GENE
- I-GENE
hydroxy I-GENE
- I-GENE
5 I-GENE
- I-GENE
methyl O
- I-GENE
4 I-GENE
- I-GENE
_RARE_ I-GENE
acid I-GENE
receptors I-GENE
reveals O
conservation O
of O
structure O
, O
function O
and O
post O
- I-GENE
transcriptional O
processes O
with O
mammalian I-GENE
receptors I-GENE
. O

_RARE_ I-GENE
, O
both O
_RARE_ I-GENE
- I-GENE
A I-GENE
and O
_RARE_ I-GENE
- I-GENE
D I-GENE
defects O
are O
associated I-GENE
with O
subunits I-GENE
of O
_RARE_ I-GENE
, O
a O
basal O
transcription I-GENE
factor I-GENE
with O
a O
second O
function O
in O
DNA I-GENE
repair I-GENE
. O

_RARE_ I-GENE
for O
age O
, O
total O
cholesterol I-GENE
, O
HDL I-GENE
cholesterol I-GENE
, O
triglycerides I-GENE
, O
current O
smoking O
, O
and O
systolic O
pressure O
slightly O
reduced O
the O
association O
between O
fibrinogen I-GENE
and O
atherosclerosis O
. O

In O
Experiment O
1 I-GENE
, O
_RARE_ I-GENE
that O
had O
received O
an O
injection O
of O
the O
_RARE_ I-GENE
N I-GENE
- I-GENE
methyl O
- I-GENE
D I-GENE
- I-GENE
aspartate I-GENE
receptor I-GENE
antagonist O
MK O
- I-GENE
801 O
( O
0 O
. O
1 I-GENE
mg O
/ I-GENE
kg O
, O
i O
. O
p O
.) O
either O
30 O
min O
before O
or O
immediately O
after O
conditioning O
_RARE_ I-GENE
less O
time O
over O
the O
conditioned O
_RARE_ I-GENE
than O
saline O
- I-GENE
treated O
controls O
. O

_RARE_ I-GENE
side O
- I-GENE
chain I-GENE
cleavage O
cytochrome I-GENE
P450 I-GENE
( O
_RARE_ I-GENE
; O
_RARE_ I-GENE
) O
gene I-GENE
expression O
is O
regulated O
by O
_RARE_ I-GENE
via O
cAMP I-GENE
in O
the O
ovary O
and O
by O
ACTH I-GENE
via O
cAMP I-GENE
in O
adrenal O
cortical O
cells O
. O

One O
possible O
solution O
is O
a O
thin O
_RARE_ I-GENE
_RARE_ I-GENE
free O
flap O
. O

Structural O
analysis O
and O
characterization O
of O
tissue I-GENE
and O
hormonal O
responsive I-GENE
expression O
of O
the O
avian I-GENE
bone O
_RARE_ I-GENE
( O
BSP I-GENE
) O
gene I-GENE
. O

_RARE_ I-GENE
receptors I-GENE
in O
suicide O
victims O
with O
major I-GENE
depression O
. O

The O
Y I-GENE
- I-GENE
type I-GENE
structural O
motif I-GENE
is O
also O
conserved O
among O
a O
number O
of O
divergent O
_RARE_ I-GENE
mRNAs I-GENE
. O

A I-GENE
false O
positive O
marker O
screen O
was O
associated I-GENE
with O
the O
occurrence O
of O
hand O
- I-GENE
foot O
syndrome O
even O
when O
the O
effect O
of O
regimen O
was O
_RARE_ I-GENE
for O
by O
_RARE_ I-GENE
( O
p O
= O
. O
01 O
). O

The O
detection O
of O
ORF I-GENE
- I-GENE
1 I-GENE
sequences I-GENE
in O
human I-GENE
tumors O
, O
while O
not O
_RARE_ I-GENE
per O
_RARE_ I-GENE
, O
is O
a O
prerequisite O
for O
_RARE_ I-GENE
its O
role O
in O
tumor I-GENE
development O
. O

_RARE_ I-GENE
analysis O
gave O
evidence O
for O
a O
close O
evolutionary O
relationship O
between O
_RARE_ I-GENE
- I-GENE
1 I-GENE
and O
members O
of O
the O
_RARE_ I-GENE
genus O
of O
the O
alpha I-GENE
- I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
herpesvirus I-GENE
in O
particular O
. O

In O
this O
method O
, O
PLP I-GENE
in O
plasma I-GENE
can O
be O
determined O
with O
high O
sensitivity O
using O
_RARE_ I-GENE
with O
sodium O
_RARE_ I-GENE
in O
the O
mobile O
phase O
. O

Both O
HEF1 I-GENE
and O
Cas I-GENE
were O
found O
to O
complex I-GENE
with O
the O
related I-GENE
adhesion I-GENE
focal I-GENE
tyrosine I-GENE
kinase I-GENE
( O
_RARE_ I-GENE
), O
and O
when O
tyrosine I-GENE
phosphorylated O
, O
with O
the O
adapter I-GENE
molecule I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
and O
_RARE_ I-GENE
do O
not O
form O
homodimers I-GENE
, O
and O
they O
do O
not O
interact O
with O
_RARE_ I-GENE
. O

_RARE_ I-GENE
of O
_RARE_ I-GENE
with O
each O
complementary O
strand O
of O
telomeric O
DNA I-GENE
and O
with O
_RARE_ I-GENE
forms O
of O
the O
guanine I-GENE
- I-GENE
rich O
strand O
had O
3 I-GENE
. O
7 O
- I-GENE
14 O
. O
6 I-GENE
nM O
dissociation O
constants O
, O
_RARE_ I-GENE
, O
whereas O
complexes I-GENE
with O
double O
- I-GENE
stranded I-GENE
telomeric O
DNA I-GENE
had O
up O
to O
100 O
- I-GENE
fold O
higher O
_RARE_ I-GENE
values O
. O

Moreover O
, O
the O
effect O
_RARE_ I-GENE
by O
_RARE_ I-GENE
appeared O
to O
be O
selective O
for O
the O
_RARE_ I-GENE
promoter I-GENE
. O

Experimental O
data O
showed O
that O
these O
abnormal O
proteins I-GENE
are O
constitutively O
localized O
in O
the O
nucleus O
, O
have O
lost O
the O
transcriptional O
repressor I-GENE
functions O
typical O
of O
normal O
NF I-GENE
- I-GENE
kappa I-GENE
_RARE_ I-GENE
and O
may O
be O
capable O
of O
transactivation O
activity O
. O

Because O
L I-GENE
- I-GENE
plastin I-GENE
expression O
in O
tissue I-GENE
- I-GENE
specifically O
regulated O
in O
both O
humans O
and O
_RARE_ I-GENE
, O
it O
is O
likely O
that O
similar O
mechanisms O
regulate O
L I-GENE
- I-GENE
plastin I-GENE
gene I-GENE
expression O
in O
human I-GENE
and O
rodent O
cells O
and O
that O
they O
could O
be O
identified O
by O
comparing O
the O
function O
and O
nucleotide I-GENE
sequences I-GENE
of O
the O
human I-GENE
and O
murine I-GENE
L I-GENE
- I-GENE
plastin I-GENE
gene I-GENE
promoters I-GENE
. O

_RARE_ I-GENE
' O
s O
new O
in O
gynecologic O
and O
_RARE_ I-GENE
surgery O
. O

The O
_RARE_ I-GENE
operon I-GENE
of O
Bacillus I-GENE
subtilis I-GENE
is O
_RARE_ I-GENE
. O

Moreover O
, O
expression O
of O
CBF1 I-GENE
in O
yeast I-GENE
was O
found O
to O
activate O
transcription I-GENE
of O
reporter I-GENE
genes I-GENE
containing O
the O
C I-GENE
- I-GENE
repeat I-GENE
/ I-GENE
DRE I-GENE
as O
an O
upstream O
activator I-GENE
sequence I-GENE
but O
not O
mutant I-GENE
_RARE_ I-GENE
of O
the O
DNA I-GENE
element I-GENE
. O

Forty O
- I-GENE
one O
ASA I-GENE
physical O
status O
I I-GENE
or O
II I-GENE
adult O
patients O
undergoing O
a O
variety O
of O
1 I-GENE
- I-GENE
1 I-GENE
. O
5 I-GENE
h O
surgical O
procedures O
were O
randomly O
allocated O
to O
receive O
_RARE_ I-GENE
with O
_RARE_ I-GENE
or O
isoflurane O
with O
ventilation O
being O
either O
spontaneous O
or O
controlled O
. O

OBJECTIVE O
: O
Our O
goal O
was O
to O
determine O
whether O
_RARE_ I-GENE
- I-GENE
infected O
women O
have O
a O
higher O
rate O
of O
_RARE_ I-GENE
complications O
after O
_RARE_ I-GENE
_RARE_ I-GENE
ligation O
. O

In O
the O
electrophoresis O
mobility I-GENE
shift O
assay O
using O
nuclear I-GENE
extracts O
of O
the O
myogenic I-GENE
cells O
, O
MyoD I-GENE
and O
myogenin I-GENE
bound O
to O
the O
right O
E I-GENE
- I-GENE
box I-GENE
in O
the O
enhancer I-GENE
region O
of O
the O
_RARE_ I-GENE
gene I-GENE
even O
in O
the O
presence O
of O
BMP I-GENE
- I-GENE
2 I-GENE
. O

A I-GENE
heterologous O
promoter I-GENE
construct I-GENE
containing O
three O
repeats I-GENE
of O
a O
consensus I-GENE
Sp1 I-GENE
site I-GENE
, O
cloned O
upstream O
of O
a O
single O
copy O
of O
the O
_RARE_ I-GENE
( O
CREB I-GENE
/ I-GENE
AP1 I-GENE
) O
element I-GENE
from O
the O
_RARE_ I-GENE
promoter I-GENE
linked O
to O
the O
beta I-GENE
- I-GENE
globin I-GENE
TATA I-GENE
box I-GENE
, O
exhibited O
phorbol O
ester O
inducibility O
. O

_RARE_ I-GENE
experiments O
showed O
that O
_RARE_ I-GENE
tasks O
rather O
than O
cognitive O
aspects O
of O
the O
_RARE_ I-GENE
task O
were O
critical O
in O
_RARE_ I-GENE
finger I-GENE
- I-GENE
_RARE_ I-GENE
performance O
. O

_RARE_ I-GENE
does O
a O
nurse O
_RARE_ I-GENE
about O
maintaining O
her I-GENE
level O
of O
_RARE_ I-GENE
when O
_RARE_ I-GENE
is O
one O
of O
the O
few O
local O
_RARE_ I-GENE
in O
her I-GENE
field O
? O
_RARE_ I-GENE
sex I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
is O
_RARE_ I-GENE
it O
by O
_RARE_ I-GENE
a O
network O
of O
_RARE_ I-GENE
and O
_RARE_ I-GENE
in O
related I-GENE
fields O
both O
at O
home O
and O
across O
the O
_RARE_ I-GENE
. O

Finally O
, O
antibody I-GENE
binding I-GENE
to O
site I-GENE
_RARE_ I-GENE
on O
the O
hCG I-GENE
- I-GENE
_RARE_ I-GENE
complex I-GENE
was O
also O
_RARE_ I-GENE
by O
an O
anti I-GENE
- I-GENE
peptide I-GENE
mAb I-GENE
directed O
against O
a O
peptide I-GENE
encoded I-GENE
by O
the O
_RARE_ I-GENE
exon O
( O
_RARE_ I-GENE
x O
8 O
) O
of O
the O
LHR I-GENE
. O

cDNA I-GENE
cloning O
, O
expression O
analysis O
, O
and O
chromosomal I-GENE
localization O
of O
a O
gene I-GENE
with O
high O
homology I-GENE
to O
wheat I-GENE
eIF I-GENE
-( O
_RARE_ I-GENE
) O
_RARE_ I-GENE
and O
mammalian I-GENE
eIF I-GENE
- I-GENE
_RARE_ I-GENE
. O

Therefore O
, O
it O
is O
important O
to O
control O
hypertension O
and O
_RARE_ I-GENE
appropriate O
renal O
blood O
flow O
during O
living O
renal O
transplantation O
surgery O
. O

The O
initial O
patients O
treated O
with O
_RARE_ I-GENE
and O
_RARE_ I-GENE
experienced O
prolonged O
bone O
marrow O
suppression O
and O
, O
therefore O
, O
subsequent O
_RARE_ I-GENE
were O
treated O
with O
G I-GENE
- I-GENE
CSF I-GENE
, O
5 I-GENE
micrograms O
/ I-GENE
kg O
, O
beginning O
the O
day O
after O
_RARE_ I-GENE
of O
the O
third O
cycle O
of O
chemotherapy O
. O

Human I-GENE
granulocyte I-GENE
- I-GENE
macrophage I-GENE
colony I-GENE
- I-GENE
stimulating I-GENE
factor I-GENE
( O
_RARE_ I-GENE
- I-GENE
CSF I-GENE
) O
activates O
a O
set O
of O
genes I-GENE
such O
as O
c I-GENE
- I-GENE
fos I-GENE
, O
jun I-GENE
, O
myc I-GENE
, O
and O
early I-GENE
growth I-GENE
response O
gene I-GENE
1 I-GENE
( O
_RARE_ I-GENE
- I-GENE
1 I-GENE
). O

In O
order O
to O
provide O
adequate O
local O
control O
without O
_RARE_ I-GENE
_RARE_ I-GENE
outcome O
, O
the O
amount O
of O
breast O
tissue I-GENE
that O
must O
be O
_RARE_ I-GENE
in O
_RARE_ I-GENE
needs O
to O
be O
_RARE_ I-GENE
. O

Surprisingly O
, O
however O
, O
TCR I-GENE
- I-GENE
mediated O
tyrosine I-GENE
phosphorylation O
of O
phospholipase I-GENE
C I-GENE
gamma I-GENE
1 I-GENE
remains O
intact O
in O
the O
Jurkat O
cells O
expressing O
the O
A2 I-GENE
/ I-GENE
_RARE_ I-GENE
chimera I-GENE
. O

The O
14 O
. O
1 I-GENE
( O
_RARE_ I-GENE
) O
gene I-GENE
is O
expressed O
in O
a O
lineage O
- I-GENE
and O
stage O
- I-GENE
restricted O
manner O
. O

The O
interferon I-GENE
( O
IFN I-GENE
)- I-GENE
induced O
double O
- I-GENE
stranded I-GENE
RNA I-GENE
( O
dsRNA I-GENE
)- I-GENE
activated I-GENE
Ser O
/ I-GENE
Thr I-GENE
protein I-GENE
kinase I-GENE
( O
PKR I-GENE
) O
plays O
a O
role O
in O
the O
_RARE_ I-GENE
and O
_RARE_ I-GENE
effects O
of O
IFN I-GENE
. O

Together O
, O
the O
data O
suggest O
that O
cAMP I-GENE
- I-GENE
dependent I-GENE
control O
of O
the O
amounts O
of O
the O
activator I-GENE
SF I-GENE
- I-GENE
1 I-GENE
vs O
. O
the O
repressor I-GENE
COUP I-GENE
- I-GENE
TF I-GENE
could O
influence O
_RARE_ I-GENE
- I-GENE
dependent I-GENE
transcription I-GENE
. O

_RARE_ I-GENE
relations O
, O
affect O
management O
, O
and O
_RARE_ I-GENE
structure O
formation O
. O

When O
expressed O
in O
COS O
- I-GENE
7 O
cells O
, O
MKP I-GENE
- I-GENE
4 I-GENE
blocks O
activation O
of O
MAP I-GENE
kinases I-GENE
with O
the O
selectivity O
ERK I-GENE
> O
p38 I-GENE
= O
JNK I-GENE
/ I-GENE
SAPK I-GENE
. O

In O
_RARE_ I-GENE
mutants I-GENE
, O
telomeric O
chromatin O
is O
_RARE_ I-GENE
: O
_RARE_ I-GENE
silencing O
is O
reduced O
and O
_RARE_ I-GENE
localization O
is O
altered O
. O

Most O
kinases I-GENE
are O
not O
significantly O
inhibited O
by O
_RARE_ I-GENE
. O
cdc2 I-GENE
/ I-GENE
cyclin I-GENE
B I-GENE
, O
cdk2 I-GENE
/ I-GENE
cyclin I-GENE
A I-GENE
, O
cdk2 I-GENE
/ I-GENE
cyclin I-GENE
E I-GENE
and O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
only O
are O
substantially O
inhibited O
( O
_RARE_ I-GENE
values O
of O
0 O
. O
65 O
, O
0 O
. O
7 O
, O
0 O
. O
7 O
and O
0 O
. O
2 I-GENE
microM O
, O
respectively O
). O
_RARE_ I-GENE
/ I-GENE
cyclin I-GENE
D1 I-GENE
and O
_RARE_ I-GENE
/ I-GENE
cyclin I-GENE
D2 I-GENE
are O
very O
poorly O
inhibited O
by O
_RARE_ I-GENE
( O
_RARE_ I-GENE
> O
100 O
microM O
). O

This O
0 O
. O
74 O
kb O
cDNA I-GENE
contains O
an O
open O
reading O
frame O
( O
ORF I-GENE
) O
of O
_RARE_ I-GENE
bp O
encoding O
a O
polypeptide I-GENE
of O
_RARE_ I-GENE
amino O
acids O
( O
aa O
) O
which O
differs O
at O
only O
one O
position O
( O
position O
65 O
) O
from O
the O
human I-GENE
U1 I-GENE
- I-GENE
C I-GENE
protein I-GENE
. O

Interaction O
of O
Ets I-GENE
- I-GENE
1 I-GENE
and O
the O
POU I-GENE
- I-GENE
homeodomain I-GENE
protein I-GENE
_RARE_ I-GENE
- I-GENE
1 I-GENE
/ I-GENE
Pit I-GENE
- I-GENE
1 I-GENE
_RARE_ I-GENE
pituitary I-GENE
- I-GENE
specific I-GENE
gene I-GENE
expression O
. O

Although O
_RARE_ I-GENE
is O
not O
essential O
for O
viability O
, O
_RARE_ I-GENE
, O
2 I-GENE
- I-GENE
_RARE_ I-GENE
kinase I-GENE
complexes I-GENE
become O
essential O
for O
_RARE_ I-GENE
in O
the O
absence O
of O
_RARE_ I-GENE
, O
2 I-GENE
- I-GENE
Cdc28 I-GENE
kinases I-GENE
. O

Using O
the O
yeast I-GENE
two O
- I-GENE
hybrid O
system O
to O
screen O
for O
proteins I-GENE
which O
interact O
with O
_RARE_ I-GENE
, O
we O
isolated O
the O
B I-GENE
subunit I-GENE
of O
the O
CCAAT I-GENE
binding I-GENE
protein I-GENE
NF I-GENE
- I-GENE
Y I-GENE
from O
a O
HeLa O
cDNA I-GENE
library O
. O

_RARE_ I-GENE
activity O
requires O
both O
the O
AP I-GENE
- I-GENE
1 I-GENE
site I-GENE
and O
these O
adjacent O
sequences I-GENE
. O

Studies O
using O
HLA I-GENE
- I-GENE
DR I-GENE
- I-GENE
B7 I-GENE
- I-GENE
1 I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
3 I-GENE
triple O
transfectants O
showed O
that O
the O
_RARE_ I-GENE
- I-GENE
3 I-GENE
- I-GENE
induced O
NF I-GENE
- I-GENE
AT I-GENE
DNA I-GENE
binding I-GENE
activity O
was O
negatively O
regulated O
by O
B7 I-GENE
- I-GENE
1 I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
activation O
of O
Rac1 I-GENE
and O
RhoA I-GENE
causes O
tumorigenic O
transformation O
of O
NIH O
3T3 O
cells O
, O
and O
their O
functions O
may O
be O
required O
for O
full I-GENE
Ras I-GENE
transformation O
. O

Furthermore O
, O
Rac1 I-GENE
activation O
of O
JNK I-GENE
or O
SRF I-GENE
, O
or O
induction O
of O
_RARE_ I-GENE
, O
was O
neither O
necessary O
nor O
sufficient O
for O
Rac1 I-GENE
transforming I-GENE
activity O
. O

Overexpression O
of O
the O
_RARE_ I-GENE
interaction O
domain I-GENE
of O
CBP I-GENE
specifically O
abolishes O
the O
positive O
cross O
_RARE_ I-GENE
between O
TR I-GENE
and O
_RARE_ I-GENE
/ I-GENE
NF I-GENE
- I-GENE
E2 I-GENE
. O

This O
inhibitory I-GENE
domain I-GENE
has O
been O
deleted O
in O
all O
naturally O
occurring O
_RARE_ I-GENE
deletion O
mutants I-GENE
described O
to O
date O
. O

Identification O
of O
a O
promoter I-GENE
- I-GENE
specific I-GENE
transactivation O
domain I-GENE
in O
the O
herpes I-GENE
simplex I-GENE
virus I-GENE
regulatory I-GENE
protein I-GENE
ICP4 I-GENE
. O

DNA I-GENE
sequencing O
of O
a O
17 O
- I-GENE
kb O
segment O
encompassing O
a O
_RARE_ I-GENE
divergent O
locus I-GENE
( O
_RARE_ I-GENE
- I-GENE
B I-GENE
) O
between O
_RARE_ I-GENE
and O
_RARE_ I-GENE
revealed O
the O
presence O
of O
nine O
viral I-GENE
ORFs O
with O
predicted O
gene I-GENE
products I-GENE
related I-GENE
to O
cellular O
proteins I-GENE
. O

Studies O
in O
mammalian I-GENE
cells O
have O
correlated O
induction O
of O
inhibitory I-GENE
tyrosine I-GENE
15 O
( O
_RARE_ I-GENE
) O
phosphorylation O
on O
p34cdc2 I-GENE
with O
the O
response O
to O
DNA I-GENE
damage O
. O

We O
report O
_RARE_ I-GENE
the O
case O
of O
a O
30 O
- I-GENE
year O
- I-GENE
old O
man O
in O
whom O
ectopic O
_RARE_ I-GENE
parathyroid I-GENE
_RARE_ I-GENE
was O
detected O
by O
99mTc O
- I-GENE
_RARE_ I-GENE
scintigraphy O
( O
99mTc O
- I-GENE
_RARE_ I-GENE
). O

Cardiac I-GENE
endothelin I-GENE
release O
and O
infarct O
size O
, O
myocardial O
blood O
flow O
, O
and O
ventricular O
function O
in O
canine O
infarction O
and O
reperfusion O
. O

The O
_RARE_ I-GENE
included O
skin O
tests O
( O
up O
to O
1 I-GENE
microgram O
/ I-GENE
ml O
, O
Pharmacia O
), O
measurement O
of O
specific I-GENE
serum I-GENE
IgE I-GENE
with O
RAST O
- I-GENE
CAP I-GENE
( O
Pharmacia O
), O
and O
_RARE_ I-GENE
with O
three O
concentrations O
of O
_RARE_ I-GENE
( O
_RARE_ I-GENE
_RARE_ I-GENE
) O
and O
_RARE_ I-GENE
( O
_RARE_ I-GENE
_RARE_ I-GENE
.) O
_RARE_ I-GENE
( O
_RARE_ I-GENE
_RARE_ I-GENE
). O

The O
proliferation O
potential O
protein I-GENE
- I-GENE
related I-GENE
( O
_RARE_ I-GENE
- I-GENE
R I-GENE
) O
gene I-GENE
with O
domains I-GENE
encoding O
heterogeneous I-GENE
nuclear I-GENE
ribonucleoprotein I-GENE
association O
and O
_RARE_ I-GENE
binding I-GENE
shows O
repressed O
expression O
during O
terminal I-GENE
differentiation O
. O

Recent O
application O
of O
recombinant I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
/ I-GENE
HIV I-GENE
- I-GENE
1 I-GENE
vectors O
as O
vaccine O
_RARE_ I-GENE
in O
HIV I-GENE
- I-GENE
1 I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
volunteers O
has O
produced O
CTL O
responses O
in O
a O
significant O
number O
of O
_RARE_ I-GENE
. O

The O
relevance O
of O
these O
elements O
in O
conferring O
anaerobic O
induction O
of O
_RARE_ I-GENE
gene I-GENE
expression O
is O
discussed O
. O

_RARE_ I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
are O
separated O
from O
each O
other O
by O
a O
124 I-GENE
- I-GENE
nucleotide I-GENE
intron O
. O

A I-GENE
MEK I-GENE
- I-GENE
specific I-GENE
inhibitor I-GENE
( O
_RARE_ I-GENE
) O
( O
_RARE_ I-GENE
, O
D I-GENE
. O

These O
data O
support O
the O
idea O
that O
the O
repression O
activity O
of O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
depends O
upon O
the O
species O
of O
promoter I-GENE
to O
which O
it O
is O
linked O
and O
upon O
the O
proteins I-GENE
that O
bind O
to O
those O
promoters I-GENE
. O

_RARE_ I-GENE
period O
- I-GENE
peak O
analysis O
of O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
using O
a O
fast O
_RARE_ I-GENE
function O
. O

In O
summary O
, O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
activity O
stimulates O
G1 I-GENE
/ I-GENE
S I-GENE
transition O
in O
immature O
_RARE_ I-GENE
and O
maintains O
cell O
viability O
via O
transduction O
of O
constitutive O
activation O
signals O
downstream O
to O
components O
of O
the O
Ras I-GENE
/ I-GENE
Raf I-GENE
/ I-GENE
MAPK I-GENE
pathway O
. O

However O
, O
the O
action O
of O
each O
cognate I-GENE
ligand O
and O
the O
accessory I-GENE
cellular O
factors I-GENE
that O
can O
differentially O
regulate O
the O
transcriptional O
responses O
of O
a O
heterodimer O
- I-GENE
DNA I-GENE
complex I-GENE
are O
not O
well O
understood O
. O

We O
have O
measured O
the O
_RARE_ I-GENE
on O
_RARE_ I-GENE
and O
its O
direction O
in O
three O
dimensions O
for O
different O
jaw O
_RARE_ I-GENE
in O
ten O
subjects O
. O

These O
findings O
suggest O
that O
_RARE_ I-GENE
_RARE_ I-GENE
chemotherapy O
should O
be O
effective O
on O
advanced O
cervical O
cancer O
. O

The O
_RARE_ I-GENE
questionnaire O
did O
not O
_RARE_ I-GENE
a O
characteristic O
basic I-GENE
symptoms O
profile O
of O
_RARE_ I-GENE
disorder O
, O
when O
compared O
with O
bipolar O
affective O
disorder O
and O
schizophrenia O
. O

The O
alternative O
sigma I-GENE
factor I-GENE
_RARE_ I-GENE
in O
Staphylococcus I-GENE
aureus I-GENE
: O
regulation O
of O
the O
_RARE_ I-GENE
operon I-GENE
in O
response O
to O
growth I-GENE
phase O
and O
heat I-GENE
shock I-GENE

_RARE_ I-GENE
promoter I-GENE
elements O
implicated O
in O
glucocorticoid I-GENE
- I-GENE
and O
cAMP I-GENE
- I-GENE
mediated O
regulation O
as O
well O
as O
in O
liver O
-, I-GENE
myeloid O
-, I-GENE
and O
lymphocyte I-GENE
- I-GENE
specific I-GENE
expression O
are O
located O
within O
the O
5 I-GENE
' O
flanking O
sequence I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
decreases O
due O
to O
_RARE_ I-GENE
alone O
within O
30 O
minutes O
are O
unlikely O
. O

We O
have O
studied O
the O
_RARE_ I-GENE
of O
_RARE_ I-GENE
labeled O
with O
_RARE_ I-GENE
- I-GENE
111 O
( O
In O
- I-GENE
111 O
). O

CD3 I-GENE
cross O
- I-GENE
linking O
induced O
tyrosine I-GENE
phosphorylation O
of O
_RARE_ I-GENE
in O
_RARE_ I-GENE
T I-GENE
cells O
. O

_RARE_ I-GENE
- I-GENE
dependent I-GENE
expression O
of O
the O
_RARE_ I-GENE
operon I-GENE
could O
be O
restored O
in O
the O
E I-GENE
. O
coli I-GENE
_RARE_ I-GENE
mutants I-GENE
by O
_RARE_ I-GENE
a O
plasmid O
carrying O
an O
intact O
_RARE_ I-GENE
, O
suggesting O
a O
transactivating O
function O
of O
the O
gene I-GENE
product I-GENE
. O

Mutations O
in O
the O
alpha I-GENE
and O
sigma I-GENE
- I-GENE
70 I-GENE
subunits I-GENE
of O
RNA I-GENE
polymerase I-GENE
affect O
expression O
of O
the O
mer I-GENE
operon I-GENE
. O

Taken O
together O
, O
we O
provide O
evidence O
for O
the O
existence O
of O
an O
activator I-GENE
, O
_RARE_ I-GENE
, O
which O
in O
combination O
with O
the O
p50 I-GENE
and O
c I-GENE
- I-GENE
Rel I-GENE
proteins I-GENE
, O
are O
part O
of O
the O
transcription I-GENE
factor I-GENE
machinery O
that O
regulates O
3 I-GENE
' O
enhancer I-GENE
activity O
, O
and O
thus O
the O
control O
of O
the O
_RARE_ I-GENE
locus I-GENE
in O
late O
B I-GENE
lymphocyte I-GENE
development O
. O

The O
_RARE_ I-GENE
efficacy O
of O
the O
selective O
N I-GENE
- I-GENE
type I-GENE
voltage O
- I-GENE
sensitive O
calcium O
channel O
blocker O
, O
_RARE_ I-GENE
- I-GENE
111 O
, O
was O
evaluated O
in O
spontaneously O
hypertensive O
rats O
subjected O
to O
60 O
min O
of O
focal I-GENE
cerebral O
ischemia O
by O
permanent O
ligation O
of O
the O
right O
common O
carotid O
artery O
and O
temporary O
occlusion O
of O
the O
right O
middle I-GENE
cerebral O
artery O
. O

The O
genes I-GENE
encoding O
the O
transcription I-GENE
factor I-GENE
_RARE_ I-GENE
, O
the O
_RARE_ I-GENE
protein I-GENE
and O
a O
putative O
glucose O
transporter I-GENE
are O
contained O
in O
a O
12 O
. O
3 I-GENE
kb O
DNA I-GENE
fragment I-GENE
on O
the O
left O
arm O
of O
Saccharomyces I-GENE
cerevisiae I-GENE
chromosome O
VII I-GENE
. O

The O
_RARE_ I-GENE
_RARE_ I-GENE
the O
estimated O
fall O
distance O
for O
fracture O
of O
the O
_RARE_ I-GENE
. O

_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
usage O
was O
associated I-GENE
with O
depressed O
CD4 I-GENE
+ I-GENE
counts O
and O
elevated O
amylase I-GENE
levels O
within O
the O
_RARE_ I-GENE
subgroup O
. O

METHODS O
: O
Fifty O
- I-GENE
eight O
patients O
who O
underwent O
a O
_RARE_ I-GENE
hepatic I-GENE
resection O
for O
_RARE_ I-GENE
and O
whose O
preoperative O
AFP I-GENE
levels O
were O
> O
100 O
ng O
/ I-GENE
ml O
, O
were O
selected O
for O
this O
study O
. O

_RARE_ I-GENE
- I-GENE
binding I-GENE
peptide I-GENE
( O
CBP I-GENE
), O
a O
peptide I-GENE
of O
26 O
amino O
acids O
derived O
from O
muscle O
myosin I-GENE
light I-GENE
chain I-GENE
kinase I-GENE
( O
_RARE_ I-GENE
), O
binds O
to O
calmodulin I-GENE
with O
_RARE_ I-GENE
affinity O
. O

Here O
we O
show O
that O
the O
type I-GENE
of O
tyrosine I-GENE
kinase I-GENE
receptor I-GENE
stimulated O
also O
participates O
in O
the O
nature O
of O
the O
cAMP I-GENE
effect O
. O

To O
gain O
insight O
into O
the O
possible O
involvement O
of O
p21 I-GENE
in O
liver O
cell O
growth I-GENE
, O
the O
expression O
and O
regulation O
of O
the O
p21 I-GENE
gene I-GENE
was O
evaluated O
in O
rodent O
models O
of O
liver O
regeneration O
and O
specimens O
of O
human I-GENE
liver O
diseases O
. O

Northern O
blot O
analysis O
of O
_RARE_ I-GENE
( O
A I-GENE
) O
and O
_RARE_ I-GENE
( O
B I-GENE
) O
showed O
that O
transcripts I-GENE
of O
both O
_RARE_ I-GENE
- I-GENE
like I-GENE
genes I-GENE
were O
more O
abundant O
in O
leaves O
than O
roots O
in O
tomato I-GENE
plants O
grown O
without O
addition O
of O
extra I-GENE
metal O
ions O
, O
a O
characteristic O
of O
type I-GENE
II I-GENE
_RARE_ I-GENE
. O

In O
co O
- I-GENE
transfection O
studies O
, O
an O
AP I-GENE
- I-GENE
2 I-GENE
but O
not O
an O
_RARE_ I-GENE
- I-GENE
1 I-GENE
expression O
vector O
activated I-GENE
_RARE_ I-GENE
/ I-GENE
VEGF I-GENE
transcription I-GENE
, O
thus O
indicating O
that O
AP I-GENE
- I-GENE
2 I-GENE
protein I-GENE
is O
functionally O
important O
in O
TGF I-GENE
alpha I-GENE
- I-GENE
induced O
_RARE_ I-GENE
/ I-GENE
VEGF I-GENE
gene I-GENE
expression O
. O

The O
_RARE_ I-GENE
gene I-GENE
is O
composed O
of O
eight O
exons O
covering O
19 O
. O
5 I-GENE
kb O
on O
the O
short O
arm O
of O
chromosome O
4 I-GENE
. O

In O
some O
instances O
, O
this O
is O
partly O
mediated O
by O
the O
expression O
of O
_RARE_ I-GENE
encoded I-GENE
proteases I-GENE
which O
lead O
to O
the O
cleavage O
of O
initiation I-GENE
factor I-GENE
_RARE_ I-GENE
. O

The O
best O
endometrial O
ablation O
was O
seen O
when O
_RARE_ I-GENE
was O
given O
by O
intrauterine O
administration O
with O
light I-GENE
treatment O
at O
150 O
J O
/ I-GENE
cm O
24 O
hours O
later O
. O

Unlike O
class I-GENE
II I-GENE
- I-GENE
and O
III I-GENE
- I-GENE
specific I-GENE
TBP I-GENE
- I-GENE
TAF I-GENE
complexes I-GENE
, O
the O
corresponding O
murine I-GENE
and O
human I-GENE
class I-GENE
I I-GENE
- I-GENE
specific I-GENE
transcription I-GENE
initiation I-GENE
factor I-GENE
TIF I-GENE
- I-GENE
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
exhibits O
a O
pronounced O
selectivity O
for O
its O
homologous O
promoter I-GENE
. O

_RARE_ I-GENE
- I-GENE
1 I-GENE
, O
a O
protein I-GENE
abundant O
in O
cells O
of O
the O
immune I-GENE
system O
, O
has O
been O
proposed O
to O
be O
a O
human I-GENE
homolog I-GENE
of O
the O
Saccharomyces I-GENE
cerevisiae I-GENE
_RARE_ I-GENE
gene I-GENE
product I-GENE
, O
which O
is O
crucial O
in O
protein I-GENE
transport O
. O

In O
this O
regard O
, O
it O
differs O
from O
a O
recently O
reported O
_RARE_ I-GENE
- I-GENE
sensitive O
ARF I-GENE
- I-GENE
_RARE_ I-GENE
that O
contains O
a O
_RARE_ I-GENE
domain I-GENE
. O

We O
now O
describe O
the O
identification O
of O
_RARE_ I-GENE
as O
this O
43 I-GENE
- I-GENE
kDa I-GENE
_RARE_ I-GENE
factor I-GENE
. O

These O
elements O
comprise O
a O
binding I-GENE
site I-GENE
for O
Krox I-GENE
proteins I-GENE
, O
one O
for O
nuclear I-GENE
factor I-GENE
1 I-GENE
, O
an O
octamer O
motif I-GENE
that O
binds O
POU I-GENE
- I-GENE
homeodomain I-GENE
proteins I-GENE
, O
and O
a O
novel O
_RARE_ I-GENE
control O
element I-GENE
. O

Tissue I-GENE
samples O
were O
obtained O
either O
from O
rats O
that O
had O
been O
exposed O
to O
opiate I-GENE
withdrawal O
following O
a O
seven O
day O
morphine O
infusion O
or O
sham O
treated O
control O
subjects O
. O

Therefore O
, O
the O
impaired O
floor I-GENE
plate I-GENE
development O
in O
_RARE_ I-GENE
mutants I-GENE
is O
not O
caused O
by O
the O
absence O
of O
the O
floor I-GENE
plate I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
. O

RESULTS O
: O
The O
_RARE_ I-GENE
of O
average O
daily O
CD34 I-GENE
+ I-GENE
cell O
yields O
for O
patients O
who O
received O
_RARE_ I-GENE
plus O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
with O
G I-GENE
- I-GENE
CSF I-GENE
were O
12 O
. O
9 O
, O
11 O
. O
03 O
, O
and O
5 I-GENE
. O
37 O
x O
10 O
( O
6 I-GENE
)/ O
kg O
, O
respectively O
, O
compared O
with O
2 I-GENE
. O
02 O
x O
10 O
( O
6 I-GENE
)/ O
kg O
in O
the O
reference O
group O
that O
received O
_RARE_ I-GENE
with O
G I-GENE
- I-GENE
CSF I-GENE
( O
P I-GENE
= O
< O
. O
0001 O
, O
. O
_RARE_ I-GENE
, O
and O
. O
09 O
, O
respectively O
). O

Increased O
p53 I-GENE
activity O
induced O
by O
_RARE_ I-GENE
is O
not O
due O
to O
elevated O
p53 I-GENE
mRNA I-GENE
nor O
to O
protein I-GENE
levels O
. O

CONCLUSION O
: O
Chronic O
administration O
of O
_RARE_ I-GENE
may O
have O
caused O
a O
negative O
_RARE_ I-GENE
effect O
in O
_RARE_ I-GENE
patients O
with O
_RARE_ I-GENE
. O

The O
intensity O
of O
the O
_RARE_ I-GENE
is O
an O
order O
of O
magnitude O
larger O
than O
that O
of O
the O
_RARE_ I-GENE
and O
_RARE_ I-GENE
the O
signal I-GENE
contrast O
if O
both O
effects O
are O
selected O
simultaneously O
. O

In O
eukaryotic I-GENE
cells O
, O
premature O
termination O
of O
translation I-GENE
at O
nonsense O
codons O
has O
been O
implicated O
as O
the O
cause O
of O
a O
variety O
of O
posttranscriptional O
events O
, O
including O
rapid O
mRNA I-GENE
decay O
in O
the O
cytoplasm O
or O
the O
nucleus O
, O
altered O
splice O
site I-GENE
selection O
, O
and O
exon O
_RARE_ I-GENE
. O

The O
region O
of O
plasmid O
_RARE_ I-GENE
encoding O
the O
_RARE_ I-GENE
locus I-GENE
_RARE_ I-GENE
- I-GENE
1 I-GENE
was O
mapped O
by O
deletion O
analysis O
and O
complementation O
studies O
to O
a O
1 I-GENE
. O
5 I-GENE
- I-GENE
kb O
_RARE_ I-GENE
/ I-GENE
II I-GENE
/ I-GENE
_RARE_ I-GENE
DNA I-GENE
fragment I-GENE
. O

Transient O
cotransfection O
of O
tat I-GENE
cDNA I-GENE
in O
sense O
orientation O
( O
tat I-GENE
/ I-GENE
S I-GENE
), O
together O
with O
a O
plasmid O
containing O
the O
c I-GENE
- I-GENE
fos I-GENE
promoter I-GENE
( O
_RARE_ I-GENE
, O
from O
- I-GENE
_RARE_ I-GENE
to O
+ I-GENE
42 O
) O
in O
front O
of O
the O
bacterial I-GENE
chloramphenicol I-GENE
acetyltransferase I-GENE
( O
CAT I-GENE
) O
gene I-GENE
significantly O
enhanced O
CAT I-GENE
activity O
in O
Jurkat O
cells O
activated I-GENE
by O
the O
addition O
of O
15 O
% O
fetal O
calf I-GENE
serum I-GENE
( O
_RARE_ I-GENE
) O
or O
5 I-GENE
micrograms O
/ I-GENE
mL O
phytohemagglutinin I-GENE
plus O
10 O
(- O
7 O
) O
mol O
/ I-GENE
L I-GENE
phorbol O
myristate O
acetate O
( O
PMA O
) O
and O
U937 O
cells O
activated I-GENE
by O
15 O
% O
_RARE_ I-GENE
or O
10 O
(- O
7 O
) O
mol O
/ I-GENE
L I-GENE
PMA O
. O

_RARE_ I-GENE
mortality O
did O
not O
differ O
among O
the O
various O
treatment O
conditions O
. O

The O
recombinant I-GENE
protein I-GENE
was O
purified O
to O
_RARE_ I-GENE
by O
( O
_RARE_ I-GENE
) O
_RARE_ I-GENE
- I-GENE
precipitation O
and O
affinity O
chromatography O
on O
5 I-GENE
' O
AMP I-GENE
- I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
of O
gene I-GENE
expression O
mediated O
by O
the O
5 I-GENE
' O
upstream O
region O
of O
the O
_RARE_ I-GENE
lyase I-GENE
gene I-GENE
of O
Candida I-GENE
_RARE_ I-GENE
is O
controlled O
by O
two O
distinct O
regulatory I-GENE
pathways O
in O
Saccharomyces I-GENE
cerevisiae I-GENE
. O

_RARE_ I-GENE
- I-GENE
motor O
task O
to O
evaluate O
right O
frontal O
lobe O
damage O
. O

To O
avoid O
complications O
, O
accurate O
quantitative O
analysis O
of O
NO O
and O
NO2 O
is O
necessary O
during O
this O
therapy O
. O

Our O
results O
demonstrate O
that O
cis O
elements O
positioned O
between O
the O
alpha I-GENE
3 I-GENE
and O
beta I-GENE
4 I-GENE
coding O
regions O
are O
important O
for O
_RARE_ I-GENE
part O
of O
the O
restricted O
CNS O
patterns O
of O
beta I-GENE
4 I-GENE
, O
alpha I-GENE
3 I-GENE
, O
and O
alpha I-GENE
5 I-GENE
gene I-GENE
transcription I-GENE
. O

RNase I-GENE
protection O
experiments O
confirmed O
the O
presence O
of O
the O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
variant I-GENE
in O
IM O
- I-GENE
9 O
cells O
and O
human I-GENE
liver O
. O

Functional O
tests O
using O
a O
reporter I-GENE
gene I-GENE
, O
containing O
Stat5 I-GENE
- I-GENE
binding I-GENE
elements O
, O
confirmed O
that O
while O
the O
variant I-GENE
form O
was O
inactive O
by O
itself O
, O
it O
could O
inhibit O
the O
function O
of O
the O
full I-GENE
- I-GENE
length I-GENE
receptor I-GENE
. O

Conversely O
, O
activated I-GENE
glucocorticoid I-GENE
receptors I-GENE
suppressed O
the O
transactivation O
function O
of O
p53 I-GENE
, O
while O
_RARE_ I-GENE
by O
p53 I-GENE
was O
largely O
unaffected O
. O

99mTc O
- I-GENE
HMPAO O
was O
distributed O
in O
the O
_RARE_ I-GENE
of O
the O
ACA I-GENE
and O
_RARE_ I-GENE
in O
the O
two O
patients O
who O
were O
treated O
with O
_RARE_ I-GENE
infusion O
of O
_RARE_ I-GENE
from O
the O
C4 I-GENE
segment O
, O
but O
was O
distributed O
only O
to O
the O
_RARE_ I-GENE
of O
the O
ACA I-GENE
in O
four O
patients O
who O
were O
treated O
with O
_RARE_ I-GENE
infusion O
of O
_RARE_ I-GENE
from O
the O
C1 I-GENE
segment O
at O
1 I-GENE
ml O
/ I-GENE
min O
. O

This O
brief O
review O
analyses O
these O
interactions O
and O
defines O
clinical O
_RARE_ I-GENE
where O
antibiotic O
- I-GENE
induced O
endotoxin I-GENE
release O
may O
prove O
to O
be O
clinically O
relevant O
. O

This O
promoter I-GENE
segment O
could O
drive O
expression O
of O
a O
luciferase I-GENE
reporter I-GENE
gene I-GENE
, O
could O
confer O
correct O
transcriptional O
initiation I-GENE
to O
the O
reporter I-GENE
and O
could O
confer O
the O
EGF I-GENE
- I-GENE
responsiveness O
previously O
observed O
in O
the O
native O
gene I-GENE
. O

This O
is O
the O
first O
report O
that O
an O
in O
vitro O
- I-GENE
synthesized O
_RARE_ I-GENE
RNA I-GENE
lacking O
a O
poly O
( O
A I-GENE
) O
tail O
can O
initiate O
infection O
and O
produce O
3 I-GENE
' O
polyadenylated O
viral I-GENE
genome O
in O
vivo O
. O

The O
human I-GENE
_RARE_ I-GENE
was O
as O
active O
as O
the O
simian I-GENE
for O
SIV O
entry O
. O

These O
changes O
in O
virus I-GENE
entry O
features O
may O
result O
in O
_RARE_ I-GENE
with O
novel O
pathogenic O
properties O
. O

RESULTS O
: O
Among O
women O
, O
the O
age O
- I-GENE
related I-GENE
decline O
in O
BMD O
at O
all O
non O
- I-GENE
spine O
skeletal I-GENE
sites I-GENE
was O
significantly O
different O
from O
zero O
, O
with O
the O
largest O
decline O
seen O
at O
the O
femoral O
neck O
_RARE_ I-GENE
_RARE_ I-GENE
g O
/ I-GENE
cm2 O
/ I-GENE
_RARE_ I-GENE
, O
p O
< O
. O
001 O
) O
and O
the O
smallest O
at O
the O
_RARE_ I-GENE
of O
the O
hip O
_RARE_ I-GENE
_RARE_ I-GENE
g O
/ I-GENE
cm2 O
/ I-GENE
_RARE_ I-GENE
, O
p O
= O
. O
03 O
). O

_RARE_ I-GENE
- I-GENE
nine O
( O
44 I-GENE
%) O
patients O
were O
administered O
250 O
MBq O
( O
7 O
mCi O
) O
_RARE_ I-GENE
- I-GENE
tetrofosmin O
at O
rest O
followed O
4 I-GENE
h O
later O
by O
750 O
MBq O
( O
21 O
mCi O
) O
during O
stress O
( O
the O
1 I-GENE
day O
protocol O
), O
whereas O
88 O
( O
56 O
%) O
patients O
had O
rest O
and O
stress O
imaging O
studies O
on O
two O
separate O
days O
, O
receiving O
a O
500 O
MBq O
( O
14 O
mCi O
) O
dose O
of O
_RARE_ I-GENE
- I-GENE
tetrofosmin O
on O
each O
_RARE_ I-GENE
( O
the O
2 I-GENE
day O
protocol O
). O

Myocardial O
_RARE_ I-GENE
imaging O
with O
_RARE_ I-GENE
- I-GENE
tetrofosmin O
in O
clinical O
practice O
: O
comparison O
of O
a O
1 I-GENE
day O
and O
a O
2 I-GENE
day O
imaging O
protocol O
. O

_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
showed O
an O
almost O
identical O
behaviour O
to O
in O
vitro O
labelled O
red I-GENE
blood O
cells O
( O
_RARE_ I-GENE
), O
which O
are O
generally O
considered O
the O
reference O
standard O
for O
blood O
pool O
agents O
. O

_RARE_ I-GENE
from O
_RARE_ I-GENE
and O
a O
subsequent O
10 O
- I-GENE
60 O
- I-GENE
fold O
increase O
in O
V I-GENE
( O
max O
) O
have O
been O
observed O
upon O
N I-GENE
- I-GENE
SH2 I-GENE
domain I-GENE
_RARE_ I-GENE
by O
a O
specific I-GENE
_RARE_ I-GENE
ligand O
or O
upon O
deletion O
of O
the O
SH2 I-GENE
domains I-GENE
to O
yield O
the O
catalytic O
_RARE_ I-GENE
domain I-GENE
. O

We O
have O
thus O
identified O
the O
first O
mammalian I-GENE
homolog I-GENE
of O
yeast I-GENE
_RARE_ I-GENE
, O
a O
protein I-GENE
that O
regulates O
levels O
of O
nonsense O
mRNA I-GENE
, O
and O
we O
tentatively O
_RARE_ I-GENE
this O
protein I-GENE
human I-GENE
_RARE_ I-GENE
( O
for O
human I-GENE
homolog I-GENE
of O
_RARE_ I-GENE
). O

A I-GENE
_RARE_ I-GENE
cure O
and O
its O
solution O

The O
addition O
of O
_RARE_ I-GENE
did O
not O
influence O
this O
transfer I-GENE
. O

DNA I-GENE
strand O
exchange I-GENE
catalyzed O
by O
_RARE_ I-GENE
protein I-GENE
is O
also O
greatly O
stimulated O
by O
RPA I-GENE
. O

_RARE_ I-GENE
, O
which O
also O
controls O
the O
expression O
of O
early I-GENE
meiotic I-GENE
genes I-GENE
, O
represses O
_RARE_ I-GENE
expression O
through O
a O
sequence I-GENE
called O
_RARE_ I-GENE
, O
as O
a O
function O
of O
nitrogen O
availability O
. O

The O
second O
class I-GENE
of O
cDNA I-GENE
hybridized O
to O
a O
13 O
kb O
transcript I-GENE
, O
which O
was O
approximately O
twice O
as O
large O
as O
the O
mammalian I-GENE
_RARE_ I-GENE
mRNA I-GENE
. O

In O
cell O
lines O
transformed O
by O
BCR I-GENE
/ I-GENE
ABL I-GENE
, O
_RARE_ I-GENE
was O
tyrosine I-GENE
phosphorylated O
, O
while O
_RARE_ I-GENE
was O
not O
. O

In O
_RARE_ I-GENE
cells O
, O
three O
major I-GENE
proteins I-GENE
_RARE_ I-GENE
with O
_RARE_ I-GENE
, O
identified O
as O
_RARE_ I-GENE
, O
_RARE_ I-GENE
and O
c I-GENE
- I-GENE
ABL I-GENE
. O

Effect O
of O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
leaf O
extract O
on O
the O
cardiovascular O
system O
. O

RESULTS O
: O
_RARE_ I-GENE
_RARE_ I-GENE
, O
mainly O
_RARE_ I-GENE
in O
distribution O
, O
were O
the O
most O
common O
finding O
, O
seen O
in O
21 O
( O
72 O
%) O
and O
15 O
( O
65 O
%) O
of O
patients O
with O
_RARE_ I-GENE
and O
_RARE_ I-GENE
, O
respectively O
. O

_RARE_ I-GENE
_RARE_ I-GENE
in O
male O
guinea O
pigs O
affected O
by O
the O
female O
_RARE_ I-GENE
and O
reproductive O
condition O
. O

In O
cellular O
supernatant O
fraction O
, O
_RARE_ I-GENE
showed O
a O
decrease O
of O
magnesium O
in O
many O
tissues O
and O
an O
elevation O
of O
the O
calcium O
to O
magnesium O
ratio O
when O
compared O
to O
age O
- I-GENE
matched O
_RARE_ I-GENE
and O
_RARE_ I-GENE
. O

_RARE_ I-GENE
transcription I-GENE
of O
a O
murine I-GENE
FGFR I-GENE
- I-GENE
3 I-GENE
_RARE_ I-GENE
during O
fetal O
_RARE_ I-GENE
. O

A I-GENE
previous O
report O
described O
that O
a O
_RARE_ I-GENE
- I-GENE
bp O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
fragment I-GENE
has O
an O
_RARE_ I-GENE
activity O
( O
_RARE_ I-GENE
; O
_RARE_ I-GENE
et O
al O
., O
_RARE_ I-GENE
. O

The O
human I-GENE
_RARE_ I-GENE
gene I-GENE
consists O
of O
8 O
exons O
that O
extend O
more O
than O
77 O
kb O
on O
the O
human I-GENE
genome O
. O

Type O
IV I-GENE
splice O
pattern O
, O
containing O
exon O
U3 I-GENE
and O
S I-GENE
was O
found O
both O
in O
kidney O
and O
ovary O
. O

GH I-GENE
deficiency O
may O
be O
absolute O
, O
but O
often O
is O
not O
and O
the O
diagnosis O
may O
be O
complicated O
by O
a O
_RARE_ I-GENE
of O
physical O
and O
hormonal O
findings O
that O
are O
along O
a O
spectrum O
from O
low O
normal O
GH I-GENE
_RARE_ I-GENE
to O
absent O
GH I-GENE
secretion O
. O

_RARE_ I-GENE
CRP I-GENE
test O
were O
seen O
. O

During O
the O
_RARE_ I-GENE
period O
, O
_RARE_ I-GENE
was O
associated I-GENE
with O
high O
levels O
of O
IgG I-GENE
, O
IL I-GENE
- I-GENE
6 I-GENE
, O
TNF I-GENE
- I-GENE
alpha I-GENE
, O
and O
PGE2 O
in O
the O
cerebrospinal O
fluid O
. O

_RARE_ I-GENE
mechanisms O
of O
the O
minus O
- I-GENE
strand O
origin O
of O
phage I-GENE
f1 I-GENE
by O
Escherichia I-GENE
coli I-GENE
RNA I-GENE
polymerase I-GENE
. O

The O
minimum O
and O
essential O
subunits I-GENE
for O
RNA I-GENE
synthesis O
have O
not O
yet O
been O
identified O
. O

_RARE_ I-GENE
- I-GENE
4 I-GENE
is O
a O
focal I-GENE
adhesion I-GENE
component O
, O
and O
this O
interaction O
may O
both O
localize O
PKC I-GENE
and O
_RARE_ I-GENE
its O
activity O
at O
sites I-GENE
of O
forming O
adhesions O
. O

The O
_RARE_ I-GENE
cells O
expressing O
_RARE_ I-GENE
with O
mutation I-GENE
of O
Ser O
- I-GENE
_RARE_ I-GENE
, O
- I-GENE
_RARE_ I-GENE
, O
and O
- I-GENE
_RARE_ I-GENE
to O
alanine I-GENE
, O
or O
with O
mutation I-GENE
of O
only O
one O
serine I-GENE
in O
this O
domain I-GENE
, O
_RARE_ I-GENE
to O
be O
phosphorylated O
in O
response O
to O
ligand O
and O
are O
60 O
- I-GENE
70 I-GENE
% O
_RARE_ I-GENE
following O
the O
initial O
ligand O
challenge O
. O

Members O
of O
the O
MAPK I-GENE
family I-GENE
include O
the O
extracellular I-GENE
response O
kinases I-GENE
( O
ERKs I-GENE
or O
_RARE_ I-GENE
/ I-GENE
44 I-GENE
( O
MAPK I-GENE
_RARE_ I-GENE
the O
c I-GENE
- I-GENE
Jun I-GENE
amino O
- I-GENE
terminal I-GENE
kinases I-GENE
( O
_RARE_ I-GENE
), O
and O
the O
p38 I-GENE
/ I-GENE
_RARE_ I-GENE
1 I-GENE
protein I-GENE
kinases I-GENE
. O

_RARE_ I-GENE
contained O
the O
characteristic O
_RARE_ I-GENE
domain I-GENE
and O
a O
variable O
C I-GENE
terminus O
; O
it O
is O
possible O
that O
the O
cDNA I-GENE
contains O
a O
bHLH I-GENE
domain I-GENE
, O
but O
the O
entire O
open O
reading O
frame O
has O
yet O
to O
be O
completed O
. O

The O
reduced O
NO O
production O
in O
these O
cells O
was O
associated I-GENE
with O
low O
levels O
of O
mRNA I-GENE
of O
inducible I-GENE
NO O
synthetase I-GENE
. O

Some O
8 O
. O
8 O
kb O
of O
the O
_RARE_ I-GENE
_RARE_ I-GENE
plasmid O
_RARE_ I-GENE
was O
sequenced O
, O
_RARE_ I-GENE
eight O
tightly O
clustered O
open O
reading O
frames O
( O
ORFs O
) O
downstream O
from O
_RARE_ I-GENE
, O
which O
encodes O
pre I-GENE
- I-GENE
_RARE_ I-GENE
S I-GENE
. O

Purified I-GENE
Pra I-GENE
was O
also O
shown O
to O
physically O
interact O
with O
_RARE_ I-GENE
kinase I-GENE
( O
_RARE_ I-GENE
); O
_RARE_ I-GENE
and O
Pra I-GENE
can O
form O
a O
complex I-GENE
, O
but O
when O
the O
12 O
- I-GENE
kDa I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
and O
Pra I-GENE
are O
all O
present O
, O
_RARE_ I-GENE
has O
a O
higher O
affinity O
than O
Pra I-GENE
for O
forming O
a O
complex I-GENE
with O
the O
12 O
- I-GENE
kDa I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
from O
iron O
regulation O
, O
_RARE_ I-GENE
expression O
was O
affected O
by O
changes O
in O
DNA I-GENE
topology O
induced O
by O
_RARE_ I-GENE
A I-GENE
but O
not O
by O
the O
global O
virulence I-GENE
regulatory I-GENE
_RARE_ I-GENE
system O
. O

Molecular O
characterization O
of O
a O
large O
_RARE_ I-GENE
_RARE_ I-GENE
motility O
operon I-GENE
which O
is O
initiated O
by O
a O
consensus I-GENE
_RARE_ I-GENE
promoter I-GENE
. O

M I-GENE
. O
_RARE_ I-GENE
OxyR I-GENE
was O
_RARE_ I-GENE
and O
purified O
, O
and O
its O
binding I-GENE
to O
the O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
intergenic O
region O
of O
M I-GENE
. O
_RARE_ I-GENE
was O
demonstrated O
. O

The O
binding I-GENE
site I-GENE
for O
OxyR I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
of O
the O
_RARE_ I-GENE
loops O
controlling O
expression O
of O
_RARE_ I-GENE
in O
enteric O
bacteria O
and O
characteristic O
of O
the O
_RARE_ I-GENE
superfamily I-GENE
in O
general O
. O

In O
the O
present O
study O
, O
we O
have O
isolated O
and O
sequenced O
several O
_RARE_ I-GENE
cDNA I-GENE
gene I-GENE
fragments I-GENE
amplified O
by O
means O
of O
polymerase I-GENE
chain I-GENE
reaction O
( O
PCR O
) O
from O
parental O
( O
_RARE_ I-GENE
) O
and O
_RARE_ I-GENE
( O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
) O
tumour I-GENE
cells O
. O

Thirty O
- I-GENE
five O
patients O
were O
included O
. O

_RARE_ I-GENE
3 I-GENE
- I-GENE
4 I-GENE
_RARE_ I-GENE
was O
present O
in O
13 O
% O
of O
the O
cycles O
. O

Therefore O
more O
active O
and O
_RARE_ I-GENE
_RARE_ I-GENE
regimens O
are O
needed O
. O

None O
of O
these O
organic O
manifestations O
was O
discovered O
by O
_RARE_ I-GENE
means O
. O

While O
TGF I-GENE
- I-GENE
beta1 I-GENE
does O
not O
alter O
the O
mitogen I-GENE
- I-GENE
induced O
expression O
and O
abundance O
of O
G1 I-GENE
phase O
cyclin I-GENE
D1 I-GENE
and O
_RARE_ I-GENE
4 I-GENE
and O
2 I-GENE
in O
_RARE_ I-GENE
, O
it O
inhibits O
cyclin I-GENE
E I-GENE
- I-GENE
_RARE_ I-GENE
2 I-GENE
activity O
, O
thus O
preventing O
mitogen I-GENE
- I-GENE
elicited O
phosphorylation O
and O
inactivation O
of O
pRb I-GENE
in O
G1 I-GENE
phase O
and O
transition O
to O
S I-GENE
phase O
. O

However O
, O
the O
range O
of O
values O
observed O
is O
suggestive O
of O
the O
need O
to O
investigate O
_RARE_ I-GENE
with O
_RARE_ I-GENE
values O
of O
_RARE_ I-GENE
with O
respect O
to O
the O
_RARE_ I-GENE
- I-GENE
relationships O
between O
_RARE_ I-GENE
characteristics O
, O
duration O
of O
symptoms O
, O
clinical O
presentation O
and O
treatment O
efficacy O
. O

The O
prominent O
lesions O
were O
confined O
to O
the O
cerebral O
surface O
layer O
and O
_RARE_ I-GENE
tissue I-GENE
including O
the O
_RARE_ I-GENE
vessels O
, O
which O
were O
all O
_RARE_ I-GENE
in O
the O
cerebrospinal O
fluid O
, O
suggesting O
that O
some O
_RARE_ I-GENE
_RARE_ I-GENE
had O
been O
secreted O
into O
the O
fluid O
by O
the O
B I-GENE
. O
_RARE_ I-GENE
. O

This O
fragment I-GENE
contained O
the O
C I-GENE
- I-GENE
terminal I-GENE
47 O
nucleotides O
of O
_RARE_ I-GENE
, O
encoding O
3 I-GENE
- I-GENE
_RARE_ I-GENE
dehydrogenase I-GENE
; O
_RARE_ I-GENE
, O
encoding O
aspartate I-GENE
- I-GENE
beta I-GENE
- I-GENE
_RARE_ I-GENE
dehydrogenase I-GENE
( O
_RARE_ I-GENE
); O
and O
_RARE_ I-GENE
, O
whose O
product I-GENE
showed O
similarity O
to O
the O
_RARE_ I-GENE
proteins I-GENE
from O
Vibrio I-GENE
_RARE_ I-GENE
. O

Transcriptional O
activity O
was O
measured O
by O
_RARE_ I-GENE
- I-GENE
blot O
hybridization O
with O
steady O
- I-GENE
state O
RNA I-GENE
isolated O
from O
lacZ I-GENE
+ I-GENE
M I-GENE
. O
_RARE_ I-GENE
clones O
. O

_RARE_ I-GENE
I I-GENE
and O
(+)- I-GENE
_RARE_ I-GENE
, O
both O
of O
which O
were O
principal O
_RARE_ I-GENE
of O
the O
active O
fractions O
from O
this O
natural O
medicine O
, O
were O
found O
to O
show O
an O
inhibitory I-GENE
activity O
on O
the O
ethanol O
- I-GENE
induced O
muscle O
relaxation O
in O
rats O
. O

_RARE_ I-GENE
time O
and O
_RARE_ I-GENE
characteristics O
were O
analyzed O
together O
with O
the O
magnitude O
of O
cerebral O
blood O
flow O
to O
identify O
areas O
of O
brain O
activity O
_RARE_ I-GENE
to O
task O
and O
movement O
variables O
. O

_RARE_ I-GENE
with O
significantly O
greater O
rCBF O
for O
targeting O
were O
the O
left O
motor O
cortex O
, O
left O
_RARE_ I-GENE
_RARE_ I-GENE
, O
and O
left O
_RARE_ I-GENE
. O

Recent O
studies O
have O
demonstrated O
that O
the O
U1 I-GENE
snRNP I-GENE
is O
recruited O
to O
the O
5 I-GENE
' O
splice O
site I-GENE
by O
protein I-GENE
/ I-GENE
protein I-GENE
interactions O
involving O
the O
SR I-GENE
domains I-GENE
of O
the O
U1 I-GENE
- I-GENE
_RARE_ I-GENE
protein I-GENE
and O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
. O

Thus O
, O
the O
_RARE_ I-GENE
- I-GENE
snRNP I-GENE
- I-GENE
specific I-GENE
_RARE_ I-GENE
protein I-GENE
could O
potentially O
be O
involved O
in O
SR I-GENE
protein I-GENE
- I-GENE
mediated O
protein I-GENE
/ I-GENE
protein I-GENE
interactions O
and O
, O
additionally O
, O
its O
phosphorylation O
state O
could O
modulate O
pre I-GENE
- I-GENE
mRNA I-GENE
splicing O
. O

Purified I-GENE
P7 I-GENE
could O
be O
assembled O
onto O
particles O
lacking O
P7 I-GENE
and O
particles O
lacking O
both O
P2 I-GENE
( O
RNA I-GENE
polymerase I-GENE
) O
and O
P7 I-GENE
. O

However O
, O
the O
same O
_RARE_ I-GENE
peptide I-GENE
, O
when O
conjugated O
to O
_RARE_ I-GENE
, O
inhibits O
vertebrate I-GENE
_RARE_ I-GENE
. O

Plasma I-GENE
levels O
of O
protein I-GENE
C I-GENE
, O
protein I-GENE
S I-GENE
, O
and O
antithrombin I-GENE
III I-GENE
in O
patients O
with O
_RARE_ I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
bilateral O
recurrent O
branch O
retinal O
arterial O
occlusion O
( O
_RARE_ I-GENE
) O
is O
a O
rare O
syndrome O
characterized O
by O
_RARE_ I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
hearing O
loss O
, O
and O
recurrent O
branch O
retinal O
artery O
occlusion O
of O
unknown O
etiology O
. O

_RARE_ I-GENE
and O
corneal O
thickness O
measurements O
by O
in O
vivo O
_RARE_ I-GENE
microscopy O
through O
focusing O
( O
_RARE_ I-GENE
). O

_RARE_ I-GENE
downstream O
of O
the O
two O
human I-GENE
CA I-GENE
genes I-GENE
, O
possibly O
containing O
homologous O
enhancer I-GENE
elements O
, O
have O
not O
yet O
been O
reported O
. O

Recombinant I-GENE
plasmids O
containing O
the O
entire O
_RARE_ I-GENE
nt O
5 I-GENE
' O
UTR I-GENE
of O
exon O
1 I-GENE
and O
a O
_RARE_ I-GENE
nt O
segment O
of O
5 I-GENE
' O
flanking O
sequence I-GENE
stimulated O
luciferase I-GENE
activity O
nearly O
70 I-GENE
times O
higher O
than O
a O
promoterless O
control O
plasmid O
. O

Analysis O
for O
DNA I-GENE
- I-GENE
protein I-GENE
interactions O
by O
in O
vitro O
DNase I-GENE
- I-GENE
I I-GENE
footprinting O
identified O
a O
broad O
region O
of O
protection O
extending O
from O
nt O
- I-GENE
12 O
to O
+ I-GENE
38 O
. O

It O
is O
also O
homologous O
to O
other O
sugar I-GENE
carriers O
from O
human I-GENE
, O
mouse I-GENE
and O
Escherichia I-GENE
coli I-GENE
. O

_RARE_ I-GENE
now O
, O
each O
of O
these O
loci I-GENE
was O
considered O
to O
contain O
three O
genes I-GENE
( O
for O
regulator I-GENE
, O
_RARE_ I-GENE
and O
alpha I-GENE
- I-GENE
_RARE_ I-GENE
), O
but O
a O
fourth O
gene I-GENE
, O
presumably O
an O
extra I-GENE
alpha I-GENE
- I-GENE
_RARE_ I-GENE
gene I-GENE
, O
was O
found O
at O
_RARE_ I-GENE
adjacent O
to O
the O
_RARE_ I-GENE
cluster I-GENE
of O
three O
genes I-GENE
. O

Although O
methods O
to O
_RARE_ I-GENE
the O
control O
and O
activation O
_RARE_ I-GENE
images O
may O
correct O
for O
some O
of O
this O
_RARE_ I-GENE
error O
, O
they O
will O
be O
incomplete O
in O
_RARE_ I-GENE
for O
those O
that O
depend O
on O
spatial O
orientation O
. O

Three O
women O
have O
had O
abnormal O
_RARE_ I-GENE
follow O
up O
_RARE_ I-GENE
suggestive O
of O
residual O
disease O
. O

_RARE_ I-GENE
- I-GENE
forming O
cells O
are O
characterized O
by O
a O
high O
activity O
of O
alkaline I-GENE
and O
acid I-GENE
phosphatases I-GENE
and O
low O
_RARE_ I-GENE
- I-GENE
test O
values O
. O

Analysis O
of O
homologous O
DNA I-GENE
sequences I-GENE
within O
the O
first O
intron O
of O
the O
mouse I-GENE
and O
human I-GENE
_RARE_ I-GENE
genes I-GENE
: O
_RARE_ I-GENE
- I-GENE
like I-GENE
site I-GENE
and O
microsatellite I-GENE
DNA I-GENE

The O
integration O
at O
the O
_RARE_ I-GENE
_RARE_ I-GENE
of O
the O
Jak I-GENE
- I-GENE
Stat I-GENE
and O
AP I-GENE
- I-GENE
1 I-GENE
signaling O
pathways O
with O
other O
pre I-GENE
- I-GENE
existing O
proteins I-GENE
provides O
a O
cellular O
mechanism O
for O
cell O
- I-GENE
and O
cytokine O
- I-GENE
specific I-GENE
signaling O
. O

These O
studies O
point O
to O
the O
involvement O
of O
the O
MAP I-GENE
kinase I-GENE
pathway O
in O
the O
activation O
of O
monocytic O
cells O
during O
_RARE_ I-GENE
to O
inflammatory O
sites I-GENE
. O

Our O
results O
show O
that O
the O
temperature O
- I-GENE
sensitive O
_RARE_ I-GENE
- I-GENE
3 I-GENE
allele I-GENE
blocks O
mitotic O
recombination O
between O
tandemly O
repeated O
_RARE_ I-GENE
satellite I-GENE
sequences I-GENE
and O
significantly O
stabilizes O
a O
human I-GENE
_RARE_ I-GENE
satellite I-GENE
- I-GENE
containing O
YAC O
clone O
. O

A I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
derivative O
with O
an O
_RARE_ I-GENE
site I-GENE
( O
_RARE_ I-GENE
_RARE_ I-GENE
[ O
A I-GENE
(- O
10 O
) O
U O
]) I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
following O
infection O
of O
these O
strains O
. O

_RARE_ I-GENE
Ac I-GENE
/ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
: O
formation O
, O
structure O
and O
fate O
. O

This O
site I-GENE
is O
upstream O
from O
the O
TATA I-GENE
box I-GENE
used O
in O
somatic O
cells O
. O

In O
this O
study O
, O
we O
have O
examined O
the O
regulation O
of O
B I-GENE
- I-GENE
Myb I-GENE
activity O
by O
cyclin I-GENE
- I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
tumor I-GENE
suppressor I-GENE
genes I-GENE
, O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
and O
_RARE_ I-GENE
( O
_RARE_ I-GENE
), O
have O
been O
mapped O
to O
this O
region O
, O
but O
by O
Southern O
blot O
analysis O
, O
no O
homozygous O
deletions O
were O
detected O
in O
either O
gene I-GENE
. O

_RARE_ I-GENE
repair I-GENE
at O
the O
level O
of O
the O
nucleotide I-GENE
in O
the O
Saccharomyces I-GENE
cerevisiae I-GENE
_RARE_ I-GENE
gene I-GENE
: O
mapping O
of O
where O
enhanced O
repair I-GENE
in O
the O
transcribed O
strand O
begins O
or O
ends O
and O
identification O
of O
only O
a O
partial O
_RARE_ I-GENE
_RARE_ I-GENE
for O
_RARE_ I-GENE
upstream O
control O
sequences I-GENE
. O

An O
aromatic O
_RARE_ I-GENE
interaction O
between O
subunits I-GENE
_RARE_ I-GENE
mediate O
DNA I-GENE
sequence I-GENE
specificity O
: O
operator I-GENE
site I-GENE
discrimination O
by O
phage I-GENE
lambda I-GENE
_RARE_ I-GENE
repressor I-GENE
. O

We O
have O
characterized O
a O
panel O
of O
6 I-GENE
monoclonal I-GENE
antibodies I-GENE
raised O
against O
human I-GENE
platelet I-GENE
_RARE_ I-GENE
by O
Western O
blotting O
, O
immune I-GENE
precipitation O
, O
and O
immunofluorescence O
, O
and O
shown O
that O
antibodies I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
disrupt O
actin I-GENE
stress O
fibers O
and O
focal I-GENE
adhesions O
, O
and O
inhibit O
cell O
motility O
when O
_RARE_ I-GENE
into O
human I-GENE
fibroblasts O
. O

This O
locus I-GENE
maps O
approximately O
160 I-GENE
kbp O
from O
the O
genes I-GENE
encoding O
_RARE_ I-GENE
- I-GENE
associated I-GENE
proteins I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
, O
and O
yet O
insertions O
_RARE_ I-GENE
result O
in O
loss O
of O
these O
proteins I-GENE
and O
a O
_RARE_ I-GENE
- I-GENE
negative O
( O
HA I-GENE
-) I-GENE
phenotype O
, O
_RARE_ I-GENE
the O
_RARE_ I-GENE
_RARE_ I-GENE
- I-GENE
regulatory I-GENE
locus I-GENE
( O
_RARE_ I-GENE
). O

_RARE_ I-GENE
186 I-GENE
B I-GENE
is O
a O
72 O
- I-GENE
amino O
acid I-GENE
protein I-GENE
belonging O
to O
the O
_RARE_ I-GENE
family I-GENE
of O
analogous O
transcription I-GENE
factors I-GENE
present O
in O
P2 I-GENE
- I-GENE
like I-GENE
phage I-GENE
, O
which O
contain O
a O
Cys I-GENE
- I-GENE
X2 O
- I-GENE
Cys I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
Cys I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
Cys I-GENE
_RARE_ I-GENE
zinc I-GENE
- I-GENE
finger I-GENE
motif I-GENE
. O

The O
UV O
absorption O
spectrum O
revealed O
a O
_RARE_ I-GENE
at O
250 O
nm O
, O
characteristic O
of O
_RARE_ I-GENE
- I-GENE
Cd O
( O
II I-GENE
) O
ligand O
- I-GENE
to O
- I-GENE
metal O
charge I-GENE
- I-GENE
transfer I-GENE
_RARE_ I-GENE
, O
and O
the O
difference O
absorption O
coefficient O
after O
acidification O
( O
delta I-GENE
epsilon I-GENE
_RARE_ I-GENE
, O
24 O
mM O
- I-GENE
1 I-GENE
cm O
- I-GENE
1 I-GENE
) O
indicated O
the O
presence O
of O
a O
Cd O
( O
Cys I-GENE
- I-GENE
S I-GENE
) O
4 I-GENE
center I-GENE
. O

_RARE_ I-GENE
kinase I-GENE
( O
_RARE_ I-GENE
) O
attenuates O
levels O
of O
second O
messenger I-GENE
_RARE_ I-GENE
in O
cells O
and O
produces O
another O
( O
putative O
) O
messenger I-GENE
, O
_RARE_ I-GENE
acid I-GENE
. O

Recently O
, O
we O
have O
reported O
the O
cloning O
of O
the O
germ I-GENE
cell O
- I-GENE
specific I-GENE
, O
nuclear I-GENE
orphan I-GENE
receptor I-GENE
germ I-GENE
cell O
nuclear I-GENE
factor I-GENE
( O
_RARE_ I-GENE
)/ O
_RARE_ I-GENE
. O

Based O
on O
the O
sequence I-GENE
of O
the O
_RARE_ I-GENE
, O
we O
located O
a O
putative O
_RARE_ I-GENE
, O
referred O
to O
as O
P2 I-GENE
- I-GENE
_RARE_ I-GENE
, O
in O
the O
5 I-GENE
' O
promoter I-GENE
- I-GENE
flanking O
region O
of O
the O
mouse I-GENE
_RARE_ I-GENE
2 I-GENE
gene I-GENE
, O
which O
is O
induced O
during O
the O
same O
stage O
of O
_RARE_ I-GENE
as O
_RARE_ I-GENE
. O

Here O
we O
report O
the O
purification O
of O
this O
larger O
form O
as O
an O
approximately O
_RARE_ I-GENE
- I-GENE
kDa I-GENE
particle I-GENE
that O
contains O
_RARE_ I-GENE
+ I-GENE
4 I-GENE
and O
nine O
additional O
polypeptides I-GENE
, O
including O
mRNA I-GENE
- I-GENE
binding I-GENE
polypeptides I-GENE
of O
34 O
and O
36 O
kDa I-GENE
and O
a O
_RARE_ I-GENE
of O
110 I-GENE
/ I-GENE
105 I-GENE
kDa I-GENE
that O
proved O
to O
be O
_RARE_ I-GENE
. O

_RARE_ I-GENE
complexes I-GENE
_RARE_ I-GENE
at O
a O
higher O
molecular O
weight O
than O
inactive O
complexes I-GENE
, O
were O
relatively O
deficient O
in O
both O
p21 I-GENE
and O
p27 I-GENE
, O
and O
contained O
Cdk2 I-GENE
with O
increased O
threonine I-GENE
160 I-GENE
phosphorylation O
, O
consistent O
with O
a O
mechanism O
of O
activation O
of O
cyclin I-GENE
E I-GENE
- I-GENE
Cdk2 I-GENE
involving O
both O
reduced O
CDK I-GENE
inhibitor I-GENE
association O
and O
CDK I-GENE
- I-GENE
activating I-GENE
kinase I-GENE
- I-GENE
mediated O
phosphorylation O
of O
Cdk2 I-GENE
. O

Thirty O
Class I-GENE
I I-GENE
and O
Class I-GENE
II I-GENE
_RARE_ I-GENE
in O
30 O
patients O
were O
treated O
with O
a O
modified O
_RARE_ I-GENE
connective O
tissue I-GENE
graft O
procedure O
. O

The O
derivatives O
of O
the O
latter O
two O
cell O
lines O
showed O
increased O
expression O
of O
the O
_RARE_ I-GENE
protein I-GENE
and O
inhibition O
of O
cell O
growth I-GENE
. O

The O
_RARE_ I-GENE
mortality O
of O
all O
patients O
was O
1 I-GENE
. O
9 O
%, O
the O
mortality O
of O
patients O
older O
than O
70 I-GENE
years O
was O
4 I-GENE
. O
3 I-GENE
%. O

Chronic O
renal O
failure O
patients O
essentially O
_RARE_ I-GENE
from O
cardiovascular O
causes O
, O
and O
the O
frequency O
of O
malignant O
disease O
responsible O
for O
death O
is O
estimated O
to O
be O
10 O
%. O

The O
new O
_RARE_ I-GENE
definition O
of O
cervical O
cancer O
stage O
IA O
: O
a O
_RARE_ I-GENE
. O

The O
effect O
of O
_RARE_ I-GENE
on O
class I-GENE
I I-GENE
biogenesis O
was O
analyzed O
in O
more O
detail O
using O
a O
_RARE_ I-GENE
- I-GENE
expressing O
recombinant I-GENE
vaccinia I-GENE
virus I-GENE
( O
_RARE_ I-GENE
). O

This O
study O
indicates O
that O
the O
phenotype O
of O
_RARE_ I-GENE
_RARE_ I-GENE
seen O
in O
_RARE_ I-GENE
patients O
which O
harbor O
either O
of O
these O
two O
mutations O
may O
not O
be O
directly O
due O
to O
the O
failure O
of O
the O
mutant I-GENE
myosin I-GENE
heavy I-GENE
chain I-GENE
protein I-GENE
to O
_RARE_ I-GENE
and O
form O
normal O
_RARE_ I-GENE
, O
but O
may O
rather O
be O
a O
secondary O
effect O
possibly O
resulting O
from O
the O
chronic O
stress O
of O
decreased O
beta I-GENE
MHC I-GENE
function O
. O

_RARE_ I-GENE
coupled I-GENE
plasma I-GENE
_RARE_ I-GENE
emission O
spectroscopy O
was O
employed O
to O
obtain O
the O
tissue I-GENE
_RARE_ I-GENE
measurements O
. O

An O
egg I-GENE
protein I-GENE
, O
lysozyme I-GENE
, O
is O
a O
still O
_RARE_ I-GENE
additive O
currently O
used O
in O
_RARE_ I-GENE
preparation O
. O

A I-GENE
method O
for O
the O
simultaneous O
determination O
of O
de O
( O
N I-GENE
- I-GENE
methyl O
)- I-GENE
N I-GENE
- I-GENE
ethyl O
- I-GENE
8 O
, O
9 O
- I-GENE
_RARE_ I-GENE
A I-GENE
6 I-GENE
, O
9 O
- I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
, O
I I-GENE
) O
and O
its O
three O
metabolites O
in O
human I-GENE
plasma I-GENE
and O
urine O
has O
been O
developed O
using O
high O
- I-GENE
performance O
liquid O
chromatography O
( O
HPLC O
) O
with O
_RARE_ I-GENE
( O
CL O
) O
detection O
. O

Similarly O
, O
the O
DNA I-GENE
- I-GENE
binding I-GENE
activity O
of O
activator I-GENE
protein I-GENE
1 I-GENE
( O
AP I-GENE
- I-GENE
1 I-GENE
) O
is O
modified O
by O
a O
DNA I-GENE
repair I-GENE
enzyme I-GENE
, O
_RARE_ I-GENE
factor I-GENE
1 I-GENE
( O
_RARE_ I-GENE
- I-GENE
1 I-GENE
), O
which O
is O
identical O
to O
a O
DNA I-GENE
repair I-GENE
enzyme I-GENE
, O
AP I-GENE
endonuclease I-GENE
. O

_RARE_ I-GENE
an O
_RARE_ I-GENE
domain I-GENE
and O
an O
SH3 I-GENE
- I-GENE
binding I-GENE
domain I-GENE
, O
_RARE_ I-GENE
and O
the O
C I-GENE
. O
elegans I-GENE
homologue I-GENE
define O
a O
novel O
family I-GENE
of O
_RARE_ I-GENE
binding I-GENE
proteins I-GENE
. O

However O
, O
its O
participation O
in O
_RARE_ I-GENE
induced O
by O
_RARE_ I-GENE
_RARE_ I-GENE
is O
unclear O
. O

The O
capacity O
to O
repair I-GENE
8 O
- I-GENE
_RARE_ I-GENE
has O
been O
measured O
in O
cell O
- I-GENE
free O
extracts O
of O
wild I-GENE
- I-GENE
type I-GENE
and O
_RARE_ I-GENE
strains O
using O
a O
_RARE_ I-GENE
DNA I-GENE
fragment I-GENE
containing O
a O
single O
8 O
- I-GENE
_RARE_ I-GENE
residue O
paired I-GENE
with O
a O
cytosine O
( O
8 O
- I-GENE
_RARE_ I-GENE
/ I-GENE
C I-GENE
) O
as O
a O
substrate I-GENE
. O

Results O
from O
our O
and O
other O
laboratories O
have O
suggested O
that O
_RARE_ I-GENE
- I-GENE
01 O
induces O
preferential O
G1 I-GENE
- I-GENE
phase O
accumulation O
in O
several O
human I-GENE
tumor I-GENE
cell O
lines O
tested O
. O

Northern O
and O
RT I-GENE
- I-GENE
PCR O
analysis O
of O
_RARE_ I-GENE
expression O
in O
mouse I-GENE
tissues O
from O
animals O
with O
segmental O
, O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
failed O
to O
detect O
substantially O
reduced O
or O
absent O
expression O
compared O
to O
control O
animals O
, O
_RARE_ I-GENE
to O
provide O
any O
evidence O
for O
maternal I-GENE
- I-GENE
specific I-GENE
expression O
from O
this O
locus I-GENE
. O

Two O
predominant O
effects O
were O
noted O
: O
( O
i O
) O
the O
_RARE_ I-GENE
residue O
in O
the O
dual O
phosphorylation O
motif I-GENE
Thr I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
Tyr I-GENE
as O
well O
as O
the O
length I-GENE
of O
L12 I-GENE
influence O
p38 I-GENE
substrate I-GENE
specificity O
, O
and O
( O
ii O
) O
the O
length I-GENE
of O
L12 I-GENE
plays O
a O
major I-GENE
role O
in O
controlling O
autophosphorylation O
. O

A I-GENE
novel O
, O
testis I-GENE
- I-GENE
specific I-GENE
mRNA I-GENE
transcript I-GENE
encoding O
an O
NH2 I-GENE
- I-GENE
terminal I-GENE
truncated I-GENE
nitric I-GENE
- I-GENE
oxide I-GENE
synthase I-GENE
. O
mRNA I-GENE
diversity O
represents O
a O
major I-GENE
_RARE_ I-GENE
of O
neuronal O
nitric I-GENE
- I-GENE
oxide I-GENE
synthase I-GENE
( O
_RARE_ I-GENE
) O
gene I-GENE
expression O
in O
somatic O
cells O
/ I-GENE
tissues O
. O

Unlike O
the O
_RARE_ I-GENE
- I-GENE
binding I-GENE
domain I-GENE
, O
the O
homeodomain I-GENE
when O
isolated O
binds O
poorly O
and O
with O
low O
specificity O
to O
DNA I-GENE
. O

Cotransfection O
of O
Ets I-GENE
- I-GENE
2 I-GENE
and O
p44 I-GENE
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
( O
MAP I-GENE
) O
kinase I-GENE
expression O
vectors O
strongly O
_RARE_ I-GENE
HB I-GENE
- I-GENE
EGF I-GENE
promoter I-GENE
activation O
in O
response O
to O
_RARE_ I-GENE
- I-GENE
1 I-GENE
: O
ER I-GENE
. O

Cyclin I-GENE
D1 I-GENE
could O
not O
be O
_RARE_ I-GENE
from O
_RARE_ I-GENE
in O
the O
resistant O
_RARE_ I-GENE
cell O
lysates O
. O

The O
importance O
of O
posttranslational O
regulation O
of O
_RARE_ I-GENE
by O
TGF I-GENE
- I-GENE
beta I-GENE
is O
_RARE_ I-GENE
by O
the O
observation O
that O
in O
TGF I-GENE
- I-GENE
beta I-GENE
- I-GENE
resistant O
_RARE_ I-GENE
, O
although O
the O
_RARE_ I-GENE
transcript I-GENE
increased O
, O
_RARE_ I-GENE
protein I-GENE
was O
not O
stabilized O
and O
did O
not O
accumulate O
, O
and O
cyclin I-GENE
D1 I-GENE
- I-GENE
_RARE_ I-GENE
association O
and O
kinase I-GENE
activation O
were O
not O
inhibited O
. O

The O
_RARE_ I-GENE
protein I-GENE
, O
a O
member O
of O
the O
MADS I-GENE
box I-GENE
family I-GENE
of O
transcription I-GENE
factors I-GENE
, O
functions O
downstream O
of O
_RARE_ I-GENE
in O
the O
pathway O
. O

To O
identify O
cis O
- I-GENE
acting O
elements O
that O
target O
c I-GENE
- I-GENE
myc I-GENE
mRNA I-GENE
for O
_RARE_ I-GENE
during O
_RARE_ I-GENE
, O
we O
stably O
transfected O
C2C12 O
cells O
with O
mutant I-GENE
myc I-GENE
genes I-GENE
or O
chimeric I-GENE
genes I-GENE
in O
which O
various O
myc I-GENE
sequences I-GENE
were O
fused O
to O
the O
human I-GENE
beta I-GENE
- I-GENE
globin I-GENE
gene I-GENE
or O
to O
the O
bacterial I-GENE
chloramphenicol I-GENE
acetyltransferase I-GENE
( O
CAT I-GENE
) O
gene I-GENE
. O

Furthermore O
, O
experiments O
with O
_RARE_ I-GENE
temperature O
- I-GENE
sensitive O
p53 I-GENE
cells O
indicate O
that O
aberrant O
tal I-GENE
- I-GENE
1 I-GENE
expression O
at O
the O
permissive O
temperature O
does O
not O
exert O
a O
proliferative O
effect O
but O
causes O
p53 I-GENE
- I-GENE
mediated O
apoptosis O
, O
i O
. O
e O
., O
the O
tal I-GENE
- I-GENE
1 I-GENE
proliferative O
effect O
depends O
on O
the O
integrity O
of O
the O
cell O
cycle O
_RARE_ I-GENE
of O
the O
host O
cell O
, O
as O
observed O
for O
c I-GENE
- I-GENE
myc I-GENE
and O
other O
oncogenes I-GENE
. O
tal I-GENE
- I-GENE
1 I-GENE
mutant I-GENE
experiments O
indicate O
that O
ectopic O
tal I-GENE
- I-GENE
1 I-GENE
effects O
are O
mediated O
by O
both O
the O
DNA I-GENE
- I-GENE
binding I-GENE
and O
the O
heterodimerization O
domains I-GENE
, O
while O
the O
N I-GENE
- I-GENE
terminally I-GENE
truncated I-GENE
tal I-GENE
- I-GENE
1 I-GENE
variant I-GENE
( O
_RARE_ I-GENE
) O
expressed O
in O
T I-GENE
- I-GENE
ALL O
malignant O
cells O
_RARE_ I-GENE
the O
effects O
of O
the O
wild I-GENE
- I-GENE
type I-GENE
protein I-GENE
. O

The O
likelihood O
that O
a O
common O
region O
of O
deletions O
would O
contain O
a O
tumor I-GENE
suppressor I-GENE
is O
strongly O
enhanced O
by O
_RARE_ I-GENE
of O
that O
region O
with O
a O
chromosome O
fragment I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
upon O
introduction O
in O
tumor I-GENE
cells O
. O

DNA I-GENE
- I-GENE
binding I-GENE
activity O
was O
not O
increased O
by O
the O
addition O
of O
forskolin O
to O
_RARE_ I-GENE
or O
luteal O
cells O
. O

However O
, O
in O
some O
of O
them O
either O
pattern O
may O
_RARE_ I-GENE
or O
be O
exclusively O
present O
. O

Upon O
induction O
of O
_RARE_ I-GENE
, O
viability O
increased O
2 I-GENE
- I-GENE
6 I-GENE
- I-GENE
fold O
. O

In O
particular O
, O
Western O
, O
supershift O
, O
and O
promoter I-GENE
deletion O
analyses O
suggested O
a O
role O
for O
CCAAT I-GENE
/ I-GENE
enhancer I-GENE
- I-GENE
binding I-GENE
protein I-GENE
- I-GENE
beta I-GENE
( O
C I-GENE
/ I-GENE
EBP I-GENE
- I-GENE
beta I-GENE
) O
binding I-GENE
site I-GENE
between O
- I-GENE
_RARE_ I-GENE
and O
- I-GENE
_RARE_ I-GENE
in O
regulating O
transcription I-GENE
of O
_RARE_ I-GENE
- I-GENE
1 I-GENE
in O
monocytic O
cells O
. O

11 O
- I-GENE
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
NH2 I-GENE
and O
11 O
- I-GENE
_RARE_ I-GENE
- I-GENE
SH I-GENE
- I-GENE
NH2 I-GENE
establish O
that O
a O
simple O
_RARE_ I-GENE
_RARE_ I-GENE
can O
maintain O
an O
appropriate O
distance O
between O
three O
elements O
critical O
for O
recognition I-GENE
by O
the O
fungal I-GENE
enzyme I-GENE
' O
s O
peptide I-GENE
- I-GENE
binding I-GENE
site I-GENE
: O
a O
simple O
omega I-GENE
- I-GENE
terminal I-GENE
amino O
group O
, O
a O
beta I-GENE
- I-GENE
_RARE_ I-GENE
, O
and O
an O
epsilon I-GENE
- I-GENE
amino O
group O
or O
an O
_RARE_ I-GENE
. O

The O
carboxyl O
- I-GENE
terminal I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
is O
structurally O
related I-GENE
to O
the O
DNA I-GENE
- I-GENE
binding I-GENE
domain I-GENE
of O
the O
erythroid I-GENE
transcription I-GENE
factor I-GENE
GATA I-GENE
- I-GENE
1 I-GENE
. O

Cdc2 I-GENE
co O
- I-GENE
_RARE_ I-GENE
with O
_RARE_ I-GENE
in O
S I-GENE
. O
pombe I-GENE
cell O
lysates O
, O
although O
Cdc2 I-GENE
may O
not O
be O
the O
major I-GENE
catalytic O
partner I-GENE
of O
a O
_RARE_ I-GENE
kinase I-GENE
in O
vivo O
. O

_RARE_ I-GENE
is O
known O
about O
the O
mechanism O
, O
but O
the O
availability O
of O
rapid O
_RARE_ I-GENE
assays O
for O
monitoring O
immunoglobulin I-GENE
_RARE_ I-GENE
would O
greatly O
aid O
the O
development O
of O
culture O
systems O
for O
_RARE_ I-GENE
B I-GENE
cells O
as O
well O
as O
the O
screening O
for O
individuals O
deficient O
in O
the O
process O
. O

Expression O
of O
the O
human I-GENE
heat I-GENE
shock I-GENE
protein I-GENE
70 I-GENE
gene I-GENE
( O
hsp70 I-GENE
) O
is O
induced O
by O
various O
_RARE_ I-GENE
of O
stress O
and O
by O
oncogenes I-GENE
. O

Of O
these O
proteins I-GENE
, O
five O
have O
previously O
been O
shown O
to O
be O
phosphorylated O
during O
mitosis O
( O
epithelial O
- I-GENE
microtubule I-GENE
associated I-GENE
protein I-GENE
- I-GENE
115 I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
factor I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
and O
_RARE_ I-GENE
protein I-GENE
_RARE_ I-GENE
), O
five O
are O
related I-GENE
to O
proteins I-GENE
postulated O
to O
have O
roles O
in O
mitosis O
( O
epithelial O
- I-GENE
microtubule I-GENE
associated I-GENE
protein I-GENE
- I-GENE
115 I-GENE
, O
Schizosaccharomyces I-GENE
pombe I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
protein I-GENE
, O
_RARE_ I-GENE
and O
the O
RNA I-GENE
helicase I-GENE
_RARE_ I-GENE
), O
and O
nine O
are O
related I-GENE
to O
transcription I-GENE
factors I-GENE
( O
_RARE_ I-GENE
, O
negative O
co O
- I-GENE
factor I-GENE
2alpha I-GENE
, O
_RARE_ I-GENE
, O
S I-GENE
. O
pombe I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
and O
two O
isoforms I-GENE
of O
_RARE_ I-GENE
). O

Thus O
, O
depending O
on O
their O
location O
, O
_RARE_ I-GENE
cross O
- I-GENE
links O
affected O
different O
steps O
in O
the O
initiation I-GENE
process O
. O

Activation O
of O
alpha I-GENE
4 I-GENE
beta I-GENE
1 I-GENE
with O
_RARE_ I-GENE
/ I-GENE
16 O
inhibited O
the O
cytoplasmic I-GENE
_RARE_ I-GENE
and O
cell O
migration O
but O
did O
not O
affect O
the O
pattern O
of O
phosphorylation O
. O

_RARE_ I-GENE
on O
two O
_RARE_ I-GENE
measures O
- I-GENE
the O
National O
Adult O
_RARE_ I-GENE
Test O
- I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
- I-GENE
R I-GENE
) O
and O
the O
_RARE_ I-GENE
_RARE_ I-GENE
from O
the O
_RARE_ I-GENE
Adult O
_RARE_ I-GENE
Scale O
- I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
- I-GENE
R I-GENE
)- I-GENE
showed O
strong O
correlations O
with O
level O
of O
education O
. O

L I-GENE
- I-GENE
_RARE_ I-GENE
, O
a O
selective O
inhibitor I-GENE
of O
the O
inducible I-GENE
nitric I-GENE
oxide I-GENE
synthase I-GENE
, O
increases O
the O
mean O
systemic O
filling O
pressure O
, O
thereby O
_RARE_ I-GENE
venous O
return O
, O
under O
these O
conditions O
. O

RESULTS O
: O
Of O
the O
29 O
patients O
who O
received O
concurrent O
chemotherapy O
and O
G I-GENE
- I-GENE
CSF I-GENE
, O
ten O
( O
34 O
%; O
95 O
% O
confidence O
interval O
[ O
CI O
], O
17 O
. O
9 O
to O
54 I-GENE
. O
3 I-GENE
%) O
were O
believed O
to O
have O
clinically O
significant O
_RARE_ I-GENE
toxicity O
. O

The O
different O
holoenzyme I-GENE
RNA I-GENE
polymerases I-GENE
generated O
upon O
_RARE_ I-GENE
these O
mutants I-GENE
independently O
with O
core I-GENE
RNA I-GENE
polymerase I-GENE
( O
_RARE_ I-GENE
beta I-GENE
') I-GENE
have O
shown O
reduced O
transcriptional O
activity O
in O
comparison O
to O
the O
enzyme I-GENE
containing O
wild I-GENE
- I-GENE
type I-GENE
sigma I-GENE
factor I-GENE
. O

These O
data O
are O
consistent O
with O
a O
model O
in O
which O
GATA I-GENE
- I-GENE
5 I-GENE
_RARE_ I-GENE
a O
unique O
temporally O
and O
spatially O
restricted O
function O
in O
the O
embryonic O
heart O
and O
lung O
. O

The O
_RARE_ I-GENE
sequence I-GENE
encodes O
a O
protein I-GENE
of O
_RARE_ I-GENE
amino O
acids O
that O
is O
nearly O
identical O
to O
the O
previously O
reported O
protein I-GENE
sequence I-GENE
of O
human I-GENE
_RARE_ I-GENE
- I-GENE
1 I-GENE
. O

Here O
we O
characterize O
an O
S I-GENE
. O
cerevisiae I-GENE
_RARE_ I-GENE
homolog I-GENE
( O
_RARE_ I-GENE
) O
and O
present O
evidence O
that O
it O
associates O
in O
a O
complex I-GENE
with O
a O
_RARE_ I-GENE
homolog I-GENE
, O
_RARE_ I-GENE
. O

Shc I-GENE
stimulates O
Ras I-GENE
/ I-GENE
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
( O
MAPK I-GENE
) O
through O
forming O
a O
complex I-GENE
with O
Grb2 I-GENE
at O
the O
phosphorylated O
tyrosine I-GENE
( O
Y I-GENE
) O
residue O
_RARE_ I-GENE
. O

In O
contrast O
, O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
Shc I-GENE
, O
but O
not O
_RARE_ I-GENE
Shc I-GENE
, O
reduced O
the O
EGF I-GENE
- I-GENE
induced O
c I-GENE
- I-GENE
myc I-GENE
message I-GENE
. O

The O
Ras I-GENE
guanine I-GENE
nucleotide I-GENE
- I-GENE
binding I-GENE
protein I-GENE
functions O
as O
a O
molecular O
switch O
in O
signalling O
downstream O
of O
protein I-GENE
- I-GENE
tyrosine I-GENE
kinases I-GENE
. O

We O
show O
that O
_RARE_ I-GENE
and O
_RARE_ I-GENE
have O
MEF2 I-GENE
- I-GENE
related I-GENE
DNA I-GENE
- I-GENE
binding I-GENE
_RARE_ I-GENE
: O
_RARE_ I-GENE
binds O
with O
the O
same O
specificity O
as O
MEF2 I-GENE
, O
_RARE_ I-GENE
( O
T I-GENE
/ I-GENE
A I-GENE
) O
_RARE_ I-GENE
, O
while O
_RARE_ I-GENE
binds O
a O
more O
extended O
consensus I-GENE
sequence I-GENE
, O
_RARE_ I-GENE
( O
T I-GENE
/ I-GENE
A I-GENE
) O
_RARE_ I-GENE
. O

_RARE_ I-GENE
I I-GENE
and O
II I-GENE
of O
B I-GENE
" O
are O
_RARE_ I-GENE
upon O
assembly O
of O
the O
_RARE_ I-GENE
- I-GENE
DNA I-GENE
complex I-GENE
, O
as O
determined O
by O
protein I-GENE
footprinting O
. O

_RARE_ I-GENE
switch O
experiments O
reveal O
that O
C I-GENE
/ I-GENE
EBP I-GENE
beta I-GENE
proteins I-GENE
containing O
either O
the O
leucine I-GENE
zipper I-GENE
or O
the O
activation O
domain I-GENE
of O
C I-GENE
/ I-GENE
EBP I-GENE
alpha I-GENE
are O
unable O
to O
stimulate O
the O
_RARE_ I-GENE
promoter I-GENE
yet O
are O
fully O
capable O
of O
transactivating O
an O
artificial O
promoter I-GENE
bearing O
a O
high O
- I-GENE
affinity O
C I-GENE
/ I-GENE
EBP I-GENE
site I-GENE
. O

The O
similar O
phenotypes O
of O
_RARE_ I-GENE
and O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
mutations O
suggest O
that O
_RARE_ I-GENE
and O
_RARE_ I-GENE
have O
related I-GENE
, O
but O
not O
identical O
, O
functions O
in O
_RARE_ I-GENE
the O
activity O
of O
the O
general O
transcription I-GENE
machinery O
in O
vivo O
. O

_RARE_ I-GENE
, O
a O
new O
nucleus O
- I-GENE
localized O
member O
of O
the O
_RARE_ I-GENE
- I-GENE
box I-GENE
protein I-GENE
family I-GENE
from O
higher O
plants O
. O

These O
activities O
are O
all O
required O
for O
stimulation O
of O
cell O
growth I-GENE
by O
middle I-GENE
- I-GENE
T I-GENE
and O
activate O
members O
of O
the O
MAP I-GENE
kinase I-GENE
family I-GENE
. O

A I-GENE
role O
for O
the O
small I-GENE
GTPase I-GENE
Rac I-GENE
in O
_RARE_ I-GENE
middle I-GENE
- I-GENE
T I-GENE
antigen I-GENE
- I-GENE
mediated O
activation O
of O
the O
serum I-GENE
response O
element I-GENE
and O
in O
cell O
transformation O
. O

_RARE_ I-GENE
- I-GENE
activity O
curves O
from O
the O
gastric O
region O
of O
interest O
were O
used O
, O
after O
_RARE_ I-GENE
to O
appropriate O
_RARE_ I-GENE
procedures O
, O
to O
_RARE_ I-GENE
the O
mean O
gastric O
transit O
time O
( O
_RARE_ I-GENE
90 O
) O
and O
the O
fraction O
of O
the O
test O
meal I-GENE
retained O
in O
the O
stomach O
after O
90 O
min O
( O
_RARE_ I-GENE
). O

This O
study O
provides O
a O
direct O
_RARE_ I-GENE
of O
a O
role O
for O
G I-GENE
_RARE_ I-GENE
in O
mediating O
the O
agonist O
- I-GENE
stimulated O
translocation O
of O
_RARE_ I-GENE
and O
_RARE_ I-GENE
in O
an O
intact O
cellular O
system O
and O
demonstrates O
isoform I-GENE
specificity O
in O
the O
interaction O
of O
these O
components O
. O

Our O
results O
indicate O
that O
RA O
- I-GENE
mediated O
repression O
of O
the O
_RARE_ I-GENE
gene I-GENE
is O
due O
to O
binding I-GENE
of O
_RARE_ I-GENE
RAR I-GENE
/ I-GENE
RXR I-GENE
to O
a O
novel O
negative O
RA O
response O
element I-GENE
. O

_RARE_ I-GENE
mutations O
of O
the O
five O
tyrosine I-GENE
residues O
in O
the O
cytoplasmic I-GENE
domain I-GENE
of O
the O
receptor I-GENE
were O
subsequently O
used O
to O
confirm O
our O
conclusions O
. O

We O
describe O
a O
novel O
method O
using O
Saccharomyces I-GENE
cerevisiae I-GENE
for O
detecting O
protein I-GENE
- I-GENE
_RARE_ I-GENE
mutations O
in O
any O
gene I-GENE
of O
interest O
. O

_RARE_ I-GENE
injury O
during O
preservation O
of O
human I-GENE
_RARE_ I-GENE
with O
_RARE_ I-GENE
and O
_RARE_ I-GENE
solution O
. O

The O
_RARE_ I-GENE
recorded O
responses O
consisted O
of O
an O
early I-GENE
R1 I-GENE
response O
in O
the O
_RARE_ I-GENE
_RARE_ I-GENE
muscle O
ipsilateral O
to O
the O
side O
of O
stimulation O
, O
a O
bilateral O
late O
response O
( O
ipsilateral O
R2 I-GENE
and O
contralateral O
_RARE_ I-GENE
) O
and O
a O
third O
, O
_RARE_ I-GENE
response O
, O
in O
the O
ipsilateral O
_RARE_ I-GENE
_RARE_ I-GENE
muscle O
. O

The O
prognosis O
of O
seven O
patients O
who O
received O
_RARE_ I-GENE
was O
significantly O
better O
than O
that O
of O
13 O
patients O
who O
received O
conventional O
therapy O
alone O
. O

( O
1994 O
, O
_RARE_ I-GENE
. O

The O
_RARE_ I-GENE
intensity O
of O
both O
_RARE_ I-GENE
colonies O
and O
_RARE_ I-GENE
of O
_RARE_ I-GENE
transformants O
was O
_RARE_ I-GENE
than O
that O
of O
the O
wild I-GENE
type I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
in O
_RARE_ I-GENE
_RARE_ I-GENE
involves O
the O
formation O
of O
_RARE_ I-GENE
- I-GENE
S I-GENE
-[ I-GENE
_RARE_ I-GENE
- I-GENE
carrier I-GENE
protein I-GENE
] O
from O
acetyl I-GENE
- I-GENE
S I-GENE
-[ I-GENE
_RARE_ I-GENE
- I-GENE
carrier I-GENE
protein I-GENE
] O
and O
_RARE_ I-GENE
, O
_RARE_ I-GENE
to O
a O
_RARE_ I-GENE
protein I-GENE
and O
its O
_RARE_ I-GENE
that O
is O
coupled I-GENE
to O
delta I-GENE
mu I-GENE
Na I-GENE
+ I-GENE
generation O
. O

The O
_RARE_ I-GENE
peptide I-GENE
sequence I-GENE
shows O
a O
' O
leucine I-GENE
- I-GENE
zipper I-GENE
' O
_RARE_ I-GENE
motif I-GENE
with O
limited O
homology I-GENE
to O
Fos I-GENE
/ I-GENE
Jun I-GENE
and O
ATF I-GENE
/ I-GENE
CREB I-GENE
proteins I-GENE
and O
several O
putative O
phosphorylation O
sites I-GENE
. O

Here O
we O
report O
the O
cloning O
of O
the O
protein I-GENE
that O
binds O
to O
enhancer I-GENE
site I-GENE
III I-GENE
. O

Further O
support O
for O
a O
direct O
interaction O
of O
_RARE_ I-GENE
, O
_RARE_ I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
from O
the O
toxicity O
of O
strong O
_RARE_ I-GENE
overexpression O
which O
is O
suppressed O
by O
co O
- I-GENE
overexpression O
of O
_RARE_ I-GENE
or O
_RARE_ I-GENE
. O

_RARE_ I-GENE
needed O
for O
iron O
- I-GENE
regulated O
expression O
of O
_RARE_ I-GENE
were O
localized O
to O
a O
_RARE_ I-GENE
bp O
region O
mapping O
2 I-GENE
. O
3 I-GENE
and O
2 I-GENE
. O
6 I-GENE
kb O
upstream O
of O
the O
ATG O
. O

A I-GENE
genetic O
screen O
applied O
to O
mutants I-GENE
in O
the O
branch O
site I-GENE
region O
shows O
that O
all O
positions O
in O
the O
conserved O
_RARE_ I-GENE
sequence I-GENE
are O
important O
for O
intron O
recognition I-GENE
. O

_RARE_ I-GENE
of O
_RARE_ I-GENE
and O
_RARE_ I-GENE
( O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
) O
activity O
in O
periodontal O
disease O
. O

Comparison O
of O
the O
p50 I-GENE
sequence I-GENE
to O
other O
cloned O
proteins I-GENE
revealed O
89 I-GENE
% O
homology I-GENE
with O
a O
_RARE_ I-GENE
- I-GENE
binding I-GENE
protein I-GENE
and O
54 I-GENE
% O
homology I-GENE
with O
Drosophila I-GENE
cell O
cycle O
control O
protein I-GENE
( O
_RARE_ I-GENE
) O
37 O
. O

A I-GENE
polypeptide I-GENE
encoded I-GENE
by O
the O
_RARE_ I-GENE
16 O
open O
reading O
frame O
has O
sequence I-GENE
similarity O
to O
the O
catalytic O
domain I-GENE
of O
several O
receptor I-GENE
protein I-GENE
kinases I-GENE
from O
plants O
including O
the O
S I-GENE
- I-GENE
receptor I-GENE
kinases I-GENE
implicated O
in O
the O
rejection O
of O
self O
- I-GENE
pollen O
in O
_RARE_ I-GENE
species O
and O
the O
_RARE_ I-GENE
gene I-GENE
product I-GENE
of O
tomato I-GENE
which O
confers O
resistance O
to O
a O
bacterial I-GENE
_RARE_ I-GENE
. O

The O
_RARE_ I-GENE
1 I-GENE
and O
_RARE_ I-GENE
2 I-GENE
types O
of O
cDNA I-GENE
sequences I-GENE
were O
the O
most O
_RARE_ I-GENE
among O
the O
28 O
different O
_RARE_ I-GENE
identified O
among O
about O
200 O
peroxidase I-GENE
encoding O
ESTs I-GENE
. O

_RARE_ I-GENE
information O
including O
echocardiographic O
sequences I-GENE
, O
_RARE_ I-GENE
_RARE_ I-GENE
sequences I-GENE
, O
x O
- I-GENE
ray O
analysis O
, O
_RARE_ I-GENE
, O
etc O
. O
is O
represented O
in O
the O
program O
. O

We O
report O
here O
that O
constitutively O
active O
_RARE_ I-GENE
could O
activate O
_RARE_ I-GENE
in O
the O
absence O
of O
oncogenic I-GENE
Ras I-GENE
. O

In O
Schizosaccharomyces I-GENE
pombe I-GENE
, O
the O
activity O
of O
the O
M I-GENE
- I-GENE
phase O
- I-GENE
inducing O
Cdc2 I-GENE
/ I-GENE
_RARE_ I-GENE
cyclin I-GENE
- I-GENE
dependent I-GENE
kinase I-GENE
is O
inhibited O
by O
Wee1 I-GENE
and O
_RARE_ I-GENE
tyrosine I-GENE
kinases I-GENE
, O
and O
activated I-GENE
by O
_RARE_ I-GENE
and O
_RARE_ I-GENE
tyrosine I-GENE
phosphatases I-GENE
. O

_RARE_ I-GENE
response O
to O
_RARE_ I-GENE
, O
_RARE_ I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
wheat I-GENE
- I-GENE
_RARE_ I-GENE
based O
_RARE_ I-GENE
in O
normal O
subjects O
. O

4 I-GENE
. O
26 O
+/- O
1 I-GENE
. O
54 I-GENE
mmol O
/ I-GENE
l O
, O
P I-GENE
< O
0 O
. O
01 O
), O
and O
systolic O
BP I-GENE
responses O
to O
intravenous O
norepinephrine O
and O
angiotensin I-GENE
II I-GENE
were O
significantly O
higher O
on O
_RARE_ I-GENE
than O
on O
_RARE_ I-GENE
( O
P I-GENE
< O
0 O
. O
02 O
and O
P I-GENE
< O
0 O
. O
05 O
, O
respectively O
). O

The O
sequencing O
of O
_RARE_ I-GENE
copies O
located O
along O
the O
_RARE_ I-GENE
cluster I-GENE
revealed O
a O
complex I-GENE
pattern O
of O
_RARE_ I-GENE
. O

The O
results O
indicate O
that O
DNA I-GENE
methylation O
, O
chromatin O
structure O
, O
and O
transactivation O
at O
an O
Sp1 I-GENE
site I-GENE
contribute O
to O
the O
highly O
restricted O
expression O
of O
this O
_RARE_ I-GENE
lineage O
specific I-GENE
gene I-GENE
. O

In O
gel O
mobility I-GENE
shift O
assays O
, O
factors I-GENE
present O
in O
nuclear I-GENE
extracts O
derived O
from O
differentiated O
_RARE_ I-GENE
bound O
to O
oligonucleotide I-GENE
probes O
containing O
the O
E I-GENE
- I-GENE
box I-GENE
1 I-GENE
and O
E I-GENE
- I-GENE
box I-GENE
2 I-GENE
elements O
. O

Laboratory O
_RARE_ I-GENE
: O
_RARE_ I-GENE
of O
the O
_RARE_ I-GENE
was O
high O
positive O
, O
chest O
_RARE_ I-GENE
shows O
_RARE_ I-GENE
bilateral O
_RARE_ I-GENE
, O
_RARE_ I-GENE
_RARE_ I-GENE
shows O
a O
tumor I-GENE
at O
the O
foot O
of O
the O
_RARE_ I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
shows O
low O
differentiated O
_RARE_ I-GENE
carcinoma O
. O

Finally O
, O
we O
show O
that O
_RARE_ I-GENE
complexes I-GENE
, O
at O
least O
partially O
, O
with O
Gbetagamma I-GENE
in O
vivo O
. O

_RARE_ I-GENE
, O
expressed O
in O
Escherichia I-GENE
coli I-GENE
, O
showed O
specific I-GENE
binding I-GENE
to O
the O
palindrome O
2 I-GENE
DNA I-GENE
fragment I-GENE
but O
not O
to O
palindrome O
1 I-GENE
or O
mutant I-GENE
palindrome O
2 I-GENE
DNA I-GENE
fragments I-GENE
, O
suggesting O
specific I-GENE
binding I-GENE
of O
_RARE_ I-GENE
to O
palindrome O
2 I-GENE
. O

Cyclin I-GENE
G2 I-GENE
is O
highly O
expressed O
in O
the O
immune I-GENE
system O
where O
immunologic O
tolerance O
subjects O
self O
- I-GENE
reactive I-GENE
lymphocytes O
to O
negative O
selection O
and O
_RARE_ I-GENE
deletion O
via O
apoptosis O
. O

A I-GENE
sterol I-GENE
- I-GENE
regulated O
protease I-GENE
_RARE_ I-GENE
release O
of O
the O
NH2 I-GENE
- I-GENE
terminal I-GENE
segments O
of O
sterol I-GENE
regulatory I-GENE
element I-GENE
- I-GENE
binding I-GENE
proteins I-GENE
( O
_RARE_ I-GENE
) O
from O
cell O
membranes O
, O
thereby O
allowing O
them O
to O
_RARE_ I-GENE
the O
nucleus O
and O
to O
stimulate O
transcription I-GENE
of O
genes I-GENE
involved O
in O
the O
uptake O
and O
synthesis O
of O
cholesterol I-GENE
and O
fatty I-GENE
acids O
. O

Thus O
, O
the O
P I-GENE
. O
aeruginosa I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
promoters I-GENE
are O
arranged O
in O
a O
back O
- I-GENE
to O
- I-GENE
back O
orientation O
rather O
than O
the O
face O
- I-GENE
to O
- I-GENE
face O
orientation O
of O
the O
_RARE_ I-GENE
and O
_RARE_ I-GENE
promoters I-GENE
. O

Sequence O
analysis O
of O
cloned O
PCR O
products I-GENE
confirmed O
the O
presence O
of O
two O
different O
_RARE_ I-GENE
- I-GENE
like I-GENE
DNA I-GENE
fragments I-GENE
, O
which O
were O
subsequently O
used O
as O
_RARE_ I-GENE
- I-GENE
and O
_RARE_ I-GENE
- I-GENE
specific I-GENE
probes O
, O
respectively O
, O
to O
clone O
_RARE_ I-GENE
fragments I-GENE
of O
2 I-GENE
. O
1 I-GENE
kbp O
( O
_RARE_ I-GENE
) O
and O
2 I-GENE
. O
6 I-GENE
kbp O
( O
_RARE_ I-GENE
). O

In O
contrast O
, O
the O
_RARE_ I-GENE
strain O
_RARE_ I-GENE
_RARE_ I-GENE
gene I-GENE
did O
not O
complement I-GENE
the O
_RARE_ I-GENE
mutation I-GENE
of O
_RARE_ I-GENE
efficiently O
. O

( O
3 I-GENE
) O
This O
effect O
occurs O
without O
removing O
_RARE_ I-GENE
from O
the O
TRE I-GENE
. O

Is O
_RARE_ I-GENE
_RARE_ I-GENE
on O
the O
island O
of O
_RARE_ I-GENE
( O
_RARE_ I-GENE
_RARE_ I-GENE
A I-GENE
human I-GENE
visceral O
case O
after O
living O
13 O
years O
in O
_RARE_ I-GENE
. O

RESULTS O
: O
Surprisingly O
, O
_RARE_ I-GENE
blockade O
increased O
mortality O
after O
trauma O
( O
5 I-GENE
of O
11 O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
animals O
versus O
1 I-GENE
of O
9 O
vehicle O
animals O
; O
p O
= O
0 O
. O
15 O
) O
and O
depressed O
cardiac O
index O
and O
O2 O
delivery O
at O
72 O
hours O
( O
p O
< O
0 O
. O
05 O
). O

This O
finding O
is O
the O
first O
example O
of O
utilization O
of O
_RARE_ I-GENE
dinucleotide O
primer O
by O
an O
RNA I-GENE
polymerase I-GENE
. O

_RARE_ I-GENE
T1 O
and O
dual O
- I-GENE
T1 O
images O
were O
_RARE_ I-GENE
evaluated O
for O
image O
quality O
( O
_RARE_ I-GENE
) O
on O
a O
five O
- I-GENE
point O
scale O
( O
0 O
= O
_RARE_ I-GENE
to O
4 I-GENE
= O
excellent O
). O

In O
a O
model O
of O
the O
ternary O
complex I-GENE
, O
the O
segment O
of O
NFAT I-GENE
_RARE_ I-GENE
AP I-GENE
- I-GENE
1 I-GENE
is O
the O
Rel I-GENE
insert O
region O
( O
_RARE_ I-GENE
), O
a O
feature O
that O
is O
_RARE_ I-GENE
for O
its O
_RARE_ I-GENE
in O
size O
and O
in O
sequence I-GENE
_RARE_ I-GENE
members O
of O
the O
Rel I-GENE
transcription I-GENE
factor I-GENE
family I-GENE
. O

We O
thus O
conclude O
that O
the O
NFAT I-GENE
_RARE_ I-GENE
plays O
an O
essential O
dual O
role O
in O
DNA I-GENE
recognition I-GENE
and O
cooperative O
binding I-GENE
to O
AP I-GENE
- I-GENE
1 I-GENE
family I-GENE
transcription I-GENE
factors I-GENE
. O

Thus O
, O
the O
association O
of O
_RARE_ I-GENE
fragments I-GENE
may O
be O
maintained O
during O
cycles O
of O
phosphorylation O
/ I-GENE
_RARE_ I-GENE
of O
the O
_RARE_ I-GENE
_RARE_ I-GENE
. O

This O
_RARE_ I-GENE
features O
a O
Type O
I I-GENE
beta I-GENE
- I-GENE
turn I-GENE
and O
has O
extensive O
hydrophobic O
contacts O
with O
the O
_RARE_ I-GENE
binding I-GENE
surface O
. O

This O
protein I-GENE
can O
bind O
to O
a O
region O
of O
the O
promoter I-GENE
of O
an O
Arabidopsis I-GENE
light I-GENE
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
a O
/ I-GENE
b I-GENE
protein I-GENE
gene I-GENE
, O
_RARE_ I-GENE
* I-GENE
3 I-GENE
, O
which O
is O
necessary O
for O
its O
regulation O
by O
_RARE_ I-GENE
. O

A I-GENE
patient O
of O
Group O
B I-GENE
had O
severe O
_RARE_ I-GENE
CP I-GENE
with O
_RARE_ I-GENE
, O
being O
unable O
to O
right O
his O
trunk O
and O
neck O
. O

_RARE_ I-GENE
movement O
of O
the O
left O
upper O
limb O
in O
a O
case O
of O
the O
right O
_RARE_ I-GENE
hemorrhage O

It O
has O
_RARE_ I-GENE
been O
shown O
that O
HCMV I-GENE
IE1 I-GENE
/ I-GENE
IE2 I-GENE
can O
independently O
transactivate O
HIV I-GENE
- I-GENE
1 I-GENE
LTR I-GENE
. O

TAR I-GENE
and O
Sp1 I-GENE
- I-GENE
independent O
transactivation O
of O
HIV I-GENE
long O
terminal I-GENE
repeat I-GENE
by O
the O
Tat I-GENE
protein I-GENE
in O
the O
presence O
of O
human I-GENE
cytomegalovirus I-GENE
IE1 I-GENE
/ I-GENE
IE2 I-GENE
. O

_RARE_ I-GENE
chain I-GENE
enzyme I-GENE
activity O
was O
normal O
. O

Children O
' O
s O
_RARE_ I-GENE
and O
maternal I-GENE
_RARE_ I-GENE
at O
_RARE_ I-GENE
1 I-GENE
( O
n O
= O
_RARE_ I-GENE
, O
aged O
2 I-GENE
- I-GENE
3 I-GENE
years O
) O
were O
considered O
predictors O
of O
future O
_RARE_ I-GENE
, O
assessed O
using O
new O
_RARE_ I-GENE
and O
_RARE_ I-GENE
measures O
. O

_RARE_ I-GENE
Csk I-GENE
was O
associated I-GENE
with O
several O
_RARE_ I-GENE
, O
some O
of O
which O
were O
interacting I-GENE
with O
the O
Csk I-GENE
SH2 I-GENE
domain I-GENE
. O

Thus O
, O
our O
studies O
suggest O
that O
_RARE_ I-GENE
- I-GENE
mediated O
activation O
of O
HIV I-GENE
- I-GENE
1 I-GENE
LTR I-GENE
activity O
is O
controlled O
by O
the O
nuclear I-GENE
translocation O
of O
the O
NF I-GENE
- I-GENE
kappaB I-GENE
transcription I-GENE
factor I-GENE
, O
which O
is O
mediated O
by O
IkappaBalpha I-GENE
serine I-GENE
phosphorylation O
and O
degradation O
, O
but O
also O
by O
a O
still O
_RARE_ I-GENE
NF I-GENE
- I-GENE
kappaB I-GENE
- I-GENE
independent O
pathway O
. O

One O
P1 I-GENE
genomic O
clone O
and O
six O
subsequent O
plasmid O
_RARE_ I-GENE
were O
isolated O
and O
analyzed O
for O
the O
exon O
- I-GENE
intron O
organization O
of O
the O
_RARE_ I-GENE
gene I-GENE
. O

FN I-GENE
- I-GENE
stimulated O
c I-GENE
- I-GENE
Src I-GENE
_RARE_ I-GENE
activity O
was O
enhanced O
by O
wild I-GENE
type I-GENE
FAK I-GENE
expression O
, O
whereas O
FN I-GENE
- I-GENE
stimulated O
activation O
of O
ERK2 I-GENE
was O
blocked O
by O
expression O
of O
the O
c I-GENE
- I-GENE
Src I-GENE
binding I-GENE
site I-GENE
Phe I-GENE
- I-GENE
_RARE_ I-GENE
mutant I-GENE
of O
FAK I-GENE
. O

A I-GENE
_RARE_ I-GENE
new O
_RARE_ I-GENE
, O
4 I-GENE
- I-GENE
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
resin O
, O
has O
shown O
remarkable O
adhesive O
properties O
as O
a O
bone O
_RARE_ I-GENE
in O
vivo O
. O

_RARE_ I-GENE
with O
_RARE_ I-GENE
predictions O
, O
the O
most O
_RARE_ I-GENE
children O
perceived O
low O
control O
over O
_RARE_ I-GENE
and O
separation O
, O
and O
_RARE_ I-GENE
by O
_RARE_ I-GENE
control O
. O

Each O
sample O
was O
analysed O
as O
_RARE_ I-GENE
as O
possible O
, O
and O
repeated O
15 O
, O
30 O
, O
60 O
and O
120 O
min O
after O
sampling O
. O

We O
also O
review O
the O
role O
of O
_RARE_ I-GENE
in O
the O
formation O
of O
complex I-GENE
molecules I-GENE
in O
_RARE_ I-GENE
molecular O
_RARE_ I-GENE
. O

Like O
the O
_RARE_ I-GENE
of O
the O
hypersensitive I-GENE
reaction O
( O
HR O
) O
produced O
by O
E I-GENE
. O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
and O
E I-GENE
. O
_RARE_ I-GENE
( O
_RARE_ I-GENE
), O
the O
deduced O
36 O
- I-GENE
kDa I-GENE
protein I-GENE
does O
not O
possess O
a O
typical O
signal I-GENE
sequence I-GENE
, O
but O
it O
contains O
a O
putative O
membrane I-GENE
- I-GENE
spanning O
domain I-GENE
. O

Molecular O
characterization O
and O
expression O
of O
the O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
gene I-GENE
, O
which O
encodes O
an O
_RARE_ I-GENE
of O
the O
hypersensitive I-GENE
reaction O
. O

The O
mRNA I-GENE
from O
this O
gene I-GENE
, O
termed O
_RARE_ I-GENE
, O
is O
ubiquitously O
expressed O
, O
but O
strongly O
so O
in O
heart O
and O
skeletal I-GENE
muscle O
. O

_RARE_ I-GENE
was O
maintained O
with O
isoflurane O
( O
_RARE_ I-GENE
)/ O
N2O O
/ I-GENE
O2 O
inhalation O
. O

They O
observed O
depressed O
protein I-GENE
C I-GENE
activity O
that O
significantly O
( O
p O
< O
0 O
. O
005 O
) O
increased O
and O
became O
normal O
immediately O
after O
hemodialysis O
while O
factor I-GENE
X I-GENE
and O
factor I-GENE
VII I-GENE
increased O
( O
p O
< O
0 O
. O
01 O
; O
p O
< O
0 O
. O
05 O
) O
despite O
_RARE_ I-GENE
together O
with O
amount O
of O
serum I-GENE
lipoprotein I-GENE
( O
a O
). O

We O
present O
a O
case O
of O
type I-GENE
II I-GENE
_RARE_ I-GENE
in O
a O
patient O
whose O
diagnosis O
had O
been O
previously O
_RARE_ I-GENE
, O
and O
who O
had O
previously O
been O
_RARE_ I-GENE
with O
rheumatoid I-GENE
arthritis O
and O
later O
_RARE_ I-GENE
. O

These O
data O
provide O
evidence O
that O
the O
2 I-GENE
. O
0 O
- I-GENE
kb O
_RARE_ I-GENE
is O
an O
intron O
of O
the O
_RARE_ I-GENE
pre I-GENE
- I-GENE
mRNA I-GENE
with O
a O
unique O
branch O
point O
. O

The O
altered O
amino O
acid I-GENE
residues O
of O
the O
seven O
mutant I-GENE
_RARE_ I-GENE
polypeptides I-GENE
clustered O
within O
three O
separate O
regions O
referred O
to O
as O
region O
I I-GENE
( O
residues O
34 O
to O
41 O
), O
region O
II I-GENE
( O
residues O
89 I-GENE
to O
91 O
), O
and O
C I-GENE
- I-GENE
terminal I-GENE
region O
III I-GENE
( O
residues O
122 O
to O
125 I-GENE
). O

Rep I-GENE
- I-GENE
Rep I-GENE
protein I-GENE
interaction O
was O
confirmed O
in O
vitro O
through O
_RARE_ I-GENE
experiments O
with O
a O
bacterially O
expressed O
_RARE_ I-GENE
- I-GENE
binding I-GENE
protein I-GENE
- I-GENE
_RARE_ I-GENE
fusion I-GENE
protein I-GENE
in O
combination O
with O
[ O
35S I-GENE
] O
methionine O
- I-GENE
labeled O
_RARE_ I-GENE
synthesized O
in O
a O
coupled I-GENE
in O
vitro O
transcription I-GENE
- I-GENE
translation I-GENE
system O
. O

The O
C I-GENE
- I-GENE
_RARE_ I-GENE
also O
was O
compared O
with O
_RARE_ I-GENE
arterial O
_RARE_ I-GENE
( O
_RARE_ I-GENE
; O
C I-GENE
- I-GENE
_RARE_ I-GENE
followed O
by O
_RARE_ I-GENE
_RARE_ I-GENE
) O
and O
_RARE_ I-GENE
ethanol O
injection O
therapy O
( O
_RARE_ I-GENE
). O

_RARE_ I-GENE
patients O
with O
New O
York O
_RARE_ I-GENE
Association O
class I-GENE
II I-GENE
_RARE_ I-GENE
heart O
failure O
were O
enrolled O
in O
a O
double O
- I-GENE
blind O
, O
cross O
- I-GENE
over O
study O
. O

The O
main O
advantages O
of O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
analysis O
are O
: O
( O
1 I-GENE
) O
_RARE_ I-GENE
acquisition O
of O
many O
_RARE_ I-GENE
; O
( O
2 I-GENE
) O
simultaneous O
collection O
of O
several O
_RARE_ I-GENE
at O
one O
recording O
site I-GENE
; O
( O
3 I-GENE
) O
possibility O
to O
analyze O
not O
only O
low O
threshold O
_RARE_ I-GENE
; O
( O
4 I-GENE
) O
less O
_RARE_ I-GENE
in O
the O
selection O
of O
_RARE_ I-GENE
and O
( O
5 I-GENE
) O
the O
reproducibility O
of O
the O
results O
that O
allow O
the O
same O
reference O
values O
to O
be O
used O
in O
different O
laboratories O
. O

We O
also O
demonstrate O
that O
_RARE_ I-GENE
_RARE_ I-GENE
are O
quite O
stable O
when O
precipitated O
with O
ethanol O
and O
_RARE_ I-GENE
in O
water O
. O

Transfection O
experiments O
using O
_RARE_ I-GENE
_RARE_ I-GENE
with O
a O
reporter I-GENE
plasmid O
containing O
the O
collagen I-GENE
promoter I-GENE
sequence I-GENE
showed O
significant O
inhibition O
of O
transcription I-GENE
when O
compared O
with O
a O
control O
_RARE_ I-GENE
_RARE_ I-GENE
. O

Thus O
, O
an O
increase O
in O
plasma I-GENE
_RARE_ I-GENE
and O
a O
shift O
from O
adrenal O
androgen O
and O
_RARE_ I-GENE
steroid I-GENE
secretion O
towards O
cortisol O
secretion O
may O
be O
endocrine O
markers O
for O
progression O
of O
the O
disease O
in O
patients O
with O
HIV I-GENE
- I-GENE
infection O
. O

In O
several O
studies O
the O
_RARE_ I-GENE
has O
shown O
evidence O
of O
reliability O
and O
validity O
. O

_RARE_ I-GENE
produces O
an O
additional O
reduction O
of O
_RARE_ I-GENE
pressure O
( O
IOP O
) O
when O
used O
in O
combination O
with O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
and O
_RARE_ I-GENE
. O

These O
results O
suggest O
that O
dietary O
_RARE_ I-GENE
phospholipids O
may O
be O
a O
valuable O
_RARE_ I-GENE
to O
_RARE_ I-GENE
for O
reducing O
liver O
triglycerides I-GENE
and O
serum I-GENE
cholesterol I-GENE
without O
any O
adverse O
effects O
. O

Using O
various O
techniques O
, O
we O
have O
undertaken O
a O
systematic O
analysis O
of O
the O
natural O
TATA I-GENE
- I-GENE
less O
human I-GENE
DNA I-GENE
polymerase I-GENE
beta I-GENE
( O
beta I-GENE
- I-GENE
pol I-GENE
) O
gene I-GENE
promoter I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
transport O
in O
_RARE_ I-GENE
:: O
lacZ I-GENE
mutants I-GENE
had O
an O
approximately O
_RARE_ I-GENE
- I-GENE
lower O
affinity O
and O
twofold O
- I-GENE
lower O
Vmax O
than O
in O
the O
parental O
strain O
. O

Transient O
overexpression O
of O
c I-GENE
- I-GENE
Jun I-GENE
induced O
_RARE_ I-GENE
- I-GENE
C I-GENE
expression O
in O
primary O
_RARE_ I-GENE
and O
in O
_RARE_ I-GENE
, O
an O
established O
fibroblast I-GENE
cell O
line O
. O

Inhibition O
of O
the O
Raf I-GENE
- I-GENE
1 I-GENE
kinase I-GENE
by O
cyclic I-GENE
AMP I-GENE
agonists O
causes O
apoptosis O
of O
v I-GENE
- I-GENE
abl I-GENE
- I-GENE
transformed O
cells O
. O

Previous O
studies O
have O
indicated O
that O
a O
hamster I-GENE
cell O
line O
( O
_RARE_ I-GENE
) O
with O
a O
point O
mutation I-GENE
in O
the O
TAF I-GENE
( O
II I-GENE
) O
250 O
/ I-GENE
_RARE_ I-GENE
( O
TAF I-GENE
( O
II I-GENE
) O
250 O
) O
gene I-GENE
shows O
temperature O
- I-GENE
sensitive O
expression O
of O
a O
subset O
of O
genes I-GENE
and O
_RARE_ I-GENE
in O
late O
G1 I-GENE
at O
39 O
. O
5 I-GENE
degrees O
C I-GENE
. O

We O
show O
here O
that O
the O
protein I-GENE
kinase I-GENE
_RARE_ I-GENE
can O
induce O
reporter I-GENE
gene I-GENE
expression O
from O
the O
atrial I-GENE
_RARE_ I-GENE
factor I-GENE
( O
_RARE_ I-GENE
) O
promoter I-GENE
, O
a O
genetic O
marker O
that O
is O
activated I-GENE
during O
in O
vivo O
hypertrophy O
. O

Overexpression O
of O
_RARE_ I-GENE
in O
C I-GENE
. O
albicans I-GENE
leads O
to O
enhanced O
filamentous I-GENE
growth I-GENE
in O
the O
form O
of O
extended O
_RARE_ I-GENE
in O
liquid O
and O
on O
solid O
media O
. O

_RARE_ I-GENE
parameters O
: O
heart O
rate O
( O
HR O
), O
arterial O
blood O
pressure O
( O
_RARE_ I-GENE
) O
and O
arterial O
O2 O
saturation O
( O
SaO2 O
) O
monitored O
by O
_RARE_ I-GENE
were O
measured O
during O
the O
procedure O
. O

To O
determine O
if O
_RARE_ I-GENE
, O
when O
established O
, O
would O
compete O
with O
_RARE_ I-GENE
when O
both O
were O
reinforced O
, O
_RARE_ I-GENE
was O
then O
_RARE_ I-GENE
. O

The O
_RARE_ I-GENE
in O
one O
of O
the O
_RARE_ I-GENE
_RARE_ I-GENE
was O
treated O
for O
hepatitis I-GENE
of O
unidentified O
etiology O
in O
an O
_RARE_ I-GENE
_RARE_ I-GENE
four O
years O
_RARE_ I-GENE
. O

Both O
quantitative O
and O
qualitative O
analysis O
of O
individual O
_RARE_ I-GENE
_RARE_ I-GENE
of O
_RARE_ I-GENE
' O
s O
nucleus O
as O
well O
as O
of O
external O
part O
of O
_RARE_ I-GENE
nucleus O
of O
_RARE_ I-GENE
was O
performed O
in O
_RARE_ I-GENE
normal O
individuals O
. O

We O
have O
tested O
this O
_RARE_ I-GENE
by O
carrying O
out O
circular O
_RARE_ I-GENE
( O
CD O
) O
and O
NMR O
experiments O
on O
the O
_RARE_ I-GENE
domain I-GENE
and O
five O
truncated I-GENE
proteins I-GENE
. O

_RARE_ I-GENE
cloning O
has O
already O
produced O
the O
sequences I-GENE
of O
more O
than O
70 I-GENE
human I-GENE
genes I-GENE
associated I-GENE
with O
specific I-GENE
diseases O
. O

_RARE_ I-GENE
for O
_RARE_ I-GENE
element I-GENE
binding I-GENE
factors I-GENE
( O
_RARE_ I-GENE
), O
belonging O
to O
a O
specific I-GENE
class I-GENE
of O
basic I-GENE
- I-GENE
region O
leucine I-GENE
zipper I-GENE
( O
bZIP I-GENE
) O
transcription I-GENE
factors I-GENE
, O
have O
been O
isolated O
in O
a O
number O
of O
plants O
. O

The O
30 O
- I-GENE
day O
mortality O
in O
the O
CPB O
group O
and O
the O
non O
- I-GENE
CPB O
group O
were O
20 O
% O
and O
4 I-GENE
. O
6 I-GENE
%, O
respectively O
which O
was O
not O
statistically O
significant O
( O
p O
= O
0 O
. O
06 O
). O

As O
opposed O
to O
in O
vitro O
co O
- I-GENE
precipitation O
studies O
, O
the O
yeast I-GENE
two O
- I-GENE
hybrid O
screen O
reveals O
in O
vivo O
protein I-GENE
- I-GENE
protein I-GENE
interactions O
. O

This O
association O
appears O
to O
be O
mediated O
by O
Src I-GENE
- I-GENE
SH2 I-GENE
domain I-GENE
, O
because O
_RARE_ I-GENE
- I-GENE
1 I-GENE
can O
be O
precipitated O
by O
a O
GST I-GENE
- I-GENE
Src I-GENE
- I-GENE
SH2 I-GENE
affinity O
matrix I-GENE
. O

_RARE_ I-GENE
autophosphorylation O
and O
activation O
of O
p38 I-GENE
was O
also O
observed O
following O
coexpression O
of O
_RARE_ I-GENE
with O
_RARE_ I-GENE
, O
but O
not O
with O
_RARE_ I-GENE
. O

An O
alternatively O
spliced O
_RARE_ I-GENE
- I-GENE
1 I-GENE
variant I-GENE
was O
identified O
that O
lacks O
exon O
4 I-GENE
encoding O
the O
_RARE_ I-GENE
domain I-GENE
, O
and O
may O
mediate O
leukocyte I-GENE
adhesion I-GENE
to O
_RARE_ I-GENE
- I-GENE
1 I-GENE
without O
adhesion I-GENE
to O
the O
alternate O
receptor I-GENE
, O
L I-GENE
- I-GENE
selectin I-GENE
. O

In O
summary O
, O
the O
data O
establish O
that O
the O
previously O
reported O
human I-GENE
_RARE_ I-GENE
- I-GENE
1 I-GENE
cDNA I-GENE
does O
indeed O
encode O
the O
human I-GENE
homologue I-GENE
of O
mouse I-GENE
_RARE_ I-GENE
- I-GENE
1 I-GENE
, O
despite O
gross O
_RARE_ I-GENE
in O
the O
_RARE_ I-GENE
- I-GENE
1 I-GENE
C I-GENE
- I-GENE
terminal I-GENE
structures O
. O

We O
have O
used O
a O
site I-GENE
- I-GENE
directed O
mutagenesis O
approach O
to O
examine O
how O
the O
_RARE_ I-GENE
and O
hydroxy I-GENE
( O
Ser O
/ I-GENE
Thr I-GENE
) O
amino O
acid I-GENE
residues O
in O
_RARE_ I-GENE
influence O
core I-GENE
- I-GENE
glycosylation O
efficiency O
. O

_RARE_ I-GENE
AND O
METHODS O
: O
The O
authors O
analyzed O
41 O
persons O
_RARE_ I-GENE
submitted O
to O
surgery O
( O
after O
8 O
years O
and O
4 I-GENE
months O
, O
as O
a O
mean O
), O
31 O
to O
highly O
selective O
vagotomy O
, O
and O
10 O
to O
_RARE_ I-GENE
or O
selective O
vagotomy O
plus O
_RARE_ I-GENE
drainage O
. O

This O
region O
does O
not O
contain O
an O
_RARE_ I-GENE
TATA I-GENE
element I-GENE
, O
indicating O
that O
transcription I-GENE
of O
the O
_RARE_ I-GENE
gene I-GENE
is O
driven O
by O
a O
TATA I-GENE
- I-GENE
less O
promoter I-GENE
. O

SRE O
activity O
is O
dependent I-GENE
upon O
the O
activation O
by O
phosphorylation O
of O
a O
ternary O
complex I-GENE
factor I-GENE
; O
included O
among O
the O
ternary O
complex I-GENE
factors I-GENE
is O
Elk I-GENE
- I-GENE
1 I-GENE
. O

Serum I-GENE
alkaline I-GENE
phosphatase I-GENE
activity O
, O
bone O
mass O
measurements O
, O
dual O
energy O
x O
- I-GENE
ray O
_RARE_ I-GENE
analysis O
of O
mineral O
density I-GENE
, O
and O
mechanical O
testing O
values O
in O
_RARE_ I-GENE
and O
_RARE_ I-GENE
of O
the O
- I-GENE
D I-GENE
_RARE_ I-GENE
animals O
did O
not O
significantly O
differ O
from O
those O
in O
+ I-GENE
D I-GENE
_RARE_ I-GENE
animals O
. O

The O
monkey I-GENE
LHR I-GENE
cDNA I-GENE
displayed O
83 O
- I-GENE
94 O
% O
overall O
sequence I-GENE
homology I-GENE
with O
the O
other O
mammalian I-GENE
LHR I-GENE
cDNAs I-GENE
. O

In O
conclusion O
, O
_RARE_ I-GENE
monkey I-GENE
LHR I-GENE
seems O
to O
lack O
the O
sequence I-GENE
corresponding O
to O
exon O
10 O
of O
the O
LHR I-GENE
gene I-GENE
in O
other O
mammalian I-GENE
species O
. O

In O
_RARE_ I-GENE
- I-GENE
4 I-GENE
mutants I-GENE
, O
VA O
motor O
neurons O
_RARE_ I-GENE
the O
pattern O
of O
synaptic O
input O
normally O
_RARE_ I-GENE
for O
their O
_RARE_ I-GENE
_RARE_ I-GENE
cells O
, O
the O
_RARE_ I-GENE
motor O
neurons O
; O
the O
loss O
of O
normal O
input O
to O
the O
_RARE_ I-GENE
produces O
a O
distinctive O
_RARE_ I-GENE
movement O
defect O
. O

_RARE_ I-GENE
irradiation O
was O
carried O
out O
with O
a O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
device O
and O
usually O
22 O
. O
5 I-GENE
Gy O
was O
given O
in O
three O
fractions O
repeated O
weekly O
. O

No O
patient O
in O
group O
2 I-GENE
developed O
_RARE_ I-GENE
( O
P I-GENE
= O
0 O
. O
_RARE_ I-GENE
versus O
group O
1 I-GENE
). O

Sequence O
comparison O
of O
the O
0 O
. O
38 O
kb O
promoter I-GENE
sequence I-GENE
with O
the O
promoters I-GENE
of O
the O
_RARE_ I-GENE
- I-GENE
E I-GENE
gene I-GENE
and O
U1 I-GENE
snRNA I-GENE
genes I-GENE
revealed O
several O
homologous O
motifs O
, O
suggesting O
that O
genes I-GENE
encoding O
the O
snRNP I-GENE
components O
may O
be O
_RARE_ I-GENE
regulated O
. O

METHODS O
: O
The O
responses O
of O
a O
31 O
- I-GENE
year O
- I-GENE
old O
woman O
with O
complex I-GENE
regional O
pain O
syndrome O
type I-GENE
I I-GENE
( O
reflex O
sympathetic O
dystrophy I-GENE
) O
to O
a O
thermal O
_RARE_ I-GENE
were O
evaluated O
before O
and O
after O
_RARE_ I-GENE
_RARE_ I-GENE
block O
. O

More O
recently O
, O
however O
, O
a O
number O
of O
_RARE_ I-GENE
such O
as O
the O
successful O
use O
of O
the O
inhaled O
steroid I-GENE
_RARE_ I-GENE
and O
oral O
dexamethasone O
have O
reinforced O
the O
_RARE_ I-GENE
for O
using O
steroids O
. O

A I-GENE
_RARE_ I-GENE
transcriptional O
fusion I-GENE
to O
the O
putative O
_RARE_ I-GENE
promoter I-GENE
showed O
low O
- I-GENE
level O
expression O
in O
wild I-GENE
- I-GENE
type I-GENE
cells O
grown O
on O
one O
- I-GENE
carbon O
( O
C1 I-GENE
) O
compounds O
and O
no O
detectable O
expression O
in O
cells O
grown O
on O
_RARE_ I-GENE
. O

In O
_RARE_ I-GENE
- I-GENE
infected O
Sf9 O
cells O
, O
late O
transcription I-GENE
initiation I-GENE
is O
detected O
from O
only O
two O
upstream O
_RARE_ I-GENE
sites I-GENE
and O
not O
from O
three O
downstream O
_RARE_ I-GENE
sites I-GENE
. O

Mutation O
of O
nucleotides O
adjacent O
to O
the O
AP I-GENE
- I-GENE
1 I-GENE
cis O
- I-GENE
response O
elements O
had O
no O
effect O
on O
trans O
- I-GENE
activation O
. O

The O
close O
_RARE_ I-GENE
of O
the O
two O
_RARE_ I-GENE
Y I-GENE
receptor I-GENE
genes I-GENE
suggests O
that O
they O
have O
evolved O
from O
a O
gene I-GENE
duplication O
event O
with O
the O
small I-GENE
intron O
_RARE_ I-GENE
the O
coding O
sequence I-GENE
of O
the O
_RARE_ I-GENE
gene I-GENE
being O
converted O
into O
a O
functional O
sequence I-GENE
within O
the O
_RARE_ I-GENE
gene I-GENE
, O
while O
the O
reverse I-GENE
complementary O
sequence I-GENE
was O
utilized O
as O
an O
alternatively O
spliced O
5 I-GENE
' O
exon O
for O
the O
_RARE_ I-GENE
gene I-GENE
. O

The O
mammalian I-GENE
_RARE_ I-GENE
3 I-GENE
- I-GENE
kinases I-GENE
( O
_RARE_ I-GENE
) O
_RARE_ I-GENE
, O
beta I-GENE
, O
and O
delta I-GENE
form O
heterodimers I-GENE
with O
Src I-GENE
homology I-GENE
2 I-GENE
( O
SH2 I-GENE
) O
domain I-GENE
- I-GENE
containing O
_RARE_ I-GENE
such O
as O
_RARE_ I-GENE
or O
p55 I-GENE
( O
_RARE_ I-GENE
). O

In O
the O
studies O
reported O
here O
, O
the O
5 I-GENE
'- O
flanking O
region O
of O
the O
human I-GENE
_RARE_ I-GENE
gene I-GENE
was O
isolated O
and O
the O
transcription I-GENE
initiation I-GENE
sites I-GENE
were O
mapped O
. O

Localization O
of O
the O
cytokine O
response O
element I-GENE
by O
5 I-GENE
'- O
deletion O
analysis O
and O
site I-GENE
- I-GENE
directed O
mutagenesis O
revealed O
a O
cis O
- I-GENE
acting O
binding I-GENE
site I-GENE
for O
activated I-GENE
STAT I-GENE
complexes I-GENE
. O

Insulin I-GENE
regulation O
of O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
kinase I-GENE
( O
MEK I-GENE
), O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
and O
casein I-GENE
kinase I-GENE
in O
the O
cell O
nucleus O
: O
a O
possible O
role O
in O
the O
regulation O
of O
gene I-GENE
expression O
. O

Sequencing O
of O
the O
three O
_RARE_ I-GENE
- I-GENE
3 I-GENE
alleles I-GENE
showed O
that O
two O
apparent O
null I-GENE
alleles I-GENE
encode O
a O
nonsense O
mutation I-GENE
before O
the O
zinc I-GENE
fingers O
and O
a O
missense O
mutation I-GENE
in O
the O
fourth O
zinc I-GENE
finger I-GENE
that O
changes O
a O
_RARE_ I-GENE
histidine O
to O
a O
tyrosine I-GENE
. O

Pax I-GENE
- I-GENE
3 I-GENE
is O
a O
paired I-GENE
- I-GENE
type I-GENE
homeobox I-GENE
gene I-GENE
that O
is O
specifically O
expressed O
in O
the O
dorsal O
and O
posterior O
neural O
tube O
. O

Instead O
, O
they O
contained O
_RARE_ I-GENE
cells O
that O
express O
_RARE_ I-GENE
marker O
proteins I-GENE
such O
as O
_RARE_ I-GENE
and O
_RARE_ I-GENE
- I-GENE
related I-GENE
protein I-GENE
1 I-GENE
. O

These O
mutations O
create O
stop O
codons O
in O
exon O
7 O
and O
8 O
, O
respectively O
, O
and O
probably O
result O
in O
truncated I-GENE
proteins I-GENE
lacking O
_RARE_ I-GENE
- I-GENE
Zip I-GENE
or O
Zip I-GENE
structure O
. O

Here O
, O
a O
case O
of O
_RARE_ I-GENE
' O
s O
syndrome O
is O
presented O
that O
was O
initially O
diagnosed O
because O
of O
dental O
_RARE_ I-GENE
, O
and O
long O
- I-GENE
term O
treatment O
of O
_RARE_ I-GENE
' O
s O
patients O
is O
discussed O
. O

Cloning O
and O
characterization O
of O
a O
cDNA I-GENE
encoding O
a O
bacteriophage I-GENE
- I-GENE
type I-GENE
RNA I-GENE
polymerase I-GENE
from O
the O
higher O
plant O
_RARE_ I-GENE
_RARE_ I-GENE
. O

Similarly O
, O
overexpression O
of O
increasing O
concentration O
of O
COUP I-GENE
- I-GENE
TFI I-GENE
, O
but O
not O
COUP I-GENE
- I-GENE
TFI I-GENE
_RARE_ I-GENE
, O
can O
_RARE_ I-GENE
the O
silencing O
activity O
of O
the O
_RARE_ I-GENE
_RARE_ I-GENE
. O

These O
six O
amino O
acids O
are O
part O
of O
an O
_RARE_ I-GENE
helix I-GENE
that O
is O
highly O
conserved O
among O
nuclear I-GENE
hormone I-GENE
receptors I-GENE
and O
contains O
the O
core I-GENE
domain I-GENE
of O
the O
ligand O
- I-GENE
dependent I-GENE
transactivation O
function O
, O
AF I-GENE
- I-GENE
2 I-GENE
. O

Surprisingly O
, O
the O
RXR I-GENE
- I-GENE
specific I-GENE
ligand O
9 O
- I-GENE
cis O
- I-GENE
retinoic I-GENE
acid I-GENE
induced O
binding I-GENE
of O
SRC I-GENE
- I-GENE
1 I-GENE
to O
the O
RXR I-GENE
component O
of O
the O
TRE I-GENE
- I-GENE
bound O
heterodimer O
. O

In O
_RARE_ I-GENE
, O
both O
mechanisms O
are O
readily O
observed O
. O

Based O
on O
the O
occurrence O
of O
several O
transcription I-GENE
signals O
in O
the O
_RARE_ I-GENE
_RARE_ I-GENE
promoter I-GENE
region O
and O
strong O
amino O
acid I-GENE
sequence I-GENE
identities O
( O
about O
60 O
%) O
between O
_RARE_ I-GENE
_RARE_ I-GENE
and O
the O
_RARE_ I-GENE
attenuation O
proteins I-GENE
of O
two O
Bacillus I-GENE
sp O
., O
we O
propose O
a O
regulatory I-GENE
mechanism O
involving O
transcriptional O
attenuation O
to O
control O
_RARE_ I-GENE
gene I-GENE
expression O
in O
_RARE_ I-GENE
. O

_RARE_ I-GENE
respiratory O
responses O
to O
a O
_RARE_ I-GENE
closed O
- I-GENE
circuit O
breathing O
apparatus O
. O

Measurement O
of O
the O
time O
constant O
of O
VO2 O
and O
oxygen O
pulse O
during O
constant O
work O
rate O
exercise O
are O
useful O
for O
the O
objective O
evaluation O
of O
the O
training O
effect O
of O
patients O
with O
COPD O
. O

Characterization O
of O
_RARE_ I-GENE
repeat I-GENE
random O
PCR O
markers O
for O
mapping O
the O
chicken I-GENE
genome O
. O

A I-GENE
reversed O
- I-GENE
phase O
high O
- I-GENE
performance O
liquid O
chromatographic O
( O
HPLC O
) O
method O
for O
the O
determination O
of O
cocaine O
metabolites O
produced O
in O
vitro O
by O
serum I-GENE
and O
liver O
_RARE_ I-GENE
is O
described O
. O

Mutational O
studies O
provide O
evidence O
to O
this O
end O
and O
indicate O
that O
the O
side O
chains I-GENE
of O
subdomain I-GENE
4 I-GENE
. O
2 I-GENE
make O
specific I-GENE
contacts O
with O
the O
nucleotides O
at O
- I-GENE
35 O
. O

It O
is O
concluded O
that O
_RARE_ I-GENE
is O
a O
highly O
useful O
agent O
in O
_RARE_ I-GENE
. O

Three O
different O
techniques O
of O
_RARE_ I-GENE
analysis O
were O
used O
in O
the O
study O
: O
1 I-GENE
) O
fast O
_RARE_ I-GENE
transformation O
( O
_RARE_ I-GENE
) O
of O
_RARE_ I-GENE
in O
a O
broad O
band O
, O
2 I-GENE
) O
developed O
by O
us O
alternative O
method O
of O
non O
- I-GENE
_RARE_ I-GENE
expansion O
of O
the O
EEG O
curves O
taking O
into O
account O
their O
shape O
, O
3 I-GENE
) O
factor I-GENE
analysis O
of O
the O
_RARE_ I-GENE
spectral O
_RARE_ I-GENE
. O

_RARE_ I-GENE
, O
_RARE_ I-GENE
histone I-GENE
H1 I-GENE
kinase I-GENE
activity O
increases O
in O
the O
former O
, O
but O
not O
in O
the O
latter O
cell O
lines O
, O
hence O
suggesting O
a O
role O
for O
this O
protein I-GENE
in O
radiation O
- I-GENE
induced O
cell O
death O
. O

Using O
PRL I-GENE
- I-GENE
R I-GENE
tagged O
both O
in O
the O
N I-GENE
- I-GENE
terminal I-GENE
or O
C I-GENE
- I-GENE
terminal I-GENE
regions O
of O
the O
mature O
receptor I-GENE
_RARE_ I-GENE
the O
possibility O
of O
a O
cleaved O
fragment I-GENE
which O
could O
have O
been O
subsequently O
_RARE_ I-GENE
into O
the O
nucleus O
. O

Thus O
, O
the O
B I-GENE
- I-GENE
S I-GENE
mutant I-GENE
does O
not O
mimic O
efficiently O
the O
_RARE_ I-GENE
_RARE_ I-GENE
, O
and O
long O
- I-GENE
range O
and O
/ I-GENE
or O
second O
- I-GENE
layer O
effects O
, O
not O
easily O
_RARE_ I-GENE
from O
visual O
_RARE_ I-GENE
of O
three O
- I-GENE
dimensional O
structures O
, O
need O
to O
be O
taken O
into O
account O
for O
_RARE_ I-GENE
a O
true O
" O
_RARE_ I-GENE
- I-GENE
like I-GENE
" O
mutant I-GENE
of O
cytosolic I-GENE
_RARE_ I-GENE
. O

Transcription O
of O
these O
genes I-GENE
was O
also O
elevated O
in O
gut O
and O
lung O
during O
_RARE_ I-GENE
, O
but O
mRNA I-GENE
levels O
in O
these O
tissues O
were O
lower O
than O
in O
liver O
. O

_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
was O
developed O
to O
_RARE_ I-GENE
_RARE_ I-GENE
Ca I-GENE
: O
P I-GENE
_RARE_ I-GENE
with O
clinical O
data O
to O
improve O
_RARE_ I-GENE
Ca I-GENE
and O
P I-GENE
administration O
. O

A I-GENE
similar O
chimera I-GENE
was O
assembled O
from O
the O
two O
_RARE_ I-GENE
of O
the O
molecule I-GENE
expressed O
separately O
in O
different O
bacteria O
and O
_RARE_ I-GENE
together O
. O

The O
conditions O
for O
obtaining O
_RARE_ I-GENE
dioxide O
from O
the O
substrates O
_RARE_ I-GENE
_RARE_ I-GENE
and O
oxygen O
and O
applying O
this O
to O
a O
surgical O
_RARE_ I-GENE
_RARE_ I-GENE
of O
the O
type I-GENE
_RARE_ I-GENE
by O
the O
plasma I-GENE
_RARE_ I-GENE
chemical O
_RARE_ I-GENE
deposition O
method O
have O
been O
determined O
. O

All O
six O
genes I-GENE
were O
cloned O
and O
_RARE_ I-GENE
. O

We O
analysed O
two O
regions O
involved O
in O
_RARE_ I-GENE
/ I-GENE
S I-GENE
gene I-GENE
transcription I-GENE
of O
the O
HBV O
_RARE_ I-GENE
subtype I-GENE
: O
the O
diverged O
TATA I-GENE
box I-GENE
and O
a O
putative O
initiator O
element I-GENE
. O

Indeed O
the O
predicted O
folding O
of O
the O
5 I-GENE
' O
and O
3 I-GENE
'- O
untranslated O
regions O
revealed O
patterns O
of O
stem O
and O
loop I-GENE
structures O
conserved O
for O
all O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
suggesting O
a O
_RARE_ I-GENE
selection O
for O
preservation O
of O
essential O
RNA I-GENE
secondary O
structures O
which O
could O
be O
involved O
in O
translational O
control O
and O
replication O
. O

EGF I-GENE
acts O
primarily O
by O
means O
of O
transactivation O
domain I-GENE
AF I-GENE
- I-GENE
1 I-GENE
, O
whereas O
cAMP I-GENE
acts O
via O
transactivation O
domain I-GENE
AF I-GENE
- I-GENE
2 I-GENE
of O
the O
ER I-GENE
. O

To O
determine O
which O
region O
of O
_RARE_ I-GENE
is O
essential O
for O
the O
inhibition O
of O
cell O
division O
, O
we O
constructed O
a O
series O
of O
N I-GENE
- I-GENE
terminal I-GENE
and O
C I-GENE
- I-GENE
terminal I-GENE
deletions O
of O
_RARE_ I-GENE
and O
a O
series O
of O
alanine I-GENE
substitution O
mutants I-GENE
. O

We O
have O
inactivated O
Krox I-GENE
- I-GENE
20 O
by O
homologous O
recombination O
in O
ES O
cells O
and O
demonstrated O
that O
the O
mutation I-GENE
leads O
to O
the O
deletion O
of O
_RARE_ I-GENE
and O
_RARE_ I-GENE
. O

Recently O
we O
have O
performed O
a O
detailed O
analysis O
of O
specific I-GENE
neuronal O
populations O
affected O
by O
the O
mutation I-GENE
which O
_RARE_ I-GENE
new O
light I-GENE
on O
the O
role O
of O
Krox I-GENE
- I-GENE
20 O
in O
the O
segmentation I-GENE
and O
on O
the O
physiological O
consequences O
of O
its O
inactivation O
. O

The O
most O
important O
one O
among O
them O
is O
_RARE_ I-GENE
A I-GENE
, O
which O
is O
a O
selective O
immunosuppressive O
drug O
. O

Consistent O
with O
its O
role O
in O
p53 I-GENE
ubiquitination O
, O
_RARE_ I-GENE
- I-GENE
AP I-GENE
was O
found O
both O
in O
the O
nucleus O
and O
cytosol O
, O
while O
_RARE_ I-GENE
- I-GENE
4 I-GENE
was O
found O
only O
in O
the O
cytosol O
. O

_RARE_ I-GENE
also O
induced O
transient O
tyrosine I-GENE
phosphorylation O
of O
focal I-GENE
adhesion I-GENE
kinase I-GENE
( O
_RARE_ I-GENE
( O
FAK I-GENE
_RARE_ I-GENE
a O
cytosolic I-GENE
tyrosine I-GENE
kinase I-GENE
that O
localizes O
in O
focal I-GENE
adhesions O
, O
and O
of O
the O
cytoskeleton I-GENE
- I-GENE
associated I-GENE
protein I-GENE
paxillin I-GENE
. O

Using O
a O
conditional O
- I-GENE
lethal O
mutant I-GENE
allele I-GENE
of O
_RARE_ I-GENE
( O
_RARE_ I-GENE
- I-GENE
2 I-GENE
) O
and O
a O
combination O
of O
in O
vivo O
and O
in O
vitro O
approaches O
, O
we O
demonstrate O
that O
the O
product I-GENE
of O
the O
_RARE_ I-GENE
gene I-GENE
( O
_RARE_ I-GENE
or O
_RARE_ I-GENE
) O
is O
a O
factor I-GENE
required O
for O
translation I-GENE
termination O
in O
yeast I-GENE
. O

Evaluation O
of O
myocardial O
perfusion O
by O
99mTc O
- I-GENE
tetrofosmin O
SPECT O
before O
and O
after O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
coronary O
_RARE_ I-GENE
for O
acute O
myocardial O
infarction O

A I-GENE
neonatal O
_RARE_ I-GENE
thrombocytopenia O
with O
an O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
_RARE_ I-GENE
was O
confirmed O
. O

_RARE_ I-GENE
was O
able O
to O
_RARE_ I-GENE
_RARE_ I-GENE
by O
3 I-GENE
years O
of O
age O
with O
then O
progressive O
_RARE_ I-GENE
of O
motor O
abilities O
. O

_RARE_ I-GENE
positive O
congenital O
muscular O
dystrophy I-GENE
with O
mental O
deficiency O
, O
epilepsy O
and O
MRI O
changes O
in O
the O
cerebral O
white O
matter O
. O

Most O
eukaryotic I-GENE
mRNAs I-GENE
are O
translated O
by O
a O
" O
scanning O
ribosome I-GENE
" O
mechanism O
. O

Comparison O
of O
Tc O
- I-GENE
99m O
_RARE_ I-GENE
perfusion O
imaging O
and O
echocardiography O
using O
an O
_RARE_ I-GENE
infusion O
for O
the O
detection O
of O
coronary O
artery O
disease O
. O

Also O
, O
transient O
overexpression O
of O
this O
protein I-GENE
in O
C2C12 O
cells O
reduced O
the O
transcription I-GENE
of O
a O
CAT I-GENE
- I-GENE
reporter I-GENE
regulated O
by O
an O
E12 I-GENE
/ I-GENE
MyoD I-GENE
driven O
enhancer I-GENE
. O

Five O
of O
these O
have O
ocular O
or O
_RARE_ I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
a O
126 O
- I-GENE
nucleotide I-GENE
5 I-GENE
' O
_RARE_ I-GENE
genomic O
sequence I-GENE
and O
a O
_RARE_ I-GENE
- I-GENE
nucleotide I-GENE
5 I-GENE
' O
noncoding O
cDNA I-GENE
sequence I-GENE
, O
the O
_RARE_ I-GENE
- I-GENE
nucleotide I-GENE
5 I-GENE
' O
CpG O
island O
lacked O
TATA I-GENE
and O
CAAT I-GENE
boxes O
but O
displayed O
a O
high O
G I-GENE
+ I-GENE
C I-GENE
content O
, O
was O
enriched O
for O
CpG O
_RARE_ I-GENE
, O
and O
contained O
a O
potential O
Sp1 I-GENE
- I-GENE
binding I-GENE
site I-GENE
, O
i O
. O
e O
., O
features O
compatible O
with O
a O
housekeeping O
gene I-GENE
. O

_RARE_ I-GENE
( O
pronounced O
_RARE_ I-GENE
) O
encodes O
a O
major I-GENE
protein I-GENE
kinase I-GENE
C I-GENE
substrate I-GENE
, O
the O
expression O
of O
which O
is O
down O
- I-GENE
regulated O
in O
src I-GENE
- I-GENE
and O
ras I-GENE
- I-GENE
transformed O
rodent O
fibroblasts O
but O
not O
in O
raf I-GENE
- I-GENE
transformed O
rodent O
fibroblasts O
( O
X I-GENE
. O

Type O
I I-GENE
position O
- I-GENE
vestibular O
- I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
I I-GENE
) O
and O
vestibular O
- I-GENE
only O
( O
V I-GENE
I I-GENE
) O
neurons O
, O
as O
well O
as O
a O
smaller O
number O
of O
other O
type I-GENE
I I-GENE
and O
type I-GENE
II I-GENE
eye O
- I-GENE
plus O
- I-GENE
vestibular O
neurons O
were O
studied O
. O

The O
1 I-GENE
. O
1 I-GENE
- I-GENE
and O
1 I-GENE
. O
3 I-GENE
- I-GENE
kb O
mRNA I-GENE
species O
were O
found O
only O
in O
the O
heart O
, O
and O
the O
2 I-GENE
. O
6 I-GENE
- I-GENE
kb O
species O
was O
found O
in O
the O
heart O
, O
kidney O
and O
brain O
, O
but O
not O
in O
skeletal I-GENE
muscle O
or O
liver O
. O

_RARE_ I-GENE
deficiency O
significantly O
depressed O
the O
amplitude O
of O
_RARE_ I-GENE
and O
_RARE_ I-GENE
. O

We O
have O
found O
that O
_RARE_ I-GENE
- I-GENE
cells O
are O
defective O
at O
activation O
of O
_RARE_ I-GENE
in O
response O
to O
various O
forms O
of O
stress O
. O

The O
extended O
rat I-GENE
SP I-GENE
- I-GENE
A I-GENE
isoforms I-GENE
were O
enriched O
in O
the O
more O
fully O
glycosylated O
and O
_RARE_ I-GENE
SP I-GENE
- I-GENE
A I-GENE
species O
separated O
on O
SDS O
- I-GENE
PAGE O
gels O
. O

Alternative O
splicing O
of O
_RARE_ I-GENE
may O
therefore O
contribute O
to O
the O
control O
of O
cell O
proliferation O
. O

This O
investigation O
was O
undertaken O
to O
determine O
whether O
_RARE_ I-GENE
several O
small I-GENE
_RARE_ I-GENE
of O
_RARE_ I-GENE
carbohydrate O
( O
CHO O
), O
rather O
than O
a O
single O
bolus O
, O
would O
affect O
blood O
glucose O
and O
insulin I-GENE
responses O
during O
rest O
and O
exercise O
. O

The O
findings O
suggest O
that O
_RARE_ I-GENE
effects O
of O
distinct O
memory O
processes O
are O
differentially O
influenced O
by O
the O
encoding O
_RARE_ I-GENE
. O

This O
coat I-GENE
protein I-GENE
consists O
of O
_RARE_ I-GENE
, O
the O
_RARE_ I-GENE
protein I-GENE
complex I-GENE
containing O
_RARE_ I-GENE
and O
_RARE_ I-GENE
, O
and O
the O
_RARE_ I-GENE
protein I-GENE
complex I-GENE
containing O
_RARE_ I-GENE
and O
a O
novel O
150 O
- I-GENE
kDa I-GENE
protein I-GENE
, O
_RARE_ I-GENE
. O

The O
second O
primary O
mutant I-GENE
contained O
a O
proline O
- I-GENE
to O
- I-GENE
leucine I-GENE
change O
at O
position O
_RARE_ I-GENE
( O
_RARE_ I-GENE
). O

Induction O
of O
correctly O
spliced O
germline I-GENE
transcripts I-GENE
is O
necessary O
to O
target O
a O
switch O
region O
for O
recombination O
and O
switching O
. O

Thus O
, O
the O
_RARE_ I-GENE
binds O
a O
_RARE_ I-GENE
dimer O
partner I-GENE
that O
_RARE_ I-GENE
unlike O
Class I-GENE
I I-GENE
Hox I-GENE
proteins I-GENE
. O

Furthermore O
, O
the O
NH2 I-GENE
- I-GENE
terminal I-GENE
portion O
of O
the O
homologue I-GENE
was O
not O
_RARE_ I-GENE
into O
the O
outer I-GENE
membrane I-GENE
without O
its O
COOH O
- I-GENE
terminal I-GENE
part O
. O

Molecular O
cloning O
and O
characterization O
of O
a O
cDNA I-GENE
, O
_RARE_ I-GENE
, O
encoding O
a O
chemokine I-GENE
receptor I-GENE
with O
a O
homology I-GENE
to O
the O
human I-GENE
C I-GENE
- I-GENE
C I-GENE
chemokine I-GENE
receptor I-GENE
, O
_RARE_ I-GENE
- I-GENE
4 I-GENE
. O

Organization O
of O
the O
human I-GENE
_RARE_ I-GENE
gene I-GENE
and O
molecular O
basis O
of O
the O
_RARE_ I-GENE
( O
a O
)/ O
_RARE_ I-GENE
( O
b I-GENE
) O
blood O
group O
polymorphism O
. O

Using O
mouse I-GENE
- I-GENE
human I-GENE
somatic O
hybrids O
and O
_RARE_ I-GENE
analysis O
, O
the O
PE I-GENE
- I-GENE
2 I-GENE
gene I-GENE
is O
localized O
to O
human I-GENE
chromosome O
_RARE_ I-GENE
. O
2 I-GENE
, O
a O
region O
involved O
in O
_RARE_ I-GENE
and O
deletions O
in O
leukemias O
and O
several O
solid O
tumors O
, O
suggesting O
that O
this O
novel O
ETS I-GENE
factor I-GENE
may O
play O
a O
role O
in O
_RARE_ I-GENE
. O

Whereas O
the O
mutant I-GENE
enzymes O
terminate O
normally O
at O
the O
late O
terminator O
in O
T7 I-GENE
DNA I-GENE
( O
T I-GENE
( O
phi I-GENE
)) O
and O
_RARE_ I-GENE
T2 I-GENE
, O
they O
fail O
to O
terminate O
at O
one O
of O
the O
termination O
sites I-GENE
of O
_RARE_ I-GENE
T1 O
, O
and O
also O
fail O
to O
recognize O
the O
PTH I-GENE
and O
_RARE_ I-GENE
signals O
. O

_RARE_ I-GENE
data O
suggest O
that O
the O
_RARE_ I-GENE
associate O
with O
a O
_RARE_ I-GENE
. O

_RARE_ I-GENE
regulatory I-GENE
unit I-GENE
1 I-GENE
( O
_RARE_ I-GENE
) O
is O
necessary O
for O
and O
sufficient O
to O
mediate O
light I-GENE
- I-GENE
dependent I-GENE
activation O
of O
the O
_RARE_ I-GENE
synthase I-GENE
( O
_RARE_ I-GENE
) O
minimal I-GENE
promoter I-GENE
in O
_RARE_ I-GENE
_RARE_ I-GENE
. O

Sequence O
divergence O
is O
observed O
in O
untranslated O
regions O
which O
allows O
the O
definition O
of O
gene I-GENE
- I-GENE
specific I-GENE
probes O
. O

The O
active O
state O
is O
_RARE_ I-GENE
by O
hydrolysis O
of O
bound O
GTP I-GENE
, O
producing O
inactive O
ARF I-GENE
- I-GENE
GDP I-GENE
. O

We O
suggest O
that O
apart O
from O
the O
_RARE_ I-GENE
_RARE_ I-GENE
for O
Children O
' O
s O
under O
- I-GENE
five O
mortality O
target O
for O
the O
year O
2000 O
, O
_RARE_ I-GENE
targets O
to O
reduce O
_RARE_ I-GENE
_RARE_ I-GENE
in O
under O
- I-GENE
five O
mortality O
should O
be O
specified O
. O

The O
_RARE_ I-GENE
, O
which O
can O
be O
of O
the O
FK506 O
- I-GENE
or O
cyclosporin O
A I-GENE
- I-GENE
binding I-GENE
class I-GENE
, O
binds O
to O
hsp90 I-GENE
via O
its O
_RARE_ I-GENE
repeat I-GENE
( O
TPR O
) O
domain I-GENE
, O
and O
different O
receptor I-GENE
_RARE_ I-GENE
exist O
depending O
upon O
which O
_RARE_ I-GENE
_RARE_ I-GENE
the O
TPR O
- I-GENE
binding I-GENE
region O
of O
hsp90 I-GENE
. O

In O
_RARE_ I-GENE
macrophages O
, O
absence O
of O
_RARE_ I-GENE
led O
to O
the O
_RARE_ I-GENE
and O
_RARE_ I-GENE
of O
_RARE_ I-GENE
/ I-GENE
59 O
( O
_RARE_ I-GENE
) O
and O
p53 I-GENE
/ I-GENE
56 O
( O
_RARE_ I-GENE
), O
but O
not O
of O
_RARE_ I-GENE
( O
c I-GENE
- I-GENE
_RARE_ I-GENE
). O

_RARE_ I-GENE
in O
milk O
and O
_RARE_ I-GENE
transfer I-GENE
of O
two O
_RARE_ I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
, O
in O
rabbits O
. O

Sequencing O
of O
the O
_RARE_ I-GENE
gene I-GENE
revealed O
that O
it O
encodes O
a O
protein I-GENE
that O
contains O
an O
N I-GENE
- I-GENE
terminal I-GENE
GAL4 I-GENE
- I-GENE
like I-GENE
Zn I-GENE
( O
II I-GENE
) O
_RARE_ I-GENE
( O
or O
C6 I-GENE
zinc I-GENE
) O
_RARE_ I-GENE
cluster I-GENE
for O
DNA I-GENE
binding I-GENE
, O
leucine I-GENE
zipper I-GENE
- I-GENE
like I-GENE
heptad I-GENE
repeat I-GENE
motifs O
and O
central O
and O
C I-GENE
- I-GENE
terminal I-GENE
acidic O
alpha I-GENE
- I-GENE
helical O
regions O
, O
consistent O
with O
a O
function O
as O
a O
DNA I-GENE
- I-GENE
binding I-GENE
transcriptional O
activator I-GENE
. O

Overexpression O
of O
_RARE_ I-GENE
allowed O
growth I-GENE
in O
the O
absence O
of O
_RARE_ I-GENE
. O

The O
coding O
region O
of O
_RARE_ I-GENE
is O
contained O
within O
a O
single O
exon O
encoding O
a O
1 I-GENE
, O
_RARE_ I-GENE
- I-GENE
amino O
- I-GENE
acid I-GENE
protein I-GENE
. O

_RARE_ I-GENE
, O
_RARE_ I-GENE
association O
of O
p107 I-GENE
or O
p130 I-GENE
with O
either O
cyclin I-GENE
E I-GENE
- I-GENE
cdk2 I-GENE
or O
cyclin I-GENE
A I-GENE
- I-GENE
cdk2 I-GENE
_RARE_ I-GENE
the O
activities O
of O
these O
kinases I-GENE
. O

Furthermore O
, O
_RARE_ I-GENE
suppresses O
actin I-GENE
_RARE_ I-GENE
, O
which O
is O
induced O
by O
smooth I-GENE
muscle O
alpha I-GENE
- I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
of O
the O
simian I-GENE
virus I-GENE
40 I-GENE
origin O
of O
replication O
mediated O
by O
human I-GENE
replication O
protein I-GENE
A I-GENE
. O

This O
effect O
was O
abolished O
once O
the O
EM O
motif I-GENE
in O
the O
promoter I-GENE
- I-GENE
reporter I-GENE
construct I-GENE
was O
mutated O
, O
thus O
suggesting O
that O
the O
synergistic O
transactivation O
function O
of O
the O
TEF I-GENE
- I-GENE
1 I-GENE
- I-GENE
Max I-GENE
_RARE_ I-GENE
complex I-GENE
is O
mediated O
through O
binding I-GENE
of O
the O
complex I-GENE
to O
the O
EM O
motif I-GENE
. O

_RARE_ I-GENE
residues O
within O
a O
small I-GENE
region O
of O
VP16 I-GENE
interact O
with O
Oct I-GENE
- I-GENE
1 I-GENE
, O
_RARE_ I-GENE
, O
and O
DNA I-GENE
. O

With O
a O
view O
to O
identifying O
other O
important O
U14 I-GENE
interactions O
, O
a O
stem O
- I-GENE
loop I-GENE
domain I-GENE
required O
for O
activity O
of O
Saccharomyces I-GENE
cerevisiae I-GENE
U14 I-GENE
RNAs I-GENE
( O
the O
Y I-GENE
domain I-GENE
) O
was O
first O
subjected O
to O
detailed O
mutational O
analysis O
. O

Based O
on O
these O
results O
and O
because O
_RARE_ I-GENE
has O
been O
implicated O
as O
a O
regulator I-GENE
of O
chromatin O
structure O
, O
we O
_RARE_ I-GENE
that O
polymerase I-GENE
alpha I-GENE
may O
interact O
with O
these O
proteins I-GENE
to O
gain O
access O
to O
its O
template O
or O
to O
origins O
of O
replication O
in O
vivo O
. O

_RARE_ I-GENE
when O
the O
_RARE_ I-GENE
size O
was O
reduced O
_RARE_ I-GENE
( O
i O
. O
e O
., O
6 I-GENE
x O
10 O
( O
6 I-GENE
) O
_RARE_ I-GENE
/ I-GENE
mouse I-GENE
), O
50 O
% O
of O
the O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
treated O
animals O
died O
within O
6 I-GENE
days O
. O

In O
12 O
cases O
( O
3 I-GENE
. O
1 I-GENE
%), O
a O
change O
in O
stage O
resulted O
. O

Promoter O
recognition I-GENE
_RARE_ I-GENE
identified O
divergent O
promoter I-GENE
elements O
within O
the O
CpG O
island O
, O
which O
lies O
between O
the O
_RARE_ I-GENE
and O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
genes I-GENE
, O
and O
provide O
evidence O
for O
a O
putative O
second O
_RARE_ I-GENE
promoter I-GENE
located O
within O
intron O
3 I-GENE
, O
immediately O
upstream O
of O
the O
first O
coding O
exon O
. O

Recombinant I-GENE
soluble I-GENE
_RARE_ I-GENE
that O
lacked O
transmembrane I-GENE
and O
cytoplasmic I-GENE
domains I-GENE
had O
factor I-GENE
I I-GENE
cofactor I-GENE
activity O
in O
_RARE_ I-GENE
cleavage O
, O
indicating O
that O
it O
is O
functionally O
, O
as O
well O
as O
structurally O
homologous O
to O
_RARE_ I-GENE
. O

Clinical O
and O
_RARE_ I-GENE
signs O
are O
not O
specific I-GENE
in O
this O
setting O
, O
and O
the O
diagnosis O
_RARE_ I-GENE
on O
histological O
features O
, O
mainly O
bone O
marrow O
examination O
. O

_RARE_ I-GENE
_RARE_ I-GENE
for O
muscle O
_RARE_ I-GENE
and O
the O
control O
of O
_RARE_ I-GENE
stability O
. O

_RARE_ I-GENE
chromatographic O
separation O
was O
achieved O
on O
a O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
column O
using O
gradient O
_RARE_ I-GENE
. O

The O
linear O
plasmid O
_RARE_ I-GENE
from O
_RARE_ I-GENE
_RARE_ I-GENE
encodes O
a O
protein I-GENE
highly O
homologous O
to O
the O
_RARE_ I-GENE
- I-GENE
plasmid O
DNA I-GENE
polymerase I-GENE
. O

The O
RNA I-GENE
- I-GENE
binding I-GENE
and O
RNA I-GENE
- I-GENE
DNA I-GENE
helicase I-GENE
activities O
of O
the O
Escherichia I-GENE
coli I-GENE
transcription I-GENE
termination O
factor I-GENE
rho I-GENE
have O
been O
investigated O
using O
natural O
RNA I-GENE
molecules I-GENE
that O
are O
_RARE_ I-GENE
and O
_RARE_ I-GENE
nucleotide I-GENE
residues O
in O
length I-GENE
and O
that O
contain O
the O
_RARE_ I-GENE
t I-GENE
' O
rho I-GENE
- I-GENE
dependent I-GENE
termination O
sequence I-GENE
of O
E I-GENE
. O
coli I-GENE
. O

The O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
gene I-GENE
is O
conserved O
among O
mammals O
but O
shows O
no O
homology I-GENE
to O
non O
- I-GENE
vertebrate I-GENE
species O
. O

The O
data O
suggest O
that O
like I-GENE
in O
yeast I-GENE
, O
in O
plants O
a O
certain O
subfamily I-GENE
of O
_RARE_ I-GENE
is O
specifically O
involved O
in O
the O
proteolytic O
degradation O
of O
abnormal O
proteins I-GENE
as O
result O
of O
stress O
. O

The O
_RARE_ I-GENE
- I-GENE
19 O
also O
encodes O
the O
AAV I-GENE
inverted O
terminal I-GENE
repeats I-GENE
for O
integration O
and O
replication O
and O
the O
herpes I-GENE
virus I-GENE
thymidine I-GENE
kinase I-GENE
promoter I-GENE
- I-GENE
driven O
gene I-GENE
for O
neomycin I-GENE
resistance O
( O
_RARE_ I-GENE
). O

We O
have O
developed O
a O
_RARE_ I-GENE
- I-GENE
mediated O
gene I-GENE
transfer I-GENE
system O
for O
the O
rat I-GENE
_RARE_ I-GENE
II I-GENE
gene I-GENE
. O

The O
serum I-GENE
levels O
of O
beta I-GENE
- I-GENE
human I-GENE
_RARE_ I-GENE
gonadotropin I-GENE
( O
_RARE_ I-GENE
) O
and O
placental I-GENE
alkaline I-GENE
phosphatase I-GENE
( O
_RARE_ I-GENE
) O
were O
not O
elevated O
. O

A I-GENE
striking O
feature O
of O
the O
recombinant I-GENE
H19 I-GENE
allele I-GENE
is O
the O
occurrence O
of O
a O
parental O
_RARE_ I-GENE
set O
on O
the O
neo I-GENE
replacement O
cassette I-GENE
. O

This O
indicates O
that O
recruitment O
of O
large O
T I-GENE
antigen I-GENE
to O
the O
rRNA I-GENE
promoter I-GENE
by O
_RARE_ I-GENE
constitutes O
a O
crucial O
step O
in O
the O
activation O
process O
. O

In O
1990 O
, O
an O
International O
_RARE_ I-GENE
for O
the O
_RARE_ I-GENE
of O
_RARE_ I-GENE
of O
_RARE_ I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
was O
established O
by O
the O
_RARE_ I-GENE
American O
Health O
Organization O
to O
_RARE_ I-GENE
determine O
if O
transmission O
was O
interrupted O
. O

Functional O
and O
regulatory I-GENE
analysis O
of O
the O
two O
copies O
of O
the O
_RARE_ I-GENE
operon I-GENE
of O
Rhizobium I-GENE
_RARE_ I-GENE
strain O
_RARE_ I-GENE
. O

This O
study O
describes O
a O
new O
MADS I-GENE
box I-GENE
gene I-GENE
, O
_RARE_ I-GENE
, O
which O
along O
with O
_RARE_ I-GENE
( O
J O
. O

Thus O
_RARE_ I-GENE
. O
_RARE_ I-GENE
is O
a O
useful O
ES O
cell O
line O
for O
_RARE_ I-GENE
the O
mouse I-GENE
genome O
using O
the O
_RARE_ I-GENE
gene I-GENE
as O
a O
selection O
marker O
and O
for O
transmission O
at O
a O
high O
frequency O
into O
the O
mouse I-GENE
germ I-GENE
line O
. O

Lung O
and O
multi I-GENE
- I-GENE
system O
damage O
were O
early I-GENE
indicators O
of O
poor O
outcome O
in O
severe O
non O
- I-GENE
fatal O
disease O
. O

The O
results O
suggest O
that O
the O
_RARE_ I-GENE
_RARE_ I-GENE
reflex O
evoked O
by O
bladder O
filling O
and O
L I-GENE
- I-GENE
_RARE_ I-GENE
involves O
a O
_RARE_ I-GENE
pathway O
where O
transmission O
is O
partly O
mediated O
by O
spinal O
alpha I-GENE
1 I-GENE
- I-GENE
adrenoceptors I-GENE
. O

OBJECTIVE O
: O
This O
study O
was O
designed O
to O
analyze O
the O
common O
cause O
of O
_RARE_ I-GENE
, O
mixed O
_RARE_ I-GENE
. O

_RARE_ I-GENE
of O
regeneration O
in O
the O
above O
pathological O
condition O
results O
from O
the O
damage O
to O
_RARE_ I-GENE
_RARE_ I-GENE
and O
loss O
of O
its O
function O
for O
the O
support O
of O
structural O
_RARE_ I-GENE
. O

_RARE_ I-GENE
, O
neck O
or O
facial O
muscles O
_RARE_ I-GENE
were O
also O
found O
in O
three O
cases O
. O

Identification O
of O
five O
new O
genes I-GENE
, O
closely O
related I-GENE
to O
the O
interleukin I-GENE
- I-GENE
1beta I-GENE
converting I-GENE
enzyme I-GENE
gene I-GENE
, O
that O
do O
not O
encode O
functional O
proteases I-GENE
. O

The O
C I-GENE
- I-GENE
terminal I-GENE
mature O
region O
is O
highly O
conserved O
in O
other O
serine I-GENE
_RARE_ I-GENE
. O

One O
RNA I-GENE
construct I-GENE
which O
consisted O
of O
112 O
nucleotides O
( O
nt O
) O
from O
nt O
_RARE_ I-GENE
to O
nt O
750 O
formed O
a O
heterodimeric I-GENE
complex I-GENE
with O
the O
RNA I-GENE
which O
consisted O
of O
200 O
nucleotides O
from O
nt O
_RARE_ I-GENE
to O
nt O
750 O
. O

Here O
we O
demonstrate O
that O
_RARE_ I-GENE
, O
which O
solely O
has O
no O
effects O
as O
a O
transcriptional O
regulator I-GENE
, O
_RARE_ I-GENE
suppresses O
transcriptional O
activation O
by O
_RARE_ I-GENE
, O
and O
that O
_RARE_ I-GENE
exhibits O
the O
higher O
affinity O
for O
DNA I-GENE
- I-GENE
binding I-GENE
than O
_RARE_ I-GENE
. O

However O
, O
we O
could O
not O
find O
the O
homologous O
regions O
with O
guanine I-GENE
nucleotide I-GENE
exchange I-GENE
factors I-GENE
or O
GTPase I-GENE
- I-GENE
activating I-GENE
proteins I-GENE
in O
the O
c I-GENE
- I-GENE
cbl I-GENE
gene I-GENE
. O

However O
, O
using O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
nuclear I-GENE
extract O
, O
we O
demonstrated O
that O
GATA I-GENE
- I-GENE
4 I-GENE
is O
the O
only O
GATA I-GENE
- I-GENE
binding I-GENE
protein I-GENE
that O
forms O
specific I-GENE
DNA I-GENE
- I-GENE
protein I-GENE
complex I-GENE
with O
the O
- I-GENE
70 I-GENE
GATA I-GENE
site I-GENE
. O

The O
impact O
of O
social O
support O
on O
the O
relationships O
of O
_RARE_ I-GENE
male O
_RARE_ I-GENE
is O
examined O
. O

The O
ubiquitously O
expressed O
hypoxia O
- I-GENE
inducible I-GENE
factor I-GENE
- I-GENE
1 I-GENE
( O
HIF I-GENE
- I-GENE
1 I-GENE
) O
is O
involved O
in O
expression O
of O
a O
large O
number O
of O
oxygen O
- I-GENE
regulated O
genes I-GENE
. O

_RARE_ I-GENE
- I-GENE
1 I-GENE
, O
matrix I-GENE
_RARE_ I-GENE
- I-GENE
3 I-GENE
( O
_RARE_ I-GENE
- I-GENE
3 I-GENE
), O
is O
an O
important O
_RARE_ I-GENE
selectively O
expressed O
by O
somatic O
cells O
in O
organ O
tissues O
. O

_RARE_ I-GENE
also O
shows O
a O
degree O
of O
_RARE_ I-GENE
. O

_RARE_ I-GENE
for O
_RARE_ I-GENE
was O
conducted O
by O
_RARE_ I-GENE
_RARE_ I-GENE
of O
treatment O
- I-GENE
group O
_RARE_ I-GENE
, O
using O
standardized O
measurements O
of O
blood O
pressure O
and O
urinary O
protein I-GENE
excretion O
at O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
for O
monitoring O
these O
measurements O
during O
the O
_RARE_ I-GENE
for O
delivery O
, O
and O
_RARE_ I-GENE
of O
medical O
records O
of O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
and O
all O
_RARE_ I-GENE
. O

_RARE_ I-GENE
hydrocarbon I-GENE
receptor I-GENE
nuclear I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
is O
a O
component O
of O
the O
transcription I-GENE
factors I-GENE
, O
_RARE_ I-GENE
hydrocarbon I-GENE
receptor I-GENE
( O
_RARE_ I-GENE
) O
and O
hypoxia O
- I-GENE
inducible I-GENE
factor I-GENE
1 I-GENE
, O
which O
transactivate O
their O
target O
genes I-GENE
, O
such O
as O
_RARE_ I-GENE
and O
erythropoietin I-GENE
, O
in O
response O
to O
_RARE_ I-GENE
aromatic O
_RARE_ I-GENE
and O
to O
low O
O2 O
concentration O
, O
respectively O
. O

DNase I-GENE
I I-GENE
footprint O
analysis O
identified O
a O
protected O
region O
from O
- I-GENE
37 O
to O
- I-GENE
53 O
. O

We O
also O
provide O
evidence O
that O
_RARE_ I-GENE
is O
phosphorylated O
in O
vitro O
by O
a O
_RARE_ I-GENE
( O
_RARE_ I-GENE
)- I-GENE
_RARE_ I-GENE
- I-GENE
bound O
kinase I-GENE
from O
Schizosaccharomyces I-GENE
pombe I-GENE
extracts O
that O
displays O
cell O
cycle O
- I-GENE
regulated O
activity O
similar O
to O
that O
of O
the O
_RARE_ I-GENE
( O
cdc2 I-GENE
( O
kinase I-GENE
. O

However O
, O
by O
_RARE_ I-GENE
metal O
affinity O
chromatography O
assay O
, O
self O
- I-GENE
association O
of O
PR I-GENE
- I-GENE
A I-GENE
was O
3 I-GENE
. O
5 I-GENE
- I-GENE
fold O
more O
efficient O
than O
that O
of O
either O
the O
_RARE_ I-GENE
or O
_RARE_ I-GENE
constructs I-GENE
. O

The O
overall O
results O
of O
this O
paper O
are O
consistent O
with O
the O
conclusion O
that O
the O
carboxyl O
- I-GENE
terminal I-GENE
_RARE_ I-GENE
is O
not O
sufficient O
for O
mediating O
PR I-GENE
dimerization O
and O
that O
multiple O
regions O
, O
including O
the O
_RARE_ I-GENE
and O
amino O
- I-GENE
terminal I-GENE
sequences I-GENE
, O
contribute O
either O
directly O
or O
indirectly O
to O
_RARE_ I-GENE
of O
PR I-GENE
. O

We O
isolated O
several O
overlapping O
A I-GENE
- I-GENE
phage I-GENE
and O
cosmid O
clones O
that O
_RARE_ I-GENE
more O
than O
100 O
kb O
of O
human I-GENE
DNA I-GENE
and O
contained O
the O
entire O
VDR I-GENE
gene I-GENE
. O

_RARE_ I-GENE
carcinoma O
: O
therapeutic O
approach O
in O
patients O
already O
treated O
with O
metastasis O
resection O

Here O
, O
we O
correlate O
_RARE_ I-GENE
effects O
on O
cell O
cycle O
with O
changes O
of O
E2F I-GENE
/ I-GENE
DP I-GENE
complexes I-GENE
and O
activity O
in O
differentiating O
C2C12 O
_RARE_ I-GENE
. O

The O
products I-GENE
of O
the O
Saccharomyces I-GENE
cerevisiae I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
and O
_RARE_ I-GENE
genes I-GENE
participate O
in O
a O
_RARE_ I-GENE
pathway O
required O
for O
normal O
microtubule I-GENE
function O
. O

_RARE_ I-GENE
was O
still O
a O
significant O
risk O
factor I-GENE
when O
_RARE_ I-GENE
_RARE_ I-GENE
were O
excluded O
. O

_RARE_ I-GENE
_RARE_ I-GENE
on O
" O
Acute O
and O
chronic O
effects O
of O
exercise O
on O
leptin I-GENE
levels O
in O
humans O
". O

Both O
promoters I-GENE
lack O
a O
TATA I-GENE
box I-GENE
, O
and O
_RARE_ I-GENE
belongs O
to O
the O
_RARE_ I-GENE
- I-GENE
1 I-GENE
class I-GENE
of O
promoters I-GENE
, O
which O
initiate O
transcription I-GENE
at O
multiple O
sites I-GENE
. O

Serum I-GENE
response O
factor I-GENE
( O
SRF I-GENE
), O
a O
member O
of O
an O
_RARE_ I-GENE
family I-GENE
of O
DNA I-GENE
- I-GENE
binding I-GENE
proteins I-GENE
, O
is O
generally O
assumed O
to O
be O
a O
ubiquitous O
transcription I-GENE
factor I-GENE
involved O
in O
regulating O
growth I-GENE
factor I-GENE
- I-GENE
responsive I-GENE
genes I-GENE
. O

We O
have O
initiated O
studies O
to O
identify O
candidate O
signal I-GENE
_RARE_ I-GENE
that O
associate O
with O
the O
cytosolic I-GENE
domain I-GENE
( O
_RARE_ I-GENE
) O
of O
the O
IL I-GENE
- I-GENE
_RARE_ I-GENE
. O

In O
this O
study O
, O
we O
sought O
to O
identify O
mechanisms O
that O
could O
account O
for O
the O
_RARE_ I-GENE
effects O
of O
IL I-GENE
- I-GENE
4 I-GENE
. O

Pseudomonas I-GENE
aeruginosa I-GENE
strains O
_RARE_ I-GENE
patients O
with O
cystic I-GENE
fibrosis I-GENE
( O
_RARE_ I-GENE
) O
_RARE_ I-GENE
a O
_RARE_ I-GENE
phenotype O
due O
to O
_RARE_ I-GENE
of O
_RARE_ I-GENE
. O

_RARE_ I-GENE
of O
_RARE_ I-GENE
in O
the O
_RARE_ I-GENE
mutant I-GENE
, O
in O
_RARE_ I-GENE
and O
in O
the O
non O
- I-GENE
_RARE_ I-GENE
strain O
_RARE_ I-GENE
was O
assessed O
by O
the O
use O
of O
a O
transcriptional O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
fusion I-GENE
. O

The O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
specificity O
of O
the O
cDNA I-GENE
construct I-GENE
was O
_RARE_ I-GENE
by O
the O
observation O
that O
all O
peptide I-GENE
sequences I-GENE
derived O
from O
a O
previously O
purified O
, O
catalytically O
active O
49 O
- I-GENE
kDa I-GENE
fragment I-GENE
were O
found O
within O
the O
coding O
region O
. O

A I-GENE
soluble I-GENE
62 O
- I-GENE
kDa I-GENE
protein I-GENE
was O
produced O
without O
the O
proteolytic O
processing O
by O
inserting O
the O
coding O
sequence I-GENE
of O
amino O
acids O
112 O
to O
_RARE_ I-GENE
of O
ORF I-GENE
- I-GENE
2 I-GENE
in O
a O
baculovirus O
expression O
vector O
and O
using O
the O
corresponding O
virus I-GENE
to O
_RARE_ I-GENE
Sf9 O
cells O
. O

The O
CPK I-GENE
- I-GENE
MB I-GENE
_RARE_ I-GENE
showed O
no O
percentage O
increase O
of O
total O
CPK I-GENE
higher O
than O
5 I-GENE
%, O
measured O
at O
6 I-GENE
, O
12 O
, O
and O
24 O
h O
after O
the O
shock I-GENE
, O
independent O
of O
the O
number O
of O
attempts O
of O
_RARE_ I-GENE
. O

Serum I-GENE
and O
peritoneal O
dialysis O
fluid O
( O
_RARE_ I-GENE
) O
were O
collected O
for O
assay O
throughout O
the O
course O
of O
the O
study O
and O
for O
5 I-GENE
days O
thereafter O
. O

Results O
support O
the O
hypothesis O
that O
endogenous I-GENE
_RARE_ I-GENE
- I-GENE
releasing I-GENE
factor I-GENE
, O
perhaps O
acting O
at O
a O
peripheral O
binding I-GENE
site I-GENE
, O
suppresses O
the O
active O
behavioral O
response O
characteristic O
of O
_RARE_ I-GENE
during O
the O
early I-GENE
phase O
of O
isolation O
in O
novel O
_RARE_ I-GENE
. O

Liver O
regional O
blood O
volume O
( O
_RARE_ I-GENE
) O
is O
altered O
by O
several O
disease O
states O
and O
various O
drugs O
. O

The O
gray O
matter O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
ratio O
clearly O
separated O
the O
two O
groups O
. O

As O
with O
the O
murine I-GENE
and O
human I-GENE
_RARE_ I-GENE
- I-GENE
1 I-GENE
genes I-GENE
, O
the O
5 I-GENE
' O
region O
of O
the O
bovine I-GENE
_RARE_ I-GENE
- I-GENE
1 I-GENE
gene I-GENE
lacked O
a O
TATA I-GENE
box I-GENE
. O

_RARE_ I-GENE
acetyltransferase I-GENE
assays O
examining O
the O
ability O
of O
_RARE_ I-GENE
to O
repress O
activity O
from O
the O
HCMV I-GENE
major I-GENE
IE I-GENE
promoter I-GENE
or O
activate O
the O
HCMV I-GENE
early I-GENE
promoter I-GENE
for O
the O
2 I-GENE
. O
2 I-GENE
- I-GENE
kb O
class I-GENE
of O
RNAs I-GENE
demonstrated O
the O
functional O
integrity O
of O
the O
_RARE_ I-GENE
protein I-GENE
. O

ORF I-GENE
M1 I-GENE
has O
striking O
homology I-GENE
to O
_RARE_ I-GENE
_RARE_ I-GENE
, O
while O
ORF I-GENE
_RARE_ I-GENE
encodes O
a O
potential O
homolog I-GENE
of O
Bcl I-GENE
- I-GENE
2 I-GENE
- I-GENE
like I-GENE
molecules I-GENE
encoded I-GENE
by O
other O
_RARE_ I-GENE
( O
gene I-GENE
16 O
of O
HVS O
and O
KSHV I-GENE
and O
the O
_RARE_ I-GENE
gene I-GENE
of O
EBV I-GENE
). O

Transcription O
factor I-GENE
binding I-GENE
sites I-GENE
downstream O
of O
the O
human I-GENE
immunodeficiency I-GENE
virus I-GENE
type I-GENE
1 I-GENE
transcription I-GENE
start O
site I-GENE
are O
important O
for O
virus I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
structure O
of O
an O
_RARE_ I-GENE
of O
proteolytic O
_RARE_ I-GENE
: O
detailed O
conformational O
analysis O
of O
the O
bovine I-GENE
ternary O
complex I-GENE
and O
implications O
for O
their O
activation O
. O

_RARE_ I-GENE
transient O
transfection O
of O
NIH3T3 O
fibroblast I-GENE
cells O
and O
gel O
mobility I-GENE
shift O
assays O
, O
the O
functional O
binding I-GENE
site I-GENE
was O
localized O
to O
a O
short O
region O
(- O
_RARE_ I-GENE
to O
- I-GENE
_RARE_ I-GENE
bp O
from O
the O
transcription I-GENE
start O
site I-GENE
) O
which O
has O
a O
_RARE_ I-GENE
sequence I-GENE
. O

We O
_RARE_ I-GENE
that O
this O
injection O
_RARE_ I-GENE
( O
0 O
. O
1 I-GENE
- I-GENE
0 O
. O
2 I-GENE
ml O
. O
s O
- I-GENE
1 I-GENE
) O
is O
suitable O
for O
spinal O
anesthesia O
. O

Alternative O
splicing O
of O
_RARE_ I-GENE
- I-GENE
6 I-GENE
( O
a O
member O
of O
the O
CIC I-GENE
chloride O
- I-GENE
channel O
family I-GENE
) O
transcripts I-GENE
generates O
three O
truncated I-GENE
isoforms I-GENE
one O
of O
which O
, O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
, O
is O
kidney O
- I-GENE
specific I-GENE
. O

The O
current O
study O
demonstrates O
that O
T3 O
- I-GENE
activated I-GENE
transcription I-GENE
of O
the O
_RARE_ I-GENE
: O
cytochrome I-GENE
P450 I-GENE
oxidoreductase I-GENE
( O
_RARE_ I-GENE
) O
gene I-GENE
is O
dependent I-GENE
on O
the O
thyroid I-GENE
hormonal O
status O
of O
the O
animal O
, O
with O
both O
transcriptional O
and O
post O
- I-GENE
transcriptional O
pathways O
being O
important O
in O
regulating O
the O
cellular O
_RARE_ I-GENE
mRNA I-GENE
level O
. O

The O
behavior O
of O
different O
types O
of O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
_RARE_ I-GENE
in O
the O
_RARE_ I-GENE
_RARE_ I-GENE
process O
of O
abdominal O
wall O
defects O
. O

The O
control O
group O
revealed O
significantly O
higher O
levels O
of O
coagulation I-GENE
factors I-GENE
II I-GENE
, O
V I-GENE
and O
VIII I-GENE
, O
compared O
to O
the O
index O
group O
. O

The O
frequency O
of O
positive O
anti I-GENE
- I-GENE
_RARE_ I-GENE
antibody I-GENE
_RARE_ I-GENE
in O
the O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
syndrome O
patients O
with O
_RARE_ I-GENE
19 O
isolates O
was O
higher O
than O
that O
in O
the O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
syndrome O
and O
_RARE_ I-GENE
' O
s O
syndrome O
patients O
without O
_RARE_ I-GENE
19 O
isolates O
. O

_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
of O
the O
_RARE_ I-GENE
resulted O
in O
seizure O
remission O
without O
complications O
20 O
months O
after O
surgery O
. O

NF I-GENE
- I-GENE
kappa I-GENE
B I-GENE
/ I-GENE
Rel I-GENE
transcription I-GENE
factors I-GENE
participate O
in O
the O
activation O
of O
numerous O
genes I-GENE
involved O
in O
immune I-GENE
regulation O
/ I-GENE
inflammation O
including O
cytokines O
, O
cell O
surface O
receptors I-GENE
, O
adhesion I-GENE
molecules I-GENE
, O
and O
acute O
phase O
proteins I-GENE
. O

If O
E I-GENE
. O
coli I-GENE
is O
present O
in O
any O
source O
water O
sample O
, O
the O
_RARE_ I-GENE
and O
any O
directly O
connected O
_RARE_ I-GENE
should O
be O
_RARE_ I-GENE
. O

However O
, O
mean O
food O
intake O
in O
the O
40 I-GENE
% O
group O
was O
half O
that O
of O
the O
_RARE_ I-GENE
group O
( O
p O
< O
0 O
. O
001 O
) O
and O
significantly O
less O
( O
p O
< O
0 O
. O
01 O
) O
than O
the O
_RARE_ I-GENE
group O
, O
which O
_RARE_ I-GENE
amounts O
equivalent O
to O
65 O
% O
of O
daily O
requirement O
. O

The O
following O
technique O
describes O
a O
modification O
to O
a O
_RARE_ I-GENE
_RARE_ I-GENE
that O
provided O
the O
advantages O
of O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
and O
consistent O
positioning O
even O
though O
one O
implant O
was O
lost O
and O
the O
_RARE_ I-GENE
of O
implants O
limited O
accuracy O
. O

In O
summary O
, O
_RARE_ I-GENE
express O
receptors I-GENE
for O
a O
broad O
panel O
of O
cytokines O
, O
even O
receptors I-GENE
for O
cytokines O
whose O
effects O
on O
DC O
are O
still O
unknown O
( O
i O
. O
e O
. O

Its O
potential O
as O
a O
diagnostic O
tool O
for O
epidemiological O
_RARE_ I-GENE
was O
assessed O
in O
comparison O
with O
three O
other O
diagnostic O
tests O
: O
_RARE_ I-GENE
examination O
, O
ELISA O
with O
soluble I-GENE
egg I-GENE
antigen I-GENE
( O
_RARE_ I-GENE
) O
and O
the O
_RARE_ I-GENE
_RARE_ I-GENE
test O
( O
_RARE_ I-GENE
). O

We O
have O
separated O
a O
_RARE_ I-GENE
sulfate I-GENE
proteoglycan I-GENE
, O
_RARE_ I-GENE
, O
from O
_RARE_ I-GENE
and O
_RARE_ I-GENE
by O
using O
_RARE_ I-GENE
extraction O
of O
bovine I-GENE
fetal O
_RARE_ I-GENE
cartilage O
, O
followed O
by O
sequential O
ion O
- I-GENE
exchange I-GENE
, O
gel O
_RARE_ I-GENE
, O
hydrophobic O
, O
and O
_RARE_ I-GENE
+ I-GENE
_RARE_ I-GENE
chromatographic O
steps O
. O

These O
analyses O
demonstrate O
that O
the O
_RARE_ I-GENE
isoforms I-GENE
are O
encoded I-GENE
by O
the O
same O
gene I-GENE
with O
isoform I-GENE
- I-GENE
specific I-GENE
transcripts I-GENE
arising O
through O
the O
use O
of O
alternative O
5 I-GENE
' O
exons O
. O

The O
selective O
5 I-GENE
- I-GENE
HT3 I-GENE
receptor I-GENE
antagonists O
_RARE_ I-GENE
( O
_RARE_ I-GENE
), O
_RARE_ I-GENE
( O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
), O
_RARE_ I-GENE
and O
_RARE_ I-GENE
, O
and O
the O
substituted O
_RARE_ I-GENE
( O
5 I-GENE
- I-GENE
_RARE_ I-GENE
receptor I-GENE
agonist O
/ I-GENE
5 I-GENE
- I-GENE
HT3 I-GENE
receptor I-GENE
antagonists O
) O
_RARE_ I-GENE
_RARE_ I-GENE
and O
SC O
- I-GENE
_RARE_ I-GENE
dose O
- I-GENE
dependently O
enhanced O
gastric O
emptying O
in O
normal O
rats O
. O

Re O
- I-GENE
evaluation O
of O
the O
biopsy O
_RARE_ I-GENE
from O
the O
right O
hip O
taken O
at O
the O
time O
of O
the O
initial O
operation O
showed O
areas O
of O
_RARE_ I-GENE
arising O
in O
the O
background O
of O
synovial O
_RARE_ I-GENE
. O

All O
corneal O
_RARE_ I-GENE
were O
processed O
for O
_RARE_ I-GENE
and O
electron O
microscopic O
studies O
. O

_RARE_ I-GENE
- I-GENE
fold O
to O
apparent O
_RARE_ I-GENE
with O
a O
41 O
% O
yield O
by O
affinity O
chromatography O
utilizing O
DNA I-GENE
- I-GENE
_RARE_ I-GENE
; O
the O
_RARE_ I-GENE
of O
the O
final O
preparation O
was O
assessed O
by O
SDS O
/ I-GENE
PAGE O
, O
lack O
of O
contamination O
by O
other O
_RARE_ I-GENE
and O
production O
of O
a O
_RARE_ I-GENE
antibody I-GENE
against O
the O
enzyme I-GENE
. O

Human I-GENE
_RARE_ I-GENE
- I-GENE
DNA I-GENE
glycosylase I-GENE
maps O
at O
chromosome O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
. O
1 I-GENE
: O
a O
region O
of O
high O
loss O
of O
heterozygosity O
in O
gastric O
cancer O
. O

_RARE_ I-GENE
is O
coexpressed O
with O
GATA I-GENE
- I-GENE
1 I-GENE
during O
embryonic O
development O
and O
in O
erythroid I-GENE
and O
_RARE_ I-GENE
cells O
. O

The O
mean O
times O
to O
detection O
of O
all O
mycobacteria O
with O
_RARE_ I-GENE
_RARE_ I-GENE
MB I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
TB I-GENE
were O
similar O
( O
10 O
. O
3 I-GENE
and O
10 O
. O
0 O
days O
, O
respectively O
). O

_RARE_ I-GENE
the O
_RARE_ I-GENE
_RARE_ I-GENE
MB I-GENE
system O
is O
recommended O
for O
respiratory O
specimens O
, O
we O
demonstrated O
that O
it O
can O
be O
successfully O
used O
also O
for O
recovery O
of O
mycobacteria O
from O
clinical O
specimens O
from O
various O
_RARE_ I-GENE
sites I-GENE
. O

We O
further O
found O
that O
_RARE_ I-GENE
is O
fully O
functional O
when O
expressed O
in O
S I-GENE
. O
cerevisiae I-GENE
. O

A I-GENE
pre I-GENE
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
was O
simulated O
by O
_RARE_ I-GENE
the O
central O
_RARE_ I-GENE
. O

_RARE_ I-GENE
neutropenia O
( O
_RARE_ I-GENE
) O
is O
a O
frequent O
cause O
of O
chronic O
neutropenia O
especially O
in O
_RARE_ I-GENE
children O
. O

With O
regard O
to O
the O
characteristic O
expression O
pattern O
of O
_RARE_ I-GENE
protein I-GENE
and O
its O
_RARE_ I-GENE
repeat I-GENE
units O
possible O
functional O
roles O
are O
discussed O
. O

_RARE_ I-GENE
analysis O
of O
long O
- I-GENE
term O
outcome O
measures O
of O
performance O
with O
the O
implant O
will O
confirm O
or O
_RARE_ I-GENE
the O
benefit O
of O
ear O
selection O
using O
the O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
. O

This O
protein I-GENE
, O
designated O
_RARE_ I-GENE
based O
on O
its O
predicted O
molecular O
weight O
( O
_RARE_ I-GENE
J O
15 O
: O
_RARE_ I-GENE
, O
1996 O
), O
contains O
multiple O
structural O
domains I-GENE
including O
two O
regions O
of O
seven O
internal O
repeats I-GENE
highly O
related I-GENE
to O
the O
cell O
cycle O
regulator I-GENE
_RARE_ I-GENE
, O
a O
guanine I-GENE
nucleotide I-GENE
exchange I-GENE
factor I-GENE
for O
the O
small I-GENE
GTP I-GENE
- I-GENE
binding I-GENE
protein I-GENE
Ran I-GENE
, O
seven O
beta I-GENE
- I-GENE
repeat I-GENE
domains I-GENE
characteristic O
of O
the O
beta I-GENE
subunit I-GENE
of O
heterotrimeric I-GENE
G I-GENE
proteins I-GENE
, O
three O
putative O
SH3 I-GENE
binding I-GENE
sites I-GENE
, O
a O
putative O
leucine I-GENE
- I-GENE
zipper I-GENE
and O
a O
carboxy I-GENE
- I-GENE
terminal I-GENE
_RARE_ I-GENE
domain I-GENE
characteristic O
of O
E3 I-GENE
ubiquitin I-GENE
- I-GENE
protein I-GENE
_RARE_ I-GENE
. O

Thus O
, O
the O
_RARE_ I-GENE
sequence I-GENE
between O
kinase I-GENE
subdomains O
IV I-GENE
and O
V I-GENE
specifies O
TGF I-GENE
- I-GENE
beta I-GENE
responsiveness O
of O
the O
type I-GENE
I I-GENE
receptor I-GENE
. O

The O
two O
mouse I-GENE
lines O
carrying O
the O
_RARE_ I-GENE
_RARE_ I-GENE
- I-GENE
lacZ I-GENE
YAC O
showed O
tissue I-GENE
- I-GENE
specific I-GENE
, O
copy O
number O
- I-GENE
dependent I-GENE
and O
position O
- I-GENE
independent O
expression O
, O
_RARE_ I-GENE
that O
170 I-GENE
kb O
of O
the O
_RARE_ I-GENE
locus I-GENE
contain O
all O
elements O
important O
in O
the O
regulation O
of O
_RARE_ I-GENE
. O

Second O
, O
plasmid O
- I-GENE
derived O
_RARE_ I-GENE
and O
gene I-GENE
targeting O
of O
the O
endogenous I-GENE
_RARE_ I-GENE
gene I-GENE
locus I-GENE
were O
used O
to O
demonstrate O
that O
the O
3 I-GENE
'- O
flanking O
region O
of O
the O
gene I-GENE
is O
necessary O
and O
sufficient O
to O
direct O
reporter I-GENE
gene I-GENE
expression O
in O
liver O
, O
pancreas O
, O
stomach O
and O
small I-GENE
intestine O
. O

This O
regulation O
requires O
two O
HMG I-GENE
- I-GENE
box I-GENE
proteins I-GENE
: O
the O
ubiquitous O
_RARE_ I-GENE
transcription I-GENE
factor I-GENE
and O
the O
M I-GENE
cell O
- I-GENE
controlling O
protein I-GENE
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
. O

Here O
we O
have O
tested O
the O
hypothesis O
that O
the O
short O
transcripts I-GENE
, O
or O
proteins I-GENE
translated O
from O
the O
short O
transcripts I-GENE
, O
are O
also O
required O
for O
respiration O
. O

Upstream O
activating I-GENE
sequences I-GENE
( O
_RARE_ I-GENE
) O
derived O
from O
known O
_RARE_ I-GENE
- I-GENE
dependent I-GENE
genes I-GENE
have O
previously O
been O
characterized O
to O
require O
either O
multiple O
_RARE_ I-GENE
or O
a O
single O
_RARE_ I-GENE
coupled I-GENE
to O
a O
binding I-GENE
site I-GENE
for O
a O
second O
protein I-GENE
. O

_RARE_ I-GENE
protein I-GENE
kinase I-GENE
cascades I-GENE
are O
those O
that O
activate O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
( O
MAP I-GENE
) O
kinases I-GENE
. O

JNK I-GENE
is O
additionally O
regulated O
by O
the O
Ras I-GENE
- I-GENE
related I-GENE
G I-GENE
proteins I-GENE
Rac I-GENE
and O
Cdc42 I-GENE
. O

In O
this O
study O
, O
we O
tested O
this O
notion O
by O
using O
ligation O
- I-GENE
mediated O
PCR O
to O
assess O
the O
formation O
of O
recombination O
- I-GENE
activating I-GENE
gene I-GENE
( O
_RARE_ I-GENE
)- I-GENE
dependent I-GENE
double O
- I-GENE
strand O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
at O
_RARE_ I-GENE
3 I-GENE
' O
of O
_RARE_ I-GENE
and O
5 I-GENE
' O
of O
_RARE_ I-GENE
. O

Recent O
studies O
have O
demonstrated O
that O
Cbl I-GENE
, O
the O
120 O
- I-GENE
kDa I-GENE
protein I-GENE
product I-GENE
of O
the O
c I-GENE
- I-GENE
cbl I-GENE
proto I-GENE
- I-GENE
oncogene I-GENE
, O
serves O
as O
a O
substrate I-GENE
of O
a O
number O
of O
receptor I-GENE
- I-GENE
coupled I-GENE
tyrosine I-GENE
kinases I-GENE
and O
forms O
complexes I-GENE
with O
SH3 I-GENE
and O
SH2 I-GENE
domain I-GENE
- I-GENE
containing O
proteins I-GENE
, O
_RARE_ I-GENE
to O
its O
role O
in O
signal I-GENE
transduction O
. O

Although O
neither O
constitutively O
activated I-GENE
MEK I-GENE
( O
MEK I-GENE
- I-GENE
_RARE_ I-GENE
) O
nor O
v I-GENE
- I-GENE
Src I-GENE
was O
sufficient O
individually O
to O
differentiate O
the O
H19 I-GENE
- I-GENE
7 O
cells O
, O
coexpression O
of O
constitutively O
activated I-GENE
MEK I-GENE
and O
v I-GENE
- I-GENE
Src I-GENE
induced O
_RARE_ I-GENE
_RARE_ I-GENE
. O

This O
mechanism O
is O
in O
contrast O
to O
other O
cases O
of O
splicing O
regulation O
by O
PTB I-GENE
, O
in O
which O
the O
protein I-GENE
represses O
the O
splice O
site I-GENE
to O
which O
it O
binds O
. O

While O
important O
for O
ligand O
- I-GENE
dependent I-GENE
transactivation O
, O
this O
interaction O
surface O
is O
not O
directly O
involved O
in O
_RARE_ I-GENE
of O
AP I-GENE
- I-GENE
1 I-GENE
activity O
. O

Gal4 I-GENE
- I-GENE
_RARE_ I-GENE
fusion I-GENE
protein I-GENE
represses O
transcription I-GENE
of O
a O
reporter I-GENE
gene I-GENE
driven O
by O
a O
promoter I-GENE
that O
contains O
Gal4 I-GENE
- I-GENE
binding I-GENE
DNA I-GENE
elements O
. O

In O
situ O
hybridization O
analysis O
in O
adult O
rat I-GENE
tissue I-GENE
reveals O
good O
correlation O
with O
this O
pattern O
and O
indicates O
that O
_RARE_ I-GENE
mRNA I-GENE
is O
most O
highly O
expressed O
in O
_RARE_ I-GENE
and O
terminally I-GENE
differentiated O
cells O
, O
such O
as O
neurons O
, O
type I-GENE
1 I-GENE
lung O
cells O
, O
and O
_RARE_ I-GENE
cells O
. O

Neither O
of O
these O
proteins I-GENE
, O
individually O
or O
as O
a O
pair O
, O
can O
bind O
the O
alpha I-GENE
- I-GENE
globin I-GENE
3 I-GENE
' O
UTR I-GENE
unless O
they O
are O
complexed O
with O
the O
remaining O
non O
- I-GENE
poly O
( O
C I-GENE
) O
binding I-GENE
proteins I-GENE
of O
the O
alpha I-GENE
- I-GENE
complex I-GENE
. O

A I-GENE
2 I-GENE
years O
and O
9 O
months O
old O
female O
patient O
, O
with O
the O
diagnosis O
of O
_RARE_ I-GENE
syndrome O
is O
reported O
. O

_RARE_ I-GENE
measures O
made O
by O
_RARE_ I-GENE
and O
additionally O
, O
_RARE_ I-GENE
for O
women O
, O
seem O
to O
_RARE_ I-GENE
this O
effect O
. O

In O
a O
series O
of O
patients O
with O
_RARE_ I-GENE
, O
_RARE_ I-GENE
disease O
, O
_RARE_ I-GENE
_RARE_ I-GENE
syndrome O
, O
_RARE_ I-GENE
, O
partial O
or O
generalized O
, O
epilepsy O
, O
we O
have O
investigated O
_RARE_ I-GENE
antibodies I-GENE
of O
IgG I-GENE
and O
IgM I-GENE
subtypes O
, O
together O
with O
anticoagulant I-GENE
factors I-GENE
, O
member O
of O
_RARE_ I-GENE
, O
sedimentation O
rate O
of O
_RARE_ I-GENE
. O

( O
_RARE_ I-GENE
) O
_RARE_ I-GENE
35 O
, O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
]. O

Second O
, O
the O
membrane I-GENE
expression O
of O
alpha I-GENE
and O
beta I-GENE
subunits I-GENE
was O
mimicked O
by O
cholesterol I-GENE
and O
17 O
- I-GENE
_RARE_ I-GENE
, O
both O
of O
which O
inhibit O
HMG I-GENE
- I-GENE
CoA I-GENE
reductase I-GENE
. O

Our O
results O
suggest O
that O
_RARE_ I-GENE
binds O
a O
central O
palindromic O
site I-GENE
, O
interacting I-GENE
predominantly O
with O
the O
major I-GENE
groove I-GENE
of O
its O
DNA I-GENE
target O
, O
and O
that O
additional O
dimers I-GENE
bind O
to O
flanking O
sites I-GENE
to O
form O
a O
nucleoprotein I-GENE
activation O
complex I-GENE
. O

_RARE_ I-GENE
activation O
of O
p21 I-GENE
expression O
is O
proposed O
to O
be O
a O
_RARE_ I-GENE
feature O
of O
the O
activity O
of O
_RARE_ I-GENE
that O
contributes O
to O
PC12 O
growth I-GENE
arrest O
during O
differentiation O

The O
remaining O
80 O
patients O
underwent O
recordings O
of O
ECG O
, O
_RARE_ I-GENE
- I-GENE
to O
- I-GENE
_RARE_ I-GENE
arterial O
oxygen O
saturation O
( O
SaO2 O
), O
and O
respiration O
during O
both O
spontaneous O
and O
controlled O
breathing O
. O

The O
mean O
total O
white O
cell O
count O
increased O
from O
a O
baseline O
of O
11 O
. O
3 I-GENE
x O
10 O
( O
9 O
)/ O
L I-GENE
( O
SD O
2 I-GENE
. O
3 I-GENE
) O
to O
16 O
. O
2 I-GENE
x O
10 O
( O
9 O
)/ O
L I-GENE
( O
SD O
4 I-GENE
. O
6 I-GENE
) O
on O
day O
1 I-GENE
, O
_RARE_ I-GENE
thereafter O
. O

A I-GENE
prospective O
_RARE_ I-GENE
study O
was O
conducted O
to O
identify O
early I-GENE
indicators O
of O
acute O
_RARE_ I-GENE
virus I-GENE
infection O
. O

In O
all O
experimental O
eyes O
, O
there O
was O
a O
marked O
reduction O
, O
but O
never O
a O
complete O
absence O
of O
adrenergic I-GENE
nerves O
in O
the O
_RARE_ I-GENE
. O

These O
lesions O
may O
be O
treated O
by O
propranolol O
or O
_RARE_ I-GENE
. O

Furthermore O
, O
_RARE_ I-GENE
negatively O
_RARE_ I-GENE
the O
alternative O
promoter I-GENE
, O
thus O
generating O
a O
_RARE_ I-GENE
loop I-GENE
. O

This O
night O
- I-GENE
day O
_RARE_ I-GENE
is O
driven O
by O
the O
endogenous I-GENE
_RARE_ I-GENE
( O
located O
in O
the O
_RARE_ I-GENE
nucleus O
, O
_RARE_ I-GENE
). O

It O
is O
present O
in O
the O
nucleus O
of O
the O
cells O
in O
which O
it O
is O
expressed O
and O
can O
phosphorylate O
and O
activate O
the O
cyclic I-GENE
AMP I-GENE
response O
element I-GENE
binding I-GENE
proteins I-GENE
CREB I-GENE
and O
_RARE_ I-GENE
tau I-GENE
in O
a O
manner O
analogous O
to O
protein I-GENE
kinase I-GENE
A I-GENE
. O

These O
cells O
fail O
to O
generate O
the O
signals O
to O
phosphorylate O
CREB I-GENE
and O
produce O
significantly O
less O
of O
the O
cytokine O
Interleukin I-GENE
- I-GENE
2 I-GENE
( O
IL I-GENE
- I-GENE
2 I-GENE
) O
in O
response O
to O
agents O
that O
either O
increase O
intracellular O
Ca2 I-GENE
+ I-GENE
and O
/ I-GENE
or O
activate O
protein I-GENE
kinase I-GENE
C I-GENE
. O

Both O
of O
these O
dogs O
had O
low O
serum I-GENE
IgG I-GENE
( O
3 I-GENE
. O
5 I-GENE
to O
7 O
. O
2 I-GENE
mg O
/ I-GENE
ml O
) O
and O
the O
second O
_RARE_ I-GENE
also O
had O
reduced O
serum I-GENE
IgA I-GENE
(< O
0 O
. O
1 I-GENE
to O
0 O
. O
15 O
mg O
/ I-GENE
ml O
). O

CONCLUSIONS O
: O
_RARE_ I-GENE
appears O
to O
inhibit O
the O
_RARE_ I-GENE
of O
_RARE_ I-GENE
- I-GENE
10 O
, O
11 O
- I-GENE
trans O
- I-GENE
_RARE_ I-GENE
, O
and O
probably O
also O
inhibits O
the O
conversion O
of O
_RARE_ I-GENE
- I-GENE
10 O
, O
11 O
- I-GENE
_RARE_ I-GENE
to O
this O
trans O
- I-GENE
_RARE_ I-GENE
derivative O
, O
rather O
than O
_RARE_ I-GENE
inhibiting O
the O
latter O
reaction O
only O
. O

The O
_RARE_ I-GENE
protein I-GENE
efficiently O
_RARE_ I-GENE
a O
DNA I-GENE
duplex O
where O
a O
_RARE_ I-GENE
AP I-GENE
site I-GENE
is O
placed O
opposite O
a O
cytosine O
( O
AP I-GENE
/ I-GENE
C I-GENE
). O

A I-GENE
consensus I-GENE
sequence I-GENE
indicates O
a O
highly O
conserved O
lysine O
residue O
, O
_RARE_ I-GENE
of O
endonuclease I-GENE
III I-GENE
or O
_RARE_ I-GENE
of O
_RARE_ I-GENE
, O
respectively O
. O

Overall O
, O
these O
findings O
demonstrate O
that O
mutations O
_RARE_ I-GENE
and O
_RARE_ I-GENE
are O
gain O
- I-GENE
of O
- I-GENE
function O
mutations O
that O
confer O
to O
the O
long O
RET I-GENE
isoform I-GENE
the O
capacity O
to O
exert O
a O
biological O
effect O
, O
although O
these O
mutations O
are O
more O
weakly O
activating I-GENE
than O
the O
_RARE_ I-GENE
and O
_RARE_ I-GENE
mutations O
. O

_RARE_ I-GENE
were O
irradiated O
on O
their O
_RARE_ I-GENE
with O
_RARE_ I-GENE
UV O
daily O
for O
5 I-GENE
d O
after O
application O
of O
the O
_RARE_ I-GENE
and O
their O
base O
_RARE_ I-GENE
to O
different O
sites I-GENE
. O

E2F I-GENE
is O
a O
heterodimeric I-GENE
complex I-GENE
consisting O
of O
E2F I-GENE
family I-GENE
members O
( O
1 I-GENE
- I-GENE
5 I-GENE
) O
and O
DP I-GENE
proteins I-GENE
( O
1 I-GENE
- I-GENE
3 I-GENE
). O

_RARE_ I-GENE
mRNA I-GENE
, O
a O
consistent O
marker O
of O
viral I-GENE
latency O
, O
was O
positive O
in O
all O
_RARE_ I-GENE
cases O
, O
although O
at O
lower O
levels O
than O
in O
the O
non O
- I-GENE
_RARE_ I-GENE
controls O
due O
to O
_RARE_ I-GENE
expression O
by O
only O
a O
variable O
subset O
of O
lymphoma O
cells O
. O

METHODS O
: O
Four O
hundred O
_RARE_ I-GENE
patients O
with O
the O
diagnosis O
of O
squamous O
cell O
carcinoma O
of O
the O
oral O
cavity O
received O
their O
primary O
treatment O
at O
_RARE_ I-GENE
_RARE_ I-GENE
Cancer O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
from O
_RARE_ I-GENE
to O
1991 O
. O

Therefore O
, O
use O
of O
_RARE_ I-GENE
is O
recommended O
for O
myocardial O
motion O
studies O
using O
_RARE_ I-GENE
PC I-GENE
velocity O
data O
. O

In O
addition O
, O
the O
DNA I-GENE
- I-GENE
binding I-GENE
experiments O
show O
that O
either O
one O
of O
the O
two O
MADS I-GENE
domains I-GENE
of O
a O
dimer O
can O
be O
sufficient O
to O
confer O
a O
particular O
DNA I-GENE
- I-GENE
binding I-GENE
specificity O
to O
the O
complex I-GENE
and O
that O
sequences I-GENE
outside O
the O
amino O
- I-GENE
terminal I-GENE
basic I-GENE
region O
of O
the O
MADS I-GENE
domain I-GENE
can O
, O
in O
some O
cases O
, O
contribute O
to O
the O
DNA I-GENE
- I-GENE
binding I-GENE
specificity O
of O
the O
proteins I-GENE
. O

PURPOSE O
/ I-GENE
OBJECTIVES O
: O
To O
examine O
the O
question O
of O
whether O
an O
early I-GENE
first O
full I-GENE
- I-GENE
term O
pregnancy O
( O
_RARE_ I-GENE
) O
_RARE_ I-GENE
against O
breast O
cancer O
and O
whether O
_RARE_ I-GENE
of O
the O
pregnancy O
with O
an O
induced O
abortion O
increases O
breast O
cancer O
risk O
. O

Two O
related I-GENE
studies O
conducted O
over O
a O
five O
week O
period O
measured O
and O
_RARE_ I-GENE
HLA I-GENE
- I-GENE
_RARE_ I-GENE
from O
accumulated O
DNA I-GENE
on O
autopsy O
room O
and O
_RARE_ I-GENE
DNA I-GENE
Laboratory O
structures O
. O

Thirty O
- I-GENE
two O
rats O
were O
divided O
into O
four O
groups O
. O

_RARE_ I-GENE
of O
the O
_RARE_ I-GENE
regulatory I-GENE
region O
revealed O
the O
presence O
of O
two O
sites I-GENE
in O
which O
insertions O
_RARE_ I-GENE
the O
_RARE_ I-GENE
- I-GENE
1 I-GENE
phenotype O
. O

BRCA1 I-GENE
, O
a O
familial O
breast O
and O
ovarian O
cancer O
susceptibility I-GENE
gene I-GENE
encodes O
nuclear I-GENE
_RARE_ I-GENE
that O
function O
as O
tumor I-GENE
suppressors O
in O
human I-GENE
breast O
cancer O
cells O
. O

The O
alternative O
splice O
sites I-GENE
for O
the O
smallest O
_RARE_ I-GENE
isoform I-GENE
, O
beta I-GENE
- I-GENE
3 I-GENE
, O
are O
alternative O
donor O
and O
acceptor O
sites I-GENE
within O
exons O
7 O
and O
12 O
. O

_RARE_ I-GENE
in O
a O
young O
man O
. O

_RARE_ I-GENE
blockade O
in O
chronic O
and O
cancer O
pain O
. O

Two O
new O
temperature O
- I-GENE
sensitive O
alleles I-GENE
of O
_RARE_ I-GENE
, O
1 I-GENE
of O
10 O
late O
- I-GENE
acting O
_RARE_ I-GENE
genes I-GENE
required O
for O
targeting O
or O
fusion I-GENE
of O
post O
- I-GENE
Golgi I-GENE
secretory I-GENE
vesicles O
to O
the O
plasma I-GENE
membrane I-GENE
in O
Saccharomyces I-GENE
cerevisiae I-GENE
, O
were O
isolated O
in O
a O
screen O
for O
temperature O
- I-GENE
sensitive O
secretory I-GENE
mutants I-GENE
that O
are O
_RARE_ I-GENE
lethal O
with O
_RARE_ I-GENE
- I-GENE
8 O
. O

Five O
cell O
strains O
of O
human I-GENE
dermal O
fibroblasts O
were O
each O
treated O
with O
three O
samples O
of O
burn O
_RARE_ I-GENE
fluid O
and O
the O
effect O
compared O
with O
the O
rate O
of O
contraction O
of O
free O
_RARE_ I-GENE
fibroblast I-GENE
_RARE_ I-GENE
collagen I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
). O

It O
is O
thus O
one O
of O
the O
key O
enzymes O
involved O
in O
the O
_RARE_ I-GENE
- I-GENE
mediated O
control O
of O
growth I-GENE
, O
differentiation O
and O
basal O
metabolism O
in O
_RARE_ I-GENE
. O

Cell O
49 O
, O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
]. O

Twenty O
- I-GENE
one O
ELISA O
- I-GENE
positive O
sera O
were O
tested O
and O
confirmed O
positive O
by O
plaque O
reduction O
_RARE_ I-GENE
testing O
. O

Patients O
received O
either O
diltiazem O
CD O
180 O
mg O
or O
placebo O
once O
/ I-GENE
day O
in O
combination O
with O
existing O
_RARE_ I-GENE
therapy O
. O

_RARE_ I-GENE
lymphoid I-GENE
hyperplasia O
was O
found O
in O
15 O
cases O
, O
2 I-GENE
cases O
had O
_RARE_ I-GENE
lymphoid I-GENE
hyperplasia O
or O
_RARE_ I-GENE
' O
s O
disease O
, O
atypical O
lymphoid I-GENE
hyperplasia O
suggestive O
of O
malignant O
lymphoma O
was O
observed O
in O
3 I-GENE
cases O
, O
and O
malignant O
lymphoma O
was O
diagnosed O
in O
the O
remaining O
4 I-GENE
cases O
. O

We O
had O
previously O
analyzed O
repair I-GENE
rates O
of O
_RARE_ I-GENE
pyrimidine O
dimers I-GENE
at O
nucleotide I-GENE
resolution O
along O
the O
human I-GENE
_RARE_ I-GENE
gene I-GENE
in O
normal O
fibroblasts O
and O
found O
very O
efficient O
repair I-GENE
of O
sequences I-GENE
near O
the O
transcription I-GENE
initiation I-GENE
site I-GENE
but O
slow O
repair I-GENE
along O
the O
promoter I-GENE
. O

Tyrosine I-GENE
_RARE_ I-GENE
forms O
a O
_RARE_ I-GENE
binding I-GENE
site I-GENE
for O
the O
Grb2 I-GENE
and O
Shc I-GENE
adaptor I-GENE
proteins I-GENE
, O
the O
p85 I-GENE
subunit I-GENE
of O
phosphatidylinositol I-GENE
3 I-GENE
'- O
kinase I-GENE
, O
phospholipase I-GENE
_RARE_ I-GENE
, O
and O
a O
phosphatase I-GENE
, O
_RARE_ I-GENE
. O

_RARE_ I-GENE
we O
correlated O
_RARE_ I-GENE
findings O
with O
the O
clinical O
features O
, O
pulmonary O
functions O
and O
_RARE_ I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
and O
studied O
their O
clinical O
significance O
. O

_RARE_ I-GENE
mRNA I-GENE
accumulates O
in O
parallel O
with O
the O
RNAs I-GENE
encoding O
the O
major I-GENE
structural O
proteins I-GENE
of O
myelin I-GENE
, O
myelin I-GENE
basic I-GENE
protein I-GENE
( O
MBP I-GENE
), O
and O
_RARE_ I-GENE
protein I-GENE
( O
PLP I-GENE
) O
during O
postnatal O
brain O
development O
; O
_RARE_ I-GENE
mRNA I-GENE
decreases O
in O
parallel O
with O
MBP I-GENE
and O
PLP I-GENE
mRNAs I-GENE
in O
the O
_RARE_ I-GENE
of O
myelin I-GENE
- I-GENE
deficient O
rats O
, O
which O
have O
a O
point O
mutation I-GENE
in O
the O
PLP I-GENE
gene I-GENE
. O

_RARE_ I-GENE
between O
Bacillus I-GENE
subtilis I-GENE
catabolite I-GENE
regulatory I-GENE
protein I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
target O
site I-GENE
. O

They O
also O
interact O
with O
GTPase I-GENE
activating I-GENE
proteins I-GENE
encoded I-GENE
by O
_RARE_ I-GENE
and O
_RARE_ I-GENE
. O

For O
E2 I-GENE
, O
each O
cat O
was O
given O
either O
5 I-GENE
( O
group O
[ O
G I-GENE
] O
1 I-GENE
) O
or O
10 O
( O
G2 I-GENE
) O
mg O
of O
_RARE_ I-GENE
/ I-GENE
kg O
( O
capsules O
) O
twice O
daily O
for O
6 I-GENE
weeks O
. O

RESULTS O
: O
For O
E1 I-GENE
, O
_RARE_ I-GENE
plasma I-GENE
drug O
concentration O
_RARE_ I-GENE
to O
time O
zero O
( O
IV I-GENE
dose O
) O
was O
5 I-GENE
. O
2 I-GENE
+/- O
1 I-GENE
. O
4 I-GENE
micrograms O
/ I-GENE
ml O
, O
and O
mean O
_RARE_ I-GENE
time O
( O
_RARE_ I-GENE
) O
was O
37 O
+/- O
16 O
hours O
. O

The O
human I-GENE
U4 I-GENE
/ I-GENE
U6 I-GENE
snRNP I-GENE
contains O
60 O
and O
_RARE_ I-GENE
proteins I-GENE
that O
are O
structurally O
homologous O
to O
the O
yeast I-GENE
splicing O
factors I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
. O

G I-GENE
- I-GENE
CSF I-GENE
was O
started O
on O
day O
3 I-GENE
of O
each O
cycle O
( O
5 I-GENE
microg O
/ I-GENE
kg O
/ I-GENE
day O
) O
and O
was O
stopped O
the O
day O
before O
the O
last O
_RARE_ I-GENE
or O
when O
absolute O
neutrophil I-GENE
count O
was O
above O
0 O
. O
5 I-GENE
x O
10 O
( O
9 O
)/ O
l O
. O

The O
used O
expression O
system O
could O
allow O
to O
produce O
mutated O
forms O
of O
_RARE_ I-GENE
- I-GENE
2 I-GENE
obtained O
by O
mutagenesis O
of O
the O
corresponding O
gene I-GENE
. O

_RARE_ I-GENE
among O
the O
pathways O
may O
explain O
how O
some O
forms O
of O
stress O
can O
contribute O
to O
the O
development O
of O
a O
malignancy O
. O

_RARE_ I-GENE
assays O
, O
using O
Jun I-GENE
and O
Fos I-GENE
family I-GENE
member O
- I-GENE
specific I-GENE
antibodies I-GENE
, O
showed O
that O
protein I-GENE
complexes I-GENE
formed O
by O
_RARE_ I-GENE
- I-GENE
20 O
cell O
nuclear I-GENE
extracts O
bound O
to O
the O
c I-GENE
- I-GENE
jun I-GENE
AP I-GENE
- I-GENE
1 I-GENE
site I-GENE
were O
comprised O
of O
Jun I-GENE
family I-GENE
members O
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
. O

The O
majority O
of O
PI I-GENE
kinase I-GENE
activity O
appeared O
to O
be O
cbl I-GENE
- I-GENE
associated I-GENE
after O
PRL I-GENE
stimulation O
. O

Mutation O
of O
_RARE_ I-GENE
, O
an O
essential O
GT I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
like I-GENE
_RARE_ I-GENE
in O
the O
context O
of O
the O
intact O
enhancer I-GENE
, O
abolishes O
silencer I-GENE
activity O
, O
and O
_RARE_ I-GENE
GT I-GENE
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
mimic O
the O
intact O
_RARE_ I-GENE
enhancer I-GENE
/ I-GENE
silencer I-GENE
activities O
in O
_RARE_ I-GENE
and O
GC I-GENE
cells O
, O
respectively O
. O

Using O
_RARE_ I-GENE
- I-GENE
affinity O
chromatography O
, O
_RARE_ I-GENE
between O
the O
pattern O
of O
O O
- I-GENE
glycosylation O
of O
_RARE_ I-GENE
and O
_RARE_ I-GENE
was O
demonstrated O
. O

Deletion O
mapping O
experiments O
determined O
that O
the O
sequences I-GENE
required O
for O
full I-GENE
activity O
in O
_RARE_ I-GENE
- I-GENE
1 I-GENE
cells O
were O
included O
within O
_RARE_ I-GENE
bp O
of O
the O
start O
site I-GENE
and O
identified O
several O
regions O
that O
demonstrated O
increased O
luciferase I-GENE
activity O
: O
the O
- I-GENE
_RARE_ I-GENE
bp O
to O
- I-GENE
_RARE_ I-GENE
bp O
, O
- I-GENE
_RARE_ I-GENE
bp O
to O
- I-GENE
_RARE_ I-GENE
bp O
, O
and O
- I-GENE
114 I-GENE
bp O
to O
- I-GENE
65 O
regions O
. O

Furthermore O
, O
the O
PH I-GENE
and O
PTB I-GENE
domains I-GENE
are O
highly O
homologous O
( O
at O
least O
40 I-GENE
% O
identical O
) O
to O
those O
found O
in O
insulin I-GENE
receptor I-GENE
substrates O
1 I-GENE
, O
2 I-GENE
, O
and O
3 I-GENE
( O
IRS I-GENE
- I-GENE
1 I-GENE
, O
IRS I-GENE
- I-GENE
2 I-GENE
, O
and O
IRS I-GENE
- I-GENE
3 I-GENE
). O

The O
mouse I-GENE
extracellular I-GENE
signal I-GENE
- I-GENE
regulated O
kinase I-GENE
2 I-GENE
gene I-GENE
. O

As O
demonstrated O
by O
gel O
mobility I-GENE
shift O
analysis O
and O
supershift O
experiments O
, O
_RARE_ I-GENE
, O
located O
between O
- I-GENE
_RARE_ I-GENE
and O
- I-GENE
_RARE_ I-GENE
, O
is O
responsible O
for O
binding I-GENE
NF I-GENE
- I-GENE
Y I-GENE
. O

MR O
imaging O
of O
_RARE_ I-GENE
head I-GENE
injuries O
using O
_RARE_ I-GENE
technique O

Gag I-GENE
protein I-GENE
sequence I-GENE
motifs O
of O
the O
_RARE_ I-GENE
domain I-GENE
of O
primate O
_RARE_ I-GENE
viruses O
assumed O
to O
be O
involved O
in O
genome O
_RARE_ I-GENE
are O
not O
conserved O
in O
_RARE_ I-GENE
. O

Induction O
of O
B I-GENE
cell O
apoptosis O
by O
co O
- I-GENE
cross O
- I-GENE
linking O
CD23 I-GENE
and O
_RARE_ I-GENE
involves O
aberrant O
regulation O
of O
c I-GENE
- I-GENE
myc I-GENE
and O
is O
inhibited O
by O
bcl I-GENE
- I-GENE
2 I-GENE
. O

_RARE_ I-GENE
AND O
MAIN O
RESULTS O
: O
Lung O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
and O
resistance O
( O
_RARE_ I-GENE
) O
were O
calculated O
from O
measurements O
of O
airway O
pressure O
, O
esophageal O
pressure O
, O
and O
airway O
flow O
in O
five O
anesthetized O
, O
_RARE_ I-GENE
dogs O
during O
_RARE_ I-GENE
_RARE_ I-GENE
at O
a O
constant O
mean O
airway O
pressure O
of O
10 O
cmH2O O
in O
a O
wide O
range O
of O
breathing O
frequencies O
( O
0 O
. O
2 I-GENE
to O
1 I-GENE
. O
0 O
Hz O
in O
intervals O
of O
0 O
. O
2 I-GENE
) O
and O
tidal O
volumes O
( O
50 O
, O
100 O
, O
200 O
, O
and O
to O
300 O
mL O
). O

Here O
, O
we O
report O
_RARE_ I-GENE
models O
for O
the O
_RARE_ I-GENE
and O
EGF I-GENE
- I-GENE
1 I-GENE
modules I-GENE
of O
human I-GENE
PS I-GENE
constructed O
using O
prothrombin I-GENE
and O
factor I-GENE
X I-GENE
experimental O
structures O
. O

The O
_RARE_ I-GENE
subunit I-GENE
is O
likely O
to O
be O
a O
target O
for O
regulating O
APC I-GENE
/ I-GENE
_RARE_ I-GENE
function O
through O
protein I-GENE
- I-GENE
protein I-GENE
interactions O
and O
phosphorylation O
. O

The O
dose O
was O
50 O
Gy O
/ I-GENE
20 O
fractions O
/ I-GENE
5 I-GENE
weeks O
. O

Because O
the O
biosynthetic O
pathway O
to O
the O
_RARE_ I-GENE
_RARE_ I-GENE
with O
the O
endocytic O
pathway O
, O
internalization O
of O
a O
bulk O
membrane I-GENE
endocytic O
marker O
_RARE_ I-GENE
4 I-GENE
- I-GENE
64 O
was O
assayed O
in O
the O
_RARE_ I-GENE
mutants I-GENE
. O

All O
the O
women O
received O
13 O
. O
5 I-GENE
mg O
_RARE_ I-GENE
_RARE_ I-GENE
via O
_RARE_ I-GENE
injection O
at O
the O
L2 O
- I-GENE
3 I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
from O
this O
being O
the O
case O
, O
however O
, O
the O
measurement O
of O
apo I-GENE
B I-GENE
has O
met I-GENE
every O
reasonable O
standard O
of O
laboratory O
_RARE_ I-GENE
and O
reliability O
to O
allow O
its O
_RARE_ I-GENE
introduction O
in O
clinical O
laboratories O
. O

Two O
soybean I-GENE
cDNA I-GENE
clones O
, O
SPK I-GENE
- I-GENE
3 I-GENE
and O
SPK I-GENE
- I-GENE
4 I-GENE
, O
encoding O
putative O
protein I-GENE
kinases I-GENE
were O
isolated O
and O
characterized O
. O

_RARE_ I-GENE
belonging O
to O
the O
ras I-GENE
superfamily I-GENE
encode O
low O
- I-GENE
molecular O
- I-GENE
weight O
GTP I-GENE
/ I-GENE
GDP I-GENE
- I-GENE
binding I-GENE
proteins I-GENE
that O
are O
highly O
conserved O
in O
wide O
variety O
of O
organisms O
. O

_RARE_ I-GENE
has O
been O
recently O
_RARE_ I-GENE
by O
the O
_RARE_ I-GENE
and O
Drug O
Administration O
for O
the O
treatment O
of O
alcohol O
dependence O
. O

_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
synthase I-GENE
from O
the O
fungus I-GENE
_RARE_ I-GENE
sp O
. O

In O
this O
report O
, O
we O
identify O
and O
characterize O
two O
overlapping O
_RARE_ I-GENE
functional O
domains I-GENE
that O
govern O
its O
interaction O
with O
RNA I-GENE
polymerase I-GENE
II I-GENE
and O
the O
ternary O
elongation I-GENE
complex I-GENE
. O

Eight O
induced O
cDNA I-GENE
sequences I-GENE
were O
identified O
and O
designated O
message I-GENE
up O
- I-GENE
regulated O
during O
death O
( O
_RARE_ I-GENE
)- I-GENE
1 I-GENE
- I-GENE
8 O
. O

The O
position O
, O
transcription I-GENE
orientation O
, O
and O
imprinted O
status O
of O
the O
genes I-GENE
immediately O
flanking O
_RARE_ I-GENE
have O
been O
assessed O
. O

Here O
, O
we O
describe O
_RARE_ I-GENE
chromosome O
_RARE_ I-GENE
studies O
starting O
from O
_RARE_ I-GENE
as O
well O
as O
_RARE_ I-GENE
. O

We O
describe O
a O
novel O
zinc I-GENE
finger I-GENE
protein I-GENE
, O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
, O
isolated O
by O
screening O
an O
expression O
library O
with O
dsRNA I-GENE
. O

Our O
results O
indicate O
that O
the O
_RARE_ I-GENE
reverse I-GENE
transcriptase I-GENE
is O
_RARE_ I-GENE
adapted O
to O
initiate O
cDNA I-GENE
synthesis O
by O
_RARE_ I-GENE
a O
3 I-GENE
' O
_RARE_ I-GENE
sequence I-GENE
. O

_RARE_ I-GENE
absorption O
was O
rapid O
, O
nasal O
_RARE_ I-GENE
was O
43 I-GENE
%, O
and O
the O
iv O
and O
nasal O
elimination O
profiles O
were O
similar O
. O

Together O
, O
these O
results O
suggest O
that O
EGF I-GENE
/ I-GENE
Ras I-GENE
/ I-GENE
Raf I-GENE
induces O
transcription I-GENE
via O
combined O
activation O
of O
_RARE_ I-GENE
/ I-GENE
c I-GENE
- I-GENE
Jun I-GENE
and O
a O
52 O
- I-GENE
kDa I-GENE
nuclear I-GENE
factor I-GENE
, O
whereas O
_RARE_ I-GENE
acts O
as O
a O
repressor I-GENE
of O
this O
response O
. O

Together O
, O
these O
data O
support O
a O
model O
in O
which O
Tax I-GENE
_RARE_ I-GENE
CBP I-GENE
to O
the O
HTLV I-GENE
- I-GENE
1 I-GENE
promoter I-GENE
, O
with O
strong O
transcriptional O
activation O
resulting O
from O
the O
CBP I-GENE
- I-GENE
associated I-GENE
activities O
of O
_RARE_ I-GENE
remodeling O
and O
recruitment O
of O
the O
general O
transcription I-GENE
machinery O
. O

DNase I-GENE
I I-GENE
and O
1 I-GENE
, O
10 O
- I-GENE
_RARE_ I-GENE
- I-GENE
copper I-GENE
footprinting O
of O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
complexes I-GENE
indicate O
that O
_RARE_ I-GENE
binds O
to O
a O
conserved O
approximately O
32 O
- I-GENE
bp O
region O
in O
the O
_RARE_ I-GENE
of O
_RARE_ I-GENE
. O

Consistent O
with O
this O
model O
, O
a O
synthetic O
construct I-GENE
containing O
three O
tandem O
copies O
of O
the O
native O
LDL I-GENE
receptor I-GENE
SREBP I-GENE
site I-GENE
linked O
to O
a O
single O
Sp1 I-GENE
site I-GENE
was O
also O
significantly O
activated I-GENE
in O
a O
_RARE_ I-GENE
- I-GENE
independent O
fashion O
. O

Various O
assays O
demonstrate O
promoter I-GENE
activity O
in O
this O
sequence I-GENE
that O
_RARE_ I-GENE
the O
normal O
control O
of O
_RARE_ I-GENE
expression O
during O
a O
growth I-GENE
stimulation O
. O

In O
the O
adult O
mouse I-GENE
, O
_RARE_ I-GENE
alpha I-GENE
is O
most O
highly O
expressed O
in O
kidney O
, O
heart O
, O
and O
brown O
adipocytes O
, O
tissues O
which O
preferentially O
_RARE_ I-GENE
fatty I-GENE
acids O
. O

The O
_RARE_ I-GENE
nuclear I-GENE
receptor I-GENE
response O
element I-GENE
1 I-GENE
( O
_RARE_ I-GENE
- I-GENE
1 I-GENE
) O
interacts O
in O
vitro O
with O
_RARE_ I-GENE
alpha I-GENE
expressed O
in O
COS O
- I-GENE
7 O
cells O
. O

Mapping O
features O
of O
HIV I-GENE
- I-GENE
1 I-GENE
integrase I-GENE
near O
selected O
sites I-GENE
on O
viral I-GENE
and O
target O
DNA I-GENE
molecules I-GENE
in O
an O
active O
enzyme I-GENE
- I-GENE
DNA I-GENE
complex I-GENE
by O
_RARE_ I-GENE
- I-GENE
cross O
- I-GENE
linking O
. O

Analysis O
of O
the O
5 I-GENE
' O
flanking O
region O
of O
the O
gene I-GENE
also O
revealed O
the O
presence O
of O
multiple O
TATA I-GENE
and O
CAAT I-GENE
sequences I-GENE
. O

Analysis O
of O
the O
5 I-GENE
' O
flanking O
region O
of O
the O
gene I-GENE
also O
revealed O
the O
presence O
of O
multiple O
TATA I-GENE
and O
CAAT I-GENE
sequences I-GENE
. O

The O
complete O
response O
( O
CR I-GENE
) O
rate O
was O
34 O
% O
in O
the O
_RARE_ I-GENE
with O
_RARE_ I-GENE
- I-GENE
CSF I-GENE
group O
and O
23 O
% O
in O
the O
_RARE_ I-GENE
alone O
group O
; O
the O
median O
survival O
was O
59 O
and O
32 O
weeks O
, O
respectively O
, O
in O
these O
groups O
( O
P I-GENE
= O
0 O
. O
_RARE_ I-GENE
). O

_RARE_ I-GENE
nuclear I-GENE
ribonucleoprotein I-GENE
A1 I-GENE
binds O
to O
the O
transcription I-GENE
- I-GENE
regulatory I-GENE
region O
of O
mouse I-GENE
hepatitis I-GENE
virus I-GENE
RNA I-GENE
. O

The O
_RARE_ I-GENE
cap I-GENE
structure O
of O
eukaryotic I-GENE
mRNA I-GENE
is O
formed O
_RARE_ I-GENE
by O
the O
sequential O
action O
of O
three O
enzymes O
: O
RNA I-GENE
_RARE_ I-GENE
, O
RNA I-GENE
_RARE_ I-GENE
, O
and O
RNA I-GENE
( O
guanine I-GENE
- I-GENE
7 O
)- I-GENE
methyltransferase I-GENE
. O

In O
the O
first O
part O
of O
our O
study O
, O
the O
highest O
_RARE_ I-GENE
was O
revealed O
by O
_RARE_ I-GENE
strain O
without O
enzymatic O
activation O
, O
suggesting O
a O
direct O
- I-GENE
acting O
_RARE_ I-GENE
prevalence O
in O
_RARE_ I-GENE
particulate O
. O

The O
addition O
of O
culture O
to O
the O
CC O
and O
CC O
: O
_RARE_ I-GENE
by O
- I-GENE
products I-GENE
resulted O
in O
pH O
values O
lower O
( O
P I-GENE
< O
0 O
. O
05 O
) O
than O
those O
without O
culture O
on O
Day O
21 O
, O
and O
the O
15 O
% O
carbohydrate O
treatment O
significantly O
reduced O
pH O
beyond O
the O
5 I-GENE
% O
carbohydrate O
. O

Myocardial O
interstitial O
edema O
is O
more O
likely O
a O
potential O
mechanism O
of O
diastolic O
dysfunction O
after O
DC O
_RARE_ I-GENE
. O

Two O
experiments O
( O
N I-GENE
= O
20 O
each O
) O
were O
carried O
out O
to O
explore O
the O
nature O
of O
_RARE_ I-GENE
_RARE_ I-GENE
in O
a O
_RARE_ I-GENE
memory O
task O
and O
in O
an O
auditory O
spatial O
memory O
task O
, O
respectively O
. O

Biol O
. O

The O
pattern O
and O
timing O
of O
_RARE_ I-GENE
mRNA I-GENE
expression O
, O
including O
transient O
expression O
in O
the O
_RARE_ I-GENE
at O
14 O
. O
5 I-GENE
days O
p O
. O
c I-GENE
., O
_RARE_ I-GENE
with O
that O
of O
_RARE_ I-GENE
. O
5 I-GENE
/ I-GENE
_RARE_ I-GENE
( O
a O
putative O
homolog I-GENE
of O
_RARE_ I-GENE
, O
the O
Drosophila I-GENE
melanogaster I-GENE
gene I-GENE
responsible O
for O
cardiac O
development O
). O

Overexpression O
of O
_RARE_ I-GENE
in O
_RARE_ I-GENE
suppresses O
cardiac O
_RARE_ I-GENE
C I-GENE
and O
atrial I-GENE
_RARE_ I-GENE
factor I-GENE
transcription I-GENE
. O

_RARE_ I-GENE
specificity O
of O
the O
RNase I-GENE
activity O
of O
yeast I-GENE
RNA I-GENE
polymerase I-GENE
III I-GENE
. O

Electrophoretic O
mobility I-GENE
shift O
assays O
and O
competition O
experiments O
showed O
that O
site I-GENE
A I-GENE
is O
recognized O
by O
an O
NF1 I-GENE
protein I-GENE
. O

Examination O
of O
the O
_RARE_ I-GENE
- I-GENE
2 I-GENE
_RARE_ I-GENE
sequence I-GENE
revealed O
an O
incomplete O
Y I-GENE
- I-GENE
box I-GENE
sequence I-GENE
( O
_RARE_ I-GENE
), O
which O
specifically O
interacted O
with O
recombinant I-GENE
_RARE_ I-GENE
- I-GENE
1 I-GENE
on O
_RARE_ I-GENE
protection O
footprinting O
analysis O
. O

Hence O
, O
_RARE_ I-GENE
only O
partially O
suppressed O
the O
ts I-GENE
phenotype O
and O
was O
unable O
to O
suppress O
the O
_RARE_ I-GENE
- I-GENE
phenotype O
of O
_RARE_ I-GENE
- I-GENE
31 O
. O

In O
contrast O
, O
both O
Sp1 I-GENE
and O
ETS I-GENE
proteins I-GENE
are O
required O
to O
_RARE_ I-GENE
about O
full I-GENE
promoter I-GENE
activity O
in O
the O
Surf I-GENE
- I-GENE
1 I-GENE
direction O
. O

CONCLUSION O
: O
Patients O
_RARE_ I-GENE
clinically O
_RARE_ I-GENE
neck O
disease O
( O
N1 O
- I-GENE
3 I-GENE
), O
histological O
evidence O
of O
metastatic O
nodal O
disease O
, O
_RARE_ I-GENE
spread O
, O
and O
three O
or O
more O
positive O
lymph O
nodes O
are O
at O
greater O
risk O
of O
developing O
failure O
at O
distant O
sites I-GENE
. O

We O
have O
subcloned O
into O
_RARE_ I-GENE
_RARE_ I-GENE
acid I-GENE
( O
DNA I-GENE
) O
sequences I-GENE
mapping O
either O
in O
the O
coding O
region O
, O
the O
5 I-GENE
' O
spacer O
, O
or O
the O
3 I-GENE
' O
spacer O
of O
the O
_RARE_ I-GENE
histone I-GENE
gene I-GENE
. O

4 I-GENE
. O

_RARE_ I-GENE
under O
the O
drug O
concentration O
- I-GENE
time O
curves O
( O
_RARE_ I-GENE
- I-GENE
24 O
hr O
) O
for O
_RARE_ I-GENE
were O
_RARE_ I-GENE
and O
_RARE_ I-GENE
ng O
* I-GENE
hr O
/ I-GENE
ml O
from O
_RARE_ I-GENE
- I-GENE
2 I-GENE
. O
5 I-GENE
% O
_RARE_ I-GENE
and O
_RARE_ I-GENE
- I-GENE
7 O
. O
5 I-GENE
% O
_RARE_ I-GENE
systems O
respectively O
. O

The O
combination O
of O
_RARE_ I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
also O
_RARE_ I-GENE
survival O
, O
but O
direct O
comparison O
of O
both O
regimens O
provided O
evidence O
for O
a O
less O
favourable O
effect O
than O
that O
of O
the O
ACE I-GENE
inhibitors O
. O

To O
address O
mechanisms O
that O
define O
interactions O
of O
Site I-GENE
II I-GENE
regulatory I-GENE
factors I-GENE
with O
this O
cell O
cycle O
control O
element I-GENE
, O
we O
have O
investigated O
these O
determinants I-GENE
of O
transcriptional O
regulation O
at O
the O
G1 I-GENE
/ I-GENE
S I-GENE
phase O
transition O
in O
_RARE_ I-GENE
- I-GENE
P1 I-GENE
hematopoietic I-GENE
progenitor I-GENE
cells O
. O

The O
goal O
of O
this O
study O
was O
to O
identify O
neuronal O
cell O
cultures O
that O
express O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
, O
to O
_RARE_ I-GENE
whether O
they O
are O
sensitive O
to O
T3 O
, O
and O
to O
examine O
the O
mechanism O
of O
regulation O
. O

There O
were O
differences O
between O
males O
( O
p O
< O
0 O
. O
05 O
) O
for O
most O
of O
the O
characteristics O
studied O
. O

Their O
circadian O
responses O
to O
both O
_RARE_ I-GENE
and O
non O
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
were O
then O
tested O
. O

Although O
previous O
data O
have O
suggested O
that O
Rev I-GENE
uses O
the O
same O
export O
pathway O
as O
_RARE_ I-GENE
- I-GENE
rich O
small I-GENE
nuclear I-GENE
RNAs I-GENE
and O
5S I-GENE
ribosomal I-GENE
RNA I-GENE
, O
the O
_RARE_ I-GENE
seems O
to O
interact O
with O
evolutionarily O
conserved O
factors I-GENE
that O
are O
essential O
for O
cellular O
mRNA I-GENE
export O
. O

Human I-GENE
_RARE_ I-GENE
contains O
a O
guanine I-GENE
nucleotide I-GENE
exchange I-GENE
factor I-GENE
( O
_RARE_ I-GENE
) O
domain I-GENE
that O
is O
likely O
to O
be O
_RARE_ I-GENE
- I-GENE
specific I-GENE
, O
a O
pleckstrin I-GENE
homology I-GENE
( O
PH I-GENE
) O
domain I-GENE
and O
spectrin I-GENE
- I-GENE
like I-GENE
repeat I-GENE
units O
. O

_RARE_ I-GENE
, O
a O
leaf O
- I-GENE
specific I-GENE
trans O
- I-GENE
acting O
factor I-GENE
, O
binds O
to O
a O
novel O
cis O
- I-GENE
acting O
element I-GENE
and O
differentially O
activates O
the O
_RARE_ I-GENE
gene I-GENE
. O

_RARE_ I-GENE
was O
shown O
to O
be O
a O
dimer O
of O
two O
equal O
subunits I-GENE
, O
each O
with O
a O
molecular O
mass O
of O
37 O
, O
000 O
Da I-GENE
. O

Plasma I-GENE
leptin I-GENE
concentrations O
were O
higher O
in O
women O
than O
men O
, O
even O
after O
the O
adjustment O
for O
differences O
in O
fat O
mass O
( O
28 O
+/- O
3 I-GENE
ng O
/ I-GENE
ml O
for O
women O
vs O
. O

Consistent O
with O
effects O
on O
STAT I-GENE
activation O
, O
altered O
SHP I-GENE
- I-GENE
1 I-GENE
expression O
also O
affected O
EGF I-GENE
- I-GENE
induced O
activation O
of O
the O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
pathway O
; O
expression O
of O
SHP I-GENE
- I-GENE
1 I-GENE
-( O
Cys I-GENE
--> I-GENE
Ser O
) O
inhibited O
activity O
of O
MEK I-GENE
by O
approximately O
25 O
%, O
whereas O
expression O
of O
SHP I-GENE
- I-GENE
1 I-GENE
resulted O
in O
a O
approximately O
25 O
% O
increase O
. O

This O
interaction O
involved O
the O
SH3 I-GENE
region O
of O
p50 I-GENE
( O
_RARE_ I-GENE
) O
and O
a O
proline O
- I-GENE
rich O
region O
( O
_RARE_ I-GENE
) O
outside O
the O
catalytic O
region O
of O
PTP I-GENE
- I-GENE
_RARE_ I-GENE
. O

Following O
2 I-GENE
. O
5 I-GENE
Gy O
, O
_RARE_ I-GENE
changes O
were O
minimal I-GENE
. O

_RARE_ I-GENE
expression O
of O
human I-GENE
intestinal O
N I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
L I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
p O
- I-GENE
_RARE_ I-GENE
acid I-GENE
_RARE_ I-GENE
( O
human I-GENE
_RARE_ I-GENE
) O
alpha I-GENE
and O
beta I-GENE
subunits I-GENE
in O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
canine O
kidney O
cells O
. O

Neither O
mutant I-GENE
exhibited O
derepression O
of O
the O
silent I-GENE
mating I-GENE
type I-GENE
loci I-GENE
. O

Among O
38 O
patients O
with O
inducible I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
who O
underwent O
_RARE_ I-GENE
study O
( O
_RARE_ I-GENE
), O
10 O
_RARE_ I-GENE
of O
six O
patients O
were O
selected O
. O

The O
cycle O
length I-GENE
of O
induced O
VT O
( O
n O
= O
10 O
_RARE_ I-GENE
) O
was O
_RARE_ I-GENE
+/- O
41 O
msec O
. O

Transient O
_RARE_ I-GENE
in O
an O
adult O
_RARE_ I-GENE
_RARE_ I-GENE
dog O
. O

We O
established O
that O
the O
2 I-GENE
. O
6 I-GENE
kb O
mRNA I-GENE
V I-GENE
- I-GENE
1 I-GENE
and O
the O
2 I-GENE
. O
3 I-GENE
kb O
_RARE_ I-GENE
mRNA I-GENE
V I-GENE
- I-GENE
2 I-GENE
_RARE_ I-GENE
, O
by O
alternate O
splicing O
, O
from O
a O
primary O
transcript I-GENE
initiated O
on O
a O
distal O
promoter I-GENE
on O
the O
rat I-GENE
_RARE_ I-GENE
gene I-GENE
. O

A I-GENE
specific I-GENE
distal O
promoter I-GENE
controls O
gamma I-GENE
- I-GENE
glutamyl I-GENE
_RARE_ I-GENE
gene I-GENE
expression O
in O
undifferentiated O
rat I-GENE
transformed O
liver O
cells O
. O

These O
repressor I-GENE
sites I-GENE
are O
pyrimidine O
rich O
and O
bind O
_RARE_ I-GENE
to O
the O
_RARE_ I-GENE
tract O
binding I-GENE
protein I-GENE
( O
PTB I-GENE
) O
in O
HeLa O
nuclear I-GENE
extracts O
as O
determined O
by O
UV O
_RARE_ I-GENE
/ I-GENE
competition O
assays O
. O

For O
higher O
expression O
of O
_RARE_ I-GENE
in O
S I-GENE
. O
_RARE_ I-GENE
, O
the O
gene I-GENE
was O
cloned O
next O
to O
the O
strong O
_RARE_ I-GENE
promoter I-GENE
. O

Within O
a O
135 O
- I-GENE
bp O
core I-GENE
homology I-GENE
region O
, O
the O
human I-GENE
_RARE_ I-GENE
enhancers I-GENE
are O
approximately O
90 O
% O
identical O
to O
the O
murine I-GENE
homolog I-GENE
and O
include O
several O
motifs O
previously O
demonstrated O
to O
be O
important O
for O
function O
of O
the O
murine I-GENE
enhancer I-GENE
; O
additional O
segments O
of O
high O
sequence I-GENE
conservation O
suggest O
the O
possibility O
of O
previously O
_RARE_ I-GENE
functional O
motifs O
. O

In O
contrast O
to O
the O
wild I-GENE
- I-GENE
type I-GENE
protein I-GENE
, O
expression O
of O
_RARE_ I-GENE
NF I-GENE
- I-GENE
E2 I-GENE
lacking O
this O
activation O
domain I-GENE
in O
an O
NF I-GENE
- I-GENE
E2 I-GENE
null I-GENE
cell O
line O
fails O
to O
support O
enhancer I-GENE
- I-GENE
dependent I-GENE
transcription I-GENE
in O
transient O
assays O
. O

These O
findings O
suggest O
one O
potential O
mechanism O
for O
direct O
recruitment O
of O
distal O
regulatory I-GENE
regions O
of O
the O
globin I-GENE
loci I-GENE
to O
the O
individual O
promoters I-GENE
. O

The O
promoter I-GENE
region O
showed O
no O
consensus I-GENE
TATA I-GENE
box I-GENE
but O
it O
contains O
CCAAT I-GENE
and O
_RARE_ I-GENE
boxes O
known O
to O
be O
involved O
in O
both O
stress O
and O
carbon O
- I-GENE
catabolite I-GENE
regulation O
of O
fungal I-GENE
promoters I-GENE
. O

The O
two O
cysteine I-GENE
residues O
located O
in O
this O
additional O
region O
may O
be O
involved O
in O
the O
formation O
of O
a O
disulfide O
_RARE_ I-GENE
associated I-GENE
with O
the O
activation O
process O
of O
the O
catalytic O
activity O
. O

The O
_RARE_ I-GENE
gene I-GENE
has O
been O
expressed O
, O
for O
the O
first O
time O
, O
in O
_RARE_ I-GENE
grown O
Escherichia I-GENE
coli I-GENE
behind O
the O
_RARE_ I-GENE
- I-GENE
beta I-GENE
- I-GENE
D I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
inducible I-GENE
_RARE_ I-GENE
promoter I-GENE
, O
resulting O
in O
the O
production O
of O
_RARE_ I-GENE
in O
its O
active O
form O
. O

When O
the O
downstream O
operator I-GENE
was O
altered O
, O
there O
was O
a O
fourfold O
reduction O
in O
reporter I-GENE
enzyme I-GENE
levels O
. O

The O
ORF3 O
mutant I-GENE
produced O
reduced O
levels O
of O
_RARE_ I-GENE
, O
indicating O
that O
ORF3 O
may O
have O
a O
role O
in O
T I-GENE
beta I-GENE
L I-GENE
biosynthesis O
. O

_RARE_ I-GENE
Cox O
models O
using O
a O
CD4 I-GENE
count O
of O
150 O
/ I-GENE
_RARE_ I-GENE
rather O
than O
200 O
/ I-GENE
_RARE_ I-GENE
to O
_RARE_ I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
yielded O
a O
_RARE_ I-GENE
model O
with O
better O
fit O
to O
the O
observed O
data O
. O

However O
, O
the O
published O
reports O
consist O
of O
a O
small I-GENE
number O
of O
patients O
and O
limited O
data O
. O

These O
transcripts I-GENE
contain O
the O
5 I-GENE
' O
ends O
of O
mature O
_RARE_ I-GENE
mRNAs I-GENE
; O
extend O
through O
_RARE_ I-GENE
, O
across O
the O
intergenic O
region O
, O
and O
a O
significant O
distance O
3 I-GENE
' O
into O
the O
_RARE_ I-GENE
gene I-GENE
. O

The O
distribution O
of O
_RARE_ I-GENE
in O
the O
intestine O
and O
number O
of O
_RARE_ I-GENE
per O
_RARE_ I-GENE
_RARE_ I-GENE
on O
different O
_RARE_ I-GENE
were O
also O
estimated O
for O
detailed O
characterization O
of O
the O
infection O
in O
_RARE_ I-GENE
as O
a O
model O
for O
experimental O
_RARE_ I-GENE
. O

As O
a O
result O
, O
the O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
blood O
flow O
ratio O
( O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
) O
increased O
from O
0 O
. O
44 I-GENE
+/- O
0 O
. O
09 O
during O
control O
stenosis O
to O
0 O
. O
85 O
+/- O
0 O
. O
13 O
after O
_RARE_ I-GENE
_RARE_ I-GENE
( O
10 O
micrograms O
/ I-GENE
kg O
/ I-GENE
min O
i O
. O
v I-GENE
.) O
and O
to O
0 O
. O
81 O
+/- O
0 O
. O
12 O
after O
_RARE_ I-GENE
. O

_RARE_ I-GENE
are O
the O
multisubunit I-GENE
protease I-GENE
involved O
in O
the O
generation O
of O
peptides I-GENE
presented O
by O
MHC I-GENE
class I-GENE
I I-GENE
molecules I-GENE
. O

In O
support O
of O
this O
interpretation O
we O
demonstrate O
that O
_RARE_ I-GENE
binds O
strongly O
5 I-GENE
of O
17 O
motif I-GENE
- I-GENE
positive O
, O
_RARE_ I-GENE
- I-GENE
derived O
synthetic O
peptides I-GENE
. O

_RARE_ I-GENE
, O
H I-GENE
. O

For O
sputum I-GENE
interleukin I-GENE
- I-GENE
8 O
there O
was O
an O
estimated O
true O
treatment O
median O
difference O
of O
142 O
pg O
/ I-GENE
ml O
( O
95 O
% O
confidence O
interval O
( O
CI O
) O
8 O
to O
_RARE_ I-GENE
pg O
/ I-GENE
ml O
) O
in O
_RARE_ I-GENE
of O
placebo O
; O
while O
for O
maximal O
expiratory O
flow O
at O
25 O
% O
( O
_RARE_ I-GENE
%) O
remaining O
_RARE_ I-GENE
vital O
capacity O
predicted O
for O
sex I-GENE
and O
height O
there O
was O
a O
15 O
percentage O
points O
( O
_RARE_ I-GENE
) O
( O
95 O
% O
CI O
4 I-GENE
to O
26 O
_RARE_ I-GENE
) O
mean O
treatment O
difference O
in O
_RARE_ I-GENE
of O
placebo O
. O

However O
, O
although O
deletion O
of O
_RARE_ I-GENE
in O
the O
_RARE_ I-GENE
gene I-GENE
yielded O
increased O
CAT I-GENE
activity O
, O
_RARE_ I-GENE
toward O
a O
negative O
regulatory I-GENE
function O
_RARE_ I-GENE
by O
this O
element I-GENE
, O
its O
insertion O
upstream O
of O
the O
_RARE_ I-GENE
basal O
promoter I-GENE
results O
in O
an O
_RARE_ I-GENE
positive O
stimulation O
of O
CAT I-GENE
gene I-GENE
expression O
. O

_RARE_ I-GENE
' O
s O
disease O
is O
a O
rare O
metabolic O
disorder O
characterized O
by O
the O
lack O
of O
beta I-GENE
- I-GENE
_RARE_ I-GENE
enzyme I-GENE
. O

These O
_RARE_ I-GENE
' O
s O
can O
be O
treated O
in O
several O
ways O
but O
up O
to O
_RARE_ I-GENE
tooth O
structure O
had O
to O
be O
removed O
in O
an O
irreversible O
manner O
in O
order O
to O
provide O
sufficient O
bulk O
for O
the O
new O
_RARE_ I-GENE
material O
. O

The O
9 O
; O
22 O
chromosomal I-GENE
translocation O
characteristic O
of O
CML O
results O
in O
a O
fused O
_RARE_ I-GENE
/ I-GENE
abl I-GENE
gene I-GENE
and O
an O
abnormal O
fusion I-GENE
protein I-GENE
, O
_RARE_ I-GENE
/ I-GENE
abl I-GENE
. O

Overexpression O
of O
_RARE_ I-GENE
- I-GENE
1 I-GENE
also O
protected O
certain O
cell O
lines O
from O
heat I-GENE
shock I-GENE
- I-GENE
induced O
cell O
death O
. O

The O
5 I-GENE
' O
flanking O
region O
contains O
potential O
binding I-GENE
sites I-GENE
for O
TATA I-GENE
- I-GENE
binding I-GENE
protein I-GENE
, O
Sp1 I-GENE
, O
nuclear I-GENE
factor I-GENE
1 I-GENE
( O
NF1 I-GENE
), O
CAAT I-GENE
- I-GENE
box I-GENE
binding I-GENE
protein I-GENE
( O
C I-GENE
/ I-GENE
EBP I-GENE
), O
hepatocyte I-GENE
nuclear I-GENE
factors I-GENE
1 I-GENE
and O
5 I-GENE
( O
_RARE_ I-GENE
, O
_RARE_ I-GENE
) O
and O
activator I-GENE
proteins I-GENE
1 I-GENE
and O
2 I-GENE
( O
AP1 I-GENE
, O
AP2 I-GENE
). O

The O
recognition I-GENE
specificity O
of O
the O
p55 I-GENE
PDZ I-GENE
domain I-GENE
appears O
to O
be O
unique O
, O
since O
the O
three O
PDZ I-GENE
domains I-GENE
of O
_RARE_ I-GENE
( O
human I-GENE
lymphocyte I-GENE
homologue I-GENE
of O
the O
Drosophila I-GENE
_RARE_ I-GENE
large O
tumor I-GENE
suppressor I-GENE
) O
do O
not O
bind O
the O
cytoplasmic I-GENE
domain I-GENE
of O
_RARE_ I-GENE
C I-GENE
. O

By O
analyzing O
the O
_RARE_ I-GENE
activity O
of O
a O
series O
of O
_RARE_ I-GENE
expressed O
_RARE_ I-GENE
mutant I-GENE
derivatives O
, O
we O
show O
that O
the O
highly O
acidic O
sequence I-GENE
in O
the O
C I-GENE
- I-GENE
terminal I-GENE
domain I-GENE
of O
both O
yeast I-GENE
proteins I-GENE
is O
_RARE_ I-GENE
for O
activating I-GENE
Ran I-GENE
- I-GENE
mediated O
GTP I-GENE
hydrolysis O
. O

In O
the O
absence O
of O
MHC I-GENE
class I-GENE
II I-GENE
, O
purified O
soluble I-GENE
_RARE_ I-GENE
TCR I-GENE
bound O
to O
Staphylococcus I-GENE
aureus I-GENE
enterotoxin I-GENE
C2 I-GENE
with O
an O
association O
rate O
of O
1 I-GENE
. O
69 O
+/- O
0 O
. O
12 O
x O
10 O
( O
4 I-GENE
) O
M I-GENE
(- O
1 I-GENE
) O
sec O
(- O
1 I-GENE
) O
and O
a O
dissociation O
rate O
of O
1 I-GENE
. O
9 O
+/- O
0 O
. O
47 O
x O
10 O
(- O
2 I-GENE
) O
sec O
(- O
1 I-GENE
), O
giving O
a O
dissociation O
constant O
of O
1 I-GENE
. O
1 I-GENE
microM O
. O

Evidence O
for O
such O
peak O
shifts O
has O
been O
found O
in O
the O
responses O
of O
auditory O
nerve I-GENE
fibers O
, O
cochlear O
_RARE_ I-GENE
, O
and O
the O
responses O
of O
outer I-GENE
_RARE_ I-GENE
cells O
and O
supporting O
cells O
in O
the O
_RARE_ I-GENE
, O
as O
well O
as O
in O
_RARE_ I-GENE
membrane I-GENE
vibration O
measurements O
, O
and O
indirectly O
, O
in O
_RARE_ I-GENE
data O
. O

_RARE_ I-GENE
: O
Max I-GENE
complexes I-GENE
also O
efficiently O
suppress O
Myc I-GENE
- I-GENE
dependent I-GENE
activation O
from O
the O
same O
promoter I-GENE
. O

In O
the O
United O
_RARE_ I-GENE
high O
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
which O
is O
difficult O
to O
_RARE_ I-GENE
is O
most O
frequently O
used O
and O
results O
in O
a O
larger O
in O
vivo O
_RARE_ I-GENE
and O
subsequent O
decrease O
in O
factor I-GENE
VIII I-GENE
/ I-GENE
von I-GENE
Willebrand I-GENE
factor I-GENE
levels O
. O

_RARE_ I-GENE
of O
total O
cholesterol I-GENE
as O
well O
as O
the O
HDL I-GENE
, O
HDL2 I-GENE
, O
LDL I-GENE
, O
triglycerides I-GENE
, O
endothelin I-GENE
- I-GENE
1 I-GENE
, O
lipoprotein I-GENE
( O
a O
), O
estradiol O
and O
FSH I-GENE
were O
also O
obtained O
at O
baseline O
before O
receiving O
_RARE_ I-GENE
and O
after O
3 I-GENE
months O
of O
_RARE_ I-GENE
. O

Six O
tandem O
repeats I-GENE
of O
the O
P I-GENE
element I-GENE
linked O
to O
the O
SV40 I-GENE
promoter I-GENE
responded O
to O
phorbol O
12 O
- I-GENE
myristate O
13 O
- I-GENE
acetate O
, O
while O
that O
of O
other O
elements O
did O
not O
. O

The O
distributed O
current O
density I-GENE
J O
is O
calculated O
within O
the O
volume O
defined O
by O
the O
motor O
unit I-GENE
. O

The O
cleavage O
_RARE_ I-GENE
of O
_RARE_ I-GENE
_RARE_ I-GENE
protease I-GENE
are O
Q I-GENE
( O
E I-GENE
)/ O
S I-GENE
( O
A I-GENE
, O
G I-GENE
). O

In O
our O
previous O
studies O
, O
transcriptional O
activation O
was O
shown O
to O
correlate O
with O
_RARE_ I-GENE
binding I-GENE
to O
both O
the O
TATA I-GENE
- I-GENE
box I-GENE
binding I-GENE
protein I-GENE
( O
TBP I-GENE
) O
and O
the O
transcription I-GENE
factor I-GENE
bound O
upstream O
. O

However O
, O
we O
were O
unable O
to O
identify O
a O
_RARE_ I-GENE
molecule I-GENE
. O

( O
iv O
) O
The O
accumulation O
of O
cyclin I-GENE
D3 I-GENE
protein I-GENE
in O
_RARE_ I-GENE
cells O
infected O
with O
an O
_RARE_ I-GENE
deletion O
mutant I-GENE
was O
reduced O
relative O
to O
that O
of O
cells O
infected O
with O
wild I-GENE
- I-GENE
type I-GENE
virus I-GENE
or O
a O
recombinant I-GENE
virus I-GENE
in O
which O
the O
deleted O
_RARE_ I-GENE
sequences I-GENE
were O
restored O
. O

We O
report O
the O
preliminary O
biochemical O
characterization O
of O
the O
T I-GENE
antigens I-GENE
encoded I-GENE
by O
three O
SV40 I-GENE
mutants I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
, O
each O
of O
which O
have O
altered O
residues O
within O
or O
near O
the O
ATP I-GENE
binding I-GENE
pocket O
. O

These O
effects O
were O
abrogated O
by O
co O
- I-GENE
expression O
of O
kinase I-GENE
- I-GENE
deficient O
PKC I-GENE
zeta I-GENE
and O
inhibition O
of O
phosphatidylinositol I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
by O
wortmannin O
, O
_RARE_ I-GENE
and O
a O
dominant I-GENE
- I-GENE
negative O
mutant I-GENE
of O
_RARE_ I-GENE
. O

Protein I-GENE
phosphatase I-GENE
2A I-GENE
is O
a O
critical O
regulator I-GENE
of O
protein I-GENE
kinase I-GENE
C I-GENE
zeta I-GENE
signaling O
targeted O
by O
SV40 I-GENE
small I-GENE
t I-GENE
to O
promote O
cell O
growth I-GENE
and O
NF I-GENE
- I-GENE
kappaB I-GENE
activation O
. O

Interestingly O
, O
the O
_RARE_ I-GENE
constitutive O
activity O
generated O
within O
heterodimers I-GENE
in O
the O
presence O
of O
_RARE_ I-GENE
requires O
the O
integrity O
of O
both O
RXR I-GENE
and O
RAR I-GENE
AF I-GENE
- I-GENE
2 I-GENE
domains I-GENE
. O

These O
introns O
contain O
only O
single O
_RARE_ I-GENE
genes I-GENE
and O
their O
processing O
involves O
_RARE_ I-GENE
release O
of O
the O
_RARE_ I-GENE
from O
_RARE_ I-GENE
intron O
_RARE_ I-GENE
. O

Recent O
studies O
have O
shown O
that O
the O
Src I-GENE
homology I-GENE
- I-GENE
2 I-GENE
( O
SH2 I-GENE
) O
domain I-GENE
- I-GENE
containing O
protein I-GENE
- I-GENE
tyrosine I-GENE
phosphatase I-GENE
, O
SHP I-GENE
- I-GENE
2 I-GENE
, O
associates O
with O
the O
cytoplasmic I-GENE
domain I-GENE
of O
_RARE_ I-GENE
- I-GENE
1 I-GENE
as O
it O
becomes O
tyrosine I-GENE
- I-GENE
phosphorylated O
during O
platelet I-GENE
aggregation O
: O
a O
process O
that O
can O
be O
mimicked O
in O
part O
by O
small I-GENE
synthetic O
phosphopeptides O
corresponding O
to O
the O
cytoplasmic I-GENE
domain I-GENE
of O
_RARE_ I-GENE
- I-GENE
1 I-GENE
encompassing O
tyrosine I-GENE
residues O
Tyr I-GENE
- I-GENE
_RARE_ I-GENE
or O
Tyr I-GENE
- I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
the O
_RARE_ I-GENE
of O
these O
risk O
variables O
were O
three O
factors I-GENE
. O

_RARE_ I-GENE
was O
stopped O
when O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
reached O
2 I-GENE
. O
0 O
g O
/ I-GENE
dL O
. O

Detection O
of O
_RARE_ I-GENE
Mycobacterium O
tuberculosis O
by O
air O
filtration O
and O
polymerase I-GENE
chain I-GENE
reaction O
. O

These O
findings O
show O
that O
_RARE_ I-GENE
is O
a O
_RARE_ I-GENE
relevant O
_RARE_ I-GENE
binding I-GENE
protein I-GENE
. O

Previously O
, O
we O
reported O
that O
_RARE_ I-GENE
translation I-GENE
, O
where O
the O
initiating O
AUG O
of O
a O
primary O
open O
reading O
frame O
is O
_RARE_ I-GENE
, O
is O
most O
likely O
to O
account O
for O
the O
presentation O
of O
_RARE_ I-GENE
epitopes I-GENE
from O
alternative O
reading O
frames O
within O
the O
influenza I-GENE
A I-GENE
PR I-GENE
/ I-GENE
8 O
/ I-GENE
34 O
nucleoprotein I-GENE
gene I-GENE
. O

This O
family I-GENE
of O
proteins I-GENE
binds O
GC I-GENE
- I-GENE
rich O
motifs O
widely O
distributed O
in O
gene I-GENE
promoters I-GENE
, O
resulting O
in O
distinct O
activation O
or O
repression O
of O
transcriptional O
activities O
. O

Deletion O
of O
the O
_RARE_ I-GENE
gene I-GENE
alone O
had O
no O
detectable O
phenotype O
, O
while O
_RARE_ I-GENE
with O
deletions O
of O
both O
the O
_RARE_ I-GENE
and O
_RARE_ I-GENE
genes I-GENE
were O
viable O
and O
able O
to O
grow O
on O
_RARE_ I-GENE
at O
30 O
degrees O
C I-GENE
, O
_RARE_ I-GENE
more O
slowly O
than O
delta I-GENE
_RARE_ I-GENE
single O
mutants I-GENE
. O

Furthermore O
, O
our O
novel O
observation O
that O
expression O
of O
a O
highly O
activated I-GENE
_RARE_ I-GENE
kinase I-GENE
domain I-GENE
is O
able O
to O
_RARE_ I-GENE
transform O
fibroblasts O
suggests O
that O
_RARE_ I-GENE
of O
_RARE_ I-GENE
has O
the O
potential O
to O
play O
a O
role O
in O
human I-GENE
_RARE_ I-GENE
. O

The O
deduced O
amino O
acid I-GENE
sequence I-GENE
of O
the O
gene I-GENE
has O
significant O
homology I-GENE
to O
the O
interferon I-GENE
regulatory I-GENE
factors I-GENE
( O
_RARE_ I-GENE
). O

_RARE_ I-GENE
of O
AP I-GENE
- I-GENE
2 I-GENE
in O
regulation O
of O
the O
R I-GENE
- I-GENE
_RARE_ I-GENE
gene I-GENE
in O
the O
developing O
chick I-GENE
retina O
. O

However O
, O
_RARE_ I-GENE
was O
found O
to O
be O
nucleolar I-GENE
and O
is O
highly O
homologous O
to O
the O
rat I-GENE
nucleolar I-GENE
protein I-GENE
_RARE_ I-GENE
, O
which O
_RARE_ I-GENE
with O
_RARE_ I-GENE
and O
which O
is O
postulated O
to O
be O
involved O
in O
nucleolar I-GENE
- I-GENE
cytoplasmic I-GENE
_RARE_ I-GENE
( O
U O
. O

This O
newly O
described O
organism O
was O
difficult O
to O
identify O
due O
to O
_RARE_ I-GENE
between O
the O
_RARE_ I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
identification O
systems O
. O

Ig I-GENE
heavy I-GENE
chain I-GENE
class I-GENE
switching O
is O
directed O
by O
cytokines O
inducing O
transcription I-GENE
from O
_RARE_ I-GENE
_RARE_ I-GENE
genes I-GENE
. O

The O
available O
data O
suggest O
that O
the O
NF I-GENE
kappa I-GENE
B2 I-GENE
nucleoprotein I-GENE
complex I-GENE
may O
cooperate O
with O
DNA I-GENE
- I-GENE
bound O
_RARE_ I-GENE
to O
achieve O
IL I-GENE
- I-GENE
4 I-GENE
- I-GENE
dependent I-GENE
activation O
of O
the O
human I-GENE
IgE I-GENE
germline I-GENE
gene I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE

_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE

The O
pheromone O
response O
pathway O
activates O
transcription I-GENE
of O
_RARE_ I-GENE
_RARE_ I-GENE
located O
within O
silent I-GENE
chromatin O
of O
Saccharomyces I-GENE
cerevisiae I-GENE
. O

In O
this O
study O
we O
have O
introduced O
mutations O
into O
the O
corresponding O
elements O
of O
two O
_RARE_ I-GENE
promoters I-GENE
and O
show O
that O
while O
the O
core I-GENE
element I-GENE
is O
essential O
for O
_RARE_ I-GENE
promoter I-GENE
activity O
, O
upstream O
element I-GENE
mutations O
have O
little O
or O
no O
effect O
. O

We O
found O
that O
multiple O
tumor I-GENE
suppressor I-GENE
genes I-GENE
( O
e O
. O
g O
., O
p53 I-GENE
, O
_RARE_ I-GENE
, O
APC I-GENE
, O
_RARE_ I-GENE
, O
BRCA1 I-GENE
, O
and O
WAF1 I-GENE
/ I-GENE
_RARE_ I-GENE
) O
were O
inactivated O
at O
different O
frequencies O
via O
various O
mechanisms O
[ O
e O
. O
g O
., O
loss O
of O
heterozygosity O
( O
_RARE_ I-GENE
), O
loss O
of O
expression O
( O
_RARE_ I-GENE
), O
mutation I-GENE
, O
and O
inactivation O
by O
cellular O
binding I-GENE
protein I-GENE
]. O

The O
histidine O
- I-GENE
tagged O
gene I-GENE
, O
_RARE_ I-GENE
, O
was O
used O
to O
replace O
the O
wild I-GENE
- I-GENE
type I-GENE
allele I-GENE
in O
the O
chromosome O
of O
S I-GENE
. O
_RARE_ I-GENE
and O
S I-GENE
. O
_RARE_ I-GENE
. O

Because O
the O
deletion O
included O
the O
TK I-GENE
gene I-GENE
, O
selection O
with O
_RARE_ I-GENE
against O
cells O
not O
having O
undergone O
recombination O
was O
possible O
. O

The O
_RARE_ I-GENE
synthase I-GENE
gene I-GENE
, O
_RARE_ I-GENE
, O
of O
the O
yeast I-GENE
Saccharomyces I-GENE
cerevisiae I-GENE
is O
transcriptionally O
regulated O
by O
the O
carbon O
source O
in O
the O
growth I-GENE
medium O
. O

By O
deletion O
analysis O
of O
the O
_RARE_ I-GENE
control O
region O
, O
we O
identified O
two O
sites I-GENE
, O
UAS1 O
and O
_RARE_ I-GENE
, O
as O
important O
for O
efficient O
derepression O
of O
the O
gene I-GENE
. O

_RARE_ I-GENE
of O
controlled O
prospective O
studies O
of O
sleep O
_RARE_ I-GENE
( O
EEG O
), O
and O
the O
use O
of O
medication O
, O
in O
children O
with O
developmental O
_RARE_ I-GENE
, O
may O
_RARE_ I-GENE
appropriate O
treatment O
strategies O
to O
children O
with O
severe O
developmental O
speech O
and O
language O
disorders O
. O

_RARE_ I-GENE
to O
_RARE_ I-GENE
2 I-GENE
to O
3 I-GENE
times O
daily O
, O
1 I-GENE
- I-GENE
2 I-GENE
_RARE_ I-GENE
of O
_RARE_ I-GENE
are O
recommended O
. O

_RARE_ I-GENE
of O
the O
abdominal O
aortic O
wall O
on O
an O
ultrasound O
examination O
was O
the O
key O
to O
the O
_RARE_ I-GENE
diagnosis O
of O
a O
clinically O
_RARE_ I-GENE
type I-GENE
B I-GENE
dissection O
. O

_RARE_ I-GENE
process O
after O
supplementation O
of O
nitrate I-GENE
, O
nitrite I-GENE
, O
_RARE_ I-GENE
acid I-GENE
bacteria O
and O
_RARE_ I-GENE
acid I-GENE

_RARE_ I-GENE
include O
the O
p21 I-GENE
( O
ras I-GENE
) O
proteins I-GENE
, O
nuclear I-GENE
_RARE_ I-GENE
, O
and O
a O
series O
of O
retinal O
proteins I-GENE
. O

_RARE_ I-GENE
of O
10 O
animals O
per O
group O
from O
16 O
studies O
in O
CD O
- I-GENE
1 I-GENE
mice O
and O
1 I-GENE
study O
each O
in O
C3H O
and O
C57BL O
/ I-GENE
6 I-GENE
mice O
were O
_RARE_ I-GENE
_RARE_ I-GENE
at O
6 I-GENE
microm O
. O

The O
_RARE_ I-GENE
- I-GENE
CT I-GENE
fusion I-GENE
protein I-GENE
was O
produced O
less O
efficiently O
( O
20 O
% O
of O
total O
soluble I-GENE
cellular O
protein I-GENE
). O

These O
results O
suggest O
that O
_RARE_ I-GENE
may O
play O
an O
important O
role O
in O
the O
_RARE_ I-GENE
of O
ubiquitin I-GENE
by O
hydrolysis O
of O
branched I-GENE
poly O
- I-GENE
ubiquitin I-GENE
chains I-GENE
generated O
by O
the O
action O
of O
26 O
S I-GENE
proteasome I-GENE
on O
poly O
- I-GENE
_RARE_ I-GENE
protein I-GENE
substrates O
, O
as O
well O
as O
in O
the O
production O
of O
free O
ubiquitin I-GENE
from O
linear O
poly O
- I-GENE
ubiquitin I-GENE
chains I-GENE
and O
of O
certain O
ribosomal I-GENE
proteins I-GENE
from O
ubiquitin I-GENE
fusion I-GENE
proteins I-GENE
. O

A I-GENE
data O
base O
homology I-GENE
search O
revealed O
that O
the O
predicted O
_RARE_ I-GENE
amino O
acid I-GENE
sequence I-GENE
contains O
three O
regions O
of O
similarity O
to O
the O
rat I-GENE
and O
human I-GENE
proteins I-GENE
encoded I-GENE
by O
the O
metastasis O
- I-GENE
associated I-GENE
gene I-GENE
, O
_RARE_ I-GENE
, O
and O
two O
regions O
of O
similarity O
to O
the O
Caenorhabditis I-GENE
elegans I-GENE
sequence I-GENE
that O
is O
similar O
to O
_RARE_ I-GENE
. O

The O
sequenced O
cDNA I-GENE
predicts O
a O
_RARE_ I-GENE
- I-GENE
amino O
acid I-GENE
protein I-GENE
80 O
% O
identical O
to O
human I-GENE
_RARE_ I-GENE
B I-GENE
. O

The O
inhibition O
by O
cytosolic I-GENE
Ca2 I-GENE
+ I-GENE
was O
caused O
by O
a O
decrease O
in O
cooperativity O
and O
by O
a O
shift O
in O
_RARE_ I-GENE
toward O
higher O
_RARE_ I-GENE
concentrations O
. O

RESULTS O
: O
The O
_RARE_ I-GENE
mortality O
ratio O
( O
_RARE_ I-GENE
) O
for O
all O
malignant O
neoplasms O
was O
94 O
( O
95 O
% O
CI O
74 O
to O
118 O
). O

Sequence O
analysis O
of O
this O
region O
revealed O
three O
eight O
- I-GENE
bp O
repetitive O
elements O
, O
the O
deletion O
of O
which O
restored O
wild I-GENE
- I-GENE
type I-GENE
levels O
of O
luciferase I-GENE
activity O
to O
the O
- I-GENE
_RARE_ I-GENE
- I-GENE
bp O
reporter I-GENE
plasmid O
. O

Using O
5 I-GENE
' O
RACE O
and O
reverse I-GENE
transcription I-GENE
- I-GENE
PCR O
( O
RT I-GENE
- I-GENE
PCR O
) O
_RARE_ I-GENE
, O
we O
cloned O
these O
sequences I-GENE
from O
brain O
and O
placenta O
and O
found O
this O
material O
to O
be O
composed O
of O
alternatively O
spliced O
exons O
using O
a O
previously O
reported O
noncoding O
exon O
( O
_RARE_ I-GENE
) O
and O
a O
novel O
97 O
- I-GENE
bp O
noncoding O
exon O
( O
1B I-GENE
). O

This O
is O
the O
first O
study O
in O
which O
mutation I-GENE
screening O
has O
been O
performed O
for O
both O
the O
_RARE_ I-GENE
and O
_RARE_ I-GENE
genes I-GENE
prior O
to O
any O
linkage O
analysis O
. O

The O
_RARE_ I-GENE
of O
large O
vitreous O
injections O
. O

_RARE_ I-GENE
emission O
tomography O
_RARE_ I-GENE
for O
dopamine I-GENE
transporters I-GENE
and O
studies O
in O
human I-GENE
and O
_RARE_ I-GENE
primates O
. O

_RARE_ I-GENE
from O
the O
_RARE_ I-GENE
A2 I-GENE
consensus I-GENE
_RARE_ I-GENE
is O
not O
necessarily O
dependent I-GENE
on O
DNA I-GENE
binding I-GENE
as O
the O
TR I-GENE
alpha I-GENE
DNA I-GENE
binding I-GENE
mutant I-GENE
was O
still O
able O
to O
inhibit O
E I-GENE
- I-GENE
dependent I-GENE
transactivation O
. O

Expression O
from O
this O
element I-GENE
is O
regulated O
by O
a O
_RARE_ I-GENE
protein I-GENE
complex I-GENE
containing O
ubiquitous O
( O
i O
. O
e O
. O
the O
_RARE_ I-GENE
- I-GENE
and O
_RARE_ I-GENE
- I-GENE
encoded I-GENE
proteins I-GENE
) O
and O
islet O
- I-GENE
enriched O
members O
of O
the O
bHLH I-GENE
family I-GENE
. O

Thus O
, O
the O
CCAAT I-GENE
box I-GENE
also O
has O
tissue I-GENE
- I-GENE
specific I-GENE
characteristics O
that O
_RARE_ I-GENE
in O
targeting O
expression O
of O
the O
alpha I-GENE
- I-GENE
subunit I-GENE
gene I-GENE
to O
_RARE_ I-GENE
. O

U4 I-GENE
/ I-GENE
U6 I-GENE
snRNP I-GENE
is O
one O
of O
four O
essential O
small I-GENE
nuclear I-GENE
ribonucleoprotein I-GENE
( O
snRNP I-GENE
) O
particles O
( O
U1 I-GENE
, O
U2 I-GENE
, O
U5 I-GENE
and O
U4 I-GENE
/ I-GENE
U6 I-GENE
) O
present O
in O
the O
spliceosome O
. O

_RARE_ I-GENE
is O
a O
77 O
kDa I-GENE
protein I-GENE
, O
which O
is O
homologous O
to O
the O
Saccharomyces I-GENE
cerevisiae I-GENE
splicing O
factor I-GENE
_RARE_ I-GENE
. O

The O
growth I-GENE
- I-GENE
promoting I-GENE
properties O
of O
the O
retroviral I-GENE
v I-GENE
- I-GENE
erbA I-GENE
oncogene I-GENE
, O
a O
highly O
mutated O
version O
of O
the O
chicken I-GENE
thyroid I-GENE
hormone I-GENE
receptor I-GENE
( O
TR I-GENE
) O
alpha I-GENE
, O
have O
so O
far O
exclusively O
been O
linked O
to O
dominant I-GENE
repression O
of O
the O
_RARE_ I-GENE
roles O
of O
TR I-GENE
and O
retinoic I-GENE
acid I-GENE
receptors I-GENE
. O

We O
cloned O
a O
complete O
cDNA I-GENE
( O
2 I-GENE
. O
9 O
kb O
) O
for O
_RARE_ I-GENE
from O
an O
_RARE_ I-GENE
- I-GENE
7 O
cDNA I-GENE
library O
. O

The O
most O
common O
grade O
3 I-GENE
toxicity O
was O
neutropenia O
, O
thrombocytopenia O
, O
and O
_RARE_ I-GENE
( O
observed O
in O
< O
10 O
% O
of O
cycles O
). O

Serum I-GENE
concentrations O
of O
E2 I-GENE
and O
_RARE_ I-GENE
were O
measured O
on O
d O
0 O
, O
1 I-GENE
, O
3 I-GENE
, O
5 I-GENE
, O
7 O
, O
13 O
, O
21 O
, O
28 O
, O
42 O
, O
56 O
, O
84 O
, O
112 O
, O
and O
140 I-GENE
in O
_RARE_ I-GENE
heifers O
administered O
the O
following O
treatments O
: O
1 I-GENE
) O
control O
; O
2 I-GENE
) O
MGA O
, O
. O
5 I-GENE
mg O
per O
_RARE_ I-GENE
daily O
; O
3 I-GENE
) O
_RARE_ I-GENE
- I-GENE
H I-GENE
( O
140 I-GENE
mg O
_RARE_ I-GENE
+ I-GENE
14 O
mg O
E2 I-GENE
); O
4 I-GENE
) O
_RARE_ I-GENE
- I-GENE
H I-GENE
+ I-GENE
MGA O
; O
5 I-GENE
) O
_RARE_ I-GENE
- I-GENE
H I-GENE
( O
200 O
mg O
_RARE_ I-GENE
); O
and O
6 I-GENE
) O
_RARE_ I-GENE
- I-GENE
H I-GENE
+ I-GENE
MGA O
. O

Serum I-GENE
E2 I-GENE
concentrations O
increased O
_RARE_ I-GENE
two O
- I-GENE
to O
threefold O
from O
d O
56 O
to O
140 I-GENE
in O
controls O
fed O
MGA O
, O
compared O
with O
controls O
not O
fed O
MGA O
. O

Interferon I-GENE
_RARE_ I-GENE
Factor I-GENE
( O
IRF I-GENE
)- I-GENE
1 I-GENE
has O
been O
characterized O
as O
an O
important O
growth I-GENE
regulatory I-GENE
and O
_RARE_ I-GENE
transcription I-GENE
factor I-GENE
. O

The O
genomic O
structure O
of O
_RARE_ I-GENE
consists O
of O
8 O
exons O
, O
whose O
boundaries O
are O
distinct O
from O
other O
non O
- I-GENE
receptor I-GENE
_RARE_ I-GENE
family I-GENE
members O
, O
again O
indicating O
a O
structural O
and O
functional O
divergence O
. O

We O
have O
previously O
reported O
that O
expression O
of O
a O
tumour I-GENE
derived O
_RARE_ I-GENE
cDNA I-GENE
in O
mouse I-GENE
embryonic O
fibroblasts O
and O
human I-GENE
mammary O
epithelial O
cells O
supports O
anchorage O
independent O
growth I-GENE
, O
and O
in O
the O
latter O
potentiates O
the O
mitogenic O
response O
to O
epidermal I-GENE
growth I-GENE
factor I-GENE
. O

Anti I-GENE
- I-GENE
hepatitis I-GENE
A I-GENE
virus I-GENE
( O
_RARE_ I-GENE
) O
titer O
after O
vaccination O
was O
measured O
in O
83 O
HIV I-GENE
- I-GENE
positive O
and O
39 O
HIV I-GENE
- I-GENE
negative O
men O
. O

One O
_RARE_ I-GENE
does O
not O
a O
species O
make O
. O

Surprisingly O
, O
calf I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
contained O
an O
additional O
, O
novel O
form O
of O
the O
64 O
- I-GENE
kDa I-GENE
subunit I-GENE
with O
a O
molecular O
mass O
of O
70 I-GENE
kDa I-GENE
. O

_RARE_ I-GENE
mutations O
in O
_RARE_ I-GENE
- I-GENE
3 I-GENE
suppress O
mutations O
in O
genes I-GENE
encoding O
this O
TGF I-GENE
- I-GENE
beta I-GENE
signal I-GENE
, O
its O
receptors I-GENE
, O
and O
associated I-GENE
Smad I-GENE
signal I-GENE
transduction O
proteins I-GENE
. O
_RARE_ I-GENE
- I-GENE
3 I-GENE
encodes O
a O
Smad I-GENE
protein I-GENE
that O
is O
most O
closely O
related I-GENE
to O
mammalian I-GENE
_RARE_ I-GENE
, O
and O
is O
expressed O
throughout O
development O
in O
many O
of O
the O
tissues O
that O
are O
_RARE_ I-GENE
during O
_RARE_ I-GENE
development O
. O

Our O
results O
_RARE_ I-GENE
the O
possibility O
that O
the O
Drosophila I-GENE
EGF I-GENE
receptor I-GENE
DER I-GENE
/ I-GENE
_RARE_ I-GENE
expressed O
by O
the O
_RARE_ I-GENE
cells O
functions O
as O
a O
receptor I-GENE
for O
_RARE_ I-GENE
. O

PATIENTS O
AND O
METHODS O
: O
In O
_RARE_ I-GENE
consecutive O
patients O
from O
the O
_RARE_ I-GENE
National O
_RARE_ I-GENE
of O
Acute O
Myocardial O
_RARE_ I-GENE
we O
analyzed O
the O
resolution O
of O
chest O
pain O
and O
ST O
segment O
elevation O
over O
50 O
% O
within O
the O
first O
90 O
min O
, O
_RARE_ I-GENE
CK I-GENE
rise O
within O
8 O
h O
and O
T I-GENE
wave O
inversion O
in O
infarct O
related I-GENE
_RARE_ I-GENE
leads O
within O
the O
first O
24 O
h O
after O
_RARE_ I-GENE
. O

Because O
of O
the O
operon I-GENE
structure O
of O
this O
organism O
, O
_RARE_ I-GENE
methods O
such O
as O
insertional I-GENE
mutagenesis O
run O
the O
risk O
of O
_RARE_ I-GENE
_RARE_ I-GENE
effects O
on O
downstream O
genes I-GENE
or O
_RARE_ I-GENE
secondary O
mutations O
_RARE_ I-GENE
in O
the O
genome O
. O

It O
has O
been O
proposed O
that O
the O
_RARE_ I-GENE
operon I-GENE
encodes O
a O
plasmid O
_RARE_ I-GENE
system O
( O
M I-GENE
. O

Furthermore O
, O
the O
insertion O
of O
the O
_RARE_ I-GENE
_RARE_ I-GENE
site I-GENE
into O
the O
_RARE_ I-GENE
plasmid O
deleted O
for O
the O
_RARE_ I-GENE
region O
failed O
to O
_RARE_ I-GENE
the O
plasmid O
in O
the O
_RARE_ I-GENE
strain O
, O
indicating O
that O
the O
_RARE_ I-GENE
resolution O
activity O
encoded I-GENE
by O
_RARE_ I-GENE
is O
not O
by O
itself O
responsible O
for O
the O
stabilization O
activity O
observed O
for O
this O
operon I-GENE
. O

To O
examine O
the O
basis O
for O
the O
apparent O
differences O
in O
_RARE_ I-GENE
_RARE_ I-GENE
between O
the O
two O
E I-GENE
. O
coli I-GENE
strains O
, O
transformation O
assays O
were O
carried O
out O
to O
determine O
the O
relative O
_RARE_ I-GENE
of O
the O
strains O
to O
the O
_RARE_ I-GENE
toxin I-GENE
protein I-GENE
. O

_RARE_ I-GENE
- I-GENE
junction O
elements O
and O
intronic I-GENE
sequences I-GENE
regulate O
alternative O
splicing O
of O
the O
Drosophila I-GENE
myosin I-GENE
heavy I-GENE
chain I-GENE
gene I-GENE
transcript I-GENE
. O

Nucleotide O
sequence I-GENE
analysis O
of O
R I-GENE
has O
revealed O
similarities O
to O
the O
R1 I-GENE
plasmid O
found O
in O
some O
_RARE_ I-GENE
American O
maize I-GENE
_RARE_ I-GENE
with O
_RARE_ I-GENE
cytoplasm O
, O
to O
the O
M1 I-GENE
plasmid O
found O
in O
one O
source O
of O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
, O
to O
the O
_RARE_ I-GENE
mitochondrial I-GENE
gene I-GENE
and O
its O
3 I-GENE
' O
flanking O
sequence I-GENE
, O
and O
also O
to O
a O
region O
3 I-GENE
' O
to O
the O
_RARE_ I-GENE
gene I-GENE
. O

We O
have O
measured O
the O
kinetics O
of O
the O
recovery O
of O
mRNA I-GENE
synthesis O
in O
the O
inducible I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
genes I-GENE
after O
exposure O
of O
yeast I-GENE
cells O
to O
_RARE_ I-GENE
( O
UV O
) O
radiation O
. O

Cloning O
of O
a O
human I-GENE
_RARE_ I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
with O
a O
C2 I-GENE
domain I-GENE
that O
displays O
reduced O
sensitivity O
to O
the O
inhibitor I-GENE
wortmannin O
. O

_RARE_ I-GENE
value O
was O
calculated O
as O
the O
ratio O
of O
the O
steady O
- I-GENE
state O
end O
- I-GENE
systolic O
aortic O
pressure O
( O
_RARE_ I-GENE
) O
to O
stroke O
volume O
( O
_RARE_ I-GENE
). O

Functional O
analysis O
of O
promoter I-GENE
activity O
of O
the O
5 I-GENE
'- O
flanking O
region O
of O
cyclin I-GENE
D2 I-GENE
suggested O
that O
the O
region O
- I-GENE
1 I-GENE
, O
100 O
to O
- I-GENE
_RARE_ I-GENE
including O
C I-GENE
/ I-GENE
EBP I-GENE
, O
PEA3 I-GENE
, O
AP2 I-GENE
, O
NF I-GENE
- I-GENE
Y I-GENE
, O
c I-GENE
- I-GENE
Myc I-GENE
, O
and O
Sp1 I-GENE
may O
have O
a O
major I-GENE
positive O
regulatory I-GENE
activity O
for O
expression O
of O
cyclin I-GENE
D2 I-GENE
. O

Effect O
of O
alcohol O
on O
minimal I-GENE
effective O
_RARE_ I-GENE
pressure O

In O
contrast O
, O
_RARE_ I-GENE
of O
a O
_RARE_ I-GENE
- I-GENE
impaired O
_RARE_ I-GENE
mutant I-GENE
( O
_RARE_ I-GENE
) O
was O
_RARE_ I-GENE
following O
the O
overexpression O
of O
either O
_RARE_ I-GENE
or O
beta I-GENE
- I-GENE
_RARE_ I-GENE
1 I-GENE
. O

The O
medium O
chains I-GENE
of O
these O
complexes I-GENE
, O
_RARE_ I-GENE
and O
_RARE_ I-GENE
, O
have O
been O
implicated O
in O
two O
types O
of O
interaction O
: O
assembly O
with O
the O
beta1 I-GENE
and O
beta2 I-GENE
chains I-GENE
of O
the O
corresponding O
complexes I-GENE
and O
recognition I-GENE
of O
tyrosine I-GENE
- I-GENE
based O
sorting I-GENE
signals O
. O

We O
have O
overexpressed O
, O
purified O
, O
characterized O
, O
and O
_RARE_ I-GENE
the O
BTB I-GENE
/ I-GENE
POZ I-GENE
domain I-GENE
from O
PLZF I-GENE
( O
PLZF I-GENE
- I-GENE
BTB I-GENE
/ I-GENE
POZ I-GENE
). O

_RARE_ I-GENE
shock I-GENE
stimulates O
_RARE_ I-GENE
translocation O
in O
_RARE_ I-GENE
adipocytes O
by O
a O
novel O
tyrosine I-GENE
kinase I-GENE
pathway O
. O

We O
also O
identified O
Sp1 I-GENE
, O
Sp3 I-GENE
, O
and O
_RARE_ I-GENE
- I-GENE
A I-GENE
/ I-GENE
_RARE_ I-GENE
- I-GENE
1 I-GENE
as O
the O
primary O
nuclear I-GENE
transcription I-GENE
factors I-GENE
binding I-GENE
to O
_RARE_ I-GENE
which O
mediate O
Tax I-GENE
responsiveness O
. O

Interestingly O
, O
segment O
_RARE_ I-GENE
differentially O
increases O
the O
copy O
number O
of O
genes I-GENE
encoded I-GENE
by O
segment O
W I-GENE
, O
suggesting O
that O
the O
unusual O
genomic O
organization O
of O
_RARE_ I-GENE
may O
be O
directly O
linked O
to O
the O
unique O
functions O
of O
this O
virus I-GENE
in O
its O
_RARE_ I-GENE
_RARE_ I-GENE
association O
with O
_RARE_ I-GENE
_RARE_ I-GENE
. O

Furthermore O
, O
deletion O
and O
mutation I-GENE
analyses O
of O
the O
_RARE_ I-GENE
- I-GENE
1 I-GENE
promoter I-GENE
performed O
with O
chloramphenicol I-GENE
acetyltransferase I-GENE
constructs I-GENE
revealed O
that O
Tax I-GENE
was O
trans O
activating I-GENE
the O
_RARE_ I-GENE
- I-GENE
1 I-GENE
promoter I-GENE
via O
two O
NF I-GENE
- I-GENE
kappaB I-GENE
sites I-GENE
present O
at O
bp O
- I-GENE
72 O
and O
- I-GENE
57 O
in O
the O
_RARE_ I-GENE
- I-GENE
1 I-GENE
gene I-GENE
promoter I-GENE
, O
with O
both O
of O
them O
being O
required O
for O
the O
Tax I-GENE
- I-GENE
induced O
expression O
of O
this O
adhesion I-GENE
molecule I-GENE
. O

The O
_RARE_ I-GENE
and O
NIH O
/ I-GENE
_RARE_ I-GENE
mouse I-GENE
_RARE_ I-GENE
proteins I-GENE
are O
97 O
. O
7 O
to O
98 O
. O
3 I-GENE
% O
and O
79 O
. O
8 O
% O
identical O
to O
the O
human I-GENE
protein I-GENE
, O
respectively O
. O

_RARE_ I-GENE
of O
DNA I-GENE
synthesis O
by O
the O
mutant I-GENE
holoenzyme I-GENE
containing O
_RARE_ I-GENE
- I-GENE
79 O
was O
unaffected O
on O
poly O
( O
_RARE_ I-GENE
) O
x O
_RARE_ I-GENE
( O
dT O
) O
but O
was O
dramatically O
reduced O
on O
a O
natural O
template O
with O
secondary O
structure O
. O

_RARE_ I-GENE
substitution O
mutations O
in O
the O
Zta I-GENE
activation O
domain I-GENE
which O
_RARE_ I-GENE
the O
ability O
of O
Zta I-GENE
to O
stimulate O
the O
D I-GENE
- I-GENE
A I-GENE
complex I-GENE
were O
examined O
. O

The O
_RARE_ I-GENE
and O
_RARE_ I-GENE
proteins I-GENE
share O
a O
homology I-GENE
domain I-GENE
with O
38 O
% O
identity O
over O
a O
length I-GENE
of O
65 O
amino O
acids O
, O
termed O
the O
_RARE_ I-GENE
domain I-GENE
, O
that O
is O
located O
at O
their O
respective O
C I-GENE
termini O
. O

It O
has O
been O
previously O
shown O
that O
genes I-GENE
transcribed O
by O
RNA I-GENE
polymerase I-GENE
II I-GENE
( O
RNAP I-GENE
II I-GENE
) O
are O
subject O
to O
position O
effect O
_RARE_ I-GENE
when O
located O
near O
yeast I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
, O
_RARE_ I-GENE
- I-GENE
delta I-GENE
reduces O
silencing O
of O
the O
telomere I-GENE
- I-GENE
located O
RNAP I-GENE
II I-GENE
- I-GENE
transcribed O
genes I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
. O

The O
amplitude O
of O
_RARE_ I-GENE
contractions O
at O
6 I-GENE
, O
12 O
, O
and O
24 O
hours O
showed O
no O
significant O
difference O
from O
that O
in O
the O
controls O
. O

In O
the O
predicted O
transmembrane I-GENE
domain I-GENE
, O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
are O
95 O
% O
identical O
to O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
. O

Recently O
, O
roles O
also O
have O
been O
suggested O
for O
the O
nuclear I-GENE
trans O
- I-GENE
factor I-GENE
GATA I-GENE
- I-GENE
1 I-GENE
in O
regulating O
progenitor I-GENE
cell O
proliferation O
. O

PET O
activation O
studies O
are O
performed O
widely O
to O
study O
human I-GENE
brain O
function O
. O

F I-GENE
- I-GENE
box I-GENE
proteins I-GENE
are O
receptors I-GENE
that O
recruit O
phosphorylated O
substrates O
to O
the O
_RARE_ I-GENE
ubiquitin I-GENE
- I-GENE
ligase I-GENE
complex I-GENE
. O

In O
the O
context O
of O
liver O
_RARE_ I-GENE
_RARE_ I-GENE
, O
our O
results O
suggest O
that O
an O
_RARE_ I-GENE
should O
not O
be O
performed O
in O
patients O
with O
cardiac O
failure O
, O
more O
than O
two O
_RARE_ I-GENE
, O
or O
an O
_RARE_ I-GENE
II I-GENE
score O
higher O
than O
30 O
. O

The O
SH3 I-GENE
domains I-GENE
of O
Grb2 I-GENE
bound O
in O
vitro O
to O
specific I-GENE
proline O
- I-GENE
rich O
motifs O
in O
the O
_RARE_ I-GENE
tail O
and O
functioned O
synergistically O
to O
direct O
the O
stable O
binding I-GENE
of O
Grb2 I-GENE
to O
_RARE_ I-GENE
in O
transfected O
_RARE_ I-GENE
cells O
. O

By O
far O
- I-GENE
Western O
analysis O
and O
_RARE_ I-GENE
studies O
, O
we O
demonstrate O
that O
_RARE_ I-GENE
interacts O
, O
via O
its O
zinc I-GENE
finger I-GENE
domain I-GENE
, O
with O
the O
_RARE_ I-GENE
largest O
subunit I-GENE
of O
RNA I-GENE
polymerase I-GENE
II I-GENE
( O
pol I-GENE
_RARE_ I-GENE
) O
but O
not O
with O
the O
_RARE_ I-GENE
form O
. O

Thus O
, O
_RARE_ I-GENE
_RARE_ I-GENE
in O
nuclear I-GENE
domains I-GENE
enriched O
in O
pre I-GENE
- I-GENE
mRNA I-GENE
_RARE_ I-GENE
factors I-GENE
, O
its O
RNA I-GENE
binding I-GENE
activity O
, O
and O
its O
direct O
_RARE_ I-GENE
interaction O
with O
the O
pol I-GENE
_RARE_ I-GENE
, O
a O
form O
of O
the O
RNA I-GENE
polymerase I-GENE
functionally O
associated I-GENE
with O
pre I-GENE
- I-GENE
mRNA I-GENE
processing O
, O
suggest O
a O
role O
for O
this O
member O
of O
the O
KRAB I-GENE
_RARE_ I-GENE
protein I-GENE
family I-GENE
in O
RNA I-GENE
processing O
. O

_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
12 O
_RARE_ I-GENE
cells O
expressed O
2 I-GENE
- I-GENE
fold O
elevated O
protein I-GENE
levels O
of O
the O
lysosomal I-GENE
cysteine I-GENE
protease I-GENE
_RARE_ I-GENE
B I-GENE
but O
did O
not O
up O
- I-GENE
regulate O
_RARE_ I-GENE
B I-GENE
mRNA I-GENE
expression O
. O

The O
cellular O
rate O
of O
anticoagulant I-GENE
_RARE_ I-GENE
sulfate I-GENE
proteoglycan I-GENE
( O
_RARE_ I-GENE
) O
generation O
is O
determined O
by O
the O
level O
of O
a O
_RARE_ I-GENE
limiting O
_RARE_ I-GENE
activity O
, O
_RARE_ I-GENE
conversion O
activity O
, O
which O
is O
predominantly O
composed O
of O
the O
long O
sought O
_RARE_ I-GENE
sulfate I-GENE
D I-GENE
- I-GENE
_RARE_ I-GENE
3 I-GENE
- I-GENE
O O
- I-GENE
_RARE_ I-GENE
( O
3 I-GENE
- I-GENE
_RARE_ I-GENE
) O
( O
_RARE_ I-GENE
, O
N I-GENE
. O

Interestingly O
, O
EGF I-GENE
, O
but O
not O
insulin I-GENE
, O
stimulated O
tyrosine I-GENE
phosphorylation O
of O
c I-GENE
- I-GENE
cbl I-GENE
and O
its O
association O
with O
Crk I-GENE
- I-GENE
II I-GENE
. O

An O
end O
to O
the O
_RARE_ I-GENE
. O

We O
previously O
showed O
that O
the O
N I-GENE
- I-GENE
terminal I-GENE
portion O
common O
to O
various O
chimeric I-GENE
_RARE_ I-GENE
products I-GENE
, O
as O
well O
as O
to O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
, O
localizes O
in O
the O
nuclei O
, O
and O
therefore O
suggested O
that O
it O
might O
play O
an O
important O
role O
in O
_RARE_ I-GENE
. O

Our O
results O
suggest O
that O
the O
pattern O
of O
blood O
supply O
is O
relevant O
to O
the O
structural O
_RARE_ I-GENE
of O
mature O
_RARE_ I-GENE
bone O
around O
the O
implant O
. O

Induction O
of O
_RARE_ I-GENE
mRNA I-GENE
accumulation O
in O
salt O
- I-GENE
treated O
seedlings O
involves O
an O
immediate I-GENE
early I-GENE
transcriptional O
response O
regulated O
by O
ABA I-GENE
signalling O
that O
is O
not O
inhibited O
by O
cycloheximide I-GENE
, O
but O
abolished O
by O
the O
deficiency O
of O
ABA I-GENE
biosynthesis O
in O
the O
_RARE_ I-GENE
Arabidopsis I-GENE
mutant I-GENE
. O

It O
thus O
appears O
that O
MAPK I-GENE
functions O
in O
meiotic I-GENE
maturation O
by O
preventing O
_RARE_ I-GENE
eggs O
from O
_RARE_ I-GENE
into O
_RARE_ I-GENE
development O
. O

( O
ii O
) O
An O
AF I-GENE
G I-GENE
- I-GENE
CSF I-GENE
level O
> O
2000 O
pg O
/ I-GENE
ml O
is O
a O
strong O
positive O
predictor O
of O
_RARE_ I-GENE
. O

A I-GENE
positive O
correlation O
between O
serum I-GENE
myoglobin I-GENE
and O
CA I-GENE
III I-GENE
concentrations O
( O
rs O
= O
0 O
. O
_RARE_ I-GENE
, O
P I-GENE
< O
0 O
. O
001 O
) O
was O
observed O
in O
_RARE_ I-GENE
patients O
with O
chronic O
renal O
failure O
. O

Furthermore O
, O
the O
over O
- I-GENE
replication O
phenotype O
produced O
by O
this O
mutant I-GENE
_RARE_ I-GENE
is O
resistant O
to O
increased O
mitotic O
cyclin I-GENE
/ I-GENE
CDK I-GENE
activity O
, O
a O
known O
inhibitor I-GENE
of O
over O
- I-GENE
replication O
. O

_RARE_ I-GENE
is O
_RARE_ I-GENE
, O
associated I-GENE
with O
nuclear I-GENE
pore I-GENE
complexes I-GENE
, O
and O
structurally O
related I-GENE
to O
the O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
family I-GENE
of O
pore I-GENE
proteins I-GENE
. O

The O
_RARE_ I-GENE
domain I-GENE
is O
similar O
at O
the O
amino O
acid I-GENE
level O
to O
the O
Escherichia I-GENE
coli I-GENE
_RARE_ I-GENE
gene I-GENE
product I-GENE
, O
while O
_RARE_ I-GENE
is O
similar O
to O
the O
E I-GENE
. O
coli I-GENE
_RARE_ I-GENE
product I-GENE
, O
with O
both O
E I-GENE
. O
coli I-GENE
products I-GENE
encoded I-GENE
by O
different O
_RARE_ I-GENE
. O

_RARE_ I-GENE
in O
each O
of O
these O
regions O
_RARE_ I-GENE
membrane I-GENE
localization O
of O
_RARE_ I-GENE
and O
membrane I-GENE
_RARE_ I-GENE
, O
suggesting O
that O
they O
function O
_RARE_ I-GENE
. O

However O
, O
_RARE_ I-GENE
the O
kinase I-GENE
catalytic O
domain I-GENE
and O
double O
leucine I-GENE
/ I-GENE
_RARE_ I-GENE
zippers I-GENE
, O
there O
was O
no O
significant O
homology I-GENE
with O
known O
proteins I-GENE
. O

RNA I-GENE
polymerase I-GENE
II I-GENE
inhibition O
increased O
the O
binding I-GENE
of O
_RARE_ I-GENE
( O
_RARE_ I-GENE
activity O
) O
and O
poly O
( O
U O
)- I-GENE
_RARE_ I-GENE
by O
cytoplasmic I-GENE
hnRNP I-GENE
A1 I-GENE
, O
while O
nuclear I-GENE
hnRNP I-GENE
A1 I-GENE
binding I-GENE
was O
unaffected O
. O

_RARE_ I-GENE
of O
_RARE_ I-GENE
response O
element I-GENE
binding I-GENE
by O
heterogeneous I-GENE
nuclear I-GENE
ribonucleoprotein I-GENE
A1 I-GENE
in O
human I-GENE
T I-GENE
lymphocytes O
. O

Histological O
_RARE_ I-GENE
of O
one O
biopsy O
of O
each O
patient O
( O
formalin O
- I-GENE
fixed O
and O
_RARE_ I-GENE
- I-GENE
embedded O
) O
were O
stained O
with O
a O
_RARE_ I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
), O
the O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
), O
and O
an O
immunohistochemical O
method O
( O
_RARE_ I-GENE
) O
using O
purified O
_RARE_ I-GENE
H I-GENE
. O
pylori I-GENE
antiserum O
( O
_RARE_ I-GENE
_RARE_ I-GENE
). O

Their O
biosynthesis O
_RARE_ I-GENE
via O
linear O
precursors I-GENE
that O
become O
branched I-GENE
by O
beta1 I-GENE
, O
6 I-GENE
- I-GENE
GlcNAc I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
, O
GlcNAc I-GENE
to O
Gal I-GENE
). O

These O
findings O
indicate O
that O
the O
t I-GENE
( O
4 I-GENE
; O
14 O
)( I-GENE
p16 I-GENE
. O
3 I-GENE
; O
_RARE_ I-GENE
) O
represents O
a O
novel O
, O
recurrent O
chromosomal I-GENE
translocation O
in O
_RARE_ I-GENE
, O
and O
suggest O
that O
the O
_RARE_ I-GENE
gene I-GENE
may O
be O
the O
target O
of O
this O
abnormality O
and O
thus O
contribute O
to O
tumorigenesis O
in O
_RARE_ I-GENE
. O

In O
addition O
, O
mutation I-GENE
of O
the O
Sp1 I-GENE
site I-GENE
also O
significantly O
reduced O
promoter I-GENE
activity O
. O

Amino O
acid I-GENE
residues O
of O
beta I-GENE
1 I-GENE
', O
alpha I-GENE
A I-GENE
', O
alpha I-GENE
B I-GENE
', O
and O
the O
loop I-GENE
containing O
_RARE_ I-GENE
of O
the O
RNase I-GENE
H I-GENE
domain I-GENE
interact O
with O
the O
primer O
strand O
of O
the O
_RARE_ I-GENE
. O

Moreover O
, O
in O
one O
patient O
with O
a O
sarcoma I-GENE
who O
underwent O
a O
leg O
- I-GENE
_RARE_ I-GENE
procedure O
, O
no O
_RARE_ I-GENE
nerve I-GENE
enlargement O
was O
seen O
postoperatively O
. O

The O
full I-GENE
length I-GENE
cDNA I-GENE
sequence I-GENE
of O
a O
Type O
I I-GENE
transforming I-GENE
growth I-GENE
factor I-GENE
- I-GENE
beta I-GENE
( O
TGF I-GENE
- I-GENE
beta I-GENE
) O
receptor I-GENE
has O
been O
isolated O
from O
the O
_RARE_ I-GENE
_RARE_ I-GENE
nematode O
_RARE_ I-GENE
_RARE_ I-GENE
. O

This O
sequence I-GENE
possessed O
homology I-GENE
with O
a O
methylation O
- I-GENE
sensitive O
promoter I-GENE
element I-GENE
, O
_RARE_ I-GENE
, O
present O
in O
the O
LTR I-GENE
of O
mouse I-GENE
_RARE_ I-GENE
A I-GENE
- I-GENE
particles O
. O

_RARE_ I-GENE
_RARE_ I-GENE
for O
high O
- I-GENE
level O
expression O
of O
human I-GENE
erythropoietin I-GENE
( O
EPO I-GENE
) O
in O
mammalian I-GENE
cells O
. O

_RARE_ I-GENE
rise O
in O
urinary O
albumin I-GENE
levels O
after O
treatment O
of O
essential O
hypertension O
. O

20 O
% O
of O
total O
_RARE_ I-GENE
transcripts I-GENE
in O
human I-GENE
subcutaneous O
adipocytes O
. O

Taken O
together O
, O
our O
data O
suggest O
that O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
is O
anchored I-GENE
within O
the O
_RARE_ I-GENE
through O
its O
coiled O
- I-GENE
coil O
region O
and O
adjacent O
sequences I-GENE
. O

In O
a O
group O
of O
13 O
patients O
with O
_RARE_ I-GENE
_RARE_ I-GENE
of O
the O
lower O
_RARE_ I-GENE
the O
plasma I-GENE
levels O
of O
_RARE_ I-GENE
( O
TM I-GENE
), O
_RARE_ I-GENE
( O
beta I-GENE
- I-GENE
TG I-GENE
), O
D I-GENE
- I-GENE
dimer O
( O
_RARE_ I-GENE
) O
and O
plasminogen I-GENE
activator I-GENE
- I-GENE
inhibitor I-GENE
( O
_RARE_ I-GENE
- I-GENE
1 I-GENE
) O
were O
measured O
, O
and O
compared O
to O
the O
values O
obtained O
from O
10 O
healthy O
volunteers O
. O

These O
residues O
, O
_RARE_ I-GENE
at O
the O
extracellular I-GENE
end O
of O
transmembrane I-GENE
helix I-GENE
3 I-GENE
, O
and O
_RARE_ I-GENE
at O
the O
COOH O
- I-GENE
terminal I-GENE
portion O
of O
extracellular I-GENE
loop I-GENE
2 I-GENE
, O
are O
replaced O
by O
Leu I-GENE
and O
Ile O
in O
the O
PTH I-GENE
- I-GENE
1 I-GENE
receptor I-GENE
, O
respectively O
. O

We O
have O
now O
shown O
that O
in O
vivo O
phosphorylation O
of O
14 O
- I-GENE
3 I-GENE
- I-GENE
3 I-GENE
zeta I-GENE
at O
the O
_RARE_ I-GENE
site I-GENE
( O
Thr I-GENE
- I-GENE
233 I-GENE
) O
negatively O
regulates O
its O
binding I-GENE
to O
c I-GENE
- I-GENE
Raf I-GENE
, O
and O
may O
be O
important O
in O
Raf I-GENE
- I-GENE
mediated O
signal I-GENE
transduction O
. O

_RARE_ I-GENE
mast I-GENE
cell O
protease I-GENE
9 O
, O
a O
novel O
member O
of O
the O
chromosome O
14 O
family I-GENE
of O
serine I-GENE
proteases I-GENE
that O
is O
selectively O
expressed O
in O
uterine O
mast I-GENE
cells O
. O

A I-GENE
DNase I-GENE
I I-GENE
- I-GENE
hypersensitive I-GENE
site I-GENE
has O
also O
been O
mapped O
in O
the O
258 O
- I-GENE
base O
pair O
enhancer I-GENE
region O
. O

[ O
_RARE_ I-GENE
vascular I-GENE
resistance O
( O
_RARE_ I-GENE
) O
during O
10 O
% O
O2 O
- I-GENE
_RARE_ I-GENE
during O
21 O
% O
O2 O
/ I-GENE
_RARE_ I-GENE
during O
21 O
% O
O2 O
] O
x O
100 O
was O
termed O
as O
hypoxic O
pulmonary O
_RARE_ I-GENE
( O
HPV I-GENE
). O

Together O
, O
our O
results O
show O
that O
_RARE_ I-GENE
is O
controlled O
by O
an O
_RARE_ I-GENE
of O
discrete O
enhancer I-GENE
elements O
that O
are O
activated I-GENE
_RARE_ I-GENE
by O
differential O
genetic O
inputs O
, O
as O
well O
as O
by O
closely O
linked O
activator I-GENE
and O
repressor I-GENE
binding I-GENE
sites I-GENE
within O
an O
early I-GENE
- I-GENE
acting O
enhancer I-GENE
, O
which O
_RARE_ I-GENE
_RARE_ I-GENE
activity O
to O
specific I-GENE
areas O
within O
the O
_RARE_ I-GENE
expression O
domain I-GENE
. O

An O
unusual O
cysteine I-GENE
triplet O
conserved O
in O
the O
sequences I-GENE
of O
TB I-GENE
domains I-GENE
is O
localized O
to O
the O
hydrophobic O
core I-GENE
, O
at O
the O
C I-GENE
- I-GENE
terminus O
of O
an O
alpha I-GENE
- I-GENE
helix I-GENE
. O

The O
_RARE_ I-GENE
protein I-GENE
regulates O
site I-GENE
- I-GENE
specific I-GENE
DNA I-GENE
inversion O
catalyzed O
by O
a O
family I-GENE
of O
DNA I-GENE
_RARE_ I-GENE
when O
bound O
to O
a O
cis O
- I-GENE
acting O
_RARE_ I-GENE
enhancer I-GENE
. O

Protein I-GENE
phosphatases I-GENE
play O
a O
critical O
role O
in O
the O
regulation O
of O
the O
eukaryotic I-GENE
cell O
cycle O
and O
signal I-GENE
transduction O
. O

The O
cell O
cycle O
- I-GENE
regulated O
transcription I-GENE
factor I-GENE
E2F I-GENE
is O
also O
known O
to O
_RARE_ I-GENE
DNA I-GENE
upon O
binding I-GENE
. O

Our O
study O
reveals O
that O
the O
_RARE_ I-GENE
structure O
of O
the O
FSH I-GENE
receptor I-GENE
gene I-GENE
generates O
motifs O
that O
allows O
coupling O
to O
different O
effectors I-GENE
. O

Transcriptional O
regulation O
of O
_RARE_ I-GENE
and O
_RARE_ I-GENE
in O
Saccharomyces I-GENE
cerevisiae I-GENE
. O

These O
studies O
serve O
as O
the O
basis O
for O
the O
further O
characterization O
of O
the O
regulatory I-GENE
mechanism O
of O
aromatase I-GENE
expression O
in O
human I-GENE
breast O
cancer O
and O
_RARE_ I-GENE
. O

Xenopus I-GENE
Ran I-GENE
- I-GENE
binding I-GENE
protein I-GENE
1 I-GENE
: O
molecular O
interactions O
and O
effects O
on O
nuclear I-GENE
assembly O
in O
Xenopus I-GENE
egg I-GENE
extracts O
. O

_RARE_ I-GENE
improved O
with O
a O
combination O
of O
_RARE_ I-GENE
and O
the O
_RARE_ I-GENE
inhibitor I-GENE
_RARE_ I-GENE
. O

METHODS O
: O
Total O
muscle O
_RARE_ I-GENE
was O
induced O
under O
general O
anesthesia O
in O
a O
group O
of O
obese O
persons O
( O
n O
= O
9 O
; O
body O
mass O
index O
, O
32 O
+/- O
3 I-GENE
kg O
_RARE_ I-GENE
2 I-GENE
]) I-GENE
and O
in O
a O
group O
of O
_RARE_ I-GENE
persons O
( O
n O
= O
9 O
; O
body O
_RARE_ I-GENE
index O
, O
21 O
+/- O
2 I-GENE
kg O
_RARE_ I-GENE
2 I-GENE
_RARE_ I-GENE

PKA I-GENE
phosphorylated O
WT1 I-GENE
at O
Ser O
- I-GENE
_RARE_ I-GENE
and O
Ser O
- I-GENE
_RARE_ I-GENE
in O
vitro O
, O
as O
well O
as O
at O
additional O
sites I-GENE
, O
and O
this O
phosphorylation O
abolished O
the O
DNA I-GENE
- I-GENE
binding I-GENE
activity O
of O
WT1 I-GENE
in O
vitro O
. O

Our O
findings O
provide O
the O
first O
evidence O
that O
the O
function O
of O
WT1 I-GENE
can O
be O
modulated O
by O
its O
phosphorylation O
in O
vivo O
. O

Re O
: O
" O
_RARE_ I-GENE
the O
direction O
of O
_RARE_ I-GENE
in O
cross O
- I-GENE
sectional O
studies O
". O

A I-GENE
second O
aim O
was O
to O
determine O
whether O
the O
decrease O
in O
muscle O
- I-GENE
tendon O
unit I-GENE
rest O
length I-GENE
produced O
by O
prolonged O
_RARE_ I-GENE
in O
a O
shortened O
position O
is O
mediated O
primarily O
by O
_RARE_ I-GENE
of O
the O
muscle O
or O
tendon O
. O

The O
presence O
of O
an O
additional O
sequence I-GENE
of O
nucleotides O
_RARE_ I-GENE
- I-GENE
165 O
from O
the O
3 I-GENE
' O
end O
of O
_RARE_ I-GENE
enhanced O
template O
recognition I-GENE
by O
_RARE_ I-GENE
in O
vitro O
and O
accumulation O
of O
_RARE_ I-GENE
in O
vivo O
to O
wild I-GENE
- I-GENE
type I-GENE
levels O
. O

We O
_RARE_ I-GENE
that O
the O
primary O
role O
of O
_RARE_ I-GENE
in O
controlling O
polarity O
is O
to O
cause O
anterior O
compartment O
cells O
to O
reverse I-GENE
their O
interpretation O
of O
an O
underlying O
_RARE_ I-GENE
_RARE_ I-GENE
. O

Restriction O
enzyme I-GENE
mapping O
, O
_RARE_ I-GENE
, O
and O
DNA I-GENE
sequencing O
analysis O
of O
recombinant I-GENE
phage I-GENE
lambda I-GENE
and O
P1 I-GENE
clones O
revealed O
that O
exons O
encoding O
the O
1 I-GENE
. O
9 O
- I-GENE
kb O
mouse I-GENE
_RARE_ I-GENE
mRNA I-GENE
are O
_RARE_ I-GENE
over O
> O
150 O
kb O
genomic O
DNA I-GENE
. O

Transfection O
analyses O
indicated O
that O
the O
expression O
of O
_RARE_ I-GENE
is O
controlled O
by O
a O
short O
( O
70 I-GENE
- I-GENE
bp O
) O
positive O
regulatory I-GENE
sequence I-GENE
and O
several O
upstream O
repressive O
elements O
. O

The O
results O
of O
this O
study O
suggest O
that O
NF I-GENE
- I-GENE
kappaB I-GENE
activity O
may O
be O
regulated O
by O
its O
interaction O
with O
the O
cell O
cycle O
regulatory I-GENE
protein I-GENE
, O
E2F I-GENE
- I-GENE
1 I-GENE
. O

The O
lysozyme I-GENE
_RARE_ I-GENE
site I-GENE
is O
immediately O
5 I-GENE
' O
to O
a O
PU I-GENE
. O

_RARE_ I-GENE
( O
OC I-GENE
) O
is O
a O
matrix I-GENE
calcium O
- I-GENE
binding I-GENE
protein I-GENE
expressed O
in O
_RARE_ I-GENE
and O
_RARE_ I-GENE
undergoing O
_RARE_ I-GENE
. O

In O
this O
study O
, O
we O
examine O
the O
effects O
of O
_RARE_ I-GENE
expression O
on O
OC I-GENE
promoter I-GENE
activation O
( O
luciferase I-GENE
reporter I-GENE
) O
by O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
in O
_RARE_ I-GENE
- I-GENE
E1 I-GENE
_RARE_ I-GENE
. O

Thus O
, O
unlike O
other O
proteins I-GENE
reported O
to O
inhibit O
SRF I-GENE
activity O
, O
the O
repressor I-GENE
activity O
associated I-GENE
with O
the O
GC I-GENE
- I-GENE
rich O
element I-GENE
does O
not O
appear O
to O
function O
through O
direct O
inhibition O
of O
SRF I-GENE
binding I-GENE
. O

However O
, O
one O
CAK I-GENE
- I-GENE
phosphorylated O
phosphopeptide I-GENE
_RARE_ I-GENE
with O
a O
Cdc2 I-GENE
- I-GENE
phosphorylated O
phosphopeptide I-GENE
previously O
shown O
to O
be O
mitosis O
- I-GENE
specific I-GENE
, O
suggesting O
that O
, O
in O
vitro O
, O
CAK I-GENE
is O
able O
to O
phosphorylate O
at O
least O
one O
site I-GENE
that O
is O
also O
phosphorylated O
in O
vivo O
. O

The O
_RARE_ I-GENE
can O
_RARE_ I-GENE
. O

The O
_RARE_ I-GENE
- I-GENE
1 I-GENE
alpha I-GENE
structural O
gene I-GENE
is O
composed O
of O
15 O
exons O
. O

However O
, O
when O
a O
second O
, O
upstream O
_RARE_ I-GENE
- I-GENE
like I-GENE
sequence I-GENE
was O
evaluated O
by O
EMSA O
, O
a O
DNA I-GENE
binding I-GENE
pattern O
distinct O
from O
that O
seen O
following O
exposure O
to O
IFN I-GENE
- I-GENE
gamma I-GENE
alone O
was O
observed O
after O
prolonged O
stimulation O
with O
both O
IFN I-GENE
- I-GENE
alpha I-GENE
and O
IFN I-GENE
- I-GENE
gamma I-GENE
. O

In O
Arabidopsis I-GENE
, O
the O
induction O
of O
a O
_RARE_ I-GENE
- I-GENE
responsive I-GENE
gene I-GENE
, O
_RARE_ I-GENE
, O
is O
mediated O
by O
_RARE_ I-GENE
acid I-GENE
( O
ABA I-GENE
) O
and O
requires O
protein I-GENE
biosynthesis O
for O
ABA I-GENE
- I-GENE
dependent I-GENE
gene I-GENE
expression O
. O

A I-GENE
cDNA I-GENE
encoding O
a O
_RARE_ I-GENE
- I-GENE
related I-GENE
DNA I-GENE
binding I-GENE
protein I-GENE
was O
isolated O
by O
DNA I-GENE
- I-GENE
ligand O
binding I-GENE
screening O
, O
using O
the O
67 O
- I-GENE
bp O
region O
as O
a O
probe O
, O
and O
designated O
_RARE_ I-GENE
. O

Human I-GENE
_RARE_ I-GENE
is O
homologous O
to O
the O
Drosophila I-GENE
protein I-GENE
kinase I-GENE
_RARE_ I-GENE
, O
which O
has O
been O
implicated O
in O
the O
regulation O
of O
sex I-GENE
differentiation O
, O
_RARE_ I-GENE
and O
_RARE_ I-GENE
. O

Thus O
, O
the O
synergistic O
effects O
of O
HNF I-GENE
- I-GENE
1beta I-GENE
and O
the O
GR I-GENE
on O
dexamethasone O
- I-GENE
stimulated O
promoter I-GENE
activity O
require O
that O
they O
are O
bound O
to O
the O
HNF I-GENE
- I-GENE
1 I-GENE
site I-GENE
and O
the O
GRE I-GENE
, O
respectively O
, O
and O
may O
involve O
protein I-GENE
- I-GENE
protein I-GENE
interactions O
between O
the O
transcription I-GENE
factors I-GENE
, O
or O
between O
them O
and O
the O
basal O
transcription I-GENE
machinery O
or O
a O
steroid I-GENE
receptor I-GENE
coactivator I-GENE
. O

Mutational O
analysis O
shows O
that O
both O
an O
AP I-GENE
- I-GENE
1 I-GENE
like I-GENE
sequence I-GENE
(- O
_RARE_ I-GENE
/- O
285 O
, O
_RARE_ I-GENE
) O
and O
an O
A I-GENE
/ I-GENE
T I-GENE
- I-GENE
rich O
myocyte I-GENE
enhancer I-GENE
factor I-GENE
( O
MEF I-GENE
)- I-GENE
2 I-GENE
like I-GENE
sequence I-GENE
(- O
_RARE_ I-GENE
/- O
_RARE_ I-GENE
, O
_RARE_ I-GENE
) O
in O
the O
33 O
- I-GENE
bp O
region O
are O
necessary O
for O
the O
_RARE_ I-GENE
- I-GENE
1 I-GENE
effect O
. O

Unlike O
most O
other O
members O
of O
the O
Bcl I-GENE
- I-GENE
2 I-GENE
family I-GENE
, O
_RARE_ I-GENE
( O
Bcl I-GENE
- I-GENE
_RARE_ I-GENE
/ I-GENE
Bcl I-GENE
- I-GENE
2 I-GENE
associated I-GENE
death O
promoter I-GENE
), O
a O
death O
enhancer I-GENE
, O
has O
no O
C I-GENE
- I-GENE
terminal I-GENE
transmembrane I-GENE
domain I-GENE
for O
targeting O
to O
the O
outer I-GENE
mitochondrial I-GENE
membrane I-GENE
and O
nuclear I-GENE
envelope I-GENE
. O

_RARE_ I-GENE
shift O
and O
cotransfection O
assays O
demonstrated O
that O
_RARE_ I-GENE
, O
but O
not O
_RARE_ I-GENE
, O
bound O
to O
its O
cognate I-GENE
site I-GENE
and O
transactivated O
_RARE_ I-GENE
gene I-GENE
expression O
. O

An O
open O
reading O
frame O
of O
_RARE_ I-GENE
bp O
encoding O
a O
_RARE_ I-GENE
amino O
acid I-GENE
protein I-GENE
was O
identified O
. O

One O
of O
these O
, O
an O
_RARE_ I-GENE
motif I-GENE
, O
has O
been O
shown O
to O
be O
a O
negative O
regulator I-GENE
in O
non O
- I-GENE
seed I-GENE
tissues O
and O
has O
a O
similarity O
to O
the O
barley I-GENE
_RARE_ I-GENE
responsive I-GENE
element I-GENE
recognized O
by O
_RARE_ I-GENE
- I-GENE
like I-GENE
DNA I-GENE
binding I-GENE
proteins I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
is O
an O
R I-GENE
. O
_RARE_ I-GENE
mutant I-GENE
induced O
by O
a O
single O
_RARE_ I-GENE
insertion O
in O
the O
promoter I-GENE
region O
of O
the O
_RARE_ I-GENE
gene I-GENE
cluster I-GENE
. O

Expression O
of O
_RARE_ I-GENE
biosynthetic O
genes I-GENE
( O
_RARE_ I-GENE
) O
and O
production O
of O
_RARE_ I-GENE
terminal I-GENE
oxidase I-GENE
_RARE_ I-GENE
in O
Rhizobium I-GENE
_RARE_ I-GENE
. O

We O
have O
cloned O
and O
sequenced O
a O
region O
encoding O
a O
lipase I-GENE
operon I-GENE
and O
a O
putative O
, O
previously O
uncharacterized O
_RARE_ I-GENE
of O
Vibrio I-GENE
cholerae I-GENE
_RARE_ I-GENE
. O

Furthermore O
, O
the O
amount O
of O
tRNA I-GENE
( O
_RARE_ I-GENE
) O
that O
was O
placed O
onto O
viral I-GENE
RNA I-GENE
in O
mutated O
viruses O
was O
significantly O
less O
than O
that O
placed O
in O
the O
wild I-GENE
- I-GENE
type I-GENE
virus I-GENE
. O

This O
protein I-GENE
is O
present O
in O
both O
HeLa O
nuclear I-GENE
extracts O
and O
_RARE_ I-GENE
extracts O
but O
absent O
from O
SR I-GENE
protein I-GENE
preparations O
, O
suggesting O
that O
it O
is O
not O
a O
classical O
SR I-GENE
protein I-GENE
. O

Differential O
regulation O
of O
the O
pre I-GENE
- I-GENE
C I-GENE
and O
_RARE_ I-GENE
promoters I-GENE
of O
human I-GENE
hepatitis I-GENE
B I-GENE
virus I-GENE
by O
members O
of O
the O
nuclear I-GENE
receptor I-GENE
superfamily I-GENE
. O

_RARE_ I-GENE
. O

_RARE_ I-GENE
containing O
IE1 I-GENE
peptides I-GENE
dramatically O
activated I-GENE
transcription I-GENE
of O
the O
basal O
promoter I-GENE
only O
when O
lac I-GENE
operator I-GENE
sequences I-GENE
were O
present O
. O

The O
results O
of O
_RARE_ I-GENE
assays O
performed O
with O
mutant I-GENE
_RARE_ I-GENE
containing O
a O
deletion O
in O
its O
RNA I-GENE
- I-GENE
binding I-GENE
domain I-GENE
suggests O
that O
the O
essential O
role O
for O
_RARE_ I-GENE
in O
replication O
is O
linked O
to O
the O
protein I-GENE
' O
s O
ability O
to O
bind O
the O
mRNA I-GENE
template O
for O
minus O
- I-GENE
strand O
synthesis O
. O

We O
previously O
described O
two O
alanine I-GENE
cluster I-GENE
mutations O
, O
_RARE_ I-GENE
to O
A I-GENE
( O
_RARE_ I-GENE
)- I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
, O
which O
selectively O
inactivated O
the O
_RARE_ I-GENE
component O
. O

Transfection O
of O
HepG2 O
and O
_RARE_ I-GENE
- I-GENE
N I-GENE
- I-GENE
MC O
cells O
with O
constructs I-GENE
deleted O
of O
additional O
5 I-GENE
'- O
flanking O
fragments I-GENE
permitted O
the O
definition O
of O
a O
minimal I-GENE
200 O
bp O
promoter I-GENE
fragment I-GENE
containing O
the O
_RARE_ I-GENE
- I-GENE
TATA I-GENE
box I-GENE
and O
two O
putative O
SP1 I-GENE
- I-GENE
binding I-GENE
sites I-GENE
. O

Both O
inserts O
are O
larger O
than O
their O
homologues O
in O
eIF I-GENE
- I-GENE
2alpha I-GENE
kinases I-GENE
. O

Three O
_RARE_ I-GENE
electrodes O
were O
inserted O
into O
the O
left O
and O
right O
lateral O
_RARE_ I-GENE
tract O
( O
_RARE_ I-GENE
) O
and O
medial O
_RARE_ I-GENE
tract O
( O
_RARE_ I-GENE
) O
of O
the O
C1 I-GENE
segment O
, O
to O
determine O
the O
pathway O
of O
_RARE_ I-GENE
. O

_RARE_ I-GENE
of O
adhesion I-GENE
- I-GENE
_RARE_ I-GENE
monoclonal I-GENE
antibodies I-GENE
map O
within O
a O
predicted O
alpha I-GENE
- I-GENE
helical O
domain I-GENE
of O
the O
integrin I-GENE
beta I-GENE
1 I-GENE
subunit I-GENE
. O

_RARE_ I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
may O
participate O
in O
a O
more O
general O
transcriptional O
mechanism O
that O
causes O
modulated O
gene I-GENE
repression O
, O
whereas O
the O
inclusion O
of O
_RARE_ I-GENE
protein I-GENE
in O
the O
complex I-GENE
at O
_RARE_ I-GENE
leads O
to O
stable O
silencing O
. O

Furthermore O
, O
both O
_RARE_ I-GENE
proteins I-GENE
function O
in O
a O
defined O
_RARE_ I-GENE
system O
reconstituted O
with O
purified O
proteins I-GENE
, O
indicating O
direct O
involvement O
of O
_RARE_ I-GENE
proteins I-GENE
in O
the O
DNA I-GENE
repair I-GENE
reaction O
via O
interaction O
with O
_RARE_ I-GENE
. O

The O
yeast I-GENE
silent I-GENE
information O
regulator I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
plasmids O
. O

These O
results O
_RARE_ I-GENE
a O
precursor I-GENE
- I-GENE
specific I-GENE
base O
- I-GENE
paired I-GENE
structure O
involving O
sequences I-GENE
on O
both O
sides O
of O
the O
mature O
cleavage O
site I-GENE
in O
the O
3 I-GENE
' O
processing O
of O
human I-GENE
U2 I-GENE
RNA I-GENE
. O

_RARE_ I-GENE
analyses O
in O
a O
temperature O
- I-GENE
sensitive O
_RARE_ I-GENE
- I-GENE
1 I-GENE
mutant I-GENE
and O
a O
_RARE_ I-GENE
- I-GENE
depleted O
strain O
reveal O
a O
decrease O
in O
the O
number O
of O
_RARE_ I-GENE
ribosomal I-GENE
subunits I-GENE
. O

Sequence O
analysis O
identified O
some O
of O
these O
cDNA I-GENE
clones O
as O
_RARE_ I-GENE
- I-GENE
1 I-GENE
, O
a O
sequence I-GENE
encoding O
a O
small I-GENE
, O
9 O
- I-GENE
kDa I-GENE
human I-GENE
homolog I-GENE
of O
the O
outer I-GENE
- I-GENE
arm O
dynein I-GENE
light I-GENE
- I-GENE
chain I-GENE
protein I-GENE
. O

_RARE_ I-GENE
, O
in O
HeLa O
and O
293 O
cells O
, O
endogenous I-GENE
and O
transfected O
I I-GENE
kappaB I-GENE
alpha I-GENE
_RARE_ I-GENE
with O
Myc I-GENE
- I-GENE
tagged O
or O
endogenous I-GENE
_RARE_ I-GENE
- I-GENE
1 I-GENE
. O

The O
mouse I-GENE
M I-GENE
- I-GENE
lysozyme I-GENE
downstream O
enhancer I-GENE
has O
been O
previously O
characterized O
on O
several O
levels O
of O
gene I-GENE
regulation O
. O

Identification O
of O
dynein I-GENE
heavy I-GENE
chain I-GENE
genes I-GENE
expressed O
in O
human I-GENE
and O
mouse I-GENE
testis I-GENE
: O
chromosomal I-GENE
localization O
of O
an O
_RARE_ I-GENE
dynein I-GENE
gene I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
contains O
_RARE_ I-GENE
_RARE_ I-GENE
; O
processing O
_RARE_ I-GENE
them O
down O
to O
_RARE_ I-GENE
_RARE_ I-GENE
and O
hydrogen O
_RARE_ I-GENE
. O

The O
proposed O
mechanism O
of O
effect O
states O
that O
mono O
( O
2 I-GENE
- I-GENE
_RARE_ I-GENE
) O
_RARE_ I-GENE
( O
_RARE_ I-GENE
), O
the O
primary O
hydrolysis O
product I-GENE
of O
_RARE_ I-GENE
, O
_RARE_ I-GENE
the O
inducing O
prostaglandins O
( O
_RARE_ I-GENE
) O
_RARE_ I-GENE
( O
2 I-GENE
), O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
in O
the O
lungs O
, O
thereby O
increasing O
the O
risk O
of O
inducing O
inflammation O
in O
the O
_RARE_ I-GENE
, O
which O
is O
a O
characteristic O
of O
asthma O
. O

We O
found O
14 O
protein I-GENE
binding I-GENE
sites I-GENE
that O
were O
occupied O
in O
vivo O
. O

_RARE_ I-GENE
protection O
of O
E2F I-GENE
recognition I-GENE
sequences I-GENE
in O
the O
human I-GENE
thymidine I-GENE
kinase I-GENE
promoter I-GENE
during O
cell O
cycle O
progression O
. O

Comparison O
of O
genomic O
sequence I-GENE
shows O
that O
the O
_RARE_ I-GENE
locus I-GENE
has O
been O
duplicated O
, O
and O
that O
it O
contains O
proximal I-GENE
and O
distal O
transcription I-GENE
units O
. O

_RARE_ I-GENE
decreased O
the O
levels O
of O
T4 I-GENE
and O
T3 O
6 I-GENE
h O
and O
72 O
h O
in O
group O
C I-GENE
, O
in O
group O
A I-GENE
at O
72 O
h O
, O
in O
group O
B I-GENE
at O
24 O
h O
postexposure O
. O

We O
have O
reviewed O
the O
experience O
of O
a O
major I-GENE
_RARE_ I-GENE
general O
practice O
with O
hepatitis I-GENE
C I-GENE
virus I-GENE
( O
HCV I-GENE
) O
infection O
from O
1991 O
to O
1995 O
. O

The O
author O
_RARE_ I-GENE
extensive O
own O
data O
based O
on O
study O
into O
particular O
features O
of O
cardiovascular O
disorders O
in O
chronic O
renal O
_RARE_ I-GENE
with O
making O
use O
of O
modern O
diagnostic O
tools O
. O

In O
this O
paper O
, O
characterization O
is O
given O
of O
clinical O
and O
biochemical O
features O
of O
VH I-GENE
B I-GENE
course O
against O
the O
background O
of O
_RARE_ I-GENE
. O

_RARE_ I-GENE
microns O
for O
A I-GENE
. O
_RARE_ I-GENE
and O
350 O
microns O
for O
A I-GENE
. O
_RARE_ I-GENE
), O
and O
fewer O
testes O
per O
_RARE_ I-GENE
( O
44 I-GENE
- I-GENE
73 O
vs O
. O

The O
_RARE_ I-GENE
cDNA I-GENE
hybridized O
to O
multiple O
transcripts I-GENE
in O
a O
thyroid I-GENE
cancer O
cell O
line O
( O
8 O
. O
0 O
, O
4 I-GENE
. O
5 I-GENE
and O
2 I-GENE
kb O
) O
that O
increased O
after O
cycloheximide I-GENE
treatment O
and O
_RARE_ I-GENE
< O
2 I-GENE
h O
after O
addition O
of O
_RARE_ I-GENE
D I-GENE
. O

_RARE_ I-GENE
S I-GENE
- I-GENE
transferase I-GENE
( O
GST I-GENE
)- I-GENE
E2F I-GENE
and O
GST I-GENE
- I-GENE
DP I-GENE
fusion I-GENE
proteins I-GENE
were O
found O
to O
cooperate O
in O
binding I-GENE
to O
the O
three O
E2F I-GENE
sites I-GENE
in O
the O
DNA I-GENE
polymerase I-GENE
alpha I-GENE
gene I-GENE
promoter I-GENE
in O
vitro O
. O

Two O
sterol I-GENE
regulatory I-GENE
element I-GENE
- I-GENE
like I-GENE
sequences I-GENE
mediate O
up O
- I-GENE
regulation O
of O
_RARE_ I-GENE
gene I-GENE
transcription I-GENE
in O
response O
to O
low O
density I-GENE
lipoprotein I-GENE
free O
cholesterol I-GENE
. O

Furthermore O
, O
DNA I-GENE
- I-GENE
bound O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
SMRT I-GENE
in O
vivo O
, O
and O
both O
overexpressed O
proteins I-GENE
completely O
_RARE_ I-GENE
in O
nuclear I-GENE
_RARE_ I-GENE
. O

CONCLUSIONS O
: O
We O
obtained O
normal O
EPO I-GENE
levels O
for O
mothers O
and O
newborns O
for O
our O
area O
, O
similarly O
to O
the O
previously O
described O
ones O
. O

_RARE_ I-GENE
was O
induced O
by O
a O
low O
flow O
rate O
of O
0 O
. O
8 O
mL O
min O
- I-GENE
1 I-GENE
for O
30 O
min O
, O
and O
was O
followed O
by O
a O
40 I-GENE
- I-GENE
minute O
reperfusion O
. O

First O
, O
two O
_RARE_ I-GENE
using O
a O
long O
electrode O
, O
3 I-GENE
cm O
in O
size O
, O
were O
performed O
in O
the O
central O
area O
of O
the O
tumor I-GENE
, O
and O
eight O
_RARE_ I-GENE
by O
a O
short O
electrode O
, O
2 I-GENE
cm O
in O
size O
, O
were O
done O
in O
the O
peripheral O
and O
surrounding O
area O
of O
the O
tumor I-GENE
. O

BACKGROUND O
: O
_RARE_ I-GENE
pathways O
prevent O
cell O
- I-GENE
cycle O
progression O
in O
the O
event O
of O
DNA I-GENE
lesions O
. O

Direct I-GENE
_RARE_ I-GENE
that O
the O
_RARE_ I-GENE
renal O
cellular O
apoptosis O
in O
_RARE_ I-GENE
is O
not O
occurring O
through O
p53 I-GENE
was O
obtained O
by O
successive O
_RARE_ I-GENE
between O
_RARE_ I-GENE
and O
p53 I-GENE
_RARE_ I-GENE
mice O
. O

_RARE_ I-GENE
evidence O
indicates O
that O
, O
upon O
stimulation O
with O
interferon I-GENE
- I-GENE
gamma I-GENE
( O
IFN I-GENE
- I-GENE
gamma I-GENE
), O
three O
beta I-GENE
- I-GENE
type I-GENE
subunits I-GENE
, O
designated O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
, O
are O
incorporated O
into O
the O
20S I-GENE
proteasome I-GENE
by O
_RARE_ I-GENE
the O
housekeeping O
beta I-GENE
- I-GENE
type I-GENE
subunits I-GENE
designated O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
, O
respectively O
. O

The O
major I-GENE
RNase I-GENE
E I-GENE
cleavage O
product I-GENE
( O
_RARE_ I-GENE
_RARE_ I-GENE
- I-GENE
6 I-GENE
) O
is O
rapidly O
degraded O
by O
_RARE_ I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
). O

This O
difference O
may O
result O
from O
the O
lower O
match O
to O
the O
_RARE_ I-GENE
box I-GENE
consensus I-GENE
of O
the O
O O
( O
_RARE_ I-GENE
) O
site I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
' O
s O
_RARE_ I-GENE
_RARE_ I-GENE
about O
_RARE_ I-GENE
indicators O
. O

All O
pigs O
had O
significant O
regional O
LV O
dysfunction O
and O
reduced O
LV O
ejection O
fraction O
( O
41 O
+/- O
11 O
%). O

The O
progress O
of O
morphological O
research O
on O
the O
_RARE_ I-GENE
nucleus O

The O
amplitudes O
of O
_RARE_ I-GENE
also O
recovered O
to O
a O
greater O
extent O
and O
outer I-GENE
_RARE_ I-GENE
cell O
_RARE_ I-GENE
were O
less O
severe O
in O
the O
R I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
treated O
ears O
. O

The O
data O
provide O
evidence O
both O
for O
a O
signal I-GENE
transduction O
pathway O
independent O
of O
JNK I-GENE
, O
ERK I-GENE
, O
and O
p38 I-GENE
MAP I-GENE
kinase I-GENE
to O
be O
involved O
in O
the O
induction O
of O
_RARE_ I-GENE
by O
_RARE_ I-GENE
stress O
, O
and O
_RARE_ I-GENE
, O
indicate O
autoregulation O
of O
_RARE_ I-GENE
. O

In O
an O
effort O
to O
separate O
domains I-GENE
of O
_RARE_ I-GENE
required O
for O
DNA I-GENE
binding I-GENE
, O
dimerization O
, O
and O
ligand O
binding I-GENE
, O
chimeric I-GENE
protein I-GENE
fusions I-GENE
between O
the O
DNA I-GENE
binding I-GENE
domain I-GENE
of O
LexA I-GENE
and O
different O
regions O
of O
_RARE_ I-GENE
were O
constructed O
. O

Inhibition O
appears O
to O
result O
from O
titration O
of O
general O
transcription I-GENE
factors I-GENE
because O
_RARE_ I-GENE
overexpression O
inhibits O
c I-GENE
- I-GENE
fos I-GENE
as O
well O
as O
other O
promoters I-GENE
in O
vivo O
and O
basal O
transcription I-GENE
in O
vitro O
. O

4 I-GENE
) O
PU I-GENE
and O
PD I-GENE
lacked O
the O
canonical O
TATA I-GENE
or O
CAAT I-GENE
motifs O
, O
and O
are O
AT I-GENE
- I-GENE
rich O
. O

We O
also O
show O
by O
_RARE_ I-GENE
electron O
microscopy O
_RARE_ I-GENE
that O
_RARE_ I-GENE
I I-GENE
is O
localized O
in O
the O
nerve I-GENE
terminal I-GENE
_RARE_ I-GENE
and O
is O
partially O
associated I-GENE
with O
endocytic O
_RARE_ I-GENE
. O

The O
mobility I-GENE
shift O
of O
both O
of O
these O
proteins I-GENE
is O
abolished O
by O
treatment O
with O
inhibitors O
of O
PKC I-GENE
or O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
/ I-GENE
extracellular I-GENE
signal I-GENE
- I-GENE
related I-GENE
kinase I-GENE
kinase I-GENE
. O

The O
_RARE_ I-GENE
for O
_RARE_ I-GENE
includes O
C1 I-GENE
- I-GENE
7 O
, O
T1 O
- I-GENE
9 O
and O
L2 O
- I-GENE
4 I-GENE
. O

During O
the O
_RARE_ I-GENE
of O
_RARE_ I-GENE
of O
the O
skin O
sympathetic O
nerve I-GENE
by O
mental O
_RARE_ I-GENE
, O
3 I-GENE
/ I-GENE
12 O
A I-GENE
delta I-GENE
units O
were O
turned O
to O
the O
active O
state O
with O
decreased O
mechanical O
threshold O
. O

In O
a O
similar O
fashion O
to O
adipose I-GENE
_RARE_ I-GENE
cells O
, O
serum I-GENE
_RARE_ I-GENE
the O
response O
to O
dexamethasone O
but O
had O
no O
effect O
on O
phorbol O
ester O
- I-GENE
stimulated O
activity O
. O

Thus O
, O
_RARE_ I-GENE
expression O
_RARE_ I-GENE
the O
_RARE_ I-GENE
_RARE_ I-GENE
molecular O
anteroposterior O
asymmetry O
in O
the O
mouse I-GENE
embryo O
and O
indicates O
that O
the O
anteroposterior O
axis O
of O
the O
embryo O
_RARE_ I-GENE
from O
conversion O
of O
a O
_RARE_ I-GENE
asymmetry O
established O
in O
the O
_RARE_ I-GENE
endoderm O
lineage O
. O

Thus O
, O
_RARE_ I-GENE
and O
_RARE_ I-GENE
promote O
both O
dorsal O
leg O
cell O
fate O
as O
well O
as O
_RARE_ I-GENE
- I-GENE
competent O
leg O
disc O
cells O
. O

CONCLUSIONS O
: O
While O
_RARE_ I-GENE
correction O
may O
be O
achieved O
by O
all O
the O
above O
methods O
, O
that O
_RARE_ I-GENE
log O
reference O
_RARE_ I-GENE
to O
log O
local O
prothrombin I-GENE
time O
by O
linear O
regression O
analysis O
is O
the O
_RARE_ I-GENE
to O
perform O
. O

RESULTS O
: O
The O
overall O
_RARE_ I-GENE
for O
1992 O
was O
12 O
. O
3 I-GENE
% O
and O
was O
19 O
. O
1 I-GENE
%, O
22 O
. O
2 I-GENE
%, O
3 I-GENE
. O
8 O
% O
and O
6 I-GENE
. O
1 I-GENE
% O
per O
successive O
_RARE_ I-GENE
in O
1992 O
. O

Western O
blot O
analysis O
of O
various O
bovine I-GENE
tissues O
with O
human I-GENE
_RARE_ I-GENE
peptide I-GENE
antibody I-GENE
indicated O
a O
common O
prominent O
immunoreactive I-GENE
band O
with O
an O
apparent O
molecular O
mass O
of O
48 O
. O
5 I-GENE
- I-GENE
50 O
kDa I-GENE
in O
all O
tissues O
. O

Transcription O
start O
sites I-GENE
of O
the O
_RARE_ I-GENE
_RARE_ I-GENE
genes I-GENE
were O
estimated O
from O
the O
_RARE_ I-GENE
cDNA I-GENE
clones O
obtained O
by O
5 I-GENE
'- O
RACE O
( O
rapid O
amplification O
of O
cDNA I-GENE
ends O
). O

AIDS O
- I-GENE
related I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
in O
_RARE_ I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
. O

Thus O
, O
_RARE_ I-GENE
acts O
as O
an O
accessory I-GENE
transcriptional O
activator I-GENE
at O
the O
_RARE_ I-GENE
promoter I-GENE
. O

These O
observations O
provide O
strong O
support O
for O
the O
idea O
that O
expression O
of O
mutant I-GENE
tRNA I-GENE
can O
confer O
a O
_RARE_ I-GENE
phenotype O
, O
including O
the O
_RARE_ I-GENE
- I-GENE
constitutive O
phenotype O
observed O
in O
_RARE_ I-GENE
and O
_RARE_ I-GENE
cells O
. O

TNF I-GENE
- I-GENE
alpha I-GENE
exposure O
markedly O
increased O
activity O
of O
several O
RNA I-GENE
- I-GENE
binding I-GENE
proteins I-GENE
, O
especially O
a O
novel O
Mr O
50 O
, O
000 O
- I-GENE
55 O
, O
000 O
RNA I-GENE
- I-GENE
binding I-GENE
protein I-GENE
. O

We O
_RARE_ I-GENE
that O
the O
human I-GENE
papillomavirus I-GENE
late O
mRNAs I-GENE
, O
produced O
from O
several O
hundred O
copies O
of O
the O
virus I-GENE
genome O
present O
in O
infected O
cells O
, O
compete O
with O
the O
c I-GENE
- I-GENE
fos I-GENE
mRNAs I-GENE
for O
_RARE_ I-GENE
cellular O
factors I-GENE
and O
that O
this O
may O
lead O
to O
elevated O
Fos I-GENE
protein I-GENE
levels O
in O
human I-GENE
papillomavirus I-GENE
infected O
cells O
. O

Two O
closely O
related I-GENE
_RARE_ I-GENE
constant O
region O
genes I-GENE
, O
_RARE_ I-GENE
and O
_RARE_ I-GENE
, O
have O
been O
sequenced O
completely O
. O

The O
aim O
of O
this O
study O
was O
to O
find O
out O
whether O
it O
was O
possible O
to O
detect O
normal O
lymph O
nodes O
by O
high O
- I-GENE
resolution O
_RARE_ I-GENE
US O
. O

To O
study O
the O
role O
of O
heavy I-GENE
chain I-GENE
motifs O
in O
substrate I-GENE
recognition I-GENE
, O
secreted O
variants I-GENE
of O
recombinant I-GENE
bovine I-GENE
_RARE_ I-GENE
were O
constructed O
by O
replacing O
the O
transmembrane I-GENE
domain I-GENE
with O
a O
signal I-GENE
peptide I-GENE
. O

_RARE_ I-GENE
- I-GENE
II I-GENE
is O
predicted O
to O
encode O
a O
type I-GENE
II I-GENE
transmembrane I-GENE
glycoprotein I-GENE
of O
43 I-GENE
kDa I-GENE
with O
five O
potential O
N I-GENE
- I-GENE
linked O
glycosylation O
sites I-GENE
. O

We O
now O
demonstrate O
that O
CCAAT I-GENE
/ I-GENE
enhancer I-GENE
- I-GENE
binding I-GENE
protein I-GENE
( O
C I-GENE
/ I-GENE
EBP I-GENE
) O
delta I-GENE
is O
a O
major I-GENE
component O
of O
a O
PGE2 O
- I-GENE
stimulated O
DNA I-GENE
- I-GENE
protein I-GENE
complex I-GENE
involving O
_RARE_ I-GENE
and O
find O
that O
C I-GENE
/ I-GENE
_RARE_ I-GENE
transactivates O
IGF I-GENE
- I-GENE
I I-GENE
promoter I-GENE
1 I-GENE
through O
this O
site I-GENE
. O

PATIENTS O
AND O
METHODS O
: O
_RARE_ I-GENE
analyses O
were O
performed O
on O
58 O
patients O
with O
stages O
I I-GENE
- I-GENE
III I-GENE
HD I-GENE
before O
, O
during O
, O
and O
after O
chemotherapy O
and O
after O
the O
sperm O
count O
recovered O
from O
the O
effects O
of O
abdominal O
radiotherapy O
that O
was O
given O
after O
chemotherapy O
. O

Thus O
, O
the O
absence O
of O
residual O
infarct O
- I-GENE
zone O
viability O
_RARE_ I-GENE
patients O
who O
develop O
progressive O
left O
ventricular O
_RARE_ I-GENE
after O
_RARE_ I-GENE
AMI O
from O
those O
who O
maintain O
normal O
left O
ventricular O
_RARE_ I-GENE
. O

With O
a O
BMI O
cutoff O
of O
27 O
, O
mean O
cardiac O
NE O
_RARE_ I-GENE
was O
46 O
% O
lower O
in O
the O
obese O
subjects O
when O
compared O
with O
the O
lean O
subjects O
( O
P I-GENE
=. O
_RARE_ I-GENE
). O

The O
gene I-GENE
( O
_RARE_ I-GENE
) O
encoding O
both O
_RARE_ I-GENE
_RARE_ I-GENE
peroxidase I-GENE
isoenzymes I-GENE
was O
isolated O
and O
the O
organization O
of O
the O
gene I-GENE
was O
determined O
. O

This O
emphasizes O
the O
conclusion O
that O
_RARE_ I-GENE
- I-GENE
1 I-GENE
is O
not O
an O
E2F I-GENE
family I-GENE
member O
and O
points O
to O
profound O
differences O
in O
the O
cell O
cycle O
regulation O
of O
_RARE_ I-GENE
- I-GENE
1 I-GENE
and O
E2F I-GENE
. O

The O
_RARE_ I-GENE
domain I-GENE
of O
Escherichia I-GENE
coli I-GENE
DNA I-GENE
polymerase I-GENE
I I-GENE
and O
other O
DNA I-GENE
and O
/ I-GENE
or O
RNA I-GENE
exonuclease I-GENE
domains I-GENE
. O

Interleukin I-GENE
- I-GENE
1 I-GENE
levels O
remained O
low O
throughout O
the O
course O
. O

_RARE_ I-GENE
_RARE_ I-GENE
-- O
this O
is O
a O
_RARE_ I-GENE
_RARE_ I-GENE

Southern O
blot O
analysis O
of O
endonuclease I-GENE
- I-GENE
_RARE_ I-GENE
genomic O
DNA I-GENE
from O
primary O
chick I-GENE
embryo O
fibroblasts O
( O
_RARE_ I-GENE
) O
suggested O
that O
_RARE_ I-GENE
is O
a O
single O
- I-GENE
copy O
gene I-GENE
in O
this O
vertebrate I-GENE
species O
. O

_RARE_ I-GENE
required O
for O
interaction O
of O
_RARE_ I-GENE
and O
_RARE_ I-GENE
- I-GENE
4 I-GENE
were O
localized O
to O
residues O
, O
_RARE_ I-GENE
in O
_RARE_ I-GENE
- I-GENE
4 I-GENE
; O
this O
sequence I-GENE
is O
N I-GENE
- I-GENE
terminal I-GENE
to O
, O
but O
_RARE_ I-GENE
with O
, O
a O
previously O
identified O
SH2 I-GENE
binding I-GENE
motif I-GENE
, O
_RARE_ I-GENE
, O
involved O
in O
_RARE_ I-GENE
- I-GENE
4 I-GENE
signaling O
. O

Here O
, O
we O
report O
that O
a O
transfected O
Chinese O
hamster I-GENE
ovary O
( O
CHO O
) O
cell O
line O
expressing O
a O
murine I-GENE
CD4 I-GENE
fragment I-GENE
containing O
the O
first O
two O
N I-GENE
- I-GENE
terminal I-GENE
domains I-GENE
_RARE_ I-GENE
both O
monomeric I-GENE
molecules I-GENE
and O
disulfide O
- I-GENE
linked O
_RARE_ I-GENE
. O

_RARE_ I-GENE
V I-GENE
( O
D I-GENE
) O
J O
recombination O
can O
be O
partly O
_RARE_ I-GENE
in O
T I-GENE
- I-GENE
lymphocytes O
by O
either O
DNA I-GENE
- I-GENE
_RARE_ I-GENE
agents O
( O
gamma I-GENE
- I-GENE
irradiation O
and O
_RARE_ I-GENE
) O
or O
a O
null I-GENE
mutation I-GENE
of O
the O
p53 I-GENE
gene I-GENE
, O
possibly O
because O
of O
transiently O
elevated O
DNA I-GENE
repair I-GENE
activity O
in O
response O
to O
DNA I-GENE
damage O
or O
to O
delayed O
apoptosis O
in O
the O
absence O
of O
p53 I-GENE
. O

_RARE_ I-GENE
of O
mouse I-GENE
PKR I-GENE
( O
1 I-GENE
- I-GENE
_RARE_ I-GENE
) O
_RARE_ I-GENE
as O
a O
Gal4 I-GENE
DNA I-GENE
- I-GENE
binding I-GENE
domain I-GENE
fusion I-GENE
with O
either O
the O
catalytic O
- I-GENE
deficient O
human I-GENE
PKR I-GENE
( O
1 I-GENE
- I-GENE
_RARE_ I-GENE
) O
_RARE_ I-GENE
mutant I-GENE
, O
the O
RNA I-GENE
- I-GENE
binding I-GENE
- I-GENE
deficient O
human I-GENE
PKR I-GENE
( O
1 I-GENE
- I-GENE
_RARE_ I-GENE
) O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
double O
mutant I-GENE
, O
or O
wild I-GENE
- I-GENE
type I-GENE
mouse I-GENE
PKR I-GENE
( O
1 I-GENE
- I-GENE
_RARE_ I-GENE
) O
_RARE_ I-GENE
as O
full I-GENE
- I-GENE
length I-GENE
PKR I-GENE
- I-GENE
Gal4 I-GENE
activation O
domain I-GENE
fusions I-GENE
resulted O
in O
activation O
of O
the O
HIS3 I-GENE
and O
lacZ I-GENE
_RARE_ I-GENE
. O

Using O
GST I-GENE
- I-GENE
PKR I-GENE
fusion I-GENE
chromatography O
, O
direct O
physical O
interaction O
between O
the O
mouse I-GENE
and O
human I-GENE
PKR I-GENE
homologs I-GENE
was O
established O
. O

An O
even O
greater O
inflammatory O
response O
was O
observed O
after O
_RARE_ I-GENE
_RARE_ I-GENE
of O
_RARE_ I-GENE
, O
but O
not O
after O
_RARE_ I-GENE
_RARE_ I-GENE
. O

Interestingly O
, O
the O
_RARE_ I-GENE
strain O
_RARE_ I-GENE
showed O
weak O
hybridization O
with O
these O
two O
probes O
, O
suggesting O
that O
these O
genes I-GENE
might O
have O
been O
deleted O
in O
the O
_RARE_ I-GENE
strain O
or O
are O
present O
in O
limited O
copy O
numbers O
as O
opposed O
to O
those O
in O
the O
virulent O
strain O
_RARE_ I-GENE
. O

These O
defects O
no O
_RARE_ I-GENE
_RARE_ I-GENE
the O
folding O
and O
configuration O
necessary O
for O
normal O
processing O
of O
the O
AVP I-GENE
gene I-GENE
precursor I-GENE
. O

_RARE_ I-GENE
between O
the O
_RARE_ I-GENE
- I-GENE
1 I-GENE
and O
phosphoenolpyruvate I-GENE
kinase I-GENE
( O
PEPCK I-GENE
) O
promoters I-GENE
, O
including O
regions O
conferring O
insulin I-GENE
, O
glucocorticoid I-GENE
, O
and O
cyclic I-GENE
adenosine I-GENE
- I-GENE
monophosphate O
responses O
, O
are O
consistent O
with O
our O
previous O
hypothesis O
that O
_RARE_ I-GENE
- I-GENE
1 I-GENE
is O
involved O
in O
regulation O
of O
glucose O
metabolism O
. O

This O
_RARE_ I-GENE
repeat I-GENE
contains O
repetitive O
DNA I-GENE
elements O
that O
include O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
medium O
_RARE_ I-GENE
frequency O
repeats I-GENE
, O
and O
a O
transposon I-GENE
- I-GENE
like I-GENE
element I-GENE
. O

At O
60 O
days O
the O
amount O
of O
_RARE_ I-GENE
was O
on O
average O
lower O
in O
females O
than O
in O
males O
, O
even O
if O
with O
some O
exception O
. O

Large I-GENE
genomic O
constructs I-GENE
_RARE_ I-GENE
at O
the O
endogenous I-GENE
locus I-GENE
by O
homologous O
recombination O
, O
but O
cDNA I-GENE
- I-GENE
derived O
sequences I-GENE
lacking O
long O
stretches O
of O
contiguous O
genomic O
DNA I-GENE
( O
due O
to O
intron O
excision O
) O
typically O
_RARE_ I-GENE
into O
chromosomal I-GENE
DNA I-GENE
by O
_RARE_ I-GENE
recombination O
. O

The O
existence O
of O
these O
two O
categories O
of O
strains O
offers O
a O
new O
genetic O
system O
in O
which O
the O
properties O
of O
a O
potential O
_RARE_ I-GENE
retrovirus O
can O
be O
tested O
. O

During O
the O
conditioning O
procedure O
, O
the O
C I-GENE
- I-GENE
fiber O
reflex O
was O
facilitated O
( O
_RARE_ I-GENE
- I-GENE
up O
) O
in O
a O
stimulus O
- I-GENE
dependent I-GENE
fashion O
in O
intact O
, O
anesthetized O
animals O
during O
the O
application O
of O
the O
first O
seven O
conditioning O
stimuli O
; O
thereafter O
, O
the O
magnitude O
of O
the O
responses O
reached O
a O
_RARE_ I-GENE
and O
then O
decreased O
. O

As O
a O
sequence I-GENE
- I-GENE
specific I-GENE
DNA I-GENE
binding I-GENE
transcription I-GENE
factor I-GENE
, O
p53 I-GENE
specifically O
binds O
to O
a O
20 O
- I-GENE
bp O
consensus I-GENE
motif I-GENE
5 I-GENE
'- O
_RARE_ I-GENE
( O
A I-GENE
/ I-GENE
T I-GENE
) O
( O
T I-GENE
/ I-GENE
A I-GENE
) O
_RARE_ I-GENE
( O
A I-GENE
/ I-GENE
T I-GENE
)( I-GENE
T I-GENE
/ I-GENE
A I-GENE
) O
_RARE_ I-GENE
- I-GENE
3 I-GENE
'. O

_RARE_ I-GENE
treatment O
, O
however O
, O
did O
not O
_RARE_ I-GENE
alter O
enhancer I-GENE
factor I-GENE
binding I-GENE
or O
the O
positioning O
of O
_RARE_ I-GENE
- I-GENE
1 I-GENE
on O
the O
majority O
of O
the O
chromatin O
templates O
indicating O
that O
protein I-GENE
acetylation O
and O
chromatin O
remodeling O
may O
be O
limiting O
steps O
that O
occur O
only O
on O
transcriptionally O
competent O
templates O
, O
or O
that O
remodeling O
of O
_RARE_ I-GENE
- I-GENE
1 I-GENE
requires O
additional O
factors I-GENE
. O

Upon O
UV O
damage O
, O
_RARE_ I-GENE
is O
transiently O
modified O
, O
probably O
phosphorylated O
, O
with O
a O
similar O
timing O
of O
phosphorylation O
in O
_RARE_ I-GENE
kinase I-GENE
, O
which O
is O
reported O
to O
_RARE_ I-GENE
Cdc2 I-GENE
activation O
. O

Moreover O
, O
moderate O
overexpression O
of O
_RARE_ I-GENE
suppresses O
the O
phenotypes O
of O
_RARE_ I-GENE
and O
_RARE_ I-GENE
mutants I-GENE
. O

_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
, O
a O
_RARE_ I-GENE
- I-GENE
dependent I-GENE
transcription I-GENE
factor I-GENE
that O
differentially O
regulates O
gene I-GENE
expression O
in O
Saccharomyces I-GENE
cerevisiae I-GENE
. O

Structure O
and O
localization O
of O
the O
human I-GENE
gene I-GENE
encoding O
SR I-GENE
- I-GENE
BI I-GENE
/ I-GENE
_RARE_ I-GENE
- I-GENE
1 I-GENE
. O

We O
introduced O
the O
gel O
technique O
as O
a O
routine O
assay O
for O
antibody I-GENE
detection O
and O
identification O
in O
1993 O
. O

_RARE_ I-GENE
of O
_RARE_ I-GENE
in O
a O
liquid O
dosage O
formulation O
stored O
for O
three O
months O
. O

Multiple O
regression O
analyses O
revealed O
that O
_RARE_ I-GENE
- I-GENE
R I-GENE
factor I-GENE
scores O
_RARE_ I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
from O
_RARE_ I-GENE
_RARE_ I-GENE
for O
up O
to O
42 O
% O
of O
the O
_RARE_ I-GENE
in O
_RARE_ I-GENE
- I-GENE
R I-GENE
and O
_RARE_ I-GENE
indices O
. O

_RARE_ I-GENE
basal O
arteries O
were O
measured O
by O
the O
_RARE_ I-GENE
approach O
with O
a O
2 I-GENE
_RARE_ I-GENE
pulsed O
Doppler O
instrument O
( O
_RARE_ I-GENE
- I-GENE
2 I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
). O

At O
the O
genomic O
level O
, O
the O
sequences I-GENE
of O
two O
members O
of O
this O
family I-GENE
are O
known O
in O
the O
rat I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
: O
the O
_RARE_ I-GENE
gene I-GENE
, O
encoding O
the O
_RARE_ I-GENE
- I-GENE
like I-GENE
polypeptide I-GENE
_RARE_ I-GENE
, O
and O
the O
_RARE_ I-GENE
gene I-GENE
, O
encoding O
a O
salivary I-GENE
Pro I-GENE
- I-GENE
rich O
polypeptide I-GENE
. O

The O
Saccharomyces I-GENE
cerevisiae I-GENE
_RARE_ I-GENE
gene I-GENE
, O
a O
homologue I-GENE
of O
Escherichia I-GENE
coli I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
, O
is O
DNA I-GENE
damage O
inducible I-GENE
and O
functions O
in O
a O
novel O
error O
- I-GENE
free O
_RARE_ I-GENE
repair I-GENE
mechanism O
. O

However O
, O
in O
a O
new O
experiment O
in O
which O
the O
deletion O
task O
was O
presented O
as O
a O
_RARE_ I-GENE
_RARE_ I-GENE
, O
and O
with O
_RARE_ I-GENE
and O
selection O
on O
_RARE_ I-GENE
deletion O
, O
a O
significantly O
higher O
level O
of O
success O
was O
achieved O
by O
the O
children O
working O
with O
the O
_RARE_ I-GENE
material O
. O

_RARE_ I-GENE
therapy O
with O
_RARE_ I-GENE
proteins I-GENE
for O
chronic O
stomach O
ulcers O

In O
_RARE_ I-GENE
patients O
, O
the O
_RARE_ I-GENE
related I-GENE
to O
the O
postoperative O
rise O
in O
IL I-GENE
- I-GENE
6 I-GENE
level O
only O
, O
even O
though O
the O
rise O
in O
plasma I-GENE
concentrations O
of O
cytokines O
_RARE_ I-GENE
. O

Resistance O
training O
shifts O
the O
power O
curve O
in O
a O
positive O
direction O
when O
the O
measurements O
are O
determined O
with O
absolute O
_RARE_ I-GENE
, O
but O
the O
increased O
power O
may O
not O
be O
transferred O
to O
an O
absolute O
performance O
task O
like I-GENE
the O
_RARE_ I-GENE
. O

Gel O
- I-GENE
shift O
assays O
identified O
two O
Sp1 I-GENE
binding I-GENE
sites I-GENE
within O
this O
element I-GENE
. O

_RARE_ I-GENE
( O
Surf I-GENE
- I-GENE
2 I-GENE
, O
Surf I-GENE
- I-GENE
4 I-GENE
), O
_RARE_ I-GENE
( O
Surf I-GENE
- I-GENE
3 I-GENE
, O
Surf I-GENE
- I-GENE
1 I-GENE
, O
Surf I-GENE
- I-GENE
6 I-GENE
), O
and O
_RARE_ I-GENE
( O
Surf I-GENE
- I-GENE
5 I-GENE
_RARE_ I-GENE

Gel O
mobility I-GENE
shift O
and O
_RARE_ I-GENE
- I-GENE
shift O
assays O
using O
liver O
nuclear I-GENE
extracts O
from O
either O
rat I-GENE
liver O
or O
_RARE_ I-GENE
- I-GENE
2 I-GENE
cells O
demonstrated O
that O
the O
CRE O
in O
the O
alpha I-GENE
1B I-GENE
- I-GENE
AR I-GENE
gene I-GENE
bound O
CRE O
binding I-GENE
protein I-GENE
. O

These O
results O
suggest O
that O
, O
in O
this O
experimental O
model O
, O
ACE I-GENE
inhibitors O
limit O
the O
arrhythmias O
following O
ischemia O
- I-GENE
reperfusion O
and O
free O
radical O
_RARE_ I-GENE
action O
of O
these O
drugs O
does O
not O
have O
a O
major I-GENE
_RARE_ I-GENE
role O
in O
their O
protective O
effect O
. O

The O
mean O
values O
of O
the O
first O
three O
components O
were O
not O
significantly O
different O
in O
_RARE_ I-GENE
patients O
and O
control O
subjects O
. O

However O
, O
the O
signaling O
cascade O
utilized O
by O
the O
urokinase I-GENE
receptor I-GENE
is O
only O
_RARE_ I-GENE
understood O
. O

The O
murine I-GENE
_RARE_ I-GENE
- I-GENE
a O
/ I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
- I-GENE
c I-GENE
genes I-GENE
are O
divergently O
transcribed O
from O
a O
shared O
TATA I-GENE
- I-GENE
less O
promoter I-GENE
. O

In O
_RARE_ I-GENE
with O
clinical O
improvement O
we O
found O
a O
decrease O
of O
laboratory O
indicators O
of O
inflammation O
( O
C I-GENE
- I-GENE
reactive I-GENE
protein I-GENE
, O
alpha I-GENE
2 I-GENE
- I-GENE
_RARE_ I-GENE
, O
prostaglandin I-GENE
E2 I-GENE
). O

We O
have O
previously O
reported O
that O
depletion O
of O
protein I-GENE
kinase I-GENE
C I-GENE
by O
long O
- I-GENE
term O
treatment O
of O
_RARE_ I-GENE
mouse I-GENE
melanoma O
cells O
with O
phorbol O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
prevented O
cell O
density I-GENE
- I-GENE
dependent I-GENE
_RARE_ I-GENE
. O

Replacement I-GENE
of O
residues O
in O
positions O
+ I-GENE
3 I-GENE
( O
_RARE_ I-GENE
) O
and O
+ I-GENE
2 I-GENE
( O
_RARE_ I-GENE
) O
of O
the O
reading O
helices O
of O
fingers O
2 I-GENE
and O
3 I-GENE
, O
respectively O
, O
prevented O
binding I-GENE
. O

Two O
_RARE_ I-GENE
_RARE_ I-GENE
, O
which O
are O
conserved O
in O
all O
_RARE_ I-GENE
molecules I-GENE
and O
many O
_RARE_ I-GENE
domains I-GENE
, O
_RARE_ I-GENE
loop I-GENE
LA O
and O
strand O
beta I-GENE
4 I-GENE
and O
loops O
_RARE_ I-GENE
and O
_RARE_ I-GENE
, O
respectively O
, O
at O
opposite O
_RARE_ I-GENE
of O
the O
same O
face O
of O
the O
domain I-GENE
. O

Mg I-GENE
- I-GENE
_RARE_ I-GENE
of O
tobacco I-GENE
: O
identification O
of O
a O
_RARE_ I-GENE
D I-GENE
cDNA I-GENE
sequence I-GENE
encoding O
a O
third O
subunit I-GENE
, O
analysis O
of O
the O
interaction O
of O
the O
three O
subunits I-GENE
with O
the O
yeast I-GENE
two O
- I-GENE
hybrid O
system O
, O
and O
_RARE_ I-GENE
of O
the O
enzyme I-GENE
activity O
by O
co O
- I-GENE
expression O
of O
recombinant I-GENE
_RARE_ I-GENE
D I-GENE
, O
_RARE_ I-GENE
H I-GENE
and O
_RARE_ I-GENE
I I-GENE
. O

One O
R I-GENE
- I-GENE
EST I-GENE
and O
one O
_RARE_ I-GENE
- I-GENE
like I-GENE
sequence I-GENE
each O
mapped O
to O
two O
locations O
. O

The O
_RARE_ I-GENE
structure O
includes O
a O
cysteine I-GENE
- I-GENE
rich O
motif I-GENE
resembling O
those O
of O
protein I-GENE
kinase I-GENE
C I-GENE
and O
n O
- I-GENE
_RARE_ I-GENE
and O
a O
putative O
pleckstrin I-GENE
homology I-GENE
domain I-GENE
. O

The O
interaction O
between O
_RARE_ I-GENE
and O
E2F1 I-GENE
can O
also O
be O
detected O
by O
_RARE_ I-GENE
experiments O
. O

_RARE_ I-GENE
: O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
, O
1996 O
). O

Nevertheless O
, O
antibodies I-GENE
directed O
against O
an O
epitope O
- I-GENE
tagged O
version O
of O
_RARE_ I-GENE
specifically O
_RARE_ I-GENE
U1 I-GENE
snRNA I-GENE
from O
yeast I-GENE
extracts O
. O

These O
results O
indicate O
that O
in O
addition O
to O
Grb2 I-GENE
- I-GENE
mediated O
activation O
of O
Ras I-GENE
, O
PLC I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
mediated O
_RARE_ I-GENE
production O
is O
required O
for O
EGF I-GENE
- I-GENE
and O
PDGF I-GENE
- I-GENE
induced O
S I-GENE
- I-GENE
phase O
entry O
and O
gene I-GENE
expression O
, O
possibly O
through O
activation O
of O
PKC I-GENE
. O

In O
this O
study O
, O
we O
investigated O
STAT I-GENE
activation O
in O
a O
panel O
of O
rodent O
fibroblast I-GENE
cell O
lines O
stably O
transformed O
by O
diverse O
viral I-GENE
oncoproteins I-GENE
. O

In O
serum I-GENE
- I-GENE
stimulated O
cells O
, O
the O
binding I-GENE
of O
NF I-GENE
- I-GENE
Y I-GENE
/ I-GENE
CBF I-GENE
to O
_RARE_ I-GENE
increased O
gradually O
, O
_RARE_ I-GENE
a O
_RARE_ I-GENE
at O
the O
S I-GENE
phase O
. O

CONCLUSION O
: O
In O
our O
animal O
model O
, O
blood O
- I-GENE
brain O
barrier O
disruption O
was O
a O
_RARE_ I-GENE
, O
integral I-GENE
finding O
of O
single O
- I-GENE
fraction O
, O
high O
- I-GENE
dose O
irradiation O
injury O
. O

To O
facilitate O
the O
investigation O
of O
parameters O
that O
govern O
selective O
export O
in O
adenovirus I-GENE
- I-GENE
infected O
cells O
, O
we O
constructed O
a O
marked O
human I-GENE
beta I-GENE
- I-GENE
actin I-GENE
_RARE_ I-GENE
under O
the O
control O
of O
the O
glucocorticoid I-GENE
- I-GENE
inducible I-GENE
enhancer I-GENE
- I-GENE
promoter I-GENE
of O
mouse I-GENE
mammary O
tumor I-GENE
virus I-GENE
and O
introduced O
it O
into O
the O
left O
end O
of O
the O
adenovirus I-GENE
type I-GENE
5 I-GENE
( O
Ad5 I-GENE
) O
genome O
. O

Cell O
factor I-GENE
- I-GENE
mediated O
regulatory I-GENE
interactions O
are O
involved O
in O
regulating O
the O
restricted O
expression O
of O
the O
HCMV I-GENE
major I-GENE
immediate I-GENE
- I-GENE
early I-GENE
( O
IE I-GENE
) O
gene I-GENE
( O
J O
. O

_RARE_ I-GENE
_RARE_ I-GENE
has O
extensive O
sequence I-GENE
similarity O
( O
92 O
%) O
with O
Escherichia I-GENE
coli I-GENE
_RARE_ I-GENE
and O
other O
members O
of O
the O
_RARE_ I-GENE
- I-GENE
60 O
family I-GENE
. O

The O
critical O
mutations O
were O
likely O
to O
have O
been O
multiple O
and O
_RARE_ I-GENE
, O
including O
elongation I-GENE
of O
the O
TM I-GENE
and O
Nef I-GENE
coding O
sequences I-GENE
; O
changes O
in O
RNA I-GENE
splice O
donor O
and O
acceptor O
sites I-GENE
, O
TATA I-GENE
box I-GENE
sites I-GENE
, O
and O
Sp1 I-GENE
sites I-GENE
; O
multiple O
changes O
in O
the O
V2 I-GENE
region O
of O
SU I-GENE
, O
including O
a O
consensus I-GENE
_RARE_ I-GENE
epitope O
; O
and O
five O
new O
N I-GENE
- I-GENE
linked O
glycosylation O
sites I-GENE
in O
SU I-GENE
. O

C I-GENE
. O

These O
are O
the O
long O
terminal I-GENE
repeat I-GENE
( O
LTR I-GENE
) O
promoter I-GENE
, O
which O
regulates O
expression O
of O
the O
viral I-GENE
structural O
proteins I-GENE
, O
and O
a O
second O
internal O
promoter I-GENE
, O
located O
towards O
the O
3 I-GENE
' O
end O
of O
the O
env I-GENE
gene I-GENE
, O
that O
directs O
expression O
of O
the O
viral I-GENE
auxiliary I-GENE
proteins I-GENE
. O

The O
5 I-GENE
' O
end O
of O
the O
genomic O
RNA I-GENE
of O
_RARE_ I-GENE
virus I-GENE
( O
_RARE_ I-GENE
) O
contains O
a O
14 O
- I-GENE
nucleotide I-GENE
( O
nt O
) O
single O
- I-GENE
stranded I-GENE
leader O
( O
_RARE_ I-GENE
- I-GENE
leader O
) O
followed O
by O
a O
stem O
- I-GENE
and O
- I-GENE
loop I-GENE
structure O
[ O
5 I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
] O
( O
nt O
15 O
to O
65 O
), O
the O
complement I-GENE
of O
which O
at O
the O
3 I-GENE
' O
end O
of O
the O
minus O
- I-GENE
strand O
RNA I-GENE
[ O
3 I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
] O
has O
been O
proposed O
to O
function O
as O
a O
promoter I-GENE
for O
synthesis O
of O
genomic O
plus O
_RARE_ I-GENE
. O

To O
investigate O
the O
requirements O
for O
CBF2 I-GENE
binding I-GENE
, O
we O
synthesized O
a O
series O
of O
oligonucleotides O
carrying O
double O
transversion O
mutations O
spanning O
both O
the O
conserved O
core I-GENE
sequence I-GENE
and O
outside O
flanking O
sequences I-GENE
. O

In O
addition O
, O
the O
affinities O
of O
CBF2 I-GENE
for O
binding I-GENE
to O
the O
LMP I-GENE
- I-GENE
1 I-GENE
, O
LMP I-GENE
- I-GENE
2 I-GENE
, O
and O
CD23 I-GENE
promoters I-GENE
were O
also O
measured O
. O

CONCLUSIONS O
: O
The O
myocardial O
uptake O
of O
99mTc O
_RARE_ I-GENE
in O
normal O
subjects O
and O
patients O
with O
coronary O
artery O
disease O
is O
comparable O
after O
exercise O
, O
_RARE_ I-GENE
, O
and O
adenosine I-GENE
stress O
. O

The O
SR I-GENE
protein I-GENE
family I-GENE
is O
involved O
in O
constitutive O
and O
regulated O
pre I-GENE
- I-GENE
mRNA I-GENE
splicing O
and O
has O
been O
found O
to O
be O
evolutionarily O
conserved O
in O
metazoan I-GENE
organisms O
. O

To O
investigate O
the O
activity O
of O
_RARE_ I-GENE
through O
this O
selected O
site I-GENE
, O
both O
alone O
and O
in O
the O
presence O
of O
_RARE_ I-GENE
, O
we O
have O
used O
a O
transient O
transfection O
assay O
. O

These O
and O
other O
comparisons O
suggest O
that O
, O
during O
evolution O
, O
both O
the O
RNA I-GENE
- I-GENE
polymerase I-GENE
specificity O
of O
telomerase I-GENE
RNA I-GENE
- I-GENE
gene I-GENE
promoters I-GENE
and O
, O
more O
recently O
, O
the O
position O
of O
the O
template O
sequence I-GENE
in O
the O
telomerase I-GENE
RNA I-GENE
changed O
. O

_RARE_ I-GENE
and O
decay O
of O
beta I-GENE
- I-GENE
globin I-GENE
mRNA I-GENE
in O
K562 O
cells O
is O
_RARE_ I-GENE
slow O
compared O
with O
NIH O
3T3 O
cells O
, O
suggesting O
that O
the O
increased O
stability O
_RARE_ I-GENE
by O
beta I-GENE
- I-GENE
globin I-GENE
mRNA I-GENE
in O
K562 O
cells O
is O
mainly O
controlled O
at O
the O
_RARE_ I-GENE
step O
. O

_RARE_ I-GENE
junction O
_RARE_ I-GENE
in O
Schizosaccharomyces I-GENE
pombe I-GENE
has O
identical O
endonuclease I-GENE
activity O
to O
the O
_RARE_ I-GENE
homologue I-GENE
_RARE_ I-GENE
. O

Ca2 I-GENE
+/ I-GENE
calmodulin I-GENE
- I-GENE
dependent I-GENE
protein I-GENE
kinase I-GENE
II I-GENE
( O
_RARE_ I-GENE
II I-GENE
) O
is O
a O
_RARE_ I-GENE
serine I-GENE
/ I-GENE
threonine I-GENE
protein I-GENE
kinase I-GENE
that O
regulates O
ion O
channels I-GENE
, O
metabolic O
enzymes O
, O
cytoskeletal O
proteins I-GENE
, O
and O
possibly O
transcription I-GENE
factors I-GENE
. O

A I-GENE
cAMP I-GENE
- I-GENE
responsive I-GENE
element I-GENE
- I-GENE
like I-GENE
( O
CRE O
- I-GENE
like I-GENE
, O
_RARE_ I-GENE
) O
promoter I-GENE
sequence I-GENE
and O
a O
protein I-GENE
kinase I-GENE
A I-GENE
signaling O
pathway O
are O
involved O
in O
this O
induction O
, O
and O
activation O
of O
both O
CRE O
binding I-GENE
protein I-GENE
( O
CREB I-GENE
) O
and O
activating I-GENE
transcription I-GENE
factor I-GENE
- I-GENE
2 I-GENE
( O
ATF I-GENE
- I-GENE
2 I-GENE
) O
is O
required O
in O
the O
above O
process O
. O

_RARE_ I-GENE
was O
named O
as O
an O
_RARE_ I-GENE
for O
intravascular O
_RARE_ I-GENE
. O

_RARE_ I-GENE
, O
a O
cystic I-GENE
_RARE_ I-GENE
was O
diagnosed O
because O
of O
the O
morphological O
features O
and O
the O
immunohistochemical O
_RARE_ I-GENE
of O
CD34 I-GENE
and O
Factor I-GENE
VIII I-GENE
related I-GENE
antigen I-GENE
which O
were O
observed O
positive O
reactions O
in O
endothelial I-GENE
cells O
of O
the O
cysts O
. O

_RARE_ I-GENE
activities O
in O
cultures O
of O
the O
streptococcal I-GENE
strains O
were O
associated I-GENE
with O
species O
of O
different O
molecular O
masses O
ranging O
from O
130 I-GENE
to O
200 O
kDa I-GENE
, O
suggesting O
posttranslational O
processing O
possibly O
as O
a O
result O
of O
_RARE_ I-GENE
at O
post O
- I-GENE
proline O
peptide I-GENE
bonds O
in O
the O
N I-GENE
- I-GENE
terminal I-GENE
parts O
of O
the O
molecules I-GENE
. O

The O
mechanism O
underlying O
such O
analgesia O
has O
been O
suggested O
to O
involve O
the O
interaction O
between O
the O
two O
separate O
but O
_RARE_ I-GENE
_RARE_ I-GENE
systems O
" O
defense O
" O
and O
" O
pain O
." I-GENE
To O
determine O
the O
developmental O
course O
of O
defense O
and O
_RARE_ I-GENE
, O
these O
processes O
were O
analyzed O
during O
early I-GENE
_RARE_ I-GENE
in O
rats O
. O

Three O
large O
field O
placement O
_RARE_ I-GENE
( O
two O
patients O
with O
11 O
. O
5 I-GENE
and O
16 O
. O
0 O
mm O
distances O
of O
the O
_RARE_ I-GENE
versus O
simulated O
_RARE_ I-GENE
, O
respectively O
and O
one O
patient O
with O
a O
7 O
degree O
_RARE_ I-GENE
error O
) O
were O
detected O
and O
, O
as O
with O
the O
smaller O
_RARE_ I-GENE
, O
were O
immediately O
corrected O
. O

In O
addition O
, O
a O
catalytically O
inactive O
version O
of O
the O
Src I-GENE
family I-GENE
member O
, O
Lck I-GENE
( O
lymphoid I-GENE
cell O
kinase I-GENE
), O
was O
expressed O
, O
purified O
, O
and O
evaluated O
as O
a O
Csk I-GENE
substrate I-GENE
. O

A I-GENE
., O
_RARE_ I-GENE
, O
A I-GENE
. O

_RARE_ I-GENE
mechanisms O
underlying O
stimulus O
- I-GENE
response O
( O
S I-GENE
- I-GENE
R I-GENE
) O
associations O
in O
S I-GENE
- I-GENE
R I-GENE
compatibility O
tasks O
were O
identified O
in O
2 I-GENE
experiments O
with O
monkeys O
. O

The O
c I-GENE
- I-GENE
myc I-GENE
/ I-GENE
TGF I-GENE
- I-GENE
alpha I-GENE
_RARE_ I-GENE
were O
also O
characterized O
by O
a O
particularly O
strong O
expression O
of O
TGF I-GENE
- I-GENE
alpha I-GENE
and O
very O
low O
apoptotic O
index O
in O
contrast O
to O
high O
levels O
of O
apoptosis O
in O
_RARE_ I-GENE
tissues O
and O
c I-GENE
- I-GENE
myc I-GENE
_RARE_ I-GENE
. O

Taken O
together O
, O
our O
data O
suggest O
that O
the O
antagonistic O
effects O
of O
CRP I-GENE
and O
_RARE_ I-GENE
on O
the O
expression O
of O
the O
_RARE_ I-GENE
genes I-GENE
occur O
by O
different O
mechanisms O
, O
including O
direct O
competition O
between O
the O
two O
regulators O
or O
between O
the O
repressor I-GENE
and O
RNA I-GENE
polymerase I-GENE
for O
the O
_RARE_ I-GENE
of O
a O
common O
DNA I-GENE
region O
on O
the O
target O
genes I-GENE
. O

The O
well O
- I-GENE
known O
Rel I-GENE
/ I-GENE
NF I-GENE
- I-GENE
kappaB I-GENE
family I-GENE
of O
vertebrate I-GENE
transcription I-GENE
factors I-GENE
comprises O
a O
number O
of O
structurally O
related I-GENE
, O
interacting I-GENE
proteins I-GENE
that O
bind O
DNA I-GENE
as O
dimers I-GENE
and O
whose O
activity O
is O
regulated O
by O
subcellular O
location O
. O

The O
_RARE_ I-GENE
gene I-GENE
is O
organized O
in O
an O
unusual O
operon I-GENE
which O
contains O
, O
in O
addition O
, O
two O
genes I-GENE
encoding O
stress O
- I-GENE
sensitive O
restriction I-GENE
enzymes O
. O

_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
reductase I-GENE
and O
_RARE_ I-GENE
dehydrogenase I-GENE
from O
Arabidopsis I-GENE
thaliana O
: O
nucleotide I-GENE
sequence I-GENE
and O
characterization O
. O

The O
purpose O
of O
this O
investigation O
was O
to O
describe O
a O
new O
formulation O
of O
silver O
_RARE_ I-GENE
in O
a O
water O
soluble I-GENE
gel O
, O
_RARE_ I-GENE
_RARE_ I-GENE
. O

The O
study O
_RARE_ I-GENE
were O
to O
isolate O
a O
full I-GENE
- I-GENE
length I-GENE
clone O
encoding O
CO I-GENE
- I-GENE
Ag I-GENE
from O
a O
bovine I-GENE
corneal O
cDNA I-GENE
library O
and O
to O
express O
this O
clone O
in O
Escherichia I-GENE
coli I-GENE
( O
E I-GENE
. O
coli I-GENE
). O

The O
_RARE_ I-GENE
gene I-GENE
from O
an O
_RARE_ I-GENE
sp O
. O
encoding O
a O
_RARE_ I-GENE
lyase I-GENE
( O
EC I-GENE
4 I-GENE
. O
2 I-GENE
. O
2 I-GENE
. O
2 I-GENE
) O
was O
isolated O
by O
activity O
screening O
a O
genomic O
DNA I-GENE
library O
in O
Streptomyces I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
. O

The O
gene I-GENE
contains O
six O
exons O
separated O
by O
1 I-GENE
. O
1 I-GENE
- I-GENE
5 I-GENE
. O
8 O
kb O
introns O
and O
has O
been O
localized O
to O
the O
murine I-GENE
chromosome O
2 I-GENE
by O
linkage O
analysis O
. O

In O
Xenopus I-GENE
embryos O
, O
the O
engineered I-GENE
PDGF I-GENE
receptor I-GENE
protein I-GENE
induced O
the O
formation O
of O
mesoderm O
from O
animal O
- I-GENE
pole O
_RARE_ I-GENE
in O
an O
_RARE_ I-GENE
- I-GENE
dependent I-GENE
manner O
. O

A I-GENE
cytosolic I-GENE
variant I-GENE
of O
the O
protein I-GENE
underwent O
efficient O
_RARE_ I-GENE
, O
yet O
failed O
to O
activate O
_RARE_ I-GENE
either O
p70 I-GENE
( O
_RARE_ I-GENE
) O
or O
MAP I-GENE
kinase I-GENE
following O
treatment O
with O
_RARE_ I-GENE
. O

_RARE_ I-GENE
- I-GENE
molecule I-GENE
control O
of O
insulin I-GENE
and O
PDGF I-GENE
receptor I-GENE
signaling O
and O
the O
role O
of O
membrane I-GENE
attachment O
. O

Conversely O
, O
the O
inactive O
_RARE_ I-GENE
subunit I-GENE
is O
_RARE_ I-GENE
activated I-GENE
by O
1 I-GENE
) O
association O
with O
a O
_RARE_ I-GENE
or O
_RARE_ I-GENE
subunit I-GENE
and O
2 I-GENE
) O
the O
_RARE_ I-GENE
driven O
_RARE_ I-GENE
affect O
of O
_RARE_ I-GENE
or O
_RARE_ I-GENE
bound O
to O
the O
_RARE_ I-GENE
subunit I-GENE
. O

CONCLUSIONS O
: O
A I-GENE
50 O
- I-GENE
mg O
daily O
dose O
of O
_RARE_ I-GENE
is O
sufficient O
when O
given O
in O
combination O
with O
an O
agent O
, O
such O
as O
a O
_RARE_ I-GENE
- I-GENE
A I-GENE
, O
that O
_RARE_ I-GENE
serum I-GENE
testosterone O
, O
but O
higher O
doses O
of O
_RARE_ I-GENE
may O
be O
needed O
when O
the O
drug O
is O
given O
as O
_RARE_ I-GENE
. O

A I-GENE
genomic O
clone O
was O
isolated O
that O
contained O
12 O
. O
5 I-GENE
kb O
of O
the O
5 I-GENE
'- O
flanking O
region O
and O
the O
first O
exon O
of O
the O
_RARE_ I-GENE
/ I-GENE
71 O
2 I-GENE
- I-GENE
_RARE_ I-GENE
synthetase I-GENE
gene I-GENE
. O

Although O
the O
gene I-GENE
is O
substantially O
smaller O
than O
the O
human I-GENE
genes I-GENE
for O
other O
mitochondrial I-GENE
enzymes O
, O
its O
intron O
/ I-GENE
exon O
organization O
is O
very O
similar O
, O
especially O
to O
that O
of O
_RARE_ I-GENE
. O

RESULTS O
: O
_RARE_ I-GENE
at O
the O
question O
of O
its O
benefits O
, O
we O
were O
unable O
to O
find O
any O
_RARE_ I-GENE
sound O
studies O
that O
have O
shown O
efficacy O
for O
_RARE_ I-GENE
in O
_RARE_ I-GENE
disorders O
, O
or O
, O
indeed O
, O
any O
psychiatric O
disorder O
. O

In O
the O
clinical O
study O
, O
the O
defect O
size O
shown O
by O
_RARE_ I-GENE
imaging O
was O
greater O
in O
anterior O
than O
in O
inferior O
_RARE_ I-GENE
( O
p O
< O
0 O
. O
001 O
) O
and O
correlated O
well O
with O
the O
risk O
area O
revealed O
by O
contrast O
_RARE_ I-GENE
( O
r O
= O
0 O
. O
80 O
, O
p O
< O
0 O
. O
0001 O
) O
CONCLUSION O
: O
The O
above O
preliminary O
data O
, O
_RARE_ I-GENE
from O
a O
small I-GENE
group O
of O
patients O
, O
suggest O
that O
_RARE_ I-GENE
_RARE_ I-GENE
imaging O
provides O
an O
accurate O
_RARE_ I-GENE
of O
defect O
size O
by O
means O
of O
a O
simple O
threshold O
technique O
and O
, O
in O
the O
subacute O
phase O
, O
permits O
determination O
of O
the O
amount O
of O
myocardium O
at O
risk O
after O
acute O
myocardial O
infarction O
. O

Transient O
overexpression O
of O
mutant I-GENE
_RARE_ I-GENE
receptors I-GENE
( O
_RARE_ I-GENE
) O
blocked O
_RARE_ I-GENE
recruitment O
to O
_RARE_ I-GENE
, O
attenuated O
downstream O
JNK I-GENE
activation O
, O
and O
blocked O
cell O
attachment O
responses O
. O

The O
promoter I-GENE
for O
HMG I-GENE
- I-GENE
CoA I-GENE
synthase I-GENE
contains O
two O
binding I-GENE
sites I-GENE
for O
the O
sterol I-GENE
regulatory I-GENE
element I-GENE
- I-GENE
binding I-GENE
proteins I-GENE
( O
_RARE_ I-GENE
). O

S I-GENE
., O
and O
_RARE_ I-GENE
, O
P I-GENE
. O

Here O
we O
demonstrate O
that O
_RARE_ I-GENE
and O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
act O
through O
those O
_RARE_ I-GENE
binding I-GENE
sites I-GENE
to O
modulate O
the O
level O
of O
_RARE_ I-GENE
- I-GENE
dependent I-GENE
transcriptional O
activation O
in O
S2 I-GENE
cells O
. O

Furthermore O
the O
median O
increase O
in O
cyclosporine O
DR I-GENE
/ I-GENE
C I-GENE
( O
SS I-GENE
trough O
) O
was O
18 O
l O
h O
- I-GENE
1 I-GENE
(- O
3 I-GENE
. O
1 I-GENE
to O
42 O
. O
1 I-GENE
l O
h O
- I-GENE
1 I-GENE
, O
_RARE_ I-GENE
range O
). O

Patients O
and O
their O
_RARE_ I-GENE
must O
be O
_RARE_ I-GENE
about O
the O
available O
effective O
treatment O
possibilities O
and O
about O
the O
right O
_RARE_ I-GENE
for O
their O
application O
in O
an O
individual O
patient O
. O

Several O
_RARE_ I-GENE
were O
expressed O
abundantly O
in O
the O
5 I-GENE
- I-GENE
FU O
- I-GENE
treated O
bone O
marrow O
stem O
cells O
. O

Expression O
of O
_RARE_ I-GENE
was O
also O
observed O
in O
human I-GENE
CD34 I-GENE
+ I-GENE
bone O
marrow O
cells O
and O
5 I-GENE
- I-GENE
FU O
- I-GENE
treated O
murine I-GENE
_RARE_ I-GENE
stem O
cells O
. O

The O
organization O
of O
_RARE_ I-GENE
genes I-GENE
involved O
in O
the O
replication O
, O
DNA I-GENE
_RARE_ I-GENE
and O
phage I-GENE
assembly O
proteins I-GENE
resembles O
the O
organization O
of O
genes I-GENE
of O
equivalent O
regions O
of O
different O
E I-GENE
. O
coli I-GENE
double O
- I-GENE
stranded I-GENE
DNA I-GENE
_RARE_ I-GENE
. O

Our O
results O
showed O
that O
compared O
to O
the O
primary O
photon O
_RARE_ I-GENE
, O
the O
extra I-GENE
- I-GENE
focal I-GENE
photon O
_RARE_ I-GENE
from O
the O
primary O
_RARE_ I-GENE
and O
the O
_RARE_ I-GENE
filter O
was O
11 O
_RARE_ I-GENE
16 O
% O
at O
the O
_RARE_ I-GENE
, O
among O
which O
70 I-GENE
% O
was O
contributed O
by O
the O
_RARE_ I-GENE
filter O
. O

The O
functional O
mature O
domain I-GENE
of O
_RARE_ I-GENE
_RARE_ I-GENE
( O
Lys O
+ I-GENE
1 I-GENE
to O
Cys I-GENE
+ I-GENE
44 I-GENE
) O
is O
targeted O
into O
the O
E I-GENE
. O
coli I-GENE
sec O
machinery O
and O
secreted O
to O
the O
_RARE_ I-GENE
in O
active O
form O
when O
fused O
in O
frame O
to O
the O
COOH O
terminus O
of O
the O
secretory I-GENE
protein I-GENE
_RARE_ I-GENE
- I-GENE
binding I-GENE
protein I-GENE
( O
MBP I-GENE
). O

_RARE_ I-GENE
were O
differentiated O
based O
on O
the O
MS O
- I-GENE
MS O
data O
of O
the O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
derivatives O
. O

Although O
_RARE_ I-GENE
, O
_RARE_ I-GENE
and O
_RARE_ I-GENE
are O
not O
required O
for O
cell O
cycle O
arrest O
when O
S I-GENE
phase O
is O
inhibited O
by O
_RARE_ I-GENE
( O
_RARE_ I-GENE
), O
they O
do O
contribute O
to O
the O
viability O
of O
yeast I-GENE
cells O
grown O
in O
the O
presence O
of O
_RARE_ I-GENE
, O
possibly O
because O
they O
are O
required O
for O
the O
repair I-GENE
of O
_RARE_ I-GENE
- I-GENE
induced O
DNA I-GENE
damage O
. O

Clinical O
value O
of O
the O
estimation O
of O
growth I-GENE
kinetics O
of O
primary O
ovarian O
cancer O
_RARE_ I-GENE
by O
_RARE_ I-GENE
_RARE_ I-GENE
time O

This O
review O
_RARE_ I-GENE
to O
_RARE_ I-GENE
the O
disease O
, O
to O
propose O
pathways O
of O
_RARE_ I-GENE
and O
to O
suggest O
ways O
in O
which O
the O
" O
_RARE_ I-GENE
" O
risk O
factors I-GENE
may O
be O
interpreted O
on O
the O
basis O
of O
_RARE_ I-GENE
knowledge O
. O

The O
patient O
underwent O
two O
_RARE_ I-GENE
sperm O
injection O
cycles O
with O
_RARE_ I-GENE
_RARE_ I-GENE
spermatozoa O
, O
in O
which O
, O
due O
to O
a O
_RARE_ I-GENE
' O
s O
_RARE_ I-GENE
, O
ovarian O
stimulation O
was O
carried O
out O
by O
a O
combination O
of O
long O
- I-GENE
acting O
_RARE_ I-GENE
- I-GENE
releasing I-GENE
hormone I-GENE
agonist O
( O
_RARE_ I-GENE
_RARE_ I-GENE
) O
and O
_RARE_ I-GENE
. O

Protein I-GENE
C I-GENE
deficiency O
or O
protein I-GENE
S I-GENE
deficiency O
was O
the O
only O
identified O
risk O
factor I-GENE
for O
5 I-GENE
. O
4 I-GENE
% O
( O
2 I-GENE
patients O
) O
and O
13 O
. O
5 I-GENE
% O
( O
5 I-GENE
patients O
), O
respectively O
, O
of O
these O
37 O
children O
. O

_RARE_ I-GENE
in O
addition O
to O
, O
or O
as O
part O
of O
, O
its O
essential O
function O
in O
late O
mitosis O
, O
_RARE_ I-GENE
is O
required O
for O
a O
cell O
cycle O
_RARE_ I-GENE
function O
necessary O
for O
the O
initiation I-GENE
of O
the O
spindle O
pole O
body O
duplication O
. O

In O
contrast O
, O
_RARE_ I-GENE
of O
_RARE_ I-GENE
is O
lethal O
in O
a O
_RARE_ I-GENE
- I-GENE
2 I-GENE
strain O
at O
the O
permissive O
temperature O
of O
25 O
degrees O
C I-GENE
. O

_RARE_ I-GENE
baseline O
( O
day O
- I-GENE
8 O
) O
PC I-GENE
levels O
( O
86 I-GENE
and O
89 I-GENE
%) O
were O
markedly O
reduced O
in O
both O
patients O
at O
the O
time O
of O
_RARE_ I-GENE
manifestation O
on O
day O
20 O
and O
40 I-GENE
, O
respectively O
( O
26 O
and O
31 O
%). O

To O
examine O
the O
role O
of O
this O
_RARE_ I-GENE
element I-GENE
in O
regulating O
_RARE_ I-GENE
expression O
in O
vivo O
, O
transgenic O
mice O
were O
generated O
which O
express O
a O
_RARE_ I-GENE
beta I-GENE
- I-GENE
galactosidase I-GENE
reporter I-GENE
gene I-GENE
that O
contains O
a O
mutation I-GENE
in O
the O
_RARE_ I-GENE
element I-GENE
. O

An O
evolutionary O
conserved O
element I-GENE
is O
essential O
for O
_RARE_ I-GENE
and O
adjacent O
mesenchymal O
expression O
of O
the O
_RARE_ I-GENE
gene I-GENE
. O

RESULTS O
: O
The O
bovine I-GENE
cDNA I-GENE
insert O
sequence I-GENE
was O
_RARE_ I-GENE
nucleotides O
in O
length I-GENE
for O
the O
entire O
mRNA I-GENE
coding O
region O
, O
_RARE_ I-GENE
nucleotides O
in O
the O
5 I-GENE
' O
untranslated O
region O
, O
83 O
nucleotides O
in O
the O
3 I-GENE
' O
untranslated O
region O
and O
a O
poly O
( O
A I-GENE
) O
tail O
. O

Altogether O
46 O
phase O
III I-GENE
activities O
were O
recorded O
. O

We O
have O
previously O
identified O
a O
liver O
- I-GENE
enriched O
transcription I-GENE
factor I-GENE
, O
HNF I-GENE
- I-GENE
6 I-GENE
, O
which O
is O
required O
for O
HNF I-GENE
- I-GENE
3 I-GENE
beta I-GENE
promoter I-GENE
activity O
and O
also O
recognizes O
the O
regulatory I-GENE
region O
of O
numerous O
hepatocyte I-GENE
- I-GENE
specific I-GENE
genes I-GENE
. O

A I-GENE
cDNA I-GENE
clone O
was O
identified O
encoding O
a O
second O
_RARE_ I-GENE
- I-GENE
R I-GENE
- I-GENE
related I-GENE
gene I-GENE
( O
_RARE_ I-GENE
). O

( O
1997 O
) O
_RARE_ I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
). O

P I-GENE
., O
_RARE_ I-GENE
, O
J O
. O

A I-GENE
_RARE_ I-GENE
clone O
( O
_RARE_ I-GENE
) O
resulting O
from O
the O
fusion I-GENE
between O
_RARE_ I-GENE
/ I-GENE
NP I-GENE
and O
human I-GENE
embryonic O
fibroblasts O
_RARE_ I-GENE
cells O
produced O
very O
large O
amounts O
of O
_RARE_ I-GENE
that O
was O
purified O
using O
_RARE_ I-GENE
_RARE_ I-GENE
( O
specific I-GENE
for O
O O
- I-GENE
_RARE_ I-GENE
) O
and O
_RARE_ I-GENE
. O

This O
information O
, O
together O
with O
estimation O
of O
the O
size O
of O
the O
_RARE_ I-GENE
A I-GENE
subunit I-GENE
relative O
to O
a O
series O
of O
C I-GENE
- I-GENE
terminal I-GENE
truncated I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
variants I-GENE
, O
_RARE_ I-GENE
cleavage O
Site I-GENE
1 I-GENE
in O
the O
vicinity O
of O
, O
or O
closely O
upstream O
to O
, O
residue O
_RARE_ I-GENE
. O

In O
vitro O
DNase I-GENE
I I-GENE
footprinting O
of O
the O
200 O
- I-GENE
bp O
proximal I-GENE
region O
of O
the O
promoter I-GENE
with O
a O
murine I-GENE
_RARE_ I-GENE
1 I-GENE
- I-GENE
6 I-GENE
cell O
nuclear I-GENE
extract O
revealed O
a O
clear O
footprint O
of O
a O
region O
corresponding O
to O
- I-GENE
80 O
to O
- I-GENE
28 O
bp O
of O
the O
murine I-GENE
_RARE_ I-GENE
gene I-GENE
, O
suggesting O
that O
liver O
factors I-GENE
interact O
with O
this O
region O
of O
the O
DNA I-GENE
. O

A I-GENE
reciprocal O
binding I-GENE
assay O
using O
IM O
- I-GENE
9 O
cells O
as O
a O
source O
of O
SHP I-GENE
- I-GENE
1 I-GENE
and O
SHP I-GENE
- I-GENE
2 I-GENE
revealed O
specific I-GENE
association O
of O
SHP I-GENE
- I-GENE
2 I-GENE
( O
but O
not O
SHP I-GENE
- I-GENE
1 I-GENE
) O
with O
a O
glutathione I-GENE
S I-GENE
- I-GENE
transferase I-GENE
fusion I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
cytoplasmic I-GENE
domain I-GENE
residues O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
, O
but O
only O
if O
the O
fusion I-GENE
was O
first O
_RARE_ I-GENE
tyrosine I-GENE
- I-GENE
phosphorylated O
. O

Both O
increasing O
basal O
FSH I-GENE
and O
age O
were O
associated I-GENE
significantly O
with O
increased O
total O
_RARE_ I-GENE
dose O
, O
and O
reduced O
number O
of O
oocytes O
collected O
and O
pregnancy O
rate O
. O

A I-GENE
comparative O
study O
was O
undertaken O
between O
an O
enzymatic O
immunohistochemical O
technique O
( O
_RARE_ I-GENE
) O
developed O
for O
the O
diagnosis O
of O
human I-GENE
_RARE_ I-GENE
and O
the O
indirect O
immunofluorescence O
test O
( O
_RARE_ I-GENE
), O
_RARE_ I-GENE
sera O
from O
_RARE_ I-GENE
of O
human I-GENE
_RARE_ I-GENE
in O
_RARE_ I-GENE
. O

Our O
results O
establish O
_RARE_ I-GENE
as O
a O
sequence I-GENE
- I-GENE
specific I-GENE
transcription I-GENE
factor I-GENE
likely O
involved O
in O
regulation O
of O
expression O
of O
endogenous I-GENE
genes I-GENE
. O

_RARE_ I-GENE
on O
a O
multicopy O
plasmid O
was O
unable O
to O
suppress O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
. O

Here O
we O
report O
that O
in O
cultured O
cells O
from O
Drosophila I-GENE
melanogaster I-GENE
human I-GENE
Sp1 I-GENE
efficiently O
activates O
transcription I-GENE
from O
synthetic O
promoters I-GENE
containing O
TATA I-GENE
boxes O
, O
but O
not O
from O
promoters I-GENE
that O
contain O
an O
initiator O
instead O
of O
a O
TATA I-GENE
box I-GENE
. O

No O
apparent O
clinical O
signs O
indicative O
of O
systemic O
toxicity O
were O
observed O
in O
the O
_RARE_ I-GENE
and O
F1 I-GENE
animals O
of O
either O
sex I-GENE
. O

We O
have O
used O
mutation I-GENE
- I-GENE
directed O
chemical O
cross O
- I-GENE
linking O
with O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
to O
investigate O
the O
architecture O
of O
the O
_RARE_ I-GENE
_RARE_ I-GENE
. O

In O
an O
effort O
to O
identify O
the O
_RARE_ I-GENE
disease O
gene I-GENE
we O
have O
isolated O
the O
region O
between O
these O
markers O
in O
yeast I-GENE
artificial O
chromosomes O
( O
YACs O
) O
using O
a O
combination O
of O
_RARE_ I-GENE
content O
mapping O
and O
Alu I-GENE
- I-GENE
PCR O
hybridization O
. O

_RARE_ I-GENE
analysis O
identified O
six O
clusters O
of O
expressed O
sequence I-GENE
tags O
( O
ESTs I-GENE
), O
two O
known O
genes I-GENE
( O
_RARE_ I-GENE
, O
_RARE_ I-GENE
) O
mapped O
previously O
to O
this O
region O
, O
and O
a O
previously O
characterized O
but O
_RARE_ I-GENE
gene I-GENE
_RARE_ I-GENE
( O
DNA I-GENE
binding I-GENE
/ I-GENE
EF I-GENE
hand O
/ I-GENE
acidic O
amino O
- I-GENE
acid I-GENE
- I-GENE
rich O
). O

A I-GENE
fusion I-GENE
protein I-GENE
composed O
of O
beta I-GENE
- I-GENE
galactosidase I-GENE
and O
full I-GENE
- I-GENE
length I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
from O
the O
cytoplasm O
to O
the O
nucleus O
in O
a O
ligand O
- I-GENE
dependent I-GENE
manner O
. O

_RARE_ I-GENE
of O
Raf I-GENE
- I-GENE
1 I-GENE
activity O
was O
observed O
only O
with O
kinase I-GENE
active O
_RARE_ I-GENE
in O
both O
cell O
lines O
. O

In O
addition O
, O
negatively O
regulatory I-GENE
region O
may O
exist O
from O
- I-GENE
_RARE_ I-GENE
to O
- I-GENE
_RARE_ I-GENE
bp O
. O

The O
hypothesis O
of O
_RARE_ I-GENE
( O
_RARE_ I-GENE
_RARE_ I-GENE
. O

The O
second O
transcript I-GENE
, O
_RARE_ I-GENE
, O
is O
_RARE_ I-GENE
. O

Consistent O
with O
this O
interpretation O
, O
a O
mutant I-GENE
form O
of O
_RARE_ I-GENE
, O
which O
encodes O
a O
5 I-GENE
'- O
3 I-GENE
' O
exonuclease I-GENE
, O
was O
identified O
as O
an O
_RARE_ I-GENE
suppressor I-GENE
that O
increases O
the O
half O
- I-GENE
life O
of O
_RARE_ I-GENE
mRNA I-GENE
, O
leading O
to O
a O
10 O
- I-GENE
fold O
increase O
in O
steady O
- I-GENE
state O
mRNA I-GENE
levels O
compared O
to O
the O
wild I-GENE
- I-GENE
type I-GENE
_RARE_ I-GENE
mRNA I-GENE
level O
. O

_RARE_ I-GENE
was O
initially O
identified O
by O
_RARE_ I-GENE
of O
its O
interaction O
with O
_RARE_ I-GENE
, O
a O
splicing O
factor I-GENE
of O
the O
SR I-GENE
family I-GENE
. O

Consistent O
with O
previous O
reports O
, O
addition O
of O
a O
_RARE_ I-GENE
signal I-GENE
to O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
_RARE_ I-GENE
it O
transforming I-GENE
for O
NIH O
3T3 O
cells O
and O
deletion O
of O
the O
_RARE_ I-GENE
C I-GENE
terminus O
( O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
) O
did O
not O
_RARE_ I-GENE
with O
this O
activity O
. O

Such O
mutations O
are O
thought O
to O
exert O
their O
dominant I-GENE
phenotype O
by O
_RARE_ I-GENE
of O
the O
guanine I-GENE
nucleotide I-GENE
exchange I-GENE
factor I-GENE
( O
_RARE_ I-GENE
). O

Several O
studies O
have O
characterized O
the O
upstream O
regulatory I-GENE
region O
of O
c I-GENE
- I-GENE
fos I-GENE
, O
and O
identified O
cis O
- I-GENE
acting O
elements O
termed O
the O
cyclic I-GENE
AMP I-GENE
( O
cAMP I-GENE
) O
response O
elements O
( O
_RARE_ I-GENE
) O
that O
are O
critical O
for O
c I-GENE
- I-GENE
fos I-GENE
transcription I-GENE
in O
response O
to O
a O
variety O
of O
extracellular I-GENE
stimuli O
. O

We O
have O
cloned O
a O
kinase I-GENE
, O
_RARE_ I-GENE
, O
that O
is O
a O
murine I-GENE
homolog I-GENE
of O
the O
Drosophila I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
gene I-GENE
. O

Our O
findings O
suggest O
that O
_RARE_ I-GENE
FDG O
and O
particularly O
_RARE_ I-GENE
are O
sensitive O
and O
effective O
measures O
of O
_RARE_ I-GENE
function O
and O
may O
help O
characterizing O
patients O
with O
multiple O
system O
atrophy O
. O

_RARE_ I-GENE
_RARE_ I-GENE
and O
the O
risk O
of O
injecting O
drug O
use O
. O

Genetic O
analysis O
has O
subsequently O
identified O
_RARE_ I-GENE
of O
the O
DNA I-GENE
structure O
_RARE_ I-GENE
, O
including O
the O
reversible O
arrest O
of O
DNA I-GENE
synthesis O
. O

Thus O
, O
_RARE_ I-GENE
promoters I-GENE
are O
responsive I-GENE
to O
CRP I-GENE
, O
a O
protein I-GENE
unrelated O
to O
_RARE_ I-GENE
activators I-GENE
, O
and O
the O
repression O
_RARE_ I-GENE
is O
the O
direct O
result O
of O
an O
interaction O
between O
_RARE_ I-GENE
and O
the O
CRP I-GENE
- I-GENE
cAMP I-GENE
complex I-GENE
. O

GlcNAc I-GENE
- I-GENE
and O
_RARE_ I-GENE
- I-GENE
PP I-GENE
- I-GENE
_RARE_ I-GENE
biosynthesis O
could O
be O
shown O
with O
isolated O
S I-GENE
. O
cerevisiae I-GENE
membranes O
from O
cells O
harboring O
the O
recombinant I-GENE
plasmid O
and O
grown O
on O
glucose O
thus O
_RARE_ I-GENE
transcription I-GENE
of O
the O
endogenous I-GENE
gene I-GENE
. O

_RARE_ I-GENE
of O
tissue I-GENE
lesions O
after O
_RARE_ I-GENE
injection O
by O
determination O
of O
creatine I-GENE
kinase I-GENE
in O
blood O

Antibodies O
raised O
against O
GST I-GENE
_RARE_ I-GENE
- I-GENE
B I-GENE
identified O
a O
cellular O
protein I-GENE
of O
92 O
kDa I-GENE
that O
was O
not O
found O
to O
be O
phosphorylated O
on O
Tyr I-GENE
. O

Interleukin I-GENE
- I-GENE
6 I-GENE
( O
IL I-GENE
- I-GENE
6 I-GENE
) O
is O
a O
pleiotropic O
cytokine O
, O
which O
is O
involved O
in O
inflammatory O
and O
immune I-GENE
responses O
, O
acute O
phase O
reactions O
, O
and O
_RARE_ I-GENE
. O

Upon O
analysis O
of O
various O
deletion O
and O
point O
- I-GENE
mutated O
variants I-GENE
of O
the O
human I-GENE
IL I-GENE
- I-GENE
6 I-GENE
gene I-GENE
promoter I-GENE
coupled I-GENE
to O
a O
reporter I-GENE
gene I-GENE
, O
we O
screened O
for O
possible O
_RARE_ I-GENE
transcription I-GENE
factors I-GENE
. O

This O
region O
, O
however O
, O
contains O
a O
_RARE_ I-GENE
box I-GENE
in O
the O
reverse I-GENE
complement I-GENE
and O
several O
GC I-GENE
boxes O
that O
are O
recognition I-GENE
sites I-GENE
for O
SP1 I-GENE
. O

Our O
purpose O
was O
to O
determine O
if O
intact O
_RARE_ I-GENE
( O
S4 I-GENE
- I-GENE
5 I-GENE
) O
_RARE_ I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
and O
_RARE_ I-GENE
( O
S2 I-GENE
- I-GENE
4 I-GENE
) O
reflex O
( O
BCR I-GENE
) O
_RARE_ I-GENE
after O
spinal O
cord O
injury O
( O
_RARE_ I-GENE
) O
are O
predictive O
of O
bladder O
function O
recovery O
. O

The O
correct O
termination O
of O
retroviral I-GENE
transcripts I-GENE
at O
the O
3 I-GENE
' O
LTR I-GENE
R I-GENE
/ I-GENE
U5 I-GENE
junction O
is O
primarily O
dependent I-GENE
on O
the O
canonical O
_RARE_ I-GENE
polyadenylation O
signal I-GENE
, O
so O
we O
have O
analyzed O
the O
effect O
of O
_RARE_ I-GENE
the O
polyadenylation O
signal I-GENE
sequences I-GENE
on O
the O
properties O
of O
a O
selectable O
murine I-GENE
retroviral I-GENE
vector O
. O

_RARE_ I-GENE
of O
the O
MEK I-GENE
inhibitor I-GENE
PD98059 O
that O
block O
EGF I-GENE
- I-GENE
induced O
_RARE_ I-GENE
and O
MAP I-GENE
kinase I-GENE
phosphorylation O
also O
abrogate O
EGF I-GENE
- I-GENE
induced O
focal I-GENE
adhesion I-GENE
_RARE_ I-GENE
and O
cell O
motility O
. O

_RARE_ I-GENE
levels O
in O
responders O
were O
lowered O
by O
46 O
% O
and O
_RARE_ I-GENE
levels O
were O
lowered O
by O
35 O
% O
after O
12 O
weeks O
of O
vitamin O
E I-GENE
treatment O
. O

Surprisingly O
, O
the O
COOH O
- I-GENE
terminal I-GENE
domain I-GENE
of O
_RARE_ I-GENE
was O
also O
found O
to O
harbor O
a O
nuclear I-GENE
localization O
signal I-GENE
. O

51 O
. O
9 O
% O
( O
P I-GENE
= O
0 O
. O
_RARE_ I-GENE
) O
in O
the O
_RARE_ I-GENE
versus O
the O
_RARE_ I-GENE
groups O
, O
respectively O
. O

Our O
study O
was O
designed O
to O
investigate O
the O
effect O
of O
_RARE_ I-GENE
on O
in O
vivo O
bone O
mineral O
metabolism O
. O

_RARE_ I-GENE
increased O
from O
15 O
. O
5 I-GENE
+/- O
5 I-GENE
. O
6 I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
+/- O
42 O
mm O
Hg O
) O
to O
17 O
. O
3 I-GENE
+/- O
6 I-GENE
. O
3 I-GENE
_RARE_ I-GENE
( O
130 I-GENE
+/- O
47 O
mm O
Hg O
) O
( O
P I-GENE
< O
0 O
. O
05 O
). O

_RARE_ I-GENE
_RARE_ I-GENE
of O
_RARE_ I-GENE
stress O
factors I-GENE
of O
_RARE_ I-GENE
_RARE_ I-GENE
children O
and O
_RARE_ I-GENE

_RARE_ I-GENE
cats O
received O
_RARE_ I-GENE
at O
a O
dosage O
of O
10 O
mg O
/ I-GENE
kg O
body O
weight O
, O
nine O
cats O
received O
_RARE_ I-GENE
at O
a O
dosage O
of O
25 O
mg O
/ I-GENE
kg O
body O
weight O
. O

Resistance O
to O
thyroid I-GENE
hormone I-GENE
: O
implications O
for O
_RARE_ I-GENE
research O
on O
the O
effects O
of O
thyroid I-GENE
hormone I-GENE
_RARE_ I-GENE
. O

Here O
, O
we O
present O
evidence O
that O
exposure O
of O
_RARE_ I-GENE
lymphoma O
B I-GENE
cells O
to O
low O
energy O
_RARE_ I-GENE
field O
( O
_RARE_ I-GENE
) O
results O
in O
a O
tyrosine I-GENE
kinase I-GENE
- I-GENE
dependent I-GENE
activation O
of O
phospholipase I-GENE
_RARE_ I-GENE
( O
PLC I-GENE
- I-GENE
_RARE_ I-GENE
) O
leading O
to O
increased O
inositol I-GENE
phospholipid I-GENE
turnover O
. O

We O
present O
the O
preliminary O
results O
obtained O
on O
36 O
patients O
which O
were O
followed O
for O
a O
mean O
period O
of O
12 O
months O
. O

Moreover O
, O
_RARE_ I-GENE
could O
block O
the O
expression O
of O
ventral O
mesoderm O
marker O
genes I-GENE
induced O
by O
_RARE_ I-GENE
or O
5 I-GENE
. O

PATIENTS O
AND O
_RARE_ I-GENE
: O
Since O
1986 O
, O
62 O
patients O
were O
irradiated O
_RARE_ I-GENE
. O

The O
assay O
exhibits O
a O
dynamic O
range O
of O
0 O
. O
1 I-GENE
- I-GENE
100 O
micrograms O
l O
- I-GENE
1 I-GENE
using O
a O
monoclonal I-GENE
antibody I-GENE
or O
alternatively O
10 O
micrograms O
l O
- I-GENE
1 I-GENE
to O
10 O
mg O
l O
- I-GENE
1 I-GENE
using O
_RARE_ I-GENE
available O
antiserum O
. O

_RARE_ I-GENE
for O
_RARE_ I-GENE
. O

A I-GENE
canonical O
TATA I-GENE
box I-GENE
was O
not O
detected O
. O

Expression O
and O
characterization O
of O
recombinant I-GENE
single O
- I-GENE
chain I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
fragments I-GENE
derived O
from O
a O
set O
of O
catalytic O
antibodies I-GENE
. O

A I-GENE
putative O
inhibitor I-GENE
( O
s O
) O
appears O
to O
co O
- I-GENE
_RARE_ I-GENE
in O
the O
inactive O
fraction O
that O
blocked O
the O
L I-GENE
( O
alpha I-GENE
) O
activity O
. O

Platelet I-GENE
aggregation O
in O
response O
to O
10 O
micrograms O
collagen I-GENE
/ I-GENE
ml O
was O
decreased O
in O
parallel O
after O
treatment O
with O
ASA I-GENE
. O

Using O
_RARE_ I-GENE
mutants I-GENE
, O
we O
confirmed O
that O
_RARE_ I-GENE
plays O
a O
role O
in O
the O
_RARE_ I-GENE
- I-GENE
dependent I-GENE
regulation O
of O
_RARE_ I-GENE
- I-GENE
lacZ I-GENE
expression O
in O
vivo O
. O

Cross O
- I-GENE
_RARE_ I-GENE
among O
Drosophila I-GENE
nuclear I-GENE
receptors I-GENE
at O
the O
_RARE_ I-GENE
response O
element I-GENE
of O
the O
ng O
- I-GENE
1 I-GENE
and O
ng O
- I-GENE
2 I-GENE
_RARE_ I-GENE
genes I-GENE
. O

The O
ipsilateral O
breast O
tumor I-GENE
relapse O
rate O
was O
similar O
between O
the O
_RARE_ I-GENE
and O
_RARE_ I-GENE
groups O
. O

_RARE_ I-GENE
aggregation O
of O
low O
- I-GENE
and O
high O
- I-GENE
density I-GENE
lipoprotein I-GENE
cholesterol I-GENE
and O
_RARE_ I-GENE
B I-GENE
and O
A I-GENE
- I-GENE
I I-GENE
levels O
in O
black O
and O
white O
children O
: O
the O
_RARE_ I-GENE
_RARE_ I-GENE
Study O
. O

The O
_RARE_ I-GENE
protein I-GENE
also O
exhibited O
several O
unique O
features O
, O
including O
a O
novel O
stretch O
of O
18 O
- I-GENE
19 O
amino O
acid I-GENE
residues O
within O
the O
X I-GENE
domain I-GENE
and O
an O
unusually O
long O
N I-GENE
- I-GENE
terminus O
which O
did O
not O
contain O
a O
_RARE_ I-GENE
EF I-GENE
- I-GENE
hand O
Ca I-GENE
( O
2 I-GENE
+)- I-GENE
binding I-GENE
domain I-GENE
. O

This O
hypothesis O
is O
consistent O
with O
the O
occurrence O
of O
PEA3 I-GENE
binding I-GENE
sites I-GENE
in O
the O
PEA3 I-GENE
promoter I-GENE
and O
with O
the O
ability O
of O
PEA3 I-GENE
to O
transactivate O
this O
promoter I-GENE
. O

_RARE_ I-GENE
- I-GENE
1 I-GENE
can O
bind O
specifically O
to O
a O
PEA3 I-GENE
ETS I-GENE
DNA I-GENE
- I-GENE
binding I-GENE
motif I-GENE
and O
can O
modulate O
transcription I-GENE
of O
synthetic O
promoter I-GENE
constructs I-GENE
in O
a O
sequence I-GENE
- I-GENE
specific I-GENE
manner O
. O

The O
protein I-GENE
expressed O
by O
_RARE_ I-GENE
cDNA I-GENE
in O
transfected O
COS O
cells O
is O
localized O
in O
the O
cytoplasm O
. O

Northern O
analysis O
indicated O
differential O
expression O
by O
tissue I-GENE
with O
highest O
expression O
in O
the O
heart O
. O

As O
well O
, O
further O
deletion O
of O
the O
promoter I-GENE
region O
to O
nucleotide I-GENE
- I-GENE
110 I-GENE
, O
which O
contains O
only O
one O
SF I-GENE
- I-GENE
1 I-GENE
binding I-GENE
site I-GENE
, O
still O
retained O
the O
ability O
to O
respond O
to O
exogenous O
SF I-GENE
- I-GENE
1 I-GENE
. O

The O
observation O
that O
beta I-GENE
_RARE_ I-GENE
with O
covalently O
attached O
peptide I-GENE
can O
effectively O
create O
CTL O
target O
structures O
in O
vitro O
offers O
new O
possibilities O
for O
the O
in O
vivo O
induction O
of O
epitope O
- I-GENE
specific I-GENE
CTL O
responses O
by O
either O
DNA I-GENE
immunization O
or O
injection O
of O
the O
purified O
epitope O
- I-GENE
linked O
beta I-GENE
_RARE_ I-GENE
. O

The O
mRNAs I-GENE
of O
these O
genes I-GENE
contain O
respectively O
one O
( O
_RARE_ I-GENE
uORF I-GENE
) O
and O
two O
( O
_RARE_ I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
) O
upstream O
open O
reading O
frames O
. O
uORF I-GENE
- I-GENE
mediated O
modulation O
of O
post O
- I-GENE
termination O
events O
on O
the O
5 I-GENE
'- O
untranslated O
region O
( O
5 I-GENE
'- O
UTR I-GENE
) O
directs O
differential O
control O
not O
only O
of O
translation I-GENE
but O
also O
of O
mRNA I-GENE
decay O
. O

To O
further O
investigate O
the O
nature O
of O
the O
site I-GENE
specificity O
a O
set O
of O
deletion O
mutants I-GENE
of O
the O
160 I-GENE
bp O
sequence I-GENE
were O
analysed O
. O

In O
the O
tissues O
tested O
, O
except O
brain O
, O
the O
message I-GENE
for O
_RARE_ I-GENE
- I-GENE
170 I-GENE
was O
more O
abundant O
than O
that O
for O
_RARE_ I-GENE
. O

BACKGROUND O
: O
_RARE_ I-GENE
vary O
considerably O
in O
their O
intrinsic O
ability O
to O
cause O
allergic O
contact O
dermatitis O
. O

_RARE_ I-GENE
_RARE_ I-GENE
of O
T I-GENE
cells O
is O
regulated O
by O
an O
_RARE_ I-GENE
tyrosine I-GENE
- I-GENE
based O
activation O
motif I-GENE
- I-GENE
dependent I-GENE
mechanism O
. O

Here O
we O
have O
examined O
the O
ability O
of O
the O
cellular O
protein I-GENE
_RARE_ I-GENE
- I-GENE
1 I-GENE
to O
modulate O
transcription I-GENE
of O
the O
HIV I-GENE
- I-GENE
1 I-GENE
promoter I-GENE
in O
a O
human I-GENE
_RARE_ I-GENE
cell O
line O
( O
U O
- I-GENE
_RARE_ I-GENE
), O
a O
neuronal O
cell O
line O
( O
_RARE_ I-GENE
- I-GENE
N I-GENE
- I-GENE
MC O
) O
and O
lymphoid I-GENE
cells O
( O
Jurkat O
) O
by O
transfection O
assay O
. O

Also O
, O
the O
deduced O
amino O
acids O
of O
the O
antigenic I-GENE
regions O
A I-GENE
, O
B I-GENE
and O
C I-GENE
of O
_RARE_ I-GENE
were O
nearly O
conserved O
within O
the O
phylogenetic O
lineages O
. O

The O
cloned O
_RARE_ I-GENE
gene I-GENE
provided O
in O
trans O
restored O
these O
_RARE_ I-GENE
system O
activities O
to O
the O
mutants I-GENE
. O

The O
cloned O
_RARE_ I-GENE
gene I-GENE
provided O
in O
trans O
restored O
these O
_RARE_ I-GENE
system O
activities O
to O
the O
mutants I-GENE
. O

Copyright O
1998 O
Academic O
Press O
. O

It O
may O
also O
be O
suggested O
that O
particular O
care O
should O
be O
taken O
when O
such O
a O
trans O
- I-GENE
dominant I-GENE
Rev I-GENE
mutant I-GENE
is O
considered O
to O
be O
used O
as O
a O
genetic O
therapy O
against O
HIV I-GENE
- I-GENE
I I-GENE
infection O
, O
in O
individuals O
infected O
with O
both O
HIV I-GENE
- I-GENE
I I-GENE
and O
HTLV I-GENE
- I-GENE
1 I-GENE
. O

PATIENTS O
AND O
METHODS O
: O
_RARE_ I-GENE
January O
1992 O
and O
_RARE_ I-GENE
1994 O
at O
_RARE_ I-GENE
. O

The O
frequency O
of O
_RARE_ I-GENE
for O
both O
the O
moderate O
and O
severe O
groups O
was O
significantly O
higher O
than O
that O
in O
patients O
with O
a O
normal O
_RARE_ I-GENE
( O
p O
< O
. O
01 O
); O
of O
154 O
_RARE_ I-GENE
with O
a O
normal O
_RARE_ I-GENE
, O
only O
9 O
( O
6 I-GENE
%) O
had O
an O
SP I-GENE
. O

We O
analyzed O
the O
P I-GENE
- I-GENE
_RARE_ I-GENE
in O
the O
time O
and O
frequency O
domain I-GENE
in O
23 O
patients O
with O
_RARE_ I-GENE
and O
19 O
controls O
. O

_RARE_ I-GENE
reverse I-GENE
transcription I-GENE
- I-GENE
polymerase I-GENE
chain I-GENE
reaction O
and O
HPLC O
analysis O
showed O
that O
_RARE_ I-GENE
- I-GENE
1alpha I-GENE
is O
the O
progesterone I-GENE
- I-GENE
dependent I-GENE
splice O
variant I-GENE
. O

_RARE_ I-GENE
is O
part O
of O
two O
related I-GENE
signaling O
pathways O
_RARE_ I-GENE
cell O
growth I-GENE
in O
Saccharomyces I-GENE
cerevisiae I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
. O

SETTING O
: O
A I-GENE
division O
of O
a O
large O
_RARE_ I-GENE
_RARE_ I-GENE
in O
_RARE_ I-GENE
. O

_RARE_ I-GENE
models O
of O
_RARE_ I-GENE
interaction O
did O
not O
fully O
account O
for O
the O
kinetic O
profiles O
obtained O
with O
the O
parental O
antibodies I-GENE
and O
the O
hybrids O
, O
and O
this O
complexity O
suggested O
the O
existence O
of O
a O
conformational O
heterogeneity O
in O
these O
molecules I-GENE
. O

In O
order O
to O
_RARE_ I-GENE
the O
pathway O
that O
leads O
to O
Hox I-GENE
gene I-GENE
induction O
, O
we O
have O
investigated O
whether O
a O
Hox I-GENE
gene I-GENE
regulator I-GENE
, O
the O
leucine I-GENE
zipper I-GENE
transcription I-GENE
factor I-GENE
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
, O
is O
itself O
transcriptionally O
regulated O
by O
the O
environmental O
signals O
. O

_RARE_ I-GENE
for O
_RARE_ I-GENE
( O
_RARE_ I-GENE
- I-GENE
abl I-GENE
) O
are O
likely O
to O
be O
involved O
in O
the O
pathogenesis O
of O
CML O
. O

_RARE_ I-GENE
constructs I-GENE
function O
in O
a O
parallel O
manner O
, O
demonstrating O
the O
key O
role O
of O
the O
_RARE_ I-GENE
in O
constitutive O
as O
well O
as O
_RARE_ I-GENE
- I-GENE
induced O
expression O
of O
_RARE_ I-GENE
in O
mouse I-GENE
embryo O
fibroblasts O
. O

Transfection O
studies O
also O
showed O
that O
3 I-GENE
'- O
deletion O
of O
sequences I-GENE
downstream O
of O
the O
transcriptional O
start O
site I-GENE
(+ O
1 I-GENE
_RARE_ I-GENE
47 O
) O
markedly O
reduced O
_RARE_ I-GENE
- I-GENE
fold O
induction O
. O

_RARE_ I-GENE
M I-GENE
stimulates O
c I-GENE
- I-GENE
Fos I-GENE
to O
bind O
a O
transcriptionally O
responsive I-GENE
AP I-GENE
- I-GENE
1 I-GENE
element I-GENE
within O
the O
tissue I-GENE
inhibitor I-GENE
of O
_RARE_ I-GENE
- I-GENE
1 I-GENE
promoter I-GENE
. O

We O
have O
isolated O
a O
new O
human I-GENE
RING I-GENE
- I-GENE
finger I-GENE
gene I-GENE
( O
_RARE_ I-GENE
) O
that O
encodes O
a O
190 O
- I-GENE
amino O
- I-GENE
acid I-GENE
protein I-GENE
. O

To O
elucidate O
the O
regulatory I-GENE
mechanism O
of O
human I-GENE
AM I-GENE
gene I-GENE
expression O
, O
functional O
elements O
of O
5 I-GENE
'- O
flanking O
region O
of O
AM I-GENE
gene I-GENE
were O
studied O
in O
human I-GENE
aortic O
endothelial I-GENE
cells O
( O
_RARE_ I-GENE
). O

The O
COOH O
- I-GENE
terminal I-GENE
region O
of O
the O
transcripts I-GENE
contained O
_RARE_ I-GENE
triplet O
repeats I-GENE
( O
_RARE_ I-GENE
; O
alanine I-GENE
) O
at O
nucleotide I-GENE
_RARE_ I-GENE
to O
_RARE_ I-GENE
, O
which O
is O
significantly O
_RARE_ I-GENE
compared O
to O
the O
rat I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
ligand O
- I-GENE
binding I-GENE
domain I-GENE
: O
high O
- I-GENE
yield O
production O
of O
active O
fusion I-GENE
and O
non O
- I-GENE
fusion I-GENE
recombinant I-GENE
proteins I-GENE
using O
the O
baculovirus O
/ I-GENE
insect O
cell O
system O
. O

Control O
of O
fatty I-GENE
liver O
syndrome O
in O
a O
_RARE_ I-GENE
herd O
by O
a O
change O
of O
diet O
and O
the O
use O
of O
recombinant I-GENE
bovine I-GENE
_RARE_ I-GENE
. O

The O
inhibition O
of O
focus O
formation O
observed O
in O
the O
presence O
of O
_RARE_ I-GENE
was O
not O
due O
to O
toxic O
effects O
on O
cell O
viability O
, O
since O
transfected O
_RARE_ I-GENE
cells O
exhibited O
the O
same O
survival O
and O
growth I-GENE
rates O
as O
_RARE_ I-GENE
NIH3T3 O
cells O
or O
cells O
transfected O
with O
plasmid O
vector O
alone O
. O

C I-GENE
. O
D2 I-GENE
- I-GENE
Chr O
4 I-GENE
_RARE_ I-GENE
strains O
harboring O
_RARE_ I-GENE
/ I-GENE
2 I-GENE
alleles I-GENE
associated I-GENE
with O
the O
_RARE_ I-GENE
locus I-GENE
contained O
_RARE_ I-GENE
/ I-GENE
2 I-GENE
" O
resistant O
" O
alleles I-GENE
of O
the O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
inhibitors O
p16 I-GENE
and O
_RARE_ I-GENE
. O

When O
tested O
with O
wild I-GENE
- I-GENE
type I-GENE
( O
_RARE_ I-GENE
/ I-GENE
2 I-GENE
) O
p16 I-GENE
, O
both O
_RARE_ I-GENE
and O
_RARE_ I-GENE
BALB O
/ I-GENE
c I-GENE
- I-GENE
specific I-GENE
variants I-GENE
of O
p16 I-GENE
were O
inefficient O
in O
their O
ability O
to O
inhibit O
the O
activity O
of O
cyclin I-GENE
D2 I-GENE
/ I-GENE
_RARE_ I-GENE
in O
kinase I-GENE
assays O
with O
retinoblastoma I-GENE
protein I-GENE
, O
suggesting O
this O
defective O
, O
inherited O
allele I-GENE
plays O
an O
important O
role O
in O
the O
genetic O
susceptibility I-GENE
of O
BALB O
/ I-GENE
c I-GENE
mice O
for O
_RARE_ I-GENE
induction O
and O
that O
p16 I-GENE
( O
_RARE_ I-GENE
) O
is O
a O
strong O
candidate O
for O
the O
_RARE_ I-GENE
locus I-GENE
. O

Despite O
this O
there O
was O
no O
difference O
in O
the O
_RARE_ I-GENE
conditions O
at O
one O
minute O
with O
25 O
excellent O
/ I-GENE
5 I-GENE
good O
in O
the O
_RARE_ I-GENE
group O
and O
27 O
excellent O
/ I-GENE
3 I-GENE
good O
in O
the O
_RARE_ I-GENE
group O
. O

Cloning O
and O
expression O
of O
two O
genes I-GENE
encoding O
_RARE_ I-GENE
- I-GENE
binding I-GENE
proteins I-GENE
from O
tobacco I-GENE
. O

Furthermore O
, O
direct O
association O
with O
D3 I-GENE
_RARE_ I-GENE
seems O
to O
be O
essential O
for O
activation O
of O
PKB I-GENE
/ I-GENE
Akt I-GENE
. O

The O
_RARE_ I-GENE
_RARE_ I-GENE
but O
not O
the O
[ O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
] O
cluster I-GENE
of O
the O
subunit I-GENE
appears O
to O
participate O
in O
this O
reaction O
. O

_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
. O

METHODS O
: O
A I-GENE
population O
survey O
was O
undertaken O
in O
10 O
, O
_RARE_ I-GENE
individuals O
to O
measure O
the O
prevalence O
and O
identify O
the O
causes O
of O
_RARE_ I-GENE
in O
_RARE_ I-GENE
. O

During O
_RARE_ I-GENE
, O
_RARE_ I-GENE
- I-GENE
8 O
expression O
is O
found O
in O
the O
_RARE_ I-GENE
mesoderm O
in O
close O
_RARE_ I-GENE
of O
the O
gut O
endoderm O
, O
suggesting O
a O
role O
in O
mesenchymal O
- I-GENE
epithelial O
induction O
of O
lung O
and O
gut O
_RARE_ I-GENE
. O

However O
, O
_RARE_ I-GENE
failed O
to O
establish O
_RARE_ I-GENE
in O
any O
cases O
of O
carcinoma O
spread O
to O
areas O
not O
_RARE_ I-GENE
to O
laparoscopic O
visualization O
. O

No O
difference O
in O
telomere I-GENE
length I-GENE
was O
seen O
in O
mutants I-GENE
affected O
in O
the O
regulation O
of O
Cdc2 I-GENE
, O
whereas O
some O
of O
the O
DNA I-GENE
repair I-GENE
mutants I-GENE
examined O
had O
slightly O
longer O
_RARE_ I-GENE
than O
did O
the O
wild I-GENE
type I-GENE
. O

The O
mean O
duration O
of O
pain O
_RARE_ I-GENE
was O
4 I-GENE
- I-GENE
6 I-GENE
weeks O
. O

The O
_RARE_ I-GENE
differs O
from O
conventional O
_RARE_ I-GENE
in O
that O
no O
sample O
preparation O
is O
needed O
, O
_RARE_ I-GENE
_RARE_ I-GENE
changes O
. O

Sp1 I-GENE
can O
activate O
transcription I-GENE
through O
immunoglobulin I-GENE
kappa I-GENE
- I-GENE
chain I-GENE
enhancer I-GENE
or O
P I-GENE
- I-GENE
selectin I-GENE
promoter I-GENE
NF I-GENE
- I-GENE
kappaB I-GENE
sites I-GENE
. O
p50 I-GENE
homodimers I-GENE
replace O
Sp1 I-GENE
from O
the O
P I-GENE
- I-GENE
selectin I-GENE
promoter I-GENE
by O
binding I-GENE
site I-GENE
competition O
and O
thereby O
either O
inhibit O
basal O
Sp1 I-GENE
- I-GENE
driven O
expression O
or O
, O
in O
_RARE_ I-GENE
with O
Bcl I-GENE
- I-GENE
3 I-GENE
, O
stimulate O
expression O
. O

The O
3 I-GENE
' O
fragment I-GENE
was O
shown O
to O
accumulate O
as O
full I-GENE
- I-GENE
length I-GENE
mRNA I-GENE
disappeared O
in O
_RARE_ I-GENE
D I-GENE
- I-GENE
treated O
cells O
, O
indicating O
a O
precursor I-GENE
- I-GENE
product I-GENE
relationship O
. O

The O
TATA I-GENE
box I-GENE
- I-GENE
binding I-GENE
protein I-GENE
( O
TBP I-GENE
) O
plays O
an O
essential O
role O
in O
transcription I-GENE
by O
all O
three O
eukaryotic I-GENE
nuclear I-GENE
RNA I-GENE
polymerases I-GENE
, O
polymerases I-GENE
( O
Pol I-GENE
) O
I I-GENE
, O
II I-GENE
, O
and O
III I-GENE
. O

A I-GENE
triple O
- I-GENE
mutant I-GENE
TBP I-GENE
( O
_RARE_ I-GENE
+ I-GENE
_RARE_ I-GENE
+ I-GENE
_RARE_ I-GENE
) O
had O
greatly O
reduced O
activity O
for O
yeast I-GENE
U6 I-GENE
snRNA I-GENE
gene I-GENE
transcription I-GENE
while O
remaining O
active O
for O
Pol I-GENE
II I-GENE
basal O
transcription I-GENE
. O

E2F I-GENE
activity O
is O
regulated O
in O
part O
by O
the O
retinoblastoma I-GENE
family I-GENE
of O
tumor I-GENE
suppressor I-GENE
proteins I-GENE
. O

This O
resulted O
in O
a O
complete O
inhibition O
of O
Site I-GENE
- I-GENE
1 I-GENE
cleavage O
that O
was O
restored O
by O
concomitant O
overexpression O
of O
full I-GENE
- I-GENE
length I-GENE
_RARE_ I-GENE
. O

To O
determine O
the O
true O
molecular O
identity O
of O
_RARE_ I-GENE
, O
both O
the O
50 O
- I-GENE
and O
57 O
- I-GENE
kDa I-GENE
polypeptides I-GENE
were O
directly O
sequenced O
. O

Molecular O
characterization O
of O
the O
50 O
- I-GENE
and O
57 O
- I-GENE
kDa I-GENE
subunits I-GENE
of O
the O
bovine I-GENE
vacuolar I-GENE
proton I-GENE
pump I-GENE
. O

In O
C I-GENE
. O
albicans I-GENE
, O
_RARE_ I-GENE
is O
expressed O
constitutively O
at O
high O
levels O
in O
the O
different O
cell O
types O
analysed O
( O
yeast I-GENE
, O
_RARE_ I-GENE
, O
white O
and O
_RARE_ I-GENE
), O
demonstrating O
that O
_RARE_ I-GENE
transcription I-GENE
is O
not O
repressed O
in O
this O
diploid O
yeast I-GENE
, O
unlike O
in O
diploid O
S I-GENE
. O
cerevisiae I-GENE
, O
and O
suggesting O
a O
basic I-GENE
biological O
function O
for O
the O
_RARE_ I-GENE
transporter I-GENE
in O
C I-GENE
. O
albicans I-GENE
. O

Furthermore O
, O
binding I-GENE
of O
recombinant I-GENE
Myb I-GENE
and O
Ets I-GENE
- I-GENE
2 I-GENE
protein I-GENE
to O
these O
fragments I-GENE
could O
be O
_RARE_ I-GENE
with O
an O
excess O
of O
double O
stranded I-GENE
_RARE_ I-GENE
containing O
canonical O
, O
but O
not O
mutated O
, O
Myb I-GENE
- I-GENE
or O
Ets I-GENE
- I-GENE
binding I-GENE
sites I-GENE
. O

This O
structure O
_RARE_ I-GENE
specific I-GENE
_RARE_ I-GENE
of O
the O
basal O
bodies O
with O
the O
_RARE_ I-GENE
_RARE_ I-GENE
that O
_RARE_ I-GENE
from O
the O
basal O
apparatus O
. O

To O
understand O
the O
regulatory I-GENE
mechanism O
controlling O
its O
expression O
at O
low O
temperature O
, O
the O
promoter I-GENE
region O
has O
been O
characterized O
. O

In O
the O
current O
study O
, O
the O
roles O
of O
two O
putative O
cis O
- I-GENE
acting O
elements O
within O
the O
- I-GENE
73 O
to O
+ I-GENE
44 I-GENE
region O
in O
basal O
exon O
2 I-GENE
promoter I-GENE
activity O
were O
evaluated O
using O
mutagenesis O
and O
nuclear I-GENE
protein I-GENE
- I-GENE
DNA I-GENE
binding I-GENE
assays O
. O

For O
the O
_RARE_ I-GENE
receptor I-GENE
the O
addition O
of O
_RARE_ I-GENE
resulted O
in O
a O
similar O
but O
smaller O
effect O
. O

We O
have O
examined O
reporter I-GENE
gene I-GENE
( O
beta I-GENE
- I-GENE
_RARE_ I-GENE
) O
expression O
directed O
by O
human I-GENE
heat I-GENE
shock I-GENE
transcription I-GENE
factors I-GENE
1 I-GENE
and O
2 I-GENE
( O
HSF1 I-GENE
and O
_RARE_ I-GENE
) O
in O
HeLa O
cells O
and O
in O
yeast I-GENE
( O
Saccharomyces I-GENE
cerevisiae I-GENE
). O

_RARE_ I-GENE
fluorescence O
was O
detectable O
only O
in O
cells O
containing O
a O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
, O
suggesting O
that O
_RARE_ I-GENE
targeting O
normally O
occurs O
only O
at O
a O
late O
stage O
of O
_RARE_ I-GENE
. O

No O
TATA I-GENE
box I-GENE
was O
found O
in O
the O
putative O
promoter I-GENE
region O
, O
but O
multiple O
GC I-GENE
boxes O
were O
found O
around O
the O
cap I-GENE
sites I-GENE
, O
supporting O
the O
previously O
_RARE_ I-GENE
housekeeping O
nature O
of O
_RARE_ I-GENE
gene I-GENE
and O
the O
existence O
of O
the O
multiple O
transcription I-GENE
initiation I-GENE
sites I-GENE
. O

Structural O
and O
evolutionary O
studies O
on O
sterol I-GENE
14 O
- I-GENE
_RARE_ I-GENE
P450 I-GENE
( O
_RARE_ I-GENE
), O
the O
most O
conserved O
P450 I-GENE
_RARE_ I-GENE
: O
I I-GENE
. O

Its O
expression O
pattern O
is O
representative O
of O
many O
B I-GENE
cell O
- I-GENE
specific I-GENE
proteins I-GENE
, O
which O
are O
essential O
for O
B I-GENE
cell O
development O
and O
activation O
but O
are O
down O
- I-GENE
regulated O
after O
B I-GENE
cells O
become O
terminally I-GENE
differentiated O
plasma I-GENE
cells O
. O

The O
_RARE_ I-GENE
gene I-GENE
junctions O
of O
vesicular O
stomatitis I-GENE
virus I-GENE
( O
_RARE_ I-GENE
) O
contain O
conserved O
sequence I-GENE
elements O
that O
are O
important O
for O
polyadenylation O
and O
transcription I-GENE
termination O
of O
upstream O
transcript I-GENE
as O
well O
as O
_RARE_ I-GENE
of O
transcription I-GENE
of O
downstream O
transcript I-GENE
. O

_RARE_ I-GENE
mutant I-GENE
virus I-GENE
_RARE_ I-GENE
was O
obtained O
only O
on O
_RARE_ I-GENE
_RARE_ I-GENE
- I-GENE
expressing O
cells O
, O
suggesting O
that O
_RARE_ I-GENE
has O
an O
important O
function O
in O
the O
replication O
cycle O
. O

_RARE_ I-GENE
and O
DNA I-GENE
joining O
reactions O
, O
carried O
out O
by O
human I-GENE
immunodeficiency I-GENE
virus I-GENE
type I-GENE
1 I-GENE
( O
HIV I-GENE
- I-GENE
1 I-GENE
) O
integrase I-GENE
, O
are O
necessary O
to O
effect O
the O
_RARE_ I-GENE
insertion O
of O
HIV I-GENE
- I-GENE
1 I-GENE
DNA I-GENE
into O
the O
host O
genome O
. O

The O
_RARE_ I-GENE
regimen O
appears O
to O
have O
significant O
activity O
in O
patients O
who O
have O
metastatic O
pancreatic O
islet O
- I-GENE
cell O
carcinoma O
, O
and O
patient O
tolerance O
of O
the O
regimen O
is O
excellent O
, O
thus O
_RARE_ I-GENE
further O
investigation O
. O

Activation O
of O
the O
mitogen I-GENE
activated I-GENE
protein I-GENE
( O
MAP I-GENE
) O
kinase I-GENE
is O
a O
primary O
consequence O
of O
Ras I-GENE
activation O
and O
plays O
a O
key O
role O
in O
mediating O
Ras I-GENE
signal I-GENE
transduction O
. O

_RARE_ I-GENE
acetylation O
levels O
in O
cells O
result O
from O
a O
dynamic O
equilibrium O
between O
_RARE_ I-GENE
histone I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
. O

CONCLUSIONS O
: O
_RARE_ I-GENE
may O
play O
a O
pivotal O
role O
in O
the O
transcriptional O
cascade O
that O
specifies O
primary O
neurons O
in O
Xenopus I-GENE
embryos O
: O
by O
maintaining O
Delta I-GENE
- I-GENE
Notch I-GENE
signalling O
, O
_RARE_ I-GENE
_RARE_ I-GENE
the O
higher O
neural O
potential O
of O
selected O
progenitor I-GENE
cells O
that O
express O
X I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
1 I-GENE
, O
_RARE_ I-GENE
the O
transition O
between O
neural O
_RARE_ I-GENE
and O
irreversible O
_RARE_ I-GENE
to O
a O
neural O
fate O
; O
and O
it O
promotes O
neuronal O
differentiation O
by O
activating I-GENE
_RARE_ I-GENE
expression O
, O
directly O
or O
indirectly O
. O

RESULTS O
: O
Patients O
in O
Group O
A I-GENE
had O
a O
higher O
incidence O
of O
_RARE_ I-GENE
wall O
motion O
abnormalities O
( O
p O
< O
0 O
. O
001 O
) O
on O
_RARE_ I-GENE
_RARE_ I-GENE
, O
a O
larger O
infarct O
area O
( O
as O
_RARE_ I-GENE
by O
higher O
peak O
creatine I-GENE
kinase I-GENE
levels O
) O
( O
p O
< O
0 O
. O
02 O
) O
and O
a O
lower O
left O
ventricular O
ejection O
fraction O
( O
LVEF O
) O
at O
hospital O
discharge O
( O
p O
< O
0 O
. O
_RARE_ I-GENE
) O
than O
those O
in O
Group O
B I-GENE
. O

_RARE_ I-GENE
transcription I-GENE
follows O
, O
and O
is O
therefore O
downstream O
of O
, O
the O
initial O
_RARE_ I-GENE
of O
these O
embryonic O
domains I-GENE
. O

_RARE_ I-GENE
- I-GENE
regulation O
downstream O
of O
cell O
type I-GENE
_RARE_ I-GENE
: O
a O
single O
_RARE_ I-GENE
element I-GENE
controls O
the O
complex I-GENE
expression O
of O
the O
_RARE_ I-GENE
gene I-GENE
in O
sea O
urchin I-GENE
embryos O
. O

We O
also O
present O
evidence O
that O
human I-GENE
_RARE_ I-GENE
is O
identical O
to O
an O
uncharacterized O
gene I-GENE
_RARE_ I-GENE
cloned O
by O
others O
from O
chromosome O
_RARE_ I-GENE
. O
3 I-GENE
that O
is O
_RARE_ I-GENE
deleted O
in O
several O
small I-GENE
- I-GENE
cell O
lung O
carcinoma O
cell O
lines O
. O

In O
patients O
with O
_RARE_ I-GENE
, O
_RARE_ I-GENE
' O
s O
syndrome O
, O
skin O
vasculitis O
and O
vascular I-GENE
diseases O
_RARE_ I-GENE
concentrations O
were O
higher O
than O
in O
patients O
without O
them O
. O

Although O
the O
expression O
of O
the O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
gene I-GENE
alone O
has O
not O
yet O
been O
_RARE_ I-GENE
, O
the O
gene I-GENE
was O
expressed O
in O
Escherichia I-GENE
coli I-GENE
[ O
_RARE_ I-GENE
( O
_RARE_ I-GENE
)] O
as O
a O
fusion I-GENE
gene I-GENE
with O
the O
glutathione I-GENE
- I-GENE
S I-GENE
- I-GENE
transferase I-GENE
( O
GST I-GENE
) O
gene I-GENE
using O
a O
prokaryotic I-GENE
gene I-GENE
fusion I-GENE
vector O
( O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
2 I-GENE
), O
which O
contains O
a O
gene I-GENE
sequence I-GENE
coding O
the O
cleavage O
site I-GENE
for O
a O
specific I-GENE
protease I-GENE
, O
alpha I-GENE
- I-GENE
thrombin I-GENE
. O

_RARE_ I-GENE
comparison O
of O
addition O
of O
autologous O
bone O
- I-GENE
marrow O
transplantation O
to O
intensive O
chemotherapy O
for O
acute O
myeloid O
_RARE_ I-GENE
in O
first O
remission O
: O
results O
of O
_RARE_ I-GENE
_RARE_ I-GENE
10 O
trial O
. O

_RARE_ I-GENE
use O
of O
_RARE_ I-GENE
. O

Analysis O
of O
_RARE_ I-GENE
_RARE_ I-GENE
shows O
that O
this O
function O
depends O
on O
the O
amino O
acid I-GENE
preceding O
the O
first O
cysteine I-GENE
residue O
of O
the O
DNA I-GENE
- I-GENE
binding I-GENE
domain I-GENE
of O
_RARE_ I-GENE
. O

_RARE_ I-GENE
visual O
stimuli O
and O
_RARE_ I-GENE
auditory O
stimuli O
were O
used O
as O
targets O
. O

A I-GENE
review O
of O
studies O
published O
between O
1983 O
and O
1995 O
shows O
that O
there O
are O
some O
common O
factors I-GENE
as O
_RARE_ I-GENE
the O
psychological O
distress O
and O
social O
and O
functional O
limitations O
this O
group O
of O
patients O
has O
to O
_RARE_ I-GENE
with O
. O

PKC I-GENE
- I-GENE
gamma I-GENE
, O
which O
is O
not O
present O
in O
_RARE_ I-GENE
, O
also O
induces O
_RARE_ I-GENE
gene I-GENE
expression O
in O
a O
TPA O
- I-GENE
independent O
manner O
, O
when O
introduced O
into O
_RARE_ I-GENE
cells O
. O

Identification O
and O
characterization O
of O
specific I-GENE
DNA I-GENE
- I-GENE
binding I-GENE
complexes I-GENE
containing O
members O
of O
the O
Myc I-GENE
/ I-GENE
Max I-GENE
/ I-GENE
_RARE_ I-GENE
network O
of O
transcriptional O
regulators O
. O

We O
further O
show O
that O
proteolytic O
targeting O
by O
_RARE_ I-GENE
II I-GENE
and O
the O
proteasome I-GENE
involves O
different O
structural O
elements O
of O
YY1 I-GENE
. O

_RARE_ I-GENE
for O
subsequent O
_RARE_ I-GENE
of O
RACE O
were O
designed O
from O
the O
5 I-GENE
'- O
ends O
of O
amplified O
RACE O
products I-GENE
. O

Human I-GENE
_RARE_ I-GENE
protein I-GENE
is O
a O
transcriptional O
repressor I-GENE
that O
interacts O
with O
the O
transcription I-GENE
activation O
domain I-GENE
of O
stage O
- I-GENE
specific I-GENE
activator I-GENE
protein I-GENE
. O

Surprisingly O
, O
the O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
was O
as O
effective O
as O
the O
_RARE_ I-GENE
/ I-GENE
IR I-GENE
in O
mediating O
CSF I-GENE
- I-GENE
1 I-GENE
protection O
of O
cells O
from O
_RARE_ I-GENE
- I-GENE
induced O
apoptosis O
. O

CONCLUSIONS O
: O
The O
special O
clinical O
presentation O
of O
our O
case O
of O
possible O
_RARE_ I-GENE
' O
s O
syndrome O
is O
discussed O
. O

These O
results O
would O
suggest O
that O
a O
high O
UV O
sensitivity O
is O
associated I-GENE
with O
high O
_RARE_ I-GENE
and O
low O
_RARE_ I-GENE
levels O
, O
and O
point O
to O
the O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
ratio O
as O
a O
novel O
chemical O
parameter O
that O
could O
be O
used O
for O
predicting O
individuals O
at O
high O
risk O
for O
skin O
cancer O
and O
melanoma O
. O

In O
_RARE_ I-GENE
naturally O
infected O
with O
H I-GENE
. O
_RARE_ I-GENE
, O
a O
single O
dose O
( O
50 O
mg O
/ I-GENE
kg O
, O
per O
_RARE_ I-GENE
) O
of O
_RARE_ I-GENE
completely O
inhibited O
bacterial I-GENE
urease I-GENE
. O

The O
cAMP I-GENE
- I-GENE
dependent I-GENE
mitogenic O
pathway O
is O
unique O
as O
it O
is O
independent O
of O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
activation O
and O
differs O
from O
growth I-GENE
factor I-GENE
- I-GENE
dependent I-GENE
pathways O
at O
the O
level O
of O
the O
expression O
of O
several O
_RARE_ I-GENE
/ I-GENE
transcription I-GENE
factors I-GENE
. O

CONCLUSIONS O
: O
Use O
of O
the O
first O
method O
was O
associated I-GENE
with O
a O
reduction O
in O
the O
time O
patients O
remained O
in O
the O
_RARE_ I-GENE
before O
transfer I-GENE
to O
another O
unit I-GENE
and O
_RARE_ I-GENE
in O
nursing O
time O
, O
but O
the O
two O
methods O
did O
not O
differ O
according O
to O
clinical O
outcomes O
. O

We O
have O
_RARE_ I-GENE
the O
exon O
- I-GENE
intron O
organization O
of O
the O
entire O
human I-GENE
_RARE_ I-GENE
gene I-GENE
, O
including O
approximately O
2 I-GENE
. O
5 I-GENE
kilobases O
( O
kb O
) O
of O
5 I-GENE
'- O
flanking O
DNA I-GENE
. O

The O
risk O
factors I-GENE
for O
_RARE_ I-GENE
in O
patients O
with O
renal O
_RARE_ I-GENE
are O
the O
elevation O
of O
urinary O
_RARE_ I-GENE
concentration O
and O
the O
subtypes O
of O
Post O
and O
_RARE_ I-GENE
. O

Two O
hundred O
_RARE_ I-GENE
- I-GENE
four O
patients O
_RARE_ I-GENE
for O
_RARE_ I-GENE
were O
randomized O
to O
receive O
intravenously O
_RARE_ I-GENE
0 O
. O
25 O
mg O
( O
_RARE_ I-GENE
- I-GENE
25 O
), O
or O
_RARE_ I-GENE
0 O
. O
5 I-GENE
mg O
( O
_RARE_ I-GENE
- I-GENE
50 O
), O
or O
_RARE_ I-GENE
20 O
mg O
as O
_RARE_ I-GENE
agent O
. O

If O
the O
_RARE_ I-GENE
concentration O
( O
Hb I-GENE
) O
was O
less O
than O
12 O
g O
dL O
- I-GENE
1 I-GENE
they O
were O
given O
a O
four O
week O
course O
of O
_RARE_ I-GENE
_RARE_ I-GENE
. O

In O
all O
cells O
, O
the O
accumulation O
of O
high O
_RARE_ I-GENE
protein I-GENE
levels O
required O
calcium O
and O
was O
not O
observed O
in O
low O
calcium O
( O
0 O
. O
05 O
- I-GENE
0 O
. O
07 O
mM O
) O
media O
. O

Based O
on O
restriction I-GENE
enzyme I-GENE
analysis O
, O
Southern O
blots O
, O
polymerase I-GENE
chain I-GENE
reaction O
analysis O
and O
DNA I-GENE
sequencing O
, O
it O
was O
confirmed O
that O
the O
three O
overlapping O
clones O
isolated O
_RARE_ I-GENE
the O
entire O
_RARE_ I-GENE
- I-GENE
1 I-GENE
gene I-GENE
, O
as O
well O
as O
approximately O
10 O
kb O
of O
the O
flanking O
regions O
on O
both O
ends O
. O

RESULTS O
: O
Using O
information O
in O
the O
_RARE_ I-GENE
database O
of O
expressed O
sequence I-GENE
tags O
, O
we O
isolated O
an O
Arabidopsis I-GENE
thaliana O
gene I-GENE
( O
_RARE_ I-GENE
) O
that O
encodes O
a O
protein I-GENE
with O
seven O
predicted O
membrane I-GENE
- I-GENE
spanning O
domains I-GENE
and O
other O
features O
characteristic O
of O
_RARE_ I-GENE
receptors I-GENE
. O

E1A I-GENE
represses O
apolipoprotein I-GENE
_RARE_ I-GENE
enhancer I-GENE
activity O
in O
liver O
cells O
through O
a O
pRb I-GENE
- I-GENE
and O
CBP I-GENE
- I-GENE
independent O
pathway O
. O

_RARE_ I-GENE
- I-GENE
independent O
expression O
of O
a O
human I-GENE
nerve I-GENE
growth I-GENE
factor I-GENE
- I-GENE
luciferase I-GENE
reporter I-GENE
gene I-GENE
cloned O
on O
a O
yeast I-GENE
artificial O
chromosome O
vector O
. O

_RARE_ I-GENE
therapy O
was O
associated I-GENE
with O
a O
decrease O
in O
serum I-GENE
_RARE_ I-GENE
levels O
( O
_RARE_ I-GENE
+/- O
_RARE_ I-GENE
. O
9 O
vs O
. O

_RARE_ I-GENE
in O
DNase I-GENE
I I-GENE
reactivity O
of O
the O
GC I-GENE
- I-GENE
response O
element I-GENE
region O
suggest O
that O
GC I-GENE
receptor I-GENE
- I-GENE
GC I-GENE
complexes I-GENE
may O
associate O
, O
in O
a O
transient O
manner O
, O
with O
the O
promoter I-GENE
in O
the O
actively O
_RARE_ I-GENE
control O
state O
. O

Most O
pituitary I-GENE
hormone I-GENE
- I-GENE
coding O
gene I-GENE
promoters I-GENE
are O
activated I-GENE
by O
_RARE_ I-GENE
. O

One O
of O
these O
small I-GENE
_RARE_ I-GENE
might O
be O
inactive O
or O
a O
" O
_RARE_ I-GENE
_RARE_ I-GENE
." I-GENE
The O
results O
suggest O
a O
_RARE_ I-GENE
architecture O
for O
_RARE_ I-GENE
, O
clarify O
their O
origin O
and O
relationship O
to O
other O
protein I-GENE
families O
, O
and O
extend O
recent O
experimental O
findings O
on O
the O
functional O
roles O
of O
_RARE_ I-GENE
N I-GENE
, O
C I-GENE
, O
and O
_RARE_ I-GENE
motifs O
. O

_RARE_ I-GENE
of O
_RARE_ I-GENE
enriched O
for O
two O
polypeptides I-GENE
of O
_RARE_ I-GENE
molecular O
mass O
15 O
kDa I-GENE
and O
16 O
kDa I-GENE
, O
designated O
_RARE_ I-GENE
and O
_RARE_ I-GENE
. O

M I-GENE
- I-GENE
66 O
identified O
the O
14 O
- I-GENE
kDa I-GENE
protein I-GENE
in O
another O
MMTV I-GENE
bearing O
T I-GENE
- I-GENE
cell O
lymphoma O
, O
_RARE_ I-GENE
- I-GENE
4 I-GENE
. O

These O
results O
indicate O
that O
TGF I-GENE
- I-GENE
_RARE_ I-GENE
potentiates O
the O
c I-GENE
- I-GENE
fos I-GENE
SRE O
activated I-GENE
by O
PKC I-GENE
through O
the O
SRF I-GENE
binding I-GENE
site I-GENE
. O

RT I-GENE
- I-GENE
PCR O
indicated O
that O
p21 I-GENE
mRNA I-GENE
was O
induced O
1 I-GENE
. O
4 I-GENE
-, I-GENE
2 I-GENE
. O
0 O
-, I-GENE
and O
3 I-GENE
. O
1 I-GENE
- I-GENE
fold O
in O
the O
2 I-GENE
- I-GENE
day O
neonatal O
, O
7 O
- I-GENE
day O
neonatal O
, O
and O
adult O
stages O
, O
respectively O
, O
compared O
to O
the O
17 O
- I-GENE
day O
fetal O
stage O
. O

_RARE_ I-GENE
and O
_RARE_ I-GENE
efficacy O
in O
AIDS O
- I-GENE
related I-GENE
CMV O
_RARE_ I-GENE
. O

BACKGROUND O
: O
_RARE_ I-GENE
, O
also O
known O
as O
human I-GENE
neutrophil I-GENE
peptides I-GENE
, O
are O
antimicrobial O
peptides I-GENE
present O
in O
the O
_RARE_ I-GENE
granules O
of O
neutrophils O
. O

The O
spontaneous O
mutation I-GENE
blocking O
_RARE_ I-GENE
gene I-GENE
expression O
was O
located O
in O
the O
promoter I-GENE
for O
the O
_RARE_ I-GENE
operon I-GENE
. O

From O
250 O
g O
of O
cells O
, O
we O
isolated O
1 I-GENE
mg O
of O
_RARE_ I-GENE
complex I-GENE
with O
a O
specific I-GENE
activity O
of O
12 O
. O
6 I-GENE
U O
/ I-GENE
mg O
of O
protein I-GENE
. O

The O
_RARE_ I-GENE
complex I-GENE
- I-GENE
encoding O
genes I-GENE
were O
identified O
by O
hybridization O
experiments O
and O
sequence I-GENE
analysis O
in O
two O
separate O
gene I-GENE
regions O
in O
the O
genome O
of O
Z I-GENE
. O
_RARE_ I-GENE
. O

We O
have O
identified O
two O
functional O
elements O
, O
both O
located O
downstream O
from O
the O
TATA I-GENE
motif I-GENE
, O
that O
control O
_RARE_ I-GENE
promoter I-GENE
activity O
. O

_RARE_ I-GENE
is O
a O
new O
generation O
_RARE_ I-GENE
antibiotic O
with O
unusual O
and O
_RARE_ I-GENE
pharmacokinetics O
, O
and O
seems O
to O
be O
a O
very O
_RARE_ I-GENE
agent O
for O
_RARE_ I-GENE
anti I-GENE
- I-GENE
H I-GENE
. O
pylori I-GENE
regimens O
. O

The O
study O
enrolled O
_RARE_ I-GENE
people O
co O
- I-GENE
infected O
with O
CMV O
and O
HIV I-GENE
, O
with O
at O
least O
one O
CD4 I-GENE
count O
recorded O
< O
100 O
x O
10 O
( O
6 I-GENE
) O
cells O
/ I-GENE
l O
. O

BACKGROUND O
AND O
OBJECTIVES O
: O
The O
_RARE_ I-GENE
transmitted O
diseases O
( O
_RARE_ I-GENE
) O
control O
program O
for O
female O
sex I-GENE
workers O
( O
_RARE_ I-GENE
) O
in O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
provided O
periodic I-GENE
serological O
tests O
for O
_RARE_ I-GENE
and O
cervical O
smears O
for O
_RARE_ I-GENE
, O
but O
not O
medication O
for O
_RARE_ I-GENE
or O
_RARE_ I-GENE
. O

National O
_RARE_ I-GENE
: O
a O
vital O
component O
of O
quality O
_RARE_ I-GENE
. O

Two O
rare O
novel O
mutations O
, O
_RARE_ I-GENE
in O
exon O
20 O
and O
_RARE_ I-GENE
in O
exon O
21 O
, O
were O
identified O
in O
the O
first O
nucleotide I-GENE
- I-GENE
binding I-GENE
fold O
( O
_RARE_ I-GENE
), O
a O
functionally O
important O
region O
of O
_RARE_ I-GENE
, O
in O
one O
patient O
each O
, O
both O
_RARE_ I-GENE
. O

_RARE_ I-GENE
VP16 I-GENE
- I-GENE
E2 I-GENE
molecules I-GENE
suggest O
that O
the O
epithelial O
specific I-GENE
transcriptional O
activation O
of O
the O
BPV I-GENE
- I-GENE
4 I-GENE
LCR I-GENE
promoter I-GENE
is O
mediated O
by O
the O
E2 I-GENE
transactivation O
domain I-GENE
. O

In O
order O
to O
examine O
the O
potential O
role O
of O
transcriptional O
silencing O
during O
_RARE_ I-GENE
HSV I-GENE
- I-GENE
1 I-GENE
infection O
, O
recombinant I-GENE
viruses O
were O
generated O
in O
which O
wild I-GENE
- I-GENE
type I-GENE
or O
mutant I-GENE
_RARE_ I-GENE
. O
5 I-GENE
promoters I-GENE
controlling O
the O
expression O
of O
a O
chloramphenicol I-GENE
acetyltransferase I-GENE
reporter I-GENE
gene I-GENE
were O
inserted O
into O
the O
thymidine I-GENE
kinase I-GENE
gene I-GENE
of O
the O
viral I-GENE
genome O
. O

These O
changes O
correlate O
directly O
with O
an O
increase O
in O
the O
acetylation O
levels O
of O
all O
four O
core I-GENE
_RARE_ I-GENE
in O
vivo O
. O

Drosophila I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
and O
murine I-GENE
_RARE_ I-GENE
genes I-GENE
_RARE_ I-GENE
this O
, O
both O
in O
terms O
of O
expression O
patterns O
and O
mutant I-GENE
phenotypes O
. O

_RARE_ I-GENE
transcripts I-GENE
are O
first O
detected O
in O
a O
_RARE_ I-GENE
region O
that O
will O
give O
rise O
to O
the O
_RARE_ I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
, O
and O
expression O
is O
maintained O
in O
this O
region O
during O
subsequent O
development O
of O
these O
organs O
. O

We O
also O
recovered O
mutations O
in O
the O
_RARE_ I-GENE
gene I-GENE
which O
encodes O
another O
TGF I-GENE
- I-GENE
beta I-GENE
- I-GENE
related I-GENE
factor I-GENE
in O
Drosophila I-GENE
. O

Cell O
lines O
are O
_RARE_ I-GENE
to O
find O
out O
whether O
they O
develop O
tumors O
in O
nude O
mice O
followed O
by O
an O
analysis O
of O
the O
_RARE_ I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
fibronectin I-GENE
in O
the O
prediction O
of O
preterm O
labour O
in O
a O
low O
- I-GENE
risk O
population O
. O

In O
addition O
, O
IgM I-GENE
can O
be O
absent O
in O
children O
with O
congenital O
_RARE_ I-GENE
or O
subjects O
with O
secondary O
_RARE_ I-GENE
. O

Both O
variants I-GENE
display O
the O
seven O
- I-GENE
transmembrane I-GENE
topology O
that O
is O
typical O
for O
G I-GENE
protein I-GENE
- I-GENE
coupled I-GENE
receptors I-GENE
. O

A I-GENE
constitutive O
allele I-GENE
of O
_RARE_ I-GENE
could O
stimulate O
growth I-GENE
of O
a O
strain O
lacking O
both O
_RARE_ I-GENE
genes I-GENE
. O

The O
COOH O
- I-GENE
terminus O
of O
this O
new O
isoform I-GENE
, O
which O
we O
_RARE_ I-GENE
beta I-GENE
4 I-GENE
, O
lacks O
a O
22 O
amino O
acid I-GENE
lysine O
- I-GENE
rich O
sequence I-GENE
common O
to O
both O
the O
human I-GENE
red I-GENE
cell O
alpha I-GENE
- I-GENE
and O
beta I-GENE
- I-GENE
_RARE_ I-GENE
subunits I-GENE
and O
homologous O
to O
a O
highly O
conserved O
region O
in O
_RARE_ I-GENE
, O
a O
filamentous I-GENE
actin I-GENE
- I-GENE
cross O
linking O
protein I-GENE
regulated O
by O
protein I-GENE
kinase I-GENE
C I-GENE
and O
calcium O
/ I-GENE
calmodulin I-GENE
. O
beta I-GENE
4 I-GENE
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
a O
previously O
identified O
calmodulin I-GENE
binding I-GENE
domain I-GENE
. O

PCR O
analysis O
indicates O
that O
this O
new O
beta I-GENE
- I-GENE
_RARE_ I-GENE
isoform I-GENE
is O
expressed O
in O
fetal O
brain O
and O
liver O
, O
bone O
marrow O
, O
and O
_RARE_ I-GENE
- I-GENE
2 I-GENE
( O
_RARE_ I-GENE
) O
cells O
, O
but O
is O
not O
detected O
in O
several O
other O
tissues O
. O

The O
gene I-GENE
lac I-GENE
- I-GENE
1 I-GENE
, O
encoding O
the O
enzyme I-GENE
_RARE_ I-GENE
, O
is O
the O
best O
characterized O
of O
a O
number O
of O
genes I-GENE
in O
the O
_RARE_ I-GENE
_RARE_ I-GENE
fungus I-GENE
, O
_RARE_ I-GENE
_RARE_ I-GENE
, O
that O
are O
repressed O
by O
_RARE_ I-GENE
, O
a O
group O
of O
virulence I-GENE
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
. O
lac I-GENE
- I-GENE
1 I-GENE
has O
also O
been O
shown O
to O
be O
transcriptionally O
activated I-GENE
by O
low O
concentrations O
of O
the O
translational O
inhibitor I-GENE
cycloheximide I-GENE
( O
_RARE_ I-GENE
) O
and O
by O
the O
_RARE_ I-GENE
cyclosporin O
A I-GENE
. O

Both O
TRE I-GENE
- I-GENE
like I-GENE
elements O
were O
capable O
of O
binding I-GENE
AP1 I-GENE
. O

The O
_RARE_ I-GENE
gamma I-GENE
protein I-GENE
interacts O
strongly O
with O
the O
activated I-GENE
_RARE_ I-GENE
but O
not O
with O
the O
kinase I-GENE
- I-GENE
negative O
mutant I-GENE
receptor I-GENE
. O
_RARE_ I-GENE
gamma I-GENE
also O
interacts O
with O
the O
insulin I-GENE
receptor I-GENE
( O
IR I-GENE
) O
in O
the O
yeast I-GENE
two O
- I-GENE
hybrid O
system O
. O

The O
plant O
protein I-GENE
maintains O
all O
the O
functional O
domains I-GENE
found O
in O
the O
other O
proteins I-GENE
, O
including O
nuclear I-GENE
localization O
signal I-GENE
, O
DNA I-GENE
- I-GENE
binding I-GENE
domain I-GENE
and O
helicase I-GENE
motifs O
, O
suggesting O
that O
it O
might O
also O
act O
as O
part O
of O
the O
RNA I-GENE
transcription I-GENE
apparatus O
, O
as O
well O
as O
nucleotide I-GENE
excision O
repair I-GENE
in O
plant O
cells O
. O

This O
paper O
describes O
the O
genomic O
organization O
of O
mouse I-GENE
_RARE_ I-GENE
and O
the O
characterization O
of O
its O
5 I-GENE
' O
flanking O
region O
. O

_RARE_ I-GENE
proteins I-GENE
have O
been O
shown O
to O
regulate O
urease I-GENE
in O
Klebsiella I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
), O
and O
catalase I-GENE
in O
Escherichia I-GENE
coli I-GENE
( O
OxyR I-GENE
), O
which O
offers O
the O
intracellular O
bacterium O
protection O
from O
_RARE_ I-GENE
damage O
. O

Also O
, O
the O
anti I-GENE
- I-GENE
inflammatory O
activities O
of O
an O
aqueous O
extract O
of O
_RARE_ I-GENE
_RARE_ I-GENE
and O
its O
principal O
_RARE_ I-GENE
_RARE_ I-GENE
were O
evaluated O
. O

Regulation O
of O
the O
Raf I-GENE
kinase I-GENE
in O
T I-GENE
cells O
differs O
from O
findings O
with O
a O
variety O
of O
cell O
lines O
that O
the O
catalytic O
domain I-GENE
of O
Raf I-GENE
( O
Raf I-GENE
( O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
)) O
shows O
no O
activity O
. O

_RARE_ I-GENE
- I-GENE
length I-GENE
_RARE_ I-GENE
clones O
were O
isolated O
from O
a O
mouse I-GENE
skeletal I-GENE
muscle O
cDNA I-GENE
library O
. O

Members O
of O
the O
_RARE_ I-GENE
and O
_RARE_ I-GENE
homeodomain I-GENE
protein I-GENE
families O
_RARE_ I-GENE
bind O
a O
cAMP I-GENE
- I-GENE
responsive I-GENE
sequence I-GENE
( O
_RARE_ I-GENE
) O
from O
bovine I-GENE
_RARE_ I-GENE
. O

We O
have O
_RARE_ I-GENE
DNA I-GENE
- I-GENE
protein I-GENE
complexes I-GENE
by O
electron O
microscopy O
and O
a O
high O
- I-GENE
affinity O
binding I-GENE
site I-GENE
of O
_RARE_ I-GENE
Rep I-GENE
protein I-GENE
within O
the O
core I-GENE
element I-GENE
has O
been O
mapped O
to O
approximately O
_RARE_ I-GENE
+/- O
18 O
bp O
upstream O
from O
the O
initiation I-GENE
site I-GENE
, O
between O
the O
start O
site I-GENE
for O
complementary O
- I-GENE
sense O
transcription I-GENE
and O
the O
TATA I-GENE
box I-GENE
. O

Rex I-GENE
- I-GENE
1 I-GENE
, O
a O
gene I-GENE
encoding O
a O
transcription I-GENE
factor I-GENE
expressed O
in O
the O
early I-GENE
embryo O
, O
is O
regulated O
via O
Oct I-GENE
- I-GENE
3 I-GENE
/ I-GENE
4 I-GENE
and O
Oct I-GENE
- I-GENE
6 I-GENE
binding I-GENE
to O
an O
octamer O
site I-GENE
and O
a O
novel O
protein I-GENE
, O
_RARE_ I-GENE
- I-GENE
1 I-GENE
, O
binding I-GENE
to O
an O
adjacent O
site I-GENE
. O

However O
, O
inhibition O
of O
both O
the O
ERK I-GENE
/ I-GENE
_RARE_ I-GENE
and O
the O
p38 I-GENE
/ I-GENE
_RARE_ I-GENE
kinase I-GENE
2 I-GENE
pathways O
completely O
abolished O
_RARE_ I-GENE
- I-GENE
induced O
CREB I-GENE
Ser O
- I-GENE
133 I-GENE
phosphorylation O
. O

_RARE_ I-GENE
respond O
to O
the O
accumulation O
of O
_RARE_ I-GENE
proteins I-GENE
in O
the O
endoplasmic O
reticulum O
( O
ER I-GENE
) O
by O
increasing O
the O
transcription I-GENE
of O
the O
genes I-GENE
encoding O
ER I-GENE
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
proteins I-GENE
. O

The O
_RARE_ I-GENE
- I-GENE
cyclic I-GENE
AMP I-GENE
- I-GENE
dependent I-GENE
protein I-GENE
kinase I-GENE
_RARE_ I-GENE
pathway O
prevents O
the O
UAS O
activity O
of O
_RARE_ I-GENE
in O
the O
presence O
of O
glucose O
as O
the O
_RARE_ I-GENE
carbon O
source O
, O
while O
the O
transcriptional O
activators I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
promote O
the O
UAS O
activity O
of O
this O
repeat I-GENE
in O
the O
presence O
of O
acetate O
. O

The O
_RARE_ I-GENE
+ I-GENE
gene I-GENE
of O
the O
fission I-GENE
yeast I-GENE
Schizosaccharomyces I-GENE
pombe I-GENE
was O
cloned O
by O
functional O
complementation O
. O

Alternative O
splicing O
of O
fibroblast I-GENE
growth I-GENE
factor I-GENE
receptor I-GENE
2 I-GENE
( O
FGF I-GENE
- I-GENE
R2 I-GENE
) O
is O
an O
example O
of O
highly O
regulated O
alternative O
splicing O
in O
which O
exons O
_RARE_ I-GENE
and O
_RARE_ I-GENE
are O
utilized O
in O
a O
_RARE_ I-GENE
_RARE_ I-GENE
manner O
in O
different O
cell O
types O
. O

In O
some O
cases O
, O
the O
aberrant O
methylation O
of O
_RARE_ I-GENE
within O
5 I-GENE
' O
regulatory I-GENE
regions O
has O
led O
to O
suppression O
of O
gene I-GENE
activity O
. O

The O
genomic O
fragments I-GENE
were O
fused O
upstream O
of O
the O
luciferase I-GENE
reporter I-GENE
gene I-GENE
. O

Cotransfection O
analyses O
of O
the O
T I-GENE
/ I-GENE
EBP I-GENE
promoter I-GENE
- I-GENE
reporter I-GENE
constructs I-GENE
with O
a O
T I-GENE
/ I-GENE
EBP I-GENE
expression O
vector O
into O
human I-GENE
HepG2 O
cells O
, O
which O
do O
not O
express O
T I-GENE
/ I-GENE
EBP I-GENE
, O
suggested O
that O
autoregulation O
may O
be O
involved O
in O
controlling O
both O
rat I-GENE
and O
human I-GENE
T I-GENE
/ I-GENE
EBP I-GENE
gene I-GENE
expression O
. O

Deletion O
of O
the O
last O
two O
Ser O
residues O
, O
including O
one O
PKC I-GENE
consensus I-GENE
site I-GENE
in O
the O
receptor I-GENE
tail O
, O
prevented O
only O
phorbol O
12 O
- I-GENE
myristate O
13 O
- I-GENE
acetate O
- I-GENE
induced O
_RARE_ I-GENE
by O
30 O
%. O

_RARE_ I-GENE
survival O
depends O
on O
the O
development O
of O
a O
small I-GENE
number O
of O
vascular I-GENE
_RARE_ I-GENE
between O
vessels O
arising O
from O
the O
_RARE_ I-GENE
and O
_RARE_ I-GENE
dermal O
vessels O
. O

_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
recent O
literature O
about O
lower O
respiratory O
tract O
infection O
in O
children O
. O

_RARE_ I-GENE
indicators O
were O
assessed O
for O
the O
two O
_RARE_ I-GENE
of O
protein I-GENE
- I-GENE
energy O
_RARE_ I-GENE
in O
the O
guidelines O
for O
integrated O
management O
of O
childhood O
illness O
: O
severe O
_RARE_ I-GENE
, O
which O
requires O
immediate I-GENE
_RARE_ I-GENE
to O
hospital O
, O
and O
very O
low O
weight O
, O
which O
_RARE_ I-GENE
for O
feeding O
assessment O
, O
nutritional O
_RARE_ I-GENE
and O
follow O
- I-GENE
up O
. O

_RARE_ I-GENE
or O
_RARE_ I-GENE
was O
infused O
for O
6 I-GENE
. O
5 I-GENE
h O
, O
beginning O
30 O
min O
before O
ischemia O
and O
_RARE_ I-GENE
throughout O
the O
duration O
of O
reperfusion O
. O

Despite O
its O
requirement O
for O
enhancer I-GENE
- I-GENE
dependent I-GENE
splicing O
activity O
in O
vitro O
, O
the O
_RARE_ I-GENE
RS I-GENE
domain I-GENE
was O
also O
_RARE_ I-GENE
in O
vivo O
. O

In O
vitro O
binding I-GENE
studies O
using O
GST I-GENE
fusion I-GENE
proteins I-GENE
and O
yeast I-GENE
extracts O
defined O
distinct O
binding I-GENE
sites I-GENE
on O
_RARE_ I-GENE
for O
_RARE_ I-GENE
and O
clathrin I-GENE
. O
_RARE_ I-GENE
proteins I-GENE
and O
_RARE_ I-GENE
, O
like I-GENE
actin I-GENE
, O
localize O
to O
peripheral O
_RARE_ I-GENE
along O
the O
plasma I-GENE
membrane I-GENE
. O

In O
vitro O
affinity O
analyses O
demonstrated O
that O
recombinant I-GENE
130 I-GENE
- I-GENE
kD I-GENE
protein I-GENE
directly O
interacts O
with O
_RARE_ I-GENE
- I-GENE
1 I-GENE
and O
the O
cytoplasmic I-GENE
domain I-GENE
of O
_RARE_ I-GENE
, O
but O
not O
with O
_RARE_ I-GENE
- I-GENE
2 I-GENE
. O

_RARE_ I-GENE
b I-GENE
in O
human I-GENE
complex I-GENE
II I-GENE
( O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
oxidoreductase I-GENE
): O
cDNA I-GENE
cloning O
of O
the O
components O
in O
liver O
mitochondria O
and O
chromosome O
assignment O
of O
the O
genes I-GENE
for O
the O
large O
( O
_RARE_ I-GENE
) O
and O
small I-GENE
( O
_RARE_ I-GENE
) O
subunits I-GENE
to O
_RARE_ I-GENE
and O
_RARE_ I-GENE
. O

A I-GENE
possible O
decrease O
in O
theophylline O
' O
s O
volume O
of O
distribution O
at O
4 I-GENE
days O
, O
but O
not O
immediately O
, O
after O
administration O
of O
_RARE_ I-GENE
was O
suggested O
, O
although O
this O
just O
failed O
to O
achieve O
statistical O
significance O
( O
p O
= O
0 O
. O
_RARE_ I-GENE
). O

The O
addition O
of O
a O
_RARE_ I-GENE
- I-GENE
containing O
extract O
does O
not O
lead O
to O
significant O
protein I-GENE
binding I-GENE
to O
these O
two O
_RARE_ I-GENE
target O
sequences I-GENE
in O
the O
absence O
of O
_RARE_ I-GENE
but O
_RARE_ I-GENE
the O
complex I-GENE
( O
_RARE_ I-GENE
) O
consisting O
of O
_RARE_ I-GENE
and O
the O
_RARE_ I-GENE
bp O
_RARE_ I-GENE
DNA I-GENE
fragment I-GENE
to O
a O
slower O
_RARE_ I-GENE
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
DNA I-GENE
complex I-GENE
( O
CI O
). O

Moreover O
, O
it O
is O
the O
_RARE_ I-GENE
behind O
steady O
- I-GENE
state O
O2 O
uptake O
that O
do O
not O
permit O
proper O
interpretation O
of O
energy O
expenditure O
during O
_RARE_ I-GENE
; O
1 I-GENE
l O
O2 O
not O
= O
20 O
. O
9 O
_RARE_ I-GENE
. O

The O
predicted O
amino O
acid I-GENE
sequence I-GENE
of O
m I-GENE
- I-GENE
_RARE_ I-GENE
is O
highly O
homologous O
to O
that O
of O
_RARE_ I-GENE
, O
another O
selenocysteine I-GENE
tRNA I-GENE
gene I-GENE
transcription I-GENE
activating I-GENE
factor I-GENE
of O
Xenopus I-GENE
laevis I-GENE
. O

_RARE_ I-GENE
- I-GENE
I I-GENE
, O
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
can O
bind O
the O
wild I-GENE
type I-GENE
forms O
of O
both O
RhoA I-GENE
and O
Cdc42 I-GENE
in O
a O
GTP I-GENE
- I-GENE
dependent I-GENE
manner O
in O
vitro O
. O

Among O
three O
isoforms I-GENE
, O
the O
beta I-GENE
isoform I-GENE
has O
the O
greatest O
Vmax O
value O
for O
the O
_RARE_ I-GENE
( O
4 I-GENE
) O
P I-GENE
kinase I-GENE
activity O
and O
the O
gamma I-GENE
isoform I-GENE
is O
most O
markedly O
stimulated O
by O
_RARE_ I-GENE
acid I-GENE
. O

The O
beta I-GENE
subunit I-GENE
of O
the O
heterotrimeric I-GENE
G I-GENE
proteins I-GENE
that O
_RARE_ I-GENE
signals O
across O
the O
plasma I-GENE
membrane I-GENE
is O
made O
up O
of O
an O
amino O
- I-GENE
terminal I-GENE
alpha I-GENE
- I-GENE
helical O
segment O
followed O
by O
seven O
repeating O
units O
called O
WD I-GENE
( O
_RARE_ I-GENE
- I-GENE
Asp I-GENE
) O
repeats I-GENE
that O
occur O
in O
about O
140 I-GENE
different O
proteins I-GENE
. O

Two O
differentially O
expressed O
_RARE_ I-GENE
_RARE_ I-GENE
encode O
overlapping O
proteins I-GENE
with O
predicted O
molecular O
masses O
of O
80 O
kDa I-GENE
( O
_RARE_ I-GENE
) O
and O
70 I-GENE
kDa I-GENE
( O
_RARE_ I-GENE
- I-GENE
b I-GENE
). O

In O
contrast O
, O
the O
contractile O
action O
of O
_RARE_ I-GENE
acid I-GENE
, O
via O
a O
presumed I-GENE
_RARE_ I-GENE
product I-GENE
that O
mediated O
the O
contractions O
caused O
by O
both O
TF I-GENE
and O
EGF I-GENE
, O
was O
not O
blocked O
by O
any O
of O
the O
signal I-GENE
pathway O
probe O
inhibitors O
. O

Recent O
studies O
have O
revealed O
_RARE_ I-GENE
myosin I-GENE
V I-GENE
to O
be O
an O
important O
actin I-GENE
- I-GENE
based O
molecular O
motor O
involved O
in O
vesicular O
movement O
. O

On O
a O
separate O
_RARE_ I-GENE
the O
T1 O
weighted O
and O
T2 I-GENE
weighted O
_RARE_ I-GENE
and O
T2 I-GENE
weighted O
axial O
sequences I-GENE
were O
reported O
blind O
in O
relation O
to O
the O
initial O
assessment O
. O

Furthermore O
, O
a O
minor O
start O
site I-GENE
was O
localized O
_RARE_ I-GENE
bp O
upstream O
of O
the O
major I-GENE
site I-GENE
using O
reverse I-GENE
transcriptase I-GENE
- I-GENE
polymerase I-GENE
chain I-GENE
reaction O
with O
various O
P1 I-GENE
primers O
( O
primer O
_RARE_ I-GENE
), O
primer O
extension O
, O
and O
cDNA I-GENE
cloning O
. O

Analysis O
of O
promoter I-GENE
and O
androgen O
regulatory I-GENE
sequences I-GENE
required O
for O
optimal O
transcription I-GENE
of O
the O
rat I-GENE
androgen O
- I-GENE
binding I-GENE
protein I-GENE
gene I-GENE
. O

The O
iron O
dependence O
of O
transcription I-GENE
and O
expression O
of O
_RARE_ I-GENE
, O
which O
encodes O
a O
transporter I-GENE
accessory I-GENE
protein I-GENE
, O
and O
_RARE_ I-GENE
, O
encoding O
the O
_RARE_ I-GENE
V I-GENE
immunity O
protein I-GENE
, O
was O
assessed O
under O
conditions O
of O
iron O
excess O
or O
depletion O
. O

In O
a O
_RARE_ I-GENE
deletion O
mutant I-GENE
, O
the O
expression O
of O
a O
chromosomal I-GENE
_RARE_ I-GENE
:: O
lacZ I-GENE
fusion I-GENE
is O
both O
high O
and O
constitutive O
, O
confirming O
that O
_RARE_ I-GENE
is O
the O
negative O
regulator I-GENE
of O
_RARE_ I-GENE
. O

Furthermore O
, O
the O
deletion O
of O
_RARE_ I-GENE
from O
the O
chromosome O
had O
no O
effect O
on O
_RARE_ I-GENE
- I-GENE
lacZ I-GENE
expression O
. O

Of O
these O
sites I-GENE
, O
PEA3 I-GENE
and O
STAT I-GENE
contributed O
specifically O
to O
induction O
by O
v I-GENE
- I-GENE
src I-GENE
, O
whereas O
the O
remaining O
elements O
were O
also O
involved O
in O
induction O
by O
the O
phorbol O
ester O
phorbol O
myristate O
acetate O
( O
PMA O
). O

BRCA1 I-GENE
protein I-GENE
contains O
an O
amino O
- I-GENE
terminal I-GENE
zinc I-GENE
finger I-GENE
motif I-GENE
and O
a O
carboxy I-GENE
- I-GENE
terminal I-GENE
acidic O
region O
. O

The O
mitochondrial I-GENE
regulatory I-GENE
region O
( O
_RARE_ I-GENE
) O
located O
between O
the O
_RARE_ I-GENE
and O
_RARE_ I-GENE
genes I-GENE
of O
mitochondrial I-GENE
DNA I-GENE
( O
_RARE_ I-GENE
) O
is O
essential O
for O
regulation O
of O
replication O
and O
transcription I-GENE
of O
the O
mitochondrial I-GENE
genome O
. O

In O
this O
report O
, O
we O
investigate O
the O
mechanism O
underlying O
Ras I-GENE
activation O
upon O
stimulation O
of O
these O
two O
types O
of O
receptors I-GENE
in O
hematopoietic I-GENE
cells O
. O

Thus O
, O
_RARE_ I-GENE
proteins I-GENE
from O
K I-GENE
. O
lactis O
have O
roles O
in O
both O
silencing O
and O
telomere I-GENE
length I-GENE
maintenance O
, O
reflecting O
conserved O
functional O
_RARE_ I-GENE
. O

Therefore O
, O
we O
conclude O
that O
_RARE_ I-GENE
may O
contact O
the O
beta I-GENE
subunit I-GENE
of O
RNA I-GENE
polymerase I-GENE
during O
activation O
of O
the O
_RARE_ I-GENE
promoter I-GENE
. O

Expression O
of O
Bcl I-GENE
- I-GENE
_RARE_ I-GENE
inhibited O
the O
association O
of O
_RARE_ I-GENE
- I-GENE
1 I-GENE
with O
_RARE_ I-GENE
- I-GENE
9 O
in O
mammalian I-GENE
cells O
. O

_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
in O
situ O
hybridization O
to O
early I-GENE
mouse I-GENE
embryos O
of O
9 O
. O
5 I-GENE
- I-GENE
10 O
. O
5 I-GENE
days O
indicated O
a O
complex I-GENE
pattern O
of O
_RARE_ I-GENE
expression O
spatially O
overlapping O
with O
the O
expression O
of O
_RARE_ I-GENE
. O

These O
mutants I-GENE
were O
tested O
for O
ability O
to O
bind O
each O
of O
the O
Site I-GENE
II I-GENE
cognate I-GENE
proteins I-GENE
, O
and O
subsequently O
evaluated O
for O
ability O
to O
confer O
H4 I-GENE
transcriptional O
activity O
using O
chimeric I-GENE
H4 I-GENE
promoter I-GENE
/ I-GENE
CAT I-GENE
fusion I-GENE
constructs I-GENE
in O
different O
cell O
types O
. O

Increased O
plasma I-GENE
IgE I-GENE
was O
also O
confirmed O
in O
the O
_RARE_ I-GENE
mice O
, O
and O
treatment O
with O
FK506 O
_RARE_ I-GENE
reduced O
the O
plasma I-GENE
IgE I-GENE
level O
. O

_RARE_ I-GENE
kinase I-GENE
release O
after O
hepatic I-GENE
artery O
_RARE_ I-GENE
in O
patients O
with O
_RARE_ I-GENE
tumors O
. O

Furthermore O
, O
in O
the O
ischemia O
/ I-GENE
_RARE_ I-GENE
II I-GENE
- I-GENE
induced O
_RARE_ I-GENE
model O
, O
_RARE_ I-GENE
decreased O
left O
ventricular O
end O
- I-GENE
diastolic O
pressure O
( O
_RARE_ I-GENE
). O

Group O
A I-GENE
( O
68 O
. O
7 O
+/- O
2 I-GENE
. O
7 O
years O
) O
consisted O
of O
patients O
with O
0 O
or O
1 I-GENE
risk O
factors I-GENE
; O
B I-GENE
( O
68 O
. O
3 I-GENE
+/- O
4 I-GENE
. O
2 I-GENE
years O
) O
those O
with O
2 I-GENE
risk O
factors I-GENE
; O
and O
C I-GENE
( O
69 O
. O
2 I-GENE
+/- O
3 I-GENE
. O
6 I-GENE
years O
) O
those O
with O
3 I-GENE
or O
more O
risk O
factors I-GENE
. O

We O
further O
demonstrate O
that O
_RARE_ I-GENE
- I-GENE
PR I-GENE
- I-GENE
B I-GENE
interacts O
physically O
with O
_RARE_ I-GENE
in O
vitro O
. O

PRL I-GENE
receptor I-GENE
also O
activates O
SHP I-GENE
- I-GENE
2 I-GENE
, O
a O
cytosolic I-GENE
tyrosine I-GENE
phosphatase I-GENE
. O

The O
dominant I-GENE
negative O
mutant I-GENE
of O
SHP I-GENE
- I-GENE
2 I-GENE
was O
found O
to O
inhibit O
the O
induction O
of O
tyrosine I-GENE
phosphorylation O
and O
DNA I-GENE
- I-GENE
binding I-GENE
activity O
of O
m I-GENE
- I-GENE
Stat5a I-GENE
, O
m I-GENE
- I-GENE
_RARE_ I-GENE
, O
and O
the O
carboxyl O
- I-GENE
terminal I-GENE
deletion O
variant I-GENE
m I-GENE
- I-GENE
_RARE_ I-GENE
, O
as O
well O
as O
the O
transactivation O
potential O
of O
m I-GENE
- I-GENE
Stat5a I-GENE
and O
m I-GENE
- I-GENE
_RARE_ I-GENE
. O

CONCLUSIONS O
: O
These O
_RARE_ I-GENE
collected O
data O
provided O
quantitative O
estimates O
of O
changes O
in O
_RARE_ I-GENE
Cl O
/ I-GENE
F I-GENE
due O
to O
_RARE_ I-GENE
and O
an O
age O
- I-GENE
related I-GENE
decrease O
in O
Cl O
/ I-GENE
F I-GENE
The O
derived O
regression O
_RARE_ I-GENE
_RARE_ I-GENE
predicted O
concentrations O
in O
a O
separate O
_RARE_ I-GENE
set O
. O

_RARE_ I-GENE
1 I-GENE
and O
4 I-GENE
in O
_RARE_ I-GENE
and O
_RARE_ I-GENE
are O
in O
a O
homologous O
location O
. O

Our O
observations O
suggest O
that O
members O
of O
the O
HMG I-GENE
- I-GENE
I I-GENE
family I-GENE
play O
an O
important O
role O
in O
SRF I-GENE
- I-GENE
dependent I-GENE
transcription I-GENE
and O
that O
their O
effect O
is O
mediated O
primarily O
by O
a O
protein I-GENE
- I-GENE
protein I-GENE
interaction O
. O

ATP I-GENE
- I-GENE
dependent I-GENE
assembly O
of O
a O
ternary O
complex I-GENE
consisting O
of O
a O
DNA I-GENE
_RARE_ I-GENE
and O
the O
yeast I-GENE
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
protein I-GENE
complexes I-GENE
. O

Mutation O
of O
the O
central O
_RARE_ I-GENE
to O
Phe I-GENE
blocks O
the O
tyrosine I-GENE
phosphorylation O
of O
the O
insulin I-GENE
receptor I-GENE
substrate I-GENE
1 I-GENE
( O
_RARE_ I-GENE
) O
and O
_RARE_ I-GENE
proliferation O
in O
response O
to O
IL I-GENE
- I-GENE
4 I-GENE
. O

Instead O
, O
it O
contained O
two O
tandem O
kappaB I-GENE
elements O
and O
a O
variant I-GENE
activating I-GENE
transcription I-GENE
factor I-GENE
/ I-GENE
cAMP I-GENE
response O
element I-GENE
site I-GENE
, O
which O
closely O
_RARE_ I-GENE
sites I-GENE
in O
the O
E I-GENE
- I-GENE
selectin I-GENE
gene I-GENE
that O
are O
required O
for O
TNF I-GENE
- I-GENE
alpha I-GENE
- I-GENE
or O
LPS I-GENE
- I-GENE
inducible I-GENE
expression O
. O

We O
recently O
characterized O
a O
single O
yeast I-GENE
hnRNP I-GENE
methyltransferase I-GENE
( O
_RARE_ I-GENE
). O

We O
recently O
characterized O
a O
single O
yeast I-GENE
hnRNP I-GENE
methyltransferase I-GENE
( O
_RARE_ I-GENE
). O

Recombinant I-GENE
_RARE_ I-GENE
protein I-GENE
encoded I-GENE
by O
the O
most O
common O
5 I-GENE
'- O
variant I-GENE
exhibited O
methyltransferase I-GENE
activity O
in O
vitro O
. O

The O
possible O
roles O
of O
_RARE_ I-GENE
and O
_RARE_ I-GENE
in O
human I-GENE
disease O
are O
currently O
unknown O
. O

Identification O
and O
characterization O
of O
two O
putative O
human I-GENE
arginine I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
and O
_RARE_ I-GENE
). O

Interestingly O
, O
the O
activated I-GENE
PDGF I-GENE
beta I-GENE
- I-GENE
receptor I-GENE
was O
found O
not O
to O
bind O
Crk I-GENE
proteins I-GENE
. O

Furthermore O
, O
interactions O
were O
identified O
between O
endogenous I-GENE
E I-GENE
- I-GENE
cadherin I-GENE
and O
the O
chimera I-GENE
containing O
the O
E I-GENE
- I-GENE
cadherin I-GENE
extracellular I-GENE
domain I-GENE
and O
the O
_RARE_ I-GENE
1 I-GENE
intracellular O
domain I-GENE
providing O
in O
vivo O
evidence O
for O
previously O
predicted O
lateral O
interactions O
of O
E I-GENE
- I-GENE
cadherin I-GENE
extracellular I-GENE
domains I-GENE
. O

The O
ether O
phospholipid I-GENE
1 I-GENE
- I-GENE
O O
- I-GENE
_RARE_ I-GENE
- I-GENE
2 I-GENE
- I-GENE
O O
- I-GENE
methyl O
- I-GENE
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
3 I-GENE
- I-GENE
_RARE_ I-GENE
( O
ET I-GENE
- I-GENE
18 O
- I-GENE
_RARE_ I-GENE
; O
_RARE_ I-GENE
) O
is O
a O
potent O
_RARE_ I-GENE
of O
apoptosis O
in O
human I-GENE
tumor I-GENE
cells O
. O

In O
addition O
to O
a O
previously O
characterized O
promoter I-GENE
( O
P1 I-GENE
), O
we O
now O
show O
the O
existence O
of O
a O
second O
promoter I-GENE
for O
the O
human I-GENE
IL I-GENE
- I-GENE
_RARE_ I-GENE
gene I-GENE
. O

Serum I-GENE
levels O
of O
testosterone O
also O
showed O
no O
significant O
changes O
by O
exposure O
to O
p O
, O
p O
'- O
_RARE_ I-GENE
under O
the O
conditions O
of O
this O
study O
. O

Overall O
agreement O
between O
rest O
/ I-GENE
_RARE_ I-GENE
technetium O
- I-GENE
99m O
tetrofosmin O
_RARE_ I-GENE
studies O
and O
rest O
/ I-GENE
_RARE_ I-GENE
or O
rest O
/ I-GENE
_RARE_ I-GENE
thallium O
- I-GENE
201 O
_RARE_ I-GENE
studies O
, O
regarding O
the O
presence O
of O
myocardial O
viability O
, O
was O
87 O
% O
and O
90 O
%, O
respectively O
. O

Their O
use O
resulted O
in O
a O
sensitivity O
of O
73 O
% O
and O
a O
specificity O
of O
74 O
% O
with O
regard O
to O
_RARE_ I-GENE
of O
_RARE_ I-GENE
levels O
increasing O
during O
the O
trial O
. O

One O
hundred O
_RARE_ I-GENE
data O
sets O
of O
100 O
subjects O
each O
were O
simulated O
for O
each O
missing O
data O
_RARE_ I-GENE
. O

_RARE_ I-GENE
accuracy O
of O
primary O
and O
secondary O
memory O
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
in O
schizophrenic O
patients O
. O

_RARE_ I-GENE
treatment O
with O
nasal O
continuous O
positive O
airway O
pressure O
( O
8 O
. O
3 I-GENE
+/- O
1 I-GENE
. O
5 I-GENE
cmH2O O
) O
for O
3 I-GENE
days O
caused O
a O
significant O
decrease O
in O
mean O
blood O
pressure O
in O
_RARE_ I-GENE
. O

When O
data O
were O
expressed O
in O
a O
cumulative O
manner O
, O
the O
response O
to O
intravenous O
adenosine I-GENE
3 I-GENE
mg O
, O
6 I-GENE
mg O
, O
9 O
mg O
and O
12 O
mg O
in O
the O
24 O
episodes O
of O
_RARE_ I-GENE
were O
5 I-GENE
episodes O
( O
21 O
%), O
16 O
episodes O
( O
67 O
%), O
20 O
episodes O
( O
83 O
%) O
and O
20 O
episodes O
( O
83 O
%) O
respectively O
. O

RNAs I-GENE
are O
not O
only O
essential O
components O
of O
both O
ribosomal I-GENE
subunits I-GENE
but O
also O
transiently O
interacting I-GENE
factors I-GENE
during O
particle I-GENE
formation O
. O

To O
study O
retinoid I-GENE
signalling O
in O
_RARE_ I-GENE
embryos O
, O
we O
developed O
a O
novel O
method O
to O
detect O
endogenous I-GENE
_RARE_ I-GENE
in O
situ O
in O
embryos O
, O
using O
a O
fusion I-GENE
protein I-GENE
of O
the O
ligand O
inducible I-GENE
transactivation O
domain I-GENE
of O
a O
retinoic I-GENE
acid I-GENE
receptor I-GENE
and O
a O
heterologous O
DNA I-GENE
binding I-GENE
domain I-GENE
. O

To O
identify O
nuclear I-GENE
regulatory I-GENE
factors I-GENE
, O
we O
have O
located O
and O
functionally O
characterized O
the O
_RARE_ I-GENE
gene I-GENE
promoter I-GENE
. O

_RARE_ I-GENE
in O
situ O
hybridization O
of O
_RARE_ I-GENE
_RARE_ I-GENE
of O
chromosome O
8 O
, O
containing O
hybrid O
cell O
line O
_RARE_ I-GENE
- I-GENE
B6 I-GENE
clone O
17 O
( O
CL O
- I-GENE
17 O
) O
with O
cosmid O
_RARE_ I-GENE
, O
placed O
the O
_RARE_ I-GENE
gene I-GENE
close O
to O
the O
telomere I-GENE
at O
_RARE_ I-GENE
. O
3 I-GENE
. O

The O
interaction O
between O
_RARE_ I-GENE
and O
_RARE_ I-GENE
was O
studied O
by O
x O
- I-GENE
ray O
_RARE_ I-GENE
( O
_RARE_ I-GENE
), O
_RARE_ I-GENE
( O
IR I-GENE
) O
spectroscopy O
and O
differential O
thermal O
analysis O
( O
_RARE_ I-GENE
) O
with O
a O
solid O
dispersion O
, O
_RARE_ I-GENE
, O
or O
physical O
mixture O
. O

Cell O
survival O
by O
Epo I-GENE
did O
not O
require O
activation O
of O
other O
known O
signaling O
pathways O
including O
PI I-GENE
- I-GENE
3 I-GENE
kinase I-GENE
, O
PLC I-GENE
- I-GENE
gamma I-GENE
, O
Ras I-GENE
or O
_RARE_ I-GENE
. O

The O
N I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
dependent I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
is O
inhibited O
by O
the O
tyrosine I-GENE
kinase I-GENE
inhibitors O
_RARE_ I-GENE
A I-GENE
and O
_RARE_ I-GENE
. O

An O
in O
vivo O
ZAP I-GENE
- I-GENE
70 I-GENE
substrate I-GENE
, O
_RARE_ I-GENE
- I-GENE
76 I-GENE
, O
implicated O
in O
_RARE_ I-GENE
activation O
, O
also O
became O
rapidly O
tyrosine I-GENE
- I-GENE
phosphorylated O
in O
Jurkat O
cells O
, O
but O
not O
in O
_RARE_ I-GENE
cells O
, O
upon O
treatment O
with O
_RARE_ I-GENE
. O

The O
pharmacokinetic O
patterns O
of O
estradiol O
( O
CAS I-GENE
50 O
- I-GENE
28 O
- I-GENE
2 I-GENE
) O
and O
of O
_RARE_ I-GENE
( O
CAS I-GENE
53 O
- I-GENE
16 O
- I-GENE
7 O
) O
were O
investigated O
in O
18 O
women O
in O
natural O
or O
surgical O
_RARE_ I-GENE
during O
the O
application O
of O
a O
new O
estradiol O
_RARE_ I-GENE
patch O
with O
active O
matrix I-GENE
and O
without O
absorption O
enhancers I-GENE
designed O
for O
_RARE_ I-GENE
applications O
of O
7 O
days O
( O
_RARE_ I-GENE
called O
" O
patch O
_RARE_ I-GENE
_RARE_ I-GENE

The O
results O
confirm O
that O
a O
single O
base O
change O
in O
the O
branchpoint O
consensus I-GENE
sequence I-GENE
of O
an O
intron O
can O
cause O
human I-GENE
disease O
although O
this O
sequence I-GENE
is O
poorly O
conserved O
in O
mammals O
. O

Conversely O
, O
the O
central O
regions O
are O
highly O
variable O
. O

Among O
the O
H I-GENE
/ I-GENE
ACA I-GENE
_RARE_ I-GENE
associated I-GENE
with O
_RARE_ I-GENE
, O
one O
can O
_RARE_ I-GENE
a O
large O
group O
of O
_RARE_ I-GENE
that O
are O
not O
essential O
in O
yeast I-GENE
and O
serve O
as O
_RARE_ I-GENE
for O
_RARE_ I-GENE
synthesis O
onto O
the O
pre I-GENE
- I-GENE
rRNA I-GENE
molecule I-GENE
. O

It O
bound O
to O
vitamin O
D I-GENE
receptor I-GENE
( O
VDR I-GENE
) O
but O
not O
retinoic I-GENE
acid I-GENE
_RARE_ I-GENE
receptor I-GENE
( O
_RARE_ I-GENE
) O
in O
the O
human I-GENE
T I-GENE
cell O
line O
_RARE_ I-GENE
cells O
. O

Further O
studies O
demonstrated O
that O
the O
PPARalpha I-GENE
ligand O
8 O
( O
S I-GENE
)- I-GENE
_RARE_ I-GENE
acid I-GENE
strongly O
promotes O
the O
interaction O
of O
PPARalpha I-GENE
with O
the O
co O
- I-GENE
activator I-GENE
_RARE_ I-GENE
- I-GENE
140 I-GENE
but O
decreases O
the O
interaction O
of O
PPARalpha I-GENE
with O
the O
co O
- I-GENE
repressor I-GENE
SMRT I-GENE
. O

Based O
on O
the O
current O
literature O
, O
the O
mechanisms O
involved O
in O
the O
toxicity O
of O
_RARE_ I-GENE
indicate O
three O
major I-GENE
effects O
: O
( O
1 I-GENE
) O
inhibition O
of O
mitochondrial I-GENE
respiration O
correlated O
with O
a O
depletion O
of O
ATP I-GENE
; O
( O
2 I-GENE
) O
inhibition O
of O
tRNA I-GENE
- I-GENE
synthetase I-GENE
accompanied O
by O
a O
reduced O
protein I-GENE
synthesis O
; O
and O
( O
3 I-GENE
) O
enhanced O
lipid O
peroxidation O
. O

We O
previously O
demonstrated O
that O
acute O
expression O
of O
the O
bovine I-GENE
papillomavirus I-GENE
type I-GENE
1 I-GENE
( O
_RARE_ I-GENE
) O
E2 I-GENE
protein I-GENE
in O
HeLa O
and O
HT O
- I-GENE
3 I-GENE
cervical O
carcinoma O
cell O
lines O
greatly O
reduced O
cellular O
proliferation O
by O
_RARE_ I-GENE
a O
specific I-GENE
G1 I-GENE
/ I-GENE
S I-GENE
phase O
growth I-GENE
arrest O
. O

Four O
possible O
isoforms I-GENE
( O
_RARE_ I-GENE
alpha I-GENE
, O
beta I-GENE
, O
gamma I-GENE
, O
and O
delta I-GENE
) O
are O
formed O
by O
combinations O
of O
two O
independent O
alternative O
_RARE_ I-GENE
, O
and O
all O
the O
isoforms I-GENE
could O
bind O
to O
a O
DNA I-GENE
motif I-GENE
, O
_RARE_ I-GENE
, O
in O
the O
LTR I-GENE
. O

_RARE_ I-GENE
actin I-GENE
tails O
that O
_RARE_ I-GENE
_RARE_ I-GENE
particles O
to O
the O
_RARE_ I-GENE
and O
virus I-GENE
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
( O
both O
common O
in O
wild I-GENE
- I-GENE
type I-GENE
- I-GENE
infected O
cells O
) O
were O
absent O
in O
cells O
infected O
with O
_RARE_ I-GENE
. O

Their O
mean O
IOP O
was O
15 O
. O
3 I-GENE
( O
SD O
3 I-GENE
. O
7 O
) O
mmHg O
prior O
to O
induction O
of O
anesthesia O
, O
13 O
. O
5 I-GENE
( O
SD O
3 I-GENE
. O
5 I-GENE
) O
mmHg O
after O
loss O
of O
_RARE_ I-GENE
reflex O
following O
injection O
of O
_RARE_ I-GENE
, O
16 O
. O
1 I-GENE
( O
SD O
2 I-GENE
. O
4 I-GENE
) O
mmHg O
after O
cessation O
of O
muscle O
_RARE_ I-GENE
induced O
by O
_RARE_ I-GENE
, O
19 O
. O
2 I-GENE
( O
SD O
5 I-GENE
. O
6 I-GENE
) O
mmHg O
after O
cessation O
of O
_RARE_ I-GENE
and O
15 O
. O
5 I-GENE
( O
SD O
4 I-GENE
. O
4 I-GENE
) O
mmHg O
following O
_RARE_ I-GENE
of O
regular O
spontaneous O
respiration O
. O

A I-GENE
cDNA I-GENE
, O
_RARE_ I-GENE
, O
was O
isolated O
that O
suppressed O
the O
CAK I-GENE
mutation I-GENE
in O
budding I-GENE
yeast I-GENE
, O
and O
it O
also O
complemented O
a O
fission I-GENE
yeast I-GENE
CAK I-GENE
mutant I-GENE
. O
_RARE_ I-GENE
encodes O
a O
protein I-GENE
related I-GENE
to O
animal O
_RARE_ I-GENE
. O

Post O
- I-GENE
translational O
modifications O
such O
as O
glycosylation O
and O
phosphorylation O
could O
be O
excluded O
as O
potential O
_RARE_ I-GENE
for O
the O
protein I-GENE
heterogeneity O
. O

In O
addition O
to O
_RARE_ I-GENE
checkpoint I-GENE
control O
, O
overexpression O
of O
_RARE_ I-GENE
+ I-GENE
inhibits O
the O
normal O
cell O
cycle O
response O
to O
osmotic O
stress O
. O

_RARE_ I-GENE
plays O
a O
pivotal O
role O
in O
the O
initiation I-GENE
of O
meiosis O
in O
a O
/ I-GENE
alpha I-GENE
diploid O
cells O
of O
Saccharomyces I-GENE
cerevisiae I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
and O
BALB O
/ I-GENE
c I-GENE
mice O
inoculated O
with O
the O
_RARE_ I-GENE
virus I-GENE
SIV O
recombinants I-GENE
failed O
to O
develop O
CTL O
responses O
against O
the O
SIV O
gene I-GENE
products I-GENE
, O
while O
one O
of O
the O
HIV I-GENE
- I-GENE
Nef I-GENE
recombinants I-GENE
induced O
a O
weak O
CTL O
response O
in O
mice O
directed O
to O
an O
_RARE_ I-GENE
Nef I-GENE
peptide I-GENE
spanning O
positions O
182 O
- I-GENE
198 O
. O

_RARE_ I-GENE
was O
most O
effective O
on O
the O
_RARE_ I-GENE
surface O
and O
produced O
100 O
% O
mortality O
of O
An O
. O
_RARE_ I-GENE
adults O
up O
to O
12 O
weeks O
, O
even O
when O
exposed O
at O
the O
lowest O
dose O
/ I-GENE
12 O
. O
5 I-GENE
mg O
/ I-GENE
m2 O
. O

_RARE_ I-GENE
, O
in O
turn I-GENE
, O
increased O
the O
AUC O
5 I-GENE
. O
0 O
( O
1 I-GENE
. O
9 O
- I-GENE
13 O
. O
4 I-GENE
), O
25 O
. O
8 O
( O
8 O
. O
2 I-GENE
- I-GENE
80 O
. O
8 O
) O
and O
2 I-GENE
. O
9 O
( O
1 I-GENE
. O
6 I-GENE
- I-GENE
5 I-GENE
. O
4 I-GENE
), O
respectively O
, O
whereas O
the O
corresponding O
values O
for O
n O
- I-GENE
_RARE_ I-GENE
were O
1 I-GENE
. O
9 O
( O
0 O
. O
7 O
- I-GENE
5 I-GENE
. O
1 I-GENE
), O
1 I-GENE
. O
5 I-GENE
( O
0 O
. O
5 I-GENE
- I-GENE
4 I-GENE
. O
6 I-GENE
), O
and O
3 I-GENE
. O
2 I-GENE
( O
1 I-GENE
. O
8 O
- I-GENE
5 I-GENE
. O
9 O
). O

_RARE_ I-GENE
structure O
of O
the O
IRF I-GENE
- I-GENE
2 I-GENE
DNA I-GENE
- I-GENE
binding I-GENE
domain I-GENE
: O
a O
novel O
subgroup O
of O
the O
_RARE_ I-GENE
helix I-GENE
- I-GENE
turn I-GENE
- I-GENE
helix I-GENE
family I-GENE
. O

In O
contrast O
, O
receptor I-GENE
/ I-GENE
G I-GENE
protein I-GENE
coupling O
appeared O
unaffected O
by O
expression O
of O
loop I-GENE
_RARE_ I-GENE
domains I-GENE
derived O
from O
two O
receptors I-GENE
coupled I-GENE
to O
G I-GENE
( O
i O
/ I-GENE
o I-GENE
) O
proteins I-GENE
( O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
- I-GENE
adrenergic I-GENE
receptors I-GENE
). O

These O
data O
indicate O
that O
the O
third O
intracellular O
loop I-GENE
of O
the O
rat I-GENE
GnRH I-GENE
- I-GENE
R I-GENE
is O
involved O
in O
receptor I-GENE
G I-GENE
( O
q I-GENE
/ I-GENE
11 O
) O
protein I-GENE
coupling O
and O
/ I-GENE
or O
selectivity O
, O
and O
in O
the O
_RARE_ I-GENE
( O
3 I-GENE
) O
1 I-GENE
' O
cell O
line O
, O
this O
loop I-GENE
is O
also O
involved O
in O
signal I-GENE
transduction O
mediated O
through O
the O
Gs I-GENE
protein I-GENE
pathway O
. O

_RARE_ I-GENE
levels O
of O
alpha2 I-GENE
- I-GENE
_RARE_ I-GENE
were O
also O
observed O
in O
the O
_RARE_ I-GENE
( O
0 O
. O
50 O
versus O
0 O
. O
61 O
U O
/ I-GENE
mL O
; O
p O
< O
0 O
. O
05 O
). O

A I-GENE
catalytic O
domain I-GENE
of O
eukaryotic I-GENE
DNA I-GENE
topoisomerase I-GENE
I I-GENE
. O

A I-GENE
cluster I-GENE
of O
basic I-GENE
amino O
acids O
, O
_RARE_ I-GENE
, O
generated O
by O
joining O
of O
the O
sequences I-GENE
encoded I-GENE
by O
the O
constitutive O
exon O
13 O
and O
the O
alternative O
exon O
16 O
, O
is O
necessary O
for O
the O
nuclear I-GENE
targeting O
of O
4 I-GENE
. O
_RARE_ I-GENE
, O
as O
demonstrated O
by O
site I-GENE
- I-GENE
directed O
mutagenesis O
analysis O
. O

Another O
stem O
- I-GENE
loop I-GENE
called O
structure O
III I-GENE
near O
the O
3 I-GENE
'- O
end O
of O
_RARE_ I-GENE
_RARE_ I-GENE
both O
the O
5 I-GENE
'- O
_RARE_ I-GENE
- I-GENE
3 I-GENE
' O
sequence I-GENE
and O
the O
_RARE_ I-GENE
ribosome I-GENE
- I-GENE
binding I-GENE
site I-GENE
. O

All O
three O
genes I-GENE
have O
been O
mapped O
precisely O
to O
a O
small I-GENE
region O
on O
human I-GENE
chromosome O
_RARE_ I-GENE
. O
1 I-GENE
- I-GENE
_RARE_ I-GENE
. O
2 I-GENE
( O
homologous O
to O
mouse I-GENE
chromosome O
7 O
), O
using O
somatic O
cell O
hybrids O
and O
cosmid O
clones O
. O

In O
_RARE_ I-GENE
mutants I-GENE
, O
the O
levels O
of O
Ty1 I-GENE
RNA I-GENE
, O
protein I-GENE
synthesis O
, O
and O
proteolytic O
processing O
were O
not O
altered O
relative O
to O
those O
in O
_RARE_ I-GENE
strains O
but O
steady O
- I-GENE
state O
levels O
of O
_RARE_ I-GENE
, O
integrase I-GENE
, O
and O
reverse I-GENE
transcriptase I-GENE
proteins I-GENE
and O
Ty1 I-GENE
cDNA I-GENE
were O
all O
increased O
. O

_RARE_ I-GENE
regulation O
of O
Ty1 I-GENE
_RARE_ I-GENE
by O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
_RARE_ I-GENE
. O

The O
general O
transcription I-GENE
factor I-GENE
IIA I-GENE
( O
_RARE_ I-GENE
) O
interacts O
with O
the O
TATA I-GENE
binding I-GENE
protein I-GENE
( O
TBP I-GENE
) O
and O
promoter I-GENE
DNA I-GENE
to O
mediate O
transcription I-GENE
activation O
in O
vitro O
. O

Their O
function O
is O
not O
only O
to O
recruit O
_RARE_ I-GENE
to O
the O
promoter I-GENE
but O
to O
allow O
cooperative O
binding I-GENE
of O
_RARE_ I-GENE
together O
with O
_RARE_ I-GENE
. O

Substitution O
of O
the O
Ser O
- I-GENE
Thr I-GENE
sites I-GENE
with O
the O
_RARE_ I-GENE
Asp I-GENE
generated O
a O
constitutively O
active O
form O
of O
IRF I-GENE
- I-GENE
3 I-GENE
that O
functioned O
as O
a O
very O
strong O
activator I-GENE
of O
promoters I-GENE
containing O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
or O
_RARE_ I-GENE
regulatory I-GENE
elements O
. O

New O
- I-GENE
onset O
angina O
preceding O
acute O
myocardial O
infarction O
is O
associated I-GENE
with O
improved O
contractile O
recovery O
after O
_RARE_ I-GENE
. O

In O
this O
study O
, O
the O
effect O
of O
acute O
administration O
of O
various O
doses O
of O
_RARE_ I-GENE
via O
oral O
and O
dermal O
routes O
to O
mice O
and O
rats O
on O
serum I-GENE
levels O
of O
histamine O
was O
evaluated O
. O

_RARE_ I-GENE
growth I-GENE
retardation O
as O
a O
cause O
of O
impaired O
ovarian O
development O
. O

Similarly O
, O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
ratio O
in O
_RARE_ I-GENE
_RARE_ I-GENE
was O
lower O
than O
that O
in O
_RARE_ I-GENE
_RARE_ I-GENE
. O

In O
addition O
to O
DNA I-GENE
- I-GENE
protein I-GENE
interactions O
, O
protein I-GENE
- I-GENE
protein I-GENE
interactions O
with O
partner I-GENE
proteins I-GENE
often O
play O
major I-GENE
roles O
in O
targeting O
ETS I-GENE
- I-GENE
domain I-GENE
proteins I-GENE
to O
specific I-GENE
promoters I-GENE
. O

Localization O
of O
67 O
exons O
on O
a O
YAC O
contig O
spanning O
1 I-GENE
. O
5 I-GENE
Mb O
around O
the O
multidrug I-GENE
resistance O
gene I-GENE
region O
of O
human I-GENE
chromosome O
_RARE_ I-GENE
. O
1 I-GENE
. O

The O
complete O
exon O
- I-GENE
intron O
organization O
of O
the O
murine I-GENE
gene I-GENE
encoding O
M I-GENE
- I-GENE
protein I-GENE
, O
a O
structural O
protein I-GENE
of O
_RARE_ I-GENE
_RARE_ I-GENE
, O
was O
determined O
. O

PURPOSE O
: O
To O
_RARE_ I-GENE
an O
image O
analysis O
of O
the O
_RARE_ I-GENE
in O
_RARE_ I-GENE
_RARE_ I-GENE
( O
PRK O
) O
for O
preoperative O
and O
early I-GENE
postoperative O
determination O
of O
changes O
in O
the O
condition O
of O
the O
_RARE_ I-GENE
. O

Mean O
+/- O
SD O
serum I-GENE
VEGF I-GENE
concentrations O
were O
significantly O
higher O
( O
P I-GENE
< O
0 O
. O
001 O
) O
in O
women O
with O
_RARE_ I-GENE
and O
_RARE_ I-GENE
( O
3 I-GENE
. O
4 I-GENE
+/- O
0 O
. O
7 O
and O
3 I-GENE
. O
2 I-GENE
+/- O
0 O
. O
66 O
ng O
/ I-GENE
ml O
respectively O
) O
compared O
with O
women O
with O
normal O
_RARE_ I-GENE
( O
2 I-GENE
. O
3 I-GENE
+/- O
0 O
. O
5 I-GENE
ng O
/ I-GENE
ml O
). O

_RARE_ I-GENE
, O
these O
cells O
contain O
a O
missense O
mutation I-GENE
of O
the O
p53 I-GENE
gene I-GENE
at O
codon O
_RARE_ I-GENE
( O
p53 I-GENE
( O
_RARE_ I-GENE
_RARE_ I-GENE
which O
_RARE_ I-GENE
alanine I-GENE
for O
glycine O
. O

The O
new O
algorithm O
, O
called O
_RARE_ I-GENE
- I-GENE
MAP I-GENE
, O
is O
based O
on O
the O
_RARE_ I-GENE
block O
_RARE_ I-GENE
EM O
( O
_RARE_ I-GENE
- I-GENE
EM O
) O
algorithm O
. O

A I-GENE
third O
ORF I-GENE
, O
_RARE_ I-GENE
, O
shows O
homology I-GENE
with O
gene I-GENE
_RARE_ I-GENE
from O
Staphylococcus I-GENE
aureus I-GENE
, O
which O
is O
involved O
in O
the O
mechanism O
of O
regulation O
of O
the O
virulence I-GENE
phenotype O
in O
this O
species O
. O

An O
association O
between O
_RARE_ I-GENE
and O
Stat I-GENE
- I-GENE
3 I-GENE
after O
MHC I-GENE
- I-GENE
I I-GENE
ligation O
was O
directly O
demonstrated O
by O
precipitating O
Stat I-GENE
- I-GENE
3 I-GENE
from O
nuclear I-GENE
extracts O
with O
_RARE_ I-GENE
_RARE_ I-GENE
probe O
and O
_RARE_ I-GENE
- I-GENE
coupled I-GENE
agarose O
. O

Transcriptional O
repression O
mediated O
by O
_RARE_ I-GENE
- I-GENE
type I-GENE
regulator I-GENE
_RARE_ I-GENE
bound O
at O
multiple O
binding I-GENE
sites I-GENE
. O

Two O
of O
these O
resulted O
in O
increased O
levels O
of O
the O
alpha I-GENE
subunit I-GENE
, O
and O
one O
caused O
a O
substitution O
of O
glycine O
for O
the O
_RARE_ I-GENE
acid I-GENE
residue O
at O
position O
_RARE_ I-GENE
, O
in O
the O
N I-GENE
- I-GENE
terminal I-GENE
domain I-GENE
. O

These O
two O
mRNA I-GENE
species O
are O
produced O
by O
differential O
polyadenylation O
site I-GENE
usage O
. O

Using O
Southern O
blot O
analysis O
and O
restriction I-GENE
mapping O
of O
genomic O
YAC O
( O
yeast I-GENE
artificial O
chromosome O
) O
and O
cosmid O
clones O
, O
we O
located O
the O
human I-GENE
_RARE_ I-GENE
gene I-GENE
240 O
- I-GENE
260 O
kb O
telomeric O
to O
the O
_RARE_ I-GENE
gene I-GENE
and O
characterized O
its O
genomic O
structure O
. O

_RARE_ I-GENE
contains O
C I-GENE
, O
D I-GENE
and O
D I-GENE
' O
boxes O
and O
a O
12 O
- I-GENE
nucleotide I-GENE
antisense I-GENE
complementarity I-GENE
to O
the O
28S I-GENE
ribosomal I-GENE
RNA I-GENE
. O

However O
, O
mandibular O
position O
( O
S I-GENE
- I-GENE
N I-GENE
- I-GENE
B I-GENE
and O
S I-GENE
- I-GENE
N I-GENE
- I-GENE
_RARE_ I-GENE
) O
was O
found O
to O
be O
significantly O
more O
_RARE_ I-GENE
in O
Class I-GENE
II I-GENE
when O
compared O
with O
Class I-GENE
I I-GENE
subjects O
. O

_RARE_ I-GENE
is O
_RARE_ I-GENE
by O
_RARE_ I-GENE
factors I-GENE
such O
as O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
an O
_RARE_ I-GENE
growing O
free O
- I-GENE
food O
_RARE_ I-GENE
, O
a O
lack O
of O
_RARE_ I-GENE
food O
_RARE_ I-GENE
, O
poor O
or O
insufficient O
_RARE_ I-GENE
, O
other O
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
_RARE_ I-GENE
conditions O
. O

The O
localization O
of O
ZAP I-GENE
- I-GENE
70 I-GENE
to O
the O
cell O
cortex O
is O
, O
therefore O
, O
regulated O
by O
the O
activity O
of O
SRC I-GENE
- I-GENE
family I-GENE
kinases I-GENE
, O
independently O
of O
their O
ability O
to O
phosphorylate O
_RARE_ I-GENE
tyrosine I-GENE
- I-GENE
based O
activation O
motifs O
of O
the O
TCR I-GENE
. O

Finally O
, O
a O
role O
for O
NF I-GENE
- I-GENE
kappaB I-GENE
in O
preventing O
apoptosis O
induced O
by O
ER I-GENE
calcium O
release O
was O
demonstrated O
by O
data O
showing O
that O
_RARE_ I-GENE
prevents O
_RARE_ I-GENE
- I-GENE
induced O
apoptosis O
, O
an O
effect O
blocked O
by O
kappaB I-GENE
_RARE_ I-GENE
DNA I-GENE
. O

Many O
cytokine O
receptors I-GENE
_RARE_ I-GENE
Janus I-GENE
protein I-GENE
tyrosine I-GENE
kinases I-GENE
( O
_RARE_ I-GENE
) O
and O
signal I-GENE
_RARE_ I-GENE
and O
activators I-GENE
of O
transcription I-GENE
( O
_RARE_ I-GENE
) O
for O
nuclear I-GENE
signaling O
. O

A I-GENE
site I-GENE
- I-GENE
directed O
_RARE_ I-GENE
mutation I-GENE
in O
the O
Stat5 I-GENE
SH2 I-GENE
domain I-GENE
abolished O
the O
phosphorylation O
by O
_RARE_ I-GENE
, O
while O
deletion O
of O
the O
C I-GENE
terminus O
led O
to O
Stat5 I-GENE
_RARE_ I-GENE
. O

The O
effect O
of O
nitric I-GENE
oxide I-GENE
synthase I-GENE
inhibitor I-GENE
on O
reperfusion O
injury O
of O
the O
brain O
under O
_RARE_ I-GENE
circulatory O
arrest O
. O

Specifically O
, O
recombination O
at O
HMR I-GENE
was O
used O
to O
produce O
_RARE_ I-GENE
that O
lacked O
the O
E I-GENE
and O
I I-GENE
_RARE_ I-GENE
. O

In O
_RARE_ I-GENE
, O
_RARE_ I-GENE
vessels O
in O
the O
mucosa O
appeared O
to O
contain O
less O
collagen I-GENE
type I-GENE
IV I-GENE
than O
similarly O
sized O
vessels O
in O
the O
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
vessels O
appeared O
in O
many O
cases O
to O
_RARE_ I-GENE
staining O
at O
the O
level O
of O
the O
_RARE_ I-GENE
_RARE_ I-GENE
. O

We O
studied O
the O
human I-GENE
_RARE_ I-GENE
- I-GENE
ocular O
reflex O
( O
_RARE_ I-GENE
) O
in O
response O
to O
head I-GENE
' O
_RARE_ I-GENE
_RARE_ I-GENE
brief O
, O
_RARE_ I-GENE
, O
passive O
, O
high O
- I-GENE
_RARE_ I-GENE
( O
up O
to O
_RARE_ I-GENE
degrees O
/ I-GENE
_RARE_ I-GENE
), O
low O
- I-GENE
amplitude O
( O
20 O
- I-GENE
30 O
degrees O
) O
head I-GENE
_RARE_ I-GENE
. O

To O
clarify O
whether O
seizure O
- I-GENE
_RARE_ I-GENE
patterns O
are O
reliable O
in O
predicting O
seizure O
outcome O
, O
we O
studied O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
in O
a O
similar O
group O
of O
patients O
with O
temporal O
lobe O
epilepsy O
( O
_RARE_ I-GENE
). O

In O
this O
study O
, O
to O
characterize O
the O
gene I-GENE
for O
protein I-GENE
Z I-GENE
, O
its O
organization O
and O
structure O
were O
determined O
by O
a O
combination O
of O
PCR O
amplification O
of O
leukocyte I-GENE
DNA I-GENE
and O
isolation O
of O
phage I-GENE
clones O
from O
a O
human I-GENE
genomic O
library O
. O

These O
modifications O
may O
improve O
the O
_RARE_ I-GENE
reproducibility O
of O
CD34 I-GENE
determinations O
due O
to O
the O
reduction O
in O
sample O
_RARE_ I-GENE
and O
_RARE_ I-GENE
of O
results O
. O

The O
present O
results O
demonstrate O
that O
rats O
with O
relatively O
small I-GENE
_RARE_ I-GENE
of O
one O
olfactory O
bulb O
can O
perform O
a O
variety O
of O
_RARE_ I-GENE
detection O
and O
discrimination O
tasks O
as O
well O
or O
nearly O
as O
well O
as O
controls O
. O

_RARE_ I-GENE
- I-GENE
GlcNAc I-GENE
: O
alpha I-GENE
- I-GENE
6 I-GENE
- I-GENE
D I-GENE
- I-GENE
_RARE_ I-GENE
beta I-GENE
- I-GENE
1 I-GENE
, O
2 I-GENE
- I-GENE
N I-GENE
- I-GENE
_RARE_ I-GENE
II I-GENE
( O
_RARE_ I-GENE
II I-GENE
; O
EC I-GENE
2 I-GENE
. O
4 I-GENE
. O
1 I-GENE
. O
143 I-GENE
) O
is O
essential O
for O
the O
normal O
assembly O
of O
complex I-GENE
Asn O
- I-GENE
linked O
_RARE_ I-GENE
. O

These O
patients O
failed O
to O
respond O
to O
intravenous O
cyclophosphamide O
and O
steroids O
and O
were O
then O
changed O
to O
receive O
oral O
cyclosporine O
A I-GENE
, O
at O
a O
dose O
of O
5 I-GENE
mg O
/ I-GENE
kg O
/ I-GENE
day O
. O

The O
predicted O
amino O
acid I-GENE
sequence I-GENE
is O
78 O
. O
0 O
% O
identical O
to O
the O
cytoplasmic I-GENE
dynein I-GENE
heavy I-GENE
chain I-GENE
of O
Neurospora I-GENE
crassa I-GENE
, O
70 I-GENE
. O
2 I-GENE
% O
identical O
to O
that O
of O
Aspergillus I-GENE
_RARE_ I-GENE
and O
24 O
. O
8 O
% O
identical O
to O
that O
of O
Saccharomyces I-GENE
cerevisiae I-GENE
. O

The O
DNA I-GENE
binding I-GENE
activities O
of O
the O
three O
repressor I-GENE
preparations O
were O
studied O
using O
fragments I-GENE
containing O
_RARE_ I-GENE
( O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
) O
from O
the O
essential O
early I-GENE
region O
as O
templates O
for O
DNase I-GENE
I I-GENE
footprinting O
. O

Molecular O
_RARE_ I-GENE
suggested O
that O
the O
_RARE_ I-GENE
domain I-GENE
was O
a O
four O
- I-GENE
helix I-GENE
bundle O
, O
stabilized O
by O
interactions O
of O
seven O
conserved O
aromatic O
amino O
acids O
. O

In O
the O
present O
study O
, O
we O
sought O
to O
investigate O
whether O
constitutive O
NF I-GENE
- I-GENE
kappaB I-GENE
activity O
in O
_RARE_ I-GENE
HIV I-GENE
- I-GENE
1 I-GENE
- I-GENE
infected O
_RARE_ I-GENE
U937 O
( O
_RARE_ I-GENE
- I-GENE
IIIB I-GENE
) O
and O
_RARE_ I-GENE
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
- I-GENE
IIIB I-GENE
) O
cells O
affects O
apoptotic O
signaling O
. O

Taken O
together O
, O
these O
results O
suggest O
that O
_RARE_ I-GENE
may O
exert O
a O
strong O
_RARE_ I-GENE
effect O
against O
_RARE_ I-GENE
and O
that O
this O
effect O
is O
likely O
to O
involve O
impairment O
of O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
mediated O
signaling O
pathway O
, O
induction O
of O
_RARE_ I-GENE
, O
and O
a O
_RARE_ I-GENE
G1 I-GENE
arrest O
. O

In O
connective O
tissue I-GENE
, O
cell O
structure O
contributes O
to O
type I-GENE
I I-GENE
collagen I-GENE
expression O
. O

To O
explore O
the O
function O
of O
human I-GENE
_RARE_ I-GENE
- I-GENE
homologous O
( O
_RARE_ I-GENE
) O
proteins I-GENE
, O
expression O
plasmids O
encoding O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
were O
transiently O
transfected O
into O
293 O
epithelial O
cells O
and O
_RARE_ I-GENE
fibroblast I-GENE
cells O
, O
resulting O
in O
growth I-GENE
arrest O
without O
induction O
of O
apoptosis O
. O

A I-GENE
point O
mutation I-GENE
in O
_RARE_ I-GENE
and O
_RARE_ I-GENE
blocks O
interaction O
with O
regulator I-GENE
of O
G I-GENE
protein I-GENE
signaling O
proteins I-GENE
. O

Indeed O
, O
it O
is O
shown O
that O
it O
mediates O
the O
formation O
of O
disulfide O
- I-GENE
linked O
homodimers I-GENE
and O
that O
the O
formation O
of O
_RARE_ I-GENE
- I-GENE
and O
heterodimers I-GENE
are O
_RARE_ I-GENE
excluded O
. O

N I-GENE
., O
and O
_RARE_ I-GENE
, O
E I-GENE
. O

We O
have O
shown O
previously O
that O
_RARE_ I-GENE
cells O
transfected O
with O
the O
rat I-GENE
GnRH I-GENE
receptor I-GENE
cDNA I-GENE
( O
_RARE_ I-GENE
- I-GENE
1 I-GENE
' O
cells O
) O
support O
the O
expression O
of O
a O
cotransfected O
fusion I-GENE
gene I-GENE
composed O
of O
_RARE_ I-GENE
base O
pairs O
of O
rat I-GENE
_RARE_ I-GENE
gene I-GENE
5 I-GENE
'- O
flanking O
sequence I-GENE
and O
the O
first O
5 I-GENE
base O
pairs O
of O
the O
5 I-GENE
'- O
untranslated O
region O
fused O
to O
a O
luciferase I-GENE
reporter I-GENE
(- O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
) O
and O
respond O
to O
a O
GnRH I-GENE
agonist O
with O
a O
10 O
- I-GENE
fold O
stimulation O
of O
activity O
. O

The O
5 I-GENE
'- O
flanking O
region O
, O
from O
nucleotide I-GENE
- I-GENE
_RARE_ I-GENE
to O
- I-GENE
_RARE_ I-GENE
, O
contains O
TATA I-GENE
and O
inverted O
CAAT I-GENE
boxes O
as O
well O
as O
GATA I-GENE
- I-GENE
1 I-GENE
/ I-GENE
SP1 I-GENE
erythroid I-GENE
- I-GENE
specific I-GENE
cis O
- I-GENE
acting O
regulatory I-GENE
elements O
. O

We O
established O
the O
_RARE_ I-GENE
cell O
line O
_RARE_ I-GENE
from O
mammary O
carcinoma O
cell O
line O
_RARE_ I-GENE
. O

In O
patients O
with O
type I-GENE
IA O
_RARE_ I-GENE
_RARE_ I-GENE
urine O
disease O
, O
the O
_RARE_ I-GENE
subunit I-GENE
is O
affected O
, O
resulting O
in O
the O
loss O
of O
E1 I-GENE
and O
branched I-GENE
- I-GENE
chain I-GENE
_RARE_ I-GENE
dehydrogenase I-GENE
catalytic O
activities O
. O

Results O
showed O
that O
the O
mean O
bond O
strength O
of O
H I-GENE
. O
T I-GENE
. O
V I-GENE
. O
specimens O
ranged O
from O
9 O
. O
6 I-GENE
to O
13 O
. O
12 O
kg O
/ I-GENE
cm2 O
, O
while O
the O
mean O
bond O
strength O
of O
R I-GENE
. O
T I-GENE
. O
V I-GENE
. O
specimens O
ranged O
from O
0 O
. O
36 O
to O
1 I-GENE
. O
75 O
kg O
/ I-GENE
cm2 O
. O

OBJECTIVES O
: O
To O
measure O
coagulation I-GENE
factor I-GENE
VIII I-GENE
: O
_RARE_ I-GENE
( O
F I-GENE
. O
VIII I-GENE
: O
C I-GENE
) O
and O
C1 I-GENE
- I-GENE
esterase I-GENE
inhibitor I-GENE
( O
C1 I-GENE
- I-GENE
_RARE_ I-GENE
), O
hemostasis O
- I-GENE
associated I-GENE
acute O
- I-GENE
phase O
_RARE_ I-GENE
proteins I-GENE
and O
coagulation I-GENE
factors I-GENE
VII I-GENE
( O
F I-GENE
. O
VII I-GENE
), O
IX I-GENE
( O
F I-GENE
. O
IX I-GENE
), O
and O
X I-GENE
( O
F I-GENE
. O
X I-GENE
), O
hemostasis O
proteins I-GENE
not O
associated I-GENE
with O
an O
acute O
- I-GENE
phase O
response O
, O
in O
a O
select O
population O
of O
horses O
with O
_RARE_ I-GENE
and O
hemostasis O
abnormalities O
, O
and O
presumed I-GENE
to O
have O
acute O
- I-GENE
phase O
changes O
. O

RESULTS O
: O
_RARE_ I-GENE
with O
_RARE_ I-GENE
had O
significantly O
higher O
fibrinogen I-GENE
concentration O
, O
greater O
alpha I-GENE
_RARE_ I-GENE
and O
protein I-GENE
C I-GENE
activities O
, O
and O
longer O
PT O
and O
_RARE_ I-GENE
than O
did O
healthy O
horses O
. O

The O
data O
suggest O
that O
plasminogen I-GENE
, O
alpha I-GENE
_RARE_ I-GENE
, O
and O
C1 I-GENE
- I-GENE
_RARE_ I-GENE
, O
should O
be O
considered O
equine I-GENE
acute O
- I-GENE
phase O
proteins I-GENE
. O

None O
of O
the O
patients O
was O
obese O
. O

Marked O
elevation O
of O
creatine I-GENE
kinase I-GENE
was O
observed O
while O
serum I-GENE
albumin I-GENE
, O
immunoglobulin I-GENE
, O
and O
complement I-GENE
were O
decreased O
. O

DESIGN O
AND O
METHODS O
: O
_RARE_ I-GENE
study O
. O

METHODS O
: O
A I-GENE
total O
of O
15 O
pigs O
were O
randomised O
to O
ligation O
of O
left O
_RARE_ I-GENE
arteries O
( O
infarction O
group O
, O
n O
= O
5 I-GENE
), O
to O
_RARE_ I-GENE
of O
the O
left O
lateral O
wall O
using O
a O
_RARE_ I-GENE
: O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
: O
_RARE_ I-GENE
) O
laser O
( O
laser O
group O
, O
n O
= O
5 I-GENE
), O
and O
to O
both O
( O
laser O
- I-GENE
infarction O
group O
, O
n O
= O
5 I-GENE
). O

_RARE_ I-GENE
, O
a O
receptor I-GENE
for O
activated I-GENE
C I-GENE
kinase I-GENE
and O
a O
homolog I-GENE
of O
the O
beta I-GENE
subunit I-GENE
of O
G I-GENE
proteins I-GENE
, O
inhibits O
activity O
of O
src I-GENE
tyrosine I-GENE
kinases I-GENE
and O
growth I-GENE
of O
NIH O
3T3 O
cells O
. O

_RARE_ I-GENE
sequences I-GENE
of O
the O
zinc I-GENE
finger I-GENE
protein I-GENE
_RARE_ I-GENE
and O
the O
transcription I-GENE
factor I-GENE
_RARE_ I-GENE
- I-GENE
1 I-GENE
were O
obtained O
. O

The O
same O
IL I-GENE
- I-GENE
4 I-GENE
- I-GENE
inducible I-GENE
reporter I-GENE
gene I-GENE
is O
also O
synergistically O
activated I-GENE
by O
the O
endogenous I-GENE
_RARE_ I-GENE
and O
NF I-GENE
- I-GENE
kappaB I-GENE
proteins I-GENE
in O
IL I-GENE
- I-GENE
4 I-GENE
- I-GENE
stimulated O
I I-GENE
. O
_RARE_ I-GENE
B I-GENE
lymphoma O
cells O
. O

HEF1 I-GENE
, O
p130 I-GENE
( O
Cas I-GENE
), O
and O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
constitute O
a O
family I-GENE
of O
_RARE_ I-GENE
_RARE_ I-GENE
proteins I-GENE
that O
have O
been O
implicated O
in O
_RARE_ I-GENE
the O
regulation O
of O
cell O
adhesion I-GENE
. O

In O
support O
of O
a O
role O
at O
the O
spindle O
, O
two O
- I-GENE
hybrid O
library O
screening O
with O
HEF1 I-GENE
identifies O
the O
human I-GENE
homolog I-GENE
of O
the O
G2 I-GENE
/ I-GENE
M I-GENE
spindle O
- I-GENE
regulatory I-GENE
protein I-GENE
_RARE_ I-GENE
as O
a O
specific I-GENE
_RARE_ I-GENE
with O
a O
region O
of O
HEF1 I-GENE
_RARE_ I-GENE
in O
p55 I-GENE
( O
HEF1 I-GENE
). O

Our O
data O
showed O
that O
activation O
of O
the O
raf I-GENE
- I-GENE
ERK I-GENE
pathway O
led O
to O
activation O
of O
TF I-GENE
expression O
in O
breast O
carcinoma O
cells O
and O
suggested O
that O
constitutive O
activation O
of O
this O
pathway O
leads O
to O
high O
TF I-GENE
expression O
in O
_RARE_ I-GENE
- I-GENE
MB I-GENE
- I-GENE
231 O
cells O
. O

However O
, O
a O
zinc I-GENE
- I-GENE
depleted O
enzyme I-GENE
was O
obtained O
after O
prolonged O
dialysis O
against O
the O
specific I-GENE
_RARE_ I-GENE
agent O
1 I-GENE
, O
10 O
- I-GENE
_RARE_ I-GENE
. O

All O
patients O
diagnosed O
of O
H I-GENE
. O
influenza I-GENE
type I-GENE
b I-GENE
meningitis O
were O
less O
than O
3 I-GENE
years O
old O
. O

The O
lines O
also O
differed O
in O
_RARE_ I-GENE
, O
but O
not O
_RARE_ I-GENE
, O
5 I-GENE
- I-GENE
_RARE_ I-GENE
receptors I-GENE
. O

_RARE_ I-GENE
seizure O
during O
a O
treatment O
with O
interferon I-GENE
alpha I-GENE
for O
chronic O
viral I-GENE
hepatitis I-GENE
C I-GENE

_RARE_ I-GENE
, O
_RARE_ I-GENE
19 O
antibody I-GENE
revealed O
strong O
staining O
in O
both O
epithelial O
and O
_RARE_ I-GENE
_RARE_ I-GENE
tissues O
. O

Genetic O
studies O
in O
Drosophila I-GENE
have O
led O
to O
the O
identification O
of O
several O
components O
of O
the O
Notch I-GENE
pathway O
. O

The O
_RARE_ I-GENE
cDNA I-GENE
( O
115 I-GENE
- I-GENE
_RARE_ I-GENE
nt O
, O
1 I-GENE
. O
8 O
kb O
), O
excluding O
sequences I-GENE
coding O
for O
N I-GENE
- I-GENE
terminal I-GENE
signal I-GENE
sequence I-GENE
and O
C I-GENE
- I-GENE
terminal I-GENE
_RARE_ I-GENE
domain I-GENE
, O
was O
PCR O
amplified O
and O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
restricted O
fragment I-GENE
cloned O
in O
frame O
downstream O
of O
the O
_RARE_ I-GENE
promoter I-GENE
under O
the O
lac I-GENE
operator I-GENE
control O
in O
a O
_RARE_ I-GENE
- I-GENE
30 O
vector O
. O

Control O
subjects O
' O
evoked O
potentials O
( O
_RARE_ I-GENE
) O
were O
characterized O
by O
an O
initial O
_RARE_ I-GENE
in O
the O
90 O
- I-GENE
140 I-GENE
ms O
range O
( O
P1 I-GENE
) O
at O
the O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
site I-GENE
. O

Class I-GENE
I I-GENE
alpha1 I-GENE
, O
2 I-GENE
- I-GENE
_RARE_ I-GENE
play O
an O
essential O
role O
in O
the O
_RARE_ I-GENE
of O
complex I-GENE
and O
hybrid O
N I-GENE
- I-GENE
_RARE_ I-GENE
in O
mammalian I-GENE
cells O
. O

Structural O
features O
of O
the O
minimal I-GENE
DNA I-GENE
binding I-GENE
domain I-GENE
( O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
) O
of O
human I-GENE
nucleotide I-GENE
excision O
repair I-GENE
protein I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
other O
_RARE_ I-GENE
, O
the O
_RARE_ I-GENE
' O
s O
importance O
lies O
in O
the O
fact O
that O
it O
associates O
an O
_RARE_ I-GENE
_RARE_ I-GENE
construction I-GENE
with O
the O
_RARE_ I-GENE
data O
, O
working O
within O
the O
possibilities O
provided O
by O
late O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
. O

The O
results O
point O
to O
the O
effectiveness O
of O
the O
_RARE_ I-GENE
intervention O
. O

The O
_RARE_ I-GENE
implications O
of O
aromatic O
non O
- I-GENE
responsiveness O
of O
autonomously I-GENE
expressed O
A I-GENE
- I-GENE
domain I-GENE
, O
despite O
its O
demonstrated O
ability O
to O
bind O
_RARE_ I-GENE
, O
are O
discussed O
. O

RESULTS O
: O
_RARE_ I-GENE
index O
returned O
to O
normal O
gradually O
as O
the O
time O
_RARE_ I-GENE
by O
and O
significantly O
within O
one O
year O
after O
the O
reduction O
of O
developmental O
dislocation O
of O
the O
hip O
. O

Recently O
, O
extremely O
high O
levels O
of O
endothelin I-GENE
- I-GENE
1 I-GENE
( O
ET I-GENE
- I-GENE
1 I-GENE
) O
were O
detected O
in O
the O
_RARE_ I-GENE
fluid O
of O
patients O
undergoing O
cardiac O
surgery O
. O

_RARE_ I-GENE
, O
it O
is O
not O
known O
how O
_RARE_ I-GENE
loading O
changes O
following O
_RARE_ I-GENE
_RARE_ I-GENE
, O
and O
how O
it O
contributes O
to O
cartilage O
degeneration O
. O

We O
show O
that O
the O
_RARE_ I-GENE
of O
tracheal O
cartilage O
matrix I-GENE
are O
collagen I-GENE
- I-GENE
rich O
and O
_RARE_ I-GENE
a O
proteoglycan I-GENE
- I-GENE
rich O
core I-GENE
. O

Comparative O
mapping O
of O
the O
_RARE_ I-GENE
S I-GENE
locus I-GENE
region O
and O
its O
_RARE_ I-GENE
in O
Arabidopsis I-GENE
. O

_RARE_ I-GENE
of O
the O
Candida I-GENE
albicans I-GENE
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
homolog I-GENE
, O
_RARE_ I-GENE
, O
in O
_RARE_ I-GENE
development O
and O
systemic O
candidiasis O
. O

Neither O
the O
reaction O
of O
_RARE_ I-GENE
nor O
the O
_RARE_ I-GENE
with O
beta I-GENE
- I-GENE
alanine I-GENE
resulted O
in O
the O
formation O
of O
_RARE_ I-GENE
. O

In O
most O
subjects O
, O
markers O
of O
bone O
formation O
and O
resorption O
were O
normal O
. O

Analysis O
of O
a O
_RARE_ I-GENE
mutant I-GENE
, O
_RARE_ I-GENE
for O
copper I-GENE
- I-GENE
dependent I-GENE
repression O
of O
the O
Cu I-GENE
( O
I I-GENE
) O
transport O
genes I-GENE
, O
showed O
an O
aberrant O
pattern O
of O
_RARE_ I-GENE
expression O
and O
copper I-GENE
sensitivity O
. O

The O
DNA I-GENE
sequencing O
of O
the O
recombinant I-GENE
clones O
revealed O
the O
expression O
of O
RXR I-GENE
alpha I-GENE
and O
RXR I-GENE
beta I-GENE
. O

A I-GENE
_RARE_ I-GENE
random O
sample O
of O
20 O
active O
_RARE_ I-GENE
from O
a O
cohort O
of O
_RARE_ I-GENE
_RARE_ I-GENE
workers O
was O
selected O
in O
1995 O
for O
determining O
_RARE_ I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
in O
blood O
lipids O
to O
assess O
the O
extent O
of O
past O
_RARE_ I-GENE
and O
_RARE_ I-GENE
exposure O
in O
this O
cohort O
and O
whether O
that O
exposure O
might O
explain O
site I-GENE
- I-GENE
specific I-GENE
cancer O
findings O
in O
the O
total O
cohort O
. O

The O
clinical O
and O
laboratory O
features O
of O
72 O
children O
with O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
purpura O
( O
_RARE_ I-GENE
) O
were O
examined O
to O
determine O
if O
there O
were O
associations O
between O
the O
laboratory O
indices O
-- O
including O
white O
blood O
cell O
( O
WBC O
) O
counts O
, O
serum I-GENE
C I-GENE
- I-GENE
reactive I-GENE
protein I-GENE
( O
CRP I-GENE
) O
levels O
, O
platelet I-GENE
( O
_RARE_ I-GENE
) O
counts O
-- O
and O
the O
clinical O
manifestations O
of O
acute O
_RARE_ I-GENE
. O

We O
provide O
community O
metabolic O
data O
that O
indicate O
that O
large O
changes O
in O
CO2 O
concentration O
can O
occur O
in O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
via O
_RARE_ I-GENE
processes O
not O
directly O
associated I-GENE
with O
_RARE_ I-GENE
, O
respiration O
, O
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
dissolution O
. O

In O
contrast O
to O
other O
known O
_RARE_ I-GENE
, O
the O
_RARE_ I-GENE
pol I-GENE
genes I-GENE
are O
expressed O
via O
spliced O
transcripts I-GENE
. O

Substitution O
of O
_RARE_ I-GENE
hydrophobic O
residues O
with O
charged O
residues O
within O
_RARE_ I-GENE
affects O
the O
fusion I-GENE
activity O
of O
the O
S I-GENE
protein I-GENE
without O
affecting O
processing O
and O
surface O
expression O
. O

_RARE_ I-GENE
and O
its O
_RARE_ I-GENE
products I-GENE
, O
mono O
- I-GENE
and O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
, O
were O
determined O
in O
water O
birds O
collected O
from O
_RARE_ I-GENE
_RARE_ I-GENE
( O
the O
_RARE_ I-GENE
_RARE_ I-GENE
), O
_RARE_ I-GENE
_RARE_ I-GENE
United O
_RARE_ I-GENE
, O
and O
the O
_RARE_ I-GENE
_RARE_ I-GENE
of O
_RARE_ I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
. O

The O
5 I-GENE
' O
flanking O
region O
of O
the O
_RARE_ I-GENE
gene I-GENE
contained O
the O
binding I-GENE
motifs O
for O
two O
cytokine O
- I-GENE
inducible I-GENE
transcription I-GENE
factors I-GENE
, O
NF I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
A I-GENE
and O
NF I-GENE
- I-GENE
IL6 I-GENE
. O

_RARE_ I-GENE
, O
M I-GENE
. O

_RARE_ I-GENE
- I-GENE
2 I-GENE
is O
the O
only O
_RARE_ I-GENE
, O
so O
far O
, O
that O
matches O
the O
genome O
organization O
of O
the O
type I-GENE
member O
of O
the O
group O
, O
_RARE_ I-GENE
, O
and O
thus O
can O
be O
_RARE_ I-GENE
classified O
as O
a O
definitive O
member O
of O
the O
genus O
_RARE_ I-GENE
. O

_RARE_ I-GENE
and O
clinical O
data O
were O
compared O
with O
a O
control O
group O
of O
_RARE_ I-GENE
healthy O
age O
- I-GENE
matched O
women O
and O
with O
a O
sample O
of O
_RARE_ I-GENE
women O
with O
wrist O
fracture O
. O

Combined O
expression O
of O
c I-GENE
- I-GENE
Jun I-GENE
and O
p65 I-GENE
induced O
_RARE_ I-GENE
transcription I-GENE
of O
IL I-GENE
- I-GENE
2 I-GENE
promoter I-GENE
- I-GENE
and O
_RARE_ I-GENE
- I-GENE
driven O
reporter I-GENE
constructs I-GENE
in O
both O
_RARE_ I-GENE
- I-GENE
3 I-GENE
- I-GENE
and O
B7 I-GENE
- I-GENE
1 I-GENE
- I-GENE
_RARE_ I-GENE
Jurkat O
cells O
. O

_RARE_ I-GENE
results O
were O
obtained O
when O
transfections O
and O
mobility I-GENE
shift O
assays O
were O
performed O
in O
primary O
rat I-GENE
hepatocytes O
in O
which O
the O
endogenous I-GENE
_RARE_ I-GENE
gene I-GENE
is O
expressed O
. O

This O
E I-GENE
box I-GENE
sequence I-GENE
( O
_RARE_ I-GENE
) O
is O
identical O
to O
the O
binding I-GENE
element I-GENE
for O
USF I-GENE
( O
upstream O
stimulatory I-GENE
factor I-GENE
), O
a O
member O
of O
the O
helix I-GENE
- I-GENE
loop I-GENE
- I-GENE
helix I-GENE
family I-GENE
of O
transcription I-GENE
factors I-GENE
. O

Interferon I-GENE
beta I-GENE
therapy O
was O
_RARE_ I-GENE
for O
4 I-GENE
weeks O
. O

_RARE_ I-GENE
chromatographic O
method O
for O
analysis O
of O
all O
- I-GENE
_RARE_ I-GENE
- I-GENE
alpha I-GENE
- I-GENE
_RARE_ I-GENE
acetate O
and O
_RARE_ I-GENE
_RARE_ I-GENE
in O
milk O
- I-GENE
based O
infant O
formula O
using O
matrix I-GENE
solid O
- I-GENE
phase O
dispersion O
. O

We O
_RARE_ I-GENE
_RARE_ I-GENE
3 I-GENE
types O
of O
_RARE_ I-GENE
_RARE_ I-GENE
, O
a O
_RARE_ I-GENE
pump I-GENE
( O
_RARE_ I-GENE
), O
a O
mixed O
flow O
pump I-GENE
( O
_RARE_ I-GENE
), O
and O
an O
axial O
flow O
pump I-GENE
( O
AFP I-GENE
), O
and O
analyzed O
their O
in O
vitro O
performance O
. O

Examination O
of O
the O
mitochondrial I-GENE
_RARE_ I-GENE
complex I-GENE
crystal O
structure O
[ O
_RARE_ I-GENE
, O
Z I-GENE
., O
_RARE_ I-GENE
, O
L I-GENE
., O
_RARE_ I-GENE
, O
V I-GENE
. O

Two O
protease I-GENE
- I-GENE
resistant O
fragments I-GENE
spanning O
the O
N I-GENE
- I-GENE
and O
C I-GENE
- I-GENE
terminal I-GENE
_RARE_ I-GENE
of O
the O
nuclease I-GENE
were O
identified O
using O
different O
proteases I-GENE
which O
_RARE_ I-GENE
the O
protein I-GENE
in O
the O
same O
region O
. O

The O
side O
- I-GENE
to O
- I-GENE
side O
difference O
was O
statistically O
significant O
at O
_RARE_ I-GENE
30 O
degrees O
/ I-GENE
s O
and O
60 O
degrees O
/ I-GENE
s O
( O
p O
< O
0 O
. O
05 O
). O

CONCLUSION O
: O
In O
women O
who O
_RARE_ I-GENE
or O
require O
conservative O
management O
of O
grade O
4 I-GENE
_RARE_ I-GENE
and O
are O
unable O
to O
_RARE_ I-GENE
a O
single O
_RARE_ I-GENE
, O
the O
placement O
of O
two O
_RARE_ I-GENE
often O
will O
be O
successful O
. O

The O
ability O
to O
maintain O
expression O
of O
_RARE_ I-GENE
in O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
Delta I-GENE
cells O
suggests O
the O
existence O
of O
another O
transcription I-GENE
factor I-GENE
, O
or O
factors I-GENE
, O
whose O
expression O
/ I-GENE
activity O
is O
inversely O
related I-GENE
to O
overall O
levels O
of O
cellular O
protein I-GENE
N I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
. O

Rev I-GENE
- I-GENE
_RARE_ I-GENE
/ I-GENE
beta I-GENE
), O
_RARE_ I-GENE
- I-GENE
1 I-GENE
and O
_RARE_ I-GENE
bHLH I-GENE
- I-GENE
_RARE_ I-GENE
proteins I-GENE
and O
the O
oncoproteins I-GENE
PLZF I-GENE
and O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
is O
mediated O
by O
the O
_RARE_ I-GENE
N I-GENE
- I-GENE
_RARE_ I-GENE
and O
SMRT I-GENE
. O

The O
identified O
isolates O
of O
CSF I-GENE
( O
20 O
of O
29 O
) O
were O
: O
ECHO O
30 O
( O
9 O
), O
ECHO O
11 O
( O
7 O
), O
ECHO O
9 O
( O
3 I-GENE
) O
and O
ECHO O
7 O
( O
1 I-GENE
). O

There O
was O
no O
evidence O
of O
any O
persistent O
_RARE_ I-GENE
within O
the O
_RARE_ I-GENE
band O
. O

The O
_RARE_ I-GENE
- I-GENE
F I-GENE
test O
alone O
was O
used O
to O
monitor O
serum I-GENE
antigen I-GENE
levels O
after O
treatment O
in O
24 O
patients O
. O

The O
purified O
recombinant I-GENE
protein I-GENE
was O
assayed O
for O
its O
enzyme I-GENE
activity O
by O
monitoring O
transfer I-GENE
of O
[ O
3H O
] O
methyl O
groups O
from O
the O
substrate I-GENE
DNA I-GENE
to O
the O
_RARE_ I-GENE
protein I-GENE
; O
the O
activity O
was O
found O
to O
be O
stable O
at O
90 O
degrees O
C I-GENE
for O
at O
least O
30 O
min O
. O

A I-GENE
_RARE_ I-GENE
procedure O
was O
coupled I-GENE
with O
a O
reversed O
- I-GENE
phase O
HPLC O
separation O
using O
a O
_RARE_ I-GENE
. O
6 I-GENE
mm O
I I-GENE
. O
D I-GENE
. O

Elimination O
of O
the O
inducible I-GENE
response O
requires O
simultaneous O
mutation I-GENE
of O
both O
sequences I-GENE
, O
however O
, O
in O
the O
presence O
of O
an O
intact O
_RARE_ I-GENE
the O
upstream O
AP I-GENE
- I-GENE
1 I-GENE
site I-GENE
is O
_RARE_ I-GENE
to O
induction O
. O

Three O
high O
mobility I-GENE
group O
- I-GENE
like I-GENE
sequences I-GENE
within O
a O
48 O
- I-GENE
base O
pair O
enhancer I-GENE
of O
the O
_RARE_ I-GENE
gene I-GENE
are O
required O
for O
cartilage O
- I-GENE
specific I-GENE
expression O
in O
vivo O
. O

The O
sequence I-GENE
contains O
an O
open O
reading O
frame O
of O
_RARE_ I-GENE
nt O
in O
the O
virus I-GENE
- I-GENE
sense O
strand O
, O
a O
3 I-GENE
' O
untranslated O
region O
of O
_RARE_ I-GENE
nt O
and O
a O
3 I-GENE
' O
poly O
( O
A I-GENE
) O
tail O
. O

A I-GENE
phylogenetic O
analysis O
of O
the O
reverse I-GENE
transcriptase I-GENE
domain I-GENE
_RARE_ I-GENE
our O
differential O
genetic O
assessment O
that O
_RARE_ I-GENE
from O
_RARE_ I-GENE
is O
a O
novel O
element I-GENE
with O
no O
specific I-GENE
relationship O
to O
the O
previously O
described O
_RARE_ I-GENE
- I-GENE
like I-GENE
elements O
from O
plants O
. O

At O
physiological O
doses O
, O
either O
insulin I-GENE
- I-GENE
like I-GENE
growth I-GENE
factor I-GENE
I I-GENE
( O
IGF I-GENE
- I-GENE
I I-GENE
) O
or O
insulin I-GENE
turned O
out O
to O
be O
as O
potent O
as O
_RARE_ I-GENE
cAMP I-GENE
( O
_RARE_ I-GENE
) O
in O
increasing O
_RARE_ I-GENE
gene I-GENE
transcription I-GENE
rate O
( O
1 I-GENE
h O
) O
and O
also O
_RARE_ I-GENE
mRNA I-GENE
accumulation O
( O
3 I-GENE
h O
), O
their O
maximal O
effect O
( O
15 O
- I-GENE
fold O
increase O
) O
reached O
upon O
treatment O
for O
24 O
h O
. O

In O
addition O
, O
insulin I-GENE
induced O
AP I-GENE
- I-GENE
1 I-GENE
DNA I-GENE
binding I-GENE
activity O
, O
this O
effect O
being O
_RARE_ I-GENE
prevented O
in O
the O
presence O
of O
MEK I-GENE
- I-GENE
1 I-GENE
inhibitor I-GENE
. O

_RARE_ I-GENE
, O
2 I-GENE
'- O
O O
- I-GENE
methyl O
_RARE_ I-GENE
( O
2 I-GENE
' O
_RARE_ I-GENE
) O
were O
delivered O
to O
the O
nuclei O
of O
primary O
_RARE_ I-GENE
myoblasts O
in O
culture O
. O

A I-GENE
large O
deletion O
in O
the O
CTD I-GENE
- I-GENE
binding I-GENE
motif I-GENE
blocks O
down O
- I-GENE
regulation O
but O
does O
not O
affect O
the O
essential O
function O
of O
_RARE_ I-GENE
. O

Regulation O
of O
the O
human I-GENE
p21 I-GENE
/ I-GENE
WAF1 I-GENE
/ I-GENE
Cip1 I-GENE
promoter I-GENE
in O
hepatic I-GENE
cells O
by O
functional O
interactions O
between O
Sp1 I-GENE
and O
Smad I-GENE
family I-GENE
members O
. O

RESULTS O
: O
We O
isolated O
a O
C I-GENE
. O
elegans I-GENE
cDNA I-GENE
that O
encoded I-GENE
a O
protein I-GENE
which O
was O
similar O
to O
, O
but O
not O
_RARE_ I-GENE
homologous O
with O
mammalian I-GENE
_RARE_ I-GENE
Ras I-GENE
- I-GENE
GAP I-GENE
. O

The O
weak O
base O
_RARE_ I-GENE
showed O
complete O
dissolution O
from O
a O
tablet O
formulation O
in O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
without O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
within O
30 O
minutes O
, O
70 I-GENE
% O
dissolution O
in O
2 I-GENE
hours O
under O
fed O
state O
simulated O
upper O
_RARE_ I-GENE
conditions O
but O
only O
6 I-GENE
% O
dissolution O
in O
2 I-GENE
hours O
under O
fasted O
state O
conditions O
. O

In O
mammals O
, O
the O
Rb I-GENE
protein I-GENE
interacts O
specifically O
with O
D I-GENE
- I-GENE
type I-GENE
_RARE_ I-GENE
and O
regulates O
cell O
proliferation O
by O
binding I-GENE
and O
inhibiting O
E2F I-GENE
transcription I-GENE
factors I-GENE
. O

In O
addition O
to O
the O
signals O
obtained O
by O
ligation O
of O
the O
TCR I-GENE
, O
T I-GENE
cells O
need O
additional O
, O
co O
- I-GENE
stimulatory I-GENE
signals O
to O
be O
activated I-GENE
. O

Moreover O
, O
the O
observation O
of O
enhanced O
luteal O
_RARE_ I-GENE
- I-GENE
27 O
phosphorylation O
in O
vivo O
, O
in O
late O
pregnancy O
, O
when O
PKC I-GENE
- I-GENE
delta I-GENE
is O
abundant O
and O
active O
, O
suggests O
that O
select O
PKC I-GENE
family I-GENE
members O
contribute O
to O
_RARE_ I-GENE
phosphorylation O
events O
in O
vivo O
. O

We O
characterized O
the O
structure O
of O
this O
leader O
mRNA I-GENE
by O
using O
the O
program O
_RARE_ I-GENE
and O
a O
combination O
of O
_RARE_ I-GENE
and O
internal O
deletions O
transcriptionally O
fused O
to O
a O
promoterless O
lac I-GENE
operon I-GENE
. O

The O
importance O
of O
these O
sites I-GENE
for O
transcriptional O
activation O
was O
studied O
by O
site I-GENE
- I-GENE
directed O
mutagenesis O
followed O
by O
promoter I-GENE
function O
analysis O
of O
the O
mutants I-GENE
with O
a O
chloramphenicol I-GENE
acetyltransferase I-GENE
reporter I-GENE
system O
. O

_RARE_ I-GENE
blood O
examination O
showed O
_RARE_ I-GENE
, O
thrombocytopenia O
, O
positive O
CRP I-GENE
, O
and O
elevated O
myocardial O
enzymes O
. O

Previous O
studies O
have O
suggested O
that O
moderate O
_RARE_ I-GENE
increases O
the O
responsiveness O
of O
vascular I-GENE
alpha2 I-GENE
- I-GENE
adrenoceptors I-GENE
. O

Two O
members O
of O
the O
Cbl I-GENE
family I-GENE
have O
since O
been O
defined O
in O
mammals O
( O
c I-GENE
- I-GENE
Cbl I-GENE
and O
Cbl I-GENE
- I-GENE
b I-GENE
), O
one O
in O
C I-GENE
. O
elegans I-GENE
( O
_RARE_ I-GENE
- I-GENE
1 I-GENE
) O
and O
one O
in O
Drosophila I-GENE
( O
D I-GENE
- I-GENE
Cbl I-GENE
). O

Anti I-GENE
- I-GENE
PTB I-GENE
antibodies I-GENE
did O
not O
inhibit O
the O
binding I-GENE
of O
PTB I-GENE
to O
RNA I-GENE
because O
they O
were O
able O
to O
supershift O
RNA I-GENE
- I-GENE
PTB I-GENE
complexes I-GENE
. O

The O
use O
of O
antibodies I-GENE
to O
the O
_RARE_ I-GENE
tract O
binding I-GENE
protein I-GENE
( O
PTB I-GENE
) O
to O
analyze O
the O
protein I-GENE
components O
that O
_RARE_ I-GENE
on O
alternatively O
spliced O
pre I-GENE
- I-GENE
mRNAs I-GENE
that O
use O
distant O
branch O
points O
. O

The O
therapeutic O
use O
of O
botulinum I-GENE
toxin I-GENE
( O
_RARE_ I-GENE
) O
is O
increasing O
in O
_RARE_ I-GENE
. O

The O
viral I-GENE
oncoprotein I-GENE
E1A I-GENE
inhibits O
NFAT I-GENE
- I-GENE
dependent I-GENE
transactivation O
in O
a O
p300 I-GENE
- I-GENE
dependent I-GENE
manner O
. O

We O
have O
applied O
the O
mRNA I-GENE
differential O
display O
method O
to O
compare O
and O
analyze O
mRNAs I-GENE
prepared O
from O
five O
normal O
_RARE_ I-GENE
epithelial O
cell O
cultures O
and O
five O
_RARE_ I-GENE
carcinoma O
cell O
lines O
. O

Similar O
experiments O
with O
TR I-GENE
support O
the O
high O
affinity O
of O
_RARE_ I-GENE
to O
the O
RXR I-GENE
subunit I-GENE
and O
also O
suggest O
that O
either O
partner I-GENE
in O
the O
TR I-GENE
/ I-GENE
RXR I-GENE
heterodimer O
can O
independently O
respond O
to O
ligand O
. O

SETTING O
: O
University O
hospital O
- I-GENE
based O
, O
tertiary O
care O
infertility O
center I-GENE
. O

_RARE_ I-GENE
( O
S I-GENE
): O
In O
patients O
with O
elevated O
FSH I-GENE
levels O
on O
cycle O
day O
3 I-GENE
, O
a O
low O
oocyte O
yield O
was O
achieved O
( O
7 O
versus O
11 O
) O
and O
a O
high O
number O
of O
_RARE_ I-GENE
of O
_RARE_ I-GENE
was O
necessary O
( O
56 O
versus O
33 O
). O

RESULTS O
: O
Of O
the O
patients O
with O
_RARE_ I-GENE
, O
67 O
% O
had O
significantly O
greater O
values O
of O
_RARE_ I-GENE
_RARE_ I-GENE
on O
the O
_RARE_ I-GENE
test O
( O
a O
measure O
of O
_RARE_ I-GENE
system O
_RARE_ I-GENE
) O
compared O
with O
control O
subjects O
. O

In O
the O
_RARE_ I-GENE
specimens O
, O
tissue I-GENE
_RARE_ I-GENE
had O
increased O
. O

As O
predicted O
by O
the O
_RARE_ I-GENE
and O
_RARE_ I-GENE
model O
, O
the O
durations O
of O
successive O
_RARE_ I-GENE
tended O
to O
be O
negatively O
correlated O
. O

Thus O
, O
included O
in O
the O
_RARE_ I-GENE
EST I-GENE
_RARE_ I-GENE
are O
_RARE_ I-GENE
for O
new O
human I-GENE
genes I-GENE
that O
may O
play O
roles O
in O
hematopoietic I-GENE
_RARE_ I-GENE
progression O
and O
lineage O
_RARE_ I-GENE
. O

We O
found O
the O
following O
: O
Specific O
mutations O
affected O
the O
precise O
carbohydrate O
structure O
and O
folding O
of O
the O
HA I-GENE
_RARE_ I-GENE
. O

The O
results O
show O
that O
ROS I-GENE
production O
by O
viable O
spermatozoa O
is O
highly O
correlated O
with O
the O
concentration O
of O
PMN I-GENE
elastase I-GENE
and O
the O
number O
of O
both O
peroxidase I-GENE
- I-GENE
positive O
and O
round O
cells O
. O

Yeast I-GENE
U1 I-GENE
snRNP I-GENE
is O
considerably O
more O
complex I-GENE
than O
its O
metazoan I-GENE
counterpart O
, O
which O
suggests O
possible O
differences O
between O
yeast I-GENE
and O
_RARE_ I-GENE
in O
early I-GENE
splicing O
events O
. O

Yeast I-GENE
U1 I-GENE
snRNP I-GENE
therefore O
contains O
16 O
different O
proteins I-GENE
, O
including O
seven O
snRNP I-GENE
core I-GENE
proteins I-GENE
, O
three O
homologues O
of O
the O
metazoan I-GENE
U1 I-GENE
snRNP I-GENE
- I-GENE
specific I-GENE
proteins I-GENE
, O
and O
six O
yeast I-GENE
- I-GENE
specific I-GENE
U1 I-GENE
snRNP I-GENE
proteins I-GENE
. O

After O
the O
first O
cycle O
, O
18 O
cases O
were O
treated O
at O
dose O
level O
1 I-GENE
, O
after O
a O
second O
cycle O
, O
13 O
cases O
were O
treated O
at O
dose O
level O
2 I-GENE
. O

The O
opioid I-GENE
antagonist O
naltrexone O
( O
0 O
. O
01 O
- I-GENE
1 I-GENE
. O
0 O
mg O
/ I-GENE
kg O
) O
_RARE_ I-GENE
the O
_RARE_ I-GENE
stimulus O
effects O
of O
_RARE_ I-GENE
, O
but O
naltrexone O
at O
doses O
up O
to O
10 O
mg O
/ I-GENE
kg O
had O
no O
effect O
on O
the O
_RARE_ I-GENE
stimulus O
effects O
of O
cocaine O
. O

In O
this O
study O
we O
examined O
hepatic I-GENE
_RARE_ I-GENE
cell O
regulation O
of O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
expression O
and O
found O
that O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
mRNA I-GENE
transcript I-GENE
levels O
increased O
in O
_RARE_ I-GENE
cells O
from O
rats O
exposed O
to O
carbon O
_RARE_ I-GENE
( O
_RARE_ I-GENE
), O
a O
potent O
_RARE_ I-GENE
_RARE_ I-GENE
. O

One O
cDNA I-GENE
clone O
designated O
_RARE_ I-GENE
- I-GENE
62 O
, O
encoded I-GENE
a O
62 O
, O
000 O
- I-GENE
Da I-GENE
protein I-GENE
that O
is O
highly O
related I-GENE
to O
_RARE_ I-GENE
, O
a O
Drosophila I-GENE
melanogaster I-GENE
nuclear I-GENE
protein I-GENE
involved O
in O
ecdysone O
- I-GENE
stimulated O
gene I-GENE
expression O
. O

These O
widely O
expressed O
proteins I-GENE
share O
a O
C I-GENE
- I-GENE
terminal I-GENE
region O
that O
_RARE_ I-GENE
significant O
sequence I-GENE
homology I-GENE
to O
a O
group O
of O
GDP I-GENE
/ I-GENE
GTP I-GENE
exchange I-GENE
proteins I-GENE
for O
the O
_RARE_ I-GENE
family I-GENE
of O
small I-GENE
GTP I-GENE
binding I-GENE
proteins I-GENE
. O

Whereas O
_RARE_ I-GENE
expression O
had O
no O
effect O
on O
ERK2 I-GENE
activation O
by O
_RARE_ I-GENE
, O
p70 I-GENE
completely O
abrogated O
this O
activity O
. O

The O
pre I-GENE
- I-GENE
mRNA I-GENE
splicing O
factor I-GENE
_RARE_ I-GENE
( O
U2 I-GENE
small I-GENE
nuclear I-GENE
ribonucleoprotein I-GENE
particle I-GENE
[ O
snRNP I-GENE
] O
auxiliary I-GENE
factor I-GENE
) O
plays O
a O
critical O
role O
in O
3 I-GENE
' O
splice O
site I-GENE
selection O
. O

The O
_RARE_ I-GENE
were O
_RARE_ I-GENE
to O
100 O
_RARE_ I-GENE
extracted O
bovine I-GENE
_RARE_ I-GENE
, O
and O
, O
after O
storage O
in O
tap I-GENE
water O
at O
room O
temperature O
for O
24 O
hours O
, O
they O
were O
subsequently O
tested O
in O
a O
shear O
mode O
using O
a O
_RARE_ I-GENE
testing O
machine O
. O

_RARE_ I-GENE
training O
has O
become O
_RARE_ I-GENE
important O
in O
the O
treatment O
of O
heart O
failure O
patients O
. O

The O
growth I-GENE
of O
_RARE_ I-GENE
. O
_RARE_ I-GENE
in O
filter O
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
extract O
was O
completely O
inhibited O
by O
0 O
. O
1 I-GENE
% O
( O
v I-GENE
/ I-GENE
v I-GENE
) O
_RARE_ I-GENE
whereas O
that O
of O
_RARE_ I-GENE
. O
_RARE_ I-GENE
was O
not O
significantly O
affected O
by O
1 I-GENE
% O
( O
v I-GENE
/ I-GENE
v I-GENE
) O
_RARE_ I-GENE
. O

Despite O
continuous O
compliance O
, O
_RARE_ I-GENE
_RARE_ I-GENE
of O
serum I-GENE
ferritin I-GENE
levels O
occurred O
in O
4 I-GENE
/ I-GENE
7 O
patients O
of O
the O
' O
_RARE_ I-GENE
' O
group O
after O
4 I-GENE
- I-GENE
5 I-GENE
years O
on O
L1 I-GENE
. O

_RARE_ I-GENE
and O
PaO2 O
did O
not O
change O
. O

Regulation O
of O
myosin I-GENE
phosphatase I-GENE
activity O
involves O
changes O
in O
subunit I-GENE
interactions O
, O
although O
molecular O
mechanisms O
are O
not O
defined O
. O

_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
is O
sufficient O
to O
control O
a O
3 I-GENE
- I-GENE
D I-GENE
ocular O
plant O
with O
_RARE_ I-GENE
. O

The O
virus I-GENE
- I-GENE
associated I-GENE
_RARE_ I-GENE
RNA I-GENE
of O
adenovirus I-GENE
is O
a O
small I-GENE
highly O
structured O
RNA I-GENE
that O
is O
required O
for O
the O
efficient O
translation I-GENE
of O
cellular O
and O
viral I-GENE
mRNAs I-GENE
at O
late O
times O
after O
infection O
. O

Structure O
of O
the O
gene I-GENE
encoding O
the O
human I-GENE
cyclin I-GENE
- I-GENE
dependent I-GENE
kinase I-GENE
inhibitor I-GENE
_RARE_ I-GENE
and O
mutational O
analysis O
in O
breast O
cancer O
. O

The O
_RARE_ I-GENE
protein I-GENE
was O
found O
to O
be O
degraded O
in O
an O
_RARE_ I-GENE
- I-GENE
dependent I-GENE
manner O
in O
vivo O
and O
in O
vitro O
, O
whereas O
the O
_RARE_ I-GENE
mutant I-GENE
protein I-GENE
, O
lacking O
eight O
amino O
acid I-GENE
residues O
within O
the O
amino O
- I-GENE
terminal I-GENE
cytoplasmic I-GENE
domain I-GENE
, O
was O
refractory O
to O
the O
degradation O
. O

The O
major I-GENE
type I-GENE
involves O
activator I-GENE
proteins I-GENE
that O
bind O
to O
DNA I-GENE
adjacent O
to O
where O
the O
RNA I-GENE
polymerase I-GENE
( O
RNAP I-GENE
) O
holoenzyme I-GENE
binds O
, O
usually O
_RARE_ I-GENE
in O
recruitment O
of O
the O
RNAP I-GENE
to O
the O
promoter I-GENE
. O

A I-GENE
conserved O
role O
for O
L1 I-GENE
as O
a O
transmembrane I-GENE
link I-GENE
between O
neuronal O
adhesion I-GENE
and O
membrane I-GENE
cytoskeleton I-GENE
assembly O
. O

_RARE_ I-GENE
_RARE_ I-GENE
, O
urinary O
_RARE_ I-GENE
acid I-GENE
( O
_RARE_ I-GENE
- I-GENE
MA I-GENE
) O
and O
leukocyte I-GENE
alkaline I-GENE
phosphatase I-GENE
activity O
( O
_RARE_ I-GENE
) O
were O
evaluated O
among O
66 O
_RARE_ I-GENE
_RARE_ I-GENE
, O
34 O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
, O
and O
28 O
_RARE_ I-GENE
workers O
. O

It O
contains O
a O
5 I-GENE
'- O
noncoding O
region O
( O
NCR O
) O
of O
73 O
nucleotides O
, O
five O
open O
reading O
frames O
( O
ORFs O
1 I-GENE
to O
5 I-GENE
) O
which O
encode O
proteins I-GENE
with O
M I-GENE
( O
r O
) O
160 I-GENE
kDa I-GENE
RNA I-GENE
- I-GENE
dependent I-GENE
RNA I-GENE
polymerase I-GENE
( O
ORF1 O
), O
26 O
kDa I-GENE
movement O
protein I-GENE
1 I-GENE
( O
ORF2 O
), O
13 O
kDa I-GENE
movement O
protein I-GENE
2 I-GENE
( O
ORF3 O
), O
10 O
kDa I-GENE
movement O
protein I-GENE
3 I-GENE
( O
_RARE_ I-GENE
), O
24 O
kDa I-GENE
coat I-GENE
protein I-GENE
( O
_RARE_ I-GENE
), O
and O
a O
3 I-GENE
' O
NCR O
of O
76 I-GENE
nucleotides O
. O

After O
profound O
_RARE_ I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
9 O
%) O
_RARE_ I-GENE
of O
LV O
MC O
and O
LV O
diastolic O
properties O
was O
found O
, O
when O
myocardial O
oxygenation O
was O
supported O
by O
i O
. O
v I-GENE
. O
_RARE_ I-GENE
_RARE_ I-GENE
, O
a O
temporary O
O2 O
carrier I-GENE
. O

Sp1 I-GENE
and O
two O
Sp3 I-GENE
isoforms I-GENE
were O
detected O
as O
the O
primary O
cellular O
_RARE_ I-GENE
of O
DNA I-GENE
- I-GENE
protein I-GENE
complexes I-GENE
formed O
with O
the O
NF I-GENE
- I-GENE
kappaB I-GENE
- I-GENE
proximal I-GENE
site I-GENE
. O

These O
genes I-GENE
may O
represent O
_RARE_ I-GENE
targets O
for O
new O
therapeutic O
strategies O
. O

It O
could O
also O
inhibit O
_RARE_ I-GENE
- I-GENE
dependent I-GENE
_RARE_ I-GENE
of O
both O
IgG I-GENE
- I-GENE
and O
IgM I-GENE
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
. O

3 I-GENE
) O
and O
one O
distal O
(- O
11 O
. O
8 O
/- O
10 O
. O
9 O
), O
presented O
an O
enhancer I-GENE
activity O
in O
pituitary I-GENE
cells O
when O
placed O
upstream O
of O
the O
SV40 I-GENE
promoter I-GENE
. O

The O
second O
patient O
had O
received O
pituitary I-GENE
- I-GENE
derived O
growth I-GENE
hormone I-GENE
for O
treatment O
of O
growth I-GENE
hormone I-GENE
deficiency O
, O
secondary O
to O
a O
third O
ventricle O
_RARE_ I-GENE
, O
_RARE_ I-GENE
13 O
yr O
earlier O
. O

3 I-GENE
-- O
It O
is O
necessary O
to O
_RARE_ I-GENE
about O
_RARE_ I-GENE
consequences O
of O
the O
_RARE_ I-GENE
flap O
and O
consider O
other O
possibilities O
of O
the O
flap O
choice O
. O

CONCLUSION O
: O
TNF I-GENE
alpha I-GENE
, O
TGF I-GENE
beta I-GENE
, O
PDGF I-GENE
and O
IL I-GENE
- I-GENE
1beta I-GENE
increased O
_RARE_ I-GENE
gene I-GENE
expression O
by O
increasing O
sterol I-GENE
- I-GENE
independent O
and O
_RARE_ I-GENE
- I-GENE
independent O
gene I-GENE
transcription I-GENE
. O

Binding O
affinities O
of O
different O
nucleotide I-GENE
mono O
-, I-GENE
_RARE_ I-GENE
- I-GENE
and O
_RARE_ I-GENE
and O
non O
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
indicate O
that O
the O
beta I-GENE
- I-GENE
phosphate I-GENE
_RARE_ I-GENE
is O
required O
for O
substrate I-GENE
binding I-GENE
. O

However O
, O
it O
is O
only O
one O
- I-GENE
half O
and O
one O
- I-GENE
third O
the O
size O
of O
the O
_RARE_ I-GENE
from O
M I-GENE
. O
_RARE_ I-GENE
and O
M I-GENE
. O
_RARE_ I-GENE
, O
respectively O
. O
_RARE_ I-GENE
is O
expressed O
in O
Escherichia I-GENE
coli I-GENE
, O
and O
it O
is O
incorporated O
into O
the O
cytoplasmic I-GENE
membrane I-GENE
despite O
the O
different O
chemical O
_RARE_ I-GENE
of O
lipids O
from O
_RARE_ I-GENE
and O
bacteria O
. O

In O
this O
report O
we O
studied O
the O
role O
of O
protein I-GENE
- I-GENE
tyrosine I-GENE
phosphatase I-GENE
SHP I-GENE
- I-GENE
2 I-GENE
in O
ErbB I-GENE
- I-GENE
mediated O
activation O
of O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
( O
MAPK I-GENE
) O
by O
overexpressing O
SHP I-GENE
- I-GENE
2 I-GENE
mutants I-GENE
in O
COS O
- I-GENE
7 O
cells O
. O

_RARE_ I-GENE
is O
a O
recently O
described O
bone O
proteoglycan I-GENE
containing O
_RARE_ I-GENE
sulfate I-GENE
. O

Intron I-GENE
8 O
_RARE_ I-GENE
a O
strong O
erythroid I-GENE
- I-GENE
specific I-GENE
enhancer I-GENE
activity O
which O
was O
orientation O
- I-GENE
dependent I-GENE
. O

The O
intron O
8 O
enhancer I-GENE
region O
was O
not O
activated I-GENE
by O
GATA I-GENE
- I-GENE
1 I-GENE
together O
with O
Sp1 I-GENE
in O
transactivation O
experiments O
in O
COS O
- I-GENE
1 I-GENE
cells O
indicating O
the O
involvement O
of O
a O
related I-GENE
Sp1 I-GENE
protein I-GENE
or O
of O
another O
unidentified O
erythroid I-GENE
factor I-GENE
. O

The O
cleavage O
of O
_RARE_ I-GENE
by O
_RARE_ I-GENE
may O
thus O
play O
an O
important O
role O
in O
the O
_RARE_ I-GENE
of O
the O
suicide O
program O
by O
_RARE_ I-GENE
the O
anti I-GENE
- I-GENE
apoptotic O
function O
of O
_RARE_ I-GENE
. O

Moreover O
, O
the O
mass O
estimated O
with O
the O
_RARE_ I-GENE
response O
through O
the O
_RARE_ I-GENE
equation O
and O
the O
mass O
which O
can O
be O
measured O
_RARE_ I-GENE
to O
other O
_RARE_ I-GENE
techniques O
, O
in O
our O
case O
an O
enzymatic O
assay O
, O
are O
different O
: O
the O
_RARE_ I-GENE
mass O
is O
generally O
_RARE_ I-GENE
by O
the O
_RARE_ I-GENE
. O

[ O
Treatment O
of O
early I-GENE
T1 O
small I-GENE
_RARE_ I-GENE
breast O
cancers O
. O

Transcription O
initiation I-GENE
occurred O
predominantly O
at O
the O
putative O
_RARE_ I-GENE
- I-GENE
dependent I-GENE
promoter I-GENE
in O
_RARE_ I-GENE
growing O
cells O
and O
was O
induced O
under O
stress O
conditions O
. O

The O
genes I-GENE
encoding O
( O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
) O
plant O
- I-GENE
like I-GENE
_RARE_ I-GENE
were O
studied O
in O
the O
widely O
used O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
. O

RNA I-GENE
of O
_RARE_ I-GENE
- I-GENE
C I-GENE
was O
detected O
in O
14 O
( O
18 O
%) O
patients O
before O
_RARE_ I-GENE
. O

A I-GENE
major I-GENE
pool O
of O
_RARE_ I-GENE
- I-GENE
plakoglobin I-GENE
complexes I-GENE
_RARE_ I-GENE
at O
_RARE_ I-GENE
and O
exhibited O
a O
1 I-GENE
: O
1 I-GENE
_RARE_ I-GENE
. O

Our O
results O
indicate O
that O
the O
binding I-GENE
of O
CBF I-GENE
/ I-GENE
NF I-GENE
- I-GENE
Y I-GENE
to O
the O
inverted O
CCAAT I-GENE
box I-GENE
is O
responsible O
for O
transcriptional O
activation O
of O
the O
_RARE_ I-GENE
gene I-GENE
. O

In O
macrophages O
, O
LPS I-GENE
- I-GENE
inducible I-GENE
HIV I-GENE
- I-GENE
1 I-GENE
gene I-GENE
expression O
is O
mediated O
in O
part O
by O
binding I-GENE
of O
NF I-GENE
- I-GENE
kappa I-GENE
B I-GENE
to O
identical O
tandem O
binding I-GENE
sites I-GENE
located O
within O
the O
long O
terminal I-GENE
repeat I-GENE
( O
LTR I-GENE
). O

The O
influence O
of O
p53 I-GENE
on O
cytokine O
- I-GENE
triggered O
Janus I-GENE
kinase I-GENE
- I-GENE
STAT I-GENE
signaling O
was O
investigated O
in O
human I-GENE
hepatoma O
_RARE_ I-GENE
cell O
lines O
engineered I-GENE
to O
constitutively O
express O
the O
temperature O
- I-GENE
sensitive O
_RARE_ I-GENE
mutant I-GENE
of O
p53 I-GENE
. O

It O
can O
also O
be O
used O
to O
examine O
various O
_RARE_ I-GENE
parameters O
obtained O
from O
_RARE_ I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
examinations O
. O

CONCLUSIONS O
: O
Two O
consecutive O
sets O
of O
_RARE_ I-GENE
ultrasound O
_RARE_ I-GENE
_RARE_ I-GENE
biopsies O
of O
the O
prostate O
performed O
in O
a O
single O
_RARE_ I-GENE
_RARE_ I-GENE
represent O
a O
cost O
- I-GENE
effective O
biopsy O
strategy O
for O
men O
presenting O
with O
an O
abnormal O
digital O
rectal O
examination O
and O
/ I-GENE
or O
elevated O
serum I-GENE
PSA I-GENE
. O

Examination O
of O
nuclear I-GENE
magnetic O
resonance O
( O
NMR O
) O
spectra O
of O
a O
series O
of O
N I-GENE
- I-GENE
terminally I-GENE
truncated I-GENE
MIP I-GENE
- I-GENE
1 I-GENE
beta I-GENE
variants I-GENE
reveals O
that O
these O
proteins I-GENE
possess O
a O
range O
of O
ability O
to O
_RARE_ I-GENE
. O

Interestingly O
, O
PKA I-GENE
activity O
is O
dispensable O
in O
a O
strain O
lacking O
_RARE_ I-GENE
and O
_RARE_ I-GENE
activity O
. O

They O
also O
indicate O
that O
direct O
interactions O
between O
C I-GENE
/ I-GENE
_RARE_ I-GENE
and O
specific I-GENE
Ets I-GENE
family I-GENE
members O
, O
together O
with O
GATA I-GENE
- I-GENE
1 I-GENE
, O
are O
important O
for O
eosinophil O
lineage O
determination O
. O

Recently O
, O
a O
human I-GENE
transcription I-GENE
elongation I-GENE
factor I-GENE
P I-GENE
- I-GENE
_RARE_ I-GENE
, O
consisting O
of O
_RARE_ I-GENE
kinase I-GENE
, O
cyclin I-GENE
T I-GENE
and O
other O
associated I-GENE
factors I-GENE
, O
has O
been O
shown O
to O
interact O
with O
Tat I-GENE
to O
_RARE_ I-GENE
Tat I-GENE
activation O
in O
HeLa O
nuclear I-GENE
extract O
depleted O
of O
P I-GENE
- I-GENE
_RARE_ I-GENE
. O

We O
have O
used O
the O
hydrophobic O
repeats I-GENE
of O
the O
HSF1 I-GENE
_RARE_ I-GENE
domain I-GENE
in O
the O
yeast I-GENE
two O
- I-GENE
hybrid O
protein I-GENE
interaction O
assay O
to O
identify O
heat I-GENE
shock I-GENE
factor I-GENE
binding I-GENE
protein I-GENE
1 I-GENE
( O
_RARE_ I-GENE
), O
a O
novel O
, O
conserved O
, O
76 I-GENE
- I-GENE
amino O
- I-GENE
acid I-GENE
protein I-GENE
that O
contains O
two O
extended O
arrays O
of O
hydrophobic O
repeats I-GENE
that O
interact O
with O
the O
HSF1 I-GENE
heptad I-GENE
repeats I-GENE
. O

Genomic O
and O
cDNA I-GENE
clones O
homologous O
to O
the O
yeast I-GENE
GCN2 I-GENE
eIF I-GENE
- I-GENE
2alpha I-GENE
kinase I-GENE
( O
_RARE_ I-GENE
) O
were O
isolated O
from O
Drosophila I-GENE
melanogaster I-GENE
. O

The O
general O
recombination O
at O
a O
_RARE_ I-GENE
voltage O
of O
300 O
V I-GENE
is O
less O
than O
2 I-GENE
% O
for O
dose O
- I-GENE
rates O
up O
to O
about O
100 O
_RARE_ I-GENE
min O
- I-GENE
1 I-GENE
. O

The O
low O
number O
of O
false O
_RARE_ I-GENE
indicates O
that O
our O
_RARE_ I-GENE
would O
not O
_RARE_ I-GENE
the O
_RARE_ I-GENE
by O
suggesting O
normal O
regions O
as O
_RARE_ I-GENE
. O

_RARE_ I-GENE
the O
biological O
_RARE_ I-GENE
_RARE_ I-GENE
and O
implications O
on O
the O
_RARE_ I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
is O
one O
of O
the O
key O
_RARE_ I-GENE
_RARE_ I-GENE
proteins I-GENE
involved O
in O
T I-GENE
- I-GENE
DNA I-GENE
processing O
and O
transfer I-GENE
. O

Taken O
together O
, O
these O
data O
indicate O
that O
the O
_RARE_ I-GENE
omega I-GENE
domain I-GENE
is O
important O
for O
efficient O
T I-GENE
- I-GENE
DNA I-GENE
integration O
. O

The O
_RARE_ I-GENE
levels O
in O
all O
stages O
of O
decreased O
BMD O
were O
significantly O
lower O
than O
those O
in O
the O
group O
with O
normal O
BMD O
. O

_RARE_ I-GENE
of O
the O
nuclear I-GENE
spin O
system O
by O
optical O
_RARE_ I-GENE
causes O
an O
_RARE_ I-GENE
shift O
of O
the O
_RARE_ I-GENE
energy O
levels O
_RARE_ I-GENE
to O
the O
degree O
of O
nuclear I-GENE
orientation O
. O

_RARE_ I-GENE
A I-GENE
, O
a O
cysteine I-GENE
proteinase I-GENE
inhibitor I-GENE
, O
is O
one O
of O
the O
precursor I-GENE
proteins I-GENE
of O
_RARE_ I-GENE
cell O
envelope I-GENE
of O
_RARE_ I-GENE
and O
is O
expressed O
during O
the O
late O
stage O
of O
_RARE_ I-GENE
differentiation O
. O

A I-GENE
role O
for O
_RARE_ I-GENE
and O
a O
novel O
Ras I-GENE
effector O
in O
the O
Ras I-GENE
- I-GENE
mediated O
inhibition O
of O
skeletal I-GENE
_RARE_ I-GENE
. O

GTPase I-GENE
activating I-GENE
specificity O
of O
_RARE_ I-GENE
and O
binding I-GENE
specificity O
of O
an O
alternatively O
spliced O
PDZ I-GENE
( O
_RARE_ I-GENE
- I-GENE
95 O
/ I-GENE
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
- I-GENE
1 I-GENE
) O
domain I-GENE
. O

However O
, O
mutations O
in O
the O
HNF I-GENE
- I-GENE
4 I-GENE
binding I-GENE
site I-GENE
on O
element I-GENE
_RARE_ I-GENE
and O
inhibition O
of O
HNF I-GENE
- I-GENE
4 I-GENE
synthesis O
in O
HepG2 O
cells O
by O
antisense I-GENE
HNF I-GENE
- I-GENE
4 I-GENE
constructs I-GENE
decreased O
the O
_RARE_ I-GENE
promoter I-GENE
activity O
to O
25 O
- I-GENE
40 I-GENE
% O
of O
the O
control O
, O
indicating O
that O
HNF I-GENE
- I-GENE
4 I-GENE
is O
a O
positive O
regulator I-GENE
of O
the O
_RARE_ I-GENE
gene I-GENE
. O

272 O
, O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
). O

In O
addition O
, O
we O
find O
that O
E2F I-GENE
- I-GENE
1 I-GENE
can O
cause O
apoptosis O
in O
p53 I-GENE
_RARE_ I-GENE
tumour I-GENE
cells O
and O
further O
p300 I-GENE
, O
which O
also O
functions O
as O
a O
co O
- I-GENE
activator I-GENE
for O
the O
E2F I-GENE
/ I-GENE
DP I-GENE
heterodimer O
, O
enhances O
the O
apoptotic O
activity O
of O
E2F I-GENE
- I-GENE
1 I-GENE
. O

_RARE_ I-GENE
shift O
/ I-GENE
supershift O
analysis O
indicates O
that O
Fos I-GENE
family I-GENE
member O
proteins I-GENE
especially O
_RARE_ I-GENE
- I-GENE
1 I-GENE
and O
_RARE_ I-GENE
- I-GENE
2 I-GENE
are O
related I-GENE
to O
progression O
and O
no O
changes O
found O
in O
the O
Jun I-GENE
family I-GENE
member O
proteins I-GENE
although O
they O
are O
present O
in O
the O
AP I-GENE
- I-GENE
1 I-GENE
/ I-GENE
DNA I-GENE
binding I-GENE
complex I-GENE
. O

_RARE_ I-GENE
, O
we O
observed O
that O
_RARE_ I-GENE
p53 I-GENE
is O
strongly O
expressed O
in O
_RARE_ I-GENE
mammary O
glands O
and O
in O
mammary O
tumors O
derived O
from O
the O
MMTV I-GENE
- I-GENE
c I-GENE
- I-GENE
myc I-GENE
strain O
. O

These O
data O
show O
that O
heterologous O
virus I-GENE
RNAs I-GENE
( O
_RARE_ I-GENE
) O
can O
serve O
as O
primer O
donors O
for O
_RARE_ I-GENE
mRNA I-GENE
_RARE_ I-GENE
RNA I-GENE
- I-GENE
primed O
transcription I-GENE
in O
_RARE_ I-GENE
infected O
plants O
. O

Human I-GENE
isoforms I-GENE
, O
designated O
1 I-GENE
to O
4 I-GENE
, O
differ O
from O
each O
other O
by O
the O
start O
codon O
used O
. O

Comparison O
of O
cDNA I-GENE
and O
genomic O
sequences I-GENE
shows O
that O
the O
_RARE_ I-GENE
gene I-GENE
spans O
approximately O
11 O
kb O
and O
is O
organized O
into O
at O
least O
four O
exons O
, O
the O
large O
3 I-GENE
'- O
end O
exon O
coding O
for O
the O
complete O
zinc I-GENE
finger I-GENE
domain I-GENE
and O
the O
3 I-GENE
' O
untranslated O
region O
. O

_RARE_ I-GENE
had O
diminished O
significantly O
by O
the O
early I-GENE
_RARE_ I-GENE
, O
and O
this O
paper O
_RARE_ I-GENE
whether O
that O
reduction O
was O
due O
to O
the O
control O
_RARE_ I-GENE
of O
the O
_RARE_ I-GENE
, O
and O
, O
if O
so O
, O
whether O
such O
_RARE_ I-GENE
should O
be O
a O
model O
for O
the O
current O
developing O
world O
, O
where O
malaria O
is O
a O
growing O
problem O
_RARE_ I-GENE
. O

The O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
- I-GENE
2 I-GENE
protein I-GENE
belongs O
to O
the O
low O
- I-GENE
density I-GENE
lipoprotein I-GENE
receptor I-GENE
gene I-GENE
family I-GENE
and O
is O
believed O
to O
function O
as O
an O
endocytic O
receptor I-GENE
for O
the O
uptake O
of O
lipoproteins I-GENE
and O
many O
other O
ligands O
. O

In O
the O
DNA I-GENE
recognition I-GENE
helix I-GENE
of O
finger I-GENE
II I-GENE
, O
the O
conserved O
Arg O
at O
position O
62 O
( O
N I-GENE
- I-GENE
terminal I-GENE
side O
of O
the O
first O
zinc I-GENE
- I-GENE
_RARE_ I-GENE
histidine O
) O
was O
changed O
to O
a O
Leu I-GENE
or O
Gln O
. O

_RARE_ I-GENE
in O
both O
cases O
was O
0 O
. O
2 I-GENE
g O
/ I-GENE
m2 O
. O

Five O
additional O
copies O
of O
_RARE_ I-GENE
elements O
were O
isolated O
, O
mapped O
by O
restriction I-GENE
digestion O
, O
and O
partially O
sequenced O
. O

_RARE_ I-GENE
relationships O
among O
putative O
RNA I-GENE
- I-GENE
dependent I-GENE
RNA I-GENE
polymerases I-GENE
encoded I-GENE
by O
a O
mitochondrial I-GENE
virus I-GENE
- I-GENE
like I-GENE
RNA I-GENE
in O
the O
_RARE_ I-GENE
_RARE_ I-GENE
disease O
fungus I-GENE
, O
_RARE_ I-GENE
novo I-GENE
- I-GENE
_RARE_ I-GENE
, O
by O
other O
viruses O
and O
virus I-GENE
- I-GENE
like I-GENE
RNAs I-GENE
and O
by O
the O
Arabidopsis I-GENE
mitochondrial I-GENE
genome O
. O

Role O
of O
the O
transcription I-GENE
start O
site I-GENE
core I-GENE
region O
and O
transcription I-GENE
factor I-GENE
YY1 I-GENE
in O
Rous I-GENE
sarcoma I-GENE
virus I-GENE
long O
terminal I-GENE
repeat I-GENE
promoter I-GENE
activity O
. O

_RARE_ I-GENE
virus I-GENE
encodes O
_RARE_ I-GENE
homologs I-GENE
of O
cellular O
alpha I-GENE
- I-GENE
_RARE_ I-GENE
, O
PC I-GENE
- I-GENE
1 I-GENE
, O
and O
an O
orphan I-GENE
human I-GENE
homolog I-GENE
of O
a O
secreted O
nematode O
protein I-GENE
. O

Addition O
of O
_RARE_ I-GENE
or O
_RARE_ I-GENE
after O
exposure O
of O
cells O
to O
progesterone I-GENE
agonist O
_RARE_ I-GENE
_RARE_ I-GENE
had O
no O
effect O
on O
induction O
of O
CAT I-GENE
activity O
. O

The O
_RARE_ I-GENE
- I-GENE
1 I-GENE
gene I-GENE
encodes O
a O
protein I-GENE
that O
is O
structurally O
related I-GENE
to O
members O
of O
the O
orphan I-GENE
nuclear I-GENE
receptor I-GENE
superfamily I-GENE
. O

He O
was O
administered O
recombinant I-GENE
IFN I-GENE
alpha I-GENE
- I-GENE
2b I-GENE
under O
the O
diagnosis O
of O
chronic O
hepatitis I-GENE
C I-GENE
. O

Further O
, O
Ser O
/ I-GENE
Thr I-GENE
phosphorylation O
of O
downstream O
molecules I-GENE
Akt I-GENE
and O
p70 I-GENE
S6 I-GENE
kinase I-GENE
was O
inhibited O
. O

Quantitative O
evaluation O
of O
the O
steady O
state O
kinetics O
of O
MEK I-GENE
inhibition O
by O
these O
compounds O
reveals O
that O
_RARE_ I-GENE
has O
approximately O
100 O
- I-GENE
fold O
higher O
affinity O
for O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
MEK I-GENE
than O
does O
_RARE_ I-GENE
. O

Regulation O
at O
37 O
degrees O
C I-GENE
, O
therefore O
, O
involves O
the O
action O
of O
three O
protein I-GENE
kinase I-GENE
cascades I-GENE
that O
repress O
HSF1 I-GENE
through O
phosphorylation O
of O
serine I-GENE
residues O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
and O
may O
promote O
growth I-GENE
by O
_RARE_ I-GENE
the O
heat I-GENE
shock I-GENE
response O
. O

Clinical O
_RARE_ I-GENE
of O
protein I-GENE
levels O
of O
IL I-GENE
- I-GENE
5 I-GENE
in O
induced O
sputum I-GENE
in O
asthmatic O
patients O
. O

In O
these O
cells O
, O
ras I-GENE
- I-GENE
induced O
transition O
is O
accompanied O
by O
a O
strong O
induction O
of O
AP I-GENE
- I-GENE
1 I-GENE
- I-GENE
binding I-GENE
activity O
along O
with O
increased O
expression O
of O
CD44 I-GENE
mRNA I-GENE
and O
protein I-GENE
. O

However O
, O
little O
is O
known O
regarding O
the O
genomic O
organization O
and O
developmental O
expression O
of O
the O
_RARE_ I-GENE
gene I-GENE
family I-GENE
. O

_RARE_ I-GENE
bond O
strengths O
between O
resin O
composite O
and O
bovine I-GENE
dentin O
using O
dentin O
adhesive O
systems O
( O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
II I-GENE
: O
_RARE_ I-GENE
II I-GENE
; O
_RARE_ I-GENE
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
: O
MP I-GENE
) O
_RARE_ I-GENE
systems O
showed O
a O
large O
_RARE_ I-GENE
among O
students O
and O
_RARE_ I-GENE
. O

This O
distribution O
_RARE_ I-GENE
that O
the O
_RARE_ I-GENE
precursor I-GENE
is O
_RARE_ I-GENE
into O
the O
_RARE_ I-GENE
for O
processing O
to O
the O
mature O
_RARE_ I-GENE
, O
and O
that O
the O
import O
or O
processing O
pathway O
involves O
coiled O
bodies O
. O

_RARE_ I-GENE
therapy O
for O
thyroid I-GENE
nodules O
. O

_RARE_ I-GENE
healthy O
male O
volunteers O
completed O
the O
study O
. O

In O
the O
absence O
of O
_RARE_ I-GENE
+, I-GENE
a O
hydrophobic O
exonuclease I-GENE
site I-GENE
_RARE_ I-GENE
over O
the O
polymerase I-GENE
site I-GENE
for O
_RARE_ I-GENE
of O
the O
primer O
terminus O
. O

As O
the O
high O
- I-GENE
affinity O
_RARE_ I-GENE
+ I-GENE
binding I-GENE
sites I-GENE
are O
filled O
, O
the O
primer O
terminus O
_RARE_ I-GENE
from O
the O
exonuclease I-GENE
site I-GENE
to O
a O
highly O
based O
_RARE_ I-GENE
polymerase I-GENE
active O
site I-GENE
. O

One O
missense O
allele I-GENE
( O
_RARE_ I-GENE
) O
with O
complete O
loss O
of O
function O
at O
30 O
_RARE_ I-GENE
and O
four O
missense O
alleles I-GENE
( O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
and O
_RARE_ I-GENE
) O
that O
conferred O
a O
temperature O
sensitive O
phenotype O
were O
identified O
. O

Structural O
analysis O
of O
the O
5 I-GENE
'- O
regulatory I-GENE
region O
reveals O
that O
the O
c I-GENE
- I-GENE
met I-GENE
promoter I-GENE
lacks O
TATA I-GENE
or O
CAAT I-GENE
elements O
but O
has O
an O
extremely O
high O
G I-GENE
- I-GENE
C I-GENE
content O
and O
multiple O
Sp1 I-GENE
binding I-GENE
sites I-GENE
. O

The O
report O
_RARE_ I-GENE
the O
possible O
contribution O
of O
stress O
factors I-GENE
in O
the O
context O
of O
therapy O
resistant O
periodontal O
disease O
, O
and O
the O
results O
seem O
to O
be O
_RARE_ I-GENE
within O
the O
context O
of O
a O
stress O
system O
disorder O
_RARE_ I-GENE
. O

Acute O
pancreatitis O
is O
a O
rather O
common O
abdominal O
disorder O
. O

To O
better O
understand O
the O
role O
of O
Ets I-GENE
proteins I-GENE
in O
Ras I-GENE
transformation O
, O
we O
have O
now O
analyzed O
the O
effects O
of O
stably O
expressing O
a O
variety O
of O
_RARE_ I-GENE
constructs I-GENE
in O
Ras I-GENE
- I-GENE
transformed O
NIH3T3 O
( O
DT I-GENE
) O
cells O
. O

Each O
binding I-GENE
site I-GENE
, O
however O
, O
was O
different O
in O
its O
preference O
for O
binding I-GENE
partners O
. O

We O
isolated O
the O
human I-GENE
FGF I-GENE
- I-GENE
BP I-GENE
promoter I-GENE
and O
determined O
by O
deletion O
analysis O
that O
TPA O
regulatory I-GENE
elements O
were O
all O
contained O
in O
the O
first O
118 O
base O
pairs O
upstream O
of O
the O
transcription I-GENE
start O
site I-GENE
. O

_RARE_ I-GENE
of O
the O
checkpoint I-GENE
regulators O
involved O
in O
cell O
cycle O
arrest O
and O
apoptosis O
may O
thus O
provide O
a O
novel O
strategy O
to O
cancer O
therapy O
. O

Electrophoretic O
mobility I-GENE
shift O
assays O
demonstrated O
specific I-GENE
nuclear I-GENE
protein I-GENE
binding I-GENE
to O
- I-GENE
85 O
/- O
64 O
, O
and O
single O
point O
mutations O
suggested O
important O
binding I-GENE
nucleotides O
between O
- I-GENE
79 O
/- O
68 O
with O
five O
critical O
bases O
between O
- I-GENE
74 O
/- O
70 I-GENE
( O
5 I-GENE
'- O
_RARE_ I-GENE
- I-GENE
3 I-GENE
_RARE_ I-GENE

The O
diagnostic O
accuracy O
of O
serum I-GENE
PE I-GENE
- I-GENE
1 I-GENE
was O
0 O
. O
80 O
, O
and O
that O
of O
amylase I-GENE
0 O
. O
97 O
. O

We O
demonstrate O
that O
_RARE_ I-GENE
interacts O
physically O
in O
vivo O
with O
_RARE_ I-GENE
, O
and O
this O
interaction O
requires O
_RARE_ I-GENE
. O

" O
_RARE_ I-GENE
partial O
" O
seizures O
. O

B I-GENE
cell O
antigen I-GENE
receptor I-GENE
( O
BCR I-GENE
)- I-GENE
mediated O
formation O
of O
a O
SHP I-GENE
- I-GENE
2 I-GENE
- I-GENE
_RARE_ I-GENE
complex I-GENE
and O
its O
inhibition O
by O
Fc I-GENE
gamma I-GENE
_RARE_ I-GENE
- I-GENE
BCR I-GENE
_RARE_ I-GENE
. O

Chem O
., O
270 O
: O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
, O
1995 O
; O
and O
_RARE_ I-GENE
_RARE_ I-GENE
et O
al O
., O
J O
. O

_RARE_ I-GENE
_RARE_ I-GENE
repressed O
meiosis O
at O
the O
same O
three O
steps O
that O
were O
inhibited O
by O
glucose O
, O
suggesting O
that O
glucose O
blocks O
meiosis O
by O
inhibiting O
_RARE_ I-GENE
. O

Here O
we O
investigate O
the O
role O
of O
c I-GENE
- I-GENE
Cbl I-GENE
in O
development O
and O
_RARE_ I-GENE
in O
mice O
by O
targeted O
disruption O
of O
the O
c I-GENE
- I-GENE
Cbl I-GENE
locus I-GENE
. O
c I-GENE
- I-GENE
Cbl I-GENE
- I-GENE
deficient O
mice O
were O
viable O
, O
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
normal O
in O
appearance O
. O

One O
is O
to O
act O
within O
the O
visceral O
endoderm O
to O
promote O
proper O
_RARE_ I-GENE
_RARE_ I-GENE
. O

We O
propose O
that O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
. O
1 I-GENE
participates O
in O
sequential O
signaling O
processes O
as O
a O
key O
_RARE_ I-GENE
of O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
boundary O
development O
. O

_RARE_ I-GENE
- I-GENE
independent O
activation O
of O
platelet I-GENE
- I-GENE
derived O
growth I-GENE
factor I-GENE
receptor I-GENE
is O
a O
necessary O
intermediate O
in O
_RARE_ I-GENE
, O
acid I-GENE
- I-GENE
stimulated O
mitogenic O
activity O
in O
L I-GENE
cells O
. O

METHODS O
: O
_RARE_ I-GENE
changes O
involving O
bone O
marrow O
were O
evaluated O
histologically O
_RARE_ I-GENE
using O
_RARE_ I-GENE
fiber O
_RARE_ I-GENE
( O
method O
of O
_RARE_ I-GENE
). O

In O
_RARE_ I-GENE
- I-GENE
treated O
rats O
, O
ANP I-GENE
infusion O
caused O
greater O
increases O
in O
sodium O
excretion O
( O
_RARE_ I-GENE
from O
3 I-GENE
. O
05 O
+/- O
0 O
. O
71 O
to O
7 O
. O
21 O
+/- O
0 O
. O
45 O
%; O
P I-GENE
< O
0 O
. O
05 O
; O
n O
= O
8 O
) O
than O
saline O
infusion O
( O
_RARE_ I-GENE
from O
4 I-GENE
. O
16 O
+/- O
1 I-GENE
. O
11 O
to O
5 I-GENE
. O
47 O
+/- O
0 O
. O
66 O
%; O
n O
= O
6 I-GENE
), O
despite O
the O
_RARE_ I-GENE
. O

We O
then O
studied O
four O
unrelated O
Japanese O
families O
with O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
, O
and O
found O
three O
novel O
mutations O
: O
a O
four O
- I-GENE
base O
deletion O
/ I-GENE
two O
- I-GENE
base O
insertion O
, O
a O
point O
mutation I-GENE
within O
a O
consensus I-GENE
splicing O
donor O
site I-GENE
, O
and O
a O
missense O
mutation I-GENE
( O
_RARE_ I-GENE
). O

Removal O
of O
the O
carboxyl O
region O
severely O
reduced O
transcriptional O
activation O
. O

A I-GENE
" O
_RARE_ I-GENE
A I-GENE
" O
in O
vitro O
/ I-GENE
in O
vivo O
correlation O
was O
established O
for O
a O
sustained O
release O
theophylline O
( O
CAS I-GENE
58 O
- I-GENE
55 O
- I-GENE
9 O
) O
preparation O
( O
_RARE_ I-GENE
) O
under O
investigation O
. O

_RARE_ I-GENE
: O
50 O
consecutive O
children O
aged O
from O
6 I-GENE
months O
to O
17 O
years O
were O
included O
into O
the O
study O
which O
comprised O
_RARE_ I-GENE
of O
patient O
and O
family I-GENE
_RARE_ I-GENE
, O
serological O
screening O
tests O
for O
common O
_RARE_ I-GENE
allergens O
( O
CAP I-GENE
_RARE_ I-GENE
), O
and O
determination O
of O
total O
serum I-GENE
immunoglobulin I-GENE
E I-GENE
( O
IgE I-GENE
) O
and O
of O
latex O
- I-GENE
specific I-GENE
serum I-GENE
IgE I-GENE
by O
solid O
- I-GENE
phase O
_RARE_ I-GENE
. O

The O
_RARE_ I-GENE
- I-GENE
subfamily I-GENE
- I-GENE
specific I-GENE
linker I-GENE
region O
_RARE_ I-GENE
, O
which O
joins O
_RARE_ I-GENE
and O
_RARE_ I-GENE
, O
is O
encoded I-GENE
by O
two O
exons O
, O
whereas O
_RARE_ I-GENE
, O
which O
joins O
_RARE_ I-GENE
to O
the O
catalytic O
unit I-GENE
, O
is O
encoded I-GENE
by O
a O
single O
exon O
. O

_RARE_ I-GENE
strains O
are O
weak O
_RARE_ I-GENE
and O
are O
defective O
for O
damage O
- I-GENE
induced O
mutagenesis O
. O

At O
the O
same O
time O
, O
the O
results O
indicate O
that O
p53 I-GENE
plays O
a O
_RARE_ I-GENE
role O
against O
HBV O
by O
transcriptionally O
repressing O
the O
HBV O
core I-GENE
promoter I-GENE
through O
liver O
- I-GENE
specific I-GENE
enhancer I-GENE
II I-GENE
and O
_RARE_ I-GENE
is O
required O
to O
_RARE_ I-GENE
this O
inhibitory I-GENE
function O
of O
p53 I-GENE
. O

To O
gain O
insight O
into O
the O
expression O
of O
the O
_RARE_ I-GENE
gene I-GENE
, O
northern O
blot O
analysis O
was O
carried O
out O
. O

The O
aim O
of O
the O
study O
was O
to O
correlate O
the O
responsiveness O
to O
_RARE_ I-GENE
with O
_RARE_ I-GENE
in O
subjects O
a O
with O
allergic O
_RARE_ I-GENE
during O
and O
out O
of O
the O
pollen O
season O
with O
total O
serum I-GENE
IgE I-GENE
and O
blood O
eosinophils O
. O

These O
results O
provide O
the O
first O
_RARE_ I-GENE
that O
an O
SR I-GENE
protein I-GENE
can O
influence O
splicing O
of O
specific I-GENE
pre I-GENE
- I-GENE
mRNAs I-GENE
in O
vivo O
. O

In O
particular O
, O
the O
potential O
for O
prostate O
cancer O
_RARE_ I-GENE
using O
_RARE_ I-GENE
anti I-GENE
- I-GENE
inflammatory O
drugs O
( O
_RARE_ I-GENE
- I-GENE
oxygenase I-GENE
inhibitors O
; O
_RARE_ I-GENE
) O
has O
received O
little O
attention O
. O

This O
study O
reports O
the O
isolation O
of O
a O
P I-GENE
. O
_RARE_ I-GENE
gene I-GENE
, O
_RARE_ I-GENE
, O
encoding O
a O
basic I-GENE
helix I-GENE
- I-GENE
loop I-GENE
- I-GENE
helix I-GENE
protein I-GENE
that O
, O
on O
the O
basis O
of O
sequence I-GENE
homology I-GENE
and O
intron O
/ I-GENE
exon O
structure O
, O
represents O
the O
P I-GENE
. O
_RARE_ I-GENE
_RARE_ I-GENE
of O
the O
Z I-GENE
. O
_RARE_ I-GENE
r O
genes I-GENE
. O

_RARE_ I-GENE
c I-GENE
- I-GENE
_RARE_ I-GENE
transcripts I-GENE
are O
expressed O
in O
normal O
human I-GENE
placental I-GENE
tissues O
. O

During O
the O
past O
4 I-GENE
years O
, O
a O
_RARE_ I-GENE
search O
was O
made O
for O
_RARE_ I-GENE
with O
_RARE_ I-GENE
reversible O
QRS O
changes O
associated I-GENE
with O
all O
acute O
injury O
pattern O
. O

_RARE_ I-GENE
a O
potential O
cleavage O
site I-GENE
located O
N I-GENE
- I-GENE
terminal I-GENE
to O
the O
protease I-GENE
domain I-GENE
, O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
, O
diminished O
processing O
. O

METHODS O
: O
_RARE_ I-GENE
_RARE_ I-GENE
membranes O
of O
three O
different O
pore I-GENE
sizes O
were O
used O
as O
model O
_RARE_ I-GENE
materials O
. O
The O
_RARE_ I-GENE
membrane I-GENE
pore I-GENE
sizes O
were O
0 O
. O
1 I-GENE
microm O
, O
0 O
. O
45 O
microm O
, O
and O
3 I-GENE
microm O
; O
the O
surface O
_RARE_ I-GENE
increased O
in O
the O
same O
order O
The O
membranes O
were O
_RARE_ I-GENE
with O
a O
thin O
layer O
of O
collagen I-GENE
I I-GENE
and O
implanted O
in O
a O
circular O
pocket O
of O
the O
anterior O
_RARE_ I-GENE
of O
adult O
cats O
, O
and O
were O
clinically O
evaluated O
for O
the O
extent O
of O
_RARE_ I-GENE
and O
the O
_RARE_ I-GENE
of O
epithelial O
attachment O
. O

The O
role O
of O
calcitonin I-GENE
, O
and O
other O
agonists O
which O
activate O
the O
cAMP I-GENE
pathway O
, O
in O
regulating O
transcription I-GENE
of O
the O
human I-GENE
parathyroid I-GENE
hormone I-GENE
- I-GENE
related I-GENE
protein I-GENE
( O
_RARE_ I-GENE
) O
gene I-GENE
was O
investigated O
in O
a O
human I-GENE
lung O
cancer O
cell O
line O
( O
_RARE_ I-GENE
). O

The O
combination O
of O
_RARE_ I-GENE
and O
another O
homeodomain I-GENE
protein I-GENE
, O
Pit I-GENE
- I-GENE
1 I-GENE
, O
yielded O
a O
synergistic O
55 O
- I-GENE
fold O
activation O
of O
the O
prolactin I-GENE
promoter I-GENE
in O
transfection O
assays O
. O

The O
biochemical O
and O
molecular O
spectrum O
of O
_RARE_ I-GENE
_RARE_ I-GENE
deficiency O
. O

To O
further O
understand O
the O
role O
of O
cis O
- I-GENE
acting O
elements O
in O
these O
regulatory I-GENE
mechanisms O
, O
we O
have O
characterized O
a O
transcriptional O
promoter I-GENE
that O
_RARE_ I-GENE
germline I-GENE
expression O
of O
TCR I-GENE
beta I-GENE
gene I-GENE
segments O
in O
vivo O
. O

Our O
results O
suggest O
that O
the O
crucial O
role O
of O
the O
mutations O
activating I-GENE
v I-GENE
- I-GENE
erbA I-GENE
as O
an O
oncogene I-GENE
is O
to O
' O
_RARE_ I-GENE
' O
c I-GENE
- I-GENE
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
in O
its O
non O
- I-GENE
_RARE_ I-GENE
, O
repressive O
conformation O
and O
to O
facilitate O
its O
overexpression O
. O

_RARE_ I-GENE
of O
_RARE_ I-GENE
expression O
in O
BCR I-GENE
/ I-GENE
ABL I-GENE
- I-GENE
expressing O
_RARE_ I-GENE
cells O
was O
associated I-GENE
with O
suppression O
of O
growth I-GENE
factor I-GENE
- I-GENE
independent O
colony I-GENE
formation O
, O
_RARE_ I-GENE
of O
G I-GENE
- I-GENE
CSF I-GENE
- I-GENE
induced O
_RARE_ I-GENE
differentiation O
and O
reduced O
tumorigenic O
potential O
in O
vivo O
. O

In O
this O
study O
, O
we O
describe O
a O
mammalian I-GENE
cell O
- I-GENE
free O
transcription I-GENE
system O
reconstituted O
with O
only O
recombinant I-GENE
proteins I-GENE
and O
epitope O
- I-GENE
tagged O
_RARE_ I-GENE
complexes I-GENE
. O

This O
repressor I-GENE
is O
however O
unlikely O
to O
mediate O
_RARE_ I-GENE
2 I-GENE
. O
3 I-GENE
3 I-GENE
' O
UTR I-GENE
silencer I-GENE
action O
since O
it O
was O
not O
detected O
in O
rat I-GENE
hepatocytes O
. O

A I-GENE
prerequisite O
for O
the O
synthesis O
of O
_RARE_ I-GENE
_RARE_ I-GENE
is O
the O
activated I-GENE
sugar I-GENE
- I-GENE
nucleotide I-GENE
_RARE_ I-GENE
5 I-GENE
'- O
monophosphate O
N I-GENE
- I-GENE
_RARE_ I-GENE
acid I-GENE
( O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
), O
which O
provides O
a O
substrate I-GENE
for O
Golgi I-GENE
_RARE_ I-GENE
. O

Thus O
, O
the O
bovine I-GENE
_RARE_ I-GENE
cDNA I-GENE
isolated O
here O
codes O
for O
a O
functional O
soluble I-GENE
secreted O
_RARE_ I-GENE
glycoprotein I-GENE
. O

We O
propose O
a O
model O
in O
which O
_RARE_ I-GENE
function O
is O
involved O
in O
the O
targeting O
of O
the O
myosin I-GENE
proteins I-GENE
to O
their O
intrinsic O
pathways O
. O

We O
found O
sequences I-GENE
related I-GENE
to O
this O
insertion O
in O
wild I-GENE
- I-GENE
type I-GENE
strains O
of O
N I-GENE
. O
crassa I-GENE
and O
other O
Neurospora I-GENE
species O
. O

When O
cysteine I-GENE
is O
_RARE_ I-GENE
through O
the O
helices O
, O
characteristic O
repeating O
patterns O
of O
solvent O
exposure O
and O
_RARE_ I-GENE
are O
observed O
. O

Human I-GENE
_RARE_ I-GENE
, O
a O
novel O
serine I-GENE
/ I-GENE
threonine I-GENE
kinase I-GENE
related I-GENE
to O
UNC I-GENE
- I-GENE
51 O
kinase I-GENE
of O
Caenorhabditis I-GENE
elegans I-GENE
: O
cDNA I-GENE
cloning O
, O
expression O
, O
and O
chromosomal I-GENE
assignment O
. O

Specifically O
, O
I I-GENE
use O
molecular O
markers O
that O
identify O
particular O
_RARE_ I-GENE
domains I-GENE
, O
all O
neuroblasts O
or O
individual O
neuroblasts O
, O
to O
show O
that O
in O
DER I-GENE
mutant I-GENE
embryos O
( O
1 I-GENE
) O
intermediate O
column O
neuroblasts O
do O
not O
form O
, O
( O
2 I-GENE
) O
medial O
column O
neuroblasts O
often O
_RARE_ I-GENE
identities O
_RARE_ I-GENE
for O
their O
position O
, O
while O
( O
3 I-GENE
) O
lateral O
neuroblasts O
develop O
normally O
. O

_RARE_ I-GENE
_RARE_ I-GENE
potentials O
in O
patients O
with O
vestibular O
_RARE_ I-GENE
. O

These O
results O
with O
_RARE_ I-GENE
_RARE_ I-GENE
that O
_RARE_ I-GENE
is O
sensitive O
to O
_RARE_ I-GENE
which O
differ O
in O
their O
mode O
of O
action O
and O
_RARE_ I-GENE
_RARE_ I-GENE
the O
value O
of O
_RARE_ I-GENE
as O
a O
test O
model O
for O
detecting O
the O
_RARE_ I-GENE
potential O
of O
novel O
drugs O
. O

The O
complement I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
receptor I-GENE
( O
_RARE_ I-GENE
) O
is O
a O
seven O
- I-GENE
transmembrane I-GENE
G I-GENE
- I-GENE
protein I-GENE
coupled I-GENE
_RARE_ I-GENE
receptor I-GENE
that O
on O
binding I-GENE
the O
_RARE_ I-GENE
peptide I-GENE
ligand O
mediates O
numerous O
cellular O
responses O
, O
including O
histamine O
release O
from O
mast I-GENE
cells O
. O
smooth I-GENE
muscle O
contraction O
, O
and O
the O
directed O
migration O
of O
eosinophils O
. O

CONCLUSIONS O
: O
Significant O
elevations O
of O
IL I-GENE
- I-GENE
1alpha I-GENE
and O
IL I-GENE
- I-GENE
1beta I-GENE
occur O
in O
patients O
with O
bacterial I-GENE
_RARE_ I-GENE
and O
microscopic O
_RARE_ I-GENE
. O

_RARE_ I-GENE
- I-GENE
shift O
assays O
were O
performed O
using O
the O
LPS I-GENE
- I-GENE
and O
IL I-GENE
- I-GENE
1 I-GENE
- I-GENE
responsive I-GENE
element I-GENE
( O
_RARE_ I-GENE
) O
oligonucleotide I-GENE
, O
a O
gamma I-GENE
interferon I-GENE
activation O
site I-GENE
- I-GENE
like I-GENE
site I-GENE
that O
is O
present O
in O
the O
human I-GENE
IL I-GENE
- I-GENE
1beta I-GENE
promoter I-GENE
. O

The O
C I-GENE
- I-GENE
terminal I-GENE
region O
contains O
the O
PTP I-GENE
- I-GENE
like I-GENE
domain I-GENE
, O
whereas O
the O
N I-GENE
- I-GENE
terminal I-GENE
region O
shows O
no O
homology I-GENE
to O
any O
known O
mammalian I-GENE
protein I-GENE
. O

In O
addition O
, O
and O
in O
support O
of O
a O
mediating O
role O
of O
_RARE_ I-GENE
in O
the O
activation O
of O
the O
p21 I-GENE
promoter I-GENE
, O
overexpression O
of O
Stat3 I-GENE
_RARE_ I-GENE
the O
cytokine O
effect O
on O
the O
p21 I-GENE
promoter I-GENE
; O
whereas O
a O
dominant I-GENE
negative O
Stat3 I-GENE
, O
or O
a O
mutation I-GENE
of O
the O
STAT I-GENE
response O
element I-GENE
on O
the O
promoter I-GENE
, O
significantly O
reduced O
the O
cytokine O
effect O
. O

The O
heterogeneous I-GENE
nuclear I-GENE
ribonucleoprotein I-GENE
C I-GENE
protein I-GENE
tetramer I-GENE
binds O
U1 I-GENE
, O
U2 I-GENE
, O
and O
U6 I-GENE
_RARE_ I-GENE
through O
its O
high O
affinity O
RNA I-GENE
binding I-GENE
domain I-GENE
( O
the O
bZIP I-GENE
- I-GENE
like I-GENE
motif I-GENE
). O

On O
the O
comparison O
of O
correlated O
_RARE_ I-GENE
for O
clustered O
data O
. O

A I-GENE
safe O
and O
simple O
system O
for O
the O
detection O
of O
_RARE_ I-GENE
infant O
death O
syndrome O
( O
_RARE_ I-GENE
) O
is O
proposed O
. O

The O
resulting O
mutants I-GENE
were O
coexpressed O
with O
_RARE_ I-GENE
in O
the O
vaccinia I-GENE
virus I-GENE
- I-GENE
based O
_RARE_ I-GENE
- I-GENE
3 I-GENE
system O
, O
and O
the O
formation O
and O
endoplasmic O
reticulum O
( O
ER I-GENE
)- I-GENE
to O
- I-GENE
Golgi I-GENE
transport O
of O
the O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
complex I-GENE
were O
monitored O
. O

Homozygous O
mutant I-GENE
mice O
, O
designated O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
, O
display O
a O
phenotype O
characterized O
by O
_RARE_ I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
. O

The O
mutant I-GENE
protein I-GENE
is O
present O
at O
levels O
slightly O
greater O
than O
wild I-GENE
- I-GENE
type I-GENE
, O
but O
exhibits O
the O
same O
tissue I-GENE
distribution O
as O
wild I-GENE
- I-GENE
type I-GENE
protein I-GENE
, O
and O
has O
approximately O
normal O
affinity O
for O
known O
target O
sequences I-GENE
( O
though O
no O
DNA I-GENE
targets O
identified O
to O
date O
require O
the O
first O
cut I-GENE
repeat I-GENE
for O
binding I-GENE
). O

METHODS O
: O
We O
_RARE_ I-GENE
reviewed O
_RARE_ I-GENE
adult O
_RARE_ I-GENE
renal O
transplant O
recipients O
treated O
between O
11 O
/ I-GENE
91 O
and O
5 I-GENE
/ I-GENE
97 O
. O

The O
spectrum O
of O
age O
- I-GENE
associated I-GENE
brain O
abnormalities O
: O
their O
measurement O
and O
histopathological O
correlates O
. O

Our O
laboratory O
has O
recently O
identified O
two O
_RARE_ I-GENE
- I-GENE
like I-GENE
orphan I-GENE
proteins I-GENE
( O
_RARE_ I-GENE
and O
_RARE_ I-GENE
) O
that O
lack O
the O
ability O
to O
interact O
with O
Gbetagamma I-GENE
. O

Reverse I-GENE
transcriptase I-GENE
- I-GENE
polymerase I-GENE
chain I-GENE
reaction O
( O
RT I-GENE
- I-GENE
PCR O
) O
was O
performed O
using O
_RARE_ I-GENE
complementary O
DNA I-GENE
of O
the O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
. O

In O
contrast O
, O
transcription I-GENE
initiating O
from O
_RARE_ I-GENE
P I-GENE
- I-GENE
1 I-GENE
( O
sigma I-GENE
A I-GENE
) O
rose O
in O
proportion O
to O
the O
external O
_RARE_ I-GENE
and O
was O
maintained O
at O
high O
levels O
. O

_RARE_ I-GENE
selected O
300 O
children O
aged O
3 I-GENE
months O
- I-GENE
3 I-GENE
yr O
were O
analysed O
over O
a O
period O
of O
one O
year O
for O
estimating O
prevalence O
of O
nutritional O
_RARE_ I-GENE
. O

In O
_RARE_ I-GENE
, O
_RARE_ I-GENE
N I-GENE
- I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
have O
been O
implicated O
in O
several O
physiological O
processes O
, O
including O
_RARE_ I-GENE
, O
inactivation O
of O
certain O
_RARE_ I-GENE
, O
and O
, O
similar O
to O
the O
function O
in O
_RARE_ I-GENE
, O
_RARE_ I-GENE
of O
the O
rate O
- I-GENE
limiting O
step O
in O
melatonin O
biosynthesis O
. O

In O
experiments O
with O
the O
D1 I-GENE
antagonist O
_RARE_ I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
- I-GENE
induced O
depression O
was O
consistently O
blocked O
, O
but O
_RARE_ I-GENE
was O
unaffected O
. O

These O
results O
establish O
that O
_RARE_ I-GENE
lead O
to O
_RARE_ I-GENE
and O
_RARE_ I-GENE
. O

IA O
- I-GENE
CT I-GENE
with O
cisplatin O
50 O
mg O
and O
_RARE_ I-GENE
30 O
mg O
was O
administered O
by O
one O
_RARE_ I-GENE
method O
in O
bilateral O
internal O
iliac O
arteries O
. O

_RARE_ I-GENE
mRNA I-GENE
was O
expressed O
in O
brain O
, O
skeletal I-GENE
muscle O
, O
13 O
. O
5 I-GENE
- I-GENE
day O
embryos O
, O
and O
P19 O
cells O
treated O
with O
retinoic I-GENE
acid I-GENE
. O

Acute O
idiopathic O
_RARE_ I-GENE
purpura O
presenting O
a O
high O
serum I-GENE
level O
of O
immunoglobulin I-GENE
E I-GENE
and O
_RARE_ I-GENE
in O
an O
elderly O
patient O
. O

The O
genomic O
structure O
and O
chromosomal I-GENE
location O
of O
the O
human I-GENE
_RARE_ I-GENE
orphan I-GENE
receptor I-GENE
, O
a O
member O
of O
the O
steroid I-GENE
receptor I-GENE
superfamily I-GENE
. O

_RARE_ I-GENE
of O
skin O
disorders O
with O
CD4 I-GENE
lymphocyte I-GENE
counts O
in O
patients O
with O
HIV I-GENE
/ I-GENE
AIDS O
. O

E2F I-GENE
- I-GENE
6 I-GENE
shares O
significant O
homology I-GENE
with O
_RARE_ I-GENE
1 I-GENE
- I-GENE
5 I-GENE
, O
especially O
within O
the O
DNA I-GENE
binding I-GENE
, O
heterodimerization O
and O
marked O
box I-GENE
domains I-GENE
. O

The O
_RARE_ I-GENE
. O
1 I-GENE
cell O
line O
was O
able O
to O
complement I-GENE
a O
recombinant I-GENE
virus I-GENE
in O
which O
both O
copies O
of O
the O
IE I-GENE
gene I-GENE
were O
replaced O
by O
insertion O
of O
the O
Escherichia I-GENE
coli I-GENE
lacZ I-GENE
gene I-GENE
. O

DNase I-GENE
I I-GENE
footprinting O
and O
electrophoretic O
mobility I-GENE
shift O
analyses O
revealed O
two O
hepatocyte I-GENE
nuclear I-GENE
factor I-GENE
- I-GENE
1 I-GENE
( O
_RARE_ I-GENE
), O
three O
CCAAT I-GENE
/ I-GENE
enhancer I-GENE
- I-GENE
binding I-GENE
protein I-GENE
( O
C I-GENE
/ I-GENE
EBP I-GENE
), O
and O
one O
consensus I-GENE
palindromic O
thyroid I-GENE
hormone I-GENE
response O
elements O
within O
the O
first O
215 O
base O
pairs O
( O
bp O
) O
of O
the O
promoter I-GENE
sequence I-GENE
of O
rat I-GENE
_RARE_ I-GENE
. O

Thus O
, O
these O
studies O
on O
rat I-GENE
_RARE_ I-GENE
promoter I-GENE
function O
indicate O
that O
( O
i O
) O
_RARE_ I-GENE
and O
C I-GENE
/ I-GENE
EBP I-GENE
are O
responsible O
for O
liver O
specificity O
of O
the O
rat I-GENE
_RARE_ I-GENE
gene I-GENE
; O
( O
ii O
) O
_RARE_ I-GENE
repression O
of O
the O
gene I-GENE
requires O
the O
presence O
of O
all O
of O
the O
_RARE_ I-GENE
- I-GENE
1 I-GENE
and O
C I-GENE
/ I-GENE
EBP I-GENE
elements O
between O
positions O
- I-GENE
231 O
and O
- I-GENE
_RARE_ I-GENE
; O
and O
( O
iii O
) O
AR I-GENE
may O
exert O
its O
negative O
regulatory I-GENE
effect O
indirectly O
through O
transcriptional O
interference O
of O
_RARE_ I-GENE
- I-GENE
1 I-GENE
and O
C I-GENE
/ I-GENE
EBP I-GENE
rather O
than O
through O
a O
direct O
DNA I-GENE
- I-GENE
AR I-GENE
interaction O
. O

Purified I-GENE
_RARE_ I-GENE
phosphorylates O
the O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
subunit I-GENE
of O
the O
six O
- I-GENE
member O
_RARE_ I-GENE
maintenance O
protein I-GENE
complex I-GENE
purified O
from O
fission I-GENE
yeast I-GENE
. O

The O
yeast I-GENE
_RARE_ I-GENE
gene I-GENE
was O
cloned O
by O
its O
ability O
to O
complement I-GENE
the O
methyl O
_RARE_ I-GENE
sensitivity O
of O
the O
_RARE_ I-GENE
- I-GENE
1 I-GENE
mutant I-GENE
and O
was O
later O
shown O
to O
be O
involved O
in O
DNA I-GENE
post O
- I-GENE
replication O
repair I-GENE
. O

Expression O
of O
the O
human I-GENE
papillomavirus I-GENE
type I-GENE
11 O
_RARE_ I-GENE
protein I-GENE
from O
the O
_RARE_ I-GENE
, O
_RARE_ I-GENE
transcript I-GENE
. O

_RARE_ I-GENE
with O
M I-GENE
/ I-GENE
K I-GENE
was O
reversed O
after O
41 O
. O
6 I-GENE
min O
of O
_RARE_ I-GENE
with O
_RARE_ I-GENE
. O

There O
was O
no O
evident O
_RARE_ I-GENE
agent O
of O
the O
disease O
. O

MK O
- I-GENE
801 O
administration O
resulted O
in O
a O
biphasic O
response O
in O
seizure O
latency O
. O

In O
contrast O
, O
the O
distribution O
of O
endocytic O
markers O
is O
not O
affected O
. O

_RARE_ I-GENE
during O
the O
therapeutic O
period O
was O
not O
significant O
in O
the O
study O
group O
compared O
with O
the O
_RARE_ I-GENE
control O
, O
treated O
with O
the O
same O
regimen O
without O
G I-GENE
- I-GENE
CSF I-GENE
. O

The O
purpose O
of O
this O
article O
is O
to O
discuss O
the O
factors I-GENE
involved O
in O
the O
selection O
of O
antibodies I-GENE
, O
_RARE_ I-GENE
and O
labeling O
methods O
in O
the O
development O
of O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
for O
non O
- I-GENE
Hodgkin O
' O
s O
lymphoma O
( O
_RARE_ I-GENE
) O
from O
a O
single O
clinical O
study O
site I-GENE
through O
_RARE_ I-GENE
trials O
and O
_RARE_ I-GENE
. O

Both O
methods O
were O
employed O
for O
various O
focal I-GENE
- I-GENE
_RARE_ I-GENE
distances O
, O
image O
_RARE_ I-GENE
tube O
modes O
and O
laser O
_RARE_ I-GENE
_RARE_ I-GENE
. O

The O
effect O
of O
Rho I-GENE
on O
AP I-GENE
- I-GENE
1 I-GENE
is O
independent O
of O
the O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
pathway O
, O
as O
a O
dominant I-GENE
- I-GENE
negative O
MEK I-GENE
and O
a O
MEK I-GENE
inhibitor I-GENE
( O
PD98059 O
) O
did O
not O
affect O
Rho I-GENE
- I-GENE
induced O
AP I-GENE
- I-GENE
1 I-GENE
activity O
. O

Site I-GENE
- I-GENE
directed O
mutagenesis O
of O
residues O
in O
this O
domain I-GENE
( O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
) O
resulted O
in O
proteins I-GENE
which O
failed O
to O
transactivate O
from O
the O
HTLV I-GENE
- I-GENE
1 I-GENE
LTR I-GENE
in O
vivo O
. O

Mutations O
within O
the O
C I-GENE
terminus O
of O
c I-GENE
- I-GENE
fos I-GENE
at O
serine I-GENE
residues O
that O
are O
phosphorylation O
targets O
for O
growth I-GENE
factors I-GENE
and O
MAP I-GENE
kinase I-GENE
completely O
abrogate O
transactivation O
and O
block O
potentiation O
by O
MAP I-GENE
kinase I-GENE
. O

In O
the O
former O
cells O
, O
ets I-GENE
- I-GENE
2 I-GENE
was O
a O
CSF I-GENE
- I-GENE
1 I-GENE
immediate I-GENE
- I-GENE
early I-GENE
response O
gene I-GENE
, O
and O
phosphorylated O
ets I-GENE
- I-GENE
2 I-GENE
was O
detected O
after O
2 I-GENE
to O
4 I-GENE
h O
, O
_RARE_ I-GENE
with O
expression O
of O
ets I-GENE
- I-GENE
2 I-GENE
protein I-GENE
. O

_RARE_ I-GENE
activation O
of O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinases I-GENE
_RARE_ I-GENE
and O
p44 I-GENE
and O
ets I-GENE
- I-GENE
2 I-GENE
phosphorylation O
in O
response O
to O
colony I-GENE
- I-GENE
stimulating I-GENE
factor I-GENE
1 I-GENE
/ I-GENE
c I-GENE
- I-GENE
fms I-GENE
signaling O
. O

Identification O
of O
a O
proline O
- I-GENE
rich O
sequence I-GENE
in O
the O
_RARE_ I-GENE
cytoplasmic I-GENE
domain I-GENE
critical O
for O
regulation O
of O
integrin I-GENE
- I-GENE
mediated O
adhesion I-GENE
and O
activation O
of O
_RARE_ I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
. O

_RARE_ I-GENE
, O
a O
_RARE_ I-GENE
- I-GENE
25 O
- I-GENE
like I-GENE
molecule I-GENE
, O
and O
_RARE_ I-GENE
, O
a O
_RARE_ I-GENE
homolog I-GENE
, O
function O
together O
in O
yeast I-GENE
vacuolar I-GENE
protein I-GENE
trafficking O
. O

We O
have O
tested O
this O
possibility O
by O
_RARE_ I-GENE
a O
consecutive O
series O
of O
cysteine I-GENE
substitutions O
in O
the O
_RARE_ I-GENE
juxtamembrane I-GENE
domain I-GENE
in O
order O
to O
force O
dimerization O
along O
a O
series O
of O
_RARE_ I-GENE
_RARE_ I-GENE
. O

It O
has O
been O
demonstrated O
previously O
that O
Pax I-GENE
- I-GENE
6 I-GENE
, O
a O
paired I-GENE
domain I-GENE
( O
PD I-GENE
)/ O
homeodomain I-GENE
( O
HD I-GENE
) O
transcription I-GENE
factor I-GENE
critical O
for O
eye O
development O
, O
contributes O
to O
the O
activation O
of O
the O
_RARE_ I-GENE
-, I-GENE
_RARE_ I-GENE
-, I-GENE
_RARE_ I-GENE
-, I-GENE
and O
zeta I-GENE
- I-GENE
_RARE_ I-GENE
genes I-GENE
in O
the O
lens O
. O

_RARE_ I-GENE
- I-GENE
1 I-GENE
binding I-GENE
required O
the O
first O
19 O
amino O
acids O
of O
Fyn I-GENE
and O
integrity O
of O
two O
lysine O
residues O
within O
this O
sequence I-GENE
that O
were O
previously O
shown O
to O
be O
important O
for O
Fyn I-GENE
interactions O
with O
the O
_RARE_ I-GENE
tyrosine I-GENE
- I-GENE
based O
activation O
motifs O
( O
_RARE_ I-GENE
) O
of O
lymphocyte I-GENE
Ag I-GENE
receptors I-GENE
. O

The O
prothrombin I-GENE
gene I-GENE
_RARE_ I-GENE
mutation I-GENE
is O
not O
found O
among O
Japanese O
patients O
with O
deep O
vein O
thrombosis O
and O
healthy O
individuals O
. O

Transcriptional O
regulation O
of O
the O
_RARE_ I-GENE
gene I-GENE
: O
neural O
- I-GENE
specific I-GENE
expression O
, O
multiple O
promoters I-GENE
, O
and O
regulatory I-GENE
elements O
. O

The O
binding I-GENE
of O
NF I-GENE
- I-GENE
_RARE_ I-GENE
, O
although O
not O
NF I-GENE
- I-GENE
_RARE_ I-GENE
, O
to O
this O
enhancer I-GENE
also O
occurs O
along O
with O
HTLV I-GENE
- I-GENE
I I-GENE
- I-GENE
mediated O
infection O
of O
human I-GENE
peripheral O
blood O
T I-GENE
- I-GENE
cells O
. O

Thus O
, O
TRAF2 I-GENE
_RARE_ I-GENE
SAPK I-GENE
and O
p38 I-GENE
activation O
by O
binding I-GENE
two O
proximal I-GENE
protein I-GENE
kinases I-GENE
: O
_RARE_ I-GENE
and O
_RARE_ I-GENE
. O

Tumor I-GENE
necrosis I-GENE
factor I-GENE
signaling O
to O
stress O
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
( O
SAPK I-GENE
)/ O
Jun I-GENE
NH2 I-GENE
- I-GENE
terminal I-GENE
kinase I-GENE
( O
JNK I-GENE
) O
and O
p38 I-GENE
. O

The O
activity O
of O
the O
minimal I-GENE
promoter I-GENE
was O
found O
to O
be O
controlled O
by O
a O
combination O
of O
the O
activities O
of O
the O
transcription I-GENE
factors I-GENE
Sp1 I-GENE
, O
Sp3 I-GENE
, O
and O
NF I-GENE
- I-GENE
Y I-GENE
. O

In O
the O
studies O
described O
in O
this O
report O
, O
we O
have O
investigated O
the O
signaling O
pathway O
( O
s O
) O
that O
are O
responsible O
for O
CREB I-GENE
activation O
in O
normal O
T I-GENE
cells O
. O

_RARE_ I-GENE
who O
_RARE_ I-GENE
with O
a O
_RARE_ I-GENE
/ I-GENE
partner I-GENE
only O
were O
less O
likely O
to O
have O
an O
_RARE_ I-GENE
BMI O
status O
than O
people O
in O
the O
other O
two O
groups O
. O

Isolation O
of O
a O
novel O
_RARE_ I-GENE
target O
gene I-GENE
from O
a O
colon O
cancer O
cell O
line O
carrying O
a O
highly O
regulated O
wild I-GENE
- I-GENE
type I-GENE
_RARE_ I-GENE
expression O
system O
. O

Overexpression O
of O
_RARE_ I-GENE
has O
been O
demonstrated O
in O
many O
cancers O
, O
both O
in O
patient O
tumors O
and O
in O
cell O
lines O
selected O
with O
a O
variety O
of O
chemotherapeutic O
agents O
. O

_RARE_ I-GENE
and O
molecular O
characterization O
of O
random O
chromosomal I-GENE
rearrangements O
activating I-GENE
the O
drug O
resistance O
gene I-GENE
, O
_RARE_ I-GENE
/ I-GENE
P I-GENE
- I-GENE
glycoprotein I-GENE
, O
in O
drug O
- I-GENE
selected O
cell O
lines O
and O
patients O
with O
drug O
refractory O
ALL O
. O

BACKGROUND O
: O
It O
is O
generally O
accepted O
that O
smoking O
increases O
blood O
pressure O
and O
inhibits O
muscle O
sympathetic O
nerve I-GENE
activity O
( O
_RARE_ I-GENE
). O

When O
the O
blood O
pressure O
increase O
in O
response O
to O
smoking O
was O
_RARE_ I-GENE
by O
_RARE_ I-GENE
infusion O
, O
there O
was O
a O
striking O
increase O
in O
muscle O
_RARE_ I-GENE
. O

After O
that O
report O
, O
_RARE_ I-GENE
D I-GENE
( O
_RARE_ I-GENE
) O
was O
subsequently O
purified O
from O
bovine I-GENE
pituitary I-GENE
and O
characterized O
as O
a O
novel O
_RARE_ I-GENE
E I-GENE
( O
_RARE_ I-GENE
)- I-GENE
like I-GENE
enzyme I-GENE
, O
with O
many O
characteristics O
in O
common O
with O
_RARE_ I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
, O
L I-GENE
., O
_RARE_ I-GENE
, O
L I-GENE
. O
D I-GENE
., O
1995 O
. O

RA O
- I-GENE
treatment O
of O
these O
transfectants O
induced O
morphologic O
and O
_RARE_ I-GENE
maturation O
, O
changes O
in O
RA O
- I-GENE
regulated O
genes I-GENE
, O
and O
a O
G1 I-GENE
cell O
cycle O
arrest O
in O
a O
manner O
similar O
to O
parental O
_RARE_ I-GENE
/ I-GENE
D1 I-GENE
cells O
. O

The O
_RARE_ I-GENE
and O
_RARE_ I-GENE
did O
not O
_RARE_ I-GENE
differ O
between O
_RARE_ I-GENE
tumors O
derived O
from O
_RARE_ I-GENE
over O
- I-GENE
expressing O
versus O
control O
transfectants O
. O

For O
smaller O
vessels O
up O
to O
a O
diameter O
of O
0 O
. O
5 I-GENE
mm O
, O
treatments O
at O
16 O
and O
18 O
J O
/ I-GENE
cm2 O
showed O
good O
results O
in O
60 O
and O
82 O
% O
respectively O
; O
for O
vessels O
up O
to O
1 I-GENE
mm O
in O
27 O
and O
33 O
%. O

_RARE_ I-GENE
ulcers O
. O

RXR I-GENE
- I-GENE
gamma I-GENE
expression O
produced O
significant O
reduction O
in O
levels O
of O
RA O
- I-GENE
responsive I-GENE
genes I-GENE
including O
the O
cyclin I-GENE
- I-GENE
dependent I-GENE
kinase I-GENE
inhibitors O
_RARE_ I-GENE
/ I-GENE
WAF1 I-GENE
and O
_RARE_ I-GENE
, O
resulting O
in O
increased O
cdc2 I-GENE
and O
cdk2 I-GENE
kinase I-GENE
activity O
and O
RB I-GENE
phosphorylation O
. O

TBP I-GENE
can O
be O
phosphorylated O
in O
vitro O
by O
extracts O
of O
U937 O
cells O
or O
by O
bacterially O
expressed O
activated I-GENE
ERK2 I-GENE
; O
the O
phosphorylation O
sites I-GENE
were O
mapped O
to O
ERK I-GENE
kinase I-GENE
consensus I-GENE
sites I-GENE
in O
the O
TBP I-GENE
amino O
- I-GENE
terminal I-GENE
domain I-GENE
. O

During O
the O
CR I-GENE
/ I-GENE
PP I-GENE
diet O
only O
the O
HS I-GENE
subjects O
did O
not O
show O
the O
stress O
- I-GENE
induced O
rise O
in O
depression O
, O
decline O
in O
_RARE_ I-GENE
and O
cortisol O
elevation O
that O
they O
showed O
after O
the O
PR I-GENE
/ I-GENE
CP I-GENE
diet O
. O

_RARE_ I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
values O
decreased O
with O
increasing O
exposure O
time O
with O
rate O
constants O
ranging O
from O
0 O
. O
03 O
to O
0 O
. O
33 O
day O
- I-GENE
1 I-GENE
( O
_RARE_ I-GENE
and O
lipid O
weight O
) O
for O
_RARE_ I-GENE
and O
0 O
. O
03 O
to O
0 O
. O
31 O
day O
- I-GENE
1 I-GENE
for O
_RARE_ I-GENE
. O

These O
sequence I-GENE
analyses O
suggest O
that O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
is O
a O
novel O
member O
of O
the O
IRS I-GENE
family I-GENE
rather O
than O
a O
Xenopus I-GENE
homolog I-GENE
of O
an O
existing O
member O
. O

The O
present O
study O
sought O
to O
develop O
an O
equation O
to O
estimate O
_RARE_ I-GENE
in O
peripheral O
arterial O
_RARE_ I-GENE
disease O
( O
_RARE_ I-GENE
) O
patients O
with O
intermittent O
_RARE_ I-GENE
and O
to O
determine O
independent O
predictors O
of O
_RARE_ I-GENE
in O
this O
population O
. O

Evidence O
for O
a O
novel O
_RARE_ I-GENE
- I-GENE
independent O
pathway O
controlling O
the O
stress O
activated I-GENE
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
MAP I-GENE
kinase I-GENE
in O
fission I-GENE
yeast I-GENE
. O

The O
_RARE_ I-GENE
_RARE_ I-GENE
Scale O
( O
_RARE_ I-GENE
), O
_RARE_ I-GENE
_RARE_ I-GENE
Scale O
and O
_RARE_ I-GENE
_RARE_ I-GENE
comprise O
a O
_RARE_ I-GENE
sound O
system O
for O
the O
analysis O
of O
injuries O
and O
_RARE_ I-GENE
patients O
. O

This O
hypothesis O
was O
tested O
by O
_RARE_ I-GENE
mutations O
at O
each O
of O
the O
three O
histidine O
pairs O
, O
the O
_RARE_ I-GENE
- I-GENE
X2 O
- I-GENE
_RARE_ I-GENE
pair O
, O
the O
_RARE_ I-GENE
- I-GENE
X2 O
- I-GENE
_RARE_ I-GENE
pair O
and O
the O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
pair O
, O
which O
constitute O
the O
histidine O
- I-GENE
rich O
region O
near O
the O
C I-GENE
terminus O
of O
_RARE_ I-GENE
. O

Using O
backcross O
analysis O
, O
both O
exons O
1 I-GENE
and O
4 I-GENE
mapped O
to O
a O
proximal I-GENE
region O
of O
murine I-GENE
_RARE_ I-GENE
4 I-GENE
indistinguishable O
from O
the O
_RARE_ I-GENE
gene I-GENE
. O

Seventy O
- I-GENE
five O
percent O
of O
children O
who O
received O
a O
second O
transplant O
for O
HCV I-GENE
hepatitis I-GENE
had O
early I-GENE
histologic O
recurrence O
that O
led O
to O
liver O
failure O
and O
death O
. O

However O
, O
both O
TPN O
groups O
showed O
a O
marked O
increase O
in O
activities O
of O
liver O
lysosomal I-GENE
enzymes O
. O

Regulation O
of O
embryonic O
growth I-GENE
and O
lysosomal I-GENE
targeting O
by O
the O
imprinted O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
gene I-GENE
. O

Furthermore O
, O
we O
demonstrated O
that O
_RARE_ I-GENE
_RARE_ I-GENE
stimulated O
Src I-GENE
family I-GENE
kinase I-GENE
activity O
and O
induced O
tyrosine I-GENE
phosphorylation O
of O
several O
proteins I-GENE
in O
_RARE_ I-GENE
- I-GENE
293 O
cells O
. O

The O
_RARE_ I-GENE
pressure O
was O
significantly O
decreased O
only O
after O
injection O
with O
_RARE_ I-GENE
- I-GENE
4 I-GENE
in O
both O
normal O
and O
_RARE_ I-GENE
rats O
. O

_RARE_ I-GENE
proliferator I-GENE
- I-GENE
activated I-GENE
receptors I-GENE
( O
_RARE_ I-GENE
) O
modulate O
transcription I-GENE
by O
binding I-GENE
to O
specific I-GENE
peroxisome I-GENE
proliferator I-GENE
- I-GENE
response O
elements O
( O
_RARE_ I-GENE
) O
through O
heterodimerization O
with O
the O
9 O
- I-GENE
cis O
retinoic I-GENE
acid I-GENE
receptor I-GENE
( O
RXR I-GENE
). O

Furthermore O
, O
early I-GENE
- I-GENE
and O
late O
- I-GENE
_RARE_ I-GENE
origins O
differ O
not O
in O
the O
timing O
of O
their O
recruitment O
of O
an O
_RARE_ I-GENE
protein I-GENE
, O
but O
in O
the O
timing O
of O
RPA I-GENE
' O
s O
recruitment O
. O

Thus O
, O
in O
the O
presence O
of O
active O
S I-GENE
- I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
may O
open O
origins O
and O
thereby O
facilitate O
the O
loading O
of O
RPA I-GENE
. O

Tyrosine I-GENE
phosphorylated O
_RARE_ I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
into O
the O
nucleus O
to O
activate O
specific I-GENE
genes I-GENE
. O

_RARE_ I-GENE
substitution O
in O
_RARE_ I-GENE
sperm O
fertilization O
genes I-GENE
_RARE_ I-GENE
substitution O
in O
introns O
and O
mitochondrial I-GENE
DNA I-GENE
. O

Gel O
retardation O
assays O
detected O
_RARE_ I-GENE
- I-GENE
dependent I-GENE
complexes I-GENE
forming O
with O
the O
_RARE_ I-GENE
operator I-GENE
- I-GENE
promoter I-GENE
and O
_RARE_ I-GENE
- I-GENE
DNA I-GENE
binding I-GENE
was O
enhanced O
by O
treatment O
with O
a O
metal O
- I-GENE
_RARE_ I-GENE
in O
vitro O
. O

CONCLUSION O
: O
Although O
quantitative O
and O
qualitative O
criteria O
for O
_RARE_ I-GENE
fatty I-GENE
liver O
on O
helical O
CT I-GENE
can O
be O
determined O
, O
they O
are O
protocol O
- I-GENE
specific I-GENE
. O

The O
PC I-GENE
- I-GENE
based O
_RARE_ I-GENE
is O
designed O
to O
run O
in O
the O
_RARE_ I-GENE
_RARE_ I-GENE
3 I-GENE
. O
11 O
environment O
( O
and O
later O
_RARE_ I-GENE
), O
for O
_RARE_ I-GENE
_RARE_ I-GENE
with O
_RARE_ I-GENE
or O
_RARE_ I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
, O
the O
similarity O
in O
apparent O
regulatory I-GENE
action O
of O
the O
genes I-GENE
may O
indicate O
allelic O
differences O
_RARE_ I-GENE
the O
_RARE_ I-GENE
_RARE_ I-GENE
allele I-GENE
may O
differ O
from O
alleles I-GENE
of O
_RARE_ I-GENE
lines O
by O
the O
_RARE_ I-GENE
to O
regulate O
both O
_RARE_ I-GENE
and O
_RARE_ I-GENE
processing O
activities O
. O

_RARE_ I-GENE
revised O
interpretation O

Molecular O
cloning O
and O
functional O
characterization O
of O
murine I-GENE
_RARE_ I-GENE
kinase I-GENE
. O

A I-GENE
human I-GENE
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
L I-GENE
_RARE_ I-GENE
complex I-GENE
distinct O
from O
transcription I-GENE
factor I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
induced O
steady O
- I-GENE
state O
levels O
of O
M I-GENE
- I-GENE
CPT I-GENE
I I-GENE
mRNA I-GENE
4 I-GENE
. O
5 I-GENE
- I-GENE
fold O
. O

Mapping O
of O
the O
DNA I-GENE
binding I-GENE
domain I-GENE
of O
the O
copper I-GENE
- I-GENE
responsive I-GENE
transcription I-GENE
factor I-GENE
_RARE_ I-GENE
from O
Saccharomyces I-GENE
cerevisiae I-GENE
. O

A I-GENE
further O
mechanism O
increasing O
specific I-GENE
activation O
was O
cooperation O
of O
receptors I-GENE
at O
multiple O
and O
weak O
_RARE_ I-GENE
, O
which O
was O
_RARE_ I-GENE
in O
the O
presence O
of O
both O
the O
AR I-GENE
N I-GENE
terminus O
and O
ligand O
binding I-GENE
domain I-GENE
. O

Previously O
, O
we O
characterized O
a O
DNA I-GENE
- I-GENE
binding I-GENE
protein I-GENE
, O
_RARE_ I-GENE
, O
that O
bound O
tightly O
to O
a O
conserved O
region O
within O
hypersensitive I-GENE
site I-GENE
2 I-GENE
( O
_RARE_ I-GENE
) O
of O
the O
human I-GENE
beta I-GENE
- I-GENE
globin I-GENE
locus I-GENE
control O
region O
( O
LCR I-GENE
) O
( O
_RARE_ I-GENE
, O
L I-GENE
. O

The O
CBF1 I-GENE
site I-GENE
within O
_RARE_ I-GENE
resides O
near O
sites I-GENE
for O
hematopoietic I-GENE
regulators O
such O
as O
GATA I-GENE
- I-GENE
1 I-GENE
, O
NF I-GENE
- I-GENE
E2 I-GENE
, O
and O
_RARE_ I-GENE
. O

The O
rat I-GENE
branched I-GENE
- I-GENE
chain I-GENE
- I-GENE
2 I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
acid I-GENE
dehydrogenase I-GENE
( O
_RARE_ I-GENE
) O
kinase I-GENE
mRNA I-GENE
is O
transcribed O
from O
a O
TATA I-GENE
- I-GENE
less O
promoter I-GENE
that O
has O
GC I-GENE
- I-GENE
rich O
sequences I-GENE
and O
two O
putative O
Sp1 I-GENE
binding I-GENE
sites I-GENE
near O
the O
transcription I-GENE
start O
site I-GENE
. O

Co O
- I-GENE
transfection O
of O
the O
Sp1 I-GENE
expression O
plasmid O
and O
the O
- I-GENE
58 O
promoter I-GENE
construct I-GENE
into O
Drosophila I-GENE
_RARE_ I-GENE
cells O
revealed O
that O
Sp1 I-GENE
contributed O
to O
the O
kinase I-GENE
basal O
promoter I-GENE
activity O
by O
binding I-GENE
to O
the O
non O
- I-GENE
consensus I-GENE
site I-GENE
in O
the O
- I-GENE
58 O
region O
. O

_RARE_ I-GENE
such O
investigations O
are O
performed O
, O
we O
conclude O
that O
the O
role O
for O
adjuvant O
treatment O
is O
_RARE_ I-GENE
and O
that O
_RARE_ I-GENE
surgery O
is O
preferred O
as O
the O
treatment O
_RARE_ I-GENE
for O
Stage O
T1 O
- I-GENE
T3 O
rectal O
cancers O
. O

_RARE_ I-GENE
, O
at O
150 O
degrees O
C I-GENE
with O
2 I-GENE
% O
_RARE_ I-GENE
the O
surface O
density I-GENE
of O
NH2 I-GENE
groups O
reached O
a O
maximum O
at O
24 O
hr O
and O
remained O
relatively O
constant O
up O
to O
96 O
hr O
. O

Taken O
together O
, O
these O
results O
suggest O
that O
the O
cooperation O
of O
transcription I-GENE
factors I-GENE
NF I-GENE
- I-GENE
kappaB I-GENE
and O
AP I-GENE
- I-GENE
1 I-GENE
is O
essential O
for O
transactivation O
of O
IL I-GENE
- I-GENE
8 O
gene I-GENE
by O
HTLV I-GENE
- I-GENE
I I-GENE
Tax I-GENE
. O

This O
study O
_RARE_ I-GENE
the O
cooperative O
effects O
of O
a O
human I-GENE
estrogen I-GENE
receptor I-GENE
- I-GENE
alpha I-GENE
( O
_RARE_ I-GENE
) O
isoform I-GENE
on O
estrogen I-GENE
( O
E2 I-GENE
)- I-GENE
mediated O
gene I-GENE
activation O
in O
U2 I-GENE
- I-GENE
_RARE_ I-GENE
osteosarcoma O
cells O
. O

Transfection O
of O
increasing O
amounts O
of O
_RARE_ I-GENE
expression O
vector O
into O
[ O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
cells O
resulted O
in O
potentiation O
of O
E2 I-GENE
- I-GENE
stimulated O
_RARE_ I-GENE
activity O
in O
a O
synergistic O
, O
dose O
- I-GENE
dependent I-GENE
manner O
. O

Studies O
using O
the O
yeast I-GENE
two O
- I-GENE
hybrid O
system O
also O
did O
not O
provide O
evidence O
for O
the O
formation O
of O
a O
VDR I-GENE
- I-GENE
TR I-GENE
protein I-GENE
- I-GENE
protein I-GENE
interaction O
. O

Our O
results O
show O
that O
, O
from O
a O
_RARE_ I-GENE
_RARE_ I-GENE
, O
melatonin O
may O
directly O
_RARE_ I-GENE
_RARE_ I-GENE
radicals O
both O
in O
_RARE_ I-GENE
and O
in O
aqueous O
solution O
. O

This O
sequence I-GENE
, O
Thr I-GENE
- I-GENE
Gly O
- I-GENE
X I-GENE
- I-GENE
X I-GENE
- I-GENE
Gly O
- I-GENE
Asp I-GENE
- I-GENE
Gly O
- I-GENE
Lys O
- I-GENE
Ile O
- I-GENE
Phe I-GENE
, O
forms O
part O
of O
the O
B I-GENE
- I-GENE
loop I-GENE
and O
is O
conserved O
in O
a O
wide O
variety O
of O
organisms O
that O
include O
bacteria O
, O
_RARE_ I-GENE
and O
_RARE_ I-GENE
. O

We O
did O
not O
observe O
any O
changes O
in O
Bcl I-GENE
- I-GENE
2 I-GENE
or O
Bcl I-GENE
- I-GENE
2 I-GENE
- I-GENE
related I-GENE
proteins I-GENE
( O
Bcl I-GENE
- I-GENE
x O
, O
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
) O
in O
control O
or O
_RARE_ I-GENE
- I-GENE
transfected O
cells O
before O
or O
after O
treatment O
with O
_RARE_ I-GENE
. O

Tyrosine I-GENE
112 O
of O
latent I-GENE
membrane I-GENE
protein I-GENE
2A I-GENE
is O
essential O
for O
protein I-GENE
tyrosine I-GENE
kinase I-GENE
loading O
and O
regulation O
of O
Epstein I-GENE
- I-GENE
Barr I-GENE
virus I-GENE
latency O
. O

The O
only O
abundant O
viral I-GENE
transcript I-GENE
expressed O
during O
latency O
is O
the O
latency O
- I-GENE
related I-GENE
( O
_RARE_ I-GENE
) O
RNA I-GENE
. O

To O
improve O
test O
efficiency O
, O
we O
modified O
our O
previously O
introduced O
contrast O
/ I-GENE
color O
_RARE_ I-GENE
test O
by O
including O
a O
_RARE_ I-GENE
test O
stimulus O
and O
reducing O
the O
number O
of O
stimuli O
in O
both O
experimental O
phases O
. O

The O
defect O
in O
these O
proteins I-GENE
was O
also O
_RARE_ I-GENE
suppressed O
by O
either O
_RARE_ I-GENE
+, I-GENE
or O
the O
_RARE_ I-GENE
B I-GENE
protein I-GENE
in O
the O
presence O
of O
ATP I-GENE
and O
target O
DNA I-GENE
. O

Using O
homology I-GENE
cloning O
techniques O
, O
we O
identified O
a O
mouse I-GENE
homologue I-GENE
of O
E I-GENE
( O
_RARE_ I-GENE
), O
termed O
_RARE_ I-GENE
, O
a O
yeast I-GENE
protein I-GENE
that O
we O
_RARE_ I-GENE
_RARE_ I-GENE
, O
and O
as O
well O
as O
additional O
ESTs I-GENE
from O
Caenorhabditis I-GENE
elegans I-GENE
, O
mice O
and O
humans O
. O

Second O
, O
the O
wild I-GENE
- I-GENE
type I-GENE
_RARE_ I-GENE
3 I-GENE
' O
UTR I-GENE
strongly O
reduces O
accumulation O
of O
heterologous O
transcripts I-GENE
in O
vivo O
, O
an O
activity O
that O
requires O
its O
K I-GENE
box I-GENE
sequences I-GENE
. O

In O
particular O
, O
_RARE_ I-GENE
- I-GENE
86 I-GENE
encodes O
a O
POU I-GENE
- I-GENE
type I-GENE
homeodomain I-GENE
protein I-GENE
needed O
for O
the O
production O
of O
the O
_RARE_ I-GENE
cells O
, O
while O
_RARE_ I-GENE
- I-GENE
3 I-GENE
encodes O
a O
LIM I-GENE
- I-GENE
type I-GENE
homeodomain I-GENE
protein I-GENE
needed O
for O
the O
differentiation O
of O
the O
_RARE_ I-GENE
cells O
. O

During O
the O
_RARE_ I-GENE
resuscitation O
period O
, O
extracellular I-GENE
aspartate I-GENE
and O
glutamate I-GENE
concentrations O
in O
the O
cerebral O
striatum I-GENE
were O
higher O
during O
_RARE_ I-GENE
resuscitation O
( O
p O
= O
0 O
. O
_RARE_ I-GENE
and O
p O
= O
0 O
. O
_RARE_ I-GENE
, O
respectively O
) O
than O
during O
resuscitation O
with O
21 O
% O
O2 O
or O
100 O
% O
O2 O
, O
suggesting O
an O
_RARE_ I-GENE
accumulation O
of O
potent O
_RARE_ I-GENE
during O
_RARE_ I-GENE
resuscitation O
. O

Expression O
of O
constitutively O
active O
_RARE_ I-GENE
, O
the O
kinase I-GENE
that O
activates O
ERKs I-GENE
, O
or O
overexpression O
of O
ERK2 I-GENE
, O
but O
not O
JNK1 I-GENE
, O
inhibited O
Stat3 I-GENE
activation O
. O

_RARE_ I-GENE
and O
ERKs I-GENE
inhibited O
IL I-GENE
- I-GENE
6 I-GENE
activation O
of O
Stat3 I-GENE
harboring O
a O
mutation I-GENE
at O
serine I-GENE
- I-GENE
_RARE_ I-GENE
, O
the O
major I-GENE
site I-GENE
for O
serine I-GENE
phosphorylation O
, O
similar O
to O
inhibition O
of O
wild I-GENE
- I-GENE
type I-GENE
Stat3 I-GENE
, O
and O
inhibited O
Janus I-GENE
kinases I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
upstream O
of O
Stat3 I-GENE
in O
the O
Jak I-GENE
- I-GENE
STAT I-GENE
- I-GENE
signaling O
pathway O
. O

Furthermore O
, O
phosphatidylinositol I-GENE
( O
3 I-GENE
, O
4 I-GENE
, O
5 I-GENE
) O
_RARE_ I-GENE
specifically O
stimulates O
the O
activity O
of O
ILK I-GENE
in O
vitro O
, O
and O
in O
addition O
, O
membrane I-GENE
_RARE_ I-GENE
constitutively O
active O
_RARE_ I-GENE
( O
3 I-GENE
) O
K I-GENE
activates O
ILK I-GENE
in O
vivo O
. O

Transfection O
and O
in O
vitro O
binding I-GENE
studies O
identified O
within O
_RARE_ I-GENE
a O
promoter I-GENE
whose O
basal O
activity O
required O
a O
GC I-GENE
box I-GENE
activated I-GENE
by O
Sp1 I-GENE
or O
Sp3 I-GENE
. O

Plasma I-GENE
was O
tested O
before O
and O
after O
( O
14 O
+/- O
7 O
. O
5 I-GENE
[ O
SD O
] O
days O
) O
surgery O
for O
IgG I-GENE
antibodies I-GENE
to O
the O
complex I-GENE
of O
heparin O
/ I-GENE
platelet I-GENE
factor I-GENE
4 I-GENE
, O
using O
a O
standardized O
, O
_RARE_ I-GENE
enzyme I-GENE
- I-GENE
linked O
immunosorbent O
assay O
( O
ELISA O
). O

_RARE_ I-GENE
_RARE_ I-GENE
in O
the O
distal O
tail O
fiber O
locus I-GENE
of O
the O
T I-GENE
- I-GENE
even O
bacteriophage I-GENE
: O
recombination O
between O
conserved O
motifs O
_RARE_ I-GENE
_RARE_ I-GENE
specificity O
. O

The O
_RARE_ I-GENE
promoter I-GENE
was O
up O
- I-GENE
regulated O
by O
insulin I-GENE
through O
the O
proximal I-GENE
insulin I-GENE
response O
sequence I-GENE
containing O
an O
E I-GENE
- I-GENE
box I-GENE
motif I-GENE
at O
the O
- I-GENE
65 O
- I-GENE
base O
pair O
position O
. O

The O
effect O
of O
independent O
predictors O
on O
survival O
was O
examined O
in O
a O
Cox O
regression O
model O
with O
adjustment O
for O
existing O
_RARE_ I-GENE
. O

Effects O
of O
_RARE_ I-GENE
- I-GENE
CSF I-GENE
on O
neutrophil I-GENE
functions O
and O
survival O
in O
sepsis O
induced O
diabetic O
rats O
. O

OBJECTIVE O
: O
The O
purpose O
of O
this O
article O
is O
to O
review O
balance O
instruments O
developed O
within O
the O
past O
10 O
years O
that O
can O
be O
used O
in O
the O
_RARE_ I-GENE
or O
home O
environment O
. O

_RARE_ I-GENE
_RARE_ I-GENE
: O
We O
observed O
a O
congenital O
skin O
defect O
located O
exclusively O
on O
the O
trunk O
. O

Whereas O
, O
in O
the O
single O
- I-GENE
_RARE_ I-GENE
body O
box I-GENE
, O
_RARE_ I-GENE
units O
( O
_RARE_ I-GENE
_RARE_ I-GENE
) O
reflect O
" O
effort O
of O
breathing O
." I-GENE
This O
is O
measured O
as O
the O
_RARE_ I-GENE
between O
_RARE_ I-GENE
and O
_RARE_ I-GENE
. O

_RARE_ I-GENE
is O
the O
first O
aromatase I-GENE
inhibitor I-GENE
to O
show O
a O
significant O
survival O
advantage O
over O
_RARE_ I-GENE
acetate O
in O
post O
- I-GENE
menopausal I-GENE
women O
with O
advanced O
breast O
cancer O
. O

W I-GENE
. O

_RARE_ I-GENE
) O
and O
contains O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
. O

Mutation O
of O
either O
the O
AP I-GENE
- I-GENE
1 I-GENE
or O
the O
ets I-GENE
component O
of O
this O
site I-GENE
also O
prevented O
promoter I-GENE
activity O
in O
_RARE_ I-GENE
. O

_RARE_ I-GENE
: O
Fifty O
dogs O
with O
naturally O
developing O
DM O
. O

Surprisingly O
, O
double O
mutants I-GENE
of O
the O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
mutant I-GENE
with O
the O
_RARE_ I-GENE
- I-GENE
deficient O
mutants I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
( O
_RARE_ I-GENE
- I-GENE
1 I-GENE
) O
and O
_RARE_ I-GENE
- I-GENE
1 I-GENE
( O
_RARE_ I-GENE
- I-GENE
201 O
) O
showed O
reduced O
_RARE_ I-GENE
response O
in O
_RARE_ I-GENE
with O
a O
longer O
_RARE_ I-GENE
, O
a O
longer O
_RARE_ I-GENE
stem O
, O
and O
a O
lower O
level O
expression O
of O
the O
_RARE_ I-GENE
gene I-GENE
than O
the O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
single O
mutant I-GENE
. O

This O
suggests O
that O
while O
_RARE_ I-GENE
of O
pain O
do O
not O
_RARE_ I-GENE
more O
, O
disruption O
on O
primary O
tasks O
and O
physiological O
impact O
are O
higher O
. O

_RARE_ I-GENE
ablation O
has O
been O
employed O
as O
a O
therapeutic O
measure O
for O
chronic O
pulmonary O
emphysema O
. O

The O
SH2 I-GENE
- I-GENE
containing O
adapter I-GENE
protein I-GENE
_RARE_ I-GENE
interacts O
with O
BCR I-GENE
- I-GENE
ABL I-GENE
. O

Saccharomyces I-GENE
cerevisiae I-GENE
contains O
four O
known O
_RARE_ I-GENE
- I-GENE
CoA I-GENE
synthetases I-GENE
( O
fatty I-GENE
acid I-GENE
activation O
proteins I-GENE
, O
_RARE_ I-GENE
). O

We O
recently O
reported O
a O
placenta O
- I-GENE
specific I-GENE
enhancer I-GENE
in O
the O
human I-GENE
leukemia I-GENE
inhibitory I-GENE
factor I-GENE
receptor I-GENE
( O
_RARE_ I-GENE
) O
gene I-GENE
and O
now O
show O
detailed O
characterization O
of O
the O
_RARE_ I-GENE
- I-GENE
base O
pair O
enhancer I-GENE
(- O
_RARE_ I-GENE
/- O
_RARE_ I-GENE
nucleotides O
). O

Copyright O
1998 O
_RARE_ I-GENE
_RARE_ I-GENE
B I-GENE
. O
V I-GENE
. O

It O
may O
be O
time O
to O
_RARE_ I-GENE
the O
_RARE_ I-GENE
between O
AD O
and O
_RARE_ I-GENE
. O

_RARE_ I-GENE
39 O
was O
a O
homolog I-GENE
of O
_RARE_ I-GENE
, O
which O
is O
a O
gene I-GENE
involved O
in O
controlling O
the O
_RARE_ I-GENE
time O
in O
Arabidopsis I-GENE
. O

_RARE_ I-GENE
and O
_RARE_ I-GENE
( O
_RARE_ I-GENE
_RARE_ I-GENE
1 I-GENE
( O
1 I-GENE
), O
3 I-GENE
- I-GENE
11 O
, O
1985 O
) O
showed O
that O
a O
thin O
vertical O
line O
induces O
_RARE_ I-GENE
_RARE_ I-GENE
of O
_RARE_ I-GENE
and O
_RARE_ I-GENE
; O
this O
study O
_RARE_ I-GENE
those O
results O
by O
more O
closely O
examining O
the O
horizontal O
and O
vertical O
_RARE_ I-GENE
of O
the O
_RARE_ I-GENE
zone O
and O
by O
using O
an O
_RARE_ I-GENE
_RARE_ I-GENE
to O
induce O
_RARE_ I-GENE
. O

The O
effects O
of O
high O
intensity O
light I-GENE
_RARE_ I-GENE
, O
produced O
by O
a O
novel O
pulsed O
power O
_RARE_ I-GENE
technique O
( O
_RARE_ I-GENE
), O
on O
the O
survival O
of O
bacterial I-GENE
populations O
of O
_RARE_ I-GENE
Escherichia I-GENE
coli I-GENE
( O
serotype I-GENE
_RARE_ I-GENE
: O
_RARE_ I-GENE
) O
and O
_RARE_ I-GENE
monocytogenes O
( O
serotype I-GENE
_RARE_ I-GENE
) O
were O
investigated O
. O

Multiple O
chemical O
sensitivity O
( O
_RARE_ I-GENE
) O
is O
a O
syndrome O
in O
which O
multiple O
symptoms O
_RARE_ I-GENE
occur O
with O
low O
- I-GENE
level O
chemical O
exposure O
. O

POU I-GENE
- I-GENE
domain I-GENE
proteins I-GENE
, O
such O
as O
the O
pituitary I-GENE
- I-GENE
specific I-GENE
factor I-GENE
Pit I-GENE
- I-GENE
1 I-GENE
, O
are O
members O
of O
the O
homeodomain I-GENE
family I-GENE
of O
proteins I-GENE
which O
are O
important O
in O
development O
and O
_RARE_ I-GENE
, O
acting O
constitutively O
or O
in O
response O
to O
signal I-GENE
- I-GENE
transduction O
pathways O
to O
either O
repress O
or O
activate O
the O
expression O
of O
specific I-GENE
genes I-GENE
. O

Wild I-GENE
- I-GENE
type I-GENE
and O
mutant I-GENE
MyoD I-GENE
were O
introduced O
into O
cells O
using O
an O
E1 I-GENE
, O
E3 I-GENE
- I-GENE
deleted O
_RARE_ I-GENE
vector O
. O

These O
results O
suggest O
that O
_RARE_ I-GENE
may O
play O
an O
important O
role O
in O
the O
regulation O
of O
MyoD I-GENE
function O
under O
conditions O
of O
high O
_RARE_ I-GENE
. O

This O
and O
previous O
results O
suggest O
that O
the O
CRE O
and O
Sp1 I-GENE
site I-GENE
may O
synergistically O
activate O
TH I-GENE
transcription I-GENE
in O
a O
promoter I-GENE
context O
- I-GENE
dependent I-GENE
manner O
. O

_RARE_ I-GENE
was O
inactive O
. O

_RARE_ I-GENE
examinations O
, O
peripheral O
white O
blood O
cell O
( O
WBC O
) O
counts O
, O
and O
assays O
of O
_RARE_ I-GENE
activity O
( O
_RARE_ I-GENE
) O
in O
_RARE_ I-GENE
of O
colon O
mucosa O
were O
performed O
after O
one O
week O
( O
4 I-GENE
% O
_RARE_ I-GENE
model O
) O
and O
eight O
weeks O
( O
1 I-GENE
% O
_RARE_ I-GENE
model O
). O

T7 I-GENE
transcription I-GENE
could O
be O
_RARE_ I-GENE
to O
achieve O
different O
levels O
of O
constitutive O
expression O
, O
through O
the O
use O
of O
promoter I-GENE
mutations O
. O

The O
primers O
were O
degenerate O
sets O
of O
oligonucleotides O
derived O
from O
known O
amino O
acid I-GENE
sequences I-GENE
of O
the O
_RARE_ I-GENE
precursor I-GENE
. O

_RARE_ I-GENE
transformed O
with O
the O
35S I-GENE
- I-GENE
1 I-GENE
- I-GENE
_RARE_ I-GENE
construct I-GENE
accumulated O
the O
_RARE_ I-GENE
1 I-GENE
- I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
), O
1 I-GENE
, O
1 I-GENE
- I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
and O
1 I-GENE
, O
1 I-GENE
, O
1 I-GENE
- I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
). O

Based O
on O
the O
comparison O
of O
the O
predicted O
amino O
acid I-GENE
sequences I-GENE
of O
1 I-GENE
- I-GENE
_RARE_ I-GENE
and O
1 I-GENE
- I-GENE
_RARE_ I-GENE
with O
those O
of O
other O
plant O
_RARE_ I-GENE
transferase I-GENE
genes I-GENE
, O
we O
_RARE_ I-GENE
that O
both O
plant O
_RARE_ I-GENE
genes I-GENE
have O
evolved O
from O
plant O
_RARE_ I-GENE
genes I-GENE
. O

However O
, O
_RARE_ I-GENE
was O
induced O
by O
ABA I-GENE
, O
and O
along O
with O
_RARE_ I-GENE
induction O
there O
was O
a O
decrease O
in O
Cdc2 I-GENE
- I-GENE
like I-GENE
histone I-GENE
H1 I-GENE
kinase I-GENE
activity O
. O

A I-GENE
5 I-GENE
. O
0 O
- I-GENE
kb O
transcript I-GENE
detected O
by O
the O
differential O
display O
_RARE_ I-GENE
_RARE_ I-GENE
was O
found O
to O
correlate O
strongly O
with O
_RARE_ I-GENE
mRNA I-GENE
expression O
in O
various O
human I-GENE
cell O
lines O
. O

The O
_RARE_ I-GENE
gene I-GENE
was O
localized O
to O
the O
long O
arm O
of O
chromosome O
10 O
( O
_RARE_ I-GENE
). O

Here O
, O
we O
report O
that O
_RARE_ I-GENE
- I-GENE
1 I-GENE
is O
a O
new O
temperature O
- I-GENE
sensitive O
allele I-GENE
of O
the O
clathrin I-GENE
heavy I-GENE
chain I-GENE
gene I-GENE
( O
_RARE_ I-GENE
- I-GENE
5 I-GENE
), O
which O
carries O
a O
frameshift O
mutation I-GENE
near O
the O
3 I-GENE
' O
end O
of O
the O
_RARE_ I-GENE
open O
reading O
frame O
. O

We O
have O
determined O
the O
molecular O
lesions O
of O
nine O
_RARE_ I-GENE
mutant I-GENE
alleles I-GENE
, O
which O
identify O
functional O
requirements O
for O
specific I-GENE
domains I-GENE
. O

_RARE_ I-GENE
, O
three O
_RARE_ I-GENE
_RARE_ I-GENE
mutations O
, O
which O
map O
within O
an O
_RARE_ I-GENE
repeat I-GENE
, O
interact O
with O
_RARE_ I-GENE
mutations O
more O
strongly O
than O
do O
_RARE_ I-GENE
null I-GENE
alleles I-GENE
. O

Northern O
analysis O
revealed O
no O
detectable O
expression O
of O
the O
transcript I-GENE
in O
_RARE_ I-GENE
- I-GENE
or O
_RARE_ I-GENE
- I-GENE
programmed O
_RARE_ I-GENE
larvae O
, O
and O
only O
_RARE_ I-GENE
expression O
in O
_RARE_ I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
the O
characterization O
and O
discussion O
of O
the O
experimental O
_RARE_ I-GENE
used O
, O
the O
rate O
constants O
obtained O
are O
discussed O
and O
compared O
with O
estimated O
values O
. O

Genomic O
locus I-GENE
of O
_RARE_ I-GENE
contains O
a O
GC I-GENE
- I-GENE
rich O
untranslated O
exon O
separated O
from O
seven O
coding O
exons O
by O
a O
long O
intron O
. O

The O
presence O
of O
PDZ I-GENE
and O
_RARE_ I-GENE
domains I-GENE
in O
the O
_RARE_ I-GENE
protein I-GENE
suggests O
that O
it O
may O
act O
as O
a O
molecular O
adaptor I-GENE
, O
promoting I-GENE
and O
_RARE_ I-GENE
information O
in O
a O
signal I-GENE
transduction O
pathway O
. O

BACKGROUND O
: O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
are O
_RARE_ I-GENE
in O
children O
because O
of O
the O
risk O
of O
cartilage O
damage O
. O

In O
analyses O
with O
control O
for O
multiple O
variables O
, O
relative O
risk O
for O
_RARE_ I-GENE
( O
urinary O
albumin I-GENE
excretion O
, O
20 O
- I-GENE
_RARE_ I-GENE
microg O
/ I-GENE
min O
) O
in O
men O
and O
women O
was O
2 I-GENE
. O
51 O
and O
1 I-GENE
. O
62 O
, O
respectively O
, O
with O
18 O
mm O
Hg O
higher O
( O
1 I-GENE
SD O
) O
systolic O
blood O
pressure O
; O
2 I-GENE
. O
25 O
and O
2 I-GENE
. O
10 O
, O
respectively O
, O
with O
1 I-GENE
. O
0 O
- I-GENE
mmol O
/ I-GENE
L I-GENE
( O
40 I-GENE
mg O
/ I-GENE
dL O
) O
higher O
plasma I-GENE
cholesterol I-GENE
level O
; O
1 I-GENE
. O
99 O
and O
1 I-GENE
. O
91 O
, O
respectively O
, O
for O
smokers O
vs O
_RARE_ I-GENE
; O
and O
1 I-GENE
. O
83 O
and O
1 I-GENE
. O
33 O
, O
respectively O
, O
with O
4 I-GENE
kg O
/ I-GENE
m2 O
higher O
body O
mass O
index O
. O

However O
, O
while O
IL I-GENE
- I-GENE
1beta I-GENE
and O
TNF I-GENE
- I-GENE
alpha I-GENE
both O
induced O
nuclear I-GENE
binding I-GENE
of O
the O
Rel I-GENE
proteins I-GENE
p50 I-GENE
and O
p65 I-GENE
to O
an O
NF I-GENE
- I-GENE
kappaB I-GENE
consensus I-GENE
oligonucleotide I-GENE
in O
gel O
shift O
assays O
and O
caused O
transient O
degradation O
of O
inhibitor I-GENE
of O
NF I-GENE
- I-GENE
kappaB I-GENE
- I-GENE
alpha I-GENE
( O
_RARE_ I-GENE
- I-GENE
alpha I-GENE
) O
in O
the O
cytoplasm O
of O
_RARE_ I-GENE
, O
only O
IL I-GENE
- I-GENE
1beta I-GENE
_RARE_ I-GENE
PDGF I-GENE
- I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
with O
ATF I-GENE
- I-GENE
2 I-GENE
and O
HNF I-GENE
- I-GENE
4 I-GENE
expression O
plasmids O
resulted O
in O
additive O
transactivation O
of O
the O
_RARE_ I-GENE
promoter I-GENE
. O

_RARE_ I-GENE
hydrolysis O
during O
_RARE_ I-GENE
exercise O
: O
the O
effect O
of O
_RARE_ I-GENE
. O

_RARE_ I-GENE
shifts O
arise O
from O
the O
_RARE_ I-GENE
_RARE_ I-GENE
average O
of O
the O
_RARE_ I-GENE
coupling O
between O
_RARE_ I-GENE
electron O
and O
nuclei O
, O
in O
the O
presence O
of O
magnetic O
susceptibility I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
- I-GENE
1 I-GENE
is O
expressed O
in O
many O
tissues O
, O
but O
is O
enriched O
in O
retina O
and O
brain O
. O

The O
interaction O
of O
U1 I-GENE
- I-GENE
_RARE_ I-GENE
with O
the O
_RARE_ I-GENE
proteins I-GENE
is O
confirmed O
further O
in O
vitro O
using O
a O
blot O
_RARE_ I-GENE
assay O
. O

The O
major I-GENE
phenotypes O
resulting O
from O
_RARE_ I-GENE
kinase I-GENE
inactivation O
include O
temperature O
- I-GENE
sensitive O
growth I-GENE
, O
vacuolar I-GENE
acidification O
defects O
, O
and O
dramatic O
increases O
in O
vacuolar I-GENE
size O
. O

_RARE_ I-GENE
GTPases I-GENE
of O
the O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
family I-GENE
are O
involved O
in O
the O
regulation O
of O
vesicular O
transport O
. O

The O
_RARE_ I-GENE
and O
GAP I-GENE
activities O
for O
_RARE_ I-GENE
localize O
to O
particulate O
cellular O
fractions O
. O

Dopamine I-GENE
beta I-GENE
- I-GENE
hydroxylase I-GENE
( O
_RARE_ I-GENE
) O
catalyzes O
the O
conversion O
of O
dopamine I-GENE
to O
noradrenaline O
and O
is O
selectively O
expressed O
in O
noradrenergic O
and O
adrenergic I-GENE
neurons O
and O
_RARE_ I-GENE
cells O
. O

Collectively O
, O
this O
study O
emphasizes O
a O
critical O
role O
of O
_RARE_ I-GENE
as O
well O
as O
its O
functional O
_RARE_ I-GENE
with O
other O
transcription I-GENE
factors I-GENE
( O
e O
. O
g O
., O
CREB I-GENE
, O
AP2 I-GENE
, O
and O
Sp1 I-GENE
) O
in O
transcriptional O
activation O
of O
the O
_RARE_ I-GENE
gene I-GENE
. O

Interestingly O
, O
an O
antibody I-GENE
against O
N I-GENE
- I-GENE
_RARE_ I-GENE
can O
abrogate O
_RARE_ I-GENE
- I-GENE
LDL I-GENE
- I-GENE
and O
TNF I-GENE
- I-GENE
alpha I-GENE
- I-GENE
induced O
apoptosis O
and O
therefore O
may O
be O
useful O
for O
in O
vivo O
studies O
of O
apoptosis O
in O
experimental O
animals O
. O

We O
found O
that O
virulent O
_RARE_ I-GENE
strains O
induce O
phosphorylation O
and O
activation O
of O
JNK I-GENE
but O
not O
of O
p38 I-GENE
kinase I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
of O
classical O
light I-GENE
_RARE_ I-GENE
elements O
of O
the O
cell O
division O
machinery O
and O
switch O
the O
_RARE_ I-GENE
of O
hearts O
on O
a O
cellular O
basis O
. O

The O
human I-GENE
T I-GENE
cell O
_RARE_ I-GENE
retrovirus O
type I-GENE
I I-GENE
( O
HTLV I-GENE
- I-GENE
I I-GENE
) O
trans O
- I-GENE
activator I-GENE
, O
Tax I-GENE
, O
interacts O
specifically O
with O
the O
basic I-GENE
- I-GENE
domain I-GENE
/ I-GENE
leucine I-GENE
- I-GENE
zipper I-GENE
( O
_RARE_ I-GENE
) O
protein I-GENE
, O
cAMP I-GENE
response O
element I-GENE
binding I-GENE
protein I-GENE
( O
CREB I-GENE
), O
bound O
to O
the O
viral I-GENE
Tax I-GENE
- I-GENE
responsive I-GENE
element I-GENE
consisting O
of O
three O
_RARE_ I-GENE
21 O
- I-GENE
base O
pair O
repeats I-GENE
, O
each O
with O
a O
cAMP I-GENE
response O
element I-GENE
core I-GENE
flanked O
by O
G I-GENE
/ I-GENE
C I-GENE
- I-GENE
rich O
sequences I-GENE
. O

This O
sequence I-GENE
is O
very O
similar O
to O
the O
insulin I-GENE
response O
sequence I-GENE
found O
in O
the O
regulatory I-GENE
region O
of O
other O
genes I-GENE
negatively O
regulated O
by O
insulin I-GENE
such O
as O
those O
encoding O
phosphoenolpyruvate I-GENE
_RARE_ I-GENE
, O
tyrosine I-GENE
aminotransferase I-GENE
, O
and O
insulin I-GENE
- I-GENE
like I-GENE
growth I-GENE
factor I-GENE
- I-GENE
binding I-GENE
protein I-GENE
1 I-GENE
. O

The O
murine I-GENE
_RARE_ I-GENE
glucose O
transporter I-GENE
isoform I-GENE
3 I-GENE
( O
_RARE_ I-GENE
3 I-GENE
) O
is O
developmentally O
regulated O
and O
is O
predominantly O
expressed O
in O
neurons O
and O
_RARE_ I-GENE
. O

However O
, O
changing O
the O
half O
- I-GENE
site I-GENE
to O
the O
consensus I-GENE
sequence I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
- I-GENE
1 I-GENE
) O
increased O
binding I-GENE
of O
_RARE_ I-GENE
. O
_RARE_ I-GENE
10 O
- I-GENE
fold O
over O
_RARE_ I-GENE
- I-GENE
1 I-GENE
and O
, O
at O
the O
same O
time O
, O
reduced O
the O
_RARE_ I-GENE
of O
the O
spacer O
length I-GENE
requirement O
, O
with O
_RARE_ I-GENE
- I-GENE
0 O
to O
_RARE_ I-GENE
- I-GENE
5 I-GENE
showing O
detectable O
binding I-GENE
. O

The O
levels O
of O
transactivation O
are O
correlated O
with O
the O
respective O
binding I-GENE
affinities O
of O
the O
response O
elements O
( O
_RARE_ I-GENE
- I-GENE
1 I-GENE
> O
DR I-GENE
- I-GENE
4 I-GENE
> O
_RARE_ I-GENE
- I-GENE
1 I-GENE
). O

The O
high O
density I-GENE
of O
_RARE_ I-GENE
_RARE_ I-GENE
on O
posterior O
half O
of O
the O
body O
and O
the O
distribution O
of O
type I-GENE
II I-GENE
_RARE_ I-GENE
on O
dorsal O
surface O
are O
considered O
to O
be O
characteristic O
of O
C I-GENE
. O
_RARE_ I-GENE
. O

_RARE_ I-GENE
of O
p53 I-GENE
but O
not O
_RARE_ I-GENE
by O
adenovirus I-GENE
type I-GENE
5 I-GENE
E1B I-GENE
55 O
- I-GENE
kilodalton I-GENE
and O
_RARE_ I-GENE
34 O
- I-GENE
kilodalton I-GENE
oncoproteins I-GENE
. O

The O
Epstein I-GENE
- I-GENE
Barr I-GENE
virus I-GENE
transactivator I-GENE
Zta I-GENE
triggers O
lytic O
gene I-GENE
expression O
and O
is O
essential O
for O
replication O
of O
the O
lytic O
origin O
, O
_RARE_ I-GENE
. O

Cotransfection O
of O
the O
helicase I-GENE
- I-GENE
primase I-GENE
proteins I-GENE
, O
one O
of O
which O
was O
fused O
to O
a O
heterologous O
activation O
domain I-GENE
, O
led O
to O
Zta I-GENE
- I-GENE
dependent I-GENE
_RARE_ I-GENE
of O
CAT I-GENE
expression O
. O

Sequence O
comparisons O
strongly O
suggest O
that O
the O
_RARE_ I-GENE
and O
the O
ubiquitin I-GENE
coding O
sequences I-GENE
found O
in O
the O
genome O
of O
CP I-GENE
_RARE_ I-GENE
were O
both O
derived O
from O
a O
bovine I-GENE
mRNA I-GENE
encoding O
a O
hybrid O
protein I-GENE
with O
the O
structure O
NH2 I-GENE
- I-GENE
ubiquitin I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
COOH O
. O

J O
. O

There O
was O
a O
trend O
in O
all O
studies O
_RARE_ I-GENE
_RARE_ I-GENE
. O

A I-GENE
single O
rectal O
dose O
of O
25 O
mg O
/ I-GENE
kg O
will O
obtain O
this O
lower O
concentration O
within O
1 I-GENE
h O
of O
administration O
and O
maintain O
it O
for O
up O
to O
6 I-GENE
h O
. O

This O
domain I-GENE
, O
although O
adjacent O
to O
the O
5 I-GENE
' O
_RARE_ I-GENE
of O
the O
SD O
sequence I-GENE
, O
does O
not O
inhibit O
ribosome I-GENE
binding I-GENE
as O
long O
as O
the O
single O
- I-GENE
stranded I-GENE
region O
of O
domain I-GENE
3 I-GENE
is O
present O
. O

Although O
_RARE_ I-GENE
is O
a O
highly O
active O
PTP I-GENE
, O
it O
preferentially O
targets O
a O
subset O
of O
tyrosine I-GENE
- I-GENE
phosphorylated O
proteins I-GENE
in O
host O
cells O
, O
including O
_RARE_ I-GENE
. O

_RARE_ I-GENE
position O
of O
the O
_RARE_ I-GENE
within O
the O
_RARE_ I-GENE
revealed O
by O
analysis O
of O
_RARE_ I-GENE
rDNA I-GENE
and O
_RARE_ I-GENE
sequences I-GENE
. O

Previous O
genetic O
studies O
led O
to O
the O
conclusion O
that O
nitrate I-GENE
and O
nitrite I-GENE
induction O
of O
_RARE_ I-GENE
operon I-GENE
expression O
is O
determined O
by O
a O
transcriptional O
_RARE_ I-GENE
mechanism O
. O

The O
activation O
and O
injury O
of O
endothelial I-GENE
cells O
induced O
by O
TNF I-GENE
and O
other O
_RARE_ I-GENE
cytokines O
may O
_RARE_ I-GENE
the O
local O
effects O
of O
these O
_RARE_ I-GENE
in O
vivo O
. O

A I-GENE
technique O
for O
thermal O
imaging O
of O
the O
animal O
and O
human I-GENE
brain O
cortex O
using O
an O
_RARE_ I-GENE
optical O
system O
is O
described O
. O

EGFR I-GENE
levels O
were O
found O
to O
be O
elevated O
5 I-GENE
-, I-GENE
3 I-GENE
. O

Here O
we O
demonstrate O
that O
_RARE_ I-GENE
NP I-GENE
contains O
a O
motif I-GENE
( O
_RARE_ I-GENE
) O
at O
amino O
acid I-GENE
positions O
_RARE_ I-GENE
- I-GENE
193 O
that O
represents O
a O
classical O
bipartite O
nuclear I-GENE
localization O
signal I-GENE
( O
NLS O
). O

As O
PP2A I-GENE
exerts O
a O
range O
of O
cellular O
functions O
including O
cell O
cycle O
regulation O
and O
cell O
fate O
determination O
, O
we O
were O
_RARE_ I-GENE
to O
find O
that O
these O
embryos O
develop O
normally O
until O
_RARE_ I-GENE
, O
around O
embryonic O
day O
5 I-GENE
. O
5 I-GENE
/ I-GENE
6 I-GENE
. O
0 O
. O

The O
most O
frequent O
risk O
factor I-GENE
for O
ischaemic O
was O
hypertension O
. O

The O
results O
indicate O
that O
_RARE_ I-GENE
_RARE_ I-GENE
B I-GENE
and O
_RARE_ I-GENE
are O
weakly O
_RARE_ I-GENE
. O

Furthermore O
, O
_RARE_ I-GENE
gene I-GENE
mapped O
to O
chromosome O
_RARE_ I-GENE
, O
a O
region O
that O
has O
been O
involved O
as O
a O
chromosomal I-GENE
breakpoint I-GENE
in O
_RARE_ I-GENE
. O

16 O
subjects O
were O
_RARE_ I-GENE
tested O
to O
_RARE_ I-GENE
chloride O
( O
_RARE_ I-GENE
) O
and O
to O
solutions O
containing O
_RARE_ I-GENE
mixed O
with O
L I-GENE
- I-GENE
cysteine I-GENE
and O
glutathione I-GENE
, O
respectively O
. O

Wild I-GENE
- I-GENE
type I-GENE
_RARE_ I-GENE
receptors I-GENE
, O
expressed O
in O
Chinese O
hamster I-GENE
ovary O
cells O
, O
rapidly O
_RARE_ I-GENE
after O
_RARE_ I-GENE
II I-GENE
stimulation O
[ O
t1 O
/ I-GENE
2 I-GENE
2 I-GENE
. O
3 I-GENE
min O
; O
maximal O
level O
of O
internalization O
( O
Ymax O
) O
78 O
. O
2 I-GENE
_RARE_ I-GENE
as O
did O
mutant I-GENE
receptors I-GENE
carrying O
single O
acidic O
substitutions O
( O
_RARE_ I-GENE
, O
t1 O
/ I-GENE
2 I-GENE
2 I-GENE
. O
7 O
min O
, O
Ymax O
76 I-GENE
. O
3 I-GENE
%; O
_RARE_ I-GENE
, O
t1 O
/ I-GENE
2 I-GENE
2 I-GENE
. O
4 I-GENE
min O
, O
Ymax O
76 I-GENE
. O
7 O
%; O
_RARE_ I-GENE
, O
t1 O
/ I-GENE
2 I-GENE
2 I-GENE
. O
5 I-GENE
min O
, O
Ymax O
78 O
. O
2 I-GENE
%; O
_RARE_ I-GENE
, O
t1 O
/ I-GENE
2 I-GENE
2 I-GENE
. O
6 I-GENE
min O
, O
Ymax O
78 O
. O
4 I-GENE
%). O

The O
activated I-GENE
glucocorticoid I-GENE
receptor I-GENE
forms O
a O
complex I-GENE
with O
Stat5 I-GENE
and O
enhances O
Stat5 I-GENE
- I-GENE
mediated O
transcriptional O
induction O
. O

T I-GENE
., O
_RARE_ I-GENE
, O
A I-GENE
., O
and O
_RARE_ I-GENE
, O
G I-GENE
. O

The O
carboxyl O
- I-GENE
terminal I-GENE
portion O
of O
_RARE_ I-GENE
contains O
three O
zinc I-GENE
fingers O
of O
the O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
type I-GENE
and O
binds O
in O
vitro O
to O
the O
_RARE_ I-GENE
motif I-GENE
of O
the O
beta I-GENE
- I-GENE
globin I-GENE
promoter I-GENE
and O
to O
the O
Sp1 I-GENE
recognition I-GENE
sequence I-GENE
. O

We O
have O
recently O
identified O
a O
mouse I-GENE
enzyme I-GENE
termed O
gamma I-GENE
- I-GENE
glutamyl I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
that O
_RARE_ I-GENE
_RARE_ I-GENE
C4 I-GENE
( O
_RARE_ I-GENE
) O
to O
_RARE_ I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
). O

UGA O
codon O
position O
affects O
the O
efficiency O
of O
selenocysteine I-GENE
incorporation O
into O
glutathione I-GENE
peroxidase I-GENE
- I-GENE
1 I-GENE
. O

_RARE_ I-GENE
significantly O
enhanced O
_RARE_ I-GENE
- I-GENE
stimulated O
expression O
of O
cyclin I-GENE
D I-GENE
and O
phosphorylation O
of O
the O
retinoblastoma I-GENE
gene I-GENE
product I-GENE
. O

The O
ARF I-GENE
promoter I-GENE
was O
also O
found O
to O
be O
highly O
responsive I-GENE
to O
E2F1 I-GENE
expression O
, O
in O
_RARE_ I-GENE
with O
previous O
results O
at O
the O
RNA I-GENE
level O
. O

RESULTS O
: O
The O
binding I-GENE
of O
99mTc O
d O
, O
1 I-GENE
- I-GENE
HMPAO O
to O
human I-GENE
placenta O
ranged O
from O
2 I-GENE
. O
95 O
% O
+/- O
1 I-GENE
. O
5 I-GENE
% O
to O
5 I-GENE
. O
82 O
% O
+/- O
0 O
. O
3 I-GENE
% O
per O
1 I-GENE
ml O
standard O
solution O
. O

CM I-GENE
reduced O
the O
nuclear I-GENE
binding I-GENE
activity O
of O
transcription I-GENE
factor I-GENE
AP I-GENE
- I-GENE
1 I-GENE
. O

NF I-GENE
- I-GENE
kappaB I-GENE
, O
which O
is O
probably O
important O
for O
basal O
activity O
of O
the O
human I-GENE
_RARE_ I-GENE
II I-GENE
promoter I-GENE
, O
is O
unlikely O
to O
function O
as O
a O
major I-GENE
effector O
of O
CM I-GENE
in O
_RARE_ I-GENE
- I-GENE
1 I-GENE
cells O
. O

_RARE_ I-GENE
with O
brain O
injury O
and O
control O
_RARE_ I-GENE
performed O
a O
_RARE_ I-GENE
task O
during O
which O
they O
received O
periodic I-GENE
_RARE_ I-GENE
of O
_RARE_ I-GENE
air O
or O
air O
_RARE_ I-GENE
with O
_RARE_ I-GENE
. O

A I-GENE
simple O
_RARE_ I-GENE
method O
for O
l O
- I-GENE
_RARE_ I-GENE
by O
high O
- I-GENE
performance O
liquid O
chromatography O
with O
a O
_RARE_ I-GENE
_RARE_ I-GENE
detector O
was O
established O
. O

RESULTS O
: O
The O
cardiac O
index O
significantly O
changed O
with O
varying O
PaCO2 O
levels O
( O
_RARE_ I-GENE
, O
- I-GENE
9 O
%; O
hypercapnia O
, O
13 O
%). O

After O
measuring O
baseline O
_RARE_ I-GENE
at O
a O
partial O
pressure O
of O
carbon O
dioxide O
in O
arterial O
blood O
( O
PaCO2 O
) O
of O
37 O
. O
7 O
+/- O
4 I-GENE
. O
5 I-GENE
mmHg O
( O
mean O
+/- O
SD O
), O
measurements O
were O
repeated O
at O
a O
_RARE_ I-GENE
of O
44 I-GENE
. O
2 I-GENE
+/- O
3 I-GENE
. O
8 O
mmHg O
, O
and O
the O
carbon O
dioxide O
reactivity O
( O
absolute O
value O
: O
cm O
x O
s O
(- O
1 I-GENE
) O
x O
mmHg O
(- O
1 I-GENE
); O
relative O
value O
: O
percentage O
of O
baseline O
_RARE_ I-GENE
/ I-GENE
mmHg O
) O
was O
calculated O
. O

_RARE_ I-GENE
Cox O
survival O
analysis O
identified O
baseline O
EF I-GENE
< O
or O
= O
30 O
%, O
presence O
of O
significant O
mitral O
_RARE_ I-GENE
(> O
2 I-GENE
+) O
before O
ablation O
, O
and O
failure O
to O
exhibit O
improved O
cardiac O
performance O
by O
1 I-GENE
month O
after O
ablation O
as O
the O
only O
independent O
predictors O
of O
death O
. O

We O
have O
developed O
a O
new O
method O
for O
estimation O
of O
regional O
CBF I-GENE
( O
rCBF O
) O
and O
_RARE_ I-GENE
reserve O
capacity O
on O
a O
_RARE_ I-GENE
- I-GENE
by O
- I-GENE
_RARE_ I-GENE
basis O
by O
means O
of O
dynamic O
magnetic O
resonance O
imaging O
( O
MRI O
). O

_RARE_ I-GENE
- I-GENE
effectiveness O
analysis O
provides O
a O
_RARE_ I-GENE
means O
of O
_RARE_ I-GENE
limited O
health O
care O
_RARE_ I-GENE
by O
allowing O
the O
comparison O
of O
the O
costs O
of O
lipid O
- I-GENE
lowering O
therapy O
, O
in O
particular O
, O
therapy O
with O
beta I-GENE
- I-GENE
hydroxy I-GENE
- I-GENE
beta I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
CoA I-GENE
( O
coenzyme I-GENE
A I-GENE
) O
reductase I-GENE
inhibitors O
( O
_RARE_ I-GENE
), O
with O
the O
costs O
of O
atherosclerosis O
that O
could O
be O
prevented O
by O
lowering O
cholesterol I-GENE
. O

Although O
_RARE_ I-GENE
lacks O
the O
transactivation O
domain I-GENE
, O
it O
stimulates O
E2F I-GENE
site I-GENE
- I-GENE
dependent I-GENE
transcription I-GENE
in O
cooperation O
with O
E2F I-GENE
- I-GENE
1 I-GENE
. O

Sequencing O
of O
a O
40 I-GENE
- I-GENE
kb O
DNA I-GENE
segment O
of O
the O
FK506 O
gene I-GENE
cluster I-GENE
from O
Streptomyces I-GENE
sp O
. O

The O
predicted O
domain I-GENE
structures O
of O
_RARE_ I-GENE
and O
_RARE_ I-GENE
are O
analogous O
to O
that O
of O
_RARE_ I-GENE
and O
comprise O
30 O
fatty I-GENE
- I-GENE
acid I-GENE
- I-GENE
synthase I-GENE
( O
_RARE_ I-GENE
)- I-GENE
like I-GENE
domains I-GENE
arranged O
in O
6 I-GENE
modules I-GENE
. O

Analysis O
of O
_RARE_ I-GENE
mRNA I-GENE
expression O
in O
_RARE_ I-GENE
and O
adult O
mouse I-GENE
testes O
, O
and O
in O
isolated O
populations O
of O
germ I-GENE
cells O
, O
reveals O
maximal O
expression O
in O
_RARE_ I-GENE
round O
_RARE_ I-GENE
, O
a O
cell O
type I-GENE
with O
abundant O
amounts O
of O
stored O
messenger I-GENE
_RARE_ I-GENE
. O

1 I-GENE
in O
_RARE_ I-GENE
Chi O
_RARE_ I-GENE
City O
was O
studied O
by O
culture O
and O
latex O
agglutination I-GENE
of O
blood O
, O
cerebrospinal O
fluid O
, O
urine O
and O
pleural I-GENE
fluid O
. O

_RARE_ I-GENE
synthesis O
and O
catabolism O
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
motility O
, O
cell O
surface O
properties O
and O
_RARE_ I-GENE
are O
modulated O
by O
_RARE_ I-GENE
in O
Escherichia I-GENE
coli I-GENE
, O
while O
the O
production O
of O
several O
secreted O
virulence I-GENE
factors I-GENE
, O
the O
plant O
hypersensitive I-GENE
response O
_RARE_ I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
and O
, O
potentially O
, O
other O
secondary O
metabolites O
are O
regulated O
by O
_RARE_ I-GENE
in O
_RARE_ I-GENE
_RARE_ I-GENE
. O

The O
_RARE_ I-GENE
- I-GENE
1 I-GENE
mutation I-GENE
was O
identified O
as O
a O
guanine I-GENE
to O
adenine O
substitution O
at O
nucleotide I-GENE
_RARE_ I-GENE
of O
the O
coding O
region O
, O
_RARE_ I-GENE
the O
change O
_RARE_ I-GENE
in O
the O
_RARE_ I-GENE
. O

Deletion O
analysis O
revealed O
that O
the O
essential O
domain I-GENE
of O
this O
promoter I-GENE
, O
termed O
the O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
transcript I-GENE
promoter I-GENE
, O
mapped O
to O
nucleotides O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
. O

Some O
of O
the O
peptide I-GENE
: O
MBP I-GENE
fusions I-GENE
were O
also O
analyzed O
using O
surface O
_RARE_ I-GENE
resonance O
. O

Cardiac I-GENE
myosin I-GENE
- I-GENE
binding I-GENE
protein I-GENE
C I-GENE
( O
_RARE_ I-GENE
- I-GENE
C I-GENE
): O
identification O
of O
protein I-GENE
kinase I-GENE
A I-GENE
and O
protein I-GENE
kinase I-GENE
C I-GENE
phosphorylation O
sites I-GENE
. O

_RARE_ I-GENE
on O
_RARE_ I-GENE
9 O
did O
not O
result O
in O
elevated O
_RARE_ I-GENE
levels O
in O
any O
of O
the O
groups O
. O

Analysis O
of O
chromosomal I-GENE
DNA I-GENE
sequence I-GENE
immediately O
downstream O
of O
the O
transposon I-GENE
insertion O
identified O
two O
open O
reading O
frames O
, O
designated O
_RARE_ I-GENE
and O
_RARE_ I-GENE
, O
which O
exhibited O
sequence I-GENE
similarity O
to O
bacterial I-GENE
two O
- I-GENE
component O
regulatory I-GENE
systems O
. O

_RARE_ I-GENE
+/- O
258 O
aggregates O
/ I-GENE
ml O
at O
0 O
_RARE_ I-GENE
; O
P I-GENE
< O
0 O
. O
001 O
). O

We O
previously O
_RARE_ I-GENE
a O
region O
in O
the O
fatty I-GENE
- I-GENE
acid I-GENE
synthase I-GENE
promoter I-GENE
, O
which O
was O
responsible O
for O
obesity O
- I-GENE
related I-GENE
overexpression O
of O
the O
fatty I-GENE
- I-GENE
acid I-GENE
synthase I-GENE
( O
_RARE_ I-GENE
) O
gene I-GENE
, O
by O
negatively O
regulating O
the O
activity O
of O
the O
downstream O
promoter I-GENE
in O
lean O
but O
not O
obese O
rat I-GENE
fat O
cells O
. O

Finally O
, O
using O
in O
vitro O
binding I-GENE
studies O
, O
we O
showed O
that O
_RARE_ I-GENE
was O
able O
to O
_RARE_ I-GENE
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
binding I-GENE
from O
the O
sterol I-GENE
regulatory I-GENE
element I-GENE
( O
SRE O
) O
site I-GENE
. O

Thus O
, O
IRF I-GENE
- I-GENE
7 O
exhibits O
functional O
similarity O
to O
IRF I-GENE
- I-GENE
3 I-GENE
; O
however O
, O
the O
preferential O
expression O
of O
IRF I-GENE
- I-GENE
7 O
in O
lymphoid I-GENE
cells O
( O
the O
cell O
type I-GENE
that O
_RARE_ I-GENE
_RARE_ I-GENE
) O
suggests O
that O
IRF I-GENE
- I-GENE
7 O
may O
play O
a O
critical O
role O
in O
regulating O
the O
_RARE_ I-GENE
gene I-GENE
expression O
. O

J O
. O

PURPOSE O
: O
The O
role O
interleukin I-GENE
- I-GENE
6 I-GENE
( O
IL I-GENE
- I-GENE
6 I-GENE
) O
in O
the O
treatment O
of O
congenital O
_RARE_ I-GENE
is O
unknown O
. O

_RARE_ I-GENE
as O
a O
CD44 I-GENE
- I-GENE
associated I-GENE
serine I-GENE
kinase I-GENE
therefore O
may O
serve O
as O
an O
important O
molecule I-GENE
in O
a O
signaling O
cascade O
that O
produces O
a O
variety O
of O
cellular O
responses O
in O
_RARE_ I-GENE
breast O
cancer O
cells O
. O

_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
, O
but O
not O
_RARE_ I-GENE
, O
activate O
SRF I-GENE
through O
RhoA I-GENE
. O

Additionally O
in O
seven O
subjects O
adrenaline O
( O
A I-GENE
) O
and O
noradrenaline O
( O
NA O
) O
concentrations O
were O
determined O
. O

Northern O
blot O
analyses O
show O
that O
the O
_RARE_ I-GENE
mRNA I-GENE
level O
is O
abundantly O
expressed O
in O
tissues O
or O
cells O
with O
a O
high O
mitotic O
index O
. O

We O
mapped O
two O
overlapping O
expressed O
sequence I-GENE
tag O
clones O
within O
a O
genomic O
contig O
on O
human I-GENE
chromosome O
5 I-GENE
, O
band O
_RARE_ I-GENE
. O

_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
is O
developmentally O
regulated O
and O
expressed O
predominantly O
in O
brain O
, O
liver O
testis I-GENE
, O
and O
weakly O
in O
kidney O
. O

_RARE_ I-GENE
transcripts I-GENE
are O
expressed O
in O
a O
variety O
of O
tissues O
including O
both O
brain O
and O
testes O
. O

Using O
an O
_RARE_ I-GENE
backcross O
panel O
, O
we O
localized O
both O
_RARE_ I-GENE
and O
_RARE_ I-GENE
to O
the O
same O
locus I-GENE
on O
chromosome O
19 O
. O

We O
also O
raised O
a O
_RARE_ I-GENE
antibody I-GENE
against O
the O
glutathione I-GENE
S I-GENE
- I-GENE
transferase I-GENE
fusion I-GENE
protein I-GENE
containing O
the O
NH2 I-GENE
- I-GENE
terminal I-GENE
86 I-GENE
amino O
acids O
of O
human I-GENE
_RARE_ I-GENE
. O

Inhibition O
of O
the O
apolipoprotein I-GENE
B I-GENE
mRNA I-GENE
_RARE_ I-GENE
enzyme I-GENE
- I-GENE
complex I-GENE
by O
hnRNP I-GENE
C1 I-GENE
protein I-GENE
and O
_RARE_ I-GENE
hnRNP I-GENE
complexes I-GENE
. O

SRC I-GENE
- I-GENE
1 I-GENE
can O
_RARE_ I-GENE
the O
NF I-GENE
- I-GENE
kappaB I-GENE
- I-GENE
mediated O
repression O
of O
GR I-GENE
activity O
. O

However O
the O
sequence I-GENE
surrounding O
the O
transcription I-GENE
start O
site I-GENE
_RARE_ I-GENE
(+ O
1 I-GENE
) O
_RARE_ I-GENE
was O
similar O
to O
the O
consensus I-GENE
_RARE_ I-GENE
(+ O
1 I-GENE
) O
_RARE_ I-GENE
( O
N I-GENE
is O
any O
_RARE_ I-GENE
) O
for O
an O
initiator O
element I-GENE
found O
in O
terminal I-GENE
_RARE_ I-GENE
and O
a O
number O
of O
other O
highly O
regulated O
genes I-GENE
. O

These O
results O
indicate O
that O
the O
total O
number O
of O
subunit I-GENE
c I-GENE
in O
_RARE_ I-GENE
should O
be O
a O
multiple O
of O
2 I-GENE
and O
3 I-GENE
. O

Expression O
of O
a O
dominant I-GENE
- I-GENE
negative O
mutant I-GENE
of O
JNK1 I-GENE
also O
suppressed O
glucose O
deprivation O
- I-GENE
induced O
JNK1 I-GENE
activation O
as O
well O
as O
HSP70 I-GENE
gene I-GENE
expression O
. O

The O
interaction O
of O
AF I-GENE
- I-GENE
1 I-GENE
with O
proteins I-GENE
that O
regulate O
distinct O
steps O
of O
transcription I-GENE
may O
provide O
a O
mechanism O
for O
synergistic O
activation O
of O
gene I-GENE
expression O
by O
AF I-GENE
- I-GENE
1 I-GENE
. O

The O
role O
of O
protein I-GENE
kinase I-GENE
C I-GENE
signaling O
in O
activated I-GENE
_RARE_ I-GENE
transcription I-GENE
. O

_RARE_ I-GENE
binding I-GENE
to O
the O
receptor I-GENE
complex I-GENE
leads O
to O
tyrosine I-GENE
phosphorylation O
and O
activation O
of O
Janus I-GENE
kinases I-GENE
( O
Jak I-GENE
), O
phosphorylation O
of O
the O
signal I-GENE
_RARE_ I-GENE
subunit I-GENE
_RARE_ I-GENE
, O
followed O
by O
recruitment O
and O
phosphorylation O
of O
the O
signal I-GENE
_RARE_ I-GENE
and O
activator I-GENE
of O
transcription I-GENE
factors I-GENE
STAT3 I-GENE
and O
STAT1 I-GENE
and O
the O
src I-GENE
homology I-GENE
domain I-GENE
( O
SH2 I-GENE
)- I-GENE
containing O
protein I-GENE
tyrosine I-GENE
phosphatase I-GENE
( O
_RARE_ I-GENE
). O

Interestingly O
, O
an O
increase O
of O
distance O
per O
_RARE_ I-GENE
did O
not O
have O
a O
_RARE_ I-GENE
effect O
on O
translation I-GENE
efficiency O
. O

We O
also O
mapped O
a O
3 I-GENE
'- O
polyadenylation O
site I-GENE
_RARE_ I-GENE
downstream O
of O
the O
_RARE_ I-GENE
stop O
codon O
, O
consistent O
with O
the O
2 I-GENE
. O
_RARE_ I-GENE
transcript I-GENE
size O
. O

_RARE_ I-GENE
protein I-GENE
turned O
out O
to O
be O
_RARE_ I-GENE
which O
was O
isolated O
as O
a O
TATA I-GENE
- I-GENE
binding I-GENE
protein I-GENE
associated I-GENE
factor I-GENE
( O
TAF I-GENE
) O
from O
a O
sub O
- I-GENE
population O
of O
TFIID I-GENE
complexes I-GENE
( O
_RARE_ I-GENE
A I-GENE
., O
_RARE_ I-GENE
, O
Y I-GENE
., O
_RARE_ I-GENE
, O
D I-GENE
. O
J O
., O
_RARE_ I-GENE
, O
P I-GENE
., O
_RARE_ I-GENE
, O
L I-GENE
., O
1996 O
. O
_RARE_ I-GENE
, O
a O
novel O
RNA I-GENE
/ I-GENE
ssDNA I-GENE
- I-GENE
binding I-GENE
protein I-GENE
with O
homology I-GENE
to O
the O
proto I-GENE
- I-GENE
oncoproteins I-GENE
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
and O
EWS I-GENE
is O
associated I-GENE
with O
both O
TFIID I-GENE
and O
RNA I-GENE
polymerase I-GENE
II I-GENE
. O

An O
electrophoretic O
mobility I-GENE
shift O
assay O
was O
performed O
to O
characterize O
the O
binding I-GENE
_RARE_ I-GENE
of O
_RARE_ I-GENE
and O
its O
truncated I-GENE
isoform I-GENE
. O

Gel O
- I-GENE
mobility I-GENE
shift O
analysis O
was O
also O
performed O
for O
the O
CCAAT I-GENE
motif I-GENE
at O
- I-GENE
67 O
. O

BACKGROUND O
: O
The O
c I-GENE
- I-GENE
myc I-GENE
proto I-GENE
- I-GENE
oncogene I-GENE
has O
been O
suggested O
to O
play O
key O
roles O
in O
cell O
proliferation O
, O
differentiation O
, O
transformation O
and O
apoptosis O
. O

_RARE_ I-GENE
- I-GENE
1 I-GENE
was O
localized O
in O
the O
cytoplasm O
in O
cells O
expressing O
c I-GENE
- I-GENE
myc I-GENE
at O
low O
levels O
, O
but O
in O
the O
nucleus O
in O
the O
cells O
of O
a O
high O
c I-GENE
- I-GENE
myc I-GENE
expression O
in O
transiently O
transfected O
cells O
. O

RESULTS O
: O
We O
identified O
a O
full I-GENE
- I-GENE
length I-GENE
cDNA I-GENE
with O
an O
open O
reading O
frame O
of O
_RARE_ I-GENE
bp O
corresponding O
to O
a O
predicted O
protein I-GENE
of O
_RARE_ I-GENE
amino O
acids O
that O
shares O
greater O
than O
95 O
% O
homology I-GENE
with O
the O
rat I-GENE
gamma I-GENE
- I-GENE
_RARE_ I-GENE
acid I-GENE
B I-GENE
( O
_RARE_ I-GENE
) O
receptor I-GENE
. O

On O
Day O
8 O
, O
the O
_RARE_ I-GENE
- I-GENE
B I-GENE
was O
removed O
and O
500 O
micrograms O
_RARE_ I-GENE
injected O
, O
IM O
. O

_RARE_ I-GENE
- I-GENE
like I-GENE
properties O
of O
some O
serotonin I-GENE
receptor I-GENE
ligands O
and O
calcium O
channel O
antagonists O
measured O
with O
the O
_RARE_ I-GENE
swimming O
test O
in O
mice O
. O

Another O
_RARE_ I-GENE
_RARE_ I-GENE
mutation I-GENE
in O
the O
third O
patient O
, O
a O
frame O
shift O
caused O
by O
a O
G I-GENE
nucleotide I-GENE
insertion O
in O
a O
_RARE_ I-GENE
repeat I-GENE
of O
six O
Gs I-GENE
in O
_RARE_ I-GENE
exon O
3 I-GENE
, O
has O
been O
reported O
previously O
in O
three O
other O
_RARE_ I-GENE
patients O
. O

SRF I-GENE
- I-GENE
deficient O
embryos O
( O
_RARE_ I-GENE
_RARE_ I-GENE
have O
a O
severe O
_RARE_ I-GENE
defect O
and O
do O
not O
develop O
to O
term O
. O

These O
characteristic O
structural O
features O
were O
used O
to O
create O
the O
_RARE_ I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
- I-GENE
rich O
_RARE_ I-GENE
_RARE_ I-GENE
protein I-GENE
). O

_RARE_ I-GENE
- I-GENE
expression O
of O
_RARE_ I-GENE
in O
the O
yeast I-GENE
cell O
does O
not O
influence O
the O
expression O
level O
of O
the O
mitochondrial I-GENE
transcription I-GENE
factor I-GENE
_RARE_ I-GENE
, O
indicating O
that O
the O
influence O
of O
_RARE_ I-GENE
on O
the O
suppression O
of O
the O
special O
mitochondrial I-GENE
RNA I-GENE
polymerase I-GENE
mutant I-GENE
is O
an O
indirect O
one O
. O

We O
have O
generated O
a O
computer O
model O
of O
the O
C I-GENE
- I-GENE
terminal I-GENE
domain I-GENE
of O
the O
_RARE_ I-GENE
repressor I-GENE
based O
on O
the O
crystal O
structure O
of O
the O
homologous O
UmuD I-GENE
' O
protein I-GENE
. O

Large I-GENE
- I-GENE
scale O
sequencing O
of O
two O
regions O
in O
human I-GENE
chromosome O
_RARE_ I-GENE
: O
analysis O
of O
_RARE_ I-GENE
kb O
of O
genomic O
sequence I-GENE
around O
the O
EPO I-GENE
and O
_RARE_ I-GENE
loci I-GENE
reveals O
17 O
genes I-GENE
. O

Because O
_RARE_ I-GENE
( O
the O
mouse I-GENE
homolog I-GENE
of O
human I-GENE
_RARE_ I-GENE
) O
is O
located O
with O
_RARE_ I-GENE
on O
chromosome O
11 O
and O
is O
critical O
in O
regulating O
cellular O
responses O
following O
exposure O
to O
DNA I-GENE
_RARE_ I-GENE
agents O
, O
we O
_RARE_ I-GENE
to O
determine O
if O
these O
mouse I-GENE
lymphoma O
cells O
harbor O
mutations O
in O
_RARE_ I-GENE
. O

One O
of O
these O
fragments I-GENE
shows O
the O
highest O
amino O
acid I-GENE
sequence I-GENE
homology I-GENE
to O
the O
insect O
ecdysone O
inducible I-GENE
gene I-GENE
_RARE_ I-GENE
. O

The O
full I-GENE
- I-GENE
length I-GENE
N I-GENE
gene I-GENE
, O
encoded I-GENE
by O
open O
reading O
frame O
7 O
, O
was O
cloned O
from O
the O
_RARE_ I-GENE
_RARE_ I-GENE
virus I-GENE
, O
PA I-GENE
- I-GENE
8 O
. O

Based O
on O
sequence I-GENE
homology I-GENE
, O
the O
genes I-GENE
were O
identified O
as O
TEF I-GENE
, O
encoding O
translation I-GENE
elongation I-GENE
factor I-GENE
- I-GENE
1 I-GENE
alpha I-GENE
and O
_RARE_ I-GENE
, O
encoding O
ribosomal I-GENE
protein I-GENE
_RARE_ I-GENE
. O

We O
have O
previously O
shown O
that O
_RARE_ I-GENE
localizes O
to O
the O
plasma I-GENE
membrane I-GENE
in O
vivo O
and O
efficiently O
catalyzes O
_RARE_ I-GENE
nucleotide I-GENE
exchange I-GENE
in O
vitro O
. O

Renal O
pathology O
and O
long O
- I-GENE
term O
outcome O
in O
childhood O
SLE O
. O

Transcription O
factors I-GENE
of O
the O
Stat I-GENE
family I-GENE
are O
controlled O
by O
protein I-GENE
kinases I-GENE
. O

We O
propose O
that O
two O
pathways O
regulate O
Stat5 I-GENE
serine I-GENE
phosphorylation O
, O
one O
that O
is O
prolactin I-GENE
- I-GENE
activated I-GENE
and O
PD98059 O
- I-GENE
resistant O
and O
one O
that O
is O
constitutively O
active O
and O
PD98059 O
- I-GENE
sensitive O
and O
preferentially O
targets O
Stat5a I-GENE
. O

An O
approximately O
37 O
- I-GENE
kDa I-GENE
cytoplasmic I-GENE
protein I-GENE
is O
rapidly O
tyrosine I-GENE
- I-GENE
phosphorylated O
in O
the O
response O
of O
mouse I-GENE
_RARE_ I-GENE
. O
_RARE_ I-GENE
macrophages O
to O
colony I-GENE
stimulating I-GENE
factor I-GENE
- I-GENE
1 I-GENE
( O
CSF I-GENE
- I-GENE
1 I-GENE
). O
_RARE_ I-GENE
was O
purified O
from O
the O
cytosolic I-GENE
fraction O
by O
anti I-GENE
- I-GENE
Tyr I-GENE
( O
P I-GENE
) O
affinity O
chromatography O
, O
size O
exclusion O
chromatography O
, O
and O
C4 I-GENE
reverse I-GENE
phase O
high O
pressure O
liquid O
chromatography O
. O

_RARE_ I-GENE
of O
20 O
_RARE_ I-GENE
were O
administered O
within O
a O
_RARE_ I-GENE
from O
0 O
. O
1 I-GENE
to O
6 I-GENE
months O
in O
order O
to O
study O
its O
_RARE_ I-GENE
, O
which O
was O
evaluated O
at O
2 I-GENE
, O
7 O
, O
and O
12 O
months O
after O
the O
first O
dose O
. O

The O
various O
available O
data O
strongly O
suggesting O
an O
environmental O
toxic O
origin O
for O
the O
" O
sperm O
fall O
" O
will O
be O
presented O
as O
well O
as O
the O
most O
frequently O
suspected O
class I-GENE
of O
substances O
, O
the O
_RARE_ I-GENE
. O

This O
association O
was O
independently O
significant O
for O
patients O
treated O
primarily O
( O
not O
for O
recurrence O
). O

CONCLUSION O
: O
_RARE_ I-GENE
control O
was O
highest O
with O
_RARE_ I-GENE
in O
patients O
presenting O
primarily O
with O
gross O
disease O
, O
and O
with O
_RARE_ I-GENE
in O
patients O
presenting O
primarily O
following O
gross O
total O
excision O
. O

Its O
interaction O
with O
_RARE_ I-GENE
and O
_RARE_ I-GENE
is O
essential O
for O
binding I-GENE
of O
the O
_RARE_ I-GENE
complex I-GENE
to O
MHC I-GENE
- I-GENE
II I-GENE
promoters I-GENE
. O

We O
have O
previously O
mapped O
the O
defect O
in O
_RARE_ I-GENE
/ I-GENE
J O
to O
distal O
mouse I-GENE
Chr O
11 O
, O
distinct O
from O
the O
_RARE_ I-GENE
locus I-GENE
on O
Chr O
6 I-GENE
. O

These O
data O
may O
also O
aid O
in O
the O
localization O
of O
other O
disease O
loci I-GENE
mapped O
to O
this O
region O
, O
including O
the O
gene I-GENE
for O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
syndrome O
and O
a O
murine I-GENE
locus I-GENE
for O
susceptibility I-GENE
to O
_RARE_ I-GENE
- I-GENE
induced O
acute O
lung O
injury O
. O

Copyright O
1998 O
Academic O
Press O
. O

An O
open O
reading O
frame O
encoding O
a O
protein I-GENE
which O
shows O
significant O
similarity O
to O
_RARE_ I-GENE
and O
_RARE_ I-GENE
was O
located O
immediately O
upstream O
of O
the O
_RARE_ I-GENE
R I-GENE
- I-GENE
M I-GENE
operon I-GENE
. O

Identification O
of O
a O
new O
gene I-GENE
in O
the O
streptococcal I-GENE
plasmid O
_RARE_ I-GENE
: O
the O
_RARE_ I-GENE
gene I-GENE
. O

_RARE_ I-GENE
, O
_RARE_ I-GENE
is O
required O
in O
late O
third O
_RARE_ I-GENE
larvae O
for O
appropriate O
developmental O
and O
transcriptional O
responses O
to O
the O
ecdysone O
pulse O
that O
triggers O
_RARE_ I-GENE
formation O
. O

An O
intact O
_RARE_ I-GENE
supply O
is O
essential O
for O
the O
viability O
of O
a O
muscle O
flap O
. O

Examination O
of O
DNA I-GENE
: O
protein I-GENE
binding I-GENE
complexes I-GENE
by O
gel O
- I-GENE
shift O
analysis O
indicated O
that O
nuclear I-GENE
factors I-GENE
from O
both O
proliferative O
and O
growth I-GENE
- I-GENE
arrested O
cells O
bound O
to O
the O
DNA I-GENE
fragment I-GENE
spanning O
- I-GENE
_RARE_ I-GENE
- I-GENE
- I-GENE
_RARE_ I-GENE
bp O
. O

BACKGROUND O
: O
Studies O
in O
lean O
men O
show O
poor O
regulation O
of O
energy O
( O
_RARE_ I-GENE
) O
and O
fat O
balance O
( O
FB O
) O
during O
_RARE_ I-GENE
of O
dietary O
ratios O
of O
fat O
to O
carbohydrate O
. O

_RARE_ I-GENE
_RARE_ I-GENE
was O
observed O
under O
following O
conditions O
: O
( O
1 I-GENE
) O
_RARE_ I-GENE
apnea O
was O
produced O
after O
a O
single O
_RARE_ I-GENE
microinjection O
in O
one O
side O
of O
the O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
( O
5 I-GENE
animals O
). O

A I-GENE
comparative O
analysis O
of O
the O
reported O
_RARE_ I-GENE
- I-GENE
associated I-GENE
malignant O
melanomas O
emphasizes O
the O
_RARE_ I-GENE
of O
our O
case O
in O
the O
_RARE_ I-GENE
character O
of O
the O
melanoma O
, O
its O
_RARE_ I-GENE
and O
the O
_RARE_ I-GENE
of O
invasive O
squamous O
cell O
carcinoma O
. O

RESULTS O
: O
An O
_RARE_ I-GENE
_RARE_ I-GENE
is O
observed O
with O
presence O
of O
type I-GENE
I I-GENE
herpes I-GENE
simplex I-GENE
virus I-GENE
( O
HSV I-GENE
I I-GENE
) O
nucleic O
acids O
in O
the O
recipient O
' O
s O
aqueous O
_RARE_ I-GENE
. O

These O
results O
indicate O
that O
HIV I-GENE
- I-GENE
1 I-GENE
Gag I-GENE
sequences I-GENE
can O
influence O
the O
viral I-GENE
PR I-GENE
- I-GENE
mediated O
processing O
of O
the O
MuLV O
TM I-GENE
Env I-GENE
protein I-GENE
_RARE_ I-GENE
( O
E I-GENE
). O

These O
results O
demonstrate O
a O
specific I-GENE
association O
of O
SIV O
and O
HIV I-GENE
- I-GENE
2 I-GENE
nef I-GENE
, O
but O
not O
HIV I-GENE
- I-GENE
1 I-GENE
nef I-GENE
, O
with O
_RARE_ I-GENE
. O

Competition O
EMSA O
established O
that O
constitutively O
expressed O
nuclear I-GENE
proteins I-GENE
bound O
the O
KCS I-GENE
element I-GENE
selectively O
; O
KCS I-GENE
protein I-GENE
binding I-GENE
activity O
correlated O
with O
promoter I-GENE
activity O
in O
the O
transient O
transfection O
reporter I-GENE
assay O
. O

Mechanism O
of O
interferon I-GENE
action O
: O
identification O
of O
essential O
positions O
within O
the O
novel O
15 O
- I-GENE
base O
- I-GENE
pair O
KCS I-GENE
element I-GENE
required O
for O
transcriptional O
activation O
of O
the O
RNA I-GENE
- I-GENE
dependent I-GENE
protein I-GENE
kinase I-GENE
_RARE_ I-GENE
gene I-GENE
. O

GH I-GENE
failed O
to O
stimulate O
phosphorylation O
or O
activation O
of O
Jun I-GENE
N I-GENE
- I-GENE
terminal I-GENE
kinase I-GENE
under O
the O
conditions O
used O
. O

Expression O
of O
a O
novel O
murine I-GENE
phospholipase I-GENE
D I-GENE
homolog I-GENE
_RARE_ I-GENE
with O
late O
neuronal O
development O
in O
the O
_RARE_ I-GENE
. O

We O
detected O
no O
effect O
of O
_RARE_ I-GENE
_RARE_ I-GENE
, O
either O
alone O
or O
in O
combination O
with O
deletion O
of O
_RARE_ I-GENE
. O

_RARE_ I-GENE
is O
also O
phosphorylated O
, O
and O
its O
mRNA I-GENE
is O
differentially O
spliced O
in O
a O
tissue I-GENE
- I-GENE
specific I-GENE
and O
developmentally O
regulated O
manner O
. O

The O
deduced O
amino O
acid I-GENE
sequence I-GENE
of O
_RARE_ I-GENE
had O
no O
significant O
similarity O
to O
any O
other O
protein I-GENE
, O
but O
it O
had O
a O
proline O
- I-GENE
rich O
domain I-GENE
at O
the O
C I-GENE
- I-GENE
terminal I-GENE
region O
. O

The O
effect O
of O
low O
- I-GENE
profile O
serine I-GENE
substitutions O
in O
the O
_RARE_ I-GENE
loop I-GENE
of O
HIV I-GENE
- I-GENE
1 I-GENE
gp120 I-GENE
IIIB I-GENE
/ I-GENE
_RARE_ I-GENE
on O
the O
_RARE_ I-GENE
of O
the O
envelope I-GENE
protein I-GENE
. O

Transcription O
start O
site I-GENE
mapping O
identified O
the O
presence O
of O
an O
_RARE_ I-GENE
- I-GENE
sensitive O
late O
transcript I-GENE
arising O
from O
a O
_RARE_ I-GENE
motif I-GENE
located O
at O
- I-GENE
_RARE_ I-GENE
nucleotides O
and O
an O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
early I-GENE
transcript I-GENE
_RARE_ I-GENE
from O
a O
_RARE_ I-GENE
motif I-GENE
located O
35 O
nucleotides O
downstream O
to O
a O
TATA I-GENE
box I-GENE
at O
- I-GENE
_RARE_ I-GENE
nucleotides O
, O
with O
respect O
to O
the O
+ I-GENE
1 I-GENE
ATG O
of O
_RARE_ I-GENE
. O

The O
human I-GENE
2 I-GENE
', O
5 I-GENE
'- O
_RARE_ I-GENE
( O
2 I-GENE
- I-GENE
_RARE_ I-GENE
) O
synthetases I-GENE
are O
members O
of O
a O
family I-GENE
interferon I-GENE
( O
IFN I-GENE
)- I-GENE
inducible I-GENE
anti I-GENE
- I-GENE
viral I-GENE
proteins I-GENE
. O

Our O
findings O
demonstrate O
a O
dose O
- I-GENE
dependent I-GENE
blockade O
of O
the O
mechanical O
sensitivity O
caused O
by O
a O
mild O
thermal O
injury O
by O
both O
_RARE_ I-GENE
and O
_RARE_ I-GENE
. O

These O
_RARE_ I-GENE
were O
caused O
by O
contact O
between O
the O
_RARE_ I-GENE
_RARE_ I-GENE
of O
the O
upper O
canine O
and O
the O
P3 I-GENE
during O
_RARE_ I-GENE
( O
canine O
/ I-GENE
_RARE_ I-GENE
complex I-GENE
). O

Low O
_RARE_ I-GENE
_RARE_ I-GENE
, O
however O
, O
could O
be O
caused O
by O
local O
_RARE_ I-GENE
, O
undetectable O
on O
CT I-GENE
or O
MRI O
. O

The O
consequences O
of O
intensive O
swine O
production O
on O
the O
environment O
and O
possible O
solutions O
by O
means O
of O
nutrition O
are O
_RARE_ I-GENE
. O

This O
study O
demonstrates O
that O
alteration O
of O
_RARE_ I-GENE
is O
one O
of O
the O
most O
frequent O
genetic O
abnormalities O
in O
prostate O
cancer O
and O
may O
contribute O
to O
prostate O
_RARE_ I-GENE
. O

The O
pharmacokinetic O
parameters O
which O
_RARE_ I-GENE
predict O
these O
_RARE_ I-GENE
included O
area O
under O
the O
curve O
and O
peak O
plasma I-GENE
level O
. O

A I-GENE
Chinese O
( O
_RARE_ I-GENE
) O
SF I-GENE
- I-GENE
36 O
survey O
form O
was O
developed O
by O
an O
_RARE_ I-GENE
translation I-GENE
process O
. O

However O
, O
the O
use O
of O
cyclosporin O
A I-GENE
is O
associated I-GENE
with O
an O
increased O
prevalence O
of O
hypertension O
in O
kidney O
transplant O
recipients O
. O

PURPOSE O
: O
To O
determine O
the O
effects O
of O
_RARE_ I-GENE
and O
atherosclerosis O
- I-GENE
induced O
chronic O
_RARE_ I-GENE
arterial O
insufficiency O
on O
_RARE_ I-GENE
smooth I-GENE
muscle O
tone O
, O
nitric I-GENE
oxide I-GENE
synthase I-GENE
( O
_RARE_ I-GENE
) O
activity O
and O
_RARE_ I-GENE
tissue I-GENE
synthesis O
of O
_RARE_ I-GENE
_RARE_ I-GENE
. O

Characterization O
of O
the O
regulatory I-GENE
regions O
of O
the O
human I-GENE
aromatase I-GENE
( O
_RARE_ I-GENE
) O
gene I-GENE
involved O
in O
placenta O
- I-GENE
specific I-GENE
expression O
. O

Recombinant I-GENE
_RARE_ I-GENE
was O
stable O
in O
the O
infusion O
pump I-GENE
for O
several O
days O
at O
room O
temperature O
and O
for O
24 O
h O
at O
body O
temperature O
. O

CD4 I-GENE
lymphocyte I-GENE
and O
viral I-GENE
load O
levels O
suggested O
an O
optimal O
response O
to O
_RARE_ I-GENE
therapy O
at O
the O
time O
_RARE_ I-GENE
developed O
. O

( O
1992 O
) O
_RARE_ I-GENE
31 O
, O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
]. O

_RARE_ I-GENE
of O
serum I-GENE
IgE I-GENE
were O
measured O
monthly O
, O
and O
nasal O
IgE I-GENE
was O
measured O
at O
the O
height O
and O
end O
of O
the O
season O
. O

A I-GENE
mutation I-GENE
in O
the O
5 I-GENE
' O
_RARE_ I-GENE
repeat I-GENE
causes O
_RARE_ I-GENE
of O
_RARE_ I-GENE
, O
whereas O
mutations O
in O
the O
3 I-GENE
' O
_RARE_ I-GENE
repeat I-GENE
cause O
the O
accumulation O
of O
two O
novel O
RNAs I-GENE
that O
_RARE_ I-GENE
in O
the O
500 O
- I-GENE
nt O
range O
. O

By O
directly O
interacting I-GENE
with O
both O
_RARE_ I-GENE
and O
tyrosine I-GENE
kinases I-GENE
involved O
in O
regulating O
cell O
growth I-GENE
and O
cytoskeletal O
organization O
, O
_RARE_ I-GENE
could O
coordinate O
membrane I-GENE
remodeling O
events O
with O
these O
processes O
. O

By O
DNase I-GENE
I I-GENE
footprint O
analysis O
of O
the O
_RARE_ I-GENE
element I-GENE
, O
a O
palindrome O
of O
two O
high O
- I-GENE
affinity O
Ets I-GENE
- I-GENE
binding I-GENE
sites I-GENE
( O
_RARE_ I-GENE
) O
was O
identified O
. O

These O
sorting I-GENE
_RARE_ I-GENE
also O
associated I-GENE
with O
the O
long O
isoform I-GENE
of O
the O
leptin I-GENE
receptor I-GENE
but O
not O
with O
the O
short O
and O
medium O
isoforms I-GENE
. O

_RARE_ I-GENE
are O
cis O
- I-GENE
trans O
- I-GENE
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
that O
bind O
to O
and O
are O
inhibited O
by O
the O
_RARE_ I-GENE
cyclosporin O
A I-GENE
( O
CsA O
). O

In O
vitro O
protein I-GENE
retention O
experiments O
in O
which O
_RARE_ I-GENE
_RARE_ I-GENE
were O
precipitated O
resulted O
in O
_RARE_ I-GENE
of O
_RARE_ I-GENE
. O

The O
Ras I-GENE
- I-GENE
related I-GENE
GTPases I-GENE
are O
small I-GENE
, O
20 O
- I-GENE
to O
25 O
- I-GENE
kDa I-GENE
proteins I-GENE
which O
cycle O
between O
an O
inactive O
GDP I-GENE
- I-GENE
bound O
form O
and O
an O
active O
GTP I-GENE
- I-GENE
bound O
state O
. O

To O
modulate O
transcription I-GENE
, O
regulatory I-GENE
factors I-GENE
_RARE_ I-GENE
with O
basal O
transcription I-GENE
factors I-GENE
and O
/ I-GENE
or O
RNA I-GENE
polymerases I-GENE
in O
a O
variety O
of O
ways O
. O

_RARE_ I-GENE
_RARE_ I-GENE
was O
_RARE_ I-GENE
detected O
interacting I-GENE
with O
assembled O
_RARE_ I-GENE
in O
RNA I-GENE
polymerase I-GENE
in O
mammalian I-GENE
cells O
. O

In O
this O
study O
, O
rabbits O
were O
used O
to O
evaluate O
the O
_RARE_ I-GENE
wound O
reaction O
with O
_RARE_ I-GENE
or O
_RARE_ I-GENE
in O
the O
_RARE_ I-GENE
flap O
1 I-GENE
, O
4 I-GENE
, O
7 O
, O
14 O
and O
28 O
days O
after O
_RARE_ I-GENE
surgery O
with O
or O
without O
the O
use O
of O
_RARE_ I-GENE
- I-GENE
C I-GENE
. O

The O
mapping O
was O
completed O
with O
Southern O
blotting O
and O
restriction I-GENE
analysis O
. O

The O
_RARE_ I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
), O
the O
extracellular I-GENE
_RARE_ I-GENE
that O
_RARE_ I-GENE
the O
oocyte O
, O
is O
well O
known O
to O
mediate O
homologous O
_RARE_ I-GENE
interaction O
. O

_RARE_ I-GENE
use O
of O
continuous O
subcutaneous O
infusion O
of O
recombinant I-GENE
human I-GENE
erythropoietin I-GENE
in O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
patients O
with O
diabetic O
nephropathy O
. O

Although O
pathological O
thyroid I-GENE
function O
is O
related I-GENE
to O
changes O
in O
energy O
expenditure O
and O
body O
composition O
, O
its O
possible O
influence O
on O
leptin I-GENE
levels O
remains O
to O
be O
determined O
. O

These O
cognitive O
deficits O
were O
prevented O
in O
animals O
treated O
with O
MK O
- I-GENE
801 O
during O
SE O
. O

Here O
we O
demonstrate O
that O
the O
mechanism O
of O
activation O
of O
HIF I-GENE
- I-GENE
1alpha I-GENE
is O
a O
multi I-GENE
- I-GENE
step O
process O
which O
includes O
hypoxia O
- I-GENE
dependent I-GENE
nuclear I-GENE
import O
and O
activation O
( O
derepression O
) O
of O
the O
transactivation O
domain I-GENE
, O
resulting O
in O
recruitment O
of O
the O
CREB I-GENE
- I-GENE
binding I-GENE
protein I-GENE
( O
CBP I-GENE
)/ O
p300 I-GENE
coactivator I-GENE
. O

Thus O
, O
hypoxia O
- I-GENE
inducible I-GENE
nuclear I-GENE
import O
and O
transactivation O
by O
recruitment O
of O
CBP I-GENE
can O
be O
functionally O
separated O
from O
one O
another O
and O
play O
critical O
roles O
in O
signal I-GENE
transduction O
by O
HIF I-GENE
- I-GENE
1alpha I-GENE
. O

The O
rat I-GENE
_RARE_ I-GENE
C I-GENE
gene I-GENE
encodes O
a O
_RARE_ I-GENE
enzyme I-GENE
strongly O
expressed O
in O
adult O
brain O
. O

A I-GENE
synergistic O
effect O
on O
_RARE_ I-GENE
promoter I-GENE
activity O
was O
observed O
at O
high O
concentrations O
of O
Sp1 I-GENE
. O

_RARE_ I-GENE
- I-GENE
binding I-GENE
domain I-GENE
and O
amino O
acid I-GENE
residues O
involved O
in O
_RARE_ I-GENE
binding I-GENE
. O

Western O
analyses O
with O
antisera O
raised O
against O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
1 I-GENE
peptides I-GENE
show O
that O
the O
N I-GENE
- I-GENE
terminal I-GENE
region O
of O
the O
predicted O
open O
reading O
frame O
is O
present O
only O
in O
the O
larger O
size O
proteins I-GENE
( O
i O
. O
e O
. O

_RARE_ I-GENE
sperm O
motility O
is O
regulated O
by O
a O
cascade O
of O
cAMP I-GENE
- I-GENE
dependent I-GENE
protein I-GENE
phosphorylation O
events O
mediated O
by O
protein I-GENE
kinase I-GENE
A I-GENE
. O

In O
this O
paper O
, O
we O
show O
that O
, O
like I-GENE
_RARE_ I-GENE
, O
the O
expression O
of O
the O
_RARE_ I-GENE
gene I-GENE
in O
S I-GENE
. O
cerevisiae I-GENE
is O
induced O
by O
the O
addition O
of O
branched I-GENE
- I-GENE
chain I-GENE
amino O
acids O
to O
the O
medium O
. O

Effect O
of O
_RARE_ I-GENE
nutritional O
products I-GENE
_RARE_ I-GENE
in O
carbohydrate O
and O
fat O
on O
indices O
of O
carbohydrate O
and O
lipid O
metabolism O
in O
patients O
with O
_RARE_ I-GENE
. O

Low O
- I-GENE
grade O
gastric O
_RARE_ I-GENE
lymphoma O
and O
_RARE_ I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
_RARE_ I-GENE

These O
studies O
support O
the O
view O
that O
HMG I-GENE
I I-GENE
( O
Y I-GENE
) O
is O
an O
important O
cofactor I-GENE
for O
HLA I-GENE
- I-GENE
_RARE_ I-GENE
gene I-GENE
activation O
by O
Oct I-GENE
- I-GENE
2A I-GENE
and O
provide O
_RARE_ I-GENE
into O
its O
mechanism O
of O
action O
. O

In O
contrast O
to O
hemodynamic O
and O
histopathological O
predictors O
of O
survival O
, O
vWF I-GENE
: O
Ag I-GENE
does O
not O
require O
invasive O
techniques O
to O
be O
determined O
. O

CONCLUSION O
: O
We O
were O
unable O
to O
identify O
features O
of O
disease O
likely O
to O
be O
associated I-GENE
with O
a O
clinically O
useful O
response O
to O
inhaled O
NO O
therapy O
using O
the O
parameters O
studied O
. O

We O
find O
that O
BCL I-GENE
- I-GENE
6 I-GENE
POZ I-GENE
domain I-GENE
mutations O
that O
disrupt O
the O
interaction O
with O
N I-GENE
- I-GENE
_RARE_ I-GENE
and O
SMRT I-GENE
no O
longer O
repress O
transcription I-GENE
. O

Partial O
characterization O
of O
the O
active O
site I-GENE
human I-GENE
platelet I-GENE
cAMP I-GENE
phosphodiesterase I-GENE
, O
_RARE_ I-GENE
, O
by O
site I-GENE
- I-GENE
directed O
mutagenesis O
. O

This O
core I-GENE
sequence I-GENE
, O
along O
with O
additional O
nonspecific O
downstream O
nucleotides O
, O
is O
sufficient O
for O
partial O
suppression O
of O
spliceosome O
assembly O
and O
splicing O
of O
BPV I-GENE
- I-GENE
1 I-GENE
pre I-GENE
- I-GENE
mRNAs I-GENE
. O

_RARE_ I-GENE
- I-GENE
expression O
of O
the O
cofactor I-GENE
p300 I-GENE
, O
which O
functions O
as O
a O
coactivator I-GENE
of O
myoD I-GENE
- I-GENE
mediated O
transcription I-GENE
, O
_RARE_ I-GENE
repression O
by O
COUP I-GENE
- I-GENE
TF I-GENE
II I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
hepatitis I-GENE
and O
C4 I-GENE
deficiency O

No O
mutations O
were O
found O
in O
follicular O
_RARE_ I-GENE
. O

Since O
glutathione I-GENE
peroxidase I-GENE
( O
_RARE_ I-GENE
) O
and O
superoxide I-GENE
dismutase I-GENE
( O
SOD I-GENE
) O
play O
a O
significant O
role O
in O
erythrocyte I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
, O
it O
is O
very O
important O
to O
determine O
their O
activity O
in O
_RARE_ I-GENE
exposed O
workers O
. O

_RARE_ I-GENE
_RARE_ I-GENE
proteins I-GENE
( O
_RARE_ I-GENE
) O
are O
_RARE_ I-GENE
- I-GENE
type I-GENE
zinc I-GENE
finger I-GENE
proteins I-GENE
that O
mediate O
virion O
RNA I-GENE
binding I-GENE
activities O
associated I-GENE
with O
retrovirus O
assembly O
and O
genomic O
RNA I-GENE
_RARE_ I-GENE
. O

The O
Schizosaccharomyces I-GENE
pombe I-GENE
_RARE_ I-GENE
+ I-GENE
cell O
cycle O
checkpoint I-GENE
control O
gene I-GENE
is O
required O
for O
S I-GENE
- I-GENE
phase O
and O
G2 I-GENE
/ I-GENE
M I-GENE
arrest O
in O
response O
to O
both O
DNA I-GENE
damage O
and O
incomplete O
DNA I-GENE
replication O
. O

It O
is O
now O
well O
established O
that O
progression O
through O
the O
eukaryotic I-GENE
cell O
cycle O
is O
controlled O
by O
_RARE_ I-GENE
in O
the O
activity O
of O
cyclin I-GENE
- I-GENE
dependent I-GENE
kinases I-GENE
( O
_RARE_ I-GENE
). O

_RARE_ I-GENE
genetic O
_RARE_ I-GENE
for O
inhibition O
of O
cyclin I-GENE
/ I-GENE
CDK I-GENE
function O
were O
characterized O
using O
the O
E I-GENE
. O
coli I-GENE
neo I-GENE
and O
yeast I-GENE
LEU2 I-GENE
genes I-GENE
. O

The O
hematopoietic I-GENE
colony I-GENE
- I-GENE
stimulating I-GENE
factors I-GENE
( O
CSF I-GENE
) O
have O
been O
introduced O
into O
clinical O
practice O
as O
additional O
_RARE_ I-GENE
measures O
that O
can O
reduce O
the O
incidence O
of O
infectious O
complications O
in O
patients O
with O
cancer O
and O
neutropenia O
. O

All O
injections O
of O
CSF I-GENE
were O
given O
after O
the O
initiation I-GENE
of O
neutropenia O
and O
continued O
until O
the O
occurrence O
of O
an O
absolute O
neutrophil I-GENE
recovery O
. O
_RARE_ I-GENE
GM I-GENE
- I-GENE
CSF I-GENE
and O
_RARE_ I-GENE
G I-GENE
- I-GENE
CSF I-GENE
, O
administered O
once O
daily O
at O
the O
250 O
microg O
m I-GENE
(- O
2 I-GENE
) O
day O
(- O
1 I-GENE
) O
and O
5 I-GENE
microg O
kg O
(- O
1 I-GENE
) O
day O
(- O
1 I-GENE
) O
level O
, O
were O
effective O
in O
increasing O
the O
absolute O
neutrophil I-GENE
count O
and O
neutrophil I-GENE
function O
, O
as O
measured O
by O
an O
automated O
_RARE_ I-GENE
system O
. O

Expression O
of O
lacZ I-GENE
from O
the O
promoter I-GENE
of O
the O
Escherichia I-GENE
coli I-GENE
_RARE_ I-GENE
operon I-GENE
cloned O
into O
vectors O
carrying O
the O
_RARE_ I-GENE
_RARE_ I-GENE
- I-GENE
lac I-GENE
fusion I-GENE
. O

We O
evaluated O
regional O
right O
ventricular O
wall O
motion O
during O
_RARE_ I-GENE
in O
patients O
with O
surgically O
_RARE_ I-GENE
_RARE_ I-GENE
of O
_RARE_ I-GENE
( O
TOF O
) O
using O
color O
_RARE_ I-GENE
imaging O
. O

RT I-GENE
- I-GENE
PCR O
analysis O
showed O
that O
PLP I-GENE
- I-GENE
H I-GENE
as O
well O
as O
PLP I-GENE
- I-GENE
C I-GENE
and O
PLP I-GENE
- I-GENE
D I-GENE
are O
expressed O
in O
all O
rat I-GENE
strains O
examined O
, O
confirming O
that O
PLP I-GENE
diversity O
is O
not O
due O
to O
strain O
differences O
. O

Molecular O
cloning O
and O
characterization O
of O
a O
new O
member O
of O
the O
rat I-GENE
placental I-GENE
prolactin I-GENE
( O
PRL I-GENE
) O
family I-GENE
, O
PRL I-GENE
- I-GENE
like I-GENE
protein I-GENE
H I-GENE
. O

Interestingly O
, O
we O
find O
that O
the O
interaction O
between O
Tat I-GENE
and O
_RARE_ I-GENE
requires O
zinc I-GENE
as O
well O
as O
essential O
cysteine I-GENE
residues O
in O
both O
proteins I-GENE
. O

Thus O
, O
we O
have O
identified O
an O
activation O
target O
of O
a O
human I-GENE
activator I-GENE
, O
Oct I-GENE
- I-GENE
1 I-GENE
, O
within O
its O
cognate I-GENE
basal O
transcription I-GENE
complex I-GENE
. O

During O
early I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
protein I-GENE
is O
restricted O
to O
ventral O
column O
_RARE_ I-GENE
and O
neuroblasts O
; O
later O
it O
is O
detected O
in O
a O
complex I-GENE
pattern O
of O
neurons O
. O

The O
repression O
domain I-GENE
, O
and O
indeed O
the O
entire O
_RARE_ I-GENE
protein I-GENE
, O
is O
highly O
conserved O
, O
as O
shown O
by O
the O
sequence I-GENE
of O
the O
_RARE_ I-GENE
functional O
homolog I-GENE
from O
the O
yeast I-GENE
_RARE_ I-GENE
lactis O
and O
by O
database O
_RARE_ I-GENE
. O

The O
_RARE_ I-GENE
alone O
has O
the O
high O
affinity O
hormone I-GENE
binding I-GENE
site I-GENE
but O
is O
not O
capable O
of O
generating O
hormonal O
signal I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
, O
a O
potent O
transcriptional O
inhibitor I-GENE
of O
the O
viral I-GENE
LTR I-GENE
, O
abrogated O
the O
cytokine O
responses O
in O
both O
U1 I-GENE
and O
_RARE_ I-GENE
- I-GENE
2 I-GENE
cells O
, O
suggesting O
a O
common O
TNF I-GENE
- I-GENE
alpha I-GENE
- I-GENE
mediated O
transcriptional O
mechanism O
in O
these O
cell O
types O
despite O
their O
different O
modes O
of O
provirus O
latency O
. O

Furthermore O
, O
synergistic O
activation O
of O
ERK2 I-GENE
occurred O
in O
the O
absence O
of O
changes O
in O
intracellular O
Ca2 I-GENE
+, I-GENE
and O
was O
not O
blocked O
by O
inhibition O
of O
protein I-GENE
kinase I-GENE
C I-GENE
activity O
and O
represents O
a O
separate O
pathway O
by O
which O
_RARE_ I-GENE
regulates O
B I-GENE
cell O
function O
. O

The O
_RARE_ I-GENE
_RARE_ I-GENE
cyst O
is O
a O
very O
rare O
site I-GENE
. O

Biochemical O
analysis O
reveals O
that O
_RARE_ I-GENE
is O
a O
nuclear I-GENE
protein I-GENE
containing O
two O
transcriptional O
repressor I-GENE
domains I-GENE
, O
R1 I-GENE
and O
R2 I-GENE
. O

However O
, O
the O
_RARE_ I-GENE
group O
showed O
inferior O
gross O
motor O
performance O
on O
the O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
Test O
of O
_RARE_ I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
_RARE_ I-GENE
). O

The O
results O
_RARE_ I-GENE
the O
possibility O
that O
pH O
induced O
post O
- I-GENE
translational O
modifications O
of O
_RARE_ I-GENE
are O
involved O
in O
events O
that O
_RARE_ I-GENE
cell O
proliferation O
and O
induce O
differentiation O
in O
Dictyostelium O
. O

We O
report O
here O
that O
, O
for O
a O
constant O
amount O
of O
transfected O
DNA I-GENE
, O
the O
level O
of O
chloramphenicol I-GENE
acetyltransferase I-GENE
( O
CAT I-GENE
) O
mRNA I-GENE
is O
increased O
in O
_RARE_ I-GENE
- I-GENE
expressing O
cells O
using O
either O
HIV I-GENE
- I-GENE
1 I-GENE
or O
a O
murine I-GENE
leukemia I-GENE
virus I-GENE
( O
_RARE_ I-GENE
) O
_RARE_ I-GENE
- I-GENE
3 I-GENE
LTR I-GENE
- I-GENE
CAT I-GENE
reporter I-GENE
construct I-GENE
. O

We O
identified O
_RARE_ I-GENE
mutations O
in O
11 O
of O
these O
unrelated O
_RARE_ I-GENE
- I-GENE
like I-GENE
individuals O
who O
carry O
a O
single O
copy O
of O
_RARE_ I-GENE
: O
these O
include O
two O
frameshift O
mutations O
( O
_RARE_ I-GENE
and O
_RARE_ I-GENE
) O
and O
three O
missense O
mutations O
( O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
). O

The O
decrease O
of O
TNF I-GENE
receptors I-GENE
by O
IL I-GENE
- I-GENE
4 I-GENE
was O
accompanied O
by O
down O
- I-GENE
regulation O
of O
TNF I-GENE
- I-GENE
induced O
activities O
, O
including O
cytotoxicity O
, O
_RARE_ I-GENE
- I-GENE
3 I-GENE
activation O
, O
NF I-GENE
- I-GENE
kappaB I-GENE
and O
AP I-GENE
- I-GENE
1 I-GENE
activation O
, O
and O
c I-GENE
- I-GENE
Jun I-GENE
N I-GENE
- I-GENE
terminal I-GENE
kinase I-GENE
induction O
. O

Type O
2 I-GENE
deiodinase I-GENE
( O
D2 I-GENE
) O
catalyzes O
the O
5 I-GENE
'- O
_RARE_ I-GENE
of O
thyroxine O
to O
form O
3 I-GENE
, O
5 I-GENE
, O
3 I-GENE
'- O
_RARE_ I-GENE
. O

We O
have O
identified O
two O
overlapping O
expressed O
sequence I-GENE
tag O
clones O
, O
which O
contain O
the O
missing O
4 I-GENE
. O
4 I-GENE
- I-GENE
kb O
3 I-GENE
'- O
UTR I-GENE
of O
the O
human I-GENE
D2 I-GENE
( O
_RARE_ I-GENE
) O
cDNA I-GENE
. O

Biol O
. O

Here O
we O
have O
investigated O
the O
structural O
requirements O
and O
consequences O
of O
regulatory I-GENE
phosphorylation O
for O
the O
interaction O
between O
c I-GENE
- I-GENE
Jun I-GENE
and O
JNK I-GENE
in O
vivo O
. O

P I-GENE
- I-GENE
_RARE_ I-GENE
, O
a O
novel O
protein I-GENE
that O
interacts O
with O
the O
cytosolic I-GENE
domain I-GENE
of O
_RARE_ I-GENE
alpha I-GENE
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
, O
is O
associated I-GENE
with O
_RARE_ I-GENE
. O

_RARE_ I-GENE
of O
_RARE_ I-GENE
revealed O
a O
cytoplasmic I-GENE
distribution O
and O
cell O
fractionation O
studies O
showed O
that O
a O
significant O
fraction O
of O
_RARE_ I-GENE
was O
recovered O
in O
a O
_RARE_ I-GENE
fraction O
of O
the O
cytosolic I-GENE
material O
. O

_RARE_ I-GENE
activation O
of O
c I-GENE
- I-GENE
Jun I-GENE
N I-GENE
- I-GENE
terminal I-GENE
kinase I-GENE
/ I-GENE
stress O
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
( O
JNK I-GENE
/ I-GENE
SAPK I-GENE
). O

Here O
we O
report O
the O
full I-GENE
- I-GENE
length I-GENE
coding O
cDNA I-GENE
sequence I-GENE
of O
the O
mouse I-GENE
homologue I-GENE
of O
_RARE_ I-GENE
. O

The O
method O
also O
_RARE_ I-GENE
_RARE_ I-GENE
of O
venous O
_RARE_ I-GENE
and O
_RARE_ I-GENE
about O
asymmetric O
_RARE_ I-GENE
transfer I-GENE
effects O
. O

Consistent O
with O
this O
, O
purified O
_RARE_ I-GENE
phosphorylated O
core I-GENE
_RARE_ I-GENE
H3 I-GENE
, O
_RARE_ I-GENE
and O
H4 I-GENE
as O
exogenous O
substrates O
and O
endogenous I-GENE
histone I-GENE
H3 I-GENE
in O
kinase I-GENE
assays O
with O
nuclear I-GENE
extracts O
. O

In O
this O
study O
we O
provide O
evidence O
that O
B I-GENE
- I-GENE
Myb I-GENE
is O
a O
direct O
physiological O
target O
for O
cyclin I-GENE
A I-GENE
/ I-GENE
Cdk2 I-GENE
. O

Neither O
Ha I-GENE
- I-GENE
Ras I-GENE
( O
_RARE_ I-GENE
, O
_RARE_ I-GENE
) O
( O
Ha I-GENE
- I-GENE
_RARE_ I-GENE
), O
which O
activates O
the O
_RARE_ I-GENE
signaling O
pathway O
, O
nor O
Ha I-GENE
- I-GENE
Ras I-GENE
( O
_RARE_ I-GENE
, O
_RARE_ I-GENE
) O
( O
Ha I-GENE
- I-GENE
_RARE_ I-GENE
), O
which O
stimulates O
the O
_RARE_ I-GENE
pathway O
, O
did O
not O
have O
significant O
effects O
on O
factor I-GENE
- I-GENE
withdrawal O
apoptosis O
of O
myeloid O
cells O
. O

We O
have O
isolated O
a O
novel O
human I-GENE
cyclin I-GENE
, O
cyclin I-GENE
E2 I-GENE
, O
that O
contains O
significant O
homology I-GENE
to O
cyclin I-GENE
E I-GENE
. O

Initial O
experience O
with O
the O
new O
technology O
indicates O
that O
_RARE_ I-GENE
is O
an O
alternative O
to O
other O
methods O
such O
as O
CT I-GENE
and O
MRI O
. O

The O
dopamine I-GENE
_RARE_ I-GENE
receptor I-GENE
as O
well O
as O
many O
other O
_RARE_ I-GENE
receptors I-GENE
contain O
several O
putative O
SH3 I-GENE
binding I-GENE
domains I-GENE
. O

The O
highly O
_RARE_ I-GENE
42 O
- I-GENE
residue O
form O
of O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
is O
the O
first O
species O
to O
be O
_RARE_ I-GENE
in O
both O
_RARE_ I-GENE
and O
familial O
AD O
. O

This O
model O
is O
supported O
by O
experiments O
showing O
that O
_RARE_ I-GENE
associates O
with O
the O
N I-GENE
- I-GENE
terminal I-GENE
regulatory I-GENE
domain I-GENE
of O
Wee1 I-GENE
in O
cell O
lysates O
and O
phosphorylates O
Wee1 I-GENE
in O
vitro O
. O

Schizosaccharomyces I-GENE
pombe I-GENE
cells O
respond O
to O
nutrient O
deprivation O
by O
altering O
G2 I-GENE
/ I-GENE
M I-GENE
cell O
size O
control O
. O

A I-GENE
- I-GENE
_RARE_ I-GENE
functioned O
best O
when O
positioned O
close O
to O
the O
- I-GENE
35 O
hexamer O
rather O
than O
one O
helical O
turn I-GENE
_RARE_ I-GENE
upstream O
, O
similar O
to O
the O
positioning O
optimal O
for O
_RARE_ I-GENE
element I-GENE
function O
. O

_RARE_ I-GENE
phosphorylation O
increased O
upon O
_RARE_ I-GENE
of O
_RARE_ I-GENE
29 O
. O
1 I-GENE
cells O
to O
fibronectin I-GENE
and O
to O
_RARE_ I-GENE
_RARE_ I-GENE
cells O
. O

Raf I-GENE
is O
a O
key O
serine I-GENE
- I-GENE
threonine I-GENE
protein I-GENE
kinase I-GENE
which O
participates O
in O
the O
transmission O
of O
growth I-GENE
, O
anti I-GENE
- I-GENE
apoptotic O
and O
differentiation O
_RARE_ I-GENE
. O

The O
US O
National O
Institute O
on O
_RARE_ I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
recognizes O
two O
forms O
of O
_RARE_ I-GENE
drinking O
: O
' O
_RARE_ I-GENE
alcohol O
_RARE_ I-GENE
', O
a O
_RARE_ I-GENE
problem O
, O
and O
' O
alcohol O
dependence O
', O
a O
true O
medical O
disorder O
, O
which O
includes O
a O
genetic O
component O
, O
that O
can O
be O
_RARE_ I-GENE
understood O
and O
_RARE_ I-GENE
treated O
. O

_RARE_ I-GENE
was O
extracted O
from O
the O
skin O
, O
and O
the O
lack O
of O
type I-GENE
III I-GENE
collagen I-GENE
was O
determined O
by O
means O
of O
sodium O
dodecyl O
sulfate I-GENE
- I-GENE
polyacrylamide O
gel O
electrophoresis O
( O
SDS O
- I-GENE
PAGE O
). O

RESULTS O
: O
During O
the O
7 O
- I-GENE
year O
period O
, O
10 O
, O
_RARE_ I-GENE
symptomatic O
duodenal O
ulcer O
diseases O
were O
diagnosed O
. O

RESULTS O
: O
Significant O
changes O
from O
pretreatment O
to O
_RARE_ I-GENE
were O
observed O
( O
p O
< O
0 O
. O
001 O
). O

In O
turn I-GENE
, O
assembly O
of O
this O
complex I-GENE
mediates O
the O
enzymatic O
activation O
of O
the O
p21 I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
1 I-GENE
and O
_RARE_ I-GENE
actin I-GENE
_RARE_ I-GENE
. O

The O
tip O
of O
the O
_RARE_ I-GENE
caused O
a O
_RARE_ I-GENE
of O
the O
posterior O
stomach O
wall O
, O
leading O
to O
death O
. O

_RARE_ I-GENE
disease O
virus I-GENE
( O
_RARE_ I-GENE
) O
is O
a O
newly O
identified O
bovine I-GENE
_RARE_ I-GENE
that O
is O
closely O
related I-GENE
to O
the O
bovine I-GENE
immunodeficiency I-GENE
virus I-GENE
( O
_RARE_ I-GENE
). O

Approximately O
50 O
% O
of O
the O
residues O
are O
conserved O
among O
all O
three O
sequences I-GENE
, O
yet O
all O
three O
viruses O
have O
retained O
response O
elements O
for O
glucocorticoids O
, O
two O
_RARE_ I-GENE
conserved O
CCAAT I-GENE
boxes O
, O
and O
_RARE_ I-GENE
conserved O
TATA I-GENE
boxes O
. O

_RARE_ I-GENE
is O
a O
highly O
basic I-GENE
protein I-GENE
that O
belongs O
to O
a O
family I-GENE
of O
putative O
RNA I-GENE
- I-GENE
binding I-GENE
proteins I-GENE
. O

This O
survey O
included O
_RARE_ I-GENE
randomly O
selected O
_RARE_ I-GENE
above O
18 O
years O
of O
age O
who O
received O
the O
European O
Organization O
for O
Research O
and O
Treatment O
of O
Cancer O
_RARE_ I-GENE
_RARE_ I-GENE
of O
_RARE_ I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
(+ O
3 I-GENE
) O
by O
_RARE_ I-GENE
. O

During O
presentation O
of O
_RARE_ I-GENE
facial O
_RARE_ I-GENE
, O
we O
detected O
a O
signal I-GENE
increase O
predominantly O
in O
the O
left O
anterior O
_RARE_ I-GENE
gyrus O
, O
bilateral O
posterior O
_RARE_ I-GENE
_RARE_ I-GENE
, O
medial O
frontal O
cortex O
and O
right O
_RARE_ I-GENE
gyrus O
, O
brain O
regions O
previously O
implicated O
in O
_RARE_ I-GENE
and O
_RARE_ I-GENE
processing O
tasks O
. O

_RARE_ I-GENE
- I-GENE
regulation O
of O
IRS I-GENE
- I-GENE
1 I-GENE
is O
linked O
to O
its O
serine I-GENE
phosphorylation O
dependent I-GENE
on O
PI I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
activity O
and O
appears O
required O
for O
differentiation O
to O
occur O
, O
as O
IRS I-GENE
- I-GENE
1 I-GENE
is O
not O
modified O
and O
_RARE_ I-GENE
to O
accumulate O
in O
a O
_RARE_ I-GENE
_RARE_ I-GENE
cell O
line O
. O

This O
study O
_RARE_ I-GENE
the O
mammalian I-GENE
two O
- I-GENE
hybrid O
system O
to O
examine O
the O
role O
of O
ligand O
in O
the O
dimerization O
of O
human I-GENE
progesterone I-GENE
receptor I-GENE
( O
_RARE_ I-GENE
). O

One O
of O
its O
unique O
features O
appears O
to O
be O
the O
unusually O
short O
5 I-GENE
'- O
untranslated O
regions O
( O
UTR I-GENE
) O
( O
1 I-GENE
- I-GENE
6 I-GENE
nucleotides O
( O
_RARE_ I-GENE
)) O
and O
the O
apparent O
absence O
of O
5 I-GENE
'- O
cap I-GENE
structures O
from O
its O
mRNAs I-GENE
. O

The O
gene I-GENE
encoding O
human I-GENE
tissue I-GENE
- I-GENE
type I-GENE
plasminogen I-GENE
activator I-GENE
( O
t I-GENE
- I-GENE
PA I-GENE
) O
is O
regulated O
in O
a O
cell O
- I-GENE
type I-GENE
- I-GENE
specific I-GENE
manner O
. O

Both O
the O
presence O
of O
arginine I-GENE
and O
_RARE_ I-GENE
are O
needed O
to O
_RARE_ I-GENE
induction O
of O
the O
pathway O
. O

Competition O
with O
a O
putative O
MADS I-GENE
box I-GENE
consensus I-GENE
binding I-GENE
site I-GENE
from O
the O
promoter I-GENE
of O
the O
_RARE_ I-GENE
regulated O
_RARE_ I-GENE
- I-GENE
phase O
- I-GENE
specific I-GENE
gene I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
and O
the O
human I-GENE
MADS I-GENE
box I-GENE
consensus I-GENE
binding I-GENE
site I-GENE
for O
serum I-GENE
response O
factor I-GENE
demonstrated O
that O
one O
of O
the O
three O
complexes I-GENE
formed O
was O
specific I-GENE
to O
the O
_RARE_ I-GENE
sequence I-GENE
. O

The O
human I-GENE
SHBG I-GENE
proximal I-GENE
promoter I-GENE
was O
analyzed O
by O
DNase I-GENE
I I-GENE
footprinting O
, O
and O
the O
functional O
significance O
of O
6 I-GENE
_RARE_ I-GENE
regions O
( O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
) O
within O
the O
proximal I-GENE
promoter I-GENE
was O
studied O
in O
human I-GENE
HepG2 O
_RARE_ I-GENE
cells O
. O

In O
vitro O
translation I-GENE
and O
in O
vivo O
_RARE_ I-GENE
profile O
analysis O
indicated O
that O
transcripts I-GENE
C I-GENE
and O
E I-GENE
were O
translated O
with O
similar O
translational O
_RARE_ I-GENE
that O
are O
substantially O
greater O
than O
that O
of O
transcript I-GENE
D I-GENE
, O
suggesting O
that O
5 I-GENE
'- O
untranslated O
regions O
play O
a O
role O
in O
translational O
control O
. O

We O
have O
introduced O
a O
mutation I-GENE
( O
_RARE_ I-GENE
--> I-GENE
Asn O
) O
into O
this O
domain I-GENE
of O
p190 I-GENE
that O
decreased O
its O
ability O
to O
bind O
guanine I-GENE
nucleotide I-GENE
when O
expressed O
as O
a O
hemagglutinin I-GENE
( O
HA I-GENE
)- I-GENE
tagged O
protein I-GENE
in O
COS O
cells O
. O

Wild I-GENE
type I-GENE
HA I-GENE
- I-GENE
p190 I-GENE
induced O
a O
phenotype O
of O
_RARE_ I-GENE
cells O
with O
long O
, O
_RARE_ I-GENE
_RARE_ I-GENE
similar O
to O
that O
seen O
when O
Rho I-GENE
function O
is O
disrupted O
by O
ADP I-GENE
- I-GENE
_RARE_ I-GENE
. O

We O
_RARE_ I-GENE
that O
_RARE_ I-GENE
- I-GENE
associated I-GENE
vasculitis O
is O
another O
important O
complication O
of O
RA O
. O

The O
downstream O
, O
TATA I-GENE
- I-GENE
less O
promoter I-GENE
has O
high O
G I-GENE
+ I-GENE
C I-GENE
content O
, O
and O
exon O
1b I-GENE
_RARE_ I-GENE
among O
abundantly O
expressed O
mRNA I-GENE
species O
. O

Although O
we O
predicted O
that O
overexpression O
of O
the O
COOH O
- I-GENE
terminal I-GENE
domains I-GENE
, O
which O
were O
thought O
to O
be O
involved O
in O
the O
regulation O
of O
SREBP I-GENE
processing O
, O
would O
result O
in O
disruption O
of O
the O
SREBP I-GENE
- I-GENE
dependent I-GENE
transcriptional O
regulation O
of O
several O
genes I-GENE
, O
the O
mRNA I-GENE
levels O
for O
3 I-GENE
- I-GENE
hydroxy I-GENE
- I-GENE
3 I-GENE
- I-GENE
_RARE_ I-GENE
coenzyme I-GENE
A I-GENE
( O
HMG I-GENE
CoA I-GENE
) O
synthase I-GENE
in O
these O
two O
cell O
lines O
were O
regulated O
in O
a O
sterol I-GENE
- I-GENE
dependent I-GENE
manner O
. O

_RARE_ I-GENE
matter O
intake O
, O
apparent O
nutrient O
_RARE_ I-GENE
, O
serum I-GENE
chemistry O
profiles O
, O
_RARE_ I-GENE
concentrations O
, O
and O
_RARE_ I-GENE
of O
_RARE_ I-GENE
in O
tissues O
were O
evaluated O
. O

However O
, O
no O
studies O
have O
been O
conducted O
to O
further O
investigate O
this O
potentially O
hazardous O
effect O
of O
lidocaine O
. O

E I-GENE
., O
_RARE_ I-GENE
, O
J O
. O

_RARE_ I-GENE
is O
constitutively O
nuclear I-GENE
in O
a O
_RARE_ I-GENE
mutant I-GENE
, O
and O
_RARE_ I-GENE
binds O
to O
a O
nuclear I-GENE
export O
sequence I-GENE
( O
_RARE_ I-GENE
)- I-GENE
like I-GENE
sequence I-GENE
in O
_RARE_ I-GENE
in O
the O
presence O
of O
_RARE_ I-GENE
. O

Mean O
intake O
of O
vitamin O
A I-GENE
_RARE_ I-GENE
to O
1 I-GENE
. O
1 I-GENE
and O
0 O
. O
9 O
mg O
_RARE_ I-GENE
/ I-GENE
day O
for O
men O
and O
women O
, O
respectively O
; O
the O
_RARE_ I-GENE
of O
meat O
, O
_RARE_ I-GENE
and O
_RARE_ I-GENE
, O
_RARE_ I-GENE
and O
_RARE_ I-GENE
products I-GENE
to O
total O
intake O
were O
35 O
%, O
24 O
%, O
16 O
%, O
and O
16 O
%, O
respectively O
. O

Also O
, O
the O
amplitude O
of O
the O
_RARE_ I-GENE
potentials O
( O
_RARE_ I-GENE
+ I-GENE
O2 O
+ I-GENE
_RARE_ I-GENE
+ I-GENE
_RARE_ I-GENE
) O
was O
significantly O
reduced O
in O
the O
early I-GENE
postoperative O
period O
. O

Furthermore O
, O
_RARE_ I-GENE
overexpression O
results O
in O
enhanced O
expression O
of O
the O
proto I-GENE
- I-GENE
oncogenes I-GENE
c I-GENE
- I-GENE
jun I-GENE
and O
c I-GENE
- I-GENE
fos I-GENE
. O

The O
yeast I-GENE
_RARE_ I-GENE
gene I-GENE
, O
identified O
by O
endoplasmic O
reticulum O
protein I-GENE
localization O
mutations O
, O
encodes O
cis O
- I-GENE
_RARE_ I-GENE
, O
a O
key O
enzyme I-GENE
in O
_RARE_ I-GENE
synthesis O
. O

The O
yeast I-GENE
retrotransposon I-GENE
_RARE_ I-GENE
preferentially O
_RARE_ I-GENE
into O
regions O
of O
silent I-GENE
chromatin O
. O

The O
loss O
of O
_RARE_ I-GENE
completely O
restored O
_RARE_ I-GENE
expression O
in O
a O
_RARE_ I-GENE
mutant I-GENE
and O
partially O
suppressed O
the O
osmotic O
stress O
sensitivity O
, O
_RARE_ I-GENE
_RARE_ I-GENE
as O
a O
downstream O
effector O
of O
the O
_RARE_ I-GENE
pathway O
. O

_RARE_ I-GENE
expression O
of O
a O
previously O
uncharacterized O
gene I-GENE
, O
_RARE_ I-GENE
, O
efficiently O
suppresses O
the O
growth I-GENE
and O
splicing O
defects O
of O
a O
temperature O
- I-GENE
sensitive O
( O
_RARE_ I-GENE
) O
mutant I-GENE
_RARE_ I-GENE
- I-GENE
1 I-GENE
. O

The O
slower O
- I-GENE
electrophoretic O
- I-GENE
mobility I-GENE
form O
of O
_RARE_ I-GENE
was O
absent O
in O
human I-GENE
cells O
in O
G1 I-GENE
/ I-GENE
S I-GENE
and O
appeared O
as O
the O
cells O
_RARE_ I-GENE
G2 I-GENE
/ I-GENE
M I-GENE
. O

We O
have O
identified O
amino O
acid I-GENE
sequences I-GENE
in O
mammalian I-GENE
and O
Xenopus I-GENE
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
that O
are O
necessary O
for O
insulin I-GENE
gene I-GENE
expression O
and O
ectopic O
_RARE_ I-GENE
. O

Both O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
transformed O
NIH O
3T3 O
fibroblasts O
, O
and O
this O
transformation O
required O
the O
_RARE_ I-GENE
domains I-GENE
for O
DNA I-GENE
binding I-GENE
and O
_RARE_ I-GENE
interaction O
. O

Recent O
studies O
have O
suggested O
that O
_RARE_ I-GENE
also O
positively O
regulate O
ZAP I-GENE
- I-GENE
70 I-GENE
function O
. O

Genetic O
and O
molecular O
data O
indicate O
that O
wild I-GENE
- I-GENE
type I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
compete O
for O
binding I-GENE
to O
_RARE_ I-GENE
, O
leading O
to O
a O
_RARE_ I-GENE
transduction O
of O
the O
_RARE_ I-GENE
signal I-GENE
in O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
animals O
and O
to O
a O
dramatic O
enhancement O
of O
the O
gain O
- I-GENE
of O
- I-GENE
function O
activity O
of O
_RARE_ I-GENE
in O
homozygous O
mutants I-GENE
. O

Another O
ORF I-GENE
, O
_RARE_ I-GENE
. O
2 I-GENE
located O
between O
_RARE_ I-GENE
and O
_RARE_ I-GENE
, O
shares O
sequence I-GENE
similarity O
with O
_RARE_ I-GENE
, O
and O
we O
_RARE_ I-GENE
it O
_RARE_ I-GENE
. O

The O
location O
of O
the O
_RARE_ I-GENE
within O
the O
_RARE_ I-GENE
structural O
gene I-GENE
, O
the O
cooperativity O
observed O
in O
footprinting O
studies O
and O
_RARE_ I-GENE
studies O
suggest O
that O
the O
_RARE_ I-GENE
participates O
in O
the O
interaction O
of O
_RARE_ I-GENE
with O
the O
upstream O
binding I-GENE
sites I-GENE
by O
_RARE_ I-GENE
out O
the O
intervening O
DNA I-GENE
. O

In O
vitro O
transcription I-GENE
assays O
demonstrate O
that O
the O
_RARE_ I-GENE
- I-GENE
cycle O
intermediate O
, O
_RARE_ I-GENE
, O
directly O
and O
specifically O
inhibits O
the O
formation O
of O
the O
_RARE_ I-GENE
transcript I-GENE
. O

_RARE_ I-GENE
analysis O
gave O
a O
_RARE_ I-GENE
of O
4 I-GENE
. O
4 I-GENE
x O
10 O
( O
10 O
) O
M I-GENE
- I-GENE
1 I-GENE
for O
the O
binding I-GENE
of O
N I-GENE
- I-GENE
A3 I-GENE
to O
_RARE_ I-GENE
. O
1 I-GENE
and O
2 I-GENE
. O
2 I-GENE
x O
10 O
( O
10 O
) O
M I-GENE
- I-GENE
1 I-GENE
for O
the O
binding I-GENE
of O
N I-GENE
- I-GENE
A3 I-GENE
to O
_RARE_ I-GENE
. O
66 O
. O

Expression O
of O
p130 I-GENE
( O
Cas I-GENE
) O
( O
Cas I-GENE
), O
a O
major I-GENE
binding I-GENE
protein I-GENE
for O
the O
Crk I-GENE
SH2 I-GENE
- I-GENE
domain I-GENE
, O
also O
induced O
JNK I-GENE
activation O
, O
which O
was O
blocked O
by O
the O
SH2 I-GENE
- I-GENE
mutant I-GENE
of O
Crk I-GENE
. O

_RARE_ I-GENE
correlations O
were O
seen O
between O
the O
measurements O
for O
protein I-GENE
intake O
( O
r O
=. O
58 O
, O
P I-GENE
=. O
_RARE_ I-GENE
) O
energy O
intake O
( O
r O
=. O
78 O
, O
P I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
), O
with O
mean O
differences O
of O
. O
_RARE_ I-GENE
g O
/ I-GENE
kg O
/ I-GENE
d O
( O
SD O
. O
38 O
) O
2 I-GENE
. O
04 O
_RARE_ I-GENE
/ I-GENE
kg O
/ I-GENE
day O
( O
SD O
6 I-GENE
. O
67 O
), O
respectively O
. O

The O
_RARE_ I-GENE
enzyme I-GENE
- I-GENE
linked O
immunosorbent O
assay O
( O
ELISA O
) O
to O
detect O
circulating O
_RARE_ I-GENE
_RARE_ I-GENE
antigen I-GENE
uses O
50 O
_RARE_ I-GENE
of O
serum I-GENE
. O

We O
now O
show O
that O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
ligation O
can O
also O
mimic O
IL I-GENE
- I-GENE
4 I-GENE
and O
have O
an O
anti I-GENE
- I-GENE
proliferative O
pro I-GENE
- I-GENE
_RARE_ I-GENE
influence O
within O
the O
immune I-GENE
system O
, O
causing O
up O
- I-GENE
regulation O
of O
co O
- I-GENE
stimulatory I-GENE
molecules I-GENE
on O
B I-GENE
lymphocytes O
. O

The O
_RARE_ I-GENE
repressor I-GENE
is O
a O
zinc I-GENE
finger I-GENE
protein I-GENE
that O
mediates O
glucose O
repression O
in O
yeast I-GENE
. O

_RARE_ I-GENE
is O
involved O
in O
_RARE_ I-GENE
_RARE_ I-GENE
and O
high O
- I-GENE
level O
_RARE_ I-GENE
I I-GENE
expression O
; O
but O
, O
it O
does O
not O
affect O
the O
spatial O
and O
temporal O
pattern O
of O
_RARE_ I-GENE
I I-GENE
expression O
. O

The O
divergence O
in O
primary O
structure O
between O
the O
sheep O
_RARE_ I-GENE
and O
the O
other O
mammalian I-GENE
_RARE_ I-GENE
is O
primarily O
localized O
to O
the O
extracellular I-GENE
amino O
terminal I-GENE
domain I-GENE
of O
the O
receptor I-GENE
( O
18 O
of O
22 O
divergent O
residues O
, O
_RARE_ I-GENE
vs O
human I-GENE
_RARE_ I-GENE
). O

_RARE_ I-GENE
- I-GENE
induced O
receptor I-GENE
internalization O
, O
determined O
as O
the O
percent O
of O
total O
[ O
_RARE_ I-GENE
] O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
bound O
located O
in O
the O
acid I-GENE
- I-GENE
resistant O
fraction O
of O
transfected O
_RARE_ I-GENE
7 O
cells O
, O
increased O
with O
time O
( O
0 O
- I-GENE
60 O
min O
at O
37 O
degrees O
C I-GENE
) O
for O
both O
wild I-GENE
- I-GENE
type I-GENE
and O
variant I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
arterial O
thrombotic O
disease O
on O
young O
onset O
and O
protein I-GENE
S I-GENE
deficiency O
. O

We O
showed O
that O
Stat3 I-GENE
and O
_RARE_ I-GENE
were O
affinity O
purified O
using O
phosphopeptides O
containing O
_RARE_ I-GENE
and O
_RARE_ I-GENE
but O
not O
by O
_RARE_ I-GENE
peptide I-GENE
analogues O
or O
by O
phosphopeptides O
containing O
_RARE_ I-GENE
and O
_RARE_ I-GENE
. O

Taken O
together O
, O
our O
results O
indicate O
that O
the O
_RARE_ I-GENE
gene I-GENE
_RARE_ I-GENE
as O
a O
negative O
regulator I-GENE
of O
drug O
resistance O
in O
C I-GENE
. O
albicans I-GENE
and O
constitute O
the O
first O
evidence O
that O
_RARE_ I-GENE
resistance O
can O
result O
from O
the O
inactivation O
of O
a O
regulatory I-GENE
factor I-GENE
such O
as O
_RARE_ I-GENE
. O

These O
findings O
suggest O
that O
late O
_RARE_ I-GENE
/ I-GENE
M I-GENE
is O
more O
useful O
than O
washout O
rate O
to O
assess O
the O
effect O
of O
treatment O
on O
heart O
failure O
due O
to O
_RARE_ I-GENE
. O

This O
study O
was O
undertaken O
to O
evaluate O
how O
_RARE_ I-GENE
and O
their O
placement O
affect O
the O
_RARE_ I-GENE
_RARE_ I-GENE
spectral O
properties O
. O

CONCLUSIONS O
: O
_RARE_ I-GENE
with O
_RARE_ I-GENE
prior O
to O
pituitary I-GENE
suppression O
in O
the O
early I-GENE
follicular O
phase O
decreases O
ovarian O
cyst O
formation O
, O
without O
an O
apparent O
effect O
on O
subsequent O
follicular O
recruitment O
or O
pregnancy O
rates O
. O

With O
regard O
to O
the O
optimal O
threshold O
values O
, O
sensitivity O
and O
specificity O
were O
100 O
_RARE_ I-GENE
97 O
% O
and O
95 O
_RARE_ I-GENE
95 O
% O
with O
FDG O
PET O
, O
compared O
to O
86 I-GENE
_RARE_ I-GENE
92 O
% O
and O
77 O
_RARE_ I-GENE
82 O
% O
with O
_RARE_ I-GENE
, O
respectively O
. O

This O
c I-GENE
- I-GENE
Jun I-GENE
activity O
is O
inhibited O
by O
c I-GENE
- I-GENE
Fos I-GENE
, O
another O
_RARE_ I-GENE
that O
can O
_RARE_ I-GENE
with O
c I-GENE
- I-GENE
Jun I-GENE
to O
form O
the O
transcription I-GENE
factor I-GENE
AP I-GENE
- I-GENE
1 I-GENE
. O

_RARE_ I-GENE
root O
_RARE_ I-GENE
neuron I-GENE
- I-GENE
specific I-GENE
promoter I-GENE
activity O
of O
the O
rabbit I-GENE
beta I-GENE
- I-GENE
_RARE_ I-GENE
alpha1 I-GENE
, O
2 I-GENE
- I-GENE
_RARE_ I-GENE
gene I-GENE
. O

CONCLUSION O
: O
Our O
study O
shows O
that O
( O
1 I-GENE
) O
total O
body O
BMD O
and O
femoral O
neck O
BMD O
were O
significantly O
higher O
in O
the O
study O
group O
that O
performed O
weight O
- I-GENE
bearing O
_RARE_ I-GENE
than O
in O
control O
subjects O
, O
( O
2 I-GENE
) O
swimming O
exercise O
had O
no O
effect O
on O
BMD O
, O
and O
( O
3 I-GENE
) O
although O
swimming O
is O
not O
a O
bone O
- I-GENE
_RARE_ I-GENE
exercise O
, O
it O
can O
significantly O
improve O
_RARE_ I-GENE
, O
back O
, O
and O
_RARE_ I-GENE
muscle O
strength O
. O

This O
suggests O
roles O
for O
both O
the O
_RARE_ I-GENE
and O
_RARE_ I-GENE
elements O
in O
regulating O
_RARE_ I-GENE
gene I-GENE
expression O
during O
development O
. O

_RARE_ I-GENE
gain O
_RARE_ I-GENE
to O
4 I-GENE
. O
2 I-GENE
+/- O
1 I-GENE
. O
3 I-GENE
mm O
, O
60 O
% O
of O
the O
defects O
showing O
_RARE_ I-GENE
gain O
> O
or O
= O
4 I-GENE
mm O
. O

_RARE_ I-GENE
with O
other O
known O
_RARE_ I-GENE
and O
_RARE_ I-GENE
- I-GENE
like I-GENE
proteins I-GENE
indicate O
that O
these O
Arabidopsis I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
are O
unique O
from O
wheat I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
fixation O
in O
dogs O
achieved O
with O
_RARE_ I-GENE
energy O
. O

However O
, O
there O
has O
not O
been O
any O
evidence O
of O
A I-GENE
. O
_RARE_ I-GENE
infections O
, O
specifically O
_RARE_ I-GENE
, O
associated I-GENE
with O
the O
fish O
in O
this O
_RARE_ I-GENE
. O

Further O
, O
we O
show O
that O
this O
EIA I-GENE
- I-GENE
inducible I-GENE
CBF I-GENE
/ I-GENE
cdc2 I-GENE
is O
related I-GENE
to O
the O
CBF I-GENE
which O
was O
shown O
to O
activate O
the O
heat I-GENE
shock I-GENE
protein I-GENE
70 I-GENE
promoter I-GENE
. O

The O
_RARE_ I-GENE
absorption O
of O
clindamycin O
was O
studied O
in O
healthy O
male O
volunteers O
, O
comparing O
two O
_RARE_ I-GENE
clindamycin O
_RARE_ I-GENE
w O
/ I-GENE
v I-GENE
)/ O
_RARE_ I-GENE
( O
0 O
. O
_RARE_ I-GENE
% O
w O
/ I-GENE
v I-GENE
) O
gels O
, O
containing O
clindamycin O
phosphate I-GENE
ester O
and O
clindamycin O
_RARE_ I-GENE
, O
respectively O
, O
relative O
to O
a O
clindamycin O
phosphate I-GENE
_RARE_ I-GENE
( O
1 I-GENE
% O
clindamycin O
; O
_RARE_ I-GENE
T I-GENE
). O

The O
BAL I-GENE
concentrations O
of O
the O
nine O
cytokines O
evaluated O
for O
the O
more O
and O
less O
affected O
lungs O
were O
compared O
: O
interleukin I-GENE
- I-GENE
6 I-GENE
( O
IL I-GENE
- I-GENE
6 I-GENE
), O
IL I-GENE
- I-GENE
8 O
, O
IL I-GENE
- I-GENE
12 O
, O
tumor I-GENE
necrosis I-GENE
factor I-GENE
- I-GENE
alpha I-GENE
( O
TNF I-GENE
- I-GENE
alpha I-GENE
), O
and O
interferon I-GENE
gamma I-GENE
( O
IFN I-GENE
- I-GENE
gamma I-GENE
) O
showed O
significant O
differences O
( O
p O
ranged O
between O
0 O
. O

_RARE_ I-GENE
analyses O
indicated O
that O
inhibition O
of O
ERK I-GENE
- I-GENE
1 I-GENE
/ I-GENE
2 I-GENE
decreased O
_RARE_ I-GENE
acid I-GENE
- I-GENE
elevated O
phosphorylation O
of O
_RARE_ I-GENE
and O
_RARE_ I-GENE
. O

Two O
- I-GENE
way O
analysis O
of O
_RARE_ I-GENE
was O
used O
to O
determine O
whether O
composite O
knowledge O
score O
differed O
among O
patient O
groups O
. O

The O
human I-GENE
pathogenic O
bacterium O
group O
A I-GENE
Streptococcus I-GENE
produces O
an O
extracellular I-GENE
cysteine I-GENE
protease I-GENE
[ O
streptococcal I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
B I-GENE
( O
_RARE_ I-GENE
)] O
that O
is O
a O
critical O
virulence I-GENE
factor I-GENE
for O
invasive O
disease O
episodes O
. O

The O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
part O
of O
the O
dorsal O
_RARE_ I-GENE
areas O
were O
preferentially O
activated I-GENE
by O
the O
self O
- I-GENE
initiated O
hand O
movement O
task O
( O
_RARE_ I-GENE
). O

_RARE_ I-GENE
the O
evidence O
base O
for O
anaesthesia O
. O

Plasma I-GENE
_RARE_ I-GENE
levels O
were O
determined O
at O
regular O
intervals O
. O

The O
peroxisome I-GENE
biogenesis O
disorders O
( O
_RARE_ I-GENE
) O
are O
a O
set O
of O
lethal O
genetic O
diseases O
characterized O
by O
_RARE_ I-GENE
metabolic O
deficiencies O
, O
_RARE_ I-GENE
abnormalities O
, O
mental O
retardation O
, O
and O
premature O
death O
. O

The O
active O
site I-GENE
includes O
the O
acidic O
_RARE_ I-GENE
_RARE_ I-GENE
( O
the O
site I-GENE
of O
phosphorylation O
), O
_RARE_ I-GENE
and O
_RARE_ I-GENE
. O

Consistent O
with O
these O
findings O
, O
relatively O
weak O
transcriptional O
silencing O
by O
the O
native O
VDR I-GENE
was O
observed O
using O
the O
_RARE_ I-GENE
VDRE I-GENE
. O

In O
_RARE_ I-GENE
- I-GENE
3 I-GENE
, O
the O
E1A I-GENE
region O
is O
located O
between O
1 I-GENE
. O
5 I-GENE
and O
3 I-GENE
. O
8 O
map O
units O
. O

Six O
putative O
MDV I-GENE
genome O
products I-GENE
, O
including O
one O
Rep I-GENE
and O
five O
non O
- I-GENE
Rep I-GENE
proteins I-GENE
, O
show O
high O
( O
70 I-GENE
. O
4 I-GENE
- I-GENE
90 O
. O
9 O
%) O
amino O
acid I-GENE
identity O
to O
the O
corresponding O
six O
_RARE_ I-GENE
proteins I-GENE
, O
whereas O
two O
other O
Rep I-GENE
proteins I-GENE
encoded I-GENE
by O
MDV I-GENE
- I-GENE
C2 I-GENE
and O
C3 I-GENE
are O
82 O
. O
3 I-GENE
% O
and O
73 O
. O
0 O
% O
identical O
to O
those O
encoded I-GENE
by O
_RARE_ I-GENE
- I-GENE
C2 I-GENE
and O
C6 I-GENE
, O
respectively O
. O

_RARE_ I-GENE
was O
labeled O
with O
1 I-GENE
mCi O
_RARE_ I-GENE
by O
a O
technique O
of O
self O
- I-GENE
labeling O
in O
the O
presence O
of O
10 O
(- O
4 I-GENE
) O
M I-GENE
hydrogen O
_RARE_ I-GENE
. O

It O
is O
related I-GENE
to O
a O
variety O
of O
mammalian I-GENE
Golgi I-GENE
- I-GENE
associated I-GENE
proteins I-GENE
and O
to O
the O
yeast I-GENE
_RARE_ I-GENE
, O
an O
essential O
protein I-GENE
involved O
in O
_RARE_ I-GENE
of O
endoplasmic O
reticulum O
- I-GENE
derived O
vesicles O
to O
the O
cis O
- I-GENE
Golgi I-GENE
. O

The O
data O
indicate O
that O
_RARE_ I-GENE
is O
directly O
regulated O
by O
retinoic I-GENE
acid I-GENE
- I-GENE
bound O
receptors I-GENE
and O
Sp1 I-GENE
. O

Both O
proteins I-GENE
were O
shown O
to O
be O
constitutively O
associated I-GENE
with O
_RARE_ I-GENE
. O

_RARE_ I-GENE
was O
found O
to O
bind O
to O
MA I-GENE
protein I-GENE
in O
vitro O
, O
as O
efficiently O
as O
in O
vivo O
in O
yeast I-GENE
cells O
. O

Fas I-GENE
- I-GENE
resistant O
DT I-GENE
- I-GENE
40 I-GENE
lymphoma O
B I-GENE
- I-GENE
cells O
_RARE_ I-GENE
_RARE_ I-GENE
- I-GENE
deficient O
through O
targeted O
disruption O
of O
the O
_RARE_ I-GENE
gene I-GENE
by O
homologous O
recombination O
_RARE_ I-GENE
underwent O
apoptosis O
after O
Fas I-GENE
ligation O
, O
but O
wild I-GENE
- I-GENE
type I-GENE
DT I-GENE
- I-GENE
40 I-GENE
cells O
or O
_RARE_ I-GENE
- I-GENE
deficient O
DT I-GENE
- I-GENE
40 I-GENE
cells O
reconstituted O
with O
wild I-GENE
- I-GENE
type I-GENE
human I-GENE
_RARE_ I-GENE
gene I-GENE
did O
not O
. O

A I-GENE
motif I-GENE
( O
_RARE_ I-GENE
) O
which O
matches O
a O
CREB I-GENE
site I-GENE
and O
is O
similar O
to O
an O
AP I-GENE
- I-GENE
1 I-GENE
site I-GENE
is O
embedded O
within O
_RARE_ I-GENE
. O

_RARE_ I-GENE
, O
four O
_RARE_ I-GENE
_RARE_ I-GENE
variants I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
and O
_RARE_ I-GENE
have O
been O
shown O
to O
be O
co O
- I-GENE
_RARE_ I-GENE
expressed O
at O
the O
_RARE_ I-GENE
gene I-GENE
locus I-GENE
. O

Therefore O
, O
in O
order O
to O
search O
for O
the O
latent I-GENE
genes I-GENE
, O
we O
used O
_RARE_ I-GENE
- I-GENE
specific I-GENE
oligonucleotides O
for O
_RARE_ I-GENE
, O
_RARE_ I-GENE
and O
_RARE_ I-GENE
to O
probe O
DNAs O
from O
both O
normal O
and O
T I-GENE
. O
_RARE_ I-GENE
- I-GENE
infected O
rabbits O
by O
Southern O
blotting O
. O

TRAF2 I-GENE
is O
known O
to O
associate O
with O
_RARE_ I-GENE
, O
and O
expression O
of O
a O
dominant I-GENE
- I-GENE
negative O
N I-GENE
- I-GENE
terminal I-GENE
deletion O
TRAF2 I-GENE
mutant I-GENE
was O
found O
to O
partially O
inhibit O
LMP1 I-GENE
- I-GENE
induced O
JNK I-GENE
activation O
in O
293 O
cells O
. O

These O
data O
further O
define O
a O
role O
for O
_RARE_ I-GENE
and O
TRAF2 I-GENE
in O
JNK I-GENE
activation O
and O
confirm O
that O
LMP1 I-GENE
_RARE_ I-GENE
signalling O
mechanisms O
used O
by O
the O
TNF I-GENE
receptor I-GENE
/ I-GENE
CD40 I-GENE
family I-GENE
to O
elicit O
its O
pleiotropic O
activities O
. O

Epstein I-GENE
- I-GENE
Barr I-GENE
virus I-GENE
- I-GENE
encoded I-GENE
latent I-GENE
membrane I-GENE
protein I-GENE
1 I-GENE
activates O
the O
JNK I-GENE
pathway O
through O
its O
extreme O
C I-GENE
terminus O
via O
a O
mechanism O
involving O
_RARE_ I-GENE
and O
TRAF2 I-GENE
. O

In O
contrast O
, O
transiently O
transfected O
cells O
expressing O
EBNA I-GENE
- I-GENE
3 I-GENE
revealed O
a O
_RARE_ I-GENE
increase O
in O
EBNA I-GENE
- I-GENE
3 I-GENE
protein I-GENE
expression O
from O
the O
genomic O
EBNA I-GENE
- I-GENE
3 I-GENE
gene I-GENE
compared O
to O
EBNA I-GENE
- I-GENE
3 I-GENE
cDNA I-GENE
. O

However O
, O
serial O
_RARE_ I-GENE
of O
fetal O
_RARE_ I-GENE
kidney O
( O
_RARE_ I-GENE
) O
cells O
, O
which O
are O
sensitive O
to O
infection O
with O
_RARE_ I-GENE
, O
after O
transient O
transfection O
revealed O
that O
mutation I-GENE
of O
a O
second O
tyrosine I-GENE
residue O
in O
the O
N I-GENE
- I-GENE
terminal I-GENE
motif I-GENE
completely O
prevented O
the O
_RARE_ I-GENE
of O
the O
virus I-GENE
. O

_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
virus I-GENE
( O
VZV I-GENE
) O
glycoprotein I-GENE
_RARE_ I-GENE
is O
a O
type I-GENE
1 I-GENE
transmembrane I-GENE
glycoprotein I-GENE
which O
is O
one O
component O
of O
the O
heterodimeric I-GENE
_RARE_ I-GENE
: O
_RARE_ I-GENE
Fc I-GENE
receptor I-GENE
complex I-GENE
. O

To O
this O
end O
, O
we O
analyzed O
the O
phosphorylation O
status O
of O
a O
_RARE_ I-GENE
tyrosine I-GENE
kinase I-GENE
substrate I-GENE
, O
the O
transforming I-GENE
Shc I-GENE
adapter I-GENE
protein I-GENE
, O
in O
fibroblasts O
expressing O
the O
viral I-GENE
oncogene I-GENE
. O

These O
genes I-GENE
were O
expressed O
in O
a O
Saccharomyces I-GENE
cerevisiae I-GENE
mutant I-GENE
in O
which O
the O
endogenous I-GENE
_RARE_ I-GENE
gene I-GENE
( O
_RARE_ I-GENE
) O
had O
been O
deleted O
, O
and O
the O
phenotypes O
of O
the O
transformants O
were O
characterized O
. O

In O
this O
study O
, O
evidence O
is O
presented O
that O
temporally O
and O
spatially O
specific I-GENE
_RARE_ I-GENE
expression O
is O
controlled O
by O
a O
complex I-GENE
_RARE_ I-GENE
of O
cis O
- I-GENE
acting O
regulatory I-GENE
modules I-GENE
that O
are O
responsive I-GENE
to O
different O
genetic O
signals O
. O

Furthermore O
, O
using O
transgenic O
mouse I-GENE
technology O
we O
localized O
independent O
cis O
- I-GENE
regulatory I-GENE
elements O
controlling O
the O
tissue I-GENE
- I-GENE
specific I-GENE
expression O
of O
_RARE_ I-GENE
. O

In O
the O
second O
experiment O
, O
a O
stable O
nickel O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
was O
given O
in O
drinking O
water O
to O
20 O
nickel O
- I-GENE
_RARE_ I-GENE
women O
and O
20 O
age O
- I-GENE
matched O
controls O
, O
both O
groups O
having O
vesicular O
hand O
_RARE_ I-GENE
of O
the O
_RARE_ I-GENE
type I-GENE
. O

_RARE_ I-GENE
tissue I-GENE
and O
_RARE_ I-GENE
collagen I-GENE
fibers O
in O
the O
_RARE_ I-GENE
_RARE_ I-GENE
permit O
its O
expansion O
during O
_RARE_ I-GENE
. O

_RARE_ I-GENE
of O
patients O
infected O
with O
_RARE_ I-GENE
mycobacteria O
( O
_RARE_ I-GENE
) O
is O
increasing O
world O
- I-GENE
wide O
in O
recent O
years O
. O

Comparison O
of O
the O
sequences I-GENE
of O
_RARE_ I-GENE
, O
_RARE_ I-GENE
and O
bacteria O
- I-GENE
_RARE_ I-GENE
junctions O
_RARE_ I-GENE
and O
_RARE_ I-GENE
showed O
a O
26 O
bp O
common O
core I-GENE
sequence I-GENE
, O
where O
recombination O
_RARE_ I-GENE
place O
, O
near O
the O
5 I-GENE
' O
end O
of O
the O
integrase I-GENE
gene I-GENE
. O

Interferon I-GENE
- I-GENE
alpha I-GENE
treatment O
of O
_RARE_ I-GENE
_RARE_ I-GENE
disorder O
in O
recipients O
of O
solid O
organ O
_RARE_ I-GENE
. O

_RARE_ I-GENE
testing O
was O
performed O
on O
all O
_RARE_ I-GENE
workers O
and O
some O
control O
volunteers O
using O
skin O
_RARE_ I-GENE
testing O
with O
_RARE_ I-GENE
, O
barley I-GENE
, O
and O
yeast I-GENE
antigens I-GENE
as O
well O
as O
other O
_RARE_ I-GENE
allergens O
, O
and O
by O
determining O
total O
serum I-GENE
IgE I-GENE
levels O
. O

OBJECTIVE O
: O
To O
evaluate O
the O
accuracy O
of O
working O
_RARE_ I-GENE
for O
_RARE_ I-GENE
and O
_RARE_ I-GENE
restorations O
made O
from O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
materials O
using O
different O
types O
of O
_RARE_ I-GENE
_RARE_ I-GENE
. O

OBJECTIVES O
: O
To O
assess O
the O
ability O
of O
pretreatment O
and O
post O
- I-GENE
treatment O
prostate O
- I-GENE
specific I-GENE
antigen I-GENE
( O
PSA I-GENE
) O
measurements O
, O
clinical O
tumor I-GENE
stage O
, O
tumor I-GENE
grade O
, O
_RARE_ I-GENE
sum O
, O
_RARE_ I-GENE
, O
age O
, O
and O
radiation O
dose O
to O
predict O
the O
recurrence O
of O
prostate O
cancer O
following O
external O
beam O
radiation O
therapy O
( O
_RARE_ I-GENE
) O
since O
the O
introduction O
of O
PSA I-GENE
as O
a O
tumor I-GENE
marker O
at O
one O
tertiary O
care O
center I-GENE
. O

To O
evaluate O
whether O
the O
human I-GENE
gene I-GENE
is O
also O
a O
target O
of O
thyroid I-GENE
hormone I-GENE
we O
have O
_RARE_ I-GENE
for O
T3 O
- I-GENE
responsive I-GENE
elements O
in O
_RARE_ I-GENE
cloned O
genomic O
fragments I-GENE
spanning O
the O
whole O
gene I-GENE
. O

The O
transcriptional O
activity O
of O
PPARgamma I-GENE
is O
positively O
modulated O
by O
ligand O
binding I-GENE
and O
negatively O
regulated O
by O
phosphorylation O
mediated O
by O
the O
MEK I-GENE
/ I-GENE
ERK I-GENE
signaling O
pathway O
. O

BACKGROUND O
: O
_RARE_ I-GENE
, O
one O
of O
the O
_RARE_ I-GENE
group O
of O
_RARE_ I-GENE
, O
is O
used O
as O
an O
_RARE_ I-GENE
drug O
for O
sedation O
and O
for O
_RARE_ I-GENE
of O
anxiety O
in O
the O
treatment O
of O
epilepsy O
. O

_RARE_ I-GENE
granuloma O
presents O
with O
_RARE_ I-GENE
shaped O
cystic I-GENE
_RARE_ I-GENE
of O
varying O
size O
containing O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
foreign O
bodies O
whereas O
_RARE_ I-GENE
granuloma O
shows O
numerous O
round O
_RARE_ I-GENE
nearly O
identical O
in O
size O
and O
shape O
_RARE_ I-GENE
round O
and O
sharply O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
foreign O
bodies O
. O

This O
_RARE_ I-GENE
- I-GENE
subfamily I-GENE
gene I-GENE
is O
likely O
to O
participate O
in O
_RARE_ I-GENE
mesoderm O
formation O
and O
_RARE_ I-GENE
in O
human I-GENE
embryo O
. O

Structure O
- I-GENE
function O
analysis O
of O
the O
Z I-GENE
- I-GENE
DNA I-GENE
- I-GENE
binding I-GENE
domain I-GENE
_RARE_ I-GENE
of O
dsRNA I-GENE
adenosine I-GENE
deaminase I-GENE
type I-GENE
I I-GENE
reveals O
similarity O
to O
the O
( O
alpha I-GENE
+ I-GENE
beta I-GENE
) O
family I-GENE
of O
helix I-GENE
- I-GENE
turn I-GENE
- I-GENE
helix I-GENE
proteins I-GENE
. O

In O
addition O
, O
the O
regulation O
of O
_RARE_ I-GENE
- I-GENE
1 I-GENE
gene I-GENE
expression O
also O
has O
potential O
applications O
to O
gene I-GENE
therapy O
, O
since O
retroviral I-GENE
vectors O
carrying O
_RARE_ I-GENE
_RARE_ I-GENE
leukemia I-GENE
virus I-GENE
envelope I-GENE
proteins I-GENE
are O
used O
for O
gene I-GENE
delivery O
into O
different O
cell O
types O
. O

_RARE_ I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
methods O
. O

Molecular O
cloning O
of O
mouse I-GENE
_RARE_ I-GENE
oxidase I-GENE
. O

In O
such O
a O
manner O
, O
activated I-GENE
PKR I-GENE
inhibits O
cell O
growth I-GENE
and O
induces O
apoptosis O
, O
whereas O
disruption O
of O
normal O
PKR I-GENE
signaling O
results O
in O
_RARE_ I-GENE
cell O
growth I-GENE
. O

We O
isolated O
a O
ribosomal I-GENE
protein I-GENE
_RARE_ I-GENE
by O
interaction O
with O
PKR I-GENE
. O

_RARE_ I-GENE
of O
the O
_RARE_ I-GENE
precursor I-GENE
requires O
_RARE_ I-GENE
also O
involved O
in O
rRNA I-GENE
processing O
, O
i O
. O
e O
., O
_RARE_ I-GENE
and O
_RARE_ I-GENE
. O

To O
search O
for O
transcriptional O
regulators O
, O
we O
used O
a O
fragment I-GENE
of O
the O
_RARE_ I-GENE
promoter I-GENE
containing O
several O
individual O
elements O
instead O
of O
the O
conventional O
_RARE_ I-GENE
that O
contains O
a O
_RARE_ I-GENE
cis O
element I-GENE
. O

As O
expected O
for O
a O
positive O
_RARE_ I-GENE
transcriptional O
regulator I-GENE
, O
the O
timing O
of O
_RARE_ I-GENE
gene I-GENE
expression O
_RARE_ I-GENE
the O
transient O
expression O
of O
_RARE_ I-GENE
in O
the O
very O
early I-GENE
sea O
urchin I-GENE
_RARE_ I-GENE
. O

Furthermore O
, O
_RARE_ I-GENE
- I-GENE
mediated O
SRE O
activation O
was O
blocked O
by O
dominant I-GENE
negative O
mutants I-GENE
of O
PKC I-GENE
- I-GENE
alpha I-GENE
or O
PKC I-GENE
- I-GENE
epsilon I-GENE
. O

_RARE_ I-GENE
- I-GENE
depleted O
cells O
exhibited O
the O
same O
defects O
as O
_RARE_ I-GENE
- I-GENE
depleted O
cells O
, O
except O
that O
they O
accumulated O
_RARE_ I-GENE
precursors I-GENE
. O

We O
show O
that O
the O
_RARE_ I-GENE
- I-GENE
binding I-GENE
site I-GENE
and O
stem O
- I-GENE
loop I-GENE
III I-GENE
structures O
are O
necessary O
for O
correct O
3 I-GENE
'- O
end O
formation O
. O

Five O
different O
subtypes O
of O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
are O
now O
recognized O
. O

Further O
experiments O
will O
be O
required O
to O
_RARE_ I-GENE
the O
in O
vivo O
role O
of O
_RARE_ I-GENE
in O
nuclear I-GENE
receptor I-GENE
functioning O
. O

Overexpression O
of O
_RARE_ I-GENE
in O
transfected O
NIH O
3T3 O
cells O
also O
stimulated O
expression O
and O
secretion O
of O
basic I-GENE
fibroblast I-GENE
growth I-GENE
factor I-GENE
, O
a O
human I-GENE
pituitary I-GENE
tumor I-GENE
growth I-GENE
- I-GENE
regulating O
factor I-GENE
. O

The O
_RARE_ I-GENE
connective O
tissue I-GENE
_RARE_ I-GENE
is O
important O
in O
_RARE_ I-GENE
the O
contraction O
of O
the O
myocardium O
by O
preventing O
lateral O
spread O
of O
conduction O
and O
by O
_RARE_ I-GENE
transmission O
of O
the O
_RARE_ I-GENE
only O
at O
the O
termination O
of O
the O
_RARE_ I-GENE
fibre O
. O

E1 I-GENE
, O
a O
DNA I-GENE
helicase I-GENE
, O
_RARE_ I-GENE
with O
the O
HPV I-GENE
E2 I-GENE
protein I-GENE
in O
_RARE_ I-GENE
- I-GENE
dependent I-GENE
replication O
. O

Here O
we O
describe O
a O
mutant I-GENE
alpha I-GENE
subunit I-GENE
designed O
to O
inhibit O
receptor I-GENE
- I-GENE
mediated O
hormonal O
activation O
of O
Gs I-GENE
, O
the O
stimulatory I-GENE
regulator I-GENE
of O
_RARE_ I-GENE
cyclase I-GENE
. O

A I-GENE
_RARE_ I-GENE
search O
with O
the O
C I-GENE
- I-GENE
terminal I-GENE
region O
of O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
revealed O
a O
36 O
- I-GENE
41 O
% O
similarity O
to O
several O
proteins I-GENE
related I-GENE
to O
signal I-GENE
transduction O
and O
cell O
replication O
, O
such O
as O
_RARE_ I-GENE
and O
_RARE_ I-GENE
. O

Northern O
blot O
analysis O
demonstrated O
the O
ubiquitous O
expression O
of O
2 I-GENE
. O
9 O
kb O
and O
3 I-GENE
. O

Additionally O
, O
a O
variety O
of O
regulatory I-GENE
_RARE_ I-GENE
contribute O
temporal O
and O
/ I-GENE
or O
spatial O
restriction I-GENE
to O
TGF I-GENE
- I-GENE
beta I-GENE
responses O
. O

Induction O
of O
anaesthesia O
was O
_RARE_ I-GENE
: O
fentanyl O
( O
3 I-GENE
micrograms O
/ I-GENE
kg O
), O
_RARE_ I-GENE
( O
5 I-GENE
mg O
/ I-GENE
kg O
), O
_RARE_ I-GENE
( O
0 O
. O
4 I-GENE
mg O
/ I-GENE
kg O
). O

A I-GENE
comparison O
of O
the O
clinical O
profile O
of O
_RARE_ I-GENE
malformations O
with O
and O
without O
associated I-GENE
venous O
malformations O
. O

_RARE_ I-GENE
and O
distinct O
roles O
of O
_RARE_ I-GENE
in O
regulation O
of O
the O
_RARE_ I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
genes I-GENE
. O

_RARE_ I-GENE
induced O
optical O
self O
- I-GENE
_RARE_ I-GENE
in O
a O
_RARE_ I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
: O
A I-GENE
simple O
model O
of O
wave O
- I-GENE
controlled O
_RARE_ I-GENE
and O
_RARE_ I-GENE
cooperative O
phenomena O
. O

_RARE_ I-GENE
rates O
and O
energy O
levels O
of O
triplet O
_RARE_ I-GENE
, O
v I-GENE
= O
1 I-GENE
_RARE_ I-GENE
states O
of O
H2 I-GENE
. O

_RARE_ I-GENE
- I-GENE
group O
approach O
to O
spin O
- I-GENE
dependent I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
approach O
to O
_RARE_ I-GENE
in O
a O
one O
- I-GENE
dimensional O
problem O
. O

_RARE_ I-GENE
- I-GENE
x O
- I-GENE
ray O
_RARE_ I-GENE
at O
32 O
. O
6 I-GENE
nm O
in O
_RARE_ I-GENE
- I-GENE
like I-GENE
_RARE_ I-GENE
ions O
driven O
by O
40 I-GENE
J O
of O
energy O
from O
two O
_RARE_ I-GENE
- I-GENE
ps I-GENE
laser O
_RARE_ I-GENE
. O

_RARE_ I-GENE
, O
to O
identify O
regions O
of O
the O
promoter I-GENE
involved O
, O
we O
examined O
a O
series O
of O
_RARE_ I-GENE
- I-GENE
C I-GENE
promoter I-GENE
constructs I-GENE
with O
5 I-GENE
' O
deletions O
and O
showed O
that O
_RARE_ I-GENE
collagen I-GENE
- I-GENE
dependent I-GENE
promoter I-GENE
activity O
was O
retained O
by O
a O
122 O
- I-GENE
base O
pair O
element I-GENE
, O
located O
- I-GENE
43 I-GENE
to O
- I-GENE
165 O
bp O
upstream O
of O
the O
RNA I-GENE
start O
site I-GENE
. O

Nuclear I-GENE
factor I-GENE
kappa I-GENE
B I-GENE
( O
NF I-GENE
- I-GENE
kappaB I-GENE
) O
is O
an O
important O
transcription I-GENE
factor I-GENE
for O
the O
genes I-GENE
of O
many O
pro I-GENE
- I-GENE
inflammatory O
proteins I-GENE
and O
is O
strongly O
activated I-GENE
by O
the O
cytokines O
interleukin I-GENE
- I-GENE
1 I-GENE
and O
tumor I-GENE
necrosis I-GENE
factor I-GENE
( O
TNF I-GENE
) O
alpha I-GENE
under O
various O
pathological O
conditions O
. O

Moreover O
, O
this O
enhancement O
of O
transcriptional O
activation O
by O
COUP I-GENE
- I-GENE
TFI I-GENE
requires O
specifically O
the O
AF I-GENE
- I-GENE
1 I-GENE
transactivation O
function O
of O
ER I-GENE
and O
can O
be O
observed O
in O
the O
presence O
of O
E2 I-GENE
or O
4 I-GENE
- I-GENE
_RARE_ I-GENE
but O
not O
_RARE_ I-GENE
_RARE_ I-GENE
. O

Recombinant I-GENE
_RARE_ I-GENE
has O
a O
_RARE_ I-GENE
point O
of O
_RARE_ I-GENE
= O
89 I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
occlusion O
and O
the O
rat I-GENE
accessory I-GENE
olfactory O
bulb O
. O

This O
region O
of O
hsp90 I-GENE
mediates O
ATP I-GENE
- I-GENE
independent O
_RARE_ I-GENE
activity O
, O
_RARE_ I-GENE
the O
hsp90 I-GENE
dimerization O
domain I-GENE
, O
and O
includes O
structural O
elements O
important O
for O
steroid I-GENE
receptor I-GENE
interaction O
. O

The O
promoter I-GENE
of O
the O
rat I-GENE
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
gene I-GENE
has O
a O
GC I-GENE
- I-GENE
rich O
region O
( O
_RARE_ I-GENE
) O
that O
is O
highly O
conserved O
in O
_RARE_ I-GENE
genes I-GENE
and O
contains O
an O
consensus I-GENE
Sp1 I-GENE
site I-GENE
. O

Sp1 I-GENE
' O
s O
role O
in O
transactivation O
of O
the O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
promoter I-GENE
was O
tested O
in O
Drosophila I-GENE
_RARE_ I-GENE
cells O
. O

Measurements O
included O
bone O
mineral O
density I-GENE
of O
the O
lumbar O
spine O
and O
proximal I-GENE
femur O
( O
by O
dual O
- I-GENE
energy O
X I-GENE
- I-GENE
ray O
_RARE_ I-GENE
) O
and O
biochemical O
markers O
of O
bone O
remodeling O
( O
serum I-GENE
bone O
- I-GENE
specific I-GENE
alkaline I-GENE
phosphatase I-GENE
by O
immunoassay O
and O
urine O
_RARE_ I-GENE
by O
high O
- I-GENE
pressure O
liquid O
chromatography O
). O

Human I-GENE
_RARE_ I-GENE
is O
a O
10 O
- I-GENE
kD I-GENE
skeletal I-GENE
extracellular I-GENE
matrix I-GENE
( O
_RARE_ I-GENE
) O
protein I-GENE
that O
consists O
of O
an O
84 O
- I-GENE
aa O
mature O
protein I-GENE
and O
a O
19 O
- I-GENE
aa O
transmembrane I-GENE
signal I-GENE
peptide I-GENE
. O

_RARE_ I-GENE
roles O
of O
_RARE_ I-GENE
, O
the O
_RARE_ I-GENE
_RARE_ I-GENE
homolog I-GENE
, O
in O
cytoplasmic I-GENE
polyadenylation O
and O
translational O
_RARE_ I-GENE
. O

The O
RNA I-GENE
polymerase I-GENE
III I-GENE
- I-GENE
_RARE_ I-GENE
factor I-GENE
_RARE_ I-GENE
induces O
a O
DNA I-GENE
_RARE_ I-GENE
between O
the O
TATA I-GENE
box I-GENE
and O
the O
transcriptional O
start O
site I-GENE
. O

The O
pattern O
of O
RNase I-GENE
E I-GENE
digestion O
of O
_RARE_ I-GENE
RNA I-GENE
differed O
from O
_RARE_ I-GENE
, O
and O
GST I-GENE
- I-GENE
_RARE_ I-GENE
did O
not O
protect O
_RARE_ I-GENE
RNA I-GENE
from O
cleavage O
in O
vitro O
. O

Transcription O
readthrough O
into O
the O
inverted O
repeats I-GENE
has O
little O
effect O
on O
this O
event O
. O

Analysis O
of O
hematopoietic I-GENE
growth I-GENE
factor I-GENE
_RARE_ I-GENE
in O
19 O
_RARE_ I-GENE
cancer O
centers O

In O
the O
second O
case O
, O
an O
epidermal I-GENE
cyst O
was O
diagnosed O
. O

_RARE_ I-GENE
also O
binds O
a O
DNA I-GENE
sequence I-GENE
( O
a O
_RARE_ I-GENE
box I-GENE
), O
centered O
at O
position O
- I-GENE
30 O
. O

We O
suggest O
that O
_RARE_ I-GENE
and O
_RARE_ I-GENE
may O
function O
like I-GENE
certain O
eukaryotic I-GENE
_RARE_ I-GENE
( O
TATA I-GENE
binding I-GENE
protein I-GENE
( O
TBP I-GENE
) O
associated I-GENE
factors I-GENE
) O
whose O
binding I-GENE
to O
TBP I-GENE
results O
in O
transcription I-GENE
from O
new O
core I-GENE
promoter I-GENE
sequences I-GENE
. O

The O
_RARE_ I-GENE
variant I-GENE
can O
better O
_RARE_ I-GENE
modified O
bases O
but O
does O
not O
tightly O
_RARE_ I-GENE
the O
_RARE_ I-GENE
base O
into O
the O
adenine O
- I-GENE
binding I-GENE
pocket O
, O
suggesting O
that O
_RARE_ I-GENE
could O
form O
a O
contact O
to O
the O
_RARE_ I-GENE
adenine O
. O

The O
high O
conservation O
of O
the O
3 I-GENE
' O
terminus O
suggests O
that O
this O
region O
directs O
the O
assembly O
of O
proteins I-GENE
required O
for O
the O
initiation I-GENE
of O
RNA I-GENE
replication O
. O

All O
_RARE_ I-GENE
were O
down O
- I-GENE
regulated O
with O
GnRH I-GENE
- I-GENE
a O
_RARE_ I-GENE
on O
day O
21 O
in O
a O
long O
protocol O
before O
gonadotropin I-GENE
stimulation O
. O

The O
sequence I-GENE
up O
to O
- I-GENE
_RARE_ I-GENE
bp O
relative O
to O
the O
transcription I-GENE
start O
site I-GENE
was O
sufficient O
to O
enhance O
reporter I-GENE
gene I-GENE
expression O
depending O
on O
the O
_RARE_ I-GENE
differentiation O
of O
P19 O
cells O
. O

Chem O
. O

No O
significant O
differences O
between O
the O
substituted O
and O
wild I-GENE
type I-GENE
peptides I-GENE
were O
observed O
, O
suggesting O
that O
this O
substitution O
in O
the O
intact O
protein I-GENE
may O
cause O
disruption O
of O
global O
rather O
than O
local O
structures O
. O

These O
results O
suggest O
that O
the O
c I-GENE
- I-GENE
met I-GENE
gene I-GENE
is O
also O
a O
target O
of O
p53 I-GENE
gene I-GENE
regulation O
. O

C3 I-GENE
toxin I-GENE
completely O
inhibited O
RhoA I-GENE
function O
, O
partially O
inhibited O
SRE O
: O
_RARE_ I-GENE
activity O
, O
but O
had O
no O
effect O
on O
_RARE_ I-GENE
- I-GENE
stimulated O
c I-GENE
- I-GENE
Fos I-GENE
expression O
. O

However O
, O
C3 I-GENE
toxin I-GENE
alone O
or O
in O
combination O
with O
growth I-GENE
factors I-GENE
did O
not O
stimulate O
AP I-GENE
- I-GENE
1 I-GENE
: O
_RARE_ I-GENE
activity O
and O
_RARE_ I-GENE
_RARE_ I-GENE
the O
synergistic O
activation O
of O
AP I-GENE
- I-GENE
1 I-GENE
: O
_RARE_ I-GENE
observed O
in O
response O
to O
co O
- I-GENE
stimulation O
with O
growth I-GENE
factors I-GENE
and O
Ro I-GENE
- I-GENE
31 O
- I-GENE
_RARE_ I-GENE
. O

The O
aim O
of O
the O
present O
study O
was O
to O
examine O
the O
antimicrobial O
susceptibility I-GENE
to O
10 O
currently O
used O
antimicrobial O
agents O
of O
50 O
strains O
of O
P I-GENE
. O
_RARE_ I-GENE
isolated O
from O
_RARE_ I-GENE
lesions O
and O
identified O
using O
a O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
II I-GENE
panel O
. O

The O
role O
of O
_RARE_ I-GENE
echocardiography O
in O
surgery O
of O
the O
heart O
and O
large O
vessels O

Taken O
together O
, O
our O
results O
demonstrate O
that O
_RARE_ I-GENE
is O
involved O
in O
multidrug I-GENE
resistance O
and O
oxidative O
stress O
response O
in O
C I-GENE
. O
albicans I-GENE
. O

_RARE_ I-GENE
is O
a O
small I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
patch O
with O
an O
absorption O
promoter I-GENE
, O
_RARE_ I-GENE
in O
two O
dose O
- I-GENE
strengths O
( O
5 I-GENE
mg O
/ I-GENE
24 O
h O
and O
10 O
mg O
/ I-GENE
24 O
h O
) O
by O
_RARE_ I-GENE
_RARE_ I-GENE
. O

The O
_RARE_ I-GENE
was O
tested O
for O
_RARE_ I-GENE
reliability O
using O
three O
simulated O
and O
10 O
actual O
patients O
. O

The O
starting O
point O
is O
the O
_RARE_ I-GENE
that O
the O
_RARE_ I-GENE
underlying O
the O
_RARE_ I-GENE
are O
not O
suitable O
to O
serve O
as O
a O
_RARE_ I-GENE
of O
a O
model O
for O
_RARE_ I-GENE
in O
_RARE_ I-GENE
because O
they O
do O
not O
reflect O
essential O
characteristics O
of O
the O
diagnostic O
process O
which O
is O
the O
basis O
for O
intervention O
. O

_RARE_ I-GENE
_RARE_ I-GENE
protein I-GENE
( O
_RARE_ I-GENE
) O
from O
_RARE_ I-GENE
_RARE_ I-GENE
is O
a O
highly O
specific I-GENE
N I-GENE
- I-GENE
_RARE_ I-GENE
removing O
adenine O
residues O
( O
_RARE_ I-GENE
in O
28S I-GENE
rRNA I-GENE
and O
_RARE_ I-GENE
in O
_RARE_ I-GENE
rRNA I-GENE
) O
from O
intact O
_RARE_ I-GENE
of O
both O
eukaryotes O
and O
_RARE_ I-GENE
. O

OBJECTIVE O
: O
This O
_RARE_ I-GENE
- I-GENE
analysis O
of O
67 O
controlled O
trials O
was O
performed O
to O
_RARE_ I-GENE
the O
cholesterol I-GENE
- I-GENE
lowering O
effect O
of O
major I-GENE
dietary O
fibers O
. O

Among O
these O
_RARE_ I-GENE
_RARE_ I-GENE
, O
a O
novel O
_RARE_ I-GENE
cDNA I-GENE
named O
_RARE_ I-GENE
( O
human I-GENE
fetal O
heart O
_RARE_ I-GENE
) O
with O
sequence I-GENE
homology I-GENE
to O
a O
_RARE_ I-GENE
- I-GENE
associated I-GENE
box I-GENE
( O
KRAB I-GENE
) O
was O
identified O
. O

The O
3 I-GENE
. O
3 I-GENE
- I-GENE
fold O
higher O
expression O
in O
the O
fetal O
heart O
than O
in O
the O
adult O
heart O
suggests O
that O
_RARE_ I-GENE
mRNA I-GENE
is O
_RARE_ I-GENE
in O
the O
process O
of O
development O
. O

When O
the O
high O
affinity O
hnRNP I-GENE
A1 I-GENE
binding I-GENE
site I-GENE
was O
inserted O
into O
the O
beta I-GENE
- I-GENE
globin I-GENE
reporter I-GENE
, O
Rev I-GENE
was O
able O
to O
increase O
the O
cytoplasmic I-GENE
levels O
of O
unspliced O
mRNAs I-GENE
to O
14 O
%. O

To O
date O
, O
two O
such O
proteins I-GENE
, O
PLZF I-GENE
and O
_RARE_ I-GENE
- I-GENE
3 I-GENE
/ I-GENE
BCL I-GENE
- I-GENE
6 I-GENE
, O
have O
been O
implicated O
in O
_RARE_ I-GENE
. O

Overexpression O
of O
_RARE_ I-GENE
inhibits O
alpha I-GENE
- I-GENE
factor I-GENE
- I-GENE
induced O
G1 I-GENE
arrest O
and O
transcriptional O
repression O
of O
the O
_RARE_ I-GENE
and O
_RARE_ I-GENE
genes I-GENE
. O

We O
now O
show O
that O
_RARE_ I-GENE
_RARE_ I-GENE
can O
be O
induced O
by O
transfection O
with O
an O
expression O
vector O
encoding O
_RARE_ I-GENE
E1B I-GENE
55 O
kDa I-GENE
alone O
but O
not O
by O
an O
E1 I-GENE
vector O
encoding O
all O
E1 I-GENE
products I-GENE
( O
3 I-GENE
E1A I-GENE
proteins I-GENE
, O
as O
well O
as O
the O
E1B I-GENE
19 O
kDa I-GENE
and O
55 O
kDa I-GENE
proteins I-GENE
). O

_RARE_ I-GENE
EMSA O
assays O
revealed O
that O
multiple O
proteins I-GENE
were O
involved O
in O
_RARE_ I-GENE
complex I-GENE
formation O
with O
KCS I-GENE
, O
one O
of O
which O
was O
identified O
as O
factor I-GENE
Sp1 I-GENE
. O

_RARE_ I-GENE
of O
DNA I-GENE
binding I-GENE
and O
transcriptional O
regulation O
by O
Caenorhabditis I-GENE
elegans I-GENE
_RARE_ I-GENE
- I-GENE
3 I-GENE
and O
Drosophila I-GENE
melanogaster I-GENE
_RARE_ I-GENE
suggests O
conservation O
of O
sex I-GENE
determining O
mechanisms O
. O

_RARE_ I-GENE
: O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
are O
3 I-GENE
new O
_RARE_ I-GENE
that O
increase O
the O
sensitivity O
and O
cost O
of O
cervical O
cancer O
screening O
. O

Experiments O
on O
_RARE_ I-GENE
cats O
demonstrated O
that O
the O
derivatives O
of O
2 I-GENE
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
the O
properties O
of O
specific I-GENE
_RARE_ I-GENE
agents O
and O
coded O
as O
CM I-GENE
- I-GENE
_RARE_ I-GENE
, O
CM I-GENE
- I-GENE
_RARE_ I-GENE
, O
and O
CM I-GENE
- I-GENE
_RARE_ I-GENE
, O
reduce O
the O
mean O
rise O
of O
segment O
ST O
on O
numerous O
leads O
of O
the O
_RARE_ I-GENE
_RARE_ I-GENE
during O
5 I-GENE
- I-GENE
min O
occlusion O
of O
the O
anterior O
_RARE_ I-GENE
branch O
of O
the O
left O
coronary O
artery O
. O

Neither O
the O
_RARE_ I-GENE
/ I-GENE
44 I-GENE
nor O
the O
JNK I-GENE
pathway O
was O
involved O
in O
the O
action O
of O
IL I-GENE
- I-GENE
1beta I-GENE
. O

In O
protocol O
2 I-GENE
, O
eight O
different O
subjects O
performed O
_RARE_ I-GENE
and O
_RARE_ I-GENE
arm O
_RARE_ I-GENE
to O
_RARE_ I-GENE
, O
followed O
by O
_RARE_ I-GENE
muscle O
ischemia O
, O
by O
using O
the O
same O
resistance O
as O
in O
protocol O
1 I-GENE
. O

_RARE_ I-GENE
was O
measured O
with O
a O
_RARE_ I-GENE
- I-GENE
designed O
_RARE_ I-GENE
and O
a O
45 O
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
long O
_RARE_ I-GENE
to O
reach O
the O
volume O
- I-GENE
measuring O
_RARE_ I-GENE
. O

Both O
mutations O
confer O
amino O
acid I-GENE
substitutions O
in O
the O
viral I-GENE
coat I-GENE
protein I-GENE
but O
differ O
in O
their O
relative O
abilities O
to O
_RARE_ I-GENE
the O
foreign O
_RARE_ I-GENE
protein I-GENE
. O

_RARE_ I-GENE
recovery O
of O
liver O
function O
after O
this O
surgery O
tended O
to O
be O
slow O
. O

Although O
both O
transcripts I-GENE
share O
the O
first O
nine O
exons O
, O
exon O
10 O
of O
_RARE_ I-GENE
- I-GENE
2 I-GENE
is O
lacking O
in O
_RARE_ I-GENE
- I-GENE
1 I-GENE
, O
and O
instead O
, O
exon O
11 O
( O
_RARE_ I-GENE
exon O
) O
of O
_RARE_ I-GENE
- I-GENE
1 I-GENE
is O
larger O
in O
size O
, O
leading O
to O
the O
longer O
3 I-GENE
'- O
UTR I-GENE
. O

Expression O
of O
the O
second O
gene I-GENE
( O
_RARE_ I-GENE
) O
was O
found O
to O
be O
conserved O
in O
human I-GENE
kidney O
, O
and O
partial O
sequence I-GENE
was O
obtained O
from O
a O
human I-GENE
cDNA I-GENE
library O
. O

IFN I-GENE
- I-GENE
gamma I-GENE
was O
elevated O
during O
active O
TB I-GENE
when O
compared O
with O
healthy O
controls O
, O
_RARE_ I-GENE
during O
and O
after O
treatment O
. O

The O
missing O
5 I-GENE
' O
sequences I-GENE
were O
obtained O
by O
5 I-GENE
'- O
rapid O
amplification O
of O
cDNA I-GENE
ends O
and O
by O
analysis O
of O
an O
_RARE_ I-GENE
genomic O
clone O
, O
and O
the O
missing O
3 I-GENE
' O
sequences I-GENE
were O
obtained O
by O
3 I-GENE
'- O
rapid O
amplification O
of O
cDNA I-GENE
ends O
. O

If O
no O
_RARE_ I-GENE
are O
detected O
, O
further O
analysis O
to O
define O
a O
role O
of O
drug O
- I-GENE
related I-GENE
or O
autoantibodies O
is O
required O
. O

This O
dependence O
, O
however O
, O
can O
be O
overcome O
to O
a O
large O
extent O
by O
_RARE_ I-GENE
min O
_RARE_ I-GENE
/ I-GENE
dt O
by O
mean O
aortic O
pressure O
. O

_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
24 O
- I-GENE
28 O
August O
1997 O
. O

_RARE_ I-GENE
structure O
of O
delta I-GENE
- I-GENE
plutonium O
and O
of O
single O
Al O
, O
Ga O
, O
and O
_RARE_ I-GENE
_RARE_ I-GENE
in O
delta I-GENE
- I-GENE
plutonium O
. O

_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
transfer I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
spectra O
for O
_RARE_ I-GENE
in O
_RARE_ I-GENE
. O

_RARE_ I-GENE
theory O
of O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
organic O
charge I-GENE
- I-GENE
transfer I-GENE
_RARE_ I-GENE
: O
Magnetic O
properties O
. O

_RARE_ I-GENE
modes O
of O
a O
_RARE_ I-GENE
. O

II I-GENE
. O

_RARE_ I-GENE
- I-GENE
function O
_RARE_ I-GENE
conditions O
for O
_RARE_ I-GENE
_RARE_ I-GENE
Al O
, O
Ga O
) O
As O
_RARE_ I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
measurements O
of O
critical O
_RARE_ I-GENE
in O
_RARE_ I-GENE
: O
A I-GENE
_RARE_ I-GENE
& O
_RARE_ I-GENE
_RARE_ I-GENE
1 I-GENE
_RARE_ I-GENE
. O

( O
2 I-GENE
) O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
cells O
showed O
a O
lower O
level O
of O
bulk O
PKC I-GENE
catalytic O
activity O
, O
lacked O
the O
expression O
of O
epsilon I-GENE
and O
_RARE_ I-GENE
PKC I-GENE
isoforms I-GENE
, O
and O
showed O
a O
weak O
or O
absent O
_RARE_ I-GENE
of O
the O
remaining O
isoforms I-GENE
, O
except O
_RARE_ I-GENE
, O
upon O
_RARE_ I-GENE
of O
Epo I-GENE
to O
growth I-GENE
factor I-GENE
- I-GENE
_RARE_ I-GENE
cells O
. O

We O
used O
expression O
cloning O
to O
identify O
interleukin I-GENE
- I-GENE
6 I-GENE
( O
IL I-GENE
- I-GENE
6 I-GENE
) O
as O
one O
factor I-GENE
that O
suppressed O
growth I-GENE
of O
a O
pre I-GENE
- I-GENE
B I-GENE
- I-GENE
cell O
variant I-GENE
line O
, O
_RARE_ I-GENE
- I-GENE
M I-GENE
. O

_RARE_ I-GENE
through O
the O
dust O
_RARE_ I-GENE
was O
controlled O
with O
a O
_RARE_ I-GENE
pump I-GENE
. O

Thus O
, O
in O
normal O
intestinal O
epithelial O
_RARE_ I-GENE
cells O
, O
_RARE_ I-GENE
and O
_RARE_ I-GENE
can O
respond O
to O
autocrine O
but O
not O
exogenous O
TGF I-GENE
- I-GENE
beta I-GENE
without O
the O
participation O
of O
_RARE_ I-GENE
. O

The O
history O
of O
exposure O
and O
_RARE_ I-GENE
levels O
should O
_RARE_ I-GENE
the O
_RARE_ I-GENE
to O
this O
diagnosis O
. O

The O
odds O
ratio O
for O
_RARE_ I-GENE
was O
1 I-GENE
. O
21 O
( O
95 O
% O
confidence O
interval O
, O
0 O
. O
84 O
- I-GENE
1 I-GENE
. O
75 O
) O
given O
a O
positive O
_RARE_ I-GENE
of O
specific I-GENE
IgG I-GENE
antibodies I-GENE
after O
adjustment O
for O
_RARE_ I-GENE
. O

Another O
group O
of O
_RARE_ I-GENE
- I-GENE
and O
_RARE_ I-GENE
- I-GENE
lesioned O
animals O
_RARE_ I-GENE
on O
the O
tasks O
after O
the O
lesion O
showed O
reduced O
_RARE_ I-GENE
of O
the O
type I-GENE
described O
above O
, O
suggesting O
that O
_RARE_ I-GENE
structures O
_RARE_ I-GENE
after O
the O
lesion O
can O
_RARE_ I-GENE
the O
role O
of O
the O
hippocampus O
to O
some O
degree O
. O

The O
case O
for O
_RARE_ I-GENE
from O
_RARE_ I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
of O
fluctuations O
in O
one O
- I-GENE
dimensional O
interface O
and O
_RARE_ I-GENE
models O
. O

_RARE_ I-GENE
of O
_RARE_ I-GENE
dynamics O
of O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
motion O
. O

NMR O
of O
_RARE_ I-GENE
_RARE_ I-GENE
in O
a O
periodic I-GENE
_RARE_ I-GENE
medium O
in O
the O
presence O
of O
a O
_RARE_ I-GENE
magnetic O
field O
. O

_RARE_ I-GENE
and O
_RARE_ I-GENE
of O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
heat I-GENE
transport O
in O
the O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
liquid O
crystal O
. O

Direct I-GENE
approach O
to O
the O
study O
of O
_RARE_ I-GENE
_RARE_ I-GENE
. O

Mutations O
affecting O
only O
CD4 I-GENE
regulation O
mapped O
to O
residues O
previously O
shown O
to O
mediate O
the O
binding I-GENE
of O
Nef I-GENE
to O
this O
receptor I-GENE
, O
such O
as O
_RARE_ I-GENE
and O
_RARE_ I-GENE
, O
as O
well O
as O
to O
an O
AP I-GENE
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
motif I-GENE
and O
to O
an O
acidic O
_RARE_ I-GENE
in O
the O
C I-GENE
- I-GENE
terminal I-GENE
region O
of O
the O
protein I-GENE
. O

Several O
mutations O
disrupted O
the O
endonuclease I-GENE
and O
helicase I-GENE
activities O
; O
however O
, O
only O
one O
amino O
- I-GENE
terminal I-GENE
- I-GENE
charge I-GENE
cluster I-GENE
mutant I-GENE
protein I-GENE
( O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
) O
completely O
lost O
AAV I-GENE
hairpin O
DNA I-GENE
binding I-GENE
activity O
. O

The O
lytic O
cycle O
of O
KSHV I-GENE
, O
probably O
under O
the O
initial O
control O
of O
the O
KSHV I-GENE
/ I-GENE
_RARE_ I-GENE
gene I-GENE
, O
may O
directly O
contribute O
to O
tumor I-GENE
pathogenesis O
. O

We O
conclude O
that O
( O
i O
) O
we O
have O
identified O
several O
candidate O
latency O
genes I-GENE
of O
murine I-GENE
_RARE_ I-GENE
, O
( O
ii O
) O
expression O
of O
genes I-GENE
during O
latency O
may O
be O
different O
in O
different O
organs O
, O
consistent O
with O
multiple O
latency O
programs O
and O
/ I-GENE
or O
multiple O
cellular O
sites I-GENE
of O
latency O
, O
and O
( O
iii O
) O
regions O
of O
the O
viral I-GENE
genome O
( O
v I-GENE
- I-GENE
bcl I-GENE
- I-GENE
2 I-GENE
gene I-GENE
, O
v I-GENE
- I-GENE
_RARE_ I-GENE
gene I-GENE
, O
and O
gene I-GENE
73 O
) O
are O
transcribed O
during O
latency O
with O
both O
_RARE_ I-GENE
and O
primate O
_RARE_ I-GENE
. O

These O
data O
indicate O
a O
functional O
role O
for O
U1 I-GENE
in O
_RARE_ I-GENE
- I-GENE
mediated O
splicing O
inhibition O
. O

This O
suggests O
that O
the O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
system O
_RARE_ I-GENE
to O
external O
substrates O
. O

Here O
we O
describe O
the O
identification O
and O
characterization O
of O
several O
_RARE_ I-GENE
splice O
variant I-GENE
proteins I-GENE
and O
support O
their O
existence O
by O
_RARE_ I-GENE
of O
the O
3 I-GENE
'- O
end O
of O
the O
_RARE_ I-GENE
gene I-GENE
. O

_RARE_ I-GENE
in O
the O
specific I-GENE
heat I-GENE
of O
_RARE_ I-GENE
_RARE_ I-GENE
induced O
by O
critical O
spin O
- I-GENE
wave O
dynamics O
. O

_RARE_ I-GENE
: O
_RARE_ I-GENE
of O
precursor I-GENE
effects O
above O
the O
_RARE_ I-GENE
transformation O
in O
a O
_RARE_ I-GENE
crystal O
of O
Li O
metal O

_RARE_ I-GENE
coupling O
in O
the O
_RARE_ I-GENE
_RARE_ I-GENE
as O
revealed O
by O
_RARE_ I-GENE
spin O
- I-GENE
echo O
double O
resonance O
. O

_RARE_ I-GENE
structure O
of O
a O
_RARE_ I-GENE
_RARE_ I-GENE
or O
_RARE_ I-GENE
layer O
in O
bulk O
_RARE_ I-GENE
. O

_RARE_ I-GENE
investigation O
of O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
. O

Effects O
of O
point O
defects O
on O
_RARE_ I-GENE
parameters O
of O
_RARE_ I-GENE
. O

_RARE_ I-GENE
electron O
dynamics O
around O
a O
single O
_RARE_ I-GENE
shaped O
_RARE_ I-GENE
. O

However O
, O
deletions O
of O
the O
C I-GENE
terminal I-GENE
11 O
or O
14 O
amino O
acids O
had O
more O
substantial O
effects O
. O

_RARE_ I-GENE
months O
after O
the O
initial O
vaccination O
, O
all O
_RARE_ I-GENE
who O
received O
annual O
follow O
- I-GENE
up O
still O
had O
protective O
levels O
of O
anti I-GENE
- I-GENE
_RARE_ I-GENE
. O

However O
, O
after O
PRK O
at O
5 I-GENE
weeks O
of O
age O
, O
partial O
_RARE_ I-GENE
may O
be O
necessary O
due O
to O
regression O
of O
the O
PRK O
effect O
. O

Its O
early I-GENE
lesions O
were O
characterized O
by O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
and O
proliferation O
of O
_RARE_ I-GENE
and O
fibroblasts O
. O

Molecular O
cloning O
of O
human I-GENE
cDNA I-GENE
encoding O
a O
novel O
beta1 I-GENE
, O
6 I-GENE
- I-GENE
N I-GENE
- I-GENE
_RARE_ I-GENE
forming O
core I-GENE
2 I-GENE
and O
core I-GENE
4 I-GENE
. O

_RARE_ I-GENE
mouse I-GENE
back O
- I-GENE
cross O
analysis O
identified O
the O
loci I-GENE
for O
mouse I-GENE
_RARE_ I-GENE
genes I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
of O
corresponding O
human I-GENE
_RARE_ I-GENE
were O
confirmed O
by O
the O
identification O
of O
mapped O
sequence I-GENE
- I-GENE
tagged O
site I-GENE
markers O
. O

The O
_RARE_ I-GENE
of O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
From O
_RARE_ I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
), O
a O
battery O
based O
on O
commonly O
used O
dementia O
rating O
instruments O
, O
was O
tested O
on O
the O
records O
of O
26 O
_RARE_ I-GENE
_RARE_ I-GENE
, O
elderly O
schizophrenia O
patients O
, O
for O
the O
purpose O
of O
_RARE_ I-GENE
evaluating O
the O
long O
- I-GENE
term O
course O
of O
cognitive O
change O
in O
schizophrenia O
and O
_RARE_ I-GENE
it O
to O
available O
autopsy O
materials O
. O

It O
was O
demonstrated O
that O
the O
processing O
signals O
in O
the O
transcript I-GENE
, O
i O
. O
e O
. O
both O
donor O
splice O
sites I-GENE
and O
the O
polyadenylation O
site I-GENE
located O
in O
the O
muscle O
- I-GENE
specific I-GENE
intron O
, O
have O
to O
be O
weak O
. O

Most O
recently O
, O
the O
use O
of O
the O
product I-GENE
of O
brain O
weight O
and O
clearance O
has O
been O
proposed O
. O

_RARE_ I-GENE
and O
transcription I-GENE
of O
the O
endogenous I-GENE
Ig I-GENE
heavy I-GENE
chain I-GENE
locus I-GENE
is O
_RARE_ I-GENE
by O
the O
Ig I-GENE
heavy I-GENE
chain I-GENE
intronic I-GENE
enhancer I-GENE
core I-GENE
region O
in O
the O
absence O
of O
the O
matrix I-GENE
attachment O
regions O
. O

Two O
of O
these O
motifs O
are O
part O
of O
a O
highly O
conserved O
and O
inducible I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
element I-GENE
shown O
previously O
to O
control O
a O
_RARE_ I-GENE
IL I-GENE
- I-GENE
2 I-GENE
enhancer I-GENE
and O
the O
_RARE_ I-GENE
promoter I-GENE
. O

In O
_RARE_ I-GENE
with O
the O
coactivator I-GENE
CREB I-GENE
binding I-GENE
protein I-GENE
/ I-GENE
p300 I-GENE
, O
which O
interacts O
with O
_RARE_ I-GENE
, O
the O
binding I-GENE
of O
_RARE_ I-GENE
and O
- I-GENE
beta I-GENE
to O
the O
_RARE_ I-GENE
_RARE_ I-GENE
element I-GENE
controls O
the O
induction O
of O
IL I-GENE
- I-GENE
16 O
promoter I-GENE
in O
T I-GENE
cells O
. O

_RARE_ I-GENE
by O
itself O
did O
not O
activate O
ERK1 I-GENE
, O
ERK2 I-GENE
and O
protein I-GENE
kinase I-GENE
C I-GENE
( O
PKC I-GENE
), O
whereas O
_RARE_ I-GENE
directly O
enhanced O
the O
PKC I-GENE
- I-GENE
dependent I-GENE
activation O
of O
ERKs I-GENE
induced O
by O
other O
agonists O
including O
thrombin I-GENE
and O
phorbol O
esters O
, O
without O
affecting O
the O
PKC I-GENE
activation O
by O
those O
agonists O
. O

BACKGROUND O
: O
In O
the O
ubiquitin I-GENE
- I-GENE
dependent I-GENE
proteolysis O
pathway O
, O
a O
ubiquitin I-GENE
ligase I-GENE
( O
E3 I-GENE
) O
is O
responsible O
for O
substrate I-GENE
selectivity O
and O
timing O
of O
degradation O
. O

CONCLUSIONS O
: O
_RARE_ I-GENE
yeast I-GENE
_RARE_ I-GENE
is O
composed O
of O
_RARE_ I-GENE
and O
_RARE_ I-GENE
, O
two O
structurally O
related I-GENE
but O
functionally O
independent O
F I-GENE
- I-GENE
box I-GENE
/ I-GENE
WD I-GENE
- I-GENE
repeat I-GENE
proteins I-GENE
. O

_RARE_ I-GENE
NMR O
studies O
in O
_RARE_ I-GENE
- I-GENE
type I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
- I-GENE
absorption O
spectra O
, O
crystal O
- I-GENE
field O
energy O
levels O
, O
and O
transition O
line O
strengths O
of O
_RARE_ I-GENE
in O
_RARE_ I-GENE
_RARE_ I-GENE

_RARE_ I-GENE
of O
_RARE_ I-GENE
interactions O
between O
_RARE_ I-GENE
defects O
at O
the O
( O
111 O
) O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
interface O
. O

_RARE_ I-GENE
- I-GENE
statistical O
theory O
of O
high O
- I-GENE
field O
transport O
phenomena O
. O

_RARE_ I-GENE
and O
NO O
interaction O
with O
_RARE_ I-GENE
( O
100 O
_RARE_ I-GENE
2 I-GENE
x O
1 I-GENE
) O
_RARE_ I-GENE
. O

_RARE_ I-GENE
- I-GENE
glass O
and O
spin O
- I-GENE
glass O
correlations O
in O
the O
two O
- I-GENE
dimensional O
random O
- I-GENE
bond O
_RARE_ I-GENE
model O
. O

_RARE_ I-GENE
modulation O
in O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
of O
_RARE_ I-GENE
- I-GENE
light I-GENE
emission O
from O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
in O
the O
_RARE_ I-GENE
chains I-GENE
of O
a O
single O
- I-GENE
domain I-GENE
_RARE_ I-GENE
- I-GENE
delta I-GENE
crystal O
. O

_RARE_ I-GENE
spin O
waves O
in O
a O
_RARE_ I-GENE
_RARE_ I-GENE
with O
a O
single O
- I-GENE
ion O
_RARE_ I-GENE
( O
_RARE_ I-GENE
and O
_RARE_ I-GENE
). O

_RARE_ I-GENE
detected O
_RARE_ I-GENE
and O
_RARE_ I-GENE
in O
crystalline O
_RARE_ I-GENE
. O

_RARE_ I-GENE
- I-GENE
relaxation O
_RARE_ I-GENE
and O
_RARE_ I-GENE
structure O
of O
a O
W I-GENE
( O
111 O
) O
surface O
. O

_RARE_ I-GENE
dependence O
of O
the O
_RARE_ I-GENE
spontaneous O
_RARE_ I-GENE
of O
_RARE_ I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
for O
electron O
self O
- I-GENE
_RARE_ I-GENE
in O
_RARE_ I-GENE
and O
_RARE_ I-GENE
. O

_RARE_ I-GENE
measurement O
of O
the O
_RARE_ I-GENE
mass O
difference O
m I-GENE
pi I-GENE
-- O
m I-GENE
pi I-GENE
0 O
. O

_RARE_ I-GENE
_RARE_ I-GENE
to O
second O
post O
- I-GENE
_RARE_ I-GENE
order O
: O
A I-GENE
field O
- I-GENE
theory O
approach O
. O

Genetic O
experiments O
using O
mutants I-GENE
defective O
in O
_RARE_ I-GENE
and O
_RARE_ I-GENE
reveal O
a O
functional O
interaction O
between O
these O
genes I-GENE
. O

In O
the O
current O
model O
, O
_RARE_ I-GENE
/ I-GENE
Wnt I-GENE
signal I-GENE
stabilizes O
_RARE_ I-GENE
/ I-GENE
beta I-GENE
- I-GENE
catenin I-GENE
, O
which O
then O
accumulates O
in O
nuclei O
and O
binds O
TCF I-GENE
/ I-GENE
_RARE_ I-GENE
family I-GENE
proteins I-GENE
, O
forming O
bipartite O
transcription I-GENE
factors I-GENE
which O
activate O
transcription I-GENE
of O
_RARE_ I-GENE
/ I-GENE
Wnt I-GENE
responsive I-GENE
genes I-GENE
. O

In O
support O
of O
clinical O
_RARE_ I-GENE
studies O
, O
the O
vasodilator O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
was O
combined O
with O
the O
beta I-GENE
- I-GENE
adrenergic I-GENE
receptor I-GENE
antagonists O
propranolol O
( O
_RARE_ I-GENE
) O
and O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
and O
with O
the O
calcium O
channel O
blocker O
diltiazem O
( O
_RARE_ I-GENE
) O
to O
determine O
their O
cardiovascular O
and O
pharmacokinetic O
interactions O
. O

Factors O
influencing O
direct O
- I-GENE
immersion O
( O
_RARE_ I-GENE
)- I-GENE
_RARE_ I-GENE
process O
were O
also O
_RARE_ I-GENE
and O
chosen O
experimentally O
. O

In O
contrast O
, O
an O
amino O
- I-GENE
terminal I-GENE
fragment I-GENE
containing O
the O
C I-GENE
/ I-GENE
H1 I-GENE
domain I-GENE
was O
sufficient O
for O
_RARE_ I-GENE
of O
Zta I-GENE
transcription I-GENE
and O
viral I-GENE
_RARE_ I-GENE
function O
. O

In O
addition O
, O
a O
potent O
splicing O
enhancer I-GENE
sequence I-GENE
isolated O
in O
the O
selection O
specifically O
binds O
a O
20 O
- I-GENE
kDa I-GENE
SR I-GENE
protein I-GENE
. O

Elimination O
of O
_RARE_ I-GENE
in O
_RARE_ I-GENE
strains O
also O
increased O
spontaneous O
mutation I-GENE
rates O
9 O
- I-GENE
or O
31 O
- I-GENE
fold O
compared O
to O
the O
wild I-GENE
type I-GENE
as O
determined O
by O
_RARE_ I-GENE
to O
adenine O
or O
lysine O
_RARE_ I-GENE
, O
respectively O
. O

Elimination O
of O
_RARE_ I-GENE
in O
_RARE_ I-GENE
strains O
also O
increased O
spontaneous O
mutation I-GENE
rates O
9 O
- I-GENE
or O
31 O
- I-GENE
fold O
compared O
to O
the O
wild I-GENE
type I-GENE
as O
determined O
by O
_RARE_ I-GENE
to O
adenine O
or O
lysine O
_RARE_ I-GENE
, O
respectively O
. O

These O
data O
suggest O
that O
other O
Ras I-GENE
effectors I-GENE
can O
_RARE_ I-GENE
with O
PI I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
and O
with O
each O
other O
to O
activate O
_RARE_ I-GENE
. O

_RARE_ I-GENE
Ras I-GENE
GTPase I-GENE
- I-GENE
activating I-GENE
protein I-GENE
( O
GAP I-GENE
), O
_RARE_ I-GENE
Ras I-GENE
- I-GENE
GAP I-GENE
, O
has O
been O
implicated O
as O
both O
a O
_RARE_ I-GENE
and O
effector O
of O
Ras I-GENE
proteins I-GENE
, O
but O
its O
precise O
role O
in O
Ras I-GENE
- I-GENE
mediated O
signal I-GENE
transduction O
pathways O
is O
unclear O
. O

Three O
_RARE_ I-GENE
- I-GENE
1 I-GENE
alleles I-GENE
possess O
premature O
stop O
codons O
and O
are O
likely O
to O
be O
null I-GENE
alleles I-GENE
, O
and O
one O
is O
a O
missense O
mutation I-GENE
and O
is O
likely O
to O
_RARE_ I-GENE
residual O
activity O
. O
_RARE_ I-GENE
- I-GENE
1 I-GENE
mRNA I-GENE
is O
expressed O
in O
both O
germ I-GENE
line O
and O
somatic O
tissues O
and O
appears O
to O
be O
ubiquitous O
. O

However O
, O
unlike O
the O
_RARE_ I-GENE
gene I-GENE
of O
Saccharomyces I-GENE
cerevisiae I-GENE
, O
_RARE_ I-GENE
(+) I-GENE
is O
essential O
for O
cell O
viability O
. O

The O
_RARE_ I-GENE
protein I-GENE
sequence I-GENE
does O
not O
contain O
readily O
_RARE_ I-GENE
motifs O
of O
known O
function O
. O

The O
distribution O
of O
the O
various O
repeats I-GENE
suggests O
its O
organization O
is O
similar O
to O
the O
beta I-GENE
- I-GENE
_RARE_ I-GENE
regions O
near O
the O
base O
of O
the O
major I-GENE
chromosome O
_RARE_ I-GENE
. O

_RARE_ I-GENE
simultaneously O
regulates O
both O
_RARE_ I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
in O
the O
spinal O
_RARE_ I-GENE
mouse I-GENE
( O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
) O
in O
vivo O
. O

Electrophoretic O
mobility I-GENE
- I-GENE
shift O
assays O
performed O
with O
the O
HNF I-GENE
- I-GENE
3 I-GENE
X I-GENE
and O
Y I-GENE
sites I-GENE
demonstrated O
that O
both O
sites I-GENE
are O
capable O
of O
binding I-GENE
HNF I-GENE
- I-GENE
_RARE_ I-GENE
and O
HNF I-GENE
- I-GENE
_RARE_ I-GENE
. O

In O
addition O
, O
we O
also O
show O
that O
_RARE_ I-GENE
may O
phosphorylate O
the O
carboxy I-GENE
- I-GENE
terminal I-GENE
domain I-GENE
( O
CTD I-GENE
) O
of O
RNA I-GENE
pol I-GENE
II I-GENE
in O
the O
absence O
of O
promoter I-GENE
_RARE_ I-GENE
. O

The O
therapy O
with O
a O
H2 I-GENE
- I-GENE
receptor I-GENE
antagonist O
is O
less O
effective O
than O
the O
triple O
_RARE_ I-GENE
with O
omeprazole O
or O
_RARE_ I-GENE
. O

In O
humans O
, O
three O
tissue I-GENE
- I-GENE
specific I-GENE
plastin I-GENE
isoforms I-GENE
have O
been O
identified O
. O

No O
TATA I-GENE
or O
_RARE_ I-GENE
sequence I-GENE
was O
found O
. O

The O
inhibition O
by O
the O
_RARE_ I-GENE
subunit I-GENE
is O
reversed O
by O
addition O
of O
_RARE_ I-GENE
concentrations O
of O
cAMP I-GENE
( O
_RARE_ I-GENE
= O
40 I-GENE
nM O
), O
thus O
demonstrating O
that O
_RARE_ I-GENE
is O
a O
novel O
, O
type I-GENE
I I-GENE
cAMP I-GENE
- I-GENE
dependent I-GENE
protein I-GENE
kinase I-GENE
that O
is O
activated I-GENE
at O
lower O
cAMP I-GENE
concentrations O
than O
the O
holoenzyme I-GENE
with O
the O
_RARE_ I-GENE
subunit I-GENE
of O
cAMP I-GENE
- I-GENE
dependent I-GENE
protein I-GENE
kinase I-GENE
. O

_RARE_ I-GENE
known O
to O
bind O
the O
PEPCK I-GENE
CRE O
include O
the O
CRE O
- I-GENE
binding I-GENE
protein I-GENE
( O
CREB I-GENE
) O
and O
members O
of O
the O
CCAAT I-GENE
/ I-GENE
enhancer I-GENE
- I-GENE
binding I-GENE
protein I-GENE
( O
C I-GENE
/ I-GENE
EBP I-GENE
) O
family I-GENE
. O

This O
construct I-GENE
, O
termed O
_RARE_ I-GENE
/ I-GENE
EBP I-GENE
, O
binds O
C I-GENE
/ I-GENE
_RARE_ I-GENE
and O
beta I-GENE
but O
not O
CREB I-GENE
, O
yet O
it O
confers O
a O
nearly O
complete O
glucocorticoid I-GENE
response O
when O
transiently O
transfected O
into O
_RARE_ I-GENE
rat I-GENE
hepatoma O
cells O
. O

In O
addition O
, O
in O
vitro O
mutagenesis O
of O
both O
_RARE_ I-GENE
and O
_RARE_ I-GENE
sites I-GENE
indicated O
that O
other O
unidentified O
sites I-GENE
are O
responsible O
for O
the O
transcriptional O
enhancement O
observed O
with O
the O
intronic I-GENE
fragment I-GENE
. O

Several O
secondary O
structure O
elements O
were O
identified O
. O

Here O
, O
we O
evidence O
that O
the O
developmental O
functions O
of O
the O
family I-GENE
of O
transcription I-GENE
factors I-GENE
characterized O
by O
the O
POU I-GENE
DNA I-GENE
binding I-GENE
motif I-GENE
exerts O
roles O
in O
mammalian I-GENE
development O
. O

High O
- I-GENE
affinity O
site I-GENE
- I-GENE
specific I-GENE
DNA I-GENE
binding I-GENE
by O
POU I-GENE
domain I-GENE
transcription I-GENE
factors I-GENE
requires O
both O
the O
POU I-GENE
- I-GENE
specific I-GENE
and O
the O
POU I-GENE
- I-GENE
homeodomain I-GENE
. O

In O
the O
Oct I-GENE
- I-GENE
1 I-GENE
crystal O
, O
the O
POU I-GENE
- I-GENE
specific I-GENE
domain I-GENE
recognizes O
a O
_RARE_ I-GENE
half O
- I-GENE
site I-GENE
, O
while O
the O
corresponding O
sequence I-GENE
recognized O
by O
the O
Pit I-GENE
- I-GENE
1 I-GENE
POU I-GENE
- I-GENE
specific I-GENE
domain I-GENE
, O
_RARE_ I-GENE
, O
is O
on O
the O
_RARE_ I-GENE
strand O
. O

_RARE_ I-GENE
functional O
analysis O
of O
_RARE_ I-GENE
/ I-GENE
V2 I-GENE
hybrid O
receptors I-GENE
showed O
that O
the O
second O
intracellular O
loop I-GENE
of O
the O
_RARE_ I-GENE
receptor I-GENE
is O
required O
and O
sufficient O
for O
efficient O
coupling O
to O
_RARE_ I-GENE
/ I-GENE
11 O
, O
whereas O
the O
third O
intracellular O
loop I-GENE
of O
the O
V2 I-GENE
receptor I-GENE
is O
required O
and O
sufficient O
for O
coupling O
to O
Gs I-GENE
. O

Most O
other O
end O
points O
were O
highly O
significant O
, O
and O
death O
, O
which O
was O
monitored O
across O
the O
U O
. O
S I-GENE
. O
program O
, O
was O
different O
with O
p O
< O
0 O
. O
0001 O
. O

The O
other O
is O
located O
at O
- I-GENE
_RARE_ I-GENE
, O
outside O
this O
highly O
conserved O
region O
. O

The O
_RARE_ I-GENE
exercise O
showed O
relatively O
high O
blood O
lactate I-GENE
concentration O
[ O
12 O
. O
5 I-GENE
( O
SD O
2 I-GENE
. O
6 I-GENE
) O
mmol O
x O
l O
(- O
1 I-GENE
)] O
and O
an O
increase O
of O
serum I-GENE
creatine I-GENE
kinase I-GENE
( O
CK I-GENE
) O
activity O
delayed O
by O
2 I-GENE
days O
[ O
_RARE_ I-GENE
( O
SD O
_RARE_ I-GENE
) O
U O
x O
l O
(- O
1 I-GENE
)]. O

_RARE_ I-GENE
_RARE_ I-GENE
aspects O
were O
distributed O
in O
two O
categories O
: O
1 I-GENE
) O
type I-GENE
I I-GENE
- I-GENE
presenting O
variable O
_RARE_ I-GENE
filling O
. O

Results O
demonstrated O
that O
the O
presence O
of O
_RARE_ I-GENE
varied O
considerably O
from O
case O
to O
case O
and O
was O
always O
related I-GENE
to O
smooth I-GENE
muscle O
cell O
dispersion O
, O
which O
occurred O
around O
medium O
- I-GENE
sized O
damaged O
portal I-GENE
vein O
_RARE_ I-GENE
. O

New O
_RARE_ I-GENE
_RARE_ I-GENE
for O
a O
_RARE_ I-GENE
and O
simultaneously O
_RARE_ I-GENE
asymmetric O
top O
. O

_RARE_ I-GENE
_RARE_ I-GENE
to O
beta I-GENE
decay O
and O
the O
possibility O
of O
a O
fourth O
generation O
. O

_RARE_ I-GENE
- I-GENE
controlled O
_RARE_ I-GENE
- I-GENE
incidence O
_RARE_ I-GENE
of O
_RARE_ I-GENE
x O
radiation O
. O

_RARE_ I-GENE
exchange I-GENE
of O
_RARE_ I-GENE
between O
_RARE_ I-GENE
containing O
_RARE_ I-GENE
_RARE_ I-GENE
. O

Structure O
determination O
of O
an O
_RARE_ I-GENE
- I-GENE
induced O
_RARE_ I-GENE
reconstruction O
: O
( O
1 I-GENE
x O
2 I-GENE
)- I-GENE
H I-GENE
/ I-GENE
_RARE_ I-GENE
( O
110 I-GENE
). O

Magnetic O
_RARE_ I-GENE
of O
spin O
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
hydrogen O
. O

Northern O
blot O
and O
in O
situ O
hybridization O
analyses O
revealed O
_RARE_ I-GENE
mRNA I-GENE
transcripts I-GENE
in O
several O
human I-GENE
and O
rat I-GENE
brain O
regions O
. O

The O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
subfamily I-GENE
of O
basic I-GENE
helix I-GENE
- I-GENE
loop I-GENE
- I-GENE
helix I-GENE
leucine I-GENE
zipper I-GENE
( O
bHLH I-GENE
- I-GENE
_RARE_ I-GENE
) O
transcription I-GENE
factors I-GENE
, O
including O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
, O
has O
been O
implicated O
in O
the O
regulation O
of O
tissue I-GENE
- I-GENE
specific I-GENE
gene I-GENE
expression O
in O
several O
cell O
lineages O
. O

Fifty O
- I-GENE
seven O
patients O
aged O
< O
55 O
years O
with O
acute O
_RARE_ I-GENE
leukemia I-GENE
( O
ALL O
) O
in O
second O
or O
third O
bone O
marrow O
( O
_RARE_ I-GENE
) O
relapse O
or O
refractory O
to O
first O
- I-GENE
line O
therapy O
were O
enrolled O
in O
an O
Italian O
cooperative O
study O
. O

The O
dorsal O
nerves O
of O
the O
_RARE_ I-GENE
were O
anesthetized O
_RARE_ I-GENE
with O
lidocaine O
. O

In O
the O
brain O
, O
_RARE_ I-GENE
receptors I-GENE
mediate O
motor O
and O
memory O
function O
by O
interaction O
with O
their O
ligand O
acetylcholine I-GENE
. O

Early O
- I-GENE
onset O
_RARE_ I-GENE
necrosis I-GENE
after O
iodine O
I I-GENE
125 I-GENE
plaque O
radiotherapy O
for O
_RARE_ I-GENE
melanoma O
. O

_RARE_ I-GENE
interaction O
of O
ARF I-GENE
and O
PKC I-GENE
- I-GENE
alpha I-GENE
with O
_RARE_ I-GENE
was O
not O
achieved O
, O
but O
a O
C I-GENE
- I-GENE
terminal I-GENE
fragment I-GENE
of O
human I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
" O
_RARE_ I-GENE
_RARE_ I-GENE
interacted O
with O
the O
active O
mutant I-GENE
of O
RhoA I-GENE
, O
_RARE_ I-GENE
- I-GENE
14 O
. O

In O
this O
study O
, O
we O
investigated O
the O
signal I-GENE
transduction O
pathways O
that O
are O
involved O
in O
_RARE_ I-GENE
- I-GENE
induced O
_RARE_ I-GENE
transcription I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
as O
a O
feature O
of O
linear O
- I-GENE
dispersion O
theory O
: O
Analysis O
and O
experimental O
observations O
. O

High O
- I-GENE
pressure O
effects O
on O
_RARE_ I-GENE
- I-GENE
relaxation O
kinetics O
of O
_RARE_ I-GENE
in O
_RARE_ I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
reduction O
in O
_RARE_ I-GENE
_RARE_ I-GENE
by O
polymers O
. O

Large I-GENE
scale O
_RARE_ I-GENE
structure O
_RARE_ I-GENE
. O

Current O
world O
literature O
. O

These O
results O
show O
that O
_RARE_ I-GENE
is O
a O
component O
of O
the O
_RARE_ I-GENE
complex I-GENE
and O
that O
_RARE_ I-GENE
is O
required O
for O
the O
transcriptional O
repression O
mediated O
by O
this O
complex I-GENE
. O

Recombinant I-GENE
_RARE_ I-GENE
acts O
synergistically O
with O
recombinant I-GENE
PTB I-GENE
to O
stimulate O
translation I-GENE
dependent I-GENE
on O
the O
_RARE_ I-GENE
_RARE_ I-GENE
. O

Analysis O
of O
the O
consensus I-GENE
binding I-GENE
sequence I-GENE
and O
the O
DNA I-GENE
- I-GENE
binding I-GENE
domain I-GENE
of O
_RARE_ I-GENE
. O

Mapping O
of O
the O
human I-GENE
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
isoforms I-GENE
1 I-GENE
and O
2 I-GENE
_RARE_ I-GENE
. O

Identification O
of O
RNase I-GENE
T I-GENE
as O
a O
high O
- I-GENE
copy O
suppressor I-GENE
of O
the O
UV O
sensitivity O
associated I-GENE
with O
single O
- I-GENE
strand O
DNA I-GENE
exonuclease I-GENE
deficiency O
in O
Escherichia I-GENE
coli I-GENE
. O

Inhibition O
of O
phosphatidylinositol I-GENE
- I-GENE
3 I-GENE
kinase I-GENE
did O
not O
have O
a O
significant O
effect O
on O
p53 I-GENE
conformation O
but O
did O
have O
a O
weak O
but O
significant O
effect O
on O
_RARE_ I-GENE
- I-GENE
enhanced O
viability O
. O

No O
difference O
in O
percentage O
of O
males O
in O
semen O
production O
was O
noted O
between O
strains O
, O
CP I-GENE
levels O
, O
or O
feeding O
regimens O
. O

The O
_RARE_ I-GENE
mouse I-GENE
mutant I-GENE
provides O
a O
model O
for O
the O
severe O
human I-GENE
neural O
tube O
defect O
( O
_RARE_ I-GENE
), O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
. O

Further O
analysis O
of O
AP I-GENE
- I-GENE
1 I-GENE
DNA I-GENE
binding I-GENE
activities O
in O
7 O
- I-GENE
to O
14 O
- I-GENE
day O
culture O
activated I-GENE
_RARE_ I-GENE
led O
to O
the O
discovery O
of O
high O
mobility I-GENE
AP I-GENE
- I-GENE
1 I-GENE
complexes I-GENE
( O
_RARE_ I-GENE
- I-GENE
1 I-GENE
). O

Mutations O
of O
the O
AP I-GENE
- I-GENE
1 I-GENE
site I-GENE
of O
the O
TIMP I-GENE
- I-GENE
1 I-GENE
promoter I-GENE
that O
prevented O
formation O
of O
_RARE_ I-GENE
- I-GENE
1 I-GENE
caused O
a O
70 I-GENE
% O
loss O
of O
activity O
in O
transfected O
activated I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
DESIGN O
: O
_RARE_ I-GENE
immunoglobulin I-GENE
A I-GENE
levels O
of O
each O
of O
20 O
subjects O
were O
determined O
on O
3 I-GENE
_RARE_ I-GENE
: O
first O
, O
while O
the O
subject O
was O
still O
smoking O
; O
second O
, O
7 O
days O
after O
cessation O
of O
smoking O
; O
third O
, O
on O
the O
_RARE_ I-GENE
day O
after O
cessation O
. O

Therefore O
, O
high O
set O
- I-GENE
up O
accuracy O
and O
reproducibility O
are O
_RARE_ I-GENE
. O

Role O
of O
_RARE_ I-GENE
in O
_RARE_ I-GENE
the O
_RARE_ I-GENE
and O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
sum O
_RARE_ I-GENE
. O

_RARE_ I-GENE
of O
negative O
ions O
utilizing O
_RARE_ I-GENE
_RARE_ I-GENE
in O
a O
_RARE_ I-GENE
coupling O
_RARE_ I-GENE
. O

_RARE_ I-GENE
structure O
effects O
of O
transport O
properties O
in O
_RARE_ I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
transmission O
spectra O
in O
the O
_RARE_ I-GENE
_RARE_ I-GENE
. O

Two O
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
: O
An O
_RARE_ I-GENE
_RARE_ I-GENE
. O

Basal O
_RARE_ I-GENE
lower O
esophageal O
_RARE_ I-GENE
pressure O
was O
similar O
in O
the O
study O
group O
( O
mean O
[ O
SD O
] O
20 O
. O
1 I-GENE
[ O
9 O
. O
1 I-GENE
] O
mmHg O
) O
and O
controls O
( O
17 O
. O
6 I-GENE
[ O
6 I-GENE
. O
0 O
] O
mmHg O
); O
the O
pressure O
did O
not O
change O
following O
_RARE_ I-GENE
or O
_RARE_ I-GENE
. O

_RARE_ I-GENE
at O
these O
three O
sites I-GENE
may O
partially O
_RARE_ I-GENE
_RARE_ I-GENE
, O
thereby O
_RARE_ I-GENE
rapid O
repair I-GENE
. O

There O
was O
no O
difference O
in O
the O
hormone I-GENE
receptor I-GENE
status O
between O
the O
cases O
without O
lymph O
node O
metastases O
and O
with O
lymph O
node O
metastases O
, O
' O
_RARE_ I-GENE
' O
or O
_RARE_ I-GENE
. O

On O
the O
other O
hand O
, O
subjects O
with O
air O
_RARE_ I-GENE
( O
residual O
volume O
( O
RV O
)/ O
total O
lung O
capacity O
( O
_RARE_ I-GENE
) O
> O
37 O
%) O
_RARE_ I-GENE
not O
only O
a O
higher O
n O
( O
_RARE_ I-GENE
) O
( O
0 O
. O
63 O
+/- O
0 O
. O
17 O
versus O
0 O
. O
43 I-GENE
+/- O
0 O
. O
07 O
_RARE_ I-GENE
x O
microm O
(- O
2 I-GENE
), O
p O
< O
0 O
. O
05 O
) O
but O
shorter O
_RARE_ I-GENE
( O
L I-GENE
( O
_RARE_ I-GENE
)) O
than O
subjects O
without O
this O
functional O
abnormality O
( O
2 I-GENE
. O
_RARE_ I-GENE
+/- O
0 O
. O
16 O
to O
2 I-GENE
. O
27 O
+/- O
0 O
. O
15 O
microm O
, O
p O
< O
0 O
. O
05 O
). O

Gel O
filtration O
, O
sedimentation O
velocity O
, O
and O
immunoprecipitation O
experiments O
revealed O
that O
_RARE_ I-GENE
is O
a O
component O
of O
a O
multisubunit I-GENE
complex I-GENE
( O
AP I-GENE
- I-GENE
4 I-GENE
) O
that O
also O
contains O
the O
_RARE_ I-GENE
polypeptide I-GENE
and O
two O
additional O
adaptor I-GENE
subunit I-GENE
homologs I-GENE
named O
_RARE_ I-GENE
( O
mu I-GENE
- I-GENE
_RARE_ I-GENE
) O
and O
epsilon I-GENE
. O

Cyclin I-GENE
D1 I-GENE
- I-GENE
associated I-GENE
kinase I-GENE
activity O
and O
protein I-GENE
levels O
were O
increased O
in O
mammary O
tumors O
from O
murine I-GENE
mammary O
tumor I-GENE
virus I-GENE
- I-GENE
_RARE_ I-GENE
( O
c I-GENE
- I-GENE
_RARE_ I-GENE
) O
transgenic O
mice O
. O

The O
SH2 I-GENE
domain I-GENE
- I-GENE
containing O
inositol I-GENE
5 I-GENE
'- O
phosphatase I-GENE
( O
_RARE_ I-GENE
) O
_RARE_ I-GENE
the O
p85 I-GENE
subunit I-GENE
of O
_RARE_ I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
during O
_RARE_ I-GENE
- I-GENE
mediated O
inhibition O
of O
B I-GENE
cell O
receptor I-GENE
signaling O
. O

We O
show O
that O
the O
mouse I-GENE
genome O
contains O
four O
copies O
of O
the O
_RARE_ I-GENE
- I-GENE
9 O
gene I-GENE
. O

An O
increase O
in O
bone O
mineral O
density I-GENE
at O
the O
spine O
, O
total O
hip O
, O
and O
total O
body O
has O
been O
reported O
with O
_RARE_ I-GENE
but O
seems O
to O
be O
less O
than O
that O
seen O
with O
estrogen I-GENE
or O
_RARE_ I-GENE
therapy O
. O

However O
, O
in O
those O
studies O
due O
to O
the O
presence O
of O
_RARE_ I-GENE
agents O
in O
the O
PKC I-GENE
preparations O
, O
the O
sensitive O
reaction O
of O
_RARE_ I-GENE
with O
_RARE_ I-GENE
- I-GENE
active O
cysteine I-GENE
residues O
in O
PKC I-GENE
was O
not O
observed O
. O

Interestingly O
, O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
. O

We O
also O
identified O
an O
alternative O
spliced O
form O
of O
_RARE_ I-GENE
RNA I-GENE
, O
_RARE_ I-GENE
. O

The O
costs O
were O
DM O
11 O
, O
_RARE_ I-GENE
for O
a O
PE I-GENE
, O
DM O
12 O
, O
_RARE_ I-GENE
for O
a O
_RARE_ I-GENE
and O
DM O
7 O
, O
_RARE_ I-GENE
for O
a O
MR O
. O

We O
now O
provide O
evidence O
for O
physical O
and O
functional O
interaction O
between O
_RARE_ I-GENE
and O
the O
proteasome I-GENE
. O

_RARE_ I-GENE
splicing O
events O
involve O
three O
previously O
described O
cassette I-GENE
exons O
, O
which O
are O
predicted O
to O
encode O
most O
of O
the O
second O
transmembrane I-GENE
domain I-GENE
. O

Each O
of O
these O
genes I-GENE
contains O
a O
putative O
upstream O
ORF I-GENE
, O
while O
_RARE_ I-GENE
has O
two O
additional O
in O
- I-GENE
frame O
AUG O
codons O
5 I-GENE
' O
to O
the O
major I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
as O
well O
as O
O O
. O
_RARE_ I-GENE
. O

In O
addition O
, O
mapping O
of O
the O
promoter I-GENE
region O
and O
the O
identification O
of O
putative O
promoter I-GENE
regulatory I-GENE
sequences I-GENE
should O
give O
insight O
into O
the O
transcriptional O
regulation O
of O
_RARE_ I-GENE
expression O
-- O
in O
particular O
by O
_RARE_ I-GENE
of O
the O
above O
mentioned O
factors I-GENE
-- O
in O
vitro O
and O
in O
vivo O
. O

The O
rate O
of O
_RARE_ I-GENE
is O
low O
and O
5 I-GENE
- I-GENE
year O
survival O
is O
very O
poor O
. O

In O
order O
to O
better O
characterize O
the O
distribution O
of O
_RARE_ I-GENE
and O
MAP I-GENE
estimates O
under O
these O
conditions O
, O
we O
_RARE_ I-GENE
a O
point O
_RARE_ I-GENE
to O
density I-GENE
values O
of O
the O
conditional O
distribution O
of O
such O
estimates O
. O

RT I-GENE
- I-GENE
PCR O
was O
performed O
using O
previously O
reported O
degenerate O
oligonucleotide I-GENE
primers O
to O
the O
ligand O
binding I-GENE
domain I-GENE
( O
_RARE_ I-GENE
) O
of O
known O
beta I-GENE
integrin I-GENE
subunits I-GENE
and O
_RARE_ I-GENE
cDNA I-GENE
. O

The O
lowest O
culture O
failure O
rate O
of O
0 O
. O
2 I-GENE
per O
cent O
was O
found O
after O
_RARE_ I-GENE
compared O
with O
0 O
. O
9 O
per O
cent O
among O
_RARE_ I-GENE
. O

_RARE_ I-GENE
expression O
of O
d O
- I-GENE
_RARE_ I-GENE
inhibited O
_RARE_ I-GENE
signaling O
. O

The O
corresponding O
differences O
in O
_RARE_ I-GENE
and O
PAI I-GENE
- I-GENE
1 I-GENE
were O
not O
statistically O
significant O
. O

Primary O
and O
secondary O
structural O
elements O
required O
for O
synthesis O
of O
barley I-GENE
yellow O
_RARE_ I-GENE
virus I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
. O

On O
the O
other O
side O
, O
when O
the O
aortic O
_RARE_ I-GENE
was O
perfused O
with O
L I-GENE
- I-GENE
_RARE_ I-GENE
( O
NO O
- I-GENE
synthesis O
inhibitor I-GENE
) O
or O
methylene O
blue O
( O
soluble I-GENE
_RARE_ I-GENE
inhibitor I-GENE
), O
the O
changes O
could O
be O
attenuated O
. O

Nevertheless O
, O
inactivation O
of O
the O
cyclin I-GENE
E I-GENE
- I-GENE
Cdk2 I-GENE
complex I-GENE
in O
response O
to O
mitogen I-GENE
starvation O
occurs O
normally O
in O
_RARE_ I-GENE
that O
have O
a O
homozygous O
deletion O
of O
the O
p27 I-GENE
gene I-GENE
. O

Identification O
and O
characterization O
of O
_RARE_ I-GENE
and O
_RARE_ I-GENE
: O
two O
distinct O
repeated O
sequences I-GENE
for O
detection O
of O
Mycobacterium O
_RARE_ I-GENE
by O
PCR O
. O

Taken O
together O
, O
these O
results O
are O
consistent O
with O
the O
possibility O
that O
_RARE_ I-GENE
protein I-GENE
contributes O
to O
the O
cell O
growth I-GENE
retardation O
activity O
of O
the O
_RARE_ I-GENE
, O
at O
least O
in O
part O
, O
by O
_RARE_ I-GENE
p21 I-GENE
protein I-GENE
levels O
. O

Similar O
results O
were O
also O
obtained O
with O
a O
HepG2 O
_RARE_ I-GENE
cell O
line O
carrying O
wt I-GENE
p53 I-GENE
. O

Partial O
sequencing O
of O
the O
region O
downstream O
of O
ORF I-GENE
- I-GENE
_RARE_ I-GENE
revealed O
homology I-GENE
to O
the O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
genes I-GENE
, O
involved O
in O
UV O
resistance O
, O
from O
plasmid O
_RARE_ I-GENE
. O

The O
_RARE_ I-GENE
associated I-GENE
kinase I-GENE
is O
not O
casein I-GENE
kinase I-GENE
2 I-GENE
, O
the O
kinase I-GENE
believed O
to O
phosphorylate O
_RARE_ I-GENE
+ I-GENE
4 I-GENE
in O
oocytes O
, O
but O
a O
yet O
unidentified O
kinase I-GENE
. O

This O
suggests O
that O
helicase I-GENE
- I-GENE
like I-GENE
genes I-GENE
may O
be O
involved O
in O
the O
biosynthesis O
of O
nucleic O
acids O
and O
proteins I-GENE
, O
and O
that O
the O
genes I-GENE
can O
be O
transcriptionally O
activated I-GENE
by O
heat I-GENE
shock I-GENE
to O
_RARE_ I-GENE
for O
the O
repressed O
synthesis O
of O
mRNA I-GENE
and O
protein I-GENE
. O

These O
data O
provide O
the O
molecular O
tools O
for O
the O
final O
identification O
of O
the O
_RARE_ I-GENE
and O
the O
_RARE_ I-GENE
genes I-GENE
. O

The O
H I-GENE
- I-GENE
reflex O
recovery O
curve O
was O
obtained O
after O
stimulation O
of O
the O
median O
nerve I-GENE
at O
the O
_RARE_ I-GENE
and O
recording O
from O
the O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
. O

The O
origins O
of O
reflected O
light I-GENE
changes O
associated I-GENE
with O
neuronal O
activity O
( O
optical O
signals O
) O
were O
investigated O
in O
rat I-GENE
_RARE_ I-GENE
cortex O
with O
optical O
imaging O
, O
_RARE_ I-GENE
, O
and O
laser O
- I-GENE
Doppler O
_RARE_ I-GENE
, O
and O
dynamic O
changes O
in O
local O
hemoglobin I-GENE
concentration O
and O
oxygenation O
were O
focused O
on O
. O

Human I-GENE
neuronal O
_RARE_ I-GENE
- I-GENE
like I-GENE
proteins I-GENE
contain O
three O
RNP I-GENE
- I-GENE
type I-GENE
RNA I-GENE
recognition I-GENE
motifs O
( O
_RARE_ I-GENE
). O

Comparison O
of O
frequencies O
of O
atrial I-GENE
fibrillation O
after O
coronary O
artery O
bypass O
_RARE_ I-GENE
with O
and O
without O
the O
use O
of O
cardiopulmonary O
bypass O
. O

The O
results O
of O
supershift O
analysis O
using O
specific I-GENE
antibodies I-GENE
against O
transcription I-GENE
factors I-GENE
suggested O
that O
both O
binding I-GENE
complexes I-GENE
contained O
the O
NF I-GENE
- I-GENE
kappaB I-GENE
components O
p50 I-GENE
and O
p65 I-GENE
, O
and O
did O
not O
contain O
other O
NF I-GENE
- I-GENE
kappaB I-GENE
proteins I-GENE
( O
_RARE_ I-GENE
, O
c I-GENE
- I-GENE
Rel I-GENE
, O
Rel I-GENE
B I-GENE
), O
AP I-GENE
- I-GENE
1 I-GENE
proteins I-GENE
( O
c I-GENE
- I-GENE
Fos I-GENE
, O
C I-GENE
- I-GENE
Jun I-GENE
), O
CREB I-GENE
or O
C I-GENE
/ I-GENE
EBPbeta I-GENE
( O
NF I-GENE
- I-GENE
IL6 I-GENE
). O

A I-GENE
set O
of O
peptides I-GENE
corresponding O
to O
the O
individual O
elements O
of O
secondary O
structure O
derived O
from O
the O
N I-GENE
- I-GENE
terminal I-GENE
domain I-GENE
of O
the O
ribosomal I-GENE
protein I-GENE
_RARE_ I-GENE
have O
been O
synthesized O
. O

The O
results O
showed O
that O
IFN I-GENE
- I-GENE
gamma I-GENE
stimulated O
the O
rapid O
accumulation O
of O
interferon I-GENE
regulated O
factor I-GENE
( O
IRF I-GENE
)- I-GENE
1 I-GENE
mRNA I-GENE
, O
followed O
by O
a O
delayed O
and O
dose O
- I-GENE
dependent I-GENE
inhibition O
of O
alpha1 I-GENE
( O
I I-GENE
) O
_RARE_ I-GENE
mRNA I-GENE
expression O
in O
skin O
fibroblasts O
from O
several O
different O
donors O
. O

Functional O
domains I-GENE
of O
c I-GENE
- I-GENE
myc I-GENE
promoter I-GENE
binding I-GENE
protein I-GENE
1 I-GENE
involved O
in O
transcriptional O
repression O
and O
cell O
growth I-GENE
regulation O
. O

Therefore O
, O
we O
have O
named O
this O
gene I-GENE
_RARE_ I-GENE
. O

These O
results O
_RARE_ I-GENE
to O
support O
the O
hypothesis O
that O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
act O
as O
a O
single O
, O
integral I-GENE
unit I-GENE
to O
regulate O
human I-GENE
globin I-GENE
gene I-GENE
transcription I-GENE
as O
a O
_RARE_ I-GENE
, O
but O
they O
can O
also O
be O
interpreted O
to O
_RARE_ I-GENE
that O
formation O
of O
a O
DNase I-GENE
I I-GENE
hypersensitive I-GENE
_RARE_ I-GENE
alone O
is O
not O
sufficient O
for O
mediating O
high O
- I-GENE
level O
globin I-GENE
gene I-GENE
transcription I-GENE
. O

To O
identify O
additional O
non O
- I-GENE
_RARE_ I-GENE
factors I-GENE
that O
affect O
rDNA I-GENE
silencing O
, O
we O
performed O
a O
genetic O
screen O
designed O
to O
isolate O
mutations O
which O
alter O
the O
expression O
of O
reporter I-GENE
genes I-GENE
integrated O
within O
the O
rDNA I-GENE
. O

Because O
there O
is O
great O
need O
for O
iron O
in O
the O
EPO I-GENE
- I-GENE
stimulated O
erythroid I-GENE
_RARE_ I-GENE
, O
it O
is O
essential O
that O
serum I-GENE
ferritin I-GENE
and O
transferrin I-GENE
saturation O
levels O
should O
be O
maintained O
over O
300 O
microg O
/ I-GENE
liter O
and O
30 O
%, O
respectively O
. O

These O
results O
indicate O
that O
the O
_RARE_ I-GENE
subunit I-GENE
of O
eIF3 I-GENE
plays O
an O
important O
role O
in O
the O
initiation I-GENE
phase O
of O
protein I-GENE
synthesis O
and O
that O
its O
RNA I-GENE
- I-GENE
binding I-GENE
domain I-GENE
is O
required O
for O
optimal O
activity O
. O

In O
this O
study O
, O
we O
elucidate O
signaling O
pathways O
induced O
by O
_RARE_ I-GENE
therapy O
( O
_RARE_ I-GENE
) O
with O
_RARE_ I-GENE
. O

These O
results O
indicate O
that O
ATF I-GENE
- I-GENE
2 I-GENE
plays O
a O
central O
role O
in O
TGF I-GENE
- I-GENE
beta I-GENE
signaling O
by O
acting O
as O
a O
common O
nuclear I-GENE
target O
of O
both O
Smad I-GENE
and O
_RARE_ I-GENE
pathways O
. O

_RARE_ I-GENE
WORDS O
: O
_RARE_ I-GENE
; O
_RARE_ I-GENE
_RARE_ I-GENE
; O
_RARE_ I-GENE
zone O
; O
_RARE_ I-GENE
level O
; O
Regulation O
schedule O

The O
systolic O
peak O
of O
pulmonary O
vein O
was O
higher O
than O
the O
diastolic O
peak O
in O
45 O
out O
of O
56 O
cases O
. O

_RARE_ I-GENE
were O
assayed O
for O
alpha I-GENE
- I-GENE
fetoprotein I-GENE
, O
_RARE_ I-GENE
_RARE_ I-GENE
, O
free O
alpha I-GENE
hCG I-GENE
, O
and O
total O
hCG I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
2000 O
. O

The O
following O
data O
were O
recorded O
at O
_RARE_ I-GENE
in O
the O
intensive O
care O
unit I-GENE
6 I-GENE
, O
12 O
, O
24 O
, O
and O
48 O
hours O
after O
termination O
of O
CPB O
: O
heart O
rate O
, O
blood O
pressure O
, O
left O
atrial I-GENE
pressure O
, O
central O
- I-GENE
peripheral O
temperature O
difference O
, O
arterial O
- I-GENE
central O
venous O
oxygen O
saturation O
difference O
, O
urine O
output O
, O
serum I-GENE
creatinine O
, O
lactate I-GENE
and O
neutrophil I-GENE
elastase I-GENE
levels O
, O
the O
Doppler O
echocardiographic O
factors I-GENE
shortening O
fraction O
and O
_RARE_ I-GENE
period O
/ I-GENE
left O
- I-GENE
ventricular O
ejection O
time O
, O
and O
cumulative O
doses O
of O
catecholamines O
( O
epinephrine O
), O
_RARE_ I-GENE
, O
and O
furosemide O
. O

_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
, O
located O
on O
chromosome O
3 I-GENE
band O
_RARE_ I-GENE
, O
encodes O
a O
zinc I-GENE
- I-GENE
finger I-GENE
DNA I-GENE
- I-GENE
binding I-GENE
transcription I-GENE
activator I-GENE
not O
detected O
in O
normal O
hematopoietic I-GENE
cells O
but O
expressed O
in O
several O
normal O
tissues O
. O

Analysis O
of O
the O
protein I-GENE
sequences I-GENE
of O
these O
two O
_RARE_ I-GENE
, O
together O
with O
previously O
characterized O
H I-GENE
. O
pylori I-GENE
plasmid O
replication O
proteins I-GENE
, O
supports O
the O
formation O
of O
a O
distinct O
class I-GENE
of O
H I-GENE
. O
pylori I-GENE
plasmid O
proteins I-GENE
. O

The O
_RARE_ I-GENE
delta I-GENE
among O
the O
three O
groups O
did O
not O
differ O
as O
well O
: O
_RARE_ I-GENE
delta I-GENE
of O
the O
VT O
group O
was O
70 I-GENE
ms O
+/- O
30 O
ms O
, O
the O
_RARE_ I-GENE
delta I-GENE
of O
the O
_RARE_ I-GENE
group O
was O
60 O
msec O
+/- O
25 O
msec O
, O
and O
the O
_RARE_ I-GENE
delta I-GENE
of O
the O
control O
group O
was O
70 I-GENE
ms O
+/- O
30 O
ms O
. O

In O
contrast O
, O
deletion O
of O
the O
upstream O
portion O
of O
the O
delta I-GENE
promoter I-GENE
led O
to O
a O
10 O
fold O
decrease O
in O
expression O
. O

Site I-GENE
- I-GENE
directed O
mutagenesis O
of O
binding I-GENE
sites I-GENE
for O
the O
repressor I-GENE
proteins I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
in O
the O
upstream O
portion O
of O
the O
beta I-GENE
globin I-GENE
gene I-GENE
flanking O
region O
led O
to O
a O
4 I-GENE
- I-GENE
6 I-GENE
fold O
increase O
in O
promoter I-GENE
activity O
. O

However O
, O
with O
the O
alpha1 I-GENE
antagonist O
_RARE_ I-GENE
( O
5 I-GENE
x O
10 O
(- O
8 O
)- I-GENE
5 I-GENE
x O
10 O
(- O
7 O
) O
M I-GENE
), O
no O
relaxation O
occurred O
. O

Differential O
expression O
of O
AP I-GENE
- I-GENE
2alpha I-GENE
and O
AP I-GENE
- I-GENE
_RARE_ I-GENE
in O
the O
developing O
chick I-GENE
retina O
: O
repression O
of O
R I-GENE
- I-GENE
_RARE_ I-GENE
promoter I-GENE
activity O
by O
AP I-GENE
- I-GENE
2 I-GENE
. O

The O
algorithm O
also O
limited O
TG I-GENE
to O
20 O
and O
64 O
%, O
_RARE_ I-GENE
to O
6 I-GENE
and O
20 O
%, O
and O
_RARE_ I-GENE
( O
a O
) O
to O
15 O
and O
56 O
%, O
of O
low O
- I-GENE
and O
high O
- I-GENE
risk O
groups O
, O
respectively O
. O

The O
mean O
value O
of O
the O
_RARE_ I-GENE
to O
the O
_RARE_ I-GENE
_RARE_ I-GENE
deleted O
ratio O
was O
0 O
. O
64 O
+/- O
0 O
. O
20 O
SD O
in O
normal O
donors O
and O
0 O
. O
44 I-GENE
+/- O
0 O
. O
27 O
SD O
in O
B I-GENE
- I-GENE
_RARE_ I-GENE
( O
P I-GENE
=. O
01 O
). O

As O
normal O
B I-GENE
cells O
also O
present O
this O
variant I-GENE
, O
the O
mechanism O
of O
_RARE_ I-GENE
posttranscriptional O
regulation O
might O
reflect O
the O
activation O
stage O
of O
the O
normal O
B I-GENE
cell O
from O
which O
B I-GENE
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
studies O
_RARE_ I-GENE
secondary O
structure O
predictions O
, O
CD O
and O
NMR O
spectroscopy O
together O
with O
ELISA O
assays O
, O
showed O
that O
the O
greater O
is O
the O
propensity O
of O
the O
epitope O
for O
helix I-GENE
formation O
the O
higher O
is O
the O
recognition I-GENE
by O
anti I-GENE
- I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
scores O
in O
the O
" O
off O
" O
state O
were O
improved O
by O
18 O
% O
and O
in O
the O
" O
on O
" O
state O
the O
scores O
declined O
by O
2 I-GENE
%. O

High O
- I-GENE
level O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
indicative O
of O
gene I-GENE
_RARE_ I-GENE
were O
identified O
at O
_RARE_ I-GENE
in O
two O
cases O
, O
and O
in O
one O
case O
each O
at O
_RARE_ I-GENE
- I-GENE
34 O
, O
_RARE_ I-GENE
- I-GENE
29 O
, O
_RARE_ I-GENE
. O
1 I-GENE
- I-GENE
15 O
. O
2 I-GENE
, O
_RARE_ I-GENE
- I-GENE
22 O
, O
_RARE_ I-GENE
. O
2 I-GENE
, O
_RARE_ I-GENE
. O
2 I-GENE
- I-GENE
12 O
, O
and O
_RARE_ I-GENE
. O

With O
respect O
to O
the O
distribution O
of O
active O
_RARE_ I-GENE
over O
the O
promoter I-GENE
region O
, O
the O
_RARE_ I-GENE
- I-GENE
IIA I-GENE
gene I-GENE
is O
largely O
different O
from O
the O
mouse I-GENE
_RARE_ I-GENE
- I-GENE
I I-GENE
gene I-GENE
, O
suggesting O
that O
_RARE_ I-GENE
arrangement O
is O
not O
an O
important O
factor I-GENE
for O
metal O
regulation O
. O

The O
cDNA I-GENE
was O
expressed O
in O
Saccharomyces I-GENE
cerevisiae I-GENE
under O
the O
control O
of O
the O
yeast I-GENE
_RARE_ I-GENE
phosphate I-GENE
isomerase I-GENE
promoter I-GENE
. O

Interestingly O
, O
the O
RNA I-GENE
sequences I-GENE
selected O
by O
the O
mutated O
zinc I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
variant I-GENE
are O
efficiently O
recognized O
by O
_RARE_ I-GENE
, O
in O
agreement O
with O
the O
fact O
that O
the O
_RARE_ I-GENE
of O
_RARE_ I-GENE
and O
_RARE_ I-GENE
are O
similar O
. O

_RARE_ I-GENE
II I-GENE
is O
a O
major I-GENE
target O
of O
the O
protein I-GENE
kinase I-GENE
casein I-GENE
kinase I-GENE
2 I-GENE
( O
PK I-GENE
_RARE_ I-GENE
) O
in O
vivo O
. O

Recent O
work O
in O
this O
laboratory O
has O
shown O
that O
the O
gene I-GENE
coding O
for O
acetate O
kinase I-GENE
( O
_RARE_ I-GENE
) O
in O
_RARE_ I-GENE
_RARE_ I-GENE
is O
up O
- I-GENE
regulated O
in O
response O
to O
phosphate I-GENE
limitation O
. O

All O
numbers O
_RARE_ I-GENE
to O
nucleotide I-GENE
positions O
on O
the O
wild I-GENE
- I-GENE
type I-GENE
HIV I-GENE
- I-GENE
1 I-GENE
transcript I-GENE
. O

Sequence O
analysis O
revealed O
that O
the O
_RARE_ I-GENE
protein I-GENE
is O
identical O
with O
a O
160 I-GENE
kDa I-GENE
nuclear I-GENE
' O
domain I-GENE
rich O
in O
_RARE_ I-GENE
' O
( O
_RARE_ I-GENE
) O
protein I-GENE
occurring O
free O
in O
the O
_RARE_ I-GENE
and O
in O
U2 I-GENE
- I-GENE
ribonucleoprotein I-GENE
structures O
. O

Here O
, O
we O
report O
the O
complete O
structure O
of O
the O
human I-GENE
topoisomerase I-GENE
_RARE_ I-GENE
gene I-GENE
, O
which O
consists O
of O
35 O
exons O
spanning O
27 O
. O
5 I-GENE
kb O
. O

_RARE_ I-GENE
modulation O
of O
_RARE_ I-GENE
activity O
of O
cat O
motor O
cortical O
neurons O
. O

Previous O
studies O
characterized O
a O
cytokine O
- I-GENE
inducible I-GENE
, O
functional O
nuclear I-GENE
factor I-GENE
( O
NF I-GENE
)- I-GENE
kappaB I-GENE
consensus I-GENE
element I-GENE
in O
the O
immediate I-GENE
5 I-GENE
' O
regulatory I-GENE
region O
of O
the O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
- I-GENE
alpha I-GENE
gene I-GENE
at O
- I-GENE
78 O
bp O
. O

An O
exon O
that O
prevents O
transport O
of O
a O
mature O
mRNA I-GENE
. O

Four O
CsA O
- I-GENE
treated O
patients O
developed O
_RARE_ I-GENE
elevated O
_RARE_ I-GENE
> O
30 O
mg O
/ I-GENE
24 O
h O
( O
n O
= O
3 I-GENE
with O
_RARE_ I-GENE
), O
whereas O
all O
the O
17 O
placebo O
- I-GENE
treated O
patients O
had O
normal O
_RARE_ I-GENE
(< O
30 O
mg O
/ I-GENE
24 O
h O
) O
after O
7 O
years O
of O
follow O
- I-GENE
up O
. O

Mutational O
analysis O
of O
the O
- I-GENE
84 O
/- O
55 O
DNA I-GENE
showed O
that O
_RARE_ I-GENE
- I-GENE
3 I-GENE
nuclear I-GENE
proteins I-GENE
bound O
to O
a O
site I-GENE
containing O
, O
but O
not O
identical O
to O
, O
the O
SF I-GENE
- I-GENE
1 I-GENE
sequence I-GENE
. O

In O
contrast O
, O
no O
change O
was O
detected O
in O
the O
phenotype O
of O
' O
_RARE_ I-GENE
' O
clones O
, O
with O
respect O
to O
any O
of O
the O
following O
parameters O
: O
proliferation O
rate O
in O
_RARE_ I-GENE
, O
serum I-GENE
- I-GENE
dependence O
for O
proliferation O
or O
survival O
, O
_RARE_ I-GENE
, O
cellular O
morphology O
, O
or O
tissue I-GENE
- I-GENE
specific I-GENE
differentiation O
markers O
. O

A I-GENE
high O
_RARE_ I-GENE
pH O
(+/- O
8 O
), O
a O
short O
solid O
retention O
time O
(< O
150 O
days O
), O
and O
the O
presence O
of O
a O
substantial O
_RARE_ I-GENE
population O
in O
the O
_RARE_ I-GENE
may O
considerably O
reduce O
the O
time O
required O
for O
acetate O
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
to O
_RARE_ I-GENE
MB I-GENE
. O

In O
_RARE_ I-GENE
_RARE_ I-GENE
, O
the O
aim O
is O
to O
correlate O
the O
effect O
of O
shear O
to O
a O
parameter O
related I-GENE
to O
the O
inner O
_RARE_ I-GENE
of O
the O
valve O
and O
to O
operating O
conditions O
. O

The O
induced O
respiratory O
burst O
was O
investigated O
by O
the O
intracellular O
oxidative O
transformation O
of O
_RARE_ I-GENE
123 O
to O
the O
fluorescent O
dye O
_RARE_ I-GENE
123 O
via O
flow O
_RARE_ I-GENE
. O

A I-GENE
mutation I-GENE
linked O
to O
the O
_RARE_ I-GENE
gene I-GENE
, O
previously O
defined O
by O
recessive O
mutations O
that O
suppress O
_RARE_ I-GENE
ts I-GENE
alleles I-GENE
and O
_RARE_ I-GENE
many O
mitochondrial I-GENE
mRNAs I-GENE
, O
was O
also O
isolated O
. O

A I-GENE
deletion O
mutation I-GENE
analysis O
of O
the O
recombinant I-GENE
protein I-GENE
has O
shown O
that O
the O
N I-GENE
- I-GENE
terminal I-GENE
region O
and O
the O
two O
leucine I-GENE
zippers I-GENE
are O
necessary O
for O
the O
binding I-GENE
. O

A I-GENE
database O
search O
has O
revealed O
as O
the O
most O
_RARE_ I-GENE
homology I-GENE
a O
match O
with O
the O
human I-GENE
mitochondrial I-GENE
transcription I-GENE
termination O
factor I-GENE
( O
_RARE_ I-GENE
), O
a O
protein I-GENE
that O
also O
binds O
DNA I-GENE
as O
a O
_RARE_ I-GENE
and O
contains O
three O
leucine I-GENE
zippers I-GENE
forming O
_RARE_ I-GENE
interactions O
. O

In O
all O
trials O
, O
antigen I-GENE
challenge O
followed O
1 I-GENE
h O
after O
the O
last O
treatment O
. O

31 O
, O
1997 O
, O
40 I-GENE
patients O
had O
died O
( O
35 O
in O
the O
_RARE_ I-GENE
- I-GENE
II I-GENE
group O
and O
5 I-GENE
in O
the O
_RARE_ I-GENE
- I-GENE
III I-GENE
group O
), O
for O
a O
crude O
mortality O
rate O
of O
8 O
. O
0 O
%. O

We O
found O
that O
total O
PSA I-GENE
can O
be O
detected O
in O
all O
cyst O
fluids O
and O
in O
about O
75 O
% O
of O
female O
sera O
. O

Type O
I I-GENE
cysts O
( O
with O
a O
high O
K I-GENE
+/ I-GENE
Na I-GENE
+ I-GENE
ratio O
) O
_RARE_ I-GENE
to O
have O
higher O
total O
PSA I-GENE
than O
Type O
II I-GENE
cysts O
. O

Despite O
this O
DNA I-GENE
binding I-GENE
activity O
, O
AP I-GENE
- I-GENE
1 I-GENE
reporter I-GENE
activity O
was O
suppressed O
in O
these O
cells O
. O

A I-GENE
single O
N I-GENE
- I-GENE
glycosylation O
site I-GENE
present O
in O
chicken I-GENE
_RARE_ I-GENE
is O
conserved O
among O
all O
five O
of O
these O
proteins I-GENE
: O
carbohydrate O
analysis O
of O
_RARE_ I-GENE
revealed O
the O
presence O
of O
a O
complex I-GENE
type I-GENE
_RARE_ I-GENE
chain I-GENE
at O
this O
site I-GENE
. O

Here O
we O
describe O
the O
_RARE_ I-GENE
and O
characterization O
of O
a O
140 I-GENE
- I-GENE
residue O
fragment I-GENE
, O
containing O
the O
_RARE_ I-GENE
domain I-GENE
of O
_RARE_ I-GENE
, O
which O
is O
suitable O
for O
structural O
studies O
. O

_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
' O
_RARE_ I-GENE
for O
_RARE_ I-GENE
hospital O
. O

_RARE_ I-GENE
_RARE_ I-GENE
laparoscopic O
_RARE_ I-GENE
bladder O
guidelines O
. O

_RARE_ I-GENE
_RARE_ I-GENE
for O
_RARE_ I-GENE
_RARE_ I-GENE
as O
_RARE_ I-GENE
gas O
_RARE_ I-GENE
multi I-GENE
- I-GENE
source O
. O

_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
from O
largest O
_RARE_ I-GENE
_RARE_ I-GENE
in O
_RARE_ I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
for O
hospitals O
' O
_RARE_ I-GENE
. O

_RARE_ I-GENE
provides O
excellent O
_RARE_ I-GENE
evaluation O
of O
spinal O
cord O
injury O
. O

_RARE_ I-GENE
is O
not O
the O
only O
organization O
_RARE_ I-GENE
controlled O
_RARE_ I-GENE
organ O
_RARE_ I-GENE
, O
however O
. O

Because O
of O
_RARE_ I-GENE
regarding O
blood O
transfusion O
- I-GENE
related I-GENE
_RARE_ I-GENE
disease O
( O
_RARE_ I-GENE
, O
acquired O
immune I-GENE
deficiency O
syndrome O
and O
non O
- I-GENE
A I-GENE
, O
non O
- I-GENE
B I-GENE
hepatitis I-GENE
), O
there O
has O
been O
increasing O
research O
effort O
into O
postoperative O
hemorrhage O
related I-GENE
to O
cardiopulmonary O
bypass O
with O
_RARE_ I-GENE
circulation O
. O

They O
contrast O
_RARE_ I-GENE
in O
fertility O
, O
life O
_RARE_ I-GENE
ratios O
, O
and O
gender O
differences O
in O
these O
_RARE_ I-GENE
with O
the O
_RARE_ I-GENE
population O
of O
the O
United O
_RARE_ I-GENE
. O

_RARE_ I-GENE
v I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
for O
_RARE_ I-GENE
_RARE_ I-GENE
physicians O
. O

Overexpression O
of O
either O
_RARE_ I-GENE
- I-GENE
1 I-GENE
or O
_RARE_ I-GENE
causes O
apoptosis O
of O
TNF I-GENE
- I-GENE
sensitive O
_RARE_ I-GENE
fibroblast I-GENE
cell O
line O
, O
as O
well O
as O
TNF I-GENE
- I-GENE
resistant O
osteosarcoma O
cell O
line O
, O
_RARE_ I-GENE
. O

This O
is O
in O
contrast O
to O
_RARE_ I-GENE
, O
which O
was O
previously O
shown O
to O
be O
phosphorylated O
at O
a O
single O
site I-GENE
in O
a O
motif I-GENE
that O
is O
not O
homologous O
to O
the O
sites I-GENE
now O
described O
in O
PPARalpha I-GENE
. O

These O
results O
suggest O
_RARE_ I-GENE
is O
a O
new O
member O
of O
the O
_RARE_ I-GENE
family I-GENE
that O
is O
under O
distinct O
regulation O
from O
_RARE_ I-GENE
. O

We O
have O
screened O
the O
elastin I-GENE
gene I-GENE
for O
mutations O
responsible O
for O
_RARE_ I-GENE
aortic O
stenosis O
( O
_RARE_ I-GENE
) O
in O
two O
large O
, O
independently O
collected O
families O
with O
isolated O
( O
_RARE_ I-GENE
) O
_RARE_ I-GENE
. O

_RARE_ I-GENE
expression O
of O
the O
_RARE_ I-GENE
gene I-GENE
is O
tightly O
regulated O
during O
development O
. O

25 O
- I-GENE
OH O
- I-GENE
D3 I-GENE
did O
not O
_RARE_ I-GENE
affect O
animal O
health O
at O
the O
proposed O
use O
level O
of O
99 O
micrograms O
/ I-GENE
kg O
feed O
when O
replacing O
vitamin O
D3 I-GENE
in O
_RARE_ I-GENE
_RARE_ I-GENE
. O

A I-GENE
_RARE_ I-GENE
of O
12 O
_RARE_ I-GENE
for O
the O
disease O
and O
37 O
diagnostic O
criteria O
were O
proposed O
to O
a O
_RARE_ I-GENE
_RARE_ I-GENE
of O
12 O
Italian O
_RARE_ I-GENE
who O
_RARE_ I-GENE
them O
in O
order O
so O
as O
to O
identify O
a O
core I-GENE
set O
of O
criteria O
. O

_RARE_ I-GENE
fluoride O
( O
_RARE_ I-GENE
): O
a O
double O
- I-GENE
blind O
, O
placebo O
- I-GENE
controlled O
study O
of O
safety O
and O
efficacy O
in O
the O
treatment O
of O
senile O
dementia O
of O
the O
Alzheimer I-GENE
type I-GENE
. O

METHODS O
: O
_RARE_ I-GENE
August O
1991 O
and O
_RARE_ I-GENE
1994 O
, O
198 O
men O
with O
clinical O
T2 I-GENE
or O
T3 O
classified O
( O
_RARE_ I-GENE
) O
prostate O
carcinoma O
( O
bone O
scan O
negative O
) O
who O
were O
at O
high O
risk O
of O
lymph O
node O
involvement O
underwent O
a O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
scan O
prior O
to O
_RARE_ I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
did O
not O
significantly O
increase O
estimated O
alanine I-GENE
or O
_RARE_ I-GENE
_RARE_ I-GENE
or O
absolute O
_RARE_ I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
after O
surgery O
, O
_RARE_ I-GENE
PGE2 O
and O
adenosine I-GENE
concentrations O
were O
3 I-GENE
. O
7 O
+/- O
0 O
. O
7 O
and O
296 O
+/- O
_RARE_ I-GENE
nM O
, O
respectively O
. O

Because O
of O
the O
probable O
_RARE_ I-GENE
relationship O
between O
constitutive O
_RARE_ I-GENE
( O
_RARE_ I-GENE
/ I-GENE
abl I-GENE
) O
protein I-GENE
tyrosine I-GENE
kinase I-GENE
activity O
and O
manifestations O
of O
chronic O
- I-GENE
phase O
chronic O
_RARE_ I-GENE
leukemia I-GENE
( O
CML O
; O
myeloid O
expansion O
), O
a O
key O
goal O
is O
to O
identify O
relevant O
_RARE_ I-GENE
substrates O
in O
primary O
chronic O
- I-GENE
phase O
CML O
hematopoietic I-GENE
progenitor I-GENE
cells O
. O

In O
vitro O
precipitation O
with O
a O
glutathione I-GENE
- I-GENE
S I-GENE
- I-GENE
transferase I-GENE
- I-GENE
fusion I-GENE
protein I-GENE
containing O
the O
C I-GENE
- I-GENE
terminal I-GENE
transactivation O
domain I-GENE
of O
_RARE_ I-GENE
showed O
GH I-GENE
- I-GENE
regulated O
association O
of O
ERK1 I-GENE
/ I-GENE
2 I-GENE
with O
the O
fusion I-GENE
protein I-GENE
, O
while O
this O
was O
not O
seen O
when O
serine I-GENE
_RARE_ I-GENE
in O
_RARE_ I-GENE
was O
changed O
to O
alanine I-GENE
. O

One O
such O
element I-GENE
, O
_RARE_ I-GENE
, O
was O
employed O
to O
clone O
from O
a O
rat I-GENE
pituitary I-GENE
cDNA I-GENE
expression O
library O
a O
novel O
_RARE_ I-GENE
- I-GENE
amino O
acid I-GENE
WD I-GENE
protein I-GENE
, O
designated O
_RARE_ I-GENE
( O
PRL I-GENE
regulatory I-GENE
element I-GENE
binding I-GENE
) O
protein I-GENE
. O

Characterization O
of O
the O
transcription I-GENE
factor I-GENE
_RARE_ I-GENE
- I-GENE
1 I-GENE
from O
the O
Japanese O
_RARE_ I-GENE
( O
_RARE_ I-GENE
_RARE_ I-GENE
) O
reveals O
evolutionary O
conservation O
of O
heavy I-GENE
metal O
stress O
response O
. O

The O
peroxisome I-GENE
proliferator I-GENE
- I-GENE
activated I-GENE
receptors I-GENE
( O
_RARE_ I-GENE
) O
are O
members O
of O
the O
nuclear I-GENE
hormone I-GENE
receptor I-GENE
superfamily I-GENE
. O

However O
, O
F I-GENE
- I-GENE
SRC I-GENE
- I-GENE
1 I-GENE
mutant I-GENE
lacking O
CBP I-GENE
- I-GENE
interacting I-GENE
domain I-GENE
still O
_RARE_ I-GENE
enhancing O
activity O
. O

The O
catalytic O
site I-GENE
has O
an O
S1 I-GENE
pocket O
_RARE_ I-GENE
with O
conserved O
hydrophobic O
residues O
to O
_RARE_ I-GENE
the O
_RARE_ I-GENE
residue O
. O

The O
complete O
circular O
_RARE_ I-GENE
genome O
contained O
a O
novel O
sequence I-GENE
of O
113 I-GENE
nt O
( O
nt O
_RARE_ I-GENE
to O
_RARE_ I-GENE
_RARE_ I-GENE
0 O
]) I-GENE
in O
between O
the O
known O
3 I-GENE
'- O
and O
5 I-GENE
'- O
end O
_RARE_ I-GENE
, O
forming O
a O
117 O
- I-GENE
nt O
GC I-GENE
- I-GENE
rich O
stretch O
( O
GC I-GENE
content O
, O
90 O
. O
6 I-GENE
% O
at O
nt O
_RARE_ I-GENE
to O
_RARE_ I-GENE
). O

The O
_RARE_ I-GENE
mouse I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
is O
resistant O
to O
infection O
by O
the O
_RARE_ I-GENE
_RARE_ I-GENE
cell O
focus O
- I-GENE
inducing O
( O
_RARE_ I-GENE
) O
subgroup O
of O
murine I-GENE
leukemia I-GENE
viruses O
( O
_RARE_ I-GENE
). O

To O
determine O
the O
function O
of O
VZV I-GENE
_RARE_ I-GENE
in O
virus I-GENE
growth I-GENE
, O
a O
series O
of O
_RARE_ I-GENE
deletion O
mutants I-GENE
were O
constructed O
with O
VZV I-GENE
cosmid O
DNA I-GENE
derived O
from O
the O
_RARE_ I-GENE
strain O
. O

CCAAT I-GENE
displacement I-GENE
protein I-GENE
binds O
to O
and O
negatively O
regulates O
human I-GENE
papillomavirus I-GENE
type I-GENE
6 I-GENE
E6 I-GENE
, O
E7 I-GENE
, O
and O
E1 I-GENE
promoters I-GENE
. O

As O
such O
the O
findings O
support O
existing O
studies O
that O
have O
identified O
given O
social O
characteristics O
of O
_RARE_ I-GENE
_RARE_ I-GENE
. O

Three O
different O
site I-GENE
- I-GENE
directed O
mutations O
of O
the O
cyclic I-GENE
AMP I-GENE
response O
element I-GENE
each O
reduced O
the O
nerve I-GENE
growth I-GENE
factor I-GENE
effect O
by O
> O
90 O
%. O

Using O
an O
RNase I-GENE
H I-GENE
protection O
assay O
and O
specific I-GENE
blocking O
oligonucleotides O
, O
we O
find O
that O
recognition I-GENE
of O
the O
5 I-GENE
' O
splice O
- I-GENE
site I-GENE
( O
5 I-GENE
' O
_RARE_ I-GENE
) O
and O
branchpoint O
sequence I-GENE
( O
_RARE_ I-GENE
) O
elements O
by O
_RARE_ I-GENE
and O
_RARE_ I-GENE
snRNPs I-GENE
, O
respectively O
, O
displays O
strong O
cooperativity O
, O
requiring O
both O
sites I-GENE
in O
the O
pre I-GENE
- I-GENE
mRNA I-GENE
substrate I-GENE
for O
efficient O
complex I-GENE
formation O
. O

Analysis O
of O
lacZ I-GENE
transcriptional O
fusions I-GENE
shows O
that O
the O
_RARE_ I-GENE
- I-GENE
binding I-GENE
sites I-GENE
negatively O
affect O
the O
expression O
of O
_RARE_ I-GENE
. O

Many O
eukaryotic I-GENE
cell O
surface O
proteins I-GENE
are O
anchored I-GENE
in O
the O
lipid O
_RARE_ I-GENE
through O
_RARE_ I-GENE
( O
GPI I-GENE
). O

In O
the O
cell O
- I-GENE
free O
import O
assay O
, O
beta I-GENE
- I-GENE
catenin I-GENE
rapidly O
_RARE_ I-GENE
into O
the O
nucleus O
without O
the O
exogenous O
addition O
of O
cytosol O
, O
Ran I-GENE
, O
or O
ATP I-GENE
/ I-GENE
GTP I-GENE
. O

In O
ischemic O
and O
hypoxic O
hypoxia O
, O
a O
strong O
correlation O
was O
found O
between O
cyt I-GENE
a O
, O
_RARE_ I-GENE
oxidation O
level O
and O
VO2 O
in O
both O
ischemic O
and O
hypoxic O
hypoxia O
( O
_RARE_ I-GENE
=. O
90 O
and O
. O
87 O
, O
respectively O
). O

An O
endogenous I-GENE
mammalian I-GENE
regulator I-GENE
of O
this O
process O
, O
named O
_RARE_ I-GENE
, O
has O
been O
identified O
( O
_RARE_ I-GENE
for O
_RARE_ I-GENE
include O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
- I-GENE
1 I-GENE
, O
_RARE_ I-GENE
, O
I I-GENE
- I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
). O

Plasma I-GENE
glucose O
, O
immunoreactive I-GENE
insulin I-GENE
( O
_RARE_ I-GENE
), O
C I-GENE
- I-GENE
peptide I-GENE
, O
glucagon I-GENE
, O
and O
_RARE_ I-GENE
- I-GENE
1 I-GENE
levels O
at O
each O
time O
point O
during O
_RARE_ I-GENE
were O
measured O
. O

Each O
recombinant I-GENE
product I-GENE
was O
a O
fusion I-GENE
protein I-GENE
with O
a O
B I-GENE
domain I-GENE
of O
_RARE_ I-GENE
protein I-GENE
A I-GENE
( O
_RARE_ I-GENE
). O

_RARE_ I-GENE
and O
ssDNA I-GENE
binding I-GENE
by O
the O
isolated O
VH I-GENE
domain I-GENE
of O
immunization O
- I-GENE
induced O
anti I-GENE
- I-GENE
Z I-GENE
- I-GENE
DNA I-GENE
Ab I-GENE
resembles O
the O
activity O
of O
natural O
autoantibodies O
and O
suggests O
that O
VH I-GENE
- I-GENE
dependent I-GENE
binding I-GENE
to O
a O
ligand O
mimicked O
by O
_RARE_ I-GENE
may O
play O
a O
role O
in O
B I-GENE
cell O
selection O
before O
immunization O
with O
Z I-GENE
- I-GENE
DNA I-GENE
. O

_RARE_ I-GENE
- I-GENE
99m O
methylene O
_RARE_ I-GENE
_RARE_ I-GENE
for O
evaluation O
of O
_RARE_ I-GENE
breast O
masses O
. O

_RARE_ I-GENE
: O
Study O
patients O
were O
randomly O
divided O
into O
four O
parallel O
groups O
to O
receive O
either O
_RARE_ I-GENE
250 O
mg O
a O
day O
for O
12 O
or O
16 O
weeks O
( O
groups O
_RARE_ I-GENE
and O
_RARE_ I-GENE
) O
or O
_RARE_ I-GENE
400 O
mg O
a O
day O
for O
1 I-GENE
week O
in O
every O
4 I-GENE
weeks O
for O
12 O
or O
16 O
weeks O
( O
groups O
_RARE_ I-GENE
and O
_RARE_ I-GENE
). O

Nuclear I-GENE
receptors I-GENE
( O
_RARE_ I-GENE
) O
can O
function O
as O
_RARE_ I-GENE
_RARE_ I-GENE
in O
both O
mammalian I-GENE
and O
yeast I-GENE
cells O
, O
indicating O
that O
important O
features O
of O
transcriptional O
control O
have O
been O
conserved O
throughout O
evolution O
. O

When O
_RARE_ I-GENE
to O
a O
heterologous O
DNA I-GENE
- I-GENE
binding I-GENE
domain I-GENE
, O
_RARE_ I-GENE
can O
activate O
transcription I-GENE
on O
its O
own O
. O

OBJECTIVE O
: O
To O
follow O
- I-GENE
up O
_RARE_ I-GENE
patients O
with O
arthritis O
after O
infection O
with O
beta I-GENE
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
of O
_RARE_ I-GENE
group O
A I-GENE
( O
beta I-GENE
_RARE_ I-GENE
), O
with O
_RARE_ I-GENE
on O
clinical O
characteristics O
and O
serological O
features O
. O

_RARE_ I-GENE
can O
also O
cause O
a O
_RARE_ I-GENE
acting O
directly O
on O
the O
inner O
ear O
: O
among O
these O
, O
_RARE_ I-GENE
_RARE_ I-GENE
, O
a O
_RARE_ I-GENE
which O
causes O
_RARE_ I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
, O
a O
_RARE_ I-GENE
that O
causes O
_RARE_ I-GENE
_RARE_ I-GENE
, O
must O
be O
mentioned O
. O

We O
found O
that O
the O
expression O
of O
the O
protein I-GENE
was O
maximum O
in O
mitosis O
and O
minimum O
in O
G1 I-GENE
, O
which O
correlated O
with O
the O
expression O
of O
its O
messenger I-GENE
RNA I-GENE
. O

These O
findings O
demonstrate O
that O
_RARE_ I-GENE
- I-GENE
tagged O
mutagenesis O
is O
a O
viable O
approach O
to O
identify O
bacterial I-GENE
genes I-GENE
associated I-GENE
with O
the O
ability O
to O
_RARE_ I-GENE
the O
urinary O
tract O
. O

_RARE_ I-GENE
. O

The O
eukaryotic I-GENE
cell O
cycle O
is O
_RARE_ I-GENE
in O
part O
by O
the O
periodic I-GENE
transcription I-GENE
of O
cyclin I-GENE
genes I-GENE
, O
whose O
protein I-GENE
products I-GENE
associate O
with O
and O
positively O
regulate O
the O
cyclin I-GENE
- I-GENE
dependent I-GENE
kinases I-GENE
. O

The O
_RARE_ I-GENE
gene I-GENE
encodes O
the O
regulatory I-GENE
subunit I-GENE
for O
a O
type I-GENE
1 I-GENE
serine I-GENE
/ I-GENE
threonine I-GENE
phosphoprotein I-GENE
phosphatase I-GENE
, O
_RARE_ I-GENE
. O

The O
results O
demonstrate O
that O
the O
_RARE_ I-GENE
phosphatase I-GENE
and O
its O
_RARE_ I-GENE
regulatory I-GENE
subunit I-GENE
play O
positive O
roles O
in O
HSF I-GENE
activation O
of O
_RARE_ I-GENE
transcription I-GENE
. O

MEF I-GENE
and O
_RARE_ I-GENE
synergistically O
transactivated O
an O
interleukin I-GENE
3 I-GENE
promoter I-GENE
reporter I-GENE
gene I-GENE
construct I-GENE
, O
yet O
the O
activating I-GENE
activity O
of O
MEF I-GENE
was O
abolished O
when O
MEF I-GENE
was O
coexpressed O
with O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
, O
the O
presence O
of O
the O
_RARE_ I-GENE
appears O
to O
stop O
further O
degradation O
of O
p50 I-GENE
and O
to O
_RARE_ I-GENE
the O
molecule I-GENE
. O

This O
phosphorylation O
can O
be O
catalyzed O
by O
a O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
double O
- I-GENE
stranded I-GENE
DNA I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
activity O
from O
the O
sea O
urchin I-GENE
nucleus O
in O
vitro O
. O

_RARE_ I-GENE
, O
the O
total O
cellular O
level O
of O
p21 I-GENE
increased O
_RARE_ I-GENE
via O
a O
posttranscriptional O
mechanism O
. O

Moreover O
, O
when O
added O
to O
the O
_RARE_ I-GENE
cultures O
, O
_RARE_ I-GENE
- I-GENE
N I-GENE
markedly O
stimulated O
the O
formation O
of O
resorption O
_RARE_ I-GENE
on O
_RARE_ I-GENE
_RARE_ I-GENE
. O

Overall O
, O
our O
results O
suggest O
that O
resistant O
_RARE_ I-GENE
exist O
among O
the O
_RARE_ I-GENE
_RARE_ I-GENE
population O
. O

The O
molecular O
mechanism O
by O
which O
_RARE_ I-GENE
and O
the O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
interaction O
function O
in O
mRNA I-GENE
export O
is O
unknown O
. O

The O
Fyn I-GENE
NH2 I-GENE
terminus O
was O
necessary O
but O
not O
sufficient O
for O
interaction O
with O
zeta I-GENE
and O
both O
Fyn I-GENE
kinase I-GENE
and O
SH2 I-GENE
domains I-GENE
were O
required O
, O
_RARE_ I-GENE
phosphorylation O
of O
zeta I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
and O
binding I-GENE
to O
zeta I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
. O

In O
budding I-GENE
yeast I-GENE
, O
the O
protein I-GENE
_RARE_ I-GENE
, O
the O
_RARE_ I-GENE
- I-GENE
family I-GENE
member O
_RARE_ I-GENE
, O
and O
the O
F I-GENE
- I-GENE
box I-GENE
/ I-GENE
WD I-GENE
- I-GENE
repeat I-GENE
protein I-GENE
_RARE_ I-GENE
form O
the O
_RARE_ I-GENE
ubiquitin I-GENE
ligase I-GENE
complex I-GENE
, O
which O
targets O
the O
cyclin I-GENE
- I-GENE
dependent I-GENE
kinase I-GENE
( O
Cdk I-GENE
) O
inhibitor I-GENE
_RARE_ I-GENE
for O
proteolysis O
[ O
3 I-GENE
] O
[ O
4 I-GENE
] O
[ O
5 I-GENE
] O
[ O
6 I-GENE
] O
[ O
7 O
] O
[ O
8 O
]. O

We O
show O
here O
that O
, O
despite O
their O
structural O
and O
functional O
similarities O
, O
the O
_RARE_ I-GENE
and O
_RARE_ I-GENE
genes I-GENE
fail O
to O
complement I-GENE
each O
other O
' O
s O
deletion O
phenotypes O
, O
indicating O
that O
they O
perform O
non O
- I-GENE
_RARE_ I-GENE
, O
but O
potentially O
_RARE_ I-GENE
, O
functions O
in O
proteolysis O
. O

_RARE_ I-GENE
III I-GENE
prevents O
60 O
min O
_RARE_ I-GENE
intestinal O
ischemia O
reperfusion O
injury O
in O
rats O
. O

In O
_RARE_ I-GENE
, O
the O
_RARE_ I-GENE
were O
_RARE_ I-GENE
applying O
_RARE_ I-GENE
criteria O
. O

These O
observations O
of O
elevated O
serum I-GENE
lipase I-GENE
and O
serum I-GENE
CA I-GENE
19 O
- I-GENE
9 O
in O
_RARE_ I-GENE
' O
s O
syndrome O
without O
evidence O
of O
malignancy O
may O
reflect O
pancreatic O
involvement O
in O
this O
disorder O
. O

Acute O
pancreatitis O
as O
a O
complication O
of O
_RARE_ I-GENE
_RARE_ I-GENE
. O

Significantly O
greater O
improvement O
( O
p O
< O
0 O
. O
05 O
) O
in O
the O
_RARE_ I-GENE
group O
first O
became O
apparent O
by O
the O
end O
of O
week O
3 I-GENE
on O
the O
Y I-GENE
- I-GENE
_RARE_ I-GENE
and O
the O
_RARE_ I-GENE
_RARE_ I-GENE
scale O
, O
and O
by O
the O
end O
of O
weeks O
6 I-GENE
and O
8 O
, O
respectively O
, O
on O
the O
_RARE_ I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
scale O
. O

_RARE_ I-GENE
- I-GENE
inducible I-GENE
protein I-GENE
kinases I-GENE
capable O
of O
activating I-GENE
c I-GENE
- I-GENE
jun I-GENE
expression O
include O
stress O
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
/ I-GENE
c I-GENE
- I-GENE
Jun I-GENE
N I-GENE
- I-GENE
terminal I-GENE
protein I-GENE
kinase I-GENE
( O
SAPK I-GENE
/ I-GENE
JNK I-GENE
) O
and O
p38 I-GENE
members O
of O
the O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
( O
MAPK I-GENE
) O
superfamily I-GENE
of O
signaling O
molecules I-GENE
. O

_RARE_ I-GENE
growth I-GENE
factor I-GENE
( O
TGF I-GENE
)- I-GENE
beta1 I-GENE
induces O
extracellular I-GENE
matrix I-GENE
deposition O
and O
proliferation O
of O
mesenchymal O
cells O
. O

_RARE_ I-GENE
in O
cardiovascular O
disease O
. O

Group O
_RARE_ I-GENE
functions O
for O
_RARE_ I-GENE
with O
hearing O
loss O
do O
not O
show O
a O
decrease O
in O
performance O
at O
the O
largest O
values O
of O
delta I-GENE
f I-GENE
included O
in O
this O
study O
. O

_RARE_ I-GENE
can O
detect O
_RARE_ I-GENE
, O
which O
may O
be O
poorly O
perceived O
or O
even O
unknown O
to O
the O
subjects O
themselves O
. O

Marked O
_RARE_ I-GENE
variation O
in O
_RARE_ I-GENE
_RARE_ I-GENE
by O
gestational O
age O
was O
evident O
. O

Significant O
correlations O
between O
mental O
status O
as O
measured O
by O
the O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
State O
Examination O
and O
NA O
/ I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
/ I-GENE
Cr I-GENE
and O
NA O
were O
found O
. O

_RARE_ I-GENE
also O
induced O
_RARE_ I-GENE
activity O
very O
strongly O
when O
the O
_RARE_ I-GENE
and O
_RARE_ I-GENE
sites I-GENE
were O
combined O
; O
induction O
of O
the O
( O
_RARE_ I-GENE
) O
3 I-GENE
( O
_RARE_ I-GENE
) O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
constructs I-GENE
was O
positively O
modulated O
by O
the O
_RARE_ I-GENE
. O

In O
this O
study O
, O
we O
report O
the O
isolation O
and O
characterization O
of O
the O
entire O
rat I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
_RARE_ I-GENE
) O
subunit I-GENE
gene I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
following O
intravenous O
infusion O
of O
calcium O
_RARE_ I-GENE
. O

Initial O
control O
of O
bleeding O
is O
similar O
, O
but O
eradication O
is O
achieved O
in O
fewer O
_RARE_ I-GENE
with O
_RARE_ I-GENE
. O

Finally O
, O
we O
determined O
the O
genomic O
organization O
of O
the O
human I-GENE
_RARE_ I-GENE
gene I-GENE
, O
which O
consists O
of O
18 O
exons O
spanning O
about O
67 O
kb O
, O
and O
its O
chromosomal I-GENE
localization O
at O
position O
_RARE_ I-GENE
. O
2 I-GENE
. O

The O
_RARE_ I-GENE
of O
this O
study O
were O
to O
determine O
and O
_RARE_ I-GENE
the O
frequency O
of O
self O
reported O
visual O
_RARE_ I-GENE
in O
daily O
tasks O
performed O
by O
glaucoma O
patients O
; O
to O
examine O
the O
_RARE_ I-GENE
between O
_RARE_ I-GENE
using O
factor I-GENE
analysis O
; O
to O
study O
the O
relation O
between O
perceived O
visual O
_RARE_ I-GENE
and O
a O
measure O
of O
the O
severity O
of O
visual O
field O
loss O
; O
to O
develop O
a O
glaucoma O
specific I-GENE
subgroup O
of O
questions O
; O
and O
examine O
the O
validity O
and O
reliability O
of O
this O
subgroup O
of O
questions O
. O

Furthermore O
, O
the O
validity O
of O
this O
new O
subset O
of O
questions O
was O
shown O
to O
be O
significant O
( O
r O
= O
0 O
. O
_RARE_ I-GENE
, O
p O
< O
0 O
. O
05 O
) O
for O
the O
correlation O
between O
a O
measure O
of O
the O
severity O
of O
_RARE_ I-GENE
visual O
field O
loss O
and O
the O
mean O
score O
of O
the O
variables O
used O
in O
the O
glaucoma O
specific I-GENE
subgroup O
of O
questions O
. O

Sequence O
comparison O
of O
_RARE_ I-GENE
_RARE_ I-GENE
and O
their O
homologs I-GENE
from O
various O
organisms O
demonstrates O
that O
the O
proteins I-GENE
can O
be O
classified O
into O
two O
_RARE_ I-GENE
, O
a O
_RARE_ I-GENE
type I-GENE
including O
E I-GENE
. O
coli I-GENE
_RARE_ I-GENE
and O
a O
more O
widely O
distributed O
type I-GENE
including O
the O
B I-GENE
. O
_RARE_ I-GENE
enzyme I-GENE
, O
suggesting O
that O
the O
latter O
type I-GENE
is O
evolutionarily O
older O
. O

_RARE_ I-GENE
_RARE_ I-GENE
is O
the O
_RARE_ I-GENE
of O
treatment O
. O

_RARE_ I-GENE
structure O
and O
mechanism O
of O
the O
_RARE_ I-GENE
_RARE_ I-GENE
. O

In O
11 O
eyes O
that O
had O
been O
selected O
at O
random O
10 O
micrograms O
of O
recombinant I-GENE
tissue I-GENE
plasminogen I-GENE
activator I-GENE
were O
injected O
_RARE_ I-GENE
24 O
hrs O
later O
. O

RESULTS O
AND O
CONCLUSIONS O
: O
_RARE_ I-GENE
' O
s O
double O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
( O
G2 I-GENE
) O
_RARE_ I-GENE
in O
_RARE_ I-GENE
_RARE_ I-GENE
increase O
of O
_RARE_ I-GENE
- I-GENE
pressure O
during O
anaesthesia O
with O
N2O O
. O

_RARE_ I-GENE
, O
we O
designated O
this O
gene I-GENE
_RARE_ I-GENE
( O
capping I-GENE
enzyme I-GENE
_RARE_ I-GENE
- I-GENE
like I-GENE
1 I-GENE
). O

The O
binding I-GENE
of O
PH I-GENE
domains I-GENE
to O
Gbetagamma I-GENE
was O
inhibited O
by O
_RARE_ I-GENE
of O
Gbetagamma I-GENE
with O
the O
GDP I-GENE
- I-GENE
bound O
but O
not O
the O
GTP I-GENE
- I-GENE
bound O
form O
of O
_RARE_ I-GENE
. O

Their O
_RARE_ I-GENE
are O
_RARE_ I-GENE
than O
_RARE_ I-GENE
and O
therefore O
are O
called O
_RARE_ I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
disease O
linked O
to O
_RARE_ I-GENE
dopamine I-GENE
agonist O
therapy O
( O
_RARE_ I-GENE
) O
for O
Parkinson O
' O
s O
disease O
. O

An O
_RARE_ I-GENE
type I-GENE
of O
_RARE_ I-GENE
is O
frequently O
associated I-GENE
with O
_RARE_ I-GENE
and O
we O
_RARE_ I-GENE
, O
therefore O
, O
that O
_RARE_ I-GENE
should O
be O
_RARE_ I-GENE
of O
a O
possible O
_RARE_ I-GENE
of O
_RARE_ I-GENE
and O
_RARE_ I-GENE
. O

In O
addition O
, O
we O
also O
constructed O
and O
expressed O
chimeric I-GENE
fusion I-GENE
protein I-GENE
that O
contains O
HIV I-GENE
- I-GENE
2 I-GENE
gag I-GENE
with O
_RARE_ I-GENE
domains I-GENE
of O
HIV I-GENE
- I-GENE
_RARE_ I-GENE
, O
HIV I-GENE
- I-GENE
_RARE_ I-GENE
, O
HIV I-GENE
- I-GENE
_RARE_ I-GENE
and O
HIV I-GENE
- I-GENE
_RARE_ I-GENE
. O

Our O
results O
indicate O
that O
_RARE_ I-GENE
peptides I-GENE
from O
all O
major I-GENE
_RARE_ I-GENE
of O
HIV I-GENE
- I-GENE
1 I-GENE
carried O
by O
HIV I-GENE
- I-GENE
2 I-GENE
gag I-GENE
can O
be O
used O
as O
a O
potential O
HIV I-GENE
/ I-GENE
AIDS O
vaccine O
. O

_RARE_ I-GENE
was O
determined O
by O
responses O
to O
question O
3 I-GENE
( O
ability O
to O
achieve O
an O
_RARE_ I-GENE
) O
and O
question O
4 I-GENE
( O
ability O
to O
maintain O
an O
_RARE_ I-GENE
) O
of O
the O
15 O
- I-GENE
_RARE_ I-GENE
International O
_RARE_ I-GENE
of O
_RARE_ I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
). O

Evidence O
for O
the O
involvement O
of O
the O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
phosphatase I-GENE
and O
the O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
kinase I-GENE
in O
the O
regulation O
of O
_RARE_ I-GENE
transcription I-GENE
in O
Saccharomyces I-GENE
cerevisiae I-GENE
. O

In O
_RARE_ I-GENE
males O
, O
two O
her I-GENE
- I-GENE
1 I-GENE
mRNAs I-GENE
, O
her I-GENE
- I-GENE
1a I-GENE
and O
her I-GENE
- I-GENE
1b I-GENE
, O
are O
transcribed O
from O
two O
separate O
promoters I-GENE
: O
P1 I-GENE
, O
located O
in O
the O
5 I-GENE
'- O
flanking O
region O
, O
and O
P2 I-GENE
, O
located O
in O
the O
large O
second O
intron O
. O

Induction O
of O
Fas I-GENE
ligand O
expression O
by O
HIV I-GENE
involves O
the O
interaction O
of O
Nef I-GENE
with O
the O
T I-GENE
cell O
receptor I-GENE
zeta I-GENE
chain I-GENE
. O

_RARE_ I-GENE
protein I-GENE
tyrosine I-GENE
phosphatases I-GENE
( O
_RARE_ I-GENE
) O
comprise O
a O
family I-GENE
of O
proteins I-GENE
that O
feature O
intracellular O
phosphatase I-GENE
domains I-GENE
and O
an O
_RARE_ I-GENE
with O
putative O
ligand O
- I-GENE
binding I-GENE
motifs O
. O

These O
well O
- I-GENE
characterized O
brain O
regions O
may O
provide O
a O
basis O
for O
future O
studies O
of O
_RARE_ I-GENE
- I-GENE
kappa I-GENE
function O
. O

_RARE_ I-GENE
used O
_RARE_ I-GENE
are O
mental O
_RARE_ I-GENE
, O
speech O
tasks O
, O
the O
Stroop O
test O
, O
_RARE_ I-GENE
_RARE_ I-GENE
, O
films O
or O
_RARE_ I-GENE
and O
_RARE_ I-GENE
. O

The O
control O
group O
included O
8 O
_RARE_ I-GENE
samples O
from O
physiological O
full I-GENE
- I-GENE
term O
_RARE_ I-GENE
. O

However O
, O
we O
identified O
a O
gene I-GENE
between O
the O
_RARE_ I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
genes I-GENE
with O
homology I-GENE
to O
the O
first O
ORF I-GENE
( O
ORF I-GENE
- I-GENE
1 I-GENE
) O
of O
equine I-GENE
herpesvirus I-GENE
type I-GENE
1 I-GENE
and O
corresponding O
gene I-GENE
identified O
in O
pseudorabies O
virus I-GENE
. O

In O
contrast O
, O
the O
loss O
of O
_RARE_ I-GENE
staining O
in O
meiosis O
was O
not O
correlated O
with O
initial O
microtubule I-GENE
attachment O
but O
was O
correlated O
with O
a O
measure O
of O
tension O
: O
the O
distance O
between O
homologous O
or O
_RARE_ I-GENE
_RARE_ I-GENE
( O
in O
meiosis O
I I-GENE
and O
II I-GENE
, O
respectively O
). O

In O
epithelial O
cells O
, O
the O
PH I-GENE
domain I-GENE
of O
Akt I-GENE
/ I-GENE
PKB I-GENE
_RARE_ I-GENE
to O
sites I-GENE
of O
cell O
- I-GENE
cell O
and O
cell O
- I-GENE
matrix I-GENE
contact O
, O
distinct O
from O
focal I-GENE
contacts O
, O
even O
in O
the O
absence O
of O
serum I-GENE
. O

The O
5 I-GENE
' O
untranslated O
and O
coding O
regions O
are O
contained O
within O
12 O
exons O
, O
with O
the O
translation I-GENE
start O
site I-GENE
located O
within O
the O
first O
exon O
. O

The O
motility O
of O
sperm O
, O
except O
for O
those O
adjacent O
to O
both O
electrodes O
, O
did O
not O
change O
after O
stimulation O
for O
_RARE_ I-GENE
, O
despite O
a O
high O
electrical O
energy O
. O

Induction O
of O
the O
_RARE_ I-GENE
promoter I-GENE
by O
IL I-GENE
- I-GENE
17 O
in O
_RARE_ I-GENE
- I-GENE
6 I-GENE
cells O
was O
TNF I-GENE
receptor I-GENE
- I-GENE
associated I-GENE
factor I-GENE
- I-GENE
6 I-GENE
( O
_RARE_ I-GENE
), O
but O
not O
TRAF2 I-GENE
, O
dependent I-GENE
. O

_RARE_ I-GENE
may O
be O
critical O
for O
tumor I-GENE
development O
and O
suppression O
through O
regulation O
of O
beta I-GENE
- I-GENE
catenin I-GENE
protein I-GENE
stability O
. O

A I-GENE
_RARE_ I-GENE
- I-GENE
dependent I-GENE
spindle O
checkpoint I-GENE
pathway O
regulates O
the O
_RARE_ I-GENE
kinase I-GENE
in O
budding I-GENE
yeast I-GENE
. O

We O
analyzed O
the O
_RARE_ I-GENE
organization O
of O
DNA I-GENE
polymerase I-GENE
beta I-GENE
and O
found O
that O
residues O
making O
contact O
with O
DNA I-GENE
_RARE_ I-GENE
were O
localized O
to O
five O
modules I-GENE
. O

RESULTS O
: O
_RARE_ I-GENE
nerves O
are O
mainly O
involved O
in O
the O
regulation O
of O
enteric O
nerve I-GENE
responses O
to O
_RARE_ I-GENE
in O
the O
normal O
_RARE_ I-GENE
. O

Two O
- I-GENE
dimensional O
gel O
electrophoresis O
of O
anti I-GENE
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
obtained O
from O
non O
- I-GENE
transformed O
resting O
human I-GENE
T I-GENE
lymphocytes O
resulted O
in O
the O
identification O
of O
an O
_RARE_ I-GENE
protein I-GENE
complex I-GENE
which O
is O
constitutively O
formed O
between O
Fyn I-GENE
and O
several O
additional O
_RARE_ I-GENE
( O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
the O
protein I-GENE
tyrosine I-GENE
kinase I-GENE
_RARE_ I-GENE
, O
as O
well O
as O
the O
two O
recently O
cloned O
adaptor I-GENE
proteins I-GENE
, O
_RARE_ I-GENE
and O
_RARE_ I-GENE
- I-GENE
130 I-GENE
). O

We O
show O
that O
other O
_RARE_ I-GENE
mutants I-GENE
also O
arrest O
in O
G1 I-GENE
. O

A I-GENE
_RARE_ I-GENE
- I-GENE
1 I-GENE
strain O
expressing O
either O
stable O
_RARE_ I-GENE
( O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
) O
or O
a O
hybrid O
_RARE_ I-GENE
5 I-GENE
'- O
_RARE_ I-GENE
mRNA I-GENE
, O
whose O
translation I-GENE
displays O
decreased O
dependence O
on O
_RARE_ I-GENE
, O
arrested O
randomly O
in O
the O
cell O
cycle O
. O

_RARE_ I-GENE
motifs O
for O
gene I-GENE
expression O
such O
as O
nuclear I-GENE
- I-GENE
factor I-GENE
- I-GENE
kappaB I-GENE
- I-GENE
binding I-GENE
- I-GENE
site I-GENE
- I-GENE
like I-GENE
sequence I-GENE
( O
kappaB I-GENE
site I-GENE
) O
and O
nuclear I-GENE
- I-GENE
factor I-GENE
- I-GENE
interleukin I-GENE
- I-GENE
6 I-GENE
- I-GENE
binding I-GENE
- I-GENE
site I-GENE
- I-GENE
like I-GENE
sequence I-GENE
( O
NF I-GENE
- I-GENE
IL I-GENE
- I-GENE
6 I-GENE
site I-GENE
) O
were O
found O
in O
the O
5 I-GENE
'- O
upstream O
regulatory I-GENE
region O
. O

The O
gene I-GENE
structure O
of O
_RARE_ I-GENE
spans O
15 O
. O
2 I-GENE
kb O
and O
consists O
of O
seven O
exons O
and O
six O
introns O
. O

Total O
serum I-GENE
calcium O
was O
7 O
. O
8 O
+/- O
0 O
. O
8 O
mg O
/ I-GENE
dl O
, O
whereas O
_RARE_ I-GENE
calcium O
was O
5 I-GENE
. O
7 O
+/- O
0 O
. O
7 O
mg O
/ I-GENE
dl O
, O
phosphorus O
3 I-GENE
. O
2 I-GENE
+/- O
1 I-GENE
. O
2 I-GENE
mg O
/ I-GENE
dl O
, O
and O
alkaline I-GENE
phosphatase I-GENE
_RARE_ I-GENE
+/- O
48 O
. O
6 I-GENE
U O
/ I-GENE
liter O
. O

Sequence O
analysis O
suggests O
that O
_RARE_ I-GENE
contains O
a O
_RARE_ I-GENE
guanine I-GENE
dinucleotide O
cofactor I-GENE
and O
a O
[ O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
] O
cluster I-GENE
, O
that O
_RARE_ I-GENE
binds O
four O
[ O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
] O
clusters O
, O
and O
that O
_RARE_ I-GENE
is O
an O
integral I-GENE
membrane I-GENE
protein I-GENE
containing O
a O
_RARE_ I-GENE
oxidation O
site I-GENE
. O

_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
differences O
in O
_RARE_ I-GENE
tissue I-GENE
formation O
: O
an O
experimental O
study O
in O
the O
rat I-GENE
. O

Site I-GENE
- I-GENE
directed O
mutagenesis O
showed O
that O
two O
adjacent O
SP1 I-GENE
sites I-GENE
proximal I-GENE
to O
exon O
1 I-GENE
were O
equally O
important O
in O
_RARE_ I-GENE
basal O
promoter I-GENE
activity O
. O

_RARE_ I-GENE
- I-GENE
fed O
newborn O
infants O
_RARE_ I-GENE
n O
- I-GENE
6 I-GENE
long O
- I-GENE
chain I-GENE
_RARE_ I-GENE
fatty I-GENE
acids O
already O
during O
the O
first O
week O
of O
life O
, O
but O
the O
contribution O
of O
endogenous I-GENE
synthesis O
to O
the O
total O
plasma I-GENE
long O
- I-GENE
chain I-GENE
_RARE_ I-GENE
pool O
is O
small I-GENE
. O

_RARE_ I-GENE
and O
reperfusion O
markedly O
increased O
the O
release O
of O
6 I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
alpha I-GENE
and O
_RARE_ I-GENE
. O

_RARE_ I-GENE
- I-GENE
specific I-GENE
antigen I-GENE
( O
PSA I-GENE
) O
promoter I-GENE
- I-GENE
driven O
androgen O
- I-GENE
inducible I-GENE
expression O
of O
sodium O
_RARE_ I-GENE
_RARE_ I-GENE
in O
prostate O
cancer O
cell O
lines O
. O

It O
is O
clear O
that O
subclinical O
and O
silent I-GENE
CD O
exist O
in O
a O
large O
subgroup O
of O
the O
_RARE_ I-GENE
population O
. O

_RARE_ I-GENE
activates O
invasive O
growth I-GENE
using O
either O
of O
two O
downstream O
signaling O
pathways O
, O
the O
_RARE_ I-GENE
MAPK I-GENE
( O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
/ I-GENE
MAPK I-GENE
) O
cascade O
or O
the O
cAMP I-GENE
- I-GENE
dependent I-GENE
protein I-GENE
kinase I-GENE
( O
_RARE_ I-GENE
/ I-GENE
cAMP I-GENE
/ I-GENE
PKA I-GENE
) O
pathway O
. O

Consistent O
with O
this O
prediction O
, O
transfections O
into O
the O
hematopoietic I-GENE
cell O
line O
Jurkat O
showed O
a O
9 O
. O
0 O
- I-GENE
and O
2 I-GENE
. O
5 I-GENE
- I-GENE
fold O
activation O
of O
the O
_RARE_ I-GENE
- I-GENE
1 I-GENE
promoter I-GENE
by O
the O
_RARE_ I-GENE
and O
_RARE_ I-GENE
isoforms I-GENE
, O
respectively O
. O

Previous O
work O
has O
shown O
that O
spleen O
necrosis I-GENE
virus I-GENE
( O
_RARE_ I-GENE
) O
long O
terminal I-GENE
repeats I-GENE
( O
_RARE_ I-GENE
) O
are O
associated I-GENE
with O
Rex I-GENE
/ I-GENE
Rex I-GENE
- I-GENE
responsive I-GENE
element I-GENE
- I-GENE
independent O
expression O
of O
bovine I-GENE
leukemia I-GENE
virus I-GENE
RNA I-GENE
and O
supports O
the O
hypothesis O
that O
_RARE_ I-GENE
RNA I-GENE
contains O
a O
cis O
- I-GENE
acting O
element I-GENE
that O
interacts O
with O
cellular O
Rex I-GENE
- I-GENE
like I-GENE
proteins I-GENE
. O

Despite O
the O
reported O
_RARE_ I-GENE
effects O
on O
CNS O
development O
, O
a O
number O
of O
animal O
studies O
have O
shown O
that O
pretreatment O
with O
corticosteroids O
_RARE_ I-GENE
protect O
the O
brain O
from O
hypoxia O
- I-GENE
ischemic O
injury O
; O
however O
, O
clinically O
such O
treatment O
is O
no O
longer O
_RARE_ I-GENE
. O

In O
one O
mechanism O
, O
a O
specialized O
ubiquitin I-GENE
- I-GENE
dependent I-GENE
proteolytic O
system O
( O
called O
the O
APC I-GENE
- I-GENE
dependent I-GENE
proteolysis O
machinery O
) O
_RARE_ I-GENE
the O
mitotic O
( O
_RARE_ I-GENE
) O
cyclin I-GENE
subunit I-GENE
. O

_RARE_ I-GENE
of O
success O
in O
_RARE_ I-GENE
_RARE_ I-GENE
: O
_RARE_ I-GENE
vs O
. O
other O
admission O
criteria O
. O

_RARE_ I-GENE
survey O
reveals O
_RARE_ I-GENE
_RARE_ I-GENE
among O
physicians O
. O

In O
a O
series O
of O
16 O
full I-GENE
- I-GENE
scale O
_RARE_ I-GENE
tests O
, O
_RARE_ I-GENE
at O
the O
_RARE_ I-GENE
Research O
Institute O
have O
concluded O
that O
automatic O
_RARE_ I-GENE
control O
in O
the O
room O
of O
_RARE_ I-GENE
origin O
can O
significantly O
reduce O
the O
spread O
of O
toxic O
smoke O
and O
gases O
. O

_RARE_ I-GENE
_RARE_ I-GENE
demonstrates O
a O
shift O
in O
identification O
of O
the O
library O
as O
an O
isolated O
unit I-GENE
to O
an O
_RARE_ I-GENE
resource O
center I-GENE
. O

_RARE_ I-GENE
of O
adverse O
events O
occurring O
during O
clinical O
trials O
of O
_RARE_ I-GENE
drugs O
is O
a O
complex I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
benefits O
revised O
-- O
again O
. O

In O
this O
paper O
, O
the O
current O
status O
of O
the O
understanding O
of O
the O
interaction O
mechanisms O
of O
ultrasound O
with O
biological O
media O
and O
the O
factors I-GENE
that O
govern O
different O
biological O
effects O
are O
_RARE_ I-GENE
. O

Members O
of O
the O
mitogen I-GENE
activated I-GENE
protein I-GENE
( O
MAP I-GENE
) O
kinase I-GENE
family I-GENE
, O
extracellular I-GENE
signal I-GENE
- I-GENE
regulated O
kinase I-GENE
, O
stress O
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
- I-GENE
1 I-GENE
/ I-GENE
c I-GENE
- I-GENE
Jun I-GENE
NH2 I-GENE
- I-GENE
terminal I-GENE
kinase I-GENE
, O
and O
p38 I-GENE
, O
are O
central O
elements O
that O
_RARE_ I-GENE
the O
signal I-GENE
generated O
by O
growth I-GENE
factors I-GENE
, O
cytokines O
, O
and O
_RARE_ I-GENE
agents O
. O

In O
the O
present O
study O
, O
we O
have O
investigated O
the O
functional O
role O
of O
the O
other O
MAP I-GENE
kinases I-GENE
in O
PDGF I-GENE
- I-GENE
mediated O
cellular O
responses O
. O

_RARE_ I-GENE
of O
tyrosine I-GENE
residue O
- I-GENE
mutated O
PDGF I-GENE
receptors I-GENE
show O
that O
Src I-GENE
homology I-GENE
2 I-GENE
domain I-GENE
- I-GENE
containing O
proteins I-GENE
including O
Src I-GENE
family I-GENE
kinases I-GENE
, O
phosphatidylinositol I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
, O
the O
GTPase I-GENE
- I-GENE
activating I-GENE
protein I-GENE
of O
Ras I-GENE
, O
the O
Src I-GENE
homology I-GENE
2 I-GENE
domain I-GENE
- I-GENE
containing O
phosphatase I-GENE
SHP I-GENE
- I-GENE
2 I-GENE
, O
phospholipase I-GENE
C I-GENE
- I-GENE
gamma I-GENE
, O
and O
Crk I-GENE
do O
not O
play O
a O
major I-GENE
role O
in O
mediating O
the O
PDGF I-GENE
- I-GENE
induced O
activation O
of O
p38 I-GENE
. O

Here O
we O
show O
that O
_RARE_ I-GENE
inhibits O
tyrosine I-GENE
phosphatases I-GENE
, O
enhancing O
tyrosine I-GENE
phosphorylation O
particularly O
of O
paxillin I-GENE
. O

Three O
- I-GENE
dimensional O
structural O
studies O
using O
electron O
_RARE_ I-GENE
showed O
that O
the O
binding I-GENE
of O
one O
_RARE_ I-GENE
( O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
) O
does O
not O
affect O
the O
conformation O
of O
the O
capsid I-GENE
, O
and O
the O
efficiency O
of O
mRNA I-GENE
production O
is O
similar O
to O
that O
of O
the O
native O
_RARE_ I-GENE
particle I-GENE
. O

Further O
, O
mutational O
analysis O
of O
_RARE_ I-GENE
assigned O
the O
SH3 I-GENE
- I-GENE
binding I-GENE
region O
to O
a O
proline O
- I-GENE
rich O
motif I-GENE
that O
is O
highly O
conserved O
among O
HCV I-GENE
_RARE_ I-GENE
. O

Taken O
together O
, O
these O
findings O
show O
that O
_RARE_ I-GENE
_RARE_ I-GENE
inhibits O
the O
VEGF I-GENE
- I-GENE
induced O
Ras I-GENE
activation O
; O
this O
_RARE_ I-GENE
represents O
a O
novel O
and O
potentially O
important O
mechanism O
for O
the O
control O
of O
angiogenesis O
. O

Analysis O
of O
SRE O
oligonucleotide I-GENE
gel O
mobility I-GENE
shift O
assays O
with O
nuclear I-GENE
extracts O
from O
_RARE_ I-GENE
cells O
demonstrated O
the O
presence O
of O
both O
the O
SRF I-GENE
and O
the O
ubiquitously O
expressed O
bHLH I-GENE
protein I-GENE
E12 I-GENE
/ I-GENE
_RARE_ I-GENE
. O

We O
calculated O
differences O
in O
late O
occlusion O
rates O
by O
the O
_RARE_ I-GENE
( O
_RARE_ I-GENE
- I-GENE
square O
) O
test O
, O
and O
found O
these O
differences O
were O
significant O
( O
P I-GENE
=. O
04 O
). O

_RARE_ I-GENE
_RARE_ I-GENE
over O
the O
surface O
of O
the O
temporal O
lobe O
and O
depth O
electrode O
recordings O
in O
the O
amygdala O
and O
hippocampus O
were O
obtained O
, O
followed O
by O
10 O
min O
of O
recording O
before O
and O
after O
the O
i O
. O
v I-GENE
. O
administration O
of O
both O
_RARE_ I-GENE
50 O
microg O
/ I-GENE
kg O
and O
fentanyl O
10 O
microg O
/ I-GENE
kg O
. O

We O
describe O
a O
genetic O
system O
for O
further O
characterizing O
the O
role O
of O
the O
extreme O
C I-GENE
- I-GENE
terminus O
of O
the O
beta I-GENE
subunit I-GENE
of O
E I-GENE
. O
coli I-GENE
RNA I-GENE
polymerase I-GENE
. O

We O
suggest O
that O
_RARE_ I-GENE
and O
_RARE_ I-GENE
are O
substrate I-GENE
- I-GENE
specific I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
that O
prevent O
oligomerization O
of O
the O
_RARE_ I-GENE
by O
binding I-GENE
to O
their O
helical O
domains I-GENE
before O
export O
. O

Post O
and O
core I-GENE
_RARE_ I-GENE
for O
divergent O
_RARE_ I-GENE
with O
a O
_RARE_ I-GENE
post O
and O
core I-GENE
and O
a O
_RARE_ I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
( O
_RARE_ I-GENE
amino O
acids O
[ O
aa O
_RARE_ I-GENE
encoded I-GENE
by O
the O
largest O
ORF I-GENE
, O
displayed O
strong O
similarity O
( O
40 I-GENE
% O
identity O
) O
to O
the O
replication O
proteins I-GENE
from O
plasmids O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
, O
indicating O
that O
the O
_RARE_ I-GENE
_RARE_ I-GENE
belongs O
to O
the O
_RARE_ I-GENE
family I-GENE
of O
gram O
- I-GENE
positive O
_RARE_ I-GENE
- I-GENE
replicating I-GENE
plasmids O
. O

Here O
we O
report O
the O
cloning O
and O
characterization O
of O
Xenopus I-GENE
Pax I-GENE
- I-GENE
5 I-GENE
and O
Pax I-GENE
- I-GENE
8 O
, O
two O
_RARE_ I-GENE
of O
the O
Pax I-GENE
- I-GENE
2 I-GENE
/ I-GENE
5 I-GENE
/ I-GENE
8 O
gene I-GENE
family I-GENE
. O

_RARE_ I-GENE
values O
for O
_RARE_ I-GENE
, O
2 I-GENE
- I-GENE
_RARE_ I-GENE
, O
NADH I-GENE
, O
glutamate I-GENE
and O
NAD I-GENE
+ I-GENE
were O
6 I-GENE
. O
5 I-GENE
, O
3 I-GENE
. O
5 I-GENE
, O
0 O
. O
06 O
, O
37 O
. O
1 I-GENE
and O
0 O
. O
_RARE_ I-GENE
mM O
, O
respectively O
. O

Interferon I-GENE
- I-GENE
alpha I-GENE
may O
_RARE_ I-GENE
_RARE_ I-GENE
- I-GENE
related I-GENE
ischemic O
manifestations O
: O
an O
adverse O
effect O
potentially O
related I-GENE
to O
its O
anti I-GENE
- I-GENE
_RARE_ I-GENE
activity O
. O

Interferon I-GENE
- I-GENE
alpha I-GENE
may O
_RARE_ I-GENE
_RARE_ I-GENE
- I-GENE
related I-GENE
ischemic O
manifestations O
: O
an O
adverse O
effect O
potentially O
related I-GENE
to O
its O
anti I-GENE
- I-GENE
_RARE_ I-GENE
activity O
. O

In O
addition O
, O
we O
demonstrate O
that O
the O
production O
of O
active O
recombinant I-GENE
telomerase I-GENE
requires O
a O
factor I-GENE
in O
rabbit I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
that O
promotes O
ribonucleoprotein I-GENE
assembly O
. O

The O
enhanced O
binding I-GENE
of O
c I-GENE
- I-GENE
Abl I-GENE
to O
DNA I-GENE
containing O
5 I-GENE
- I-GENE
_RARE_ I-GENE
residues O
may O
result O
from O
an O
increased O
propensity O
of O
the O
double O
helix I-GENE
to O
_RARE_ I-GENE
locally O
coupled I-GENE
with O
a O
protein I-GENE
- I-GENE
induced O
reduction O
in O
the O
base O
_RARE_ I-GENE
interaction O
. O

Homozygous O
mutation I-GENE
in O
two O
children O
led O
to O
_RARE_ I-GENE
of O
_RARE_ I-GENE
due O
to O
purpura O
_RARE_ I-GENE
. O

According O
to O
_RARE_ I-GENE
experiments O
which O
considered O
various O
durations O
of O
global O
no O
- I-GENE
flow O
ischemia O
ranging O
from O
10 O
to O
20 O
minutes O
, O
two O
durations O
were O
chosen O
for O
the O
present O
study O
: O
20 O
minutes O
( O
group O
20 O
) O
in O
which O
ventricular O
fibrillation O
( O
VF O
) O
was O
the O
predominant O
form O
of O
arrhythmias O
, O
and O
18 O
minutes O
( O
group O
18 O
) O
in O
which O
the O
prevalence O
of O
VF O
was O
markedly O
lower O
despite O
the O
small I-GENE
difference O
in O
the O
duration O
of O
ischemia O
. O

An O
end O
- I-GENE
to O
- I-GENE
end O
_RARE_ I-GENE
using O
a O
mechanical O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
device O
. O

We O
further O
demonstrate O
that O
the O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
Protein I-GENE
- I-GENE
_RARE_ I-GENE
( O
SAPK I-GENE
) O
target O
sites I-GENE
of O
_RARE_ I-GENE
, O
_RARE_ I-GENE
and O
_RARE_ I-GENE
are O
not O
required O
for O
the O
formation O
of O
the O
p300 I-GENE
/ I-GENE
CBP I-GENE
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
complex I-GENE
. O

Blood O
samples O
were O
obtained O
daily O
during O
this O
supplementation O
period O
and O
5 I-GENE
d O
thereafter O
( O
d O
11 O
to O
15 O
). O

These O
results O
suggest O
that O
mitochondrial I-GENE
_RARE_ I-GENE
interact O
with O
the O
_RARE_ I-GENE
- I-GENE
hsp70 I-GENE
during O
or O
after O
mitochondrial I-GENE
protein I-GENE
import O
. O

The O
3 I-GENE
' O
terminus O
of O
the O
genome O
can O
be O
folded O
into O
a O
tRNA I-GENE
- I-GENE
like I-GENE
secondary O
structure O
that O
has O
a O
_RARE_ I-GENE
_RARE_ I-GENE
; O
the O
tRNA I-GENE
- I-GENE
like I-GENE
structure O
lacks O
a O
_RARE_ I-GENE
in O
the O
_RARE_ I-GENE
stem O
, O
a O
feature O
common O
to O
both O
_RARE_ I-GENE
of O
_RARE_ I-GENE
. O

O O
. O
novo I-GENE
- I-GENE
_RARE_ I-GENE
RNA I-GENE
- I-GENE
7 O
, O
previously O
believed O
to O
be O
a O
satellite I-GENE
- I-GENE
like I-GENE
RNA I-GENE
, O
is O
shown O
to O
be O
a O
defective O
RNA I-GENE
, O
derived O
from O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
RNA I-GENE
by O
multiple O
internal O
deletions O
. O

Only O
one O
gene I-GENE
, O
fibronectin I-GENE
( O
FN I-GENE
), O
was O
highly O
overexpressed O
(> O
60 O
- I-GENE
fold O
) O
in O
_RARE_ I-GENE
- I-GENE
r O
cells O
, O
consistent O
with O
previously O
reported O
overexpression O
of O
FN I-GENE
in O
prostate O
cancer O
. O

We O
also O
observed O
that O
cell O
surface O
CD4 I-GENE
_RARE_ I-GENE
CD8 I-GENE
_RARE_ I-GENE
CD3 I-GENE
_RARE_ I-GENE
cells O
with O
rearranged I-GENE
TCR I-GENE
genes I-GENE
developed O
from O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
but O
not O
from O
control O
- I-GENE
_RARE_ I-GENE
pre I-GENE
- I-GENE
T I-GENE
cells O
in O
an O
_RARE_ I-GENE
. O

As O
determined O
in O
a O
modified O
yeast I-GENE
two O
- I-GENE
hybrid O
system O
, O
_RARE_ I-GENE
bound O
strongly O
to O
the O
p85 I-GENE
subunit I-GENE
of O
phosphatidylinositol I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
. O

Insulin I-GENE
stimulation O
promoted O
the O
association O
of O
_RARE_ I-GENE
with O
p85 I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
and O
Shc I-GENE
. O

The O
mRNA I-GENE
expression O
of O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
was O
detected O
ubiquitously O
, O
but O
in O
transient O
- I-GENE
transfection O
assays O
, O
_RARE_ I-GENE
_RARE_ I-GENE
binding I-GENE
sites I-GENE
in O
front O
of O
a O
basal O
promoter I-GENE
efficiently O
functioned O
in O
a O
tissue I-GENE
- I-GENE
and O
lineage O
- I-GENE
specific I-GENE
manner O
. O

In O
the O
case O
of O
the O
_RARE_ I-GENE
intron O
, O
repression O
of O
luciferase I-GENE
expression O
likely O
involved O
two O
_RARE_ I-GENE
- I-GENE
binding I-GENE
sequences I-GENE
, O
since O
luciferase I-GENE
expression O
was O
increased O
by O
deletion O
of O
these O
sites I-GENE
. O

Thus O
, O
VDR I-GENE
acts O
selectively O
on O
the O
two O
components O
required O
for O
activation O
of O
this O
promoter I-GENE
/ I-GENE
enhancer I-GENE
: O
it O
_RARE_ I-GENE
with O
_RARE_ I-GENE
for O
binding I-GENE
to O
the O
composite O
site I-GENE
, O
positioning O
itself O
adjacent O
to O
Jun I-GENE
- I-GENE
Fos I-GENE
on O
the O
DNA I-GENE
. O

Two O
evolutionarily O
conserved O
kinases I-GENE
, O
the O
cyclin I-GENE
B I-GENE
( O
_RARE_ I-GENE
)/ O
cyclin I-GENE
- I-GENE
dependent I-GENE
kinase I-GENE
( O
Cdk I-GENE
/ I-GENE
_RARE_ I-GENE
) O
and O
_RARE_ I-GENE
along O
with O
its O
interacting I-GENE
factor I-GENE
_RARE_ I-GENE
, O
are O
required O
late O
in O
G1 I-GENE
to O
initiate O
DNA I-GENE
replication O
. O

The O
_RARE_ I-GENE
_RARE_ I-GENE
leads O
to O
accumulation O
of O
_RARE_ I-GENE
at O
the O
cytoplasmic I-GENE
_RARE_ I-GENE
of O
the O
nuclear I-GENE
pore I-GENE
complex I-GENE
( O
_RARE_ I-GENE
) O
in O
association O
with O
the O
p62 I-GENE
complex I-GENE
and O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
. O

All O
of O
the O
elements O
exhibited O
a O
uniform O
structure O
. O

In O
contrast O
, O
the O
deduced O
amino O
acid I-GENE
sequence I-GENE
of O
a O
second O
family I-GENE
( O
_RARE_ I-GENE
) O
of O
_RARE_ I-GENE
, O
cloned O
from O
murine I-GENE
lymphoma O
cells O
and O
expressed O
in O
high O
abundance O
in O
testis I-GENE
, O
displays O
a O
hydrophobic O
amino O
terminus O
, O
consistent O
with O
a O
signal I-GENE
sequence I-GENE
, O
but O
lacks O
a O
hydrophobic O
signal I-GENE
sequence I-GENE
at O
its O
carboxyl O
terminus O
, O
suggesting O
that O
the O
protein I-GENE
is O
_RARE_ I-GENE
for O
export O
. O

RESULTS O
: O
Each O
year O
, O
on O
average O
39 O
% O
of O
cases O
seen O
in O
_RARE_ I-GENE
are O
_RARE_ I-GENE
; O
_RARE_ I-GENE
( O
40 I-GENE
%) O
of O
the O
_RARE_ I-GENE
patients O
_RARE_ I-GENE
during O
the O
study O
period O
were O
never O
seen O
by O
regional O
medical O
_RARE_ I-GENE
. O

This O
dimer O
interface O
is O
likely O
important O
for O
increasing O
the O
DNA I-GENE
- I-GENE
binding I-GENE
specificity O
and O
affinity O
of O
the O
_RARE_ I-GENE
form O
of O
HSF I-GENE
, O
as O
well O
as O
for O
increasing O
cooperativity O
between O
adjacent O
_RARE_ I-GENE
. O

The O
_RARE_ I-GENE
fusion I-GENE
( O
F I-GENE
) O
protein I-GENE
mediates O
membrane I-GENE
fusion I-GENE
. O

Additionally O
, O
deletion O
analysis O
of O
the O
_RARE_ I-GENE
promoter I-GENE
- I-GENE
_RARE_ I-GENE
constructs I-GENE
indicated O
that O
the O
minimal I-GENE
region O
exhibiting O
the O
promoter I-GENE
activity O
was O
located O
between O
nt O
- I-GENE
33 O
and O
+ I-GENE
100 O
, O
and O
that O
a O
strong O
enhancer I-GENE
was O
present O
within O
_RARE_ I-GENE
bp O
of O
the O
5 I-GENE
'- O
promoter I-GENE
region O
. O

The O
_RARE_ I-GENE
gene I-GENE
_RARE_ I-GENE
more O
than O
_RARE_ I-GENE
and O
consists O
of O
16 O
exons O
. O

Both O
_RARE_ I-GENE
mRNA I-GENE
and O
_RARE_ I-GENE
levels O
are O
increased O
in O
_RARE_ I-GENE
21 O
. O

In O
reperfusion O
B I-GENE
, O
only O
the O
diabetic O
group O
demonstrated O
a O
significant O
increase O
in O
IL I-GENE
- I-GENE
8 O
concentrations O
at O
1 I-GENE
and O
15 O
min O
compared O
to O
_RARE_ I-GENE
. O

This O
repression O
was O
reversed O
agonists O
of O
either O
receptor I-GENE
demonstrating O
a O
functional O
interaction O
between O
_RARE_ I-GENE
and O
PPARalpha I-GENE
. O
_RARE_ I-GENE
heterodimeric I-GENE
complexes I-GENE
in O
mammalian I-GENE
cells O
. O

In O
the O
present O
study O
, O
we O
show O
that O
_RARE_ I-GENE
/ I-GENE
300 O
is O
required O
for O
a O
_RARE_ I-GENE
- I-GENE
rich O
_RARE_ I-GENE
to O
promote O
the O
splicing O
of O
a O
pre I-GENE
- I-GENE
mRNA I-GENE
derived O
from O
the O
Drosophila I-GENE
_RARE_ I-GENE
gene I-GENE
. O

_RARE_ I-GENE
also O
was O
identified O
as O
a O
component O
of O
a O
cytoplasmic I-GENE
SPB O
_RARE_ I-GENE
containing O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
. O

The O
average O
coefficients O
of O
correlation O
were O
0 O
. O
_RARE_ I-GENE
and O
0 O
. O
_RARE_ I-GENE
for O
the O
_RARE_ I-GENE
and O
the O
_RARE_ I-GENE
system O
, O
respectively O
. O

The O
5 I-GENE
- I-GENE
year O
_RARE_ I-GENE
for O
stage O
IIIB I-GENE
was O
30 O
. O
9 O
%, O
compared O
to O
7 O
. O
8 O
% O
for O
stage O
IV I-GENE
. O

Furthermore O
, O
heparin O
lyase I-GENE
treatment O
of O
extracts O
of O
cells O
expressing O
recombinant I-GENE
_RARE_ I-GENE
- I-GENE
repeat I-GENE
protein I-GENE
_RARE_ I-GENE
this O
protein I-GENE
from O
high O
molecular O
mass O
aggregates O
. O

The O
coefficient O
of O
determination O
, O
_RARE_ I-GENE
, O
of O
the O
other O
scores O
ranged O
from O
0 O
. O
56 O
to O
0 O
. O
61 O
. O

While O
determination O
of O
the O
protein I-GENE
content O
of O
the O
_RARE_ I-GENE
gave O
no O
_RARE_ I-GENE
information O
, O
RAST O
/ I-GENE
_RARE_ I-GENE
inhibition O
was O
highest O
for O
_RARE_ I-GENE
' O
s O
milk O
, O
followed O
by O
the O
partially O
_RARE_ I-GENE
_RARE_ I-GENE
formula O
, O
partially O
_RARE_ I-GENE
_RARE_ I-GENE
/ I-GENE
casein I-GENE
formula O
, O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
collagen I-GENE
formula O
, O
and O
the O
amino O
acid I-GENE
formula O
. O

In O
light I-GENE
of O
the O
importance O
of O
_RARE_ I-GENE
, O
the O
molecular O
mechanisms O
underlying O
the O
transcriptional O
regulation O
of O
the O
human I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
gene I-GENE
become O
a O
key O
_RARE_ I-GENE
in O
understanding O
human I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
mobility I-GENE
shift O
assays O
using O
either O
_RARE_ I-GENE
- I-GENE
1 I-GENE
nuclear I-GENE
extract O
or O
recombinant I-GENE
SF I-GENE
- I-GENE
1 I-GENE
protein I-GENE
clearly O
indicated O
that O
SF I-GENE
- I-GENE
1 I-GENE
is O
able O
to O
interact O
specifically O
with O
this O
_RARE_ I-GENE
element I-GENE
positioned O
at O
- I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
3 I-GENE
_RARE_ I-GENE
was O
reported O
in O
1 I-GENE
patient O
. O

_RARE_ I-GENE
kinase I-GENE
activities O
were O
unaffected O
, O
as O
were O
the O
levels O
of O
the O
CDK I-GENE
inhibitor I-GENE
_RARE_ I-GENE
present O
in O
cyclin I-GENE
E I-GENE
_RARE_ I-GENE
. O

The O
recombinant I-GENE
purified O
protein I-GENE
expressed O
in O
the O
baculovirus O
system O
had O
an O
_RARE_ I-GENE
molecular O
size O
20 O
kDa I-GENE
with O
amino O
- I-GENE
terminal I-GENE
sequence I-GENE
of O
_RARE_ I-GENE
. O

Induction O
of O
the O
urokinase I-GENE
promoter I-GENE
by O
HGF I-GENE
/ I-GENE
SF I-GENE
via O
the O
Met I-GENE
receptor I-GENE
was O
blocked O
by O
co O
- I-GENE
expression O
of O
a O
dominant I-GENE
- I-GENE
negative O
Grb2 I-GENE
and O
_RARE_ I-GENE
expression O
construct I-GENE
. O

_RARE_ I-GENE
phosphorylation O
of O
STAT3 I-GENE
was O
only O
apparent O
after O
somatostatin I-GENE
treatment O
and O
was O
abolished O
by O
pertussis I-GENE
toxin I-GENE
or O
PD I-GENE
_RARE_ I-GENE
, O
together O
with O
the O
associated I-GENE
increases O
in O
proliferation O
. O

Nevertheless O
, O
we O
demonstrate O
that O
the O
entire O
three O
- I-GENE
component O
yeast I-GENE
capping I-GENE
apparatus O
, O
consisting O
of O
RNA I-GENE
5 I-GENE
'- O
_RARE_ I-GENE
( O
_RARE_ I-GENE
), O
RNA I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
), O
and O
_RARE_ I-GENE
could O
be O
replaced O
in O
vivo O
by O
the O
two O
- I-GENE
component O
mammalian I-GENE
apparatus O
consisting O
of O
a O
_RARE_ I-GENE
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
and O
the O
methyltransferase I-GENE
_RARE_ I-GENE
( O
121 I-GENE
- I-GENE
_RARE_ I-GENE
) O
p O
. O

The O
_RARE_ I-GENE
values O
for O
rat I-GENE
and O
dog O
urinary O
bladder O
were O
3 I-GENE
. O
9 O
x O
10 O
(- O
6 I-GENE
) O
M I-GENE
and O
3 I-GENE
. O
8 O
x O
10 O
(- O
6 I-GENE
) O
M I-GENE
, O
respectively O
. O

Although O
it O
has O
two O
potential O
binding I-GENE
sites I-GENE
, O
the O
purified O
_RARE_ I-GENE
homodimer I-GENE
binds O
only O
one O
Hg O
( O
II I-GENE
) O
ion O
, O
employing O
_RARE_ I-GENE
from O
one O
_RARE_ I-GENE
and O
_RARE_ I-GENE
and O
_RARE_ I-GENE
from O
the O
other O
. O

The O
influence O
of O
Epstein I-GENE
- I-GENE
Barr I-GENE
virus I-GENE
_RARE_ I-GENE
on O
the O
efficacy O
of O
intravenous O
immune I-GENE
globulin I-GENE
in O
children O
with O
immune I-GENE
_RARE_ I-GENE
purpura O
. O

The O
results O
of O
the O
_RARE_ I-GENE
and O
field O
tests O
yielded O
high O
levels O
of O
_RARE_ I-GENE
in O
larvae O
with O
values O
ranging O
from O
90 O
to O
100 O
% O
and O
from O
85 O
to O
95 O
%, O
respectively O
. O

_RARE_ I-GENE
400 O
mg O
had O
several O
adverse O
effects O
on O
_RARE_ I-GENE
and O
, O
although O
less O
severe O
, O
on O
cognitive O
performance O
on O
the O
_RARE_ I-GENE
day O
only O
. O

_RARE_ I-GENE
is O
an O
adenine O
- I-GENE
DNA I-GENE
glycosylase I-GENE
with O
specificity O
for O
_RARE_ I-GENE
involving O
8 O
- I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
. O
A I-GENE
) O
or O
guanine I-GENE
( O
G I-GENE
. O
A I-GENE
). O

The O
kinetics O
of O
kinase I-GENE
activity O
within O
these O
complexes I-GENE
compared O
to O
_RARE_ I-GENE
alone O
indicate O
approximately O
a O
50 O
% O
decrease O
in O
the O
_RARE_ I-GENE
for O
ATP I-GENE
and O
a O
100 O
- I-GENE
fold O
increase O
in O
the O
Vmax O
. O

_RARE_ I-GENE
, O
a O
_RARE_ I-GENE
A I-GENE
inhibitor I-GENE
, O
is O
expressed O
in O
a O
cell O
type I-GENE
- I-GENE
specific I-GENE
manner O
in O
both O
central O
and O
peripheral O
nervous O
systems O
in O
the O
rat I-GENE
. O

_RARE_ I-GENE
analyses O
identified O
7 O
risk O
and O
7 O
protective O
factors I-GENE
with O
minimal I-GENE
overlap O
. O

During O
1985 O
, O
1990 O
, O
and O
1995 O
, O
respectively O
, O
11 O
. O
7 O
, O
11 O
. O
3 I-GENE
, O
and O
11 O
. O
4 I-GENE
infants O
per O
100 O
, O
000 O
live O
births O
had O
a O
diagnosis O
of O
HSV I-GENE
( O
P I-GENE
=. O
98 O
). O

_RARE_ I-GENE
of O
patients O
were O
performed O
according O
to O
the O
severity O
of O
trauma O
( O
_RARE_ I-GENE
< O
9 O
; O
9 O
- I-GENE
17 O
; O
18 O
- I-GENE
31 O
; O
> O
32 O
), O
based O
on O
the O
different O
injury O
pattern O
, O
and O
_RARE_ I-GENE
versus O
_RARE_ I-GENE
as O
well O
. O

The O
median O
age O
was O
33 O
years O
( O
range O
17 O
- I-GENE
56 O
years O
). O

_RARE_ I-GENE
follow O
- I-GENE
up O
at O
age O
2 I-GENE
years O
was O
performed O
. O

In O
the O
whole O
group O
of O
infected O
children O
, O
an O
age O
- I-GENE
specific I-GENE
z O
score O
< O
- I-GENE
2 I-GENE
for O
weight O
and O
for O
_RARE_ I-GENE
was O
significantly O
associated I-GENE
with O
an O
increased O
risk O
of O
death O
[ O
relative O
risk O
( O
95 O
% O
CI O
) O
= O
11 O
. O
4 I-GENE
( O
3 I-GENE
. O
1 I-GENE
, O
41 O
. O
0 O
) O
and O
5 I-GENE
. O
1 I-GENE
( O
1 I-GENE
. O
5 I-GENE
, O
18 O
. O
2 I-GENE
), O
respectively O
_RARE_ I-GENE
when O
only O
children O
with O
more O
severe O
disease O
were O
considered O
, O
only O
z O
score O
for O
weight O
was O
significantly O
associated I-GENE
with O
an O
increased O
risk O
[ O
4 I-GENE
. O
6 I-GENE
( O
1 I-GENE
. O
4 I-GENE
, O
14 O
. O
9 O
)]. O

In O
addition O
, O
these O
cells O
contained O
one O
, O
two O
, O
or O
multiple O
nuclei O
indicative O
of O
a O
G2 I-GENE
/ I-GENE
M I-GENE
delay O
in O
nuclear I-GENE
division O
and O
also O
a O
defect O
in O
_RARE_ I-GENE
and O
/ I-GENE
or O
cell O
separation O
. O

_RARE_ I-GENE
is O
known O
to O
be O
a O
component O
of O
a O
signaling O
pathway O
that O
has O
been O
partially O
_RARE_ I-GENE
genetically O
and O
includes O
homologues O
of O
the O
insulin I-GENE
/ I-GENE
IGF I-GENE
- I-GENE
1 I-GENE
receptor I-GENE
, O
_RARE_ I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
and O
PKB I-GENE
. O

However O
, O
neu I-GENE
differentiation O
factor I-GENE
- I-GENE
induced O
heterodimers I-GENE
of O
_RARE_ I-GENE
and O
_RARE_ I-GENE
activated I-GENE
Stat5 I-GENE
. O

Although O
linker I-GENE
regions O
in O
transcription I-GENE
factors I-GENE
are O
known O
to O
modulate O
DNA I-GENE
binding I-GENE
specificity O
, O
our O
studies O
suggest O
that O
the O
human I-GENE
HSF1 I-GENE
linker I-GENE
plays O
no O
role O
in O
determining O
HSF1 I-GENE
binding I-GENE
_RARE_ I-GENE
in O
vivo O
but O
is O
a O
critical O
determinant O
in O
regulating O
the O
HSF1 I-GENE
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
equilibrium O
. O

_RARE_ I-GENE
of O
human I-GENE
heat I-GENE
shock I-GENE
factor I-GENE
_RARE_ I-GENE
by O
the O
linker I-GENE
domain I-GENE
. O

Both O
functional O
analyses O
in O
undifferentiated O
and O
differentiated O
F9 O
cells O
and O
characterization O
of O
DNA I-GENE
- I-GENE
protein I-GENE
complexes I-GENE
in O
vitro O
have O
identified O
the O
sequence I-GENE
motifs O
_RARE_ I-GENE
( O
C I-GENE
), O
_RARE_ I-GENE
, O
and O
GATA I-GENE
as O
the O
key O
transcription I-GENE
factor I-GENE
binding I-GENE
sites I-GENE
. O

These O
results O
suggest O
that O
the O
phenotype O
of O
_RARE_ I-GENE
may O
result O
from O
_RARE_ I-GENE
signaling O
not O
only O
through O
_RARE_ I-GENE
, O
but O
also O
other O
cell O
surface O
molecules I-GENE
that O
_RARE_ I-GENE
_RARE_ I-GENE
as O
a O
signaling O
adaptor I-GENE
protein I-GENE
. O

We O
also O
localized O
the O
_RARE_ I-GENE
- I-GENE
2 I-GENE
phosphorylation O
sites I-GENE
by O
MAPK I-GENE
to O
three O
threonine I-GENE
and O
three O
serine I-GENE
residues O
in O
the O
COOH O
- I-GENE
terminal I-GENE
region O
by O
means O
of O
site I-GENE
- I-GENE
directed O
mutagenesis O
and O
showed O
that O
the O
threonine I-GENE
residues O
were O
more O
susceptible O
to O
MAPK I-GENE
. O

Nevertheless O
, O
they O
are O
functionally O
distinct O
in O
that O
_RARE_ I-GENE
binds O
human I-GENE
IgA I-GENE
( O
_RARE_ I-GENE
) O
but O
not O
bovine I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
), O
whereas O
_RARE_ I-GENE
binds O
_RARE_ I-GENE
but O
not O
_RARE_ I-GENE
. O

_RARE_ I-GENE
was O
found O
to O
bind O
the O
_RARE_ I-GENE
homologue I-GENE
_RARE_ I-GENE
. O

In O
a O
heterologous O
transcriptional O
system O
in O
which O
the O
upstream O
regions O
of O
_RARE_ I-GENE
were O
inserted O
in O
front O
of O
simian I-GENE
virus I-GENE
40 I-GENE
( O
SV40 I-GENE
) O
promoter I-GENE
, O
the O
regions O
between O
bases O
- I-GENE
_RARE_ I-GENE
and O
- I-GENE
_RARE_ I-GENE
were O
determined O
as O
being O
the O
enhancer I-GENE
region O
required O
for O
_RARE_ I-GENE
- I-GENE
SV40 I-GENE
- I-GENE
CAT I-GENE
transactivation O
. O

In O
co O
- I-GENE
transfection O
studies O
, O
the O
expression O
of O
c I-GENE
- I-GENE
Jun I-GENE
plus O
c I-GENE
- I-GENE
Fos I-GENE
enhanced O
the O
transactivation O
of O
_RARE_ I-GENE
- I-GENE
CAT I-GENE
but O
the O
expression O
of O
GATA I-GENE
- I-GENE
1 I-GENE
, O
GATA I-GENE
- I-GENE
2 I-GENE
or O
GATA I-GENE
- I-GENE
3 I-GENE
did O
not O
. O

To O
identify O
these O
sites I-GENE
, O
Cdk2 I-GENE
- I-GENE
phosphorylated O
_RARE_ I-GENE
was O
_RARE_ I-GENE
with O
_RARE_ I-GENE
_RARE_ I-GENE
and O
analysed O
by O
_RARE_ I-GENE
MS O
. O

The O
yeast I-GENE
_RARE_ I-GENE
gene I-GENE
encoding O
_RARE_ I-GENE
dehydrogenase I-GENE
is O
subject O
to O
the O
general O
control O
of O
amino O
acid I-GENE
biosynthesis O
mediated O
by O
the O
GCN4 I-GENE
transcription I-GENE
factor I-GENE
. O

The O
relatively O
mild O
defects O
observed O
in O
_RARE_ I-GENE
mutants I-GENE
suggest O
that O
the O
recently O
identified O
_RARE_ I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
proteins I-GENE
do O
not O
function O
solely O
through O
the O
recruitment O
of O
histone I-GENE
_RARE_ I-GENE
. O

However O
, O
the O
serum I-GENE
TNF I-GENE
- I-GENE
a O
concentration O
decreased O
significantly O
in O
patients O
receiving O
_RARE_ I-GENE
( O
basal O
_RARE_ I-GENE
+/- O
_RARE_ I-GENE
pg O
/ I-GENE
ml O
; O
_RARE_ I-GENE
month O
_RARE_ I-GENE
+/- O
_RARE_ I-GENE
pg O
/ I-GENE
ml O
, O
p O
< O
0 O
. O
01 O
), O
but O
not O
in O
the O
control O
group O
. O

In O
addition O
, O
we O
show O
that O
the O
expression O
of O
individual O
members O
of O
one O
subfamily I-GENE
of O
KRAB I-GENE
zinc I-GENE
finger I-GENE
genes I-GENE
is O
restricted O
to O
specific I-GENE
hematopoietic I-GENE
cell O
lineages O
. O

_RARE_ I-GENE
fluorescence O
spectroscopy O
and O
circular O
_RARE_ I-GENE
, O
we O
showed O
that O
the O
binding I-GENE
of O
Ca2 I-GENE
+ I-GENE
to O
_RARE_ I-GENE
- I-GENE
2 I-GENE
induced O
significant O
conformational O
changes O
in O
both O
the O
N I-GENE
- I-GENE
terminal I-GENE
and O
C I-GENE
- I-GENE
terminal I-GENE
domains I-GENE
of O
the O
protein I-GENE
. O

They O
also O
occur O
in O
similar O
locations O
in O
the O
promoters I-GENE
of O
several O
other O
ribosomal I-GENE
protein I-GENE
genes I-GENE
. O

Both O
carbachol O
( O
100 O
microM O
) O
and O
EGF I-GENE
( O
10 O
nM O
) O
induced O
Ras I-GENE
activation O
. O

_RARE_ I-GENE
negative O
Sos I-GENE
did O
not O
affect O
carbachol O
stimulation O
of O
HA I-GENE
- I-GENE
ERK2 I-GENE
but O
inhibited O
the O
stimulatory I-GENE
effect O
of O
EGF I-GENE
by O
60 O
%. O

RESULTS O
: O
_RARE_ I-GENE
passage O
of O
contrast O
occurred O
in O
sufficient O
amounts O
to O
enhance O
the O
intensity O
of O
the O
Doppler O
signal I-GENE
significantly O
, O
but O
the O
duration O
of O
this O
effect O
was O
short O
. O

In O
this O
paper O
, O
such O
lesions O
in O
two O
cases O
were O
evaluated O
by O
ultrasonography O
. O

These O
regions O
contain O
inverted O
E I-GENE
- I-GENE
box I-GENE
palindromic O
or O
direct O
repeat I-GENE
motifs O
and O
bind O
SREBP I-GENE
- I-GENE
1 I-GENE
with O
different O
affinities O
. O

To O
address O
these O
questions O
, O
a O
recombinant I-GENE
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
protein I-GENE
and O
a O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
were O
utilized O
in O
in O
vitro O
kinase I-GENE
assays O
to O
phosphorylate O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
has O
a O
_RARE_ I-GENE
double O
zinc I-GENE
finger I-GENE
domain I-GENE
, O
which O
specifically O
binds O
phosphatidylinositol I-GENE
( O
3 I-GENE
)- I-GENE
phosphate I-GENE
and O
is O
conserved O
in O
several O
proteins I-GENE
involved O
in O
vesicular O
_RARE_ I-GENE
. O

The O
coexpression O
of O
full I-GENE
- I-GENE
length I-GENE
expression O
constructs I-GENE
for O
both O
DBP I-GENE
and O
hepatic I-GENE
leukemia I-GENE
factor I-GENE
resulted O
in O
a O
dramatic O
increase O
in O
activation O
mediated O
by O
the O
GAL4 I-GENE
- I-GENE
DBP I-GENE
fusion I-GENE
proteins I-GENE
, O
suggesting O
the O
involvement O
of O
a O
regulated O
coactivator I-GENE
in O
this O
process O
. O

Three O
_RARE_ I-GENE
also O
comprised O
15 O
to O
75 O
nucleotides O
derived O
from O
the O
5 I-GENE
' O
part O
of O
the O
_RARE_ I-GENE
gene I-GENE
. O

Cp I-GENE
is O
normally O
the O
main O
promoter I-GENE
for O
EBNA I-GENE
mRNA I-GENE
initiation I-GENE
, O
so O
it O
appears O
that O
_RARE_ I-GENE
contributes O
to O
a O
negative O
_RARE_ I-GENE
control O
loop I-GENE
. O

These O
_RARE_ I-GENE
of O
_RARE_ I-GENE
signalling O
in O
the O
absence O
of O
tyrosine I-GENE
118 O
were O
_RARE_ I-GENE
by O
sustained O
activation O
of O
STAT3 I-GENE
. O

With O
exon O
_RARE_ I-GENE
, O
we O
could O
isolate O
five O
potential O
exons O
from O
the O
YAC O
_RARE_ I-GENE
that O
spans O
the O
region O
, O
four O
of O
which O
could O
be O
placed O
in O
the O
contig O
in O
the O
vicinity O
of O
the O
breakpoints O
. O

_RARE_ I-GENE
dysplasia O
translocation O
breakpoints O
are O
_RARE_ I-GENE
over O
1 I-GENE
Mb O
proximal I-GENE
to O
_RARE_ I-GENE
: O
evidence O
for O
an O
extended O
control O
region O
. O

The O
most O
common O
characteristics O
of O
_RARE_ I-GENE
patients O
were O
recent O
prior O
vancomycin O
use O
, O
recent O
prior O
susceptible O
_RARE_ I-GENE
infection O
, O
_RARE_ I-GENE
with O
other O
microbial I-GENE
pathogens O
, O
and O
concurrent O
fungal I-GENE
infection O
. O

A I-GENE
coiled O
- I-GENE
coil O
domain I-GENE
, O
conserved O
within O
each O
encoded I-GENE
protein I-GENE
, O
serves O
as O
a O
potential O
interaction O
motif I-GENE
for O
FLI I-GENE
_RARE_ I-GENE
. O

Binding O
affinities O
of O
these O
recombinant I-GENE
_RARE_ I-GENE
as O
determined O
by O
the O
retention O
of O
these O
_RARE_ I-GENE
by O
a O
His O
- I-GENE
tag O
_RARE_ I-GENE
_RARE_ I-GENE
column O
, O
and O
by O
co O
- I-GENE
immunoprecipitation O
with O
purified O
terminase I-GENE
supported O
the O
specific I-GENE
nature O
of O
the O
portal I-GENE
protein I-GENE
and O
terminase I-GENE
interaction O
sites I-GENE
. O

Although O
the O
terminase I-GENE
apparently O
interacts O
with O
this O
_RARE_ I-GENE
portal I-GENE
peptide I-GENE
, O
_RARE_ I-GENE
antibody I-GENE
against O
the O
portal I-GENE
peptide I-GENE
appears O
unable O
to O
access O
it O
in O
the O
native O
structure O
, O
suggesting O
_RARE_ I-GENE
association O
of O
_RARE_ I-GENE
and O
_RARE_ I-GENE
possibly O
_RARE_ I-GENE
terminase I-GENE
regions O
within O
the O
portal I-GENE
in O
the O
_RARE_ I-GENE
complex I-GENE
. O

The O
hybrid O
viruses O
were O
found O
to O
accumulate O
to O
high O
levels O
in O
infected O
plants O
, O
to O
form O
stable O
virions O
, O
and O
to O
be O
_RARE_ I-GENE
_RARE_ I-GENE
. O

cDNA I-GENE
and O
structural O
organization O
of O
the O
gene I-GENE
_RARE_ I-GENE
for O
the O
mouse I-GENE
DNA I-GENE
polymerase I-GENE
epsilon I-GENE
catalytic O
subunit I-GENE
. O

Nevertheless O
_RARE_ I-GENE
of O
spermatozoa O
in O
a O
medium O
containing O
neither O
SP I-GENE
nor O
biological O
substances O
could O
offer O
an O
acceptable O
_RARE_ I-GENE
of O
spermatozoa O
to O
be O
used O
in O
_RARE_ I-GENE
fertilization O
procedures O
, O
especially O
for O
_RARE_ I-GENE
sperm O
injection O
. O

A I-GENE
liquid O
chromatographic O
method O
is O
described O
for O
analysis O
of O
beta I-GENE
- I-GENE
_RARE_ I-GENE
in O
medical O
food O
. O

The O
_RARE_ I-GENE
conditions O
were O
as O
follows O
: O
2 I-GENE
_RARE_ I-GENE
maximum O
electrical O
power O
consumption O
, O
800 O
V I-GENE
maximum O
_RARE_ I-GENE
voltage O
, O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
( O
180 O
_RARE_ I-GENE
rise O
time O
), O
and O
5 I-GENE
- I-GENE
30 O
Hz O
frequency O
. O

_RARE_ I-GENE
_RARE_ I-GENE
resulted O
in O
statistically O
significant O
changes O
in O
the O
mean O
values O
of O
the O
above O
_RARE_ I-GENE
in O
addition O
to O
the O
following O
increases O
: O
alanine I-GENE
aminotransferase I-GENE
, O
calcium O
, O
and O
serum I-GENE
_RARE_ I-GENE
( O
P I-GENE
< O
0 O
. O
001 O
) O
and O
albumin I-GENE
and O
total O
protein I-GENE
( O
P I-GENE
< O
0 O
. O
01 O
). O

EMSA O
with O
crude O
nuclear I-GENE
extracts O
demonstrated O
that O
stimulation O
with O
_RARE_ I-GENE
results O
in O
the O
induction O
of O
NF I-GENE
- I-GENE
kappaB I-GENE
complexes I-GENE
that O
bind O
to O
each O
of O
the O
three O
NF I-GENE
- I-GENE
kappaB I-GENE
sites I-GENE
and O
are O
composed O
mainly O
of O
p50 I-GENE
and O
_RARE_ I-GENE
, O
but O
also O
include O
c I-GENE
- I-GENE
Rel I-GENE
and O
p65 I-GENE
. O

_RARE_ I-GENE
monitoring O
of O
_RARE_ I-GENE
remains O
_RARE_ I-GENE
. O

The O
major I-GENE
transcription I-GENE
factors I-GENE
controlling O
arginine I-GENE
metabolism O
in O
Escherichia I-GENE
coli I-GENE
and O
Bacillus I-GENE
subtilis I-GENE
, O
_RARE_ I-GENE
and O
_RARE_ I-GENE
, O
respectively O
, O
are O
homologous O
_RARE_ I-GENE
proteins I-GENE
that O
form O
l O
- I-GENE
arginine I-GENE
- I-GENE
dependent I-GENE
DNA I-GENE
- I-GENE
binding I-GENE
complexes I-GENE
capable O
of O
repressing O
transcription I-GENE
of O
the O
biosynthetic O
genes I-GENE
( O
both O
), O
activating I-GENE
transcription I-GENE
of O
_RARE_ I-GENE
genes I-GENE
( O
_RARE_ I-GENE
only O
) O
or O
facilitating O
plasmid O
dimer O
resolution O
( O
both O
). O

The O
studied O
protein I-GENE
fragments I-GENE
consist O
of O
residues O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
of O
the O
human I-GENE
ER I-GENE
and O
residues O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
of O
the O
rat I-GENE
GR I-GENE
. O

The O
exon O
: O
intron O
structure O
of O
chicken I-GENE
_RARE_ I-GENE
corresponds O
almost O
_RARE_ I-GENE
to O
that O
of O
human I-GENE
_RARE_ I-GENE
and O
differs O
from O
those O
of O
other O
known O
mammalian I-GENE
_RARE_ I-GENE
chemokine I-GENE
genes I-GENE
. O

The O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
gene I-GENE
, O
specifically O
expressed O
during O
_RARE_ I-GENE
differentiation O
of O
the O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
, O
was O
cloned O
. O

The O
main O
causes O
of O
liver O
disease O
in O
the O
patients O
with O
_RARE_ I-GENE
were O
hepatitis I-GENE
C I-GENE
virus I-GENE
( O
HCV I-GENE
) O
( O
77 O
%), O
alcohol O
_RARE_ I-GENE
( O
73 O
%), O
and O
the O
combination O
of O
HCV I-GENE
and O
alcohol O
_RARE_ I-GENE
( O
50 O
%). O

Three O
new O
aromatase I-GENE
inhibitors O
have O
recently O
completed O
phase O
III I-GENE
evaluation O
as O
treatment O
of O
metastatic O
breast O
cancer O
in O
post O
- I-GENE
menopausal I-GENE
women O
whose O
disease O
has O
progressed O
despite O
_RARE_ I-GENE
therapy O
: O
_RARE_ I-GENE
( O
_RARE_ I-GENE
, O
_RARE_ I-GENE
), O
_RARE_ I-GENE
( O
_RARE_ I-GENE
, O
_RARE_ I-GENE
) O
and O
_RARE_ I-GENE
( O
_RARE_ I-GENE
, O
_RARE_ I-GENE
). O

CONCLUSIONS O
: O
_RARE_ I-GENE
is O
a O
valuable O
tool O
in O
asthmatic O
patients O
' O
training O
, O
allowing O
identification O
and O
improvement O
of O
an O
_RARE_ I-GENE
inhalation O
technique O
with O
_RARE_ I-GENE
. O

Of O
those O
injuries O
, O
143 I-GENE
cases O
were O
_RARE_ I-GENE
related I-GENE
and O
_RARE_ I-GENE
cases O
were O
_RARE_ I-GENE
related I-GENE
. O

The O
femoral O
artery O
/ I-GENE
vein O
and O
the O
_RARE_ I-GENE
and O
_RARE_ I-GENE
muscles O
were O
examined O
in O
healthy O
human I-GENE
male O
volunteers O
. O

_RARE_ I-GENE
acts O
as O
a O
naturally O
occurring O
dominant I-GENE
negative O
regulatory I-GENE
mutant I-GENE
that O
blocks O
SRF I-GENE
- I-GENE
dependent I-GENE
skeletal I-GENE
alpha I-GENE
- I-GENE
actin I-GENE
, O
cardiac O
alpha I-GENE
- I-GENE
actin I-GENE
, O
smooth I-GENE
alpha I-GENE
- I-GENE
actin I-GENE
, O
_RARE_ I-GENE
, O
and O
SRF I-GENE
promoter I-GENE
- I-GENE
luciferase I-GENE
reporter I-GENE
activities O
. O

In O
serum I-GENE
- I-GENE
free O
media O
, O
_RARE_ I-GENE
accelerated O
E1A I-GENE
- I-GENE
induced O
apoptosis O
. O

The O
potency O
of O
the O
effect O
of O
_RARE_ I-GENE
( O
0 O
. O
5 I-GENE
mg O
. O
kg O
- I-GENE
1 I-GENE
i O
. O
p O
.) O
was O
similar O
to O
that O
of O
_RARE_ I-GENE
( O
10 O
mg O
. O
kg O
- I-GENE
1 I-GENE
i O
. O
p O
.). O

CONCLUSION O
: O
_RARE_ I-GENE
pre I-GENE
- I-GENE
treatment O
or O
post O
- I-GENE
treatment O
markedly O
enhanced O
the O
rCBF O
to O
striatum I-GENE
in O
_RARE_ I-GENE
rats O
. O

_RARE_ I-GENE
after O
first O
- I-GENE
line O
chemotherapy O
was O
associated I-GENE
with O
significantly O
_RARE_ I-GENE
survival O
for O
patients O
with O
metastasis O
. O

Mutations O
within O
human I-GENE
_RARE_ I-GENE
modulate O
_RARE_ I-GENE
- I-GENE
1 I-GENE
expression O
by O
interfering O
with O
mRNA I-GENE
translational O
efficiency O
in O
transfected O
cells O
and O
in O
an O
in O
vitro O
translation I-GENE
system O
. O

As O
is O
deduced O
from O
the O
nucleotide I-GENE
sequence I-GENE
of O
the O
cDNA I-GENE
, O
_RARE_ I-GENE
- I-GENE
1 I-GENE
contains O
an O
open O
reading O
frame O
consisting O
of O
182 O
amino O
acids O
, O
with O
a O
molecular O
weight O
of O
19 O
. O
_RARE_ I-GENE
. O

_RARE_ I-GENE
and O
_RARE_ I-GENE
input O
_RARE_ I-GENE
from O
the O
_RARE_ I-GENE
motor O
area O
in O
the O
_RARE_ I-GENE
monkey I-GENE
: O
comparison O
with O
the O
input O
_RARE_ I-GENE
from O
the O
supplementary O
motor O
area O
. O

_RARE_ I-GENE
fibroblast I-GENE
growth I-GENE
factor I-GENE
( O
_RARE_ I-GENE
) O
has O
been O
shown O
to O
induce O
angiogenesis O
in O
various O
animal O
models O
, O
but O
the O
methods O
of O
administration O
used O
experimentally O
are O
not O
clinically O
_RARE_ I-GENE
. O

Both O
_RARE_ I-GENE
equally O
contributed O
to O
elevation O
of O
iliac O
venous O
pressure O
( O
median O
, O
9 O
. O
3 I-GENE
and O
7 O
. O
2 I-GENE
mm O
Hg O
[ O
n O
= O
9 O
] O
with O
the O
_RARE_ I-GENE
filter O
and O
_RARE_ I-GENE
filter O
, O
respectively O
). O

12 O
healthy O
women O
( O
age O
18 O
- I-GENE
38 O
years O
) O
were O
examined O
using O
the O
2 I-GENE
- I-GENE
hour O
' O
s O
method O
of O
passive O
leg O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
in O
follicular O
( O
_RARE_ I-GENE
) O
and O
luteal O
( O
_RARE_ I-GENE
) O
phases O
of O
normal O
_RARE_ I-GENE
cycle O
. O

Thus O
, O
_RARE_ I-GENE
has O
the O
3 I-GENE
' O
_RARE_ I-GENE
in O
its O
5 I-GENE
' O
UTR I-GENE
. O

These O
single O
mutational O
defects O
in O
the O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
interaction O
became O
evident O
when O
either O
truncated I-GENE
protein I-GENE
_RARE_ I-GENE
or O
C I-GENE
- I-GENE
terminally I-GENE
altered O
_RARE_ I-GENE
proteins I-GENE
were O
used O
for O
the O
_RARE_ I-GENE
protein I-GENE
, O
providing O
further O
support O
for O
the O
presence O
of O
a O
C I-GENE
- I-GENE
terminal I-GENE
interaction O
. O

Removal O
of O
each O
of O
three O
contiguous O
segments O
from O
the O
N I-GENE
- I-GENE
terminal I-GENE
half O
specifically O
inhibits O
the O
formation O
of O
5 I-GENE
. O
_RARE_ I-GENE
rRNA I-GENE
, O
whereas O
_RARE_ I-GENE
part O
of O
the O
C I-GENE
- I-GENE
terminal I-GENE
region O
of O
the O
protein I-GENE
only O
blocks O
the O
production O
of O
_RARE_ I-GENE
rRNA I-GENE
. O

Ras I-GENE
is O
not O
associated I-GENE
with O
the O
_RARE_ I-GENE
. O

_RARE_ I-GENE
fluorescent O
protein I-GENE
- I-GENE
tagged O
UNC I-GENE
- I-GENE
_RARE_ I-GENE
and O
UNC I-GENE
- I-GENE
_RARE_ I-GENE
subunits I-GENE
are O
coexpressed O
in O
muscle O
cells O
and O
are O
_RARE_ I-GENE
to O
synaptic O
regions O
. O

We O
show O
that O
a O
protein I-GENE
, O
_RARE_ I-GENE
, O
interacts O
specifically O
with O
_RARE_ I-GENE
in O
vitro O
and O
in O
vivo O
. O

The O
aim O
of O
this O
study O
was O
to O
investigate O
the O
spontaneous O
reports O
of O
suspected O
adverse O
drug O
reactions O
, O
observed O
in O
elderly O
patients O
( O
over O
65 O
years O
of O
age O
) O
in O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
during O
the O
period O
from O
1 I-GENE
January O
1995 O
to O
31 O
_RARE_ I-GENE
1997 O
. O

_RARE_ I-GENE
of O
_RARE_ I-GENE
are O
capable O
of O
_RARE_ I-GENE
stimulated O
radiation O
( O
_RARE_ I-GENE
). O

The O
major I-GENE
findings O
of O
our O
studies O
are O
as O
follows O
: O
1 I-GENE
) O
There O
are O
no O
detectable O
signals O
around O
_RARE_ I-GENE
- I-GENE
9 O
- I-GENE
deficient O
_RARE_ I-GENE
for O
several O
_RARE_ I-GENE
cell O
layer O
markers O
[ O
i O
. O
e O
. O

Interestingly O
, O
highly O
charged O
residues O
were O
abundantly O
possessed O
in O
the O
carboxy I-GENE
- I-GENE
terminal I-GENE
part O
of O
the O
_RARE_ I-GENE
_RARE_ I-GENE
protein I-GENE
. O

Identification O
and O
structure O
of O
the O
_RARE_ I-GENE
' O
s O
disease O
virus I-GENE
serotype I-GENE
2 I-GENE
glycoprotein I-GENE
M I-GENE
gene I-GENE
: O
comparison O
with O
glycoprotein I-GENE
M I-GENE
genes I-GENE
of O
_RARE_ I-GENE
family I-GENE
. O

OBJECTIVE O
: O
To O
perform O
a O
cost O
- I-GENE
effectiveness O
analysis O
( O
CEA I-GENE
) O
between O
a O
standard O
_RARE_ I-GENE
regimen O
- I-GENE
_RARE_ I-GENE
+ I-GENE
dexamethasone O
( O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
)- I-GENE
and O
a O
5 I-GENE
- I-GENE
HT3 I-GENE
receptor I-GENE
antagonist O
- I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
_RARE_ I-GENE
in O
the O
control O
of O
acute O
_RARE_ I-GENE
induced O
by O
highly O
_RARE_ I-GENE
chemotherapy O
in O
children O
, O
_RARE_ I-GENE
two O
_RARE_ I-GENE
_RARE_ I-GENE
: O
hospital O
and O
patients O
. O

_RARE_ I-GENE
data O
were O
obtained O
from O
10 O
adults O
. O

A I-GENE
comparison O
of O
the O
nucleotide I-GENE
and O
deduced O
amino O
acid I-GENE
sequences I-GENE
of O
the O
core I-GENE
regions O
of O
the O
RNA I-GENE
- I-GENE
dependent I-GENE
RNA I-GENE
polymerase I-GENE
domains I-GENE
found O
in O
these O
three O
_RARE_ I-GENE
suggested O
that O
these O
_RARE_ I-GENE
probably O
evolved O
independently O
within O
each O
host O
plant O
from O
a O
common O
ancestor O
. O

Consistent O
with O
this O
possibility O
, O
a O
non O
- I-GENE
_RARE_ I-GENE
region O
of O
_RARE_ I-GENE
was O
sufficient O
to O
recruit O
a O
repression O
function O
to O
DNA I-GENE
that O
was O
unrelated O
to O
histone I-GENE
_RARE_ I-GENE
. O

Forty O
- I-GENE
eight O
sequences I-GENE
, O
30 O
not O
previously O
identified O
as O
IR I-GENE
- I-GENE
responsive I-GENE
, O
were O
significantly O
regulated O
by O
IR I-GENE
. O

A I-GENE
recently O
described O
protein I-GENE
, O
_RARE_ I-GENE
1 I-GENE
, O
serves O
as O
a O
component O
of O
a O
_RARE_ I-GENE
import O
complex I-GENE
in O
the O
outer I-GENE
membrane I-GENE
of O
the O
mammalian I-GENE
_RARE_ I-GENE
. O

Molecular O
cloning O
of O
rat I-GENE
SH2 I-GENE
- I-GENE
containing O
inositol I-GENE
phosphatase I-GENE
2 I-GENE
( O
_RARE_ I-GENE
) O
and O
its O
role O
in O
the O
regulation O
of O
insulin I-GENE
signaling O
. O

_RARE_ I-GENE
represses O
transcription I-GENE
via O
this O
binding I-GENE
site I-GENE
in O
yeast I-GENE
cells O
, O
consistent O
with O
its O
role O
as O
a O
direct O
repressor I-GENE
of O
_RARE_ I-GENE
_RARE_ I-GENE
in O
_RARE_ I-GENE
regions O
during O
late O
stages O
of O
embryogenesis O
. O

The O
results O
of O
these O
studies O
support O
a O
model O
in O
which O
_RARE_ I-GENE
dimers I-GENE
or O
_RARE_ I-GENE
contribute O
structural O
information O
for O
the O
assembly O
of O
a O
_RARE_ I-GENE
channel O
competent O
for O
_RARE_ I-GENE
DNA I-GENE
transfer I-GENE
, O
whereas O
an O
ATP I-GENE
- I-GENE
dependent I-GENE
activity O
is O
required O
for O
_RARE_ I-GENE
this O
channel O
as O
a O
_RARE_ I-GENE
export O
machine O
. O

The O
penicillin I-GENE
binding I-GENE
proteins I-GENE
( O
_RARE_ I-GENE
) O
_RARE_ I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
, O
the O
structural O
component O
of O
the O
bacterial I-GENE
cell O
wall O
. O

TCR I-GENE
alpha I-GENE
( O
_RARE_ I-GENE
) O
expression O
was O
examined O
in O
RNA I-GENE
samples O
from O
_RARE_ I-GENE
and O
isolated O
populations O
of O
CD4 I-GENE
+, I-GENE
CD8 I-GENE
+, I-GENE
and O
_RARE_ I-GENE
T I-GENE
cells O
from O
15 O
healthy O
individuals O
. O

Similar O
results O
were O
obtained O
with O
_RARE_ I-GENE
, O
an O
activator I-GENE
of O
the O
_RARE_ I-GENE
phosphate I-GENE
pathway O
. O

The O
high O
density I-GENE
lipoprotein I-GENE
( O
HDL I-GENE
) O
receptor I-GENE
mediates O
the O
uptake O
of O
cholesterol I-GENE
and O
_RARE_ I-GENE
esters O
, O
substrates O
for O
_RARE_ I-GENE
, O
from O
an O
HDL I-GENE
particle I-GENE
in O
the O
adrenal O
gland O
and O
_RARE_ I-GENE
. O

_RARE_ I-GENE
is O
physically O
located O
at O
or O
near O
the O
_RARE_ I-GENE
locus I-GENE
, O
while O
_RARE_ I-GENE
and O
_RARE_ I-GENE
are O
flanking O
the O
locus I-GENE
at O
about O
17 O
. O
5 I-GENE
_RARE_ I-GENE
genetic O
distance O
each O
side O
. O

The O
_RARE_ I-GENE
of O
recovery O
decreased O
with O
storage O
time O
, O
although O
the O
addition O
of O
_RARE_ I-GENE
( O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
80 O
) O
before O
storage O
appeared O
to O
partially O
prevent O
adhesion I-GENE
. O

_RARE_ I-GENE
mutations O
of O
the O
site I-GENE
that O
suppressed O
Pit I-GENE
- I-GENE
1 I-GENE
binding I-GENE
in O
vitro O
restored O
full I-GENE
_RARE_ I-GENE
promoter I-GENE
activity O
. O

A I-GENE
human I-GENE
Raf I-GENE
- I-GENE
responsive I-GENE
zinc I-GENE
- I-GENE
finger I-GENE
protein I-GENE
that O
binds O
to O
divergent O
sequences I-GENE
. O

We O
are O
_RARE_ I-GENE
an O
autopsy O
case O
of O
so O
- I-GENE
called O
" O
acute O
multiple O
sclerosis O
" O
that O
was O
difficult O
to O
differentiate O
from O
a O
brain O
tumor I-GENE
on O
MRI O
findings O
. O

Furthermore O
, O
_RARE_ I-GENE
- I-GENE
4 I-GENE
and O
_RARE_ I-GENE
bind O
related I-GENE
proteins I-GENE
that O
promote O
their O
kinase I-GENE
activities O
. O

BACKGROUND O
: O
The O
_RARE_ I-GENE
- I-GENE
III I-GENE
is O
the O
surgical O
treatment O
of O
choice O
for O
_RARE_ I-GENE
refractory O
atrial I-GENE
fibrillation O
. O

_RARE_ I-GENE
, O
a O
new O
pleckstrin I-GENE
homology I-GENE
domain I-GENE
- I-GENE
containing O
adapter I-GENE
protein I-GENE
, O
acts O
to O
_RARE_ I-GENE
signaling O
from O
ERK I-GENE
kinase I-GENE
to O
Elk I-GENE
- I-GENE
1 I-GENE
. O

The O
presence O
of O
cutaneous O
_RARE_ I-GENE
with O
normal O
serum I-GENE
lipid O
levels O
is O
due O
to O
the O
_RARE_ I-GENE
activity O
of O
the O
monoclonal I-GENE
immunoglobulin I-GENE
. O

In O
an O
attempt O
to O
reduce O
the O
incidence O
of O
NSAID O
- I-GENE
induced O
gastrointestinal O
lesions O
, O
the O
following O
approaches O
have O
been O
proposed O
: O
( O
i O
) O
use O
of O
the O
prostaglandin I-GENE
analogue O
_RARE_ I-GENE
, O
which O
is O
an O
_RARE_ I-GENE
drug O
which O
has O
been O
proven O
to O
be O
as O
effective O
in O
the O
prevention O
of O
NSAID O
- I-GENE
induced O
gastric O
and O
duodenal O
ulcers O
as O
in O
the O
reduction O
of O
serious O
upper O
gastrointestinal O
complications O
; O
( O
ii O
) O
histamine O
H2 I-GENE
receptor I-GENE
antagonists O
( O
H2 I-GENE
antagonists O
), O
e O
. O
g O
. O
ranitidine O
, O
cimetidine O
and O
_RARE_ I-GENE
, O
which O
are O
useful O
in O
the O
prevention O
of O
NSAID O
- I-GENE
induced O
duodenal O
ulcers O
during O
long O
term O
treatment O
, O
but O
not O
in O
the O
prevention O
of O
NSAID O
- I-GENE
induced O
gastric O
ulcers O
; O
( O
iii O
) O
proton I-GENE
pump I-GENE
inhibitors O
, O
e O
. O
g O
omeprazole O
, O
and O
_RARE_ I-GENE
, O
whose O
efficacy O
in O
preventing O
NSAID O
- I-GENE
associated I-GENE
ulcers O
has O
been O
recently O
demonstrated O
; O
and O
( O
iv O
) O
barrier O
agents O
, O
e O
. O
g O
. O
_RARE_ I-GENE
, O
which O
cannot O
be O
recommended O
as O
prophylactic O
agents O
to O
prevent O
NSAID O
- I-GENE
induced O
_RARE_ I-GENE
. O

Lung O
_RARE_ I-GENE
serves O
as O
a O
' O
_RARE_ I-GENE
' O
_RARE_ I-GENE
of O
lung O
_RARE_ I-GENE
by O
secreting O
soluble I-GENE
peptide I-GENE
growth I-GENE
factors I-GENE
. O

The O
activation O
of O
the O
HIV I-GENE
promoter I-GENE
required O
the O
nuclear I-GENE
localization O
of O
c I-GENE
- I-GENE
Abl I-GENE
and O
could O
be O
correlated O
with O
increased O
tyrosine I-GENE
phosphorylation O
of O
RNA I-GENE
polymerase I-GENE
II I-GENE
. O

The O
bovine I-GENE
papillomavirus I-GENE
E2 I-GENE
protein I-GENE
can O
inhibit O
the O
proliferation O
of O
HT O
- I-GENE
3 I-GENE
cells O
, O
a O
p53 I-GENE
- I-GENE
negative O
cervical O
carcinoma O
cell O
line O
containing O
integrated O
human I-GENE
papillomavirus I-GENE
type I-GENE
30 O
DNA I-GENE
. O

E2 I-GENE
point O
mutants I-GENE
unable O
to O
inhibit O
cell O
growth I-GENE
did O
not O
repress O
_RARE_ I-GENE
and O
_RARE_ I-GENE
expression O
, O
nor O
did O
the O
cell O
cycle O
inhibitors O
_RARE_ I-GENE
and O
_RARE_ I-GENE
. O

BACKGROUND O
/ I-GENE
PURPOSE O
: O
_RARE_ I-GENE
arrangement O
of O
the O
_RARE_ I-GENE
duct O
( O
_RARE_ I-GENE
) O
is O
closely O
related I-GENE
to O
congenital O
biliary O
dilatation O
and O
frequently O
associated I-GENE
with O
biliary O
tract O
malignancy O
. O

Neurospora I-GENE
crassa I-GENE
_RARE_ I-GENE
- I-GENE
18 O
, O
can O
rescue O
the O
_RARE_ I-GENE
_RARE_ I-GENE
and O
intron O
mutants I-GENE
which O
cause O
a O
structural O
defect O
. O

_RARE_ I-GENE
also O
localizes O
to O
_RARE_ I-GENE
in O
_RARE_ I-GENE
nuclei O
of O
larval I-GENE
neuroblasts O
. O

In O
a O
reconstituted O
human I-GENE
DNA I-GENE
repair I-GENE
system O
containing O
DNA I-GENE
polymerase I-GENE
beta I-GENE
and O
DNA I-GENE
ligase I-GENE
III I-GENE
- I-GENE
_RARE_ I-GENE
, O
accurate O
_RARE_ I-GENE
of O
a O
3 I-GENE
' O
_RARE_ I-GENE
base O
residue O
at O
a O
single O
- I-GENE
strand O
_RARE_ I-GENE
is O
dependent I-GENE
on O
addition O
of O
the O
exonuclease I-GENE
. O

The O
_RARE_ I-GENE
clone O
with O
an O
insert O
size O
of O
_RARE_ I-GENE
was O
isolated O
and O
mapped O
by O
restriction I-GENE
analysis O
. O

Sequence O
of O
_RARE_ I-GENE
locus I-GENE
surrounding O
the O
_RARE_ I-GENE
oncogene I-GENE
reveals O
a O
new O
gene I-GENE
_RARE_ I-GENE
expressed O
in O
a O
T I-GENE
- I-GENE
ALL O
cell O
line O
. O

_RARE_ I-GENE
20 O
kb O
upstream O
of O
_RARE_ I-GENE
we O
found O
a O
gene I-GENE
encoding O
a O
transcribed O
, O
non O
- I-GENE
processed O
_RARE_ I-GENE
- I-GENE
like I-GENE
pseudogene I-GENE
( O
_RARE_ I-GENE
). O

Site I-GENE
- I-GENE
directed O
mutagenesis O
of O
the O
R2 I-GENE
protein I-GENE
was O
used O
to O
provide O
evidence O
that O
this O
motif I-GENE
is O
also O
part O
of O
the O
active O
site I-GENE
of O
the O
endonuclease I-GENE
encoded I-GENE
by O
this O
element I-GENE
. O

The O
infected O
cell O
protein I-GENE
no O
. O
0 O
( O
_RARE_ I-GENE
) O
of O
herpes I-GENE
simplex I-GENE
virus I-GENE
1 I-GENE
is O
a O
_RARE_ I-GENE
transactivator I-GENE
shown O
to O
enhance O
the O
expression O
of O
genes I-GENE
_RARE_ I-GENE
into O
cells O
by O
infection O
or O
transfection O
. O

_RARE_ I-GENE
measurement O
of O
blood O
pressure O
: O
some O
critical O
_RARE_ I-GENE
to O
_RARE_ I-GENE
. O

G I-GENE
- I-GENE
box I-GENE
- I-GENE
directed O
expression O
in O
leaves O
required O
the O
presence O
of O
an O
enhancer I-GENE
region O
from O
the O
_RARE_ I-GENE
mosaic O
virus I-GENE
( O
_RARE_ I-GENE
) O
35S I-GENE
promoter I-GENE
. O

Another O
element I-GENE
necessary O
for O
_RARE_ I-GENE
the O
amplitude O
of O
the O
_RARE_ I-GENE
lies O
between O
- I-GENE
_RARE_ I-GENE
and O
- I-GENE
264 O
. O

This O
_RARE_ I-GENE
was O
therefore O
used O
as O
control O
in O
experiments O
where O
another O
anti I-GENE
- I-GENE
Ras I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
_RARE_ I-GENE
, O
derived O
from O
the O
_RARE_ I-GENE
anti I-GENE
- I-GENE
Ras I-GENE
mAb I-GENE
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
) O
blocked O
the O
Ras I-GENE
pathway O
in O
vitro O
and O
led O
to O
tumor I-GENE
regression O
in O
a O
nude O
mouse I-GENE
model O
[ O
_RARE_ I-GENE
, O
O O
., O
_RARE_ I-GENE
, O
M I-GENE
., O
_RARE_ I-GENE
, O
I I-GENE
., O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
, O
A I-GENE
., O
_RARE_ I-GENE
, O
M I-GENE
. O
C I-GENE
., O
_RARE_ I-GENE
, O
W I-GENE
. O
H I-GENE
., O
_RARE_ I-GENE
, O
F I-GENE
., O
_RARE_ I-GENE
, O
J O
. O
L I-GENE
., O
_RARE_ I-GENE
, O
B I-GENE
., O
1998 O
. O

There O
was O
no O
competition O
between O
activin I-GENE
A I-GENE
and O
_RARE_ I-GENE
- I-GENE
1 I-GENE
for O
availability O
of O
_RARE_ I-GENE
, O
indicating O
that O
the O
concentration O
of O
this O
common O
signal I-GENE
_RARE_ I-GENE
is O
not O
limiting O
for O
generating O
the O
observed O
biological O
responses O
. O

Our O
data O
therefore O
indicate O
that O
it O
is O
possible O
to O
_RARE_ I-GENE
the O
HA I-GENE
envelope I-GENE
glycoprotein I-GENE
by O
_RARE_ I-GENE
ligands O
to O
its O
amino O
- I-GENE
terminal I-GENE
end O
without O
affecting O
its O
fusion I-GENE
activity O
. O

However O
, O
the O
_RARE_ I-GENE
, O
parallel O
beta I-GENE
helix I-GENE
model O
is O
a O
_RARE_ I-GENE
coil O
of O
ten O
_RARE_ I-GENE
arranged O
beta I-GENE
_RARE_ I-GENE
forming O
two O
parallel O
beta I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
. O

This O
is O
predicted O
to O
encode O
a O
_RARE_ I-GENE
- I-GENE
residue O
protein I-GENE
containing O
seven O
hydrophobic O
helical O
regions O
and O
a O
17 O
amino O
acid I-GENE
motif I-GENE
characteristic O
of O
the O
_RARE_ I-GENE
family I-GENE
of O
G I-GENE
- I-GENE
protein I-GENE
coupled I-GENE
membrane I-GENE
- I-GENE
bound O
receptors I-GENE
. O

_RARE_ I-GENE
of O
the O
chicken I-GENE
apolipoprotein I-GENE
A I-GENE
- I-GENE
I I-GENE
gene I-GENE
5 I-GENE
'- O
flanking O
region O
. O

These O
results O
suggest O
that O
members O
of O
the O
ATF I-GENE
family I-GENE
are O
involved O
in O
mediating O
the O
transcriptional O
regulation O
of O
the O
_RARE_ I-GENE
gene I-GENE
in O
response O
to O
extracellular I-GENE
stimuli O
via O
a O
novel O
CRE O
regulatory I-GENE
element I-GENE
. O

Moreover O
, O
a O
high O
proportion O
of O
blood O
samples O
from O
a O
random O
sample O
of O
the O
rest O
of O
the O
_RARE_ I-GENE
tested O
positive O
for O
_RARE_ I-GENE
- I-GENE
specific I-GENE
DNA I-GENE
by O
PCR O
( O
79 O
. O
9 O
% O
for O
T I-GENE
. O
b I-GENE
. O
_RARE_ I-GENE
and O
13 O
. O
9 O
% O
for O
T I-GENE
. O
b I-GENE
. O
_RARE_ I-GENE
). O

A I-GENE
multi I-GENE
- I-GENE
_RARE_ I-GENE
evaluation O
of O
the O
_RARE_ I-GENE
indirect O
agglutination I-GENE
test O
for O
_RARE_ I-GENE
( O
_RARE_ I-GENE
_RARE_ I-GENE
). O

Results O
for O
men O
who O
_RARE_ I-GENE
up O
to O
two O
_RARE_ I-GENE
per O
day O
suggest O
that O
if O
the O
dependence O
criteria O
were O
_RARE_ I-GENE
, O
reductions O
in O
the O
prevalence O
of O
specific I-GENE
indicators O
of O
alcohol O
dependence O
would O
range O
from O
0 O
. O
3 I-GENE
% O
to O
5 I-GENE
. O
2 I-GENE
%. O

_RARE_ I-GENE
of O
the O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
elements O
and O
Sp1 I-GENE
sites I-GENE
in O
this O
region O
, O
alone O
or O
in O
combination O
, O
reduced O
transcriptional O
activity O
by O
40 I-GENE
- I-GENE
60 O
% O
in O
_RARE_ I-GENE
growing O
cells O
and O
abolished O
cell O
cycle O
_RARE_ I-GENE
in O
G2 I-GENE
- I-GENE
M I-GENE
- I-GENE
_RARE_ I-GENE
cells O
. O

Using O
_RARE_ I-GENE
' O
s O
procedure O
as O
an O
_RARE_ I-GENE
, O
comparisons O
are O
made O
to O
_RARE_ I-GENE
sample O
size O
methods O
that O
_RARE_ I-GENE
_RARE_ I-GENE
the O
_RARE_ I-GENE
nature O
of O
_RARE_ I-GENE
. O

The O
crystal O
structure O
of O
the O
VP16 I-GENE
core I-GENE
has O
been O
determined O
at O
2 I-GENE
. O
1 I-GENE
A I-GENE
resolution O
. O

_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
and O
_RARE_ I-GENE
were O
more O
effective O
than O
_RARE_ I-GENE
in O
increasing O
rCBF O
at O
the O
_RARE_ I-GENE
. O

The O
latter O
method O
_RARE_ I-GENE
_RARE_ I-GENE
of O
the O
inferior O
_RARE_ I-GENE
_RARE_ I-GENE
, O
which O
results O
in O
hypotension O
, O
requiring O
invasive O
_RARE_ I-GENE
management O
. O

By O
contrast O
, O
_RARE_ I-GENE
or O
_RARE_ I-GENE
promoter I-GENE
constructs I-GENE
yielded O
functional O
_RARE_ I-GENE
only O
if O
_RARE_ I-GENE
was O
coexpressed O
with O
_RARE_ I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
virus I-GENE
5 I-GENE
( O
_RARE_ I-GENE
) O
is O
a O
prototype O
of O
the O
_RARE_ I-GENE
family I-GENE
of O
_RARE_ I-GENE
negative O
- I-GENE
sense O
RNA I-GENE
viruses O
. O

To O
investigate O
the O
functions O
of O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
and O
GS I-GENE
sequences I-GENE
in O
transcription I-GENE
, O
we O
constructed O
plasmids O
containing O
cDNAs I-GENE
of O
the O
full I-GENE
- I-GENE
length I-GENE
_RARE_ I-GENE
genome O
in O
which O
the O
gene I-GENE
junction O
sequences I-GENE
( O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
and O
GS I-GENE
sequences I-GENE
) O
located O
between O
the O
hemagglutinin I-GENE
- I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
and O
the O
polymerase I-GENE
( O
L I-GENE
) O
genes I-GENE
were O
replaced O
with O
the O
counterpart O
sequences I-GENE
from O
other O
gene I-GENE
junctions O
. O

_RARE_ I-GENE
is O
a O
chemokine I-GENE
receptor I-GENE
and O
a O
_RARE_ I-GENE
for O
T I-GENE
- I-GENE
cell O
- I-GENE
line O
- I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
and O
dual O
- I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
human I-GENE
immunodeficiency I-GENE
virus I-GENE
type I-GENE
1 I-GENE
( O
HIV I-GENE
- I-GENE
1 I-GENE
) O
isolates O
. O

These O
data O
will O
help O
us O
to O
better O
detail O
the O
_RARE_ I-GENE
structural O
requirements O
exhibited O
by O
different O
HIV I-GENE
- I-GENE
1 I-GENE
strains O
and O
will O
direct O
further O
mutagenesis O
_RARE_ I-GENE
aimed O
at O
better O
_RARE_ I-GENE
the O
domains I-GENE
in O
_RARE_ I-GENE
involved O
in O
the O
HIV I-GENE
- I-GENE
1 I-GENE
Env I-GENE
- I-GENE
mediated O
fusion I-GENE
process O
. O

The O
results O
of O
these O
analyses O
indicate O
that O
the O
proteinase I-GENE
_RARE_ I-GENE
at O
amino O
acid I-GENE
residues O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
; O
however O
, O
the O
cleavage O
efficiency O
is O
varied O
. O

_RARE_ I-GENE
. O

_RARE_ I-GENE
is O
also O
shown O
to O
be O
associated I-GENE
in O
vivo O
with O
other O
components O
of O
the O
_RARE_ I-GENE
1 I-GENE
export O
pathway O
, O
including O
the O
small I-GENE
GTPase I-GENE
Ran I-GENE
and O
the O
_RARE_ I-GENE
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
. O

Identification O
of O
a O
spliced O
gene I-GENE
from O
Kaposi O
' O
s O
sarcoma I-GENE
- I-GENE
associated I-GENE
herpesvirus I-GENE
encoding O
a O
protein I-GENE
with O
similarities O
to O
latent I-GENE
membrane I-GENE
proteins I-GENE
1 I-GENE
and O
2A I-GENE
of O
Epstein I-GENE
- I-GENE
Barr I-GENE
virus I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
were O
given O
at O
a O
rate O
of O
20 O
s O
(- O
1 I-GENE
). O

_RARE_ I-GENE
light I-GENE
chain I-GENE
kinase I-GENE
functions O
downstream O
of O
Ras I-GENE
/ I-GENE
ERK I-GENE
to O
promote O
migration O
of O
urokinase I-GENE
- I-GENE
type I-GENE
plasminogen I-GENE
activator I-GENE
- I-GENE
stimulated O
cells O
in O
an O
integrin I-GENE
- I-GENE
selective O
manner O
. O

The O
inhibition O
of O
_RARE_ I-GENE
gene I-GENE
transcription I-GENE
by O
_RARE_ I-GENE
- I-GENE
1 I-GENE
was O
dose O
- I-GENE
dependent I-GENE
reducing O
transcription I-GENE
to O
6 I-GENE
% O
of O
control O
levels O
. O

In O
a O
prospective O
randomized O
study O
, O
_RARE_ I-GENE
patients O
with O
advanced O
non O
- I-GENE
small I-GENE
cell O
lung O
cancer O
( O
_RARE_ I-GENE
) O
stage O
_RARE_ I-GENE
or O
IV I-GENE
with O
_RARE_ I-GENE
performance O
status O
( O
PS I-GENE
) O
0 O
- I-GENE
1 I-GENE
or O
2 I-GENE
were O
randomly O
assigned O
to O
receive O
either O
best O
_RARE_ I-GENE
care O
( O
_RARE_ I-GENE
) O
or O
_RARE_ I-GENE
care O
plus O
combination O
chemotherapy O
( O
_RARE_ I-GENE
regimen O
: O
_RARE_ I-GENE
3 I-GENE
_RARE_ I-GENE
/ I-GENE
m2 O
IV I-GENE
with O
_RARE_ I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
60 O
mg O
/ I-GENE
m2 O
IV I-GENE
on O
day O
1 I-GENE
and O
cisplatin O
60 O
mg O
/ I-GENE
m2 O
IV I-GENE
on O
day O
2 I-GENE
; O
or O
_RARE_ I-GENE
regimen O
: O
_RARE_ I-GENE
- I-GENE
C I-GENE
8 O
mg O
/ I-GENE
m2 O
, O
cisplatin O
100 O
mg O
/ I-GENE
m2 O
IV I-GENE
on O
day O
1 I-GENE
, O
_RARE_ I-GENE
4 I-GENE
mg O
/ I-GENE
m2 O
IV I-GENE
on O
days O
1 I-GENE
and O
15 O
). O

Using O
sequence I-GENE
information O
from O
human I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
cDNAs I-GENE
previously O
reported O
by O
our O
laboratory O
, O
we O
have O
isolated O
and O
characterized O
cDNAs I-GENE
encoding O
three O
splice O
variants I-GENE
of O
the O
mouse I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
gene I-GENE
. O

Comparison O
with O
the O
bHLH I-GENE
/ I-GENE
_RARE_ I-GENE
family I-GENE
genes I-GENE
revealed O
that O
the O
intron O
/ I-GENE
exon O
splice O
pattern O
of O
_RARE_ I-GENE
most O
closely O
matches O
that O
of O
the O
_RARE_ I-GENE
, O
which O
suggests O
that O
_RARE_ I-GENE
and O
_RARE_ I-GENE
belong O
to O
the O
same O
_RARE_ I-GENE
and O
may O
be O
derived O
from O
a O
common O
_RARE_ I-GENE
gene I-GENE
. O

The O
transcriptional O
activities O
of O
the O
full I-GENE
- I-GENE
length I-GENE
promoter I-GENE
(- O
_RARE_ I-GENE
to O
+ I-GENE
85 O
) O
and O
of O
three O
deletion O
constructs I-GENE
(- O
_RARE_ I-GENE
, O
- I-GENE
154 O
and O
- I-GENE
74 O
to O
+ I-GENE
85 O
) O
were O
significantly O
down O
- I-GENE
regulated O
in O
resistant O
cells O
. O

We O
were O
able O
to O
detect O
significant O
differences O
in O
functional O
residual O
capacity O
adjusted O
for O
weight O
or O
height O
, O
and O
compliance O
of O
the O
respiratory O
system O
adjusted O
for O
weight O
or O
lung O
volume O
in O
the O
_RARE_ I-GENE
infants O
compared O
to O
the O
healthy O
controls O
or O
infants O
who O
had O
_RARE_ I-GENE
, O
indicating O
that O
these O
_RARE_ I-GENE
were O
sensitive O
enough O
to O
determine O
abnormal O
lung O
function O
in O
this O
age O
group O
. O

A I-GENE
13 O
- I-GENE
bp O
cis O
- I-GENE
regulatory I-GENE
element I-GENE
in O
the O
LTR I-GENE
promoter I-GENE
of O
the O
tobacco I-GENE
retrotransposon I-GENE
_RARE_ I-GENE
is O
involved O
in O
responsiveness O
to O
tissue I-GENE
culture O
, O
_RARE_ I-GENE
, O
methyl O
_RARE_ I-GENE
and O
fungal I-GENE
_RARE_ I-GENE
. O

In O
this O
study O
we O
describe O
that O
platelet I-GENE
- I-GENE
derived O
growth I-GENE
factor I-GENE
( O
PDGF I-GENE
), O
12 O
- I-GENE
O O
- I-GENE
_RARE_ I-GENE
- I-GENE
phorbol O
- I-GENE
acetate O
( O
TPA O
), O
and O
forskolin O
induced O
CREB I-GENE
( O
cAMP I-GENE
- I-GENE
responsive I-GENE
element I-GENE
- I-GENE
binding I-GENE
protein I-GENE
) O
Ser O
- I-GENE
133 I-GENE
phosphorylation O
with O
comparable O
magnitude O
and O
kinetics O
in O
NIH O
3T3 O
cells O
. O

This O
constitutes O
evidence O
for O
an O
in O
vivo O
role O
of O
SRC I-GENE
- I-GENE
1 I-GENE
in O
dimerization O
- I-GENE
induced O
activation O
by O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
. O

By O
contrast O
, O
_RARE_ I-GENE
_RARE_ I-GENE
in O
vivo O
with O
another O
component O
of O
the O
_RARE_ I-GENE
complex I-GENE
( O
_RARE_ I-GENE
), O
which O
directly O
contacts O
TR I-GENE
and O
the O
vitamin O
D I-GENE
receptor I-GENE
in O
a O
ligand O
- I-GENE
dependent I-GENE
manner O
. O

This O
sequence I-GENE
also O
confers O
VDR I-GENE
and O
vitamin O
D I-GENE
responsiveness O
to O
a O
heterologous O
promoter I-GENE
. O

_RARE_ I-GENE
ligand O
- I-GENE
activated I-GENE
nuclear I-GENE
receptors I-GENE
( O
e O
. O
g O
. O
thyroid I-GENE
hormone I-GENE
receptor I-GENE
, O
retinoic I-GENE
acid I-GENE
receptor I-GENE
), O
orphan I-GENE
nuclear I-GENE
receptors I-GENE
( O
e O
. O
g O
. O

Expression O
of O
GlcNAc I-GENE
- I-GENE
_RARE_ I-GENE
mRNA I-GENE
in O
tobacco I-GENE
leaves O
was O
detected O
using O
RT I-GENE
- I-GENE
PCR O
. O

Chemical O
stability O
tests O
and O
site I-GENE
- I-GENE
specific I-GENE
mutagenesis O
identified O
amino O
acids O
_RARE_ I-GENE
and O
_RARE_ I-GENE
of O
_RARE_ I-GENE
and O
_RARE_ I-GENE
, O
respectively O
, O
as O
the O
phosphorylated O
residues O
. O

An O
overexpression O
of O
the O
_RARE_ I-GENE
gene I-GENE
in O
certain O
areas O
of O
the O
AD O
brain O
has O
been O
suggested O
to O
be O
an O
important O
factor I-GENE
in O
the O
_RARE_ I-GENE
of O
AD O
. O

For O
functional O
studies O
, O
two O
promoter I-GENE
regions O
were O
cloned O
upstream O
of O
the O
reporter I-GENE
gene I-GENE
, O
chloramphenicol I-GENE
acetyl I-GENE
transferase I-GENE
( O
CAT I-GENE
): O
( O
i O
) O
_RARE_ I-GENE
- I-GENE
B I-GENE
- I-GENE
the O
plasmid O
that O
contains O
the O
human I-GENE
( O
h O
) O
promoter I-GENE
region O
(- O
_RARE_ I-GENE
to O
+ I-GENE
101 I-GENE
) O
including O
_RARE_ I-GENE
, O
and O
( O
ii O
) O
_RARE_ I-GENE
- I-GENE
B I-GENE
- I-GENE
the O
plasmid O
that O
contains O
the O
rhesus I-GENE
( O
_RARE_ I-GENE
) O
promoter I-GENE
region O
excluding O
_RARE_ I-GENE
as O
it O
lacks O
a O
270 O
bp O
region O
of O
the O
_RARE_ I-GENE
promoter I-GENE
(- O
_RARE_ I-GENE
to O
- I-GENE
_RARE_ I-GENE
). O

67 O
_RARE_ I-GENE
bp O
of O
contiguous O
DNA I-GENE
located O
between O
markers O
_RARE_ I-GENE
and O
_RARE_ I-GENE
on O
the O
right O
arm O
of O
fission I-GENE
yeast I-GENE
chromosome O
II I-GENE
has O
been O
sequenced O
as O
part O
of O
the O
European O
_RARE_ I-GENE
Schizosaccharomyces I-GENE
pombe I-GENE
genome O
sequencing O
_RARE_ I-GENE
. O

67 O
_RARE_ I-GENE
bp O
of O
contiguous O
DNA I-GENE
located O
between O
markers O
_RARE_ I-GENE
and O
_RARE_ I-GENE
on O
the O
right O
arm O
of O
fission I-GENE
yeast I-GENE
chromosome O
II I-GENE
has O
been O
sequenced O
as O
part O
of O
the O
European O
_RARE_ I-GENE
Schizosaccharomyces I-GENE
pombe I-GENE
genome O
sequencing O
_RARE_ I-GENE
. O

G I-GENE
- I-GENE
CSF I-GENE
( O
_RARE_ I-GENE
micrograms O
subcutaneously O
( O
s O
. O
c I-GENE
_RARE_ I-GENE
were O
used O
in O
55 O
and O
GM I-GENE
- I-GENE
CSF I-GENE
( O
400 O
micrograms O
s O
. O
c I-GENE
.) O
in O
28 O
chemotherapeutic O
cycles O
. O

Overexpression O
of O
_RARE_ I-GENE
cDNA I-GENE
in O
the O
_RARE_ I-GENE
264 O
. O
7 O
macrophage I-GENE
cell O
line O
promoted O
an O
increased O
growth I-GENE
rate O
, O
suggesting O
that O
expression O
of O
_RARE_ I-GENE
is O
part O
of O
the O
proliferative O
cell O
response O
to O
LPS I-GENE
. O

Human I-GENE
expressed O
sequence I-GENE
tag O
clones O
were O
identified O
by O
sequence I-GENE
similarity O
to O
mammalian I-GENE
and O
yeast I-GENE
_RARE_ I-GENE
- I-GENE
processing O
_RARE_ I-GENE
, O
and O
the O
full I-GENE
- I-GENE
length I-GENE
coding O
region O
of O
the O
putative O
_RARE_ I-GENE
homolog I-GENE
was O
isolated O
by O
a O
combination O
of O
5 I-GENE
'- O
rapid O
amplification O
of O
cDNA I-GENE
ends O
and O
direct O
polymerase I-GENE
chain I-GENE
reaction O
from O
human I-GENE
placental I-GENE
cDNA I-GENE
. O

Activation O
of O
ERK1 I-GENE
/ I-GENE
2 I-GENE
is O
correlated O
with O
induction O
of O
the O
immediate I-GENE
- I-GENE
early I-GENE
response O
genes I-GENE
. O

The O
transcription I-GENE
of O
most O
RP I-GENE
genes I-GENE
is O
activated I-GENE
by O
two O
_RARE_ I-GENE
binding I-GENE
sites I-GENE
, O
250 O
to O
400 O
bp O
upstream O
from O
the O
initiation I-GENE
of O
transcription I-GENE
. O

We O
have O
isolated O
three O
mutant I-GENE
alleles I-GENE
of O
_RARE_ I-GENE
( O
_RARE_ I-GENE
- I-GENE
10 O
, O
_RARE_ I-GENE
- I-GENE
11 O
, O
and O
_RARE_ I-GENE
- I-GENE
16 O
) O
which O
suppress O
the O
nuclear I-GENE
division O
defect O
of O
_RARE_ I-GENE
- I-GENE
1 I-GENE
cells O
. O

Role O
of O
secondary O
structure O
in O
discrimination O
between O
constitutive O
and O
inducible I-GENE
activators I-GENE
. O

In O
summary O
, O
Ca I-GENE
( O
2 I-GENE
+)- I-GENE
dependent I-GENE
activation O
of O
NO O
production O
mediates O
apoptosis O
after O
TG I-GENE
exposure O
in O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
cells O
. O

_RARE_ I-GENE
of O
the O
U4 I-GENE
/ I-GENE
U6 I-GENE
duplex O
was O
_RARE_ I-GENE
by O
overexpression O
of O
wild I-GENE
- I-GENE
type I-GENE
_RARE_ I-GENE
. O

Our O
results O
, O
when O
combined O
with O
previously O
published O
in O
vitro O
results O
, O
support O
a O
direct O
role O
for O
_RARE_ I-GENE
in O
_RARE_ I-GENE
of O
the O
U4 I-GENE
/ I-GENE
U6 I-GENE
helix I-GENE
. O

This O
approximately O
125 I-GENE
- I-GENE
nt O
RNA I-GENE
proved O
to O
arise O
via O
RNase I-GENE
E I-GENE
cleavage O
from O
the O
3 I-GENE
'- O
terminal I-GENE
region O
of O
the O
mRNAs I-GENE
bearing O
the O
terminator O
. O

The O
_RARE_ I-GENE
of O
_RARE_ I-GENE
variability O
in O
_RARE_ I-GENE
skin O
cancer O
incidence O
. O

In O
Saccharomyces I-GENE
cerevisiae I-GENE
the O
cAMP I-GENE
- I-GENE
dependent I-GENE
kinases I-GENE
( O
_RARE_ I-GENE
) O
promote O
cytoplasmic I-GENE
growth I-GENE
and O
modulate O
the O
growth I-GENE
- I-GENE
regulated O
mechanism O
_RARE_ I-GENE
the O
begin O
of O
DNA I-GENE
synthesis O
. O

We O
have O
shown O
previously O
that O
in O
contrast O
to O
other O
extracellular I-GENE
matrix I-GENE
molecules I-GENE
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
collagen I-GENE
VI I-GENE
( O
_RARE_ I-GENE
) O
can O
stimulate O
DNA I-GENE
synthesis O
of O
various O
mesenchymal O
cell O
types O
, O
apparently O
independent O
of O
integrin I-GENE
- I-GENE
mediated O
signal I-GENE
transduction O
. O

A I-GENE
recombinant I-GENE
derivative O
harboring O
the O
_RARE_ I-GENE
replication O
region O
proved O
to O
be O
compatible O
with O
_RARE_ I-GENE
, O
a O
plasmid O
containing O
the O
iron O
acquisition O
system O
required O
for O
the O
virulence I-GENE
of O
V I-GENE
. O
_RARE_ I-GENE
_RARE_ I-GENE
, O
another O
important O
_RARE_ I-GENE
that O
causes O
_RARE_ I-GENE
. O

FAK I-GENE
localizes O
to O
sites I-GENE
of O
transmembrane I-GENE
integrin I-GENE
receptor I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
intracellular O
signaling O
events O
. O

Expression O
of O
various O
FAK I-GENE
mutants I-GENE
in O
the O
FAK I-GENE
- I-GENE
cells O
showed O
that O
FAK I-GENE
kinase I-GENE
activity O
, O
the O
Tyr I-GENE
- I-GENE
_RARE_ I-GENE
/ I-GENE
SH2 I-GENE
domain I-GENE
binding I-GENE
site I-GENE
, O
and O
the O
first O
proline O
- I-GENE
rich O
SH3 I-GENE
binding I-GENE
region O
in O
the O
FAK I-GENE
C I-GENE
- I-GENE
terminal I-GENE
domain I-GENE
were O
individually O
needed O
to O
promote O
full I-GENE
FAK I-GENE
- I-GENE
mediated O
FAK I-GENE
- I-GENE
cell O
migration O
to O
FN I-GENE
whereas O
direct O
paxillin I-GENE
binding I-GENE
to O
FAK I-GENE
was O
not O
required O
. O

This O
dominant I-GENE
- I-GENE
negative O
effect O
of O
_RARE_ I-GENE
was O
reversed O
by O
a O
point O
mutation I-GENE
( O
Leu I-GENE
- I-GENE
_RARE_ I-GENE
to O
Ser O
) O
which O
prevented O
_RARE_ I-GENE
localization O
to O
focal I-GENE
contact O
sites I-GENE
. O

Fifty O
six O
young O
patients O
( O
age O
< O
45 O
yr O
) O
with O
_RARE_ I-GENE
- I-GENE
proven O
_RARE_ I-GENE
were O
investigated O
for O
the O
presence O
of O
resistance O
to O
activated I-GENE
protein I-GENE
C I-GENE
( O
APC I-GENE
- I-GENE
R I-GENE
), O
lupus O
anticoagulant I-GENE
( O
LA O
), O
_RARE_ I-GENE
antibodies I-GENE
and O
deficiencies O
of O
protein I-GENE
C I-GENE
, O
protein I-GENE
S I-GENE
, O
_RARE_ I-GENE
activities O
. O

DESIGN O
: O
Comparison O
of O
number O
of O
women O
with O
_RARE_ I-GENE
aged O
15 O
- I-GENE
44 I-GENE
years O
on O
the O
_RARE_ I-GENE
_RARE_ I-GENE
database O
( O
observed O
number O
) O
with O
expected O
number O
derived O
from O
population O
data O
. O

PURPOSE O
: O
The O
_RARE_ I-GENE
of O
the O
present O
study O
were O
to O
assess O
the O
effects O
of O
a O
12 O
- I-GENE
wk O
laboratory O
based O
aerobic O
exercise O
program O
on O
cardiopulmonary O
function O
, O
CD4 I-GENE
cell O
count O
, O
and O
_RARE_ I-GENE
- I-GENE
assessed O
health O
status O
among O
symptomatic O
pre I-GENE
- I-GENE
AIDS O
HIV I-GENE
- I-GENE
infected O
individuals O
( O
N I-GENE
= O
28 O
) O
and O
to O
assess O
the O
degree O
to O
which O
_RARE_ I-GENE
health O
was O
associated I-GENE
with O
exercise O
relapse O
. O

The O
enzyme I-GENE
displays O
optimal O
activity O
at O
about O
0 O
. O
5 I-GENE
mM O
_RARE_ I-GENE
( O
_RARE_ I-GENE
( O
cat O
) O
0 O
. O
63 O
s O
(- O
1 I-GENE
)) O
and O
at O
pH O
7 O
. O
8 O
. O

Taken O
together O
, O
these O
results O
demonstrate O
that O
the O
RP I-GENE
, O
like I-GENE
the O
20S I-GENE
proteasome I-GENE
, O
is O
functionally O
and O
structurally O
conserved O
among O
eukaryotes O
and O
indicate O
that O
the O
plant O
_RARE_ I-GENE
subunits I-GENE
, O
like I-GENE
their O
yeast I-GENE
counterparts O
, O
have O
non O
- I-GENE
_RARE_ I-GENE
functions O
. O

_RARE_ I-GENE
evidence O
indicates O
that O
estrogen I-GENE
replacement O
therapy O
after O
_RARE_ I-GENE
increases O
breast O
cancer O
risk O
. O

In O
addition O
to O
its O
elongation I-GENE
activity O
, O
_RARE_ I-GENE
contains O
a O
novel O
type I-GENE
of O
RNA I-GENE
polymerase I-GENE
II I-GENE
interaction O
domain I-GENE
that O
is O
capable O
of O
repressing O
polymerase I-GENE
activity O
in O
promoter I-GENE
- I-GENE
specific I-GENE
transcription I-GENE
. O

A I-GENE
diagnosis O
of O
IgA I-GENE
lambda I-GENE
multiple O
myeloma O
with O
peritoneal O
involvement O
was O
made O
. O

The O
radiation O
burden O
associated I-GENE
with O
the O
majority O
of O
examinations O
in O
nuclear I-GENE
medicine O
expressed O
as O
the O
effective O
dose O
is O
comparable O
with O
the O
radiation O
burden O
of O
_RARE_ I-GENE
examinations O
, O
only O
after O
administration O
of O
preparations O
with O
131I O
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
and O
_RARE_ I-GENE
it O
is O
markedly O
higher O
. O

Although O
the O
risk O
of O
_RARE_ I-GENE
in O
children O
born O
after O
_RARE_ I-GENE
is O
not O
increased O
there O
is O
an O
increased O
risk O
to O
_RARE_ I-GENE
genetic O
abnormalities O
in O
case O
of O
_RARE_ I-GENE
( O
such O
as O
the O
rate O
of O
sex I-GENE
chromosome O
, O
or O
_RARE_ I-GENE
of O
the O
Y I-GENE
chromosome O
) O
and O
in O
case O
of O
congenital O
_RARE_ I-GENE
( O
mutations O
of O
the O
cystic I-GENE
fibrosis I-GENE
gene I-GENE
). O

_RARE_ I-GENE
particles O
have O
a O
_RARE_ I-GENE
density I-GENE
of O
1 I-GENE
. O
296 O
g O
/ I-GENE
cm3 O
in O
_RARE_ I-GENE
and O
consist O
of O
two O
capsid I-GENE
proteins I-GENE
of O
56 O
and O
6 I-GENE
kDa I-GENE
. O

CONCLUSION O
: O
These O
results O
suggest O
that O
vibration O
- I-GENE
induced O
neural O
involvement O
can O
be O
considered O
neither O
pure O
digital O
neuropathy I-GENE
, O
nor O
definite O
_RARE_ I-GENE
, O
as O
previously O
described O
. O

In O
about O
_RARE_ I-GENE
bp O
upstream O
region O
of O
_RARE_ I-GENE
that O
has O
been O
cloned O
and O
sequenced O
, O
multiple O
transcription I-GENE
factor I-GENE
binding I-GENE
sites I-GENE
including O
a O
CRE O
( O
cAMP I-GENE
- I-GENE
responsive I-GENE
element I-GENE
) O
were O
found O
. O

The O
in O
vitro O
_RARE_ I-GENE
of O
the O
complex I-GENE
is O
16 O
. O
24 O
s O
(- O
1 I-GENE
) O
mM O
(- O
1 I-GENE
). O

Structure O
and O
expression O
of O
the O
mouse I-GENE
growth I-GENE
hormone I-GENE
receptor I-GENE
/ I-GENE
growth I-GENE
hormone I-GENE
binding I-GENE
protein I-GENE
gene I-GENE
. O

_RARE_ I-GENE
recovery O
of O
SA O
from O
the O
liver O
/ I-GENE
spleen O
and O
the O
_RARE_ I-GENE
_RARE_ I-GENE
in O
contact O
_RARE_ I-GENE
and O
SG I-GENE
from O
contact O
chicks O
treated O
with O
ILK I-GENE
was O
dramatically O
reduced O
when O
compared O
to O
non O
- I-GENE
treated O
contact O
_RARE_ I-GENE
and O
chicks O
. O

The O
results O
of O
the O
_RARE_ I-GENE
- I-GENE
2 I-GENE
trial O
and O
the O
data O
from O
the O
_RARE_ I-GENE
_RARE_ I-GENE
' O
_RARE_ I-GENE
indicated O
that O
aspirin I-GENE
is O
_RARE_ I-GENE
in O
patients O
with O
acute O
myocardial O
infarction O
and O
for O
secondary O
prevention O
. O

This O
study O
was O
performed O
to O
assess O
the O
role O
of O
additional O
diagnostic O
_RARE_ I-GENE
in O
the O
preoperative O
_RARE_ I-GENE
of O
patients O
with O
adenocarcinoma O
of O
the O
_RARE_ I-GENE
, O
gastric O
cancer O
and O
pancreatic O
cancer O
prior O
to O
_RARE_ I-GENE
_RARE_ I-GENE
surgery O
. O

This O
report O
presents O
state O
- I-GENE
specific I-GENE
_RARE_ I-GENE
for O
1987 O
- I-GENE
1996 O
, O
focusing O
on O
persistent O
_RARE_ I-GENE
in O
maternal I-GENE
mortality O
between O
black O
and O
white O
women O
. O

_RARE_ I-GENE
_RARE_ I-GENE
mass O
level O
did O
not O
significantly O
differ O
in O
individuals O
from O
19 O
to O
70 I-GENE
years O
old O
, O
for O
both O
men O
and O
women O
. O

A I-GENE
decrease O
in O
insulin I-GENE
- I-GENE
induced O
receptor I-GENE
kinase I-GENE
activity O
was O
observed O
for O
_RARE_ I-GENE
chimeric I-GENE
receptors I-GENE
. O

_RARE_ I-GENE
- I-GENE
1 I-GENE
is O
identical O
to O
the O
recently O
identified O
binding I-GENE
partner I-GENE
for O
the O
beta I-GENE
- I-GENE
adrenergic I-GENE
receptor I-GENE
kinase I-GENE
( O
_RARE_ I-GENE
or O
_RARE_ I-GENE
- I-GENE
2 I-GENE
), O
which O
was O
shown O
to O
have O
_RARE_ I-GENE
- I-GENE
GAP I-GENE
activity O
. O

_RARE_ I-GENE
proteins I-GENE
are O
tyrosine I-GENE
- I-GENE
phosphorylated O
when O
co O
- I-GENE
expressed O
in O
cells O
with O
the O
focal I-GENE
adhesion I-GENE
kinase I-GENE
_RARE_ I-GENE
and O
Src I-GENE
. O

_RARE_ I-GENE
experiments O
using O
_RARE_ I-GENE
- I-GENE
specific I-GENE
antibodies I-GENE
revealed O
an O
interaction O
between O
endogenous I-GENE
_RARE_ I-GENE
and O
a O
150 O
- I-GENE
kDa I-GENE
protein I-GENE
that O
is O
tyrosine I-GENE
- I-GENE
phosphorylated O
in O
EGF I-GENE
- I-GENE
stimulated O
_RARE_ I-GENE
/ I-GENE
3 I-GENE
cells O
. O

_RARE_ I-GENE
are O
a O
family I-GENE
of O
proteins I-GENE
that O
_RARE_ I-GENE
long O
- I-GENE
term O
extension O
of O
isolated O
plant O
cell O
_RARE_ I-GENE
due O
to O
an O
as O
yet O
unknown O
biochemical O
mechanism O
. O

This O
review O
_RARE_ I-GENE
the O
clinical O
evidence O
to O
support O
current O
_RARE_ I-GENE
in O
_RARE_ I-GENE
bowel O
syndrome O
( O
_RARE_ I-GENE
). O

The O
responsive I-GENE
region O
of O
the O
alpha I-GENE
2 I-GENE
( O
V I-GENE
) O
collagen I-GENE
gene I-GENE
was O
localized O
to O
a O
fragment I-GENE
including O
100 O
bp O
of O
basal O
promoter I-GENE
and O
150 O
bp O
of O
exon O
1 I-GENE
sequences I-GENE
, O
which O
contained O
two O
CRE O
- I-GENE
like I-GENE
elements O
. O

Furthermore O
, O
addition O
of O
B I-GENE
- I-GENE
Myb I-GENE
- I-GENE
_RARE_ I-GENE
S I-GENE
- I-GENE
transferase I-GENE
fusion I-GENE
protein I-GENE
inhibited O
complex I-GENE
formation O
. O

_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
count O
predicts O
age O
when O
prevalence O
of O
AD O
increases O
, O
then O
_RARE_ I-GENE
: O
the O
_RARE_ I-GENE
_RARE_ I-GENE
Study O
. O

_RARE_ I-GENE
of O
double O
- I-GENE
strand O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
in O
chromosomal I-GENE
DNA I-GENE
by O
_RARE_ I-GENE
end O
- I-GENE
joining O
( O
_RARE_ I-GENE
) O
is O
not O
well O
characterized O
in O
the O
yeast I-GENE
Saccharomyces I-GENE
cerevisiae I-GENE
. O

A I-GENE
new O
DNA I-GENE
repair I-GENE
gene I-GENE
from O
Schizosaccharomyces I-GENE
pombe I-GENE
with O
homology I-GENE
to O
_RARE_ I-GENE
was O
identified O
and O
characterized O
. O

Among O
mucus O
- I-GENE
secreting O
cells O
, O
the O
gastric O
gland O
_RARE_ I-GENE
cells O
, O
_RARE_ I-GENE
' O
s O
glands O
, O
accessory I-GENE
glands O
of O
_RARE_ I-GENE
tract O
, O
and O
pancreatic O
_RARE_ I-GENE
exhibiting O
gastric O
_RARE_ I-GENE
are O
unique O
in O
that O
they O
express O
class I-GENE
III I-GENE
_RARE_ I-GENE
identified O
by O
_RARE_ I-GENE
_RARE_ I-GENE
A I-GENE
staining O
composed O
of O
_RARE_ I-GENE
oxidation O
, O
sodium O
_RARE_ I-GENE
reduction O
, O
_RARE_ I-GENE
A I-GENE
, O
and O
_RARE_ I-GENE
peroxidase I-GENE
reaction O
. O

The O
C I-GENE
- I-GENE
terminal I-GENE
mutants I-GENE
were O
strongly O
dominant I-GENE
over O
_RARE_ I-GENE
, O
suggesting O
that O
they O
can O
form O
_RARE_ I-GENE
with O
the O
wild I-GENE
- I-GENE
type I-GENE
activator I-GENE
. O

Thus O
, O
_RARE_ I-GENE
C I-GENE
is O
found O
to O
_RARE_ I-GENE
in O
solution O
and O
to O
undergo O
significant O
structural O
rearrangements O
upon O
binding I-GENE
of O
two O
different O
partner I-GENE
proteins I-GENE
. O

The O
data O
imply O
that O
_RARE_ I-GENE
/ I-GENE
STAT I-GENE
signaling O
has O
a O
role O
in O
EBV I-GENE
- I-GENE
associated I-GENE
_RARE_ I-GENE
. O

There O
were O
27 O
men O
and O
156 I-GENE
women O
. O

A I-GENE
., O
_RARE_ I-GENE
, O
K I-GENE
. O
E I-GENE
, O
and O
_RARE_ I-GENE
, O
C I-GENE
. O

_RARE_ I-GENE
is O
transcribed O
in O
one O
open O
reading O
frame O
that O
contains O
the O
DNA I-GENE
binding I-GENE
domain I-GENE
, O
nuclear I-GENE
localization O
signal I-GENE
and O
transactivation O
domain I-GENE
. O

The O
molecular O
mechanism O
of O
Tax I-GENE
- I-GENE
mediated O
trans O
- I-GENE
activation O
has O
been O
well O
investigated O
. O

Gel O
filtration O
and O
co O
- I-GENE
immunoprecipitation O
analyses O
reveal O
that O
_RARE_ I-GENE
tightly O
associates O
with O
another O
spindle O
checkpoint I-GENE
component O
, O
_RARE_ I-GENE
. O

METHODS O
: O
_RARE_ I-GENE
suspected O
cases O
with O
SS I-GENE
underwent O
the O
biopsies O
. O

We O
also O
identify O
several O
regulatory I-GENE
domain I-GENE
mutants I-GENE
in O
which O
Cd O
( O
2 I-GENE
+) O
tolerance O
of O
the O
mutant I-GENE
strain O
and O
transport O
activity O
of O
the O
protein I-GENE
are O
_RARE_ I-GENE
. O

The O
human I-GENE
immunodeficiency I-GENE
virus I-GENE
type I-GENE
- I-GENE
1 I-GENE
( O
HIV I-GENE
- I-GENE
1 I-GENE
) O
Tat I-GENE
protein I-GENE
regulates O
transcription I-GENE
by O
stimulating I-GENE
RNA I-GENE
polymerase I-GENE
_RARE_ I-GENE
. O

One O
of O
these O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
was O
shown O
to O
be O
the O
product I-GENE
of O
the O
homeotic I-GENE
gene I-GENE
fork I-GENE
head I-GENE
. O

_RARE_ I-GENE
elements O
in O
tRNA I-GENE
for O
mono O
- I-GENE
and O
_RARE_ I-GENE
reactions O
by O
the O
recombinant I-GENE
_RARE_ I-GENE
were O
identified O
using O
in O
vitro O
T7 I-GENE
transcripts I-GENE
of O
33 O
variants I-GENE
of O
tRNA I-GENE
( O
Asp I-GENE
) O
and O
tRNA I-GENE
( O
Phe I-GENE
) O
from O
yeast I-GENE
. O

In O
insulin I-GENE
- I-GENE
responsive I-GENE
cells O
, O
Akt I-GENE
phosphorylates O
and O
_RARE_ I-GENE
the O
serine I-GENE
/ I-GENE
threonine I-GENE
kinase I-GENE
glycogen I-GENE
synthase I-GENE
kinase I-GENE
- I-GENE
3 I-GENE
( O
_RARE_ I-GENE
- I-GENE
3 I-GENE
). O

The O
B I-GENE
cell O
antigen I-GENE
receptor I-GENE
activates O
the O
Akt I-GENE
( O
protein I-GENE
kinase I-GENE
B I-GENE
)/ O
glycogen I-GENE
synthase I-GENE
kinase I-GENE
- I-GENE
3 I-GENE
signaling O
pathway O
via O
phosphatidylinositol I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
. O

_RARE_ I-GENE
recombination O
events O
are O
detected O
in O
four O
different O
B I-GENE
and O
T I-GENE
cell O
lines O
that O
do O
not O
undergo O
switch O
recombination O
of O
their O
endogenous I-GENE
genes I-GENE
. O

IL I-GENE
- I-GENE
1 I-GENE
and O
TNF I-GENE
increase O
AND O
- I-GENE
34 O
transcript I-GENE
levels O
in O
thymic I-GENE
cortical O
_RARE_ I-GENE
, O
thymic I-GENE
nurse O
, O
and O
fibroblast I-GENE
cell O
lines O
. O

To O
determine O
what O
role O
_RARE_ I-GENE
might O
play O
in O
c I-GENE
- I-GENE
myc I-GENE
expression O
, O
the O
c I-GENE
- I-GENE
myc I-GENE
5 I-GENE
' O
untranslated O
region O
( O
UTR I-GENE
) O
was O
fused O
in O
- I-GENE
frame O
to O
CAT I-GENE
_RARE_ I-GENE
, O
and O
several O
more O
derivative O
constructs I-GENE
were O
made O
. O

Analysis O
of O
cell O
cycle O
proteins I-GENE
showed O
that O
24 O
h O
of O
_RARE_ I-GENE
treatment O
in O
the O
control O
cells O
caused O
an O
elevation O
in O
the O
levels O
of O
the O
cyclin I-GENE
- I-GENE
dependent I-GENE
kinase I-GENE
inhibitor I-GENE
p27 I-GENE
( O
_RARE_ I-GENE
), O
inhibition O
of O
both O
cyclin I-GENE
E I-GENE
- I-GENE
and O
cyclin I-GENE
A I-GENE
- I-GENE
dependent I-GENE
kinase I-GENE
activity O
, O
and O
decreased O
levels O
of O
_RARE_ I-GENE
retinoblastoma I-GENE
protein I-GENE
( O
pRb I-GENE
). O

RESULTS O
: O
_RARE_ I-GENE
leptin I-GENE
concentrations O
in O
_RARE_ I-GENE
were O
3 I-GENE
. O
5 I-GENE
+/- O
0 O
. O
5 I-GENE
versus O
7 O
. O
6 I-GENE
+/- O
1 I-GENE
. O
2 I-GENE
ng O
/ I-GENE
ml O
in O
control O
subjects O
. O

Copyright O
_RARE_ I-GENE
Academic O
Press O
. O

_RARE_ I-GENE
probes O
corresponding O
to O
wild I-GENE
- I-GENE
type I-GENE
and O
mutant I-GENE
_RARE_ I-GENE
sequences I-GENE
were O
used O
in O
gel O
- I-GENE
shift O
and O
_RARE_ I-GENE
- I-GENE
shift O
analyses O
to O
identify O
proteins I-GENE
binding I-GENE
. O

_RARE_ I-GENE
had O
high O
sequence I-GENE
homology I-GENE
with O
_RARE_ I-GENE
, O
_RARE_ I-GENE
isolated O
PKN I-GENE
, O
especially O
in O
the O
repeats I-GENE
of O
charged O
amino O
acid I-GENE
- I-GENE
rich O
region O
with O
leucine I-GENE
- I-GENE
zipper I-GENE
like I-GENE
sequences I-GENE
( O
_RARE_ I-GENE
region O
/ I-GENE
_RARE_ I-GENE
), O
in O
the O
carboxyl O
- I-GENE
terminal I-GENE
catalytic O
domain I-GENE
, O
and O
in O
approximately O
130 I-GENE
amino O
acid I-GENE
stretch O
( O
D I-GENE
region O
/ I-GENE
_RARE_ I-GENE
), O
located O
between O
_RARE_ I-GENE
region O
/ I-GENE
_RARE_ I-GENE
and O
the O
catalytic O
domain I-GENE
. O

At O
baseline O
, O
serum I-GENE
levels O
of O
_RARE_ I-GENE
and O
_RARE_ I-GENE
were O
_RARE_ I-GENE
high O
and O
serum I-GENE
_RARE_ I-GENE
was O
correlated O
significantly O
with O
plasma I-GENE
cyclosporine O
levels O
( O
r O
= O
0 O
. O
_RARE_ I-GENE
, O
p O
= O
0 O
. O
_RARE_ I-GENE
). O

BACKGROUND O
: O
Chronic O
alcohol O
consumption O
has O
been O
demonstrated O
to O
be O
_RARE_ I-GENE
to O
bone O
health O
. O

Interestingly O
, O
following O
induction O
of O
stress O
by O
heat I-GENE
shock I-GENE
, O
high O
salt O
, O
or O
ethanol O
, O
conditions O
under O
which O
most O
mRNA I-GENE
export O
is O
blocked O
, O
_RARE_ I-GENE
is O
still O
_RARE_ I-GENE
from O
the O
nucleus O
. O

For O
symptomatic O
_RARE_ I-GENE
and O
inhibition O
of O
the O
growth I-GENE
of O
the O
metastases O
interferon I-GENE
- I-GENE
a O
and O
somatostatin I-GENE
analogues O
can O
be O
employed O
. O

In O
summary O
, O
the O
no O
- I-GENE
adverse O
- I-GENE
effect O
- I-GENE
level O
for O
this O
study O
was O
determined O
to O
be O
1000 O
ppm O
, O
based O
on O
decreased O
weight O
gain O
in O
female O
rats O
, O
and O
on O
slight O
organ O
weight O
changes O
in O
both O
_RARE_ I-GENE
at O
_RARE_ I-GENE
ppm O
. O

Some O
of O
them O
produce O
_RARE_ I-GENE
sperm O
several O
times O
the O
total O
male O
body O
length I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE

PDGF I-GENE
A I-GENE
- I-GENE
chain I-GENE
levels O
increase O
in O
cultured O
vascular I-GENE
smooth I-GENE
muscle O
cells O
( O
_RARE_ I-GENE
) O
exposed O
to O
_RARE_ I-GENE
. O

M I-GENE
- I-GENE
Ras I-GENE
interacted O
poorly O
in O
a O
yeast I-GENE
two O
- I-GENE
hybrid O
assay O
with O
multiple O
Ras I-GENE
effectors I-GENE
, O
including O
c I-GENE
- I-GENE
Raf I-GENE
- I-GENE
1 I-GENE
, O
A I-GENE
- I-GENE
Raf I-GENE
, O
B I-GENE
- I-GENE
Raf I-GENE
, O
_RARE_ I-GENE
- I-GENE
3 I-GENE
kinase I-GENE
delta I-GENE
, O
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
. O

Deletion O
mapping O
of O
the O
human I-GENE
_RARE_ I-GENE
- I-GENE
1 I-GENE
( O
_RARE_ I-GENE
) O
promoter I-GENE
_RARE_ I-GENE
the O
most O
active O
fragment I-GENE
from O
- I-GENE
118 O
to O
+ I-GENE
_RARE_ I-GENE
in O
relation O
to O
the O
transcription I-GENE
start O
site I-GENE
mapped O
in O
this O
study O
, O
in O
both O
human I-GENE
neuroblastoma O
_RARE_ I-GENE
- I-GENE
N I-GENE
- I-GENE
SH I-GENE
and O
hepatoma O
HepG2 O
cells O
. O

_RARE_ I-GENE
oxygenation O
and O
_RARE_ I-GENE
in O
sepsis O
and O
shock I-GENE
. O

Analysis O
of O
the O
E2F1 I-GENE
gene I-GENE
promoter I-GENE
showed O
that O
the O
- I-GENE
_RARE_ I-GENE
to O
- I-GENE
54 I-GENE
region O
was O
required O
for O
E2 I-GENE
- I-GENE
responsiveness O
in O
transient O
transfection O
assays O
, O
and O
subsequent O
deletion O
/ I-GENE
mutation I-GENE
analysis O
showed O
that O
a O
single O
upstream O
GC I-GENE
- I-GENE
rich O
and O
two O
downstream O
CCAAT I-GENE
- I-GENE
binding I-GENE
sites I-GENE
were O
required O
for O
transactivation O
by O
E2 I-GENE
. O

In O
the O
course O
of O
_RARE_ I-GENE
the O
mechanisms O
by O
which O
_RARE_ I-GENE
and O
_RARE_ I-GENE
regulated O
_RARE_ I-GENE
transcription I-GENE
, O
we O
found O
that O
_RARE_ I-GENE
and O
_RARE_ I-GENE
bound O
Sp1 I-GENE
and O
Sp3 I-GENE
in O
_RARE_ I-GENE
- I-GENE
3 I-GENE
cells O
. O

In O
contrast O
, O
the O
differentiation O
of O
_RARE_ I-GENE
transformed O
cells O
does O
not O
repress O
mitogenic O
responsiveness O
or O
junB I-GENE
or O
c I-GENE
- I-GENE
fos I-GENE
inducibility O
. O

_RARE_ I-GENE
differentiation O
of O
_RARE_ I-GENE
cells O
also O
markedly O
represses O
the O
ability O
of O
SRF I-GENE
to O
bind O
to O
the O
junB I-GENE
SRE O
, O
the O
c I-GENE
- I-GENE
fos I-GENE
SRE O
, O
and O
other O
_RARE_ I-GENE
, O
as O
determined O
by O
mobility I-GENE
shift O
and O
gel O
supershift O
assays O
, O
without O
affecting O
the O
DNA I-GENE
binding I-GENE
characteristics O
of O
the O
nuclear I-GENE
protein I-GENE
SP I-GENE
- I-GENE
1 I-GENE
. O

_RARE_ I-GENE
blocks O
differentiation O
- I-GENE
induced O
inhibition O
of O
serum I-GENE
response O
factor I-GENE
interactions O
with O
serum I-GENE
response O
elements O
. O

The O
core I-GENE
enzyme I-GENE
is O
homologous O
to O
those O
of O
_RARE_ I-GENE
T3 O
, O
T7 I-GENE
and O
_RARE_ I-GENE
whereas O
the O
specificity O
factor I-GENE
shows O
similarities O
with O
bacterial I-GENE
sigma I-GENE
factors I-GENE
. O

The O
Cr I-GENE
. O
_RARE_ I-GENE
- I-GENE
4 I-GENE
ORF I-GENE
contains O
an O
H I-GENE
- I-GENE
N I-GENE
- I-GENE
H I-GENE
motif I-GENE
, O
and O
possibly O
a O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
motif I-GENE
. O

The O
interaction O
of O
_RARE_ I-GENE
- I-GENE
6 I-GENE
with O
full I-GENE
- I-GENE
length I-GENE
5 I-GENE
S I-GENE
RNA I-GENE
was O
far O
more O
sensitive O
to O
non O
- I-GENE
specific I-GENE
competitor O
concentration O
than O
was O
the O
_RARE_ I-GENE
- I-GENE
7 O
: O
5 I-GENE
S I-GENE
RNA I-GENE
interaction O
, O
suggesting O
that O
finger I-GENE
seven O
contributes O
to O
both O
affinity O
and O
specificity O
in O
this O
protein I-GENE
: O
RNA I-GENE
interaction O
. O

The O
STAT I-GENE
protein I-GENE
accumulation O
resulting O
from O
C I-GENE
/ I-GENE
EBP I-GENE
expression O
was O
tightly O
coupled I-GENE
to O
the O
morphological O
conversion O
of O
fibroblasts O
to O
adipocytes O
and O
represents O
an O
expression O
profile O
identical O
to O
that O
reported O
for O
mature O
adipocytes O
in O
vivo O
. O

The O
median O
durations O
for O
response O
and O
survival O
time O
in O
the O
late O
phase O
II I-GENE
trial O
were O
2 I-GENE
. O
3 I-GENE
months O
and O
5 I-GENE
. O
8 O
months O
, O
respectively O
. O

The O
role O
of O
' O
_RARE_ I-GENE
_RARE_ I-GENE
' O
in O
understanding O
patients O
with O
chronic O
schizophrenia O
or O
severe O
_RARE_ I-GENE
disorder O
. O

Myocardial O
antioxidant O
enzymes O
, O
catalase I-GENE
, O
glutathione I-GENE
peroxidase I-GENE
and O
superoxide I-GENE
dismutase I-GENE
, O
in O
the O
_RARE_ I-GENE
- I-GENE
treated O
rats O
were O
not O
different O
compared O
to O
control O
rats O
. O

The O
second O
goal O
was O
to O
_RARE_ I-GENE
the O
_RARE_ I-GENE
arrangement O
of O
the O
_RARE_ I-GENE
in O
PD I-GENE
. O

These O
overall O
results O
indicate O
that O
there O
is O
generally O
one O
_RARE_ I-GENE
copy O
per O
integration O
site I-GENE
. O

The O
present O
investigation O
conducted O
in O
a O
population O
of O
258 O
_RARE_ I-GENE
_RARE_ I-GENE
individuals O
in O
the O
age O
range O
20 O
- I-GENE
69 O
years O
, O
was O
initiated O
to O
elucidate O
the O
relationship O
between O
tobacco I-GENE
smoking O
and O
_RARE_ I-GENE
_RARE_ I-GENE
, O
taking O
into O
account O
possible O
_RARE_ I-GENE
factors I-GENE
such O
as O
age O
, O
gender O
, O
oral O
_RARE_ I-GENE
and O
_RARE_ I-GENE
inflammation O
. O

OBJECTIVE O
: O
To O
determine O
whether O
administration O
of O
_RARE_ I-GENE
prevents O
gastric O
hemorrhage O
in O
healthy O
dogs O
treated O
with O
high O
doses O
of O
_RARE_ I-GENE
sodium O
_RARE_ I-GENE
( O
_RARE_ I-GENE
). O

Patients O
were O
assessed O
for O
cardiac O
_RARE_ I-GENE
uptake O
, O
circulating O
norepinephrine O
concentration O
, O
LVEF O
, O
peak O
_RARE_ I-GENE
, O
x O
- I-GENE
ray O
_RARE_ I-GENE
ratio O
, O
M I-GENE
- I-GENE
mode O
_RARE_ I-GENE
end O
- I-GENE
diastolic O
diameter O
and O
right O
- I-GENE
_RARE_ I-GENE
heart O
_RARE_ I-GENE
parameters O
. O

Nuclear I-GENE
hormone I-GENE
receptors I-GENE
( O
_RARE_ I-GENE
) O
are O
ligand O
- I-GENE
inducible I-GENE
transcription I-GENE
factors I-GENE
that O
mediate O
critical O
functions O
in O
many O
species O
. O

These O
cells O
were O
able O
to O
present O
influenza I-GENE
virus I-GENE
particles O
to O
HLA I-GENE
- I-GENE
DR1 I-GENE
- I-GENE
restricted O
T I-GENE
cell O
clones O
. O

Sequencing O
of O
_RARE_ I-GENE
( O
_RARE_ I-GENE
_RARE_ I-GENE
) O
bacterial I-GENE
artificial O
chromosome O
and O
P1 I-GENE
artificial O
chromosome O
genomic O
clone O
fragments I-GENE
and O
of O
cDNA I-GENE
clones O
has O
led O
to O
the O
identification O
of O
five O
new O
loci I-GENE
coding O
for O
beta I-GENE
subunits I-GENE
of O
_RARE_ I-GENE
( O
_RARE_ I-GENE
). O

In O
addition O
to O
homologues O
of O
the O
human I-GENE
genes I-GENE
_RARE_ I-GENE
through O
_RARE_ I-GENE
, O
two O
new O
genes I-GENE
, O
_RARE_ I-GENE
and O
_RARE_ I-GENE
, O
have O
been O
found O
for O
which O
there O
are O
no O
known O
corresponding O
genes I-GENE
in O
humans O
. O

It O
_RARE_ I-GENE
_RARE_ I-GENE
' O
s O
_RARE_ I-GENE
_RARE_ I-GENE
, O
which O
attempts O
to O
_RARE_ I-GENE
the O
biological O
and O
_RARE_ I-GENE
models O
of O
_RARE_ I-GENE
sexual O
and O
reproductive O
behaviour O
. O

_RARE_ I-GENE
and O
height O
z O
- I-GENE
scores O
were O
significantly O
associated I-GENE
with O
BMD O
z O
- I-GENE
scores O
. O

A I-GENE
limited O
sampling O
strategy O
was O
used O
based O
on O
a O
_RARE_ I-GENE
parameter O
estimation O
algorithm O
that O
is O
part O
of O
the O
_RARE_ I-GENE
II I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
. O

Interaction O
of O
_RARE_ I-GENE
with O
_RARE_ I-GENE
was O
required O
for O
the O
transformation O
of O
_RARE_ I-GENE
, O
as O
the O
_RARE_ I-GENE
antagonist O
_RARE_ I-GENE
acid I-GENE
inhibited O
the O
folding O
of O
_RARE_ I-GENE
into O
a O
mature O
- I-GENE
competent O
conformation O
. O

The O
amino O
acid I-GENE
changes O
_RARE_ I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
or O
in O
combination O
the O
exonuclease I-GENE
activity O
in O
vivo O
. O

Previous O
experimental O
evidence O
had O
indicated O
that O
_RARE_ I-GENE
might O
target O
_RARE_ I-GENE
to O
nuclear I-GENE
substrates O
such O
as O
the O
_RARE_ I-GENE
kinase I-GENE
complex I-GENE
. O

In O
the O
budding I-GENE
yeast I-GENE
, O
Saccharomyces I-GENE
cerevisiae I-GENE
, O
_RARE_ I-GENE
can O
function O
outside O
the O
chromosome O
as O
autonomously I-GENE
replicating I-GENE
sequence I-GENE
( O
ARS I-GENE
) O
elements O
; O
however O
, O
within O
chromosome O
III I-GENE
, O
certain O
_RARE_ I-GENE
near O
the O
transcriptionally O
silent I-GENE
HML I-GENE
locus I-GENE
show O
no O
replication O
origin O
activity O
. O

These O
results O
suggest O
that O
, O
for O
the O
HML I-GENE
ARS I-GENE
cluster I-GENE
( O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
), O
_RARE_ I-GENE
of O
origins O
is O
independent O
of O
local O
transcriptional O
silencing O
, O
even O
though O
origins O
and O
_RARE_ I-GENE
share O
key O
cis O
- I-GENE
and O
trans O
- I-GENE
acting O
components O
. O

In O
the O
present O
study O
, O
we O
demonstrate O
that O
expression O
of O
_RARE_ I-GENE
- I-GENE
IkappaBalpha I-GENE
blocked O
phorbol O
myristate O
acetate O
- I-GENE
phytohemagglutinin I-GENE
or O
tumor I-GENE
necrosis I-GENE
factor I-GENE
alpha I-GENE
- I-GENE
induced O
IkappaBalpha I-GENE
gene I-GENE
transcription I-GENE
and O
abolished O
NF I-GENE
- I-GENE
kappaB I-GENE
DNA I-GENE
binding I-GENE
activity O
, O
due O
to O
the O
continued O
cytoplasmic I-GENE
_RARE_ I-GENE
of O
RelA I-GENE
( O
p65 I-GENE
) O
by O
_RARE_ I-GENE
- I-GENE
IkappaBalpha I-GENE
. O

( O
i O
) O
_RARE_ I-GENE
_RARE_ I-GENE
expression O
from O
cDNA I-GENE
with O
an O
ecdysone O
- I-GENE
regulated O
transient O
expression O
system O
stimulated O
PDGF I-GENE
- I-GENE
BB I-GENE
-, I-GENE
IGF I-GENE
- I-GENE
I I-GENE
, O
and O
insulin I-GENE
- I-GENE
but O
not O
epidermal I-GENE
growth I-GENE
factor I-GENE
( O
EGF I-GENE
)- I-GENE
induced O
DNA I-GENE
synthesis O
in O
an O
ecdysone O
dose O
- I-GENE
responsive I-GENE
fashion O
. O

The O
analysis O
of O
two O
distinct O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
pathways O
shows O
that O
stress O
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
- I-GENE
Jun I-GENE
N I-GENE
- I-GENE
terminal I-GENE
kinase I-GENE
activation O
, O
resulting O
in O
the O
phosphorylation O
of O
ATF I-GENE
- I-GENE
2 I-GENE
, O
c I-GENE
- I-GENE
Jun I-GENE
, O
and O
_RARE_ I-GENE
, O
is O
required O
not O
only O
for O
the O
IL I-GENE
- I-GENE
1 I-GENE
- I-GENE
but O
also O
for O
the O
TPA O
- I-GENE
dependent I-GENE
induction O
, O
while O
the O
extracellular I-GENE
signal I-GENE
- I-GENE
related I-GENE
kinase I-GENE
1 I-GENE
( O
ERK I-GENE
- I-GENE
1 I-GENE
) O
and O
ERK I-GENE
- I-GENE
2 I-GENE
activation O
is O
involved O
in O
the O
TPA O
- I-GENE
but O
not O
in O
the O
IL I-GENE
- I-GENE
1 I-GENE
- I-GENE
dependent I-GENE
stimulation O
of O
the O
uPA I-GENE
enhancer I-GENE
. O

CONCLUSIONS O
: O
In O
healthy O
individuals O
, O
whole O
body O
insulin I-GENE
sensitivity O
is O
related I-GENE
, O
or O
" O
coupled I-GENE
, O
" O
to O
the O
anaerobic O
threshold O
. O

_RARE_ I-GENE
signaling O
in O
a O
two O
- I-GENE
domain I-GENE
fragment I-GENE
of O
the O
human I-GENE
glucocorticoid I-GENE
receptor I-GENE
. O

In O
contrast O
, O
the O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
gene I-GENE
needs O
the O
binding I-GENE
of O
the O
seven O
_RARE_ I-GENE
zinc I-GENE
fingers O
, O
but O
not O
Oct I-GENE
- I-GENE
1 I-GENE
, O
for O
optimal O
transcriptional O
capacity O
. O

Collectively O
, O
these O
results O
show O
that O
the O
differential O
utilization O
of O
_RARE_ I-GENE
zinc I-GENE
finger I-GENE
1 I-GENE
represents O
a O
new O
, O
critical O
determinant O
of O
the O
transcriptional O
activation O
mechanism O
for O
the O
Xenopus I-GENE
tRNA I-GENE
( O
_RARE_ I-GENE
) O
and O
human I-GENE
U6 I-GENE
snRNA I-GENE
genes I-GENE
. O

In O
B I-GENE
cells O
, O
HEF1 I-GENE
is O
phosphorylated O
by O
a O
cytoskeleton I-GENE
- I-GENE
dependent I-GENE
mechanism O
that O
is O
triggered O
by O
integrin I-GENE
ligation O
. O

The O
calcitonin I-GENE
- I-GENE
induced O
tyrosine I-GENE
phosphorylation O
of O
HEF1 I-GENE
increased O
in O
a O
time O
- I-GENE
and O
dose O
- I-GENE
dependent I-GENE
manner O
. O

_RARE_ I-GENE
_RARE_ I-GENE
muscle O
stimulation O
increased O
VI I-GENE
, O
max O
( O
peak O
increase O
61 O
%, O
P I-GENE
< O
0 O
. O
05 O
), O
did O
not O
change O
_RARE_ I-GENE
, O
and O
decreased O
_RARE_ I-GENE
( O
peak O
decrease O
of O
41 O
%, O
P I-GENE
< O
0 O
. O
05 O
). O

We O
report O
the O
construction I-GENE
of O
an O
approximately O
1 I-GENE
. O
7 O
- I-GENE
Mb O
sequence I-GENE
- I-GENE
_RARE_ I-GENE
YAC O
/ I-GENE
_RARE_ I-GENE
clone O
contig O
of O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
. O

The O
human I-GENE
_RARE_ I-GENE
and O
mouse I-GENE
_RARE_ I-GENE
mRNA I-GENE
transcripts I-GENE
, O
like I-GENE
many O
repair I-GENE
proteins I-GENE
, O
are O
highly O
expressed O
in O
the O
testis I-GENE
. O

Analysis O
of O
the O
mouse I-GENE
_RARE_ I-GENE
gene I-GENE
isolated O
from O
the O
genomic O
library O
revealed O
that O
the O
_RARE_ I-GENE
gene I-GENE
spans O
a O
region O
of O
over O
11 O
kb O
and O
comprises O
eight O
exons O
. O

A I-GENE
reduced O
matrix I-GENE
distribution O
and O
enhanced O
cell O
density I-GENE
were O
observed O
as O
the O
_RARE_ I-GENE
aged O
. O

After O
10 O
months O
of O
treatment O
with O
the O
conjugated O
estrogen I-GENE
, O
both O
his O
height O
and O
weight O
showed O
improvement O
, O
while O
his O
bone O
mineral O
density I-GENE
and O
bone O
age O
were O
increased O
. O

_RARE_ I-GENE
experiments O
on O
the O
catalytic O
fragment I-GENE
kinase I-GENE
reaction O
demonstrated O
that O
the O
chemical O
( O
_RARE_ I-GENE
transfer I-GENE
) O
step O
had O
a O
reduced O
rate O
. O

_RARE_ I-GENE
sedimentation O
, O
cross O
- I-GENE
linking O
, O
and O
immunoprecipitation O
analyses O
of O
detergent O
- I-GENE
_RARE_ I-GENE
rat I-GENE
brain O
revealed O
that O
the O
32 O
and O
34 O
kDa I-GENE
polypeptides I-GENE
reside O
within O
_RARE_ I-GENE
. O

In O
vitro O
expression O
levels O
of O
the O
different O
plasmids O
differed O
by O
as O
much O
as O
_RARE_ I-GENE
. O

In O
EEG O
only O
single O
slow O
waves O
above O
left O
temporal O
region O
were O
revealed O
. O

Molecular O
characterization O
of O
type I-GENE
- I-GENE
specific I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
biosynthesis O
genes I-GENE
of O
Streptococcus I-GENE
_RARE_ I-GENE
type I-GENE
_RARE_ I-GENE
. O

( O
1998 O
) O
_RARE_ I-GENE
J O
. O

IL I-GENE
- I-GENE
1beta I-GENE
( O
10 O
ng O
/ I-GENE
ml O
) O
_RARE_ I-GENE
increased O
both O
_RARE_ I-GENE
and O
CCAAT I-GENE
/ I-GENE
enhancer I-GENE
- I-GENE
binding I-GENE
protein I-GENE
delta I-GENE
( O
C I-GENE
/ I-GENE
_RARE_ I-GENE
) O
mRNA I-GENE
levels O
in O
a O
time O
dependent I-GENE
manner O
. O

The O
recruitment O
of O
constitutively O
phosphorylated O
_RARE_ I-GENE
( O
neu I-GENE
) O
and O
the O
activated I-GENE
mitogenic O
pathway O
proteins I-GENE
to O
this O
membrane I-GENE
- I-GENE
_RARE_ I-GENE
interaction O
site I-GENE
provides O
a O
physical O
model O
for O
_RARE_ I-GENE
the O
assembly O
of O
the O
mitogenic O
pathway O
with O
the O
transmission O
of O
growth I-GENE
factor I-GENE
signal I-GENE
to O
the O
cytoskeleton I-GENE
. O

Transient O
tyrosine I-GENE
phosphorylation O
of O
Crk I-GENE
in O
fibroblast I-GENE
growth I-GENE
factor I-GENE
- I-GENE
2 I-GENE
- I-GENE
stimulated O
endothelial I-GENE
cells O
was O
dependent I-GENE
on O
the O
juxtamembrane I-GENE
tyrosine I-GENE
residue O
_RARE_ I-GENE
in O
FGFR I-GENE
- I-GENE
1 I-GENE
, O
and O
a O
Crk I-GENE
SH2 I-GENE
domain I-GENE
precipitated O
FGFR I-GENE
- I-GENE
1 I-GENE
via O
phosphorylated O
Tyr I-GENE
- I-GENE
_RARE_ I-GENE
, O
indicating O
direct O
complex I-GENE
formation O
between O
Crk I-GENE
and O
FGFR I-GENE
- I-GENE
1 I-GENE
. O

ECG O
- I-GENE
gated O
myocardial O
_RARE_ I-GENE
- I-GENE
99m O
_RARE_ I-GENE
SPECT O
is O
a O
useful O
technique O
to O
measure O
myocardial O
perfusion O
and O
function O
simultaneously O
. O

Role O
of O
the O
3 I-GENE
' O
untranslated O
region O
of O
baculovirus O
_RARE_ I-GENE
mRNA I-GENE
in O
high O
- I-GENE
level O
expression O
of O
foreign O
genes I-GENE
. O

The O
intron O
RNA I-GENE
consists O
of O
_RARE_ I-GENE
nucleotides O
which O
can O
be O
folded O
into O
a O
secondary O
structure O
with O
all O
the O
expected O
sequence I-GENE
motifs O
of O
subgroup O
- I-GENE
_RARE_ I-GENE
introns O
( O
_RARE_ I-GENE
et O
al O
. O

The O
intron O
is O
capable O
of O
splicing O
despite O
the O
fact O
that O
both O
the O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
and O
the O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
sequence I-GENE
motifs O
, O
thought O
to O
be O
necessary O
for O
correct O
splicing O
, O
extend O
over O
5 I-GENE
instead O
of O
6 I-GENE
bp O
. O

The O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
Growth I-GENE
Factor I-GENE
receptor I-GENE
mediates O
the O
rapid O
activation O
of O
a O
number O
of O
intracellular O
signaling O
proteins I-GENE
, O
including O
phosphatidylinositol I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
( O
PI I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
). O

The O
_RARE_ I-GENE
of O
significance O
testing O
: O
_RARE_ I-GENE
and O
_RARE_ I-GENE
. O

Chemical O
uptake O
into O
human I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
in O
vivo O
from O
volatile O
and O
non O
- I-GENE
volatile O
_RARE_ I-GENE
. O

Like O
DNA I-GENE
binding I-GENE
, O
transcriptional O
enhancement O
required O
amino O
- I-GENE
terminally I-GENE
located O
basic I-GENE
amino O
acid I-GENE
residues O
but O
not O
the O
carboxyl O
- I-GENE
terminal I-GENE
portion O
of O
_RARE_ I-GENE
known O
to O
participate O
in O
hsp70 I-GENE
interaction O
. O

We O
have O
tested O
the O
function O
of O
two O
potential O
NF I-GENE
- I-GENE
kappaB I-GENE
- I-GENE
like I-GENE
sites I-GENE
present O
in O
the O
PAI I-GENE
- I-GENE
2 I-GENE
proximal I-GENE
promoter I-GENE
for O
responsiveness O
to O
_RARE_ I-GENE
using O
chloramphenicol I-GENE
acetyl I-GENE
transferase I-GENE
reporter I-GENE
gene I-GENE
deletion O
and O
mutation I-GENE
analyses O
. O

N I-GENE
- I-GENE
terminal I-GENE
sequence I-GENE
analysis O
and O
NMR O
measurements O
revealed O
that O
this O
fragment I-GENE
_RARE_ I-GENE
from O
the O
C I-GENE
- I-GENE
terminal I-GENE
80 O
residues O
of O
_RARE_ I-GENE
and O
form O
a O
well O
structured O
C I-GENE
- I-GENE
terminal I-GENE
domain I-GENE
of O
_RARE_ I-GENE
, O
_RARE_ I-GENE
. O

The O
_RARE_ I-GENE
response O
associated I-GENE
with O
immediate I-GENE
- I-GENE
early I-GENE
gene I-GENE
induction O
is O
mediated O
via O
alternative O
MAP I-GENE
kinase I-GENE
cascades I-GENE
: O
_RARE_ I-GENE
as O
a O
potential O
histone I-GENE
H3 I-GENE
/ I-GENE
HMG I-GENE
- I-GENE
14 O
kinase I-GENE
. O

The O
arrangement O
of O
these O
cutoff O
- I-GENE
levels O
leads O
to O
a O
sensitivity O
of O
85 O
% O
at O
a O
specificity O
of O
55 O
% O
for O
Protein I-GENE
_RARE_ I-GENE
when O
measured O
by O
_RARE_ I-GENE
, O
and O
to O
a O
sensitivity O
of O
77 O
% O
at O
a O
specificity O
of O
61 O
% O
when O
measured O
by O
_RARE_ I-GENE
. O

272 O
, O
_RARE_ I-GENE
]. O

Using O
16 O
strains O
of O
C I-GENE
. O
_RARE_ I-GENE
in O
_RARE_ I-GENE
assays O
, O
we O
found O
the O
RT I-GENE
- I-GENE
PCR O
method O
consistently O
more O
sensitive O
than O
the O
conventional O
technique O
for O
all O
eight O
_RARE_ I-GENE
tested O
, O
with O
_RARE_ I-GENE
MICs O
determined O
by O
RT I-GENE
- I-GENE
PCR O
ranging O
from O
1 I-GENE
. O
6 I-GENE
- I-GENE
fold O
higher O
( O
_RARE_ I-GENE
) O
to O
>/= O
_RARE_ I-GENE
- I-GENE
fold O
higher O
( O
amoxicillin O
). O

_RARE_ I-GENE
alleles I-GENE
of O
_RARE_ I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
the O
role O
of O
the O
_RARE_ I-GENE
binding I-GENE
site I-GENE
of O
the O
HMR I-GENE
- I-GENE
E I-GENE
silencer I-GENE
but O
not O
the O
role O
of O
the O
_RARE_ I-GENE
or O
_RARE_ I-GENE
binding I-GENE
site I-GENE
. O

Recent O
molecular O
analysis O
has O
revealed O
that O
the O
S I-GENE
locus I-GENE
is O
highly O
polymorphic O
and O
contains O
several O
genes I-GENE
, O
i O
. O
e O
., O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
the O
as O
- I-GENE
yet O
- I-GENE
unidentified O
pollen O
S I-GENE
gene I-GENE
( O
s O
), O
and O
other O
linked O
genes I-GENE
. O

A I-GENE
cDNA I-GENE
encoding O
a O
putative O
RNA I-GENE
and O
/ I-GENE
or O
DNA I-GENE
helicase I-GENE
has O
been O
isolated O
from O
Arabidopsis I-GENE
thaliana O
cDNA I-GENE
libraries O
. O

In O
vivo O
, O
MyoD I-GENE
requires O
this O
tryptophan I-GENE
motif I-GENE
to O
_RARE_ I-GENE
chromatin O
remodeling O
in O
the O
_RARE_ I-GENE
promoter I-GENE
and O
to O
activate O
_RARE_ I-GENE
transcription I-GENE
. O

RESULTS O
: O
256 O
_RARE_ I-GENE
of O
_RARE_ I-GENE
or O
_RARE_ I-GENE
were O
reported O
by O
men O
and O
_RARE_ I-GENE
by O
women O
. O

_RARE_ I-GENE
intake O
and O
_RARE_ I-GENE
_RARE_ I-GENE
were O
decreased O
( O
P I-GENE
< O
0 O
. O
05 O
) O
by O
dietary O
treatments O
containing O
M I-GENE
. O

The O
N I-GENE
terminus O
of O
beta I-GENE
( O
95 O
kDa I-GENE
) O
corresponds O
to O
alpha I-GENE
with O
the O
integrase I-GENE
domain I-GENE
attached O
to O
the O
C I-GENE
terminus O
( O
32 O
kDa I-GENE
). O

_RARE_ I-GENE
- I-GENE
1a I-GENE
lacking O
the O
C I-GENE
- I-GENE
terminal I-GENE
region O
completely O
lost O
transactivation O
ability O
, O
irrespective O
of O
the O
promoter I-GENE
tested O
, O
and O
was O
able O
to O
block O
transactivation O
by O
normal O
_RARE_ I-GENE
- I-GENE
1a I-GENE
in O
competition O
assays O
. O

In O
early I-GENE
Xenopus I-GENE
embryos O
, O
the O
transforming I-GENE
growth I-GENE
factor I-GENE
- I-GENE
beta I-GENE
member O
activin I-GENE
induces O
the O
gene I-GENE
_RARE_ I-GENE
. O
2 I-GENE
by O
stimulating I-GENE
the O
formation O
of O
a O
_RARE_ I-GENE
complex I-GENE
, O
activin I-GENE
- I-GENE
responsive I-GENE
factor I-GENE
( O
ARF I-GENE
). O

To O
further O
characterize O
the O
structure O
and O
evolutionary O
synthesis O
of O
the O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
repeat I-GENE
, O
fluorescent O
in O
situ O
hybridization O
( O
_RARE_ I-GENE
) O
analysis O
and O
heterologous O
PCR O
- I-GENE
based O
assays O
were O
carried O
out O
for O
a O
series O
of O
primates O
. O

_RARE_ I-GENE
. O

In O
the O
face O
of O
the O
outbreak O
, O
there O
was O
a O
delay O
before O
vaccination O
was O
able O
to O
stop O
deaths O
. O

Here O
we O
show O
that O
a O
novel O
isoform I-GENE
of O
_RARE_ I-GENE
GTPase I-GENE
- I-GENE
activating I-GENE
protein I-GENE
, O
called O
_RARE_ I-GENE
, O
binds O
specifically O
to O
the O
alpha I-GENE
- I-GENE
subunits I-GENE
of O
the O
G I-GENE
( O
i O
) O
family I-GENE
of O
heterotrimeric I-GENE
G I-GENE
- I-GENE
proteins I-GENE
. O

The O
B I-GENE
- I-GENE
_RARE_ I-GENE
of O
pertussis I-GENE
toxin I-GENE
_RARE_ I-GENE
CC O
chemokine I-GENE
receptor I-GENE
5 I-GENE
and O
blocks O
entry O
of O
M I-GENE
- I-GENE
_RARE_ I-GENE
HIV I-GENE
- I-GENE
1 I-GENE
strains O
. O

Cross O
- I-GENE
linking O
the O
B I-GENE
cell O
Ag I-GENE
receptor I-GENE
( O
BCR I-GENE
) O
to O
surface O
Fc I-GENE
receptors I-GENE
for O
IgG I-GENE
( O
Fc I-GENE
gamma I-GENE
R I-GENE
) O
inhibits O
G1 I-GENE
- I-GENE
to O
- I-GENE
S I-GENE
progression O
; O
the O
mechanism O
by O
which O
this O
occurs O
is O
not O
completely O
known O
. O

Cross O
- I-GENE
linking O
the O
B I-GENE
cell O
Ag I-GENE
receptor I-GENE
( O
BCR I-GENE
) O
to O
surface O
Fc I-GENE
receptors I-GENE
for O
IgG I-GENE
( O
Fc I-GENE
gamma I-GENE
R I-GENE
) O
inhibits O
G1 I-GENE
- I-GENE
to O
- I-GENE
S I-GENE
progression O
; O
the O
mechanism O
by O
which O
this O
occurs O
is O
not O
completely O
known O
. O

TRAF2 I-GENE
is O
a O
potent O
activator I-GENE
of O
a O
95 O
- I-GENE
kDa I-GENE
serine I-GENE
/ I-GENE
threonine I-GENE
kinase I-GENE
termed O
_RARE_ I-GENE
center I-GENE
kinase I-GENE
related I-GENE
( O
_RARE_ I-GENE
, O
also O
referred O
to O
as O
_RARE_ I-GENE
), O
which O
signals O
activation O
of O
the O
SAPK I-GENE
pathway O
. O

An O
activation O
- I-GENE
responsive I-GENE
element I-GENE
in O
single O
C I-GENE
motif I-GENE
- I-GENE
1 I-GENE
/ I-GENE
_RARE_ I-GENE
promoter I-GENE
is O
a O
site I-GENE
of O
constitutive O
and O
inducible I-GENE
DNA I-GENE
- I-GENE
protein I-GENE
interactions O
involving O
nuclear I-GENE
factor I-GENE
of O
activated I-GENE
T I-GENE
cell O
. O

_RARE_ I-GENE
- I-GENE
induced O
NF I-GENE
- I-GENE
kappa I-GENE
B I-GENE
DNA I-GENE
binding I-GENE
activity O
, O
RelA I-GENE
nuclear I-GENE
translocation O
, O
I I-GENE
kappa I-GENE
B I-GENE
alpha I-GENE
degradation O
, O
I I-GENE
kappa I-GENE
B I-GENE
serine I-GENE
32 O
phosphorylation O
, O
and O
I I-GENE
kappa I-GENE
B I-GENE
kinase I-GENE
( O
_RARE_ I-GENE
) O
activity O
were O
blocked O
by O
_RARE_ I-GENE
treatment O
. O

A I-GENE
portion O
of O
_RARE_ I-GENE
is O
nuclear I-GENE
and O
localizes O
to O
the O
mitotic O
spindle O
. O

The O
main O
issues O
are O
the O
need O
to O
explain O
a O
number O
of O
still O
unknown O
mechanisms O
, O
to O
determine O
which O
" O
natural O
diet O
" O
carries O
the O
minimum O
coronary O
risk O
and O
whether O
" O
new O
" O
_RARE_ I-GENE
produced O
by O
modern O
technology O
are O
_RARE_ I-GENE
needed O
to O
contrast O
this O
epidemic O
. O

Cotransfection O
of O
the O
coactivator I-GENE
CREB I-GENE
- I-GENE
binding I-GENE
protein I-GENE
_RARE_ I-GENE
the O
transcriptional O
repression O
of O
_RARE_ I-GENE
by O
_RARE_ I-GENE
, O
suggesting O
that O
the O
dominant I-GENE
negative O
effect O
of O
_RARE_ I-GENE
might O
occur O
through O
competition O
for O
essential O
_RARE_ I-GENE
. O

SF I-GENE
- I-GENE
1 I-GENE
does O
not O
have O
an O
N I-GENE
- I-GENE
terminal I-GENE
_RARE_ I-GENE
domain I-GENE
. O

To O
estimate O
the O
locations O
of O
sources O
with O
the O
TF I-GENE
- I-GENE
_RARE_ I-GENE
algorithm O
, O
we O
first O
set O
the O
target O
region O
on O
the O
_RARE_ I-GENE
of O
the O
_RARE_ I-GENE
responses O
. O

We O
discuss O
these O
results O
in O
terms O
of O
the O
influence O
that O
time O
and O
nutritional O
_RARE_ I-GENE
have O
on O
_RARE_ I-GENE
development O
patterns O
and O
fitness O
. O

OBJECTIVE O
: O
1998 O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
Results O
( O
_RARE_ I-GENE
) O
data O
estimate O
an O
83 O
. O
1 I-GENE
% O
5 I-GENE
- I-GENE
year O
survival O
rate O
for O
_RARE_ I-GENE
_RARE_ I-GENE
adenocarcinoma O
_RARE_ I-GENE
stage O
II I-GENE
. O

A I-GENE
novel O
Drosophila I-GENE
A I-GENE
kinase I-GENE
anchor I-GENE
protein I-GENE
, O
Drosophila I-GENE
A I-GENE
kinase I-GENE
anchor I-GENE
protein I-GENE
200 O
( O
_RARE_ I-GENE
), O
is O
predicted O
to O
be O
involved O
in O
_RARE_ I-GENE
, O
mediating O
, O
and O
_RARE_ I-GENE
signals O
carried O
by O
cAMP I-GENE
, O
Ca I-GENE
( O
2 I-GENE
+), O
and O
_RARE_ I-GENE
( O
Li O
, O
Z I-GENE
., O
_RARE_ I-GENE
, O
E I-GENE
. O

In O
vitro O
transcription I-GENE
results O
indicate O
that O
this O
5 I-GENE
' O
structure O
functions O
in O
the O
attenuation O
mechanism O
, O
since O
deletion O
of O
the O
stem O
- I-GENE
loop I-GENE
caused O
an O
increase O
in O
transcription I-GENE
readthrough O
. O

A I-GENE
5 I-GENE
' O
RNA I-GENE
stem O
- I-GENE
loop I-GENE
participates O
in O
the O
transcription I-GENE
attenuation O
mechanism O
that O
controls O
expression O
of O
the O
Bacillus I-GENE
subtilis I-GENE
_RARE_ I-GENE
operon I-GENE
. O

_RARE_ I-GENE
- I-GENE
alanine I-GENE
- I-GENE
substitution O
mutations O
had O
minimal I-GENE
, O
if O
any O
, O
effects O
on O
S I-GENE
- I-GENE
induced O
cell O
- I-GENE
to O
- I-GENE
cell O
fusion I-GENE
. O

Furthermore O
, O
we O
demonstrate O
that O
transcription I-GENE
from O
the O
MMTV I-GENE
5 I-GENE
' O
LTR I-GENE
is O
highly O
active O
in O
the O
absence O
of O
Stat5a I-GENE
, O
a O
transcription I-GENE
factor I-GENE
that O
had O
been O
shown O
previously O
to O
be O
required O
for O
transcription I-GENE
from O
the O
MMTV I-GENE
LTR I-GENE
. O

_RARE_ I-GENE
insertional I-GENE
mutagenesis O
of O
specific I-GENE
genes I-GENE
on O
the O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
locus I-GENE
of O
Arabidopsis I-GENE
thaliana O
chromosome O
5 I-GENE
using O
the O
Ac I-GENE
/ I-GENE
_RARE_ I-GENE
transposon I-GENE
in O
combination O
with O
the O
cDNA I-GENE
scanning O
method O
. O

RESULTS O
: O
CK I-GENE
- I-GENE
MB I-GENE
elevation O
was O
detected O
in O
_RARE_ I-GENE
patients O
( O
18 O
. O
7 O
%), O
with O
1 I-GENE
- I-GENE
_RARE_ I-GENE
in O
12 O
. O
8 O
%, O
3 I-GENE
- I-GENE
_RARE_ I-GENE
in O
3 I-GENE
. O
5 I-GENE
% O
and O
> O
_RARE_ I-GENE
normal O
in O
2 I-GENE
. O
4 I-GENE
% O
of O
patients O
. O

Thus O
, O
_RARE_ I-GENE
- I-GENE
R I-GENE
performance O
may O
not O
be O
a O
_RARE_ I-GENE
estimate O
of O
baseline O
_RARE_ I-GENE
for O
patients O
with O
neurologic O
disorders O
with O
suspected O
language O
impairment O
. O

_RARE_ I-GENE
areas O
have O
been O
identified O
by O
means O
of O
cross O
- I-GENE
correlation O
analysis O
. O

_RARE_ I-GENE
Haemophilus O
influenzae O
type I-GENE
b I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
antibodies I-GENE
in O
_RARE_ I-GENE
infants O
and O
children O
from O
_RARE_ I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
) O
and O
_RARE_ I-GENE
: O
a O
cross O
- I-GENE
sectional O
_RARE_ I-GENE
. O

In O
this O
study O
, O
we O
identified O
Sp1 I-GENE
and O
Sp3 I-GENE
as O
major I-GENE
factors I-GENE
binding I-GENE
to O
the O
Sp1 I-GENE
sites I-GENE
of O
the O
p21 I-GENE
/ I-GENE
WAF1 I-GENE
/ I-GENE
Cip1 I-GENE
promoter I-GENE
in O
_RARE_ I-GENE
cells O
through O
electrophoretic O
mobility I-GENE
shift O
assays O
and O
showed O
that O
_RARE_ I-GENE
treatment O
did O
not O
change O
their O
binding I-GENE
activities O
. O

_RARE_ I-GENE
has O
_RARE_ I-GENE
the O
results O
of O
his O
discovery O
of O
_RARE_ I-GENE
_RARE_ I-GENE
. O

To O
study O
the O
regulation O
of O
its O
expression O
, O
the O
human I-GENE
_RARE_ I-GENE
reductase I-GENE
gene I-GENE
and O
promoter I-GENE
were O
cloned O
and O
characterized O
. O

_RARE_ I-GENE
staining O
with O
_RARE_ I-GENE
- I-GENE
1 I-GENE
and O
p53 I-GENE
antibodies I-GENE
showed O
low O
(< O
1 I-GENE
%) O
and O
negative O
reaction O
. O

The O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
is O
encoded I-GENE
as O
a O
_RARE_ I-GENE
of O
_RARE_ I-GENE
amino O
acids O
containing O
a O
putative O
chloroplast I-GENE
- I-GENE
targeting O
signal I-GENE
of O
65 O
amino O
acids O
at O
its O
N I-GENE
- I-GENE
terminus O
. O

_RARE_ I-GENE
before O
surgery O
patients O
received O
either O
intravenous O
_RARE_ I-GENE
100 O
mg O
or O
placebo O
in O
random O
, O
double O
- I-GENE
blind O
order O
. O

A I-GENE
tyrosine I-GENE
- I-GENE
based O
sorting I-GENE
signal I-GENE
in O
the O
beta2 I-GENE
integrin I-GENE
cytoplasmic I-GENE
domain I-GENE
mediates O
its O
_RARE_ I-GENE
to O
the O
plasma I-GENE
membrane I-GENE
and O
is O
required O
for O
ligand O
- I-GENE
supported O
migration O
. O

The O
injection O
of O
_RARE_ I-GENE
protein I-GENE
into O
_RARE_ I-GENE
Xenopus I-GENE
eggs O
blocked O
embryonic O
cell O
division O
. O

Using O
transgenic O
Xenopus I-GENE
embryos O
, O
we O
demonstrate O
that O
the O
integrity O
of O
these O
two O
sequences I-GENE
is O
necessary O
for O
correct O
spatial O
expression O
of O
a O
_RARE_ I-GENE
promoter I-GENE
- I-GENE
driven O
reporter I-GENE
gene I-GENE
. O

In O
order O
to O
screen O
for O
such O
_RARE_ I-GENE
, O
we O
have O
used O
a O
transcriptionally O
inactive O
mutant I-GENE
of O
Xenopus I-GENE
_RARE_ I-GENE
in O
a O
yeast I-GENE
two O
- I-GENE
hybrid O
screen O
. O

_RARE_ I-GENE
has O
an O
apparent O
molecular O
mass O
of O
1 I-GENE
. O
3 I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
transcription I-GENE
is O
negatively O
regulated O
by O
_RARE_ I-GENE
fatty I-GENE
acids O
and O
oxygen O
. O

Two O
patients O
with O
recurrent O
tumors O
had O
high O
S I-GENE
- I-GENE
phase O
fractions O
both O
on O
the O
first O
_RARE_ I-GENE
specimens O
and O
at O
the O
time O
of O
the O
second O
operation O
. O

Mutation O
of O
TTF I-GENE
- I-GENE
1 I-GENE
- I-GENE
binding I-GENE
sites I-GENE
( O
_RARE_ I-GENE
) O
1 I-GENE
, O
3 I-GENE
, O
and O
4 I-GENE
in O
combination O
markedly O
decreased O
transcriptional O
activity O
of O
SP I-GENE
- I-GENE
A I-GENE
promoter I-GENE
- I-GENE
chloramphenicol I-GENE
acetyltransferase I-GENE
constructs I-GENE
containing O
SP I-GENE
- I-GENE
A I-GENE
gene I-GENE
sequences I-GENE
from O
- I-GENE
256 O
to O
+ I-GENE
45 O
. O

Insulin I-GENE
- I-GENE
like I-GENE
growth I-GENE
factor I-GENE
- I-GENE
I I-GENE
induces O
bcl I-GENE
- I-GENE
2 I-GENE
promoter I-GENE
through O
the O
transcription I-GENE
factor I-GENE
cAMP I-GENE
- I-GENE
response O
element I-GENE
- I-GENE
binding I-GENE
protein I-GENE
. O

_RARE_ I-GENE
of O
antisense I-GENE
RNA I-GENE
and O
S I-GENE
phase O
- I-GENE
dependent I-GENE
binding I-GENE
of O
E2F I-GENE
complexes I-GENE
in O
intron O
1 I-GENE
. O

Identification O
of O
_RARE_ I-GENE
- I-GENE
3 I-GENE
will O
further O
promote O
our O
understanding O
of O
the O
control O
of O
eosinophil O
trafficking O
and O
other O
_RARE_ I-GENE
- I-GENE
mediated O
biological O
phenomena O
. O

NF I-GENE
- I-GENE
kappaB I-GENE
plays O
a O
critical O
role O
in O
activation O
of O
HIV I-GENE
- I-GENE
1 I-GENE
gene I-GENE
expression O
by O
cytokines O
and O
other O
stimuli O
, O
but O
the O
signal I-GENE
transduction O
pathways O
that O
regulate O
the O
switch O
from O
latent I-GENE
to O
_RARE_ I-GENE
infection O
have O
not O
been O
defined O
. O

These O
studies O
suggest O
that O
MAPK I-GENE
acts O
by O
stimulating I-GENE
AP I-GENE
- I-GENE
1 I-GENE
and O
a O
subsequent O
physical O
and O
functional O
interaction O
of O
AP I-GENE
- I-GENE
1 I-GENE
with O
NF I-GENE
- I-GENE
kappaB I-GENE
, O
resulting O
in O
a O
complex I-GENE
that O
synergistically O
transactivates O
the O
HIV I-GENE
- I-GENE
1 I-GENE
LTR I-GENE
. O

ERK I-GENE
MAP I-GENE
kinase I-GENE
links O
cytokine O
signals O
to O
activation O
of O
latent I-GENE
HIV I-GENE
- I-GENE
1 I-GENE
infection O
by O
stimulating I-GENE
a O
cooperative O
interaction O
of O
AP I-GENE
- I-GENE
1 I-GENE
and O
NF I-GENE
- I-GENE
kappaB I-GENE
. O

A I-GENE
human I-GENE
nuclear I-GENE
- I-GENE
localized O
_RARE_ I-GENE
that O
regulates O
dimerization O
, O
DNA I-GENE
binding I-GENE
, O
and O
transcriptional O
activity O
of O
bZIP I-GENE
proteins I-GENE
. O

Clinical O
differentiation O
of O
patients O
with O
mild O
_RARE_ I-GENE
cerebral O
_RARE_ I-GENE
( O
CP I-GENE
) O
and O
idiopathic O
toe O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
can O
be O
difficult O
. O

_RARE_ I-GENE
IL I-GENE
- I-GENE
8 O
and O
_RARE_ I-GENE
were O
significantly O
increased O
after O
_RARE_ I-GENE
in O
both O
_RARE_ I-GENE
- I-GENE
and O
_RARE_ I-GENE
dust O
- I-GENE
asthma O
( O
P I-GENE
< O
0 O
. O
05 O
). O

_RARE_ I-GENE
reduces O
airway O
_RARE_ I-GENE
inflammation O
in O
asthma O
: O
a O
randomized O
, O
controlled O
trial O
. O

Treatment O
of O
unstable O
angina O
: O
role O
of O
_RARE_ I-GENE
therapy O
. O

Here O
, O
we O
demonstrate O
that O
kinase I-GENE
- I-GENE
_RARE_ I-GENE
but O
not O
wild I-GENE
- I-GENE
type I-GENE
forms O
of O
Fyn I-GENE
, O
Lck I-GENE
, O
and O
ZAP I-GENE
- I-GENE
70 I-GENE
block O
_RARE_ I-GENE
Cbl I-GENE
- I-GENE
mediated O
NFAT I-GENE
activation O
. O

_RARE_ I-GENE
of O
region O
I I-GENE
with O
synthetic O
sequences I-GENE
showed O
that O
no O
specific I-GENE
sequence I-GENE
but O
rather O
repeats I-GENE
of O
three O
or O
more O
consecutive O
_RARE_ I-GENE
or O
_RARE_ I-GENE
, O
without O
_RARE_ I-GENE
by O
guanine I-GENE
or O
cytosine O
, O
are O
required O
for O
the O
ARS I-GENE
activity O
. O

In O
Saccharomyces I-GENE
cerevisiae I-GENE
, O
_RARE_ I-GENE
encodes O
a O
cyclin I-GENE
- I-GENE
dependent I-GENE
protein I-GENE
kinase I-GENE
( O
Cdk I-GENE
) O
catalytic O
subunit I-GENE
with O
multiple O
regulatory I-GENE
roles O
thought O
to O
be O
specified O
by O
association O
with O
different O
cyclin I-GENE
partners O
( O
_RARE_ I-GENE
). O

_RARE_ I-GENE
with O
mild O
_RARE_ I-GENE
alleles I-GENE
grow O
to O
become O
adults O
with O
multiple O
aberrant O
_RARE_ I-GENE
in O
the O
_RARE_ I-GENE
, O
compound O
eye O
, O
and O
_RARE_ I-GENE
. O

In O
fact O
, O
_RARE_ I-GENE
activity O
in O
the O
_RARE_ I-GENE
expressing O
epitope O
- I-GENE
tagged O
_RARE_ I-GENE
was O
absorbed O
by O
epitope O
- I-GENE
specific I-GENE
antibody I-GENE
. O

Mutations O
of O
the O
RET I-GENE
gene I-GENE
, O
encoding O
a O
receptor I-GENE
tyrosine I-GENE
kinase I-GENE
, O
have O
been O
associated I-GENE
with O
the O
inherited O
cancer O
syndromes O
_RARE_ I-GENE
2A I-GENE
and O
_RARE_ I-GENE
2B I-GENE
. O

These O
results O
show O
that O
targeting O
of O
Ras I-GENE
- I-GENE
GAP I-GENE
could O
represent O
a O
novel O
_RARE_ I-GENE
approach O
. O

_RARE_ I-GENE
- I-GENE
1 I-GENE
, O
a O
tyrosine I-GENE
kinase I-GENE
signal I-GENE
transduction O
gene I-GENE
, O
is O
transcriptionally O
activated I-GENE
in O
the O
t I-GENE
( O
1 I-GENE
; O
19 O
) O
subset O
of O
pre I-GENE
- I-GENE
B I-GENE
ALL O
, O
which O
express O
oncoprotein I-GENE
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
. O

Protein I-GENE
kinase I-GENE
A I-GENE
- I-GENE
_RARE_ I-GENE
subunit I-GENE
- I-GENE
directed O
antisense I-GENE
inhibition O
of O
ovarian O
cancer O
cell O
growth I-GENE
: O
_RARE_ I-GENE
with O
tyrosine I-GENE
kinase I-GENE
signaling O
pathway O
. O

_RARE_ I-GENE
encodes O
a O
POZ I-GENE
/ I-GENE
Zn I-GENE
finger I-GENE
protein I-GENE
, O
a O
structure O
similar O
to O
that O
of O
many O
Drosophila I-GENE
developmental O
regulators O
and O
to O
another O
protein I-GENE
involved O
in O
a O
human I-GENE
hematopoietic I-GENE
malignancy O
, O
PLZF I-GENE
. O

_RARE_ I-GENE
1 I-GENE
integrin I-GENE
- I-GENE
and O
proteoglycan I-GENE
- I-GENE
mediated O
stimulation O
of O
T I-GENE
lymphoma O
cell O
adhesion I-GENE
and O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
signaling O
by O
_RARE_ I-GENE
- I-GENE
1 I-GENE
and O
_RARE_ I-GENE
- I-GENE
1 I-GENE
peptides I-GENE
. O

_RARE_ I-GENE
CD O
, O
and O
spectral O
and O
activity O
analyses O
were O
used O
to O
examine O
reactivity O
of O
_RARE_ I-GENE
_RARE_ I-GENE
with O
NO O
species O
produced O
by O
NO O
donors O
. O

The O
phosphotransferase I-GENE
system O
( O
_RARE_ I-GENE
) O
of O
Streptomyces I-GENE
_RARE_ I-GENE
identification O
and O
biochemical O
analysis O
of O
a O
histidine O
_RARE_ I-GENE
protein I-GENE
_RARE_ I-GENE
encoded I-GENE
by O
the O
gene I-GENE
_RARE_ I-GENE
. O

Serum I-GENE
concentrations O
of O
bone O
specific I-GENE
alkaline I-GENE
phosphatase I-GENE
( O
_RARE_ I-GENE
) O
and O
_RARE_ I-GENE
( O
bone O
_RARE_ I-GENE
protein I-GENE
, O
_RARE_ I-GENE
), O
urinary O
levels O
of O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
and O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
and O
computed O
tomography O
( O
CT I-GENE
) O
measurements O
of O
the O
cross O
- I-GENE
sectional O
areas O
of O
the O
_RARE_ I-GENE
and O
the O
_RARE_ I-GENE
, O
the O
apparent O
density I-GENE
of O
_RARE_ I-GENE
bone O
in O
the O
_RARE_ I-GENE
, O
and O
the O
volume O
and O
the O
material O
density I-GENE
of O
cortical O
bone O
in O
the O
_RARE_ I-GENE
were O
determined O
in O
126 O
boys O
and O
143 I-GENE
girls O
, O
ages O
7 O
- I-GENE
18 O
years O
. O

In O
another O
study O
, O
intravenous O
administration O
of O
_RARE_ I-GENE
, O
a O
specific I-GENE
_RARE_ I-GENE
- I-GENE
A I-GENE
receptor I-GENE
antagonist O
, O
at O
a O
dose O
of O
0 O
. O
1 I-GENE
mg O
/ I-GENE
kg O
/ I-GENE
hr O
was O
_RARE_ I-GENE
15 O
min O
before O
_RARE_ I-GENE
saline O
intake O
and O
continued O
for O
1 I-GENE
hr O
. O

This O
cluster I-GENE
consisted O
of O
four O
apparently O
unrelated O
ESTs I-GENE
and O
two O
genes I-GENE
, O
pregnancy O
- I-GENE
associated I-GENE
plasma I-GENE
protein I-GENE
- I-GENE
A I-GENE
( O
_RARE_ I-GENE
- I-GENE
A I-GENE
) O
and O
a O
novel O
gene I-GENE
( O
tentatively O
named O
EST I-GENE
- I-GENE
_RARE_ I-GENE
). O

_RARE_ I-GENE
value O
of O
a O
_RARE_ I-GENE
exercise O
score O
in O
symptomatic O
patients O
with O
nonspecific O
ST O
- I-GENE
T I-GENE
abnormalities O
on O
resting O
ECG O
. O

Structural O
changes O
in O
the O
C I-GENE
- I-GENE
terminus O
of O
Ca2 I-GENE
+- I-GENE
bound O
rat I-GENE
_RARE_ I-GENE
( O
beta I-GENE
beta I-GENE
) O
upon O
binding I-GENE
to O
a O
peptide I-GENE
derived O
from O
the O
C I-GENE
- I-GENE
terminal I-GENE
regulatory I-GENE
domain I-GENE
of O
p53 I-GENE
. O

We O
propose O
that O
_RARE_ I-GENE
is O
part O
of O
a O
putative O
" O
_RARE_ I-GENE
_RARE_ I-GENE
" O
involved O
in O
the O
stabilization O
of O
the O
transition O
state O
similar O
to O
the O
C I-GENE
group O
of O
the O
esterase I-GENE
/ I-GENE
lipase I-GENE
family I-GENE
. O

The O
solution O
structure O
of O
the O
_RARE_ I-GENE
derived O
from O
the O
_RARE_ I-GENE
_RARE_ I-GENE
of O
the O
_RARE_ I-GENE
region O
_RARE_ I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
) O
_RARE_ I-GENE
of O
anti I-GENE
- I-GENE
11 O
, O
12 O
- I-GENE
_RARE_ I-GENE
- I-GENE
13 O
, O
14 O
- I-GENE
_RARE_ I-GENE
- I-GENE
11 O
, O
12 O
, O
13 O
, O
14 O
- I-GENE
_RARE_ I-GENE
[ O
g O
] O
_RARE_ I-GENE
, O
(+)- I-GENE
anti I-GENE
- I-GENE
B I-GENE
[ O
g O
] O
_RARE_ I-GENE
, O
to O
the O
_RARE_ I-GENE
N I-GENE
( O
6 I-GENE
) O
amino O
group O
of O
the O
adenine O
residue O
_RARE_ I-GENE
, O
( O
designated O
(+)- I-GENE
trans O
- I-GENE
anti I-GENE
-( O
B I-GENE
[ O
g O
] O
C I-GENE
) O
_RARE_ I-GENE
), O
positioned O
opposite O
a O
_RARE_ I-GENE
residue O
_RARE_ I-GENE
in O
the O
DNA I-GENE
sequence I-GENE
context O
d O
( O
C1 I-GENE
- I-GENE
T2 I-GENE
- I-GENE
C3 I-GENE
- I-GENE
T4 I-GENE
- I-GENE
_RARE_ I-GENE
-( O
B I-GENE
[ O
g O
] O
C I-GENE
) O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
). O
d O
( O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
+- I-GENE
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
) O
( O
designated O
( O
B I-GENE
[ O
g O
] O
C I-GENE
) O
_RARE_ I-GENE
. O
dT O
11 O
- I-GENE
mer I-GENE
duplex O
), O
has O
been O
studied O
using O
structural O
information O
derived O
from O
NMR O
data O
in O
combination O
with O
molecular O
dynamics O
( O
_RARE_ I-GENE
) O
_RARE_ I-GENE
. O

Since O
_RARE_ I-GENE
_RARE_ I-GENE
on O
the O
_RARE_ I-GENE
, O
it O
seems O
that O
the O
place O
of O
_RARE_ I-GENE
is O
reduced O
because O
comparative O
studies O
give O
better O
results O
for O
_RARE_ I-GENE
than O
_RARE_ I-GENE
( O
70 I-GENE
% O
vs O
40 I-GENE
%) O
and O
of O
course O
with O
a O
better O
_RARE_ I-GENE
. O

Serum I-GENE
antibodies I-GENE
were O
detected O
in O
at O
least O
95 O
% O
of O
the O
infected O
guinea O
pigs O
between O
4 I-GENE
- I-GENE
30 O
_RARE_ I-GENE
and O
rats O
between O
3 I-GENE
- I-GENE
16 O
_RARE_ I-GENE
. O

During O
both O
_RARE_ I-GENE
episodes O
, O
CSF I-GENE
protein I-GENE
and O
immunoglobulin I-GENE
G I-GENE
( O
IgG I-GENE
) O
levels O
were O
elevated O
without O
an O
increased O
IgG I-GENE
index O
or O
IgG I-GENE
synthesis O
rate O
. O

CONCLUSIONS O
: O
These O
results O
show O
that O
once O
daily O
oral O
_RARE_ I-GENE
can O
produce O
exposures O
of O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
_RARE_ I-GENE
those O
_RARE_ I-GENE
using O
intravenous O
_RARE_ I-GENE
10 O
mg O
/ I-GENE
kg O
. O

_RARE_ I-GENE
for O
_RARE_ I-GENE
of O
_RARE_ I-GENE
retinal O
vessels O
at O
a O
light I-GENE
dose O
of O
150 O
J O
/ I-GENE
cm2 O
, O
no O
other O
adverse O
events O
were O
of O
_RARE_ I-GENE
. O

_RARE_ I-GENE
for O
_RARE_ I-GENE
of O
_RARE_ I-GENE
retinal O
vessels O
at O
a O
light I-GENE
dose O
of O
150 O
J O
/ I-GENE
cm2 O
, O
no O
other O
adverse O
events O
were O
of O
_RARE_ I-GENE
. O

The O
healing O
rate O
in O
HIV I-GENE
- I-GENE
positive O
patients O
was O
66 O
percent O
after O
14 O
weeks O
and O
100 O
percent O
after O
32 O
weeks O
; O
the O
corresponding O
_RARE_ I-GENE
for O
patients O
with O
acquired O
immunodeficiency I-GENE
syndrome O
were O
0 O
and O
50 O
percent O
. O

The O
P I-GENE
mRNA I-GENE
also O
contains O
a O
third O
ORF I-GENE
for O
the O
V I-GENE
protein I-GENE
, O
although O
it O
is O
unclear O
how O
or O
whether O
this O
ORF I-GENE
is O
_RARE_ I-GENE
. O

A I-GENE
genetic O
screen O
in O
yeast I-GENE
has O
allowed O
us O
to O
identify O
a O
novel O
transcriptional O
factor I-GENE
binding I-GENE
to O
the O
_RARE_ I-GENE
, O
i O
. O
e O
. O
the O
chicken I-GENE
_RARE_ I-GENE
upstream O
promoter I-GENE
- I-GENE
transcription I-GENE
factor I-GENE
II I-GENE
( O
COUP I-GENE
- I-GENE
_RARE_ I-GENE
). O

We O
have O
cloned O
the O
single O
- I-GENE
copy O
gene I-GENE
for O
the O
trans O
- I-GENE
_RARE_ I-GENE
U5 I-GENE
snRNA I-GENE
from O
the O
_RARE_ I-GENE
species O
_RARE_ I-GENE
_RARE_ I-GENE
, O
using O
U5 I-GENE
RNA I-GENE
affinity O
selection O
and O
cDNA I-GENE
cloning O
. O

The O
MMPI O
- I-GENE
A I-GENE
( O
_RARE_ I-GENE
et O
al O
., O
1992 O
), O
like I-GENE
the O
older O
MMPI O
( O
_RARE_ I-GENE
& O
_RARE_ I-GENE
, O
1983 O
), O
_RARE_ I-GENE
between O
_RARE_ I-GENE
and O
_RARE_ I-GENE
. O

On O
the O
other O
hand O
, O
_RARE_ I-GENE
inositol I-GENE
4 I-GENE
, O
5 I-GENE
_RARE_ I-GENE
( O
PIP2 O
) O
hydrolysis O
requires O
direct O
phosphorylation O
at O
tyrosine I-GENE
residue O
of O
the O
PLC I-GENE
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
. O

A I-GENE
_RARE_ I-GENE
mutant I-GENE
of O
M I-GENE
- I-GENE
Ras I-GENE
was O
constitutively O
active O
and O
its O
expression O
in O
an O
interleukin I-GENE
- I-GENE
3 I-GENE
( O
IL I-GENE
- I-GENE
3 I-GENE
)- I-GENE
dependent I-GENE
mast I-GENE
cell O
/ I-GENE
_RARE_ I-GENE
cell O
line O
resulted O
in O
increased O
survival O
in O
the O
absence O
of O
IL I-GENE
- I-GENE
3 I-GENE
, O
increased O
growth I-GENE
in O
IL I-GENE
- I-GENE
4 I-GENE
, O
and O
, O
at O
high O
expression O
levels O
, O
in O
factor I-GENE
- I-GENE
independent O
growth I-GENE
. O

_RARE_ I-GENE
M I-GENE
- I-GENE
Ras I-GENE
and O
a O
Caenorhabditis I-GENE
elegans I-GENE
_RARE_ I-GENE
exhibit O
conserved O
structural O
features O
, O
and O
these O
are O
likely O
to O
mediate O
activation O
of O
distinctive O
signaling O
_RARE_ I-GENE
that O
function O
in O
parallel O
to O
those O
downstream O
of O
p21 I-GENE
Ras I-GENE
. O

Taken O
together O
, O
our O
data O
suggest O
that O
_RARE_ I-GENE
attenuates O
_RARE_ I-GENE
and O
_RARE_ I-GENE
expression O
rather O
than O
acting O
as O
a O
true O
repressor I-GENE
like I-GENE
_RARE_ I-GENE
. O

These O
observations O
establish O
that O
_RARE_ I-GENE
negatively O
regulates O
_RARE_ I-GENE
transcription I-GENE
but O
positively O
affects O
_RARE_ I-GENE
production O
. O

All O
were O
experienced O
hearing O
aid O
users O
who O
_RARE_ I-GENE
linear O
Class I-GENE
D I-GENE
instruments O
with O
input O
compression O
limiting O
at O
the O
time O
of O
their O
_RARE_ I-GENE
in O
this O
study O
. O

_RARE_ I-GENE
testing O
of O
food O
- I-GENE
restricted O
animals O
, O
using O
a O
multiple O
fixed O
ratio O
( O
FR I-GENE
)/ O
fixed O
interval O
( O
_RARE_ I-GENE
) O
schedule O
( O
_RARE_ I-GENE
: O
_RARE_ I-GENE
), O
was O
conducted O
prior O
to O
each O
exposure O
to O
maintain O
the O
_RARE_ I-GENE
behavior O
; O
the O
data O
from O
_RARE_ I-GENE
- I-GENE
1 I-GENE
, O
4 I-GENE
, O
8 O
, O
and O
13 O
were O
evaluated O
for O
evidence O
of O
neurotoxicity O
. O

_RARE_ I-GENE
protection O
assays O
revealed O
that O
_RARE_ I-GENE
and O
_RARE_ I-GENE
are O
differentially O
expressed O
in O
a O
developmentally O
- I-GENE
and O
spatially O
- I-GENE
modulated O
manner O
during O
_RARE_ I-GENE
of O
specialized O
_RARE_ I-GENE
- I-GENE
containing O
_RARE_ I-GENE
glands O
in O
embryos O
. O

Differential O
expression O
was O
confirmed O
by O
Northern O
blot O
analysis O
employing O
multiple O
normal O
and O
tumor I-GENE
cell O
lines O
. O

_RARE_ I-GENE
of O
the O
Neurospora I-GENE
crassa I-GENE
mitochondrial I-GENE
outer I-GENE
membrane I-GENE
protein I-GENE
_RARE_ I-GENE
by O
repeat I-GENE
- I-GENE
induced O
point O
mutation I-GENE
( O
_RARE_ I-GENE
) O
causes O
defects O
in O
mitochondrial I-GENE
protein I-GENE
import O
and O
morphology O
. O

Several O
genes I-GENE
or O
transcriptional O
units O
were O
identified O
, O
including O
the O
3 I-GENE
' O
end O
of O
ribosomal I-GENE
_RARE_ I-GENE
kinase I-GENE
( O
_RARE_ I-GENE
); O
two O
apparently O
intronless O
and O
ORF I-GENE
- I-GENE
less O
genes I-GENE
; O
and O
_RARE_ I-GENE
, O
an O
intronless O
, O
putative O
G I-GENE
- I-GENE
protein I-GENE
coupled I-GENE
receptor I-GENE
. O

The O
results O
suggest O
that O
GATA I-GENE
- I-GENE
5 I-GENE
may O
have O
specific I-GENE
downstream O
targets O
and O
that O
GATA I-GENE
- I-GENE
4 I-GENE
, O
- I-GENE
5 I-GENE
, O
and O
- I-GENE
6 I-GENE
can O
only O
partially O
substitute O
for O
each O
other O
in O
_RARE_ I-GENE
. O

This O
study O
was O
designed O
to O
compare O
the O
efficacy O
of O
_RARE_ I-GENE
plus O
_RARE_ I-GENE
versus O
heparin O
plus O
accelerated O
tissue I-GENE
plasminogen I-GENE
activator I-GENE
( O
TPA O
) O
in O
coronary O
reperfusion O
in O
acute O
MI O
. O

Recently O
, O
cell O
- I-GENE
surface O
_RARE_ I-GENE
has O
been O
shown O
to O
be O
expressed O
by O
activated I-GENE
human I-GENE
and O
mouse I-GENE
T I-GENE
lymphocytes O
, O
_RARE_ I-GENE
the O
possibility O
that O
_RARE_ I-GENE
might O
be O
involved O
in O
T I-GENE
cell O
- I-GENE
mediated O
cytotoxicity O
and O
/ I-GENE
or O
immune I-GENE
regulation O
. O

A I-GENE
panel O
of O
_RARE_ I-GENE
inhibitors O
was O
used O
to O
investigate O
the O
signal I-GENE
transduction O
pathways O
involved O
in O
_RARE_ I-GENE
gene I-GENE
induction O
following O
T I-GENE
lymphocyte I-GENE
activation O
. O

From O
_RARE_ I-GENE
1991 O
to O
August O
1997 O
, O
124 I-GENE
patients O
with O
endometrial O
carcinoma O
were O
treated O
postoperatively O
with O
high O
- I-GENE
dose O
- I-GENE
rate O
vaginal O
_RARE_ I-GENE
_RARE_ I-GENE
as O
the O
only O
adjuvant O
treatment O
. O

_RARE_ I-GENE
patients O
had O
stage O
_RARE_ I-GENE
, O
14 O
had O
_RARE_ I-GENE
, O
9 O
had O
_RARE_ I-GENE
, O
and O
3 I-GENE
had O
_RARE_ I-GENE
disease O
. O

_RARE_ I-GENE
provirus O
genomes O
of O
human I-GENE
T I-GENE
- I-GENE
cell O
leukemia I-GENE
virus I-GENE
type I-GENE
I I-GENE
are O
frequently O
detected O
in O
lymphocytes O
from O
infected O
individuals O
and O
in O
infected O
cell O
lines O
. O

A I-GENE
total O
of O
_RARE_ I-GENE
primer O
pairs O
gave O
_RARE_ I-GENE
_RARE_ I-GENE
patterns O
, O
_RARE_ I-GENE
( O
79 O
%) O
of O
which O
revealed O
at O
least O
two O
alleles I-GENE
on O
native O
polyacrylamide O
gels O
. O

A I-GENE
population O
pharmacokinetic O
study O
of O
cyclosporin O
in O
organ O
transplant O
patients O
, O
including O
elderly O
_RARE_ I-GENE
recipients O
up O
to O
75 O
years O
of O
age O
, O
did O
not O
identify O
age O
as O
a O
_RARE_ I-GENE
influencing O
cyclosporin O
pharmacokinetics O
. O

_RARE_ I-GENE
data O
indicated O
that O
once O
bound O
to O
the O
mutant I-GENE
receptor I-GENE
, O
fluorescent O
- I-GENE
labeled O
_RARE_ I-GENE
co O
- I-GENE
localized O
with O
markers O
of O
the O
_RARE_ I-GENE
pathway O
, O
whereas O
, O
in O
cells O
expressing O
the O
wild I-GENE
- I-GENE
type I-GENE
receptor I-GENE
, O
_RARE_ I-GENE
fluorescence O
co O
- I-GENE
localized O
with O
lysosomal I-GENE
markers O
. O

Interleukin I-GENE
- I-GENE
12 O
( O
IL I-GENE
- I-GENE
12 O
) O
is O
a O
cytokine O
produced O
by O
peripheral O
blood O
mononuclear O
cells O
( O
_RARE_ I-GENE
) O
that O
causes O
interferon I-GENE
- I-GENE
gamma I-GENE
( O
IFN I-GENE
- I-GENE
gamma I-GENE
) O
production O
and O
enhancement O
of O
cell O
- I-GENE
mediated O
cytotoxicity O
. O

IL I-GENE
- I-GENE
12 O
production O
was O
correlated O
with O
_RARE_ I-GENE
concentration O
measured O
at O
the O
_RARE_ I-GENE
of O
_RARE_ I-GENE
after O
15 O
min O
of O
dialysis O
( O
r O
= O
0 O
. O
69 O
, O
P I-GENE
< O
0 O
. O
01 O
). O

In O
HeLa O
cells O
, O
the O
_RARE_ I-GENE
- I-GENE
JNK1 I-GENE
fusion I-GENE
protein I-GENE
showed O
significant O
JNK I-GENE
activity O
, O
which O
was O
comparable O
with O
that O
of O
JNK1 I-GENE
activated I-GENE
by O
many O
stimuli O
and O
activators I-GENE
, O
including O
EGF I-GENE
, O
TNF I-GENE
- I-GENE
alpha I-GENE
, O
_RARE_ I-GENE
, O
UV O
irradiation O
, O
_RARE_ I-GENE
, O
and O
small I-GENE
GTP I-GENE
binding I-GENE
proteins I-GENE
Rac1 I-GENE
and O
_RARE_ I-GENE
. O

J O
. O

Our O
results O
_RARE_ I-GENE
TGF I-GENE
- I-GENE
beta I-GENE
RII I-GENE
as O
a O
direct O
target O
of O
EWS I-GENE
- I-GENE
FLI1 I-GENE
. O

The O
reduction O
in O
_RARE_ I-GENE
fatty I-GENE
acids O
intake O
led O
to O
_RARE_ I-GENE
( O
but O
in O
group O
1 I-GENE
significant O
) O
0 O
. O
15 O
mmol O
/ I-GENE
l O
( O
2 I-GENE
. O
5 I-GENE
%) O
reduction O
in O
total O
serum I-GENE
cholesterol I-GENE
level O
. O

_RARE_ I-GENE
, O
an O
ethanol O
repression O
autoregulation O
( O
_RARE_ I-GENE
)/ O
_RARE_ I-GENE
- I-GENE
fold O
TA O
repeat I-GENE
( O
_RARE_ I-GENE
) O
repressor I-GENE
element I-GENE
was O
identified O
within O
the O
promoter I-GENE
region O
of O
the O
_RARE_ I-GENE
gene I-GENE
. O

A I-GENE
crucial O
transcription I-GENE
factor I-GENE
in O
this O
process O
is O
_RARE_ I-GENE
, O
which O
binds O
to O
a O
specific I-GENE
DNA I-GENE
element I-GENE
upon O
cytokine O
activation O
. O

CONCLUSIONS O
: O
_RARE_ I-GENE
horizontal O
_RARE_ I-GENE
_RARE_ I-GENE
is O
rare O
and O
its O
cause O
is O
unknown O
. O

A I-GENE
local O
, O
high O
- I-GENE
density I-GENE
, O
single O
- I-GENE
nucleotide I-GENE
polymorphism O
map O
used O
to O
clone O
Caenorhabditis I-GENE
elegans I-GENE
_RARE_ I-GENE
- I-GENE
1 I-GENE
. O

This O
machinery O
involves O
a O
secondary O
structure O
, O
SECIS O
element I-GENE
, O
in O
the O
_RARE_ I-GENE
- I-GENE
encoding O
mRNA I-GENE
, O
_RARE_ I-GENE
selenocysteine I-GENE
insertion O
at O
the O
position O
of O
an O
_RARE_ I-GENE
( O
UGA O
) O
codon O
, O
normally O
conferring O
termination O
of O
translation I-GENE
. O

High O
- I-GENE
level O
expression O
in O
Escherichia I-GENE
coli I-GENE
of O
selenocysteine I-GENE
- I-GENE
containing O
rat I-GENE
_RARE_ I-GENE
reductase I-GENE
utilizing O
gene I-GENE
fusions I-GENE
with O
engineered I-GENE
bacterial I-GENE
- I-GENE
type I-GENE
SECIS O
elements O
and O
co O
- I-GENE
expression O
with O
the O
_RARE_ I-GENE
, O
_RARE_ I-GENE
and O
_RARE_ I-GENE
genes I-GENE
. O

In O
Wnt I-GENE
signaling O
, O
beta I-GENE
- I-GENE
catenin I-GENE
and O
plakoglobin I-GENE
_RARE_ I-GENE
signals O
to O
the O
nucleus O
through O
interactions O
with O
TCF I-GENE
- I-GENE
type I-GENE
transcription I-GENE
factors I-GENE
. O

_RARE_ I-GENE
of O
a O
complex I-GENE
between O
FAK I-GENE
and O
Src I-GENE
kinases I-GENE
may O
serve O
to O
regulate O
the O
subcellular O
localization O
and O
the O
enzymatic O
activity O
of O
members O
of O
the O
Src I-GENE
family I-GENE
of O
kinases I-GENE
. O

For O
_RARE_ I-GENE
3 I-GENE
, O
10 O
, O
or O
40 I-GENE
, O
the O
_RARE_ I-GENE
_RARE_ I-GENE
25 O
% O
for O
7 O
, O
3 I-GENE
, O
and O
1 I-GENE
in O
the O
8 O
- I-GENE
predictor O
model O
respectively O
, O
when O
a O
conventional O
selection O
criterion O
was O
used O
( O
alpha I-GENE
= O
0 O
. O
05 O
). O

Our O
study O
also O
demonstrated O
significant O
increases O
in O
the O
number O
of O
larger O
_RARE_ I-GENE
fibers O
_RARE_ I-GENE
the O
repair I-GENE
site I-GENE
in O
comparison O
with O
the O
neonatal O
and O
adult O
groups O
( O
p O
< O
0 O
. O
04 O
). O

_RARE_ I-GENE
( O
2 I-GENE
) O
_RARE_ I-GENE
- I-GENE
induced O
neuronal O
differentiation O
of O
_RARE_ I-GENE
- I-GENE
115 I-GENE
neuroblastoma O
cells O
increased O
both O
the O
expression O
of O
the O
endogenous I-GENE
_RARE_ I-GENE
- I-GENE
1 I-GENE
gene I-GENE
and O
reporter I-GENE
genes I-GENE
driven O
by O
_RARE_ I-GENE
- I-GENE
1 I-GENE
promoter I-GENE
sequences I-GENE
by O
3 I-GENE
- I-GENE
4 I-GENE
- I-GENE
fold O
. O

_RARE_ I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
. O

In O
the O
work O
reported O
here O
, O
we O
used O
peptide I-GENE
mapping O
, O
mass O
spectrometry O
, O
and O
site I-GENE
- I-GENE
directed O
mutagenesis O
to O
identify O
two O
sets O
of O
_RARE_ I-GENE
phosphorylation O
sites I-GENE
. O

Both O
_RARE_ I-GENE
- I-GENE
K I-GENE
type I-GENE
1 I-GENE
and O
2 I-GENE
clones O
were O
isolated O
. O

_RARE_ I-GENE
, O
and O
F I-GENE
. O

At O
all O
time O
- I-GENE
points O
, O
most O
patients O
_RARE_ I-GENE
87 O
%) O
were O
receiving O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
alone O
. O

_RARE_ I-GENE
of O
dopamine I-GENE
D2 I-GENE
receptor I-GENE
activity O
by O
_RARE_ I-GENE
in O
Parkinson O
' O
s O
disease O
: O
an O
in O
vivo O
study O
by O
PET O
. O

High O
- I-GENE
affinity O
binding I-GENE
sites I-GENE
for O
both O
GR I-GENE
and O
AP I-GENE
- I-GENE
1 I-GENE
_RARE_ I-GENE
were O
identified O
at O
adjacent O
elements O
within O
the O
_RARE_ I-GENE
. O

When O
the O
73 O
- I-GENE
bp O
fragment I-GENE
was O
fused O
to O
an O
alpha1 I-GENE
- I-GENE
globin I-GENE
promoter I-GENE
- I-GENE
CAT I-GENE
construct I-GENE
and O
cotransfected O
with O
CCAAT I-GENE
transcription I-GENE
factor I-GENE
1 I-GENE
( O
_RARE_ I-GENE
)/ O
NF1 I-GENE
into O
Drosophila I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
insect O
cells O
( O
which O
lack O
NF1 I-GENE
- I-GENE
like I-GENE
proteins I-GENE
) O
trans O
- I-GENE
activation O
of O
CAT I-GENE
activity O
was O
observed O
. O

Western O
blot O
analysis O
showed O
a O
rapid O
corresponding O
increase O
in O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
protein I-GENE
, O
whereas O
protein I-GENE
levels O
of O
another O
member O
of O
the O
cyclin I-GENE
- I-GENE
dependent I-GENE
kinase I-GENE
inhibitor I-GENE
family I-GENE
, O
_RARE_ I-GENE
, O
were O
unchanged O
. O

_RARE_ I-GENE
of O
_RARE_ I-GENE
- I-GENE
deficient O
embryonic O
stem O
cells O
with O
wild I-GENE
- I-GENE
type I-GENE
_RARE_ I-GENE
embryos O
, O
which O
contribute O
exclusively O
to O
_RARE_ I-GENE
tissues O
, O
_RARE_ I-GENE
_RARE_ I-GENE
lethality O
and O
allows O
development O
to O
progress O
to O
early I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
- I-GENE
1 I-GENE
and O
_RARE_ I-GENE
- I-GENE
2 I-GENE
, O
two O
genes I-GENE
related I-GENE
to O
Drosophila I-GENE
_RARE_ I-GENE
, O
regulate O
_RARE_ I-GENE
germ I-GENE
cell O
development O
and O
survival O
in O
Caenorhabditis I-GENE
elegans I-GENE
. O

Although O
upstream O
regulators O
of O
_RARE_ I-GENE
family I-GENE
kinases I-GENE
are O
relatively O
well O
characterized O
, O
little O
is O
known O
of O
the O
downstream O
effectors I-GENE
of O
these O
enzymes O
. O

_RARE_ I-GENE
phosphorylation O
of O
_RARE_ I-GENE
by O
_RARE_ I-GENE
required O
the O
PH I-GENE
and O
SH2 I-GENE
domains I-GENE
as O
well O
as O
the O
kinase I-GENE
domain I-GENE
of O
the O
latter O
. O

CONCLUSION O
: O
These O
findings O
imply O
that O
_RARE_ I-GENE
either O
is O
_RARE_ I-GENE
involved O
in O
acute O
asthma O
or O
serves O
as O
a O
_RARE_ I-GENE
for O
activity O
of O
the O
_RARE_ I-GENE
receptor I-GENE
ligand O
system O
, O
which O
is O
functionally O
linked O
to O
asthma O
. O

The O
expression O
analysis O
of O
the O
_RARE_ I-GENE
gene I-GENE
under O
phosphate I-GENE
starvation O
or O
high O
adenine O
supply O
shows O
that O
factors I-GENE
, O
such O
as O
_RARE_ I-GENE
or O
_RARE_ I-GENE
, O
involved O
in O
the O
basal O
control O
may O
also O
_RARE_ I-GENE
in O
a O
different O
way O
in O
K I-GENE
. O
lactis O
. O

These O
thyroid I-GENE
hormone I-GENE
changes O
may O
be O
mediated O
in O
part O
by O
cytokines O
or O
other O
inflammatory O
_RARE_ I-GENE
, O
acting O
at O
the O
level O
of O
the O
hypothalamus O
and O
pituitary I-GENE
gland O
, O
the O
thyroid I-GENE
gland O
, O
and O
the O
hepatic I-GENE
deiodinase I-GENE
system O
. O

_RARE_ I-GENE
type I-GENE
1 I-GENE
, O
with O
_RARE_ I-GENE
low O
and O
_RARE_ I-GENE
and O
TSH I-GENE
normal O
, O
is O
the O
most O
frequent O
form O
. O

METHODS O
: O
We O
studied O
20 O
symptomatic O
patients O
with O
_RARE_ I-GENE
( O
12 O
men O
), O
mean O
age O
52 O
+/- O
17 O
years O
, O
before O
and O
after O
septal O
reduction O
using O
echocardiography O
and O
electrocardiogram O
( O
ECG O
). O

_RARE_ I-GENE
data O
from O
the O
_RARE_ I-GENE
_RARE_ I-GENE
, O
used O
as O
a O
_RARE_ I-GENE
for O
sea O
surface O
temperature O
, O
reveal O
that O
surface O
slope O
_RARE_ I-GENE
_RARE_ I-GENE
of O
the O
_RARE_ I-GENE
_RARE_ I-GENE
experienced O
_RARE_ I-GENE
during O
the O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
of O
the O
_RARE_ I-GENE
to O
_RARE_ I-GENE
_RARE_ I-GENE
and O
support O
the O
notion O
of O
an O
_RARE_ I-GENE
- I-GENE
driven O
coupled I-GENE
system O
. O

This O
effect O
required O
( O
i O
) O
IR I-GENE
activation O
since O
it O
was O
abrogated O
by O
IR I-GENE
mutation I-GENE
at O
_RARE_ I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
and O
( O
ii O
) O
NF I-GENE
- I-GENE
kappaB I-GENE
activation O
since O
it O
was O
abolished O
by O
overexpression O
of O
dominant I-GENE
- I-GENE
negative O
_RARE_ I-GENE
- I-GENE
alpha I-GENE
( O
_RARE_ I-GENE
/ I-GENE
36 O
) O
and O
mimicked O
by O
overexpression O
of O
the O
NF I-GENE
- I-GENE
kappaB I-GENE
c I-GENE
- I-GENE
Rel I-GENE
subunit I-GENE
. O

The O
factor I-GENE
designated O
B I-GENE
formed O
a O
complex I-GENE
centered O
on O
the O
sequence I-GENE
_RARE_ I-GENE
, O
a O
core I-GENE
motif I-GENE
recognized O
by O
members O
of O
the O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
transcription I-GENE
factor I-GENE
family I-GENE
. O

Furthermore O
, O
overexpression O
of O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
could O
rescue O
the O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
repression O
. O

We O
examined O
Akt I-GENE
activation O
in O
Lyn I-GENE
-, I-GENE
_RARE_ I-GENE
- I-GENE
and O
_RARE_ I-GENE
- I-GENE
deficient O
_RARE_ I-GENE
cells O
and O
B I-GENE
cells O
from O
Lyn I-GENE
_RARE_ I-GENE
mice O
. O

_RARE_ I-GENE
of O
G I-GENE
protein I-GENE
signaling O
( O
_RARE_ I-GENE
) O
proteins I-GENE
that O
contain O
_RARE_ I-GENE
( O
_RARE_ I-GENE
, O
_RARE_ I-GENE
- I-GENE
10 O
, O
pleckstrin I-GENE
) O
and O
_RARE_ I-GENE
( O
G I-GENE
protein I-GENE
gamma I-GENE
subunit I-GENE
- I-GENE
like I-GENE
) O
domains I-GENE
form O
a O
subfamily I-GENE
that O
includes O
the O
mammalian I-GENE
_RARE_ I-GENE
proteins I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
. O

Cloning O
and O
expression O
of O
a O
specific I-GENE
human I-GENE
alpha I-GENE
1 I-GENE
, O
2 I-GENE
- I-GENE
_RARE_ I-GENE
that O
_RARE_ I-GENE
_RARE_ I-GENE
to O
_RARE_ I-GENE
_RARE_ I-GENE
B I-GENE
during O
N I-GENE
- I-GENE
_RARE_ I-GENE
biosynthesis O
. O

The O
_RARE_ I-GENE
of O
GC I-GENE
, O
adjusted O
for O
age O
and O
sex I-GENE
, O
varied O
from O
17 O
. O
1 I-GENE
, O
for O
those O
with O
baseline O
_RARE_ I-GENE
of O
superficial O
intestinal O
_RARE_ I-GENE
( O
IM O
), O
to O
29 O
. O
3 I-GENE
, O
for O
those O
with O
deep O
IM O
or O
mild O
dysplasia O
( O
_RARE_ I-GENE
) O
or O
IM O
with O
_RARE_ I-GENE
atrophy O
and O
neck O
hyperplasia O
, O
to O
104 O
. O
2 I-GENE
, O
for O
those O
with O
moderate O
or O
severe O
_RARE_ I-GENE
, O
as O
compared O
with O
subjects O
with O
superficial O
_RARE_ I-GENE
( O
SG I-GENE
) O
or O
chronic O
_RARE_ I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
at O
baseline O
. O

Here O
we O
report O
that O
_RARE_ I-GENE
and O
_RARE_ I-GENE
interact O
through O
their O
_RARE_ I-GENE
domains I-GENE
. O

Thus O
, O
the O
nematode O
genes I-GENE
could O
be O
the O
homologs I-GENE
of O
_RARE_ I-GENE
molecules I-GENE
in O
other O
_RARE_ I-GENE
. O

A I-GENE
subset O
of O
mutations O
in O
the O
_RARE_ I-GENE
synthase I-GENE
domain I-GENE
_RARE_ I-GENE
association O
of O
the O
altered O
_RARE_ I-GENE
proteins I-GENE
with O
selected O
box I-GENE
H I-GENE
/ I-GENE
ACA I-GENE
_RARE_ I-GENE
, O
suggesting O
that O
the O
functional O
catalytic O
domain I-GENE
is O
essential O
for O
that O
interaction O
. O

Although O
the O
Src I-GENE
tyrosine I-GENE
kinase I-GENE
induces O
constitutive O
Stat3 I-GENE
phosphorylation O
on O
tyrosine I-GENE
, O
activation O
of O
Stat3 I-GENE
- I-GENE
mediated O
gene I-GENE
regulation O
requires O
both O
tyrosine I-GENE
and O
serine I-GENE
phosphorylation O
of O
Stat3 I-GENE
. O

The O
transcription I-GENE
factor I-GENE
CHOP I-GENE
( O
C I-GENE
/ I-GENE
EBP I-GENE
homologous O
protein I-GENE
10 O
) O
is O
a O
bZIP I-GENE
protein I-GENE
induced O
by O
a O
variety O
of O
stimuli O
that O
_RARE_ I-GENE
cellular O
stress O
responses O
and O
has O
been O
shown O
to O
arrest O
cell O
growth I-GENE
and O
to O
promote O
programmed O
cell O
death O
. O

Thus O
, O
CHOP I-GENE
not O
only O
is O
a O
negative O
or O
a O
positive O
regulator I-GENE
of O
C I-GENE
/ I-GENE
EBP I-GENE
target O
genes I-GENE
but O
also O
, O
when O
_RARE_ I-GENE
to O
AP I-GENE
- I-GENE
1 I-GENE
factors I-GENE
, O
can O
activate O
AP I-GENE
- I-GENE
1 I-GENE
target O
genes I-GENE
. O

This O
motif I-GENE
, O
first O
described O
for O
the O
Drosophila I-GENE
homeobox I-GENE
activator I-GENE
_RARE_ I-GENE
- I-GENE
1 I-GENE
, O
identifies O
an O
_RARE_ I-GENE
group O
of O
metazoan I-GENE
transcriptional O
_RARE_ I-GENE
. O

RNase I-GENE
MRP I-GENE
is O
a O
ribonucleoprotein I-GENE
_RARE_ I-GENE
that O
has O
been O
shown O
to O
have O
roles O
in O
both O
mitochondrial I-GENE
DNA I-GENE
replication O
and O
nuclear I-GENE
5 I-GENE
. O
_RARE_ I-GENE
rRNA I-GENE
processing O
. O

We O
have O
examined O
the O
regulation O
of O
the O
FGFR I-GENE
- I-GENE
1 I-GENE
gene I-GENE
( O
_RARE_ I-GENE
- I-GENE
1 I-GENE
) O
in O
avian I-GENE
myogenic I-GENE
cultures O
by O
_RARE_ I-GENE
and O
Northern O
blot O
analysis O
. O

Regulation O
of O
avian I-GENE
fibroblast I-GENE
growth I-GENE
factor I-GENE
receptor I-GENE
1 I-GENE
( O
FGFR I-GENE
- I-GENE
1 I-GENE
) O
gene I-GENE
expression O
during O
skeletal I-GENE
muscle O
differentiation O
. O

The O
_RARE_ I-GENE
dynamics O
of O
residues O
located O
in O
the O
folded O
part O
of O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
_RARE_ I-GENE
have O
been O
characterized O
by O
proton I-GENE
- I-GENE
detected O
( O
15 O
) O
N I-GENE
NMR O
spectroscopy O
. O

Rac I-GENE
causes O
_RARE_ I-GENE
of O
actin I-GENE
_RARE_ I-GENE
( O
F I-GENE
- I-GENE
actin I-GENE
) O
at O
the O
plus O
- I-GENE
ends O
, O
through O
phosphatidylinositol I-GENE
4 I-GENE
, O
5 I-GENE
_RARE_ I-GENE
( O
PIP2 O
), O
and O
_RARE_ I-GENE
induces O
membrane I-GENE
_RARE_ I-GENE
. O

However O
, O
a O
specific I-GENE
ICE I-GENE
/ I-GENE
_RARE_ I-GENE
- I-GENE
1 I-GENE
inhibitor I-GENE
called O
_RARE_ I-GENE
completely O
abolished O
the O
CK I-GENE
- I-GENE
induced O
apoptosis O
by O
_RARE_ I-GENE
PKB I-GENE
, O
but O
without O
affecting O
the O
CK I-GENE
- I-GENE
induced O
suppression O
of O
Ras I-GENE
transformation O
. O

OBJECTIVE O
: O
Although O
the O
_RARE_ I-GENE
of O
findings O
offer O
support O
for O
transient O
( O
where O
is O
it O
_RARE_ I-GENE
as O
opposed O
to O
sustained O
( O
what O
is O
it O
_RARE_ I-GENE
deficit O
, O
a O
need O
remains O
for O
specific I-GENE
_RARE_ I-GENE
of O
the O
deficit O
. O

The O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
: O
the O
next O
generation O
_RARE_ I-GENE
_RARE_ I-GENE
for O
plutonium O
_RARE_ I-GENE
at O
the O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
. O

RESULTS O
: O
Factors O
associated I-GENE
with O
significantly O
( O
P I-GENE
_RARE_ I-GENE
05 O
) O
increased O
risk O
of O
treatment O
failure O
in O
a O
Cox O
multivariate O
analysis O
included O
age O
older O
than O
45 O
years O
( O
relative O
_RARE_ I-GENE
, O
1 I-GENE
. O
17 O
; O
95 O
% O
confidence O
interval O
[ O
CI O
], O
1 I-GENE
. O
02 O
- I-GENE
1 I-GENE
. O
33 O
), O
_RARE_ I-GENE
performance O
score O
less O
than O
90 O
% O
( O
1 I-GENE
. O
27 O
; O
95 O
% O
CI O
, O
1 I-GENE
. O
07 O
- I-GENE
1 I-GENE
. O
51 O
), O
absence O
of O
hormone I-GENE
receptors I-GENE
( O
1 I-GENE
. O
31 O
; O
95 O
% O
CI O
, O
1 I-GENE
. O
15 O
- I-GENE
1 I-GENE
. O
51 O
), O
prior O
use O
of O
adjuvant O
chemotherapy O
( O
1 I-GENE
. O
31 O
; O
95 O
% O
CI O
, O
1 I-GENE
. O
10 O
- I-GENE
1 I-GENE
. O
56 O
), O
initial O
disease O
- I-GENE
free O
survival O
interval O
after O
adjuvant O
treatment O
of O
no O
more O
than O
18 O
months O
( O
1 I-GENE
. O
99 O
; O
95 O
% O
CI O
, O
1 I-GENE
. O
62 O
- I-GENE
2 I-GENE
. O
43 I-GENE
), O
metastases O
in O
the O
liver O
( O
1 I-GENE
. O
47 O
; O
95 O
% O
CI O
, O
1 I-GENE
. O
20 O
- I-GENE
1 I-GENE
. O
80 O
) O
or O
central O
nervous O
system O
( O
1 I-GENE
. O
56 O
; O
95 O
% O
CI O
, O
0 O
. O
99 O
- I-GENE
2 I-GENE
. O
46 O
[ O
approaches O
significance O
]) I-GENE
vs O
soft O
tissue I-GENE
, O
bone O
, O
or O
lung O
, O
3 I-GENE
or O
more O
sites I-GENE
of O
metastatic O
disease O
( O
1 I-GENE
. O
32 O
; O
95 O
% O
CI O
, O
1 I-GENE
. O
13 O
- I-GENE
1 I-GENE
. O
54 I-GENE
), O
and O
incomplete O
response O
vs O
complete O
response O
to O
standard O
- I-GENE
dose O
chemotherapy O
( O
1 I-GENE
. O
65 O
; O
95 O
% O
CI O
, O
1 I-GENE
. O
36 O
- I-GENE
1 I-GENE
. O
99 O
). O

One O
form O
of O
the O
_RARE_ I-GENE
gene I-GENE
transcript I-GENE
in O
12 O
- I-GENE
day O
old O
_RARE_ I-GENE
contained O
the O
exon O
I I-GENE
+ I-GENE
II I-GENE
+ I-GENE
III I-GENE
combination O
at O
the O
5 I-GENE
' O
end O
, O
whereas O
other O
forms O
differed O
by O
inclusion O
of O
intron O
1 I-GENE
or O
exclusion O
of O
exon O
II I-GENE
sequences I-GENE
. O

In O
PC I-GENE
, O
rare O
_RARE_ I-GENE
had O
_RARE_ I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
. O

16 O
percent O
, O
P I-GENE
< O
0 O
. O
001 O
), O
and O
sustained O
_RARE_ I-GENE
of O
serum I-GENE
alanine I-GENE
aminotransferase I-GENE
levels O
( O
41 O
percent O
vs O
. O

Its O
C I-GENE
- I-GENE
terminal I-GENE
catalytic O
domain I-GENE
was O
found O
to O
be O
highly O
conserved O
in O
the O
homologues O
_RARE_ I-GENE
( O
ras I-GENE
- I-GENE
_RARE_ I-GENE
) O
and O
Sos I-GENE
. O

_RARE_ I-GENE
, O
93 O
- I-GENE
98 O
]. O

The O
proteasome I-GENE
is O
a O
large O
complex I-GENE
consisting O
of O
two O
multisubunit I-GENE
structures O
, O
the O
20S I-GENE
and O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
or O
_RARE_ I-GENE
complexes I-GENE
, O
that O
_RARE_ I-GENE
to O
form O
the O
_RARE_ I-GENE
particles O
. O

In O
assays O
with O
purified O
enzymes O
, O
wild I-GENE
- I-GENE
type I-GENE
but O
not O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
was O
a O
specific I-GENE
substrate I-GENE
for O
the O
cGMP I-GENE
- I-GENE
dependent I-GENE
protein I-GENE
kinase I-GENE
( O
_RARE_ I-GENE
) O
type I-GENE
I I-GENE
and O
II I-GENE
. O

R I-GENE
., O
_RARE_ I-GENE
, O
R I-GENE
., O
_RARE_ I-GENE
, O
J O
. O

The O
N I-GENE
- I-GENE
terminal I-GENE
domain I-GENE
of O
approximately O
70 I-GENE
kDa I-GENE
exhibits O
11 O
_RARE_ I-GENE
amino O
acid I-GENE
repeats I-GENE
that O
show O
some O
homology I-GENE
to O
_RARE_ I-GENE
surface O
glycoproteins I-GENE
of O
the O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
complex I-GENE
. O

In O
contrast O
to O
previously O
characterized O
_RARE_ I-GENE
, O
the O
_RARE_ I-GENE
gene I-GENE
product I-GENE
is O
predominantly O
membrane I-GENE
- I-GENE
associated I-GENE
and O
it O
is O
expressed O
on O
the O
_RARE_ I-GENE
cell O
surface O
. O

Most O
important O
, O
infection O
of O
the O
cells O
with O
an O
_RARE_ I-GENE
construct I-GENE
expressing O
this O
mutant I-GENE
inhibited O
the O
induction O
of O
VEGF I-GENE
mRNA I-GENE
under O
conditions O
that O
mimic O
hypoxia O
. O

_RARE_ I-GENE
stimulates O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
, O
members O
of O
the O
ErbB I-GENE
family I-GENE
of O
receptor I-GENE
tyrosine I-GENE
kinases I-GENE
. O

Our O
results O
suggest O
that O
_RARE_ I-GENE
is O
the O
yeast I-GENE
homologue I-GENE
of O
mammalian I-GENE
epsilon I-GENE
- I-GENE
_RARE_ I-GENE
and O
the O
_RARE_ I-GENE
accumulation O
of O
the O
ER I-GENE
membrane I-GENE
caused O
by O
a O
_RARE_ I-GENE
of O
the O
early I-GENE
protein I-GENE
transport O
pathway O
leads O
to O
alteration O
of O
nuclear I-GENE
morphology O
of O
the O
budding I-GENE
yeast I-GENE
cells O
. O

In O
PC12 O
cells O
, O
nerve I-GENE
growth I-GENE
factor I-GENE
induces O
neuronal O
differentiation O
and O
repressed O
expression O
of O
_RARE_ I-GENE
- I-GENE
1 I-GENE
. O

In O
a O
PC12 O
cell O
mutant I-GENE
that O
is O
deficient O
in O
protein I-GENE
kinase I-GENE
A I-GENE
activity O
( O
_RARE_ I-GENE
. O
11 O
), O
all O
three O
differentiating O
agents O
were O
unable O
to O
down O
- I-GENE
regulate O
_RARE_ I-GENE
- I-GENE
1 I-GENE
mRNA I-GENE
. O

_RARE_ I-GENE
mutations O
include O
two O
nonsense O
mutations O
, O
four O
insertions O
, O
and O
three O
splice O
mutations O
. O

_RARE_ I-GENE
patients O
without O
abnormalities O
in O
the O
_RARE_ I-GENE
are O
assumed O
to O
harbor O
missense O
mutations O
, O
probably O
in O
_RARE_ I-GENE
. O

The O
first O
algorithm O
, O
_RARE_ I-GENE
, O
is O
a O
fast O
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
algorithm O
that O
allows O
_RARE_ I-GENE
of O
the O
3 I-GENE
- I-GENE
D I-GENE
attenuation O
correction O
factors I-GENE
( O
_RARE_ I-GENE
' O
s O
) O
directly O
from O
a O
two O
- I-GENE
dimensional O
( O
2 I-GENE
- I-GENE
D I-GENE
) O
transmission O
scan O
, O
without O
first O
_RARE_ I-GENE
the O
attenuation O
map O
and O
then O
_RARE_ I-GENE
a O
3 I-GENE
- I-GENE
D I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
. O

We O
have O
cloned O
cDNA I-GENE
and O
genomic O
DNA I-GENE
for O
a O
mouse I-GENE
gene I-GENE
encoding O
a O
protein I-GENE
with O
significant O
sequence I-GENE
similarity O
to O
conserved O
domains I-GENE
found O
in O
proteins I-GENE
of O
the O
_RARE_ I-GENE
family I-GENE
. O

RT I-GENE
- I-GENE
PCR O
and O
in O
situ O
hybridization O
analyses O
of O
a O
time O
course O
of O
juvenile O
testis I-GENE
development O
indicate O
that O
_RARE_ I-GENE
expression O
begins O
in O
early I-GENE
meiotic I-GENE
_RARE_ I-GENE
I I-GENE
, O
prior O
to O
the O
_RARE_ I-GENE
stage O
, O
with O
increasing O
accumulation O
of O
mRNA I-GENE
through O
the O
_RARE_ I-GENE
stage O
. O

Animals O
were O
_RARE_ I-GENE
to O
death O
8 O
weeks O
later O
and O
the O
grafts O
were O
_RARE_ I-GENE
_RARE_ I-GENE
and O
analyzed O
via O
_RARE_ I-GENE
culture O
and O
standard O
histologic O
procedures O
for O
evidence O
of O
infection O
. O

The O
_RARE_ I-GENE
was O
measured O
twice O
in O
each O
phase O
and O
found O
to O
be O
similar O
( O
F I-GENE
( O
1 I-GENE
, O
18 O
) O
= O
0 O
. O
_RARE_ I-GENE
) O
across O
the O
follicular O
( O
_RARE_ I-GENE
_RARE_ I-GENE
/ I-GENE
24 O
h O
) O
and O
the O
luteal O
( O
_RARE_ I-GENE
_RARE_ I-GENE
/ I-GENE
24 O
h O
) O
phases O
. O

_RARE_ I-GENE
( O
_RARE_ I-GENE
), O
which O
can O
be O
administered O
orally O
, O
is O
the O
_RARE_ I-GENE
of O
_RARE_ I-GENE
, O
a O
potent O
and O
selective O
inhibitor I-GENE
of O
_RARE_ I-GENE
_RARE_ I-GENE
. O

In O
gel O
mobility I-GENE
shift O
assays O
, O
we O
found O
no O
evidence O
for O
VDR I-GENE
- I-GENE
TR I-GENE
heterodimer O
interaction O
with O
any O
tested O
element I-GENE
. O

The O
relative O
importance O
of O
these O
two O
mechanisms O
differed O
in O
a O
response O
element I-GENE
- I-GENE
specific I-GENE
manner O
. O

After O
14 O
d O
of O
_RARE_ I-GENE
, O
hepatic I-GENE
PL I-GENE
profiles O
were O
identical O
in O
the O
two O
_RARE_ I-GENE
and O
similar O
to O
that O
in O
control O
_RARE_ I-GENE
; O
_RARE_ I-GENE
- I-GENE
containing O
PL I-GENE
_RARE_ I-GENE
for O
95 O
% O
of O
total O
PL I-GENE
. O

C I-GENE
- I-GENE
SP I-GENE
duration O
was O
significantly O
reduced O
in O
_RARE_ I-GENE
patients O
compared O
to O
controls O
at O
low O
stimulation O
intensity O
corresponding O
to O
an O
_RARE_ I-GENE
threshold O
increased O
by O
15 O
%. O

These O
data O
show O
that O
the O
_RARE_ I-GENE
virulence I-GENE
genes I-GENE
belong O
simultaneously O
to O
several O
_RARE_ I-GENE
in O
the O
cell O
, O
_RARE_ I-GENE
the O
possibility O
that O
_RARE_ I-GENE
expression O
can O
be O
fine O
- I-GENE
_RARE_ I-GENE
in O
response O
to O
multiple O
environmental O
inputs O
. O

_RARE_ I-GENE
synthesis O
of O
_RARE_ I-GENE
in O
the O
cells O
of O
microvascular O
wall O
_RARE_ I-GENE
of O
their O
high O
functional O
activity O
, O
and O
the O
synthesis O
of O
DNA I-GENE
in O
them O
showed O
their O
ability O
for O
proliferation O
, O
i O
. O
g O
_RARE_ I-GENE
for O
growth I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
combined O
with O
_RARE_ I-GENE
ligation O
( O
_RARE_ I-GENE
& O
PL I-GENE
) O
_RARE_ I-GENE
a O
reduction O
of O
19 O
. O
9 O
% O
( O
n O
. O
s O
.). O

_RARE_ I-GENE
- I-GENE
deficient O
erbB I-GENE
proteins I-GENE
reduced O
epidermal I-GENE
growth I-GENE
factor I-GENE
( O
EGF I-GENE
)- I-GENE
induced O
tyrosine I-GENE
phosphorylation O
of O
endogenous I-GENE
Shc I-GENE
proteins I-GENE
and O
also O
reduced O
immediate I-GENE
and O
sustained O
EGF I-GENE
- I-GENE
induced O
ERK I-GENE
MAPK I-GENE
activities O
in O
human I-GENE
_RARE_ I-GENE
cells O
, O
although O
basal O
ERK I-GENE
MAPK I-GENE
activities O
were O
unaffected O
. O

Using O
_RARE_ I-GENE
, O
we O
observe O
that O
_RARE_ I-GENE
, O
a O
440 O
- I-GENE
bp O
_RARE_ I-GENE
element I-GENE
that O
contains O
information O
sufficient O
to O
drive O
amplification O
, O
directs O
_RARE_ I-GENE
localization O
in O
follicle I-GENE
cells O
. O

Therefore O
, O
homozygous O
co O
- I-GENE
deletions O
of O
_RARE_ I-GENE
and O
_RARE_ I-GENE
rather O
than O
mutations O
targeting O
individual O
transcripts I-GENE
are O
frequently O
selected O
for O
in O
these O
tumors O
. O

Here O
, O
we O
show O
that O
aortic O
_RARE_ I-GENE
isolated O
from O
PPARalpha I-GENE
- I-GENE
null I-GENE
mice O
display O
an O
_RARE_ I-GENE
response O
to O
inflammatory O
stimuli O
, O
such O
as O
lipopolysaccharide O
( O
LPS I-GENE
), O
as O
demonstrated O
by O
increased O
IL I-GENE
- I-GENE
6 I-GENE
secretion O
. O

_RARE_ I-GENE
expression O
is O
maintained O
in O
the O
liver O
by O
a O
combination O
of O
liver O
- I-GENE
enriched O
transcription I-GENE
factors I-GENE
such O
as O
CAAT I-GENE
enhancer I-GENE
- I-GENE
binding I-GENE
protein I-GENE
( O
C I-GENE
/ I-GENE
EBP I-GENE
) O
alpha I-GENE
and O
C I-GENE
/ I-GENE
EBPbeta I-GENE
. O

The O
requirement O
for O
proteolytic O
activity O
of O
both O
_RARE_ I-GENE
and O
_RARE_ I-GENE
suggests O
that O
protease I-GENE
- I-GENE
activated I-GENE
receptors I-GENE
may O
be O
involved O
. O

_RARE_ I-GENE
beta I-GENE
- I-GENE
protein I-GENE
( O
_RARE_ I-GENE
) O
is O
the O
main O
_RARE_ I-GENE
of O
_RARE_ I-GENE
_RARE_ I-GENE
found O
in O
senile O
_RARE_ I-GENE
and O
cerebral O
vessels O
in O
Alzheimer I-GENE
' O
s O
disease O
( O
AD O
) O
and O
is O
derived O
by O
proteolysis O
from O
the O
beta I-GENE
- I-GENE
_RARE_ I-GENE
precursor I-GENE
protein I-GENE
( O
_RARE_ I-GENE
). O

We O
also O
show O
that O
activation O
of O
protein I-GENE
kinase I-GENE
A I-GENE
( O
PKA I-GENE
) O
signaling O
is O
sufficient O
to O
down O
- I-GENE
regulate O
_RARE_ I-GENE
- I-GENE
1 I-GENE
protein I-GENE
expression O
and O
promoter I-GENE
activity O
. O

The O
_RARE_ I-GENE
alpha I-GENE
. O
beta I-GENE
heterodimer O
mediates O
nuclear I-GENE
import O
of O
proteins I-GENE
containing O
classical O
nuclear I-GENE
localization O
signals O
. O

The O
expressed O
G1 I-GENE
- I-GENE
G2 I-GENE
bound O
to O
both O
_RARE_ I-GENE
and O
link I-GENE
protein I-GENE
indicating O
that O
the O
immunoglobulin I-GENE
- I-GENE
fold O
motif I-GENE
and O
proteoglycan I-GENE
tandem O
repeat I-GENE
loops O
of O
the O
G1 I-GENE
domain I-GENE
were O
correctly O
folded O
. O

The O
results O
suggest O
that O
the O
presence O
or O
absence O
per O
_RARE_ I-GENE
of O
_RARE_ I-GENE
sulfate I-GENE
on O
native O
G1 I-GENE
- I-GENE
G2 I-GENE
does O
not O
affect O
the O
activity O
of O
_RARE_ I-GENE
C I-GENE
toward O
the O
two O
sites I-GENE
. O

Despite O
i O
. O
v I-GENE
. O
steroid I-GENE
therapy O
, O
[ O
_RARE_ I-GENE
] O
remained O
elevated O
throughout O
recovery O
( O
37 O
. O
9 O
+/- O
4 I-GENE
. O
8 O
ppb O
, O
p O
< O
0 O
. O
001 O
) O
until O
discharge O
( O
40 I-GENE
. O
9 O
+/- O
4 I-GENE
. O
3 I-GENE
ppb O
, O
p O
< O
0 O
. O
001 O
). O

It O
contains O
binding I-GENE
sites I-GENE
for O
several O
transcription I-GENE
factors I-GENE
, O
for O
example O
: O
( O
i O
) O
a O
well O
- I-GENE
characterized O
binding I-GENE
site I-GENE
for O
rel I-GENE
/ I-GENE
NF I-GENE
- I-GENE
kappaB I-GENE
transcription I-GENE
factors I-GENE
in O
its O
3 I-GENE
'- O
end O
( O
the O
_RARE_ I-GENE
or O
_RARE_ I-GENE
element I-GENE
), O
( O
ii O
) O
a O
second O
kappaB I-GENE
site I-GENE
( O
the O
_RARE_ I-GENE
element I-GENE
), O
which O
is O
located O
immediately O
adjacent O
5 I-GENE
' O
to O
the O
_RARE_ I-GENE
element I-GENE
and O
which O
is O
recognized O
by O
p65 I-GENE
/ I-GENE
_RARE_ I-GENE
in O
the O
human I-GENE
HLA I-GENE
system O
, O
and O
( O
iii O
) O
an O
AP I-GENE
- I-GENE
1 I-GENE
/ I-GENE
ATF I-GENE
recognition I-GENE
sequence I-GENE
in O
the O
5 I-GENE
' O
end O
( O
_RARE_ I-GENE
- I-GENE
TRE I-GENE
). O

The O
tumorigenic O
E1A I-GENE
+ I-GENE
_RARE_ I-GENE
- I-GENE
ras I-GENE
cells O
are O
characterized O
by O
high O
and O
constitutive O
DNA I-GENE
binding I-GENE
activities O
of O
AP I-GENE
- I-GENE
1 I-GENE
, O
in O
contrast O
to O
_RARE_ I-GENE
cells O
and O
the O
E1A I-GENE
cells O
. O

The O
yeast I-GENE
C I-GENE
- I-GENE
type I-GENE
cyclin I-GENE
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
and O
its O
cyclin I-GENE
- I-GENE
dependent I-GENE
kinase I-GENE
( O
Cdk I-GENE
) O
_RARE_ I-GENE
are O
required O
for O
the O
full I-GENE
repression O
of O
genes I-GENE
involved O
in O
the O
stress O
response O
or O
meiosis O
. O

In O
particular O
, O
the O
S1 I-GENE
' O
specificity O
site I-GENE
is O
a O
deep O
and O
highly O
hydrophobic O
cavity O
. O

_RARE_ I-GENE
is O
homologous O
to O
_RARE_ I-GENE
and O
_RARE_ I-GENE
, O
and O
overall O
amino O
acid I-GENE
identity O
is O
as O
follows O
: O
_RARE_ I-GENE
vs O
_RARE_ I-GENE
, O
51 O
. O
6 I-GENE
%; O
_RARE_ I-GENE
vs O
_RARE_ I-GENE
, O
51 O
. O
2 I-GENE
%; O
_RARE_ I-GENE
vs O
_RARE_ I-GENE
, O
65 O
. O
7 O
%. O

The O
NF I-GENE
- I-GENE
kappaB I-GENE
responsive I-GENE
reporter I-GENE
construct I-GENE
, O
( O
_RARE_ I-GENE
)( I-GENE
4 I-GENE
)- I-GENE
CAT I-GENE
, O
was O
used O
to O
explore O
transcription I-GENE
resulting O
from O
NF I-GENE
- I-GENE
kappaB I-GENE
activated I-GENE
by O
Tat I-GENE
. O

The O
RNA I-GENE
transcripts I-GENE
structurally O
equivalent O
to O
I I-GENE
( O
2 I-GENE
) O
_RARE_ I-GENE
of O
_RARE_ I-GENE
U1 I-GENE
and O
_RARE_ I-GENE
, O
but O
containing O
a O
hairpin O
structure O
( O
H I-GENE
) O
immediately O
upstream O
of O
_RARE_ I-GENE
( O
MP I-GENE
, O
75 O
) O
( O
_RARE_ I-GENE
( O
MP I-GENE
), O
( O
75 O
)( I-GENE
CR I-GENE
)- I-GENE
MP I-GENE
- I-GENE
CP I-GENE
- I-GENE
3 I-GENE
' O
UTR I-GENE
; O
_RARE_ I-GENE
( O
MP I-GENE
, O
75 O
)( I-GENE
U1 I-GENE
)- I-GENE
MP I-GENE
- I-GENE
CP I-GENE
- I-GENE
3 I-GENE
' O
UTR I-GENE
), O
were O
able O
to O
express O
the O
MP I-GENE
gene I-GENE
in O
vitro O
. O

_RARE_ I-GENE
LTR I-GENE
sequence I-GENE
variability O
is O
confined O
mostly O
to O
a O
small I-GENE
portion O
of O
the O
enhancer I-GENE
within O
the O
U3 I-GENE
segment O
of O
the O
LTR I-GENE
. O

_RARE_ I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
requirement O
in O
activation O
of O
the O
ras I-GENE
/ I-GENE
C I-GENE
- I-GENE
raf I-GENE
- I-GENE
1 I-GENE
/ I-GENE
MEK I-GENE
/ I-GENE
ERK I-GENE
and O
p70 I-GENE
( O
_RARE_ I-GENE
) O
signaling O
cascade O
by O
the O
_RARE_ I-GENE
agent O
_RARE_ I-GENE
sulfate I-GENE
. O

The O
core I-GENE
of O
this O
enhancer I-GENE
contains O
two O
evolutionarily O
conserved O
binding I-GENE
sites I-GENE
for O
the O
homeodomain I-GENE
protein I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
), O
expressed O
in O
developing O
cardiac O
, O
somatic O
, O
and O
visceral O
muscle O
lineages O
. O

For O
example O
, O
introduction O
of O
_RARE_ I-GENE
and O
purification O
tag O
sequences I-GENE
into O
the O
C I-GENE
- I-GENE
terminal I-GENE
coding O
region O
significantly O
decreased O
_RARE_ I-GENE
gene I-GENE
mRNA I-GENE
and O
protein I-GENE
accumulation O
. O

Furthermore O
, O
the O
striking O
ability O
of O
_RARE_ I-GENE
middle I-GENE
T I-GENE
antigens I-GENE
to O
promote O
retinoic I-GENE
acid I-GENE
- I-GENE
induced O
differentiation O
appears O
to O
_RARE_ I-GENE
ERK I-GENE
, O
but O
not O
JNK I-GENE
/ I-GENE
SPK I-GENE
or O
p38 I-GENE
signaling O
. O

We O
_RARE_ I-GENE
that O
_RARE_ I-GENE
block O
with O
_RARE_ I-GENE
should O
be O
used O
in O
conjunction O
with O
i O
. O
v I-GENE
. O
sedation O
/ I-GENE
analgesia O
during O
egg I-GENE
collection O
performed O
through O
the O
_RARE_ I-GENE
route O
under O
ultrasound O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
to O
reduce O
the O
pain O
of O
the O
procedure O
. O

All O
loci I-GENE
have O
a O
similar O
organization O
, O
except O
for O
H1 I-GENE
. O
8 O
that O
_RARE_ I-GENE
two O
_RARE_ I-GENE
genes I-GENE
arranged O
in O
tandem O
and O
separated O
by O
a O
short O
repetitive O
sequence I-GENE
, O
named O
_RARE_ I-GENE
( O
short O
interspersed O
repetitive O
element I-GENE
), O
which O
is O
also O
found O
upstream O
of O
the O
first O
gene I-GENE
of O
the O
tandem O
and O
downstream O
of O
the O
second O
. O

A I-GENE
proportion O
of O
APC I-GENE
wild I-GENE
- I-GENE
type I-GENE
colon O
carcinomas O
and O
melanomas O
also O
contains O
constitutive O
nuclear I-GENE
_RARE_ I-GENE
- I-GENE
4 I-GENE
/ I-GENE
beta I-GENE
- I-GENE
catenin I-GENE
complexes I-GENE
as O
a O
result O
of O
dominant I-GENE
mutations O
in O
the O
N I-GENE
terminus O
of O
beta I-GENE
- I-GENE
catenin I-GENE
that O
_RARE_ I-GENE
it O
_RARE_ I-GENE
to O
_RARE_ I-GENE
by O
APC I-GENE
, O
_RARE_ I-GENE
beta I-GENE
, O
and O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
. O

Similar O
mechanisms O
leading O
to O
_RARE_ I-GENE
of O
_RARE_ I-GENE
target O
gene I-GENE
activity O
are O
likely O
to O
be O
involved O
in O
melanoma O
and O
other O
forms O
of O
cancer O
. O

This O
report O
describes O
a O
patient O
with O
a O
previous O
inferior O
acute O
myocardial O
infarction O
who O
developed O
right O
ventricular O
infarction O
with O
significant O
anterior O
lead O
ST O
segment O
elevation O
( O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
) O
caused O
by O
the O
loss O
of O
two O
large O
right O
ventricular O
_RARE_ I-GENE
during O
a O
coronary O
_RARE_ I-GENE
of O
the O
right O
coronary O
artery O
. O

PATIENTS O
AND O
METHODS O
: O
_RARE_ I-GENE
before O
radical O
_RARE_ I-GENE
, O
bone O
marrow O
_RARE_ I-GENE
from O
both O
sides O
of O
the O
iliac O
_RARE_ I-GENE
were O
taken O
from O
_RARE_ I-GENE
patients O
. O

PURPOSE O
: O
Previous O
WR O
- I-GENE
2721 O
human I-GENE
pharmacokinetic O
studies O
were O
limited O
to O
plasma I-GENE
levels O
in O
patients O
receiving O
_RARE_ I-GENE
- I-GENE
based O
compounds O
, O
and O
none O
includes O
the O
effects O
of O
WR O
- I-GENE
2721 O
on O
endogenous I-GENE
_RARE_ I-GENE
. O

With O
regard O
to O
_RARE_ I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
infection O
and O
elevated O
serum I-GENE
alkaline I-GENE
phosphatase I-GENE
of O
grade O
3 I-GENE
or O
over O
were O
observed O
in O
2 I-GENE
% O
of O
cycles O
, O
but O
were O
_RARE_ I-GENE
and O
reversible O
. O

_RARE_ I-GENE
is O
expressed O
in O
pituitary I-GENE
_RARE_ I-GENE
cells O
and O
_RARE_ I-GENE
is O
expressed O
in O
placental I-GENE
_RARE_ I-GENE
cells O
. O

Regulation O
of O
HIV I-GENE
- I-GENE
1 I-GENE
transcription I-GENE
. O

Human I-GENE
_RARE_ I-GENE
- I-GENE
1 I-GENE
is O
known O
to O
exist O
in O
different O
forms O
. O

In O
an O
earlier O
study O
( O
_RARE_ I-GENE
, O
Y I-GENE
., O
_RARE_ I-GENE
, O
K I-GENE
., O
_RARE_ I-GENE
, O
M I-GENE
., O
and O
_RARE_ I-GENE
, O
D I-GENE
. O

It O
consists O
of O
_RARE_ I-GENE
amino O
acid I-GENE
residues O
encoded I-GENE
by O
a O
9 O
- I-GENE
kilobase O
pair O
mRNA I-GENE
; O
several O
splice O
variants I-GENE
have O
been O
detected O
in O
human I-GENE
and O
rat I-GENE
cDNA I-GENE
libraries O
. O

_RARE_ I-GENE
AMP I-GENE
- I-GENE
dependent I-GENE
protein I-GENE
kinase I-GENE
binding I-GENE
to O
A I-GENE
- I-GENE
kinase I-GENE
_RARE_ I-GENE
proteins I-GENE
in O
living O
cells O
by O
fluorescence O
resonance O
energy O
transfer I-GENE
of O
green I-GENE
fluorescent O
protein I-GENE
fusion I-GENE
proteins I-GENE
. O

CONCLUSIONS O
: O
In O
addition O
to O
the O
_RARE_ I-GENE
of O
_RARE_ I-GENE
- I-GENE
filled O
microspheres O
to O
air O
- I-GENE
filled O
microspheres O
for O
LV O
_RARE_ I-GENE
, O
the O
efficacy O
of O
_RARE_ I-GENE
is O
relatively O
unaffected O
by O
impaired O
LV O
function O
and O
is O
less O
susceptible O
to O
the O
effects O
of O
poor O
_RARE_ I-GENE
than O
_RARE_ I-GENE
. O

Factor I-GENE
_RARE_ I-GENE
deficiency O
is O
a O
rare O
hereditary I-GENE
bleeding O
disorder O
affecting O
the O
intrinsic O
pathway O
. O

The O
_RARE_ I-GENE
samples O
show O
a O
range O
encompassing O
three O
_RARE_ I-GENE
levels O
. O

The O
more O
_RARE_ I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
citrate I-GENE
and O
_RARE_ I-GENE
, O
will O
be O
reviewed O
along O
with O
such O
modern O
drugs O
as O
_RARE_ I-GENE
and O
_RARE_ I-GENE
, O
with O
_RARE_ I-GENE
upon O
their O
actions O
on O
breast O
, O
_RARE_ I-GENE
, O
bone O
and O
lipids O
. O

_RARE_ I-GENE
exhibited O
a O
_RARE_ I-GENE
- I-GENE
like I-GENE
morphology O
. O

This O
organization O
suggests O
that O
duplication O
events O
that O
have O
generated O
the O
primate O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
cluster I-GENE
might O
have O
occurred O
through O
a O
long O
- I-GENE
interspersed O
- I-GENE
nuclear I-GENE
- I-GENE
element I-GENE
- I-GENE
based O
mechanism O
of O
_RARE_ I-GENE
_RARE_ I-GENE
over O
, O
as O
described O
for O
the O
globin I-GENE
cluster I-GENE
. O

S I-GENE
., O
_RARE_ I-GENE
, O
S I-GENE
. O

The O
_RARE_ I-GENE
region O
also O
_RARE_ I-GENE
a O
region O
of O
plasmid O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
encompassing O
a O
stem O
- I-GENE
loop I-GENE
structure O
, O
the O
_RARE_ I-GENE
promoter I-GENE
, O
_RARE_ I-GENE
, O
as O
well O
as O
two O
distinct O
_RARE_ I-GENE
binding I-GENE
sites I-GENE
, O
_RARE_ I-GENE
- I-GENE
1 I-GENE
and O
_RARE_ I-GENE
- I-GENE
2 I-GENE
. O

_RARE_ I-GENE
constructs I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
and O
positive O
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
kinetics O
indicated O
slow O
_RARE_ I-GENE
of O
precursors I-GENE
to O
the O
two O
_RARE_ I-GENE
. O

The O
_RARE_ I-GENE
protein I-GENE
family I-GENE
includes O
members O
from O
yeast I-GENE
to O
humans O
, O
which O
function O
in O
various O
biological O
systems O
, O
and O
share O
a O
DNA I-GENE
- I-GENE
binding I-GENE
domain I-GENE
and O
a O
conserved O
C I-GENE
- I-GENE
terminal I-GENE
region O
. O

Binding O
to O
_RARE_ I-GENE
and O
the O
alpha I-GENE
- I-GENE
_RARE_ I-GENE
receptor I-GENE
was O
much O
stronger O
and O
required O
at O
least O
two O
_RARE_ I-GENE
modules I-GENE
. O

Here O
, O
we O
propose O
that O
an O
antagonistic O
, O
BMP I-GENE
/ I-GENE
_RARE_ I-GENE
/ I-GENE
Smad I-GENE
- I-GENE
mediated O
signaling O
pathway O
is O
active O
on O
the O
right O
side O
of O
the O
Xenopus I-GENE
embryo O
. O

These O
kinases I-GENE
belong O
to O
a O
new O
subfamily I-GENE
related I-GENE
to O
the O
_RARE_ I-GENE
subfamily I-GENE
. O

The O
data O
indicate O
that O
_RARE_ I-GENE
- I-GENE
1 I-GENE
is O
essential O
for O
muscle O
development O
in O
C I-GENE
. O
elegans I-GENE
, O
perhaps O
by O
_RARE_ I-GENE
a O
role O
in O
post O
- I-GENE
transcriptional O
processing O
of O
some O
muscle O
component O
, O
and O
thus O
suggesting O
a O
possible O
conservation O
of O
gene I-GENE
function O
with O
human I-GENE
_RARE_ I-GENE
- I-GENE
bp O
. O

_RARE_ I-GENE
given O
by O
_RARE_ I-GENE
and O
_RARE_ I-GENE
significantly O
decreased O
the O
sputum I-GENE
_RARE_ I-GENE
density I-GENE
( O
p O
< O
0 O
. O
05 O
), O
by O
almost O
one O
order O
of O
magnitude O
. O

CONCLUSIONS O
: O
The O
largest O
value O
of O
the O
joint O
space O
may O
be O
used O
when O
evaluating O
rheumatoid I-GENE
AC I-GENE
joint O
space O
. O

An O
analysis O
of O
sequence I-GENE
of O
the O
mutant I-GENE
_RARE_ I-GENE
gene I-GENE
revealed O
a O
G I-GENE
: O
C I-GENE
to O
T I-GENE
: O
A I-GENE
transversion O
near O
the O
3 I-GENE
' O
end O
of O
the O
coding O
region O
. O

Nevertheless O
, O
in O
view O
of O
the O
potential O
transmission O
rates O
of O
_RARE_ I-GENE
and O
the O
lack O
of O
effective O
immunization O
, O
_RARE_ I-GENE
should O
be O
regarded O
as O
a O
potential O
_RARE_ I-GENE
_RARE_ I-GENE
for O
medical O
and O
dental O
_RARE_ I-GENE
. O

Detection O
of O
poisoning O
by O
_RARE_ I-GENE
( O
_RARE_ I-GENE
_RARE_ I-GENE
) O
in O
a O
_RARE_ I-GENE
and O
child O
. O

We O
have O
previously O
identified O
mouse I-GENE
and O
human I-GENE
cDNAs I-GENE
encoding O
UNC I-GENE
- I-GENE
51 O
- I-GENE
like I-GENE
kinase I-GENE
( O
_RARE_ I-GENE
). O

_RARE_ I-GENE
and O
UNC I-GENE
- I-GENE
51 O
share O
a O
typical O
domain I-GENE
structure O
of O
an O
amino O
- I-GENE
terminal I-GENE
kinase I-GENE
domain I-GENE
, O
a O
central O
proline O
/ I-GENE
serine I-GENE
rich O
( O
PS I-GENE
) O
domain I-GENE
, O
and O
a O
carboxy I-GENE
- I-GENE
terminal I-GENE
( O
C I-GENE
) O
domain I-GENE
. O

These O
results O
suggest O
that O
_RARE_ I-GENE
is O
involved O
in O
a O
previously O
uncharacterized O
signaling O
pathway O
in O
mammalian I-GENE
cells O
. O

_RARE_ I-GENE
enhancer I-GENE
of O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
is O
a O
_RARE_ I-GENE
protein I-GENE
required O
for O
_RARE_ I-GENE
signaling O
. O

In O
_RARE_ I-GENE
organisms O
, O
the O
ATP I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
kinase I-GENE
reactions O
are O
catalyzed O
by O
separate O
enzymes O
encoded I-GENE
by O
two O
or O
three O
genes I-GENE
, O
suggesting O
that O
a O
fusion I-GENE
of O
separate O
genes I-GENE
during O
the O
course O
of O
evolution O
generated O
the O
_RARE_ I-GENE
enzyme I-GENE
. O

Epstein I-GENE
- I-GENE
Barr I-GENE
virus I-GENE
( O
EBV I-GENE
) O
latent I-GENE
membrane I-GENE
protein I-GENE
1 I-GENE
( O
LMP1 I-GENE
) O
is O
essential O
for O
EBV I-GENE
- I-GENE
mediated O
transformation O
of O
primary O
B I-GENE
lymphocytes O
. O

The O
amino O
- I-GENE
terminal I-GENE
half O
of O
1a I-GENE
is O
a O
distant O
homolog I-GENE
of O
_RARE_ I-GENE
_RARE_ I-GENE
protein I-GENE
_RARE_ I-GENE
, O
which O
has O
been O
implicated O
in O
capping I-GENE
viral I-GENE
RNAs I-GENE
. O

Moreover O
, O
a O
recombinant I-GENE
_RARE_ I-GENE
expressing O
Ad5 I-GENE
_RARE_ I-GENE
/ I-GENE
7 O
induced O
apoptosis O
in O
rat I-GENE
cells O
when O
_RARE_ I-GENE
with O
wild I-GENE
- I-GENE
type I-GENE
p53 I-GENE
- I-GENE
expressing O
_RARE_ I-GENE
. O

In O
HCMV I-GENE
( O
_RARE_ I-GENE
)- I-GENE
infected O
HF I-GENE
cells O
at O
24 O
to O
48 O
h O
, O
IE2 I-GENE
also O
accumulated O
in O
newly O
formed O
viral I-GENE
DNA I-GENE
replication O
_RARE_ I-GENE
containing O
the O
polymerase I-GENE
_RARE_ I-GENE
factor I-GENE
( O
_RARE_ I-GENE
), O
the O
single O
- I-GENE
stranded I-GENE
DNA I-GENE
binding I-GENE
protein I-GENE
( O
SSB I-GENE
; O
_RARE_ I-GENE
), O
the O
_RARE_ I-GENE
- I-GENE
113 I-GENE
accessory I-GENE
protein I-GENE
, O
and O
newly O
incorporated O
_RARE_ I-GENE
( O
_RARE_ I-GENE
). O

_RARE_ I-GENE
_RARE_ I-GENE
on O
heart O
_RARE_ I-GENE
have O
indicated O
that O
the O
_RARE_ I-GENE
of O
the O
_RARE_ I-GENE
system O
differs O
from O
that O
of O
the O
normal O
myocardium O
. O

CONCLUSION O
( O
S I-GENE
): O
_RARE_ I-GENE
urinary O
LH I-GENE
levels O
is O
an O
excellent O
method O
for O
determining O
ovulation O
. O

However O
, O
_RARE_ I-GENE
for O
_RARE_ I-GENE
cervical O
disease O
( O
group O
3 I-GENE
) O
rarely O
results O
in O
normal O
calcitonin I-GENE
levels O
and O
is O
associated I-GENE
with O
a O
high O
incidence O
of O
permanent O
_RARE_ I-GENE
. O

We O
present O
a O
case O
of O
carcinoma O
of O
the O
breast O
presenting O
_RARE_ I-GENE
with O
_RARE_ I-GENE
that O
subsequently O
progressed O
to O
dialysis O
- I-GENE
dependent I-GENE
renal O
failure O
in O
just O
1 I-GENE
month O
. O

PURPOSE O
: O
To O
evaluate O
the O
disease O
- I-GENE
free O
survival O
( O
_RARE_ I-GENE
) O
and O
overall O
survival O
( O
_RARE_ I-GENE
), O
prognostic O
factors I-GENE
, O
and O
treatment O
- I-GENE
related I-GENE
mortality O
of O
women O
with O
stage O
IIIB I-GENE
inflammatory O
breast O
cancer O
( O
_RARE_ I-GENE
) O
treated O
with O
combined O
modality O
therapy O
( O
_RARE_ I-GENE
) O
and O
high O
- I-GENE
dose O
chemotherapy O
( O
_RARE_ I-GENE
) O
with O
autologous O
stem O
- I-GENE
cell O
transplantation O
. O

The O
GPI I-GENE
anchor I-GENE
_RARE_ I-GENE
is O
either O
absent O
or O
present O
at O
a O
very O
low O
level O
in O
the O
polypeptide I-GENE
expressed O
from O
the O
cDNA I-GENE
that O
contained O
both O
the O
signal I-GENE
peptide I-GENE
and O
GPI I-GENE
signal I-GENE
sequences I-GENE
. O

We O
have O
cloned O
a O
novel O
100 O
- I-GENE
kDa I-GENE
mammalian I-GENE
protein I-GENE
, O
which O
was O
recognized O
by O
an O
anti I-GENE
- I-GENE
peptide I-GENE
antibody I-GENE
against O
an O
epitope O
- I-GENE
containing O
nuclear I-GENE
localization O
signal I-GENE
of O
NF I-GENE
- I-GENE
kappaB I-GENE
p65 I-GENE
subunit I-GENE
. O

Insulin I-GENE
- I-GENE
regulated O
events O
, O
however O
, O
occur O
in O
all O
cells O
. O

_RARE_ I-GENE
regions O
in O
the O
promoter I-GENE
and O
third O
intron O
of O
the O
growth I-GENE
hormone I-GENE
gene I-GENE
in O
_RARE_ I-GENE
trout I-GENE
, O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
. O

Although O
most O
SFV I-GENE
genes I-GENE
have O
homologs I-GENE
encoded I-GENE
by O
other O
_RARE_ I-GENE
, O
the O
SFV I-GENE
genome O
lacks O
a O
key O
gene I-GENE
required O
for O
the O
production O
of O
extracellular I-GENE
_RARE_ I-GENE
virus I-GENE
. O

They O
self O
- I-GENE
completed O
the O
SF I-GENE
- I-GENE
36 O
questionnaire O
and O
their O
_RARE_ I-GENE
was O
described O
and O
_RARE_ I-GENE
compared O
to O
that O
of O
_RARE_ I-GENE
controls O
. O

There O
was O
a O
trend O
toward O
an O
association O
between O
_RARE_ I-GENE
and O
_RARE_ I-GENE
nerve I-GENE
_RARE_ I-GENE
fiber O
_RARE_ I-GENE
( O
r O
= O
0 O
. O
32 O
, O
p O
= O
0 O
. O
_RARE_ I-GENE
). O

In O
addition O
, O
media O
containing O
F I-GENE
beta I-GENE
alpha I-GENE
/ I-GENE
CG I-GENE
beta I-GENE
displayed O
high O
- I-GENE
affinity O
binding I-GENE
to O
both O
CG I-GENE
and O
FSH I-GENE
receptors I-GENE
. O

In O
contrast O
, O
AP I-GENE
- I-GENE
2 I-GENE
binding I-GENE
activity O
was O
significantly O
greater O
in O
_RARE_ I-GENE
cells O
, O
and O
Western O
blots O
confirmed O
increased O
AP I-GENE
- I-GENE
2 I-GENE
protein I-GENE
levels O
in O
these O
cells O
. O

N I-GENE
. O
_RARE_ I-GENE
_RARE_ I-GENE
, O
and O
M I-GENE
. O

Here O
, O
we O
describe O
a O
tyrosine I-GENE
- I-GENE
phosphorylated O
nuclear I-GENE
protein I-GENE
, O
_RARE_ I-GENE
- I-GENE
B I-GENE
, O
and O
show O
that O
it O
interacts O
with O
the O
nuclear I-GENE
_RARE_ I-GENE
component O
_RARE_ I-GENE
attachment O
factor I-GENE
B I-GENE
, O
and O
the O
68 O
- I-GENE
kDa I-GENE
Src I-GENE
substrate I-GENE
associated I-GENE
during O
mitosis O
, O
_RARE_ I-GENE
. O

These O
mutants I-GENE
all O
failed O
to O
interact O
with O
the O
_RARE_ I-GENE
fusion I-GENE
in O
the O
two O
- I-GENE
hybrid O
system O
. O

_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
homologues O
in O
Pseudomonas I-GENE
aeruginosa I-GENE
regulate O
expression O
of O
the O
outer I-GENE
- I-GENE
membrane I-GENE
protein I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
B I-GENE
resistance O
. O

Deletion O
of O
_RARE_ I-GENE
revealed O
a O
dual O
regulatory I-GENE
effect O
of O
_RARE_ I-GENE
on O
the O
_RARE_ I-GENE
operon I-GENE
by O
acting O
as O
transcriptional O
activator I-GENE
in O
the O
presence O
of O
formate O
or O
as O
repressor I-GENE
in O
the O
absence O
of O
formate O
. O

With O
constructs I-GENE
containing O
the O
binding I-GENE
site I-GENE
of O
one O
gene I-GENE
fused O
to O
the O
promoter I-GENE
of O
the O
other O
, O
we O
demonstrated O
that O
the O
_RARE_ I-GENE
requirements O
are O
a O
function O
of O
the O
specific I-GENE
binding I-GENE
site I-GENE
, O
not O
the O
promoter I-GENE
. O

In O
addition O
, O
all O
three O
_RARE_ I-GENE
proteins I-GENE
of O
_RARE_ I-GENE
bind O
equally O
well O
to O
HeLa O
cells O
transfected O
with O
cDNA I-GENE
encoding O
the O
_RARE_ I-GENE
antigen I-GENE
[ O
CEA I-GENE
( O
_RARE_ I-GENE
)] O
subgroup O
of O
the O
_RARE_ I-GENE
family I-GENE
, O
but O
show O
distinct O
_RARE_ I-GENE
for O
_RARE_ I-GENE
- I-GENE
( O
_RARE_ I-GENE
) O
and O
_RARE_ I-GENE
( O
_RARE_ I-GENE
)- I-GENE
expressing O
cells O
. O

_RARE_ I-GENE
using O
a O
whole O
chromosome O
4 I-GENE
_RARE_ I-GENE
demonstrated O
multiple O
rearrangements O
involving O
chromosome O
4 I-GENE
in O
_RARE_ I-GENE
- I-GENE
7 O
_RARE_ I-GENE
and O
_RARE_ I-GENE
- I-GENE
7 O
_RARE_ I-GENE
, O
while O
S1 I-GENE
- I-GENE
M1 I-GENE
- I-GENE
80 O
contained O
only O
a O
simple O
reciprocal O
translocation O
. O

The O
_RARE_ I-GENE
gene I-GENE
encodes O
a O
half O
- I-GENE
transporter I-GENE
and O
the O
absence O
of O
cytogenetic O
evidence O
of O
_RARE_ I-GENE
of O
other O
regions O
suggests O
that O
a O
partner I-GENE
may O
not O
be O
overexpressed O
, O
and O
instead O
the O
_RARE_ I-GENE
half O
- I-GENE
transporter I-GENE
_RARE_ I-GENE
to O
mediate O
drug O
transport O
. O

The O
effect O
of O
smoking O
was O
not O
examined O
in O
this O
study O
, O
as O
such O
data O
were O
not O
available O
. O

Serum I-GENE
insulin I-GENE
- I-GENE
like I-GENE
growth I-GENE
factor I-GENE
I I-GENE
( O
IGF I-GENE
- I-GENE
I I-GENE
) O
SD O
score O
increased O
from O
- I-GENE
2 I-GENE
. O
2 I-GENE
and O
- I-GENE
4 I-GENE
. O
2 I-GENE
in O
men O
and O
women O
, O
respectively O
, O
to O
1 I-GENE
. O
8 O
and O
- I-GENE
0 O
. O
9 O
at O
6 I-GENE
months O
and O
0 O
. O
8 O
and O
- I-GENE
0 O
. O
7 O
at O
12 O
months O
. O

BACKGROUND O
: O
Measurement O
of O
_RARE_ I-GENE
at O
varying O
distances O
, O
by O
real O
or O
simulated O
depth O
_RARE_ I-GENE
tests O
, O
is O
helpful O
in O
the O
evaluation O
of O
patients O
with O
_RARE_ I-GENE
_RARE_ I-GENE
or O
_RARE_ I-GENE
. O

_RARE_ I-GENE
studies O
revealed O
that O
bovine I-GENE
brain O
Galpha I-GENE
( O
q I-GENE
/ I-GENE
11 O
) O
could O
also O
bind O
to O
an O
N I-GENE
- I-GENE
terminal I-GENE
construct I-GENE
of O
_RARE_ I-GENE
, O
while O
no O
binding I-GENE
of O
Galpha I-GENE
( O
q I-GENE
/ I-GENE
11 O
), O
Galpha I-GENE
( O
s O
), O
Galpha I-GENE
( O
i O
), O
or O
Galpha I-GENE
( O
12 O
/ I-GENE
13 O
) O
to O
comparable O
constructs I-GENE
of O
_RARE_ I-GENE
or O
_RARE_ I-GENE
was O
observed O
. O

The O
_RARE_ I-GENE
kinase I-GENE
functions O
in O
a O
mitotic O
signaling O
network O
in O
budding I-GENE
yeast I-GENE
. O

Reverse I-GENE
transcription I-GENE
( O
RT I-GENE
)- I-GENE
PCR O
products I-GENE
were O
synthesized O
with O
two O
degenerate O
primers O
derived O
from O
the O
conserved O
motifs O
of O
various O
tyrosine I-GENE
kinases I-GENE
. O

In O
addition O
, O
the O
acetyltransferase I-GENE
activity O
of O
p300 I-GENE
was O
observed O
to O
be O
distinct O
from O
the O
broadly O
essential O
activation O
function O
of O
the O
_RARE_ I-GENE
domain I-GENE
/ I-GENE
E1A I-GENE
- I-GENE
binding I-GENE
region O
. O

The O
proliferation O
- I-GENE
specific I-GENE
HNF I-GENE
- I-GENE
3 I-GENE
/ I-GENE
fork I-GENE
head I-GENE
homolog I-GENE
- I-GENE
_RARE_ I-GENE
protein I-GENE
( O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
; O
also O
known O
as O
_RARE_ I-GENE
and O
_RARE_ I-GENE
) O
is O
a O
family I-GENE
member O
of O
the O
_RARE_ I-GENE
helix I-GENE
/ I-GENE
fork I-GENE
head I-GENE
transcription I-GENE
factors I-GENE
and O
in O
_RARE_ I-GENE
liver O
its O
expression O
is O
_RARE_ I-GENE
prior O
to O
hepatocyte I-GENE
entry O
into O
DNA I-GENE
replication O
( O
S I-GENE
phase O
). O

In O
the O
mouse I-GENE
, O
_RARE_ I-GENE
is O
expressed O
from O
embryo O
to O
adult O
, O
but O
_RARE_ I-GENE
is O
mainly O
expressed O
during O
embryogenesis O
. O

The O
multiple O
functions O
of O
_RARE_ I-GENE
described O
here O
suggest O
that O
several O
nuclear I-GENE
proteins I-GENE
are O
regulated O
by O
_RARE_ I-GENE
conjugation O
. O

The O
role O
of O
transport O
by O
sea O
_RARE_ I-GENE
from O
the O
_RARE_ I-GENE
_RARE_ I-GENE
into O
the O
_RARE_ I-GENE
_RARE_ I-GENE
was O
assessed O
by O
a O
small I-GENE
subgroup O
at O
_RARE_ I-GENE
. O

We O
determined O
whether O
a O
single O
injection O
of O
slow O
- I-GENE
release O
estradiol O
- I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
would O
induce O
_RARE_ I-GENE
in O
_RARE_ I-GENE
and O
whether O
_RARE_ I-GENE
would O
_RARE_ I-GENE
the O
_RARE_ I-GENE
_RARE_ I-GENE
( O
CL O
) O
of O
_RARE_ I-GENE
. O

The O
level O
of O
serum I-GENE
creatine I-GENE
kinase I-GENE
was O
significantly O
high O
2 I-GENE
days O
after O
_RARE_ I-GENE
, O
but O
it O
recovered O
in O
a O
week O
. O

Among O
the O
remaining O
22 O
sites I-GENE
, O
six O
are O
in O
the O
promoters I-GENE
of O
known O
alpha I-GENE
- I-GENE
specific I-GENE
genes I-GENE
and O
two O
other O
sites I-GENE
have O
an O
alpha2 I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
dependent I-GENE
role O
in O
determining O
the O
direction O
of O
mating I-GENE
type I-GENE
switching O
. O

Activation O
of O
T I-GENE
cells O
via O
the O
TCR I-GENE
and O
other O
_RARE_ I-GENE
receptors I-GENE
triggers O
a O
number O
of O
signaling O
cascades I-GENE
. O

A I-GENE
phylogenetic O
analysis O
with O
the O
TK I-GENE
domains I-GENE
from O
these O
sequences I-GENE
and O
a O
fourth O
, O
from O
a O
novel O
_RARE_ I-GENE
_RARE_ I-GENE
( O
all O
domains I-GENE
comprise O
the O
_RARE_ I-GENE
for O
the O
TK I-GENE
class I-GENE
II I-GENE
receptors I-GENE
), O
showed O
that O
they O
are O
distantly O
related I-GENE
to O
the O
insulin I-GENE
and O
insulin I-GENE
- I-GENE
like I-GENE
receptors I-GENE
. O

Several O
_RARE_ I-GENE
RNA I-GENE
- I-GENE
encoding O
sequences I-GENE
and O
various O
intergenic O
_RARE_ I-GENE
were O
amplified O
from O
the O
individual O
HindIII I-GENE
fragments I-GENE
of O
about O
1 I-GENE
. O
3 I-GENE
and O
2 I-GENE
. O
8 O
kb O
. O

Results O
confirmed O
that O
stress O
produced O
CA3 O
_RARE_ I-GENE
atrophy O
and O
_RARE_ I-GENE
prevented O
it O
. O

We O
have O
isolated O
a O
binding I-GENE
partner I-GENE
for O
the O
_RARE_ I-GENE
anemia I-GENE
group O
C I-GENE
protein I-GENE
( O
_RARE_ I-GENE
) O
by O
yeast I-GENE
two O
- I-GENE
hybrid O
screening O
. O

These O
results O
suggest O
that O
both O
transcription I-GENE
activators I-GENE
depend O
on O
or O
interact O
with O
different O
subunits I-GENE
of O
RNA I-GENE
polymerase I-GENE
, O
although O
their O
role O
in O
formation O
of O
proper O
DNA I-GENE
_RARE_ I-GENE
may O
also O
be O
crucial O
. O

Klebsiella I-GENE
_RARE_ I-GENE
can O
_RARE_ I-GENE
nitrate I-GENE
and O
nitrite I-GENE
by O
using O
enzymes O
encoded I-GENE
by O
the O
_RARE_ I-GENE
operon I-GENE
. O

Marked O
_RARE_ I-GENE
significantly O
increased O
plasma I-GENE
values O
of O
potassium O
, O
phosphorus O
, O
total O
protein I-GENE
, O
and O
aspartate I-GENE
aminotransferase I-GENE
. O

Studies O
have O
_RARE_ I-GENE
the O
involvement O
of O
numerous O
loci I-GENE
on O
certain O
chromosomes O
; O
in O
excess O
of O
10 O
chromosomes O
are O
thought O
to O
be O
involved O
. O

By O
negatively O
regulating O
_RARE_ I-GENE
- I-GENE
mediated O
receptor I-GENE
phosphorylation O
, O
beta I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
mediated O
processes O
such O
as O
Src I-GENE
recruitment O
and O
clathrin I-GENE
- I-GENE
mediated O
internalization O
, O
which O
are O
required O
for O
_RARE_ I-GENE
- I-GENE
mediated O
ERK I-GENE
activation O
, O
are O
inhibited O
, O
thus O
_RARE_ I-GENE
further O
ERK I-GENE
activation O
. O

Based O
on O
subcellular O
fractionation O
, O
the O
47 O
- I-GENE
kDa I-GENE
P I-GENE
- I-GENE
_RARE_ I-GENE
protein I-GENE
is O
mostly O
cytosolic I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
identified O
that O
upstream O
stimulatory I-GENE
factor I-GENE
- I-GENE
1 I-GENE
and O
- I-GENE
2 I-GENE
( O
USF I-GENE
- I-GENE
1 I-GENE
and O
- I-GENE
2 I-GENE
) O
were O
part O
of O
these O
complexes I-GENE
. O

Conversely O
, O
E1A I-GENE
binding I-GENE
to O
only O
p300 I-GENE
/ I-GENE
CBP I-GENE
results O
in O
an O
increase O
in O
_RARE_ I-GENE
enzyme I-GENE
activity O
and O
_RARE_ I-GENE
in O
cell O
death O
susceptibility I-GENE
to O
irradiation O
, O
which O
is O
effectively O
_RARE_ I-GENE
by O
the O
_RARE_ I-GENE
chemical O
inhibitor I-GENE
3 I-GENE
- I-GENE
_RARE_ I-GENE
. O

Analysis O
of O
its O
genomic O
region O
revealed O
that O
the O
13 O
- I-GENE
kb O
_RARE_ I-GENE
gene I-GENE
is O
divided O
into O
12 O
exons O
by O
11 O
introns O
. O

These O
include O
the O
_RARE_ I-GENE
and O
CAAT I-GENE
motifs O
. O

_RARE_ I-GENE
pH O
changes O
associated I-GENE
with O
_RARE_ I-GENE
. O

This O
_RARE_ I-GENE
was O
based O
upon O
whether O
the O
diagnosis O
provided O
a O
_RARE_ I-GENE
range O
of O
_RARE_ I-GENE
or O
an O
_RARE_ I-GENE
clinical O
_RARE_ I-GENE
. O

The O
availability O
of O
potent O
regulatory I-GENE
DNA I-GENE
_RARE_ I-GENE
harboring O
the O
murine I-GENE
_RARE_ I-GENE
gene I-GENE
promoter I-GENE
could O
aid O
testing O
the O
neuronal O
- I-GENE
specific I-GENE
expression O
of O
_RARE_ I-GENE
in O
vivo O
. O

It O
may O
be O
dependent I-GENE
on O
location O
of O
a O
focus O
( O
according O
to O
EEG O
) O
as O
well O
as O
on O
the O
character O
and O
manifestation O
of O
the O
accompanying O
_RARE_ I-GENE
_RARE_ I-GENE
. O

The O
results O
of O
these O
studies O
demonstrate O
that O
the O
rat I-GENE
HDL I-GENE
receptor I-GENE
SR I-GENE
- I-GENE
BI I-GENE
promoter I-GENE
contains O
two O
sterol I-GENE
response O
elements O
( O
_RARE_ I-GENE
and O
_RARE_ I-GENE
) O
through O
which O
SREBP I-GENE
- I-GENE
1a I-GENE
can O
bind O
and O
activate O
transcription I-GENE
of O
this O
gene I-GENE
. O

_RARE_ I-GENE
of O
myosin I-GENE
- I-GENE
binding I-GENE
subunit I-GENE
( O
_RARE_ I-GENE
) O
of O
myosin I-GENE
phosphatase I-GENE
by O
Rho I-GENE
- I-GENE
kinase I-GENE
in O
vivo O
. O

Of O
these O
patients O
, O
46 O
, O
_RARE_ I-GENE
were O
placed O
on O
a O
_RARE_ I-GENE
_RARE_ I-GENE
for O
transplantation O
, O
23 O
, O
_RARE_ I-GENE
of O
whom O
received O
a O
first O
_RARE_ I-GENE
transplant O
between O
1991 O
and O
1997 O
. O

In O
electrophoretic O
mobility I-GENE
shift O
assay O
( O
EMSA O
), O
this O
_RARE_ I-GENE
repressor I-GENE
element I-GENE
( O
_RARE_ I-GENE
) O
generated O
specific I-GENE
bands O
with O
nuclear I-GENE
extracts O
from O
_RARE_ I-GENE
, O
but O
not O
from O
adipocytes O
. O

_RARE_ I-GENE
of O
abnormal O
fat O
_RARE_ I-GENE
and O
metabolic O
complications O
in O
HIV I-GENE
- I-GENE
infected O
patients O
. O

_RARE_ I-GENE
with O
_RARE_ I-GENE
in O
radiotherapy O
or O
_RARE_ I-GENE
- I-GENE
chemotherapy O
of O
head I-GENE
and O
neck O
tumors O

_RARE_ I-GENE
staining O
was O
positive O
for O
S I-GENE
- I-GENE
100 O
in O
all O
9 O
cases O
stained O
, O
positive O
for O
_RARE_ I-GENE
- I-GENE
45 O
in O
9 O
( O
90 O
%) O
of O
10 O
, O
and O
negative O
for O
_RARE_ I-GENE
in O
all O
9 O
cases O
in O
which O
_RARE_ I-GENE
melanoma O
remained O
in O
the O
block O
after O
previous O
sections O
. O

Patients O
with O
types O
I I-GENE
and O
III I-GENE
_RARE_ I-GENE
did O
not O
differ O
in O
age O
at O
apparent O
onset O
, O
age O
at O
diagnosis O
, O
or O
interval O
from O
apparent O
onset O
of O
symptoms O
to O
diagnosis O
( O
biopsy O
). O

_RARE_ I-GENE
urinary O
abnormalities O
were O
significantly O
more O
frequent O
in O
patients O
with O
type I-GENE
III I-GENE
than O
type I-GENE
I I-GENE
_RARE_ I-GENE
. O

Taken O
together O
, O
differences O
in O
signaling O
and O
tissue I-GENE
expression O
suggest O
that O
the O
human I-GENE
intermediate O
_RARE_ I-GENE
differs O
from O
the O
long O
_RARE_ I-GENE
in O
physiological O
function O
. O

We O
describe O
here O
a O
Drosophila I-GENE
melanogaster I-GENE
FAK I-GENE
homologue I-GENE
, O
_RARE_ I-GENE
, O
which O
maps O
to O
band O
_RARE_ I-GENE
on O
the O
right O
arm O
of O
the O
second O
chromosome O
. O

Because O
the O
Pit I-GENE
- I-GENE
1 I-GENE
sites I-GENE
in O
the O
hGH I-GENE
- I-GENE
N I-GENE
gene I-GENE
promoter I-GENE
are O
insufficient O
for O
such O
gene I-GENE
activation O
in O
vivo O
, O
these O
data O
suggested O
a O
unique O
chromatin O
- I-GENE
mediated O
developmental O
role O
for O
Pit I-GENE
- I-GENE
1 I-GENE
in O
the O
hGH I-GENE
LCR I-GENE
. O

Recombinant I-GENE
_RARE_ I-GENE
lyase I-GENE
was O
produced O
in O
a O
baculovirus O
- I-GENE
Sf9 O
expression O
system O
. O

We O
show O
here O
that O
the O
third O
SH3 I-GENE
domain I-GENE
binds O
to O
Sos I-GENE
, O
a O
guanine I-GENE
nucleotide I-GENE
exchange I-GENE
factor I-GENE
for O
Ras I-GENE
and O
Rac I-GENE
, O
both O
in O
vitro O
and O
in O
vivo O
. O

_RARE_ I-GENE
mutations O
in O
the O
third O
SH3 I-GENE
domain I-GENE
abolished O
the O
_RARE_ I-GENE
- I-GENE
Sos I-GENE
interaction O
. O

In O
gel O
mobility I-GENE
shift O
assays O
, O
low O
binding I-GENE
activity O
of O
CBF I-GENE
to O
the O
wild I-GENE
- I-GENE
type I-GENE
_RARE_ I-GENE
promoter I-GENE
sequence I-GENE
was O
observed O
with O
nuclear I-GENE
extracts O
from O
tissue I-GENE
with O
low O
_RARE_ I-GENE
expression O
levels O
, O
i O
. O
e O
. O
extracts O
from O
_RARE_ I-GENE
and O
_RARE_ I-GENE
seedlings O
, O
whereas O
high O
binding I-GENE
activity O
was O
detectable O
with O
extracts O
from O
tissues O
with O
high O
_RARE_ I-GENE
expression O
levels O
, O
i O
. O
e O
. O
extracts O
from O
light I-GENE
- I-GENE
grown O
seedlings O
and O
_RARE_ I-GENE
seedlings O
treated O
with O
_RARE_ I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
infections O
are O
easily O
_RARE_ I-GENE
because O
conventional O
methods O
for O
bacterial I-GENE
detection O
may O
fail O
. O

For O
this O
purpose O
, O
we O
used O
a O
series O
of O
plasmid O
constructs I-GENE
encoding O
different O
forms O
of O
the O
envelope I-GENE
glycoprotein I-GENE
E I-GENE
of O
the O
_RARE_ I-GENE
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
virus I-GENE
. O

They O
are O
_RARE_ I-GENE
into O
two O
types O
that O
activate O
transduction O
pathways O
via O
different O
cell O
surface O
receptors I-GENE
. O

We O
report O
here O
that O
out O
of O
the O
major I-GENE
pro I-GENE
- I-GENE
inflammatory O
cytokines O
examined O
, O
IL I-GENE
- I-GENE
1alpha I-GENE
, O
IL I-GENE
- I-GENE
1beta I-GENE
, O
TNF I-GENE
- I-GENE
alpha I-GENE
and O
IL I-GENE
- I-GENE
6 I-GENE
, O
only O
IL I-GENE
- I-GENE
6 I-GENE
was O
generated O
and O
secreted O
in O
_RARE_ I-GENE
- I-GENE
expressing O
cells O
without O
any O
additional O
_RARE_ I-GENE
in O
serum I-GENE
- I-GENE
supplemented O
cultures O
( O
10 O
% O
_RARE_ I-GENE
). O

_RARE_ I-GENE
diseases O
involving O
the O
_RARE_ I-GENE
matter O
were O
very O
rare O
, O
but O
we O
must O
consider O
the O
presence O
of O
_RARE_ I-GENE
_RARE_ I-GENE
involvement O
in O
patients O
with O
_RARE_ I-GENE
. O

To O
define O
the O
minimal I-GENE
VDRE I-GENE
binding I-GENE
domain I-GENE
for O
human I-GENE
VDR I-GENE
( O
_RARE_ I-GENE
), O
a O
series O
of O
C I-GENE
- I-GENE
terminally I-GENE
truncated I-GENE
_RARE_ I-GENE
mutants I-GENE
( O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
) O
was O
generated O
and O
expressed O
in O
bacteria O
. O

By O
an O
induced O
- I-GENE
fit O
mechanism O
, O
contacts O
with O
the O
_RARE_ I-GENE
can O
activate O
formation O
of O
a O
_RARE_ I-GENE
transition O
state O
at O
a O
site I-GENE
over O
70 I-GENE
A I-GENE
_RARE_ I-GENE
. O

These O
_RARE_ I-GENE
, O
or O
clusters O
of O
_RARE_ I-GENE
loci I-GENE
, O
are O
15 O
- I-GENE
100 O
kb O
and O
harbor O
at O
least O
four O
ESTs I-GENE
and O
an O
expressed O
_RARE_ I-GENE
pseudogene I-GENE
. O

This O
revealed O
a O
minimum O
of O
six O
novel O
_RARE_ I-GENE
- I-GENE
related I-GENE
proteins I-GENE
, O
designated O
_RARE_ I-GENE
- I-GENE
1 I-GENE
to O
_RARE_ I-GENE
- I-GENE
6 I-GENE
. O

In O
part O
as O
a O
result O
of O
its O
_RARE_ I-GENE
to O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
, O
the O
BB I-GENE
_RARE_ I-GENE
has O
extremely O
low O
_RARE_ I-GENE
power O
requirements O
. O

In O
addition O
, O
_RARE_ I-GENE
expression O
was O
induced O
approximately O
20 O
- I-GENE
fold O
_RARE_ I-GENE
in O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
canine O
kidney O
epithelial O
cells O
and O
16 O
- I-GENE
fold O
in O
intracellular O
_RARE_ I-GENE
medium O
, O
which O
is O
believed O
to O
mimic O
the O
intracellular O
_RARE_ I-GENE
. O

However O
, O
mechanisms O
underlying O
HIV I-GENE
- I-GENE
1 I-GENE
gene I-GENE
expression O
in O
the O
CNS O
are O
poorly O
understood O
. O

Is O
radical O
_RARE_ I-GENE
a O
safe O
alternative O
to O
radical O
hysterectomy O
for O
patients O
with O
stage O
IA O
- I-GENE
B I-GENE
carcinoma O
of O
the O
cervix O
? O
BACKGROUND O
: O
The O
prognosis O
associated I-GENE
with O
lymph O
node O
negative O
, O
early I-GENE
stage O
carcinoma O
of O
the O
cervix O
is O
excellent O
, O
with O
5 I-GENE
- I-GENE
year O
survival O
rates O
greater O
than O
90 O
%. O

A I-GENE
key O
event O
in O
this O
process O
is O
the O
selective O
recognition I-GENE
of O
the O
target O
membrane I-GENE
by O
the O
vesicle O
and O
the O
current O
view O
is O
that O
_RARE_ I-GENE
protein I-GENE
interactions O
likely O
play O
a O
central O
role O
in O
vesicle O
- I-GENE
target O
recognition I-GENE
and O
or O
membrane I-GENE
fusion I-GENE
. O

_RARE_ I-GENE
with O
a O
Type O
I I-GENE
configuration O
were O
found O
to O
have O
low O
values O
for O
the O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
angle O
and O
_RARE_ I-GENE
overlap O
, O
which O
are O
known O
to O
be O
associated I-GENE
with O
a O
short O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
distance O
. O

Measurements O
in O
the O
_RARE_ I-GENE
p O
. O
a O
. O
, O
_RARE_ I-GENE
_RARE_ I-GENE
. O
and O
at O
_RARE_ I-GENE
' O
s O
_RARE_ I-GENE
were O
made O
in O
a O
total O
of O
100 O
patients O
. O

A I-GENE
group O
of O
66 O
_RARE_ I-GENE
- I-GENE
IV I-GENE
_RARE_ I-GENE
schizophrenic O
in O
- I-GENE
patients O
were O
assessed O
three O
times O
using O
the O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
and O
_RARE_ I-GENE
. O

In O
conclusion O
: O
( O
i O
) O
_RARE_ I-GENE
kit I-GENE
is O
suggested O
to O
be O
used O
for O
screening O
SE O
producing O
strains O
; O
( O
ii O
) O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
are O
suitable O
for O
epidemiological O
investigation O
of O
SE O
types O
, O
but O
the O
lack O
of O
ability O
for O
detecting O
_RARE_ I-GENE
, O
long O
time O
required O
for O
testing O
with O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
kit I-GENE
and O
high O
background O
when O
using O
_RARE_ I-GENE
kit I-GENE
must O
be O
overcome O
; O
and O
( O
iii O
) O
because O
of O
the O
complicated O
test O
procedures O
and O
the O
lack O
of O
ability O
for O
detecting O
_RARE_ I-GENE
, O
the O
_RARE_ I-GENE
of O
_RARE_ I-GENE
- I-GENE
EIA I-GENE
kit I-GENE
in O
screening O
and O
epidemiological O
research O
_RARE_ I-GENE
is O
low O
. O

Comparison O
of O
immunoassay O
_RARE_ I-GENE
for O
detection O
of O
_RARE_ I-GENE
_RARE_ I-GENE
produced O
by O
Staphylococcus I-GENE
aureus I-GENE

Despite O
the O
high O
frequency O
of O
natural O
infection O
, O
the O
seropositive O
rates O
of O
_RARE_ I-GENE
antibody I-GENE
still O
correlated O
well O
with O
the O
dose O
of O
vaccine O
received O
, O
i O
. O
e O
., O
67 O
% O
( O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
), O
66 O
% O
( O
65 O
/ I-GENE
97 O
), O
33 O
% O
( O
4 I-GENE
/ I-GENE
12 O
) O
and O
40 I-GENE
% O
( O
19 O
/ I-GENE
47 O
) O
for O
children O
receiving O
3 I-GENE
, O
2 I-GENE
, O
1 I-GENE
, O
and O
0 O
dose O
of O
_RARE_ I-GENE
vaccines O
, O
respectively O
( O
P I-GENE
< O
0 O
. O
0001 O
Chi O
- I-GENE
square O
for O
trend O
test O
). O

Furthermore O
, O
in O
vivo O
and O
in O
vitro O
protein I-GENE
- I-GENE
protein I-GENE
interaction O
experiments O
have O
shown O
that O
_RARE_ I-GENE
protein I-GENE
interacts O
with O
itself O
and O
with O
_RARE_ I-GENE
protein I-GENE
but O
not O
with O
two O
other O
members O
( O
_RARE_ I-GENE
and O
_RARE_ I-GENE
) O
of O
the O
SR I-GENE
family I-GENE
that O
are O
known O
to O
interact O
with O
the O
Arabidopsis I-GENE
full I-GENE
- I-GENE
length I-GENE
U O
- I-GENE
_RARE_ I-GENE
only O
. O

In O
summary O
, O
WT1 I-GENE
is O
enriched O
by O
_RARE_ I-GENE
( O
dT O
) O
chromatography O
, O
as O
are O
_RARE_ I-GENE
, O
the O
U5 I-GENE
small I-GENE
nuclear I-GENE
RNP I-GENE
- I-GENE
associated I-GENE
protein I-GENE
_RARE_ I-GENE
and O
hnRNP I-GENE
A1 I-GENE
. O

Six O
out O
of O
ten O
hearts O
from O
_RARE_ I-GENE
_RARE_ I-GENE
infants O
showed O
varying O
degrees O
of O
positive O
staining O
. O

_RARE_ I-GENE
maps O
to O
distal O
mouse I-GENE
Chr O
1 I-GENE
and O
human I-GENE
Chr O
_RARE_ I-GENE
, O
chromosomal I-GENE
regions O
that O
have O
not O
shown O
evidence O
for O
imprinting O
and O
, O
in O
contrast O
to O
_RARE_ I-GENE
, O
_RARE_ I-GENE
is O
expressed O
equally O
from O
both O
parental O
alleles I-GENE
. O

A I-GENE
novel O
pleckstrin I-GENE
homology I-GENE
- I-GENE
related I-GENE
gene I-GENE
family I-GENE
defined O
by O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
: O
tissue I-GENE
- I-GENE
specific I-GENE
expression O
, O
chromosomal I-GENE
location O
, O
and O
parental O
imprinting O
. O

The O
potential O
for O
highly O
reactive I-GENE
_RARE_ I-GENE
( O
RNP I-GENE
) O
to O
_RARE_ I-GENE
_RARE_ I-GENE
, O
i O
. O
e O
. O
to O
_RARE_ I-GENE
highly O
toxic O
substances O
such O
as O
the O
_RARE_ I-GENE
agents O
GA I-GENE
, O
_RARE_ I-GENE
, O
HD I-GENE
and O
_RARE_ I-GENE
, O
has O
been O
demonstrated O
in O
the O
laboratory O
. O

There O
were O
minimal I-GENE
negative O
effects O
on O
_RARE_ I-GENE
parameters O
, O
acid I-GENE
- I-GENE
base O
status O
, O
and O
blood O
gases O
. O

_RARE_ I-GENE
out O
of O
43 I-GENE
renal O
failure O
patients O
had O
_RARE_ I-GENE
I I-GENE
0 O
. O
13 O
- I-GENE
0 O
. O
9 O
microg O
/ I-GENE
l O
using O
_RARE_ I-GENE
method O
and O
4 I-GENE
had O
levels O
of O
0 O
. O
07 O
- I-GENE
0 O
. O
13 O
microg O
/ I-GENE
l O
using O
_RARE_ I-GENE
1 I-GENE
. O

Therefore O
, O
we O
propose O
that O
p27 I-GENE
represents O
a O
crucial O
molecule I-GENE
in O
_RARE_ I-GENE
signaling O
that O
cannot O
be O
replaced O
by O
p21 I-GENE
. O

Transient O
, O
high O
- I-GENE
level O
Ras I-GENE
- I-GENE
expression O
induces O
transcriptional O
activation O
of O
p21 I-GENE
mediated O
by O
a O
GC I-GENE
- I-GENE
rich O
region O
in O
p21 I-GENE
promoter I-GENE
- I-GENE
83 O
- I-GENE
54 I-GENE
bp O
relative O
to O
the O
transcription I-GENE
initiation I-GENE
site I-GENE
containing O
binding I-GENE
sites I-GENE
for O
Sp1 I-GENE
- I-GENE
family I-GENE
transcription I-GENE
factors I-GENE
. O

The O
RET I-GENE
/ I-GENE
_RARE_ I-GENE
rearrangement O
is O
formed O
by O
fusion I-GENE
of O
the O
_RARE_ I-GENE
and O
RET I-GENE
genes I-GENE
, O
and O
is O
highly O
_RARE_ I-GENE
in O
radiation O
- I-GENE
induced O
post O
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
thyroid I-GENE
carcinomas O
. O

_RARE_ I-GENE
of O
small I-GENE
cells O
is O
still O
observed O
after O
co O
- I-GENE
transfection O
of O
_RARE_ I-GENE
and O
LMP1 I-GENE
but O
in O
addition O
a O
few O
apoptotic O
HD I-GENE
- I-GENE
_RARE_ I-GENE
cells O
with O
large O
fused O
nuclear I-GENE
masses O
are O
identified O
suggesting O
that O
specific I-GENE
inhibition O
of O
JNK I-GENE
leads O
also O
to O
apoptosis O
of O
LMP1 I-GENE
induced O
RS I-GENE
cells O
. O

In O
addition O
to O
the O
bZIP I-GENE
protein I-GENE
_RARE_ I-GENE
( O
O2 O
), O
there O
are O
other O
maize I-GENE
_RARE_ I-GENE
nuclear I-GENE
proteins I-GENE
that O
recognize O
the O
O2 O
box I-GENE
in O
22 O
kDa I-GENE
_RARE_ I-GENE
gene I-GENE
promoters I-GENE
. O

The O
_RARE_ I-GENE
- I-GENE
1 I-GENE
protein I-GENE
can O
activate O
transcription I-GENE
from O
a O
truncated I-GENE
promoter I-GENE
containing O
a O
_RARE_ I-GENE
of O
the O
O2 O
site I-GENE
in O
yeast I-GENE
cells O
; O
however O
, O
it O
inhibited O
regulated O
transcription I-GENE
of O
a O
22 O
kDa I-GENE
_RARE_ I-GENE
promoter I-GENE
in O
a O
transient O
expression O
assay O
using O
cultured O
maize I-GENE
_RARE_ I-GENE
cells O
. O

_RARE_ I-GENE
, O
2 I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
are O
some O
of O
these O
recent O
substances O
. O

There O
were O
15 O
deaths O
, O
seven O
of O
which O
were O
_RARE_ I-GENE
to O
be O
_RARE_ I-GENE
. O

With O
this O
GH I-GENE
and O
estrogen I-GENE
treatment O
regimen O
, O
most O
girls O
with O
_RARE_ I-GENE
can O
grow O
and O
develop O
much O
more O
in O
_RARE_ I-GENE
with O
their O
healthy O
_RARE_ I-GENE
. O

We O
propose O
that O
the O
reduced O
responsiveness O
of O
_RARE_ I-GENE
is O
the O
result O
of O
preferential O
binding I-GENE
of O
COUP I-GENE
- I-GENE
TF I-GENE
at O
the O
_RARE_ I-GENE
_RARE_ I-GENE
- I-GENE
1 I-GENE
site I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
basal O
activity O
appears O
to O
be O
due O
to O
an O
E I-GENE
- I-GENE
box I-GENE
in O
_RARE_ I-GENE
that O
interacts O
with O
_RARE_ I-GENE
, O
a O
ubiquitous O
bHLH I-GENE
/ I-GENE
leucine I-GENE
zipper I-GENE
transcription I-GENE
factor I-GENE
. O

The O
first O
one O
is O
a O
TPA O
- I-GENE
responsive I-GENE
element I-GENE
that O
controls O
the O
base O
- I-GENE
line O
_RARE_ I-GENE
promoter I-GENE
activity O
but O
is O
not O
required O
for O
its O
activation O
. O

To O
understand O
the O
basis O
for O
the O
increased O
cell O
surface O
stability O
compared O
with O
wild I-GENE
- I-GENE
type I-GENE
peptide I-GENE
and O
to O
understand O
the O
differences O
in O
T I-GENE
cell O
recognition I-GENE
between O
_RARE_ I-GENE
and O
_RARE_ I-GENE
, O
we O
determined O
the O
x O
- I-GENE
ray O
crystal O
structures O
of O
the O
two O
class I-GENE
I I-GENE
MHC I-GENE
- I-GENE
peptide I-GENE
complexes I-GENE
. O

_RARE_ I-GENE
of O
_RARE_ I-GENE
I I-GENE
was O
also O
observed O
in O
cells O
incubated O
at O
15 O
degrees O
C I-GENE
. O

In O
addition O
, O
using O
biochemical O
activity O
assays O
for O
Rho I-GENE
- I-GENE
like I-GENE
GTPases I-GENE
, O
we O
show O
that O
the O
expression O
of O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
or O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
in O
_RARE_ I-GENE
or O
_RARE_ I-GENE
cells O
triggers O
activation O
of O
both O
RhoA I-GENE
and O
Rac1 I-GENE
, O
but O
not O
of O
Cdc42 I-GENE
. O

In O
conclusion O
, O
our O
data O
do O
not O
support O
a O
role O
for O
_RARE_ I-GENE
in O
the O
_RARE_ I-GENE
of O
stable O
multiple O
sclerosis O
lesions O
as O
measured O
by O
central O
conduction O
time O
. O

The O
_RARE_ I-GENE
_RARE_ I-GENE
growing O
on O
the O
right O
flank O
of O
male O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
rats O
was O
_RARE_ I-GENE
for O
2 I-GENE
or O
4 I-GENE
h O
at O
20 O
degrees O
C I-GENE
or O
37 O
degrees O
C I-GENE
. O

_RARE_ I-GENE
to O
_RARE_ I-GENE
control O
_RARE_ I-GENE
( O
e O
. O
g O
., O
_RARE_ I-GENE
), O
these O
_RARE_ I-GENE
- I-GENE
dependent I-GENE
_RARE_ I-GENE
anomalies O
elicited O
a O
large O
_RARE_ I-GENE
effect O
that O
_RARE_ I-GENE
at O
about O
200 O
to O
250 O
msec O
after O
_RARE_ I-GENE
onset O
. O

These O
synergistic O
effects O
were O
strongly O
_RARE_ I-GENE
- I-GENE
1 I-GENE
dose O
- I-GENE
dependent I-GENE
. O

Like O
the O
_RARE_ I-GENE
protein I-GENE
, O
_RARE_ I-GENE
inhibited O
cell O
cycle O
progression O
from O
the O
_RARE_ I-GENE
/ I-GENE
G1 I-GENE
to O
S I-GENE
phases O
. O

The O
coordinate O
increase O
in O
cyclin I-GENE
D1 I-GENE
and O
p21 I-GENE
had O
the O
effect O
of O
decreasing O
the O
specific I-GENE
but O
not O
absolute O
activity O
of O
cyclin I-GENE
D1 I-GENE
/ I-GENE
_RARE_ I-GENE
. O
p53 I-GENE
was O
not O
involved O
since O
CSF I-GENE
- I-GENE
1 I-GENE
induction O
of O
p21 I-GENE
was O
unaffected O
by O
dominant I-GENE
- I-GENE
negative O
p53 I-GENE
expression O
. O

In O
addition O
, O
_RARE_ I-GENE
displays O
high O
homology I-GENE
to O
microtubule I-GENE
and O
nuclear I-GENE
associated I-GENE
protein I-GENE
( O
M I-GENE
- I-GENE
_RARE_ I-GENE
) O
and O
_RARE_ I-GENE
- I-GENE
46 O
, O
both O
of O
unknown O
function O
. O

In O
this O
study O
26 O
patients O
( O
20 O
females O
and O
6 I-GENE
males O
) O
were O
evaluated O
. O

The O
signalling O
molecules I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
, O
implicated O
in O
the O
activation O
of O
_RARE_ I-GENE
in O
myogenic I-GENE
progenitor I-GENE
cells O
in O
the O
_RARE_ I-GENE
, O
are O
also O
produced O
in O
the O
_RARE_ I-GENE
of O
the O
_RARE_ I-GENE
expression O
domain I-GENE
in O
the O
_RARE_ I-GENE
. O

_RARE_ I-GENE
DESIGN O
AND O
METHODS O
: O
A I-GENE
study O
was O
initiated O
to O
compare O
the O
collection O
of O
_RARE_ I-GENE
with O
the O
new O
device O
, O
the O
_RARE_ I-GENE
( O
version O
[ O
V I-GENE
] O
6 I-GENE
. O
0 O
with O
_RARE_ I-GENE
_RARE_ I-GENE
set O
), O
and O
that O
with O
the O
_RARE_ I-GENE
( O
mononuclear O
cell O
) O
procedure O
( O
_RARE_ I-GENE
. O
7 O
with O
white O
cell O
_RARE_ I-GENE
set O
), O
for O
patients O
and O
healthy O
donors O
. O

_RARE_ I-GENE
dialysis O
: O
effective O
removal O
of O
copper I-GENE
in O
a O
patient O
with O
_RARE_ I-GENE
_RARE_ I-GENE
disease O
and O
successful O
_RARE_ I-GENE
to O
liver O
transplantation O
: O
a O
new O
possibility O
for O
the O
elimination O
of O
protein I-GENE
- I-GENE
bound O
_RARE_ I-GENE
. O

Some O
artificial O
promoter I-GENE
constructs I-GENE
containing O
multiple O
Sp1 I-GENE
sites I-GENE
were O
highly O
responsive I-GENE
to O
ethanol O
, O
but O
others O
were O
not O
, O
suggesting O
that O
the O
organization O
of O
the O
proximal I-GENE
promoter I-GENE
region O
was O
an O
additional O
factor I-GENE
that O
affected O
the O
ethanol O
response O
. O

Overexpression O
of O
CDP I-GENE
/ I-GENE
cut I-GENE
in O
ROS I-GENE
17 O
/ I-GENE
2 I-GENE
. O
8 O
osteosarcoma O
cells O
results O
in O
repression O
of O
OC I-GENE
promoter I-GENE
activity O
; O
this O
repression O
is O
abrogated O
by O
_RARE_ I-GENE
OC I-GENE
box I-GENE
I I-GENE
. O

_RARE_ I-GENE
of O
double O
- I-GENE
stranded I-GENE
RNA I-GENE
into O
C I-GENE
. O
elegans I-GENE
results O
in O
embryonic O
lethality O
; O
thus O
, O
the O
_RARE_ I-GENE
gene I-GENE
is O
essential O
not O
only O
in O
yeast I-GENE
but O
also O
in O
at O
least O
one O
metazoan I-GENE
. O

Both O
domains I-GENE
were O
required O
for O
specific I-GENE
DNA I-GENE
binding I-GENE
to O
the O
beta I-GENE
- I-GENE
retinoic I-GENE
acid I-GENE
receptor I-GENE
element I-GENE
, O
producing O
a O
DNase I-GENE
I I-GENE
footprint O
covering O
predominantly O
one O
strand O
. O

_RARE_ I-GENE
family I-GENE
proteins I-GENE
are O
zinc I-GENE
finger I-GENE
transcriptional O
regulators O
first O
identified O
in O
Drosophila I-GENE
which O
play O
critical O
roles O
in O
cell O
fate O
determination O
. O

Consistent O
with O
this O
finding O
, O
beta I-GENE
- I-GENE
catenin I-GENE
interacted O
directly O
with O
the O
RA O
receptor I-GENE
( O
RAR I-GENE
) O
in O
a O
retinoid I-GENE
- I-GENE
dependent I-GENE
manner O
, O
but O
not O
with O
the O
retinoid I-GENE
X I-GENE
receptor I-GENE
( O
RXR I-GENE
), O
and O
RAR I-GENE
_RARE_ I-GENE
with O
TCF I-GENE
for O
beta I-GENE
- I-GENE
catenin I-GENE
binding I-GENE
. O

Sequence O
analysis O
of O
the O
promoter I-GENE
region O
showed O
no O
TATA I-GENE
box I-GENE
but O
identified O
consensus I-GENE
binding I-GENE
motifs O
for O
Sp1 I-GENE
, O
CREB I-GENE
, O
and O
half O
sites I-GENE
of O
the O
estrogen I-GENE
receptor I-GENE
binding I-GENE
site I-GENE
. O

_RARE_ I-GENE
kinase I-GENE
gene I-GENE
structure O
and O
transcriptional O
regulation O
. O

_RARE_ I-GENE
was O
followed O
by O
a O
similar O
increase O
of O
platelet I-GENE
activity O
with O
maximal O
values O
reached O
at O
the O
_RARE_ I-GENE
hour O
in O
both O
groups O
( O
_RARE_ I-GENE
+/- O
43 I-GENE
IU O
/ I-GENE
ml O
in O
Group O
1 I-GENE
and O
192 I-GENE
+/- O
39 O
in O
Group O
2 I-GENE
: O
p O
& O
_RARE_ I-GENE
; O
_RARE_ I-GENE
baseline O
and O
p O
NS I-GENE
between O
the O
groups O
). O

Similar O
to O
_RARE_ I-GENE
, O
isolated O
_RARE_ I-GENE
binds O
DNA I-GENE
with O
moderate O
strength O
and O
was O
a O
specificity O
for O
double O
- I-GENE
stranded I-GENE
primer O
- I-GENE
template O
DNA I-GENE
. O

Finally O
, O
three O
new O
missense O
mutations O
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
, O
were O
identified O
in O
the O
human I-GENE
AC I-GENE
gene I-GENE
from O
_RARE_ I-GENE
patients O
. O

These O
data O
indicate O
that O
the O
interaction O
of O
_RARE_ I-GENE
with O
the O
middle I-GENE
region O
of O
_RARE_ I-GENE
is O
necessary O
for O
translation I-GENE
, O
whereas O
the O
interaction O
of O
_RARE_ I-GENE
with O
the O
C I-GENE
- I-GENE
terminal I-GENE
region O
plays O
a O
_RARE_ I-GENE
role O
. O

The O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
apoptotic O
form O
was O
more O
potent O
than O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
in O
these O
functional O
assays O
. O

12 O
: O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
, O
1998 O
): O
a O
key O
step O
of O
this O
model O
is O
the O
activation O
of O
the O
MAPK I-GENE
_RARE_ I-GENE
through O
the O
G I-GENE
( O
_RARE_ I-GENE
)- I-GENE
dependent I-GENE
_RARE_ I-GENE
of O
the O
_RARE_ I-GENE
- I-GENE
MAPK I-GENE
cascade O
to O
the O
plasma I-GENE
membrane I-GENE
. O

Consistent O
with O
this O
finding O
, O
wild I-GENE
- I-GENE
type I-GENE
_RARE_ I-GENE
inhibits O
TBP I-GENE
binding I-GENE
to O
the O
HIS3 I-GENE
promoter I-GENE
in O
vitro O
, O
while O
_RARE_ I-GENE
lacking O
_RARE_ I-GENE
or O
_RARE_ I-GENE
is O
not O
inhibitory I-GENE
. O

Saccharomyces I-GENE
cerevisiae I-GENE
contains O
a O
genetically O
and O
_RARE_ I-GENE
proven O
CAK I-GENE
gene I-GENE
, O
_RARE_ I-GENE
, O
that O
encodes O
a O
monomeric I-GENE
44 I-GENE
- I-GENE
kDa I-GENE
_RARE_ I-GENE
protein I-GENE
unrelated O
to O
_RARE_ I-GENE
. O

Northern O
blot O
and O
reverse I-GENE
transcription I-GENE
- I-GENE
PCR O
analyses O
of O
human I-GENE
mRNA I-GENE
samples O
demonstrate O
that O
_RARE_ I-GENE
is O
expressed O
exclusively O
in O
the O
retina O
, O
with O
transcripts I-GENE
of O
approximately O
7 O
. O
5 I-GENE
kb O
, O
approximately O
3 I-GENE
. O
0 O
kb O
, O
and O
approximately O
2 I-GENE
. O
3 I-GENE
kb O
by O
Northern O
blot O
analysis O
. O

_RARE_ I-GENE
striking O
was O
the O
conservation O
of O
an O
AP I-GENE
- I-GENE
4 I-GENE
binding I-GENE
site I-GENE
within O
100 O
nucleotides O
upstream O
of O
the O
transcription I-GENE
initiation I-GENE
site I-GENE
in O
both O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
genes I-GENE
. O

Based O
on O
a O
type I-GENE
I I-GENE
error O
of O
0 O
. O
05 O
, O
our O
study O
had O
a O
power O
greater O
than O
or O
equal O
to O
75 O
% O
to O
detect O
group O
differences O
in O
treatment O
effect O
of O
greater O
than O
or O
equal O
to O
15 O
% O
to O
20 O
%. O

CONCLUSIONS O
: O
Serum I-GENE
levels O
of O
S I-GENE
- I-GENE
_RARE_ I-GENE
are O
reliable O
markers O
for O
adverse O
neurologic O
outcomes O
after O
cardiac O
surgery O
. O

However O
, O
no O
genetic O
alteration O
was O
detected O
in O
any O
of O
the O
cancers O
examined O
. O

All O
problems O
were O
associated I-GENE
with O
_RARE_ I-GENE
or O
lost O
_RARE_ I-GENE
. O

_RARE_ I-GENE
: O
lower O
lipids O
and O
better O
_RARE_ I-GENE
? O
Although O
_RARE_ I-GENE
are O
widely O
used O
as O
cholesterol I-GENE
- I-GENE
lowering O
drugs O
, O
a O
recent O
study O
suggests O
that O
these O
compounds O
have O
_RARE_ I-GENE
effects O
on O
bone O
and O
could O
be O
developed O
into O
new O
treatments O
for O
common O
metabolic O
bone O
diseases O
such O
as O
_RARE_ I-GENE

The O
accumulated O
products I-GENE
of O
_RARE_ I-GENE
duplication O
events O
can O
be O
readily O
observed O
among O
the O
genes I-GENE
encoding O
voltage O
- I-GENE
dependent I-GENE
Ca I-GENE
( O
2 I-GENE
+) O
ion O
channels I-GENE
. O

The O
_RARE_ I-GENE
response O
regulator I-GENE
from O
_RARE_ I-GENE
_RARE_ I-GENE
binds O
independently O
to O
two O
_RARE_ I-GENE
direct O
repeats I-GENE
located O
upstream O
of O
the O
_RARE_ I-GENE
promoter I-GENE
. O

Cloning O
and O
sequencing O
of O
the O
upstream O
region O
of O
_RARE_ I-GENE
revealed O
the O
presence O
of O
two O
ORFs O
of O
_RARE_ I-GENE
and O
1 I-GENE
, O
_RARE_ I-GENE
bp O
that O
were O
shown O
to O
be O
able O
to O
encode O
proteins I-GENE
with O
high O
homology I-GENE
to O
_RARE_ I-GENE
and O
_RARE_ I-GENE
proteins I-GENE
, O
respectively O
. O

_RARE_ I-GENE
: O
To O
evaluate O
endometrial O
thickness O
and O
the O
incidence O
of O
uterine O
bleeding O
in O
_RARE_ I-GENE
women O
using O
either O
_RARE_ I-GENE
2 I-GENE
. O
5 I-GENE
mg O
or O
continuous O
combined O
2 I-GENE
mg O
estradiol O
and O
1 I-GENE
mg O
_RARE_ I-GENE
acetate O
( O
E I-GENE
+ I-GENE
_RARE_ I-GENE
) O
daily O
as O
hormone I-GENE
replacement O
therapy O
. O

_RARE_ I-GENE
cultures O
, O
prepared O
from O
blood O
_RARE_ I-GENE
from O
these O
18 O
children O
at O
6 I-GENE
months O
of O
age O
, O
produced O
lower O
yields O
of O
IFN I-GENE
than O
those O
of O
the O
remaining O
53 O
children O
, O
when O
stimulated O
with O
adenovirus I-GENE
( O
P I-GENE
< O
0 O
. O
001 O
), O
coronavirus O
( O
P I-GENE
< O
0 O
. O
001 O
) O
or O
_RARE_ I-GENE
( O
P I-GENE
= O
0 O
. O
_RARE_ I-GENE
). O

In O
the O
BF I-GENE
_RARE_ I-GENE
group O
the O
- I-GENE
age O
based O
dose O
would O
have O
been O
similarly O
dependent I-GENE
on O
the O
initial O
seizure O
threshold O
level O
. O

Histological O
analysis O
showed O
that O
the O
neuronal O
loss O
in O
the O
_RARE_ I-GENE
- I-GENE
treated O
group O
was O
_RARE_ I-GENE
reduced O
in O
the O
hippocampal O
area O
( O
_RARE_ I-GENE
) O
of O
ischemic O
rats O
and O
in O
the O
_RARE_ I-GENE
gyrus O
and O
hippocampal O
area O
( O
_RARE_ I-GENE
and O
CA3 O
) O
of O
EC I-GENE
- I-GENE
lesioned O
rats O
compared O
with O
the O
_RARE_ I-GENE
group O
. O

The O
_RARE_ I-GENE
of O
phosphorylation O
of O
_RARE_ I-GENE
and O
_RARE_ I-GENE
were O
1 I-GENE
: O
1 I-GENE
, O
whereas O
those O
of O
the O
four O
minor O
sites I-GENE
all O
together O
were O
< O
30 O
% O
of O
the O
major I-GENE
one O
. O

Serum I-GENE
HBV O
- I-GENE
DNA I-GENE
, O
viral I-GENE
_RARE_ I-GENE
, O
and O
liver O
enzymes O
were O
measured O
_RARE_ I-GENE
; O
liver O
_RARE_ I-GENE
was O
taken O
before O
and O
during O
treatment O
in O
12 O
patients O
. O

Chem O
. O

_RARE_ I-GENE
induction O
of O
AP I-GENE
- I-GENE
1 I-GENE
was O
reached O
at O
a O
concentration O
of O
250 O
nmol O
/ I-GENE
L I-GENE
of O
_RARE_ I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
n O
. O
g O
., O
n O
. O
sp O
. O

_RARE_ I-GENE
were O
_RARE_ I-GENE
and O
testis I-GENE
size O
was O
estimated O
by O
_RARE_ I-GENE
at O
each O
time O
period O
. O

_RARE_ I-GENE
studies O
showed O
that O
beam O
_RARE_ I-GENE
significantly O
improved O
_RARE_ I-GENE
and O
angiographic O
image O
quality O
. O

Role O
of O
estrogen I-GENE
receptor I-GENE
ligand O
and O
estrogen I-GENE
response O
element I-GENE
sequence I-GENE
on O
interaction O
with O
chicken I-GENE
_RARE_ I-GENE
upstream O
promoter I-GENE
transcription I-GENE
factor I-GENE
( O
COUP I-GENE
- I-GENE
TF I-GENE
). O

CONCLUSION O
: O
In O
_RARE_ I-GENE
functioning O
throughout O
the O
cell O
cycle O
, O
tyrosine I-GENE
phosphorylation O
is O
inhibitory I-GENE
to O
the O
activation O
of O
kinase I-GENE
, O
whereas O
the O
phosphorylation O
of O
threonine I-GENE
in O
the O
T I-GENE
- I-GENE
loop I-GENE
is O
essential O
for O
activation O
. O

We O
also O
report O
that O
_RARE_ I-GENE
interacts O
with O
COUP I-GENE
- I-GENE
TF I-GENE
in O
transfected O
_RARE_ I-GENE
- I-GENE
1 I-GENE
cells O
. O

_RARE_ I-GENE
. O

The O
prevalence O
of O
hepatitis I-GENE
C I-GENE
virus I-GENE
( O
HCV I-GENE
) O
infection O
is O
relatively O
low O
in O
childhood O
, O
with O
anti I-GENE
- I-GENE
HCV I-GENE
prevalence O
rates O
of O
0 O
. O
1 I-GENE
- I-GENE
0 O
. O
4 I-GENE
% O
in O
the O
Western O
world O
. O

_RARE_ I-GENE
and O
_RARE_ I-GENE
- I-GENE
based O
information O
should O
be O
provided O
to O
patients O
as O
to O
the O
means O
of O
prevention O
with O
special O
attention O
to O
individual O
risk O
groups O
such O
as O
IV I-GENE
drug O
_RARE_ I-GENE
. O

During O
latency O
, O
more O
than O
1 I-GENE
% O
of O
neurons O
in O
_RARE_ I-GENE
that O
_RARE_ I-GENE
the O
_RARE_ I-GENE
expressed O
beta I-GENE
- I-GENE
galactosidase I-GENE
, O
with O
the O
number O
of O
positive O
cells O
remaining O
constant O
for O
at O
least O
5 I-GENE
months O
. O

As O
an O
alternative O
approach O
to O
this O
question O
, O
we O
have O
studied O
the O
effects O
of O
_RARE_ I-GENE
expressed O
_RARE_ I-GENE
, O
SHP I-GENE
- I-GENE
1 I-GENE
, O
or O
SHP I-GENE
- I-GENE
2 I-GENE
SH2 I-GENE
- I-GENE
containing O
_RARE_ I-GENE
proteins I-GENE
on O
Fc I-GENE
gamma I-GENE
_RARE_ I-GENE
signaling O
. O

_RARE_ I-GENE
to O
those O
with O
normal O
renal O
functions O
, O
these O
patients O
were O
older O
( O
P I-GENE
< O
or O
= O
0 O
. O
01 O
), O
had O
significantly O
elevated O
blood O
pressures O
( O
P I-GENE
< O
0 O
. O
01 O
or O
P I-GENE
= O
0 O
. O
0001 O
), O
and O
in O
the O
case O
of O
Type O
1 I-GENE
DM O
, O
with O
a O
higher O
body O
mass O
index O
( O
P I-GENE
= O
0 O
. O
0001 O
) O
and O
_RARE_ I-GENE
- I-GENE
hip O
ratio O
( O
P I-GENE
< O
0 O
. O
01 O
). O

In O
all O
tissues O
examined O
only O
transcripts I-GENE
positive O
for O
insert O
3 I-GENE
, O
an O
18 O
bp O
insertion O
in O
repeat I-GENE
21 O
, O
were O
amplified O
, O
even O
under O
conditions O
in O
which O
a O
30 O
% O
level O
of O
insert O
3 I-GENE
negative O
transcript I-GENE
could O
be O
easily O
detected O
in O
artificially O
prepared O
control O
samples O
. O

These O
results O
show O
that O
the O
CAAT I-GENE
- I-GENE
region O
is O
involved O
in O
_RARE_ I-GENE
the O
_RARE_ I-GENE
promoter I-GENE
in O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
cells O
. O

Both O
receptors I-GENE
_RARE_ I-GENE
protein I-GENE
tyrosine I-GENE
kinases I-GENE
( O
_RARE_ I-GENE
) O
for O
the O
phosphorylation O
of O
various O
signaling O
molecules I-GENE
, O
a O
process O
that O
is O
critical O
for O
the O
function O
of O
both O
receptors I-GENE
. O

_RARE_ I-GENE
After O
Cardiac I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
Study O
Group O
. O

The O
synergistic O
effect O
due O
to O
the O
5 I-GENE
'- O
3 I-GENE
' O
cooperation O
was O
at O
least O
fourfold O
greater O
than O
the O
sum O
of O
the O
_RARE_ I-GENE
of O
the O
individual O
_RARE_ I-GENE
. O

We O
demonstrate O
that O
both O
R I-GENE
and O
Z I-GENE
activate O
the O
cellular O
stress O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
( O
MAP I-GENE
) O
kinases I-GENE
, O
p38 I-GENE
and O
JNK I-GENE
, O
resulting O
in O
phosphorylation O
( O
and O
activation O
) O
of O
the O
cellular O
transcription I-GENE
factor I-GENE
_RARE_ I-GENE
. O

Two O
US O
commercial O
_RARE_ I-GENE
( O
_RARE_ I-GENE
and O
_RARE_ I-GENE
), O
three O
European O
commercial O
_RARE_ I-GENE
( O
_RARE_ I-GENE
, O
139 O
, O
_RARE_ I-GENE
) O
and O
five O
New O
_RARE_ I-GENE
_RARE_ I-GENE
( O
Rex I-GENE
, O
_RARE_ I-GENE
' O
s O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
) O
were O
evaluated O
. O

_RARE_ I-GENE
of O
the O
uterine O
artery O
. O

However O
, O
activation O
of O
the O
cAMP I-GENE
pathway O
, O
which O
is O
known O
to O
regulate O
_RARE_ I-GENE
alpha I-GENE
expression O
, O
greatly O
enhanced O
the O
actions O
of O
SF I-GENE
- I-GENE
1 I-GENE
. O

Deletion O
and O
site I-GENE
- I-GENE
directed O
mutagenesis O
localized O
a O
novel O
SF I-GENE
- I-GENE
1 I-GENE
regulatory I-GENE
element I-GENE
( O
_RARE_ I-GENE
_RARE_ I-GENE
; O
- I-GENE
_RARE_ I-GENE
to O
- I-GENE
_RARE_ I-GENE
) O
adjacent O
to O
a O
variant I-GENE
cAMP I-GENE
- I-GENE
response O
element I-GENE
( O
CRE O
; O
- I-GENE
120 O
to O
- I-GENE
114 I-GENE
). O

Previously O
, O
we O
showed O
that O
the O
_RARE_ I-GENE
is O
a O
cytokine O
[ O
tumor I-GENE
necrosis I-GENE
factor I-GENE
- I-GENE
alpha I-GENE
( O
_RARE_ I-GENE
_RARE_ I-GENE
inducible I-GENE
enhancer I-GENE
by O
binding I-GENE
the O
heterodimeric I-GENE
nuclear I-GENE
factor I-GENE
- I-GENE
kappaB I-GENE
( O
NF I-GENE
- I-GENE
kappaB I-GENE
) O
complex I-GENE
Rel I-GENE
A I-GENE
x O
NF I-GENE
- I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
II I-GENE
induces O
nuclear I-GENE
factor I-GENE
( O
NF I-GENE
)- I-GENE
_RARE_ I-GENE
isoforms I-GENE
to O
bind O
the O
_RARE_ I-GENE
gene I-GENE
acute O
- I-GENE
phase O
response O
element I-GENE
: O
a O
stimulus O
- I-GENE
specific I-GENE
pathway O
for O
NF I-GENE
- I-GENE
kappaB I-GENE
activation O
. O

_RARE_ I-GENE
ligands O
have O
been O
identified O
that O
_RARE_ I-GENE
and O
_RARE_ I-GENE
the O
cycle O
of O
_RARE_ I-GENE
GH I-GENE
secretion O
by O
interacting I-GENE
with O
the O
orphan I-GENE
GH I-GENE
- I-GENE
_RARE_ I-GENE
receptor I-GENE
( O
_RARE_ I-GENE
- I-GENE
R I-GENE
). O

The O
collection O
of O
mutants I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
sorting I-GENE
defects O
includes O
members O
with O
mutations O
in O
previously O
identified O
vacuolar I-GENE
protein I-GENE
sorting I-GENE
genes I-GENE
( O
_RARE_ I-GENE
), O
including O
the O
_RARE_ I-GENE
family I-GENE
member O
_RARE_ I-GENE
. O

Also O
in O
the O
spectrum O
of O
mutants I-GENE
with O
_RARE_ I-GENE
sorting I-GENE
defects O
are O
isolates O
with O
mutations O
in O
the O
following O
: O
_RARE_ I-GENE
, O
encoding O
a O
product I-GENE
_RARE_ I-GENE
proposed O
to O
participate O
in O
ribosome I-GENE
biogenesis O
; O
_RARE_ I-GENE
, O
encoding O
a O
product I-GENE
potentially O
involved O
in O
_RARE_ I-GENE
and O
microtubule I-GENE
organization O
; O
and O
_RARE_ I-GENE
, O
encoding O
a O
_RARE_ I-GENE
- I-GENE
like I-GENE
inositol I-GENE
_RARE_ I-GENE
5 I-GENE
- I-GENE
phosphatase I-GENE
. O

The O
single O
_RARE_ I-GENE
is O
manifested O
as O
a O
terminal I-GENE
extension O
of O
the O
G I-GENE
- I-GENE
rich O
strand O
( O
G I-GENE
tails O
) O
that O
can O
occur O
independently O
of O
telomerase I-GENE
, O
suggesting O
that O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
mutants I-GENE
exhibit O
defects O
in O
telomeric O
_RARE_ I-GENE
- I-GENE
strand O
synthesis O
. O

In O
addition O
, O
_RARE_ I-GENE
formed O
specific I-GENE
complexes I-GENE
with O
the O
_RARE_ I-GENE
region O
of O
the O
S I-GENE
. O
cerevisiae I-GENE
_RARE_ I-GENE
gene I-GENE
. O

Furthermore O
, O
the O
wide O
distribution O
of O
the O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
protein I-GENE
to O
all O
_RARE_ I-GENE
of O
the O
mitotic O
apparatus O
provides O
a O
valuable O
tool O
for O
future O
studies O
on O
cell O
cycle O
during O
development O
. O

An O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
for O
_RARE_ I-GENE
depth O
analysis O
in O
_RARE_ I-GENE
- I-GENE
real O
- I-GENE
time O
based O
on O
visual O
cortical O
cell O
behavior O
. O

However O
, O
_RARE_ I-GENE
C I-GENE
, O
a O
specific I-GENE
inhibitor I-GENE
of O
PKC I-GENE
, O
abolished O
the O
TPA O
- I-GENE
induced O
increase O
in O
_RARE_ I-GENE
mRNA I-GENE
levels O
. O

_RARE_ I-GENE
IgG I-GENE
, O
anti I-GENE
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
fragments I-GENE
, O
_RARE_ I-GENE
polymers O
and O
monomeric I-GENE
N I-GENE
- I-GENE
_RARE_ I-GENE
had O
no O
effect O
. O

_RARE_ I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
is O
maintained O
as O
a O
_RARE_ I-GENE
of O
_RARE_ I-GENE
because O
the O
_RARE_ I-GENE
between O
two O
and O
three O
_RARE_ I-GENE
types O
is O
made O
_RARE_ I-GENE
when O
the O
transition O
between O
the O
_RARE_ I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
is O
_RARE_ I-GENE
. O

We O
describe O
a O
case O
of O
_RARE_ I-GENE
_RARE_ I-GENE
that O
was O
treated O
with O
both O
hemodialysis O
( O
HD I-GENE
) O
and O
_RARE_ I-GENE
due O
to O
severe O
_RARE_ I-GENE
and O
slow O
drug O
clearance O
. O

Following O
conditioning O
, O
a O
single O
coat I-GENE
of O
adhesive O
was O
applied O
and O
light I-GENE
- I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
of O
the O
G I-GENE
- I-GENE
A I-GENE
anastomosis O
, O
the O
RD I-GENE
, O
CC O
, O
E I-GENE
( O
p O
) O
and O
loop I-GENE
areas O
were O
significantly O
different O
from O
_RARE_ I-GENE
, O
but O
significantly O
different O
from O
A I-GENE
- I-GENE
A I-GENE
. O

_RARE_ I-GENE
expression O
of O
c I-GENE
- I-GENE
myc I-GENE
is O
likely O
to O
contribute O
to O
the O
proliferation O
of O
_RARE_ I-GENE
- I-GENE
null I-GENE
cells O
in O
response O
to O
_RARE_ I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
Group O
trial O
_RARE_ I-GENE
was O
initiated O
to O
explore O
this O
question O
. O

We O
determined O
how O
DNA I-GENE
repair I-GENE
is O
affected O
by O
_RARE_ I-GENE
conditional O
mutations O
. O

These O
_RARE_ I-GENE
both O
report O
the O
results O
of O
multi I-GENE
- I-GENE
_RARE_ I-GENE
, O
randomized O
, O
phase O
3 I-GENE
trials O
for O
the O
treatment O
of O
patients O
with O
localized O
( O
T1 O
- I-GENE
3 I-GENE
_RARE_ I-GENE
- I-GENE
1 I-GENE
_RARE_ I-GENE
) O
esophageal O
squamous O
cell O
carcinoma O
( O
_RARE_ I-GENE
) O
or O
esophageal O
adenocarcinoma O
. O

Studies O
of O
_RARE_ I-GENE
gene I-GENE
regulation O
can O
help O
to O
elucidate O
the O
mechanism O
of O
normal O
and O
abnormal O
myeloid O
differentiation O
. O

_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
was O
co O
- I-GENE
precipitated O
with O
PKN I-GENE
from O
the O
_RARE_ I-GENE
of O
COS O
- I-GENE
7 O
cells O
transfected O
with O
both O
expression O
constructs I-GENE
for O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
and O
PKN I-GENE
. O

Transient O
transfection O
assays O
using O
P19 O
cells O
revealed O
that O
expression O
of O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
increased O
the O
transactivation O
of O
the O
rat I-GENE
insulin I-GENE
promoter I-GENE
element I-GENE
3 I-GENE
( O
_RARE_ I-GENE
) O
enhancer I-GENE
up O
to O
approximately O
12 O
- I-GENE
fold O
and O
that O
co O
- I-GENE
expression O
of O
catalytically O
active O
form O
of O
PKN I-GENE
, O
but O
not O
kinase I-GENE
- I-GENE
deficient O
derivative O
, O
resulted O
in O
a O
further O
threefold O
increase O
of O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
- I-GENE
mediated O
transcription I-GENE
. O

Two O
_RARE_ I-GENE
/ I-GENE
5 I-GENE
/ I-GENE
8 O
- I-GENE
binding I-GENE
sites I-GENE
in O
_RARE_ I-GENE
are O
required O
for O
proper O
initiation I-GENE
of O
endogenous I-GENE
mid O
- I-GENE
_RARE_ I-GENE
expression O
. O

Upon O
tyrosine I-GENE
phosphorylation O
at O
the O
_RARE_ I-GENE
, O
these O
molecules I-GENE
recruit O
SH2 I-GENE
domain I-GENE
- I-GENE
containing O
phosphatases I-GENE
such O
as O
SH2 I-GENE
- I-GENE
containing O
tyrosine I-GENE
phosphatase I-GENE
- I-GENE
1 I-GENE
and O
negatively O
regulate O
cell O
activity O
. O

_RARE_ I-GENE
. O

_RARE_ I-GENE
of O
the O
cervical O
spine O
, O
vertebral O
abnormalities O
, O
and O
disc O
changes O
also O
were O
evaluated O
. O

The O
concomitant O
interaction O
of O
_RARE_ I-GENE
with O
hsp70 I-GENE
and O
hsp90 I-GENE
at O
its O
N I-GENE
- I-GENE
and O
C I-GENE
- I-GENE
termini O
respectively O
is O
mediated O
by O
the O
_RARE_ I-GENE
repeat I-GENE
( O
TPR O
) O
motifs O
in O
these O
regions O
. O

Competition O
experiments O
demonstrate O
a O
negative O
_RARE_ I-GENE
relationship O
between O
these O
_RARE_ I-GENE
recognition I-GENE
sites I-GENE
. O

Sequence O
analysis O
showed O
that O
the O
5 I-GENE
'- O
flanking O
region O
upstream O
to O
the O
ATG O
codon O
did O
not O
contain O
a O
conventional O
TATA I-GENE
box I-GENE
. O

After O
i O
. O
v I-GENE
. O
administration O
of O
500 O
mg O
_RARE_ I-GENE
and O
_RARE_ I-GENE
of O
the O
_RARE_ I-GENE
, O
50 O
micrograms O
_RARE_ I-GENE
- I-GENE
PA I-GENE
in O
0 O
. O
1 I-GENE
ml O
( O
_RARE_ I-GENE
) O
and O
0 O
. O
5 I-GENE
ml O
_RARE_ I-GENE
were O
injected O
_RARE_ I-GENE
. O

These O
results O
suggest O
that O
_RARE_ I-GENE
was O
efficiently O
transported O
to O
the O
nucleus O
and O
localized O
in O
the O
discrete O
_RARE_ I-GENE
regions O
, O
possibly O
with O
_RARE_ I-GENE
and O
_RARE_ I-GENE
. O

Differential O
expression O
and O
regulation O
by O
20 O
- I-GENE
_RARE_ I-GENE
of O
_RARE_ I-GENE
_RARE_ I-GENE
isoforms I-GENE
. O

The O
three O
isoforms I-GENE
purified O
with O
anti I-GENE
- I-GENE
_RARE_ I-GENE
antibody I-GENE
affinity O
column O
transferred O
sulfate I-GENE
to O
_RARE_ I-GENE
sulfate I-GENE
and O
heparin O
but O
not O
to O
other O
_RARE_ I-GENE
. O

The O
differentiation O
and O
maintenance O
of O
a O
_RARE_ I-GENE
phenotype O
is O
_RARE_ I-GENE
by O
the O
interaction O
of O
exogenous O
_RARE_ I-GENE
with O
intrinsic O
genetic O
machinery O
. O

Analysis O
of O
functional O
domains I-GENE
of O
_RARE_ I-GENE
reveals O
an O
N I-GENE
- I-GENE
terminal I-GENE
activation O
domain I-GENE
and O
a O
C I-GENE
- I-GENE
terminal I-GENE
repression O
domain I-GENE
. O

BACKGROUND O
: O
_RARE_ I-GENE
ventricular O
hypertrophy O
is O
a O
heterogeneous I-GENE
disorder O
with O
distinct O
_RARE_ I-GENE
. O

_RARE_ I-GENE
predictors O
were O
_RARE_ I-GENE
remodeling O
( O
P I-GENE
< O
0 O
. O
0001 O
; O
odds O
ratio O
, O
13 O
. O
5 I-GENE
), O
left O
ventricular O
ejection O
fraction O
> O
2 I-GENE
SD O
above O
normal O
( O
P I-GENE
< O
0 O
. O
0001 O
), O
and O
single O
- I-GENE
vessel O
left O
_RARE_ I-GENE
disease O
( O
P I-GENE
< O
0 O
. O
_RARE_ I-GENE
; O
odds O
ratio O
, O
7 O
. O
6 I-GENE
). O

The O
case O
for O
_RARE_ I-GENE
the O
_RARE_ I-GENE
when O
positive O
lymph O
nodes O
are O
found O
during O
radical O
hysterectomy O
for O
cervical O
carcinoma O
. O

Overexpression O
of O
_RARE_ I-GENE
in O
COS O
- I-GENE
1 I-GENE
- I-GENE
transfected O
cells O
induced O
an O
enhanced O
expression O
of O
endogenous I-GENE
topoisomerase I-GENE
_RARE_ I-GENE
. O

The O
RNA I-GENE
_RARE_ I-GENE
contains O
three O
_RARE_ I-GENE
separated O
by O
a O
pair O
of O
two O
- I-GENE
base O
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
an O
_RARE_ I-GENE
fold O
in O
which O
both O
_RARE_ I-GENE
sites I-GENE
are O
anchored I-GENE
through O
base O
triple O
formation O
. O

The O
study O
suggests O
the O
presence O
of O
an O
anatomical O
_RARE_ I-GENE
at O
the O
_RARE_ I-GENE
which O
seems O
to O
regulate O
the O
passage O
of O
_RARE_ I-GENE
from O
the O
_RARE_ I-GENE
colon O
to O
the O
_RARE_ I-GENE
. O

Isolation O
of O
cDNAs I-GENE
encoding O
_RARE_ I-GENE
and O
monkey I-GENE
platelet I-GENE
and O
T I-GENE
cell O
activation O
antigen I-GENE
1 I-GENE
( O
_RARE_ I-GENE
). O

To O
_RARE_ I-GENE
any O
mechanical O
inhibitory I-GENE
effect O
of O
nasal O
intermittent O
positive O
pressure O
ventilation O
( O
_RARE_ I-GENE
) O
on O
inspiratory O
activity O
of O
the O
diaphragm O
we O
ventilated O
five O
conscious O
_RARE_ I-GENE
subjects O
on O
two O
_RARE_ I-GENE
at O
respiratory O
rates O
similar O
to O
_RARE_ I-GENE
breathing O
( O
_RARE_ I-GENE
) O
and O
at O
three O
levels O
of O
applied O
pressure O
( O
_RARE_ I-GENE
_RARE_ I-GENE
6 I-GENE
, O
9 O
and O
12 O
cmH2O O
, O
each O
during O
_RARE_ I-GENE
( O
P I-GENE
( O
CO2 O
) O
allowed O
to O
decrease O
) O
and O
_RARE_ I-GENE
( O
CO2 O
added O
to O
_RARE_ I-GENE
gas O
). O

METHODS O
: O
_RARE_ I-GENE
Willebrand I-GENE
factor I-GENE
( O
vWF I-GENE
) O
and O
the O
_RARE_ I-GENE
factors I-GENE
tissue I-GENE
plasminogen I-GENE
activator I-GENE
( O
_RARE_ I-GENE
), O
measured O
as O
_RARE_ I-GENE
capacity O
, O
and O
plasminogen I-GENE
activator I-GENE
inhibitor I-GENE
1 I-GENE
( O
PAI I-GENE
- I-GENE
1 I-GENE
), O
platelets O
, O
fibrinogen I-GENE
, O
and O
inflammatory O
markers O
were O
measured O
in O
74 O
patients O
with O
active O
seropositive O
RA O
. O

_RARE_ I-GENE
signaling O
properties O
are O
largely O
determined O
by O
the O
_RARE_ I-GENE
and O
combination O
of O
ion O
channels I-GENE
expressed O
. O

Treatment O
also O
led O
to O
a O
significant O
dose O
dependent I-GENE
reduction O
in O
the O
sum O
of O
ST O
segment O
depression O
at O
both O
trough O
and O
peak O
concentrations O
. O

We O
have O
investigated O
the O
contribution O
of O
specific I-GENE
TATA I-GENE
- I-GENE
binding I-GENE
protein I-GENE
( O
TBP I-GENE
)- I-GENE
TATA I-GENE
interactions O
to O
the O
promoter I-GENE
activity O
of O
a O
constitutively O
expressed O
_RARE_ I-GENE
tRNA I-GENE
( O
C I-GENE
)( I-GENE
Ala I-GENE
) O
gene I-GENE
and O
have O
also O
_RARE_ I-GENE
whether O
the O
lack O
of O
similar O
interactions O
_RARE_ I-GENE
for O
the O
low O
promoter I-GENE
activity O
of O
a O
_RARE_ I-GENE
gland O
- I-GENE
specific I-GENE
tRNA I-GENE
( O
SG I-GENE
)( I-GENE
Ala I-GENE
) O
gene I-GENE
. O

The O
sequences I-GENE
showed O
extensive O
homologies O
with O
_RARE_ I-GENE
synthase I-GENE
genes I-GENE
and O
enzymes O
from O
a O
number O
of O
other O
organisms O
and O
extreme O
amino O
acid I-GENE
conservation O
within O
the O
binding I-GENE
and O
catalytic O
domains I-GENE
. O

All O
clones O
and O
strains O
produced O
have O
been O
_RARE_ I-GENE
in O
the O
_RARE_ I-GENE
genetic O
_RARE_ I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
, O
_RARE_ I-GENE
). O

Two O
episodes O
of O
_RARE_ I-GENE
occurred O
while O
the O
patient O
received O
_RARE_ I-GENE
( O
1 I-GENE
_RARE_ I-GENE
/ I-GENE
3 I-GENE
. O
5 I-GENE
patient O
- I-GENE
months O
). O

Copyright O
2000 O
The O
_RARE_ I-GENE
_RARE_ I-GENE
of O
_RARE_ I-GENE
. O

Two O
estrogen I-GENE
receptor I-GENE
( O
ER I-GENE
) O
isoforms I-GENE
with O
different O
estrogen I-GENE
_RARE_ I-GENE
are O
generated O
from O
the O
trout I-GENE
ER I-GENE
gene I-GENE
. O

Induction O
was O
reversed O
by O
coexpression O
of O
A I-GENE
- I-GENE
Fos I-GENE
, O
a O
dominant I-GENE
negative O
to O
AP I-GENE
- I-GENE
1 I-GENE
. O

In O
_RARE_ I-GENE
_RARE_ I-GENE
, O
both O
isoforms I-GENE
of O
the O
progesterone I-GENE
receptor I-GENE
, O
PR I-GENE
- I-GENE
B I-GENE
and O
PR I-GENE
- I-GENE
A I-GENE
, O
caused O
a O
ligand O
- I-GENE
dependent I-GENE
activation O
of O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
B I-GENE
(- O
_RARE_ I-GENE
/- O
_RARE_ I-GENE
) O
shows O
more O
than O
80 O
% O
homology I-GENE
to O
a O
consensus I-GENE
c I-GENE
- I-GENE
myb I-GENE
element I-GENE
, O
but O
formed O
two O
specific I-GENE
complexes I-GENE
that O
differed O
from O
that O
of O
c I-GENE
- I-GENE
myb I-GENE
in O
the O
electrophoretic O
mobility I-GENE
shift O
assay O
. O

High O
resolution O
computed O
tomography O
of O
the O
lungs O
in O
patients O
with O
rheumatoid I-GENE
arthritis O
. O

Stable O
transfection O
of O
the O
truncated I-GENE
reduced O
folate I-GENE
carrier I-GENE
cDNA I-GENE
into O
mouse I-GENE
_RARE_ I-GENE
leukemia I-GENE
cells O
: O
increased O
folate I-GENE
accumulation O
, O
decreased O
their O
_RARE_ I-GENE
and O
_RARE_ I-GENE
acid I-GENE
growth I-GENE
requirements O
, O
and O
increased O
their O
sensitivity O
to O
methotrexate O
. O

Characterization O
of O
a O
human I-GENE
alternatively O
spliced O
truncated I-GENE
reduced O
folate I-GENE
carrier I-GENE
increasing O
folate I-GENE
accumulation O
in O
parental O
leukemia I-GENE
cells O
. O

_RARE_ I-GENE
microscopic O
and O
enzymatic O
analyses O
revealed O
that O
the O
_RARE_ I-GENE
genome O
is O
a O
linear O
, O
_RARE_ I-GENE
_RARE_ I-GENE
, O
terminally I-GENE
_RARE_ I-GENE
collection O
of O
double O
- I-GENE
stranded I-GENE
DNA I-GENE
molecules I-GENE
. O

Moreover O
, O
increasing O
the O
dosage O
of O
wild I-GENE
- I-GENE
type I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
the O
inhibition O
of O
both O
Ty1 I-GENE
_RARE_ I-GENE
and O
invasive O
growth I-GENE
. O

_RARE_ I-GENE
, O
activation O
of O
c I-GENE
- I-GENE
Jun I-GENE
N I-GENE
- I-GENE
terminal I-GENE
kinase I-GENE
downstream O
of O
Rho I-GENE
family I-GENE
GTP I-GENE
- I-GENE
binding I-GENE
proteins I-GENE
was O
also O
enhanced O
when O
_RARE_ I-GENE
was O
tyrosine I-GENE
- I-GENE
phosphorylated O
. O

However O
, O
its O
participation O
in O
collagen I-GENE
binding I-GENE
has O
not O
been O
shown O
. O

Together O
, O
these O
data O
suggest O
that O
the O
carboxyl O
terminus O
of O
CFTR I-GENE
contains O
a O
tyrosine I-GENE
- I-GENE
based O
internalization O
signal I-GENE
that O
interacts O
with O
the O
endocytic O
adaptor I-GENE
complex I-GENE
AP I-GENE
- I-GENE
2 I-GENE
to O
facilitate O
efficient O
entry O
of O
CFTR I-GENE
into O
clathrin I-GENE
- I-GENE
_RARE_ I-GENE
vesicles O
. O

The O
insulin I-GENE
therapy O
regimen O
did O
not O
affect O
the O
evolution O
of O
the O
patients O
and O
no O
significant O
relationship O
existed O
between O
the O
age O
at O
diagnosis O
, O
duration O
of O
diabetes O
, O
daily O
insulin I-GENE
dosage O
or O
metabolic O
control O
and O
height O
or O
BMI O
. O

_RARE_ I-GENE
maps O
to O
_RARE_ I-GENE
- I-GENE
D2 I-GENE
. O
1 I-GENE
in O
mice O
. O

The O
_RARE_ I-GENE
of O
laparoscopic O
donor O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
has O
not O
been O
assessed O
in O
the O
obese O
donor O
. O

_RARE_ I-GENE
treatment O
stimulated O
collagen I-GENE
remodeling O
in O
the O
peripheral O
region O
and O
inhibited O
swelling O
of O
the O
_RARE_ I-GENE
_RARE_ I-GENE
in O
the O
inner O
region O
. O

We O
have O
addressed O
these O
issues O
by O
_RARE_ I-GENE
and O
characterizing O
the O
KRAB I-GENE
: O
_RARE_ I-GENE
- I-GENE
1 I-GENE
- I-GENE
_RARE_ I-GENE
interaction O
using O
purified O
components O
. O

The O
RING I-GENE
finger I-GENE
, O
B2 I-GENE
box I-GENE
, O
and O
coiled O
- I-GENE
coil O
region O
are O
required O
for O
oligomerization O
of O
_RARE_ I-GENE
- I-GENE
1 I-GENE
- I-GENE
_RARE_ I-GENE
and O
KRAB I-GENE
binding I-GENE
, O
as O
mutations O
in O
these O
domains I-GENE
_RARE_ I-GENE
abolished O
these O
functions O
. O

_RARE_ I-GENE
show O
two O
different O
forms O
of O
N I-GENE
- I-GENE
terminal I-GENE
processing O
dependent I-GENE
on O
their O
N I-GENE
- I-GENE
terminal I-GENE
sequence I-GENE
. O

All O
four O
domains I-GENE
were O
linked O
via O
proline O
- I-GENE
threonine I-GENE
- I-GENE
rich O
peptides I-GENE
. O

_RARE_ I-GENE
53 O
, O
resulting O
in O
a O
compression O
ratio O
of O
1 I-GENE
: O
21 O
, O
does O
not O
_RARE_ I-GENE
the O
diagnostic O
performance O
in O
general O
. O

We O
_RARE_ I-GENE
assess O
current O
systematic O
_RARE_ I-GENE
and O
determine O
the O
_RARE_ I-GENE
Li O
abundance O
within O
new O
, O
much O
_RARE_ I-GENE
limits O
: O
& O
_RARE_ I-GENE
; O
_RARE_ I-GENE
; O
Li O
& O
_RARE_ I-GENE
; O
_RARE_ I-GENE
; O
H I-GENE
& O
_RARE_ I-GENE
; O
_RARE_ I-GENE
; O
p O
= O
1 I-GENE
. O
23 O
+ I-GENE
0 O
. O
68 O
- I-GENE
0 O
. O
_RARE_ I-GENE
- I-GENE
10 O
. O

Like O
their O
yeast I-GENE
counterpart O
, O
the O
mouse I-GENE
GCN2 I-GENE
isoforms I-GENE
contain O
_RARE_ I-GENE
- I-GENE
related I-GENE
sequences I-GENE
_RARE_ I-GENE
to O
the O
kinase I-GENE
catalytic O
domain I-GENE
. O

Five O
women O
( O
15 O
. O
6 I-GENE
%) O
met I-GENE
criteria O
for O
_RARE_ I-GENE
. O

_RARE_ I-GENE
and O
_RARE_ I-GENE
showed O
similar O
_RARE_ I-GENE
values O
, O
but O
the O
former O
disappeared O
slower O
in O
the O
serum I-GENE
than O
the O
latter O
and O
resulted O
in O
its O
larger O
AUC O
values O
. O

Another O
long O
insertion O
in O
the O
_RARE_ I-GENE
X I-GENE
amino O
acid I-GENE
sequence I-GENE
forms O
a O
beta I-GENE
- I-GENE
hairpin O
_RARE_ I-GENE
_RARE_ I-GENE
from O
the O
active O
site I-GENE
. O

Transfection O
experiments O
demonstrated O
that O
the O
5 I-GENE
'- O
flanking O
region O
(- O
_RARE_ I-GENE
to O
+ I-GENE
37 O
) O
of O
the O
_RARE_ I-GENE
gene I-GENE
_RARE_ I-GENE
transcription I-GENE
in O
mouse I-GENE
_RARE_ I-GENE
cells O
and O
that O
a O
construct I-GENE
containing O
a O
fragment I-GENE
from O
- I-GENE
_RARE_ I-GENE
to O
+ I-GENE
37 O
showed O
the O
highest O
transcriptional O
activity O
. O

Further O
studies O
in O
T I-GENE
- I-GENE
24 O
cells O
demonstrated O
that O
HA I-GENE
fragments I-GENE
also O
induced O
I I-GENE
kappa I-GENE
B I-GENE
alpha I-GENE
phosphorylation O
and O
degradation O
, O
kappa I-GENE
B I-GENE
- I-GENE
linked O
reporter I-GENE
gene I-GENE
expression O
, O
and O
_RARE_ I-GENE
- I-GENE
1 I-GENE
promoter I-GENE
activity O
in O
an O
NF I-GENE
- I-GENE
kappa I-GENE
B I-GENE
- I-GENE
dependent I-GENE
manner O
. O

_RARE_ I-GENE
of O
cells O
or O
mouse I-GENE
skin O
with O
antisense I-GENE
oligonucleotides O
of O
_RARE_ I-GENE
impaired O
UV O
- I-GENE
induced O
activation O
of O
AP I-GENE
- I-GENE
1 I-GENE
in O
_RARE_ I-GENE
cells O
as O
well O
as O
in O
AP I-GENE
- I-GENE
1 I-GENE
- I-GENE
luciferase I-GENE
transgenic O
mice O
. O

The O
level O
of O
subclinical O
infection O
was O
75 O
% O
among O
seropositive O
dogs O
. O

METHODS O
: O
The O
former O
group O
included O
patients O
who O
had O
been O
treated O
with O
at O
least O
four O
_RARE_ I-GENE
alpha I-GENE
- I-GENE
_RARE_ I-GENE
, O
short O
- I-GENE
term O
treatment O
cycles O
per O
year O
while O
the O
latter O
was O
a O
_RARE_ I-GENE
reference O
group O
_RARE_ I-GENE
without O
prostaglandins O
. O

_RARE_ I-GENE
1a I-GENE
and O
_RARE_ I-GENE
2 I-GENE
would O
be O
more O
potent O
against O
_RARE_ I-GENE
than O
_RARE_ I-GENE
in O
vitro O
against O
two O
strains O
( O
_RARE_ I-GENE
and O
_RARE_ I-GENE
) O
of O
_RARE_ I-GENE
falciparum O
. O

The O
_RARE_ I-GENE
, O
_RARE_ I-GENE
mutant I-GENE
was O
partially O
_RARE_ I-GENE
by O
inactivation O
of O
_RARE_ I-GENE
or O
_RARE_ I-GENE
, O
suggesting O
an O
interaction O
between O
the O
_RARE_ I-GENE
genes I-GENE
and O
the O
_RARE_ I-GENE
signal I-GENE
transduction O
pathway O
. O

Members O
of O
the O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
family I-GENE
of O
tyrosine I-GENE
kinases I-GENE
mediate O
phosphorylation O
of O
STAT3 I-GENE
at O
_RARE_ I-GENE
during O
_RARE_ I-GENE
signaling O
; O
however O
, O
the O
kinase I-GENE
responsible O
for O
phosphorylation O
at O
STAT3 I-GENE
_RARE_ I-GENE
appears O
to O
depend O
on O
both O
the O
extracellular I-GENE
stimulus O
and O
the O
cellular O
context O
. O

In O
vivo O
, O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
activated I-GENE
transcription I-GENE
from O
an O
HD I-GENE
- I-GENE
_RARE_ I-GENE
luciferase I-GENE
reporter I-GENE
construct I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
encodes O
a O
_RARE_ I-GENE
Growth I-GENE
Factor I-GENE
beta I-GENE
( O
_RARE_ I-GENE
) O
signaling O
factor I-GENE
closely O
related I-GENE
to O
mouse I-GENE
_RARE_ I-GENE
. O

Thus O
, O
_RARE_ I-GENE
is O
a O
good O
candidate O
gene I-GENE
_RARE_ I-GENE
to O
the O
mental O
retardation O
phenotype O
seen O
in O
_RARE_ I-GENE
- I-GENE
16 O
patients O
. O

The O
genome O
organization O
of O
the O
mite I-GENE
- I-GENE
transmitted O
wheat I-GENE
_RARE_ I-GENE
mosaic O
virus I-GENE
( O
_RARE_ I-GENE
) O
appears O
to O
parallel O
that O
of O
members O
of O
the O
_RARE_ I-GENE
with O
_RARE_ I-GENE
genomes O
, O
but O
there O
are O
substantial O
amino O
acid I-GENE
_RARE_ I-GENE
with O
other O
_RARE_ I-GENE
_RARE_ I-GENE
. O

The O
two O
- I-GENE
hybrid O
assay O
was O
then O
performed O
using O
full I-GENE
- I-GENE
length I-GENE
genes I-GENE
of O
CI O
, O
_RARE_ I-GENE
- I-GENE
Pro I-GENE
, O
P1 I-GENE
, O
P3 I-GENE
, O
and O
CP I-GENE
, O
but O
no O
heterologous O
interactions O
were O
detected O
. O

_RARE_ I-GENE
endogenous I-GENE
light I-GENE
chains I-GENE
contribute O
to O
_RARE_ I-GENE
membrane I-GENE
reactivity O
in O
_RARE_ I-GENE
mice O
transgenic O
for O
an O
anti I-GENE
- I-GENE
_RARE_ I-GENE
Ig I-GENE
heavy I-GENE
chain I-GENE
. O

_RARE_ I-GENE
test O
results O
obtained O
with O
corticosteroid I-GENE
allergic O
patients O
tested O
with O
a O
large O
corticosteroid I-GENE
series O
_RARE_ I-GENE
the O
earlier O
classification O
of O
corticosteroid I-GENE
molecules I-GENE
in O
four O
groups O
of O
cross O
- I-GENE
_RARE_ I-GENE
molecules I-GENE
: O
i O
. O
e O
., O
group O
A I-GENE
( O
_RARE_ I-GENE
type I-GENE
), O
group O
B I-GENE
( O
_RARE_ I-GENE
), O
group O
C I-GENE
( O
_RARE_ I-GENE
type I-GENE
- I-GENE
non O
_RARE_ I-GENE
) O
and O
group O
D I-GENE
( O
esters O
). O

_RARE_ I-GENE
of O
_RARE_ I-GENE
in O
regional O
anesthesia O
of O
long O
duration O

An O
increase O
in O
the O
level O
of O
serum I-GENE
enzymes O
, O
such O
as O
aspartate I-GENE
_RARE_ I-GENE
, O
alkaline I-GENE
phosphatase I-GENE
, O
creatine I-GENE
_RARE_ I-GENE
, O
lactate I-GENE
dehydrogenase I-GENE
after O
D I-GENE
. O
_RARE_ I-GENE
_RARE_ I-GENE
injection O
in O
_RARE_ I-GENE
rats O
is O
indicative O
of O
cell O
or O
tissue I-GENE
damage O
. O

The O
partial O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
the O
importance O
of O
reducing O
sub O
- I-GENE
clinical O
lesions O
in O
a O
_RARE_ I-GENE
. O

Surprisingly O
, O
3 I-GENE
full I-GENE
- I-GENE
length I-GENE
murine I-GENE
_RARE_ I-GENE
cDNA I-GENE
clones O
were O
isolated O
, O
predicting O
the O
existence O
of O
3 I-GENE
distinct O
_RARE_ I-GENE
proteins I-GENE
. O

Thus O
, O
the O
induction O
of O
E2F I-GENE
binding I-GENE
to O
the O
E2F I-GENE
- I-GENE
1 I-GENE
promoter I-GENE
by O
the O
_RARE_ I-GENE
- I-GENE
6 I-GENE
/ I-GENE
7 O
protein I-GENE
observed O
in O
vitro O
correlates O
with O
transactivation O
of O
E2F I-GENE
- I-GENE
1 I-GENE
promoter I-GENE
activity O
in O
vivo O
. O

We O
show O
that O
stabilization O
of O
the O
hairpin O
reduced O
the O
amount O
of O
tRNA I-GENE
primer O
that O
is O
_RARE_ I-GENE
to O
the O
_RARE_ I-GENE
. O

_RARE_ I-GENE
- I-GENE
induced O
biphasic O
arrhythmias O
were O
suppressed O
in O
both O
_RARE_ I-GENE
and O
propranolol O
groups O
. O

_RARE_ I-GENE
and O
_RARE_ I-GENE
genes I-GENE
appear O
to O
be O
the O
splice O
variants I-GENE
transcribed O
from O
the O
same O
gene I-GENE
. O

CONCLUSION O
: O
_RARE_ I-GENE
of O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
seems O
to O
increase O
the O
risk O
for O
dementia O
and O
AD O
independently O
of O
its O
effect O
on O
_RARE_ I-GENE
and O
_RARE_ I-GENE
. O

No O
definite O
conclusions O
are O
possible O
because O
of O
the O
small I-GENE
number O
of O
patients O
involved O
in O
this O
phase O
II I-GENE
trial O
. O

Two O
distinct O
Salmonella I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
and O
_RARE_ I-GENE
, O
_RARE_ I-GENE
thin O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
, O
respectively O
, O
were O
each O
genetically O
engineered I-GENE
to O
carry O
_RARE_ I-GENE
, O
an O
alpha I-GENE
- I-GENE
helical O
16 O
- I-GENE
amino O
acid I-GENE
Leishmania I-GENE
T I-GENE
- I-GENE
cell O
epitope O
derived O
from O
the O
_RARE_ I-GENE
_RARE_ I-GENE
. O

In O
marked O
contrast O
to O
_RARE_ I-GENE
, O
none O
of O
the O
chimeric I-GENE
_RARE_ I-GENE
proteins I-GENE
were O
expressed O
or O
assembled O
into O
_RARE_ I-GENE
. O

_RARE_ I-GENE
growth I-GENE
of O
phage I-GENE
_RARE_ I-GENE
in O
wild I-GENE
- I-GENE
type I-GENE
Salmonella I-GENE
_RARE_ I-GENE
correlates O
with O
the O
presence O
of O
_RARE_ I-GENE
, O
but O
is O
independent O
of O
the O
absolute O
level O
of O
ATP I-GENE
- I-GENE
dependent I-GENE
nuclease I-GENE
activity O
, O
suggesting O
a O
qualitative O
change O
in O
the O
nature O
of O
_RARE_ I-GENE
- I-GENE
modified O
_RARE_ I-GENE
nuclease I-GENE
activity O
relative O
to O
the O
native O
enzyme I-GENE
. O

In O
this O
study O
, O
we O
investigated O
the O
molecular O
mechanisms O
underlying O
the O
inducible I-GENE
expression O
of O
the O
_RARE_ I-GENE
- I-GENE
1 I-GENE
gene I-GENE
during O
the O
activation O
of O
_RARE_ I-GENE
- I-GENE
1 I-GENE
cells O
. O

There O
was O
a O
2 I-GENE
. O
4 I-GENE
- I-GENE
fold O
difference O
in O
CAT I-GENE
produced O
from O
these O
transcripts I-GENE
in O
HeLa O
cells O
, O
which O
contain O
a O
greater O
natural O
abundance O
of O
PTB I-GENE
. O

Multiple O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
signaling O
pathways O
_RARE_ I-GENE
the O
_RARE_ I-GENE
oncoprotein I-GENE
to O
the O
c I-GENE
- I-GENE
jun I-GENE
promoter I-GENE
and O
to O
cellular O
transformation O
. O

_RARE_ I-GENE
is O
no O
exception O
. O

4 I-GENE
. O

In O
the O
present O
study O
we O
have O
investigated O
the O
regulatory I-GENE
mechanism O
for O
_RARE_ I-GENE
expression O
. O

Protein I-GENE
sequence I-GENE
analysis O
reveals O
that O
_RARE_ I-GENE
shares O
a O
conserved O
globular O
domain I-GENE
of O
approximately O
40 I-GENE
amino O
acids O
, O
which O
we O
term O
the O
_RARE_ I-GENE
_RARE_ I-GENE
, O
with O
inner O
nuclear I-GENE
membrane I-GENE
proteins I-GENE
_RARE_ I-GENE
- I-GENE
associated I-GENE
polypeptide I-GENE
2 I-GENE
and O
_RARE_ I-GENE
. O

Molecular O
cloning O
of O
a O
novel O
human I-GENE
I I-GENE
- I-GENE
_RARE_ I-GENE
domain I-GENE
- I-GENE
containing O
protein I-GENE
that O
differently O
regulates O
human I-GENE
T I-GENE
- I-GENE
cell O
leukemia I-GENE
virus I-GENE
type I-GENE
I I-GENE
and O
HIV I-GENE
- I-GENE
1 I-GENE
expression O
. O

The O
encoded I-GENE
amino O
acid I-GENE
sequences I-GENE
in O
the O
full I-GENE
- I-GENE
length I-GENE
bovine I-GENE
and O
porcine I-GENE
cDNAs I-GENE
were O
identical O
, O
consisting O
of O
_RARE_ I-GENE
amino O
acid I-GENE
residues O
, O
and O
were O
nearly O
the O
same O
as O
the O
published O
sequence I-GENE
determined O
by O
_RARE_ I-GENE
degradation O
. O

With O
chemical O
shift O
imaging O
, O
the O
signal I-GENE
intensity O
decreased O
on O
the O
out O
- I-GENE
of O
- I-GENE
phase O
images O
in O
six O
of O
seven O
( O
86 I-GENE
%) O
patients O
with O
_RARE_ I-GENE
and O
in O
eight O
of O
nine O
( O
89 I-GENE
%) O
patients O
with O
_RARE_ I-GENE
. O

For O
each O
night O
, O
the O
_RARE_ I-GENE
allowed O
the O
_RARE_ I-GENE
measurement O
of O
_RARE_ I-GENE
, O
_RARE_ I-GENE
time O
, O
time O
in O
_RARE_ I-GENE
( O
_RARE_ I-GENE
), O
sleep O
efficiency O
, O
number O
of O
minutes O
of O
_RARE_ I-GENE
after O
sleep O
onset O
( O
_RARE_ I-GENE
), O
_RARE_ I-GENE
on O
_RARE_ I-GENE
, O
and O
percentage O
of O
_RARE_ I-GENE
_RARE_ I-GENE
an O
_RARE_ I-GENE
( O
or O
a O
_RARE_ I-GENE
functioning O
as O
one O
). O

_RARE_ I-GENE
. O

Copyright O
2000 O
Academic O
Press O
. O

The O
central O
( O
R I-GENE
) O
domain I-GENE
is O
responsible O
for O
receptor I-GENE
- I-GENE
binding I-GENE
activity O
whereas O
the O
N I-GENE
- I-GENE
terminal I-GENE
( O
T I-GENE
) O
domain I-GENE
mediates O
translocation O
, O
the O
process O
by O
which O
the O
C I-GENE
- I-GENE
terminal I-GENE
cytotoxic O
domain I-GENE
is O
transported O
from O
the O
receptor I-GENE
to O
the O
site I-GENE
of O
its O
cytotoxicity O
. O

We O
have O
previously O
demonstrated O
that O
expression O
of O
the O
gene I-GENE
for O
the O
reproductive O
_RARE_ I-GENE
, O
GnRH I-GENE
, O
is O
repressed O
by O
the O
glutamate I-GENE
/ I-GENE
NO O
/ I-GENE
cyclic I-GENE
_RARE_ I-GENE
( O
cGMP I-GENE
) O
signal I-GENE
transduction O
pathway O
through O
cGMP I-GENE
- I-GENE
dependent I-GENE
protein I-GENE
kinase I-GENE
in O
the O
_RARE_ I-GENE
GnRH I-GENE
- I-GENE
secreting O
neuronal O
cell O
line O
_RARE_ I-GENE
- I-GENE
7 O
. O

These O
data O
suggest O
that O
combined O
lesions O
of O
cholinergic O
and O
_RARE_ I-GENE
neurons O
in O
the O
rat I-GENE
brain O
do O
not O
alter O
olfactory O
_RARE_ I-GENE
or O
olfactory O
short O
- I-GENE
term O
memory O
. O

_RARE_ I-GENE
potency O
of O
botulinum I-GENE
toxin I-GENE
. O

In O
contrast O
, O
c I-GENE
- I-GENE
Src I-GENE
activated I-GENE
by O
isoproterenol O
led O
to O
tyrosine I-GENE
phosphorylation O
of O
Shc I-GENE
and O
subsequent O
_RARE_ I-GENE
activation O
, O
but O
not O
tyrosine I-GENE
phosphorylation O
of O
_RARE_ I-GENE
or O
Stat3 I-GENE
. O

_RARE_ I-GENE
are O
believed O
to O
regulate O
DNA I-GENE
replication O
, O
transcription I-GENE
, O
_RARE_ I-GENE
and O
cell O
cycle O
progression O
by O
interacting I-GENE
with O
the O
C I-GENE
- I-GENE
_RARE_ I-GENE
protein I-GENE
. O

For O
wild I-GENE
type I-GENE
_RARE_ I-GENE
and O
its O
_RARE_ I-GENE
and O
_RARE_ I-GENE
mutants I-GENE
, O
_RARE_ I-GENE
of O
log O
( O
_RARE_ I-GENE
( O
cat O
)) O
versus O
pH O
exhibited O
a O
limiting O
slope O
of O
1 I-GENE
on O
the O
ascending O
limb O
and O
then O
a O
_RARE_ I-GENE
, O
i O
. O
e O
., O
a O
sharply O
defined O
maximum O
near O
pH O
8 O
followed O
by O
a O
_RARE_ I-GENE
, O
_RARE_ I-GENE
apparent O
_RARE_ I-GENE
( O
a O
) O
values O
of O
7 O
. O
6 I-GENE
+/- O
0 O
. O
3 I-GENE
and O
8 O
. O
4 I-GENE
+/- O
0 O
. O
4 I-GENE
for O
an O
essential O
base O
and O
a O
_RARE_ I-GENE
acid I-GENE
_RARE_ I-GENE
, O
respectively O
, O
in O
the O
active O
_RARE_ I-GENE
_RARE_ I-GENE
- I-GENE
Mg I-GENE
( O
2 I-GENE
+)- I-GENE
_RARE_ I-GENE
- I-GENE
Mg I-GENE
( O
2 I-GENE
+) O
complex I-GENE
. O

Structural O
changes O
in O
the O
_RARE_ I-GENE
more O
damaged O
_RARE_ I-GENE
mutant I-GENE
detected O
in O
( O
1 I-GENE
) O
H I-GENE
-( O
15 O
) O
N I-GENE
_RARE_ I-GENE
spectra O
were O
largely O
limited O
to O
the O
loop I-GENE
I I-GENE
- I-GENE
helix I-GENE
I I-GENE
motif I-GENE
, O
suggesting O
that O
Glu O
- I-GENE
44 I-GENE
stabilizes O
the O
active O
site I-GENE
region O
. O

In O
vitro O
expression O
of O
four O
different O
naturally O
occurring O
nonsense O
and O
missense O
mutations O
revealed O
a O
dramatically O
altered O
subcellular O
location O
of O
the O
protein I-GENE
in O
cultured O
cells O
. O

After O
i O
. O
v I-GENE
. O

_RARE_ I-GENE
acquired O
by O
mice O
during O
I I-GENE
. O
_RARE_ I-GENE
_RARE_ I-GENE
activity O
in O
early I-GENE
summer O
may O
_RARE_ I-GENE
a O
large O
proportion O
of O
the O
mouse I-GENE
population O
from O
maintaining O
E I-GENE
. O
_RARE_ I-GENE
during O
the O
period O
of O
larval I-GENE
activity O
later O
in O
the O
season O
. O

The O
_RARE_ I-GENE
view O
based O
on O
studies O
in O
yeast I-GENE
is O
that O
each O
class I-GENE
of O
_RARE_ I-GENE
is O
composed O
of O
a O
unique O
set O
of O
proteins I-GENE
. O

BCR I-GENE
cross O
- I-GENE
linking O
also O
led O
to O
increased O
MAPK I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
- I-GENE
2 I-GENE
activity O
, O
an O
enzyme I-GENE
that O
lies O
immediately O
downstream O
from O
p38 I-GENE
MAPK I-GENE
; O
MAPK I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
- I-GENE
2 I-GENE
immune I-GENE
complexes I-GENE
phosphorylated O
a O
peptide I-GENE
substrate I-GENE
containing O
the O
CREB I-GENE
serine I-GENE
133 I-GENE
_RARE_ I-GENE
motif I-GENE
. O

Activation O
of O
a O
CRE O
- I-GENE
dependent I-GENE
junB I-GENE
promoter I-GENE
/ I-GENE
chloramphenicol I-GENE
acetyltransferase I-GENE
( O
CAT I-GENE
) O
reporter I-GENE
gene I-GENE
by O
the O
BCR I-GENE
was O
also O
blocked O
by O
_RARE_ I-GENE
. O

We O
present O
evidence O
that O
the O
upstream O
open O
reading O
frame O
( O
uORF I-GENE
) O
represses O
the O
translation I-GENE
of O
the O
downstream O
major I-GENE
open O
reading O
frame O
( O
_RARE_ I-GENE
). O

METHODS O
: O
_RARE_ I-GENE
measurements O
were O
performed O
in O
31 O
female O
_RARE_ I-GENE
with O
breast O
carcinoma O
who O
were O
undergoing O
standard O
cyclophosphamide O
, O
methotrexate O
, O
and O
5 I-GENE
- I-GENE
fluorouracil O
( O
_RARE_ I-GENE
)- I-GENE
based O
chemotherapy O
( O
median O
age O
, O
48 O
years O
; O
range O
, O
26 O
- I-GENE
77 O
years O
). O

A I-GENE
_RARE_ I-GENE
bp O
_RARE_ I-GENE
Response O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
was O
identified O
whose O
glucocorticoid I-GENE
induction O
was O
enhanced O
by O
_RARE_ I-GENE
- I-GENE
cAMP I-GENE
and O
reduced O
by O
phorbol O
esters O
. O

No O
somatic O
mutations O
were O
found O
in O
any O
of O
the O
samples O
, O
suggesting O
that O
_RARE_ I-GENE
is O
not O
a O
tumor I-GENE
suppressor I-GENE
gene I-GENE
target O
in O
head I-GENE
and O
neck O
cancer O
. O

Ras I-GENE
- I-GENE
_RARE_ I-GENE
transiently O
expressed O
with O
v I-GENE
- I-GENE
Src I-GENE
was O
tyrosine I-GENE
- I-GENE
phosphorylated O
and O
showed O
significant O
_RARE_ I-GENE
activity O
toward O
Rac I-GENE
, O
but O
not O
Rho I-GENE
and O
Cdc42 I-GENE
, O
which O
was O
comparable O
with O
that O
induced O
by O
Gbetagamma I-GENE
. O

As O
no O
complete O
PPARgamma I-GENE
antagonists O
have O
been O
described O
hitherto O
, O
we O
have O
constructed O
a O
dominant I-GENE
- I-GENE
negative O
mutant I-GENE
receptor I-GENE
to O
inhibit O
wild I-GENE
- I-GENE
type I-GENE
PPARgamma I-GENE
action O
. O

EMSA O
showed O
that O
nuclear I-GENE
proteins I-GENE
from O
PC12 O
but O
not O
C6 I-GENE
or O
_RARE_ I-GENE
cells O
bind O
the O
CRE O
as O
a O
complex I-GENE
containing O
activating I-GENE
transcription I-GENE
factor I-GENE
( O
ATF I-GENE
)- I-GENE
4 I-GENE
and O
CCAAT I-GENE
enhancer I-GENE
- I-GENE
binding I-GENE
protein I-GENE
beta I-GENE
, O
while O
both O
PC12 O
and O
C6 I-GENE
cell O
nuclear I-GENE
extracts O
were O
recruited O
by O
the O
CCAAT I-GENE
- I-GENE
box I-GENE
as O
a O
complex I-GENE
containing O
nuclear I-GENE
factor I-GENE
Y I-GENE
. O

EMSA O
showed O
that O
nuclear I-GENE
proteins I-GENE
from O
PC12 O
but O
not O
C6 I-GENE
or O
_RARE_ I-GENE
cells O
bind O
the O
CRE O
as O
a O
complex I-GENE
containing O
activating I-GENE
transcription I-GENE
factor I-GENE
( O
ATF I-GENE
)- I-GENE
4 I-GENE
and O
CCAAT I-GENE
enhancer I-GENE
- I-GENE
binding I-GENE
protein I-GENE
beta I-GENE
, O
while O
both O
PC12 O
and O
C6 I-GENE
cell O
nuclear I-GENE
extracts O
were O
recruited O
by O
the O
CCAAT I-GENE
- I-GENE
box I-GENE
as O
a O
complex I-GENE
containing O
nuclear I-GENE
factor I-GENE
Y I-GENE
. O

Despite O
resolution O
of O
the O
solid O
portion O
of O
the O
tumor I-GENE
, O
serial O
MRI O
showed O
enlargement O
of O
a O
_RARE_ I-GENE
tumor I-GENE
cyst O
3 I-GENE
years O
after O
the O
original O
diagnosis O
. O

_RARE_ I-GENE
and O
SOD I-GENE
levels O
were O
measured O
at O
five O
points O
before O
and O
during O
the O
operation O
. O

_RARE_ I-GENE
ventricular O
tachycardia O
and O
its O
successful O
prophylaxis O
during O
high O
- I-GENE
dose O
bolus O
interleukin I-GENE
- I-GENE
2 I-GENE
therapy O
for O
metastatic O
renal O
cell O
carcinoma O
. O

Second O
, O
when O
the O
_RARE_ I-GENE
+ I-GENE
R I-GENE
protein I-GENE
, O
the O
_RARE_ I-GENE
protein I-GENE
, O
and O
a O
mixture O
of O
the O
two O
proteins I-GENE
were O
folded O
separately O
and O
analyzed O
by O
molecular O
_RARE_ I-GENE
_RARE_ I-GENE
, O
the O
mixture O
was O
found O
to O
_RARE_ I-GENE
prior O
to O
either O
_RARE_ I-GENE
+ I-GENE
R I-GENE
or O
_RARE_ I-GENE
. O

Collectively O
, O
these O
experiments O
demonstrate O
that O
CFTR I-GENE
' O
s O
_RARE_ I-GENE
+ I-GENE
R I-GENE
region O
and O
its O
_RARE_ I-GENE
domain I-GENE
, O
after O
folding O
separately O
as O
distinct O
units O
, O
have O
a O
strong O
propensity O
to O
interact O
and O
that O
this O
interaction O
is O
stable O
in O
the O
absence O
of O
added O
nucleotides O
or O
_RARE_ I-GENE
induced O
phosphorylation O
. O

Copyright O
2000 O
Academic O
Press O
. O

_RARE_ I-GENE
titration O
with O
_RARE_ I-GENE
, O
monitored O
by O
_RARE_ I-GENE
the O
residual O
_RARE_ I-GENE
after O
reaction O
with O
a O
_RARE_ I-GENE
derivative O
of O
_RARE_ I-GENE
, O
revealed O
a O
striking O
difference O
in O
the O
apparent O
_RARE_ I-GENE
( O
a O
) O
values O
of O
the O
_RARE_ I-GENE
at O
the O
two O
splice O
junctions O
. O

After O
nitric I-GENE
oxide I-GENE
inhalation O
, O
the O
results O
showed O
moderate O
increases O
in O
PaO2 O
and O
SaO2 O
( O
P I-GENE
> O
0 O
. O
05 O
) O
and O
a O
significant O
decrease O
in O
_RARE_ I-GENE
/ I-GENE
Q I-GENE
tau I-GENE
ratio O
( O
P I-GENE
< O
0 O
. O
01 O
). O

The O
results O
showed O
that O
MIP I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
. O
1 I-GENE
and O
minute O
ventilation O
( O
_RARE_ I-GENE
) O
were O
significantly O
increased O
after O
administration O
of O
_RARE_ I-GENE
and O
_RARE_ I-GENE
. O

Forty O
4 I-GENE
- I-GENE
month O
old O
SD O
female O
rats O
were O
randomly O
divided O
into O
four O
groups O
, O
namely O
sham O
operation O
, O
bilateral O
_RARE_ I-GENE
, O
_RARE_ I-GENE
plus O
supplementary O
_RARE_ I-GENE
estradiol O
( O
0 O
. O
2 I-GENE
microgram O
/ I-GENE
100 O
g O
B I-GENE
. O

It O
has O
also O
been O
shown O
that O
a O
variety O
of O
extracellular I-GENE
factors I-GENE
stimulate O
a O
pair O
of O
MAPK I-GENE
p44 I-GENE
and O
MAPK I-GENE
_RARE_ I-GENE
of O
MAPK I-GENE
family I-GENE
members O
. O

_RARE_ I-GENE
modification O
of O
the O
transactivator I-GENE
protein I-GENE
IE2 I-GENE
- I-GENE
_RARE_ I-GENE
of O
human I-GENE
cytomegalovirus I-GENE
by O
conjugation O
to O
the O
ubiquitin I-GENE
- I-GENE
homologous O
proteins I-GENE
_RARE_ I-GENE
- I-GENE
1 I-GENE
and O
_RARE_ I-GENE
. O

73 O
: O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
). O

The O
interaction O
between O
U O
( O
L I-GENE
) O
3 I-GENE
. O

_RARE_ I-GENE
and O
heparin O
doses O
, O
their O
sum O
( O
_RARE_ I-GENE
- I-GENE
dose O
) O
and O
differential O
( O
Delta I-GENE
- I-GENE
dose O
) O
doses O
, O
and O
activated I-GENE
clotting I-GENE
times O
were O
_RARE_ I-GENE
. O

In O
this O
study O
, O
a O
common O
mechanism O
has O
been O
identified O
to O
coordinate O
the O
growth I-GENE
- I-GENE
and O
_RARE_ I-GENE
- I-GENE
dependent I-GENE
expression O
of O
_RARE_ I-GENE
. O

Comparison O
of O
the O
plant O
nuclear I-GENE
tRNA I-GENE
3 I-GENE
' O
processing O
enzyme I-GENE
with O
the O
plant O
mitochondrial I-GENE
one O
suggests O
that O
both O
activities O
are O
different O
enzymes O
. O

The O
requirement O
of O
3 I-GENE
' O
complementarity I-GENE
for O
a O
ligation O
reaction O
is O
_RARE_ I-GENE
by O
results O
from O
1 I-GENE
nt O
insertions O
on O
either O
the O
3 I-GENE
'- O
or O
5 I-GENE
'- O
side O
of O
the O
_RARE_ I-GENE
. O

_RARE_ I-GENE
. O
1 I-GENE
is O
a O
member O
of O
the O
_RARE_ I-GENE
family I-GENE
of O
homeodomain I-GENE
- I-GENE
containing O
transcription I-GENE
factors I-GENE
whose O
targeted O
disruption O
in O
mouse I-GENE
results O
in O
the O
absence O
of O
thyroid I-GENE
tissue I-GENE
and O
a O
severely O
abnormal O
lung O
phenotype O
. O

National O
abortion O
_RARE_ I-GENE
usually O
do O
not O
allow O
abortion O
when O
a O
_RARE_ I-GENE
is O
independently O
viable O
, O
i O
. O
e O
. O
from O
a O
gestational O
age O
of O
about O
24 O
weeks O
. O

Expression O
in O
early I-GENE
postnatal O
pituitary I-GENE
and O
in O
pre I-GENE
- I-GENE
_RARE_ I-GENE
cells O
suggests O
that O
Zn I-GENE
- I-GENE
16 O
could O
play O
a O
role O
in O
pituitary I-GENE
development O
prior O
to O
_RARE_ I-GENE
differentiation O
. O

_RARE_ I-GENE
growth I-GENE
hormone I-GENE
transcription I-GENE
factor I-GENE
Zn I-GENE
- I-GENE
16 O
: O
unique O
bipartite O
structure O
containing O
tandemly O
repeated O
zinc I-GENE
finger I-GENE
domains I-GENE
not O
reported O
in O
rat I-GENE
Zn I-GENE
- I-GENE
15 O
. O

The O
CCAAT I-GENE
core I-GENE
sequence I-GENE
mutants I-GENE
in O
which O
both O
_RARE_ I-GENE
and O
CI O
/ I-GENE
_RARE_ I-GENE
were O
abolished O
, O
also O
increased O
the O
promoter I-GENE
activity O
. O

_RARE_ I-GENE
is O
considered O
to O
be O
immature O
in O
infants O
and O
to O
mature O
_RARE_ I-GENE
. O

This O
repression O
does O
not O
require O
the O
PU I-GENE
. O
1 I-GENE
transactivation O
or O
_RARE_ I-GENE
domains I-GENE
and O
cannot O
be O
reversed O
by O
p300 I-GENE
expression O
. O

First O
, O
human I-GENE
erythroid I-GENE
K562 O
cells O
stably O
integrated O
with O
various O
HS I-GENE
- I-GENE
40 I-GENE
mutants I-GENE
cis O
linked O
to O
a O
human I-GENE
alpha I-GENE
- I-GENE
globin I-GENE
promoter I-GENE
- I-GENE
growth I-GENE
hormone I-GENE
hybrid O
gene I-GENE
were O
analyzed O
by O
genomic O
footprinting O
and O
expression O
analysis O
. O

Interestingly O
, O
addition O
of O
purified O
CBP I-GENE
to O
the O
nuclear I-GENE
extracts O
of O
_RARE_ I-GENE
cells O
markedly O
stimulated O
progesterone I-GENE
- I-GENE
and O
PR I-GENE
- I-GENE
dependent I-GENE
transcription I-GENE
from O
a O
_RARE_ I-GENE
- I-GENE
free O
, O
progesterone I-GENE
response O
element I-GENE
( O
_RARE_ I-GENE
)- I-GENE
linked O
reporter I-GENE
DNA I-GENE
template O
. O

Its O
cognate I-GENE
binding I-GENE
protein I-GENE
, O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
, O
is O
an O
essential O
transcription I-GENE
factor I-GENE
; O
its O
null I-GENE
mutations O
result O
in O
embryonic O
lethality O
, O
and O
its O
dominant I-GENE
negative O
mutants I-GENE
produce O
aberrant O
expression O
of O
neuron I-GENE
- I-GENE
specific I-GENE
genes I-GENE
. O

Removal O
of O
all O
core I-GENE
histone I-GENE
tail O
domains I-GENE
by O
limited O
trypsin I-GENE
proteolysis O
or O
acetylation O
of O
the O
core I-GENE
histone I-GENE
tails O
significantly O
_RARE_ I-GENE
this O
inhibition O
and O
allows O
_RARE_ I-GENE
to O
exhibit O
high O
- I-GENE
affinity O
binding I-GENE
to O
_RARE_ I-GENE
DNA I-GENE
. O

Finally O
, O
the O
mechanism O
of O
_RARE_ I-GENE
activation O
involves O
, O
in O
part O
, O
_RARE_ I-GENE
- I-GENE
oligomerization O
. O

OUTCOME O
: O
_RARE_ I-GENE
receptor I-GENE
antibodies I-GENE
and O
single O
- I-GENE
fibre O
_RARE_ I-GENE
were O
useful O
in O
the O
diagnosis O
of O
_RARE_ I-GENE
_RARE_ I-GENE
. O

Two O
other O
patients O
underwent O
_RARE_ I-GENE
. O

The O
variations O
were O
caused O
by O
opposite O
shifts O
in O
TSH I-GENE
frequency O
distribution O
in O
mothers O
and O
neonates O
. O

Characterization O
of O
the O
5 I-GENE
'- O
flanking O
region O
of O
the O
human I-GENE
multidrug I-GENE
resistance O
protein I-GENE
2 I-GENE
( O
_RARE_ I-GENE
) O
gene I-GENE
and O
its O
regulation O
in O
comparison O
_RARE_ I-GENE
multidrug I-GENE
resistance O
protein I-GENE
3 I-GENE
( O
_RARE_ I-GENE
) O
gene I-GENE
. O

However O
, O
such O
a O
mechanism O
was O
not O
detected O
in O
preliminary O
observations O
on O
M I-GENE
. O
_RARE_ I-GENE
. O

These O
results O
suggest O
that O
the O
M I-GENE
. O
_RARE_ I-GENE
as O
well O
as O
related I-GENE
_RARE_ I-GENE
20S I-GENE
_RARE_ I-GENE
require O
a O
_RARE_ I-GENE
complex I-GENE
such O
as O
_RARE_ I-GENE
to O
mediate O
the O
energy O
- I-GENE
dependent I-GENE
hydrolysis O
of O
folded O
- I-GENE
substrate I-GENE
proteins I-GENE
and O
that O
the O
N I-GENE
- I-GENE
terminal I-GENE
73 O
amino O
acid I-GENE
residues O
of O
_RARE_ I-GENE
are O
not O
_RARE_ I-GENE
required O
for O
this O
reaction O
. O

The O
transcription I-GENE
factor I-GENE
E2F I-GENE
plays O
an O
important O
role O
in O
G I-GENE
( O
1 I-GENE
) O
to O
S I-GENE
phase O
transition O
in O
the O
higher O
eukaryotic I-GENE
cell O
cycle O
. O

In O
two O
- I-GENE
field O
nodal O
dissection O
, O
two O
components O
are O
included O
with O
( O
modern O
two O
- I-GENE
field O
) O
or O
without O
( O
_RARE_ I-GENE
two O
- I-GENE
field O
) O
nodal O
dissection O
around O
both O
recurrent O
_RARE_ I-GENE
nerve I-GENE
chains I-GENE
in O
the O
upper O
_RARE_ I-GENE
. O

Of O
the O
_RARE_ I-GENE
patients O
studied O
, O
CK I-GENE
- I-GENE
MB I-GENE
results O
were O
positive O
in O
91 O
( O
59 O
%) O
patients O
; O
ECG O
revealed O
AMI O
in O
72 O
( O
47 O
%) O
patients O
. O

The O
effect O
of O
_RARE_ I-GENE
on O
the O
dose O
- I-GENE
response O
curve O
of O
_RARE_ I-GENE
applied O
noradrenaline O
was O
also O
studied O
. O

The O
regional O
blockade O
of O
_RARE_ I-GENE
was O
observed O
mainly O
in O
the O
frontal O
, O
temporal O
and O
anterior O
_RARE_ I-GENE
_RARE_ I-GENE
, O
and O
the O
intravenous O
administration O
of O
d O
- I-GENE
_RARE_ I-GENE
as O
a O
therapeutic O
dose O
( O
2 I-GENE
mg O
) O
blocked O
over O
60 O
% O
of O
_RARE_ I-GENE
in O
the O
frontal O
_RARE_ I-GENE
. O

The O
expression O
of O
the O
_RARE_ I-GENE
(+) I-GENE
cDNA I-GENE
in O
the O
_RARE_ I-GENE
mutant I-GENE
cells O
partially O
_RARE_ I-GENE
the O
mid O
phenotype O
and O
resulted O
in O
a O
slight O
increase O
in O
Ca I-GENE
( O
2 I-GENE
+) O
uptake O
activity O
. O

_RARE_ I-GENE
overall O
infection O
rates O
( O
events O
/ I-GENE
100 O
patient O
- I-GENE
days O
) O
were O
2 I-GENE
. O
05 O
+/- O
0 O
. O
33 O
( O
heart O
- I-GENE
lung O
) O
and O
2 I-GENE
. O
34 O
+/- O
0 O
. O
34 O
( O
double O
- I-GENE
lung O
; O
P I-GENE
= O
NS I-GENE
) O
at O
3 I-GENE
months O
. O

_RARE_ I-GENE
and O
dynamic O
compliance O
was O
measured O
after O
induction O
of O
anesthesia O
, O
before O
and O
immediately O
after O
filtration O
in O
the O
operating O
_RARE_ I-GENE
, O
1 I-GENE
hour O
after O
return O
to O
the O
pediatric O
intensive O
care O
unit I-GENE
, O
and O
24 O
hours O
after O
the O
operation O
. O

_RARE_ I-GENE
therapy O
: O
_RARE_ I-GENE
_RARE_ I-GENE
, O
diagnostic O
implications O
, O
and O
clinical O
consequences O
. O

There O
is O
no O
correlation O
between O
C2 I-GENE
- I-GENE
C3 I-GENE
_RARE_ I-GENE
morphology O
and O
the O
_RARE_ I-GENE
_RARE_ I-GENE
response O
. O

_RARE_ I-GENE
, O
a O
_RARE_ I-GENE
- I-GENE
like I-GENE
kinase I-GENE
with O
mitogenic O
potential O
and O
_RARE_ I-GENE
to O
activate O
the O
SAPK I-GENE
/ I-GENE
JNK I-GENE
pathway O
. O

_RARE_ I-GENE
has O
an O
intrinsic O
kinase I-GENE
activity O
required O
for O
up O
- I-GENE
regulation O
of O
a O
subset O
of O
apoptotic O
genes I-GENE
. O

We O
have O
mapped O
the O
human I-GENE
_RARE_ I-GENE
gene I-GENE
to O
the O
_RARE_ I-GENE
region O
of O
chromosome O
7 O
; O
six O
human I-GENE
_RARE_ I-GENE
- I-GENE
related I-GENE
genes I-GENE
have O
also O
been O
mapped O
: O
two O
at O
_RARE_ I-GENE
near O
the O
functional O
gene I-GENE
, O
one O
at O
_RARE_ I-GENE
. O
22 O
, O
and O
three O
at O
_RARE_ I-GENE
. O
23 O
, O
two O
of O
them O
flanking O
the O
breakpoints O
commonly O
associated I-GENE
with O
the O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
syndrome O
( O
_RARE_ I-GENE
) O
deletion O
. O

_RARE_ I-GENE
time O
( O
RT I-GENE
) O
and O
_RARE_ I-GENE
were O
collected O
simultaneously O
. O

In O
experiment O
2 I-GENE
the O
rats O
had O
free O
access O
to O
two O
_RARE_ I-GENE
, O
one O
of O
which O
contained O
tap I-GENE
water O
, O
and O
the O
other O
contained O
either O
an O
ethanol O
( O
6 I-GENE
%) O
or O
a O
sucrose O
( O
5 I-GENE
%) O
solution O
. O

Furthermore O
, O
_RARE_ I-GENE
' O
s O
method O
is O
used O
to O
balance O
the O
number O
of O
patients O
allocated O
to O
the O
two O
groups O
within O
each O
_RARE_ I-GENE
( O
M I-GENE
. O

RESULTS O
: O
In O
this O
group O
of O
patients O
, O
male O
gender O
( O
P I-GENE
= O
0 O
. O

Selective O
visual O
attention O
involves O
dynamic O
_RARE_ I-GENE
between O
_RARE_ I-GENE
control O
systems O
and O
sensory O
brain O
structures O
. O

The O
patient O
had O
developed O
left O
- I-GENE
_RARE_ I-GENE
low O
- I-GENE
frequency O
tremor O
and O
_RARE_ I-GENE
after O
a O
severe O
head I-GENE
trauma O
sustained O
at O
15 O
years O
of O
age O
. O

However O
, O
the O
_RARE_ I-GENE
isoform I-GENE
is O
expressed O
most O
_RARE_ I-GENE
in O
brain O
and O
heart O
, O
_RARE_ I-GENE
in O
liver O
and O
kidney O
, O
and O
_RARE_ I-GENE
in O
liver O
, O
lung O
, O
heart O
, O
brain O
, O
spleen O
, O
and O
kidney O
. O

During O
the O
cloning O
by O
reverse I-GENE
transcriptase I-GENE
- I-GENE
polymerase I-GENE
chain I-GENE
reaction O
of O
the O
human I-GENE
HIF I-GENE
- I-GENE
1alpha I-GENE
subunit I-GENE
, O
we O
isolated O
two O
cDNA I-GENE
clones O
which O
corresponded O
to O
alternative O
splicing O
of O
the O
HIF I-GENE
- I-GENE
1alpha I-GENE
gene I-GENE
. O

To O
assess O
the O
relationship O
between O
G I-GENE
( O
q I-GENE
)/ O
G I-GENE
( O
11 O
) O
function O
with O
the O
phosphatidylinositol I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
dependent I-GENE
pathway O
, O
expression O
of O
a O
dominant I-GENE
- I-GENE
interfering O
p85 I-GENE
regulatory I-GENE
subunit I-GENE
, O
as O
well O
as O
wortmannin O
treatment O
inhibited O
insulin I-GENE
- I-GENE
stimulated O
but O
not O
G I-GENE
( O
q I-GENE
)/ O
_RARE_ I-GENE
- I-GENE
stimulated O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
translocation O
. O

In O
_RARE_ I-GENE
_RARE_ I-GENE
, O
the O
_RARE_ I-GENE
/ I-GENE
p130 I-GENE
gene I-GENE
is O
mutated O
in O
most O
of O
the O
cases O
, O
and O
the O
protein I-GENE
is O
restricted O
to O
the O
cytoplasm O
. O

Together O
, O
these O
data O
identify O
ERK2 I-GENE
as O
a O
specific I-GENE
and O
direct O
target O
of O
_RARE_ I-GENE
and O
are O
consistent O
with O
a O
model O
in O
which O
_RARE_ I-GENE
negatively O
regulates O
ERK2 I-GENE
activity O
as O
part O
of O
a O
_RARE_ I-GENE
mechanism O
. O

Cross O
- I-GENE
reaction O
between O
a O
monoclonal I-GENE
antibody I-GENE
and O
two O
alpha I-GENE
beta I-GENE
T I-GENE
cell O
receptors I-GENE
. O

_RARE_ I-GENE
nitrate I-GENE
mixed O
with O
_RARE_ I-GENE
acid I-GENE
, O
in O
comparison O
with O
_RARE_ I-GENE
acid I-GENE
alone O
, O
markedly O
( O
p O
< O
0 O
. O
01 O
) O
shortened O
the O
duration O
of O
the O
_RARE_ I-GENE
_RARE_ I-GENE
from O
24 O
. O
4 I-GENE
+/- O
4 I-GENE
. O
1 I-GENE
( O
mean O
+/- O
_RARE_ I-GENE
) O
min O
to O
8 O
. O
9 O
+/- O
3 I-GENE
. O
7 O
( O
mean O
+/- O
_RARE_ I-GENE
) O
min O
, O
and O
significantly O
( O
p O
< O
0 O
. O
05 O
) O
reduced O
the O
mean O
magnitude O
of O
the O
_RARE_ I-GENE
_RARE_ I-GENE
at O
all O
time O
points O
( O
overall O
). O

The O
_RARE_ I-GENE
- I-GENE
reactive I-GENE
_RARE_ I-GENE
groups O
were O
located O
exclusively O
in O
the O
_RARE_ I-GENE
half O
of O
the O
plasma I-GENE
membrane I-GENE
and O
, O
when O
presented O
in O
a O
helical O
model O
, O
_RARE_ I-GENE
along O
one O
side O
of O
the O
helices O
. O

Analysis O
of O
1 I-GENE
Mb O
of O
published O
sequence I-GENE
from O
the O
region O
of O
conserved O
_RARE_ I-GENE
on O
human I-GENE
chromosome O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
identified O
45 O
gene I-GENE
_RARE_ I-GENE
, O
including O
35 O
expressed O
genes I-GENE
in O
the O
human I-GENE
IL I-GENE
- I-GENE
4 I-GENE
cytokine O
gene I-GENE
cluster I-GENE
. O

Human I-GENE
AP I-GENE
- I-GENE
_RARE_ I-GENE
repressed O
both O
reporter I-GENE
expression O
from O
a O
transiently O
transfected O
AP I-GENE
- I-GENE
2alpha I-GENE
promoter I-GENE
and O
the O
endogenous I-GENE
AP I-GENE
- I-GENE
2alpha I-GENE
gene I-GENE
and O
inversely O
was O
negatively O
regulated O
by O
AP I-GENE
- I-GENE
2alpha I-GENE
. O

In O
order O
to O
gain O
_RARE_ I-GENE
insight O
into O
the O
role O
of O
the O
amino O
- I-GENE
terminal I-GENE
domain I-GENE
of O
the O
_RARE_ I-GENE
( O
CA I-GENE
) O
protein I-GENE
during O
viral I-GENE
replication O
, O
eight O
highly O
conserved O
proline O
residues O
known O
to O
promote O
_RARE_ I-GENE
and O
to O
terminate O
alpha I-GENE
- I-GENE
helices O
within O
the O
_RARE_ I-GENE
tertiary O
structure O
were O
replaced O
by O
a O
leucine I-GENE
residue O
( O
P I-GENE
- I-GENE
position O
- I-GENE
L I-GENE
). O

_RARE_ I-GENE
/ I-GENE
Cdc28 I-GENE
kinases I-GENE
promote O
nuclear I-GENE
export O
of O
the O
replication O
initiator O
proteins I-GENE
_RARE_ I-GENE
- I-GENE
7 O
. O

_RARE_ I-GENE
, O
PC12 O
- I-GENE
E2 I-GENE
cells O
were O
submitted O
to O
treatment O
with O
antibodies I-GENE
to O
the O
fibroblast I-GENE
growth I-GENE
factor I-GENE
( O
FGF I-GENE
) O
receptor I-GENE
, O
inhibitors O
of O
the O
_RARE_ I-GENE
tyrosine I-GENE
kinase I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
), O
PLC I-GENE
, O
PKC I-GENE
and O
MEK I-GENE
and O
an O
activator I-GENE
of O
PKC I-GENE
, O
phorbol O
- I-GENE
12 O
- I-GENE
myristate O
- I-GENE
13 O
- I-GENE
acetate O
( O
PMA O
). O

_RARE_ I-GENE
roles O
of O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
- I-GENE
related I-GENE
proteins I-GENE
in O
the O
formation O
of O
the O
dorsal O
_RARE_ I-GENE
in O
_RARE_ I-GENE
. O

_RARE_ I-GENE
sodium O
administered O
at O
30 O
and O
10 O
min O
before O
or O
5 I-GENE
, O
10 O
and O
15 O
min O
after O
exposure O
to O
_RARE_ I-GENE
- I-GENE
5 I-GENE
, O
but O
not O
thereafter O
, O
significantly O
attenuated O
NO O
- I-GENE
induced O
neurotoxicity O
compared O
with O
controls O
. O

We O
also O
show O
that O
_RARE_ I-GENE
activated I-GENE
_RARE_ I-GENE
transcripts I-GENE
are O
restricted O
to O
_RARE_ I-GENE
- I-GENE
posterior O
specific I-GENE
regions O
and O
induced O
by O
UV O
- I-GENE
irradiation O
and O
BMP I-GENE
- I-GENE
4 I-GENE
overexpression O
in O
cycloheximide I-GENE
- I-GENE
dependent I-GENE
way O
. O
_RARE_ I-GENE
26 O
: O
198 O
- I-GENE
_RARE_ I-GENE
, O
2000 O
. O

In O
all O
other O
cases O
, O
vestibular O
_RARE_ I-GENE
or O
chemical O
vestibular O
_RARE_ I-GENE
, O
by O
means O
of O
_RARE_ I-GENE
low O
concentration O
_RARE_ I-GENE
( O
20 O
mg O
/ I-GENE
mL O
), O
are O
indicated O
. O

However O
, O
when O
, O
where O
and O
how O
the O
_RARE_ I-GENE
is O
cleaved O
into O
_RARE_ I-GENE
and O
_RARE_ I-GENE
is O
not O
clear O
. O

It O
has O
a O
_RARE_ I-GENE
prognosis O
with O
> O
70 I-GENE
% O
mortality O
in O
3 I-GENE
months O
, O
despite O
mechanical O
ventilation O
. O

We O
found O
that O
TCR I-GENE
signaling O
induces O
AP I-GENE
- I-GENE
1 I-GENE
binding I-GENE
to O
this O
site I-GENE
and O
regulates O
the O
_RARE_ I-GENE
promoter I-GENE
function O
in O
a O
fashion O
dependent I-GENE
on O
NF I-GENE
- I-GENE
kappaB I-GENE
binding I-GENE
. O

Thus O
, O
patients O
with O
metastatic O
melanoma O
are O
not O
_RARE_ I-GENE
to O
_RARE_ I-GENE
Ag I-GENE
based O
on O
the O
detection O
of O
CD8 I-GENE
+ I-GENE
T I-GENE
cells O
specific I-GENE
for O
multiple O
HLA I-GENE
- I-GENE
A I-GENE
* I-GENE
_RARE_ I-GENE
- I-GENE
restricted O
, O
_RARE_ I-GENE
- I-GENE
derived O
epitopes I-GENE
. O

Approximately O
20 O
% O
of O
_RARE_ I-GENE
that O
express O
_RARE_ I-GENE
do O
not O
contain O
the O
t I-GENE
( O
2 I-GENE
; O
5 I-GENE
), O
suggesting O
that O
other O
genetic O
abnormalities O
can O
result O
in O
aberrant O
_RARE_ I-GENE
expression O
. O

In O
addition O
, O
expected O
decreases O
in O
_RARE_ I-GENE
enzymatic O
function O
in O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
containing O
lymphomas O
may O
_RARE_ I-GENE
these O
tumors O
more O
sensitive O
to O
_RARE_ I-GENE
drugs O
such O
as O
methotrexate O
. O

Following O
the O
observation O
that O
non O
- I-GENE
organ O
- I-GENE
specific I-GENE
antibodies I-GENE
are O
related I-GENE
with O
pregnancy O
loss O
and O
_RARE_ I-GENE
, O
the O
role O
of O
organ O
- I-GENE
specific I-GENE
antibodies I-GENE
is O
currently O
being O
extensively O
investigated O
. O

_RARE_ I-GENE
ions O
were O
found O
to O
be O
essential O
for O
autophosphorylation O
of O
_RARE_ I-GENE
, O
and O
magnesium O
can O
stimulate O
the O
activity O
. O

The O
_RARE_ I-GENE
5 I-GENE
' O
flanking O
region O
contains O
a O
functional O
ER I-GENE
stress O
- I-GENE
responsive I-GENE
element I-GENE
which O
is O
sufficient O
for O
induction O
by O
_RARE_ I-GENE
. O

_RARE_ I-GENE
point O
feature O
_RARE_ I-GENE
using O
_RARE_ I-GENE
information O
. O

_RARE_ I-GENE
is O
a O
serotonin I-GENE
antagonist O
and O
has O
been O
demonstrated O
to O
reduce O
wound O
blood O
flow O
and O
edema O
formation O
. O

Serum I-GENE
leptin I-GENE
concentrations O
in O
women O
during O
gonadotropin I-GENE
stimulation O
cycles O
. O

_RARE_ I-GENE
families O
: O
social O
work O
practice O
with O
families O
from O
a O
strengths O
_RARE_ I-GENE
. O

PURPOSE O
: O
A I-GENE
two O
- I-GENE
generation O
_RARE_ I-GENE
_RARE_ I-GENE
family I-GENE
with O
_RARE_ I-GENE
recessive O
_RARE_ I-GENE
congenital O
_RARE_ I-GENE
( O
_RARE_ I-GENE
, O
_RARE_ I-GENE
_RARE_ I-GENE
, O
000 O
) O
and O
_RARE_ I-GENE
was O
identified O
. O

_RARE_ I-GENE
was O
targeted O
to O
the O
plasma I-GENE
membrane I-GENE
even O
in O
the O
absence O
of O
_RARE_ I-GENE
or O
_RARE_ I-GENE
. O

Here O
, O
we O
show O
that O
IRF I-GENE
- I-GENE
1 I-GENE
is O
degraded O
via O
the O
ubiquitin I-GENE
- I-GENE
proteasome I-GENE
pathway O
. O

An O
amino O
- I-GENE
acid I-GENE
sequence I-GENE
comparison O
revealed O
that O
Bacillus I-GENE
_RARE_ I-GENE
- I-GENE
1 I-GENE
_RARE_ I-GENE
shared O
71 O
% O
homology I-GENE
with O
Bacillus I-GENE
subtilis I-GENE
_RARE_ I-GENE
and O
49 O
% O
with O
Escherichia I-GENE
coli I-GENE
and O
Pseudomonas I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
to O
this O
system O
, O
the O
activity O
of O
_RARE_ I-GENE
is O
negatively O
modulated O
by O
an O
_RARE_ I-GENE
called O
_RARE_ I-GENE
. O

As O
assessed O
by O
a O
genetic O
assay O
that O
measures O
_RARE_ I-GENE
- I-GENE
dependent I-GENE
DNA I-GENE
binding I-GENE
, O
_RARE_ I-GENE
inhibited O
_RARE_ I-GENE
function O
before O
and O
after O
the O
transcription I-GENE
factor I-GENE
had O
bound O
to O
its O
DNA I-GENE
recognition I-GENE
site I-GENE
. O

Here O
we O
show O
that O
_RARE_ I-GENE
pre I-GENE
- I-GENE
mRNA I-GENE
splicing O
is O
activated I-GENE
more O
than O
200 O
- I-GENE
fold O
in O
nuclear I-GENE
extracts O
prepared O
from O
late O
adenovirus I-GENE
- I-GENE
infected O
cells O
( O
_RARE_ I-GENE
- I-GENE
NE O
) O
compared O
to O
_RARE_ I-GENE
HeLa O
cell O
nuclear I-GENE
extracts O
( O
HeLa O
- I-GENE
NE O
). O

_RARE_ I-GENE
of O
_RARE_ I-GENE
also O
suppresses O
several O
_RARE_ I-GENE
( O
ts I-GENE
) O
defects O
, O
and O
the O
double O
mutant I-GENE
accumulates O
far O
fewer O
_RARE_ I-GENE
- I-GENE
protein I-GENE
_RARE_ I-GENE
than O
either O
single O
mutant I-GENE
. O

Collectively O
, O
the O
results O
suggest O
that O
ARF I-GENE
binding I-GENE
to O
_RARE_ I-GENE
induces O
a O
conformational O
change O
that O
_RARE_ I-GENE
nucleolar I-GENE
import O
of O
the O
ARF I-GENE
- I-GENE
_RARE_ I-GENE
complex I-GENE
and O
p53 I-GENE
- I-GENE
dependent I-GENE
cell O
cycle O
arrest O
. O

Cyclin I-GENE
A I-GENE
expression O
is O
repressed O
in O
_RARE_ I-GENE
cells O
by O
E2F I-GENE
acting O
in O
conjunction O
with O
its O
pocket O
protein I-GENE
partners O
Rb I-GENE
, O
p107 I-GENE
, O
and O
p130 I-GENE
; O
however O
, O
v I-GENE
- I-GENE
Jun I-GENE
_RARE_ I-GENE
this O
control O
, O
causing O
phosphorylated O
Rb I-GENE
and O
proliferation O
- I-GENE
specific I-GENE
E2F I-GENE
- I-GENE
p107 I-GENE
complexes I-GENE
to O
_RARE_ I-GENE
after O
mitogen I-GENE
withdrawal O
. O

D I-GENE
- I-GENE
cyclin I-GENE
- I-GENE
_RARE_ I-GENE
activity O
is O
required O
for O
Rb I-GENE
phosphorylation O
in O
v I-GENE
- I-GENE
Jun I-GENE
- I-GENE
transformed O
cells O
, O
since O
ectopic O
expression O
of O
the O
_RARE_ I-GENE
- I-GENE
and O
_RARE_ I-GENE
- I-GENE
specific I-GENE
inhibitor I-GENE
p16 I-GENE
( O
_RARE_ I-GENE
) O
inhibits O
both O
DNA I-GENE
synthesis O
and O
cell O
proliferation O
. O

CONCLUSION O
: O
A I-GENE
valve O
- I-GENE
like I-GENE
mechanism O
formed O
by O
the O
_RARE_ I-GENE
_RARE_ I-GENE
partially O
_RARE_ I-GENE
to O
the O
_RARE_ I-GENE
optic O
can O
occur O
postoperatively O
. O

The O
protein I-GENE
first O
identified O
by O
the O
monoclonal I-GENE
antibody I-GENE
_RARE_ I-GENE
is O
encoded I-GENE
by O
a O
gene I-GENE
located O
in O
_RARE_ I-GENE
on O
_RARE_ I-GENE
chromosomes O
and O
has O
been O
_RARE_ I-GENE
named O
_RARE_ I-GENE
. O

3 I-GENE
' O
RNA I-GENE
boundary O
experiments O
indicate O
that O
the O
5 I-GENE
' O
structure O
reduces O
the O
number O
of O
( O
G I-GENE
/ I-GENE
U O
) O
_RARE_ I-GENE
repeats I-GENE
required O
for O
stable O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
leader O
RNA I-GENE
association O
. O

Gene I-GENE
silencing O
associated I-GENE
with O
repeated O
DNA I-GENE
sequences I-GENE
has O
been O
reported O
for O
many O
eukaryotes O
, O
including O
plants O
. O

The O
_RARE_ I-GENE
genes I-GENE
were O
differentially O
regulated O
by O
ethylene O
and O
by O
_RARE_ I-GENE
stress O
conditions O
, O
such O
as O
_RARE_ I-GENE
, O
cold O
, O
high O
_RARE_ I-GENE
, O
or O
_RARE_ I-GENE
, O
via O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
)- I-GENE
dependent I-GENE
or O
- I-GENE
independent O
pathways O
. O

Animals O
received O
a O
dose O
of O
dexamethasone O
( O
10 O
mg O
/ I-GENE
kg O
i O
. O
p O
.) O
prior O
to O
the O
protein I-GENE
- I-GENE
free O
surfactant I-GENE
preparation O
_RARE_ I-GENE
( O
pure O
phospholipids O
containing O
surfactant I-GENE
, O
_RARE_ I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
) O
and O
a O
_RARE_ I-GENE
- I-GENE
C I-GENE
based O
surfactant I-GENE
, O
respectively O
. O

BACKGROUND O
: O
The O
aim O
of O
this O
study O
was O
to O
determine O
the O
response O
rates O
and O
toxicity O
of O
two O
regimens O
containing O
granulocyte I-GENE
- I-GENE
macrophage I-GENE
- I-GENE
colony I-GENE
stimulating I-GENE
factor I-GENE
( O
GM I-GENE
- I-GENE
CSF I-GENE
) O
in O
combination O
with O
interleukin I-GENE
- I-GENE
2 I-GENE
( O
IL I-GENE
- I-GENE
2 I-GENE
) O
in O
the O
treatment O
of O
patients O
with O
metastatic O
renal O
cell O
carcinoma O
. O

We O
show O
, O
by O
injection O
of O
synthetic O
mRNAs I-GENE
, O
that O
the O
cis O
- I-GENE
acting O
sequences I-GENE
responsible O
for O
repression O
of O
cyclin I-GENE
B1 I-GENE
mRNA I-GENE
reside O
within O
its O
3 I-GENE
' O
UTR I-GENE
. O

These O
data O
indicate O
that O
expansion O
of O
the O
_RARE_ I-GENE
repeat I-GENE
located O
in O
the O
proximal I-GENE
promoter I-GENE
of O
_RARE_ I-GENE
severely O
_RARE_ I-GENE
the O
function O
of O
the O
promoter I-GENE
and O
thereby O
reduces O
transcription I-GENE
of O
_RARE_ I-GENE
. O

Thus O
, O
while O
the O
genomic O
organization O
of O
_RARE_ I-GENE
is O
similar O
to O
the O
neural O
- I-GENE
restricted O
members O
of O
the O
_RARE_ I-GENE
family I-GENE
, O
the O
promoter I-GENE
element I-GENE
differs O
substantially O
both O
by O
sequence I-GENE
analysis O
and O
transcriptional O
activity O
in O
non O
- I-GENE
neural O
cell O
types O
. O

Analysis O
of O
the O
5 I-GENE
' O
end O
of O
the O
mouse I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
gene I-GENE
reveals O
a O
transcriptional O
regulatory I-GENE
element I-GENE
and O
evidence O
for O
conserved O
genomic O
organization O
. O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
belongs O
to O
a O
highly O
conserved O
family I-GENE
of O
genes I-GENE
encoding O
RNA I-GENE
- I-GENE
binding I-GENE
proteins I-GENE
and O
has O
been O
linked O
to O
cell O
growth I-GENE
and O
proliferation O
through O
its O
regulation O
of O
mRNA I-GENE
stability O
. O

Electrophoretic O
mobility I-GENE
shift O
assays O
revealed O
that O
Sp1 I-GENE
binds O
to O
two O
different O
regions O
in O
the O
proximal I-GENE
promoter I-GENE
, O
a O
typical O
Sp1 I-GENE
site I-GENE
located O
at O
(- O
38 O
; O
- I-GENE
33 O
) O
and O
a O
G I-GENE
/ I-GENE
C I-GENE
- I-GENE
rich O
region O
between O
(- O
67 O
; O
- I-GENE
62 O
). O

_RARE_ I-GENE
and O
_RARE_ I-GENE
share O
a O
high O
degree O
of O
sequence I-GENE
identity O
that O
spans O
> O
_RARE_ I-GENE
contiguous O
amino O
acid I-GENE
residues O
. O

Molecular O
cloning O
of O
mouse I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
. O

The O
HPLC O
method O
involves O
an O
_RARE_ I-GENE
column O
at O
55 O
degrees O
C I-GENE
, O
a O
mixture O
of O
water O
- I-GENE
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
acid I-GENE
( O
_RARE_ I-GENE
: O
220 O
: O
1 I-GENE
, O
v I-GENE
/ I-GENE
v I-GENE
) O
as O
mobile O
phase O
and O
detection O
at O
_RARE_ I-GENE
nm O
. O

Eight O
patients O
received O
1 I-GENE
. O
5 I-GENE
mg O
of O
_RARE_ I-GENE
_RARE_ I-GENE
per O
kg O
of O
body O
weight O
, O
and O
six O
patients O
received O
3 I-GENE
. O
0 O
mg O
of O
_RARE_ I-GENE
_RARE_ I-GENE
per O
kg O
. O

_RARE_ I-GENE
encodes O
a O
24 O
- I-GENE
kDa I-GENE
protein I-GENE
that O
has O
sequence I-GENE
identity O
to O
the O
Neurospora I-GENE
crassa I-GENE
_RARE_ I-GENE
and O
the O
S I-GENE
. O
cerevisiae I-GENE
_RARE_ I-GENE
cyclin I-GENE
. O

To O
determine O
if O
_RARE_ I-GENE
is O
found O
in O
a O
complex I-GENE
with O
previously O
identified O
_RARE_ I-GENE
cdc2 I-GENE
- I-GENE
related I-GENE
kinases I-GENE
( O
_RARE_ I-GENE
), O
the O
_RARE_ I-GENE
gene I-GENE
was O
fused O
to O
the O
_RARE_ I-GENE
epitope O
tag O
, O
integrated O
into O
the O
_RARE_ I-GENE
genome O
, O
and O
expressed O
under O
inducible I-GENE
control O
. O

These O
findings O
indicate O
the O
involvement O
of O
Sp1 I-GENE
and O
an O
_RARE_ I-GENE
in O
non O
- I-GENE
cell O
- I-GENE
specific I-GENE
regulation O
and O
a O
_RARE_ I-GENE
- I-GENE
like I-GENE
transcription I-GENE
factor I-GENE
and O
Sp1 I-GENE
in O
the O
cell O
- I-GENE
specific I-GENE
regulation O
of O
the O
_RARE_ I-GENE
( O
4 I-GENE
) O
S I-GENE
gene I-GENE
. O

Here O
we O
review O
progress O
to O
date O
in O
this O
area O
. O

Additionally O
, O
the O
mouse I-GENE
promoter I-GENE
contains O
22 O
copies O
of O
a O
CT I-GENE
dinucleotide O
repeat I-GENE
sequence I-GENE
located O
approximately O
_RARE_ I-GENE
bp O
5 I-GENE
' O
to O
exon O
1 I-GENE
. O

The O
newly O
defined O
region O
contains O
an O
intron O
that O
may O
be O
alternatively O
spliced O
and O
seven O
polyadenylation O
signal I-GENE
sequences I-GENE
. O

_RARE_ I-GENE
and O
enriched O
_RARE_ I-GENE
standard O
reference O
materials O
were O
used O
to O
_RARE_ I-GENE
the O
system O
. O

Therefore O
, O
the O
positive O
cAMP I-GENE
control O
of O
the O
hypoxic O
_RARE_ I-GENE
and O
_RARE_ I-GENE
genes I-GENE
was O
_RARE_ I-GENE
from O
the O
_RARE_ I-GENE
pathway O
. O

Most O
likely O
they O
might O
represent O
regulatory I-GENE
RNAs I-GENE
or O
transcribed O
_RARE_ I-GENE
elements O
. O

This O
paper O
_RARE_ I-GENE
the O
_RARE_ I-GENE
- I-GENE
based O
approach O
adopted O
by O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
- I-GENE
1 I-GENE
and O
the O
_RARE_ I-GENE
necessary O
for O
the O
_RARE_ I-GENE
record O
based O
on O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
' O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
'. O

Sequence O
analyses O
of O
_RARE_ I-GENE
mutant I-GENE
alleles I-GENE
reveal O
that O
both O
the O
N I-GENE
- I-GENE
terminal I-GENE
catalytic O
domain I-GENE
and O
the O
C I-GENE
- I-GENE
terminal I-GENE
regulatory I-GENE
domain I-GENE
of O
_RARE_ I-GENE
are O
functionally O
essential O
. O

A I-GENE
mutation I-GENE
which O
_RARE_ I-GENE
the O
binding I-GENE
of O
these O
factors I-GENE
reduces O
_RARE_ I-GENE
reporter I-GENE
activity O
specifically O
in O
B I-GENE
cell O
lines O
, O
whereas O
a O
mutation I-GENE
which O
_RARE_ I-GENE
the O
site I-GENE
to O
a O
consensus I-GENE
CREB I-GENE
- I-GENE
binding I-GENE
sequence I-GENE
maintains O
wild I-GENE
- I-GENE
type I-GENE
promoter I-GENE
function O
. O

Here O
we O
describe O
the O
cloning O
, O
tissue I-GENE
- I-GENE
specific I-GENE
expression O
pattern O
, O
and O
functional O
characterization O
of O
two O
novel O
TEF I-GENE
- I-GENE
1 I-GENE
isoforms I-GENE
, O
TEF I-GENE
- I-GENE
1beta I-GENE
and O
TEF I-GENE
- I-GENE
_RARE_ I-GENE
. O

Therefore O
the O
binding I-GENE
sites I-GENE
for O
liver O
- I-GENE
enriched O
factors I-GENE
, O
present O
in O
the O
hamster I-GENE
_RARE_ I-GENE
proximal I-GENE
promoter I-GENE
in O
close O
vicinity O
and O
conserved O
between O
species O
, O
constitute O
a O
regulatory I-GENE
unit I-GENE
important O
for O
basal O
hepatic I-GENE
expression O
and O
tissue I-GENE
restriction I-GENE
of O
the O
action O
of O
hormones O
such O
as O
insulin I-GENE
. O

The O
kinase I-GENE
activity O
of O
_RARE_ I-GENE
is O
sensitive O
to O
CDK I-GENE
inhibitors O
such O
as O
_RARE_ I-GENE
and O
_RARE_ I-GENE
. O

Although O
MAP I-GENE
( O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
) O
kinases I-GENE
are O
implicated O
in O
cell O
proliferation O
and O
differentiation O
in O
many O
cell O
types O
, O
the O
role O
of O
MAP I-GENE
kinases I-GENE
in O
cardiac O
hypertrophy O
remains O
unclear O
. O

Transfection O
with O
a O
CSF I-GENE
- I-GENE
_RARE_ I-GENE
expression O
plasmid O
permitted O
CSF I-GENE
- I-GENE
1 I-GENE
- I-GENE
dependent I-GENE
activation O
of O
the O
signalling O
pathway O
targeting O
an O
Ets I-GENE
/ I-GENE
AP1 I-GENE
( O
activator I-GENE
protein I-GENE
1 I-GENE
) O
element I-GENE
in O
the O
uPA I-GENE
promoter I-GENE
that O
has O
been O
shown O
previously O
to O
be O
a O
target O
of O
oncogenic I-GENE
ras I-GENE
and O
protein I-GENE
kinase I-GENE
C I-GENE
pathways O
. O

Regulation O
of O
urokinase I-GENE
plasminogen I-GENE
activator I-GENE
gene I-GENE
transcription I-GENE
in O
the O
_RARE_ I-GENE
murine I-GENE
macrophage I-GENE
cell O
line O
by O
macrophage I-GENE
colony I-GENE
- I-GENE
stimulating I-GENE
factor I-GENE
( O
CSF I-GENE
- I-GENE
1 I-GENE
) O
is O
dependent I-GENE
upon O
the O
level O
of O
cell O
- I-GENE
surface O
receptor I-GENE
. O

_RARE_ I-GENE
( O
s O
) O
secreted O
by O
neuronal O
cultures O
contribute O
to O
this O
induction O
of O
_RARE_ I-GENE
- I-GENE
1 I-GENE
, O
but O
little O
is O
known O
about O
the O
signaling O
pathways O
mediating O
this O
regulation O
. O

_RARE_ I-GENE
of O
endogenous I-GENE
or O
exogenous O
G I-GENE
( O
q I-GENE
)- I-GENE
coupled I-GENE
receptors I-GENE
with O
the O
delta I-GENE
- I-GENE
opioid I-GENE
receptor I-GENE
produced O
strong O
_RARE_ I-GENE
of O
_RARE_ I-GENE
and O
such O
responses O
could O
be O
partially O
blocked O
by O
pertussis I-GENE
toxin I-GENE
. O

Patients O
enrolled O
in O
the O
_RARE_ I-GENE
to O
_RARE_ I-GENE
Platelet I-GENE
_RARE_ I-GENE
and O
Coronary O
_RARE_ I-GENE
- I-GENE
II I-GENE
( O
_RARE_ I-GENE
- I-GENE
II I-GENE
) O
trial O
were O
analyzed O
. O

The O
Wnt I-GENE
signaling O
pathway O
functions O
_RARE_ I-GENE
during O
animal O
development O
to O
control O
cell O
fate O
_RARE_ I-GENE
. O

This O
mutation I-GENE
no O
longer O
repressed O
the O
HPV I-GENE
- I-GENE
11 O
upstream O
regulatory I-GENE
region O
- I-GENE
controlled O
reporter I-GENE
expression O
. O

In O
the O
_RARE_ I-GENE
_RARE_ I-GENE
capsid I-GENE
, O
this O
sequence I-GENE
forms O
the O
carboxy I-GENE
end O
of O
the O
_RARE_ I-GENE
beta I-GENE
- I-GENE
strand O
I I-GENE
( O
_RARE_ I-GENE
), O
and O
all O
its O
basic I-GENE
residues O
are O
_RARE_ I-GENE
positioned O
at O
the O
face O
that O
in O
the O
_RARE_ I-GENE
subunit I-GENE
would O
be O
exposed O
to O
solvent O
. O

The O
two O
contiguous O
_RARE_ I-GENE
( O
human I-GENE
insulin I-GENE
- I-GENE
like I-GENE
growth I-GENE
factor I-GENE
II I-GENE
) O
and O
H19 I-GENE
genes I-GENE
are O
_RARE_ I-GENE
imprinted O
in O
both O
human I-GENE
and O
mouse I-GENE
. O

The O
asymmetric O
methylation O
was O
associated I-GENE
with O
tissue I-GENE
- I-GENE
specific I-GENE
disruption O
of O
H19 I-GENE
genomic O
imprinting O
in O
fetal O
brain O
. O

The O
comparison O
of O
the O
expression O
patterns O
of O
the O
known O
_RARE_ I-GENE
family I-GENE
members O
shows O
subtype I-GENE
specificity O
with O
significant O
_RARE_ I-GENE
. O

Early O
treatment O
_RARE_ I-GENE
of O
the O
Class I-GENE
II I-GENE
division O
2 I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
use O
of O
the O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
would O
support O
further O
development O
as O
a O
research O
tool O
for O
a O
simple O
assessment O
of O
disease O
severity O
that O
could O
be O
used O
in O
epidemiological O
studies O
. O

The O
consensus I-GENE
_RARE_ I-GENE
the O
importance O
of O
residues O
other O
than O
the O
eight O
motifs O
that O
are O
often O
associated I-GENE
with O
_RARE_ I-GENE
- I-GENE
box I-GENE
RNA I-GENE
_RARE_ I-GENE
, O
as O
well O
as O
de O
- I-GENE
_RARE_ I-GENE
the O
importance O
of O
the O
" O
A I-GENE
" O
residue O
within O
the O
" O
_RARE_ I-GENE
" O
motif I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
was O
defined O
as O
an O
_RARE_ I-GENE
larger O
than O
10 O
mm O
or O
an O
_RARE_ I-GENE
of O
any O
size O
with O
_RARE_ I-GENE
component O
, O
high O
- I-GENE
grade O
dysplasia O
or O
invasive O
carcinoma O
. O

In O
transient O
assays O
, O
using O
rice I-GENE
_RARE_ I-GENE
- I-GENE
cultured O
cells O
transformed O
by O
particle I-GENE
_RARE_ I-GENE
, O
we O
showed O
previously O
that O
_RARE_ I-GENE
can O
transcriptionally O
repress O
the O
activity O
of O
reporter I-GENE
gene I-GENE
constructs I-GENE
with O
upstream O
HD I-GENE
- I-GENE
Zip I-GENE
binding I-GENE
sites I-GENE
. O

Results O
of O
two O
- I-GENE
hybrid O
assays O
and O
electrophoretic O
mobility I-GENE
shift O
assays O
strongly O
suggest O
that O
all O
HD I-GENE
- I-GENE
Zip I-GENE
proteins I-GENE
of O
families O
I I-GENE
and O
II I-GENE
can O
form O
homodimers I-GENE
and O
also O
heterodimers I-GENE
with O
all O
HD I-GENE
- I-GENE
Zip I-GENE
proteins I-GENE
of O
the O
same O
family I-GENE
. O

Among O
mammalian I-GENE
_RARE_ I-GENE
, O
HSF1 I-GENE
has O
been O
shown O
to O
be O
important O
for O
regulation O
of O
the O
heat I-GENE
- I-GENE
induced O
stress O
gene I-GENE
expression O
, O
whereas O
the O
function O
of O
_RARE_ I-GENE
in O
stress O
response O
is O
unclear O
. O

_RARE_ I-GENE
, O
concomitant O
expression O
of O
constitutive O
activated I-GENE
Raf I-GENE
and O
_RARE_ I-GENE
Ras I-GENE
results O
in O
almost O
complete O
loss O
of O
TTF I-GENE
- I-GENE
1 I-GENE
activity O
. O

They O
share O
many O
downstream O
targets O
, O
including O
remodeling O
of O
the O
actin I-GENE
cytoskeleton I-GENE
, O
activation O
of O
p70 I-GENE
( O
S6 I-GENE
) O
kinase I-GENE
and O
c I-GENE
- I-GENE
jun I-GENE
N I-GENE
- I-GENE
terminal I-GENE
kinase I-GENE
( O
JNK I-GENE
), O
and O
regulation O
of O
transcription I-GENE
and O
cell O
proliferation O
. O

Expression O
of O
activated I-GENE
Cdc42 I-GENE
results O
in O
the O
translocation O
of O
_RARE_ I-GENE
from O
the O
nucleus O
into O
the O
cytosol O
, O
and O
Cdc42 I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
at O
the O
plasma I-GENE
membrane I-GENE
and O
in O
the O
cytoplasm O
. O

Copyright O
2000 O
Academic O
Press O
. O

To O
understand O
whether O
Shc I-GENE
localization O
in O
membrane I-GENE
_RARE_ I-GENE
is O
sufficient O
to O
regulate O
Shc I-GENE
function O
, O
we O
constructed O
a O
Shc I-GENE
chimera I-GENE
containing O
the O
Ras I-GENE
membrane I-GENE
localization O
motif I-GENE
at O
the O
C I-GENE
- I-GENE
terminus O
. O

Southern O
blotting O
and O
single O
strand O
conformation O
polymorphism O
analyses O
did O
not O
show O
tumor I-GENE
- I-GENE
specific I-GENE
alterations O
of O
this O
gene I-GENE
in O
_RARE_ I-GENE
and O
RT I-GENE
- I-GENE
PCR O
studies O
showed O
expression O
in O
glioma O
cell O
lines O
, O
suggesting O
that O
_RARE_ I-GENE
is O
not O
the O
chromosome O
_RARE_ I-GENE
glioma O
tumor I-GENE
suppressor I-GENE
gene I-GENE
. O

_RARE_ I-GENE
is O
a O
positive O
yet O
_RARE_ I-GENE
regulator I-GENE
of O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
expression O
. O

_RARE_ I-GENE
I I-GENE
of O
the O
phosphoenolpyruvate I-GENE
: O
sugar I-GENE
phosphotransferase I-GENE
system O
. O

Based O
on O
these O
data O
, O
we O
conclude O
that O
transcription I-GENE
of O
_RARE_ I-GENE
is O
initiated O
from O
the O
_RARE_ I-GENE
promoter I-GENE
in O
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
_RARE_ I-GENE
its O
transcription I-GENE
either O
by O
mediating O
transcriptional O
readthrough O
or O
increasing O
mRNA I-GENE
stability O
. O

It O
was O
established O
that O
_RARE_ I-GENE
or O
_RARE_ I-GENE
_RARE_ I-GENE
, O
elevated O
the O
_RARE_ I-GENE
threshold O
for O
mechanical O
stimuli O
in O
the O
formalin O
test O
in O
rats O
. O

Molecular O
_RARE_ I-GENE
of O
human I-GENE
cytokine O
and O
cytokine O
response O
pathway O
genes I-GENE
by O
KSHV I-GENE
. O

_RARE_ I-GENE
environment O
was O
an O
important O
influence O
on O
_RARE_ I-GENE
relationships O
, O
_RARE_ I-GENE
use O
, O
and O
social O
support O
. O

By O
electrophoresis O
mobility I-GENE
shift O
assays O
using O
probes O
corresponding O
to O
different O
segments O
of O
the O
putative O
human I-GENE
c I-GENE
- I-GENE
myb I-GENE
intron O
1 I-GENE
transcription I-GENE
_RARE_ I-GENE
region O
and O
nuclear I-GENE
extracts O
from O
myeloid O
leukemia I-GENE
HL I-GENE
60 O
and O
fibroblast I-GENE
_RARE_ I-GENE
38 O
cells O
, O
we O
detected O
a O
HL I-GENE
- I-GENE
60 O
- I-GENE
specific I-GENE
DNA I-GENE
- I-GENE
protein I-GENE
complex I-GENE
with O
a O
123 O
- I-GENE
bp O
fragment I-GENE
containing O
binding I-GENE
sites I-GENE
for O
the O
interferon I-GENE
regulatory I-GENE
factors I-GENE
( O
_RARE_ I-GENE
) O
nuclear I-GENE
proteins I-GENE
. O

_RARE_ I-GENE
DESIGN O
: O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
smears O
from O
21 O
cases O
of O
invasive O
_RARE_ I-GENE
carcinoma O
( O
_RARE_ I-GENE
) O
of O
breast O
were O
subjected O
to O
detailed O
_RARE_ I-GENE
analysis O
. O

_RARE_ I-GENE
Response O
_RARE_ I-GENE
( O
_RARE_ I-GENE
), O
located O
in O
5 I-GENE
'- O
flanking O
sequences I-GENE
of O
both O
the O
_RARE_ I-GENE
and O
_RARE_ I-GENE
subunit I-GENE
genes I-GENE
, O
are O
_RARE_ I-GENE
to O
at O
least O
partially O
mediate O
gene I-GENE
induction O
following O
_RARE_ I-GENE
exposure O
. O

A I-GENE
new O
technique O
to O
create O
an O
artificial O
stenosis O
in O
the O
native O
LAD O
using O
a O
_RARE_ I-GENE
. O

_RARE_ I-GENE
is O
mutated O
in O
the O
X I-GENE
- I-GENE
ray O
- I-GENE
induced O
mouse I-GENE
mutant I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
), O
causing O
a O
variety O
of O
_RARE_ I-GENE
defects O
similar O
to O
SD O
phenotypes O
. O

_RARE_ I-GENE
, O
J O
. O

_RARE_ I-GENE
behaviour O
was O
also O
studied O
during O
the O
cell O
cycle O
; O
_RARE_ I-GENE
always O
_RARE_ I-GENE
to O
a O
discrete O
structure O
that O
duplicated O
very O
early I-GENE
in O
mitosis O
and O
_RARE_ I-GENE
to O
daughter O
cells O
in O
a O
coordinate O
manner O
with O
the O
basal O
body O
and O
_RARE_ I-GENE
, O
suggesting O
the O
involvement O
of O
_RARE_ I-GENE
. O

The O
early I-GENE
_RARE_ I-GENE
. O
of O
rejection O
and O
especially O
acute O
rejection O
, O
it O
' O
s O
adequate O
management O
, O
decreased O
risk O
for O
the O
future O
chronic O
rejection O
nephropathy O
. O

_RARE_ I-GENE
are O
responsible O
for O
the O
_RARE_ I-GENE
of O
sucrose O
to O
fructose I-GENE
and O
glucose O
. O

To O
investigate O
the O
molecular O
mechanisms O
of O
this O
Tax I-GENE
- I-GENE
mediated O
inhibition O
, O
we O
analyzed O
its O
effect O
on O
the O
transcriptional O
activity O
of O
the O
myogenic I-GENE
MyoD I-GENE
protein I-GENE
, O
which O
was O
used O
as O
a O
_RARE_ I-GENE
of O
bHLH I-GENE
factors I-GENE
. O

The O
human I-GENE
T I-GENE
cell O
leukemia I-GENE
/ I-GENE
_RARE_ I-GENE
virus I-GENE
type I-GENE
1 I-GENE
Tax I-GENE
protein I-GENE
represses O
MyoD I-GENE
- I-GENE
dependent I-GENE
transcription I-GENE
by O
inhibiting O
MyoD I-GENE
- I-GENE
binding I-GENE
to O
the O
_RARE_ I-GENE
domain I-GENE
of O
p300 I-GENE
. O

_RARE_ I-GENE
and O
spindle O
pole O
body O
localization O
of O
the O
_RARE_ I-GENE
mitotic O
regulatory I-GENE
protein I-GENE
kinase I-GENE
in O
budding I-GENE
yeast I-GENE
. O

Thus O
, O
both O
the O
hyperplasia O
and O
thrombotic O
complications O
which O
often O
follow O
_RARE_ I-GENE
might O
be O
_RARE_ I-GENE
by O
employing O
_RARE_ I-GENE
_RARE_ I-GENE
, O
which O
have O
a O
greater O
capacity O
than O
_RARE_ I-GENE
in O
supporting O
a O
functional O
neo I-GENE
- I-GENE
endothelium O
. O

The O
cell O
cycle O
and O
transcriptional O
defects O
caused O
by O
_RARE_ I-GENE
( O
_RARE_ I-GENE
- I-GENE
1 I-GENE
) O
are O
consistent O
with O
the O
role O
of O
TAF I-GENE
( O
II I-GENE
) O
s O
as O
_RARE_ I-GENE
of O
transcriptional O
activation O
and O
may O
reflect O
a O
role O
for O
_RARE_ I-GENE
in O
regulating O
activation O
by O
SBF I-GENE
and O
_RARE_ I-GENE
. O

_RARE_ I-GENE
- I-GENE
regulated O
kinase I-GENE
( O
ERK I-GENE
) O
activation O
and O
molecular O
coupling O
of O
the O
adaptor I-GENE
proteins I-GENE
p130 I-GENE
Crk I-GENE
- I-GENE
associated I-GENE
substrate I-GENE
( O
CAS I-GENE
) O
and O
c I-GENE
- I-GENE
_RARE_ I-GENE
( O
Crk I-GENE
) O
represent O
two O
distinct O
pathways O
that O
induce O
cell O
invasion O
and O
protect O
cells O
from O
apoptosis O
in O
a O
three O
- I-GENE
dimensional O
collagen I-GENE
matrix I-GENE
. O

_RARE_ I-GENE
of O
_RARE_ I-GENE
and O
_RARE_ I-GENE
DNA I-GENE
- I-GENE
protein I-GENE
complexes I-GENE
has O
revealed O
the O
extent O
of O
these O
sequences I-GENE
, O
and O
C I-GENE
- I-GENE
terminally I-GENE
extended O
molecules I-GENE
with O
substantially O
enhanced O
DNA I-GENE
binding I-GENE
activity O
compared O
to O
the O
core I-GENE
domains I-GENE
alone O
have O
been O
produced O
. O

The O
evolution O
of O
the O
_RARE_ I-GENE
cis O
- I-GENE
regulatory I-GENE
region O
versus O
the O
open O
reading O
frame O
as O
well O
as O
among O
different O
domains I-GENE
of O
the O
open O
reading O
frame O
differed O
from O
one O
another O
. O

These O
results O
indicate O
that O
residue O
_RARE_ I-GENE
serves O
as O
a O
" O
protein I-GENE
_RARE_ I-GENE
" O
of O
altered O
minor O
groove I-GENE
interactions O
and O
identifies O
which O
base O
pair O
interactions O
are O
altered O
by O
these O
lesions O
. O

The O
recombinant I-GENE
enzymes O
exist O
as O
_RARE_ I-GENE
. O

A I-GENE
pathway O
for O
regulation O
of O
B I-GENE
lymphocyte I-GENE
antigen I-GENE
receptor I-GENE
- I-GENE
induced O
calcium O
_RARE_ I-GENE
. O

We O
now O
describe O
a O
second O
_RARE_ I-GENE
protein I-GENE
, O
called O
_RARE_ I-GENE
, O
that O
is O
highly O
homologous O
to O
_RARE_ I-GENE
and O
also O
expressed O
primarily O
in O
brain O
. O

_RARE_ I-GENE
- I-GENE
1 I-GENE
( O
I I-GENE
- I-GENE
1 I-GENE
) O
and O
inhibitor I-GENE
- I-GENE
2 I-GENE
( O
I I-GENE
- I-GENE
2 I-GENE
) O
selectively O
inhibit O
type I-GENE
1 I-GENE
protein I-GENE
serine I-GENE
/ I-GENE
threonine I-GENE
phosphatases I-GENE
( O
_RARE_ I-GENE
). O

_RARE_ I-GENE
mutations O
throughout O
the O
AC I-GENE
element I-GENE
_RARE_ I-GENE
with O
induction O
but O
allowed O
us O
to O
define O
five O
overlapping O
sites I-GENE
for O
regulatory I-GENE
factors I-GENE
in O
AC I-GENE
and O
to O
design O
probes O
binding I-GENE
just O
one O
or O
two O
factors I-GENE
. O

The O
substrates O
for O
_RARE_ I-GENE
synthesis O
in O
the O
_RARE_ I-GENE
of O
the O
Golgi I-GENE
are O
nucleotide I-GENE
sugars O
that O
must O
be O
transported O
from O
the O
cytosol O
by O
specific I-GENE
membrane I-GENE
- I-GENE
bound O
transporters I-GENE
. O

_RARE_ I-GENE
targeting O
of O
the O
_RARE_ I-GENE
density I-GENE
protein I-GENE
_RARE_ I-GENE
- I-GENE
95 O
mediated O
by O
a O
tyrosine I-GENE
- I-GENE
based O
trafficking O
signal I-GENE
. O

( O
1998 O
) O
J O
. O

_RARE_ I-GENE
by O
two O
species O
of O
_RARE_ I-GENE
( O
_RARE_ I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
) O
can O
lead O
to O
extensive O
swelling O
with O
_RARE_ I-GENE
failure O
. O

Both O
normal O
and O
transforming I-GENE
_RARE_ I-GENE
proteins I-GENE
have O
_RARE_ I-GENE
_RARE_ I-GENE
activity O
but O
only O
the O
oncoprotein I-GENE
_RARE_ I-GENE
with O
Ras I-GENE
in O
activating I-GENE
extracellular I-GENE
signal I-GENE
- I-GENE
regulated O
kinase I-GENE
ERK1 I-GENE
. O

These O
results O
indicate O
that O
virulence I-GENE
- I-GENE
associated I-GENE
genes I-GENE
and O
their O
overall O
chromosomal I-GENE
arrangement O
are O
relatively O
well O
conserved O
between O
B I-GENE
. O
_RARE_ I-GENE
and O
other O
gram O
- I-GENE
negative O
bacteria O
such O
as O
A I-GENE
. O
_RARE_ I-GENE
. O

An O
important O
mechanism O
by O
which O
the O
tumor I-GENE
suppressor I-GENE
p53 I-GENE
maintains O
genomic O
stability O
is O
to O
induce O
cell O
cycle O
arrest O
through O
activation O
of O
the O
cyclin I-GENE
- I-GENE
dependent I-GENE
kinase I-GENE
inhibitor I-GENE
p21 I-GENE
( O
WAF1 I-GENE
/ I-GENE
Cip1 I-GENE
) O
gene I-GENE
. O

_RARE_ I-GENE
acts O
as O
an O
adaptor I-GENE
molecule I-GENE
in O
integrin I-GENE
signaling O
. O

Thus O
, O
growth I-GENE
factor I-GENE
activation O
of O
ER I-GENE
can O
mediate O
transactivation O
vs O
ER I-GENE
/ I-GENE
Sp1 I-GENE
binding I-GENE
to O
GC I-GENE
- I-GENE
rich O
sites I-GENE
and O
represents O
a O
novel O
pathway O
for O
ligand O
- I-GENE
independent O
ER I-GENE
action O
. O

Furthermore O
, O
analysis O
of O
deletion O
promoter I-GENE
- I-GENE
reporter I-GENE
constructs I-GENE
found O
that O
the O
basal O
activity O
of O
P2 I-GENE
_RARE_ I-GENE
in O
the O
proximal I-GENE
region O
of O
P2 I-GENE
. O

RESULTS O
: O
_RARE_ I-GENE
_RARE_ I-GENE
collected O
during O
_RARE_ I-GENE
tests O
increased O
gradually O
in O
proportion O
with O
age O
, O
especially O
in O
the O
hypertensive O
group O
( O
p O
< O
0 O
. O
05 O
). O

In O
addition O
, O
the O
transcription I-GENE
of O
c I-GENE
- I-GENE
_RARE_ I-GENE
promoter I-GENE
was O
strongly O
up O
- I-GENE
regulated O
when O
CD40 I-GENE
or O
Epstein I-GENE
- I-GENE
Barr I-GENE
virus I-GENE
latent I-GENE
membrane I-GENE
protein I-GENE
1 I-GENE
was O
overexpressed O
. O

A I-GENE
variety O
of O
_RARE_ I-GENE
and O
self O
- I-GENE
applied O
fluoride O
products I-GENE
are O
available O
and O
new O
fluoride O
delivery O
systems O
have O
recently O
_RARE_ I-GENE
the O
_RARE_ I-GENE
. O

These O
studies O
identify O
several O
of O
the O
signal I-GENE
- I-GENE
transduction O
events O
involved O
in O
the O
apoptosis O
of O
malignant O
B I-GENE
cells O
that O
_RARE_ I-GENE
following O
ligation O
of O
_RARE_ I-GENE
by O
anti I-GENE
- I-GENE
_RARE_ I-GENE
antibodies I-GENE
in O
the O
presence O
of O
Fc I-GENE
- I-GENE
receptor I-GENE
- I-GENE
expressing O
cells O
or O
secondary O
_RARE_ I-GENE
anti I-GENE
-( O
mouse I-GENE
Ig I-GENE
) O
antibodies I-GENE
and O
which O
may O
contribute O
to O
the O
tumor I-GENE
_RARE_ I-GENE
observed O
in O
mouse I-GENE
models O
and O
clinical O
trials O
. O

CONCLUSION O
: O
Treatment O
of O
sepsis O
with O
the O
platelet I-GENE
- I-GENE
activating I-GENE
factor I-GENE
antagonist O
BB I-GENE
- I-GENE
_RARE_ I-GENE
offers O
no O
advantage O
over O
placebo O
on O
survival O
, O
hemodynamic O
status O
, O
respiratory O
function O
, O
or O
organ O
failure O
scores O
. O

_RARE_ I-GENE
potentiates O
the O
local O
_RARE_ I-GENE
effect O
of O
lidocaine O
in O
mice O
. O

The O
_RARE_ I-GENE
of O
all O
the O
mutated O
proteins I-GENE
was O
remarkably O
reduced O
. O

Recently O
, O
identical O
_RARE_ I-GENE
sequences I-GENE
have O
been O
identified O
at O
other O
locations O
in O
the O
human I-GENE
genome O
. O

EM O
analysis O
demonstrated O
that O
only O
one O
Rep I-GENE
- I-GENE
DNA I-GENE
complex I-GENE
was O
formed O
on O
_RARE_ I-GENE
- I-GENE
19 O
target O
DNA I-GENE
. O

The O
protein I-GENE
was O
associated I-GENE
with O
purified O
vaccinia I-GENE
virus I-GENE
particles O
and O
with O
membranes O
of O
immature O
and O
mature O
virions O
that O
were O
_RARE_ I-GENE
by O
electron O
microscopy O
of O
infected O
cells O
. O

In O
vivo O
dimethyl O
sulfate I-GENE
footprinting O
of O
the O
cyclin I-GENE
E I-GENE
promoter I-GENE
revealed O
several O
regions O
of O
protection O
and O
hypersensitivity O
that O
were O
unique O
to O
infected O
cells O
. O

A I-GENE
total O
of O
_RARE_ I-GENE
_RARE_ I-GENE
map O
to O
this O
interval O
of O
3 I-GENE
Mb O
, O
giving O
an O
average O
marker O
resolution O
of O
approximately O
one O
per O
15 O
kb O
. O

Recently O
, O
a O
mutation I-GENE
in O
the O
amino O
- I-GENE
terminus O
of O
_RARE_ I-GENE
was O
associated I-GENE
with O
diabetes O
. O

CONCLUSION O
: O
More O
than O
50 O
% O
of O
patients O
with O
_RARE_ I-GENE
_RARE_ I-GENE
and O
CRS I-GENE
do O
not O
improve O
after O
surgery O
, O
a O
response O
that O
may O
be O
predicted O
by O
more O
cells O
expressing O
IL I-GENE
- I-GENE
5 I-GENE
mRNA I-GENE
in O
the O
_RARE_ I-GENE
_RARE_ I-GENE
. O

Biol O
. O

On O
the O
basis O
of O
size O
, O
the O
CRS I-GENE
sequence I-GENE
to O
which O
it O
binds O
, O
and O
its O
_RARE_ I-GENE
identification O
as O
a O
zinc I-GENE
finger I-GENE
protein I-GENE
, O
_RARE_ I-GENE
factor I-GENE
has O
been O
identified O
as O
a O
_RARE_ I-GENE
- I-GENE
like I-GENE
zinc I-GENE
finger I-GENE
protein I-GENE
( O
a O
mouse I-GENE
_RARE_ I-GENE
- I-GENE
89 I-GENE
homologue I-GENE
). O

METHODS O
: O
The O
most O
distal O
muscle O
fibres O
from O
the O
deep O
and O
superficial O
finger I-GENE
_RARE_ I-GENE
were O
measured O
relative O
to O
the O
_RARE_ I-GENE
bone O
in O
18 O
_RARE_ I-GENE
specimens O
. O

Here O
we O
report O
on O
the O
isolation O
of O
_RARE_ I-GENE
, O
and O
show O
that O
it O
interacts O
with O
_RARE_ I-GENE
, O
but O
not O
with O
a O
second O
CDK I-GENE
from O
Arabidopsis I-GENE
, O
_RARE_ I-GENE
. O

_RARE_ I-GENE
impact O
of O
risk O
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
. O

METHODS O
: O
We O
determined O
an O
odds O
ratio O
( O
OR O
), O
as O
a O
measure O
of O
the O
relative O
risk O
of O
being O
exposed O
to O
a O
potential O
interaction O
, O
comparing O
the O
use O
of O
the O
H2 I-GENE
- I-GENE
receptor I-GENE
antagonist O
, O
cimetidine O
, O
with O
that O
of O
the O
_RARE_ I-GENE
agents O
ranitidine O
, O
_RARE_ I-GENE
and O
_RARE_ I-GENE
in O
users O
and O
_RARE_ I-GENE
of O
_RARE_ I-GENE
, O
phenytoin O
and O
theophylline O
. O

The O
prevalence O
of O
_RARE_ I-GENE
was O
30 O
% O
in O
the O
47 O
patients O
without O
_RARE_ I-GENE
and O
was O
significantly O
higher O
( O
70 I-GENE
%, O
P I-GENE
< O
0 O
. O
001 O
) O
in O
the O
70 I-GENE
patients O
with O
_RARE_ I-GENE
, O
who O
also O
had O
lower O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
plasma I-GENE
IGF I-GENE
- I-GENE
1 I-GENE
, O
serum I-GENE
creatinine O
( O
_RARE_ I-GENE
), O
and O
blood O
hemoglobin I-GENE
. O

Our O
data O
suggest O
that O
, O
at O
least O
at O
high O
temperature O
, O
a O
critical O
minimal I-GENE
level O
of O
_RARE_ I-GENE
protein I-GENE
_RARE_ I-GENE
is O
required O
for O
maintaining O
vesicle O
_RARE_ I-GENE
. O

The O
second O
functional O
pair O
of O
_RARE_ I-GENE
sites I-GENE
is O
located O
between O
the O
two O
transcription I-GENE
initiation I-GENE
sites I-GENE
. O

A I-GENE
distinct O
staining O
pattern O
for O
the O
N I-GENE
- I-GENE
_RARE_ I-GENE
was O
not O
detectable O
, O
although O
it O
was O
expected O
to O
_RARE_ I-GENE
at O
the O
actin I-GENE
stress O
fibers O
. O

The O
' O
_RARE_ I-GENE
' O
model O
, O
which O
is O
based O
on O
_RARE_ I-GENE
' O
s O
T2 I-GENE
_RARE_ I-GENE
, O
proved O
to O
be O
more O
sensitive O
and O
diagnosed O
a O
systematic O
displacement I-GENE
for O
three O
prostate O
patients O
. O

The O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
_RARE_ I-GENE
are O
not O
homologs I-GENE
; O
however O
, O
like I-GENE
the O
_RARE_ I-GENE
methyltransferase I-GENE
gene I-GENE
, O
the O
genes I-GENE
encoding O
the O
_RARE_ I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
each O
contain O
a O
single O
in O
- I-GENE
frame O
_RARE_ I-GENE
codon O
. O

After O
phosphorylation O
, O
STAT I-GENE
proteins I-GENE
are O
transported O
into O
the O
nucleus O
and O
exhibit O
transcriptional O
activity O
. O

Overexpression O
of O
_RARE_ I-GENE
- I-GENE
1 I-GENE
is O
sufficient O
to O
protect O
against O
apoptosis O
, O
while O
transfection O
of O
a O
_RARE_ I-GENE
- I-GENE
1 I-GENE
antisense I-GENE
plasmid O
causes O
cell O
death O
. O

Thus O
, O
although O
multiple O
_RARE_ I-GENE
pathways O
are O
activated I-GENE
in O
response O
to O
a O
ras I-GENE
oncogene I-GENE
, O
inactivation O
of O
_RARE_ I-GENE
secretion O
or O
response O
is O
sufficient O
to O
block O
the O
_RARE_ I-GENE
program O
. O

In O
this O
study O
, O
the O
abilities O
of O
constitutive O
and O
conditional O
forms O
of O
the O
three O
Raf I-GENE
kinases I-GENE
to O
abrogate O
the O
cytokine O
_RARE_ I-GENE
of O
_RARE_ I-GENE
- I-GENE
P1 I-GENE
cells O
were O
examined O
. O

_RARE_ I-GENE
of O
the O
method O
to O
a O
representative O
set O
of O
50 O
known O
genes I-GENE
from O
Arabidopsis I-GENE
thaliana O
showed O
significant O
improvement O
in O
prediction O
accuracy O
compared O
to O
previous O
spliced O
alignment O
methods O
. O

The O
complete O
cDNA I-GENE
sequence I-GENE
of O
human I-GENE
_RARE_ I-GENE
spectrin I-GENE
is O
available O
from O
_RARE_ I-GENE
( O
TM I-GENE
) O
as O
_RARE_ I-GENE
number O
. O

_RARE_ I-GENE
of O
naturally O
occurring O
HIV I-GENE
- I-GENE
1 I-GENE
long O
terminal I-GENE
repeats I-GENE
by O
the O
JNK I-GENE
signaling O
pathway O
. O

These O
data O
show O
that O
the O
alpha I-GENE
- I-GENE
helix I-GENE
domain I-GENE
of O
_RARE_ I-GENE
( O
_RARE_ I-GENE
), O
which O
is O
conserved O
in O
the O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
proteins I-GENE
, O
is O
implicated O
in O
protein I-GENE
- I-GENE
protein I-GENE
interaction O
and O
confers O
a O
specific I-GENE
regulatory I-GENE
mechanism O
, O
outside O
of O
their O
Cdk I-GENE
- I-GENE
inhibitory I-GENE
activity O
, O
by O
which O
the O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
family I-GENE
members O
positively O
act O
on O
myogenic I-GENE
differentiation O
. O

The O
mode O
of O
resistance O
to O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
was O
not O
evident O
( O
_RARE_ I-GENE
A I-GENE
- I-GENE
negative O
by O
PCR O
); O
and O
these O
cases O
_RARE_ I-GENE
the O
existence O
of O
_RARE_ I-GENE
- I-GENE
resistant O
isolates O
before O
the O
introduction O
of O
this O
antimicrobial O
class I-GENE
into O
human I-GENE
clinical O
practice O
. O

This O
study O
was O
carried O
out O
to O
analyze O
PRL I-GENE
secretion O
in O
metastatic O
prostate O
cancer O
patients O
both O
at O
basal O
conditions O
and O
in O
response O
to O
L I-GENE
- I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
, O
which O
represents O
the O
most O
classical O
inhibitory I-GENE
and O
stimulatory I-GENE
tests O
for O
PRL I-GENE
secretion O
, O
respectively O
. O

_RARE_ I-GENE
adhesion I-GENE
receptors I-GENE
_RARE_ I-GENE
signals O
that O
control O
complex I-GENE
cell O
functions O
which O
require O
the O
regulation O
of O
gene I-GENE
expression O
, O
such O
as O
proliferation O
, O
differentiation O
and O
survival O
. O

_RARE_ I-GENE
, O
replication O
, O
repair I-GENE
: O
from O
complexity O
to O
_RARE_ I-GENE
. O

The O
_RARE_ I-GENE
_RARE_ I-GENE
: O
a O
question O
of O
_RARE_ I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
- I-GENE
operative O
ultrasound O
( O
_RARE_ I-GENE
) O
has O
been O
widely O
used O
in O
an O
attempt O
to O
overcome O
these O
_RARE_ I-GENE
, O
but O
is O
limited O
by O
its O
two O
- I-GENE
dimensional O
nature O
, O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
variability O
, O
and O
image O
_RARE_ I-GENE
with O
_RARE_ I-GENE
or O
_RARE_ I-GENE
techniques O
. O

CONCLUSIONS O
: O
This O
randomized O
study O
shows O
that O
_RARE_ I-GENE
fibrin I-GENE
_RARE_ I-GENE
is O
effective O
in O
preventing O
air O
_RARE_ I-GENE
after O
small I-GENE
lung O
_RARE_ I-GENE
in O
pigs O
, O
even O
at O
high O
inspiratory O
pressures O
. O

_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
disease O
is O
caused O
by O
mutations O
in O
_RARE_ I-GENE
encoding O
a O
novel O
Ca I-GENE
( O
2 I-GENE
+) O
pump I-GENE
. O

_RARE_ I-GENE
is O
expressed O
in O
the O
developing O
liver O
_RARE_ I-GENE
with O
the O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
helix I-GENE
transcription I-GENE
factor I-GENE
, O
_RARE_ I-GENE
Nuclear I-GENE
Factor I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
). O

As O
an O
extension O
of O
our O
structural O
characterization O
of O
the O
exon O
- I-GENE
intron O
organization O
of O
the O
mouse I-GENE
_RARE_ I-GENE
gene I-GENE
, O
we O
now O
have O
isolated O
and O
characterized O
the O
mouse I-GENE
_RARE_ I-GENE
promoter I-GENE
region O
required O
for O
IFN I-GENE
- I-GENE
inducible I-GENE
transcription I-GENE
. O

The O
CRE O
, O
5 I-GENE
'- O
_RARE_ I-GENE
- I-GENE
3 I-GENE
', O
has O
been O
described O
as O
the O
consensus I-GENE
sequence I-GENE
for O
the O
cis O
- I-GENE
element I-GENE
that O
directs O
cAMP I-GENE
- I-GENE
regulated O
gene I-GENE
expression O
. O

_RARE_ I-GENE
length I-GENE
did O
not O
significantly O
differ O
between O
right O
and O
left O
, O
however O
, O
kidney O
_RARE_ I-GENE
, O
cortical O
thickness O
and O
size O
did O
( O
p O
< O
0 O
. O
05 O
). O

The O
clinical O
stage O
was O
I I-GENE
( O
_RARE_ I-GENE
), O
and O
S2 I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
with O
lymph O
node O
dissection O
( O
R I-GENE
2 I-GENE
b I-GENE
) O
was O
performed O
. O

_RARE_ I-GENE
for O
_RARE_ I-GENE
- I-GENE
induced O
night O
_RARE_ I-GENE
. O

A I-GENE
cause O
of O
increase O
of O
alkaline I-GENE
phosphatase I-GENE
in O
children O

The O
physicians O
in O
charge I-GENE
of O
all O
patients O
with O
evidence O
of O
acute O
Q I-GENE
fever O
( O
_RARE_ I-GENE
and O
/ I-GENE
or O
presence O
of O
IgM I-GENE
) O
or O
chronic O
Q I-GENE
fever O
( O
prolonged O
disease O
and O
/ I-GENE
or O
IgG I-GENE
antibody I-GENE
titer O
to O
phase O
I I-GENE
of O
_RARE_ I-GENE
_RARE_ I-GENE
> O
or O
= O
800 O
) O
were O
_RARE_ I-GENE
to O
complete O
a O
questionnaire O
, O
which O
was O
computerized O
. O

Copyright O
2000 O
Academic O
Press O
. O

_RARE_ I-GENE
cell O
- I-GENE
to O
- I-GENE
cell O
movement O
of O
_RARE_ I-GENE
CP I-GENE
mutant I-GENE
was O
complemented O
in O
_RARE_ I-GENE
_RARE_ I-GENE
cv O
. O

Induction O
of O
_RARE_ I-GENE
expression O
by O
stimulation O
of O
U937 O
cells O
with O
IFN I-GENE
- I-GENE
gamma I-GENE
revealed O
the O
presence O
of O
two O
functional O
_RARE_ I-GENE
( O
gamma I-GENE
- I-GENE
interferon I-GENE
activation O
site I-GENE
) O
elements O
. O

Significantly O
, O
two O
proximal I-GENE
GATA I-GENE
- I-GENE
1 I-GENE
- I-GENE
binding I-GENE
sites I-GENE
(- O
118 O
/- O
113 I-GENE
and O
- I-GENE
98 O
/- O
93 O
) O
and O
a O
region O
located O
within O
- I-GENE
_RARE_ I-GENE
to O
- I-GENE
_RARE_ I-GENE
of O
the O
mouse I-GENE
_RARE_ I-GENE
promoter I-GENE
were O
essential O
for O
transcriptional O
activation O
during O
_RARE_ I-GENE
induced O
differentiation O
of O
_RARE_ I-GENE
cells O
, O
implying O
their O
importance O
in O
conferring O
erythroid I-GENE
specificity O
to O
the O
_RARE_ I-GENE
transcriptional O
activation O
. O

_RARE_ I-GENE
- I-GENE
23 O
plays O
an O
important O
role O
in O
the O
regulation O
of O
vesicle O
trafficking O
in O
mammalian I-GENE
cells O
. O

The O
HMG I-GENE
domain I-GENE
of O
both O
_RARE_ I-GENE
proteins I-GENE
is O
most O
similar O
to O
that O
of O
yeast I-GENE
_RARE_ I-GENE
( O
38 O
% O
to O
42 O
%). O

IgM I-GENE
and O
IgG I-GENE
anti I-GENE
A I-GENE
and O
anti I-GENE
B I-GENE
antibody I-GENE
status O
of O
100 O
_RARE_ I-GENE
O O
group O
mothers O
( O
who O
had O
non O
O O
group O
_RARE_ I-GENE
) O
were O
studied O
. O

In O
an O
attempt O
to O
understand O
Wee1 I-GENE
regulation O
during O
cell O
cycle O
, O
yeast I-GENE
two O
- I-GENE
hybrid O
screening O
was O
used O
to O
identify O
Wee1 I-GENE
- I-GENE
binding I-GENE
protein I-GENE
( O
s O
). O

_RARE_ I-GENE
transduction O
of O
T I-GENE
/ I-GENE
T I-GENE
( O
L I-GENE
) O
causes O
a O
rapidly O
fatal O
_RARE_ I-GENE
disease O
in O
a O
murine I-GENE
bone O
marrow O
transplant O
( O
_RARE_ I-GENE
) O
model O
, O
whereas O
T I-GENE
/ I-GENE
T I-GENE
( O
F I-GENE
) O
causes O
a O
long O
- I-GENE
latency O
, O
pre I-GENE
- I-GENE
B I-GENE
- I-GENE
cell O
_RARE_ I-GENE
lymphoma O
. O

Ab I-GENE
- I-GENE
_RARE_ I-GENE
strains O
expressing O
_RARE_ I-GENE
/ I-GENE
S2 I-GENE
failed O
to O
transform O
NIH O
3T3 O
cells O
and O
demonstrated O
a O
greatly O
reduced O
capacity O
to O
mediate O
signaling O
events O
associated I-GENE
with O
the O
Ras I-GENE
- I-GENE
dependent I-GENE
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
( O
MAP I-GENE
) O
kinase I-GENE
pathway O
. O

The O
codon O
usage O
is O
particularly O
marked O
for O
the O
gag I-GENE
, O
pol I-GENE
, O
and O
env I-GENE
genes I-GENE
. O

The O
p53 I-GENE
- I-GENE
homolog I-GENE
_RARE_ I-GENE
also O
activated I-GENE
the O
_RARE_ I-GENE
promoter I-GENE
, O
but O
in O
contrast O
to O
p53 I-GENE
, O
the O
proline O
- I-GENE
rich O
domain I-GENE
of O
_RARE_ I-GENE
( O
residues O
81 O
- I-GENE
113 I-GENE
) O
was O
dispensable O
to O
induce O
the O
_RARE_ I-GENE
promoter I-GENE
. O

Results O
from O
transient O
assays O
using O
these O
mutants I-GENE
showed O
that O
the O
_RARE_ I-GENE
received O
signals O
from O
_RARE_ I-GENE
A I-GENE
and O
B I-GENE
, O
demonstrating O
that O
this O
element I-GENE
is O
indeed O
a O
light I-GENE
- I-GENE
responsive I-GENE
element I-GENE
. O

Co O
- I-GENE
immunoprecipitation O
and O
DNA I-GENE
affinity O
chromatography O
prove O
that O
Sp1 I-GENE
_RARE_ I-GENE
with O
_RARE_ I-GENE
- I-GENE
89 I-GENE
when O
bound O
to O
the O
silencer I-GENE
element I-GENE
to O
yield O
a O
DNA I-GENE
- I-GENE
protein I-GENE
complex I-GENE
whose O
mobility I-GENE
is O
indistinguishable O
from O
that O
displayed O
by O
HeLa O
nuclear I-GENE
extract O
in O
band O
shift O
assays O
. O

The O
_RARE_ I-GENE
gene I-GENE
is O
mapped O
distal O
to O
marker O
RP I-GENE
_RARE_ I-GENE
1 I-GENE
in O
the O
human I-GENE
chromosome O
_RARE_ I-GENE
region O
, O
by O
RH O
mapping O
. O

The O
C I-GENE
- I-GENE
terminal I-GENE
Cdk2 I-GENE
_RARE_ I-GENE
, O
however O
, O
were O
non O
- I-GENE
functional O
in O
these O
strains O
and O
thus O
dependent I-GENE
for O
activity O
on O
the O
_RARE_ I-GENE
coding O
region O
which O
remained O
in O
the O
mutant I-GENE
_RARE_ I-GENE
:: O
HIS3 I-GENE
chromosomal I-GENE
locus I-GENE
. O

We O
report O
here O
on O
the O
molecular O
nature O
of O
an O
_RARE_ I-GENE
- I-GENE
induced O
mutant I-GENE
, O
_RARE_ I-GENE
- I-GENE
89 I-GENE
, O
a O
_RARE_ I-GENE
_RARE_ I-GENE
allele I-GENE
of O
the O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
seed I-GENE
locus I-GENE
that O
encodes O
a O
seed I-GENE
- I-GENE
specific I-GENE
cell O
wall O
_RARE_ I-GENE
, O
_RARE_ I-GENE
. O

We O
conclude O
that O
, O
both O
in O
atrial I-GENE
_RARE_ I-GENE
and O
in O
Xenopus I-GENE
oocytes O
, O
beta I-GENE
- I-GENE
adrenergic I-GENE
stimulation O
potentiates O
the O
_RARE_ I-GENE
- I-GENE
evoked O
_RARE_ I-GENE
channels I-GENE
via O
a O
pathway O
that O
involves O
PKA I-GENE
- I-GENE
catalyzed O
phosphorylation O
downstream O
from O
beta I-GENE
( O
2 I-GENE
) O
AR I-GENE
. O

_RARE_ I-GENE
negatively O
regulates O
Src I-GENE
mitogenic O
function O
but O
does O
not O
_RARE_ I-GENE
Src I-GENE
- I-GENE
induced O
cell O
morphology O
changes O
. O

Identification O
of O
a O
novel O
_RARE_ I-GENE
product I-GENE
suggests O
a O
mechanism O
for O
determining O
specificity O
of O
repression O
by O
Rb I-GENE
proteins I-GENE
. O

In O
DNase I-GENE
I I-GENE
footprinting O
protection O
analysis O
, O
both O
_RARE_ I-GENE
and O
_RARE_ I-GENE
regions O
were O
protected O
by O
glutathione I-GENE
S I-GENE
- I-GENE
transferase I-GENE
- I-GENE
_RARE_ I-GENE
fusion I-GENE
protein I-GENE
. O

_RARE_ I-GENE
the O
coactivator I-GENE
, O
_RARE_ I-GENE
or O
_RARE_ I-GENE
, O
further O
enhances O
_RARE_ I-GENE
- I-GENE
induced O
transcriptional O
activity O
. O

_RARE_ I-GENE
receptor I-GENE
- I-GENE
related I-GENE
receptor I-GENE
alpha I-GENE
1 I-GENE
interacts O
with O
coactivator I-GENE
and O
constitutively O
activates O
the O
estrogen I-GENE
response O
elements O
of O
the O
human I-GENE
_RARE_ I-GENE
gene I-GENE
. O

We O
examine O
current O
models O
of O
the O
effects O
of O
aging O
on O
mean O
response O
time O
and O
show O
how O
they O
might O
be O
_RARE_ I-GENE
. O

The O
effects O
of O
these O
mutations O
on O
protein I-GENE
function O
require O
further O
examination O
. O

The O
median O
levels O
of O
particles O
with O
50 O
% O
cut I-GENE
- I-GENE
off O
_RARE_ I-GENE
diameters O
of O
10 O
( O
_RARE_ I-GENE
) O
and O
2 I-GENE
. O
5 I-GENE
microm O
( O
_RARE_ I-GENE
. O
5 I-GENE
) O
were O
170 I-GENE
( O
range O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
) O
and O
95 O
( O
range O
61 O
- I-GENE
_RARE_ I-GENE
) O
micro O
x O
m I-GENE
- I-GENE
3 I-GENE
, O
respectively O
. O

Kaposi O
' O
s O
sarcoma I-GENE
- I-GENE
associated I-GENE
herpesvirus I-GENE
viral I-GENE
interferon I-GENE
regulatory I-GENE
factor I-GENE
confers O
resistance O
to O
the O
_RARE_ I-GENE
effect O
of O
interferon I-GENE
- I-GENE
alpha I-GENE
. O

Specific O
and O
_RARE_ I-GENE
genetic O
interference O
by O
double O
- I-GENE
stranded I-GENE
RNA I-GENE
in O
Arabidopsis I-GENE
thaliana O
. O

Comparison O
of O
sequences I-GENE
from O
- I-GENE
215 O
to O
+ I-GENE
1 I-GENE
bp O
identified O
consensus I-GENE
binding I-GENE
sites I-GENE
for O
the O
homeodomain I-GENE
transcription I-GENE
factor I-GENE
thyroid I-GENE
transcription I-GENE
factor I-GENE
- I-GENE
1 I-GENE
( O
TTF I-GENE
- I-GENE
1 I-GENE
). O

Two O
additional O
cis O
- I-GENE
acting O
sequences I-GENE
, O
conserved O
in O
both O
the O
region O
1 I-GENE
and O
3 I-GENE
promoters I-GENE
, O
were O
identified O
, O
suggesting O
a O
role O
for O
these O
sequences I-GENE
in O
the O
coordinate O
regulation O
of O
transcription I-GENE
from O
these O
promoters I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
bacteria O
are O
capable O
of O
generating O
cellular O
energy O
from O
several O
sources O
, O
including O
_RARE_ I-GENE
, O
respiration O
, O
and O
H I-GENE
( O
2 I-GENE
) O
oxidation O
. O

An O
analysis O
of O
synthetic O
peptides I-GENE
revealed O
a O
minimal I-GENE
CTD I-GENE
sequence I-GENE
that O
is O
sufficient O
to O
bind O
to O
the O
second O
_RARE_ I-GENE
_RARE_ I-GENE
domain I-GENE
( O
_RARE_ I-GENE
_RARE_ I-GENE
) O
in O
vitro O
and O
in O
yeast I-GENE
two O
- I-GENE
hybrid O
assays O
. O

Furthermore O
, O
bone O
marrow O
- I-GENE
derived O
macrophages O
from O
_RARE_ I-GENE
- I-GENE
deficient O
mice O
displayed O
reduced O
phagocytic O
efficiency O
in O
comparison O
to O
the O
macrophages O
from O
wild I-GENE
- I-GENE
type I-GENE
mice O
. O

T1 O
- I-GENE
weighted O
MRI O
on O
the O
_RARE_ I-GENE
postoperative O
day O
demonstrated O
bilateral O
and O
_RARE_ I-GENE
_RARE_ I-GENE
lesions O
in O
the O
_RARE_ I-GENE
_RARE_ I-GENE
. O

The O
method O
is O
applied O
to O
determine O
_RARE_ I-GENE
constants O
of O
a O
_RARE_ I-GENE
_RARE_ I-GENE
/ I-GENE
UT O
_RARE_ I-GENE
with O
correction O
of O
the O
three O
- I-GENE
fold O
_RARE_ I-GENE
. O

The O
interaction O
does O
not O
depend O
on O
the O
presence O
of O
the O
correct O
amino O
- I-GENE
terminal I-GENE
DNA I-GENE
binding I-GENE
domain I-GENE
or O
the O
amino O
acid I-GENE
sequences I-GENE
between O
the O
DNA I-GENE
binding I-GENE
domain I-GENE
and O
the O
last O
ten O
amino O
acids O
. O

_RARE_ I-GENE
: O
The O
sample O
of O
subjects O
was O
_RARE_ I-GENE
from O
the O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
Health O
_RARE_ I-GENE
, O
a O
longitudinal O
_RARE_ I-GENE
study O
of O
first O
- I-GENE
hospitalized O
subjects O
with O
_RARE_ I-GENE
disorders O
; O
the O
present O
study O
focused O
on O
patients O
with O
schizophrenic O
disorders O
. O

_RARE_ I-GENE
dysplasia O
is O
a O
major I-GENE
characteristic O
of O
patients O
with O
_RARE_ I-GENE
syndrome O
( O
_RARE_ I-GENE
), O
along O
with O
marrow O
_RARE_ I-GENE
, O
_RARE_ I-GENE
and O
cytogenetic O
anomalies O
. O

Eight O
of O
the O
non O
- I-GENE
acceptable O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
and O
five O
of O
the O
direct O
restorations O
were O
replaced O
, O
while O
the O
other O
ones O
were O
_RARE_ I-GENE
with O
resin O
composite O
. O

_RARE_ I-GENE
plants O
respond O
to O
_RARE_ I-GENE
by O
the O
range O
of O
_RARE_ I-GENE
and O
pathogens O
that O
_RARE_ I-GENE
them O
in O
the O
field O
is O
the O
subject O
of O
considerable O
research O
by O
both O
molecular O
_RARE_ I-GENE
and O
_RARE_ I-GENE
. O

CONCLUSION O
: O
The O
_RARE_ I-GENE
of O
cardiopulmonary O
complications O
increases O
significantly O
when O
patients O
develop O
class I-GENE
1 I-GENE
_RARE_ I-GENE
syndrome O
. O

The O
rate O
- I-GENE
limiting O
step O
for O
telomerase I-GENE
activity O
seems O
to O
be O
the O
expression O
of O
the O
catalytic O
subunit I-GENE
of O
the O
enzyme I-GENE
, O
encoded I-GENE
by O
the O
human I-GENE
telomerase I-GENE
reverse I-GENE
transcriptase I-GENE
( O
_RARE_ I-GENE
) O
gene I-GENE
. O

In O
the O
control O
group O
, O
platelet I-GENE
markers O
increased O
1 I-GENE
h O
after O
surgery O
. O

However O
, O
the O
element I-GENE
proximal I-GENE
to O
the O
transcription I-GENE
start O
site I-GENE
is O
dependent I-GENE
on O
the O
SRE O
- I-GENE
1 I-GENE
. O

_RARE_ I-GENE
white O
paper O
identifies O
ways O
to O
improve O
_RARE_ I-GENE
care O
in O
_RARE_ I-GENE
. O

Since O
proteins I-GENE
containing O
TPR O
elements O
are O
typically O
involved O
in O
multiple O
protein I-GENE
- I-GENE
protein I-GENE
interactions O
, O
we O
suggest O
that O
the O
_RARE_ I-GENE
protein I-GENE
interacts O
within O
the O
_RARE_ I-GENE
- I-GENE
snRNP I-GENE
with O
both O
the O
U5 I-GENE
and O
U4 I-GENE
/ I-GENE
U6 I-GENE
snRNPs I-GENE
, O
thus O
_RARE_ I-GENE
the O
two O
particles O
. O

Antibodies O
raised O
against O
a O
C I-GENE
- I-GENE
terminal I-GENE
portion O
of O
_RARE_ I-GENE
co O
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
and O
inhibit O
ER I-GENE
- I-GENE
Golgi I-GENE
transport O
of O
temperature O
- I-GENE
arrested O
vesicular O
stomatitis I-GENE
G I-GENE
protein I-GENE
in O
a O
_RARE_ I-GENE
- I-GENE
intact O
cell O
assay O
. O

Regulation O
of O
mitochondrial I-GENE
single O
- I-GENE
stranded I-GENE
DNA I-GENE
- I-GENE
binding I-GENE
protein I-GENE
gene I-GENE
expression O
links O
nuclear I-GENE
and O
mitochondrial I-GENE
DNA I-GENE
replication O
in O
_RARE_ I-GENE
. O

Genetic O
and O
molecular O
complexity O
of O
the O
position O
effect O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
in O
Drosophila I-GENE
. O
_RARE_ I-GENE
( O
_RARE_ I-GENE
), O
also O
known O
as O
E I-GENE
( O
var I-GENE
) O
3 I-GENE
- I-GENE
_RARE_ I-GENE
, O
is O
involved O
in O
a O
variety O
of O
processes O
, O
such O
as O
gene I-GENE
silencing O
in O
position O
effect O
_RARE_ I-GENE
( O
_RARE_ I-GENE
), O
the O
control O
of O
_RARE_ I-GENE
_RARE_ I-GENE
sequences I-GENE
, O
regulation O
of O
homeotic I-GENE
gene I-GENE
expression O
, O
and O
programmed O
cell O
death O
. O

They O
are O
present O
in O
many O
_RARE_ I-GENE
of O
living O
_RARE_ I-GENE
, O
but O
their O
functions O
, O
especially O
those O
in O
humans O
, O
are O
unclear O
. O

This O
tendency O
is O
likely O
due O
to O
the O
_RARE_ I-GENE
nucleotide I-GENE
composition O
of O
the O
_RARE_ I-GENE
genome O
, O
rather O
than O
to O
the O
translational O
selection O
for O
specific I-GENE
codons O
. O

_RARE_ I-GENE
of O
the O
human I-GENE
_RARE_ I-GENE
cell O
line O
K562 O
showed O
that O
viral I-GENE
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
transfer I-GENE
the O
_RARE_ I-GENE
gene I-GENE
to O
approximately O
35 O
% O
of O
target O
K562 O
cells O
, O
of O
which O
at O
least O
one O
third O
are O
capable O
of O
proliferating I-GENE
in O
the O
presence O
of O
otherwise O
toxic O
concentrations O
of O
_RARE_ I-GENE
. O

Regulation O
of O
pituitary I-GENE
vasopressin I-GENE
_RARE_ I-GENE
receptors I-GENE
plays O
a O
critical O
role O
in O
regulating O
pituitary I-GENE
_RARE_ I-GENE
hormone I-GENE
( O
ACTH I-GENE
) O
secretion O
during O
adaptation O
to O
stress O
. O

Identification O
of O
an O
_RARE_ I-GENE
homologue I-GENE
( O
_RARE_ I-GENE
) O
from O
Streptomyces I-GENE
_RARE_ I-GENE
as O
a O
pleiotropic O
regulator I-GENE
controlling O
_RARE_ I-GENE
biosynthesis O
, O
_RARE_ I-GENE
biosynthesis O
and O
_RARE_ I-GENE
M1 I-GENE
resistance O
. O

Because O
the O
mutant I-GENE
defective O
in O
DNA I-GENE
binding I-GENE
also O
fails O
to O
stimulate O
_RARE_ I-GENE
_RARE_ I-GENE
DNA I-GENE
- I-GENE
binding I-GENE
activity O
, O
our O
results O
suggest O
that O
_RARE_ I-GENE
DNA I-GENE
- I-GENE
binding I-GENE
activity O
may O
play O
a O
pivotal O
role O
in O
the O
initiation I-GENE
of O
DNA I-GENE
replication O
. O

_RARE_ I-GENE
its O
relative O
_RARE_ I-GENE
on O
the O
_RARE_ I-GENE
, O
_RARE_ I-GENE
_RARE_ I-GENE
have O
been O
in O
a O
unique O
position O
to O
observe O
_RARE_ I-GENE
in O
_RARE_ I-GENE
. O

The O
structural O
study O
of O
peptides I-GENE
belonging O
to O
the O
terminal I-GENE
domains I-GENE
of O
histone I-GENE
H1 I-GENE
can O
be O
considered O
as O
a O
step O
toward O
the O
understanding O
of O
the O
function O
of O
H1 I-GENE
in O
chromatin O
. O

The O
recovery O
rates O
for O
the O
MB I-GENE
/ I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
_RARE_ I-GENE
, O
and O
solid O
media O
were O
91 O
. O
6 I-GENE
, O
87 O
. O
4 I-GENE
, O
and O
54 I-GENE
. O
7 O
%, O
respectively O
, O
for O
all O
mycobacteria O
; O
the O
recovery O
rates O
were O
93 O
. O
6 I-GENE
, O
88 O
. O
9 O
, O
and O
63 O
. O
4 I-GENE
%, O
respectively O
, O
for O
M I-GENE
. O
tuberculosis O
complex I-GENE
alone O
, O
and O
87 O
. O
5 I-GENE
, O
84 O
. O
4 I-GENE
, O
and O
37 O
. O
5 I-GENE
%, O
respectively O
, O
for O
all O
_RARE_ I-GENE
mycobacteria O
. O

_RARE_ I-GENE
vasculitis O
secondary O
to O
Crohn O
' O
s O
disease O
seems O
to O
be O
a O
very O
rare O
phenomenon O
. O

_RARE_ I-GENE
_RARE_ I-GENE
: O
_RARE_ I-GENE
and O
possibly O
randomised O
trials O
using O
_RARE_ I-GENE
to O
treat O
asthma O
and O
asthma O
- I-GENE
like I-GENE
symptoms O
. O

_RARE_ I-GENE
_RARE_ I-GENE
: O
_RARE_ I-GENE
trials O
comparing O
children O
undergoing O
systematic O
therapy O
focusing O
on O
the O
family I-GENE
in O
conjunction O
with O
asthma O
medication O
, O
with O
children O
taking O
asthma O
medication O
only O
. O

To O
test O
the O
hypothesis O
that O
_RARE_ I-GENE
- I-GENE
mediated O
increases O
in O
resting O
core I-GENE
temperature O
and O
the O
core I-GENE
temperature O
threshold O
for O
_RARE_ I-GENE
onset O
are O
_RARE_ I-GENE
by O
estrogen I-GENE
, O
we O
studied O
eight O
women O
( O
24 O
+/- O
2 I-GENE
yr O
) O
at O
27 O
degrees O
C I-GENE
rest O
, O
during O
20 O
min O
of O
passive O
_RARE_ I-GENE
( O
35 O
degrees O
C I-GENE
), O
and O
during O
40 I-GENE
min O
of O
exercise O
at O
35 O
degrees O
C I-GENE
. O

The O
models O
were O
tested O
by O
studying O
their O
response O
to O
disturbances O
of O
the O
_RARE_ I-GENE
signal I-GENE
from O
the O
bladder O
. O

Our O
data O
show O
also O
that O
phagocytic O
_RARE_ I-GENE
of O
_RARE_ I-GENE
is O
probably O
a O
more O
consistent O
assay O
than O
antibody I-GENE
titer O
levels O
for O
_RARE_ I-GENE
immunity O
, O
especially O
in O
_RARE_ I-GENE
- I-GENE
deficient O
patients O
. O

These O
studies O
suggest O
an O
additional O
component O
or O
cellular O
environment O
is O
required O
for O
_RARE_ I-GENE
activation O
by O
Cdc42 I-GENE
. O

M I-GENE
. O

_RARE_ I-GENE
DNA I-GENE
- I-GENE
binding I-GENE
sites I-GENE
were O
not O
required O
for O
this O
activation O
, O
and O
a O
mutant I-GENE
EBNA I-GENE
- I-GENE
3C I-GENE
protein I-GENE
unable O
to O
bind O
_RARE_ I-GENE
activated I-GENE
transcription I-GENE
as O
efficiently O
as O
wild I-GENE
- I-GENE
type I-GENE
EBNA I-GENE
- I-GENE
3C I-GENE
, O
indicating O
that O
EBNA I-GENE
- I-GENE
3C I-GENE
can O
regulate O
transcription I-GENE
through O
a O
mechanism O
that O
is O
independent O
of O
_RARE_ I-GENE
. O

Thus O
, O
both O
YY1 I-GENE
and O
CDP I-GENE
appear O
to O
be O
negative O
regulators O
of O
the O
differentiation O
- I-GENE
induced O
HPV I-GENE
- I-GENE
6 I-GENE
E1 I-GENE
promoter I-GENE
and O
thereby O
the O
HPV I-GENE
life O
cycle O
. O

_RARE_ I-GENE
cleavage O
by O
_RARE_ I-GENE
and O
_RARE_ I-GENE
is O
involved O
in O
processing O
HIV I-GENE
- I-GENE
1 I-GENE
_RARE_ I-GENE
epitope O
for O
endogenous I-GENE
MHC I-GENE
class I-GENE
I I-GENE
antigen I-GENE
presentation O
. O

Cloning O
and O
characterization O
of O
human I-GENE
_RARE_ I-GENE
, O
an O
adaptor I-GENE
protein I-GENE
with O
pleckstrin I-GENE
homology I-GENE
and O
Src I-GENE
homology I-GENE
2 I-GENE
domains I-GENE
that O
can O
inhibit O
T I-GENE
cell O
activation O
. O

_RARE_ I-GENE
data O
were O
analyzed O
according O
to O
a O
one O
- I-GENE
compartment O
open O
model O
with O
use O
of O
_RARE_ I-GENE
population O
pharmacokinetic O
_RARE_ I-GENE
. O

Finally O
, O
Cas I-GENE
existed O
mainly O
in O
cytosol O
and O
membrane I-GENE
cytoskeleton I-GENE
fractions O
in O
the O
resting O
state O
, O
and O
remained O
unchanged O
during O
platelet I-GENE
aggregation O
, O
when O
FAK I-GENE
_RARE_ I-GENE
to O
the O
cytoskeletal O
fraction O
. O

We O
also O
show O
that O
p65 I-GENE
binds O
to O
these O
targets O
with O
almost O
equal O
affinity O
and O
that O
different O
residues O
have O
variable O
roles O
in O
binding I-GENE
different O
kappaB I-GENE
targets O
. O

Transcriptional O
regulation O
of O
the O
yeast I-GENE
_RARE_ I-GENE
promoter I-GENE
in O
comparison O
to O
the O
_RARE_ I-GENE
_RARE_ I-GENE
promoter I-GENE
. O

The O
_RARE_ I-GENE
are O
a O
subfamily I-GENE
of O
I I-GENE
- I-GENE
type I-GENE
_RARE_ I-GENE
( O
immunoglobulin I-GENE
superfamily I-GENE
proteins I-GENE
that O
bind O
sugars O
) O
that O
specifically O
recognize O
_RARE_ I-GENE
acids O
. O

Our O
data O
provide O
a O
biochemical O
explanation O
for O
the O
similarity O
in O
phenotype O
between O
A I-GENE
- I-GENE
T I-GENE
and O
_RARE_ I-GENE
. O

PATIENTS O
OR O
_RARE_ I-GENE
_RARE_ I-GENE
: O
Twenty O
children O
met I-GENE
the O
criteria O
for O
being O
learning O
_RARE_ I-GENE
. O

_RARE_ I-GENE
on O
maternal I-GENE
- I-GENE
fetal O
infections O
by O
hepatitis I-GENE
C I-GENE
, O
HIV I-GENE
and O
cytomegalovirus I-GENE

In O
the O
present O
study O
, O
we O
characterized O
cis O
- I-GENE
elements O
of O
the O
human I-GENE
PCI I-GENE
gene I-GENE
required O
for O
expression O
in O
the O
hepatoma O
- I-GENE
derived O
cell O
line O
, O
HepG2 O
cells O
, O
and O
also O
evaluated O
rat I-GENE
PCI I-GENE
mRNA I-GENE
expression O
, O
particularly O
on O
the O
effect O
of O
androgen O
in O
rat I-GENE
reproductive O
tissues O
. O

In O
the O
study O
on O
PCI I-GENE
mRNA I-GENE
expression O
in O
the O
reproductive O
organs O
, O
we O
first O
cloned O
rat I-GENE
PCI I-GENE
cDNA I-GENE
and O
then O
evaluated O
the O
effect O
of O
androgen O
on O
the O
PCI I-GENE
mRNA I-GENE
expression O
. O

To O
_RARE_ I-GENE
its O
performance O
, O
measurements O
of O
_RARE_ I-GENE
in O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
are O
presented O
. O

The O
_RARE_ I-GENE
of O
the O
complexes I-GENE
formed O
with O
the O
_RARE_ I-GENE
- I-GENE
satellite I-GENE
C I-GENE
strand O
suggests O
that O
, O
in O
_RARE_ I-GENE
, O
the O
15 O
consecutive O
_RARE_ I-GENE
domains I-GENE
are O
organized O
such O
that O
they O
define O
two O
nucleic O
acid I-GENE
binding I-GENE
_RARE_ I-GENE
. O

Mutational O
analysis O
of O
mammalian I-GENE
translation I-GENE
initiation I-GENE
factor I-GENE
5 I-GENE
( O
_RARE_ I-GENE
): O
role O
of O
interaction O
between O
the O
beta I-GENE
subunit I-GENE
of O
_RARE_ I-GENE
and O
_RARE_ I-GENE
in O
_RARE_ I-GENE
function O
in O
vitro O
and O
in O
vivo O
. O

_RARE_ I-GENE
evidence O
indicates O
that O
p38 I-GENE
is O
an O
activator I-GENE
of O
MyoD I-GENE
: O
( O
i O
) O
p38 I-GENE
kinase I-GENE
activity O
is O
required O
for O
the O
expression O
of O
MyoD I-GENE
- I-GENE
responsive I-GENE
genes I-GENE
, O
( O
ii O
) O
_RARE_ I-GENE
induction O
of O
p38 I-GENE
stimulates O
the O
transcriptional O
activity O
of O
a O
Gal4 I-GENE
- I-GENE
MyoD I-GENE
fusion I-GENE
protein I-GENE
and O
allows O
efficient O
activation O
of O
chromatin O
- I-GENE
integrated O
_RARE_ I-GENE
by O
MyoD I-GENE
, O
and O
( O
iii O
) O
MyoD I-GENE
- I-GENE
dependent I-GENE
myogenic I-GENE
conversion O
is O
reduced O
in O
mouse I-GENE
embryonic O
fibroblasts O
derived O
from O
_RARE_ I-GENE
_RARE_ I-GENE
embryos O
. O

This O
activity O
is O
stimulated O
by O
complex I-GENE
formation O
with O
the O
other O
_RARE_ I-GENE
subunits I-GENE
. O

Our O
analysis O
of O
nonsense O
mutations O
indicates O
that O
the O
C I-GENE
terminus O
of O
_RARE_ I-GENE
( O
residues O
_RARE_ I-GENE
to O
_RARE_ I-GENE
) O
is O
required O
for O
both O
catalytic O
activity O
and O
interaction O
with O
_RARE_ I-GENE
. O

In O
contrast O
, O
mutations O
affecting O
the O
other O
two O
_RARE_ I-GENE
- I-GENE
related I-GENE
kinases I-GENE
in O
S I-GENE
. O
cerevisiae I-GENE
, O
_RARE_ I-GENE
and O
_RARE_ I-GENE
, O
produce O
no O
detectable O
effect O
on O
_RARE_ I-GENE
organization O
. O

CONCLUSIONS O
: O
_RARE_ I-GENE
pacing O
provides O
little O
benefit O
over O
ventricular O
pacing O
for O
the O
prevention O
of O
stroke O
or O
death O
due O
to O
cardiovascular O
causes O
. O

Among O
non O
- I-GENE
_RARE_ I-GENE
, O
lack O
of O
portal I-GENE
vein O
_RARE_ I-GENE
had O
a O
90 O
% O
sensitivity O
, O
88 O
% O
specificity O
, O
94 O
% O
negative O
predictive O
value O
, O
and O
83 O
% O
positive O
predictive O
value O
in O
the O
diagnosis O
of O
pre I-GENE
- I-GENE
_RARE_ I-GENE
portal I-GENE
hypertension O
. O

_RARE_ I-GENE
/ I-GENE
D1 I-GENE
( O
CT I-GENE
) O
or O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
( O
CT I-GENE
) O
tail O
substitution O
mutants I-GENE
displayed O
a O
_RARE_ I-GENE
order O
of O
potency O
and O
agonist O
affinities O
virtually O
_RARE_ I-GENE
wild I-GENE
- I-GENE
type I-GENE
( O
wt I-GENE
) O
D1 I-GENE
receptors I-GENE
, O
as O
_RARE_ I-GENE
by O
both O
ligand O
binding I-GENE
and O
dopamine I-GENE
- I-GENE
stimulated O
cAMP I-GENE
accumulation O
assays O
, O
and O
, O
similar O
to O
wt I-GENE
D1 I-GENE
receptors I-GENE
, O
did O
not O
exhibit O
receptor I-GENE
constitutive O
activity O
or O
responsiveness O
to O
_RARE_ I-GENE
agonists O
. O

_RARE_ I-GENE
also O
revealed O
a O
very O
hydrophobic O
surface O
due O
to O
the O
absence O
of O
_RARE_ I-GENE
, O
_RARE_ I-GENE
residues O
from O
H3 I-GENE
, O
loop I-GENE
3 I-GENE
- I-GENE
4 I-GENE
, O
H4 I-GENE
, O
and O
_RARE_ I-GENE
. O

The O
serine I-GENE
- I-GENE
threonine I-GENE
kinase I-GENE
gene I-GENE
is O
likely O
functional O
, O
whereas O
the O
zinc I-GENE
finger I-GENE
motif I-GENE
is O
likely O
_RARE_ I-GENE
. O

Stat I-GENE
activation O
in O
response O
to O
GH I-GENE
and O
IL I-GENE
- I-GENE
6 I-GENE
was O
determined O
by O
reporter I-GENE
gene I-GENE
induction O
. O

_RARE_ I-GENE
_RARE_ I-GENE
had O
a O
greater O
tendency O
to O
take O
up O
_RARE_ I-GENE
from O
the O
environment O
than O
did O
_RARE_ I-GENE
_RARE_ I-GENE
. O

RESULTS O
: O
Abnormal O
color O
_RARE_ I-GENE
was O
found O
in O
32 O
% O
of O
the O
epilepsy O
patients O
treated O
with O
_RARE_ I-GENE
_RARE_ I-GENE
and O
28 O
% O
of O
the O
epilepsy O
patients O
treated O
with O
_RARE_ I-GENE
_RARE_ I-GENE
. O

In O
the O
_RARE_ I-GENE
screening O
test O
, O
a O
few O
plates O
were O
not O
seen O
in O
both O
groups O
. O

_RARE_ I-GENE
- I-GENE
activated I-GENE
protein I-GENE
( O
MAP I-GENE
) O
kinase I-GENE
phosphatase I-GENE
- I-GENE
3 I-GENE
( O
MKP I-GENE
- I-GENE
3 I-GENE
) O
is O
a O
dual O
specificity O
phosphatase I-GENE
that O
_RARE_ I-GENE
extracellular I-GENE
signal I-GENE
- I-GENE
regulated O
kinase I-GENE
( O
ERK I-GENE
) O
MAP I-GENE
kinases I-GENE
. O

Consistent O
with O
this O
, O
we O
show O
that O
peptides I-GENE
representing O
_RARE_ I-GENE
sites I-GENE
within O
the O
target O
substrates O
Elk I-GENE
- I-GENE
1 I-GENE
and O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
inhibit O
ERK I-GENE
- I-GENE
dependent I-GENE
activation O
of O
MKP I-GENE
- I-GENE
3 I-GENE
. O

HPLC O
phosphopeptide I-GENE
mapping O
, O
amino O
acid I-GENE
sequencing O
, O
and O
site I-GENE
- I-GENE
directed O
mutagenesis O
determined O
that O
_RARE_ I-GENE
phosphorylates O
Ser O
( O
67 O
) O
of O
I I-GENE
- I-GENE
1 I-GENE
. O

When O
the O
entire O
diet O
consisted O
of O
SBF I-GENE
, O
_RARE_ I-GENE
feed O
intake O
was O
reduced O
, O
indicating O
that O
SBF I-GENE
should O
not O
be O
fed O
to O
_RARE_ I-GENE
as O
the O
_RARE_ I-GENE
dietary O
_RARE_ I-GENE
. O

Hepatitis I-GENE
C I-GENE
virus I-GENE
infection O
and O
_RARE_ I-GENE
diseases O
in O
_RARE_ I-GENE
: O
a O
national O
study O
. O

The O
immune I-GENE
system O
is O
closely O
integrated O
with O
the O
_RARE_ I-GENE
system O
, O
and O
infection O
- I-GENE
induced O
increases O
in O
cytokines O
such O
as O
IL I-GENE
- I-GENE
1 I-GENE
, O
IL I-GENE
- I-GENE
6 I-GENE
and O
TNF I-GENE
have O
numerous O
effects O
on O
the O
central O
nervous O
system O
. O

Interestingly O
, O
a O
decreased O
transcription I-GENE
from O
the O
endogenous I-GENE
c I-GENE
- I-GENE
Myb I-GENE
promoter I-GENE
was O
observed O
in O
several O
HTLV I-GENE
- I-GENE
I I-GENE
transformed O
T I-GENE
- I-GENE
cell O
lines O
. O

H19 I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
expression O
is O
regulated O
in O
two O
distinct O
ways O
by O
a O
shared O
cis O
acting O
regulatory I-GENE
region O
upstream O
of O
H19 I-GENE
. O

C I-GENE
. O
elegans I-GENE
_RARE_ I-GENE
- I-GENE
11 O
/ I-GENE
_RARE_ I-GENE
- I-GENE
3 I-GENE
/ I-GENE
_RARE_ I-GENE
- I-GENE
1 I-GENE
: O
_RARE_ I-GENE
of O
the O
sea O
urchin I-GENE
_RARE_ I-GENE
- I-GENE
II I-GENE
, O
and O
mouse I-GENE
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
complexes I-GENE
. O

_RARE_ I-GENE
from O
_RARE_ I-GENE
_RARE_ I-GENE
. O

BACKGROUND O
: O
_RARE_ I-GENE
_RARE_ I-GENE
is O
a O
_RARE_ I-GENE
syndrome O
associated I-GENE
with O
acute O
liver O
failure O
, O
chronic O
_RARE_ I-GENE
liver O
disease O
or O
portal I-GENE
systemic O
anastomosis O
. O

These O
natural O
antisense I-GENE
S I-GENE
transcripts I-GENE
co O
- I-GENE
exist O
with O
several O
less O
abundant O
sense O
S I-GENE
transcripts I-GENE
. O

_RARE_ I-GENE
is O
such O
adjustment O
possible O
unless O
one O
_RARE_ I-GENE
a O
model O
that O
_RARE_ I-GENE
the O
missing O
observations O
to O
other O
observed O
information O
for O
each O
subject O
- I-GENE
models O
that O
are O
_RARE_ I-GENE
_RARE_ I-GENE
. O

However O
, O
the O
presence O
of O
_RARE_ I-GENE
seems O
to O
be O
a O
more O
reliable O
and O
_RARE_ I-GENE
parameter O
that O
will O
be O
preferred O
in O
that O
prediction O
. O

The O
data O
are O
compatible O
with O
the O
idea O
that O
_RARE_ I-GENE
_RARE_ I-GENE
the O
_RARE_ I-GENE
to O
the O
inner O
alpha1 I-GENE
- I-GENE
2 I-GENE
- I-GENE
linked O
_RARE_ I-GENE
, O
i O
. O
e O
. O
the O
group O
that O
links O
the O
GPI I-GENE
lipid O
anchor I-GENE
to O
proteins I-GENE
, O
whereas O
_RARE_ I-GENE
and O
_RARE_ I-GENE
transfer I-GENE
_RARE_ I-GENE
onto O
the O
alpha1 I-GENE
- I-GENE
4 I-GENE
- I-GENE
and O
alpha1 I-GENE
- I-GENE
6 I-GENE
- I-GENE
linked O
_RARE_ I-GENE
of O
the O
GPI I-GENE
anchor I-GENE
, O
respectively O
. O

The O
C I-GENE
terminus O
of O
_RARE_ I-GENE
binds O
to O
CBP I-GENE
/ I-GENE
p300 I-GENE
and O
_RARE_ I-GENE
, O
a O
component O
of O
the O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
/ I-GENE
ARC I-GENE
complex I-GENE
, O
which O
suggests O
that O
_RARE_ I-GENE
may O
activate O
transcription I-GENE
by O
means O
of O
such O
interactions O
. O

The O
patients O
who O
presented O
with O
_RARE_ I-GENE
disease O
also O
had O
low O
CD4 I-GENE
+ I-GENE
T I-GENE
lymphocyte I-GENE
counts O
, O
and O
most O
of O
them O
had O
AIDS O
_RARE_ I-GENE
_RARE_ I-GENE
. O

Increased O
dietary O
energy O
decreased O
_RARE_ I-GENE
and O
the O
use O
of O
added O
dietary O
CO I-GENE
rather O
than O
_RARE_ I-GENE
decreased O
_RARE_ I-GENE
in O
_RARE_ I-GENE
_RARE_ I-GENE
between O
26 O
and O
47 O
wk O
of O
age O
. O

The O
gene I-GENE
amplification O
model O
of O
_RARE_ I-GENE
et O
al O
. O

_RARE_ I-GENE
of O
protein I-GENE
tyrosine I-GENE
kinases I-GENE
in O
interleukin I-GENE
- I-GENE
2 I-GENE
( O
IL I-GENE
- I-GENE
2 I-GENE
) O
signaling O
: O
activation O
of O
_RARE_ I-GENE
depends O
on O
_RARE_ I-GENE
; O
however O
, O
neither O
_RARE_ I-GENE
nor O
Lck I-GENE
is O
required O
for O
IL I-GENE
- I-GENE
2 I-GENE
- I-GENE
mediated O
STAT I-GENE
activation O
. O

_RARE_ I-GENE
dimers I-GENE
of O
N I-GENE
- I-GENE
cadherin I-GENE
- I-GENE
Fc I-GENE
chimera I-GENE
mimic O
cadherin I-GENE
- I-GENE
mediated O
cell O
contact O
formation O
: O
contribution O
of O
both O
outside O
- I-GENE
in O
and O
_RARE_ I-GENE
- I-GENE
out O
signals O
. O

Although O
the O
OC I-GENE
promoter I-GENE
is O
activated I-GENE
in O
a O
C I-GENE
terminus O
dependent I-GENE
manner O
, O
the O
_RARE_ I-GENE
, O
LTR I-GENE
and O
BSP I-GENE
promoters I-GENE
are O
repressed O
by O
three O
distinct O
mechanisms O
, O
either O
independent O
of O
or O
involving O
the O
_RARE_ I-GENE
C I-GENE
terminus O
, O
or O
requiring O
only O
the O
conserved O
C I-GENE
- I-GENE
terminal I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
. O

The O
monoclonal I-GENE
immunoglobulin I-GENE
products I-GENE
of O
plasma I-GENE
cell O
_RARE_ I-GENE
can O
give O
rise O
to O
a O
variety O
of O
manifestations O
including O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
neuropathy I-GENE
, O
and O
renal O
failure O
. O

_RARE_ I-GENE
of O
the O
structural O
basis O
of O
the O
interaction O
between O
human I-GENE
_RARE_ I-GENE
and O
gp120 I-GENE
shows O
that O
the O
viral I-GENE
gp120 I-GENE
_RARE_ I-GENE
can O
interact O
only O
with O
a O
subset O
of O
human I-GENE
V I-GENE
( O
H I-GENE
) O
3 I-GENE
+ I-GENE
_RARE_ I-GENE
. O

Double O
- I-GENE
blind O
, O
placebo O
- I-GENE
controlled O
trial O
. O

Here O
, O
it O
is O
shown O
that O
_RARE_ I-GENE
, O
the O
largest O
subunit I-GENE
of O
TFIID I-GENE
, O
contains O
two O
tandem O
_RARE_ I-GENE
modules I-GENE
that O
bind O
selectively O
to O
_RARE_ I-GENE
_RARE_ I-GENE
histone I-GENE
H4 I-GENE
peptides I-GENE
. O

_RARE_ I-GENE
treatment O
for O
10 O
minutes O
or O
24 O
hours O
induced O
tyrosine I-GENE
phosphorylation O
of O
_RARE_ I-GENE
and O
formation O
of O
_RARE_ I-GENE
complexes I-GENE
. O

Therefore O
, O
_RARE_ I-GENE
of O
vitamin O
D3 I-GENE
have O
been O
investigated O
in O
a O
number O
of O
trials O
showing O
improvement O
of O
psoriasis O
. O

The O
transcript I-GENE
was O
initially O
identified O
as O
a O
partial O
cDNA I-GENE
sequence I-GENE
in O
the O
course O
of O
_RARE_ I-GENE
a O
transcript I-GENE
map O
of O
the O
region O
between O
markers O
_RARE_ I-GENE
and O
_RARE_ I-GENE
known O
to O
_RARE_ I-GENE
the O
gene I-GENE
causing O
_RARE_ I-GENE
disease O
. O

The O
real O
challenge O
for O
the O
future O
will O
be O
the O
management O
of O
patients O
who O
do O
not O
respond O
to O
first O
- I-GENE
line O
treatment O
. O

_RARE_ I-GENE
deficiency O
disorders O
in O
_RARE_ I-GENE
. O

The O
network O
evolution O
was O
interpreted O
by O
an O
approach O
based O
on O
the O
_RARE_ I-GENE
model O
. O

RESULTS O
: O
_RARE_ I-GENE
CD23 I-GENE
levels O
were O
significantly O
higher O
in O
women O
with O
_RARE_ I-GENE
before O
treatment O
than O
in O
ten O
normal O
controls O
. O

CONCLUSION O
: O
Our O
findings O
suggest O
that O
_RARE_ I-GENE
increases O
soluble I-GENE
CD23 I-GENE
levels O
, O
which O
can O
be O
suppressed O
with O
either O
_RARE_ I-GENE
or O
_RARE_ I-GENE
acetate O
injection O
. O

To O
isolate O
this O
gene I-GENE
, O
a O
P I-GENE
- I-GENE
1 I-GENE
artificial O
chromosome O
( O
_RARE_ I-GENE
) O
library O
was O
screened O
with O
a O
full I-GENE
length I-GENE
_RARE_ I-GENE
probe O
and O
a O
clone O
of O
approximately O
100 O
kb O
in O
length I-GENE
was O
isolated O
. O

_RARE_ I-GENE
>/= O
50 O
years O
( O
odds O
ratio O
[ O
OR O
], O
14 O
. O
1 I-GENE
), O
BMI O
>/= O
28 O
kg O
/ I-GENE
m I-GENE
( O
2 I-GENE
) O
( O
OR O
, O
5 I-GENE
. O
7 O
), O
triglycerides I-GENE
>/= O
1 I-GENE
. O
7 O
mmol O
/ I-GENE
L I-GENE
( O
OR O
, O
5 I-GENE
), O
and O
alanine I-GENE
aminotransferase I-GENE
( O
_RARE_ I-GENE
) O
>/= O
_RARE_ I-GENE
( O
OR O
, O
4 I-GENE
. O
6 I-GENE
) O
were O
independently O
associated I-GENE
with O
septal O
fibrosis I-GENE
. O

_RARE_ I-GENE
significant O
amounts O
of O
platelet I-GENE
activating I-GENE
factor I-GENE
were O
_RARE_ I-GENE
from O
the O
_RARE_ I-GENE
during O
the O
entire O
treatment O
time O
. O

However O
, O
the O
elderly O
group O
showed O
significantly O
longer O
mean O
_RARE_ I-GENE
times O
( O
_RARE_ I-GENE
) O
and O
lower O
plasma I-GENE
clearance O
of O
lidocaine O
during O
the O
period O
compared O
with O
the O
adult O
group O
( O
P I-GENE
< O
. O
05 O
). O

Here O
, O
we O
show O
that O
the O
zinc I-GENE
finger I-GENE
protein I-GENE
_RARE_ I-GENE
acts O
as O
a O
dosage O
- I-GENE
dependent I-GENE
suppressor I-GENE
of O
the O
_RARE_ I-GENE
defect O
in O
nutrient O
limitation O
- I-GENE
induced O
transcriptional O
derepression O
of O
_RARE_ I-GENE
. O

The O
so O
- I-GENE
called O
" O
SH3 I-GENE
" O
segment O
of O
the O
linker I-GENE
domain I-GENE
, O
in O
contrast O
, O
shows O
species O
- I-GENE
specific I-GENE
sequence I-GENE
identity O
in O
all O
but O
one O
amino O
acid I-GENE
residues O
in O
both O
factors I-GENE
, O
in O
cattle O
, O
human I-GENE
, O
and O
mouse I-GENE
. O

No O
differences O
in O
total O
cholesterol I-GENE
levels O
were O
observed O
between O
_RARE_ I-GENE
and O
_RARE_ I-GENE
. O

_RARE_ I-GENE
to O
95 O
% O
of O
the O
total O
UV O
exposure O
received O
is O
in O
the O
UV O
- I-GENE
A I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
- I-GENE
400 O
nm O
). O

To O
begin O
to O
characterize O
the O
role O
of O
the O
RNA I-GENE
subunits I-GENE
in O
enzyme I-GENE
function O
and O
substrate I-GENE
specificity O
, O
we O
_RARE_ I-GENE
two O
hairpin O
structures O
( O
_RARE_ I-GENE
and O
P3 I-GENE
) O
between O
RNase I-GENE
MRP I-GENE
RNA I-GENE
and O
RNase I-GENE
P I-GENE
RNA I-GENE
of O
S I-GENE
. O
cerevisiae I-GENE
. O

Among O
genes I-GENE
induced O
by O
added O
_RARE_ I-GENE
is O
_RARE_ I-GENE
- I-GENE
8 O
, O
a O
signaling O
factor I-GENE
that O
induces O
a O
similar O
_RARE_ I-GENE
of O
marker O
genes I-GENE
and O
a O
similar O
cellular O
phenotype O
. O

_RARE_ I-GENE
, O
no O
Ha I-GENE
- I-GENE
ras I-GENE
codon O
12 O
mutations O
are O
found O
in O
the O
_RARE_ I-GENE
- I-GENE
induced O
mammary O
tumors O
. O

_RARE_ I-GENE
positive O
PET O
FDG O
corresponded O
to O
lung O
infection O
, O
_RARE_ I-GENE
bone O
disease O
, O
and O
reconstruction O
_RARE_ I-GENE
. O

Tumor I-GENE
stages O
were O
_RARE_ I-GENE
( O
T3 O
_RARE_ I-GENE
) O
in O
52 O
%, O
_RARE_ I-GENE
in O
15 O
%, O
and O
IIIB I-GENE
in O
27 O
% O
of O
patients O
. O

Similarly O
, O
comparison O
of O
percentage O
reductions O
of O
heart O
rate O
at O
supine O
, O
_RARE_ I-GENE
and O
exercise O
by O
repeated O
measure O
analysis O
showed O
the O
_RARE_ I-GENE
to O
have O
significantly O
higher O
change O
compared O
to O
the O
Chinese O
( O
p O
= O
0 O
. O
_RARE_ I-GENE
). O

Consistent O
with O
our O
model O
, O
CTCF I-GENE
binding I-GENE
is O
abolished O
by O
DNA I-GENE
methylation O
. O

OBJECTIVE O
: O
To O
determine O
the O
efficacy O
and O
safety O
of O
amphotericin O
B I-GENE
oral O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
for O
the O
treatment O
of O
_RARE_ I-GENE
refractory O
oral O
candidiasis O
in O
persons O
with O
HIV I-GENE
infection O
. O

_RARE_ I-GENE
gene I-GENE
expression O
has O
been O
shown O
to O
be O
altered O
in O
many O
intestinal O
diseases O
and O
especially O
cancers O
of O
the O
gastrointestinal O
tract O
. O

The O
experimentally O
mapped O
regions O
of O
_RARE_ I-GENE
involved O
in O
these O
interactions O
correspond O
to O
distinct O
and O
surface O
- I-GENE
exposed O
alpha I-GENE
- I-GENE
helical O
structures O
. O

The O
model O
indicates O
that O
a O
0 O
. O
_RARE_ I-GENE
% O
reduction O
in O
_RARE_ I-GENE
consumption O
is O
associated I-GENE
with O
the O
availability O
of O
nicotine O
_RARE_ I-GENE
after O
1992 O
. O

_RARE_ I-GENE
_RARE_ I-GENE
. O

The O
_RARE_ I-GENE
locus I-GENE
also O
contains O
at O
least O
four O
_RARE_ I-GENE
- I-GENE
like I-GENE
_RARE_ I-GENE
, O
including O
_RARE_ I-GENE
, O
a O
gene I-GENE
expressed O
in O
dogs O
but O
not O
in O
humans O
. O

The O
cellular O
part O
of O
the O
third O
chimeric I-GENE
clone O
shows O
significant O
homology I-GENE
to O
an O
exon O
of O
the O
human I-GENE
tyrosine I-GENE
phosphatase I-GENE
1 I-GENE
gene I-GENE
, O
although O
_RARE_ I-GENE
in O
the O
antisense I-GENE
direction O
compared O
to O
the O
adjacent O
LTR I-GENE
. O

OBJECTIVE O
: O
This O
study O
was O
conducted O
to O
assess O
the O
relative O
roles O
of O
99mTc O
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
in O
the O
evaluation O
of O
breast O
lesions O
that O
are O
_RARE_ I-GENE
or O
_RARE_ I-GENE
on O
_RARE_ I-GENE
or O
clinical O
examination O
. O

Mutational O
analyses O
showed O
that O
in O
- I-GENE
frame O
stop O
codons O
introduced O
into O
five O
of O
seven O
RNA I-GENE
2 I-GENE
ORFs O
did O
not O
affect O
accumulation O
of O
_RARE_ I-GENE
_RARE_ I-GENE
RNA I-GENE
1 I-GENE
or O
RNA I-GENE
2 I-GENE
, O
confirming O
that O
RNA I-GENE
2 I-GENE
does O
not O
encode O
proteins I-GENE
necessary O
for O
_RARE_ I-GENE
RNA I-GENE
replication O
. O

Role O
of O
_RARE_ I-GENE
( O
2 I-GENE
)- I-GENE
and O
COOH O
- I-GENE
terminal I-GENE
domains I-GENE
of O
the O
P I-GENE
protein I-GENE
of O
human I-GENE
_RARE_ I-GENE
virus I-GENE
type I-GENE
3 I-GENE
in O
transcription I-GENE
and O
replication O
. O

_RARE_ I-GENE
of O
tyrosine I-GENE
residues O
in O
the O
kinase I-GENE
domain I-GENE
and O
juxtamembrane I-GENE
region O
regulates O
the O
biological O
and O
catalytic O
activities O
of O
_RARE_ I-GENE
receptors I-GENE
. O

RESULTS O
: O
_RARE_ I-GENE
' O
s O
_RARE_ I-GENE
occurs O
_RARE_ I-GENE
. O

Genomic O
DNA I-GENE
sequencing O
in O
the O
vicinity O
of O
_RARE_ I-GENE
- I-GENE
CoA I-GENE
_RARE_ I-GENE
gene I-GENE
( O
_RARE_ I-GENE
) O
from O
a O
_RARE_ I-GENE
SV O
- I-GENE
producing O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
allowed O
us O
to O
clone O
, O
sequence I-GENE
, O
and O
identify O
a O
gene I-GENE
encoding O
a O
novel O
serine I-GENE
/ I-GENE
threonine I-GENE
protein I-GENE
kinase I-GENE
( O
_RARE_ I-GENE
). O

IL I-GENE
- I-GENE
2 I-GENE
is O
accepted O
as O
a O
standard O
treatment O
used O
alone O
, O
or O
in O
combination O
with O
chemotherapy O
or O
_RARE_ I-GENE
in O
the O
management O
of O
metastatic O
melanoma O
and O
metastatic O
renal O
cell O
carcinoma O
. O

Moreover O
, O
expression O
of O
antisense I-GENE
Ha I-GENE
- I-GENE
Ras I-GENE
or O
dominant I-GENE
negative O
Raf I-GENE
- I-GENE
1 I-GENE
abrogated O
the O
mitogenic O
effect O
of O
TGF I-GENE
- I-GENE
beta1 I-GENE
in O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
, O
and O
the O
TGF I-GENE
- I-GENE
beta1 I-GENE
inhibition O
of O
_RARE_ I-GENE
was O
_RARE_ I-GENE
to O
stimulation O
by O
_RARE_ I-GENE
- I-GENE
Ras I-GENE
transfection O
. O

Taken O
together O
, O
our O
data O
suggest O
that O
prostate O
carcinomas O
with O
the O
Ras I-GENE
/ I-GENE
MAPK I-GENE
pathway O
activation O
might O
have O
a O
selective O
growth I-GENE
advantage O
by O
autocrine O
TGF I-GENE
- I-GENE
beta1 I-GENE
production O
. O

_RARE_ I-GENE
segments O
are O
_RARE_ I-GENE
to O
_RARE_ I-GENE
rearrangements O
, O
with O
little O
or O
no O
direct O
_RARE_ I-GENE
to O
_RARE_ I-GENE
joining O
, O
despite O
12 O
/ I-GENE
23 O
compatibility O
of O
_RARE_ I-GENE
23 O
- I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
. O

For O
oral O
administration O
, O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
was O
58 O
. O
47 O
+/- O
16 O
. O
37 O
microg O
x O
h O
/ I-GENE
ml O
, O
t1 O
/ I-GENE
_RARE_ I-GENE
was O
18 O
. O
39 O
+/- O
0 O
. O
06 O
hours O
, O
maximum O
concentration O
( O
_RARE_ I-GENE
) O
was O
2 I-GENE
. O
12 O
+/- O
00 O
. O
51 O
microg O
/ I-GENE
ml O
, O
time O
to O
_RARE_ I-GENE
was O
2 I-GENE
. O
20 O
+/- O
2 I-GENE
. O
17 O
hours O
, O
mean O
absorption O
time O
was O
2 I-GENE
. O
09 O
+/- O
0 O
. O
51 O
hours O
, O
and O
_RARE_ I-GENE
was O
42 O
+/- O
0 O
. O
42 O
%. O

In O
experiment O
2 I-GENE
, O
no O
difference O
in O
gastric O
emptying O
of O
40 I-GENE
% O
_RARE_ I-GENE
or O
25 O
% O
glucose O
was O
found O
between O
rats O
receiving O
TPN O
and O
those O
receiving O
_RARE_ I-GENE
nutrition O
for O
10 O
to O
12 O
days O
. O

In O
contrast O
, O
H I-GENE
- I-GENE
NS I-GENE
negative O
regulation O
operated O
only O
in O
the O
absence O
of O
Fur I-GENE
. O

Thus O
, O
_RARE_ I-GENE
appears O
to O
control O
cell O
cycle O
progression O
in O
yeast I-GENE
by O
promoting I-GENE
ubiquitination O
and O
degradation O
of O
cell O
cycle O
regulatory I-GENE
proteins I-GENE
. O

E2F I-GENE
- I-GENE
1 I-GENE
is O
a O
transcription I-GENE
factor I-GENE
that O
regulates O
cell O
cycle O
progression O
into O
S I-GENE
- I-GENE
phase O
. O

It O
_RARE_ I-GENE
about O
_RARE_ I-GENE
, O
negative O
_RARE_ I-GENE
, O
and O
impaired O
health O
, O
sleep O
, O
safety O
, O
and O
working O
capacity O
. O

This O
demonstrates O
that O
treatment O
of O
the O
graft O
recipient O
for O
a O
relatively O
short O
period O
during O
and O
after O
surgery O
has O
a O
_RARE_ I-GENE
effect O
on O
the O
survival O
of O
_RARE_ I-GENE
dopaminergic O
neurons O
. O

The O
relationships O
among O
blood O
concentrations O
of O
thyroid I-GENE
hormones O
and O
selenium O
, O
zinc I-GENE
, O
retinol I-GENE
, O
and O
alpha I-GENE
- I-GENE
_RARE_ I-GENE
were O
studied O
in O
44 I-GENE
healthy O
Northern O
Italian O
_RARE_ I-GENE
- I-GENE
old O
subjects O
( O
age O
range O
, O
90 O
- I-GENE
_RARE_ I-GENE
yr O
), O
selected O
by O
the O
criteria O
of O
the O
_RARE_ I-GENE
protocol O
. O

Chinese O
_RARE_ I-GENE
( O
CS I-GENE
) O
carrying O
the O
Q I-GENE
gene I-GENE
to O
those O
of O
a O
chromosome O
deletion O
line O
of O
CS I-GENE
, O
namely O
, O
_RARE_ I-GENE
, O
which O
lacks O
15 O
% O
of O
_RARE_ I-GENE
including O
the O
Q I-GENE
gene I-GENE
. O

_RARE_ I-GENE
using O
hippocampal O
_RARE_ I-GENE
maintained O
in O
vitro O
have O
demonstrated O
that O
_RARE_ I-GENE
of O
_RARE_ I-GENE
field O
potentials O
in O
the O
gamma I-GENE
frequency O
range O
( O
30 O
- I-GENE
80 O
Hz O
) O
are O
followed O
by O
a O
slower O
_RARE_ I-GENE
in O
the O
beta I-GENE
1 I-GENE
range O
( O
12 O
- I-GENE
20 O
Hz O
). O

_RARE_ I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE

During O
surgery O
bone O
cysts O
were O
_RARE_ I-GENE
and O
filled O
by O
bone O
grafts O
. O

_RARE_ I-GENE
_RARE_ I-GENE
increased O
after O
both O
_RARE_ I-GENE
the O
rise O
being O
higher O
following O
oral O
as O
compared O
to O
inhalation O
_RARE_ I-GENE
( O
p O
= O
0 O
. O
0001 O
). O

Basal O
_RARE_ I-GENE
was O
reduced O
by O
approximately O
18 O
% O
by O
_RARE_ I-GENE
and O
_RARE_ I-GENE
, O
but O
_RARE_ I-GENE
responses O
to O
noradrenaline O
, O
angiotensin I-GENE
II I-GENE
, O
acetylcholine I-GENE
and O
_RARE_ I-GENE
were O
unaffected O
. O

Three O
FGF I-GENE
- I-GENE
AS I-GENE
cDNAs I-GENE
were O
isolated O
; O
the O
full I-GENE
- I-GENE
length I-GENE
FGF I-GENE
- I-GENE
AS I-GENE
mRNA I-GENE
and O
two O
alternative O
splice O
variants I-GENE
lacking O
exon O
2 I-GENE
or O
exons O
2 I-GENE
and O
3 I-GENE
of O
the O
FGF I-GENE
- I-GENE
AS I-GENE
sequence I-GENE
. O

Taken O
together O
, O
these O
results O
indicate O
that O
MAP I-GENE
kinase I-GENE
stimulates O
the O
_RARE_ I-GENE
- I-GENE
B I-GENE
enhancer I-GENE
by O
an O
NF I-GENE
- I-GENE
IL I-GENE
- I-GENE
6 I-GENE
- I-GENE
dependent I-GENE
pathway O
. O

Characterization O
of O
polymorphic O
_RARE_ I-GENE
in O
novel O
and O
even O
known O
genes I-GENE
expressed O
in O
human I-GENE
spinal O
cord O
is O
likely O
to O
help O
in O
the O
identification O
of O
new O
_RARE_ I-GENE
for O
genes I-GENE
involved O
in O
_RARE_ I-GENE
disorders O
. O

Finally O
, O
in O
situ O
RNA I-GENE
hybridization O
studies O
revealed O
a O
very O
specific I-GENE
pattern O
of O
_RARE_ I-GENE
gene I-GENE
expression O
restricted O
to O
the O
_RARE_ I-GENE
region O
of O
_RARE_ I-GENE
_RARE_ I-GENE
during O
embryonic O
development O
. O

Transfection O
of O
cDNAs I-GENE
for O
three O
mutant I-GENE
enzymes O
into O
_RARE_ I-GENE
- I-GENE
null I-GENE
Chinese O
hamster I-GENE
ovary O
cells O
restored O
a O
reduced O
level O
of O
_RARE_ I-GENE
growth I-GENE
, O
whereas O
a O
_RARE_ I-GENE
mutant I-GENE
supported O
growth I-GENE
at O
a O
level O
comparable O
to O
that O
of O
the O
wild I-GENE
- I-GENE
type I-GENE
enzyme I-GENE
. O

SETTING O
: O
University O
of O
_RARE_ I-GENE
VII I-GENE
hospital O
. O
_RARE_ I-GENE
( O
s O
): O
_RARE_ I-GENE
women O
had O
_RARE_ I-GENE
for O
symptomatic O
_RARE_ I-GENE
, O
with O
12 O
_RARE_ I-GENE
observed O
. O

_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
quality O
: O
mechanical O
preparation O
and O
filling O
level O
. O

The O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
Scale O
( O
MRS O
I I-GENE
) O
was O
used O
in O
clinical O
practice O
since O
1992 O
. O

The O
MRS O
II I-GENE
_RARE_ I-GENE
a O
high O
_RARE_ I-GENE
standard O
as O
an O
instrument O
standardized O
in O
the O
population O
. O

The O
protein I-GENE
encoded I-GENE
by O
the O
_RARE_ I-GENE
transcript I-GENE
is O
well O
conserved O
with O
the O
D I-GENE
. O
melanogaster I-GENE
type I-GENE
A I-GENE
protein I-GENE
, O
particularly O
the O
BTB I-GENE
protein I-GENE
- I-GENE
protein I-GENE
- I-GENE
binding I-GENE
domain I-GENE
, O
which O
is O
encoded I-GENE
by O
exons O
I I-GENE
and O
II I-GENE
and O
is O
100 O
% O
conserved O
. O

In O
addition O
, O
the O
mouse I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
) O
was O
cloned O
, O
and O
the O
Caenorhabditis I-GENE
elegans I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
was O
identified O
in O
the O
_RARE_ I-GENE
database O
. O

_RARE_ I-GENE
and O
_RARE_ I-GENE
were O
evaluated O
against O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
, O
respectively O
. O

_RARE_ I-GENE
and O
_RARE_ I-GENE
levels O
in O
serum I-GENE
were O
measured O
before O
and O
after O
the O
last O
oral O
challenge O
. O

_RARE_ I-GENE
users O
were O
7 O
. O
5 I-GENE
times O
more O
likely O
to O
have O
received O
another O
_RARE_ I-GENE
drug O
( O
RR O
7 O
. O
5 I-GENE
, O
95 O
% O
CI O
4 I-GENE
. O
8 O
to O
11 O
. O
9 O
). O

For O
an O
_RARE_ I-GENE
program O
, O
the O
costs O
were O
estimated O
at O
_RARE_ I-GENE
_RARE_ I-GENE
for O
the O
first O
year O
and O
_RARE_ I-GENE
73 O
for O
all O
additional O
years O
. O

The O
presence O
of O
such O
a O
putative O
RNA I-GENE
- I-GENE
binding I-GENE
domain I-GENE
suggests O
a O
mechanism O
for O
the O
observed O
autoregulation O
of O
bacteriophage I-GENE
T4 I-GENE
DNA I-GENE
polymerase I-GENE
synthesis O
by O
binding I-GENE
to O
its O
own O
mRNA I-GENE
. O

Deletion O
and O
mutational O
analyses O
revealed O
two O
positive O
cis O
- I-GENE
regulatory I-GENE
elements O
in O
this O
region O
that O
are O
essential O
for O
_RARE_ I-GENE
expression O
in O
_RARE_ I-GENE
. O

Functional O
studies O
which O
introduced O
a O
mutation I-GENE
in O
the O
AP2 I-GENE
core I-GENE
binding I-GENE
region O
as O
well O
as O
cotransfection O
experiments O
using O
an O
AP2 I-GENE
expression O
vector O
revealed O
that O
AP2 I-GENE
exerts O
a O
repressive O
role O
on O
the O
HGF I-GENE
gene I-GENE
promoter I-GENE
activity O
. O

Using O
_RARE_ I-GENE
transfer I-GENE
of O
IkappaBalpha I-GENE
( O
IkappaBalpha I-GENE
overexpression O
), O
the O
production O
of O
TNF I-GENE
- I-GENE
alpha I-GENE
induced O
by O
whole O
_RARE_ I-GENE
was O
inhibited O
by O
only O
20 O
%. O

In O
_RARE_ I-GENE
experiments O
, O
we O
first O
showed O
that O
expression O
in O
the O
_RARE_ I-GENE
264 O
. O
7 O
cell O
line O
of O
C I-GENE
- I-GENE
terminal I-GENE
Src I-GENE
kinase I-GENE
( O
Csk I-GENE
) O
inhibited O
and O
that O
of O
a O
membrane I-GENE
- I-GENE
anchored I-GENE
, O
gain O
- I-GENE
of O
- I-GENE
function O
Csk I-GENE
abolished O
the O
Fc I-GENE
gamma I-GENE
R I-GENE
- I-GENE
mediated O
signaling O
that O
leads O
to O
_RARE_ I-GENE
in O
a O
kinase I-GENE
- I-GENE
dependent I-GENE
manner O
. O

In O
contrast O
, O
c I-GENE
- I-GENE
Src I-GENE
- I-GENE
derived O
construct I-GENE
( O
a O
- I-GENE
Src I-GENE
), O
that O
was O
excluded O
from O
detergent O
- I-GENE
resistant O
membranes O
, O
could O
not O
_RARE_ I-GENE
the O
series O
of O
_RARE_ I-GENE
signaling O
. O

The O
delta I-GENE
_RARE_ I-GENE
mutation I-GENE
also O
influenced O
on O
the O
transcript I-GENE
levels O
of O
meiosis O
- I-GENE
inducing O
genes I-GENE
called O
IME1 I-GENE
and O
_RARE_ I-GENE
: O
the O
mutation I-GENE
elevated O
the O
transcript I-GENE
level O
of O
IME1 I-GENE
but O
reduced O
that O
of O
_RARE_ I-GENE
, O
resulting O
in O
partial O
defects O
in O
_RARE_ I-GENE
DNA I-GENE
synthesis O
and O
meiosis O
. O

We O
also O
found O
that O
environmental O
conditions O
for O
meiosis O
_RARE_ I-GENE
regulate O
the O
transcript I-GENE
levels O
of O
_RARE_ I-GENE
and O
_RARE_ I-GENE
, O
such O
that O
nitrogen O
starvation O
first O
_RARE_ I-GENE
them O
but O
subsequent O
_RARE_ I-GENE
of O
medium O
decreases O
them O
. O

The O
_RARE_ I-GENE
vectors O
differ O
among O
them O
in O
: O
( O
a O
) O
the O
selectable O
marker O
( O
Saccharomyces I-GENE
cerevisiae I-GENE
_RARE_ I-GENE
2 I-GENE
gene I-GENE
, O
which O
_RARE_ I-GENE
S I-GENE
. O
pombe I-GENE
_RARE_ I-GENE
- I-GENE
gene I-GENE
and O
S I-GENE
. O
pombe I-GENE
_RARE_ I-GENE
+ I-GENE
and O
_RARE_ I-GENE
+ I-GENE
genes I-GENE
); O
( O
b I-GENE
) O
the O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
promoter I-GENE
( O
_RARE_ I-GENE
, O
_RARE_ I-GENE
and O
_RARE_ I-GENE
with O
extremely O
high O
, O
moderate O
or O
low O
transcription I-GENE
efficiency O
, O
respectively O
); O
and O
( O
c I-GENE
) O
the O
multiple O
cloning O
site I-GENE
( O
two O
multiple O
cloning O
sites I-GENE
, O
with O
12 O
restriction I-GENE
sites I-GENE
each O
). O

( O
_RARE_ I-GENE
) O
_RARE_ I-GENE
of O
30 O
_RARE_ I-GENE
negative O
healthy O
adults O
( O
age O
/ I-GENE
sex I-GENE
matched O
) O
were O
taken O
as O
control O
by O
detecting O
IgG I-GENE
anti I-GENE
bodies O
to O
_RARE_ I-GENE
antigen I-GENE
. O

The O
effect O
of O
acute O
, O
mid O
- I-GENE
cervical O
spinal O
cord O
lesions O
on O
neuronal O
and O
reflex O
activity O
evoked O
by O
the O
_RARE_ I-GENE
visceral O
stimulus O
, O
_RARE_ I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
; O
80 O
mmHg O
, O
20 O
s O
), O
was O
determined O
in O
halothane O
- I-GENE
anesthetized O
rats O
. O

_RARE_ I-GENE
_RARE_ I-GENE
-- O
his O
life O
, O
_RARE_ I-GENE
and O
diseases O

The O
results O
suggest O
that O
the O
role O
of O
S I-GENE
. O
_RARE_ I-GENE
in O
the O
_RARE_ I-GENE
of O
_RARE_ I-GENE
larvae O
in O
nature O
is O
limited O
in O
comparison O
to O
the O
role O
played O
by O
mammals O
with O
_RARE_ I-GENE
and O
_RARE_ I-GENE
behavior O
. O

The O
equilibrium O
dissociation O
binding I-GENE
constant O
for O
the O
interaction O
of O
_RARE_ I-GENE
with O
the O
_RARE_ I-GENE
promoter I-GENE
fragment I-GENE
was O
7 O
. O
7 O
nM O
under O
the O
conditions O
used O
here O
. O

These O
results O
demonstrate O
that O
N I-GENE
- I-GENE
_RARE_ I-GENE
flanking O
the O
receptor I-GENE
- I-GENE
binding I-GENE
site I-GENE
of O
the O
HA I-GENE
molecule I-GENE
are O
potent O
regulators O
of O
influenza I-GENE
virus I-GENE
growth I-GENE
, O
with O
the O
_RARE_ I-GENE
at O
_RARE_ I-GENE
being O
dominant I-GENE
and O
that O
at O
_RARE_ I-GENE
being O
less O
effective O
. O

RESULTS O
: O
The O
introduction O
of O
the O
_RARE_ I-GENE
resulted O
in O
a O
significant O
( O
p O
< O
0 O
. O
001 O
) O
reduction O
in O
_RARE_ I-GENE
_RARE_ I-GENE
( O
median O
, O
30 O
, O
000 O
) O
from O
the O
numbers O
seen O
with O
_RARE_ I-GENE
( O
median O
, O
2 I-GENE
, O
300 O
, O
000 O
) O
while O
maintaining O
the O
separation O
efficacy O
( O
47 O
%) O
and O
separation O
time O
. O

All O
were O
tested O
for O
serum I-GENE
ferritin I-GENE
( O
SF I-GENE
), O
hemoglobin I-GENE
( O
Hb I-GENE
) O
level O
and O
_RARE_ I-GENE
for O
detailed O
_RARE_ I-GENE
of O
_RARE_ I-GENE
and O
iron O
supplementation O
. O

_RARE_ I-GENE
endothelial I-GENE
growth I-GENE
factor I-GENE
( O
VEGF I-GENE
), O
a O
potent O
agonist O
secreted O
by O
virtually O
all O
cells O
, O
controls O
migration O
and O
division O
of O
vascular I-GENE
endothelial I-GENE
cells O
. O

The O
antioxidant O
agent O
_RARE_ I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
has O
been O
shown O
to O
protect O
endothelial I-GENE
cells O
( O
EC I-GENE
) O
from O
pro I-GENE
- I-GENE
inflammatory O
- I-GENE
induced O
and O
pro I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
induced O
NF I-GENE
- I-GENE
kappaB I-GENE
activation O
. O

We O
further O
studied O
the O
effects O
of O
_RARE_ I-GENE
- I-GENE
1 I-GENE
_RARE_ I-GENE
on O
_RARE_ I-GENE
induction O
by O
STAT I-GENE
activation O
. O

_RARE_ I-GENE
antibody I-GENE
- I-GENE
immunoreactive I-GENE
peptides I-GENE
are O
seen O
in O
light I-GENE
- I-GENE
adapted O
mouse I-GENE
retinal O
cytosolic I-GENE
and O
nuclear I-GENE
extracts O
. O

In O
the O
pRb I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
- I-GENE
2 I-GENE
cell O
line O
transiently O
transfected O
with O
a O
reporter I-GENE
plasmid O
containing O
six O
tal I-GENE
- I-GENE
1 I-GENE
binding I-GENE
site I-GENE
, O
pRb I-GENE
enhances O
the O
transcriptional O
activity O
of O
tal I-GENE
- I-GENE
1 I-GENE
- I-GENE
E12 I-GENE
- I-GENE
_RARE_ I-GENE
and O
tal I-GENE
- I-GENE
1 I-GENE
- I-GENE
E12 I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
complexes I-GENE
but O
not O
that O
of O
a O
tal I-GENE
- I-GENE
1 I-GENE
- I-GENE
E12 I-GENE
heterodimer O
. O

This O
effect O
was O
not O
seen O
in O
conjunction O
with O
_RARE_ I-GENE
, O
a O
morphine O
- I-GENE
like I-GENE
mu I-GENE
- I-GENE
receptor I-GENE
agonist O
. O

In O
contrast O
to O
the O
morphological O
criteria O
, O
the O
few O
data O
available O
from O
recent O
studies O
at O
the O
genetic O
level O
have O
suggested O
that O
_RARE_ I-GENE
_RARE_ I-GENE
different O
insect O
_RARE_ I-GENE
are O
_RARE_ I-GENE
distant O
. O

_RARE_ I-GENE
of O
the O
breast O
in O
a O
patient O
with O
_RARE_ I-GENE
von I-GENE
_RARE_ I-GENE

In O
the O
_RARE_ I-GENE
period O
male O
rate O
of O
aggression O
was O
not O
significantly O
correlated O
with O
testosterone O
level O
. O

These O
results O
support O
the O
hypothesis O
that O
in O
the O
presence O
of O
tryptophan I-GENE
the O
ribosome I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
blocks O
Rho I-GENE
' O
s O
access O
to O
the O
_RARE_ I-GENE
and O
_RARE_ I-GENE
sites I-GENE
, O
thereby O
preventing O
transcription I-GENE
termination O
. O

In O
situ O
hybridization O
with O
the O
antisense I-GENE
RNA I-GENE
probes O
further O
supported O
the O
expression O
changes O
of O
these O
six O
clones O
and O
localized O
the O
changes O
in O
multiple O
germ I-GENE
cell O
stages O
as O
well O
as O
other O
cell O
types O
( O
_RARE_ I-GENE
, O
interstitial O
and O
_RARE_ I-GENE
cells O
). O

The O
administration O
of O
the O
GnRH I-GENE
agonist O
reduced O
the O
bone O
mineral O
density I-GENE
in O
the O
whole O
femur O
to O
91 O
. O
0 O
% O
of O
that O
in O
the O
control O
group O
. O

Prevention O
, O
differential O
diagnosis O
and O
therapy O
of O
_RARE_ I-GENE
_RARE_ I-GENE

This O
study O
shows O
that O
C I-GENE
/ I-GENE
EBPbeta I-GENE
is O
the O
predominant O
C I-GENE
/ I-GENE
EBP I-GENE
isoform I-GENE
found O
in O
activated I-GENE
_RARE_ I-GENE
cells O
and O
that O
increased O
C I-GENE
/ I-GENE
EBPbeta I-GENE
protein I-GENE
and O
C I-GENE
/ I-GENE
EBPbeta I-GENE
binding I-GENE
to O
a O
proximal I-GENE
C I-GENE
/ I-GENE
EBP I-GENE
binding I-GENE
site I-GENE
in O
the O
promoter I-GENE
mediates O
the O
activating I-GENE
effect O
of O
_RARE_ I-GENE
. O

Mutation O
analysis O
demonstrates O
that O
the O
motif I-GENE
_RARE_ I-GENE
is O
critical O
for O
_RARE_ I-GENE
interaction O
. O

As O
with O
VP16 I-GENE
, O
the O
transactivation O
function O
of O
_RARE_ I-GENE
is O
also O
regulated O
by O
_RARE_ I-GENE
. O

After O
two O
successive O
_RARE_ I-GENE
of O
selection O
by O
focus O
formation O
assay O
, O
a O
transforming I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
was O
identified O
. O

G I-GENE
., O
and O
_RARE_ I-GENE
, O
C I-GENE
. O

Our O
results O
suggest O
that O
proteasome I-GENE
inhibition O
leads O
to O
_RARE_ I-GENE
of O
specific I-GENE
members O
of O
transcription I-GENE
factor I-GENE
families O
controlling O
cellular O
stress O
response O
and O
proliferation O
. O

The O
_RARE_ I-GENE
- I-GENE
X I-GENE
syndrome O
results O
from O
mutations O
of O
the O
_RARE_ I-GENE
gene I-GENE
, O
located O
on O
the O
X I-GENE
chromosome O
( O
_RARE_ I-GENE
. O
3 I-GENE
) O
and O
coding O
for O
a O
_RARE_ I-GENE
factor I-GENE
which O
regulates O
gene I-GENE
expression O
. O

_RARE_ I-GENE
: O
To O
evaluate O
the O
role O
of O
environmental O
intra O
- I-GENE
uterine O
factors I-GENE
in O
determining O
the O
_RARE_ I-GENE
of O
_RARE_ I-GENE
with O
increased O
susceptibility I-GENE
to O
diabetes O
and O
_RARE_ I-GENE
for O
abnormal O
responses O
to O
the O
oral O
glucose O
tolerance O
test O
( O
_RARE_ I-GENE
) O
and O
_RARE_ I-GENE
the O
possible O
association O
of O
within O
- I-GENE
pair O
_RARE_ I-GENE
differences O
and O
metabolic O
abnormalities O
in O
adult O
life O
. O

In O
_RARE_ I-GENE
III I-GENE
, O
a O
_RARE_ I-GENE
_RARE_ I-GENE
occurred O
that O
allocated O
a O
_RARE_ I-GENE
number O
of O
patients O
with O
no O
motor O
deficit O
( O
and O
therefore O
no O
_RARE_ I-GENE
for O
recovery O
) O
to O
the O
lower O
dose O
control O
group O
. O

_RARE_ I-GENE
_RARE_ I-GENE
( O
PA I-GENE
) O
from O
Escherichia I-GENE
coli I-GENE
_RARE_ I-GENE
is O
a O
_RARE_ I-GENE
heterodimer O
consisting O
of O
a O
24 O
kDa I-GENE
small I-GENE
subunit I-GENE
and O
a O
65 O
kDa I-GENE
large O
subunit I-GENE
. O

A I-GENE
murine I-GENE
expressed O
sequence I-GENE
tag O
( O
EST I-GENE
) O
showing O
homology I-GENE
with O
erythropoietin I-GENE
receptor I-GENE
( O
_RARE_ I-GENE
) O
was O
identified O
in O
the O
EST I-GENE
database O
. O

When O
the O
_RARE_ I-GENE
was O
partially O
occluded O
, O
mild O
_RARE_ I-GENE
- I-GENE
induced O
tachycardia O
resulted O
in O
decreased O
_RARE_ I-GENE
( O
P I-GENE
= O
0 O
. O
_RARE_ I-GENE
) O
as O
well O
as O
in O
decreased O
SV O
( O
P I-GENE
= O
0 O
. O
_RARE_ I-GENE
); O
the O
_RARE_ I-GENE
remained O
high O
( O
P I-GENE
= O
0 O
. O
_RARE_ I-GENE
). O

Activation O
of O
nuclear I-GENE
factor I-GENE
( O
NF I-GENE
)- I-GENE
kappaB I-GENE
and O
subsequent O
_RARE_ I-GENE
gene I-GENE
expression O
in O
human I-GENE
airway O
epithelial O
cells O
can O
be O
evoked O
by O
oxidative O
stress O
. O

GAP I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
: O
_RARE_ I-GENE
. O

We O
have O
isolated O
and O
functionally O
characterized O
the O
mouse I-GENE
gene I-GENE
for O
the O
C2 I-GENE
subunit I-GENE
of O
the O
20S I-GENE
proteasome I-GENE
. O

Furthermore O
, O
as O
in O
the O
human I-GENE
gene I-GENE
, O
the O
3 I-GENE
' O
end O
of O
the O
_RARE_ I-GENE
gene I-GENE
maps O
within O
5 I-GENE
kb O
of O
the O
5 I-GENE
' O
end O
of O
the O
mouse I-GENE
_RARE_ I-GENE
gene I-GENE
in O
a O
region O
_RARE_ I-GENE
to O
_RARE_ I-GENE
. O
23 O
. O

With O
the O
human I-GENE
_RARE_ I-GENE
cDNA I-GENE
as O
a O
probe O
, O
Northern O
hybridization O
revealed O
that O
a O
4 I-GENE
. O
0 O
- I-GENE
kb O
transcript I-GENE
was O
expressed O
at O
a O
high O
level O
in O
prostate O
and O
at O
a O
middle I-GENE
level O
in O
13 O
of O
16 O
tissues O
examined O
, O
but O
it O
cannot O
be O
detected O
in O
liver O
and O
lung O
tissues O
. O

Similarly O
, O
co O
- I-GENE
expression O
of O
a O
dominant I-GENE
- I-GENE
negative O
mutant I-GENE
of O
_RARE_ I-GENE
, O
but O
not O
of O
ERK1 I-GENE
, O
ERK2 I-GENE
, O
JNK1 I-GENE
, O
or O
_RARE_ I-GENE
, O
reduces O
basal O
and O
cadmium O
- I-GENE
induced O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
activity O
. O

BACKGROUND O
: O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
is O
a O
safe O
and O
effective O
alternative O
to O
surgery O
for O
_RARE_ I-GENE
lesions O
. O

In O
_RARE_ I-GENE
patients O
( O
Epo I-GENE
and O
Non O
- I-GENE
Epo I-GENE
group O
) O
leptin I-GENE
levels O
were O
significantly O
higher O
when O
compared O
to O
_RARE_ I-GENE
patients O
( O
Epo I-GENE
and O
Non O
- I-GENE
Epo I-GENE
group O
, O
respectively O
). O

It O
is O
mainly O
transcribed O
in O
neural O
structures O
and O
in O
developing O
organs O
characterized O
by O
epithelial O
- I-GENE
mesenchymal O
interactions O
. O

CONCLUSION O
: O
The O
alpha2 I-GENE
- I-GENE
adrenergic I-GENE
antagonist O
_RARE_ I-GENE
increases O
glucose O
- I-GENE
induced O
sympathetic O
activity O
but O
not O
energy O
expenditure O
in O
obese O
subjects O
. O

_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
toxin I-GENE
_RARE_ I-GENE
particle I-GENE
diagnostic O
agent O
_RARE_ I-GENE
by O
_RARE_ I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
was O
_RARE_ I-GENE
at O
_RARE_ I-GENE
laboratory O
of O
Institute O
of O
_RARE_ I-GENE
_RARE_ I-GENE
in O
_RARE_ I-GENE
. O

_RARE_ I-GENE
, O
we O
show O
that O
two O
_RARE_ I-GENE
- I-GENE
induced O
mutations O
, O
previously O
shown O
to O
interact O
genetically O
with O
zipper I-GENE
( O
_RARE_ I-GENE
), O
disrupt O
the O
RhoA I-GENE
locus I-GENE
. O

Therefore O
, O
the O
results O
indicate O
that O
repeated O
exposure O
to O
amphetamine O
or O
_RARE_ I-GENE
_RARE_ I-GENE
the O
context O
- I-GENE
dependent I-GENE
component O
of O
sensitization O
of O
amphetamine O
- I-GENE
or O
_RARE_ I-GENE
- I-GENE
induced O
_RARE_ I-GENE
behavior O
. O

_RARE_ I-GENE
for O
serum I-GENE
IgM I-GENE
binding I-GENE
to O
_RARE_ I-GENE
_RARE_ I-GENE
in O
clinical O
practice O
. O

_RARE_ I-GENE
responses O
also O
occurred O
in O
studies O
that O
explored O
sequential O
use O
of O
_RARE_ I-GENE
after O
failure O
of O
_RARE_ I-GENE
( O
26 O
% O
with O
_RARE_ I-GENE
200 O
mg O
/ I-GENE
day O
) O
or O
other O
_RARE_ I-GENE
aromatase I-GENE
inhibitors O
( O
6 I-GENE
. O
6 I-GENE
% O
with O
_RARE_ I-GENE
25 O
mg O
/ I-GENE
day O
). O

_RARE_ I-GENE
reviewed O
here O
include O
: O
data O
supporting O
the O
association O
of O
myositis O
with O
cancer O
and O
the O
appropriate O
_RARE_ I-GENE
for O
malignancy O
in O
a O
myositis O
patient O
; O
an O
approach O
to O
the O
assessment O
of O
patients O
with O
_RARE_ I-GENE
_RARE_ I-GENE
myositis O
; O
the O
_RARE_ I-GENE
of O
the O
_RARE_ I-GENE
and O
serological O
_RARE_ I-GENE
; O
a O
discussion O
of O
whether O
childhood O
and O
adult O
myositis O
are O
the O
same O
or O
different O
_RARE_ I-GENE
; O
a O
review O
of O
those O
prognostic O
factors I-GENE
to O
consider O
in O
the O
clinical O
management O
of O
myositis O
patients O
; O
current O
approaches O
and O
their O
limitations O
for O
assessing O
disease O
activity O
and O
damage O
. O

The O
_RARE_ I-GENE
of O
tissue I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
III I-GENE
( O
_RARE_ I-GENE
) O
of O
Escherichia I-GENE
coli I-GENE
is O
a O
DNA I-GENE
glycosylase I-GENE
essential O
for O
the O
removal O
of O
_RARE_ I-GENE
pyrimidine O
base O
residues O
from O
DNA I-GENE
. O

The O
duration O
of O
reactive I-GENE
_RARE_ I-GENE
decreased O
with O
aging O
, O
but O
the O
difference O
between O
males O
and O
females O
was O
not O
significant O
at O
any O
age O
. O

_RARE_ I-GENE
bile O
duct O
_RARE_ I-GENE
: O
entry O
of O
_RARE_ I-GENE
agent O
into O
an O
intrahepatic O
abscess O
. O

Furthermore O
, O
this O
study O
_RARE_ I-GENE
at O
the O
impact O
of O
synthesis O
conditions O
on O
block O
length I-GENE
and O
_RARE_ I-GENE
, O
and O
the O
impact O
of O
the O
blocking O
on O
both O
, O
_RARE_ I-GENE
and O
_RARE_ I-GENE
of O
the O
polymers O
. O

However O
, O
little O
was O
understood O
about O
the O
normal O
function O
of O
CREB I-GENE
- I-GENE
2 I-GENE
in O
mammalian I-GENE
development O
or O
organ O
physiology O
. O

The O
outer I-GENE
diameter O
and O
the O
thickness O
of O
the O
_RARE_ I-GENE
are O
60 O
mm O
and O
8 O
mm O
, O
respectively O
. O

Both O
the O
_RARE_ I-GENE
and O
the O
maximum O
EMG O
activity O
in O
the O
right O
_RARE_ I-GENE
and O
the O
left O
anterior O
_RARE_ I-GENE
muscles O
were O
significantly O
decreased O
during O
muscle O
pain O
when O
the O
subjects O
_RARE_ I-GENE
on O
the O
_RARE_ I-GENE
side O
. O

CONCLUSIONS O
: O
There O
is O
a O
relation O
in O
the O
_RARE_ I-GENE
of O
some O
visual O
field O
areas O
assessed O
by O
_RARE_ I-GENE
and O
the O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
area O
, O
which O
may O
play O
a O
role O
in O
the O
diagnosis O
and O
follow O
- I-GENE
up O
of O
suspected O
glaucoma O
. O

The O
total O
_RARE_ I-GENE
contained O
in O
the O
_RARE_ I-GENE
of O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
was O
lower O
than O
the O
limits O
recommended O
for O
food O
safety O
. O

The O
detection O
success O
rate O
was O
determined O
for O
different O
markers O
using O
this O
MEK I-GENE
. O

_RARE_ I-GENE
, O
we O
show O
that O
_RARE_ I-GENE
physically O
interacts O
with O
the O
HMG I-GENE
box I-GENE
domain I-GENE
of O
_RARE_ I-GENE
and O
that O
_RARE_ I-GENE
and O
Wnt I-GENE
pathways O
_RARE_ I-GENE
to O
activate O
transcription I-GENE
of O
the O
Xenopus I-GENE
homeobox I-GENE
gene I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
). O

The O
transmembrane I-GENE
topology O
of O
Na I-GENE
_RARE_ I-GENE
H I-GENE
(+) I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
has O
been O
studied O
using O
in O
vitro O
transcription I-GENE
/ I-GENE
translation I-GENE
of O
two O
types O
of O
fusion I-GENE
vectors O
designed O
to O
test O
membrane I-GENE
insertion O
properties O
of O
cDNA I-GENE
sequences I-GENE
encoding O
putative O
_RARE_ I-GENE
membrane I-GENE
spanning O
domains I-GENE
( O
_RARE_ I-GENE
). O

ACE I-GENE
- I-GENE
2 I-GENE
has O
a O
hydrophobic O
C I-GENE
terminus O
of O
H I-GENE
type I-GENE
. O

Members O
of O
the O
_RARE_ I-GENE
/ I-GENE
myosin I-GENE
light I-GENE
chain I-GENE
kinase I-GENE
family I-GENE
play O
an O
essential O
role O
in O
the O
organization O
of O
the O
actin I-GENE
/ I-GENE
myosin I-GENE
cytoskeleton I-GENE
, O
especially O
in O
_RARE_ I-GENE
assembly O
and O
function O
. O

We O
concluded O
that O
activation O
of O
c I-GENE
- I-GENE
_RARE_ I-GENE
mediated O
transcriptional O
inhibition O
of O
p21 I-GENE
( O
Cip1 I-GENE
/ I-GENE
WAF1 I-GENE
) O
through O
a O
previously O
uncharacterized O
AP I-GENE
- I-GENE
1 I-GENE
site I-GENE
, O
_RARE_ I-GENE
an O
important O
role O
for O
c I-GENE
- I-GENE
fos I-GENE
in O
negative O
control O
of O
cell O
cycle O
regulatory I-GENE
genes I-GENE
. O

Furthermore O
, O
a O
_RARE_ I-GENE
Shc I-GENE
phosphopeptide I-GENE
selectively O
recognized O
Grb2 I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
and O
the O
p85 I-GENE
subunit I-GENE
of O
phosphatidylinositol I-GENE
3 I-GENE
' O
kinase I-GENE
from O
mast I-GENE
cells O
, O
as O
characterized O
by O
mass O
spectrometry O
. O

Although O
increased O
expression O
of O
the O
HMG I-GENE
- I-GENE
I I-GENE
/ I-GENE
Y I-GENE
proteins I-GENE
is O
associated I-GENE
with O
cellular O
proliferation O
, O
neoplastic O
transformation O
, O
and O
several O
human I-GENE
cancers O
, O
the O
role O
of O
these O
proteins I-GENE
in O
the O
pathogenesis O
of O
malignancy O
remains O
unclear O
. O

The O
naltrexone O
/ I-GENE
_RARE_ I-GENE
combination O
was O
associated I-GENE
with O
a O
more O
rapid O
resolution O
of O
the O
opiate I-GENE
withdrawal O
syndrome O
than O
a O
7 O
- I-GENE
day O
_RARE_ I-GENE
- I-GENE
only O
treatment O
schedule O
, O
without O
substantial O
increases O
in O
withdrawal O
symptoms O
or O
hypotensive O
side O
- I-GENE
effects O
. O

The O
first O
symptoms O
of O
_RARE_ I-GENE
_RARE_ I-GENE
were O
noted O
in O
_RARE_ I-GENE
1998 O
, O
when O
some O
of O
the O
cows O
developed O
locomotor O
abnormalities O
. O

_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
and O
treatment O
for O
alcohol O
and O
_RARE_ I-GENE
drug O
use O
should O
be O
essential O
components O
in O
_RARE_ I-GENE
_RARE_ I-GENE
care O
. O

Transcriptional O
regulation O
of O
the O
mouse I-GENE
cytosolic I-GENE
_RARE_ I-GENE
subunit I-GENE
gene I-GENE
_RARE_ I-GENE
/ I-GENE
t I-GENE
- I-GENE
complex I-GENE
polypeptide I-GENE
1 I-GENE
by O
selenocysteine I-GENE
tRNA I-GENE
gene I-GENE
transcription I-GENE
activating I-GENE
factor I-GENE
family I-GENE
zinc I-GENE
finger I-GENE
proteins I-GENE
. O

The O
_RARE_ I-GENE
protein I-GENE
response O
regulates O
multiple O
aspects O
of O
secretory I-GENE
and O
membrane I-GENE
protein I-GENE
biogenesis O
and O
endoplasmic O
reticulum O
quality O
control O
. O

_RARE_ I-GENE
: O
a O
proline O
- I-GENE
rich O
nuclear I-GENE
receptor I-GENE
_RARE_ I-GENE
protein I-GENE
that O
_RARE_ I-GENE
transcriptional O
activation O
of O
multiple O
nuclear I-GENE
receptors I-GENE
including O
orphan I-GENE
receptors I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
factor I-GENE
1 I-GENE
) O
and O
_RARE_ I-GENE
( O
estrogen I-GENE
related I-GENE
receptor I-GENE
alpha I-GENE
- I-GENE
1 I-GENE
). O

Studies O
using O
a O
reporter I-GENE
plasmid O
with O
a O
functionally O
disrupted O
sterol I-GENE
- I-GENE
responsive I-GENE
element I-GENE
( O
SRE O
)- I-GENE
1 I-GENE
revealed O
a O
reduced O
stimulatory I-GENE
response O
to O
IL I-GENE
- I-GENE
6 I-GENE
. O

However O
, O
there O
is O
still O
a O
subset O
of O
tumors O
that O
displayed O
no O
changes O
in O
these O
genes I-GENE
. O

We O
have O
shown O
that O
the O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
delivery O
of O
morphine O
_RARE_ I-GENE
in O
_RARE_ I-GENE
liposomes O
( O
_RARE_ I-GENE
drug O
delivery O
system O
) O
produces O
a O
sustained O
clearance O
of O
morphine O
and O
a O
prolonged O
analgesia O
. O

Following O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
, O
but O
not O
saline O
or O
_RARE_ I-GENE
vehicle O
, O
there O
were O
transient O
(< O
72 O
hr O
) O
decreases O
in O
food O
consumption O
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
muscle O
tone O
, O
and O
body O
temperature O
. O

_RARE_ I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
were O
the O
most O
accurate O
with O
100 O
% O
_RARE_ I-GENE
within O
+/- O
1 I-GENE
. O
0 O
g O
of O
10 O
g O
. O

_RARE_ I-GENE
: O
_RARE_ I-GENE
sample O
of O
ambulatory O
_RARE_ I-GENE
with O
hereditary I-GENE
motor O
and O
sensory O
neuropathy I-GENE
, O
type I-GENE
I I-GENE
( O
n O
= O
9 O
), O
_RARE_ I-GENE
muscular O
dystrophy I-GENE
( O
n O
= O
10 O
), O
and O
able O
- I-GENE
_RARE_ I-GENE
controls O
( O
n O
= O
11 O
). O

The O
effect O
of O
water O
deprivation O
for O
19 O
h O
on O
renal O
Na I-GENE
excretion O
of O
conscious O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
sheep O
maintained O
on O
a O
constant O
intravenous O
infusion O
of O
aldosterone O
and O
cortisol O
( O
_RARE_ I-GENE
- I-GENE
constant O
steroid I-GENE
sheep O
) O
was O
investigated O
. O

Neither O
is O
it O
a O
major I-GENE
cause O
of O
_RARE_ I-GENE
- I-GENE
induced O
renal O
Na I-GENE
retention O
. O

CONCLUSION O
: O
_RARE_ I-GENE
fever O
in O
the O
_RARE_ I-GENE
area O
is O
still O
manifest O
. O

_RARE_ I-GENE
III I-GENE
deficiency O
: O
when O
substitute O
, O
when O
heparin O
? O
_RARE_ I-GENE
_RARE_ I-GENE
, O
3 I-GENE
: O
The O
role O
of O
antithrombin I-GENE
III I-GENE

Specific O
class I-GENE
I I-GENE
and O
II I-GENE
histone I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
interact O
in O
vivo O
with O
_RARE_ I-GENE
, O
suggesting O
that O
_RARE_ I-GENE
may O
functionally O
link I-GENE
these O
two O
classes O
of O
_RARE_ I-GENE
. O

This O
is O
the O
first O
example O
of O
a O
eukaryotic I-GENE
transcription I-GENE
factor I-GENE
complex I-GENE
containing O
both O
a O
MADS I-GENE
- I-GENE
box I-GENE
and O
a O
_RARE_ I-GENE
protein I-GENE
, O
and O
it O
has O
important O
implications O
for O
the O
regulation O
of O
mammalian I-GENE
gene I-GENE
expression O
. O

After O
screening O
the O
_RARE_ I-GENE
Drosophila I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
database O
with O
sequences I-GENE
from O
a O
recently O
characterized O
Leu I-GENE
- I-GENE
rich O
repeats I-GENE
- I-GENE
containing O
G I-GENE
protein I-GENE
- I-GENE
coupled I-GENE
receptor I-GENE
( O
_RARE_ I-GENE
) O
from O
Drosophila I-GENE
( O
_RARE_ I-GENE
- I-GENE
1 I-GENE
), O
we O
identified O
a O
second O
gene I-GENE
for O
a O
different O
_RARE_ I-GENE
( O
_RARE_ I-GENE
- I-GENE
2 I-GENE
) O
and O
cloned O
its O
cDNA I-GENE
. O

_RARE_ I-GENE
primers O
homologous O
to O
highly O
conserved O
regions O
of O
known O
_RARE_ I-GENE
sequences I-GENE
were O
used O
for O
initial O
RT I-GENE
- I-GENE
_RARE_ I-GENE
. O

When O
cells O
were O
_RARE_ I-GENE
with O
_RARE_ I-GENE
designed O
to O
bind O
to O
a O
30 O
- I-GENE
bp O
_RARE_ I-GENE
site I-GENE
situated O
between O
the O
two O
TK I-GENE
genes I-GENE
, O
recombination O
was O
observed O
at O
frequencies O
in O
the O
range O
of O
1 I-GENE
%, O
2 I-GENE
, O
500 O
- I-GENE
fold O
above O
the O
background O
. O

_RARE_ I-GENE
was O
used O
as O
the O
internal O
standard O
. O

Resistance O
ratios O
for O
the O
other O
field O
strains O
obtained O
by O
comparison O
with O
the O
_RARE_ I-GENE
strain O
ranged O
from O
24 O
. O
5 I-GENE
to O
239 O
for O
_RARE_ I-GENE
application O
and O
from O
1 I-GENE
. O
2 I-GENE
to O
9 O
. O
8 O
for O
the O
glass O
_RARE_ I-GENE
method O
. O

Only O
transcripts I-GENE
specific I-GENE
for O
_RARE_ I-GENE
- I-GENE
2 I-GENE
are O
detected O
in O
ovary O
and O
testes O
tissues O
of O
adults O
as O
well O
as O
in O
_RARE_ I-GENE
, O
while O
neither O
gene I-GENE
is O
expressed O
during O
the O
larval I-GENE
developmental O
stages O
. O

In O
a O
gel O
retardation O
assay O
using O
HepG2 O
nuclear I-GENE
extracts O
, O
the O
5 I-GENE
' O
flanking O
sequence I-GENE
from O
- I-GENE
74 O
to O
- I-GENE
46 O
showed O
a O
shifted O
band O
. O

_RARE_ I-GENE
of O
cervical O
range O
of O
motion O
using O
the O
_RARE_ I-GENE
CA I-GENE
_RARE_ I-GENE
spine O
motion O
_RARE_ I-GENE
on O
asymptomatic O
and O
symptomatic O
subjects O
. O

_RARE_ I-GENE
experiments O
performed O
in O
transfected O
cells O
showed O
that O
_RARE_ I-GENE
associates O
with O
_RARE_ I-GENE
- I-GENE
associated I-GENE
factor I-GENE
( O
_RARE_ I-GENE
) O
1 I-GENE
, O
TRAF2 I-GENE
, O
and O
_RARE_ I-GENE
adaptor I-GENE
proteins I-GENE
. O

Since O
the O
_RARE_ I-GENE
gene I-GENE
is O
likely O
an O
_RARE_ I-GENE
of O
the O
_RARE_ I-GENE
_RARE_ I-GENE
gene I-GENE
, O
it O
has O
been O
named O
_RARE_ I-GENE
by O
the O
Human I-GENE
Gene I-GENE
_RARE_ I-GENE
Committee O
. O

The O
chromosomal I-GENE
localization O
on O
distal O
chromosome O
7 O
_RARE_ I-GENE
it O
in O
a O
cluster I-GENE
of O
imprinted O
genes I-GENE
, O
flanked O
by O
the O
previously O
described O
_RARE_ I-GENE
and O
_RARE_ I-GENE
genes I-GENE
. O

Activation O
of O
PKA I-GENE
by O
8 O
- I-GENE
_RARE_ I-GENE
- I-GENE
cyclic I-GENE
AMP I-GENE
or O
forskolin O
, O
and O
inhibition O
of O
PKC I-GENE
by O
_RARE_ I-GENE
C I-GENE
, O
resulted O
in O
a O
significant O
decrease O
in O
_RARE_ I-GENE
activity O
as O
well O
as O
in O
vitro O
ERK I-GENE
kinase I-GENE
activity O
in O
_RARE_ I-GENE
. O

The O
present O
study O
was O
designed O
to O
evaluate O
the O
sensitivity O
and O
specificity O
of O
AMP I-GENE
CT I-GENE
( O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
_RARE_ I-GENE
, O
CA I-GENE
, O
_RARE_ I-GENE
) O
on O
_RARE_ I-GENE
specimens O
taken O
from O
symptomatic O
patients O
and O
on O
first O
_RARE_ I-GENE
urine O
( O
_RARE_ I-GENE
) O
specimens O
from O
asymptomatic O
patients O
. O

_RARE_ I-GENE
also O
shares O
homology I-GENE
with O
motifs O
found O
in O
the O
_RARE_ I-GENE
endonuclease I-GENE
superfamily I-GENE
. O

Double O
mutant I-GENE
analysis O
suggests O
that O
_RARE_ I-GENE
and O
_RARE_ I-GENE
act O
in O
one O
pathway O
for O
the O
repair I-GENE
of O
, O
or O
tolerance O
to O
, O
UV O
- I-GENE
induced O
DNA I-GENE
damage O
. O

The O
linear O
plasmid O
_RARE_ I-GENE
from O
the O
yeast I-GENE
_RARE_ I-GENE
lactis O
normally O
_RARE_ I-GENE
in O
the O
cytoplasm O
, O
with O
the O
aid O
of O
the O
_RARE_ I-GENE
linear O
plasmid O
_RARE_ I-GENE
, O
using O
terminal I-GENE
protein I-GENE
( O
_RARE_ I-GENE
) O
as O
a O
primer O
. O

The O
repetitive O
_RARE_ I-GENE
( O
early I-GENE
transposon I-GENE
) O
family I-GENE
of O
sequences I-GENE
represents O
an O
active O
" O
mobile O
_RARE_ I-GENE
" O
in O
the O
mouse I-GENE
genome O
. O

The O
two O
main O
experimental O
variables O
were O
the O
_RARE_ I-GENE
_RARE_ I-GENE
( O
left O
or O
right O
) O
and O
the O
proportion O
of O
trials O
requiring O
a O
shift O
within O
that O
_RARE_ I-GENE
( O
20 O
% O
or O
80 O
%). O

The O
measurement O
of O
NO O
in O
biological O
systems O
using O
_RARE_ I-GENE
. O

Biochemical O
examinations O
of O
calcium O
- I-GENE
phosphorus O
metabolism O
included O
ions O
and O
PTH I-GENE
concentrations O
in O
blood O
serum I-GENE
, O
and O
the O
activity O
of O
bone O
_RARE_ I-GENE
of O
AP I-GENE
. O

_RARE_ I-GENE
was O
the O
most O
cost O
- I-GENE
effective O
HMG I-GENE
- I-GENE
CoA I-GENE
reductase I-GENE
inhibitor I-GENE
. O

_RARE_ I-GENE
assessment O
of O
HMG I-GENE
- I-GENE
CoA I-GENE
reductase I-GENE
inhibitor I-GENE
therapy O
: O
an O
analysis O
based O
on O
the O
_RARE_ I-GENE
study O
. O

Interestingly O
, O
although O
E I-GENE
domains I-GENE
of O
these O
two O
receptors I-GENE
are O
much O
less O
conserved O
, O
replacement O
of O
this O
domain I-GENE
in O
_RARE_ I-GENE
by O
its O
human I-GENE
counterpart O
resulted O
in O
higher O
estradiol O
sensitivity O
but O
no O
increase O
in O
the O
magnitude O
of O
transactivation O
. O

G I-GENE
- I-GENE
DNA I-GENE
is O
a O
four O
- I-GENE
stranded I-GENE
DNA I-GENE
structure O
with O
diverse O
putative O
biological O
roles O
. O

The O
effectiveness O
of O
_RARE_ I-GENE
appears O
to O
be O
largely O
independent O
of O
the O
intensity O
of O
additional O
support O
provided O
to O
the O
_RARE_ I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
: O
All O
controlled O
trials O
where O
adults O
with O
schizophrenia O
or O
similar O
_RARE_ I-GENE
were O
randomised O
to O
_RARE_ I-GENE
, O
placebo O
or O
other O
neuroleptic O
drugs O
and O
where O
clinically O
relevant O
outcomes O
were O
reported O
. O

8 O
% O
( O
95 O
% O
CI O
, O
21 O
. O
3 I-GENE
- I-GENE
44 I-GENE
. O
3 I-GENE
%). O

In O
contrast O
, O
the O
action O
of O
_RARE_ I-GENE
- I-GENE
1 I-GENE
at O
the O
CRE O
was O
not O
blocked O
by O
cotransfection O
with O
M1 I-GENE
- I-GENE
CREB I-GENE
, O
an O
isoform I-GENE
that O
lacks O
a O
consensus I-GENE
serine I-GENE
residue O
_RARE_ I-GENE
as O
substrate I-GENE
for O
PKA I-GENE
- I-GENE
mediated O
phosphorylation O
. O

Because O
all O
_RARE_ I-GENE
fusions I-GENE
described O
thus O
far O
result O
in O
splicing O
to O
a O
common O
exon O
of O
this O
gene I-GENE
, O
we O
performed O
5 I-GENE
'- O
rapid O
amplification O
of O
cDNA I-GENE
ends O
PCR O
on O
patient O
RNA I-GENE
. O

CONCLUSIONS O
: O
In O
essential O
hypertension O
an O
acute O
protein I-GENE
load O
induces O
a O
decrease O
in O
GFR O
that O
may O
_RARE_ I-GENE
under O
antihypertensive O
treatment O
. O

This O
finding O
suggested O
that O
the O
_RARE_ I-GENE
- I-GENE
Akt I-GENE
activation O
pathway O
plays O
some O
role O
in O
the O
_RARE_ I-GENE
effect O
of O
EPO I-GENE
. O

_RARE_ I-GENE
DNA I-GENE
fragments I-GENE
that O
were O
specifically O
recognized O
and O
bound O
by O
histidine O
- I-GENE
tagged O
_RARE_ I-GENE
were O
isolated O
by O
cycles O
of O
a O
gel O
mobility I-GENE
shift O
- I-GENE
PCR O
method O
. O

To O
determine O
whether O
the O
_RARE_ I-GENE
- I-GENE
binding I-GENE
motif I-GENE
is O
important O
for O
_RARE_ I-GENE
function O
, O
we O
mutated O
the O
conserved O
lysine O
( O
115 I-GENE
) O
residue O
in O
this O
motif I-GENE
. O

The O
carboxyl O
- I-GENE
terminal I-GENE
proline O
- I-GENE
rich O
domain I-GENE
of O
_RARE_ I-GENE
is O
involved O
in O
the O
interaction O
with O
the O
PLC I-GENE
- I-GENE
_RARE_ I-GENE
SH3 I-GENE
domain I-GENE
. O

From O
transient O
expression O
studies O
, O
we O
could O
demonstrate O
that O
the O
SH3 I-GENE
domain I-GENE
of O
PLC I-GENE
- I-GENE
_RARE_ I-GENE
is O
necessary O
for O
the O
association O
with O
_RARE_ I-GENE
in O
vivo O
. O

Six O
distinct O
Ets I-GENE
mRNAs I-GENE
were O
identified O
: O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
. O

A I-GENE
2 I-GENE
kb O
transcript I-GENE
was O
isolated O
from O
brain O
that O
encodes O
a O
approximately O
57 O
kDa I-GENE
protein I-GENE
; O
the O
predicted O
protein I-GENE
contains O
the O
known O
N I-GENE
- I-GENE
terminal I-GENE
Ets I-GENE
domain I-GENE
of O
_RARE_ I-GENE
and O
a O
novel O
C I-GENE
- I-GENE
terminal I-GENE
domain I-GENE
with O
_RARE_ I-GENE
homology I-GENE
to O
murine I-GENE
_RARE_ I-GENE
. O

Twenty O
_RARE_ I-GENE
patients O
with O
cirrhosis O
were O
randomized O
into O
two O
groups O
: O
10 O
patients O
treated O
with O
6 I-GENE
million O
units O
of O
natural O
IFN I-GENE
- I-GENE
beta I-GENE
twice O
a O
week O
for O
36 O
months O
and O
10 O
patients O
without O
IFN I-GENE
therapy O
. O

Wnt I-GENE
- I-GENE
1 I-GENE
overexpression O
in O
mammary O
epithelial O
cells O
induced O
cyclin I-GENE
D1 I-GENE
mRNA I-GENE
and O
targeted O
overexpression O
of O
Wnt I-GENE
- I-GENE
1 I-GENE
in O
the O
mammary O
gland O
of O
transgenic O
mice O
increased O
both O
ILK I-GENE
activity O
and O
cyclin I-GENE
D1 I-GENE
levels O
. O

Intravenous O
versus O
oral O
administration O
of O
_RARE_ I-GENE
in O
patients O
with O
major I-GENE
depression O
. O

Deletion O
of O
the O
_RARE_ I-GENE
domain I-GENE
resulted O
in O
loss O
of O
Ca I-GENE
( O
2 I-GENE
+)- I-GENE
dependent I-GENE
activation O
. O

_RARE_ I-GENE
regression O
analysis O
revealed O
that O
physicians O
were O
3 I-GENE
. O
6 I-GENE
times O
more O
likely O
to O
detect O
thin O
lesions O
_RARE_ I-GENE
0 O
. O
75 O
mm O
) O
compared O
with O
_RARE_ I-GENE
_RARE_ I-GENE
( O
95 O
% O
confidence O
interval O
[ O
95 O
% O
CI O
], O
2 I-GENE
. O
1 I-GENE
, O
6 I-GENE
. O
5 I-GENE
; O
P I-GENE
= O
0 O
. O
0001 O
). O

_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
induced O
by O
granulocyte I-GENE
colony I-GENE
- I-GENE
stimulating I-GENE
factor I-GENE
in O
an O
_RARE_ I-GENE
peripheral O
blood O
stem O
cell O
donor O
. O

_RARE_ I-GENE
and O
_RARE_ I-GENE
co O
- I-GENE
immunoprecipitated O
with O
_RARE_ I-GENE
, O
but O
not O
with O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
or O
_RARE_ I-GENE
. O

While O
interactions O
of O
_RARE_ I-GENE
and O
variant I-GENE
TGF I-GENE
- I-GENE
alpha I-GENE
with O
the O
_RARE_ I-GENE
all O
result O
in O
_RARE_ I-GENE
activation O
, O
they O
produce O
different O
biological O
consequences O
, O
suggesting O
that O
the O
various O
TGF I-GENE
- I-GENE
alpha I-GENE
precursors I-GENE
differentially O
modulate O
ErbB I-GENE
signaling O
. O

It O
is O
now O
well O
accepted O
that O
the O
p53 I-GENE
C I-GENE
- I-GENE
terminus O
plays O
a O
central O
role O
in O
controlling O
the O
activity O
of O
the O
wild I-GENE
- I-GENE
type I-GENE
molecule I-GENE
. O

In O
contrast O
to O
full I-GENE
- I-GENE
length I-GENE
E2F I-GENE
- I-GENE
3 I-GENE
, O
which O
is O
expressed O
only O
at O
the O
G1 I-GENE
/ I-GENE
S I-GENE
boundary O
, O
E2F I-GENE
- I-GENE
_RARE_ I-GENE
is O
detected O
throughout O
the O
cell O
cycle O
with O
peak O
levels O
in O
_RARE_ I-GENE
where O
it O
is O
associated I-GENE
with O
Rb I-GENE
. O

The O
transcription I-GENE
factor I-GENE
Jun I-GENE
( O
c I-GENE
- I-GENE
Jun I-GENE
) O
functions O
as O
a O
recipient O
of O
extracellular I-GENE
growth I-GENE
signals O
and O
_RARE_ I-GENE
them O
into O
patterns O
of O
gene I-GENE
expression O
. O

_RARE_ I-GENE
toxicity O
of O
the O
class I-GENE
III I-GENE
antiarrhythmic O
agent O
_RARE_ I-GENE
in O
mice O
. O

This O
compound O
is O
the O
main O
_RARE_ I-GENE
metabolite O
of O
_RARE_ I-GENE
II I-GENE
( O
_RARE_ I-GENE
, O
CAS I-GENE
_RARE_ I-GENE
- I-GENE
31 O
- I-GENE
8 O
), O
an O
_RARE_ I-GENE
widely O
used O
for O
intestinal O
diseases O
since O
_RARE_ I-GENE
. O

In O
addition O
to O
its O
effect O
in O
_RARE_ I-GENE
the O
neutrophil I-GENE
response O
to O
_RARE_ I-GENE
exercise O
, O
vitamin O
E I-GENE
causes O
a O
greater O
increase O
in O
circulating O
creatine I-GENE
kinase I-GENE
activity O
, O
perhaps O
indicating O
increased O
skeletal I-GENE
muscle O
repair I-GENE
. O

This O
_RARE_ I-GENE
the O
formation O
of O
stem O
- I-GENE
loop I-GENE
templates O
with O
the O
fusion I-GENE
point O
of O
the O
chimeric I-GENE
transcript I-GENE
in O
the O
loop I-GENE
and O
the O
use O
of O
_RARE_ I-GENE
primers O
in O
two O
- I-GENE
_RARE_ I-GENE
PCR O
. O

CONCLUSION O
: O
The O
authors O
_RARE_ I-GENE
that O
the O
initial O
management O
of O
primary O
_RARE_ I-GENE
should O
be O
adequate O
and O
suggest O
that O
_RARE_ I-GENE
margin O
of O
> O
or O
= O
2 I-GENE
cm O
should O
be O
_RARE_ I-GENE
to O
. O

Measurements O
were O
compared O
with O
two O
_RARE_ I-GENE
treatment O
planning O
systems O
-- O
_RARE_ I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
. O
_RARE_ I-GENE
. O

Activation O
was O
biphasic O
; O
_RARE_ I-GENE
at O
5 I-GENE
- I-GENE
10 O
min O
and O
24 O
h O
after O
treatment O
. O

Whereas O
_RARE_ I-GENE
is O
clearly O
detectable O
in O
crude O
lysates O
, O
cytosolic I-GENE
and O
ribosomal I-GENE
salt O
- I-GENE
_RARE_ I-GENE
fractions O
, O
and O
in O
nuclear I-GENE
extracts O
, O
_RARE_ I-GENE
is O
preferentially O
found O
in O
the O
ribosomal I-GENE
salt O
- I-GENE
_RARE_ I-GENE
preparation O
. O

It O
contains O
25 O
exons O
coding O
for O
a O
4 I-GENE
. O
_RARE_ I-GENE
transcript I-GENE
including O
large O
5 I-GENE
'- O
and O
3 I-GENE
'- O
( O
_RARE_ I-GENE
and O
_RARE_ I-GENE
, O
respectively O
) O
untranslated O
regions O
( O
_RARE_ I-GENE
). O

Five O
of O
the O
_RARE_ I-GENE
isoforms I-GENE
differ O
by O
the O
substitution O
or O
insertion O
of O
amino O
acids O
at O
or O
near O
the O
N I-GENE
- I-GENE
terminal I-GENE
of O
the O
protein I-GENE
. O

The O
_RARE_ I-GENE
technique O
for O
the O
pathological O
examination O
of O
_RARE_ I-GENE
lymph O
nodes O
( O
_RARE_ I-GENE
) O
is O
still O
under O
_RARE_ I-GENE
. O

Partial O
correction O
of O
anemia I-GENE
with O
recombinant I-GENE
human I-GENE
erythropoietin I-GENE
likely O
reduces O
left O
ventricular O
mass O
and O
volume O
. O

This O
study O
demonstrated O
that O
the O
_RARE_ I-GENE
- I-GENE
100 O
_RARE_ I-GENE
can O
accurately O
assess O
vWF I-GENE
- I-GENE
dependent I-GENE
platelet I-GENE
function O
and O
detect O
other O
platelet I-GENE
defects O
under O
high O
shear O
stress O
in O
complex I-GENE
patient O
populations O
. O

We O
recently O
reported O
the O
molecular O
cloning O
of O
a O
PL I-GENE
_RARE_ I-GENE
of O
human I-GENE
( O
_RARE_ I-GENE
) O
and O
mouse I-GENE
origin O
, O
respectively O
. O

To O
analyze O
the O
regulatory I-GENE
activity O
of O
_RARE_ I-GENE
, O
we O
first O
identified O
the O
optimal O
_RARE_ I-GENE
- I-GENE
binding I-GENE
sequence I-GENE
using O
an O
in O
vitro O
DNA I-GENE
- I-GENE
binding I-GENE
assay O
. O

Using O
an O
_RARE_ I-GENE
duplex O
5 I-GENE
'- O
A I-GENE
( O
_RARE_ I-GENE
)( I-GENE
5 I-GENE
)- I-GENE
3 I-GENE
_RARE_ I-GENE
5 I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
)( I-GENE
5 I-GENE
) O
T I-GENE
- I-GENE
3 I-GENE
' O
as O
a O
template O
- I-GENE
primer O
, O
we O
show O
that O
both O
the O
_RARE_ I-GENE
fragment I-GENE
of O
Escherichia I-GENE
coli I-GENE
DNA I-GENE
polymerase I-GENE
I I-GENE
and O
HIV I-GENE
reverse I-GENE
transcriptase I-GENE
could O
_RARE_ I-GENE
telomere I-GENE
DNA I-GENE
sequences I-GENE
as O
well O
, O
giving O
products I-GENE
greater O
than O
the O
size O
of O
the O
template O
DNA I-GENE
. O

Cdk2 I-GENE
and O
MAPK I-GENE
_RARE_ I-GENE
from O
untreated O
tumor I-GENE
lysates O
phosphorylated O
recombinant I-GENE
wild I-GENE
- I-GENE
type I-GENE
p27 I-GENE
but O
not O
the O
_RARE_ I-GENE
mutant I-GENE
in O
vitro O
. O

The O
loss O
of O
_RARE_ I-GENE
activity O
because O
of O
mutations O
in O
the O
acidic O
transcriptional O
activation O
domain I-GENE
was O
restored O
by O
addition O
of O
the O
activation O
domain I-GENE
from O
the O
herpes I-GENE
simplex I-GENE
viral I-GENE
protein I-GENE
VP16 I-GENE
. O

Mutations O
in O
the O
_RARE_ I-GENE
locus I-GENE
at O
_RARE_ I-GENE
. O
3 I-GENE
were O
found O
in O
a O
further O
10 O
- I-GENE
20 O
% O
of O
_RARE_ I-GENE
patients O
, O
as O
predicted O
from O
linkage O
studies O
. O

The O
limit O
between O
the O
_RARE_ I-GENE
and O
the O
ascending O
colon O
was O
_RARE_ I-GENE
marked O
by O
the O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
. O

_RARE_ I-GENE
, O
HD I-GENE
inhibited O
healing O
because O
it O
significantly O
delayed O
_RARE_ I-GENE
and O
caused O
_RARE_ I-GENE
inflammation O
. O

The O
effectiveness O
of O
the O
_RARE_ I-GENE
_RARE_ I-GENE
for O
second O
- I-GENE
_RARE_ I-GENE
wound O
healing O
in O
horses O
and O
_RARE_ I-GENE
. O

Although O
there O
is O
little O
evidence O
that O
diet O
composition O
plays O
a O
clinically O
important O
role O
in O
the O
absorption O
or O
expenditure O
of O
energy O
, O
it O
does O
appear O
to O
play O
a O
role O
in O
food O
intake O
. O

These O
findings O
were O
reinforced O
by O
an O
analysis O
that O
was O
restricted O
to O
living O
donor O
_RARE_ I-GENE
without O
acute O
rejection O
. O

These O
results O
further O
support O
an O
important O
role O
for O
CBF2 I-GENE
in O
mediating O
EBNA2 I-GENE
transactivation O
; O
they O
identify O
the O
hnRNP I-GENE
protein I-GENE
_RARE_ I-GENE
as O
a O
major I-GENE
component O
of O
CBF2 I-GENE
and O
are O
also O
the O
first O
evidence O
of O
a O
cis O
- I-GENE
acting O
sequence I-GENE
other O
than O
a O
CBF1 I-GENE
binding I-GENE
element I-GENE
that O
is O
able O
to O
confer O
responsiveness O
to O
EBNA2 I-GENE
. O

The O
genome O
of O
the O
human I-GENE
herpesvirus I-GENE
8 O
( O
_RARE_ I-GENE
- I-GENE
8 O
) O
contains O
a O
cluster I-GENE
of O
open O
reading O
frames O
( O
ORFs O
) O
encoding O
proteins I-GENE
with O
homology I-GENE
to O
the O
cellular O
transcription I-GENE
factors I-GENE
of O
the O
interferon I-GENE
regulatory I-GENE
factor I-GENE
( O
IRF I-GENE
) O
family I-GENE
. O

Despite O
these O
limitations O
the O
_RARE_ I-GENE
monitor O
provides O
an O
_RARE_ I-GENE
to O
record O
physiological O
data O
previously O
_RARE_ I-GENE
in O
the O
home O
. O

_RARE_ I-GENE
_RARE_ I-GENE
: O
_RARE_ I-GENE
ultrasound O
has O
been O
shown O
to O
improve O
upon O
demonstrated O
_RARE_ I-GENE
of O
coronary O
angiography O
. O

TB I-GENE
bone O
area O
( O
p O
< O
0 O
. O
001 O
), O
height O
( O
p O
< O
0 O
. O
01 O
), O
years O
in O
present O
colony I-GENE
( O
p O
= O
0 O
. O
03 O
), O
and O
_RARE_ I-GENE
( O
p O
< O
0 O
. O
01 O
) O
predicted O
TB I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
syndrome O
; O
a O
changing O
clinical O
significance O

_RARE_ I-GENE
also O
induced O
an O
endogenous I-GENE
PPARgamma I-GENE
target O
gene I-GENE
in O
_RARE_ I-GENE
cells O
, O
_RARE_ I-GENE
- I-GENE
type I-GENE
fatty I-GENE
acid I-GENE
binding I-GENE
protein I-GENE
( O
A I-GENE
- I-GENE
_RARE_ I-GENE
), O
the O
expression O
of O
which O
correlates O
with O
bladder O
cancer O
differentiation O
. O

_RARE_ I-GENE
were O
isolated O
from O
9 O
lungs O
: O
7 O
with O
PI I-GENE
- I-GENE
_RARE_ I-GENE
, O
1 I-GENE
with O
_RARE_ I-GENE
_RARE_ I-GENE
type I-GENE
1 I-GENE
, O
and O
1 I-GENE
with O
both O
_RARE_ I-GENE
- I-GENE
1 I-GENE
and O
_RARE_ I-GENE
. O

The O
_RARE_ I-GENE
human I-GENE
_RARE_ I-GENE
tandem O
repetitive O
sequence I-GENE
encodes O
a O
novel O
_RARE_ I-GENE
enzyme I-GENE
with O
a O
functional O
promoter I-GENE
. O

Previous O
experience O
and O
_RARE_ I-GENE
_RARE_ I-GENE
are O
essential O
elements O
in O
the O
generation O
of O
a O
_RARE_ I-GENE
prediction O
. O

To O
characterize O
this O
effect O
, O
we O
_RARE_ I-GENE
for O
targets O
of O
NS1 I-GENE
influenza I-GENE
virus I-GENE
protein I-GENE
among O
cellular O
translation I-GENE
factors I-GENE
. O

Collectively O
, O
these O
and O
previously O
published O
data O
suggest O
a O
model O
where O
NS1 I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
specifically O
to O
the O
5 I-GENE
' O
untranslated O
region O
( O
5 I-GENE
' O
UTR I-GENE
) O
of O
the O
viral I-GENE
mRNA I-GENE
, O
allowing O
for O
the O
preferential O
translation I-GENE
of O
the O
influenza I-GENE
virus I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
translation I-GENE
initiation I-GENE
factor I-GENE
_RARE_ I-GENE
is O
a O
cellular O
target O
for O
NS1 I-GENE
protein I-GENE
, O
a O
translational O
activator I-GENE
of O
influenza I-GENE
virus I-GENE
. O

_RARE_ I-GENE
of O
the O
K I-GENE
- I-GENE
_RARE_ I-GENE
alternative O
exon O
of O
the O
fibroblast I-GENE
growth I-GENE
factor I-GENE
receptor I-GENE
2 I-GENE
gene I-GENE
is O
_RARE_ I-GENE
dependent I-GENE
on O
the O
U O
- I-GENE
rich O
sequence I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
immediately O
downstream O
from O
its O
5 I-GENE
' O
splice O
site I-GENE
. O

( O
iii O
) O
In O
these O
cells O
, O
_RARE_ I-GENE
plays O
a O
unique O
Ras I-GENE
- I-GENE
independent O
role O
in O
mediating O
insulin I-GENE
but O
not O
EGF I-GENE
or O
other O
growth I-GENE
factor I-GENE
mitogenic O
signals O
. O

However O
, O
it O
is O
not O
known O
whether O
the O
recently O
identified O
isoforms I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
, O
which O
are O
broadly O
expressed O
, O
can O
_RARE_ I-GENE
with O
similar O
classes O
of O
receptors I-GENE
, O
nor O
is O
it O
known O
whether O
all O
_RARE_ I-GENE
isoforms I-GENE
possess O
identical O
functional O
activities O
. O

Transcriptional O
regulation O
of O
_RARE_ I-GENE
promoter I-GENE
constructs I-GENE
containing O
only O
UAS1 O
or O
_RARE_ I-GENE
_RARE_ I-GENE
that O
the O
PKA I-GENE
and O
MAPK I-GENE
regulation O
is O
targeted O
to O
both O
sites I-GENE
. O

X I-GENE
- I-GENE
ray O
_RARE_ I-GENE
data O
show O
that O
the O
PLZF I-GENE
BTB I-GENE
/ I-GENE
POZ I-GENE
domain I-GENE
forms O
an O
_RARE_ I-GENE
homodimer I-GENE
via O
an O
extensive O
interface O
. O

The O
ability O
of O
SMRT I-GENE
to O
associate O
with O
these O
transcription I-GENE
factors I-GENE
and O
thereby O
to O
mediate O
repression O
is O
strongly O
inhibited O
by O
activation O
of O
tyrosine I-GENE
kinase I-GENE
signaling O
pathways O
, O
such O
as O
that O
represented O
by O
the O
epidermal I-GENE
growth I-GENE
factor I-GENE
receptor I-GENE
. O

In O
addition O
, O
the O
_RARE_ I-GENE
- I-GENE
treated O
rats O
had O
more O
neurons O
and O
_RARE_ I-GENE
cells O
surrounding O
the O
ventricles O
. O

The O
differences O
were O
as O
follows O
: O
for O
overall O
response O
rate O
p O
= O
0 O
. O
_RARE_ I-GENE
; O
power O
( O
for O
p O
= O
0 O
. O
05 O
) O
85 O
%; O
for O
survival O
p O
= O
0 O
. O
09 O
; O
for O
grade O
IV I-GENE
_RARE_ I-GENE
p O
= O
0 O
. O
3 I-GENE
; O
and O
for O
_RARE_ I-GENE
neutropenia O
p O
= O
0 O
. O
61 O
. O

Patients O
were O
randomly O
assigned O
to O
treatment O
with O
the O
ACE I-GENE
inhibitor I-GENE
_RARE_ I-GENE
( O
and O
the O
diuretic O
_RARE_ I-GENE
for O
those O
with O
no O
definite O
indication O
for O
or O
_RARE_ I-GENE
to O
treatment O
with O
a O
diuretic O
) O
or O
_RARE_ I-GENE
placebo O
( O
s O
). O

The O
results O
indicate O
that O
the O
open O
- I-GENE
section O
effect O
decreases O
the O
_RARE_ I-GENE
stiffness O
and O
stress O
concentration O
effects O
decrease O
the O
_RARE_ I-GENE
strength O
of O
a O
long O
bone O
with O
a O
longitudinal O
defect O
. O

These O
regions O
may O
be O
differentially O
involved O
in O
tissue I-GENE
- I-GENE
specificity O
, O
and O
/ I-GENE
or O
circadian O
regulation O
, O
of O
the O
human I-GENE
_RARE_ I-GENE
gene I-GENE
transcription I-GENE
. O

Additionally O
, O
putative O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
transcription I-GENE
factor I-GENE
elements O
were O
found O
in O
the O
upstream O
regions O
of O
_RARE_ I-GENE
and O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
genes I-GENE
respectively O
. O

Sequence O
analysis O
reveals O
that O
the O
newly O
discovered O
_RARE_ I-GENE
gene I-GENE
represents O
a O
pseudogene I-GENE
that O
is O
still O
transcribed O
, O
but O
is O
not O
functionally O
translated O
. O

Genomic O
and O
functional O
characterization O
of O
the O
_RARE_ I-GENE
gene I-GENE
family I-GENE
encoding O
O O
- I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
_RARE_ I-GENE
, O
enzymes O
_RARE_ I-GENE
the O
final O
step O
in O
cysteine I-GENE
biosynthesis O
in O
Arabidopsis I-GENE
thaliana O
. O

Two O
distinct O
recessive O
susceptibility I-GENE
loci I-GENE
for O
vasculitis O
were O
mapped O
on O
chromosome O
( O
Chr O
) O
4 I-GENE
at O
_RARE_ I-GENE
and O
_RARE_ I-GENE
in O
both O
_RARE_ I-GENE
. O

During O
treatment O
, O
the O
phosphorylation O
state O
of O
Rb I-GENE
shifted O
to O
a O
_RARE_ I-GENE
form O
. O
mRNA I-GENE
for O
the O
HPV I-GENE
E6 I-GENE
/ I-GENE
E7 I-GENE
genes I-GENE
decreased O
; O
however O
, O
significant O
changes O
in O
the O
E7 I-GENE
protein I-GENE
were O
not O
observed O
, O
while O
increased O
levels O
of O
Rb I-GENE
immunoprecipitated O
with O
anti I-GENE
- I-GENE
E7 I-GENE
antibodies I-GENE
were O
observed O
. O

Further O
characterization O
of O
these O
putative O
_RARE_ I-GENE
- I-GENE
1 I-GENE
target O
genes I-GENE
will O
aid O
in O
_RARE_ I-GENE
the O
functions O
of O
the O
_RARE_ I-GENE
- I-GENE
1 I-GENE
protein I-GENE
in O
the O
differentiation O
processes O
which O
occur O
during O
embryogenesis O
. O

The O
ability O
of O
U6 I-GENE
- I-GENE
_RARE_ I-GENE
mutants I-GENE
to O
influence O
the O
fidelity I-GENE
of O
both O
branch O
site I-GENE
and O
3 I-GENE
' O
splice O
site I-GENE
recognition I-GENE
suggests O
that O
this O
nucleotide I-GENE
may O
participate O
in O
the O
formation O
of O
the O
active O
site I-GENE
( O
s O
) O
of O
the O
spliceosome O
. O

We O
have O
determined O
the O
structure O
of O
the O
_RARE_ I-GENE
- I-GENE
2B I-GENE
gene I-GENE
. O

The O
role O
of O
_RARE_ I-GENE
in O
induction O
therapy O
for O
adult O
acute O
myeloid O
leukemia I-GENE

Five O
of O
the O
_RARE_ I-GENE
strains O
and O
one O
of O
V I-GENE
cholerae I-GENE
non O
- I-GENE
_RARE_ I-GENE
were O
positive O
for O
enterotoxin I-GENE
activity O
. O

TNF I-GENE
- I-GENE
alpha I-GENE
induced O
a O
dose O
- I-GENE
and O
time O
- I-GENE
dependent I-GENE
increase O
in O
_RARE_ I-GENE
- I-GENE
2 I-GENE
( O
_RARE_ I-GENE
- I-GENE
2 I-GENE
) O
expression O
and O
PGE2 O
formation O
in O
human I-GENE
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
epithelial O
cells O
. O

The O
therapy O
time O
to O
_RARE_ I-GENE
the O
_RARE_ I-GENE
therapeutic O
dose O
of O
_RARE_ I-GENE
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
, O
is O
27 O
times O
longer O
when O
_RARE_ I-GENE
is O
used O
instead O
of O
_RARE_ I-GENE
. O

_RARE_ I-GENE
is O
needed O
for O
the O
formation O
of O
_RARE_ I-GENE
ribosome I-GENE
RNA I-GENE
, O
and O
may O
hence O
direct O
the O
level O
of O
proteins I-GENE
required O
for O
the O
coupling O
. O

_RARE_ I-GENE
_RARE_ I-GENE
For O
_RARE_ I-GENE
. O

CONCLUSION O
: O
_RARE_ I-GENE
for O
vitreous O
hemorrhage O
in O
_RARE_ I-GENE
syndrome O
is O
a O
safe O
and O
effective O
procedure O
, O
_RARE_ I-GENE
a O
rapid O
and O
prolonged O
improvement O
in O
vision O
. O

RNA I-GENE
in O
situ O
hybridization O
on O
brain O
sections O
of O
normal O
human I-GENE
embryos O
revealed O
a O
strong O
labeling O
in O
restricted O
areas O
of O
the O
cerebral O
cortex O
. O

To O
facilitate O
_RARE_ I-GENE
of O
large O
genomic O
sequences I-GENE
, O
we O
developed O
a O
method O
of O
converting I-GENE
Escherichia I-GENE
coli I-GENE
P1 I-GENE
artificial O
chromosomes O
( O
_RARE_ I-GENE
) O
into O
yeast I-GENE
artificial O
chromosomes O
( O
YACs O
). O

After O
gamma I-GENE
- I-GENE
irradiation O
, O
the O
majority O
of O
F9 O
cells O
undergo O
apoptosis O
implying O
that O
wt I-GENE
- I-GENE
p53 I-GENE
likely O
triggers O
pro I-GENE
- I-GENE
apoptotic O
gene I-GENE
expression O
in O
DNA I-GENE
damaged O
cells O
. O

_RARE_ I-GENE
with O
cyclophosphamide O
and O
granulocyte I-GENE
- I-GENE
colony I-GENE
stimulating I-GENE
factor I-GENE
was O
effective O
in O
terms O
of O
CD34 I-GENE
+ I-GENE
cell O
shift O
to O
peripheral O
blood O
and O
the O
good O
quality O
_RARE_ I-GENE
_RARE_ I-GENE
led O
to O
_RARE_ I-GENE
recovery O
after O
_RARE_ I-GENE
. O

This O
suggests O
that O
cardiovascular O
magnetic O
resonance O
is O
the O
preferred O
technique O
for O
volume O
and O
ejection O
fraction O
estimation O
in O
heart O
failure O
patients O
, O
because O
of O
its O
_RARE_ I-GENE
approach O
for O
non O
- I-GENE
_RARE_ I-GENE
ventricles O
and O
superior O
image O
quality O
. O

A I-GENE
degenerate O
DNA I-GENE
transposon I-GENE
, O
_RARE_ I-GENE
, O
was O
identified O
in O
the O
genomes O
of O
various O
wild I-GENE
- I-GENE
type I-GENE
strains O
of O
the O
filamentous I-GENE
fungus I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
. O

However O
, O
the O
presence O
of O
Tax I-GENE
I I-GENE
increased O
the O
extent O
and O
altered O
the O
profile O
of O
proteins I-GENE
binding I-GENE
TRE I-GENE
- I-GENE
2 I-GENE
in O
vivo O
. O

We O
have O
also O
identified O
a O
functional O
domain I-GENE
in O
the O
ORF I-GENE
50 O
protein I-GENE
, O
an O
immediate I-GENE
- I-GENE
early I-GENE
gene I-GENE
product I-GENE
that O
is O
mainly O
encoded I-GENE
by O
ORF I-GENE
50 O
. O

A I-GENE
2 I-GENE
. O
3 I-GENE
- I-GENE
kb O
full I-GENE
- I-GENE
length I-GENE
cDNA I-GENE
clone O
of O
an O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
gene I-GENE
was O
isolated O
from O
a O
liver O
cDNA I-GENE
library O
. O

_RARE_ I-GENE
- I-GENE
3 I-GENE
is O
a O
new O
_RARE_ I-GENE
protocol O
of O
natural O
speech O
in O
3 I-GENE
- I-GENE
year O
- I-GENE
old O
children O
. O

Once O
_RARE_ I-GENE
II I-GENE
is O
suspected O
, O
heparin O
( O
and O
low O
- I-GENE
molecular O
- I-GENE
weight O
_RARE_ I-GENE
) O
should O
be O
stopped O
immediately O
. O

The O
reduced O
efficiency O
in O
the O
glycosylase I-GENE
activity O
is O
also O
reflected O
in O
a O
reduced O
ability O
of O
_RARE_ I-GENE
_RARE_ I-GENE
to O
prevent O
DNA I-GENE
mutations O
in O
vivo O
. O

METHODS O
AND O
RESULTS O
: O
We O
_RARE_ I-GENE
compared O
the O
automated O
measurements O
of O
left O
ventricular O
ejection O
fraction O
( O
LVEF O
) O
and O
volumes O
from O
rest O
- I-GENE
injected O
gated O
_RARE_ I-GENE
99m O
( O
_RARE_ I-GENE
) O
perfusion O
SPECT O
with O
equilibrium O
_RARE_ I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
in O
62 O
patients O
and O
the O
assessment O
of O
regional O
function O
with O
echocardiography O
in O
22 O
patients O
. O

The O
2 I-GENE
cDNAs I-GENE
differed O
in O
the O
length I-GENE
of O
their O
respective O
3 I-GENE
' O
untranslated O
regions O
, O
of O
_RARE_ I-GENE
bp O
in O
Cp I-GENE
. O
_RARE_ I-GENE
and O
72 O
bp O
in O
Cp I-GENE
. O
_RARE_ I-GENE
, O
in O
both O
of O
which O
a O
putative O
polyadenylation O
signal I-GENE
was O
identified O
. O

This O
intracellular O
signaling O
, O
known O
as O
the O
_RARE_ I-GENE
protein I-GENE
response O
( O
_RARE_ I-GENE
), O
is O
mediated O
by O
the O
cis O
- I-GENE
acting O
ER I-GENE
stress O
response O
element I-GENE
( O
_RARE_ I-GENE
) O
in O
mammals O
. O

A I-GENE
Y I-GENE
. O
_RARE_ I-GENE
_RARE_ I-GENE
mutant I-GENE
was O
isolated O
that O
restored O
interaction O
with O
an O
_RARE_ I-GENE
mutant I-GENE
, O
suggesting O
that O
the O
interaction O
with O
_RARE_ I-GENE
could O
be O
nucleotide I-GENE
and O
/ I-GENE
or O
conformation O
dependent I-GENE
. O

We O
have O
carried O
out O
a O
_RARE_ I-GENE
and O
systematic O
mutagenesis O
of O
the O
_RARE_ I-GENE
N I-GENE
terminus O
to O
analyze O
its O
function O
. O

The O
_RARE_ I-GENE
of O
the O
essential O
N I-GENE
- I-GENE
terminal I-GENE
domain I-GENE
( O
_RARE_ I-GENE
) O
relative O
to O
the O
_RARE_ I-GENE
can O
be O
changed O
significantly O
without O
an O
apparent O
effect O
on O
_RARE_ I-GENE
function O
. O

The O
bases O
of O
this O
comparison O
are O
reviewed O
and O
discussed O
. O

In O
_RARE_ I-GENE
, O
_RARE_ I-GENE
is O
encoded I-GENE
as O
a O
fusion I-GENE
protein I-GENE
with O
_RARE_ I-GENE
, O
a O
member O
of O
the O
_RARE_ I-GENE
superfamily I-GENE
. O

Platelet I-GENE
counts O
and O
function O
as O
well O
as O
fibrinogen I-GENE
and O
von I-GENE
Willebrand I-GENE
factor I-GENE
( O
vWF I-GENE
) O
levels O
were O
determined O
in O
each O
sample O
. O

The O
manifestations O
often O
include O
a O
moderate O
thrombocytopenia O
and O
, O
less O
commonly O
, O
_RARE_ I-GENE
. O

A I-GENE
beta2 I-GENE
_RARE_ I-GENE
reporter I-GENE
construct I-GENE
in O
which O
the O
methylation O
- I-GENE
susceptible O
_RARE_ I-GENE
in O
the O
sense O
strand O
were O
replaced O
by O
_RARE_ I-GENE
displayed O
marked O
loss O
of O
activity O
in O
a O
_RARE_ I-GENE
chromatin O
- I-GENE
dependent I-GENE
manner O
. O

Non O
- I-GENE
_RARE_ I-GENE
AFP I-GENE
rate O
had O
increased O
from O
0 O
. O
9 O
in O
1997 O
to O
2 I-GENE
. O
8 O
in O
1998 O
. O

_RARE_ I-GENE
is O
connected O
with O
attention O
, O
working O
memory O
and O
_RARE_ I-GENE
. O

_RARE_ I-GENE
had O
a O
protective O
effect O
with O
0 O
. O
66 O
less O
risk O
( O
95 O
% O
CI O
0 O
. O
44 I-GENE
- I-GENE
0 O
. O
99 O
). O

_RARE_ I-GENE
the O
_RARE_ I-GENE
. O

The O
aim O
of O
our O
study O
was O
to O
evaluate O
the O
level O
of O
oxidative O
stress O
in O
healthy O
controls O
( O
CTL O
) O
compared O
with O
CRF I-GENE
and O
HD I-GENE
patients O
before O
( O
pre I-GENE
- I-GENE
HD I-GENE
) O
and O
after O
( O
post O
- I-GENE
HD I-GENE
) O
the O
dialysis O
session O
, O
carried O
out O
on O
a O
high O
_RARE_ I-GENE
_RARE_ I-GENE
membrane I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
plasma I-GENE
parameters O
such O
as O
vitamin O
E I-GENE
, O
_RARE_ I-GENE
and O
uric O
acid I-GENE
levels O
were O
also O
_RARE_ I-GENE
. O

Only O
two O
of O
27 O
_RARE_ I-GENE
( O
7 O
. O
4 I-GENE
%) O
with O
definite O
_RARE_ I-GENE
had O
been O
previously O
diagnosed O
and O
treated O
, O
and O
66 O
. O
7 O
% O
of O
the O
previously O
_RARE_ I-GENE
had O
IOP O
less O
than O
22 O
mmHg O
. O

Taken O
together O
, O
they O
_RARE_ I-GENE
the O
_RARE_ I-GENE
_RARE_ I-GENE
that O
women O
with O
ER I-GENE
(+) I-GENE
cancers O
may O
not O
benefit O
significantly O
from O
endocrine O
treatment O
if O
the O
tumors O
also O
_RARE_ I-GENE
_RARE_ I-GENE
- I-GENE
2 I-GENE
. O

Promoter O
activity O
was O
dose O
- I-GENE
dependently O
inhibited O
by O
cotransfection O
with O
either O
ras I-GENE
or O
mos I-GENE
oncogenes I-GENE
, O
but O
oncogene I-GENE
inhibition O
was O
reversed O
and O
the O
overall O
activity O
increased O
when O
cells O
were O
treated O
with O
the O
MAP I-GENE
kinase I-GENE
kinase I-GENE
( O
_RARE_ I-GENE
) O
inhibitor I-GENE
PD98059 O
. O

Our O
results O
indicate O
that O
the O
expression O
of O
_RARE_ I-GENE
, O
a O
gene I-GENE
associated I-GENE
with O
early I-GENE
development O
and O
cell O
transformation O
, O
is O
sensitive O
to O
_RARE_ I-GENE
levels O
and O
may O
be O
regulated O
via O
multiple O
transcription I-GENE
factor I-GENE
complexes I-GENE
. O

_RARE_ I-GENE
: O
_RARE_ I-GENE
tissue I-GENE
PO2 O
and O
PCO2 O
_RARE_ I-GENE
were O
measured O
directly O
in O
patients O
with O
_RARE_ I-GENE
_RARE_ I-GENE
and O
in O
healthy O
volunteers O
during O
_RARE_ I-GENE
and O
_RARE_ I-GENE
conditions O
. O

Because O
GH I-GENE
- I-GENE
induced O
Akt I-GENE
activation O
was O
completely O
inhibited O
in O
both O
cells O
by O
the O
same O
concentration O
of O
_RARE_ I-GENE
, O
these O
findings O
indicate O
that O
the O
wortmannin O
sensitivity O
of O
both O
the O
IRS I-GENE
- I-GENE
1 I-GENE
- I-GENE
independent O
and O
- I-GENE
dependent I-GENE
GH I-GENE
- I-GENE
induced O
MAP I-GENE
kinase I-GENE
activation O
may O
reflect O
the O
activity O
of O
another O
wortmannin O
- I-GENE
sensitive O
target O
( O
s O
) O
in O
addition O
to O
_RARE_ I-GENE
in O
_RARE_ I-GENE
of O
GH I-GENE
- I-GENE
induced O
MAP I-GENE
kinase I-GENE
activation O
in O
these O
cells O
. O

Insulin I-GENE
receptor I-GENE
substrate I-GENE
- I-GENE
1 I-GENE
- I-GENE
mediated O
enhancement O
of O
growth I-GENE
hormone I-GENE
- I-GENE
induced O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
activation O
. O

Functional O
magnetic O
resonance O
imaging O
( O
_RARE_ I-GENE
) O
has O
been O
_RARE_ I-GENE
used O
in O
studying O
human I-GENE
brain O
function O
given O
its O
non O
- I-GENE
invasive O
feature O
and O
good O
spatial O
resolution O
. O

After O
_RARE_ I-GENE
of O
the O
aorta O
, O
there O
were O
also O
severe O
edema O
, O
local O
fibre O
necrosis I-GENE
, O
and O
adhesion I-GENE
of O
_RARE_ I-GENE
, O
whereas O
muscle O
fibre O
areas O
became O
3 I-GENE
, O
_RARE_ I-GENE
. O
18 O
micro O
_RARE_ I-GENE
microm O
( O
2 I-GENE
) O
for O
type I-GENE
I I-GENE
and O
5 I-GENE
, O
_RARE_ I-GENE
+/- O
1 I-GENE
, O
_RARE_ I-GENE
microm O
( O
2 I-GENE
) O
for O
type I-GENE
II I-GENE
. O

The O
results O
indicate O
that O
the O
relationship O
between O
_RARE_ I-GENE
and O
production O
is O
different O
at O
different O
stages O
in O
development O
. O

It O
was O
found O
that O
increase O
in O
the O
RH O
level O
_RARE_ I-GENE
the O
current O
values O
by O
2 I-GENE
- I-GENE
3 I-GENE
_RARE_ I-GENE
of O
magnitude O
; O
_RARE_ I-GENE
, O
the O
voltage O
values O
rise O
by O
about O
three O
times O
with O
drop O
in O
the O
RH O
. O

On O
long O
- I-GENE
term O
follow O
- I-GENE
up O
, O
there O
was O
no O
significant O
difference O
in O
the O
incidence O
of O
_RARE_ I-GENE
( O
1 I-GENE
per O
2 I-GENE
. O
1 I-GENE
vs O
. O

Genomic O
libraries O
were O
stored O
as O
_RARE_ I-GENE
cultures O
in O
a O
96 O
- I-GENE
well O
_RARE_ I-GENE
, O
each O
well O
containing O
approximately O
300 O
- I-GENE
600 O
colonies O
( O
12 O
plates O
for O
small I-GENE
library O
, O
four O
for O
medium O
- I-GENE
size O
library O
and O
four O
for O
large O
library O
). O

In O
several O
cell O
lines O
, O
_RARE_ I-GENE
or O
its O
downstream O
targets O
can O
be O
regulated O
by O
phosphatidylinositol I-GENE
( O
PI I-GENE
) O
3 I-GENE
- I-GENE
kinase I-GENE
; O
protein I-GENE
kinases I-GENE
A I-GENE
, O
B I-GENE
, O
and O
C I-GENE
; O
heterotrimeric I-GENE
G I-GENE
- I-GENE
proteins I-GENE
; O
a O
PD98059 O
- I-GENE
sensitive O
kinase I-GENE
or O
calcium O
; O
as O
well O
as O
by O
amino O
acids O
. O

The O
tumor I-GENE
- I-GENE
suppressor I-GENE
protein I-GENE
p53 I-GENE
is O
involved O
in O
maintaining O
genomic O
stability O
. O

_RARE_ I-GENE
of O
p53 I-GENE
function O
by O
E6 I-GENE
resulted O
in O
an O
increase O
in O
the O
spontaneous O
mutation I-GENE
frequencies O
at O
the O
_RARE_ I-GENE
thymidine I-GENE
kinase I-GENE
( O
TK I-GENE
) O
locus I-GENE
but O
not O
at O
the O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
transferase I-GENE
( O
_RARE_ I-GENE
) O
locus I-GENE
. O

_RARE_ I-GENE
analysis O
of O
_RARE_ I-GENE
mutants I-GENE
by O
chromosome O
_RARE_ I-GENE
indicated O
a O
mosaic O
of O
chromosomal I-GENE
_RARE_ I-GENE
involving O
chromosome O
17 O
, O
in O
which O
partial O
chromosome O
deletions O
, O
_RARE_ I-GENE
, O
and O
multiple O
_RARE_ I-GENE
appeared O
_RARE_ I-GENE
in O
a O
single O
mutant I-GENE
. O

These O
results O
support O
a O
model O
in O
which O
p53 I-GENE
protein I-GENE
contributes O
to O
the O
maintenance O
of O
genomic O
integrity O
through O
_RARE_ I-GENE
repair I-GENE
. O

The O
importance O
of O
this O
new O
epidemiological O
profile O
of O
_RARE_ I-GENE
in O
the O
State O
of O
_RARE_ I-GENE
_RARE_ I-GENE
on O
the O
fact O
that O
it O
can O
be O
related I-GENE
with O
the O
_RARE_ I-GENE
human I-GENE
interference O
on O
the O
environment O
. O

In O
patients O
with O
type I-GENE
II I-GENE
tumors O
, O
the O
pattern O
of O
_RARE_ I-GENE
spread O
was O
primarily O
directed O
toward O
the O
_RARE_ I-GENE
, O
lesser O
_RARE_ I-GENE
, O
and O
left O
gastric O
artery O
nodes O
; O
_RARE_ I-GENE
offered O
no O
survival O
benefit O
over O
extended O
_RARE_ I-GENE
in O
these O
patients O
. O

RESULTS O
: O
No O
significant O
_RARE_ I-GENE
in O
vertebral O
artery O
flow O
was O
noted O
in O
the O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
Stage O
I I-GENE
injuries O
within O
the O
_RARE_ I-GENE
range O
of O
cervical O
_RARE_ I-GENE
. O

We O
screened O
a O
K562 O
cDNA I-GENE
library O
and O
identified O
novel O
transcripts I-GENE
, O
_RARE_ I-GENE
and O
_RARE_ I-GENE
. O

The O
human I-GENE
cDNA I-GENE
clone O
_RARE_ I-GENE
( O
previously O
designated O
_RARE_ I-GENE
) O
encodes O
a O
novel O
protein I-GENE
( O
_RARE_ I-GENE
amino O
acids O
in O
length I-GENE
; O
calculated O
molecular O
mass O
_RARE_ I-GENE
, O
440 O
D I-GENE
) O
with O
possible O
_RARE_ I-GENE
domains I-GENE
at O
its O
carboxy I-GENE
terminus O
( O
amino O
acid I-GENE
residues O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
). O

RESULTS O
: O
Neither O
basal O
FSH I-GENE
level O
nor O
stimulated O
FSH I-GENE
level O
alone O
were O
statistically O
significant O
predictors O
of O
_RARE_ I-GENE
success O
; O
however O
, O
no O
patient O
with O
a O
day O
3 I-GENE
FSH I-GENE
level O
> O
11 O
. O
1 I-GENE
_RARE_ I-GENE
/ I-GENE
ml O
or O
a O
stimulated O
day O
10 O
FSH I-GENE
level O
> O
13 O
. O
5 I-GENE
_RARE_ I-GENE
/ I-GENE
ml O
_RARE_ I-GENE
and O
carried O
a O
pregnancy O
. O

_RARE_ I-GENE
hormone I-GENE
regulation O
of O
bone O
_RARE_ I-GENE
( O
BSP I-GENE
) O
gene I-GENE
transcription I-GENE
is O
mediated O
through O
a O
pituitary I-GENE
- I-GENE
specific I-GENE
transcription I-GENE
factor I-GENE
- I-GENE
1 I-GENE
( O
Pit I-GENE
- I-GENE
1 I-GENE
) O
motif I-GENE
in O
the O
rat I-GENE
BSP I-GENE
gene I-GENE
promoter I-GENE
. O

Recent O
target O
BP I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
by O
the O
_RARE_ I-GENE
_RARE_ I-GENE
from O
the O
_RARE_ I-GENE
National O
Committee O
( O
_RARE_ I-GENE
VI I-GENE
) O
are O
based O
on O
the O
_RARE_ I-GENE
that O
the O
intensity O
of O
treatment O
directly O
corresponds O
to O
the O
magnitude O
of O
pretreatment O
risk O
. O

_RARE_ I-GENE
continuous O
community O
- I-GENE
based O
morbidity O
recording O
of O
influenza I-GENE
- I-GENE
like I-GENE
illness O
( O
_RARE_ I-GENE
) O
with O
_RARE_ I-GENE
sampling O
has O
consistently O
proved O
its O
value O
as O
one O
of O
the O
_RARE_ I-GENE
indicators O
of O
circulating O
influenza I-GENE
activity O
. O

The O
_RARE_ I-GENE
is O
a O
new O
host O
record O
for O
T I-GENE
. O
_RARE_ I-GENE
. O

These O
include O
_RARE_ I-GENE
repeats I-GENE
, O
a O
leucine I-GENE
heptad I-GENE
repeat I-GENE
enriched O
in O
charged O
residues O
, O
and O
a O
proline O
- I-GENE
rich O
SH3 I-GENE
- I-GENE
like I-GENE
and O
/ I-GENE
or O
_RARE_ I-GENE
domain I-GENE
- I-GENE
binding I-GENE
site I-GENE
in O
the O
N I-GENE
- I-GENE
terminal I-GENE
domain I-GENE
, O
which O
is O
followed O
by O
a O
membrane I-GENE
core I-GENE
containing O
four O
putative O
transmembrane I-GENE
spans O
and O
three O
_RARE_ I-GENE
segments O
that O
are O
the O
most O
highly O
conserved O
structural O
elements O
. O

We O
show O
here O
that O
this O
difference O
is O
due O
to O
the O
presence O
of O
a O
_RARE_ I-GENE
binding I-GENE
site I-GENE
in O
_RARE_ I-GENE
. O

The O
article O
_RARE_ I-GENE
with O
the O
_RARE_ I-GENE
and O
correction O
of O
reversible O
ischemia O
of O
the O
intestine O
. O

_RARE_ I-GENE
application O
of O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
, O
however O
, O
did O
not O
cause O
PD I-GENE
reduction O
and O
luminal O
H I-GENE
+ I-GENE
loss O
, O
but O
produced O
a O
marked O
_RARE_ I-GENE
, O
resulting O
in O
no O
damage O
in O
the O
stomach O
of O
both O
normal O
and O
_RARE_ I-GENE
- I-GENE
diabetic O
rats O
. O

Functional O
recognition I-GENE
of O
5 I-GENE
' O
splice O
site I-GENE
by O
U4 I-GENE
/ I-GENE
U6 I-GENE
. O
U5 I-GENE
_RARE_ I-GENE
- I-GENE
snRNP I-GENE
defines O
a O
novel O
ATP I-GENE
- I-GENE
dependent I-GENE
step O
in O
early I-GENE
spliceosome O
assembly O
. O

As O
control O
, O
the O
cells O
were O
transfected O
with O
DNA I-GENE
_RARE_ I-GENE
containing O
vector O
_RARE_ I-GENE
- I-GENE
C1 I-GENE
or O
_RARE_ I-GENE
- I-GENE
C2 I-GENE
. O

The O
amino O
acid I-GENE
sequence I-GENE
of O
_RARE_ I-GENE
- I-GENE
2 I-GENE
also O
contains O
a O
threonine I-GENE
residue O
adjacent O
to O
the O
Zn I-GENE
- I-GENE
binding I-GENE
site I-GENE
that O
has O
been O
defined O
as O
a O
specific I-GENE
feature O
of O
_RARE_ I-GENE
. O

In O
this O
regard O
, O
we O
have O
recently O
observed O
that O
a O
constitutively O
active O
G I-GENE
protein I-GENE
- I-GENE
coupled I-GENE
receptor I-GENE
( O
_RARE_ I-GENE
) O
encoded I-GENE
by O
the O
Kaposi O
' O
s O
sarcoma I-GENE
- I-GENE
associated I-GENE
herpes I-GENE
virus I-GENE
( O
KSHV I-GENE
)/ O
human I-GENE
herpes I-GENE
virus I-GENE
8 O
is O
oncogenic I-GENE
and O
stimulates O
angiogenesis O
by O
increasing O
the O
secretion O
of O
vascular I-GENE
endothelial I-GENE
growth I-GENE
factor I-GENE
( O
VEGF I-GENE
), O
which O
is O
a O
key O
_RARE_ I-GENE
_RARE_ I-GENE
and O
a O
critical O
mitogen I-GENE
for O
the O
development O
of O
Kaposi O
' O
s O
sarcoma I-GENE
. O

No O
specific I-GENE
subgroup O
of O
_RARE_ I-GENE
_RARE_ I-GENE
more O
from O
_RARE_ I-GENE
, O
although O
a O
prospective O
study O
employing O
random O
assignment O
might O
be O
more O
successful O
in O
identifying O
such O
a O
group O
. O

In O
the O
_RARE_ I-GENE
, O
23 O
% O
of O
the O
sites I-GENE
are O
occupied O
, O
95 O
% O
of O
the O
_RARE_ I-GENE
are O
in O
the O
lowest O
energy O
magnetic O
_RARE_ I-GENE
, O
and O
37 O
% O
are O
in O
the O
lowest O
_RARE_ I-GENE
_RARE_ I-GENE
state O
. O

_RARE_ I-GENE
vertical O
and O
horizontal O
one O
and O
a O
half O
syndromes O
. O

As O
in O
the O
other O
three O
members O
whose O
gene I-GENE
expression O
is O
altered O
during O
tumorigenesis O
, O
_RARE_ I-GENE
expression O
was O
found O
to O
be O
down O
- I-GENE
regulated O
in O
tumor I-GENE
brain O
tissues O
and O
in O
two O
brain O
cancer O
cell O
lines O
: O
U O
- I-GENE
87 O
_RARE_ I-GENE
and O
H4 I-GENE
. O

_RARE_ I-GENE
" O
the O
relation O
between O
sexual O
orientation O
and O
_RARE_ I-GENE
size O
," O
by O
A I-GENE
. O

This O
slope O
was O
further O
significantly O
decreased O
at O
5 I-GENE
min O
ischemia O
(- O
26 O
. O
5 I-GENE
+/- O
8 O
. O
8 O
microm O
/ I-GENE
mmHg O
) O
but O
returned O
toward O
control O
values O
in O
short O
- I-GENE
term O
_RARE_ I-GENE
myocardium O
at O
90 O
min O
ischemia O
(- O
17 O
. O
2 I-GENE
+/- O
6 I-GENE
. O
6 I-GENE
microm O
/ I-GENE
mmHg O
). O

Whereas O
both O
MAP I-GENE
and O
_RARE_ I-GENE
increase O
during O
_RARE_ I-GENE
, O
the O
transition O
from O
_RARE_ I-GENE
to O
_RARE_ I-GENE
is O
characterized O
by O
a O
transient O
reduction O
in O
MAP I-GENE
but O
sustained O
elevation O
in O
_RARE_ I-GENE
, O
facilitating O
separation O
of O
these O
factors I-GENE
in O
vivo O
. O

Analysis O
of O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
_RARE_ I-GENE
, O
gave O
a O
mean O
value O
of O
0 O
. O
95 O
+/- O
0 O
. O
_RARE_ I-GENE
mg O
vitamin O
K I-GENE
/ I-GENE
kg O
( O
K I-GENE
or O
K1 I-GENE
_RARE_ I-GENE
( O
n O
= O
31 O
) O
with O
a O
coefficient O
of O
variation O
of O
9 O
. O
26 O
. O

We O
have O
recently O
discovered O
that O
_RARE_ I-GENE
/ I-GENE
enhancer I-GENE
- I-GENE
binding I-GENE
protein I-GENE
- I-GENE
beta I-GENE
( O
C I-GENE
/ I-GENE
EBP I-GENE
- I-GENE
beta I-GENE
) O
induces O
gene I-GENE
transcription I-GENE
through O
a O
novel O
IFN I-GENE
response O
element I-GENE
called O
the O
gamma I-GENE
- I-GENE
IFN I-GENE
- I-GENE
activated I-GENE
transcriptional O
element I-GENE

Northern O
blot O
analysis O
demonstrated O
that O
the O
_RARE_ I-GENE
gene I-GENE
has O
a O
ubiquitous O
pattern O
of O
expression O
similar O
to O
that O
of O
the O
_RARE_ I-GENE
gene I-GENE
. O

In O
the O
_RARE_ I-GENE
patients O
the O
_RARE_ I-GENE
: O
Cr I-GENE
ratios O
were O
reduced O
in O
the O
seizure O
focus O
, O
while O
in O
the O
_RARE_ I-GENE
patients O
they O
were O
not O
always O
reduced O
in O
the O
seizure O
focus O
. O

The O
_RARE_ I-GENE
residues O
making O
up O
the O
hydrophobic O
patch O
are O
very O
similar O
in O
all O
response O
regulators O
suggesting O
that O
the O
binding I-GENE
is O
initiated O
through O
the O
same O
residues O
in O
all O
interacting I-GENE
response O
regulator I-GENE
- I-GENE
kinase I-GENE
pairs O
. O

The O
_RARE_ I-GENE
factors I-GENE
associated I-GENE
_RARE_ I-GENE
serious O
illness O
, O
terminal I-GENE
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
_RARE_ I-GENE
the O
_RARE_ I-GENE
even O
more O
as O
compared O
with O
that O
of O
_RARE_ I-GENE
pain O
. O

However O
, O
if O
the O
spatial O
resolution O
is O
not O
critical O
and O
interest O
is O
to O
compare O
a O
pathologic O
area O
with O
a O
contralateral O
_RARE_ I-GENE
, O
then O
the O
acquisition O
of O
two O
single O
- I-GENE
_RARE_ I-GENE
spectra O
may O
be O
preferred O
. O

Quantitative O
evaluation O
of O
_RARE_ I-GENE
- I-GENE
optical O
parameters O
is O
necessary O
in O
order O
to O
_RARE_ I-GENE
scanning O
near O
- I-GENE
field O
optical O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
technology O
to O
the O
study O
of O
_RARE_ I-GENE
on O
the O
_RARE_ I-GENE
scale O
. O

We O
found O
that O
the O
amplitude O
of O
the O
cortical O
evoked O
potentials O
( O
amplitude O
of O
the O
N2 O
/ I-GENE
P2 I-GENE
peak O
) O
increased O
from O
5 I-GENE
. O
1 I-GENE
+/- O
0 O
. O
7 O
_RARE_ I-GENE
at O
5 I-GENE
_RARE_ I-GENE
to O
16 O
. O
3 I-GENE
+/- O
1 I-GENE
. O
1 I-GENE
_RARE_ I-GENE
at O
20 O
_RARE_ I-GENE
. O

While O
mutations O
in O
K I-GENE
- I-GENE
Rev I-GENE
that O
_RARE_ I-GENE
any O
one O
of O
these O
properties O
also O
blocked O
K I-GENE
- I-GENE
Rev I-GENE
- I-GENE
dependent I-GENE
nuclear I-GENE
RNA I-GENE
export O
, O
several O
K I-GENE
- I-GENE
Rev I-GENE
mutants I-GENE
were O
comparable O
to O
wild I-GENE
type I-GENE
when O
assayed O
for O
any O
of O
these O
individual O
activities O
yet O
_RARE_ I-GENE
defective O
for O
RNA I-GENE
export O
. O

LMP I-GENE
- I-GENE
1 I-GENE
is O
targeted O
to O
the O
plasma I-GENE
membrane I-GENE
, O
where O
it O
binds O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
molecules I-GENE
to O
activate O
NF I-GENE
- I-GENE
kappaB I-GENE
-, I-GENE
AP I-GENE
- I-GENE
1 I-GENE
-, I-GENE
and O
STAT I-GENE
- I-GENE
dependent I-GENE
pathways O
as O
does O
CD40 I-GENE
. O

Identification O
of O
an O
enhancer I-GENE
and O
an O
alternative O
promoter I-GENE
in O
the O
first O
intron O
of O
the O
alpha I-GENE
- I-GENE
fetoprotein I-GENE
gene I-GENE
. O

_RARE_ I-GENE
intracellular O
signaling O
pathways O
, O
which O
may O
be O
involved O
in O
malignant O
transformation O
of O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
expressing O
NIH3T3 O
cells O
, O
we O
could O
demonstrate O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
dependent I-GENE
phosphorylation O
of O
insulin I-GENE
receptor I-GENE
substrate I-GENE
- I-GENE
2 I-GENE
( O
IRS I-GENE
- I-GENE
2 I-GENE
) O
with O
consecutive O
activation O
of O
phosphatidylinositol I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
( O
PI I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
) O
and O
protein I-GENE
kinase I-GENE
B I-GENE
( O
PKB I-GENE
/ I-GENE
_RARE_ I-GENE
). O

METHODS O
: O
In O
the O
current O
study O
the O
authors O
reported O
on O
_RARE_ I-GENE
cases O
from O
a O
national O
retrospective O
search O
performed O
in O
18 O
Italian O
_RARE_ I-GENE
for O
_RARE_ I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
centers O
. O

_RARE_ I-GENE
analysis O
showed O
that O
the O
_RARE_ I-GENE
isolates O
from O
_RARE_ I-GENE
constitute O
a O
group O
of O
viruses O
separated O
from O
those O
of O
Northern O
_RARE_ I-GENE
. O

_RARE_ I-GENE
the O
_RARE_ I-GENE
- I-GENE
binding I-GENE
motif I-GENE
_RARE_ I-GENE
in O
the O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
subunit I-GENE
of O
_RARE_ I-GENE
to O
_RARE_ I-GENE
led O
to O
both O
synthetic O
phenotypes O
in O
certain O
_RARE_ I-GENE
_RARE_ I-GENE
double O
mutants I-GENE
and O
a O
reduced O
ability O
of O
_RARE_ I-GENE
to O
activate O
transcription I-GENE
when O
it O
is O
artificially O
_RARE_ I-GENE
to O
a O
promoter I-GENE
. O

These O
results O
suggest O
that O
_RARE_ I-GENE
is O
in O
fact O
required O
for O
pheromone O
response O
and O
that O
interaction O
with O
the O
_RARE_ I-GENE
_RARE_ I-GENE
is O
critical O
for O
that O
role O
. O

Deletion O
of O
an O
intergenic O
DNA I-GENE
- I-GENE
binding I-GENE
site I-GENE
for O
this O
complex I-GENE
from O
a O
human I-GENE
beta I-GENE
- I-GENE
globin I-GENE
locus I-GENE
construct I-GENE
results O
in O
delayed O
human I-GENE
gamma I-GENE
- I-GENE
to O
beta I-GENE
- I-GENE
globin I-GENE
switching O
in O
transgenic O
mice O
, O
suggesting O
that O
the O
_RARE_ I-GENE
complex I-GENE
acts O
to O
facilitate O
the O
switch O
. O

The O
product I-GENE
of O
rat I-GENE
gene I-GENE
33 O
was O
identified O
as O
an O
ErbB I-GENE
- I-GENE
2 I-GENE
- I-GENE
interacting I-GENE
protein I-GENE
in O
a O
two O
- I-GENE
hybrid O
screen O
employing O
the O
ErbB I-GENE
- I-GENE
2 I-GENE
juxtamembrane I-GENE
and O
kinase I-GENE
domains I-GENE
as O
_RARE_ I-GENE
. O

Studies O
suggest O
that O
the O
_RARE_ I-GENE
without O
acid I-GENE
reflux O
may O
result O
in O
symptoms O
but O
unless O
acid I-GENE
reflux O
is O
present O
simultaneously O
, O
it O
does O
not O
cause O
_RARE_ I-GENE
. O

_RARE_ I-GENE
, O
however O
, O
appear O
to O
correlate O
poorly O
with O
_RARE_ I-GENE
; O
hence O
, O
severe O
symptoms O
do O
not O
indicate O
there O
is O
greater O
_RARE_ I-GENE
damage O
. O

OBJECTIVE O
: O
To O
evaluate O
the O
relationship O
between O
blood O
flow O
in O
the O
tumor I-GENE
assessed O
by O
color O
Doppler O
ultrasound O
, O
_RARE_ I-GENE
density I-GENE
, O
and O
vascular I-GENE
endothelial I-GENE
growth I-GENE
factor I-GENE
levels O
in O
endometrial O
carcinoma O
. O

These O
results O
demonstrate O
Ras I-GENE
- I-GENE
and O
Raf I-GENE
- I-GENE
independent O
ERK I-GENE
MAPK I-GENE
activation O
maintains O
cell O
viability O
following O
heat I-GENE
shock I-GENE
. O

Three O
cDNAs I-GENE
encoding O
basic I-GENE
leucine I-GENE
zipper I-GENE
( O
bZIP I-GENE
)- I-GENE
type I-GENE
_RARE_ I-GENE
- I-GENE
binding I-GENE
proteins I-GENE
were O
isolated O
by O
using O
the O
yeast I-GENE
one O
- I-GENE
hybrid O
system O
and O
were O
designated O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
( O
ABA I-GENE
- I-GENE
responsive I-GENE
element I-GENE
binding I-GENE
protein I-GENE
). O

Recombinant I-GENE
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
displayed O
high O
binding I-GENE
to O
single O
- I-GENE
stranded I-GENE
DNA I-GENE
and O
poly O
( O
A I-GENE
) O
_RARE_ I-GENE
suggesting O
that O
this O
protein I-GENE
could O
play O
a O
role O
in O
mRNA I-GENE
maturation O
/ I-GENE
metabolism O
. O

The O
protein I-GENE
- I-GENE
tyrosine I-GENE
kinase I-GENE
_RARE_ I-GENE
associates O
with O
signaling O
complexes I-GENE
containing O
insulin I-GENE
receptor I-GENE
substrate I-GENE
- I-GENE
1 I-GENE
and O
phosphatidylinositol I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
. O

The O
variable O
phenotype O
of O
the O
_RARE_ I-GENE
could O
not O
be O
explained O
by O
_RARE_ I-GENE
abnormalities O
. O

In O
the O
_RARE_ I-GENE
target O
area O
but O
not O
in O
the O
_RARE_ I-GENE
area O
an O
improvement O
in O
regional O
myocardial O
flow O
reserve O
occurs O
in O
wall O
segments O
with O
initially O
severely O
or O
moderately O
reduced O
stress O
perfusion O
. O

Analysis O
of O
intron O
/ I-GENE
exon O
boundaries O
of O
the O
genomic O
_RARE_ I-GENE
clones O
demonstrate O
that O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
beta I-GENE
- I-GENE
hydroxylase I-GENE
result O
from O
alternative O
splicing O
of O
the O
same O
gene I-GENE
. O

It O
is O
now O
estimated O
that O
inactivation O
mutants I-GENE
of O
_RARE_ I-GENE
exist O
in O
60 O
% O
of O
all O
forms O
of O
solid O
tumors O
. O

We O
have O
demonstrated O
that O
the O
activity O
of O
ILK I-GENE
is O
constitutively O
elevated O
in O
_RARE_ I-GENE
mutant I-GENE
cells O
. O

The O
growth I-GENE
factor I-GENE
receptor I-GENE
- I-GENE
bound O
protein I-GENE
2 I-GENE
( O
Grb2 I-GENE
) O
adaptor I-GENE
when O
complexed O
with O
Sos I-GENE
( O
_RARE_ I-GENE
of O
_RARE_ I-GENE
), O
the O
exchange I-GENE
factor I-GENE
of O
Ras I-GENE
, O
_RARE_ I-GENE
the O
signal I-GENE
induced O
by O
tyrosine I-GENE
kinase I-GENE
- I-GENE
activated I-GENE
receptor I-GENE
to O
Ras I-GENE
by O
_RARE_ I-GENE
Sos I-GENE
to O
the O
membrane I-GENE
, O
allowing O
activation O
of O
Ras I-GENE
. O

Mutations O
in O
genes I-GENE
encoding O
_RARE_ I-GENE
/ I-GENE
A I-GENE
subunits I-GENE
have O
been O
identified O
in O
several O
different O
human I-GENE
cancers O
and O
the O
PP2A I-GENE
inhibitor I-GENE
, O
termed O
_RARE_ I-GENE
, O
is O
being O
tested O
as O
an O
_RARE_ I-GENE
drug O
. O

For O
this O
purpose O
, O
a O
segment O
of O
_RARE_ I-GENE
was O
amplified O
from O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
- I-GENE
1 I-GENE
DNA I-GENE
via O
PCR O
using O
oligonucleotides O
for O
conserved O
regions O
. O

_RARE_ I-GENE
learning O
for O
a O
pattern O
discrimination O
task O
. O

The O
detector O
has O
the O
advantage O
of O
finding O
both O
ST O
segment O
_RARE_ I-GENE
and O
entire O
ST O
- I-GENE
T I-GENE
complex I-GENE
changes O
thereby O
providing O
a O
_RARE_ I-GENE
characterization O
of O
the O
potential O
ischemic O
events O
. O

While O
this O
Saccharomyces I-GENE
cerevisiae I-GENE
_RARE_ I-GENE
gene I-GENE
product I-GENE
is O
a O
component O
of O
a O
_RARE_ I-GENE
complex I-GENE
associated I-GENE
with O
RNA I-GENE
polymerase I-GENE
II I-GENE
, O
various O
studies O
suggest O
the O
involvement O
of O
_RARE_ I-GENE
in O
the O
alteration O
of O
higher O
- I-GENE
order O
chromatin O
structure O
. O

Primary O
adrenal O
hypersensitivity O
to O
ACTH I-GENE
drive O
in O
obesity O
has O
also O
been O
suggested O
. O

In O
addition O
, O
a O
_RARE_ I-GENE
C I-GENE
/ I-GENE
EBP I-GENE
- I-GENE
binding I-GENE
site I-GENE
within O
the O
_RARE_ I-GENE
promoter I-GENE
where O
C I-GENE
/ I-GENE
EBPbeta I-GENE
and O
C I-GENE
/ I-GENE
_RARE_ I-GENE
could O
bind O
, O
was O
identified O
by O
electrophoretic O
mobility I-GENE
shift O
assay O
( O
EMSA O
) O
and O
reporter I-GENE
gene I-GENE
analysis O
. O

Src I-GENE
activation O
induced O
by O
_RARE_ I-GENE
was O
blocked O
by O
the O
SH2 I-GENE
domain I-GENE
of O
Src I-GENE
and O
_RARE_ I-GENE
, O
a O
specific I-GENE
inhibitor I-GENE
of O
Src I-GENE
. O

The O
use O
of O
the O
_RARE_ I-GENE
inhibitory I-GENE
peptide I-GENE
, O
neomycin I-GENE
and O
the O
calcium O
_RARE_ I-GENE
_RARE_ I-GENE
- I-GENE
AM I-GENE
on O
oocytes O
expressing O
_RARE_ I-GENE
or O
the O
stimulation O
by O
PDGF I-GENE
- I-GENE
BB I-GENE
of O
oocytes O
expressing O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
mutated O
on O
the O
_RARE_ I-GENE
binding I-GENE
site I-GENE
, O
prevented O
_RARE_ I-GENE
and O
ERK2 I-GENE
phosphorylation O
. O

Multiple O
transcription I-GENE
start O
sites I-GENE
were O
revealed O
by O
primer O
extension O
analysis O
of O
the O
mouse I-GENE
gene I-GENE
, O
and O
transfection O
constructs I-GENE
containing O
the O
prospective O
promoter I-GENE
generated O
transcriptional O
activity O
comparable O
to O
that O
of O
the O
SV40 I-GENE
promoter I-GENE
. O

From O
two O
inhibitor I-GENE
_RARE_ I-GENE
, O
we O
have O
identified O
potent O
and O
selective O
inhibitors O
for O
_RARE_ I-GENE
kinases I-GENE
from O
five O
distinct O
_RARE_ I-GENE
. O

To O
determine O
whether O
interaction O
of O
_RARE_ I-GENE
with O
the O
hormone I-GENE
- I-GENE
binding I-GENE
domain I-GENE
results O
in O
receptor I-GENE
activation O
, O
COS O
- I-GENE
1 I-GENE
cells O
were O
transiently O
cotransfected O
with O
the O
chimeric I-GENE
receptors I-GENE
_RARE_ I-GENE
- I-GENE
ER I-GENE
, O
which O
contains O
the O
hormone I-GENE
- I-GENE
binding I-GENE
domain I-GENE
of O
_RARE_ I-GENE
and O
the O
DNA I-GENE
- I-GENE
binding I-GENE
domain I-GENE
of O
the O
transcription I-GENE
factor I-GENE
GAL4 I-GENE
, O
and O
a O
GAL4 I-GENE
- I-GENE
responsive I-GENE
CAT I-GENE
reporter I-GENE
gene I-GENE
. O

By O
progressive O
5 I-GENE
'- O
deletion O
studies O
, O
we O
have O
identified O
a O
_RARE_ I-GENE
- I-GENE
bp O
DNA I-GENE
fragment I-GENE
(- O
_RARE_ I-GENE
to O
- I-GENE
_RARE_ I-GENE
, O
relative O
to O
the O
translation I-GENE
start O
site I-GENE
) O
at O
the O
5 I-GENE
'- O
flanking O
region O
of O
the O
human I-GENE
_RARE_ I-GENE
gene I-GENE
that O
is O
responsible O
for O
the O
_RARE_ I-GENE
- I-GENE
mediated O
down O
- I-GENE
regulation O
of O
human I-GENE
_RARE_ I-GENE
promoter I-GENE
activity O
. O

The O
mean O
day O
of O
diagnosis O
of O
_RARE_ I-GENE
_RARE_ I-GENE
was O
3 I-GENE
+/- O
2 I-GENE
days O
( O
range O
1 I-GENE
- I-GENE
11 O
days O
), O
and O
of O
cystic I-GENE
_RARE_ I-GENE
21 O
+/- O
8 O
days O
( O
range O
2 I-GENE
- I-GENE
47 O
days O
). O

The O
_RARE_ I-GENE
protein I-GENE
kinase I-GENE
encoded I-GENE
by O
the O
_RARE_ I-GENE
locus I-GENE
of O
Drosophila I-GENE
is O
required O
in O
both O
somatic O
and O
germline I-GENE
cells O
and O
is O
expressed O
as O
both O
nuclear I-GENE
and O
cytoplasmic I-GENE
isoforms I-GENE
throughout O
development O
. O

We O
have O
mutated O
to O
cysteine I-GENE
, O
one O
at O
a O
time O
, O
21 O
consecutive O
residues O
in O
the O
fourth O
_RARE_ I-GENE
( O
_RARE_ I-GENE
). O

( O
1995 O
) O
J O
. O

_RARE_ I-GENE
: O
The O
aim O
of O
this O
study O
was O
to O
investigate O
the O
oxidative O
susceptibility I-GENE
of O
apolipoprotein I-GENE
B I-GENE
- I-GENE
containing O
lipoproteins I-GENE
and O
antioxidant O
status O
in O
patients O
with O
acute O
coronary O
syndromes O
and O
chronic O
stable O
angina O
pectoris O
. O

In O
group O
B I-GENE
37 O
MBq O
in O
150 O
_RARE_ I-GENE
of O
99mTc O
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
was O
additionally O
injected O
_RARE_ I-GENE
18 O
h O
before O
surgery O
( O
3 I-GENE
- I-GENE
6 I-GENE
_RARE_ I-GENE
injected O
_RARE_ I-GENE
). O

Post O
- I-GENE
operative O
functional O
outcome O
is O
related I-GENE
to O
pre I-GENE
- I-GENE
operative O
functional O
status O
. O

We O
cloned O
a O
DNA I-GENE
fragment I-GENE
encoding O
the O
N I-GENE
- I-GENE
terminal I-GENE
part O
of O
a O
protein I-GENE
with O
significant O
similarity O
to O
members O
of O
the O
_RARE_ I-GENE
family I-GENE
of O
transcriptional O
regulators O
( O
_RARE_ I-GENE
). O

_RARE_ I-GENE
is O
similar O
to O
_RARE_ I-GENE
- I-GENE
2 I-GENE
required O
for O
_RARE_ I-GENE
and O
_RARE_ I-GENE
- I-GENE
1 I-GENE
required O
for O
_RARE_ I-GENE
. O

_RARE_ I-GENE
localization O
studies O
using O
the O
_RARE_ I-GENE
- I-GENE
3 I-GENE
/ I-GENE
_RARE_ I-GENE
fusion I-GENE
protein I-GENE
, O
cell O
fractionation O
and O
protease I-GENE
protection O
experiments O
localized O
_RARE_ I-GENE
- I-GENE
3 I-GENE
to O
the O
mitochondrial I-GENE
matrix I-GENE
. O

We O
could O
demonstrate O
the O
involvement O
of O
cAMP I-GENE
- I-GENE
dependent I-GENE
protein I-GENE
kinase I-GENE
( O
PKA I-GENE
) O
in O
the O
phosphorylation O
of O
_RARE_ I-GENE
in O
fibroblasts O
overexpressing O
this O
_RARE_ I-GENE
as O
well O
as O
in O
mouse I-GENE
brain O
_RARE_ I-GENE
membranes O
. O

_RARE_ I-GENE
gene I-GENE
expression O
analyses O
indicate O
that O
both O
_RARE_ I-GENE
promoters I-GENE
show O
high O
levels O
of O
expression O
in O
different O
hematopoietic I-GENE
cell O
lines O
. O

We O
find O
that O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
has O
a O
pronounced O
effect O
on O
the O
line O
shape O
and O
_RARE_ I-GENE
decay O
rate O
of O
emission O
from O
the O
_RARE_ I-GENE
state O
and O
that O
the O
extent O
of O
_RARE_ I-GENE
depends O
_RARE_ I-GENE
on O
the O
magnitude O
of O
_RARE_ I-GENE
_RARE_ I-GENE
. O

A I-GENE
total O
of O
_RARE_ I-GENE
1 I-GENE
- I-GENE
day O
- I-GENE
old O
_RARE_ I-GENE
_RARE_ I-GENE
chicks O
were O
_RARE_ I-GENE
in O
six O
treatment O
groups O
[ O
six O
_RARE_ I-GENE
of O
16 O
each O
; O
control O
, O
_RARE_ I-GENE
( O
15 O
g O
kg O
(- O
1 I-GENE
) O
diet O
), O
50 O
parts O
per O
_RARE_ I-GENE
( O
ppb O
) O
AF I-GENE
, O
50 O
ppb O
AF I-GENE
plus O
_RARE_ I-GENE
, O
100 O
ppb O
AF I-GENE
, O
100 O
ppb O
AF I-GENE
plus O
_RARE_ I-GENE
] O
for O
42 O
days O
. O

The O
cost O
per O
test O
is O
less O
than O
those O
for O
CC O
, O
_RARE_ I-GENE
and O
_RARE_ I-GENE
. O

Altogether O
these O
results O
suggest O
that O
, O
in O
_RARE_ I-GENE
cells O
, O
_RARE_ I-GENE
can O
stimulate O
in O
parallel O
PC I-GENE
- I-GENE
PLC I-GENE
and O
_RARE_ I-GENE
, O
whose O
lipid O
products I-GENE
activate O
in O
turn I-GENE
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
( O
MAP I-GENE
kinase I-GENE
) O
and O
NF I-GENE
- I-GENE
kappaB I-GENE
signalling O
respectively O
. O

_RARE_ I-GENE
, O
we O
monitored O
_RARE_ I-GENE
conditions O
and O
used O
time O
- I-GENE
activity O
_RARE_ I-GENE
data O
of O
free O
- I-GENE
living O
birds O
and O
laboratory O
data O
on O
resting O
metabolic O
rate O
to O
construct I-GENE
time O
- I-GENE
activity O
laboratory O
( O
_RARE_ I-GENE
) O
estimates O
of O
daily O
energy O
expenditure O
( O
_RARE_ I-GENE
) O
and O
to O
_RARE_ I-GENE
the O
_RARE_ I-GENE
' O
energy O
_RARE_ I-GENE
into O
_RARE_ I-GENE
, O
activity O
and O
basal O
components O
. O

L I-GENE
/ I-GENE
H I-GENE
> O
0 O
. O
61 O
( O
_RARE_ I-GENE
( O
2 I-GENE
_RARE_ I-GENE
10 O
. O
8 O
; O
P I-GENE
_RARE_ I-GENE
0 O
. O
001 O
) O
and O
a O
restrictive O
filling O
pattern O
( O
_RARE_ I-GENE
( O
2 I-GENE
_RARE_ I-GENE
3 I-GENE
. O
6 I-GENE
; O
P I-GENE
_RARE_ I-GENE
0 O
. O
05 O
) O
were O
independent O
predictors O
of O
events O
. O

The O
high O
selectivity O
of O
_RARE_ I-GENE
for O
this O
particular O
functional O
form O
of O
receptor I-GENE
_RARE_ I-GENE
their O
_RARE_ I-GENE
binding I-GENE
and O
dissociation O
. O

When O
cotransfected O
in O
fibroblasts O
with O
a O
C I-GENE
/ I-GENE
EBP I-GENE
alpha I-GENE
expression O
vector O
, O
reporter I-GENE
gene I-GENE
expression O
increased O
3 I-GENE
- I-GENE
fold O
only O
in O
the O
wild I-GENE
- I-GENE
type I-GENE
constructs I-GENE
. O

Expression O
of O
a O
dominant I-GENE
negative O
_RARE_ I-GENE
significantly O
reduces O
the O
level O
of O
luciferase I-GENE
reporter I-GENE
activity O
induced O
by O
nodal O
treatment O
. O

_RARE_ I-GENE
alpha1 I-GENE
( O
I I-GENE
) O
collagen I-GENE
mRNA I-GENE
showed O
no O
significant O
reduction O
when O
AR I-GENE
or O
IR I-GENE
was O
expressed O
from O
the O
_RARE_ I-GENE
- I-GENE
1 I-GENE
- I-GENE
neo I-GENE
vector O
and O
a O
small I-GENE
( O
10 O
- I-GENE
20 O
%) O
but O
significant O
reduction O
when O
either O
_RARE_ I-GENE
was O
expressed O
from O
the O
_RARE_ I-GENE
. O
neo I-GENE
vector O
. O

_RARE_ I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
) O
that O
the O
amino O
acid I-GENE
sequences I-GENE
of O
peptide I-GENE
fragments I-GENE
obtained O
from O
a O
polypeptide I-GENE
found O
in O
a O
complex I-GENE
of O
proteins I-GENE
that O
alters O
chromatin O
structure O
( O
ARC I-GENE
) O
are O
identical O
to O
portions O
of O
the O
deduced O
open O
reading O
frame O
of O
_RARE_ I-GENE
- I-GENE
1 I-GENE
mRNA I-GENE
. O

_RARE_ I-GENE
of O
plasma I-GENE
_RARE_ I-GENE
were O
observed O
only O
in O
patients O
with O
delayed O
gastric O
emptying O
. O

5 I-GENE
( O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
) O
were O
determined O
using O
liquid O
chromatography O
/ I-GENE
mass O
spectrometry O
( O
_RARE_ I-GENE
/ I-GENE
MS O
) O
with O
_RARE_ I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
and O
_RARE_ I-GENE
ribosome I-GENE
fractions O
were O
severely O
decreased O
in O
the O
_RARE_ I-GENE
mutant I-GENE
and O
_RARE_ I-GENE
- I-GENE
depleted O
cells O
. O

They O
also O
negatively O
modulate O
the O
PI I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
catalytic O
activity O
but O
to O
different O
_RARE_ I-GENE
, O
dependent I-GENE
on O
the O
unique O
N I-GENE
- I-GENE
terminal I-GENE
structure O
of O
each O
isoform I-GENE
. O

_RARE_ I-GENE
kinase I-GENE
II I-GENE
induces O
in O
vivo O
phosphorylation O
of O
_RARE_ I-GENE
and O
_RARE_ I-GENE
and O
, O
to O
a O
lesser O
extent O
, O
_RARE_ I-GENE
. O

The O
Drosophila I-GENE
melanogaster I-GENE
suppressor I-GENE
of O
_RARE_ I-GENE
gene I-GENE
, O
_RARE_ I-GENE
( O
s O
), O
encodes O
a O
novel O
, O
150 O
- I-GENE
kDa I-GENE
nuclear I-GENE
RNA I-GENE
binding I-GENE
protein I-GENE
, O
SU I-GENE
( O
S I-GENE
), O
that O
negatively O
regulates O
RNA I-GENE
accumulation O
from O
mutant I-GENE
alleles I-GENE
of O
other O
genes I-GENE
that O
have O
transposon I-GENE
insertions O
in O
the O
5 I-GENE
' O
transcribed O
region O
. O

As O
a O
result O
, O
we O
have O
defined O
two O
arginine I-GENE
- I-GENE
rich O
motifs O
( O
_RARE_ I-GENE
and O
_RARE_ I-GENE
) O
that O
mediate O
the O
RNA I-GENE
binding I-GENE
activity O
of O
SU I-GENE
( O
S I-GENE
). O

This O
interaction O
inhibits O
the O
histone I-GENE
acetyltransferase I-GENE
activity O
of O
p300 I-GENE
, O
resulting O
in O
_RARE_ I-GENE
reduction O
of O
_RARE_ I-GENE
histone I-GENE
acetylation O
and O
alteration O
of O
chromatin O
structure O
. O

Recombinant I-GENE
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
on O
serine I-GENE
( O
Ser O
) O
and O
threonine I-GENE
( O
Thr I-GENE
) O
residues O
with O
p O
- I-GENE
Ser O
_RARE_ I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
was O
used O
for O
cell O
cycle O
analysis O
. O

Further O
research O
is O
required O
to O
better O
measure O
treatment O
effects O
, O
modification O
of O
MS O
natural O
history O
, O
and O
_RARE_ I-GENE
_RARE_ I-GENE
costs O
of O
IFN I-GENE
beta I-GENE
- I-GENE
1b I-GENE
in O
_RARE_ I-GENE
. O

_RARE_ I-GENE
- I-GENE
effectiveness O
of O
interferon I-GENE
beta I-GENE
- I-GENE
1b I-GENE
in O
_RARE_ I-GENE
multiple O
sclerosis O
_RARE_ I-GENE
progression O
. O

Both O
the O
_RARE_ I-GENE
and O
AUC O
values O
were O
almost O
_RARE_ I-GENE
with O
_RARE_ I-GENE
the O
dose O
. O

_RARE_ I-GENE
of O
Cdc2 I-GENE
in O
fission I-GENE
yeast I-GENE
causes O
cells O
to O
undergo O
a O
lethal O
premature O
mitosis O
called O
mitotic O
_RARE_ I-GENE
. O

_RARE_ I-GENE
. O

_RARE_ I-GENE
differentiate O
in O
response O
to O
various O
extracellular I-GENE
stimuli O
. O

_RARE_ I-GENE
growth I-GENE
factor I-GENE
- I-GENE
beta1 I-GENE
( O
TGF I-GENE
- I-GENE
beta1 I-GENE
) O
can O
act O
as O
a O
tumor I-GENE
suppressor I-GENE
or O
a O
tumor I-GENE
promoter I-GENE
depending O
on O
the O
characteristics O
of O
the O
malignant O
cell O
. O

_RARE_ I-GENE
intestinal O
peptide I-GENE
and O
pituitary I-GENE
adenylate I-GENE
cyclase I-GENE
- I-GENE
activating I-GENE
polypeptide I-GENE
inhibit O
nuclear I-GENE
factor I-GENE
- I-GENE
kappa I-GENE
B I-GENE
- I-GENE
dependent I-GENE
gene I-GENE
activation O
at O
multiple O
levels O
in O
the O
human I-GENE
monocytic O
cell O
line O
_RARE_ I-GENE
- I-GENE
1 I-GENE
. O

_RARE_ I-GENE
+ I-GENE
increased O
both O
the O
junction O
binding I-GENE
and O
_RARE_ I-GENE
activities O
of O
the O
mutant I-GENE
proteins I-GENE
. O

While O
_RARE_ I-GENE
; O
_RARE_ I-GENE
; O
1 I-GENE
and O
_RARE_ I-GENE
; O
_RARE_ I-GENE
; O
1 I-GENE
were O
expressed O
in O
all O
tissues O
examined O
, O
the O
transcripts I-GENE
accumulated O
abundantly O
in O
_RARE_ I-GENE
cells O
. O

Moreover O
, O
an O
in O
vitro O
_RARE_ I-GENE
- I-GENE
down O
assay O
showed O
that O
_RARE_ I-GENE
; O
_RARE_ I-GENE
; O
1 I-GENE
specifically O
bound O
to O
R2 I-GENE
but O
not O
to O
other O
rice I-GENE
_RARE_ I-GENE
. O

In O
transient O
analysis O
using O
particle I-GENE
_RARE_ I-GENE
of O
tobacco I-GENE
leaf O
sections O
, O
a O
tetramer I-GENE
of O
the O
_RARE_ I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
acid I-GENE
- I-GENE
responsive I-GENE
element I-GENE
) O
mediated O
transactivation O
by O
_RARE_ I-GENE
and O
_RARE_ I-GENE
- I-GENE
dependent I-GENE
response O
to O
ABA I-GENE
, O
whereas O
a O
tetramer I-GENE
of O
the O
composite O
_RARE_ I-GENE
/ I-GENE
G I-GENE
complex I-GENE
, O
containing O
_RARE_ I-GENE
repeats I-GENE
and O
a O
G I-GENE
- I-GENE
box I-GENE
, O
mediated O
only O
ABA I-GENE
- I-GENE
independent O
transactivation O
by O
_RARE_ I-GENE
. O

The O
major I-GENE
neurological O
manifestations O
of O
brain O
injury O
in O
these O
babies O
are O
_RARE_ I-GENE
motor O
deficits O
. O

_RARE_ I-GENE
from O
_RARE_ I-GENE
_RARE_ I-GENE
were O
_RARE_ I-GENE
in O
_RARE_ I-GENE
water O
( O
1 I-GENE
x O
10 O
( O
6 I-GENE
) O
_RARE_ I-GENE
/ I-GENE
mL O
) O
and O
used O
as O
_RARE_ I-GENE
. O

Overexpression O
of O
_RARE_ I-GENE
in O
a O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
(+) I-GENE
S I-GENE
. O
pombe I-GENE
diploid O
resulted O
in O
a O
4 I-GENE
- I-GENE
fold O
increase O
in O
specific I-GENE
_RARE_ I-GENE
synthase I-GENE
activity O
. O

The O
_RARE_ I-GENE
FGF I-GENE
- I-GENE
2 I-GENE
up O
- I-GENE
regulated O
the O
PKC I-GENE
epsilon I-GENE
levels O
by O
1 I-GENE
. O
6 I-GENE
- I-GENE
fold O
; O
by O
contrast O
the O
_RARE_ I-GENE
isoform I-GENE
down O
- I-GENE
regulated O
the O
level O
of O
this O
PKC I-GENE
_RARE_ I-GENE
by O
about O
3 I-GENE
- I-GENE
fold O
and O
increased O
the O
amount O
of O
PKC I-GENE
delta I-GENE
by O
1 I-GENE
. O
7 O
- I-GENE
fold O
. O

_RARE_ I-GENE
pylori I-GENE
and O
stomach O
diseases O
: O
from O
clinical O
point O
of O
view O

For O
this O
purpose O
, O
the O
_RARE_ I-GENE
test O
, O
_RARE_ I-GENE
and O
formalin O
induced O
- I-GENE
pain O
in O
mice O
were O
used O
. O

2000 O
_RARE_ I-GENE
of O
_RARE_ I-GENE
for O
the O
use O
of O
hematopoietic I-GENE
colony I-GENE
- I-GENE
stimulating I-GENE
factors I-GENE
: O
evidence O
- I-GENE
based O
, O
clinical O
practice O
guidelines O
. O

_RARE_ I-GENE
findings O
were O
chronic O
pancreatitis O
with O
_RARE_ I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
_RARE_ I-GENE
, O
testicular I-GENE
atrophy O
, O
candidiasis O
and O
bacterial I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
. O

Taken O
together O
, O
our O
data O
indicate O
that O
multiple O
survival O
pathways O
are O
triggered O
via O
this O
receptor I-GENE
, O
whereas O
NF I-GENE
- I-GENE
kappaB I-GENE
/ I-GENE
Rel I-GENE
and O
PI I-GENE
- I-GENE
_RARE_ I-GENE
are O
crucial O
for O
CD40 I-GENE
- I-GENE
induced O
proliferation O
. O

In O
vitro O
, O
_RARE_ I-GENE
and O
_RARE_ I-GENE
form O
DNA I-GENE
- I-GENE
independent O
_RARE_ I-GENE
and O
exhibit O
cooperative O
binding I-GENE
to O
the O
_RARE_ I-GENE
regulatory I-GENE
element I-GENE
, O
which O
contains O
two O
homeodomain I-GENE
recognition I-GENE
sites I-GENE
. O

We O
conclude O
from O
this O
study O
that O
_RARE_ I-GENE
and O
_RARE_ I-GENE
exhibit O
indistinguishable O
and O
independent O
transcriptional O
regulatory I-GENE
properties O
on O
the O
_RARE_ I-GENE
promoter I-GENE
. O

METHODS O
AND O
RESULTS O
: O
Studies O
were O
undertaken O
in O
9 O
isolated O
guinea O
pig O
hearts O
, O
which O
demonstrated O
reverse I-GENE
use O
- I-GENE
dependent I-GENE
prolongation O
of O
cardiac O
_RARE_ I-GENE
by O
100 O
nmol O
/ I-GENE
L I-GENE
_RARE_ I-GENE
. O

The O
N I-GENE
- I-GENE
terminal I-GENE
small I-GENE
segment O
of O
yeast I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
binds O
to O
TBP I-GENE
and O
thereby O
inhibits O
TBP I-GENE
function O
. O

OBJECTIVE O
: O
To O
evaluate O
the O
overall O
performance O
of O
a O
new O
_RARE_ I-GENE
wrist O
blood O
pressure O
monitor O
( O
_RARE_ I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
) O
as O
defined O
by O
the O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
- I-GENE
1992 O
guidelines O
, O
and O
to O
analyze O
the O
data O
for O
the O
_RARE_ I-GENE
selection O
of O
the O
algorithm O
that O
_RARE_ I-GENE
the O
blood O
pressure O
values O
from O
the O
_RARE_ I-GENE
blood O
pressure O
curves O
. O

Following O
the O
results O
of O
toxicological O
experiments O
in O
the O
target O
animals O
" O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
for O
Animals O
" O
can O
be O
established O
. O

An O
increase O
in O
_RARE_ I-GENE
expression O
of O
at O
least O
two O
of O
the O
erbB I-GENE
receptors I-GENE
is O
initiated O
before O
the O
_RARE_ I-GENE
_RARE_ I-GENE
of O
_RARE_ I-GENE
steroid I-GENE
secretion O
and O
is O
completed O
on O
the O
day O
of O
the O
first O
_RARE_ I-GENE
_RARE_ I-GENE
of O
_RARE_ I-GENE
. O

_RARE_ I-GENE
is O
required O
for O
two O
different O
pathways O
, O
the O
Wnt I-GENE
pathway O
and O
_RARE_ I-GENE
polarity O
pathway O
in O
Drosophila I-GENE
. O

_RARE_ I-GENE
- I-GENE
up O
growth I-GENE
and O
_RARE_ I-GENE
dimensions O
following O
administration O
of O
the O
_RARE_ I-GENE
agent O
vincristine O
to O
young O
rats O
. O

CONCLUSIONS O
: O
_RARE_ I-GENE
_RARE_ I-GENE
, O
like I-GENE
other O
inner O
ear O
malformations O
such O
as O
large O
vestibular O
_RARE_ I-GENE
and O
X I-GENE
- I-GENE
linked O
mixed O
_RARE_ I-GENE
with O
_RARE_ I-GENE
_RARE_ I-GENE
, O
can O
be O
associated I-GENE
with O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
or O
normal O
hearing O
. O

_RARE_ I-GENE
to O
180 O
mg O
/ I-GENE
m2 O
was O
to O
be O
carried O
out O
if O
white O
blood O
cell O
_RARE_ I-GENE
count O
was O
> O
2 I-GENE
. O
0 O
x O
10 O
( O
9 O
)/ O
l O
and O
platelet I-GENE
_RARE_ I-GENE
count O
was O
> O
75 O
x O
10 O
( O
9 O
)/ O
l O
. O

_RARE_ I-GENE
formate O
was O
used O
as O
the O
solvent O
of O
_RARE_ I-GENE
_RARE_ I-GENE
for O
the O
_RARE_ I-GENE
of O
microspheres O
with O
_RARE_ I-GENE
bovine I-GENE
serum I-GENE
albumin I-GENE
( O
_RARE_ I-GENE
). O

The O
small I-GENE
monomeric I-GENE
GTP I-GENE
- I-GENE
binding I-GENE
proteins I-GENE
of O
the O
_RARE_ I-GENE
subfamily I-GENE
are O
key O
regulatory I-GENE
elements O
of O
the O
machinery O
that O
controls O
membrane I-GENE
_RARE_ I-GENE
in O
eukaryotic I-GENE
cells O
. O

Furthermore O
, O
loss O
of O
methylation O
also O
greatly O
reduced O
the O
association O
of O
another O
yeast I-GENE
B I-GENE
- I-GENE
type I-GENE
subunit I-GENE
, O
_RARE_ I-GENE
. O

Thus O
, O
methylation O
of O
_RARE_ I-GENE
is O
important O
for O
formation O
of O
PP2A I-GENE
_RARE_ I-GENE
and O
dimeric I-GENE
complexes I-GENE
, O
and O
_RARE_ I-GENE
, O
for O
PP2A I-GENE
function O
. O

The O
purpose O
of O
this O
study O
was O
to O
analyze O
the O
temporal O
characteristics O
and O
the O
spatial O
mapping O
of O
the O
independent O
components O
identified O
by O
_RARE_ I-GENE
when O
the O
subject O
_RARE_ I-GENE
a O
finger I-GENE
- I-GENE
_RARE_ I-GENE
task O
. O

The O
authors O
present O
the O
only O
two O
studies O
that O
have O
proved O
successful O
in O
_RARE_ I-GENE
animal O
models O
of O
_RARE_ I-GENE
using O
gene I-GENE
therapy O
, O
and O
propose O
an O
_RARE_ I-GENE
of O
several O
strategies O
for O
the O
development O
of O
gene I-GENE
therapy O
in O
_RARE_ I-GENE
treatment O
in O
the O
future O
. O

Together O
, O
these O
results O
indicate O
that O
IL I-GENE
- I-GENE
1 I-GENE
beta I-GENE
induces O
VEGF I-GENE
gene I-GENE
expression O
at O
both O
transcriptional O
and O
post O
- I-GENE
transcriptional O
levels O
, O
and O
IL I-GENE
- I-GENE
1 I-GENE
beta I-GENE
_RARE_ I-GENE
p38 I-GENE
MAPK I-GENE
and O
JNK I-GENE
_RARE_ I-GENE
, O
which O
in O
turn I-GENE
stimulate O
the O
transcription I-GENE
of O
the O
VEGF I-GENE
gene I-GENE
through O
Sp1 I-GENE
- I-GENE
binding I-GENE
sites I-GENE
. O

Binding O
of O
_RARE_ I-GENE
to O
RNA I-GENE
in O
the O
presence O
of O
alpha I-GENE
or O
N I-GENE
involves O
an O
amino O
- I-GENE
terminal I-GENE
S1 I-GENE
homology I-GENE
region O
that O
is O
otherwise O
inactive O
in O
full I-GENE
- I-GENE
length I-GENE
_RARE_ I-GENE
. O

The O
subjects O
were O
diagnosed O
on O
the O
basis O
of O
_RARE_ I-GENE
- I-GENE
IV I-GENE
pathological O
_RARE_ I-GENE
criteria O
and O
completed O
the O
_RARE_ I-GENE
_RARE_ I-GENE
of O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
). O

Lys O
( O
193 O
) O
and O
Arg O
( O
_RARE_ I-GENE
), O
located O
at O
the O
COOH O
- I-GENE
terminal I-GENE
end O
of O
HD I-GENE
, O
are O
essential O
for O
dimerization O
. O

_RARE_ I-GENE
of O
intracellular O
Ca I-GENE
( O
2 I-GENE
+) O
levels O
are O
also O
involved O
because O
treatment O
with O
receptor I-GENE
- I-GENE
associated I-GENE
protein I-GENE
, O
nifedipine O
, O
_RARE_ I-GENE
, O
removal O
of O
Ca I-GENE
( O
2 I-GENE
+) O
from O
the O
medium O
and O
_RARE_ I-GENE
all O
_RARE_ I-GENE
to O
inhibit O
calcium O
elevation O
and O
_RARE_ I-GENE
the O
activation O
of O
CREB I-GENE
. O

The O
present O
study O
shows O
that O
phosphatidylinositol I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
- I-GENE
dependent I-GENE
p38 I-GENE
kinase I-GENE
activation O
regulates O
Akt I-GENE
phosphorylation O
and O
activity O
in O
human I-GENE
neutrophils O
. O

When O
_RARE_ I-GENE
was O
taken O
as O
the O
reference O
, O
W I-GENE
/ I-GENE
A I-GENE
Z I-GENE
scores O
showed O
consistent O
positive O
_RARE_ I-GENE
, O
from O
birth O
in O
girls O
and O
1 I-GENE
mo O
in O
boys O
. O

These O
probable O
_RARE_ I-GENE
sequences I-GENE
are O
closely O
related I-GENE
to O
those O
of O
other O
known O
T I-GENE
- I-GENE
regions O
and O
define O
a O
second O
T I-GENE
- I-GENE
region O
of O
_RARE_ I-GENE
, O
called O
T I-GENE
- I-GENE
right O
( O
TR I-GENE
), O
that O
confers O
production O
of O
the O
_RARE_ I-GENE
. O

Using O
purified O
recombinant I-GENE
HMG I-GENE
I I-GENE
, O
we O
have O
identified O
several O
high O
- I-GENE
affinity O
binding I-GENE
sites I-GENE
which O
overlap O
important O
transcription I-GENE
factor I-GENE
binding I-GENE
sites I-GENE
. O

High O
- I-GENE
mobility I-GENE
- I-GENE
group O
protein I-GENE
I I-GENE
can O
modulate O
binding I-GENE
of O
transcription I-GENE
factors I-GENE
to O
the O
U5 I-GENE
region O
of O
the O
human I-GENE
immunodeficiency I-GENE
virus I-GENE
type I-GENE
1 I-GENE
proviral I-GENE
promoter I-GENE
. O

Another O
cis O
- I-GENE
acting O
element I-GENE
, O
_RARE_ I-GENE
splicing O
suppressor I-GENE
1 I-GENE
( O
_RARE_ I-GENE
), O
represses O
use O
of O
the O
nt O
_RARE_ I-GENE
3 I-GENE
' O
splice O
site I-GENE
. O

_RARE_ I-GENE
does O
not O
correlate O
with O
the O
actual O
or O
mean O
blood O
pressure O
reading O
nor O
with O
stage O
of O
hypertension O
according O
to O
the O
_RARE_ I-GENE
classification O
. O

5 I-GENE
'- O
RACE O
analysis O
suggested O
a O
single O
transcription I-GENE
initiation I-GENE
site I-GENE
_RARE_ I-GENE
bp O
upstream O
from O
the O
translational O
start O
site I-GENE
. O

Thus O
, O
_RARE_ I-GENE
treatment O
of O
nuclear I-GENE
extracts O
strongly O
reduces O
the O
binding I-GENE
of O
_RARE_ I-GENE
proteins I-GENE
, O
and O
the O
addition O
of O
higher O
concentrations O
of O
_RARE_ I-GENE
to O
nuclear I-GENE
extracts O
from O
TG I-GENE
- I-GENE
treated O
cells O
restores O
_RARE_ I-GENE
- I-GENE
DNA I-GENE
binding I-GENE
to O
levels O
in O
extracts O
from O
untreated O
cells O
. O

_RARE_ I-GENE
enhances O
Lyn I-GENE
and O
_RARE_ I-GENE
ubiquitination O
in O
vivo O
in O
a O
fashion O
that O
depends O
on O
the O
activity O
of O
_RARE_ I-GENE
family I-GENE
members O
and O
correlates O
with O
_RARE_ I-GENE
of O
the O
Lyn I-GENE
tyrosine I-GENE
kinase I-GENE
. O

Further O
, O
Tax I-GENE
- I-GENE
mediated O
apoptosis O
was O
effectively O
prevented O
by O
ectopic O
expression O
of O
the O
p300 I-GENE
coactivator I-GENE
. O

Our O
results O
, O
however O
, O
were O
obtained O
for O
Z I-GENE
itself O
and O
not O
for O
[ O
Z I-GENE
]. O

_RARE_ I-GENE
' O
s O
_RARE_ I-GENE
test O
or O
_RARE_ I-GENE
' O
s O
_RARE_ I-GENE
test O
were O
used O
for O
statistical O
analysis O
. O

RESULTS O
: O
In O
the O
pregnant O
group O
, O
serum I-GENE
_RARE_ I-GENE
concentrations O
were O
markedly O
increased O
after O
ET I-GENE
, O
and O
a O
significant O
difference O
between O
the O
pregnant O
group O
and O
the O
_RARE_ I-GENE
group O
was O
observed O
8 O
days O
following O
ET I-GENE
( O
p O
< O
0 O
. O
01 O
). O

_RARE_ I-GENE
is O
a O
test O
that O
could O
potentially O
correlate O
with O
the O
degree O
of O
_RARE_ I-GENE
produced O
by O
low O
molecular O
weight O
heparin O
. O

High O
expression O
of O
the O
peroxisome I-GENE
proliferator I-GENE
- I-GENE
activated I-GENE
receptor I-GENE
alpha I-GENE
( O
PPARalpha I-GENE
) O
_RARE_ I-GENE
brown O
fat O
from O
white O
, O
and O
is O
related I-GENE
to O
its O
high O
capacity O
of O
lipid O
oxidation O
. O

This O
- I-GENE
_RARE_ I-GENE
/- O
_RARE_ I-GENE
element I-GENE
bound O
PPARalpha I-GENE
and O
PPARgamma I-GENE
from O
brown O
fat O
nuclei O
. O

These O
results O
provide O
direct O
evidence O
for O
differential O
susceptibility I-GENE
to O
endonuclease I-GENE
- I-GENE
mediated O
mRNA I-GENE
decay O
resulting O
from O
the O
differential O
affinity O
of O
a O
RNA I-GENE
- I-GENE
binding I-GENE
protein I-GENE
for O
cis O
- I-GENE
acting O
stability O
determinants I-GENE
. O

RESULTS O
: O
Twenty O
- I-GENE
two O
( O
26 O
%) O
patients O
had O
_RARE_ I-GENE
before O
( O
group O
A I-GENE
) O
and O
64 O
( O
74 O
%) O
developed O
_RARE_ I-GENE
after O
_RARE_ I-GENE
eradication O
( O
group O
B I-GENE
). O

Response O
was O
extremely O
poor O
in O
African O
_RARE_ I-GENE
and O
those O
with O
HCV I-GENE
_RARE_ I-GENE
1 I-GENE
. O

_RARE_ I-GENE
causes O
_RARE_ I-GENE
ulcers O
_RARE_ I-GENE
by O
reducing O
gastric O
mucosal I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
activity O
and O
prostaglandin I-GENE
synthesis O
. O

A I-GENE
total O
of O
_RARE_ I-GENE
clones O
were O
randomly O
selected O
for O
sequencing O
of O
one O
end O
. O

Expression O
of O
a O
hybrid O
protein I-GENE
containing O
the O
cytoplasmic I-GENE
C I-GENE
- I-GENE
terminal I-GENE
half O
of O
_RARE_ I-GENE
fused O
to O
glutathione I-GENE
S I-GENE
- I-GENE
transferase I-GENE
( O
GST I-GENE
) O
also O
_RARE_ I-GENE
with O
_RARE_ I-GENE
signaling O
. O

CONCLUSIONS O
: O
The O
surgical O
or O
_RARE_ I-GENE
treatment O
of O
_RARE_ I-GENE
has O
provided O
a O
good O
_RARE_ I-GENE
control O
( O
78 O
%) O
and O
68 O
% O
10 O
- I-GENE
year O
survival O
in O
a O
series O
of O
patients O
treated O
at O
the O
_RARE_ I-GENE
_RARE_ I-GENE
of O
a O
general O
hospital O
in O
_RARE_ I-GENE
, O
_RARE_ I-GENE
. O

RESULTS O
: O
_RARE_ I-GENE
_RARE_ I-GENE
were O
divided O
into O
two O
groups O
according O
to O
their O
_RARE_ I-GENE
results O
: O
high O
risk O
( O
with O
_RARE_ I-GENE
abnormalities O
) O
and O
low O
risk O
( O
with O
normal O
_RARE_ I-GENE
result O
). O

The O
gene I-GENE
is O
separated O
into O
four O
exons O
by O
three O
short O
introns O
, O
and O
the O
open O
reading O
frame O
consists O
of O
_RARE_ I-GENE
base O
pairs O
( O
bp O
) O
capable O
of O
encoding O
a O
polypeptide I-GENE
of O
_RARE_ I-GENE
amino O
acid I-GENE
residues O
. O

Like O
the O
p190 I-GENE
- I-GENE
B I-GENE
exon O
, O
the O
first O
exon O
of O
p190 I-GENE
- I-GENE
A I-GENE
is O
extremely O
large O
( O
3 I-GENE
. O
7 O
kb O
in O
length I-GENE
), O
encoding O
both O
the O
GTPase I-GENE
and O
middle I-GENE
domains I-GENE
( O
residues O
1 I-GENE
- I-GENE
_RARE_ I-GENE
), O
but O
not O
the O
remaining O
GAP I-GENE
domain I-GENE
, O
suggesting O
a O
high O
conservation O
of O
genomic O
structure O
between O
two O
p190 I-GENE
genes I-GENE
. O

The O
entire O
human I-GENE
_RARE_ I-GENE
- I-GENE
1 I-GENE
( O
_RARE_ I-GENE
) O
gene I-GENE
is O
contained O
in O
eight O
_RARE_ I-GENE
clones O
representing O
part O
of O
the O
chromosomal I-GENE
locus I-GENE
_RARE_ I-GENE
. O

The O
_RARE_ I-GENE
_RARE_ I-GENE
and O
multiple O
localized O
_RARE_ I-GENE
are O
characteristic O
of O
NF1 I-GENE
. O

In O
general O
_RARE_ I-GENE
, O
all O
patients O
who O
received O
blood O
before O
being O
tested O
for O
hepatitis I-GENE
C I-GENE
are O
_RARE_ I-GENE
to O
undergo O
testing O
. O

The O
proposed O
algorithm O
consists O
of O
several O
steps O
. O

It O
contained O
seven O
extra I-GENE
amino O
acids O
of O
_RARE_ I-GENE
; O
this O
short O
stretch O
of O
extra I-GENE
sequence I-GENE
was O
found O
between O
Gln O
( O
_RARE_ I-GENE
) O
and O
Phe I-GENE
( O
_RARE_ I-GENE
) O
within O
the O
_RARE_ I-GENE
( O
_RARE_ I-GENE
- I-GENE
9 O
, O
_RARE_ I-GENE
- I-GENE
of O
- I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
) O
interacting I-GENE
domain I-GENE
( O
_RARE_ I-GENE
) O
of O
_RARE_ I-GENE
. O

_RARE_ I-GENE
has O
a O
weak O
glycosylase I-GENE
activity O
on O
the O
_RARE_ I-GENE
_RARE_ I-GENE
3 I-GENE
, O
N I-GENE
( O
4 I-GENE
)- I-GENE
_RARE_ I-GENE
, O
a O
metabolite O
of O
vinyl O
chloride O
and O
ethyl O
_RARE_ I-GENE
. O

There O
were O
no O
instances O
of O
major I-GENE
flap O
necrosis I-GENE
although O
two O
_RARE_ I-GENE
showed O
tip O
ischaemia O
. O

These O
results O
suggest O
that O
_RARE_ I-GENE
is O
a O
novel O
cytoplasmic I-GENE
GTPase I-GENE
involved O
in O
nuclear I-GENE
localization O
of O
_RARE_ I-GENE
. O

One O
of O
these O
factors I-GENE
, O
IRF I-GENE
- I-GENE
2 I-GENE
, O
was O
initially O
cloned O
as O
an O
antagonistic O
counterpart O
to O
IRF I-GENE
- I-GENE
1 I-GENE
with O
oncogenic I-GENE
potential O
. O

Among O
the O
total O
_RARE_ I-GENE
, O
8 O
. O
8 O
% O
match O
sequences I-GENE
of O
proteins I-GENE
found O
only O
in O
Bacillus I-GENE
subtilis I-GENE
and O
66 O
. O
7 O
% O
are O
widely O
conserved O
in O
comparison O
with O
the O
proteins I-GENE
of O
various O
organisms O
, O
including O
B I-GENE
. O
subtilis I-GENE
. O

_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
administered O
i O
. O
v I-GENE
. O
showed O
a O
prolonged O
circulation O
time O
compared O
to O
the O
i O
. O
v I-GENE
. O
administered O
_RARE_ I-GENE
solution O
. O

_RARE_ I-GENE
. O

_RARE_ I-GENE
_RARE_ I-GENE
transferase I-GENE
- I-GENE
mediated O
_RARE_ I-GENE
end O
labeling O
assays O
revealed O
that O
hormonal O
activation O
of O
the O
_RARE_ I-GENE
_RARE_ I-GENE
induced O
extensive O
apoptosis O
that O
correlated O
with O
down O
- I-GENE
regulation O
of O
BCL I-GENE
- I-GENE
X I-GENE
( O
L I-GENE
) O
expression O
. O

VEGF I-GENE
promoter I-GENE
activity O
in O
transient O
transfections O
was O
decreased O
by O
either O
pharmacological O
or O
genetic O
inhibition O
of O
EGFR I-GENE
, O
Ras I-GENE
, O
or O
phosphatidylinositol I-GENE
3 I-GENE
'- O
kinase I-GENE
[ O
PI I-GENE
( O
3 I-GENE
) O
kinase I-GENE
]. O

_RARE_ I-GENE
growth I-GENE
factor I-GENE
receptor I-GENE
transcriptionally O
up O
- I-GENE
regulates O
vascular I-GENE
endothelial I-GENE
growth I-GENE
factor I-GENE
expression O
in O
human I-GENE
_RARE_ I-GENE
cells O
via O
a O
pathway O
involving O
phosphatidylinositol I-GENE
3 I-GENE
'- O
kinase I-GENE
and O
distinct O
from O
that O
induced O
by O
hypoxia O
. O

Thus O
, O
_RARE_ I-GENE
is O
closely O
related I-GENE
to O
_RARE_ I-GENE
of O
the O
genus O
_RARE_ I-GENE
in O
the O
family I-GENE
_RARE_ I-GENE
, O
and O
we O
therefore O
propose O
to O
_RARE_ I-GENE
this O
virus I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
). O

_RARE_ I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
1 I-GENE
( O
_RARE_ I-GENE
), O
also O
called O
c I-GENE
- I-GENE
Jun I-GENE
N I-GENE
- I-GENE
terminal I-GENE
kinase I-GENE
( O
JNK I-GENE
), O
becomes O
activated I-GENE
in O
vivo O
in O
response O
to O
pro I-GENE
- I-GENE
inflammatory O
cytokines O
or O
cellular O
stresses O
. O

_RARE_ I-GENE
activation O
of O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
( O
MAP I-GENE
) O
kinase I-GENE
phosphatase I-GENE
- I-GENE
1 I-GENE
by O
binding I-GENE
to O
p38 I-GENE
MAP I-GENE
kinase I-GENE
: O
critical O
role O
of O
the O
p38 I-GENE
C I-GENE
- I-GENE
terminal I-GENE
domain I-GENE
in O
its O
negative O
regulation O
. O

Thus O
, O
the O
class I-GENE
C I-GENE
- I-GENE
_RARE_ I-GENE
complex I-GENE
directs O
multiple O
reactions O
during O
the O
_RARE_ I-GENE
and O
fusion I-GENE
of O
vesicles O
with O
the O
_RARE_ I-GENE
, O
each O
of O
which O
contributes O
to O
the O
overall O
specificity O
and O
efficiency O
of O
this O
transport O
process O
. O

Combined O
intravenous O
and O
intra O
- I-GENE
arterial O
recombinant I-GENE
tissue I-GENE
plasminogen I-GENE
activator I-GENE
in O
acute O
ischemic O
stroke O
. O

To O
begin O
to O
understand O
this O
role O
, O
we O
overexpressed O
ATF I-GENE
- I-GENE
2 I-GENE
in O
a O
human I-GENE
cancer O
cell O
line O
. O

_RARE_ I-GENE
transduction O
via O
modulation O
of O
phosphorylation O
after O
selective O
inhibition O
of O
protein I-GENE
phosphatase I-GENE
( O
PP I-GENE
) O
1 I-GENE
and O
/ I-GENE
or O
PP2A I-GENE
appears O
to O
play O
a O
role O
in O
_RARE_ I-GENE
acid I-GENE
( O
_RARE_ I-GENE
)- I-GENE
mediated O
effects O
. O

_RARE_ I-GENE
toxin I-GENE
A I-GENE
in O
the O
treatment O
of O
_RARE_ I-GENE
_RARE_ I-GENE
foot O
drop O
-- O
clinical O
and O
functional O
outcomes O
. O

_RARE_ I-GENE
A I-GENE
is O
located O
approximately O
7 O
kb O
5 I-GENE
' O
to O
the O
_RARE_ I-GENE
translation I-GENE
start O
site I-GENE
. O

NF I-GENE
- I-GENE
kappaB I-GENE
is O
a O
_RARE_ I-GENE
- I-GENE
sensitive O
transcription I-GENE
factor I-GENE
known O
to O
be O
activated I-GENE
by O
oxidative O
stress O
as O
well O
as O
chemical O
and O
biological O
_RARE_ I-GENE
. O

_RARE_ I-GENE
risk O
factors I-GENE
and O
antihypertensive O
treatment O
. O

_RARE_ I-GENE
to O
_RARE_ I-GENE
for O
during O
a O
compliance O
review O
: O
10 O
common O
_RARE_ I-GENE
made O
by O
_RARE_ I-GENE
. O

CONCLUSIONS O
: O
_RARE_ I-GENE
technology O
allows O
_RARE_ I-GENE
invasive O
evaluation O
of O
_RARE_ I-GENE
_RARE_ I-GENE
function O
and O
permits O
assessment O
of O
microvascular O
_RARE_ I-GENE
distribution O
in O
different O
functional O
components O
. O

These O
two O
_RARE_ I-GENE
used O
the O
same O
V I-GENE
( O
H I-GENE
) O
and O
J O
( O
H I-GENE
) O
gene I-GENE
segments O
, O
but O
different O
D I-GENE
, O
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
genes I-GENE
. O

_RARE_ I-GENE
experiments O
were O
carried O
out O
in O
_RARE_ I-GENE
- I-GENE
scale O
_RARE_ I-GENE
( O
_RARE_ I-GENE
with O
CO2 O
and O
volatile O
organic O
_RARE_ I-GENE
) O
containing O
a O
mixture O
of O
_RARE_ I-GENE
materials O
and O
a O
radiolabeled O
_RARE_ I-GENE
. O

Characterization O
of O
a O
Xenopus I-GENE
laevis I-GENE
_RARE_ I-GENE
chemokine I-GENE
receptor I-GENE
4 I-GENE
: O
implications O
for O
hematopoietic I-GENE
cell O
development O
in O
the O
vertebrate I-GENE
embryo O
. O

Patients O
had O
to O
have O
adequate O
liver O
, O
renal O
, O
and O
marrow O
functions O
. O

Inhibition O
of O
_RARE_ I-GENE
translation I-GENE
was O
selective O
, O
with O
no O
effect O
on O
general O
cellular O
translation I-GENE
or O
translation I-GENE
of O
_RARE_ I-GENE
_RARE_ I-GENE
- I-GENE
encoded I-GENE
replication O
factor I-GENE
1a I-GENE
, O
and O
was O
independent O
of O
_RARE_ I-GENE
, O
a O
cellular O
antagonist O
of O
_RARE_ I-GENE
function O
in O
translation I-GENE
. O

_RARE_ I-GENE
: O
CAS I-GENE
, O
_RARE_ I-GENE
- I-GENE
associated I-GENE
substrate I-GENE
; O
_RARE_ I-GENE
, O
_RARE_ I-GENE
- I-GENE
homology I-GENE
domain I-GENE
; O
_RARE_ I-GENE
, O
C I-GENE
- I-GENE
terminal I-GENE
SRC I-GENE
kinase I-GENE
; O
E6 I-GENE
, O
_RARE_ I-GENE
E6 I-GENE
protein I-GENE
; O
FAK I-GENE
, O
focal I-GENE
adhesion I-GENE
kinase I-GENE
; O
_RARE_ I-GENE
, O
_RARE_ I-GENE
_RARE_ I-GENE
; O
_RARE_ I-GENE
, O
heterotrimeric I-GENE
- I-GENE
G I-GENE
- I-GENE
protein I-GENE
- I-GENE
coupled I-GENE
receptor I-GENE
; O
_RARE_ I-GENE
, O
G I-GENE
- I-GENE
protein I-GENE
- I-GENE
coupled I-GENE
- I-GENE
receptor I-GENE
kinase I-GENE
; O
MAPK I-GENE
, O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
kinase I-GENE
( O
ERK I-GENE
, O
p38 I-GENE
, O
JNK I-GENE
); O
_RARE_ I-GENE
, O
p21 I-GENE
- I-GENE
activated I-GENE
kinase I-GENE
; O
_RARE_ I-GENE
, O
paxillin I-GENE
- I-GENE
binding I-GENE
subdomain I-GENE
; O
_RARE_ I-GENE
, O
_RARE_ I-GENE
- I-GENE
interacting I-GENE
exchange I-GENE
factor I-GENE
; O
_RARE_ I-GENE
, O
paxillin I-GENE
kinase I-GENE
linker I-GENE
; O
_RARE_ I-GENE
, O
partner I-GENE
of O
Rac I-GENE
; O
PS I-GENE
, O
_RARE_ I-GENE
; O
PT O
, O
_RARE_ I-GENE
; O
_RARE_ I-GENE
, O
phosphotyrosine I-GENE
; O
_RARE_ I-GENE
, O
growth I-GENE
factor I-GENE
receptor I-GENE
tyrosine I-GENE
kinase I-GENE
; O
SH I-GENE
, O
SRC I-GENE
- I-GENE
homology I-GENE
domain I-GENE
. O

In O
15 O
_RARE_ I-GENE
- I-GENE
dependent I-GENE
, O
_RARE_ I-GENE
, O
and O
actively O
_RARE_ I-GENE
patients O
, O
we O
found O
that O
the O
difference O
_RARE_ I-GENE
( O
i O
), O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
, O
total O
decay O
( O
mean O
+/- O
SD O
, O
5 I-GENE
. O
7 O
+/- O
1 I-GENE
. O
9 O
cm O
H I-GENE
( O
2 I-GENE
) O
O O
) O
was O
quite O
similar O
to O
_RARE_ I-GENE
( O
i O
), O
_RARE_ I-GENE
_RARE_ I-GENE
( O
5 I-GENE
. O
3 I-GENE
+/- O
1 I-GENE
. O
9 O
cm O
H I-GENE
( O
2 I-GENE
) O
O O
). O

Of O
_RARE_ I-GENE
_RARE_ I-GENE
subjects O
, O
82 O
received O
_RARE_ I-GENE
_RARE_ I-GENE
at O
a O
dose O
of O
_RARE_ I-GENE
mg O
twice O
weekly O
for O
6 I-GENE
mo O
( O
_RARE_ I-GENE
A I-GENE
), O
73 O
received O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
mg O
twice O
weekly O
for O
6 I-GENE
mo O
( O
_RARE_ I-GENE
B I-GENE
), O
and O
53 O
received O
_RARE_ I-GENE
_RARE_ I-GENE
300 O
mg O
daily O
for O
6 I-GENE
mo O
( O
_RARE_ I-GENE
C I-GENE
). O

There O
were O
122 O
cases O
of O
tuberculosis O
over O
an O
average O
10 O
. O
3 I-GENE
yr O
of O
follow O
- I-GENE
up O
( O
crude O
annual O
incidence O
, O
76 I-GENE
. O
2 I-GENE
/ I-GENE
100 O
, O
000 O
). O

These O
results O
suggested O
that O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
to O
the O
nucleus O
through O
BTB I-GENE
domain I-GENE
- I-GENE
mediated O
interaction O
. O

The O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
and O
the O
_RARE_ I-GENE
+ I-GENE
gene I-GENE
products I-GENE
transactivated O
the O
HIV I-GENE
LTR I-GENE
. O

Transcription O
of O
the O
six O
EBNA I-GENE
genes I-GENE
, O
which O
are O
expressed O
in O
EBV I-GENE
- I-GENE
_RARE_ I-GENE
primary O
B I-GENE
cells O
, O
_RARE_ I-GENE
from O
one O
of O
two O
promoters I-GENE
, O
Cp I-GENE
and O
_RARE_ I-GENE
, O
located O
near O
the O
left O
end O
of O
the O
viral I-GENE
genome O
. O

The O
_RARE_ I-GENE
- I-GENE
2 I-GENE
sequences I-GENE
possess O
similarity O
to O
the O
_RARE_ I-GENE
domain I-GENE
of O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
, O
a O
_RARE_ I-GENE
non O
- I-GENE
LTR I-GENE
retrotransposon I-GENE
. O

This O
dynamic O
response O
strongly O
suggests O
that O
the O
p53 I-GENE
and O
Rb I-GENE
tumor I-GENE
suppressor I-GENE
pathways O
are O
intact O
in O
HeLa O
cells O
and O
that O
repression O
of O
HPV I-GENE
E6 I-GENE
and O
E7 I-GENE
_RARE_ I-GENE
these O
pathways O
in O
an O
_RARE_ I-GENE
fashion O
to O
_RARE_ I-GENE
growth I-GENE
inhibitory I-GENE
signals O
to O
the O
cells O
. O

Thus O
, O
blocks O
in O
the O
_RARE_ I-GENE
- I-GENE
specific I-GENE
pathway O
of O
retinoid I-GENE
- I-GENE
induced O
differentiation O
may O
be O
_RARE_ I-GENE
during O
retinoid I-GENE
induction O
of O
FR I-GENE
- I-GENE
beta I-GENE
expression O
. O

Is O
more O
better O
? O
_RARE_ I-GENE
dose O
levels O
of O
ACE I-GENE
inhibitors O
in O
chronic O
heart O
failure O
. O

To O
test O
whether O
or O
not O
_RARE_ I-GENE
- I-GENE
3 I-GENE
also O
binds O
to O
the O
_RARE_ I-GENE
, O
we O
cloned O
human I-GENE
_RARE_ I-GENE
- I-GENE
3 I-GENE
by O
reverse I-GENE
transcription I-GENE
- I-GENE
polymerase I-GENE
chain I-GENE
reaction O
from O
human I-GENE
skeletal I-GENE
muscle O
mRNA I-GENE
. O

A I-GENE
protein I-GENE
lacking O
the O
SH2 I-GENE
and O
RING I-GENE
finger I-GENE
domains I-GENE
has O
no O
activity O
, O
but O
a O
chimeric I-GENE
protein I-GENE
with O
the O
SH2 I-GENE
and O
RING I-GENE
finger I-GENE
domains I-GENE
of O
_RARE_ I-GENE
- I-GENE
1 I-GENE
replaced O
by O
the O
equivalent O
domains I-GENE
of O
c I-GENE
- I-GENE
Cbl I-GENE
has O
activity O
. O

To O
evaluate O
the O
effects O
of O
_RARE_ I-GENE
on O
those O
factors I-GENE
in O
end O
- I-GENE
stage O
renal O
disease O
( O
_RARE_ I-GENE
) O
patients O
, O
we O
evaluated O
the O
changes O
of O
lipid O
profile O
, O
coagulation I-GENE
and O
_RARE_ I-GENE
markers O
, O
and O
plasma I-GENE
_RARE_ I-GENE
levels O
after O
treatment O
. O

There O
was O
a O
weak O
significant O
correlation O
between O
TGF I-GENE
beta I-GENE
1 I-GENE
levels O
and O
normal O
cell O
_RARE_ I-GENE
( O
lymphocyte I-GENE
_RARE_ I-GENE
). O

Acute O
feasibility O
and O
safety O
of O
a O
smoking O
reduction O
strategy O
for O
smokers O
with O
schizophrenia O
. O

_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
degradation O
of O
proteins I-GENE
critical O
for O
cell O
cycle O
control O
_RARE_ I-GENE
a O
role O
of O
the O
proteasome I-GENE
in O
maintaining O
cell O
proliferation O
and O
cell O
survival O
. O

The O
_RARE_ I-GENE
nucleotide I-GENE
was O
_RARE_ I-GENE
out O
to O
allow O
_RARE_ I-GENE
of O
this O
U O
. O
G I-GENE
pair O
on O
the O
adjacent O
helical O
region O
. O

Functional O
analysis O
of O
the O
mutant I-GENE
_RARE_ I-GENE
in O
_RARE_ I-GENE
( O
_RARE_ I-GENE
-) I-GENE
cells O
showed O
aggregation O
of O
abnormal O
_RARE_ I-GENE
_RARE_ I-GENE
of O
_RARE_ I-GENE
positive O
material O
_RARE_ I-GENE
throughout O
the O
cytoplasm O
. O

Patients O
with O
lesions O
affecting O
the O
_RARE_ I-GENE
but O
_RARE_ I-GENE
the O
_RARE_ I-GENE
, O
and O
patients O
with O
lesions O
affecting O
both O
_RARE_ I-GENE
and O
_RARE_ I-GENE
, O
performed O
an O
_RARE_ I-GENE
delayed O
response O
task O
with O
_RARE_ I-GENE
varied O
memory O
_RARE_ I-GENE
of O
up O
to O
30 O
s O
. O

In O
addition O
, O
26 O
amino O
acid I-GENE
residues O
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
and O
_RARE_ I-GENE
( O
mouse I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
), O
all O
of O
which O
are O
implicated O
in O
the O
formation O
of O
the O
_RARE_ I-GENE
phosphate I-GENE
- I-GENE
binding I-GENE
domain I-GENE
and O
the O
substrate I-GENE
- I-GENE
binding I-GENE
domain I-GENE
and O
in O
dimer O
stabilization O
with O
the O
eukaryotic I-GENE
_RARE_ I-GENE
, O
were O
also O
conserved O
in O
S I-GENE
. O
_RARE_ I-GENE
_RARE_ I-GENE
. O

The O
_RARE_ I-GENE
cDNA I-GENE
contained O
an O
open O
reading O
frame O
homologous O
to O
_RARE_ I-GENE
family I-GENE
proteins I-GENE
. O

Our O
results O
indicate O
that O
_RARE_ I-GENE
can O
drive O
continued O
_RARE_ I-GENE
in O
immature O
, O
proliferating I-GENE
_RARE_ I-GENE
. O

The O
QT O
interval O
was O
related I-GENE
to O
various O
components O
of O
the O
insulin I-GENE
resistance O
syndrome O
, O
including O
BP I-GENE
and O
insulin I-GENE
sensitivity O
. O

The O
_RARE_ I-GENE
corresponding O
to O
the O
normal O
modes O
of O
vibration O
were O
calculated O
using O
the O
_RARE_ I-GENE
( O
_RARE_ I-GENE
/ I-GENE
6 I-GENE
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
and O
their O
agreement O
with O
the O
measured O
values O
improved O
after O
_RARE_ I-GENE
of O
the O
associated I-GENE
force O
field O
. O

The O
data O
provide O
strong O
evidence O
that O
_RARE_ I-GENE
is O
involved O
in O
the O
metabolism O
of O
both O
acid I-GENE
and O
solvent O
formation O
, O
whereas O
the O
physiological O
function O
of O
_RARE_ I-GENE
has O
yet O
to O
be O
_RARE_ I-GENE
. O

In O
addition O
, O
_RARE_ I-GENE
, O
which O
is O
usually O
_RARE_ I-GENE
with O
_RARE_ I-GENE
by O
MMTV I-GENE
insertion O
, O
was O
not O
up O
- I-GENE
regulated O
by O
_RARE_ I-GENE
in O
SC O
- I-GENE
3 I-GENE
cells O
. O

Experiments O
with O
epitope O
- I-GENE
tagged O
proteins I-GENE
show O
that O
_RARE_ I-GENE
is O
a O
nuclear I-GENE
protein I-GENE
, O
whereas O
both O
_RARE_ I-GENE
and O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
localize O
to O
cytoplasmic I-GENE
structures O
, O
indicating O
that O
the O
_RARE_ I-GENE
domain I-GENE
_RARE_ I-GENE
the O
cytoplasmic I-GENE
localization O
of O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
phosphorylation O
of O
human I-GENE
p53 I-GENE
at O
_RARE_ I-GENE
stimulates O
p53 I-GENE
- I-GENE
dependent I-GENE
transcription I-GENE
. O
p53 I-GENE
protein I-GENE
activity O
as O
a O
transcription I-GENE
factor I-GENE
can O
be O
activated I-GENE
in O
vivo O
by O
antibodies I-GENE
that O
target O
its O
C I-GENE
- I-GENE
terminal I-GENE
negative O
regulatory I-GENE
domain I-GENE
suggesting O
that O
cellular O
enzymes O
that O
target O
this O
domain I-GENE
may O
play O
a O
role O
in O
stimulating I-GENE
p53 I-GENE
- I-GENE
dependent I-GENE
gene I-GENE
expression O
. O

Interestingly O
, O
this O
mutant I-GENE
cell O
line O
lacks O
expression O
of O
the O
_RARE_ I-GENE
regulatory I-GENE
protein I-GENE
, O
_RARE_ I-GENE
. O

The O
Tax I-GENE
/ I-GENE
_RARE_ I-GENE
interaction O
serves O
to O
recruit O
Tax I-GENE
to O
the O
_RARE_ I-GENE
catalytic O
subunits I-GENE
, O
_RARE_ I-GENE
and O
_RARE_ I-GENE
, O
and O
this O
recruitment O
appears O
to O
be O
an O
essential O
mechanism O
by O
which O
Tax I-GENE
stimulates O
the O
activity O
of O
_RARE_ I-GENE
. O

An O
anchored I-GENE
_RARE_ I-GENE
- I-GENE
and O
retrotransposon I-GENE
- I-GENE
based O
map O
of O
diploid O
_RARE_ I-GENE
. O

In O
addition O
, O
we O
identified O
a O
novel O
type I-GENE
of O
inhibitory I-GENE
domain I-GENE
in O
the O
N I-GENE
- I-GENE
terminal I-GENE
60 O
amino O
acids O
of O
IRF I-GENE
- I-GENE
1 I-GENE
which O
strongly O
inhibits O
its O
transcriptional O
activity O
. O

Effects O
of O
spatial O
and O
temporal O
_RARE_ I-GENE
on O
stimulated O
_RARE_ I-GENE
_RARE_ I-GENE
in O
the O
independent O
- I-GENE
hot O
- I-GENE
_RARE_ I-GENE
model O
limit O
The O
influence O
of O
laser O
beam O
_RARE_ I-GENE
on O
stimulated O
_RARE_ I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
is O
studied O
_RARE_ I-GENE
in O
the O
limit O
of O
the O
independent O
hot O
_RARE_ I-GENE
model O
. O

_RARE_ I-GENE
determination O
of O
theophylline O
and O
its O
metabolites O
by O
HPLC O
] O
A I-GENE
high O
performance O
liquid O
chromatography O
( O
HPLC O
) O
method O
has O
been O
developed O
for O
the O
simultaneous O
determination O
of O
theophylline O
and O
its O
metabolites O
, O
with O
caffeine O
and O
its O
metabolites O
. O

Ten O
males O
performed O
both O
test O
conditions O
and O
oxygen O
uptake O
VO2 O
, O
heart O
rate O
, O
minute O
ventilation O
VE O
, O
perceived O
_RARE_ I-GENE
and O
spinal O
_RARE_ I-GENE
were O
recorded O
. O

CONCLUSION O
: O
_RARE_ I-GENE
is O
more O
useful O
than O
_RARE_ I-GENE
in O
differentiating O
patients O
_RARE_ I-GENE
to O
_RARE_ I-GENE
. O

_RARE_ I-GENE
groups O
were O
( O
1 I-GENE
) O
untreated O
control O
, O
n O
= O
12 O
; O
( O
2 I-GENE
) O
FK O
- I-GENE
1 I-GENE
, O
n O
= O
8 O
; O
( O
3 I-GENE
) O
FK O
- I-GENE
3 I-GENE
, O
n O
= O
8 O
. O

DNA I-GENE
binding I-GENE
and O
glutathione I-GENE
S I-GENE
- I-GENE
transferase I-GENE
_RARE_ I-GENE
- I-GENE
down O
assays O
demonstrate O
that O
binding I-GENE
requires O
Elk I-GENE
- I-GENE
1 I-GENE
( O
1 I-GENE
- I-GENE
_RARE_ I-GENE
) O
but O
not O
the O
C I-GENE
- I-GENE
terminal I-GENE
transactivation O
domain I-GENE
. O

_RARE_ I-GENE
, O
_RARE_ I-GENE
signaling O
produced O
a O
remarkable O
change O
in O
cell O
morphology O
characterized O
by O
cell O
_RARE_ I-GENE
and O
_RARE_ I-GENE
of O
_RARE_ I-GENE
, O
short O
cell O
processes O
. O

The O
_RARE_ I-GENE
- I-GENE
1 I-GENE
allele I-GENE
recovered O
from O
the O
original O
screen O
carries O
a O
point O
mutation I-GENE
in O
its O
_RARE_ I-GENE
repeat I-GENE
( O
TPR O
) O
domain I-GENE
, O
a O
motif I-GENE
not O
found O
in O
_RARE_ I-GENE
but O
known O
in O
other O
proteins I-GENE
to O
mediate O
interaction O
with O
heat I-GENE
- I-GENE
shock I-GENE
proteins I-GENE
. O

Association O
of O
stress O
during O
delivery O
with O
increased O
numbers O
of O
_RARE_ I-GENE
cells O
and O
hematopoietic I-GENE
progenitor I-GENE
cells O
in O
_RARE_ I-GENE
cord O
blood O
. O

In O
slightly O
older O
embryos O
, O
the O
expression O
was O
_RARE_ I-GENE
to O
one O
side O
of O
the O
embryo O
and O
by O
E6 I-GENE
. O
5 I-GENE
, O
at O
the O
onset O
of O
_RARE_ I-GENE
, O
expression O
was O
seen O
in O
the O
_RARE_ I-GENE
, O
visceral O
endoderm O
, O
_RARE_ I-GENE
mesoderm O
, O
and O
the O
_RARE_ I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
of O
the O
_RARE_ I-GENE
mutant I-GENE
with O
_RARE_ I-GENE
+ I-GENE
restores O
the O
wild I-GENE
- I-GENE
type I-GENE
phenotype O
. O

The O
authors O
proposed O
that O
the O
highly O
_RARE_ I-GENE
inputs O
to O
the O
_RARE_ I-GENE
cortex O
indicate O
this O
region O
may O
be O
particularly O
important O
for O
_RARE_ I-GENE
or O
_RARE_ I-GENE
information O
. O

Influence O
of O
oil O
_RARE_ I-GENE
and O
_RARE_ I-GENE
on O
post O
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
changes O
in O
_RARE_ I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
_RARE_ I-GENE
) O
was O
studied O
. O

_RARE_ I-GENE
analysis O
of O
alpha1 I-GENE
, O
_RARE_ I-GENE
transcripts I-GENE
revealed O
two O
major I-GENE
alternative O
splicing O
patterns O
in O
the O
5 I-GENE
'- O
untranslated O
region O
( O
5 I-GENE
'- O
UTR I-GENE
) O
and O
evidence O
for O
minor O
splicing O
activity O
that O
occurs O
in O
a O
tissue I-GENE
- I-GENE
specific I-GENE
manner O
. O

A I-GENE
thermal O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
condition O
_RARE_ I-GENE
due O
to O
the O
coupling O
of O
a O
computer O
to O
a O
strong O
periodic I-GENE
source O
, O
namely O
, O
the O
daily O
and O
weekly O
usage O
patterns O
of O
the O
system O
. O

The O
non O
- I-GENE
homologous O
sequences I-GENE
in O
the O
5 I-GENE
' O
untranslated O
regions O
might O
be O
acquired O
at O
or O
after O
transcription I-GENE
during O
_RARE_ I-GENE
of O
the O
_RARE_ I-GENE
elements O
. O

The O
time O
course O
of O
_RARE_ I-GENE
replication O
and O
_RARE_ I-GENE
synthesis O
in O
induced O
yeast I-GENE
_RARE_ I-GENE
that O
in O
yeast I-GENE
transfected O
with O
natural O
_RARE_ I-GENE
virion O
RNA I-GENE
. O

The O
transcription I-GENE
and O
alternative O
splicing O
of O
human I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
are O
cell O
- I-GENE
type I-GENE
specific I-GENE
. O

RESULTS O
: O
The O
main O
effect O
of O
muscle O
pain O
, O
compared O
to O
non O
- I-GENE
_RARE_ I-GENE
stimulation O
, O
was O
a O
significant O
and O
long O
- I-GENE
lasting O
increase O
of O
delta I-GENE
( O
1 I-GENE
- I-GENE
3 I-GENE
Hz O
) O
power O
and O
an O
alpha I-GENE
- I-GENE
1 I-GENE
( O
9 O
- I-GENE
11 O
Hz O
) O
power O
increase O
over O
the O
contralateral O
_RARE_ I-GENE
locus I-GENE
. O

The O
extraction O
was O
subsequently O
_RARE_ I-GENE
as O
' O
_RARE_ I-GENE
' O
or O
' O
difficult O
'. O
_RARE_ I-GENE
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
class I-GENE
C I-GENE
as O
a O
predictor O
of O
a O
' O
difficult O
' O
extraction O
, O
specificity O
was O
88 O
% O
but O
sensitivity O
was O
low O
at O
15 O
%. O

In O
addition O
, O
our O
results O
show O
that O
ERKs I-GENE
and O
_RARE_ I-GENE
can O
_RARE_ I-GENE
to O
_RARE_ I-GENE
_RARE_ I-GENE
into O
mesoderm O
. O

Based O
on O
_RARE_ I-GENE
rRNA I-GENE
gene I-GENE
sequence I-GENE
analysis O
, O
the O
11 O
species O
having O
two O
_RARE_ I-GENE
genes I-GENE
all O
have O
a O
common O
ancestor O
, O
while O
the O
six O
species O
having O
only O
one O
copy O
diverged O
from O
the O
_RARE_ I-GENE
lineage O
before O
that O
common O
ancestor O
. O

Nevertheless O
, O
protein I-GENE
kinase I-GENE
A I-GENE
stimulation O
induces O
_RARE_ I-GENE
to O
activate O
the O
complex I-GENE
native O
promoter I-GENE
in O
the O
phosphoenolpyruvate I-GENE
_RARE_ I-GENE
( O
PEPCK I-GENE
) O
gene I-GENE
. O

Another O
putative O
_RARE_ I-GENE
site I-GENE
in O
close O
_RARE_ I-GENE
to O
a O
NF1 I-GENE
/ I-GENE
_RARE_ I-GENE
site I-GENE
was O
localized O
upstream O
of O
the O
silencer I-GENE
- I-GENE
like I-GENE
element I-GENE
. O

This O
transcriptional O
regulation O
occurs O
through O
modulation O
of O
the O
_RARE_ I-GENE
transcription I-GENE
factor I-GENE
_RARE_ I-GENE
- I-GENE
L1 I-GENE
, O
and O
IL I-GENE
- I-GENE
3 I-GENE
inhibited O
_RARE_ I-GENE
- I-GENE
L1 I-GENE
activity O
in O
a O
_RARE_ I-GENE
- I-GENE
dependent I-GENE
manner O
. O

Taken O
together O
, O
these O
observations O
indicate O
that O
inhibition O
of O
p27 I-GENE
( O
_RARE_ I-GENE
) O
transcription I-GENE
through O
_RARE_ I-GENE
- I-GENE
induced O
_RARE_ I-GENE
- I-GENE
L1 I-GENE
phosphorylation O
provides O
a O
novel O
mechanism O
of O
regulating O
cytokine O
- I-GENE
mediated O
survival O
and O
proliferation O
. O

DNase I-GENE
I I-GENE
genomic O
footprinting O
revealed O
that O
the O
c I-GENE
- I-GENE
Myb I-GENE
site I-GENE
is O
occupied O
in O
a O
tissue I-GENE
- I-GENE
specific I-GENE
fashion O
in O
vivo O
. O

We O
conclude O
that O
c I-GENE
- I-GENE
Myb I-GENE
regulates O
the O
_RARE_ I-GENE
- I-GENE
2 I-GENE
promoter I-GENE
in O
T I-GENE
cells O
by O
binding I-GENE
to O
this O
consensus I-GENE
c I-GENE
- I-GENE
Myb I-GENE
binding I-GENE
site I-GENE
. O

A I-GENE
recently O
reported O
new O
member O
of O
the O
_RARE_ I-GENE
family I-GENE
proteins I-GENE
, O
_RARE_ I-GENE
has O
been O
identified O
as O
a O
_RARE_ I-GENE
receptor I-GENE
protein I-GENE
tyrosine I-GENE
kinase I-GENE
( O
_RARE_ I-GENE
) O
interacting I-GENE
protein I-GENE
by O
yeast I-GENE
two O
- I-GENE
hybrid O
screening O
. O

_RARE_ I-GENE
, O
we O
show O
that O
the O
_RARE_ I-GENE
of O
the O
r O
- I-GENE
_RARE_ I-GENE
gene I-GENE
in O
highly O
malignant O
rat I-GENE
thyroid I-GENE
cells O
transformed O
by O
_RARE_ I-GENE
carrying O
the O
v I-GENE
- I-GENE
mos I-GENE
and O
v I-GENE
- I-GENE
ras I-GENE
- I-GENE
_RARE_ I-GENE
oncogenes I-GENE
suppresses O
their O
malignant O
phenotype O
. O

_RARE_ I-GENE
expression O
of O
_RARE_ I-GENE
is O
associated I-GENE
with O
transformation O
of O
_RARE_ I-GENE
epithelial O
cells O
by O
the O
Raf I-GENE
- I-GENE
MEK I-GENE
- I-GENE
extracellular I-GENE
signal I-GENE
- I-GENE
regulated O
kinase I-GENE
pathway O
. O

The O
activity O
of O
the O
transcription I-GENE
factor I-GENE
CREB I-GENE
is O
regulated O
by O
extracellular I-GENE
stimuli O
that O
result O
in O
its O
phosphorylation O
at O
a O
critical O
serine I-GENE
residue O
, O
_RARE_ I-GENE
. O

RESULTS O
: O
_RARE_ I-GENE
age O
at O
_RARE_ I-GENE
onset O
was O
41 O
. O
2 I-GENE
years O
. O

When O
10 O
fields O
were O
analysed O
, O
a O
strong O
relationship O
was O
found O
between O
the O
presence O
of O
bacteria O
on O
Gram O
staining O
and O
the O
final O
diagnosis O
of O
_RARE_ I-GENE
( O
for O
_RARE_ I-GENE
and O
_RARE_ I-GENE
respectively O
: O
sensitivity O
74 O
and O
81 O
%, O
specificity O
94 O
and O
100 O
%, O
positive O
predictive O
value O
91 O
and O
100 O
%, O
negative O
predictive O
value O
82 O
and O
88 O
%). O

Unlike O
the O
mammalian I-GENE
proteins I-GENE
, O
_RARE_ I-GENE
is O
efficiently O
secreted O
as O
a O
Mr O
31 O
, O
000 O
glycoprotein I-GENE
, O
_RARE_ I-GENE
, O
which O
undergoes O
proteolytic O
cleavage O
to O
produce O
an O
NH2 I-GENE
- I-GENE
terminally I-GENE
truncated I-GENE
product I-GENE
, O
_RARE_ I-GENE
. O

NH2 I-GENE
- I-GENE
terminal I-GENE
_RARE_ I-GENE
of O
Xenopus I-GENE
and O
mammalian I-GENE
_RARE_ I-GENE
may O
therefore O
be O
a O
prerequisite O
of O
optimal O
biological O
activity O
. O

Here O
, O
we O
identified O
three O
cis O
- I-GENE
elements O
required O
for O
replication O
within O
the O
200 O
bp O
promoter I-GENE
, O
using O
autonomously I-GENE
replicating I-GENE
plasmids O
carrying O
various O
mutations O
and O
deletions O
. O

_RARE_ I-GENE
in O
the O
_RARE_ I-GENE
of O
Coronary O
_RARE_ I-GENE
_RARE_ I-GENE
. O

The O
_RARE_ I-GENE
of O
the O
present O
study O
were O
to O
evaluate O
the O
effects O
of O
adding O
_RARE_ I-GENE
to O
a O
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
, O
_RARE_ I-GENE
the O
semen O
in O
1 I-GENE
or O
2 I-GENE
steps O
, O
_RARE_ I-GENE
according O
to O
2 I-GENE
methods O
, O
_RARE_ I-GENE
at O
2 I-GENE
rates O
, O
and O
the O
interactions O
between O
these O
treatments O
, O
on O
the O
post O
- I-GENE
_RARE_ I-GENE
survival O
of O
dog O
spermatozoa O
at O
38 O
degrees O
C I-GENE
. O

This O
study O
is O
a O
further O
and O
more O
extensive O
_RARE_ I-GENE
of O
the O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
p O
. O

The O
_RARE_ I-GENE
locus I-GENE
was O
mapped O
to O
mouse I-GENE
chromosome O
_RARE_ I-GENE
- I-GENE
A3 I-GENE
by O
fluorescent O
in O
situ O
hybridization O
. O

_RARE_ I-GENE
disorders O
in O
children O
and O
_RARE_ I-GENE
carry O
considerable O
morbidity O
, O
_RARE_ I-GENE
development O
, O
and O
carry O
a O
significant O
mortality O
by O
suicide O
. O

Molecular O
cloning O
and O
expression O
of O
human I-GENE
_RARE_ I-GENE
- I-GENE
d O
- I-GENE
_RARE_ I-GENE
: O
proteoglycan I-GENE
core I-GENE
protein I-GENE
beta I-GENE
- I-GENE
d O
- I-GENE
_RARE_ I-GENE
and O
its O
first O
isoform I-GENE
_RARE_ I-GENE
- I-GENE
II I-GENE
. O

_RARE_ I-GENE
due O
to O
_RARE_ I-GENE
is O
difficult O
to O
treat O
and O
is O
further O
complicated O
by O
the O
pro I-GENE
- I-GENE
_RARE_ I-GENE
potential O
of O
_RARE_ I-GENE
and O
the O
_RARE_ I-GENE
antiarrhythmic O
effect O
after O
_RARE_ I-GENE
withdrawal O
. O

_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
thus O
play O
important O
roles O
within O
cell O
cycle O
processes O
. O

_RARE_ I-GENE
signalling O
by O
E2F1 I-GENE
has O
recently O
been O
linked O
to O
stabilization O
and O
activation O
of O
the O
tumour I-GENE
suppressor I-GENE
p53 I-GENE
( O
_RARE_ I-GENE
1 I-GENE
, O
3 I-GENE
, O
4 I-GENE
). O

This O
study O
allows O
us O
to O
_RARE_ I-GENE
conclusions O
about O
the O
identity O
of O
proteins I-GENE
required O
for O
the O
development O
of O
the O
nervous O
system O
in O
Drosophila I-GENE
and O
provides O
an O
example O
of O
a O
molecular O
approach O
to O
characterize O
en I-GENE
_RARE_ I-GENE
transposon I-GENE
- I-GENE
tagged O
mutations O
identified O
in O
genetic O
_RARE_ I-GENE
. O

We O
describe O
the O
identification O
and O
initial O
characterization O
of O
_RARE_ I-GENE
, O
a O
neuron I-GENE
- I-GENE
specific I-GENE
_RARE_ I-GENE
protein I-GENE
of O
_RARE_ I-GENE
kDa I-GENE
with O
a O
high O
- I-GENE
affinity O
binding I-GENE
site I-GENE
( O
K I-GENE
( O
d O
), O
10 O
nm O
) O
for O
the O
type I-GENE
II I-GENE
regulatory I-GENE
subunit I-GENE
of O
protein I-GENE
kinase I-GENE
A I-GENE
( O
PKA I-GENE
RII I-GENE
). O

Children O
with O
_RARE_ I-GENE
showed O
an O
attenuated O
frontal O
CNV O
- I-GENE
1 I-GENE
amplitude O
and O
a O
trend O
towards O
increased O
CNV O
- I-GENE
1 I-GENE
and O
CNV O
- I-GENE
2 I-GENE
_RARE_ I-GENE
amplitudes O
. O

_RARE_ I-GENE
_RARE_ I-GENE
is O
_RARE_ I-GENE
. O

Overexpression O
of O
c I-GENE
- I-GENE
Myc I-GENE
in O
serum I-GENE
- I-GENE
_RARE_ I-GENE
human I-GENE
or O
mouse I-GENE
embryonic O
cells O
leads O
to O
apoptosis O
which O
is O
significantly O
reduced O
in O
the O
presence O
of O
growth I-GENE
factor I-GENE
- I-GENE
containing O
serum I-GENE
. O
c I-GENE
- I-GENE
Myc I-GENE
- I-GENE
induced O
apoptosis O
appears O
to O
be O
deficient O
in O
_RARE_ I-GENE
- I-GENE
null I-GENE
as O
compared O
with O
_RARE_ I-GENE
- I-GENE
wild I-GENE
- I-GENE
type I-GENE
mouse I-GENE
embryonic O
fibroblasts O
. O

_RARE_ I-GENE
_RARE_ I-GENE
of O
Klebsiella I-GENE
pneumoniae I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
beta I-GENE
- I-GENE
lactamase I-GENE
( O
_RARE_ I-GENE
) O
_RARE_ I-GENE
in O
_RARE_ I-GENE
in O
_RARE_ I-GENE
. O

CONCLUSION O
: O
Our O
results O
suggest O
that O
_RARE_ I-GENE
peak O
saturation O
leads O
to O
a O
significant O
systematic O
error O
in O
the O
determination O
of O
_RARE_ I-GENE
and O
CBF I-GENE
values O
and O
has O
necessarily O
to O
be O
taken O
into O
account O
for O
dynamic O
contrast O
- I-GENE
enhanced O
MR O
perfusion O
studies O
. O

METHODS O
: O
T2 I-GENE
_RARE_ I-GENE
weighted O
, O
three O
- I-GENE
dimensional O
gradient O
- I-GENE
echo O
images O
were O
acquired O
by O
_RARE_ I-GENE
the O
magnetic O
susceptibility I-GENE
difference O
between O
_RARE_ I-GENE
and O
_RARE_ I-GENE
hemoglobin I-GENE
in O
the O
_RARE_ I-GENE
and O
_RARE_ I-GENE
. O

In O
the O
COPD O
patients O
, O
the O
variability O
of O
Delta I-GENE
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
( O
30 O
%) O
was O
greater O
than O
that O
of O
_RARE_ I-GENE
_RARE_ I-GENE
( O
21 O
%). O

_RARE_ I-GENE
this O
end O
, O
we O
prepared O
synthetic O
proteins I-GENE
with O
either O
the O
catalytic O
domain I-GENE
of O
_RARE_ I-GENE
- I-GENE
1 I-GENE
( O
C I-GENE
- I-GENE
terminal I-GENE
_RARE_ I-GENE
amino O
acids O
) O
or O
its O
inactive O
form O
( O
_RARE_ I-GENE
--> I-GENE
Ser O
) O
fused O
to O
glutathione I-GENE
- I-GENE
S I-GENE
- I-GENE
transferase I-GENE
( O
GST I-GENE
). O

Thus O
, O
_RARE_ I-GENE
could O
play O
dual O
roles O
in O
both O
membrane I-GENE
localization O
and O
regulation O
of O
_RARE_ I-GENE
synthesis O
within O
mitochondria O
. O

Furthermore O
, O
transfection O
of O
cells O
with O
the O
spacer O
- I-GENE
RING I-GENE
domain I-GENE
alone O
suppressed O
the O
_RARE_ I-GENE
function O
of O
the O
N I-GENE
- I-GENE
terminal I-GENE
_RARE_ I-GENE
domain I-GENE
of O
c I-GENE
- I-GENE
_RARE_ I-GENE
and O
induced O
apoptosis O
. O

The O
determination O
of O
the O
double O
_RARE_ I-GENE
in O
blood O
serum I-GENE
lipids O
by O
titration O
with O
_RARE_ I-GENE
: O
the O
pathophysiology O
and O
diagnostic O
significance O
] O
In O
this O
article O
the O
method O
of O
definition O
of O
double O
_RARE_ I-GENE
in O
lipids O
of O
blood O
serum I-GENE
in O
patients O
with O
different O
diseases O
_RARE_ I-GENE
atherosclerosis O
and O
ischemic O
heart O
disease O
, O
with O
use O
titration O
by O
_RARE_ I-GENE
is O
given O
. O

_RARE_ I-GENE
II I-GENE
- I-GENE
induced O
fibronectin I-GENE
mRNA I-GENE
was O
not O
affected O
by O
PKC I-GENE
inhibitors O
or O
PKC I-GENE
depletion O
, O
whereas O
specific I-GENE
inhibition O
of O
EGF I-GENE
- I-GENE
R I-GENE
function O
by O
a O
dominant I-GENE
negative O
EGF I-GENE
- I-GENE
R I-GENE
mutant I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
abolished O
induction O
of O
fibronectin I-GENE
mRNA I-GENE
. O

_RARE_ I-GENE
. O

_RARE_ I-GENE
images O
of O
the O
_RARE_ I-GENE
were O
_RARE_ I-GENE
and O
then O
analyzed O
for O
area O
, O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
principal O
axis O
, O
_RARE_ I-GENE
about O
the O
major I-GENE
and O
minor O
_RARE_ I-GENE
( O
_RARE_ I-GENE
, O
_RARE_ I-GENE
), O
_RARE_ I-GENE
, O
_RARE_ I-GENE
, O
lateral O
_RARE_ I-GENE
, O
_RARE_ I-GENE
angle O
, O
and O
_RARE_ I-GENE
angle O
. O

MS O
characteristics O
of O
_RARE_ I-GENE
, O
_RARE_ I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
with O
different O
substitution O
patterns O
were O
determined O
on O
the O
basis O
of O
the O
response O
obtained O
with O
the O
_RARE_ I-GENE
interface O
. O

_RARE_ I-GENE
fish O
( O
_RARE_ I-GENE
_RARE_ I-GENE
) O
were O
exposed O
to O
_RARE_ I-GENE
( O
micro O
g O
) O
for O
9 O
to O
10 O
days O
during O
space O
_RARE_ I-GENE
_RARE_ I-GENE
- I-GENE
55 O
and O
_RARE_ I-GENE
- I-GENE
84 O
, O
or O
to O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
for O
9 O
days O
. O

_RARE_ I-GENE
is O
highly O
homologous O
to O
_RARE_ I-GENE
in O
the O
core I-GENE
kinase I-GENE
and O
linker I-GENE
regulatory I-GENE
domains I-GENE
but O
differs O
from O
_RARE_ I-GENE
in O
the O
N I-GENE
- I-GENE
and O
C I-GENE
- I-GENE
terminal I-GENE
regions O
and O
is O
differently O
localized O
primarily O
to O
the O
nucleus O
because O
of O
a O
C I-GENE
- I-GENE
terminal I-GENE
nuclear I-GENE
localization O
signal I-GENE
unique O
to O
_RARE_ I-GENE
. O

_RARE_ I-GENE
of O
cells O
with O
the O
mitogen I-GENE
- I-GENE
activated I-GENE
protein I-GENE
- I-GENE
extracellular I-GENE
signal I-GENE
- I-GENE
regulated O
kinase I-GENE
kinase I-GENE
( O
MEK I-GENE
) O
inhibitor I-GENE
_RARE_ I-GENE
inhibited O
_RARE_ I-GENE
activation O
to O
a O
greater O
extent O
than O
_RARE_ I-GENE
. O

T I-GENE
cells O
express O
two O
isoforms I-GENE
of O
_RARE_ I-GENE
: O
a O
70 I-GENE
kDa I-GENE
cytoplasmic I-GENE
kinase I-GENE
and O
an O
85 O
kDa I-GENE
isoform I-GENE
that O
has O
a O
_RARE_ I-GENE
nuclear I-GENE
_RARE_ I-GENE
. O

_RARE_ I-GENE
, O
a O
hypotensive O
drug O
with O
5 I-GENE
- I-GENE
HT2 I-GENE
receptor I-GENE
_RARE_ I-GENE
, O
when O
administered O
by O
_RARE_ I-GENE
infusion O
of O
a O
0 O
. O
25 O
% O
w O
/ I-GENE
v I-GENE
solution O
by O
corneal O
and O
_RARE_ I-GENE
applications O
, O
was O
found O
to O
lower O
_RARE_ I-GENE
pressure O
with O
four O
times O
more O
activity O
than O
its O
metabolite O
, O
_RARE_ I-GENE
. O

A I-GENE
_RARE_ I-GENE
gated O
_RARE_ I-GENE
axial O
sequence I-GENE
with O
velocity O
encoding O
in O
the O
_RARE_ I-GENE
direction O
in O
the O
cervical O
region O
was O
set O
at O
a O
velocity O
of O
+/- O
10 O
cm O
/ I-GENE
s O
. O

It O
was O
subsequently O
shown O
that O
_RARE_ I-GENE
had O
histone I-GENE
acetyltransferase I-GENE
( O
_RARE_ I-GENE
) O
activity O
. O

Our O
data O
show O
that O
multiple O
_RARE_ I-GENE
transcripts I-GENE
, O
both O
constitutively O
expressed O
and O
inducible I-GENE
, O
are O
present O
in O
cultured O
_RARE_ I-GENE
melanoma O
cells O
, O
and O
suggest O
that O
_RARE_ I-GENE
expression O
can O
be O
regulated O
at O
the O
level O
of O
both O
transcription I-GENE
and O
mRNA I-GENE
processing O
. O

Copyright O
2000 O
Academic O
Press O
. O

_RARE_ I-GENE
and O
_RARE_ I-GENE
have O
_RARE_ I-GENE
- I-GENE
containing O
domains I-GENE
at O
their O
C I-GENE
- I-GENE
termini O
and O
we O
further O
demonstrate O
that O
the O
_RARE_ I-GENE
- I-GENE
containing O
domain I-GENE
of O
_RARE_ I-GENE
, O
but O
not O
_RARE_ I-GENE
, O
can O
bind O
to O
_RARE_ I-GENE
in O
vivo O
. O

Characterization O
of O
the O
microtubule I-GENE
binding I-GENE
domain I-GENE
of O
microtubule I-GENE
actin I-GENE
_RARE_ I-GENE
factor I-GENE
( O
_RARE_ I-GENE
): O
identification O
of O
a O
novel O
group O
of O
microtubule I-GENE
associated I-GENE
proteins I-GENE
. O

These O
results O
also O
suggest O
the O
involvement O
of O
additional O
elements O
in O
the O
_RARE_ I-GENE
. O

We O
show O
that O
in O
contrast O
to O
_RARE_ I-GENE
, O
direct O
binding I-GENE
of O
CBP I-GENE
to O
the O
estrogen I-GENE
receptor I-GENE
is O
weak O
, O
suggesting O
that O
_RARE_ I-GENE
functions O
primarily O
as O
an O
adaptor I-GENE
to O
recruit O
CBP I-GENE
and O
p300 I-GENE
. O

_RARE_ I-GENE
, O
a O
construct I-GENE
corresponding O
to O
residues O
_RARE_ I-GENE
to O
_RARE_ I-GENE
, O
which O
contains O
only O
the O
_RARE_ I-GENE
motifs O
and O
the O
_RARE_ I-GENE
region O
of O
_RARE_ I-GENE
, O
retained O
strong O
coactivator I-GENE
activity O
in O
our O
assays O
. O

Since O
MEK I-GENE
acts O
as O
a O
cytoplasmic I-GENE
anchor I-GENE
for O
the O
ERKs I-GENE
, O
the O
lack O
of O
a O
MEK I-GENE
interaction O
resulted O
in O
the O
aberrant O
nuclear I-GENE
localization O
of O
ERK2 I-GENE
- I-GENE
_RARE_ I-GENE
- I-GENE
25 O
mutants I-GENE
in O
serum I-GENE
- I-GENE
_RARE_ I-GENE
cells O
. O

_RARE_ I-GENE
is O
a O
member O
of O
a O
six O
- I-GENE
protein I-GENE
family I-GENE
in O
yeast I-GENE
that O
catalyzes O
the O
first O
step O
in O
O O
_RARE_ I-GENE
of O
target O
proteins I-GENE
. O

_RARE_ I-GENE
samples O
were O
collected O
at O
the O
beginning O
and O
end O
of O
each O
trial O
period O
and O
were O
analyzed O
for O
gastrointestinal O
nematode O
eggs O
and O
_RARE_ I-GENE
cyst O
. O

The O
aim O
of O
this O
study O
was O
to O
determine O
the O
risk O
factors I-GENE
for O
background O
diabetic O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
and O
_RARE_ I-GENE
by O
following O
_RARE_ I-GENE
Japanese O
patients O
with O
early I-GENE
- I-GENE
onset O
type I-GENE
2 I-GENE
diabetes O
diagnosed O
before O
30 O
years O
of O
age O
( O
mean O
age O
27 O
, O
mean O
blood O
pressure O
at O
entry O
_RARE_ I-GENE
/ I-GENE
73 O
mm O
Hg O
). O

Of O
the O
21 O
_RARE_ I-GENE
positive O
in O
the O
controls O
, O
17 O
were O
correlated O
with O
previously O
detected O
jaw O
_RARE_ I-GENE
. O

Four O
cases O
of O
synovial O
_RARE_ I-GENE
are O
presented O
. O

Previous O
studies O
have O
shown O
that O
the O
pro I-GENE
- I-GENE
inflammatory O
cytokines O
tumor I-GENE
necrosis I-GENE
factor I-GENE
alpha I-GENE
and O
interferon I-GENE
gamma I-GENE
reduce O
the O
expression O
of O
the O
cystic I-GENE
fibrosis I-GENE
transmembrane I-GENE
conductance I-GENE
regulator I-GENE
( O
CFTR I-GENE
) O
gene I-GENE
( O
CFTR I-GENE
) O
in O
HT O
- I-GENE
29 O
and O
_RARE_ I-GENE
cells O
by O
acting O
post O
- I-GENE
transcriptionally O
. O

Regulation O
of O
RhoA I-GENE
is O
required O
to O
maintain O
adhesion I-GENE
in O
stationary O
cells O
, O
but O
is O
also O
critical O
for O
cell O
_RARE_ I-GENE
and O
migration O
[ O
3 I-GENE
]. O

Here O
we O
show O
in O
mouse I-GENE
fibroblasts O
stably O
transformed O
by O
v I-GENE
- I-GENE
Src I-GENE
that O
mRNA I-GENE
and O
protein I-GENE
levels O
of O
p21 I-GENE
( O
WAF1 I-GENE
/ I-GENE
_RARE_ I-GENE
), O
cyclin I-GENE
D1 I-GENE
, O
and O
cyclin I-GENE
E I-GENE
are O
elevated O
. O

_RARE_ I-GENE
and O
_RARE_ I-GENE
were O
constitutively O
cotranscribed O
as O
determined O
by O
primer O
extension O
analysis O
. O

_RARE_ I-GENE
_RARE_ I-GENE
is O
a O
_RARE_ I-GENE
expressed O
gene I-GENE
encoding O
an O
evolutionarily O
conserved O
protein I-GENE
of O
unknown O
function O
. O

These O
cells O
produced O
_RARE_ I-GENE
( O
11 O
) O
mRNA I-GENE
during O
culture O
. O

_RARE_ I-GENE
studies O
indicate O
that O
insulin I-GENE
and O
PKB I-GENE
suppress O
transactivation O
by O
C I-GENE
/ I-GENE
EBPbeta I-GENE
, O
but O
not O
C I-GENE
/ I-GENE
_RARE_ I-GENE
, O
and O
that O
N I-GENE
- I-GENE
terminal I-GENE
transactivation O
domains I-GENE
in O
C I-GENE
/ I-GENE
EBPbeta I-GENE
are O
required O
. O

Among O
eight O
_RARE_ I-GENE
species O
tested O
, O
_RARE_ I-GENE
expression O
was O
observed O
only O
in O
_RARE_ I-GENE
- I-GENE
deficient O
roots O
of O
H I-GENE
. O
_RARE_ I-GENE
and O
_RARE_ I-GENE
_RARE_ I-GENE
. O
which O
not O
only O
_RARE_ I-GENE
2 I-GENE
'- O
_RARE_ I-GENE
acid I-GENE
( O
_RARE_ I-GENE
), O
but O
also O
_RARE_ I-GENE
acid I-GENE
( O
MA I-GENE
) O
and O
3 I-GENE
- I-GENE
_RARE_ I-GENE
acid I-GENE
( O
_RARE_ I-GENE
, O
H I-GENE
. O
_RARE_ I-GENE
), O
and O
3 I-GENE
- I-GENE
_RARE_ I-GENE
acid I-GENE
( O
_RARE_ I-GENE
, O
S I-GENE
. O
_RARE_ I-GENE
). O

In O
contrast O
, O
high O
COUP I-GENE
- I-GENE
TFI I-GENE
expression O
_RARE_ I-GENE
the O
neuronal O
differentiation O
of O
P19 O
cells O
induced O
with O
RA O
, O
resulting O
in O
cell O
cultures O
lacking O
neurons O
. O

Because O
PET O
is O
also O
useful O
for O
the O
pretreatment O
and O
follow O
- I-GENE
up O
evaluation O
, O
the O
use O
of O
_RARE_ I-GENE
PET O
in O
these O
patients O
can O
_RARE_ I-GENE
an O
accurate O
comparison O
of O
PET O
- I-GENE
based O
metabolic O
data O
with O
MR O
- I-GENE
based O
anatomical O
data O
. O

Therefore O
, O
in O
our O
in O
vitro O
model O
, O
the O
localization O
of O
the O
mutation I-GENE
in O
the O
K I-GENE
- I-GENE
ras I-GENE
gene I-GENE
_RARE_ I-GENE
to O
a O
different O
level O
of O
_RARE_ I-GENE
in O
the O
transforming I-GENE
phenotype O
. O

Here O
, O
we O
describe O
the O
isolation O
of O
_RARE_ I-GENE
, O
a O
_RARE_ I-GENE
homologue I-GENE
from O
the O
plant O
species O
_RARE_ I-GENE
( O
_RARE_ I-GENE
_RARE_ I-GENE
) O
and O
show O
that O
it O
has O
the O
same O
phosphorylation O
- I-GENE
specific I-GENE
substrate I-GENE
specificity O
and O
can O
be O
inhibited O
by O
_RARE_ I-GENE
in O
vitro O
, O
as O
is O
the O
case O
for O
_RARE_ I-GENE
. O

Differential O
association O
of O
products I-GENE
of O
alternative O
transcripts I-GENE
of O
the O
candidate O
tumor I-GENE
suppressor I-GENE
_RARE_ I-GENE
with O
the O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
transcriptional O
_RARE_ I-GENE
complex I-GENE
. O

These O
and O
other O
data O
presented O
suggest O
that O
_RARE_ I-GENE
' O
re O
- I-GENE
models O
' O
host O
cell O
transcription I-GENE
factors I-GENE
that O
are O
used O
early I-GENE
in O
viral I-GENE
infection O
, O
and O
thereby O
_RARE_ I-GENE
an O
event O
that O
naturally O
occurs O
during O
transformation O
. O

This O
sensitivity O
analysis O
showed O
that O
the O
_RARE_ I-GENE
limits O
of O
the O
accuracy O
of O
the O
used O
screening O
test O
_RARE_ I-GENE
the O
estimation O
of O
the O
true O
herd O
prevalence O
within O
reasonable O
confidence O
limits O
, O
because O
the O
within O
- I-GENE
herd O
PTB I-GENE
true O
prevalence O
was O
low O
. O
For O
this O
_RARE_ I-GENE
we O
augmented O
the O
herd O
specificity O
for O
_RARE_ I-GENE
with O
larger O
adult O
herd O
size O
(> O
5 I-GENE
). O

_RARE_ I-GENE
. O
5 I-GENE
encodes O
a O
protein I-GENE
, O
latency O
- I-GENE
associated I-GENE
nuclear I-GENE
antigen I-GENE
2 I-GENE
( O
_RARE_ I-GENE
), O
which O
is O
expressed O
in O
KSHV I-GENE
- I-GENE
infected O
hematopoietic I-GENE
tissues O
, O
including O
_RARE_ I-GENE
and O
CD O
but O
not O
KS O
lesions O
. O

As O
_RARE_ I-GENE
, O
_RARE_ I-GENE
showed O
relatively O
higher O
right O
_RARE_ I-GENE
activation O
and O
reduced O
_RARE_ I-GENE
asymmetry O
of O
functional O
complexity O
. O

In O
Xenopus I-GENE
, O
_RARE_ I-GENE
act O
as O
epidermal I-GENE
_RARE_ I-GENE
and O
also O
as O
negative O
regulators O
of O
_RARE_ I-GENE
. O

_RARE_ I-GENE
four O
unique O
variants I-GENE
carrying O
distinct O
_RARE_ I-GENE
sequences I-GENE
in O
the O
N I-GENE
- I-GENE
terminal I-GENE
region O
have O
been O
identified O
. O

Genomic O
organization O
of O
the O
human I-GENE
phosphodiesterase I-GENE
_RARE_ I-GENE
gene I-GENE
. O

The O
present O
findings O
revealed O
that O
the O
_RARE_ I-GENE
- I-GENE
2 I-GENE
protein I-GENE
was O
a O
unique O
alpha1 I-GENE
, O
4 I-GENE
- I-GENE
N I-GENE
- I-GENE
_RARE_ I-GENE
involved O
in O
the O
biosynthetic O
initiation I-GENE
and O
elongation I-GENE
of O
_RARE_ I-GENE
sulfate I-GENE
. O

Inhibition O
of O
the O
_RARE_ I-GENE
/ I-GENE
_RARE_ I-GENE
pathway O
in O
_RARE_ I-GENE
/ I-GENE
ras I-GENE
cells O
, O
using O
the O
_RARE_ I-GENE
inhibitor I-GENE
, O
PD98059 O
, O
resulted O
in O
complete O
cytoskeletal O
recovery O
, O
indistinguishable O
from O
that O
induced O
by O
_RARE_ I-GENE
. O

The O
transcription I-GENE
factor I-GENE
CHOP I-GENE
/ I-GENE
_RARE_ I-GENE
gene I-GENE
is O
induced O
by O
cellular O
stress O
and O
is O
involved O
in O
mediating O
apoptosis O
. O

Addition O
of O
synthetic O
tyrosine I-GENE
- I-GENE
phosphorylated O
peptides I-GENE
derived O
from O
_RARE_ I-GENE
cytoplasmic I-GENE
_RARE_ I-GENE
prior O
to O
GM I-GENE
- I-GENE
CSF I-GENE
stimulation O
inhibited O
the O
in O
vitro O
activation O
of O
STAT5 I-GENE
. O

MAIN O
OUTCOME O
_RARE_ I-GENE
: O
_RARE_ I-GENE
change O
in O
the O
apnea O
- I-GENE
_RARE_ I-GENE
index O
( O
_RARE_ I-GENE
; O
apnea O
events O
+ I-GENE
_RARE_ I-GENE
events O
per O
hour O
of O
sleep O
) O
and O
odds O
of O
developing O
moderate O
- I-GENE
to O
- I-GENE
severe O
_RARE_ I-GENE
( O
defined O
by O
an O
_RARE_ I-GENE
> O
or O
= O
15 O
events O
per O
hour O
of O
sleep O
), O
with O
respect O
to O
change O
in O
weight O
. O

_RARE_ I-GENE
_RARE_ I-GENE
syndromes O
. O

This O
article O
_RARE_ I-GENE
recent O
information O
on O
the O
frequency O
, O
characteristics O
, O
and O
possible O
pathogenic O
mechanisms O
of O
the O
_RARE_ I-GENE
occurring O
in O
patients O
with O
the O
main O
connective O
tissue I-GENE
diseases O
. O

_RARE_ I-GENE
kinase I-GENE
signaling O
in O
T I-GENE
cells O
is O
regulated O
by O
phosphatidylinositol I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
and O
the O
_RARE_ I-GENE
pleckstrin I-GENE
homology I-GENE
domain I-GENE
. O

Current O
evidence O
for O
this O
type I-GENE
of O
DNA I-GENE
_RARE_ I-GENE
- I-GENE
dependent I-GENE
transcriptional O
coupling O
, O
based O
largely O
on O
the O
in O
vivo O
activities O
of O
promoters I-GENE
contained O
in O
engineered I-GENE
DNA I-GENE
constructs I-GENE
, O
suggests O
that O
the O
transcription I-GENE
complex I-GENE
must O
be O
physically O
_RARE_ I-GENE
to O
generate O
DNA I-GENE
_RARE_ I-GENE
and O
to O
prevent O
their O
diffusion O
throughout O
the O
DNA I-GENE
duplex O
. O

The O
structure O
of O
the O
free O
SH2 I-GENE
domain I-GENE
has O
been O
compared O
to O
that O
of O
the O
SH2 I-GENE
complexed O
with O
a O
_RARE_ I-GENE
phosphorylated O
peptide I-GENE
derived O
from O
_RARE_ I-GENE
middle I-GENE
T I-GENE
antigen I-GENE
( O
_RARE_ I-GENE
). O

We O
have O
identified O
three O
binding I-GENE
sites I-GENE
for O
protein I-GENE
complexes I-GENE
: O
a O
palindrome O
, O
a O
direct O
repeat I-GENE
, O
and O
a O
C I-GENE
+ I-GENE
T I-GENE
sequence I-GENE
that O
corresponds O
to O
seven O
_RARE_ I-GENE
motifs O
on O
the O
transcribed O
strand O
. O

Copyright O
2000 O
Academic O
Press O
. O

Nucleotide O
sequence I-GENE
, O
genome O
organization O
and O
phylogenetic O
analysis O
of O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
- I-GENE
associated I-GENE
virus I-GENE
- I-GENE
2 I-GENE
. O

Patients O
underwent O
pretreatment O
_RARE_ I-GENE
and O
detailed O
tumor I-GENE
mapping O
, O
and O
were O
treated O
with O
75 O
mg O
. O
/ I-GENE
m I-GENE
. O
2 I-GENE
cisplatin O
on O
day O
1 I-GENE
and O
1 I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
m I-GENE
. O
2 I-GENE
daily O
, O
5 I-GENE
- I-GENE
fluorouracil O
on O
days O
1 I-GENE
to O
4 I-GENE
and O
definitive O
radiotherapy O
. O

All O
9 O
untreated O
patients O
underwent O
_RARE_ I-GENE
, O
which O
identified O
3 I-GENE
intra O
- I-GENE
abdominal O
, O
3 I-GENE
_RARE_ I-GENE
and O
2 I-GENE
_RARE_ I-GENE
testes O
, O
and O
1 I-GENE
_RARE_ I-GENE
testis I-GENE
in O
the O
_RARE_ I-GENE
_RARE_ I-GENE
. O

This O
_RARE_ I-GENE
was O
_RARE_ I-GENE
for O
the O
compound O
RP I-GENE
_RARE_ I-GENE
, O
a O
specific I-GENE
phosphodiesterase I-GENE
IV I-GENE
inhibitor I-GENE
, O
that O
was O
being O
developed O
simultaneously O
for O
delivery O
by O
both O
oral O
and O
pulmonary O
routes O
of O
administration O
. O

Increased O
levels O
of O
_RARE_ I-GENE
immunoglobulin I-GENE
G I-GENE
may O
also O
cause O
bleeding O
. O

RESULTS O
: O
_RARE_ I-GENE
of O
obesity O
( O
BMI O
SDS O
> O
2 I-GENE
. O
0 O
) O
was O
< O
2 I-GENE
% O
at O
diagnosis O
, O
but O
increased O
to O
16 O
% O
at O
_RARE_ I-GENE
. O

One O
of O
the O
_RARE_ I-GENE
of O
the O
_RARE_ I-GENE
- I-GENE
antibodies I-GENE
is O
an O
impaired O
_RARE_ I-GENE
circulation O
. O

_RARE_ I-GENE
to O
aid O
smoking O
cessation O
. O

Using O
a O
natural O
dominant I-GENE
negative O
for O
AP I-GENE
- I-GENE
1 I-GENE
transcriptional O
activity O
in O
ROS I-GENE
17 O
/ I-GENE
2 I-GENE
. O
8 O
cells O
, O
we O
then O
showed O
that O
AP I-GENE
- I-GENE
1 I-GENE
transcription I-GENE
factors I-GENE
mediated O
TGF I-GENE
- I-GENE
beta1 I-GENE
- I-GENE
and O
BMP I-GENE
- I-GENE
2 I-GENE
- I-GENE
regulated O
expression O
of O
the O
( O
alpha1 I-GENE
) O
collagen I-GENE
I I-GENE
gene I-GENE
as O
well O
as O
TGF I-GENE
- I-GENE
beta1 I-GENE
- I-GENE
regulated O
expression O
of O
the O
parathyroid I-GENE
hormone I-GENE
( O
PTH I-GENE
)/ O
PTH I-GENE
- I-GENE
related I-GENE
peptide I-GENE
( O
_RARE_ I-GENE
) O
receptor I-GENE
. O

_RARE_ I-GENE
12 O
or O
18 O
mg O
/ I-GENE
kg O
daily O
plus O
a O
standard O
dose O
of O
_RARE_ I-GENE
for O
21 O
days O
was O
statistically O
more O
effective O
than O
_RARE_ I-GENE
in O
producing O
a O
final O
cure O
for O
patients O
with O
_RARE_ I-GENE
in O
_RARE_ I-GENE
, O
_RARE_ I-GENE
. O

_RARE_ I-GENE
therapy O
for O
colon O
cancer O
] O
_RARE_ I-GENE
alone O
may O
fail O
to O
cure O
a O
considerable O
number O
of O
locally O
advanced O
colon O
cancers O
. O

There O
were O
significant O
differences O
( O
p O
< O
0 O
. O
05 O
) O
between O
the O
fracture O
and O
_RARE_ I-GENE
groups O
in O
the O
total O
femur O
BMD O
( O
13 O
%), O
_RARE_ I-GENE
BMD O
in O
the O
distal O
_RARE_ I-GENE
( O
4 I-GENE
%), O
and O
the O
_RARE_ I-GENE
_RARE_ I-GENE
in O
the O
radiographs O
( O
_RARE_ I-GENE
) O
( O
3 I-GENE
%). O

BACKGROUND O
: O
The O
aim O
of O
this O
study O
was O
to O
determine O
and O
compare O
interleukin I-GENE
- I-GENE
6 I-GENE
( O
IL I-GENE
- I-GENE
6 I-GENE
) O
levels O
in O
_RARE_ I-GENE
_RARE_ I-GENE
fluid O
( O
_RARE_ I-GENE
) O
and O
clinical O
periodontal O
findings O
in O
patients O
with O
rheumatoid I-GENE
arthritis O
( O
RA O
) O
and O
adult O
_RARE_ I-GENE
( O
AP I-GENE
). O

In O
a O
prospective O
, O
_RARE_ I-GENE
trial O
the O
efficacy O
of O
an O
_RARE_ I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
L I-GENE
extract O
_RARE_ I-GENE
440 O
was O
investigated O
in O
50 O
patients O
with O
pre I-GENE
- I-GENE
menstrual O
syndrome O
( O
_RARE_ I-GENE
). O

Studies O
are O
necessary O
to O
assess O
the O
source O
of O
contamination O
and O
potential O
role O
of O
_RARE_ I-GENE
- I-GENE
contaminated O
milk O
in O
the O
transmission O
of O
_RARE_ I-GENE
to O
neonates O
. O

Effects O
of O
Trypanosoma O
_RARE_ I-GENE
on O
pregnancy O
of O
_RARE_ I-GENE
sheep O
and O
the O
results O
of O
_RARE_ I-GENE
chloride O
chemotherapy O
. O

NF I-GENE
kappa I-GENE
B I-GENE
was O
activated I-GENE
to O
a O
much O
greater O
extent O
by O
_RARE_ I-GENE
in O
the O
_RARE_ I-GENE
cells O
than O
in O
_RARE_ I-GENE
cells O
. O

_RARE_ I-GENE
on O
treatment O
exposures O
, O
this O
at O
- I-GENE
risk O
population O
may O
experience O
life O
- I-GENE
_RARE_ I-GENE
late O
effects O
, O
such O
as O
cirrhosis O
secondary O
to O
hepatitis I-GENE
C I-GENE
or O
late O
- I-GENE
onset O
_RARE_ I-GENE
- I-GENE
induced O
cardiomyopathy O
, O
or O
life O
- I-GENE
changing O
late O
effects O
, O
such O
as O
cognitive O
dysfunction O
. O

The O
presence O
of O
locus I-GENE
- I-GENE
specific I-GENE
residues O
throughout O
the O
entire O
promoter I-GENE
region O
strongly O
suggests O
that O
the O
various O
HLA I-GENE
class I-GENE
I I-GENE
loci I-GENE
are O
differentially O
regulated O
. O

Because O
the O
number O
of O
parameters O
required O
by O
a O
_RARE_ I-GENE
series O
_RARE_ I-GENE
rapidly O
with O
both O
the O
length I-GENE
of O
its O
memory O
and O
the O
order O
of O
its O
_RARE_ I-GENE
, O
methods O
for O
identifying O
these O
models O
from O
measurements O
of O
input O
/ I-GENE
output O
data O
are O
limited O
to O
low O
- I-GENE
order O
systems O
with O
relatively O
short O
_RARE_ I-GENE
. O

The O
standard O
method O
for O
_RARE_ I-GENE
the O
composite O
score O
on O
the O
S I-GENE
- I-GENE
B I-GENE
IV I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
with O
a O
_RARE_ I-GENE
score O
of O
0 O
, O
which O
_RARE_ I-GENE
cognitive O
functioning O
in O
young O
biologically O
high O
risk O
children O
. O

_RARE_ I-GENE
( O
2 I-GENE
)- I-GENE
induced O
_RARE_ I-GENE
- I-GENE
1 I-GENE
synthesis O
required O
activation O
of O
NF I-GENE
- I-GENE
kappaB I-GENE
since O
mutation I-GENE
of O
NF I-GENE
- I-GENE
kappaB I-GENE
- I-GENE
binding I-GENE
sites I-GENE
in O
the O
promoter I-GENE
resulted O
in O
complete O
loss O
of O
inducible I-GENE
promoter I-GENE
activity O
. O

_RARE_ I-GENE
of O
human I-GENE
_RARE_ I-GENE
by O
mitogenic O
pairs O
of O
anti I-GENE
- I-GENE
_RARE_ I-GENE
mAb I-GENE
induces O
tyrosine I-GENE
phosphorylation O
of O
a O
number O
of O
intracellular O
proteins I-GENE
including O
a O
120 O
kDa I-GENE
phosphoprotein I-GENE
that O
we O
identify O
as O
the O
proto I-GENE
- I-GENE
oncogene I-GENE
c I-GENE
- I-GENE
Cbl I-GENE
. O

_RARE_ I-GENE
of O
_RARE_ I-GENE
spectroscopy O
for O
_RARE_ I-GENE
measuring O
muscle O
oxidative O
metabolic O
rate O
in O
exercise O
. O

Previous O
studies O
have O
demonstrated O
that O
tissue I-GENE
- I-GENE
restricted O
transcription I-GENE
factors I-GENE
including O
PU I-GENE
. O
1 I-GENE
and O
PU I-GENE
. O
1 I-GENE
interaction O
partner I-GENE
( O
_RARE_ I-GENE
) O
function O
synergistically O
with O
c I-GENE
- I-GENE
Fos I-GENE
plus O
c I-GENE
- I-GENE
Jun I-GENE
to O
stimulate O
the O
_RARE_ I-GENE
'- O
enhancer I-GENE
in O
3T3 O
cells O
. O

The O
murine I-GENE
int I-GENE
- I-GENE
6 I-GENE
locus I-GENE
, O
identified O
as O
a O
frequent O
integration O
site I-GENE
of O
mouse I-GENE
mammary O
tumor I-GENE
viruses O
, O
encodes O
the O
48 O
- I-GENE
kDa I-GENE
_RARE_ I-GENE
subunit I-GENE
of O
translation I-GENE
initiation I-GENE
factor I-GENE
eIF3 I-GENE
. O

An O
_RARE_ I-GENE
deletion O
( O
_RARE_ I-GENE
) O
mutant I-GENE
was O
viable O
but O
_RARE_ I-GENE
slowly O
in O
minimal I-GENE
medium O
. O

Additionally O
, O
MIP I-GENE
- I-GENE
2A I-GENE
_RARE_ I-GENE
cell O
growth I-GENE
regulatory I-GENE
role O
of O
MBP I-GENE
- I-GENE
1 I-GENE
. O

We O
produced O
transgenic O
plants O
expressing O
the O
antisense I-GENE
Arabidopsis I-GENE
HD I-GENE
( O
_RARE_ I-GENE
) O
gene I-GENE
. O

3 I-GENE
. O
04 O
+/- O
1 I-GENE
. O
2 I-GENE
, O
P I-GENE
< O
0 O
. O
0001 O
), O
large O
_RARE_ I-GENE
/ I-GENE
30 O
min O
( O
1 I-GENE
. O
46 O
+/- O
1 I-GENE
. O
96 O
vs O
. O

Four O
transcription I-GENE
initiation I-GENE
sites I-GENE
have O
been O
identified O
by O
full I-GENE
- I-GENE
length I-GENE
RNA I-GENE
ligase I-GENE
- I-GENE
mediated O
rapid O
amplification O
of O
cDNA I-GENE
ends O
( O
_RARE_ I-GENE
- I-GENE
RACE O
) O
between O
- I-GENE
61 O
and O
- I-GENE
32 O
bp O
from O
the O
translation I-GENE
initiation I-GENE
codon O
. O
Reverse I-GENE
transcription I-GENE
- I-GENE
PCR O
analysis O
revealed O
that O
PFK I-GENE
- I-GENE
A I-GENE
, O
PFK I-GENE
- I-GENE
B I-GENE
and O
PFK I-GENE
- I-GENE
C I-GENE
genes I-GENE
were O
expressed O
, O
in O
all O
mouse I-GENE
tissues O
tested O
, O
at O
varying O
levels O
. O

PFK I-GENE
- I-GENE
A I-GENE
mRNA I-GENE
was O
more O
abundantly O
expressed O
in O
all O
tissues O
than O
were O
the O
PFK I-GENE
- I-GENE
B I-GENE
and O
PFK I-GENE
- I-GENE
C I-GENE
genes I-GENE
. O

We O
used O
the O
_RARE_ I-GENE
_RARE_ I-GENE
system O
, O
which O
is O
composed O
of O
an O
X I-GENE
- I-GENE
ray O
_RARE_ I-GENE
system O
and O
a O
digital O
image O
_RARE_ I-GENE
circuit O
. O

In O
whole O
_RARE_ I-GENE
, O
_RARE_ I-GENE
acid I-GENE
was O
detected O
in O
levels O
_RARE_ I-GENE
_RARE_ I-GENE
the O
regulatory I-GENE
limit O
. O

In O
addition O
, O
we O
identified O
two O
mutations O
, O
Delta I-GENE
_RARE_ I-GENE
and O
_RARE_ I-GENE
+ I-GENE
_RARE_ I-GENE
--> I-GENE
A I-GENE
, O
in O
a O
_RARE_ I-GENE
_RARE_ I-GENE
patient O
. O

_RARE_ I-GENE
: O
a O
resource O
for O
_RARE_ I-GENE
who O
smoke O
. O

[ O
18F O
_RARE_ I-GENE
4 I-GENE
- I-GENE
_RARE_ I-GENE
( O
_RARE_ I-GENE
), O
which O
selectively O
binds O
to O
the O
vesicular O
acetylcholine I-GENE
transporter I-GENE
in O
the O
_RARE_ I-GENE
cholinergic O
neuron I-GENE
, O
has O
previously O
been O
shown O
to O
be O
a O
useful O
ligand O
for O
the O
study O
of O
cholinergic O
terminal I-GENE
density I-GENE
in O
the O
basal O
_RARE_ I-GENE
with O
PET O
. O

We O
demonstrate O
that O
the O
protein I-GENE
is O
a O
murine I-GENE
homologue I-GENE
of O
_RARE_ I-GENE
- I-GENE
A I-GENE
which O
has O
been O
shown O
to O
bind O
selectively O
to O
_RARE_ I-GENE
and O
is O
responsible O
for O
the O
_RARE_ I-GENE
- I-GENE
binding I-GENE
activity O
in O
the O
chromatographic O
fractions O
. O

The O
molecular O
associations O
_RARE_ I-GENE
_RARE_ I-GENE
behavior O
during O
mitosis O
are O
currently O
unknown O
. O

_RARE_ I-GENE
II I-GENE
significantly O
induced O
_RARE_ I-GENE
mRNA I-GENE
_RARE_ I-GENE
without O
affecting O
_RARE_ I-GENE
or O
_RARE_ I-GENE
expression O
, O
which O
was O
inhibited O
by O
protein I-GENE
kinase I-GENE
C I-GENE
inhibitors O
and O
by O
intracellular O
Ca I-GENE
( O
2 I-GENE
+) O
_RARE_ I-GENE
agents O
. O

Promoter O
analysis O
demonstrated O
that O
the O
sequence I-GENE
identical O
to O
consensus I-GENE
cAMP I-GENE
- I-GENE
responsive I-GENE
element I-GENE
( O
CRE O
) O
located O
at O
- I-GENE
_RARE_ I-GENE
of O
the O
_RARE_ I-GENE
promoter I-GENE
was O
critical O
for O
_RARE_ I-GENE
responsiveness O
. O

LH I-GENE
/ I-GENE
CG I-GENE
receptor I-GENE
activation O
of O
_RARE_ I-GENE
is O
not O
mediated O
by O
activation O
of O
phosphatidylinositol I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
( O
PI I-GENE
3 I-GENE
- I-GENE
kinase I-GENE
) O
or O
by O
G I-GENE
protein I-GENE
beta I-GENE
gamma I-GENE
subunits I-GENE
. O

Deletion O
analysis O
showed O
that O
the O
- I-GENE
_RARE_ I-GENE
_RARE_ I-GENE
41 O
sequence I-GENE
was O
sufficient O
for O
both O
the O
constitutive O
promoter I-GENE
activity O
and O
_RARE_ I-GENE
- I-GENE
activation O
and O
electrophoretic O
mobility I-GENE
shift O
assays O
identified O
the O
interaction O
of O
C I-GENE
/ I-GENE
_RARE_ I-GENE
and O
Sp1 I-GENE
to O
this O
region O
. O

_RARE_ I-GENE
of O
induced O
VT O
on O
the O
first O
attempt O
was O
comparable O
with O
_RARE_ I-GENE
pacing O
( O
87 O
. O
4 I-GENE
%) O
versus O
RV O
pacing O
( O
89 I-GENE
. O
6 I-GENE
%). O

We O
compare O
the O
results O
of O
this O
algorithm O
with O
the O
results O
obtained O
with O
two O
other O
_RARE_ I-GENE
, O
the O
optimal O
algorithm O
for O
_RARE_ I-GENE
_RARE_ I-GENE
noise O
and O
the O
optimal O
algorithm O
for O
_RARE_ I-GENE
additive O
noise O
, O
and O
we O
show O
that O
in O
both O
cases O
improvement O
can O
be O
obtained O
. O

Changes O
in O
stimulation O
levels O
over O
time O
in O
nucleus O
22 O
cochlear O
implant O
users O
. O

_RARE_ I-GENE
_RARE_ I-GENE
and O
structure O
- I-GENE
directed O
mutagenesis O
revealed O
that O
the O
105 I-GENE
- I-GENE
nt O
_RARE_ I-GENE
( O
_RARE_ I-GENE
) O
forms O
a O
_RARE_ I-GENE
secondary O
structure O
containing O
four O
helices O
connected O
by O
single O
- I-GENE
stranded I-GENE
regions O
. O

_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
has O
the O
extra I-GENE
_RARE_ I-GENE
of O
operating O
in O
live O
_RARE_ I-GENE
situations O
using O
_RARE_ I-GENE
input O
. O

A I-GENE
marked O
decrease O
in O
the O
type I-GENE
1 I-GENE
insulin I-GENE
- I-GENE
like I-GENE
growth I-GENE
factor I-GENE
( O
IGF I-GENE
) O
receptor I-GENE
( O
IGF I-GENE
- I-GENE
IR I-GENE
) O
occurs O
in O
prostate O
epithelial O
cells O
during O
transformation O
from O
the O
benign O
to O
the O
metastatic O
state O
. O

The O
_RARE_ I-GENE
cell O
line O
was O
derived O
by O
_RARE_ I-GENE
of O
human I-GENE
primary O
prostate O
epithelial O
cells O
with O
simian I-GENE
virus I-GENE
- I-GENE
40 I-GENE
T I-GENE
antigen I-GENE
and O
is O
rarely O
tumorigenic O
. O

We O
determined O
whether O
the O
human I-GENE
_RARE_ I-GENE
promoter I-GENE
is O
responsive I-GENE
to O
sterol I-GENE
regulatory I-GENE
element I-GENE
- I-GENE
binding I-GENE
proteins I-GENE
( O
_RARE_ I-GENE
). O

Expression O
of O
SREBP I-GENE
- I-GENE
1a I-GENE
stimulated O
_RARE_ I-GENE
promoter I-GENE
activity O
in O
the O
context O
of O
COS O
- I-GENE
1 I-GENE
cells O
and O
human I-GENE
_RARE_ I-GENE
- I-GENE
_RARE_ I-GENE
cells O
. O

Because O
the O
high O
- I-GENE
density I-GENE
lipoprotein I-GENE
receptor I-GENE
( O
HDL I-GENE
- I-GENE
R I-GENE
) O
is O
a O
key O
element I-GENE
in O
cholesterol I-GENE
_RARE_ I-GENE
and O
a O
potential O
therapeutic O
target O
for O
_RARE_ I-GENE
drugs O
, O
an O
understanding O
of O
HDL I-GENE
- I-GENE
R I-GENE
regulation O
is O
essential O
. O

IFN I-GENE
- I-GENE
stimulated O
gene I-GENE
factor I-GENE
- I-GENE
3 I-GENE
and O
STAT1 I-GENE
homodimers I-GENE
formed O
and O
bound O
an O
IFN I-GENE
- I-GENE
stimulated O
response O
element I-GENE
( O
_RARE_ I-GENE
) O
and O
gamma I-GENE
- I-GENE
activated I-GENE
sequence I-GENE
( O
_RARE_ I-GENE
) O
element I-GENE
, O
respectively O
. O

We O
have O
therefore O
studied O
the O
molecular O
mechanisms O
of O
TGF I-GENE
- I-GENE
beta1 I-GENE
action O
on O
_RARE_ I-GENE
( O
TG I-GENE
) O
gene I-GENE
expression O
by O
focusing O
our O
attention O
on O
TGF I-GENE
- I-GENE
beta1 I-GENE
regulation O
of O
thyroid I-GENE
- I-GENE
specific I-GENE
transcription I-GENE
factors I-GENE
. O

The O
epitope O
- I-GENE
protected O
lysine O
( O
K I-GENE
) O
was O
present O
in O
a O
30 O
- I-GENE
aa O
_RARE_ I-GENE
fragment I-GENE
that O
, O
by O
N I-GENE
- I-GENE
terminal I-GENE
sequencing O
, O
was O
found O
to O
be O
_RARE_ I-GENE
. O

To O
understand O
the O
molecular O
regulation O
of O
these O
genes I-GENE
in O
thyroid I-GENE
cells O
, O
the O
effect O
of O
thyroid I-GENE
transcription I-GENE
factor I-GENE
1 I-GENE
( O
TTF I-GENE
- I-GENE
1 I-GENE
) O
and O
the O
paired I-GENE
domain I-GENE
- I-GENE
containing O
protein I-GENE
8 O
( O
Pax I-GENE
- I-GENE
8 O
) O
on O
the O
transcriptional O
activity O
of O
the O
deiodinase I-GENE
promoters I-GENE
were O
studied O
. O

